sent-id,token,pos,label
ncbi-sent-1,Clustering,NN,O
ncbi-sent-1,of,IN,O
ncbi-sent-1,missense,JJ,O
ncbi-sent-1,mutations,NNS,O
ncbi-sent-1,in,IN,O
ncbi-sent-1,the,DT,O
ncbi-sent-1,ataxia,NN,B-DISEASE
ncbi-sent-1,-,:,I-DISEASE
ncbi-sent-1,telangiectasia,NN,I-DISEASE
ncbi-sent-1,gene,NN,O
ncbi-sent-1,in,IN,O
ncbi-sent-1,a,DT,O
ncbi-sent-1,sporadic,JJ,B-DISEASE
ncbi-sent-1,T,NNP,I-DISEASE
ncbi-sent-1,-,:,I-DISEASE
ncbi-sent-1,cell,NN,I-DISEASE
ncbi-sent-1,leukaemia,NN,I-DISEASE
ncbi-sent-1,.,.,O
ncbi-sent-2,Ataxia,NNP,B-DISEASE
ncbi-sent-2,-,:,I-DISEASE
ncbi-sent-2,telangiectasia,NN,I-DISEASE
ncbi-sent-2,(,(,O
ncbi-sent-2,A,DT,B-DISEASE
ncbi-sent-2,-,:,I-DISEASE
ncbi-sent-2,T,NN,I-DISEASE
ncbi-sent-2,),),O
ncbi-sent-2,is,VBZ,O
ncbi-sent-2,a,DT,O
ncbi-sent-2,recessive,JJ,B-DISEASE
ncbi-sent-2,multi,NN,I-DISEASE
ncbi-sent-2,-,:,I-DISEASE
ncbi-sent-2,system,NN,I-DISEASE
ncbi-sent-2,disorder,NN,I-DISEASE
ncbi-sent-2,caused,VBN,O
ncbi-sent-2,by,IN,O
ncbi-sent-2,mutations,NNS,O
ncbi-sent-2,in,IN,O
ncbi-sent-2,the,DT,O
ncbi-sent-2,ATM,NNP,O
ncbi-sent-2,gene,NN,O
ncbi-sent-2,at,IN,O
ncbi-sent-2,11q22,CD,O
ncbi-sent-2,-,:,O
ncbi-sent-2,q23,NN,O
ncbi-sent-2,(,(,O
ncbi-sent-2,ref,NN,O
ncbi-sent-2,.,.,O
ncbi-sent-3,3,CD,O
ncbi-sent-3,),),O
ncbi-sent-3,.,.,O
ncbi-sent-4,The,DT,O
ncbi-sent-4,risk,NN,O
ncbi-sent-4,of,IN,O
ncbi-sent-4,cancer,NN,B-DISEASE
ncbi-sent-4,",",",",O
ncbi-sent-4,especially,RB,O
ncbi-sent-4,lymphoid,JJ,B-DISEASE
ncbi-sent-4,neoplasias,NN,I-DISEASE
ncbi-sent-4,",",",",O
ncbi-sent-4,is,VBZ,O
ncbi-sent-4,substantially,RB,O
ncbi-sent-4,elevated,VBN,O
ncbi-sent-4,in,IN,O
ncbi-sent-4,A,NNP,B-DISEASE
ncbi-sent-4,-,:,I-DISEASE
ncbi-sent-4,T,NN,I-DISEASE
ncbi-sent-4,patients,NNS,O
ncbi-sent-4,and,CC,O
ncbi-sent-4,has,VBZ,O
ncbi-sent-4,long,RB,O
ncbi-sent-4,been,VBN,O
ncbi-sent-4,associated,VBN,O
ncbi-sent-4,with,IN,O
ncbi-sent-4,chromosomal,JJ,O
ncbi-sent-4,instability,NN,O
ncbi-sent-4,.,.,O
ncbi-sent-5,By,IN,O
ncbi-sent-5,analysing,VBG,O
ncbi-sent-5,tumour,JJ,B-DISEASE
ncbi-sent-5,DNA,NN,O
ncbi-sent-5,from,IN,O
ncbi-sent-5,patients,NNS,O
ncbi-sent-5,with,IN,O
ncbi-sent-5,sporadic,JJ,B-DISEASE
ncbi-sent-5,T,NNP,I-DISEASE
ncbi-sent-5,-,:,I-DISEASE
ncbi-sent-5,cell,NN,I-DISEASE
ncbi-sent-5,prolymphocytic,JJ,I-DISEASE
ncbi-sent-5,leukaemia,NN,I-DISEASE
ncbi-sent-5,(,(,O
ncbi-sent-5,T,NNP,B-DISEASE
ncbi-sent-5,-,:,I-DISEASE
ncbi-sent-5,PLL,NN,I-DISEASE
ncbi-sent-5,),),O
ncbi-sent-5,",",",",O
ncbi-sent-5,a,DT,O
ncbi-sent-5,rare,JJ,O
ncbi-sent-5,clonal,JJ,B-DISEASE
ncbi-sent-5,malignancy,NN,I-DISEASE
ncbi-sent-5,with,IN,O
ncbi-sent-5,similarities,NNS,O
ncbi-sent-5,to,TO,O
ncbi-sent-5,a,DT,O
ncbi-sent-5,mature,NN,B-DISEASE
ncbi-sent-5,T,NNP,I-DISEASE
ncbi-sent-5,-,:,I-DISEASE
ncbi-sent-5,cell,NN,I-DISEASE
ncbi-sent-5,leukaemia,NN,I-DISEASE
ncbi-sent-5,seen,VBN,O
ncbi-sent-5,in,IN,O
ncbi-sent-5,A,NNP,B-DISEASE
ncbi-sent-5,-,:,I-DISEASE
ncbi-sent-5,T,NN,I-DISEASE
ncbi-sent-5,",",",",O
ncbi-sent-5,we,PRP,O
ncbi-sent-5,demonstrate,VBP,O
ncbi-sent-5,a,DT,O
ncbi-sent-5,high,JJ,O
ncbi-sent-5,frequency,NN,O
ncbi-sent-5,of,IN,O
ncbi-sent-5,ATM,NNP,O
ncbi-sent-5,mutations,NNS,O
ncbi-sent-5,in,IN,O
ncbi-sent-5,T,NNP,B-DISEASE
ncbi-sent-5,-,:,I-DISEASE
ncbi-sent-5,PLL,NN,I-DISEASE
ncbi-sent-5,.,.,O
ncbi-sent-6,In,IN,O
ncbi-sent-6,marked,JJ,O
ncbi-sent-6,contrast,NN,O
ncbi-sent-6,to,TO,O
ncbi-sent-6,the,DT,O
ncbi-sent-6,ATM,NNP,O
ncbi-sent-6,mutation,NN,O
ncbi-sent-6,pattern,NN,O
ncbi-sent-6,in,IN,O
ncbi-sent-6,A,NNP,B-DISEASE
ncbi-sent-6,-,:,I-DISEASE
ncbi-sent-6,T,NN,I-DISEASE
ncbi-sent-6,",",",",O
ncbi-sent-6,the,DT,O
ncbi-sent-6,most,RBS,O
ncbi-sent-6,frequent,JJ,O
ncbi-sent-6,nucleotide,NN,O
ncbi-sent-6,changes,NNS,O
ncbi-sent-6,in,IN,O
ncbi-sent-6,this,DT,O
ncbi-sent-6,leukaemia,NN,B-DISEASE
ncbi-sent-6,were,VBD,O
ncbi-sent-6,missense,JJ,O
ncbi-sent-6,mutations,NNS,O
ncbi-sent-6,.,.,O
ncbi-sent-7,These,DT,O
ncbi-sent-7,clustered,VBN,O
ncbi-sent-7,in,IN,O
ncbi-sent-7,the,DT,O
ncbi-sent-7,region,NN,O
ncbi-sent-7,corresponding,VBG,O
ncbi-sent-7,to,TO,O
ncbi-sent-7,the,DT,O
ncbi-sent-7,kinase,NN,O
ncbi-sent-7,domain,NN,O
ncbi-sent-7,",",",",O
ncbi-sent-7,which,WDT,O
ncbi-sent-7,is,VBZ,O
ncbi-sent-7,highly,RB,O
ncbi-sent-7,conserved,VBN,O
ncbi-sent-7,in,IN,O
ncbi-sent-7,ATM,NNP,O
ncbi-sent-7,-,:,O
ncbi-sent-7,related,JJ,O
ncbi-sent-7,proteins,NNS,O
ncbi-sent-7,in,IN,O
ncbi-sent-7,mouse,NN,O
ncbi-sent-7,",",",",O
ncbi-sent-7,yeast,NN,O
ncbi-sent-7,and,CC,O
ncbi-sent-7,Drosophila,NNP,O
ncbi-sent-7,.,.,O
ncbi-sent-8,The,DT,O
ncbi-sent-8,resulting,VBG,O
ncbi-sent-8,amino,JJ,O
ncbi-sent-8,-,:,O
ncbi-sent-8,acid,NN,O
ncbi-sent-8,substitutions,NNS,O
ncbi-sent-8,are,VBP,O
ncbi-sent-8,predicted,VBN,O
ncbi-sent-8,to,TO,O
ncbi-sent-8,interfere,VB,O
ncbi-sent-8,with,IN,O
ncbi-sent-8,ATP,NNP,O
ncbi-sent-8,binding,VBG,O
ncbi-sent-8,or,CC,O
ncbi-sent-8,substrate,JJ,O
ncbi-sent-8,recognition,NN,O
ncbi-sent-8,.,.,O
ncbi-sent-9,Two,CD,O
ncbi-sent-9,of,IN,O
ncbi-sent-9,seventeen,NN,O
ncbi-sent-9,mutated,VBN,O
ncbi-sent-9,T,NNP,B-DISEASE
ncbi-sent-9,-,:,I-DISEASE
ncbi-sent-9,PLL,NN,I-DISEASE
ncbi-sent-9,samples,NNS,O
ncbi-sent-9,had,VBD,O
ncbi-sent-9,a,DT,O
ncbi-sent-9,previously,RB,O
ncbi-sent-9,reported,VBN,O
ncbi-sent-9,A,NNP,B-DISEASE
ncbi-sent-9,-,:,I-DISEASE
ncbi-sent-9,T,NN,I-DISEASE
ncbi-sent-9,allele,NN,O
ncbi-sent-9,.,.,O
ncbi-sent-10,In,IN,O
ncbi-sent-10,contrast,NN,O
ncbi-sent-10,",",",",O
ncbi-sent-10,no,DT,O
ncbi-sent-10,mutations,NNS,O
ncbi-sent-10,were,VBD,O
ncbi-sent-10,detected,VBN,O
ncbi-sent-10,in,IN,O
ncbi-sent-10,the,DT,O
ncbi-sent-10,p53,NN,O
ncbi-sent-10,gene,NN,O
ncbi-sent-10,",",",",O
ncbi-sent-10,suggesting,VBG,O
ncbi-sent-10,that,IN,O
ncbi-sent-10,this,DT,O
ncbi-sent-10,tumour,NN,B-DISEASE
ncbi-sent-10,suppressor,NN,O
ncbi-sent-10,is,VBZ,O
ncbi-sent-10,not,RB,O
ncbi-sent-10,frequently,RB,O
ncbi-sent-10,altered,VBN,O
ncbi-sent-10,in,IN,O
ncbi-sent-10,this,DT,O
ncbi-sent-10,leukaemia,NN,B-DISEASE
ncbi-sent-10,.,.,O
ncbi-sent-11,Occasional,JJ,O
ncbi-sent-11,missense,NN,O
ncbi-sent-11,mutations,NNS,O
ncbi-sent-11,in,IN,O
ncbi-sent-11,ATM,NNP,O
ncbi-sent-11,were,VBD,O
ncbi-sent-11,also,RB,O
ncbi-sent-11,found,VBN,O
ncbi-sent-11,in,IN,O
ncbi-sent-11,tumour,JJ,B-DISEASE
ncbi-sent-11,DNA,NN,O
ncbi-sent-11,from,IN,O
ncbi-sent-11,patients,NNS,O
ncbi-sent-11,with,IN,O
ncbi-sent-11,B,NNP,B-DISEASE
ncbi-sent-11,-,:,I-DISEASE
ncbi-sent-11,cell,NN,I-DISEASE
ncbi-sent-11,non,SYM,I-DISEASE
ncbi-sent-11,-,:,I-DISEASE
ncbi-sent-11,Hodgkins,VBZ,I-DISEASE
ncbi-sent-11,lymphomas,FW,I-DISEASE
ncbi-sent-11,(,(,O
ncbi-sent-11,B,NNP,B-DISEASE
ncbi-sent-11,-,:,I-DISEASE
ncbi-sent-11,NHL,NN,I-DISEASE
ncbi-sent-11,),),O
ncbi-sent-11,and,CC,O
ncbi-sent-11,a,DT,O
ncbi-sent-11,B,NNP,B-DISEASE
ncbi-sent-11,-,:,I-DISEASE
ncbi-sent-11,NHL,NNP,I-DISEASE
ncbi-sent-11,cell,NN,O
ncbi-sent-11,line,NN,O
ncbi-sent-11,.,.,O
ncbi-sent-12,The,DT,O
ncbi-sent-12,evidence,NN,O
ncbi-sent-12,of,IN,O
ncbi-sent-12,a,DT,O
ncbi-sent-12,significant,JJ,O
ncbi-sent-12,proportion,NN,O
ncbi-sent-12,of,IN,O
ncbi-sent-12,loss,NN,O
ncbi-sent-12,-,:,O
ncbi-sent-12,of,IN,O
ncbi-sent-12,-,:,O
ncbi-sent-12,function,NN,O
ncbi-sent-12,mutations,NNS,O
ncbi-sent-12,and,CC,O
ncbi-sent-12,a,DT,O
ncbi-sent-12,complete,JJ,O
ncbi-sent-12,absence,NN,O
ncbi-sent-12,of,IN,O
ncbi-sent-12,the,DT,O
ncbi-sent-12,normal,JJ,O
ncbi-sent-12,copy,NN,O
ncbi-sent-12,of,IN,O
ncbi-sent-12,ATM,NNP,O
ncbi-sent-12,in,IN,O
ncbi-sent-12,the,DT,O
ncbi-sent-12,majority,NN,O
ncbi-sent-12,of,IN,O
ncbi-sent-12,mutated,JJ,O
ncbi-sent-12,tumours,NNS,B-DISEASE
ncbi-sent-12,establishes,VBZ,O
ncbi-sent-12,somatic,JJ,O
ncbi-sent-12,inactivation,NN,O
ncbi-sent-12,of,IN,O
ncbi-sent-12,this,DT,O
ncbi-sent-12,gene,NN,O
ncbi-sent-12,in,IN,O
ncbi-sent-12,the,DT,O
ncbi-sent-12,pathogenesis,NN,O
ncbi-sent-12,of,IN,O
ncbi-sent-12,sporadic,JJ,B-DISEASE
ncbi-sent-12,T,NNP,I-DISEASE
ncbi-sent-12,-,:,I-DISEASE
ncbi-sent-12,PLL,NN,I-DISEASE
ncbi-sent-12,and,CC,O
ncbi-sent-12,suggests,VBZ,O
ncbi-sent-12,that,IN,O
ncbi-sent-12,ATM,NNP,O
ncbi-sent-12,acts,VBZ,O
ncbi-sent-12,as,IN,O
ncbi-sent-12,a,DT,O
ncbi-sent-12,tumour,NN,B-DISEASE
ncbi-sent-12,suppressor,NN,O
ncbi-sent-12,.,.,O
ncbi-sent-13,As,IN,O
ncbi-sent-13,constitutional,JJ,O
ncbi-sent-13,DNA,NNP,O
ncbi-sent-13,was,VBD,O
ncbi-sent-13,not,RB,O
ncbi-sent-13,available,JJ,O
ncbi-sent-13,",",",",O
ncbi-sent-13,a,DT,O
ncbi-sent-13,putative,JJ,O
ncbi-sent-13,hereditary,JJ,O
ncbi-sent-13,predisposition,NN,O
ncbi-sent-13,to,TO,O
ncbi-sent-13,T,NNP,B-DISEASE
ncbi-sent-13,-,:,I-DISEASE
ncbi-sent-13,PLL,NN,I-DISEASE
ncbi-sent-13,will,MD,O
ncbi-sent-13,require,VB,O
ncbi-sent-13,further,JJ,O
ncbi-sent-13,investigation,NN,O
ncbi-sent-13,.,.,O
ncbi-sent-14,.,.,O
ncbi-sent-15,Myotonic,JJ,B-DISEASE
ncbi-sent-15,dystrophy,NN,I-DISEASE
ncbi-sent-15,protein,NN,O
ncbi-sent-15,kinase,NN,O
ncbi-sent-15,is,VBZ,O
ncbi-sent-15,involved,VBN,O
ncbi-sent-15,in,IN,O
ncbi-sent-15,the,DT,O
ncbi-sent-15,modulation,NN,O
ncbi-sent-15,of,IN,O
ncbi-sent-15,the,DT,O
ncbi-sent-15,Ca2,NNP,O
ncbi-sent-15,+,NNP,O
ncbi-sent-15,homeostasis,NN,O
ncbi-sent-15,in,IN,O
ncbi-sent-15,skeletal,JJ,O
ncbi-sent-15,muscle,NN,O
ncbi-sent-15,cells,NNS,O
ncbi-sent-15,.,.,O
ncbi-sent-16,Myotonic,NNP,B-DISEASE
ncbi-sent-16,dystrophy,NN,I-DISEASE
ncbi-sent-16,(,(,O
ncbi-sent-16,DM,NNP,B-DISEASE
ncbi-sent-16,),),O
ncbi-sent-16,",",",",O
ncbi-sent-16,the,DT,O
ncbi-sent-16,most,RBS,O
ncbi-sent-16,prevalent,JJ,O
ncbi-sent-16,muscular,JJ,B-DISEASE
ncbi-sent-16,disorder,NN,I-DISEASE
ncbi-sent-16,in,IN,O
ncbi-sent-16,adults,NNS,O
ncbi-sent-16,",",",",O
ncbi-sent-16,is,VBZ,O
ncbi-sent-16,caused,VBN,O
ncbi-sent-16,by,IN,O
ncbi-sent-16,(,(,O
ncbi-sent-16,CTG,NNP,O
ncbi-sent-16,),),O
ncbi-sent-16,n,SYM,O
ncbi-sent-16,-,:,O
ncbi-sent-16,repeat,NN,O
ncbi-sent-16,expansion,NN,O
ncbi-sent-16,in,IN,O
ncbi-sent-16,a,DT,O
ncbi-sent-16,gene,NN,O
ncbi-sent-16,encoding,VBG,O
ncbi-sent-16,a,DT,O
ncbi-sent-16,protein,NN,O
ncbi-sent-16,kinase,NN,O
ncbi-sent-16,(,(,O
ncbi-sent-16,DM,NNP,B-DISEASE
ncbi-sent-16,protein,RB,O
ncbi-sent-16,kinase,VBD,O
ncbi-sent-16,;,:,O
ncbi-sent-16,DMPK,NNP,O
ncbi-sent-16,),),O
ncbi-sent-16,and,CC,O
ncbi-sent-16,involves,VBZ,O
ncbi-sent-16,changes,NNS,O
ncbi-sent-16,in,IN,O
ncbi-sent-16,cytoarchitecture,NN,O
ncbi-sent-16,and,CC,O
ncbi-sent-16,ion,NN,O
ncbi-sent-16,homeostasis,NN,O
ncbi-sent-16,.,.,O
ncbi-sent-17,To,TO,O
ncbi-sent-17,obtain,VB,O
ncbi-sent-17,clues,NNS,O
ncbi-sent-17,to,TO,O
ncbi-sent-17,the,DT,O
ncbi-sent-17,normal,JJ,O
ncbi-sent-17,biological,JJ,O
ncbi-sent-17,role,NN,O
ncbi-sent-17,of,IN,O
ncbi-sent-17,DMPK,NNP,O
ncbi-sent-17,in,IN,O
ncbi-sent-17,cellular,JJ,O
ncbi-sent-17,ion,NN,O
ncbi-sent-17,homeostasis,NN,O
ncbi-sent-17,",",",",O
ncbi-sent-17,we,PRP,O
ncbi-sent-17,have,VBP,O
ncbi-sent-17,compared,VBN,O
ncbi-sent-17,the,DT,O
ncbi-sent-17,resting,VBG,O
ncbi-sent-17,[,NNP,O
ncbi-sent-17,Ca2,NNP,O
ncbi-sent-17,+,NNP,O
ncbi-sent-17,],NNP,O
ncbi-sent-17,i,NN,O
ncbi-sent-17,",",",",O
ncbi-sent-17,the,DT,O
ncbi-sent-17,amplitude,NN,O
ncbi-sent-17,and,CC,O
ncbi-sent-17,shape,NN,O
ncbi-sent-17,of,IN,O
ncbi-sent-17,depolarization,NN,O
ncbi-sent-17,-,:,O
ncbi-sent-17,induced,JJ,O
ncbi-sent-17,Ca2,NNP,O
ncbi-sent-17,+,NN,O
ncbi-sent-17,transients,NNS,O
ncbi-sent-17,",",",",O
ncbi-sent-17,and,CC,O
ncbi-sent-17,the,DT,O
ncbi-sent-17,content,NN,O
ncbi-sent-17,of,IN,O
ncbi-sent-17,ATP,NNP,O
ncbi-sent-17,-,:,O
ncbi-sent-17,driven,JJ,O
ncbi-sent-17,ion,NN,O
ncbi-sent-17,pumps,NNS,O
ncbi-sent-17,in,IN,O
ncbi-sent-17,cultured,JJ,O
ncbi-sent-17,skeletal,JJ,O
ncbi-sent-17,muscle,NN,O
ncbi-sent-17,cells,NNS,O
ncbi-sent-17,of,IN,O
ncbi-sent-17,wild,JJ,O
ncbi-sent-17,-,:,O
ncbi-sent-17,type,NN,O
ncbi-sent-17,and,CC,O
ncbi-sent-17,DMPK,NNP,O
ncbi-sent-17,[,NNP,O
ncbi-sent-17,-,:,O
ncbi-sent-17,/,SYM,O
ncbi-sent-17,-,:,O
ncbi-sent-17,],NN,O
ncbi-sent-17,knockout,NN,O
ncbi-sent-17,mice,NN,O
ncbi-sent-17,.,.,O
ncbi-sent-18,In,IN,O
ncbi-sent-18,vitro,JJ,O
ncbi-sent-18,-,:,O
ncbi-sent-18,differentiated,VBN,O
ncbi-sent-18,DMPK,NNP,O
ncbi-sent-18,[,NNP,O
ncbi-sent-18,-,:,O
ncbi-sent-18,/,SYM,O
ncbi-sent-18,-,:,O
ncbi-sent-18,],NN,O
ncbi-sent-18,myotubes,NNS,O
ncbi-sent-18,exhibit,VBP,O
ncbi-sent-18,a,DT,O
ncbi-sent-18,higher,JJR,O
ncbi-sent-18,resting,NN,O
ncbi-sent-18,[,JJ,O
ncbi-sent-18,Ca2,NNP,O
ncbi-sent-18,+,NNP,O
ncbi-sent-18,],NNP,O
ncbi-sent-18,i,NN,O
ncbi-sent-18,than,IN,O
ncbi-sent-18,do,VBP,O
ncbi-sent-18,wild,JJ,O
ncbi-sent-18,-,:,O
ncbi-sent-18,type,NN,O
ncbi-sent-18,myotubes,NNS,O
ncbi-sent-18,because,IN,O
ncbi-sent-18,of,IN,O
ncbi-sent-18,an,DT,O
ncbi-sent-18,altered,JJ,O
ncbi-sent-18,open,JJ,O
ncbi-sent-18,probability,NN,O
ncbi-sent-18,of,IN,O
ncbi-sent-18,voltage,NN,O
ncbi-sent-18,-,:,O
ncbi-sent-18,dependent,NN,O
ncbi-sent-18,l,NN,O
ncbi-sent-18,-,:,O
ncbi-sent-18,type,NN,O
ncbi-sent-18,Ca2,NNP,O
ncbi-sent-18,+,NNP,O
ncbi-sent-18,and,CC,O
ncbi-sent-18,Na,NNP,O
ncbi-sent-18,+,NNP,O
ncbi-sent-18,channels,NNS,O
ncbi-sent-18,.,.,O
ncbi-sent-19,The,DT,O
ncbi-sent-19,mutant,JJ,O
ncbi-sent-19,myotubes,NNS,O
ncbi-sent-19,exhibit,VBP,O
ncbi-sent-19,smaller,JJR,O
ncbi-sent-19,and,CC,O
ncbi-sent-19,slower,JJR,O
ncbi-sent-19,Ca2,NNP,O
ncbi-sent-19,+,NNP,O
ncbi-sent-19,responses,VBZ,O
ncbi-sent-19,upon,IN,O
ncbi-sent-19,triggering,VBG,O
ncbi-sent-19,by,IN,O
ncbi-sent-19,acetylcholine,NN,O
ncbi-sent-19,or,CC,O
ncbi-sent-19,high,JJ,O
ncbi-sent-19,external,JJ,O
ncbi-sent-19,K,NNP,O
ncbi-sent-19,+,NNP,O
ncbi-sent-19,.,.,O
ncbi-sent-20,In,IN,O
ncbi-sent-20,addition,NN,O
ncbi-sent-20,",",",",O
ncbi-sent-20,we,PRP,O
ncbi-sent-20,observed,VBD,O
ncbi-sent-20,that,IN,O
ncbi-sent-20,these,DT,O
ncbi-sent-20,Ca2,NNP,O
ncbi-sent-20,+,NN,O
ncbi-sent-20,transients,NNS,O
ncbi-sent-20,partially,RB,O
ncbi-sent-20,result,VBP,O
ncbi-sent-20,from,IN,O
ncbi-sent-20,an,DT,O
ncbi-sent-20,influx,NN,O
ncbi-sent-20,of,IN,O
ncbi-sent-20,extracellular,JJ,O
ncbi-sent-20,Ca2,NNP,O
ncbi-sent-20,+,NNP,O
ncbi-sent-20,through,IN,O
ncbi-sent-20,the,DT,O
ncbi-sent-20,l,NN,O
ncbi-sent-20,-,:,O
ncbi-sent-20,type,NN,O
ncbi-sent-20,Ca2,NNP,O
ncbi-sent-20,+,NNP,O
ncbi-sent-20,channel,NN,O
ncbi-sent-20,.,.,O
ncbi-sent-21,Neither,CC,O
ncbi-sent-21,the,DT,O
ncbi-sent-21,content,NN,O
ncbi-sent-21,nor,CC,O
ncbi-sent-21,the,DT,O
ncbi-sent-21,activity,NN,O
ncbi-sent-21,of,IN,O
ncbi-sent-21,Na,NNP,O
ncbi-sent-21,+,NNP,O
ncbi-sent-21,/,NNP,O
ncbi-sent-21,K,NNP,O
ncbi-sent-21,+,NNP,O
ncbi-sent-21,ATPase,NNP,O
ncbi-sent-21,and,CC,O
ncbi-sent-21,sarcoplasmic,JJ,O
ncbi-sent-21,reticulum,NN,O
ncbi-sent-21,Ca2,NNP,O
ncbi-sent-21,+,NNP,O
ncbi-sent-21,-,:,O
ncbi-sent-21,ATPase,NN,O
ncbi-sent-21,are,VBP,O
ncbi-sent-21,affected,VBN,O
ncbi-sent-21,by,IN,O
ncbi-sent-21,DMPK,NNP,O
ncbi-sent-21,absence,NN,O
ncbi-sent-21,.,.,O
ncbi-sent-22,In,IN,O
ncbi-sent-22,conclusion,NN,O
ncbi-sent-22,",",",",O
ncbi-sent-22,our,PRP$,O
ncbi-sent-22,data,NNS,O
ncbi-sent-22,suggest,VBP,O
ncbi-sent-22,that,IN,O
ncbi-sent-22,DMPK,NNP,O
ncbi-sent-22,is,VBZ,O
ncbi-sent-22,involved,VBN,O
ncbi-sent-22,in,IN,O
ncbi-sent-22,modulating,VBG,O
ncbi-sent-22,the,DT,O
ncbi-sent-22,initial,JJ,O
ncbi-sent-22,events,NNS,O
ncbi-sent-22,of,IN,O
ncbi-sent-22,excitation,NN,O
ncbi-sent-22,-,:,O
ncbi-sent-22,contraction,NN,O
ncbi-sent-22,coupling,NN,O
ncbi-sent-22,in,IN,O
ncbi-sent-22,skeletal,JJ,O
ncbi-sent-22,muscle,NN,O
ncbi-sent-22,.,.,O
ncbi-sent-23,.,.,O
ncbi-sent-24,Constitutional,JJ,O
ncbi-sent-24,RB1,NNP,O
ncbi-sent-24,-,:,O
ncbi-sent-24,gene,NN,O
ncbi-sent-24,mutations,NNS,O
ncbi-sent-24,in,IN,O
ncbi-sent-24,patients,NNS,O
ncbi-sent-24,with,IN,O
ncbi-sent-24,isolated,JJ,O
ncbi-sent-24,unilateral,JJ,B-DISEASE
ncbi-sent-24,retinoblastoma,NN,I-DISEASE
ncbi-sent-24,.,.,O
ncbi-sent-25,In,IN,O
ncbi-sent-25,most,JJS,O
ncbi-sent-25,patients,NNS,O
ncbi-sent-25,with,IN,O
ncbi-sent-25,isolated,JJ,O
ncbi-sent-25,unilateral,JJ,B-DISEASE
ncbi-sent-25,retinoblastoma,NN,I-DISEASE
ncbi-sent-25,",",",",O
ncbi-sent-25,tumor,NN,B-DISEASE
ncbi-sent-25,development,NN,O
ncbi-sent-25,is,VBZ,O
ncbi-sent-25,initiated,VBN,O
ncbi-sent-25,by,IN,O
ncbi-sent-25,somatic,JJ,O
ncbi-sent-25,inactivation,NN,O
ncbi-sent-25,of,IN,O
ncbi-sent-25,both,DT,O
ncbi-sent-25,alleles,NNS,O
ncbi-sent-25,of,IN,O
ncbi-sent-25,the,DT,O
ncbi-sent-25,RB1,NNP,O
ncbi-sent-25,gene,NN,O
ncbi-sent-25,.,.,O
ncbi-sent-26,However,RB,O
ncbi-sent-26,",",",",O
ncbi-sent-26,some,DT,O
ncbi-sent-26,of,IN,O
ncbi-sent-26,these,DT,O
ncbi-sent-26,patients,NNS,O
ncbi-sent-26,can,MD,O
ncbi-sent-26,transmit,VB,O
ncbi-sent-26,retinoblastoma,VB,B-DISEASE
ncbi-sent-26,predisposition,NN,O
ncbi-sent-26,to,TO,O
ncbi-sent-26,their,PRP$,O
ncbi-sent-26,offspring,NN,O
ncbi-sent-26,.,.,O
ncbi-sent-27,To,TO,O
ncbi-sent-27,determine,VB,O
ncbi-sent-27,the,DT,O
ncbi-sent-27,frequency,NN,O
ncbi-sent-27,and,CC,O
ncbi-sent-27,nature,NN,O
ncbi-sent-27,of,IN,O
ncbi-sent-27,constitutional,JJ,O
ncbi-sent-27,RB1,NNP,O
ncbi-sent-27,-,:,O
ncbi-sent-27,gene,NN,O
ncbi-sent-27,mutations,NNS,O
ncbi-sent-27,in,IN,O
ncbi-sent-27,patients,NNS,O
ncbi-sent-27,with,IN,O
ncbi-sent-27,isolated,JJ,O
ncbi-sent-27,unilateral,JJ,B-DISEASE
ncbi-sent-27,retinoblastoma,NN,I-DISEASE
ncbi-sent-27,",",",",O
ncbi-sent-27,we,PRP,O
ncbi-sent-27,analyzed,VBD,O
ncbi-sent-27,DNA,NN,O
ncbi-sent-27,from,IN,O
ncbi-sent-27,peripheral,JJ,O
ncbi-sent-27,blood,NN,O
ncbi-sent-27,and,CC,O
ncbi-sent-27,from,IN,O
ncbi-sent-27,tumor,NN,B-DISEASE
ncbi-sent-27,tissue,NN,O
ncbi-sent-27,.,.,O
ncbi-sent-28,The,DT,O
ncbi-sent-28,analysis,NN,O
ncbi-sent-28,of,IN,O
ncbi-sent-28,tumors,NNS,B-DISEASE
ncbi-sent-28,from,IN,O
ncbi-sent-28,54,CD,O
ncbi-sent-28,(,(,O
ncbi-sent-28,71,CD,O
ncbi-sent-28,%,NN,O
ncbi-sent-28,),),O
ncbi-sent-28,of,IN,O
ncbi-sent-28,76,CD,O
ncbi-sent-28,informative,JJ,O
ncbi-sent-28,patients,NNS,O
ncbi-sent-28,showed,VBD,O
ncbi-sent-28,loss,NN,O
ncbi-sent-28,of,IN,O
ncbi-sent-28,constitutional,JJ,O
ncbi-sent-28,heterozygosity,NN,O
ncbi-sent-28,(,(,O
ncbi-sent-28,LOH,NNP,O
ncbi-sent-28,),),O
ncbi-sent-28,at,IN,O
ncbi-sent-28,intragenic,JJ,O
ncbi-sent-28,loci,NN,O
ncbi-sent-28,.,.,O
ncbi-sent-29,Three,CD,O
ncbi-sent-29,of,IN,O
ncbi-sent-29,13,CD,O
ncbi-sent-29,uninformative,JJ,O
ncbi-sent-29,patients,NNS,O
ncbi-sent-29,had,VBD,O
ncbi-sent-29,constitutional,JJ,O
ncbi-sent-29,deletions,NNS,O
ncbi-sent-29,.,.,O
ncbi-sent-30,For,IN,O
ncbi-sent-30,39,CD,O
ncbi-sent-30,randomly,RB,O
ncbi-sent-30,selected,VBN,O
ncbi-sent-30,tumors,NNS,B-DISEASE
ncbi-sent-30,",",",",O
ncbi-sent-30,SSCP,NNP,O
ncbi-sent-30,",",",",O
ncbi-sent-30,hetero,SYM,O
ncbi-sent-30,-,:,O
ncbi-sent-30,duplex,JJ,O
ncbi-sent-30,analysis,NN,O
ncbi-sent-30,",",",",O
ncbi-sent-30,sequencing,NN,O
ncbi-sent-30,",",",",O
ncbi-sent-30,and,CC,O
ncbi-sent-30,Southern,NNP,O
ncbi-sent-30,blot,NN,O
ncbi-sent-30,analysis,NN,O
ncbi-sent-30,were,VBD,O
ncbi-sent-30,used,VBN,O
ncbi-sent-30,to,TO,O
ncbi-sent-30,identify,VB,O
ncbi-sent-30,mutations,NNS,O
ncbi-sent-30,.,.,O
ncbi-sent-31,Mutations,NNS,O
ncbi-sent-31,were,VBD,O
ncbi-sent-31,detected,VBN,O
ncbi-sent-31,in,IN,O
ncbi-sent-31,21,CD,O
ncbi-sent-31,(,(,O
ncbi-sent-31,91,CD,O
ncbi-sent-31,%,NN,O
ncbi-sent-31,),),O
ncbi-sent-31,of,IN,O
ncbi-sent-31,23,CD,O
ncbi-sent-31,tumors,NNS,B-DISEASE
ncbi-sent-31,with,IN,O
ncbi-sent-31,LOH,NNP,O
ncbi-sent-31,.,.,O
ncbi-sent-32,In,IN,O
ncbi-sent-32,6,CD,O
ncbi-sent-32,(,(,O
ncbi-sent-32,38,CD,O
ncbi-sent-32,%,NN,O
ncbi-sent-32,),),O
ncbi-sent-32,of,IN,O
ncbi-sent-32,16,CD,O
ncbi-sent-32,tumors,NNS,B-DISEASE
ncbi-sent-32,without,IN,O
ncbi-sent-32,LOH,NNP,O
ncbi-sent-32,",",",",O
ncbi-sent-32,one,CD,O
ncbi-sent-32,mutation,NN,O
ncbi-sent-32,was,VBD,O
ncbi-sent-32,detected,VBN,O
ncbi-sent-32,",",",",O
ncbi-sent-32,and,CC,O
ncbi-sent-32,in,IN,O
ncbi-sent-32,9,CD,O
ncbi-sent-32,(,(,O
ncbi-sent-32,56,CD,O
ncbi-sent-32,%,NN,O
ncbi-sent-32,),),O
ncbi-sent-32,of,IN,O
ncbi-sent-32,the,DT,O
ncbi-sent-32,tumors,NNS,B-DISEASE
ncbi-sent-32,without,IN,O
ncbi-sent-32,LOH,NNP,O
ncbi-sent-32,",",",",O
ncbi-sent-32,both,DT,O
ncbi-sent-32,mutations,NNS,O
ncbi-sent-32,were,VBD,O
ncbi-sent-32,found,VBN,O
ncbi-sent-32,.,.,O
ncbi-sent-33,Thus,RB,O
ncbi-sent-33,",",",",O
ncbi-sent-33,a,DT,O
ncbi-sent-33,total,NN,O
ncbi-sent-33,of,IN,O
ncbi-sent-33,45,CD,O
ncbi-sent-33,mutations,NNS,O
ncbi-sent-33,were,VBD,O
ncbi-sent-33,identified,VBN,O
ncbi-sent-33,in,IN,O
ncbi-sent-33,tumors,NNS,B-DISEASE
ncbi-sent-33,of,IN,O
ncbi-sent-33,36,CD,O
ncbi-sent-33,patients,NNS,O
ncbi-sent-33,.,.,O
ncbi-sent-34,Thirty,NNP,O
ncbi-sent-34,-,:,O
ncbi-sent-34,nine,CD,O
ncbi-sent-34,of,IN,O
ncbi-sent-34,the,DT,O
ncbi-sent-34,mutations,NNS,O
ncbi-sent-34,-,:,O
ncbi-sent-34,including,VBG,O
ncbi-sent-34,34,CD,O
ncbi-sent-34,small,JJ,O
ncbi-sent-34,mutations,NNS,O
ncbi-sent-34,",",",",O
ncbi-sent-34,2,CD,O
ncbi-sent-34,large,JJ,O
ncbi-sent-34,structural,JJ,O
ncbi-sent-34,alterations,NNS,O
ncbi-sent-34,",",",",O
ncbi-sent-34,and,CC,O
ncbi-sent-34,hypermethylation,NN,O
ncbi-sent-34,in,IN,O
ncbi-sent-34,3,CD,O
ncbi-sent-34,tumors,NNS,O
ncbi-sent-34,-,:,O
ncbi-sent-34,were,VBD,O
ncbi-sent-34,not,RB,O
ncbi-sent-34,detected,VBN,O
ncbi-sent-34,in,IN,O
ncbi-sent-34,the,DT,O
ncbi-sent-34,corresponding,JJ,O
ncbi-sent-34,peripheral,JJ,O
ncbi-sent-34,blood,NN,O
ncbi-sent-34,DNA,NN,O
ncbi-sent-34,.,.,O
ncbi-sent-35,In,IN,O
ncbi-sent-35,6,CD,O
ncbi-sent-35,(,(,O
ncbi-sent-35,17,CD,O
ncbi-sent-35,%,NN,O
ncbi-sent-35,),),O
ncbi-sent-35,of,IN,O
ncbi-sent-35,the,DT,O
ncbi-sent-35,36,CD,O
ncbi-sent-35,patients,NNS,O
ncbi-sent-35,",",",",O
ncbi-sent-35,a,DT,O
ncbi-sent-35,mutation,NN,O
ncbi-sent-35,was,VBD,O
ncbi-sent-35,detected,VBN,O
ncbi-sent-35,in,IN,O
ncbi-sent-35,constitutional,JJ,O
ncbi-sent-35,DNA,NNP,O
ncbi-sent-35,",",",",O
ncbi-sent-35,and,CC,O
ncbi-sent-35,1,CD,O
ncbi-sent-35,of,IN,O
ncbi-sent-35,these,DT,O
ncbi-sent-35,mutations,NNS,O
ncbi-sent-35,is,VBZ,O
ncbi-sent-35,known,VBN,O
ncbi-sent-35,to,TO,O
ncbi-sent-35,be,VB,O
ncbi-sent-35,associated,VBN,O
ncbi-sent-35,with,IN,O
ncbi-sent-35,reduced,JJ,O
ncbi-sent-35,expressivity,NN,O
ncbi-sent-35,.,.,O
ncbi-sent-36,The,DT,O
ncbi-sent-36,presence,NN,O
ncbi-sent-36,of,IN,O
ncbi-sent-36,a,DT,O
ncbi-sent-36,constitutional,JJ,O
ncbi-sent-36,mutation,NN,O
ncbi-sent-36,was,VBD,O
ncbi-sent-36,not,RB,O
ncbi-sent-36,associated,VBN,O
ncbi-sent-36,with,IN,O
ncbi-sent-36,an,DT,O
ncbi-sent-36,early,JJ,O
ncbi-sent-36,age,NN,O
ncbi-sent-36,at,IN,O
ncbi-sent-36,treatment,NN,O
ncbi-sent-36,.,.,O
ncbi-sent-37,In,IN,O
ncbi-sent-37,1,CD,O
ncbi-sent-37,patient,NN,O
ncbi-sent-37,",",",",O
ncbi-sent-37,somatic,JJ,O
ncbi-sent-37,mosaicism,NN,O
ncbi-sent-37,was,VBD,O
ncbi-sent-37,demonstrated,VBN,O
ncbi-sent-37,by,IN,O
ncbi-sent-37,molecular,JJ,O
ncbi-sent-37,analysis,NN,O
ncbi-sent-37,of,IN,O
ncbi-sent-37,DNA,NNP,O
ncbi-sent-37,and,CC,O
ncbi-sent-37,RNA,NNP,O
ncbi-sent-37,from,IN,O
ncbi-sent-37,peripheral,JJ,O
ncbi-sent-37,blood,NN,O
ncbi-sent-37,.,.,O
ncbi-sent-38,In,IN,O
ncbi-sent-38,2,CD,O
ncbi-sent-38,patients,NNS,O
ncbi-sent-38,without,IN,O
ncbi-sent-38,a,DT,O
ncbi-sent-38,detectable,JJ,O
ncbi-sent-38,mutation,NN,O
ncbi-sent-38,in,IN,O
ncbi-sent-38,peripheral,JJ,O
ncbi-sent-38,blood,NN,O
ncbi-sent-38,",",",",O
ncbi-sent-38,mosaicism,NN,O
ncbi-sent-38,was,VBD,O
ncbi-sent-38,suggested,VBN,O
ncbi-sent-38,because,IN,O
ncbi-sent-38,1,CD,O
ncbi-sent-38,of,IN,O
ncbi-sent-38,the,DT,O
ncbi-sent-38,patients,NNS,O
ncbi-sent-38,showed,VBD,O
ncbi-sent-38,multifocal,JJ,O
ncbi-sent-38,tumors,NNS,B-DISEASE
ncbi-sent-38,and,CC,O
ncbi-sent-38,the,DT,O
ncbi-sent-38,other,JJ,O
ncbi-sent-38,later,RB,O
ncbi-sent-38,developed,VBN,O
ncbi-sent-38,bilateral,JJ,B-DISEASE
ncbi-sent-38,retinoblastoma,NN,I-DISEASE
ncbi-sent-38,.,.,O
ncbi-sent-39,In,IN,O
ncbi-sent-39,conclusion,NN,O
ncbi-sent-39,",",",",O
ncbi-sent-39,our,PRP$,O
ncbi-sent-39,results,NNS,O
ncbi-sent-39,emphasize,VB,O
ncbi-sent-39,that,IN,O
ncbi-sent-39,the,DT,O
ncbi-sent-39,manifestation,NN,O
ncbi-sent-39,and,CC,O
ncbi-sent-39,transmissibility,NN,O
ncbi-sent-39,of,IN,O
ncbi-sent-39,retinoblastoma,NN,B-DISEASE
ncbi-sent-39,depend,NN,O
ncbi-sent-39,on,IN,O
ncbi-sent-39,the,DT,O
ncbi-sent-39,nature,NN,O
ncbi-sent-39,of,IN,O
ncbi-sent-39,the,DT,O
ncbi-sent-39,first,JJ,O
ncbi-sent-39,mutation,NN,O
ncbi-sent-39,",",",",O
ncbi-sent-39,its,PRP$,O
ncbi-sent-39,time,NN,O
ncbi-sent-39,in,IN,O
ncbi-sent-39,development,NN,O
ncbi-sent-39,",",",",O
ncbi-sent-39,and,CC,O
ncbi-sent-39,the,DT,O
ncbi-sent-39,number,NN,O
ncbi-sent-39,and,CC,O
ncbi-sent-39,types,NNS,O
ncbi-sent-39,of,IN,O
ncbi-sent-39,cells,NNS,O
ncbi-sent-39,that,WDT,O
ncbi-sent-39,are,VBP,O
ncbi-sent-39,affected,VBN,O
ncbi-sent-39,.,.,O
ncbi-sent-40,.,.,O
ncbi-sent-41,Hereditary,JJ,B-DISEASE
ncbi-sent-41,deficiency,NN,I-DISEASE
ncbi-sent-41,of,IN,I-DISEASE
ncbi-sent-41,the,DT,I-DISEASE
ncbi-sent-41,fifth,JJ,I-DISEASE
ncbi-sent-41,component,NN,I-DISEASE
ncbi-sent-41,of,IN,I-DISEASE
ncbi-sent-41,complement,NN,I-DISEASE
ncbi-sent-41,in,IN,O
ncbi-sent-41,man,NN,O
ncbi-sent-41,.,.,O
ncbi-sent-42,I,PRP,O
ncbi-sent-42,.,.,O
ncbi-sent-43,Clinical,JJ,O
ncbi-sent-43,",",",",O
ncbi-sent-43,immunochemical,JJ,O
ncbi-sent-43,",",",",O
ncbi-sent-43,and,CC,O
ncbi-sent-43,family,NN,O
ncbi-sent-43,studies,NNS,O
ncbi-sent-43,.,.,O
ncbi-sent-44,The,DT,O
ncbi-sent-44,first,JJ,O
ncbi-sent-44,recognized,VBN,O
ncbi-sent-44,human,JJ,O
ncbi-sent-44,kindred,VBN,O
ncbi-sent-44,with,IN,O
ncbi-sent-44,hereditary,JJ,B-DISEASE
ncbi-sent-44,deficiency,NN,I-DISEASE
ncbi-sent-44,of,IN,I-DISEASE
ncbi-sent-44,the,DT,I-DISEASE
ncbi-sent-44,fifth,JJ,I-DISEASE
ncbi-sent-44,component,NN,I-DISEASE
ncbi-sent-44,of,IN,I-DISEASE
ncbi-sent-44,complement,NN,I-DISEASE
ncbi-sent-44,(,(,O
ncbi-sent-44,C5,NNP,O
ncbi-sent-44,),),O
ncbi-sent-44,is,VBZ,O
ncbi-sent-44,described,VBN,O
ncbi-sent-44,.,.,O
ncbi-sent-45,The,DT,O
ncbi-sent-45,proband,NN,O
ncbi-sent-45,",",",",O
ncbi-sent-45,a,DT,O
ncbi-sent-45,20,CD,O
ncbi-sent-45,-,:,O
ncbi-sent-45,year,NN,O
ncbi-sent-45,-,:,O
ncbi-sent-45,old,JJ,O
ncbi-sent-45,black,JJ,O
ncbi-sent-45,female,NN,O
ncbi-sent-45,with,IN,O
ncbi-sent-45,systemic,JJ,B-DISEASE
ncbi-sent-45,lupus,NN,I-DISEASE
ncbi-sent-45,erythematosus,NN,I-DISEASE
ncbi-sent-45,since,IN,O
ncbi-sent-45,age,NN,O
ncbi-sent-45,11,CD,O
ncbi-sent-45,",",",",O
ncbi-sent-45,lacked,VBD,O
ncbi-sent-45,serum,JJ,O
ncbi-sent-45,hemolytic,JJ,O
ncbi-sent-45,complement,NN,O
ncbi-sent-45,activity,NN,O
ncbi-sent-45,",",",",O
ncbi-sent-45,even,RB,O
ncbi-sent-45,during,IN,O
ncbi-sent-45,remission,NN,O
ncbi-sent-45,.,.,O
ncbi-sent-46,C5,NNP,O
ncbi-sent-46,was,VBD,O
ncbi-sent-46,undetectable,JJ,O
ncbi-sent-46,in,IN,O
ncbi-sent-46,her,PRP$,O
ncbi-sent-46,serum,NN,O
ncbi-sent-46,by,IN,O
ncbi-sent-46,both,DT,O
ncbi-sent-46,immunodiffusion,NN,O
ncbi-sent-46,and,CC,O
ncbi-sent-46,hemolytic,JJ,O
ncbi-sent-46,assays,NNS,O
ncbi-sent-46,.,.,O
ncbi-sent-47,Other,JJ,O
ncbi-sent-47,complement,JJ,O
ncbi-sent-47,components,NNS,O
ncbi-sent-47,were,VBD,O
ncbi-sent-47,normal,JJ,O
ncbi-sent-47,during,IN,O
ncbi-sent-47,remission,NN,O
ncbi-sent-47,of,IN,O
ncbi-sent-47,lupus,NN,O
ncbi-sent-47,",",",",O
ncbi-sent-47,but,CC,O
ncbi-sent-47,C1,NNP,O
ncbi-sent-47,",",",",O
ncbi-sent-47,C4,NNP,O
ncbi-sent-47,",",",",O
ncbi-sent-47,C2,NNP,O
ncbi-sent-47,",",",",O
ncbi-sent-47,and,CC,O
ncbi-sent-47,C3,NNP,O
ncbi-sent-47,levels,NNS,O
ncbi-sent-47,fell,VBD,O
ncbi-sent-47,during,IN,O
ncbi-sent-47,exacerbations,NNS,O
ncbi-sent-47,.,.,O
ncbi-sent-48,A,NNP,O
ncbi-sent-48,younger,JJR,O
ncbi-sent-48,half,NN,O
ncbi-sent-48,-,:,O
ncbi-sent-48,sister,NN,O
ncbi-sent-48,",",",",O
ncbi-sent-48,who,WP,O
ncbi-sent-48,had,VBD,O
ncbi-sent-48,no,DT,O
ncbi-sent-48,underlying,JJ,O
ncbi-sent-48,disease,NN,O
ncbi-sent-48,",",",",O
ncbi-sent-48,was,VBD,O
ncbi-sent-48,also,RB,O
ncbi-sent-48,found,VBN,O
ncbi-sent-48,to,TO,O
ncbi-sent-48,lack,VB,O
ncbi-sent-48,immunochemically,RB,O
ncbi-sent-48,detectable,JJ,O
ncbi-sent-48,C5,NNP,O
ncbi-sent-48,.,.,O
ncbi-sent-49,By,IN,O
ncbi-sent-49,hemolytic,JJ,O
ncbi-sent-49,assay,NN,O
ncbi-sent-49,",",",",O
ncbi-sent-49,she,PRP,O
ncbi-sent-49,exhibited,VBD,O
ncbi-sent-49,1,CD,O
ncbi-sent-49,-,:,O
ncbi-sent-49,2,CD,O
ncbi-sent-49,%,NN,O
ncbi-sent-49,of,IN,O
ncbi-sent-49,the,DT,O
ncbi-sent-49,normal,JJ,O
ncbi-sent-49,serum,NN,O
ncbi-sent-49,C5,NNP,O
ncbi-sent-49,level,NN,O
ncbi-sent-49,and,CC,O
ncbi-sent-49,normal,JJ,O
ncbi-sent-49,concentrations,NNS,O
ncbi-sent-49,of,IN,O
ncbi-sent-49,other,JJ,O
ncbi-sent-49,complement,JJ,O
ncbi-sent-49,components,NNS,O
ncbi-sent-49,.,.,O
ncbi-sent-50,C5,NNP,O
ncbi-sent-50,levels,NNS,O
ncbi-sent-50,of,IN,O
ncbi-sent-50,other,JJ,O
ncbi-sent-50,family,NN,O
ncbi-sent-50,members,NNS,O
ncbi-sent-50,were,VBD,O
ncbi-sent-50,either,RB,O
ncbi-sent-50,normal,JJ,O
ncbi-sent-50,or,CC,O
ncbi-sent-50,approximately,RB,O
ncbi-sent-50,half,JJ,O
ncbi-sent-50,-,:,O
ncbi-sent-50,normal,JJ,O
ncbi-sent-50,",",",",O
ncbi-sent-50,consistent,JJ,O
ncbi-sent-50,with,IN,O
ncbi-sent-50,autosomal,JJ,O
ncbi-sent-50,codominant,JJ,O
ncbi-sent-50,inheritance,NN,O
ncbi-sent-50,of,IN,O
ncbi-sent-50,the,DT,O
ncbi-sent-50,gene,NN,O
ncbi-sent-50,determining,VBG,O
ncbi-sent-50,C5,NNP,B-DISEASE
ncbi-sent-50,deficiency,NN,I-DISEASE
ncbi-sent-50,.,.,O
ncbi-sent-51,Normal,NNP,O
ncbi-sent-51,hemolytic,JJ,O
ncbi-sent-51,titers,NNS,O
ncbi-sent-51,were,VBD,O
ncbi-sent-51,restored,VBN,O
ncbi-sent-51,to,TO,O
ncbi-sent-51,both,DT,O
ncbi-sent-51,homozygous,JJ,O
ncbi-sent-51,C5,NNP,B-DISEASE
ncbi-sent-51,-,:,I-DISEASE
ncbi-sent-51,deficient,NN,I-DISEASE
ncbi-sent-51,(,(,O
ncbi-sent-51,C5D,NNP,B-DISEASE
ncbi-sent-51,),),O
ncbi-sent-51,sera,NN,O
ncbi-sent-51,by,IN,O
ncbi-sent-51,addition,NN,O
ncbi-sent-51,of,IN,O
ncbi-sent-51,highly,RB,O
ncbi-sent-51,purified,VBN,O
ncbi-sent-51,human,JJ,O
ncbi-sent-51,C5,NNP,O
ncbi-sent-51,.,.,O
ncbi-sent-52,In,IN,O
ncbi-sent-52,specific,JJ,O
ncbi-sent-52,C5,NNP,O
ncbi-sent-52,titrations,NNS,O
ncbi-sent-52,",",",",O
ncbi-sent-52,however,RB,O
ncbi-sent-52,",",",",O
ncbi-sent-52,it,PRP,O
ncbi-sent-52,was,VBD,O
ncbi-sent-52,noted,VBN,O
ncbi-sent-52,that,IN,O
ncbi-sent-52,when,WRB,O
ncbi-sent-52,limited,JJ,O
ncbi-sent-52,amounts,NNS,O
ncbi-sent-52,of,IN,O
ncbi-sent-52,C5,NNP,O
ncbi-sent-52,were,VBD,O
ncbi-sent-52,assayed,VBN,O
ncbi-sent-52,in,IN,O
ncbi-sent-52,the,DT,O
ncbi-sent-52,presence,NN,O
ncbi-sent-52,of,IN,O
ncbi-sent-52,low,JJ,O
ncbi-sent-52,dilutions,NNS,O
ncbi-sent-52,of,IN,O
ncbi-sent-52,either,DT,O
ncbi-sent-52,C5D,NNP,B-DISEASE
ncbi-sent-52,serum,NN,O
ncbi-sent-52,",",",",O
ncbi-sent-52,curving,VBG,O
ncbi-sent-52,rather,RB,O
ncbi-sent-52,than,IN,O
ncbi-sent-52,linear,VB,O
ncbi-sent-52,dose,JJ,O
ncbi-sent-52,-,:,O
ncbi-sent-52,response,NN,O
ncbi-sent-52,plots,NNS,O
ncbi-sent-52,were,VBD,O
ncbi-sent-52,consistently,RB,O
ncbi-sent-52,obtained,VBN,O
ncbi-sent-52,",",",",O
ncbi-sent-52,suggesting,VBG,O
ncbi-sent-52,some,DT,O
ncbi-sent-52,inhibitory,JJ,O
ncbi-sent-52,effect,NN,O
ncbi-sent-52,.,.,O
ncbi-sent-53,Further,JJ,O
ncbi-sent-53,studies,NNS,O
ncbi-sent-53,suggested,VBD,O
ncbi-sent-53,that,IN,O
ncbi-sent-53,low,JJ,O
ncbi-sent-53,dilutions,NNS,O
ncbi-sent-53,of,IN,O
ncbi-sent-53,C5D,NNP,B-DISEASE
ncbi-sent-53,serum,NN,O
ncbi-sent-53,contain,NN,O
ncbi-sent-53,a,DT,O
ncbi-sent-53,factor,NN,O
ncbi-sent-53,(,(,O
ncbi-sent-53,or,CC,O
ncbi-sent-53,factors,NNS,O
ncbi-sent-53,),),O
ncbi-sent-53,interfering,VBG,O
ncbi-sent-53,at,IN,O
ncbi-sent-53,some,DT,O
ncbi-sent-53,step,NN,O
ncbi-sent-53,in,IN,O
ncbi-sent-53,the,DT,O
ncbi-sent-53,hemolytic,JJ,O
ncbi-sent-53,assay,NN,O
ncbi-sent-53,of,IN,O
ncbi-sent-53,C5,NNP,O
ncbi-sent-53,",",",",O
ncbi-sent-53,rather,RB,O
ncbi-sent-53,than,IN,O
ncbi-sent-53,a,DT,O
ncbi-sent-53,true,JJ,O
ncbi-sent-53,C5,NNP,O
ncbi-sent-53,inhibitor,NN,O
ncbi-sent-53,or,CC,O
ncbi-sent-53,inactivator,NN,O
ncbi-sent-53,.,.,O
ncbi-sent-54,Of,IN,O
ncbi-sent-54,clinical,JJ,O
ncbi-sent-54,interest,NN,O
ncbi-sent-54,are,VBP,O
ncbi-sent-54,(,(,O
ncbi-sent-54,a,DT,O
ncbi-sent-54,),),O
ncbi-sent-54,the,DT,O
ncbi-sent-54,documentation,NN,O
ncbi-sent-54,of,IN,O
ncbi-sent-54,membranous,JJ,O
ncbi-sent-54,glomerulonephritis,NN,B-DISEASE
ncbi-sent-54,",",",",O
ncbi-sent-54,vasculitis,NN,B-DISEASE
ncbi-sent-54,",",",",O
ncbi-sent-54,and,CC,O
ncbi-sent-54,arthritis,NN,B-DISEASE
ncbi-sent-54,in,IN,O
ncbi-sent-54,an,DT,O
ncbi-sent-54,individual,JJ,O
ncbi-sent-54,lacking,NN,O
ncbi-sent-54,C5,NNP,O
ncbi-sent-54,(,(,O
ncbi-sent-54,and,CC,O
ncbi-sent-54,its,PRP$,O
ncbi-sent-54,biologic,JJ,O
ncbi-sent-54,functions,NNS,O
ncbi-sent-54,),),O
ncbi-sent-54,",",",",O
ncbi-sent-54,and,CC,O
ncbi-sent-54,(,(,O
ncbi-sent-54,b,NN,O
ncbi-sent-54,),),O
ncbi-sent-54,a,DT,O
ncbi-sent-54,remarkable,JJ,O
ncbi-sent-54,propensity,NN,O
ncbi-sent-54,to,TO,O
ncbi-sent-54,bacterial,JJ,B-DISEASE
ncbi-sent-54,infections,NNS,I-DISEASE
ncbi-sent-54,in,IN,O
ncbi-sent-54,the,DT,O
ncbi-sent-54,proband,NN,O
ncbi-sent-54,",",",",O
ncbi-sent-54,even,RB,O
ncbi-sent-54,during,IN,O
ncbi-sent-54,periods,NNS,O
ncbi-sent-54,of,IN,O
ncbi-sent-54,low,JJ,O
ncbi-sent-54,-,:,O
ncbi-sent-54,dose,NN,O
ncbi-sent-54,or,CC,O
ncbi-sent-54,alternate,JJ,O
ncbi-sent-54,-,:,O
ncbi-sent-54,day,NN,O
ncbi-sent-54,corticosteroid,JJ,O
ncbi-sent-54,therapy,NN,O
ncbi-sent-54,.,.,O
ncbi-sent-55,Other,JJ,O
ncbi-sent-55,observations,NNS,O
ncbi-sent-55,indicate,VBP,O
ncbi-sent-55,that,IN,O
ncbi-sent-55,the,DT,O
ncbi-sent-55,C5D,NNP,B-DISEASE
ncbi-sent-55,state,NN,O
ncbi-sent-55,is,VBZ,O
ncbi-sent-55,compatible,JJ,O
ncbi-sent-55,with,IN,O
ncbi-sent-55,normal,JJ,O
ncbi-sent-55,coagulation,NN,O
ncbi-sent-55,function,NN,O
ncbi-sent-55,and,CC,O
ncbi-sent-55,the,DT,O
ncbi-sent-55,capacity,NN,O
ncbi-sent-55,to,TO,O
ncbi-sent-55,mount,VB,O
ncbi-sent-55,a,DT,O
ncbi-sent-55,neutrophilic,JJ,O
ncbi-sent-55,leukocytosis,NN,O
ncbi-sent-55,during,IN,O
ncbi-sent-55,pyogenic,JJ,B-DISEASE
ncbi-sent-55,infection,NN,I-DISEASE
ncbi-sent-55,.,.,O
ncbi-sent-56,.,.,O
ncbi-sent-57,Susceptibility,NN,O
ncbi-sent-57,to,TO,O
ncbi-sent-57,ankylosing,VBG,B-DISEASE
ncbi-sent-57,spondylitis,NN,I-DISEASE
ncbi-sent-57,in,IN,O
ncbi-sent-57,twins,NNS,O
ncbi-sent-57,:,:,O
ncbi-sent-57,the,DT,O
ncbi-sent-57,role,NN,O
ncbi-sent-57,of,IN,O
ncbi-sent-57,genes,NNS,O
ncbi-sent-57,",",",",O
ncbi-sent-57,HLA,NNP,O
ncbi-sent-57,",",",",O
ncbi-sent-57,and,CC,O
ncbi-sent-57,the,DT,O
ncbi-sent-57,environment,NN,O
ncbi-sent-57,.,.,O
ncbi-sent-58,OBJECTIVE,UH,O
ncbi-sent-58,To,TO,O
ncbi-sent-58,determine,VB,O
ncbi-sent-58,the,DT,O
ncbi-sent-58,relative,JJ,O
ncbi-sent-58,effects,NNS,O
ncbi-sent-58,of,IN,O
ncbi-sent-58,genetic,JJ,O
ncbi-sent-58,and,CC,O
ncbi-sent-58,environmental,JJ,O
ncbi-sent-58,factors,NNS,O
ncbi-sent-58,in,IN,O
ncbi-sent-58,susceptibility,NN,O
ncbi-sent-58,to,TO,O
ncbi-sent-58,ankylosing,VBG,B-DISEASE
ncbi-sent-58,spondylitis,NN,I-DISEASE
ncbi-sent-58,(,(,O
ncbi-sent-58,AS,IN,B-DISEASE
ncbi-sent-58,),),O
ncbi-sent-58,.,.,O
ncbi-sent-59,METHODS,NNP,O
ncbi-sent-59,Twins,VBZ,O
ncbi-sent-59,with,IN,O
ncbi-sent-59,AS,NNP,B-DISEASE
ncbi-sent-59,were,VBD,O
ncbi-sent-59,identified,VBN,O
ncbi-sent-59,from,IN,O
ncbi-sent-59,the,DT,O
ncbi-sent-59,Royal,NNP,O
ncbi-sent-59,National,NNP,O
ncbi-sent-59,Hospital,NNP,O
ncbi-sent-59,for,IN,O
ncbi-sent-59,Rheumatic,NNP,B-DISEASE
ncbi-sent-59,Diseases,NNP,I-DISEASE
ncbi-sent-59,database,NN,O
ncbi-sent-59,.,.,O
ncbi-sent-60,Clinical,JJ,O
ncbi-sent-60,and,CC,O
ncbi-sent-60,radiographic,JJ,O
ncbi-sent-60,examinations,NNS,O
ncbi-sent-60,were,VBD,O
ncbi-sent-60,performed,VBN,O
ncbi-sent-60,to,TO,O
ncbi-sent-60,establish,VB,O
ncbi-sent-60,diagnoses,NNS,O
ncbi-sent-60,",",",",O
ncbi-sent-60,and,CC,O
ncbi-sent-60,disease,NN,O
ncbi-sent-60,severity,NN,O
ncbi-sent-60,was,VBD,O
ncbi-sent-60,assessed,VBN,O
ncbi-sent-60,using,VBG,O
ncbi-sent-60,a,DT,O
ncbi-sent-60,combination,NN,O
ncbi-sent-60,of,IN,O
ncbi-sent-60,validated,JJ,O
ncbi-sent-60,scoring,VBG,O
ncbi-sent-60,systems,NNS,O
ncbi-sent-60,.,.,O
ncbi-sent-61,HLA,NNP,O
ncbi-sent-61,typing,VBG,O
ncbi-sent-61,for,IN,O
ncbi-sent-61,HLA,NNP,O
ncbi-sent-61,-,:,O
ncbi-sent-61,B27,NNP,O
ncbi-sent-61,",",",",O
ncbi-sent-61,HLA,NNP,O
ncbi-sent-61,-,:,O
ncbi-sent-61,B60,NNP,O
ncbi-sent-61,",",",",O
ncbi-sent-61,and,CC,O
ncbi-sent-61,HLA,NNP,O
ncbi-sent-61,-,:,O
ncbi-sent-61,DR1,NN,O
ncbi-sent-61,was,VBD,O
ncbi-sent-61,performed,VBN,O
ncbi-sent-61,by,IN,O
ncbi-sent-61,polymerase,NN,O
ncbi-sent-61,chain,NN,O
ncbi-sent-61,reaction,NN,O
ncbi-sent-61,with,IN,O
ncbi-sent-61,sequence,NN,O
ncbi-sent-61,-,:,O
ncbi-sent-61,specific,JJ,O
ncbi-sent-61,primers,NNS,O
ncbi-sent-61,",",",",O
ncbi-sent-61,and,CC,O
ncbi-sent-61,zygosity,NN,O
ncbi-sent-61,was,VBD,O
ncbi-sent-61,assessed,VBN,O
ncbi-sent-61,using,VBG,O
ncbi-sent-61,microsatellite,JJ,O
ncbi-sent-61,markers,NNS,O
ncbi-sent-61,.,.,O
ncbi-sent-62,Genetic,NNP,O
ncbi-sent-62,and,CC,O
ncbi-sent-62,environmental,JJ,O
ncbi-sent-62,variance,NN,O
ncbi-sent-62,components,NNS,O
ncbi-sent-62,were,VBD,O
ncbi-sent-62,assessed,VBN,O
ncbi-sent-62,with,IN,O
ncbi-sent-62,the,DT,O
ncbi-sent-62,program,NN,O
ncbi-sent-62,Mx,NNP,O
ncbi-sent-62,",",",",O
ncbi-sent-62,using,VBG,O
ncbi-sent-62,data,NNS,O
ncbi-sent-62,from,IN,O
ncbi-sent-62,this,DT,O
ncbi-sent-62,and,CC,O
ncbi-sent-62,previous,JJ,O
ncbi-sent-62,studies,NNS,O
ncbi-sent-62,of,IN,O
ncbi-sent-62,twins,NNS,O
ncbi-sent-62,with,IN,O
ncbi-sent-62,AS,NNP,B-DISEASE
ncbi-sent-62,.,.,O
ncbi-sent-63,RESULTS,NNP,O
ncbi-sent-63,Six,NNP,O
ncbi-sent-63,of,IN,O
ncbi-sent-63,8,CD,O
ncbi-sent-63,monozygotic,JJ,O
ncbi-sent-63,(,(,O
ncbi-sent-63,MZ,NNP,O
ncbi-sent-63,),),O
ncbi-sent-63,twin,VBP,O
ncbi-sent-63,pairs,NNS,O
ncbi-sent-63,were,VBD,O
ncbi-sent-63,disease,JJ,O
ncbi-sent-63,concordant,NN,O
ncbi-sent-63,",",",",O
ncbi-sent-63,compared,VBN,O
ncbi-sent-63,with,IN,O
ncbi-sent-63,4,CD,O
ncbi-sent-63,of,IN,O
ncbi-sent-63,15,CD,O
ncbi-sent-63,B27,NNP,O
ncbi-sent-63,-,:,O
ncbi-sent-63,positive,JJ,O
ncbi-sent-63,dizygotic,JJ,O
ncbi-sent-63,(,(,O
ncbi-sent-63,DZ,NNP,O
ncbi-sent-63,),),O
ncbi-sent-63,twin,NN,O
ncbi-sent-63,pairs,NNS,O
ncbi-sent-63,(,(,O
ncbi-sent-63,27,CD,O
ncbi-sent-63,%,NN,O
ncbi-sent-63,),),O
ncbi-sent-63,and,CC,O
ncbi-sent-63,4,CD,O
ncbi-sent-63,of,IN,O
ncbi-sent-63,32,CD,O
ncbi-sent-63,DZ,NNP,O
ncbi-sent-63,twin,NN,O
ncbi-sent-63,pairs,NNS,O
ncbi-sent-63,overall,JJ,O
ncbi-sent-63,(,(,O
ncbi-sent-63,12,CD,O
ncbi-sent-63,.,.,O
ncbi-sent-64,5,CD,O
ncbi-sent-64,%,NN,O
ncbi-sent-64,),),O
ncbi-sent-64,.,.,O
ncbi-sent-65,Nonsignificant,JJ,O
ncbi-sent-65,increases,NNS,O
ncbi-sent-65,in,IN,O
ncbi-sent-65,similarity,NN,O
ncbi-sent-65,with,IN,O
ncbi-sent-65,regard,NN,O
ncbi-sent-65,to,TO,O
ncbi-sent-65,age,NN,O
ncbi-sent-65,at,IN,O
ncbi-sent-65,disease,NN,O
ncbi-sent-65,onset,NN,O
ncbi-sent-65,and,CC,O
ncbi-sent-65,all,DT,O
ncbi-sent-65,of,IN,O
ncbi-sent-65,the,DT,O
ncbi-sent-65,disease,NN,O
ncbi-sent-65,severity,NN,O
ncbi-sent-65,scores,NNS,O
ncbi-sent-65,assessed,VBN,O
ncbi-sent-65,were,VBD,O
ncbi-sent-65,noted,VBN,O
ncbi-sent-65,in,IN,O
ncbi-sent-65,disease,NN,O
ncbi-sent-65,-,:,O
ncbi-sent-65,concordant,NN,O
ncbi-sent-65,MZ,NNP,O
ncbi-sent-65,twins,NNS,O
ncbi-sent-65,compared,VBN,O
ncbi-sent-65,with,IN,O
ncbi-sent-65,concordant,JJ,O
ncbi-sent-65,DZ,NNP,O
ncbi-sent-65,twins,NNS,O
ncbi-sent-65,.,.,O
ncbi-sent-66,HLA,NNP,O
ncbi-sent-66,-,:,O
ncbi-sent-66,B27,NNP,O
ncbi-sent-66,and,CC,O
ncbi-sent-66,B60,NNP,O
ncbi-sent-66,were,VBD,O
ncbi-sent-66,associated,VBN,O
ncbi-sent-66,with,IN,O
ncbi-sent-66,the,DT,O
ncbi-sent-66,disease,NN,O
ncbi-sent-66,in,IN,O
ncbi-sent-66,probands,NNS,O
ncbi-sent-66,",",",",O
ncbi-sent-66,and,CC,O
ncbi-sent-66,the,DT,O
ncbi-sent-66,rate,NN,O
ncbi-sent-66,of,IN,O
ncbi-sent-66,disease,NN,O
ncbi-sent-66,concordance,NN,O
ncbi-sent-66,was,VBD,O
ncbi-sent-66,significantly,RB,O
ncbi-sent-66,increased,VBN,O
ncbi-sent-66,among,IN,O
ncbi-sent-66,DZ,NNP,O
ncbi-sent-66,twin,VBP,O
ncbi-sent-66,pairs,NNS,O
ncbi-sent-66,in,IN,O
ncbi-sent-66,which,WDT,O
ncbi-sent-66,the,DT,O
ncbi-sent-66,co,NN,O
ncbi-sent-66,-,:,O
ncbi-sent-66,twin,NN,O
ncbi-sent-66,was,VBD,O
ncbi-sent-66,positive,JJ,O
ncbi-sent-66,for,IN,O
ncbi-sent-66,both,DT,O
ncbi-sent-66,B27,NNP,O
ncbi-sent-66,and,CC,O
ncbi-sent-66,DR1,NNP,O
ncbi-sent-66,.,.,O
ncbi-sent-67,Additive,NNP,O
ncbi-sent-67,genetic,JJ,O
ncbi-sent-67,effects,NNS,O
ncbi-sent-67,were,VBD,O
ncbi-sent-67,estimated,VBN,O
ncbi-sent-67,to,TO,O
ncbi-sent-67,contribute,VB,O
ncbi-sent-67,97,CD,O
ncbi-sent-67,%,NN,O
ncbi-sent-67,of,IN,O
ncbi-sent-67,the,DT,O
ncbi-sent-67,population,NN,O
ncbi-sent-67,variance,NN,O
ncbi-sent-67,.,.,O
ncbi-sent-68,CONCLUSION,NNP,O
ncbi-sent-68,Susceptibility,NNP,O
ncbi-sent-68,to,TO,O
ncbi-sent-68,AS,NNP,B-DISEASE
ncbi-sent-68,is,VBZ,O
ncbi-sent-68,largely,RB,O
ncbi-sent-68,genetically,RB,O
ncbi-sent-68,determined,VBN,O
ncbi-sent-68,",",",",O
ncbi-sent-68,and,CC,O
ncbi-sent-68,the,DT,O
ncbi-sent-68,environmental,JJ,O
ncbi-sent-68,trigger,NN,O
ncbi-sent-68,for,IN,O
ncbi-sent-68,the,DT,O
ncbi-sent-68,disease,NN,O
ncbi-sent-68,is,VBZ,O
ncbi-sent-68,probably,RB,O
ncbi-sent-68,ubiquitous,JJ,O
ncbi-sent-68,.,.,O
ncbi-sent-69,HLA,NNP,O
ncbi-sent-69,-,:,O
ncbi-sent-69,B27,NNP,O
ncbi-sent-69,accounts,NNS,O
ncbi-sent-69,for,IN,O
ncbi-sent-69,a,DT,O
ncbi-sent-69,minority,NN,O
ncbi-sent-69,of,IN,O
ncbi-sent-69,the,DT,O
ncbi-sent-69,overall,JJ,O
ncbi-sent-69,genetic,JJ,O
ncbi-sent-69,susceptibility,NN,O
ncbi-sent-69,to,TO,O
ncbi-sent-69,AS,NNP,B-DISEASE
ncbi-sent-69,.,.,O
ncbi-sent-70,Cell,NNP,O
ncbi-sent-70,cycle,NN,O
ncbi-sent-70,-,:,O
ncbi-sent-70,dependent,JJ,O
ncbi-sent-70,colocalization,NN,O
ncbi-sent-70,of,IN,O
ncbi-sent-70,BARD1,NNP,O
ncbi-sent-70,and,CC,O
ncbi-sent-70,BRCA1,NNP,O
ncbi-sent-70,proteins,NNS,O
ncbi-sent-70,in,IN,O
ncbi-sent-70,discrete,JJ,O
ncbi-sent-70,nuclear,JJ,O
ncbi-sent-70,domains,NNS,O
ncbi-sent-70,.,.,O
ncbi-sent-71,Germ,NNP,O
ncbi-sent-71,-,:,O
ncbi-sent-71,line,NN,O
ncbi-sent-71,mutations,NNS,O
ncbi-sent-71,of,IN,O
ncbi-sent-71,the,DT,O
ncbi-sent-71,BRCA1,NNP,O
ncbi-sent-71,gene,NN,O
ncbi-sent-71,predispose,JJ,O
ncbi-sent-71,women,NNS,O
ncbi-sent-71,to,TO,O
ncbi-sent-71,early,JJ,O
ncbi-sent-71,-,:,O
ncbi-sent-71,onset,NN,O
ncbi-sent-71,breast,NN,B-DISEASE
ncbi-sent-71,and,CC,I-DISEASE
ncbi-sent-71,ovarian,JJ,I-DISEASE
ncbi-sent-71,cancer,NN,I-DISEASE
ncbi-sent-71,by,IN,O
ncbi-sent-71,compromising,VBG,O
ncbi-sent-71,the,DT,O
ncbi-sent-71,genes,NNS,O
ncbi-sent-71,presumptive,JJ,O
ncbi-sent-71,function,NN,O
ncbi-sent-71,as,IN,O
ncbi-sent-71,a,DT,O
ncbi-sent-71,tumor,NN,B-DISEASE
ncbi-sent-71,suppressor,NN,O
ncbi-sent-71,.,.,O
ncbi-sent-72,Although,IN,O
ncbi-sent-72,the,DT,O
ncbi-sent-72,biochemical,JJ,O
ncbi-sent-72,properties,NNS,O
ncbi-sent-72,of,IN,O
ncbi-sent-72,BRCA1,NNP,O
ncbi-sent-72,polypeptides,NNS,O
ncbi-sent-72,are,VBP,O
ncbi-sent-72,not,RB,O
ncbi-sent-72,understood,JJ,O
ncbi-sent-72,",",",",O
ncbi-sent-72,their,PRP$,O
ncbi-sent-72,expression,NN,O
ncbi-sent-72,pattern,NN,O
ncbi-sent-72,and,CC,O
ncbi-sent-72,subcellular,JJ,O
ncbi-sent-72,localization,NN,O
ncbi-sent-72,suggest,VBP,O
ncbi-sent-72,a,DT,O
ncbi-sent-72,role,NN,O
ncbi-sent-72,in,IN,O
ncbi-sent-72,cell,NN,O
ncbi-sent-72,-,:,O
ncbi-sent-72,cycle,NN,O
ncbi-sent-72,regulation,NN,O
ncbi-sent-72,.,.,O
ncbi-sent-73,When,WRB,O
ncbi-sent-73,resting,VBG,O
ncbi-sent-73,cells,NNS,O
ncbi-sent-73,are,VBP,O
ncbi-sent-73,induced,VBN,O
ncbi-sent-73,to,TO,O
ncbi-sent-73,proliferate,VB,O
ncbi-sent-73,",",",",O
ncbi-sent-73,the,DT,O
ncbi-sent-73,steady,JJ,O
ncbi-sent-73,-,:,O
ncbi-sent-73,state,NN,O
ncbi-sent-73,levels,NNS,O
ncbi-sent-73,of,IN,O
ncbi-sent-73,BRCA1,NNP,O
ncbi-sent-73,increase,NN,O
ncbi-sent-73,in,IN,O
ncbi-sent-73,late,JJ,O
ncbi-sent-73,G1,NNP,O
ncbi-sent-73,and,CC,O
ncbi-sent-73,reach,VB,O
ncbi-sent-73,a,DT,O
ncbi-sent-73,maximum,JJ,O
ncbi-sent-73,during,IN,O
ncbi-sent-73,S,NNP,O
ncbi-sent-73,phase,NN,O
ncbi-sent-73,.,.,O
ncbi-sent-74,Moreover,RB,O
ncbi-sent-74,",",",",O
ncbi-sent-74,in,IN,O
ncbi-sent-74,S,NNP,O
ncbi-sent-74,phase,NN,O
ncbi-sent-74,cells,NNS,O
ncbi-sent-74,",",",",O
ncbi-sent-74,BRCA1,NNP,O
ncbi-sent-74,polypeptides,NNS,O
ncbi-sent-74,are,VBP,O
ncbi-sent-74,hyperphosphorylated,VBN,O
ncbi-sent-74,and,CC,O
ncbi-sent-74,accumulate,VB,O
ncbi-sent-74,into,IN,O
ncbi-sent-74,discrete,JJ,O
ncbi-sent-74,subnuclear,JJ,O
ncbi-sent-74,foci,NN,O
ncbi-sent-74,termed,VBD,O
ncbi-sent-74,"	O
BRCA1	O
nuclear	O
dots	O
.	O

",NNP,O
ncbi-sent-74,BRCA1,NNP,O
ncbi-sent-74,associates,NNS,O
ncbi-sent-74,in,IN,O
ncbi-sent-74,vivo,NN,O
ncbi-sent-74,with,IN,O
ncbi-sent-74,a,DT,O
ncbi-sent-74,structurally,RB,O
ncbi-sent-74,related,JJ,O
ncbi-sent-74,protein,NN,O
ncbi-sent-74,termed,VBD,O
ncbi-sent-74,BARD1,NNP,O
ncbi-sent-74,.,.,O
ncbi-sent-75,Here,RB,O
ncbi-sent-75,we,PRP,O
ncbi-sent-75,show,VBP,O
ncbi-sent-75,that,IN,O
ncbi-sent-75,the,DT,O
ncbi-sent-75,steady,JJ,O
ncbi-sent-75,-,:,O
ncbi-sent-75,state,NN,O
ncbi-sent-75,levels,NNS,O
ncbi-sent-75,of,IN,O
ncbi-sent-75,BARD1,NNP,O
ncbi-sent-75,",",",",O
ncbi-sent-75,unlike,IN,O
ncbi-sent-75,those,DT,O
ncbi-sent-75,of,IN,O
ncbi-sent-75,BRCA1,NNP,O
ncbi-sent-75,",",",",O
ncbi-sent-75,remain,VBP,O
ncbi-sent-75,relatively,RB,O
ncbi-sent-75,constant,JJ,O
ncbi-sent-75,during,IN,O
ncbi-sent-75,cell,NN,O
ncbi-sent-75,cycle,NN,O
ncbi-sent-75,progression,NN,O
ncbi-sent-75,.,.,O
ncbi-sent-76,However,RB,O
ncbi-sent-76,",",",",O
ncbi-sent-76,immunostaining,VBG,O
ncbi-sent-76,revealed,VBD,O
ncbi-sent-76,that,IN,O
ncbi-sent-76,BARD1,NNP,O
ncbi-sent-76,resides,NNS,O
ncbi-sent-76,within,IN,O
ncbi-sent-76,BRCA1,NNP,O
ncbi-sent-76,nuclear,JJ,O
ncbi-sent-76,dots,NNS,O
ncbi-sent-76,during,IN,O
ncbi-sent-76,S,NNP,O
ncbi-sent-76,phase,NN,O
ncbi-sent-76,of,IN,O
ncbi-sent-76,the,DT,O
ncbi-sent-76,cell,NN,O
ncbi-sent-76,cycle,NN,O
ncbi-sent-76,",",",",O
ncbi-sent-76,but,CC,O
ncbi-sent-76,not,RB,O
ncbi-sent-76,during,IN,O
ncbi-sent-76,the,DT,O
ncbi-sent-76,G1,NNP,O
ncbi-sent-76,phase,NN,O
ncbi-sent-76,.,.,O
ncbi-sent-77,Nevertheless,NNP,O
ncbi-sent-77,",",",",O
ncbi-sent-77,BARD1,NNP,O
ncbi-sent-77,polypeptides,NNS,O
ncbi-sent-77,are,VBP,O
ncbi-sent-77,found,VBN,O
ncbi-sent-77,exclusively,RB,O
ncbi-sent-77,in,IN,O
ncbi-sent-77,the,DT,O
ncbi-sent-77,nuclear,JJ,O
ncbi-sent-77,fractions,NNS,O
ncbi-sent-77,of,IN,O
ncbi-sent-77,both,DT,O
ncbi-sent-77,G1,NNP,O
ncbi-sent-77,-,:,O
ncbi-sent-77,and,CC,O
ncbi-sent-77,S,NNP,O
ncbi-sent-77,-,:,O
ncbi-sent-77,phase,NN,O
ncbi-sent-77,cells,NNS,O
ncbi-sent-77,.,.,O
ncbi-sent-78,Therefore,RB,O
ncbi-sent-78,",",",",O
ncbi-sent-78,progression,NN,O
ncbi-sent-78,to,TO,O
ncbi-sent-78,S,NNP,O
ncbi-sent-78,phase,NN,O
ncbi-sent-78,is,VBZ,O
ncbi-sent-78,accompanied,VBN,O
ncbi-sent-78,by,IN,O
ncbi-sent-78,the,DT,O
ncbi-sent-78,aggregation,NN,O
ncbi-sent-78,of,IN,O
ncbi-sent-78,nuclear,JJ,O
ncbi-sent-78,BARD1,NNP,O
ncbi-sent-78,polypeptides,NNS,O
ncbi-sent-78,into,IN,O
ncbi-sent-78,BRCA1,NNP,O
ncbi-sent-78,nuclear,JJ,O
ncbi-sent-78,dots,NNS,O
ncbi-sent-78,.,.,O
ncbi-sent-79,This,DT,O
ncbi-sent-79,cell,NN,O
ncbi-sent-79,cycle,NN,O
ncbi-sent-79,-,:,O
ncbi-sent-79,dependent,JJ,O
ncbi-sent-79,colocalization,NN,O
ncbi-sent-79,of,IN,O
ncbi-sent-79,BARD1,NNP,O
ncbi-sent-79,and,CC,O
ncbi-sent-79,BRCA1,NNP,O
ncbi-sent-79,indicates,VBZ,O
ncbi-sent-79,a,DT,O
ncbi-sent-79,role,NN,O
ncbi-sent-79,for,IN,O
ncbi-sent-79,BARD1,NNP,O
ncbi-sent-79,in,IN,O
ncbi-sent-79,BRCA1,NNP,O
ncbi-sent-79,-,:,O
ncbi-sent-79,mediated,VBD,O
ncbi-sent-79,tumor,JJ,B-DISEASE
ncbi-sent-79,suppression,NN,O
ncbi-sent-79,.,.,O
ncbi-sent-80,Ethnic,JJ,O
ncbi-sent-80,differences,NNS,O
ncbi-sent-80,in,IN,O
ncbi-sent-80,the,DT,O
ncbi-sent-80,HFE,NNP,O
ncbi-sent-80,codon,NN,O
ncbi-sent-80,282,CD,O
ncbi-sent-80,(,(,O
ncbi-sent-80,Cys,NNP,O
ncbi-sent-80,/,NNP,O
ncbi-sent-80,Tyr,NNP,O
ncbi-sent-80,),),O
ncbi-sent-80,polymorphism,NN,O
ncbi-sent-80,.,.,O
ncbi-sent-81,Recent,JJ,O
ncbi-sent-81,studies,NNS,O
ncbi-sent-81,have,VBP,O
ncbi-sent-81,shown,VBN,O
ncbi-sent-81,that,IN,O
ncbi-sent-81,hereditary,JJ,B-DISEASE
ncbi-sent-81,hemochromatosis,NN,I-DISEASE
ncbi-sent-81,(,(,O
ncbi-sent-81,HH,NNP,B-DISEASE
ncbi-sent-81,),),O
ncbi-sent-81,is,VBZ,O
ncbi-sent-81,likely,JJ,O
ncbi-sent-81,to,TO,O
ncbi-sent-81,be,VB,O
ncbi-sent-81,caused,VBN,O
ncbi-sent-81,by,IN,O
ncbi-sent-81,homozygosity,NN,O
ncbi-sent-81,for,IN,O
ncbi-sent-81,a,DT,O
ncbi-sent-81,Cys282Tyr,NNP,O
ncbi-sent-81,mutation,NN,O
ncbi-sent-81,in,IN,O
ncbi-sent-81,the,DT,O
ncbi-sent-81,HFE,NNP,O
ncbi-sent-81,gene,NN,O
ncbi-sent-81,located,VBD,O
ncbi-sent-81,4,CD,O
ncbi-sent-81,.,.,O
ncbi-sent-82,5,CD,O
ncbi-sent-82,Mb,NNP,O
ncbi-sent-82,telomeric,NN,O
ncbi-sent-82,to,TO,O
ncbi-sent-82,HLA,NNP,O
ncbi-sent-82,-,:,O
ncbi-sent-82,A,DT,O
ncbi-sent-82,.,.,O
ncbi-sent-83,Population,NNP,O
ncbi-sent-83,studies,NNS,O
ncbi-sent-83,of,IN,O
ncbi-sent-83,this,DT,O
ncbi-sent-83,polymorphism,NN,O
ncbi-sent-83,are,VBP,O
ncbi-sent-83,facilitated,VBN,O
ncbi-sent-83,by,IN,O
ncbi-sent-83,the,DT,O
ncbi-sent-83,fact,NN,O
ncbi-sent-83,that,IN,O
ncbi-sent-83,the,DT,O
ncbi-sent-83,Cys282Tyr,NNP,O
ncbi-sent-83,mutation,NN,O
ncbi-sent-83,creates,VBZ,O
ncbi-sent-83,a,DT,O
ncbi-sent-83,Rsal,NNP,O
ncbi-sent-83,restriction,NN,O
ncbi-sent-83,site,NN,O
ncbi-sent-83,.,.,O
ncbi-sent-84,We,PRP,O
ncbi-sent-84,have,VBP,O
ncbi-sent-84,studied,VBN,O
ncbi-sent-84,the,DT,O
ncbi-sent-84,codon,NN,O
ncbi-sent-84,282,CD,O
ncbi-sent-84,(,(,O
ncbi-sent-84,Cys,NNP,O
ncbi-sent-84,/,NNP,O
ncbi-sent-84,Tyr,NNP,O
ncbi-sent-84,),),O
ncbi-sent-84,polymorphism,NN,O
ncbi-sent-84,in,IN,O
ncbi-sent-84,different,JJ,O
ncbi-sent-84,ethnic,JJ,O
ncbi-sent-84,groups,NNS,O
ncbi-sent-84,.,.,O
ncbi-sent-85,In,IN,O
ncbi-sent-85,agreement,NN,O
ncbi-sent-85,with,IN,O
ncbi-sent-85,previous,JJ,O
ncbi-sent-85,observations,NNS,O
ncbi-sent-85,the,DT,O
ncbi-sent-85,Tyr,NNP,O
ncbi-sent-85,allele,NN,O
ncbi-sent-85,appeared,VBD,O
ncbi-sent-85,to,TO,O
ncbi-sent-85,be,VB,O
ncbi-sent-85,rare,JJ,O
ncbi-sent-85,or,CC,O
ncbi-sent-85,absent,NN,O
ncbi-sent-85,in,IN,O
ncbi-sent-85,Asiatic,NNP,O
ncbi-sent-85,(,(,O
ncbi-sent-85,Indian,JJ,O
ncbi-sent-85,",",",",O
ncbi-sent-85,Chinese,JJ,O
ncbi-sent-85,),),O
ncbi-sent-85,populations,NNS,O
ncbi-sent-85,.,.,O
ncbi-sent-86,The,DT,O
ncbi-sent-86,highest,JJS,O
ncbi-sent-86,allele,JJ,O
ncbi-sent-86,frequency,NN,O
ncbi-sent-86,(,(,O
ncbi-sent-86,7,CD,O
ncbi-sent-86,.,.,O
ncbi-sent-87,5,CD,O
ncbi-sent-87,%,NN,O
ncbi-sent-87,),),O
ncbi-sent-87,was,VBD,O
ncbi-sent-87,found,VBN,O
ncbi-sent-87,in,IN,O
ncbi-sent-87,Swedes,NNP,O
ncbi-sent-87,.,.,O
ncbi-sent-88,Saamis,NNP,O
ncbi-sent-88,(,(,O
ncbi-sent-88,2,CD,O
ncbi-sent-88,%,NN,O
ncbi-sent-88,),),O
ncbi-sent-88,and,CC,O
ncbi-sent-88,Mordvinians,NNPS,O
ncbi-sent-88,(,(,O
ncbi-sent-88,1,CD,O
ncbi-sent-88,.,.,O
ncbi-sent-89,8,CD,O
ncbi-sent-89,%,NN,O
ncbi-sent-89,),),O
ncbi-sent-89,had,VBD,O
ncbi-sent-89,significantly,RB,O
ncbi-sent-89,lower,JJR,O
ncbi-sent-89,frequencies,NNS,O
ncbi-sent-89,of,IN,O
ncbi-sent-89,the,DT,O
ncbi-sent-89,Tyr,NNP,O
ncbi-sent-89,allele,NN,O
ncbi-sent-89,.,.,O
ncbi-sent-90,Comparisons,NNS,O
ncbi-sent-90,with,IN,O
ncbi-sent-90,allele,JJ,O
ncbi-sent-90,frequencies,NNS,O
ncbi-sent-90,based,VBN,O
ncbi-sent-90,on,IN,O
ncbi-sent-90,prevalence,NN,O
ncbi-sent-90,estimates,NNS,O
ncbi-sent-90,of,IN,O
ncbi-sent-90,HH,NNP,B-DISEASE
ncbi-sent-90,showed,VBD,O
ncbi-sent-90,some,DT,O
ncbi-sent-90,disagreements,NNS,O
ncbi-sent-90,with,IN,O
ncbi-sent-90,the,DT,O
ncbi-sent-90,RFLP,NNP,O
ncbi-sent-90,data,NNS,O
ncbi-sent-90,",",",",O
ncbi-sent-90,particularly,RB,O
ncbi-sent-90,in,IN,O
ncbi-sent-90,Finns,NNP,O
ncbi-sent-90,.,.,O
ncbi-sent-91,The,DT,O
ncbi-sent-91,newly,RB,O
ncbi-sent-91,described,VBN,O
ncbi-sent-91,HFE,NNP,O
ncbi-sent-91,marker,NN,O
ncbi-sent-91,provides,VBZ,O
ncbi-sent-91,a,DT,O
ncbi-sent-91,new,JJ,O
ncbi-sent-91,approach,NN,O
ncbi-sent-91,to,TO,O
ncbi-sent-91,the,DT,O
ncbi-sent-91,screening,NN,O
ncbi-sent-91,of,IN,O
ncbi-sent-91,HH,NNP,B-DISEASE
ncbi-sent-91,as,RB,O
ncbi-sent-91,well,RB,O
ncbi-sent-91,as,IN,O
ncbi-sent-91,studies,NNS,O
ncbi-sent-91,of,IN,O
ncbi-sent-91,the,DT,O
ncbi-sent-91,relationship,NN,O
ncbi-sent-91,between,IN,O
ncbi-sent-91,the,DT,O
ncbi-sent-91,HFE,NNP,O
ncbi-sent-91,Tyr,NNP,O
ncbi-sent-91,allele,NN,O
ncbi-sent-91,and,CC,O
ncbi-sent-91,different,JJ,O
ncbi-sent-91,disorders,NNS,O
ncbi-sent-91,including,VBG,O
ncbi-sent-91,cancer,NN,B-DISEASE
ncbi-sent-91,Autosomal,NNP,B-DISEASE
ncbi-sent-91,dominant,JJ,I-DISEASE
ncbi-sent-91,neurohypophyseal,NN,I-DISEASE
ncbi-sent-91,diabetes,VBZ,I-DISEASE
ncbi-sent-91,insipidus,RB,I-DISEASE
ncbi-sent-91,associated,VBN,O
ncbi-sent-91,with,IN,O
ncbi-sent-91,a,DT,O
ncbi-sent-91,missense,JJ,O
ncbi-sent-91,mutation,NN,O
ncbi-sent-91,encoding,VBG,O
ncbi-sent-91,Gly23,NNP,O
ncbi-sent-91,-,:,O
ncbi-sent-91,-,:,O
ncbi-sent-91,>,NN,O
ncbi-sent-91,Val,NNP,O
ncbi-sent-91,in,IN,O
ncbi-sent-91,neurophysin,JJ,O
ncbi-sent-91,II,NNP,O
ncbi-sent-91,.,.,O
ncbi-sent-92,Autosomal,NNP,B-DISEASE
ncbi-sent-92,dominant,JJ,I-DISEASE
ncbi-sent-92,neurohypophyseal,NN,I-DISEASE
ncbi-sent-92,diabetes,NNS,I-DISEASE
ncbi-sent-92,insipidus,VBP,I-DISEASE
ncbi-sent-92,(,(,O
ncbi-sent-92,ADNDI,NNP,B-DISEASE
ncbi-sent-92,),),O
ncbi-sent-92,is,VBZ,O
ncbi-sent-92,an,DT,O
ncbi-sent-92,inherited,JJ,B-DISEASE
ncbi-sent-92,disease,NN,I-DISEASE
ncbi-sent-92,caused,VBN,O
ncbi-sent-92,by,IN,O
ncbi-sent-92,progressive,JJ,O
ncbi-sent-92,degeneration,NN,O
ncbi-sent-92,of,IN,O
ncbi-sent-92,the,DT,O
ncbi-sent-92,magnocellular,JJ,O
ncbi-sent-92,neurons,NNS,O
ncbi-sent-92,of,IN,O
ncbi-sent-92,the,DT,O
ncbi-sent-92,hypothalamus,NN,O
ncbi-sent-92,leading,VBG,O
ncbi-sent-92,to,TO,O
ncbi-sent-92,decreased,VBN,O
ncbi-sent-92,ability,NN,O
ncbi-sent-92,to,TO,O
ncbi-sent-92,produce,VB,O
ncbi-sent-92,the,DT,O
ncbi-sent-92,hormone,NN,O
ncbi-sent-92,arginine,NN,O
ncbi-sent-92,vasopressin,NN,O
ncbi-sent-92,(,(,O
ncbi-sent-92,AVP,NNP,O
ncbi-sent-92,),),O
ncbi-sent-92,.,.,O
ncbi-sent-93,Affected,JJ,O
ncbi-sent-93,individuals,NNS,O
ncbi-sent-93,are,VBP,O
ncbi-sent-93,not,RB,O
ncbi-sent-93,symptomatic,JJ,O
ncbi-sent-93,at,IN,O
ncbi-sent-93,birth,NN,O
ncbi-sent-93,",",",",O
ncbi-sent-93,but,CC,O
ncbi-sent-93,usually,RB,O
ncbi-sent-93,develop,VB,O
ncbi-sent-93,diabetes,NNS,B-DISEASE
ncbi-sent-93,insipidus,VBP,I-DISEASE
ncbi-sent-93,at,IN,O
ncbi-sent-93,1,CD,O
ncbi-sent-93,-,:,O
ncbi-sent-93,6,CD,O
ncbi-sent-93,yr,NN,O
ncbi-sent-93,of,IN,O
ncbi-sent-93,age,NN,O
ncbi-sent-93,.,.,O
ncbi-sent-94,The,DT,O
ncbi-sent-94,genetic,JJ,O
ncbi-sent-94,locus,NN,O
ncbi-sent-94,of,IN,O
ncbi-sent-94,the,DT,O
ncbi-sent-94,disease,NN,O
ncbi-sent-94,is,VBZ,O
ncbi-sent-94,the,DT,O
ncbi-sent-94,AVP,NNP,O
ncbi-sent-94,-,:,O
ncbi-sent-94,neurophysin,NN,O
ncbi-sent-94,II,NNP,O
ncbi-sent-94,(,(,O
ncbi-sent-94,NPII,NNP,O
ncbi-sent-94,),),O
ncbi-sent-94,gene,NN,O
ncbi-sent-94,",",",",O
ncbi-sent-94,and,CC,O
ncbi-sent-94,mutations,NNS,O
ncbi-sent-94,that,WDT,O
ncbi-sent-94,cause,VBP,O
ncbi-sent-94,ADNDI,NNP,B-DISEASE
ncbi-sent-94,have,VBP,O
ncbi-sent-94,been,VBN,O
ncbi-sent-94,found,VBN,O
ncbi-sent-94,in,IN,O
ncbi-sent-94,both,DT,O
ncbi-sent-94,the,DT,O
ncbi-sent-94,signal,JJ,O
ncbi-sent-94,peptide,NN,O
ncbi-sent-94,of,IN,O
ncbi-sent-94,the,DT,O
ncbi-sent-94,prepro,JJ,O
ncbi-sent-94,-,:,O
ncbi-sent-94,AVP,NNP,O
ncbi-sent-94,-,:,O
ncbi-sent-94,NPII,NNP,O
ncbi-sent-94,precursor,NN,O
ncbi-sent-94,and,CC,O
ncbi-sent-94,within,IN,O
ncbi-sent-94,NPII,NNP,O
ncbi-sent-94,itself,PRP,O
ncbi-sent-94,.,.,O
ncbi-sent-95,An,DT,O
ncbi-sent-95,affected,JJ,O
ncbi-sent-95,girl,NN,O
ncbi-sent-95,who,WP,O
ncbi-sent-95,presented,VBD,O
ncbi-sent-95,at,IN,O
ncbi-sent-95,9,CD,O
ncbi-sent-95,months,NNS,O
ncbi-sent-95,of,IN,O
ncbi-sent-95,age,NN,O
ncbi-sent-95,and,CC,O
ncbi-sent-95,her,PRP$,O
ncbi-sent-95,similarly,RB,O
ncbi-sent-95,affected,JJ,O
ncbi-sent-95,younger,JJR,O
ncbi-sent-95,brother,NN,O
ncbi-sent-95,and,CC,O
ncbi-sent-95,father,NN,O
ncbi-sent-95,were,VBD,O
ncbi-sent-95,all,DT,O
ncbi-sent-95,found,VBN,O
ncbi-sent-95,to,TO,O
ncbi-sent-95,have,VB,O
ncbi-sent-95,a,DT,O
ncbi-sent-95,novel,JJ,O
ncbi-sent-95,missense,NN,O
ncbi-sent-95,mutation,NN,O
ncbi-sent-95,(,(,O
ncbi-sent-95,G1758,NNP,O
ncbi-sent-95,-,:,O
ncbi-sent-95,-,:,O
ncbi-sent-95,>,NN,O
ncbi-sent-95,T,NNP,O
ncbi-sent-95,),),O
ncbi-sent-95,encoding,VBG,O
ncbi-sent-95,the,DT,O
ncbi-sent-95,amino,NN,O
ncbi-sent-95,acid,JJ,O
ncbi-sent-95,substitution,NN,O
ncbi-sent-95,Gly23,NNP,O
ncbi-sent-95,-,:,O
ncbi-sent-95,-,:,O
ncbi-sent-95,>,NN,O
ncbi-sent-95,Val,NNP,O
ncbi-sent-95,within,IN,O
ncbi-sent-95,NPII,NNP,O
ncbi-sent-95,.,.,O
ncbi-sent-96,The,DT,O
ncbi-sent-96,mutation,NN,O
ncbi-sent-96,was,VBD,O
ncbi-sent-96,confirmed,VBN,O
ncbi-sent-96,by,IN,O
ncbi-sent-96,restriction,NN,O
ncbi-sent-96,endonuclease,NN,O
ncbi-sent-96,analysis,NN,O
ncbi-sent-96,.,.,O
ncbi-sent-97,A,DT,O
ncbi-sent-97,T1,NNP,O
ncbi-sent-97,-,:,O
ncbi-sent-97,weighted,VBD,O
ncbi-sent-97,magnetic,JJ,O
ncbi-sent-97,resonance,NN,O
ncbi-sent-97,imaging,NN,O
ncbi-sent-97,of,IN,O
ncbi-sent-97,the,DT,O
ncbi-sent-97,fathers,NNS,O
ncbi-sent-97,pituitary,JJ,O
ncbi-sent-97,gland,NN,O
ncbi-sent-97,demonstrates,VBZ,O
ncbi-sent-97,an,DT,O
ncbi-sent-97,attenuated,JJ,O
ncbi-sent-97,posterior,JJ,O
ncbi-sent-97,pituitary,JJ,O
ncbi-sent-97,bright,NN,O
ncbi-sent-97,spot,NN,O
ncbi-sent-97,.,.,O
ncbi-sent-98,This,DT,O
ncbi-sent-98,mutation,NN,O
ncbi-sent-98,may,MD,O
ncbi-sent-98,be,VB,O
ncbi-sent-98,valuable,JJ,O
ncbi-sent-98,for,IN,O
ncbi-sent-98,developing,VBG,O
ncbi-sent-98,models,NNS,O
ncbi-sent-98,of,IN,O
ncbi-sent-98,dominantly,RB,B-DISEASE
ncbi-sent-98,inherited,VBN,I-DISEASE
ncbi-sent-98,neurodegeneration,NN,I-DISEASE
ncbi-sent-98,",",",",O
ncbi-sent-98,as,IN,O
ncbi-sent-98,the,DT,O
ncbi-sent-98,early,JJ,O
ncbi-sent-98,age,NN,O
ncbi-sent-98,of,IN,O
ncbi-sent-98,onset,NN,O
ncbi-sent-98,of,IN,O
ncbi-sent-98,symptoms,NNS,O
ncbi-sent-98,suggests,VBZ,O
ncbi-sent-98,that,IN,O
ncbi-sent-98,this,DT,O
ncbi-sent-98,mutation,NN,O
ncbi-sent-98,may,MD,O
ncbi-sent-98,be,VB,O
ncbi-sent-98,particularly,RB,O
ncbi-sent-98,deleterious,JJ,O
ncbi-sent-98,to,TO,O
ncbi-sent-98,the,DT,O
ncbi-sent-98,magnocellular,JJ,O
ncbi-sent-98,neuron,NN,O
ncbi-sent-98,.,.,O
ncbi-sent-99,.,.,O
ncbi-sent-100,Frequent,JJ,O
ncbi-sent-100,inactivation,NN,O
ncbi-sent-100,of,IN,O
ncbi-sent-100,PTEN,NNP,O
ncbi-sent-100,/,NNP,O
ncbi-sent-100,MMAC1,NNP,O
ncbi-sent-100,in,IN,O
ncbi-sent-100,primary,JJ,O
ncbi-sent-100,prostate,NN,B-DISEASE
ncbi-sent-100,cancer,NN,I-DISEASE
ncbi-sent-100,.,.,O
ncbi-sent-101,Sporadic,JJ,B-DISEASE
ncbi-sent-101,prostate,NN,I-DISEASE
ncbi-sent-101,carcinoma,NN,I-DISEASE
ncbi-sent-101,is,VBZ,O
ncbi-sent-101,the,DT,O
ncbi-sent-101,most,RBS,O
ncbi-sent-101,common,JJ,O
ncbi-sent-101,male,NN,B-DISEASE
ncbi-sent-101,cancer,NN,I-DISEASE
ncbi-sent-101,in,IN,O
ncbi-sent-101,the,DT,O
ncbi-sent-101,Western,JJ,O
ncbi-sent-101,world,NN,O
ncbi-sent-101,",",",",O
ncbi-sent-101,yet,RB,O
ncbi-sent-101,many,JJ,O
ncbi-sent-101,of,IN,O
ncbi-sent-101,the,DT,O
ncbi-sent-101,major,JJ,O
ncbi-sent-101,genetic,JJ,O
ncbi-sent-101,events,NNS,O
ncbi-sent-101,involved,VBN,O
ncbi-sent-101,in,IN,O
ncbi-sent-101,the,DT,O
ncbi-sent-101,progression,NN,O
ncbi-sent-101,of,IN,O
ncbi-sent-101,this,DT,O
ncbi-sent-101,often,RB,O
ncbi-sent-101,fatal,JJ,O
ncbi-sent-101,cancer,NN,B-DISEASE
ncbi-sent-101,remain,NN,O
ncbi-sent-101,to,TO,O
ncbi-sent-101,be,VB,O
ncbi-sent-101,elucidated,VBN,O
ncbi-sent-101,.,.,O
ncbi-sent-102,Numerous,JJ,O
ncbi-sent-102,cytogenetic,JJ,O
ncbi-sent-102,and,CC,O
ncbi-sent-102,allelotype,JJ,O
ncbi-sent-102,studies,NNS,O
ncbi-sent-102,have,VBP,O
ncbi-sent-102,reported,VBN,O
ncbi-sent-102,frequent,JJ,O
ncbi-sent-102,loss,NN,O
ncbi-sent-102,of,IN,O
ncbi-sent-102,heterozygosity,NN,O
ncbi-sent-102,on,IN,O
ncbi-sent-102,chromosomal,JJ,O
ncbi-sent-102,arm,NN,O
ncbi-sent-102,10q,CD,O
ncbi-sent-102,in,IN,O
ncbi-sent-102,sporadic,JJ,B-DISEASE
ncbi-sent-102,prostate,NN,I-DISEASE
ncbi-sent-102,cancer,NN,I-DISEASE
ncbi-sent-102,.,.,O
ncbi-sent-103,Deletion,NNP,O
ncbi-sent-103,mapping,VBG,O
ncbi-sent-103,studies,NNS,O
ncbi-sent-103,have,VBP,O
ncbi-sent-103,unambiguously,RB,O
ncbi-sent-103,identified,VBN,O
ncbi-sent-103,a,DT,O
ncbi-sent-103,region,NN,O
ncbi-sent-103,of,IN,O
ncbi-sent-103,chromosome,NN,O
ncbi-sent-103,10q23,CD,O
ncbi-sent-103,to,TO,O
ncbi-sent-103,be,VB,O
ncbi-sent-103,the,DT,O
ncbi-sent-103,minimal,JJ,O
ncbi-sent-103,area,NN,O
ncbi-sent-103,of,IN,O
ncbi-sent-103,loss,NN,O
ncbi-sent-103,.,.,O
ncbi-sent-104,A,DT,O
ncbi-sent-104,new,JJ,O
ncbi-sent-104,tumor,NN,B-DISEASE
ncbi-sent-104,suppressor,NN,O
ncbi-sent-104,gene,NN,O
ncbi-sent-104,",",",",O
ncbi-sent-104,PTEN,NNP,O
ncbi-sent-104,/,NNP,O
ncbi-sent-104,MMAC1,NNP,O
ncbi-sent-104,",",",",O
ncbi-sent-104,was,VBD,O
ncbi-sent-104,isolated,VBN,O
ncbi-sent-104,recently,RB,O
ncbi-sent-104,at,IN,O
ncbi-sent-104,this,DT,O
ncbi-sent-104,region,NN,O
ncbi-sent-104,of,IN,O
ncbi-sent-104,chromosome,NN,O
ncbi-sent-104,10q23,CD,O
ncbi-sent-104,and,CC,O
ncbi-sent-104,found,VBD,O
ncbi-sent-104,to,TO,O
ncbi-sent-104,be,VB,O
ncbi-sent-104,inactivated,VBN,O
ncbi-sent-104,by,IN,O
ncbi-sent-104,mutation,NN,O
ncbi-sent-104,in,IN,O
ncbi-sent-104,three,CD,O
ncbi-sent-104,prostate,NN,B-DISEASE
ncbi-sent-104,cancer,NN,I-DISEASE
ncbi-sent-104,cell,NN,O
ncbi-sent-104,lines,NNS,O
ncbi-sent-104,.,.,O
ncbi-sent-105,We,PRP,O
ncbi-sent-105,screened,VBD,O
ncbi-sent-105,80,CD,O
ncbi-sent-105,prostate,NN,B-DISEASE
ncbi-sent-105,tumors,NNS,I-DISEASE
ncbi-sent-105,by,IN,O
ncbi-sent-105,microsatellite,JJ,O
ncbi-sent-105,analysis,NN,O
ncbi-sent-105,and,CC,O
ncbi-sent-105,found,VBD,O
ncbi-sent-105,chromosome,RB,O
ncbi-sent-105,10q23,CD,O
ncbi-sent-105,to,TO,O
ncbi-sent-105,be,VB,O
ncbi-sent-105,deleted,VBN,O
ncbi-sent-105,in,IN,O
ncbi-sent-105,23,CD,O
ncbi-sent-105,cases,NNS,O
ncbi-sent-105,.,.,O
ncbi-sent-106,We,PRP,O
ncbi-sent-106,then,RB,O
ncbi-sent-106,proceeded,VBD,O
ncbi-sent-106,with,IN,O
ncbi-sent-106,sequence,NN,O
ncbi-sent-106,analysis,NN,O
ncbi-sent-106,of,IN,O
ncbi-sent-106,the,DT,O
ncbi-sent-106,entire,JJ,O
ncbi-sent-106,PTEN,NNP,O
ncbi-sent-106,/,NNP,O
ncbi-sent-106,MMAC1,NNP,O
ncbi-sent-106,coding,VBG,O
ncbi-sent-106,region,NN,O
ncbi-sent-106,and,CC,O
ncbi-sent-106,tested,VBN,O
ncbi-sent-106,for,IN,O
ncbi-sent-106,homozygous,JJ,O
ncbi-sent-106,deletion,NN,O
ncbi-sent-106,with,IN,O
ncbi-sent-106,new,JJ,O
ncbi-sent-106,intragenic,JJ,O
ncbi-sent-106,markers,NNS,O
ncbi-sent-106,in,IN,O
ncbi-sent-106,these,DT,O
ncbi-sent-106,23,CD,O
ncbi-sent-106,cases,NNS,O
ncbi-sent-106,with,IN,O
ncbi-sent-106,10q23,CD,O
ncbi-sent-106,loss,NN,O
ncbi-sent-106,of,IN,O
ncbi-sent-106,heterozygosity,NN,O
ncbi-sent-106,.,.,O
ncbi-sent-107,The,DT,O
ncbi-sent-107,identification,NN,O
ncbi-sent-107,of,IN,O
ncbi-sent-107,the,DT,O
ncbi-sent-107,second,JJ,O
ncbi-sent-107,mutational,JJ,O
ncbi-sent-107,event,NN,O
ncbi-sent-107,in,IN,O
ncbi-sent-107,10,CD,O
ncbi-sent-107,(,(,O
ncbi-sent-107,43,CD,O
ncbi-sent-107,%,NN,O
ncbi-sent-107,),),O
ncbi-sent-107,tumors,NNS,B-DISEASE
ncbi-sent-107,establishes,VBP,O
ncbi-sent-107,PTEN,NNP,O
ncbi-sent-107,/,NNP,O
ncbi-sent-107,MMAC1,NNP,O
ncbi-sent-107,as,IN,O
ncbi-sent-107,a,DT,O
ncbi-sent-107,main,JJ,O
ncbi-sent-107,inactivation,NN,O
ncbi-sent-107,target,NN,O
ncbi-sent-107,of,IN,O
ncbi-sent-107,10q,CD,O
ncbi-sent-107,loss,NN,O
ncbi-sent-107,in,IN,O
ncbi-sent-107,sporadic,JJ,B-DISEASE
ncbi-sent-107,prostate,NN,I-DISEASE
ncbi-sent-107,cancer,NN,I-DISEASE
ncbi-sent-107,.,.,O
ncbi-sent-108,.,.,O
ncbi-sent-109,Risk,NN,O
ncbi-sent-109,reversals,NNS,O
ncbi-sent-109,in,IN,O
ncbi-sent-109,predictive,JJ,O
ncbi-sent-109,testing,NN,O
ncbi-sent-109,for,IN,O
ncbi-sent-109,Huntington,NNP,B-DISEASE
ncbi-sent-109,disease,NN,I-DISEASE
ncbi-sent-109,.,.,O
ncbi-sent-110,The,DT,O
ncbi-sent-110,first,JJ,O
ncbi-sent-110,predictive,JJ,O
ncbi-sent-110,testing,NN,O
ncbi-sent-110,for,IN,O
ncbi-sent-110,Huntington,NNP,B-DISEASE
ncbi-sent-110,disease,NN,I-DISEASE
ncbi-sent-110,(,(,O
ncbi-sent-110,HD,NNP,B-DISEASE
ncbi-sent-110,),),O
ncbi-sent-110,was,VBD,O
ncbi-sent-110,based,VBN,O
ncbi-sent-110,on,IN,O
ncbi-sent-110,analysis,NN,O
ncbi-sent-110,of,IN,O
ncbi-sent-110,linked,VBN,O
ncbi-sent-110,polymorphic,JJ,O
ncbi-sent-110,DNA,NNP,O
ncbi-sent-110,markers,NNS,O
ncbi-sent-110,to,TO,O
ncbi-sent-110,estimate,VB,O
ncbi-sent-110,the,DT,O
ncbi-sent-110,likelihood,NN,O
ncbi-sent-110,of,IN,O
ncbi-sent-110,inheriting,VBG,O
ncbi-sent-110,the,DT,O
ncbi-sent-110,mutation,NN,O
ncbi-sent-110,for,IN,O
ncbi-sent-110,HD,NNP,B-DISEASE
ncbi-sent-110,.,.,O
ncbi-sent-111,Limits,NNS,O
ncbi-sent-111,to,TO,O
ncbi-sent-111,accuracy,VB,O
ncbi-sent-111,included,JJ,O
ncbi-sent-111,recombination,NN,O
ncbi-sent-111,between,IN,O
ncbi-sent-111,the,DT,O
ncbi-sent-111,DNA,NNP,O
ncbi-sent-111,markers,NNS,O
ncbi-sent-111,and,CC,O
ncbi-sent-111,the,DT,O
ncbi-sent-111,mutation,NN,O
ncbi-sent-111,",",",",O
ncbi-sent-111,pedigree,JJ,O
ncbi-sent-111,structure,NN,O
ncbi-sent-111,",",",",O
ncbi-sent-111,and,CC,O
ncbi-sent-111,whether,IN,O
ncbi-sent-111,DNA,NN,O
ncbi-sent-111,samples,NNS,O
ncbi-sent-111,were,VBD,O
ncbi-sent-111,available,JJ,O
ncbi-sent-111,from,IN,O
ncbi-sent-111,family,NN,O
ncbi-sent-111,members,NNS,O
ncbi-sent-111,.,.,O
ncbi-sent-112,With,IN,O
ncbi-sent-112,direct,JJ,O
ncbi-sent-112,tests,NNS,O
ncbi-sent-112,for,IN,O
ncbi-sent-112,the,DT,O
ncbi-sent-112,HD,NNP,B-DISEASE
ncbi-sent-112,mutation,NN,O
ncbi-sent-112,",",",",O
ncbi-sent-112,we,PRP,O
ncbi-sent-112,have,VBP,O
ncbi-sent-112,assessed,VBN,O
ncbi-sent-112,the,DT,O
ncbi-sent-112,accuracy,NN,O
ncbi-sent-112,of,IN,O
ncbi-sent-112,results,NNS,O
ncbi-sent-112,obtained,VBN,O
ncbi-sent-112,by,IN,O
ncbi-sent-112,linkage,NN,O
ncbi-sent-112,approaches,NNS,O
ncbi-sent-112,when,WRB,O
ncbi-sent-112,requested,VBN,O
ncbi-sent-112,to,TO,O
ncbi-sent-112,do,VB,O
ncbi-sent-112,so,RB,O
ncbi-sent-112,by,IN,O
ncbi-sent-112,the,DT,O
ncbi-sent-112,test,NN,O
ncbi-sent-112,individuals,NNS,O
ncbi-sent-112,.,.,O
ncbi-sent-113,For,IN,O
ncbi-sent-113,six,CD,O
ncbi-sent-113,such,JJ,O
ncbi-sent-113,individuals,NNS,O
ncbi-sent-113,",",",",O
ncbi-sent-113,there,EX,O
ncbi-sent-113,was,VBD,O
ncbi-sent-113,significant,JJ,O
ncbi-sent-113,disparity,NN,O
ncbi-sent-113,between,IN,O
ncbi-sent-113,the,DT,O
ncbi-sent-113,tests,NNS,O
ncbi-sent-113,.,.,O
ncbi-sent-114,Three,CD,O
ncbi-sent-114,went,VBD,O
ncbi-sent-114,from,IN,O
ncbi-sent-114,a,DT,O
ncbi-sent-114,decreased,VBN,O
ncbi-sent-114,risk,NN,O
ncbi-sent-114,to,TO,O
ncbi-sent-114,an,DT,O
ncbi-sent-114,increased,VBN,O
ncbi-sent-114,risk,NN,O
ncbi-sent-114,",",",",O
ncbi-sent-114,while,IN,O
ncbi-sent-114,in,IN,O
ncbi-sent-114,another,DT,O
ncbi-sent-114,three,CD,O
ncbi-sent-114,the,DT,O
ncbi-sent-114,risk,NN,O
ncbi-sent-114,was,VBD,O
ncbi-sent-114,decreased,VBN,O
ncbi-sent-114,.,.,O
ncbi-sent-115,Knowledge,NNP,O
ncbi-sent-115,of,IN,O
ncbi-sent-115,the,DT,O
ncbi-sent-115,potential,JJ,O
ncbi-sent-115,reasons,NNS,O
ncbi-sent-115,for,IN,O
ncbi-sent-115,these,DT,O
ncbi-sent-115,changes,NNS,O
ncbi-sent-115,in,IN,O
ncbi-sent-115,results,NNS,O
ncbi-sent-115,and,CC,O
ncbi-sent-115,impact,NN,O
ncbi-sent-115,of,IN,O
ncbi-sent-115,these,DT,O
ncbi-sent-115,risk,NN,O
ncbi-sent-115,reversals,NNS,O
ncbi-sent-115,on,IN,O
ncbi-sent-115,both,DT,O
ncbi-sent-115,patients,NNS,O
ncbi-sent-115,and,CC,O
ncbi-sent-115,the,DT,O
ncbi-sent-115,counseling,NN,O
ncbi-sent-115,team,NN,O
ncbi-sent-115,can,MD,O
ncbi-sent-115,assist,VB,O
ncbi-sent-115,in,IN,O
ncbi-sent-115,the,DT,O
ncbi-sent-115,development,NN,O
ncbi-sent-115,of,IN,O
ncbi-sent-115,strategies,NNS,O
ncbi-sent-115,for,IN,O
ncbi-sent-115,the,DT,O
ncbi-sent-115,prevention,NN,O
ncbi-sent-115,and,CC,O
ncbi-sent-115,",",",",O
ncbi-sent-115,where,WRB,O
ncbi-sent-115,necessary,JJ,O
ncbi-sent-115,",",",",O
ncbi-sent-115,management,NN,O
ncbi-sent-115,of,IN,O
ncbi-sent-115,a,DT,O
ncbi-sent-115,risk,NN,O
ncbi-sent-115,reversal,NN,O
ncbi-sent-115,in,IN,O
ncbi-sent-115,any,DT,O
ncbi-sent-115,predictive,JJ,O
ncbi-sent-115,testing,NN,O
ncbi-sent-115,program,NN,O
ncbi-sent-115,.,.,O
ncbi-sent-116,.,.,O
ncbi-sent-117,A,DT,O
ncbi-sent-117,novel,JJ,O
ncbi-sent-117,common,JJ,O
ncbi-sent-117,missense,NN,O
ncbi-sent-117,mutation,NN,O
ncbi-sent-117,G301C,NNP,O
ncbi-sent-117,in,IN,O
ncbi-sent-117,the,DT,O
ncbi-sent-117,N,NNP,O
ncbi-sent-117,-,:,O
ncbi-sent-117,acetylgalactosamine,NN,O
ncbi-sent-117,-,:,O
ncbi-sent-117,6,CD,O
ncbi-sent-117,-,:,O
ncbi-sent-117,sulfate,NN,O
ncbi-sent-117,sulfatase,NN,O
ncbi-sent-117,gene,NN,O
ncbi-sent-117,in,IN,O
ncbi-sent-117,mucopolysaccharidosis,NN,B-DISEASE
ncbi-sent-117,IVA,NNP,I-DISEASE
ncbi-sent-117,.,.,O
ncbi-sent-118,Mucopolysaccharidosis,NNP,B-DISEASE
ncbi-sent-118,IVA,NNP,I-DISEASE
ncbi-sent-118,(,(,O
ncbi-sent-118,MPS,NNP,B-DISEASE
ncbi-sent-118,IVA,NNP,I-DISEASE
ncbi-sent-118,),),O
ncbi-sent-118,is,VBZ,O
ncbi-sent-118,an,DT,O
ncbi-sent-118,autosomal,JJ,B-DISEASE
ncbi-sent-118,recessive,NN,I-DISEASE
ncbi-sent-118,lysosomal,JJ,I-DISEASE
ncbi-sent-118,storage,NN,I-DISEASE
ncbi-sent-118,disorder,NN,I-DISEASE
ncbi-sent-118,caused,VBN,O
ncbi-sent-118,by,IN,O
ncbi-sent-118,a,DT,O
ncbi-sent-118,genetic,JJ,B-DISEASE
ncbi-sent-118,defect,NN,I-DISEASE
ncbi-sent-118,in,IN,O
ncbi-sent-118,N,NNP,O
ncbi-sent-118,-,:,O
ncbi-sent-118,acetylgalactosamine,NN,O
ncbi-sent-118,-,:,O
ncbi-sent-118,6,CD,O
ncbi-sent-118,-,:,O
ncbi-sent-118,sulfate,NN,O
ncbi-sent-118,sulfatase,NN,O
ncbi-sent-118,(,(,O
ncbi-sent-118,GALNS,NNP,O
ncbi-sent-118,),),O
ncbi-sent-118,.,.,O
ncbi-sent-119,In,IN,O
ncbi-sent-119,previous,JJ,O
ncbi-sent-119,studies,NNS,O
ncbi-sent-119,",",",",O
ncbi-sent-119,we,PRP,O
ncbi-sent-119,have,VBP,O
ncbi-sent-119,found,VBN,O
ncbi-sent-119,two,CD,O
ncbi-sent-119,common,JJ,O
ncbi-sent-119,mutations,NNS,O
ncbi-sent-119,in,IN,O
ncbi-sent-119,Caucasians,NNPS,O
ncbi-sent-119,and,CC,O
ncbi-sent-119,Japanese,JJ,O
ncbi-sent-119,",",",",O
ncbi-sent-119,respectively,RB,O
ncbi-sent-119,.,.,O
ncbi-sent-120,To,TO,O
ncbi-sent-120,characterize,VB,O
ncbi-sent-120,the,DT,O
ncbi-sent-120,mutational,JJ,O
ncbi-sent-120,spectrum,NN,O
ncbi-sent-120,in,IN,O
ncbi-sent-120,various,JJ,O
ncbi-sent-120,ethnic,JJ,O
ncbi-sent-120,groups,NNS,O
ncbi-sent-120,",",",",O
ncbi-sent-120,mutations,NNS,O
ncbi-sent-120,in,IN,O
ncbi-sent-120,the,DT,O
ncbi-sent-120,GALNS,NNP,O
ncbi-sent-120,gene,NN,O
ncbi-sent-120,in,IN,O
ncbi-sent-120,Colombian,JJ,O
ncbi-sent-120,MPS,NNP,B-DISEASE
ncbi-sent-120,IVA,NNP,I-DISEASE
ncbi-sent-120,patients,NNS,O
ncbi-sent-120,were,VBD,O
ncbi-sent-120,investigated,VBN,O
ncbi-sent-120,",",",",O
ncbi-sent-120,and,CC,O
ncbi-sent-120,genetic,JJ,O
ncbi-sent-120,backgrounds,NNS,O
ncbi-sent-120,were,VBD,O
ncbi-sent-120,extensively,RB,O
ncbi-sent-120,analyzed,VBN,O
ncbi-sent-120,to,TO,O
ncbi-sent-120,identify,VB,O
ncbi-sent-120,racial,JJ,O
ncbi-sent-120,origin,NN,O
ncbi-sent-120,",",",",O
ncbi-sent-120,based,VBN,O
ncbi-sent-120,on,IN,O
ncbi-sent-120,mitochondrial,JJ,O
ncbi-sent-120,DNA,NNP,O
ncbi-sent-120,(,(,O
ncbi-sent-120,mtDNA,NN,O
ncbi-sent-120,),),O
ncbi-sent-120,lineages,VBZ,O
ncbi-sent-120,.,.,O
ncbi-sent-121,Three,CD,O
ncbi-sent-121,novel,JJ,O
ncbi-sent-121,missense,NN,O
ncbi-sent-121,mutations,NNS,O
ncbi-sent-121,never,RB,O
ncbi-sent-121,identified,VBN,O
ncbi-sent-121,previously,RB,O
ncbi-sent-121,in,IN,O
ncbi-sent-121,other,JJ,O
ncbi-sent-121,populations,NNS,O
ncbi-sent-121,and,CC,O
ncbi-sent-121,found,VBN,O
ncbi-sent-121,in,IN,O
ncbi-sent-121,16,CD,O
ncbi-sent-121,out,IN,O
ncbi-sent-121,of,IN,O
ncbi-sent-121,19,CD,O
ncbi-sent-121,Colombian,JJ,O
ncbi-sent-121,MPS,NNP,B-DISEASE
ncbi-sent-121,IVA,NNP,I-DISEASE
ncbi-sent-121,unrelated,JJ,O
ncbi-sent-121,alleles,NNS,O
ncbi-sent-121,account,VBP,O
ncbi-sent-121,for,IN,O
ncbi-sent-121,84,CD,O
ncbi-sent-121,.,.,O
ncbi-sent-122,2,CD,O
ncbi-sent-122,%,NN,O
ncbi-sent-122,of,IN,O
ncbi-sent-122,the,DT,O
ncbi-sent-122,alleles,NNS,O
ncbi-sent-122,in,IN,O
ncbi-sent-122,this,DT,O
ncbi-sent-122,study,NN,O
ncbi-sent-122,.,.,O
ncbi-sent-123,The,DT,O
ncbi-sent-123,G301C,NNP,O
ncbi-sent-123,and,CC,O
ncbi-sent-123,S162F,NNP,O
ncbi-sent-123,mutations,NNS,O
ncbi-sent-123,account,VBP,O
ncbi-sent-123,for,IN,O
ncbi-sent-123,68,CD,O
ncbi-sent-123,.,.,O
ncbi-sent-124,4,CD,O
ncbi-sent-124,%,NN,O
ncbi-sent-124,and,CC,O
ncbi-sent-124,10,CD,O
ncbi-sent-124,.,.,O
ncbi-sent-125,5,CD,O
ncbi-sent-125,%,NN,O
ncbi-sent-125,of,IN,O
ncbi-sent-125,mutations,NNS,O
ncbi-sent-125,",",",",O
ncbi-sent-125,respectively,RB,O
ncbi-sent-125,",",",",O
ncbi-sent-125,whereas,IN,O
ncbi-sent-125,the,DT,O
ncbi-sent-125,remaining,VBG,O
ncbi-sent-125,F69V,NNP,O
ncbi-sent-125,is,VBZ,O
ncbi-sent-125,limited,VBN,O
ncbi-sent-125,to,TO,O
ncbi-sent-125,a,DT,O
ncbi-sent-125,single,JJ,O
ncbi-sent-125,allele,NN,O
ncbi-sent-125,.,.,O
ncbi-sent-126,The,DT,O
ncbi-sent-126,skewed,JJ,O
ncbi-sent-126,prevalence,NN,O
ncbi-sent-126,of,IN,O
ncbi-sent-126,G301C,NNP,O
ncbi-sent-126,in,IN,O
ncbi-sent-126,only,RB,O
ncbi-sent-126,Colombian,JJ,O
ncbi-sent-126,patients,NNS,O
ncbi-sent-126,and,CC,O
ncbi-sent-126,haplotype,JJ,O
ncbi-sent-126,analysis,NN,O
ncbi-sent-126,by,IN,O
ncbi-sent-126,restriction,NN,O
ncbi-sent-126,fragment,NN,O
ncbi-sent-126,length,NN,O
ncbi-sent-126,polymorphisms,NN,O
ncbi-sent-126,in,IN,O
ncbi-sent-126,the,DT,O
ncbi-sent-126,GALNS,NNP,O
ncbi-sent-126,gene,NN,O
ncbi-sent-126,suggest,VBP,O
ncbi-sent-126,that,IN,O
ncbi-sent-126,G301C,NNP,O
ncbi-sent-126,originated,VBD,O
ncbi-sent-126,from,IN,O
ncbi-sent-126,a,DT,O
ncbi-sent-126,common,JJ,O
ncbi-sent-126,ancestor,NN,O
ncbi-sent-126,.,.,O
ncbi-sent-127,Investigation,NN,O
ncbi-sent-127,of,IN,O
ncbi-sent-127,the,DT,O
ncbi-sent-127,genetic,JJ,O
ncbi-sent-127,background,NN,O
ncbi-sent-127,by,IN,O
ncbi-sent-127,means,NNS,O
ncbi-sent-127,of,IN,O
ncbi-sent-127,mtDNA,NN,O
ncbi-sent-127,lineages,NNS,O
ncbi-sent-127,indicate,VBP,O
ncbi-sent-127,that,IN,O
ncbi-sent-127,all,DT,O
ncbi-sent-127,our,PRP$,O
ncbi-sent-127,patients,NNS,O
ncbi-sent-127,are,VBP,O
ncbi-sent-127,probably,RB,O
ncbi-sent-127,of,IN,O
ncbi-sent-127,native,JJ,O
ncbi-sent-127,American,JJ,O
ncbi-sent-127,descent,NN,O
ncbi-sent-127,Low,NNP,O
ncbi-sent-127,frequency,NN,O
ncbi-sent-127,of,IN,O
ncbi-sent-127,BRCA1,NNP,O
ncbi-sent-127,germline,NN,O
ncbi-sent-127,mutations,NNS,O
ncbi-sent-127,in,IN,O
ncbi-sent-127,45,CD,O
ncbi-sent-127,German,JJ,O
ncbi-sent-127,breast,NN,B-DISEASE
ncbi-sent-127,/,NNP,I-DISEASE
ncbi-sent-127,ovarian,JJ,I-DISEASE
ncbi-sent-127,cancer,NN,I-DISEASE
ncbi-sent-127,families,NNS,O
ncbi-sent-127,.,.,O
ncbi-sent-128,In,IN,O
ncbi-sent-128,this,DT,O
ncbi-sent-128,study,NN,O
ncbi-sent-128,we,PRP,O
ncbi-sent-128,investigated,VBD,O
ncbi-sent-128,45,CD,O
ncbi-sent-128,German,JJ,O
ncbi-sent-128,breast,NN,B-DISEASE
ncbi-sent-128,/,NNP,I-DISEASE
ncbi-sent-128,ovarian,JJ,I-DISEASE
ncbi-sent-128,cancer,NN,I-DISEASE
ncbi-sent-128,families,NNS,O
ncbi-sent-128,for,IN,O
ncbi-sent-128,germline,JJ,O
ncbi-sent-128,mutations,NNS,O
ncbi-sent-128,in,IN,O
ncbi-sent-128,the,DT,O
ncbi-sent-128,BRCA1,NNP,O
ncbi-sent-128,gene,NN,O
ncbi-sent-128,.,.,O
ncbi-sent-129,We,PRP,O
ncbi-sent-129,identified,VBD,O
ncbi-sent-129,four,CD,O
ncbi-sent-129,germline,NN,O
ncbi-sent-129,mutations,NNS,O
ncbi-sent-129,in,IN,O
ncbi-sent-129,three,CD,O
ncbi-sent-129,breast,NN,B-DISEASE
ncbi-sent-129,cancer,NN,I-DISEASE
ncbi-sent-129,families,NNS,O
ncbi-sent-129,and,CC,O
ncbi-sent-129,in,IN,O
ncbi-sent-129,one,CD,O
ncbi-sent-129,breast,NN,B-DISEASE
ncbi-sent-129,-,:,I-DISEASE
ncbi-sent-129,ovarian,JJ,I-DISEASE
ncbi-sent-129,cancer,NN,I-DISEASE
ncbi-sent-129,family,NN,O
ncbi-sent-129,.,.,O
ncbi-sent-130,among,IN,O
ncbi-sent-130,these,DT,O
ncbi-sent-130,were,VBD,O
ncbi-sent-130,one,CD,O
ncbi-sent-130,frameshift,NN,O
ncbi-sent-130,mutation,NN,O
ncbi-sent-130,",",",",O
ncbi-sent-130,one,CD,O
ncbi-sent-130,nonsense,NN,O
ncbi-sent-130,mutation,NN,O
ncbi-sent-130,",",",",O
ncbi-sent-130,one,CD,O
ncbi-sent-130,novel,NN,O
ncbi-sent-130,splice,NN,O
ncbi-sent-130,site,NN,O
ncbi-sent-130,mutation,NN,O
ncbi-sent-130,",",",",O
ncbi-sent-130,and,CC,O
ncbi-sent-130,one,CD,O
ncbi-sent-130,missense,NN,O
ncbi-sent-130,mutation,NN,O
ncbi-sent-130,.,.,O
ncbi-sent-131,The,DT,O
ncbi-sent-131,missense,JJ,O
ncbi-sent-131,mutation,NN,O
ncbi-sent-131,was,VBD,O
ncbi-sent-131,also,RB,O
ncbi-sent-131,found,VBN,O
ncbi-sent-131,in,IN,O
ncbi-sent-131,2,CD,O
ncbi-sent-131,.,.,O
ncbi-sent-132,8,CD,O
ncbi-sent-132,%,NN,O
ncbi-sent-132,of,IN,O
ncbi-sent-132,the,DT,O
ncbi-sent-132,general,JJ,O
ncbi-sent-132,population,NN,O
ncbi-sent-132,",",",",O
ncbi-sent-132,suggesting,VBG,O
ncbi-sent-132,that,IN,O
ncbi-sent-132,it,PRP,O
ncbi-sent-132,is,VBZ,O
ncbi-sent-132,not,RB,O
ncbi-sent-132,disease,JJ,O
ncbi-sent-132,associated,VBN,O
ncbi-sent-132,.,.,O
ncbi-sent-133,The,DT,O
ncbi-sent-133,average,JJ,O
ncbi-sent-133,age,NN,O
ncbi-sent-133,of,IN,O
ncbi-sent-133,disease,NN,O
ncbi-sent-133,onset,VBN,O
ncbi-sent-133,in,IN,O
ncbi-sent-133,those,DT,O
ncbi-sent-133,families,NNS,O
ncbi-sent-133,harbouring,VBG,O
ncbi-sent-133,causative,JJ,O
ncbi-sent-133,mutations,NNS,O
ncbi-sent-133,was,VBD,O
ncbi-sent-133,between,IN,O
ncbi-sent-133,32,CD,O
ncbi-sent-133,.,.,O
ncbi-sent-134,3,CD,O
ncbi-sent-134,and,CC,O
ncbi-sent-134,37,CD,O
ncbi-sent-134,.,.,O
ncbi-sent-135,4,CD,O
ncbi-sent-135,years,NNS,O
ncbi-sent-135,",",",",O
ncbi-sent-135,whereas,IN,O
ncbi-sent-135,the,DT,O
ncbi-sent-135,family,NN,O
ncbi-sent-135,harbouring,VBG,O
ncbi-sent-135,the,DT,O
ncbi-sent-135,missense,NN,O
ncbi-sent-135,mutation,NN,O
ncbi-sent-135,had,VBD,O
ncbi-sent-135,an,DT,O
ncbi-sent-135,average,JJ,O
ncbi-sent-135,age,NN,O
ncbi-sent-135,of,IN,O
ncbi-sent-135,onset,NN,O
ncbi-sent-135,of,IN,O
ncbi-sent-135,51,CD,O
ncbi-sent-135,.,.,O
ncbi-sent-136,2,CD,O
ncbi-sent-136,years,NNS,O
ncbi-sent-136,.,.,O
ncbi-sent-137,These,DT,O
ncbi-sent-137,findings,NNS,O
ncbi-sent-137,show,VBP,O
ncbi-sent-137,that,IN,O
ncbi-sent-137,BRCA1,NNP,O
ncbi-sent-137,is,VBZ,O
ncbi-sent-137,implicated,VBN,O
ncbi-sent-137,in,IN,O
ncbi-sent-137,a,DT,O
ncbi-sent-137,small,JJ,O
ncbi-sent-137,fraction,NN,O
ncbi-sent-137,of,IN,O
ncbi-sent-137,breast,NN,B-DISEASE
ncbi-sent-137,/,JJ,I-DISEASE
ncbi-sent-137,ovarian,JJ,I-DISEASE
ncbi-sent-137,cancer,NN,I-DISEASE
ncbi-sent-137,families,NNS,O
ncbi-sent-137,suggesting,VBG,O
ncbi-sent-137,the,DT,O
ncbi-sent-137,involvement,NN,O
ncbi-sent-137,of,IN,O
ncbi-sent-137,another,DT,O
ncbi-sent-137,susceptibility,NN,O
ncbi-sent-137,gene,NN,O
ncbi-sent-137,(,(,O
ncbi-sent-137,s,PRP,O
ncbi-sent-137,),),O
ncbi-sent-137,Paternal,NNP,O
ncbi-sent-137,transmission,NN,O
ncbi-sent-137,of,IN,O
ncbi-sent-137,congenital,JJ,B-DISEASE
ncbi-sent-137,myotonic,JJ,I-DISEASE
ncbi-sent-137,dystrophy,NN,I-DISEASE
ncbi-sent-137,.,.,O
ncbi-sent-138,We,PRP,O
ncbi-sent-138,report,VBP,O
ncbi-sent-138,a,DT,O
ncbi-sent-138,rare,JJ,O
ncbi-sent-138,case,NN,O
ncbi-sent-138,of,IN,O
ncbi-sent-138,paternally,RB,O
ncbi-sent-138,transmitted,VBN,O
ncbi-sent-138,congenital,JJ,B-DISEASE
ncbi-sent-138,myotonic,JJ,I-DISEASE
ncbi-sent-138,dystrophy,NN,I-DISEASE
ncbi-sent-138,(,(,O
ncbi-sent-138,DM,NNP,B-DISEASE
ncbi-sent-138,),),O
ncbi-sent-138,.,.,O
ncbi-sent-139,The,DT,O
ncbi-sent-139,proband,NN,O
ncbi-sent-139,is,VBZ,O
ncbi-sent-139,a,DT,O
ncbi-sent-139,23,CD,O
ncbi-sent-139,year,NN,O
ncbi-sent-139,old,JJ,O
ncbi-sent-139,",",",",O
ncbi-sent-139,mentally,RB,B-DISEASE
ncbi-sent-139,retarded,JJ,I-DISEASE
ncbi-sent-139,male,NN,O
ncbi-sent-139,who,WP,O
ncbi-sent-139,suffers,VBZ,O
ncbi-sent-139,severe,JJ,O
ncbi-sent-139,muscular,JJ,B-DISEASE
ncbi-sent-139,weakness,NN,I-DISEASE
ncbi-sent-139,.,.,O
ncbi-sent-140,He,PRP,O
ncbi-sent-140,presented,VBD,O
ncbi-sent-140,with,IN,O
ncbi-sent-140,respiratory,NN,O
ncbi-sent-140,and,CC,O
ncbi-sent-140,feeding,NN,O
ncbi-sent-140,difficulties,NNS,O
ncbi-sent-140,at,IN,O
ncbi-sent-140,birth,NN,O
ncbi-sent-140,.,.,O
ncbi-sent-141,His,PRP$,O
ncbi-sent-141,two,CD,O
ncbi-sent-141,sibs,NNS,O
ncbi-sent-141,suffer,VBP,O
ncbi-sent-141,from,IN,O
ncbi-sent-141,childhood,NN,O
ncbi-sent-141,onset,VBN,O
ncbi-sent-141,DM,NNP,B-DISEASE
ncbi-sent-141,.,.,O
ncbi-sent-142,Their,PRP$,O
ncbi-sent-142,late,JJ,O
ncbi-sent-142,father,NN,O
ncbi-sent-142,had,VBD,O
ncbi-sent-142,the,DT,O
ncbi-sent-142,adult,NN,O
ncbi-sent-142,type,NN,O
ncbi-sent-142,of,IN,O
ncbi-sent-142,DM,NNP,B-DISEASE
ncbi-sent-142,",",",",O
ncbi-sent-142,with,IN,O
ncbi-sent-142,onset,VBN,O
ncbi-sent-142,around,IN,O
ncbi-sent-142,30,CD,O
ncbi-sent-142,years,NNS,O
ncbi-sent-142,.,.,O
ncbi-sent-143,Only,RB,O
ncbi-sent-143,six,CD,O
ncbi-sent-143,other,JJ,O
ncbi-sent-143,cases,NNS,O
ncbi-sent-143,of,IN,O
ncbi-sent-143,paternal,JJ,O
ncbi-sent-143,transmission,NN,O
ncbi-sent-143,of,IN,O
ncbi-sent-143,congenital,JJ,B-DISEASE
ncbi-sent-143,DM,NNP,I-DISEASE
ncbi-sent-143,have,VBP,O
ncbi-sent-143,been,VBN,O
ncbi-sent-143,reported,VBN,O
ncbi-sent-143,recently,RB,O
ncbi-sent-143,.,.,O
ncbi-sent-144,We,PRP,O
ncbi-sent-144,review,VBP,O
ncbi-sent-144,the,DT,O
ncbi-sent-144,sex,NN,O
ncbi-sent-144,related,JJ,O
ncbi-sent-144,effects,NNS,O
ncbi-sent-144,on,IN,O
ncbi-sent-144,transmission,NN,O
ncbi-sent-144,of,IN,O
ncbi-sent-144,congenital,JJ,B-DISEASE
ncbi-sent-144,DM,NNP,I-DISEASE
ncbi-sent-144,.,.,O
ncbi-sent-145,Decreased,VBN,O
ncbi-sent-145,fertility,NN,O
ncbi-sent-145,of,IN,O
ncbi-sent-145,males,NNS,O
ncbi-sent-145,with,IN,O
ncbi-sent-145,adult,NN,O
ncbi-sent-145,onset,VBN,O
ncbi-sent-145,DM,NNP,B-DISEASE
ncbi-sent-145,and,CC,O
ncbi-sent-145,contraction,NN,O
ncbi-sent-145,of,IN,O
ncbi-sent-145,the,DT,O
ncbi-sent-145,repeat,NN,O
ncbi-sent-145,upon,IN,O
ncbi-sent-145,male,JJ,O
ncbi-sent-145,transmission,NN,O
ncbi-sent-145,contribute,NN,O
ncbi-sent-145,to,TO,O
ncbi-sent-145,the,DT,O
ncbi-sent-145,almost,RB,O
ncbi-sent-145,absent,JJ,O
ncbi-sent-145,occurrence,NN,O
ncbi-sent-145,of,IN,O
ncbi-sent-145,paternal,JJ,O
ncbi-sent-145,transmission,NN,O
ncbi-sent-145,of,IN,O
ncbi-sent-145,congenital,JJ,B-DISEASE
ncbi-sent-145,DM,NNP,I-DISEASE
ncbi-sent-145,.,.,O
ncbi-sent-146,Also,RB,O
ncbi-sent-146,the,DT,O
ncbi-sent-146,fathers,NNS,O
ncbi-sent-146,of,IN,O
ncbi-sent-146,the,DT,O
ncbi-sent-146,reported,VBN,O
ncbi-sent-146,congenitally,RB,O
ncbi-sent-146,affected,JJ,O
ncbi-sent-146,children,NNS,O
ncbi-sent-146,showed,VBD,O
ncbi-sent-146,",",",",O
ncbi-sent-146,on,IN,O
ncbi-sent-146,average,NN,O
ncbi-sent-146,",",",",O
ncbi-sent-146,shorter,JJR,O
ncbi-sent-146,CTG,NNP,O
ncbi-sent-146,repeat,NN,O
ncbi-sent-146,lengths,NNS,O
ncbi-sent-146,and,CC,O
ncbi-sent-146,hence,RB,O
ncbi-sent-146,less,JJR,O
ncbi-sent-146,severe,JJ,O
ncbi-sent-146,clinical,NN,O
ncbi-sent-146,symptoms,NNS,O
ncbi-sent-146,than,IN,O
ncbi-sent-146,the,DT,O
ncbi-sent-146,mothers,NNS,O
ncbi-sent-146,of,IN,O
ncbi-sent-146,children,NNS,O
ncbi-sent-146,with,IN,O
ncbi-sent-146,congenital,JJ,B-DISEASE
ncbi-sent-146,DM,NNP,I-DISEASE
ncbi-sent-146,.,.,O
ncbi-sent-147,We,PRP,O
ncbi-sent-147,conclude,VBP,O
ncbi-sent-147,that,IN,O
ncbi-sent-147,paternal,JJ,O
ncbi-sent-147,transmission,NN,O
ncbi-sent-147,of,IN,O
ncbi-sent-147,congenital,JJ,B-DISEASE
ncbi-sent-147,DM,NNP,I-DISEASE
ncbi-sent-147,is,VBZ,O
ncbi-sent-147,rare,JJ,O
ncbi-sent-147,and,CC,O
ncbi-sent-147,preferentially,RB,O
ncbi-sent-147,occurs,VBZ,O
ncbi-sent-147,with,IN,O
ncbi-sent-147,onset,NN,O
ncbi-sent-147,of,IN,O
ncbi-sent-147,DM,NNP,B-DISEASE
ncbi-sent-147,past,IN,O
ncbi-sent-147,30,CD,O
ncbi-sent-147,years,NNS,O
ncbi-sent-147,in,IN,O
ncbi-sent-147,the,DT,O
ncbi-sent-147,father,NN,O
ncbi-sent-147,.,.,O
ncbi-sent-148,.,.,O
ncbi-sent-149,The,DT,O
ncbi-sent-149,RB1,NNP,O
ncbi-sent-149,gene,NN,O
ncbi-sent-149,mutation,NN,O
ncbi-sent-149,in,IN,O
ncbi-sent-149,a,DT,O
ncbi-sent-149,child,NN,O
ncbi-sent-149,with,IN,O
ncbi-sent-149,ectopic,JJ,B-DISEASE
ncbi-sent-149,intracranial,JJ,I-DISEASE
ncbi-sent-149,retinoblastoma,NN,I-DISEASE
ncbi-sent-149,.,.,O
ncbi-sent-150,The,DT,O
ncbi-sent-150,RB1,NNP,O
ncbi-sent-150,gene,NN,O
ncbi-sent-150,mutation,NN,O
ncbi-sent-150,was,VBD,O
ncbi-sent-150,investigated,VBN,O
ncbi-sent-150,in,IN,O
ncbi-sent-150,a,DT,O
ncbi-sent-150,child,NN,O
ncbi-sent-150,with,IN,O
ncbi-sent-150,ectopic,JJ,B-DISEASE
ncbi-sent-150,intracranial,JJ,I-DISEASE
ncbi-sent-150,retinoblastoma,NN,I-DISEASE
ncbi-sent-150,using,VBG,O
ncbi-sent-150,DNA,NNP,O
ncbi-sent-150,obtained,VBN,O
ncbi-sent-150,from,IN,O
ncbi-sent-150,both,CC,O
ncbi-sent-150,the,DT,O
ncbi-sent-150,pineal,NN,B-DISEASE
ncbi-sent-150,and,CC,I-DISEASE
ncbi-sent-150,retinal,JJ,I-DISEASE
ncbi-sent-150,tumours,NN,I-DISEASE
ncbi-sent-150,of,IN,O
ncbi-sent-150,the,DT,O
ncbi-sent-150,patient,NN,O
ncbi-sent-150,.,.,O
ncbi-sent-151,A,DT,O
ncbi-sent-151,nonsense,JJ,O
ncbi-sent-151,mutation,NN,O
ncbi-sent-151,in,IN,O
ncbi-sent-151,exon,JJ,O
ncbi-sent-151,17,CD,O
ncbi-sent-151,(,(,O
ncbi-sent-151,codon,VB,O
ncbi-sent-151,556,CD,O
ncbi-sent-151,),),O
ncbi-sent-151,of,IN,O
ncbi-sent-151,the,DT,O
ncbi-sent-151,RB1,NNP,O
ncbi-sent-151,gene,NN,O
ncbi-sent-151,was,VBD,O
ncbi-sent-151,found,VBN,O
ncbi-sent-151,to,TO,O
ncbi-sent-151,be,VB,O
ncbi-sent-151,present,JJ,O
ncbi-sent-151,homozygously,RB,O
ncbi-sent-151,in,IN,O
ncbi-sent-151,both,CC,O
ncbi-sent-151,the,DT,O
ncbi-sent-151,retinal,NN,B-DISEASE
ncbi-sent-151,and,CC,I-DISEASE
ncbi-sent-151,the,DT,I-DISEASE
ncbi-sent-151,pineal,NN,I-DISEASE
ncbi-sent-151,tumours,NN,I-DISEASE
ncbi-sent-151,.,.,O
ncbi-sent-152,The,DT,O
ncbi-sent-152,same,JJ,O
ncbi-sent-152,mutation,NN,O
ncbi-sent-152,was,VBD,O
ncbi-sent-152,present,JJ,O
ncbi-sent-152,heterozygously,RB,O
ncbi-sent-152,in,IN,O
ncbi-sent-152,the,DT,O
ncbi-sent-152,DNA,NN,O
ncbi-sent-152,from,IN,O
ncbi-sent-152,the,DT,O
ncbi-sent-152,constitutional,JJ,O
ncbi-sent-152,cells,NNS,O
ncbi-sent-152,of,IN,O
ncbi-sent-152,the,DT,O
ncbi-sent-152,patient,NN,O
ncbi-sent-152,",",",",O
ncbi-sent-152,proving,VBG,O
ncbi-sent-152,it,PRP,O
ncbi-sent-152,to,TO,O
ncbi-sent-152,be,VB,O
ncbi-sent-152,of,IN,O
ncbi-sent-152,germline,JJ,O
ncbi-sent-152,origin,NN,O
ncbi-sent-152,.,.,O
ncbi-sent-153,The,DT,O
ncbi-sent-153,initial,JJ,O
ncbi-sent-153,mutation,NN,O
ncbi-sent-153,was,VBD,O
ncbi-sent-153,shown,VBN,O
ncbi-sent-153,to,TO,O
ncbi-sent-153,have,VB,O
ncbi-sent-153,occurred,VBN,O
ncbi-sent-153,in,IN,O
ncbi-sent-153,the,DT,O
ncbi-sent-153,paternally,RB,O
ncbi-sent-153,derived,VBN,O
ncbi-sent-153,RB1,NNP,O
ncbi-sent-153,allele,NN,O
ncbi-sent-153,.,.,O
ncbi-sent-154,The,DT,O
ncbi-sent-154,mutation,NN,O
ncbi-sent-154,is,VBZ,O
ncbi-sent-154,in,IN,O
ncbi-sent-154,an,DT,O
ncbi-sent-154,area,NN,O
ncbi-sent-154,of,IN,O
ncbi-sent-154,the,DT,O
ncbi-sent-154,gene,NN,O
ncbi-sent-154,that,WDT,O
ncbi-sent-154,encodes,VBZ,O
ncbi-sent-154,the,DT,O
ncbi-sent-154,protein,NN,O
ncbi-sent-154,-,:,O
ncbi-sent-154,binding,JJ,O
ncbi-sent-154,region,NN,O
ncbi-sent-154,known,VBN,O
ncbi-sent-154,as,IN,O
ncbi-sent-154,the,DT,O
ncbi-sent-154,pocket,NN,O
ncbi-sent-154,region,NN,O
ncbi-sent-154,and,CC,O
ncbi-sent-154,has,VBZ,O
ncbi-sent-154,been,VBN,O
ncbi-sent-154,detected,VBN,O
ncbi-sent-154,in,IN,O
ncbi-sent-154,other,JJ,O
ncbi-sent-154,cases,NNS,O
ncbi-sent-154,of,IN,O
ncbi-sent-154,retinoblastoma,NN,B-DISEASE
ncbi-sent-154,.,.,O
ncbi-sent-155,.,.,O
ncbi-sent-156,Low,JJ,O
ncbi-sent-156,levels,NNS,O
ncbi-sent-156,of,IN,O
ncbi-sent-156,beta,NN,O
ncbi-sent-156,hexosaminidase,NN,O
ncbi-sent-156,A,NNP,O
ncbi-sent-156,in,IN,O
ncbi-sent-156,healthy,JJ,O
ncbi-sent-156,individuals,NNS,O
ncbi-sent-156,with,IN,O
ncbi-sent-156,apparent,JJ,O
ncbi-sent-156,deficiency,NN,O
ncbi-sent-156,of,IN,O
ncbi-sent-156,this,DT,O
ncbi-sent-156,enzyme,NN,O
ncbi-sent-156,.,.,O
ncbi-sent-157,Appreciable,JJ,O
ncbi-sent-157,beta,NN,O
ncbi-sent-157,hexosaminidase,NN,O
ncbi-sent-157,A,NNP,O
ncbi-sent-157,(,(,O
ncbi-sent-157,hex,VB,O
ncbi-sent-157,A,DT,O
ncbi-sent-157,),),O
ncbi-sent-157,activity,NN,O
ncbi-sent-157,has,VBZ,O
ncbi-sent-157,been,VBN,O
ncbi-sent-157,detected,VBN,O
ncbi-sent-157,in,IN,O
ncbi-sent-157,cultured,JJ,O
ncbi-sent-157,skin,NN,O
ncbi-sent-157,fibroblasts,NNS,O
ncbi-sent-157,and,CC,O
ncbi-sent-157,melanoma,NNS,B-DISEASE
ncbi-sent-157,tissue,NN,O
ncbi-sent-157,from,IN,O
ncbi-sent-157,healthy,JJ,O
ncbi-sent-157,individuals,NNS,O
ncbi-sent-157,previously,RB,O
ncbi-sent-157,reported,VBD,O
ncbi-sent-157,as,IN,O
ncbi-sent-157,having,VBG,O
ncbi-sent-157,deficiency,NN,B-DISEASE
ncbi-sent-157,of,IN,I-DISEASE
ncbi-sent-157,hex,NN,I-DISEASE
ncbi-sent-157,A,NNP,I-DISEASE
ncbi-sent-157,activity,NN,O
ncbi-sent-157,indistinguishable,NN,O
ncbi-sent-157,from,IN,O
ncbi-sent-157,that,DT,O
ncbi-sent-157,of,IN,O
ncbi-sent-157,patients,NNS,O
ncbi-sent-157,with,IN,O
ncbi-sent-157,Tay,NNP,B-DISEASE
ncbi-sent-157,-,:,I-DISEASE
ncbi-sent-157,Sachs,NNP,I-DISEASE
ncbi-sent-157,disease,NN,I-DISEASE
ncbi-sent-157,(,(,O
ncbi-sent-157,TSD,NNP,B-DISEASE
ncbi-sent-157,),),O
ncbi-sent-157,.,.,O
ncbi-sent-158,Identification,NN,O
ncbi-sent-158,and,CC,O
ncbi-sent-158,quantitation,NN,O
ncbi-sent-158,of,IN,O
ncbi-sent-158,hex,NN,O
ncbi-sent-158,A,NNP,O
ncbi-sent-158,",",",",O
ncbi-sent-158,amounting,VBG,O
ncbi-sent-158,to,TO,O
ncbi-sent-158,3,CD,O
ncbi-sent-158,.,.,O
ncbi-sent-159,5,CD,O
ncbi-sent-159,%,NN,O
ncbi-sent-159,-,:,O
ncbi-sent-159,6,CD,O
ncbi-sent-159,.,.,O
ncbi-sent-160,9,CD,O
ncbi-sent-160,%,NN,O
ncbi-sent-160,of,IN,O
ncbi-sent-160,total,JJ,O
ncbi-sent-160,beta,JJ,O
ncbi-sent-160,hexosaminidase,NN,O
ncbi-sent-160,activity,NN,O
ncbi-sent-160,",",",",O
ncbi-sent-160,has,VBZ,O
ncbi-sent-160,been,VBN,O
ncbi-sent-160,obtained,VBN,O
ncbi-sent-160,by,IN,O
ncbi-sent-160,cellulose,JJ,O
ncbi-sent-160,acetate,NN,O
ncbi-sent-160,gel,NN,O
ncbi-sent-160,electrophoresis,NN,O
ncbi-sent-160,",",",",O
ncbi-sent-160,DEAE,NNP,O
ncbi-sent-160,-,:,O
ncbi-sent-160,cellulose,NN,O
ncbi-sent-160,ion,NN,O
ncbi-sent-160,-,:,O
ncbi-sent-160,exchange,NN,O
ncbi-sent-160,chromatography,NN,O
ncbi-sent-160,",",",",O
ncbi-sent-160,radial,JJ,O
ncbi-sent-160,immunodiffusion,NN,O
ncbi-sent-160,",",",",O
ncbi-sent-160,and,CC,O
ncbi-sent-160,radioimmunoassay,VB,O
ncbi-sent-160,.,.,O
ncbi-sent-161,Previous,JJ,O
ncbi-sent-161,family,NN,O
ncbi-sent-161,studies,NNS,O
ncbi-sent-161,suggested,VBD,O
ncbi-sent-161,that,IN,O
ncbi-sent-161,these,DT,O
ncbi-sent-161,individuals,NNS,O
ncbi-sent-161,may,MD,O
ncbi-sent-161,be,VB,O
ncbi-sent-161,compound,VBN,O
ncbi-sent-161,heterozygotes,NNS,O
ncbi-sent-161,for,IN,O
ncbi-sent-161,the,DT,O
ncbi-sent-161,common,JJ,O
ncbi-sent-161,mutant,NN,O
ncbi-sent-161,TSD,NNP,B-DISEASE
ncbi-sent-161,gene,NN,O
ncbi-sent-161,and,CC,O
ncbi-sent-161,a,DT,O
ncbi-sent-161,rare,JJ,O
ncbi-sent-161,(,(,O
ncbi-sent-161,allelic,JJ,O
ncbi-sent-161,),),O
ncbi-sent-161,mutant,JJ,O
ncbi-sent-161,gene,NN,O
ncbi-sent-161,.,.,O
ncbi-sent-162,Thus,RB,O
ncbi-sent-162,",",",",O
ncbi-sent-162,the,DT,O
ncbi-sent-162,postulated,JJ,O
ncbi-sent-162,rate,NN,O
ncbi-sent-162,mutant,JJ,O
ncbi-sent-162,gene,NN,O
ncbi-sent-162,appears,VBZ,O
ncbi-sent-162,to,TO,O
ncbi-sent-162,code,VB,O
ncbi-sent-162,for,IN,O
ncbi-sent-162,the,DT,O
ncbi-sent-162,expression,NN,O
ncbi-sent-162,of,IN,O
ncbi-sent-162,low,JJ,O
ncbi-sent-162,amounts,NNS,O
ncbi-sent-162,of,IN,O
ncbi-sent-162,hex,NN,O
ncbi-sent-162,A,NNP,O
ncbi-sent-162,.,.,O
ncbi-sent-163,Heterozygotes,VBZ,O
ncbi-sent-163,for,IN,O
ncbi-sent-163,the,DT,O
ncbi-sent-163,rare,JJ,O
ncbi-sent-163,mutant,NN,O
ncbi-sent-163,may,MD,O
ncbi-sent-163,be,VB,O
ncbi-sent-163,indistinguishable,JJ,O
ncbi-sent-163,from,IN,O
ncbi-sent-163,heterozygotes,NNS,O
ncbi-sent-163,for,IN,O
ncbi-sent-163,the,DT,O
ncbi-sent-163,common,JJ,O
ncbi-sent-163,TSD,NNP,B-DISEASE
ncbi-sent-163,mutant,NN,O
ncbi-sent-163,.,.,O
ncbi-sent-164,However,RB,O
ncbi-sent-164,",",",",O
ncbi-sent-164,direct,JJ,O
ncbi-sent-164,visualization,NN,O
ncbi-sent-164,and,CC,O
ncbi-sent-164,quantitation,NN,O
ncbi-sent-164,of,IN,O
ncbi-sent-164,hex,NN,O
ncbi-sent-164,A,NNP,O
ncbi-sent-164,by,IN,O
ncbi-sent-164,the,DT,O
ncbi-sent-164,methods,NNS,O
ncbi-sent-164,described,VBD,O
ncbi-sent-164,may,MD,O
ncbi-sent-164,prevent,VB,O
ncbi-sent-164,false,JJ,O
ncbi-sent-164,-,:,O
ncbi-sent-164,positive,JJ,O
ncbi-sent-164,prenatal,JJ,O
ncbi-sent-164,diagnosis,NN,O
ncbi-sent-164,of,IN,O
ncbi-sent-164,TSD,NNP,B-DISEASE
ncbi-sent-164,in,IN,O
ncbi-sent-164,fetuses,NNS,O
ncbi-sent-164,having,VBG,O
ncbi-sent-164,the,DT,O
ncbi-sent-164,incomplete,JJ,O
ncbi-sent-164,hex,NN,B-DISEASE
ncbi-sent-164,A,NNP,I-DISEASE
ncbi-sent-164,deficiency,NN,I-DISEASE
ncbi-sent-164,of,IN,O
ncbi-sent-164,the,DT,O
ncbi-sent-164,type,NN,O
ncbi-sent-164,described,VBN,O
ncbi-sent-164,in,IN,O
ncbi-sent-164,the,DT,O
ncbi-sent-164,four,CD,O
ncbi-sent-164,healthy,JJ,O
ncbi-sent-164,individuals,NNS,O
ncbi-sent-164,The,DT,O
ncbi-sent-164,tumor,NN,B-DISEASE
ncbi-sent-164,suppressor,NN,O
ncbi-sent-164,gene,NN,O
ncbi-sent-164,Smad4,NNP,O
ncbi-sent-164,/,NNP,O
ncbi-sent-164,Dpc4,NNP,O
ncbi-sent-164,is,VBZ,O
ncbi-sent-164,required,VBN,O
ncbi-sent-164,for,IN,O
ncbi-sent-164,gastrulation,NN,O
ncbi-sent-164,and,CC,O
ncbi-sent-164,later,RB,O
ncbi-sent-164,for,IN,O
ncbi-sent-164,anterior,JJ,O
ncbi-sent-164,development,NN,O
ncbi-sent-164,of,IN,O
ncbi-sent-164,the,DT,O
ncbi-sent-164,mouse,NN,O
ncbi-sent-164,embryo,NN,O
ncbi-sent-164,.,.,O
ncbi-sent-165,Mutations,NNS,O
ncbi-sent-165,in,IN,O
ncbi-sent-165,the,DT,O
ncbi-sent-165,SMAD4,NNP,O
ncbi-sent-165,/,NNP,O
ncbi-sent-165,DPC4,NNP,O
ncbi-sent-165,tumor,NN,B-DISEASE
ncbi-sent-165,suppressor,NN,O
ncbi-sent-165,gene,NN,O
ncbi-sent-165,",",",",O
ncbi-sent-165,a,DT,O
ncbi-sent-165,key,JJ,O
ncbi-sent-165,signal,JJ,O
ncbi-sent-165,transducer,NN,O
ncbi-sent-165,in,IN,O
ncbi-sent-165,most,JJS,O
ncbi-sent-165,TGFbeta,NNP,O
ncbi-sent-165,-,:,O
ncbi-sent-165,related,JJ,O
ncbi-sent-165,pathways,NNS,O
ncbi-sent-165,",",",",O
ncbi-sent-165,are,VBP,O
ncbi-sent-165,involved,VBN,O
ncbi-sent-165,in,IN,O
ncbi-sent-165,50,CD,O
ncbi-sent-165,%,NN,O
ncbi-sent-165,of,IN,O
ncbi-sent-165,pancreatic,JJ,B-DISEASE
ncbi-sent-165,cancers,NNS,I-DISEASE
ncbi-sent-165,.,.,O
ncbi-sent-166,Homozygous,JJ,O
ncbi-sent-166,Smad4,NNP,O
ncbi-sent-166,mutant,NN,O
ncbi-sent-166,mice,NN,O
ncbi-sent-166,die,NN,O
ncbi-sent-166,before,IN,O
ncbi-sent-166,day,NN,O
ncbi-sent-166,7,CD,O
ncbi-sent-166,.,.,O
ncbi-sent-167,5,CD,O
ncbi-sent-167,of,IN,O
ncbi-sent-167,embryogenesis,NN,O
ncbi-sent-167,.,.,O
ncbi-sent-168,Mutant,NNP,O
ncbi-sent-168,embryos,NN,O
ncbi-sent-168,have,VBP,O
ncbi-sent-168,reduced,VBN,O
ncbi-sent-168,size,NN,O
ncbi-sent-168,",",",",O
ncbi-sent-168,fail,VBP,O
ncbi-sent-168,to,TO,O
ncbi-sent-168,gastrulate,VB,O
ncbi-sent-168,or,CC,O
ncbi-sent-168,express,VB,O
ncbi-sent-168,a,DT,O
ncbi-sent-168,mesodermal,JJ,O
ncbi-sent-168,marker,NN,O
ncbi-sent-168,",",",",O
ncbi-sent-168,and,CC,O
ncbi-sent-168,show,VB,O
ncbi-sent-168,abnormal,JJ,O
ncbi-sent-168,visceral,JJ,O
ncbi-sent-168,endoderm,NN,O
ncbi-sent-168,development,NN,O
ncbi-sent-168,.,.,O
ncbi-sent-169,Growth,NNP,B-DISEASE
ncbi-sent-169,retardation,NN,I-DISEASE
ncbi-sent-169,of,IN,O
ncbi-sent-169,the,DT,O
ncbi-sent-169,Smad4,NNP,O
ncbi-sent-169,-,:,O
ncbi-sent-169,deficient,NN,O
ncbi-sent-169,embryos,JJ,O
ncbi-sent-169,results,NNS,O
ncbi-sent-169,from,IN,O
ncbi-sent-169,reduced,VBN,O
ncbi-sent-169,cell,NN,O
ncbi-sent-169,proliferation,NN,O
ncbi-sent-169,rather,RB,O
ncbi-sent-169,than,IN,O
ncbi-sent-169,increased,VBN,O
ncbi-sent-169,apoptosis,NN,O
ncbi-sent-169,.,.,O
ncbi-sent-170,Aggregation,NN,O
ncbi-sent-170,of,IN,O
ncbi-sent-170,mutant,JJ,O
ncbi-sent-170,Smad4,NNP,O
ncbi-sent-170,ES,NNP,O
ncbi-sent-170,cells,NNS,O
ncbi-sent-170,with,IN,O
ncbi-sent-170,wild,JJ,O
ncbi-sent-170,-,:,O
ncbi-sent-170,type,NN,O
ncbi-sent-170,tetraploid,NN,O
ncbi-sent-170,morulae,NN,O
ncbi-sent-170,rescues,VBZ,O
ncbi-sent-170,the,DT,O
ncbi-sent-170,gastrulation,NN,B-DISEASE
ncbi-sent-170,defect,NN,I-DISEASE
ncbi-sent-170,.,.,O
ncbi-sent-171,These,DT,O
ncbi-sent-171,results,NNS,O
ncbi-sent-171,indicate,VBP,O
ncbi-sent-171,that,IN,O
ncbi-sent-171,Smad4,NNP,O
ncbi-sent-171,is,VBZ,O
ncbi-sent-171,initially,RB,O
ncbi-sent-171,required,VBN,O
ncbi-sent-171,for,IN,O
ncbi-sent-171,the,DT,O
ncbi-sent-171,differentiation,NN,O
ncbi-sent-171,of,IN,O
ncbi-sent-171,the,DT,O
ncbi-sent-171,visceral,JJ,O
ncbi-sent-171,endoderm,NN,O
ncbi-sent-171,and,CC,O
ncbi-sent-171,that,IN,O
ncbi-sent-171,the,DT,O
ncbi-sent-171,gastrulation,NN,B-DISEASE
ncbi-sent-171,defect,NN,I-DISEASE
ncbi-sent-171,in,IN,O
ncbi-sent-171,the,DT,O
ncbi-sent-171,epiblast,NN,O
ncbi-sent-171,is,VBZ,O
ncbi-sent-171,secondary,JJ,O
ncbi-sent-171,and,CC,O
ncbi-sent-171,non,JJ,O
ncbi-sent-171,-,:,O
ncbi-sent-171,cell,NN,O
ncbi-sent-171,autonomous,JJ,O
ncbi-sent-171,.,.,O
ncbi-sent-172,Rescued,VBN,O
ncbi-sent-172,embryos,JJ,O
ncbi-sent-172,show,NN,O
ncbi-sent-172,severe,JJ,O
ncbi-sent-172,anterior,JJ,O
ncbi-sent-172,truncations,NNS,O
ncbi-sent-172,",",",",O
ncbi-sent-172,indicating,VBG,O
ncbi-sent-172,a,DT,O
ncbi-sent-172,second,JJ,O
ncbi-sent-172,important,JJ,O
ncbi-sent-172,role,NN,O
ncbi-sent-172,for,IN,O
ncbi-sent-172,Smad4,NNP,O
ncbi-sent-172,in,IN,O
ncbi-sent-172,anterior,JJ,O
ncbi-sent-172,patterning,NN,O
ncbi-sent-172,during,IN,O
ncbi-sent-172,embryogenesis,NN,O
ncbi-sent-172,.,.,O
ncbi-sent-173,Prevalence,NN,O
ncbi-sent-173,of,IN,O
ncbi-sent-173,p16,NN,O
ncbi-sent-173,and,CC,O
ncbi-sent-173,CDK4,NNP,O
ncbi-sent-173,germline,VBP,O
ncbi-sent-173,mutations,NNS,O
ncbi-sent-173,in,IN,O
ncbi-sent-173,48,CD,O
ncbi-sent-173,melanoma,NN,B-DISEASE
ncbi-sent-173,-,:,O
ncbi-sent-173,prone,NN,O
ncbi-sent-173,families,NNS,O
ncbi-sent-173,in,IN,O
ncbi-sent-173,France,NNP,O
ncbi-sent-173,.,.,O
ncbi-sent-174,The,DT,O
ncbi-sent-174,French,JJ,O
ncbi-sent-174,Familial,NNP,B-DISEASE
ncbi-sent-174,Melanoma,NNP,I-DISEASE
ncbi-sent-174,Study,NNP,O
ncbi-sent-174,Group,NNP,O
ncbi-sent-174,.,.,O
ncbi-sent-175,Germline,NNP,O
ncbi-sent-175,mutations,NNS,O
ncbi-sent-175,in,IN,O
ncbi-sent-175,the,DT,O
ncbi-sent-175,p16,NN,O
ncbi-sent-175,and,CC,O
ncbi-sent-175,CDK4,NNP,O
ncbi-sent-175,genes,NNS,O
ncbi-sent-175,have,VBP,O
ncbi-sent-175,been,VBN,O
ncbi-sent-175,reported,VBN,O
ncbi-sent-175,in,IN,O
ncbi-sent-175,a,DT,O
ncbi-sent-175,subset,NN,O
ncbi-sent-175,of,IN,O
ncbi-sent-175,melanoma,NN,B-DISEASE
ncbi-sent-175,pedigrees,NNS,O
ncbi-sent-175,",",",",O
ncbi-sent-175,but,CC,O
ncbi-sent-175,their,PRP$,O
ncbi-sent-175,prevalence,NN,O
ncbi-sent-175,is,VBZ,O
ncbi-sent-175,not,RB,O
ncbi-sent-175,well,RB,O
ncbi-sent-175,known,VBN,O
ncbi-sent-175,.,.,O
ncbi-sent-176,We,PRP,O
ncbi-sent-176,searched,VBD,O
ncbi-sent-176,for,IN,O
ncbi-sent-176,such,JJ,O
ncbi-sent-176,germline,JJ,O
ncbi-sent-176,mutations,NNS,O
ncbi-sent-176,in,IN,O
ncbi-sent-176,48,CD,O
ncbi-sent-176,French,JJ,O
ncbi-sent-176,melanoma,NN,B-DISEASE
ncbi-sent-176,-,:,O
ncbi-sent-176,prone,NN,O
ncbi-sent-176,families,NNS,O
ncbi-sent-176,selected,VBN,O
ncbi-sent-176,according,VBG,O
ncbi-sent-176,to,TO,O
ncbi-sent-176,two,CD,O
ncbi-sent-176,major,JJ,O
ncbi-sent-176,criteria,NNS,O
ncbi-sent-176,families,NNS,O
ncbi-sent-176,with,IN,O
ncbi-sent-176,at,IN,O
ncbi-sent-176,least,JJS,O
ncbi-sent-176,three,CD,O
ncbi-sent-176,affected,JJ,O
ncbi-sent-176,members,NNS,O
ncbi-sent-176,(,(,O
ncbi-sent-176,n,JJ,O
ncbi-sent-176,=,NNP,O
ncbi-sent-176,20,CD,O
ncbi-sent-176,),),O
ncbi-sent-176,or,CC,O
ncbi-sent-176,families,NNS,O
ncbi-sent-176,with,IN,O
ncbi-sent-176,two,CD,O
ncbi-sent-176,affected,JJ,O
ncbi-sent-176,members,NNS,O
ncbi-sent-176,",",",",O
ncbi-sent-176,one,CD,O
ncbi-sent-176,of,IN,O
ncbi-sent-176,them,PRP,O
ncbi-sent-176,affected,VBD,O
ncbi-sent-176,before,IN,O
ncbi-sent-176,the,DT,O
ncbi-sent-176,age,NN,O
ncbi-sent-176,of,IN,O
ncbi-sent-176,50,CD,O
ncbi-sent-176,(,(,O
ncbi-sent-176,n,JJ,O
ncbi-sent-176,=,NNP,O
ncbi-sent-176,28,CD,O
ncbi-sent-176,),),O
ncbi-sent-176,",",",",O
ncbi-sent-176,and,CC,O
ncbi-sent-176,one,CD,O
ncbi-sent-176,additional,JJ,O
ncbi-sent-176,minor,JJ,O
ncbi-sent-176,criterion,NN,O
ncbi-sent-176,.,.,O
ncbi-sent-177,Sixteen,JJ,O
ncbi-sent-177,different,JJ,O
ncbi-sent-177,p16,NN,O
ncbi-sent-177,germline,NN,O
ncbi-sent-177,mutations,NNS,O
ncbi-sent-177,were,VBD,O
ncbi-sent-177,found,VBN,O
ncbi-sent-177,in,IN,O
ncbi-sent-177,21,CD,O
ncbi-sent-177,families,NNS,O
ncbi-sent-177,",",",",O
ncbi-sent-177,while,IN,O
ncbi-sent-177,one,CD,O
ncbi-sent-177,germline,NN,O
ncbi-sent-177,mutation,NN,O
ncbi-sent-177,",",",",O
ncbi-sent-177,Arg24His,NNP,O
ncbi-sent-177,",",",",O
ncbi-sent-177,was,VBD,O
ncbi-sent-177,detected,VBN,O
ncbi-sent-177,in,IN,O
ncbi-sent-177,the,DT,O
ncbi-sent-177,CDK4,NNP,O
ncbi-sent-177,gene,NN,O
ncbi-sent-177,.,.,O
ncbi-sent-178,The,DT,O
ncbi-sent-178,frequency,NN,O
ncbi-sent-178,of,IN,O
ncbi-sent-178,p16,JJ,O
ncbi-sent-178,gene,NN,O
ncbi-sent-178,mutation,NN,O
ncbi-sent-178,in,IN,O
ncbi-sent-178,our,PRP$,O
ncbi-sent-178,sample,NN,O
ncbi-sent-178,(,(,O
ncbi-sent-178,44,CD,O
ncbi-sent-178,%,NN,O
ncbi-sent-178,),),O
ncbi-sent-178,is,VBZ,O
ncbi-sent-178,among,IN,O
ncbi-sent-178,the,DT,O
ncbi-sent-178,highest,JJS,O
ncbi-sent-178,rates,NNS,O
ncbi-sent-178,yet,RB,O
ncbi-sent-178,reported,VBN,O
ncbi-sent-178,and,CC,O
ncbi-sent-178,the,DT,O
ncbi-sent-178,CDK4,NNP,O
ncbi-sent-178,mutation,NN,O
ncbi-sent-178,is,VBZ,O
ncbi-sent-178,the,DT,O
ncbi-sent-178,second,JJ,O
ncbi-sent-178,mutation,NN,O
ncbi-sent-178,detected,VBN,O
ncbi-sent-178,in,IN,O
ncbi-sent-178,this,DT,O
ncbi-sent-178,gene,NN,O
ncbi-sent-178,worldwide,NN,O
ncbi-sent-178,.,.,O
ncbi-sent-179,In,IN,O
ncbi-sent-179,summary,JJ,O
ncbi-sent-179,",",",",O
ncbi-sent-179,our,PRP$,O
ncbi-sent-179,results,NNS,O
ncbi-sent-179,show,VBP,O
ncbi-sent-179,frequent,JJ,O
ncbi-sent-179,involvement,NN,O
ncbi-sent-179,of,IN,O
ncbi-sent-179,the,DT,O
ncbi-sent-179,p16,JJ,O
ncbi-sent-179,gene,NN,O
ncbi-sent-179,in,IN,O
ncbi-sent-179,familial,JJ,B-DISEASE
ncbi-sent-179,melanoma,NN,I-DISEASE
ncbi-sent-179,and,CC,O
ncbi-sent-179,confirm,VBP,O
ncbi-sent-179,the,DT,O
ncbi-sent-179,role,NN,O
ncbi-sent-179,of,IN,O
ncbi-sent-179,the,DT,O
ncbi-sent-179,CDK4,NNP,O
ncbi-sent-179,gene,NN,O
ncbi-sent-179,as,IN,O
ncbi-sent-179,a,DT,O
ncbi-sent-179,melanoma,NN,B-DISEASE
ncbi-sent-179,-,:,O
ncbi-sent-179,predisposing,NN,O
ncbi-sent-179,gene,NN,O
ncbi-sent-179,.,.,O
ncbi-sent-180,.,.,O
ncbi-sent-181,Progression,NN,O
ncbi-sent-181,of,IN,O
ncbi-sent-181,somatic,JJ,O
ncbi-sent-181,CTG,NNP,O
ncbi-sent-181,repeat,NN,O
ncbi-sent-181,length,NN,O
ncbi-sent-181,heterogeneity,NN,O
ncbi-sent-181,in,IN,O
ncbi-sent-181,the,DT,O
ncbi-sent-181,blood,NN,O
ncbi-sent-181,cells,NNS,O
ncbi-sent-181,of,IN,O
ncbi-sent-181,myotonic,JJ,B-DISEASE
ncbi-sent-181,dystrophy,NN,I-DISEASE
ncbi-sent-181,patients,NNS,O
ncbi-sent-181,.,.,O
ncbi-sent-182,The,DT,O
ncbi-sent-182,genetic,JJ,O
ncbi-sent-182,basis,NN,O
ncbi-sent-182,of,IN,O
ncbi-sent-182,myotonic,JJ,B-DISEASE
ncbi-sent-182,dystrophy,NN,I-DISEASE
ncbi-sent-182,(,(,O
ncbi-sent-182,DM,NNP,B-DISEASE
ncbi-sent-182,),),O
ncbi-sent-182,is,VBZ,O
ncbi-sent-182,the,DT,O
ncbi-sent-182,expansion,NN,O
ncbi-sent-182,of,IN,O
ncbi-sent-182,an,DT,O
ncbi-sent-182,unstable,JJ,O
ncbi-sent-182,CTG,NNP,O
ncbi-sent-182,repeat,NN,O
ncbi-sent-182,in,IN,O
ncbi-sent-182,the,DT,O
ncbi-sent-182,34,CD,O
ncbi-sent-182,UTR,NNP,O
ncbi-sent-182,of,IN,O
ncbi-sent-182,the,DT,O
ncbi-sent-182,DM,NNP,B-DISEASE
ncbi-sent-182,protein,NN,O
ncbi-sent-182,kinase,VBD,O
ncbi-sent-182,gene,NN,O
ncbi-sent-182,on,IN,O
ncbi-sent-182,chromosome,NN,O
ncbi-sent-182,19,CD,O
ncbi-sent-182,.,.,O
ncbi-sent-183,One,CD,O
ncbi-sent-183,of,IN,O
ncbi-sent-183,the,DT,O
ncbi-sent-183,principal,JJ,O
ncbi-sent-183,features,NNS,O
ncbi-sent-183,of,IN,O
ncbi-sent-183,the,DT,O
ncbi-sent-183,DM,NNP,B-DISEASE
ncbi-sent-183,mutation,NN,O
ncbi-sent-183,is,VBZ,O
ncbi-sent-183,an,DT,O
ncbi-sent-183,extraordinarily,RB,O
ncbi-sent-183,high,JJ,O
ncbi-sent-183,level,NN,O
ncbi-sent-183,of,IN,O
ncbi-sent-183,somatic,JJ,O
ncbi-sent-183,mosaicism,NN,O
ncbi-sent-183,",",",",O
ncbi-sent-183,due,JJ,O
ncbi-sent-183,to,TO,O
ncbi-sent-183,an,DT,O
ncbi-sent-183,extremely,RB,O
ncbi-sent-183,high,JJ,O
ncbi-sent-183,degree,NN,O
ncbi-sent-183,of,IN,O
ncbi-sent-183,somatic,JJ,O
ncbi-sent-183,instability,NN,O
ncbi-sent-183,both,DT,O
ncbi-sent-183,within,IN,O
ncbi-sent-183,and,CC,O
ncbi-sent-183,between,IN,O
ncbi-sent-183,different,JJ,O
ncbi-sent-183,tissues,NNS,O
ncbi-sent-183,.,.,O
ncbi-sent-184,This,DT,O
ncbi-sent-184,instability,NN,O
ncbi-sent-184,appears,VBZ,O
ncbi-sent-184,to,TO,O
ncbi-sent-184,be,VB,O
ncbi-sent-184,biased,VBN,O
ncbi-sent-184,towards,IN,O
ncbi-sent-184,further,JJ,O
ncbi-sent-184,expansion,NN,O
ncbi-sent-184,and,CC,O
ncbi-sent-184,continuous,JJ,O
ncbi-sent-184,throughout,IN,O
ncbi-sent-184,the,DT,O
ncbi-sent-184,life,NN,O
ncbi-sent-184,of,IN,O
ncbi-sent-184,an,DT,O
ncbi-sent-184,individual,NN,O
ncbi-sent-184,",",",",O
ncbi-sent-184,features,VBZ,O
ncbi-sent-184,that,DT,O
ncbi-sent-184,could,MD,O
ncbi-sent-184,be,VB,O
ncbi-sent-184,associated,VBN,O
ncbi-sent-184,with,IN,O
ncbi-sent-184,the,DT,O
ncbi-sent-184,progressive,JJ,O
ncbi-sent-184,nature,NN,O
ncbi-sent-184,of,IN,O
ncbi-sent-184,the,DT,O
ncbi-sent-184,disease,NN,O
ncbi-sent-184,.,.,O
ncbi-sent-185,Although,IN,O
ncbi-sent-185,increasing,VBG,O
ncbi-sent-185,measured,VBN,O
ncbi-sent-185,allele,JJ,O
ncbi-sent-185,size,NN,O
ncbi-sent-185,between,IN,O
ncbi-sent-185,patients,NNS,O
ncbi-sent-185,clearly,RB,O
ncbi-sent-185,correlates,VBZ,O
ncbi-sent-185,with,IN,O
ncbi-sent-185,an,DT,O
ncbi-sent-185,increased,JJ,O
ncbi-sent-185,severity,NN,O
ncbi-sent-185,of,IN,O
ncbi-sent-185,symptoms,NNS,O
ncbi-sent-185,and,CC,O
ncbi-sent-185,an,DT,O
ncbi-sent-185,earlier,JJR,O
ncbi-sent-185,age,NN,O
ncbi-sent-185,of,IN,O
ncbi-sent-185,onset,NN,O
ncbi-sent-185,",",",",O
ncbi-sent-185,this,DT,O
ncbi-sent-185,correlation,NN,O
ncbi-sent-185,is,VBZ,O
ncbi-sent-185,not,RB,O
ncbi-sent-185,precise,JJ,O
ncbi-sent-185,and,CC,O
ncbi-sent-185,measured,VBD,O
ncbi-sent-185,allele,NNS,O
ncbi-sent-185,length,NN,O
ncbi-sent-185,cannot,NN,O
ncbi-sent-185,be,VB,O
ncbi-sent-185,used,VBN,O
ncbi-sent-185,as,IN,O
ncbi-sent-185,an,DT,O
ncbi-sent-185,accurate,JJ,O
ncbi-sent-185,predictor,NN,O
ncbi-sent-185,of,IN,O
ncbi-sent-185,age,NN,O
ncbi-sent-185,of,IN,O
ncbi-sent-185,onset,NN,O
ncbi-sent-185,.,.,O
ncbi-sent-186,In,IN,O
ncbi-sent-186,order,NN,O
ncbi-sent-186,to,TO,O
ncbi-sent-186,further,RBR,O
ncbi-sent-186,characterize,VB,O
ncbi-sent-186,the,DT,O
ncbi-sent-186,dynamics,NNS,O
ncbi-sent-186,of,IN,O
ncbi-sent-186,DM,NNP,B-DISEASE
ncbi-sent-186,CTG,NNP,O
ncbi-sent-186,repeat,NN,O
ncbi-sent-186,somatic,JJ,O
ncbi-sent-186,instability,NN,O
ncbi-sent-186,",",",",O
ncbi-sent-186,we,PRP,O
ncbi-sent-186,have,VBP,O
ncbi-sent-186,studied,VBN,O
ncbi-sent-186,repeat,NN,O
ncbi-sent-186,length,NN,O
ncbi-sent-186,changes,NNS,O
ncbi-sent-186,over,IN,O
ncbi-sent-186,time,NN,O
ncbi-sent-186,in,IN,O
ncbi-sent-186,111,CD,O
ncbi-sent-186,myotonic,JJ,B-DISEASE
ncbi-sent-186,dystrophy,NN,I-DISEASE
ncbi-sent-186,patients,NNS,O
ncbi-sent-186,with,IN,O
ncbi-sent-186,varying,VBG,O
ncbi-sent-186,clinical,JJ,O
ncbi-sent-186,severity,NN,O
ncbi-sent-186,and,CC,O
ncbi-sent-186,CTG,NNP,O
ncbi-sent-186,repeat,NN,O
ncbi-sent-186,size,NN,O
ncbi-sent-186,over,IN,O
ncbi-sent-186,time,NN,O
ncbi-sent-186,intervals,NNS,O
ncbi-sent-186,of,IN,O
ncbi-sent-186,1,CD,O
ncbi-sent-186,-,:,O
ncbi-sent-186,7,CD,O
ncbi-sent-186,years,NNS,O
ncbi-sent-186,.,.,O
ncbi-sent-187,We,PRP,O
ncbi-sent-187,have,VBP,O
ncbi-sent-187,found,VBN,O
ncbi-sent-187,a,DT,O
ncbi-sent-187,direct,JJ,O
ncbi-sent-187,progression,NN,O
ncbi-sent-187,of,IN,O
ncbi-sent-187,the,DT,O
ncbi-sent-187,size,NN,O
ncbi-sent-187,heterogeneity,NN,O
ncbi-sent-187,over,IN,O
ncbi-sent-187,time,NN,O
ncbi-sent-187,related,VBN,O
ncbi-sent-187,to,TO,O
ncbi-sent-187,initial,JJ,O
ncbi-sent-187,CTG,NNP,O
ncbi-sent-187,repeat,NN,O
ncbi-sent-187,size,NN,O
ncbi-sent-187,and,CC,O
ncbi-sent-187,the,DT,O
ncbi-sent-187,time,NN,O
ncbi-sent-187,interval,NN,O
ncbi-sent-187,and,CC,O
ncbi-sent-187,always,RB,O
ncbi-sent-187,biased,VBN,O
ncbi-sent-187,towards,NNS,O
ncbi-sent-187,further,JJ,O
ncbi-sent-187,expansion,NN,O
ncbi-sent-187,.,.,O
ncbi-sent-188,Attempts,NNS,O
ncbi-sent-188,to,TO,O
ncbi-sent-188,mathematically,RB,O
ncbi-sent-188,model,VB,O
ncbi-sent-188,the,DT,O
ncbi-sent-188,dynamics,NNS,O
ncbi-sent-188,have,VBP,O
ncbi-sent-188,proved,VBN,O
ncbi-sent-188,only,RB,O
ncbi-sent-188,partially,RB,O
ncbi-sent-188,successful,JJ,O
ncbi-sent-188,suggesting,VBG,O
ncbi-sent-188,that,IN,O
ncbi-sent-188,individual,JJ,O
ncbi-sent-188,specific,JJ,O
ncbi-sent-188,genetic,JJ,O
ncbi-sent-188,and,CC,O
ncbi-sent-188,/,NN,O
ncbi-sent-188,or,CC,O
ncbi-sent-188,environmental,JJ,O
ncbi-sent-188,factors,NNS,O
ncbi-sent-188,also,RB,O
ncbi-sent-188,play,VBP,O
ncbi-sent-188,a,DT,O
ncbi-sent-188,role,NN,O
ncbi-sent-188,in,IN,O
ncbi-sent-188,somatic,JJ,O
ncbi-sent-188,mosaicism,NN,O
ncbi-sent-188,.,.,O
ncbi-sent-189,.,.,O
ncbi-sent-190,Aspartylglucosaminuria,NNP,B-DISEASE
ncbi-sent-190,among,IN,O
ncbi-sent-190,Palestinian,JJ,O
ncbi-sent-190,Arabs,NNPS,O
ncbi-sent-190,.,.,O
ncbi-sent-191,Aspartylglucosaminuria,NNP,B-DISEASE
ncbi-sent-191,(,(,O
ncbi-sent-191,AGU,NNP,B-DISEASE
ncbi-sent-191,),),O
ncbi-sent-191,is,VBZ,O
ncbi-sent-191,a,DT,O
ncbi-sent-191,rare,JJ,O
ncbi-sent-191,disorder,NN,B-DISEASE
ncbi-sent-191,of,IN,I-DISEASE
ncbi-sent-191,glycoprotein,JJ,I-DISEASE
ncbi-sent-191,metabolism,NN,I-DISEASE
ncbi-sent-191,caused,VBN,O
ncbi-sent-191,by,IN,O
ncbi-sent-191,the,DT,O
ncbi-sent-191,deficiency,NN,B-DISEASE
ncbi-sent-191,of,IN,I-DISEASE
ncbi-sent-191,the,DT,I-DISEASE
ncbi-sent-191,lysosomal,JJ,I-DISEASE
ncbi-sent-191,enzyme,NN,I-DISEASE
ncbi-sent-191,aspartylglucosaminidase,NN,I-DISEASE
ncbi-sent-191,(,(,O
ncbi-sent-191,AGA,NNP,O
ncbi-sent-191,),),O
ncbi-sent-191,.,.,O
ncbi-sent-192,AGU,NNP,B-DISEASE
ncbi-sent-192,is,VBZ,O
ncbi-sent-192,inherited,VBN,O
ncbi-sent-192,as,IN,O
ncbi-sent-192,an,DT,O
ncbi-sent-192,autosomal,JJ,O
ncbi-sent-192,recessive,JJ,O
ncbi-sent-192,trait,NN,O
ncbi-sent-192,and,CC,O
ncbi-sent-192,occurs,VBZ,O
ncbi-sent-192,with,IN,O
ncbi-sent-192,a,DT,O
ncbi-sent-192,high,JJ,O
ncbi-sent-192,frequency,NN,O
ncbi-sent-192,in,IN,O
ncbi-sent-192,Finland,NNP,O
ncbi-sent-192,because,IN,O
ncbi-sent-192,of,IN,O
ncbi-sent-192,a,DT,O
ncbi-sent-192,founder,NN,O
ncbi-sent-192,effect,NN,O
ncbi-sent-192,.,.,O
ncbi-sent-193,While,IN,O
ncbi-sent-193,very,RB,O
ncbi-sent-193,few,JJ,O
ncbi-sent-193,patients,NNS,O
ncbi-sent-193,with,IN,O
ncbi-sent-193,AGU,NNP,B-DISEASE
ncbi-sent-193,have,VBP,O
ncbi-sent-193,been,VBN,O
ncbi-sent-193,reported,VBN,O
ncbi-sent-193,from,IN,O
ncbi-sent-193,non,JJ,O
ncbi-sent-193,-,:,O
ncbi-sent-193,Finnish,JJ,O
ncbi-sent-193,origin,NN,O
ncbi-sent-193,",",",",O
ncbi-sent-193,we,PRP,O
ncbi-sent-193,diagnosed,VBD,O
ncbi-sent-193,the,DT,O
ncbi-sent-193,disorder,NN,O
ncbi-sent-193,in,IN,O
ncbi-sent-193,8,CD,O
ncbi-sent-193,patients,NNS,O
ncbi-sent-193,originating,VBG,O
ncbi-sent-193,from,IN,O
ncbi-sent-193,3,CD,O
ncbi-sent-193,unrelated,JJ,O
ncbi-sent-193,families,NNS,O
ncbi-sent-193,",",",",O
ncbi-sent-193,all,DT,O
ncbi-sent-193,Palestinian,JJ,O
ncbi-sent-193,Arabs,NNP,O
ncbi-sent-193,from,IN,O
ncbi-sent-193,the,DT,O
ncbi-sent-193,region,NN,O
ncbi-sent-193,of,IN,O
ncbi-sent-193,Jerusalem,NNP,O
ncbi-sent-193,.,.,O
ncbi-sent-194,The,DT,O
ncbi-sent-194,clinical,JJ,O
ncbi-sent-194,diagnosis,NN,O
ncbi-sent-194,of,IN,O
ncbi-sent-194,AGU,NNP,B-DISEASE
ncbi-sent-194,is,VBZ,O
ncbi-sent-194,often,RB,O
ncbi-sent-194,difficult,JJ,O
ncbi-sent-194,",",",",O
ncbi-sent-194,in,IN,O
ncbi-sent-194,particular,JJ,O
ncbi-sent-194,early,JJ,O
ncbi-sent-194,in,IN,O
ncbi-sent-194,the,DT,O
ncbi-sent-194,course,NN,O
ncbi-sent-194,of,IN,O
ncbi-sent-194,the,DT,O
ncbi-sent-194,disease,NN,O
ncbi-sent-194,",",",",O
ncbi-sent-194,and,CC,O
ncbi-sent-194,most,JJS,O
ncbi-sent-194,of,IN,O
ncbi-sent-194,the,DT,O
ncbi-sent-194,patients,NNS,O
ncbi-sent-194,are,VBP,O
ncbi-sent-194,diagnosed,VBN,O
ncbi-sent-194,after,IN,O
ncbi-sent-194,the,DT,O
ncbi-sent-194,age,NN,O
ncbi-sent-194,of,IN,O
ncbi-sent-194,5,CD,O
ncbi-sent-194,years,NNS,O
ncbi-sent-194,.,.,O
ncbi-sent-195,However,RB,O
ncbi-sent-195,",",",",O
ncbi-sent-195,since,IN,O
ncbi-sent-195,these,DT,O
ncbi-sent-195,patients,NNS,O
ncbi-sent-195,excrete,VBP,O
ncbi-sent-195,early,RB,O
ncbi-sent-195,large,JJ,O
ncbi-sent-195,amounts,NNS,O
ncbi-sent-195,of,IN,O
ncbi-sent-195,aspartylglucosamine,NN,O
ncbi-sent-195,in,IN,O
ncbi-sent-195,urine,NN,O
ncbi-sent-195,",",",",O
ncbi-sent-195,biochemical,JJ,O
ncbi-sent-195,screening,NN,O
ncbi-sent-195,is,VBZ,O
ncbi-sent-195,easy,JJ,O
ncbi-sent-195,by,IN,O
ncbi-sent-195,urine,JJ,O
ncbi-sent-195,chromatography,NN,O
ncbi-sent-195,.,.,O
ncbi-sent-196,.,.,O
ncbi-sent-197,Detection,NN,O
ncbi-sent-197,of,IN,O
ncbi-sent-197,heterozygous,JJ,O
ncbi-sent-197,carriers,NNS,O
ncbi-sent-197,of,IN,O
ncbi-sent-197,the,DT,O
ncbi-sent-197,ataxia,JJ,B-DISEASE
ncbi-sent-197,-,:,I-DISEASE
ncbi-sent-197,telangiectasia,NN,I-DISEASE
ncbi-sent-197,(,(,O
ncbi-sent-197,ATM,NNP,O
ncbi-sent-197,),),O
ncbi-sent-197,gene,NN,O
ncbi-sent-197,by,IN,O
ncbi-sent-197,G2,NNP,O
ncbi-sent-197,phase,NN,O
ncbi-sent-197,chromosomal,JJ,O
ncbi-sent-197,radiosensitivity,NN,O
ncbi-sent-197,of,IN,O
ncbi-sent-197,peripheral,JJ,O
ncbi-sent-197,blood,NN,O
ncbi-sent-197,lymphocytes,NNS,O
ncbi-sent-197,.,.,O
ncbi-sent-198,In,IN,O
ncbi-sent-198,ataxia,JJ,B-DISEASE
ncbi-sent-198,-,:,I-DISEASE
ncbi-sent-198,telangiectasia,NN,I-DISEASE
ncbi-sent-198,(,(,O
ncbi-sent-198,A,DT,B-DISEASE
ncbi-sent-198,-,:,I-DISEASE
ncbi-sent-198,T,NN,I-DISEASE
ncbi-sent-198,),),O
ncbi-sent-198,patients,NNS,O
ncbi-sent-198,",",",",O
ncbi-sent-198,mutations,NNS,O
ncbi-sent-198,in,IN,O
ncbi-sent-198,a,DT,O
ncbi-sent-198,single,JJ,O
ncbi-sent-198,gene,NN,O
ncbi-sent-198,",",",",O
ncbi-sent-198,ATM,NNP,O
ncbi-sent-198,",",",",O
ncbi-sent-198,result,NN,O
ncbi-sent-198,in,IN,O
ncbi-sent-198,an,DT,O
ncbi-sent-198,autosomal,JJ,B-DISEASE
ncbi-sent-198,recessive,JJ,I-DISEASE
ncbi-sent-198,syndrome,NN,I-DISEASE
ncbi-sent-198,that,WDT,O
ncbi-sent-198,embraces,VBZ,O
ncbi-sent-198,a,DT,O
ncbi-sent-198,variety,NN,O
ncbi-sent-198,of,IN,O
ncbi-sent-198,clinical,JJ,O
ncbi-sent-198,features,NNS,O
ncbi-sent-198,and,CC,O
ncbi-sent-198,manifests,NNS,O
ncbi-sent-198,extreme,VBP,O
ncbi-sent-198,radiosensitivity,NN,O
ncbi-sent-198,and,CC,O
ncbi-sent-198,a,DT,O
ncbi-sent-198,strong,JJ,O
ncbi-sent-198,pre,NN,O
ncbi-sent-198,-,:,O
ncbi-sent-198,disposition,NN,O
ncbi-sent-198,to,TO,O
ncbi-sent-198,malignancy,NN,B-DISEASE
ncbi-sent-198,.,.,O
ncbi-sent-199,Heterozygotes,VBZ,O
ncbi-sent-199,for,IN,O
ncbi-sent-199,the,DT,O
ncbi-sent-199,ATM,NNP,O
ncbi-sent-199,gene,NN,O
ncbi-sent-199,have,VBP,O
ncbi-sent-199,no,DT,O
ncbi-sent-199,clinical,JJ,O
ncbi-sent-199,expression,NN,O
ncbi-sent-199,of,IN,O
ncbi-sent-199,A,NNP,B-DISEASE
ncbi-sent-199,-,:,I-DISEASE
ncbi-sent-199,T,NN,I-DISEASE
ncbi-sent-199,but,CC,O
ncbi-sent-199,may,MD,O
ncbi-sent-199,be,VB,O
ncbi-sent-199,cancer,NN,B-DISEASE
ncbi-sent-199,prone,NN,O
ncbi-sent-199,with,IN,O
ncbi-sent-199,a,DT,O
ncbi-sent-199,moderate,JJ,O
ncbi-sent-199,increase,NN,O
ncbi-sent-199,in,IN,O
ncbi-sent-199,in,IN,O
ncbi-sent-199,vitro,JJ,O
ncbi-sent-199,radiosensitivity,NN,O
ncbi-sent-199,.,.,O
ncbi-sent-200,We,PRP,O
ncbi-sent-200,performed,VBD,O
ncbi-sent-200,a,DT,O
ncbi-sent-200,blind,NN,O
ncbi-sent-200,chromosomal,JJ,O
ncbi-sent-200,analysis,NN,O
ncbi-sent-200,on,IN,O
ncbi-sent-200,G2,NNP,O
ncbi-sent-200,-,:,O
ncbi-sent-200,phase,NN,O
ncbi-sent-200,lymphocytes,VBZ,O
ncbi-sent-200,from,IN,O
ncbi-sent-200,7,CD,O
ncbi-sent-200,unrelated,VBD,O
ncbi-sent-200,A,NNP,B-DISEASE
ncbi-sent-200,-,:,I-DISEASE
ncbi-sent-200,T,NN,I-DISEASE
ncbi-sent-200,patients,NNS,O
ncbi-sent-200,",",",",O
ncbi-sent-200,13,CD,O
ncbi-sent-200,obligate,NN,O
ncbi-sent-200,A,NNP,B-DISEASE
ncbi-sent-200,-,:,I-DISEASE
ncbi-sent-200,T,NN,I-DISEASE
ncbi-sent-200,heterozygotes,NNS,O
ncbi-sent-200,(,(,O
ncbi-sent-200,parents,NNS,O
ncbi-sent-200,of,IN,O
ncbi-sent-200,the,DT,O
ncbi-sent-200,patients,NNS,O
ncbi-sent-200,),),O
ncbi-sent-200,",",",",O
ncbi-sent-200,and,CC,O
ncbi-sent-200,14,CD,O
ncbi-sent-200,normal,JJ,O
ncbi-sent-200,controls,NNS,O
ncbi-sent-200,following,VBG,O
ncbi-sent-200,X,NNP,O
ncbi-sent-200,-,:,O
ncbi-sent-200,irradiation,NN,O
ncbi-sent-200,with,IN,O
ncbi-sent-200,1,CD,O
ncbi-sent-200,Gy,NNP,O
ncbi-sent-200,in,IN,O
ncbi-sent-200,order,NN,O
ncbi-sent-200,to,TO,O
ncbi-sent-200,evaluate,VB,O
ncbi-sent-200,this,DT,O
ncbi-sent-200,cytogenetic,JJ,O
ncbi-sent-200,method,NN,O
ncbi-sent-200,as,IN,O
ncbi-sent-200,a,DT,O
ncbi-sent-200,tool,NN,O
ncbi-sent-200,for,IN,O
ncbi-sent-200,detection,NN,O
ncbi-sent-200,of,IN,O
ncbi-sent-200,ATM,NNP,O
ncbi-sent-200,carriers,NNS,O
ncbi-sent-200,.,.,O
ncbi-sent-201,Both,CC,O
ncbi-sent-201,A,NNP,B-DISEASE
ncbi-sent-201,-,:,I-DISEASE
ncbi-sent-201,T,NN,I-DISEASE
ncbi-sent-201,homozygotes,NNS,O
ncbi-sent-201,and,CC,O
ncbi-sent-201,heterozygotes,NNS,O
ncbi-sent-201,showed,VBD,O
ncbi-sent-201,significantly,RB,O
ncbi-sent-201,increased,VBN,O
ncbi-sent-201,levels,NNS,O
ncbi-sent-201,of,IN,O
ncbi-sent-201,radiation,NN,O
ncbi-sent-201,-,:,O
ncbi-sent-201,induced,JJ,O
ncbi-sent-201,chromatid,JJ,O
ncbi-sent-201,damage,NN,O
ncbi-sent-201,relative,NN,O
ncbi-sent-201,to,TO,O
ncbi-sent-201,that,DT,O
ncbi-sent-201,of,IN,O
ncbi-sent-201,normal,JJ,O
ncbi-sent-201,controls,NNS,O
ncbi-sent-201,.,.,O
ncbi-sent-202,These,DT,O
ncbi-sent-202,results,NNS,O
ncbi-sent-202,show,VBP,O
ncbi-sent-202,that,IN,O
ncbi-sent-202,the,DT,O
ncbi-sent-202,G2,NNP,O
ncbi-sent-202,-,:,O
ncbi-sent-202,phase,NN,O
ncbi-sent-202,chromosomal,JJ,O
ncbi-sent-202,radiosensitivity,NN,O
ncbi-sent-202,assay,VBP,O
ncbi-sent-202,can,MD,O
ncbi-sent-202,be,VB,O
ncbi-sent-202,used,VBN,O
ncbi-sent-202,for,IN,O
ncbi-sent-202,the,DT,O
ncbi-sent-202,detection,NN,O
ncbi-sent-202,of,IN,O
ncbi-sent-202,A,NNP,B-DISEASE
ncbi-sent-202,-,:,I-DISEASE
ncbi-sent-202,T,NN,I-DISEASE
ncbi-sent-202,heterozygotes,NNS,O
ncbi-sent-202,.,.,O
ncbi-sent-203,In,IN,O
ncbi-sent-203,combination,NN,O
ncbi-sent-203,with,IN,O
ncbi-sent-203,molecular,JJ,O
ncbi-sent-203,genetic,JJ,O
ncbi-sent-203,analyses,NNS,O
ncbi-sent-203,",",",",O
ncbi-sent-203,this,DT,O
ncbi-sent-203,test,NN,O
ncbi-sent-203,may,MD,O
ncbi-sent-203,be,VB,O
ncbi-sent-203,of,IN,O
ncbi-sent-203,value,NN,O
ncbi-sent-203,in,IN,O
ncbi-sent-203,studies,NNS,O
ncbi-sent-203,of,IN,O
ncbi-sent-203,familial,JJ,B-DISEASE
ncbi-sent-203,and,CC,I-DISEASE
ncbi-sent-203,sporadic,JJ,I-DISEASE
ncbi-sent-203,cancers,NNS,I-DISEASE
ncbi-sent-203,aimed,VBN,O
ncbi-sent-203,at,IN,O
ncbi-sent-203,determination,NN,O
ncbi-sent-203,of,IN,O
ncbi-sent-203,the,DT,O
ncbi-sent-203,potential,JJ,O
ncbi-sent-203,involvement,NN,O
ncbi-sent-203,of,IN,O
ncbi-sent-203,ATM,NNP,O
ncbi-sent-203,mutations,NNS,O
ncbi-sent-203,in,IN,O
ncbi-sent-203,tumor,NN,B-DISEASE
ncbi-sent-203,risk,NN,O
ncbi-sent-203,or,CC,O
ncbi-sent-203,development,NN,O
ncbi-sent-203,.,.,O
ncbi-sent-204,.,.,O
ncbi-sent-205,Ataxia,NNP,B-DISEASE
ncbi-sent-205,-,:,I-DISEASE
ncbi-sent-205,telangiectasia,NN,I-DISEASE
ncbi-sent-205,:,:,O
ncbi-sent-205,identification,NN,O
ncbi-sent-205,and,CC,O
ncbi-sent-205,detection,NN,O
ncbi-sent-205,of,IN,O
ncbi-sent-205,founder,NN,O
ncbi-sent-205,-,:,O
ncbi-sent-205,effect,NN,O
ncbi-sent-205,mutations,NNS,O
ncbi-sent-205,in,IN,O
ncbi-sent-205,the,DT,O
ncbi-sent-205,ATM,NNP,O
ncbi-sent-205,gene,NN,O
ncbi-sent-205,in,IN,O
ncbi-sent-205,ethnic,JJ,O
ncbi-sent-205,populations,NNS,O
ncbi-sent-205,.,.,O
ncbi-sent-206,To,TO,O
ncbi-sent-206,facilitate,VB,O
ncbi-sent-206,the,DT,O
ncbi-sent-206,evaluation,NN,O
ncbi-sent-206,of,IN,O
ncbi-sent-206,ATM,NNP,O
ncbi-sent-206,heterozygotes,NNS,O
ncbi-sent-206,for,IN,O
ncbi-sent-206,susceptibility,NN,O
ncbi-sent-206,to,TO,O
ncbi-sent-206,other,JJ,O
ncbi-sent-206,diseases,NNS,O
ncbi-sent-206,",",",",O
ncbi-sent-206,such,JJ,O
ncbi-sent-206,as,IN,O
ncbi-sent-206,breast,NN,B-DISEASE
ncbi-sent-206,cancer,NN,I-DISEASE
ncbi-sent-206,",",",",O
ncbi-sent-206,we,PRP,O
ncbi-sent-206,have,VBP,O
ncbi-sent-206,attempted,VBN,O
ncbi-sent-206,to,TO,O
ncbi-sent-206,define,VB,O
ncbi-sent-206,the,DT,O
ncbi-sent-206,most,RBS,O
ncbi-sent-206,common,JJ,O
ncbi-sent-206,mutations,NNS,O
ncbi-sent-206,and,CC,O
ncbi-sent-206,their,PRP$,O
ncbi-sent-206,frequencies,NNS,O
ncbi-sent-206,in,IN,O
ncbi-sent-206,ataxia,JJ,B-DISEASE
ncbi-sent-206,-,:,I-DISEASE
ncbi-sent-206,telangiectasia,NN,I-DISEASE
ncbi-sent-206,(,(,O
ncbi-sent-206,A,DT,B-DISEASE
ncbi-sent-206,-,:,I-DISEASE
ncbi-sent-206,T,NN,I-DISEASE
ncbi-sent-206,),),O
ncbi-sent-206,homozygotes,VBZ,O
ncbi-sent-206,from,IN,O
ncbi-sent-206,10,CD,O
ncbi-sent-206,ethnic,JJ,O
ncbi-sent-206,populations,NNS,O
ncbi-sent-206,.,.,O
ncbi-sent-207,Both,DT,O
ncbi-sent-207,genomic,JJ,O
ncbi-sent-207,mutations,NNS,O
ncbi-sent-207,and,CC,O
ncbi-sent-207,their,PRP$,O
ncbi-sent-207,effects,NNS,O
ncbi-sent-207,on,IN,O
ncbi-sent-207,cDNA,NN,O
ncbi-sent-207,were,VBD,O
ncbi-sent-207,characterized,VBN,O
ncbi-sent-207,.,.,O
ncbi-sent-208,Protein,NNP,O
ncbi-sent-208,-,:,O
ncbi-sent-208,truncation,NN,O
ncbi-sent-208,testing,NN,O
ncbi-sent-208,of,IN,O
ncbi-sent-208,the,DT,O
ncbi-sent-208,entire,JJ,O
ncbi-sent-208,ATM,NNP,O
ncbi-sent-208,cDNA,NN,O
ncbi-sent-208,detected,VBD,O
ncbi-sent-208,92,CD,O
ncbi-sent-208,(,(,O
ncbi-sent-208,66,CD,O
ncbi-sent-208,%,NN,O
ncbi-sent-208,),),O
ncbi-sent-208,truncating,VBG,O
ncbi-sent-208,mutations,NNS,O
ncbi-sent-208,in,IN,O
ncbi-sent-208,140,CD,O
ncbi-sent-208,mutant,JJ,O
ncbi-sent-208,alleles,NNS,O
ncbi-sent-208,screened,VBN,O
ncbi-sent-208,.,.,O
ncbi-sent-209,The,DT,O
ncbi-sent-209,haplotyping,NN,O
ncbi-sent-209,of,IN,O
ncbi-sent-209,patients,NNS,O
ncbi-sent-209,with,IN,O
ncbi-sent-209,identical,JJ,O
ncbi-sent-209,mutations,NNS,O
ncbi-sent-209,indicates,VBZ,O
ncbi-sent-209,that,IN,O
ncbi-sent-209,almost,RB,O
ncbi-sent-209,all,DT,O
ncbi-sent-209,of,IN,O
ncbi-sent-209,these,DT,O
ncbi-sent-209,represent,JJ,O
ncbi-sent-209,common,JJ,O
ncbi-sent-209,ancestry,NN,O
ncbi-sent-209,and,CC,O
ncbi-sent-209,that,DT,O
ncbi-sent-209,very,RB,O
ncbi-sent-209,few,JJ,O
ncbi-sent-209,spontaneously,RB,O
ncbi-sent-209,recurring,VBG,O
ncbi-sent-209,ATM,NNP,O
ncbi-sent-209,mutations,NNS,O
ncbi-sent-209,exist,VBP,O
ncbi-sent-209,.,.,O
ncbi-sent-210,Assays,NNS,O
ncbi-sent-210,requiring,VBG,O
ncbi-sent-210,minimal,JJ,O
ncbi-sent-210,amounts,NNS,O
ncbi-sent-210,of,IN,O
ncbi-sent-210,genomic,JJ,O
ncbi-sent-210,DNA,NNP,O
ncbi-sent-210,were,VBD,O
ncbi-sent-210,designed,VBN,O
ncbi-sent-210,to,TO,O
ncbi-sent-210,allow,VB,O
ncbi-sent-210,rapid,JJ,O
ncbi-sent-210,screening,NN,O
ncbi-sent-210,for,IN,O
ncbi-sent-210,common,JJ,O
ncbi-sent-210,ethnic,JJ,O
ncbi-sent-210,mutations,NNS,O
ncbi-sent-210,.,.,O
ncbi-sent-211,These,DT,O
ncbi-sent-211,rapid,JJ,O
ncbi-sent-211,assays,NNS,O
ncbi-sent-211,detected,VBN,O
ncbi-sent-211,mutations,NNS,O
ncbi-sent-211,in,IN,O
ncbi-sent-211,76,CD,O
ncbi-sent-211,%,NN,O
ncbi-sent-211,of,IN,O
ncbi-sent-211,Costa,JJ,O
ncbi-sent-211,Rican,JJ,O
ncbi-sent-211,patients,NNS,O
ncbi-sent-211,(,(,O
ncbi-sent-211,3,CD,O
ncbi-sent-211,),),O
ncbi-sent-211,",",",",O
ncbi-sent-211,50,CD,O
ncbi-sent-211,%,NN,O
ncbi-sent-211,of,IN,O
ncbi-sent-211,Norwegian,JJ,O
ncbi-sent-211,patients,NNS,O
ncbi-sent-211,(,(,O
ncbi-sent-211,1,CD,O
ncbi-sent-211,),),O
ncbi-sent-211,",",",",O
ncbi-sent-211,25,CD,O
ncbi-sent-211,%,NN,O
ncbi-sent-211,of,IN,O
ncbi-sent-211,Polish,JJ,O
ncbi-sent-211,patients,NNS,O
ncbi-sent-211,(,(,O
ncbi-sent-211,4,CD,O
ncbi-sent-211,),),O
ncbi-sent-211,",",",",O
ncbi-sent-211,and,CC,O
ncbi-sent-211,14,CD,O
ncbi-sent-211,%,NN,O
ncbi-sent-211,of,IN,O
ncbi-sent-211,Italian,JJ,O
ncbi-sent-211,patients,NNS,O
ncbi-sent-211,(,(,O
ncbi-sent-211,1,CD,O
ncbi-sent-211,),),O
ncbi-sent-211,",",",",O
ncbi-sent-211,as,RB,O
ncbi-sent-211,well,RB,O
ncbi-sent-211,as,IN,O
ncbi-sent-211,in,IN,O
ncbi-sent-211,patients,NNS,O
ncbi-sent-211,of,IN,O
ncbi-sent-211,Amish,NNP,O
ncbi-sent-211,/,NNP,O
ncbi-sent-211,Mennonite,NNP,O
ncbi-sent-211,and,CC,O
ncbi-sent-211,Irish,NNP,O
ncbi-sent-211,English,NNP,O
ncbi-sent-211,backgrounds,VBZ,O
ncbi-sent-211,.,.,O
ncbi-sent-212,Additional,JJ,O
ncbi-sent-212,mutations,NNS,O
ncbi-sent-212,were,VBD,O
ncbi-sent-212,observed,VBN,O
ncbi-sent-212,in,IN,O
ncbi-sent-212,Japanese,JJ,O
ncbi-sent-212,",",",",O
ncbi-sent-212,Utah,NNP,O
ncbi-sent-212,Mormon,NNP,O
ncbi-sent-212,",",",",O
ncbi-sent-212,and,CC,O
ncbi-sent-212,African,JJ,O
ncbi-sent-212,American,JJ,O
ncbi-sent-212,patients,NNS,O
ncbi-sent-212,.,.,O
ncbi-sent-213,These,DT,O
ncbi-sent-213,assays,NNS,O
ncbi-sent-213,should,MD,O
ncbi-sent-213,facilitate,VB,O
ncbi-sent-213,screening,VBG,O
ncbi-sent-213,for,IN,O
ncbi-sent-213,A,NNP,B-DISEASE
ncbi-sent-213,-,:,I-DISEASE
ncbi-sent-213,T,NN,I-DISEASE
ncbi-sent-213,heterozygotes,NNS,O
ncbi-sent-213,in,IN,O
ncbi-sent-213,the,DT,O
ncbi-sent-213,populations,NNS,O
ncbi-sent-213,studied,VBN,O
ncbi-sent-213,.,.,O
ncbi-sent-214,.,.,O
ncbi-sent-215,The,DT,O
ncbi-sent-215,von,NN,B-DISEASE
ncbi-sent-215,Hippel,NNP,I-DISEASE
ncbi-sent-215,-,:,I-DISEASE
ncbi-sent-215,Lindau,NNP,I-DISEASE
ncbi-sent-215,tumor,NN,I-DISEASE
ncbi-sent-215,suppressor,NN,O
ncbi-sent-215,gene,NN,O
ncbi-sent-215,is,VBZ,O
ncbi-sent-215,required,VBN,O
ncbi-sent-215,for,IN,O
ncbi-sent-215,cell,NN,O
ncbi-sent-215,cycle,NN,O
ncbi-sent-215,exit,NN,O
ncbi-sent-215,upon,IN,O
ncbi-sent-215,serum,NN,O
ncbi-sent-215,withdrawal,NN,O
ncbi-sent-215,.,.,O
ncbi-sent-216,The,DT,O
ncbi-sent-216,inactivation,NN,O
ncbi-sent-216,of,IN,O
ncbi-sent-216,the,DT,O
ncbi-sent-216,von,NN,B-DISEASE
ncbi-sent-216,Hippel,NNP,I-DISEASE
ncbi-sent-216,-,:,I-DISEASE
ncbi-sent-216,Lindau,NNP,I-DISEASE
ncbi-sent-216,(,(,I-DISEASE
ncbi-sent-216,VHL,NNP,I-DISEASE
ncbi-sent-216,),),I-DISEASE
ncbi-sent-216,tumor,NN,I-DISEASE
ncbi-sent-216,suppressor,NN,O
ncbi-sent-216,gene,NN,O
ncbi-sent-216,predisposes,NNS,O
ncbi-sent-216,affected,VBD,O
ncbi-sent-216,individuals,NNS,O
ncbi-sent-216,to,TO,O
ncbi-sent-216,the,DT,O
ncbi-sent-216,human,JJ,O
ncbi-sent-216,VHL,NNP,B-DISEASE
ncbi-sent-216,cancer,NN,I-DISEASE
ncbi-sent-216,syndrome,NN,I-DISEASE
ncbi-sent-216,and,CC,O
ncbi-sent-216,is,VBZ,O
ncbi-sent-216,associated,VBN,O
ncbi-sent-216,with,IN,O
ncbi-sent-216,sporadic,JJ,B-DISEASE
ncbi-sent-216,renal,JJ,I-DISEASE
ncbi-sent-216,cell,NN,I-DISEASE
ncbi-sent-216,carcinomas,NN,I-DISEASE
ncbi-sent-216,(,(,O
ncbi-sent-216,RCC,NNP,B-DISEASE
ncbi-sent-216,),),O
ncbi-sent-216,and,CC,O
ncbi-sent-216,brain,NN,B-DISEASE
ncbi-sent-216,hemangioblastomas,NN,I-DISEASE
ncbi-sent-216,.,.,O
ncbi-sent-217,VHL,NNP,O
ncbi-sent-217,-,:,O
ncbi-sent-217,negative,JJ,O
ncbi-sent-217,786,CD,O
ncbi-sent-217,-,:,O
ncbi-sent-217,0,CD,O
ncbi-sent-217,RCC,NNP,B-DISEASE
ncbi-sent-217,cells,NNS,O
ncbi-sent-217,are,VBP,O
ncbi-sent-217,tumorigenic,JJ,O
ncbi-sent-217,in,IN,O
ncbi-sent-217,nude,JJ,O
ncbi-sent-217,mice,NN,O
ncbi-sent-217,which,WDT,O
ncbi-sent-217,is,VBZ,O
ncbi-sent-217,suppressed,VBN,O
ncbi-sent-217,by,IN,O
ncbi-sent-217,the,DT,O
ncbi-sent-217,reintroduction,NN,O
ncbi-sent-217,of,IN,O
ncbi-sent-217,VHL,NNP,B-DISEASE
ncbi-sent-217,.,.,O
ncbi-sent-218,Remarkably,RB,O
ncbi-sent-218,",",",",O
ncbi-sent-218,this,DT,O
ncbi-sent-218,occurs,VBZ,O
ncbi-sent-218,without,IN,O
ncbi-sent-218,affecting,VBG,O
ncbi-sent-218,the,DT,O
ncbi-sent-218,growth,NN,O
ncbi-sent-218,rate,NN,O
ncbi-sent-218,and,CC,O
ncbi-sent-218,cell,NN,O
ncbi-sent-218,cycle,NN,O
ncbi-sent-218,profile,NN,O
ncbi-sent-218,of,IN,O
ncbi-sent-218,these,DT,O
ncbi-sent-218,cells,NNS,O
ncbi-sent-218,in,IN,O
ncbi-sent-218,culture,NN,O
ncbi-sent-218,.,.,O
ncbi-sent-219,The,DT,O
ncbi-sent-219,786,CD,O
ncbi-sent-219,-,:,O
ncbi-sent-219,0,CD,O
ncbi-sent-219,cell,NN,O
ncbi-sent-219,line,NN,O
ncbi-sent-219,",",",",O
ncbi-sent-219,like,IN,O
ncbi-sent-219,many,JJ,O
ncbi-sent-219,cancer,NN,B-DISEASE
ncbi-sent-219,cells,NNS,O
ncbi-sent-219,",",",",O
ncbi-sent-219,fails,VBZ,O
ncbi-sent-219,to,TO,O
ncbi-sent-219,exit,VB,O
ncbi-sent-219,the,DT,O
ncbi-sent-219,cell,NN,O
ncbi-sent-219,cycle,NN,O
ncbi-sent-219,upon,IN,O
ncbi-sent-219,serum,NN,O
ncbi-sent-219,withdrawal,NN,O
ncbi-sent-219,.,.,O
ncbi-sent-220,Here,RB,O
ncbi-sent-220,",",",",O
ncbi-sent-220,it,PRP,O
ncbi-sent-220,is,VBZ,O
ncbi-sent-220,shown,VBN,O
ncbi-sent-220,that,IN,O
ncbi-sent-220,reintroduction,NN,O
ncbi-sent-220,of,IN,O
ncbi-sent-220,the,DT,O
ncbi-sent-220,wild,JJ,O
ncbi-sent-220,-,:,O
ncbi-sent-220,type,NN,O
ncbi-sent-220,VHL,NNP,B-DISEASE
ncbi-sent-220,gene,NN,O
ncbi-sent-220,restores,VBZ,O
ncbi-sent-220,the,DT,O
ncbi-sent-220,ability,NN,O
ncbi-sent-220,of,IN,O
ncbi-sent-220,VHL,NNP,O
ncbi-sent-220,-,:,O
ncbi-sent-220,negative,JJ,O
ncbi-sent-220,RCC,NNP,B-DISEASE
ncbi-sent-220,cancer,NN,I-DISEASE
ncbi-sent-220,cells,NNS,O
ncbi-sent-220,to,TO,O
ncbi-sent-220,exit,VB,O
ncbi-sent-220,the,DT,O
ncbi-sent-220,cell,NN,O
ncbi-sent-220,cycle,NN,O
ncbi-sent-220,and,CC,O
ncbi-sent-220,enter,NN,O
ncbi-sent-220,G0,NNP,O
ncbi-sent-220,/,NNP,O
ncbi-sent-220,quiescence,NN,O
ncbi-sent-220,in,IN,O
ncbi-sent-220,low,JJ,O
ncbi-sent-220,serum,NN,O
ncbi-sent-220,.,.,O
ncbi-sent-221,Both,DT,O
ncbi-sent-221,VHL,NNP,O
ncbi-sent-221,-,:,O
ncbi-sent-221,positive,JJ,O
ncbi-sent-221,and,CC,O
ncbi-sent-221,VHL,NNP,O
ncbi-sent-221,-,:,O
ncbi-sent-221,negative,JJ,O
ncbi-sent-221,RCC,NNP,B-DISEASE
ncbi-sent-221,cells,NNS,O
ncbi-sent-221,exit,VBP,O
ncbi-sent-221,the,DT,O
ncbi-sent-221,cell,NN,O
ncbi-sent-221,cycle,NN,O
ncbi-sent-221,by,IN,O
ncbi-sent-221,contact,JJ,O
ncbi-sent-221,inhibition,NN,O
ncbi-sent-221,.,.,O
ncbi-sent-222,The,DT,O
ncbi-sent-222,cyclin,NN,O
ncbi-sent-222,-,:,O
ncbi-sent-222,dependent,JJ,O
ncbi-sent-222,kinase,NN,O
ncbi-sent-222,inhibitor,NN,O
ncbi-sent-222,",",",",O
ncbi-sent-222,p27,NN,O
ncbi-sent-222,",",",",O
ncbi-sent-222,accumulates,VBZ,O
ncbi-sent-222,upon,IN,O
ncbi-sent-222,serum,NN,O
ncbi-sent-222,withdrawal,NN,O
ncbi-sent-222,",",",",O
ncbi-sent-222,only,RB,O
ncbi-sent-222,in,IN,O
ncbi-sent-222,the,DT,O
ncbi-sent-222,presence,NN,O
ncbi-sent-222,of,IN,O
ncbi-sent-222,VHL,NNP,B-DISEASE
ncbi-sent-222,",",",",O
ncbi-sent-222,as,IN,O
ncbi-sent-222,a,DT,O
ncbi-sent-222,result,NN,O
ncbi-sent-222,of,IN,O
ncbi-sent-222,the,DT,O
ncbi-sent-222,stabilization,NN,O
ncbi-sent-222,of,IN,O
ncbi-sent-222,the,DT,O
ncbi-sent-222,protein,NN,O
ncbi-sent-222,.,.,O
ncbi-sent-223,We,PRP,O
ncbi-sent-223,propose,VBP,O
ncbi-sent-223,that,IN,O
ncbi-sent-223,the,DT,O
ncbi-sent-223,loss,NN,O
ncbi-sent-223,of,IN,O
ncbi-sent-223,wild,JJ,O
ncbi-sent-223,-,:,O
ncbi-sent-223,type,NN,O
ncbi-sent-223,VHL,NNP,B-DISEASE
ncbi-sent-223,gene,NN,O
ncbi-sent-223,results,NNS,O
ncbi-sent-223,in,IN,O
ncbi-sent-223,a,DT,O
ncbi-sent-223,specific,JJ,O
ncbi-sent-223,cellular,JJ,O
ncbi-sent-223,defect,NN,O
ncbi-sent-223,in,IN,O
ncbi-sent-223,serum,JJ,O
ncbi-sent-223,-,:,O
ncbi-sent-223,dependent,JJ,O
ncbi-sent-223,growth,NN,O
ncbi-sent-223,control,NN,O
ncbi-sent-223,",",",",O
ncbi-sent-223,which,WDT,O
ncbi-sent-223,may,MD,O
ncbi-sent-223,initiate,VB,O
ncbi-sent-223,tumor,NN,B-DISEASE
ncbi-sent-223,formation,NN,O
ncbi-sent-223,.,.,O
ncbi-sent-224,This,DT,O
ncbi-sent-224,is,VBZ,O
ncbi-sent-224,corrected,VBN,O
ncbi-sent-224,by,IN,O
ncbi-sent-224,the,DT,O
ncbi-sent-224,reintroduction,NN,O
ncbi-sent-224,of,IN,O
ncbi-sent-224,wild,JJ,O
ncbi-sent-224,-,:,O
ncbi-sent-224,type,NN,O
ncbi-sent-224,VHL,NNP,B-DISEASE
ncbi-sent-224,",",",",O
ncbi-sent-224,implicating,VBG,O
ncbi-sent-224,VHL,NNP,B-DISEASE
ncbi-sent-224,as,IN,O
ncbi-sent-224,the,DT,O
ncbi-sent-224,first,JJ,O
ncbi-sent-224,tumor,NN,B-DISEASE
ncbi-sent-224,suppressor,NN,O
ncbi-sent-224,involved,VBN,O
ncbi-sent-224,in,IN,O
ncbi-sent-224,the,DT,O
ncbi-sent-224,regulation,NN,O
ncbi-sent-224,of,IN,O
ncbi-sent-224,cell,NN,O
ncbi-sent-224,cycle,NN,O
ncbi-sent-224,exit,NN,O
ncbi-sent-224,",",",",O
ncbi-sent-224,which,WDT,O
ncbi-sent-224,is,VBZ,O
ncbi-sent-224,consistent,JJ,O
ncbi-sent-224,with,IN,O
ncbi-sent-224,its,PRP$,O
ncbi-sent-224,gatekeeper,NN,O
ncbi-sent-224,function,NN,O
ncbi-sent-224,in,IN,O
ncbi-sent-224,the,DT,O
ncbi-sent-224,kidney,NN,O
ncbi-sent-224,.,.,O
ncbi-sent-225,.,.,O
ncbi-sent-226,Piebaldism,NN,B-DISEASE
ncbi-sent-226,with,IN,O
ncbi-sent-226,deafness,NN,B-DISEASE
ncbi-sent-226,:,:,O
ncbi-sent-226,molecular,JJ,O
ncbi-sent-226,evidence,NN,O
ncbi-sent-226,for,IN,O
ncbi-sent-226,an,DT,O
ncbi-sent-226,expanded,JJ,O
ncbi-sent-226,syndrome,NN,O
ncbi-sent-226,.,.,O
ncbi-sent-227,In,IN,O
ncbi-sent-227,a,DT,O
ncbi-sent-227,South,JJ,O
ncbi-sent-227,African,JJ,O
ncbi-sent-227,girl,NN,O
ncbi-sent-227,of,IN,O
ncbi-sent-227,Xhosa,NNP,O
ncbi-sent-227,stock,NN,O
ncbi-sent-227,with,IN,O
ncbi-sent-227,severe,JJ,O
ncbi-sent-227,piebaldism,NN,B-DISEASE
ncbi-sent-227,and,CC,O
ncbi-sent-227,profound,JJ,O
ncbi-sent-227,congenital,JJ,O
ncbi-sent-227,sensorineural,JJ,B-DISEASE
ncbi-sent-227,deafness,NN,I-DISEASE
ncbi-sent-227,we,PRP,O
ncbi-sent-227,identified,VBD,O
ncbi-sent-227,a,DT,O
ncbi-sent-227,novel,JJ,O
ncbi-sent-227,missense,NN,O
ncbi-sent-227,substitution,NN,O
ncbi-sent-227,at,IN,O
ncbi-sent-227,a,DT,O
ncbi-sent-227,highly,RB,O
ncbi-sent-227,conserved,VBN,O
ncbi-sent-227,residue,NN,O
ncbi-sent-227,in,IN,O
ncbi-sent-227,the,DT,O
ncbi-sent-227,intracellular,JJ,O
ncbi-sent-227,kinase,NN,O
ncbi-sent-227,domain,NN,O
ncbi-sent-227,of,IN,O
ncbi-sent-227,the,DT,O
ncbi-sent-227,KIT,NNP,O
ncbi-sent-227,proto,NN,O
ncbi-sent-227,-,:,O
ncbi-sent-227,oncogene,NN,O
ncbi-sent-227,",",",",O
ncbi-sent-227,R796G,NNP,O
ncbi-sent-227,.,.,O
ncbi-sent-228,Though,NNP,O
ncbi-sent-228,auditory,JJ,B-DISEASE
ncbi-sent-228,anomalies,NNS,I-DISEASE
ncbi-sent-228,have,VBP,O
ncbi-sent-228,been,VBN,O
ncbi-sent-228,observed,VBN,O
ncbi-sent-228,in,IN,O
ncbi-sent-228,mice,NN,O
ncbi-sent-228,with,IN,O
ncbi-sent-228,dominant,JJ,O
ncbi-sent-228,white,JJ,O
ncbi-sent-228,spotting,NN,O
ncbi-sent-228,(,(,O
ncbi-sent-228,W,NNP,O
ncbi-sent-228,),),O
ncbi-sent-228,due,JJ,O
ncbi-sent-228,to,TO,O
ncbi-sent-228,KIT,NNP,O
ncbi-sent-228,mutations,NNS,O
ncbi-sent-228,",",",",O
ncbi-sent-228,deafness,NN,B-DISEASE
ncbi-sent-228,is,VBZ,O
ncbi-sent-228,not,RB,O
ncbi-sent-228,typical,JJ,O
ncbi-sent-228,in,IN,O
ncbi-sent-228,human,JJ,O
ncbi-sent-228,piebaldism,NN,B-DISEASE
ncbi-sent-228,.,.,O
ncbi-sent-229,Thus,RB,O
ncbi-sent-229,",",",",O
ncbi-sent-229,the,DT,O
ncbi-sent-229,occurrence,NN,O
ncbi-sent-229,of,IN,O
ncbi-sent-229,sensorineural,JJ,B-DISEASE
ncbi-sent-229,deafness,NN,I-DISEASE
ncbi-sent-229,in,IN,O
ncbi-sent-229,this,DT,O
ncbi-sent-229,patient,JJ,O
ncbi-sent-229,extends,VBZ,O
ncbi-sent-229,considerably,RB,O
ncbi-sent-229,the,DT,O
ncbi-sent-229,phenotypic,NN,O
ncbi-sent-229,range,NN,O
ncbi-sent-229,of,IN,O
ncbi-sent-229,piebaldism,NN,B-DISEASE
ncbi-sent-229,due,JJ,O
ncbi-sent-229,to,TO,O
ncbi-sent-229,KIT,NNP,O
ncbi-sent-229,gene,NN,O
ncbi-sent-229,mutation,NN,O
ncbi-sent-229,in,IN,O
ncbi-sent-229,humans,NNS,O
ncbi-sent-229,and,CC,O
ncbi-sent-229,tightens,VBZ,O
ncbi-sent-229,the,DT,O
ncbi-sent-229,clinical,JJ,O
ncbi-sent-229,similarity,NN,O
ncbi-sent-229,between,IN,O
ncbi-sent-229,piebaldism,NN,B-DISEASE
ncbi-sent-229,and,CC,O
ncbi-sent-229,the,DT,O
ncbi-sent-229,various,JJ,O
ncbi-sent-229,forms,NNS,O
ncbi-sent-229,of,IN,O
ncbi-sent-229,Waardenburg,NNP,B-DISEASE
ncbi-sent-229,syndrome,NN,I-DISEASE
ncbi-sent-229,.,.,O
ncbi-sent-230,.,.,O
ncbi-sent-231,Cycloheximide,NNP,O
ncbi-sent-231,facilitates,VBZ,O
ncbi-sent-231,the,DT,O
ncbi-sent-231,identification,NN,O
ncbi-sent-231,of,IN,O
ncbi-sent-231,aberrant,JJ,O
ncbi-sent-231,transcripts,NNS,O
ncbi-sent-231,resulting,VBG,O
ncbi-sent-231,from,IN,O
ncbi-sent-231,a,DT,O
ncbi-sent-231,novel,JJ,O
ncbi-sent-231,splice,NN,O
ncbi-sent-231,-,:,O
ncbi-sent-231,site,NN,O
ncbi-sent-231,mutation,NN,O
ncbi-sent-231,in,IN,O
ncbi-sent-231,COL17A1,NNP,O
ncbi-sent-231,in,IN,O
ncbi-sent-231,a,DT,O
ncbi-sent-231,patient,NN,O
ncbi-sent-231,with,IN,O
ncbi-sent-231,generalized,JJ,O
ncbi-sent-231,atrophic,JJ,B-DISEASE
ncbi-sent-231,benign,NN,I-DISEASE
ncbi-sent-231,epidermolysis,NN,I-DISEASE
ncbi-sent-231,bullosa,NN,I-DISEASE
ncbi-sent-231,.,.,O
ncbi-sent-232,Patients,NNS,O
ncbi-sent-232,with,IN,O
ncbi-sent-232,generalized,JJ,O
ncbi-sent-232,atrophic,JJ,B-DISEASE
ncbi-sent-232,benign,NN,I-DISEASE
ncbi-sent-232,epidermolysis,NN,I-DISEASE
ncbi-sent-232,bullosa,NN,I-DISEASE
ncbi-sent-232,often,RB,O
ncbi-sent-232,show,VBP,O
ncbi-sent-232,decreased,JJ,O
ncbi-sent-232,expression,NN,O
ncbi-sent-232,of,IN,O
ncbi-sent-232,type,NN,O
ncbi-sent-232,XVII,NNP,O
ncbi-sent-232,collagen,NN,O
ncbi-sent-232,",",",",O
ncbi-sent-232,a,DT,O
ncbi-sent-232,transmembrane,NN,O
ncbi-sent-232,hemidesmosomal,JJ,O
ncbi-sent-232,protein,NN,O
ncbi-sent-232,encoded,VBN,O
ncbi-sent-232,by,IN,O
ncbi-sent-232,COL17A1,NNP,O
ncbi-sent-232,.,.,O
ncbi-sent-233,This,DT,O
ncbi-sent-233,report,NN,O
ncbi-sent-233,documents,NNS,O
ncbi-sent-233,a,DT,O
ncbi-sent-233,novel,JJ,O
ncbi-sent-233,splice,NN,O
ncbi-sent-233,-,:,O
ncbi-sent-233,site,NN,O
ncbi-sent-233,mutation,NN,O
ncbi-sent-233,in,IN,O
ncbi-sent-233,COL17A1,NNP,O
ncbi-sent-233,in,IN,O
ncbi-sent-233,a,DT,O
ncbi-sent-233,patient,NN,O
ncbi-sent-233,with,IN,O
ncbi-sent-233,generalized,JJ,O
ncbi-sent-233,atrophic,JJ,B-DISEASE
ncbi-sent-233,benign,NN,I-DISEASE
ncbi-sent-233,epidermolysis,NN,I-DISEASE
ncbi-sent-233,bullosa,NN,I-DISEASE
ncbi-sent-233,",",",",O
ncbi-sent-233,and,CC,O
ncbi-sent-233,applies,VBZ,O
ncbi-sent-233,a,DT,O
ncbi-sent-233,new,JJ,O
ncbi-sent-233,methodology,NN,O
ncbi-sent-233,to,TO,O
ncbi-sent-233,define,VB,O
ncbi-sent-233,and,CC,O
ncbi-sent-233,characterize,VB,O
ncbi-sent-233,the,DT,O
ncbi-sent-233,resulting,VBG,O
ncbi-sent-233,mRNA,JJ,O
ncbi-sent-233,splice,NN,O
ncbi-sent-233,variants,NNS,O
ncbi-sent-233,.,.,O
ncbi-sent-234,Mutational,JJ,O
ncbi-sent-234,analysis,NN,O
ncbi-sent-234,of,IN,O
ncbi-sent-234,COL17A1,NNP,O
ncbi-sent-234,identified,VBD,O
ncbi-sent-234,a,DT,O
ncbi-sent-234,maternally,RB,O
ncbi-sent-234,inherited,VBN,O
ncbi-sent-234,G,NNP,O
ncbi-sent-234,-,:,O
ncbi-sent-234,to,TO,O
ncbi-sent-234,-,:,O
ncbi-sent-234,T,VB,O
ncbi-sent-234,transversion,NN,O
ncbi-sent-234,at,IN,O
ncbi-sent-234,the,DT,O
ncbi-sent-234,-,:,O
ncbi-sent-234,1,CD,O
ncbi-sent-234,position,NN,O
ncbi-sent-234,of,IN,O
ncbi-sent-234,exon,JJ,O
ncbi-sent-234,32,CD,O
ncbi-sent-234,.,.,O
ncbi-sent-235,This,DT,O
ncbi-sent-235,acceptor,NN,O
ncbi-sent-235,splice,NN,O
ncbi-sent-235,-,:,O
ncbi-sent-235,site,NN,O
ncbi-sent-235,mutation,NN,O
ncbi-sent-235,led,VBD,O
ncbi-sent-235,to,TO,O
ncbi-sent-235,the,DT,O
ncbi-sent-235,formation,NN,O
ncbi-sent-235,of,IN,O
ncbi-sent-235,aberrant,JJ,O
ncbi-sent-235,transcripts,NNS,O
ncbi-sent-235,present,JJ,O
ncbi-sent-235,at,IN,O
ncbi-sent-235,extremely,RB,O
ncbi-sent-235,low,JJ,O
ncbi-sent-235,levels,NNS,O
ncbi-sent-235,.,.,O
ncbi-sent-236,Based,VBN,O
ncbi-sent-236,on,IN,O
ncbi-sent-236,our,PRP$,O
ncbi-sent-236,recent,JJ,O
ncbi-sent-236,finding,NN,O
ncbi-sent-236,that,IN,O
ncbi-sent-236,cycloheximide,NN,O
ncbi-sent-236,stabilized,VBD,O
ncbi-sent-236,mutant,JJ,O
ncbi-sent-236,COL17A1,NNP,O
ncbi-sent-236,transcripts,NNS,O
ncbi-sent-236,in,IN,O
ncbi-sent-236,keratinocytes,NNS,O
ncbi-sent-236,homozygous,JJ,O
ncbi-sent-236,for,IN,O
ncbi-sent-236,a,DT,O
ncbi-sent-236,frameshift,NN,O
ncbi-sent-236,mutation,NN,O
ncbi-sent-236,",",",",O
ncbi-sent-236,the,DT,O
ncbi-sent-236,effects,NNS,O
ncbi-sent-236,of,IN,O
ncbi-sent-236,the,DT,O
ncbi-sent-236,splice,NN,O
ncbi-sent-236,-,:,O
ncbi-sent-236,site,NN,O
ncbi-sent-236,mutation,NN,O
ncbi-sent-236,on,IN,O
ncbi-sent-236,splicing,NN,O
ncbi-sent-236,of,IN,O
ncbi-sent-236,COL17A1,NNP,O
ncbi-sent-236,transcripts,NNS,O
ncbi-sent-236,were,VBD,O
ncbi-sent-236,determined,VBN,O
ncbi-sent-236,using,VBG,O
ncbi-sent-236,reverse,JJ,O
ncbi-sent-236,transcriptase,NN,O
ncbi-sent-236,polymerase,NN,O
ncbi-sent-236,chain,NN,O
ncbi-sent-236,reaction,NN,O
ncbi-sent-236,of,IN,O
ncbi-sent-236,total,JJ,O
ncbi-sent-236,RNA,NNP,O
ncbi-sent-236,from,IN,O
ncbi-sent-236,keratinocytes,NNS,O
ncbi-sent-236,incubated,VBN,O
ncbi-sent-236,for,IN,O
ncbi-sent-236,2,CD,O
ncbi-sent-236,.,.,O
ncbi-sent-237,5,CD,O
ncbi-sent-237,h,NN,O
ncbi-sent-237,in,IN,O
ncbi-sent-237,the,DT,O
ncbi-sent-237,presence,NN,O
ncbi-sent-237,or,CC,O
ncbi-sent-237,absence,NN,O
ncbi-sent-237,of,IN,O
ncbi-sent-237,10,CD,O
ncbi-sent-237,microg,NNS,O
ncbi-sent-237,cycloheximide,JJ,O
ncbi-sent-237,per,IN,O
ncbi-sent-237,ml,NN,O
ncbi-sent-237,.,.,O
ncbi-sent-238,Using,VBG,O
ncbi-sent-238,this,DT,O
ncbi-sent-238,approach,NN,O
ncbi-sent-238,",",",",O
ncbi-sent-238,an,DT,O
ncbi-sent-238,abnormally,RB,O
ncbi-sent-238,spliced,JJ,O
ncbi-sent-238,transcript,NN,O
ncbi-sent-238,was,VBD,O
ncbi-sent-238,identified,VBN,O
ncbi-sent-238,that,IN,O
ncbi-sent-238,contains,VBZ,O
ncbi-sent-238,an,DT,O
ncbi-sent-238,extra,JJ,O
ncbi-sent-238,264,CD,O
ncbi-sent-238,bases,NNS,O
ncbi-sent-238,upstream,RB,O
ncbi-sent-238,from,IN,O
ncbi-sent-238,exon,JJ,O
ncbi-sent-238,32,CD,O
ncbi-sent-238,",",",",O
ncbi-sent-238,resulting,VBG,O
ncbi-sent-238,in,IN,O
ncbi-sent-238,a,DT,O
ncbi-sent-238,premature,NN,O
ncbi-sent-238,termination,NN,O
ncbi-sent-238,codon,VBZ,O
ncbi-sent-238,27,CD,O
ncbi-sent-238,bp,NN,O
ncbi-sent-238,downstream,NN,O
ncbi-sent-238,from,IN,O
ncbi-sent-238,the,DT,O
ncbi-sent-238,cryptic,JJ,O
ncbi-sent-238,splice,NN,O
ncbi-sent-238,site,NN,O
ncbi-sent-238,.,.,O
ncbi-sent-239,Three,CD,O
ncbi-sent-239,other,JJ,O
ncbi-sent-239,splice,NN,O
ncbi-sent-239,variants,NNS,O
ncbi-sent-239,",",",",O
ncbi-sent-239,including,VBG,O
ncbi-sent-239,one,CD,O
ncbi-sent-239,derived,VBN,O
ncbi-sent-239,from,IN,O
ncbi-sent-239,the,DT,O
ncbi-sent-239,skipping,NN,O
ncbi-sent-239,of,IN,O
ncbi-sent-239,exon,$,O
ncbi-sent-239,32,CD,O
ncbi-sent-239,",",",",O
ncbi-sent-239,were,VBD,O
ncbi-sent-239,also,RB,O
ncbi-sent-239,identified,VBN,O
ncbi-sent-239,.,.,O
ncbi-sent-240,These,DT,O
ncbi-sent-240,results,NNS,O
ncbi-sent-240,indicate,VBP,O
ncbi-sent-240,the,DT,O
ncbi-sent-240,usefulness,NN,O
ncbi-sent-240,of,IN,O
ncbi-sent-240,cycloheximide,JJ,O
ncbi-sent-240,treatment,NN,O
ncbi-sent-240,in,IN,O
ncbi-sent-240,evaluating,VBG,O
ncbi-sent-240,the,DT,O
ncbi-sent-240,abnormal,JJ,O
ncbi-sent-240,processing,NN,O
ncbi-sent-240,of,IN,O
ncbi-sent-240,mRNA,NN,O
ncbi-sent-240,due,JJ,O
ncbi-sent-240,to,TO,O
ncbi-sent-240,splice,VB,O
ncbi-sent-240,-,:,O
ncbi-sent-240,site,NN,O
ncbi-sent-240,mutations,NNS,O
ncbi-sent-240,",",",",O
ncbi-sent-240,because,IN,O
ncbi-sent-240,(,(,O
ncbi-sent-240,i,NN,O
ncbi-sent-240,),),O
ncbi-sent-240,aberrant,NN,O
ncbi-sent-240,splicing,VBG,O
ncbi-sent-240,often,RB,O
ncbi-sent-240,generates,VBZ,O
ncbi-sent-240,a,DT,O
ncbi-sent-240,premature,JJ,O
ncbi-sent-240,termination,NN,O
ncbi-sent-240,codon,NN,O
ncbi-sent-240,",",",",O
ncbi-sent-240,(,(,O
ncbi-sent-240,ii,NN,O
ncbi-sent-240,),),O
ncbi-sent-240,transcripts,NNS,O
ncbi-sent-240,with,IN,O
ncbi-sent-240,premature,JJ,O
ncbi-sent-240,termination,NN,O
ncbi-sent-240,codons,NNS,O
ncbi-sent-240,can,MD,O
ncbi-sent-240,occur,VB,O
ncbi-sent-240,at,IN,O
ncbi-sent-240,low,JJ,O
ncbi-sent-240,or,CC,O
ncbi-sent-240,undetectable,JJ,O
ncbi-sent-240,levels,NNS,O
ncbi-sent-240,due,JJ,O
ncbi-sent-240,to,TO,O
ncbi-sent-240,nonsense,VB,O
ncbi-sent-240,-,:,O
ncbi-sent-240,mediated,VBN,O
ncbi-sent-240,mRNA,NN,O
ncbi-sent-240,decay,NN,O
ncbi-sent-240,",",",",O
ncbi-sent-240,and,CC,O
ncbi-sent-240,(,(,O
ncbi-sent-240,iii,NN,O
ncbi-sent-240,),),O
ncbi-sent-240,the,DT,O
ncbi-sent-240,levels,NNS,O
ncbi-sent-240,of,IN,O
ncbi-sent-240,these,DT,O
ncbi-sent-240,transcripts,NNS,O
ncbi-sent-240,can,MD,O
ncbi-sent-240,be,VB,O
ncbi-sent-240,increased,VBN,O
ncbi-sent-240,by,IN,O
ncbi-sent-240,cycloheximide,NN,O
ncbi-sent-240,.,.,O
ncbi-sent-241,A,DT,O
ncbi-sent-241,deletion,NN,O
ncbi-sent-241,mutation,NN,O
ncbi-sent-241,in,IN,O
ncbi-sent-241,COL17A1,NNP,O
ncbi-sent-241,in,IN,O
ncbi-sent-241,five,CD,O
ncbi-sent-241,Austrian,JJ,O
ncbi-sent-241,families,NNS,O
ncbi-sent-241,with,IN,O
ncbi-sent-241,generalized,JJ,O
ncbi-sent-241,atrophic,JJ,B-DISEASE
ncbi-sent-241,benign,NN,I-DISEASE
ncbi-sent-241,epidermolysis,NN,I-DISEASE
ncbi-sent-241,bullosa,NN,I-DISEASE
ncbi-sent-241,represents,VBZ,O
ncbi-sent-241,propagation,NN,O
ncbi-sent-241,of,IN,O
ncbi-sent-241,an,DT,O
ncbi-sent-241,ancestral,JJ,O
ncbi-sent-241,allele,NN,O
ncbi-sent-241,.,.,O
ncbi-sent-242,Patients,NNS,O
ncbi-sent-242,with,IN,O
ncbi-sent-242,generalized,JJ,O
ncbi-sent-242,atrophic,JJ,B-DISEASE
ncbi-sent-242,benign,NN,I-DISEASE
ncbi-sent-242,epidermolysis,NN,I-DISEASE
ncbi-sent-242,bullosa,NN,I-DISEASE
ncbi-sent-242,",",",",O
ncbi-sent-242,a,DT,O
ncbi-sent-242,usually,RB,O
ncbi-sent-242,nonlethal,JJ,O
ncbi-sent-242,form,NN,O
ncbi-sent-242,of,IN,O
ncbi-sent-242,junctional,JJ,B-DISEASE
ncbi-sent-242,epidermolysis,NN,I-DISEASE
ncbi-sent-242,bullosa,NN,I-DISEASE
ncbi-sent-242,",",",",O
ncbi-sent-242,have,VBP,O
ncbi-sent-242,generalized,VBN,O
ncbi-sent-242,blistering,NN,B-DISEASE
ncbi-sent-242,",",",",O
ncbi-sent-242,nail,JJ,B-DISEASE
ncbi-sent-242,dystrophy,NN,I-DISEASE
ncbi-sent-242,",",",",O
ncbi-sent-242,patchy,NN,B-DISEASE
ncbi-sent-242,alopecia,NN,I-DISEASE
ncbi-sent-242,",",",",O
ncbi-sent-242,and,CC,O
ncbi-sent-242,dental,JJ,B-DISEASE
ncbi-sent-242,abnormalities,NNS,I-DISEASE
ncbi-sent-242,.,.,O
ncbi-sent-243,Skin,NNP,B-DISEASE
ncbi-sent-243,fragility,NN,I-DISEASE
ncbi-sent-243,in,IN,O
ncbi-sent-243,most,JJS,O
ncbi-sent-243,cases,NNS,O
ncbi-sent-243,is,VBZ,O
ncbi-sent-243,due,JJ,O
ncbi-sent-243,to,TO,O
ncbi-sent-243,mutations,NNS,O
ncbi-sent-243,in,IN,O
ncbi-sent-243,the,DT,O
ncbi-sent-243,gene,NN,O
ncbi-sent-243,encoding,VBG,O
ncbi-sent-243,type,JJ,O
ncbi-sent-243,XVII,NN,O
ncbi-sent-243,collagen,NN,O
ncbi-sent-243,(,(,O
ncbi-sent-243,COL17A1,NNP,O
ncbi-sent-243,),),O
ncbi-sent-243,.,.,O
ncbi-sent-244,Recently,RB,O
ncbi-sent-244,",",",",O
ncbi-sent-244,we,PRP,O
ncbi-sent-244,reported,VBD,O
ncbi-sent-244,five,CD,O
ncbi-sent-244,Austrian,JJ,O
ncbi-sent-244,families,NNS,O
ncbi-sent-244,with,IN,O
ncbi-sent-244,generalized,JJ,O
ncbi-sent-244,atrophic,JJ,B-DISEASE
ncbi-sent-244,benign,NN,I-DISEASE
ncbi-sent-244,epidermolysis,NN,I-DISEASE
ncbi-sent-244,bullosa,NN,I-DISEASE
ncbi-sent-244,who,WP,O
ncbi-sent-244,share,NN,O
ncbi-sent-244,the,DT,O
ncbi-sent-244,same,JJ,O
ncbi-sent-244,COL17A1,NNP,O
ncbi-sent-244,mutation,NN,O
ncbi-sent-244,.,.,O
ncbi-sent-245,Affected,JJ,O
ncbi-sent-245,individuals,NNS,O
ncbi-sent-245,in,IN,O
ncbi-sent-245,three,CD,O
ncbi-sent-245,families,NNS,O
ncbi-sent-245,are,VBP,O
ncbi-sent-245,homozygous,JJ,O
ncbi-sent-245,for,IN,O
ncbi-sent-245,4003delTC,CD,O
ncbi-sent-245,",",",",O
ncbi-sent-245,whereas,NNS,O
ncbi-sent-245,those,DT,O
ncbi-sent-245,in,IN,O
ncbi-sent-245,two,CD,O
ncbi-sent-245,others,NNS,O
ncbi-sent-245,are,VBP,O
ncbi-sent-245,compound,JJ,O
ncbi-sent-245,heterozygotes,NNS,O
ncbi-sent-245,.,.,O
ncbi-sent-246,To,TO,O
ncbi-sent-246,determine,VB,O
ncbi-sent-246,if,IN,O
ncbi-sent-246,the,DT,O
ncbi-sent-246,occurrence,NN,O
ncbi-sent-246,of,IN,O
ncbi-sent-246,4003delTC,CD,O
ncbi-sent-246,in,IN,O
ncbi-sent-246,these,DT,O
ncbi-sent-246,unrelated,JJ,O
ncbi-sent-246,families,NNS,O
ncbi-sent-246,signifies,VBZ,O
ncbi-sent-246,propagation,NN,O
ncbi-sent-246,of,IN,O
ncbi-sent-246,an,DT,O
ncbi-sent-246,ancestral,JJ,O
ncbi-sent-246,allele,NN,O
ncbi-sent-246,or,CC,O
ncbi-sent-246,a,DT,O
ncbi-sent-246,mutational,JJ,O
ncbi-sent-246,hot,JJ,O
ncbi-sent-246,spot,NN,O
ncbi-sent-246,",",",",O
ncbi-sent-246,haplotypes,NNS,O
ncbi-sent-246,were,VBD,O
ncbi-sent-246,determined,VBN,O
ncbi-sent-246,for,IN,O
ncbi-sent-246,polymorphisms,NNS,O
ncbi-sent-246,both,DT,O
ncbi-sent-246,within,IN,O
ncbi-sent-246,and,CC,O
ncbi-sent-246,flanking,VBG,O
ncbi-sent-246,COL17A1,NNP,O
ncbi-sent-246,.,.,O
ncbi-sent-247,Five,CD,O
ncbi-sent-247,intragenic,JJ,O
ncbi-sent-247,polymorphisms,NNS,O
ncbi-sent-247,were,VBD,O
ncbi-sent-247,chosen,VBN,O
ncbi-sent-247,based,VBN,O
ncbi-sent-247,on,IN,O
ncbi-sent-247,their,PRP$,O
ncbi-sent-247,informativeness,NN,O
ncbi-sent-247,.,.,O
ncbi-sent-248,One,CD,O
ncbi-sent-248,of,IN,O
ncbi-sent-248,these,DT,O
ncbi-sent-248,",",",",O
ncbi-sent-248,not,RB,O
ncbi-sent-248,previously,RB,O
ncbi-sent-248,reported,VBN,O
ncbi-sent-248,",",",",O
ncbi-sent-248,was,VBD,O
ncbi-sent-248,2988,CD,O
ncbi-sent-248,A,NNP,O
ncbi-sent-248,or,CC,O
ncbi-sent-248,C,NNP,O
ncbi-sent-248,that,WDT,O
ncbi-sent-248,introduces,VBZ,O
ncbi-sent-248,a,DT,O
ncbi-sent-248,new,JJ,O
ncbi-sent-248,restriction,NN,O
ncbi-sent-248,site,NN,O
ncbi-sent-248,for,IN,O
ncbi-sent-248,Eco0109,NNP,O
ncbi-sent-248,I,PRP,O
ncbi-sent-248,.,.,O
ncbi-sent-249,All,PDT,O
ncbi-sent-249,the,DT,O
ncbi-sent-249,4003delTC,CD,O
ncbi-sent-249,alleles,NNS,O
ncbi-sent-249,showed,VBD,O
ncbi-sent-249,the,DT,O
ncbi-sent-249,same,JJ,O
ncbi-sent-249,haplotype,NN,O
ncbi-sent-249,for,IN,O
ncbi-sent-249,these,DT,O
ncbi-sent-249,five,CD,O
ncbi-sent-249,polymorphic,JJ,O
ncbi-sent-249,markers,NNS,O
ncbi-sent-249,.,.,O
ncbi-sent-250,Fourteen,NNP,O
ncbi-sent-250,microsatellite,JJ,O
ncbi-sent-250,polymorphisms,NNS,O
ncbi-sent-250,were,VBD,O
ncbi-sent-250,selected,VBN,O
ncbi-sent-250,based,VBN,O
ncbi-sent-250,on,IN,O
ncbi-sent-250,their,PRP$,O
ncbi-sent-250,high,JJ,O
ncbi-sent-250,heterozygosity,NN,O
ncbi-sent-250,and,CC,O
ncbi-sent-250,their,PRP$,O
ncbi-sent-250,location,NN,O
ncbi-sent-250,within,IN,O
ncbi-sent-250,10q23,CD,O
ncbi-sent-250,-,:,O
ncbi-sent-250,q25,NN,O
ncbi-sent-250,near,IN,O
ncbi-sent-250,COL17A1,NNP,O
ncbi-sent-250,.,.,O
ncbi-sent-251,Three,NNP,O
ncbi-sent-251,families,NNS,O
ncbi-sent-251,shared,VBD,O
ncbi-sent-251,microsatellite,JJ,O
ncbi-sent-251,polymorphisms,NNS,O
ncbi-sent-251,covering,VBG,O
ncbi-sent-251,at,IN,O
ncbi-sent-251,most,JJS,O
ncbi-sent-251,19,CD,O
ncbi-sent-251,cM,NN,O
ncbi-sent-251,",",",",O
ncbi-sent-251,whereas,IN,O
ncbi-sent-251,the,DT,O
ncbi-sent-251,others,NNS,O
ncbi-sent-251,shared,VBD,O
ncbi-sent-251,smaller,JJR,O
ncbi-sent-251,regions,NNS,O
ncbi-sent-251,consistent,VBP,O
ncbi-sent-251,with,IN,O
ncbi-sent-251,cross,NN,O
ncbi-sent-251,-,:,O
ncbi-sent-251,over,IN,O
ncbi-sent-251,events,NNS,O
ncbi-sent-251,during,IN,O
ncbi-sent-251,passage,NN,O
ncbi-sent-251,of,IN,O
ncbi-sent-251,this,DT,O
ncbi-sent-251,mutation,NN,O
ncbi-sent-251,through,IN,O
ncbi-sent-251,several,JJ,O
ncbi-sent-251,generations,NNS,O
ncbi-sent-251,.,.,O
ncbi-sent-252,These,DT,O
ncbi-sent-252,results,NNS,O
ncbi-sent-252,indicate,VBP,O
ncbi-sent-252,that,IN,O
ncbi-sent-252,4003delTC,CD,O
ncbi-sent-252,occurs,NNS,O
ncbi-sent-252,on,IN,O
ncbi-sent-252,a,DT,O
ncbi-sent-252,single,JJ,O
ncbi-sent-252,ancestral,JJ,O
ncbi-sent-252,allele,NN,O
ncbi-sent-252,.,.,O
ncbi-sent-253,.,.,O
ncbi-sent-254,The,DT,O
ncbi-sent-254,haptoglobin,NN,O
ncbi-sent-254,-,:,O
ncbi-sent-254,gene,NN,O
ncbi-sent-254,deletion,NN,O
ncbi-sent-254,responsible,JJ,O
ncbi-sent-254,for,IN,O
ncbi-sent-254,anhaptoglobinemia,NN,B-DISEASE
ncbi-sent-254,.,.,O
ncbi-sent-255,We,PRP,O
ncbi-sent-255,have,VBP,O
ncbi-sent-255,found,VBN,O
ncbi-sent-255,an,DT,O
ncbi-sent-255,allelic,JJ,O
ncbi-sent-255,deletion,NN,O
ncbi-sent-255,of,IN,O
ncbi-sent-255,the,DT,O
ncbi-sent-255,haptoglobin,NN,O
ncbi-sent-255,(,(,O
ncbi-sent-255,Hp,NNP,O
ncbi-sent-255,),),O
ncbi-sent-255,gene,NN,O
ncbi-sent-255,from,IN,O
ncbi-sent-255,an,DT,O
ncbi-sent-255,individual,NN,O
ncbi-sent-255,with,IN,O
ncbi-sent-255,anhaptoglobinemia,NN,B-DISEASE
ncbi-sent-255,.,.,O
ncbi-sent-256,The,DT,O
ncbi-sent-256,Hp,NNP,O
ncbi-sent-256,gene,NN,O
ncbi-sent-256,cluster,NN,O
ncbi-sent-256,consists,VBZ,O
ncbi-sent-256,of,IN,O
ncbi-sent-256,coding,VBG,O
ncbi-sent-256,regions,NNS,O
ncbi-sent-256,of,IN,O
ncbi-sent-256,the,DT,O
ncbi-sent-256,alpha,NN,O
ncbi-sent-256,chain,NN,O
ncbi-sent-256,and,CC,O
ncbi-sent-256,beta,NN,O
ncbi-sent-256,chain,NN,O
ncbi-sent-256,of,IN,O
ncbi-sent-256,the,DT,O
ncbi-sent-256,haptoglobin,NN,O
ncbi-sent-256,gene,NN,O
ncbi-sent-256,(,(,O
ncbi-sent-256,Hp,NNP,O
ncbi-sent-256,),),O
ncbi-sent-256,and,CC,O
ncbi-sent-256,of,IN,O
ncbi-sent-256,the,DT,O
ncbi-sent-256,alpha,NN,O
ncbi-sent-256,chain,NN,O
ncbi-sent-256,and,CC,O
ncbi-sent-256,beta,NN,O
ncbi-sent-256,chain,NN,O
ncbi-sent-256,of,IN,O
ncbi-sent-256,the,DT,O
ncbi-sent-256,haptoglobin,NN,O
ncbi-sent-256,-,:,O
ncbi-sent-256,related,VBN,O
ncbi-sent-256,gene,NN,O
ncbi-sent-256,(,(,O
ncbi-sent-256,Hpr,NNP,O
ncbi-sent-256,),),O
ncbi-sent-256,",",",",O
ncbi-sent-256,in,IN,O
ncbi-sent-256,tandem,NN,O
ncbi-sent-256,from,IN,O
ncbi-sent-256,the,DT,O
ncbi-sent-256,5,CD,O
ncbi-sent-256,side,NN,O
ncbi-sent-256,.,.,O
ncbi-sent-257,Southern,JJ,O
ncbi-sent-257,blot,NN,O
ncbi-sent-257,and,CC,O
ncbi-sent-257,PCR,NNP,O
ncbi-sent-257,analyses,NNS,O
ncbi-sent-257,have,VBP,O
ncbi-sent-257,indicated,VBN,O
ncbi-sent-257,that,IN,O
ncbi-sent-257,the,DT,O
ncbi-sent-257,individual,NN,O
ncbi-sent-257,with,IN,O
ncbi-sent-257,anhaptoglobinemia,NN,B-DISEASE
ncbi-sent-257,was,VBD,O
ncbi-sent-257,homozygous,JJ,O
ncbi-sent-257,for,IN,O
ncbi-sent-257,the,DT,O
ncbi-sent-257,gene,NN,O
ncbi-sent-257,deletion,NN,O
ncbi-sent-257,and,CC,O
ncbi-sent-257,that,IN,O
ncbi-sent-257,the,DT,O
ncbi-sent-257,gene,NN,O
ncbi-sent-257,deletion,NN,O
ncbi-sent-257,was,VBD,O
ncbi-sent-257,included,VBN,O
ncbi-sent-257,at,IN,O
ncbi-sent-257,least,JJS,O
ncbi-sent-257,from,IN,O
ncbi-sent-257,the,DT,O
ncbi-sent-257,promoter,NN,O
ncbi-sent-257,region,NN,O
ncbi-sent-257,of,IN,O
ncbi-sent-257,Hp,NNP,O
ncbi-sent-257,to,TO,O
ncbi-sent-257,Hpr,NNP,O
ncbi-sent-257,alpha,NN,O
ncbi-sent-257,but,CC,O
ncbi-sent-257,not,RB,O
ncbi-sent-257,to,TO,O
ncbi-sent-257,Hpr,NNP,O
ncbi-sent-257,beta,NN,O
ncbi-sent-257,(,(,O
ncbi-sent-257,Hpdel,NNP,O
ncbi-sent-257,),),O
ncbi-sent-257,.,.,O
ncbi-sent-258,In,IN,O
ncbi-sent-258,addition,NN,O
ncbi-sent-258,",",",",O
ncbi-sent-258,we,PRP,O
ncbi-sent-258,found,VBD,O
ncbi-sent-258,seven,CD,O
ncbi-sent-258,individuals,NNS,O
ncbi-sent-258,with,IN,O
ncbi-sent-258,hypohaptoglobinemia,NN,B-DISEASE
ncbi-sent-258,in,IN,O
ncbi-sent-258,three,CD,O
ncbi-sent-258,families,NNS,O
ncbi-sent-258,",",",",O
ncbi-sent-258,and,CC,O
ncbi-sent-258,the,DT,O
ncbi-sent-258,genotypes,NNS,O
ncbi-sent-258,of,IN,O
ncbi-sent-258,six,CD,O
ncbi-sent-258,of,IN,O
ncbi-sent-258,the,DT,O
ncbi-sent-258,seven,CD,O
ncbi-sent-258,individuals,NNS,O
ncbi-sent-258,were,VBD,O
ncbi-sent-258,found,VBN,O
ncbi-sent-258,to,TO,O
ncbi-sent-258,be,VB,O
ncbi-sent-258,Hp2,NNP,O
ncbi-sent-258,/,NNP,O
ncbi-sent-258,Hpdel,NNP,O
ncbi-sent-258,.,.,O
ncbi-sent-259,The,DT,O
ncbi-sent-259,phenotypes,NNS,O
ncbi-sent-259,and,CC,O
ncbi-sent-259,genotypes,NNS,O
ncbi-sent-259,in,IN,O
ncbi-sent-259,one,CD,O
ncbi-sent-259,of,IN,O
ncbi-sent-259,these,DT,O
ncbi-sent-259,three,CD,O
ncbi-sent-259,families,NNS,O
ncbi-sent-259,showed,VBD,O
ncbi-sent-259,the,DT,O
ncbi-sent-259,father,NN,O
ncbi-sent-259,to,TO,O
ncbi-sent-259,be,VB,O
ncbi-sent-259,hypohaptoglobinemic,JJ,B-DISEASE
ncbi-sent-259,(,(,O
ncbi-sent-259,Hp2,NNP,O
ncbi-sent-259,),),O
ncbi-sent-259,and,CC,O
ncbi-sent-259,Hp2,NNP,O
ncbi-sent-259,/,NNP,O
ncbi-sent-259,Hpdel,NNP,O
ncbi-sent-259,",",",",O
ncbi-sent-259,the,DT,O
ncbi-sent-259,mother,NN,O
ncbi-sent-259,to,TO,O
ncbi-sent-259,be,VB,O
ncbi-sent-259,Hp2,NNP,O
ncbi-sent-259,-,:,O
ncbi-sent-259,1,CD,O
ncbi-sent-259,and,CC,O
ncbi-sent-259,Hp1,NNP,O
ncbi-sent-259,/,NNP,O
ncbi-sent-259,Hp2,NNP,O
ncbi-sent-259,",",",",O
ncbi-sent-259,one,CD,O
ncbi-sent-259,of,IN,O
ncbi-sent-259,the,DT,O
ncbi-sent-259,two,CD,O
ncbi-sent-259,children,NNS,O
ncbi-sent-259,to,TO,O
ncbi-sent-259,be,VB,O
ncbi-sent-259,hypohaptoglobinemic,JJ,B-DISEASE
ncbi-sent-259,(,(,O
ncbi-sent-259,Hp2,NNP,O
ncbi-sent-259,),),O
ncbi-sent-259,and,CC,O
ncbi-sent-259,Hp2,NNP,O
ncbi-sent-259,/,NNP,O
ncbi-sent-259,Hpdel,NNP,O
ncbi-sent-259,",",",",O
ncbi-sent-259,and,CC,O
ncbi-sent-259,the,DT,O
ncbi-sent-259,other,JJ,O
ncbi-sent-259,child,NN,O
ncbi-sent-259,to,TO,O
ncbi-sent-259,be,VB,O
ncbi-sent-259,Hp1,NNP,O
ncbi-sent-259,and,CC,O
ncbi-sent-259,Hp1,NNP,O
ncbi-sent-259,/,NNP,O
ncbi-sent-259,Hpdel,NNP,O
ncbi-sent-259,",",",",O
ncbi-sent-259,showing,VBG,O
ncbi-sent-259,an,DT,O
ncbi-sent-259,anomalous,JJ,O
ncbi-sent-259,inheritance,NN,O
ncbi-sent-259,of,IN,O
ncbi-sent-259,Hp,NNP,O
ncbi-sent-259,phenotypes,NNS,O
ncbi-sent-259,in,IN,O
ncbi-sent-259,the,DT,O
ncbi-sent-259,child,NN,O
ncbi-sent-259,with,IN,O
ncbi-sent-259,Hp1,NNP,O
ncbi-sent-259,.,.,O
ncbi-sent-260,The,DT,O
ncbi-sent-260,Hp2,NNP,O
ncbi-sent-260,/,NNP,O
ncbi-sent-260,Hpdel,NNP,O
ncbi-sent-260,individuals,NNS,O
ncbi-sent-260,had,VBD,O
ncbi-sent-260,an,DT,O
ncbi-sent-260,extremely,RB,O
ncbi-sent-260,low,JJ,O
ncbi-sent-260,level,NN,O
ncbi-sent-260,of,IN,O
ncbi-sent-260,Hp,NNP,O
ncbi-sent-260,(,(,O
ncbi-sent-260,mean,JJ,O
ncbi-sent-260,+,NNP,O
ncbi-sent-260,/,NNP,O
ncbi-sent-260,-,:,O
ncbi-sent-260,SD,NNP,O
ncbi-sent-260,=,VBZ,O
ncbi-sent-260,0,CD,O
ncbi-sent-260,.,.,O
ncbi-sent-261,049,CD,O
ncbi-sent-261,+,JJ,O
ncbi-sent-261,/,NNP,O
ncbi-sent-261,-,:,O
ncbi-sent-261,0,CD,O
ncbi-sent-261,.,.,O
ncbi-sent-262,043,CD,O
ncbi-sent-262,mg,JJ,O
ncbi-sent-262,/,NNP,O
ncbi-sent-262,ml,NN,O
ncbi-sent-262,;,:,O
ncbi-sent-262,n,CC,O
ncbi-sent-262,=,VB,O
ncbi-sent-262,6,CD,O
ncbi-sent-262,),),O
ncbi-sent-262,",",",",O
ncbi-sent-262,compared,VBN,O
ncbi-sent-262,with,IN,O
ncbi-sent-262,the,DT,O
ncbi-sent-262,level,NN,O
ncbi-sent-262,(,(,O
ncbi-sent-262,1,CD,O
ncbi-sent-262,.,.,O
ncbi-sent-263,64,CD,O
ncbi-sent-263,+,JJ,O
ncbi-sent-263,/,NNP,O
ncbi-sent-263,-,:,O
ncbi-sent-263,1,CD,O
ncbi-sent-263,.,.,O
ncbi-sent-264,07,CD,O
ncbi-sent-264,mg,JJ,O
ncbi-sent-264,/,NNP,O
ncbi-sent-264,ml,NN,O
ncbi-sent-264,),),O
ncbi-sent-264,obtained,VBD,O
ncbi-sent-264,from,IN,O
ncbi-sent-264,52,CD,O
ncbi-sent-264,healthy,JJ,O
ncbi-sent-264,volunteers,NNS,O
ncbi-sent-264,having,VBG,O
ncbi-sent-264,phenotype,NN,O
ncbi-sent-264,Hp2,NNP,O
ncbi-sent-264,",",",",O
ncbi-sent-264,whereas,IN,O
ncbi-sent-264,the,DT,O
ncbi-sent-264,serum,NN,O
ncbi-sent-264,Hp,NNP,O
ncbi-sent-264,level,NN,O
ncbi-sent-264,of,IN,O
ncbi-sent-264,an,DT,O
ncbi-sent-264,individual,NN,O
ncbi-sent-264,with,IN,O
ncbi-sent-264,Hp1,NNP,O
ncbi-sent-264,/,NNP,O
ncbi-sent-264,Hpdel,NNP,O
ncbi-sent-264,was,VBD,O
ncbi-sent-264,0,CD,O
ncbi-sent-264,.,.,O
ncbi-sent-265,50,CD,O
ncbi-sent-265,mg,JJ,O
ncbi-sent-265,/,NNP,O
ncbi-sent-265,ml,NN,O
ncbi-sent-265,",",",",O
ncbi-sent-265,which,WDT,O
ncbi-sent-265,was,VBD,O
ncbi-sent-265,approximately,RB,O
ncbi-sent-265,half,PDT,O
ncbi-sent-265,the,DT,O
ncbi-sent-265,level,NN,O
ncbi-sent-265,of,IN,O
ncbi-sent-265,Hp,NNP,O
ncbi-sent-265,in,IN,O
ncbi-sent-265,control,NN,O
ncbi-sent-265,sera,NN,O
ncbi-sent-265,from,IN,O
ncbi-sent-265,the,DT,O
ncbi-sent-265,Hp1,NNP,O
ncbi-sent-265,phenotype,NN,O
ncbi-sent-265,(,(,O
ncbi-sent-265,1,CD,O
ncbi-sent-265,.,.,O
ncbi-sent-266,26,CD,O
ncbi-sent-266,+,JJ,O
ncbi-sent-266,/,NNP,O
ncbi-sent-266,-,:,O
ncbi-sent-266,0,CD,O
ncbi-sent-266,.,.,O
ncbi-sent-267,33,CD,O
ncbi-sent-267,mg,JJ,O
ncbi-sent-267,/,NNP,O
ncbi-sent-267,ml,NN,O
ncbi-sent-267,;,:,O
ncbi-sent-267,n,CC,O
ncbi-sent-267,=,VB,O
ncbi-sent-267,9,CD,O
ncbi-sent-267,),),O
ncbi-sent-267,",",",",O
ncbi-sent-267,showing,VBG,O
ncbi-sent-267,a,DT,O
ncbi-sent-267,gene,NN,O
ncbi-sent-267,-,:,O
ncbi-sent-267,dosage,NN,O
ncbi-sent-267,effect,NN,O
ncbi-sent-267,.,.,O
ncbi-sent-268,The,DT,O
ncbi-sent-268,other,JJ,O
ncbi-sent-268,allele,NN,O
ncbi-sent-268,(,(,O
ncbi-sent-268,Hp2,NNP,O
ncbi-sent-268,),),O
ncbi-sent-268,of,IN,O
ncbi-sent-268,individuals,NNS,O
ncbi-sent-268,with,IN,O
ncbi-sent-268,Hp2,NNP,O
ncbi-sent-268,/,NNP,O
ncbi-sent-268,Hpdel,NNP,O
ncbi-sent-268,was,VBD,O
ncbi-sent-268,found,VBN,O
ncbi-sent-268,to,TO,O
ncbi-sent-268,have,VB,O
ncbi-sent-268,",",",",O
ncbi-sent-268,in,IN,O
ncbi-sent-268,all,DT,O
ncbi-sent-268,exons,NNS,O
ncbi-sent-268,",",",",O
ncbi-sent-268,no,DT,O
ncbi-sent-268,mutation,NN,O
ncbi-sent-268,",",",",O
ncbi-sent-268,by,IN,O
ncbi-sent-268,DNA,NNP,O
ncbi-sent-268,sequencing,VBG,O
ncbi-sent-268,.,.,O
ncbi-sent-269,On,IN,O
ncbi-sent-269,the,DT,O
ncbi-sent-269,basis,NN,O
ncbi-sent-269,of,IN,O
ncbi-sent-269,the,DT,O
ncbi-sent-269,present,JJ,O
ncbi-sent-269,study,NN,O
ncbi-sent-269,",",",",O
ncbi-sent-269,the,DT,O
ncbi-sent-269,mechanism,NN,O
ncbi-sent-269,of,IN,O
ncbi-sent-269,anhaptoglobinemia,NN,B-DISEASE
ncbi-sent-269,and,CC,O
ncbi-sent-269,the,DT,O
ncbi-sent-269,mechanism,NN,O
ncbi-sent-269,of,IN,O
ncbi-sent-269,anomalous,JJ,O
ncbi-sent-269,inheritance,NN,O
ncbi-sent-269,of,IN,O
ncbi-sent-269,Hp,NNP,O
ncbi-sent-269,phenotypes,NNS,O
ncbi-sent-269,were,VBD,O
ncbi-sent-269,well,RB,O
ncbi-sent-269,explained,VBN,O
ncbi-sent-269,.,.,O
ncbi-sent-270,However,RB,O
ncbi-sent-270,",",",",O
ncbi-sent-270,the,DT,O
ncbi-sent-270,mechanism,NN,O
ncbi-sent-270,of,IN,O
ncbi-sent-270,hypohaptoglobinemia,NN,B-DISEASE
ncbi-sent-270,remains,VBZ,O
ncbi-sent-270,unknown,JJ,O
ncbi-sent-270,ATM,NNP,O
ncbi-sent-270,mutations,NNS,O
ncbi-sent-270,and,CC,O
ncbi-sent-270,phenotypes,NNS,O
ncbi-sent-270,in,IN,O
ncbi-sent-270,ataxia,JJ,B-DISEASE
ncbi-sent-270,-,:,I-DISEASE
ncbi-sent-270,telangiectasia,NN,I-DISEASE
ncbi-sent-270,families,NNS,O
ncbi-sent-270,in,IN,O
ncbi-sent-270,the,DT,O
ncbi-sent-270,British,JJ,O
ncbi-sent-270,Isles,NNS,O
ncbi-sent-270,:,:,O
ncbi-sent-270,expression,NN,O
ncbi-sent-270,of,IN,O
ncbi-sent-270,mutant,JJ,O
ncbi-sent-270,ATM,NNP,O
ncbi-sent-270,and,CC,O
ncbi-sent-270,the,DT,O
ncbi-sent-270,risk,NN,O
ncbi-sent-270,of,IN,O
ncbi-sent-270,leukemia,NN,B-DISEASE
ncbi-sent-270,",",",",O
ncbi-sent-270,lymphoma,NN,B-DISEASE
ncbi-sent-270,",",",",O
ncbi-sent-270,and,CC,O
ncbi-sent-270,breast,NN,B-DISEASE
ncbi-sent-270,cancer,NN,I-DISEASE
ncbi-sent-270,.,.,O
ncbi-sent-271,We,PRP,O
ncbi-sent-271,report,VBP,O
ncbi-sent-271,the,DT,O
ncbi-sent-271,spectrum,NN,O
ncbi-sent-271,of,IN,O
ncbi-sent-271,59,CD,O
ncbi-sent-271,ATM,NNP,O
ncbi-sent-271,mutations,NNS,O
ncbi-sent-271,observed,VBD,O
ncbi-sent-271,in,IN,O
ncbi-sent-271,ataxia,JJ,B-DISEASE
ncbi-sent-271,-,:,I-DISEASE
ncbi-sent-271,telangiectasia,NN,I-DISEASE
ncbi-sent-271,(,(,O
ncbi-sent-271,A,DT,B-DISEASE
ncbi-sent-271,-,:,I-DISEASE
ncbi-sent-271,T,NN,I-DISEASE
ncbi-sent-271,),),O
ncbi-sent-271,patients,NNS,O
ncbi-sent-271,in,IN,O
ncbi-sent-271,the,DT,O
ncbi-sent-271,British,JJ,O
ncbi-sent-271,Isles,NNP,O
ncbi-sent-271,.,.,O
ncbi-sent-272,Of,IN,O
ncbi-sent-272,51,CD,O
ncbi-sent-272,ATM,NNP,O
ncbi-sent-272,mutations,NNS,O
ncbi-sent-272,identified,VBN,O
ncbi-sent-272,in,IN,O
ncbi-sent-272,families,NNS,O
ncbi-sent-272,native,VBP,O
ncbi-sent-272,to,TO,O
ncbi-sent-272,the,DT,O
ncbi-sent-272,British,JJ,O
ncbi-sent-272,Isles,NNP,O
ncbi-sent-272,",",",",O
ncbi-sent-272,11,CD,O
ncbi-sent-272,were,VBD,O
ncbi-sent-272,founder,NN,O
ncbi-sent-272,mutations,NNS,O
ncbi-sent-272,",",",",O
ncbi-sent-272,and,CC,O
ncbi-sent-272,2,CD,O
ncbi-sent-272,of,IN,O
ncbi-sent-272,these,DT,O
ncbi-sent-272,11,CD,O
ncbi-sent-272,conferred,VBD,O
ncbi-sent-272,a,DT,O
ncbi-sent-272,milder,NN,O
ncbi-sent-272,clinical,JJ,O
ncbi-sent-272,phenotype,NN,O
ncbi-sent-272,with,IN,O
ncbi-sent-272,respect,NN,O
ncbi-sent-272,to,TO,O
ncbi-sent-272,both,DT,O
ncbi-sent-272,cerebellar,JJ,B-DISEASE
ncbi-sent-272,degeneration,NN,I-DISEASE
ncbi-sent-272,and,CC,O
ncbi-sent-272,cellular,JJ,O
ncbi-sent-272,features,NNS,O
ncbi-sent-272,.,.,O
ncbi-sent-273,We,PRP,O
ncbi-sent-273,report,VBP,O
ncbi-sent-273,",",",",O
ncbi-sent-273,in,IN,O
ncbi-sent-273,two,CD,O
ncbi-sent-273,A,NNP,B-DISEASE
ncbi-sent-273,-,:,I-DISEASE
ncbi-sent-273,T,NN,I-DISEASE
ncbi-sent-273,families,NNS,O
ncbi-sent-273,",",",",O
ncbi-sent-273,an,DT,O
ncbi-sent-273,ATM,NNP,O
ncbi-sent-273,mutation,NN,O
ncbi-sent-273,(,(,O
ncbi-sent-273,7271T,CD,O
ncbi-sent-273,-,:,O
ncbi-sent-273,-,:,O
ncbi-sent-273,>,NN,O
ncbi-sent-273,G,NNP,O
ncbi-sent-273,),),O
ncbi-sent-273,that,WDT,O
ncbi-sent-273,may,MD,O
ncbi-sent-273,be,VB,O
ncbi-sent-273,associated,VBN,O
ncbi-sent-273,with,IN,O
ncbi-sent-273,an,DT,O
ncbi-sent-273,increased,VBN,O
ncbi-sent-273,risk,NN,O
ncbi-sent-273,of,IN,O
ncbi-sent-273,breast,NN,B-DISEASE
ncbi-sent-273,cancer,NN,I-DISEASE
ncbi-sent-273,in,IN,O
ncbi-sent-273,both,DT,O
ncbi-sent-273,homozygotes,NNS,O
ncbi-sent-273,and,CC,O
ncbi-sent-273,heterozygotes,NNS,O
ncbi-sent-273,(,(,O
ncbi-sent-273,relative,JJ,O
ncbi-sent-273,risk,NN,O
ncbi-sent-273,12,CD,O
ncbi-sent-273,.,.,O
ncbi-sent-274,7,CD,O
ncbi-sent-274,;,:,O
ncbi-sent-274,P,NNP,O
ncbi-sent-274,=,NNP,O
ncbi-sent-274,.,.,O
ncbi-sent-275,0025,CD,O
ncbi-sent-275,),),O
ncbi-sent-275,",",",",O
ncbi-sent-275,although,IN,O
ncbi-sent-275,there,EX,O
ncbi-sent-275,is,VBZ,O
ncbi-sent-275,a,DT,O
ncbi-sent-275,less,RBR,O
ncbi-sent-275,severe,JJ,O
ncbi-sent-275,A,NNP,B-DISEASE
ncbi-sent-275,-,:,I-DISEASE
ncbi-sent-275,T,NN,I-DISEASE
ncbi-sent-275,phenotype,NN,O
ncbi-sent-275,in,IN,O
ncbi-sent-275,terms,NNS,O
ncbi-sent-275,of,IN,O
ncbi-sent-275,the,DT,O
ncbi-sent-275,degree,NN,O
ncbi-sent-275,of,IN,O
ncbi-sent-275,cerebellar,JJ,B-DISEASE
ncbi-sent-275,degeneration,NN,I-DISEASE
ncbi-sent-275,.,.,O
ncbi-sent-276,This,DT,O
ncbi-sent-276,mutation,NN,O
ncbi-sent-276,(,(,O
ncbi-sent-276,7271T,CD,O
ncbi-sent-276,-,:,O
ncbi-sent-276,-,:,O
ncbi-sent-276,>,NN,O
ncbi-sent-276,G,NNP,O
ncbi-sent-276,),),O
ncbi-sent-276,also,RB,O
ncbi-sent-276,allows,VBZ,O
ncbi-sent-276,expression,NN,O
ncbi-sent-276,of,IN,O
ncbi-sent-276,full,JJ,O
ncbi-sent-276,-,:,O
ncbi-sent-276,length,NN,O
ncbi-sent-276,ATM,NNP,O
ncbi-sent-276,protein,NN,O
ncbi-sent-276,at,IN,O
ncbi-sent-276,a,DT,O
ncbi-sent-276,level,NN,O
ncbi-sent-276,comparable,JJ,O
ncbi-sent-276,with,IN,O
ncbi-sent-276,that,DT,O
ncbi-sent-276,in,IN,O
ncbi-sent-276,unaffected,JJ,O
ncbi-sent-276,individuals,NNS,O
ncbi-sent-276,.,.,O
ncbi-sent-277,In,IN,O
ncbi-sent-277,addition,NN,O
ncbi-sent-277,",",",",O
ncbi-sent-277,we,PRP,O
ncbi-sent-277,have,VBP,O
ncbi-sent-277,studied,VBN,O
ncbi-sent-277,18,CD,O
ncbi-sent-277,A,NNP,B-DISEASE
ncbi-sent-277,-,:,I-DISEASE
ncbi-sent-277,T,NN,I-DISEASE
ncbi-sent-277,patients,NNS,O
ncbi-sent-277,",",",",O
ncbi-sent-277,in,IN,O
ncbi-sent-277,15,CD,O
ncbi-sent-277,families,NNS,O
ncbi-sent-277,",",",",O
ncbi-sent-277,who,WP,O
ncbi-sent-277,developed,VBD,O
ncbi-sent-277,leukemia,NN,B-DISEASE
ncbi-sent-277,",",",",O
ncbi-sent-277,lymphoma,NN,B-DISEASE
ncbi-sent-277,",",",",O
ncbi-sent-277,preleukemic,JJ,O
ncbi-sent-277,T,NNP,O
ncbi-sent-277,-,:,O
ncbi-sent-277,cell,NN,O
ncbi-sent-277,proliferation,NN,O
ncbi-sent-277,",",",",O
ncbi-sent-277,or,CC,O
ncbi-sent-277,Hodgkin,NNP,B-DISEASE
ncbi-sent-277,lymphoma,NN,I-DISEASE
ncbi-sent-277,",",",",O
ncbi-sent-277,mostly,RB,O
ncbi-sent-277,in,IN,O
ncbi-sent-277,childhood,NN,O
ncbi-sent-277,.,.,O
ncbi-sent-278,A,DT,O
ncbi-sent-278,wide,JJ,O
ncbi-sent-278,variety,NN,O
ncbi-sent-278,of,IN,O
ncbi-sent-278,ATM,NNP,O
ncbi-sent-278,mutation,NN,O
ncbi-sent-278,types,NNS,O
ncbi-sent-278,",",",",O
ncbi-sent-278,including,VBG,O
ncbi-sent-278,missense,JJ,O
ncbi-sent-278,mutations,NNS,O
ncbi-sent-278,and,CC,O
ncbi-sent-278,in,IN,O
ncbi-sent-278,-,:,O
ncbi-sent-278,frame,NN,O
ncbi-sent-278,deletions,NNS,O
ncbi-sent-278,",",",",O
ncbi-sent-278,were,VBD,O
ncbi-sent-278,seen,VBN,O
ncbi-sent-278,in,IN,O
ncbi-sent-278,these,DT,O
ncbi-sent-278,patients,NNS,O
ncbi-sent-278,.,.,O
ncbi-sent-279,We,PRP,O
ncbi-sent-279,also,RB,O
ncbi-sent-279,show,VBP,O
ncbi-sent-279,that,IN,O
ncbi-sent-279,25,CD,O
ncbi-sent-279,%,NN,O
ncbi-sent-279,of,IN,O
ncbi-sent-279,all,PDT,O
ncbi-sent-279,A,DT,B-DISEASE
ncbi-sent-279,-,:,I-DISEASE
ncbi-sent-279,T,NN,I-DISEASE
ncbi-sent-279,patients,NNS,O
ncbi-sent-279,carried,VBD,O
ncbi-sent-279,in,IN,O
ncbi-sent-279,-,:,O
ncbi-sent-279,frame,NN,O
ncbi-sent-279,deletions,NNS,O
ncbi-sent-279,or,CC,O
ncbi-sent-279,missense,NN,O
ncbi-sent-279,mutations,NNS,O
ncbi-sent-279,",",",",O
ncbi-sent-279,many,JJ,O
ncbi-sent-279,of,IN,O
ncbi-sent-279,which,WDT,O
ncbi-sent-279,were,VBD,O
ncbi-sent-279,also,RB,O
ncbi-sent-279,associated,VBN,O
ncbi-sent-279,with,IN,O
ncbi-sent-279,expression,NN,O
ncbi-sent-279,of,IN,O
ncbi-sent-279,mutant,JJ,O
ncbi-sent-279,ATM,NNP,O
ncbi-sent-279,protein,NN,O
ncbi-sent-279,.,.,O
ncbi-sent-280,The,DT,O
ncbi-sent-280,DMPK,NNP,O
ncbi-sent-280,gene,NN,O
ncbi-sent-280,of,IN,O
ncbi-sent-280,severely,RB,O
ncbi-sent-280,affected,JJ,O
ncbi-sent-280,myotonic,JJ,B-DISEASE
ncbi-sent-280,dystrophy,NN,I-DISEASE
ncbi-sent-280,patients,NNS,O
ncbi-sent-280,is,VBZ,O
ncbi-sent-280,hypermethylated,VBN,O
ncbi-sent-280,proximal,JJ,O
ncbi-sent-280,to,TO,O
ncbi-sent-280,the,DT,O
ncbi-sent-280,largely,RB,O
ncbi-sent-280,expanded,JJ,O
ncbi-sent-280,CTG,NNP,O
ncbi-sent-280,repeat,NN,O
ncbi-sent-280,.,.,O
ncbi-sent-281,Using,VBG,O
ncbi-sent-281,methylation,NN,O
ncbi-sent-281,-,:,O
ncbi-sent-281,sensitive,JJ,O
ncbi-sent-281,restriction,NN,O
ncbi-sent-281,enzymes,NNS,O
ncbi-sent-281,",",",",O
ncbi-sent-281,we,PRP,O
ncbi-sent-281,characterized,VBD,O
ncbi-sent-281,the,DT,O
ncbi-sent-281,methylation,NN,O
ncbi-sent-281,pattern,NN,O
ncbi-sent-281,on,IN,O
ncbi-sent-281,the,DT,O
ncbi-sent-281,5,CD,O
ncbi-sent-281,side,NN,O
ncbi-sent-281,of,IN,O
ncbi-sent-281,the,DT,O
ncbi-sent-281,CTG,NNP,O
ncbi-sent-281,repeat,NN,O
ncbi-sent-281,in,IN,O
ncbi-sent-281,the,DT,O
ncbi-sent-281,DMPK,NNP,O
ncbi-sent-281,gene,NN,O
ncbi-sent-281,of,IN,O
ncbi-sent-281,normal,JJ,O
ncbi-sent-281,individuals,NNS,O
ncbi-sent-281,and,CC,O
ncbi-sent-281,of,IN,O
ncbi-sent-281,patients,NNS,O
ncbi-sent-281,affected,VBN,O
ncbi-sent-281,with,IN,O
ncbi-sent-281,myotonic,JJ,B-DISEASE
ncbi-sent-281,dystrophy,NN,I-DISEASE
ncbi-sent-281,",",",",O
ncbi-sent-281,showing,VBG,O
ncbi-sent-281,expansions,NNS,O
ncbi-sent-281,of,IN,O
ncbi-sent-281,the,DT,O
ncbi-sent-281,repetitive,JJ,O
ncbi-sent-281,sequence,NN,O
ncbi-sent-281,.,.,O
ncbi-sent-282,The,DT,O
ncbi-sent-282,gene,NN,O
ncbi-sent-282,segment,NN,O
ncbi-sent-282,analyzed,VBD,O
ncbi-sent-282,corresponds,NNS,O
ncbi-sent-282,to,TO,O
ncbi-sent-282,the,DT,O
ncbi-sent-282,genomic,JJ,O
ncbi-sent-282,SacI,NNP,O
ncbi-sent-282,-,:,O
ncbi-sent-282,HindIII,NNP,O
ncbi-sent-282,fragment,NN,O
ncbi-sent-282,carrying,VBG,O
ncbi-sent-282,exons,NNS,O
ncbi-sent-282,11,CD,O
ncbi-sent-282,-,:,O
ncbi-sent-282,15,CD,O
ncbi-sent-282,.,.,O
ncbi-sent-283,There,EX,O
ncbi-sent-283,is,VBZ,O
ncbi-sent-283,constitutive,JJ,O
ncbi-sent-283,methylation,NN,O
ncbi-sent-283,in,IN,O
ncbi-sent-283,intron,NN,O
ncbi-sent-283,12,CD,O
ncbi-sent-283,at,IN,O
ncbi-sent-283,restriction,NN,O
ncbi-sent-283,sites,NNS,O
ncbi-sent-283,of,IN,O
ncbi-sent-283,SacII,NNP,O
ncbi-sent-283,and,CC,O
ncbi-sent-283,HhaI,NNP,O
ncbi-sent-283,",",",",O
ncbi-sent-283,localized,VBD,O
ncbi-sent-283,1,CD,O
ncbi-sent-283,",",",",O
ncbi-sent-283,159,CD,O
ncbi-sent-283,-,:,O
ncbi-sent-283,1,CD,O
ncbi-sent-283,",",",",O
ncbi-sent-283,232,CD,O
ncbi-sent-283,bp,NN,O
ncbi-sent-283,upstream,NN,O
ncbi-sent-283,of,IN,O
ncbi-sent-283,the,DT,O
ncbi-sent-283,CTG,NNP,O
ncbi-sent-283,repeat,NN,O
ncbi-sent-283,",",",",O
ncbi-sent-283,whereas,IN,O
ncbi-sent-283,most,JJS,O
ncbi-sent-283,",",",",O
ncbi-sent-283,if,IN,O
ncbi-sent-283,not,RB,O
ncbi-sent-283,all,DT,O
ncbi-sent-283,",",",",O
ncbi-sent-283,of,IN,O
ncbi-sent-283,the,DT,O
ncbi-sent-283,other,JJ,O
ncbi-sent-283,sites,NNS,O
ncbi-sent-283,of,IN,O
ncbi-sent-283,SacII,NNP,O
ncbi-sent-283,",",",",O
ncbi-sent-283,HhaI,NNP,O
ncbi-sent-283,",",",",O
ncbi-sent-283,and,CC,O
ncbi-sent-283,HpaII,NNP,O
ncbi-sent-283,in,IN,O
ncbi-sent-283,this,DT,O
ncbi-sent-283,region,NN,O
ncbi-sent-283,are,VBP,O
ncbi-sent-283,unmethylated,VBN,O
ncbi-sent-283,",",",",O
ncbi-sent-283,in,IN,O
ncbi-sent-283,normal,JJ,O
ncbi-sent-283,individuals,NNS,O
ncbi-sent-283,and,CC,O
ncbi-sent-283,most,JJS,O
ncbi-sent-283,of,IN,O
ncbi-sent-283,the,DT,O
ncbi-sent-283,patients,NNS,O
ncbi-sent-283,.,.,O
ncbi-sent-284,In,IN,O
ncbi-sent-284,a,DT,O
ncbi-sent-284,number,NN,O
ncbi-sent-284,of,IN,O
ncbi-sent-284,young,JJ,O
ncbi-sent-284,and,CC,O
ncbi-sent-284,severely,RB,O
ncbi-sent-284,affected,JJ,O
ncbi-sent-284,patients,NNS,O
ncbi-sent-284,",",",",O
ncbi-sent-284,however,RB,O
ncbi-sent-284,",",",",O
ncbi-sent-284,complete,JJ,O
ncbi-sent-284,methylation,NN,O
ncbi-sent-284,of,IN,O
ncbi-sent-284,these,DT,O
ncbi-sent-284,restriction,NN,O
ncbi-sent-284,sites,NNS,O
ncbi-sent-284,was,VBD,O
ncbi-sent-284,found,VBN,O
ncbi-sent-284,in,IN,O
ncbi-sent-284,the,DT,O
ncbi-sent-284,mutated,JJ,O
ncbi-sent-284,allele,NN,O
ncbi-sent-284,.,.,O
ncbi-sent-285,In,IN,O
ncbi-sent-285,most,JJS,O
ncbi-sent-285,of,IN,O
ncbi-sent-285,these,DT,O
ncbi-sent-285,patients,NNS,O
ncbi-sent-285,",",",",O
ncbi-sent-285,the,DT,O
ncbi-sent-285,onset,NN,O
ncbi-sent-285,of,IN,O
ncbi-sent-285,the,DT,O
ncbi-sent-285,disease,NN,O
ncbi-sent-285,was,VBD,O
ncbi-sent-285,congenital,JJ,O
ncbi-sent-285,.,.,O
ncbi-sent-286,Preliminary,NNP,O
ncbi-sent-286,in,IN,O
ncbi-sent-286,vivo,NN,O
ncbi-sent-286,footprinting,VBG,O
ncbi-sent-286,data,NNS,O
ncbi-sent-286,gave,VBD,O
ncbi-sent-286,evidence,NN,O
ncbi-sent-286,for,IN,O
ncbi-sent-286,protein,NN,O
ncbi-sent-286,-,:,O
ncbi-sent-286,DNA,NN,O
ncbi-sent-286,contact,NN,O
ncbi-sent-286,in,IN,O
ncbi-sent-286,normal,JJ,O
ncbi-sent-286,genes,NNS,O
ncbi-sent-286,at,IN,O
ncbi-sent-286,an,DT,O
ncbi-sent-286,Sp1,NNP,O
ncbi-sent-286,consensus,NN,O
ncbi-sent-286,binding,VBG,O
ncbi-sent-286,site,NN,O
ncbi-sent-286,upstream,NN,O
ncbi-sent-286,of,IN,O
ncbi-sent-286,the,DT,O
ncbi-sent-286,CTG,NNP,O
ncbi-sent-286,repeat,NN,O
ncbi-sent-286,and,CC,O
ncbi-sent-286,for,IN,O
ncbi-sent-286,a,DT,O
ncbi-sent-286,significant,JJ,O
ncbi-sent-286,reduction,NN,O
ncbi-sent-286,of,IN,O
ncbi-sent-286,this,DT,O
ncbi-sent-286,interaction,NN,O
ncbi-sent-286,in,IN,O
ncbi-sent-286,cells,NNS,O
ncbi-sent-286,with,IN,O
ncbi-sent-286,a,DT,O
ncbi-sent-286,hypermethylated,VBN,O
ncbi-sent-286,DMPK,NNP,O
ncbi-sent-286,gene,NN,O
ncbi-sent-286,.,.,O
ncbi-sent-287,.,.,O
ncbi-sent-288,The,DT,O
ncbi-sent-288,hemochromatosis,NN,B-DISEASE
ncbi-sent-288,gene,NN,O
ncbi-sent-288,product,NN,O
ncbi-sent-288,complexes,NNS,O
ncbi-sent-288,with,IN,O
ncbi-sent-288,the,DT,O
ncbi-sent-288,transferrin,NN,O
ncbi-sent-288,receptor,NN,O
ncbi-sent-288,and,CC,O
ncbi-sent-288,lowers,VBZ,O
ncbi-sent-288,its,PRP$,O
ncbi-sent-288,affinity,NN,O
ncbi-sent-288,for,IN,O
ncbi-sent-288,ligand,NN,O
ncbi-sent-288,binding,NN,O
ncbi-sent-288,.,.,O
ncbi-sent-289,We,PRP,O
ncbi-sent-289,recently,RB,O
ncbi-sent-289,reported,VBD,O
ncbi-sent-289,the,DT,O
ncbi-sent-289,positional,JJ,O
ncbi-sent-289,cloning,NN,O
ncbi-sent-289,of,IN,O
ncbi-sent-289,a,DT,O
ncbi-sent-289,candidate,NN,O
ncbi-sent-289,gene,NN,O
ncbi-sent-289,for,IN,O
ncbi-sent-289,hereditary,JJ,B-DISEASE
ncbi-sent-289,hemochromatosis,NN,I-DISEASE
ncbi-sent-289,called,VBN,O
ncbi-sent-289,HFE,NNP,O
ncbi-sent-289,.,.,O
ncbi-sent-290,The,DT,O
ncbi-sent-290,gene,NN,O
ncbi-sent-290,product,NN,O
ncbi-sent-290,",",",",O
ncbi-sent-290,a,DT,O
ncbi-sent-290,member,NN,O
ncbi-sent-290,of,IN,O
ncbi-sent-290,the,DT,O
ncbi-sent-290,major,JJ,O
ncbi-sent-290,histocompatibility,NN,O
ncbi-sent-290,complex,JJ,O
ncbi-sent-290,class,NN,O
ncbi-sent-290,I,PRP,O
ncbi-sent-290,-,:,O
ncbi-sent-290,like,IN,O
ncbi-sent-290,family,NN,O
ncbi-sent-290,",",",",O
ncbi-sent-290,was,VBD,O
ncbi-sent-290,found,VBN,O
ncbi-sent-290,to,TO,O
ncbi-sent-290,have,VB,O
ncbi-sent-290,a,DT,O
ncbi-sent-290,mutation,NN,O
ncbi-sent-290,",",",",O
ncbi-sent-290,Cys,NNP,O
ncbi-sent-290,-,:,O
ncbi-sent-290,282,CD,O
ncbi-sent-290,-,:,O
ncbi-sent-290,-,:,O
ncbi-sent-290,>,NN,O
ncbi-sent-290,Tyr,NNP,O
ncbi-sent-290,(,(,O
ncbi-sent-290,C282Y,NNP,O
ncbi-sent-290,),),O
ncbi-sent-290,",",",",O
ncbi-sent-290,in,IN,O
ncbi-sent-290,85,CD,O
ncbi-sent-290,%,NN,O
ncbi-sent-290,of,IN,O
ncbi-sent-290,patient,JJ,O
ncbi-sent-290,chromosomes,NNS,O
ncbi-sent-290,.,.,O
ncbi-sent-291,This,DT,O
ncbi-sent-291,mutation,NN,O
ncbi-sent-291,eliminates,VBZ,O
ncbi-sent-291,the,DT,O
ncbi-sent-291,ability,NN,O
ncbi-sent-291,of,IN,O
ncbi-sent-291,HFE,NNP,O
ncbi-sent-291,to,TO,O
ncbi-sent-291,associate,VB,O
ncbi-sent-291,with,IN,O
ncbi-sent-291,beta2,JJ,O
ncbi-sent-291,-,:,O
ncbi-sent-291,microglobulin,NN,O
ncbi-sent-291,(,(,O
ncbi-sent-291,beta2m,NN,O
ncbi-sent-291,),),O
ncbi-sent-291,and,CC,O
ncbi-sent-291,prevents,NNS,O
ncbi-sent-291,cell,VBP,O
ncbi-sent-291,-,:,O
ncbi-sent-291,surface,NN,O
ncbi-sent-291,expression,NN,O
ncbi-sent-291,.,.,O
ncbi-sent-292,A,DT,O
ncbi-sent-292,second,JJ,O
ncbi-sent-292,mutation,NN,O
ncbi-sent-292,that,WDT,O
ncbi-sent-292,has,VBZ,O
ncbi-sent-292,no,DT,O
ncbi-sent-292,effect,NN,O
ncbi-sent-292,on,IN,O
ncbi-sent-292,beta2m,NN,O
ncbi-sent-292,association,NN,O
ncbi-sent-292,",",",",O
ncbi-sent-292,H63D,NNP,O
ncbi-sent-292,",",",",O
ncbi-sent-292,was,VBD,O
ncbi-sent-292,found,VBN,O
ncbi-sent-292,in,IN,O
ncbi-sent-292,eight,CD,O
ncbi-sent-292,out,IN,O
ncbi-sent-292,of,IN,O
ncbi-sent-292,nine,CD,O
ncbi-sent-292,patients,NNS,O
ncbi-sent-292,heterozygous,JJ,O
ncbi-sent-292,for,IN,O
ncbi-sent-292,the,DT,O
ncbi-sent-292,C282Y,NNP,O
ncbi-sent-292,mutant,NN,O
ncbi-sent-292,.,.,O
ncbi-sent-293,In,IN,O
ncbi-sent-293,this,DT,O
ncbi-sent-293,report,NN,O
ncbi-sent-293,",",",",O
ncbi-sent-293,we,PRP,O
ncbi-sent-293,demonstrate,VBP,O
ncbi-sent-293,in,IN,O
ncbi-sent-293,cultured,JJ,O
ncbi-sent-293,293,CD,O
ncbi-sent-293,cells,NNS,O
ncbi-sent-293,overexpressing,VBG,O
ncbi-sent-293,wild,JJ,O
ncbi-sent-293,-,:,O
ncbi-sent-293,type,NN,O
ncbi-sent-293,or,CC,O
ncbi-sent-293,mutant,JJ,O
ncbi-sent-293,HFE,NNP,O
ncbi-sent-293,proteins,VBZ,O
ncbi-sent-293,that,IN,O
ncbi-sent-293,both,DT,O
ncbi-sent-293,the,DT,O
ncbi-sent-293,wild,JJ,O
ncbi-sent-293,-,:,O
ncbi-sent-293,type,NN,O
ncbi-sent-293,and,CC,O
ncbi-sent-293,H63D,NNP,O
ncbi-sent-293,HFE,NNP,O
ncbi-sent-293,proteins,VBZ,O
ncbi-sent-293,form,VB,O
ncbi-sent-293,stable,JJ,O
ncbi-sent-293,complexes,NNS,O
ncbi-sent-293,with,IN,O
ncbi-sent-293,the,DT,O
ncbi-sent-293,transferrin,NN,O
ncbi-sent-293,receptor,NN,O
ncbi-sent-293,(,(,O
ncbi-sent-293,TfR,NNP,O
ncbi-sent-293,),),O
ncbi-sent-293,.,.,O
ncbi-sent-294,The,DT,O
ncbi-sent-294,C282Y,NNP,O
ncbi-sent-294,mutation,NN,O
ncbi-sent-294,nearly,RB,O
ncbi-sent-294,completely,RB,O
ncbi-sent-294,prevents,VBZ,O
ncbi-sent-294,the,DT,O
ncbi-sent-294,association,NN,O
ncbi-sent-294,of,IN,O
ncbi-sent-294,the,DT,O
ncbi-sent-294,mutant,JJ,O
ncbi-sent-294,HFE,NNP,O
ncbi-sent-294,protein,NN,O
ncbi-sent-294,with,IN,O
ncbi-sent-294,the,DT,O
ncbi-sent-294,TfR,NNP,O
ncbi-sent-294,.,.,O
ncbi-sent-295,Studies,NNS,O
ncbi-sent-295,on,IN,O
ncbi-sent-295,cell,NN,O
ncbi-sent-295,-,:,O
ncbi-sent-295,associated,VBN,O
ncbi-sent-295,transferrin,NN,O
ncbi-sent-295,at,IN,O
ncbi-sent-295,37,CD,O
ncbi-sent-295,degrees,NNS,O
ncbi-sent-295,C,NNP,O
ncbi-sent-295,suggest,VBP,O
ncbi-sent-295,that,IN,O
ncbi-sent-295,the,DT,O
ncbi-sent-295,overexpressed,JJ,O
ncbi-sent-295,wild,JJ,O
ncbi-sent-295,-,:,O
ncbi-sent-295,type,NN,O
ncbi-sent-295,HFE,NNP,O
ncbi-sent-295,protein,NN,O
ncbi-sent-295,decreases,VBZ,O
ncbi-sent-295,the,DT,O
ncbi-sent-295,affinity,NN,O
ncbi-sent-295,of,IN,O
ncbi-sent-295,the,DT,O
ncbi-sent-295,TfR,NNP,O
ncbi-sent-295,for,IN,O
ncbi-sent-295,transferrin,NN,O
ncbi-sent-295,.,.,O
ncbi-sent-296,The,DT,O
ncbi-sent-296,overexpressed,JJ,O
ncbi-sent-296,H63D,NNP,O
ncbi-sent-296,protein,NN,O
ncbi-sent-296,does,VBZ,O
ncbi-sent-296,not,RB,O
ncbi-sent-296,have,VB,O
ncbi-sent-296,this,DT,O
ncbi-sent-296,effect,NN,O
ncbi-sent-296,",",",",O
ncbi-sent-296,providing,VBG,O
ncbi-sent-296,the,DT,O
ncbi-sent-296,first,JJ,O
ncbi-sent-296,direct,JJ,O
ncbi-sent-296,evidence,NN,O
ncbi-sent-296,for,IN,O
ncbi-sent-296,a,DT,O
ncbi-sent-296,functional,JJ,O
ncbi-sent-296,consequence,NN,O
ncbi-sent-296,of,IN,O
ncbi-sent-296,the,DT,O
ncbi-sent-296,H63D,NNP,O
ncbi-sent-296,mutation,NN,O
ncbi-sent-296,.,.,O
ncbi-sent-297,Addition,NN,O
ncbi-sent-297,of,IN,O
ncbi-sent-297,soluble,JJ,O
ncbi-sent-297,wild,JJ,O
ncbi-sent-297,-,:,O
ncbi-sent-297,type,NN,O
ncbi-sent-297,HFE,NNP,O
ncbi-sent-297,/,NNP,O
ncbi-sent-297,beta2m,NN,O
ncbi-sent-297,heterodimers,NNS,O
ncbi-sent-297,to,TO,O
ncbi-sent-297,cultured,VB,O
ncbi-sent-297,cells,NNS,O
ncbi-sent-297,also,RB,O
ncbi-sent-297,decreased,VBD,O
ncbi-sent-297,the,DT,O
ncbi-sent-297,apparent,JJ,O
ncbi-sent-297,affinity,NN,O
ncbi-sent-297,of,IN,O
ncbi-sent-297,the,DT,O
ncbi-sent-297,TfR,NNP,O
ncbi-sent-297,for,IN,O
ncbi-sent-297,its,PRP$,O
ncbi-sent-297,ligand,NN,O
ncbi-sent-297,under,IN,O
ncbi-sent-297,steady,JJ,O
ncbi-sent-297,-,:,O
ncbi-sent-297,state,NN,O
ncbi-sent-297,conditions,NNS,O
ncbi-sent-297,",",",",O
ncbi-sent-297,both,DT,O
ncbi-sent-297,in,IN,O
ncbi-sent-297,293,CD,O
ncbi-sent-297,cells,NNS,O
ncbi-sent-297,and,CC,O
ncbi-sent-297,in,IN,O
ncbi-sent-297,HeLa,NNP,O
ncbi-sent-297,cells,NNS,O
ncbi-sent-297,.,.,O
ncbi-sent-298,Furthermore,RB,O
ncbi-sent-298,",",",",O
ncbi-sent-298,at,IN,O
ncbi-sent-298,4,CD,O
ncbi-sent-298,degrees,NNS,O
ncbi-sent-298,C,NNP,O
ncbi-sent-298,",",",",O
ncbi-sent-298,the,DT,O
ncbi-sent-298,added,JJ,O
ncbi-sent-298,soluble,JJ,O
ncbi-sent-298,complex,NN,O
ncbi-sent-298,of,IN,O
ncbi-sent-298,HFE,NNP,O
ncbi-sent-298,/,NNP,O
ncbi-sent-298,beta2m,NN,O
ncbi-sent-298,inhibited,VBD,O
ncbi-sent-298,binding,NN,O
ncbi-sent-298,of,IN,O
ncbi-sent-298,transferrin,NN,O
ncbi-sent-298,to,TO,O
ncbi-sent-298,HeLa,NNP,O
ncbi-sent-298,cell,NN,O
ncbi-sent-298,TfR,NNP,O
ncbi-sent-298,in,IN,O
ncbi-sent-298,a,DT,O
ncbi-sent-298,concentration,NN,O
ncbi-sent-298,-,:,O
ncbi-sent-298,dependent,JJ,O
ncbi-sent-298,manner,NN,O
ncbi-sent-298,.,.,O
ncbi-sent-299,Scatchard,NNP,O
ncbi-sent-299,plots,NNS,O
ncbi-sent-299,of,IN,O
ncbi-sent-299,these,DT,O
ncbi-sent-299,data,NNS,O
ncbi-sent-299,indicate,VBP,O
ncbi-sent-299,that,IN,O
ncbi-sent-299,the,DT,O
ncbi-sent-299,added,JJ,O
ncbi-sent-299,heterodimer,NN,O
ncbi-sent-299,substantially,RB,O
ncbi-sent-299,reduced,VBD,O
ncbi-sent-299,the,DT,O
ncbi-sent-299,affinity,NN,O
ncbi-sent-299,of,IN,O
ncbi-sent-299,TfR,NNP,O
ncbi-sent-299,for,IN,O
ncbi-sent-299,transferrin,NN,O
ncbi-sent-299,.,.,O
ncbi-sent-300,These,DT,O
ncbi-sent-300,results,NNS,O
ncbi-sent-300,establish,VB,O
ncbi-sent-300,a,DT,O
ncbi-sent-300,molecular,JJ,O
ncbi-sent-300,link,NN,O
ncbi-sent-300,between,IN,O
ncbi-sent-300,HFE,NNP,O
ncbi-sent-300,and,CC,O
ncbi-sent-300,a,DT,O
ncbi-sent-300,key,JJ,O
ncbi-sent-300,protein,NN,O
ncbi-sent-300,involved,VBN,O
ncbi-sent-300,in,IN,O
ncbi-sent-300,iron,NN,O
ncbi-sent-300,transport,NN,O
ncbi-sent-300,",",",",O
ncbi-sent-300,the,DT,O
ncbi-sent-300,TfR,NNP,O
ncbi-sent-300,",",",",O
ncbi-sent-300,and,CC,O
ncbi-sent-300,raise,VB,O
ncbi-sent-300,the,DT,O
ncbi-sent-300,possibility,NN,O
ncbi-sent-300,that,IN,O
ncbi-sent-300,alterations,NNS,O
ncbi-sent-300,in,IN,O
ncbi-sent-300,this,DT,O
ncbi-sent-300,regulatory,JJ,O
ncbi-sent-300,mechanism,NN,O
ncbi-sent-300,may,MD,O
ncbi-sent-300,play,VB,O
ncbi-sent-300,a,DT,O
ncbi-sent-300,role,NN,O
ncbi-sent-300,in,IN,O
ncbi-sent-300,the,DT,O
ncbi-sent-300,pathogenesis,NN,O
ncbi-sent-300,of,IN,O
ncbi-sent-300,hereditary,JJ,B-DISEASE
ncbi-sent-300,hemochromatosis,NN,I-DISEASE
ncbi-sent-300,.,.,O
ncbi-sent-301,.,.,O
ncbi-sent-302,Genomic,JJ,O
ncbi-sent-302,organization,NN,O
ncbi-sent-302,of,IN,O
ncbi-sent-302,the,DT,O
ncbi-sent-302,UBE3A,NNP,O
ncbi-sent-302,/,NNP,O
ncbi-sent-302,E6,NNP,O
ncbi-sent-302,-,:,O
ncbi-sent-302,AP,NNP,O
ncbi-sent-302,gene,NN,O
ncbi-sent-302,and,CC,O
ncbi-sent-302,related,JJ,O
ncbi-sent-302,pseudogenes,NNS,O
ncbi-sent-302,.,.,O
ncbi-sent-303,The,DT,O
ncbi-sent-303,UBE3A,NNP,O
ncbi-sent-303,gene,NN,O
ncbi-sent-303,encodes,VBZ,O
ncbi-sent-303,the,DT,O
ncbi-sent-303,E6,NNP,O
ncbi-sent-303,-,:,O
ncbi-sent-303,AP,NNP,O
ncbi-sent-303,ubiquitin,JJ,O
ncbi-sent-303,-,:,O
ncbi-sent-303,protein,NN,O
ncbi-sent-303,ligase,NN,O
ncbi-sent-303,and,CC,O
ncbi-sent-303,has,VBZ,O
ncbi-sent-303,recently,RB,O
ncbi-sent-303,been,VBN,O
ncbi-sent-303,shown,VBN,O
ncbi-sent-303,to,TO,O
ncbi-sent-303,be,VB,O
ncbi-sent-303,mutated,VBN,O
ncbi-sent-303,in,IN,O
ncbi-sent-303,Angelman,NNP,B-DISEASE
ncbi-sent-303,syndrome,JJ,I-DISEASE
ncbi-sent-303,patients,NNS,O
ncbi-sent-303,who,WP,O
ncbi-sent-303,lack,VBP,O
ncbi-sent-303,15q11,CD,O
ncbi-sent-303,-,:,O
ncbi-sent-303,q13,NN,O
ncbi-sent-303,deletions,NNS,O
ncbi-sent-303,or,CC,O
ncbi-sent-303,chromosome,VB,O
ncbi-sent-303,15,CD,O
ncbi-sent-303,paternal,JJ,O
ncbi-sent-303,uniparental,JJ,B-DISEASE
ncbi-sent-303,disomy,NN,I-DISEASE
ncbi-sent-303,.,.,O
ncbi-sent-304,Previous,JJ,O
ncbi-sent-304,UBE3A,NNP,O
ncbi-sent-304,cDNA,NN,O
ncbi-sent-304,analysis,NN,O
ncbi-sent-304,has,VBZ,O
ncbi-sent-304,shown,VBN,O
ncbi-sent-304,a,DT,O
ncbi-sent-304,coding,VBG,O
ncbi-sent-304,region,NN,O
ncbi-sent-304,of,IN,O
ncbi-sent-304,approximately,RB,O
ncbi-sent-304,2,CD,O
ncbi-sent-304,.,.,O
ncbi-sent-305,6,CD,O
ncbi-sent-305,kb,NN,O
ncbi-sent-305,and,CC,O
ncbi-sent-305,a,DT,O
ncbi-sent-305,3,CD,O
ncbi-sent-305,-,:,O
ncbi-sent-305,untranslated,JJ,O
ncbi-sent-305,region,NN,O
ncbi-sent-305,(,(,O
ncbi-sent-305,UTR,NNP,O
ncbi-sent-305,),),O
ncbi-sent-305,of,IN,O
ncbi-sent-305,<,$,O
ncbi-sent-305,50,CD,O
ncbi-sent-305,bp,NN,O
ncbi-sent-305,",",",",O
ncbi-sent-305,whereas,JJ,O
ncbi-sent-305,Northern,NNP,O
ncbi-sent-305,analysis,NN,O
ncbi-sent-305,has,VBZ,O
ncbi-sent-305,indicated,VBN,O
ncbi-sent-305,mRNA,JJ,O
ncbi-sent-305,sizes,NNS,O
ncbi-sent-305,of,IN,O
ncbi-sent-305,5,CD,O
ncbi-sent-305,-,:,O
ncbi-sent-305,8,CD,O
ncbi-sent-305,kb,NN,O
ncbi-sent-305,.,.,O
ncbi-sent-306,We,PRP,O
ncbi-sent-306,have,VBP,O
ncbi-sent-306,analyzed,VBN,O
ncbi-sent-306,additional,JJ,O
ncbi-sent-306,cDNA,NN,O
ncbi-sent-306,clones,NNS,O
ncbi-sent-306,and,CC,O
ncbi-sent-306,provide,VB,O
ncbi-sent-306,evidence,NN,O
ncbi-sent-306,for,IN,O
ncbi-sent-306,an,DT,O
ncbi-sent-306,additional,JJ,O
ncbi-sent-306,0,CD,O
ncbi-sent-306,.,.,O
ncbi-sent-307,5,CD,O
ncbi-sent-307,kb,NN,O
ncbi-sent-307,of,IN,O
ncbi-sent-307,5,CD,O
ncbi-sent-307,-,:,O
ncbi-sent-307,UTR,NN,O
ncbi-sent-307,and,CC,O
ncbi-sent-307,>,$,O
ncbi-sent-307,2,CD,O
ncbi-sent-307,kb,NN,O
ncbi-sent-307,of,IN,O
ncbi-sent-307,3,CD,O
ncbi-sent-307,-,:,O
ncbi-sent-307,UTR,NN,O
ncbi-sent-307,.,.,O
ncbi-sent-308,We,PRP,O
ncbi-sent-308,have,VBP,O
ncbi-sent-308,established,VBN,O
ncbi-sent-308,the,DT,O
ncbi-sent-308,genomic,JJ,O
ncbi-sent-308,organization,NN,O
ncbi-sent-308,of,IN,O
ncbi-sent-308,UBE3A,NNP,O
ncbi-sent-308,and,CC,O
ncbi-sent-308,the,DT,O
ncbi-sent-308,sequence,NN,O
ncbi-sent-308,of,IN,O
ncbi-sent-308,intron,NN,O
ncbi-sent-308,-,:,O
ncbi-sent-308,exon,NN,O
ncbi-sent-308,borders,NNS,O
ncbi-sent-308,.,.,O
ncbi-sent-309,We,PRP,O
ncbi-sent-309,have,VBP,O
ncbi-sent-309,also,RB,O
ncbi-sent-309,mapped,VBN,O
ncbi-sent-309,two,CD,O
ncbi-sent-309,highly,RB,O
ncbi-sent-309,homologous,JJ,O
ncbi-sent-309,processed,VBN,O
ncbi-sent-309,pseudogenes,NNS,O
ncbi-sent-309,",",",",O
ncbi-sent-309,UBE3AP1,NNP,O
ncbi-sent-309,and,CC,O
ncbi-sent-309,UBE3AP2,NNP,O
ncbi-sent-309,",",",",O
ncbi-sent-309,to,TO,O
ncbi-sent-309,chromosomes,VB,O
ncbi-sent-309,2,CD,O
ncbi-sent-309,and,CC,O
ncbi-sent-309,21,CD,O
ncbi-sent-309,",",",",O
ncbi-sent-309,respectively,RB,O
ncbi-sent-309,",",",",O
ncbi-sent-309,and,CC,O
ncbi-sent-309,determined,VBD,O
ncbi-sent-309,their,PRP$,O
ncbi-sent-309,genomic,JJ,O
ncbi-sent-309,organization,NN,O
ncbi-sent-309,.,.,O
ncbi-sent-310,These,DT,O
ncbi-sent-310,results,NNS,O
ncbi-sent-310,will,MD,O
ncbi-sent-310,form,VB,O
ncbi-sent-310,the,DT,O
ncbi-sent-310,basis,NN,O
ncbi-sent-310,for,IN,O
ncbi-sent-310,studies,NNS,O
ncbi-sent-310,of,IN,O
ncbi-sent-310,mutation,NN,O
ncbi-sent-310,and,CC,O
ncbi-sent-310,imprinting,NN,O
ncbi-sent-310,of,IN,O
ncbi-sent-310,UBE3A,NNP,O
ncbi-sent-310,.,.,O
ncbi-sent-311,Mutation,NNP,O
ncbi-sent-311,spectrum,NN,O
ncbi-sent-311,and,CC,O
ncbi-sent-311,genotype,NN,O
ncbi-sent-311,-,:,O
ncbi-sent-311,phenotype,NN,O
ncbi-sent-311,analyses,NNS,O
ncbi-sent-311,in,IN,O
ncbi-sent-311,Cowden,NNP,B-DISEASE
ncbi-sent-311,disease,NN,I-DISEASE
ncbi-sent-311,and,CC,O
ncbi-sent-311,Bannayan,NNP,B-DISEASE
ncbi-sent-311,-,:,I-DISEASE
ncbi-sent-311,Zonana,NNP,I-DISEASE
ncbi-sent-311,syndrome,NN,I-DISEASE
ncbi-sent-311,",",",",O
ncbi-sent-311,two,CD,O
ncbi-sent-311,hamartoma,NN,B-DISEASE
ncbi-sent-311,syndromes,NNS,I-DISEASE
ncbi-sent-311,with,IN,O
ncbi-sent-311,germline,NN,O
ncbi-sent-311,PTEN,NNP,O
ncbi-sent-311,mutation,NN,O
ncbi-sent-311,.,.,O
ncbi-sent-312,The,DT,O
ncbi-sent-312,tumour,NN,B-DISEASE
ncbi-sent-312,suppressor,NN,O
ncbi-sent-312,gene,NN,O
ncbi-sent-312,PTEN,NNP,O
ncbi-sent-312,",",",",O
ncbi-sent-312,which,WDT,O
ncbi-sent-312,maps,VBZ,O
ncbi-sent-312,to,TO,O
ncbi-sent-312,10q23,CD,O
ncbi-sent-312,.,.,O
ncbi-sent-313,3,CD,O
ncbi-sent-313,and,CC,O
ncbi-sent-313,encodes,VBZ,O
ncbi-sent-313,a,DT,O
ncbi-sent-313,403,CD,O
ncbi-sent-313,amino,NN,O
ncbi-sent-313,acid,JJ,O
ncbi-sent-313,dual,JJ,O
ncbi-sent-313,specificity,NN,O
ncbi-sent-313,phosphatase,NN,O
ncbi-sent-313,(,(,O
ncbi-sent-313,protein,JJ,O
ncbi-sent-313,tyrosine,NN,O
ncbi-sent-313,phosphatase,NN,O
ncbi-sent-313,;,:,O
ncbi-sent-313,PTPase,NNP,O
ncbi-sent-313,),),O
ncbi-sent-313,",",",",O
ncbi-sent-313,was,VBD,O
ncbi-sent-313,shown,VBN,O
ncbi-sent-313,recently,RB,O
ncbi-sent-313,to,TO,O
ncbi-sent-313,play,VB,O
ncbi-sent-313,a,DT,O
ncbi-sent-313,broad,JJ,O
ncbi-sent-313,role,NN,O
ncbi-sent-313,in,IN,O
ncbi-sent-313,human,JJ,O
ncbi-sent-313,malignancy,NN,B-DISEASE
ncbi-sent-313,.,.,O
ncbi-sent-314,Somatic,JJ,O
ncbi-sent-314,PTEN,NNP,O
ncbi-sent-314,deletions,NNS,O
ncbi-sent-314,and,CC,O
ncbi-sent-314,mutations,NNS,O
ncbi-sent-314,were,VBD,O
ncbi-sent-314,observed,VBN,O
ncbi-sent-314,in,IN,O
ncbi-sent-314,sporadic,JJ,B-DISEASE
ncbi-sent-314,breast,NN,I-DISEASE
ncbi-sent-314,",",",",I-DISEASE
ncbi-sent-314,brain,NN,I-DISEASE
ncbi-sent-314,",",",",I-DISEASE
ncbi-sent-314,prostate,NN,I-DISEASE
ncbi-sent-314,and,CC,I-DISEASE
ncbi-sent-314,kidney,NN,I-DISEASE
ncbi-sent-314,cancer,NN,I-DISEASE
ncbi-sent-314,cell,NN,O
ncbi-sent-314,lines,NNS,O
ncbi-sent-314,and,CC,O
ncbi-sent-314,in,IN,O
ncbi-sent-314,several,JJ,O
ncbi-sent-314,primary,JJ,O
ncbi-sent-314,tumours,NNS,B-DISEASE
ncbi-sent-314,such,JJ,O
ncbi-sent-314,as,IN,O
ncbi-sent-314,endometrial,JJ,B-DISEASE
ncbi-sent-314,carcinomas,NN,I-DISEASE
ncbi-sent-314,",",",",O
ncbi-sent-314,malignant,JJ,B-DISEASE
ncbi-sent-314,melanoma,NN,I-DISEASE
ncbi-sent-314,and,CC,O
ncbi-sent-314,thyroid,JJ,B-DISEASE
ncbi-sent-314,tumours,NN,I-DISEASE
ncbi-sent-314,.,.,O
ncbi-sent-315,In,IN,O
ncbi-sent-315,addition,NN,O
ncbi-sent-315,",",",",O
ncbi-sent-315,PTEN,NNP,O
ncbi-sent-315,was,VBD,O
ncbi-sent-315,identified,VBN,O
ncbi-sent-315,as,IN,O
ncbi-sent-315,the,DT,O
ncbi-sent-315,susceptibility,NN,O
ncbi-sent-315,gene,NN,O
ncbi-sent-315,for,IN,O
ncbi-sent-315,two,CD,O
ncbi-sent-315,hamartoma,NN,B-DISEASE
ncbi-sent-315,syndromes,NNS,I-DISEASE
ncbi-sent-315,Cowden,NNP,B-DISEASE
ncbi-sent-315,disease,NN,I-DISEASE
ncbi-sent-315,(,(,O
ncbi-sent-315,CD,NN,B-DISEASE
ncbi-sent-315,;,:,O
ncbi-sent-315,MIM,NNP,O
ncbi-sent-315,158350,CD,O
ncbi-sent-315,),),O
ncbi-sent-315,and,CC,O
ncbi-sent-315,Bannayan,NNP,B-DISEASE
ncbi-sent-315,-,:,I-DISEASE
ncbi-sent-315,Zonana,NNP,I-DISEASE
ncbi-sent-315,(,(,I-DISEASE
ncbi-sent-315,BZS,NNP,I-DISEASE
ncbi-sent-315,),),I-DISEASE
ncbi-sent-315,or,CC,I-DISEASE
ncbi-sent-315,Ruvalcaba,NNP,I-DISEASE
ncbi-sent-315,-,:,I-DISEASE
ncbi-sent-315,Riley,NNP,I-DISEASE
ncbi-sent-315,-,:,I-DISEASE
ncbi-sent-315,Smith,NNP,I-DISEASE
ncbi-sent-315,syndrome,NN,I-DISEASE
ncbi-sent-315,(,(,O
ncbi-sent-315,MIM,NNP,O
ncbi-sent-315,153480,CD,O
ncbi-sent-315,),),O
ncbi-sent-315,.,.,O
ncbi-sent-316,Constitutive,JJ,O
ncbi-sent-316,DNA,NN,O
ncbi-sent-316,from,IN,O
ncbi-sent-316,37,CD,O
ncbi-sent-316,CD,NN,B-DISEASE
ncbi-sent-316,families,NNS,O
ncbi-sent-316,and,CC,O
ncbi-sent-316,seven,CD,O
ncbi-sent-316,BZS,NNP,B-DISEASE
ncbi-sent-316,families,NNS,O
ncbi-sent-316,was,VBD,O
ncbi-sent-316,screened,VBN,O
ncbi-sent-316,for,IN,O
ncbi-sent-316,germline,NN,O
ncbi-sent-316,PTEN,NNP,O
ncbi-sent-316,mutations,NNS,O
ncbi-sent-316,.,.,O
ncbi-sent-317,PTEN,NNP,O
ncbi-sent-317,mutations,NNS,O
ncbi-sent-317,were,VBD,O
ncbi-sent-317,identified,VBN,O
ncbi-sent-317,in,IN,O
ncbi-sent-317,30,CD,O
ncbi-sent-317,of,IN,O
ncbi-sent-317,37,CD,O
ncbi-sent-317,(,(,O
ncbi-sent-317,81,CD,O
ncbi-sent-317,%,NN,O
ncbi-sent-317,),),O
ncbi-sent-317,CD,NN,B-DISEASE
ncbi-sent-317,families,NNS,O
ncbi-sent-317,",",",",O
ncbi-sent-317,including,VBG,O
ncbi-sent-317,missense,NN,O
ncbi-sent-317,and,CC,O
ncbi-sent-317,nonsense,JJ,O
ncbi-sent-317,point,NN,O
ncbi-sent-317,mutations,NNS,O
ncbi-sent-317,",",",",O
ncbi-sent-317,deletions,NNS,O
ncbi-sent-317,",",",",O
ncbi-sent-317,insertions,NNS,O
ncbi-sent-317,",",",",O
ncbi-sent-317,a,DT,O
ncbi-sent-317,deletion,NN,O
ncbi-sent-317,/,POS,O
ncbi-sent-317,insertion,NN,O
ncbi-sent-317,and,CC,O
ncbi-sent-317,splice,NN,O
ncbi-sent-317,site,NN,O
ncbi-sent-317,mutations,NNS,O
ncbi-sent-317,.,.,O
ncbi-sent-318,These,DT,O
ncbi-sent-318,mutations,NNS,O
ncbi-sent-318,were,VBD,O
ncbi-sent-318,scattered,VBN,O
ncbi-sent-318,over,IN,O
ncbi-sent-318,the,DT,O
ncbi-sent-318,entire,JJ,O
ncbi-sent-318,length,NN,O
ncbi-sent-318,of,IN,O
ncbi-sent-318,PTEN,NNP,O
ncbi-sent-318,",",",",O
ncbi-sent-318,with,IN,O
ncbi-sent-318,the,DT,O
ncbi-sent-318,exception,NN,O
ncbi-sent-318,of,IN,O
ncbi-sent-318,the,DT,O
ncbi-sent-318,first,JJ,O
ncbi-sent-318,",",",",O
ncbi-sent-318,fourth,JJ,O
ncbi-sent-318,and,CC,O
ncbi-sent-318,last,JJ,O
ncbi-sent-318,exons,NNS,O
ncbi-sent-318,.,.,O
ncbi-sent-319,A,DT,O
ncbi-sent-319,hot,JJ,O
ncbi-sent-319,spot,NN,O
ncbi-sent-319,for,IN,O
ncbi-sent-319,PTEN,NNP,O
ncbi-sent-319,mutation,NN,O
ncbi-sent-319,in,IN,O
ncbi-sent-319,CD,NN,B-DISEASE
ncbi-sent-319,was,VBD,O
ncbi-sent-319,identified,VBN,O
ncbi-sent-319,in,IN,O
ncbi-sent-319,exon,CC,O
ncbi-sent-319,5,CD,O
ncbi-sent-319,that,WDT,O
ncbi-sent-319,contains,VBZ,O
ncbi-sent-319,the,DT,O
ncbi-sent-319,PTPase,NNP,O
ncbi-sent-319,core,NN,O
ncbi-sent-319,motif,NN,O
ncbi-sent-319,",",",",O
ncbi-sent-319,with,IN,O
ncbi-sent-319,13,CD,O
ncbi-sent-319,of,IN,O
ncbi-sent-319,30,CD,O
ncbi-sent-319,(,(,O
ncbi-sent-319,43,CD,O
ncbi-sent-319,%,NN,O
ncbi-sent-319,),),O
ncbi-sent-319,CD,NN,B-DISEASE
ncbi-sent-319,mutations,NNS,O
ncbi-sent-319,identified,VBN,O
ncbi-sent-319,in,IN,O
ncbi-sent-319,this,DT,O
ncbi-sent-319,exon,NN,O
ncbi-sent-319,.,.,O
ncbi-sent-320,Seven,NNP,O
ncbi-sent-320,of,IN,O
ncbi-sent-320,30,CD,O
ncbi-sent-320,(,(,O
ncbi-sent-320,23,CD,O
ncbi-sent-320,%,NN,O
ncbi-sent-320,),),O
ncbi-sent-320,were,VBD,O
ncbi-sent-320,within,IN,O
ncbi-sent-320,the,DT,O
ncbi-sent-320,core,NN,O
ncbi-sent-320,motif,NN,O
ncbi-sent-320,",",",",O
ncbi-sent-320,the,DT,O
ncbi-sent-320,majority,NN,O
ncbi-sent-320,(,(,O
ncbi-sent-320,five,CD,O
ncbi-sent-320,of,IN,O
ncbi-sent-320,seven,CD,O
ncbi-sent-320,),),O
ncbi-sent-320,of,IN,O
ncbi-sent-320,which,WDT,O
ncbi-sent-320,were,VBD,O
ncbi-sent-320,missense,JJ,O
ncbi-sent-320,mutations,NNS,O
ncbi-sent-320,",",",",O
ncbi-sent-320,possibly,RB,O
ncbi-sent-320,pointing,VBG,O
ncbi-sent-320,to,TO,O
ncbi-sent-320,the,DT,O
ncbi-sent-320,functional,JJ,O
ncbi-sent-320,significance,NN,O
ncbi-sent-320,of,IN,O
ncbi-sent-320,this,DT,O
ncbi-sent-320,region,NN,O
ncbi-sent-320,.,.,O
ncbi-sent-321,Germline,NNP,O
ncbi-sent-321,PTEN,NNP,O
ncbi-sent-321,mutations,NNS,O
ncbi-sent-321,were,VBD,O
ncbi-sent-321,identified,VBN,O
ncbi-sent-321,in,IN,O
ncbi-sent-321,four,CD,O
ncbi-sent-321,of,IN,O
ncbi-sent-321,seven,CD,O
ncbi-sent-321,(,(,O
ncbi-sent-321,57,CD,O
ncbi-sent-321,%,NN,O
ncbi-sent-321,),),O
ncbi-sent-321,BZS,NNP,B-DISEASE
ncbi-sent-321,families,NNS,O
ncbi-sent-321,studied,VBN,O
ncbi-sent-321,.,.,O
ncbi-sent-322,Interestingly,NNP,O
ncbi-sent-322,",",",",O
ncbi-sent-322,none,NN,O
ncbi-sent-322,of,IN,O
ncbi-sent-322,these,DT,O
ncbi-sent-322,mutations,NNS,O
ncbi-sent-322,was,VBD,O
ncbi-sent-322,observed,VBN,O
ncbi-sent-322,in,IN,O
ncbi-sent-322,the,DT,O
ncbi-sent-322,PTPase,NNP,O
ncbi-sent-322,core,NN,O
ncbi-sent-322,motif,NN,O
ncbi-sent-322,.,.,O
ncbi-sent-323,It,PRP,O
ncbi-sent-323,is,VBZ,O
ncbi-sent-323,also,RB,O
ncbi-sent-323,worthy,JJ,O
ncbi-sent-323,of,IN,O
ncbi-sent-323,note,NN,O
ncbi-sent-323,that,IN,O
ncbi-sent-323,a,DT,O
ncbi-sent-323,single,JJ,O
ncbi-sent-323,nonsense,NN,O
ncbi-sent-323,point,NN,O
ncbi-sent-323,mutation,NN,O
ncbi-sent-323,",",",",O
ncbi-sent-323,R233X,NNP,O
ncbi-sent-323,",",",",O
ncbi-sent-323,was,VBD,O
ncbi-sent-323,observed,VBN,O
ncbi-sent-323,in,IN,O
ncbi-sent-323,the,DT,O
ncbi-sent-323,germline,NN,O
ncbi-sent-323,DNA,NN,O
ncbi-sent-323,from,IN,O
ncbi-sent-323,two,CD,O
ncbi-sent-323,unrelated,JJ,O
ncbi-sent-323,CD,NN,B-DISEASE
ncbi-sent-323,families,NNS,O
ncbi-sent-323,and,CC,O
ncbi-sent-323,one,CD,O
ncbi-sent-323,BZS,NNP,B-DISEASE
ncbi-sent-323,family,NN,O
ncbi-sent-323,.,.,O
ncbi-sent-324,Genotype,NNP,O
ncbi-sent-324,-,:,O
ncbi-sent-324,phenotype,NN,O
ncbi-sent-324,studies,NNS,O
ncbi-sent-324,were,VBD,O
ncbi-sent-324,not,RB,O
ncbi-sent-324,performed,VBN,O
ncbi-sent-324,on,IN,O
ncbi-sent-324,this,DT,O
ncbi-sent-324,small,JJ,O
ncbi-sent-324,group,NN,O
ncbi-sent-324,of,IN,O
ncbi-sent-324,BZS,NNP,B-DISEASE
ncbi-sent-324,families,NNS,O
ncbi-sent-324,.,.,O
ncbi-sent-325,However,RB,O
ncbi-sent-325,",",",",O
ncbi-sent-325,genotype,JJ,O
ncbi-sent-325,-,:,O
ncbi-sent-325,phenotype,NN,O
ncbi-sent-325,analysis,NN,O
ncbi-sent-325,inthe,NN,O
ncbi-sent-325,group,NN,O
ncbi-sent-325,of,IN,O
ncbi-sent-325,CD,NNP,B-DISEASE
ncbi-sent-325,families,NNS,O
ncbi-sent-325,revealed,VBD,O
ncbi-sent-325,two,CD,O
ncbi-sent-325,possible,JJ,O
ncbi-sent-325,associations,NNS,O
ncbi-sent-325,worthy,NN,O
ncbi-sent-325,of,IN,O
ncbi-sent-325,follow,JJ,O
ncbi-sent-325,-,:,O
ncbi-sent-325,up,RB,O
ncbi-sent-325,in,IN,O
ncbi-sent-325,independent,JJ,O
ncbi-sent-325,analyses,NNS,O
ncbi-sent-325,.,.,O
ncbi-sent-326,The,DT,O
ncbi-sent-326,first,JJ,O
ncbi-sent-326,was,VBD,O
ncbi-sent-326,an,DT,O
ncbi-sent-326,association,NN,O
ncbi-sent-326,noted,VBD,O
ncbi-sent-326,in,IN,O
ncbi-sent-326,the,DT,O
ncbi-sent-326,group,NN,O
ncbi-sent-326,of,IN,O
ncbi-sent-326,CD,NNP,B-DISEASE
ncbi-sent-326,families,NNS,O
ncbi-sent-326,with,IN,O
ncbi-sent-326,breast,NN,B-DISEASE
ncbi-sent-326,disease,NN,I-DISEASE
ncbi-sent-326,.,.,O
ncbi-sent-327,A,DT,O
ncbi-sent-327,correlation,NN,O
ncbi-sent-327,was,VBD,O
ncbi-sent-327,observed,VBN,O
ncbi-sent-327,between,IN,O
ncbi-sent-327,the,DT,O
ncbi-sent-327,presence,NN,O
ncbi-sent-327,/,NNP,O
ncbi-sent-327,absence,NN,O
ncbi-sent-327,of,IN,O
ncbi-sent-327,a,DT,O
ncbi-sent-327,PTEN,NNP,O
ncbi-sent-327,mutation,NN,O
ncbi-sent-327,and,CC,O
ncbi-sent-327,the,DT,O
ncbi-sent-327,type,NN,O
ncbi-sent-327,of,IN,O
ncbi-sent-327,breast,NN,O
ncbi-sent-327,involvement,NN,O
ncbi-sent-327,(,(,O
ncbi-sent-327,unaffected,JJ,O
ncbi-sent-327,versus,NN,O
ncbi-sent-327,benign,NN,O
ncbi-sent-327,versus,NN,O
ncbi-sent-327,malignant,NN,O
ncbi-sent-327,),),O
ncbi-sent-327,.,.,O
ncbi-sent-328,Specifically,RB,O
ncbi-sent-328,and,CC,O
ncbi-sent-328,more,RBR,O
ncbi-sent-328,directly,RB,O
ncbi-sent-328,",",",",O
ncbi-sent-328,an,DT,O
ncbi-sent-328,association,NN,O
ncbi-sent-328,was,VBD,O
ncbi-sent-328,also,RB,O
ncbi-sent-328,observed,VBN,O
ncbi-sent-328,between,IN,O
ncbi-sent-328,the,DT,O
ncbi-sent-328,presence,NN,O
ncbi-sent-328,of,IN,O
ncbi-sent-328,a,DT,O
ncbi-sent-328,PTEN,NNP,O
ncbi-sent-328,mutation,NN,O
ncbi-sent-328,and,CC,O
ncbi-sent-328,malignant,JJ,B-DISEASE
ncbi-sent-328,breast,NN,I-DISEASE
ncbi-sent-328,disease,NN,I-DISEASE
ncbi-sent-328,.,.,O
ncbi-sent-329,Secondly,RB,O
ncbi-sent-329,",",",",O
ncbi-sent-329,there,EX,O
ncbi-sent-329,appeared,VBD,O
ncbi-sent-329,to,TO,O
ncbi-sent-329,be,VB,O
ncbi-sent-329,an,DT,O
ncbi-sent-329,interdependent,JJ,O
ncbi-sent-329,association,NN,O
ncbi-sent-329,between,IN,O
ncbi-sent-329,mutations,NNS,O
ncbi-sent-329,upstream,RB,O
ncbi-sent-329,and,CC,O
ncbi-sent-329,within,IN,O
ncbi-sent-329,the,DT,O
ncbi-sent-329,PTPase,NNP,O
ncbi-sent-329,core,NN,O
ncbi-sent-329,motif,NN,O
ncbi-sent-329,",",",",O
ncbi-sent-329,the,DT,O
ncbi-sent-329,core,NN,O
ncbi-sent-329,motif,NN,O
ncbi-sent-329,containing,VBG,O
ncbi-sent-329,the,DT,O
ncbi-sent-329,majority,NN,O
ncbi-sent-329,of,IN,O
ncbi-sent-329,missense,JJ,O
ncbi-sent-329,mutations,NNS,O
ncbi-sent-329,",",",",O
ncbi-sent-329,and,CC,O
ncbi-sent-329,the,DT,O
ncbi-sent-329,involvement,NN,O
ncbi-sent-329,of,IN,O
ncbi-sent-329,all,DT,O
ncbi-sent-329,major,JJ,O
ncbi-sent-329,organ,JJ,O
ncbi-sent-329,systems,NNS,O
ncbi-sent-329,(,(,O
ncbi-sent-329,central,JJ,O
ncbi-sent-329,nervous,JJ,O
ncbi-sent-329,system,NN,O
ncbi-sent-329,",",",",O
ncbi-sent-329,thyroid,NN,O
ncbi-sent-329,",",",",O
ncbi-sent-329,breast,NN,O
ncbi-sent-329,",",",",O
ncbi-sent-329,skin,NN,O
ncbi-sent-329,and,CC,O
ncbi-sent-329,gastrointestinal,JJ,O
ncbi-sent-329,tract,NN,O
ncbi-sent-329,),),O
ncbi-sent-329,.,.,O
ncbi-sent-330,However,RB,O
ncbi-sent-330,",",",",O
ncbi-sent-330,these,DT,O
ncbi-sent-330,observations,NNS,O
ncbi-sent-330,would,MD,O
ncbi-sent-330,need,VB,O
ncbi-sent-330,to,TO,O
ncbi-sent-330,be,VB,O
ncbi-sent-330,confirmed,VBN,O
ncbi-sent-330,by,IN,O
ncbi-sent-330,studying,VBG,O
ncbi-sent-330,a,DT,O
ncbi-sent-330,larger,JJR,O
ncbi-sent-330,number,NN,O
ncbi-sent-330,of,IN,O
ncbi-sent-330,CD,NNP,B-DISEASE
ncbi-sent-330,families,NNS,O
ncbi-sent-330,.,.,O
ncbi-sent-331,Molecular,JJ,O
ncbi-sent-331,defects,NNS,O
ncbi-sent-331,leading,VBG,O
ncbi-sent-331,to,TO,O
ncbi-sent-331,human,JJ,O
ncbi-sent-331,complement,NN,B-DISEASE
ncbi-sent-331,component,NN,I-DISEASE
ncbi-sent-331,C6,NNP,I-DISEASE
ncbi-sent-331,deficiency,NN,I-DISEASE
ncbi-sent-331,in,IN,O
ncbi-sent-331,an,DT,O
ncbi-sent-331,African,JJ,O
ncbi-sent-331,-,:,O
ncbi-sent-331,American,JJ,O
ncbi-sent-331,family,NN,O
ncbi-sent-331,.,.,O
ncbi-sent-332,Complement,NNP,B-DISEASE
ncbi-sent-332,component,NN,I-DISEASE
ncbi-sent-332,C6,NNP,I-DISEASE
ncbi-sent-332,deficiency,NN,I-DISEASE
ncbi-sent-332,(,(,O
ncbi-sent-332,C6D,NNP,B-DISEASE
ncbi-sent-332,),),O
ncbi-sent-332,was,VBD,O
ncbi-sent-332,diagnosed,VBN,O
ncbi-sent-332,in,IN,O
ncbi-sent-332,a,DT,O
ncbi-sent-332,16,CD,O
ncbi-sent-332,-,:,O
ncbi-sent-332,year,NN,O
ncbi-sent-332,-,:,O
ncbi-sent-332,old,JJ,O
ncbi-sent-332,African,JJ,O
ncbi-sent-332,-,:,O
ncbi-sent-332,American,JJ,O
ncbi-sent-332,male,NN,O
ncbi-sent-332,with,IN,O
ncbi-sent-332,meningococcal,JJ,B-DISEASE
ncbi-sent-332,meningitis,NN,I-DISEASE
ncbi-sent-332,.,.,O
ncbi-sent-333,The,DT,O
ncbi-sent-333,patients,NNS,O
ncbi-sent-333,father,RB,O
ncbi-sent-333,and,CC,O
ncbi-sent-333,two,CD,O
ncbi-sent-333,brothers,NNS,O
ncbi-sent-333,also,RB,O
ncbi-sent-333,had,VBD,O
ncbi-sent-333,C6D,NNP,B-DISEASE
ncbi-sent-333,",",",",O
ncbi-sent-333,but,CC,O
ncbi-sent-333,gave,VBD,O
ncbi-sent-333,no,DT,O
ncbi-sent-333,history,NN,O
ncbi-sent-333,of,IN,O
ncbi-sent-333,meningitis,NN,B-DISEASE
ncbi-sent-333,or,CC,O
ncbi-sent-333,other,JJ,O
ncbi-sent-333,neisserial,JJ,B-DISEASE
ncbi-sent-333,infection,NN,I-DISEASE
ncbi-sent-333,.,.,O
ncbi-sent-334,By,IN,O
ncbi-sent-334,using,VBG,O
ncbi-sent-334,exon,JJ,O
ncbi-sent-334,-,:,O
ncbi-sent-334,specific,JJ,O
ncbi-sent-334,polymerase,NN,O
ncbi-sent-334,chain,NN,O
ncbi-sent-334,reaction,NN,O
ncbi-sent-334,(,(,O
ncbi-sent-334,PCR,NNP,O
ncbi-sent-334,),),O
ncbi-sent-334,/,VBP,O
ncbi-sent-334,single,JJ,O
ncbi-sent-334,-,:,O
ncbi-sent-334,strand,NN,O
ncbi-sent-334,conformation,NN,O
ncbi-sent-334,polymorphism,NN,O
ncbi-sent-334,as,IN,O
ncbi-sent-334,a,DT,O
ncbi-sent-334,screening,JJ,O
ncbi-sent-334,step,NN,O
ncbi-sent-334,and,CC,O
ncbi-sent-334,nucleotide,JJ,O
ncbi-sent-334,sequencing,NN,O
ncbi-sent-334,of,IN,O
ncbi-sent-334,target,NN,O
ncbi-sent-334,exons,NNS,O
ncbi-sent-334,",",",",O
ncbi-sent-334,we,PRP,O
ncbi-sent-334,determined,VBD,O
ncbi-sent-334,that,IN,O
ncbi-sent-334,the,DT,O
ncbi-sent-334,proband,NN,O
ncbi-sent-334,was,VBD,O
ncbi-sent-334,a,DT,O
ncbi-sent-334,compound,NN,O
ncbi-sent-334,heterozygote,NN,O
ncbi-sent-334,for,IN,O
ncbi-sent-334,two,CD,O
ncbi-sent-334,C6,NNP,O
ncbi-sent-334,gene,NN,O
ncbi-sent-334,mutations,NNS,O
ncbi-sent-334,.,.,O
ncbi-sent-335,The,DT,O
ncbi-sent-335,first,JJ,O
ncbi-sent-335,",",",",O
ncbi-sent-335,1195delC,CD,O
ncbi-sent-335,located,VBN,O
ncbi-sent-335,in,IN,O
ncbi-sent-335,exon,JJ,O
ncbi-sent-335,7,CD,O
ncbi-sent-335,",",",",O
ncbi-sent-335,is,VBZ,O
ncbi-sent-335,a,DT,O
ncbi-sent-335,novel,JJ,O
ncbi-sent-335,mutation,NN,O
ncbi-sent-335,",",",",O
ncbi-sent-335,while,IN,O
ncbi-sent-335,the,DT,O
ncbi-sent-335,second,JJ,O
ncbi-sent-335,",",",",O
ncbi-sent-335,1936delG,CD,O
ncbi-sent-335,in,IN,O
ncbi-sent-335,exon,NN,O
ncbi-sent-335,12,CD,O
ncbi-sent-335,",",",",O
ncbi-sent-335,has,VBZ,O
ncbi-sent-335,been,VBN,O
ncbi-sent-335,described,VBN,O
ncbi-sent-335,before,IN,O
ncbi-sent-335,to,TO,O
ncbi-sent-335,cause,VB,O
ncbi-sent-335,C6D,NNP,B-DISEASE
ncbi-sent-335,in,IN,O
ncbi-sent-335,an,DT,O
ncbi-sent-335,unrelated,JJ,O
ncbi-sent-335,African,JJ,O
ncbi-sent-335,-,:,O
ncbi-sent-335,American,JJ,O
ncbi-sent-335,individual,NN,O
ncbi-sent-335,.,.,O
ncbi-sent-336,Both,DT,O
ncbi-sent-336,mutations,NNS,O
ncbi-sent-336,result,VBP,O
ncbi-sent-336,in,IN,O
ncbi-sent-336,premature,NN,O
ncbi-sent-336,termination,NN,O
ncbi-sent-336,codons,NNS,O
ncbi-sent-336,and,CC,O
ncbi-sent-336,C6,NNP,O
ncbi-sent-336,,JJ,O
ncbi-sent-336,alleles,NNS,O
ncbi-sent-336,.,.,O
ncbi-sent-337,Allele,NNP,O
ncbi-sent-337,-,:,O
ncbi-sent-337,specific,JJ,O
ncbi-sent-337,PCR,NNP,O
ncbi-sent-337,indicated,VBD,O
ncbi-sent-337,that,IN,O
ncbi-sent-337,the,DT,O
ncbi-sent-337,probands,NNS,O
ncbi-sent-337,two,CD,O
ncbi-sent-337,brothers,NNS,O
ncbi-sent-337,also,RB,O
ncbi-sent-337,inherited,VBD,O
ncbi-sent-337,the,DT,O
ncbi-sent-337,1195delC,CD,O
ncbi-sent-337,mutation,NN,O
ncbi-sent-337,from,IN,O
ncbi-sent-337,their,PRP$,O
ncbi-sent-337,heterozygous,JJ,O
ncbi-sent-337,mother,NN,O
ncbi-sent-337,and,CC,O
ncbi-sent-337,the,DT,O
ncbi-sent-337,1936delG,CD,O
ncbi-sent-337,mutation,NN,O
ncbi-sent-337,from,IN,O
ncbi-sent-337,their,PRP$,O
ncbi-sent-337,homozygous,JJ,O
ncbi-sent-337,father,NN,O
ncbi-sent-337,.,.,O
ncbi-sent-338,.,.,O
ncbi-sent-339,PAX6,JJ,O
ncbi-sent-339,mutations,NNS,O
ncbi-sent-339,reviewed,VBN,O
ncbi-sent-339,.,.,O
ncbi-sent-340,Mutations,NNS,O
ncbi-sent-340,in,IN,O
ncbi-sent-340,PAX6,NNP,O
ncbi-sent-340,are,VBP,O
ncbi-sent-340,responsible,JJ,O
ncbi-sent-340,for,IN,O
ncbi-sent-340,human,JJ,O
ncbi-sent-340,aniridia,NN,B-DISEASE
ncbi-sent-340,and,CC,O
ncbi-sent-340,have,VBP,O
ncbi-sent-340,also,RB,O
ncbi-sent-340,been,VBN,O
ncbi-sent-340,found,VBN,O
ncbi-sent-340,in,IN,O
ncbi-sent-340,patients,NNS,O
ncbi-sent-340,with,IN,O
ncbi-sent-340,Peters,NNP,B-DISEASE
ncbi-sent-340,anomaly,VBP,I-DISEASE
ncbi-sent-340,",",",",O
ncbi-sent-340,with,IN,O
ncbi-sent-340,congenital,JJ,B-DISEASE
ncbi-sent-340,cataracts,NNS,I-DISEASE
ncbi-sent-340,",",",",O
ncbi-sent-340,with,IN,O
ncbi-sent-340,autosomal,JJ,B-DISEASE
ncbi-sent-340,dominant,JJ,I-DISEASE
ncbi-sent-340,keratitis,NN,I-DISEASE
ncbi-sent-340,",",",",O
ncbi-sent-340,and,CC,O
ncbi-sent-340,with,IN,O
ncbi-sent-340,isolated,JJ,B-DISEASE
ncbi-sent-340,foveal,NN,I-DISEASE
ncbi-sent-340,hypoplasia,NN,I-DISEASE
ncbi-sent-340,.,.,O
ncbi-sent-341,No,DT,O
ncbi-sent-341,locus,NN,O
ncbi-sent-341,other,JJ,O
ncbi-sent-341,than,IN,O
ncbi-sent-341,chromosome,NN,O
ncbi-sent-341,11p13,CD,O
ncbi-sent-341,has,VBZ,O
ncbi-sent-341,been,VBN,O
ncbi-sent-341,implicated,VBN,O
ncbi-sent-341,in,IN,O
ncbi-sent-341,aniridia,NN,B-DISEASE
ncbi-sent-341,",",",",O
ncbi-sent-341,and,CC,O
ncbi-sent-341,PAX6,NNP,O
ncbi-sent-341,is,VBZ,O
ncbi-sent-341,clearly,RB,O
ncbi-sent-341,the,DT,O
ncbi-sent-341,major,JJ,O
ncbi-sent-341,",",",",O
ncbi-sent-341,if,IN,O
ncbi-sent-341,not,RB,O
ncbi-sent-341,only,RB,O
ncbi-sent-341,",",",",O
ncbi-sent-341,gene,NN,O
ncbi-sent-341,responsible,JJ,O
ncbi-sent-341,.,.,O
ncbi-sent-342,Twenty,NNP,O
ncbi-sent-342,-,:,O
ncbi-sent-342,eight,CD,O
ncbi-sent-342,percent,NN,O
ncbi-sent-342,of,IN,O
ncbi-sent-342,identified,JJ,O
ncbi-sent-342,PAX6,NNP,O
ncbi-sent-342,mutations,NNS,O
ncbi-sent-342,are,VBP,O
ncbi-sent-342,C,NNP,O
ncbi-sent-342,-,:,O
ncbi-sent-342,T,NN,O
ncbi-sent-342,changes,NNS,O
ncbi-sent-342,at,IN,O
ncbi-sent-342,CpG,NNP,O
ncbi-sent-342,dinucleotides,NNS,O
ncbi-sent-342,",",",",O
ncbi-sent-342,20,CD,O
ncbi-sent-342,%,NN,O
ncbi-sent-342,are,VBP,O
ncbi-sent-342,splicing,VBG,O
ncbi-sent-342,errors,NNS,O
ncbi-sent-342,",",",",O
ncbi-sent-342,and,CC,O
ncbi-sent-342,more,JJR,O
ncbi-sent-342,than,IN,O
ncbi-sent-342,30,CD,O
ncbi-sent-342,%,NN,O
ncbi-sent-342,are,VBP,O
ncbi-sent-342,deletion,NN,O
ncbi-sent-342,or,CC,O
ncbi-sent-342,insertion,NN,O
ncbi-sent-342,events,NNS,O
ncbi-sent-342,.,.,O
ncbi-sent-343,There,EX,O
ncbi-sent-343,is,VBZ,O
ncbi-sent-343,a,DT,O
ncbi-sent-343,noticeably,RB,O
ncbi-sent-343,elevated,JJ,O
ncbi-sent-343,level,NN,O
ncbi-sent-343,of,IN,O
ncbi-sent-343,mutation,NN,O
ncbi-sent-343,in,IN,O
ncbi-sent-343,the,DT,O
ncbi-sent-343,paired,JJ,O
ncbi-sent-343,domain,NN,O
ncbi-sent-343,compared,VBN,O
ncbi-sent-343,with,IN,O
ncbi-sent-343,the,DT,O
ncbi-sent-343,rest,NN,O
ncbi-sent-343,of,IN,O
ncbi-sent-343,the,DT,O
ncbi-sent-343,gene,NN,O
ncbi-sent-343,.,.,O
ncbi-sent-344,Increased,VBN,O
ncbi-sent-344,mutation,NN,O
ncbi-sent-344,in,IN,O
ncbi-sent-344,the,DT,O
ncbi-sent-344,homeodomain,NN,O
ncbi-sent-344,is,VBZ,O
ncbi-sent-344,accounted,VBN,O
ncbi-sent-344,for,IN,O
ncbi-sent-344,by,IN,O
ncbi-sent-344,the,DT,O
ncbi-sent-344,hypermutable,JJ,O
ncbi-sent-344,CpG,NNP,O
ncbi-sent-344,dinucleotide,NN,O
ncbi-sent-344,in,IN,O
ncbi-sent-344,codon,NN,O
ncbi-sent-344,240,CD,O
ncbi-sent-344,.,.,O
ncbi-sent-345,Very,RB,O
ncbi-sent-345,nearly,RB,O
ncbi-sent-345,all,DT,O
ncbi-sent-345,mutations,NNS,O
ncbi-sent-345,appear,VBP,O
ncbi-sent-345,to,TO,O
ncbi-sent-345,cause,VB,O
ncbi-sent-345,loss,NN,O
ncbi-sent-345,of,IN,O
ncbi-sent-345,function,NN,O
ncbi-sent-345,of,IN,O
ncbi-sent-345,the,DT,O
ncbi-sent-345,mutant,JJ,O
ncbi-sent-345,allele,NN,O
ncbi-sent-345,",",",",O
ncbi-sent-345,and,CC,O
ncbi-sent-345,more,JJR,O
ncbi-sent-345,than,IN,O
ncbi-sent-345,80,CD,O
ncbi-sent-345,%,NN,O
ncbi-sent-345,of,IN,O
ncbi-sent-345,exonic,JJ,O
ncbi-sent-345,substitutions,NNS,O
ncbi-sent-345,result,VBP,O
ncbi-sent-345,in,IN,O
ncbi-sent-345,nonsense,JJ,O
ncbi-sent-345,codons,NNS,O
ncbi-sent-345,.,.,O
ncbi-sent-346,In,IN,O
ncbi-sent-346,a,DT,O
ncbi-sent-346,gene,NN,O
ncbi-sent-346,with,IN,O
ncbi-sent-346,such,JJ,O
ncbi-sent-346,extraordinarily,RB,O
ncbi-sent-346,high,JJ,O
ncbi-sent-346,sequence,NN,O
ncbi-sent-346,conservation,NN,O
ncbi-sent-346,throughout,IN,O
ncbi-sent-346,evolution,NN,O
ncbi-sent-346,",",",",O
ncbi-sent-346,there,EX,O
ncbi-sent-346,are,VBP,O
ncbi-sent-346,presumed,VBN,O
ncbi-sent-346,undiscovered,JJ,O
ncbi-sent-346,missense,NN,O
ncbi-sent-346,mutations,NNS,O
ncbi-sent-346,",",",",O
ncbi-sent-346,these,DT,O
ncbi-sent-346,are,VBP,O
ncbi-sent-346,hypothesized,VBN,O
ncbi-sent-346,to,TO,O
ncbi-sent-346,exist,VB,O
ncbi-sent-346,in,IN,O
ncbi-sent-346,as,IN,O
ncbi-sent-346,-,:,O
ncbi-sent-346,yet,RB,O
ncbi-sent-346,unidentified,JJ,O
ncbi-sent-346,phenotypes,NNS,O
ncbi-sent-346,.,.,O
ncbi-sent-347,.,.,O
ncbi-sent-348,Genetic,JJ,O
ncbi-sent-348,heterogeneity,NN,O
ncbi-sent-348,and,CC,O
ncbi-sent-348,penetrance,NN,O
ncbi-sent-348,analysis,NN,O
ncbi-sent-348,of,IN,O
ncbi-sent-348,the,DT,O
ncbi-sent-348,BRCA1,NNP,O
ncbi-sent-348,and,CC,O
ncbi-sent-348,BRCA2,NNP,O
ncbi-sent-348,genes,NNS,O
ncbi-sent-348,in,IN,O
ncbi-sent-348,breast,NN,B-DISEASE
ncbi-sent-348,cancer,NN,I-DISEASE
ncbi-sent-348,families,NNS,O
ncbi-sent-348,.,.,O
ncbi-sent-349,The,DT,O
ncbi-sent-349,Breast,NNP,B-DISEASE
ncbi-sent-349,Cancer,NNP,I-DISEASE
ncbi-sent-349,Linkage,NNP,O
ncbi-sent-349,Consortium,NNP,O
ncbi-sent-349,.,.,O
ncbi-sent-350,The,DT,O
ncbi-sent-350,contribution,NN,O
ncbi-sent-350,of,IN,O
ncbi-sent-350,BRCA1,NNP,O
ncbi-sent-350,and,CC,O
ncbi-sent-350,BRCA2,NNP,O
ncbi-sent-350,to,TO,O
ncbi-sent-350,inherited,VB,B-DISEASE
ncbi-sent-350,breast,NN,I-DISEASE
ncbi-sent-350,cancer,NN,I-DISEASE
ncbi-sent-350,was,VBD,O
ncbi-sent-350,assessed,VBN,O
ncbi-sent-350,by,IN,O
ncbi-sent-350,linkage,NN,O
ncbi-sent-350,and,CC,O
ncbi-sent-350,mutation,NN,O
ncbi-sent-350,analysis,NN,O
ncbi-sent-350,in,IN,O
ncbi-sent-350,237,CD,O
ncbi-sent-350,families,NNS,O
ncbi-sent-350,",",",",O
ncbi-sent-350,each,DT,O
ncbi-sent-350,with,IN,O
ncbi-sent-350,at,IN,O
ncbi-sent-350,least,JJS,O
ncbi-sent-350,four,CD,O
ncbi-sent-350,cases,NNS,O
ncbi-sent-350,of,IN,O
ncbi-sent-350,breast,NN,B-DISEASE
ncbi-sent-350,cancer,NN,I-DISEASE
ncbi-sent-350,",",",",O
ncbi-sent-350,collected,VBN,O
ncbi-sent-350,by,IN,O
ncbi-sent-350,the,DT,O
ncbi-sent-350,Breast,NNP,B-DISEASE
ncbi-sent-350,Cancer,NNP,I-DISEASE
ncbi-sent-350,Linkage,NNP,O
ncbi-sent-350,Consortium,NNP,O
ncbi-sent-350,.,.,O
ncbi-sent-351,Families,NNS,O
ncbi-sent-351,were,VBD,O
ncbi-sent-351,included,VBN,O
ncbi-sent-351,without,IN,O
ncbi-sent-351,regard,NN,O
ncbi-sent-351,to,TO,O
ncbi-sent-351,the,DT,O
ncbi-sent-351,occurrence,NN,O
ncbi-sent-351,of,IN,O
ncbi-sent-351,ovarian,JJ,B-DISEASE
ncbi-sent-351,or,CC,I-DISEASE
ncbi-sent-351,other,JJ,I-DISEASE
ncbi-sent-351,cancers,NNS,I-DISEASE
ncbi-sent-351,.,.,O
ncbi-sent-352,Overall,JJ,O
ncbi-sent-352,",",",",O
ncbi-sent-352,disease,NN,O
ncbi-sent-352,was,VBD,O
ncbi-sent-352,linked,VBN,O
ncbi-sent-352,to,TO,O
ncbi-sent-352,BRCA1,NNP,O
ncbi-sent-352,in,IN,O
ncbi-sent-352,an,DT,O
ncbi-sent-352,estimated,JJ,O
ncbi-sent-352,52,CD,O
ncbi-sent-352,%,NN,O
ncbi-sent-352,of,IN,O
ncbi-sent-352,families,NNS,O
ncbi-sent-352,",",",",O
ncbi-sent-352,to,TO,O
ncbi-sent-352,BRCA2,NNP,O
ncbi-sent-352,in,IN,O
ncbi-sent-352,32,CD,O
ncbi-sent-352,%,NN,O
ncbi-sent-352,of,IN,O
ncbi-sent-352,families,NNS,O
ncbi-sent-352,",",",",O
ncbi-sent-352,and,CC,O
ncbi-sent-352,to,TO,O
ncbi-sent-352,neither,DT,O
ncbi-sent-352,gene,NN,O
ncbi-sent-352,in,IN,O
ncbi-sent-352,16,CD,O
ncbi-sent-352,%,NN,O
ncbi-sent-352,(,(,O
ncbi-sent-352,95,CD,O
ncbi-sent-352,%,NN,O
ncbi-sent-352,confidence,NN,O
ncbi-sent-352,interval,NN,O
ncbi-sent-352,[,NNP,O
ncbi-sent-352,CI,NNP,O
ncbi-sent-352,],VBD,O
ncbi-sent-352,6,CD,O
ncbi-sent-352,%,NN,O
ncbi-sent-352,-,:,O
ncbi-sent-352,28,CD,O
ncbi-sent-352,%,NN,O
ncbi-sent-352,),),O
ncbi-sent-352,",",",",O
ncbi-sent-352,suggesting,VBG,O
ncbi-sent-352,other,JJ,O
ncbi-sent-352,predisposition,NN,O
ncbi-sent-352,genes,NNS,O
ncbi-sent-352,.,.,O
ncbi-sent-353,The,DT,O
ncbi-sent-353,majority,NN,O
ncbi-sent-353,(,(,O
ncbi-sent-353,81,CD,O
ncbi-sent-353,%,NN,O
ncbi-sent-353,),),O
ncbi-sent-353,of,IN,O
ncbi-sent-353,the,DT,O
ncbi-sent-353,breast,NN,B-DISEASE
ncbi-sent-353,-,:,I-DISEASE
ncbi-sent-353,ovarian,JJ,I-DISEASE
ncbi-sent-353,cancer,NN,I-DISEASE
ncbi-sent-353,families,NNS,O
ncbi-sent-353,were,VBD,O
ncbi-sent-353,due,JJ,O
ncbi-sent-353,to,TO,O
ncbi-sent-353,BRCA1,NNP,O
ncbi-sent-353,",",",",O
ncbi-sent-353,with,IN,O
ncbi-sent-353,most,JJS,O
ncbi-sent-353,others,NNS,O
ncbi-sent-353,(,(,O
ncbi-sent-353,14,CD,O
ncbi-sent-353,%,NN,O
ncbi-sent-353,),),O
ncbi-sent-353,due,JJ,O
ncbi-sent-353,to,TO,O
ncbi-sent-353,BRCA2,NNP,O
ncbi-sent-353,.,.,O
ncbi-sent-354,Conversely,RB,O
ncbi-sent-354,",",",",O
ncbi-sent-354,the,DT,O
ncbi-sent-354,majority,NN,O
ncbi-sent-354,of,IN,O
ncbi-sent-354,families,NNS,O
ncbi-sent-354,with,IN,O
ncbi-sent-354,male,NN,B-DISEASE
ncbi-sent-354,and,CC,I-DISEASE
ncbi-sent-354,female,JJ,I-DISEASE
ncbi-sent-354,breast,NN,I-DISEASE
ncbi-sent-354,cancer,NN,I-DISEASE
ncbi-sent-354,were,VBD,O
ncbi-sent-354,due,JJ,O
ncbi-sent-354,to,TO,O
ncbi-sent-354,BRCA2,NNP,O
ncbi-sent-354,(,(,O
ncbi-sent-354,76,CD,O
ncbi-sent-354,%,NN,O
ncbi-sent-354,),),O
ncbi-sent-354,.,.,O
ncbi-sent-355,The,DT,O
ncbi-sent-355,largest,JJS,O
ncbi-sent-355,proportion,NN,O
ncbi-sent-355,(,(,O
ncbi-sent-355,67,CD,O
ncbi-sent-355,%,NN,O
ncbi-sent-355,),),O
ncbi-sent-355,of,IN,O
ncbi-sent-355,families,NNS,O
ncbi-sent-355,due,JJ,O
ncbi-sent-355,to,TO,O
ncbi-sent-355,other,JJ,O
ncbi-sent-355,genes,NNS,O
ncbi-sent-355,was,VBD,O
ncbi-sent-355,found,VBN,O
ncbi-sent-355,in,IN,O
ncbi-sent-355,families,NNS,O
ncbi-sent-355,with,IN,O
ncbi-sent-355,four,CD,O
ncbi-sent-355,or,CC,O
ncbi-sent-355,five,CD,O
ncbi-sent-355,cases,NNS,O
ncbi-sent-355,of,IN,O
ncbi-sent-355,female,JJ,O
ncbi-sent-355,breast,NN,B-DISEASE
ncbi-sent-355,cancer,NN,I-DISEASE
ncbi-sent-355,only,RB,O
ncbi-sent-355,.,.,O
ncbi-sent-356,These,DT,O
ncbi-sent-356,estimates,NNS,O
ncbi-sent-356,were,VBD,O
ncbi-sent-356,not,RB,O
ncbi-sent-356,substantially,RB,O
ncbi-sent-356,affected,VBN,O
ncbi-sent-356,either,RB,O
ncbi-sent-356,by,IN,O
ncbi-sent-356,changing,VBG,O
ncbi-sent-356,the,DT,O
ncbi-sent-356,assumed,JJ,O
ncbi-sent-356,penetrance,NN,O
ncbi-sent-356,model,NN,O
ncbi-sent-356,for,IN,O
ncbi-sent-356,BRCA1,NNP,O
ncbi-sent-356,or,CC,O
ncbi-sent-356,by,IN,O
ncbi-sent-356,including,VBG,O
ncbi-sent-356,or,CC,O
ncbi-sent-356,excluding,VBG,O
ncbi-sent-356,BRCA1,NNP,O
ncbi-sent-356,mutation,NN,O
ncbi-sent-356,data,NNS,O
ncbi-sent-356,.,.,O
ncbi-sent-357,Among,IN,O
ncbi-sent-357,those,DT,O
ncbi-sent-357,families,NNS,O
ncbi-sent-357,with,IN,O
ncbi-sent-357,disease,NN,O
ncbi-sent-357,due,JJ,O
ncbi-sent-357,to,TO,O
ncbi-sent-357,BRCA1,VB,O
ncbi-sent-357,that,WDT,O
ncbi-sent-357,were,VBD,O
ncbi-sent-357,tested,VBN,O
ncbi-sent-357,by,IN,O
ncbi-sent-357,one,CD,O
ncbi-sent-357,of,IN,O
ncbi-sent-357,the,DT,O
ncbi-sent-357,standard,JJ,O
ncbi-sent-357,screening,NN,O
ncbi-sent-357,methods,NNS,O
ncbi-sent-357,",",",",O
ncbi-sent-357,mutations,NNS,O
ncbi-sent-357,were,VBD,O
ncbi-sent-357,detected,VBN,O
ncbi-sent-357,in,IN,O
ncbi-sent-357,the,DT,O
ncbi-sent-357,coding,NN,O
ncbi-sent-357,sequence,NN,O
ncbi-sent-357,or,CC,O
ncbi-sent-357,splice,NN,O
ncbi-sent-357,sites,NNS,O
ncbi-sent-357,in,IN,O
ncbi-sent-357,an,DT,O
ncbi-sent-357,estimated,JJ,O
ncbi-sent-357,63,CD,O
ncbi-sent-357,%,NN,O
ncbi-sent-357,(,(,O
ncbi-sent-357,95,CD,O
ncbi-sent-357,%,NN,O
ncbi-sent-357,CI,NNP,O
ncbi-sent-357,51,CD,O
ncbi-sent-357,%,NN,O
ncbi-sent-357,-,:,O
ncbi-sent-357,77,CD,O
ncbi-sent-357,%,NN,O
ncbi-sent-357,),),O
ncbi-sent-357,.,.,O
ncbi-sent-358,The,DT,O
ncbi-sent-358,estimated,JJ,O
ncbi-sent-358,sensitivity,NN,O
ncbi-sent-358,was,VBD,O
ncbi-sent-358,identical,JJ,O
ncbi-sent-358,for,IN,O
ncbi-sent-358,direct,JJ,O
ncbi-sent-358,sequencing,NN,O
ncbi-sent-358,and,CC,O
ncbi-sent-358,other,JJ,O
ncbi-sent-358,techniques,NNS,O
ncbi-sent-358,.,.,O
ncbi-sent-359,The,DT,O
ncbi-sent-359,penetrance,NN,O
ncbi-sent-359,of,IN,O
ncbi-sent-359,BRCA2,NNP,O
ncbi-sent-359,was,VBD,O
ncbi-sent-359,estimated,VBN,O
ncbi-sent-359,by,IN,O
ncbi-sent-359,maximizing,VBG,O
ncbi-sent-359,the,DT,O
ncbi-sent-359,LOD,NNP,O
ncbi-sent-359,score,NN,O
ncbi-sent-359,in,IN,O
ncbi-sent-359,BRCA2,NNP,O
ncbi-sent-359,-,:,O
ncbi-sent-359,mutation,NN,O
ncbi-sent-359,families,NNS,O
ncbi-sent-359,",",",",O
ncbi-sent-359,over,IN,O
ncbi-sent-359,all,DT,O
ncbi-sent-359,possible,JJ,O
ncbi-sent-359,penetrance,NN,O
ncbi-sent-359,functions,NNS,O
ncbi-sent-359,.,.,O
ncbi-sent-360,The,DT,O
ncbi-sent-360,estimated,JJ,O
ncbi-sent-360,cumulative,JJ,O
ncbi-sent-360,risk,NN,O
ncbi-sent-360,of,IN,O
ncbi-sent-360,breast,NN,B-DISEASE
ncbi-sent-360,cancer,NN,I-DISEASE
ncbi-sent-360,reached,VBD,O
ncbi-sent-360,28,CD,O
ncbi-sent-360,%,NN,O
ncbi-sent-360,(,(,O
ncbi-sent-360,95,CD,O
ncbi-sent-360,%,NN,O
ncbi-sent-360,CI,NNP,O
ncbi-sent-360,9,CD,O
ncbi-sent-360,%,NN,O
ncbi-sent-360,-,:,O
ncbi-sent-360,44,CD,O
ncbi-sent-360,%,NN,O
ncbi-sent-360,),),O
ncbi-sent-360,by,IN,O
ncbi-sent-360,age,NN,O
ncbi-sent-360,50,CD,O
ncbi-sent-360,years,NNS,O
ncbi-sent-360,and,CC,O
ncbi-sent-360,84,CD,O
ncbi-sent-360,%,NN,O
ncbi-sent-360,(,(,O
ncbi-sent-360,95,CD,O
ncbi-sent-360,%,NN,O
ncbi-sent-360,CI,NNP,O
ncbi-sent-360,43,CD,O
ncbi-sent-360,%,NN,O
ncbi-sent-360,-,:,O
ncbi-sent-360,95,CD,O
ncbi-sent-360,%,NN,O
ncbi-sent-360,),),O
ncbi-sent-360,by,IN,O
ncbi-sent-360,age,NN,O
ncbi-sent-360,70,CD,O
ncbi-sent-360,years,NNS,O
ncbi-sent-360,.,.,O
ncbi-sent-361,The,DT,O
ncbi-sent-361,corresponding,JJ,O
ncbi-sent-361,ovarian,JJ,B-DISEASE
ncbi-sent-361,cancer,NN,I-DISEASE
ncbi-sent-361,risks,NNS,O
ncbi-sent-361,were,VBD,O
ncbi-sent-361,0,CD,O
ncbi-sent-361,.,.,O
ncbi-sent-362,4,CD,O
ncbi-sent-362,%,NN,O
ncbi-sent-362,(,(,O
ncbi-sent-362,95,CD,O
ncbi-sent-362,%,NN,O
ncbi-sent-362,CI,NNP,O
ncbi-sent-362,0,CD,O
ncbi-sent-362,%,NN,O
ncbi-sent-362,-,:,O
ncbi-sent-362,1,CD,O
ncbi-sent-362,%,NN,O
ncbi-sent-362,),),O
ncbi-sent-362,by,IN,O
ncbi-sent-362,age,NN,O
ncbi-sent-362,50,CD,O
ncbi-sent-362,years,NNS,O
ncbi-sent-362,and,CC,O
ncbi-sent-362,27,CD,O
ncbi-sent-362,%,NN,O
ncbi-sent-362,(,(,O
ncbi-sent-362,95,CD,O
ncbi-sent-362,%,NN,O
ncbi-sent-362,CI,NNP,O
ncbi-sent-362,0,CD,O
ncbi-sent-362,%,NN,O
ncbi-sent-362,-,:,O
ncbi-sent-362,47,CD,O
ncbi-sent-362,%,NN,O
ncbi-sent-362,),),O
ncbi-sent-362,by,IN,O
ncbi-sent-362,age,NN,O
ncbi-sent-362,70,CD,O
ncbi-sent-362,years,NNS,O
ncbi-sent-362,.,.,O
ncbi-sent-363,The,DT,O
ncbi-sent-363,lifetime,NN,O
ncbi-sent-363,risk,NN,O
ncbi-sent-363,of,IN,O
ncbi-sent-363,breast,NN,B-DISEASE
ncbi-sent-363,cancer,NN,I-DISEASE
ncbi-sent-363,appears,VBZ,O
ncbi-sent-363,similar,JJ,O
ncbi-sent-363,to,TO,O
ncbi-sent-363,the,DT,O
ncbi-sent-363,risk,NN,O
ncbi-sent-363,in,IN,O
ncbi-sent-363,BRCA1,NNP,O
ncbi-sent-363,carriers,NNS,O
ncbi-sent-363,",",",",O
ncbi-sent-363,but,CC,O
ncbi-sent-363,there,EX,O
ncbi-sent-363,was,VBD,O
ncbi-sent-363,some,DT,O
ncbi-sent-363,suggestion,NN,O
ncbi-sent-363,of,IN,O
ncbi-sent-363,a,DT,O
ncbi-sent-363,lower,JJR,O
ncbi-sent-363,risk,NN,O
ncbi-sent-363,in,IN,O
ncbi-sent-363,BRCA2,NNP,O
ncbi-sent-363,carriers,NNS,O
ncbi-sent-363,<,VBP,O
ncbi-sent-363,50,CD,O
ncbi-sent-363,years,NNS,O
ncbi-sent-363,of,IN,O
ncbi-sent-363,age,NN,O
ncbi-sent-363,.,.,O
ncbi-sent-364,Eye,NNP,B-DISEASE
ncbi-sent-364,movement,NN,I-DISEASE
ncbi-sent-364,abnormalities,NNS,I-DISEASE
ncbi-sent-364,correlate,VBP,O
ncbi-sent-364,with,IN,O
ncbi-sent-364,genotype,NN,O
ncbi-sent-364,in,IN,O
ncbi-sent-364,autosomal,JJ,O
ncbi-sent-364,dominant,JJ,O
ncbi-sent-364,cerebellar,JJ,B-DISEASE
ncbi-sent-364,ataxia,NN,I-DISEASE
ncbi-sent-364,type,NN,I-DISEASE
ncbi-sent-364,I,PRP,I-DISEASE
ncbi-sent-364,.,.,O
ncbi-sent-365,We,PRP,O
ncbi-sent-365,compared,VBN,O
ncbi-sent-365,horizontal,JJ,O
ncbi-sent-365,eye,NN,O
ncbi-sent-365,movements,NNS,O
ncbi-sent-365,(,(,O
ncbi-sent-365,visually,RB,O
ncbi-sent-365,guided,VBN,O
ncbi-sent-365,saccades,NNS,O
ncbi-sent-365,",",",",O
ncbi-sent-365,antisaccades,NNS,O
ncbi-sent-365,",",",",O
ncbi-sent-365,and,CC,O
ncbi-sent-365,smooth,VB,O
ncbi-sent-365,pursuit,NN,O
ncbi-sent-365,),),O
ncbi-sent-365,in,IN,O
ncbi-sent-365,control,NN,O
ncbi-sent-365,subjects,NNS,O
ncbi-sent-365,(,(,O
ncbi-sent-365,n,JJ,O
ncbi-sent-365,=,NNP,O
ncbi-sent-365,14,CD,O
ncbi-sent-365,),),O
ncbi-sent-365,and,CC,O
ncbi-sent-365,patients,NNS,O
ncbi-sent-365,with,IN,O
ncbi-sent-365,three,CD,O
ncbi-sent-365,forms,NNS,O
ncbi-sent-365,of,IN,O
ncbi-sent-365,autosomal,JJ,O
ncbi-sent-365,dominant,JJ,O
ncbi-sent-365,cerebellar,JJ,B-DISEASE
ncbi-sent-365,ataxias,NN,I-DISEASE
ncbi-sent-365,type,NN,I-DISEASE
ncbi-sent-365,I,PRP,I-DISEASE
ncbi-sent-365,spinocerebellar,VBP,B-DISEASE
ncbi-sent-365,ataxias,JJ,I-DISEASE
ncbi-sent-365,1,CD,I-DISEASE
ncbi-sent-365,and,CC,I-DISEASE
ncbi-sent-365,2,CD,I-DISEASE
ncbi-sent-365,(,(,O
ncbi-sent-365,SCA1,NNP,B-DISEASE
ncbi-sent-365,",",",",O
ncbi-sent-365,n,JJ,O
ncbi-sent-365,=,VBP,O
ncbi-sent-365,11,CD,O
ncbi-sent-365,;,:,O
ncbi-sent-365,SCA2,NNP,B-DISEASE
ncbi-sent-365,",",",",O
ncbi-sent-365,n,JJ,O
ncbi-sent-365,=,NNP,O
ncbi-sent-365,10,CD,O
ncbi-sent-365,),),O
ncbi-sent-365,and,CC,O
ncbi-sent-365,SCA3,NNP,B-DISEASE
ncbi-sent-365,/,NNP,O
ncbi-sent-365,Machado,NNP,B-DISEASE
ncbi-sent-365,-,:,I-DISEASE
ncbi-sent-365,Joseph,NNP,I-DISEASE
ncbi-sent-365,disease,NN,I-DISEASE
ncbi-sent-365,(,(,O
ncbi-sent-365,MJD,NNP,B-DISEASE
ncbi-sent-365,),),O
ncbi-sent-365,(,(,O
ncbi-sent-365,n,JJ,O
ncbi-sent-365,=,NNP,O
ncbi-sent-365,16,CD,O
ncbi-sent-365,),),O
ncbi-sent-365,.,.,O
ncbi-sent-366,In,IN,O
ncbi-sent-366,SCA1,NNP,B-DISEASE
ncbi-sent-366,",",",",O
ncbi-sent-366,saccade,VBD,O
ncbi-sent-366,amplitude,NN,O
ncbi-sent-366,was,VBD,O
ncbi-sent-366,significantly,RB,O
ncbi-sent-366,increased,VBN,O
ncbi-sent-366,",",",",O
ncbi-sent-366,resulting,VBG,O
ncbi-sent-366,in,IN,O
ncbi-sent-366,hypermetria,NN,B-DISEASE
ncbi-sent-366,.,.,O
ncbi-sent-367,The,DT,O
ncbi-sent-367,smooth,JJ,O
ncbi-sent-367,pursuit,NN,O
ncbi-sent-367,gain,NN,O
ncbi-sent-367,was,VBD,O
ncbi-sent-367,decreased,VBN,O
ncbi-sent-367,.,.,O
ncbi-sent-368,In,IN,O
ncbi-sent-368,SCA2,NNP,B-DISEASE
ncbi-sent-368,",",",",O
ncbi-sent-368,saccade,VBD,O
ncbi-sent-368,velocity,NN,O
ncbi-sent-368,was,VBD,O
ncbi-sent-368,markedly,RB,O
ncbi-sent-368,decreased,VBN,O
ncbi-sent-368,.,.,O
ncbi-sent-369,The,DT,O
ncbi-sent-369,percentage,NN,O
ncbi-sent-369,of,IN,O
ncbi-sent-369,errors,NNS,O
ncbi-sent-369,in,IN,O
ncbi-sent-369,antisaccades,NNS,O
ncbi-sent-369,was,VBD,O
ncbi-sent-369,greatly,RB,O
ncbi-sent-369,increased,JJ,O
ncbi-sent-369,and,CC,O
ncbi-sent-369,was,VBD,O
ncbi-sent-369,significantly,RB,O
ncbi-sent-369,correlated,VBN,O
ncbi-sent-369,with,IN,O
ncbi-sent-369,age,NN,O
ncbi-sent-369,at,IN,O
ncbi-sent-369,disease,NN,O
ncbi-sent-369,onset,NN,O
ncbi-sent-369,.,.,O
ncbi-sent-370,In,IN,O
ncbi-sent-370,addition,NN,O
ncbi-sent-370,",",",",O
ncbi-sent-370,a,DT,O
ncbi-sent-370,correlation,NN,O
ncbi-sent-370,between,IN,O
ncbi-sent-370,smooth,JJ,O
ncbi-sent-370,pursuit,NN,O
ncbi-sent-370,gain,NN,O
ncbi-sent-370,and,CC,O
ncbi-sent-370,the,DT,O
ncbi-sent-370,number,NN,O
ncbi-sent-370,of,IN,O
ncbi-sent-370,trinucleotide,JJ,O
ncbi-sent-370,repeats,NNS,O
ncbi-sent-370,was,VBD,O
ncbi-sent-370,found,VBN,O
ncbi-sent-370,.,.,O
ncbi-sent-371,In,IN,O
ncbi-sent-371,SCA3,NNP,B-DISEASE
ncbi-sent-371,",",",",O
ncbi-sent-371,gaze,SYM,B-DISEASE
ncbi-sent-371,-,:,I-DISEASE
ncbi-sent-371,evoked,JJ,I-DISEASE
ncbi-sent-371,nystagmus,NN,I-DISEASE
ncbi-sent-371,was,VBD,O
ncbi-sent-371,often,RB,O
ncbi-sent-371,present,JJ,O
ncbi-sent-371,as,IN,O
ncbi-sent-371,was,VBD,O
ncbi-sent-371,saccade,VBN,O
ncbi-sent-371,hypometria,NN,O
ncbi-sent-371,and,CC,O
ncbi-sent-371,smooth,JJ,O
ncbi-sent-371,pursuit,NN,O
ncbi-sent-371,gain,NN,O
ncbi-sent-371,was,VBD,O
ncbi-sent-371,markedly,RB,O
ncbi-sent-371,decreased,VBN,O
ncbi-sent-371,.,.,O
ncbi-sent-372,Three,CD,O
ncbi-sent-372,major,JJ,O
ncbi-sent-372,criteria,NNS,O
ncbi-sent-372,",",",",O
ncbi-sent-372,saccade,JJ,O
ncbi-sent-372,amplitude,NN,O
ncbi-sent-372,",",",",O
ncbi-sent-372,saccade,JJ,O
ncbi-sent-372,velocity,NN,O
ncbi-sent-372,",",",",O
ncbi-sent-372,and,CC,O
ncbi-sent-372,presence,NN,O
ncbi-sent-372,of,IN,O
ncbi-sent-372,gaze,JJ,B-DISEASE
ncbi-sent-372,-,:,I-DISEASE
ncbi-sent-372,evoked,JJ,I-DISEASE
ncbi-sent-372,nystagmus,NN,I-DISEASE
ncbi-sent-372,",",",",O
ncbi-sent-372,permitted,VBD,O
ncbi-sent-372,the,DT,O
ncbi-sent-372,correct,JJ,O
ncbi-sent-372,assignment,NN,O
ncbi-sent-372,of,IN,O
ncbi-sent-372,90,CD,O
ncbi-sent-372,%,NN,O
ncbi-sent-372,of,IN,O
ncbi-sent-372,the,DT,O
ncbi-sent-372,SCA1,NNP,B-DISEASE
ncbi-sent-372,",",",",O
ncbi-sent-372,90,CD,O
ncbi-sent-372,%,NN,O
ncbi-sent-372,of,IN,O
ncbi-sent-372,the,DT,O
ncbi-sent-372,SCA2,NNP,B-DISEASE
ncbi-sent-372,",",",",O
ncbi-sent-372,and,CC,O
ncbi-sent-372,93,CD,O
ncbi-sent-372,%,NN,O
ncbi-sent-372,of,IN,O
ncbi-sent-372,the,DT,O
ncbi-sent-372,patients,NNS,O
ncbi-sent-372,with,IN,O
ncbi-sent-372,SCA3,NNP,B-DISEASE
ncbi-sent-372,to,TO,O
ncbi-sent-372,their,PRP$,O
ncbi-sent-372,genetically,RB,O
ncbi-sent-372,confirmed,VBN,O
ncbi-sent-372,patient,NN,O
ncbi-sent-372,group,NN,O
ncbi-sent-372,and,CC,O
ncbi-sent-372,",",",",O
ncbi-sent-372,therefore,RB,O
ncbi-sent-372,",",",",O
ncbi-sent-372,may,MD,O
ncbi-sent-372,help,VB,O
ncbi-sent-372,orient,VB,O
ncbi-sent-372,diagnoses,NNS,O
ncbi-sent-372,of,IN,O
ncbi-sent-372,SCA1,NNP,B-DISEASE
ncbi-sent-372,",",",",O
ncbi-sent-372,SCA2,NNP,B-DISEASE
ncbi-sent-372,",",",",O
ncbi-sent-372,and,CC,O
ncbi-sent-372,SCA3,NNP,B-DISEASE
ncbi-sent-372,at,IN,O
ncbi-sent-372,early,RB,O
ncbi-sent-372,clinical,JJ,O
ncbi-sent-372,stages,NNS,O
ncbi-sent-372,of,IN,O
ncbi-sent-372,the,DT,O
ncbi-sent-372,diseases,NNS,O
ncbi-sent-372,.,.,O
ncbi-sent-373,.,.,O
ncbi-sent-374,Genetic,JJ,O
ncbi-sent-374,basis,NN,O
ncbi-sent-374,and,CC,O
ncbi-sent-374,molecular,JJ,O
ncbi-sent-374,mechanism,NN,O
ncbi-sent-374,for,IN,O
ncbi-sent-374,idiopathic,JJ,B-DISEASE
ncbi-sent-374,ventricular,JJ,I-DISEASE
ncbi-sent-374,fibrillation,NN,I-DISEASE
ncbi-sent-374,.,.,O
ncbi-sent-375,Ventricular,JJ,B-DISEASE
ncbi-sent-375,fibrillation,NN,I-DISEASE
ncbi-sent-375,causes,VBZ,O
ncbi-sent-375,more,JJR,O
ncbi-sent-375,than,IN,O
ncbi-sent-375,300,CD,O
ncbi-sent-375,",",",",O
ncbi-sent-375,000,CD,O
ncbi-sent-375,sudden,JJ,O
ncbi-sent-375,deaths,NNS,O
ncbi-sent-375,each,DT,O
ncbi-sent-375,year,NN,O
ncbi-sent-375,in,IN,O
ncbi-sent-375,the,DT,O
ncbi-sent-375,USA,NNP,O
ncbi-sent-375,alone,RB,O
ncbi-sent-375,.,.,O
ncbi-sent-376,In,IN,O
ncbi-sent-376,approximately,RB,O
ncbi-sent-376,5,CD,O
ncbi-sent-376,-,:,O
ncbi-sent-376,12,CD,O
ncbi-sent-376,%,NN,O
ncbi-sent-376,of,IN,O
ncbi-sent-376,these,DT,O
ncbi-sent-376,cases,NNS,O
ncbi-sent-376,",",",",O
ncbi-sent-376,there,EX,O
ncbi-sent-376,are,VBP,O
ncbi-sent-376,no,DT,O
ncbi-sent-376,demonstrable,JJ,O
ncbi-sent-376,cardiac,NN,O
ncbi-sent-376,or,CC,O
ncbi-sent-376,non,JJ,O
ncbi-sent-376,-,:,O
ncbi-sent-376,cardiac,JJ,O
ncbi-sent-376,causes,NNS,O
ncbi-sent-376,to,TO,O
ncbi-sent-376,account,VB,O
ncbi-sent-376,for,IN,O
ncbi-sent-376,the,DT,O
ncbi-sent-376,episode,NN,O
ncbi-sent-376,",",",",O
ncbi-sent-376,which,WDT,O
ncbi-sent-376,is,VBZ,O
ncbi-sent-376,therefore,RB,O
ncbi-sent-376,classified,JJ,O
ncbi-sent-376,as,IN,O
ncbi-sent-376,idiopathic,JJ,B-DISEASE
ncbi-sent-376,ventricular,JJ,I-DISEASE
ncbi-sent-376,fibrillation,NN,I-DISEASE
ncbi-sent-376,(,(,O
ncbi-sent-376,IVF,NNP,B-DISEASE
ncbi-sent-376,),),O
ncbi-sent-376,.,.,O
ncbi-sent-377,A,DT,O
ncbi-sent-377,distinct,JJ,O
ncbi-sent-377,group,NN,O
ncbi-sent-377,of,IN,O
ncbi-sent-377,IVF,NNP,B-DISEASE
ncbi-sent-377,patients,NNS,O
ncbi-sent-377,has,VBZ,O
ncbi-sent-377,been,VBN,O
ncbi-sent-377,found,VBN,O
ncbi-sent-377,to,TO,O
ncbi-sent-377,present,VB,O
ncbi-sent-377,with,IN,O
ncbi-sent-377,a,DT,O
ncbi-sent-377,characteristic,JJ,O
ncbi-sent-377,electrocardiographic,JJ,O
ncbi-sent-377,pattern,NN,O
ncbi-sent-377,.,.,O
ncbi-sent-378,Because,IN,O
ncbi-sent-378,of,IN,O
ncbi-sent-378,the,DT,O
ncbi-sent-378,small,JJ,O
ncbi-sent-378,size,NN,O
ncbi-sent-378,of,IN,O
ncbi-sent-378,most,JJS,O
ncbi-sent-378,pedigrees,NNS,O
ncbi-sent-378,and,CC,O
ncbi-sent-378,the,DT,O
ncbi-sent-378,high,JJ,O
ncbi-sent-378,incidence,NN,O
ncbi-sent-378,of,IN,O
ncbi-sent-378,sudden,JJ,B-DISEASE
ncbi-sent-378,death,NN,I-DISEASE
ncbi-sent-378,",",",",O
ncbi-sent-378,however,RB,O
ncbi-sent-378,",",",",O
ncbi-sent-378,molecular,JJ,O
ncbi-sent-378,genetic,JJ,O
ncbi-sent-378,studies,NNS,O
ncbi-sent-378,of,IN,O
ncbi-sent-378,IVF,NNP,B-DISEASE
ncbi-sent-378,have,VBP,O
ncbi-sent-378,not,RB,O
ncbi-sent-378,yet,RB,O
ncbi-sent-378,been,VBN,O
ncbi-sent-378,done,VBN,O
ncbi-sent-378,.,.,O
ncbi-sent-379,Because,IN,O
ncbi-sent-379,IVF,NNP,B-DISEASE
ncbi-sent-379,causes,VBZ,O
ncbi-sent-379,cardiac,JJ,O
ncbi-sent-379,rhythm,NN,O
ncbi-sent-379,disturbance,NN,O
ncbi-sent-379,",",",",O
ncbi-sent-379,we,PRP,O
ncbi-sent-379,investigated,VBD,O
ncbi-sent-379,whether,IN,O
ncbi-sent-379,malfunction,NN,O
ncbi-sent-379,of,IN,O
ncbi-sent-379,ion,NN,O
ncbi-sent-379,channels,NNS,O
ncbi-sent-379,could,MD,O
ncbi-sent-379,cause,VB,O
ncbi-sent-379,the,DT,O
ncbi-sent-379,disorder,NN,O
ncbi-sent-379,by,IN,O
ncbi-sent-379,studying,VBG,O
ncbi-sent-379,mutations,NNS,O
ncbi-sent-379,in,IN,O
ncbi-sent-379,the,DT,O
ncbi-sent-379,cardiac,JJ,O
ncbi-sent-379,sodium,NN,O
ncbi-sent-379,channel,NN,O
ncbi-sent-379,gene,NN,O
ncbi-sent-379,SCN5A,NNP,O
ncbi-sent-379,.,.,O
ncbi-sent-380,We,PRP,O
ncbi-sent-380,have,VBP,O
ncbi-sent-380,now,RB,O
ncbi-sent-380,identified,VBN,O
ncbi-sent-380,a,DT,O
ncbi-sent-380,missense,NN,O
ncbi-sent-380,mutation,NN,O
ncbi-sent-380,",",",",O
ncbi-sent-380,a,DT,O
ncbi-sent-380,splice,NN,O
ncbi-sent-380,-,:,O
ncbi-sent-380,donor,NN,O
ncbi-sent-380,mutation,NN,O
ncbi-sent-380,",",",",O
ncbi-sent-380,and,CC,O
ncbi-sent-380,a,DT,O
ncbi-sent-380,frameshift,JJ,O
ncbi-sent-380,mutation,NN,O
ncbi-sent-380,in,IN,O
ncbi-sent-380,the,DT,O
ncbi-sent-380,coding,JJ,O
ncbi-sent-380,region,NN,O
ncbi-sent-380,of,IN,O
ncbi-sent-380,SCN5A,NNP,O
ncbi-sent-380,in,IN,O
ncbi-sent-380,three,CD,O
ncbi-sent-380,IVF,NNP,B-DISEASE
ncbi-sent-380,families,NNS,O
ncbi-sent-380,.,.,O
ncbi-sent-381,We,PRP,O
ncbi-sent-381,show,VBP,O
ncbi-sent-381,that,IN,O
ncbi-sent-381,sodium,NN,O
ncbi-sent-381,channels,NNS,O
ncbi-sent-381,with,IN,O
ncbi-sent-381,the,DT,O
ncbi-sent-381,missense,NN,O
ncbi-sent-381,mutation,NN,O
ncbi-sent-381,recover,NN,O
ncbi-sent-381,from,IN,O
ncbi-sent-381,inactivation,NN,O
ncbi-sent-381,more,RBR,O
ncbi-sent-381,rapidly,RB,O
ncbi-sent-381,than,IN,O
ncbi-sent-381,normal,JJ,O
ncbi-sent-381,and,CC,O
ncbi-sent-381,that,IN,O
ncbi-sent-381,the,DT,O
ncbi-sent-381,frameshift,NN,O
ncbi-sent-381,mutation,NN,O
ncbi-sent-381,causes,VBZ,O
ncbi-sent-381,the,DT,O
ncbi-sent-381,sodium,NN,O
ncbi-sent-381,channel,NN,O
ncbi-sent-381,to,TO,O
ncbi-sent-381,be,VB,O
ncbi-sent-381,non,JJ,O
ncbi-sent-381,-,:,O
ncbi-sent-381,functional,NN,O
ncbi-sent-381,.,.,O
ncbi-sent-382,Our,PRP$,O
ncbi-sent-382,results,NNS,O
ncbi-sent-382,indicate,VBP,O
ncbi-sent-382,that,IN,O
ncbi-sent-382,mutations,NNS,O
ncbi-sent-382,in,IN,O
ncbi-sent-382,cardiac,JJ,O
ncbi-sent-382,ion,NN,O
ncbi-sent-382,-,:,O
ncbi-sent-382,channel,NN,O
ncbi-sent-382,genes,NNS,O
ncbi-sent-382,contribute,VBP,O
ncbi-sent-382,to,TO,O
ncbi-sent-382,the,DT,O
ncbi-sent-382,risk,NN,O
ncbi-sent-382,of,IN,O
ncbi-sent-382,developing,VBG,O
ncbi-sent-382,IVF,NNP,B-DISEASE
ncbi-sent-382,.,.,O
ncbi-sent-383,.,.,O
ncbi-sent-384,Molecular,JJ,O
ncbi-sent-384,heterogeneity,NN,O
ncbi-sent-384,in,IN,O
ncbi-sent-384,mucopolysaccharidosis,NN,B-DISEASE
ncbi-sent-384,IVA,NNP,I-DISEASE
ncbi-sent-384,in,IN,O
ncbi-sent-384,Australia,NNP,O
ncbi-sent-384,and,CC,O
ncbi-sent-384,Northern,NNP,O
ncbi-sent-384,Ireland,NNP,O
ncbi-sent-384,:,:,O
ncbi-sent-384,nine,CD,O
ncbi-sent-384,novel,JJ,O
ncbi-sent-384,mutations,NNS,O
ncbi-sent-384,including,VBG,O
ncbi-sent-384,T312S,NNP,O
ncbi-sent-384,",",",",O
ncbi-sent-384,a,DT,O
ncbi-sent-384,common,JJ,O
ncbi-sent-384,allele,NN,O
ncbi-sent-384,that,IN,O
ncbi-sent-384,confers,VBZ,O
ncbi-sent-384,a,DT,O
ncbi-sent-384,mild,JJ,O
ncbi-sent-384,phenotype,NN,O
ncbi-sent-384,.,.,O
ncbi-sent-385,Mucopolysaccharidosis,NNP,B-DISEASE
ncbi-sent-385,IVA,NNP,I-DISEASE
ncbi-sent-385,(,(,O
ncbi-sent-385,MPS,NNP,B-DISEASE
ncbi-sent-385,IVA,NNP,I-DISEASE
ncbi-sent-385,),),O
ncbi-sent-385,is,VBZ,O
ncbi-sent-385,an,DT,O
ncbi-sent-385,autosomal,JJ,B-DISEASE
ncbi-sent-385,recessive,NN,I-DISEASE
ncbi-sent-385,lysosomal,JJ,I-DISEASE
ncbi-sent-385,storage,NN,I-DISEASE
ncbi-sent-385,disorder,NN,I-DISEASE
ncbi-sent-385,caused,VBN,O
ncbi-sent-385,by,IN,O
ncbi-sent-385,a,DT,O
ncbi-sent-385,genetic,JJ,B-DISEASE
ncbi-sent-385,defect,NN,I-DISEASE
ncbi-sent-385,in,IN,O
ncbi-sent-385,N,NNP,O
ncbi-sent-385,-,:,O
ncbi-sent-385,acetylgalactosamine,NN,O
ncbi-sent-385,-,:,O
ncbi-sent-385,6,CD,O
ncbi-sent-385,-,:,O
ncbi-sent-385,sulfate,NN,O
ncbi-sent-385,sulfatase,NN,O
ncbi-sent-385,(,(,O
ncbi-sent-385,GALNS,NNP,O
ncbi-sent-385,),),O
ncbi-sent-385,.,.,O
ncbi-sent-386,Previous,JJ,O
ncbi-sent-386,studies,NNS,O
ncbi-sent-386,of,IN,O
ncbi-sent-386,patients,NNS,O
ncbi-sent-386,from,IN,O
ncbi-sent-386,a,DT,O
ncbi-sent-386,British,JJ,O
ncbi-sent-386,-,:,O
ncbi-sent-386,Irish,JJ,O
ncbi-sent-386,population,NN,O
ncbi-sent-386,showed,VBD,O
ncbi-sent-386,that,IN,O
ncbi-sent-386,the,DT,O
ncbi-sent-386,I113F,NNP,O
ncbi-sent-386,mutation,NN,O
ncbi-sent-386,is,VBZ,O
ncbi-sent-386,the,DT,O
ncbi-sent-386,most,RBS,O
ncbi-sent-386,common,JJ,O
ncbi-sent-386,single,JJ,O
ncbi-sent-386,mutation,NN,O
ncbi-sent-386,among,IN,O
ncbi-sent-386,MPS,NNP,B-DISEASE
ncbi-sent-386,IVA,NNP,I-DISEASE
ncbi-sent-386,patients,NNS,O
ncbi-sent-386,and,CC,O
ncbi-sent-386,produces,VBZ,O
ncbi-sent-386,a,DT,O
ncbi-sent-386,severe,JJ,O
ncbi-sent-386,clinical,JJ,O
ncbi-sent-386,phenotype,NN,O
ncbi-sent-386,.,.,O
ncbi-sent-387,We,PRP,O
ncbi-sent-387,studied,VBD,O
ncbi-sent-387,mutations,NNS,O
ncbi-sent-387,in,IN,O
ncbi-sent-387,the,DT,O
ncbi-sent-387,GALNS,NNP,O
ncbi-sent-387,gene,NN,O
ncbi-sent-387,from,IN,O
ncbi-sent-387,23,CD,O
ncbi-sent-387,additional,JJ,O
ncbi-sent-387,MPS,NNP,B-DISEASE
ncbi-sent-387,IVA,NNP,I-DISEASE
ncbi-sent-387,patients,NNS,O
ncbi-sent-387,(,(,O
ncbi-sent-387,15,CD,O
ncbi-sent-387,from,IN,O
ncbi-sent-387,Australia,NNP,O
ncbi-sent-387,",",",",O
ncbi-sent-387,8,CD,O
ncbi-sent-387,from,IN,O
ncbi-sent-387,Northern,NNP,O
ncbi-sent-387,Ireland,NNP,O
ncbi-sent-387,),),O
ncbi-sent-387,",",",",O
ncbi-sent-387,with,IN,O
ncbi-sent-387,various,JJ,O
ncbi-sent-387,clinical,JJ,O
ncbi-sent-387,phenotypes,NNS,O
ncbi-sent-387,(,(,O
ncbi-sent-387,severe,JJ,O
ncbi-sent-387,",",",",O
ncbi-sent-387,16,CD,O
ncbi-sent-387,cases,NNS,O
ncbi-sent-387,;,:,O
ncbi-sent-387,intermediate,VB,O
ncbi-sent-387,",",",",O
ncbi-sent-387,4,CD,O
ncbi-sent-387,cases,NNS,O
ncbi-sent-387,;,:,O
ncbi-sent-387,mild,VB,O
ncbi-sent-387,",",",",O
ncbi-sent-387,3,CD,O
ncbi-sent-387,cases,NNS,O
ncbi-sent-387,),),O
ncbi-sent-387,.,.,O
ncbi-sent-388,We,PRP,O
ncbi-sent-388,found,VBD,O
ncbi-sent-388,two,CD,O
ncbi-sent-388,common,JJ,O
ncbi-sent-388,mutations,NNS,O
ncbi-sent-388,that,IN,O
ncbi-sent-388,together,RB,O
ncbi-sent-388,accounted,VBD,O
ncbi-sent-388,for,IN,O
ncbi-sent-388,32,CD,O
ncbi-sent-388,%,NN,O
ncbi-sent-388,of,IN,O
ncbi-sent-388,the,DT,O
ncbi-sent-388,44,CD,O
ncbi-sent-388,unrelated,JJ,O
ncbi-sent-388,alleles,NNS,O
ncbi-sent-388,in,IN,O
ncbi-sent-388,these,DT,O
ncbi-sent-388,patients,NNS,O
ncbi-sent-388,.,.,O
ncbi-sent-389,One,CD,O
ncbi-sent-389,is,VBZ,O
ncbi-sent-389,the,DT,O
ncbi-sent-389,T312S,NNP,O
ncbi-sent-389,mutation,NN,O
ncbi-sent-389,",",",",O
ncbi-sent-389,a,DT,O
ncbi-sent-389,novel,JJ,O
ncbi-sent-389,mutation,NN,O
ncbi-sent-389,found,VBD,O
ncbi-sent-389,exclusively,RB,O
ncbi-sent-389,in,IN,O
ncbi-sent-389,milder,NN,O
ncbi-sent-389,patients,NNS,O
ncbi-sent-389,.,.,O
ncbi-sent-390,The,DT,O
ncbi-sent-390,other,JJ,O
ncbi-sent-390,is,VBZ,O
ncbi-sent-390,the,DT,O
ncbi-sent-390,previously,RB,O
ncbi-sent-390,described,VBN,O
ncbi-sent-390,I113F,NNP,O
ncbi-sent-390,that,WDT,O
ncbi-sent-390,produces,VBZ,O
ncbi-sent-390,a,DT,O
ncbi-sent-390,severe,JJ,O
ncbi-sent-390,phenotype,NN,O
ncbi-sent-390,.,.,O
ncbi-sent-391,The,DT,O
ncbi-sent-391,I113F,NNP,O
ncbi-sent-391,and,CC,O
ncbi-sent-391,T312S,NNP,O
ncbi-sent-391,mutations,NNS,O
ncbi-sent-391,accounted,VBD,O
ncbi-sent-391,for,IN,O
ncbi-sent-391,8,CD,O
ncbi-sent-391,(,(,O
ncbi-sent-391,18,CD,O
ncbi-sent-391,%,NN,O
ncbi-sent-391,),),O
ncbi-sent-391,and,CC,O
ncbi-sent-391,6,CD,O
ncbi-sent-391,(,(,O
ncbi-sent-391,14,CD,O
ncbi-sent-391,%,NN,O
ncbi-sent-391,),),O
ncbi-sent-391,of,IN,O
ncbi-sent-391,44,CD,O
ncbi-sent-391,unrelated,JJ,O
ncbi-sent-391,alleles,NNS,O
ncbi-sent-391,",",",",O
ncbi-sent-391,respectively,RB,O
ncbi-sent-391,.,.,O
ncbi-sent-392,The,DT,O
ncbi-sent-392,relatively,RB,O
ncbi-sent-392,high,JJ,O
ncbi-sent-392,residual,JJ,O
ncbi-sent-392,GALNS,NNP,O
ncbi-sent-392,activity,NN,O
ncbi-sent-392,seen,VBN,O
ncbi-sent-392,when,WRB,O
ncbi-sent-392,the,DT,O
ncbi-sent-392,T312S,NNP,O
ncbi-sent-392,mutant,NN,O
ncbi-sent-392,cDNA,NN,O
ncbi-sent-392,is,VBZ,O
ncbi-sent-392,overexpressed,VBN,O
ncbi-sent-392,in,IN,O
ncbi-sent-392,mutant,JJ,O
ncbi-sent-392,cells,NNS,O
ncbi-sent-392,provides,VBZ,O
ncbi-sent-392,an,DT,O
ncbi-sent-392,explanation,NN,O
ncbi-sent-392,for,IN,O
ncbi-sent-392,the,DT,O
ncbi-sent-392,mild,JJ,O
ncbi-sent-392,phenotype,NN,O
ncbi-sent-392,in,IN,O
ncbi-sent-392,patients,NNS,O
ncbi-sent-392,with,IN,O
ncbi-sent-392,this,DT,O
ncbi-sent-392,mutation,NN,O
ncbi-sent-392,.,.,O
ncbi-sent-393,The,DT,O
ncbi-sent-393,distribution,NN,O
ncbi-sent-393,and,CC,O
ncbi-sent-393,relative,JJ,O
ncbi-sent-393,frequencies,NNS,O
ncbi-sent-393,of,IN,O
ncbi-sent-393,the,DT,O
ncbi-sent-393,I113F,NNP,O
ncbi-sent-393,and,CC,O
ncbi-sent-393,T312S,NNP,O
ncbi-sent-393,mutations,NNS,O
ncbi-sent-393,in,IN,O
ncbi-sent-393,Australia,NNP,O
ncbi-sent-393,corresponded,VBD,O
ncbi-sent-393,to,TO,O
ncbi-sent-393,those,DT,O
ncbi-sent-393,observed,VBN,O
ncbi-sent-393,in,IN,O
ncbi-sent-393,Northern,NNP,O
ncbi-sent-393,Ireland,NNP,O
ncbi-sent-393,and,CC,O
ncbi-sent-393,are,VBP,O
ncbi-sent-393,unique,JJ,O
ncbi-sent-393,to,TO,O
ncbi-sent-393,these,DT,O
ncbi-sent-393,two,CD,O
ncbi-sent-393,populations,NNS,O
ncbi-sent-393,",",",",O
ncbi-sent-393,suggesting,VBG,O
ncbi-sent-393,that,IN,O
ncbi-sent-393,both,DT,O
ncbi-sent-393,mutations,NNS,O
ncbi-sent-393,were,VBD,O
ncbi-sent-393,probably,RB,O
ncbi-sent-393,introduced,VBN,O
ncbi-sent-393,to,TO,O
ncbi-sent-393,Australia,NNP,O
ncbi-sent-393,by,IN,O
ncbi-sent-393,Irish,JJ,O
ncbi-sent-393,migrants,NNS,O
ncbi-sent-393,during,IN,O
ncbi-sent-393,the,DT,O
ncbi-sent-393,19th,JJ,O
ncbi-sent-393,century,NN,O
ncbi-sent-393,.,.,O
ncbi-sent-394,Haplotype,NNP,O
ncbi-sent-394,analysis,NN,O
ncbi-sent-394,using,VBG,O
ncbi-sent-394,6,CD,O
ncbi-sent-394,RFLPs,NNP,O
ncbi-sent-394,provides,VBZ,O
ncbi-sent-394,additional,JJ,O
ncbi-sent-394,data,NNS,O
ncbi-sent-394,that,IN,O
ncbi-sent-394,the,DT,O
ncbi-sent-394,I113F,NNP,O
ncbi-sent-394,mutation,NN,O
ncbi-sent-394,originated,VBD,O
ncbi-sent-394,from,IN,O
ncbi-sent-394,a,DT,O
ncbi-sent-394,common,JJ,O
ncbi-sent-394,ancestor,NN,O
ncbi-sent-394,.,.,O
ncbi-sent-395,The,DT,O
ncbi-sent-395,other,JJ,O
ncbi-sent-395,9,CD,O
ncbi-sent-395,novel,JJ,O
ncbi-sent-395,mutations,NNS,O
ncbi-sent-395,identified,VBN,O
ncbi-sent-395,in,IN,O
ncbi-sent-395,these,DT,O
ncbi-sent-395,23,CD,O
ncbi-sent-395,patients,NNS,O
ncbi-sent-395,were,VBD,O
ncbi-sent-395,each,DT,O
ncbi-sent-395,limited,VBN,O
ncbi-sent-395,to,TO,O
ncbi-sent-395,a,DT,O
ncbi-sent-395,single,JJ,O
ncbi-sent-395,family,NN,O
ncbi-sent-395,.,.,O
ncbi-sent-396,These,DT,O
ncbi-sent-396,data,NNS,O
ncbi-sent-396,provide,VBP,O
ncbi-sent-396,further,JJ,O
ncbi-sent-396,evidence,NN,O
ncbi-sent-396,for,IN,O
ncbi-sent-396,extensive,JJ,O
ncbi-sent-396,allelic,JJ,O
ncbi-sent-396,heterogeneity,NN,O
ncbi-sent-396,in,IN,O
ncbi-sent-396,MPS,NNP,B-DISEASE
ncbi-sent-396,IVA,NNP,I-DISEASE
ncbi-sent-396,in,IN,O
ncbi-sent-396,British,NNP,O
ncbi-sent-396,-,:,O
ncbi-sent-396,Irish,JJ,O
ncbi-sent-396,patients,NNS,O
ncbi-sent-396,and,CC,O
ncbi-sent-396,provide,VB,O
ncbi-sent-396,evidence,NN,O
ncbi-sent-396,for,IN,O
ncbi-sent-396,their,PRP$,O
ncbi-sent-396,transmission,NN,O
ncbi-sent-396,to,TO,O
ncbi-sent-396,Australia,NNP,O
ncbi-sent-396,by,IN,O
ncbi-sent-396,British,NNP,O
ncbi-sent-396,-,:,O
ncbi-sent-396,Irish,JJ,O
ncbi-sent-396,migrants,NNS,O
ncbi-sent-396,.,.,O
ncbi-sent-397,.,.,O
ncbi-sent-398,Identification,NN,O
ncbi-sent-398,of,IN,O
ncbi-sent-398,constitutional,JJ,O
ncbi-sent-398,WT1,NNP,O
ncbi-sent-398,mutations,NNS,O
ncbi-sent-398,",",",",O
ncbi-sent-398,in,IN,O
ncbi-sent-398,patients,NNS,O
ncbi-sent-398,with,IN,O
ncbi-sent-398,isolated,JJ,O
ncbi-sent-398,diffuse,NN,B-DISEASE
ncbi-sent-398,mesangial,JJ,I-DISEASE
ncbi-sent-398,sclerosis,NN,I-DISEASE
ncbi-sent-398,",",",",O
ncbi-sent-398,and,CC,O
ncbi-sent-398,analysis,NN,O
ncbi-sent-398,of,IN,O
ncbi-sent-398,genotype,NN,O
ncbi-sent-398,/,NNP,O
ncbi-sent-398,phenotype,NN,O
ncbi-sent-398,correlations,NNS,O
ncbi-sent-398,by,IN,O
ncbi-sent-398,use,NN,O
ncbi-sent-398,of,IN,O
ncbi-sent-398,a,DT,O
ncbi-sent-398,computerized,JJ,O
ncbi-sent-398,mutation,NN,O
ncbi-sent-398,database,NN,O
ncbi-sent-398,.,.,O
ncbi-sent-399,Constitutional,JJ,O
ncbi-sent-399,mutations,NNS,O
ncbi-sent-399,of,IN,O
ncbi-sent-399,the,DT,O
ncbi-sent-399,WT1,NNP,O
ncbi-sent-399,gene,NN,O
ncbi-sent-399,",",",",O
ncbi-sent-399,encoding,VBG,O
ncbi-sent-399,a,DT,O
ncbi-sent-399,zinc,NN,O
ncbi-sent-399,-,:,O
ncbi-sent-399,finger,NN,O
ncbi-sent-399,transcription,NN,O
ncbi-sent-399,factor,NN,O
ncbi-sent-399,involved,VBN,O
ncbi-sent-399,in,IN,O
ncbi-sent-399,renal,JJ,O
ncbi-sent-399,and,CC,O
ncbi-sent-399,gonadal,JJ,O
ncbi-sent-399,development,NN,O
ncbi-sent-399,",",",",O
ncbi-sent-399,are,VBP,O
ncbi-sent-399,found,VBN,O
ncbi-sent-399,in,IN,O
ncbi-sent-399,most,JJS,O
ncbi-sent-399,patients,NNS,O
ncbi-sent-399,with,IN,O
ncbi-sent-399,Denys,NNP,B-DISEASE
ncbi-sent-399,-,:,I-DISEASE
ncbi-sent-399,Drash,NNP,I-DISEASE
ncbi-sent-399,syndrome,NN,I-DISEASE
ncbi-sent-399,(,(,O
ncbi-sent-399,DDS,NNP,B-DISEASE
ncbi-sent-399,),),O
ncbi-sent-399,",",",",O
ncbi-sent-399,or,CC,O
ncbi-sent-399,diffuse,VB,B-DISEASE
ncbi-sent-399,mesangial,JJ,I-DISEASE
ncbi-sent-399,sclerosis,NN,I-DISEASE
ncbi-sent-399,(,(,O
ncbi-sent-399,DMS,NNP,B-DISEASE
ncbi-sent-399,),),O
ncbi-sent-399,associated,VBN,O
ncbi-sent-399,with,IN,O
ncbi-sent-399,pseudohermaphroditism,NN,B-DISEASE
ncbi-sent-399,and,CC,O
ncbi-sent-399,/,NN,O
ncbi-sent-399,or,CC,O
ncbi-sent-399,Wilms,NNP,B-DISEASE
ncbi-sent-399,tumor,NN,I-DISEASE
ncbi-sent-399,(,(,O
ncbi-sent-399,WT,NNP,B-DISEASE
ncbi-sent-399,),),O
ncbi-sent-399,.,.,O
ncbi-sent-400,Most,JJS,O
ncbi-sent-400,mutations,NNS,O
ncbi-sent-400,in,IN,O
ncbi-sent-400,DDS,NNP,B-DISEASE
ncbi-sent-400,patients,NNS,O
ncbi-sent-400,lie,VBP,O
ncbi-sent-400,in,IN,O
ncbi-sent-400,exon,$,O
ncbi-sent-400,8,CD,O
ncbi-sent-400,or,CC,O
ncbi-sent-400,exon,VB,O
ncbi-sent-400,9,CD,O
ncbi-sent-400,",",",",O
ncbi-sent-400,encoding,VBG,O
ncbi-sent-400,zinc,NN,O
ncbi-sent-400,finger,NN,O
ncbi-sent-400,2,CD,O
ncbi-sent-400,or,CC,O
ncbi-sent-400,zinc,VB,O
ncbi-sent-400,finger,JJR,O
ncbi-sent-400,3,CD,O
ncbi-sent-400,",",",",O
ncbi-sent-400,respectively,RB,O
ncbi-sent-400,",",",",O
ncbi-sent-400,with,IN,O
ncbi-sent-400,a,DT,O
ncbi-sent-400,hot,JJ,O
ncbi-sent-400,spot,NN,O
ncbi-sent-400,(,(,O
ncbi-sent-400,R394W,NNP,O
ncbi-sent-400,),),O
ncbi-sent-400,in,IN,O
ncbi-sent-400,exon,$,O
ncbi-sent-400,9,CD,O
ncbi-sent-400,.,.,O
ncbi-sent-401,We,PRP,O
ncbi-sent-401,analyzed,VBD,O
ncbi-sent-401,a,DT,O
ncbi-sent-401,series,NN,O
ncbi-sent-401,of,IN,O
ncbi-sent-401,24,CD,O
ncbi-sent-401,patients,NNS,O
ncbi-sent-401,",",",",O
ncbi-sent-401,10,CD,O
ncbi-sent-401,with,IN,O
ncbi-sent-401,isolated,JJ,B-DISEASE
ncbi-sent-401,DMS,NNP,I-DISEASE
ncbi-sent-401,(,(,O
ncbi-sent-401,IDMS,NNP,B-DISEASE
ncbi-sent-401,),),O
ncbi-sent-401,",",",",O
ncbi-sent-401,10,CD,O
ncbi-sent-401,with,IN,O
ncbi-sent-401,DDS,NNP,B-DISEASE
ncbi-sent-401,",",",",O
ncbi-sent-401,and,CC,O
ncbi-sent-401,4,CD,O
ncbi-sent-401,with,IN,O
ncbi-sent-401,urogenital,JJ,B-DISEASE
ncbi-sent-401,abnormalities,NNS,I-DISEASE
ncbi-sent-401,and,CC,O
ncbi-sent-401,/,NN,O
ncbi-sent-401,or,CC,O
ncbi-sent-401,WT,NNP,B-DISEASE
ncbi-sent-401,.,.,O
ncbi-sent-402,We,PRP,O
ncbi-sent-402,report,VBP,O
ncbi-sent-402,WT1,NNP,O
ncbi-sent-402,heterozygous,JJ,O
ncbi-sent-402,mutations,NNS,O
ncbi-sent-402,in,IN,O
ncbi-sent-402,16,CD,O
ncbi-sent-402,patients,NNS,O
ncbi-sent-402,",",",",O
ncbi-sent-402,4,CD,O
ncbi-sent-402,of,IN,O
ncbi-sent-402,whom,WP,O
ncbi-sent-402,presented,VBN,O
ncbi-sent-402,with,IN,O
ncbi-sent-402,IDMS,NNP,B-DISEASE
ncbi-sent-402,.,.,O
ncbi-sent-403,One,CD,O
ncbi-sent-403,male,NN,O
ncbi-sent-403,and,CC,O
ncbi-sent-403,two,CD,O
ncbi-sent-403,female,JJ,O
ncbi-sent-403,IDMS,NNP,B-DISEASE
ncbi-sent-403,patients,NNS,O
ncbi-sent-403,with,IN,O
ncbi-sent-403,WT1,NNP,O
ncbi-sent-403,mutations,NNS,O
ncbi-sent-403,underwent,JJ,O
ncbi-sent-403,normal,JJ,O
ncbi-sent-403,puberty,NN,O
ncbi-sent-403,.,.,O
ncbi-sent-404,Two,CD,O
ncbi-sent-404,mutations,NNS,O
ncbi-sent-404,associated,VBN,O
ncbi-sent-404,with,IN,O
ncbi-sent-404,IDMS,NNP,B-DISEASE
ncbi-sent-404,are,VBP,O
ncbi-sent-404,different,JJ,O
ncbi-sent-404,from,IN,O
ncbi-sent-404,those,DT,O
ncbi-sent-404,described,VBN,O
ncbi-sent-404,in,IN,O
ncbi-sent-404,DDS,NNP,B-DISEASE
ncbi-sent-404,patients,NNS,O
ncbi-sent-404,.,.,O
ncbi-sent-405,No,DT,O
ncbi-sent-405,WT1,JJ,O
ncbi-sent-405,mutations,NNS,O
ncbi-sent-405,were,VBD,O
ncbi-sent-405,detected,VBN,O
ncbi-sent-405,in,IN,O
ncbi-sent-405,the,DT,O
ncbi-sent-405,six,CD,O
ncbi-sent-405,other,JJ,O
ncbi-sent-405,IDMS,NNP,B-DISEASE
ncbi-sent-405,patients,NNS,O
ncbi-sent-405,",",",",O
ncbi-sent-405,suggesting,VBG,O
ncbi-sent-405,genetic,JJ,O
ncbi-sent-405,heterogeneity,NN,O
ncbi-sent-405,of,IN,O
ncbi-sent-405,this,DT,O
ncbi-sent-405,disease,NN,O
ncbi-sent-405,.,.,O
ncbi-sent-406,We,PRP,O
ncbi-sent-406,analyzed,VBD,O
ncbi-sent-406,genotype,JJ,O
ncbi-sent-406,/,NNP,O
ncbi-sent-406,phenotype,NN,O
ncbi-sent-406,correlations,NNS,O
ncbi-sent-406,",",",",O
ncbi-sent-406,on,IN,O
ncbi-sent-406,the,DT,O
ncbi-sent-406,basis,NN,O
ncbi-sent-406,of,IN,O
ncbi-sent-406,the,DT,O
ncbi-sent-406,constitution,NN,O
ncbi-sent-406,of,IN,O
ncbi-sent-406,a,DT,O
ncbi-sent-406,WT1,NNP,O
ncbi-sent-406,mutation,NN,O
ncbi-sent-406,database,NN,O
ncbi-sent-406,of,IN,O
ncbi-sent-406,84,CD,O
ncbi-sent-406,germ,JJ,O
ncbi-sent-406,-,:,O
ncbi-sent-406,line,NN,O
ncbi-sent-406,mutations,NNS,O
ncbi-sent-406,",",",",O
ncbi-sent-406,to,TO,O
ncbi-sent-406,compare,VB,O
ncbi-sent-406,the,DT,O
ncbi-sent-406,distribution,NN,O
ncbi-sent-406,and,CC,O
ncbi-sent-406,type,NN,O
ncbi-sent-406,of,IN,O
ncbi-sent-406,mutations,NNS,O
ncbi-sent-406,",",",",O
ncbi-sent-406,according,VBG,O
ncbi-sent-406,to,TO,O
ncbi-sent-406,the,DT,O
ncbi-sent-406,different,JJ,O
ncbi-sent-406,symptoms,NNS,O
ncbi-sent-406,.,.,O
ncbi-sent-407,This,DT,O
ncbi-sent-407,demonstrated,VBD,O
ncbi-sent-407,(,(,O
ncbi-sent-407,1,CD,O
ncbi-sent-407,),),O
ncbi-sent-407,the,DT,O
ncbi-sent-407,association,NN,O
ncbi-sent-407,between,IN,O
ncbi-sent-407,mutations,NNS,O
ncbi-sent-407,in,IN,O
ncbi-sent-407,exons,NNS,O
ncbi-sent-407,8,CD,O
ncbi-sent-407,and,CC,O
ncbi-sent-407,9,CD,O
ncbi-sent-407,and,CC,O
ncbi-sent-407,DMS,NNP,B-DISEASE
ncbi-sent-407,;,:,O
ncbi-sent-407,(,(,O
ncbi-sent-407,2,CD,O
ncbi-sent-407,),),O
ncbi-sent-407,among,IN,O
ncbi-sent-407,patients,NNS,O
ncbi-sent-407,with,IN,O
ncbi-sent-407,DMS,NNP,B-DISEASE
ncbi-sent-407,",",",",O
ncbi-sent-407,a,DT,O
ncbi-sent-407,higher,JJR,O
ncbi-sent-407,frequency,NN,O
ncbi-sent-407,of,IN,O
ncbi-sent-407,exon,$,O
ncbi-sent-407,8,CD,O
ncbi-sent-407,mutations,NNS,O
ncbi-sent-407,among,IN,O
ncbi-sent-407,46,CD,O
ncbi-sent-407,",",",",O
ncbi-sent-407,XY,NN,O
ncbi-sent-407,patients,NNS,O
ncbi-sent-407,with,IN,O
ncbi-sent-407,female,JJ,O
ncbi-sent-407,phenotype,NN,O
ncbi-sent-407,than,IN,O
ncbi-sent-407,among,IN,O
ncbi-sent-407,46,CD,O
ncbi-sent-407,",",",",O
ncbi-sent-407,XY,NN,O
ncbi-sent-407,patients,NNS,O
ncbi-sent-407,with,IN,O
ncbi-sent-407,sexual,JJ,O
ncbi-sent-407,ambiguity,NN,O
ncbi-sent-407,or,CC,O
ncbi-sent-407,male,JJ,O
ncbi-sent-407,phenotype,NN,O
ncbi-sent-407,;,:,O
ncbi-sent-407,and,CC,O
ncbi-sent-407,(,(,O
ncbi-sent-407,3,CD,O
ncbi-sent-407,),),O
ncbi-sent-407,statistically,RB,O
ncbi-sent-407,significant,JJ,O
ncbi-sent-407,evidence,NN,O
ncbi-sent-407,that,IN,O
ncbi-sent-407,mutations,NNS,O
ncbi-sent-407,in,IN,O
ncbi-sent-407,exons,NNS,O
ncbi-sent-407,8,CD,O
ncbi-sent-407,and,CC,O
ncbi-sent-407,9,CD,O
ncbi-sent-407,preferentially,RB,O
ncbi-sent-407,affect,JJ,O
ncbi-sent-407,amino,NN,O
ncbi-sent-407,acids,NNS,O
ncbi-sent-407,with,IN,O
ncbi-sent-407,different,JJ,O
ncbi-sent-407,functions,NNS,O
ncbi-sent-407,.,.,O
ncbi-sent-408,.,.,O
ncbi-sent-409,The,DT,O
ncbi-sent-409,185delAG,CD,O
ncbi-sent-409,BRCA1,NNP,O
ncbi-sent-409,mutation,NN,O
ncbi-sent-409,originated,VBD,O
ncbi-sent-409,before,IN,O
ncbi-sent-409,the,DT,O
ncbi-sent-409,dispersion,NN,O
ncbi-sent-409,of,IN,O
ncbi-sent-409,Jews,NNP,O
ncbi-sent-409,in,IN,O
ncbi-sent-409,the,DT,O
ncbi-sent-409,diaspora,NN,O
ncbi-sent-409,and,CC,O
ncbi-sent-409,is,VBZ,O
ncbi-sent-409,not,RB,O
ncbi-sent-409,limited,VBN,O
ncbi-sent-409,to,TO,O
ncbi-sent-409,Ashkenazim,NNP,O
ncbi-sent-409,.,.,O
ncbi-sent-410,The,DT,O
ncbi-sent-410,185delAG,CD,O
ncbi-sent-410,mutation,NN,O
ncbi-sent-410,in,IN,O
ncbi-sent-410,BRCA1,NNP,O
ncbi-sent-410,is,VBZ,O
ncbi-sent-410,detected,VBN,O
ncbi-sent-410,in,IN,O
ncbi-sent-410,Ashkenazi,NNP,O
ncbi-sent-410,Jews,NNP,O
ncbi-sent-410,both,DT,O
ncbi-sent-410,in,IN,O
ncbi-sent-410,familial,JJ,B-DISEASE
ncbi-sent-410,breast,NN,I-DISEASE
ncbi-sent-410,and,CC,I-DISEASE
ncbi-sent-410,ovarian,JJ,I-DISEASE
ncbi-sent-410,cancer,NN,I-DISEASE
ncbi-sent-410,and,CC,O
ncbi-sent-410,in,IN,O
ncbi-sent-410,the,DT,O
ncbi-sent-410,general,JJ,O
ncbi-sent-410,population,NN,O
ncbi-sent-410,.,.,O
ncbi-sent-411,All,DT,O
ncbi-sent-411,tested,VBD,O
ncbi-sent-411,Ashkenazi,NNP,O
ncbi-sent-411,mutation,NN,O
ncbi-sent-411,carriers,NNS,O
ncbi-sent-411,share,NN,O
ncbi-sent-411,the,DT,O
ncbi-sent-411,same,JJ,O
ncbi-sent-411,allelic,JJ,O
ncbi-sent-411,pattern,NN,O
ncbi-sent-411,at,IN,O
ncbi-sent-411,the,DT,O
ncbi-sent-411,BRCA1,NNP,O
ncbi-sent-411,locus,NN,O
ncbi-sent-411,.,.,O
ncbi-sent-412,Our,PRP$,O
ncbi-sent-412,previous,JJ,O
ncbi-sent-412,study,NN,O
ncbi-sent-412,showed,VBD,O
ncbi-sent-412,that,IN,O
ncbi-sent-412,this,DT,O
ncbi-sent-412,Ashkenazi,NNP,O
ncbi-sent-412,mutation,NN,O
ncbi-sent-412,also,RB,O
ncbi-sent-412,occurs,VBZ,O
ncbi-sent-412,in,IN,O
ncbi-sent-412,Iraqi,NNP,O
ncbi-sent-412,Jews,NNP,O
ncbi-sent-412,with,IN,O
ncbi-sent-412,a,DT,O
ncbi-sent-412,similar,JJ,O
ncbi-sent-412,allelic,JJ,O
ncbi-sent-412,pattern,NN,O
ncbi-sent-412,.,.,O
ncbi-sent-413,We,PRP,O
ncbi-sent-413,extended,VBD,O
ncbi-sent-413,our,PRP$,O
ncbi-sent-413,analysis,NN,O
ncbi-sent-413,to,TO,O
ncbi-sent-413,other,JJ,O
ncbi-sent-413,non,JJ,O
ncbi-sent-413,-,:,O
ncbi-sent-413,Ashkenazi,NNP,O
ncbi-sent-413,subsets,VBZ,O
ncbi-sent-413,354,CD,O
ncbi-sent-413,of,IN,O
ncbi-sent-413,Moroccan,NNP,O
ncbi-sent-413,origin,NN,O
ncbi-sent-413,",",",",O
ncbi-sent-413,200,CD,O
ncbi-sent-413,Yemenites,NNS,O
ncbi-sent-413,and,CC,O
ncbi-sent-413,150,CD,O
ncbi-sent-413,Iranian,JJ,O
ncbi-sent-413,Jews,NNPS,O
ncbi-sent-413,.,.,O
ncbi-sent-414,Heteroduplex,NNP,O
ncbi-sent-414,analysis,NN,O
ncbi-sent-414,complemented,VBN,O
ncbi-sent-414,by,IN,O
ncbi-sent-414,direct,JJ,O
ncbi-sent-414,DNA,NNP,O
ncbi-sent-414,sequencing,NN,O
ncbi-sent-414,of,IN,O
ncbi-sent-414,abnormally,RB,O
ncbi-sent-414,migrating,VBG,O
ncbi-sent-414,bands,NNS,O
ncbi-sent-414,were,VBD,O
ncbi-sent-414,employed,VBN,O
ncbi-sent-414,.,.,O
ncbi-sent-415,Four,CD,O
ncbi-sent-415,of,IN,O
ncbi-sent-415,Moroccan,NNP,O
ncbi-sent-415,origin,NN,O
ncbi-sent-415,(,(,O
ncbi-sent-415,1,CD,O
ncbi-sent-415,.,.,O
ncbi-sent-416,1,CD,O
ncbi-sent-416,%,NN,O
ncbi-sent-416,),),O
ncbi-sent-416,and,CC,O
ncbi-sent-416,none,NN,O
ncbi-sent-416,of,IN,O
ncbi-sent-416,the,DT,O
ncbi-sent-416,Yemenites,NNS,O
ncbi-sent-416,or,CC,O
ncbi-sent-416,Iranians,NNP,O
ncbi-sent-416,was,VBD,O
ncbi-sent-416,a,DT,O
ncbi-sent-416,carrier,NN,O
ncbi-sent-416,of,IN,O
ncbi-sent-416,the,DT,O
ncbi-sent-416,185delAG,CD,O
ncbi-sent-416,mutation,NN,O
ncbi-sent-416,.,.,O
ncbi-sent-417,BRCA1,NNP,O
ncbi-sent-417,allelic,JJ,O
ncbi-sent-417,patterns,NNS,O
ncbi-sent-417,were,VBD,O
ncbi-sent-417,determined,VBN,O
ncbi-sent-417,for,IN,O
ncbi-sent-417,four,CD,O
ncbi-sent-417,of,IN,O
ncbi-sent-417,these,DT,O
ncbi-sent-417,individuals,NNS,O
ncbi-sent-417,and,CC,O
ncbi-sent-417,for,IN,O
ncbi-sent-417,12,CD,O
ncbi-sent-417,additional,JJ,O
ncbi-sent-417,non,NN,O
ncbi-sent-417,-,:,O
ncbi-sent-417,Ashkenazi,$,O
ncbi-sent-417,185delAG,CD,O
ncbi-sent-417,mutation,NN,O
ncbi-sent-417,carriers,NNS,O
ncbi-sent-417,who,WP,O
ncbi-sent-417,had,VBD,O
ncbi-sent-417,breast,VBN,B-DISEASE
ncbi-sent-417,/,JJ,I-DISEASE
ncbi-sent-417,ovarian,JJ,I-DISEASE
ncbi-sent-417,cancer,NN,I-DISEASE
ncbi-sent-417,.,.,O
ncbi-sent-418,Six,NNP,O
ncbi-sent-418,non,SYM,O
ncbi-sent-418,-,:,O
ncbi-sent-418,Ashkenazi,JJ,O
ncbi-sent-418,individuals,NNS,O
ncbi-sent-418,shared,VBD,O
ncbi-sent-418,the,DT,O
ncbi-sent-418,common,JJ,O
ncbi-sent-418,Ashkenazi,NNP,O
ncbi-sent-418,haplotype,NN,O
ncbi-sent-418,",",",",O
ncbi-sent-418,four,CD,O
ncbi-sent-418,had,VBD,O
ncbi-sent-418,a,DT,O
ncbi-sent-418,closely,RB,O
ncbi-sent-418,related,JJ,O
ncbi-sent-418,pattern,NN,O
ncbi-sent-418,",",",",O
ncbi-sent-418,and,CC,O
ncbi-sent-418,the,DT,O
ncbi-sent-418,rest,NN,O
ncbi-sent-418,(,(,O
ncbi-sent-418,n,JJ,O
ncbi-sent-418,=,NNP,O
ncbi-sent-418,6,CD,O
ncbi-sent-418,),),O
ncbi-sent-418,displayed,VBD,O
ncbi-sent-418,a,DT,O
ncbi-sent-418,distinct,JJ,O
ncbi-sent-418,BRCA1,NNP,O
ncbi-sent-418,allelic,NN,O
ncbi-sent-418,pattern,NN,O
ncbi-sent-418,.,.,O
ncbi-sent-419,We,PRP,O
ncbi-sent-419,conclude,VBP,O
ncbi-sent-419,that,IN,O
ncbi-sent-419,the,DT,O
ncbi-sent-419,185delAG,CD,O
ncbi-sent-419,BRCA1,NNP,O
ncbi-sent-419,mutation,NN,O
ncbi-sent-419,occurs,VBZ,O
ncbi-sent-419,in,IN,O
ncbi-sent-419,some,DT,O
ncbi-sent-419,non,JJ,O
ncbi-sent-419,-,:,O
ncbi-sent-419,Ashkenazi,JJ,O
ncbi-sent-419,populations,NNS,O
ncbi-sent-419,at,IN,O
ncbi-sent-419,rates,NNS,O
ncbi-sent-419,comparable,JJ,O
ncbi-sent-419,with,IN,O
ncbi-sent-419,that,DT,O
ncbi-sent-419,of,IN,O
ncbi-sent-419,Ashkenazim,NNP,O
ncbi-sent-419,.,.,O
ncbi-sent-420,The,DT,O
ncbi-sent-420,majority,NN,O
ncbi-sent-420,of,IN,O
ncbi-sent-420,Jewish,JJ,O
ncbi-sent-420,185delAG,CD,O
ncbi-sent-420,mutation,NN,O
ncbi-sent-420,carriers,NNS,O
ncbi-sent-420,have,VBP,O
ncbi-sent-420,a,DT,O
ncbi-sent-420,common,JJ,O
ncbi-sent-420,allelic,JJ,O
ncbi-sent-420,pattern,NN,O
ncbi-sent-420,",",",",O
ncbi-sent-420,supporting,VBG,O
ncbi-sent-420,the,DT,O
ncbi-sent-420,founder,NN,O
ncbi-sent-420,effect,NN,O
ncbi-sent-420,notion,NN,O
ncbi-sent-420,",",",",O
ncbi-sent-420,but,CC,O
ncbi-sent-420,dating,VBG,O
ncbi-sent-420,the,DT,O
ncbi-sent-420,mutations,NNS,O
ncbi-sent-420,origin,VBP,O
ncbi-sent-420,to,TO,O
ncbi-sent-420,an,DT,O
ncbi-sent-420,earlier,JJR,O
ncbi-sent-420,date,NN,O
ncbi-sent-420,than,IN,O
ncbi-sent-420,currently,RB,O
ncbi-sent-420,estimated,VBN,O
ncbi-sent-420,.,.,O
ncbi-sent-421,However,RB,O
ncbi-sent-421,",",",",O
ncbi-sent-421,the,DT,O
ncbi-sent-421,different,JJ,O
ncbi-sent-421,allelic,JJ,O
ncbi-sent-421,pattern,NN,O
ncbi-sent-421,at,IN,O
ncbi-sent-421,the,DT,O
ncbi-sent-421,BRCA1,NNP,O
ncbi-sent-421,locus,VBD,O
ncbi-sent-421,even,RB,O
ncbi-sent-421,in,IN,O
ncbi-sent-421,some,DT,O
ncbi-sent-421,Jewish,JJ,O
ncbi-sent-421,mutation,NN,O
ncbi-sent-421,carriers,NNS,O
ncbi-sent-421,",",",",O
ncbi-sent-421,might,MD,O
ncbi-sent-421,suggest,VB,O
ncbi-sent-421,that,IN,O
ncbi-sent-421,the,DT,O
ncbi-sent-421,mutation,NN,O
ncbi-sent-421,arose,VBD,O
ncbi-sent-421,independently,RB,O
ncbi-sent-421,.,.,O
ncbi-sent-422,.,.,O
ncbi-sent-423,Crystal,JJ,O
ncbi-sent-423,structure,NN,O
ncbi-sent-423,of,IN,O
ncbi-sent-423,the,DT,O
ncbi-sent-423,hemochromatosis,NN,B-DISEASE
ncbi-sent-423,protein,NN,O
ncbi-sent-423,HFE,NNP,O
ncbi-sent-423,and,CC,O
ncbi-sent-423,characterization,NN,O
ncbi-sent-423,of,IN,O
ncbi-sent-423,its,PRP$,O
ncbi-sent-423,interaction,NN,O
ncbi-sent-423,with,IN,O
ncbi-sent-423,transferrin,JJ,O
ncbi-sent-423,receptor,NN,O
ncbi-sent-423,.,.,O
ncbi-sent-424,HFE,NNP,O
ncbi-sent-424,is,VBZ,O
ncbi-sent-424,an,DT,O
ncbi-sent-424,MHC,NNP,O
ncbi-sent-424,-,:,O
ncbi-sent-424,related,JJ,O
ncbi-sent-424,protein,NN,O
ncbi-sent-424,that,WDT,O
ncbi-sent-424,is,VBZ,O
ncbi-sent-424,mutated,VBN,O
ncbi-sent-424,in,IN,O
ncbi-sent-424,the,DT,O
ncbi-sent-424,iron,NN,B-DISEASE
ncbi-sent-424,-,:,I-DISEASE
ncbi-sent-424,overload,NN,I-DISEASE
ncbi-sent-424,disease,NN,I-DISEASE
ncbi-sent-424,hereditary,JJ,B-DISEASE
ncbi-sent-424,hemochromatosis,NN,I-DISEASE
ncbi-sent-424,.,.,O
ncbi-sent-425,HFE,NNP,O
ncbi-sent-425,binds,VBZ,O
ncbi-sent-425,to,TO,O
ncbi-sent-425,transferrin,VB,O
ncbi-sent-425,receptor,NN,O
ncbi-sent-425,(,(,O
ncbi-sent-425,TfR,NNP,O
ncbi-sent-425,),),O
ncbi-sent-425,and,CC,O
ncbi-sent-425,reduces,VBZ,O
ncbi-sent-425,its,PRP$,O
ncbi-sent-425,affinity,NN,O
ncbi-sent-425,for,IN,O
ncbi-sent-425,iron,NN,O
ncbi-sent-425,-,:,O
ncbi-sent-425,loaded,JJ,O
ncbi-sent-425,transferrin,NN,O
ncbi-sent-425,",",",",O
ncbi-sent-425,implicating,VBG,O
ncbi-sent-425,HFE,NNP,O
ncbi-sent-425,in,IN,O
ncbi-sent-425,iron,NN,O
ncbi-sent-425,metabolism,NN,O
ncbi-sent-425,.,.,O
ncbi-sent-426,The,DT,O
ncbi-sent-426,2,CD,O
ncbi-sent-426,.,.,O
ncbi-sent-427,6,CD,O
ncbi-sent-427,A,NNP,O
ncbi-sent-427,crystal,JJ,O
ncbi-sent-427,structure,NN,O
ncbi-sent-427,of,IN,O
ncbi-sent-427,HFE,NNP,O
ncbi-sent-427,reveals,VBZ,O
ncbi-sent-427,the,DT,O
ncbi-sent-427,locations,NNS,O
ncbi-sent-427,of,IN,O
ncbi-sent-427,hemochromatosis,NN,B-DISEASE
ncbi-sent-427,mutations,NNS,O
ncbi-sent-427,and,CC,O
ncbi-sent-427,a,DT,O
ncbi-sent-427,patch,NN,O
ncbi-sent-427,of,IN,O
ncbi-sent-427,histidines,NNS,O
ncbi-sent-427,that,WDT,O
ncbi-sent-427,could,MD,O
ncbi-sent-427,be,VB,O
ncbi-sent-427,involved,VBN,O
ncbi-sent-427,in,IN,O
ncbi-sent-427,pH,JJ,O
ncbi-sent-427,-,:,O
ncbi-sent-427,dependent,JJ,O
ncbi-sent-427,interactions,NNS,O
ncbi-sent-427,.,.,O
ncbi-sent-428,We,PRP,O
ncbi-sent-428,also,RB,O
ncbi-sent-428,demonstrate,VBP,O
ncbi-sent-428,that,IN,O
ncbi-sent-428,soluble,JJ,O
ncbi-sent-428,TfR,NNP,O
ncbi-sent-428,and,CC,O
ncbi-sent-428,HFE,NNP,O
ncbi-sent-428,bind,VBP,O
ncbi-sent-428,tightly,RB,O
ncbi-sent-428,at,IN,O
ncbi-sent-428,the,DT,O
ncbi-sent-428,basic,JJ,O
ncbi-sent-428,pH,NN,O
ncbi-sent-428,of,IN,O
ncbi-sent-428,the,DT,O
ncbi-sent-428,cell,NN,O
ncbi-sent-428,surface,NN,O
ncbi-sent-428,",",",",O
ncbi-sent-428,but,CC,O
ncbi-sent-428,not,RB,O
ncbi-sent-428,at,IN,O
ncbi-sent-428,the,DT,O
ncbi-sent-428,acidic,JJ,O
ncbi-sent-428,pH,NN,O
ncbi-sent-428,of,IN,O
ncbi-sent-428,intracellular,JJ,O
ncbi-sent-428,vesicles,NNS,O
ncbi-sent-428,.,.,O
ncbi-sent-429,TfR,NNP,O
ncbi-sent-429,HFE,NNP,O
ncbi-sent-429,stoichiometry,NN,O
ncbi-sent-429,(,(,O
ncbi-sent-429,2,CD,O
ncbi-sent-429,1,CD,O
ncbi-sent-429,),),O
ncbi-sent-429,differs,NNS,O
ncbi-sent-429,from,IN,O
ncbi-sent-429,TfR,NNP,O
ncbi-sent-429,transferrin,NN,O
ncbi-sent-429,stoichiometry,NN,O
ncbi-sent-429,(,(,O
ncbi-sent-429,2,CD,O
ncbi-sent-429,2,CD,O
ncbi-sent-429,),),O
ncbi-sent-429,",",",",O
ncbi-sent-429,implying,VBG,O
ncbi-sent-429,a,DT,O
ncbi-sent-429,different,JJ,O
ncbi-sent-429,mode,NN,O
ncbi-sent-429,of,IN,O
ncbi-sent-429,binding,VBG,O
ncbi-sent-429,for,IN,O
ncbi-sent-429,HFE,NNP,O
ncbi-sent-429,and,CC,O
ncbi-sent-429,transferrin,NN,O
ncbi-sent-429,to,TO,O
ncbi-sent-429,TfR,NNP,O
ncbi-sent-429,",",",",O
ncbi-sent-429,consistent,NN,O
ncbi-sent-429,with,IN,O
ncbi-sent-429,our,PRP$,O
ncbi-sent-429,demonstration,NN,O
ncbi-sent-429,that,IN,O
ncbi-sent-429,HFE,NNP,O
ncbi-sent-429,",",",",O
ncbi-sent-429,transferrin,NN,O
ncbi-sent-429,",",",",O
ncbi-sent-429,and,CC,O
ncbi-sent-429,TfR,NNP,O
ncbi-sent-429,form,VBP,O
ncbi-sent-429,a,DT,O
ncbi-sent-429,ternary,JJ,O
ncbi-sent-429,complex,NN,O
ncbi-sent-429,.,.,O
ncbi-sent-430,Identification,NN,O
ncbi-sent-430,of,IN,O
ncbi-sent-430,three,CD,O
ncbi-sent-430,novel,JJ,O
ncbi-sent-430,mutations,NNS,O
ncbi-sent-430,and,CC,O
ncbi-sent-430,a,DT,O
ncbi-sent-430,high,JJ,O
ncbi-sent-430,frequency,NN,O
ncbi-sent-430,of,IN,O
ncbi-sent-430,the,DT,O
ncbi-sent-430,Arg778Leu,NNP,O
ncbi-sent-430,mutation,NN,O
ncbi-sent-430,in,IN,O
ncbi-sent-430,Korean,JJ,O
ncbi-sent-430,patients,NNS,O
ncbi-sent-430,with,IN,O
ncbi-sent-430,Wilson,NNP,B-DISEASE
ncbi-sent-430,disease,NN,I-DISEASE
ncbi-sent-430,.,.,O
ncbi-sent-431,Four,CD,O
ncbi-sent-431,mutations,NNS,O
ncbi-sent-431,-,:,O
ncbi-sent-431,-,:,O
ncbi-sent-431,R778L,NN,O
ncbi-sent-431,",",",",O
ncbi-sent-431,A874V,NNP,O
ncbi-sent-431,",",",",O
ncbi-sent-431,L1083F,NNP,O
ncbi-sent-431,",",",",O
ncbi-sent-431,and,CC,O
ncbi-sent-431,2304delC,CD,O
ncbi-sent-431,-,:,O
ncbi-sent-431,-,:,O
ncbi-sent-431,in,IN,O
ncbi-sent-431,the,DT,O
ncbi-sent-431,copper,NN,O
ncbi-sent-431,-,:,O
ncbi-sent-431,transporting,NN,O
ncbi-sent-431,enzyme,NN,O
ncbi-sent-431,",",",",O
ncbi-sent-431,P,NNP,O
ncbi-sent-431,-,:,O
ncbi-sent-431,type,NN,O
ncbi-sent-431,ATPase,NNP,O
ncbi-sent-431,(,(,O
ncbi-sent-431,ATP7B,NNP,O
ncbi-sent-431,),),O
ncbi-sent-431,",",",",O
ncbi-sent-431,were,VBD,O
ncbi-sent-431,identified,VBN,O
ncbi-sent-431,in,IN,O
ncbi-sent-431,Korean,JJ,O
ncbi-sent-431,Patients,NNS,O
ncbi-sent-431,with,IN,O
ncbi-sent-431,Wilson,NNP,B-DISEASE
ncbi-sent-431,disease,NN,I-DISEASE
ncbi-sent-431,.,.,O
ncbi-sent-432,Arg778Leu,NNP,O
ncbi-sent-432,",",",",O
ncbi-sent-432,the,DT,O
ncbi-sent-432,most,RBS,O
ncbi-sent-432,frequently,RB,O
ncbi-sent-432,reported,VBN,O
ncbi-sent-432,mutation,NN,O
ncbi-sent-432,of,IN,O
ncbi-sent-432,this,DT,O
ncbi-sent-432,enzyme,NN,O
ncbi-sent-432,",",",",O
ncbi-sent-432,was,VBD,O
ncbi-sent-432,found,VBN,O
ncbi-sent-432,in,IN,O
ncbi-sent-432,six,CD,O
ncbi-sent-432,of,IN,O
ncbi-sent-432,eight,CD,O
ncbi-sent-432,unrelated,JJ,O
ncbi-sent-432,patients,NNS,O
ncbi-sent-432,studied,VBN,O
ncbi-sent-432,",",",",O
ncbi-sent-432,an,DT,O
ncbi-sent-432,allele,JJ,O
ncbi-sent-432,frequency,NN,O
ncbi-sent-432,of,IN,O
ncbi-sent-432,37,CD,O
ncbi-sent-432,.,.,O
ncbi-sent-433,5,CD,O
ncbi-sent-433,%,NN,O
ncbi-sent-433,",",",",O
ncbi-sent-433,which,WDT,O
ncbi-sent-433,is,VBZ,O
ncbi-sent-433,considerably,RB,O
ncbi-sent-433,higher,JJR,O
ncbi-sent-433,than,IN,O
ncbi-sent-433,those,DT,O
ncbi-sent-433,in,IN,O
ncbi-sent-433,other,JJ,O
ncbi-sent-433,Asian,JJ,O
ncbi-sent-433,populations,NNS,O
ncbi-sent-433,.,.,O
ncbi-sent-434,The,DT,O
ncbi-sent-434,novel,JJ,O
ncbi-sent-434,single,JJ,O
ncbi-sent-434,nucleotide,NN,O
ncbi-sent-434,deletion,NN,O
ncbi-sent-434,",",",",O
ncbi-sent-434,2304delC,CD,O
ncbi-sent-434,",",",",O
ncbi-sent-434,was,VBD,O
ncbi-sent-434,found,VBN,O
ncbi-sent-434,in,IN,O
ncbi-sent-434,one,CD,O
ncbi-sent-434,patient,NN,O
ncbi-sent-434,.,.,O
ncbi-sent-435,Since,IN,O
ncbi-sent-435,a,DT,O
ncbi-sent-435,mutation,NN,O
ncbi-sent-435,at,IN,O
ncbi-sent-435,cDNA,NN,O
ncbi-sent-435,nucleotide,NN,O
ncbi-sent-435,2302,CD,O
ncbi-sent-435,(,(,O
ncbi-sent-435,2302insC,CD,O
ncbi-sent-435,),),O
ncbi-sent-435,had,VBD,O
ncbi-sent-435,been,VBN,O
ncbi-sent-435,previously,RB,O
ncbi-sent-435,described,VBN,O
ncbi-sent-435,",",",",O
ncbi-sent-435,this,DT,O
ncbi-sent-435,region,NN,O
ncbi-sent-435,of,IN,O
ncbi-sent-435,the,DT,O
ncbi-sent-435,ATP7B,NNP,O
ncbi-sent-435,gene,NN,O
ncbi-sent-435,may,MD,O
ncbi-sent-435,be,VB,O
ncbi-sent-435,susceptible,JJ,O
ncbi-sent-435,to,TO,O
ncbi-sent-435,gene,NN,O
ncbi-sent-435,rearrangements,NNS,O
ncbi-sent-435,causing,VBG,O
ncbi-sent-435,Wilson,NNP,B-DISEASE
ncbi-sent-435,disease,NN,I-DISEASE
ncbi-sent-435,.,.,O
ncbi-sent-436,Disruption,NN,O
ncbi-sent-436,of,IN,O
ncbi-sent-436,splicing,VBG,O
ncbi-sent-436,regulated,VBN,O
ncbi-sent-436,by,IN,O
ncbi-sent-436,a,DT,O
ncbi-sent-436,CUG,NNP,O
ncbi-sent-436,-,:,O
ncbi-sent-436,binding,VBG,O
ncbi-sent-436,protein,NN,O
ncbi-sent-436,in,IN,O
ncbi-sent-436,myotonic,JJ,B-DISEASE
ncbi-sent-436,dystrophy,NN,I-DISEASE
ncbi-sent-436,.,.,O
ncbi-sent-437,Myotonic,JJ,B-DISEASE
ncbi-sent-437,dystrophy,NN,I-DISEASE
ncbi-sent-437,(,(,O
ncbi-sent-437,DM,NNP,B-DISEASE
ncbi-sent-437,),),O
ncbi-sent-437,is,VBZ,O
ncbi-sent-437,caused,VBN,O
ncbi-sent-437,by,IN,O
ncbi-sent-437,a,DT,O
ncbi-sent-437,CTG,NNP,O
ncbi-sent-437,expansion,NN,O
ncbi-sent-437,in,IN,O
ncbi-sent-437,the,DT,O
ncbi-sent-437,3,CD,O
ncbi-sent-437,untranslated,JJ,O
ncbi-sent-437,region,NN,O
ncbi-sent-437,of,IN,O
ncbi-sent-437,the,DT,O
ncbi-sent-437,DM,NNP,B-DISEASE
ncbi-sent-437,gene,NN,O
ncbi-sent-437,.,.,O
ncbi-sent-438,One,CD,O
ncbi-sent-438,model,NN,O
ncbi-sent-438,of,IN,O
ncbi-sent-438,DM,NNP,B-DISEASE
ncbi-sent-438,pathogenesis,NN,O
ncbi-sent-438,suggests,VBZ,O
ncbi-sent-438,that,IN,O
ncbi-sent-438,RNAs,NNP,O
ncbi-sent-438,from,IN,O
ncbi-sent-438,the,DT,O
ncbi-sent-438,expanded,VBN,O
ncbi-sent-438,allele,NN,O
ncbi-sent-438,create,VB,O
ncbi-sent-438,a,DT,O
ncbi-sent-438,gain,NN,O
ncbi-sent-438,-,:,O
ncbi-sent-438,of,IN,O
ncbi-sent-438,-,:,O
ncbi-sent-438,function,NN,O
ncbi-sent-438,mutation,NN,O
ncbi-sent-438,by,IN,O
ncbi-sent-438,the,DT,O
ncbi-sent-438,inappropriate,JJ,O
ncbi-sent-438,binding,NN,O
ncbi-sent-438,of,IN,O
ncbi-sent-438,proteins,NNS,O
ncbi-sent-438,to,TO,O
ncbi-sent-438,the,DT,O
ncbi-sent-438,CUG,NNP,O
ncbi-sent-438,repeats,NNS,O
ncbi-sent-438,.,.,O
ncbi-sent-439,Data,NNP,O
ncbi-sent-439,presented,VBD,O
ncbi-sent-439,here,RB,O
ncbi-sent-439,indicate,JJ,O
ncbi-sent-439,that,IN,O
ncbi-sent-439,the,DT,O
ncbi-sent-439,conserved,VBN,O
ncbi-sent-439,heterogeneous,JJ,O
ncbi-sent-439,nuclear,JJ,O
ncbi-sent-439,ribonucleoprotein,NN,O
ncbi-sent-439,",",",",O
ncbi-sent-439,CUG,NNP,O
ncbi-sent-439,-,:,O
ncbi-sent-439,binding,NN,O
ncbi-sent-439,protein,NN,O
ncbi-sent-439,(,(,O
ncbi-sent-439,CUG,NNP,O
ncbi-sent-439,-,:,O
ncbi-sent-439,BP,NNP,O
ncbi-sent-439,),),O
ncbi-sent-439,",",",",O
ncbi-sent-439,may,MD,O
ncbi-sent-439,mediate,VB,O
ncbi-sent-439,the,DT,O
ncbi-sent-439,trans,NNS,O
ncbi-sent-439,-,:,O
ncbi-sent-439,dominant,JJ,O
ncbi-sent-439,effect,NN,O
ncbi-sent-439,of,IN,O
ncbi-sent-439,the,DT,O
ncbi-sent-439,RNA,NNP,O
ncbi-sent-439,.,.,O
ncbi-sent-440,CUG,NNP,O
ncbi-sent-440,-,:,O
ncbi-sent-440,BP,NNP,O
ncbi-sent-440,was,VBD,O
ncbi-sent-440,found,VBN,O
ncbi-sent-440,to,TO,O
ncbi-sent-440,bind,VB,O
ncbi-sent-440,to,TO,O
ncbi-sent-440,the,DT,O
ncbi-sent-440,human,JJ,O
ncbi-sent-440,cardiac,JJ,O
ncbi-sent-440,troponin,NN,O
ncbi-sent-440,T,NNP,O
ncbi-sent-440,(,(,O
ncbi-sent-440,cTNT,NN,O
ncbi-sent-440,),),O
ncbi-sent-440,pre,VBZ,O
ncbi-sent-440,-,:,O
ncbi-sent-440,messenger,NN,O
ncbi-sent-440,RNA,NNP,O
ncbi-sent-440,and,CC,O
ncbi-sent-440,regulate,VB,O
ncbi-sent-440,its,PRP$,O
ncbi-sent-440,alternative,JJ,O
ncbi-sent-440,splicing,NN,O
ncbi-sent-440,.,.,O
ncbi-sent-441,Splicing,VBG,O
ncbi-sent-441,of,IN,O
ncbi-sent-441,cTNT,NN,O
ncbi-sent-441,was,VBD,O
ncbi-sent-441,disrupted,VBN,O
ncbi-sent-441,in,IN,O
ncbi-sent-441,DM,NNP,B-DISEASE
ncbi-sent-441,striated,VBD,O
ncbi-sent-441,muscle,NN,O
ncbi-sent-441,and,CC,O
ncbi-sent-441,in,IN,O
ncbi-sent-441,normal,JJ,O
ncbi-sent-441,cells,NNS,O
ncbi-sent-441,expressing,VBG,O
ncbi-sent-441,transcripts,NNS,O
ncbi-sent-441,that,WDT,O
ncbi-sent-441,contain,VBP,O
ncbi-sent-441,CUG,NNP,O
ncbi-sent-441,repeats,NNS,O
ncbi-sent-441,.,.,O
ncbi-sent-442,Altered,NNP,O
ncbi-sent-442,expression,NN,O
ncbi-sent-442,of,IN,O
ncbi-sent-442,genes,NNS,O
ncbi-sent-442,regulated,VBN,O
ncbi-sent-442,posttranscriptionally,RB,O
ncbi-sent-442,by,IN,O
ncbi-sent-442,CUG,NNP,O
ncbi-sent-442,-,:,O
ncbi-sent-442,BP,NNP,O
ncbi-sent-442,therefore,NN,O
ncbi-sent-442,may,MD,O
ncbi-sent-442,contribute,VB,O
ncbi-sent-442,to,TO,O
ncbi-sent-442,DM,NNP,B-DISEASE
ncbi-sent-442,pathogenesis,NN,O
ncbi-sent-442,.,.,O
ncbi-sent-443,.,.,O
ncbi-sent-444,Identification,NN,O
ncbi-sent-444,of,IN,O
ncbi-sent-444,a,DT,O
ncbi-sent-444,novel,JJ,O
ncbi-sent-444,nonsense,JJ,O
ncbi-sent-444,mutation,NN,O
ncbi-sent-444,and,CC,O
ncbi-sent-444,a,DT,O
ncbi-sent-444,missense,JJ,O
ncbi-sent-444,substitution,NN,O
ncbi-sent-444,in,IN,O
ncbi-sent-444,the,DT,O
ncbi-sent-444,vasopressin,NN,O
ncbi-sent-444,-,:,O
ncbi-sent-444,neurophysin,NN,O
ncbi-sent-444,II,NNP,O
ncbi-sent-444,gene,NN,O
ncbi-sent-444,in,IN,O
ncbi-sent-444,two,CD,O
ncbi-sent-444,Spanish,JJ,O
ncbi-sent-444,kindreds,NNS,O
ncbi-sent-444,with,IN,O
ncbi-sent-444,familial,JJ,B-DISEASE
ncbi-sent-444,neurohypophyseal,NN,I-DISEASE
ncbi-sent-444,diabetes,VBZ,I-DISEASE
ncbi-sent-444,insipidus,RB,I-DISEASE
ncbi-sent-444,.,.,O
ncbi-sent-445,Familial,JJ,B-DISEASE
ncbi-sent-445,neurohypophyseal,JJ,I-DISEASE
ncbi-sent-445,diabetes,NNS,I-DISEASE
ncbi-sent-445,insipidus,VBP,I-DISEASE
ncbi-sent-445,(,(,O
ncbi-sent-445,FNDI,NNP,B-DISEASE
ncbi-sent-445,),),O
ncbi-sent-445,is,VBZ,O
ncbi-sent-445,an,DT,O
ncbi-sent-445,autosomal,JJ,B-DISEASE
ncbi-sent-445,dominant,JJ,I-DISEASE
ncbi-sent-445,disease,NN,I-DISEASE
ncbi-sent-445,caused,VBN,O
ncbi-sent-445,by,IN,O
ncbi-sent-445,deficiency,NN,O
ncbi-sent-445,in,IN,O
ncbi-sent-445,the,DT,O
ncbi-sent-445,antidiuretic,JJ,O
ncbi-sent-445,hormone,NN,O
ncbi-sent-445,arginine,NN,O
ncbi-sent-445,vasopressin,NN,O
ncbi-sent-445,(,(,O
ncbi-sent-445,AVP,NNP,O
ncbi-sent-445,),),O
ncbi-sent-445,encoded,VBN,O
ncbi-sent-445,by,IN,O
ncbi-sent-445,the,DT,O
ncbi-sent-445,AVP,NNP,O
ncbi-sent-445,-,:,O
ncbi-sent-445,neurophysin,NN,O
ncbi-sent-445,II,NNP,O
ncbi-sent-445,(,(,O
ncbi-sent-445,AVP,NNP,O
ncbi-sent-445,-,:,O
ncbi-sent-445,NPII,NN,O
ncbi-sent-445,),),O
ncbi-sent-445,gene,NN,O
ncbi-sent-445,on,IN,O
ncbi-sent-445,chromosome,NN,O
ncbi-sent-445,20p13,CD,O
ncbi-sent-445,.,.,O
ncbi-sent-446,In,IN,O
ncbi-sent-446,this,DT,O
ncbi-sent-446,study,NN,O
ncbi-sent-446,",",",",O
ncbi-sent-446,we,PRP,O
ncbi-sent-446,analyzed,VBD,O
ncbi-sent-446,two,CD,O
ncbi-sent-446,families,NNS,O
ncbi-sent-446,with,IN,O
ncbi-sent-446,FNDI,NNP,B-DISEASE
ncbi-sent-446,using,VBG,O
ncbi-sent-446,direct,JJ,O
ncbi-sent-446,automated,VBN,O
ncbi-sent-446,fluorescent,NN,O
ncbi-sent-446,",",",",O
ncbi-sent-446,solid,JJ,O
ncbi-sent-446,phase,NN,O
ncbi-sent-446,",",",",O
ncbi-sent-446,single,JJ,O
ncbi-sent-446,-,:,O
ncbi-sent-446,stranded,VBD,O
ncbi-sent-446,DNA,NNP,O
ncbi-sent-446,sequencing,NN,O
ncbi-sent-446,of,IN,O
ncbi-sent-446,PCR,NNP,O
ncbi-sent-446,-,:,O
ncbi-sent-446,amplified,VBD,O
ncbi-sent-446,AVP,NNP,O
ncbi-sent-446,-,:,O
ncbi-sent-446,NPII,NNP,O
ncbi-sent-446,DNA,NNP,O
ncbi-sent-446,.,.,O
ncbi-sent-447,In,IN,O
ncbi-sent-447,one,CD,O
ncbi-sent-447,of,IN,O
ncbi-sent-447,the,DT,O
ncbi-sent-447,families,NNS,O
ncbi-sent-447,",",",",O
ncbi-sent-447,affected,JJ,O
ncbi-sent-447,individuals,NNS,O
ncbi-sent-447,presented,VBD,O
ncbi-sent-447,a,DT,O
ncbi-sent-447,novel,JJ,O
ncbi-sent-447,nonsense,JJ,O
ncbi-sent-447,mutation,NN,O
ncbi-sent-447,in,IN,O
ncbi-sent-447,exon,JJ,O
ncbi-sent-447,3,CD,O
ncbi-sent-447,of,IN,O
ncbi-sent-447,the,DT,O
ncbi-sent-447,gene,NN,O
ncbi-sent-447,",",",",O
ncbi-sent-447,consisting,VBG,O
ncbi-sent-447,in,IN,O
ncbi-sent-447,a,DT,O
ncbi-sent-447,G,NNP,O
ncbi-sent-447,to,TO,O
ncbi-sent-447,T,VB,O
ncbi-sent-447,transition,NN,O
ncbi-sent-447,at,IN,O
ncbi-sent-447,nucleotide,JJ,O
ncbi-sent-447,2101,CD,O
ncbi-sent-447,",",",",O
ncbi-sent-447,which,WDT,O
ncbi-sent-447,produces,VBZ,O
ncbi-sent-447,a,DT,O
ncbi-sent-447,stop,JJ,O
ncbi-sent-447,signal,NN,O
ncbi-sent-447,in,IN,O
ncbi-sent-447,codon,NN,O
ncbi-sent-447,82,CD,O
ncbi-sent-447,(,(,O
ncbi-sent-447,Glu,NNP,O
ncbi-sent-447,),),O
ncbi-sent-447,of,IN,O
ncbi-sent-447,NPII,NNP,O
ncbi-sent-447,.,.,O
ncbi-sent-448,The,DT,O
ncbi-sent-448,premature,NN,O
ncbi-sent-448,termination,NN,O
ncbi-sent-448,eliminates,VBZ,O
ncbi-sent-448,part,NN,O
ncbi-sent-448,of,IN,O
ncbi-sent-448,the,DT,O
ncbi-sent-448,C,NNP,O
ncbi-sent-448,-,:,O
ncbi-sent-448,terminal,JJ,O
ncbi-sent-448,domain,NN,O
ncbi-sent-448,of,IN,O
ncbi-sent-448,NPII,NNP,O
ncbi-sent-448,",",",",O
ncbi-sent-448,including,VBG,O
ncbi-sent-448,a,DT,O
ncbi-sent-448,cysteine,NN,O
ncbi-sent-448,residue,NN,O
ncbi-sent-448,in,IN,O
ncbi-sent-448,position,NN,O
ncbi-sent-448,85,CD,O
ncbi-sent-448,",",",",O
ncbi-sent-448,which,WDT,O
ncbi-sent-448,could,MD,O
ncbi-sent-448,be,VB,O
ncbi-sent-448,involved,VBN,O
ncbi-sent-448,in,IN,O
ncbi-sent-448,the,DT,O
ncbi-sent-448,correct,JJ,O
ncbi-sent-448,folding,NN,O
ncbi-sent-448,of,IN,O
ncbi-sent-448,the,DT,O
ncbi-sent-448,prohormone,NN,O
ncbi-sent-448,.,.,O
ncbi-sent-449,In,IN,O
ncbi-sent-449,the,DT,O
ncbi-sent-449,second,JJ,O
ncbi-sent-449,family,NN,O
ncbi-sent-449,",",",",O
ncbi-sent-449,a,DT,O
ncbi-sent-449,G279A,NNP,O
ncbi-sent-449,substitution,NN,O
ncbi-sent-449,at,IN,O
ncbi-sent-449,position,NN,O
ncbi-sent-449,-,:,O
ncbi-sent-449,1,CD,O
ncbi-sent-449,of,IN,O
ncbi-sent-449,the,DT,O
ncbi-sent-449,signal,JJ,O
ncbi-sent-449,peptide,NN,O
ncbi-sent-449,was,VBD,O
ncbi-sent-449,observed,VBN,O
ncbi-sent-449,in,IN,O
ncbi-sent-449,all,DT,O
ncbi-sent-449,affected,JJ,O
ncbi-sent-449,individuals,NNS,O
ncbi-sent-449,.,.,O
ncbi-sent-450,This,DT,O
ncbi-sent-450,missense,JJ,O
ncbi-sent-450,mutation,NN,O
ncbi-sent-450,",",",",O
ncbi-sent-450,which,WDT,O
ncbi-sent-450,replaces,VBZ,O
ncbi-sent-450,Ala,NNP,O
ncbi-sent-450,with,IN,O
ncbi-sent-450,Thr,NNP,O
ncbi-sent-450,",",",",O
ncbi-sent-450,is,VBZ,O
ncbi-sent-450,frequent,JJ,O
ncbi-sent-450,among,IN,O
ncbi-sent-450,FNDI,JJ,B-DISEASE
ncbi-sent-450,patients,NNS,O
ncbi-sent-450,and,CC,O
ncbi-sent-450,is,VBZ,O
ncbi-sent-450,thought,VBN,O
ncbi-sent-450,to,TO,O
ncbi-sent-450,reduce,VB,O
ncbi-sent-450,the,DT,O
ncbi-sent-450,efficiency,NN,O
ncbi-sent-450,of,IN,O
ncbi-sent-450,cleavage,NN,O
ncbi-sent-450,by,IN,O
ncbi-sent-450,signal,JJ,O
ncbi-sent-450,peptidases,NNS,O
ncbi-sent-450,.,.,O
ncbi-sent-451,.,.,O
ncbi-sent-452,Genetic,JJ,O
ncbi-sent-452,heterogeneity,NN,O
ncbi-sent-452,of,IN,O
ncbi-sent-452,Saethre,NNP,B-DISEASE
ncbi-sent-452,-,:,I-DISEASE
ncbi-sent-452,Chotzen,NNP,I-DISEASE
ncbi-sent-452,syndrome,NN,I-DISEASE
ncbi-sent-452,",",",",O
ncbi-sent-452,due,JJ,O
ncbi-sent-452,to,TO,O
ncbi-sent-452,TWIST,NNP,O
ncbi-sent-452,and,CC,O
ncbi-sent-452,FGFR,NNP,O
ncbi-sent-452,mutations,NNS,O
ncbi-sent-452,.,.,O
ncbi-sent-453,Thirty,NNP,O
ncbi-sent-453,-,:,O
ncbi-sent-453,two,CD,O
ncbi-sent-453,unrelated,JJ,O
ncbi-sent-453,patients,NNS,O
ncbi-sent-453,with,IN,O
ncbi-sent-453,features,NNS,O
ncbi-sent-453,of,IN,O
ncbi-sent-453,Saethre,NNP,B-DISEASE
ncbi-sent-453,-,:,I-DISEASE
ncbi-sent-453,Chotzen,NNP,I-DISEASE
ncbi-sent-453,syndrome,NN,I-DISEASE
ncbi-sent-453,",",",",O
ncbi-sent-453,a,DT,O
ncbi-sent-453,common,JJ,O
ncbi-sent-453,autosomal,JJ,B-DISEASE
ncbi-sent-453,dominant,JJ,I-DISEASE
ncbi-sent-453,condition,NN,I-DISEASE
ncbi-sent-453,of,IN,O
ncbi-sent-453,craniosynostosis,NN,B-DISEASE
ncbi-sent-453,and,CC,O
ncbi-sent-453,limb,NN,B-DISEASE
ncbi-sent-453,anomalies,NNS,I-DISEASE
ncbi-sent-453,",",",",O
ncbi-sent-453,were,VBD,O
ncbi-sent-453,screened,VBN,O
ncbi-sent-453,for,IN,O
ncbi-sent-453,mutations,NNS,O
ncbi-sent-453,in,IN,O
ncbi-sent-453,TWIST,NNP,O
ncbi-sent-453,",",",",O
ncbi-sent-453,FGFR2,NNP,O
ncbi-sent-453,",",",",O
ncbi-sent-453,and,CC,O
ncbi-sent-453,FGFR3,NNP,O
ncbi-sent-453,.,.,O
ncbi-sent-454,Nine,NNP,O
ncbi-sent-454,novel,NN,O
ncbi-sent-454,and,CC,O
ncbi-sent-454,three,CD,O
ncbi-sent-454,recurrent,NN,O
ncbi-sent-454,TWIST,NNP,O
ncbi-sent-454,mutations,NNS,O
ncbi-sent-454,were,VBD,O
ncbi-sent-454,found,VBN,O
ncbi-sent-454,in,IN,O
ncbi-sent-454,12,CD,O
ncbi-sent-454,families,NNS,O
ncbi-sent-454,.,.,O
ncbi-sent-455,Seven,JJ,O
ncbi-sent-455,families,NNS,O
ncbi-sent-455,were,VBD,O
ncbi-sent-455,found,VBN,O
ncbi-sent-455,to,TO,O
ncbi-sent-455,have,VB,O
ncbi-sent-455,the,DT,O
ncbi-sent-455,FGFR3,NNP,O
ncbi-sent-455,P250R,NNP,O
ncbi-sent-455,mutation,NN,O
ncbi-sent-455,",",",",O
ncbi-sent-455,and,CC,O
ncbi-sent-455,one,CD,O
ncbi-sent-455,individual,NN,O
ncbi-sent-455,was,VBD,O
ncbi-sent-455,found,VBN,O
ncbi-sent-455,to,TO,O
ncbi-sent-455,have,VB,O
ncbi-sent-455,an,DT,O
ncbi-sent-455,FGFR2,NNP,O
ncbi-sent-455,VV269,NNP,O
ncbi-sent-455,-,:,O
ncbi-sent-455,270,CD,O
ncbi-sent-455,deletion,NN,O
ncbi-sent-455,.,.,O
ncbi-sent-456,To,TO,O
ncbi-sent-456,date,NN,O
ncbi-sent-456,",",",",O
ncbi-sent-456,our,PRP$,O
ncbi-sent-456,detection,NN,O
ncbi-sent-456,rate,NN,O
ncbi-sent-456,for,IN,O
ncbi-sent-456,TWIST,NNP,O
ncbi-sent-456,or,CC,O
ncbi-sent-456,FGFR,NNP,O
ncbi-sent-456,mutations,NNS,O
ncbi-sent-456,is,VBZ,O
ncbi-sent-456,68,CD,O
ncbi-sent-456,%,NN,O
ncbi-sent-456,in,IN,O
ncbi-sent-456,our,PRP$,O
ncbi-sent-456,Saethre,NNP,B-DISEASE
ncbi-sent-456,-,:,I-DISEASE
ncbi-sent-456,Chotzen,NNP,I-DISEASE
ncbi-sent-456,syndrome,NN,I-DISEASE
ncbi-sent-456,patients,NNS,O
ncbi-sent-456,",",",",O
ncbi-sent-456,including,VBG,O
ncbi-sent-456,our,PRP$,O
ncbi-sent-456,five,CD,O
ncbi-sent-456,patients,NNS,O
ncbi-sent-456,elsewhere,RB,O
ncbi-sent-456,reported,VBN,O
ncbi-sent-456,with,IN,O
ncbi-sent-456,TWIST,NNP,O
ncbi-sent-456,mutations,NNS,O
ncbi-sent-456,.,.,O
ncbi-sent-457,More,JJR,O
ncbi-sent-457,than,IN,O
ncbi-sent-457,35,CD,O
ncbi-sent-457,different,JJ,O
ncbi-sent-457,TWIST,NNP,O
ncbi-sent-457,mutations,NNS,O
ncbi-sent-457,are,VBP,O
ncbi-sent-457,now,RB,O
ncbi-sent-457,known,VBN,O
ncbi-sent-457,in,IN,O
ncbi-sent-457,the,DT,O
ncbi-sent-457,literature,NN,O
ncbi-sent-457,.,.,O
ncbi-sent-458,The,DT,O
ncbi-sent-458,most,RBS,O
ncbi-sent-458,common,JJ,O
ncbi-sent-458,phenotypic,NN,O
ncbi-sent-458,features,NNS,O
ncbi-sent-458,",",",",O
ncbi-sent-458,present,JJ,O
ncbi-sent-458,in,IN,O
ncbi-sent-458,more,JJR,O
ncbi-sent-458,than,IN,O
ncbi-sent-458,a,DT,O
ncbi-sent-458,third,JJ,O
ncbi-sent-458,of,IN,O
ncbi-sent-458,our,PRP$,O
ncbi-sent-458,patients,NNS,O
ncbi-sent-458,with,IN,O
ncbi-sent-458,TWIST,NNP,O
ncbi-sent-458,mutations,NNS,O
ncbi-sent-458,",",",",O
ncbi-sent-458,are,VBP,O
ncbi-sent-458,coronal,JJ,B-DISEASE
ncbi-sent-458,synostosis,NN,I-DISEASE
ncbi-sent-458,",",",",O
ncbi-sent-458,brachycephaly,NN,B-DISEASE
ncbi-sent-458,",",",",O
ncbi-sent-458,low,JJ,B-DISEASE
ncbi-sent-458,frontal,JJ,I-DISEASE
ncbi-sent-458,hairline,NN,I-DISEASE
ncbi-sent-458,",",",",O
ncbi-sent-458,facial,JJ,B-DISEASE
ncbi-sent-458,asymmetry,NN,I-DISEASE
ncbi-sent-458,",",",",O
ncbi-sent-458,ptosis,NN,B-DISEASE
ncbi-sent-458,",",",",O
ncbi-sent-458,hypertelorism,NN,B-DISEASE
ncbi-sent-458,",",",",O
ncbi-sent-458,broad,JJ,B-DISEASE
ncbi-sent-458,great,JJ,I-DISEASE
ncbi-sent-458,toes,NNS,I-DISEASE
ncbi-sent-458,",",",",O
ncbi-sent-458,and,CC,O
ncbi-sent-458,clinodactyly,NN,B-DISEASE
ncbi-sent-458,.,.,O
ncbi-sent-459,Significant,NNP,O
ncbi-sent-459,intra,JJ,O
ncbi-sent-459,-,:,O
ncbi-sent-459,and,CC,O
ncbi-sent-459,interfamilial,JJ,O
ncbi-sent-459,phenotypic,NN,O
ncbi-sent-459,variability,NN,O
ncbi-sent-459,is,VBZ,O
ncbi-sent-459,present,JJ,O
ncbi-sent-459,for,IN,O
ncbi-sent-459,either,DT,O
ncbi-sent-459,TWIST,NNP,O
ncbi-sent-459,mutations,NNS,O
ncbi-sent-459,or,CC,O
ncbi-sent-459,FGFR,NNP,O
ncbi-sent-459,mutations,NNS,O
ncbi-sent-459,.,.,O
ncbi-sent-460,The,DT,O
ncbi-sent-460,overlap,NN,O
ncbi-sent-460,in,IN,O
ncbi-sent-460,clinical,JJ,O
ncbi-sent-460,features,NNS,O
ncbi-sent-460,and,CC,O
ncbi-sent-460,the,DT,O
ncbi-sent-460,presence,NN,O
ncbi-sent-460,",",",",O
ncbi-sent-460,in,IN,O
ncbi-sent-460,the,DT,O
ncbi-sent-460,same,JJ,O
ncbi-sent-460,genes,NNS,O
ncbi-sent-460,",",",",O
ncbi-sent-460,of,IN,O
ncbi-sent-460,mutations,NNS,O
ncbi-sent-460,for,IN,O
ncbi-sent-460,more,JJR,O
ncbi-sent-460,than,IN,O
ncbi-sent-460,one,CD,O
ncbi-sent-460,craniosynostotic,JJ,B-DISEASE
ncbi-sent-460,condition,NN,I-DISEASE
ncbi-sent-460,-,:,O
ncbi-sent-460,such,JJ,O
ncbi-sent-460,as,IN,O
ncbi-sent-460,Saethre,NNP,B-DISEASE
ncbi-sent-460,-,:,I-DISEASE
ncbi-sent-460,Chotzen,NNP,I-DISEASE
ncbi-sent-460,",",",",I-DISEASE
ncbi-sent-460,Crouzon,NNP,I-DISEASE
ncbi-sent-460,",",",",I-DISEASE
ncbi-sent-460,and,CC,I-DISEASE
ncbi-sent-460,Pfeiffer,NNP,I-DISEASE
ncbi-sent-460,syndromes,VBZ,I-DISEASE
ncbi-sent-460,-,:,O
ncbi-sent-460,support,NN,O
ncbi-sent-460,the,DT,O
ncbi-sent-460,hypothesis,NN,O
ncbi-sent-460,that,WDT,O
ncbi-sent-460,TWIST,NNP,O
ncbi-sent-460,and,CC,O
ncbi-sent-460,FGFRs,NNP,O
ncbi-sent-460,are,VBP,O
ncbi-sent-460,components,NNS,O
ncbi-sent-460,of,IN,O
ncbi-sent-460,the,DT,O
ncbi-sent-460,same,JJ,O
ncbi-sent-460,molecular,JJ,O
ncbi-sent-460,pathway,NN,O
ncbi-sent-460,involved,VBN,O
ncbi-sent-460,in,IN,O
ncbi-sent-460,the,DT,O
ncbi-sent-460,modulation,NN,O
ncbi-sent-460,of,IN,O
ncbi-sent-460,craniofacial,JJ,O
ncbi-sent-460,and,CC,O
ncbi-sent-460,limb,JJ,O
ncbi-sent-460,development,NN,O
ncbi-sent-460,in,IN,O
ncbi-sent-460,humans,NNS,O
ncbi-sent-460,.,.,O
ncbi-sent-461,.,.,O
ncbi-sent-462,Mutation,NNP,O
ncbi-sent-462,analysis,NN,O
ncbi-sent-462,of,IN,O
ncbi-sent-462,UBE3A,NNP,O
ncbi-sent-462,in,IN,O
ncbi-sent-462,Angelman,NNP,B-DISEASE
ncbi-sent-462,syndrome,NN,I-DISEASE
ncbi-sent-462,patients,NNS,O
ncbi-sent-462,.,.,O
ncbi-sent-463,Angelman,NNP,B-DISEASE
ncbi-sent-463,syndrome,NN,I-DISEASE
ncbi-sent-463,(,(,O
ncbi-sent-463,AS,IN,B-DISEASE
ncbi-sent-463,),),O
ncbi-sent-463,is,VBZ,O
ncbi-sent-463,caused,VBN,O
ncbi-sent-463,by,IN,O
ncbi-sent-463,chromosome,NN,O
ncbi-sent-463,15q11,CD,O
ncbi-sent-463,-,:,O
ncbi-sent-463,q13,NN,O
ncbi-sent-463,deletions,NNS,O
ncbi-sent-463,of,IN,O
ncbi-sent-463,maternal,JJ,O
ncbi-sent-463,origin,NN,O
ncbi-sent-463,",",",",O
ncbi-sent-463,by,IN,O
ncbi-sent-463,paternal,JJ,O
ncbi-sent-463,uniparental,JJ,B-DISEASE
ncbi-sent-463,disomy,NN,I-DISEASE
ncbi-sent-463,(,(,O
ncbi-sent-463,UPD,NNP,B-DISEASE
ncbi-sent-463,),),O
ncbi-sent-463,15,CD,O
ncbi-sent-463,",",",",O
ncbi-sent-463,by,IN,O
ncbi-sent-463,imprinting,VBG,O
ncbi-sent-463,defects,NNS,O
ncbi-sent-463,",",",",O
ncbi-sent-463,and,CC,O
ncbi-sent-463,by,IN,O
ncbi-sent-463,mutations,NNS,O
ncbi-sent-463,in,IN,O
ncbi-sent-463,the,DT,O
ncbi-sent-463,UBE3A,NNP,O
ncbi-sent-463,gene,NN,O
ncbi-sent-463,.,.,O
ncbi-sent-464,UBE3A,NNP,O
ncbi-sent-464,encodes,VBZ,O
ncbi-sent-464,a,DT,O
ncbi-sent-464,ubiquitin,JJ,O
ncbi-sent-464,-,:,O
ncbi-sent-464,protein,NN,O
ncbi-sent-464,ligase,NN,O
ncbi-sent-464,and,CC,O
ncbi-sent-464,shows,VBZ,O
ncbi-sent-464,brain,NN,O
ncbi-sent-464,-,:,O
ncbi-sent-464,specific,JJ,O
ncbi-sent-464,imprinting,NN,O
ncbi-sent-464,.,.,O
ncbi-sent-465,Here,RB,O
ncbi-sent-465,we,PRP,O
ncbi-sent-465,describe,VBP,O
ncbi-sent-465,UBE3A,NNP,O
ncbi-sent-465,coding,VBG,O
ncbi-sent-465,-,:,O
ncbi-sent-465,region,NN,O
ncbi-sent-465,mutations,NNS,O
ncbi-sent-465,detected,VBN,O
ncbi-sent-465,by,IN,O
ncbi-sent-465,SSCP,NNP,O
ncbi-sent-465,analysis,NN,O
ncbi-sent-465,in,IN,O
ncbi-sent-465,13,CD,O
ncbi-sent-465,AS,IN,B-DISEASE
ncbi-sent-465,individuals,NNS,O
ncbi-sent-465,or,CC,O
ncbi-sent-465,families,NNS,O
ncbi-sent-465,.,.,O
ncbi-sent-466,Two,CD,O
ncbi-sent-466,identical,JJ,O
ncbi-sent-466,de,FW,O
ncbi-sent-466,novo,FW,O
ncbi-sent-466,5,CD,O
ncbi-sent-466,-,:,O
ncbi-sent-466,bp,NN,O
ncbi-sent-466,duplications,NNS,O
ncbi-sent-466,in,IN,O
ncbi-sent-466,exon,JJ,O
ncbi-sent-466,16,CD,O
ncbi-sent-466,were,VBD,O
ncbi-sent-466,found,VBN,O
ncbi-sent-466,.,.,O
ncbi-sent-467,Among,IN,O
ncbi-sent-467,the,DT,O
ncbi-sent-467,other,JJ,O
ncbi-sent-467,11,CD,O
ncbi-sent-467,unique,JJ,O
ncbi-sent-467,mutations,NNS,O
ncbi-sent-467,",",",",O
ncbi-sent-467,8,CD,O
ncbi-sent-467,were,VBD,O
ncbi-sent-467,small,JJ,O
ncbi-sent-467,deletions,NNS,O
ncbi-sent-467,or,CC,O
ncbi-sent-467,insertions,NNS,O
ncbi-sent-467,predicted,VBN,O
ncbi-sent-467,to,TO,O
ncbi-sent-467,cause,VB,O
ncbi-sent-467,frameshifts,NNS,O
ncbi-sent-467,",",",",O
ncbi-sent-467,1,CD,O
ncbi-sent-467,was,VBD,O
ncbi-sent-467,a,DT,O
ncbi-sent-467,mutation,NN,O
ncbi-sent-467,to,TO,O
ncbi-sent-467,a,DT,O
ncbi-sent-467,stop,NN,O
ncbi-sent-467,codon,NN,O
ncbi-sent-467,",",",",O
ncbi-sent-467,1,CD,O
ncbi-sent-467,was,VBD,O
ncbi-sent-467,a,DT,O
ncbi-sent-467,missense,JJ,O
ncbi-sent-467,mutation,NN,O
ncbi-sent-467,",",",",O
ncbi-sent-467,and,CC,O
ncbi-sent-467,1,CD,O
ncbi-sent-467,was,VBD,O
ncbi-sent-467,predicted,VBN,O
ncbi-sent-467,to,TO,O
ncbi-sent-467,cause,VB,O
ncbi-sent-467,insertion,NN,O
ncbi-sent-467,of,IN,O
ncbi-sent-467,an,DT,O
ncbi-sent-467,isoleucine,NN,O
ncbi-sent-467,in,IN,O
ncbi-sent-467,the,DT,O
ncbi-sent-467,hect,NN,O
ncbi-sent-467,domain,NN,O
ncbi-sent-467,of,IN,O
ncbi-sent-467,the,DT,O
ncbi-sent-467,UBE3A,NNP,O
ncbi-sent-467,protein,NN,O
ncbi-sent-467,",",",",O
ncbi-sent-467,which,WDT,O
ncbi-sent-467,functions,NNS,O
ncbi-sent-467,in,IN,O
ncbi-sent-467,E2,NNP,O
ncbi-sent-467,binding,NN,O
ncbi-sent-467,and,CC,O
ncbi-sent-467,ubiquitin,JJ,O
ncbi-sent-467,transfer,NN,O
ncbi-sent-467,.,.,O
ncbi-sent-468,Eight,CD,O
ncbi-sent-468,of,IN,O
ncbi-sent-468,the,DT,O
ncbi-sent-468,cases,NNS,O
ncbi-sent-468,were,VBD,O
ncbi-sent-468,familial,JJ,O
ncbi-sent-468,",",",",O
ncbi-sent-468,and,CC,O
ncbi-sent-468,five,CD,O
ncbi-sent-468,were,VBD,O
ncbi-sent-468,sporadic,JJ,O
ncbi-sent-468,.,.,O
ncbi-sent-469,In,IN,O
ncbi-sent-469,two,CD,O
ncbi-sent-469,familial,JJ,O
ncbi-sent-469,cases,NNS,O
ncbi-sent-469,and,CC,O
ncbi-sent-469,one,CD,O
ncbi-sent-469,sporadic,JJ,O
ncbi-sent-469,case,NN,O
ncbi-sent-469,",",",",O
ncbi-sent-469,mosaicism,NN,O
ncbi-sent-469,for,IN,O
ncbi-sent-469,UBE3A,NNP,O
ncbi-sent-469,mutations,NNS,O
ncbi-sent-469,was,VBD,O
ncbi-sent-469,detected,VBN,O
ncbi-sent-469,in,IN,O
ncbi-sent-469,the,DT,O
ncbi-sent-469,mother,NN,O
ncbi-sent-469,of,IN,O
ncbi-sent-469,three,CD,O
ncbi-sent-469,AS,IN,B-DISEASE
ncbi-sent-469,sons,NNS,O
ncbi-sent-469,",",",",O
ncbi-sent-469,in,IN,O
ncbi-sent-469,the,DT,O
ncbi-sent-469,maternal,JJ,O
ncbi-sent-469,grandfather,NN,O
ncbi-sent-469,of,IN,O
ncbi-sent-469,two,CD,O
ncbi-sent-469,AS,IN,B-DISEASE
ncbi-sent-469,first,JJ,O
ncbi-sent-469,cousins,NNS,O
ncbi-sent-469,",",",",O
ncbi-sent-469,and,CC,O
ncbi-sent-469,in,IN,O
ncbi-sent-469,the,DT,O
ncbi-sent-469,mother,NN,O
ncbi-sent-469,of,IN,O
ncbi-sent-469,an,DT,O
ncbi-sent-469,AS,NNP,B-DISEASE
ncbi-sent-469,daughter,NN,O
ncbi-sent-469,.,.,O
ncbi-sent-470,The,DT,O
ncbi-sent-470,frequencies,NNS,O
ncbi-sent-470,with,IN,O
ncbi-sent-470,which,WDT,O
ncbi-sent-470,we,PRP,O
ncbi-sent-470,detected,VBD,O
ncbi-sent-470,mutations,NNS,O
ncbi-sent-470,were,VBD,O
ncbi-sent-470,5,CD,O
ncbi-sent-470,(,(,O
ncbi-sent-470,14,CD,O
ncbi-sent-470,%,NN,O
ncbi-sent-470,),),O
ncbi-sent-470,of,IN,O
ncbi-sent-470,35,CD,O
ncbi-sent-470,in,IN,O
ncbi-sent-470,sporadic,JJ,O
ncbi-sent-470,cases,NNS,O
ncbi-sent-470,and,CC,O
ncbi-sent-470,8,CD,O
ncbi-sent-470,(,(,O
ncbi-sent-470,80,CD,O
ncbi-sent-470,%,NN,O
ncbi-sent-470,),),O
ncbi-sent-470,of,IN,O
ncbi-sent-470,10,CD,O
ncbi-sent-470,in,IN,O
ncbi-sent-470,familial,JJ,O
ncbi-sent-470,cases,NNS,O
ncbi-sent-470,.,.,O
ncbi-sent-471,.,.,O
ncbi-sent-472,The,DT,O
ncbi-sent-472,hemochromatosis,NN,B-DISEASE
ncbi-sent-472,845,CD,O
ncbi-sent-472,G,NNP,O
ncbi-sent-472,-,:,O
ncbi-sent-472,-,:,O
ncbi-sent-472,>,VB,O
ncbi-sent-472,A,DT,O
ncbi-sent-472,and,CC,O
ncbi-sent-472,187,CD,O
ncbi-sent-472,C,NNP,O
ncbi-sent-472,-,:,O
ncbi-sent-472,-,:,O
ncbi-sent-472,>,NN,O
ncbi-sent-472,G,NNP,O
ncbi-sent-472,mutations,NNS,O
ncbi-sent-472,:,:,O
ncbi-sent-472,prevalence,NN,O
ncbi-sent-472,in,IN,O
ncbi-sent-472,non,JJ,O
ncbi-sent-472,-,:,O
ncbi-sent-472,Caucasian,JJ,O
ncbi-sent-472,populations,NNS,O
ncbi-sent-472,.,.,O
ncbi-sent-473,Hemochromatosis,NNP,B-DISEASE
ncbi-sent-473,",",",",O
ncbi-sent-473,the,DT,O
ncbi-sent-473,inherited,JJ,B-DISEASE
ncbi-sent-473,disorder,NN,I-DISEASE
ncbi-sent-473,of,IN,I-DISEASE
ncbi-sent-473,iron,NN,I-DISEASE
ncbi-sent-473,metabolism,NN,I-DISEASE
ncbi-sent-473,",",",",O
ncbi-sent-473,leads,VBZ,O
ncbi-sent-473,",",",",O
ncbi-sent-473,if,IN,O
ncbi-sent-473,untreated,VBN,O
ncbi-sent-473,",",",",O
ncbi-sent-473,to,TO,O
ncbi-sent-473,progressive,VB,O
ncbi-sent-473,iron,NN,B-DISEASE
ncbi-sent-473,overload,NN,I-DISEASE
ncbi-sent-473,and,CC,O
ncbi-sent-473,premature,JJ,B-DISEASE
ncbi-sent-473,death,NN,I-DISEASE
ncbi-sent-473,.,.,O
ncbi-sent-474,The,DT,O
ncbi-sent-474,hemochromatosis,NN,B-DISEASE
ncbi-sent-474,gene,NN,O
ncbi-sent-474,",",",",O
ncbi-sent-474,HFE,NNP,O
ncbi-sent-474,",",",",O
ncbi-sent-474,recently,RB,O
ncbi-sent-474,has,VBZ,O
ncbi-sent-474,been,VBN,O
ncbi-sent-474,identified,VBN,O
ncbi-sent-474,",",",",O
ncbi-sent-474,and,CC,O
ncbi-sent-474,characterization,NN,O
ncbi-sent-474,of,IN,O
ncbi-sent-474,this,DT,O
ncbi-sent-474,gene,NN,O
ncbi-sent-474,has,VBZ,O
ncbi-sent-474,shown,VBN,O
ncbi-sent-474,that,IN,O
ncbi-sent-474,it,PRP,O
ncbi-sent-474,contains,VBZ,O
ncbi-sent-474,two,CD,O
ncbi-sent-474,mutations,NNS,O
ncbi-sent-474,that,WDT,O
ncbi-sent-474,result,VBP,O
ncbi-sent-474,in,IN,O
ncbi-sent-474,amino,NN,O
ncbi-sent-474,acid,NN,O
ncbi-sent-474,substitutions,NNS,O
ncbi-sent-474,-,:,O
ncbi-sent-474,cDNA,NN,O
ncbi-sent-474,nucleotides,VBZ,O
ncbi-sent-474,845,CD,O
ncbi-sent-474,G,NNP,O
ncbi-sent-474,-,:,O
ncbi-sent-474,-,:,O
ncbi-sent-474,>,VB,O
ncbi-sent-474,A,NNP,O
ncbi-sent-474,(,(,O
ncbi-sent-474,C282Y,NNP,O
ncbi-sent-474,),),O
ncbi-sent-474,and,CC,O
ncbi-sent-474,187,CD,O
ncbi-sent-474,C,NNP,O
ncbi-sent-474,-,:,O
ncbi-sent-474,-,:,O
ncbi-sent-474,>,NN,O
ncbi-sent-474,G,NNP,O
ncbi-sent-474,(,(,O
ncbi-sent-474,H63D,NNP,O
ncbi-sent-474,),),O
ncbi-sent-474,.,.,O
ncbi-sent-475,Although,IN,O
ncbi-sent-475,hemochromatosis,NN,B-DISEASE
ncbi-sent-475,is,VBZ,O
ncbi-sent-475,common,JJ,O
ncbi-sent-475,in,IN,O
ncbi-sent-475,Caucasians,NNPS,O
ncbi-sent-475,",",",",O
ncbi-sent-475,affecting,VBG,O
ncbi-sent-475,>,JJ,O
ncbi-sent-475,=,$,O
ncbi-sent-475,1,CD,O
ncbi-sent-475,/,$,O
ncbi-sent-475,300,CD,O
ncbi-sent-475,individuals,NNS,O
ncbi-sent-475,of,IN,O
ncbi-sent-475,northern,JJ,O
ncbi-sent-475,European,JJ,O
ncbi-sent-475,origin,NN,O
ncbi-sent-475,",",",",O
ncbi-sent-475,it,PRP,O
ncbi-sent-475,has,VBZ,O
ncbi-sent-475,not,RB,O
ncbi-sent-475,been,VBN,O
ncbi-sent-475,recognized,VBN,O
ncbi-sent-475,in,IN,O
ncbi-sent-475,other,JJ,O
ncbi-sent-475,populations,NNS,O
ncbi-sent-475,.,.,O
ncbi-sent-476,The,DT,O
ncbi-sent-476,present,JJ,O
ncbi-sent-476,study,NN,O
ncbi-sent-476,used,VBN,O
ncbi-sent-476,PCR,NNP,O
ncbi-sent-476,and,CC,O
ncbi-sent-476,restriction,NN,O
ncbi-sent-476,-,:,O
ncbi-sent-476,enzyme,NN,O
ncbi-sent-476,digestion,NN,O
ncbi-sent-476,to,TO,O
ncbi-sent-476,analyze,VB,O
ncbi-sent-476,the,DT,O
ncbi-sent-476,frequency,NN,O
ncbi-sent-476,of,IN,O
ncbi-sent-476,the,DT,O
ncbi-sent-476,845,CD,O
ncbi-sent-476,G,NNP,O
ncbi-sent-476,-,:,O
ncbi-sent-476,-,:,O
ncbi-sent-476,>,VB,O
ncbi-sent-476,A,DT,O
ncbi-sent-476,and,CC,O
ncbi-sent-476,187,CD,O
ncbi-sent-476,C,NNP,O
ncbi-sent-476,-,:,O
ncbi-sent-476,-,:,O
ncbi-sent-476,>,NN,O
ncbi-sent-476,G,NNP,O
ncbi-sent-476,mutations,NNS,O
ncbi-sent-476,in,IN,O
ncbi-sent-476,HLA,NNP,O
ncbi-sent-476,-,:,O
ncbi-sent-476,typed,VBD,O
ncbi-sent-476,samples,NNS,O
ncbi-sent-476,from,IN,O
ncbi-sent-476,non,JJ,O
ncbi-sent-476,-,:,O
ncbi-sent-476,Caucasian,JJ,O
ncbi-sent-476,populations,NNS,O
ncbi-sent-476,",",",",O
ncbi-sent-476,comprising,VBG,O
ncbi-sent-476,Australian,JJ,O
ncbi-sent-476,Aboriginal,NNP,O
ncbi-sent-476,",",",",O
ncbi-sent-476,Chinese,NNP,O
ncbi-sent-476,",",",",O
ncbi-sent-476,and,CC,O
ncbi-sent-476,Pacific,NNP,O
ncbi-sent-476,Islanders,NNP,O
ncbi-sent-476,.,.,O
ncbi-sent-477,Results,NNP,O
ncbi-sent-477,showed,VBD,O
ncbi-sent-477,that,IN,O
ncbi-sent-477,the,DT,O
ncbi-sent-477,845,CD,O
ncbi-sent-477,G,NNP,O
ncbi-sent-477,-,:,O
ncbi-sent-477,-,:,O
ncbi-sent-477,>,VB,O
ncbi-sent-477,A,DT,O
ncbi-sent-477,mutation,NN,O
ncbi-sent-477,was,VBD,O
ncbi-sent-477,present,JJ,O
ncbi-sent-477,in,IN,O
ncbi-sent-477,these,DT,O
ncbi-sent-477,populations,NNS,O
ncbi-sent-477,(,(,O
ncbi-sent-477,allele,JJ,O
ncbi-sent-477,frequency,NN,O
ncbi-sent-477,0,CD,O
ncbi-sent-477,.,.,O
ncbi-sent-478,32,CD,O
ncbi-sent-478,%,NN,O
ncbi-sent-478,),),O
ncbi-sent-478,",",",",O
ncbi-sent-478,and,CC,O
ncbi-sent-478,",",",",O
ncbi-sent-478,furthermore,RB,O
ncbi-sent-478,",",",",O
ncbi-sent-478,it,PRP,O
ncbi-sent-478,was,VBD,O
ncbi-sent-478,always,RB,O
ncbi-sent-478,seen,VBN,O
ncbi-sent-478,in,IN,O
ncbi-sent-478,conjunction,NN,O
ncbi-sent-478,with,IN,O
ncbi-sent-478,HLA,NNP,O
ncbi-sent-478,haplotypes,NNS,O
ncbi-sent-478,common,JJ,O
ncbi-sent-478,in,IN,O
ncbi-sent-478,Caucasians,NNPS,O
ncbi-sent-478,",",",",O
ncbi-sent-478,suggesting,VBG,O
ncbi-sent-478,that,IN,O
ncbi-sent-478,845,CD,O
ncbi-sent-478,G,NNP,O
ncbi-sent-478,-,:,O
ncbi-sent-478,-,:,O
ncbi-sent-478,>,VB,O
ncbi-sent-478,A,DT,O
ncbi-sent-478,may,MD,O
ncbi-sent-478,have,VB,O
ncbi-sent-478,been,VBN,O
ncbi-sent-478,introduced,VBN,O
ncbi-sent-478,into,IN,O
ncbi-sent-478,these,DT,O
ncbi-sent-478,populations,NNS,O
ncbi-sent-478,by,IN,O
ncbi-sent-478,Caucasian,JJ,O
ncbi-sent-478,admixture,NN,O
ncbi-sent-478,.,.,O
ncbi-sent-479,187,CD,O
ncbi-sent-479,C,NNP,O
ncbi-sent-479,-,:,O
ncbi-sent-479,-,:,O
ncbi-sent-479,>,NN,O
ncbi-sent-479,G,NNP,O
ncbi-sent-479,was,VBD,O
ncbi-sent-479,present,JJ,O
ncbi-sent-479,at,IN,O
ncbi-sent-479,an,DT,O
ncbi-sent-479,allele,JJ,O
ncbi-sent-479,frequency,NN,O
ncbi-sent-479,of,IN,O
ncbi-sent-479,2,CD,O
ncbi-sent-479,.,.,O
ncbi-sent-480,68,CD,O
ncbi-sent-480,%,NN,O
ncbi-sent-480,in,IN,O
ncbi-sent-480,the,DT,O
ncbi-sent-480,two,CD,O
ncbi-sent-480,populations,NNS,O
ncbi-sent-480,analyzed,VBN,O
ncbi-sent-480,(,(,O
ncbi-sent-480,Australian,JJ,O
ncbi-sent-480,Aboriginal,NNP,O
ncbi-sent-480,and,CC,O
ncbi-sent-480,Chinese,NNP,O
ncbi-sent-480,),),O
ncbi-sent-480,.,.,O
ncbi-sent-481,In,IN,O
ncbi-sent-481,the,DT,O
ncbi-sent-481,Australian,JJ,O
ncbi-sent-481,Aboriginal,NNP,O
ncbi-sent-481,samples,NNS,O
ncbi-sent-481,",",",",O
ncbi-sent-481,187,CD,O
ncbi-sent-481,C,NNP,O
ncbi-sent-481,-,:,O
ncbi-sent-481,-,:,O
ncbi-sent-481,>,NN,O
ncbi-sent-481,G,NNP,O
ncbi-sent-481,was,VBD,O
ncbi-sent-481,found,VBN,O
ncbi-sent-481,to,TO,O
ncbi-sent-481,be,VB,O
ncbi-sent-481,associated,VBN,O
ncbi-sent-481,with,IN,O
ncbi-sent-481,HLA,NNP,O
ncbi-sent-481,haplotypes,NNS,O
ncbi-sent-481,common,JJ,O
ncbi-sent-481,in,IN,O
ncbi-sent-481,Caucasians,NNPS,O
ncbi-sent-481,",",",",O
ncbi-sent-481,suggesting,VBG,O
ncbi-sent-481,that,IN,O
ncbi-sent-481,it,PRP,O
ncbi-sent-481,was,VBD,O
ncbi-sent-481,introduced,VBN,O
ncbi-sent-481,by,IN,O
ncbi-sent-481,recent,JJ,O
ncbi-sent-481,admixture,NN,O
ncbi-sent-481,.,.,O
ncbi-sent-482,In,IN,O
ncbi-sent-482,the,DT,O
ncbi-sent-482,Chinese,JJ,O
ncbi-sent-482,samples,NNS,O
ncbi-sent-482,analyzed,VBN,O
ncbi-sent-482,",",",",O
ncbi-sent-482,187,CD,O
ncbi-sent-482,C,NNP,O
ncbi-sent-482,-,:,O
ncbi-sent-482,-,:,O
ncbi-sent-482,>,NN,O
ncbi-sent-482,G,NNP,O
ncbi-sent-482,was,VBD,O
ncbi-sent-482,present,JJ,O
ncbi-sent-482,in,IN,O
ncbi-sent-482,association,NN,O
ncbi-sent-482,with,IN,O
ncbi-sent-482,a,DT,O
ncbi-sent-482,wide,JJ,O
ncbi-sent-482,variety,NN,O
ncbi-sent-482,of,IN,O
ncbi-sent-482,HLA,NNP,O
ncbi-sent-482,haplotypes,NNS,O
ncbi-sent-482,",",",",O
ncbi-sent-482,showing,VBG,O
ncbi-sent-482,this,DT,O
ncbi-sent-482,mutation,NN,O
ncbi-sent-482,to,TO,O
ncbi-sent-482,be,VB,O
ncbi-sent-482,widespread,JJ,O
ncbi-sent-482,and,CC,O
ncbi-sent-482,likely,JJ,O
ncbi-sent-482,to,TO,O
ncbi-sent-482,predate,VB,O
ncbi-sent-482,the,DT,O
ncbi-sent-482,more,RBR,O
ncbi-sent-482,genetically,RB,O
ncbi-sent-482,restricted,VBN,O
ncbi-sent-482,845,CD,O
ncbi-sent-482,G,NNP,O
ncbi-sent-482,-,:,O
ncbi-sent-482,-,:,O
ncbi-sent-482,>,VB,O
ncbi-sent-482,A,DT,O
ncbi-sent-482,mutation,NN,O
ncbi-sent-482,.,.,O
ncbi-sent-483,Genotype,NNP,O
ncbi-sent-483,-,:,O
ncbi-sent-483,phenotype,NN,O
ncbi-sent-483,correlations,NNS,O
ncbi-sent-483,in,IN,O
ncbi-sent-483,attenuated,JJ,B-DISEASE
ncbi-sent-483,adenomatous,JJ,I-DISEASE
ncbi-sent-483,polyposis,NN,I-DISEASE
ncbi-sent-483,coli,NN,I-DISEASE
ncbi-sent-483,.,.,O
ncbi-sent-484,Germ,NNP,O
ncbi-sent-484,-,:,O
ncbi-sent-484,line,NN,O
ncbi-sent-484,mutations,NNS,O
ncbi-sent-484,of,IN,O
ncbi-sent-484,the,DT,O
ncbi-sent-484,tumor,NN,B-DISEASE
ncbi-sent-484,suppressor,NN,O
ncbi-sent-484,APC,NNP,O
ncbi-sent-484,are,VBP,O
ncbi-sent-484,implicated,VBN,O
ncbi-sent-484,in,IN,O
ncbi-sent-484,attenuated,JJ,B-DISEASE
ncbi-sent-484,adenomatous,JJ,I-DISEASE
ncbi-sent-484,polyposis,NN,I-DISEASE
ncbi-sent-484,coli,NN,I-DISEASE
ncbi-sent-484,(,(,O
ncbi-sent-484,AAPC,NNP,B-DISEASE
ncbi-sent-484,),),O
ncbi-sent-484,",",",",O
ncbi-sent-484,a,DT,O
ncbi-sent-484,variant,NN,O
ncbi-sent-484,of,IN,O
ncbi-sent-484,familial,JJ,B-DISEASE
ncbi-sent-484,adenomatous,JJ,I-DISEASE
ncbi-sent-484,polyposis,NN,I-DISEASE
ncbi-sent-484,(,(,O
ncbi-sent-484,FAP,NNP,B-DISEASE
ncbi-sent-484,),),O
ncbi-sent-484,.,.,O
ncbi-sent-485,AAPC,NNP,B-DISEASE
ncbi-sent-485,is,VBZ,O
ncbi-sent-485,recognized,VBN,O
ncbi-sent-485,by,IN,O
ncbi-sent-485,the,DT,O
ncbi-sent-485,occurrence,NN,O
ncbi-sent-485,of,IN,O
ncbi-sent-485,<,$,O
ncbi-sent-485,100,CD,O
ncbi-sent-485,colonic,JJ,B-DISEASE
ncbi-sent-485,adenomas,NN,I-DISEASE
ncbi-sent-485,and,CC,O
ncbi-sent-485,a,DT,O
ncbi-sent-485,later,JJ,O
ncbi-sent-485,onset,NN,O
ncbi-sent-485,of,IN,O
ncbi-sent-485,colorectal,JJ,B-DISEASE
ncbi-sent-485,cancer,NN,I-DISEASE
ncbi-sent-485,(,(,O
ncbi-sent-485,age,NN,O
ncbi-sent-485,>,VBZ,O
ncbi-sent-485,40,CD,O
ncbi-sent-485,years,NNS,O
ncbi-sent-485,),),O
ncbi-sent-485,.,.,O
ncbi-sent-486,The,DT,O
ncbi-sent-486,aim,NN,O
ncbi-sent-486,of,IN,O
ncbi-sent-486,this,DT,O
ncbi-sent-486,study,NN,O
ncbi-sent-486,was,VBD,O
ncbi-sent-486,to,TO,O
ncbi-sent-486,assess,VB,O
ncbi-sent-486,genotype,JJ,O
ncbi-sent-486,-,:,O
ncbi-sent-486,phenotype,NN,O
ncbi-sent-486,correlations,NNS,O
ncbi-sent-486,in,IN,O
ncbi-sent-486,AAPC,NNP,B-DISEASE
ncbi-sent-486,families,NNS,O
ncbi-sent-486,.,.,O
ncbi-sent-487,By,IN,O
ncbi-sent-487,protein,JJ,O
ncbi-sent-487,-,:,O
ncbi-sent-487,truncation,NN,O
ncbi-sent-487,test,NN,O
ncbi-sent-487,(,(,O
ncbi-sent-487,PTT,NNP,O
ncbi-sent-487,),),O
ncbi-sent-487,assay,VBP,O
ncbi-sent-487,",",",",O
ncbi-sent-487,the,DT,O
ncbi-sent-487,entire,JJ,O
ncbi-sent-487,coding,NN,O
ncbi-sent-487,region,NN,O
ncbi-sent-487,of,IN,O
ncbi-sent-487,the,DT,O
ncbi-sent-487,APC,NNP,B-DISEASE
ncbi-sent-487,gene,NN,O
ncbi-sent-487,was,VBD,O
ncbi-sent-487,screened,VBN,O
ncbi-sent-487,in,IN,O
ncbi-sent-487,affected,JJ,O
ncbi-sent-487,individuals,NNS,O
ncbi-sent-487,from,IN,O
ncbi-sent-487,11,CD,O
ncbi-sent-487,AAPC,NNP,B-DISEASE
ncbi-sent-487,kindreds,NNS,O
ncbi-sent-487,",",",",O
ncbi-sent-487,and,CC,O
ncbi-sent-487,their,PRP$,O
ncbi-sent-487,phenotypic,NN,O
ncbi-sent-487,differences,NNS,O
ncbi-sent-487,were,VBD,O
ncbi-sent-487,examined,VBN,O
ncbi-sent-487,.,.,O
ncbi-sent-488,Five,CD,O
ncbi-sent-488,novel,JJ,O
ncbi-sent-488,germ,NN,O
ncbi-sent-488,-,:,O
ncbi-sent-488,line,NN,O
ncbi-sent-488,APC,NNP,B-DISEASE
ncbi-sent-488,mutations,NNS,O
ncbi-sent-488,were,VBD,O
ncbi-sent-488,identified,VBN,O
ncbi-sent-488,in,IN,O
ncbi-sent-488,seven,CD,O
ncbi-sent-488,kindreds,NNS,O
ncbi-sent-488,.,.,O
ncbi-sent-489,Mutations,NNS,O
ncbi-sent-489,were,VBD,O
ncbi-sent-489,located,VBN,O
ncbi-sent-489,in,IN,O
ncbi-sent-489,three,CD,O
ncbi-sent-489,different,JJ,O
ncbi-sent-489,regions,NNS,O
ncbi-sent-489,of,IN,O
ncbi-sent-489,the,DT,O
ncbi-sent-489,APC,NNP,B-DISEASE
ncbi-sent-489,gene,NN,O
ncbi-sent-489,(,(,O
ncbi-sent-489,1,CD,O
ncbi-sent-489,),),O
ncbi-sent-489,at,IN,O
ncbi-sent-489,the,DT,O
ncbi-sent-489,5,CD,O
ncbi-sent-489,end,NN,O
ncbi-sent-489,spanning,VBG,O
ncbi-sent-489,exons,NNS,O
ncbi-sent-489,4,CD,O
ncbi-sent-489,and,CC,O
ncbi-sent-489,5,CD,O
ncbi-sent-489,",",",",O
ncbi-sent-489,(,(,O
ncbi-sent-489,2,CD,O
ncbi-sent-489,),),O
ncbi-sent-489,within,IN,O
ncbi-sent-489,exon,$,O
ncbi-sent-489,9,CD,O
ncbi-sent-489,",",",",O
ncbi-sent-489,and,CC,O
ncbi-sent-489,(,(,O
ncbi-sent-489,3,CD,O
ncbi-sent-489,),),O
ncbi-sent-489,at,IN,O
ncbi-sent-489,the,DT,O
ncbi-sent-489,3,CD,O
ncbi-sent-489,distal,JJ,O
ncbi-sent-489,end,NN,O
ncbi-sent-489,of,IN,O
ncbi-sent-489,the,DT,O
ncbi-sent-489,gene,NN,O
ncbi-sent-489,.,.,O
ncbi-sent-490,Variability,NNP,O
ncbi-sent-490,in,IN,O
ncbi-sent-490,the,DT,O
ncbi-sent-490,number,NN,O
ncbi-sent-490,of,IN,O
ncbi-sent-490,colorectal,JJ,B-DISEASE
ncbi-sent-490,adenomas,NN,I-DISEASE
ncbi-sent-490,was,VBD,O
ncbi-sent-490,most,RBS,O
ncbi-sent-490,apparent,JJ,O
ncbi-sent-490,in,IN,O
ncbi-sent-490,individuals,NNS,O
ncbi-sent-490,with,IN,O
ncbi-sent-490,mutations,NNS,O
ncbi-sent-490,in,IN,O
ncbi-sent-490,region,NN,O
ncbi-sent-490,1,CD,O
ncbi-sent-490,",",",",O
ncbi-sent-490,and,CC,O
ncbi-sent-490,upper,JJ,O
ncbi-sent-490,-,:,O
ncbi-sent-490,gastrointestinal,JJ,O
ncbi-sent-490,manifestations,NNS,O
ncbi-sent-490,were,VBD,O
ncbi-sent-490,more,RBR,O
ncbi-sent-490,severe,JJ,O
ncbi-sent-490,in,IN,O
ncbi-sent-490,them,PRP,O
ncbi-sent-490,.,.,O
ncbi-sent-491,In,IN,O
ncbi-sent-491,individuals,NNS,O
ncbi-sent-491,with,IN,O
ncbi-sent-491,mutations,NNS,O
ncbi-sent-491,in,IN,O
ncbi-sent-491,either,DT,O
ncbi-sent-491,region,NN,O
ncbi-sent-491,2,CD,O
ncbi-sent-491,or,CC,O
ncbi-sent-491,region,NN,O
ncbi-sent-491,3,CD,O
ncbi-sent-491,",",",",O
ncbi-sent-491,the,DT,O
ncbi-sent-491,average,JJ,O
ncbi-sent-491,number,NN,O
ncbi-sent-491,of,IN,O
ncbi-sent-491,adenomas,NN,B-DISEASE
ncbi-sent-491,tended,VBN,O
ncbi-sent-491,to,TO,O
ncbi-sent-491,be,VB,O
ncbi-sent-491,lower,JJR,O
ncbi-sent-491,than,IN,O
ncbi-sent-491,those,DT,O
ncbi-sent-491,in,IN,O
ncbi-sent-491,individuals,NNS,O
ncbi-sent-491,with,IN,O
ncbi-sent-491,mutations,NNS,O
ncbi-sent-491,in,IN,O
ncbi-sent-491,region,NN,O
ncbi-sent-491,1,CD,O
ncbi-sent-491,",",",",O
ncbi-sent-491,although,IN,O
ncbi-sent-491,age,NN,O
ncbi-sent-491,at,IN,O
ncbi-sent-491,diagnosis,NN,O
ncbi-sent-491,was,VBD,O
ncbi-sent-491,similar,JJ,O
ncbi-sent-491,.,.,O
ncbi-sent-492,In,IN,O
ncbi-sent-492,all,DT,O
ncbi-sent-492,AAPC,NNP,B-DISEASE
ncbi-sent-492,kindreds,NNS,O
ncbi-sent-492,",",",",O
ncbi-sent-492,a,DT,O
ncbi-sent-492,predominance,NN,O
ncbi-sent-492,of,IN,O
ncbi-sent-492,right,JJ,O
ncbi-sent-492,-,:,O
ncbi-sent-492,sided,VBD,O
ncbi-sent-492,colorectal,JJ,B-DISEASE
ncbi-sent-492,adenomas,NN,I-DISEASE
ncbi-sent-492,and,CC,O
ncbi-sent-492,rectal,JJ,B-DISEASE
ncbi-sent-492,polyp,NN,I-DISEASE
ncbi-sent-492,sparing,NN,O
ncbi-sent-492,was,VBD,O
ncbi-sent-492,observed,VBN,O
ncbi-sent-492,.,.,O
ncbi-sent-493,No,DT,O
ncbi-sent-493,desmoid,JJ,B-DISEASE
ncbi-sent-493,tumors,NNS,I-DISEASE
ncbi-sent-493,were,VBD,O
ncbi-sent-493,found,VBN,O
ncbi-sent-493,in,IN,O
ncbi-sent-493,these,DT,O
ncbi-sent-493,kindreds,NNS,O
ncbi-sent-493,.,.,O
ncbi-sent-494,Our,PRP$,O
ncbi-sent-494,data,NNS,O
ncbi-sent-494,suggest,VBP,O
ncbi-sent-494,that,IN,O
ncbi-sent-494,",",",",O
ncbi-sent-494,in,IN,O
ncbi-sent-494,AAPC,NNP,B-DISEASE
ncbi-sent-494,families,NNS,O
ncbi-sent-494,",",",",O
ncbi-sent-494,the,DT,O
ncbi-sent-494,location,NN,O
ncbi-sent-494,of,IN,O
ncbi-sent-494,the,DT,O
ncbi-sent-494,APC,NNP,B-DISEASE
ncbi-sent-494,mutation,NN,O
ncbi-sent-494,may,MD,O
ncbi-sent-494,partially,RB,O
ncbi-sent-494,predict,VB,O
ncbi-sent-494,specific,JJ,O
ncbi-sent-494,phenotypic,NN,O
ncbi-sent-494,expression,NN,O
ncbi-sent-494,.,.,O
ncbi-sent-495,This,DT,O
ncbi-sent-495,should,MD,O
ncbi-sent-495,help,VB,O
ncbi-sent-495,in,IN,O
ncbi-sent-495,the,DT,O
ncbi-sent-495,design,NN,O
ncbi-sent-495,of,IN,O
ncbi-sent-495,tailored,JJ,O
ncbi-sent-495,clinical,JJ,O
ncbi-sent-495,-,:,O
ncbi-sent-495,management,NN,O
ncbi-sent-495,protocols,NNS,O
ncbi-sent-495,in,IN,O
ncbi-sent-495,this,DT,O
ncbi-sent-495,subset,NN,O
ncbi-sent-495,of,IN,O
ncbi-sent-495,FAP,NNP,B-DISEASE
ncbi-sent-495,patients,NNS,O
ncbi-sent-495,.,.,O
ncbi-sent-496,.,.,O
ncbi-sent-497,Wilms,NNP,B-DISEASE
ncbi-sent-497,',POS,I-DISEASE
ncbi-sent-497,tumor,NN,I-DISEASE
ncbi-sent-497,1,CD,O
ncbi-sent-497,and,CC,O
ncbi-sent-497,Dax,NNP,O
ncbi-sent-497,-,:,O
ncbi-sent-497,1,CD,O
ncbi-sent-497,modulate,NN,O
ncbi-sent-497,the,DT,O
ncbi-sent-497,orphan,JJ,O
ncbi-sent-497,nuclear,JJ,O
ncbi-sent-497,receptor,NN,O
ncbi-sent-497,SF,NNP,O
ncbi-sent-497,-,:,O
ncbi-sent-497,1,CD,O
ncbi-sent-497,in,IN,O
ncbi-sent-497,sex,NN,O
ncbi-sent-497,-,:,O
ncbi-sent-497,specific,JJ,O
ncbi-sent-497,gene,NN,O
ncbi-sent-497,expression,NN,O
ncbi-sent-497,.,.,O
ncbi-sent-498,Products,NNS,O
ncbi-sent-498,of,IN,O
ncbi-sent-498,steroidogenic,JJ,O
ncbi-sent-498,factor,NN,O
ncbi-sent-498,1,CD,O
ncbi-sent-498,(,(,O
ncbi-sent-498,SF,NNP,O
ncbi-sent-498,-,:,O
ncbi-sent-498,1,CD,O
ncbi-sent-498,),),O
ncbi-sent-498,and,CC,O
ncbi-sent-498,Wilms,NNP,B-DISEASE
ncbi-sent-498,tumor,NN,I-DISEASE
ncbi-sent-498,1,CD,O
ncbi-sent-498,(,(,O
ncbi-sent-498,WT1,NNP,O
ncbi-sent-498,),),O
ncbi-sent-498,genes,NNS,O
ncbi-sent-498,are,VBP,O
ncbi-sent-498,essential,JJ,O
ncbi-sent-498,for,IN,O
ncbi-sent-498,mammalian,JJ,O
ncbi-sent-498,gonadogenesis,NN,O
ncbi-sent-498,prior,RB,O
ncbi-sent-498,to,TO,O
ncbi-sent-498,sexual,JJ,O
ncbi-sent-498,differentiation,NN,O
ncbi-sent-498,.,.,O
ncbi-sent-499,In,IN,O
ncbi-sent-499,males,NNS,O
ncbi-sent-499,",",",",O
ncbi-sent-499,SF,NNP,O
ncbi-sent-499,-,:,O
ncbi-sent-499,1,CD,O
ncbi-sent-499,participates,NNS,O
ncbi-sent-499,in,IN,O
ncbi-sent-499,sexual,JJ,O
ncbi-sent-499,development,NN,O
ncbi-sent-499,by,IN,O
ncbi-sent-499,regulating,VBG,O
ncbi-sent-499,expression,NN,O
ncbi-sent-499,of,IN,O
ncbi-sent-499,the,DT,O
ncbi-sent-499,polypeptide,NN,O
ncbi-sent-499,hormone,NN,O
ncbi-sent-499,Mullerian,JJ,O
ncbi-sent-499,inhibiting,NN,O
ncbi-sent-499,substance,NN,O
ncbi-sent-499,(,(,O
ncbi-sent-499,MIS,NNP,O
ncbi-sent-499,),),O
ncbi-sent-499,.,.,O
ncbi-sent-500,Here,RB,O
ncbi-sent-500,",",",",O
ncbi-sent-500,we,PRP,O
ncbi-sent-500,show,VBP,O
ncbi-sent-500,that,IN,O
ncbi-sent-500,WT1,NNP,O
ncbi-sent-500,-,:,O
ncbi-sent-500,KTS,NNP,O
ncbi-sent-500,isoforms,NNS,O
ncbi-sent-500,associate,VBP,O
ncbi-sent-500,and,CC,O
ncbi-sent-500,synergize,VBP,O
ncbi-sent-500,with,IN,O
ncbi-sent-500,SF,NNP,O
ncbi-sent-500,-,:,O
ncbi-sent-500,1,CD,O
ncbi-sent-500,to,TO,O
ncbi-sent-500,promote,VB,O
ncbi-sent-500,MIS,NNP,O
ncbi-sent-500,expression,NN,O
ncbi-sent-500,.,.,O
ncbi-sent-501,In,IN,O
ncbi-sent-501,contrast,NN,O
ncbi-sent-501,",",",",O
ncbi-sent-501,WT1,NNP,O
ncbi-sent-501,missense,NN,O
ncbi-sent-501,mutations,NNS,O
ncbi-sent-501,",",",",O
ncbi-sent-501,associated,VBN,O
ncbi-sent-501,with,IN,O
ncbi-sent-501,male,JJ,B-DISEASE
ncbi-sent-501,pseudohermaphroditism,NN,I-DISEASE
ncbi-sent-501,in,IN,O
ncbi-sent-501,Denys,NNP,B-DISEASE
ncbi-sent-501,-,:,I-DISEASE
ncbi-sent-501,Drash,NNP,I-DISEASE
ncbi-sent-501,syndrome,NN,I-DISEASE
ncbi-sent-501,",",",",O
ncbi-sent-501,fail,VBP,O
ncbi-sent-501,to,TO,O
ncbi-sent-501,synergize,VB,O
ncbi-sent-501,with,IN,O
ncbi-sent-501,SF,NNP,O
ncbi-sent-501,-,:,O
ncbi-sent-501,1,CD,O
ncbi-sent-501,.,.,O
ncbi-sent-502,Additionally,RB,O
ncbi-sent-502,",",",",O
ncbi-sent-502,the,DT,O
ncbi-sent-502,X,NNP,O
ncbi-sent-502,-,:,O
ncbi-sent-502,linked,VBN,O
ncbi-sent-502,",",",",O
ncbi-sent-502,candidate,JJ,O
ncbi-sent-502,dosage,NN,O
ncbi-sent-502,-,:,O
ncbi-sent-502,sensitive,JJ,O
ncbi-sent-502,sex,NN,O
ncbi-sent-502,-,:,O
ncbi-sent-502,reversal,NN,O
ncbi-sent-502,gene,NN,O
ncbi-sent-502,",",",",O
ncbi-sent-502,Dax,NNP,O
ncbi-sent-502,-,:,O
ncbi-sent-502,1,CD,O
ncbi-sent-502,",",",",O
ncbi-sent-502,antagonizes,VBZ,O
ncbi-sent-502,synergy,NN,O
ncbi-sent-502,between,IN,O
ncbi-sent-502,SF,NNP,O
ncbi-sent-502,-,:,O
ncbi-sent-502,1,CD,O
ncbi-sent-502,and,CC,O
ncbi-sent-502,WT1,NNP,O
ncbi-sent-502,",",",",O
ncbi-sent-502,most,JJS,O
ncbi-sent-502,likely,RB,O
ncbi-sent-502,through,IN,O
ncbi-sent-502,a,DT,O
ncbi-sent-502,direct,JJ,O
ncbi-sent-502,interaction,NN,O
ncbi-sent-502,with,IN,O
ncbi-sent-502,SF,NNP,O
ncbi-sent-502,-,:,O
ncbi-sent-502,1,CD,O
ncbi-sent-502,.,.,O
ncbi-sent-503,We,PRP,O
ncbi-sent-503,propose,VBP,O
ncbi-sent-503,that,IN,O
ncbi-sent-503,WT1,NNP,O
ncbi-sent-503,and,CC,O
ncbi-sent-503,Dax,NNP,O
ncbi-sent-503,-,:,O
ncbi-sent-503,1,CD,O
ncbi-sent-503,functionally,RB,O
ncbi-sent-503,oppose,VBP,O
ncbi-sent-503,each,DT,O
ncbi-sent-503,other,JJ,O
ncbi-sent-503,in,IN,O
ncbi-sent-503,testis,NN,O
ncbi-sent-503,development,NN,O
ncbi-sent-503,by,IN,O
ncbi-sent-503,modulating,VBG,O
ncbi-sent-503,SF,NNP,O
ncbi-sent-503,-,:,O
ncbi-sent-503,1,CD,O
ncbi-sent-503,-,:,O
ncbi-sent-503,mediated,VBN,O
ncbi-sent-503,transactivation,NN,O
ncbi-sent-503,.,.,O
ncbi-sent-504,.,.,O
ncbi-sent-505,A,DT,O
ncbi-sent-505,mouse,NN,O
ncbi-sent-505,model,NN,O
ncbi-sent-505,for,IN,O
ncbi-sent-505,Prader,NNP,B-DISEASE
ncbi-sent-505,-,:,I-DISEASE
ncbi-sent-505,Willi,NNP,I-DISEASE
ncbi-sent-505,syndrome,VBP,I-DISEASE
ncbi-sent-505,imprinting,VBG,O
ncbi-sent-505,-,:,O
ncbi-sent-505,centre,NN,O
ncbi-sent-505,mutations,NNS,O
ncbi-sent-505,.,.,O
ncbi-sent-506,Imprinting,VBG,O
ncbi-sent-506,in,IN,O
ncbi-sent-506,the,DT,O
ncbi-sent-506,15q11,CD,O
ncbi-sent-506,-,:,O
ncbi-sent-506,q13,JJ,O
ncbi-sent-506,region,NN,O
ncbi-sent-506,involves,VBZ,O
ncbi-sent-506,an,DT,O
ncbi-sent-506,imprinting,NN,O
ncbi-sent-506,centre,NN,O
ncbi-sent-506,(,(,O
ncbi-sent-506,IC,NNP,O
ncbi-sent-506,),),O
ncbi-sent-506,",",",",O
ncbi-sent-506,mapping,VBG,O
ncbi-sent-506,in,IN,O
ncbi-sent-506,part,NN,O
ncbi-sent-506,to,TO,O
ncbi-sent-506,the,DT,O
ncbi-sent-506,promoter,NN,O
ncbi-sent-506,and,CC,O
ncbi-sent-506,first,JJ,O
ncbi-sent-506,exon,NN,O
ncbi-sent-506,of,IN,O
ncbi-sent-506,SNRPN,NNP,O
ncbi-sent-506,.,.,O
ncbi-sent-507,Deletion,NN,O
ncbi-sent-507,of,IN,O
ncbi-sent-507,this,DT,O
ncbi-sent-507,IC,NNP,O
ncbi-sent-507,abolishes,VBZ,O
ncbi-sent-507,local,JJ,O
ncbi-sent-507,paternally,RB,O
ncbi-sent-507,derived,VBN,O
ncbi-sent-507,gene,NN,O
ncbi-sent-507,expression,NN,O
ncbi-sent-507,and,CC,O
ncbi-sent-507,results,NNS,O
ncbi-sent-507,in,IN,O
ncbi-sent-507,Prader,NNP,B-DISEASE
ncbi-sent-507,-,:,I-DISEASE
ncbi-sent-507,Willi,NNP,I-DISEASE
ncbi-sent-507,syndrome,NN,I-DISEASE
ncbi-sent-507,(,(,O
ncbi-sent-507,PWS,NNP,B-DISEASE
ncbi-sent-507,),),O
ncbi-sent-507,.,.,O
ncbi-sent-508,We,PRP,O
ncbi-sent-508,have,VBP,O
ncbi-sent-508,created,VBN,O
ncbi-sent-508,two,CD,O
ncbi-sent-508,deletion,NN,O
ncbi-sent-508,mutations,NNS,O
ncbi-sent-508,in,IN,O
ncbi-sent-508,mice,NN,O
ncbi-sent-508,to,TO,O
ncbi-sent-508,understand,VB,O
ncbi-sent-508,PWS,NNP,B-DISEASE
ncbi-sent-508,and,CC,O
ncbi-sent-508,the,DT,O
ncbi-sent-508,mechanism,NN,O
ncbi-sent-508,of,IN,O
ncbi-sent-508,this,DT,O
ncbi-sent-508,IC,NNP,O
ncbi-sent-508,.,.,O
ncbi-sent-509,Mice,NNP,O
ncbi-sent-509,harbouring,VBG,O
ncbi-sent-509,an,DT,O
ncbi-sent-509,intragenic,JJ,O
ncbi-sent-509,deletion,NN,O
ncbi-sent-509,in,IN,O
ncbi-sent-509,Snrpn,NNP,O
ncbi-sent-509,are,VBP,O
ncbi-sent-509,phenotypically,RB,O
ncbi-sent-509,normal,JJ,O
ncbi-sent-509,",",",",O
ncbi-sent-509,suggesting,VBG,O
ncbi-sent-509,that,IN,O
ncbi-sent-509,mutations,NNS,O
ncbi-sent-509,of,IN,O
ncbi-sent-509,SNRPN,NNP,O
ncbi-sent-509,are,VBP,O
ncbi-sent-509,not,RB,O
ncbi-sent-509,sufficient,JJ,O
ncbi-sent-509,to,TO,O
ncbi-sent-509,induce,VB,O
ncbi-sent-509,PWS,NNP,B-DISEASE
ncbi-sent-509,.,.,O
ncbi-sent-510,Mice,NNP,O
ncbi-sent-510,with,IN,O
ncbi-sent-510,a,DT,O
ncbi-sent-510,larger,JJR,O
ncbi-sent-510,deletion,NN,O
ncbi-sent-510,involving,VBG,O
ncbi-sent-510,both,DT,O
ncbi-sent-510,Snrpn,NNP,O
ncbi-sent-510,and,CC,O
ncbi-sent-510,the,DT,O
ncbi-sent-510,putative,JJ,O
ncbi-sent-510,PWS,NNP,O
ncbi-sent-510,-,:,O
ncbi-sent-510,IC,NNP,O
ncbi-sent-510,lack,VBP,O
ncbi-sent-510,expression,NN,O
ncbi-sent-510,of,IN,O
ncbi-sent-510,the,DT,O
ncbi-sent-510,imprinted,JJ,O
ncbi-sent-510,genes,NNS,O
ncbi-sent-510,Zfp127,NNP,O
ncbi-sent-510,(,(,O
ncbi-sent-510,mouse,IN,O
ncbi-sent-510,homologue,NN,O
ncbi-sent-510,of,IN,O
ncbi-sent-510,ZNF127,NNP,O
ncbi-sent-510,),),O
ncbi-sent-510,",",",",O
ncbi-sent-510,Ndn,NNP,O
ncbi-sent-510,and,CC,O
ncbi-sent-510,Ipw,NNP,O
ncbi-sent-510,",",",",O
ncbi-sent-510,and,CC,O
ncbi-sent-510,manifest,JJS,O
ncbi-sent-510,several,JJ,O
ncbi-sent-510,phenotypes,NNS,O
ncbi-sent-510,common,JJ,O
ncbi-sent-510,to,TO,O
ncbi-sent-510,PWS,NNP,B-DISEASE
ncbi-sent-510,infants,NNS,O
ncbi-sent-510,.,.,O
ncbi-sent-511,These,DT,O
ncbi-sent-511,data,NNS,O
ncbi-sent-511,demonstrate,NN,O
ncbi-sent-511,that,IN,O
ncbi-sent-511,both,CC,O
ncbi-sent-511,the,DT,O
ncbi-sent-511,position,NN,O
ncbi-sent-511,of,IN,O
ncbi-sent-511,the,DT,O
ncbi-sent-511,IC,NNP,O
ncbi-sent-511,and,CC,O
ncbi-sent-511,its,PRP$,O
ncbi-sent-511,role,NN,O
ncbi-sent-511,in,IN,O
ncbi-sent-511,the,DT,O
ncbi-sent-511,coordinate,JJ,O
ncbi-sent-511,expression,NN,O
ncbi-sent-511,of,IN,O
ncbi-sent-511,genes,NNS,O
ncbi-sent-511,is,VBZ,O
ncbi-sent-511,conserved,VBN,O
ncbi-sent-511,between,IN,O
ncbi-sent-511,mouse,NN,O
ncbi-sent-511,and,CC,O
ncbi-sent-511,human,NN,O
ncbi-sent-511,",",",",O
ncbi-sent-511,and,CC,O
ncbi-sent-511,indicate,VBP,O
ncbi-sent-511,that,IN,O
ncbi-sent-511,the,DT,O
ncbi-sent-511,mouse,NN,O
ncbi-sent-511,is,VBZ,O
ncbi-sent-511,a,DT,O
ncbi-sent-511,suitable,JJ,O
ncbi-sent-511,model,NN,O
ncbi-sent-511,system,NN,O
ncbi-sent-511,in,IN,O
ncbi-sent-511,which,WDT,O
ncbi-sent-511,to,TO,O
ncbi-sent-511,investigate,VB,O
ncbi-sent-511,the,DT,O
ncbi-sent-511,molecular,JJ,O
ncbi-sent-511,mechanisms,NN,O
ncbi-sent-511,of,IN,O
ncbi-sent-511,imprinting,VBG,O
ncbi-sent-511,in,IN,O
ncbi-sent-511,this,DT,O
ncbi-sent-511,region,NN,O
ncbi-sent-511,of,IN,O
ncbi-sent-511,the,DT,O
ncbi-sent-511,genome,NN,O
ncbi-sent-511,.,.,O
ncbi-sent-512,.,.,O
ncbi-sent-513,Mutations,NNS,O
ncbi-sent-513,of,IN,O
ncbi-sent-513,the,DT,O
ncbi-sent-513,ATM,NNP,O
ncbi-sent-513,gene,NN,O
ncbi-sent-513,detected,VBD,O
ncbi-sent-513,in,IN,O
ncbi-sent-513,Japanese,JJ,O
ncbi-sent-513,ataxia,JJ,B-DISEASE
ncbi-sent-513,-,:,I-DISEASE
ncbi-sent-513,telangiectasia,NN,I-DISEASE
ncbi-sent-513,patients,NNS,O
ncbi-sent-513,:,:,O
ncbi-sent-513,possible,JJ,O
ncbi-sent-513,preponderance,NN,O
ncbi-sent-513,of,IN,O
ncbi-sent-513,the,DT,O
ncbi-sent-513,two,CD,O
ncbi-sent-513,founder,NN,O
ncbi-sent-513,mutations,NNS,O
ncbi-sent-513,4612del165,CD,O
ncbi-sent-513,and,CC,O
ncbi-sent-513,7883del5,CD,O
ncbi-sent-513,.,.,O
ncbi-sent-514,The,DT,O
ncbi-sent-514,ATM,NNP,O
ncbi-sent-514,(,(,O
ncbi-sent-514,A,NNP,O
ncbi-sent-514,-,:,O
ncbi-sent-514,T,NN,O
ncbi-sent-514,",",",",O
ncbi-sent-514,mutated,VBN,O
ncbi-sent-514,),),O
ncbi-sent-514,gene,NN,O
ncbi-sent-514,on,IN,O
ncbi-sent-514,human,JJ,O
ncbi-sent-514,chromosome,NN,O
ncbi-sent-514,11q22,CD,O
ncbi-sent-514,.,.,O
ncbi-sent-515,3,CD,O
ncbi-sent-515,has,VBZ,O
ncbi-sent-515,recently,RB,O
ncbi-sent-515,been,VBN,O
ncbi-sent-515,identified,VBN,O
ncbi-sent-515,as,IN,O
ncbi-sent-515,the,DT,O
ncbi-sent-515,gene,NN,O
ncbi-sent-515,responsible,JJ,O
ncbi-sent-515,for,IN,O
ncbi-sent-515,the,DT,O
ncbi-sent-515,human,JJ,O
ncbi-sent-515,recessive,JJ,B-DISEASE
ncbi-sent-515,disease,NN,I-DISEASE
ncbi-sent-515,ataxia,SYM,B-DISEASE
ncbi-sent-515,-,:,I-DISEASE
ncbi-sent-515,telangiectasia,NN,I-DISEASE
ncbi-sent-515,(,(,O
ncbi-sent-515,A,DT,B-DISEASE
ncbi-sent-515,-,:,I-DISEASE
ncbi-sent-515,T,NN,I-DISEASE
ncbi-sent-515,),),O
ncbi-sent-515,.,.,O
ncbi-sent-516,In,IN,O
ncbi-sent-516,order,NN,O
ncbi-sent-516,to,TO,O
ncbi-sent-516,define,VB,O
ncbi-sent-516,the,DT,O
ncbi-sent-516,types,NNS,O
ncbi-sent-516,of,IN,O
ncbi-sent-516,disease,NN,O
ncbi-sent-516,-,:,O
ncbi-sent-516,causing,NN,O
ncbi-sent-516,ATM,NNP,O
ncbi-sent-516,mutations,NNS,O
ncbi-sent-516,in,IN,O
ncbi-sent-516,Japanese,JJ,O
ncbi-sent-516,A,NNP,B-DISEASE
ncbi-sent-516,-,:,I-DISEASE
ncbi-sent-516,T,NN,I-DISEASE
ncbi-sent-516,patients,NNS,O
ncbi-sent-516,as,RB,O
ncbi-sent-516,well,RB,O
ncbi-sent-516,as,IN,O
ncbi-sent-516,to,TO,O
ncbi-sent-516,look,VB,O
ncbi-sent-516,for,IN,O
ncbi-sent-516,possible,JJ,O
ncbi-sent-516,mutational,JJ,O
ncbi-sent-516,hotspots,NNS,O
ncbi-sent-516,",",",",O
ncbi-sent-516,reverse,VB,O
ncbi-sent-516,-,:,O
ncbi-sent-516,transcribed,NN,O
ncbi-sent-516,RNA,NNP,O
ncbi-sent-516,derived,VBD,O
ncbi-sent-516,from,IN,O
ncbi-sent-516,ten,JJ,O
ncbi-sent-516,patients,NNS,O
ncbi-sent-516,belonging,VBG,O
ncbi-sent-516,to,TO,O
ncbi-sent-516,eight,CD,O
ncbi-sent-516,unrelated,JJ,O
ncbi-sent-516,Japanese,PDT,O
ncbi-sent-516,A,DT,B-DISEASE
ncbi-sent-516,-,:,I-DISEASE
ncbi-sent-516,T,NN,I-DISEASE
ncbi-sent-516,families,NNS,O
ncbi-sent-516,was,VBD,O
ncbi-sent-516,analyzed,VBN,O
ncbi-sent-516,for,IN,O
ncbi-sent-516,mutations,NNS,O
ncbi-sent-516,by,IN,O
ncbi-sent-516,the,DT,O
ncbi-sent-516,restriction,NN,O
ncbi-sent-516,endonuclease,NN,O
ncbi-sent-516,fingerprinting,VBG,O
ncbi-sent-516,method,NN,O
ncbi-sent-516,.,.,O
ncbi-sent-517,As,IN,O
ncbi-sent-517,has,VBZ,O
ncbi-sent-517,been,VBN,O
ncbi-sent-517,reported,VBN,O
ncbi-sent-517,by,IN,O
ncbi-sent-517,others,NNS,O
ncbi-sent-517,",",",",O
ncbi-sent-517,mutations,NNS,O
ncbi-sent-517,that,WDT,O
ncbi-sent-517,lead,VBP,O
ncbi-sent-517,to,TO,O
ncbi-sent-517,exon,VB,O
ncbi-sent-517,skipping,VBG,O
ncbi-sent-517,or,CC,O
ncbi-sent-517,premature,JJ,O
ncbi-sent-517,protein,JJ,O
ncbi-sent-517,truncation,NN,O
ncbi-sent-517,were,VBD,O
ncbi-sent-517,also,RB,O
ncbi-sent-517,predominant,JJ,O
ncbi-sent-517,in,IN,O
ncbi-sent-517,our,PRP$,O
ncbi-sent-517,mutants,NNS,O
ncbi-sent-517,.,.,O
ncbi-sent-518,Six,CD,O
ncbi-sent-518,different,JJ,O
ncbi-sent-518,mutations,NNS,O
ncbi-sent-518,were,VBD,O
ncbi-sent-518,identified,VBN,O
ncbi-sent-518,on,IN,O
ncbi-sent-518,12,CD,O
ncbi-sent-518,of,IN,O
ncbi-sent-518,the,DT,O
ncbi-sent-518,16,CD,O
ncbi-sent-518,alleles,NNS,O
ncbi-sent-518,examined,VBN,O
ncbi-sent-518,.,.,O
ncbi-sent-519,Four,CD,O
ncbi-sent-519,were,VBD,O
ncbi-sent-519,deletions,NNS,O
ncbi-sent-519,involving,VBG,O
ncbi-sent-519,a,DT,O
ncbi-sent-519,loss,NN,O
ncbi-sent-519,of,IN,O
ncbi-sent-519,a,DT,O
ncbi-sent-519,single,JJ,O
ncbi-sent-519,exon,NN,O
ncbi-sent-519,exon,VBD,O
ncbi-sent-519,7,CD,O
ncbi-sent-519,",",",",O
ncbi-sent-519,exon,RB,O
ncbi-sent-519,16,CD,O
ncbi-sent-519,",",",",O
ncbi-sent-519,exon,VBZ,O
ncbi-sent-519,33,CD,O
ncbi-sent-519,or,CC,O
ncbi-sent-519,exon,VB,O
ncbi-sent-519,35,CD,O
ncbi-sent-519,.,.,O
ncbi-sent-520,The,DT,O
ncbi-sent-520,others,NNS,O
ncbi-sent-520,were,VBD,O
ncbi-sent-520,minute,JJ,O
ncbi-sent-520,deletions,NNS,O
ncbi-sent-520,",",",",O
ncbi-sent-520,4649delA,CD,O
ncbi-sent-520,in,IN,O
ncbi-sent-520,exon,JJ,O
ncbi-sent-520,33,CD,O
ncbi-sent-520,and,CC,O
ncbi-sent-520,7883del5,CD,O
ncbi-sent-520,in,IN,O
ncbi-sent-520,exon,JJ,O
ncbi-sent-520,55,CD,O
ncbi-sent-520,.,.,O
ncbi-sent-521,The,DT,O
ncbi-sent-521,mutations,NNS,O
ncbi-sent-521,4612del165,CD,O
ncbi-sent-521,and,CC,O
ncbi-sent-521,7883del5,CD,O
ncbi-sent-521,were,VBD,O
ncbi-sent-521,found,VBN,O
ncbi-sent-521,in,IN,O
ncbi-sent-521,more,JJR,O
ncbi-sent-521,than,IN,O
ncbi-sent-521,two,CD,O
ncbi-sent-521,unrelated,JJ,O
ncbi-sent-521,families,NNS,O
ncbi-sent-521,;,:,O
ncbi-sent-521,44,CD,O
ncbi-sent-521,%,NN,O
ncbi-sent-521,(,(,O
ncbi-sent-521,7,CD,O
ncbi-sent-521,of,IN,O
ncbi-sent-521,16,CD,O
ncbi-sent-521,),),O
ncbi-sent-521,of,IN,O
ncbi-sent-521,the,DT,O
ncbi-sent-521,mutant,JJ,O
ncbi-sent-521,alleles,NNS,O
ncbi-sent-521,had,VBD,O
ncbi-sent-521,one,CD,O
ncbi-sent-521,of,IN,O
ncbi-sent-521,the,DT,O
ncbi-sent-521,two,CD,O
ncbi-sent-521,mutations,NNS,O
ncbi-sent-521,.,.,O
ncbi-sent-522,The,DT,O
ncbi-sent-522,4612del165,CD,O
ncbi-sent-522,mutations,NNS,O
ncbi-sent-522,in,IN,O
ncbi-sent-522,three,CD,O
ncbi-sent-522,different,JJ,O
ncbi-sent-522,families,NNS,O
ncbi-sent-522,were,VBD,O
ncbi-sent-522,all,DT,O
ncbi-sent-522,ascribed,VBN,O
ncbi-sent-522,to,TO,O
ncbi-sent-522,the,DT,O
ncbi-sent-522,same,JJ,O
ncbi-sent-522,T,NNP,O
ncbi-sent-522,-,:,O
ncbi-sent-522,-,:,O
ncbi-sent-522,>,VB,O
ncbi-sent-522,A,DT,O
ncbi-sent-522,substitution,NN,O
ncbi-sent-522,at,IN,O
ncbi-sent-522,the,DT,O
ncbi-sent-522,splice,NN,O
ncbi-sent-522,donor,NN,O
ncbi-sent-522,site,NN,O
ncbi-sent-522,in,IN,O
ncbi-sent-522,intron,NN,O
ncbi-sent-522,33,CD,O
ncbi-sent-522,.,.,O
ncbi-sent-523,Microsatellite,NNP,O
ncbi-sent-523,genotyping,VBG,O
ncbi-sent-523,around,IN,O
ncbi-sent-523,the,DT,O
ncbi-sent-523,ATM,NNP,O
ncbi-sent-523,locus,NN,O
ncbi-sent-523,also,RB,O
ncbi-sent-523,indicated,VBD,O
ncbi-sent-523,that,IN,O
ncbi-sent-523,a,DT,O
ncbi-sent-523,common,JJ,O
ncbi-sent-523,haplotype,NN,O
ncbi-sent-523,was,VBD,O
ncbi-sent-523,shared,VBN,O
ncbi-sent-523,by,IN,O
ncbi-sent-523,the,DT,O
ncbi-sent-523,mutant,JJ,O
ncbi-sent-523,alleles,NNS,O
ncbi-sent-523,in,IN,O
ncbi-sent-523,both,DT,O
ncbi-sent-523,mutations,NNS,O
ncbi-sent-523,.,.,O
ncbi-sent-524,This,DT,O
ncbi-sent-524,suggests,VBZ,O
ncbi-sent-524,that,IN,O
ncbi-sent-524,these,DT,O
ncbi-sent-524,two,CD,O
ncbi-sent-524,founder,NN,O
ncbi-sent-524,mutations,NNS,O
ncbi-sent-524,may,MD,O
ncbi-sent-524,be,VB,O
ncbi-sent-524,predominant,JJ,O
ncbi-sent-524,among,IN,O
ncbi-sent-524,Japanese,JJ,O
ncbi-sent-524,ATM,NNP,O
ncbi-sent-524,mutant,JJ,O
ncbi-sent-524,alleles,NNS,O
ncbi-sent-524,.,.,O
ncbi-sent-525,W474C,NNP,O
ncbi-sent-525,amino,NN,O
ncbi-sent-525,acid,NN,O
ncbi-sent-525,substitution,NN,O
ncbi-sent-525,affects,VBZ,O
ncbi-sent-525,early,JJ,O
ncbi-sent-525,processing,NN,O
ncbi-sent-525,of,IN,O
ncbi-sent-525,the,DT,O
ncbi-sent-525,alpha,JJ,O
ncbi-sent-525,-,:,O
ncbi-sent-525,subunit,NN,O
ncbi-sent-525,of,IN,O
ncbi-sent-525,beta,NN,O
ncbi-sent-525,-,:,O
ncbi-sent-525,hexosaminidase,NN,O
ncbi-sent-525,A,DT,O
ncbi-sent-525,and,CC,O
ncbi-sent-525,is,VBZ,O
ncbi-sent-525,associated,VBN,O
ncbi-sent-525,with,IN,O
ncbi-sent-525,subacute,NN,O
ncbi-sent-525,G,NNP,B-DISEASE
ncbi-sent-525,(,(,I-DISEASE
ncbi-sent-525,M2,NNP,I-DISEASE
ncbi-sent-525,),),I-DISEASE
ncbi-sent-525,gangliosidosis,NN,I-DISEASE
ncbi-sent-525,.,.,O
ncbi-sent-526,Mutations,NNS,O
ncbi-sent-526,in,IN,O
ncbi-sent-526,the,DT,O
ncbi-sent-526,HEXA,NNP,O
ncbi-sent-526,gene,NN,O
ncbi-sent-526,",",",",O
ncbi-sent-526,encoding,VBG,O
ncbi-sent-526,the,DT,O
ncbi-sent-526,alpha,NN,O
ncbi-sent-526,-,:,O
ncbi-sent-526,subunit,NN,O
ncbi-sent-526,of,IN,O
ncbi-sent-526,beta,NN,O
ncbi-sent-526,-,:,O
ncbi-sent-526,hexosaminidase,NN,O
ncbi-sent-526,A,NNP,O
ncbi-sent-526,(,(,O
ncbi-sent-526,Hex,NNP,O
ncbi-sent-526,A,NNP,O
ncbi-sent-526,),),O
ncbi-sent-526,",",",",O
ncbi-sent-526,that,IN,O
ncbi-sent-526,abolish,JJ,O
ncbi-sent-526,Hex,NNP,O
ncbi-sent-526,A,NNP,O
ncbi-sent-526,enzyme,NN,O
ncbi-sent-526,activity,NN,O
ncbi-sent-526,cause,NN,O
ncbi-sent-526,Tay,NNP,B-DISEASE
ncbi-sent-526,-,:,I-DISEASE
ncbi-sent-526,Sachs,NNP,I-DISEASE
ncbi-sent-526,disease,NN,I-DISEASE
ncbi-sent-526,(,(,O
ncbi-sent-526,TSD,NNP,B-DISEASE
ncbi-sent-526,),),O
ncbi-sent-526,",",",",O
ncbi-sent-526,the,DT,O
ncbi-sent-526,fatal,JJ,O
ncbi-sent-526,infantile,JJ,B-DISEASE
ncbi-sent-526,form,NN,I-DISEASE
ncbi-sent-526,of,IN,I-DISEASE
ncbi-sent-526,G,NNP,I-DISEASE
ncbi-sent-526,(,(,I-DISEASE
ncbi-sent-526,M2,NNP,I-DISEASE
ncbi-sent-526,),),I-DISEASE
ncbi-sent-526,gangliosidosis,NN,I-DISEASE
ncbi-sent-526,",",",",I-DISEASE
ncbi-sent-526,Type,NNP,I-DISEASE
ncbi-sent-526,1,CD,I-DISEASE
ncbi-sent-526,.,.,O
ncbi-sent-527,Less,JJR,O
ncbi-sent-527,severe,JJ,O
ncbi-sent-527,",",",",O
ncbi-sent-527,subacute,JJ,O
ncbi-sent-527,(,(,O
ncbi-sent-527,juvenile,JJ,O
ncbi-sent-527,-,:,O
ncbi-sent-527,onset,NN,O
ncbi-sent-527,),),O
ncbi-sent-527,and,CC,O
ncbi-sent-527,chronic,JJ,O
ncbi-sent-527,(,(,O
ncbi-sent-527,adult,JJ,O
ncbi-sent-527,-,:,O
ncbi-sent-527,onset,NN,O
ncbi-sent-527,),),O
ncbi-sent-527,variants,NNS,O
ncbi-sent-527,are,VBP,O
ncbi-sent-527,characterized,VBN,O
ncbi-sent-527,by,IN,O
ncbi-sent-527,a,DT,O
ncbi-sent-527,broad,JJ,O
ncbi-sent-527,spectrum,NN,O
ncbi-sent-527,of,IN,O
ncbi-sent-527,clinical,JJ,O
ncbi-sent-527,manifestations,NNS,O
ncbi-sent-527,and,CC,O
ncbi-sent-527,are,VBP,O
ncbi-sent-527,associated,VBN,O
ncbi-sent-527,with,IN,O
ncbi-sent-527,residual,JJ,O
ncbi-sent-527,levels,NNS,O
ncbi-sent-527,of,IN,O
ncbi-sent-527,Hex,NNP,O
ncbi-sent-527,A,NNP,O
ncbi-sent-527,enzyme,NN,O
ncbi-sent-527,activity,NN,O
ncbi-sent-527,.,.,O
ncbi-sent-528,We,PRP,O
ncbi-sent-528,identified,VBD,O
ncbi-sent-528,a,DT,O
ncbi-sent-528,1422,CD,O
ncbi-sent-528,G,NNP,O
ncbi-sent-528,-,:,O
ncbi-sent-528,-,:,O
ncbi-sent-528,>,NN,O
ncbi-sent-528,C,NNP,O
ncbi-sent-528,(,(,O
ncbi-sent-528,amino,JJ,O
ncbi-sent-528,acid,VBP,O
ncbi-sent-528,W474C,NNP,O
ncbi-sent-528,),),O
ncbi-sent-528,substitution,NN,O
ncbi-sent-528,in,IN,O
ncbi-sent-528,the,DT,O
ncbi-sent-528,first,JJ,O
ncbi-sent-528,position,NN,O
ncbi-sent-528,of,IN,O
ncbi-sent-528,exon,JJ,O
ncbi-sent-528,13,CD,O
ncbi-sent-528,of,IN,O
ncbi-sent-528,HEXA,NNP,O
ncbi-sent-528,of,IN,O
ncbi-sent-528,a,DT,O
ncbi-sent-528,non,JJ,O
ncbi-sent-528,-,:,O
ncbi-sent-528,Jewish,JJ,O
ncbi-sent-528,proband,NN,O
ncbi-sent-528,who,WP,O
ncbi-sent-528,manifested,VBD,O
ncbi-sent-528,a,DT,O
ncbi-sent-528,subacute,JJ,O
ncbi-sent-528,variant,NN,O
ncbi-sent-528,of,IN,O
ncbi-sent-528,G,NNP,B-DISEASE
ncbi-sent-528,(,(,I-DISEASE
ncbi-sent-528,M2,NNP,I-DISEASE
ncbi-sent-528,),),I-DISEASE
ncbi-sent-528,gangliosidosis,NN,I-DISEASE
ncbi-sent-528,.,.,O
ncbi-sent-529,On,IN,O
ncbi-sent-529,the,DT,O
ncbi-sent-529,second,JJ,O
ncbi-sent-529,maternally,RB,O
ncbi-sent-529,inherited,VBN,O
ncbi-sent-529,allele,RB,O
ncbi-sent-529,",",",",O
ncbi-sent-529,we,PRP,O
ncbi-sent-529,identified,VBD,O
ncbi-sent-529,the,DT,O
ncbi-sent-529,common,JJ,O
ncbi-sent-529,infantile,NN,O
ncbi-sent-529,disease,NN,O
ncbi-sent-529,-,:,O
ncbi-sent-529,causing,VBG,O
ncbi-sent-529,4,CD,O
ncbi-sent-529,-,:,O
ncbi-sent-529,bp,NN,O
ncbi-sent-529,insertion,NN,O
ncbi-sent-529,",",",",O
ncbi-sent-529,+,NNP,O
ncbi-sent-529,TATC,NNP,O
ncbi-sent-529,1278,CD,O
ncbi-sent-529,",",",",O
ncbi-sent-529,in,IN,O
ncbi-sent-529,exon,JJ,O
ncbi-sent-529,11,CD,O
ncbi-sent-529,.,.,O
ncbi-sent-530,Pulse,NNP,O
ncbi-sent-530,-,:,O
ncbi-sent-530,chase,NN,O
ncbi-sent-530,analysis,NN,O
ncbi-sent-530,using,VBG,O
ncbi-sent-530,proband,NN,O
ncbi-sent-530,fibroblasts,NNS,O
ncbi-sent-530,revealed,VBD,O
ncbi-sent-530,that,IN,O
ncbi-sent-530,the,DT,O
ncbi-sent-530,W474C,NNP,O
ncbi-sent-530,-,:,O
ncbi-sent-530,containing,VBG,O
ncbi-sent-530,alpha,JJ,O
ncbi-sent-530,-,:,O
ncbi-sent-530,subunit,NN,O
ncbi-sent-530,precursor,NN,O
ncbi-sent-530,was,VBD,O
ncbi-sent-530,normally,RB,O
ncbi-sent-530,synthesized,VBN,O
ncbi-sent-530,",",",",O
ncbi-sent-530,but,CC,O
ncbi-sent-530,not,RB,O
ncbi-sent-530,phosphorylated,VBD,O
ncbi-sent-530,or,CC,O
ncbi-sent-530,secreted,VBN,O
ncbi-sent-530,",",",",O
ncbi-sent-530,and,CC,O
ncbi-sent-530,the,DT,O
ncbi-sent-530,mature,NN,O
ncbi-sent-530,lysosomal,JJ,O
ncbi-sent-530,alpha,SYM,O
ncbi-sent-530,-,:,O
ncbi-sent-530,subunit,NN,O
ncbi-sent-530,was,VBD,O
ncbi-sent-530,not,RB,O
ncbi-sent-530,detected,VBN,O
ncbi-sent-530,.,.,O
ncbi-sent-531,When,WRB,O
ncbi-sent-531,the,DT,O
ncbi-sent-531,W474C,NNP,O
ncbi-sent-531,-,:,O
ncbi-sent-531,containing,VBG,O
ncbi-sent-531,alpha,JJ,O
ncbi-sent-531,-,:,O
ncbi-sent-531,subunit,NN,O
ncbi-sent-531,was,VBD,O
ncbi-sent-531,transiently,RB,O
ncbi-sent-531,co,JJ,O
ncbi-sent-531,-,:,O
ncbi-sent-531,expressed,VBN,O
ncbi-sent-531,with,IN,O
ncbi-sent-531,the,DT,O
ncbi-sent-531,beta,NN,O
ncbi-sent-531,-,:,O
ncbi-sent-531,subunit,NN,O
ncbi-sent-531,to,TO,O
ncbi-sent-531,produce,VB,O
ncbi-sent-531,Hex,NNP,O
ncbi-sent-531,A,NNP,O
ncbi-sent-531,(,(,O
ncbi-sent-531,alphabeta,NN,O
ncbi-sent-531,),),O
ncbi-sent-531,in,IN,O
ncbi-sent-531,COS,NNP,O
ncbi-sent-531,-,:,O
ncbi-sent-531,7,CD,O
ncbi-sent-531,cells,NNS,O
ncbi-sent-531,",",",",O
ncbi-sent-531,the,DT,O
ncbi-sent-531,mature,NN,O
ncbi-sent-531,alpha,SYM,O
ncbi-sent-531,-,:,O
ncbi-sent-531,subunit,NN,O
ncbi-sent-531,was,VBD,O
ncbi-sent-531,present,JJ,O
ncbi-sent-531,",",",",O
ncbi-sent-531,but,CC,O
ncbi-sent-531,its,PRP$,O
ncbi-sent-531,level,NN,O
ncbi-sent-531,was,VBD,O
ncbi-sent-531,much,RB,O
ncbi-sent-531,lower,JJR,O
ncbi-sent-531,than,IN,O
ncbi-sent-531,that,DT,O
ncbi-sent-531,from,IN,O
ncbi-sent-531,normal,JJ,O
ncbi-sent-531,alpha,JJ,O
ncbi-sent-531,-,:,O
ncbi-sent-531,subunit,NN,O
ncbi-sent-531,transfections,NNS,O
ncbi-sent-531,",",",",O
ncbi-sent-531,although,IN,O
ncbi-sent-531,higher,JJR,O
ncbi-sent-531,than,IN,O
ncbi-sent-531,in,IN,O
ncbi-sent-531,those,DT,O
ncbi-sent-531,cells,NNS,O
ncbi-sent-531,transfected,VBN,O
ncbi-sent-531,with,IN,O
ncbi-sent-531,an,DT,O
ncbi-sent-531,alpha,JJ,O
ncbi-sent-531,-,:,O
ncbi-sent-531,subunit,NN,O
ncbi-sent-531,associated,VBN,O
ncbi-sent-531,with,IN,O
ncbi-sent-531,infantile,JJ,O
ncbi-sent-531,TSD,NNP,B-DISEASE
ncbi-sent-531,.,.,O
ncbi-sent-532,Furthermore,NNP,O
ncbi-sent-532,",",",",O
ncbi-sent-532,the,DT,O
ncbi-sent-532,precursor,NN,O
ncbi-sent-532,level,NN,O
ncbi-sent-532,of,IN,O
ncbi-sent-532,the,DT,O
ncbi-sent-532,W474C,NNP,O
ncbi-sent-532,alpha,SYM,O
ncbi-sent-532,-,:,O
ncbi-sent-532,subunit,NN,O
ncbi-sent-532,was,VBD,O
ncbi-sent-532,found,VBN,O
ncbi-sent-532,to,TO,O
ncbi-sent-532,accumulate,VB,O
ncbi-sent-532,in,IN,O
ncbi-sent-532,comparison,NN,O
ncbi-sent-532,to,TO,O
ncbi-sent-532,the,DT,O
ncbi-sent-532,normal,JJ,O
ncbi-sent-532,alpha,JJ,O
ncbi-sent-532,-,:,O
ncbi-sent-532,subunit,NN,O
ncbi-sent-532,precursor,NN,O
ncbi-sent-532,levels,NNS,O
ncbi-sent-532,.,.,O
ncbi-sent-533,We,PRP,O
ncbi-sent-533,conclude,VBP,O
ncbi-sent-533,that,IN,O
ncbi-sent-533,the,DT,O
ncbi-sent-533,1422,CD,O
ncbi-sent-533,G,NNP,O
ncbi-sent-533,-,:,O
ncbi-sent-533,-,:,O
ncbi-sent-533,>,NN,O
ncbi-sent-533,C,NNP,O
ncbi-sent-533,mutation,NN,O
ncbi-sent-533,is,VBZ,O
ncbi-sent-533,the,DT,O
ncbi-sent-533,cause,NN,O
ncbi-sent-533,of,IN,O
ncbi-sent-533,Hex,NNP,B-DISEASE
ncbi-sent-533,A,NNP,I-DISEASE
ncbi-sent-533,enzyme,JJ,I-DISEASE
ncbi-sent-533,deficiency,NN,I-DISEASE
ncbi-sent-533,in,IN,O
ncbi-sent-533,the,DT,O
ncbi-sent-533,proband,NN,O
ncbi-sent-533,.,.,O
ncbi-sent-534,The,DT,O
ncbi-sent-534,resulting,VBG,O
ncbi-sent-534,W474C,NNP,O
ncbi-sent-534,substitution,NN,O
ncbi-sent-534,clearly,RB,O
ncbi-sent-534,interferes,VBZ,O
ncbi-sent-534,with,IN,O
ncbi-sent-534,alpha,JJ,O
ncbi-sent-534,-,:,O
ncbi-sent-534,subunit,NN,O
ncbi-sent-534,processing,NN,O
ncbi-sent-534,",",",",O
ncbi-sent-534,but,CC,O
ncbi-sent-534,because,IN,O
ncbi-sent-534,the,DT,O
ncbi-sent-534,base,NN,O
ncbi-sent-534,substitution,NN,O
ncbi-sent-534,falls,VBZ,O
ncbi-sent-534,at,IN,O
ncbi-sent-534,the,DT,O
ncbi-sent-534,first,JJ,O
ncbi-sent-534,position,NN,O
ncbi-sent-534,of,IN,O
ncbi-sent-534,exon,JJ,O
ncbi-sent-534,13,CD,O
ncbi-sent-534,",",",",O
ncbi-sent-534,aberrant,JJ,O
ncbi-sent-534,splicing,NN,O
ncbi-sent-534,may,MD,O
ncbi-sent-534,also,RB,O
ncbi-sent-534,contribute,VB,O
ncbi-sent-534,to,TO,O
ncbi-sent-534,Hex,VB,B-DISEASE
ncbi-sent-534,A,DT,I-DISEASE
ncbi-sent-534,deficiency,NN,I-DISEASE
ncbi-sent-534,in,IN,O
ncbi-sent-534,this,DT,O
ncbi-sent-534,proband,NN,O
ncbi-sent-534,.,.,O
ncbi-sent-535,.,.,O
ncbi-sent-536,Two,CD,O
ncbi-sent-536,frequent,JJ,O
ncbi-sent-536,missense,NN,O
ncbi-sent-536,mutations,NNS,O
ncbi-sent-536,in,IN,O
ncbi-sent-536,Pendred,NNP,B-DISEASE
ncbi-sent-536,syndrome,NN,I-DISEASE
ncbi-sent-536,.,.,O
ncbi-sent-537,Pendred,NNP,B-DISEASE
ncbi-sent-537,syndrome,NN,I-DISEASE
ncbi-sent-537,is,VBZ,O
ncbi-sent-537,an,DT,O
ncbi-sent-537,autosomal,JJ,B-DISEASE
ncbi-sent-537,recessive,JJ,I-DISEASE
ncbi-sent-537,disorder,NN,I-DISEASE
ncbi-sent-537,characterized,VBN,O
ncbi-sent-537,by,IN,O
ncbi-sent-537,early,JJ,O
ncbi-sent-537,childhood,NN,O
ncbi-sent-537,deafness,NN,B-DISEASE
ncbi-sent-537,and,CC,O
ncbi-sent-537,goiter,NN,B-DISEASE
ncbi-sent-537,.,.,O
ncbi-sent-538,A,DT,O
ncbi-sent-538,century,NN,O
ncbi-sent-538,after,IN,O
ncbi-sent-538,its,PRP$,O
ncbi-sent-538,recognition,NN,O
ncbi-sent-538,as,IN,O
ncbi-sent-538,a,DT,O
ncbi-sent-538,syndrome,NN,O
ncbi-sent-538,by,IN,O
ncbi-sent-538,Vaughan,NNP,O
ncbi-sent-538,Pendred,NNP,O
ncbi-sent-538,",",",",O
ncbi-sent-538,the,DT,O
ncbi-sent-538,disease,NN,O
ncbi-sent-538,gene,NN,O
ncbi-sent-538,(,(,O
ncbi-sent-538,PDS,NNP,O
ncbi-sent-538,),),O
ncbi-sent-538,was,VBD,O
ncbi-sent-538,mapped,VBN,O
ncbi-sent-538,to,TO,O
ncbi-sent-538,chromosome,VB,O
ncbi-sent-538,7q22,CD,O
ncbi-sent-538,-,:,O
ncbi-sent-538,q31,NN,O
ncbi-sent-538,.,.,O
ncbi-sent-539,1,CD,O
ncbi-sent-539,and,CC,O
ncbi-sent-539,",",",",O
ncbi-sent-539,recently,RB,O
ncbi-sent-539,",",",",O
ncbi-sent-539,found,VBD,O
ncbi-sent-539,to,TO,O
ncbi-sent-539,encode,VB,O
ncbi-sent-539,a,DT,O
ncbi-sent-539,putative,JJ,O
ncbi-sent-539,sulfate,NN,O
ncbi-sent-539,transporter,NN,O
ncbi-sent-539,.,.,O
ncbi-sent-540,We,PRP,O
ncbi-sent-540,performed,VBD,O
ncbi-sent-540,mutation,NN,O
ncbi-sent-540,analysis,NN,O
ncbi-sent-540,of,IN,O
ncbi-sent-540,the,DT,O
ncbi-sent-540,PDS,NNP,B-DISEASE
ncbi-sent-540,gene,NN,O
ncbi-sent-540,in,IN,O
ncbi-sent-540,patients,NNS,O
ncbi-sent-540,from,IN,O
ncbi-sent-540,14,CD,O
ncbi-sent-540,Pendred,NNP,B-DISEASE
ncbi-sent-540,families,NNS,O
ncbi-sent-540,originating,VBG,O
ncbi-sent-540,from,IN,O
ncbi-sent-540,seven,CD,O
ncbi-sent-540,countries,NNS,O
ncbi-sent-540,and,CC,O
ncbi-sent-540,identified,VBD,O
ncbi-sent-540,all,DT,O
ncbi-sent-540,mutations,NNS,O
ncbi-sent-540,.,.,O
ncbi-sent-541,The,DT,O
ncbi-sent-541,mutations,NNS,O
ncbi-sent-541,include,VBP,O
ncbi-sent-541,three,CD,O
ncbi-sent-541,single,JJ,O
ncbi-sent-541,base,NN,O
ncbi-sent-541,deletions,NNS,O
ncbi-sent-541,",",",",O
ncbi-sent-541,one,CD,O
ncbi-sent-541,splice,NN,O
ncbi-sent-541,site,NN,O
ncbi-sent-541,mutation,NN,O
ncbi-sent-541,and,CC,O
ncbi-sent-541,10,CD,O
ncbi-sent-541,missense,NN,O
ncbi-sent-541,mutations,NNS,O
ncbi-sent-541,.,.,O
ncbi-sent-542,One,CD,O
ncbi-sent-542,missense,NN,O
ncbi-sent-542,mutation,NN,O
ncbi-sent-542,(,(,O
ncbi-sent-542,L236P,NNP,O
ncbi-sent-542,),),O
ncbi-sent-542,was,VBD,O
ncbi-sent-542,found,VBN,O
ncbi-sent-542,in,IN,O
ncbi-sent-542,a,DT,O
ncbi-sent-542,homozygous,JJ,O
ncbi-sent-542,state,NN,O
ncbi-sent-542,in,IN,O
ncbi-sent-542,two,CD,O
ncbi-sent-542,consanguineous,JJ,O
ncbi-sent-542,families,NNS,O
ncbi-sent-542,and,CC,O
ncbi-sent-542,in,IN,O
ncbi-sent-542,a,DT,O
ncbi-sent-542,heterozygous,JJ,O
ncbi-sent-542,state,NN,O
ncbi-sent-542,in,IN,O
ncbi-sent-542,five,CD,O
ncbi-sent-542,additional,JJ,O
ncbi-sent-542,non,NN,O
ncbi-sent-542,-,:,O
ncbi-sent-542,consanguineous,JJ,O
ncbi-sent-542,families,NNS,O
ncbi-sent-542,.,.,O
ncbi-sent-543,Another,DT,O
ncbi-sent-543,missense,NN,O
ncbi-sent-543,mutation,NN,O
ncbi-sent-543,(,(,O
ncbi-sent-543,T416P,NNP,O
ncbi-sent-543,),),O
ncbi-sent-543,was,VBD,O
ncbi-sent-543,found,VBN,O
ncbi-sent-543,in,IN,O
ncbi-sent-543,a,DT,O
ncbi-sent-543,homozygous,JJ,O
ncbi-sent-543,state,NN,O
ncbi-sent-543,in,IN,O
ncbi-sent-543,one,CD,O
ncbi-sent-543,family,NN,O
ncbi-sent-543,and,CC,O
ncbi-sent-543,in,IN,O
ncbi-sent-543,a,DT,O
ncbi-sent-543,heterozygous,JJ,O
ncbi-sent-543,state,NN,O
ncbi-sent-543,in,IN,O
ncbi-sent-543,four,CD,O
ncbi-sent-543,families,NNS,O
ncbi-sent-543,.,.,O
ncbi-sent-544,Pendred,VBD,B-DISEASE
ncbi-sent-544,patients,NNS,O
ncbi-sent-544,in,IN,O
ncbi-sent-544,three,CD,O
ncbi-sent-544,non,SYM,O
ncbi-sent-544,-,:,O
ncbi-sent-544,consanguineous,JJ,O
ncbi-sent-544,families,NNS,O
ncbi-sent-544,were,VBD,O
ncbi-sent-544,shown,VBN,O
ncbi-sent-544,to,TO,O
ncbi-sent-544,be,VB,O
ncbi-sent-544,compound,VBN,O
ncbi-sent-544,heterozygotes,NNS,O
ncbi-sent-544,for,IN,O
ncbi-sent-544,L236P,NNP,O
ncbi-sent-544,and,CC,O
ncbi-sent-544,T416P,NNP,O
ncbi-sent-544,.,.,O
ncbi-sent-545,In,IN,O
ncbi-sent-545,total,JJ,O
ncbi-sent-545,",",",",O
ncbi-sent-545,one,CD,O
ncbi-sent-545,or,CC,O
ncbi-sent-545,both,DT,O
ncbi-sent-545,of,IN,O
ncbi-sent-545,these,DT,O
ncbi-sent-545,mutations,NNS,O
ncbi-sent-545,were,VBD,O
ncbi-sent-545,found,VBN,O
ncbi-sent-545,in,IN,O
ncbi-sent-545,nine,CD,O
ncbi-sent-545,of,IN,O
ncbi-sent-545,the,DT,O
ncbi-sent-545,14,CD,O
ncbi-sent-545,families,NNS,O
ncbi-sent-545,analyzed,VBN,O
ncbi-sent-545,.,.,O
ncbi-sent-546,The,DT,O
ncbi-sent-546,identification,NN,O
ncbi-sent-546,of,IN,O
ncbi-sent-546,two,CD,O
ncbi-sent-546,frequent,JJ,O
ncbi-sent-546,PDS,NNP,B-DISEASE
ncbi-sent-546,mutations,NNS,O
ncbi-sent-546,will,MD,O
ncbi-sent-546,facilitate,VB,O
ncbi-sent-546,the,DT,O
ncbi-sent-546,molecular,JJ,O
ncbi-sent-546,diagnosis,NN,O
ncbi-sent-546,of,IN,O
ncbi-sent-546,Pendred,NNP,B-DISEASE
ncbi-sent-546,syndrome,NN,I-DISEASE
ncbi-sent-546,.,.,O
ncbi-sent-547,Insertional,JJ,O
ncbi-sent-547,mutation,NN,O
ncbi-sent-547,by,IN,O
ncbi-sent-547,transposable,JJ,O
ncbi-sent-547,element,NN,O
ncbi-sent-547,",",",",O
ncbi-sent-547,L1,NNP,O
ncbi-sent-547,",",",",O
ncbi-sent-547,in,IN,O
ncbi-sent-547,the,DT,O
ncbi-sent-547,DMD,NNP,B-DISEASE
ncbi-sent-547,gene,NN,O
ncbi-sent-547,results,NNS,O
ncbi-sent-547,in,IN,O
ncbi-sent-547,X,NNP,B-DISEASE
ncbi-sent-547,-,:,I-DISEASE
ncbi-sent-547,linked,VBN,I-DISEASE
ncbi-sent-547,dilated,JJ,I-DISEASE
ncbi-sent-547,cardiomyopathy,NN,I-DISEASE
ncbi-sent-547,.,.,O
ncbi-sent-548,X,SYM,B-DISEASE
ncbi-sent-548,-,:,I-DISEASE
ncbi-sent-548,linked,VBN,I-DISEASE
ncbi-sent-548,dilated,VBN,I-DISEASE
ncbi-sent-548,cardiomyopathy,NN,I-DISEASE
ncbi-sent-548,(,(,O
ncbi-sent-548,XLDCM,NNP,B-DISEASE
ncbi-sent-548,),),O
ncbi-sent-548,is,VBZ,O
ncbi-sent-548,a,DT,O
ncbi-sent-548,clinical,JJ,O
ncbi-sent-548,phenotype,NN,O
ncbi-sent-548,of,IN,O
ncbi-sent-548,dystrophinopathy,NN,B-DISEASE
ncbi-sent-548,which,WDT,O
ncbi-sent-548,is,VBZ,O
ncbi-sent-548,characterized,VBN,O
ncbi-sent-548,by,IN,O
ncbi-sent-548,preferential,JJ,O
ncbi-sent-548,myocardial,JJ,B-DISEASE
ncbi-sent-548,involvement,NN,I-DISEASE
ncbi-sent-548,without,IN,O
ncbi-sent-548,any,DT,O
ncbi-sent-548,overt,JJ,O
ncbi-sent-548,clinical,JJ,O
ncbi-sent-548,signs,NNS,O
ncbi-sent-548,of,IN,O
ncbi-sent-548,skeletal,JJ,B-DISEASE
ncbi-sent-548,myopathy,NN,I-DISEASE
ncbi-sent-548,.,.,O
ncbi-sent-549,To,TO,O
ncbi-sent-549,date,NN,O
ncbi-sent-549,",",",",O
ncbi-sent-549,several,JJ,O
ncbi-sent-549,mutations,NNS,O
ncbi-sent-549,in,IN,O
ncbi-sent-549,the,DT,O
ncbi-sent-549,Duchenne,NNP,B-DISEASE
ncbi-sent-549,muscular,JJ,I-DISEASE
ncbi-sent-549,dystrophy,NN,I-DISEASE
ncbi-sent-549,gene,NN,O
ncbi-sent-549,",",",",O
ncbi-sent-549,DMD,NNP,O
ncbi-sent-549,",",",",O
ncbi-sent-549,have,VBP,O
ncbi-sent-549,been,VBN,O
ncbi-sent-549,identified,VBN,O
ncbi-sent-549,in,IN,O
ncbi-sent-549,patients,NNS,O
ncbi-sent-549,with,IN,O
ncbi-sent-549,XLDCM,NNP,B-DISEASE
ncbi-sent-549,",",",",O
ncbi-sent-549,but,CC,O
ncbi-sent-549,a,DT,O
ncbi-sent-549,pathogenic,JJ,O
ncbi-sent-549,correlation,NN,O
ncbi-sent-549,of,IN,O
ncbi-sent-549,these,DT,O
ncbi-sent-549,cardiospecific,JJ,O
ncbi-sent-549,mutations,NNS,O
ncbi-sent-549,in,IN,O
ncbi-sent-549,DMD,NNP,O
ncbi-sent-549,with,IN,O
ncbi-sent-549,the,DT,O
ncbi-sent-549,XLDCM,NNP,B-DISEASE
ncbi-sent-549,phenotype,NN,O
ncbi-sent-549,has,VBZ,O
ncbi-sent-549,remained,VBN,O
ncbi-sent-549,to,TO,O
ncbi-sent-549,be,VB,O
ncbi-sent-549,elucidated,VBN,O
ncbi-sent-549,.,.,O
ncbi-sent-550,We,PRP,O
ncbi-sent-550,report,VBP,O
ncbi-sent-550,here,RB,O
ncbi-sent-550,the,DT,O
ncbi-sent-550,identification,NN,O
ncbi-sent-550,of,IN,O
ncbi-sent-550,a,DT,O
ncbi-sent-550,unique,JJ,O
ncbi-sent-550,de,FW,O
ncbi-sent-550,novo,FW,O
ncbi-sent-550,L1,NNP,O
ncbi-sent-550,insertion,NN,O
ncbi-sent-550,in,IN,O
ncbi-sent-550,the,DT,O
ncbi-sent-550,muscle,NN,O
ncbi-sent-550,exon,VBD,O
ncbi-sent-550,1,CD,O
ncbi-sent-550,in,IN,O
ncbi-sent-550,DMD,NNP,O
ncbi-sent-550,in,IN,O
ncbi-sent-550,three,CD,O
ncbi-sent-550,XLDCM,NN,B-DISEASE
ncbi-sent-550,patients,NNS,O
ncbi-sent-550,from,IN,O
ncbi-sent-550,two,CD,O
ncbi-sent-550,unrelated,JJ,O
ncbi-sent-550,Japanese,JJ,O
ncbi-sent-550,families,NNS,O
ncbi-sent-550,.,.,O
ncbi-sent-551,The,DT,O
ncbi-sent-551,insertion,NN,O
ncbi-sent-551,was,VBD,O
ncbi-sent-551,a,DT,O
ncbi-sent-551,5,CD,O
ncbi-sent-551,-,:,O
ncbi-sent-551,truncated,JJ,O
ncbi-sent-551,form,NN,O
ncbi-sent-551,of,IN,O
ncbi-sent-551,human,JJ,O
ncbi-sent-551,L1,NNP,O
ncbi-sent-551,inversely,RB,O
ncbi-sent-551,integrated,VBD,O
ncbi-sent-551,in,IN,O
ncbi-sent-551,the,DT,O
ncbi-sent-551,5,CD,O
ncbi-sent-551,-,:,O
ncbi-sent-551,untranslated,JJ,O
ncbi-sent-551,region,NN,O
ncbi-sent-551,in,IN,O
ncbi-sent-551,the,DT,O
ncbi-sent-551,muscle,NN,O
ncbi-sent-551,exon,VBZ,O
ncbi-sent-551,1,CD,O
ncbi-sent-551,",",",",O
ncbi-sent-551,which,WDT,O
ncbi-sent-551,affected,VBD,O
ncbi-sent-551,the,DT,O
ncbi-sent-551,transcription,NN,O
ncbi-sent-551,or,CC,O
ncbi-sent-551,the,DT,O
ncbi-sent-551,stability,NN,O
ncbi-sent-551,of,IN,O
ncbi-sent-551,the,DT,O
ncbi-sent-551,muscle,NN,O
ncbi-sent-551,form,NN,O
ncbi-sent-551,of,IN,O
ncbi-sent-551,dystrophin,JJ,O
ncbi-sent-551,transcripts,NNS,O
ncbi-sent-551,but,CC,O
ncbi-sent-551,not,RB,O
ncbi-sent-551,that,IN,O
ncbi-sent-551,of,IN,O
ncbi-sent-551,the,DT,O
ncbi-sent-551,brain,NN,O
ncbi-sent-551,or,CC,O
ncbi-sent-551,Purkinje,NNP,O
ncbi-sent-551,cell,NN,O
ncbi-sent-551,form,NN,O
ncbi-sent-551,",",",",O
ncbi-sent-551,probably,RB,O
ncbi-sent-551,due,JJ,O
ncbi-sent-551,to,TO,O
ncbi-sent-551,its,PRP$,O
ncbi-sent-551,unique,JJ,O
ncbi-sent-551,site,NN,O
ncbi-sent-551,of,IN,O
ncbi-sent-551,integration,NN,O
ncbi-sent-551,.,.,O
ncbi-sent-552,We,PRP,O
ncbi-sent-552,speculate,VBP,O
ncbi-sent-552,that,IN,O
ncbi-sent-552,this,DT,O
ncbi-sent-552,insertion,NN,O
ncbi-sent-552,of,IN,O
ncbi-sent-552,an,DT,O
ncbi-sent-552,L1,NNP,O
ncbi-sent-552,sequence,NN,O
ncbi-sent-552,in,IN,O
ncbi-sent-552,DMD,NNP,O
ncbi-sent-552,is,VBZ,O
ncbi-sent-552,responsible,JJ,O
ncbi-sent-552,for,IN,O
ncbi-sent-552,some,DT,O
ncbi-sent-552,of,IN,O
ncbi-sent-552,the,DT,O
ncbi-sent-552,population,NN,O
ncbi-sent-552,of,IN,O
ncbi-sent-552,Japanese,JJ,O
ncbi-sent-552,patients,NNS,O
ncbi-sent-552,with,IN,O
ncbi-sent-552,XLDCM,NNP,B-DISEASE
ncbi-sent-552,.,.,O
ncbi-sent-553,.,.,O
ncbi-sent-554,Severe,JJ,O
ncbi-sent-554,early,JJ,O
ncbi-sent-554,-,:,O
ncbi-sent-554,onset,NN,O
ncbi-sent-554,obesity,NN,B-DISEASE
ncbi-sent-554,",",",",O
ncbi-sent-554,adrenal,JJ,B-DISEASE
ncbi-sent-554,insufficiency,NN,I-DISEASE
ncbi-sent-554,and,CC,O
ncbi-sent-554,red,JJ,O
ncbi-sent-554,hair,NN,O
ncbi-sent-554,pigmentation,NN,O
ncbi-sent-554,caused,VBN,O
ncbi-sent-554,by,IN,O
ncbi-sent-554,POMC,NNP,O
ncbi-sent-554,mutations,NNS,O
ncbi-sent-554,in,IN,O
ncbi-sent-554,humans,NNS,O
ncbi-sent-554,.,.,O
ncbi-sent-555,Sequential,JJ,O
ncbi-sent-555,cleavage,NN,O
ncbi-sent-555,of,IN,O
ncbi-sent-555,the,DT,O
ncbi-sent-555,precursor,NN,O
ncbi-sent-555,protein,NN,O
ncbi-sent-555,pre,SYM,O
ncbi-sent-555,-,:,O
ncbi-sent-555,pro,JJ,O
ncbi-sent-555,-,:,O
ncbi-sent-555,opiomelanocortin,NN,O
ncbi-sent-555,(,(,O
ncbi-sent-555,POMC,NNP,O
ncbi-sent-555,),),O
ncbi-sent-555,generates,VBZ,O
ncbi-sent-555,the,DT,O
ncbi-sent-555,melanocortin,NN,O
ncbi-sent-555,peptides,NNS,O
ncbi-sent-555,adrenocorticotrophin,VBP,O
ncbi-sent-555,(,(,O
ncbi-sent-555,ACTH,NNP,O
ncbi-sent-555,),),O
ncbi-sent-555,",",",",O
ncbi-sent-555,melanocyte,SYM,O
ncbi-sent-555,-,:,O
ncbi-sent-555,stimulating,NN,O
ncbi-sent-555,hormones,NNS,O
ncbi-sent-555,(,(,O
ncbi-sent-555,MSH,NNP,O
ncbi-sent-555,),),O
ncbi-sent-555,alpha,NN,O
ncbi-sent-555,",",",",O
ncbi-sent-555,beta,NN,O
ncbi-sent-555,and,CC,O
ncbi-sent-555,gamma,NN,O
ncbi-sent-555,as,RB,O
ncbi-sent-555,well,RB,O
ncbi-sent-555,as,IN,O
ncbi-sent-555,the,DT,O
ncbi-sent-555,opioid,JJ,O
ncbi-sent-555,-,:,O
ncbi-sent-555,receptor,NN,O
ncbi-sent-555,ligand,NN,O
ncbi-sent-555,beta,SYM,O
ncbi-sent-555,-,:,O
ncbi-sent-555,endorphin,NN,O
ncbi-sent-555,.,.,O
ncbi-sent-556,While,IN,O
ncbi-sent-556,a,DT,O
ncbi-sent-556,few,JJ,O
ncbi-sent-556,cases,NNS,O
ncbi-sent-556,of,IN,O
ncbi-sent-556,isolated,JJ,O
ncbi-sent-556,ACTH,NNP,B-DISEASE
ncbi-sent-556,deficiency,NN,I-DISEASE
ncbi-sent-556,have,VBP,O
ncbi-sent-556,been,VBN,O
ncbi-sent-556,reported,VBN,O
ncbi-sent-556,(,(,O
ncbi-sent-556,OMIM,NNP,O
ncbi-sent-556,201400,CD,O
ncbi-sent-556,),),O
ncbi-sent-556,",",",",O
ncbi-sent-556,an,DT,O
ncbi-sent-556,inherited,JJ,O
ncbi-sent-556,POMC,NNP,O
ncbi-sent-556,defect,NN,O
ncbi-sent-556,has,VBZ,O
ncbi-sent-556,not,RB,O
ncbi-sent-556,been,VBN,O
ncbi-sent-556,described,VBN,O
ncbi-sent-556,so,RB,O
ncbi-sent-556,far,RB,O
ncbi-sent-556,.,.,O
ncbi-sent-557,Recent,JJ,O
ncbi-sent-557,studies,NNS,O
ncbi-sent-557,in,IN,O
ncbi-sent-557,animal,JJ,O
ncbi-sent-557,models,NNS,O
ncbi-sent-557,elucidated,VBD,O
ncbi-sent-557,a,DT,O
ncbi-sent-557,central,JJ,O
ncbi-sent-557,role,NN,O
ncbi-sent-557,of,IN,O
ncbi-sent-557,alpha,JJ,O
ncbi-sent-557,-,:,O
ncbi-sent-557,MSH,NN,O
ncbi-sent-557,in,IN,O
ncbi-sent-557,the,DT,O
ncbi-sent-557,regulation,NN,O
ncbi-sent-557,of,IN,O
ncbi-sent-557,food,NN,O
ncbi-sent-557,intake,NN,O
ncbi-sent-557,by,IN,O
ncbi-sent-557,activation,NN,O
ncbi-sent-557,of,IN,O
ncbi-sent-557,the,DT,O
ncbi-sent-557,brain,NN,O
ncbi-sent-557,melanocortin,SYM,O
ncbi-sent-557,-,:,O
ncbi-sent-557,4,CD,O
ncbi-sent-557,-,:,O
ncbi-sent-557,receptor,NN,O
ncbi-sent-557,(,(,O
ncbi-sent-557,MC4,NNP,O
ncbi-sent-557,-,:,O
ncbi-sent-557,R,NN,O
ncbi-sent-557,;,:,O
ncbi-sent-557,refs,CC,O
ncbi-sent-557,3,CD,O
ncbi-sent-557,-,:,O
ncbi-sent-557,5,CD,O
ncbi-sent-557,),),O
ncbi-sent-557,and,CC,O
ncbi-sent-557,the,DT,O
ncbi-sent-557,linkage,NN,O
ncbi-sent-557,of,IN,O
ncbi-sent-557,human,JJ,O
ncbi-sent-557,obesity,NN,B-DISEASE
ncbi-sent-557,to,TO,O
ncbi-sent-557,chromosome,VB,O
ncbi-sent-557,2,CD,O
ncbi-sent-557,in,IN,O
ncbi-sent-557,close,JJ,O
ncbi-sent-557,proximity,NN,O
ncbi-sent-557,to,TO,O
ncbi-sent-557,the,DT,O
ncbi-sent-557,POMC,NNP,O
ncbi-sent-557,locus,NN,O
ncbi-sent-557,",",",",O
ncbi-sent-557,led,VBN,O
ncbi-sent-557,to,TO,O
ncbi-sent-557,the,DT,O
ncbi-sent-557,proposal,NN,O
ncbi-sent-557,of,IN,O
ncbi-sent-557,an,DT,O
ncbi-sent-557,association,NN,O
ncbi-sent-557,of,IN,O
ncbi-sent-557,POMC,NNP,O
ncbi-sent-557,with,IN,O
ncbi-sent-557,human,JJ,O
ncbi-sent-557,obesity,NN,B-DISEASE
ncbi-sent-557,.,.,O
ncbi-sent-558,The,DT,O
ncbi-sent-558,dual,JJ,O
ncbi-sent-558,role,NN,O
ncbi-sent-558,of,IN,O
ncbi-sent-558,alpha,JJ,O
ncbi-sent-558,-,:,O
ncbi-sent-558,MSH,NN,O
ncbi-sent-558,in,IN,O
ncbi-sent-558,regulating,VBG,O
ncbi-sent-558,food,NN,O
ncbi-sent-558,intake,NN,O
ncbi-sent-558,and,CC,O
ncbi-sent-558,influencing,VBG,O
ncbi-sent-558,hair,NN,O
ncbi-sent-558,pigmentation,NN,O
ncbi-sent-558,predicts,VBZ,O
ncbi-sent-558,that,IN,O
ncbi-sent-558,the,DT,O
ncbi-sent-558,phenotype,NN,O
ncbi-sent-558,associated,VBN,O
ncbi-sent-558,with,IN,O
ncbi-sent-558,a,DT,O
ncbi-sent-558,defect,NN,O
ncbi-sent-558,in,IN,O
ncbi-sent-558,POMC,NNP,O
ncbi-sent-558,function,NN,O
ncbi-sent-558,would,MD,O
ncbi-sent-558,include,VB,O
ncbi-sent-558,obesity,NN,B-DISEASE
ncbi-sent-558,",",",",O
ncbi-sent-558,alteration,NN,O
ncbi-sent-558,in,IN,O
ncbi-sent-558,pigmentation,NN,O
ncbi-sent-558,and,CC,O
ncbi-sent-558,ACTH,NNP,B-DISEASE
ncbi-sent-558,deficiency,NN,I-DISEASE
ncbi-sent-558,.,.,O
ncbi-sent-559,The,DT,O
ncbi-sent-559,observation,NN,O
ncbi-sent-559,of,IN,O
ncbi-sent-559,these,DT,O
ncbi-sent-559,symptoms,NNS,O
ncbi-sent-559,in,IN,O
ncbi-sent-559,two,CD,O
ncbi-sent-559,probands,NNS,O
ncbi-sent-559,prompted,VBD,O
ncbi-sent-559,us,PRP,O
ncbi-sent-559,to,TO,O
ncbi-sent-559,search,VB,O
ncbi-sent-559,for,IN,O
ncbi-sent-559,mutations,NNS,O
ncbi-sent-559,within,IN,O
ncbi-sent-559,their,PRP$,O
ncbi-sent-559,POMC,NNP,O
ncbi-sent-559,genes,NNS,O
ncbi-sent-559,.,.,O
ncbi-sent-560,Patient,JJ,O
ncbi-sent-560,1,CD,O
ncbi-sent-560,was,VBD,O
ncbi-sent-560,found,VBN,O
ncbi-sent-560,to,TO,O
ncbi-sent-560,be,VB,O
ncbi-sent-560,a,DT,O
ncbi-sent-560,compound,NN,O
ncbi-sent-560,heterozygote,NN,O
ncbi-sent-560,for,IN,O
ncbi-sent-560,two,CD,O
ncbi-sent-560,mutations,NNS,O
ncbi-sent-560,in,IN,O
ncbi-sent-560,exon,JJ,O
ncbi-sent-560,3,CD,O
ncbi-sent-560,(,(,O
ncbi-sent-560,G7013T,NNP,O
ncbi-sent-560,",",",",O
ncbi-sent-560,C7133delta,NNP,O
ncbi-sent-560,),),O
ncbi-sent-560,which,WDT,O
ncbi-sent-560,interfere,VBP,O
ncbi-sent-560,with,IN,O
ncbi-sent-560,appropriate,JJ,O
ncbi-sent-560,synthesis,NN,O
ncbi-sent-560,of,IN,O
ncbi-sent-560,ACTH,NNP,O
ncbi-sent-560,and,CC,O
ncbi-sent-560,alpha,SYM,O
ncbi-sent-560,-,:,O
ncbi-sent-560,MSH,NNP,O
ncbi-sent-560,.,.,O
ncbi-sent-561,Patient,NNP,O
ncbi-sent-561,2,CD,O
ncbi-sent-561,was,VBD,O
ncbi-sent-561,homozygous,JJ,O
ncbi-sent-561,for,IN,O
ncbi-sent-561,a,DT,O
ncbi-sent-561,mutation,NN,O
ncbi-sent-561,in,IN,O
ncbi-sent-561,exon,JJ,O
ncbi-sent-561,2,CD,O
ncbi-sent-561,(,(,O
ncbi-sent-561,C3804A,NNP,O
ncbi-sent-561,),),O
ncbi-sent-561,which,WDT,O
ncbi-sent-561,abolishes,VBZ,O
ncbi-sent-561,POMC,NNP,O
ncbi-sent-561,translation,NN,O
ncbi-sent-561,.,.,O
ncbi-sent-562,These,DT,O
ncbi-sent-562,findings,NNS,O
ncbi-sent-562,represent,VBP,O
ncbi-sent-562,the,DT,O
ncbi-sent-562,first,JJ,O
ncbi-sent-562,examples,NNS,O
ncbi-sent-562,of,IN,O
ncbi-sent-562,a,DT,O
ncbi-sent-562,genetic,JJ,B-DISEASE
ncbi-sent-562,defect,NN,I-DISEASE
ncbi-sent-562,within,IN,O
ncbi-sent-562,the,DT,O
ncbi-sent-562,POMC,NNP,O
ncbi-sent-562,gene,NN,O
ncbi-sent-562,and,CC,O
ncbi-sent-562,define,VB,O
ncbi-sent-562,a,DT,O
ncbi-sent-562,new,JJ,O
ncbi-sent-562,monogenic,JJ,B-DISEASE
ncbi-sent-562,endocrine,NN,I-DISEASE
ncbi-sent-562,disorder,NN,I-DISEASE
ncbi-sent-562,resulting,VBG,O
ncbi-sent-562,in,IN,O
ncbi-sent-562,early,JJ,O
ncbi-sent-562,-,:,O
ncbi-sent-562,onset,NN,O
ncbi-sent-562,obesity,NN,B-DISEASE
ncbi-sent-562,",",",",O
ncbi-sent-562,adrenal,JJ,B-DISEASE
ncbi-sent-562,insufficiency,NN,I-DISEASE
ncbi-sent-562,and,CC,O
ncbi-sent-562,red,JJ,O
ncbi-sent-562,hair,NN,O
ncbi-sent-562,pigmentation,NN,O
ncbi-sent-562,.,.,O
ncbi-sent-563,.,.,O
ncbi-sent-564,A,DT,O
ncbi-sent-564,European,JJ,O
ncbi-sent-564,multicenter,NN,O
ncbi-sent-564,study,NN,O
ncbi-sent-564,of,IN,O
ncbi-sent-564,phenylalanine,JJ,B-DISEASE
ncbi-sent-564,hydroxylase,NN,I-DISEASE
ncbi-sent-564,deficiency,NN,I-DISEASE
ncbi-sent-564,:,:,O
ncbi-sent-564,classification,NN,O
ncbi-sent-564,of,IN,O
ncbi-sent-564,105,CD,O
ncbi-sent-564,mutations,NNS,O
ncbi-sent-564,and,CC,O
ncbi-sent-564,a,DT,O
ncbi-sent-564,general,JJ,O
ncbi-sent-564,system,NN,O
ncbi-sent-564,for,IN,O
ncbi-sent-564,genotype,NN,O
ncbi-sent-564,-,:,O
ncbi-sent-564,based,VBN,O
ncbi-sent-564,prediction,NN,O
ncbi-sent-564,of,IN,O
ncbi-sent-564,metabolic,JJ,O
ncbi-sent-564,phenotype,NN,O
ncbi-sent-564,.,.,O
ncbi-sent-565,Phenylketonuria,NNP,B-DISEASE
ncbi-sent-565,(,(,O
ncbi-sent-565,PKU,NNP,B-DISEASE
ncbi-sent-565,),),O
ncbi-sent-565,and,CC,O
ncbi-sent-565,mild,JJ,B-DISEASE
ncbi-sent-565,hyperphenylalaninemia,NN,I-DISEASE
ncbi-sent-565,(,(,O
ncbi-sent-565,MHP,NNP,B-DISEASE
ncbi-sent-565,),),O
ncbi-sent-565,are,VBP,O
ncbi-sent-565,allelic,JJ,B-DISEASE
ncbi-sent-565,disorders,NNS,I-DISEASE
ncbi-sent-565,caused,VBN,O
ncbi-sent-565,by,IN,O
ncbi-sent-565,mutations,NNS,O
ncbi-sent-565,in,IN,O
ncbi-sent-565,the,DT,O
ncbi-sent-565,gene,NN,O
ncbi-sent-565,encoding,VBG,O
ncbi-sent-565,phenylalanine,JJ,O
ncbi-sent-565,hydroxylase,NN,O
ncbi-sent-565,(,(,O
ncbi-sent-565,PAH,NNP,O
ncbi-sent-565,),),O
ncbi-sent-565,.,.,O
ncbi-sent-566,Previous,JJ,O
ncbi-sent-566,studies,NNS,O
ncbi-sent-566,have,VBP,O
ncbi-sent-566,suggested,VBN,O
ncbi-sent-566,that,IN,O
ncbi-sent-566,the,DT,O
ncbi-sent-566,highly,RB,O
ncbi-sent-566,variable,JJ,O
ncbi-sent-566,metabolic,JJ,O
ncbi-sent-566,phenotypes,NNS,O
ncbi-sent-566,of,IN,O
ncbi-sent-566,PAH,NNP,B-DISEASE
ncbi-sent-566,deficiency,NN,I-DISEASE
ncbi-sent-566,correlate,NN,O
ncbi-sent-566,with,IN,O
ncbi-sent-566,PAH,NNP,O
ncbi-sent-566,genotypes,NNS,O
ncbi-sent-566,.,.,O
ncbi-sent-567,We,PRP,O
ncbi-sent-567,identified,VBD,O
ncbi-sent-567,both,DT,O
ncbi-sent-567,causative,JJ,O
ncbi-sent-567,mutations,NNS,O
ncbi-sent-567,in,IN,O
ncbi-sent-567,686,CD,O
ncbi-sent-567,patients,NNS,O
ncbi-sent-567,from,IN,O
ncbi-sent-567,seven,CD,O
ncbi-sent-567,European,JJ,O
ncbi-sent-567,centers,NNS,O
ncbi-sent-567,.,.,O
ncbi-sent-568,On,IN,O
ncbi-sent-568,the,DT,O
ncbi-sent-568,basis,NN,O
ncbi-sent-568,of,IN,O
ncbi-sent-568,the,DT,O
ncbi-sent-568,phenotypic,NN,O
ncbi-sent-568,characteristics,NNS,O
ncbi-sent-568,of,IN,O
ncbi-sent-568,297,CD,O
ncbi-sent-568,functionally,RB,O
ncbi-sent-568,hemizygous,JJ,O
ncbi-sent-568,patients,NNS,O
ncbi-sent-568,",",",",O
ncbi-sent-568,105,CD,O
ncbi-sent-568,of,IN,O
ncbi-sent-568,the,DT,O
ncbi-sent-568,mutations,NNS,O
ncbi-sent-568,were,VBD,O
ncbi-sent-568,assigned,VBN,O
ncbi-sent-568,to,TO,O
ncbi-sent-568,one,CD,O
ncbi-sent-568,of,IN,O
ncbi-sent-568,four,CD,O
ncbi-sent-568,arbitrary,JJ,O
ncbi-sent-568,phenotype,NN,O
ncbi-sent-568,categories,NNS,O
ncbi-sent-568,.,.,O
ncbi-sent-569,We,PRP,O
ncbi-sent-569,proposed,VBD,O
ncbi-sent-569,and,CC,O
ncbi-sent-569,tested,VBD,O
ncbi-sent-569,a,DT,O
ncbi-sent-569,simple,JJ,O
ncbi-sent-569,model,NN,O
ncbi-sent-569,for,IN,O
ncbi-sent-569,correlation,NN,O
ncbi-sent-569,between,IN,O
ncbi-sent-569,genotype,NN,O
ncbi-sent-569,and,CC,O
ncbi-sent-569,phenotypic,NN,O
ncbi-sent-569,outcome,NN,O
ncbi-sent-569,.,.,O
ncbi-sent-570,The,DT,O
ncbi-sent-570,observed,JJ,O
ncbi-sent-570,phenotype,NN,O
ncbi-sent-570,matched,VBD,O
ncbi-sent-570,the,DT,O
ncbi-sent-570,predicted,JJ,O
ncbi-sent-570,phenotype,NN,O
ncbi-sent-570,in,IN,O
ncbi-sent-570,79,CD,O
ncbi-sent-570,%,NN,O
ncbi-sent-570,of,IN,O
ncbi-sent-570,the,DT,O
ncbi-sent-570,cases,NNS,O
ncbi-sent-570,",",",",O
ncbi-sent-570,and,CC,O
ncbi-sent-570,in,IN,O
ncbi-sent-570,only,RB,O
ncbi-sent-570,5,CD,O
ncbi-sent-570,of,IN,O
ncbi-sent-570,184,CD,O
ncbi-sent-570,patients,NNS,O
ncbi-sent-570,was,VBD,O
ncbi-sent-570,the,DT,O
ncbi-sent-570,observed,JJ,O
ncbi-sent-570,phenotype,NN,O
ncbi-sent-570,more,JJR,O
ncbi-sent-570,than,IN,O
ncbi-sent-570,one,CD,O
ncbi-sent-570,category,NN,O
ncbi-sent-570,away,RB,O
ncbi-sent-570,from,IN,O
ncbi-sent-570,that,DT,O
ncbi-sent-570,expected,VBN,O
ncbi-sent-570,.,.,O
ncbi-sent-571,Among,IN,O
ncbi-sent-571,the,DT,O
ncbi-sent-571,seven,CD,O
ncbi-sent-571,contributing,NN,O
ncbi-sent-571,centers,NNS,O
ncbi-sent-571,",",",",O
ncbi-sent-571,the,DT,O
ncbi-sent-571,proportion,NN,O
ncbi-sent-571,of,IN,O
ncbi-sent-571,patients,NNS,O
ncbi-sent-571,for,IN,O
ncbi-sent-571,whom,WP,O
ncbi-sent-571,the,DT,O
ncbi-sent-571,observed,JJ,O
ncbi-sent-571,phenotype,NN,O
ncbi-sent-571,did,VBD,O
ncbi-sent-571,not,RB,O
ncbi-sent-571,match,VB,O
ncbi-sent-571,the,DT,O
ncbi-sent-571,predicted,JJ,O
ncbi-sent-571,phenotype,NN,O
ncbi-sent-571,was,VBD,O
ncbi-sent-571,4,CD,O
ncbi-sent-571,%,NN,O
ncbi-sent-571,-,:,O
ncbi-sent-571,23,CD,O
ncbi-sent-571,%,NN,O
ncbi-sent-571,(,(,O
ncbi-sent-571,P,NNP,O
ncbi-sent-571,<,NNP,O
ncbi-sent-571,.,.,O
ncbi-sent-572,0001,CD,O
ncbi-sent-572,),),O
ncbi-sent-572,",",",",O
ncbi-sent-572,suggesting,VBG,O
ncbi-sent-572,that,IN,O
ncbi-sent-572,differences,NNS,O
ncbi-sent-572,in,IN,O
ncbi-sent-572,methods,NNS,O
ncbi-sent-572,used,VBN,O
ncbi-sent-572,for,IN,O
ncbi-sent-572,mutation,NN,O
ncbi-sent-572,detection,NN,O
ncbi-sent-572,or,CC,O
ncbi-sent-572,phenotype,JJ,O
ncbi-sent-572,classification,NN,O
ncbi-sent-572,may,MD,O
ncbi-sent-572,account,VB,O
ncbi-sent-572,for,IN,O
ncbi-sent-572,a,DT,O
ncbi-sent-572,considerable,JJ,O
ncbi-sent-572,proportion,NN,O
ncbi-sent-572,of,IN,O
ncbi-sent-572,genotype,JJ,O
ncbi-sent-572,-,:,O
ncbi-sent-572,phenotype,NN,O
ncbi-sent-572,inconsistencies,NNS,O
ncbi-sent-572,.,.,O
ncbi-sent-573,Our,PRP$,O
ncbi-sent-573,data,NNS,O
ncbi-sent-573,indicate,VBP,O
ncbi-sent-573,that,IN,O
ncbi-sent-573,the,DT,O
ncbi-sent-573,PAH,NNP,O
ncbi-sent-573,-,:,O
ncbi-sent-573,mutation,NN,O
ncbi-sent-573,genotype,NN,O
ncbi-sent-573,is,VBZ,O
ncbi-sent-573,the,DT,O
ncbi-sent-573,main,JJ,O
ncbi-sent-573,determinant,NN,O
ncbi-sent-573,of,IN,O
ncbi-sent-573,metabolic,JJ,O
ncbi-sent-573,phenotype,NN,O
ncbi-sent-573,in,IN,O
ncbi-sent-573,most,JJS,O
ncbi-sent-573,patients,NNS,O
ncbi-sent-573,with,IN,O
ncbi-sent-573,PAH,NNP,B-DISEASE
ncbi-sent-573,deficiency,NN,I-DISEASE
ncbi-sent-573,.,.,O
ncbi-sent-574,In,IN,O
ncbi-sent-574,the,DT,O
ncbi-sent-574,present,JJ,O
ncbi-sent-574,study,NN,O
ncbi-sent-574,",",",",O
ncbi-sent-574,the,DT,O
ncbi-sent-574,classification,NN,O
ncbi-sent-574,of,IN,O
ncbi-sent-574,105,CD,O
ncbi-sent-574,PAH,NNP,O
ncbi-sent-574,mutations,NNS,O
ncbi-sent-574,may,MD,O
ncbi-sent-574,allow,VB,O
ncbi-sent-574,the,DT,O
ncbi-sent-574,prediction,NN,O
ncbi-sent-574,of,IN,O
ncbi-sent-574,the,DT,O
ncbi-sent-574,biochemical,JJ,O
ncbi-sent-574,phenotype,NN,O
ncbi-sent-574,in,IN,O
ncbi-sent-574,>,JJ,O
ncbi-sent-574,10,CD,O
ncbi-sent-574,",",",",O
ncbi-sent-574,000,CD,O
ncbi-sent-574,genotypes,NNS,O
ncbi-sent-574,",",",",O
ncbi-sent-574,which,WDT,O
ncbi-sent-574,may,MD,O
ncbi-sent-574,be,VB,O
ncbi-sent-574,useful,JJ,O
ncbi-sent-574,for,IN,O
ncbi-sent-574,the,DT,O
ncbi-sent-574,management,NN,O
ncbi-sent-574,of,IN,O
ncbi-sent-574,hyperphenylalaninemia,NN,B-DISEASE
ncbi-sent-574,in,IN,O
ncbi-sent-574,newborns,NNS,O
ncbi-sent-574,.,.,O
ncbi-sent-575,Somatic,JJ,O
ncbi-sent-575,instability,NN,O
ncbi-sent-575,of,IN,O
ncbi-sent-575,the,DT,O
ncbi-sent-575,CTG,NNP,O
ncbi-sent-575,repeat,NN,O
ncbi-sent-575,in,IN,O
ncbi-sent-575,mice,NN,O
ncbi-sent-575,transgenic,NN,O
ncbi-sent-575,for,IN,O
ncbi-sent-575,the,DT,O
ncbi-sent-575,myotonic,JJ,B-DISEASE
ncbi-sent-575,dystrophy,NN,I-DISEASE
ncbi-sent-575,region,NN,O
ncbi-sent-575,is,VBZ,O
ncbi-sent-575,age,NN,O
ncbi-sent-575,dependent,JJ,O
ncbi-sent-575,but,CC,O
ncbi-sent-575,not,RB,O
ncbi-sent-575,correlated,VBN,O
ncbi-sent-575,to,TO,O
ncbi-sent-575,the,DT,O
ncbi-sent-575,relative,JJ,O
ncbi-sent-575,intertissue,NN,O
ncbi-sent-575,transcription,NN,O
ncbi-sent-575,levels,NNS,O
ncbi-sent-575,and,CC,O
ncbi-sent-575,proliferative,JJ,O
ncbi-sent-575,capacities,NNS,O
ncbi-sent-575,.,.,O
ncbi-sent-576,A,DT,O
ncbi-sent-576,(,(,O
ncbi-sent-576,CTG,NNP,O
ncbi-sent-576,),),O
ncbi-sent-576,nexpansion,NN,O
ncbi-sent-576,in,IN,O
ncbi-sent-576,the,DT,O
ncbi-sent-576,3,CD,O
ncbi-sent-576,-,:,O
ncbi-sent-576,untranslated,JJ,O
ncbi-sent-576,region,NN,O
ncbi-sent-576,(,(,O
ncbi-sent-576,UTR,NNP,O
ncbi-sent-576,),),O
ncbi-sent-576,of,IN,O
ncbi-sent-576,the,DT,O
ncbi-sent-576,DM,NNP,O
ncbi-sent-576,protein,NN,O
ncbi-sent-576,kinase,NN,O
ncbi-sent-576,gene,NN,O
ncbi-sent-576,(,(,O
ncbi-sent-576,DMPK,NNP,O
ncbi-sent-576,),),O
ncbi-sent-576,is,VBZ,O
ncbi-sent-576,responsible,JJ,O
ncbi-sent-576,for,IN,O
ncbi-sent-576,causing,VBG,O
ncbi-sent-576,myotonic,JJ,B-DISEASE
ncbi-sent-576,dystrophy,NN,I-DISEASE
ncbi-sent-576,(,(,O
ncbi-sent-576,DM,NNP,B-DISEASE
ncbi-sent-576,),),O
ncbi-sent-576,.,.,O
ncbi-sent-577,Major,JJ,O
ncbi-sent-577,instability,NN,O
ncbi-sent-577,",",",",O
ncbi-sent-577,with,IN,O
ncbi-sent-577,very,RB,O
ncbi-sent-577,large,JJ,O
ncbi-sent-577,expansions,NNS,O
ncbi-sent-577,between,IN,O
ncbi-sent-577,generations,NNS,O
ncbi-sent-577,and,CC,O
ncbi-sent-577,high,JJ,O
ncbi-sent-577,levels,NNS,O
ncbi-sent-577,of,IN,O
ncbi-sent-577,somatic,JJ,O
ncbi-sent-577,mosaicism,NN,O
ncbi-sent-577,",",",",O
ncbi-sent-577,is,VBZ,O
ncbi-sent-577,observed,VBN,O
ncbi-sent-577,in,IN,O
ncbi-sent-577,patients,NNS,O
ncbi-sent-577,.,.,O
ncbi-sent-578,There,EX,O
ncbi-sent-578,is,VBZ,O
ncbi-sent-578,a,DT,O
ncbi-sent-578,good,JJ,O
ncbi-sent-578,correlation,NN,O
ncbi-sent-578,between,IN,O
ncbi-sent-578,repeat,NN,O
ncbi-sent-578,size,NN,O
ncbi-sent-578,(,(,O
ncbi-sent-578,at,IN,O
ncbi-sent-578,least,JJS,O
ncbi-sent-578,in,IN,O
ncbi-sent-578,leucocytes,NNS,O
ncbi-sent-578,),),O
ncbi-sent-578,",",",",O
ncbi-sent-578,clinical,JJ,O
ncbi-sent-578,severity,NN,O
ncbi-sent-578,and,CC,O
ncbi-sent-578,age,NN,O
ncbi-sent-578,of,IN,O
ncbi-sent-578,onset,NN,O
ncbi-sent-578,.,.,O
ncbi-sent-579,The,DT,O
ncbi-sent-579,trinucleotide,JJ,O
ncbi-sent-579,repeat,NN,O
ncbi-sent-579,instability,NN,O
ncbi-sent-579,mechanisms,NNS,O
ncbi-sent-579,involved,VBN,O
ncbi-sent-579,in,IN,O
ncbi-sent-579,DM,NNP,B-DISEASE
ncbi-sent-579,and,CC,O
ncbi-sent-579,other,JJ,O
ncbi-sent-579,human,JJ,O
ncbi-sent-579,genetic,JJ,B-DISEASE
ncbi-sent-579,diseases,NNS,I-DISEASE
ncbi-sent-579,are,VBP,O
ncbi-sent-579,unknown,JJ,O
ncbi-sent-579,.,.,O
ncbi-sent-580,We,PRP,O
ncbi-sent-580,studied,VBD,O
ncbi-sent-580,somatic,JJ,O
ncbi-sent-580,instability,NN,O
ncbi-sent-580,by,IN,O
ncbi-sent-580,measuring,VBG,O
ncbi-sent-580,the,DT,O
ncbi-sent-580,CTG,NNP,O
ncbi-sent-580,repeat,NN,O
ncbi-sent-580,length,NN,O
ncbi-sent-580,at,IN,O
ncbi-sent-580,several,JJ,O
ncbi-sent-580,ages,NNS,O
ncbi-sent-580,in,IN,O
ncbi-sent-580,various,JJ,O
ncbi-sent-580,tissues,NNS,O
ncbi-sent-580,of,IN,O
ncbi-sent-580,transgenic,JJ,O
ncbi-sent-580,mice,NN,O
ncbi-sent-580,carrying,VBG,O
ncbi-sent-580,a,DT,O
ncbi-sent-580,(,(,O
ncbi-sent-580,CTG,NNP,O
ncbi-sent-580,),),O
ncbi-sent-580,55expansion,CD,O
ncbi-sent-580,surrounded,VBN,O
ncbi-sent-580,by,IN,O
ncbi-sent-580,45,CD,O
ncbi-sent-580,kb,NNS,O
ncbi-sent-580,of,IN,O
ncbi-sent-580,the,DT,O
ncbi-sent-580,human,JJ,O
ncbi-sent-580,DM,NNP,B-DISEASE
ncbi-sent-580,region,NN,O
ncbi-sent-580,",",",",O
ncbi-sent-580,using,VBG,O
ncbi-sent-580,small,JJ,O
ncbi-sent-580,-,:,O
ncbi-sent-580,pool,NN,O
ncbi-sent-580,PCR,NNP,O
ncbi-sent-580,.,.,O
ncbi-sent-581,These,DT,O
ncbi-sent-581,mice,NNS,O
ncbi-sent-581,have,VBP,O
ncbi-sent-581,been,VBN,O
ncbi-sent-581,shown,VBN,O
ncbi-sent-581,to,TO,O
ncbi-sent-581,reproduce,VB,O
ncbi-sent-581,the,DT,O
ncbi-sent-581,intergenerational,JJ,O
ncbi-sent-581,and,CC,O
ncbi-sent-581,somatic,JJ,O
ncbi-sent-581,instability,NN,O
ncbi-sent-581,of,IN,O
ncbi-sent-581,the,DT,O
ncbi-sent-581,55,CD,O
ncbi-sent-581,CTG,NNP,O
ncbi-sent-581,repeat,NN,O
ncbi-sent-581,suggesting,VBG,O
ncbi-sent-581,that,IN,O
ncbi-sent-581,surrounding,VBG,O
ncbi-sent-581,sequences,NNS,O
ncbi-sent-581,and,CC,O
ncbi-sent-581,the,DT,O
ncbi-sent-581,chromatin,NN,O
ncbi-sent-581,environment,NN,O
ncbi-sent-581,are,VBP,O
ncbi-sent-581,involved,VBN,O
ncbi-sent-581,in,IN,O
ncbi-sent-581,instability,NN,O
ncbi-sent-581,mechanisms,NN,O
ncbi-sent-581,.,.,O
ncbi-sent-582,As,IN,O
ncbi-sent-582,observed,VBN,O
ncbi-sent-582,in,IN,O
ncbi-sent-582,some,DT,O
ncbi-sent-582,of,IN,O
ncbi-sent-582,the,DT,O
ncbi-sent-582,tissues,NNS,O
ncbi-sent-582,of,IN,O
ncbi-sent-582,DM,NNP,B-DISEASE
ncbi-sent-582,patients,NNS,O
ncbi-sent-582,",",",",O
ncbi-sent-582,there,EX,O
ncbi-sent-582,is,VBZ,O
ncbi-sent-582,a,DT,O
ncbi-sent-582,tendency,NN,O
ncbi-sent-582,for,IN,O
ncbi-sent-582,repeat,NN,O
ncbi-sent-582,length,NN,O
ncbi-sent-582,and,CC,O
ncbi-sent-582,somatic,JJ,O
ncbi-sent-582,mosaicism,NN,O
ncbi-sent-582,to,TO,O
ncbi-sent-582,increase,VB,O
ncbi-sent-582,with,IN,O
ncbi-sent-582,the,DT,O
ncbi-sent-582,age,NN,O
ncbi-sent-582,of,IN,O
ncbi-sent-582,the,DT,O
ncbi-sent-582,mouse,NN,O
ncbi-sent-582,.,.,O
ncbi-sent-583,Furthermore,RB,O
ncbi-sent-583,",",",",O
ncbi-sent-583,we,PRP,O
ncbi-sent-583,observed,VBD,O
ncbi-sent-583,no,DT,O
ncbi-sent-583,correlation,NN,O
ncbi-sent-583,between,IN,O
ncbi-sent-583,the,DT,O
ncbi-sent-583,somatic,JJ,O
ncbi-sent-583,mutation,NN,O
ncbi-sent-583,rate,NN,O
ncbi-sent-583,and,CC,O
ncbi-sent-583,tissue,NN,O
ncbi-sent-583,proliferation,NN,O
ncbi-sent-583,capacity,NN,O
ncbi-sent-583,.,.,O
ncbi-sent-584,The,DT,O
ncbi-sent-584,somatic,JJ,O
ncbi-sent-584,mutation,NN,O
ncbi-sent-584,rates,NNS,O
ncbi-sent-584,in,IN,O
ncbi-sent-584,different,JJ,O
ncbi-sent-584,tissues,NNS,O
ncbi-sent-584,were,VBD,O
ncbi-sent-584,also,RB,O
ncbi-sent-584,not,RB,O
ncbi-sent-584,correlated,VBN,O
ncbi-sent-584,to,TO,O
ncbi-sent-584,the,DT,O
ncbi-sent-584,relative,JJ,O
ncbi-sent-584,inter,NN,O
ncbi-sent-584,-,:,O
ncbi-sent-584,tissue,NN,O
ncbi-sent-584,difference,NN,O
ncbi-sent-584,in,IN,O
ncbi-sent-584,transcriptional,JJ,O
ncbi-sent-584,levels,NNS,O
ncbi-sent-584,of,IN,O
ncbi-sent-584,the,DT,O
ncbi-sent-584,three,CD,O
ncbi-sent-584,genes,NNS,O
ncbi-sent-584,(,(,O
ncbi-sent-584,DMAHP,NNP,O
ncbi-sent-584,",",",",O
ncbi-sent-584,DMPK,NNP,O
ncbi-sent-584,and,CC,O
ncbi-sent-584,59,CD,O
ncbi-sent-584,),),O
ncbi-sent-584,surrounding,VBG,O
ncbi-sent-584,the,DT,O
ncbi-sent-584,repeat,NN,O
ncbi-sent-584,.,.,O
ncbi-sent-585,.,.,O
ncbi-sent-586,A,DT,O
ncbi-sent-586,novel,JJ,O
ncbi-sent-586,missense,NN,O
ncbi-sent-586,mutation,NN,O
ncbi-sent-586,in,IN,O
ncbi-sent-586,patients,NNS,O
ncbi-sent-586,from,IN,O
ncbi-sent-586,a,DT,O
ncbi-sent-586,retinoblastoma,NN,B-DISEASE
ncbi-sent-586,pedigree,NN,O
ncbi-sent-586,showing,VBG,O
ncbi-sent-586,only,RB,O
ncbi-sent-586,mild,JJ,O
ncbi-sent-586,expression,NN,O
ncbi-sent-586,of,IN,O
ncbi-sent-586,the,DT,O
ncbi-sent-586,tumor,NN,B-DISEASE
ncbi-sent-586,phenotype,NN,O
ncbi-sent-586,.,.,O
ncbi-sent-587,We,PRP,O
ncbi-sent-587,have,VBP,O
ncbi-sent-587,used,VBN,O
ncbi-sent-587,single,JJ,O
ncbi-sent-587,strand,NN,O
ncbi-sent-587,conformation,NN,O
ncbi-sent-587,polymorphism,NN,O
ncbi-sent-587,analysis,NN,O
ncbi-sent-587,to,TO,O
ncbi-sent-587,study,VB,O
ncbi-sent-587,the,DT,O
ncbi-sent-587,27,CD,O
ncbi-sent-587,exons,NNS,O
ncbi-sent-587,of,IN,O
ncbi-sent-587,the,DT,O
ncbi-sent-587,RB1,NNP,O
ncbi-sent-587,gene,NN,O
ncbi-sent-587,in,IN,O
ncbi-sent-587,individuals,NNS,O
ncbi-sent-587,from,IN,O
ncbi-sent-587,a,DT,O
ncbi-sent-587,family,NN,O
ncbi-sent-587,showing,VBG,O
ncbi-sent-587,mild,JJ,O
ncbi-sent-587,expression,NN,O
ncbi-sent-587,of,IN,O
ncbi-sent-587,the,DT,O
ncbi-sent-587,retinoblastoma,NN,B-DISEASE
ncbi-sent-587,phenotype,NN,O
ncbi-sent-587,.,.,O
ncbi-sent-588,In,IN,O
ncbi-sent-588,this,DT,O
ncbi-sent-588,family,NN,O
ncbi-sent-588,affected,VBD,O
ncbi-sent-588,individuals,NNS,O
ncbi-sent-588,developed,VBD,O
ncbi-sent-588,unilateral,JJ,B-DISEASE
ncbi-sent-588,tumors,NNS,I-DISEASE
ncbi-sent-588,and,CC,O
ncbi-sent-588,",",",",O
ncbi-sent-588,as,IN,O
ncbi-sent-588,a,DT,O
ncbi-sent-588,result,NN,O
ncbi-sent-588,of,IN,O
ncbi-sent-588,linkage,NN,O
ncbi-sent-588,analysis,NN,O
ncbi-sent-588,",",",",O
ncbi-sent-588,unaffected,JJ,O
ncbi-sent-588,mutation,NN,O
ncbi-sent-588,carriers,NNS,O
ncbi-sent-588,were,VBD,O
ncbi-sent-588,also,RB,O
ncbi-sent-588,identified,VBN,O
ncbi-sent-588,within,IN,O
ncbi-sent-588,the,DT,O
ncbi-sent-588,pedigree,NN,O
ncbi-sent-588,.,.,O
ncbi-sent-589,A,DT,O
ncbi-sent-589,single,JJ,O
ncbi-sent-589,band,NN,O
ncbi-sent-589,shift,NN,O
ncbi-sent-589,using,VBG,O
ncbi-sent-589,SSCP,NNP,O
ncbi-sent-589,was,VBD,O
ncbi-sent-589,identified,VBN,O
ncbi-sent-589,in,IN,O
ncbi-sent-589,exon,NN,O
ncbi-sent-589,21,CD,O
ncbi-sent-589,which,WDT,O
ncbi-sent-589,resulted,VBD,O
ncbi-sent-589,in,IN,O
ncbi-sent-589,a,DT,O
ncbi-sent-589,missense,JJ,O
ncbi-sent-589,mutation,NN,O
ncbi-sent-589,converting,VBG,O
ncbi-sent-589,a,DT,O
ncbi-sent-589,cys,NN,O
ncbi-sent-589,-,:,O
ncbi-sent-589,-,:,O
ncbi-sent-589,>,NN,O
ncbi-sent-589,arg,NN,O
ncbi-sent-589,at,IN,O
ncbi-sent-589,nucleotide,JJ,O
ncbi-sent-589,position,NN,O
ncbi-sent-589,28,CD,O
ncbi-sent-589,in,IN,O
ncbi-sent-589,the,DT,O
ncbi-sent-589,exon,NN,O
ncbi-sent-589,.,.,O
ncbi-sent-590,The,DT,O
ncbi-sent-590,mutation,NN,O
ncbi-sent-590,destroyed,VBD,O
ncbi-sent-590,an,DT,O
ncbi-sent-590,NdeI,NNP,O
ncbi-sent-590,restriction,NN,O
ncbi-sent-590,enzyme,NN,O
ncbi-sent-590,site,NN,O
ncbi-sent-590,.,.,O
ncbi-sent-591,Analysis,NN,O
ncbi-sent-591,of,IN,O
ncbi-sent-591,all,DT,O
ncbi-sent-591,family,NN,O
ncbi-sent-591,members,NNS,O
ncbi-sent-591,demonstrated,VBD,O
ncbi-sent-591,that,IN,O
ncbi-sent-591,the,DT,O
ncbi-sent-591,missense,NN,O
ncbi-sent-591,mutation,NN,O
ncbi-sent-591,co,SYM,O
ncbi-sent-591,-,:,O
ncbi-sent-591,segregated,VBN,O
ncbi-sent-591,with,IN,O
ncbi-sent-591,patients,NNS,O
ncbi-sent-591,with,IN,O
ncbi-sent-591,tumors,NNS,B-DISEASE
ncbi-sent-591,or,CC,O
ncbi-sent-591,who,WP,O
ncbi-sent-591,",",",",O
ncbi-sent-591,as,IN,O
ncbi-sent-591,a,DT,O
ncbi-sent-591,result,NN,O
ncbi-sent-591,of,IN,O
ncbi-sent-591,linkage,NN,O
ncbi-sent-591,analysis,NN,O
ncbi-sent-591,had,VBD,O
ncbi-sent-591,been,VBN,O
ncbi-sent-591,predicted,VBN,O
ncbi-sent-591,to,TO,O
ncbi-sent-591,carry,VB,O
ncbi-sent-591,the,DT,O
ncbi-sent-591,predisposing,NN,O
ncbi-sent-591,mutation,NN,O
ncbi-sent-591,.,.,O
ncbi-sent-592,These,DT,O
ncbi-sent-592,observations,NNS,O
ncbi-sent-592,point,NN,O
ncbi-sent-592,to,TO,O
ncbi-sent-592,another,DT,O
ncbi-sent-592,region,NN,O
ncbi-sent-592,of,IN,O
ncbi-sent-592,the,DT,O
ncbi-sent-592,RB1,NNP,O
ncbi-sent-592,gene,NN,O
ncbi-sent-592,where,WRB,O
ncbi-sent-592,mutations,NNS,O
ncbi-sent-592,only,RB,O
ncbi-sent-592,modify,VBP,O
ncbi-sent-592,the,DT,O
ncbi-sent-592,function,NN,O
ncbi-sent-592,of,IN,O
ncbi-sent-592,the,DT,O
ncbi-sent-592,gene,NN,O
ncbi-sent-592,and,CC,O
ncbi-sent-592,raise,VB,O
ncbi-sent-592,important,JJ,O
ncbi-sent-592,questions,NNS,O
ncbi-sent-592,for,IN,O
ncbi-sent-592,genetic,JJ,O
ncbi-sent-592,counseling,NN,O
ncbi-sent-592,in,IN,O
ncbi-sent-592,families,NNS,O
ncbi-sent-592,with,IN,O
ncbi-sent-592,these,DT,O
ncbi-sent-592,distinctive,JJ,O
ncbi-sent-592,phenotypes,NNS,O
ncbi-sent-592,.,.,O
ncbi-sent-593,.,.,O
ncbi-sent-594,Maternal,JJ,B-DISEASE
ncbi-sent-594,disomy,NN,I-DISEASE
ncbi-sent-594,and,CC,O
ncbi-sent-594,Prader,NNP,B-DISEASE
ncbi-sent-594,-,:,I-DISEASE
ncbi-sent-594,Willi,NNP,I-DISEASE
ncbi-sent-594,syndrome,JJ,I-DISEASE
ncbi-sent-594,consistent,NN,O
ncbi-sent-594,with,IN,O
ncbi-sent-594,gamete,JJ,O
ncbi-sent-594,complementation,NN,O
ncbi-sent-594,in,IN,O
ncbi-sent-594,a,DT,O
ncbi-sent-594,case,NN,O
ncbi-sent-594,of,IN,O
ncbi-sent-594,familial,JJ,O
ncbi-sent-594,translocation,NN,O
ncbi-sent-594,(,(,O
ncbi-sent-594,3,CD,O
ncbi-sent-594,;,:,O
ncbi-sent-594,15,CD,O
ncbi-sent-594,),),O
ncbi-sent-594,(,(,O
ncbi-sent-594,p25,NN,O
ncbi-sent-594,;,:,O
ncbi-sent-594,q11,NN,O
ncbi-sent-594,.,.,O
ncbi-sent-595,2,CD,O
ncbi-sent-595,),),O
ncbi-sent-595,.,.,O
ncbi-sent-596,Maternal,JJ,B-DISEASE
ncbi-sent-596,uniparental,JJ,I-DISEASE
ncbi-sent-596,disomy,NN,I-DISEASE
ncbi-sent-596,(,(,I-DISEASE
ncbi-sent-596,UPD,NNP,I-DISEASE
ncbi-sent-596,),),I-DISEASE
ncbi-sent-596,for,IN,I-DISEASE
ncbi-sent-596,chromosome,NN,I-DISEASE
ncbi-sent-596,15,CD,I-DISEASE
ncbi-sent-596,is,VBZ,O
ncbi-sent-596,responsible,JJ,O
ncbi-sent-596,for,IN,O
ncbi-sent-596,an,DT,O
ncbi-sent-596,estimated,JJ,O
ncbi-sent-596,30,CD,O
ncbi-sent-596,%,NN,O
ncbi-sent-596,of,IN,O
ncbi-sent-596,cases,NNS,O
ncbi-sent-596,of,IN,O
ncbi-sent-596,Prader,NNP,B-DISEASE
ncbi-sent-596,-,:,I-DISEASE
ncbi-sent-596,Willi,NNP,I-DISEASE
ncbi-sent-596,syndrome,NN,I-DISEASE
ncbi-sent-596,(,(,O
ncbi-sent-596,PWS,NNP,B-DISEASE
ncbi-sent-596,),),O
ncbi-sent-596,.,.,O
ncbi-sent-597,We,PRP,O
ncbi-sent-597,report,VBP,O
ncbi-sent-597,on,IN,O
ncbi-sent-597,an,DT,O
ncbi-sent-597,unusual,JJ,O
ncbi-sent-597,case,NN,O
ncbi-sent-597,of,IN,O
ncbi-sent-597,maternal,JJ,B-DISEASE
ncbi-sent-597,disomy,NN,I-DISEASE
ncbi-sent-597,15,CD,I-DISEASE
ncbi-sent-597,in,IN,O
ncbi-sent-597,PWS,NNP,B-DISEASE
ncbi-sent-597,that,WDT,O
ncbi-sent-597,is,VBZ,O
ncbi-sent-597,most,RBS,O
ncbi-sent-597,consistent,JJ,O
ncbi-sent-597,with,IN,O
ncbi-sent-597,adjacent,JJ,O
ncbi-sent-597,-,:,O
ncbi-sent-597,1,CD,O
ncbi-sent-597,segregation,NN,O
ncbi-sent-597,of,IN,O
ncbi-sent-597,a,DT,O
ncbi-sent-597,paternal,JJ,O
ncbi-sent-597,t,NN,O
ncbi-sent-597,(,(,O
ncbi-sent-597,3,CD,O
ncbi-sent-597,;,:,O
ncbi-sent-597,15,CD,O
ncbi-sent-597,),),O
ncbi-sent-597,(,(,O
ncbi-sent-597,p25,NN,O
ncbi-sent-597,;,:,O
ncbi-sent-597,q11,NN,O
ncbi-sent-597,.,.,O
ncbi-sent-598,2,CD,O
ncbi-sent-598,),),O
ncbi-sent-598,with,IN,O
ncbi-sent-598,simultaneous,JJ,O
ncbi-sent-598,maternal,JJ,O
ncbi-sent-598,meiotic,JJ,O
ncbi-sent-598,nondisjunction,NN,O
ncbi-sent-598,for,IN,O
ncbi-sent-598,chromosome,NN,O
ncbi-sent-598,15,CD,O
ncbi-sent-598,.,.,O
ncbi-sent-599,The,DT,O
ncbi-sent-599,patient,NN,O
ncbi-sent-599,(,(,O
ncbi-sent-599,J,NNP,O
ncbi-sent-599,.,.,O
ncbi-sent-600,B,NNP,O
ncbi-sent-600,.,.,O
ncbi-sent-601,),),O
ncbi-sent-601,",",",",O
ncbi-sent-601,a,DT,O
ncbi-sent-601,17,CD,O
ncbi-sent-601,-,:,O
ncbi-sent-601,year,NN,O
ncbi-sent-601,-,:,O
ncbi-sent-601,old,JJ,O
ncbi-sent-601,white,JJ,O
ncbi-sent-601,male,NN,O
ncbi-sent-601,with,IN,O
ncbi-sent-601,PWS,NNP,B-DISEASE
ncbi-sent-601,",",",",O
ncbi-sent-601,was,VBD,O
ncbi-sent-601,found,VBN,O
ncbi-sent-601,to,TO,O
ncbi-sent-601,have,VB,O
ncbi-sent-601,47,CD,O
ncbi-sent-601,chromosomes,NNS,O
ncbi-sent-601,with,IN,O
ncbi-sent-601,a,DT,O
ncbi-sent-601,supernumerary,JJ,O
ncbi-sent-601,",",",",O
ncbi-sent-601,paternal,JJ,O
ncbi-sent-601,der,NN,O
ncbi-sent-601,(,(,O
ncbi-sent-601,15,CD,O
ncbi-sent-601,),),O
ncbi-sent-601,consisting,NN,O
ncbi-sent-601,of,IN,O
ncbi-sent-601,the,DT,O
ncbi-sent-601,short,JJ,O
ncbi-sent-601,arm,NN,O
ncbi-sent-601,and,CC,O
ncbi-sent-601,the,DT,O
ncbi-sent-601,proximal,JJ,O
ncbi-sent-601,long,JJ,O
ncbi-sent-601,arm,NN,O
ncbi-sent-601,of,IN,O
ncbi-sent-601,chromosome,NN,O
ncbi-sent-601,15,CD,O
ncbi-sent-601,",",",",O
ncbi-sent-601,and,CC,O
ncbi-sent-601,distal,JJ,O
ncbi-sent-601,chromosome,NN,O
ncbi-sent-601,arm,NN,O
ncbi-sent-601,3p,CD,O
ncbi-sent-601,.,.,O
ncbi-sent-602,The,DT,O
ncbi-sent-602,t,NN,O
ncbi-sent-602,(,(,O
ncbi-sent-602,3,CD,O
ncbi-sent-602,;,:,O
ncbi-sent-602,15,CD,O
ncbi-sent-602,),),O
ncbi-sent-602,was,VBD,O
ncbi-sent-602,present,JJ,O
ncbi-sent-602,in,IN,O
ncbi-sent-602,the,DT,O
ncbi-sent-602,balanced,JJ,O
ncbi-sent-602,state,NN,O
ncbi-sent-602,in,IN,O
ncbi-sent-602,the,DT,O
ncbi-sent-602,patients,NNS,O
ncbi-sent-602,father,NN,O
ncbi-sent-602,and,CC,O
ncbi-sent-602,a,DT,O
ncbi-sent-602,sister,NN,O
ncbi-sent-602,.,.,O
ncbi-sent-603,Fluorescent,NN,O
ncbi-sent-603,in,IN,O
ncbi-sent-603,situ,JJ,O
ncbi-sent-603,hybridization,NN,O
ncbi-sent-603,analysis,NN,O
ncbi-sent-603,demonstrated,VBD,O
ncbi-sent-603,that,IN,O
ncbi-sent-603,the,DT,O
ncbi-sent-603,PWS,NNP,B-DISEASE
ncbi-sent-603,critical,JJ,O
ncbi-sent-603,region,NN,O
ncbi-sent-603,resided,VBD,O
ncbi-sent-603,on,IN,O
ncbi-sent-603,the,DT,O
ncbi-sent-603,derivative,JJ,O
ncbi-sent-603,chromosome,NN,O
ncbi-sent-603,3,CD,O
ncbi-sent-603,and,CC,O
ncbi-sent-603,that,IN,O
ncbi-sent-603,there,EX,O
ncbi-sent-603,was,VBD,O
ncbi-sent-603,no,DT,O
ncbi-sent-603,deletion,NN,O
ncbi-sent-603,of,IN,O
ncbi-sent-603,the,DT,O
ncbi-sent-603,PWS,NNP,B-DISEASE
ncbi-sent-603,region,NN,O
ncbi-sent-603,on,IN,O
ncbi-sent-603,the,DT,O
ncbi-sent-603,normal,JJ,O
ncbi-sent-603,pair,NN,O
ncbi-sent-603,of,IN,O
ncbi-sent-603,15s,CD,O
ncbi-sent-603,present,JJ,O
ncbi-sent-603,in,IN,O
ncbi-sent-603,J,NNP,O
ncbi-sent-603,.,.,O
ncbi-sent-604,B,NNP,O
ncbi-sent-604,.,.,O
ncbi-sent-605,Methylation,NN,O
ncbi-sent-605,analysis,NN,O
ncbi-sent-605,at,IN,O
ncbi-sent-605,exon,JJ,O
ncbi-sent-605,alpha,NN,O
ncbi-sent-605,of,IN,O
ncbi-sent-605,the,DT,O
ncbi-sent-605,small,JJ,O
ncbi-sent-605,nuclear,JJ,O
ncbi-sent-605,ribonucleoprotein,NN,O
ncbi-sent-605,-,:,O
ncbi-sent-605,associated,VBN,O
ncbi-sent-605,polypeptide,IN,O
ncbi-sent-605,N,NNP,O
ncbi-sent-605,(,(,O
ncbi-sent-605,SNRPN,NNP,O
ncbi-sent-605,),),O
ncbi-sent-605,gene,NN,O
ncbi-sent-605,showed,VBD,O
ncbi-sent-605,a,DT,O
ncbi-sent-605,pattern,JJ,O
ncbi-sent-605,characteristic,NN,O
ncbi-sent-605,of,IN,O
ncbi-sent-605,only,RB,O
ncbi-sent-605,the,DT,O
ncbi-sent-605,maternal,JJ,O
ncbi-sent-605,chromosome,NN,O
ncbi-sent-605,15,CD,O
ncbi-sent-605,in,IN,O
ncbi-sent-605,J,NNP,O
ncbi-sent-605,.,.,O
ncbi-sent-606,B,NNP,O
ncbi-sent-606,.,.,O
ncbi-sent-607,Maternal,NNP,B-DISEASE
ncbi-sent-607,disomy,NN,I-DISEASE
ncbi-sent-607,was,VBD,O
ncbi-sent-607,confirmed,VBN,O
ncbi-sent-607,by,IN,O
ncbi-sent-607,polymerase,NN,O
ncbi-sent-607,chain,NN,O
ncbi-sent-607,reaction,NN,O
ncbi-sent-607,analysis,NN,O
ncbi-sent-607,of,IN,O
ncbi-sent-607,microsatellite,JJ,O
ncbi-sent-607,repeats,NNS,O
ncbi-sent-607,at,IN,O
ncbi-sent-607,the,DT,O
ncbi-sent-607,gamma,NN,O
ncbi-sent-607,-,:,O
ncbi-sent-607,aminobutyric,JJ,O
ncbi-sent-607,acid,NN,O
ncbi-sent-607,receptor,NN,O
ncbi-sent-607,beta3,NN,O
ncbi-sent-607,subunit,NN,O
ncbi-sent-607,(,(,O
ncbi-sent-607,GABRB3,NNP,O
ncbi-sent-607,),),O
ncbi-sent-607,locus,NN,O
ncbi-sent-607,.,.,O
ncbi-sent-608,A,DT,O
ncbi-sent-608,niece,NN,O
ncbi-sent-608,(,(,O
ncbi-sent-608,B,NNP,O
ncbi-sent-608,.,.,O
ncbi-sent-609,B,NNP,O
ncbi-sent-609,.,.,O
ncbi-sent-610,),),O
ncbi-sent-610,with,IN,O
ncbi-sent-610,45,CD,O
ncbi-sent-610,chromosomes,NNS,O
ncbi-sent-610,and,CC,O
ncbi-sent-610,the,DT,O
ncbi-sent-610,derivative,JJ,O
ncbi-sent-610,3,CD,O
ncbi-sent-610,but,CC,O
ncbi-sent-610,without,IN,O
ncbi-sent-610,the,DT,O
ncbi-sent-610,der,NN,O
ncbi-sent-610,(,(,O
ncbi-sent-610,15,CD,O
ncbi-sent-610,),),O
ncbi-sent-610,demonstrated,VBD,O
ncbi-sent-610,a,DT,O
ncbi-sent-610,phenotype,JJ,O
ncbi-sent-610,consistent,NN,O
ncbi-sent-610,with,IN,O
ncbi-sent-610,that,DT,O
ncbi-sent-610,reported,VBD,O
ncbi-sent-610,for,IN,O
ncbi-sent-610,haploinsufficiency,NN,O
ncbi-sent-610,of,IN,O
ncbi-sent-610,distal,JJ,O
ncbi-sent-610,3,CD,O
ncbi-sent-610,p,NN,O
ncbi-sent-610,.,.,O
ncbi-sent-611,Uniparental,JJ,B-DISEASE
ncbi-sent-611,disomy,NN,I-DISEASE
ncbi-sent-611,associated,VBN,O
ncbi-sent-611,with,IN,O
ncbi-sent-611,unbalanced,JJ,O
ncbi-sent-611,segregation,NN,O
ncbi-sent-611,of,IN,O
ncbi-sent-611,non,JJ,O
ncbi-sent-611,-,:,O
ncbi-sent-611,Robertsonian,JJ,O
ncbi-sent-611,translocations,NNS,O
ncbi-sent-611,has,VBZ,O
ncbi-sent-611,been,VBN,O
ncbi-sent-611,reported,VBN,O
ncbi-sent-611,previously,RB,O
ncbi-sent-611,but,CC,O
ncbi-sent-611,has,VBZ,O
ncbi-sent-611,not,RB,O
ncbi-sent-611,",",",",O
ncbi-sent-611,to,TO,O
ncbi-sent-611,our,PRP$,O
ncbi-sent-611,knowledge,NN,O
ncbi-sent-611,",",",",O
ncbi-sent-611,been,VBN,O
ncbi-sent-611,observed,VBN,O
ncbi-sent-611,in,IN,O
ncbi-sent-611,a,DT,O
ncbi-sent-611,case,NN,O
ncbi-sent-611,of,IN,O
ncbi-sent-611,PWS,NNP,B-DISEASE
ncbi-sent-611,.,.,O
ncbi-sent-612,Furthermore,RB,O
ncbi-sent-612,",",",",O
ncbi-sent-612,our,PRP$,O
ncbi-sent-612,findings,NNS,O
ncbi-sent-612,are,VBP,O
ncbi-sent-612,best,RB,O
ncbi-sent-612,interpreted,VBN,O
ncbi-sent-612,as,IN,O
ncbi-sent-612,true,JJ,O
ncbi-sent-612,gamete,JJ,O
ncbi-sent-612,complementation,NN,O
ncbi-sent-612,resulting,VBG,O
ncbi-sent-612,in,IN,O
ncbi-sent-612,maternal,JJ,B-DISEASE
ncbi-sent-612,UPD,NNP,I-DISEASE
ncbi-sent-612,15,CD,I-DISEASE
ncbi-sent-612,and,CC,O
ncbi-sent-612,PWS,NNP,B-DISEASE
ncbi-sent-612,Schwartz,NNP,B-DISEASE
ncbi-sent-612,-,:,I-DISEASE
ncbi-sent-612,Jampel,NNP,I-DISEASE
ncbi-sent-612,syndrome,VBD,I-DISEASE
ncbi-sent-612,type,JJ,I-DISEASE
ncbi-sent-612,2,CD,I-DISEASE
ncbi-sent-612,and,CC,O
ncbi-sent-612,Stuve,NNP,B-DISEASE
ncbi-sent-612,-,:,I-DISEASE
ncbi-sent-612,Wiedemann,JJ,I-DISEASE
ncbi-sent-612,syndrome,NN,I-DISEASE
ncbi-sent-612,:,:,O
ncbi-sent-612,a,DT,O
ncbi-sent-612,case,NN,O
ncbi-sent-612,for,IN,O
ncbi-sent-612,"	O
lumping	O
",NN,O
ncbi-sent-612,.,.,O
ncbi-sent-613,Recent,JJ,O
ncbi-sent-613,studies,NNS,O
ncbi-sent-613,demonstrated,VBD,O
ncbi-sent-613,the,DT,O
ncbi-sent-613,existence,NN,O
ncbi-sent-613,of,IN,O
ncbi-sent-613,a,DT,O
ncbi-sent-613,genetically,RB,O
ncbi-sent-613,distinct,JJ,O
ncbi-sent-613,",",",",O
ncbi-sent-613,usually,RB,O
ncbi-sent-613,lethal,JJ,O
ncbi-sent-613,form,NN,O
ncbi-sent-613,of,IN,O
ncbi-sent-613,the,DT,O
ncbi-sent-613,Schwartz,NNP,B-DISEASE
ncbi-sent-613,-,:,I-DISEASE
ncbi-sent-613,Jampel,NNP,I-DISEASE
ncbi-sent-613,syndrome,NN,I-DISEASE
ncbi-sent-613,(,(,O
ncbi-sent-613,SJS,NNP,B-DISEASE
ncbi-sent-613,),),O
ncbi-sent-613,of,IN,O
ncbi-sent-613,myotonia,NN,B-DISEASE
ncbi-sent-613,and,CC,O
ncbi-sent-613,skeletal,JJ,B-DISEASE
ncbi-sent-613,dysplasia,NN,I-DISEASE
ncbi-sent-613,",",",",O
ncbi-sent-613,which,WDT,O
ncbi-sent-613,we,PRP,O
ncbi-sent-613,called,VBD,O
ncbi-sent-613,SJS,NNP,B-DISEASE
ncbi-sent-613,type,NN,I-DISEASE
ncbi-sent-613,2,CD,I-DISEASE
ncbi-sent-613,.,.,O
ncbi-sent-614,This,DT,O
ncbi-sent-614,disorder,NN,O
ncbi-sent-614,is,VBZ,O
ncbi-sent-614,reminiscent,JJ,O
ncbi-sent-614,of,IN,O
ncbi-sent-614,another,DT,O
ncbi-sent-614,rare,JJ,O
ncbi-sent-614,condition,NN,O
ncbi-sent-614,",",",",O
ncbi-sent-614,the,DT,O
ncbi-sent-614,Stuve,NNP,B-DISEASE
ncbi-sent-614,-,:,I-DISEASE
ncbi-sent-614,Wiedemann,NNP,I-DISEASE
ncbi-sent-614,syndrome,NN,I-DISEASE
ncbi-sent-614,(,(,O
ncbi-sent-614,SWS,NNP,B-DISEASE
ncbi-sent-614,),),O
ncbi-sent-614,",",",",O
ncbi-sent-614,which,WDT,O
ncbi-sent-614,comprises,VBZ,O
ncbi-sent-614,campomelia,NN,B-DISEASE
ncbi-sent-614,at,IN,O
ncbi-sent-614,birth,NN,O
ncbi-sent-614,with,IN,O
ncbi-sent-614,skeletal,JJ,B-DISEASE
ncbi-sent-614,dysplasia,NN,I-DISEASE
ncbi-sent-614,",",",",O
ncbi-sent-614,contractures,NNS,B-DISEASE
ncbi-sent-614,",",",",O
ncbi-sent-614,and,CC,O
ncbi-sent-614,early,JJ,B-DISEASE
ncbi-sent-614,death,NN,I-DISEASE
ncbi-sent-614,.,.,O
ncbi-sent-615,To,TO,O
ncbi-sent-615,test,VB,O
ncbi-sent-615,for,IN,O
ncbi-sent-615,possible,JJ,O
ncbi-sent-615,nosologic,JJ,O
ncbi-sent-615,identity,NN,O
ncbi-sent-615,between,IN,O
ncbi-sent-615,these,DT,O
ncbi-sent-615,disorders,NNS,O
ncbi-sent-615,",",",",O
ncbi-sent-615,we,PRP,O
ncbi-sent-615,reviewed,VBD,O
ncbi-sent-615,the,DT,O
ncbi-sent-615,literature,NN,O
ncbi-sent-615,and,CC,O
ncbi-sent-615,obtained,VBD,O
ncbi-sent-615,a,DT,O
ncbi-sent-615,follow,JJ,O
ncbi-sent-615,-,:,O
ncbi-sent-615,up,IN,O
ncbi-sent-615,of,IN,O
ncbi-sent-615,the,DT,O
ncbi-sent-615,only,JJ,O
ncbi-sent-615,two,CD,O
ncbi-sent-615,surviving,VBG,O
ncbi-sent-615,patients,NNS,O
ncbi-sent-615,",",",",O
ncbi-sent-615,one,CD,O
ncbi-sent-615,with,IN,O
ncbi-sent-615,SJS,NNP,B-DISEASE
ncbi-sent-615,type,NN,I-DISEASE
ncbi-sent-615,2,CD,I-DISEASE
ncbi-sent-615,at,IN,O
ncbi-sent-615,age,NN,O
ncbi-sent-615,10,CD,O
ncbi-sent-615,years,NNS,O
ncbi-sent-615,and,CC,O
ncbi-sent-615,another,DT,O
ncbi-sent-615,with,IN,O
ncbi-sent-615,SWS,NNP,B-DISEASE
ncbi-sent-615,at,IN,O
ncbi-sent-615,age,NN,O
ncbi-sent-615,7,CD,O
ncbi-sent-615,years,NNS,O
ncbi-sent-615,.,.,O
ncbi-sent-616,Patients,NNS,O
ncbi-sent-616,reported,VBD,O
ncbi-sent-616,as,IN,O
ncbi-sent-616,having,VBG,O
ncbi-sent-616,either,CC,O
ncbi-sent-616,neonatal,JJ,O
ncbi-sent-616,SJS,NNP,B-DISEASE
ncbi-sent-616,or,CC,O
ncbi-sent-616,SWS,NNP,B-DISEASE
ncbi-sent-616,presented,VBD,O
ncbi-sent-616,a,DT,O
ncbi-sent-616,combination,NN,O
ncbi-sent-616,of,IN,O
ncbi-sent-616,a,DT,O
ncbi-sent-616,severe,JJ,O
ncbi-sent-616,",",",",O
ncbi-sent-616,prenatal,JJ,O
ncbi-sent-616,-,:,O
ncbi-sent-616,onset,NN,O
ncbi-sent-616,neuromuscular,JJ,B-DISEASE
ncbi-sent-616,disorder,NN,I-DISEASE
ncbi-sent-616,(,(,O
ncbi-sent-616,with,IN,O
ncbi-sent-616,congenital,JJ,B-DISEASE
ncbi-sent-616,joint,NN,I-DISEASE
ncbi-sent-616,contractures,NNS,I-DISEASE
ncbi-sent-616,",",",",O
ncbi-sent-616,respiratory,NN,O
ncbi-sent-616,and,CC,O
ncbi-sent-616,feeding,NN,O
ncbi-sent-616,difficulties,NNS,O
ncbi-sent-616,",",",",O
ncbi-sent-616,tendency,NN,O
ncbi-sent-616,to,TO,O
ncbi-sent-616,hyperthermia,VB,B-DISEASE
ncbi-sent-616,",",",",O
ncbi-sent-616,and,CC,O
ncbi-sent-616,frequent,JJ,O
ncbi-sent-616,death,NN,O
ncbi-sent-616,in,IN,O
ncbi-sent-616,infancy,NN,O
ncbi-sent-616,),),O
ncbi-sent-616,with,IN,O
ncbi-sent-616,a,DT,O
ncbi-sent-616,distinct,JJ,O
ncbi-sent-616,campomelic,JJ,B-DISEASE
ncbi-sent-616,-,:,I-DISEASE
ncbi-sent-616,metaphyseal,NN,I-DISEASE
ncbi-sent-616,skeletal,JJ,I-DISEASE
ncbi-sent-616,dysplasia,NN,I-DISEASE
ncbi-sent-616,.,.,O
ncbi-sent-617,The,DT,O
ncbi-sent-617,similarity,NN,O
ncbi-sent-617,of,IN,O
ncbi-sent-617,the,DT,O
ncbi-sent-617,clinical,JJ,O
ncbi-sent-617,and,CC,O
ncbi-sent-617,radiographic,JJ,O
ncbi-sent-617,findings,NNS,O
ncbi-sent-617,is,VBZ,O
ncbi-sent-617,so,RB,O
ncbi-sent-617,extensive,JJ,O
ncbi-sent-617,that,IN,O
ncbi-sent-617,these,DT,O
ncbi-sent-617,disorders,NNS,O
ncbi-sent-617,appear,VBP,O
ncbi-sent-617,to,TO,O
ncbi-sent-617,be,VB,O
ncbi-sent-617,a,DT,O
ncbi-sent-617,single,JJ,O
ncbi-sent-617,entity,NN,O
ncbi-sent-617,.,.,O
ncbi-sent-618,The,DT,O
ncbi-sent-618,follow,NN,O
ncbi-sent-618,-,:,O
ncbi-sent-618,up,IN,O
ncbi-sent-618,observation,NN,O
ncbi-sent-618,of,IN,O
ncbi-sent-618,an,DT,O
ncbi-sent-618,identical,JJ,O
ncbi-sent-618,and,CC,O
ncbi-sent-618,unique,JJ,O
ncbi-sent-618,pattern,NN,O
ncbi-sent-618,of,IN,O
ncbi-sent-618,progressive,JJ,O
ncbi-sent-618,bone,NN,B-DISEASE
ncbi-sent-618,dysplasia,NN,I-DISEASE
ncbi-sent-618,in,IN,O
ncbi-sent-618,the,DT,O
ncbi-sent-618,two,CD,O
ncbi-sent-618,patients,NNS,O
ncbi-sent-618,(,(,O
ncbi-sent-618,one,CD,O
ncbi-sent-618,with,IN,O
ncbi-sent-618,SJS,NNP,B-DISEASE
ncbi-sent-618,type,NN,I-DISEASE
ncbi-sent-618,2,CD,I-DISEASE
ncbi-sent-618,",",",",O
ncbi-sent-618,one,CD,O
ncbi-sent-618,with,IN,O
ncbi-sent-618,SWS,NNP,B-DISEASE
ncbi-sent-618,),),O
ncbi-sent-618,surviving,VBG,O
ncbi-sent-618,beyond,IN,O
ncbi-sent-618,infancy,NN,O
ncbi-sent-618,adds,VBZ,O
ncbi-sent-618,to,TO,O
ncbi-sent-618,the,DT,O
ncbi-sent-618,evidence,NN,O
ncbi-sent-618,in,IN,O
ncbi-sent-618,favor,NN,O
ncbi-sent-618,of,IN,O
ncbi-sent-618,identity,NN,O
ncbi-sent-618,.,.,O
ncbi-sent-619,The,DT,O
ncbi-sent-619,hypothesis,NN,O
ncbi-sent-619,that,WDT,O
ncbi-sent-619,SWS,NNP,B-DISEASE
ncbi-sent-619,and,CC,O
ncbi-sent-619,SJS,NNP,B-DISEASE
ncbi-sent-619,type,NN,I-DISEASE
ncbi-sent-619,2,CD,I-DISEASE
ncbi-sent-619,are,VBP,O
ncbi-sent-619,the,DT,O
ncbi-sent-619,same,JJ,O
ncbi-sent-619,disorder,NN,O
ncbi-sent-619,should,MD,O
ncbi-sent-619,be,VB,O
ncbi-sent-619,testable,JJ,O
ncbi-sent-619,by,IN,O
ncbi-sent-619,molecular,JJ,O
ncbi-sent-619,methods,NNS,O
ncbi-sent-619,.,.,O
ncbi-sent-620,.,.,O
ncbi-sent-621,A,DT,O
ncbi-sent-621,mouse,NN,O
ncbi-sent-621,model,NN,O
ncbi-sent-621,of,IN,O
ncbi-sent-621,severe,JJ,O
ncbi-sent-621,von,NN,B-DISEASE
ncbi-sent-621,Willebrand,NNP,I-DISEASE
ncbi-sent-621,disease,NN,I-DISEASE
ncbi-sent-621,:,:,O
ncbi-sent-621,defects,NNS,O
ncbi-sent-621,in,IN,O
ncbi-sent-621,hemostasis,NN,O
ncbi-sent-621,and,CC,O
ncbi-sent-621,thrombosis,NN,B-DISEASE
ncbi-sent-621,.,.,O
ncbi-sent-622,von,JJ,B-DISEASE
ncbi-sent-622,Willebrand,NNP,I-DISEASE
ncbi-sent-622,factor,NN,I-DISEASE
ncbi-sent-622,(,(,I-DISEASE
ncbi-sent-622,vWf,NN,I-DISEASE
ncbi-sent-622,),),I-DISEASE
ncbi-sent-622,deficiency,NN,I-DISEASE
ncbi-sent-622,causes,VBZ,O
ncbi-sent-622,severe,JJ,O
ncbi-sent-622,von,NN,B-DISEASE
ncbi-sent-622,Willebrand,NNP,I-DISEASE
ncbi-sent-622,disease,NN,I-DISEASE
ncbi-sent-622,in,IN,O
ncbi-sent-622,humans,NNS,O
ncbi-sent-622,.,.,O
ncbi-sent-623,We,PRP,O
ncbi-sent-623,generated,VBD,O
ncbi-sent-623,a,DT,O
ncbi-sent-623,mouse,NN,O
ncbi-sent-623,model,NN,O
ncbi-sent-623,for,IN,O
ncbi-sent-623,this,DT,O
ncbi-sent-623,disease,NN,O
ncbi-sent-623,by,IN,O
ncbi-sent-623,using,VBG,O
ncbi-sent-623,gene,NN,O
ncbi-sent-623,targeting,VBG,O
ncbi-sent-623,.,.,O
ncbi-sent-624,vWf,NN,B-DISEASE
ncbi-sent-624,-,:,I-DISEASE
ncbi-sent-624,deficient,NN,I-DISEASE
ncbi-sent-624,mice,RB,O
ncbi-sent-624,appeared,VBD,O
ncbi-sent-624,normal,JJ,O
ncbi-sent-624,at,IN,O
ncbi-sent-624,birth,NN,O
ncbi-sent-624,;,:,O
ncbi-sent-624,they,PRP,O
ncbi-sent-624,were,VBD,O
ncbi-sent-624,viable,JJ,O
ncbi-sent-624,and,CC,O
ncbi-sent-624,fertile,JJ,O
ncbi-sent-624,.,.,O
ncbi-sent-625,Neither,CC,O
ncbi-sent-625,vWf,JJ,O
ncbi-sent-625,nor,CC,O
ncbi-sent-625,vWf,JJ,O
ncbi-sent-625,propolypeptide,NN,O
ncbi-sent-625,(,(,O
ncbi-sent-625,von,JJ,B-DISEASE
ncbi-sent-625,Willebrand,NNP,I-DISEASE
ncbi-sent-625,antigen,NN,O
ncbi-sent-625,II,NNP,O
ncbi-sent-625,),),O
ncbi-sent-625,were,VBD,O
ncbi-sent-625,detectable,JJ,O
ncbi-sent-625,in,IN,O
ncbi-sent-625,plasma,NN,O
ncbi-sent-625,",",",",O
ncbi-sent-625,platelets,NNS,O
ncbi-sent-625,",",",",O
ncbi-sent-625,or,CC,O
ncbi-sent-625,endothelial,JJ,O
ncbi-sent-625,cells,NNS,O
ncbi-sent-625,of,IN,O
ncbi-sent-625,the,DT,O
ncbi-sent-625,homozygous,JJ,O
ncbi-sent-625,mutant,JJ,O
ncbi-sent-625,mice,NN,O
ncbi-sent-625,.,.,O
ncbi-sent-626,The,DT,O
ncbi-sent-626,mutant,JJ,O
ncbi-sent-626,mice,NN,O
ncbi-sent-626,exhibited,VBD,O
ncbi-sent-626,defects,NNS,O
ncbi-sent-626,in,IN,O
ncbi-sent-626,hemostasis,NN,O
ncbi-sent-626,with,IN,O
ncbi-sent-626,a,DT,O
ncbi-sent-626,highly,RB,O
ncbi-sent-626,prolonged,JJ,O
ncbi-sent-626,bleeding,NN,O
ncbi-sent-626,time,NN,O
ncbi-sent-626,and,CC,O
ncbi-sent-626,spontaneous,JJ,O
ncbi-sent-626,bleeding,VBG,O
ncbi-sent-626,events,NNS,O
ncbi-sent-626,in,IN,O
ncbi-sent-626,approximately,RB,O
ncbi-sent-626,10,CD,O
ncbi-sent-626,%,NN,O
ncbi-sent-626,of,IN,O
ncbi-sent-626,neonates,NNS,O
ncbi-sent-626,.,.,O
ncbi-sent-627,As,IN,O
ncbi-sent-627,in,IN,O
ncbi-sent-627,the,DT,O
ncbi-sent-627,human,JJ,O
ncbi-sent-627,disease,NN,O
ncbi-sent-627,",",",",O
ncbi-sent-627,the,DT,O
ncbi-sent-627,factor,NN,O
ncbi-sent-627,VIII,NNP,O
ncbi-sent-627,level,NN,O
ncbi-sent-627,in,IN,O
ncbi-sent-627,these,DT,O
ncbi-sent-627,mice,NN,O
ncbi-sent-627,was,VBD,O
ncbi-sent-627,reduced,VBN,O
ncbi-sent-627,strongly,RB,O
ncbi-sent-627,as,IN,O
ncbi-sent-627,a,DT,O
ncbi-sent-627,result,NN,O
ncbi-sent-627,of,IN,O
ncbi-sent-627,the,DT,O
ncbi-sent-627,lack,NN,O
ncbi-sent-627,of,IN,O
ncbi-sent-627,protection,NN,O
ncbi-sent-627,provided,VBN,O
ncbi-sent-627,by,IN,O
ncbi-sent-627,vWf,NN,O
ncbi-sent-627,.,.,O
ncbi-sent-628,Defective,JJ,O
ncbi-sent-628,thrombosis,NN,B-DISEASE
ncbi-sent-628,in,IN,O
ncbi-sent-628,mutant,JJ,O
ncbi-sent-628,mice,NN,O
ncbi-sent-628,was,VBD,O
ncbi-sent-628,also,RB,O
ncbi-sent-628,evident,JJ,O
ncbi-sent-628,in,IN,O
ncbi-sent-628,an,DT,O
ncbi-sent-628,in,IN,O
ncbi-sent-628,vivo,JJ,O
ncbi-sent-628,model,NN,O
ncbi-sent-628,of,IN,O
ncbi-sent-628,vascular,JJ,B-DISEASE
ncbi-sent-628,injury,NN,I-DISEASE
ncbi-sent-628,.,.,O
ncbi-sent-629,In,IN,O
ncbi-sent-629,this,DT,O
ncbi-sent-629,model,NN,O
ncbi-sent-629,",",",",O
ncbi-sent-629,the,DT,O
ncbi-sent-629,exteriorized,JJ,O
ncbi-sent-629,mesentery,NN,O
ncbi-sent-629,was,VBD,O
ncbi-sent-629,superfused,VBN,O
ncbi-sent-629,with,IN,O
ncbi-sent-629,ferric,JJ,O
ncbi-sent-629,chloride,NN,O
ncbi-sent-629,and,CC,O
ncbi-sent-629,the,DT,O
ncbi-sent-629,accumulation,NN,O
ncbi-sent-629,of,IN,O
ncbi-sent-629,fluorescently,RB,O
ncbi-sent-629,labeled,VBN,O
ncbi-sent-629,platelets,NNS,O
ncbi-sent-629,was,VBD,O
ncbi-sent-629,observed,VBN,O
ncbi-sent-629,by,IN,O
ncbi-sent-629,intravital,JJ,O
ncbi-sent-629,microscopy,NN,O
ncbi-sent-629,.,.,O
ncbi-sent-630,We,PRP,O
ncbi-sent-630,conclude,VBP,O
ncbi-sent-630,that,IN,O
ncbi-sent-630,these,DT,O
ncbi-sent-630,mice,NNS,O
ncbi-sent-630,very,RB,O
ncbi-sent-630,closely,RB,O
ncbi-sent-630,mimic,JJ,O
ncbi-sent-630,severe,JJ,O
ncbi-sent-630,human,JJ,O
ncbi-sent-630,von,NN,B-DISEASE
ncbi-sent-630,Willebrand,NNP,I-DISEASE
ncbi-sent-630,disease,NN,I-DISEASE
ncbi-sent-630,and,CC,O
ncbi-sent-630,will,MD,O
ncbi-sent-630,be,VB,O
ncbi-sent-630,very,RB,O
ncbi-sent-630,useful,JJ,O
ncbi-sent-630,for,IN,O
ncbi-sent-630,investigating,VBG,O
ncbi-sent-630,the,DT,O
ncbi-sent-630,role,NN,O
ncbi-sent-630,of,IN,O
ncbi-sent-630,vWf,NN,O
ncbi-sent-630,in,IN,O
ncbi-sent-630,normal,JJ,O
ncbi-sent-630,physiology,NN,O
ncbi-sent-630,and,CC,O
ncbi-sent-630,in,IN,O
ncbi-sent-630,disease,NN,O
ncbi-sent-630,models,NNS,O
ncbi-sent-630,.,.,O
ncbi-sent-631,.,.,O
ncbi-sent-632,Oral,JJ,O
ncbi-sent-632,contraceptives,NNS,O
ncbi-sent-632,and,CC,O
ncbi-sent-632,the,DT,O
ncbi-sent-632,risk,NN,O
ncbi-sent-632,of,IN,O
ncbi-sent-632,hereditary,JJ,B-DISEASE
ncbi-sent-632,ovarian,JJ,I-DISEASE
ncbi-sent-632,cancer,NN,I-DISEASE
ncbi-sent-632,.,.,O
ncbi-sent-633,Hereditary,JJ,B-DISEASE
ncbi-sent-633,Ovarian,JJ,I-DISEASE
ncbi-sent-633,Cancer,NNP,I-DISEASE
ncbi-sent-633,Clinical,NNP,O
ncbi-sent-633,Study,NNP,O
ncbi-sent-633,Group,NNP,O
ncbi-sent-633,.,.,O
ncbi-sent-634,BACKGROUND,NNP,O
ncbi-sent-634,Women,NNP,O
ncbi-sent-634,with,IN,O
ncbi-sent-634,mutations,NNS,O
ncbi-sent-634,in,IN,O
ncbi-sent-634,either,CC,O
ncbi-sent-634,the,DT,O
ncbi-sent-634,BRCA1,NNP,O
ncbi-sent-634,or,CC,O
ncbi-sent-634,the,DT,O
ncbi-sent-634,BRCA2,NNP,O
ncbi-sent-634,gene,NN,O
ncbi-sent-634,have,VBP,O
ncbi-sent-634,a,DT,O
ncbi-sent-634,high,JJ,O
ncbi-sent-634,lifetime,NN,O
ncbi-sent-634,risk,NN,O
ncbi-sent-634,of,IN,O
ncbi-sent-634,ovarian,JJ,B-DISEASE
ncbi-sent-634,cancer,NN,I-DISEASE
ncbi-sent-634,.,.,O
ncbi-sent-635,Oral,NNP,O
ncbi-sent-635,contraceptives,VBZ,O
ncbi-sent-635,protect,VBP,O
ncbi-sent-635,against,IN,O
ncbi-sent-635,ovarian,JJ,B-DISEASE
ncbi-sent-635,cancer,NN,I-DISEASE
ncbi-sent-635,in,IN,O
ncbi-sent-635,general,JJ,O
ncbi-sent-635,",",",",O
ncbi-sent-635,but,CC,O
ncbi-sent-635,it,PRP,O
ncbi-sent-635,is,VBZ,O
ncbi-sent-635,not,RB,O
ncbi-sent-635,known,VBN,O
ncbi-sent-635,whether,IN,O
ncbi-sent-635,they,PRP,O
ncbi-sent-635,also,RB,O
ncbi-sent-635,protect,VBP,O
ncbi-sent-635,against,IN,O
ncbi-sent-635,hereditary,JJ,B-DISEASE
ncbi-sent-635,forms,NNS,I-DISEASE
ncbi-sent-635,of,IN,I-DISEASE
ncbi-sent-635,ovarian,JJ,I-DISEASE
ncbi-sent-635,cancer,NN,I-DISEASE
ncbi-sent-635,.,.,O
ncbi-sent-636,METHODS,NNP,O
ncbi-sent-636,We,PRP,O
ncbi-sent-636,enrolled,VBD,O
ncbi-sent-636,207,CD,O
ncbi-sent-636,women,NNS,O
ncbi-sent-636,with,IN,O
ncbi-sent-636,hereditary,JJ,B-DISEASE
ncbi-sent-636,ovarian,JJ,I-DISEASE
ncbi-sent-636,cancer,NN,I-DISEASE
ncbi-sent-636,and,CC,O
ncbi-sent-636,161,CD,O
ncbi-sent-636,of,IN,O
ncbi-sent-636,their,PRP$,O
ncbi-sent-636,sisters,NNS,O
ncbi-sent-636,as,IN,O
ncbi-sent-636,controls,NNS,O
ncbi-sent-636,in,IN,O
ncbi-sent-636,a,DT,O
ncbi-sent-636,case,NN,O
ncbi-sent-636,-,:,O
ncbi-sent-636,control,NN,O
ncbi-sent-636,study,NN,O
ncbi-sent-636,.,.,O
ncbi-sent-637,All,PDT,O
ncbi-sent-637,the,DT,O
ncbi-sent-637,patients,NNS,O
ncbi-sent-637,carried,VBD,O
ncbi-sent-637,a,DT,O
ncbi-sent-637,pathogenic,JJ,O
ncbi-sent-637,mutation,NN,O
ncbi-sent-637,in,IN,O
ncbi-sent-637,either,DT,O
ncbi-sent-637,BRCA1,NNP,O
ncbi-sent-637,(,(,O
ncbi-sent-637,179,CD,O
ncbi-sent-637,women,NNS,O
ncbi-sent-637,),),O
ncbi-sent-637,or,CC,O
ncbi-sent-637,BRCA2,NNP,O
ncbi-sent-637,(,(,O
ncbi-sent-637,28,CD,O
ncbi-sent-637,women,NNS,O
ncbi-sent-637,),),O
ncbi-sent-637,.,.,O
ncbi-sent-638,The,DT,O
ncbi-sent-638,control,JJ,O
ncbi-sent-638,women,NNS,O
ncbi-sent-638,were,VBD,O
ncbi-sent-638,enrolled,JJ,O
ncbi-sent-638,regardless,NN,O
ncbi-sent-638,of,IN,O
ncbi-sent-638,whether,IN,O
ncbi-sent-638,or,CC,O
ncbi-sent-638,not,RB,O
ncbi-sent-638,they,PRP,O
ncbi-sent-638,had,VBD,O
ncbi-sent-638,either,DT,O
ncbi-sent-638,mutation,NN,O
ncbi-sent-638,.,.,O
ncbi-sent-639,Lifetime,NNP,O
ncbi-sent-639,histories,NNS,O
ncbi-sent-639,of,IN,O
ncbi-sent-639,oral,JJ,O
ncbi-sent-639,-,:,O
ncbi-sent-639,contraceptive,NN,O
ncbi-sent-639,use,NN,O
ncbi-sent-639,were,VBD,O
ncbi-sent-639,obtained,VBN,O
ncbi-sent-639,by,IN,O
ncbi-sent-639,interview,NN,O
ncbi-sent-639,or,CC,O
ncbi-sent-639,by,IN,O
ncbi-sent-639,written,VBN,O
ncbi-sent-639,questionnaire,NN,O
ncbi-sent-639,and,CC,O
ncbi-sent-639,were,VBD,O
ncbi-sent-639,compared,VBN,O
ncbi-sent-639,between,IN,O
ncbi-sent-639,patients,NNS,O
ncbi-sent-639,and,CC,O
ncbi-sent-639,control,VB,O
ncbi-sent-639,women,NNS,O
ncbi-sent-639,",",",",O
ncbi-sent-639,after,IN,O
ncbi-sent-639,adjustment,NN,O
ncbi-sent-639,for,IN,O
ncbi-sent-639,year,NN,O
ncbi-sent-639,of,IN,O
ncbi-sent-639,birth,NN,O
ncbi-sent-639,and,CC,O
ncbi-sent-639,parity,NN,O
ncbi-sent-639,.,.,O
ncbi-sent-640,RESULTS,VB,O
ncbi-sent-640,The,DT,O
ncbi-sent-640,adjusted,JJ,O
ncbi-sent-640,odds,NNS,O
ncbi-sent-640,ratio,NN,O
ncbi-sent-640,for,IN,O
ncbi-sent-640,ovarian,JJ,B-DISEASE
ncbi-sent-640,cancer,NN,I-DISEASE
ncbi-sent-640,associated,VBN,O
ncbi-sent-640,with,IN,O
ncbi-sent-640,any,DT,O
ncbi-sent-640,past,JJ,O
ncbi-sent-640,use,NN,O
ncbi-sent-640,of,IN,O
ncbi-sent-640,oral,JJ,O
ncbi-sent-640,contraceptives,NNS,O
ncbi-sent-640,was,VBD,O
ncbi-sent-640,0,CD,O
ncbi-sent-640,.,.,O
ncbi-sent-641,5,CD,O
ncbi-sent-641,(,(,O
ncbi-sent-641,95,CD,O
ncbi-sent-641,percent,NN,O
ncbi-sent-641,confidence,NN,O
ncbi-sent-641,interval,NN,O
ncbi-sent-641,",",",",O
ncbi-sent-641,0,CD,O
ncbi-sent-641,.,.,O
ncbi-sent-642,3,CD,O
ncbi-sent-642,to,TO,O
ncbi-sent-642,0,CD,O
ncbi-sent-642,.,.,O
ncbi-sent-643,8,CD,O
ncbi-sent-643,),),O
ncbi-sent-643,.,.,O
ncbi-sent-644,The,DT,O
ncbi-sent-644,risk,NN,O
ncbi-sent-644,decreased,VBD,O
ncbi-sent-644,with,IN,O
ncbi-sent-644,increasing,VBG,O
ncbi-sent-644,duration,NN,O
ncbi-sent-644,of,IN,O
ncbi-sent-644,use,NN,O
ncbi-sent-644,(,(,O
ncbi-sent-644,P,NNP,O
ncbi-sent-644,for,IN,O
ncbi-sent-644,trend,NN,O
ncbi-sent-644,",",",",O
ncbi-sent-644,<,RB,O
ncbi-sent-644,0,CD,O
ncbi-sent-644,.,.,O
ncbi-sent-645,001,CD,O
ncbi-sent-645,),),O
ncbi-sent-645,;,:,O
ncbi-sent-645,use,NN,O
ncbi-sent-645,for,IN,O
ncbi-sent-645,six,CD,O
ncbi-sent-645,or,CC,O
ncbi-sent-645,more,JJR,O
ncbi-sent-645,years,NNS,O
ncbi-sent-645,was,VBD,O
ncbi-sent-645,associated,VBN,O
ncbi-sent-645,with,IN,O
ncbi-sent-645,a,DT,O
ncbi-sent-645,60,CD,O
ncbi-sent-645,percent,NN,O
ncbi-sent-645,reduction,NN,O
ncbi-sent-645,in,IN,O
ncbi-sent-645,risk,NN,O
ncbi-sent-645,.,.,O
ncbi-sent-646,Oral,NNP,O
ncbi-sent-646,-,:,O
ncbi-sent-646,contraceptive,NN,O
ncbi-sent-646,use,NN,O
ncbi-sent-646,protected,VBN,O
ncbi-sent-646,against,IN,O
ncbi-sent-646,ovarian,JJ,B-DISEASE
ncbi-sent-646,cancer,NN,I-DISEASE
ncbi-sent-646,both,DT,O
ncbi-sent-646,for,IN,O
ncbi-sent-646,carriers,NNS,O
ncbi-sent-646,of,IN,O
ncbi-sent-646,the,DT,O
ncbi-sent-646,BRCA1,NNP,O
ncbi-sent-646,mutation,NN,O
ncbi-sent-646,(,(,O
ncbi-sent-646,odds,NNS,O
ncbi-sent-646,ratio,NN,O
ncbi-sent-646,",",",",O
ncbi-sent-646,0,CD,O
ncbi-sent-646,.,.,O
ncbi-sent-647,5,CD,O
ncbi-sent-647,;,:,O
ncbi-sent-647,95,CD,O
ncbi-sent-647,percent,NN,O
ncbi-sent-647,confidence,NN,O
ncbi-sent-647,interval,NN,O
ncbi-sent-647,",",",",O
ncbi-sent-647,0,CD,O
ncbi-sent-647,.,.,O
ncbi-sent-648,3,CD,O
ncbi-sent-648,to,TO,O
ncbi-sent-648,0,CD,O
ncbi-sent-648,.,.,O
ncbi-sent-649,9,CD,O
ncbi-sent-649,),),O
ncbi-sent-649,and,CC,O
ncbi-sent-649,for,IN,O
ncbi-sent-649,carriers,NNS,O
ncbi-sent-649,of,IN,O
ncbi-sent-649,the,DT,O
ncbi-sent-649,BRCA2,NNP,O
ncbi-sent-649,mutation,NN,O
ncbi-sent-649,(,(,O
ncbi-sent-649,odds,NNS,O
ncbi-sent-649,ratio,NN,O
ncbi-sent-649,",",",",O
ncbi-sent-649,0,CD,O
ncbi-sent-649,.,.,O
ncbi-sent-650,4,CD,O
ncbi-sent-650,;,:,O
ncbi-sent-650,95,CD,O
ncbi-sent-650,percent,NN,O
ncbi-sent-650,confidence,NN,O
ncbi-sent-650,interval,NN,O
ncbi-sent-650,",",",",O
ncbi-sent-650,0,CD,O
ncbi-sent-650,.,.,O
ncbi-sent-651,2,CD,O
ncbi-sent-651,to,TO,O
ncbi-sent-651,1,CD,O
ncbi-sent-651,.,.,O
ncbi-sent-652,1,CD,O
ncbi-sent-652,),),O
ncbi-sent-652,.,.,O
ncbi-sent-653,CONCLUSIONS,NNP,O
ncbi-sent-653,Oral,NNP,O
ncbi-sent-653,-,:,O
ncbi-sent-653,contraceptive,NN,O
ncbi-sent-653,use,NN,O
ncbi-sent-653,may,MD,O
ncbi-sent-653,reduce,VB,O
ncbi-sent-653,the,DT,O
ncbi-sent-653,risk,NN,O
ncbi-sent-653,of,IN,O
ncbi-sent-653,ovarian,JJ,B-DISEASE
ncbi-sent-653,cancer,NN,I-DISEASE
ncbi-sent-653,in,IN,O
ncbi-sent-653,women,NNS,O
ncbi-sent-653,with,IN,O
ncbi-sent-653,pathogenic,JJ,O
ncbi-sent-653,mutations,NNS,O
ncbi-sent-653,in,IN,O
ncbi-sent-653,the,DT,O
ncbi-sent-653,BRCA1,NNP,O
ncbi-sent-653,or,CC,O
ncbi-sent-653,BRCA2,NNP,O
ncbi-sent-653,gene,NN,O
ncbi-sent-653,A,NNP,O
ncbi-sent-653,Japanese,JJ,O
ncbi-sent-653,family,NN,O
ncbi-sent-653,with,IN,O
ncbi-sent-653,adrenoleukodystrophy,NN,B-DISEASE
ncbi-sent-653,with,IN,O
ncbi-sent-653,a,DT,O
ncbi-sent-653,codon,NN,O
ncbi-sent-653,291,CD,O
ncbi-sent-653,deletion,NN,O
ncbi-sent-653,:,:,O
ncbi-sent-653,a,DT,O
ncbi-sent-653,clinical,JJ,O
ncbi-sent-653,",",",",O
ncbi-sent-653,biochemical,JJ,O
ncbi-sent-653,",",",",O
ncbi-sent-653,pathological,JJ,O
ncbi-sent-653,",",",",O
ncbi-sent-653,and,CC,O
ncbi-sent-653,genetic,JJ,O
ncbi-sent-653,report,NN,O
ncbi-sent-653,.,.,O
ncbi-sent-654,We,PRP,O
ncbi-sent-654,report,VBP,O
ncbi-sent-654,a,DT,O
ncbi-sent-654,Japanese,JJ,O
ncbi-sent-654,family,NN,O
ncbi-sent-654,with,IN,O
ncbi-sent-654,adrenoleukodystrophy,NN,B-DISEASE
ncbi-sent-654,(,(,O
ncbi-sent-654,ALD,NNP,B-DISEASE
ncbi-sent-654,),),O
ncbi-sent-654,with,IN,O
ncbi-sent-654,a,DT,O
ncbi-sent-654,three,CD,O
ncbi-sent-654,base,NN,O
ncbi-sent-654,pair,NN,O
ncbi-sent-654,deletion,NN,O
ncbi-sent-654,(,(,O
ncbi-sent-654,delGAG,JJ,O
ncbi-sent-654,291,CD,O
ncbi-sent-654,),),O
ncbi-sent-654,in,IN,O
ncbi-sent-654,the,DT,O
ncbi-sent-654,ALD,NNP,B-DISEASE
ncbi-sent-654,gene,NN,O
ncbi-sent-654,.,.,O
ncbi-sent-655,A,DT,O
ncbi-sent-655,variety,NN,O
ncbi-sent-655,of,IN,O
ncbi-sent-655,phenotypes,NNS,O
ncbi-sent-655,were,VBD,O
ncbi-sent-655,observed,VBN,O
ncbi-sent-655,within,IN,O
ncbi-sent-655,this,DT,O
ncbi-sent-655,family,NN,O
ncbi-sent-655,.,.,O
ncbi-sent-656,While,IN,O
ncbi-sent-656,the,DT,O
ncbi-sent-656,proband,NN,O
ncbi-sent-656,(,(,O
ncbi-sent-656,patient,JJ,O
ncbi-sent-656,1,CD,O
ncbi-sent-656,),),O
ncbi-sent-656,was,VBD,O
ncbi-sent-656,classified,VBN,O
ncbi-sent-656,as,IN,O
ncbi-sent-656,having,VBG,O
ncbi-sent-656,a,DT,O
ncbi-sent-656,rare,JJ,O
ncbi-sent-656,intermediate,JJ,O
ncbi-sent-656,type,NN,O
ncbi-sent-656,of,IN,O
ncbi-sent-656,adult,JJ,O
ncbi-sent-656,cerebral,JJ,O
ncbi-sent-656,and,CC,O
ncbi-sent-656,cerebello,JJ,O
ncbi-sent-656,-,:,O
ncbi-sent-656,brain,NN,O
ncbi-sent-656,stem,NN,O
ncbi-sent-656,forms,NNS,O
ncbi-sent-656,",",",",O
ncbi-sent-656,his,PRP$,O
ncbi-sent-656,younger,JJR,O
ncbi-sent-656,brother,NN,O
ncbi-sent-656,(,(,O
ncbi-sent-656,patient,JJ,O
ncbi-sent-656,2,CD,O
ncbi-sent-656,),),O
ncbi-sent-656,and,CC,O
ncbi-sent-656,nephew,$,O
ncbi-sent-656,(,(,O
ncbi-sent-656,patient,JJ,O
ncbi-sent-656,3,CD,O
ncbi-sent-656,),),O
ncbi-sent-656,had,VBD,O
ncbi-sent-656,a,DT,O
ncbi-sent-656,childhood,NN,O
ncbi-sent-656,ALD,NNP,B-DISEASE
ncbi-sent-656,type,NN,O
ncbi-sent-656,.,.,O
ncbi-sent-657,Another,DT,O
ncbi-sent-657,nephew,NN,O
ncbi-sent-657,(,(,O
ncbi-sent-657,patient,JJ,O
ncbi-sent-657,4,CD,O
ncbi-sent-657,),),O
ncbi-sent-657,of,IN,O
ncbi-sent-657,patient,NN,O
ncbi-sent-657,1,CD,O
ncbi-sent-657,was,VBD,O
ncbi-sent-657,classified,VBN,O
ncbi-sent-657,as,IN,O
ncbi-sent-657,having,VBG,O
ncbi-sent-657,an,DT,O
ncbi-sent-657,adolescent,JJ,O
ncbi-sent-657,form,NN,O
ncbi-sent-657,.,.,O
ncbi-sent-658,The,DT,O
ncbi-sent-658,tau,JJ,O
ncbi-sent-658,level,NN,O
ncbi-sent-658,in,IN,O
ncbi-sent-658,the,DT,O
ncbi-sent-658,cerebrospinal,JJ,O
ncbi-sent-658,fluid,NN,O
ncbi-sent-658,(,(,O
ncbi-sent-658,CSF,NNP,O
ncbi-sent-658,),),O
ncbi-sent-658,in,IN,O
ncbi-sent-658,patient,NN,O
ncbi-sent-658,1,CD,O
ncbi-sent-658,was,VBD,O
ncbi-sent-658,as,RB,O
ncbi-sent-658,high,JJ,O
ncbi-sent-658,as,IN,O
ncbi-sent-658,that,DT,O
ncbi-sent-658,of,IN,O
ncbi-sent-658,patients,NNS,O
ncbi-sent-658,with,IN,O
ncbi-sent-658,Alzheimers,NNP,B-DISEASE
ncbi-sent-658,disease,NN,I-DISEASE
ncbi-sent-658,(,(,O
ncbi-sent-658,AD,NNP,B-DISEASE
ncbi-sent-658,),),O
ncbi-sent-658,.,.,O
ncbi-sent-659,His,PRP$,O
ncbi-sent-659,brain,NN,O
ncbi-sent-659,magnetic,JJ,O
ncbi-sent-659,resonance,NN,O
ncbi-sent-659,image,NN,O
ncbi-sent-659,(,(,O
ncbi-sent-659,MRI,NNP,O
ncbi-sent-659,),),O
ncbi-sent-659,showed,VBD,O
ncbi-sent-659,abnormalities,NNS,B-DISEASE
ncbi-sent-659,in,IN,I-DISEASE
ncbi-sent-659,the,DT,I-DISEASE
ncbi-sent-659,bilateral,JJ,I-DISEASE
ncbi-sent-659,cerebellar,NN,I-DISEASE
ncbi-sent-659,hemispheres,NNS,I-DISEASE
ncbi-sent-659,and,CC,O
ncbi-sent-659,brain,NN,O
ncbi-sent-659,stem,NN,O
ncbi-sent-659,",",",",O
ncbi-sent-659,but,CC,O
ncbi-sent-659,not,RB,O
ncbi-sent-659,in,IN,O
ncbi-sent-659,the,DT,O
ncbi-sent-659,cerebral,JJ,O
ncbi-sent-659,white,JJ,O
ncbi-sent-659,matter,NN,O
ncbi-sent-659,",",",",O
ncbi-sent-659,where,WRB,O
ncbi-sent-659,marked,JJ,O
ncbi-sent-659,reductions,NNS,O
ncbi-sent-659,of,IN,O
ncbi-sent-659,the,DT,O
ncbi-sent-659,cerebral,JJ,O
ncbi-sent-659,blood,NN,O
ncbi-sent-659,flow,NN,O
ncbi-sent-659,and,CC,O
ncbi-sent-659,oxygen,NN,O
ncbi-sent-659,metabolism,NN,O
ncbi-sent-659,were,VBD,O
ncbi-sent-659,clearly,RB,O
ncbi-sent-659,demonstrated,VBN,O
ncbi-sent-659,by,IN,O
ncbi-sent-659,positron,NN,O
ncbi-sent-659,emission,NN,O
ncbi-sent-659,tomography,NN,O
ncbi-sent-659,(,(,O
ncbi-sent-659,PET,NNP,O
ncbi-sent-659,),),O
ncbi-sent-659,.,.,O
ncbi-sent-660,In,IN,O
ncbi-sent-660,patients,NNS,O
ncbi-sent-660,2,CD,O
ncbi-sent-660,and,CC,O
ncbi-sent-660,3,CD,O
ncbi-sent-660,",",",",O
ncbi-sent-660,the,DT,O
ncbi-sent-660,autopsy,NN,O
ncbi-sent-660,findings,NNS,O
ncbi-sent-660,showed,VBD,O
ncbi-sent-660,massive,JJ,O
ncbi-sent-660,demyelination,NN,B-DISEASE
ncbi-sent-660,of,IN,I-DISEASE
ncbi-sent-660,the,DT,I-DISEASE
ncbi-sent-660,cerebral,JJ,I-DISEASE
ncbi-sent-660,white,JJ,I-DISEASE
ncbi-sent-660,matter,NN,I-DISEASE
ncbi-sent-660,with,IN,O
ncbi-sent-660,sparing,NN,O
ncbi-sent-660,of,IN,O
ncbi-sent-660,the,DT,O
ncbi-sent-660,U,NNP,O
ncbi-sent-660,-,:,O
ncbi-sent-660,fibers,NNS,O
ncbi-sent-660,",",",",O
ncbi-sent-660,compatible,JJ,O
ncbi-sent-660,with,IN,O
ncbi-sent-660,the,DT,O
ncbi-sent-660,findings,NNS,O
ncbi-sent-660,of,IN,O
ncbi-sent-660,childhood,NN,O
ncbi-sent-660,ALD,NNP,B-DISEASE
ncbi-sent-660,.,.,O
ncbi-sent-661,Oleic,NNP,O
ncbi-sent-661,and,CC,O
ncbi-sent-661,erucic,JJ,O
ncbi-sent-661,acids,NNS,O
ncbi-sent-661,(,(,O
ncbi-sent-661,Lorenzos,NNP,O
ncbi-sent-661,Oil,NNP,O
ncbi-sent-661,),),O
ncbi-sent-661,were,VBD,O
ncbi-sent-661,administered,VBN,O
ncbi-sent-661,to,TO,O
ncbi-sent-661,patients,NNS,O
ncbi-sent-661,1,CD,O
ncbi-sent-661,and,CC,O
ncbi-sent-661,4,CD,O
ncbi-sent-661,",",",",O
ncbi-sent-661,but,CC,O
ncbi-sent-661,sufficient,JJ,O
ncbi-sent-661,effectiveness,NN,O
ncbi-sent-661,was,VBD,O
ncbi-sent-661,not,RB,O
ncbi-sent-661,obtained,VBN,O
ncbi-sent-661,.,.,O
ncbi-sent-662,The,DT,O
ncbi-sent-662,findings,NNS,O
ncbi-sent-662,in,IN,O
ncbi-sent-662,this,DT,O
ncbi-sent-662,family,NN,O
ncbi-sent-662,suggest,VBP,O
ncbi-sent-662,that,IN,O
ncbi-sent-662,delGAG291,NN,O
ncbi-sent-662,is,VBZ,O
ncbi-sent-662,part,NN,O
ncbi-sent-662,of,IN,O
ncbi-sent-662,the,DT,O
ncbi-sent-662,cause,NN,O
ncbi-sent-662,of,IN,O
ncbi-sent-662,Japanese,JJ,O
ncbi-sent-662,ALD,NNP,B-DISEASE
ncbi-sent-662,with,IN,O
ncbi-sent-662,phenotypic,JJ,O
ncbi-sent-662,variations,NNS,O
ncbi-sent-662,.,.,O
ncbi-sent-663,Moreover,RB,O
ncbi-sent-663,",",",",O
ncbi-sent-663,although,IN,O
ncbi-sent-663,the,DT,O
ncbi-sent-663,scale,NN,O
ncbi-sent-663,of,IN,O
ncbi-sent-663,the,DT,O
ncbi-sent-663,study,NN,O
ncbi-sent-663,is,VBZ,O
ncbi-sent-663,limited,VBN,O
ncbi-sent-663,",",",",O
ncbi-sent-663,there,EX,O
ncbi-sent-663,is,VBZ,O
ncbi-sent-663,a,DT,O
ncbi-sent-663,possibility,NN,O
ncbi-sent-663,that,IN,O
ncbi-sent-663,PET,NNP,O
ncbi-sent-663,can,MD,O
ncbi-sent-663,detect,VB,O
ncbi-sent-663,an,DT,O
ncbi-sent-663,insidious,JJ,B-DISEASE
ncbi-sent-663,lesion,NN,I-DISEASE
ncbi-sent-663,which,WDT,O
ncbi-sent-663,is,VBZ,O
ncbi-sent-663,undetectable,JJ,O
ncbi-sent-663,by,IN,O
ncbi-sent-663,computed,JJ,O
ncbi-sent-663,tomogram,NN,O
ncbi-sent-663,(,(,O
ncbi-sent-663,CT,NNP,O
ncbi-sent-663,),),O
ncbi-sent-663,or,CC,O
ncbi-sent-663,MRI,NNP,O
ncbi-sent-663,analysis,NN,O
ncbi-sent-663,",",",",O
ncbi-sent-663,and,CC,O
ncbi-sent-663,that,IN,O
ncbi-sent-663,the,DT,O
ncbi-sent-663,higher,JJR,O
ncbi-sent-663,level,NN,O
ncbi-sent-663,of,IN,O
ncbi-sent-663,tau,NN,O
ncbi-sent-663,reflects,VBZ,O
ncbi-sent-663,the,DT,O
ncbi-sent-663,process,NN,O
ncbi-sent-663,of,IN,O
ncbi-sent-663,neuronal,JJ,B-DISEASE
ncbi-sent-663,degeneration,NN,I-DISEASE
ncbi-sent-663,in,IN,O
ncbi-sent-663,ALD,NNP,B-DISEASE
ncbi-sent-663,.,.,O
ncbi-sent-664,Lorenzos,NNP,O
ncbi-sent-664,Oil,NNP,O
ncbi-sent-664,should,MD,O
ncbi-sent-664,be,VB,O
ncbi-sent-664,given,VBN,O
ncbi-sent-664,in,IN,O
ncbi-sent-664,the,DT,O
ncbi-sent-664,early,JJ,O
ncbi-sent-664,stage,NN,O
ncbi-sent-664,.,.,O
ncbi-sent-665,.,.,O
ncbi-sent-666,Nonsense,JJ,O
ncbi-sent-666,mutation,NN,O
ncbi-sent-666,in,IN,O
ncbi-sent-666,exon,JJ,O
ncbi-sent-666,4,CD,O
ncbi-sent-666,of,IN,O
ncbi-sent-666,human,JJ,O
ncbi-sent-666,complement,NN,O
ncbi-sent-666,C9,NNP,O
ncbi-sent-666,gene,NN,O
ncbi-sent-666,is,VBZ,O
ncbi-sent-666,the,DT,O
ncbi-sent-666,major,JJ,O
ncbi-sent-666,cause,NN,O
ncbi-sent-666,of,IN,O
ncbi-sent-666,Japanese,JJ,O
ncbi-sent-666,complement,NN,B-DISEASE
ncbi-sent-666,C9,NNP,I-DISEASE
ncbi-sent-666,deficiency,NN,I-DISEASE
ncbi-sent-666,.,.,O
ncbi-sent-667,Deficiency,NN,B-DISEASE
ncbi-sent-667,of,IN,I-DISEASE
ncbi-sent-667,the,DT,I-DISEASE
ncbi-sent-667,ninth,JJ,I-DISEASE
ncbi-sent-667,component,NN,I-DISEASE
ncbi-sent-667,of,IN,I-DISEASE
ncbi-sent-667,human,JJ,I-DISEASE
ncbi-sent-667,complement,NN,I-DISEASE
ncbi-sent-667,(,(,O
ncbi-sent-667,C9,NNP,O
ncbi-sent-667,),),O
ncbi-sent-667,is,VBZ,O
ncbi-sent-667,the,DT,O
ncbi-sent-667,most,RBS,O
ncbi-sent-667,common,JJ,O
ncbi-sent-667,complement,NN,B-DISEASE
ncbi-sent-667,deficiency,NN,I-DISEASE
ncbi-sent-667,in,IN,O
ncbi-sent-667,Japan,NNP,O
ncbi-sent-667,but,CC,O
ncbi-sent-667,is,VBZ,O
ncbi-sent-667,rare,JJ,O
ncbi-sent-667,in,IN,O
ncbi-sent-667,other,JJ,O
ncbi-sent-667,countries,NNS,O
ncbi-sent-667,.,.,O
ncbi-sent-668,We,PRP,O
ncbi-sent-668,studied,VBD,O
ncbi-sent-668,the,DT,O
ncbi-sent-668,molecular,JJ,O
ncbi-sent-668,basis,NN,O
ncbi-sent-668,of,IN,O
ncbi-sent-668,C9,NNP,B-DISEASE
ncbi-sent-668,deficiency,NN,I-DISEASE
ncbi-sent-668,in,IN,O
ncbi-sent-668,four,CD,O
ncbi-sent-668,Japanese,JJ,O
ncbi-sent-668,C9,NNP,B-DISEASE
ncbi-sent-668,-,:,I-DISEASE
ncbi-sent-668,deficient,NN,I-DISEASE
ncbi-sent-668,patients,NNS,O
ncbi-sent-668,who,WP,O
ncbi-sent-668,had,VBD,O
ncbi-sent-668,suffered,VBN,O
ncbi-sent-668,from,IN,O
ncbi-sent-668,meningococcal,JJ,B-DISEASE
ncbi-sent-668,meningitis,NN,I-DISEASE
ncbi-sent-668,.,.,O
ncbi-sent-669,Direct,JJ,O
ncbi-sent-669,sequencing,NN,O
ncbi-sent-669,of,IN,O
ncbi-sent-669,amplified,JJ,O
ncbi-sent-669,C9,NNP,O
ncbi-sent-669,cDNA,NN,O
ncbi-sent-669,and,CC,O
ncbi-sent-669,DNA,NNP,O
ncbi-sent-669,revealed,VBD,O
ncbi-sent-669,a,DT,O
ncbi-sent-669,nonsense,JJ,O
ncbi-sent-669,substitution,NN,O
ncbi-sent-669,(,(,O
ncbi-sent-669,CGA,NNP,O
ncbi-sent-669,-,:,O
ncbi-sent-669,-,:,O
ncbi-sent-669,>,NN,O
ncbi-sent-669,TGA,NNP,O
ncbi-sent-669,),),O
ncbi-sent-669,at,IN,O
ncbi-sent-669,codon,$,O
ncbi-sent-669,95,CD,O
ncbi-sent-669,in,IN,O
ncbi-sent-669,exon,JJ,O
ncbi-sent-669,4,CD,O
ncbi-sent-669,in,IN,O
ncbi-sent-669,the,DT,O
ncbi-sent-669,four,CD,O
ncbi-sent-669,C9,NNP,B-DISEASE
ncbi-sent-669,-,:,I-DISEASE
ncbi-sent-669,deficient,NN,I-DISEASE
ncbi-sent-669,individuals,NNS,O
ncbi-sent-669,.,.,O
ncbi-sent-670,An,DT,O
ncbi-sent-670,allele,JJ,O
ncbi-sent-670,-,:,O
ncbi-sent-670,specific,JJ,O
ncbi-sent-670,polymerase,NN,O
ncbi-sent-670,chain,NN,O
ncbi-sent-670,reaction,NN,O
ncbi-sent-670,system,NN,O
ncbi-sent-670,designed,VBN,O
ncbi-sent-670,to,TO,O
ncbi-sent-670,detect,VB,O
ncbi-sent-670,exclusively,RB,O
ncbi-sent-670,only,RB,O
ncbi-sent-670,one,CD,O
ncbi-sent-670,of,IN,O
ncbi-sent-670,the,DT,O
ncbi-sent-670,normal,JJ,O
ncbi-sent-670,and,CC,O
ncbi-sent-670,mutant,JJ,O
ncbi-sent-670,alleles,NNS,O
ncbi-sent-670,indicated,VBD,O
ncbi-sent-670,that,IN,O
ncbi-sent-670,all,PDT,O
ncbi-sent-670,the,DT,O
ncbi-sent-670,four,CD,O
ncbi-sent-670,patients,NNS,O
ncbi-sent-670,were,VBD,O
ncbi-sent-670,homozygous,JJ,O
ncbi-sent-670,for,IN,O
ncbi-sent-670,the,DT,O
ncbi-sent-670,mutation,NN,O
ncbi-sent-670,in,IN,O
ncbi-sent-670,exon,CC,O
ncbi-sent-670,4,CD,O
ncbi-sent-670,and,CC,O
ncbi-sent-670,that,IN,O
ncbi-sent-670,the,DT,O
ncbi-sent-670,parents,NNS,O
ncbi-sent-670,of,IN,O
ncbi-sent-670,patient,JJ,O
ncbi-sent-670,2,CD,O
ncbi-sent-670,were,VBD,O
ncbi-sent-670,heterozygous,JJ,O
ncbi-sent-670,.,.,O
ncbi-sent-671,The,DT,O
ncbi-sent-671,common,JJ,O
ncbi-sent-671,mutation,NN,O
ncbi-sent-671,at,IN,O
ncbi-sent-671,codon,NN,O
ncbi-sent-671,95,CD,O
ncbi-sent-671,in,IN,O
ncbi-sent-671,exon,JJ,O
ncbi-sent-671,4,CD,O
ncbi-sent-671,might,MD,O
ncbi-sent-671,be,VB,O
ncbi-sent-671,responsible,JJ,O
ncbi-sent-671,for,IN,O
ncbi-sent-671,most,JJS,O
ncbi-sent-671,Japanese,JJ,O
ncbi-sent-671,C9,NNP,B-DISEASE
ncbi-sent-671,deficiency,NN,I-DISEASE
ncbi-sent-671,.,.,O
ncbi-sent-672,.,.,O
ncbi-sent-673,BRCA1,NNP,O
ncbi-sent-673,required,VBD,O
ncbi-sent-673,for,IN,O
ncbi-sent-673,transcription,NN,O
ncbi-sent-673,-,:,O
ncbi-sent-673,coupled,VBN,O
ncbi-sent-673,repair,NN,O
ncbi-sent-673,of,IN,O
ncbi-sent-673,oxidative,JJ,O
ncbi-sent-673,DNA,NNP,O
ncbi-sent-673,damage,NN,O
ncbi-sent-673,.,.,O
ncbi-sent-674,The,DT,O
ncbi-sent-674,breast,NN,B-DISEASE
ncbi-sent-674,and,CC,I-DISEASE
ncbi-sent-674,ovarian,JJ,I-DISEASE
ncbi-sent-674,cancer,NN,I-DISEASE
ncbi-sent-674,susceptibility,NN,O
ncbi-sent-674,gene,NN,O
ncbi-sent-674,BRCA1,NNP,O
ncbi-sent-674,encodes,VBZ,O
ncbi-sent-674,a,DT,O
ncbi-sent-674,zinc,NN,O
ncbi-sent-674,finger,NN,O
ncbi-sent-674,protein,NN,O
ncbi-sent-674,of,IN,O
ncbi-sent-674,unknown,JJ,O
ncbi-sent-674,function,NN,O
ncbi-sent-674,.,.,O
ncbi-sent-675,Association,NNP,O
ncbi-sent-675,of,IN,O
ncbi-sent-675,the,DT,O
ncbi-sent-675,BRCA1,NNP,O
ncbi-sent-675,protein,NN,O
ncbi-sent-675,with,IN,O
ncbi-sent-675,the,DT,O
ncbi-sent-675,DNA,NNP,O
ncbi-sent-675,repair,NN,O
ncbi-sent-675,protein,NN,O
ncbi-sent-675,Rad51,NNP,O
ncbi-sent-675,and,CC,O
ncbi-sent-675,changes,NNS,O
ncbi-sent-675,in,IN,O
ncbi-sent-675,the,DT,O
ncbi-sent-675,phosphorylation,NN,O
ncbi-sent-675,and,CC,O
ncbi-sent-675,cellular,JJ,O
ncbi-sent-675,localization,NN,O
ncbi-sent-675,of,IN,O
ncbi-sent-675,the,DT,O
ncbi-sent-675,protein,NN,O
ncbi-sent-675,after,IN,O
ncbi-sent-675,exposure,NN,O
ncbi-sent-675,to,TO,O
ncbi-sent-675,DNA,NNP,O
ncbi-sent-675,-,:,O
ncbi-sent-675,damaging,NN,O
ncbi-sent-675,agents,NNS,O
ncbi-sent-675,are,VBP,O
ncbi-sent-675,consistent,JJ,O
ncbi-sent-675,with,IN,O
ncbi-sent-675,a,DT,O
ncbi-sent-675,role,NN,O
ncbi-sent-675,for,IN,O
ncbi-sent-675,BRCA1,NNP,O
ncbi-sent-675,in,IN,O
ncbi-sent-675,DNA,NNP,O
ncbi-sent-675,repair,NN,O
ncbi-sent-675,.,.,O
ncbi-sent-676,Here,RB,O
ncbi-sent-676,",",",",O
ncbi-sent-676,it,PRP,O
ncbi-sent-676,is,VBZ,O
ncbi-sent-676,shown,VBN,O
ncbi-sent-676,that,IN,O
ncbi-sent-676,mouse,NN,O
ncbi-sent-676,embryonic,JJ,O
ncbi-sent-676,stem,NN,O
ncbi-sent-676,cells,NNS,O
ncbi-sent-676,deficient,NN,B-DISEASE
ncbi-sent-676,in,IN,I-DISEASE
ncbi-sent-676,BRCA1,NNP,I-DISEASE
ncbi-sent-676,are,VBP,O
ncbi-sent-676,defective,JJ,O
ncbi-sent-676,in,IN,O
ncbi-sent-676,the,DT,O
ncbi-sent-676,ability,NN,O
ncbi-sent-676,to,TO,O
ncbi-sent-676,carry,VB,O
ncbi-sent-676,out,RP,O
ncbi-sent-676,transcription,NN,O
ncbi-sent-676,-,:,O
ncbi-sent-676,coupled,VBN,O
ncbi-sent-676,repair,NN,O
ncbi-sent-676,of,IN,O
ncbi-sent-676,oxidative,JJ,O
ncbi-sent-676,DNA,NNP,O
ncbi-sent-676,damage,NN,O
ncbi-sent-676,",",",",O
ncbi-sent-676,and,CC,O
ncbi-sent-676,are,VBP,O
ncbi-sent-676,hypersensitive,JJ,O
ncbi-sent-676,to,TO,O
ncbi-sent-676,ionizing,VBG,O
ncbi-sent-676,radiation,NN,O
ncbi-sent-676,and,CC,O
ncbi-sent-676,hydrogen,NN,O
ncbi-sent-676,peroxide,NN,O
ncbi-sent-676,.,.,O
ncbi-sent-677,These,DT,O
ncbi-sent-677,results,NNS,O
ncbi-sent-677,suggest,VBP,O
ncbi-sent-677,that,IN,O
ncbi-sent-677,BRCA1,NNP,O
ncbi-sent-677,participates,NNS,O
ncbi-sent-677,",",",",O
ncbi-sent-677,directly,RB,O
ncbi-sent-677,or,CC,O
ncbi-sent-677,indirectly,RB,O
ncbi-sent-677,",",",",O
ncbi-sent-677,in,IN,O
ncbi-sent-677,transcription,NN,O
ncbi-sent-677,-,:,O
ncbi-sent-677,coupled,VBN,O
ncbi-sent-677,repair,NN,O
ncbi-sent-677,of,IN,O
ncbi-sent-677,oxidative,JJ,O
ncbi-sent-677,DNA,NNP,O
ncbi-sent-677,damage,NN,O
ncbi-sent-677,.,.,O
ncbi-sent-678,.,.,O
ncbi-sent-679,Truncation,NN,O
ncbi-sent-679,mutations,NNS,O
ncbi-sent-679,in,IN,O
ncbi-sent-679,the,DT,O
ncbi-sent-679,transactivation,NN,O
ncbi-sent-679,region,NN,O
ncbi-sent-679,of,IN,O
ncbi-sent-679,PAX6,NNP,O
ncbi-sent-679,result,NN,O
ncbi-sent-679,in,IN,O
ncbi-sent-679,dominant,JJ,O
ncbi-sent-679,-,:,O
ncbi-sent-679,negative,JJ,O
ncbi-sent-679,mutants,NNS,O
ncbi-sent-679,.,.,O
ncbi-sent-680,PAX6,NNP,O
ncbi-sent-680,is,VBZ,O
ncbi-sent-680,a,DT,O
ncbi-sent-680,transcription,NN,O
ncbi-sent-680,factor,NN,O
ncbi-sent-680,with,IN,O
ncbi-sent-680,two,CD,O
ncbi-sent-680,DNA,NNP,O
ncbi-sent-680,-,:,O
ncbi-sent-680,binding,NN,O
ncbi-sent-680,domains,NNS,O
ncbi-sent-680,(,(,O
ncbi-sent-680,paired,VBN,O
ncbi-sent-680,box,NN,O
ncbi-sent-680,and,CC,O
ncbi-sent-680,homeobox,NN,O
ncbi-sent-680,),),O
ncbi-sent-680,and,CC,O
ncbi-sent-680,a,DT,O
ncbi-sent-680,proline,JJ,O
ncbi-sent-680,-,:,O
ncbi-sent-680,serine,NN,O
ncbi-sent-680,-,:,O
ncbi-sent-680,threonine,NN,O
ncbi-sent-680,(,(,O
ncbi-sent-680,PST,NNP,O
ncbi-sent-680,),),O
ncbi-sent-680,-,:,O
ncbi-sent-680,rich,JJ,O
ncbi-sent-680,transactivation,NN,O
ncbi-sent-680,domain,NN,O
ncbi-sent-680,.,.,O
ncbi-sent-681,PAX6,NNP,O
ncbi-sent-681,regulates,VBZ,O
ncbi-sent-681,eye,NN,O
ncbi-sent-681,development,NN,O
ncbi-sent-681,in,IN,O
ncbi-sent-681,animals,NNS,O
ncbi-sent-681,ranging,VBG,O
ncbi-sent-681,from,IN,O
ncbi-sent-681,jellyfish,NN,O
ncbi-sent-681,to,TO,O
ncbi-sent-681,Drosophila,NNP,O
ncbi-sent-681,to,TO,O
ncbi-sent-681,humans,NNS,O
ncbi-sent-681,.,.,O
ncbi-sent-682,Heterozygous,JJ,O
ncbi-sent-682,mutations,NNS,O
ncbi-sent-682,in,IN,O
ncbi-sent-682,the,DT,O
ncbi-sent-682,human,JJ,O
ncbi-sent-682,PAX6,NNP,O
ncbi-sent-682,gene,NN,O
ncbi-sent-682,result,NN,O
ncbi-sent-682,in,IN,O
ncbi-sent-682,various,JJ,O
ncbi-sent-682,phenotypes,NNS,O
ncbi-sent-682,",",",",O
ncbi-sent-682,including,VBG,O
ncbi-sent-682,aniridia,NN,B-DISEASE
ncbi-sent-682,",",",",O
ncbi-sent-682,Peters,NNP,B-DISEASE
ncbi-sent-682,anomaly,VBP,I-DISEASE
ncbi-sent-682,",",",",O
ncbi-sent-682,autosomal,JJ,B-DISEASE
ncbi-sent-682,dominant,JJ,I-DISEASE
ncbi-sent-682,keratitis,NN,I-DISEASE
ncbi-sent-682,",",",",O
ncbi-sent-682,and,CC,O
ncbi-sent-682,familial,JJ,B-DISEASE
ncbi-sent-682,foveal,NN,I-DISEASE
ncbi-sent-682,dysplasia,NN,I-DISEASE
ncbi-sent-682,.,.,O
ncbi-sent-683,It,PRP,O
ncbi-sent-683,is,VBZ,O
ncbi-sent-683,believed,VBN,O
ncbi-sent-683,that,IN,O
ncbi-sent-683,the,DT,O
ncbi-sent-683,mutated,JJ,O
ncbi-sent-683,allele,NN,O
ncbi-sent-683,of,IN,O
ncbi-sent-683,PAX6,NNP,O
ncbi-sent-683,produces,VBZ,O
ncbi-sent-683,an,DT,O
ncbi-sent-683,inactive,JJ,O
ncbi-sent-683,protein,NN,O
ncbi-sent-683,and,CC,O
ncbi-sent-683,aniridia,NN,B-DISEASE
ncbi-sent-683,is,VBZ,O
ncbi-sent-683,caused,VBN,O
ncbi-sent-683,due,JJ,O
ncbi-sent-683,to,TO,O
ncbi-sent-683,genetic,JJ,O
ncbi-sent-683,haploinsufficiency,NN,O
ncbi-sent-683,.,.,O
ncbi-sent-684,However,RB,O
ncbi-sent-684,",",",",O
ncbi-sent-684,several,JJ,O
ncbi-sent-684,truncation,NN,O
ncbi-sent-684,mutations,NNS,O
ncbi-sent-684,have,VBP,O
ncbi-sent-684,been,VBN,O
ncbi-sent-684,found,VBN,O
ncbi-sent-684,to,TO,O
ncbi-sent-684,occur,VB,O
ncbi-sent-684,in,IN,O
ncbi-sent-684,the,DT,O
ncbi-sent-684,C,NNP,O
ncbi-sent-684,-,:,O
ncbi-sent-684,terminal,JJ,O
ncbi-sent-684,half,NN,O
ncbi-sent-684,of,IN,O
ncbi-sent-684,PAX6,NNP,O
ncbi-sent-684,in,IN,O
ncbi-sent-684,patients,NNS,O
ncbi-sent-684,with,IN,O
ncbi-sent-684,Aniridia,NNP,B-DISEASE
ncbi-sent-684,resulting,VBG,O
ncbi-sent-684,in,IN,O
ncbi-sent-684,mutant,JJ,O
ncbi-sent-684,proteins,NNS,O
ncbi-sent-684,that,WDT,O
ncbi-sent-684,retain,VBP,O
ncbi-sent-684,the,DT,O
ncbi-sent-684,DNA,NNP,O
ncbi-sent-684,-,:,O
ncbi-sent-684,binding,NN,O
ncbi-sent-684,domains,NNS,O
ncbi-sent-684,but,CC,O
ncbi-sent-684,have,VBP,O
ncbi-sent-684,lost,VBN,O
ncbi-sent-684,most,JJS,O
ncbi-sent-684,of,IN,O
ncbi-sent-684,the,DT,O
ncbi-sent-684,transactivation,NN,O
ncbi-sent-684,domain,NN,O
ncbi-sent-684,.,.,O
ncbi-sent-685,It,PRP,O
ncbi-sent-685,is,VBZ,O
ncbi-sent-685,not,RB,O
ncbi-sent-685,clear,JJ,O
ncbi-sent-685,whether,IN,O
ncbi-sent-685,such,JJ,O
ncbi-sent-685,mutants,NNS,O
ncbi-sent-685,really,RB,O
ncbi-sent-685,behave,VBP,O
ncbi-sent-685,as,IN,O
ncbi-sent-685,loss,NN,O
ncbi-sent-685,-,:,O
ncbi-sent-685,of,IN,O
ncbi-sent-685,-,:,O
ncbi-sent-685,function,NN,O
ncbi-sent-685,mutants,NNS,O
ncbi-sent-685,as,IN,O
ncbi-sent-685,predicted,VBN,O
ncbi-sent-685,by,IN,O
ncbi-sent-685,haploinsufficiency,NN,O
ncbi-sent-685,.,.,O
ncbi-sent-686,Contrary,JJ,O
ncbi-sent-686,to,TO,O
ncbi-sent-686,this,DT,O
ncbi-sent-686,theory,NN,O
ncbi-sent-686,",",",",O
ncbi-sent-686,our,PRP$,O
ncbi-sent-686,data,NNS,O
ncbi-sent-686,showed,VBD,O
ncbi-sent-686,that,IN,O
ncbi-sent-686,these,DT,O
ncbi-sent-686,mutants,NNS,O
ncbi-sent-686,are,VBP,O
ncbi-sent-686,dominant,JJ,O
ncbi-sent-686,-,:,O
ncbi-sent-686,negative,JJ,O
ncbi-sent-686,in,IN,O
ncbi-sent-686,transient,JJ,O
ncbi-sent-686,transfection,NN,O
ncbi-sent-686,assays,NNS,O
ncbi-sent-686,when,WRB,O
ncbi-sent-686,they,PRP,O
ncbi-sent-686,are,VBP,O
ncbi-sent-686,coexpressed,VBN,O
ncbi-sent-686,with,IN,O
ncbi-sent-686,wild,JJ,O
ncbi-sent-686,-,:,O
ncbi-sent-686,type,NN,O
ncbi-sent-686,PAX6,NNP,O
ncbi-sent-686,.,.,O
ncbi-sent-687,We,PRP,O
ncbi-sent-687,found,VBD,O
ncbi-sent-687,that,IN,O
ncbi-sent-687,the,DT,O
ncbi-sent-687,dominant,JJ,O
ncbi-sent-687,-,:,O
ncbi-sent-687,negative,JJ,O
ncbi-sent-687,effects,NNS,O
ncbi-sent-687,result,VBP,O
ncbi-sent-687,from,IN,O
ncbi-sent-687,the,DT,O
ncbi-sent-687,enhanced,JJ,O
ncbi-sent-687,DNA,NNP,O
ncbi-sent-687,binding,VBG,O
ncbi-sent-687,ability,NN,O
ncbi-sent-687,of,IN,O
ncbi-sent-687,these,DT,O
ncbi-sent-687,mutants,NNS,O
ncbi-sent-687,.,.,O
ncbi-sent-688,Kinetic,NNP,O
ncbi-sent-688,studies,NNS,O
ncbi-sent-688,of,IN,O
ncbi-sent-688,binding,NN,O
ncbi-sent-688,and,CC,O
ncbi-sent-688,dissociation,NN,O
ncbi-sent-688,revealed,VBD,O
ncbi-sent-688,that,IN,O
ncbi-sent-688,various,JJ,O
ncbi-sent-688,truncation,NN,O
ncbi-sent-688,mutants,NNS,O
ncbi-sent-688,have,VBP,O
ncbi-sent-688,3,CD,O
ncbi-sent-688,-,:,O
ncbi-sent-688,5,CD,O
ncbi-sent-688,-,:,O
ncbi-sent-688,fold,NN,O
ncbi-sent-688,higher,JJR,O
ncbi-sent-688,affinity,NN,O
ncbi-sent-688,to,TO,O
ncbi-sent-688,various,JJ,O
ncbi-sent-688,DNA,NNP,O
ncbi-sent-688,-,:,O
ncbi-sent-688,binding,NN,O
ncbi-sent-688,sites,NNS,O
ncbi-sent-688,when,WRB,O
ncbi-sent-688,compared,VBN,O
ncbi-sent-688,with,IN,O
ncbi-sent-688,the,DT,O
ncbi-sent-688,wild,JJ,O
ncbi-sent-688,-,:,O
ncbi-sent-688,type,NN,O
ncbi-sent-688,PAX6,NNP,O
ncbi-sent-688,.,.,O
ncbi-sent-689,These,DT,O
ncbi-sent-689,results,NNS,O
ncbi-sent-689,provide,VBP,O
ncbi-sent-689,a,DT,O
ncbi-sent-689,new,JJ,O
ncbi-sent-689,insight,NN,O
ncbi-sent-689,into,IN,O
ncbi-sent-689,the,DT,O
ncbi-sent-689,role,NN,O
ncbi-sent-689,of,IN,O
ncbi-sent-689,mutant,JJ,O
ncbi-sent-689,PAX6,NNP,O
ncbi-sent-689,in,IN,O
ncbi-sent-689,causing,VBG,O
ncbi-sent-689,aniridia,NN,B-DISEASE
ncbi-sent-689,.,.,O
ncbi-sent-690,.,.,O
ncbi-sent-691,Reversal,NNP,O
ncbi-sent-691,of,IN,O
ncbi-sent-691,severe,JJ,O
ncbi-sent-691,hypertrophic,JJ,B-DISEASE
ncbi-sent-691,cardiomyopathy,NN,I-DISEASE
ncbi-sent-691,and,CC,O
ncbi-sent-691,excellent,JJ,O
ncbi-sent-691,neuropsychologic,JJ,O
ncbi-sent-691,outcome,NN,O
ncbi-sent-691,in,IN,O
ncbi-sent-691,very,RB,B-DISEASE
ncbi-sent-691,-,:,I-DISEASE
ncbi-sent-691,long,JJ,I-DISEASE
ncbi-sent-691,-,:,I-DISEASE
ncbi-sent-691,chain,NN,I-DISEASE
ncbi-sent-691,acyl,IN,I-DISEASE
ncbi-sent-691,-,:,I-DISEASE
ncbi-sent-691,coenzyme,NN,I-DISEASE
ncbi-sent-691,A,DT,I-DISEASE
ncbi-sent-691,dehydrogenase,NN,I-DISEASE
ncbi-sent-691,deficiency,NN,I-DISEASE
ncbi-sent-691,.,.,O
ncbi-sent-692,Very,RB,B-DISEASE
ncbi-sent-692,-,:,I-DISEASE
ncbi-sent-692,long,JJ,I-DISEASE
ncbi-sent-692,-,:,I-DISEASE
ncbi-sent-692,chain,NN,I-DISEASE
ncbi-sent-692,acyl,IN,I-DISEASE
ncbi-sent-692,-,:,I-DISEASE
ncbi-sent-692,coenzyme,NN,I-DISEASE
ncbi-sent-692,A,DT,I-DISEASE
ncbi-sent-692,dehydrogenase,NN,I-DISEASE
ncbi-sent-692,(,(,I-DISEASE
ncbi-sent-692,VLCAD,NNP,I-DISEASE
ncbi-sent-692,),),I-DISEASE
ncbi-sent-692,deficiency,NN,I-DISEASE
ncbi-sent-692,is,VBZ,O
ncbi-sent-692,a,DT,O
ncbi-sent-692,disorder,NN,O
ncbi-sent-692,of,IN,O
ncbi-sent-692,fatty,JJ,O
ncbi-sent-692,acid,JJ,O
ncbi-sent-692,beta,NN,O
ncbi-sent-692,oxidation,NN,O
ncbi-sent-692,that,WDT,O
ncbi-sent-692,reportedly,RB,O
ncbi-sent-692,has,VBZ,O
ncbi-sent-692,high,JJ,O
ncbi-sent-692,rates,NNS,O
ncbi-sent-692,of,IN,O
ncbi-sent-692,morbidity,NN,O
ncbi-sent-692,and,CC,O
ncbi-sent-692,mortality,NN,O
ncbi-sent-692,.,.,O
ncbi-sent-693,We,PRP,O
ncbi-sent-693,describe,VBP,O
ncbi-sent-693,the,DT,O
ncbi-sent-693,outcome,NN,O
ncbi-sent-693,of,IN,O
ncbi-sent-693,a,DT,O
ncbi-sent-693,5,CD,O
ncbi-sent-693,-,:,O
ncbi-sent-693,year,NN,O
ncbi-sent-693,-,:,O
ncbi-sent-693,old,JJ,O
ncbi-sent-693,girl,NN,O
ncbi-sent-693,with,IN,O
ncbi-sent-693,VLCAD,NNP,B-DISEASE
ncbi-sent-693,deficiency,NN,I-DISEASE
ncbi-sent-693,who,WP,O
ncbi-sent-693,was,VBD,O
ncbi-sent-693,first,RB,O
ncbi-sent-693,seen,VBN,O
ncbi-sent-693,at,IN,O
ncbi-sent-693,5,CD,O
ncbi-sent-693,months,NNS,O
ncbi-sent-693,of,IN,O
ncbi-sent-693,age,NN,O
ncbi-sent-693,with,IN,O
ncbi-sent-693,severe,JJ,O
ncbi-sent-693,hypertrophic,JJ,B-DISEASE
ncbi-sent-693,cardiomyopathy,NN,I-DISEASE
ncbi-sent-693,",",",",O
ncbi-sent-693,hepatomegaly,NN,B-DISEASE
ncbi-sent-693,",",",",O
ncbi-sent-693,encephalopathy,NN,B-DISEASE
ncbi-sent-693,",",",",O
ncbi-sent-693,and,CC,O
ncbi-sent-693,hypotonia,NN,B-DISEASE
ncbi-sent-693,.,.,O
ncbi-sent-694,Biochemical,JJ,O
ncbi-sent-694,studies,NNS,O
ncbi-sent-694,indicated,VBD,O
ncbi-sent-694,VLCAD,NNP,B-DISEASE
ncbi-sent-694,deficiency,NN,I-DISEASE
ncbi-sent-694,caused,VBN,O
ncbi-sent-694,by,IN,O
ncbi-sent-694,a,DT,O
ncbi-sent-694,stable,JJ,O
ncbi-sent-694,yet,RB,O
ncbi-sent-694,inactive,JJ,O
ncbi-sent-694,enzyme,NN,O
ncbi-sent-694,.,.,O
ncbi-sent-695,Molecular,JJ,O
ncbi-sent-695,genetic,JJ,O
ncbi-sent-695,analysis,NN,O
ncbi-sent-695,of,IN,O
ncbi-sent-695,her,PRP$,O
ncbi-sent-695,VLCAD,NNP,O
ncbi-sent-695,gene,NN,O
ncbi-sent-695,revealed,VBD,O
ncbi-sent-695,a,DT,O
ncbi-sent-695,T1372C,NNP,O
ncbi-sent-695,(,(,O
ncbi-sent-695,F458L,NNP,O
ncbi-sent-695,),),O
ncbi-sent-695,missense,NN,O
ncbi-sent-695,mutation,NN,O
ncbi-sent-695,and,CC,O
ncbi-sent-695,a,DT,O
ncbi-sent-695,1668,CD,O
ncbi-sent-695,ACAG,NNP,O
ncbi-sent-695,1669,CD,O
ncbi-sent-695,splice,NN,O
ncbi-sent-695,site,NN,O
ncbi-sent-695,mutation,NN,O
ncbi-sent-695,.,.,O
ncbi-sent-696,After,IN,O
ncbi-sent-696,initial,JJ,O
ncbi-sent-696,treatment,NN,O
ncbi-sent-696,with,IN,O
ncbi-sent-696,intravenous,JJ,O
ncbi-sent-696,glucose,NNS,O
ncbi-sent-696,and,CC,O
ncbi-sent-696,carnitine,NN,O
ncbi-sent-696,",",",",O
ncbi-sent-696,the,DT,O
ncbi-sent-696,patient,NN,O
ncbi-sent-696,has,VBZ,O
ncbi-sent-696,thrived,VBN,O
ncbi-sent-696,on,IN,O
ncbi-sent-696,a,DT,O
ncbi-sent-696,low,JJ,O
ncbi-sent-696,-,:,O
ncbi-sent-696,fat,NN,O
ncbi-sent-696,diet,JJ,O
ncbi-sent-696,supplemented,VBN,O
ncbi-sent-696,with,IN,O
ncbi-sent-696,medium,NN,O
ncbi-sent-696,-,:,O
ncbi-sent-696,chain,NN,O
ncbi-sent-696,triglyceride,JJ,O
ncbi-sent-696,oil,NN,O
ncbi-sent-696,and,CC,O
ncbi-sent-696,carnitine,NN,O
ncbi-sent-696,and,CC,O
ncbi-sent-696,avoidance,NN,O
ncbi-sent-696,of,IN,O
ncbi-sent-696,fasting,VBG,O
ncbi-sent-696,.,.,O
ncbi-sent-697,Her,PRP$,O
ncbi-sent-697,ventricular,JJ,O
ncbi-sent-697,hypertrophy,NN,O
ncbi-sent-697,resolved,VBD,O
ncbi-sent-697,significantly,RB,O
ncbi-sent-697,over,IN,O
ncbi-sent-697,1,CD,O
ncbi-sent-697,year,NN,O
ncbi-sent-697,",",",",O
ncbi-sent-697,and,CC,O
ncbi-sent-697,cognitively,RB,O
ncbi-sent-697,",",",",O
ncbi-sent-697,she,PRP,O
ncbi-sent-697,is,VBZ,O
ncbi-sent-697,in,IN,O
ncbi-sent-697,the,DT,O
ncbi-sent-697,superior,JJ,O
ncbi-sent-697,range,NN,O
ncbi-sent-697,for,IN,O
ncbi-sent-697,age,NN,O
ncbi-sent-697,.,.,O
ncbi-sent-698,Clinical,JJ,O
ncbi-sent-698,recognition,NN,O
ncbi-sent-698,of,IN,O
ncbi-sent-698,VLCAD,NNP,B-DISEASE
ncbi-sent-698,deficiency,NN,I-DISEASE
ncbi-sent-698,is,VBZ,O
ncbi-sent-698,important,JJ,O
ncbi-sent-698,because,IN,O
ncbi-sent-698,it,PRP,O
ncbi-sent-698,is,VBZ,O
ncbi-sent-698,one,CD,O
ncbi-sent-698,of,IN,O
ncbi-sent-698,the,DT,O
ncbi-sent-698,few,JJ,O
ncbi-sent-698,directly,RB,O
ncbi-sent-698,treatable,JJ,O
ncbi-sent-698,causes,NNS,O
ncbi-sent-698,of,IN,O
ncbi-sent-698,cardiomyopathy,NN,B-DISEASE
ncbi-sent-698,in,IN,O
ncbi-sent-698,children,NNS,O
ncbi-sent-698,.,.,O
ncbi-sent-699,.,.,O
ncbi-sent-700,Cloning,NN,O
ncbi-sent-700,of,IN,O
ncbi-sent-700,a,DT,O
ncbi-sent-700,novel,JJ,O
ncbi-sent-700,member,NN,O
ncbi-sent-700,of,IN,O
ncbi-sent-700,the,DT,O
ncbi-sent-700,low,JJ,O
ncbi-sent-700,-,:,O
ncbi-sent-700,density,NN,O
ncbi-sent-700,lipoprotein,NN,O
ncbi-sent-700,receptor,NN,O
ncbi-sent-700,family,NN,O
ncbi-sent-700,.,.,O
ncbi-sent-701,A,DT,O
ncbi-sent-701,gene,NN,O
ncbi-sent-701,encoding,VBG,O
ncbi-sent-701,a,DT,O
ncbi-sent-701,novel,JJ,O
ncbi-sent-701,transmembrane,NN,O
ncbi-sent-701,protein,NN,O
ncbi-sent-701,was,VBD,O
ncbi-sent-701,identified,VBN,O
ncbi-sent-701,by,IN,O
ncbi-sent-701,DNA,NNP,O
ncbi-sent-701,sequence,NN,O
ncbi-sent-701,analysis,NN,O
ncbi-sent-701,within,IN,O
ncbi-sent-701,the,DT,O
ncbi-sent-701,insulin,NN,B-DISEASE
ncbi-sent-701,-,:,I-DISEASE
ncbi-sent-701,dependent,NN,I-DISEASE
ncbi-sent-701,diabetes,VBZ,I-DISEASE
ncbi-sent-701,mellitus,NNS,I-DISEASE
ncbi-sent-701,(,(,O
ncbi-sent-701,IDDM,NNP,B-DISEASE
ncbi-sent-701,),),O
ncbi-sent-701,locus,VBZ,O
ncbi-sent-701,IDDM4,NNP,O
ncbi-sent-701,on,IN,O
ncbi-sent-701,chromosome,NN,O
ncbi-sent-701,11q13,CD,O
ncbi-sent-701,.,.,O
ncbi-sent-702,Based,VBN,O
ncbi-sent-702,on,IN,O
ncbi-sent-702,its,PRP$,O
ncbi-sent-702,chromosomal,JJ,O
ncbi-sent-702,position,NN,O
ncbi-sent-702,",",",",O
ncbi-sent-702,this,DT,O
ncbi-sent-702,gene,NN,O
ncbi-sent-702,is,VBZ,O
ncbi-sent-702,a,DT,O
ncbi-sent-702,candidate,NN,O
ncbi-sent-702,for,IN,O
ncbi-sent-702,conferring,VBG,O
ncbi-sent-702,susceptibility,NN,O
ncbi-sent-702,to,TO,O
ncbi-sent-702,diabetes,NNS,B-DISEASE
ncbi-sent-702,.,.,O
ncbi-sent-703,The,DT,O
ncbi-sent-703,gene,NN,O
ncbi-sent-703,",",",",O
ncbi-sent-703,termed,VBD,O
ncbi-sent-703,low,JJ,O
ncbi-sent-703,-,:,O
ncbi-sent-703,density,NN,O
ncbi-sent-703,lipoprotein,VBZ,O
ncbi-sent-703,receptor,NN,O
ncbi-sent-703,related,JJ,O
ncbi-sent-703,protein,NN,O
ncbi-sent-703,5,CD,O
ncbi-sent-703,(,(,O
ncbi-sent-703,LRP5,NNP,O
ncbi-sent-703,),),O
ncbi-sent-703,",",",",O
ncbi-sent-703,encodes,VBZ,O
ncbi-sent-703,a,DT,O
ncbi-sent-703,protein,NN,O
ncbi-sent-703,of,IN,O
ncbi-sent-703,1615,CD,O
ncbi-sent-703,amino,NN,O
ncbi-sent-703,acids,NNS,O
ncbi-sent-703,that,WDT,O
ncbi-sent-703,contains,VBZ,O
ncbi-sent-703,conserved,VBN,O
ncbi-sent-703,modules,NNS,O
ncbi-sent-703,which,WDT,O
ncbi-sent-703,are,VBP,O
ncbi-sent-703,characteristic,JJ,O
ncbi-sent-703,of,IN,O
ncbi-sent-703,the,DT,O
ncbi-sent-703,low,JJ,O
ncbi-sent-703,-,:,O
ncbi-sent-703,density,NN,O
ncbi-sent-703,lipoprotein,NN,O
ncbi-sent-703,(,(,O
ncbi-sent-703,LDL,NNP,O
ncbi-sent-703,),),O
ncbi-sent-703,receptor,NN,O
ncbi-sent-703,family,NN,O
ncbi-sent-703,.,.,O
ncbi-sent-704,These,DT,O
ncbi-sent-704,modules,NNS,O
ncbi-sent-704,include,VBP,O
ncbi-sent-704,a,DT,O
ncbi-sent-704,putative,JJ,O
ncbi-sent-704,signal,NN,O
ncbi-sent-704,peptide,NN,O
ncbi-sent-704,for,IN,O
ncbi-sent-704,protein,NN,O
ncbi-sent-704,export,NN,O
ncbi-sent-704,",",",",O
ncbi-sent-704,four,CD,O
ncbi-sent-704,epidermal,JJ,O
ncbi-sent-704,growth,NN,O
ncbi-sent-704,factor,NN,O
ncbi-sent-704,(,(,O
ncbi-sent-704,EGF,NNP,O
ncbi-sent-704,),),O
ncbi-sent-704,repeats,VBZ,O
ncbi-sent-704,with,IN,O
ncbi-sent-704,associated,JJ,O
ncbi-sent-704,spacer,NN,O
ncbi-sent-704,domains,NNS,O
ncbi-sent-704,",",",",O
ncbi-sent-704,three,CD,O
ncbi-sent-704,LDL,NNP,O
ncbi-sent-704,-,:,O
ncbi-sent-704,receptor,NN,O
ncbi-sent-704,(,(,O
ncbi-sent-704,LDLR,NNP,O
ncbi-sent-704,),),O
ncbi-sent-704,repeats,VBZ,O
ncbi-sent-704,",",",",O
ncbi-sent-704,a,DT,O
ncbi-sent-704,single,JJ,O
ncbi-sent-704,transmembrane,NN,O
ncbi-sent-704,spanning,VBG,O
ncbi-sent-704,domain,NN,O
ncbi-sent-704,",",",",O
ncbi-sent-704,and,CC,O
ncbi-sent-704,a,DT,O
ncbi-sent-704,cytoplasmic,JJ,O
ncbi-sent-704,domain,NN,O
ncbi-sent-704,.,.,O
ncbi-sent-705,The,DT,O
ncbi-sent-705,encoded,JJ,O
ncbi-sent-705,protein,NN,O
ncbi-sent-705,has,VBZ,O
ncbi-sent-705,a,DT,O
ncbi-sent-705,unique,JJ,O
ncbi-sent-705,organization,NN,O
ncbi-sent-705,of,IN,O
ncbi-sent-705,EGF,NNP,O
ncbi-sent-705,and,CC,O
ncbi-sent-705,LDLR,NNP,O
ncbi-sent-705,repeats,NNS,O
ncbi-sent-705,;,:,O
ncbi-sent-705,therefore,RB,O
ncbi-sent-705,",",",",O
ncbi-sent-705,LRP5,NNP,O
ncbi-sent-705,likely,JJ,O
ncbi-sent-705,represents,VBZ,O
ncbi-sent-705,a,DT,O
ncbi-sent-705,new,JJ,O
ncbi-sent-705,category,NN,O
ncbi-sent-705,of,IN,O
ncbi-sent-705,the,DT,O
ncbi-sent-705,LDLR,NNP,O
ncbi-sent-705,family,NN,O
ncbi-sent-705,.,.,O
ncbi-sent-706,Both,DT,O
ncbi-sent-706,human,JJ,O
ncbi-sent-706,and,CC,O
ncbi-sent-706,mouse,NN,O
ncbi-sent-706,LRP5,NNP,O
ncbi-sent-706,cDNAs,NN,O
ncbi-sent-706,have,VBP,O
ncbi-sent-706,been,VBN,O
ncbi-sent-706,isolated,VBN,O
ncbi-sent-706,and,CC,O
ncbi-sent-706,the,DT,O
ncbi-sent-706,encoded,JJ,O
ncbi-sent-706,mature,NN,O
ncbi-sent-706,proteins,NNS,O
ncbi-sent-706,are,VBP,O
ncbi-sent-706,95,CD,O
ncbi-sent-706,%,NN,O
ncbi-sent-706,identical,JJ,O
ncbi-sent-706,",",",",O
ncbi-sent-706,indicating,VBG,O
ncbi-sent-706,a,DT,O
ncbi-sent-706,high,JJ,O
ncbi-sent-706,degree,NN,O
ncbi-sent-706,of,IN,O
ncbi-sent-706,evolutionary,JJ,O
ncbi-sent-706,conservation,NN,O
ncbi-sent-706,.,.,O
ncbi-sent-707,.,.,O
ncbi-sent-708,The,DT,O
ncbi-sent-708,APC,NNP,B-DISEASE
ncbi-sent-708,variants,NNS,O
ncbi-sent-708,I1307K,NNP,O
ncbi-sent-708,and,CC,O
ncbi-sent-708,E1317Q,NNP,O
ncbi-sent-708,are,VBP,O
ncbi-sent-708,associated,VBN,O
ncbi-sent-708,with,IN,O
ncbi-sent-708,colorectal,JJ,B-DISEASE
ncbi-sent-708,tumors,NNS,I-DISEASE
ncbi-sent-708,",",",",O
ncbi-sent-708,but,CC,O
ncbi-sent-708,not,RB,O
ncbi-sent-708,always,RB,O
ncbi-sent-708,with,IN,O
ncbi-sent-708,a,DT,O
ncbi-sent-708,family,NN,O
ncbi-sent-708,history,NN,O
ncbi-sent-708,.,.,O
ncbi-sent-709,Classical,JJ,O
ncbi-sent-709,familial,JJ,B-DISEASE
ncbi-sent-709,adenomatous,JJ,I-DISEASE
ncbi-sent-709,polyposis,NN,I-DISEASE
ncbi-sent-709,(,(,O
ncbi-sent-709,FAP,NNP,B-DISEASE
ncbi-sent-709,),),O
ncbi-sent-709,is,VBZ,O
ncbi-sent-709,a,DT,O
ncbi-sent-709,high,JJ,O
ncbi-sent-709,-,:,O
ncbi-sent-709,penetrance,NN,O
ncbi-sent-709,autosomal,JJ,B-DISEASE
ncbi-sent-709,dominant,JJ,I-DISEASE
ncbi-sent-709,disease,NN,I-DISEASE
ncbi-sent-709,that,WDT,O
ncbi-sent-709,predisposes,VBZ,O
ncbi-sent-709,to,TO,O
ncbi-sent-709,hundreds,NNS,O
ncbi-sent-709,or,CC,O
ncbi-sent-709,thousands,NNS,O
ncbi-sent-709,of,IN,O
ncbi-sent-709,colorectal,JJ,B-DISEASE
ncbi-sent-709,adenomas,NN,I-DISEASE
ncbi-sent-709,and,CC,I-DISEASE
ncbi-sent-709,carcinoma,NN,I-DISEASE
ncbi-sent-709,and,CC,O
ncbi-sent-709,that,IN,O
ncbi-sent-709,results,NNS,O
ncbi-sent-709,from,IN,O
ncbi-sent-709,truncating,VBG,O
ncbi-sent-709,mutations,NNS,O
ncbi-sent-709,in,IN,O
ncbi-sent-709,the,DT,O
ncbi-sent-709,APC,NNP,B-DISEASE
ncbi-sent-709,gene,NN,O
ncbi-sent-709,.,.,O
ncbi-sent-710,A,DT,O
ncbi-sent-710,variant,NN,O
ncbi-sent-710,of,IN,O
ncbi-sent-710,FAP,NNP,B-DISEASE
ncbi-sent-710,is,VBZ,O
ncbi-sent-710,attenuated,VBN,B-DISEASE
ncbi-sent-710,adenomatous,JJ,I-DISEASE
ncbi-sent-710,polyposis,NN,I-DISEASE
ncbi-sent-710,coli,NN,I-DISEASE
ncbi-sent-710,",",",",O
ncbi-sent-710,which,WDT,O
ncbi-sent-710,results,NNS,O
ncbi-sent-710,from,IN,O
ncbi-sent-710,germ,JJ,O
ncbi-sent-710,-,:,O
ncbi-sent-710,line,NN,O
ncbi-sent-710,mutations,NNS,O
ncbi-sent-710,in,IN,O
ncbi-sent-710,the,DT,O
ncbi-sent-710,5,CD,O
ncbi-sent-710,and,CC,O
ncbi-sent-710,3,CD,O
ncbi-sent-710,regions,NNS,O
ncbi-sent-710,of,IN,O
ncbi-sent-710,the,DT,O
ncbi-sent-710,APC,NNP,B-DISEASE
ncbi-sent-710,gene,NN,O
ncbi-sent-710,.,.,O
ncbi-sent-711,Attenuated,NNP,B-DISEASE
ncbi-sent-711,adenomatous,JJ,I-DISEASE
ncbi-sent-711,polyposis,NN,I-DISEASE
ncbi-sent-711,coli,NN,I-DISEASE
ncbi-sent-711,patients,NNS,O
ncbi-sent-711,have,VBP,O
ncbi-sent-711,"	O
multiple	O
",VBN,O
ncbi-sent-711,colorectal,JJ,B-DISEASE
ncbi-sent-711,adenomas,NN,I-DISEASE
ncbi-sent-711,(,(,O
ncbi-sent-711,typically,RB,O
ncbi-sent-711,fewer,JJR,O
ncbi-sent-711,than,IN,O
ncbi-sent-711,100,CD,O
ncbi-sent-711,),),O
ncbi-sent-711,without,IN,O
ncbi-sent-711,the,DT,O
ncbi-sent-711,florid,JJ,O
ncbi-sent-711,phenotype,NN,O
ncbi-sent-711,of,IN,O
ncbi-sent-711,classical,JJ,O
ncbi-sent-711,FAP,NNP,B-DISEASE
ncbi-sent-711,.,.,O
ncbi-sent-712,Another,DT,O
ncbi-sent-712,group,NN,O
ncbi-sent-712,of,IN,O
ncbi-sent-712,patients,NNS,O
ncbi-sent-712,with,IN,O
ncbi-sent-712,multiple,JJ,O
ncbi-sent-712,adenomas,NN,B-DISEASE
ncbi-sent-712,has,VBZ,O
ncbi-sent-712,no,DT,O
ncbi-sent-712,mutations,NNS,O
ncbi-sent-712,in,IN,O
ncbi-sent-712,the,DT,O
ncbi-sent-712,APC,NNP,B-DISEASE
ncbi-sent-712,gene,NN,O
ncbi-sent-712,",",",",O
ncbi-sent-712,and,CC,O
ncbi-sent-712,their,PRP$,O
ncbi-sent-712,phenotype,NN,O
ncbi-sent-712,probably,RB,O
ncbi-sent-712,results,NNS,O
ncbi-sent-712,from,IN,O
ncbi-sent-712,variation,NN,O
ncbi-sent-712,at,IN,O
ncbi-sent-712,a,DT,O
ncbi-sent-712,locus,NN,O
ncbi-sent-712,",",",",O
ncbi-sent-712,or,CC,O
ncbi-sent-712,loci,NN,O
ncbi-sent-712,",",",",O
ncbi-sent-712,elsewhere,RB,O
ncbi-sent-712,in,IN,O
ncbi-sent-712,the,DT,O
ncbi-sent-712,genome,NN,O
ncbi-sent-712,.,.,O
ncbi-sent-713,Recently,RB,O
ncbi-sent-713,",",",",O
ncbi-sent-713,however,RB,O
ncbi-sent-713,",",",",O
ncbi-sent-713,a,DT,O
ncbi-sent-713,missense,NN,O
ncbi-sent-713,variant,NN,O
ncbi-sent-713,of,IN,O
ncbi-sent-713,APC,NNP,B-DISEASE
ncbi-sent-713,(,(,O
ncbi-sent-713,I1307K,NNP,O
ncbi-sent-713,),),O
ncbi-sent-713,was,VBD,O
ncbi-sent-713,described,VBN,O
ncbi-sent-713,that,IN,O
ncbi-sent-713,confers,NNS,O
ncbi-sent-713,an,DT,O
ncbi-sent-713,increased,VBN,O
ncbi-sent-713,risk,NN,O
ncbi-sent-713,of,IN,O
ncbi-sent-713,colorectal,JJ,B-DISEASE
ncbi-sent-713,tumors,NNS,I-DISEASE
ncbi-sent-713,",",",",O
ncbi-sent-713,including,VBG,O
ncbi-sent-713,multiple,JJ,O
ncbi-sent-713,adenomas,NN,B-DISEASE
ncbi-sent-713,",",",",O
ncbi-sent-713,in,IN,O
ncbi-sent-713,Ashkenazim,NNP,O
ncbi-sent-713,.,.,O
ncbi-sent-714,We,PRP,O
ncbi-sent-714,have,VBP,O
ncbi-sent-714,studied,VBN,O
ncbi-sent-714,a,DT,O
ncbi-sent-714,set,NN,O
ncbi-sent-714,of,IN,O
ncbi-sent-714,164,CD,O
ncbi-sent-714,patients,NNS,O
ncbi-sent-714,with,IN,O
ncbi-sent-714,multiple,JJ,O
ncbi-sent-714,colorectal,JJ,B-DISEASE
ncbi-sent-714,adenomas,NN,I-DISEASE
ncbi-sent-714,and,CC,I-DISEASE
ncbi-sent-714,/,NN,I-DISEASE
ncbi-sent-714,or,CC,I-DISEASE
ncbi-sent-714,carcinoma,NN,I-DISEASE
ncbi-sent-714,and,CC,O
ncbi-sent-714,analyzed,VBD,O
ncbi-sent-714,codons,NNS,O
ncbi-sent-714,1263,CD,O
ncbi-sent-714,-,:,O
ncbi-sent-714,1377,CD,O
ncbi-sent-714,(,(,O
ncbi-sent-714,exon,VB,O
ncbi-sent-714,15G,CD,O
ncbi-sent-714,),),O
ncbi-sent-714,of,IN,O
ncbi-sent-714,the,DT,O
ncbi-sent-714,APC,NNP,B-DISEASE
ncbi-sent-714,gene,NN,O
ncbi-sent-714,for,IN,O
ncbi-sent-714,germ,JJ,O
ncbi-sent-714,-,:,O
ncbi-sent-714,line,NN,O
ncbi-sent-714,variants,NNS,O
ncbi-sent-714,.,.,O
ncbi-sent-715,Three,CD,O
ncbi-sent-715,patients,NNS,O
ncbi-sent-715,with,IN,O
ncbi-sent-715,the,DT,O
ncbi-sent-715,I1307K,NNP,O
ncbi-sent-715,allele,NN,O
ncbi-sent-715,were,VBD,O
ncbi-sent-715,detected,VBN,O
ncbi-sent-715,",",",",O
ncbi-sent-715,each,DT,O
ncbi-sent-715,of,IN,O
ncbi-sent-715,Ashkenazi,NNP,O
ncbi-sent-715,descent,NN,O
ncbi-sent-715,.,.,O
ncbi-sent-716,Four,CD,O
ncbi-sent-716,patients,NNS,O
ncbi-sent-716,had,VBD,O
ncbi-sent-716,a,DT,O
ncbi-sent-716,germ,JJ,O
ncbi-sent-716,-,:,O
ncbi-sent-716,line,NN,O
ncbi-sent-716,E1317Q,NNP,O
ncbi-sent-716,missense,NN,O
ncbi-sent-716,variant,NN,O
ncbi-sent-716,of,IN,O
ncbi-sent-716,APC,NNP,O
ncbi-sent-716,that,WDT,O
ncbi-sent-716,was,VBD,O
ncbi-sent-716,not,RB,O
ncbi-sent-716,present,JJ,O
ncbi-sent-716,in,IN,O
ncbi-sent-716,controls,NNS,O
ncbi-sent-716,;,:,O
ncbi-sent-716,one,CD,O
ncbi-sent-716,of,IN,O
ncbi-sent-716,these,DT,O
ncbi-sent-716,individuals,NNS,O
ncbi-sent-716,had,VBD,O
ncbi-sent-716,an,DT,O
ncbi-sent-716,unusually,RB,O
ncbi-sent-716,large,JJ,O
ncbi-sent-716,number,NN,O
ncbi-sent-716,of,IN,O
ncbi-sent-716,metaplastic,JJ,B-DISEASE
ncbi-sent-716,polyps,NNS,I-DISEASE
ncbi-sent-716,of,IN,I-DISEASE
ncbi-sent-716,the,DT,I-DISEASE
ncbi-sent-716,colorectum,NN,I-DISEASE
ncbi-sent-716,.,.,O
ncbi-sent-717,There,EX,O
ncbi-sent-717,is,VBZ,O
ncbi-sent-717,increasing,VBG,O
ncbi-sent-717,evidence,NN,O
ncbi-sent-717,that,IN,O
ncbi-sent-717,there,EX,O
ncbi-sent-717,exist,VBP,O
ncbi-sent-717,germ,SYM,O
ncbi-sent-717,-,:,O
ncbi-sent-717,line,NN,O
ncbi-sent-717,variants,NNS,O
ncbi-sent-717,of,IN,O
ncbi-sent-717,the,DT,O
ncbi-sent-717,APC,NNP,B-DISEASE
ncbi-sent-717,gene,NN,O
ncbi-sent-717,that,WDT,O
ncbi-sent-717,predispose,VBP,O
ncbi-sent-717,to,TO,O
ncbi-sent-717,the,DT,O
ncbi-sent-717,development,NN,O
ncbi-sent-717,of,IN,O
ncbi-sent-717,multiple,JJ,O
ncbi-sent-717,colorectal,JJ,B-DISEASE
ncbi-sent-717,adenomas,NN,I-DISEASE
ncbi-sent-717,and,CC,I-DISEASE
ncbi-sent-717,carcinoma,NN,I-DISEASE
ncbi-sent-717,",",",",O
ncbi-sent-717,but,CC,O
ncbi-sent-717,without,IN,O
ncbi-sent-717,the,DT,O
ncbi-sent-717,florid,JJ,O
ncbi-sent-717,phenotype,NN,O
ncbi-sent-717,of,IN,O
ncbi-sent-717,classical,JJ,O
ncbi-sent-717,FAP,NNP,B-DISEASE
ncbi-sent-717,",",",",O
ncbi-sent-717,and,CC,O
ncbi-sent-717,possibly,RB,O
ncbi-sent-717,with,IN,O
ncbi-sent-717,importance,NN,O
ncbi-sent-717,for,IN,O
ncbi-sent-717,colorectal,JJ,B-DISEASE
ncbi-sent-717,cancer,NN,I-DISEASE
ncbi-sent-717,risk,NN,O
ncbi-sent-717,in,IN,O
ncbi-sent-717,the,DT,O
ncbi-sent-717,general,JJ,O
ncbi-sent-717,population,NN,O
ncbi-sent-717,.,.,O
ncbi-sent-718,.,.,O
ncbi-sent-719,Genomic,JJ,O
ncbi-sent-719,structure,NN,O
ncbi-sent-719,of,IN,O
ncbi-sent-719,the,DT,O
ncbi-sent-719,human,JJ,O
ncbi-sent-719,congenital,JJ,B-DISEASE
ncbi-sent-719,chloride,NN,I-DISEASE
ncbi-sent-719,diarrhea,NN,I-DISEASE
ncbi-sent-719,(,(,O
ncbi-sent-719,CLD,NNP,B-DISEASE
ncbi-sent-719,),),O
ncbi-sent-719,gene,NN,O
ncbi-sent-719,.,.,O
ncbi-sent-720,Congenital,NNP,B-DISEASE
ncbi-sent-720,chloride,NN,I-DISEASE
ncbi-sent-720,diarrhea,NN,I-DISEASE
ncbi-sent-720,(,(,O
ncbi-sent-720,CLD,NNP,B-DISEASE
ncbi-sent-720,),),O
ncbi-sent-720,is,VBZ,O
ncbi-sent-720,caused,VBN,O
ncbi-sent-720,by,IN,O
ncbi-sent-720,mutations,NNS,O
ncbi-sent-720,in,IN,O
ncbi-sent-720,a,DT,O
ncbi-sent-720,gene,NN,O
ncbi-sent-720,which,WDT,O
ncbi-sent-720,encodes,VBZ,O
ncbi-sent-720,an,DT,O
ncbi-sent-720,intestinal,JJ,O
ncbi-sent-720,anion,NN,O
ncbi-sent-720,transporter,NN,O
ncbi-sent-720,.,.,O
ncbi-sent-721,We,PRP,O
ncbi-sent-721,report,VBP,O
ncbi-sent-721,here,RB,O
ncbi-sent-721,the,DT,O
ncbi-sent-721,complete,JJ,O
ncbi-sent-721,genomic,JJ,O
ncbi-sent-721,organization,NN,O
ncbi-sent-721,of,IN,O
ncbi-sent-721,the,DT,O
ncbi-sent-721,human,JJ,O
ncbi-sent-721,CLD,NNP,B-DISEASE
ncbi-sent-721,gene,NN,O
ncbi-sent-721,which,WDT,O
ncbi-sent-721,spans,VBZ,O
ncbi-sent-721,approximately,RB,O
ncbi-sent-721,39kb,CD,O
ncbi-sent-721,",",",",O
ncbi-sent-721,and,CC,O
ncbi-sent-721,comprises,VBZ,O
ncbi-sent-721,21,CD,O
ncbi-sent-721,exons,NNS,O
ncbi-sent-721,.,.,O
ncbi-sent-722,All,DT,O
ncbi-sent-722,exon,JJ,O
ncbi-sent-722,/,NNP,O
ncbi-sent-722,intron,NN,O
ncbi-sent-722,boundaries,NNS,O
ncbi-sent-722,conform,VBP,O
ncbi-sent-722,to,TO,O
ncbi-sent-722,the,DT,O
ncbi-sent-722,GT,NNP,O
ncbi-sent-722,/,NNP,O
ncbi-sent-722,AG,NNP,O
ncbi-sent-722,rule,NN,O
ncbi-sent-722,.,.,O
ncbi-sent-723,An,DT,O
ncbi-sent-723,analysis,NN,O
ncbi-sent-723,of,IN,O
ncbi-sent-723,the,DT,O
ncbi-sent-723,putative,JJ,O
ncbi-sent-723,promoter,NN,O
ncbi-sent-723,region,NN,O
ncbi-sent-723,sequence,NN,O
ncbi-sent-723,shows,VBZ,O
ncbi-sent-723,a,DT,O
ncbi-sent-723,putative,JJ,O
ncbi-sent-723,TATA,NNP,O
ncbi-sent-723,box,NN,O
ncbi-sent-723,and,CC,O
ncbi-sent-723,predicts,VBZ,O
ncbi-sent-723,multiple,JJ,O
ncbi-sent-723,transcription,NN,O
ncbi-sent-723,factor,NN,O
ncbi-sent-723,binding,VBG,O
ncbi-sent-723,sites,NNS,O
ncbi-sent-723,.,.,O
ncbi-sent-724,The,DT,O
ncbi-sent-724,genomic,JJ,O
ncbi-sent-724,structure,NN,O
ncbi-sent-724,was,VBD,O
ncbi-sent-724,determined,VBN,O
ncbi-sent-724,using,VBG,O
ncbi-sent-724,DNA,NN,O
ncbi-sent-724,from,IN,O
ncbi-sent-724,several,JJ,O
ncbi-sent-724,sources,NNS,O
ncbi-sent-724,including,VBG,O
ncbi-sent-724,multiple,JJ,O
ncbi-sent-724,large,JJ,O
ncbi-sent-724,-,:,O
ncbi-sent-724,insert,NN,O
ncbi-sent-724,libaries,NNS,O
ncbi-sent-724,and,CC,O
ncbi-sent-724,genomic,JJ,O
ncbi-sent-724,DNA,NN,O
ncbi-sent-724,from,IN,O
ncbi-sent-724,Finnish,JJ,O
ncbi-sent-724,CLD,NNP,B-DISEASE
ncbi-sent-724,patients,NNS,O
ncbi-sent-724,and,CC,O
ncbi-sent-724,controls,NNS,O
ncbi-sent-724,.,.,O
ncbi-sent-725,Exon,NNP,O
ncbi-sent-725,-,:,O
ncbi-sent-725,specific,JJ,O
ncbi-sent-725,primers,NNS,O
ncbi-sent-725,developed,VBD,O
ncbi-sent-725,in,IN,O
ncbi-sent-725,this,DT,O
ncbi-sent-725,study,NN,O
ncbi-sent-725,will,MD,O
ncbi-sent-725,facilitate,VB,O
ncbi-sent-725,mutation,NN,O
ncbi-sent-725,screening,VBG,O
ncbi-sent-725,studies,NNS,O
ncbi-sent-725,of,IN,O
ncbi-sent-725,patients,NNS,O
ncbi-sent-725,with,IN,O
ncbi-sent-725,the,DT,O
ncbi-sent-725,disease,NN,O
ncbi-sent-725,.,.,O
ncbi-sent-726,Genomic,NNP,O
ncbi-sent-726,sequencing,NN,O
ncbi-sent-726,of,IN,O
ncbi-sent-726,a,DT,O
ncbi-sent-726,BAC,NNP,O
ncbi-sent-726,clone,NN,O
ncbi-sent-726,H,NNP,O
ncbi-sent-726,_,NNP,O
ncbi-sent-726,RG364P16,NNP,O
ncbi-sent-726,revealed,VBD,O
ncbi-sent-726,the,DT,O
ncbi-sent-726,presence,NN,O
ncbi-sent-726,of,IN,O
ncbi-sent-726,another,DT,O
ncbi-sent-726,",",",",O
ncbi-sent-726,highly,RB,O
ncbi-sent-726,homologous,JJ,O
ncbi-sent-726,gene,NN,O
ncbi-sent-726,3,CD,O
ncbi-sent-726,of,IN,O
ncbi-sent-726,the,DT,O
ncbi-sent-726,CLD,NNP,B-DISEASE
ncbi-sent-726,gene,NN,O
ncbi-sent-726,",",",",O
ncbi-sent-726,with,IN,O
ncbi-sent-726,a,DT,O
ncbi-sent-726,similar,JJ,O
ncbi-sent-726,genomic,JJ,O
ncbi-sent-726,structure,NN,O
ncbi-sent-726,",",",",O
ncbi-sent-726,recently,RB,O
ncbi-sent-726,identified,VBN,O
ncbi-sent-726,as,IN,O
ncbi-sent-726,the,DT,O
ncbi-sent-726,Pendred,NNP,B-DISEASE
ncbi-sent-726,syndrome,JJ,I-DISEASE
ncbi-sent-726,gene,NN,O
ncbi-sent-726,(,(,O
ncbi-sent-726,PDS,NNP,B-DISEASE
ncbi-sent-726,),),O
ncbi-sent-726,.,.,O
ncbi-sent-727,.,.,O
ncbi-sent-728,The,DT,O
ncbi-sent-728,APCI1307K,NNP,O
ncbi-sent-728,allele,NN,O
ncbi-sent-728,and,CC,O
ncbi-sent-728,cancer,NN,B-DISEASE
ncbi-sent-728,risk,NN,O
ncbi-sent-728,in,IN,O
ncbi-sent-728,a,DT,O
ncbi-sent-728,community,NN,O
ncbi-sent-728,-,:,O
ncbi-sent-728,based,VBN,O
ncbi-sent-728,study,NN,O
ncbi-sent-728,of,IN,O
ncbi-sent-728,Ashkenazi,NNP,O
ncbi-sent-728,Jews,NNP,O
ncbi-sent-728,.,.,O
ncbi-sent-729,Mutations,NNS,O
ncbi-sent-729,in,IN,O
ncbi-sent-729,APC,NNP,O
ncbi-sent-729,are,VBP,O
ncbi-sent-729,classically,RB,O
ncbi-sent-729,associated,VBN,O
ncbi-sent-729,with,IN,O
ncbi-sent-729,familial,JJ,B-DISEASE
ncbi-sent-729,adenomatous,JJ,I-DISEASE
ncbi-sent-729,polyposis,NN,I-DISEASE
ncbi-sent-729,(,(,O
ncbi-sent-729,FAP,NNP,B-DISEASE
ncbi-sent-729,),),O
ncbi-sent-729,",",",",O
ncbi-sent-729,a,DT,O
ncbi-sent-729,highly,RB,O
ncbi-sent-729,penetrant,JJ,O
ncbi-sent-729,autosomal,JJ,B-DISEASE
ncbi-sent-729,dominant,JJ,I-DISEASE
ncbi-sent-729,disorder,NN,I-DISEASE
ncbi-sent-729,characterized,VBN,O
ncbi-sent-729,by,IN,O
ncbi-sent-729,multiple,JJ,O
ncbi-sent-729,intestinal,JJ,O
ncbi-sent-729,polyps,NNS,B-DISEASE
ncbi-sent-729,and,CC,O
ncbi-sent-729,",",",",O
ncbi-sent-729,without,IN,O
ncbi-sent-729,surgical,JJ,O
ncbi-sent-729,intervention,NN,O
ncbi-sent-729,",",",",O
ncbi-sent-729,the,DT,O
ncbi-sent-729,development,NN,O
ncbi-sent-729,of,IN,O
ncbi-sent-729,colorectal,JJ,B-DISEASE
ncbi-sent-729,cancer,NN,I-DISEASE
ncbi-sent-729,(,(,O
ncbi-sent-729,CRC,NNP,B-DISEASE
ncbi-sent-729,),),O
ncbi-sent-729,.,.,O
ncbi-sent-730,APC,NNP,B-DISEASE
ncbi-sent-730,is,VBZ,O
ncbi-sent-730,a,DT,O
ncbi-sent-730,tumour,JJ,O
ncbi-sent-730,-,:,O
ncbi-sent-730,suppressor,NN,O
ncbi-sent-730,gene,NN,O
ncbi-sent-730,",",",",O
ncbi-sent-730,and,CC,O
ncbi-sent-730,somatic,JJ,O
ncbi-sent-730,loss,NN,O
ncbi-sent-730,occurs,VBZ,O
ncbi-sent-730,in,IN,O
ncbi-sent-730,tumours,NN,B-DISEASE
ncbi-sent-730,.,.,O
ncbi-sent-731,The,DT,O
ncbi-sent-731,germline,NN,O
ncbi-sent-731,T,NNP,O
ncbi-sent-731,-,:,O
ncbi-sent-731,to,TO,O
ncbi-sent-731,-,:,O
ncbi-sent-731,A,DT,O
ncbi-sent-731,transversion,NN,O
ncbi-sent-731,responsible,JJ,O
ncbi-sent-731,for,IN,O
ncbi-sent-731,the,DT,O
ncbi-sent-731,APC,NNP,O
ncbi-sent-731,I1307K,NNP,O
ncbi-sent-731,allele,NN,O
ncbi-sent-731,converts,VBZ,O
ncbi-sent-731,the,DT,O
ncbi-sent-731,wild,JJ,O
ncbi-sent-731,-,:,O
ncbi-sent-731,type,NN,O
ncbi-sent-731,sequence,NN,O
ncbi-sent-731,to,TO,O
ncbi-sent-731,a,DT,O
ncbi-sent-731,homopolymer,NN,O
ncbi-sent-731,tract,NN,O
ncbi-sent-731,(,(,O
ncbi-sent-731,A8,NNP,O
ncbi-sent-731,),),O
ncbi-sent-731,that,WDT,O
ncbi-sent-731,is,VBZ,O
ncbi-sent-731,genetically,RB,O
ncbi-sent-731,unstable,JJ,O
ncbi-sent-731,and,CC,O
ncbi-sent-731,prone,NN,O
ncbi-sent-731,to,TO,O
ncbi-sent-731,somatic,JJ,O
ncbi-sent-731,mutation,NN,O
ncbi-sent-731,.,.,O
ncbi-sent-732,The,DT,O
ncbi-sent-732,I1307K,NNP,O
ncbi-sent-732,allele,NN,O
ncbi-sent-732,was,VBD,O
ncbi-sent-732,found,VBN,O
ncbi-sent-732,in,IN,O
ncbi-sent-732,6,CD,O
ncbi-sent-732,.,.,O
ncbi-sent-733,1,CD,O
ncbi-sent-733,%,NN,O
ncbi-sent-733,of,IN,O
ncbi-sent-733,unselected,JJ,O
ncbi-sent-733,Ashkenazi,NNP,O
ncbi-sent-733,Jews,NNPS,O
ncbi-sent-733,and,CC,O
ncbi-sent-733,higher,JJR,O
ncbi-sent-733,proportions,NNS,O
ncbi-sent-733,of,IN,O
ncbi-sent-733,Ashkenazim,NNP,O
ncbi-sent-733,with,IN,O
ncbi-sent-733,family,NN,O
ncbi-sent-733,or,CC,O
ncbi-sent-733,personal,JJ,O
ncbi-sent-733,histories,NNS,O
ncbi-sent-733,of,IN,O
ncbi-sent-733,CRC,NNP,B-DISEASE
ncbi-sent-733,(,(,O
ncbi-sent-733,ref,NN,O
ncbi-sent-733,.,.,O
ncbi-sent-734,2,CD,O
ncbi-sent-734,),),O
ncbi-sent-734,.,.,O
ncbi-sent-735,To,TO,O
ncbi-sent-735,evaluate,VB,O
ncbi-sent-735,the,DT,O
ncbi-sent-735,role,NN,O
ncbi-sent-735,of,IN,O
ncbi-sent-735,I1307K,NNP,O
ncbi-sent-735,in,IN,O
ncbi-sent-735,cancer,NN,B-DISEASE
ncbi-sent-735,",",",",O
ncbi-sent-735,we,PRP,O
ncbi-sent-735,genotyped,VBD,O
ncbi-sent-735,5,CD,O
ncbi-sent-735,",",",",O
ncbi-sent-735,081,CD,O
ncbi-sent-735,Ashkenazi,NNP,O
ncbi-sent-735,volunteers,NNS,O
ncbi-sent-735,in,IN,O
ncbi-sent-735,a,DT,O
ncbi-sent-735,community,NN,O
ncbi-sent-735,survey,NN,O
ncbi-sent-735,.,.,O
ncbi-sent-736,Risk,NN,O
ncbi-sent-736,of,IN,O
ncbi-sent-736,developing,VBG,O
ncbi-sent-736,colorectal,JJ,B-DISEASE
ncbi-sent-736,",",",",I-DISEASE
ncbi-sent-736,breast,NN,I-DISEASE
ncbi-sent-736,and,CC,I-DISEASE
ncbi-sent-736,other,JJ,I-DISEASE
ncbi-sent-736,cancers,NNS,I-DISEASE
ncbi-sent-736,were,VBD,O
ncbi-sent-736,compared,VBN,O
ncbi-sent-736,between,IN,O
ncbi-sent-736,genotyped,VBN,O
ncbi-sent-736,I1307K,NNP,O
ncbi-sent-736,carriers,NNS,O
ncbi-sent-736,and,CC,O
ncbi-sent-736,non,SYM,O
ncbi-sent-736,-,:,O
ncbi-sent-736,carriers,NNS,O
ncbi-sent-736,and,CC,O
ncbi-sent-736,their,PRP$,O
ncbi-sent-736,first,JJ,O
ncbi-sent-736,-,:,O
ncbi-sent-736,degree,NN,O
ncbi-sent-736,relatives,NNS,O
ncbi-sent-736,.,.,O
ncbi-sent-737,Sperm,NNP,O
ncbi-sent-737,DNA,NNP,O
ncbi-sent-737,analysis,NN,O
ncbi-sent-737,in,IN,O
ncbi-sent-737,a,DT,O
ncbi-sent-737,Friedreich,NNP,B-DISEASE
ncbi-sent-737,ataxia,NN,I-DISEASE
ncbi-sent-737,premutation,NN,O
ncbi-sent-737,carrier,NN,O
ncbi-sent-737,suggests,VBZ,O
ncbi-sent-737,both,DT,O
ncbi-sent-737,meiotic,JJ,O
ncbi-sent-737,and,CC,O
ncbi-sent-737,mitotic,JJ,O
ncbi-sent-737,expansion,NN,O
ncbi-sent-737,in,IN,O
ncbi-sent-737,the,DT,O
ncbi-sent-737,FRDA,NNP,B-DISEASE
ncbi-sent-737,gene,NN,O
ncbi-sent-737,.,.,O
ncbi-sent-738,Friedreich,NNP,B-DISEASE
ncbi-sent-738,ataxia,NN,I-DISEASE
ncbi-sent-738,is,VBZ,O
ncbi-sent-738,usually,RB,O
ncbi-sent-738,caused,VBN,O
ncbi-sent-738,by,IN,O
ncbi-sent-738,an,DT,O
ncbi-sent-738,expansion,NN,O
ncbi-sent-738,of,IN,O
ncbi-sent-738,a,DT,O
ncbi-sent-738,GAA,NNP,O
ncbi-sent-738,trinucleotide,NN,O
ncbi-sent-738,repeat,NN,O
ncbi-sent-738,in,IN,O
ncbi-sent-738,intron,NN,O
ncbi-sent-738,1,CD,O
ncbi-sent-738,of,IN,O
ncbi-sent-738,the,DT,O
ncbi-sent-738,FRDA,NNP,B-DISEASE
ncbi-sent-738,gene,NN,O
ncbi-sent-738,.,.,O
ncbi-sent-739,Occasionally,RB,O
ncbi-sent-739,",",",",O
ncbi-sent-739,a,DT,O
ncbi-sent-739,fully,RB,O
ncbi-sent-739,expanded,VBN,O
ncbi-sent-739,allele,NN,O
ncbi-sent-739,has,VBZ,O
ncbi-sent-739,been,VBN,O
ncbi-sent-739,found,VBN,O
ncbi-sent-739,to,TO,O
ncbi-sent-739,arise,VB,O
ncbi-sent-739,from,IN,O
ncbi-sent-739,a,DT,O
ncbi-sent-739,premutation,NN,O
ncbi-sent-739,of,IN,O
ncbi-sent-739,100,CD,O
ncbi-sent-739,or,CC,O
ncbi-sent-739,less,JJR,O
ncbi-sent-739,triplet,JJ,O
ncbi-sent-739,repeats,NNS,O
ncbi-sent-739,.,.,O
ncbi-sent-740,We,PRP,O
ncbi-sent-740,have,VBP,O
ncbi-sent-740,examined,VBN,O
ncbi-sent-740,the,DT,O
ncbi-sent-740,sperm,JJ,O
ncbi-sent-740,DNA,NNP,O
ncbi-sent-740,of,IN,O
ncbi-sent-740,a,DT,O
ncbi-sent-740,premutation,NN,O
ncbi-sent-740,carrier,NN,O
ncbi-sent-740,.,.,O
ncbi-sent-741,This,DT,O
ncbi-sent-741,mans,VBZ,O
ncbi-sent-741,leucocyte,JJ,O
ncbi-sent-741,DNA,NN,O
ncbi-sent-741,showed,VBD,O
ncbi-sent-741,one,CD,O
ncbi-sent-741,normal,JJ,O
ncbi-sent-741,allele,NN,O
ncbi-sent-741,and,CC,O
ncbi-sent-741,one,CD,O
ncbi-sent-741,allele,NN,O
ncbi-sent-741,of,IN,O
ncbi-sent-741,approximately,RB,O
ncbi-sent-741,100,CD,O
ncbi-sent-741,repeats,NNS,O
ncbi-sent-741,.,.,O
ncbi-sent-742,His,PRP$,O
ncbi-sent-742,sperm,NN,O
ncbi-sent-742,showed,VBD,O
ncbi-sent-742,an,DT,O
ncbi-sent-742,expanded,VBN,O
ncbi-sent-742,allele,NN,O
ncbi-sent-742,in,IN,O
ncbi-sent-742,a,DT,O
ncbi-sent-742,tight,JJ,O
ncbi-sent-742,range,NN,O
ncbi-sent-742,centering,VBG,O
ncbi-sent-742,on,IN,O
ncbi-sent-742,a,DT,O
ncbi-sent-742,size,NN,O
ncbi-sent-742,of,IN,O
ncbi-sent-742,approximately,RB,O
ncbi-sent-742,320,CD,O
ncbi-sent-742,trinucleotide,JJ,O
ncbi-sent-742,repeats,NNS,O
ncbi-sent-742,.,.,O
ncbi-sent-743,His,PRP$,O
ncbi-sent-743,affected,JJ,O
ncbi-sent-743,son,NN,O
ncbi-sent-743,has,VBZ,O
ncbi-sent-743,repeat,NN,O
ncbi-sent-743,sizes,NNS,O
ncbi-sent-743,of,IN,O
ncbi-sent-743,1040,CD,O
ncbi-sent-743,and,CC,O
ncbi-sent-743,540,CD,O
ncbi-sent-743,.,.,O
ncbi-sent-744,These,DT,O
ncbi-sent-744,data,NNS,O
ncbi-sent-744,suggest,VBP,O
ncbi-sent-744,that,IN,O
ncbi-sent-744,expansion,NN,O
ncbi-sent-744,occurs,NNS,O
ncbi-sent-744,in,IN,O
ncbi-sent-744,two,CD,O
ncbi-sent-744,stages,NNS,O
ncbi-sent-744,",",",",O
ncbi-sent-744,the,DT,O
ncbi-sent-744,first,JJ,O
ncbi-sent-744,during,IN,O
ncbi-sent-744,meiosis,NN,O
ncbi-sent-744,followed,VBN,O
ncbi-sent-744,by,IN,O
ncbi-sent-744,a,DT,O
ncbi-sent-744,second,JJ,O
ncbi-sent-744,mitotic,JJ,O
ncbi-sent-744,expansion,NN,O
ncbi-sent-744,.,.,O
ncbi-sent-745,We,PRP,O
ncbi-sent-745,also,RB,O
ncbi-sent-745,show,VBP,O
ncbi-sent-745,that,IN,O
ncbi-sent-745,in,IN,O
ncbi-sent-745,all,DT,O
ncbi-sent-745,informative,JJ,O
ncbi-sent-745,carrier,NN,O
ncbi-sent-745,father,NN,O
ncbi-sent-745,to,TO,O
ncbi-sent-745,affected,JJ,O
ncbi-sent-745,child,NN,O
ncbi-sent-745,transmissions,NNS,O
ncbi-sent-745,",",",",O
ncbi-sent-745,with,IN,O
ncbi-sent-745,the,DT,O
ncbi-sent-745,notable,JJ,O
ncbi-sent-745,exception,NN,O
ncbi-sent-745,of,IN,O
ncbi-sent-745,the,DT,O
ncbi-sent-745,premutation,NN,O
ncbi-sent-745,carrier,NN,O
ncbi-sent-745,",",",",O
ncbi-sent-745,the,DT,O
ncbi-sent-745,expansion,NN,O
ncbi-sent-745,size,NN,O
ncbi-sent-745,decreases,NNS,O
ncbi-sent-745,.,.,O
ncbi-sent-746,.,.,O
ncbi-sent-747,The,DT,O
ncbi-sent-747,R496H,NNP,O
ncbi-sent-747,mutation,NN,O
ncbi-sent-747,of,IN,O
ncbi-sent-747,arylsulfatase,NN,O
ncbi-sent-747,A,NNP,O
ncbi-sent-747,does,VBZ,O
ncbi-sent-747,not,RB,O
ncbi-sent-747,cause,VB,O
ncbi-sent-747,metachromatic,JJ,B-DISEASE
ncbi-sent-747,leukodystrophy,NN,I-DISEASE
ncbi-sent-747,.,.,O
ncbi-sent-748,Deficiency,NN,B-DISEASE
ncbi-sent-748,of,IN,I-DISEASE
ncbi-sent-748,arylsulfatase,NN,I-DISEASE
ncbi-sent-748,A,NNP,I-DISEASE
ncbi-sent-748,(,(,O
ncbi-sent-748,ARSA,NNP,O
ncbi-sent-748,),),O
ncbi-sent-748,enzyme,VBP,O
ncbi-sent-748,activity,NN,O
ncbi-sent-748,causes,VBZ,O
ncbi-sent-748,metachromatic,JJ,B-DISEASE
ncbi-sent-748,leukodystrophy,NN,I-DISEASE
ncbi-sent-748,(,(,O
ncbi-sent-748,MLD,NNP,B-DISEASE
ncbi-sent-748,),),O
ncbi-sent-748,.,.,O
ncbi-sent-749,A,DT,O
ncbi-sent-749,number,NN,O
ncbi-sent-749,of,IN,O
ncbi-sent-749,ARSA,NNP,O
ncbi-sent-749,gene,NN,O
ncbi-sent-749,mutations,NNS,O
ncbi-sent-749,responsible,JJ,O
ncbi-sent-749,for,IN,O
ncbi-sent-749,MLD,NNP,B-DISEASE
ncbi-sent-749,have,VBP,O
ncbi-sent-749,been,VBN,O
ncbi-sent-749,identified,VBN,O
ncbi-sent-749,.,.,O
ncbi-sent-750,Recently,RB,O
ncbi-sent-750,",",",",O
ncbi-sent-750,the,DT,O
ncbi-sent-750,R496H,NNP,O
ncbi-sent-750,mutation,NN,O
ncbi-sent-750,of,IN,O
ncbi-sent-750,ARSA,NNP,O
ncbi-sent-750,was,VBD,O
ncbi-sent-750,proposed,VBN,O
ncbi-sent-750,to,TO,O
ncbi-sent-750,be,VB,O
ncbi-sent-750,a,DT,O
ncbi-sent-750,cause,NN,O
ncbi-sent-750,of,IN,O
ncbi-sent-750,MLD,NNP,B-DISEASE
ncbi-sent-750,(,(,O
ncbi-sent-750,Draghia,NNP,O
ncbi-sent-750,et,RB,O
ncbi-sent-750,al,RB,O
ncbi-sent-750,.,.,O
ncbi-sent-751,",",",",O
ncbi-sent-751,1997,CD,O
ncbi-sent-751,),),O
ncbi-sent-751,.,.,O
ncbi-sent-752,We,PRP,O
ncbi-sent-752,have,VBP,O
ncbi-sent-752,investigated,VBN,O
ncbi-sent-752,the,DT,O
ncbi-sent-752,R496H,NNP,O
ncbi-sent-752,mutation,NN,O
ncbi-sent-752,and,CC,O
ncbi-sent-752,found,VBD,O
ncbi-sent-752,this,DT,O
ncbi-sent-752,mutation,NN,O
ncbi-sent-752,at,IN,O
ncbi-sent-752,a,DT,O
ncbi-sent-752,relatively,RB,O
ncbi-sent-752,high,JJ,O
ncbi-sent-752,frequency,NN,O
ncbi-sent-752,in,IN,O
ncbi-sent-752,an,DT,O
ncbi-sent-752,African,JJ,O
ncbi-sent-752,American,JJ,O
ncbi-sent-752,population,NN,O
ncbi-sent-752,(,(,O
ncbi-sent-752,f,JJ,O
ncbi-sent-752,=,NN,O
ncbi-sent-752,0,CD,O
ncbi-sent-752,.,.,O
ncbi-sent-753,09,CD,O
ncbi-sent-753,",",",",O
ncbi-sent-753,n,RB,O
ncbi-sent-753,=,VBZ,O
ncbi-sent-753,61,CD,O
ncbi-sent-753,subjects,NNS,O
ncbi-sent-753,),),O
ncbi-sent-753,.,.,O
ncbi-sent-754,The,DT,O
ncbi-sent-754,ARSA,NNP,O
ncbi-sent-754,enzyme,NN,O
ncbi-sent-754,activity,NN,O
ncbi-sent-754,in,IN,O
ncbi-sent-754,subjects,NNS,O
ncbi-sent-754,with,IN,O
ncbi-sent-754,and,CC,O
ncbi-sent-754,without,IN,O
ncbi-sent-754,the,DT,O
ncbi-sent-754,R496H,NNP,O
ncbi-sent-754,mutation,NN,O
ncbi-sent-754,was,VBD,O
ncbi-sent-754,determined,VBN,O
ncbi-sent-754,and,CC,O
ncbi-sent-754,found,VBN,O
ncbi-sent-754,to,TO,O
ncbi-sent-754,be,VB,O
ncbi-sent-754,normal,JJ,O
ncbi-sent-754,.,.,O
ncbi-sent-755,It,PRP,O
ncbi-sent-755,is,VBZ,O
ncbi-sent-755,therefore,RB,O
ncbi-sent-755,concluded,VBD,O
ncbi-sent-755,that,IN,O
ncbi-sent-755,the,DT,O
ncbi-sent-755,R496H,NNP,O
ncbi-sent-755,mutation,NN,O
ncbi-sent-755,of,IN,O
ncbi-sent-755,ARSA,NNP,O
ncbi-sent-755,does,VBZ,O
ncbi-sent-755,not,RB,O
ncbi-sent-755,negatively,RB,O
ncbi-sent-755,influence,VB,O
ncbi-sent-755,the,DT,O
ncbi-sent-755,activity,NN,O
ncbi-sent-755,of,IN,O
ncbi-sent-755,ARSA,NNP,O
ncbi-sent-755,and,CC,O
ncbi-sent-755,is,VBZ,O
ncbi-sent-755,not,RB,O
ncbi-sent-755,a,DT,O
ncbi-sent-755,cause,NN,O
ncbi-sent-755,of,IN,O
ncbi-sent-755,MLD,NNP,B-DISEASE
ncbi-sent-755,Down,NNP,O
ncbi-sent-755,-,:,O
ncbi-sent-755,regulation,NN,O
ncbi-sent-755,of,IN,O
ncbi-sent-755,transmembrane,NN,O
ncbi-sent-755,carbonic,JJ,O
ncbi-sent-755,anhydrases,NNS,O
ncbi-sent-755,in,IN,O
ncbi-sent-755,renal,JJ,B-DISEASE
ncbi-sent-755,cell,NN,I-DISEASE
ncbi-sent-755,carcinoma,NN,I-DISEASE
ncbi-sent-755,cell,NN,O
ncbi-sent-755,lines,NNS,O
ncbi-sent-755,by,IN,O
ncbi-sent-755,wild,JJ,O
ncbi-sent-755,-,:,O
ncbi-sent-755,type,NN,O
ncbi-sent-755,von,NN,B-DISEASE
ncbi-sent-755,Hippel,NNP,I-DISEASE
ncbi-sent-755,-,:,I-DISEASE
ncbi-sent-755,Lindau,NNP,I-DISEASE
ncbi-sent-755,transgenes,NNS,O
ncbi-sent-755,.,.,O
ncbi-sent-756,To,TO,O
ncbi-sent-756,discover,VB,O
ncbi-sent-756,genes,NNS,O
ncbi-sent-756,involved,VBN,O
ncbi-sent-756,in,IN,O
ncbi-sent-756,von,NN,B-DISEASE
ncbi-sent-756,Hippel,NNP,I-DISEASE
ncbi-sent-756,-,:,I-DISEASE
ncbi-sent-756,Lindau,NNP,I-DISEASE
ncbi-sent-756,(,(,O
ncbi-sent-756,VHL,NNP,B-DISEASE
ncbi-sent-756,),),O
ncbi-sent-756,-,:,O
ncbi-sent-756,mediated,VBN,O
ncbi-sent-756,carcinogenesis,NN,O
ncbi-sent-756,",",",",O
ncbi-sent-756,we,PRP,O
ncbi-sent-756,used,VBD,O
ncbi-sent-756,renal,JJ,B-DISEASE
ncbi-sent-756,cell,NN,I-DISEASE
ncbi-sent-756,carcinoma,NN,I-DISEASE
ncbi-sent-756,cell,NN,O
ncbi-sent-756,lines,NNS,O
ncbi-sent-756,stably,RB,O
ncbi-sent-756,transfected,VBN,O
ncbi-sent-756,with,IN,O
ncbi-sent-756,wild,JJ,O
ncbi-sent-756,-,:,O
ncbi-sent-756,type,NN,O
ncbi-sent-756,VHL,NNP,O
ncbi-sent-756,-,:,O
ncbi-sent-756,expressing,VBG,O
ncbi-sent-756,transgenes,NNS,O
ncbi-sent-756,.,.,O
ncbi-sent-757,Large,NNP,O
ncbi-sent-757,-,:,O
ncbi-sent-757,scale,NN,O
ncbi-sent-757,RNA,NNP,O
ncbi-sent-757,differential,JJ,O
ncbi-sent-757,display,NN,O
ncbi-sent-757,technology,NN,O
ncbi-sent-757,applied,VBN,O
ncbi-sent-757,to,TO,O
ncbi-sent-757,these,DT,O
ncbi-sent-757,cell,NN,O
ncbi-sent-757,lines,NNS,O
ncbi-sent-757,identified,VBD,O
ncbi-sent-757,several,JJ,O
ncbi-sent-757,differentially,RB,O
ncbi-sent-757,expressed,VBN,O
ncbi-sent-757,genes,NNS,O
ncbi-sent-757,",",",",O
ncbi-sent-757,including,VBG,O
ncbi-sent-757,an,DT,O
ncbi-sent-757,alpha,NN,O
ncbi-sent-757,carbonic,JJ,O
ncbi-sent-757,anhydrase,NN,O
ncbi-sent-757,gene,NN,O
ncbi-sent-757,",",",",O
ncbi-sent-757,termed,VBD,O
ncbi-sent-757,CA12,NNP,O
ncbi-sent-757,.,.,O
ncbi-sent-758,The,DT,O
ncbi-sent-758,deduced,JJ,O
ncbi-sent-758,protein,NN,O
ncbi-sent-758,sequence,NN,O
ncbi-sent-758,was,VBD,O
ncbi-sent-758,classified,VBN,O
ncbi-sent-758,as,IN,O
ncbi-sent-758,a,DT,O
ncbi-sent-758,one,CD,O
ncbi-sent-758,-,:,O
ncbi-sent-758,pass,NN,O
ncbi-sent-758,transmembrane,NN,O
ncbi-sent-758,CA,NNP,O
ncbi-sent-758,possessing,VBG,O
ncbi-sent-758,an,DT,O
ncbi-sent-758,apparently,RB,O
ncbi-sent-758,intact,JJ,O
ncbi-sent-758,catalytic,JJ,O
ncbi-sent-758,domain,NN,O
ncbi-sent-758,in,IN,O
ncbi-sent-758,the,DT,O
ncbi-sent-758,extracellular,JJ,O
ncbi-sent-758,CA,NNP,O
ncbi-sent-758,module,NN,O
ncbi-sent-758,.,.,O
ncbi-sent-759,Reintroduced,NNP,O
ncbi-sent-759,wild,JJ,O
ncbi-sent-759,-,:,O
ncbi-sent-759,type,NN,O
ncbi-sent-759,VHL,NNP,B-DISEASE
ncbi-sent-759,strongly,RB,O
ncbi-sent-759,inhibited,VBD,O
ncbi-sent-759,the,DT,O
ncbi-sent-759,overexpression,NN,O
ncbi-sent-759,of,IN,O
ncbi-sent-759,the,DT,O
ncbi-sent-759,CA12,NNP,O
ncbi-sent-759,gene,NN,O
ncbi-sent-759,in,IN,O
ncbi-sent-759,the,DT,O
ncbi-sent-759,parental,JJ,O
ncbi-sent-759,renal,NN,B-DISEASE
ncbi-sent-759,cell,NN,I-DISEASE
ncbi-sent-759,carcinoma,NN,I-DISEASE
ncbi-sent-759,cell,NN,O
ncbi-sent-759,lines,NNS,O
ncbi-sent-759,.,.,O
ncbi-sent-760,Similar,JJ,O
ncbi-sent-760,results,NNS,O
ncbi-sent-760,were,VBD,O
ncbi-sent-760,obtained,VBN,O
ncbi-sent-760,with,IN,O
ncbi-sent-760,CA9,NNP,O
ncbi-sent-760,",",",",O
ncbi-sent-760,encoding,VBG,O
ncbi-sent-760,another,DT,O
ncbi-sent-760,transmembrane,NN,O
ncbi-sent-760,CA,NNP,O
ncbi-sent-760,with,IN,O
ncbi-sent-760,an,DT,O
ncbi-sent-760,intact,JJ,O
ncbi-sent-760,catalytic,JJ,O
ncbi-sent-760,domain,NN,O
ncbi-sent-760,.,.,O
ncbi-sent-761,Although,IN,O
ncbi-sent-761,both,DT,O
ncbi-sent-761,domains,NNS,O
ncbi-sent-761,of,IN,O
ncbi-sent-761,the,DT,O
ncbi-sent-761,VHL,NNP,B-DISEASE
ncbi-sent-761,protein,NN,O
ncbi-sent-761,contribute,NN,O
ncbi-sent-761,to,TO,O
ncbi-sent-761,regulation,NN,O
ncbi-sent-761,of,IN,O
ncbi-sent-761,CA12,NNP,O
ncbi-sent-761,expression,NN,O
ncbi-sent-761,",",",",O
ncbi-sent-761,the,DT,O
ncbi-sent-761,elongin,NN,O
ncbi-sent-761,binding,VBG,O
ncbi-sent-761,domain,NN,O
ncbi-sent-761,alone,RB,O
ncbi-sent-761,could,MD,O
ncbi-sent-761,effectively,RB,O
ncbi-sent-761,regulate,VB,O
ncbi-sent-761,CA9,NNP,O
ncbi-sent-761,expression,NN,O
ncbi-sent-761,.,.,O
ncbi-sent-762,We,PRP,O
ncbi-sent-762,mapped,VBD,O
ncbi-sent-762,CA12,NNP,O
ncbi-sent-762,and,CC,O
ncbi-sent-762,CA9,NNP,O
ncbi-sent-762,loci,VBP,O
ncbi-sent-762,to,TO,O
ncbi-sent-762,chromosome,VB,O
ncbi-sent-762,bands,NNS,O
ncbi-sent-762,15q22,CD,O
ncbi-sent-762,and,CC,O
ncbi-sent-762,17q21,CD,O
ncbi-sent-762,.,.,O
ncbi-sent-763,2,CD,O
ncbi-sent-763,respectively,RB,O
ncbi-sent-763,",",",",O
ncbi-sent-763,regions,NNS,O
ncbi-sent-763,prone,VBP,O
ncbi-sent-763,to,TO,O
ncbi-sent-763,amplification,NN,O
ncbi-sent-763,in,IN,O
ncbi-sent-763,some,DT,O
ncbi-sent-763,human,JJ,O
ncbi-sent-763,cancers,NNS,B-DISEASE
ncbi-sent-763,.,.,O
ncbi-sent-764,Additional,JJ,O
ncbi-sent-764,experiments,NNS,O
ncbi-sent-764,are,VBP,O
ncbi-sent-764,needed,VBN,O
ncbi-sent-764,to,TO,O
ncbi-sent-764,define,VB,O
ncbi-sent-764,the,DT,O
ncbi-sent-764,role,NN,O
ncbi-sent-764,of,IN,O
ncbi-sent-764,CA,NNP,O
ncbi-sent-764,IX,NNP,O
ncbi-sent-764,and,CC,O
ncbi-sent-764,CA,NNP,O
ncbi-sent-764,XII,NNP,O
ncbi-sent-764,enzymes,VBZ,O
ncbi-sent-764,in,IN,O
ncbi-sent-764,the,DT,O
ncbi-sent-764,regulation,NN,O
ncbi-sent-764,of,IN,O
ncbi-sent-764,pH,NN,O
ncbi-sent-764,in,IN,O
ncbi-sent-764,the,DT,O
ncbi-sent-764,extracellular,JJ,O
ncbi-sent-764,microenvironment,NN,O
ncbi-sent-764,and,CC,O
ncbi-sent-764,its,PRP$,O
ncbi-sent-764,potential,JJ,O
ncbi-sent-764,impact,NN,O
ncbi-sent-764,on,IN,O
ncbi-sent-764,cancer,NN,B-DISEASE
ncbi-sent-764,cell,NN,O
ncbi-sent-764,growth,NN,O
ncbi-sent-764,.,.,O
ncbi-sent-765,A,DT,O
ncbi-sent-765,gene,NN,O
ncbi-sent-765,encoding,VBG,O
ncbi-sent-765,a,DT,O
ncbi-sent-765,transmembrane,NN,O
ncbi-sent-765,protein,NN,O
ncbi-sent-765,is,VBZ,O
ncbi-sent-765,mutated,VBN,O
ncbi-sent-765,in,IN,O
ncbi-sent-765,patients,NNS,O
ncbi-sent-765,with,IN,O
ncbi-sent-765,diabetes,NNS,B-DISEASE
ncbi-sent-765,mellitus,NNS,I-DISEASE
ncbi-sent-765,and,CC,O
ncbi-sent-765,optic,JJ,B-DISEASE
ncbi-sent-765,atrophy,NN,I-DISEASE
ncbi-sent-765,(,(,O
ncbi-sent-765,Wolfram,NNP,B-DISEASE
ncbi-sent-765,syndrome,NN,I-DISEASE
ncbi-sent-765,),),O
ncbi-sent-765,.,.,O
ncbi-sent-766,Wolfram,NNP,B-DISEASE
ncbi-sent-766,syndrome,NN,I-DISEASE
ncbi-sent-766,(,(,O
ncbi-sent-766,WFS,NNP,B-DISEASE
ncbi-sent-766,;,:,O
ncbi-sent-766,OMIM,NNP,O
ncbi-sent-766,222300,CD,O
ncbi-sent-766,),),O
ncbi-sent-766,is,VBZ,O
ncbi-sent-766,an,DT,O
ncbi-sent-766,autosomal,JJ,B-DISEASE
ncbi-sent-766,recessive,JJ,I-DISEASE
ncbi-sent-766,neurodegenerative,JJ,I-DISEASE
ncbi-sent-766,disorder,NN,I-DISEASE
ncbi-sent-766,defined,VBN,O
ncbi-sent-766,by,IN,O
ncbi-sent-766,young,JJ,O
ncbi-sent-766,-,:,O
ncbi-sent-766,onset,NN,O
ncbi-sent-766,non,SYM,O
ncbi-sent-766,-,:,O
ncbi-sent-766,immune,JJ,O
ncbi-sent-766,insulin,NN,B-DISEASE
ncbi-sent-766,-,:,I-DISEASE
ncbi-sent-766,dependent,NN,I-DISEASE
ncbi-sent-766,diabetes,VBZ,I-DISEASE
ncbi-sent-766,mellitus,NNS,I-DISEASE
ncbi-sent-766,and,CC,O
ncbi-sent-766,progressive,JJ,O
ncbi-sent-766,optic,JJ,B-DISEASE
ncbi-sent-766,atrophy,NN,I-DISEASE
ncbi-sent-766,.,.,O
ncbi-sent-767,Linkage,NN,O
ncbi-sent-767,to,TO,O
ncbi-sent-767,markers,NNS,O
ncbi-sent-767,on,IN,O
ncbi-sent-767,chromosome,NN,O
ncbi-sent-767,4p,CD,O
ncbi-sent-767,was,VBD,O
ncbi-sent-767,confirmed,VBN,O
ncbi-sent-767,in,IN,O
ncbi-sent-767,five,CD,O
ncbi-sent-767,families,NNS,O
ncbi-sent-767,.,.,O
ncbi-sent-768,On,IN,O
ncbi-sent-768,the,DT,O
ncbi-sent-768,basis,NN,O
ncbi-sent-768,of,IN,O
ncbi-sent-768,meiotic,JJ,O
ncbi-sent-768,recombinants,NNS,O
ncbi-sent-768,and,CC,O
ncbi-sent-768,disease,VB,O
ncbi-sent-768,-,:,O
ncbi-sent-768,associated,VBN,O
ncbi-sent-768,haplotypes,NNS,O
ncbi-sent-768,",",",",O
ncbi-sent-768,the,DT,O
ncbi-sent-768,WFS,NNP,B-DISEASE
ncbi-sent-768,gene,NN,O
ncbi-sent-768,was,VBD,O
ncbi-sent-768,localized,VBN,O
ncbi-sent-768,to,TO,O
ncbi-sent-768,a,DT,O
ncbi-sent-768,BAC,NNP,O
ncbi-sent-768,/,NNP,O
ncbi-sent-768,P1,NNP,O
ncbi-sent-768,contig,NN,O
ncbi-sent-768,of,IN,O
ncbi-sent-768,less,JJR,O
ncbi-sent-768,than,IN,O
ncbi-sent-768,250,CD,O
ncbi-sent-768,kb,NN,O
ncbi-sent-768,.,.,O
ncbi-sent-769,Mutations,NNS,O
ncbi-sent-769,in,IN,O
ncbi-sent-769,a,DT,O
ncbi-sent-769,novel,JJ,O
ncbi-sent-769,gene,NN,O
ncbi-sent-769,(,(,O
ncbi-sent-769,WFS1,NNP,O
ncbi-sent-769,),),O
ncbi-sent-769,encoding,VBG,O
ncbi-sent-769,a,DT,O
ncbi-sent-769,putative,JJ,O
ncbi-sent-769,transmembrane,NN,O
ncbi-sent-769,protein,NN,O
ncbi-sent-769,were,VBD,O
ncbi-sent-769,found,VBN,O
ncbi-sent-769,in,IN,O
ncbi-sent-769,all,DT,O
ncbi-sent-769,affected,JJ,O
ncbi-sent-769,individuals,NNS,O
ncbi-sent-769,in,IN,O
ncbi-sent-769,six,CD,O
ncbi-sent-769,WFS,NNP,B-DISEASE
ncbi-sent-769,families,NNS,O
ncbi-sent-769,",",",",O
ncbi-sent-769,and,CC,O
ncbi-sent-769,these,DT,O
ncbi-sent-769,mutations,NNS,O
ncbi-sent-769,were,VBD,O
ncbi-sent-769,associated,VBN,O
ncbi-sent-769,with,IN,O
ncbi-sent-769,the,DT,O
ncbi-sent-769,disease,NN,O
ncbi-sent-769,phenotype,NN,O
ncbi-sent-769,.,.,O
ncbi-sent-770,WFS1,NNP,O
ncbi-sent-770,appears,VBZ,O
ncbi-sent-770,to,TO,O
ncbi-sent-770,function,VB,O
ncbi-sent-770,in,IN,O
ncbi-sent-770,survival,NN,O
ncbi-sent-770,of,IN,O
ncbi-sent-770,islet,NN,O
ncbi-sent-770,beta,SYM,O
ncbi-sent-770,-,:,O
ncbi-sent-770,cells,NNS,O
ncbi-sent-770,and,CC,O
ncbi-sent-770,neurons,NNS,O
ncbi-sent-770,.,.,O
ncbi-sent-771,.,.,O
ncbi-sent-772,Stable,JJ,O
ncbi-sent-772,interaction,NN,O
ncbi-sent-772,between,IN,O
ncbi-sent-772,the,DT,O
ncbi-sent-772,products,NNS,O
ncbi-sent-772,of,IN,O
ncbi-sent-772,the,DT,O
ncbi-sent-772,BRCA1,NNP,O
ncbi-sent-772,and,CC,O
ncbi-sent-772,BRCA2,NNP,O
ncbi-sent-772,tumor,NN,B-DISEASE
ncbi-sent-772,suppressor,NN,O
ncbi-sent-772,genes,NNS,O
ncbi-sent-772,in,IN,O
ncbi-sent-772,mitotic,JJ,O
ncbi-sent-772,and,CC,O
ncbi-sent-772,meiotic,JJ,O
ncbi-sent-772,cells,NNS,O
ncbi-sent-772,.,.,O
ncbi-sent-773,BRCA1,NNP,O
ncbi-sent-773,and,CC,O
ncbi-sent-773,BRCA2,NNP,O
ncbi-sent-773,account,NN,O
ncbi-sent-773,for,IN,O
ncbi-sent-773,most,JJS,O
ncbi-sent-773,cases,NNS,O
ncbi-sent-773,of,IN,O
ncbi-sent-773,familial,JJ,O
ncbi-sent-773,",",",",O
ncbi-sent-773,early,JJ,O
ncbi-sent-773,onset,VBN,O
ncbi-sent-773,breast,NN,B-DISEASE
ncbi-sent-773,and,CC,I-DISEASE
ncbi-sent-773,/,NN,I-DISEASE
ncbi-sent-773,or,CC,I-DISEASE
ncbi-sent-773,ovarian,JJ,I-DISEASE
ncbi-sent-773,cancer,NN,I-DISEASE
ncbi-sent-773,and,CC,O
ncbi-sent-773,encode,NN,O
ncbi-sent-773,products,NNS,O
ncbi-sent-773,that,IN,O
ncbi-sent-773,each,DT,O
ncbi-sent-773,interact,NN,O
ncbi-sent-773,with,IN,O
ncbi-sent-773,hRAD51,NN,O
ncbi-sent-773,.,.,O
ncbi-sent-774,Results,NNS,O
ncbi-sent-774,presented,VBD,O
ncbi-sent-774,here,RB,O
ncbi-sent-774,show,VBP,O
ncbi-sent-774,that,IN,O
ncbi-sent-774,BRCA1,NNP,O
ncbi-sent-774,and,CC,O
ncbi-sent-774,BRCA2,NNP,O
ncbi-sent-774,coexist,NN,O
ncbi-sent-774,in,IN,O
ncbi-sent-774,a,DT,O
ncbi-sent-774,biochemical,JJ,O
ncbi-sent-774,complex,NN,O
ncbi-sent-774,and,CC,O
ncbi-sent-774,colocalize,NN,O
ncbi-sent-774,in,IN,O
ncbi-sent-774,subnuclear,JJ,O
ncbi-sent-774,foci,NN,O
ncbi-sent-774,in,IN,O
ncbi-sent-774,somatic,JJ,O
ncbi-sent-774,cells,NNS,O
ncbi-sent-774,and,CC,O
ncbi-sent-774,on,IN,O
ncbi-sent-774,the,DT,O
ncbi-sent-774,axial,JJ,O
ncbi-sent-774,elements,NNS,O
ncbi-sent-774,of,IN,O
ncbi-sent-774,developing,VBG,O
ncbi-sent-774,synaptonemal,JJ,O
ncbi-sent-774,complexes,NNS,O
ncbi-sent-774,.,.,O
ncbi-sent-775,Like,IN,O
ncbi-sent-775,BRCA1,NNP,O
ncbi-sent-775,and,CC,O
ncbi-sent-775,RAD51,NNP,O
ncbi-sent-775,",",",",O
ncbi-sent-775,BRCA2,NNP,O
ncbi-sent-775,relocates,VBZ,O
ncbi-sent-775,to,TO,O
ncbi-sent-775,PCNA,NNP,O
ncbi-sent-775,+,NNP,O
ncbi-sent-775,replication,NN,O
ncbi-sent-775,sites,NNS,O
ncbi-sent-775,following,VBG,O
ncbi-sent-775,exposure,NN,O
ncbi-sent-775,of,IN,O
ncbi-sent-775,S,NNP,O
ncbi-sent-775,phase,NN,O
ncbi-sent-775,cells,NNS,O
ncbi-sent-775,to,TO,O
ncbi-sent-775,hydroxyurea,VB,O
ncbi-sent-775,or,CC,O
ncbi-sent-775,UV,NNP,O
ncbi-sent-775,irradiation,NN,O
ncbi-sent-775,.,.,O
ncbi-sent-776,Thus,RB,O
ncbi-sent-776,",",",",O
ncbi-sent-776,BRCA1,NNP,O
ncbi-sent-776,and,CC,O
ncbi-sent-776,BRCA2,NNP,O
ncbi-sent-776,participate,VB,O
ncbi-sent-776,",",",",O
ncbi-sent-776,together,RB,O
ncbi-sent-776,",",",",O
ncbi-sent-776,in,IN,O
ncbi-sent-776,a,DT,O
ncbi-sent-776,pathway,NN,O
ncbi-sent-776,(,(,O
ncbi-sent-776,s,PRP,O
ncbi-sent-776,),),O
ncbi-sent-776,associated,VBN,O
ncbi-sent-776,with,IN,O
ncbi-sent-776,the,DT,O
ncbi-sent-776,activation,NN,O
ncbi-sent-776,of,IN,O
ncbi-sent-776,double,JJ,O
ncbi-sent-776,-,:,O
ncbi-sent-776,strand,NN,O
ncbi-sent-776,break,NN,O
ncbi-sent-776,repair,NN,O
ncbi-sent-776,and,CC,O
ncbi-sent-776,/,NN,O
ncbi-sent-776,or,CC,O
ncbi-sent-776,homologous,JJ,O
ncbi-sent-776,recombination,NN,O
ncbi-sent-776,.,.,O
ncbi-sent-777,Dysfunction,NN,O
ncbi-sent-777,of,IN,O
ncbi-sent-777,this,DT,O
ncbi-sent-777,pathway,NN,O
ncbi-sent-777,may,MD,O
ncbi-sent-777,be,VB,O
ncbi-sent-777,a,DT,O
ncbi-sent-777,general,JJ,O
ncbi-sent-777,phenomenon,NN,O
ncbi-sent-777,in,IN,O
ncbi-sent-777,the,DT,O
ncbi-sent-777,majority,NN,O
ncbi-sent-777,of,IN,O
ncbi-sent-777,cases,NNS,O
ncbi-sent-777,of,IN,O
ncbi-sent-777,hereditary,JJ,B-DISEASE
ncbi-sent-777,breast,NN,I-DISEASE
ncbi-sent-777,and,CC,I-DISEASE
ncbi-sent-777,/,NN,I-DISEASE
ncbi-sent-777,or,CC,I-DISEASE
ncbi-sent-777,ovarian,JJ,I-DISEASE
ncbi-sent-777,cancer,NN,I-DISEASE
ncbi-sent-777,.,.,O
ncbi-sent-778,.,.,O
ncbi-sent-779,A,DT,O
ncbi-sent-779,novel,JJ,O
ncbi-sent-779,Arg362Ser,NNP,O
ncbi-sent-779,mutation,NN,O
ncbi-sent-779,in,IN,O
ncbi-sent-779,the,DT,O
ncbi-sent-779,sterol,NN,O
ncbi-sent-779,27,CD,O
ncbi-sent-779,-,:,O
ncbi-sent-779,hydroxylase,NN,O
ncbi-sent-779,gene,NN,O
ncbi-sent-779,(,(,O
ncbi-sent-779,CYP27,NNP,O
ncbi-sent-779,),),O
ncbi-sent-779,:,:,O
ncbi-sent-779,its,PRP$,O
ncbi-sent-779,effects,NNS,O
ncbi-sent-779,on,IN,O
ncbi-sent-779,pre,NN,O
ncbi-sent-779,-,:,O
ncbi-sent-779,mRNA,NN,O
ncbi-sent-779,splicing,NN,O
ncbi-sent-779,and,CC,O
ncbi-sent-779,enzyme,JJ,O
ncbi-sent-779,activity,NN,O
ncbi-sent-779,.,.,O
ncbi-sent-780,A,DT,O
ncbi-sent-780,novel,JJ,O
ncbi-sent-780,C,NNP,O
ncbi-sent-780,to,TO,O
ncbi-sent-780,A,DT,O
ncbi-sent-780,mutation,NN,O
ncbi-sent-780,in,IN,O
ncbi-sent-780,the,DT,O
ncbi-sent-780,sterol,NN,O
ncbi-sent-780,27,CD,O
ncbi-sent-780,-,:,O
ncbi-sent-780,hydroxylase,NN,O
ncbi-sent-780,gene,NN,O
ncbi-sent-780,(,(,O
ncbi-sent-780,CYP27,NNP,O
ncbi-sent-780,),),O
ncbi-sent-780,was,VBD,O
ncbi-sent-780,identified,VBN,O
ncbi-sent-780,by,IN,O
ncbi-sent-780,sequencing,VBG,O
ncbi-sent-780,amplified,VBN,O
ncbi-sent-780,CYP27,NNP,O
ncbi-sent-780,gene,NN,O
ncbi-sent-780,products,NNS,O
ncbi-sent-780,from,IN,O
ncbi-sent-780,a,DT,O
ncbi-sent-780,patient,NN,O
ncbi-sent-780,with,IN,O
ncbi-sent-780,cerebrotendinous,JJ,B-DISEASE
ncbi-sent-780,xanthomatosis,NN,I-DISEASE
ncbi-sent-780,(,(,O
ncbi-sent-780,CTX,NNP,B-DISEASE
ncbi-sent-780,),),O
ncbi-sent-780,.,.,O
ncbi-sent-781,The,DT,O
ncbi-sent-781,mutation,NN,O
ncbi-sent-781,changed,VBD,O
ncbi-sent-781,the,DT,O
ncbi-sent-781,adrenodoxin,NN,O
ncbi-sent-781,cofactor,NN,O
ncbi-sent-781,binding,VBG,O
ncbi-sent-781,residue,JJ,O
ncbi-sent-781,362Arg,CD,O
ncbi-sent-781,to,TO,O
ncbi-sent-781,362Ser,CD,O
ncbi-sent-781,(,(,O
ncbi-sent-781,CGT,NNP,O
ncbi-sent-781,362Arg,CD,O
ncbi-sent-781,to,TO,O
ncbi-sent-781,AGT,NNP,O
ncbi-sent-781,362Ser,CD,O
ncbi-sent-781,),),O
ncbi-sent-781,",",",",O
ncbi-sent-781,and,CC,O
ncbi-sent-781,was,VBD,O
ncbi-sent-781,responsible,JJ,O
ncbi-sent-781,for,IN,O
ncbi-sent-781,deficiency,NN,O
ncbi-sent-781,in,IN,O
ncbi-sent-781,the,DT,O
ncbi-sent-781,sterol,NN,O
ncbi-sent-781,27,CD,O
ncbi-sent-781,-,:,O
ncbi-sent-781,hydroxylase,NN,O
ncbi-sent-781,activity,NN,O
ncbi-sent-781,",",",",O
ncbi-sent-781,as,IN,O
ncbi-sent-781,confirmed,VBN,O
ncbi-sent-781,by,IN,O
ncbi-sent-781,expression,NN,O
ncbi-sent-781,of,IN,O
ncbi-sent-781,mutant,JJ,O
ncbi-sent-781,cDNA,NN,O
ncbi-sent-781,into,IN,O
ncbi-sent-781,COS,NNP,O
ncbi-sent-781,-,:,O
ncbi-sent-781,1,CD,O
ncbi-sent-781,cells,NNS,O
ncbi-sent-781,.,.,O
ncbi-sent-782,Quantitative,JJ,O
ncbi-sent-782,analysis,NN,O
ncbi-sent-782,showed,VBD,O
ncbi-sent-782,that,IN,O
ncbi-sent-782,the,DT,O
ncbi-sent-782,expression,NN,O
ncbi-sent-782,of,IN,O
ncbi-sent-782,CYP27,NNP,O
ncbi-sent-782,gene,NN,O
ncbi-sent-782,mRNA,NN,O
ncbi-sent-782,in,IN,O
ncbi-sent-782,the,DT,O
ncbi-sent-782,patient,NN,O
ncbi-sent-782,represented,VBD,O
ncbi-sent-782,52,CD,O
ncbi-sent-782,.,.,O
ncbi-sent-783,5,CD,O
ncbi-sent-783,%,NN,O
ncbi-sent-783,of,IN,O
ncbi-sent-783,the,DT,O
ncbi-sent-783,normal,JJ,O
ncbi-sent-783,level,NN,O
ncbi-sent-783,.,.,O
ncbi-sent-784,As,IN,O
ncbi-sent-784,the,DT,O
ncbi-sent-784,mutation,NN,O
ncbi-sent-784,occurred,VBD,O
ncbi-sent-784,at,IN,O
ncbi-sent-784,the,DT,O
ncbi-sent-784,penultimate,NN,O
ncbi-sent-784,nucleotide,NN,O
ncbi-sent-784,of,IN,O
ncbi-sent-784,exon,$,O
ncbi-sent-784,6,CD,O
ncbi-sent-784,(,(,O
ncbi-sent-784,-,:,O
ncbi-sent-784,2,CD,O
ncbi-sent-784,position,NN,O
ncbi-sent-784,of,IN,O
ncbi-sent-784,exon,$,O
ncbi-sent-784,6,CD,O
ncbi-sent-784,-,:,O
ncbi-sent-784,intron,NN,O
ncbi-sent-784,6,CD,O
ncbi-sent-784,splice,NN,O
ncbi-sent-784,site,NN,O
ncbi-sent-784,),),O
ncbi-sent-784,of,IN,O
ncbi-sent-784,the,DT,O
ncbi-sent-784,gene,NN,O
ncbi-sent-784,",",",",O
ncbi-sent-784,we,PRP,O
ncbi-sent-784,hypothesized,VBD,O
ncbi-sent-784,that,IN,O
ncbi-sent-784,the,DT,O
ncbi-sent-784,mutation,NN,O
ncbi-sent-784,may,MD,O
ncbi-sent-784,partially,RB,O
ncbi-sent-784,affect,VB,O
ncbi-sent-784,the,DT,O
ncbi-sent-784,normal,JJ,O
ncbi-sent-784,splicing,JJ,O
ncbi-sent-784,efficiency,NN,O
ncbi-sent-784,in,IN,O
ncbi-sent-784,exon,CC,O
ncbi-sent-784,6,CD,O
ncbi-sent-784,and,CC,O
ncbi-sent-784,cause,VB,O
ncbi-sent-784,alternative,JJ,O
ncbi-sent-784,splicing,NN,O
ncbi-sent-784,elsewhere,RB,O
ncbi-sent-784,",",",",O
ncbi-sent-784,which,WDT,O
ncbi-sent-784,resulted,VBD,O
ncbi-sent-784,in,IN,O
ncbi-sent-784,decreased,JJ,O
ncbi-sent-784,transcript,NN,O
ncbi-sent-784,in,IN,O
ncbi-sent-784,the,DT,O
ncbi-sent-784,patient,NN,O
ncbi-sent-784,.,.,O
ncbi-sent-785,Transfection,NN,O
ncbi-sent-785,of,IN,O
ncbi-sent-785,constructed,JJ,O
ncbi-sent-785,minigenes,NNS,O
ncbi-sent-785,",",",",O
ncbi-sent-785,with,IN,O
ncbi-sent-785,or,CC,O
ncbi-sent-785,without,IN,O
ncbi-sent-785,the,DT,O
ncbi-sent-785,mutation,NN,O
ncbi-sent-785,",",",",O
ncbi-sent-785,into,IN,O
ncbi-sent-785,COS,NNP,O
ncbi-sent-785,-,:,O
ncbi-sent-785,1,CD,O
ncbi-sent-785,cells,NNS,O
ncbi-sent-785,confirmed,VBD,O
ncbi-sent-785,that,IN,O
ncbi-sent-785,the,DT,O
ncbi-sent-785,mutant,JJ,O
ncbi-sent-785,minigene,NN,O
ncbi-sent-785,was,VBD,O
ncbi-sent-785,responsible,JJ,O
ncbi-sent-785,for,IN,O
ncbi-sent-785,a,DT,O
ncbi-sent-785,mRNA,NN,O
ncbi-sent-785,species,VBZ,O
ncbi-sent-785,alternatively,RB,O
ncbi-sent-785,spliced,VBN,O
ncbi-sent-785,at,IN,O
ncbi-sent-785,an,DT,O
ncbi-sent-785,activated,JJ,O
ncbi-sent-785,cryptic,JJ,O
ncbi-sent-785,5,CD,O
ncbi-sent-785,splice,NN,O
ncbi-sent-785,site,NN,O
ncbi-sent-785,88,CD,O
ncbi-sent-785,bp,NN,O
ncbi-sent-785,upstream,NN,O
ncbi-sent-785,from,IN,O
ncbi-sent-785,the,DT,O
ncbi-sent-785,3,CD,O
ncbi-sent-785,end,NN,O
ncbi-sent-785,of,IN,O
ncbi-sent-785,exon,JJ,O
ncbi-sent-785,6,CD,O
ncbi-sent-785,.,.,O
ncbi-sent-786,Our,PRP$,O
ncbi-sent-786,data,NNS,O
ncbi-sent-786,suggest,VBP,O
ncbi-sent-786,that,IN,O
ncbi-sent-786,the,DT,O
ncbi-sent-786,C,NNP,O
ncbi-sent-786,to,TO,O
ncbi-sent-786,A,DT,O
ncbi-sent-786,mutation,NN,O
ncbi-sent-786,at,IN,O
ncbi-sent-786,the,DT,O
ncbi-sent-786,penultimate,NN,O
ncbi-sent-786,nucleotide,NN,O
ncbi-sent-786,of,IN,O
ncbi-sent-786,exon,JJ,O
ncbi-sent-786,6,CD,O
ncbi-sent-786,of,IN,O
ncbi-sent-786,the,DT,O
ncbi-sent-786,CYP27,NNP,O
ncbi-sent-786,gene,NN,O
ncbi-sent-786,not,RB,O
ncbi-sent-786,only,RB,O
ncbi-sent-786,causes,VBZ,O
ncbi-sent-786,the,DT,O
ncbi-sent-786,deficiency,NN,B-DISEASE
ncbi-sent-786,in,IN,I-DISEASE
ncbi-sent-786,the,DT,I-DISEASE
ncbi-sent-786,sterol,NN,I-DISEASE
ncbi-sent-786,27,CD,I-DISEASE
ncbi-sent-786,-,:,I-DISEASE
ncbi-sent-786,hydroxylase,NN,I-DISEASE
ncbi-sent-786,activity,NN,I-DISEASE
ncbi-sent-786,",",",",O
ncbi-sent-786,but,CC,O
ncbi-sent-786,also,RB,O
ncbi-sent-786,partially,RB,O
ncbi-sent-786,leads,VBZ,O
ncbi-sent-786,to,TO,O
ncbi-sent-786,alternative,VB,O
ncbi-sent-786,pre,JJ,O
ncbi-sent-786,-,:,O
ncbi-sent-786,mRNA,NN,O
ncbi-sent-786,splicing,NN,O
ncbi-sent-786,of,IN,O
ncbi-sent-786,the,DT,O
ncbi-sent-786,gene,NN,O
ncbi-sent-786,.,.,O
ncbi-sent-787,To,TO,O
ncbi-sent-787,our,PRP$,O
ncbi-sent-787,knowledge,NN,O
ncbi-sent-787,",",",",O
ncbi-sent-787,this,DT,O
ncbi-sent-787,is,VBZ,O
ncbi-sent-787,the,DT,O
ncbi-sent-787,first,JJ,O
ncbi-sent-787,report,NN,O
ncbi-sent-787,regarding,VBG,O
ncbi-sent-787,effects,NNS,O
ncbi-sent-787,on,IN,O
ncbi-sent-787,pre,NN,O
ncbi-sent-787,-,:,O
ncbi-sent-787,mRNA,NN,O
ncbi-sent-787,splicing,NN,O
ncbi-sent-787,of,IN,O
ncbi-sent-787,a,DT,O
ncbi-sent-787,mutation,NN,O
ncbi-sent-787,at,IN,O
ncbi-sent-787,the,DT,O
ncbi-sent-787,-,:,O
ncbi-sent-787,2,CD,O
ncbi-sent-787,position,NN,O
ncbi-sent-787,of,IN,O
ncbi-sent-787,a,DT,O
ncbi-sent-787,5,CD,O
ncbi-sent-787,splice,NN,O
ncbi-sent-787,site,NN,O
ncbi-sent-787,.,.,O
ncbi-sent-788,ATM,NNP,O
ncbi-sent-788,germline,JJ,O
ncbi-sent-788,mutations,NNS,O
ncbi-sent-788,in,IN,O
ncbi-sent-788,classical,JJ,O
ncbi-sent-788,ataxia,NN,B-DISEASE
ncbi-sent-788,-,:,I-DISEASE
ncbi-sent-788,telangiectasia,NN,I-DISEASE
ncbi-sent-788,patients,NNS,O
ncbi-sent-788,in,IN,O
ncbi-sent-788,the,DT,O
ncbi-sent-788,Dutch,JJ,O
ncbi-sent-788,population,NN,O
ncbi-sent-788,.,.,O
ncbi-sent-789,Germline,NNP,O
ncbi-sent-789,mutations,NNS,O
ncbi-sent-789,in,IN,O
ncbi-sent-789,the,DT,O
ncbi-sent-789,ATM,NNP,O
ncbi-sent-789,gene,NN,O
ncbi-sent-789,are,VBP,O
ncbi-sent-789,responsible,JJ,O
ncbi-sent-789,for,IN,O
ncbi-sent-789,the,DT,O
ncbi-sent-789,autosomal,JJ,B-DISEASE
ncbi-sent-789,recessive,JJ,I-DISEASE
ncbi-sent-789,disorder,NN,I-DISEASE
ncbi-sent-789,ataxia,SYM,B-DISEASE
ncbi-sent-789,-,:,I-DISEASE
ncbi-sent-789,telangiectasia,NN,I-DISEASE
ncbi-sent-789,(,(,O
ncbi-sent-789,A,DT,B-DISEASE
ncbi-sent-789,-,:,I-DISEASE
ncbi-sent-789,T,NN,I-DISEASE
ncbi-sent-789,),),O
ncbi-sent-789,.,.,O
ncbi-sent-790,In,IN,O
ncbi-sent-790,our,PRP$,O
ncbi-sent-790,study,NN,O
ncbi-sent-790,",",",",O
ncbi-sent-790,we,PRP,O
ncbi-sent-790,have,VBP,O
ncbi-sent-790,determined,VBN,O
ncbi-sent-790,the,DT,O
ncbi-sent-790,ATM,NNP,O
ncbi-sent-790,mutation,NN,O
ncbi-sent-790,spectrum,NN,O
ncbi-sent-790,in,IN,O
ncbi-sent-790,19,CD,O
ncbi-sent-790,classical,JJ,O
ncbi-sent-790,A,NNP,B-DISEASE
ncbi-sent-790,-,:,I-DISEASE
ncbi-sent-790,T,NN,I-DISEASE
ncbi-sent-790,patients,NNS,O
ncbi-sent-790,",",",",O
ncbi-sent-790,including,VBG,O
ncbi-sent-790,some,DT,O
ncbi-sent-790,immigrant,JJ,O
ncbi-sent-790,populations,NNS,O
ncbi-sent-790,",",",",O
ncbi-sent-790,as,RB,O
ncbi-sent-790,well,RB,O
ncbi-sent-790,as,IN,O
ncbi-sent-790,12,CD,O
ncbi-sent-790,of,IN,O
ncbi-sent-790,Dutch,NNP,O
ncbi-sent-790,ethnic,JJ,O
ncbi-sent-790,origin,NN,O
ncbi-sent-790,.,.,O
ncbi-sent-791,Both,CC,O
ncbi-sent-791,the,DT,O
ncbi-sent-791,protein,NN,O
ncbi-sent-791,truncation,NN,O
ncbi-sent-791,test,NN,O
ncbi-sent-791,(,(,O
ncbi-sent-791,PTT,NNP,O
ncbi-sent-791,),),O
ncbi-sent-791,and,CC,O
ncbi-sent-791,the,DT,O
ncbi-sent-791,restriction,NN,O
ncbi-sent-791,endonuclease,NN,O
ncbi-sent-791,fingerprinting,NN,O
ncbi-sent-791,(,(,O
ncbi-sent-791,REF,NNP,O
ncbi-sent-791,),),O
ncbi-sent-791,method,NN,O
ncbi-sent-791,were,VBD,O
ncbi-sent-791,used,VBN,O
ncbi-sent-791,and,CC,O
ncbi-sent-791,compared,VBN,O
ncbi-sent-791,for,IN,O
ncbi-sent-791,their,PRP$,O
ncbi-sent-791,detection,NN,O
ncbi-sent-791,efficiency,NN,O
ncbi-sent-791,",",",",O
ncbi-sent-791,identifying,VBG,O
ncbi-sent-791,76,CD,O
ncbi-sent-791,%,NN,O
ncbi-sent-791,and,CC,O
ncbi-sent-791,60,CD,O
ncbi-sent-791,%,NN,O
ncbi-sent-791,of,IN,O
ncbi-sent-791,the,DT,O
ncbi-sent-791,mutations,NNS,O
ncbi-sent-791,",",",",O
ncbi-sent-791,respectively,RB,O
ncbi-sent-791,.,.,O
ncbi-sent-792,Most,JJS,O
ncbi-sent-792,patients,NNS,O
ncbi-sent-792,were,VBD,O
ncbi-sent-792,found,VBN,O
ncbi-sent-792,to,TO,O
ncbi-sent-792,be,VB,O
ncbi-sent-792,compound,JJ,O
ncbi-sent-792,heterozygote,NN,O
ncbi-sent-792,.,.,O
ncbi-sent-793,Seventeen,JJ,O
ncbi-sent-793,mutations,NNS,O
ncbi-sent-793,were,VBD,O
ncbi-sent-793,distinct,JJ,O
ncbi-sent-793,",",",",O
ncbi-sent-793,of,IN,O
ncbi-sent-793,which,WDT,O
ncbi-sent-793,10,CD,O
ncbi-sent-793,were,VBD,O
ncbi-sent-793,not,RB,O
ncbi-sent-793,reported,VBN,O
ncbi-sent-793,previously,RB,O
ncbi-sent-793,.,.,O
ncbi-sent-794,Mutations,NNS,O
ncbi-sent-794,are,VBP,O
ncbi-sent-794,small,JJ,O
ncbi-sent-794,deletions,NNS,O
ncbi-sent-794,or,CC,O
ncbi-sent-794,point,NN,O
ncbi-sent-794,mutations,NNS,O
ncbi-sent-794,frequently,RB,O
ncbi-sent-794,affecting,VBG,O
ncbi-sent-794,splice,NN,O
ncbi-sent-794,sites,NNS,O
ncbi-sent-794,.,.,O
ncbi-sent-795,Moreover,RB,O
ncbi-sent-795,",",",",O
ncbi-sent-795,a,DT,O
ncbi-sent-795,16,CD,O
ncbi-sent-795,.,.,O
ncbi-sent-796,7,CD,O
ncbi-sent-796,-,:,O
ncbi-sent-796,kb,NN,O
ncbi-sent-796,genomic,JJ,O
ncbi-sent-796,deletion,NN,O
ncbi-sent-796,of,IN,O
ncbi-sent-796,the,DT,O
ncbi-sent-796,3,CD,O
ncbi-sent-796,end,NN,O
ncbi-sent-796,of,IN,O
ncbi-sent-796,the,DT,O
ncbi-sent-796,gene,NN,O
ncbi-sent-796,",",",",O
ncbi-sent-796,most,RBS,O
ncbi-sent-796,likely,RB,O
ncbi-sent-796,a,DT,O
ncbi-sent-796,result,NN,O
ncbi-sent-796,of,IN,O
ncbi-sent-796,recombination,NN,O
ncbi-sent-796,between,IN,O
ncbi-sent-796,two,CD,O
ncbi-sent-796,LINE,NNP,O
ncbi-sent-796,elements,NNS,O
ncbi-sent-796,",",",",O
ncbi-sent-796,was,VBD,O
ncbi-sent-796,identified,VBN,O
ncbi-sent-796,.,.,O
ncbi-sent-797,The,DT,O
ncbi-sent-797,most,RBS,O
ncbi-sent-797,frequently,RB,O
ncbi-sent-797,found,VBN,O
ncbi-sent-797,mutation,NN,O
ncbi-sent-797,",",",",O
ncbi-sent-797,identified,VBN,O
ncbi-sent-797,in,IN,O
ncbi-sent-797,three,CD,O
ncbi-sent-797,unrelated,JJ,O
ncbi-sent-797,Turkish,PDT,O
ncbi-sent-797,A,DT,B-DISEASE
ncbi-sent-797,-,:,I-DISEASE
ncbi-sent-797,T,NN,I-DISEASE
ncbi-sent-797,individuals,NNS,O
ncbi-sent-797,",",",",O
ncbi-sent-797,was,VBD,O
ncbi-sent-797,previously,RB,O
ncbi-sent-797,described,VBN,O
ncbi-sent-797,to,TO,O
ncbi-sent-797,be,VB,O
ncbi-sent-797,a,DT,O
ncbi-sent-797,Turkish,JJ,O
ncbi-sent-797,A,NNP,B-DISEASE
ncbi-sent-797,-,:,I-DISEASE
ncbi-sent-797,T,NN,I-DISEASE
ncbi-sent-797,founder,NN,O
ncbi-sent-797,mutation,NN,O
ncbi-sent-797,.,.,O
ncbi-sent-798,The,DT,O
ncbi-sent-798,presence,NN,O
ncbi-sent-798,of,IN,O
ncbi-sent-798,a,DT,O
ncbi-sent-798,founder,NN,O
ncbi-sent-798,mutation,NN,O
ncbi-sent-798,among,IN,O
ncbi-sent-798,relatively,RB,O
ncbi-sent-798,small,JJ,O
ncbi-sent-798,ethnic,JJ,O
ncbi-sent-798,population,NN,O
ncbi-sent-798,groups,NNS,O
ncbi-sent-798,in,IN,O
ncbi-sent-798,Western,NNP,O
ncbi-sent-798,Europe,NNP,O
ncbi-sent-798,could,MD,O
ncbi-sent-798,indicate,VB,O
ncbi-sent-798,a,DT,O
ncbi-sent-798,high,JJ,O
ncbi-sent-798,carrier,NN,O
ncbi-sent-798,frequency,NN,O
ncbi-sent-798,in,IN,O
ncbi-sent-798,such,JJ,O
ncbi-sent-798,communities,NNS,O
ncbi-sent-798,.,.,O
ncbi-sent-799,In,IN,O
ncbi-sent-799,patients,NNS,O
ncbi-sent-799,of,IN,O
ncbi-sent-799,Dutch,NNP,O
ncbi-sent-799,ethnic,JJ,O
ncbi-sent-799,origin,NN,O
ncbi-sent-799,",",",",O
ncbi-sent-799,however,RB,O
ncbi-sent-799,",",",",O
ncbi-sent-799,no,DT,O
ncbi-sent-799,significant,JJ,O
ncbi-sent-799,founder,NN,O
ncbi-sent-799,effect,NN,O
ncbi-sent-799,could,MD,O
ncbi-sent-799,be,VB,O
ncbi-sent-799,identified,VBN,O
ncbi-sent-799,.,.,O
ncbi-sent-800,The,DT,O
ncbi-sent-800,observed,JJ,O
ncbi-sent-800,genetic,JJ,O
ncbi-sent-800,heterogeneity,NN,O
ncbi-sent-800,including,VBG,O
ncbi-sent-800,the,DT,O
ncbi-sent-800,relative,JJ,O
ncbi-sent-800,high,JJ,O
ncbi-sent-800,percentage,NN,O
ncbi-sent-800,of,IN,O
ncbi-sent-800,splice,NN,O
ncbi-sent-800,-,:,O
ncbi-sent-800,site,NN,O
ncbi-sent-800,mutations,NNS,O
ncbi-sent-800,had,VBD,O
ncbi-sent-800,no,DT,O
ncbi-sent-800,reflection,NN,O
ncbi-sent-800,on,IN,O
ncbi-sent-800,the,DT,O
ncbi-sent-800,phenotype,NN,O
ncbi-sent-800,.,.,O
ncbi-sent-801,All,DT,O
ncbi-sent-801,patients,NNS,O
ncbi-sent-801,manifested,VBD,O
ncbi-sent-801,classical,JJ,O
ncbi-sent-801,A,NNP,B-DISEASE
ncbi-sent-801,-,:,I-DISEASE
ncbi-sent-801,T,NN,I-DISEASE
ncbi-sent-801,and,CC,O
ncbi-sent-801,increased,VBD,O
ncbi-sent-801,cellular,JJ,O
ncbi-sent-801,radioresistant,NN,O
ncbi-sent-801,DNA,NNP,O
ncbi-sent-801,synthesis,NN,O
ncbi-sent-801,.,.,O
ncbi-sent-802,Determination,NN,O
ncbi-sent-802,of,IN,O
ncbi-sent-802,the,DT,O
ncbi-sent-802,genomic,JJ,O
ncbi-sent-802,structure,NN,O
ncbi-sent-802,of,IN,O
ncbi-sent-802,the,DT,O
ncbi-sent-802,COL4A4,NNP,O
ncbi-sent-802,gene,NN,O
ncbi-sent-802,and,CC,O
ncbi-sent-802,of,IN,O
ncbi-sent-802,novel,JJ,O
ncbi-sent-802,mutations,NNS,O
ncbi-sent-802,causing,VBG,O
ncbi-sent-802,autosomal,JJ,B-DISEASE
ncbi-sent-802,recessive,JJ,I-DISEASE
ncbi-sent-802,Alport,NNP,I-DISEASE
ncbi-sent-802,syndrome,NN,I-DISEASE
ncbi-sent-802,.,.,O
ncbi-sent-803,Autosomal,NNP,B-DISEASE
ncbi-sent-803,recessive,JJ,I-DISEASE
ncbi-sent-803,Alport,NNP,I-DISEASE
ncbi-sent-803,syndrome,NN,I-DISEASE
ncbi-sent-803,is,VBZ,O
ncbi-sent-803,a,DT,O
ncbi-sent-803,progressive,JJ,O
ncbi-sent-803,hematuric,NN,B-DISEASE
ncbi-sent-803,glomerulonephritis,NN,I-DISEASE
ncbi-sent-803,characterized,VBN,O
ncbi-sent-803,by,IN,O
ncbi-sent-803,glomerular,JJ,B-DISEASE
ncbi-sent-803,basement,NN,I-DISEASE
ncbi-sent-803,membrane,NN,I-DISEASE
ncbi-sent-803,abnormalities,NNS,I-DISEASE
ncbi-sent-803,and,CC,O
ncbi-sent-803,associated,VBN,O
ncbi-sent-803,with,IN,O
ncbi-sent-803,mutations,NNS,O
ncbi-sent-803,in,IN,O
ncbi-sent-803,either,CC,O
ncbi-sent-803,the,DT,O
ncbi-sent-803,COL4A3,NNP,O
ncbi-sent-803,or,CC,O
ncbi-sent-803,the,DT,O
ncbi-sent-803,COL4A4,NNP,O
ncbi-sent-803,gene,NN,O
ncbi-sent-803,",",",",O
ncbi-sent-803,which,WDT,O
ncbi-sent-803,encode,VBP,O
ncbi-sent-803,the,DT,O
ncbi-sent-803,alpha3,NN,O
ncbi-sent-803,and,CC,O
ncbi-sent-803,alpha4,JJ,O
ncbi-sent-803,type,NN,O
ncbi-sent-803,IV,NNP,O
ncbi-sent-803,collagen,NN,O
ncbi-sent-803,chains,NNS,O
ncbi-sent-803,",",",",O
ncbi-sent-803,respectively,RB,O
ncbi-sent-803,.,.,O
ncbi-sent-804,To,TO,O
ncbi-sent-804,date,NN,O
ncbi-sent-804,",",",",O
ncbi-sent-804,mutation,NN,O
ncbi-sent-804,screening,NN,O
ncbi-sent-804,in,IN,O
ncbi-sent-804,the,DT,O
ncbi-sent-804,two,CD,O
ncbi-sent-804,genes,NNS,O
ncbi-sent-804,has,VBZ,O
ncbi-sent-804,been,VBN,O
ncbi-sent-804,hampered,VBN,O
ncbi-sent-804,by,IN,O
ncbi-sent-804,the,DT,O
ncbi-sent-804,lack,NN,O
ncbi-sent-804,of,IN,O
ncbi-sent-804,genomic,JJ,O
ncbi-sent-804,structure,NN,O
ncbi-sent-804,information,NN,O
ncbi-sent-804,.,.,O
ncbi-sent-805,We,PRP,O
ncbi-sent-805,report,VBP,O
ncbi-sent-805,here,RB,O
ncbi-sent-805,the,DT,O
ncbi-sent-805,complete,JJ,O
ncbi-sent-805,characterization,NN,O
ncbi-sent-805,of,IN,O
ncbi-sent-805,the,DT,O
ncbi-sent-805,48,CD,O
ncbi-sent-805,exons,NNS,O
ncbi-sent-805,of,IN,O
ncbi-sent-805,the,DT,O
ncbi-sent-805,COL4A4,NNP,O
ncbi-sent-805,gene,NN,O
ncbi-sent-805,",",",",O
ncbi-sent-805,a,DT,O
ncbi-sent-805,comprehensive,JJ,O
ncbi-sent-805,gene,NN,O
ncbi-sent-805,screen,NN,O
ncbi-sent-805,",",",",O
ncbi-sent-805,and,CC,O
ncbi-sent-805,the,DT,O
ncbi-sent-805,subsequent,JJ,O
ncbi-sent-805,detection,NN,O
ncbi-sent-805,of,IN,O
ncbi-sent-805,10,CD,O
ncbi-sent-805,novel,JJ,O
ncbi-sent-805,mutations,NNS,O
ncbi-sent-805,in,IN,O
ncbi-sent-805,eight,CD,O
ncbi-sent-805,patients,NNS,O
ncbi-sent-805,diagnosed,VBN,O
ncbi-sent-805,with,IN,O
ncbi-sent-805,autosomal,JJ,B-DISEASE
ncbi-sent-805,recessive,JJ,I-DISEASE
ncbi-sent-805,Alport,NNP,I-DISEASE
ncbi-sent-805,syndrome,NN,I-DISEASE
ncbi-sent-805,.,.,O
ncbi-sent-806,Furthermore,RB,O
ncbi-sent-806,",",",",O
ncbi-sent-806,we,PRP,O
ncbi-sent-806,identified,VBD,O
ncbi-sent-806,a,DT,O
ncbi-sent-806,glycine,NN,O
ncbi-sent-806,to,TO,O
ncbi-sent-806,alanine,VB,O
ncbi-sent-806,substitution,NN,O
ncbi-sent-806,in,IN,O
ncbi-sent-806,the,DT,O
ncbi-sent-806,collagenous,JJ,O
ncbi-sent-806,domain,NN,O
ncbi-sent-806,that,WDT,O
ncbi-sent-806,is,VBZ,O
ncbi-sent-806,apparently,RB,O
ncbi-sent-806,silent,JJ,O
ncbi-sent-806,in,IN,O
ncbi-sent-806,the,DT,O
ncbi-sent-806,heterozygous,JJ,O
ncbi-sent-806,carriers,NNS,O
ncbi-sent-806,",",",",O
ncbi-sent-806,in,IN,O
ncbi-sent-806,11,CD,O
ncbi-sent-806,.,.,O
ncbi-sent-807,5,CD,O
ncbi-sent-807,%,NN,O
ncbi-sent-807,of,IN,O
ncbi-sent-807,all,DT,O
ncbi-sent-807,control,NN,O
ncbi-sent-807,individuals,NNS,O
ncbi-sent-807,",",",",O
ncbi-sent-807,and,CC,O
ncbi-sent-807,in,IN,O
ncbi-sent-807,one,CD,O
ncbi-sent-807,control,NN,O
ncbi-sent-807,individual,JJ,O
ncbi-sent-807,homozygous,JJ,O
ncbi-sent-807,for,IN,O
ncbi-sent-807,this,DT,O
ncbi-sent-807,glycine,JJ,O
ncbi-sent-807,substitution,NN,O
ncbi-sent-807,.,.,O
ncbi-sent-808,There,EX,O
ncbi-sent-808,has,VBZ,O
ncbi-sent-808,been,VBN,O
ncbi-sent-808,no,DT,O
ncbi-sent-808,previous,JJ,O
ncbi-sent-808,finding,NN,O
ncbi-sent-808,of,IN,O
ncbi-sent-808,a,DT,O
ncbi-sent-808,glycine,JJ,O
ncbi-sent-808,substitution,NN,O
ncbi-sent-808,that,WDT,O
ncbi-sent-808,is,VBZ,O
ncbi-sent-808,not,RB,O
ncbi-sent-808,associated,VBN,O
ncbi-sent-808,with,IN,O
ncbi-sent-808,any,DT,O
ncbi-sent-808,obvious,JJ,O
ncbi-sent-808,phenotype,NN,O
ncbi-sent-808,in,IN,O
ncbi-sent-808,homozygous,JJ,O
ncbi-sent-808,individuals,NNS,O
ncbi-sent-808,.,.,O
ncbi-sent-809,Founder,NNP,O
ncbi-sent-809,BRCA1,NNP,O
ncbi-sent-809,and,CC,O
ncbi-sent-809,BRCA2,NNP,O
ncbi-sent-809,mutations,NNS,O
ncbi-sent-809,in,IN,O
ncbi-sent-809,French,JJ,O
ncbi-sent-809,Canadian,JJ,O
ncbi-sent-809,breast,NN,B-DISEASE
ncbi-sent-809,and,CC,I-DISEASE
ncbi-sent-809,ovarian,JJ,I-DISEASE
ncbi-sent-809,cancer,NN,I-DISEASE
ncbi-sent-809,families,NNS,O
ncbi-sent-809,.,.,O
ncbi-sent-810,We,PRP,O
ncbi-sent-810,have,VBP,O
ncbi-sent-810,identified,VBN,O
ncbi-sent-810,four,CD,O
ncbi-sent-810,mutations,NNS,O
ncbi-sent-810,in,IN,O
ncbi-sent-810,each,DT,O
ncbi-sent-810,of,IN,O
ncbi-sent-810,the,DT,O
ncbi-sent-810,breast,NN,B-DISEASE
ncbi-sent-810,cancer,NN,I-DISEASE
ncbi-sent-810,-,:,O
ncbi-sent-810,susceptibility,NN,O
ncbi-sent-810,genes,NNS,O
ncbi-sent-810,",",",",O
ncbi-sent-810,BRCA1,NNP,O
ncbi-sent-810,and,CC,O
ncbi-sent-810,BRCA2,NNP,O
ncbi-sent-810,",",",",O
ncbi-sent-810,in,IN,O
ncbi-sent-810,French,JJ,O
ncbi-sent-810,Canadian,JJ,O
ncbi-sent-810,breast,NN,B-DISEASE
ncbi-sent-810,cancer,NN,I-DISEASE
ncbi-sent-810,and,CC,O
ncbi-sent-810,breast,NN,B-DISEASE
ncbi-sent-810,/,JJ,I-DISEASE
ncbi-sent-810,ovarian,JJ,I-DISEASE
ncbi-sent-810,cancer,NN,I-DISEASE
ncbi-sent-810,families,NNS,O
ncbi-sent-810,from,IN,O
ncbi-sent-810,Quebec,NNP,O
ncbi-sent-810,.,.,O
ncbi-sent-811,To,TO,O
ncbi-sent-811,identify,VB,O
ncbi-sent-811,founder,NN,O
ncbi-sent-811,effects,NNS,O
ncbi-sent-811,",",",",O
ncbi-sent-811,we,PRP,O
ncbi-sent-811,examined,VBD,O
ncbi-sent-811,independently,RB,O
ncbi-sent-811,ascertained,VBN,O
ncbi-sent-811,French,JJ,O
ncbi-sent-811,Canadian,JJ,O
ncbi-sent-811,cancer,NN,B-DISEASE
ncbi-sent-811,families,NNS,O
ncbi-sent-811,for,IN,O
ncbi-sent-811,the,DT,O
ncbi-sent-811,distribution,NN,O
ncbi-sent-811,of,IN,O
ncbi-sent-811,these,DT,O
ncbi-sent-811,eight,CD,O
ncbi-sent-811,mutations,NNS,O
ncbi-sent-811,.,.,O
ncbi-sent-812,Mutations,NNS,O
ncbi-sent-812,were,VBD,O
ncbi-sent-812,found,VBN,O
ncbi-sent-812,in,IN,O
ncbi-sent-812,41,CD,O
ncbi-sent-812,of,IN,O
ncbi-sent-812,97,CD,O
ncbi-sent-812,families,NNS,O
ncbi-sent-812,.,.,O
ncbi-sent-813,Six,CD,O
ncbi-sent-813,of,IN,O
ncbi-sent-813,eight,CD,O
ncbi-sent-813,mutations,NNS,O
ncbi-sent-813,were,VBD,O
ncbi-sent-813,observed,VBN,O
ncbi-sent-813,at,IN,O
ncbi-sent-813,least,JJS,O
ncbi-sent-813,twice,RB,O
ncbi-sent-813,.,.,O
ncbi-sent-814,The,DT,O
ncbi-sent-814,BRCA1,NNP,O
ncbi-sent-814,C4446T,NNP,O
ncbi-sent-814,mutation,NN,O
ncbi-sent-814,was,VBD,O
ncbi-sent-814,the,DT,O
ncbi-sent-814,most,RBS,O
ncbi-sent-814,common,JJ,O
ncbi-sent-814,mutation,NN,O
ncbi-sent-814,found,VBD,O
ncbi-sent-814,",",",",O
ncbi-sent-814,followed,VBN,O
ncbi-sent-814,by,IN,O
ncbi-sent-814,the,DT,O
ncbi-sent-814,BRCA2,NNP,O
ncbi-sent-814,8765delAG,CD,O
ncbi-sent-814,mutation,NN,O
ncbi-sent-814,.,.,O
ncbi-sent-815,Together,RB,O
ncbi-sent-815,",",",",O
ncbi-sent-815,these,DT,O
ncbi-sent-815,mutations,NNS,O
ncbi-sent-815,were,VBD,O
ncbi-sent-815,found,VBN,O
ncbi-sent-815,in,IN,O
ncbi-sent-815,28,CD,O
ncbi-sent-815,of,IN,O
ncbi-sent-815,41,CD,O
ncbi-sent-815,families,NNS,O
ncbi-sent-815,identified,VBN,O
ncbi-sent-815,to,TO,O
ncbi-sent-815,have,VB,O
ncbi-sent-815,a,DT,O
ncbi-sent-815,mutation,NN,O
ncbi-sent-815,.,.,O
ncbi-sent-816,The,DT,O
ncbi-sent-816,odds,NNS,O
ncbi-sent-816,of,IN,O
ncbi-sent-816,detection,NN,O
ncbi-sent-816,of,IN,O
ncbi-sent-816,any,DT,O
ncbi-sent-816,of,IN,O
ncbi-sent-816,the,DT,O
ncbi-sent-816,four,CD,O
ncbi-sent-816,BRCA1,NNP,O
ncbi-sent-816,mutations,NNS,O
ncbi-sent-816,was,VBD,O
ncbi-sent-816,18,CD,O
ncbi-sent-816,.,.,O
ncbi-sent-817,7x,CD,O
ncbi-sent-817,greater,JJR,O
ncbi-sent-817,if,IN,O
ncbi-sent-817,one,CD,O
ncbi-sent-817,or,CC,O
ncbi-sent-817,more,JJR,O
ncbi-sent-817,cases,NNS,O
ncbi-sent-817,of,IN,O
ncbi-sent-817,ovarian,JJ,B-DISEASE
ncbi-sent-817,cancer,NN,I-DISEASE
ncbi-sent-817,were,VBD,O
ncbi-sent-817,also,RB,O
ncbi-sent-817,present,JJ,O
ncbi-sent-817,in,IN,O
ncbi-sent-817,the,DT,O
ncbi-sent-817,family,NN,O
ncbi-sent-817,.,.,O
ncbi-sent-818,The,DT,O
ncbi-sent-818,odds,NNS,O
ncbi-sent-818,of,IN,O
ncbi-sent-818,detection,NN,O
ncbi-sent-818,of,IN,O
ncbi-sent-818,any,DT,O
ncbi-sent-818,of,IN,O
ncbi-sent-818,the,DT,O
ncbi-sent-818,four,CD,O
ncbi-sent-818,BRCA2,NNP,O
ncbi-sent-818,mutations,NNS,O
ncbi-sent-818,was,VBD,O
ncbi-sent-818,5,CD,O
ncbi-sent-818,.,.,O
ncbi-sent-819,3x,CD,O
ncbi-sent-819,greater,JJR,O
ncbi-sent-819,if,IN,O
ncbi-sent-819,there,EX,O
ncbi-sent-819,were,VBD,O
ncbi-sent-819,at,IN,O
ncbi-sent-819,least,JJS,O
ncbi-sent-819,five,CD,O
ncbi-sent-819,cases,NNS,O
ncbi-sent-819,of,IN,O
ncbi-sent-819,breast,NN,B-DISEASE
ncbi-sent-819,cancer,NN,I-DISEASE
ncbi-sent-819,in,IN,O
ncbi-sent-819,the,DT,O
ncbi-sent-819,family,NN,O
ncbi-sent-819,.,.,O
ncbi-sent-820,Interestingly,RB,O
ncbi-sent-820,",",",",O
ncbi-sent-820,the,DT,O
ncbi-sent-820,presence,NN,O
ncbi-sent-820,of,IN,O
ncbi-sent-820,a,DT,O
ncbi-sent-820,breast,NN,B-DISEASE
ncbi-sent-820,cancer,NN,I-DISEASE
ncbi-sent-820,case,NN,O
ncbi-sent-820,<,VBZ,O
ncbi-sent-820,36,CD,O
ncbi-sent-820,years,NNS,O
ncbi-sent-820,of,IN,O
ncbi-sent-820,age,NN,O
ncbi-sent-820,was,VBD,O
ncbi-sent-820,strongly,RB,O
ncbi-sent-820,predictive,JJ,O
ncbi-sent-820,of,IN,O
ncbi-sent-820,the,DT,O
ncbi-sent-820,presence,NN,O
ncbi-sent-820,of,IN,O
ncbi-sent-820,any,DT,O
ncbi-sent-820,of,IN,O
ncbi-sent-820,the,DT,O
ncbi-sent-820,eight,CD,O
ncbi-sent-820,mutations,NNS,O
ncbi-sent-820,screened,VBD,O
ncbi-sent-820,.,.,O
ncbi-sent-821,Carriers,NNS,O
ncbi-sent-821,of,IN,O
ncbi-sent-821,the,DT,O
ncbi-sent-821,same,JJ,O
ncbi-sent-821,mutation,NN,O
ncbi-sent-821,",",",",O
ncbi-sent-821,from,IN,O
ncbi-sent-821,different,JJ,O
ncbi-sent-821,families,NNS,O
ncbi-sent-821,",",",",O
ncbi-sent-821,shared,VBD,O
ncbi-sent-821,similar,JJ,O
ncbi-sent-821,haplotypes,NNS,O
ncbi-sent-821,",",",",O
ncbi-sent-821,indicating,VBG,O
ncbi-sent-821,that,IN,O
ncbi-sent-821,the,DT,O
ncbi-sent-821,mutant,JJ,O
ncbi-sent-821,alleles,NNS,O
ncbi-sent-821,were,VBD,O
ncbi-sent-821,likely,JJ,O
ncbi-sent-821,to,TO,O
ncbi-sent-821,be,VB,O
ncbi-sent-821,identical,JJ,O
ncbi-sent-821,by,IN,O
ncbi-sent-821,descent,NN,O
ncbi-sent-821,for,IN,O
ncbi-sent-821,a,DT,O
ncbi-sent-821,mutation,NN,O
ncbi-sent-821,in,IN,O
ncbi-sent-821,the,DT,O
ncbi-sent-821,founder,NN,O
ncbi-sent-821,population,NN,O
ncbi-sent-821,.,.,O
ncbi-sent-822,The,DT,O
ncbi-sent-822,identification,NN,O
ncbi-sent-822,of,IN,O
ncbi-sent-822,common,JJ,O
ncbi-sent-822,BRCA1,NNP,O
ncbi-sent-822,and,CC,O
ncbi-sent-822,BRCA2,NNP,O
ncbi-sent-822,mutations,NNS,O
ncbi-sent-822,will,MD,O
ncbi-sent-822,facilitate,VB,O
ncbi-sent-822,carrier,NN,O
ncbi-sent-822,detection,NN,O
ncbi-sent-822,in,IN,O
ncbi-sent-822,French,JJ,O
ncbi-sent-822,Canadian,JJ,O
ncbi-sent-822,breast,NN,B-DISEASE
ncbi-sent-822,cancer,NN,I-DISEASE
ncbi-sent-822,and,CC,O
ncbi-sent-822,breast,NN,B-DISEASE
ncbi-sent-822,/,JJ,I-DISEASE
ncbi-sent-822,ovarian,JJ,I-DISEASE
ncbi-sent-822,cancer,NN,I-DISEASE
ncbi-sent-822,families,NNS,O
ncbi-sent-822,.,.,O
ncbi-sent-823,Are,NNP,O
ncbi-sent-823,Dp71,NNP,O
ncbi-sent-823,and,CC,O
ncbi-sent-823,Dp140,NNP,O
ncbi-sent-823,brain,NN,O
ncbi-sent-823,dystrophin,NN,O
ncbi-sent-823,isoforms,NNS,O
ncbi-sent-823,related,VBN,O
ncbi-sent-823,to,TO,O
ncbi-sent-823,cognitive,JJ,B-DISEASE
ncbi-sent-823,impairment,NN,I-DISEASE
ncbi-sent-823,in,IN,O
ncbi-sent-823,Duchenne,NNP,B-DISEASE
ncbi-sent-823,muscular,JJ,I-DISEASE
ncbi-sent-823,dystrophy,NN,I-DISEASE
ncbi-sent-823,?,.,O
ncbi-sent-823,Molecular,NNP,O
ncbi-sent-823,study,NN,O
ncbi-sent-823,and,CC,O
ncbi-sent-823,neuropsychological,JJ,O
ncbi-sent-823,analysis,NN,O
ncbi-sent-823,were,VBD,O
ncbi-sent-823,performed,VBN,O
ncbi-sent-823,concurrently,RB,O
ncbi-sent-823,on,IN,O
ncbi-sent-823,49,CD,O
ncbi-sent-823,patients,NNS,O
ncbi-sent-823,with,IN,O
ncbi-sent-823,Duchenne,NNP,B-DISEASE
ncbi-sent-823,muscular,JJ,I-DISEASE
ncbi-sent-823,dystrophy,NN,I-DISEASE
ncbi-sent-823,(,(,O
ncbi-sent-823,DMD,NNP,B-DISEASE
ncbi-sent-823,),),O
ncbi-sent-823,in,IN,O
ncbi-sent-823,order,NN,O
ncbi-sent-823,to,TO,O
ncbi-sent-823,find,VB,O
ncbi-sent-823,a,DT,O
ncbi-sent-823,molecular,JJ,O
ncbi-sent-823,explanation,NN,O
ncbi-sent-823,for,IN,O
ncbi-sent-823,the,DT,O
ncbi-sent-823,cognitive,JJ,B-DISEASE
ncbi-sent-823,impairment,NN,I-DISEASE
ncbi-sent-823,observed,VBN,O
ncbi-sent-823,in,IN,O
ncbi-sent-823,most,JJS,O
ncbi-sent-823,DMD,JJ,B-DISEASE
ncbi-sent-823,patients,NNS,O
ncbi-sent-823,.,.,O
ncbi-sent-824,Complete,JJ,O
ncbi-sent-824,analysis,NN,O
ncbi-sent-824,of,IN,O
ncbi-sent-824,the,DT,O
ncbi-sent-824,dystrophin,JJ,O
ncbi-sent-824,gene,NN,O
ncbi-sent-824,was,VBD,O
ncbi-sent-824,performed,VBN,O
ncbi-sent-824,to,TO,O
ncbi-sent-824,define,VB,O
ncbi-sent-824,the,DT,O
ncbi-sent-824,localization,NN,O
ncbi-sent-824,of,IN,O
ncbi-sent-824,deletions,NNS,O
ncbi-sent-824,and,CC,O
ncbi-sent-824,duplications,NNS,O
ncbi-sent-824,in,IN,O
ncbi-sent-824,relation,NN,O
ncbi-sent-824,to,TO,O
ncbi-sent-824,the,DT,O
ncbi-sent-824,different,JJ,O
ncbi-sent-824,DMD,NNP,B-DISEASE
ncbi-sent-824,promoters,NNS,O
ncbi-sent-824,.,.,O
ncbi-sent-825,Qualitative,JJ,O
ncbi-sent-825,analysis,NN,O
ncbi-sent-825,of,IN,O
ncbi-sent-825,the,DT,O
ncbi-sent-825,Dp71,NNP,O
ncbi-sent-825,transcript,NN,O
ncbi-sent-825,and,CC,O
ncbi-sent-825,testing,VBG,O
ncbi-sent-825,for,IN,O
ncbi-sent-825,the,DT,O
ncbi-sent-825,specific,NN,O
ncbi-sent-825,first,JJ,O
ncbi-sent-825,exon,NN,O
ncbi-sent-825,of,IN,O
ncbi-sent-825,Dp140,NNP,O
ncbi-sent-825,were,VBD,O
ncbi-sent-825,also,RB,O
ncbi-sent-825,carried,VBN,O
ncbi-sent-825,out,RP,O
ncbi-sent-825,.,.,O
ncbi-sent-826,Neuropsychological,JJ,O
ncbi-sent-826,analysis,NN,O
ncbi-sent-826,assessed,VBD,O
ncbi-sent-826,verbal,JJ,O
ncbi-sent-826,and,CC,O
ncbi-sent-826,visuospatial,JJ,O
ncbi-sent-826,intelligence,NN,O
ncbi-sent-826,",",",",O
ncbi-sent-826,verbal,JJ,O
ncbi-sent-826,memory,NN,O
ncbi-sent-826,",",",",O
ncbi-sent-826,and,CC,O
ncbi-sent-826,reading,VBG,O
ncbi-sent-826,skills,NNS,O
ncbi-sent-826,.,.,O
ncbi-sent-827,Comparison,NNP,O
ncbi-sent-827,of,IN,O
ncbi-sent-827,molecular,JJ,O
ncbi-sent-827,and,CC,O
ncbi-sent-827,psychometric,JJ,O
ncbi-sent-827,findings,NNS,O
ncbi-sent-827,demonstrated,VBD,O
ncbi-sent-827,that,IN,O
ncbi-sent-827,deletions,NNS,O
ncbi-sent-827,and,CC,O
ncbi-sent-827,duplications,NNS,O
ncbi-sent-827,that,WDT,O
ncbi-sent-827,were,VBD,O
ncbi-sent-827,localized,VBN,O
ncbi-sent-827,in,IN,O
ncbi-sent-827,the,DT,O
ncbi-sent-827,distal,JJ,O
ncbi-sent-827,part,NN,O
ncbi-sent-827,of,IN,O
ncbi-sent-827,the,DT,O
ncbi-sent-827,gene,NN,O
ncbi-sent-827,seemed,VBD,O
ncbi-sent-827,to,TO,O
ncbi-sent-827,be,VB,O
ncbi-sent-827,preferentially,RB,O
ncbi-sent-827,associated,VBN,O
ncbi-sent-827,with,IN,O
ncbi-sent-827,cognitive,JJ,B-DISEASE
ncbi-sent-827,impairment,NN,I-DISEASE
ncbi-sent-827,.,.,O
ncbi-sent-828,Two,CD,O
ncbi-sent-828,altered,VBD,O
ncbi-sent-828,Dp71,NNP,O
ncbi-sent-828,transcripts,NNS,O
ncbi-sent-828,and,CC,O
ncbi-sent-828,two,CD,O
ncbi-sent-828,deleted,VBD,O
ncbi-sent-828,Dp140,NNP,O
ncbi-sent-828,DNA,NNP,O
ncbi-sent-828,sequences,NNS,O
ncbi-sent-828,were,VBD,O
ncbi-sent-828,found,VBN,O
ncbi-sent-828,in,IN,O
ncbi-sent-828,four,CD,O
ncbi-sent-828,patients,NNS,O
ncbi-sent-828,with,IN,O
ncbi-sent-828,severe,JJ,O
ncbi-sent-828,cerebral,JJ,B-DISEASE
ncbi-sent-828,dysfunction,NN,I-DISEASE
ncbi-sent-828,.,.,O
ncbi-sent-829,These,DT,O
ncbi-sent-829,findings,NNS,O
ncbi-sent-829,suggest,VBP,O
ncbi-sent-829,that,IN,O
ncbi-sent-829,some,DT,O
ncbi-sent-829,sequences,NNS,O
ncbi-sent-829,located,VBN,O
ncbi-sent-829,in,IN,O
ncbi-sent-829,the,DT,O
ncbi-sent-829,distal,JJ,O
ncbi-sent-829,part,NN,O
ncbi-sent-829,of,IN,O
ncbi-sent-829,the,DT,O
ncbi-sent-829,gene,NN,O
ncbi-sent-829,and,CC,O
ncbi-sent-829,",",",",O
ncbi-sent-829,in,IN,O
ncbi-sent-829,particular,JJ,O
ncbi-sent-829,",",",",O
ncbi-sent-829,some,DT,O
ncbi-sent-829,DMD,NNP,B-DISEASE
ncbi-sent-829,isoforms,NNS,O
ncbi-sent-829,expressed,VBD,O
ncbi-sent-829,in,IN,O
ncbi-sent-829,the,DT,O
ncbi-sent-829,brain,NN,O
ncbi-sent-829,may,MD,O
ncbi-sent-829,be,VB,O
ncbi-sent-829,related,VBN,O
ncbi-sent-829,to,TO,O
ncbi-sent-829,the,DT,O
ncbi-sent-829,cognitive,JJ,B-DISEASE
ncbi-sent-829,impairment,NN,I-DISEASE
ncbi-sent-829,associated,VBN,O
ncbi-sent-829,with,IN,O
ncbi-sent-829,DMD,NNP,B-DISEASE
ncbi-sent-829,.,.,O
ncbi-sent-830,.,.,O
ncbi-sent-831,I1307K,NNP,O
ncbi-sent-831,APC,NNP,O
ncbi-sent-831,and,CC,O
ncbi-sent-831,hMLH1,JJ,O
ncbi-sent-831,mutations,NNS,O
ncbi-sent-831,in,IN,O
ncbi-sent-831,a,DT,O
ncbi-sent-831,non,JJ,O
ncbi-sent-831,-,:,O
ncbi-sent-831,Jewish,JJ,O
ncbi-sent-831,family,NN,O
ncbi-sent-831,with,IN,O
ncbi-sent-831,hereditary,JJ,B-DISEASE
ncbi-sent-831,non,SYM,I-DISEASE
ncbi-sent-831,-,:,I-DISEASE
ncbi-sent-831,polyposis,NN,I-DISEASE
ncbi-sent-831,colorectal,JJ,I-DISEASE
ncbi-sent-831,cancer,NN,I-DISEASE
ncbi-sent-831,.,.,O
ncbi-sent-832,We,PRP,O
ncbi-sent-832,describe,VBP,O
ncbi-sent-832,a,DT,O
ncbi-sent-832,French,JJ,O
ncbi-sent-832,Canadian,JJ,O
ncbi-sent-832,hereditary,NN,B-DISEASE
ncbi-sent-832,non,SYM,I-DISEASE
ncbi-sent-832,-,:,I-DISEASE
ncbi-sent-832,polyposis,NN,I-DISEASE
ncbi-sent-832,colorectal,JJ,I-DISEASE
ncbi-sent-832,cancer,NN,I-DISEASE
ncbi-sent-832,(,(,O
ncbi-sent-832,HNPCC,NNP,B-DISEASE
ncbi-sent-832,),),O
ncbi-sent-832,kindred,VBD,O
ncbi-sent-832,which,WDT,O
ncbi-sent-832,carries,VBZ,O
ncbi-sent-832,a,DT,O
ncbi-sent-832,novel,JJ,O
ncbi-sent-832,truncating,VBG,O
ncbi-sent-832,mutation,NN,O
ncbi-sent-832,in,IN,O
ncbi-sent-832,hMLH1,NN,O
ncbi-sent-832,.,.,O
ncbi-sent-833,Interestingly,RB,O
ncbi-sent-833,",",",",O
ncbi-sent-833,the,DT,O
ncbi-sent-833,I1307K,NNP,O
ncbi-sent-833,APC,NNP,O
ncbi-sent-833,polymorphism,NN,O
ncbi-sent-833,",",",",O
ncbi-sent-833,associated,VBN,O
ncbi-sent-833,with,IN,O
ncbi-sent-833,an,DT,O
ncbi-sent-833,increased,VBN,O
ncbi-sent-833,risk,NN,O
ncbi-sent-833,of,IN,O
ncbi-sent-833,colorectal,JJ,B-DISEASE
ncbi-sent-833,cancer,NN,I-DISEASE
ncbi-sent-833,",",",",O
ncbi-sent-833,is,VBZ,O
ncbi-sent-833,also,RB,O
ncbi-sent-833,present,JJ,O
ncbi-sent-833,in,IN,O
ncbi-sent-833,this,DT,O
ncbi-sent-833,family,NN,O
ncbi-sent-833,.,.,O
ncbi-sent-834,The,DT,O
ncbi-sent-834,I1307K,NNP,O
ncbi-sent-834,polymorphism,NN,O
ncbi-sent-834,has,VBZ,O
ncbi-sent-834,previously,RB,O
ncbi-sent-834,only,RB,O
ncbi-sent-834,been,VBN,O
ncbi-sent-834,identified,VBN,O
ncbi-sent-834,in,IN,O
ncbi-sent-834,individuals,NNS,O
ncbi-sent-834,of,IN,O
ncbi-sent-834,self,NN,O
ncbi-sent-834,-,:,O
ncbi-sent-834,reported,VBD,O
ncbi-sent-834,Ashkenazi,NNP,O
ncbi-sent-834,Jewish,NNP,O
ncbi-sent-834,origins,NNS,O
ncbi-sent-834,.,.,O
ncbi-sent-835,In,IN,O
ncbi-sent-835,addition,NN,O
ncbi-sent-835,",",",",O
ncbi-sent-835,in,IN,O
ncbi-sent-835,this,DT,O
ncbi-sent-835,family,NN,O
ncbi-sent-835,",",",",O
ncbi-sent-835,there,EX,O
ncbi-sent-835,appears,VBZ,O
ncbi-sent-835,to,TO,O
ncbi-sent-835,be,VB,O
ncbi-sent-835,no,DT,O
ncbi-sent-835,relationship,NN,O
ncbi-sent-835,between,IN,O
ncbi-sent-835,the,DT,O
ncbi-sent-835,I1307K,NNP,O
ncbi-sent-835,polymorphism,NN,O
ncbi-sent-835,and,CC,O
ncbi-sent-835,the,DT,O
ncbi-sent-835,presence,NN,O
ncbi-sent-835,or,CC,O
ncbi-sent-835,absence,NN,O
ncbi-sent-835,of,IN,O
ncbi-sent-835,cancer,NN,B-DISEASE
ncbi-sent-835,.,.,O
ncbi-sent-836,.,.,O
ncbi-sent-837,Identification,NN,O
ncbi-sent-837,of,IN,O
ncbi-sent-837,a,DT,O
ncbi-sent-837,novel,JJ,O
ncbi-sent-837,mutation,NN,O
ncbi-sent-837,of,IN,O
ncbi-sent-837,the,DT,O
ncbi-sent-837,CPO,NNP,O
ncbi-sent-837,gene,NN,O
ncbi-sent-837,in,IN,O
ncbi-sent-837,a,DT,O
ncbi-sent-837,Japanese,JJ,O
ncbi-sent-837,hereditary,JJ,B-DISEASE
ncbi-sent-837,coproporphyria,NNS,I-DISEASE
ncbi-sent-837,family,NN,O
ncbi-sent-837,.,.,O
ncbi-sent-838,Hereditary,JJ,B-DISEASE
ncbi-sent-838,coproporphyria,NN,I-DISEASE
ncbi-sent-838,(,(,O
ncbi-sent-838,HCP,NNP,B-DISEASE
ncbi-sent-838,),),O
ncbi-sent-838,is,VBZ,O
ncbi-sent-838,an,DT,O
ncbi-sent-838,autosomal,JJ,B-DISEASE
ncbi-sent-838,dominant,JJ,I-DISEASE
ncbi-sent-838,disease,NN,I-DISEASE
ncbi-sent-838,characterized,VBN,O
ncbi-sent-838,by,IN,O
ncbi-sent-838,a,DT,O
ncbi-sent-838,deficiency,NN,B-DISEASE
ncbi-sent-838,of,IN,I-DISEASE
ncbi-sent-838,coproporphyrinogen,NN,I-DISEASE
ncbi-sent-838,oxidase,NN,I-DISEASE
ncbi-sent-838,(,(,O
ncbi-sent-838,CPO,NNP,O
ncbi-sent-838,),),O
ncbi-sent-838,caused,VBN,O
ncbi-sent-838,by,IN,O
ncbi-sent-838,a,DT,O
ncbi-sent-838,mutation,NN,O
ncbi-sent-838,in,IN,O
ncbi-sent-838,the,DT,O
ncbi-sent-838,CPO,NNP,O
ncbi-sent-838,gene,NN,O
ncbi-sent-838,.,.,O
ncbi-sent-839,Only,RB,O
ncbi-sent-839,11,CD,O
ncbi-sent-839,mutations,NNS,O
ncbi-sent-839,of,IN,O
ncbi-sent-839,the,DT,O
ncbi-sent-839,gene,NN,O
ncbi-sent-839,have,VBP,O
ncbi-sent-839,been,VBN,O
ncbi-sent-839,reported,VBN,O
ncbi-sent-839,in,IN,O
ncbi-sent-839,HCP,NNP,B-DISEASE
ncbi-sent-839,patients,NNS,O
ncbi-sent-839,.,.,O
ncbi-sent-840,We,PRP,O
ncbi-sent-840,report,VBP,O
ncbi-sent-840,another,DT,O
ncbi-sent-840,mutation,NN,O
ncbi-sent-840,in,IN,O
ncbi-sent-840,a,DT,O
ncbi-sent-840,Japanese,JJ,O
ncbi-sent-840,family,NN,O
ncbi-sent-840,.,.,O
ncbi-sent-841,Polymerase,NNP,O
ncbi-sent-841,chain,NN,O
ncbi-sent-841,reaction,NN,O
ncbi-sent-841,-,:,O
ncbi-sent-841,single,JJ,O
ncbi-sent-841,strand,VBP,O
ncbi-sent-841,conformational,JJ,O
ncbi-sent-841,polymorphism,NN,O
ncbi-sent-841,and,CC,O
ncbi-sent-841,direct,JJ,O
ncbi-sent-841,sequence,NN,O
ncbi-sent-841,analyses,NNS,O
ncbi-sent-841,demonstrated,VBD,O
ncbi-sent-841,a,DT,O
ncbi-sent-841,C,NNP,O
ncbi-sent-841,to,TO,O
ncbi-sent-841,T,NNP,O
ncbi-sent-841,substitution,NN,O
ncbi-sent-841,in,IN,O
ncbi-sent-841,exon,JJ,O
ncbi-sent-841,1,CD,O
ncbi-sent-841,of,IN,O
ncbi-sent-841,the,DT,O
ncbi-sent-841,CPO,NNP,O
ncbi-sent-841,gene,NN,O
ncbi-sent-841,at,IN,O
ncbi-sent-841,nucleotide,JJ,O
ncbi-sent-841,position,NN,O
ncbi-sent-841,85,CD,O
ncbi-sent-841,",",",",O
ncbi-sent-841,which,WDT,O
ncbi-sent-841,lies,VBZ,O
ncbi-sent-841,in,IN,O
ncbi-sent-841,the,DT,O
ncbi-sent-841,putative,JJ,O
ncbi-sent-841,presequence,NN,O
ncbi-sent-841,for,IN,O
ncbi-sent-841,targeting,VBG,O
ncbi-sent-841,to,TO,O
ncbi-sent-841,mitochondria,VB,O
ncbi-sent-841,.,.,O
ncbi-sent-842,This,DT,O
ncbi-sent-842,mutation,NN,O
ncbi-sent-842,changes,VBZ,O
ncbi-sent-842,the,DT,O
ncbi-sent-842,codon,NN,O
ncbi-sent-842,for,IN,O
ncbi-sent-842,glutamine,NN,O
ncbi-sent-842,to,TO,O
ncbi-sent-842,a,DT,O
ncbi-sent-842,termination,NN,O
ncbi-sent-842,codon,NN,O
ncbi-sent-842,at,IN,O
ncbi-sent-842,amino,NN,O
ncbi-sent-842,acid,JJ,O
ncbi-sent-842,position,NN,O
ncbi-sent-842,29,CD,O
ncbi-sent-842,.,.,O
ncbi-sent-843,MaeI,NNP,O
ncbi-sent-843,restriction,NN,O
ncbi-sent-843,analysis,NN,O
ncbi-sent-843,showed,VBD,O
ncbi-sent-843,two,CD,O
ncbi-sent-843,other,JJ,O
ncbi-sent-843,carriers,NNS,O
ncbi-sent-843,in,IN,O
ncbi-sent-843,the,DT,O
ncbi-sent-843,family,NN,O
ncbi-sent-843,.,.,O
ncbi-sent-844,The,DT,O
ncbi-sent-844,C,NNP,O
ncbi-sent-844,-,:,O
ncbi-sent-844,T,NNP,O
ncbi-sent-844,mutation,NN,O
ncbi-sent-844,is,VBZ,O
ncbi-sent-844,located,VBN,O
ncbi-sent-844,within,IN,O
ncbi-sent-844,a,DT,O
ncbi-sent-844,recently,RB,O
ncbi-sent-844,proposed,VBN,O
ncbi-sent-844,putative,JJ,O
ncbi-sent-844,alternative,JJ,O
ncbi-sent-844,translation,NN,O
ncbi-sent-844,initiation,NN,O
ncbi-sent-844,codon,NN,O
ncbi-sent-844,(,(,O
ncbi-sent-844,TIC,NNP,O
ncbi-sent-844,-,:,O
ncbi-sent-844,1,CD,O
ncbi-sent-844,),),O
ncbi-sent-844,",",",",O
ncbi-sent-844,supporting,VBG,O
ncbi-sent-844,that,IN,O
ncbi-sent-844,TIC,NNP,O
ncbi-sent-844,-,:,O
ncbi-sent-844,1,CD,O
ncbi-sent-844,is,VBZ,O
ncbi-sent-844,the,DT,O
ncbi-sent-844,real,JJ,O
ncbi-sent-844,TIC,NNP,O
ncbi-sent-844,rather,RB,O
ncbi-sent-844,than,IN,O
ncbi-sent-844,TIC,NNP,O
ncbi-sent-844,-,:,O
ncbi-sent-844,2,CD,O
ncbi-sent-844,.,.,O
ncbi-sent-845,.,.,O
ncbi-sent-846,Human,JJ,B-DISEASE
ncbi-sent-846,complement,NN,I-DISEASE
ncbi-sent-846,factor,NN,I-DISEASE
ncbi-sent-846,H,NNP,I-DISEASE
ncbi-sent-846,deficiency,NN,I-DISEASE
ncbi-sent-846,associated,VBN,O
ncbi-sent-846,with,IN,O
ncbi-sent-846,hemolytic,JJ,B-DISEASE
ncbi-sent-846,uremic,JJ,I-DISEASE
ncbi-sent-846,syndrome,NN,I-DISEASE
ncbi-sent-846,.,.,O
ncbi-sent-847,This,DT,O
ncbi-sent-847,study,NN,O
ncbi-sent-847,reports,NNS,O
ncbi-sent-847,on,IN,O
ncbi-sent-847,six,CD,O
ncbi-sent-847,cases,NNS,O
ncbi-sent-847,of,IN,O
ncbi-sent-847,deficiency,NN,B-DISEASE
ncbi-sent-847,in,IN,I-DISEASE
ncbi-sent-847,the,DT,I-DISEASE
ncbi-sent-847,human,JJ,I-DISEASE
ncbi-sent-847,complement,NN,I-DISEASE
ncbi-sent-847,regulatory,JJ,I-DISEASE
ncbi-sent-847,protein,NN,I-DISEASE
ncbi-sent-847,Factor,NNP,I-DISEASE
ncbi-sent-847,H,NNP,I-DISEASE
ncbi-sent-847,(,(,O
ncbi-sent-847,FH,NNP,O
ncbi-sent-847,),),O
ncbi-sent-847,in,IN,O
ncbi-sent-847,the,DT,O
ncbi-sent-847,context,NN,O
ncbi-sent-847,of,IN,O
ncbi-sent-847,an,DT,O
ncbi-sent-847,acute,JJ,B-DISEASE
ncbi-sent-847,renal,JJ,I-DISEASE
ncbi-sent-847,disease,NN,I-DISEASE
ncbi-sent-847,.,.,O
ncbi-sent-848,Five,CD,O
ncbi-sent-848,of,IN,O
ncbi-sent-848,the,DT,O
ncbi-sent-848,cases,NNS,O
ncbi-sent-848,were,VBD,O
ncbi-sent-848,observed,VBN,O
ncbi-sent-848,in,IN,O
ncbi-sent-848,children,NNS,O
ncbi-sent-848,presenting,VBG,O
ncbi-sent-848,with,IN,O
ncbi-sent-848,idiopathic,JJ,O
ncbi-sent-848,hemolytic,JJ,B-DISEASE
ncbi-sent-848,uremic,JJ,I-DISEASE
ncbi-sent-848,syndrome,NN,I-DISEASE
ncbi-sent-848,(,(,O
ncbi-sent-848,HUS,NNP,B-DISEASE
ncbi-sent-848,),),O
ncbi-sent-848,.,.,O
ncbi-sent-849,Two,CD,O
ncbi-sent-849,of,IN,O
ncbi-sent-849,the,DT,O
ncbi-sent-849,children,NNS,O
ncbi-sent-849,exhibited,VBD,O
ncbi-sent-849,a,DT,O
ncbi-sent-849,homozygous,JJ,O
ncbi-sent-849,deficiency,NN,O
ncbi-sent-849,characterized,VBN,O
ncbi-sent-849,by,IN,O
ncbi-sent-849,the,DT,O
ncbi-sent-849,absence,NN,O
ncbi-sent-849,of,IN,O
ncbi-sent-849,the,DT,O
ncbi-sent-849,150,CD,O
ncbi-sent-849,-,:,O
ncbi-sent-849,kD,NN,O
ncbi-sent-849,form,NN,O
ncbi-sent-849,of,IN,O
ncbi-sent-849,Factor,NNP,O
ncbi-sent-849,H,NNP,O
ncbi-sent-849,and,CC,O
ncbi-sent-849,the,DT,O
ncbi-sent-849,presence,NN,O
ncbi-sent-849,",",",",O
ncbi-sent-849,upon,IN,O
ncbi-sent-849,immunoblotting,VBG,O
ncbi-sent-849,",",",",O
ncbi-sent-849,of,IN,O
ncbi-sent-849,the,DT,O
ncbi-sent-849,42,CD,O
ncbi-sent-849,-,:,O
ncbi-sent-849,kD,NN,O
ncbi-sent-849,Factor,NNP,O
ncbi-sent-849,H,NNP,O
ncbi-sent-849,-,:,O
ncbi-sent-849,like,IN,O
ncbi-sent-849,protein,NN,O
ncbi-sent-849,1,CD,O
ncbi-sent-849,(,(,O
ncbi-sent-849,FHL,NNP,O
ncbi-sent-849,-,:,O
ncbi-sent-849,1,CD,O
ncbi-sent-849,),),O
ncbi-sent-849,and,CC,O
ncbi-sent-849,other,JJ,O
ncbi-sent-849,FH,NNP,O
ncbi-sent-849,-,:,O
ncbi-sent-849,related,VBN,O
ncbi-sent-849,protein,NN,O
ncbi-sent-849,(,(,O
ncbi-sent-849,FHR,NNP,O
ncbi-sent-849,),),O
ncbi-sent-849,bands,VBZ,O
ncbi-sent-849,.,.,O
ncbi-sent-850,Southern,JJ,O
ncbi-sent-850,blot,NN,O
ncbi-sent-850,and,CC,O
ncbi-sent-850,PCR,NNP,O
ncbi-sent-850,analysis,NN,O
ncbi-sent-850,of,IN,O
ncbi-sent-850,DNA,NN,O
ncbi-sent-850,of,IN,O
ncbi-sent-850,one,CD,O
ncbi-sent-850,patient,NN,O
ncbi-sent-850,with,IN,O
ncbi-sent-850,homozygous,JJ,O
ncbi-sent-850,deficiency,NN,O
ncbi-sent-850,ruled,VBD,O
ncbi-sent-850,out,RP,O
ncbi-sent-850,the,DT,O
ncbi-sent-850,presence,NN,O
ncbi-sent-850,of,IN,O
ncbi-sent-850,a,DT,O
ncbi-sent-850,large,JJ,O
ncbi-sent-850,deletion,NN,O
ncbi-sent-850,of,IN,O
ncbi-sent-850,the,DT,O
ncbi-sent-850,FH,NNP,O
ncbi-sent-850,gene,NN,O
ncbi-sent-850,as,IN,O
ncbi-sent-850,the,DT,O
ncbi-sent-850,underlying,VBG,O
ncbi-sent-850,defect,NN,O
ncbi-sent-850,for,IN,O
ncbi-sent-850,the,DT,O
ncbi-sent-850,deficiency,NN,O
ncbi-sent-850,.,.,O
ncbi-sent-851,The,DT,O
ncbi-sent-851,other,JJ,O
ncbi-sent-851,four,CD,O
ncbi-sent-851,children,NNS,O
ncbi-sent-851,presented,VBN,O
ncbi-sent-851,with,IN,O
ncbi-sent-851,heterozygous,JJ,O
ncbi-sent-851,deficiency,NN,O
ncbi-sent-851,and,CC,O
ncbi-sent-851,exhibited,VBD,O
ncbi-sent-851,a,DT,O
ncbi-sent-851,normal,JJ,O
ncbi-sent-851,immunoblotting,NN,O
ncbi-sent-851,pattern,NN,O
ncbi-sent-851,of,IN,O
ncbi-sent-851,proteins,NNS,O
ncbi-sent-851,of,IN,O
ncbi-sent-851,the,DT,O
ncbi-sent-851,FH,NNP,O
ncbi-sent-851,family,NN,O
ncbi-sent-851,.,.,O
ncbi-sent-852,Factor,NNP,B-DISEASE
ncbi-sent-852,H,NNP,I-DISEASE
ncbi-sent-852,deficiency,NN,I-DISEASE
ncbi-sent-852,is,VBZ,O
ncbi-sent-852,the,DT,O
ncbi-sent-852,only,JJ,O
ncbi-sent-852,complement,NN,B-DISEASE
ncbi-sent-852,deficiency,NN,I-DISEASE
ncbi-sent-852,associated,VBN,O
ncbi-sent-852,with,IN,O
ncbi-sent-852,HUS,NNP,B-DISEASE
ncbi-sent-852,.,.,O
ncbi-sent-853,These,DT,O
ncbi-sent-853,observations,NNS,O
ncbi-sent-853,suggest,VBP,O
ncbi-sent-853,a,DT,O
ncbi-sent-853,role,NN,O
ncbi-sent-853,for,IN,O
ncbi-sent-853,FH,NNP,O
ncbi-sent-853,and,CC,O
ncbi-sent-853,/,NNP,O
ncbi-sent-853,or,CC,O
ncbi-sent-853,FH,NNP,O
ncbi-sent-853,receptors,NNS,O
ncbi-sent-853,in,IN,O
ncbi-sent-853,the,DT,O
ncbi-sent-853,pathogenesis,NN,O
ncbi-sent-853,of,IN,O
ncbi-sent-853,idiopathic,JJ,O
ncbi-sent-853,HUS,NNP,B-DISEASE
ncbi-sent-853,.,.,O
ncbi-sent-854,.,.,O
ncbi-sent-855,Further,JJ,O
ncbi-sent-855,evidence,NN,O
ncbi-sent-855,for,IN,O
ncbi-sent-855,a,DT,O
ncbi-sent-855,major,JJ,O
ncbi-sent-855,ancient,NN,O
ncbi-sent-855,mutation,NN,O
ncbi-sent-855,underlying,VBG,O
ncbi-sent-855,myotonic,JJ,B-DISEASE
ncbi-sent-855,dystrophy,NN,I-DISEASE
ncbi-sent-855,from,IN,O
ncbi-sent-855,linkage,NN,O
ncbi-sent-855,disequilibrium,NN,O
ncbi-sent-855,studies,NNS,O
ncbi-sent-855,in,IN,O
ncbi-sent-855,the,DT,O
ncbi-sent-855,Japanese,JJ,O
ncbi-sent-855,population,NN,O
ncbi-sent-855,.,.,O
ncbi-sent-856,The,DT,O
ncbi-sent-856,myotonic,JJ,B-DISEASE
ncbi-sent-856,dystrophy,NN,I-DISEASE
ncbi-sent-856,(,(,O
ncbi-sent-856,DM,NNP,B-DISEASE
ncbi-sent-856,),),O
ncbi-sent-856,mutation,NN,O
ncbi-sent-856,is,VBZ,O
ncbi-sent-856,an,DT,O
ncbi-sent-856,unstable,JJ,O
ncbi-sent-856,(,(,O
ncbi-sent-856,CTG,NNP,O
ncbi-sent-856,),),O
ncbi-sent-856,n,RB,O
ncbi-sent-856,repeat,NN,O
ncbi-sent-856,",",",",O
ncbi-sent-856,present,NN,O
ncbi-sent-856,at,IN,O
ncbi-sent-856,a,DT,O
ncbi-sent-856,copy,NN,O
ncbi-sent-856,number,NN,O
ncbi-sent-856,of,IN,O
ncbi-sent-856,5,CD,O
ncbi-sent-856,-,:,O
ncbi-sent-856,37,CD,O
ncbi-sent-856,repeats,NNS,O
ncbi-sent-856,on,IN,O
ncbi-sent-856,normal,JJ,O
ncbi-sent-856,chromosomes,NNS,O
ncbi-sent-856,but,CC,O
ncbi-sent-856,amplified,VBD,O
ncbi-sent-856,to,TO,O
ncbi-sent-856,50,CD,O
ncbi-sent-856,-,:,O
ncbi-sent-856,3000,CD,O
ncbi-sent-856,copies,NNS,O
ncbi-sent-856,on,IN,O
ncbi-sent-856,DM,NNP,B-DISEASE
ncbi-sent-856,chromosomes,NNS,O
ncbi-sent-856,.,.,O
ncbi-sent-857,Previous,JJ,O
ncbi-sent-857,findings,NNS,O
ncbi-sent-857,in,IN,O
ncbi-sent-857,Caucasian,JJ,O
ncbi-sent-857,populations,NNS,O
ncbi-sent-857,of,IN,O
ncbi-sent-857,a,DT,O
ncbi-sent-857,DM,NNP,B-DISEASE
ncbi-sent-857,founder,NN,O
ncbi-sent-857,chromosome,NN,O
ncbi-sent-857,raise,VB,O
ncbi-sent-857,a,DT,O
ncbi-sent-857,question,NN,O
ncbi-sent-857,about,IN,O
ncbi-sent-857,the,DT,O
ncbi-sent-857,molecular,JJ,O
ncbi-sent-857,events,NNS,O
ncbi-sent-857,involved,VBN,O
ncbi-sent-857,in,IN,O
ncbi-sent-857,the,DT,O
ncbi-sent-857,expansion,NN,O
ncbi-sent-857,mutation,NN,O
ncbi-sent-857,.,.,O
ncbi-sent-858,To,TO,O
ncbi-sent-858,investigate,VB,O
ncbi-sent-858,whether,IN,O
ncbi-sent-858,a,DT,O
ncbi-sent-858,founder,NN,O
ncbi-sent-858,chromosome,NN,O
ncbi-sent-858,for,IN,O
ncbi-sent-858,the,DT,O
ncbi-sent-858,DM,NNP,B-DISEASE
ncbi-sent-858,mutation,NN,O
ncbi-sent-858,exists,VBZ,O
ncbi-sent-858,in,IN,O
ncbi-sent-858,the,DT,O
ncbi-sent-858,Japanese,JJ,O
ncbi-sent-858,population,NN,O
ncbi-sent-858,",",",",O
ncbi-sent-858,we,PRP,O
ncbi-sent-858,genotyped,VBD,O
ncbi-sent-858,families,NNS,O
ncbi-sent-858,using,VBG,O
ncbi-sent-858,polymorphic,JJ,O
ncbi-sent-858,markers,NNS,O
ncbi-sent-858,near,IN,O
ncbi-sent-858,the,DT,O
ncbi-sent-858,(,(,O
ncbi-sent-858,CTG,NNP,O
ncbi-sent-858,),),O
ncbi-sent-858,n,RB,O
ncbi-sent-858,repeat,JJ,O
ncbi-sent-858,region,NN,O
ncbi-sent-858,and,CC,O
ncbi-sent-858,constructed,VBD,O
ncbi-sent-858,haplotypes,NNS,O
ncbi-sent-858,.,.,O
ncbi-sent-859,Six,CD,O
ncbi-sent-859,different,JJ,O
ncbi-sent-859,haplotypes,NNS,O
ncbi-sent-859,were,VBD,O
ncbi-sent-859,found,VBN,O
ncbi-sent-859,and,CC,O
ncbi-sent-859,DM,NNP,B-DISEASE
ncbi-sent-859,alleles,NNS,O
ncbi-sent-859,were,VBD,O
ncbi-sent-859,always,RB,O
ncbi-sent-859,haplotype,VBN,O
ncbi-sent-859,A,NNP,O
ncbi-sent-859,.,.,O
ncbi-sent-860,To,TO,O
ncbi-sent-860,find,VB,O
ncbi-sent-860,an,DT,O
ncbi-sent-860,origin,NN,O
ncbi-sent-860,of,IN,O
ncbi-sent-860,the,DT,O
ncbi-sent-860,(,(,O
ncbi-sent-860,CTG,NNP,O
ncbi-sent-860,),),O
ncbi-sent-860,n,RB,O
ncbi-sent-860,repeat,JJ,O
ncbi-sent-860,mutation,NN,O
ncbi-sent-860,and,CC,O
ncbi-sent-860,to,TO,O
ncbi-sent-860,investigate,VB,O
ncbi-sent-860,the,DT,O
ncbi-sent-860,mechanism,NN,O
ncbi-sent-860,of,IN,O
ncbi-sent-860,the,DT,O
ncbi-sent-860,expansion,NN,O
ncbi-sent-860,mutation,NN,O
ncbi-sent-860,in,IN,O
ncbi-sent-860,the,DT,O
ncbi-sent-860,Japanese,JJ,O
ncbi-sent-860,population,NN,O
ncbi-sent-860,we,PRP,O
ncbi-sent-860,have,VBP,O
ncbi-sent-860,studied,VBN,O
ncbi-sent-860,90,CD,O
ncbi-sent-860,Japanese,JJ,O
ncbi-sent-860,DM,NNP,B-DISEASE
ncbi-sent-860,families,NNS,O
ncbi-sent-860,comprising,VBG,O
ncbi-sent-860,190,CD,O
ncbi-sent-860,affected,JJ,O
ncbi-sent-860,and,CC,O
ncbi-sent-860,130,CD,O
ncbi-sent-860,unaffected,JJ,O
ncbi-sent-860,members,NNS,O
ncbi-sent-860,.,.,O
ncbi-sent-861,The,DT,O
ncbi-sent-861,results,NNS,O
ncbi-sent-861,suggest,VBP,O
ncbi-sent-861,that,IN,O
ncbi-sent-861,a,DT,O
ncbi-sent-861,few,JJ,O
ncbi-sent-861,common,JJ,O
ncbi-sent-861,ancestral,JJ,O
ncbi-sent-861,mutations,NNS,O
ncbi-sent-861,in,IN,O
ncbi-sent-861,both,DT,O
ncbi-sent-861,Caucasian,NNP,O
ncbi-sent-861,and,CC,O
ncbi-sent-861,Japanese,JJ,O
ncbi-sent-861,populations,NNS,O
ncbi-sent-861,have,VBP,O
ncbi-sent-861,originated,VBN,O
ncbi-sent-861,by,IN,O
ncbi-sent-861,expansion,NN,O
ncbi-sent-861,of,IN,O
ncbi-sent-861,an,DT,O
ncbi-sent-861,ancestral,JJ,O
ncbi-sent-861,n,NN,O
ncbi-sent-861,=,VBD,O
ncbi-sent-861,5,CD,O
ncbi-sent-861,repeat,NN,O
ncbi-sent-861,to,TO,O
ncbi-sent-861,n,VB,O
ncbi-sent-861,=,$,O
ncbi-sent-861,19,CD,O
ncbi-sent-861,-,:,O
ncbi-sent-861,37,CD,O
ncbi-sent-861,copies,NNS,O
ncbi-sent-861,.,.,O
ncbi-sent-862,These,DT,O
ncbi-sent-862,data,NNS,O
ncbi-sent-862,support,NN,O
ncbi-sent-862,multistep,NN,O
ncbi-sent-862,models,NNS,O
ncbi-sent-862,of,IN,O
ncbi-sent-862,triplet,NN,O
ncbi-sent-862,repeat,NN,O
ncbi-sent-862,expansion,NN,O
ncbi-sent-862,that,WDT,O
ncbi-sent-862,have,VBP,O
ncbi-sent-862,been,VBN,O
ncbi-sent-862,proposed,VBN,O
ncbi-sent-862,for,IN,O
ncbi-sent-862,both,DT,O
ncbi-sent-862,DM,NNP,B-DISEASE
ncbi-sent-862,and,CC,O
ncbi-sent-862,Friedreichs,NNP,B-DISEASE
ncbi-sent-862,ataxia,NN,I-DISEASE
ncbi-sent-862,.,.,O
ncbi-sent-863,.,.,O
ncbi-sent-864,The,DT,O
ncbi-sent-864,molecular,JJ,O
ncbi-sent-864,basis,NN,O
ncbi-sent-864,of,IN,O
ncbi-sent-864,C6,NNP,B-DISEASE
ncbi-sent-864,deficiency,NN,I-DISEASE
ncbi-sent-864,in,IN,O
ncbi-sent-864,the,DT,O
ncbi-sent-864,western,JJ,O
ncbi-sent-864,Cape,NNP,O
ncbi-sent-864,",",",",O
ncbi-sent-864,South,NNP,O
ncbi-sent-864,Africa,NNP,O
ncbi-sent-864,.,.,O
ncbi-sent-865,Deficiency,NN,B-DISEASE
ncbi-sent-865,of,IN,I-DISEASE
ncbi-sent-865,the,DT,I-DISEASE
ncbi-sent-865,sixth,JJ,I-DISEASE
ncbi-sent-865,component,NN,I-DISEASE
ncbi-sent-865,of,IN,I-DISEASE
ncbi-sent-865,human,JJ,I-DISEASE
ncbi-sent-865,complement,NN,I-DISEASE
ncbi-sent-865,(,(,O
ncbi-sent-865,C6,NNP,O
ncbi-sent-865,),),O
ncbi-sent-865,has,VBZ,O
ncbi-sent-865,been,VBN,O
ncbi-sent-865,reported,VBN,O
ncbi-sent-865,in,IN,O
ncbi-sent-865,a,DT,O
ncbi-sent-865,number,NN,O
ncbi-sent-865,of,IN,O
ncbi-sent-865,families,NNS,O
ncbi-sent-865,from,IN,O
ncbi-sent-865,the,DT,O
ncbi-sent-865,western,JJ,O
ncbi-sent-865,Cape,NNP,O
ncbi-sent-865,",",",",O
ncbi-sent-865,South,NNP,O
ncbi-sent-865,Africa,NNP,O
ncbi-sent-865,.,.,O
ncbi-sent-866,Meningococcal,NNP,B-DISEASE
ncbi-sent-866,disease,NN,I-DISEASE
ncbi-sent-866,is,VBZ,O
ncbi-sent-866,endemic,JJ,O
ncbi-sent-866,in,IN,O
ncbi-sent-866,the,DT,O
ncbi-sent-866,Cape,NNP,O
ncbi-sent-866,and,CC,O
ncbi-sent-866,almost,RB,O
ncbi-sent-866,all,DT,O
ncbi-sent-866,pedigrees,NNS,O
ncbi-sent-866,of,IN,O
ncbi-sent-866,total,JJ,O
ncbi-sent-866,C6,NNP,B-DISEASE
ncbi-sent-866,deficiency,NN,I-DISEASE
ncbi-sent-866,(,(,O
ncbi-sent-866,C6Q0,NNP,O
ncbi-sent-866,),),O
ncbi-sent-866,have,VBP,O
ncbi-sent-866,been,VBN,O
ncbi-sent-866,ascertained,VBN,O
ncbi-sent-866,because,IN,O
ncbi-sent-866,of,IN,O
ncbi-sent-866,recurrent,JJ,O
ncbi-sent-866,disease,NN,O
ncbi-sent-866,.,.,O
ncbi-sent-867,We,PRP,O
ncbi-sent-867,have,VBP,O
ncbi-sent-867,sequenced,VBN,O
ncbi-sent-867,the,DT,O
ncbi-sent-867,expressed,JJ,O
ncbi-sent-867,exons,NNS,O
ncbi-sent-867,of,IN,O
ncbi-sent-867,the,DT,O
ncbi-sent-867,C6,NNP,O
ncbi-sent-867,gene,NN,O
ncbi-sent-867,from,IN,O
ncbi-sent-867,selected,VBN,O
ncbi-sent-867,cases,NNS,O
ncbi-sent-867,and,CC,O
ncbi-sent-867,have,VBP,O
ncbi-sent-867,found,VBN,O
ncbi-sent-867,three,CD,O
ncbi-sent-867,molecular,JJ,O
ncbi-sent-867,defects,NNS,O
ncbi-sent-867,leading,VBG,O
ncbi-sent-867,to,TO,O
ncbi-sent-867,total,JJ,O
ncbi-sent-867,deficiency,NN,O
ncbi-sent-867,879delG,CD,O
ncbi-sent-867,",",",",O
ncbi-sent-867,which,WDT,O
ncbi-sent-867,is,VBZ,O
ncbi-sent-867,the,DT,O
ncbi-sent-867,common,JJ,O
ncbi-sent-867,defect,NN,O
ncbi-sent-867,in,IN,O
ncbi-sent-867,the,DT,O
ncbi-sent-867,Cape,NNP,O
ncbi-sent-867,and,CC,O
ncbi-sent-867,hitherto,NN,O
ncbi-sent-867,unreported,JJ,O
ncbi-sent-867,",",",",O
ncbi-sent-867,and,CC,O
ncbi-sent-867,1195delC,CD,O
ncbi-sent-867,and,CC,O
ncbi-sent-867,1936delG,CD,O
ncbi-sent-867,",",",",O
ncbi-sent-867,which,WDT,O
ncbi-sent-867,have,VBP,O
ncbi-sent-867,been,VBN,O
ncbi-sent-867,previously,RB,O
ncbi-sent-867,reported,VBN,O
ncbi-sent-867,in,IN,O
ncbi-sent-867,African,NNP,O
ncbi-sent-867,-,:,O
ncbi-sent-867,Americans,NNPS,O
ncbi-sent-867,.,.,O
ncbi-sent-868,We,PRP,O
ncbi-sent-868,also,RB,O
ncbi-sent-868,show,VBP,O
ncbi-sent-868,that,IN,O
ncbi-sent-868,the,DT,O
ncbi-sent-868,879delG,CD,O
ncbi-sent-868,and,CC,O
ncbi-sent-868,1195delC,CD,O
ncbi-sent-868,defects,NNS,O
ncbi-sent-868,are,VBP,O
ncbi-sent-868,associated,VBN,O
ncbi-sent-868,with,IN,O
ncbi-sent-868,characteristic,JJ,O
ncbi-sent-868,C6,NNP,O
ncbi-sent-868,/,NNP,O
ncbi-sent-868,C7,NNP,O
ncbi-sent-868,region,NN,O
ncbi-sent-868,DNA,NNP,O
ncbi-sent-868,marker,NN,O
ncbi-sent-868,haplotypes,NNS,O
ncbi-sent-868,",",",",O
ncbi-sent-868,although,IN,O
ncbi-sent-868,small,JJ,O
ncbi-sent-868,variations,NNS,O
ncbi-sent-868,were,VBD,O
ncbi-sent-868,observed,VBN,O
ncbi-sent-868,.,.,O
ncbi-sent-869,The,DT,O
ncbi-sent-869,1936delG,CD,O
ncbi-sent-869,defect,NN,O
ncbi-sent-869,was,VBD,O
ncbi-sent-869,observed,VBN,O
ncbi-sent-869,only,RB,O
ncbi-sent-869,once,RB,O
ncbi-sent-869,in,IN,O
ncbi-sent-869,the,DT,O
ncbi-sent-869,Cape,NNP,O
ncbi-sent-869,",",",",O
ncbi-sent-869,but,CC,O
ncbi-sent-869,its,PRP$,O
ncbi-sent-869,associated,JJ,O
ncbi-sent-869,haplotype,NN,O
ncbi-sent-869,could,MD,O
ncbi-sent-869,be,VB,O
ncbi-sent-869,deduced,VBN,O
ncbi-sent-869,.,.,O
ncbi-sent-870,The,DT,O
ncbi-sent-870,data,NN,O
ncbi-sent-870,from,IN,O
ncbi-sent-870,the,DT,O
ncbi-sent-870,haplotypes,NNS,O
ncbi-sent-870,indicate,VBP,O
ncbi-sent-870,that,IN,O
ncbi-sent-870,these,DT,O
ncbi-sent-870,three,CD,O
ncbi-sent-870,molecular,NN,O
ncbi-sent-870,defects,NNS,O
ncbi-sent-870,account,VBP,O
ncbi-sent-870,for,IN,O
ncbi-sent-870,the,DT,O
ncbi-sent-870,defects,NNS,O
ncbi-sent-870,in,IN,O
ncbi-sent-870,all,PDT,O
ncbi-sent-870,the,DT,O
ncbi-sent-870,38,CD,O
ncbi-sent-870,unrelated,JJ,O
ncbi-sent-870,C6Q0,NNP,O
ncbi-sent-870,individuals,NNS,O
ncbi-sent-870,we,PRP,O
ncbi-sent-870,have,VBP,O
ncbi-sent-870,studied,VBN,O
ncbi-sent-870,from,IN,O
ncbi-sent-870,the,DT,O
ncbi-sent-870,Cape,NNP,O
ncbi-sent-870,.,.,O
ncbi-sent-871,We,PRP,O
ncbi-sent-871,have,VBP,O
ncbi-sent-871,also,RB,O
ncbi-sent-871,observed,VBN,O
ncbi-sent-871,the,DT,O
ncbi-sent-871,879delG,CD,O
ncbi-sent-871,defect,NN,O
ncbi-sent-871,in,IN,O
ncbi-sent-871,two,CD,O
ncbi-sent-871,Dutch,NNP,O
ncbi-sent-871,C6,NNP,B-DISEASE
ncbi-sent-871,-,:,I-DISEASE
ncbi-sent-871,deficient,NN,I-DISEASE
ncbi-sent-871,kindreds,NNS,O
ncbi-sent-871,",",",",O
ncbi-sent-871,but,CC,O
ncbi-sent-871,the,DT,O
ncbi-sent-871,879delG,CD,O
ncbi-sent-871,defect,NN,O
ncbi-sent-871,in,IN,O
ncbi-sent-871,the,DT,O
ncbi-sent-871,Cape,NNP,O
ncbi-sent-871,probably,RB,O
ncbi-sent-871,did,VBD,O
ncbi-sent-871,not,RB,O
ncbi-sent-871,come,VBN,O
ncbi-sent-871,from,IN,O
ncbi-sent-871,The,DT,O
ncbi-sent-871,Netherlands,NNP,O
ncbi-sent-871,.,.,O
ncbi-sent-872,.,.,O
ncbi-sent-873,Complement,JJ,B-DISEASE
ncbi-sent-873,C7,NNP,I-DISEASE
ncbi-sent-873,deficiency,NN,I-DISEASE
ncbi-sent-873,:,:,O
ncbi-sent-873,seven,CD,O
ncbi-sent-873,further,JJR,O
ncbi-sent-873,molecular,JJ,O
ncbi-sent-873,defects,NNS,O
ncbi-sent-873,and,CC,O
ncbi-sent-873,their,PRP$,O
ncbi-sent-873,associated,VBN,O
ncbi-sent-873,marker,NN,O
ncbi-sent-873,haplotypes,NNS,O
ncbi-sent-873,.,.,O
ncbi-sent-874,Seven,NNP,O
ncbi-sent-874,further,JJ,O
ncbi-sent-874,molecular,JJ,O
ncbi-sent-874,bases,NNS,O
ncbi-sent-874,of,IN,O
ncbi-sent-874,C7,NNP,B-DISEASE
ncbi-sent-874,deficiency,NN,I-DISEASE
ncbi-sent-874,are,VBP,O
ncbi-sent-874,described,VBN,O
ncbi-sent-874,.,.,O
ncbi-sent-875,All,PDT,O
ncbi-sent-875,these,DT,O
ncbi-sent-875,new,JJ,O
ncbi-sent-875,molecular,NN,O
ncbi-sent-875,defects,NNS,O
ncbi-sent-875,involve,VBP,O
ncbi-sent-875,single,JJ,O
ncbi-sent-875,-,:,O
ncbi-sent-875,nucleotide,JJ,O
ncbi-sent-875,events,NNS,O
ncbi-sent-875,",",",",O
ncbi-sent-875,deletions,NNS,O
ncbi-sent-875,and,CC,O
ncbi-sent-875,substitutions,NNS,O
ncbi-sent-875,",",",",O
ncbi-sent-875,some,DT,O
ncbi-sent-875,of,IN,O
ncbi-sent-875,which,WDT,O
ncbi-sent-875,alter,NN,O
ncbi-sent-875,splice,NN,O
ncbi-sent-875,sites,NNS,O
ncbi-sent-875,",",",",O
ncbi-sent-875,and,CC,O
ncbi-sent-875,others,NNS,O
ncbi-sent-875,codons,NNS,O
ncbi-sent-875,.,.,O
ncbi-sent-876,They,PRP,O
ncbi-sent-876,are,VBP,O
ncbi-sent-876,distributed,VBN,O
ncbi-sent-876,along,IN,O
ncbi-sent-876,the,DT,O
ncbi-sent-876,C7,NNP,O
ncbi-sent-876,gene,NN,O
ncbi-sent-876,",",",",O
ncbi-sent-876,but,CC,O
ncbi-sent-876,predominantly,RB,O
ncbi-sent-876,towards,VBZ,O
ncbi-sent-876,the,DT,O
ncbi-sent-876,3,CD,O
ncbi-sent-876,end,NN,O
ncbi-sent-876,.,.,O
ncbi-sent-877,All,DT,O
ncbi-sent-877,were,VBD,O
ncbi-sent-877,found,VBN,O
ncbi-sent-877,in,IN,O
ncbi-sent-877,compound,NN,O
ncbi-sent-877,heterozygous,JJ,O
ncbi-sent-877,individuals,NNS,O
ncbi-sent-877,.,.,O
ncbi-sent-878,The,DT,O
ncbi-sent-878,C6,NNP,O
ncbi-sent-878,/,NNP,O
ncbi-sent-878,C7,NNP,O
ncbi-sent-878,marker,NN,O
ncbi-sent-878,haplotypes,NNS,O
ncbi-sent-878,associated,VBN,O
ncbi-sent-878,with,IN,O
ncbi-sent-878,most,JJS,O
ncbi-sent-878,C7,NNP,B-DISEASE
ncbi-sent-878,defects,NNS,I-DISEASE
ncbi-sent-878,are,VBP,O
ncbi-sent-878,tabulated,VBN,O
ncbi-sent-878,.,.,O
ncbi-sent-879,.,.,O
ncbi-sent-880,A,DT,O
ncbi-sent-880,genome,JJ,O
ncbi-sent-880,-,:,O
ncbi-sent-880,wide,JJ,O
ncbi-sent-880,search,NN,O
ncbi-sent-880,for,IN,O
ncbi-sent-880,chromosomal,JJ,O
ncbi-sent-880,loci,NN,O
ncbi-sent-880,linked,VBN,O
ncbi-sent-880,to,TO,O
ncbi-sent-880,mental,JJ,O
ncbi-sent-880,health,NN,O
ncbi-sent-880,wellness,NN,O
ncbi-sent-880,in,IN,O
ncbi-sent-880,relatives,NNS,O
ncbi-sent-880,at,IN,O
ncbi-sent-880,high,JJ,O
ncbi-sent-880,risk,NN,O
ncbi-sent-880,for,IN,O
ncbi-sent-880,bipolar,JJ,B-DISEASE
ncbi-sent-880,affective,JJ,I-DISEASE
ncbi-sent-880,disorder,NN,I-DISEASE
ncbi-sent-880,among,IN,O
ncbi-sent-880,the,DT,O
ncbi-sent-880,Old,NNP,O
ncbi-sent-880,Order,NNP,O
ncbi-sent-880,Amish,NNP,O
ncbi-sent-880,.,.,O
ncbi-sent-881,Bipolar,NNP,B-DISEASE
ncbi-sent-881,affective,JJ,I-DISEASE
ncbi-sent-881,disorder,NN,I-DISEASE
ncbi-sent-881,(,(,O
ncbi-sent-881,BPAD,NNP,B-DISEASE
ncbi-sent-881,;,:,O
ncbi-sent-881,manic,JJ,B-DISEASE
ncbi-sent-881,-,:,I-DISEASE
ncbi-sent-881,depressive,JJ,I-DISEASE
ncbi-sent-881,illness,NN,I-DISEASE
ncbi-sent-881,),),O
ncbi-sent-881,is,VBZ,O
ncbi-sent-881,characterized,VBN,O
ncbi-sent-881,by,IN,O
ncbi-sent-881,episodes,NNS,O
ncbi-sent-881,of,IN,O
ncbi-sent-881,mania,NN,B-DISEASE
ncbi-sent-881,and,CC,O
ncbi-sent-881,/,NN,O
ncbi-sent-881,or,CC,O
ncbi-sent-881,hypomania,NN,B-DISEASE
ncbi-sent-881,interspersed,VBN,O
ncbi-sent-881,with,IN,O
ncbi-sent-881,periods,NNS,O
ncbi-sent-881,of,IN,O
ncbi-sent-881,depression,NN,B-DISEASE
ncbi-sent-881,.,.,O
ncbi-sent-882,Compelling,JJ,O
ncbi-sent-882,evidence,NN,O
ncbi-sent-882,supports,VBZ,O
ncbi-sent-882,a,DT,O
ncbi-sent-882,significant,JJ,O
ncbi-sent-882,genetic,JJ,O
ncbi-sent-882,component,NN,O
ncbi-sent-882,in,IN,O
ncbi-sent-882,the,DT,O
ncbi-sent-882,susceptibility,NN,O
ncbi-sent-882,to,TO,O
ncbi-sent-882,develop,VB,O
ncbi-sent-882,BPAD,NNP,B-DISEASE
ncbi-sent-882,.,.,O
ncbi-sent-883,To,TO,O
ncbi-sent-883,date,NN,O
ncbi-sent-883,",",",",O
ncbi-sent-883,however,RB,O
ncbi-sent-883,",",",",O
ncbi-sent-883,linkage,NN,O
ncbi-sent-883,studies,NNS,O
ncbi-sent-883,have,VBP,O
ncbi-sent-883,attempted,VBN,O
ncbi-sent-883,only,RB,O
ncbi-sent-883,to,TO,O
ncbi-sent-883,identify,VB,O
ncbi-sent-883,chromosomal,JJ,O
ncbi-sent-883,loci,NN,O
ncbi-sent-883,that,WDT,O
ncbi-sent-883,cause,NN,O
ncbi-sent-883,or,CC,O
ncbi-sent-883,increase,VB,O
ncbi-sent-883,the,DT,O
ncbi-sent-883,risk,NN,O
ncbi-sent-883,of,IN,O
ncbi-sent-883,developing,VBG,O
ncbi-sent-883,BPAD,NNP,B-DISEASE
ncbi-sent-883,.,.,O
ncbi-sent-884,To,TO,O
ncbi-sent-884,determine,VB,O
ncbi-sent-884,whether,IN,O
ncbi-sent-884,there,EX,O
ncbi-sent-884,could,MD,O
ncbi-sent-884,be,VB,O
ncbi-sent-884,protective,JJ,O
ncbi-sent-884,alleles,NNS,O
ncbi-sent-884,that,WDT,O
ncbi-sent-884,prevent,VBP,O
ncbi-sent-884,or,CC,O
ncbi-sent-884,reduce,VB,O
ncbi-sent-884,the,DT,O
ncbi-sent-884,risk,NN,O
ncbi-sent-884,of,IN,O
ncbi-sent-884,developing,VBG,O
ncbi-sent-884,BPAD,NNP,B-DISEASE
ncbi-sent-884,",",",",O
ncbi-sent-884,similar,JJ,O
ncbi-sent-884,to,TO,O
ncbi-sent-884,what,WP,O
ncbi-sent-884,is,VBZ,O
ncbi-sent-884,observed,VBN,O
ncbi-sent-884,in,IN,O
ncbi-sent-884,other,JJ,O
ncbi-sent-884,genetic,JJ,B-DISEASE
ncbi-sent-884,disorders,NNS,I-DISEASE
ncbi-sent-884,",",",",O
ncbi-sent-884,we,PRP,O
ncbi-sent-884,used,VBD,O
ncbi-sent-884,mental,JJ,O
ncbi-sent-884,health,NN,O
ncbi-sent-884,wellness,NN,O
ncbi-sent-884,(,(,O
ncbi-sent-884,absence,NN,O
ncbi-sent-884,of,IN,O
ncbi-sent-884,any,DT,O
ncbi-sent-884,psychiatric,JJ,B-DISEASE
ncbi-sent-884,disorder,NN,I-DISEASE
ncbi-sent-884,),),O
ncbi-sent-884,as,IN,O
ncbi-sent-884,the,DT,O
ncbi-sent-884,phenotype,NN,O
ncbi-sent-884,in,IN,O
ncbi-sent-884,our,PRP$,O
ncbi-sent-884,genome,JJ,O
ncbi-sent-884,-,:,O
ncbi-sent-884,wide,JJ,O
ncbi-sent-884,linkage,NN,O
ncbi-sent-884,scan,NN,O
ncbi-sent-884,of,IN,O
ncbi-sent-884,several,JJ,O
ncbi-sent-884,large,JJ,O
ncbi-sent-884,multigeneration,NN,O
ncbi-sent-884,Old,NNP,O
ncbi-sent-884,Order,NNP,O
ncbi-sent-884,Amish,NNP,O
ncbi-sent-884,pedigrees,NNS,O
ncbi-sent-884,exhibiting,VBG,O
ncbi-sent-884,an,DT,O
ncbi-sent-884,extremely,RB,O
ncbi-sent-884,high,JJ,O
ncbi-sent-884,incidence,NN,O
ncbi-sent-884,of,IN,O
ncbi-sent-884,BPAD,NNP,B-DISEASE
ncbi-sent-884,.,.,O
ncbi-sent-885,We,PRP,O
ncbi-sent-885,have,VBP,O
ncbi-sent-885,found,VBN,O
ncbi-sent-885,strong,JJ,O
ncbi-sent-885,evidence,NN,O
ncbi-sent-885,for,IN,O
ncbi-sent-885,a,DT,O
ncbi-sent-885,locus,NN,O
ncbi-sent-885,on,IN,O
ncbi-sent-885,chromosome,NN,O
ncbi-sent-885,4p,CD,O
ncbi-sent-885,at,IN,O
ncbi-sent-885,D4S2949,NNP,O
ncbi-sent-885,(,(,O
ncbi-sent-885,maximum,JJ,O
ncbi-sent-885,GENEHUNTER,NNP,O
ncbi-sent-885,-,:,O
ncbi-sent-885,PLUS,NNP,O
ncbi-sent-885,nonparametric,JJ,O
ncbi-sent-885,linkage,NN,O
ncbi-sent-885,score,VBD,O
ncbi-sent-885,=,JJ,O
ncbi-sent-885,4,CD,O
ncbi-sent-885,.,.,O
ncbi-sent-886,05,CD,O
ncbi-sent-886,",",",",O
ncbi-sent-886,P,NNP,O
ncbi-sent-886,=,VBZ,O
ncbi-sent-886,5,CD,O
ncbi-sent-886,.,.,O
ncbi-sent-887,22,CD,O
ncbi-sent-887,x,JJ,O
ncbi-sent-887,10,CD,O
ncbi-sent-887,(,(,O
ncbi-sent-887,-,:,O
ncbi-sent-887,4,CD,O
ncbi-sent-887,),),O
ncbi-sent-887,;,:,O
ncbi-sent-887,SIBPAL,NNP,O
ncbi-sent-887,Pempirical,NNP,O
ncbi-sent-887,value,NN,O
ncbi-sent-887,<,VBD,O
ncbi-sent-887,3,CD,O
ncbi-sent-887,x,JJ,O
ncbi-sent-887,10,CD,O
ncbi-sent-887,(,(,O
ncbi-sent-887,-,:,O
ncbi-sent-887,5,CD,O
ncbi-sent-887,),),O
ncbi-sent-887,),),O
ncbi-sent-887,and,CC,O
ncbi-sent-887,suggestive,JJ,O
ncbi-sent-887,evidence,NN,O
ncbi-sent-887,for,IN,O
ncbi-sent-887,a,DT,O
ncbi-sent-887,locus,NN,O
ncbi-sent-887,on,IN,O
ncbi-sent-887,chromosome,NN,O
ncbi-sent-887,4q,CD,O
ncbi-sent-887,at,IN,O
ncbi-sent-887,D4S397,NNP,O
ncbi-sent-887,(,(,O
ncbi-sent-887,maximum,JJ,O
ncbi-sent-887,GENEHUNTER,NNP,O
ncbi-sent-887,-,:,O
ncbi-sent-887,PLUS,NNP,O
ncbi-sent-887,nonparametric,JJ,O
ncbi-sent-887,linkage,NN,O
ncbi-sent-887,score,VBD,O
ncbi-sent-887,=,JJ,O
ncbi-sent-887,3,CD,O
ncbi-sent-887,.,.,O
ncbi-sent-888,29,CD,O
ncbi-sent-888,",",",",O
ncbi-sent-888,P,NNP,O
ncbi-sent-888,=,VBZ,O
ncbi-sent-888,2,CD,O
ncbi-sent-888,.,.,O
ncbi-sent-889,57,CD,O
ncbi-sent-889,x,JJ,O
ncbi-sent-889,10,CD,O
ncbi-sent-889,(,(,O
ncbi-sent-889,-,:,O
ncbi-sent-889,3,CD,O
ncbi-sent-889,),),O
ncbi-sent-889,;,:,O
ncbi-sent-889,SIBPAL,NNP,O
ncbi-sent-889,Pempirical,NNP,O
ncbi-sent-889,value,NN,O
ncbi-sent-889,<,VBD,O
ncbi-sent-889,1,CD,O
ncbi-sent-889,x,JJ,O
ncbi-sent-889,10,CD,O
ncbi-sent-889,(,(,O
ncbi-sent-889,-,:,O
ncbi-sent-889,3,CD,O
ncbi-sent-889,),),O
ncbi-sent-889,),),O
ncbi-sent-889,that,WDT,O
ncbi-sent-889,are,VBP,O
ncbi-sent-889,linked,VBN,O
ncbi-sent-889,to,TO,O
ncbi-sent-889,mental,JJ,O
ncbi-sent-889,health,NN,O
ncbi-sent-889,wellness,NN,O
ncbi-sent-889,.,.,O
ncbi-sent-890,These,DT,O
ncbi-sent-890,findings,NNS,O
ncbi-sent-890,are,VBP,O
ncbi-sent-890,consistent,JJ,O
ncbi-sent-890,with,IN,O
ncbi-sent-890,the,DT,O
ncbi-sent-890,hypothesis,NN,O
ncbi-sent-890,that,WDT,O
ncbi-sent-890,certain,JJ,O
ncbi-sent-890,alleles,NNS,O
ncbi-sent-890,could,MD,O
ncbi-sent-890,prevent,VB,O
ncbi-sent-890,or,CC,O
ncbi-sent-890,modify,VB,O
ncbi-sent-890,the,DT,O
ncbi-sent-890,clinical,JJ,O
ncbi-sent-890,manifestations,NNS,O
ncbi-sent-890,of,IN,O
ncbi-sent-890,BPAD,NNP,B-DISEASE
ncbi-sent-890,and,CC,O
ncbi-sent-890,perhaps,RB,O
ncbi-sent-890,other,JJ,O
ncbi-sent-890,related,JJ,O
ncbi-sent-890,affective,JJ,B-DISEASE
ncbi-sent-890,disorders,NNS,I-DISEASE
ncbi-sent-890,.,.,O
ncbi-sent-891,Segregation,NNP,O
ncbi-sent-891,distortion,NN,O
ncbi-sent-891,in,IN,O
ncbi-sent-891,myotonic,JJ,B-DISEASE
ncbi-sent-891,dystrophy,NN,I-DISEASE
ncbi-sent-891,.,.,O
ncbi-sent-892,Myotonic,JJ,B-DISEASE
ncbi-sent-892,dystrophy,NN,I-DISEASE
ncbi-sent-892,(,(,O
ncbi-sent-892,DM,NNP,B-DISEASE
ncbi-sent-892,),),O
ncbi-sent-892,is,VBZ,O
ncbi-sent-892,an,DT,O
ncbi-sent-892,autosomal,JJ,B-DISEASE
ncbi-sent-892,dominant,NN,I-DISEASE
ncbi-sent-892,disease,NN,I-DISEASE
ncbi-sent-892,which,WDT,O
ncbi-sent-892,",",",",O
ncbi-sent-892,in,IN,O
ncbi-sent-892,the,DT,O
ncbi-sent-892,typical,JJ,O
ncbi-sent-892,pedigree,NN,O
ncbi-sent-892,",",",",O
ncbi-sent-892,shows,VBZ,O
ncbi-sent-892,a,DT,O
ncbi-sent-892,three,CD,O
ncbi-sent-892,generation,NN,O
ncbi-sent-892,anticipation,NN,O
ncbi-sent-892,cascade,NN,O
ncbi-sent-892,.,.,O
ncbi-sent-893,This,DT,O
ncbi-sent-893,results,NNS,O
ncbi-sent-893,in,IN,O
ncbi-sent-893,infertility,NN,B-DISEASE
ncbi-sent-893,and,CC,O
ncbi-sent-893,congenital,JJ,B-DISEASE
ncbi-sent-893,myotonic,JJ,I-DISEASE
ncbi-sent-893,dystrophy,NN,I-DISEASE
ncbi-sent-893,(,(,O
ncbi-sent-893,CDM,NNP,B-DISEASE
ncbi-sent-893,),),O
ncbi-sent-893,with,IN,O
ncbi-sent-893,the,DT,O
ncbi-sent-893,disappearance,NN,O
ncbi-sent-893,of,IN,O
ncbi-sent-893,DM,NNP,B-DISEASE
ncbi-sent-893,in,IN,O
ncbi-sent-893,that,DT,O
ncbi-sent-893,pedigree,NN,O
ncbi-sent-893,.,.,O
ncbi-sent-894,The,DT,O
ncbi-sent-894,concept,NN,O
ncbi-sent-894,of,IN,O
ncbi-sent-894,segregation,NN,O
ncbi-sent-894,distortion,NN,O
ncbi-sent-894,",",",",O
ncbi-sent-894,where,WRB,O
ncbi-sent-894,there,EX,O
ncbi-sent-894,is,VBZ,O
ncbi-sent-894,preferential,JJ,O
ncbi-sent-894,transmission,NN,O
ncbi-sent-894,of,IN,O
ncbi-sent-894,the,DT,O
ncbi-sent-894,larger,JJR,O
ncbi-sent-894,allele,NN,O
ncbi-sent-894,at,IN,O
ncbi-sent-894,the,DT,O
ncbi-sent-894,DM,NNP,B-DISEASE
ncbi-sent-894,locus,NN,O
ncbi-sent-894,",",",",O
ncbi-sent-894,has,VBZ,O
ncbi-sent-894,been,VBN,O
ncbi-sent-894,put,VBN,O
ncbi-sent-894,forward,RB,O
ncbi-sent-894,to,TO,O
ncbi-sent-894,explain,VB,O
ncbi-sent-894,partially,RB,O
ncbi-sent-894,the,DT,O
ncbi-sent-894,maintenance,NN,O
ncbi-sent-894,of,IN,O
ncbi-sent-894,DM,NNP,B-DISEASE
ncbi-sent-894,in,IN,O
ncbi-sent-894,the,DT,O
ncbi-sent-894,population,NN,O
ncbi-sent-894,.,.,O
ncbi-sent-895,In,IN,O
ncbi-sent-895,a,DT,O
ncbi-sent-895,survey,NN,O
ncbi-sent-895,of,IN,O
ncbi-sent-895,DM,NNP,B-DISEASE
ncbi-sent-895,in,IN,O
ncbi-sent-895,Northern,NNP,O
ncbi-sent-895,Ireland,NNP,O
ncbi-sent-895,",",",",O
ncbi-sent-895,59,CD,O
ncbi-sent-895,pedigrees,NNS,O
ncbi-sent-895,were,VBD,O
ncbi-sent-895,ascertained,VBN,O
ncbi-sent-895,.,.,O
ncbi-sent-896,Sibships,NNP,O
ncbi-sent-896,where,WRB,O
ncbi-sent-896,the,DT,O
ncbi-sent-896,status,NN,O
ncbi-sent-896,of,IN,O
ncbi-sent-896,all,PDT,O
ncbi-sent-896,the,DT,O
ncbi-sent-896,members,NNS,O
ncbi-sent-896,had,VBD,O
ncbi-sent-896,been,VBN,O
ncbi-sent-896,identified,VBN,O
ncbi-sent-896,were,VBD,O
ncbi-sent-896,examined,VBN,O
ncbi-sent-896,to,TO,O
ncbi-sent-896,determine,VB,O
ncbi-sent-896,the,DT,O
ncbi-sent-896,transmission,NN,O
ncbi-sent-896,of,IN,O
ncbi-sent-896,the,DT,O
ncbi-sent-896,DM,NNP,B-DISEASE
ncbi-sent-896,expansion,NN,O
ncbi-sent-896,from,IN,O
ncbi-sent-896,affected,JJ,O
ncbi-sent-896,parents,NNS,O
ncbi-sent-896,to,TO,O
ncbi-sent-896,their,PRP$,O
ncbi-sent-896,offspring,NN,O
ncbi-sent-896,.,.,O
ncbi-sent-897,Where,WRB,O
ncbi-sent-897,the,DT,O
ncbi-sent-897,transmitting,NN,O
ncbi-sent-897,parent,NN,O
ncbi-sent-897,was,VBD,O
ncbi-sent-897,male,JJ,O
ncbi-sent-897,",",",",O
ncbi-sent-897,58,CD,O
ncbi-sent-897,.,.,O
ncbi-sent-898,3,CD,O
ncbi-sent-898,%,NN,O
ncbi-sent-898,of,IN,O
ncbi-sent-898,the,DT,O
ncbi-sent-898,offspring,NN,O
ncbi-sent-898,were,VBD,O
ncbi-sent-898,affected,VBN,O
ncbi-sent-898,",",",",O
ncbi-sent-898,and,CC,O
ncbi-sent-898,in,IN,O
ncbi-sent-898,the,DT,O
ncbi-sent-898,case,NN,O
ncbi-sent-898,of,IN,O
ncbi-sent-898,a,DT,O
ncbi-sent-898,female,JJ,O
ncbi-sent-898,transmitting,NN,O
ncbi-sent-898,parent,NN,O
ncbi-sent-898,",",",",O
ncbi-sent-898,68,CD,O
ncbi-sent-898,.,.,O
ncbi-sent-899,7,CD,O
ncbi-sent-899,%,NN,O
ncbi-sent-899,were,VBD,O
ncbi-sent-899,affected,VBN,O
ncbi-sent-899,.,.,O
ncbi-sent-900,Studies,NNS,O
ncbi-sent-900,on,IN,O
ncbi-sent-900,meiotic,JJ,O
ncbi-sent-900,drive,NN,O
ncbi-sent-900,in,IN,O
ncbi-sent-900,DM,NNP,B-DISEASE
ncbi-sent-900,have,VBP,O
ncbi-sent-900,shown,VBN,O
ncbi-sent-900,increased,JJ,O
ncbi-sent-900,transmission,NN,O
ncbi-sent-900,of,IN,O
ncbi-sent-900,the,DT,O
ncbi-sent-900,larger,JJR,O
ncbi-sent-900,allele,NN,O
ncbi-sent-900,at,IN,O
ncbi-sent-900,the,DT,O
ncbi-sent-900,DM,NNP,B-DISEASE
ncbi-sent-900,locus,NN,O
ncbi-sent-900,in,IN,O
ncbi-sent-900,non,JJ,O
ncbi-sent-900,-,:,O
ncbi-sent-900,DM,NN,O
ncbi-sent-900,heterozygotes,NNS,O
ncbi-sent-900,for,IN,O
ncbi-sent-900,CTGn,NNP,O
ncbi-sent-900,.,.,O
ncbi-sent-901,This,DT,O
ncbi-sent-901,study,NN,O
ncbi-sent-901,provides,VBZ,O
ncbi-sent-901,further,JJ,O
ncbi-sent-901,evidence,NN,O
ncbi-sent-901,that,IN,O
ncbi-sent-901,the,DT,O
ncbi-sent-901,DM,NNP,B-DISEASE
ncbi-sent-901,expansion,NN,O
ncbi-sent-901,tends,VBZ,O
ncbi-sent-901,to,TO,O
ncbi-sent-901,be,VB,O
ncbi-sent-901,transmitted,VBN,O
ncbi-sent-901,preferentially,RB,O
ncbi-sent-901,.,.,O
ncbi-sent-902,Diagnosis,NN,O
ncbi-sent-902,of,IN,O
ncbi-sent-902,hemochromatosis,NN,B-DISEASE
ncbi-sent-902,.,.,O
ncbi-sent-903,If,IN,O
ncbi-sent-903,untreated,JJ,O
ncbi-sent-903,",",",",O
ncbi-sent-903,hemochromatosis,NN,B-DISEASE
ncbi-sent-903,can,MD,O
ncbi-sent-903,cause,VB,O
ncbi-sent-903,serious,JJ,O
ncbi-sent-903,illness,NN,O
ncbi-sent-903,and,CC,O
ncbi-sent-903,early,JJ,B-DISEASE
ncbi-sent-903,death,NN,I-DISEASE
ncbi-sent-903,",",",",O
ncbi-sent-903,but,CC,O
ncbi-sent-903,the,DT,O
ncbi-sent-903,disease,NN,O
ncbi-sent-903,is,VBZ,O
ncbi-sent-903,still,RB,O
ncbi-sent-903,substantially,RB,O
ncbi-sent-903,under,IN,O
ncbi-sent-903,-,:,O
ncbi-sent-903,diagnosed,VBN,O
ncbi-sent-903,.,.,O
ncbi-sent-904,The,DT,O
ncbi-sent-904,cornerstone,NN,O
ncbi-sent-904,of,IN,O
ncbi-sent-904,screening,NN,O
ncbi-sent-904,and,CC,O
ncbi-sent-904,case,NN,O
ncbi-sent-904,detection,NN,O
ncbi-sent-904,is,VBZ,O
ncbi-sent-904,the,DT,O
ncbi-sent-904,measurement,NN,O
ncbi-sent-904,of,IN,O
ncbi-sent-904,serum,NN,O
ncbi-sent-904,transferrin,NN,O
ncbi-sent-904,saturation,NN,O
ncbi-sent-904,and,CC,O
ncbi-sent-904,the,DT,O
ncbi-sent-904,serum,NN,O
ncbi-sent-904,ferritin,NN,O
ncbi-sent-904,level,NN,O
ncbi-sent-904,.,.,O
ncbi-sent-905,Once,IN,O
ncbi-sent-905,the,DT,O
ncbi-sent-905,diagnosis,NN,O
ncbi-sent-905,is,VBZ,O
ncbi-sent-905,suspected,VBN,O
ncbi-sent-905,",",",",O
ncbi-sent-905,physicians,NNS,O
ncbi-sent-905,must,MD,O
ncbi-sent-905,use,VB,O
ncbi-sent-905,serum,JJ,O
ncbi-sent-905,ferritin,NN,O
ncbi-sent-905,levels,NNS,O
ncbi-sent-905,and,CC,O
ncbi-sent-905,hepatic,JJ,O
ncbi-sent-905,iron,NN,O
ncbi-sent-905,stores,NNS,O
ncbi-sent-905,on,IN,O
ncbi-sent-905,liver,NN,O
ncbi-sent-905,biopsy,NN,O
ncbi-sent-905,specimens,VBZ,O
ncbi-sent-905,to,TO,O
ncbi-sent-905,assess,VB,O
ncbi-sent-905,patients,NNS,O
ncbi-sent-905,for,IN,O
ncbi-sent-905,the,DT,O
ncbi-sent-905,presence,NN,O
ncbi-sent-905,of,IN,O
ncbi-sent-905,iron,NN,B-DISEASE
ncbi-sent-905,overload,NN,I-DISEASE
ncbi-sent-905,.,.,O
ncbi-sent-906,Liver,NNP,O
ncbi-sent-906,biopsy,NN,O
ncbi-sent-906,is,VBZ,O
ncbi-sent-906,also,RB,O
ncbi-sent-906,used,VBN,O
ncbi-sent-906,to,TO,O
ncbi-sent-906,establish,VB,O
ncbi-sent-906,the,DT,O
ncbi-sent-906,presence,NN,O
ncbi-sent-906,or,CC,O
ncbi-sent-906,absence,NN,O
ncbi-sent-906,of,IN,O
ncbi-sent-906,cirrhosis,NN,B-DISEASE
ncbi-sent-906,",",",",O
ncbi-sent-906,which,WDT,O
ncbi-sent-906,can,MD,O
ncbi-sent-906,affect,VB,O
ncbi-sent-906,prognosis,NN,O
ncbi-sent-906,and,CC,O
ncbi-sent-906,management,NN,O
ncbi-sent-906,.,.,O
ncbi-sent-907,A,DT,O
ncbi-sent-907,DNA,NNP,O
ncbi-sent-907,-,:,O
ncbi-sent-907,based,VBN,O
ncbi-sent-907,test,NN,O
ncbi-sent-907,for,IN,O
ncbi-sent-907,the,DT,O
ncbi-sent-907,HFE,NNP,O
ncbi-sent-907,gene,NN,O
ncbi-sent-907,is,VBZ,O
ncbi-sent-907,commercially,RB,O
ncbi-sent-907,available,JJ,O
ncbi-sent-907,",",",",O
ncbi-sent-907,but,CC,O
ncbi-sent-907,its,PRP$,O
ncbi-sent-907,place,NN,O
ncbi-sent-907,in,IN,O
ncbi-sent-907,the,DT,O
ncbi-sent-907,diagnosis,NN,O
ncbi-sent-907,of,IN,O
ncbi-sent-907,hemochromatosis,NN,B-DISEASE
ncbi-sent-907,is,VBZ,O
ncbi-sent-907,still,RB,O
ncbi-sent-907,being,VBG,O
ncbi-sent-907,evaluated,VBN,O
ncbi-sent-907,.,.,O
ncbi-sent-908,Currently,RB,O
ncbi-sent-908,",",",",O
ncbi-sent-908,the,DT,O
ncbi-sent-908,most,RBS,O
ncbi-sent-908,useful,JJ,O
ncbi-sent-908,role,NN,O
ncbi-sent-908,for,IN,O
ncbi-sent-908,this,DT,O
ncbi-sent-908,test,NN,O
ncbi-sent-908,is,VBZ,O
ncbi-sent-908,in,IN,O
ncbi-sent-908,the,DT,O
ncbi-sent-908,detection,NN,O
ncbi-sent-908,of,IN,O
ncbi-sent-908,hemochromatosis,NN,B-DISEASE
ncbi-sent-908,in,IN,O
ncbi-sent-908,the,DT,O
ncbi-sent-908,family,NN,O
ncbi-sent-908,members,NNS,O
ncbi-sent-908,of,IN,O
ncbi-sent-908,patients,NNS,O
ncbi-sent-908,with,IN,O
ncbi-sent-908,a,DT,O
ncbi-sent-908,proven,JJ,O
ncbi-sent-908,case,NN,O
ncbi-sent-908,of,IN,O
ncbi-sent-908,the,DT,O
ncbi-sent-908,disease,NN,O
ncbi-sent-908,.,.,O
ncbi-sent-909,It,PRP,O
ncbi-sent-909,is,VBZ,O
ncbi-sent-909,crucial,JJ,O
ncbi-sent-909,to,TO,O
ncbi-sent-909,diagnose,VB,O
ncbi-sent-909,hemochromatosis,NN,B-DISEASE
ncbi-sent-909,before,IN,O
ncbi-sent-909,hepatic,JJ,B-DISEASE
ncbi-sent-909,cirrhosis,NN,I-DISEASE
ncbi-sent-909,develops,VBZ,O
ncbi-sent-909,because,IN,O
ncbi-sent-909,phlebotomy,JJ,O
ncbi-sent-909,therapy,NN,O
ncbi-sent-909,can,MD,O
ncbi-sent-909,avert,VB,O
ncbi-sent-909,serious,JJ,O
ncbi-sent-909,chronic,JJ,O
ncbi-sent-909,disease,NN,O
ncbi-sent-909,and,CC,O
ncbi-sent-909,can,MD,O
ncbi-sent-909,even,RB,O
ncbi-sent-909,lead,VB,O
ncbi-sent-909,to,TO,O
ncbi-sent-909,normal,JJ,O
ncbi-sent-909,life,NN,O
ncbi-sent-909,expectancy,NN,O
ncbi-sent-909,.,.,O
ncbi-sent-910,.,.,O
ncbi-sent-911,Prevalence,NN,O
ncbi-sent-911,of,IN,O
ncbi-sent-911,the,DT,O
ncbi-sent-911,I1307K,NNP,O
ncbi-sent-911,APC,NNP,B-DISEASE
ncbi-sent-911,gene,NN,O
ncbi-sent-911,variant,NN,O
ncbi-sent-911,in,IN,O
ncbi-sent-911,Israeli,NNP,O
ncbi-sent-911,Jews,NNP,O
ncbi-sent-911,of,IN,O
ncbi-sent-911,differing,VBG,O
ncbi-sent-911,ethnic,JJ,O
ncbi-sent-911,origin,NN,O
ncbi-sent-911,and,CC,O
ncbi-sent-911,risk,NN,O
ncbi-sent-911,for,IN,O
ncbi-sent-911,colorectal,JJ,B-DISEASE
ncbi-sent-911,cancer,NN,I-DISEASE
ncbi-sent-911,.,.,O
ncbi-sent-912,BACKGROUND,NNP,O
ncbi-sent-912,&,CC,O
ncbi-sent-912,AIMS,NNP,O
ncbi-sent-912,Israeli,NNP,O
ncbi-sent-912,Jews,NNP,O
ncbi-sent-912,of,IN,O
ncbi-sent-912,European,NNP,O
ncbi-sent-912,birth,NN,O
ncbi-sent-912,",",",",O
ncbi-sent-912,i,NN,O
ncbi-sent-912,.,.,O
ncbi-sent-913,e,NN,O
ncbi-sent-913,.,.,O
ncbi-sent-914,",",",",O
ncbi-sent-914,Ashkenazim,NNP,O
ncbi-sent-914,",",",",O
ncbi-sent-914,have,VBP,O
ncbi-sent-914,the,DT,O
ncbi-sent-914,highest,JJS,O
ncbi-sent-914,colorectal,JJ,B-DISEASE
ncbi-sent-914,cancer,NN,I-DISEASE
ncbi-sent-914,incidence,NN,O
ncbi-sent-914,of,IN,O
ncbi-sent-914,any,DT,O
ncbi-sent-914,Israeli,NNP,O
ncbi-sent-914,ethnic,JJ,O
ncbi-sent-914,group,NN,O
ncbi-sent-914,.,.,O
ncbi-sent-915,The,DT,O
ncbi-sent-915,I1307K,NNP,O
ncbi-sent-915,APC,NNP,B-DISEASE
ncbi-sent-915,gene,NN,O
ncbi-sent-915,variant,NN,O
ncbi-sent-915,was,VBD,O
ncbi-sent-915,found,VBN,O
ncbi-sent-915,in,IN,O
ncbi-sent-915,6,CD,O
ncbi-sent-915,.,.,O
ncbi-sent-916,1,CD,O
ncbi-sent-916,%,NN,O
ncbi-sent-916,of,IN,O
ncbi-sent-916,American,JJ,O
ncbi-sent-916,Jews,NNP,O
ncbi-sent-916,",",",",O
ncbi-sent-916,28,CD,O
ncbi-sent-916,%,NN,O
ncbi-sent-916,of,IN,O
ncbi-sent-916,their,PRP$,O
ncbi-sent-916,familial,JJ,O
ncbi-sent-916,colorectal,NN,B-DISEASE
ncbi-sent-916,cancer,NN,I-DISEASE
ncbi-sent-916,cases,NNS,O
ncbi-sent-916,",",",",O
ncbi-sent-916,but,CC,O
ncbi-sent-916,not,RB,O
ncbi-sent-916,in,IN,O
ncbi-sent-916,non,JJ,O
ncbi-sent-916,-,:,O
ncbi-sent-916,Jews,NNPS,O
ncbi-sent-916,.,.,O
ncbi-sent-917,We,PRP,O
ncbi-sent-917,assessed,VBD,O
ncbi-sent-917,the,DT,O
ncbi-sent-917,I1307K,NNP,O
ncbi-sent-917,prevalence,NN,O
ncbi-sent-917,in,IN,O
ncbi-sent-917,Israeli,NNP,O
ncbi-sent-917,Jews,NNP,O
ncbi-sent-917,of,IN,O
ncbi-sent-917,differing,VBG,O
ncbi-sent-917,ethnic,JJ,O
ncbi-sent-917,origin,NN,O
ncbi-sent-917,and,CC,O
ncbi-sent-917,risk,NN,O
ncbi-sent-917,for,IN,O
ncbi-sent-917,colorectal,JJ,B-DISEASE
ncbi-sent-917,cancer,NN,I-DISEASE
ncbi-sent-917,.,.,O
ncbi-sent-918,METHODS,NNP,O
ncbi-sent-918,DNA,NNP,O
ncbi-sent-918,samples,NNS,O
ncbi-sent-918,from,IN,O
ncbi-sent-918,500,CD,O
ncbi-sent-918,unrelated,JJ,O
ncbi-sent-918,Jews,NNPS,O
ncbi-sent-918,of,IN,O
ncbi-sent-918,European,JJ,O
ncbi-sent-918,or,CC,O
ncbi-sent-918,non,JJ,O
ncbi-sent-918,-,:,O
ncbi-sent-918,European,JJ,O
ncbi-sent-918,origin,NN,O
ncbi-sent-918,",",",",O
ncbi-sent-918,with,IN,O
ncbi-sent-918,or,CC,O
ncbi-sent-918,without,IN,O
ncbi-sent-918,a,DT,O
ncbi-sent-918,personal,JJ,O
ncbi-sent-918,and,CC,O
ncbi-sent-918,/,JJ,O
ncbi-sent-918,or,CC,O
ncbi-sent-918,family,NN,O
ncbi-sent-918,history,NN,O
ncbi-sent-918,of,IN,O
ncbi-sent-918,neoplasia,NN,B-DISEASE
ncbi-sent-918,",",",",O
ncbi-sent-918,were,VBD,O
ncbi-sent-918,examined,VBN,O
ncbi-sent-918,for,IN,O
ncbi-sent-918,the,DT,O
ncbi-sent-918,I1307K,NNP,O
ncbi-sent-918,variant,NN,O
ncbi-sent-918,by,IN,O
ncbi-sent-918,the,DT,O
ncbi-sent-918,allele,NN,O
ncbi-sent-918,-,:,O
ncbi-sent-918,specific,JJ,O
ncbi-sent-918,oligonucleotide,NN,O
ncbi-sent-918,(,(,O
ncbi-sent-918,ASO,NNP,O
ncbi-sent-918,),),O
ncbi-sent-918,method,NN,O
ncbi-sent-918,.,.,O
ncbi-sent-919,RESULTS,NNP,O
ncbi-sent-919,In,IN,O
ncbi-sent-919,persons,NNS,O
ncbi-sent-919,at,IN,O
ncbi-sent-919,average,JJ,O
ncbi-sent-919,risk,NN,O
ncbi-sent-919,for,IN,O
ncbi-sent-919,colorectal,JJ,B-DISEASE
ncbi-sent-919,cancer,NN,I-DISEASE
ncbi-sent-919,",",",",O
ncbi-sent-919,I1307K,NNP,O
ncbi-sent-919,was,VBD,O
ncbi-sent-919,found,VBN,O
ncbi-sent-919,in,IN,O
ncbi-sent-919,5,CD,O
ncbi-sent-919,.,.,O
ncbi-sent-920,0,CD,O
ncbi-sent-920,%,NN,O
ncbi-sent-920,of,IN,O
ncbi-sent-920,120,CD,O
ncbi-sent-920,European,JJ,O
ncbi-sent-920,and,CC,O
ncbi-sent-920,1,CD,O
ncbi-sent-920,.,.,O
ncbi-sent-921,6,CD,O
ncbi-sent-921,%,NN,O
ncbi-sent-921,of,IN,O
ncbi-sent-921,188,CD,O
ncbi-sent-921,non,JJ,O
ncbi-sent-921,-,:,O
ncbi-sent-921,European,JJ,O
ncbi-sent-921,Jews,NNP,O
ncbi-sent-921,(,(,O
ncbi-sent-921,P,NNP,O
ncbi-sent-921,=,VBZ,O
ncbi-sent-921,0,CD,O
ncbi-sent-921,.,.,O
ncbi-sent-922,08,CD,O
ncbi-sent-922,),),O
ncbi-sent-922,.,.,O
ncbi-sent-923,It,PRP,O
ncbi-sent-923,occurred,VBD,O
ncbi-sent-923,in,IN,O
ncbi-sent-923,15,CD,O
ncbi-sent-923,.,.,O
ncbi-sent-924,4,CD,O
ncbi-sent-924,%,NN,O
ncbi-sent-924,of,IN,O
ncbi-sent-924,52,CD,O
ncbi-sent-924,Ashkenazi,NNP,O
ncbi-sent-924,Israelis,NNP,O
ncbi-sent-924,with,IN,O
ncbi-sent-924,familial,JJ,O
ncbi-sent-924,cancer,NN,B-DISEASE
ncbi-sent-924,(,(,O
ncbi-sent-924,P,NNP,O
ncbi-sent-924,=,VBZ,O
ncbi-sent-924,0,CD,O
ncbi-sent-924,.,.,O
ncbi-sent-925,02,CD,O
ncbi-sent-925,),),O
ncbi-sent-925,and,CC,O
ncbi-sent-925,was,VBD,O
ncbi-sent-925,not,RB,O
ncbi-sent-925,detected,VBN,O
ncbi-sent-925,in,IN,O
ncbi-sent-925,51,CD,O
ncbi-sent-925,non,JJ,O
ncbi-sent-925,-,:,O
ncbi-sent-925,European,JJ,O
ncbi-sent-925,Jews,NNP,O
ncbi-sent-925,at,IN,O
ncbi-sent-925,increased,JJ,O
ncbi-sent-925,cancer,NN,B-DISEASE
ncbi-sent-925,risk,NN,O
ncbi-sent-925,.,.,O
ncbi-sent-926,Colorectal,NNP,B-DISEASE
ncbi-sent-926,neoplasia,RB,I-DISEASE
ncbi-sent-926,occurred,VBD,O
ncbi-sent-926,personally,RB,O
ncbi-sent-926,or,CC,O
ncbi-sent-926,in,IN,O
ncbi-sent-926,the,DT,O
ncbi-sent-926,families,NNS,O
ncbi-sent-926,of,IN,O
ncbi-sent-926,13,CD,O
ncbi-sent-926,of,IN,O
ncbi-sent-926,20,CD,O
ncbi-sent-926,Ashkenazi,NNP,O
ncbi-sent-926,I1307K,NNP,O
ncbi-sent-926,carriers,NNS,O
ncbi-sent-926,",",",",O
ncbi-sent-926,8,CD,O
ncbi-sent-926,of,IN,O
ncbi-sent-926,whom,WP,O
ncbi-sent-926,also,RB,O
ncbi-sent-926,had,VBD,O
ncbi-sent-926,a,DT,O
ncbi-sent-926,personal,JJ,O
ncbi-sent-926,or,CC,O
ncbi-sent-926,family,NN,O
ncbi-sent-926,history,NN,O
ncbi-sent-926,of,IN,O
ncbi-sent-926,noncolonic,JJ,O
ncbi-sent-926,neoplasia,NN,B-DISEASE
ncbi-sent-926,.,.,O
ncbi-sent-927,CONCLUSIONS,VB,O
ncbi-sent-927,The,DT,O
ncbi-sent-927,I1307K,NNP,O
ncbi-sent-927,APC,NNP,O
ncbi-sent-927,variant,NN,O
ncbi-sent-927,may,MD,O
ncbi-sent-927,represent,VB,O
ncbi-sent-927,a,DT,O
ncbi-sent-927,susceptibility,NN,O
ncbi-sent-927,gene,NN,O
ncbi-sent-927,for,IN,O
ncbi-sent-927,colorectal,JJ,B-DISEASE
ncbi-sent-927,",",",",I-DISEASE
ncbi-sent-927,or,CC,I-DISEASE
ncbi-sent-927,other,JJ,I-DISEASE
ncbi-sent-927,",",",",I-DISEASE
ncbi-sent-927,cancers,NNS,I-DISEASE
ncbi-sent-927,in,IN,O
ncbi-sent-927,Ashkenazi,NNP,O
ncbi-sent-927,Jews,NNP,O
ncbi-sent-927,",",",",O
ncbi-sent-927,and,CC,O
ncbi-sent-927,partially,RB,O
ncbi-sent-927,explains,VBZ,O
ncbi-sent-927,the,DT,O
ncbi-sent-927,higher,JJR,O
ncbi-sent-927,incidence,NN,O
ncbi-sent-927,of,IN,O
ncbi-sent-927,colorectal,JJ,B-DISEASE
ncbi-sent-927,cancer,NN,I-DISEASE
ncbi-sent-927,in,IN,O
ncbi-sent-927,European,JJ,O
ncbi-sent-927,Israelis,NNP,O
ncbi-sent-927,.,.,O
ncbi-sent-928,Systematic,JJ,O
ncbi-sent-928,analysis,NN,O
ncbi-sent-928,of,IN,O
ncbi-sent-928,coproporphyrinogen,NN,O
ncbi-sent-928,oxidase,NN,O
ncbi-sent-928,gene,NN,O
ncbi-sent-928,defects,NNS,O
ncbi-sent-928,in,IN,O
ncbi-sent-928,hereditary,JJ,B-DISEASE
ncbi-sent-928,coproporphyria,NNS,I-DISEASE
ncbi-sent-928,and,CC,O
ncbi-sent-928,mutation,NN,O
ncbi-sent-928,update,NN,O
ncbi-sent-928,.,.,O
ncbi-sent-929,Hereditary,JJ,B-DISEASE
ncbi-sent-929,coproporphyria,NN,I-DISEASE
ncbi-sent-929,(,(,O
ncbi-sent-929,HC,NNP,B-DISEASE
ncbi-sent-929,),),O
ncbi-sent-929,is,VBZ,O
ncbi-sent-929,an,DT,O
ncbi-sent-929,acute,JJ,O
ncbi-sent-929,hepatic,JJ,B-DISEASE
ncbi-sent-929,porphyria,NN,I-DISEASE
ncbi-sent-929,with,IN,O
ncbi-sent-929,autosomal,JJ,O
ncbi-sent-929,dominant,JJ,O
ncbi-sent-929,inheritance,NN,O
ncbi-sent-929,caused,VBN,O
ncbi-sent-929,by,IN,O
ncbi-sent-929,deficient,JJ,B-DISEASE
ncbi-sent-929,activity,NN,I-DISEASE
ncbi-sent-929,of,IN,I-DISEASE
ncbi-sent-929,coproporphyrinogen,NN,I-DISEASE
ncbi-sent-929,III,NNP,I-DISEASE
ncbi-sent-929,oxidase,NN,I-DISEASE
ncbi-sent-929,(,(,O
ncbi-sent-929,CPO,NNP,O
ncbi-sent-929,),),O
ncbi-sent-929,.,.,O
ncbi-sent-930,Clinical,JJ,O
ncbi-sent-930,manifestations,NNS,O
ncbi-sent-930,of,IN,O
ncbi-sent-930,the,DT,O
ncbi-sent-930,disease,NN,O
ncbi-sent-930,are,VBP,O
ncbi-sent-930,characterized,VBN,O
ncbi-sent-930,by,IN,O
ncbi-sent-930,acute,JJ,O
ncbi-sent-930,attacks,NNS,O
ncbi-sent-930,of,IN,O
ncbi-sent-930,neurological,JJ,B-DISEASE
ncbi-sent-930,dysfunction,NN,I-DISEASE
ncbi-sent-930,often,RB,O
ncbi-sent-930,precipitated,VBN,O
ncbi-sent-930,by,IN,O
ncbi-sent-930,drugs,NNS,O
ncbi-sent-930,",",",",O
ncbi-sent-930,fasting,NN,O
ncbi-sent-930,",",",",O
ncbi-sent-930,cyclical,JJ,O
ncbi-sent-930,hormonal,NN,O
ncbi-sent-930,changes,NNS,O
ncbi-sent-930,",",",",O
ncbi-sent-930,or,CC,O
ncbi-sent-930,infectious,JJ,B-DISEASE
ncbi-sent-930,diseases,NNS,I-DISEASE
ncbi-sent-930,.,.,O
ncbi-sent-931,Skin,NNP,O
ncbi-sent-931,photosensitivity,NN,O
ncbi-sent-931,may,MD,O
ncbi-sent-931,also,RB,O
ncbi-sent-931,be,VB,O
ncbi-sent-931,present,JJ,O
ncbi-sent-931,.,.,O
ncbi-sent-932,The,DT,O
ncbi-sent-932,seven,CD,O
ncbi-sent-932,exons,NNS,O
ncbi-sent-932,",",",",O
ncbi-sent-932,the,DT,O
ncbi-sent-932,exon,NN,O
ncbi-sent-932,/,NNP,O
ncbi-sent-932,intron,NN,O
ncbi-sent-932,boundaries,NNS,O
ncbi-sent-932,and,CC,O
ncbi-sent-932,part,NN,O
ncbi-sent-932,of,IN,O
ncbi-sent-932,3,CD,O
ncbi-sent-932,noncoding,VBG,O
ncbi-sent-932,sequence,NN,O
ncbi-sent-932,of,IN,O
ncbi-sent-932,the,DT,O
ncbi-sent-932,CPO,NNP,O
ncbi-sent-932,gene,NN,O
ncbi-sent-932,were,VBD,O
ncbi-sent-932,systematically,RB,O
ncbi-sent-932,analyzed,VBN,O
ncbi-sent-932,by,IN,O
ncbi-sent-932,an,DT,O
ncbi-sent-932,exon,JJ,O
ncbi-sent-932,-,:,O
ncbi-sent-932,by,IN,O
ncbi-sent-932,-,:,O
ncbi-sent-932,exon,NN,O
ncbi-sent-932,denaturing,VBG,O
ncbi-sent-932,gradient,JJ,O
ncbi-sent-932,gel,NN,O
ncbi-sent-932,electrophoresis,NN,O
ncbi-sent-932,(,(,O
ncbi-sent-932,DGGE,NNP,O
ncbi-sent-932,),),O
ncbi-sent-932,strategy,NN,O
ncbi-sent-932,followed,VBN,O
ncbi-sent-932,by,IN,O
ncbi-sent-932,direct,JJ,O
ncbi-sent-932,sequencing,NN,O
ncbi-sent-932,in,IN,O
ncbi-sent-932,seven,CD,O
ncbi-sent-932,unrelated,JJ,O
ncbi-sent-932,heterozygous,JJ,O
ncbi-sent-932,HC,NNP,B-DISEASE
ncbi-sent-932,patients,NNS,O
ncbi-sent-932,from,IN,O
ncbi-sent-932,France,NNP,O
ncbi-sent-932,",",",",O
ncbi-sent-932,Holland,NNP,O
ncbi-sent-932,",",",",O
ncbi-sent-932,and,CC,O
ncbi-sent-932,Czech,NNP,O
ncbi-sent-932,Republic,NNP,O
ncbi-sent-932,.,.,O
ncbi-sent-933,Seven,NNP,O
ncbi-sent-933,novel,JJ,O
ncbi-sent-933,mutations,NNS,O
ncbi-sent-933,and,CC,O
ncbi-sent-933,two,CD,O
ncbi-sent-933,new,JJ,O
ncbi-sent-933,polymorphisms,NNS,O
ncbi-sent-933,were,VBD,O
ncbi-sent-933,detected,VBN,O
ncbi-sent-933,.,.,O
ncbi-sent-934,Among,IN,O
ncbi-sent-934,these,DT,O
ncbi-sent-934,mutations,NNS,O
ncbi-sent-934,two,CD,O
ncbi-sent-934,are,VBP,O
ncbi-sent-934,missense,JJ,O
ncbi-sent-934,(,(,O
ncbi-sent-934,G197W,NNP,O
ncbi-sent-934,",",",",O
ncbi-sent-934,W427R,NNP,O
ncbi-sent-934,),),O
ncbi-sent-934,",",",",O
ncbi-sent-934,two,CD,O
ncbi-sent-934,are,VBP,O
ncbi-sent-934,nonsense,JJ,O
ncbi-sent-934,(,(,O
ncbi-sent-934,Q306X,NNP,O
ncbi-sent-934,",",",",O
ncbi-sent-934,Q385X,NNP,O
ncbi-sent-934,),),O
ncbi-sent-934,",",",",O
ncbi-sent-934,two,CD,O
ncbi-sent-934,are,VBP,O
ncbi-sent-934,small,JJ,O
ncbi-sent-934,deletions,NNS,O
ncbi-sent-934,(,(,O
ncbi-sent-934,662de14bp,CD,O
ncbi-sent-934,;,:,O
ncbi-sent-934,1168del3bp,CD,O
ncbi-sent-934,removing,VBG,O
ncbi-sent-934,a,DT,O
ncbi-sent-934,glycine,NN,O
ncbi-sent-934,at,IN,O
ncbi-sent-934,position,NN,O
ncbi-sent-934,390,CD,O
ncbi-sent-934,),),O
ncbi-sent-934,",",",",O
ncbi-sent-934,and,CC,O
ncbi-sent-934,one,CD,O
ncbi-sent-934,is,VBZ,O
ncbi-sent-934,a,DT,O
ncbi-sent-934,splicing,VBG,O
ncbi-sent-934,mutation,NN,O
ncbi-sent-934,(,(,O
ncbi-sent-934,IVS1,NNP,O
ncbi-sent-934,-,:,O
ncbi-sent-934,15c,CD,O
ncbi-sent-934,-,:,O
ncbi-sent-934,-,:,O
ncbi-sent-934,>,NN,O
ncbi-sent-934,g,NN,O
ncbi-sent-934,),),O
ncbi-sent-934,which,WDT,O
ncbi-sent-934,creates,VBZ,O
ncbi-sent-934,a,DT,O
ncbi-sent-934,new,JJ,O
ncbi-sent-934,acceptor,NN,O
ncbi-sent-934,splice,NN,O
ncbi-sent-934,site,NN,O
ncbi-sent-934,.,.,O
ncbi-sent-935,The,DT,O
ncbi-sent-935,pathological,JJ,O
ncbi-sent-935,significance,NN,O
ncbi-sent-935,of,IN,O
ncbi-sent-935,the,DT,O
ncbi-sent-935,point,NN,O
ncbi-sent-935,mutations,NNS,O
ncbi-sent-935,G197W,NNP,O
ncbi-sent-935,",",",",O
ncbi-sent-935,W427R,NNP,O
ncbi-sent-935,",",",",O
ncbi-sent-935,and,CC,O
ncbi-sent-935,the,DT,O
ncbi-sent-935,in,IN,O
ncbi-sent-935,-,:,O
ncbi-sent-935,frame,NN,O
ncbi-sent-935,deletion,NN,O
ncbi-sent-935,390delGly,CD,O
ncbi-sent-935,were,VBD,O
ncbi-sent-935,assessed,VBN,O
ncbi-sent-935,by,IN,O
ncbi-sent-935,their,PRP$,O
ncbi-sent-935,respective,JJ,O
ncbi-sent-935,expression,NN,O
ncbi-sent-935,in,IN,O
ncbi-sent-935,a,DT,O
ncbi-sent-935,prokaryotic,JJ,O
ncbi-sent-935,system,NN,O
ncbi-sent-935,using,VBG,O
ncbi-sent-935,site,NN,O
ncbi-sent-935,-,:,O
ncbi-sent-935,directed,JJ,O
ncbi-sent-935,mutagenesis,NN,O
ncbi-sent-935,.,.,O
ncbi-sent-936,These,DT,O
ncbi-sent-936,mutations,NNS,O
ncbi-sent-936,resulted,VBD,O
ncbi-sent-936,in,IN,O
ncbi-sent-936,the,DT,O
ncbi-sent-936,absence,NN,O
ncbi-sent-936,or,CC,O
ncbi-sent-936,a,DT,O
ncbi-sent-936,dramatic,JJ,O
ncbi-sent-936,decrease,NN,O
ncbi-sent-936,of,IN,O
ncbi-sent-936,CPO,NNP,O
ncbi-sent-936,activity,NN,O
ncbi-sent-936,.,.,O
ncbi-sent-937,The,DT,O
ncbi-sent-937,two,CD,O
ncbi-sent-937,polymorphisms,NNS,O
ncbi-sent-937,were,VBD,O
ncbi-sent-937,localized,VBN,O
ncbi-sent-937,in,IN,O
ncbi-sent-937,noncoding,VBG,O
ncbi-sent-937,part,NN,O
ncbi-sent-937,of,IN,O
ncbi-sent-937,the,DT,O
ncbi-sent-937,gene,NN,O
ncbi-sent-937,1,CD,O
ncbi-sent-937,),),O
ncbi-sent-937,a,DT,O
ncbi-sent-937,C,NNP,O
ncbi-sent-937,/,NNP,O
ncbi-sent-937,G,NNP,O
ncbi-sent-937,polymorphism,NN,O
ncbi-sent-937,in,IN,O
ncbi-sent-937,the,DT,O
ncbi-sent-937,promotor,NN,O
ncbi-sent-937,region,NN,O
ncbi-sent-937,",",",",O
ncbi-sent-937,142,CD,O
ncbi-sent-937,bp,NN,O
ncbi-sent-937,upstream,NN,O
ncbi-sent-937,from,IN,O
ncbi-sent-937,the,DT,O
ncbi-sent-937,transcriptional,JJ,O
ncbi-sent-937,initiation,NN,O
ncbi-sent-937,site,NN,O
ncbi-sent-937,(,(,O
ncbi-sent-937,-,:,O
ncbi-sent-937,142C,CD,O
ncbi-sent-937,/,NNP,O
ncbi-sent-937,G,NNP,O
ncbi-sent-937,),),O
ncbi-sent-937,",",",",O
ncbi-sent-937,and,CC,O
ncbi-sent-937,2,CD,O
ncbi-sent-937,),),O
ncbi-sent-937,a,DT,O
ncbi-sent-937,6,CD,O
ncbi-sent-937,bp,NN,O
ncbi-sent-937,deletion,NN,O
ncbi-sent-937,polymorphism,NN,O
ncbi-sent-937,in,IN,O
ncbi-sent-937,the,DT,O
ncbi-sent-937,3,CD,O
ncbi-sent-937,noncoding,JJ,O
ncbi-sent-937,part,NN,O
ncbi-sent-937,of,IN,O
ncbi-sent-937,the,DT,O
ncbi-sent-937,CPO,NNP,O
ncbi-sent-937,gene,NN,O
ncbi-sent-937,",",",",O
ncbi-sent-937,574,CD,O
ncbi-sent-937,bp,NN,O
ncbi-sent-937,downstream,NN,O
ncbi-sent-937,of,IN,O
ncbi-sent-937,the,DT,O
ncbi-sent-937,last,JJ,O
ncbi-sent-937,base,NN,O
ncbi-sent-937,of,IN,O
ncbi-sent-937,the,DT,O
ncbi-sent-937,normal,JJ,O
ncbi-sent-937,termination,NN,O
ncbi-sent-937,codon,NN,O
ncbi-sent-937,(,(,O
ncbi-sent-937,+,JJ,O
ncbi-sent-937,574,CD,O
ncbi-sent-937,delATTCTT,NN,O
ncbi-sent-937,),),O
ncbi-sent-937,.,.,O
ncbi-sent-938,Five,CD,O
ncbi-sent-938,intragenic,JJ,O
ncbi-sent-938,dimorphisms,NNS,O
ncbi-sent-938,are,VBP,O
ncbi-sent-938,now,RB,O
ncbi-sent-938,well,RB,O
ncbi-sent-938,characterized,VBN,O
ncbi-sent-938,and,CC,O
ncbi-sent-938,the,DT,O
ncbi-sent-938,high,JJ,O
ncbi-sent-938,degree,NN,O
ncbi-sent-938,of,IN,O
ncbi-sent-938,allelic,JJ,O
ncbi-sent-938,heterogeneity,NN,O
ncbi-sent-938,in,IN,O
ncbi-sent-938,HC,NNP,B-DISEASE
ncbi-sent-938,is,VBZ,O
ncbi-sent-938,demonstrated,VBN,O
ncbi-sent-938,with,IN,O
ncbi-sent-938,seven,CD,O
ncbi-sent-938,new,JJ,O
ncbi-sent-938,different,JJ,O
ncbi-sent-938,mutations,NNS,O
ncbi-sent-938,making,VBG,O
ncbi-sent-938,a,DT,O
ncbi-sent-938,total,NN,O
ncbi-sent-938,of,IN,O
ncbi-sent-938,nineteen,JJ,O
ncbi-sent-938,CPO,NNP,O
ncbi-sent-938,gene,NN,B-DISEASE
ncbi-sent-938,defects,NNS,I-DISEASE
ncbi-sent-938,reported,VBN,O
ncbi-sent-938,so,RB,O
ncbi-sent-938,far,RB,O
ncbi-sent-938,.,.,O
ncbi-sent-939,.,.,O
ncbi-sent-940,Coincidence,NN,O
ncbi-sent-940,of,IN,O
ncbi-sent-940,two,CD,O
ncbi-sent-940,novel,JJ,O
ncbi-sent-940,arylsulfatase,VBD,O
ncbi-sent-940,A,NNP,O
ncbi-sent-940,alleles,NNS,O
ncbi-sent-940,and,CC,O
ncbi-sent-940,mutation,NN,O
ncbi-sent-940,459,CD,O
ncbi-sent-940,+,NN,O
ncbi-sent-940,1G,CD,O
ncbi-sent-940,>,NN,O
ncbi-sent-940,A,NNP,O
ncbi-sent-940,within,IN,O
ncbi-sent-940,a,DT,O
ncbi-sent-940,family,NN,O
ncbi-sent-940,with,IN,O
ncbi-sent-940,metachromatic,JJ,B-DISEASE
ncbi-sent-940,leukodystrophy,NN,I-DISEASE
ncbi-sent-940,:,:,O
ncbi-sent-940,molecular,JJ,O
ncbi-sent-940,basis,NN,O
ncbi-sent-940,of,IN,O
ncbi-sent-940,phenotypic,NN,O
ncbi-sent-940,heterogeneity,NN,O
ncbi-sent-940,.,.,O
ncbi-sent-941,In,IN,O
ncbi-sent-941,a,DT,O
ncbi-sent-941,family,NN,O
ncbi-sent-941,with,IN,O
ncbi-sent-941,three,CD,O
ncbi-sent-941,siblings,NNS,O
ncbi-sent-941,",",",",O
ncbi-sent-941,one,CD,O
ncbi-sent-941,developed,VBD,O
ncbi-sent-941,classical,JJ,O
ncbi-sent-941,late,RB,O
ncbi-sent-941,infantile,JJ,O
ncbi-sent-941,metachromatic,JJ,B-DISEASE
ncbi-sent-941,leukodystrophy,NN,I-DISEASE
ncbi-sent-941,(,(,O
ncbi-sent-941,MLD,NNP,B-DISEASE
ncbi-sent-941,),),O
ncbi-sent-941,",",",",O
ncbi-sent-941,fatal,JJ,O
ncbi-sent-941,at,IN,O
ncbi-sent-941,age,NN,O
ncbi-sent-941,5,CD,O
ncbi-sent-941,years,NNS,O
ncbi-sent-941,",",",",O
ncbi-sent-941,with,IN,O
ncbi-sent-941,deficient,JJ,O
ncbi-sent-941,arylsulfatase,NN,O
ncbi-sent-941,A,NNP,O
ncbi-sent-941,(,(,O
ncbi-sent-941,ARSA,NNP,O
ncbi-sent-941,),),O
ncbi-sent-941,activity,NN,O
ncbi-sent-941,and,CC,O
ncbi-sent-941,increased,VBD,O
ncbi-sent-941,galactosylsulfatide,NN,O
ncbi-sent-941,(,(,O
ncbi-sent-941,GS,NNP,O
ncbi-sent-941,),),O
ncbi-sent-941,excretion,NN,O
ncbi-sent-941,.,.,O
ncbi-sent-942,The,DT,O
ncbi-sent-942,two,CD,O
ncbi-sent-942,other,JJ,O
ncbi-sent-942,siblings,NNS,O
ncbi-sent-942,",",",",O
ncbi-sent-942,apparently,RB,O
ncbi-sent-942,healthy,JJ,O
ncbi-sent-942,at,IN,O
ncbi-sent-942,12,CD,O
ncbi-sent-942,(,(,O
ncbi-sent-942,1,CD,O
ncbi-sent-942,/,RB,O
ncbi-sent-942,2,CD,O
ncbi-sent-942,),),O
ncbi-sent-942,and,CC,O
ncbi-sent-942,15,CD,O
ncbi-sent-942,years,NNS,O
ncbi-sent-942,",",",",O
ncbi-sent-942,respectively,RB,O
ncbi-sent-942,",",",",O
ncbi-sent-942,and,CC,O
ncbi-sent-942,their,PRP$,O
ncbi-sent-942,father,NN,O
ncbi-sent-942,",",",",O
ncbi-sent-942,apparently,RB,O
ncbi-sent-942,healthy,JJ,O
ncbi-sent-942,as,RB,O
ncbi-sent-942,well,RB,O
ncbi-sent-942,",",",",O
ncbi-sent-942,presented,VBN,O
ncbi-sent-942,ARSA,NNP,O
ncbi-sent-942,and,CC,O
ncbi-sent-942,GS,NNP,O
ncbi-sent-942,values,NNS,O
ncbi-sent-942,within,IN,O
ncbi-sent-942,the,DT,O
ncbi-sent-942,range,NN,O
ncbi-sent-942,of,IN,O
ncbi-sent-942,MLD,NNP,B-DISEASE
ncbi-sent-942,patients,NNS,O
ncbi-sent-942,.,.,O
ncbi-sent-943,Mutation,NNP,O
ncbi-sent-943,screening,NN,O
ncbi-sent-943,and,CC,O
ncbi-sent-943,sequence,NN,O
ncbi-sent-943,analysis,NN,O
ncbi-sent-943,disclosed,VBD,O
ncbi-sent-943,the,DT,O
ncbi-sent-943,involvement,NN,O
ncbi-sent-943,of,IN,O
ncbi-sent-943,three,CD,O
ncbi-sent-943,different,JJ,O
ncbi-sent-943,ARSA,NNP,O
ncbi-sent-943,mutations,NNS,O
ncbi-sent-943,being,VBG,O
ncbi-sent-943,the,DT,O
ncbi-sent-943,molecular,JJ,O
ncbi-sent-943,basis,NN,O
ncbi-sent-943,of,IN,O
ncbi-sent-943,intrafamilial,JJ,O
ncbi-sent-943,phenotypic,NN,O
ncbi-sent-943,heterogeneity,NN,O
ncbi-sent-943,.,.,O
ncbi-sent-944,The,DT,O
ncbi-sent-944,late,JJ,O
ncbi-sent-944,infantile,NN,O
ncbi-sent-944,patient,NN,O
ncbi-sent-944,inherited,VBN,O
ncbi-sent-944,from,IN,O
ncbi-sent-944,his,PRP$,O
ncbi-sent-944,mother,NN,O
ncbi-sent-944,the,DT,O
ncbi-sent-944,frequent,NN,O
ncbi-sent-944,0,CD,O
ncbi-sent-944,-,:,O
ncbi-sent-944,type,NN,O
ncbi-sent-944,mutation,NN,O
ncbi-sent-944,459,CD,O
ncbi-sent-944,+,NN,O
ncbi-sent-944,1G,CD,O
ncbi-sent-944,>,NN,O
ncbi-sent-944,A,NNP,O
ncbi-sent-944,",",",",O
ncbi-sent-944,and,CC,O
ncbi-sent-944,from,IN,O
ncbi-sent-944,his,PRP$,O
ncbi-sent-944,father,NN,O
ncbi-sent-944,a,DT,O
ncbi-sent-944,novel,NN,O
ncbi-sent-944,",",",",O
ncbi-sent-944,single,JJ,O
ncbi-sent-944,basepair,NN,O
ncbi-sent-944,microdeletion,NN,O
ncbi-sent-944,of,IN,O
ncbi-sent-944,guanine,NN,O
ncbi-sent-944,at,IN,O
ncbi-sent-944,nucleotide,JJ,O
ncbi-sent-944,7,CD,O
ncbi-sent-944,in,IN,O
ncbi-sent-944,exon,NN,O
ncbi-sent-944,1,CD,O
ncbi-sent-944,(,(,O
ncbi-sent-944,7delG,CD,O
ncbi-sent-944,),),O
ncbi-sent-944,.,.,O
ncbi-sent-945,The,DT,O
ncbi-sent-945,two,CD,O
ncbi-sent-945,clinically,RB,O
ncbi-sent-945,unaffected,JJ,O
ncbi-sent-945,siblings,NNS,O
ncbi-sent-945,carried,VBD,O
ncbi-sent-945,the,DT,O
ncbi-sent-945,maternal,JJ,O
ncbi-sent-945,mutation,NN,O
ncbi-sent-945,459,CD,O
ncbi-sent-945,+,NN,O
ncbi-sent-945,1G,CD,O
ncbi-sent-945,>,NN,O
ncbi-sent-945,A,DT,O
ncbi-sent-945,and,CC,O
ncbi-sent-945,",",",",O
ncbi-sent-945,on,IN,O
ncbi-sent-945,their,PRP$,O
ncbi-sent-945,paternal,JJ,O
ncbi-sent-945,allele,NN,O
ncbi-sent-945,",",",",O
ncbi-sent-945,a,DT,O
ncbi-sent-945,novel,JJ,O
ncbi-sent-945,cytosine,NN,O
ncbi-sent-945,to,TO,O
ncbi-sent-945,thymidine,VB,O
ncbi-sent-945,transition,NN,O
ncbi-sent-945,at,IN,O
ncbi-sent-945,nucleotide,JJ,O
ncbi-sent-945,2435,CD,O
ncbi-sent-945,in,IN,O
ncbi-sent-945,exon,JJ,O
ncbi-sent-945,8,CD,O
ncbi-sent-945,",",",",O
ncbi-sent-945,resulting,VBG,O
ncbi-sent-945,in,IN,O
ncbi-sent-945,substitution,NN,O
ncbi-sent-945,of,IN,O
ncbi-sent-945,alanine,JJ,O
ncbi-sent-945,464,CD,O
ncbi-sent-945,by,IN,O
ncbi-sent-945,valine,NN,O
ncbi-sent-945,(,(,O
ncbi-sent-945,A464V,NNP,O
ncbi-sent-945,),),O
ncbi-sent-945,.,.,O
ncbi-sent-946,The,DT,O
ncbi-sent-946,fathers,NNS,O
ncbi-sent-946,genotype,VBP,O
ncbi-sent-946,thus,RB,O
ncbi-sent-946,was,VBD,O
ncbi-sent-946,7delG,CD,O
ncbi-sent-946,/,JJ,O
ncbi-sent-946,A464V,NNP,O
ncbi-sent-946,.,.,O
ncbi-sent-947,Mutation,NNP,O
ncbi-sent-947,A464V,NNP,O
ncbi-sent-947,was,VBD,O
ncbi-sent-947,not,RB,O
ncbi-sent-947,found,VBN,O
ncbi-sent-947,in,IN,O
ncbi-sent-947,18,CD,O
ncbi-sent-947,unrelated,JJ,O
ncbi-sent-947,MLD,NNP,B-DISEASE
ncbi-sent-947,patients,NNS,O
ncbi-sent-947,and,CC,O
ncbi-sent-947,50,CD,O
ncbi-sent-947,controls,NNS,O
ncbi-sent-947,.,.,O
ncbi-sent-948,A464V,NNP,O
ncbi-sent-948,",",",",O
ncbi-sent-948,although,IN,O
ncbi-sent-948,clearly,RB,O
ncbi-sent-948,modifying,VBG,O
ncbi-sent-948,ARSA,NNP,O
ncbi-sent-948,and,CC,O
ncbi-sent-948,GS,NNP,O
ncbi-sent-948,levels,NNS,O
ncbi-sent-948,",",",",O
ncbi-sent-948,apparently,RB,O
ncbi-sent-948,bears,VBZ,O
ncbi-sent-948,little,JJ,O
ncbi-sent-948,significance,NN,O
ncbi-sent-948,for,IN,O
ncbi-sent-948,clinical,JJ,O
ncbi-sent-948,manifestation,NN,O
ncbi-sent-948,of,IN,O
ncbi-sent-948,MLD,NNP,B-DISEASE
ncbi-sent-948,",",",",O
ncbi-sent-948,mimicking,VBG,O
ncbi-sent-948,the,DT,O
ncbi-sent-948,frequent,JJ,O
ncbi-sent-948,ARSA,NNP,O
ncbi-sent-948,pseudodeficiency,NN,O
ncbi-sent-948,allele,NN,O
ncbi-sent-948,.,.,O
ncbi-sent-949,Our,PRP$,O
ncbi-sent-949,results,NNS,O
ncbi-sent-949,demonstrate,VBP,O
ncbi-sent-949,that,IN,O
ncbi-sent-949,in,IN,O
ncbi-sent-949,certain,JJ,O
ncbi-sent-949,genetic,JJ,O
ncbi-sent-949,conditions,NNS,O
ncbi-sent-949,MLD,NNP,B-DISEASE
ncbi-sent-949,-,:,O
ncbi-sent-949,like,IN,O
ncbi-sent-949,ARSA,NNP,O
ncbi-sent-949,and,CC,O
ncbi-sent-949,GS,NNP,O
ncbi-sent-949,values,NNS,O
ncbi-sent-949,need,VBP,O
ncbi-sent-949,not,RB,O
ncbi-sent-949,be,VB,O
ncbi-sent-949,paralleled,VBN,O
ncbi-sent-949,by,IN,O
ncbi-sent-949,clinical,JJ,O
ncbi-sent-949,disease,NN,O
ncbi-sent-949,",",",",O
ncbi-sent-949,a,DT,O
ncbi-sent-949,finding,NN,O
ncbi-sent-949,with,IN,O
ncbi-sent-949,serious,JJ,O
ncbi-sent-949,diagnostic,JJ,O
ncbi-sent-949,and,CC,O
ncbi-sent-949,prognostic,JJ,O
ncbi-sent-949,implications,NNS,O
ncbi-sent-949,.,.,O
ncbi-sent-950,Moreover,RB,O
ncbi-sent-950,",",",",O
ncbi-sent-950,further,JJ,O
ncbi-sent-950,ARSA,NNP,O
ncbi-sent-950,alleles,NNS,O
ncbi-sent-950,functionally,RB,O
ncbi-sent-950,similar,JJ,O
ncbi-sent-950,to,TO,O
ncbi-sent-950,A464V,VB,O
ncbi-sent-950,might,MD,O
ncbi-sent-950,exist,VB,O
ncbi-sent-950,which,WDT,O
ncbi-sent-950,",",",",O
ncbi-sent-950,together,RB,O
ncbi-sent-950,with,IN,O
ncbi-sent-950,0,CD,O
ncbi-sent-950,-,:,O
ncbi-sent-950,type,NN,O
ncbi-sent-950,mutations,NNS,O
ncbi-sent-950,",",",",O
ncbi-sent-950,may,MD,O
ncbi-sent-950,cause,VB,O
ncbi-sent-950,pathological,JJ,O
ncbi-sent-950,ARSA,NNP,O
ncbi-sent-950,and,CC,O
ncbi-sent-950,GS,NNP,O
ncbi-sent-950,levels,NNS,O
ncbi-sent-950,",",",",O
ncbi-sent-950,but,CC,O
ncbi-sent-950,not,RB,O
ncbi-sent-950,clinical,JJ,O
ncbi-sent-950,outbreak,NN,O
ncbi-sent-950,of,IN,O
ncbi-sent-950,the,DT,O
ncbi-sent-950,disease,NN,O
ncbi-sent-950,.,.,O
ncbi-sent-951,.,.,O
ncbi-sent-952,Human,NNP,O
ncbi-sent-952,MLH1,NNP,O
ncbi-sent-952,deficiency,NN,O
ncbi-sent-952,predisposes,NNS,O
ncbi-sent-952,to,TO,O
ncbi-sent-952,hematological,JJ,B-DISEASE
ncbi-sent-952,malignancy,NN,I-DISEASE
ncbi-sent-952,and,CC,O
ncbi-sent-952,neurofibromatosis,NN,B-DISEASE
ncbi-sent-952,type,NN,I-DISEASE
ncbi-sent-952,1,CD,I-DISEASE
ncbi-sent-952,.,.,O
ncbi-sent-953,Heterozygous,JJ,O
ncbi-sent-953,germ,JJ,O
ncbi-sent-953,-,:,O
ncbi-sent-953,line,NN,O
ncbi-sent-953,mutations,NNS,O
ncbi-sent-953,in,IN,O
ncbi-sent-953,the,DT,O
ncbi-sent-953,DNA,NNP,O
ncbi-sent-953,mismatch,NN,O
ncbi-sent-953,repair,NN,O
ncbi-sent-953,genes,NNS,O
ncbi-sent-953,lead,VBP,O
ncbi-sent-953,to,TO,O
ncbi-sent-953,hereditary,JJ,B-DISEASE
ncbi-sent-953,nonpolyposis,NN,I-DISEASE
ncbi-sent-953,colorectal,JJ,I-DISEASE
ncbi-sent-953,cancer,NN,I-DISEASE
ncbi-sent-953,.,.,O
ncbi-sent-954,The,DT,O
ncbi-sent-954,disease,NN,O
ncbi-sent-954,susceptibility,NN,O
ncbi-sent-954,of,IN,O
ncbi-sent-954,individuals,NNS,O
ncbi-sent-954,who,WP,O
ncbi-sent-954,constitutionally,RB,O
ncbi-sent-954,lack,VBP,O
ncbi-sent-954,both,DT,O
ncbi-sent-954,wild,JJ,O
ncbi-sent-954,-,:,O
ncbi-sent-954,type,NN,O
ncbi-sent-954,alleles,NNS,O
ncbi-sent-954,is,VBZ,O
ncbi-sent-954,unknown,JJ,O
ncbi-sent-954,.,.,O
ncbi-sent-955,We,PRP,O
ncbi-sent-955,have,VBP,O
ncbi-sent-955,identified,VBN,O
ncbi-sent-955,three,CD,O
ncbi-sent-955,offspring,VBG,O
ncbi-sent-955,in,IN,O
ncbi-sent-955,a,DT,O
ncbi-sent-955,hereditary,JJ,B-DISEASE
ncbi-sent-955,nonpolyposis,NN,I-DISEASE
ncbi-sent-955,colorectal,NN,I-DISEASE
ncbi-sent-955,cancer,NN,I-DISEASE
ncbi-sent-955,family,NN,O
ncbi-sent-955,who,WP,O
ncbi-sent-955,developed,VBD,O
ncbi-sent-955,hematological,JJ,B-DISEASE
ncbi-sent-955,malignancy,NN,I-DISEASE
ncbi-sent-955,at,IN,O
ncbi-sent-955,a,DT,O
ncbi-sent-955,very,RB,O
ncbi-sent-955,early,JJ,O
ncbi-sent-955,age,NN,O
ncbi-sent-955,",",",",O
ncbi-sent-955,and,CC,O
ncbi-sent-955,at,IN,O
ncbi-sent-955,least,JJS,O
ncbi-sent-955,two,CD,O
ncbi-sent-955,of,IN,O
ncbi-sent-955,them,PRP,O
ncbi-sent-955,displayed,VBD,O
ncbi-sent-955,signs,NNS,O
ncbi-sent-955,of,IN,O
ncbi-sent-955,neurofibromatosis,NN,B-DISEASE
ncbi-sent-955,type,NN,I-DISEASE
ncbi-sent-955,1,CD,I-DISEASE
ncbi-sent-955,(,(,O
ncbi-sent-955,NF1,NNP,B-DISEASE
ncbi-sent-955,),),O
ncbi-sent-955,.,.,O
ncbi-sent-956,DNA,NN,O
ncbi-sent-956,sequence,NN,O
ncbi-sent-956,analysis,NN,O
ncbi-sent-956,and,CC,O
ncbi-sent-956,allele,VB,O
ncbi-sent-956,-,:,O
ncbi-sent-956,specific,JJ,O
ncbi-sent-956,amplification,NN,O
ncbi-sent-956,in,IN,O
ncbi-sent-956,two,CD,O
ncbi-sent-956,siblings,NNS,O
ncbi-sent-956,revealed,VBD,O
ncbi-sent-956,a,DT,O
ncbi-sent-956,homozygous,JJ,O
ncbi-sent-956,MLH1,NNP,O
ncbi-sent-956,mutation,NN,O
ncbi-sent-956,(,(,O
ncbi-sent-956,C676T,NNP,O
ncbi-sent-956,-,:,O
ncbi-sent-956,-,:,O
ncbi-sent-956,>,NN,O
ncbi-sent-956,Arg226Stop,NNP,O
ncbi-sent-956,),),O
ncbi-sent-956,.,.,O
ncbi-sent-957,Thus,RB,O
ncbi-sent-957,",",",",O
ncbi-sent-957,a,DT,O
ncbi-sent-957,homozygous,JJ,O
ncbi-sent-957,germ,NN,O
ncbi-sent-957,-,:,O
ncbi-sent-957,line,NN,O
ncbi-sent-957,MLH1,NNP,O
ncbi-sent-957,mutation,NN,O
ncbi-sent-957,and,CC,O
ncbi-sent-957,consequent,JJ,O
ncbi-sent-957,mismatch,NN,O
ncbi-sent-957,repair,NN,O
ncbi-sent-957,deficiency,NN,O
ncbi-sent-957,results,NNS,O
ncbi-sent-957,in,IN,O
ncbi-sent-957,a,DT,O
ncbi-sent-957,mutator,NN,O
ncbi-sent-957,phenotype,NN,O
ncbi-sent-957,characterized,VBN,O
ncbi-sent-957,by,IN,O
ncbi-sent-957,leukemia,NN,B-DISEASE
ncbi-sent-957,and,CC,O
ncbi-sent-957,/,NN,O
ncbi-sent-957,or,CC,O
ncbi-sent-957,lymphoma,NN,B-DISEASE
ncbi-sent-957,associated,VBN,O
ncbi-sent-957,with,IN,O
ncbi-sent-957,neurofibromatosis,NN,B-DISEASE
ncbi-sent-957,type,NN,I-DISEASE
ncbi-sent-957,1,CD,I-DISEASE
ncbi-sent-957,.,.,O
ncbi-sent-958,.,.,O
ncbi-sent-959,Missense,JJ,O
ncbi-sent-959,mutations,NNS,O
ncbi-sent-959,in,IN,O
ncbi-sent-959,the,DT,O
ncbi-sent-959,most,RBS,O
ncbi-sent-959,ancient,JJ,O
ncbi-sent-959,residues,NNS,O
ncbi-sent-959,of,IN,O
ncbi-sent-959,the,DT,O
ncbi-sent-959,PAX6,NNP,O
ncbi-sent-959,paired,VBD,O
ncbi-sent-959,domain,NN,O
ncbi-sent-959,underlie,IN,O
ncbi-sent-959,a,DT,O
ncbi-sent-959,spectrum,NN,O
ncbi-sent-959,of,IN,O
ncbi-sent-959,human,JJ,O
ncbi-sent-959,congenital,JJ,B-DISEASE
ncbi-sent-959,eye,NN,I-DISEASE
ncbi-sent-959,malformations,NNS,I-DISEASE
ncbi-sent-959,.,.,O
ncbi-sent-960,Mutations,NNS,O
ncbi-sent-960,of,IN,O
ncbi-sent-960,the,DT,O
ncbi-sent-960,human,JJ,O
ncbi-sent-960,PAX6,NNP,O
ncbi-sent-960,gene,NN,O
ncbi-sent-960,underlie,JJ,O
ncbi-sent-960,aniridia,NN,B-DISEASE
ncbi-sent-960,(,(,O
ncbi-sent-960,congenital,JJ,B-DISEASE
ncbi-sent-960,absence,NN,I-DISEASE
ncbi-sent-960,of,IN,I-DISEASE
ncbi-sent-960,the,DT,I-DISEASE
ncbi-sent-960,iris,NN,I-DISEASE
ncbi-sent-960,),),O
ncbi-sent-960,",",",",O
ncbi-sent-960,a,DT,O
ncbi-sent-960,rare,JJ,O
ncbi-sent-960,dominant,JJ,O
ncbi-sent-960,malformation,NN,B-DISEASE
ncbi-sent-960,of,IN,I-DISEASE
ncbi-sent-960,the,DT,I-DISEASE
ncbi-sent-960,eye,NN,I-DISEASE
ncbi-sent-960,.,.,O
ncbi-sent-961,The,DT,O
ncbi-sent-961,spectrum,NN,O
ncbi-sent-961,of,IN,O
ncbi-sent-961,PAX6,NNP,O
ncbi-sent-961,mutations,NNS,O
ncbi-sent-961,in,IN,O
ncbi-sent-961,aniridia,JJ,B-DISEASE
ncbi-sent-961,patients,NNS,O
ncbi-sent-961,is,VBZ,O
ncbi-sent-961,highly,RB,O
ncbi-sent-961,biased,VBN,O
ncbi-sent-961,",",",",O
ncbi-sent-961,with,IN,O
ncbi-sent-961,92,CD,O
ncbi-sent-961,%,NN,O
ncbi-sent-961,of,IN,O
ncbi-sent-961,all,DT,O
ncbi-sent-961,reported,VBN,O
ncbi-sent-961,mutations,NNS,O
ncbi-sent-961,leading,VBG,O
ncbi-sent-961,to,TO,O
ncbi-sent-961,premature,VB,O
ncbi-sent-961,truncation,NN,O
ncbi-sent-961,of,IN,O
ncbi-sent-961,the,DT,O
ncbi-sent-961,protein,NN,O
ncbi-sent-961,(,(,O
ncbi-sent-961,nonsense,JJ,O
ncbi-sent-961,",",",",O
ncbi-sent-961,splicing,VBG,O
ncbi-sent-961,",",",",O
ncbi-sent-961,insertions,NNS,O
ncbi-sent-961,and,CC,O
ncbi-sent-961,deletions,NNS,O
ncbi-sent-961,),),O
ncbi-sent-961,and,CC,O
ncbi-sent-961,just,RB,O
ncbi-sent-961,2,CD,O
ncbi-sent-961,%,NN,O
ncbi-sent-961,leading,VBG,O
ncbi-sent-961,to,TO,O
ncbi-sent-961,substitution,NN,O
ncbi-sent-961,of,IN,O
ncbi-sent-961,one,CD,O
ncbi-sent-961,amino,NN,O
ncbi-sent-961,acid,NN,O
ncbi-sent-961,by,IN,O
ncbi-sent-961,another,DT,O
ncbi-sent-961,(,(,O
ncbi-sent-961,missense,NN,O
ncbi-sent-961,),),O
ncbi-sent-961,.,.,O
ncbi-sent-962,The,DT,O
ncbi-sent-962,extraordinary,JJ,O
ncbi-sent-962,conservation,NN,O
ncbi-sent-962,of,IN,O
ncbi-sent-962,the,DT,O
ncbi-sent-962,PAX6,NNP,O
ncbi-sent-962,protein,NN,O
ncbi-sent-962,at,IN,O
ncbi-sent-962,the,DT,O
ncbi-sent-962,amino,NN,O
ncbi-sent-962,acid,VBP,O
ncbi-sent-962,level,NN,O
ncbi-sent-962,amongst,NN,O
ncbi-sent-962,vertebrates,VBZ,O
ncbi-sent-962,predicts,NNS,O
ncbi-sent-962,that,WDT,O
ncbi-sent-962,pathological,JJ,O
ncbi-sent-962,missense,NN,O
ncbi-sent-962,mutations,NNS,O
ncbi-sent-962,should,MD,O
ncbi-sent-962,in,IN,O
ncbi-sent-962,fact,NN,O
ncbi-sent-962,be,VB,O
ncbi-sent-962,common,JJ,O
ncbi-sent-962,even,RB,O
ncbi-sent-962,though,IN,O
ncbi-sent-962,they,PRP,O
ncbi-sent-962,are,VBP,O
ncbi-sent-962,hardly,RB,O
ncbi-sent-962,ever,RB,O
ncbi-sent-962,seen,VBN,O
ncbi-sent-962,in,IN,O
ncbi-sent-962,aniridia,JJ,B-DISEASE
ncbi-sent-962,patients,NNS,O
ncbi-sent-962,.,.,O
ncbi-sent-963,This,DT,O
ncbi-sent-963,indicates,VBZ,O
ncbi-sent-963,that,IN,O
ncbi-sent-963,there,EX,O
ncbi-sent-963,is,VBZ,O
ncbi-sent-963,a,DT,O
ncbi-sent-963,heavy,JJ,O
ncbi-sent-963,ascertainment,NN,O
ncbi-sent-963,bias,NN,O
ncbi-sent-963,in,IN,O
ncbi-sent-963,the,DT,O
ncbi-sent-963,selection,NN,O
ncbi-sent-963,of,IN,O
ncbi-sent-963,patients,NNS,O
ncbi-sent-963,for,IN,O
ncbi-sent-963,PAX6,NNP,O
ncbi-sent-963,mutation,NN,O
ncbi-sent-963,analysis,NN,O
ncbi-sent-963,and,CC,O
ncbi-sent-963,that,IN,O
ncbi-sent-963,the,DT,O
ncbi-sent-963,missing,VBG,O
ncbi-sent-963,PAX6,NNP,O
ncbi-sent-963,missense,NN,O
ncbi-sent-963,mutations,NNS,O
ncbi-sent-963,frequently,RB,O
ncbi-sent-963,may,MD,O
ncbi-sent-963,underlie,VB,O
ncbi-sent-963,phenotypes,NNS,O
ncbi-sent-963,distinct,JJ,O
ncbi-sent-963,from,IN,O
ncbi-sent-963,textbook,NN,O
ncbi-sent-963,aniridia,NN,B-DISEASE
ncbi-sent-963,.,.,O
ncbi-sent-964,Here,RB,O
ncbi-sent-964,we,PRP,O
ncbi-sent-964,present,VBP,O
ncbi-sent-964,four,CD,O
ncbi-sent-964,novel,NN,O
ncbi-sent-964,PAX6,NNP,O
ncbi-sent-964,missense,NN,O
ncbi-sent-964,mutations,NNS,O
ncbi-sent-964,",",",",O
ncbi-sent-964,two,CD,O
ncbi-sent-964,in,IN,O
ncbi-sent-964,association,NN,O
ncbi-sent-964,with,IN,O
ncbi-sent-964,atypical,JJ,O
ncbi-sent-964,phenotypes,NNS,O
ncbi-sent-964,ectopia,VBP,B-DISEASE
ncbi-sent-964,pupillae,NN,I-DISEASE
ncbi-sent-964,(,(,O
ncbi-sent-964,displaced,VBN,B-DISEASE
ncbi-sent-964,pupils,NNS,I-DISEASE
ncbi-sent-964,),),O
ncbi-sent-964,and,CC,O
ncbi-sent-964,congenital,JJ,B-DISEASE
ncbi-sent-964,nystagmus,NN,I-DISEASE
ncbi-sent-964,(,(,O
ncbi-sent-964,searching,VBG,B-DISEASE
ncbi-sent-964,gaze,NN,I-DISEASE
ncbi-sent-964,),),O
ncbi-sent-964,",",",",O
ncbi-sent-964,and,CC,O
ncbi-sent-964,two,CD,O
ncbi-sent-964,in,IN,O
ncbi-sent-964,association,NN,O
ncbi-sent-964,with,IN,O
ncbi-sent-964,more,RBR,O
ncbi-sent-964,recognizable,JJ,O
ncbi-sent-964,aniridia,NN,B-DISEASE
ncbi-sent-964,phenotypes,NNS,O
ncbi-sent-964,.,.,O
ncbi-sent-965,Strikingly,RB,O
ncbi-sent-965,",",",",O
ncbi-sent-965,all,DT,O
ncbi-sent-965,four,CD,O
ncbi-sent-965,mutations,NNS,O
ncbi-sent-965,are,VBP,O
ncbi-sent-965,located,VBN,O
ncbi-sent-965,within,IN,O
ncbi-sent-965,the,DT,O
ncbi-sent-965,PAX6,NNP,O
ncbi-sent-965,paired,VBD,O
ncbi-sent-965,domain,NN,O
ncbi-sent-965,and,CC,O
ncbi-sent-965,affect,VB,O
ncbi-sent-965,amino,NN,O
ncbi-sent-965,acids,NNS,O
ncbi-sent-965,which,WDT,O
ncbi-sent-965,are,VBP,O
ncbi-sent-965,highly,RB,O
ncbi-sent-965,conserved,VBN,O
ncbi-sent-965,in,IN,O
ncbi-sent-965,all,DT,O
ncbi-sent-965,known,VBN,O
ncbi-sent-965,paired,VBD,O
ncbi-sent-965,domain,NN,O
ncbi-sent-965,proteins,NNS,O
ncbi-sent-965,.,.,O
ncbi-sent-966,Our,PRP$,O
ncbi-sent-966,results,NNS,O
ncbi-sent-966,support,VB,O
ncbi-sent-966,the,DT,O
ncbi-sent-966,hypothesis,NN,O
ncbi-sent-966,that,IN,O
ncbi-sent-966,the,DT,O
ncbi-sent-966,under,IN,O
ncbi-sent-966,-,:,O
ncbi-sent-966,representation,NN,O
ncbi-sent-966,of,IN,O
ncbi-sent-966,missense,JJ,O
ncbi-sent-966,mutations,NNS,O
ncbi-sent-966,is,VBZ,O
ncbi-sent-966,caused,VBN,O
ncbi-sent-966,by,IN,O
ncbi-sent-966,ascertainment,JJ,O
ncbi-sent-966,bias,NN,O
ncbi-sent-966,and,CC,O
ncbi-sent-966,suggest,VBP,O
ncbi-sent-966,that,IN,O
ncbi-sent-966,a,DT,O
ncbi-sent-966,substantial,JJ,O
ncbi-sent-966,burden,NN,O
ncbi-sent-966,of,IN,O
ncbi-sent-966,PAX6,NNP,B-DISEASE
ncbi-sent-966,-,:,I-DISEASE
ncbi-sent-966,related,JJ,I-DISEASE
ncbi-sent-966,disease,NN,I-DISEASE
ncbi-sent-966,remains,VBZ,O
ncbi-sent-966,to,TO,O
ncbi-sent-966,be,VB,O
ncbi-sent-966,uncovered,VBN,O
ncbi-sent-966,.,.,O
ncbi-sent-967,.,.,O
ncbi-sent-968,The,DT,O
ncbi-sent-968,chromosomal,JJ,O
ncbi-sent-968,order,NN,O
ncbi-sent-968,of,IN,O
ncbi-sent-968,genes,NNS,O
ncbi-sent-968,controlling,VBG,O
ncbi-sent-968,the,DT,O
ncbi-sent-968,major,JJ,O
ncbi-sent-968,histocompatibility,NN,O
ncbi-sent-968,complex,NN,O
ncbi-sent-968,",",",",O
ncbi-sent-968,properdin,NN,O
ncbi-sent-968,factor,NN,O
ncbi-sent-968,B,NNP,O
ncbi-sent-968,",",",",O
ncbi-sent-968,and,CC,O
ncbi-sent-968,deficiency,NN,B-DISEASE
ncbi-sent-968,of,IN,I-DISEASE
ncbi-sent-968,the,DT,I-DISEASE
ncbi-sent-968,second,JJ,I-DISEASE
ncbi-sent-968,component,NN,I-DISEASE
ncbi-sent-968,of,IN,I-DISEASE
ncbi-sent-968,complement,NN,I-DISEASE
ncbi-sent-968,.,.,O
ncbi-sent-969,The,DT,O
ncbi-sent-969,relationship,NN,O
ncbi-sent-969,of,IN,O
ncbi-sent-969,the,DT,O
ncbi-sent-969,genes,NNS,O
ncbi-sent-969,coding,VBG,O
ncbi-sent-969,for,IN,O
ncbi-sent-969,HLA,NNP,O
ncbi-sent-969,to,TO,O
ncbi-sent-969,those,DT,O
ncbi-sent-969,coding,VBG,O
ncbi-sent-969,for,IN,O
ncbi-sent-969,properdin,NN,O
ncbi-sent-969,Factor,NNP,O
ncbi-sent-969,B,NNP,O
ncbi-sent-969,allotypes,NNS,O
ncbi-sent-969,and,CC,O
ncbi-sent-969,for,IN,O
ncbi-sent-969,deficiency,NN,B-DISEASE
ncbi-sent-969,of,IN,I-DISEASE
ncbi-sent-969,the,DT,I-DISEASE
ncbi-sent-969,second,JJ,I-DISEASE
ncbi-sent-969,component,NN,I-DISEASE
ncbi-sent-969,of,IN,I-DISEASE
ncbi-sent-969,complement,NN,I-DISEASE
ncbi-sent-969,(,(,O
ncbi-sent-969,C2,NNP,O
ncbi-sent-969,),),O
ncbi-sent-969,was,VBD,O
ncbi-sent-969,studied,VBN,O
ncbi-sent-969,in,IN,O
ncbi-sent-969,families,NNS,O
ncbi-sent-969,of,IN,O
ncbi-sent-969,patients,NNS,O
ncbi-sent-969,with,IN,O
ncbi-sent-969,connective,JJ,O
ncbi-sent-969,tissue,NN,O
ncbi-sent-969,disorders,NNS,O
ncbi-sent-969,.,.,O
ncbi-sent-970,Patients,NNS,O
ncbi-sent-970,were,VBD,O
ncbi-sent-970,selected,VBN,O
ncbi-sent-970,because,IN,O
ncbi-sent-970,they,PRP,O
ncbi-sent-970,were,VBD,O
ncbi-sent-970,heterozygous,JJ,O
ncbi-sent-970,or,CC,O
ncbi-sent-970,homozygous,JJ,O
ncbi-sent-970,for,IN,O
ncbi-sent-970,C2,NNP,B-DISEASE
ncbi-sent-970,deficiency,NN,I-DISEASE
ncbi-sent-970,.,.,O
ncbi-sent-971,12,CD,O
ncbi-sent-971,families,NNS,O
ncbi-sent-971,with,IN,O
ncbi-sent-971,15,CD,O
ncbi-sent-971,matings,NNS,O
ncbi-sent-971,informative,JJ,O
ncbi-sent-971,for,IN,O
ncbi-sent-971,C2,NNP,B-DISEASE
ncbi-sent-971,deficiency,NN,I-DISEASE
ncbi-sent-971,were,VBD,O
ncbi-sent-971,found,VBN,O
ncbi-sent-971,.,.,O
ncbi-sent-972,Of,IN,O
ncbi-sent-972,57,CD,O
ncbi-sent-972,informative,JJ,O
ncbi-sent-972,meioses,NNS,O
ncbi-sent-972,",",",",O
ncbi-sent-972,two,CD,O
ncbi-sent-972,crossovers,NNS,O
ncbi-sent-972,were,VBD,O
ncbi-sent-972,noted,VBN,O
ncbi-sent-972,between,IN,O
ncbi-sent-972,the,DT,O
ncbi-sent-972,C2,NNP,B-DISEASE
ncbi-sent-972,deficiency,NN,I-DISEASE
ncbi-sent-972,gene,NN,O
ncbi-sent-972,and,CC,O
ncbi-sent-972,the,DT,O
ncbi-sent-972,HLA,NNP,O
ncbi-sent-972,-,:,O
ncbi-sent-972,B,NNP,O
ncbi-sent-972,gene,NN,O
ncbi-sent-972,",",",",O
ncbi-sent-972,with,IN,O
ncbi-sent-972,a,DT,O
ncbi-sent-972,recombinant,JJ,O
ncbi-sent-972,fraction,NN,O
ncbi-sent-972,of,IN,O
ncbi-sent-972,0,CD,O
ncbi-sent-972,.,.,O
ncbi-sent-973,035,CD,O
ncbi-sent-973,.,.,O
ncbi-sent-974,A,DT,O
ncbi-sent-974,lod,JJ,O
ncbi-sent-974,score,NN,O
ncbi-sent-974,of,IN,O
ncbi-sent-974,13,CD,O
ncbi-sent-974,was,VBD,O
ncbi-sent-974,calculated,VBN,O
ncbi-sent-974,for,IN,O
ncbi-sent-974,linkage,NN,O
ncbi-sent-974,between,IN,O
ncbi-sent-974,C2,NNP,B-DISEASE
ncbi-sent-974,deficiency,NN,I-DISEASE
ncbi-sent-974,and,CC,O
ncbi-sent-974,HLA,NNP,O
ncbi-sent-974,-,:,O
ncbi-sent-974,B,NN,O
ncbi-sent-974,at,IN,O
ncbi-sent-974,a,DT,O
ncbi-sent-974,maximum,JJ,O
ncbi-sent-974,likelihood,NN,O
ncbi-sent-974,value,NN,O
ncbi-sent-974,of,IN,O
ncbi-sent-974,the,DT,O
ncbi-sent-974,recombinant,JJ,O
ncbi-sent-974,fraction,NN,O
ncbi-sent-974,of,IN,O
ncbi-sent-974,0,CD,O
ncbi-sent-974,.,.,O
ncbi-sent-975,04,CD,O
ncbi-sent-975,.,.,O
ncbi-sent-976,18,CD,O
ncbi-sent-976,families,NNS,O
ncbi-sent-976,with,IN,O
ncbi-sent-976,21,CD,O
ncbi-sent-976,informative,JJ,O
ncbi-sent-976,matings,NNS,O
ncbi-sent-976,for,IN,O
ncbi-sent-976,both,DT,O
ncbi-sent-976,properdin,JJ,O
ncbi-sent-976,Factor,NN,O
ncbi-sent-976,B,NNP,O
ncbi-sent-976,allotype,NN,O
ncbi-sent-976,and,CC,O
ncbi-sent-976,HLA,NNP,O
ncbi-sent-976,-,:,O
ncbi-sent-976,B,NN,O
ncbi-sent-976,were,VBD,O
ncbi-sent-976,found,VBN,O
ncbi-sent-976,.,.,O
ncbi-sent-977,Of,IN,O
ncbi-sent-977,72,CD,O
ncbi-sent-977,informative,JJ,O
ncbi-sent-977,meioses,NNS,O
ncbi-sent-977,",",",",O
ncbi-sent-977,three,CD,O
ncbi-sent-977,recombinants,NNS,O
ncbi-sent-977,were,VBD,O
ncbi-sent-977,found,VBN,O
ncbi-sent-977,",",",",O
ncbi-sent-977,giving,VBG,O
ncbi-sent-977,a,DT,O
ncbi-sent-977,recombinant,JJ,O
ncbi-sent-977,fraction,NN,O
ncbi-sent-977,of,IN,O
ncbi-sent-977,0,CD,O
ncbi-sent-977,.,.,O
ncbi-sent-978,042,CD,O
ncbi-sent-978,.,.,O
ncbi-sent-979,A,DT,O
ncbi-sent-979,lod,JJ,O
ncbi-sent-979,score,NN,O
ncbi-sent-979,of,IN,O
ncbi-sent-979,16,CD,O
ncbi-sent-979,between,IN,O
ncbi-sent-979,HLA,NNP,O
ncbi-sent-979,-,:,O
ncbi-sent-979,B,NN,O
ncbi-sent-979,and,CC,O
ncbi-sent-979,Factor,NNP,O
ncbi-sent-979,B,NNP,O
ncbi-sent-979,allotypes,NNS,O
ncbi-sent-979,was,VBD,O
ncbi-sent-979,calculated,VBN,O
ncbi-sent-979,at,IN,O
ncbi-sent-979,a,DT,O
ncbi-sent-979,maximum,JJ,O
ncbi-sent-979,likelihood,NN,O
ncbi-sent-979,value,NN,O
ncbi-sent-979,of,IN,O
ncbi-sent-979,the,DT,O
ncbi-sent-979,recombinant,JJ,O
ncbi-sent-979,fraction,NN,O
ncbi-sent-979,of,IN,O
ncbi-sent-979,0,CD,O
ncbi-sent-979,.,.,O
ncbi-sent-980,04,CD,O
ncbi-sent-980,.,.,O
ncbi-sent-981,A,DT,O
ncbi-sent-981,crossover,NN,O
ncbi-sent-981,was,VBD,O
ncbi-sent-981,shown,VBN,O
ncbi-sent-981,to,TO,O
ncbi-sent-981,have,VB,O
ncbi-sent-981,occurred,VBN,O
ncbi-sent-981,between,IN,O
ncbi-sent-981,genes,NNS,O
ncbi-sent-981,for,IN,O
ncbi-sent-981,Factor,NNP,O
ncbi-sent-981,B,NNP,O
ncbi-sent-981,and,CC,O
ncbi-sent-981,HLA,NNP,O
ncbi-sent-981,-,:,O
ncbi-sent-981,D,NN,O
ncbi-sent-981,",",",",O
ncbi-sent-981,in,IN,O
ncbi-sent-981,which,WDT,O
ncbi-sent-981,HLA,NNP,O
ncbi-sent-981,-,:,O
ncbi-sent-981,D,NN,O
ncbi-sent-981,segregared,VBD,O
ncbi-sent-981,with,IN,O
ncbi-sent-981,HLA,NNP,O
ncbi-sent-981,-,:,O
ncbi-sent-981,A,DT,O
ncbi-sent-981,and,CC,O
ncbi-sent-981,B,NNP,O
ncbi-sent-981,.,.,O
ncbi-sent-982,These,DT,O
ncbi-sent-982,studies,NNS,O
ncbi-sent-982,suggest,VBP,O
ncbi-sent-982,that,IN,O
ncbi-sent-982,the,DT,O
ncbi-sent-982,genes,NNS,O
ncbi-sent-982,for,IN,O
ncbi-sent-982,Factor,NNP,O
ncbi-sent-982,B,NNP,O
ncbi-sent-982,and,CC,O
ncbi-sent-982,C2,NNP,B-DISEASE
ncbi-sent-982,deficiency,NN,I-DISEASE
ncbi-sent-982,are,VBP,O
ncbi-sent-982,located,VBN,O
ncbi-sent-982,outside,IN,O
ncbi-sent-982,those,DT,O
ncbi-sent-982,for,IN,O
ncbi-sent-982,HLA,NNP,O
ncbi-sent-982,",",",",O
ncbi-sent-982,that,IN,O
ncbi-sent-982,the,DT,O
ncbi-sent-982,order,NN,O
ncbi-sent-982,of,IN,O
ncbi-sent-982,genese,NN,O
ncbi-sent-982,is,VBZ,O
ncbi-sent-982,HLA,NNP,O
ncbi-sent-982,-,:,O
ncbi-sent-982,A,NN,O
ncbi-sent-982,",",",",O
ncbi-sent-982,-,:,O
ncbi-sent-982,B,NN,O
ncbi-sent-982,",",",",O
ncbi-sent-982,-,:,O
ncbi-sent-982,D,NN,O
ncbi-sent-982,",",",",O
ncbi-sent-982,Factor,NNP,O
ncbi-sent-982,B,NNP,O
ncbi-sent-982,allotype,NN,O
ncbi-sent-982,",",",",O
ncbi-sent-982,C2,NNP,B-DISEASE
ncbi-sent-982,deficiency,NN,I-DISEASE
ncbi-sent-982,",",",",O
ncbi-sent-982,that,IN,O
ncbi-sent-982,the,DT,O
ncbi-sent-982,genes,NNS,O
ncbi-sent-982,coding,VBG,O
ncbi-sent-982,for,IN,O
ncbi-sent-982,C2,NNP,B-DISEASE
ncbi-sent-982,deficiency,NN,I-DISEASE
ncbi-sent-982,and,CC,O
ncbi-sent-982,Factor,NNP,O
ncbi-sent-982,B,NNP,O
ncbi-sent-982,allotypes,NNS,O
ncbi-sent-982,are,VBP,O
ncbi-sent-982,approximately,RB,O
ncbi-sent-982,3,CD,O
ncbi-sent-982,-,:,O
ncbi-sent-982,-,:,O
ncbi-sent-982,5,CD,O
ncbi-sent-982,centimorgans,NNS,O
ncbi-sent-982,from,IN,O
ncbi-sent-982,the,DT,O
ncbi-sent-982,HLA,NNP,O
ncbi-sent-982,-,:,O
ncbi-sent-982,A,DT,O
ncbi-sent-982,and,CC,O
ncbi-sent-982,HLA,NNP,O
ncbi-sent-982,-,:,O
ncbi-sent-982,B,NNP,O
ncbi-sent-982,loci,NN,O
ncbi-sent-982,",",",",O
ncbi-sent-982,and,CC,O
ncbi-sent-982,that,IN,O
ncbi-sent-982,the,DT,O
ncbi-sent-982,apparent,JJ,O
ncbi-sent-982,lack,NN,O
ncbi-sent-982,of,IN,O
ncbi-sent-982,recombinants,NNS,O
ncbi-sent-982,between,IN,O
ncbi-sent-982,the,DT,O
ncbi-sent-982,Factor,NNP,O
ncbi-sent-982,B,NNP,O
ncbi-sent-982,gene,NN,O
ncbi-sent-982,and,CC,O
ncbi-sent-982,C2,NNP,B-DISEASE
ncbi-sent-982,deficiency,NN,I-DISEASE
ncbi-sent-982,gene,NN,O
ncbi-sent-982,suggests,VBZ,O
ncbi-sent-982,that,IN,O
ncbi-sent-982,these,DT,O
ncbi-sent-982,two,CD,O
ncbi-sent-982,genes,NNS,O
ncbi-sent-982,lie,RBR,O
ncbi-sent-982,in,IN,O
ncbi-sent-982,close,JJ,O
ncbi-sent-982,proximity,NN,O
ncbi-sent-982,to,TO,O
ncbi-sent-982,one,CD,O
ncbi-sent-982,another,DT,O
ncbi-sent-982,.,.,O
ncbi-sent-983,Distribution,NN,O
ncbi-sent-983,of,IN,O
ncbi-sent-983,emerin,NN,O
ncbi-sent-983,and,CC,O
ncbi-sent-983,lamins,NNS,O
ncbi-sent-983,in,IN,O
ncbi-sent-983,the,DT,O
ncbi-sent-983,heart,NN,O
ncbi-sent-983,and,CC,O
ncbi-sent-983,implications,NNS,O
ncbi-sent-983,for,IN,O
ncbi-sent-983,Emery,NNP,B-DISEASE
ncbi-sent-983,-,:,I-DISEASE
ncbi-sent-983,Dreifuss,NNP,I-DISEASE
ncbi-sent-983,muscular,JJ,I-DISEASE
ncbi-sent-983,dystrophy,NN,I-DISEASE
ncbi-sent-983,.,.,O
ncbi-sent-984,Emerin,NNP,O
ncbi-sent-984,is,VBZ,O
ncbi-sent-984,a,DT,O
ncbi-sent-984,nuclear,JJ,O
ncbi-sent-984,membrane,NN,O
ncbi-sent-984,protein,NN,O
ncbi-sent-984,which,WDT,O
ncbi-sent-984,is,VBZ,O
ncbi-sent-984,missing,VBG,O
ncbi-sent-984,or,CC,O
ncbi-sent-984,defective,JJ,O
ncbi-sent-984,in,IN,O
ncbi-sent-984,Emery,NNP,B-DISEASE
ncbi-sent-984,-,:,I-DISEASE
ncbi-sent-984,Dreifuss,NNP,I-DISEASE
ncbi-sent-984,muscular,JJ,I-DISEASE
ncbi-sent-984,dystrophy,NN,I-DISEASE
ncbi-sent-984,(,(,O
ncbi-sent-984,EDMD,NNP,B-DISEASE
ncbi-sent-984,),),O
ncbi-sent-984,.,.,O
ncbi-sent-985,It,PRP,O
ncbi-sent-985,is,VBZ,O
ncbi-sent-985,one,CD,O
ncbi-sent-985,member,NN,O
ncbi-sent-985,of,IN,O
ncbi-sent-985,a,DT,O
ncbi-sent-985,family,NN,O
ncbi-sent-985,of,IN,O
ncbi-sent-985,lamina,JJ,O
ncbi-sent-985,-,:,O
ncbi-sent-985,associated,VBN,O
ncbi-sent-985,proteins,NNS,O
ncbi-sent-985,which,WDT,O
ncbi-sent-985,includes,VBZ,O
ncbi-sent-985,LAP1,NNP,O
ncbi-sent-985,",",",",O
ncbi-sent-985,LAP2,NNP,O
ncbi-sent-985,and,CC,O
ncbi-sent-985,lamin,NN,O
ncbi-sent-985,B,NNP,O
ncbi-sent-985,receptor,NN,O
ncbi-sent-985,(,(,O
ncbi-sent-985,LBR,NNP,O
ncbi-sent-985,),),O
ncbi-sent-985,.,.,O
ncbi-sent-986,A,DT,O
ncbi-sent-986,panel,NN,O
ncbi-sent-986,of,IN,O
ncbi-sent-986,16,CD,O
ncbi-sent-986,monoclonal,JJ,O
ncbi-sent-986,antibodies,NNS,O
ncbi-sent-986,(,(,O
ncbi-sent-986,mAbs,NN,O
ncbi-sent-986,),),O
ncbi-sent-986,has,VBZ,O
ncbi-sent-986,been,VBN,O
ncbi-sent-986,mapped,VBN,O
ncbi-sent-986,to,TO,O
ncbi-sent-986,six,CD,O
ncbi-sent-986,specific,JJ,O
ncbi-sent-986,sites,NNS,O
ncbi-sent-986,throughout,IN,O
ncbi-sent-986,the,DT,O
ncbi-sent-986,emerin,NN,O
ncbi-sent-986,molecule,NN,O
ncbi-sent-986,using,VBG,O
ncbi-sent-986,phage,NN,O
ncbi-sent-986,-,:,O
ncbi-sent-986,displayed,VBN,O
ncbi-sent-986,peptide,IN,O
ncbi-sent-986,libraries,NNS,O
ncbi-sent-986,and,CC,O
ncbi-sent-986,has,VBZ,O
ncbi-sent-986,been,VBN,O
ncbi-sent-986,used,VBN,O
ncbi-sent-986,to,TO,O
ncbi-sent-986,localize,VB,O
ncbi-sent-986,emerin,NN,O
ncbi-sent-986,in,IN,O
ncbi-sent-986,human,JJ,O
ncbi-sent-986,and,CC,O
ncbi-sent-986,rabbit,JJ,O
ncbi-sent-986,heart,NN,O
ncbi-sent-986,.,.,O
ncbi-sent-987,Several,JJ,O
ncbi-sent-987,mAbs,NN,O
ncbi-sent-987,against,IN,O
ncbi-sent-987,different,JJ,O
ncbi-sent-987,emerin,JJ,O
ncbi-sent-987,epitopes,NNS,O
ncbi-sent-987,did,VBD,O
ncbi-sent-987,not,RB,O
ncbi-sent-987,recognize,VB,O
ncbi-sent-987,intercalated,JJ,O
ncbi-sent-987,discs,NN,O
ncbi-sent-987,in,IN,O
ncbi-sent-987,the,DT,O
ncbi-sent-987,heart,NN,O
ncbi-sent-987,",",",",O
ncbi-sent-987,though,IN,O
ncbi-sent-987,they,PRP,O
ncbi-sent-987,recognized,VBD,O
ncbi-sent-987,cardiomyocyte,NN,O
ncbi-sent-987,nuclei,NN,O
ncbi-sent-987,strongly,RB,O
ncbi-sent-987,",",",",O
ncbi-sent-987,both,DT,O
ncbi-sent-987,at,IN,O
ncbi-sent-987,the,DT,O
ncbi-sent-987,rim,NN,O
ncbi-sent-987,and,CC,O
ncbi-sent-987,in,IN,O
ncbi-sent-987,intranuclear,JJ,O
ncbi-sent-987,spots,NNS,O
ncbi-sent-987,or,CC,O
ncbi-sent-987,channels,NNS,O
ncbi-sent-987,.,.,O
ncbi-sent-988,A,DT,O
ncbi-sent-988,polyclonal,JJ,O
ncbi-sent-988,rabbit,NN,O
ncbi-sent-988,antiserum,NN,O
ncbi-sent-988,against,IN,O
ncbi-sent-988,emerin,NN,O
ncbi-sent-988,did,VBD,O
ncbi-sent-988,recognize,VB,O
ncbi-sent-988,both,DT,O
ncbi-sent-988,nuclear,JJ,O
ncbi-sent-988,membrane,NN,O
ncbi-sent-988,and,CC,O
ncbi-sent-988,intercalated,JJ,O
ncbi-sent-988,discs,NN,O
ncbi-sent-988,but,CC,O
ncbi-sent-988,",",",",O
ncbi-sent-988,after,IN,O
ncbi-sent-988,affinity,NN,O
ncbi-sent-988,purification,NN,O
ncbi-sent-988,against,IN,O
ncbi-sent-988,a,DT,O
ncbi-sent-988,pure,JJ,O
ncbi-sent-988,-,:,O
ncbi-sent-988,emerin,NN,O
ncbi-sent-988,band,NN,O
ncbi-sent-988,on,IN,O
ncbi-sent-988,a,DT,O
ncbi-sent-988,western,JJ,O
ncbi-sent-988,blot,NN,O
ncbi-sent-988,",",",",O
ncbi-sent-988,it,PRP,O
ncbi-sent-988,stained,VBD,O
ncbi-sent-988,only,RB,O
ncbi-sent-988,the,DT,O
ncbi-sent-988,nuclear,JJ,O
ncbi-sent-988,membrane,NN,O
ncbi-sent-988,.,.,O
ncbi-sent-989,These,DT,O
ncbi-sent-989,results,NNS,O
ncbi-sent-989,would,MD,O
ncbi-sent-989,not,RB,O
ncbi-sent-989,be,VB,O
ncbi-sent-989,expected,VBN,O
ncbi-sent-989,if,IN,O
ncbi-sent-989,immunostaining,NN,O
ncbi-sent-989,at,IN,O
ncbi-sent-989,intercalated,JJ,O
ncbi-sent-989,discs,NN,O
ncbi-sent-989,were,VBD,O
ncbi-sent-989,due,JJ,O
ncbi-sent-989,to,TO,O
ncbi-sent-989,a,DT,O
ncbi-sent-989,product,NN,O
ncbi-sent-989,of,IN,O
ncbi-sent-989,the,DT,O
ncbi-sent-989,emerin,JJ,O
ncbi-sent-989,gene,NN,O
ncbi-sent-989,and,CC,O
ncbi-sent-989,",",",",O
ncbi-sent-989,therefore,RB,O
ncbi-sent-989,",",",",O
ncbi-sent-989,cast,VBD,O
ncbi-sent-989,some,DT,O
ncbi-sent-989,doubt,NN,O
ncbi-sent-989,upon,IN,O
ncbi-sent-989,the,DT,O
ncbi-sent-989,hypothesis,NN,O
ncbi-sent-989,that,WDT,O
ncbi-sent-989,cardiac,JJ,B-DISEASE
ncbi-sent-989,defects,NNS,I-DISEASE
ncbi-sent-989,in,IN,O
ncbi-sent-989,EDMD,NNP,B-DISEASE
ncbi-sent-989,are,VBP,O
ncbi-sent-989,caused,VBN,O
ncbi-sent-989,by,IN,O
ncbi-sent-989,absence,NN,O
ncbi-sent-989,of,IN,O
ncbi-sent-989,emerin,NN,O
ncbi-sent-989,from,IN,O
ncbi-sent-989,intercalated,VBN,O
ncbi-sent-989,discs,NN,O
ncbi-sent-989,.,.,O
ncbi-sent-990,Although,IN,O
ncbi-sent-990,emerin,NN,O
ncbi-sent-990,was,VBD,O
ncbi-sent-990,abundant,JJ,O
ncbi-sent-990,in,IN,O
ncbi-sent-990,the,DT,O
ncbi-sent-990,membranes,NNS,O
ncbi-sent-990,of,IN,O
ncbi-sent-990,cardiomyocyte,NN,O
ncbi-sent-990,nuclei,NN,O
ncbi-sent-990,",",",",O
ncbi-sent-990,it,PRP,O
ncbi-sent-990,was,VBD,O
ncbi-sent-990,absent,JJ,O
ncbi-sent-990,from,IN,O
ncbi-sent-990,many,JJ,O
ncbi-sent-990,non,SYM,O
ncbi-sent-990,-,:,O
ncbi-sent-990,myocyte,NN,O
ncbi-sent-990,cells,NNS,O
ncbi-sent-990,in,IN,O
ncbi-sent-990,the,DT,O
ncbi-sent-990,heart,NN,O
ncbi-sent-990,.,.,O
ncbi-sent-991,This,DT,O
ncbi-sent-991,distribution,NN,O
ncbi-sent-991,of,IN,O
ncbi-sent-991,emerin,NN,O
ncbi-sent-991,was,VBD,O
ncbi-sent-991,similar,JJ,O
ncbi-sent-991,to,TO,O
ncbi-sent-991,that,DT,O
ncbi-sent-991,of,IN,O
ncbi-sent-991,lamin,NN,O
ncbi-sent-991,A,NNP,O
ncbi-sent-991,",",",",O
ncbi-sent-991,a,DT,O
ncbi-sent-991,candidate,NN,O
ncbi-sent-991,gene,NN,O
ncbi-sent-991,for,IN,O
ncbi-sent-991,an,DT,O
ncbi-sent-991,autosomal,JJ,O
ncbi-sent-991,form,NN,O
ncbi-sent-991,of,IN,O
ncbi-sent-991,EDMD,NNP,B-DISEASE
ncbi-sent-991,.,.,O
ncbi-sent-992,In,IN,O
ncbi-sent-992,contrast,NN,O
ncbi-sent-992,",",",",O
ncbi-sent-992,lamin,FW,O
ncbi-sent-992,B1,NNP,O
ncbi-sent-992,was,VBD,O
ncbi-sent-992,absent,JJ,O
ncbi-sent-992,from,IN,O
ncbi-sent-992,cardiomyocyte,NN,O
ncbi-sent-992,nuclei,NN,O
ncbi-sent-992,",",",",O
ncbi-sent-992,showing,VBG,O
ncbi-sent-992,that,IN,O
ncbi-sent-992,lamin,JJ,O
ncbi-sent-992,B1,NNP,O
ncbi-sent-992,is,VBZ,O
ncbi-sent-992,not,RB,O
ncbi-sent-992,essential,JJ,O
ncbi-sent-992,for,IN,O
ncbi-sent-992,localization,NN,O
ncbi-sent-992,of,IN,O
ncbi-sent-992,emerin,NN,O
ncbi-sent-992,to,TO,O
ncbi-sent-992,the,DT,O
ncbi-sent-992,nuclear,JJ,O
ncbi-sent-992,lamina,NN,O
ncbi-sent-992,.,.,O
ncbi-sent-993,Lamin,NNP,O
ncbi-sent-993,B1,NNP,O
ncbi-sent-993,is,VBZ,O
ncbi-sent-993,also,RB,O
ncbi-sent-993,almost,RB,O
ncbi-sent-993,completely,RB,O
ncbi-sent-993,absent,JJ,O
ncbi-sent-993,from,IN,O
ncbi-sent-993,skeletal,JJ,O
ncbi-sent-993,muscle,NN,O
ncbi-sent-993,nuclei,NN,O
ncbi-sent-993,.,.,O
ncbi-sent-994,In,IN,O
ncbi-sent-994,EDMD,NNP,B-DISEASE
ncbi-sent-994,",",",",O
ncbi-sent-994,the,DT,O
ncbi-sent-994,additional,JJ,O
ncbi-sent-994,absence,NN,O
ncbi-sent-994,of,IN,O
ncbi-sent-994,lamin,JJ,O
ncbi-sent-994,B1,NNP,O
ncbi-sent-994,from,IN,O
ncbi-sent-994,heart,NN,O
ncbi-sent-994,and,CC,O
ncbi-sent-994,skeletal,JJ,O
ncbi-sent-994,muscle,NN,O
ncbi-sent-994,nuclei,NN,O
ncbi-sent-994,which,WDT,O
ncbi-sent-994,already,RB,O
ncbi-sent-994,lack,VBP,O
ncbi-sent-994,emerin,NN,O
ncbi-sent-994,may,MD,O
ncbi-sent-994,offer,VB,O
ncbi-sent-994,an,DT,O
ncbi-sent-994,alternative,JJ,O
ncbi-sent-994,explanation,NN,O
ncbi-sent-994,of,IN,O
ncbi-sent-994,why,WRB,O
ncbi-sent-994,these,DT,O
ncbi-sent-994,tissues,NNS,O
ncbi-sent-994,are,VBP,O
ncbi-sent-994,particularly,RB,O
ncbi-sent-994,affected,VBN,O
ncbi-sent-994,.,.,O
ncbi-sent-995,.,.,O
ncbi-sent-996,Genetic,JJ,O
ncbi-sent-996,mapping,NN,O
ncbi-sent-996,of,IN,O
ncbi-sent-996,the,DT,O
ncbi-sent-996,copper,NN,B-DISEASE
ncbi-sent-996,toxicosis,NN,I-DISEASE
ncbi-sent-996,locus,NN,O
ncbi-sent-996,in,IN,O
ncbi-sent-996,Bedlington,NNP,O
ncbi-sent-996,terriers,NNS,O
ncbi-sent-996,to,TO,O
ncbi-sent-996,dog,VB,O
ncbi-sent-996,chromosome,NN,O
ncbi-sent-996,10,CD,O
ncbi-sent-996,",",",",O
ncbi-sent-996,in,IN,O
ncbi-sent-996,a,DT,O
ncbi-sent-996,region,NN,O
ncbi-sent-996,syntenic,NN,O
ncbi-sent-996,to,TO,O
ncbi-sent-996,human,JJ,O
ncbi-sent-996,chromosome,NN,O
ncbi-sent-996,region,NN,O
ncbi-sent-996,2p13,CD,O
ncbi-sent-996,-,:,O
ncbi-sent-996,p16,NN,O
ncbi-sent-996,.,.,O
ncbi-sent-997,Abnormal,NNP,O
ncbi-sent-997,hepatic,JJ,B-DISEASE
ncbi-sent-997,copper,NN,I-DISEASE
ncbi-sent-997,accumulation,NN,I-DISEASE
ncbi-sent-997,is,VBZ,O
ncbi-sent-997,recognized,VBN,O
ncbi-sent-997,as,IN,O
ncbi-sent-997,an,DT,O
ncbi-sent-997,inherited,JJ,B-DISEASE
ncbi-sent-997,disorder,NN,I-DISEASE
ncbi-sent-997,in,IN,O
ncbi-sent-997,man,NN,O
ncbi-sent-997,",",",",O
ncbi-sent-997,mouse,NN,O
ncbi-sent-997,",",",",O
ncbi-sent-997,rat,NN,O
ncbi-sent-997,and,CC,O
ncbi-sent-997,dog,NN,O
ncbi-sent-997,.,.,O
ncbi-sent-998,The,DT,O
ncbi-sent-998,major,JJ,O
ncbi-sent-998,cause,NN,O
ncbi-sent-998,of,IN,O
ncbi-sent-998,hepatic,JJ,B-DISEASE
ncbi-sent-998,copper,NN,I-DISEASE
ncbi-sent-998,accumulation,NN,I-DISEASE
ncbi-sent-998,in,IN,O
ncbi-sent-998,man,NN,O
ncbi-sent-998,is,VBZ,O
ncbi-sent-998,a,DT,O
ncbi-sent-998,dysfunctional,JJ,O
ncbi-sent-998,ATP7B,NNP,O
ncbi-sent-998,gene,NN,O
ncbi-sent-998,",",",",O
ncbi-sent-998,causing,VBG,O
ncbi-sent-998,Wilson,NNP,B-DISEASE
ncbi-sent-998,disease,NN,I-DISEASE
ncbi-sent-998,(,(,O
ncbi-sent-998,WD,NNP,B-DISEASE
ncbi-sent-998,),),O
ncbi-sent-998,.,.,O
ncbi-sent-999,Mutations,NNS,O
ncbi-sent-999,in,IN,O
ncbi-sent-999,the,DT,O
ncbi-sent-999,ATP7B,NNP,O
ncbi-sent-999,genes,NNS,O
ncbi-sent-999,have,VBP,O
ncbi-sent-999,also,RB,O
ncbi-sent-999,been,VBN,O
ncbi-sent-999,demonstrated,VBN,O
ncbi-sent-999,in,IN,O
ncbi-sent-999,mouse,NN,O
ncbi-sent-999,and,CC,O
ncbi-sent-999,rat,NN,O
ncbi-sent-999,.,.,O
ncbi-sent-1000,The,DT,O
ncbi-sent-1000,ATP7B,NNP,O
ncbi-sent-1000,gene,NN,O
ncbi-sent-1000,has,VBZ,O
ncbi-sent-1000,been,VBN,O
ncbi-sent-1000,excluded,VBN,O
ncbi-sent-1000,in,IN,O
ncbi-sent-1000,the,DT,O
ncbi-sent-1000,much,JJ,O
ncbi-sent-1000,rarer,NN,O
ncbi-sent-1000,human,JJ,O
ncbi-sent-1000,copper,NN,B-DISEASE
ncbi-sent-1000,overload,NN,I-DISEASE
ncbi-sent-1000,disease,NN,O
ncbi-sent-1000,non,SYM,B-DISEASE
ncbi-sent-1000,-,:,I-DISEASE
ncbi-sent-1000,Indian,JJ,I-DISEASE
ncbi-sent-1000,childhood,NN,I-DISEASE
ncbi-sent-1000,cirrhosis,NN,I-DISEASE
ncbi-sent-1000,",",",",O
ncbi-sent-1000,indicating,VBG,O
ncbi-sent-1000,genetic,JJ,O
ncbi-sent-1000,heterogeneity,NN,O
ncbi-sent-1000,.,.,O
ncbi-sent-1001,By,IN,O
ncbi-sent-1001,investigating,VBG,O
ncbi-sent-1001,the,DT,O
ncbi-sent-1001,common,JJ,O
ncbi-sent-1001,autosomal,JJ,O
ncbi-sent-1001,recessive,JJ,O
ncbi-sent-1001,copper,NN,B-DISEASE
ncbi-sent-1001,toxicosis,NN,I-DISEASE
ncbi-sent-1001,(,(,O
ncbi-sent-1001,CT,NNP,B-DISEASE
ncbi-sent-1001,),),O
ncbi-sent-1001,in,IN,O
ncbi-sent-1001,Bedlington,NNP,O
ncbi-sent-1001,terriers,NNS,O
ncbi-sent-1001,",",",",O
ncbi-sent-1001,we,PRP,O
ncbi-sent-1001,have,VBP,O
ncbi-sent-1001,identified,VBN,O
ncbi-sent-1001,a,DT,O
ncbi-sent-1001,new,JJ,O
ncbi-sent-1001,locus,NN,O
ncbi-sent-1001,involved,VBN,O
ncbi-sent-1001,in,IN,O
ncbi-sent-1001,progressive,JJ,O
ncbi-sent-1001,liver,NN,B-DISEASE
ncbi-sent-1001,disease,NN,I-DISEASE
ncbi-sent-1001,.,.,O
ncbi-sent-1002,We,PRP,O
ncbi-sent-1002,examined,VBD,O
ncbi-sent-1002,whether,IN,O
ncbi-sent-1002,the,DT,O
ncbi-sent-1002,WD,NNP,B-DISEASE
ncbi-sent-1002,gene,NN,O
ncbi-sent-1002,ATP7B,NNP,O
ncbi-sent-1002,was,VBD,O
ncbi-sent-1002,also,RB,O
ncbi-sent-1002,causative,JJ,O
ncbi-sent-1002,for,IN,O
ncbi-sent-1002,CT,NNP,B-DISEASE
ncbi-sent-1002,by,IN,O
ncbi-sent-1002,investigating,VBG,O
ncbi-sent-1002,the,DT,O
ncbi-sent-1002,chromosomal,JJ,O
ncbi-sent-1002,co,NN,O
ncbi-sent-1002,-,:,O
ncbi-sent-1002,localization,NN,O
ncbi-sent-1002,of,IN,O
ncbi-sent-1002,ATP7B,NNP,O
ncbi-sent-1002,and,CC,O
ncbi-sent-1002,C04107,NNP,O
ncbi-sent-1002,",",",",O
ncbi-sent-1002,using,VBG,O
ncbi-sent-1002,fluorescence,NN,O
ncbi-sent-1002,in,IN,O
ncbi-sent-1002,situ,JJ,O
ncbi-sent-1002,hybridization,NN,O
ncbi-sent-1002,(,(,O
ncbi-sent-1002,FISH,NNP,O
ncbi-sent-1002,),),O
ncbi-sent-1002,.,.,O
ncbi-sent-1003,C04107,NNP,O
ncbi-sent-1003,is,VBZ,O
ncbi-sent-1003,an,DT,O
ncbi-sent-1003,anonymous,JJ,O
ncbi-sent-1003,microsatellite,NN,O
ncbi-sent-1003,marker,NN,O
ncbi-sent-1003,closely,RB,O
ncbi-sent-1003,linked,VBN,O
ncbi-sent-1003,to,TO,O
ncbi-sent-1003,CT,NNP,B-DISEASE
ncbi-sent-1003,.,.,O
ncbi-sent-1004,However,RB,O
ncbi-sent-1004,",",",",O
ncbi-sent-1004,BAC,NNP,O
ncbi-sent-1004,clones,VBZ,O
ncbi-sent-1004,containing,VBG,O
ncbi-sent-1004,ATP7B,NNP,O
ncbi-sent-1004,and,CC,O
ncbi-sent-1004,C04107,NNP,O
ncbi-sent-1004,mapped,VBD,O
ncbi-sent-1004,to,TO,O
ncbi-sent-1004,the,DT,O
ncbi-sent-1004,canine,NN,O
ncbi-sent-1004,chromosome,NN,O
ncbi-sent-1004,regions,NNS,O
ncbi-sent-1004,CFA22q11,NNP,O
ncbi-sent-1004,and,CC,O
ncbi-sent-1004,CFA10q26,NNP,O
ncbi-sent-1004,",",",",O
ncbi-sent-1004,respectively,RB,O
ncbi-sent-1004,",",",",O
ncbi-sent-1004,demonstrating,VBG,O
ncbi-sent-1004,that,IN,O
ncbi-sent-1004,WD,NNP,B-DISEASE
ncbi-sent-1004,cannot,NN,O
ncbi-sent-1004,be,VB,O
ncbi-sent-1004,homologous,JJ,O
ncbi-sent-1004,to,TO,O
ncbi-sent-1004,CT,NNP,B-DISEASE
ncbi-sent-1004,.,.,O
ncbi-sent-1005,The,DT,O
ncbi-sent-1005,copper,NN,O
ncbi-sent-1005,transport,NN,O
ncbi-sent-1005,genes,NNS,O
ncbi-sent-1005,CTR1,NNP,O
ncbi-sent-1005,and,CC,O
ncbi-sent-1005,CTR2,NNP,O
ncbi-sent-1005,were,VBD,O
ncbi-sent-1005,also,RB,O
ncbi-sent-1005,excluded,VBN,O
ncbi-sent-1005,as,IN,O
ncbi-sent-1005,candidate,NN,O
ncbi-sent-1005,genes,NNS,O
ncbi-sent-1005,for,IN,O
ncbi-sent-1005,CT,NNP,B-DISEASE
ncbi-sent-1005,since,IN,O
ncbi-sent-1005,they,PRP,O
ncbi-sent-1005,both,DT,O
ncbi-sent-1005,mapped,VBD,O
ncbi-sent-1005,to,TO,O
ncbi-sent-1005,canine,VB,O
ncbi-sent-1005,chromosome,JJ,O
ncbi-sent-1005,region,NN,O
ncbi-sent-1005,CFA11q22,NNP,O
ncbi-sent-1005,.,.,O
ncbi-sent-1006,2,CD,O
ncbi-sent-1006,-,:,O
ncbi-sent-1006,22,CD,O
ncbi-sent-1006,.,.,O
ncbi-sent-1007,5,CD,O
ncbi-sent-1007,.,.,O
ncbi-sent-1008,A,DT,O
ncbi-sent-1008,transcribed,JJ,O
ncbi-sent-1008,sequence,NN,O
ncbi-sent-1008,identified,VBN,O
ncbi-sent-1008,from,IN,O
ncbi-sent-1008,the,DT,O
ncbi-sent-1008,C04107,NNP,O
ncbi-sent-1008,-,:,O
ncbi-sent-1008,containing,VBG,O
ncbi-sent-1008,BAC,NNP,O
ncbi-sent-1008,was,VBD,O
ncbi-sent-1008,found,VBN,O
ncbi-sent-1008,to,TO,O
ncbi-sent-1008,be,VB,O
ncbi-sent-1008,homologous,JJ,O
ncbi-sent-1008,to,TO,O
ncbi-sent-1008,a,DT,O
ncbi-sent-1008,gene,NN,O
ncbi-sent-1008,expressed,VBN,O
ncbi-sent-1008,from,IN,O
ncbi-sent-1008,human,JJ,O
ncbi-sent-1008,chromosome,NN,O
ncbi-sent-1008,2p13,CD,O
ncbi-sent-1008,-,:,O
ncbi-sent-1008,p16,NN,O
ncbi-sent-1008,",",",",O
ncbi-sent-1008,a,DT,O
ncbi-sent-1008,region,NN,O
ncbi-sent-1008,devoid,NN,O
ncbi-sent-1008,of,IN,O
ncbi-sent-1008,any,DT,O
ncbi-sent-1008,positional,JJ,O
ncbi-sent-1008,candidate,NN,O
ncbi-sent-1008,genes,NNS,O
ncbi-sent-1008,.,.,O
ncbi-sent-1009,Molecular,JJ,O
ncbi-sent-1009,analysis,NN,O
ncbi-sent-1009,of,IN,O
ncbi-sent-1009,the,DT,O
ncbi-sent-1009,APC,NNP,B-DISEASE
ncbi-sent-1009,gene,NN,O
ncbi-sent-1009,in,IN,O
ncbi-sent-1009,205,CD,O
ncbi-sent-1009,families,NNS,O
ncbi-sent-1009,:,:,O
ncbi-sent-1009,extended,VBN,O
ncbi-sent-1009,genotype,NN,O
ncbi-sent-1009,-,:,O
ncbi-sent-1009,phenotype,NN,O
ncbi-sent-1009,correlations,NNS,O
ncbi-sent-1009,in,IN,O
ncbi-sent-1009,FAP,NNP,B-DISEASE
ncbi-sent-1009,and,CC,O
ncbi-sent-1009,evidence,NN,O
ncbi-sent-1009,for,IN,O
ncbi-sent-1009,the,DT,O
ncbi-sent-1009,role,NN,O
ncbi-sent-1009,of,IN,O
ncbi-sent-1009,APC,NNP,B-DISEASE
ncbi-sent-1009,amino,NN,O
ncbi-sent-1009,acid,NN,O
ncbi-sent-1009,changes,NNS,O
ncbi-sent-1009,in,IN,O
ncbi-sent-1009,colorectal,JJ,B-DISEASE
ncbi-sent-1009,cancer,NN,I-DISEASE
ncbi-sent-1009,predisposition,NN,O
ncbi-sent-1009,.,.,O
ncbi-sent-1010,BACKGROUND,NNP,O
ncbi-sent-1010,/,NNP,O
ncbi-sent-1010,AIMS,NNP,O
ncbi-sent-1010,The,DT,O
ncbi-sent-1010,development,NN,O
ncbi-sent-1010,of,IN,O
ncbi-sent-1010,colorectal,JJ,B-DISEASE
ncbi-sent-1010,cancer,NN,I-DISEASE
ncbi-sent-1010,and,CC,O
ncbi-sent-1010,a,DT,O
ncbi-sent-1010,variable,JJ,O
ncbi-sent-1010,range,NN,O
ncbi-sent-1010,of,IN,O
ncbi-sent-1010,extracolonic,JJ,O
ncbi-sent-1010,manifestations,NNS,O
ncbi-sent-1010,in,IN,O
ncbi-sent-1010,familial,JJ,B-DISEASE
ncbi-sent-1010,adenomatous,JJ,I-DISEASE
ncbi-sent-1010,polyposis,NN,I-DISEASE
ncbi-sent-1010,(,(,O
ncbi-sent-1010,FAP,NNP,B-DISEASE
ncbi-sent-1010,),),O
ncbi-sent-1010,is,VBZ,O
ncbi-sent-1010,the,DT,O
ncbi-sent-1010,result,NN,O
ncbi-sent-1010,of,IN,O
ncbi-sent-1010,the,DT,O
ncbi-sent-1010,dominant,JJ,O
ncbi-sent-1010,inheritance,NN,O
ncbi-sent-1010,of,IN,O
ncbi-sent-1010,adenomatous,JJ,B-DISEASE
ncbi-sent-1010,polyposis,NN,I-DISEASE
ncbi-sent-1010,coli,NN,I-DISEASE
ncbi-sent-1010,(,(,O
ncbi-sent-1010,APC,NNP,B-DISEASE
ncbi-sent-1010,),),O
ncbi-sent-1010,gene,NN,O
ncbi-sent-1010,mutations,NNS,O
ncbi-sent-1010,.,.,O
ncbi-sent-1011,In,IN,O
ncbi-sent-1011,this,DT,O
ncbi-sent-1011,study,NN,O
ncbi-sent-1011,",",",",O
ncbi-sent-1011,direct,JJ,O
ncbi-sent-1011,mutation,NN,O
ncbi-sent-1011,analysis,NN,O
ncbi-sent-1011,of,IN,O
ncbi-sent-1011,the,DT,O
ncbi-sent-1011,APC,NNP,B-DISEASE
ncbi-sent-1011,gene,NN,O
ncbi-sent-1011,was,VBD,O
ncbi-sent-1011,performed,VBN,O
ncbi-sent-1011,to,TO,O
ncbi-sent-1011,determine,VB,O
ncbi-sent-1011,genotype,JJ,O
ncbi-sent-1011,-,:,O
ncbi-sent-1011,phenotype,NN,O
ncbi-sent-1011,correlations,NNS,O
ncbi-sent-1011,for,IN,O
ncbi-sent-1011,nine,CD,O
ncbi-sent-1011,extracolonic,JJ,O
ncbi-sent-1011,manifestations,NNS,O
ncbi-sent-1011,and,CC,O
ncbi-sent-1011,to,TO,O
ncbi-sent-1011,investigate,VB,O
ncbi-sent-1011,the,DT,O
ncbi-sent-1011,incidence,NN,O
ncbi-sent-1011,of,IN,O
ncbi-sent-1011,APC,NNP,B-DISEASE
ncbi-sent-1011,mutations,NNS,O
ncbi-sent-1011,in,IN,O
ncbi-sent-1011,non,JJ,O
ncbi-sent-1011,-,:,O
ncbi-sent-1011,FAP,NNP,O
ncbi-sent-1011,colorectal,JJ,B-DISEASE
ncbi-sent-1011,cancer,NN,I-DISEASE
ncbi-sent-1011,.,.,O
ncbi-sent-1012,METHODS,NNP,O
ncbi-sent-1012,The,DT,O
ncbi-sent-1012,APC,NNP,B-DISEASE
ncbi-sent-1012,gene,NN,O
ncbi-sent-1012,was,VBD,O
ncbi-sent-1012,analysed,VBN,O
ncbi-sent-1012,in,IN,O
ncbi-sent-1012,190,CD,O
ncbi-sent-1012,unrelated,JJ,O
ncbi-sent-1012,FAP,NNP,B-DISEASE
ncbi-sent-1012,and,CC,O
ncbi-sent-1012,15,CD,O
ncbi-sent-1012,non,JJ,O
ncbi-sent-1012,-,:,O
ncbi-sent-1012,FAP,NNP,O
ncbi-sent-1012,colorectal,JJ,B-DISEASE
ncbi-sent-1012,cancer,NN,I-DISEASE
ncbi-sent-1012,patients,NNS,O
ncbi-sent-1012,using,VBG,O
ncbi-sent-1012,denaturing,VBG,O
ncbi-sent-1012,gradient,JJ,O
ncbi-sent-1012,gel,NN,O
ncbi-sent-1012,electrophoresis,NN,O
ncbi-sent-1012,",",",",O
ncbi-sent-1012,the,DT,O
ncbi-sent-1012,protein,NN,O
ncbi-sent-1012,truncation,NN,O
ncbi-sent-1012,test,NN,O
ncbi-sent-1012,",",",",O
ncbi-sent-1012,and,CC,O
ncbi-sent-1012,direct,JJ,O
ncbi-sent-1012,sequencing,NN,O
ncbi-sent-1012,.,.,O
ncbi-sent-1013,RESULTS,NNP,O
ncbi-sent-1013,Chain,NNP,O
ncbi-sent-1013,terminating,VBG,O
ncbi-sent-1013,signals,NNS,O
ncbi-sent-1013,were,VBD,O
ncbi-sent-1013,only,RB,O
ncbi-sent-1013,identified,VBN,O
ncbi-sent-1013,in,IN,O
ncbi-sent-1013,patients,NNS,O
ncbi-sent-1013,belonging,VBG,O
ncbi-sent-1013,to,TO,O
ncbi-sent-1013,the,DT,O
ncbi-sent-1013,FAP,NNP,B-DISEASE
ncbi-sent-1013,group,NN,O
ncbi-sent-1013,(,(,O
ncbi-sent-1013,105,CD,O
ncbi-sent-1013,patients,NNS,O
ncbi-sent-1013,),),O
ncbi-sent-1013,.,.,O
ncbi-sent-1014,Amino,NNP,O
ncbi-sent-1014,acid,JJ,O
ncbi-sent-1014,changes,NNS,O
ncbi-sent-1014,were,VBD,O
ncbi-sent-1014,identified,VBN,O
ncbi-sent-1014,in,IN,O
ncbi-sent-1014,four,CD,O
ncbi-sent-1014,patients,NNS,O
ncbi-sent-1014,",",",",O
ncbi-sent-1014,three,CD,O
ncbi-sent-1014,of,IN,O
ncbi-sent-1014,whom,WP,O
ncbi-sent-1014,belonged,VBD,O
ncbi-sent-1014,to,TO,O
ncbi-sent-1014,the,DT,O
ncbi-sent-1014,non,JJ,O
ncbi-sent-1014,-,:,O
ncbi-sent-1014,FAP,NNP,O
ncbi-sent-1014,group,NN,O
ncbi-sent-1014,of,IN,O
ncbi-sent-1014,colorectal,JJ,B-DISEASE
ncbi-sent-1014,cancer,NN,I-DISEASE
ncbi-sent-1014,patients,NNS,O
ncbi-sent-1014,.,.,O
ncbi-sent-1015,Genotype,NNP,O
ncbi-sent-1015,-,:,O
ncbi-sent-1015,phenotype,NN,O
ncbi-sent-1015,correlations,NNS,O
ncbi-sent-1015,identified,VBN,O
ncbi-sent-1015,significant,JJ,O
ncbi-sent-1015,differences,NNS,O
ncbi-sent-1015,in,IN,O
ncbi-sent-1015,the,DT,O
ncbi-sent-1015,nature,NN,O
ncbi-sent-1015,of,IN,O
ncbi-sent-1015,certain,JJ,O
ncbi-sent-1015,extracolonic,JJ,O
ncbi-sent-1015,manifestations,NNS,O
ncbi-sent-1015,in,IN,O
ncbi-sent-1015,FAP,NNP,B-DISEASE
ncbi-sent-1015,patients,NNS,O
ncbi-sent-1015,belonging,VBG,O
ncbi-sent-1015,to,TO,O
ncbi-sent-1015,three,CD,O
ncbi-sent-1015,mutation,NN,O
ncbi-sent-1015,subgroups,NNS,O
ncbi-sent-1015,.,.,O
ncbi-sent-1016,CONCLUSIONS,NNP,O
ncbi-sent-1016,Extended,VBD,O
ncbi-sent-1016,genotype,JJ,O
ncbi-sent-1016,-,:,O
ncbi-sent-1016,phenotype,NN,O
ncbi-sent-1016,correlations,NNS,O
ncbi-sent-1016,made,VBN,O
ncbi-sent-1016,in,IN,O
ncbi-sent-1016,this,DT,O
ncbi-sent-1016,study,NN,O
ncbi-sent-1016,may,MD,O
ncbi-sent-1016,have,VB,O
ncbi-sent-1016,the,DT,O
ncbi-sent-1016,potential,NN,O
ncbi-sent-1016,to,TO,O
ncbi-sent-1016,determine,VB,O
ncbi-sent-1016,the,DT,O
ncbi-sent-1016,most,RBS,O
ncbi-sent-1016,appropriate,JJ,O
ncbi-sent-1016,surveillance,NN,O
ncbi-sent-1016,and,CC,O
ncbi-sent-1016,prophylactic,JJ,O
ncbi-sent-1016,treatment,NN,O
ncbi-sent-1016,regimens,NNS,O
ncbi-sent-1016,for,IN,O
ncbi-sent-1016,those,DT,O
ncbi-sent-1016,patients,NNS,O
ncbi-sent-1016,with,IN,O
ncbi-sent-1016,mutations,NNS,O
ncbi-sent-1016,associated,VBN,O
ncbi-sent-1016,with,IN,O
ncbi-sent-1016,life,NN,O
ncbi-sent-1016,threatening,VBG,O
ncbi-sent-1016,conditions,NNS,O
ncbi-sent-1016,.,.,O
ncbi-sent-1017,This,DT,O
ncbi-sent-1017,study,NN,O
ncbi-sent-1017,also,RB,O
ncbi-sent-1017,provided,VBD,O
ncbi-sent-1017,evidence,NN,O
ncbi-sent-1017,for,IN,O
ncbi-sent-1017,the,DT,O
ncbi-sent-1017,pathological,JJ,O
ncbi-sent-1017,nature,NN,O
ncbi-sent-1017,of,IN,O
ncbi-sent-1017,amino,NN,O
ncbi-sent-1017,acid,NN,O
ncbi-sent-1017,changes,NNS,O
ncbi-sent-1017,in,IN,O
ncbi-sent-1017,APC,NNP,O
ncbi-sent-1017,associated,VBN,O
ncbi-sent-1017,with,IN,O
ncbi-sent-1017,both,DT,O
ncbi-sent-1017,FAP,NNP,B-DISEASE
ncbi-sent-1017,and,CC,O
ncbi-sent-1017,non,SYM,O
ncbi-sent-1017,-,:,O
ncbi-sent-1017,FAP,NNP,O
ncbi-sent-1017,colorectal,JJ,B-DISEASE
ncbi-sent-1017,cancer,NN,I-DISEASE
ncbi-sent-1017,patients,NNS,O
ncbi-sent-1017,.,.,O
ncbi-sent-1018,.,.,O
ncbi-sent-1019,Inherited,JJ,B-DISEASE
ncbi-sent-1019,colorectal,JJ,I-DISEASE
ncbi-sent-1019,polyposis,NN,I-DISEASE
ncbi-sent-1019,and,CC,O
ncbi-sent-1019,cancer,NN,B-DISEASE
ncbi-sent-1019,risk,NN,O
ncbi-sent-1019,of,IN,O
ncbi-sent-1019,the,DT,O
ncbi-sent-1019,APC,NNP,O
ncbi-sent-1019,I1307K,NNP,O
ncbi-sent-1019,polymorphism,NN,O
ncbi-sent-1019,.,.,O
ncbi-sent-1020,Germ,NNP,O
ncbi-sent-1020,-,:,O
ncbi-sent-1020,line,NN,O
ncbi-sent-1020,and,CC,O
ncbi-sent-1020,somatic,JJ,O
ncbi-sent-1020,truncating,NN,O
ncbi-sent-1020,mutations,NNS,O
ncbi-sent-1020,of,IN,O
ncbi-sent-1020,the,DT,O
ncbi-sent-1020,APC,NNP,B-DISEASE
ncbi-sent-1020,gene,NN,O
ncbi-sent-1020,are,VBP,O
ncbi-sent-1020,thought,VBN,O
ncbi-sent-1020,to,TO,O
ncbi-sent-1020,initiate,VB,O
ncbi-sent-1020,colorectal,JJ,B-DISEASE
ncbi-sent-1020,tumor,NN,I-DISEASE
ncbi-sent-1020,formation,NN,O
ncbi-sent-1020,in,IN,O
ncbi-sent-1020,familial,JJ,B-DISEASE
ncbi-sent-1020,adenomatous,JJ,I-DISEASE
ncbi-sent-1020,polyposis,NN,I-DISEASE
ncbi-sent-1020,syndrome,NN,I-DISEASE
ncbi-sent-1020,and,CC,O
ncbi-sent-1020,sporadic,JJ,O
ncbi-sent-1020,colorectal,JJ,O
ncbi-sent-1020,carcinogenesis,NN,O
ncbi-sent-1020,",",",",O
ncbi-sent-1020,respectively,RB,O
ncbi-sent-1020,.,.,O
ncbi-sent-1021,Recently,RB,O
ncbi-sent-1021,",",",",O
ncbi-sent-1021,an,DT,O
ncbi-sent-1021,isoleucine,NN,O
ncbi-sent-1021,-,:,O
ncbi-sent-1021,-,:,O
ncbi-sent-1021,>,NN,O
ncbi-sent-1021,lysine,JJ,O
ncbi-sent-1021,polymorphism,NN,O
ncbi-sent-1021,at,IN,O
ncbi-sent-1021,codon,NN,O
ncbi-sent-1021,1307,CD,O
ncbi-sent-1021,(,(,O
ncbi-sent-1021,I1307K,NNP,O
ncbi-sent-1021,),),O
ncbi-sent-1021,of,IN,O
ncbi-sent-1021,the,DT,O
ncbi-sent-1021,APC,NNP,B-DISEASE
ncbi-sent-1021,gene,NN,O
ncbi-sent-1021,has,VBZ,O
ncbi-sent-1021,been,VBN,O
ncbi-sent-1021,identified,VBN,O
ncbi-sent-1021,in,IN,O
ncbi-sent-1021,6,CD,O
ncbi-sent-1021,%,NN,O
ncbi-sent-1021,-,:,O
ncbi-sent-1021,7,CD,O
ncbi-sent-1021,%,NN,O
ncbi-sent-1021,of,IN,O
ncbi-sent-1021,the,DT,O
ncbi-sent-1021,Ashkenazi,NNP,O
ncbi-sent-1021,Jewish,NNP,O
ncbi-sent-1021,population,NN,O
ncbi-sent-1021,.,.,O
ncbi-sent-1022,To,TO,O
ncbi-sent-1022,assess,VB,O
ncbi-sent-1022,the,DT,O
ncbi-sent-1022,risk,NN,O
ncbi-sent-1022,of,IN,O
ncbi-sent-1022,this,DT,O
ncbi-sent-1022,common,JJ,O
ncbi-sent-1022,APC,NNP,B-DISEASE
ncbi-sent-1022,allelic,JJ,O
ncbi-sent-1022,variant,NN,O
ncbi-sent-1022,in,IN,O
ncbi-sent-1022,colorectal,JJ,O
ncbi-sent-1022,carcinogenesis,NN,O
ncbi-sent-1022,",",",",O
ncbi-sent-1022,we,PRP,O
ncbi-sent-1022,have,VBP,O
ncbi-sent-1022,analyzed,VBN,O
ncbi-sent-1022,a,DT,O
ncbi-sent-1022,large,JJ,O
ncbi-sent-1022,cohort,NN,O
ncbi-sent-1022,of,IN,O
ncbi-sent-1022,unselected,JJ,O
ncbi-sent-1022,Ashkenazi,NNP,O
ncbi-sent-1022,Jewish,NNP,O
ncbi-sent-1022,subjects,NNS,O
ncbi-sent-1022,with,IN,O
ncbi-sent-1022,adenomatous,JJ,B-DISEASE
ncbi-sent-1022,polyps,NNS,I-DISEASE
ncbi-sent-1022,and,CC,O
ncbi-sent-1022,.,.,O
ncbi-sent-1023,or,CC,O
ncbi-sent-1023,colorectal,JJ,B-DISEASE
ncbi-sent-1023,cancer,NN,I-DISEASE
ncbi-sent-1023,",",",",I-DISEASE
ncbi-sent-1023,for,IN,O
ncbi-sent-1023,the,DT,O
ncbi-sent-1023,APC,NNP,O
ncbi-sent-1023,I1307K,NNP,O
ncbi-sent-1023,polymorphism,NN,O
ncbi-sent-1023,.,.,O
ncbi-sent-1024,The,DT,O
ncbi-sent-1024,APC,NNP,O
ncbi-sent-1024,I1307K,NNP,O
ncbi-sent-1024,allele,NN,O
ncbi-sent-1024,was,VBD,O
ncbi-sent-1024,identified,VBN,O
ncbi-sent-1024,in,IN,O
ncbi-sent-1024,48,CD,O
ncbi-sent-1024,(,(,O
ncbi-sent-1024,10,CD,O
ncbi-sent-1024,.,.,O
ncbi-sent-1025,1,CD,O
ncbi-sent-1025,%,NN,O
ncbi-sent-1025,),),O
ncbi-sent-1025,of,IN,O
ncbi-sent-1025,476,CD,O
ncbi-sent-1025,patients,NNS,O
ncbi-sent-1025,.,.,O
ncbi-sent-1026,Compared,VBN,O
ncbi-sent-1026,with,IN,O
ncbi-sent-1026,the,DT,O
ncbi-sent-1026,frequency,NN,O
ncbi-sent-1026,in,IN,O
ncbi-sent-1026,two,CD,O
ncbi-sent-1026,separate,JJ,O
ncbi-sent-1026,population,NN,O
ncbi-sent-1026,control,NN,O
ncbi-sent-1026,groups,NNS,O
ncbi-sent-1026,",",",",O
ncbi-sent-1026,the,DT,O
ncbi-sent-1026,APC,NNP,O
ncbi-sent-1026,I1307K,NNP,O
ncbi-sent-1026,allele,NN,O
ncbi-sent-1026,is,VBZ,O
ncbi-sent-1026,associated,VBN,O
ncbi-sent-1026,with,IN,O
ncbi-sent-1026,an,DT,O
ncbi-sent-1026,estimated,VBN,O
ncbi-sent-1026,relative,JJ,O
ncbi-sent-1026,risk,NN,O
ncbi-sent-1026,of,IN,O
ncbi-sent-1026,1,CD,O
ncbi-sent-1026,.,.,O
ncbi-sent-1027,5,CD,O
ncbi-sent-1027,-,:,O
ncbi-sent-1027,1,CD,O
ncbi-sent-1027,.,.,O
ncbi-sent-1028,7,CD,O
ncbi-sent-1028,for,IN,O
ncbi-sent-1028,colorectal,JJ,B-DISEASE
ncbi-sent-1028,neoplasia,NN,I-DISEASE
ncbi-sent-1028,(,(,O
ncbi-sent-1028,both,DT,O
ncbi-sent-1028,P,NNP,O
ncbi-sent-1028,=,NNP,O
ncbi-sent-1028,.,.,O
ncbi-sent-1029,01,CD,O
ncbi-sent-1029,),),O
ncbi-sent-1029,.,.,O
ncbi-sent-1030,Furthermore,UH,O
ncbi-sent-1030,",",",",O
ncbi-sent-1030,compared,VBN,O
ncbi-sent-1030,with,IN,O
ncbi-sent-1030,noncarriers,NNS,O
ncbi-sent-1030,",",",",O
ncbi-sent-1030,APC,NNP,O
ncbi-sent-1030,I1307K,NNP,O
ncbi-sent-1030,carriers,NNS,O
ncbi-sent-1030,had,VBD,O
ncbi-sent-1030,increased,VBN,O
ncbi-sent-1030,numbers,NNS,O
ncbi-sent-1030,of,IN,O
ncbi-sent-1030,adenomas,NN,B-DISEASE
ncbi-sent-1030,and,CC,O
ncbi-sent-1030,colorectal,JJ,B-DISEASE
ncbi-sent-1030,cancers,NNS,I-DISEASE
ncbi-sent-1030,per,IN,O
ncbi-sent-1030,patient,NN,O
ncbi-sent-1030,(,(,O
ncbi-sent-1030,P,NNP,O
ncbi-sent-1030,=,NNP,O
ncbi-sent-1030,.,.,O
ncbi-sent-1031,03,CD,O
ncbi-sent-1031,),),O
ncbi-sent-1031,",",",",O
ncbi-sent-1031,as,RB,O
ncbi-sent-1031,well,RB,O
ncbi-sent-1031,as,IN,O
ncbi-sent-1031,a,DT,O
ncbi-sent-1031,younger,JJR,O
ncbi-sent-1031,age,NN,O
ncbi-sent-1031,at,IN,O
ncbi-sent-1031,diagnosis,NN,O
ncbi-sent-1031,.,.,O
ncbi-sent-1032,We,PRP,O
ncbi-sent-1032,conclude,VBP,O
ncbi-sent-1032,that,IN,O
ncbi-sent-1032,the,DT,O
ncbi-sent-1032,APC,NNP,O
ncbi-sent-1032,I1307K,NNP,O
ncbi-sent-1032,variant,JJ,O
ncbi-sent-1032,leads,VBZ,O
ncbi-sent-1032,to,TO,O
ncbi-sent-1032,increased,VBN,O
ncbi-sent-1032,adenoma,NN,B-DISEASE
ncbi-sent-1032,formation,NN,O
ncbi-sent-1032,and,CC,O
ncbi-sent-1032,directly,RB,O
ncbi-sent-1032,contributes,VBZ,O
ncbi-sent-1032,to,TO,O
ncbi-sent-1032,3,CD,O
ncbi-sent-1032,%,NN,O
ncbi-sent-1032,-,:,O
ncbi-sent-1032,4,CD,O
ncbi-sent-1032,%,NN,O
ncbi-sent-1032,of,IN,O
ncbi-sent-1032,all,DT,O
ncbi-sent-1032,Ashkenazi,NNP,O
ncbi-sent-1032,Jewish,NNP,O
ncbi-sent-1032,colorectal,NN,B-DISEASE
ncbi-sent-1032,cancer,NN,I-DISEASE
ncbi-sent-1032,.,.,O
ncbi-sent-1033,The,DT,O
ncbi-sent-1033,estimated,JJ,O
ncbi-sent-1033,relative,JJ,O
ncbi-sent-1033,risk,NN,O
ncbi-sent-1033,for,IN,O
ncbi-sent-1033,carriers,NNS,O
ncbi-sent-1033,may,MD,O
ncbi-sent-1033,justify,VB,O
ncbi-sent-1033,specific,JJ,O
ncbi-sent-1033,clinical,JJ,O
ncbi-sent-1033,screening,NN,O
ncbi-sent-1033,for,IN,O
ncbi-sent-1033,the,DT,O
ncbi-sent-1033,360,CD,O
ncbi-sent-1033,",",",",O
ncbi-sent-1033,000,CD,O
ncbi-sent-1033,Americans,NNPS,O
ncbi-sent-1033,expected,VBN,O
ncbi-sent-1033,to,TO,O
ncbi-sent-1033,harbor,VB,O
ncbi-sent-1033,this,DT,O
ncbi-sent-1033,allele,NN,O
ncbi-sent-1033,",",",",O
ncbi-sent-1033,and,CC,O
ncbi-sent-1033,genetic,JJ,O
ncbi-sent-1033,testing,NN,O
ncbi-sent-1033,in,IN,O
ncbi-sent-1033,the,DT,O
ncbi-sent-1033,setting,NN,O
ncbi-sent-1033,of,IN,O
ncbi-sent-1033,long,JJ,O
ncbi-sent-1033,-,:,O
ncbi-sent-1033,term,NN,O
ncbi-sent-1033,-,:,O
ncbi-sent-1033,outcome,NN,O
ncbi-sent-1033,studies,NNS,O
ncbi-sent-1033,may,MD,O
ncbi-sent-1033,impact,VB,O
ncbi-sent-1033,significantly,RB,O
ncbi-sent-1033,on,IN,O
ncbi-sent-1033,colorectal,JJ,B-DISEASE
ncbi-sent-1033,cancer,NN,I-DISEASE
ncbi-sent-1033,prevention,NN,O
ncbi-sent-1033,in,IN,O
ncbi-sent-1033,this,DT,O
ncbi-sent-1033,population,NN,O
ncbi-sent-1033,.,.,O
ncbi-sent-1034,Localization,NNP,O
ncbi-sent-1034,of,IN,O
ncbi-sent-1034,human,JJ,O
ncbi-sent-1034,BRCA1,NNP,O
ncbi-sent-1034,and,CC,O
ncbi-sent-1034,its,PRP$,O
ncbi-sent-1034,loss,NN,O
ncbi-sent-1034,in,IN,O
ncbi-sent-1034,high,JJ,O
ncbi-sent-1034,-,:,O
ncbi-sent-1034,grade,NN,O
ncbi-sent-1034,",",",",O
ncbi-sent-1034,non,SYM,B-DISEASE
ncbi-sent-1034,-,:,I-DISEASE
ncbi-sent-1034,inherited,VBN,I-DISEASE
ncbi-sent-1034,breast,NN,I-DISEASE
ncbi-sent-1034,carcinomas,NN,I-DISEASE
ncbi-sent-1034,.,.,O
ncbi-sent-1035,Although,IN,O
ncbi-sent-1035,the,DT,O
ncbi-sent-1035,link,NN,O
ncbi-sent-1035,between,IN,O
ncbi-sent-1035,the,DT,O
ncbi-sent-1035,BRCA1,NNP,O
ncbi-sent-1035,tumour,SYM,B-DISEASE
ncbi-sent-1035,-,:,O
ncbi-sent-1035,suppressor,NN,O
ncbi-sent-1035,gene,NN,O
ncbi-sent-1035,and,CC,O
ncbi-sent-1035,hereditary,JJ,B-DISEASE
ncbi-sent-1035,breast,NN,I-DISEASE
ncbi-sent-1035,and,CC,I-DISEASE
ncbi-sent-1035,ovarian,JJ,I-DISEASE
ncbi-sent-1035,cancer,NN,I-DISEASE
ncbi-sent-1035,is,VBZ,O
ncbi-sent-1035,established,VBN,O
ncbi-sent-1035,",",",",O
ncbi-sent-1035,the,DT,O
ncbi-sent-1035,role,NN,O
ncbi-sent-1035,",",",",O
ncbi-sent-1035,if,IN,O
ncbi-sent-1035,any,DT,O
ncbi-sent-1035,",",",",O
ncbi-sent-1035,of,IN,O
ncbi-sent-1035,BRCA1,NNP,O
ncbi-sent-1035,in,IN,O
ncbi-sent-1035,non,JJ,B-DISEASE
ncbi-sent-1035,-,:,I-DISEASE
ncbi-sent-1035,familial,JJ,I-DISEASE
ncbi-sent-1035,cancers,NNS,I-DISEASE
ncbi-sent-1035,is,VBZ,O
ncbi-sent-1035,unclear,JJ,O
ncbi-sent-1035,.,.,O
ncbi-sent-1036,BRCA1,NNP,O
ncbi-sent-1036,mutations,NNS,O
ncbi-sent-1036,are,VBP,O
ncbi-sent-1036,rare,JJ,O
ncbi-sent-1036,in,IN,O
ncbi-sent-1036,sporadic,JJ,B-DISEASE
ncbi-sent-1036,cancers,NNS,I-DISEASE
ncbi-sent-1036,",",",",O
ncbi-sent-1036,but,CC,O
ncbi-sent-1036,loss,NN,O
ncbi-sent-1036,of,IN,O
ncbi-sent-1036,BRCA1,NNP,O
ncbi-sent-1036,resulting,VBG,O
ncbi-sent-1036,from,IN,O
ncbi-sent-1036,reduced,VBN,O
ncbi-sent-1036,expression,NN,O
ncbi-sent-1036,or,CC,O
ncbi-sent-1036,incorrect,VB,O
ncbi-sent-1036,subcellular,JJ,O
ncbi-sent-1036,localization,NN,O
ncbi-sent-1036,is,VBZ,O
ncbi-sent-1036,postulated,VBN,O
ncbi-sent-1036,to,TO,O
ncbi-sent-1036,be,VB,O
ncbi-sent-1036,important,JJ,O
ncbi-sent-1036,in,IN,O
ncbi-sent-1036,non,JJ,B-DISEASE
ncbi-sent-1036,-,:,I-DISEASE
ncbi-sent-1036,familial,JJ,I-DISEASE
ncbi-sent-1036,breast,NN,I-DISEASE
ncbi-sent-1036,and,CC,I-DISEASE
ncbi-sent-1036,ovarian,JJ,I-DISEASE
ncbi-sent-1036,cancers,NNS,I-DISEASE
ncbi-sent-1036,.,.,O
ncbi-sent-1037,Epigenetic,JJ,O
ncbi-sent-1037,loss,NN,O
ncbi-sent-1037,",",",",O
ncbi-sent-1037,however,RB,O
ncbi-sent-1037,",",",",O
ncbi-sent-1037,has,VBZ,O
ncbi-sent-1037,not,RB,O
ncbi-sent-1037,received,VBN,O
ncbi-sent-1037,general,JJ,O
ncbi-sent-1037,acceptance,NN,O
ncbi-sent-1037,due,JJ,O
ncbi-sent-1037,to,TO,O
ncbi-sent-1037,controversy,VB,O
ncbi-sent-1037,regarding,VBG,O
ncbi-sent-1037,the,DT,O
ncbi-sent-1037,subcellular,JJ,O
ncbi-sent-1037,localization,NN,O
ncbi-sent-1037,of,IN,O
ncbi-sent-1037,BRCA1,NNP,O
ncbi-sent-1037,proteins,NNS,O
ncbi-sent-1037,",",",",O
ncbi-sent-1037,reports,NNS,O
ncbi-sent-1037,of,IN,O
ncbi-sent-1037,which,WDT,O
ncbi-sent-1037,have,VBP,O
ncbi-sent-1037,ranged,VBN,O
ncbi-sent-1037,from,IN,O
ncbi-sent-1037,exclusively,RB,O
ncbi-sent-1037,nuclear,JJ,O
ncbi-sent-1037,",",",",O
ncbi-sent-1037,to,TO,O
ncbi-sent-1037,conditionally,RB,O
ncbi-sent-1037,nuclear,JJ,O
ncbi-sent-1037,",",",",O
ncbi-sent-1037,to,TO,O
ncbi-sent-1037,the,DT,O
ncbi-sent-1037,ER,NNP,O
ncbi-sent-1037,/,NNP,O
ncbi-sent-1037,golgi,NN,O
ncbi-sent-1037,",",",",O
ncbi-sent-1037,to,TO,O
ncbi-sent-1037,cytoplasmic,VB,O
ncbi-sent-1037,invaginations,NNS,O
ncbi-sent-1037,into,IN,O
ncbi-sent-1037,the,DT,O
ncbi-sent-1037,nucleus,NN,O
ncbi-sent-1037,.,.,O
ncbi-sent-1038,In,IN,O
ncbi-sent-1038,an,DT,O
ncbi-sent-1038,attempt,NN,O
ncbi-sent-1038,to,TO,O
ncbi-sent-1038,resolve,VB,O
ncbi-sent-1038,this,DT,O
ncbi-sent-1038,issue,NN,O
ncbi-sent-1038,",",",",O
ncbi-sent-1038,we,PRP,O
ncbi-sent-1038,have,VBP,O
ncbi-sent-1038,comprehensively,RB,O
ncbi-sent-1038,characterized,VBN,O
ncbi-sent-1038,19,CD,O
ncbi-sent-1038,anti,JJ,O
ncbi-sent-1038,-,:,O
ncbi-sent-1038,BRCA1,NNP,O
ncbi-sent-1038,antibodies,NNS,O
ncbi-sent-1038,.,.,O
ncbi-sent-1039,These,DT,O
ncbi-sent-1039,reagents,NNS,O
ncbi-sent-1039,detect,VBP,O
ncbi-sent-1039,a,DT,O
ncbi-sent-1039,220,CD,O
ncbi-sent-1039,-,:,O
ncbi-sent-1039,kD,NN,O
ncbi-sent-1039,protein,NN,O
ncbi-sent-1039,localized,VBN,O
ncbi-sent-1039,in,IN,O
ncbi-sent-1039,discrete,JJ,O
ncbi-sent-1039,nuclear,JJ,O
ncbi-sent-1039,foci,NN,O
ncbi-sent-1039,in,IN,O
ncbi-sent-1039,all,DT,O
ncbi-sent-1039,epithelial,JJ,O
ncbi-sent-1039,cell,NN,O
ncbi-sent-1039,lines,NNS,O
ncbi-sent-1039,",",",",O
ncbi-sent-1039,including,VBG,O
ncbi-sent-1039,those,DT,O
ncbi-sent-1039,derived,VBN,O
ncbi-sent-1039,from,IN,O
ncbi-sent-1039,breast,NN,B-DISEASE
ncbi-sent-1039,malignancies,NNS,I-DISEASE
ncbi-sent-1039,.,.,O
ncbi-sent-1040,Immunohistochemical,JJ,O
ncbi-sent-1040,staining,NN,O
ncbi-sent-1040,of,IN,O
ncbi-sent-1040,human,JJ,O
ncbi-sent-1040,breast,NN,O
ncbi-sent-1040,specimens,NNS,O
ncbi-sent-1040,also,RB,O
ncbi-sent-1040,revealed,VBD,O
ncbi-sent-1040,BRCA1,NNP,O
ncbi-sent-1040,nuclear,JJ,O
ncbi-sent-1040,foci,NN,O
ncbi-sent-1040,in,IN,O
ncbi-sent-1040,benign,JJ,O
ncbi-sent-1040,breast,NN,O
ncbi-sent-1040,",",",",O
ncbi-sent-1040,invasive,JJ,B-DISEASE
ncbi-sent-1040,lobular,NN,I-DISEASE
ncbi-sent-1040,cancers,NNS,I-DISEASE
ncbi-sent-1040,and,CC,O
ncbi-sent-1040,low,JJ,B-DISEASE
ncbi-sent-1040,-,:,I-DISEASE
ncbi-sent-1040,grade,NN,I-DISEASE
ncbi-sent-1040,ductal,JJ,I-DISEASE
ncbi-sent-1040,carcinomas,NN,I-DISEASE
ncbi-sent-1040,.,.,O
ncbi-sent-1041,Conversely,RB,O
ncbi-sent-1041,",",",",O
ncbi-sent-1041,BRCA1,NNP,O
ncbi-sent-1041,expression,NN,O
ncbi-sent-1041,was,VBD,O
ncbi-sent-1041,reduced,VBN,O
ncbi-sent-1041,or,CC,O
ncbi-sent-1041,undetectable,JJ,O
ncbi-sent-1041,in,IN,O
ncbi-sent-1041,the,DT,O
ncbi-sent-1041,majority,NN,O
ncbi-sent-1041,of,IN,O
ncbi-sent-1041,high,JJ,O
ncbi-sent-1041,-,:,O
ncbi-sent-1041,grade,NN,O
ncbi-sent-1041,",",",",O
ncbi-sent-1041,ductal,JJ,B-DISEASE
ncbi-sent-1041,carcinomas,NN,I-DISEASE
ncbi-sent-1041,",",",",O
ncbi-sent-1041,suggesting,VBG,O
ncbi-sent-1041,that,IN,O
ncbi-sent-1041,absence,NN,O
ncbi-sent-1041,of,IN,O
ncbi-sent-1041,BRCA1,NNP,O
ncbi-sent-1041,may,MD,O
ncbi-sent-1041,contribute,VB,O
ncbi-sent-1041,to,TO,O
ncbi-sent-1041,the,DT,O
ncbi-sent-1041,pathogenesis,NN,O
ncbi-sent-1041,of,IN,O
ncbi-sent-1041,a,DT,O
ncbi-sent-1041,significant,JJ,O
ncbi-sent-1041,percentage,NN,O
ncbi-sent-1041,of,IN,O
ncbi-sent-1041,sporadic,JJ,B-DISEASE
ncbi-sent-1041,breast,NN,I-DISEASE
ncbi-sent-1041,cancers,NNS,I-DISEASE
ncbi-sent-1041,.,.,O
ncbi-sent-1042,.,.,O
,Torsade,NNP,B-DISEASE
,de,FW,I-DISEASE
,pointes,VBZ,I-DISEASE
,ventricular,JJ,B-DISEASE
,tachycardia,NN,I-DISEASE
,during,IN,O
,low,JJ,O
,dose,JJ,O
,intermittent,NN,O
,dobutamine,NN,O
,treatment,NN,O
,in,IN,O
,a,DT,O
,patient,NN,O
,with,IN,O
,dilated,VBN,B-DISEASE
,cardiomyopathy,NN,I-DISEASE
,and,CC,O
,congestive,JJ,B-DISEASE
,heart,NN,I-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,The,DT,O
,authors,NNS,O
,describe,VBP,O
,the,DT,O
,case,NN,O
,of,IN,O
,a,DT,O
,56,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,with,IN,O
,chronic,JJ,O
,",",",",O
,severe,JJ,O
,heart,NN,B-DISEASE
,failure,NN,I-DISEASE
,secondary,JJ,O
,to,TO,O
,dilated,VBN,B-DISEASE
,cardiomyopathy,NN,I-DISEASE
,and,CC,O
,absence,NN,O
,of,IN,O
,significant,JJ,O
,ventricular,JJ,B-DISEASE
,arrhythmias,NNS,I-DISEASE
,who,WP,O
,developed,VBD,O
,QT,NNP,B-DISEASE
,prolongation,NN,I-DISEASE
,and,CC,O
,torsade,NN,B-DISEASE
,de,FW,I-DISEASE
,pointes,VBZ,I-DISEASE
,ventricular,JJ,B-DISEASE
,tachycardia,NN,I-DISEASE
,during,IN,O
,one,CD,O
,cycle,NN,O
,of,IN,O
,intermittent,JJ,O
,low,JJ,O
,dose,NN,O
,(,(,O
,2,CD,O
,.,.,O
,5,CD,O
,mcg,JJ,O
,/,NNP,O
,kg,NN,O
,per,IN,O
,min,NN,O
,),),O
,dobutamine,NN,O
,.,.,O
,This,DT,O
,report,NN,O
,of,IN,O
,torsade,NN,B-DISEASE
,de,FW,I-DISEASE
,pointes,VBZ,I-DISEASE
,ventricular,JJ,B-DISEASE
,tachycardia,NN,I-DISEASE
,during,IN,O
,intermittent,JJ,O
,dobutamine,NN,O
,supports,VBZ,O
,the,DT,O
,hypothesis,NN,O
,that,WDT,O
,unpredictable,JJ,O
,fatal,JJ,O
,arrhythmias,NN,B-DISEASE
,may,MD,O
,occur,VB,O
,even,RB,O
,with,IN,O
,low,JJ,O
,doses,NNS,O
,and,CC,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,no,DT,O
,history,NN,O
,of,IN,O
,significant,JJ,O
,rhythm,NN,O
,disturbances,NNS,O
,.,.,O
,The,DT,O
,mechanisms,NN,O
,of,IN,O
,proarrhythmic,JJ,O
,effects,NNS,O
,of,IN,O
,Dubutamine,NNP,O
,are,VBP,O
,discussed,VBN,O
,.,.,O
,Positive,JJ,O
,skin,NN,O
,tests,NNS,O
,in,IN,O
,late,JJ,O
,reactions,NNS,O
,to,TO,O
,radiographic,VB,O
,contrast,NN,O
,media,NNS,O
,.,.,O
,In,IN,O
,the,DT,O
,last,JJ,O
,few,JJ,O
,years,NNS,O
,delayed,VBN,O
,reactions,NNS,O
,several,JJ,O
,hours,NNS,O
,after,IN,O
,the,DT,O
,injection,NN,O
,of,IN,O
,radiographic,JJ,O
,and,CC,O
,contrast,JJ,O
,materials,NNS,O
,(,(,O
,PRC,NNP,O
,),),O
,have,VBP,O
,been,VBN,O
,described,VBN,O
,with,IN,O
,increasing,VBG,O
,frequency,NN,O
,.,.,O
,The,DT,O
,authors,NNS,O
,report,VBP,O
,two,CD,O
,observations,NNS,O
,on,IN,O
,patients,NNS,O
,with,IN,O
,delayed,JJ,O
,reactions,NNS,O
,in,IN,O
,whom,WP,O
,intradermoreactions,NNS,O
,(,(,O
,IDR,NNP,O
,),),O
,and,CC,O
,patch,NN,O
,tests,NNS,O
,to,TO,O
,a,DT,O
,series,NN,O
,of,IN,O
,ionic,JJ,O
,and,CC,O
,non,JJ,O
,ionic,JJ,O
,PRC,NNP,O
,were,VBD,O
,studied,VBN,O
,.,.,O
,After,IN,O
,angiography,NN,O
,by,IN,O
,the,DT,O
,venous,JJ,O
,route,NN,O
,in,IN,O
,patient,JJ,O
,n,JJ,O
,degree,NN,O
,1,CD,O
,a,DT,O
,biphasic,JJ,O
,reaction,NN,O
,with,IN,O
,an,DT,O
,immediate,JJ,O
,reaction,NN,O
,(,(,O
,dyspnea,NN,B-DISEASE
,",",",",O
,loss,NN,B-DISEASE
,of,IN,I-DISEASE
,consciousness,NN,I-DISEASE
,),),O
,and,CC,O
,delayed,VBN,O
,macro,SYM,B-DISEASE
,-,:,I-DISEASE
,papular,JJ,I-DISEASE
,rash,NN,I-DISEASE
,appeared,VBD,O
,",",",",O
,whilst,JJ,O
,patient,NN,O
,n,RB,O
,degree,JJ,O
,2,CD,O
,developed,VBD,O
,a,DT,O
,generalised,JJ,O
,sensation,NN,O
,of,IN,O
,heat,NN,O
,",",",",O
,persistent,JJ,O
,pain,NN,B-DISEASE
,at,IN,O
,the,DT,O
,site,NN,O
,of,IN,O
,injection,NN,O
,immediately,RB,O
,and,CC,O
,a,DT,O
,generalised,JJ,O
,macro,NN,O
,-,:,O
,papular,JJ,O
,reaction,NN,O
,after,IN,O
,24,CD,O
,hours,NNS,O
,.,.,O
,The,DT,O
,skin,NN,O
,tests,NNS,O
,revealed,VBD,O
,positive,JJ,O
,delayed,JJ,O
,reactions,NNS,O
,of,IN,O
,24,CD,O
,hours,NNS,O
,and,CC,O
,48,CD,O
,hours,NNS,O
,by,IN,O
,IDR,NNP,O
,and,CC,O
,patch,NN,O
,tests,NNS,O
,to,TO,O
,only,RB,O
,some,DT,O
,PRC,NN,O
,with,IN,O
,common,JJ,O
,chains,NNS,O
,in,IN,O
,their,PRP$,O
,structures,NNS,O
,.,.,O
,The,DT,O
,positive,JJ,O
,skin,NN,O
,tests,NNS,O
,are,VBP,O
,in,IN,O
,favour,NN,O
,of,IN,O
,immunological,JJ,O
,reactions,NNS,O
,and,CC,O
,may,MD,O
,help,VB,O
,in,IN,O
,diagnosis,NN,O
,of,IN,O
,allergy,NN,B-DISEASE
,in,IN,O
,the,DT,O
,patients,NNS,O
,.,.,O
,Risk,NN,O
,of,IN,O
,transient,JJ,O
,hyperammonemic,JJ,B-DISEASE
,encephalopathy,NN,I-DISEASE
,in,IN,O
,cancer,NN,B-DISEASE
,patients,NNS,O
,who,WP,O
,received,VBD,O
,continuous,JJ,O
,infusion,NN,O
,of,IN,O
,5,CD,O
,-,:,O
,fluorouracil,NN,O
,with,IN,O
,the,DT,O
,complication,NN,O
,of,IN,O
,dehydration,NN,B-DISEASE
,and,CC,O
,infection,NN,B-DISEASE
,.,.,O
,From,IN,O
,1986,CD,O
,to,TO,O
,1998,CD,O
,",",",",O
,29,CD,O
,cancer,NN,B-DISEASE
,patients,NNS,O
,who,WP,O
,had,VBD,O
,32,CD,O
,episodes,NNS,O
,of,IN,O
,transient,JJ,O
,hyperammonemic,JJ,B-DISEASE
,encephalopathy,NN,I-DISEASE
,related,VBN,O
,to,TO,O
,continuous,JJ,O
,infusion,NN,O
,of,IN,O
,5,CD,O
,-,:,O
,fluorouracil,NN,O
,(,(,O
,5,CD,O
,-,:,O
,FU,NN,O
,),),O
,were,VBD,O
,identified,VBN,O
,.,.,O
,None,NN,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,had,VBD,O
,decompensated,VBN,O
,liver,RB,B-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,Onset,NNP,O
,of,IN,O
,hyperammonemic,JJ,B-DISEASE
,encephalopathy,JJ,I-DISEASE
,varied,VBN,O
,from,IN,O
,0,CD,O
,.,.,O
,5,CD,O
,to,TO,O
,5,CD,O
,days,NNS,O
,(,(,O
,mean,JJ,O
,:,:,O
,2,CD,O
,.,.,O
,6,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,3,CD,O
,days,NNS,O
,),),O
,after,IN,O
,the,DT,O
,initiation,NN,O
,of,IN,O
,chemotherapy,NN,O
,.,.,O
,Plasma,NNP,O
,ammonium,JJ,O
,level,NN,O
,ranged,VBD,O
,from,IN,O
,248,CD,O
,to,TO,O
,2387,CD,O
,microg,NN,O
,%,NN,O
,(,(,O
,mean,JJ,O
,:,:,O
,626,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,431,CD,O
,microg,CD,O
,%,NN,O
,),),O
,.,.,O
,Among,IN,O
,the,DT,O
,32,CD,O
,episodes,NNS,O
,",",",",O
,26,CD,O
,(,(,O
,81,CD,O
,%,NN,O
,),),O
,had,VBD,O
,various,JJ,O
,degrees,NNS,O
,of,IN,O
,azotemia,NN,B-DISEASE
,",",",",O
,18,CD,O
,(,(,O
,56,CD,O
,%,NN,O
,),),O
,occurred,VBD,O
,during,IN,O
,bacterial,JJ,B-DISEASE
,infections,NNS,I-DISEASE
,and,CC,O
,14,CD,O
,(,(,O
,44,CD,O
,%,NN,O
,),),O
,without,IN,O
,infection,NN,B-DISEASE
,occurred,VBD,O
,during,IN,O
,periods,NNS,O
,of,IN,O
,dehydration,NN,B-DISEASE
,.,.,O
,Higher,JJR,O
,plasma,JJ,O
,ammonium,NN,O
,levels,NNS,O
,and,CC,O
,more,RBR,O
,rapid,JJ,O
,onset,NN,O
,of,IN,O
,hyperammonemia,NN,B-DISEASE
,were,VBD,O
,seen,VBN,O
,in,IN,O
,18,CD,O
,patients,NNS,O
,with,IN,O
,bacterial,JJ,B-DISEASE
,infections,NNS,I-DISEASE
,(,(,O
,p,JJ,O
,=,NN,O
,0,CD,O
,.,.,O
,003,CD,O
,and,CC,O
,0,CD,O
,.,.,O
,0006,CD,O
,",",",",O
,respectively,RB,O
,),),O
,and,CC,O
,in,IN,O
,nine,CD,O
,patients,NNS,O
,receiving,VBG,O
,high,JJ,O
,daily,JJ,O
,doses,NNS,O
,(,(,O
,2600,CD,O
,or,CC,O
,1800,CD,O
,mg,NN,O
,/,NNP,O
,m2,NN,O
,),),O
,of,IN,O
,5,CD,O
,-,:,O
,FU,NN,O
,(,(,O
,p,JJ,O
,=,NN,O
,0,CD,O
,.,.,O
,0001,CD,O
,and,CC,O
,<,$,O
,0,CD,O
,.,.,O
,0001,CD,O
,",",",",O
,respectively,RB,O
,),),O
,.,.,O
,In,IN,O
,25,CD,O
,out,IN,O
,of,IN,O
,32,CD,O
,episodes,NNS,O
,(,(,O
,78,CD,O
,%,NN,O
,),),O
,",",",",O
,plasma,JJ,O
,ammonium,NN,O
,levels,NNS,O
,and,CC,O
,mental,JJ,O
,status,NN,O
,returned,VBD,O
,to,TO,O
,normal,JJ,O
,within,IN,O
,2,CD,O
,days,NNS,O
,after,IN,O
,adequate,JJ,O
,management,NN,O
,.,.,O
,In,IN,O
,conclusion,NN,O
,",",",",O
,hyperammonemic,JJ,B-DISEASE
,encephalopathy,NN,I-DISEASE
,can,MD,O
,occur,VB,O
,in,IN,O
,patients,NNS,O
,receiving,VBG,O
,continuous,JJ,O
,infusion,NN,O
,of,IN,O
,5,CD,O
,-,:,O
,FU,NN,O
,.,.,O
,Azotemia,NNP,B-DISEASE
,",",",",O
,body,NN,O
,fluid,JJ,O
,insufficiency,NN,O
,and,CC,O
,bacterial,JJ,B-DISEASE
,infections,NNS,I-DISEASE
,were,VBD,O
,frequently,RB,O
,found,VBN,O
,in,IN,O
,these,DT,O
,patients,NNS,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,therefore,RB,O
,important,JJ,O
,to,TO,O
,recognize,VB,O
,this,DT,O
,condition,NN,O
,in,IN,O
,patients,NNS,O
,receiving,VBG,O
,continuous,JJ,O
,infusion,NN,O
,of,IN,O
,5,CD,O
,-,:,O
,FU,NN,O
,.,.,O
,The,DT,O
,effects,NNS,O
,of,IN,O
,quinine,NN,O
,and,CC,O
,4,CD,O
,-,:,O
,aminopyridine,NN,O
,on,IN,O
,conditioned,JJ,O
,place,NN,O
,preference,NN,O
,and,CC,O
,changes,NNS,O
,in,IN,O
,motor,NN,O
,activity,NN,O
,induced,VBN,O
,by,IN,O
,morphine,NN,O
,in,IN,O
,rats,NNS,O
,.,.,O
,1,CD,O
,.,.,O
,The,DT,O
,effects,NNS,O
,of,IN,O
,two,CD,O
,unselective,JJ,O
,potassium,NN,O
,(,(,O
,K,NNP,O
,(,(,O
,+,NNP,O
,),),O
,-,:,O
,),),O
,channel,NN,O
,blockers,NNS,O
,",",",",O
,quinine,NN,O
,(,(,O
,12,CD,O
,.,.,O
,5,CD,O
,",",",",O
,25,CD,O
,and,CC,O
,50,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,and,CC,O
,4,CD,O
,-,:,O
,aminopyridine,NN,O
,(,(,O
,1,CD,O
,and,CC,O
,2,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,",",",",O
,on,IN,O
,conditioned,JJ,O
,place,NN,O
,preference,NN,O
,and,CC,O
,biphasic,JJ,O
,changes,NNS,O
,in,IN,O
,motor,NN,O
,activity,NN,O
,induced,VBN,O
,by,IN,O
,morphine,NN,O
,(,(,O
,10,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,were,VBD,O
,tested,VBN,O
,in,IN,O
,Wistar,NNP,O
,rats,NNS,O
,.,.,O
,Quinine,NNP,O
,is,VBZ,O
,known,VBN,O
,to,TO,O
,block,VB,O
,voltage,NN,O
,-,:,O
,",",",",O
,calcium,NN,O
,-,:,O
,and,CC,O
,ATP,NNP,O
,-,:,O
,sensitive,JJ,O
,K,NNP,O
,(,(,O
,+,NNP,O
,),),O
,-,:,O
,channels,NNS,O
,while,IN,O
,4,CD,O
,-,:,O
,aminopyridine,NN,O
,is,VBZ,O
,known,VBN,O
,to,TO,O
,block,VB,O
,voltage,NN,O
,-,:,O
,sensitive,JJ,O
,K,NNP,O
,(,(,O
,+,NNP,O
,),),O
,-,:,O
,channels,NNS,O
,.,.,O
,2,CD,O
,.,.,O
,In,IN,O
,the,DT,O
,counterbalanced,JJ,O
,method,NN,O
,",",",",O
,quinine,NN,O
,attenuated,VBN,O
,morphine,JJ,O
,-,:,O
,induced,JJ,O
,place,NN,O
,preference,NN,O
,",",",",O
,whereas,IN,O
,4,CD,O
,-,:,O
,aminopyridine,NN,O
,was,VBD,O
,ineffective,JJ,O
,.,.,O
,In,IN,O
,the,DT,O
,motor,NN,O
,activity,NN,O
,test,NN,O
,measured,VBN,O
,with,IN,O
,an,DT,O
,Animex,NNP,O
,-,:,O
,activity,NN,O
,meter,NN,O
,neither,DT,O
,of,IN,O
,the,DT,O
,K,NNP,O
,(,(,O
,+,NNP,O
,),),O
,-,:,O
,channel,NN,O
,blockers,NNS,O
,affected,VBD,O
,morphine,JJ,O
,-,:,O
,induced,JJ,O
,hypoactivity,NN,B-DISEASE
,",",",",O
,but,CC,O
,both,DT,O
,K,NNP,O
,(,(,O
,+,NNP,O
,),),O
,-,:,O
,channel,NN,O
,blockers,NNS,O
,prevented,VBD,O
,morphine,JJ,O
,-,:,O
,induced,JJ,O
,secondary,JJ,O
,hyperactivity,NN,B-DISEASE
,.,.,O
,3,CD,O
,.,.,O
,These,DT,O
,results,NNS,O
,suggest,VBP,O
,the,DT,O
,involvement,NN,O
,of,IN,O
,quinine,JJ,O
,-,:,O
,sensitive,JJ,O
,but,CC,O
,not,RB,O
,4,CD,O
,-,:,O
,aminopyridine,NN,O
,-,:,O
,sensitive,JJ,O
,K,NNP,O
,(,(,O
,+,NNP,O
,),),O
,-,:,O
,channels,NNS,O
,in,IN,O
,morphine,JJ,O
,reward,NN,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,also,RB,O
,suggested,VBN,O
,that,IN,O
,the,DT,O
,blockade,NN,O
,of,IN,O
,K,NNP,O
,(,(,O
,+,NNP,O
,),),O
,-,:,O
,channels,NNS,O
,sensitive,VBP,O
,to,TO,O
,these,DT,O
,blockers,NNS,O
,is,VBZ,O
,not,RB,O
,sufficient,JJ,O
,to,TO,O
,prevent,VB,O
,morphine,JJ,O
,-,:,O
,induced,JJ,O
,hypoactivity,NN,B-DISEASE
,whereas,NNS,O
,morphine,VBP,O
,-,:,O
,induced,JJ,O
,hyperactivity,NN,B-DISEASE
,seems,VBZ,O
,to,TO,O
,be,VB,O
,connected,VBN,O
,to,TO,O
,both,DT,O
,quinine,JJ,O
,-,:,O
,and,CC,O
,4,CD,O
,-,:,O
,aminopyridine,NN,O
,-,:,O
,sensitive,JJ,O
,K,NNP,O
,(,(,O
,+,NNP,O
,),),O
,-,:,O
,channels,NNS,O
,.,.,O
,Nociceptin,NNP,O
,/,JJ,O
,orphanin,NN,O
,FQ,NNP,O
,and,CC,O
,nocistatin,RB,O
,on,IN,O
,learning,NN,B-DISEASE
,and,CC,I-DISEASE
,memory,NN,I-DISEASE
,impairment,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,scopolamine,NN,O
,in,IN,O
,mice,NN,O
,.,.,O
,1,CD,O
,.,.,O
,Nociceptin,NNP,O
,",",",",O
,also,RB,O
,known,VBN,O
,as,IN,O
,orphanin,NN,O
,FQ,NNP,O
,",",",",O
,is,VBZ,O
,an,DT,O
,endogenous,JJ,O
,ligand,NN,O
,for,IN,O
,the,DT,O
,orphan,JJ,O
,opioid,NN,O
,receptor,NN,O
,-,:,O
,like,IN,O
,receptor,NN,O
,1,CD,O
,(,(,O
,ORL1,NNP,O
,),),O
,and,CC,O
,involves,VBZ,O
,in,IN,O
,various,JJ,O
,functions,NNS,O
,in,IN,O
,the,DT,O
,central,JJ,O
,nervous,JJ,O
,system,NN,O
,(,(,O
,CNS,NNP,O
,),),O
,.,.,O
,On,IN,O
,the,DT,O
,other,JJ,O
,hand,NN,O
,",",",",O
,nocistatin,NN,O
,is,VBZ,O
,recently,RB,O
,isolated,VBN,O
,from,IN,O
,the,DT,O
,same,JJ,O
,precursor,NN,O
,as,IN,O
,nociceptin,NN,O
,and,CC,O
,blocks,NNS,O
,nociceptin,SYM,O
,-,:,O
,induced,VBN,O
,allodynia,NN,B-DISEASE
,and,CC,O
,hyperalgesia,NN,B-DISEASE
,.,.,O
,2,CD,O
,.,.,O
,Although,IN,O
,ORL1,NNP,O
,receptors,NNS,O
,which,WDT,O
,display,VBP,O
,a,DT,O
,high,JJ,O
,degree,NN,O
,of,IN,O
,sequence,NN,O
,homology,NN,O
,with,IN,O
,classical,JJ,O
,opioid,NN,O
,receptors,NNS,O
,are,VBP,O
,abundant,JJ,O
,in,IN,O
,the,DT,O
,hippocampus,NN,O
,",",",",O
,little,JJ,O
,is,VBZ,O
,known,VBN,O
,regarding,VBG,O
,their,PRP$,O
,role,NN,O
,in,IN,O
,learning,VBG,O
,and,CC,O
,memory,NN,O
,.,.,O
,3,CD,O
,.,.,O
,The,DT,O
,present,JJ,O
,study,NN,O
,was,VBD,O
,designed,VBN,O
,to,TO,O
,investigate,VB,O
,whether,IN,O
,nociceptin,JJ,O
,/,NNP,O
,orphanin,NN,O
,FQ,NNP,O
,and,CC,O
,nocistatin,NN,O
,could,MD,O
,modulate,VB,O
,impairment,NN,B-DISEASE
,of,IN,I-DISEASE
,learning,NN,I-DISEASE
,and,CC,I-DISEASE
,memory,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,scopolamine,NN,O
,",",",",O
,a,DT,O
,muscarinic,JJ,O
,cholinergic,NN,O
,receptor,NN,O
,antagonist,NN,O
,",",",",O
,using,VBG,O
,spontaneous,JJ,O
,alternation,NN,O
,of,IN,O
,Y,NNP,O
,-,:,O
,maze,NN,O
,and,CC,O
,step,NN,O
,-,:,O
,down,RB,O
,type,RB,O
,passive,JJ,O
,avoidance,NN,O
,tasks,NNS,O
,in,IN,O
,mice,NN,O
,.,.,O
,4,CD,O
,.,.,O
,While,IN,O
,nocistatin,NN,O
,(,(,O
,0,CD,O
,.,.,O
,5,CD,O
,-,:,O
,5,CD,O
,.,.,O
,0,CD,O
,nmol,JJ,O
,mouse,NN,O
,-,:,O
,1,CD,O
,",",",",O
,i,NN,O
,.,.,O
,c,NN,O
,.,.,O
,v,NN,O
,.,.,O
,),),O
,administered,VBD,O
,30,CD,O
,min,NN,O
,before,IN,O
,spontaneous,JJ,O
,alternation,NN,O
,performance,NN,O
,or,CC,O
,the,DT,O
,training,NN,O
,session,NN,O
,of,IN,O
,the,DT,O
,passive,JJ,O
,avoidance,NN,O
,task,NN,O
,",",",",O
,had,VBD,O
,no,DT,O
,effect,NN,O
,on,IN,O
,spontaneous,JJ,O
,alternation,NN,O
,or,CC,O
,passive,JJ,O
,avoidance,NN,O
,behaviours,NNS,O
,",",",",O
,a,DT,O
,lower,JJR,O
,per,IN,O
,cent,NN,O
,alternation,NN,O
,and,CC,O
,shorter,JJR,O
,median,JJ,O
,step,NN,O
,-,:,O
,down,RB,O
,latency,NN,O
,in,IN,O
,the,DT,O
,retention,NN,O
,test,NN,O
,were,VBD,O
,obtained,VBN,O
,in,IN,O
,nociceptin,NN,O
,(,(,O
,1,CD,O
,.,.,O
,5,CD,O
,and,CC,O
,/,NNP,O
,or,CC,O
,5,CD,O
,.,.,O
,0,CD,O
,nmol,JJ,O
,mouse,NN,O
,-,:,O
,1,CD,O
,",",",",O
,i,NN,O
,.,.,O
,c,NN,O
,.,.,O
,v,NN,O
,.,.,O
,),),O
,-,:,O
,treated,VBN,O
,normal,JJ,O
,mice,NN,O
,.,.,O
,5,CD,O
,.,.,O
,Administration,NN,O
,of,IN,O
,nocistatin,NN,O
,(,(,O
,1,CD,O
,.,.,O
,5,CD,O
,and,CC,O
,/,NNP,O
,or,CC,O
,5,CD,O
,.,.,O
,0,CD,O
,nmol,JJ,O
,mouse,NN,O
,-,:,O
,1,CD,O
,",",",",O
,i,NN,O
,.,.,O
,c,NN,O
,.,.,O
,v,NN,O
,.,.,O
,),),O
,30,CD,O
,min,NN,O
,before,IN,O
,spontaneous,JJ,O
,alternation,NN,O
,performance,NN,O
,or,CC,O
,the,DT,O
,training,NN,O
,session,NN,O
,of,IN,O
,the,DT,O
,passive,JJ,O
,avoidance,NN,O
,task,NN,O
,",",",",O
,attenuated,VBD,O
,the,DT,O
,scopolamine,NN,O
,-,:,O
,induced,JJ,O
,impairment,NN,O
,of,IN,O
,spontaneous,JJ,O
,alternation,NN,O
,and,CC,O
,passive,JJ,O
,avoidance,NN,O
,behaviours,NNS,O
,.,.,O
,6,CD,O
,.,.,O
,These,DT,O
,results,NNS,O
,indicated,VBD,O
,that,IN,O
,nocistatin,NN,O
,",",",",O
,a,DT,O
,new,JJ,O
,biologically,RB,O
,active,JJ,O
,peptide,NN,O
,",",",",O
,ameliorates,VBZ,O
,impairments,NNS,O
,of,IN,O
,spontaneous,JJ,O
,alternation,NN,O
,and,CC,O
,passive,JJ,O
,avoidance,NN,O
,induced,VBN,O
,by,IN,O
,scopolamine,NN,O
,",",",",O
,and,CC,O
,suggested,VBD,O
,that,IN,O
,these,DT,O
,peptides,NNS,O
,play,VBP,O
,opposite,JJ,O
,roles,NNS,O
,in,IN,O
,learning,NN,O
,and,CC,O
,memory,NN,O
,.,.,O
,Meloxicam,NNP,O
,-,:,O
,induced,VBD,O
,liver,JJ,B-DISEASE
,toxicity,NN,I-DISEASE
,.,.,O
,We,PRP,O
,report,VBP,O
,the,DT,O
,case,NN,O
,of,IN,O
,a,DT,O
,female,JJ,O
,patient,NN,O
,with,IN,O
,rheumatoid,JJ,B-DISEASE
,arthritis,NN,I-DISEASE
,who,WP,O
,developed,VBD,O
,acute,VB,O
,cytolytic,JJ,O
,hepatitis,NN,B-DISEASE
,due,JJ,O
,to,TO,O
,meloxicam,VB,O
,.,.,O
,Recently,RB,O
,introduced,VBN,O
,in,IN,O
,Belgium,NNP,O
,",",",",O
,meloxicam,NN,O
,is,VBZ,O
,the,DT,O
,first,JJ,O
,nonsteroidal,JJ,O
,antiinflammatory,JJ,O
,drug,NN,O
,with,IN,O
,selective,JJ,O
,action,NN,O
,on,IN,O
,the,DT,O
,inducible,JJ,O
,form,NN,O
,of,IN,O
,cyclooxygenase,NN,O
,2,CD,O
,.,.,O
,The,DT,O
,acute,JJ,O
,cytolytic,JJ,O
,hepatitis,NN,B-DISEASE
,occurred,VBD,O
,rapidly,RB,O
,after,IN,O
,meloxicam,JJ,O
,administration,NN,O
,and,CC,O
,was,VBD,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,antinuclear,JJ,O
,antibodies,NNS,O
,suggesting,VBG,O
,a,DT,O
,hypersensitivity,NN,B-DISEASE
,mechanism,NN,O
,.,.,O
,This,DT,O
,first,JJ,O
,case,NN,O
,of,IN,O
,meloxicam,NN,O
,related,VBN,O
,liver,JJ,B-DISEASE
,toxicity,NN,I-DISEASE
,demonstrates,VBZ,O
,the,DT,O
,potential,NN,O
,of,IN,O
,this,DT,O
,drug,NN,O
,to,TO,O
,induce,VB,O
,hepatic,JJ,B-DISEASE
,damage,NN,I-DISEASE
,.,.,O
,Induction,NN,O
,of,IN,O
,apoptosis,NN,O
,by,IN,O
,remoxipride,NN,O
,metabolites,NNS,O
,in,IN,O
,HL60,NNP,O
,and,CC,O
,CD34,NNP,O
,+,NNP,O
,/,NNP,O
,CD19,NNP,O
,-,:,O
,human,JJ,O
,bone,NN,O
,marrow,NN,O
,progenitor,NN,O
,cells,NNS,O
,:,:,O
,potential,JJ,O
,relevance,NN,O
,to,TO,O
,remoxipride,VB,O
,-,:,O
,induced,VBN,O
,aplastic,JJ,B-DISEASE
,anemia,NN,I-DISEASE
,.,.,O
,The,DT,O
,antipsychotic,JJ,O
,agent,NN,O
,",",",",O
,remoxipride,VB,O
,[,NNP,O
,(,(,O
,S,NNP,O
,),),O
,-,:,O
,(,(,O
,-,:,O
,),),O
,-,:,O
,3,CD,O
,-,:,O
,bromo,NN,O
,-,:,O
,N,NNP,O
,-,:,O
,[,NN,O
,(,(,O
,1,CD,O
,-,:,O
,ethyl,NN,O
,-,:,O
,2,CD,O
,-,:,O
,pyrrolidinyl,NN,O
,),),O
,methyl,NN,O
,],SYM,O
,-,:,O
,2,CD,O
,",",",",O
,6,CD,O
,-,:,O
,dimethoxybenz,NN,O
,amide,NN,O
,],NNP,O
,has,VBZ,O
,been,VBN,O
,associated,VBN,O
,with,IN,O
,acquired,VBN,O
,aplastic,JJ,B-DISEASE
,anemia,NN,I-DISEASE
,.,.,O
,We,PRP,O
,have,VBP,O
,examined,VBN,O
,the,DT,O
,ability,NN,O
,of,IN,O
,remoxipride,NN,O
,",",",",O
,three,CD,O
,pyrrolidine,NN,O
,ring,VBG,O
,metabolites,NNS,O
,and,CC,O
,five,CD,O
,aromatic,JJ,O
,ring,NN,O
,metabolites,NNS,O
,of,IN,O
,the,DT,O
,parent,NN,O
,compound,NN,O
,to,TO,O
,induce,VB,O
,apoptosis,NN,O
,in,IN,O
,HL60,NNP,O
,cells,NNS,O
,and,CC,O
,human,JJ,O
,bone,NN,O
,marrow,NN,O
,progenitor,NN,O
,(,(,O
,HBMP,NNP,O
,),),O
,cells,NNS,O
,.,.,O
,Cells,NNS,O
,were,VBD,O
,treated,VBN,O
,for,IN,O
,0,CD,O
,-,:,O
,24,CD,O
,h,NN,O
,with,IN,O
,each,DT,O
,compound,NN,O
,(,(,O
,0,CD,O
,-,:,O
,200,CD,O
,microM,NN,O
,),),O
,.,.,O
,Apoptosis,NN,O
,was,VBD,O
,assessed,VBN,O
,by,IN,O
,fluorescence,NN,O
,microscopy,NN,O
,in,IN,O
,Hoechst,NNP,O
,33342,CD,O
,-,:,O
,and,CC,O
,propidium,VB,O
,iodide,NN,O
,stained,VBN,O
,cell,NN,O
,samples,NNS,O
,.,.,O
,Results,NNS,O
,were,VBD,O
,confirmed,VBN,O
,by,IN,O
,determination,NN,O
,of,IN,O
,internucleosomal,JJ,O
,DNA,NNP,O
,fragmentation,NN,O
,using,VBG,O
,gel,JJ,O
,electrophoresis,NN,O
,for,IN,O
,HL60,NNP,O
,cell,NN,O
,samples,NNS,O
,and,CC,O
,terminal,JJ,O
,deoxynucleotidyl,NN,O
,transferase,NN,O
,assay,VBP,O
,in,IN,O
,HBMP,NNP,O
,cells,NNS,O
,.,.,O
,The,DT,O
,catechol,NN,O
,and,CC,O
,hydroquinone,NN,O
,metabolites,NNS,O
,",",",",O
,NCQ436,NNP,O
,and,CC,O
,NCQ344,NNP,O
,",",",",O
,induced,VBD,O
,apoptosis,NN,O
,in,IN,O
,HL60,NNP,O
,and,CC,O
,HBMP,NNP,O
,cells,NNS,O
,in,IN,O
,a,DT,O
,time,NN,O
,-,:,O
,and,CC,O
,concentration,NN,O
,dependent,JJ,O
,manner,NN,O
,",",",",O
,while,IN,O
,the,DT,O
,phenols,NNS,O
,",",",",O
,NCR181,NNP,O
,",",",",O
,FLA873,NNP,O
,",",",",O
,and,CC,O
,FLA797,NNP,O
,",",",",O
,and,CC,O
,the,DT,O
,derivatives,NNS,O
,formed,VBN,O
,by,IN,O
,oxidation,NN,O
,of,IN,O
,the,DT,O
,pyrrolidine,NN,O
,ring,NN,O
,",",",",O
,FLA838,NNP,O
,",",",",O
,NCM001,NNP,O
,",",",",O
,and,CC,O
,NCL118,NNP,O
,",",",",O
,had,VBD,O
,no,DT,O
,effect,NN,O
,.,.,O
,No,DT,O
,necrosis,NN,B-DISEASE
,was,VBD,O
,observed,VBN,O
,in,IN,O
,cells,NNS,O
,treated,VBN,O
,with,IN,O
,NCQ436,NNP,O
,but,CC,O
,NCQ344,NNP,O
,had,VBD,O
,a,DT,O
,biphasic,JJ,O
,effect,NN,O
,in,IN,O
,both,DT,O
,cell,NN,O
,types,NNS,O
,",",",",O
,inducing,VBG,O
,apoptosis,NN,O
,at,IN,O
,lower,JJR,O
,concentrations,NNS,O
,and,CC,O
,necrosis,NN,B-DISEASE
,at,IN,O
,higher,JJR,O
,concentrations,NNS,O
,.,.,O
,These,DT,O
,data,NNS,O
,show,VBP,O
,that,IN,O
,the,DT,O
,catechol,NN,O
,and,CC,O
,hydroquinone,NN,O
,metabolites,NNS,O
,of,IN,O
,remoxipride,NN,O
,have,VBP,O
,direct,JJ,O
,toxic,NN,O
,effects,NNS,O
,in,IN,O
,HL60,NNP,O
,and,CC,O
,HBMP,NNP,O
,cells,NNS,O
,",",",",O
,leading,VBG,O
,to,TO,O
,apoptosis,VB,O
,",",",",O
,while,IN,O
,the,DT,O
,phenol,NN,O
,metabolites,NNS,O
,were,VBD,O
,inactive,JJ,O
,.,.,O
,Similarly,RB,O
,",",",",O
,benzene,SYM,O
,-,:,O
,derived,VBN,O
,catechol,NN,O
,and,CC,O
,hydroquinone,NN,O
,",",",",O
,but,CC,O
,not,RB,O
,phenol,VB,O
,",",",",O
,induce,VB,O
,apoptosis,NN,O
,in,IN,O
,HBMP,NNP,O
,cells,NNS,O
,[,NNP,O
,Moran,NNP,O
,et,FW,O
,al,NN,O
,.,.,O
,",",",",O
,Mol,NNP,O
,.,.,O
,Pharmacol,NNP,O
,.,.,O
,",",",",O
,50,CD,O
,(,(,O
,1996,CD,O
,),),O
,610,CD,O
,-,:,O
,615,CD,O
,],NN,O
,.,.,O
,We,PRP,O
,propose,VBP,O
,that,IN,O
,remoxipride,NN,O
,and,CC,O
,benzene,NN,O
,may,MD,O
,induce,VB,O
,aplastic,JJ,B-DISEASE
,anemia,NN,I-DISEASE
,via,IN,O
,production,NN,O
,of,IN,O
,similar,JJ,O
,reactive,JJ,O
,metabolites,NNS,O
,and,CC,O
,that,IN,O
,the,DT,O
,ability,NN,O
,of,IN,O
,NCQ436,NNP,O
,and,CC,O
,NCQ344,NNP,O
,to,TO,O
,induce,VB,O
,apoptosis,NN,O
,in,IN,O
,HBMP,NNP,O
,cells,NNS,O
,may,MD,O
,contribute,VB,O
,to,TO,O
,the,DT,O
,mechanism,NN,O
,underlying,VBG,O
,acquired,VBN,O
,aplastic,JJ,B-DISEASE
,anemia,NN,I-DISEASE
,that,WDT,O
,has,VBZ,O
,been,VBN,O
,associated,VBN,O
,with,IN,O
,remoxipride,NN,O
,.,.,O
,Synthesis,NN,O
,and,CC,O
,preliminary,JJ,O
,pharmacological,JJ,O
,investigations,NNS,O
,of,IN,O
,1,CD,O
,-,:,O
,(,(,O
,1,CD,O
,",",",",O
,2,CD,O
,-,:,O
,dihydro,NN,O
,-,:,O
,2,CD,O
,-,:,O
,acenaphthylenyl,NN,O
,),),O
,piperazine,NN,O
,derivatives,NNS,O
,as,IN,O
,potential,JJ,O
,atypical,JJ,O
,antipsychotic,JJ,O
,agents,NNS,O
,in,IN,O
,mice,NN,O
,.,.,O
,In,IN,O
,research,NN,O
,towards,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,new,JJ,O
,atypical,JJ,O
,antipsychotic,JJ,O
,agents,NNS,O
,",",",",O
,one,CD,O
,strategy,NN,O
,is,VBZ,O
,that,IN,O
,the,DT,O
,dopaminergic,NN,O
,system,NN,O
,can,MD,O
,be,VB,O
,modulated,VBN,O
,through,IN,O
,manipulation,NN,O
,of,IN,O
,the,DT,O
,serotonergic,NN,O
,system,NN,O
,.,.,O
,The,DT,O
,synthesis,NN,O
,and,CC,O
,preliminary,JJ,O
,pharmacological,JJ,O
,evaluation,NN,O
,of,IN,O
,a,DT,O
,series,NN,O
,of,IN,O
,potential,JJ,O
,atypical,JJ,O
,antipsychotic,JJ,O
,agents,NNS,O
,based,VBN,O
,on,IN,O
,the,DT,O
,structure,NN,O
,of,IN,O
,1,CD,O
,-,:,O
,(,(,O
,1,CD,O
,",",",",O
,2,CD,O
,-,:,O
,dihydro,NN,O
,-,:,O
,2,CD,O
,-,:,O
,acenaphthylenyl,NN,O
,),),O
,piperazine,NN,O
,(,(,O
,7,CD,O
,),),O
,is,VBZ,O
,described,VBN,O
,.,.,O
,Compound,NNP,O
,7e,CD,O
,",",",",O
,5,CD,O
,-,:,O
,{,(,O
,2,CD,O
,-,:,O
,[,NN,O
,4,CD,O
,-,:,O
,(,(,O
,1,CD,O
,",",",",O
,2,CD,O
,-,:,O
,dihydro,NN,O
,-,:,O
,2,CD,O
,-,:,O
,acenaphthylenyl,NN,O
,),),O
,piperazinyl,NN,O
,],JJ,O
,ethyl,NN,O
,},),O
,-,:,O
,2,CD,O
,",",",",O
,3,CD,O
,-,:,O
,dihy,NN,O
,dro,SYM,O
,-,:,O
,1H,CD,O
,-,:,O
,indol,NN,O
,-,:,O
,2,CD,O
,-,:,O
,one,CD,O
,",",",",O
,from,IN,O
,this,DT,O
,series,NN,O
,showed,VBD,O
,significant,JJ,O
,affinities,NNS,O
,at,IN,O
,the,DT,O
,5,CD,O
,-,:,O
,HT1A,NN,O
,and,CC,O
,5,CD,O
,-,:,O
,HT2A,NN,O
,receptors,NNS,O
,and,CC,O
,moderate,JJ,O
,affinity,NN,O
,at,IN,O
,the,DT,O
,D2,NNP,O
,receptor,NN,O
,.,.,O
,7e,CD,O
,exhibits,VBZ,O
,a,DT,O
,high,JJ,O
,reversal,NN,O
,of,IN,O
,catalepsy,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,haloperidol,NN,O
,indicating,VBG,O
,its,PRP$,O
,atypical,JJ,O
,antipsychotic,JJ,O
,nature,NN,O
,.,.,O
,Sub,NNP,O
,-,:,O
,chronic,JJ,O
,inhibition,NN,O
,of,IN,O
,nitric,JJ,O
,-,:,O
,oxide,JJ,O
,synthesis,NN,O
,modifies,NNS,O
,haloperidol,VBP,O
,-,:,O
,induced,JJ,O
,catalepsy,NN,B-DISEASE
,and,CC,O
,the,DT,O
,number,NN,O
,of,IN,O
,NADPH,NNP,O
,-,:,O
,diaphorase,NN,O
,neurons,NNS,O
,in,IN,O
,mice,NN,O
,.,.,O
,RATIONALE,NN,O
,:,:,O
,NG,NNP,O
,-,:,O
,nitro,JJ,O
,-,:,O
,L,NNP,O
,-,:,O
,arginine,NN,O
,(,(,O
,L,NNP,O
,-,:,O
,NOARG,NN,O
,),),O
,",",",",O
,an,DT,O
,inhibitor,NN,O
,of,IN,O
,nitric,JJ,O
,-,:,O
,oxide,JJ,O
,synthase,NN,O
,(,(,O
,NOS,NNP,O
,),),O
,",",",",O
,induces,VBZ,O
,catalepsy,NN,B-DISEASE
,in,IN,O
,mice,NN,O
,.,.,O
,This,DT,O
,effect,NN,O
,undergoes,VBZ,O
,rapid,JJ,O
,tolerance,NN,O
,",",",",O
,showing,VBG,O
,a,DT,O
,significant,JJ,O
,decrease,NN,O
,after,IN,O
,2,CD,O
,days,NNS,O
,of,IN,O
,sub,JJ,O
,-,:,O
,chronic,NN,O
,L,NNP,O
,-,:,O
,NOARG,NNP,O
,treatment,NN,O
,.,.,O
,Nitric,NNP,O
,oxide,IN,O
,(,(,O
,NO,NNP,O
,),),O
,has,VBZ,O
,been,VBN,O
,shown,VBN,O
,to,TO,O
,influence,VB,O
,dopaminergic,JJ,O
,neurotransmission,NN,O
,in,IN,O
,the,DT,O
,striatum,NN,O
,.,.,O
,Neuroleptic,JJ,O
,drugs,NNS,O
,such,JJ,O
,as,IN,O
,haloperidol,NN,O
,",",",",O
,which,WDT,O
,block,VBP,O
,dopamine,NN,O
,receptors,NNS,O
,",",",",O
,also,RB,O
,cause,VBP,O
,catalepsy,NN,B-DISEASE
,in,IN,O
,rodents,NNS,O
,.,.,O
,OBJECTIVES,NN,O
,:,:,O
,To,TO,O
,investigate,VB,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,subchronic,JJ,O
,L,NNP,O
,-,:,O
,NOARG,NNP,O
,treatment,NN,O
,in,IN,O
,haloperidol,JJ,O
,-,:,O
,induced,JJ,O
,catalepsy,NN,B-DISEASE
,and,CC,O
,the,DT,O
,number,NN,O
,of,IN,O
,NOS,NNP,O
,neurons,NNS,O
,in,IN,O
,areas,NNS,O
,related,VBN,O
,to,TO,O
,motor,VB,O
,control,NN,O
,.,.,O
,METHODS,NNP,O
,:,:,O
,Male,NNP,O
,albino,NN,O
,Swiss,NNP,O
,mice,NN,O
,were,VBD,O
,treated,VBN,O
,sub,JJ,O
,-,:,O
,chronically,RB,O
,(,(,O
,twice,RB,O
,a,DT,O
,day,NN,O
,for,IN,O
,4,CD,O
,days,NNS,O
,),),O
,with,IN,O
,L,NNP,O
,-,:,O
,NOARG,NNP,O
,(,(,O
,40,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,or,CC,O
,haloperidol,NN,O
,(,(,O
,1,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,.,.,O
,Catalepsy,NNP,B-DISEASE
,was,VBD,O
,evaluated,VBN,O
,at,IN,O
,the,DT,O
,beginning,NN,O
,and,CC,O
,the,DT,O
,end,NN,O
,of,IN,O
,the,DT,O
,treatments,NNS,O
,.,.,O
,Reduced,NNP,O
,nicotinamide,JJ,O
,adenine,NN,O
,dinucleotide,NN,O
,phosphate,NN,O
,-,:,O
,diaphorase,NN,O
,(,(,O
,NADPH,NNP,O
,-,:,O
,d,NN,O
,),),O
,histochemistry,NN,O
,was,VBD,O
,also,RB,O
,employed,VBN,O
,to,TO,O
,visualize,VB,O
,NOS,NNP,O
,as,IN,O
,an,DT,O
,index,NN,O
,of,IN,O
,enzyme,JJ,O
,expression,NN,O
,in,IN,O
,mice,NN,O
,brain,NN,O
,regions,NNS,O
,related,VBN,O
,to,TO,O
,motor,VB,O
,control,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,L,NNP,O
,-,:,O
,NOARG,NNP,O
,sub,SYM,O
,-,:,O
,chronic,JJ,O
,administration,NN,O
,produced,VBD,O
,tolerance,NN,O
,of,IN,O
,L,NNP,O
,-,:,O
,NOARG,NNP,O
,and,CC,O
,of,IN,O
,haloperidol,JJ,O
,-,:,O
,induced,JJ,O
,catalepsy,NN,B-DISEASE
,.,.,O
,It,PRP,O
,also,RB,O
,induced,VBD,O
,an,DT,O
,increase,NN,O
,in,IN,O
,the,DT,O
,number,NN,O
,of,IN,O
,NADPH,NNP,O
,-,:,O
,d,NN,O
,-,:,O
,positive,JJ,O
,cells,NNS,O
,in,IN,O
,the,DT,O
,dorsal,JJ,O
,part,NN,O
,of,IN,O
,the,DT,O
,caudate,NN,O
,and,CC,O
,accumbens,VBZ,O
,nuclei,NNS,O
,compared,VBN,O
,with,IN,O
,haloperidol,NN,O
,and,CC,O
,in,IN,O
,the,DT,O
,pedunculopontine,NN,O
,tegmental,JJ,O
,nucleus,NNS,O
,compared,VBN,O
,with,IN,O
,saline,NN,O
,.,.,O
,In,IN,O
,contrast,NN,O
,",",",",O
,there,EX,O
,was,VBD,O
,a,DT,O
,decrease,NN,O
,in,IN,O
,NADPH,NNP,O
,-,:,O
,d,NN,O
,neuron,JJ,O
,number,NN,O
,in,IN,O
,the,DT,O
,substantia,NN,O
,nigra,NN,O
,",",",",O
,pars,NNS,O
,compacta,VBP,O
,in,IN,O
,both,DT,O
,haloperidol,JJ,O
,-,:,O
,treated,VBN,O
,and,CC,O
,L,NNP,O
,-,:,O
,NOARG,NNP,O
,-,:,O
,treated,JJ,O
,animals,NNS,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,The,DT,O
,results,NNS,O
,give,VBP,O
,further,JJ,O
,support,NN,O
,to,TO,O
,the,DT,O
,hypothesis,NN,O
,that,IN,O
,NO,NNP,O
,plays,VBZ,O
,a,DT,O
,role,NN,O
,in,IN,O
,motor,NN,O
,behavior,NN,O
,control,NN,O
,and,CC,O
,suggest,VBP,O
,that,IN,O
,it,PRP,O
,may,MD,O
,take,VB,O
,part,NN,O
,in,IN,O
,the,DT,O
,synaptic,JJ,O
,changes,NNS,O
,produced,VBN,O
,by,IN,O
,antipsychotic,JJ,O
,treatment,NN,O
,.,.,O
,Prolonged,VBN,O
,left,VBD,B-DISEASE
,ventricular,JJ,I-DISEASE
,dysfunction,NN,I-DISEASE
,occurs,NNS,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,coronary,JJ,B-DISEASE
,artery,NN,I-DISEASE
,disease,NN,I-DISEASE
,after,IN,O
,both,DT,O
,dobutamine,NN,O
,and,CC,O
,exercise,NN,O
,induced,VBN,O
,myocardial,JJ,B-DISEASE
,ischaemia,NN,I-DISEASE
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,To,TO,O
,determine,VB,O
,whether,IN,O
,pharmacological,JJ,O
,stress,NN,O
,leads,VBZ,O
,to,TO,O
,prolonged,VB,O
,but,CC,O
,reversible,JJ,O
,left,VBD,B-DISEASE
,ventricular,JJ,I-DISEASE
,dysfunction,NN,I-DISEASE
,in,IN,O
,patients,NNS,O
,with,IN,O
,coronary,JJ,B-DISEASE
,artery,NN,I-DISEASE
,disease,NN,I-DISEASE
,",",",",O
,similar,JJ,O
,to,TO,O
,that,DT,O
,seen,VBN,O
,after,IN,O
,exercise,NN,O
,.,.,O
,DESIGN,NN,O
,:,:,O
,A,DT,O
,randomised,VBN,O
,crossover,NN,O
,study,NN,O
,of,IN,O
,recovery,NN,O
,time,NN,O
,of,IN,O
,systolic,JJ,O
,and,CC,O
,diastolic,JJ,O
,left,VBD,O
,ventricular,JJ,O
,function,NN,O
,after,IN,O
,exercise,NN,O
,and,CC,O
,dobutamine,NN,O
,induced,VBN,O
,ischaemia,NN,B-DISEASE
,.,.,O
,SUBJECTS,NN,O
,:,:,O
,10,CD,O
,patients,NNS,O
,with,IN,O
,stable,JJ,B-DISEASE
,angina,NN,I-DISEASE
,",",",",O
,angiographically,RB,O
,proven,JJ,O
,coronary,JJ,B-DISEASE
,artery,NN,I-DISEASE
,disease,NN,I-DISEASE
,",",",",O
,and,CC,O
,normal,JJ,O
,left,VBD,O
,ventricular,JJ,O
,function,NN,O
,.,.,O
,INTERVENTIONS,NN,O
,:,:,O
,Treadmill,NNP,O
,exercise,NN,O
,and,CC,O
,dobutamine,NN,O
,stress,NN,O
,were,VBD,O
,performed,VBN,O
,on,IN,O
,different,JJ,O
,days,NNS,O
,.,.,O
,Quantitative,JJ,O
,assessment,NN,O
,of,IN,O
,systolic,JJ,O
,and,CC,O
,diastolic,JJ,O
,left,VBD,O
,ventricular,JJ,O
,function,NN,O
,was,VBD,O
,performed,VBN,O
,using,VBG,O
,transthoracic,JJ,O
,echocardiography,NN,O
,at,IN,O
,baseline,NN,O
,and,CC,O
,at,IN,O
,regular,JJ,O
,intervals,NNS,O
,after,IN,O
,each,DT,O
,test,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Both,DT,O
,forms,NNS,O
,of,IN,O
,stress,NN,O
,led,VBN,O
,to,TO,O
,prolonged,VBN,O
,but,CC,O
,reversible,JJ,O
,systolic,NN,O
,and,CC,O
,diastolic,JJ,O
,dysfunction,NN,O
,.,.,O
,There,EX,O
,was,VBD,O
,no,DT,O
,difference,NN,O
,in,IN,O
,the,DT,O
,maximum,JJ,O
,double,JJ,O
,product,NN,O
,(,(,O
,p,JJ,O
,=,NN,O
,0,CD,O
,.,.,O
,53,CD,O
,),),O
,or,CC,O
,ST,NNP,O
,depression,NN,B-DISEASE
,(,(,O
,p,JJ,O
,=,NN,O
,0,CD,O
,.,.,O
,63,CD,O
,),),O
,with,IN,O
,either,DT,O
,form,NN,O
,of,IN,O
,stress,NN,O
,.,.,O
,After,IN,O
,exercise,NN,O
,",",",",O
,ejection,NN,O
,fraction,NN,O
,was,VBD,O
,reduced,VBN,O
,at,IN,O
,15,CD,O
,and,CC,O
,30,CD,O
,minutes,NNS,O
,compared,VBN,O
,with,IN,O
,baseline,NN,O
,(,(,O
,mean,JJ,O
,(,(,O
,SEM,NNP,O
,),),O
,",",",",O
,-,:,O
,5,CD,O
,.,.,O
,6,CD,O
,(,(,O
,1,CD,O
,.,.,O
,5,CD,O
,),),O
,%,NN,O
,",",",",O
,p,NN,O
,<,VBD,O
,0,CD,O
,.,.,O
,05,CD,O
,;,:,O
,and,CC,O
,-,:,O
,6,CD,O
,.,.,O
,1,CD,O
,(,(,O
,2,CD,O
,.,.,O
,2,CD,O
,),),O
,%,NN,O
,",",",",O
,p,NN,O
,<,VBD,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,",",",",O
,and,CC,O
,at,IN,O
,30,CD,O
,and,CC,O
,45,CD,O
,minutes,NNS,O
,after,IN,O
,dobutamine,NN,O
,(,(,O
,-,:,O
,10,CD,O
,.,.,O
,8,CD,O
,(,(,O
,1,CD,O
,.,.,O
,8,CD,O
,),),O
,%,NN,O
,and,CC,O
,-,:,O
,5,CD,O
,.,.,O
,5,CD,O
,(,(,O
,1,CD,O
,.,.,O
,8,CD,O
,),),O
,%,NN,O
,",",",",O
,both,DT,O
,p,VBP,O
,<,$,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,Regional,JJ,O
,analysis,NN,O
,showed,VBD,O
,a,DT,O
,reduction,NN,O
,in,IN,O
,the,DT,O
,worst,JJS,O
,affected,JJ,O
,segment,NN,O
,15,CD,O
,and,CC,O
,30,CD,O
,minutes,NNS,O
,after,IN,O
,exercise,NN,O
,(,(,O
,-,:,O
,27,CD,O
,.,.,O
,9,CD,O
,(,(,O
,7,CD,O
,.,.,O
,2,CD,O
,),),O
,%,NN,O
,and,CC,O
,-,:,O
,28,CD,O
,.,.,O
,6,CD,O
,(,(,O
,5,CD,O
,.,.,O
,7,CD,O
,),),O
,%,NN,O
,",",",",O
,both,DT,O
,p,VBP,O
,<,$,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,",",",",O
,and,CC,O
,at,IN,O
,30,CD,O
,minutes,NNS,O
,after,IN,O
,dobutamine,NN,O
,(,(,O
,-,:,O
,32,CD,O
,(,(,O
,5,CD,O
,.,.,O
,3,CD,O
,),),O
,%,NN,O
,",",",",O
,p,NN,O
,<,VBD,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,The,DT,O
,isovolumic,JJ,O
,relaxation,NN,O
,period,NN,O
,was,VBD,O
,prolonged,JJ,O
,45,CD,O
,minutes,NNS,O
,after,IN,O
,each,DT,O
,form,NN,O
,of,IN,O
,stress,NN,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,In,IN,O
,patients,NNS,O
,with,IN,O
,coronary,JJ,B-DISEASE
,artery,NN,I-DISEASE
,disease,NN,I-DISEASE
,",",",",O
,dobutamine,NN,O
,induced,VBD,O
,ischaemia,JJ,B-DISEASE
,results,NNS,O
,in,IN,O
,prolonged,JJ,O
,reversible,JJ,O
,left,VBD,B-DISEASE
,ventricular,JJ,I-DISEASE
,dysfunction,NN,I-DISEASE
,",",",",O
,presumed,VBN,O
,to,TO,O
,be,VB,O
,myocardial,JJ,B-DISEASE
,stunning,NN,I-DISEASE
,",",",",O
,similar,JJ,O
,to,TO,O
,that,DT,O
,seen,VBN,O
,after,IN,O
,exercise,NN,O
,.,.,O
,Dobutamine,NNP,O
,induced,VBD,O
,ischaemia,NN,B-DISEASE
,could,MD,O
,therefore,RB,O
,be,VB,O
,used,VBN,O
,to,TO,O
,study,VB,O
,the,DT,O
,pathophysiology,NN,O
,of,IN,O
,this,DT,O
,phenomenon,NN,O
,further,RBR,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,coronary,JJ,B-DISEASE
,artery,NN,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,Anorexigens,NNP,O
,and,CC,O
,pulmonary,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,in,IN,O
,the,DT,O
,United,NNP,O
,States,NNPS,O
,:,:,O
,results,NNS,O
,from,IN,O
,the,DT,O
,surveillance,NN,O
,of,IN,O
,North,JJ,O
,American,JJ,O
,pulmonary,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,The,DT,O
,use,NN,O
,of,IN,O
,appetite,JJ,O
,suppressants,NNS,O
,in,IN,O
,Europe,NNP,O
,has,VBZ,O
,been,VBN,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,primary,JJ,B-DISEASE
,pulmonary,JJ,I-DISEASE
,hypertension,NN,I-DISEASE
,(,(,O
,PPH,NNP,B-DISEASE
,),),O
,.,.,O
,Recently,RB,O
,",",",",O
,fenfluramine,JJ,O
,appetite,JJ,O
,suppressants,NNS,O
,became,VBD,O
,widely,RB,O
,used,VBN,O
,in,IN,O
,the,DT,O
,United,NNP,O
,States,NNPS,O
,but,CC,O
,were,VBD,O
,withdrawn,VBN,O
,in,IN,O
,September,NNP,O
,1997,CD,O
,because,IN,O
,of,IN,O
,concerns,NNS,O
,over,IN,O
,adverse,JJ,O
,effects,NNS,O
,.,.,O
,MATERIALS,NNP,O
,AND,CC,O
,METHODS,NNP,O
,:,:,O
,We,PRP,O
,conducted,VBD,O
,a,DT,O
,prospective,JJ,O
,surveillance,NN,O
,study,NN,O
,on,IN,O
,patients,NNS,O
,diagnosed,VBN,O
,with,IN,O
,pulmonary,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,at,IN,O
,12,CD,O
,large,JJ,O
,referral,JJ,O
,centers,NNS,O
,in,IN,O
,North,NNP,O
,America,NNP,O
,.,.,O
,Data,NNP,O
,collected,VBD,O
,on,IN,O
,patients,NNS,O
,seen,VBN,O
,from,IN,O
,September,NNP,O
,1,CD,O
,",",",",O
,1996,CD,O
,",",",",O
,to,TO,O
,December,NNP,O
,31,CD,O
,",",",",O
,1997,CD,O
,",",",",O
,included,VBD,O
,the,DT,O
,cause,NN,O
,of,IN,O
,the,DT,O
,pulmonary,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,and,CC,O
,its,PRP$,O
,severity,NN,O
,.,.,O
,Patients,NNS,O
,with,IN,O
,no,DT,O
,identifiable,JJ,O
,cause,NN,O
,of,IN,O
,pulmonary,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,were,VBD,O
,classed,VBN,O
,as,IN,O
,PPH,NNP,B-DISEASE
,.,.,O
,A,NNP,O
,history,NN,O
,of,IN,O
,drug,NN,O
,exposure,NN,O
,also,RB,O
,was,VBD,O
,taken,VBN,O
,with,IN,O
,special,JJ,O
,attention,NN,O
,on,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,antidepressants,NNS,O
,",",",",O
,anorexigens,NNS,O
,",",",",O
,and,CC,O
,amphetamines,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Five,CD,O
,hundred,VBD,O
,seventy,NN,O
,-,:,O
,nine,CD,O
,patients,NNS,O
,were,VBD,O
,studied,VBN,O
,",",",",O
,205,CD,O
,with,IN,O
,PPH,NNP,B-DISEASE
,and,CC,O
,374,CD,O
,with,IN,O
,pulmonary,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,from,IN,O
,other,JJ,O
,causes,NNS,O
,(,(,O
,secondary,JJ,O
,pulmonary,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,[,NNP,O
,SPH,NNP,O
,],NNP,O
,),),O
,.,.,O
,The,DT,O
,use,NN,O
,of,IN,O
,anorexigens,NNS,O
,was,VBD,O
,common,JJ,O
,in,IN,O
,both,DT,O
,groups,NNS,O
,.,.,O
,However,RB,O
,",",",",O
,of,IN,O
,the,DT,O
,medications,NNS,O
,surveyed,VBN,O
,",",",",O
,only,RB,O
,the,DT,O
,fenfluramines,NNS,O
,had,VBD,O
,a,DT,O
,significant,JJ,O
,preferential,JJ,O
,association,NN,O
,with,IN,O
,PPH,NNP,B-DISEASE
,as,IN,O
,compared,VBN,O
,with,IN,O
,SPH,NNP,O
,(,(,O
,adjusted,VBN,O
,odds,NNS,O
,ratio,NN,O
,for,IN,O
,use,NN,O
,>,JJ,O
,6,CD,O
,months,NNS,O
,",",",",O
,7,CD,O
,.,.,O
,5,CD,O
,;,:,O
,95,CD,O
,%,NN,O
,confidence,NN,O
,interval,NN,O
,",",",",O
,1,CD,O
,.,.,O
,7,CD,O
,to,TO,O
,32,CD,O
,.,.,O
,4,CD,O
,),),O
,.,.,O
,The,DT,O
,association,NN,O
,was,VBD,O
,stronger,JJR,O
,with,IN,O
,longer,JJR,O
,duration,NN,O
,of,IN,O
,use,NN,O
,when,WRB,O
,compared,VBN,O
,to,TO,O
,shorter,JJR,O
,duration,NN,O
,of,IN,O
,use,NN,O
,and,CC,O
,was,VBD,O
,more,RBR,O
,pronounced,JJ,O
,in,IN,O
,recent,JJ,O
,users,NNS,O
,than,IN,O
,in,IN,O
,remote,JJ,O
,users,NNS,O
,.,.,O
,An,DT,O
,unexpectedly,RB,O
,high,JJ,O
,(,(,O
,11,CD,O
,.,.,O
,4,CD,O
,%,NN,O
,),),O
,number,NN,O
,of,IN,O
,patients,NNS,O
,with,IN,O
,SPH,NNP,O
,had,VBD,O
,used,VBN,O
,anorexigens,NNS,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,The,DT,O
,magnitude,NN,O
,of,IN,O
,the,DT,O
,association,NN,O
,with,IN,O
,PPH,NNP,B-DISEASE
,",",",",O
,the,DT,O
,increase,NN,O
,of,IN,O
,association,NN,O
,with,IN,O
,increasing,VBG,O
,duration,NN,O
,of,IN,O
,use,NN,O
,",",",",O
,and,CC,O
,the,DT,O
,specificity,NN,O
,for,IN,O
,fenfluramines,NNS,O
,are,VBP,O
,consistent,JJ,O
,with,IN,O
,previous,JJ,O
,studies,NNS,O
,indicating,VBG,O
,that,IN,O
,fenfluramines,NNS,O
,are,VBP,O
,causally,RB,O
,related,VBN,O
,to,TO,O
,PPH,NNP,B-DISEASE
,.,.,O
,The,DT,O
,high,JJ,O
,prevalence,NN,O
,of,IN,O
,anorexigen,NN,O
,use,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,SPH,NNP,O
,also,RB,O
,raises,VBZ,O
,the,DT,O
,possibility,NN,O
,that,IN,O
,these,DT,O
,drugs,NNS,O
,precipitate,VBP,O
,pulmonary,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,in,IN,O
,patients,NNS,O
,with,IN,O
,underlying,JJ,O
,conditions,NNS,O
,associated,VBN,O
,with,IN,O
,SPH,NNP,O
,.,.,O
,Clinical,JJ,O
,aspects,NNS,O
,of,IN,O
,heparin,NN,O
,-,:,O
,induced,VBN,O
,thrombocytopenia,NN,B-DISEASE
,and,CC,O
,thrombosis,NN,B-DISEASE
,and,CC,O
,other,JJ,O
,side,NN,O
,effects,NNS,O
,of,IN,O
,heparin,NN,O
,therapy,NN,O
,.,.,O
,Heparin,NNP,O
,",",",",O
,first,RB,O
,used,VBN,O
,to,TO,O
,prevent,VB,O
,the,DT,O
,clotting,NN,O
,of,IN,O
,blood,NN,O
,in,IN,O
,vitro,NN,O
,",",",",O
,has,VBZ,O
,been,VBN,O
,clinically,RB,O
,used,VBN,O
,to,TO,O
,treat,VB,O
,thrombosis,NN,B-DISEASE
,for,IN,O
,more,JJR,O
,than,IN,O
,50,CD,O
,years,NNS,O
,.,.,O
,Although,IN,O
,several,JJ,O
,new,JJ,O
,anticoagulant,JJ,O
,drugs,NNS,O
,are,VBP,O
,in,IN,O
,development,NN,O
,",",",",O
,heparin,NN,O
,remains,VBZ,O
,the,DT,O
,anticoagulant,NN,O
,of,IN,O
,choice,NN,O
,to,TO,O
,treat,VB,O
,acute,JJ,O
,thrombotic,JJ,B-DISEASE
,episodes,NNS,O
,.,.,O
,The,DT,O
,clinical,JJ,O
,effects,NNS,O
,of,IN,O
,heparin,NN,O
,are,VBP,O
,meritorious,JJ,O
,",",",",O
,but,CC,O
,side,JJ,O
,effects,NNS,O
,do,VBP,O
,exist,VB,O
,.,.,O
,Bleeding,NNP,B-DISEASE
,is,VBZ,O
,the,DT,O
,primary,JJ,O
,untoward,JJ,O
,effect,NN,O
,of,IN,O
,heparin,NN,O
,.,.,O
,Major,JJ,O
,bleeding,NN,B-DISEASE
,is,VBZ,O
,of,IN,O
,primary,JJ,O
,concern,NN,O
,in,IN,O
,patients,NNS,O
,receiving,VBG,O
,heparin,JJ,O
,therapy,NN,O
,.,.,O
,However,RB,O
,",",",",O
,additional,JJ,O
,important,JJ,O
,untoward,JJ,O
,effects,NNS,O
,of,IN,O
,heparin,JJ,O
,therapy,NN,O
,include,VBP,O
,heparin,SYM,O
,-,:,O
,induced,VBN,O
,thrombocytopenia,NN,B-DISEASE
,",",",",O
,heparin,SYM,O
,-,:,O
,associated,VBN,O
,osteoporosis,NN,B-DISEASE
,",",",",O
,eosinophilia,NN,B-DISEASE
,",",",",O
,skin,JJ,B-DISEASE
,reactions,NNS,I-DISEASE
,",",",",O
,allergic,JJ,B-DISEASE
,reactions,NNS,I-DISEASE
,other,JJ,O
,than,IN,O
,thrombocytopenia,NN,B-DISEASE
,",",",",O
,alopecia,NN,B-DISEASE
,",",",",O
,transaminasemia,NN,O
,",",",",O
,hyperkalemia,NN,B-DISEASE
,",",",",O
,hypoaldosteronism,NN,B-DISEASE
,",",",",O
,and,CC,O
,priapism,NN,B-DISEASE
,.,.,O
,These,DT,O
,side,JJ,O
,effects,NNS,O
,are,VBP,O
,relatively,RB,O
,rare,JJ,O
,in,IN,O
,a,DT,O
,given,VBN,O
,individual,NN,O
,",",",",O
,but,CC,O
,given,VBN,O
,the,DT,O
,extremely,RB,O
,widespread,JJ,O
,use,NN,O
,of,IN,O
,heparin,NN,O
,",",",",O
,some,DT,O
,are,VBP,O
,quite,JJ,O
,common,JJ,O
,",",",",O
,particularly,RB,O
,HITT,NNP,B-DISEASE
,and,CC,O
,osteoporosis,NN,B-DISEASE
,.,.,O
,Although,IN,O
,reasonable,JJ,O
,incidences,NNS,O
,of,IN,O
,many,JJ,O
,of,IN,O
,these,DT,O
,side,JJ,O
,effects,NNS,O
,can,MD,O
,be,VB,O
,"""",VBN,O
,softly,RB,O
,"""",RB,O
,deduced,VBN,O
,from,IN,O
,current,JJ,O
,reports,NNS,O
,dealing,VBG,O
,with,IN,O
,unfractionated,JJ,O
,heparin,NN,O
,",",",",O
,at,IN,O
,present,JJ,O
,the,DT,O
,incidences,NNS,O
,of,IN,O
,these,DT,O
,side,NN,O
,effects,NNS,O
,with,IN,O
,newer,JJR,O
,low,JJ,O
,molecular,JJ,O
,weight,NN,O
,heparins,NNS,O
,appear,VBP,O
,to,TO,O
,be,VB,O
,much,RB,O
,less,JJR,O
,common,JJ,O
,.,.,O
,However,RB,O
,",",",",O
,only,RB,O
,longer,JJR,O
,experience,NN,O
,will,MD,O
,more,RBR,O
,clearly,RB,O
,define,VB,O
,the,DT,O
,incidence,NN,O
,of,IN,O
,each,DT,O
,side,NN,O
,effect,NN,O
,with,IN,O
,low,JJ,O
,molecular,JJ,O
,weight,NN,O
,preparations,NNS,O
,.,.,O
,A,DT,O
,case,NN,O
,of,IN,O
,bilateral,JJ,O
,optic,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,in,IN,O
,a,DT,O
,patient,NN,O
,on,IN,O
,tacrolimus,NN,O
,(,(,O
,FK506,NNP,O
,),),O
,therapy,NN,O
,after,IN,O
,liver,JJ,O
,transplantation,NN,O
,.,.,O
,PURPOSE,NN,O
,:,:,O
,To,TO,O
,report,VB,O
,a,DT,O
,case,NN,O
,of,IN,O
,bilateral,JJ,O
,optic,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,in,IN,O
,a,DT,O
,patient,NN,O
,receiving,VBG,O
,tacrolimus,NN,O
,(,(,O
,FK,NNP,O
,506,CD,O
,",",",",O
,Prograf,NNP,O
,;,:,O
,Fujisawa,NNP,O
,USA,NNP,O
,",",",",O
,Inc,NNP,O
,",",",",O
,Deerfield,NNP,O
,",",",",O
,Illinois,NNP,O
,),),O
,for,IN,O
,immunosuppression,NN,O
,after,IN,O
,orthotropic,NN,O
,liver,NN,O
,transplantation,NN,O
,.,.,O
,METHOD,NN,O
,:,:,O
,Case,NNP,O
,report,NN,O
,.,.,O
,In,IN,O
,a,DT,O
,58,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,man,NN,O
,receiving,VBG,O
,tacrolimus,NN,O
,after,IN,O
,orthotropic,NN,O
,liver,NN,O
,transplantation,NN,O
,",",",",O
,serial,JJ,O
,neuro,SYM,O
,-,:,O
,ophthalmologic,JJ,O
,examinations,NNS,O
,and,CC,O
,laboratory,NN,O
,studies,NNS,O
,were,VBD,O
,performed,VBN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,The,DT,O
,patient,NN,O
,had,VBD,O
,episodic,JJ,O
,deterioration,NN,O
,of,IN,O
,vision,NN,O
,in,IN,O
,both,DT,O
,eyes,NNS,O
,",",",",O
,with,IN,O
,clinical,JJ,O
,features,NNS,O
,resembling,VBG,O
,ischemic,JJ,B-DISEASE
,optic,JJ,I-DISEASE
,neuropathies,NNS,I-DISEASE
,.,.,O
,Deterioration,NN,B-DISEASE
,of,IN,I-DISEASE
,vision,NN,I-DISEASE
,occurred,VBD,O
,despite,IN,O
,discontinuation,NN,O
,of,IN,O
,the,DT,O
,tacrolimus,NN,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Tacrolimus,NN,O
,and,CC,O
,other,JJ,O
,immunosuppressive,JJ,O
,agents,NNS,O
,may,MD,O
,be,VB,O
,associated,VBN,O
,with,IN,O
,optic,JJ,B-DISEASE
,nerve,NN,I-DISEASE
,toxicity,NN,I-DISEASE
,.,.,O
,Hypercalcemia,NNP,B-DISEASE
,",",",",O
,arrhythmia,NN,B-DISEASE
,",",",",O
,and,CC,O
,mood,NN,O
,stabilizers,NNS,O
,.,.,O
,Recent,JJ,O
,findings,NNS,O
,in,IN,O
,a,DT,O
,bipolar,JJ,B-DISEASE
,patient,NN,O
,receiving,VBG,O
,maintenance,NN,O
,lithium,NN,O
,therapy,NN,O
,who,WP,O
,developed,VBD,O
,hypercalcemia,NN,B-DISEASE
,and,CC,O
,severe,JJ,O
,bradyarrhythmia,NN,B-DISEASE
,prompted,VBD,O
,the,DT,O
,authors,NNS,O
,to,TO,O
,conduct,VB,O
,a,DT,O
,retrospective,JJ,O
,study,NN,O
,of,IN,O
,bipolar,JJ,B-DISEASE
,patients,NNS,O
,with,IN,O
,lithium,JJ,O
,-,:,O
,associated,VBN,O
,hypercalcemia,NN,B-DISEASE
,.,.,O
,A,DT,O
,printout,NN,O
,of,IN,O
,all,DT,O
,cases,NNS,O
,of,IN,O
,hypercalcemia,NN,B-DISEASE
,that,WDT,O
,presented,VBD,O
,during,IN,O
,a,DT,O
,1,CD,O
,-,:,O
,year,NN,O
,period,NN,O
,was,VBD,O
,generated,VBN,O
,.,.,O
,After,IN,O
,eliminating,VBG,O
,spurious,JJ,O
,hypercalcemias,NN,B-DISEASE
,or,CC,O
,those,DT,O
,associated,VBN,O
,with,IN,O
,intravenous,JJ,O
,fluids,NNS,O
,",",",",O
,the,DT,O
,authors,NNS,O
,identified,VBD,O
,18,CD,O
,non,JJ,O
,-,:,O
,lithium,NN,O
,-,:,O
,treated,JJ,O
,patients,NNS,O
,with,IN,O
,hypercalcemias,NNS,B-DISEASE
,related,VBN,O
,to,TO,O
,malignancies,NNS,B-DISEASE
,and,CC,O
,other,JJ,O
,medical,JJ,O
,conditions,NNS,O
,(,(,O
,group,NN,O
,A,NNP,O
,),),O
,and,CC,O
,12,CD,O
,patients,NNS,O
,with,IN,O
,lithium,JJ,O
,-,:,O
,associated,VBN,O
,hypercalcemia,NN,B-DISEASE
,(,(,O
,group,NN,O
,B,NNP,O
,),),O
,.,.,O
,Patients,NNS,O
,in,IN,O
,group,NN,O
,B,NNP,O
,were,VBD,O
,not,RB,O
,comparable,JJ,O
,to,TO,O
,those,DT,O
,in,IN,O
,group,NN,O
,A,NNP,O
,",",",",O
,as,IN,O
,the,DT,O
,latter,NN,O
,were,VBD,O
,medically,RB,O
,compromised,VBN,O
,and,CC,O
,were,VBD,O
,receiving,VBG,O
,multiple,JJ,O
,pharmacotherapies,NNS,O
,.,.,O
,Thus,RB,O
,",",",",O
,two,CD,O
,control,NN,O
,groups,NNS,O
,were,VBD,O
,generated,VBN,O
,:,:,O
,group,NN,O
,C1,NNP,O
,",",",",O
,which,WDT,O
,included,VBD,O
,age,NN,O
,-,:,O
,and,CC,O
,sex,NN,O
,-,:,O
,comparable,JJ,O
,lithium,NN,O
,-,:,O
,treated,VBN,O
,bipolar,JJ,B-DISEASE
,normocalcemic,JJ,O
,patients,NNS,O
,",",",",O
,and,CC,O
,group,NN,O
,C2,NNP,O
,",",",",O
,which,WDT,O
,included,VBD,O
,bipolar,JJ,B-DISEASE
,normocalcemic,JJ,O
,patients,NNS,O
,treated,VBN,O
,with,IN,O
,anticonvulsant,JJ,O
,mood,NN,O
,stabilizers,NNS,O
,.,.,O
,The,DT,O
,electrocardiographic,JJ,O
,(,(,O
,ECG,NNP,O
,),),O
,findings,NNS,O
,for,IN,O
,patients,NNS,O
,in,IN,O
,group,NN,O
,B,NNP,O
,were,VBD,O
,compared,VBN,O
,with,IN,O
,those,DT,O
,of,IN,O
,patients,NNS,O
,in,IN,O
,groups,NNS,O
,C1,NNP,O
,and,CC,O
,C2,NNP,O
,.,.,O
,It,PRP,O
,was,VBD,O
,found,VBN,O
,that,IN,O
,these,DT,O
,groups,NNS,O
,did,VBD,O
,not,RB,O
,differ,VB,O
,in,IN,O
,their,PRP$,O
,overall,JJ,O
,frequency,NN,O
,of,IN,O
,ECG,NNP,O
,abnormalities,NNS,O
,;,:,O
,however,RB,O
,",",",",O
,there,EX,O
,were,VBD,O
,significant,JJ,O
,differences,NNS,O
,in,IN,O
,the,DT,O
,frequency,NN,O
,of,IN,O
,conduction,NN,O
,defects,NNS,O
,.,.,O
,Patients,NNS,O
,with,IN,O
,hypercalcemia,JJ,B-DISEASE
,resulting,VBG,O
,from,IN,O
,medical,JJ,O
,diseases,NNS,O
,and,CC,O
,bipolar,JJ,B-DISEASE
,patients,NNS,O
,with,IN,O
,lithium,JJ,O
,-,:,O
,associated,VBN,O
,hypercalcemia,NN,B-DISEASE
,had,VBD,O
,significantly,RB,O
,higher,JJR,O
,frequencies,NNS,O
,of,IN,O
,conduction,NN,O
,defects,NNS,O
,.,.,O
,Patients,NNS,O
,in,IN,O
,group,NN,O
,A,NNP,O
,had,VBD,O
,significant,JJ,O
,mortality,NN,O
,at,IN,O
,2,CD,O
,-,:,O
,year,NN,O
,follow,SYM,O
,-,:,O
,up,RB,O
,(,(,O
,28,CD,O
,%,NN,O
,),),O
,",",",",O
,in,IN,O
,contrast,NN,O
,to,TO,O
,zero,CD,O
,mortality,NN,O
,in,IN,O
,the,DT,O
,other,JJ,O
,three,CD,O
,groups,NNS,O
,.,.,O
,The,DT,O
,clinical,JJ,O
,implications,NNS,O
,of,IN,O
,these,DT,O
,findings,NNS,O
,are,VBP,O
,discussed,VBN,O
,.,.,O
,Attenuation,NNP,O
,of,IN,O
,nephrotoxicity,NN,B-DISEASE
,by,IN,O
,a,DT,O
,novel,JJ,O
,lipid,NN,O
,nanosphere,RB,O
,(,(,O
,NS,NNP,O
,-,:,O
,718,CD,O
,),),O
,incorporating,VBG,O
,amphotericin,NN,O
,B,NNP,O
,.,.,O
,NS,NNP,O
,-,:,O
,718,CD,O
,",",",",O
,a,DT,O
,lipid,JJ,O
,nanosphere,RB,O
,incorporating,VBG,O
,amphotericin,NN,O
,B,NNP,O
,",",",",O
,is,VBZ,O
,effective,JJ,O
,against,IN,O
,pathogenic,JJ,O
,fungi,NN,O
,and,CC,O
,has,VBZ,O
,low,JJ,O
,toxicity,NN,B-DISEASE
,.,.,O
,We,PRP,O
,compared,VBN,O
,the,DT,O
,toxicity,NN,B-DISEASE
,of,IN,O
,NS,NNP,O
,-,:,O
,718,CD,O
,with,IN,O
,that,DT,O
,of,IN,O
,Fungizone,NNP,O
,(,(,O
,amphotericin,NN,O
,B,NNP,O
,-,:,O
,sodium,NN,O
,deoxycholate,NN,O
,;,:,O
,D,NNP,O
,-,:,O
,AmB,NN,O
,),),O
,in,IN,O
,vitro,NN,O
,using,VBG,O
,renal,JJ,O
,cell,NN,O
,cultures,NNS,O
,and,CC,O
,in,IN,O
,vivo,NN,O
,by,IN,O
,biochemical,JJ,O
,analysis,NN,O
,",",",",O
,histopathological,JJ,O
,study,NN,O
,of,IN,O
,the,DT,O
,kidney,NN,O
,and,CC,O
,pharmacokinetic,JJ,O
,study,NN,O
,of,IN,O
,amphotericin,NN,O
,B,NNP,O
,following,VBG,O
,intravenous,JJ,O
,infusion,NN,O
,of,IN,O
,the,DT,O
,formulation,NN,O
,in,IN,O
,rats,NNS,O
,.,.,O
,Incubation,NN,O
,with,IN,O
,NS,NNP,O
,-,:,O
,718,CD,O
,resulted,VBD,O
,in,IN,O
,significantly,RB,O
,less,JJR,O
,damage,NN,O
,of,IN,O
,cultured,JJ,O
,human,JJ,O
,renal,JJ,O
,proximal,NN,O
,tubular,JJ,O
,epithelial,JJ,O
,cells,NNS,O
,compared,VBN,O
,with,IN,O
,D,NNP,O
,-,:,O
,AmB,NNP,O
,.,.,O
,Serum,NNP,O
,blood,NN,O
,urea,NN,O
,and,CC,O
,creatinine,JJ,O
,concentrations,NNS,O
,increased,VBD,O
,significantly,RB,O
,in,IN,O
,rats,NNS,O
,given,VBN,O
,an,DT,O
,iv,JJ,O
,infusion,NN,O
,of,IN,O
,D,NNP,O
,-,:,O
,AmB,$,O
,3,CD,O
,mg,NN,O
,/,NN,O
,kg,NN,O
,but,CC,O
,not,RB,O
,in,IN,O
,those,DT,O
,given,VBN,O
,the,DT,O
,same,JJ,O
,dose,NN,O
,of,IN,O
,NS,NNP,O
,-,:,O
,718,CD,O
,.,.,O
,Histopathological,JJ,O
,examination,NN,O
,of,IN,O
,the,DT,O
,kidney,NN,O
,showed,VBD,O
,tubular,JJ,B-DISEASE
,necrosis,NN,I-DISEASE
,in,IN,O
,D,NNP,O
,-,:,O
,AmB,NNP,O
,-,:,O
,treated,VBD,O
,rats,NNS,O
,but,CC,O
,no,DT,O
,change,NN,O
,in,IN,O
,NS,NNP,O
,-,:,O
,718,CD,O
,-,:,O
,treated,VBN,O
,rats,NNS,O
,.,.,O
,Amphotericin,NNP,O
,B,NNP,O
,concentrations,NNS,O
,in,IN,O
,the,DT,O
,kidney,NN,O
,in,IN,O
,NS,NNP,O
,-,:,O
,718,CD,O
,-,:,O
,treated,VBN,O
,rats,NNS,O
,were,VBD,O
,higher,JJR,O
,than,IN,O
,those,DT,O
,in,IN,O
,D,NNP,O
,-,:,O
,AmB,NNP,O
,-,:,O
,treated,VBD,O
,rats,NNS,O
,.,.,O
,Our,PRP$,O
,in,IN,O
,vitro,NN,O
,and,CC,O
,in,IN,O
,vivo,JJ,O
,results,NNS,O
,suggest,VBP,O
,that,IN,O
,incorporation,NN,O
,of,IN,O
,amphotericin,NN,O
,B,NNP,O
,into,IN,O
,lipid,JJ,O
,nanospheres,NNS,O
,of,IN,O
,NS,NNP,O
,-,:,O
,718,CD,O
,attenuates,VBZ,O
,the,DT,O
,nephrotoxicity,NN,B-DISEASE
,of,IN,O
,amphotericin,NN,O
,B,NNP,O
,.,.,O
,Patterns,NNP,O
,of,IN,O
,sulfadiazine,JJ,O
,acute,JJ,B-DISEASE
,nephrotoxicity,NN,I-DISEASE
,.,.,O
,Sulfadiazine,NNP,O
,acute,JJ,B-DISEASE
,nephrotoxicity,NN,I-DISEASE
,is,VBZ,O
,reviving,VBG,O
,specially,RB,O
,because,IN,O
,of,IN,O
,its,PRP$,O
,use,NN,O
,in,IN,O
,toxoplasmosis,NN,B-DISEASE
,in,IN,O
,HIV,NNP,O
,-,:,O
,positive,JJ,O
,patients,NNS,O
,.,.,O
,We,PRP,O
,report,VBP,O
,4,CD,O
,cases,NNS,O
,",",",",O
,one,CD,O
,of,IN,O
,them,PRP,O
,in,IN,O
,a,DT,O
,previously,RB,O
,healthy,JJ,O
,person,NN,O
,.,.,O
,Under,IN,O
,treatment,NN,O
,with,IN,O
,sulfadiazine,NN,O
,they,PRP,O
,developed,VBD,O
,oliguria,NNS,B-DISEASE
,",",",",O
,abdominal,JJ,B-DISEASE
,pain,NN,I-DISEASE
,",",",",O
,renal,JJ,B-DISEASE
,failure,NN,I-DISEASE
,and,CC,O
,showed,VBD,O
,multiple,JJ,O
,radiolucent,JJ,O
,renal,JJ,B-DISEASE
,calculi,NN,I-DISEASE
,in,IN,O
,echography,NN,O
,.,.,O
,All,DT,O
,patients,NNS,O
,recovered,VBD,O
,their,PRP$,O
,previous,JJ,O
,normal,JJ,O
,renal,JJ,O
,function,NN,O
,after,IN,O
,adequate,JJ,O
,hydration,NN,O
,and,CC,O
,alcalinization,NN,O
,.,.,O
,A,DT,O
,nephrostomy,JJ,O
,tube,NN,O
,had,VBD,O
,to,TO,O
,be,VB,O
,placed,VBN,O
,in,IN,O
,one,CD,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,for,IN,O
,ureteral,JJ,B-DISEASE
,lithiasis,NN,I-DISEASE
,in,IN,O
,a,DT,O
,single,JJ,O
,functional,JJ,O
,kidney,NN,O
,.,.,O
,None,NN,O
,of,IN,O
,them,PRP,O
,needed,VBN,O
,dialysis,NN,O
,or,CC,O
,a,DT,O
,renal,JJ,O
,biopsy,NN,O
,because,IN,O
,of,IN,O
,a,DT,O
,typical,JJ,O
,benign,NN,O
,course,NN,O
,.,.,O
,Treatment,NN,O
,with,IN,O
,sulfadiazine,JJ,O
,requires,VBZ,O
,exquisite,JJ,O
,control,NN,O
,of,IN,O
,renal,JJ,O
,function,NN,O
,",",",",O
,an,DT,O
,increase,NN,O
,in,IN,O
,water,NN,O
,ingestion,NN,O
,and,CC,O
,possibly,RB,O
,the,DT,O
,alcalinization,NN,O
,of,IN,O
,the,DT,O
,urine,NN,O
,.,.,O
,We,PRP,O
,communicate,VBP,O
,a,DT,O
,case,NN,O
,in,IN,O
,a,DT,O
,previously,RB,O
,healthy,JJ,O
,person,NN,O
,",",",",O
,a,DT,O
,fact,NN,O
,not,RB,O
,found,VBN,O
,in,IN,O
,the,DT,O
,recent,JJ,O
,literature,NN,O
,.,.,O
,Probably,RB,O
,many,JJ,O
,more,JJR,O
,cases,NNS,O
,are,VBP,O
,not,RB,O
,detected,VBN,O
,.,.,O
,We,PRP,O
,think,VBP,O
,that,IN,O
,a,DT,O
,prospective,JJ,O
,study,NN,O
,would,MD,O
,be,VB,O
,useful,JJ,O
,.,.,O
,Downbeat,NNP,B-DISEASE
,nystagmus,RB,I-DISEASE
,associated,VBD,O
,with,IN,O
,intravenous,JJ,O
,patient,NN,O
,-,:,O
,controlled,VBN,O
,administration,NN,O
,of,IN,O
,morphine,NN,O
,.,.,O
,IMPLICATIONS,NN,O
,:,:,O
,This,DT,O
,case,NN,O
,documents,NNS,O
,a,DT,O
,patient,NN,O
,who,WP,O
,developed,VBD,O
,dizziness,NN,B-DISEASE
,with,IN,O
,downbeating,VBG,B-DISEASE
,nystagmus,NNS,I-DISEASE
,while,IN,O
,receiving,VBG,O
,a,DT,O
,relatively,RB,O
,large,JJ,O
,dose,NN,O
,of,IN,O
,IV,NNP,O
,patient,NN,O
,-,:,O
,controlled,VBN,O
,analgesia,JJ,O
,morphine,NN,O
,.,.,O
,Although,IN,O
,there,EX,O
,have,VBP,O
,been,VBN,O
,case,NN,O
,reports,NNS,O
,of,IN,O
,epidural,JJ,O
,morphine,NN,O
,with,IN,O
,these,DT,O
,symptoms,NNS,O
,and,CC,O
,signs,NNS,O
,",",",",O
,this,DT,O
,has,VBZ,O
,not,RB,O
,been,VBN,O
,previously,RB,O
,documented,VBN,O
,with,IN,O
,IV,NNP,O
,or,CC,O
,patient,JJ,O
,-,:,O
,controlled,VBN,O
,analgesia,JJ,O
,morphine,NN,O
,.,.,O
,Hemodynamic,NNP,O
,and,CC,O
,antiadrenergic,JJ,O
,effects,NNS,O
,of,IN,O
,dronedarone,NN,O
,and,CC,O
,amiodarone,NN,O
,in,IN,O
,animals,NNS,O
,with,IN,O
,a,DT,O
,healed,VBN,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,.,.,O
,The,DT,O
,hemodynamic,JJ,O
,and,CC,O
,antiadrenergic,JJ,O
,effects,NNS,O
,of,IN,O
,dronedarone,NN,O
,",",",",O
,a,DT,O
,noniodinated,JJ,O
,compound,NN,O
,structurally,RB,O
,related,VBN,O
,to,TO,O
,amiodarone,VB,O
,",",",",O
,were,VBD,O
,compared,VBN,O
,with,IN,O
,those,DT,O
,of,IN,O
,amiodarone,NN,O
,after,IN,O
,prolonged,JJ,O
,oral,JJ,O
,administration,NN,O
,",",",",O
,both,DT,O
,at,IN,O
,rest,NN,O
,and,CC,O
,during,IN,O
,sympathetic,JJ,O
,stimulation,NN,O
,in,IN,O
,conscious,JJ,O
,dogs,NNS,O
,with,IN,O
,a,DT,O
,healed,VBN,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,.,.,O
,All,DT,O
,dogs,NNS,O
,(,(,O
,n,JJ,O
,=,NNP,O
,6,CD,O
,),),O
,randomly,RB,O
,received,VBN,O
,orally,RB,O
,dronedarone,JJ,O
,(,(,O
,10,CD,O
,and,CC,O
,30,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,",",",",O
,amiodarone,NN,O
,(,(,O
,10,CD,O
,and,CC,O
,30,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,",",",",O
,and,CC,O
,placebo,VB,O
,twice,RB,O
,daily,RB,O
,for,IN,O
,7,CD,O
,days,NNS,O
,",",",",O
,with,IN,O
,a,DT,O
,3,CD,O
,-,:,O
,week,NN,O
,washout,NN,O
,between,IN,O
,consecutive,JJ,O
,treatments,NNS,O
,.,.,O
,Heart,NNP,O
,rate,NN,O
,(,(,O
,HR,NNP,O
,),),O
,",",",",O
,mean,JJ,O
,arterial,JJ,O
,pressure,NN,O
,(,(,O
,MBP,NNP,O
,),),O
,",",",",O
,positive,JJ,O
,rate,NN,O
,of,IN,O
,increase,NN,O
,of,IN,O
,left,JJ,O
,ventricular,JJ,O
,pressure,NN,O
,(,(,O
,+,JJ,O
,LVdP,NNP,O
,/,NNP,O
,dt,NN,O
,),),O
,",",",",O
,echocardiographically,RB,O
,assessed,VBN,O
,left,VBD,O
,ventricular,JJ,O
,ejection,NN,O
,fraction,NN,O
,(,(,O
,LVEF,NNP,O
,),),O
,",",",",O
,and,CC,O
,fractional,JJ,O
,shortening,NN,O
,(,(,O
,FS,NNP,O
,),),O
,",",",",O
,as,RB,O
,well,RB,O
,as,IN,O
,chronotropic,NN,O
,response,NN,O
,to,TO,O
,isoproterenol,VB,O
,and,CC,O
,exercise,VB,O
,-,:,O
,induced,VBN,O
,sympathetic,JJ,O
,stimulation,NN,O
,were,VBD,O
,evaluated,VBN,O
,under,IN,O
,baseline,NN,O
,and,CC,O
,posttreatment,JJ,O
,conditions,NNS,O
,.,.,O
,Resting,VBG,O
,values,NNS,O
,of,IN,O
,LVEF,NNP,O
,",",",",O
,FS,NNP,O
,",",",",O
,+,NNP,O
,LVdP,NNP,O
,/,NNP,O
,dt,NN,O
,",",",",O
,and,CC,O
,MBP,NNP,O
,remained,VBD,O
,unchanged,JJ,O
,whatever,IN,O
,the,DT,O
,drug,NN,O
,and,CC,O
,the,DT,O
,dosing,VBG,O
,regimen,NNS,O
,",",",",O
,whereas,IN,O
,resting,VBG,O
,HR,NNP,O
,was,VBD,O
,significantly,RB,O
,and,CC,O
,dose,VB,O
,-,:,O
,dependently,RB,O
,lowered,VBN,O
,after,IN,O
,dronedarone,NN,O
,and,CC,O
,to,TO,O
,a,DT,O
,lesser,JJR,O
,extent,NN,O
,after,IN,O
,amiodarone,NN,O
,.,.,O
,Both,DT,O
,dronedarone,NN,O
,and,CC,O
,amiodarone,NN,O
,significantly,RB,O
,reduced,VBD,O
,the,DT,O
,exercise,NN,O
,-,:,O
,induced,JJ,O
,tachycardia,NN,B-DISEASE
,and,CC,O
,",",",",O
,at,IN,O
,the,DT,O
,highest,JJS,O
,dose,NN,O
,",",",",O
,decreased,VBD,O
,the,DT,O
,isoproterenol,NN,O
,-,:,O
,induced,JJ,O
,tachycardia,NN,B-DISEASE
,.,.,O
,Thus,RB,O
,",",",",O
,dronedarone,NN,O
,and,CC,O
,amiodarone,NN,O
,displayed,VBD,O
,a,DT,O
,similar,JJ,O
,level,NN,O
,of,IN,O
,antiadrenergic,JJ,O
,effect,NN,O
,and,CC,O
,did,VBD,O
,not,RB,O
,impair,VB,O
,the,DT,O
,resting,NN,O
,left,VBD,O
,ventricular,JJ,O
,function,NN,O
,.,.,O
,Consequently,RB,O
,",",",",O
,dronedarone,NN,O
,might,MD,O
,be,VB,O
,particularly,RB,O
,suitable,JJ,O
,for,IN,O
,the,DT,O
,treatment,NN,O
,and,CC,O
,prevention,NN,O
,of,IN,O
,various,JJ,O
,clinical,JJ,O
,arrhythmias,NN,B-DISEASE
,",",",",O
,without,IN,O
,compromising,VBG,O
,the,DT,O
,left,NN,O
,ventricular,JJ,O
,function,NN,O
,.,.,O
,Phase,VB,O
,2,CD,O
,trial,NN,O
,of,IN,O
,liposomal,JJ,O
,doxorubicin,NN,O
,(,(,O
,40,CD,O
,mg,NN,O
,/,NNP,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,),),O
,in,IN,O
,platinum,NN,O
,/,NN,O
,paclitaxel,SYM,O
,-,:,O
,refractory,NN,O
,ovarian,JJ,B-DISEASE
,and,CC,I-DISEASE
,fallopian,JJ,I-DISEASE
,tube,NN,I-DISEASE
,cancers,NNS,I-DISEASE
,and,CC,O
,primary,JJ,O
,carcinoma,NN,B-DISEASE
,of,IN,I-DISEASE
,the,DT,I-DISEASE
,peritoneum,NN,I-DISEASE
,.,.,O
,BACKGROUND,NNP,O
,:,:,O
,Several,JJ,O
,studies,NNS,O
,have,VBP,O
,demonstrated,VBN,O
,liposomal,JJ,O
,doxorubicin,NN,O
,(,(,O
,Doxil,NNP,O
,),),O
,to,TO,O
,be,VB,O
,an,DT,O
,active,JJ,O
,antineoplastic,JJ,O
,agent,NN,O
,in,IN,O
,platinum,NN,O
,-,:,O
,resistant,JJ,O
,ovarian,JJ,B-DISEASE
,cancer,NN,I-DISEASE
,",",",",O
,with,IN,O
,dose,JJ,O
,limiting,VBG,O
,toxicity,NN,B-DISEASE
,of,IN,O
,the,DT,O
,standard,JJ,O
,dosing,VBG,O
,regimen,NNS,O
,(,(,O
,50,CD,O
,mg,NN,O
,/,NNP,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,q,RB,O
,4,CD,O
,weeks,NNS,O
,),),O
,being,VBG,O
,severe,JJ,O
,erythrodysesthesia,NN,B-DISEASE
,(,(,O
,"""",JJ,O
,hand,NN,B-DISEASE
,-,:,I-DISEASE
,foot,NN,I-DISEASE
,syndrome,JJ,I-DISEASE
,"""",NN,O
,),),O
,and,CC,O
,stomatitis,NN,B-DISEASE
,.,.,O
,We,PRP,O
,wished,VBD,O
,to,TO,O
,develop,VB,O
,a,DT,O
,more,RBR,O
,tolerable,JJ,O
,liposomal,JJ,O
,doxorubicin,NN,O
,treatment,NN,O
,regimen,NNS,O
,and,CC,O
,document,NN,O
,its,PRP$,O
,level,NN,O
,of,IN,O
,activity,NN,O
,in,IN,O
,a,DT,O
,well,NN,O
,-,:,O
,defined,VBN,O
,patient,JJ,O
,population,NN,O
,with,IN,O
,platinum,NN,O
,/,NN,O
,paclitaxel,SYM,O
,-,:,O
,refractory,NN,O
,disease,NN,O
,.,.,O
,METHODS,NNP,O
,AND,CC,O
,MATERIALS,NNP,O
,:,:,O
,Patients,NNS,O
,with,IN,O
,ovarian,JJ,B-DISEASE
,or,CC,I-DISEASE
,fallopian,JJ,I-DISEASE
,tube,NN,I-DISEASE
,cancers,NNS,I-DISEASE
,or,CC,O
,primary,JJ,O
,peritoneal,JJ,B-DISEASE
,carcinoma,NN,I-DISEASE
,with,IN,O
,platinum,NN,O
,/,NN,O
,paclitaxel,SYM,O
,-,:,O
,refractory,NN,O
,disease,NN,O
,(,(,O
,stable,JJ,O
,or,CC,O
,progressive,JJ,O
,disease,NN,O
,following,VBG,O
,treatment,NN,O
,with,IN,O
,these,DT,O
,agents,NNS,O
,or,CC,O
,previous,JJ,O
,objective,JJ,O
,response,NN,O
,<,VBZ,O
,3,CD,O
,months,NNS,O
,in,IN,O
,duration,NN,O
,),),O
,were,VBD,O
,treated,VBN,O
,with,IN,O
,liposomal,JJ,O
,doxorubicin,NN,O
,at,IN,O
,a,DT,O
,dose,NN,O
,of,IN,O
,40,CD,O
,mg,NNS,O
,/,JJ,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,q,RB,O
,4,CD,O
,weeks,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,A,DT,O
,total,NN,O
,of,IN,O
,49,CD,O
,patients,NNS,O
,(,(,O
,median,JJ,O
,age,NN,O
,:,:,O
,60,CD,O
,;,:,O
,range,NN,O
,41,CD,O
,-,:,O
,81,CD,O
,),),O
,entered,VBD,O
,this,DT,O
,phase,NN,O
,2,CD,O
,trial,NN,O
,.,.,O
,The,DT,O
,median,JJ,O
,number,NN,O
,of,IN,O
,prior,JJ,O
,regimens,NNS,O
,was,VBD,O
,2,CD,O
,(,(,O
,range,NN,O
,:,:,O
,1,CD,O
,-,:,O
,6,CD,O
,),),O
,.,.,O
,Six,NNP,O
,(,(,O
,12,CD,O
,%,NN,O
,),),O
,and,CC,O
,4,CD,O
,(,(,O
,8,CD,O
,%,NN,O
,),),O
,patients,NNS,O
,experienced,VBD,O
,grade,JJ,O
,2,CD,O
,hand,NN,B-DISEASE
,-,:,I-DISEASE
,foot,NN,I-DISEASE
,syndrome,NN,I-DISEASE
,and,CC,O
,stomatitis,NN,B-DISEASE
,",",",",O
,respectively,RB,O
,(,(,O
,no,DT,O
,episodes,NNS,O
,of,IN,O
,grade,NN,O
,3,CD,O
,),),O
,.,.,O
,One,CD,O
,patient,NN,O
,developed,VBD,O
,grade,JJ,O
,3,CD,O
,diarrhea,NN,B-DISEASE
,requiring,VBG,O
,hospitalization,NN,O
,for,IN,O
,hydration,NN,O
,.,.,O
,Six,NNP,O
,(,(,O
,12,CD,O
,%,NN,O
,),),O
,individuals,NNS,O
,required,VBN,O
,dose,JJ,O
,reductions,NNS,O
,.,.,O
,The,DT,O
,median,JJ,O
,number,NN,O
,of,IN,O
,courses,NNS,O
,of,IN,O
,liposomal,JJ,O
,doxorubicin,NN,O
,administered,VBN,O
,on,IN,O
,this,DT,O
,protocol,NN,O
,was,VBD,O
,2,CD,O
,(,(,O
,range,NN,O
,:,:,O
,1,CD,O
,-,:,O
,12,CD,O
,),),O
,.,.,O
,Four,CD,O
,of,IN,O
,44,CD,O
,patients,NNS,O
,(,(,O
,9,CD,O
,%,NN,O
,),),O
,evaluable,NN,O
,for,IN,O
,response,NN,O
,exhibited,VBN,O
,objective,JJ,O
,and,CC,O
,subjective,JJ,O
,evidence,NN,O
,of,IN,O
,an,DT,O
,antineoplastic,JJ,O
,effect,NN,O
,of,IN,O
,therapy,NN,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,This,DT,O
,modified,VBD,O
,liposomal,JJ,O
,doxorubicin,JJ,O
,regimen,NNS,O
,results,NNS,O
,in,IN,O
,less,JJR,O
,toxicity,NN,B-DISEASE
,(,(,O
,stomatitis,NN,B-DISEASE
,",",",",O
,hand,NN,B-DISEASE
,-,:,I-DISEASE
,foot,NN,I-DISEASE
,syndrome,NN,I-DISEASE
,),),O
,than,IN,O
,the,DT,O
,standard,JJ,O
,FDA,NNP,O
,-,:,O
,approved,VBD,O
,dose,JJ,O
,schedule,NN,O
,.,.,O
,Definite,NNP,O
,",",",",O
,although,IN,O
,limited,JJ,O
,",",",",O
,antineoplastic,JJ,O
,activity,NN,O
,is,VBZ,O
,observed,VBN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,well,RB,O
,-,:,O
,defined,VBN,O
,platinum,NN,O
,-,:,O
,and,CC,O
,paclitaxel,VB,O
,-,:,O
,refractory,NN,O
,ovarian,JJ,B-DISEASE
,cancer,NN,I-DISEASE
,.,.,O
,Efficacy,NN,O
,of,IN,O
,olanzapine,NN,O
,in,IN,O
,acute,JJ,O
,bipolar,JJ,B-DISEASE
,mania,NN,I-DISEASE
,:,:,O
,a,DT,O
,double,JJ,O
,-,:,O
,blind,NN,O
,",",",",O
,placebo,SYM,O
,-,:,O
,controlled,VBN,O
,study,NN,O
,.,.,O
,The,DT,O
,Olanzipine,NNP,O
,HGGW,NNP,O
,Study,NNP,O
,Group,NNP,O
,.,.,O
,BACKGROUND,NNP,O
,:,:,O
,We,PRP,O
,compared,VBN,O
,the,DT,O
,efficacy,NN,O
,and,CC,O
,safety,NN,O
,of,IN,O
,olanzapine,JJ,O
,vs,NN,O
,placebo,NN,O
,for,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,acute,JJ,O
,bipolar,JJ,B-DISEASE
,mania,NN,I-DISEASE
,.,.,O
,METHODS,NNP,O
,:,:,O
,Four,CD,O
,-,:,O
,week,NN,O
,",",",",O
,randomized,VBN,O
,",",",",O
,double,JJ,O
,-,:,O
,blind,NN,O
,",",",",O
,parallel,JJ,O
,study,NN,O
,.,.,O
,A,DT,O
,total,NN,O
,of,IN,O
,115,CD,O
,patients,NNS,O
,with,IN,O
,a,DT,O
,DSM,NNP,O
,-,:,O
,IV,NNP,O
,diagnosis,NN,O
,of,IN,O
,bipolar,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,",",",",O
,manic,NN,B-DISEASE
,or,CC,O
,mixed,JJ,O
,",",",",O
,were,VBD,O
,randomized,VBN,O
,to,TO,O
,olanzapine,VB,O
,",",",",O
,5,CD,O
,to,TO,O
,20,CD,O
,mg,NNS,O
,/,JJ,O
,d,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,55,CD,O
,),),O
,",",",",O
,or,CC,O
,placebo,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,60,CD,O
,),),O
,.,.,O
,The,DT,O
,primary,JJ,O
,efficacy,NN,O
,measure,NN,O
,was,VBD,O
,the,DT,O
,Young,NNP,O
,-,:,O
,Mania,NN,B-DISEASE
,Rating,VBG,O
,Scale,NNP,O
,(,(,O
,Y,NNP,O
,-,:,O
,MRS,NNP,O
,),),O
,total,NN,O
,score,NN,O
,.,.,O
,Response,NNP,O
,and,CC,O
,euthymia,NN,O
,were,VBD,O
,defined,VBN,O
,",",",",O
,a,DT,O
,priori,NN,O
,",",",",O
,as,IN,O
,at,IN,O
,least,JJS,O
,a,DT,O
,50,CD,O
,%,NN,O
,improvement,NN,O
,from,IN,O
,baseline,NN,O
,to,TO,O
,end,VB,O
,point,NN,O
,and,CC,O
,as,IN,O
,a,DT,O
,score,NN,O
,of,IN,O
,no,DT,O
,less,JJR,O
,than,IN,O
,12,CD,O
,at,IN,O
,end,NN,O
,point,NN,O
,in,IN,O
,the,DT,O
,Y,NNP,O
,-,:,O
,MRS,NNP,O
,total,JJ,O
,score,NN,O
,",",",",O
,respectively,RB,O
,.,.,O
,Safety,NNP,O
,was,VBD,O
,assessed,VBN,O
,using,VBG,O
,adverse,JJ,O
,events,NNS,O
,",",",",O
,Extrapyramidal,NNP,B-DISEASE
,Symptom,NNP,I-DISEASE
,(,(,O
,EPS,NNP,B-DISEASE
,),),O
,rating,NN,O
,scales,NNS,O
,",",",",O
,laboratory,NN,O
,values,NNS,O
,",",",",O
,electrocardiograms,NNS,O
,",",",",O
,vital,JJ,O
,signs,NNS,O
,",",",",O
,and,CC,O
,weight,VBD,O
,change,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Olanzapine,NNP,O
,-,:,O
,treated,VBD,O
,patients,NNS,O
,demonstrated,VBD,O
,a,DT,O
,statistically,RB,O
,significant,JJ,O
,greater,JJR,O
,mean,NN,O
,(,(,O
,+,JJ,O
,/,NNP,O
,-,:,O
,SD,NN,O
,),),O
,improvement,NN,O
,in,IN,O
,Y,NNP,O
,-,:,O
,MRS,NNP,O
,total,NN,O
,score,NN,O
,than,IN,O
,placebo,FW,O
,-,:,O
,treated,VBN,O
,patients,NNS,O
,(,(,O
,-,:,O
,14,CD,O
,.,.,O
,8,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,12,CD,O
,.,.,O
,5,CD,O
,and,CC,O
,-,:,O
,8,CD,O
,.,.,O
,1,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,12,CD,O
,.,.,O
,7,CD,O
,",",",",O
,respectively,RB,O
,;,:,O
,P,NNP,O
,<,NNP,O
,.,.,O
,001,CD,O
,),),O
,",",",",O
,which,WDT,O
,was,VBD,O
,evident,JJ,O
,at,IN,O
,the,DT,O
,first,JJ,O
,postbaseline,NN,O
,observation,NN,O
,1,CD,O
,week,NN,O
,after,IN,O
,randomization,NN,O
,and,CC,O
,was,VBD,O
,maintained,VBN,O
,throughout,IN,O
,the,DT,O
,study,NN,O
,(,(,O
,last,JJ,O
,observation,NN,O
,carried,VBD,O
,forward,RB,O
,),),O
,.,.,O
,Olanzapine,NNP,O
,-,:,O
,treated,VBD,O
,patients,NNS,O
,demonstrated,VBD,O
,a,DT,O
,higher,JJR,O
,rate,NN,O
,of,IN,O
,response,NN,O
,(,(,O
,65,CD,O
,%,NN,O
,vs,JJ,O
,43,CD,O
,%,NN,O
,",",",",O
,respectively,RB,O
,;,:,O
,P,NNP,O
,=,NNP,O
,.,.,O
,02,CD,O
,),),O
,and,CC,O
,euthymia,NN,O
,(,(,O
,61,CD,O
,%,NN,O
,vs,JJ,O
,36,CD,O
,%,NN,O
,",",",",O
,respectively,RB,O
,;,:,O
,P,NNP,O
,=,NNP,O
,.,.,O
,01,CD,O
,),),O
,than,IN,O
,placebo,NN,O
,-,:,O
,treated,JJ,O
,patients,NNS,O
,.,.,O
,There,EX,O
,were,VBD,O
,no,DT,O
,statistically,RB,O
,significant,JJ,O
,differences,NNS,O
,in,IN,O
,EPSs,NNP,B-DISEASE
,between,IN,O
,groups,NNS,O
,.,.,O
,However,RB,O
,",",",",O
,olanzapine,PRP,O
,-,:,O
,treated,VBD,O
,patients,NNS,O
,had,VBD,O
,a,DT,O
,statistically,RB,O
,significant,JJ,O
,greater,JJR,O
,mean,NN,O
,(,(,O
,+,JJ,O
,/,NNP,O
,-,:,O
,SD,NN,O
,),),O
,weight,VBD,B-DISEASE
,gain,NN,I-DISEASE
,than,IN,O
,placebo,SYM,O
,-,:,O
,treated,VBN,O
,patients,NNS,O
,(,(,O
,2,CD,O
,.,.,O
,1,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,2,CD,O
,.,.,O
,8,CD,O
,vs,JJ,O
,0,CD,O
,.,.,O
,45,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,2,CD,O
,.,.,O
,3,CD,O
,kg,NN,O
,",",",",O
,respectively,RB,O
,),),O
,and,CC,O
,also,RB,O
,experienced,VBD,O
,more,RBR,O
,treatment,NN,O
,-,:,O
,emergent,NN,O
,somnolence,NN,B-DISEASE
,(,(,O
,21,CD,O
,patients,NNS,O
,[,JJ,O
,38,CD,O
,.,.,O
,2,CD,O
,%,NN,O
,],NNP,O
,vs,NN,O
,5,CD,O
,[,NN,O
,8,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,],NN,O
,",",",",O
,respectively,RB,O
,),),O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Olanzapine,NN,O
,demonstrated,VBD,O
,greater,JJR,O
,efficacy,NN,O
,than,IN,O
,placebo,NN,O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,acute,JJ,O
,bipolar,JJ,B-DISEASE
,mania,NN,I-DISEASE
,and,CC,O
,was,VBD,O
,generally,RB,O
,well,RB,O
,tolerated,VBN,O
,.,.,O
,The,DT,O
,effect,NN,O
,of,IN,O
,pupil,NN,B-DISEASE
,dilation,NN,I-DISEASE
,with,IN,O
,tropicamide,NN,O
,on,IN,O
,vision,NN,O
,and,CC,O
,driving,VBG,O
,simulator,NN,O
,performance,NN,O
,.,.,O
,PURPOSE,NN,O
,:,:,O
,To,TO,O
,assess,VB,O
,the,DT,O
,effect,NN,O
,of,IN,O
,pupil,NN,B-DISEASE
,dilation,NN,I-DISEASE
,on,IN,O
,vision,NN,O
,and,CC,O
,driving,VBG,O
,ability,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,A,DT,O
,series,NN,O
,of,IN,O
,tests,NNS,O
,on,IN,O
,various,JJ,O
,parameters,NNS,O
,of,IN,O
,visual,JJ,O
,function,NN,O
,and,CC,O
,driving,VBG,O
,simulator,NN,O
,performance,NN,O
,were,VBD,O
,performed,VBN,O
,on,IN,O
,12,CD,O
,healthy,JJ,O
,drivers,NNS,O
,",",",",O
,before,IN,O
,and,CC,O
,after,IN,O
,pupil,JJ,B-DISEASE
,dilation,NN,I-DISEASE
,using,VBG,O
,guttae,JJ,O
,tropicamide,RB,O
,1,CD,O
,%,NN,O
,.,.,O
,A,DT,O
,driving,JJ,O
,simulator,NN,O
,(,(,O
,Transport,NNP,O
,Research,NNP,O
,Laboratory,NNP,O
,),),O
,was,VBD,O
,used,VBN,O
,to,TO,O
,measure,VB,O
,reaction,NN,O
,time,NN,O
,(,(,O
,RT,NNP,O
,),),O
,",",",",O
,speed,JJ,O
,maintenance,NN,O
,and,CC,O
,steering,VBG,O
,accuracy,NN,O
,.,.,O
,Tests,NNS,O
,of,IN,O
,basic,JJ,O
,visual,JJ,O
,function,NN,O
,included,VBD,O
,high,JJ,O
,-,:,O
,and,CC,O
,low,JJ,O
,-,:,O
,contrast,NN,O
,visual,JJ,O
,acuity,NN,O
,(,(,O
,HCVA,NNP,O
,and,CC,O
,LCVA,NNP,O
,),),O
,",",",",O
,Pelli,NNP,O
,-,:,O
,Robson,NNP,O
,contrast,NN,O
,threshold,NN,O
,(,(,O
,CT,NNP,O
,),),O
,and,CC,O
,Goldmann,NNP,O
,perimetry,NN,O
,(,(,O
,FIELDS,NNP,O
,),),O
,.,.,O
,Useful,JJ,O
,Field,NNP,O
,of,IN,O
,View,NNP,O
,(,(,O
,UFOV,NNP,O
,-,:,O
,-,:,O
,a,DT,O
,test,NN,O
,of,IN,O
,visual,JJ,O
,attention,NN,O
,),),O
,was,VBD,O
,also,RB,O
,undertaken,JJ,O
,.,.,O
,The,DT,O
,mean,JJ,O
,differences,NNS,O
,in,IN,O
,the,DT,O
,pre,NN,O
,-,:,O
,and,CC,O
,post,VB,O
,-,:,O
,dilatation,NN,O
,measurements,NNS,O
,were,VBD,O
,tested,VBN,O
,for,IN,O
,statistical,JJ,O
,significance,NN,O
,at,IN,O
,the,DT,O
,95,CD,O
,%,NN,O
,level,NN,O
,using,VBG,O
,one,CD,O
,-,:,O
,tail,NN,O
,paired,VBN,O
,t,JJ,O
,-,:,O
,tests,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Pupillary,JJ,B-DISEASE
,dilation,NN,I-DISEASE
,resulted,VBD,O
,in,IN,O
,a,DT,O
,statistically,RB,O
,significant,JJ,O
,deterioration,NN,O
,in,IN,O
,CT,NNP,O
,and,CC,O
,HCVA,NNP,O
,only,RB,O
,.,.,O
,Five,CD,O
,of,IN,O
,12,CD,O
,drivers,NNS,O
,also,RB,O
,exhibited,VBD,O
,deterioration,NN,O
,in,IN,O
,LCVA,NNP,O
,",",",",O
,CT,NNP,O
,and,CC,O
,RT,NNP,O
,.,.,O
,Little,JJ,O
,evidence,NN,O
,emerged,VBD,O
,for,IN,O
,deterioration,NN,O
,in,IN,O
,FIELDS,NNP,O
,and,CC,O
,UFOV,NNP,O
,.,.,O
,Also,RB,O
,",",",",O
,7,CD,O
,of,IN,O
,12,CD,O
,drivers,NNS,O
,appeared,VBD,O
,to,TO,O
,adjust,VB,O
,their,PRP$,O
,driving,VBG,O
,behaviour,VBN,O
,by,IN,O
,reducing,VBG,O
,their,PRP$,O
,speed,NN,O
,on,IN,O
,the,DT,O
,driving,NN,O
,simulator,NN,O
,",",",",O
,leading,VBG,O
,to,TO,O
,improved,VBN,O
,steering,VBG,O
,accuracy,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Pupillary,JJ,B-DISEASE
,dilation,NN,I-DISEASE
,may,MD,O
,lead,VB,O
,to,TO,O
,a,DT,O
,decrease,NN,O
,in,IN,O
,vision,NN,O
,and,CC,O
,daylight,JJ,O
,driving,VBG,O
,performance,NN,O
,in,IN,O
,young,JJ,O
,people,NNS,O
,.,.,O
,A,DT,O
,larger,JJR,O
,study,NN,O
,",",",",O
,including,VBG,O
,a,DT,O
,broader,JJR,O
,spectrum,NN,O
,of,IN,O
,subjects,NNS,O
,",",",",O
,is,VBZ,O
,warranted,VBN,O
,before,IN,O
,guidelines,NNS,O
,can,MD,O
,be,VB,O
,recommended,VBN,O
,.,.,O
,A,DT,O
,case,NN,O
,of,IN,O
,isotretinoin,NN,B-DISEASE
,embryopathy,NN,I-DISEASE
,with,IN,O
,bilateral,JJ,O
,anotia,NN,B-DISEASE
,and,CC,O
,Taussig,NNP,B-DISEASE
,-,:,I-DISEASE
,Bing,VBG,I-DISEASE
,malformation,NN,I-DISEASE
,.,.,O
,We,PRP,O
,report,VBP,O
,a,DT,O
,newborn,JJ,O
,infant,NN,O
,with,IN,O
,multiple,JJ,O
,congenital,JJ,O
,anomalies,NNS,O
,(,(,O
,anotia,NN,B-DISEASE
,and,CC,O
,Taussig,NNP,B-DISEASE
,-,:,I-DISEASE
,Bing,NNP,I-DISEASE
,malformation,NN,I-DISEASE
,),),O
,due,JJ,O
,to,TO,O
,exposure,VB,O
,to,TO,O
,isotretinoin,VB,O
,within,IN,O
,the,DT,O
,first,JJ,O
,trimester,NN,O
,.,.,O
,In,IN,O
,this,DT,O
,paper,NN,O
,we,PRP,O
,aim,VBP,O
,to,TO,O
,draw,VB,O
,to,TO,O
,the,DT,O
,fact,NN,O
,that,IN,O
,caution,NN,O
,is,VBZ,O
,needed,VBN,O
,when,WRB,O
,prescribing,VBG,O
,vitamin,NN,O
,A,NNP,O
,-,:,O
,containing,VBG,O
,drugs,NNS,O
,to,TO,O
,women,NNS,O
,of,IN,O
,childbearing,VBG,O
,years,NNS,O
,.,.,O
,Effect,NN,O
,of,IN,O
,methoxamine,NN,O
,on,IN,O
,maximum,JJ,O
,urethral,JJ,O
,pressure,NN,O
,in,IN,O
,women,NNS,O
,with,IN,O
,genuine,JJ,O
,stress,NN,B-DISEASE
,incontinence,NN,I-DISEASE
,:,:,O
,a,DT,O
,placebo,NN,O
,-,:,O
,controlled,VBN,O
,",",",",O
,double,JJ,O
,-,:,O
,blind,NN,O
,crossover,NN,O
,study,NN,O
,.,.,O
,The,DT,O
,aim,NN,O
,of,IN,O
,the,DT,O
,study,NN,O
,was,VBD,O
,to,TO,O
,evaluate,VB,O
,the,DT,O
,potential,JJ,O
,role,NN,O
,for,IN,O
,a,DT,O
,selective,JJ,O
,alpha1,NN,O
,-,:,O
,adrenoceptor,NN,O
,agonist,NN,O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,urinary,JJ,B-DISEASE
,stress,NN,I-DISEASE
,incontinence,NN,I-DISEASE
,.,.,O
,A,DT,O
,randomised,JJ,O
,",",",",O
,double,JJ,O
,-,:,O
,blind,NN,O
,",",",",O
,placebo,SYM,O
,-,:,O
,controlled,VBN,O
,",",",",O
,crossover,NN,O
,study,NN,O
,design,NN,O
,was,VBD,O
,employed,VBN,O
,.,.,O
,Half,NNP,O
,log,JJ,O
,incremental,JJ,O
,doses,NNS,O
,of,IN,O
,intravenous,JJ,O
,methoxamine,NN,O
,or,CC,O
,placebo,NN,O
,(,(,O
,saline,NN,O
,),),O
,were,VBD,O
,administered,VBN,O
,to,TO,O
,a,DT,O
,group,NN,O
,of,IN,O
,women,NNS,O
,with,IN,O
,genuine,JJ,O
,stress,NN,B-DISEASE
,incontinence,NN,I-DISEASE
,while,IN,O
,measuring,VBG,O
,maximum,JJ,O
,urethral,JJ,O
,pressure,NN,O
,(,(,O
,MUP,NNP,O
,),),O
,",",",",O
,blood,NN,O
,pressure,NN,O
,",",",",O
,heart,NN,O
,rate,NN,O
,",",",",O
,and,CC,O
,symptomatic,JJ,O
,side,NN,O
,effects,NNS,O
,.,.,O
,Methoxamine,NNP,O
,evoked,VBD,O
,non,JJ,O
,-,:,O
,significant,JJ,O
,increases,NNS,O
,in,IN,O
,MUP,NNP,O
,and,CC,O
,diastolic,JJ,O
,blood,NN,O
,pressure,NN,O
,but,CC,O
,caused,VBD,O
,a,DT,B-DISEASE
,significant,JJ,I-DISEASE
,rise,NN,I-DISEASE
,in,IN,I-DISEASE
,systolic,JJ,I-DISEASE
,blood,NN,I-DISEASE
,pressure,NN,I-DISEASE
,and,CC,O
,significant,JJ,O
,fall,NN,O
,in,IN,O
,heart,NN,O
,rate,NN,O
,at,IN,O
,maximum,JJ,O
,dosage,NN,O
,.,.,O
,Systemic,JJ,O
,side,NN,O
,effects,NNS,O
,including,VBG,O
,piloerection,NN,O
,",",",",O
,headache,NN,B-DISEASE
,",",",",O
,and,CC,O
,cold,JJ,O
,extremities,NNS,O
,were,VBD,O
,experienced,VBN,O
,in,IN,O
,all,DT,O
,subjects,NNS,O
,.,.,O
,The,DT,O
,results,NNS,O
,indicate,VBP,O
,that,IN,O
,the,DT,O
,clinical,JJ,O
,usefulness,NN,O
,of,IN,O
,direct,JJ,O
,",",",",O
,peripherally,RB,O
,acting,VBG,O
,sub,SYM,O
,-,:,O
,type,NN,O
,-,:,O
,selective,JJ,O
,alpha1,NN,O
,-,:,O
,adrenoceptor,NN,O
,agonists,NNS,O
,in,IN,O
,the,DT,O
,medical,JJ,O
,treatment,NN,O
,of,IN,O
,stress,JJ,B-DISEASE
,incontinence,NN,I-DISEASE
,may,MD,O
,be,VB,O
,limited,VBN,O
,by,IN,O
,associated,JJ,O
,piloerection,NN,O
,and,CC,O
,cardiovascular,JJ,O
,side,NN,O
,effects,NNS,O
,.,.,O
,Hyperglycemic,NNP,B-DISEASE
,effect,NN,O
,of,IN,O
,amino,NN,O
,compounds,NNS,O
,structurally,RB,O
,related,VBN,O
,to,TO,O
,caproate,VB,O
,in,IN,O
,rats,NNS,O
,.,.,O
,The,DT,O
,chronic,JJ,O
,feeding,NN,O
,of,IN,O
,small,JJ,O
,amounts,NNS,O
,(,(,O
,0,CD,O
,.,.,O
,3,CD,O
,-,:,O
,3,CD,O
,%,NN,O
,of,IN,O
,diet,JJ,O
,weight,NN,O
,),),O
,of,IN,O
,certain,JJ,O
,amino,JJ,O
,derivatives,NNS,O
,of,IN,O
,caproate,NN,O
,resulted,VBN,O
,in,IN,O
,hyperglycemia,NN,B-DISEASE
,",",",",O
,an,DT,O
,elevated,VBN,O
,glucose,NN,O
,tolerance,NN,O
,curve,NN,O
,and,CC,O
,",",",",O
,occasionally,RB,O
,",",",",O
,glucosuria,NNS,B-DISEASE
,.,.,O
,Effective,JJ,O
,compounds,NNS,O
,included,VBD,O
,norleucine,NN,O
,",",",",O
,norvaline,NN,O
,",",",",O
,glutamate,NN,O
,",",",",O
,epsilon,SYM,O
,-,:,O
,aminocaproate,NN,O
,",",",",O
,methionine,NN,O
,",",",",O
,and,CC,O
,leucine,NN,O
,.,.,O
,Toleration,NN,O
,of,IN,O
,high,JJ,O
,doses,NNS,O
,of,IN,O
,angiotensin,NN,O
,-,:,O
,converting,VBG,O
,enzyme,JJ,O
,inhibitors,NNS,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,chronic,JJ,O
,heart,NN,B-DISEASE
,failure,NN,I-DISEASE
,:,:,O
,results,NNS,O
,from,IN,O
,the,DT,O
,ATLAS,NNP,O
,trial,NN,O
,.,.,O
,The,DT,O
,Assessment,NNP,O
,of,IN,O
,Treatment,NNP,O
,with,IN,O
,Lisinopril,NNP,O
,and,CC,O
,Survival,NNP,O
,.,.,O
,BACKGROUND,NNP,O
,:,:,O
,Treatment,NN,O
,with,IN,O
,angiotensin,JJ,O
,-,:,O
,converting,VBG,O
,enzyme,NN,O
,(,(,O
,ACE,NNP,O
,),),O
,inhibitors,NNS,O
,reduces,VBZ,O
,mortality,NN,O
,and,CC,O
,morbidity,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,chronic,JJ,O
,heart,NN,B-DISEASE
,failure,NN,I-DISEASE
,(,(,O
,CHF,NNP,B-DISEASE
,),),O
,",",",",O
,but,CC,O
,most,JJS,O
,affected,JJ,O
,patients,NNS,O
,are,VBP,O
,not,RB,O
,receiving,VBG,O
,these,DT,O
,agents,NNS,O
,or,CC,O
,are,VBP,O
,being,VBG,O
,treated,VBN,O
,with,IN,O
,doses,NNS,O
,lower,JJR,O
,than,IN,O
,those,DT,O
,found,VBN,O
,to,TO,O
,be,VB,O
,efficacious,JJ,O
,in,IN,O
,trials,NNS,O
,",",",",O
,primarily,RB,O
,because,IN,O
,of,IN,O
,concerns,NNS,O
,about,IN,O
,the,DT,O
,safety,NN,O
,and,CC,O
,tolerability,NN,O
,of,IN,O
,these,DT,O
,agents,NNS,O
,",",",",O
,especially,RB,O
,at,IN,O
,the,DT,O
,recommended,JJ,O
,doses,NNS,O
,.,.,O
,The,DT,O
,present,JJ,O
,study,NN,O
,examines,VBZ,O
,the,DT,O
,safety,NN,O
,and,CC,O
,tolerability,NN,O
,of,IN,O
,high,JJ,O
,-,:,O
,compared,VBN,O
,with,IN,O
,low,JJ,O
,-,:,O
,dose,NN,O
,lisinopril,NN,O
,in,IN,O
,CHF,NNP,B-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,The,DT,O
,Assessment,NNP,O
,of,IN,O
,Lisinopril,NNP,O
,and,CC,O
,Survival,NNP,O
,study,NN,O
,was,VBD,O
,a,DT,O
,multicenter,NN,O
,",",",",O
,randomized,VBN,O
,",",",",O
,double,JJ,O
,-,:,O
,blind,NN,O
,trial,NN,O
,in,IN,O
,which,WDT,O
,patients,NNS,O
,with,IN,O
,or,CC,O
,without,IN,O
,previous,JJ,O
,ACE,NNP,O
,inhibitor,NN,O
,treatment,NN,O
,were,VBD,O
,stabilized,VBN,O
,receiving,VBG,O
,medium,NN,O
,-,:,O
,dose,NN,O
,lisinopril,NN,O
,(,(,O
,12,CD,O
,.,.,O
,5,CD,O
,or,CC,O
,15,CD,O
,.,.,O
,0,CD,O
,mg,JJ,O
,once,RB,O
,daily,JJ,O
,[,NNP,O
,OD,NNP,O
,],NNP,O
,),),O
,for,IN,O
,2,CD,O
,to,TO,O
,4,CD,O
,weeks,NNS,O
,and,CC,O
,then,RB,O
,randomized,VBN,O
,to,TO,O
,high,JJ,O
,-,:,O
,(,(,O
,35,CD,O
,.,.,O
,0,CD,O
,or,CC,O
,32,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,OD,NNP,O
,),),O
,or,CC,O
,low,JJ,O
,-,:,O
,dose,NN,O
,(,(,O
,5,CD,O
,.,.,O
,0,CD,O
,or,CC,O
,2,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,OD,NNP,O
,),),O
,groups,NNS,O
,.,.,O
,Patients,NNS,O
,with,IN,O
,New,NNP,O
,York,NNP,O
,Heart,NNP,O
,Association,NNP,O
,classes,VBZ,O
,II,NNP,O
,to,TO,O
,IV,NNP,O
,CHF,NNP,B-DISEASE
,and,CC,O
,left,VBD,O
,ventricular,JJ,O
,ejection,NN,O
,fractions,NNS,O
,of,IN,O
,no,DT,O
,greater,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,30,CD,O
,(,(,O
,n,JJ,O
,=,NN,O
,3164,CD,O
,),),O
,were,VBD,O
,randomized,VBN,O
,and,CC,O
,followed,VBN,O
,up,RP,O
,for,IN,O
,a,DT,O
,median,NN,O
,of,IN,O
,46,CD,O
,months,NNS,O
,.,.,O
,We,PRP,O
,examined,VBD,O
,the,DT,O
,occurrence,NN,O
,of,IN,O
,adverse,JJ,O
,events,NNS,O
,and,CC,O
,the,DT,O
,need,NN,O
,for,IN,O
,discontinuation,NN,O
,and,CC,O
,dose,JJ,O
,reduction,NN,O
,during,IN,O
,treatment,NN,O
,",",",",O
,with,IN,O
,a,DT,O
,focus,NN,O
,on,IN,O
,hypotension,NN,B-DISEASE
,and,CC,O
,renal,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,.,.,O
,RESULTS,NN,O
,:,:,O
,Of,IN,O
,405,CD,O
,patients,NNS,O
,not,RB,O
,previously,RB,O
,receiving,VBG,O
,an,DT,O
,ACE,NNP,O
,inhibitor,NN,O
,",",",",O
,doses,VBZ,O
,in,IN,O
,only,RB,O
,4,CD,O
,.,.,O
,2,CD,O
,%,NN,O
,could,MD,O
,not,RB,O
,be,VB,O
,titrated,VBN,O
,to,TO,O
,the,DT,O
,medium,NN,O
,doses,VBZ,O
,required,VBN,O
,for,IN,O
,randomization,NN,O
,because,IN,O
,of,IN,O
,symptoms,NNS,O
,possibly,RB,O
,related,VBN,O
,to,TO,O
,hypotension,NN,B-DISEASE
,(,(,O
,2,CD,O
,.,.,O
,0,CD,O
,%,NN,O
,),),O
,or,CC,O
,because,IN,O
,of,IN,O
,renal,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,or,CC,O
,hyperkalemia,NN,B-DISEASE
,(,(,O
,2,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,),),O
,.,.,O
,Doses,VBZ,O
,in,IN,O
,more,JJR,O
,than,IN,O
,90,CD,O
,%,NN,O
,of,IN,O
,randomized,JJ,O
,patients,NNS,O
,in,IN,O
,the,DT,O
,high,JJ,O
,-,:,O
,and,CC,O
,low,JJ,O
,-,:,O
,dose,NN,O
,groups,NNS,O
,were,VBD,O
,titrated,VBN,O
,to,TO,O
,their,PRP$,O
,assigned,VBN,O
,target,NN,O
,",",",",O
,and,CC,O
,the,DT,O
,mean,JJ,O
,doses,NNS,O
,of,IN,O
,blinded,JJ,O
,medication,NN,O
,in,IN,O
,both,DT,O
,groups,NNS,O
,remained,VBD,O
,similar,JJ,O
,throughout,IN,O
,the,DT,O
,study,NN,O
,.,.,O
,Withdrawals,NNS,O
,occurred,VBD,O
,in,IN,O
,27,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,high,JJ,O
,-,:,O
,and,CC,O
,30,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,low,JJ,O
,-,:,O
,dose,NN,O
,groups,NNS,O
,.,.,O
,Subgroups,NNP,O
,presumed,VBD,O
,to,TO,O
,be,VB,O
,at,IN,O
,higher,JJR,O
,risk,NN,O
,for,IN,O
,ACE,NNP,O
,inhibitor,NN,O
,intolerance,NN,O
,(,(,O
,blood,NN,O
,pressure,NN,O
,",",",",O
,<,VBZ,O
,120,CD,O
,mm,NN,O
,Hg,NNP,O
,;,:,O
,creatinine,NN,O
,",",",",O
,>,'',O
,or,CC,O
,=,VB,O
,132,CD,O
,.,.,O
,6,CD,O
,micromol,JJ,O
,/,NNP,O
,L,NNP,O
,[,NNP,O
,>,NNP,O
,or,CC,O
,=,$,O
,1,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,/,NNP,O
,dL,NN,O
,],NN,O
,;,:,O
,age,NN,O
,",",",",O
,>,'',O
,or,CC,O
,=,$,O
,70,CD,O
,years,NNS,O
,;,:,O
,and,CC,O
,patients,NNS,O
,with,IN,O
,diabetes,NNS,B-DISEASE
,),),O
,generally,RB,O
,tolerated,VBN,O
,the,DT,O
,high,JJ,O
,-,:,O
,dose,NN,O
,strategy,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,These,DT,O
,findings,NNS,O
,demonstrate,VBP,O
,that,IN,O
,ACE,NNP,O
,inhibitor,NN,O
,therapy,NN,O
,in,IN,O
,most,JJS,O
,patients,NNS,O
,with,IN,O
,CHF,NNP,B-DISEASE
,can,MD,O
,be,VB,O
,successfully,RB,O
,titrated,VBN,O
,to,TO,O
,and,CC,O
,maintained,VBN,O
,at,IN,O
,high,JJ,O
,doses,NNS,O
,",",",",O
,and,CC,O
,that,IN,O
,more,RBR,O
,aggressive,JJ,O
,use,NN,O
,of,IN,O
,these,DT,O
,agents,NNS,O
,is,VBZ,O
,warranted,VBN,O
,.,.,O
,Cocaine,NNP,O
,",",",",O
,ethanol,NN,O
,",",",",O
,and,CC,O
,cocaethylene,JJ,O
,cardiotoxity,NN,B-DISEASE
,in,IN,O
,an,DT,O
,animal,JJ,O
,model,NN,O
,of,IN,O
,cocaine,NN,B-DISEASE
,and,CC,I-DISEASE
,ethanol,NN,I-DISEASE
,abuse,NN,I-DISEASE
,.,.,O
,OBJECTIVES,CC,O
,:,:,O
,Simultaneous,JJ,O
,abuse,NN,B-DISEASE
,of,IN,I-DISEASE
,cocaine,NN,I-DISEASE
,and,CC,I-DISEASE
,ethanol,JJ,I-DISEASE
,affects,NNS,O
,12,CD,O
,million,CD,O
,Americans,NNPS,O
,annually,RB,O
,.,.,O
,In,IN,O
,combination,NN,O
,",",",",O
,these,DT,O
,substances,NNS,O
,are,VBP,O
,substantially,RB,O
,more,JJR,O
,toxic,NN,O
,than,IN,O
,either,DT,O
,drug,NN,O
,alone,RB,O
,.,.,O
,Their,PRP$,O
,combined,JJ,O
,cardiac,JJ,B-DISEASE
,toxicity,NN,I-DISEASE
,may,MD,O
,be,VB,O
,due,JJ,O
,to,TO,O
,independent,JJ,O
,effects,NNS,O
,of,IN,O
,each,DT,O
,drug,NN,O
,;,:,O
,however,RB,O
,",",",",O
,they,PRP,O
,may,MD,O
,also,RB,O
,be,VB,O
,due,JJ,O
,to,TO,O
,cocaethylene,VB,O
,(,(,O
,CE,NNP,O
,),),O
,",",",",O
,a,DT,O
,cocaine,NN,O
,metabolite,NN,O
,formed,VBD,O
,only,RB,O
,in,IN,O
,the,DT,O
,presence,NN,O
,of,IN,O
,ethanol,NN,O
,.,.,O
,The,DT,O
,purpose,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,was,VBD,O
,to,TO,O
,delineate,VB,O
,the,DT,O
,role,NN,O
,of,IN,O
,CE,NNP,O
,in,IN,O
,the,DT,O
,combined,JJ,O
,cardiotoxicity,NN,B-DISEASE
,of,IN,O
,cocaine,NN,O
,and,CC,O
,ethanol,NN,O
,in,IN,O
,a,DT,O
,model,NN,O
,simulating,VBG,O
,their,PRP$,O
,abuse,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,Twenty,NNP,O
,-,:,O
,three,CD,O
,dogs,NNS,O
,were,VBD,O
,randomized,VBN,O
,to,TO,O
,receive,VB,O
,either,RB,O
,1,CD,O
,),),O
,three,CD,O
,intravenous,JJ,O
,(,(,O
,IV,NNP,O
,),),O
,boluses,NNS,O
,of,IN,O
,cocaine,NN,O
,7,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,with,IN,O
,ethanol,NN,O
,(,(,O
,1,CD,O
,g,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,as,IN,O
,an,DT,O
,IV,NNP,O
,infusion,NN,O
,(,(,O
,C,NNP,O
,+,NNP,O
,E,NNP,O
,",",",",O
,n,JJ,O
,=,NNP,O
,8,CD,O
,),),O
,",",",",O
,2,CD,O
,),),O
,three,CD,O
,cocaine,NN,O
,boluses,VBZ,O
,only,RB,O
,(,(,O
,C,NNP,O
,",",",",O
,n,JJ,O
,=,NNP,O
,6,CD,O
,),),O
,",",",",O
,3,CD,O
,),),O
,ethanol,NN,O
,infusion,NN,O
,only,RB,O
,(,(,O
,E,NNP,O
,",",",",O
,n,JJ,O
,=,NNP,O
,5,CD,O
,),),O
,",",",",O
,or,CC,O
,4,CD,O
,),),O
,placebo,NN,O
,boluses,NNS,O
,and,CC,O
,infusion,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,4,CD,O
,),),O
,.,.,O
,Hemodynamic,JJ,O
,measurements,NNS,O
,",",",",O
,electrocardiograms,NNS,O
,",",",",O
,and,CC,O
,serum,JJ,O
,drug,NN,O
,concentrations,NNS,O
,were,VBD,O
,obtained,VBN,O
,at,IN,O
,baseline,NN,O
,",",",",O
,and,CC,O
,then,RB,O
,at,IN,O
,fixed,JJ,O
,time,NN,O
,intervals,NNS,O
,after,IN,O
,each,DT,O
,drug,NN,O
,was,VBD,O
,administered,VBN,O
,.,.,O
,RESULTS,NNS,O
,:,:,O
,Two,CD,O
,of,IN,O
,eight,CD,O
,dogs,NNS,O
,in,IN,O
,the,DT,O
,C,NNP,O
,+,NNP,O
,E,NNP,O
,group,NN,O
,experienced,VBD,O
,cardiovascular,JJ,B-DISEASE
,collapse,NN,I-DISEASE
,.,.,O
,The,DT,O
,most,RBS,O
,dramatic,JJ,O
,hemodynamic,JJ,O
,changes,NNS,O
,occurred,VBD,O
,after,IN,O
,each,DT,O
,cocaine,NN,O
,bolus,NN,O
,in,IN,O
,the,DT,O
,C,NNP,O
,+,NNP,O
,E,NNP,O
,and,CC,O
,C,NNP,O
,only,RB,O
,groups,NNS,O
,;,:,O
,however,RB,O
,",",",",O
,persistent,JJ,O
,hemodynamic,JJ,O
,changes,NNS,O
,occurred,VBD,O
,in,IN,O
,the,DT,O
,C,NNP,O
,+,NNP,O
,E,NNP,O
,group,NN,O
,.,.,O
,Peak,NNP,O
,CE,NNP,O
,levels,NNS,O
,were,VBD,O
,associated,VBN,O
,with,IN,O
,a,DT,O
,45,CD,O
,%,NN,O
,(,(,O
,SD,NNP,O
,+,NNP,O
,/,NNP,O
,-,:,O
,22,CD,O
,%,NN,O
,",",",",O
,95,CD,O
,%,NN,O
,CI,NNP,O
,=,NNP,O
,22,CD,O
,%,NN,O
,to,TO,O
,69,CD,O
,%,NN,O
,),),O
,decrease,NN,B-DISEASE
,in,IN,I-DISEASE
,cardiac,JJ,I-DISEASE
,output,NN,I-DISEASE
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,",",",",O
,a,DT,O
,56,CD,O
,%,NN,O
,(,(,O
,SD,NNP,O
,+,NNP,O
,/,NNP,O
,-,:,O
,23,CD,O
,%,NN,O
,",",",",O
,95,CD,O
,%,NN,O
,CI,NNP,O
,=,NNP,O
,32,CD,O
,%,NN,O
,to,TO,O
,80,CD,O
,%,NN,O
,),),O
,decrease,NN,O
,in,IN,O
,dP,NN,O
,/,NN,O
,dt,NN,O
,(,(,O
,max,NN,O
,),),O
,(,(,O
,p,JJ,O
,<,NNP,O
,.,.,O
,006,CD,O
,),),O
,",",",",O
,and,CC,O
,a,DT,O
,23,CD,O
,%,NN,O
,(,(,O
,SD,NNP,O
,+,NNP,O
,/,NNP,O
,-,:,O
,15,CD,O
,%,NN,O
,",",",",O
,95,CD,O
,%,NN,O
,CI,NNP,O
,=,NNP,O
,7,CD,O
,%,NN,O
,to,TO,O
,49,CD,O
,%,NN,O
,),),O
,decrease,NN,O
,in,IN,O
,SVO,NNP,O
,(,(,O
,2,CD,O
,),),O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,025,CD,O
,),),O
,.,.,O
,Ventricular,JJ,B-DISEASE
,arrhythmias,NNS,I-DISEASE
,were,VBD,O
,primarily,RB,O
,observed,VBN,O
,in,IN,O
,the,DT,O
,C,NNP,O
,+,NNP,O
,E,NNP,O
,group,NN,O
,",",",",O
,in,IN,O
,which,WDT,O
,four,CD,O
,of,IN,O
,eight,CD,O
,dogs,NNS,O
,experienced,VBD,O
,ventricular,JJ,B-DISEASE
,tachycardia,NN,I-DISEASE
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Cocaine,NN,O
,and,CC,O
,ethanol,NN,O
,in,IN,O
,combination,NN,O
,were,VBD,O
,more,JJR,O
,toxic,JJ,O
,than,IN,O
,either,DT,O
,substance,NN,O
,alone,RB,O
,.,.,O
,Co,NNP,O
,-,:,O
,administration,NN,O
,resulted,VBD,O
,in,IN,O
,prolonged,JJ,O
,cardiac,JJ,B-DISEASE
,toxicity,NN,I-DISEASE
,and,CC,O
,was,VBD,O
,dysrhythmogenic,JJ,O
,.,.,O
,Peak,NNP,O
,serum,JJ,O
,cocaethylene,NN,O
,concentrations,NNS,O
,were,VBD,O
,associated,VBN,O
,with,IN,O
,prolonged,JJ,O
,myocardial,JJ,B-DISEASE
,depression,NN,I-DISEASE
,.,.,O
,Worsening,NNP,O
,of,IN,O
,Parkinsonism,NNP,B-DISEASE
,after,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,veralipride,NN,O
,for,IN,O
,treatment,NN,O
,of,IN,O
,menopause,NN,O
,:,:,O
,case,NN,O
,report,NN,O
,.,.,O
,We,PRP,O
,describe,VBP,O
,a,DT,O
,female,JJ,O
,patient,NN,O
,with,IN,O
,stable,JJ,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,who,WP,O
,has,VBZ,O
,shown,VBN,O
,a,DT,O
,marked,JJ,O
,worsening,NN,O
,of,IN,O
,her,PRP$,O
,motor,NN,O
,functions,NNS,O
,following,VBG,O
,therapy,NN,O
,of,IN,O
,menopause,NN,O
,related,VBN,O
,symptoms,NNS,O
,with,IN,O
,veralipride,NN,O
,",",",",O
,as,RB,O
,well,RB,O
,as,IN,O
,the,DT,O
,improvement,NN,O
,of,IN,O
,her,PRP$,O
,symptoms,NNS,O
,back,RB,O
,to,TO,O
,baseline,NN,O
,after,IN,O
,discontinuation,NN,O
,of,IN,O
,the,DT,O
,drug,NN,O
,.,.,O
,We,PRP,O
,emphasize,VBP,O
,the,DT,O
,anti,JJ,O
,-,:,O
,dopaminergic,JJ,O
,effect,NN,O
,of,IN,O
,veralipride,NN,O
,.,.,O
,Viracept,NNP,O
,and,CC,O
,irregular,JJ,B-DISEASE
,heartbeat,NN,I-DISEASE
,warning,NN,O
,.,.,O
,A,DT,O
,group,NN,O
,of,IN,O
,doctors,NNS,O
,in,IN,O
,Boston,NNP,O
,warn,NN,O
,that,IN,O
,the,DT,O
,protease,NN,O
,inhibitor,NN,O
,Viracept,NNP,O
,may,MD,O
,cause,VB,O
,an,DT,O
,irregular,JJ,B-DISEASE
,heart,NN,I-DISEASE
,beat,NN,I-DISEASE
,",",",",O
,known,VBN,O
,as,IN,O
,bradycardia,NN,B-DISEASE
,",",",",O
,in,IN,O
,people,NNS,O
,with,IN,O
,HIV,NNP,O
,.,.,O
,Bradycardia,NNP,B-DISEASE
,occurred,VBD,O
,in,IN,O
,a,DT,O
,45,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,male,JJ,O
,patient,NN,O
,who,WP,O
,was,VBD,O
,Viracept,NNP,O
,in,IN,O
,combination,NN,O
,with,IN,O
,other,JJ,O
,anti,JJ,O
,-,:,O
,HIV,NNP,O
,drugs,NNS,O
,.,.,O
,The,DT,O
,symptoms,NNS,O
,ceased,VBN,O
,after,IN,O
,switching,VBG,O
,to,TO,O
,another,DT,O
,drug,NN,O
,combination,NN,O
,.,.,O
,Frequency,NN,O
,of,IN,O
,appearance,NN,O
,of,IN,O
,myeloperoxidase,NN,O
,-,:,O
,antineutrophil,JJ,O
,cytoplasmic,JJ,O
,antibody,NN,O
,(,(,O
,MPO,NNP,O
,-,:,O
,ANCA,NN,O
,),),O
,in,IN,O
,Graves,NNP,B-DISEASE
,',POS,I-DISEASE
,disease,NN,I-DISEASE
,patients,NNS,O
,treated,VBN,O
,with,IN,O
,propylthiouracil,NN,O
,and,CC,O
,the,DT,O
,relationship,NN,O
,between,IN,O
,MPO,NNP,O
,-,:,O
,ANCA,NNP,O
,and,CC,O
,clinical,JJ,O
,manifestations,NNS,O
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,Myeloperoxidase,NNP,O
,antineutrophil,VB,O
,cytoplasmic,JJ,O
,antibody,NN,O
,(,(,O
,MPO,NNP,O
,-,:,O
,ANCA,NN,O
,),),O
,-,:,O
,positive,JJ,O
,vasculitis,NN,B-DISEASE
,has,VBZ,O
,been,VBN,O
,reported,VBN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,Graves,NNP,B-DISEASE
,',POS,I-DISEASE
,disease,NN,I-DISEASE
,who,WP,O
,were,VBD,O
,treated,VBN,O
,with,IN,O
,propylthiouracil,NN,O
,(,(,O
,PTU,NNP,O
,),),O
,.,.,O
,The,DT,O
,appearance,NN,O
,of,IN,O
,MPO,NNP,O
,-,:,O
,ANCA,NN,O
,in,IN,O
,these,DT,O
,cases,NNS,O
,was,VBD,O
,suspected,VBN,O
,of,IN,O
,being,VBG,O
,related,VBN,O
,to,TO,O
,PTU,NNP,O
,because,IN,O
,the,DT,O
,titres,NNS,O
,of,IN,O
,MPO,NNP,O
,-,:,O
,ANCA,NNP,O
,decreased,VBD,O
,when,WRB,O
,PTU,NNP,O
,was,VBD,O
,stopped,VBN,O
,.,.,O
,Nevertheless,RB,O
,",",",",O
,there,EX,O
,have,VBP,O
,been,VBN,O
,no,DT,O
,studies,NNS,O
,on,IN,O
,the,DT,O
,temporal,JJ,O
,relationship,NN,O
,between,IN,O
,the,DT,O
,appearance,NN,O
,of,IN,O
,MPO,NNP,O
,-,:,O
,ANCA,NNP,O
,and,CC,O
,vasculitis,NN,B-DISEASE
,during,IN,O
,PTU,NNP,O
,therapy,NN,O
,",",",",O
,or,CC,O
,on,IN,O
,the,DT,O
,incidence,NN,O
,of,IN,O
,MPO,NNP,O
,-,:,O
,ANCA,NN,O
,in,IN,O
,untreated,JJ,O
,Graves,NNP,B-DISEASE
,',POS,I-DISEASE
,disease,NN,I-DISEASE
,patients,NNS,O
,.,.,O
,Therefore,RB,O
,",",",",O
,we,PRP,O
,sought,VBD,O
,to,TO,O
,address,VB,O
,these,DT,O
,parameters,NNS,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,Graves,NNP,B-DISEASE
,',POS,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,PATIENTS,NNS,O
,:,:,O
,We,PRP,O
,investigated,VBD,O
,102,CD,O
,untreated,JJ,O
,patients,NNS,O
,with,IN,O
,hyperthyroidism,NN,B-DISEASE
,due,JJ,O
,to,TO,O
,Graves,NNP,B-DISEASE
,',POS,I-DISEASE
,disease,NN,I-DISEASE
,for,IN,O
,the,DT,O
,presence,NN,O
,of,IN,O
,MPO,NNP,O
,-,:,O
,ANCA,NNP,O
,",",",",O
,and,CC,O
,for,IN,O
,the,DT,O
,development,NN,O
,vasculitis,NN,B-DISEASE
,after,IN,O
,starting,VBG,O
,PTU,NNP,O
,therapy,NN,O
,.,.,O
,Twenty,NNP,O
,-,:,O
,nine,CD,O
,of,IN,O
,them,PRP,O
,were,VBD,O
,later,RB,O
,excluded,VBN,O
,because,IN,O
,of,IN,O
,adverse,JJ,O
,effects,NNS,O
,of,IN,O
,PTU,NNP,O
,or,CC,O
,because,IN,O
,the,DT,O
,observation,NN,O
,period,NN,O
,was,VBD,O
,less,JJR,O
,than,IN,O
,3,CD,O
,months,NNS,O
,.,.,O
,The,DT,O
,remaining,VBG,O
,73,CD,O
,patients,NNS,O
,(,(,O
,55,CD,O
,women,NNS,O
,and,CC,O
,18,CD,O
,men,NNS,O
,),),O
,",",",",O
,all,DT,O
,of,IN,O
,whom,WP,O
,were,VBD,O
,examined,VBN,O
,for,IN,O
,more,JJR,O
,than,IN,O
,3,CD,O
,months,NNS,O
,",",",",O
,were,VBD,O
,adopted,VBN,O
,as,IN,O
,the,DT,O
,subjects,NNS,O
,of,IN,O
,the,DT,O
,investigation,NN,O
,.,.,O
,The,DT,O
,median,JJ,O
,observation,NN,O
,period,NN,O
,was,VBD,O
,23,CD,O
,.,.,O
,6,CD,O
,months,NNS,O
,(,(,O
,range,NN,O
,:,:,O
,3,CD,O
,-,:,O
,37,CD,O
,months,NNS,O
,),),O
,.,.,O
,MEASUREMENTS,NNS,O
,:,:,O
,MPO,NNP,O
,-,:,O
,ANCA,NNP,O
,was,VBD,O
,measured,VBN,O
,at,IN,O
,intervals,NNS,O
,of,IN,O
,2,CD,O
,-,:,O
,6,CD,O
,months,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Before,IN,O
,treatment,NN,O
,",",",",O
,the,DT,O
,MPO,NNP,O
,-,:,O
,ANCA,NNP,O
,titres,NNS,O
,of,IN,O
,all,DT,O
,102,CD,O
,untreated,JJ,O
,Graves,NNPS,B-DISEASE
,',POS,I-DISEASE
,disease,NN,I-DISEASE
,patients,NNS,O
,were,VBD,O
,within,IN,O
,the,DT,O
,reference,NN,O
,range,NN,O
,(,(,O
,below,IN,O
,10,CD,O
,U,NNP,O
,/,NNP,O
,ml,NN,O
,),),O
,.,.,O
,Three,NNP,O
,(,(,O
,4,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,),),O
,of,IN,O
,the,DT,O
,73,CD,O
,patients,NNS,O
,were,VBD,O
,positive,JJ,O
,for,IN,O
,MPO,NNP,O
,-,:,O
,ANCA,NN,O
,at,IN,O
,13,CD,O
,",",",",O
,16,CD,O
,and,CC,O
,17,CD,O
,months,NNS,O
,",",",",O
,respectively,RB,O
,",",",",O
,after,IN,O
,the,DT,O
,start,NN,O
,of,IN,O
,PTU,NNP,O
,therapy,NN,O
,.,.,O
,In,IN,O
,two,CD,O
,of,IN,O
,them,PRP,O
,",",",",O
,the,DT,O
,MPO,NNP,O
,-,:,O
,ANCA,NNP,O
,titres,VBZ,O
,transiently,RB,O
,increased,VBN,O
,to,TO,O
,12,CD,O
,.,.,O
,8,CD,O
,and,CC,O
,15,CD,O
,.,.,O
,0,CD,O
,U,NNP,O
,/,NNP,O
,ml,NN,O
,",",",",O
,respectively,RB,O
,",",",",O
,despite,IN,O
,continued,JJ,O
,PTU,NNP,O
,therapy,NN,O
,",",",",O
,but,CC,O
,no,DT,O
,vasculitic,JJ,B-DISEASE
,disorders,NNS,I-DISEASE
,developed,VBD,O
,.,.,O
,In,IN,O
,the,DT,O
,third,JJ,O
,patient,NN,O
,",",",",O
,the,DT,O
,MPO,NNP,O
,-,:,O
,ANCA,NNP,O
,titre,NN,O
,increased,VBD,O
,to,TO,O
,204,CD,O
,U,NNP,O
,/,NNP,O
,ml,NN,O
,and,CC,O
,she,PRP,O
,developed,VBD,O
,a,DT,O
,higher,JJR,O
,fever,NN,B-DISEASE
,",",",",O
,oral,JJ,B-DISEASE
,ulcers,NNS,I-DISEASE
,and,CC,O
,polyarthralgia,NN,B-DISEASE
,",",",",O
,but,CC,O
,the,DT,O
,symptoms,NNS,O
,resolved,VBD,O
,2,CD,O
,weeks,NNS,O
,after,IN,O
,stopping,VBG,O
,PTU,NNP,O
,therapy,NN,O
,",",",",O
,and,CC,O
,the,DT,O
,MPO,NNP,O
,-,:,O
,ANCA,NNP,O
,titre,NN,O
,decreased,VBD,O
,to,TO,O
,20,CD,O
,.,.,O
,7,CD,O
,U,NNP,O
,/,NNP,O
,ml,NN,O
,by,IN,O
,4,CD,O
,months,NNS,O
,after,IN,O
,discontinuing,VBG,O
,PTU,NNP,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,PTU,NNP,O
,therapy,NN,O
,may,MD,O
,be,VB,O
,related,VBN,O
,to,TO,O
,the,DT,O
,appearance,NN,O
,of,IN,O
,MPO,NNP,O
,-,:,O
,ANCA,NN,O
,",",",",O
,but,CC,O
,MPO,NNP,O
,-,:,O
,ANCA,NN,O
,does,VBZ,O
,not,RB,O
,appear,VB,O
,to,TO,O
,be,VB,O
,closely,RB,O
,related,VBN,O
,to,TO,O
,vasculitis,NN,B-DISEASE
,.,.,O
,Prevalence,NN,O
,of,IN,O
,heart,NN,B-DISEASE
,disease,NN,I-DISEASE
,in,IN,O
,asymptomatic,JJ,O
,chronic,JJ,O
,cocaine,NN,O
,users,NNS,O
,.,.,O
,To,TO,O
,determine,VB,O
,the,DT,O
,prevalence,NN,O
,of,IN,O
,heart,NN,B-DISEASE
,disease,NN,I-DISEASE
,in,IN,O
,outpatient,JJ,O
,young,JJ,O
,asymptomatic,JJ,O
,chronic,JJ,O
,cocaine,NN,O
,users,NNS,O
,",",",",O
,35,CD,O
,cocaine,NN,O
,users,NNS,O
,and,CC,O
,32,CD,O
,age,NN,O
,-,:,O
,matched,VBN,O
,controls,NNS,O
,underwent,JJ,O
,resting,NN,O
,and,CC,O
,exercise,NN,O
,electrocardiography,NN,O
,(,(,O
,ECG,NNP,O
,),),O
,and,CC,O
,Doppler,NNP,O
,echocardiography,NN,O
,.,.,O
,Findings,NNS,O
,consistent,JJ,O
,with,IN,O
,coronary,JJ,B-DISEASE
,artery,NN,I-DISEASE
,disease,NN,I-DISEASE
,were,VBD,O
,detected,VBN,O
,in,IN,O
,12,CD,O
,(,(,O
,34,CD,O
,%,NN,O
,),),O
,patients,NNS,O
,and,CC,O
,3,CD,O
,(,(,O
,9,CD,O
,%,NN,O
,),),O
,controls,VBZ,O
,(,(,O
,p,JJ,O
,=,NN,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,Decreased,VBN,O
,left,VBD,O
,ventricular,JJ,O
,systolic,JJ,O
,function,NN,O
,was,VBD,O
,demonstrated,VBN,O
,in,IN,O
,5,CD,O
,(,(,O
,14,CD,O
,%,NN,O
,),),O
,patients,NNS,O
,",",",",O
,but,CC,O
,in,IN,O
,none,NN,O
,of,IN,O
,the,DT,O
,controls,NNS,O
,(,(,O
,p,VB,O
,=,RB,O
,0,CD,O
,.,.,O
,055,CD,O
,),),O
,.,.,O
,Finally,RB,O
,",",",",O
,resting,VBG,O
,and,CC,O
,peak,JJ,O
,exercise,NN,O
,abnormal,NN,B-DISEASE
,left,VBD,I-DISEASE
,ventricular,JJ,I-DISEASE
,filling,NN,I-DISEASE
,was,VBD,O
,detected,VBN,O
,in,IN,O
,38,CD,O
,and,CC,O
,35,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,as,IN,O
,compared,VBN,O
,to,TO,O
,19,CD,O
,and,CC,O
,9,CD,O
,%,NN,O
,of,IN,O
,controls,NNS,O
,",",",",O
,respectively,RB,O
,(,(,O
,p,JJ,O
,=,NN,O
,0,CD,O
,.,.,O
,11,CD,O
,and,CC,O
,0,CD,O
,.,.,O
,02,CD,O
,",",",",O
,respectively,RB,O
,),),O
,.,.,O
,We,PRP,O
,conclude,VBP,O
,that,IN,O
,coronary,JJ,B-DISEASE
,artery,NN,I-DISEASE
,or,CC,I-DISEASE
,myocardial,JJ,I-DISEASE
,disease,NN,I-DISEASE
,is,VBZ,O
,common,JJ,O
,(,(,O
,38,CD,O
,%,NN,O
,),),O
,in,IN,O
,young,JJ,O
,asymptomatic,JJ,O
,chronic,JJ,O
,cocaine,NN,O
,users,NNS,O
,.,.,O
,Therefore,RB,O
,",",",",O
,screening,VBG,O
,ECG,NNP,O
,and,CC,O
,echocardiography,NN,O
,may,MD,O
,be,VB,O
,warranted,VBN,O
,in,IN,O
,these,DT,O
,patients,NNS,O
,.,.,O
,Cardioprotective,JJ,O
,effects,NNS,O
,of,IN,O
,Picrorrhiza,NNP,O
,kurroa,FW,O
,against,IN,O
,isoproterenol,JJ,O
,-,:,O
,induced,JJ,O
,myocardial,JJ,O
,stress,NN,O
,in,IN,O
,rats,NNS,O
,.,.,O
,The,DT,O
,cardioprotective,JJ,O
,effect,NN,O
,of,IN,O
,the,DT,O
,ethanol,JJ,O
,extract,NN,O
,of,IN,O
,Picrorrhiza,NNP,O
,kurroa,NNP,O
,rhizomes,NNS,O
,and,CC,O
,roots,NNS,O
,(,(,O
,PK,NNP,O
,),),O
,on,IN,O
,isoproterenol,NN,O
,-,:,O
,induced,JJ,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,in,IN,O
,rats,NNS,O
,with,IN,O
,respect,NN,O
,to,TO,O
,lipid,JJ,O
,metabolism,NN,O
,in,IN,O
,serum,NN,O
,and,CC,O
,heart,NN,O
,tissue,NN,O
,has,VBZ,O
,been,VBN,O
,investigated,VBN,O
,.,.,O
,Oral,NNP,O
,pre,SYM,O
,-,:,O
,treatment,NN,O
,with,IN,O
,PK,NNP,O
,(,(,O
,80,CD,O
,mg,NN,O
,kg,NN,O
,(,(,O
,-,:,O
,1,CD,O
,),),O
,day,NN,O
,(,(,O
,-,:,O
,1,CD,O
,),),O
,for,IN,O
,15,CD,O
,days,NNS,O
,),),O
,significantly,RB,O
,prevented,VBD,O
,the,DT,O
,isoproterenol,NN,O
,-,:,O
,induced,JJ,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,and,CC,O
,maintained,VBD,O
,the,DT,O
,rats,NNS,O
,at,IN,O
,near,IN,O
,normal,JJ,O
,status,NN,O
,.,.,O
,Phase,VB,O
,2,CD,O
,early,JJ,O
,afterdepolarization,NN,O
,as,IN,O
,a,DT,O
,trigger,NN,O
,of,IN,O
,polymorphic,JJ,O
,ventricular,JJ,B-DISEASE
,tachycardia,NN,I-DISEASE
,in,IN,O
,acquired,VBN,O
,long,RB,B-DISEASE
,-,:,I-DISEASE
,QT,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,:,:,O
,direct,JJ,O
,evidence,NN,O
,from,IN,O
,intracellular,JJ,O
,recordings,NNS,O
,in,IN,O
,the,DT,O
,intact,JJ,O
,left,VBD,O
,ventricular,JJ,O
,wall,NN,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,This,DT,O
,study,NN,O
,examined,VBD,O
,the,DT,O
,role,NN,O
,of,IN,O
,phase,NN,O
,2,CD,O
,early,JJ,O
,afterdepolarization,NN,O
,(,(,O
,EAD,NNP,O
,),),O
,in,IN,O
,producing,VBG,O
,a,DT,O
,trigger,NN,O
,to,TO,O
,initiate,VB,O
,torsade,NN,B-DISEASE
,de,IN,I-DISEASE
,pointes,NNS,I-DISEASE
,(,(,O
,TdP,NNP,B-DISEASE
,),),O
,with,IN,O
,QT,NNP,B-DISEASE
,prolongation,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,dl,JJ,O
,-,:,O
,sotalol,NN,O
,and,CC,O
,azimilide,NN,O
,.,.,O
,The,DT,O
,contribution,NN,O
,of,IN,O
,transmural,JJ,O
,dispersion,NN,O
,of,IN,O
,repolarization,NN,O
,(,(,O
,TDR,NNP,O
,),),O
,to,TO,O
,transmural,JJ,O
,propagation,NN,O
,of,IN,O
,EAD,NNP,O
,and,CC,O
,the,DT,O
,maintenance,NN,O
,of,IN,O
,TdP,NNP,B-DISEASE
,was,VBD,O
,also,RB,O
,evaluated,VBN,O
,.,.,O
,METHODS,NNP,O
,AND,CC,O
,RESULTS,NNP,O
,:,:,O
,Transmembrane,NNP,O
,action,NN,O
,potentials,NNS,O
,from,IN,O
,epicardium,NN,O
,",",",",O
,midmyocardium,NN,O
,",",",",O
,and,CC,O
,endocardium,NN,O
,were,VBD,O
,recorded,VBN,O
,simultaneously,RB,O
,",",",",O
,together,RB,O
,with,IN,O
,a,DT,O
,transmural,JJ,O
,ECG,NNP,O
,",",",",O
,in,IN,O
,arterially,RB,O
,perfused,VBN,O
,canine,NN,O
,and,CC,O
,rabbit,NN,O
,left,VBD,O
,ventricular,JJ,O
,preparations,NNS,O
,.,.,O
,dl,VB,O
,-,:,O
,Sotalol,NNP,O
,preferentially,RB,O
,prolonged,VBD,O
,action,NN,O
,potential,JJ,O
,duration,NN,O
,(,(,O
,APD,NNP,O
,),),O
,in,IN,O
,M,NNP,O
,cells,NNS,O
,dose,JJ,O
,-,:,O
,dependently,RB,O
,(,(,O
,1,CD,O
,to,TO,O
,100,CD,O
,micromol,NNS,O
,/,NNP,O
,L,NNP,O
,),),O
,",",",",O
,leading,VBG,O
,to,TO,O
,QT,NNP,B-DISEASE
,prolongation,NN,I-DISEASE
,and,CC,O
,an,DT,O
,increase,NN,O
,in,IN,O
,TDR,NNP,O
,.,.,O
,Azimilide,NNP,O
,",",",",O
,however,RB,O
,",",",",O
,significantly,RB,O
,prolonged,VBN,O
,APD,NNP,O
,and,CC,O
,QT,NNP,O
,interval,NN,O
,at,IN,O
,concentrations,NNS,O
,from,IN,O
,0,CD,O
,.,.,O
,1,CD,O
,to,TO,O
,10,CD,O
,micromol,NNS,O
,/,JJ,O
,L,NNP,O
,but,CC,O
,shortened,VBD,O
,them,PRP,O
,at,IN,O
,30,CD,O
,micromol,NN,O
,/,NNP,O
,L,NNP,O
,.,.,O
,Unlike,IN,O
,dl,JJ,O
,-,:,O
,sotalol,NN,O
,",",",",O
,azimilide,RB,O
,(,(,O
,>,JJ,O
,3,CD,O
,micromol,NN,O
,/,NNP,O
,L,NNP,O
,),),O
,increased,VBD,O
,epicardial,JJ,O
,APD,NNP,O
,markedly,RB,O
,",",",",O
,causing,VBG,O
,a,DT,O
,diminished,JJ,O
,TDR,NNP,O
,.,.,O
,Although,IN,O
,both,DT,O
,dl,JJ,O
,-,:,O
,sotalol,NN,O
,and,CC,O
,azimilide,VB,O
,rarely,RB,O
,induced,JJ,O
,EADs,NNP,O
,in,IN,O
,canine,NN,O
,left,VBD,O
,ventricles,NNS,O
,",",",",O
,they,PRP,O
,produced,VBD,O
,frequent,JJ,O
,EADs,NNP,O
,in,IN,O
,rabbits,NNS,O
,",",",",O
,in,IN,O
,which,WDT,O
,more,RBR,O
,pronounced,JJ,O
,QT,NNP,B-DISEASE
,prolongation,NN,I-DISEASE
,was,VBD,O
,seen,VBN,O
,.,.,O
,An,DT,O
,increase,NN,O
,in,IN,O
,TDR,NNP,O
,by,IN,O
,dl,SYM,O
,-,:,O
,sotalol,NN,O
,facilitated,VBD,O
,transmural,JJ,O
,propagation,NN,O
,of,IN,O
,EADs,NNP,O
,that,WDT,O
,initiated,VBD,O
,multiple,JJ,O
,episodes,NNS,O
,of,IN,O
,spontaneous,JJ,O
,TdP,NNP,B-DISEASE
,in,IN,O
,3,CD,O
,of,IN,O
,6,CD,O
,rabbit,NN,O
,left,VBD,O
,ventricles,NNS,O
,.,.,O
,Of,IN,O
,note,NN,O
,",",",",O
,although,IN,O
,azimilide,NN,O
,(,(,O
,3,CD,O
,to,TO,O
,10,CD,O
,micromol,NNS,O
,/,NNP,O
,L,NNP,O
,),),O
,increased,VBD,O
,APD,NNP,O
,more,JJR,O
,than,IN,O
,dl,SYM,O
,-,:,O
,sotalol,NN,O
,",",",",O
,its,PRP$,O
,EADs,NNP,O
,often,RB,O
,failed,VBD,O
,to,TO,O
,propagate,VB,O
,transmurally,RB,O
,",",",",O
,probably,RB,O
,because,IN,O
,of,IN,O
,a,DT,O
,diminished,JJ,O
,TDR,NNP,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,This,DT,O
,study,NN,O
,provides,VBZ,O
,the,DT,O
,first,JJ,O
,direct,JJ,O
,evidence,NN,O
,from,IN,O
,intracellular,JJ,O
,action,NN,O
,potential,JJ,O
,recordings,NNS,O
,that,WDT,O
,phase,VBP,O
,2,CD,O
,EAD,NNP,O
,can,MD,O
,be,VB,O
,generated,VBN,O
,from,IN,O
,intact,JJ,O
,ventricular,JJ,O
,wall,NN,O
,and,CC,O
,produce,VB,O
,a,DT,O
,trigger,NN,O
,to,TO,O
,initiate,VB,O
,the,DT,O
,onset,NN,O
,of,IN,O
,TdP,NNP,B-DISEASE
,under,IN,O
,QT,NNP,B-DISEASE
,prolongation,NN,I-DISEASE
,.,.,O
,A,DT,O
,pilot,NN,O
,study,NN,O
,to,TO,O
,assess,VB,O
,the,DT,O
,safety,NN,O
,of,IN,O
,dobutamine,JJ,O
,stress,NN,O
,echocardiography,NN,O
,in,IN,O
,the,DT,O
,emergency,NN,O
,department,NN,O
,evaluation,NN,O
,of,IN,O
,cocaine,NN,O
,-,:,O
,associated,VBN,O
,chest,JJS,B-DISEASE
,pain,NN,I-DISEASE
,.,.,O
,STUDY,NNP,O
,OBJECTIVE,NNP,O
,:,:,O
,Chest,JJS,B-DISEASE
,pain,NN,I-DISEASE
,in,IN,O
,the,DT,O
,setting,NN,O
,of,IN,O
,cocaine,NN,O
,use,NN,O
,poses,VBZ,O
,a,DT,O
,diagnostic,JJ,O
,dilemma,NN,O
,.,.,O
,Dobutamine,NNP,O
,stress,NN,O
,echocardiography,NN,O
,(,(,O
,DSE,NNP,O
,),),O
,is,VBZ,O
,a,DT,O
,widely,RB,O
,available,JJ,O
,and,CC,O
,sensitive,JJ,O
,test,NN,O
,for,IN,O
,evaluating,VBG,O
,cardiac,JJ,O
,ischemia,NN,B-DISEASE
,.,.,O
,Because,IN,O
,of,IN,O
,the,DT,O
,theoretical,JJ,O
,concern,NN,O
,regarding,VBG,O
,administration,NN,O
,of,IN,O
,dobutamine,NN,O
,in,IN,O
,the,DT,O
,setting,NN,O
,of,IN,O
,cocaine,NN,O
,use,NN,O
,",",",",O
,we,PRP,O
,conducted,VBD,O
,a,DT,O
,pilot,NN,O
,study,NN,O
,to,TO,O
,assess,VB,O
,the,DT,O
,safety,NN,O
,of,IN,O
,DSE,NNP,O
,in,IN,O
,emergency,NN,O
,department,NN,O
,patients,NNS,O
,with,IN,O
,cocaine,JJ,O
,-,:,O
,associated,VBN,O
,chest,JJS,B-DISEASE
,pain,NN,I-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,A,DT,O
,prospective,JJ,O
,case,NN,O
,series,NN,O
,was,VBD,O
,conducted,VBN,O
,in,IN,O
,the,DT,O
,intensive,JJ,O
,diagnostic,JJ,O
,and,CC,O
,treatment,NN,O
,unit,NN,O
,in,IN,O
,the,DT,O
,ED,NNP,O
,of,IN,O
,an,DT,O
,urban,JJ,O
,tertiary,JJ,O
,-,:,O
,care,NN,O
,teaching,VBG,O
,hospital,NN,O
,.,.,O
,Patients,NNS,O
,were,VBD,O
,eligible,JJ,O
,for,IN,O
,DSE,NNP,O
,if,IN,O
,they,PRP,O
,had,VBD,O
,used,VBN,O
,cocaine,NN,O
,within,IN,O
,24,CD,O
,hours,NNS,O
,preceding,VBG,O
,the,DT,O
,onset,NN,O
,of,IN,O
,chest,NN,B-DISEASE
,pain,NN,I-DISEASE
,and,CC,O
,had,VBD,O
,a,DT,O
,normal,JJ,O
,ECG,NNP,O
,and,CC,O
,tropinin,NN,O
,I,PRP,O
,level,VBP,O
,.,.,O
,Patients,NNS,O
,exhibiting,VBG,O
,signs,NNS,O
,of,IN,O
,continuing,VBG,O
,cocaine,JJ,O
,toxicity,NN,B-DISEASE
,were,VBD,O
,excluded,VBN,O
,from,IN,O
,the,DT,O
,study,NN,O
,.,.,O
,All,DT,O
,patients,NNS,O
,were,VBD,O
,admitted,VBN,O
,to,TO,O
,the,DT,O
,hospital,NN,O
,for,IN,O
,serial,JJ,O
,testing,NN,O
,after,IN,O
,the,DT,O
,DSE,NNP,O
,testing,NN,O
,in,IN,O
,the,DT,O
,intensive,JJ,O
,diagnostic,JJ,O
,and,CC,O
,treatment,NN,O
,unit,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Twenty,NNP,O
,-,:,O
,four,CD,O
,patients,NNS,O
,were,VBD,O
,enrolled,VBN,O
,.,.,O
,Two,CD,O
,patients,NNS,O
,had,VBD,O
,inadequate,JJ,O
,resting,NN,O
,images,NNS,O
,",",",",O
,one,CD,O
,DSE,NNP,O
,was,VBD,O
,terminated,VBN,O
,because,IN,O
,of,IN,O
,inferior,JJ,O
,hypokinesis,NN,B-DISEASE
,",",",",O
,another,DT,O
,DSE,NNP,O
,was,VBD,O
,terminated,VBN,O
,because,IN,O
,of,IN,O
,a,DT,O
,rate,NN,O
,-,:,O
,related,VBN,O
,atrial,JJ,O
,conduction,NN,O
,deficit,NN,O
,",",",",O
,and,CC,O
,1,CD,O
,patient,NN,O
,did,VBD,O
,not,RB,O
,reach,VB,O
,the,DT,O
,target,NN,O
,heart,NN,O
,rate,NN,O
,.,.,O
,Thus,NNP,O
,",",",",O
,19,CD,O
,patients,NNS,O
,completed,VBD,O
,a,DT,O
,DSE,NNP,O
,and,CC,O
,reached,VBD,O
,their,PRP$,O
,target,NN,O
,heart,NN,O
,rates,NNS,O
,.,.,O
,None,NN,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,experienced,VBD,O
,signs,NNS,O
,of,IN,O
,exaggerated,JJ,O
,adrenergic,JJ,O
,response,NN,O
,",",",",O
,which,WDT,O
,was,VBD,O
,defined,VBN,O
,as,IN,O
,a,DT,O
,systolic,JJ,O
,blood,NN,O
,pressure,NN,O
,of,IN,O
,greater,JJR,O
,than,IN,O
,200,CD,O
,mm,JJ,O
,Hg,NNP,O
,or,CC,O
,the,DT,O
,occurrence,NN,O
,of,IN,O
,tachydysrhythmias,NN,B-DISEASE
,(,(,O
,excluding,VBG,O
,sinus,RB,B-DISEASE
,tachycardia,NN,I-DISEASE
,),),O
,.,.,O
,Further,RBR,O
,suggesting,VBG,O
,lack,NN,O
,of,IN,O
,exaggerated,JJ,O
,adrenergic,JJ,O
,response,NN,O
,",",",",O
,13,CD,O
,(,(,O
,65,CD,O
,%,NN,O
,),),O
,of,IN,O
,20,CD,O
,patients,NNS,O
,required,VBN,O
,supplemental,JJ,O
,atropine,NN,O
,to,TO,O
,reach,VB,O
,their,PRP$,O
,target,NN,O
,heart,NN,O
,rates,NNS,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,No,DT,O
,exaggerated,JJ,O
,adrenergic,JJ,O
,response,NN,O
,was,VBD,O
,detected,VBN,O
,when,WRB,O
,dobutamine,NN,O
,was,VBD,O
,administered,VBN,O
,to,TO,O
,patients,NNS,O
,with,IN,O
,cocaine,JJ,O
,-,:,O
,related,JJ,O
,chest,NN,B-DISEASE
,pain,NN,I-DISEASE
,.,.,O
,Prenatal,JJ,O
,cocaine,NN,O
,exposure,NN,O
,and,CC,O
,cranial,JJ,O
,sonographic,JJ,O
,findings,NNS,O
,in,IN,O
,preterm,JJ,B-DISEASE
,infants,NNS,I-DISEASE
,.,.,O
,PURPOSE,NN,O
,:,:,O
,Prenatal,JJ,O
,cocaine,NN,O
,exposure,NN,O
,has,VBZ,O
,been,VBN,O
,linked,VBN,O
,with,IN,O
,subependymal,JJ,O
,hemorrhage,NN,B-DISEASE
,and,CC,O
,the,DT,O
,formation,NN,O
,of,IN,O
,cysts,NNS,B-DISEASE
,that,WDT,O
,are,VBP,O
,detectable,JJ,O
,on,IN,O
,cranial,JJ,O
,sonography,NN,O
,in,IN,O
,neonates,NNS,O
,born,VBN,O
,at,IN,O
,term,NN,O
,.,.,O
,We,PRP,O
,sought,VBD,O
,to,TO,O
,determine,VB,O
,if,IN,O
,prenatal,JJ,O
,cocaine,NN,O
,exposure,NN,O
,increases,VBZ,O
,the,DT,O
,incidence,NN,O
,of,IN,O
,subependymal,JJ,B-DISEASE
,cysts,NNS,I-DISEASE
,in,IN,O
,preterm,JJ,B-DISEASE
,infants,NNS,I-DISEASE
,.,.,O
,METHODS,NNS,O
,:,:,O
,We,PRP,O
,retrospectively,RB,O
,reviewed,VBD,O
,the,DT,O
,medical,JJ,O
,records,NNS,O
,and,CC,O
,cranial,JJ,O
,sonograms,NNS,O
,obtained,VBD,O
,during,IN,O
,a,DT,O
,1,CD,O
,-,:,O
,year,NN,O
,period,NN,O
,on,IN,O
,122,CD,O
,premature,NN,B-DISEASE
,(,(,I-DISEASE
,<,JJ,I-DISEASE
,36,CD,I-DISEASE
,weeks,NNS,I-DISEASE
,of,IN,I-DISEASE
,gestation,NN,I-DISEASE
,),),I-DISEASE
,infants,NNS,I-DISEASE
,.,.,O
,Infants,NNS,O
,were,VBD,O
,categorized,VBN,O
,into,IN,O
,1,CD,O
,of,IN,O
,2,CD,O
,groups,NNS,O
,:,:,O
,those,DT,O
,exposed,VBN,O
,to,TO,O
,cocaine,VB,O
,and,CC,O
,those,DT,O
,not,RB,O
,exposed,VBN,O
,to,TO,O
,cocaine,VB,O
,.,.,O
,Infants,NNS,O
,were,VBD,O
,assigned,VBN,O
,to,TO,O
,the,DT,O
,cocaine,NN,O
,-,:,O
,exposed,VBN,O
,group,NN,O
,if,IN,O
,there,EX,O
,was,VBD,O
,a,DT,O
,maternal,JJ,O
,history,NN,O
,of,IN,O
,cocaine,NN,B-DISEASE
,abuse,NN,I-DISEASE
,during,IN,O
,pregnancy,NN,O
,or,CC,O
,if,IN,O
,maternal,JJ,O
,or,CC,O
,neonatal,JJ,O
,urine,JJ,O
,toxicology,NN,O
,results,NNS,O
,were,VBD,O
,positive,JJ,O
,at,IN,O
,the,DT,O
,time,NN,O
,of,IN,O
,delivery,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Five,CD,O
,of,IN,O
,the,DT,O
,122,CD,O
,infants,NNS,O
,were,VBD,O
,excluded,VBN,O
,from,IN,O
,the,DT,O
,study,NN,O
,because,IN,O
,of,IN,O
,insufficient,JJ,O
,medical,JJ,O
,and,CC,O
,drug,NN,O
,histories,NNS,O
,.,.,O
,The,DT,O
,incidence,NN,O
,of,IN,O
,subependymal,JJ,B-DISEASE
,cysts,NNS,I-DISEASE
,in,IN,O
,the,DT,O
,117,CD,O
,remaining,VBG,O
,infants,NNS,O
,was,VBD,O
,14,CD,O
,%,NN,O
,(,(,O
,16,CD,O
,of,IN,O
,117,CD,O
,),),O
,.,.,O
,The,DT,O
,incidence,NN,O
,of,IN,O
,subependymal,JJ,B-DISEASE
,cysts,NNS,I-DISEASE
,in,IN,O
,infants,NNS,O
,exposed,VBN,O
,to,TO,O
,cocaine,VB,O
,prenatally,RB,O
,was,VBD,O
,44,CD,O
,%,NN,O
,(,(,O
,8,CD,O
,of,IN,O
,18,CD,O
,),),O
,compared,VBN,O
,with,IN,O
,8,CD,O
,%,NN,O
,(,(,O
,8,CD,O
,of,IN,O
,99,CD,O
,),),O
,in,IN,O
,the,DT,O
,unexposed,JJ,O
,group,NN,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,We,PRP,O
,found,VBD,O
,an,DT,O
,increased,JJ,O
,incidence,NN,O
,of,IN,O
,subependymal,JJ,B-DISEASE
,cyst,NN,I-DISEASE
,formation,NN,O
,in,IN,O
,preterm,JJ,B-DISEASE
,infants,NNS,I-DISEASE
,who,WP,O
,were,VBD,O
,exposed,VBN,O
,to,TO,O
,cocaine,VB,O
,prenatally,RB,O
,.,.,O
,This,DT,O
,result,NN,O
,is,VBZ,O
,consistent,JJ,O
,with,IN,O
,results,NNS,O
,of,IN,O
,similar,JJ,O
,studies,NNS,O
,in,IN,O
,term,NN,O
,infants,NNS,O
,.,.,O
,Thalidomide,NNP,O
,neuropathy,JJ,B-DISEASE
,in,IN,O
,patients,NNS,O
,treated,VBN,O
,for,IN,O
,metastatic,JJ,O
,prostate,NN,B-DISEASE
,cancer,NN,I-DISEASE
,.,.,O
,We,PRP,O
,prospectively,RB,O
,evaluated,VBD,O
,thalidomide,JJ,O
,-,:,O
,induced,VBN,O
,neuropathy,JJ,B-DISEASE
,using,VBG,O
,electrodiagnostic,JJ,O
,studies,NNS,O
,.,.,O
,Sixty,NNP,O
,-,:,O
,seven,CD,O
,men,NNS,O
,with,IN,O
,metastatic,JJ,O
,androgen,NN,O
,-,:,O
,independent,JJ,O
,prostate,NN,B-DISEASE
,cancer,NN,I-DISEASE
,in,IN,O
,an,DT,O
,open,JJ,O
,-,:,O
,label,JJ,O
,trial,NN,O
,of,IN,O
,oral,JJ,O
,thalidomide,JJ,O
,underwent,JJ,O
,neurologic,JJ,O
,examinations,NNS,O
,and,CC,O
,nerve,NN,O
,conduction,NN,O
,studies,NNS,O
,(,(,O
,NCS,NNP,O
,),),O
,prior,RB,O
,to,TO,O
,and,CC,O
,at,IN,O
,3,CD,O
,-,:,O
,month,NN,O
,intervals,NNS,O
,during,IN,O
,treatment,NN,O
,.,.,O
,NCS,NNP,O
,included,VBD,O
,recording,NN,O
,of,IN,O
,sensory,JJ,O
,nerve,NN,O
,action,NN,O
,potentials,NNS,O
,(,(,O
,SNAPs,NNP,O
,),),O
,from,IN,O
,median,JJ,O
,",",",",O
,radial,JJ,O
,",",",",O
,ulnar,JJ,O
,",",",",O
,and,CC,O
,sural,JJ,O
,nerves,NNS,O
,.,.,O
,SNAP,NNP,O
,amplitudes,NNS,O
,for,IN,O
,each,DT,O
,nerve,NN,O
,were,VBD,O
,expressed,VBN,O
,as,IN,O
,the,DT,O
,percentage,NN,O
,of,IN,O
,its,PRP$,O
,baseline,NN,O
,",",",",O
,and,CC,O
,the,DT,O
,mean,NN,O
,of,IN,O
,the,DT,O
,four,CD,O
,was,VBD,O
,termed,VBN,O
,the,DT,O
,SNAP,NNP,O
,index,NN,O
,.,.,O
,A,DT,O
,40,CD,O
,%,NN,O
,decline,NN,O
,in,IN,O
,the,DT,O
,SNAP,NNP,O
,index,NN,O
,was,VBD,O
,considered,VBN,O
,clinically,RB,O
,significant,JJ,O
,.,.,O
,Thalidomide,NNP,O
,was,VBD,O
,discontinued,VBN,O
,in,IN,O
,55,CD,O
,patients,NNS,O
,for,IN,O
,lack,NN,O
,of,IN,O
,therapeutic,JJ,O
,response,NN,O
,.,.,O
,Of,IN,O
,67,CD,O
,patients,NNS,O
,initially,RB,O
,enrolled,VBD,O
,",",",",O
,24,CD,O
,remained,VBD,O
,on,IN,O
,thalidomide,NN,O
,for,IN,O
,3,CD,O
,months,NNS,O
,",",",",O
,8,CD,O
,remained,VBD,O
,at,IN,O
,6,CD,O
,months,NNS,O
,",",",",O
,and,CC,O
,3,CD,O
,remained,VBD,O
,at,IN,O
,9,CD,O
,months,NNS,O
,.,.,O
,Six,CD,O
,patients,NNS,O
,developed,VBD,O
,neuropathy,JJ,B-DISEASE
,.,.,O
,Clinical,JJ,O
,symptoms,NNS,O
,and,CC,O
,a,DT,O
,decline,NN,O
,in,IN,O
,the,DT,O
,SNAP,NNP,O
,index,NN,O
,occurred,VBD,O
,concurrently,RB,O
,.,.,O
,Older,JJR,O
,age,NN,O
,and,CC,O
,cumulative,JJ,O
,dose,NN,O
,were,VBD,O
,possible,JJ,O
,contributing,JJ,O
,factors,NNS,O
,.,.,O
,Neuropathy,NNP,B-DISEASE
,may,MD,O
,thus,RB,O
,be,VB,O
,a,DT,O
,common,JJ,O
,complication,NN,O
,of,IN,O
,thalidomide,NN,O
,in,IN,O
,older,JJR,O
,patients,NNS,O
,.,.,O
,The,DT,O
,SNAP,NNP,O
,index,NN,O
,can,MD,O
,be,VB,O
,used,VBN,O
,to,TO,O
,monitor,VB,O
,peripheral,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,",",",",O
,but,CC,O
,not,RB,O
,for,IN,O
,early,JJ,O
,detection,NN,O
,.,.,O
,Overexpression,NN,O
,of,IN,O
,copper,NN,O
,/,NNP,O
,zinc,NNP,O
,-,:,O
,superoxide,NN,O
,dismutase,NN,O
,protects,VBZ,O
,from,IN,O
,kanamycin,SYM,O
,-,:,O
,induced,JJ,O
,hearing,NN,B-DISEASE
,loss,NN,I-DISEASE
,.,.,O
,The,DT,O
,participation,NN,O
,of,IN,O
,reactive,JJ,O
,oxygen,NN,O
,species,NNS,O
,in,IN,O
,aminoglycoside,JJ,O
,-,:,O
,induced,JJ,O
,ototoxicity,NN,B-DISEASE
,has,VBZ,O
,been,VBN,O
,deduced,VBN,O
,from,IN,O
,observations,NNS,O
,that,WDT,O
,aminoglycoside,VBP,O
,-,:,O
,iron,NN,O
,complexes,NNS,O
,catalyze,VBP,O
,the,DT,O
,formation,NN,O
,of,IN,O
,superoxide,JJ,O
,radicals,NNS,O
,in,IN,O
,vitro,NN,O
,and,CC,O
,that,IN,O
,antioxidants,NNS,O
,attenuate,VBP,O
,ototoxicity,NN,B-DISEASE
,in,IN,O
,vivo,NN,O
,.,.,O
,We,PRP,O
,therefore,VBP,O
,hypothesized,VBD,O
,that,IN,O
,overexpression,NN,O
,of,IN,O
,Cu,NNP,O
,/,NNP,O
,Zn,NNP,O
,-,:,O
,superoxide,NN,O
,dismutase,NN,O
,(,(,O
,h,JJ,O
,-,:,O
,SOD1,NN,O
,),),O
,should,MD,O
,protect,VB,O
,transgenic,JJ,O
,mice,NN,O
,from,IN,O
,ototoxicity,NN,B-DISEASE
,.,.,O
,Immunocytochemistry,NNP,O
,confirmed,VBD,O
,expression,NN,O
,of,IN,O
,h,JJ,O
,-,:,O
,SOD1,NN,O
,in,IN,O
,inner,JJ,O
,ear,JJ,O
,tissues,NNS,O
,of,IN,O
,transgenic,JJ,O
,C57BL,NNP,O
,/,NNP,O
,6,CD,O
,-,:,O
,TgN,NN,O
,[,JJ,O
,SOD1,NNP,O
,],NNP,O
,3Cje,CD,O
,mice,NN,O
,.,.,O
,Transgenic,NNP,O
,and,CC,O
,nontransgenic,JJ,O
,littermates,NNS,O
,received,VBD,O
,kanamycin,NN,O
,(,(,O
,400,CD,O
,mg,NN,O
,/,NNP,O
,kg,VBZ,O
,body,NN,O
,weight,JJ,O
,/,NNP,O
,day,NN,O
,),),O
,for,IN,O
,10,CD,O
,days,NNS,O
,beginning,VBG,O
,on,IN,O
,day,NN,O
,10,CD,O
,after,IN,O
,birth,NN,O
,.,.,O
,Auditory,JJ,O
,thresholds,NNS,O
,were,VBD,O
,tested,VBN,O
,by,IN,O
,evoked,JJ,O
,auditory,NN,O
,brain,NN,O
,stem,NN,O
,responses,NNS,O
,at,IN,O
,1,CD,O
,month,NN,O
,after,IN,O
,birth,NN,O
,.,.,O
,In,IN,O
,nontransgenic,JJ,O
,animals,NNS,O
,",",",",O
,the,DT,O
,threshold,NN,O
,in,IN,O
,the,DT,O
,kanamycin,NN,O
,-,:,O
,treated,VBN,O
,group,NN,O
,was,VBD,O
,45,CD,O
,-,:,O
,50,CD,O
,dB,NN,O
,higher,JJR,O
,than,IN,O
,in,IN,O
,saline,JJ,O
,-,:,O
,injected,JJ,O
,controls,NNS,O
,.,.,O
,In,IN,O
,the,DT,O
,transgenic,JJ,O
,group,NN,O
,",",",",O
,kanamycin,NN,O
,increased,VBD,O
,the,DT,O
,threshold,NN,O
,by,IN,O
,only,RB,O
,15,CD,O
,dB,NN,O
,over,IN,O
,the,DT,O
,respective,JJ,O
,controls,NNS,O
,.,.,O
,The,DT,O
,effects,NNS,O
,were,VBD,O
,similar,JJ,O
,at,IN,O
,12,CD,O
,and,CC,O
,24,CD,O
,kHz,NN,O
,.,.,O
,The,DT,O
,protection,NN,O
,by,IN,O
,overexpression,NN,O
,of,IN,O
,superoxide,JJ,O
,dismutase,NN,O
,supports,VBZ,O
,the,DT,O
,hypothesis,NN,O
,that,WDT,O
,oxidant,JJ,O
,stress,NN,O
,plays,VBZ,O
,a,DT,O
,significant,JJ,O
,role,NN,O
,in,IN,O
,aminoglycoside,JJ,O
,-,:,O
,induced,JJ,O
,ototoxicity,NN,B-DISEASE
,.,.,O
,The,DT,O
,results,NNS,O
,also,RB,O
,suggest,VBP,O
,transgenic,JJ,O
,animals,NNS,O
,as,IN,O
,suitable,JJ,O
,models,NNS,O
,to,TO,O
,investigate,VB,O
,the,DT,O
,underlying,JJ,O
,mechanisms,NNS,O
,and,CC,O
,possible,JJ,O
,strategies,NNS,O
,for,IN,O
,prevention,NN,O
,.,.,O
,Fatty,NNP,B-DISEASE
,liver,RB,I-DISEASE
,induced,VBN,O
,by,IN,O
,tetracycline,NN,O
,in,IN,O
,the,DT,O
,rat,NN,O
,.,.,O
,Dose,NNP,O
,-,:,O
,response,NN,O
,relationships,NNS,O
,and,CC,O
,effect,NN,O
,of,IN,O
,sex,NN,O
,.,.,O
,Dose,NNP,O
,-,:,O
,response,NN,O
,relationships,NNS,O
,",",",",O
,biochemical,JJ,O
,mechanisms,NN,O
,",",",",O
,and,CC,O
,sex,NN,O
,differences,NNS,O
,in,IN,O
,the,DT,O
,experimental,JJ,O
,fatty,NN,B-DISEASE
,liver,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,tetracycline,NN,O
,were,VBD,O
,studied,VBN,O
,in,IN,O
,the,DT,O
,intact,JJ,O
,rat,NN,O
,and,CC,O
,with,IN,O
,the,DT,O
,isolated,JJ,O
,perfused,JJ,O
,rat,NN,O
,liver,NN,O
,in,IN,O
,vitro,NN,O
,.,.,O
,In,IN,O
,the,DT,O
,intact,JJ,O
,male,NN,O
,and,CC,O
,female,JJ,O
,rat,NN,O
,",",",",O
,no,DT,O
,direct,JJ,O
,relationship,NN,O
,was,VBD,O
,observed,VBN,O
,between,IN,O
,dose,NN,O
,of,IN,O
,tetracycline,NN,O
,and,CC,O
,hepatic,JJ,O
,accumulation,NN,O
,of,IN,O
,triglyceride,NN,O
,.,.,O
,With,IN,O
,provision,NN,O
,of,IN,O
,adequate,JJ,O
,oleic,JJ,O
,acid,NN,O
,as,IN,O
,a,DT,O
,substrate,NN,O
,for,IN,O
,the,DT,O
,isolated,JJ,O
,perfused,JJ,O
,liver,NN,O
,",",",",O
,a,DT,O
,direct,JJ,O
,relationship,NN,O
,was,VBD,O
,observed,VBN,O
,between,IN,O
,dose,NN,O
,of,IN,O
,tetracycline,NN,O
,and,CC,O
,both,DT,O
,accumulation,NN,O
,of,IN,O
,triglyceride,NN,O
,in,IN,O
,the,DT,O
,liver,NN,O
,and,CC,O
,depression,NN,B-DISEASE
,of,IN,O
,output,NN,O
,of,IN,O
,triglyceride,NN,O
,by,IN,O
,livers,NNS,O
,from,IN,O
,male,NN,O
,and,CC,O
,female,JJ,O
,rats,NNS,O
,.,.,O
,Marked,VBN,O
,differences,NNS,O
,were,VBD,O
,observed,VBN,O
,between,IN,O
,female,JJ,O
,and,CC,O
,male,JJ,O
,rats,NNS,O
,with,IN,O
,regard,NN,O
,to,TO,O
,base,VB,O
,line,NN,O
,(,(,O
,control,NN,O
,),),O
,hepatic,JJ,O
,concentration,NN,O
,of,IN,O
,triglyceride,NN,O
,and,CC,O
,output,NN,O
,of,IN,O
,triglyceride,NN,O
,.,.,O
,Accumulation,NN,O
,of,IN,O
,hepatic,JJ,O
,triglyceride,NN,O
,",",",",O
,as,IN,O
,a,DT,O
,per,IN,O
,cent,NN,O
,of,IN,O
,control,NN,O
,values,NNS,O
,",",",",O
,in,IN,O
,response,NN,O
,to,TO,O
,graded,JJ,O
,doses,NNS,O
,of,IN,O
,tetracycline,NN,O
,",",",",O
,did,VBD,O
,not,RB,O
,differ,VB,O
,significantly,RB,O
,between,IN,O
,male,NN,O
,",",",",O
,female,JJ,O
,and,CC,O
,pregnant,JJ,O
,rat,NN,O
,livers,NNS,O
,.,.,O
,However,RB,O
,",",",",O
,livers,NNS,O
,from,IN,O
,female,NN,O
,",",",",O
,and,CC,O
,especially,RB,O
,pregnant,JJ,O
,female,JJ,O
,rats,NNS,O
,",",",",O
,were,VBD,O
,strikingly,RB,O
,resistant,JJ,O
,to,TO,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,tetracycline,NN,O
,on,IN,O
,depression,NN,B-DISEASE
,of,IN,O
,output,NN,O
,of,IN,O
,triglyceride,NN,O
,under,IN,O
,these,DT,O
,experimental,JJ,O
,conditions,NNS,O
,.,.,O
,These,DT,O
,differences,NNS,O
,between,IN,O
,the,DT,O
,sexes,NNS,O
,could,MD,O
,not,RB,O
,be,VB,O
,related,VBN,O
,to,TO,O
,altered,VBN,O
,disposition,NN,O
,of,IN,O
,tetracycline,NN,O
,or,CC,O
,altered,JJ,O
,uptake,NN,O
,of,IN,O
,oleic,JJ,O
,acid,NN,O
,.,.,O
,Depressed,VBN,O
,hepatic,JJ,O
,secretion,NN,O
,of,IN,O
,triglyceride,NN,O
,accounted,VBD,O
,only,RB,O
,for,IN,O
,30,CD,O
,to,TO,O
,50,CD,O
,%,NN,O
,of,IN,O
,accumulated,JJ,O
,hepatic,JJ,O
,triglyceride,NN,O
,",",",",O
,indicating,VBG,O
,that,IN,O
,additional,JJ,O
,mechanisms,NNS,O
,must,MD,O
,be,VB,O
,involved,VBN,O
,in,IN,O
,the,DT,O
,production,NN,O
,of,IN,O
,the,DT,O
,triglyceride,NN,O
,-,:,O
,rich,JJ,O
,fatty,JJ,B-DISEASE
,liver,NN,I-DISEASE
,in,IN,O
,response,NN,O
,to,TO,O
,tetracycline,VB,O
,.,.,O
,Prednisone,NNP,O
,induces,VBZ,O
,anxiety,NN,B-DISEASE
,and,CC,O
,glial,JJ,O
,cerebral,JJ,O
,changes,NNS,O
,in,IN,O
,rats,NNS,O
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,To,TO,O
,assess,VB,O
,whether,IN,O
,prednisone,NN,O
,(,(,O
,PDN,NNP,O
,),),O
,produces,VBZ,O
,anxiety,NN,B-DISEASE
,and,CC,O
,/,NN,O
,or,CC,O
,cerebral,JJ,O
,glial,JJ,O
,changes,NNS,O
,in,IN,O
,rats,NNS,O
,.,.,O
,METHODS,NN,O
,:,:,O
,Male,JJ,O
,Wistar,NNP,O
,rats,NNS,O
,were,VBD,O
,studied,VBN,O
,and,CC,O
,3,CD,O
,groups,NNS,O
,were,VBD,O
,formed,VBN,O
,(,(,O
,8,CD,O
,rats,NNS,O
,per,IN,O
,group,NN,O
,),),O
,.,.,O
,The,DT,O
,moderate,JJ,O
,-,:,O
,dose,NN,O
,group,NN,O
,received,VBD,O
,5,CD,O
,mg,NNS,O
,/,JJ,O
,kg,JJ,O
,/,NNP,O
,day,NN,O
,PDN,NNP,O
,released,VBN,O
,from,IN,O
,a,DT,O
,subcutaneous,JJ,O
,implant,NN,O
,.,.,O
,In,IN,O
,the,DT,O
,high,JJ,O
,-,:,O
,dose,NN,O
,group,NN,O
,",",",",O
,implants,NNS,O
,containing,VBG,O
,PDN,NNP,O
,equivalent,NN,O
,to,TO,O
,60,CD,O
,mg,NNS,O
,/,JJ,O
,kg,JJ,O
,/,JJ,O
,day,NN,O
,were,VBD,O
,applied,VBN,O
,.,.,O
,In,IN,O
,the,DT,O
,control,NN,O
,group,NN,O
,implants,NNS,O
,contained,VBD,O
,no,DT,O
,PDN,NNP,O
,.,.,O
,Anxiety,NNP,B-DISEASE
,was,VBD,O
,assessed,VBN,O
,using,VBG,O
,an,DT,O
,open,JJ,O
,field,NN,O
,and,CC,O
,elevated,JJ,O
,plus,CC,O
,-,:,O
,maze,NN,O
,devices,NNS,O
,.,.,O
,The,DT,O
,number,NN,O
,of,IN,O
,cells,NNS,O
,and,CC,O
,cytoplasmic,JJ,O
,transformation,NN,O
,of,IN,O
,astrocytes,NNS,O
,and,CC,O
,microglia,NNS,O
,cells,NNS,O
,were,VBD,O
,assessed,VBN,O
,by,IN,O
,immunohistochemical,JJ,O
,analyses,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Anxiety,NN,B-DISEASE
,was,VBD,O
,documented,VBN,O
,in,IN,O
,both,DT,O
,groups,NNS,O
,of,IN,O
,PDN,NNP,O
,treated,VBD,O
,rats,NNS,O
,compared,VBN,O
,with,IN,O
,controls,NNS,O
,.,.,O
,The,DT,O
,magnitude,NN,O
,of,IN,O
,transformation,NN,O
,of,IN,O
,the,DT,O
,microglia,NNS,O
,assessed,VBN,O
,by,IN,O
,the,DT,O
,number,NN,O
,of,IN,O
,intersections,NNS,O
,was,VBD,O
,significantly,RB,O
,higher,JJR,O
,in,IN,O
,the,DT,O
,PDN,NNP,O
,groups,NNS,O
,than,IN,O
,in,IN,O
,controls,NNS,O
,in,IN,O
,the,DT,O
,prefrontal,JJ,O
,cortex,NN,O
,(,(,O
,moderate,JJ,O
,-,:,O
,dose,NN,O
,",",",",O
,24,CD,O
,.,.,O
,1,CD,O
,;,:,O
,high,JJ,O
,-,:,O
,dose,NN,O
,",",",",O
,23,CD,O
,.,.,O
,6,CD,O
,;,:,O
,controls,NNS,O
,18,CD,O
,.,.,O
,7,CD,O
,;,:,O
,p,NN,O
,<,VBZ,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,and,CC,O
,striatum,NN,O
,(,(,O
,moderate,JJ,O
,-,:,O
,dose,JJ,O
,25,CD,O
,.,.,O
,6,CD,O
,;,:,O
,high,JJ,O
,-,:,O
,dose,JJ,O
,26,CD,O
,.,.,O
,3,CD,O
,;,:,O
,controls,NNS,O
,18,CD,O
,.,.,O
,9,CD,O
,;,:,O
,p,NN,O
,<,VBZ,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,",",",",O
,but,CC,O
,not,RB,O
,in,IN,O
,hippocampus,NN,O
,.,.,O
,The,DT,O
,number,NN,O
,of,IN,O
,stained,JJ,O
,microglia,NNS,O
,cells,NNS,O
,was,VBD,O
,significantly,RB,O
,higher,JJR,O
,in,IN,O
,the,DT,O
,PDN,NNP,O
,treated,VBD,O
,groups,NNS,O
,in,IN,O
,the,DT,O
,prefrontal,NN,O
,cortex,NN,O
,than,IN,O
,in,IN,O
,controls,NNS,O
,(,(,O
,moderate,JJ,O
,-,:,O
,dose,NN,O
,",",",",O
,29,CD,O
,.,.,O
,1,CD,O
,;,:,O
,high,JJ,O
,-,:,O
,dose,NN,O
,",",",",O
,28,CD,O
,.,.,O
,4,CD,O
,;,:,O
,control,NN,O
,",",",",O
,17,CD,O
,.,.,O
,7,CD,O
,cells,NNS,O
,per,IN,O
,field,NN,O
,;,:,O
,p,CC,O
,<,$,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,Stained,VBN,O
,microglia,JJ,O
,cells,NNS,O
,were,VBD,O
,significantly,RB,O
,more,RBR,O
,numerous,JJ,O
,striatum,NN,O
,and,CC,O
,hippocampus,NN,O
,in,IN,O
,the,DT,O
,high,JJ,O
,-,:,O
,dose,NN,O
,group,NN,O
,compared,VBN,O
,to,TO,O
,controls,NNS,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Subacute,JJ,O
,exposure,NN,O
,to,TO,O
,PDN,NNP,O
,induced,JJ,O
,anxiety,NN,B-DISEASE
,and,CC,O
,reactivity,NN,O
,of,IN,O
,microglia,NN,O
,.,.,O
,The,DT,O
,relevance,NN,O
,of,IN,O
,these,DT,O
,features,NNS,O
,for,IN,O
,patients,NNS,O
,using,VBG,O
,PDN,NNP,O
,remains,VBZ,O
,to,TO,O
,be,VB,O
,elucidated,VBN,O
,.,.,O
,Phase,NNP,O
,II,NNP,O
,study,NN,O
,of,IN,O
,carboplatin,NN,O
,and,CC,O
,liposomal,JJ,O
,doxorubicin,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,recurrent,JJ,O
,squamous,JJ,B-DISEASE
,cell,NN,I-DISEASE
,carcinoma,NN,I-DISEASE
,of,IN,I-DISEASE
,the,DT,I-DISEASE
,cervix,NN,I-DISEASE
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,The,DT,O
,activity,NN,O
,of,IN,O
,the,DT,O
,combination,NN,O
,of,IN,O
,carboplatin,NN,O
,and,CC,O
,liposomal,JJ,O
,doxorubicin,NN,O
,was,VBD,O
,tested,VBN,O
,in,IN,O
,a,DT,O
,Phase,NNP,O
,II,NNP,O
,study,NN,O
,of,IN,O
,patients,NNS,O
,with,IN,O
,recurrent,JJ,O
,cervical,JJ,B-DISEASE
,carcinoma,NN,I-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,The,DT,O
,combination,NN,O
,of,IN,O
,carboplatin,NN,O
,(,(,O
,area,NN,O
,under,IN,O
,the,DT,O
,concentration,NN,O
,curve,NN,O
,[,NNP,O
,AUC,NNP,O
,],NNP,O
,",",",",O
,5,CD,O
,),),O
,and,CC,O
,liposomal,JJ,O
,doxorubicin,NN,O
,(,(,O
,Doxil,NNP,O
,;,:,O
,starting,VBG,O
,dose,NN,O
,",",",",O
,40,CD,O
,mg,NN,O
,/,NNP,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,),),O
,was,VBD,O
,administered,VBN,O
,intravenously,RB,O
,every,DT,O
,28,CD,O
,days,NNS,O
,to,TO,O
,37,CD,O
,patients,NNS,O
,with,IN,O
,recurrent,JJ,O
,squamous,JJ,B-DISEASE
,cell,NN,I-DISEASE
,cervical,JJ,I-DISEASE
,carcinoma,NN,I-DISEASE
,to,TO,O
,determine,VB,O
,antitumor,NN,O
,activity,NN,O
,and,CC,O
,toxicity,NN,B-DISEASE
,profile,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Twenty,NNP,O
,-,:,O
,nine,CD,O
,patients,NNS,O
,were,VBD,O
,assessable,JJ,O
,for,IN,O
,response,NN,O
,",",",",O
,and,CC,O
,35,CD,O
,patients,NNS,O
,were,VBD,O
,assessable,JJ,O
,for,IN,O
,toxicity,NN,B-DISEASE
,.,.,O
,The,DT,O
,overall,JJ,O
,response,NN,O
,rate,NN,O
,was,VBD,O
,38,CD,O
,%,NN,O
,",",",",O
,the,DT,O
,median,JJ,O
,time,NN,O
,to,TO,O
,response,NN,O
,was,VBD,O
,10,CD,O
,weeks,NNS,O
,",",",",O
,the,DT,O
,median,JJ,O
,duration,NN,O
,of,IN,O
,response,NN,O
,was,VBD,O
,26,CD,O
,weeks,NNS,O
,",",",",O
,and,CC,O
,the,DT,O
,median,JJ,O
,survival,NN,O
,was,VBD,O
,37,CD,O
,weeks,NNS,O
,.,.,O
,The,DT,O
,main,JJ,O
,toxic,NN,O
,effect,NN,O
,was,VBD,O
,myelosuppression,NN,B-DISEASE
,",",",",O
,with,IN,O
,Grade,NNP,O
,3,CD,O
,and,CC,O
,4,CD,O
,neutropenia,NN,B-DISEASE
,in,IN,O
,16,CD,O
,patients,NNS,O
,",",",",O
,anemia,NN,B-DISEASE
,in,IN,O
,12,CD,O
,patients,NNS,O
,",",",",O
,thrombocytopenia,NN,B-DISEASE
,in,IN,O
,11,CD,O
,patients,NNS,O
,",",",",O
,and,CC,O
,neutropenic,JJ,B-DISEASE
,fever,NN,I-DISEASE
,in,IN,O
,3,CD,O
,patients,NNS,O
,.,.,O
,Four,CD,O
,patients,NNS,O
,had,VBD,O
,five,CD,O
,infusion,NN,O
,-,:,O
,related,JJ,O
,reactions,NNS,O
,during,IN,O
,the,DT,O
,infusion,NN,O
,of,IN,O
,liposomal,JJ,O
,doxorubicin,NN,O
,",",",",O
,leading,VBG,O
,to,TO,O
,treatment,NN,O
,discontinuation,NN,O
,in,IN,O
,three,CD,O
,patients,NNS,O
,.,.,O
,Grade,NNP,O
,>,VBD,O
,or,CC,O
,=,$,O
,2,CD,O
,nonhematologic,JJ,O
,toxicity,NN,B-DISEASE
,included,VBD,O
,nausea,NN,B-DISEASE
,in,IN,O
,17,CD,O
,patients,NNS,O
,",",",",O
,emesis,NN,B-DISEASE
,in,IN,O
,14,CD,O
,patients,NNS,O
,",",",",O
,fatigue,NN,B-DISEASE
,in,IN,O
,9,CD,O
,patients,NNS,O
,",",",",O
,mucositis,NN,B-DISEASE
,and,CC,O
,/,NN,O
,or,CC,O
,stomatitis,NN,B-DISEASE
,in,IN,O
,8,CD,O
,patients,NNS,O
,",",",",O
,constipation,NN,B-DISEASE
,in,IN,O
,6,CD,O
,patients,NNS,O
,",",",",O
,weight,JJ,B-DISEASE
,loss,NN,I-DISEASE
,in,IN,O
,5,CD,O
,patients,NNS,O
,",",",",O
,hand,NN,B-DISEASE
,-,:,I-DISEASE
,foot,NN,I-DISEASE
,syndrome,NN,I-DISEASE
,in,IN,O
,2,CD,O
,patients,NNS,O
,",",",",O
,and,CC,O
,skin,JJ,B-DISEASE
,reactions,NNS,I-DISEASE
,in,IN,O
,3,CD,O
,patients,NNS,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,The,DT,O
,combination,NN,O
,of,IN,O
,carboplatin,NN,O
,and,CC,O
,liposomal,JJ,O
,doxorubicin,NN,O
,has,VBZ,O
,modest,JJ,O
,activity,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,recurrent,JJ,O
,cervical,JJ,B-DISEASE
,carcinoma,NN,I-DISEASE
,.,.,O
,Antimicrobial,NNP,O
,-,:,O
,induced,VBN,O
,mania,NN,B-DISEASE
,(,(,O
,antibiomania,NN,B-DISEASE
,),),O
,:,:,O
,a,DT,O
,review,NN,O
,of,IN,O
,spontaneous,JJ,O
,reports,NNS,O
,.,.,O
,The,DT,O
,authors,NNS,O
,reviewed,VBD,O
,reported,JJ,O
,cases,NNS,O
,of,IN,O
,antibiotic,JJ,O
,-,:,O
,induced,JJ,O
,manic,JJ,B-DISEASE
,episodes,NNS,O
,by,IN,O
,means,NNS,O
,of,IN,O
,a,DT,O
,MEDLINE,NNP,O
,and,CC,O
,PsychLit,NNP,O
,search,NN,O
,for,IN,O
,reports,NNS,O
,of,IN,O
,antibiotic,JJ,O
,-,:,O
,induced,VBN,O
,mania,NN,B-DISEASE
,.,.,O
,Unpublished,VBN,O
,reports,NNS,O
,were,VBD,O
,requested,VBN,O
,from,IN,O
,the,DT,O
,World,NNP,O
,Health,NNP,O
,Organization,NNP,O
,(,(,O
,WHO,NNP,O
,),),O
,and,CC,O
,the,DT,O
,Food,NNP,O
,and,CC,O
,Drug,NNP,O
,Administration,NNP,O
,(,(,O
,FDA,NNP,O
,),),O
,.,.,O
,Twenty,NNP,O
,-,:,O
,one,CD,O
,reports,NNS,O
,of,IN,O
,antimicrobial,JJ,O
,-,:,O
,induced,VBN,O
,mania,NN,B-DISEASE
,were,VBD,O
,found,VBN,O
,in,IN,O
,the,DT,O
,literature,NN,O
,.,.,O
,There,EX,O
,were,VBD,O
,6,CD,O
,cases,NNS,O
,implicating,VBG,O
,clarithromycin,NN,O
,",",",",O
,13,CD,O
,implicating,NN,O
,isoniazid,NN,O
,",",",",O
,and,CC,O
,1,CD,O
,case,NN,O
,each,DT,O
,implicating,VBG,O
,erythromycin,NN,O
,and,CC,O
,amoxicillin,NN,O
,.,.,O
,The,DT,O
,WHO,NNP,O
,reported,VBD,O
,82,CD,O
,cases,NNS,O
,.,.,O
,Of,IN,O
,these,DT,O
,",",",",O
,clarithromycin,NN,O
,was,VBD,O
,implicated,VBN,O
,in,IN,O
,23,CD,O
,(,(,O
,27,CD,O
,.,.,O
,6,CD,O
,%,NN,O
,),),O
,cases,NNS,O
,",",",",O
,ciprofloxacin,NN,O
,in,IN,O
,12,CD,O
,(,(,O
,14,CD,O
,.,.,O
,4,CD,O
,%,NN,O
,),),O
,cases,NNS,O
,",",",",O
,and,CC,O
,ofloxacin,NN,O
,in,IN,O
,10,CD,O
,(,(,O
,12,CD,O
,%,NN,O
,),),O
,cases,NNS,O
,.,.,O
,Cotrimoxazole,NNP,O
,",",",",O
,metronidazole,NN,O
,",",",",O
,and,CC,O
,erythromycin,NN,O
,were,VBD,O
,involved,VBN,O
,in,IN,O
,15,CD,O
,reported,VBD,O
,manic,JJ,B-DISEASE
,episodes,NNS,O
,.,.,O
,Cases,NNS,O
,reported,VBN,O
,by,IN,O
,the,DT,O
,FDA,NNP,O
,showed,VBD,O
,clarithromycin,NNS,O
,and,CC,O
,ciprofloxacin,NN,O
,to,TO,O
,be,VB,O
,the,DT,O
,most,RBS,O
,frequently,RB,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,mania,NN,B-DISEASE
,.,.,O
,Statistical,JJ,O
,analysis,NN,O
,of,IN,O
,the,DT,O
,data,NNS,O
,would,MD,O
,not,RB,O
,have,VB,O
,demonstrated,VBN,O
,a,DT,O
,significant,JJ,O
,statistical,JJ,O
,correlative,NN,O
,risk,NN,O
,and,CC,O
,was,VBD,O
,therefore,RB,O
,not,RB,O
,undertaken,JJ,O
,.,.,O
,Patients,NNS,O
,have,VBP,O
,an,DT,O
,increased,VBN,O
,risk,NN,O
,of,IN,O
,developing,VBG,O
,mania,NN,B-DISEASE
,while,IN,O
,being,VBG,O
,treated,VBN,O
,with,IN,O
,antimicrobials,NNS,O
,.,.,O
,Although,IN,O
,this,DT,O
,is,VBZ,O
,not,RB,O
,a,DT,O
,statistically,RB,O
,significant,JJ,O
,risk,NN,O
,",",",",O
,physicians,NNS,O
,must,MD,O
,be,VB,O
,aware,JJ,O
,of,IN,O
,the,DT,O
,effect,NN,O
,and,CC,O
,reversibility,NN,O
,.,.,O
,Further,NNP,O
,research,NN,O
,clearly,RB,O
,is,VBZ,O
,required,VBN,O
,to,TO,O
,determine,VB,O
,the,DT,O
,incidence,NN,O
,of,IN,O
,antimicrobial,JJ,O
,-,:,O
,induced,JJ,O
,mania,NN,B-DISEASE
,",",",",O
,the,DT,O
,relative,JJ,O
,risk,NN,O
,factors,NNS,O
,of,IN,O
,developing,VBG,O
,an,DT,O
,antimicrobial,JJ,O
,-,:,O
,induced,JJ,O
,manic,JJ,B-DISEASE
,episode,NN,O
,among,IN,O
,various,JJ,O
,demographic,JJ,O
,populations,NNS,O
,",",",",O
,and,CC,O
,the,DT,O
,incidence,NN,O
,of,IN,O
,patients,NNS,O
,who,WP,O
,continue,VBP,O
,to,TO,O
,have,VB,O
,persistent,JJ,O
,affective,JJ,O
,disorders,NNS,O
,once,RB,O
,the,DT,O
,initial,JJ,O
,episode,NN,O
,",",",",O
,which,WDT,O
,occurs,VBZ,O
,while,IN,O
,the,DT,O
,patient,NN,O
,is,VBZ,O
,taking,VBG,O
,antibiotics,NNS,O
,",",",",O
,subsides,NNS,O
,.,.,O
,The,DT,O
,authors,NNS,O
,elected,VBD,O
,to,TO,O
,name,VB,O
,this,DT,O
,syndrome,JJ,O
,"""",NNP,O
,antibiomania,NN,B-DISEASE
,.,.,O
,"""",CC,O
,Levodopa,NNP,O
,-,:,O
,induced,VBD,O
,ocular,JJ,B-DISEASE
,dyskinesias,NN,I-DISEASE
,in,IN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,Levodopa,NNP,O
,-,:,O
,induced,VBD,O
,ocular,JJ,B-DISEASE
,dyskinesias,NNS,I-DISEASE
,are,VBP,O
,very,RB,O
,uncommon,JJ,O
,.,.,O
,Usually,RB,O
,they,PRP,O
,occur,VBP,O
,simultaneously,RB,O
,with,IN,O
,limb,NN,O
,peak,NN,O
,-,:,O
,dose,JJ,O
,choreatic,JJ,B-DISEASE
,dyskinesias,NN,I-DISEASE
,.,.,O
,We,PRP,O
,report,VBP,O
,on,IN,O
,a,DT,O
,patient,NN,O
,with,IN,O
,leftward,NN,O
,and,CC,O
,upward,JJ,O
,deviations,NNS,O
,of,IN,O
,gaze,NN,O
,during,IN,O
,the,DT,O
,peak,JJ,O
,effect,NN,O
,of,IN,O
,levodopa,NN,O
,",",",",O
,and,CC,O
,hypothesize,VB,O
,that,IN,O
,a,DT,O
,severe,JJ,O
,dopaminergic,JJ,O
,denervation,NN,O
,in,IN,O
,the,DT,O
,caudate,NN,O
,nucleus,NN,O
,is,VBZ,O
,needed,VBN,O
,for,IN,O
,the,DT,O
,appearance,NN,O
,of,IN,O
,these,DT,O
,levodopa,SYM,O
,-,:,O
,induce,VB,O
,ocular,JJ,B-DISEASE
,dyskinesias,NN,I-DISEASE
,.,.,O
,A,DT,O
,comparison,NN,O
,of,IN,O
,glyceryl,JJ,O
,trinitrate,NN,O
,with,IN,O
,diclofenac,NN,O
,for,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,primary,JJ,O
,dysmenorrhea,NN,B-DISEASE
,:,:,O
,an,DT,O
,open,JJ,O
,",",",",O
,randomized,VBN,O
,",",",",O
,cross,SYM,O
,-,:,O
,over,IN,O
,trial,NN,O
,.,.,O
,Primary,JJ,O
,dysmenorrhea,NN,B-DISEASE
,is,VBZ,O
,a,DT,O
,syndrome,JJ,O
,characterized,VBN,O
,by,IN,O
,painful,JJ,O
,uterine,JJ,O
,contractility,NN,O
,caused,VBN,O
,by,IN,O
,a,DT,O
,hypersecretion,NN,O
,of,IN,O
,endometrial,JJ,O
,prostaglandins,NNS,O
,;,:,O
,non,CC,O
,-,:,O
,steroidal,NN,O
,anti,SYM,O
,-,:,O
,inflammatory,NN,O
,drugs,NNS,O
,are,VBP,O
,the,DT,O
,first,JJ,O
,choice,NN,O
,for,IN,O
,its,PRP$,O
,treatment,NN,O
,.,.,O
,However,RB,O
,",",",",O
,in,IN,O
,vivo,NN,O
,and,CC,O
,in,IN,O
,vitro,JJ,O
,studies,NNS,O
,have,VBP,O
,demonstrated,VBN,O
,that,IN,O
,myometrial,JJ,O
,cells,NNS,O
,are,VBP,O
,also,RB,O
,targets,NNS,O
,of,IN,O
,the,DT,O
,relaxant,JJ,O
,effects,NNS,O
,of,IN,O
,nitric,JJ,O
,oxide,NN,O
,(,(,O
,NO,NNP,O
,),),O
,.,.,O
,The,DT,O
,aim,NN,O
,of,IN,O
,the,DT,O
,present,JJ,O
,study,NN,O
,was,VBD,O
,to,TO,O
,determine,VB,O
,the,DT,O
,efficacy,NN,O
,of,IN,O
,glyceryl,NN,O
,trinitrate,NN,O
,(,(,O
,GTN,NNP,O
,),),O
,",",",",O
,an,DT,O
,NO,NNP,O
,donor,NN,O
,",",",",O
,in,IN,O
,the,DT,O
,resolution,NN,O
,of,IN,O
,primary,JJ,O
,dysmenorrhea,NN,B-DISEASE
,in,IN,O
,comparison,NN,O
,with,IN,O
,diclofenac,NN,O
,(,(,O
,DCF,NNP,O
,),),O
,.,.,O
,A,DT,O
,total,NN,O
,of,IN,O
,24,CD,O
,patients,NNS,O
,with,IN,O
,the,DT,O
,diagnosis,NN,O
,of,IN,O
,severe,JJ,O
,primary,JJ,O
,dysmenorrhea,NN,B-DISEASE
,were,VBD,O
,studied,VBN,O
,during,IN,O
,two,CD,O
,consecutive,JJ,O
,menstrual,JJ,O
,cycles,NNS,O
,.,.,O
,In,IN,O
,an,DT,O
,open,JJ,O
,",",",",O
,cross,JJ,O
,-,:,O
,over,IN,O
,",",",",O
,controlled,VBD,O
,design,NN,O
,",",",",O
,patients,NNS,O
,were,VBD,O
,randomized,VBN,O
,to,TO,O
,receive,VB,O
,either,DT,O
,DCF,NNP,O
,per,IN,O
,os,NN,O
,or,CC,O
,GTN,NNP,O
,patches,VBZ,O
,the,DT,O
,first,JJ,O
,days,NNS,O
,of,IN,O
,menses,NNS,O
,",",",",O
,when,WRB,O
,menstrual,JJ,O
,cramps,NNS,O
,became,VBD,O
,unendurable,JJ,O
,.,.,O
,In,IN,O
,the,DT,O
,subsequent,JJ,O
,cycle,NN,O
,the,DT,O
,other,JJ,O
,treatment,NN,O
,was,VBD,O
,used,VBN,O
,.,.,O
,Patients,NNS,O
,received,VBD,O
,up,RB,O
,to,TO,O
,3,CD,O
,doses,NNS,O
,/,JJ,O
,day,NN,O
,of,IN,O
,50,CD,O
,mg,NNS,O
,DCF,NNP,O
,or,CC,O
,2,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,/,$,O
,24,CD,O
,h,NN,O
,transdermal,JJ,O
,GTN,NNP,O
,for,IN,O
,the,DT,O
,first,JJ,O
,3,CD,O
,days,NNS,O
,of,IN,O
,the,DT,O
,cycle,NN,O
,",",",",O
,according,VBG,O
,to,TO,O
,their,PRP$,O
,needs,NNS,O
,.,.,O
,The,DT,O
,participants,NNS,O
,recorded,VBD,O
,menstrual,JJ,O
,symptoms,NNS,O
,and,CC,O
,possible,JJ,O
,side,NN,O
,-,:,O
,effects,NNS,O
,at,IN,O
,different,JJ,O
,times,NNS,O
,(,(,O
,0,CD,O
,",",",",O
,30,CD,O
,",",",",O
,60,CD,O
,",",",",O
,120,CD,O
,minutes,NNS,O
,),),O
,after,IN,O
,the,DT,O
,first,JJ,O
,dose,NN,O
,of,IN,O
,medication,NN,O
,on,IN,O
,the,DT,O
,first,JJ,O
,day,NN,O
,of,IN,O
,the,DT,O
,cycle,NN,O
,",",",",O
,with,IN,O
,both,DT,O
,drugs,NNS,O
,.,.,O
,The,DT,O
,difference,NN,O
,in,IN,O
,pain,NN,B-DISEASE
,intensity,NN,O
,score,NN,O
,(,(,O
,DPI,NNP,O
,),),O
,was,VBD,O
,the,DT,O
,main,JJ,O
,outcome,NN,O
,variable,NN,O
,.,.,O
,Both,DT,O
,treatments,NNS,O
,significantly,RB,O
,reduced,VBN,O
,DPI,NNP,O
,by,IN,O
,the,DT,O
,30th,JJ,O
,minute,NN,O
,(,(,O
,GTN,NNP,O
,",",",",O
,-,:,O
,12,CD,O
,.,.,O
,8,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,17,CD,O
,.,.,O
,9,CD,O
,;,:,O
,DCF,NNP,O
,",",",",O
,-,:,O
,18,CD,O
,.,.,O
,9,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,16,CD,O
,.,.,O
,6,CD,O
,),),O
,.,.,O
,However,RB,O
,",",",",O
,DCF,NNP,O
,continued,VBD,O
,to,TO,O
,be,VB,O
,effective,JJ,O
,in,IN,O
,reducing,VBG,O
,pelvic,JJ,B-DISEASE
,pain,NN,I-DISEASE
,for,IN,O
,two,CD,O
,hours,NNS,O
,",",",",O
,whereas,JJ,O
,GTN,NNP,O
,scores,NNS,O
,remained,VBD,O
,more,RBR,O
,or,CC,O
,less,RBR,O
,stable,JJ,O
,after,IN,O
,30,CD,O
,min,NN,O
,and,CC,O
,significantly,RB,O
,higher,JJR,O
,than,IN,O
,those,DT,O
,for,IN,O
,DFC,NNP,O
,(,(,O
,after,IN,O
,one,CD,O
,hour,NN,O
,:,:,O
,GTN,NNP,O
,",",",",O
,-,:,O
,12,CD,O
,.,.,O
,8,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,17,CD,O
,.,.,O
,9,CD,O
,;,:,O
,DFC,NNP,O
,",",",",O
,-,:,O
,18,CD,O
,.,.,O
,9,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,16,CD,O
,.,.,O
,6,CD,O
,and,CC,O
,after,IN,O
,two,CD,O
,hours,NNS,O
,:,:,O
,GTN,NNP,O
,",",",",O
,-,:,O
,23,CD,O
,.,.,O
,7,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,20,CD,O
,.,.,O
,5,CD,O
,;,:,O
,DFC,NNP,O
,",",",",O
,-,:,O
,59,CD,O
,.,.,O
,7,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,17,CD,O
,.,.,O
,9,CD,O
,",",",",O
,p,NN,O
,=,VBD,O
,0,CD,O
,.,.,O
,0001,CD,O
,),),O
,.,.,O
,Low,NNP,B-DISEASE
,back,RB,I-DISEASE
,pain,NN,I-DISEASE
,was,VBD,O
,also,RB,O
,relieved,VBN,O
,by,IN,O
,both,DT,O
,drugs,NNS,O
,.,.,O
,Headache,NNP,B-DISEASE
,was,VBD,O
,significantly,RB,O
,increased,VBN,O
,by,IN,O
,GTN,NNP,O
,but,CC,O
,not,RB,O
,by,IN,O
,DCF,NNP,O
,.,.,O
,Eight,CD,O
,patients,NNS,O
,stopped,VBD,O
,using,VBG,O
,GTN,NNP,O
,because,IN,O
,headache,NN,B-DISEASE
,-,:,O
,-,:,O
,attributed,VBD,O
,to,TO,O
,its,PRP$,O
,use,NN,O
,-,:,O
,-,:,O
,became,VBD,O
,intolerable,JJ,O
,.,.,O
,These,DT,O
,findings,NNS,O
,indicate,VBP,O
,that,IN,O
,GTN,NNP,O
,has,VBZ,O
,a,DT,O
,reduced,VBN,O
,efficacy,NN,O
,and,CC,O
,tolerability,NN,O
,by,IN,O
,comparison,NN,O
,with,IN,O
,DCF,NNP,O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,primary,JJ,O
,dysmenorrhea,NN,B-DISEASE
,.,.,O
,Temocapril,NNP,O
,",",",",O
,a,DT,O
,long,JJ,O
,-,:,O
,acting,VBG,O
,non,SYM,O
,-,:,O
,SH,NNP,O
,group,NN,O
,angiotensin,VBD,O
,converting,VBG,O
,enzyme,NN,O
,inhibitor,NN,O
,",",",",O
,modulates,VBZ,O
,glomerular,JJ,B-DISEASE
,injury,NN,I-DISEASE
,in,IN,O
,chronic,JJ,O
,puromycin,NN,O
,aminonucleoside,IN,O
,nephrosis,NN,B-DISEASE
,.,.,O
,The,DT,O
,purpose,NN,O
,of,IN,O
,the,DT,O
,present,JJ,O
,study,NN,O
,was,VBD,O
,to,TO,O
,determine,VB,O
,whether,IN,O
,chronic,JJ,O
,administration,NN,O
,of,IN,O
,temocapril,NN,O
,",",",",O
,a,DT,O
,long,JJ,O
,-,:,O
,acting,VBG,O
,non,SYM,O
,-,:,O
,SH,NNP,O
,group,NN,O
,angiotensin,VBD,O
,converting,VBG,O
,enzyme,NN,O
,(,(,O
,ACE,NNP,O
,),),O
,inhibitor,NN,O
,",",",",O
,reduced,VBD,O
,proteinuria,NN,B-DISEASE
,",",",",O
,inhibited,VBD,O
,glomerular,JJ,O
,hypertrophy,NN,B-DISEASE
,and,CC,O
,prevented,JJ,O
,glomerulosclerosis,NN,B-DISEASE
,in,IN,O
,chronic,JJ,O
,puromycin,NN,O
,aminonucleoside,NN,O
,(,(,O
,PAN,NNP,O
,),),O
,-,:,O
,induced,VBN,O
,nephrotic,JJ,B-DISEASE
,rats,NNS,O
,.,.,O
,Nephrosis,NN,B-DISEASE
,was,VBD,O
,induced,VBN,O
,by,IN,O
,injection,NN,O
,of,IN,O
,PAN,NNP,O
,(,(,O
,15mg,CD,O
,/,RB,O
,100g,CD,O
,body,NN,O
,weight,NN,O
,),),O
,in,IN,O
,male,NN,O
,Sprague,NNP,O
,-,:,O
,Dawley,NNP,O
,(,(,O
,SD,NNP,O
,),),O
,rats,VBZ,O
,.,.,O
,Four,CD,O
,groups,NNS,O
,were,VBD,O
,used,VBN,O
,",",",",O
,i,NN,O
,),),O
,the,DT,O
,PAN,NNP,O
,group,NN,O
,(,(,O
,14,CD,O
,),),O
,",",",",O
,ii,NN,O
,),),O
,PAN,NNP,O
,/,NNP,O
,temocapril,NN,O
,(,(,O
,13,CD,O
,),),O
,",",",",O
,iii,NN,O
,),),O
,temocapril,NN,O
,(,(,O
,14,CD,O
,),),O
,and,CC,O
,iv,NN,O
,),),O
,untreated,VBD,O
,controls,NNS,O
,(,(,O
,15,CD,O
,),),O
,.,.,O
,Temocapril,NNP,O
,(,(,O
,8,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,/,NNP,O
,day,NN,O
,),),O
,was,VBD,O
,administered,VBN,O
,to,TO,O
,the,DT,O
,rats,NNS,O
,which,WDT,O
,were,VBD,O
,killed,VBN,O
,at,IN,O
,weeks,NNS,O
,4,CD,O
,",",",",O
,14,CD,O
,or,CC,O
,20,CD,O
,.,.,O
,At,IN,O
,each,DT,O
,time,NN,O
,point,NN,O
,",",",",O
,systolic,JJ,O
,blood,NN,O
,pressure,NN,O
,(,(,O
,BP,NNP,O
,),),O
,",",",",O
,urinary,JJ,O
,protein,NN,O
,excretion,NN,O
,and,CC,O
,renal,JJ,O
,histopathological,JJ,O
,findings,NNS,O
,were,VBD,O
,evaluated,VBN,O
,",",",",O
,and,CC,O
,morphometric,JJ,O
,image,NN,O
,analysis,NN,O
,was,VBD,O
,done,VBN,O
,.,.,O
,Systolic,NNP,O
,BP,NNP,O
,in,IN,O
,the,DT,O
,PAN,NNP,O
,group,NN,O
,was,VBD,O
,significantly,RB,O
,high,JJ,O
,at,IN,O
,4,CD,O
,",",",",O
,14,CD,O
,and,CC,O
,20,CD,O
,weeks,NNS,O
,",",",",O
,but,CC,O
,was,VBD,O
,normal,JJ,O
,in,IN,O
,the,DT,O
,PAN,NNP,O
,/,NNP,O
,temocapril,NN,O
,group,NN,O
,.,.,O
,Urinary,NNP,O
,protein,NN,O
,excretion,NN,O
,in,IN,O
,the,DT,O
,PAN,NNP,O
,group,NN,O
,increased,VBD,O
,significantly,RB,O
,",",",",O
,peaking,VBG,O
,at,IN,O
,8,CD,O
,days,NNS,O
,",",",",O
,then,RB,O
,decreased,VBD,O
,at,IN,O
,4,CD,O
,weeks,NNS,O
,",",",",O
,but,CC,O
,rose,VBD,O
,again,RB,O
,significantly,RB,O
,at,IN,O
,14,CD,O
,and,CC,O
,20,CD,O
,weeks,NNS,O
,.,.,O
,Temocapril,NNP,O
,did,VBD,O
,not,RB,O
,attenuate,VB,O
,proteinuria,NNS,B-DISEASE
,at,IN,O
,8,CD,O
,days,NNS,O
,",",",",O
,but,CC,O
,it,PRP,O
,did,VBD,O
,markedly,RB,O
,lower,JJR,O
,it,PRP,O
,from,IN,O
,weeks,NNS,O
,4,CD,O
,to,TO,O
,20,CD,O
,.,.,O
,The,DT,O
,glomerulosclerosis,NN,B-DISEASE
,index,NN,O
,(,(,O
,GSI,NNP,O
,),),O
,was,VBD,O
,6,CD,O
,.,.,O
,21,CD,O
,%,NN,O
,at,IN,O
,4,CD,O
,weeks,NNS,O
,and,CC,O
,respectively,RB,O
,25,CD,O
,.,.,O
,35,CD,O
,%,NN,O
,and,CC,O
,30,CD,O
,.,.,O
,49,CD,O
,%,NN,O
,at,IN,O
,14,CD,O
,and,CC,O
,20,CD,O
,weeks,NNS,O
,in,IN,O
,the,DT,O
,PAN,NNP,O
,group,NN,O
,.,.,O
,There,EX,O
,was,VBD,O
,a,DT,O
,significant,JJ,O
,correlation,NN,O
,between,IN,O
,urinary,JJ,O
,protein,NN,O
,excretion,NN,O
,and,CC,O
,GSI,NNP,O
,(,(,O
,r,VB,O
,=,RB,O
,0,CD,O
,.,.,O
,808,CD,O
,",",",",O
,p,NN,O
,<,VBD,O
,0,CD,O
,.,.,O
,0001,CD,O
,),),O
,.,.,O
,The,DT,O
,ratio,NN,O
,of,IN,O
,glomerular,JJ,O
,tuft,JJ,O
,area,NN,O
,to,TO,O
,the,DT,O
,area,NN,O
,of,IN,O
,Bowman,NNP,O
,',POS,O
,s,NN,O
,capsules,NNS,O
,(,(,O
,GT,NNP,O
,/,NNP,O
,BC,NNP,O
,),),O
,in,IN,O
,the,DT,O
,PAN,NNP,O
,group,NN,O
,was,VBD,O
,significantly,RB,O
,increased,VBN,O
,",",",",O
,but,CC,O
,it,PRP,O
,was,VBD,O
,significantly,RB,O
,lower,JJR,O
,in,IN,O
,the,DT,O
,PAN,NNP,O
,/,NNP,O
,temocapril,NN,O
,group,NN,O
,.,.,O
,It,PRP,O
,appears,VBZ,O
,that,IN,O
,temocapril,NN,O
,was,VBD,O
,effective,JJ,O
,in,IN,O
,retarding,VBG,O
,renal,JJ,O
,progression,NN,O
,and,CC,O
,protected,VBD,O
,renal,JJ,O
,function,NN,O
,in,IN,O
,PAN,NNP,O
,neprotic,JJ,B-DISEASE
,rats,NNS,O
,.,.,O
,Pulmonary,NNP,B-DISEASE
,hypertension,NN,I-DISEASE
,after,IN,O
,ibuprofen,JJ,O
,prophylaxis,NN,O
,in,IN,O
,very,RB,O
,preterm,JJ,O
,infants,NNS,O
,.,.,O
,We,PRP,O
,report,VBP,O
,three,CD,O
,cases,NNS,O
,of,IN,O
,severe,JJ,O
,hypoxaemia,NN,B-DISEASE
,after,IN,O
,ibuprofen,JJ,O
,administration,NN,O
,during,IN,O
,a,DT,O
,randomised,VBN,O
,controlled,VBN,O
,trial,NN,O
,of,IN,O
,prophylactic,JJ,O
,treatment,NN,O
,of,IN,O
,patent,NN,B-DISEASE
,ductus,NN,I-DISEASE
,arteriosus,NN,I-DISEASE
,with,IN,O
,ibuprofen,NN,O
,in,IN,O
,premature,NN,O
,infants,NNS,O
,born,VBN,O
,at,IN,O
,less,JJR,O
,than,IN,O
,28,CD,O
,weeks,NNS,O
,of,IN,O
,gestation,NN,O
,.,.,O
,Echocardiography,NN,O
,showed,VBD,O
,severely,RB,O
,decreased,JJ,O
,pulmonary,JJ,O
,blood,NN,O
,flow,NN,O
,.,.,O
,Hypoxaemia,NNP,B-DISEASE
,resolved,VBD,O
,quickly,RB,O
,on,IN,O
,inhaled,JJ,O
,nitric,JJ,O
,oxide,NN,O
,therapy,NN,O
,.,.,O
,We,PRP,O
,suggest,VBP,O
,that,IN,O
,investigators,NNS,O
,involved,VBN,O
,in,IN,O
,similar,JJ,O
,trials,NNS,O
,pay,VBP,O
,close,JJ,O
,attention,NN,O
,to,TO,O
,pulmonary,JJ,O
,pressure,NN,O
,if,IN,O
,hypoxaemia,NN,B-DISEASE
,occurs,VBZ,O
,after,IN,O
,prophylactic,JJ,O
,administration,NN,O
,of,IN,O
,ibuprofen,NN,O
,.,.,O
,Hyponatremia,NNP,B-DISEASE
,and,CC,O
,syndrome,NN,B-DISEASE
,of,IN,I-DISEASE
,inappropriate,JJ,I-DISEASE
,anti,NNS,I-DISEASE
,-,:,I-DISEASE
,diuretic,JJ,I-DISEASE
,hormone,NN,I-DISEASE
,reported,VBD,O
,with,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,Vincristine,NNP,O
,:,:,O
,an,DT,O
,over,IN,O
,-,:,O
,representation,NN,O
,of,IN,O
,Asians,NNPS,O
,?,.,O
,PURPOSE,NNPS,O
,:,:,O
,This,DT,O
,retrospective,NN,O
,study,NN,O
,used,VBD,O
,a,DT,O
,pharmaceutical,JJ,O
,company,NN,O
,',POS,O
,s,NN,O
,global,JJ,O
,safety,NN,O
,database,NN,O
,to,TO,O
,determine,VB,O
,the,DT,O
,reporting,NN,O
,rate,NN,O
,of,IN,O
,hyponatremia,NN,B-DISEASE
,and,CC,O
,/,NN,O
,or,CC,O
,syndrome,NN,B-DISEASE
,of,IN,I-DISEASE
,inappropriate,JJ,I-DISEASE
,secretion,NN,I-DISEASE
,of,IN,I-DISEASE
,anti,JJ,I-DISEASE
,-,:,I-DISEASE
,diuretic,JJ,I-DISEASE
,hormone,NN,I-DISEASE
,(,(,O
,SIADH,NNP,B-DISEASE
,),),O
,among,IN,O
,vincristine,JJ,O
,-,:,O
,treated,JJ,O
,patients,NNS,O
,and,CC,O
,to,TO,O
,explore,VB,O
,the,DT,O
,possibility,NN,O
,of,IN,O
,at,IN,O
,-,:,O
,risk,NN,O
,population,NN,O
,subgroups,NNS,O
,.,.,O
,METHOD,NN,O
,:,:,O
,We,PRP,O
,searched,VBD,O
,the,DT,O
,Eli,NNP,O
,Lilly,NNP,O
,and,CC,O
,Company,NNP,O
,',POS,O
,s,NN,O
,computerized,VBD,O
,adverse,JJ,O
,event,NN,O
,database,NN,O
,for,IN,O
,all,DT,O
,reported,VBN,O
,cases,NNS,O
,of,IN,O
,hyponatremia,NN,B-DISEASE
,and,CC,O
,/,NN,O
,or,CC,O
,SIADH,NNP,B-DISEASE
,as,IN,O
,of,IN,O
,1,CD,O
,November,NNP,O
,1999,CD,O
,that,WDT,O
,had,VBD,O
,been,VBN,O
,reported,VBN,O
,during,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,vincristine,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,A,DT,O
,total,NN,O
,of,IN,O
,76,CD,O
,cases,NNS,O
,of,IN,O
,hyponatremia,NN,B-DISEASE
,and,CC,O
,/,NN,O
,or,CC,O
,SIADH,NNP,B-DISEASE
,associated,VBN,O
,with,IN,O
,vincristine,NN,O
,use,NN,O
,were,VBD,O
,identified,VBN,O
,.,.,O
,The,DT,O
,overall,JJ,O
,reporting,NN,O
,rate,NN,O
,was,VBD,O
,estimated,VBN,O
,to,TO,O
,be,VB,O
,1,CD,O
,.,.,O
,3,CD,O
,/,JJ,O
,100,CD,O
,",",",",O
,000,CD,O
,treated,VBD,O
,patients,NNS,O
,.,.,O
,The,DT,O
,average,JJ,O
,age,NN,O
,of,IN,O
,patients,NNS,O
,was,VBD,O
,35,CD,O
,.,.,O
,6,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,28,CD,O
,.,.,O
,3,CD,O
,years,NNS,O
,",",",",O
,and,CC,O
,62,CD,O
,%,NN,O
,were,VBD,O
,males,NNS,O
,.,.,O
,Approximately,RB,O
,75,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,were,VBD,O
,receiving,VBG,O
,treatment,NN,O
,for,IN,O
,leukemia,NN,B-DISEASE
,or,CC,O
,lymphoma,NN,B-DISEASE
,.,.,O
,Among,IN,O
,the,DT,O
,39,CD,O
,reports,NNS,O
,that,WDT,O
,included,VBD,O
,information,NN,O
,on,IN,O
,race,NN,O
,",",",",O
,the,DT,O
,racial,JJ,O
,distribution,NN,O
,was,VBD,O
,:,:,O
,1,CD,O
,Black,NNP,O
,",",",",O
,3,CD,O
,Caucasian,JJ,O
,",",",",O
,and,CC,O
,35,CD,O
,Asian,JJ,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Our,PRP$,O
,data,NNS,O
,suggest,VBP,O
,that,IN,O
,Asian,JJ,O
,patients,NNS,O
,may,MD,O
,be,VB,O
,at,IN,O
,increased,JJ,O
,risk,NN,O
,of,IN,O
,hyponatremia,NN,B-DISEASE
,and,CC,O
,/,NN,O
,or,CC,O
,SIADH,NNP,B-DISEASE
,associated,VBN,O
,with,IN,O
,vincristine,NN,O
,use,NN,O
,.,.,O
,Although,IN,O
,the,DT,O
,overall,JJ,O
,reported,VBD,O
,rate,NN,O
,of,IN,O
,SIADH,NNP,B-DISEASE
,associated,VBN,O
,with,IN,O
,vincristine,NN,O
,is,VBZ,O
,very,RB,O
,low,JJ,O
,",",",",O
,physicians,NNS,O
,caring,VBG,O
,for,IN,O
,Asian,JJ,O
,oncology,NN,O
,patients,NNS,O
,should,MD,O
,be,VB,O
,aware,JJ,O
,of,IN,O
,this,DT,O
,potential,JJ,O
,serious,JJ,O
,but,CC,O
,reversible,JJ,O
,adverse,JJ,O
,event,NN,O
,.,.,O
,Delayed,NNP,O
,toxicity,NN,B-DISEASE
,of,IN,O
,cyclophosphamide,NN,O
,on,IN,O
,the,DT,O
,bladder,NN,O
,of,IN,O
,DBA,NNP,O
,/,NNP,O
,2,CD,O
,and,CC,O
,C57BL,NNP,O
,/,NNP,O
,6,CD,O
,female,NN,O
,mouse,NN,O
,.,.,O
,The,DT,O
,present,JJ,O
,study,NN,O
,describes,VBZ,O
,the,DT,O
,delayed,JJ,O
,development,NN,O
,of,IN,O
,a,DT,O
,severe,JJ,O
,bladder,NN,O
,pathology,NN,O
,in,IN,O
,a,DT,O
,susceptible,JJ,O
,strain,NN,O
,of,IN,O
,mice,NN,O
,(,(,O
,DBA,NNP,O
,/,NNP,O
,2,CD,O
,),),O
,but,CC,O
,not,RB,O
,in,IN,O
,a,DT,O
,resistant,JJ,O
,strain,NN,O
,(,(,O
,C57BL,NNP,O
,/,NNP,O
,6,CD,O
,),),O
,when,WRB,O
,both,DT,O
,were,VBD,O
,treated,VBN,O
,with,IN,O
,a,DT,O
,single,JJ,O
,300,CD,O
,mg,NN,O
,/,NNP,O
,kg,NNP,O
,dose,NN,O
,of,IN,O
,cyclophosphamide,NN,O
,(,(,O
,CY,NNP,O
,),),O
,.,.,O
,Inbred,VBN,O
,DBA,NNP,O
,/,$,O
,2,CD,O
,and,CC,O
,C57BL,NNP,O
,/,NNP,O
,6,CD,O
,female,JJ,O
,mice,NNS,O
,were,VBD,O
,injected,VBN,O
,with,IN,O
,CY,NNP,O
,",",",",O
,and,CC,O
,the,DT,O
,effect,NN,O
,of,IN,O
,the,DT,O
,drug,NN,O
,on,IN,O
,the,DT,O
,bladder,NN,O
,was,VBD,O
,assessed,VBN,O
,during,IN,O
,100,CD,O
,days,NNS,O
,by,IN,O
,light,JJ,O
,microscopy,NNS,O
,using,VBG,O
,different,JJ,O
,staining,NN,O
,procedures,NNS,O
,",",",",O
,and,CC,O
,after,IN,O
,30,CD,O
,days,NNS,O
,by,IN,O
,conventional,JJ,O
,electron,NN,O
,microscopy,NN,O
,.,.,O
,Early,JJ,O
,CY,NNP,O
,toxicity,NN,B-DISEASE
,caused,VBD,O
,a,DT,O
,typical,JJ,O
,haemorrhagic,NN,B-DISEASE
,cystitis,NN,B-DISEASE
,in,IN,O
,both,DT,O
,strains,NNS,O
,that,WDT,O
,was,VBD,O
,completely,RB,O
,repaired,VBN,O
,in,IN,O
,about,RB,O
,7,CD,O
,-,:,O
,10,CD,O
,days,NNS,O
,.,.,O
,After,IN,O
,30,CD,O
,days,NNS,O
,of,IN,O
,CY,NNP,O
,injection,NN,O
,ulcerous,JJ,O
,and,CC,O
,non,JJ,O
,-,:,O
,ulcerous,JJ,O
,forms,NNS,O
,of,IN,O
,chronic,JJ,O
,cystitis,NN,B-DISEASE
,appeared,VBD,O
,in,IN,O
,86,CD,O
,%,NN,O
,of,IN,O
,DBA,NNP,O
,/,NNP,O
,2,CD,O
,mice,NN,O
,but,CC,O
,only,RB,O
,in,IN,O
,4,CD,O
,%,NN,O
,of,IN,O
,C57BL,NNP,O
,/,NNP,O
,6,CD,O
,mice,NN,O
,.,.,O
,Delayed,NNP,O
,cystitis,NN,B-DISEASE
,was,VBD,O
,characterized,VBN,O
,by,IN,O
,infiltration,NN,O
,and,CC,O
,transepithelial,JJ,O
,passage,NN,O
,into,IN,O
,the,DT,O
,lumen,NNS,O
,of,IN,O
,inflammatory,JJ,O
,cells,NNS,O
,and,CC,O
,by,IN,O
,frequent,JJ,O
,exfoliation,NN,O
,of,IN,O
,the,DT,O
,urothelium,NN,O
,.,.,O
,Mast,NNP,O
,cells,NNS,O
,appeared,VBD,O
,in,IN,O
,the,DT,O
,connective,NN,O
,and,CC,O
,muscular,JJ,O
,layers,NNS,O
,of,IN,O
,the,DT,O
,bladder,NN,O
,at,IN,O
,a,DT,O
,much,RB,O
,higher,JJR,O
,number,NN,O
,in,IN,O
,DBA,NNP,O
,/,NNP,O
,2,CD,O
,mice,NN,O
,than,IN,O
,in,IN,O
,C57BL,NNP,O
,/,NNP,O
,6,CD,O
,mice,NN,O
,or,CC,O
,untreated,JJ,O
,controls,NNS,O
,.,.,O
,Electron,NNP,O
,microscopy,NN,O
,disclosed,VBD,O
,the,DT,O
,absence,NN,O
,of,IN,O
,the,DT,O
,typical,JJ,O
,discoidal,NN,O
,vesicles,NNS,O
,normally,RB,O
,present,JJ,O
,in,IN,O
,the,DT,O
,cytoplasm,NN,O
,of,IN,O
,surface,NN,O
,cells,NNS,O
,.,.,O
,Instead,RB,O
,",",",",O
,numerous,JJ,O
,abnormal,JJ,O
,vesicles,NNS,O
,containing,VBG,O
,one,CD,O
,or,CC,O
,several,JJ,O
,dark,JJ,O
,granules,NNS,O
,were,VBD,O
,observed,VBN,O
,in,IN,O
,the,DT,O
,cytoplasm,NN,O
,of,IN,O
,cells,NNS,O
,from,IN,O
,all,PDT,O
,the,DT,O
,epithelial,JJ,O
,layers,NNS,O
,.,.,O
,Delayed,NNP,O
,cystitis,NN,B-DISEASE
,still,RB,O
,persisted,VBN,O
,in,IN,O
,DBA,NNP,O
,/,NNP,O
,2,CD,O
,mice,NN,O
,100,CD,O
,days,NNS,O
,after,IN,O
,treatment,NN,O
,.,.,O
,These,DT,O
,results,NNS,O
,indicate,VBP,O
,that,IN,O
,delayed,JJ,O
,toxicity,NN,B-DISEASE
,of,IN,O
,CY,NNP,O
,in,IN,O
,female,JJ,O
,DBA,NNP,O
,/,NNP,O
,2,CD,O
,mice,NN,O
,causes,VBZ,O
,a,DT,O
,bladder,NN,O
,pathology,NN,O
,that,WDT,O
,is,VBZ,O
,not,RB,O
,observed,VBN,O
,in,IN,O
,C57BL,NNP,O
,/,NNP,O
,6,CD,O
,mice,NN,O
,.,.,O
,This,DT,O
,pathology,NN,O
,resembles,VBZ,O
,interstitial,JJ,B-DISEASE
,cystitis,NN,I-DISEASE
,in,IN,O
,humans,NNS,O
,and,CC,O
,could,MD,O
,perhaps,RB,O
,be,VB,O
,used,VBN,O
,as,IN,O
,an,DT,O
,animal,JJ,O
,model,NN,O
,for,IN,O
,studies,NNS,O
,on,IN,O
,the,DT,O
,disease,NN,O
,.,.,O
,High,NNP,O
,-,:,O
,dose,NN,O
,5,CD,O
,-,:,O
,fluorouracil,NN,O
,/,NNP,O
,folinic,JJ,O
,acid,NN,O
,in,IN,O
,combination,NN,O
,with,IN,O
,three,CD,O
,-,:,O
,weekly,JJ,O
,mitomycin,NN,O
,C,NNP,O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,advanced,JJ,O
,gastric,JJ,B-DISEASE
,cancer,NN,I-DISEASE
,.,.,O
,A,DT,O
,phase,NN,O
,II,NNP,O
,study,NN,O
,.,.,O
,BACKGROUND,NNP,O
,:,:,O
,The,DT,O
,24,CD,O
,-,:,O
,hour,NN,O
,continuous,JJ,O
,infusion,NN,O
,of,IN,O
,5,CD,O
,-,:,O
,fluorouracil,NN,O
,(,(,O
,5,CD,O
,-,:,O
,FU,NN,O
,),),O
,and,CC,O
,folinic,JJ,O
,acid,NN,O
,(,(,O
,FA,NNP,O
,),),O
,as,IN,O
,part,NN,O
,of,IN,O
,several,JJ,O
,new,JJ,O
,multidrug,NNS,O
,chemotherapy,NN,O
,regimens,VBZ,O
,in,IN,O
,advanced,JJ,O
,gastric,JJ,B-DISEASE
,cancer,NN,I-DISEASE
,(,(,O
,AGC,NNP,B-DISEASE
,),),O
,has,VBZ,O
,shown,VBN,O
,to,TO,O
,be,VB,O
,effective,JJ,O
,",",",",O
,with,IN,O
,low,JJ,O
,toxicity,NN,B-DISEASE
,.,.,O
,In,IN,O
,a,DT,O
,previous,JJ,O
,phase,NN,O
,II,NNP,O
,study,NN,O
,with,IN,O
,3,CD,O
,-,:,O
,weekly,JJ,O
,bolus,NN,O
,5,CD,O
,-,:,O
,FU,NN,O
,",",",",O
,FA,NNP,O
,and,CC,O
,mitomycin,VB,O
,C,NNP,O
,(,(,O
,MMC,NNP,O
,),),O
,we,PRP,O
,found,VBD,O
,a,DT,O
,low,JJ,O
,toxicity,NN,B-DISEASE
,rate,NN,O
,and,CC,O
,response,NN,O
,rates,NNS,O
,comparable,JJ,O
,to,TO,O
,those,DT,O
,of,IN,O
,regimens,NNS,O
,such,JJ,O
,as,IN,O
,ELF,NNP,O
,",",",",O
,FAM,NNP,O
,or,CC,O
,FAMTX,NNP,O
,",",",",O
,and,CC,O
,a,DT,O
,promising,JJ,O
,median,JJ,O
,overall,JJ,O
,survival,NN,O
,.,.,O
,In,IN,O
,order,NN,O
,to,TO,O
,improve,VB,O
,this,DT,O
,MMC,NNP,O
,-,:,O
,dependent,JJ,O
,schedule,NN,O
,we,PRP,O
,initiated,VBD,O
,a,DT,O
,phase,NN,O
,II,NNP,O
,study,NN,O
,with,IN,O
,high,JJ,O
,-,:,O
,dose,NN,O
,5,CD,O
,-,:,O
,FU,NNP,O
,/,NNP,O
,FA,NNP,O
,and,CC,O
,3,CD,O
,-,:,O
,weekly,JJ,O
,bolus,NN,O
,MMC,NNP,O
,.,.,O
,PATIENTS,NNP,O
,AND,CC,O
,METHODS,NNP,O
,:,:,O
,From,IN,O
,February,NNP,O
,",",",",O
,1998,CD,O
,to,TO,O
,September,NNP,O
,",",",",O
,2000,CD,O
,we,PRP,O
,recruited,VBD,O
,33,CD,O
,patients,NNS,O
,with,IN,O
,AGC,NNP,B-DISEASE
,to,TO,O
,receive,VB,O
,weekly,JJ,O
,24,CD,O
,-,:,O
,hour,NN,O
,5,CD,O
,-,:,O
,FU,NN,O
,2,CD,O
,",",",",O
,600,CD,O
,mg,NN,O
,/,NNP,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,preceded,VBN,O
,by,IN,O
,2,CD,O
,-,:,O
,hour,NN,O
,FA,NNP,O
,500,CD,O
,mg,NN,O
,/,NNP,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,for,IN,O
,6,CD,O
,weeks,NNS,O
,",",",",O
,followed,VBN,O
,by,IN,O
,a,DT,O
,2,CD,O
,-,:,O
,week,NN,O
,rest,JJ,O
,period,NN,O
,.,.,O
,Bolus,CC,O
,MMC,NNP,O
,10,CD,O
,mg,NN,O
,/,NNP,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,was,VBD,O
,added,VBN,O
,in,IN,O
,3,CD,O
,-,:,O
,weekly,JJ,O
,intervals,NNS,O
,.,.,O
,Treatment,NNP,O
,given,VBN,O
,on,IN,O
,an,DT,O
,outpatient,JJ,O
,basis,NN,O
,",",",",O
,using,VBG,O
,portable,JJ,O
,pump,NN,O
,systems,NNS,O
,",",",",O
,was,VBD,O
,repeated,VBN,O
,on,IN,O
,day,NN,O
,57,CD,O
,.,.,O
,Patients,NNS,O
,',POS,O
,characteristics,NNS,O
,were,VBD,O
,:,:,O
,male,NN,O
,/,NNP,O
,female,NN,O
,ratio,NN,O
,20,CD,O
,/,NN,O
,13,CD,O
,;,:,O
,median,JJ,O
,age,NN,O
,57,CD,O
,(,(,O
,27,CD,O
,-,:,O
,75,CD,O
,),),O
,years,NNS,O
,;,:,O
,median,NN,O
,WHO,NNP,O
,status,NN,O
,1,CD,O
,(,(,O
,0,CD,O
,-,:,O
,2,CD,O
,),),O
,.,.,O
,18,CD,O
,patients,NNS,O
,had,VBD,O
,a,DT,O
,primary,JJ,O
,AGC,NNP,B-DISEASE
,",",",",O
,and,CC,O
,15,CD,O
,showed,VBD,O
,a,DT,O
,relapsed,JJ,O
,AGC,NNP,B-DISEASE
,.,.,O
,Median,JJ,O
,follow,NN,O
,-,:,O
,up,NN,O
,was,VBD,O
,11,CD,O
,.,.,O
,8,CD,O
,months,NNS,O
,(,(,O
,range,NN,O
,of,IN,O
,those,DT,O
,surviving,VBG,O
,:,:,O
,2,CD,O
,.,.,O
,7,CD,O
,-,:,O
,11,CD,O
,.,.,O
,8,CD,O
,months,NNS,O
,),),O
,.,.,O
,RESULTS,NN,O
,:,:,O
,32,CD,O
,patients,NNS,O
,were,VBD,O
,evaluable,JJ,O
,for,IN,O
,response,NN,O
,-,:,O
,complete,JJ,O
,remission,NN,O
,9,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,3,CD,O
,),),O
,",",",",O
,partial,JJ,O
,remission,NN,O
,45,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,15,CD,O
,),),O
,",",",",O
,no,DT,O
,change,NN,O
,27,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,9,CD,O
,),),O
,",",",",O
,progressive,JJ,O
,disease,NN,O
,15,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,5,CD,O
,),),O
,.,.,O
,Median,JJ,O
,overall,JJ,O
,survival,NN,O
,time,NN,O
,was,VBD,O
,10,CD,O
,.,.,O
,2,CD,O
,months,NNS,O
,[,RB,O
,95,CD,O
,%,NN,O
,confidence,NN,O
,interval,NN,O
,(,(,O
,CI,NNP,O
,),),O
,:,:,O
,8,CD,O
,.,.,O
,7,CD,O
,-,:,O
,11,CD,O
,.,.,O
,6,CD,O
,],NN,O
,",",",",O
,and,CC,O
,median,JJ,O
,progression,NN,O
,-,:,O
,free,JJ,O
,survival,NN,O
,time,NN,O
,was,VBD,O
,7,CD,O
,.,.,O
,6,CD,O
,months,NNS,O
,(,(,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,:,:,O
,4,CD,O
,.,.,O
,4,CD,O
,-,:,O
,10,CD,O
,.,.,O
,9,CD,O
,),),O
,.,.,O
,The,DT,O
,worst,JJS,O
,toxicities,NNS,B-DISEASE
,(,(,O
,%,NN,O
,),),O
,observed,VBN,O
,were,VBD,O
,(,(,O
,CTC,NNP,O
,-,:,O
,NCI,NN,O
,1,CD,O
,/,NN,O
,2,CD,O
,/,$,O
,3,CD,O
,),),O
,:,:,O
,leukopenia,$,B-DISEASE
,45,CD,O
,.,.,O
,5,CD,O
,/,JJ,O
,18,CD,O
,.,.,O
,2,CD,O
,/,JJ,O
,6,CD,O
,.,.,O
,1,CD,O
,",",",",O
,thrombocytopenia,VBD,B-DISEASE
,33,CD,O
,.,.,O
,3,CD,O
,/,JJ,O
,9,CD,O
,.,.,O
,1,CD,O
,/,JJ,O
,6,CD,O
,.,.,O
,1,CD,O
,",",",",O
,vomitus,NN,B-DISEASE
,24,CD,O
,.,.,O
,2,CD,O
,/,JJ,O
,9,CD,O
,.,.,O
,1,CD,O
,/,JJ,O
,0,CD,O
,",",",",O
,diarrhea,RB,B-DISEASE
,36,CD,O
,.,.,O
,4,CD,O
,/,JJ,O
,6,CD,O
,.,.,O
,1,CD,O
,/,JJ,O
,3,CD,O
,.,.,O
,0,CD,O
,",",",",O
,stomatitis,NN,B-DISEASE
,18,CD,O
,.,.,O
,2,CD,O
,/,JJ,O
,9,CD,O
,.,.,O
,1,CD,O
,/,JJ,O
,0,CD,O
,",",",",O
,hand,NN,B-DISEASE
,-,:,I-DISEASE
,foot,NN,I-DISEASE
,syndrome,JJ,I-DISEASE
,12,CD,O
,.,.,O
,1,CD,O
,/,JJ,O
,0,CD,O
,/,JJ,O
,0,CD,O
,.,.,O
,Two,CD,O
,patients,NNS,O
,developed,VBD,O
,hemolytic,JJ,B-DISEASE
,-,:,I-DISEASE
,uremic,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,(,(,O
,HUS,NNP,B-DISEASE
,),),O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,High,JJ,O
,-,:,O
,dose,NN,O
,5,CD,O
,-,:,O
,FU,NNP,O
,/,NNP,O
,FA,NNP,O
,/,NNP,O
,MMC,NNP,O
,is,VBZ,O
,an,DT,O
,effective,JJ,O
,and,CC,O
,well,RB,O
,-,:,O
,tolerated,VBN,O
,outpatient,JJ,O
,regimen,NNS,O
,for,IN,O
,AGC,NNP,B-DISEASE
,(,(,O
,objective,JJ,O
,response,NN,O
,rate,NN,O
,54,CD,O
,.,.,O
,6,CD,O
,%,NN,O
,),),O
,.,.,O
,It,PRP,O
,may,MD,O
,serve,VB,O
,as,IN,O
,an,DT,O
,alternative,NN,O
,to,TO,O
,cisplatin,VB,O
,-,:,O
,containing,NN,O
,regimens,NNS,O
,;,:,O
,however,RB,O
,",",",",O
,it,PRP,O
,has,VBZ,O
,to,TO,O
,be,VB,O
,considered,VBN,O
,that,IN,O
,possibly,RB,O
,HUS,NNP,B-DISEASE
,may,MD,O
,occur,VB,O
,.,.,O
,Persistent,NNP,O
,sterile,JJ,O
,leukocyturia,NN,B-DISEASE
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,impaired,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,function,NN,I-DISEASE
,in,IN,O
,human,JJ,B-DISEASE
,immunodeficiency,NN,I-DISEASE
,virus,NN,I-DISEASE
,type,NN,I-DISEASE
,1,CD,I-DISEASE
,-,:,I-DISEASE
,infected,JJ,I-DISEASE
,children,NNS,O
,treated,VBN,O
,with,IN,O
,indinavir,NN,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Prolonged,JJ,O
,administration,NN,O
,of,IN,O
,indinavir,NN,O
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,occurrence,NN,O
,of,IN,O
,a,DT,O
,variety,NN,O
,of,IN,O
,renal,JJ,O
,complications,NNS,O
,in,IN,O
,adults,NNS,O
,.,.,O
,These,DT,O
,well,RB,O
,-,:,O
,documented,VBN,O
,side,NN,O
,effects,NNS,O
,have,VBP,O
,restricted,VBN,O
,the,DT,O
,use,NN,O
,of,IN,O
,this,DT,O
,potent,JJ,O
,protease,NN,O
,inhibitor,NN,O
,in,IN,O
,children,NNS,O
,.,.,O
,DESIGN,NN,O
,:,:,O
,A,DT,O
,prospective,JJ,O
,study,NN,O
,to,TO,O
,monitor,VB,O
,indinavir,JJ,O
,-,:,O
,related,JJ,O
,nephrotoxicity,NN,B-DISEASE
,in,IN,O
,a,DT,O
,cohort,NN,O
,of,IN,O
,30,CD,O
,human,JJ,B-DISEASE
,immunodeficiency,NN,I-DISEASE
,virus,NN,I-DISEASE
,type,NN,I-DISEASE
,1,CD,I-DISEASE
,-,:,I-DISEASE
,infected,JJ,I-DISEASE
,children,NNS,O
,treated,VBN,O
,with,IN,O
,indinavir,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,Urinary,JJ,O
,pH,NN,O
,",",",",O
,albumin,NN,O
,",",",",O
,creatinine,NN,O
,",",",",O
,the,DT,O
,presence,NN,O
,of,IN,O
,erythrocytes,NNS,O
,",",",",O
,leukocytes,NNS,O
,",",",",O
,bacteria,NNS,O
,and,CC,O
,crystals,NNS,O
,",",",",O
,and,CC,O
,culture,NN,O
,were,VBD,O
,analyzed,VBN,O
,every,DT,O
,3,CD,O
,months,NNS,O
,for,IN,O
,96,CD,O
,weeks,NNS,O
,.,.,O
,Serum,NNP,O
,creatinine,NN,O
,levels,NNS,O
,were,VBD,O
,routinely,RB,O
,determined,VBN,O
,at,IN,O
,the,DT,O
,same,JJ,O
,time,NN,O
,points,NNS,O
,.,.,O
,Steady,JJ,O
,-,:,O
,state,NN,O
,pharmacokinetics,NNS,O
,of,IN,O
,indinavir,NN,O
,were,VBD,O
,done,VBN,O
,at,IN,O
,week,NN,O
,4,CD,O
,after,IN,O
,the,DT,O
,initiation,NN,O
,of,IN,O
,indinavir,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,The,DT,O
,cumulative,JJ,O
,incidence,NN,O
,of,IN,O
,persistent,NN,O
,sterile,JJ,O
,leukocyturia,NN,B-DISEASE
,(,(,O
,>,CD,O
,or,CC,O
,=,VB,O
,75,CD,O
,cells,NNS,O
,/,JJ,O
,micro,JJ,O
,L,NNP,O
,in,IN,O
,at,IN,O
,least,JJS,O
,2,CD,O
,consecutive,JJ,O
,visits,NNS,O
,),),O
,after,IN,O
,96,CD,O
,weeks,NNS,O
,was,VBD,O
,53,CD,O
,%,NN,O
,.,.,O
,Persistent,NNP,O
,sterile,JJ,O
,leukocyturia,NN,B-DISEASE
,was,VBD,O
,frequently,RB,O
,associated,VBN,O
,with,IN,O
,a,DT,O
,mild,JJ,O
,increase,NN,O
,in,IN,O
,the,DT,O
,urine,JJ,O
,albumin,NN,O
,/,NNP,O
,creatinine,NN,O
,ratio,NN,O
,and,CC,O
,by,IN,O
,microscopic,NN,O
,hematuria,NN,B-DISEASE
,.,.,O
,The,DT,O
,cumulative,JJ,O
,incidence,NN,O
,of,IN,O
,serum,JJ,O
,creatinine,NN,O
,levels,NNS,O
,>,VBP,O
,50,CD,O
,%,NN,O
,above,IN,O
,normal,JJ,O
,was,VBD,O
,33,CD,O
,%,NN,O
,after,IN,O
,96,CD,O
,weeks,NNS,O
,.,.,O
,Children,NNP,O
,with,IN,O
,persistent,NN,O
,sterile,JJ,O
,leukocyturia,NN,B-DISEASE
,more,RBR,O
,frequently,RB,O
,had,VBD,O
,serum,VBN,O
,creatinine,NN,O
,levels,NNS,O
,of,IN,O
,50,CD,O
,%,NN,O
,above,IN,O
,normal,JJ,O
,than,IN,O
,those,DT,O
,children,NNS,O
,without,IN,O
,persistent,NN,O
,sterile,NN,O
,leukocyturia,NN,B-DISEASE
,.,.,O
,In,IN,O
,children,NNS,O
,younger,JJR,O
,than,IN,O
,5,CD,O
,.,.,O
,6,CD,O
,years,NNS,O
,",",",",O
,persistent,NN,O
,sterile,JJ,O
,leukocyturia,NN,B-DISEASE
,was,VBD,O
,significantly,RB,O
,more,RBR,O
,frequent,JJ,O
,than,IN,O
,in,IN,O
,older,JJR,O
,children,NNS,O
,.,.,O
,A,DT,O
,higher,JJR,O
,cumulative,JJ,O
,incidence,NN,O
,of,IN,O
,persistent,JJ,O
,leukocyturia,NN,B-DISEASE
,was,VBD,O
,found,VBN,O
,in,IN,O
,children,NNS,O
,with,IN,O
,an,DT,O
,area,NN,O
,under,IN,O
,the,DT,O
,curve,NN,O
,>,VBD,O
,19,CD,O
,mg,NN,O
,/,NNP,O
,L,NNP,O
,x,NNP,O
,h,NN,O
,or,CC,O
,a,DT,O
,peak,JJ,O
,serum,JJ,O
,level,NN,O
,of,IN,O
,indinavir,JJ,O
,>,FW,O
,12,CD,O
,mg,NN,O
,/,NNP,O
,L,NNP,O
,.,.,O
,In,IN,O
,4,CD,O
,children,NNS,O
,",",",",O
,indinavir,NN,O
,was,VBD,O
,discontinued,VBN,O
,because,IN,O
,of,IN,O
,nephrotoxicity,NN,B-DISEASE
,.,.,O
,Subsequently,RB,O
,",",",",O
,the,DT,O
,serum,NN,O
,creatinine,NN,O
,levels,NNS,O
,decreased,VBN,O
,",",",",O
,the,DT,O
,urine,JJ,O
,albumin,NN,O
,/,NNP,O
,creatinine,NN,O
,ratios,NNS,O
,returned,VBD,O
,to,TO,O
,zero,CD,O
,",",",",O
,and,CC,O
,the,DT,O
,leukocyturia,NN,B-DISEASE
,disappeared,VBD,O
,within,IN,O
,3,CD,O
,months,NNS,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Children,NNP,O
,treated,VBD,O
,with,IN,O
,indinavir,NNS,O
,have,VBP,O
,a,DT,O
,high,JJ,O
,cumulative,JJ,O
,incidence,NN,O
,of,IN,O
,persistent,NN,O
,sterile,JJ,O
,leukocyturia,NN,B-DISEASE
,.,.,O
,Children,NNP,O
,with,IN,O
,persistent,NN,O
,sterile,JJ,O
,leukocyturia,NN,B-DISEASE
,more,RBR,O
,frequently,RB,O
,had,VBD,O
,an,DT,O
,increase,NN,O
,in,IN,O
,serum,JJ,O
,creatinine,NN,O
,levels,NNS,O
,of,IN,O
,>,$,O
,50,CD,O
,%,NN,O
,above,IN,O
,normal,JJ,O
,.,.,O
,Younger,JJR,O
,children,NNS,O
,have,VBP,O
,an,DT,O
,additional,JJ,O
,risk,NN,O
,for,IN,O
,renal,JJ,O
,complications,NNS,O
,.,.,O
,The,DT,O
,impairment,NN,B-DISEASE
,of,IN,I-DISEASE
,the,DT,I-DISEASE
,renal,JJ,I-DISEASE
,function,NN,I-DISEASE
,in,IN,O
,these,DT,O
,children,NNS,O
,occurred,VBD,O
,in,IN,O
,the,DT,O
,absence,NN,O
,of,IN,O
,clinical,JJ,O
,symptoms,NNS,O
,of,IN,O
,nephrolithiasis,NN,B-DISEASE
,.,.,O
,Indinavir,NNP,O
,-,:,O
,associated,VBN,O
,nephrotoxicity,NN,B-DISEASE
,must,MD,O
,be,VB,O
,monitored,VBN,O
,closely,RB,O
,",",",",O
,especially,RB,O
,in,IN,O
,children,NNS,O
,with,IN,O
,risk,NN,O
,factors,NNS,O
,such,JJ,O
,as,IN,O
,persistent,NN,O
,sterile,NN,O
,leukocyturia,NN,B-DISEASE
,",",",",O
,age,NN,O
,<,VBD,O
,5,CD,O
,.,.,O
,6,CD,O
,years,NNS,O
,",",",",O
,an,DT,O
,area,NN,O
,under,IN,O
,the,DT,O
,curve,NN,O
,of,IN,O
,indinavir,JJ,O
,>,FW,O
,19,CD,O
,mg,NN,O
,/,NNP,O
,L,NNP,O
,x,NNP,O
,h,NN,O
,",",",",O
,and,CC,O
,a,DT,O
,C,NNP,O
,(,(,O
,max,NN,O
,),),O
,>,VBZ,O
,12,CD,O
,mg,NN,O
,/,NNP,O
,L,NNP,O
,.,.,O
,Utility,NNP,O
,of,IN,O
,troponin,NN,O
,I,PRP,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,cocaine,JJ,O
,-,:,O
,associated,VBN,O
,chest,JJS,B-DISEASE
,pain,NN,I-DISEASE
,.,.,O
,Baseline,NNP,O
,electrocardiogram,JJ,O
,abnormalities,NNS,O
,and,CC,O
,market,NN,O
,elevations,NNS,O
,not,RB,O
,associated,VBN,O
,with,IN,O
,myocardial,JJ,B-DISEASE
,necrosis,NN,I-DISEASE
,make,VBP,O
,accurate,JJ,O
,diagnosis,NN,O
,of,IN,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,(,(,O
,MI,NNP,B-DISEASE
,),),O
,difficult,JJ,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,cocaine,JJ,O
,-,:,O
,associated,VBN,O
,chest,JJS,B-DISEASE
,pain,NN,I-DISEASE
,.,.,O
,Troponin,NNP,O
,sampling,NN,O
,may,MD,O
,offer,VB,O
,greater,JJR,O
,diagnostic,JJ,O
,utility,NN,O
,in,IN,O
,these,DT,O
,patients,NNS,O
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,To,TO,O
,assess,VB,O
,outcomes,NNS,O
,based,VBN,O
,on,IN,O
,troponin,JJ,O
,positivity,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,cocaine,JJ,O
,chest,NN,B-DISEASE
,pain,NN,I-DISEASE
,admitted,VBD,O
,for,IN,O
,exclusion,NN,O
,of,IN,O
,MI,NNP,B-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,Outcomes,NNS,O
,were,VBD,O
,examined,VBN,O
,in,IN,O
,patients,NNS,O
,admitted,VBN,O
,for,IN,O
,possible,JJ,O
,MI,NNP,B-DISEASE
,after,IN,O
,cocaine,NN,O
,use,NN,O
,.,.,O
,All,DT,O
,patients,NNS,O
,underwent,VBD,O
,a,DT,O
,rapid,JJ,O
,rule,NN,O
,-,:,O
,in,IN,O
,protocol,NN,O
,that,WDT,O
,included,VBD,O
,serial,JJ,O
,sampling,NN,O
,of,IN,O
,creatine,NN,O
,kinase,NN,O
,(,(,O
,CK,NNP,O
,),),O
,",",",",O
,CK,NNP,O
,-,:,O
,MB,NNP,O
,",",",",O
,and,CC,O
,cardiac,JJ,O
,troponin,NN,O
,I,PRP,O
,(,(,O
,cTnI,NN,O
,),),O
,over,IN,O
,eight,CD,O
,hours,NNS,O
,.,.,O
,Outcomes,NNP,O
,included,VBD,O
,CK,NNP,O
,-,:,O
,MB,NNP,O
,MI,NNP,B-DISEASE
,(,(,O
,CK,NNP,O
,-,:,O
,MB,NNP,O
,>,NNP,O
,or,CC,O
,=,$,O
,8,CD,O
,ng,JJ,O
,/,NNP,O
,mL,NN,O
,with,IN,O
,a,DT,O
,relative,JJ,O
,index,NN,O
,[,NNP,O
,(,(,O
,CK,NNP,O
,-,:,O
,MB,NNP,O
,x,NNP,O
,100,CD,O
,),),O
,/,NN,O
,total,JJ,O
,CK,NNP,O
,],NNP,O
,>,NNP,O
,or,CC,O
,=,$,O
,4,CD,O
,",",",",O
,cardiac,JJ,B-DISEASE
,death,NN,I-DISEASE
,",",",",O
,and,CC,O
,significant,JJ,O
,coronary,JJ,B-DISEASE
,disease,NN,I-DISEASE
,(,(,O
,>,CD,O
,or,CC,O
,=,VB,O
,50,CD,O
,%,NN,O
,),),O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Of,IN,O
,the,DT,O
,246,CD,O
,admitted,JJ,O
,patients,NNS,O
,",",",",O
,34,CD,O
,(,(,O
,14,CD,O
,%,NN,O
,),),O
,met,VBD,O
,CK,NNP,O
,-,:,O
,MB,NNP,O
,criteria,NNS,O
,for,IN,O
,MI,NNP,B-DISEASE
,and,CC,O
,38,CD,O
,(,(,O
,16,CD,O
,%,NN,O
,),),O
,had,VBD,O
,cTnI,VBN,O
,elevations,NNS,O
,.,.,O
,Angiography,NNP,O
,was,VBD,O
,performed,VBN,O
,in,IN,O
,29,CD,O
,of,IN,O
,38,CD,O
,patients,NNS,O
,who,WP,O
,were,VBD,O
,cTnI,JJ,O
,-,:,O
,positive,JJ,O
,",",",",O
,with,IN,O
,significant,JJ,O
,disease,NN,O
,present,NN,O
,in,IN,O
,25,CD,O
,(,(,O
,86,CD,O
,%,NN,O
,),),O
,.,.,O
,Three,CD,O
,of,IN,O
,the,DT,O
,four,CD,O
,patients,NNS,O
,without,IN,O
,significant,JJ,O
,disease,NN,O
,who,WP,O
,had,VBD,O
,cTnI,VBN,O
,elevations,NNS,O
,met,VBD,O
,CK,NNP,O
,-,:,O
,MB,NNP,O
,criteria,NNS,O
,for,IN,O
,MI,NNP,B-DISEASE
,",",",",O
,and,CC,O
,the,DT,O
,other,JJ,O
,had,VBD,O
,a,DT,O
,peak,JJ,O
,CK,NNP,O
,-,:,O
,MB,NNP,O
,level,NN,O
,of,IN,O
,13,CD,O
,ng,JJ,O
,/,NNP,O
,mL,NN,O
,.,.,O
,Sensitivities,NNS,O
,",",",",O
,specificities,NNS,O
,",",",",O
,and,CC,O
,positive,JJ,O
,and,CC,O
,negative,JJ,O
,likelihood,NN,O
,ratios,NNS,O
,for,IN,O
,predicting,VBG,O
,cardiac,JJ,B-DISEASE
,death,NN,I-DISEASE
,or,CC,O
,significant,JJ,O
,disease,NN,O
,were,VBD,O
,high,JJ,O
,for,IN,O
,both,DT,O
,CK,NNP,O
,-,:,O
,MB,NNP,O
,MI,NNP,B-DISEASE
,and,CC,O
,cTnI,NN,O
,and,CC,O
,were,VBD,O
,not,RB,O
,significantly,RB,O
,different,JJ,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Most,JJS,O
,patients,NNS,O
,with,IN,O
,cTnI,JJ,O
,elevations,NNS,O
,meet,VBP,O
,CK,NNP,O
,-,:,O
,MB,NNP,O
,criteria,NNS,O
,for,IN,O
,MI,NNP,B-DISEASE
,",",",",O
,as,RB,O
,well,RB,O
,as,IN,O
,have,VBP,O
,a,DT,O
,high,JJ,O
,incidence,NN,O
,of,IN,O
,underlying,VBG,O
,significant,JJ,O
,disease,NN,O
,.,.,O
,Troponin,NNP,O
,appears,VBZ,O
,to,TO,O
,have,VB,O
,an,DT,O
,equivalent,JJ,O
,diagnostic,JJ,O
,accuracy,NN,O
,compared,VBN,O
,with,IN,O
,CK,NNP,O
,-,:,O
,MB,NN,O
,for,IN,O
,diagnosing,VBG,O
,necrosis,NN,B-DISEASE
,in,IN,O
,patients,NNS,O
,with,IN,O
,cocaine,JJ,O
,-,:,O
,associated,VBN,O
,chest,NN,B-DISEASE
,pain,NN,I-DISEASE
,and,CC,O
,suspected,VBD,O
,MI,NNP,B-DISEASE
,.,.,O
,Acute,NNP,O
,interstitial,JJ,B-DISEASE
,nephritis,NN,I-DISEASE
,due,JJ,O
,to,TO,O
,nicergoline,VB,O
,(,(,O
,Sermion,NNP,O
,),),O
,.,.,O
,We,PRP,O
,report,VBP,O
,a,DT,O
,case,NN,O
,of,IN,O
,acute,JJ,O
,interstitial,JJ,B-DISEASE
,nephritis,NN,I-DISEASE
,(,(,O
,AIN,NNP,B-DISEASE
,),),O
,due,JJ,O
,to,TO,O
,nicergoline,VB,O
,(,(,O
,Sermion,NNP,O
,),),O
,.,.,O
,A,DT,O
,50,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,patient,NN,O
,admitted,VBD,O
,to,TO,O
,our,PRP$,O
,hospital,NN,O
,for,IN,O
,fever,NN,B-DISEASE
,and,CC,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,Before,IN,O
,admission,NN,O
,",",",",O
,he,PRP,O
,had,VBD,O
,been,VBN,O
,taking,VBG,O
,nicergoline,JJ,O
,and,CC,O
,bendazac,JJ,O
,lysine,NN,O
,due,JJ,O
,to,TO,O
,retinal,JJ,B-DISEASE
,vein,NN,I-DISEASE
,occlusion,NN,I-DISEASE
,at,IN,O
,ophthalmologic,JJ,O
,department,NN,O
,.,.,O
,Thereafter,RB,O
,",",",",O
,he,PRP,O
,experienced,VBD,O
,intermittent,JJ,O
,fever,NN,B-DISEASE
,and,CC,O
,skin,NN,B-DISEASE
,rash,NN,I-DISEASE
,.,.,O
,On,IN,O
,admission,NN,O
,",",",",O
,clinical,JJ,O
,symptoms,NNS,O
,(,(,O
,i,NN,O
,.,.,O
,e,NN,O
,.,.,O
,arthralgia,NN,B-DISEASE
,and,CC,O
,fever,NN,B-DISEASE
,),),O
,and,CC,O
,laboratory,JJ,O
,findings,NNS,O
,(,(,O
,i,NN,O
,.,.,O
,e,NN,O
,.,.,O
,eosinophilia,NN,B-DISEASE
,and,CC,O
,renal,JJ,B-DISEASE
,failure,NN,I-DISEASE
,),),O
,suggested,VBD,O
,AIN,NNP,B-DISEASE
,",",",",O
,and,CC,O
,which,WDT,O
,was,VBD,O
,confirmed,VBN,O
,by,IN,O
,pathologic,JJ,O
,findings,NNS,O
,on,IN,O
,renal,JJ,O
,biopsy,NN,O
,.,.,O
,A,DT,O
,lymphocyte,JJ,O
,transformation,NN,O
,test,NN,O
,demonstrated,VBD,O
,a,DT,O
,positive,JJ,O
,result,NN,O
,against,IN,O
,nicergoline,NN,O
,.,.,O
,Treatment,NNP,O
,was,VBD,O
,consisted,VBN,O
,of,IN,O
,withdrawal,NN,O
,of,IN,O
,nicergoline,NN,O
,and,CC,O
,intravenous,JJ,O
,methylprednisolone,NN,O
,",",",",O
,and,CC,O
,his,PRP$,O
,renal,JJ,O
,function,NN,O
,was,VBD,O
,completely,RB,O
,recovered,VBN,O
,.,.,O
,To,TO,O
,our,PRP$,O
,knowledge,NN,O
,",",",",O
,this,DT,O
,is,VBZ,O
,the,DT,O
,first,JJ,O
,report,NN,O
,of,IN,O
,nicergoline,JJ,O
,-,:,O
,associated,VBN,O
,AIN,NNP,B-DISEASE
,.,.,O
,Neuroleptic,NNP,B-DISEASE
,malignant,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,complicated,VBN,O
,by,IN,O
,massive,JJ,O
,intestinal,JJ,O
,bleeding,NN,B-DISEASE
,in,IN,O
,a,DT,O
,patient,NN,O
,with,IN,O
,chronic,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,A,DT,O
,patient,NN,O
,with,IN,O
,chronic,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,(,(,O
,CRF,NNP,B-DISEASE
,),),O
,developed,VBD,O
,neuroleptic,JJ,B-DISEASE
,malignant,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,(,(,O
,NMS,NNP,B-DISEASE
,),),O
,after,IN,O
,administration,NN,O
,of,IN,O
,risperidone,NN,O
,and,CC,O
,levomepromazine,NN,O
,.,.,O
,In,IN,O
,addition,NN,O
,to,TO,O
,the,DT,O
,typical,JJ,O
,symptoms,NNS,O
,of,IN,O
,NMS,NNP,B-DISEASE
,",",",",O
,massive,JJ,O
,intestinal,JJ,O
,bleeding,NN,B-DISEASE
,was,VBD,O
,observed,VBN,O
,during,IN,O
,the,DT,O
,episode,NN,O
,.,.,O
,This,DT,O
,report,NN,O
,suggests,VBZ,O
,that,IN,O
,NMS,NNP,B-DISEASE
,in,IN,O
,a,DT,O
,patient,NN,O
,with,IN,O
,CRF,NNP,B-DISEASE
,may,MD,O
,be,VB,O
,complicated,VBN,O
,by,IN,O
,intestinal,JJ,O
,bleeding,NN,B-DISEASE
,and,CC,O
,needs,VBZ,O
,special,JJ,O
,caution,NN,O
,for,IN,O
,this,DT,O
,complication,NN,O
,.,.,O
,Blood,NNP,O
,brain,NN,O
,barrier,NN,O
,in,IN,O
,right,JJ,O
,-,:,O
,and,CC,O
,left,VBD,O
,-,:,O
,pawed,VBN,O
,female,JJ,O
,rats,NNS,O
,assessed,VBN,O
,by,IN,O
,a,DT,O
,new,JJ,O
,staining,NN,O
,method,NN,O
,.,.,O
,The,DT,O
,asymmetrical,JJ,O
,breakdown,NN,O
,of,IN,O
,the,DT,O
,blood,NN,O
,-,:,O
,brain,NN,O
,barrier,NN,O
,(,(,O
,BBB,NNP,O
,),),O
,was,VBD,O
,studied,VBN,O
,in,IN,O
,female,JJ,O
,rats,NNS,O
,.,.,O
,Paw,NNP,O
,preference,NN,O
,was,VBD,O
,assessed,VBN,O
,by,IN,O
,a,DT,O
,food,NN,O
,reaching,VBG,O
,test,NN,O
,.,.,O
,Adrenaline,NNP,O
,-,:,O
,induced,JJ,O
,hypertension,NN,B-DISEASE
,was,VBD,O
,used,VBN,O
,to,TO,O
,destroy,VB,O
,the,DT,O
,BBB,NNP,O
,",",",",O
,which,WDT,O
,was,VBD,O
,evaluated,VBN,O
,using,VBG,O
,triphenyltetrazolium,NN,O
,(,(,O
,TTC,NNP,O
,),),O
,staining,NN,O
,of,IN,O
,the,DT,O
,brain,NN,O
,slices,NNS,O
,just,RB,O
,after,IN,O
,giving,VBG,O
,adrenaline,NN,O
,for,IN,O
,30,CD,O
,s,NN,O
,.,.,O
,In,IN,O
,normal,JJ,O
,rats,NNS,O
,",",",",O
,the,DT,O
,whole,JJ,O
,brain,NN,O
,sections,NNS,O
,exhibited,VBD,O
,complete,JJ,O
,staining,VBG,O
,with,IN,O
,TTC,NNP,O
,.,.,O
,After,IN,O
,adrenaline,JJ,O
,infusion,NN,O
,for,IN,O
,30,CD,O
,s,NN,O
,",",",",O
,there,EX,O
,were,VBD,O
,large,JJ,O
,unstained,JJ,O
,areas,NNS,O
,in,IN,O
,the,DT,O
,left,NN,O
,brain,NN,O
,in,IN,O
,right,JJ,O
,-,:,O
,pawed,VBN,O
,animals,NNS,O
,",",",",O
,and,CC,O
,vice,NN,O
,versa,NN,O
,in,IN,O
,left,JJ,O
,-,:,O
,pawed,VBN,O
,animals,NNS,O
,.,.,O
,Similar,JJ,O
,results,NNS,O
,were,VBD,O
,obtained,VBN,O
,in,IN,O
,seizure,NN,B-DISEASE
,-,:,O
,induced,JJ,O
,breakdown,NN,O
,of,IN,O
,BBB,NNP,O
,.,.,O
,These,DT,O
,results,NNS,O
,were,VBD,O
,explained,VBN,O
,by,IN,O
,an,DT,O
,asymmetric,JJ,O
,cerebral,JJ,O
,blood,NN,O
,flow,NN,O
,depending,VBG,O
,upon,IN,O
,the,DT,O
,paw,NN,O
,preference,NN,O
,in,IN,O
,rats,NNS,O
,.,.,O
,It,PRP,O
,was,VBD,O
,suggested,VBN,O
,that,IN,O
,this,DT,O
,new,JJ,O
,method,NN,O
,and,CC,O
,the,DT,O
,results,NNS,O
,are,VBP,O
,consistent,JJ,O
,with,IN,O
,contralateral,JJ,O
,motor,NN,O
,control,NN,O
,that,WDT,O
,may,MD,O
,be,VB,O
,important,JJ,O
,in,IN,O
,determining,VBG,O
,the,DT,O
,dominant,JJ,O
,cerebral,NN,O
,hemisphere,NN,O
,in,IN,O
,animals,NNS,O
,.,.,O
,Carvedilol,NNP,O
,protects,VBZ,O
,against,IN,O
,doxorubicin,SYM,O
,-,:,O
,induced,JJ,O
,mitochondrial,JJ,O
,cardiomyopathy,NN,B-DISEASE
,.,.,O
,Several,JJ,O
,cytopathic,JJ,O
,mechanisms,NNS,O
,have,VBP,O
,been,VBN,O
,suggested,VBN,O
,to,TO,O
,mediate,VB,O
,the,DT,O
,dose,JJ,O
,-,:,O
,limiting,VBG,O
,cumulative,JJ,O
,and,CC,O
,irreversible,JJ,O
,cardiomyopathy,NN,B-DISEASE
,caused,VBN,O
,by,IN,O
,doxorubicin,NN,O
,.,.,O
,Recent,JJ,O
,evidence,NN,O
,indicates,VBZ,O
,that,IN,O
,oxidative,JJ,O
,stress,NN,O
,and,CC,O
,mitochondrial,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,are,VBP,O
,key,JJ,O
,factors,NNS,O
,in,IN,O
,the,DT,O
,pathogenic,JJ,O
,process,NN,O
,.,.,O
,The,DT,O
,objective,NN,O
,of,IN,O
,this,DT,O
,investigation,NN,O
,was,VBD,O
,to,TO,O
,test,VB,O
,the,DT,O
,hypothesis,NN,O
,that,WDT,O
,carvedilol,NN,O
,",",",",O
,a,DT,O
,nonselective,JJ,O
,beta,NN,O
,-,:,O
,adrenergic,JJ,O
,receptor,NN,O
,antagonist,NN,O
,with,IN,O
,potent,JJ,O
,antioxidant,JJ,O
,properties,NNS,O
,",",",",O
,protects,NNS,O
,against,IN,O
,the,DT,O
,cardiac,NN,O
,and,CC,O
,hepatic,JJ,O
,mitochondrial,JJ,O
,bioenergetic,JJ,O
,dysfunction,NN,O
,associated,VBN,O
,with,IN,O
,subchronic,JJ,O
,doxorubicin,NN,O
,toxicity,NN,B-DISEASE
,.,.,O
,Heart,NNP,O
,and,CC,O
,liver,RB,O
,mitochondria,NNS,O
,were,VBD,O
,isolated,VBN,O
,from,IN,O
,rats,NNS,O
,treated,VBN,O
,for,IN,O
,7,CD,O
,weeks,NNS,O
,with,IN,O
,doxorubicin,NN,O
,(,(,O
,2,CD,O
,mg,NN,O
,/,NNP,O
,kg,NNP,O
,sc,NN,O
,/,NNP,O
,week,NN,O
,),),O
,",",",",O
,carvedilol,NN,O
,(,(,O
,1,CD,O
,mg,NN,O
,/,NNP,O
,kg,NNP,O
,ip,NN,O
,/,NNP,O
,week,NN,O
,),),O
,",",",",O
,or,CC,O
,the,DT,O
,combination,NN,O
,of,IN,O
,the,DT,O
,two,CD,O
,drugs,NNS,O
,.,.,O
,Heart,NNP,O
,mitochondria,NN,O
,isolated,VBD,O
,from,IN,O
,doxorubicin,JJ,O
,-,:,O
,treated,JJ,O
,rats,NNS,O
,exhibited,VBD,O
,depressed,JJ,O
,rates,NNS,O
,for,IN,O
,state,NN,O
,3,CD,O
,respiration,NN,O
,(,(,O
,336,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,26,CD,O
,versus,NN,O
,425,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,53,CD,O
,natom,JJ,O
,O,NNP,O
,/,NNP,O
,min,NNP,O
,/,NNP,O
,mg,NNP,O
,protein,NN,O
,),),O
,and,CC,O
,a,DT,O
,lower,JJR,O
,respiratory,NN,O
,control,NN,O
,ratio,NN,O
,(,(,O
,RCR,NNP,O
,),),O
,(,(,O
,4,CD,O
,.,.,O
,3,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,6,CD,O
,versus,NN,O
,5,CD,O
,.,.,O
,8,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,4,CD,O
,),),O
,compared,VBN,O
,with,IN,O
,cardiac,JJ,O
,mitochondria,NNS,O
,isolated,VBN,O
,from,IN,O
,saline,JJ,O
,-,:,O
,treated,JJ,O
,rats,NNS,O
,.,.,O
,Mitochondrial,NNP,O
,calcium,NN,O
,-,:,O
,loading,NN,O
,capacity,NN,O
,and,CC,O
,the,DT,O
,activity,NN,O
,of,IN,O
,NADH,NNP,O
,-,:,O
,dehydrogenase,NN,O
,were,VBD,O
,also,RB,O
,suppressed,VBN,O
,in,IN,O
,cardiac,JJ,O
,mitochondria,NN,O
,from,IN,O
,doxorubicin,JJ,O
,-,:,O
,treated,JJ,O
,rats,NNS,O
,.,.,O
,Doxorubicin,NNP,O
,treatment,NN,O
,also,RB,O
,caused,VBD,O
,a,DT,O
,decrease,NN,O
,in,IN,O
,RCR,NNP,O
,for,IN,O
,liver,NN,O
,mitochondria,NN,O
,(,(,O
,3,CD,O
,.,.,O
,9,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,9,CD,O
,versus,NN,O
,5,CD,O
,.,.,O
,6,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,7,CD,O
,for,IN,O
,control,NN,O
,rats,NNS,O
,),),O
,and,CC,O
,inhibition,NN,O
,of,IN,O
,hepatic,JJ,O
,cytochrome,JJ,O
,oxidase,NN,O
,activity,NN,O
,.,.,O
,Coadministration,NN,O
,of,IN,O
,carvedilol,NN,O
,decreased,VBD,O
,the,DT,O
,extent,NN,O
,of,IN,O
,cellular,JJ,O
,vacuolization,NN,O
,in,IN,O
,cardiac,JJ,O
,myocytes,NNS,O
,and,CC,O
,prevented,VBD,O
,the,DT,O
,inhibitory,JJ,O
,effect,NN,O
,of,IN,O
,doxorubicin,NN,O
,on,IN,O
,mitochondrial,JJ,O
,respiration,NN,O
,in,IN,O
,both,DT,O
,heart,NN,O
,and,CC,O
,liver,NN,O
,.,.,O
,Carvedilol,NNP,O
,also,RB,O
,prevented,VBD,O
,the,DT,O
,decrease,NN,O
,in,IN,O
,mitochondrial,JJ,O
,Ca,NNP,O
,(,(,O
,2,CD,O
,+,NN,O
,),),O
,loading,NN,O
,capacity,NN,O
,and,CC,O
,the,DT,O
,inhibition,NN,O
,of,IN,O
,the,DT,O
,respiratory,NN,O
,complexes,NNS,O
,of,IN,O
,heart,NN,O
,mitochondria,NNS,O
,caused,VBN,O
,by,IN,O
,doxorubicin,NN,O
,.,.,O
,Carvedilol,NN,O
,by,IN,O
,itself,PRP,O
,did,VBD,O
,not,RB,O
,affect,VB,O
,any,DT,O
,of,IN,O
,the,DT,O
,parameters,NNS,O
,measured,VBD,O
,for,IN,O
,heart,NN,O
,or,CC,O
,liver,NN,O
,mitochondria,NNS,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,concluded,VBN,O
,that,IN,O
,this,DT,O
,protection,NN,O
,by,IN,O
,carvedilol,NN,O
,against,IN,O
,both,CC,O
,the,DT,O
,structural,JJ,O
,and,CC,O
,functional,JJ,O
,cardiac,JJ,O
,tissue,NN,O
,damage,NN,O
,may,MD,O
,afford,VB,O
,significant,JJ,O
,clinical,JJ,O
,advantage,NN,O
,in,IN,O
,minimizing,VBG,O
,the,DT,O
,dose,JJ,O
,-,:,O
,limiting,VBG,O
,mitochondrial,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,and,CC,O
,cardiomyopathy,NN,B-DISEASE
,that,WDT,O
,accompanies,VBZ,O
,long,RB,O
,-,:,O
,term,NN,O
,doxorubicin,NN,O
,therapy,NN,O
,in,IN,O
,cancer,NN,B-DISEASE
,patients,NNS,O
,.,.,O
,Cocaine,NNP,O
,-,:,O
,induced,JJ,O
,hyperactivity,NN,B-DISEASE
,is,VBZ,O
,more,RBR,O
,influenced,JJ,O
,by,IN,O
,adenosine,JJ,O
,receptor,NN,O
,agonists,NNS,O
,than,IN,O
,amphetamine,JJ,O
,-,:,O
,induced,JJ,O
,hyperactivity,NN,B-DISEASE
,.,.,O
,The,DT,O
,influence,NN,O
,of,IN,O
,adenosine,NN,O
,receptor,NN,O
,agonists,NNS,O
,and,CC,O
,antagonists,NNS,O
,on,IN,O
,cocaine,NN,O
,-,:,O
,and,CC,O
,amphetamine,VB,O
,-,:,O
,induced,JJ,O
,hyperactivity,NN,B-DISEASE
,was,VBD,O
,examined,VBN,O
,in,IN,O
,mice,NN,O
,.,.,O
,All,DT,O
,adenosine,JJ,O
,receptor,NN,O
,agonists,NNS,O
,significantly,RB,O
,decreased,VBD,B-DISEASE
,the,DT,I-DISEASE
,locomotor,NN,I-DISEASE
,activity,NN,I-DISEASE
,in,IN,O
,mice,NN,O
,",",",",O
,and,CC,O
,the,DT,O
,effects,NNS,O
,were,VBD,O
,dose,JJ,O
,-,:,O
,dependent,NN,O
,.,.,O
,It,PRP,O
,seems,VBZ,O
,that,IN,O
,adenosine,NN,O
,A1,NNP,O
,and,CC,O
,A2,NNP,O
,receptors,NNS,O
,might,MD,O
,be,VB,O
,involved,VBN,O
,in,IN,O
,this,DT,O
,reaction,NN,O
,.,.,O
,Moreover,RB,O
,",",",",O
,all,DT,O
,adenosine,VBP,O
,receptor,NN,O
,agonists,NNS,O
,:,:,O
,2,CD,O
,-,:,O
,p,NN,O
,-,:,O
,(,(,O
,2,CD,O
,-,:,O
,carboxyethyl,NN,O
,),),O
,phenethylamino,NN,O
,-,:,O
,5,CD,O
,','',O
,-,:,O
,N,NNP,O
,-,:,O
,ethylcarboxamidoadenosine,NN,O
,(,(,O
,CGS,NNP,O
,21680,CD,O
,),),O
,",",",",O
,A2A,NNP,O
,receptor,NN,O
,agonist,NN,O
,",",",",O
,N6,NNP,O
,-,:,O
,cyclopentyladenosine,NN,O
,(,(,O
,CPA,NNP,O
,),),O
,",",",",O
,A1,NNP,O
,receptor,NN,O
,agonist,NN,O
,",",",",O
,and,CC,O
,5,CD,O
,','',O
,-,:,O
,N,NNP,O
,-,:,O
,ethylcarboxamidoadenosine,NN,O
,(,(,O
,NECA,NNP,O
,),),O
,",",",",O
,A2,NNP,O
,/,NNP,O
,A1,NNP,O
,receptor,NN,O
,agonist,NN,O
,significantly,RB,O
,and,CC,O
,dose,VB,O
,-,:,O
,dependently,RB,O
,decreased,VBN,O
,cocaine,NN,O
,-,:,O
,induced,JJ,O
,locomotor,NN,O
,activity,NN,O
,.,.,O
,CPA,NNP,O
,reduced,VBD,O
,cocaine,JJ,O
,action,NN,O
,at,IN,O
,the,DT,O
,doses,NNS,O
,which,WDT,O
,",",",",O
,given,VBN,O
,alone,RB,O
,",",",",O
,did,VBD,O
,not,RB,O
,influence,VB,O
,motility,NN,O
,",",",",O
,while,IN,O
,CGS,NNP,O
,21680,CD,O
,and,CC,O
,NECA,NNP,O
,decreased,VBD,O
,the,DT,O
,action,NN,O
,of,IN,O
,cocaine,NN,O
,at,IN,O
,the,DT,O
,doses,NNS,O
,which,WDT,O
,",",",",O
,given,VBN,O
,alone,RB,O
,",",",",O
,decreased,JJ,O
,locomotor,NN,O
,activity,NN,O
,in,IN,O
,animals,NNS,O
,.,.,O
,These,DT,O
,results,NNS,O
,suggest,VBP,O
,the,DT,O
,involvement,NN,O
,of,IN,O
,both,DT,O
,adenosine,JJ,O
,receptors,NNS,O
,in,IN,O
,the,DT,O
,action,NN,O
,of,IN,O
,cocaine,NN,O
,although,IN,O
,agonists,NNS,O
,of,IN,O
,A1,NNP,O
,receptors,NNS,O
,seem,VBP,O
,to,TO,O
,have,VB,O
,stronger,JJR,O
,influence,NN,O
,on,IN,O
,it,PRP,O
,.,.,O
,The,DT,O
,selective,JJ,O
,blockade,NN,O
,of,IN,O
,A2,NNP,O
,adenosine,NN,O
,receptor,NN,O
,by,IN,O
,DMPX,NNP,O
,(,(,O
,3,CD,O
,",",",",O
,7,CD,O
,-,:,O
,dimethyl,NN,O
,-,:,O
,1,CD,O
,-,:,O
,propargylxanthine,NN,O
,),),O
,significantly,RB,O
,enhanced,VBN,O
,cocaine,NN,O
,-,:,O
,induced,JJ,O
,locomotor,NN,O
,activity,NN,O
,of,IN,O
,animals,NNS,O
,.,.,O
,Caffeine,NNP,O
,had,VBD,O
,similar,JJ,O
,action,NN,O
,but,CC,O
,the,DT,O
,effect,NN,O
,was,VBD,O
,not,RB,O
,significant,JJ,O
,.,.,O
,CPT,NNP,O
,(,(,O
,8,CD,O
,-,:,O
,cyclopentyltheophylline,NN,O
,),),O
,-,:,O
,-,:,O
,A1,NNP,O
,receptor,NN,O
,antagonist,NN,O
,",",",",O
,did,VBD,O
,not,RB,O
,show,VB,O
,any,DT,O
,influence,NN,O
,in,IN,O
,this,DT,O
,test,NN,O
,.,.,O
,Similarly,RB,O
,",",",",O
,all,DT,O
,adenosine,VBP,O
,receptor,NN,O
,agonists,NNS,O
,decreased,VBD,O
,amphetamine,JJ,O
,-,:,O
,induced,JJ,O
,hyperactivity,NN,B-DISEASE
,",",",",O
,but,CC,O
,at,IN,O
,the,DT,O
,higher,JJR,O
,doses,NNS,O
,than,IN,O
,those,DT,O
,which,WDT,O
,were,VBD,O
,active,JJ,O
,in,IN,O
,cocaine,NN,O
,-,:,O
,induced,JJ,O
,hyperactivity,NN,B-DISEASE
,.,.,O
,The,DT,O
,selective,JJ,O
,blockade,NN,O
,of,IN,O
,A2,NNP,O
,adenosine,NN,O
,receptors,NNS,O
,(,(,O
,DMPX,NNP,O
,),),O
,and,CC,O
,non,$,O
,-,:,O
,selective,JJ,O
,blockade,NN,O
,of,IN,O
,adenosine,JJ,O
,receptors,NNS,O
,(,(,O
,caffeine,NN,O
,),),O
,significantly,RB,O
,increased,VBD,O
,the,DT,O
,action,NN,O
,of,IN,O
,amphetamine,NN,O
,in,IN,O
,the,DT,O
,locomotor,NN,O
,activity,NN,O
,test,NN,O
,.,.,O
,Our,PRP$,O
,results,NNS,O
,have,VBP,O
,shown,VBN,O
,that,IN,O
,all,DT,O
,adenosine,JJ,O
,receptor,NN,O
,agonists,NNS,O
,(,(,O
,A1,NNP,O
,and,CC,O
,A2,NNP,O
,),),O
,reduce,VB,O
,cocaine,NN,O
,-,:,O
,and,CC,O
,amphetamine,VB,O
,-,:,O
,induced,JJ,O
,locomotor,NN,O
,activity,NN,O
,and,CC,O
,indicate,NN,O
,that,WDT,O
,cocaine,VBP,O
,-,:,O
,induced,JJ,O
,hyperactivity,NN,B-DISEASE
,is,VBZ,O
,more,RBR,O
,influenced,JJ,O
,by,IN,O
,adenosine,JJ,O
,receptor,NN,O
,agonists,NNS,O
,(,(,O
,particularly,RB,O
,A1,NNP,O
,receptors,NNS,O
,),),O
,than,IN,O
,amphetamine,JJ,O
,-,:,O
,induced,JJ,O
,hyperactivity,NN,B-DISEASE
,.,.,O
,Amiodarone,NN,O
,and,CC,O
,the,DT,O
,risk,NN,O
,of,IN,O
,bradyarrhythmia,NN,B-DISEASE
,requiring,VBG,O
,permanent,JJ,O
,pacemaker,NN,O
,in,IN,O
,elderly,JJ,O
,patients,NNS,O
,with,IN,O
,atrial,JJ,B-DISEASE
,fibrillation,NN,I-DISEASE
,and,CC,O
,prior,JJ,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,.,.,O
,OBJECTIVES,CC,O
,:,:,O
,The,DT,O
,aim,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,was,VBD,O
,to,TO,O
,determine,VB,O
,whether,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,amiodarone,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,atrial,JJ,B-DISEASE
,fibrillation,NN,I-DISEASE
,(,(,O
,AF,NNP,B-DISEASE
,),),O
,increases,VBZ,O
,the,DT,O
,risk,NN,O
,of,IN,O
,bradyarrhythmia,NN,B-DISEASE
,requiring,VBG,O
,a,DT,O
,permanent,JJ,O
,pacemaker,NN,O
,.,.,O
,BACKGROUND,NNP,O
,:,:,O
,Reports,NNS,O
,of,IN,O
,severe,JJ,O
,bradyarrhythmia,NN,B-DISEASE
,during,IN,O
,amiodarone,NN,O
,therapy,NN,O
,are,VBP,O
,infrequent,JJ,O
,and,CC,O
,limited,JJ,O
,to,TO,O
,studies,NNS,O
,assessing,VBG,O
,the,DT,O
,therapy,NN,O
,',POS,O
,s,NN,O
,use,NN,O
,in,IN,O
,the,DT,O
,management,NN,O
,of,IN,O
,patients,NNS,O
,with,IN,O
,ventricular,JJ,B-DISEASE
,arrhythmias,NNS,I-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,A,DT,O
,study,NN,O
,cohort,NN,O
,of,IN,O
,8,CD,O
,",",",",O
,770,CD,O
,patients,NNS,O
,age,NN,O
,>,VBD,O
,or,CC,O
,=,$,O
,65,CD,O
,years,NNS,O
,with,IN,O
,a,DT,O
,new,JJ,O
,diagnosis,NN,O
,of,IN,O
,AF,NNP,B-DISEASE
,was,VBD,O
,identified,VBN,O
,from,IN,O
,a,DT,O
,provincewide,JJ,O
,database,NN,O
,of,IN,O
,Quebec,NNP,O
,residents,NNS,O
,with,IN,O
,a,DT,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,(,(,O
,MI,NNP,B-DISEASE
,),),O
,between,IN,O
,1991,CD,O
,and,CC,O
,1999,CD,O
,.,.,O
,Using,VBG,O
,a,DT,O
,nested,JJ,O
,case,NN,O
,-,:,O
,control,NN,O
,design,NN,O
,",",",",O
,477,CD,O
,cases,NNS,O
,of,IN,O
,bradyarrhythmia,NN,B-DISEASE
,requiring,VBG,O
,a,DT,O
,permanent,JJ,O
,pacemaker,NN,O
,were,VBD,O
,matched,VBN,O
,(,(,O
,1,CD,O
,:,:,O
,4,CD,O
,),),O
,to,TO,O
,1,CD,O
,",",",",O
,908,CD,O
,controls,NNS,O
,.,.,O
,Multivariable,JJ,O
,logistic,JJ,O
,regression,NN,O
,was,VBD,O
,used,VBN,O
,to,TO,O
,estimate,VB,O
,the,DT,O
,odds,NNS,O
,ratio,NN,O
,(,(,O
,OR,NNP,O
,),),O
,of,IN,O
,pacemaker,NN,O
,insertion,NN,O
,associated,VBN,O
,with,IN,O
,amiodarone,NN,O
,use,NN,O
,",",",",O
,controlling,VBG,O
,for,IN,O
,baseline,NN,O
,risk,NN,O
,factors,NNS,O
,and,CC,O
,exposure,NN,O
,to,TO,O
,sotalol,VB,O
,",",",",O
,Class,NNP,O
,I,PRP,O
,antiarrhythmic,VBP,O
,agents,NNS,O
,",",",",O
,beta,SYM,O
,-,:,O
,blockers,NNS,O
,",",",",O
,calcium,NN,O
,channel,NN,O
,blockers,NNS,O
,",",",",O
,and,CC,O
,digoxin,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,amiodarone,NN,O
,use,NN,O
,was,VBD,O
,associated,VBN,O
,with,IN,O
,an,DT,O
,increased,VBN,O
,risk,NN,O
,of,IN,O
,pacemaker,NN,O
,insertion,NN,O
,(,(,O
,OR,NNP,O
,:,:,O
,2,CD,O
,.,.,O
,14,CD,O
,",",",",O
,95,CD,O
,%,NN,O
,confidence,NN,O
,interval,NN,O
,[,NNP,O
,CI,NNP,O
,],NN,O
,:,:,O
,1,CD,O
,.,.,O
,30,CD,O
,to,TO,O
,3,CD,O
,.,.,O
,54,CD,O
,),),O
,.,.,O
,This,DT,O
,effect,NN,O
,was,VBD,O
,modified,VBN,O
,by,IN,O
,gender,NN,O
,",",",",O
,with,IN,O
,a,DT,O
,greater,JJR,O
,risk,NN,O
,in,IN,O
,women,NNS,O
,versus,IN,O
,men,NNS,O
,(,(,O
,OR,NN,O
,:,:,O
,3,CD,O
,.,.,O
,86,CD,O
,",",",",O
,95,CD,O
,%,NN,O
,CI,NNP,O
,:,:,O
,1,CD,O
,.,.,O
,70,CD,O
,to,TO,O
,8,CD,O
,.,.,O
,75,CD,O
,vs,NN,O
,.,.,O
,OR,CC,O
,:,:,O
,1,CD,O
,.,.,O
,52,CD,O
,",",",",O
,95,CD,O
,%,NN,O
,CI,NNP,O
,:,:,O
,0,CD,O
,.,.,O
,80,CD,O
,to,TO,O
,2,CD,O
,.,.,O
,89,CD,O
,),),O
,.,.,O
,Digoxin,NN,O
,was,VBD,O
,the,DT,O
,only,JJ,O
,other,JJ,O
,medication,NN,O
,associated,VBN,O
,with,IN,O
,an,DT,O
,increased,VBN,O
,risk,NN,O
,of,IN,O
,pacemaker,NN,O
,insertion,NN,O
,(,(,O
,OR,NNP,O
,:,:,O
,1,CD,O
,.,.,O
,78,CD,O
,",",",",O
,95,CD,O
,%,NN,O
,CI,NNP,O
,:,:,O
,1,CD,O
,.,.,O
,37,CD,O
,to,TO,O
,2,CD,O
,.,.,O
,31,CD,O
,),),O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,This,DT,O
,study,NN,O
,suggests,VBZ,O
,that,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,amiodarone,NN,O
,in,IN,O
,elderly,JJ,O
,patients,NNS,O
,with,IN,O
,AF,NNP,B-DISEASE
,and,CC,O
,a,DT,O
,previous,JJ,O
,MI,NNP,B-DISEASE
,increases,VBZ,O
,the,DT,O
,risk,NN,O
,of,IN,O
,bradyarrhythmia,NN,B-DISEASE
,requiring,VBG,O
,a,DT,O
,permanent,JJ,O
,pacemaker,NN,O
,.,.,O
,The,DT,O
,finding,NN,O
,of,IN,O
,an,DT,O
,augmented,JJ,O
,risk,NN,O
,of,IN,O
,pacemaker,NN,O
,insertion,NN,O
,in,IN,O
,elderly,JJ,O
,women,NNS,O
,receiving,VBG,O
,amiodarone,NN,O
,requires,VBZ,O
,further,JJ,O
,investigation,NN,O
,.,.,O
,Indomethacin,NNP,O
,-,:,O
,induced,VBD,O
,morphologic,JJ,O
,changes,NNS,O
,in,IN,O
,the,DT,O
,rat,NN,O
,urinary,JJ,O
,bladder,NN,O
,epithelium,NN,O
,.,.,O
,OBJECTIVES,NN,O
,:,:,O
,To,TO,O
,evaluate,VB,O
,the,DT,O
,morphologic,NN,O
,changes,NNS,O
,in,IN,O
,rat,NN,O
,urothelium,NN,O
,induced,VBN,O
,by,IN,O
,indomethacin,NN,O
,.,.,O
,Nonsteroidal,NNP,O
,anti,SYM,O
,-,:,O
,inflammatory,JJ,O
,drug,NN,O
,-,:,O
,induced,JJ,O
,cystitis,NN,B-DISEASE
,is,VBZ,O
,a,DT,O
,poorly,RB,O
,recognized,VBN,O
,and,CC,O
,under,IN,O
,-,:,O
,reported,VBN,O
,condition,NN,O
,.,.,O
,In,IN,O
,addition,NN,O
,to,TO,O
,tiaprofenic,JJ,O
,acid,NN,O
,",",",",O
,indomethacin,NN,O
,has,VBZ,O
,been,VBN,O
,reported,VBN,O
,to,TO,O
,be,VB,O
,associated,VBN,O
,with,IN,O
,this,DT,O
,condition,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,Three,CD,O
,groups,NNS,O
,were,VBD,O
,established,VBN,O
,:,:,O
,a,DT,O
,control,NN,O
,group,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,10,CD,O
,),),O
,",",",",O
,a,DT,O
,high,JJ,O
,-,:,O
,dose,NN,O
,group,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,10,CD,O
,),),O
,",",",",O
,treated,VBN,O
,with,IN,O
,one,CD,O
,intraperitoneal,NN,O
,injection,NN,O
,of,IN,O
,indomethacin,JJ,O
,20,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,and,CC,O
,a,DT,O
,therapeutic,JJ,O
,dose,NN,O
,group,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,10,CD,O
,),),O
,in,IN,O
,which,WDT,O
,oral,JJ,O
,indomethacin,NN,O
,was,VBD,O
,administered,VBN,O
,3,CD,O
,.,.,O
,25,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,body,NN,O
,weight,VBD,O
,daily,RB,O
,for,IN,O
,3,CD,O
,weeks,NNS,O
,.,.,O
,The,DT,O
,animals,NNS,O
,were,VBD,O
,then,RB,O
,killed,VBN,O
,and,CC,O
,the,DT,O
,bladders,NNS,O
,removed,VBD,O
,for,IN,O
,light,NN,O
,and,CC,O
,electron,NN,O
,microscopic,NN,O
,studies,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,The,DT,O
,light,JJ,O
,microscopic,NN,O
,findings,NNS,O
,showed,VBD,O
,some,DT,O
,focal,JJ,O
,epithelial,JJ,O
,degeneration,NN,O
,that,WDT,O
,was,VBD,O
,more,RBR,O
,prominent,JJ,O
,in,IN,O
,the,DT,O
,high,JJ,O
,-,:,O
,dose,NN,O
,group,NN,O
,.,.,O
,When,WRB,O
,compared,VBN,O
,with,IN,O
,the,DT,O
,control,NN,O
,group,NN,O
,",",",",O
,both,DT,O
,indomethacin,JJ,O
,groups,NNS,O
,revealed,VBD,O
,statistically,RB,O
,increased,JJ,O
,numbers,NNS,O
,of,IN,O
,mast,NN,O
,cells,NNS,O
,in,IN,O
,the,DT,O
,mucosa,NN,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,0001,CD,O
,),),O
,and,CC,O
,penetration,NN,O
,of,IN,O
,lanthanum,NN,O
,nitrate,NN,O
,through,IN,O
,intercellular,JJ,O
,areas,NNS,O
,of,IN,O
,the,DT,O
,epithelium,NN,O
,.,.,O
,Furthermore,RB,O
,",",",",O
,the,DT,O
,difference,NN,O
,in,IN,O
,mast,NN,O
,cell,NN,O
,counts,VBZ,O
,between,IN,O
,the,DT,O
,high,JJ,O
,and,CC,O
,therapeutic,JJ,O
,dose,NN,O
,groups,NNS,O
,was,VBD,O
,also,RB,O
,statistically,RB,O
,significant,JJ,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,0001,CD,O
,),),O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Indomethacin,NNP,O
,resulted,VBD,O
,in,IN,O
,histopathologic,JJ,O
,findings,NNS,O
,typical,JJ,O
,of,IN,O
,interstitial,JJ,B-DISEASE
,cystitis,NN,I-DISEASE
,",",",",O
,such,JJ,O
,as,IN,O
,leaky,JJ,O
,bladder,NN,O
,epithelium,NN,O
,and,CC,O
,mucosal,JJ,O
,mastocytosis,NN,B-DISEASE
,.,.,O
,The,DT,O
,true,JJ,O
,incidence,NN,O
,of,IN,O
,nonsteroidal,JJ,O
,anti,SYM,O
,-,:,O
,inflammatory,JJ,O
,drug,NN,O
,-,:,O
,induced,JJ,O
,cystitis,NN,B-DISEASE
,in,IN,O
,humans,NNS,O
,must,MD,O
,be,VB,O
,clarified,VBN,O
,by,IN,O
,prospective,JJ,O
,clinical,JJ,O
,trials,NNS,O
,.,.,O
,An,DT,O
,open,JJ,O
,-,:,O
,label,NN,O
,phase,NN,O
,II,NNP,O
,study,NN,O
,of,IN,O
,low,JJ,O
,-,:,O
,dose,NN,O
,thalidomide,NN,O
,in,IN,O
,androgen,NN,O
,-,:,O
,independent,JJ,O
,prostate,NN,B-DISEASE
,cancer,NN,I-DISEASE
,.,.,O
,The,DT,O
,antiangiogenic,JJ,O
,effects,NNS,O
,of,IN,O
,thalidomide,NN,O
,have,VBP,O
,been,VBN,O
,assessed,VBN,O
,in,IN,O
,clinical,JJ,O
,trials,NNS,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,various,JJ,O
,solid,JJ,O
,and,CC,O
,haematological,JJ,B-DISEASE
,malignancies,NNS,I-DISEASE
,.,.,O
,Thalidomide,NN,O
,blocks,VBZ,O
,the,DT,O
,activity,NN,O
,of,IN,O
,angiogenic,JJ,O
,agents,NNS,O
,including,VBG,O
,bFGF,NN,O
,",",",",O
,VEGF,NNP,O
,and,CC,O
,IL,NNP,O
,-,:,O
,6,CD,O
,.,.,O
,We,PRP,O
,undertook,VBD,O
,an,DT,O
,open,JJ,O
,-,:,O
,label,NN,O
,study,NN,O
,using,VBG,O
,thalidomide,JJ,O
,100,CD,O
,mg,NN,O
,once,RB,O
,daily,RB,O
,for,IN,O
,up,IN,O
,to,TO,O
,6,CD,O
,months,NNS,O
,in,IN,O
,20,CD,O
,men,NNS,O
,with,IN,O
,androgen,NN,O
,-,:,O
,independent,JJ,O
,prostate,NN,B-DISEASE
,cancer,NN,I-DISEASE
,.,.,O
,The,DT,O
,mean,JJ,O
,time,NN,O
,of,IN,O
,study,NN,O
,was,VBD,O
,109,CD,O
,days,NNS,O
,(,(,O
,median,JJ,O
,107,CD,O
,",",",",O
,range,NN,O
,4,CD,O
,-,:,O
,184,CD,O
,days,NNS,O
,),),O
,.,.,O
,Patients,NNPS,O
,underwent,JJ,O
,regular,JJ,O
,measurement,NN,O
,of,IN,O
,prostate,NN,O
,-,:,O
,specific,JJ,O
,antigen,NN,O
,(,(,O
,PSA,NNP,O
,),),O
,",",",",O
,urea,JJ,O
,and,CC,O
,electrolytes,NNS,O
,",",",",O
,serum,NN,O
,bFGF,NN,O
,and,CC,O
,VEGF,NNP,O
,.,.,O
,Three,CD,O
,men,NNS,O
,(,(,O
,15,CD,O
,%,NN,O
,),),O
,showed,VBD,O
,a,DT,O
,decline,NN,O
,in,IN,O
,serum,JJ,O
,PSA,NNP,O
,of,IN,O
,at,IN,O
,least,JJS,O
,50,CD,O
,%,NN,O
,",",",",O
,sustained,VBN,O
,throughout,IN,O
,treatment,NN,O
,.,.,O
,Of,IN,O
,16,CD,O
,men,NNS,O
,treated,VBN,O
,for,IN,O
,at,IN,O
,least,JJS,O
,2,CD,O
,months,NNS,O
,",",",",O
,six,CD,O
,(,(,O
,37,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,),),O
,showed,VBD,O
,a,DT,O
,fall,NN,O
,in,IN,O
,absolute,JJ,O
,PSA,NNP,O
,by,IN,O
,a,DT,O
,median,NN,O
,of,IN,O
,48,CD,O
,%,NN,O
,.,.,O
,Increasing,VBG,O
,levels,NNS,O
,of,IN,O
,serum,NN,O
,bFGF,NN,O
,and,CC,O
,VEGF,NNP,O
,were,VBD,O
,associated,VBN,O
,with,IN,O
,progressive,JJ,O
,disease,NN,O
,;,:,O
,five,CD,O
,of,IN,O
,six,CD,O
,men,NNS,O
,who,WP,O
,demonstrated,VBD,O
,a,DT,O
,fall,NN,O
,in,IN,O
,PSA,NNP,O
,also,RB,O
,showed,VBD,O
,a,DT,O
,decline,NN,O
,in,IN,O
,bFGF,NN,O
,and,CC,O
,VEGF,NNP,O
,levels,NNS,O
,",",",",O
,and,CC,O
,three,CD,O
,of,IN,O
,four,CD,O
,men,NNS,O
,with,IN,O
,a,DT,O
,rising,VBG,O
,PSA,NNP,O
,showed,VBD,O
,an,DT,O
,increase,NN,O
,in,IN,O
,both,DT,O
,growth,NN,O
,factors,NNS,O
,.,.,O
,Adverse,JJ,O
,effects,NNS,O
,included,VBD,O
,constipation,NN,B-DISEASE
,",",",",O
,morning,NN,O
,drowsiness,NN,B-DISEASE
,",",",",O
,dizziness,NN,B-DISEASE
,and,CC,O
,rash,NN,B-DISEASE
,",",",",O
,and,CC,O
,resulted,VBD,O
,in,IN,O
,withdrawal,NN,O
,from,IN,O
,the,DT,O
,study,NN,O
,by,IN,O
,three,CD,O
,men,NNS,O
,.,.,O
,Evidence,NN,O
,of,IN,O
,peripheral,JJ,B-DISEASE
,sensory,NN,I-DISEASE
,neuropathy,NN,I-DISEASE
,was,VBD,O
,found,VBN,O
,in,IN,O
,nine,CD,O
,of,IN,O
,13,CD,O
,men,NNS,O
,before,IN,O
,treatment,NN,O
,.,.,O
,In,IN,O
,the,DT,O
,seven,CD,O
,men,NNS,O
,who,WP,O
,completed,VBD,O
,six,CD,O
,months,NNS,O
,on,IN,O
,thalidomide,NN,O
,",",",",O
,subclinical,JJ,O
,evidence,NN,O
,of,IN,O
,peripheral,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,was,VBD,O
,found,VBN,O
,in,IN,O
,four,CD,O
,before,IN,O
,treatment,NN,O
,",",",",O
,but,CC,O
,in,IN,O
,all,DT,O
,seven,CD,O
,at,IN,O
,repeat,NN,O
,testing,VBG,O
,.,.,O
,The,DT,O
,findings,NNS,O
,indicate,VBP,O
,that,IN,O
,thalidomide,NN,O
,may,MD,O
,be,VB,O
,an,DT,O
,option,NN,O
,for,IN,O
,patients,NNS,O
,who,WP,O
,have,VBP,O
,failed,VBN,O
,other,JJ,O
,forms,NNS,O
,of,IN,O
,therapy,NN,O
,",",",",O
,provided,VBD,O
,close,RB,O
,follow,JJ,O
,-,:,O
,up,NN,O
,is,VBZ,O
,maintained,VBN,O
,for,IN,O
,development,NN,O
,of,IN,O
,peripheral,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,.,.,O
,Central,NNP,B-DISEASE
,nervous,JJ,I-DISEASE
,system,NN,I-DISEASE
,toxicity,NN,I-DISEASE
,following,VBG,O
,the,DT,O
,administration,NN,O
,of,IN,O
,levobupivacaine,NN,O
,for,IN,O
,lumbar,NN,O
,plexus,NN,O
,block,NN,O
,:,:,O
,A,DT,O
,report,NN,O
,of,IN,O
,two,CD,O
,cases,NNS,O
,.,.,O
,BACKGROUND,NNP,O
,AND,CC,O
,OBJECTIVES,NNP,O
,:,:,O
,Central,NNP,B-DISEASE
,nervous,JJ,I-DISEASE
,system,NN,I-DISEASE
,and,CC,I-DISEASE
,cardiac,JJ,I-DISEASE
,toxicity,NN,I-DISEASE
,following,VBG,O
,the,DT,O
,administration,NN,O
,of,IN,O
,local,JJ,O
,anesthetics,NNS,O
,is,VBZ,O
,a,DT,O
,recognized,JJ,O
,complication,NN,O
,of,IN,O
,regional,JJ,O
,anesthesia,NN,O
,.,.,O
,Levobupivacaine,NNP,O
,",",",",O
,the,DT,O
,pure,NN,O
,S,NNP,O
,(,(,O
,-,:,O
,),),O
,enantiomer,NN,O
,of,IN,O
,bupivacaine,NN,O
,",",",",O
,was,VBD,O
,developed,VBN,O
,to,TO,O
,improve,VB,O
,the,DT,O
,cardiac,JJ,O
,safety,NN,O
,profile,NN,O
,of,IN,O
,bupivacaine,NN,O
,.,.,O
,We,PRP,O
,describe,VBP,O
,2,CD,O
,cases,NNS,O
,of,IN,O
,grand,JJ,B-DISEASE
,mal,JJ,I-DISEASE
,seizures,NNS,I-DISEASE
,following,VBG,O
,accidental,JJ,O
,intravascular,JJ,O
,injection,NN,O
,of,IN,O
,levobupivacaine,NN,O
,.,.,O
,CASE,NNP,O
,REPORT,NNP,O
,:,:,O
,Two,CD,O
,patients,NNS,O
,presenting,VBG,O
,for,IN,O
,elective,JJ,O
,orthopedic,JJ,O
,surgery,NN,O
,of,IN,O
,the,DT,O
,lower,JJR,O
,limb,NN,O
,underwent,JJ,O
,blockade,NN,O
,of,IN,O
,the,DT,O
,lumbar,NN,O
,plexus,NN,O
,via,IN,O
,the,DT,O
,posterior,JJ,O
,approach,NN,O
,.,.,O
,Immediately,RB,O
,after,IN,O
,the,DT,O
,administration,NN,O
,of,IN,O
,levobupivacaine,JJ,O
,0,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,with,IN,O
,epinephrine,JJ,O
,2,CD,O
,.,.,O
,5,CD,O
,microgram,JJ,O
,/,NNP,O
,mL,NN,O
,",",",",O
,the,DT,O
,patients,NNS,O
,developed,VBD,O
,grand,JJ,B-DISEASE
,mal,NN,I-DISEASE
,seizures,NNS,I-DISEASE
,",",",",O
,despite,IN,O
,negative,JJ,O
,aspiration,NN,O
,for,IN,O
,blood,NN,O
,and,CC,O
,no,DT,O
,clinical,JJ,O
,signs,NNS,O
,of,IN,O
,intravenous,JJ,O
,epinephrine,JJ,O
,administration,NN,O
,.,.,O
,The,DT,O
,seizures,NNS,B-DISEASE
,were,VBD,O
,successfully,RB,O
,treated,VBN,O
,with,IN,O
,sodium,NN,O
,thiopental,NN,O
,in,IN,O
,addition,NN,O
,to,TO,O
,succinylcholine,VB,O
,in,IN,O
,1,CD,O
,patient,NN,O
,.,.,O
,Neither,CC,O
,patient,JJ,O
,developed,JJ,O
,signs,NNS,O
,of,IN,O
,cardiovascular,JJ,B-DISEASE
,toxicity,NN,I-DISEASE
,.,.,O
,Both,DT,O
,patients,NNS,O
,were,VBD,O
,treated,VBN,O
,preoperatively,RB,O
,with,IN,O
,beta,NN,O
,-,:,O
,adrenergic,JJ,O
,antagonist,JJ,O
,medications,NNS,O
,",",",",O
,which,WDT,O
,may,MD,O
,have,VB,O
,masked,VBN,O
,the,DT,O
,cardiovascular,JJ,O
,signs,NNS,O
,of,IN,O
,the,DT,O
,unintentional,JJ,O
,intravascular,JJ,O
,administration,NN,O
,of,IN,O
,levobupivacaine,NN,O
,with,IN,O
,epinephrine,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Although,IN,O
,levobupivacaine,NN,O
,may,MD,O
,have,VB,O
,a,DT,O
,safer,JJR,O
,cardiac,JJ,B-DISEASE
,toxicity,NN,I-DISEASE
,profile,NN,O
,than,IN,O
,racemic,JJ,O
,bupivacaine,NN,O
,",",",",O
,if,IN,O
,adequate,JJ,O
,amounts,NNS,O
,of,IN,O
,levobupivacaine,NN,O
,reach,VBP,O
,the,DT,O
,circulation,NN,O
,",",",",O
,it,PRP,O
,will,MD,O
,result,VB,O
,in,IN,O
,convulsions,NNS,B-DISEASE
,.,.,O
,Plasma,NNP,O
,concentrations,NNS,O
,sufficient,NN,O
,to,TO,O
,result,VB,O
,in,IN,O
,central,JJ,B-DISEASE
,nervous,JJ,I-DISEASE
,system,NN,I-DISEASE
,toxicity,NN,I-DISEASE
,did,VBD,O
,not,RB,O
,produce,VB,O
,manifestations,NNS,O
,of,IN,O
,cardiac,JJ,B-DISEASE
,toxicity,NN,I-DISEASE
,in,IN,O
,these,DT,O
,2,CD,O
,patients,NNS,O
,.,.,O
,Amiodarone,NNP,O
,-,:,O
,induced,VBD,O
,torsade,NN,B-DISEASE
,de,FW,I-DISEASE
,pointes,NNS,I-DISEASE
,during,IN,O
,bladder,NN,O
,irrigation,NN,O
,:,:,O
,an,DT,O
,unusual,JJ,O
,presentation,NN,O
,-,:,O
,-,:,O
,a,DT,O
,case,NN,O
,report,NN,O
,.,.,O
,The,DT,O
,authors,NNS,O
,present,VBP,O
,a,DT,O
,case,NN,O
,of,IN,O
,early,JJ,O
,(,(,O
,within,IN,O
,4,CD,O
,days,NNS,O
,),),O
,development,NN,O
,of,IN,O
,torsade,NN,B-DISEASE
,de,FW,I-DISEASE
,pointes,FW,I-DISEASE
,(,(,O
,TdP,NNP,B-DISEASE
,),),O
,associated,VBN,O
,with,IN,O
,oral,JJ,O
,amiodarone,NN,O
,therapy,NN,O
,.,.,O
,Consistent,JJ,O
,with,IN,O
,other,JJ,O
,reports,NNS,O
,this,DT,O
,case,NN,O
,of,IN,O
,TdP,NNP,B-DISEASE
,occurred,VBD,O
,in,IN,O
,the,DT,O
,context,NN,O
,of,IN,O
,multiple,JJ,O
,exacerbating,VBG,O
,factors,NNS,O
,including,VBG,O
,hypokalemia,NN,B-DISEASE
,and,CC,O
,digoxin,NN,O
,excess,NN,O
,.,.,O
,Transient,JJ,O
,prolongation,NN,O
,of,IN,O
,the,DT,O
,QT,NNP,O
,during,IN,O
,bladder,NN,O
,irrigation,NN,O
,prompted,VBD,O
,the,DT,O
,episode,NN,O
,of,IN,O
,TdP,NNP,B-DISEASE
,.,.,O
,It,PRP,O
,is,VBZ,O
,well,RB,O
,known,VBN,O
,that,IN,O
,bradycardia,NN,B-DISEASE
,exacerbates,NNS,O
,acquired,VBD,O
,TdP,NNP,B-DISEASE
,.,.,O
,The,DT,O
,authors,NNS,O
,speculate,VBP,O
,that,IN,O
,the,DT,O
,increased,JJ,O
,vagal,NN,O
,tone,NN,O
,during,IN,O
,bladder,NN,O
,irrigation,NN,O
,",",",",O
,a,DT,O
,vagal,JJ,O
,maneuver,NN,O
,",",",",O
,in,IN,O
,the,DT,O
,context,NN,O
,of,IN,O
,amiodarone,NN,O
,therapy,NN,O
,resulted,VBD,O
,in,IN,O
,amiodarone,NN,O
,-,:,O
,induced,JJ,O
,proarrhythmia,NN,B-DISEASE
,.,.,O
,In,IN,O
,the,DT,O
,absence,NN,O
,of,IN,O
,amiodarone,NN,O
,therapy,NN,O
,",",",",O
,a,DT,O
,second,JJ,O
,bladder,NN,O
,irrigation,NN,O
,did,VBD,O
,not,RB,O
,induce,VB,O
,TdP,NNP,B-DISEASE
,despite,IN,O
,hypokalemia,NN,B-DISEASE
,and,CC,O
,hypomagnesemia,NN,B-DISEASE
,.,.,O
,Anaesthetic,JJ,O
,complications,NNS,O
,associated,VBN,O
,with,IN,O
,myotonia,NN,B-DISEASE
,congenita,NN,I-DISEASE
,:,:,O
,case,NN,O
,study,NN,O
,and,CC,O
,comparison,NN,O
,with,IN,O
,other,JJ,O
,myotonic,JJ,B-DISEASE
,disorders,NNS,I-DISEASE
,.,.,O
,Myotonia,NNP,B-DISEASE
,congenita,NN,I-DISEASE
,(,(,O
,MC,NNP,B-DISEASE
,),),O
,is,VBZ,O
,caused,VBN,O
,by,IN,O
,a,DT,O
,defect,NN,O
,in,IN,O
,the,DT,O
,skeletal,JJ,O
,muscle,NN,O
,chloride,NN,O
,channel,NN,O
,function,NN,O
,",",",",O
,which,WDT,O
,may,MD,O
,cause,VB,O
,sustained,VBD,B-DISEASE
,membrane,JJ,I-DISEASE
,depolarisation,NN,I-DISEASE
,.,.,O
,We,PRP,O
,describe,VBP,O
,a,DT,O
,previously,RB,O
,healthy,JJ,O
,32,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,who,WP,O
,developed,VBD,O
,a,DT,O
,life,NN,O
,-,:,O
,threatening,JJ,O
,muscle,NN,B-DISEASE
,spasm,NN,I-DISEASE
,and,CC,O
,secondary,JJ,O
,ventilation,NN,O
,difficulties,NNS,O
,following,VBG,O
,a,DT,O
,preoperative,JJ,O
,injection,NN,O
,of,IN,O
,suxamethonium,NN,O
,.,.,O
,The,DT,O
,muscle,NN,B-DISEASE
,spasms,NN,I-DISEASE
,disappeared,VBD,O
,spontaneously,RB,O
,and,CC,O
,the,DT,O
,surgery,NN,O
,proceeded,VBD,O
,without,IN,O
,further,JJ,O
,problems,NNS,O
,.,.,O
,When,WRB,O
,subsequently,RB,O
,questioned,VBN,O
,",",",",O
,she,PRP,O
,reported,VBD,O
,minor,JJ,O
,symptoms,NNS,O
,suggesting,VBG,O
,a,DT,O
,myotonic,JJ,B-DISEASE
,condition,NN,I-DISEASE
,.,.,O
,Myotonia,NNP,B-DISEASE
,was,VBD,O
,found,VBN,O
,on,IN,O
,clinical,JJ,O
,examination,NN,O
,and,CC,O
,EMG,NNP,O
,.,.,O
,The,DT,O
,diagnosis,NN,O
,MC,NNP,B-DISEASE
,was,VBD,O
,confirmed,VBN,O
,genetically,RB,O
,.,.,O
,Neither,CC,O
,the,DT,O
,patient,NN,O
,nor,CC,O
,the,DT,O
,anaesthetist,NN,O
,were,VBD,O
,aware,JJ,O
,of,IN,O
,the,DT,O
,diagnosis,NN,O
,before,IN,O
,this,DT,O
,potentially,RB,O
,lethal,JJ,O
,complication,NN,O
,occurred,VBD,O
,.,.,O
,We,PRP,O
,give,VBP,O
,a,DT,O
,brief,JJ,O
,overview,NN,O
,of,IN,O
,ion,NN,B-DISEASE
,channel,NN,I-DISEASE
,disorders,NNS,I-DISEASE
,including,VBG,O
,malignant,JJ,B-DISEASE
,hyperthermia,NN,I-DISEASE
,and,CC,O
,their,PRP$,O
,anaesthetic,JJ,O
,considerations,NNS,O
,.,.,O
,Respiratory,NNP,O
,pattern,NN,O
,in,IN,O
,a,DT,O
,rat,NN,O
,model,NN,O
,of,IN,O
,epilepsy,NN,B-DISEASE
,.,.,O
,PURPOSE,NN,O
,:,:,O
,Apnea,NNP,B-DISEASE
,is,VBZ,O
,known,VBN,O
,to,TO,O
,occur,VB,O
,during,IN,O
,seizures,NNS,B-DISEASE
,",",",",O
,but,CC,O
,systematic,JJ,O
,studies,NNS,O
,of,IN,O
,ictal,JJ,O
,respiratory,NN,O
,changes,NNS,O
,in,IN,O
,adults,NNS,O
,are,VBP,O
,few,JJ,O
,.,.,O
,Data,NNP,O
,regarding,VBG,O
,respiratory,NN,O
,pattern,NN,O
,defects,NNS,O
,during,IN,O
,interictal,JJ,O
,periods,NNS,O
,also,RB,O
,are,VBP,O
,scarce,JJ,O
,.,.,O
,Here,RB,O
,we,PRP,O
,sought,VBD,O
,to,TO,O
,generate,VB,O
,information,NN,O
,with,IN,O
,regard,NN,O
,to,TO,O
,the,DT,O
,interictal,JJ,O
,period,NN,O
,in,IN,O
,animals,NNS,O
,with,IN,O
,pilocarpine,JJ,O
,-,:,O
,induced,JJ,O
,epilepsy,NN,B-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,Twelve,CD,O
,rats,NNS,O
,(,(,O
,six,CD,O
,chronically,RB,O
,epileptic,JJ,B-DISEASE
,animals,NNS,O
,and,CC,O
,six,CD,O
,controls,NNS,O
,),),O
,were,VBD,O
,anesthetized,VBN,O
,",",",",O
,given,VBN,O
,tracheotomies,NNS,O
,",",",",O
,and,CC,O
,subjected,VBN,O
,to,TO,O
,hyperventilation,NN,B-DISEASE
,or,CC,O
,hypoventilation,NN,O
,conditions,NNS,O
,.,.,O
,Breathing,VBG,O
,movements,NNS,O
,caused,VBN,O
,changes,NNS,O
,in,IN,O
,thoracic,NN,O
,volume,NN,O
,and,CC,O
,forced,VBD,O
,air,NN,O
,to,TO,O
,flow,VB,O
,tidally,RB,O
,through,IN,O
,a,DT,O
,pneumotachograph,NN,O
,.,.,O
,This,DT,O
,flow,NN,O
,was,VBD,O
,measured,VBN,O
,by,IN,O
,using,VBG,O
,a,DT,O
,differential,JJ,O
,pressure,NN,O
,transducer,NN,O
,",",",",O
,passed,VBN,O
,through,IN,O
,a,DT,O
,polygraph,NN,O
,",",",",O
,and,CC,O
,from,IN,O
,this,DT,O
,to,TO,O
,a,DT,O
,computer,NN,O
,with,IN,O
,custom,NN,O
,software,NN,O
,that,WDT,O
,derived,VBD,O
,ventilation,NN,O
,(,(,O
,VE,NNP,O
,),),O
,",",",",O
,tidal,JJ,O
,volume,NN,O
,(,(,O
,VT,NNP,O
,),),O
,",",",",O
,inspiratory,JJ,O
,time,NN,O
,(,(,O
,TI,NNP,O
,),),O
,",",",",O
,expiratory,JJ,O
,time,NN,O
,(,(,O
,TE,NNP,O
,),),O
,",",",",O
,breathing,VBG,O
,frequency,NN,O
,(,(,O
,f,NN,O
,),),O
,",",",",O
,and,CC,O
,mean,JJ,O
,inspiratory,NN,O
,flow,NN,O
,(,(,O
,VT,NNP,O
,/,NNP,O
,TI,NNP,O
,),),O
,on,IN,O
,a,DT,O
,breath,NN,O
,-,:,O
,by,IN,O
,-,:,O
,breath,NN,O
,basis,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,The,DT,O
,hyperventilation,NN,B-DISEASE
,maneuver,NN,O
,caused,VBD,O
,a,DT,O
,decrease,NN,O
,in,IN,O
,spontaneous,JJ,O
,ventilation,NN,O
,in,IN,O
,pilocarpine,JJ,O
,-,:,O
,treated,VBN,O
,and,CC,O
,control,VB,O
,rats,NNS,O
,.,.,O
,Although,IN,O
,VE,NNP,O
,had,VBD,O
,a,DT,O
,similar,JJ,O
,decrease,NN,O
,in,IN,O
,both,DT,O
,groups,NNS,O
,",",",",O
,in,IN,O
,the,DT,O
,epileptic,JJ,B-DISEASE
,group,NN,O
,",",",",O
,the,DT,O
,decrease,NN,O
,in,IN,O
,VE,NNP,O
,was,VBD,O
,due,JJ,O
,to,TO,O
,a,DT,O
,significant,JJ,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,increase,NN,O
,in,IN,O
,TE,NNP,O
,peak,NN,O
,in,IN,O
,relation,NN,O
,to,TO,O
,that,DT,O
,of,IN,O
,the,DT,O
,control,NN,O
,animals,NNS,O
,.,.,O
,The,DT,O
,hypoventilation,NN,O
,maneuver,NN,O
,led,VBD,O
,to,TO,O
,an,DT,O
,increase,NN,O
,in,IN,O
,the,DT,O
,arterial,JJ,O
,Paco2,NNP,O
,",",",",O
,followed,VBN,O
,by,IN,O
,an,DT,O
,increase,NN,O
,in,IN,O
,VE,NNP,O
,.,.,O
,In,IN,O
,the,DT,O
,epileptic,JJ,B-DISEASE
,group,NN,O
,",",",",O
,the,DT,O
,increase,NN,O
,in,IN,O
,VE,NNP,O
,was,VBD,O
,mediated,VBN,O
,by,IN,O
,a,DT,O
,significant,JJ,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,decrease,NN,O
,in,IN,O
,TE,NNP,O
,peak,NN,O
,compared,VBN,O
,with,IN,O
,the,DT,O
,control,NN,O
,group,NN,O
,.,.,O
,Systemic,NNP,O
,application,NN,O
,of,IN,O
,KCN,NNP,O
,",",",",O
,to,TO,O
,evaluate,VB,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,peripheral,JJ,O
,chemoreception,NN,O
,activation,NN,O
,on,IN,O
,ventilation,NN,O
,",",",",O
,led,VBN,O
,to,TO,O
,a,DT,O
,similar,JJ,O
,increase,NN,O
,in,IN,O
,VE,NNP,O
,for,IN,O
,both,DT,O
,groups,NNS,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,The,DT,O
,data,NNS,O
,indicate,VBP,O
,that,IN,O
,pilocarpine,NN,O
,-,:,O
,treated,VBN,O
,animals,NNS,O
,have,VBP,O
,an,DT,O
,altered,JJ,O
,ability,NN,O
,to,TO,O
,react,VB,O
,to,TO,O
,(,(,O
,or,CC,O
,compensate,VB,O
,for,IN,O
,),),O
,blood,NN,O
,gas,NN,O
,changes,NNS,O
,with,IN,O
,changes,NNS,O
,in,IN,O
,ventilation,NN,O
,and,CC,O
,suggest,VBP,O
,that,IN,O
,it,PRP,O
,is,VBZ,O
,centrally,RB,O
,determined,VBN,O
,.,.,O
,We,PRP,O
,speculate,VBP,O
,on,IN,O
,the,DT,O
,possible,JJ,O
,relation,NN,O
,of,IN,O
,the,DT,O
,current,JJ,O
,findings,NNS,O
,on,IN,O
,treating,VBG,O
,different,JJ,O
,epilepsy,NN,B-DISEASE
,-,:,O
,associated,JJ,O
,conditions,NNS,O
,.,.,O
,Fatal,NNP,O
,myeloencephalopathy,JJ,B-DISEASE
,due,JJ,O
,to,TO,O
,intrathecal,JJ,O
,vincristine,NN,O
,administration,NN,O
,.,.,O
,Vincristine,NNP,O
,was,VBD,O
,accidentally,RB,O
,given,VBN,O
,intrathecally,RB,O
,to,TO,O
,a,DT,O
,child,NN,O
,with,IN,O
,leukaemia,NN,B-DISEASE
,",",",",O
,producing,VBG,O
,sensory,NN,B-DISEASE
,and,CC,I-DISEASE
,motor,NN,I-DISEASE
,dysfunction,NN,I-DISEASE
,followed,VBN,O
,by,IN,O
,encephalopathy,JJ,B-DISEASE
,and,CC,O
,death,NN,O
,.,.,O
,Separate,NNP,O
,times,NNS,O
,for,IN,O
,administering,VBG,O
,vincristine,NN,O
,and,CC,O
,intrathecal,JJ,O
,therapy,NN,O
,is,VBZ,O
,recommended,VBN,O
,.,.,O
,Progesterone,NNP,O
,potentiation,NN,O
,of,IN,O
,bupivacaine,JJ,O
,arrhythmogenicity,NN,O
,in,IN,O
,pentobarbital,JJ,O
,-,:,O
,anesthetized,JJ,O
,rats,NNS,O
,and,CC,O
,beating,VBG,O
,rat,JJ,O
,heart,NN,O
,cell,NN,O
,cultures,NNS,O
,.,.,O
,The,DT,O
,effects,NNS,O
,of,IN,O
,progesterone,NN,O
,treatment,NN,O
,on,IN,O
,bupivacaine,NN,O
,arrhythmogenicity,NN,O
,in,IN,O
,beating,VBG,O
,rat,JJ,O
,heart,NN,O
,myocyte,NN,O
,cultures,NNS,O
,and,CC,O
,on,IN,O
,anesthetized,JJ,O
,rats,NNS,O
,were,VBD,O
,determined,VBN,O
,.,.,O
,After,IN,O
,determining,VBG,O
,the,DT,O
,bupivacaine,NN,O
,AD50,NNP,O
,(,(,O
,the,DT,O
,concentration,NN,O
,of,IN,O
,bupivacaine,NN,O
,that,WDT,O
,caused,VBD,O
,50,CD,O
,%,NN,O
,of,IN,O
,all,DT,O
,beating,VBG,O
,rat,JJ,O
,heart,NN,O
,myocyte,NN,O
,cultures,NNS,O
,to,TO,O
,become,VB,O
,arrhythmic,JJ,B-DISEASE
,),),O
,",",",",O
,we,PRP,O
,determined,VBD,O
,the,DT,O
,effect,NN,O
,of,IN,O
,1,CD,O
,-,:,O
,hour,NN,O
,progesterone,NN,O
,HCl,NNP,O
,exposure,NN,O
,on,IN,O
,myocyte,NN,O
,contractile,NN,O
,rhythm,NN,O
,.,.,O
,Each,DT,O
,concentration,NN,O
,of,IN,O
,progesterone,NN,O
,(,(,O
,6,CD,O
,.,.,O
,25,CD,O
,",",",",O
,12,CD,O
,.,.,O
,5,CD,O
,",",",",O
,25,CD,O
,",",",",O
,and,CC,O
,50,CD,O
,micrograms,NNS,O
,/,NNP,O
,ml,NN,O
,),),O
,caused,VBD,O
,a,DT,O
,significant,JJ,O
,and,CC,O
,concentration,NN,O
,-,:,O
,dependent,JJ,O
,reduction,NN,O
,in,IN,O
,the,DT,O
,AD50,NNP,O
,for,IN,O
,bupivacaine,NN,O
,.,.,O
,Estradiol,NNP,O
,treatment,NN,O
,also,RB,O
,increased,VBD,O
,the,DT,O
,arrhythmogenicity,NN,O
,of,IN,O
,bupivacaine,NN,O
,in,IN,O
,myocyte,NN,O
,cultures,NNS,O
,",",",",O
,but,CC,O
,was,VBD,O
,only,RB,O
,one,CD,O
,fourth,JJ,O
,as,RB,O
,potent,NN,O
,as,IN,O
,progesterone,NN,O
,.,.,O
,Neither,CC,O
,progesterone,JJ,O
,nor,CC,O
,estradiol,JJ,O
,effects,NNS,O
,on,IN,O
,bupivacaine,NN,O
,arrhythmogenicity,NN,O
,were,VBD,O
,potentiated,VBN,O
,by,IN,O
,epinephrine,NN,O
,.,.,O
,Chronic,NNP,O
,progesterone,NN,O
,pretreatment,NN,O
,(,(,O
,5,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,/,NNP,O
,day,NN,O
,for,IN,O
,21,CD,O
,days,NNS,O
,),),O
,caused,VBD,O
,a,DT,O
,significant,JJ,O
,increase,NN,O
,in,IN,O
,bupivacaine,JJ,O
,arrhythmogenicity,NN,O
,in,IN,O
,intact,JJ,O
,pentobarbital,JJ,O
,-,:,O
,anesthetized,JJ,O
,rats,NNS,O
,.,.,O
,There,EX,O
,was,VBD,O
,a,DT,O
,significant,JJ,O
,decrease,NN,O
,in,IN,O
,the,DT,O
,time,NN,O
,to,TO,O
,onset,VB,O
,of,IN,O
,arrhythmia,NN,B-DISEASE
,as,IN,O
,compared,VBN,O
,with,IN,O
,control,NN,O
,nonprogesterone,CD,O
,-,:,O
,treated,VBN,O
,rats,NNS,O
,(,(,O
,6,CD,O
,.,.,O
,2,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,3,CD,O
,vs,NN,O
,.,.,O
,30,CD,O
,.,.,O
,8,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,2,CD,O
,.,.,O
,5,CD,O
,min,NN,O
,",",",",O
,mean,JJ,O
,+,NNP,O
,/,NNP,O
,-,:,O
,SE,NN,O
,),),O
,.,.,O
,The,DT,O
,results,NNS,O
,of,IN,O
,this,DT,O
,study,NN,O
,indicate,VBP,O
,that,IN,O
,progesterone,NN,O
,can,MD,O
,potentiate,VB,O
,bupivacaine,JJ,O
,arrhythmogenicity,NN,O
,both,DT,O
,in,IN,O
,vivo,NN,O
,and,CC,O
,in,IN,O
,vitro,NN,O
,.,.,O
,Potentiation,NN,O
,of,IN,O
,bupivacaine,NN,O
,arrhythmia,NN,B-DISEASE
,in,IN,O
,myocyte,NN,O
,cultures,NNS,O
,suggests,VBZ,O
,that,IN,O
,this,DT,O
,effect,NN,O
,is,VBZ,O
,at,IN,O
,least,JJS,O
,partly,RB,O
,mediated,VBN,O
,at,IN,O
,the,DT,O
,myocyte,NN,O
,level,NN,O
,.,.,O
,Increased,VBN,O
,serum,NN,O
,soluble,JJ,O
,Fas,NNP,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,acute,JJ,B-DISEASE
,liver,NN,I-DISEASE
,failure,NN,I-DISEASE
,due,JJ,O
,to,TO,O
,paracetamol,VB,O
,overdose,RB,B-DISEASE
,.,.,O
,BACKGROUND,NNP,O
,/,VBD,O
,AIMS,NNP,O
,:,:,O
,Experimental,JJ,O
,studies,NNS,O
,have,VBP,O
,suggested,VBN,O
,that,IN,O
,apoptosis,NN,O
,via,IN,O
,the,DT,O
,Fas,NNP,O
,/,NNP,O
,Fas,NNP,O
,Ligand,NNP,O
,signaling,VBG,O
,system,NN,O
,may,MD,O
,play,VB,O
,an,DT,O
,important,JJ,O
,role,NN,O
,in,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,acute,NN,B-DISEASE
,liver,NN,I-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,The,DT,O
,aim,NN,O
,of,IN,O
,the,DT,O
,study,NN,O
,was,VBD,O
,to,TO,O
,investigate,VB,O
,the,DT,O
,soluble,JJ,O
,form,NN,O
,of,IN,O
,Fas,NNP,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,acute,JJ,B-DISEASE
,liver,NN,I-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,METHODOLOGY,NN,O
,:,:,O
,Serum,NNP,O
,levels,NNS,O
,of,IN,O
,sFas,NN,O
,(,(,O
,soluble,JJ,O
,Fas,NNP,O
,),),O
,were,VBD,O
,measured,VBN,O
,by,IN,O
,ELISA,NNP,O
,in,IN,O
,24,CD,O
,patients,NNS,O
,with,IN,O
,acute,JJ,B-DISEASE
,liver,NN,I-DISEASE
,failure,NN,I-DISEASE
,and,CC,O
,10,CD,O
,normal,JJ,O
,control,NN,O
,subjects,NNS,O
,.,.,O
,Serum,NNP,O
,levels,NNS,O
,of,IN,O
,tumor,NN,B-DISEASE
,necrosis,NN,B-DISEASE
,factor,NN,O
,-,:,O
,alpha,NN,O
,and,CC,O
,interferon,NN,O
,-,:,O
,gamma,NN,O
,were,VBD,O
,also,RB,O
,determined,VBN,O
,by,IN,O
,ELISA,NNP,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Serum,NNP,O
,sFas,NN,O
,was,VBD,O
,significantly,RB,O
,increased,VBN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,acute,JJ,B-DISEASE
,liver,NN,I-DISEASE
,failure,NN,I-DISEASE
,(,(,O
,median,JJ,O
,",",",",O
,26,CD,O
,.,.,O
,8,CD,O
,U,NNP,O
,/,NNP,O
,mL,NN,O
,;,:,O
,range,NN,O
,",",",",O
,6,CD,O
,.,.,O
,9,CD,O
,-,:,O
,52,CD,O
,.,.,O
,7,CD,O
,U,NNP,O
,/,NNP,O
,mL,NN,O
,),),O
,compared,VBN,O
,to,TO,O
,the,DT,O
,normal,JJ,O
,controls,NNS,O
,(,(,O
,median,JJ,O
,",",",",O
,8,CD,O
,.,.,O
,6,CD,O
,U,NNP,O
,/,NNP,O
,mL,NN,O
,;,:,O
,range,NN,O
,",",",",O
,6,CD,O
,.,.,O
,5,CD,O
,-,:,O
,12,CD,O
,.,.,O
,0,CD,O
,U,NNP,O
,/,NNP,O
,mL,NN,O
,",",",",O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,0001,CD,O
,),),O
,.,.,O
,Levels,NNS,O
,were,VBD,O
,significantly,RB,O
,greater,JJR,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,acute,JJ,B-DISEASE
,liver,NN,I-DISEASE
,failure,NN,I-DISEASE
,due,JJ,O
,to,TO,O
,paracetamol,VB,O
,overdose,JJ,B-DISEASE
,(,(,O
,median,JJ,O
,",",",",O
,28,CD,O
,.,.,O
,7,CD,O
,U,NNP,O
,/,NNP,O
,mL,NN,O
,;,:,O
,range,NN,O
,",",",",O
,12,CD,O
,.,.,O
,8,CD,O
,-,:,O
,52,CD,O
,.,.,O
,7,CD,O
,U,NNP,O
,/,NNP,O
,mL,NN,O
,",",",",O
,n,JJ,O
,=,NNP,O
,17,CD,O
,),),O
,than,IN,O
,those,DT,O
,due,JJ,O
,to,TO,O
,non,VB,O
,-,:,O
,A,DT,O
,to,TO,O
,E,NNP,O
,hepatitis,NN,B-DISEASE
,(,(,O
,median,JJ,O
,",",",",O
,12,CD,O
,.,.,O
,5,CD,O
,U,NNP,O
,/,NNP,O
,mL,NN,O
,;,:,O
,range,NN,O
,",",",",O
,6,CD,O
,.,.,O
,9,CD,O
,-,:,O
,46,CD,O
,.,.,O
,0,CD,O
,U,NNP,O
,/,NNP,O
,mL,NN,O
,",",",",O
,n,JJ,O
,=,NN,O
,7,CD,O
,",",",",O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,There,EX,O
,was,VBD,O
,no,DT,O
,relationship,NN,O
,of,IN,O
,sFas,NN,O
,to,TO,O
,eventual,JJ,O
,outcome,NN,O
,in,IN,O
,the,DT,O
,patients,NNS,O
,.,.,O
,A,DT,O
,significant,JJ,O
,correlation,NN,O
,was,VBD,O
,observed,VBN,O
,between,IN,O
,serum,NN,O
,sFas,NN,O
,levels,NNS,O
,and,CC,O
,aspartate,VB,O
,aminotransferase,NN,O
,(,(,O
,r,JJ,O
,=,NN,O
,0,CD,O
,.,.,O
,613,CD,O
,",",",",O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,The,DT,O
,increased,JJ,O
,concentration,NN,O
,of,IN,O
,sFas,NN,O
,in,IN,O
,serum,NN,O
,of,IN,O
,patients,NNS,O
,with,IN,O
,acute,JJ,B-DISEASE
,liver,JJ,I-DISEASE
,failure,NN,I-DISEASE
,may,MD,O
,reflect,VB,O
,activation,NN,O
,of,IN,O
,Fas,NNP,O
,-,:,O
,mediated,VBD,O
,apoptosis,NN,O
,in,IN,O
,the,DT,O
,liver,NN,O
,and,CC,O
,this,DT,O
,together,RB,O
,with,IN,O
,increased,JJ,O
,tumor,NN,B-DISEASE
,necrosis,NN,B-DISEASE
,factor,NN,O
,-,:,O
,alpha,NN,O
,may,MD,O
,be,VB,O
,an,DT,O
,important,JJ,O
,factor,NN,O
,in,IN,O
,liver,NN,O
,cell,NN,O
,loss,NN,O
,.,.,O
,Bilateral,JJ,O
,subthalamic,JJ,O
,nucleus,NN,O
,stimulation,NN,O
,for,IN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,High,JJ,O
,frequency,NN,O
,stimulation,NN,O
,of,IN,O
,the,DT,O
,subthalamic,JJ,O
,nucleus,NN,O
,(,(,O
,STN,NNP,O
,),),O
,is,VBZ,O
,known,VBN,O
,to,TO,O
,ameliorate,VB,O
,the,DT,O
,signs,NNS,O
,and,CC,O
,symptoms,NNS,O
,of,IN,O
,advanced,JJ,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,AIM,CC,O
,:,:,O
,We,PRP,O
,studied,VBD,O
,the,DT,O
,effect,NN,O
,of,IN,O
,high,JJ,O
,frequency,NN,O
,STN,NNP,O
,stimulation,NN,O
,in,IN,O
,23,CD,O
,patients,NNS,O
,.,.,O
,METHOD,NNP,O
,:,:,O
,Twenty,CD,O
,-,:,O
,three,CD,O
,patients,NNS,O
,suffering,VBG,O
,from,IN,O
,severe,JJ,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,NN,I-DISEASE
,disease,NN,I-DISEASE
,(,(,O
,Stages,NNP,O
,III,NNP,O
,-,:,O
,V,NN,O
,on,IN,O
,Hoehn,NNP,O
,and,CC,O
,Yahr,NNP,O
,scale,NN,O
,),),O
,and,CC,O
,",",",",O
,particularly,RB,O
,bradykinesia,NN,B-DISEASE
,",",",",O
,rigidity,NN,B-DISEASE
,",",",",O
,and,CC,O
,levodopa,SYM,O
,-,:,O
,induced,JJ,O
,dyskinesias,JJ,B-DISEASE
,underwent,JJ,O
,bilateral,JJ,O
,implantation,NN,O
,of,IN,O
,electrodes,NNS,O
,in,IN,O
,the,DT,O
,STN,NNP,O
,.,.,O
,Preoperative,NNP,O
,and,CC,O
,postoperative,JJ,O
,assessments,NNS,O
,of,IN,O
,these,DT,O
,patients,NNS,O
,at,IN,O
,1,CD,O
,",",",",O
,3,CD,O
,",",",",O
,6,CD,O
,and,CC,O
,12,CD,O
,months,NNS,O
,follow,VBP,O
,-,:,O
,up,RB,O
,",",",",O
,in,IN,O
,"""",NN,O
,on,IN,O
,"""",NN,O
,and,CC,O
,"""",VB,O
,off,RP,O
,"""",JJ,O
,drug,NN,O
,conditions,NNS,O
,",",",",O
,was,VBD,O
,carried,VBN,O
,out,RP,O
,using,VBG,O
,Unified,NNP,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,Disease,NNP,I-DISEASE
,Rating,NNP,O
,Scale,NNP,O
,",",",",O
,Hoehn,NNP,O
,and,CC,O
,Yahr,NNP,O
,staging,NN,O
,",",",",O
,England,NNP,O
,activities,NNS,O
,of,IN,O
,daily,JJ,O
,living,VBG,O
,score,NN,O
,and,CC,O
,video,NN,O
,recordings,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,After,IN,O
,one,CD,O
,year,NN,O
,of,IN,O
,electrical,JJ,O
,stimulation,NN,O
,of,IN,O
,the,DT,O
,STN,NNP,O
,",",",",O
,the,DT,O
,patients,NNS,O
,',POS,O
,scores,NNS,O
,for,IN,O
,activities,NNS,O
,of,IN,O
,daily,JJ,O
,living,NN,O
,and,CC,O
,motor,NN,O
,examination,NN,O
,scores,NNS,O
,(,(,O
,Unified,NNP,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,Disease,NNP,I-DISEASE
,Rating,NNP,O
,Scale,NNP,O
,parts,NNS,O
,II,NNP,O
,and,CC,O
,III,NNP,O
,),),O
,off,IN,O
,medication,NN,O
,improved,VBN,O
,by,IN,O
,62,CD,O
,%,NN,O
,and,CC,O
,61,CD,O
,%,NN,O
,respectively,RB,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,0005,CD,O
,),),O
,.,.,O
,The,DT,O
,subscores,NNS,O
,for,IN,O
,the,DT,O
,akinesia,NN,B-DISEASE
,",",",",O
,rigidity,NN,B-DISEASE
,",",",",O
,tremor,NN,B-DISEASE
,and,CC,O
,gait,NN,O
,also,RB,O
,improved,VBN,O
,.,.,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,0005,CD,O
,),),O
,.,.,O
,The,DT,O
,average,JJ,O
,levodopa,NN,O
,dose,NN,O
,decreased,VBN,O
,from,IN,O
,813,CD,O
,mg,NNS,O
,to,TO,O
,359,CD,O
,mg,NN,O
,.,.,O
,The,DT,O
,cognitive,JJ,O
,functions,NNS,O
,remained,VBD,O
,unchanged,JJ,O
,.,.,O
,Two,CD,O
,patients,NNS,O
,developed,VBD,O
,device,SYM,O
,-,:,O
,related,JJ,O
,complications,NNS,O
,and,CC,O
,two,CD,O
,patients,NNS,O
,experienced,VBD,O
,abnormal,JJ,O
,weight,NN,O
,gain,NN,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Bilateral,JJ,O
,subthalamic,JJ,O
,nucleus,JJ,O
,stimulation,NN,O
,is,VBZ,O
,an,DT,O
,effective,JJ,O
,treatment,NN,O
,for,IN,O
,advanced,JJ,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,It,PRP,O
,reduces,VBZ,O
,the,DT,O
,severity,NN,O
,of,IN,O
,"""",NNP,O
,off,IN,O
,"""",NNP,O
,phase,NN,O
,symptoms,NNS,O
,",",",",O
,improves,VBZ,O
,the,DT,O
,axial,JJ,O
,symptoms,NNS,O
,and,CC,O
,reduces,NNS,O
,levodopa,JJ,O
,requirements,NNS,O
,.,.,O
,The,DT,O
,reduction,NN,O
,in,IN,O
,the,DT,O
,levodopa,NN,O
,dose,NN,O
,is,VBZ,O
,useful,JJ,O
,in,IN,O
,controlling,VBG,O
,drug,NN,B-DISEASE
,-,:,I-DISEASE
,induced,JJ,I-DISEASE
,dyskinesias,NN,I-DISEASE
,.,.,O
,Acute,NNP,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,occurring,VBG,O
,during,IN,O
,intravenous,JJ,O
,desferrioxamine,JJ,O
,therapy,NN,O
,:,:,O
,recovery,NN,O
,after,IN,O
,haemodialysis,NN,O
,.,.,O
,A,DT,O
,patient,NN,O
,with,IN,O
,transfusion,NN,O
,-,:,O
,dependent,NN,O
,thalassemia,NN,B-DISEASE
,was,VBD,O
,undergoing,JJ,O
,home,NN,O
,intravenous,JJ,O
,desferrioxamine,NN,O
,(,(,O
,DFX,NNP,O
,),),O
,treatment,NN,O
,by,IN,O
,means,NNS,O
,of,IN,O
,a,DT,O
,totally,RB,O
,implanted,JJ,O
,system,NN,O
,because,IN,O
,of,IN,O
,his,PRP$,O
,poor,JJ,O
,compliance,NN,O
,with,IN,O
,the,DT,O
,nightly,RB,O
,subcutaneous,JJ,O
,therapy,NN,O
,.,.,O
,Due,NNP,O
,to,TO,O
,an,DT,O
,accidental,JJ,O
,malfunctioning,NN,O
,of,IN,O
,the,DT,O
,infusion,NN,O
,pump,NN,O
,",",",",O
,the,DT,O
,patient,NN,O
,was,VBD,O
,inadvertently,RB,O
,administered,VBN,O
,a,DT,O
,toxic,JJ,O
,dosage,NN,O
,of,IN,O
,the,DT,O
,drug,NN,O
,which,WDT,O
,caused,VBD,O
,renal,JJ,B-DISEASE
,insufficiency,NN,I-DISEASE
,.,.,O
,Given,VBN,O
,the,DT,O
,progressive,JJ,O
,deterioration,NN,O
,of,IN,O
,the,DT,O
,symptoms,NNS,O
,and,CC,O
,of,IN,O
,the,DT,O
,laboratory,NN,O
,values,NNS,O
,",",",",O
,despite,IN,O
,adequate,JJ,O
,medical,JJ,O
,treatment,NN,O
,",",",",O
,a,DT,O
,decision,NN,O
,was,VBD,O
,made,VBN,O
,to,TO,O
,introduce,VB,O
,haemodialytical,JJ,O
,therapy,NN,O
,in,IN,O
,order,NN,O
,to,TO,O
,remove,VB,O
,the,DT,O
,drug,NN,O
,and,CC,O
,therapy,NN,O
,reduce,VB,O
,the,DT,O
,nephrotoxicity,NN,B-DISEASE
,.,.,O
,From,IN,O
,the,DT,O
,results,NNS,O
,obtained,VBD,O
,",",",",O
,haemodialysis,NN,O
,can,MD,O
,therefore,RB,O
,be,VB,O
,suggested,VBN,O
,as,IN,O
,a,DT,O
,useful,JJ,O
,therapy,NN,O
,in,IN,O
,rare,JJ,O
,cases,NNS,O
,of,IN,O
,progressive,JJ,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,caused,VBN,O
,by,IN,O
,desferrioxamine,NN,O
,.,.,O
,Ocular,JJ,O
,motility,NN,O
,changes,NNS,O
,after,IN,O
,subtenon,NN,O
,carboplatin,NN,O
,chemotherapy,NN,O
,for,IN,O
,retinoblastoma,NN,B-DISEASE
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Focal,JJ,O
,subtenon,NN,O
,carboplatin,NN,O
,injections,NNS,O
,have,VBP,O
,recently,RB,O
,been,VBN,O
,used,VBN,O
,as,IN,O
,a,DT,O
,presumably,NN,O
,toxicity,NN,B-DISEASE
,-,:,O
,free,JJ,O
,adjunct,NN,O
,to,TO,O
,systemic,VB,O
,chemotherapy,NN,O
,for,IN,O
,intraocular,JJ,O
,retinoblastoma,NN,B-DISEASE
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,To,TO,O
,report,VB,O
,our,PRP$,O
,clinical,JJ,O
,experience,NN,O
,with,IN,O
,abnormal,JJ,B-DISEASE
,ocular,JJ,I-DISEASE
,motility,NN,I-DISEASE
,in,IN,O
,patients,NNS,O
,treated,VBN,O
,with,IN,O
,subtenon,NN,O
,carboplatin,NN,O
,chemotherapy,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,We,PRP,O
,noted,VBD,O
,abnormal,JJ,B-DISEASE
,ocular,JJ,I-DISEASE
,motility,NN,I-DISEASE
,in,IN,O
,10,CD,O
,consecutive,JJ,O
,patients,NNS,O
,with,IN,O
,retinoblastoma,NN,B-DISEASE
,who,WP,O
,had,VBD,O
,received,VBN,O
,subtenon,JJ,O
,carboplatin,NN,O
,.,.,O
,During,IN,O
,ocular,JJ,O
,manipulation,NN,O
,under,IN,O
,general,JJ,O
,anesthesia,NN,O
,",",",",O
,we,PRP,O
,assessed,VBD,O
,their,PRP$,O
,eyes,NNS,O
,by,IN,O
,forced,JJ,O
,duction,NN,O
,testing,NN,O
,",",",",O
,comparing,VBG,O
,ocular,JJ,O
,motility,NN,O
,after,IN,O
,tumor,NN,B-DISEASE
,control,NN,O
,with,IN,O
,ocular,JJ,O
,motility,NN,O
,at,IN,O
,diagnosis,NN,O
,.,.,O
,Eyes,NNS,O
,subsequently,RB,O
,enucleated,VBD,O
,because,IN,O
,of,IN,O
,treatment,NN,O
,failure,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,4,CD,O
,),),O
,were,VBD,O
,examined,VBN,O
,histologically,RB,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Limitation,NN,O
,of,IN,O
,ocular,JJ,O
,motility,NN,O
,was,VBD,O
,detected,VBN,O
,in,IN,O
,all,DT,O
,12,CD,O
,eyes,NNS,O
,of,IN,O
,10,CD,O
,patients,NNS,O
,treated,VBN,O
,for,IN,O
,intraocular,JJ,O
,retinoblastoma,NN,B-DISEASE
,with,IN,O
,1,CD,O
,to,TO,O
,6,CD,O
,injections,NNS,O
,of,IN,O
,subtenon,NN,O
,carboplatin,NN,O
,as,IN,O
,part,NN,O
,of,IN,O
,multimodality,NN,O
,therapy,NN,O
,.,.,O
,Histopathological,JJ,O
,examination,NN,O
,revealed,VBD,O
,many,JJ,O
,lipophages,NNS,O
,in,IN,O
,the,DT,O
,periorbital,JJ,O
,fat,NN,O
,surrounding,VBG,O
,the,DT,O
,optic,JJ,O
,nerve,NN,O
,in,IN,O
,1,CD,O
,eye,NN,O
,",",",",O
,indicative,JJ,O
,of,IN,O
,phagocytosis,NN,O
,of,IN,O
,previously,RB,O
,existing,VBG,O
,fat,JJ,O
,cells,NNS,O
,and,CC,O
,suggesting,VBG,O
,prior,JJ,O
,fat,JJ,O
,necrosis,NN,B-DISEASE
,.,.,O
,The,DT,O
,enucleations,NNS,O
,were,VBD,O
,technically,RB,O
,difficult,JJ,O
,and,CC,O
,hazardous,JJ,O
,for,IN,O
,globe,NN,O
,rupture,NN,B-DISEASE
,because,IN,O
,of,IN,O
,extensive,JJ,O
,orbital,JJ,O
,soft,JJ,O
,tissue,NN,O
,adhesions,NNS,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Subtenon,NNP,O
,carboplatin,NN,O
,chemotherapy,NN,O
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,significant,JJ,O
,fibrosis,NN,B-DISEASE
,of,IN,O
,orbital,JJ,O
,soft,JJ,O
,tissues,NNS,O
,",",",",O
,leading,VBG,O
,to,TO,O
,mechanical,JJ,O
,restriction,NN,O
,of,IN,O
,eye,NN,O
,movements,NNS,O
,and,CC,O
,making,VBG,O
,subsequent,JJ,O
,enucleation,NN,O
,difficult,JJ,O
,.,.,O
,Subtenon,NNP,O
,carboplatin,NN,O
,is,VBZ,O
,not,RB,O
,free,JJ,O
,of,IN,O
,toxicity,NN,B-DISEASE
,",",",",O
,and,CC,O
,its,PRP$,O
,use,NN,O
,is,VBZ,O
,best,RB,O
,restricted,VBN,O
,to,TO,O
,specific,JJ,O
,indications,NNS,O
,.,.,O
,Ethambutol,NNP,O
,and,CC,O
,optic,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,.,.,O
,PURPOSE,NN,O
,:,:,O
,To,TO,O
,demonstrate,VB,O
,the,DT,O
,association,NN,O
,between,IN,O
,ethambutol,NN,O
,and,CC,O
,optic,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,.,.,O
,METHOD,NN,O
,:,:,O
,Thirteen,JJ,O
,patients,NNS,O
,who,WP,O
,developed,VBD,O
,optic,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,after,IN,O
,being,VBG,O
,treated,VBN,O
,with,IN,O
,ethambutol,NN,O
,for,IN,O
,tuberculosis,NN,B-DISEASE
,of,IN,I-DISEASE
,the,DT,I-DISEASE
,lung,NN,I-DISEASE
,or,CC,I-DISEASE
,lymph,NN,I-DISEASE
,node,NN,I-DISEASE
,at,IN,O
,Siriraj,NNP,O
,Hospital,NNP,O
,between,IN,O
,1997,CD,O
,and,CC,O
,2001,CD,O
,were,VBD,O
,retrospectively,RB,O
,reviewed,VBN,O
,.,.,O
,The,DT,O
,clinical,JJ,O
,characteristics,NNS,O
,and,CC,O
,initial,JJ,O
,and,CC,O
,final,JJ,O
,visual,JJ,O
,acuity,NN,O
,were,VBD,O
,analyzed,VBN,O
,to,TO,O
,determine,VB,O
,visual,JJ,O
,outcome,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,All,DT,O
,patients,NNS,O
,had,VBD,O
,optic,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,between,IN,O
,1,CD,O
,to,TO,O
,6,CD,O
,months,NNS,O
,(,(,O
,mean,JJ,O
,=,NN,O
,2,CD,O
,.,.,O
,9,CD,O
,months,NNS,O
,),),O
,after,IN,O
,starting,VBG,O
,ethambutol,JJ,O
,therapy,NN,O
,at,IN,O
,a,DT,O
,dosage,NN,O
,ranging,VBG,O
,from,IN,O
,13,CD,O
,to,TO,O
,20,CD,O
,mg,NNS,O
,/,JJ,O
,kg,JJ,O
,/,JJ,O
,day,NN,O
,(,(,O
,mean,JJ,O
,=,VBP,O
,17,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,/,NNP,O
,day,NN,O
,),),O
,.,.,O
,Seven,NNP,O
,(,(,O
,54,CD,O
,%,NN,O
,),),O
,of,IN,O
,the,DT,O
,13,CD,O
,patients,NNS,O
,experienced,VBD,O
,visual,JJ,O
,recovery,NN,O
,after,IN,O
,stopping,VBG,O
,the,DT,O
,drug,NN,O
,.,.,O
,Of,IN,O
,6,CD,O
,patients,NNS,O
,with,IN,O
,irreversible,JJ,O
,visual,JJ,B-DISEASE
,impairment,NN,I-DISEASE
,",",",",O
,4,CD,O
,patients,NNS,O
,had,VBD,O
,diabetes,NNS,B-DISEASE
,mellitus,NNS,I-DISEASE
,",",",",O
,glaucoma,NN,B-DISEASE
,and,CC,O
,a,DT,O
,history,NN,O
,of,IN,O
,heavy,JJ,O
,smoking,NN,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Early,JJ,O
,recognition,NN,O
,of,IN,O
,optic,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,should,MD,O
,be,VB,O
,considered,VBN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,ethambutol,JJ,O
,therapy,NN,O
,.,.,O
,A,DT,O
,low,JJ,O
,dose,NN,O
,and,CC,O
,prompt,JJ,O
,discontinuation,NN,O
,of,IN,O
,the,DT,O
,drug,NN,O
,is,VBZ,O
,recommended,VBN,O
,particularly,RB,O
,in,IN,O
,individuals,NNS,O
,with,IN,O
,diabetes,NNS,B-DISEASE
,mellitus,NNS,I-DISEASE
,",",",",O
,glaucoma,NN,B-DISEASE
,or,CC,O
,who,WP,O
,are,VBP,O
,heavy,JJ,O
,smokers,NNS,O
,.,.,O
,Treatment,NN,O
,of,IN,O
,compensatory,JJ,O
,gustatory,JJ,B-DISEASE
,hyperhidrosis,NN,I-DISEASE
,with,IN,O
,topical,JJ,O
,glycopyrrolate,NN,O
,.,.,O
,Gustatory,NNP,B-DISEASE
,hyperhidrosis,NN,I-DISEASE
,is,VBZ,O
,facial,JJ,O
,sweating,VBG,B-DISEASE
,usually,RB,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,eating,NN,O
,of,IN,O
,hot,JJ,O
,spicy,NN,O
,food,NN,O
,or,CC,O
,even,RB,O
,smelling,VBG,O
,this,DT,O
,food,NN,O
,.,.,O
,Current,NNP,O
,options,NNS,O
,of,IN,O
,treatment,NN,O
,include,VBP,O
,oral,JJ,O
,anticholinergic,JJ,O
,drugs,NNS,O
,",",",",O
,the,DT,O
,topical,JJ,O
,application,NN,O
,of,IN,O
,anticholinergics,NNS,O
,or,CC,O
,aluminum,NN,O
,chloride,NN,O
,",",",",O
,and,CC,O
,the,DT,O
,injection,NN,O
,of,IN,O
,botulinum,NN,O
,toxin,NN,O
,.,.,O
,Thirteen,JJ,O
,patients,NNS,O
,have,VBP,O
,been,VBN,O
,treated,VBN,O
,to,TO,O
,date,NN,O
,with,IN,O
,1,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,or,CC,O
,2,CD,O
,%,NN,O
,topical,JJ,O
,glycopyrrolate,NN,O
,.,.,O
,All,DT,O
,patients,NNS,O
,had,VBD,O
,gustatory,JJ,B-DISEASE
,hyperhidrosis,NN,I-DISEASE
,",",",",O
,which,WDT,O
,interfered,VBD,O
,with,IN,O
,their,PRP$,O
,social,JJ,O
,activities,NNS,O
,",",",",O
,after,IN,O
,transthroacic,JJ,O
,endoscopic,NN,O
,sympathectomy,NN,O
,",",",",O
,and,CC,O
,which,WDT,O
,was,VBD,O
,associated,VBN,O
,with,IN,O
,compensatory,JJ,O
,focal,JJ,O
,hyperhidrosis,NN,B-DISEASE
,.,.,O
,After,IN,O
,applying,VBG,O
,topical,JJ,O
,glycopyrrolate,NN,O
,",",",",O
,the,DT,O
,subjective,JJ,O
,effect,NN,O
,was,VBD,O
,excellent,JJ,O
,(,(,O
,no,DT,O
,sweating,NN,B-DISEASE
,after,IN,O
,eating,VBG,O
,hot,JJ,O
,spicy,NN,O
,food,NN,O
,),),O
,in,IN,O
,10,CD,O
,patients,NNS,O
,(,(,O
,77,CD,O
,%,NN,O
,),),O
,",",",",O
,and,CC,O
,fair,NN,O
,(,(,O
,clearly,RB,O
,reduced,VBN,O
,sweating,VBG,B-DISEASE
,),),O
,in,IN,O
,3,CD,O
,patients,NNS,O
,(,(,O
,23,CD,O
,%,NN,O
,),),O
,.,.,O
,All,DT,O
,had,VBD,O
,reported,VBN,O
,incidents,NNS,O
,of,IN,O
,being,VBG,O
,very,RB,O
,embarrassed,JJ,O
,whilst,NN,O
,eating,VBG,O
,hot,JJ,O
,spicy,NN,O
,foods,NNS,O
,.,.,O
,Adverse,JJ,O
,effects,NNS,O
,included,VBD,O
,a,DT,O
,mildly,RB,O
,dry,JJ,B-DISEASE
,mouth,NN,I-DISEASE
,and,CC,O
,a,DT,O
,sore,NN,B-DISEASE
,throat,NN,I-DISEASE
,in,IN,O
,2,CD,O
,patients,NNS,O
,(,(,O
,2,CD,O
,%,NN,O
,glycopyrrolate,NN,O
,),),O
,",",",",O
,a,DT,O
,light,JJ,O
,headache,NN,B-DISEASE
,in,IN,O
,1,CD,O
,patient,NN,O
,(,(,O
,1,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,glycopyrrolate,NN,O
,),),O
,.,.,O
,The,DT,O
,topical,JJ,O
,application,NN,O
,of,IN,O
,a,DT,O
,glycopyrrolate,NN,O
,pad,NN,O
,appeared,VBD,O
,to,TO,O
,be,VB,O
,safe,JJ,O
,",",",",O
,efficacious,JJ,O
,",",",",O
,well,RB,O
,tolerated,VBN,O
,",",",",O
,and,CC,O
,a,DT,O
,convenient,JJ,O
,method,NN,O
,of,IN,O
,treatment,NN,O
,for,IN,O
,moderate,JJ,O
,to,TO,O
,severe,VB,O
,symptoms,NNS,O
,of,IN,O
,gustatory,JJ,B-DISEASE
,hyperhidrosis,NN,I-DISEASE
,in,IN,O
,post,NN,O
,transthoracic,NN,O
,endoscopic,NN,O
,sympathectomy,NN,O
,or,CC,O
,sympathicotomy,NN,O
,patients,NNS,O
,",",",",O
,with,IN,O
,few,JJ,O
,side,NN,O
,effects,NNS,O
,.,.,O
,Neuroleptic,JJ,O
,-,:,O
,associated,VBN,O
,hyperprolactinemia,NN,B-DISEASE
,.,.,O
,Can,VB,O
,it,PRP,O
,be,VB,O
,treated,VBN,O
,with,IN,O
,bromocriptine,NN,O
,?,.,O
,Six,NNP,O
,stable,JJ,O
,psychiatric,JJ,O
,outpatients,NNS,O
,with,IN,O
,hyperprolactinemia,NN,B-DISEASE
,and,CC,O
,amenorrhea,JJ,B-DISEASE
,/,NNP,O
,oligomenorrhea,NN,B-DISEASE
,associated,VBN,O
,with,IN,O
,their,PRP$,O
,neuroleptic,JJ,O
,medications,NNS,O
,were,VBD,O
,treated,VBN,O
,with,IN,O
,bromocriptine,NN,O
,.,.,O
,Daily,JJ,O
,dosages,NNS,O
,of,IN,O
,5,CD,O
,-,:,O
,10,CD,O
,mg,NN,O
,corrected,VBD,O
,the,DT,O
,hyperprolactinemia,NN,B-DISEASE
,and,CC,O
,restored,JJ,O
,menstruation,NN,O
,in,IN,O
,four,CD,O
,of,IN,O
,the,DT,O
,six,CD,O
,patients,NNS,O
,.,.,O
,One,CD,O
,woman,NN,O
,",",",",O
,however,RB,O
,",",",",O
,developed,VBD,O
,worsened,VBN,O
,psychiatric,JJ,B-DISEASE
,symptoms,NNS,I-DISEASE
,while,IN,O
,taking,VBG,O
,bromocriptine,NN,O
,",",",",O
,and,CC,O
,it,PRP,O
,was,VBD,O
,discontinued,VBN,O
,.,.,O
,Thus,RB,O
,",",",",O
,three,CD,O
,of,IN,O
,six,CD,O
,patients,NNS,O
,had,VBD,O
,their,PRP$,O
,menstrual,JJ,O
,irregularity,NN,O
,successfully,RB,O
,corrected,VBN,O
,with,IN,O
,bromocriptine,NN,O
,.,.,O
,This,DT,O
,suggests,VBZ,O
,that,IN,O
,bromocriptine,NN,O
,should,MD,O
,be,VB,O
,further,RB,O
,evaluated,VBN,O
,as,IN,O
,potential,JJ,O
,therapy,NN,O
,for,IN,O
,neuroleptic,JJ,O
,-,:,O
,associated,VBN,O
,hyperprolactinemia,NN,B-DISEASE
,and,CC,O
,amenorrhea,JJ,B-DISEASE
,/,NNP,O
,galactorrhea,NN,B-DISEASE
,.,.,O
,Ethacrynic,NNP,O
,acid,IN,O
,-,:,O
,induced,JJ,O
,convulsions,NNS,B-DISEASE
,and,CC,O
,brain,NN,O
,neurotransmitters,NNS,O
,in,IN,O
,mice,NN,O
,.,.,O
,Intracerebroventricular,JJ,O
,injection,NN,O
,of,IN,O
,ethacrynic,JJ,O
,acid,NN,O
,(,(,O
,50,CD,O
,%,NN,O
,convulsive,JJ,B-DISEASE
,dose,NN,O
,;,:,O
,50,CD,O
,micrograms,NNS,O
,/,NNP,O
,mouse,NN,O
,),),O
,accelerated,VBD,O
,the,DT,O
,synthesis,NN,O
,/,NNP,O
,turnover,NN,O
,of,IN,O
,5,CD,O
,-,:,O
,hydroxytryptamine,NN,O
,(,(,O
,5,CD,O
,-,:,O
,HT,NN,O
,),),O
,but,CC,O
,suppressed,VBD,O
,the,DT,O
,synthesis,NN,O
,of,IN,O
,gamma,NN,O
,-,:,O
,aminobutyric,JJ,O
,acid,NN,O
,and,CC,O
,acetylcholine,NN,O
,in,IN,O
,mouse,NN,O
,brain,NN,O
,.,.,O
,These,DT,O
,effects,NNS,O
,were,VBD,O
,completely,RB,O
,antagonized,VBN,O
,by,IN,O
,pretreatment,NN,O
,with,IN,O
,a,DT,O
,glutamate,NN,O
,/,NN,O
,N,NNP,O
,-,:,O
,methyl,NN,O
,-,:,O
,D,NNP,O
,-,:,O
,aspartate,NN,O
,antagonist,NN,O
,",",",",O
,aminophosphonovaleric,JJ,O
,acid,NN,O
,.,.,O
,In,IN,O
,ethacrynic,JJ,O
,acid,NN,O
,-,:,O
,induced,JJ,O
,convulsions,NNS,B-DISEASE
,",",",",O
,these,DT,O
,neurotransmitter,JJ,O
,systems,NNS,O
,may,MD,O
,be,VB,O
,differentially,RB,O
,modulated,VBN,O
,",",",",O
,probably,RB,O
,through,IN,O
,activation,NN,O
,of,IN,O
,glutaminergic,JJ,O
,neurons,NNS,O
,in,IN,O
,the,DT,O
,brain,NN,O
,.,.,O
,Pharmacology,NNP,O
,of,IN,O
,gamma,NN,O
,-,:,O
,aminobutyric,JJ,O
,acidA,JJ,O
,receptor,NN,O
,complex,NN,O
,after,IN,O
,the,DT,O
,in,IN,O
,vivo,JJ,O
,administration,NN,O
,of,IN,O
,the,DT,O
,anxioselective,JJ,O
,and,CC,O
,anticonvulsant,JJ,O
,beta,NN,O
,-,:,O
,carboline,NN,O
,derivative,JJ,O
,abecarnil,NN,O
,.,.,O
,In,IN,O
,rodents,NNS,O
,",",",",O
,the,DT,O
,effect,NN,O
,of,IN,O
,the,DT,O
,beta,NN,O
,-,:,O
,carboline,NN,O
,derivative,JJ,O
,isopropyl,NN,O
,-,:,O
,6,CD,O
,-,:,O
,benzyloxy,NN,O
,-,:,O
,4,CD,O
,-,:,O
,methoxymethyl,NN,O
,-,:,O
,beta,NN,O
,-,:,O
,carboline,NN,O
,-,:,O
,3,CD,O
,-,:,O
,carboxylate,NN,O
,(,(,O
,abecarrnil,NN,O
,),),O
,",",",",O
,a,DT,O
,new,JJ,O
,ligand,NN,O
,for,IN,O
,benzodiazepine,NN,O
,receptors,NNS,O
,possessing,VBG,O
,anxiolytic,JJ,O
,and,CC,O
,anticonvulsant,JJ,O
,properties,NNS,O
,",",",",O
,was,VBD,O
,evaluated,VBN,O
,on,IN,O
,the,DT,O
,function,NN,O
,of,IN,O
,central,JJ,O
,gamma,NN,O
,-,:,O
,aminobutyric,JJ,O
,acid,NN,O
,(,(,O
,GABA,NNP,O
,),),O
,A,NNP,O
,receptor,NN,O
,complex,NN,O
,",",",",O
,both,DT,O
,in,IN,O
,vitro,NN,O
,and,CC,O
,in,IN,O
,vivo,NN,O
,.,.,O
,Added,VBN,O
,in,IN,O
,vitro,NN,O
,to,TO,O
,rat,VB,O
,cortical,JJ,O
,membrane,NN,O
,preparation,NN,O
,",",",",O
,abecarnil,NN,O
,increased,VBD,O
,[,$,O
,3H,CD,O
,],NNP,O
,GABA,NNP,O
,binding,NN,O
,",",",",O
,enhanced,VBD,O
,muscimol,SYM,O
,-,:,O
,stimulated,VBD,O
,36Cl,CD,O
,-,:,O
,uptake,NN,O
,and,CC,O
,reduced,VBD,O
,the,DT,O
,binding,NN,O
,of,IN,O
,t,JJ,O
,-,:,O
,[,NN,O
,35S,CD,O
,],NN,O
,butylbicyclophosphorothionate,NN,O
,(,(,O
,[,JJ,O
,35S,CD,O
,],NNP,O
,TBPS,NNP,O
,),),O
,.,.,O
,These,DT,O
,effects,NNS,O
,were,VBD,O
,similar,JJ,O
,to,TO,O
,those,DT,O
,induced,VBN,O
,by,IN,O
,diazepam,NN,O
,",",",",O
,whereas,IN,O
,the,DT,O
,partial,JJ,O
,agonist,NN,O
,Ro,NNP,O
,16,CD,O
,-,:,O
,6028,CD,O
,(,(,O
,tert,JJ,O
,-,:,O
,butyl,NN,O
,-,:,O
,(,(,O
,S,NNP,O
,),),O
,-,:,O
,8,CD,O
,-,:,O
,bromo,NN,O
,-,:,O
,11,CD,O
,",",",",O
,12,CD,O
,",",",",O
,13,CD,O
,",",",",O
,13a,CD,O
,-,:,O
,tetrahydro,NN,O
,-,:,O
,9,CD,O
,-,:,O
,oxo,NN,O
,-,:,O
,9H,CD,O
,-,:,O
,imidazo,NN,O
,[,VBZ,O
,1,CD,O
,",",",",O
,5,CD,O
,-,:,O
,a,DT,O
,],JJ,O
,-,:,O
,pyrrolo,NN,O
,-,:,O
,[,NN,O
,2,CD,O
,",",",",O
,1,CD,O
,-,:,O
,c,NN,O
,],NNP,O
,[,NNP,O
,1,CD,O
,",",",",O
,4,CD,O
,],NN,O
,benzodiazepine,NN,O
,-,:,O
,1,CD,O
,-,:,O
,carboxylate,NN,O
,),),O
,showed,VBD,O
,very,RB,O
,weak,JJ,O
,efficacy,NN,O
,in,IN,O
,these,DT,O
,biochemical,JJ,O
,tests,NNS,O
,.,.,O
,After,IN,O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,injection,NN,O
,to,TO,O
,rats,VB,O
,",",",",O
,abecarnil,NN,O
,and,CC,O
,diazepam,NN,O
,decreased,VBN,O
,in,IN,O
,a,DT,O
,time,NN,O
,-,:,O
,dependent,NN,O
,and,CC,O
,dose,VB,O
,-,:,O
,related,VBN,O
,(,(,O
,0,CD,O
,.,.,O
,25,CD,O
,-,:,O
,20,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,manner,NN,O
,[,$,O
,35S,CD,O
,],NNP,O
,TBPS,NNP,O
,binding,NN,O
,measured,VBD,O
,ex,JJ,O
,vivo,NN,O
,in,IN,O
,the,DT,O
,cerebral,JJ,O
,cortex,NN,O
,.,.,O
,Moreover,RB,O
,",",",",O
,both,DT,O
,drugs,NNS,O
,at,IN,O
,the,DT,O
,dose,NN,O
,of,IN,O
,0,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,antagonized,VBD,O
,completely,RB,O
,the,DT,O
,convulsant,NN,O
,activity,NN,O
,and,CC,O
,the,DT,O
,increase,NN,O
,of,IN,O
,[,JJ,O
,35S,CD,O
,],JJ,O
,TBPS,NNP,O
,binding,NN,O
,induced,VBN,O
,by,IN,O
,isoniazide,NN,O
,(,(,O
,350,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,s,NN,O
,.,.,O
,c,NN,O
,.,.,O
,),),O
,as,RB,O
,well,RB,O
,as,IN,O
,the,DT,O
,increase,NN,O
,of,IN,O
,[,JJ,O
,35S,CD,O
,],JJ,O
,TBPS,NNP,O
,binding,NN,O
,induced,VBN,O
,by,IN,O
,foot,NN,O
,-,:,O
,shock,NN,O
,stress,NN,O
,.,.,O
,To,TO,O
,better,RBR,O
,correlate,VB,O
,the,DT,O
,biochemical,JJ,O
,and,CC,O
,the,DT,O
,pharmacological,JJ,O
,effects,NNS,O
,",",",",O
,we,PRP,O
,studied,VBD,O
,the,DT,O
,action,NN,O
,of,IN,O
,abecarnil,NN,O
,on,IN,O
,[,$,O
,35S,CD,O
,],NNP,O
,TBPS,NNP,O
,binding,NN,O
,",",",",O
,exploratory,JJ,O
,motility,NN,O
,and,CC,O
,on,IN,O
,isoniazid,JJ,O
,-,:,O
,induced,JJ,O
,biochemical,JJ,O
,and,CC,O
,pharmacological,JJ,O
,effects,NNS,O
,in,IN,O
,mice,NN,O
,.,.,O
,In,IN,O
,these,DT,O
,animals,NNS,O
,",",",",O
,abecarnil,RB,O
,produced,VBD,O
,a,DT,O
,paralleled,VBN,O
,dose,NN,O
,-,:,O
,dependent,NN,O
,(,(,O
,0,CD,O
,.,.,O
,05,CD,O
,-,:,O
,1,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,reduction,NN,O
,of,IN,O
,both,DT,O
,motor,NN,O
,behavior,NN,O
,and,CC,O
,cortical,JJ,O
,[,NN,O
,35S,CD,O
,],NN,O
,TBPS,NNP,O
,binding,NN,O
,.,.,O
,Moreover,RB,O
,",",",",O
,0,CD,O
,.,.,O
,05,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,of,IN,O
,this,DT,O
,beta,NN,O
,-,:,O
,carboline,NN,O
,reduced,VBN,O
,markedly,RB,O
,the,DT,O
,increase,NN,O
,of,IN,O
,[,JJ,O
,35S,CD,O
,],JJ,O
,TBPS,NNP,O
,binding,NN,O
,and,CC,O
,the,DT,O
,convulsions,NNS,B-DISEASE
,induced,VBN,O
,by,IN,O
,isoniazid,NN,O
,(,(,O
,200,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,s,NN,O
,.,.,O
,c,NN,O
,.,.,O
,),),O
,.,.,O
,(,(,O
,ABSTRACT,NNP,O
,TRUNCATED,NNP,O
,AT,NNP,O
,250,CD,O
,WORDS,NNP,O
,),),O
,Recurrent,NNP,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,in,IN,O
,a,DT,O
,postpartum,NN,O
,patient,NN,O
,receiving,VBG,O
,bromocriptine,NN,O
,.,.,O
,Myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,in,IN,O
,puerperium,NN,O
,is,VBZ,O
,infrequently,RB,O
,reported,VBN,O
,.,.,O
,Spasm,NNP,B-DISEASE
,",",",",O
,coronary,JJ,O
,dissection,NN,O
,",",",",O
,or,CC,O
,atheromatous,JJ,O
,etiology,NN,O
,has,VBZ,O
,been,VBN,O
,described,VBN,O
,.,.,O
,Bromocriptine,NNP,O
,has,VBZ,O
,been,VBN,O
,implicated,VBN,O
,in,IN,O
,several,JJ,O
,previous,JJ,O
,case,NN,O
,reports,NNS,O
,of,IN,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,in,IN,O
,the,DT,O
,puerperium,NN,O
,.,.,O
,Our,PRP$,O
,case,NN,O
,(,(,O
,including,VBG,O
,an,DT,O
,inadvertent,JJ,O
,rechallenge,NN,O
,),),O
,suggests,VBZ,O
,such,PDT,O
,a,DT,O
,relationship,NN,O
,.,.,O
,Although,IN,O
,generally,RB,O
,regarded,VBN,O
,as,IN,O
,"""",NNP,O
,safe,JJ,O
,",",",",O
,"""",NNP,O
,possible,JJ,O
,serious,JJ,O
,cardiac,JJ,O
,effects,NNS,O
,of,IN,O
,bromocriptine,NN,O
,should,MD,O
,be,VB,O
,acknowledged,VBN,O
,.,.,O
,Asterixis,NNP,B-DISEASE
,induced,VBN,O
,by,IN,O
,carbamazepine,NN,O
,therapy,NN,O
,.,.,O
,There,EX,O
,are,VBP,O
,very,RB,O
,few,JJ,O
,reports,NNS,O
,about,RB,O
,asterixis,RB,B-DISEASE
,as,IN,O
,a,DT,O
,side,NN,O
,effect,NN,O
,of,IN,O
,treatment,NN,O
,with,IN,O
,psychopharmacologic,JJ,O
,agents,NNS,O
,.,.,O
,In,IN,O
,this,DT,O
,report,NN,O
,we,PRP,O
,present,VBP,O
,four,CD,O
,patients,NNS,O
,treated,VBN,O
,with,IN,O
,a,DT,O
,combination,NN,O
,of,IN,O
,different,JJ,O
,psychotropic,NN,O
,drugs,NNS,O
,",",",",O
,in,IN,O
,whom,WP,O
,asterixis,NN,B-DISEASE
,was,VBD,O
,triggered,VBN,O
,either,RB,O
,by,IN,O
,adding,VBG,O
,carbamazepine,NN,O
,(,(,O
,CBZ,NNP,O
,),),O
,to,TO,O
,a,DT,O
,treatment,NN,O
,regimen,NN,O
,",",",",O
,or,CC,O
,by,IN,O
,increasing,VBG,O
,its,PRP$,O
,dosage,NN,O
,.,.,O
,Neither,CC,O
,dosage,NN,O
,nor,CC,O
,serum,JJ,O
,levels,NNS,O
,of,IN,O
,CBZ,NNP,O
,were,VBD,O
,in,IN,O
,a,DT,O
,higher,JJR,O
,range,NN,O
,.,.,O
,We,PRP,O
,consider,VBP,O
,asterixis,DT,B-DISEASE
,to,TO,O
,be,VB,O
,an,DT,O
,easily,RB,O
,overlooked,JJ,O
,sign,NN,O
,of,IN,O
,neurotoxicity,NN,B-DISEASE
,",",",",O
,which,WDT,O
,may,MD,O
,occur,VB,O
,even,RB,O
,at,IN,O
,low,JJ,O
,or,CC,O
,moderate,JJ,O
,dosage,NN,O
,levels,NNS,O
,",",",",O
,if,IN,O
,certain,JJ,O
,drugs,NNS,O
,as,IN,O
,lithium,NN,O
,or,CC,O
,clozapine,NN,O
,are,VBP,O
,used,VBN,O
,in,IN,O
,combination,NN,O
,with,IN,O
,CBZ,NNP,O
,.,.,O
,Pharmacodynamics,NNS,O
,of,IN,O
,the,DT,O
,hypotensive,JJ,B-DISEASE
,effect,NN,O
,of,IN,O
,levodopa,NN,O
,in,IN,O
,parkinsonian,JJ,B-DISEASE
,patients,NNS,O
,.,.,O
,Blood,NNP,O
,pressure,NN,O
,effects,NNS,O
,of,IN,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,levodopa,NN,O
,were,VBD,O
,examined,VBN,O
,in,IN,O
,parkinsonian,JJ,B-DISEASE
,patients,NNS,O
,with,IN,O
,stable,JJ,O
,and,CC,O
,fluctuating,JJ,O
,responses,NNS,O
,to,TO,O
,levodopa,VB,O
,.,.,O
,The,DT,O
,magnitude,NN,O
,of,IN,O
,the,DT,O
,hypotensive,JJ,B-DISEASE
,effect,NN,O
,of,IN,O
,levodopa,NN,O
,was,VBD,O
,concentration,NN,O
,dependent,NN,O
,and,CC,O
,was,VBD,O
,fit,VBN,O
,to,TO,O
,an,DT,O
,Emax,NNP,O
,model,NN,O
,in,IN,O
,fluctuating,VBG,O
,responders,NNS,O
,.,.,O
,Stable,JJ,O
,responders,NNS,O
,demonstrated,VBD,O
,a,DT,O
,small,JJ,O
,hypotensive,JJ,B-DISEASE
,response,NN,O
,.,.,O
,Baseline,NNP,O
,blood,NN,O
,pressures,NNS,O
,were,VBD,O
,higher,JJR,O
,in,IN,O
,fluctuating,VBG,O
,patients,NNS,O
,;,:,O
,a,DT,O
,higher,JJR,O
,baseline,NN,O
,blood,NN,O
,pressure,NN,O
,correlated,VBN,O
,with,IN,O
,greater,JJR,O
,hypotensive,JJ,B-DISEASE
,effects,NNS,O
,.,.,O
,Antiparkinsonian,JJ,O
,effects,NNS,O
,of,IN,O
,levodopa,NN,O
,temporally,RB,O
,correlated,VBN,O
,with,IN,O
,blood,NN,O
,pressure,NN,O
,changes,NNS,O
,.,.,O
,Phenylalanine,NNP,O
,",",",",O
,a,DT,O
,large,JJ,O
,neutral,JJ,O
,amino,NN,O
,acid,NN,O
,(,(,O
,LNAA,NNP,O
,),),O
,competing,VBG,O
,with,IN,O
,levodopa,NN,O
,for,IN,O
,transport,NN,O
,across,IN,O
,the,DT,O
,blood,NN,O
,-,:,O
,brain,NN,O
,barrier,NN,O
,",",",",O
,reduced,VBD,O
,the,DT,O
,hypotensive,NN,B-DISEASE
,and,CC,O
,antiparkinsonian,JJ,O
,effects,NNS,O
,of,IN,O
,levodopa,NN,O
,.,.,O
,We,PRP,O
,conclude,VBP,O
,that,DT,O
,levodopa,NN,O
,has,VBZ,O
,a,DT,O
,central,JJ,O
,hypotensive,JJ,B-DISEASE
,action,NN,O
,that,WDT,O
,parallels,VBZ,O
,the,DT,O
,motor,NN,O
,effects,NNS,O
,in,IN,O
,fluctuating,VBG,O
,patients,NNS,O
,.,.,O
,The,DT,O
,hypotensive,JJ,B-DISEASE
,effect,NN,O
,appears,VBZ,O
,to,TO,O
,be,VB,O
,related,VBN,O
,to,TO,O
,the,DT,O
,higher,JJR,O
,baseline,NN,O
,blood,NN,O
,pressure,NN,O
,we,PRP,O
,observed,VBD,O
,in,IN,O
,fluctuating,VBG,O
,patients,NNS,O
,relative,JJ,O
,to,TO,O
,stable,JJ,O
,patients,NNS,O
,.,.,O
,Syndrome,NNP,B-DISEASE
,of,IN,I-DISEASE
,inappropriate,JJ,I-DISEASE
,secretion,NN,I-DISEASE
,of,IN,I-DISEASE
,antidiuretic,JJ,I-DISEASE
,hormone,NN,I-DISEASE
,after,IN,O
,infusional,JJ,O
,vincristine,NN,O
,.,.,O
,A,DT,O
,77,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,with,IN,O
,refractory,JJ,O
,multiple,JJ,B-DISEASE
,myeloma,NN,I-DISEASE
,was,VBD,O
,treated,VBN,O
,with,IN,O
,a,DT,O
,4,CD,O
,-,:,O
,day,NN,O
,continuous,JJ,O
,intravenous,JJ,O
,infusion,NN,O
,of,IN,O
,vincristine,NN,O
,and,CC,O
,doxorubicin,NN,O
,and,CC,O
,4,CD,O
,days,NNS,O
,of,IN,O
,oral,JJ,O
,dexamethasone,NN,O
,.,.,O
,Nine,NNP,O
,days,NNS,O
,after,IN,O
,her,PRP$,O
,second,JJ,O
,cycle,NN,O
,she,PRP,O
,presented,VBD,O
,with,IN,O
,lethargy,NN,B-DISEASE
,and,CC,O
,weakness,NN,B-DISEASE
,associated,VBN,O
,with,IN,O
,hyponatremia,NN,B-DISEASE
,.,.,O
,Evaluation,NN,O
,revealed,VBD,O
,the,DT,O
,syndrome,NN,B-DISEASE
,of,IN,I-DISEASE
,inappropriate,JJ,I-DISEASE
,secretion,NN,I-DISEASE
,of,IN,I-DISEASE
,antidiuretic,JJ,I-DISEASE
,hormone,NN,I-DISEASE
,",",",",O
,which,WDT,O
,was,VBD,O
,attributed,VBN,O
,to,TO,O
,the,DT,O
,vincristine,NN,O
,infusion,NN,O
,.,.,O
,After,IN,O
,normal,JJ,O
,serum,JJ,O
,sodium,NN,O
,levels,NNS,O
,returned,VBN,O
,",",",",O
,further,JJ,O
,doxorubicin,NN,O
,and,CC,O
,dexamethasone,NN,O
,chemotherapy,NN,O
,without,IN,O
,vincristine,NN,O
,did,VBD,O
,not,RB,O
,produce,VB,O
,this,DT,O
,complication,NN,O
,.,.,O
,Heart,JJ,B-DISEASE
,failure,NN,I-DISEASE
,:,:,O
,to,TO,O
,digitalise,VB,O
,or,CC,O
,not,RB,O
,?,.,O
,The,DT,O
,view,NN,O
,against,IN,O
,.,.,O
,Despite,IN,O
,extensive,JJ,O
,clinical,JJ,O
,experience,NN,O
,the,DT,O
,role,NN,O
,of,IN,O
,digoxin,NN,O
,is,VBZ,O
,still,RB,O
,not,RB,O
,well,RB,O
,defined,VBN,O
,.,.,O
,In,IN,O
,patients,NNS,O
,with,IN,O
,atrial,JJ,B-DISEASE
,fibrillation,NN,I-DISEASE
,digoxin,NN,O
,is,VBZ,O
,beneficial,JJ,O
,for,IN,O
,ventricular,JJ,O
,rate,NN,O
,control,NN,O
,.,.,O
,For,IN,O
,patients,NNS,O
,in,IN,O
,sinus,JJ,O
,rhythm,NN,O
,and,CC,O
,heart,NN,B-DISEASE
,failure,NN,I-DISEASE
,the,DT,O
,situation,NN,O
,is,VBZ,O
,less,RBR,O
,clear,JJ,O
,.,.,O
,Digoxin,NNP,O
,has,VBZ,O
,a,DT,O
,narrow,JJ,O
,therapeutic,JJ,O
,:,:,O
,toxic,NN,O
,ratio,NN,O
,and,CC,O
,concentrations,NNS,O
,are,VBP,O
,affected,VBN,O
,by,IN,O
,a,DT,O
,number,NN,O
,of,IN,O
,drugs,NNS,O
,.,.,O
,Also,RB,O
,",",",",O
,digoxin,NN,O
,has,VBZ,O
,undesirable,JJ,O
,effects,NNS,O
,such,JJ,O
,as,IN,O
,increasing,VBG,O
,peripheral,JJ,O
,resistance,NN,O
,and,CC,O
,myocardial,JJ,O
,demands,NNS,O
,",",",",O
,and,CC,O
,causing,VBG,O
,arrhythmias,RB,B-DISEASE
,.,.,O
,There,EX,O
,is,VBZ,O
,a,DT,O
,paucity,NN,O
,of,IN,O
,data,NNS,O
,from,IN,O
,well,RB,O
,-,:,O
,designed,VBN,O
,trials,NNS,O
,.,.,O
,The,DT,O
,trials,NNS,O
,that,WDT,O
,are,VBP,O
,available,JJ,O
,are,VBP,O
,generally,RB,O
,small,JJ,O
,with,IN,O
,limitations,NNS,O
,in,IN,O
,design,NN,O
,and,CC,O
,these,DT,O
,show,NN,O
,variation,NN,O
,in,IN,O
,patient,JJ,O
,benefit,NN,O
,.,.,O
,More,RBR,O
,convincing,JJ,O
,evidence,NN,O
,is,VBZ,O
,required,VBN,O
,showing,VBG,O
,that,IN,O
,digoxin,NN,O
,improves,VBZ,O
,symptoms,NNS,O
,or,CC,O
,exercise,NN,O
,capacity,NN,O
,.,.,O
,Furthermore,NNP,O
,",",",",O
,no,DT,O
,trial,NN,O
,has,VBZ,O
,had,VBN,O
,sufficient,JJ,O
,power,NN,O
,to,TO,O
,evaluate,VB,O
,mortality,NN,O
,.,.,O
,Pooled,VBD,O
,analysis,NN,O
,of,IN,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,other,JJ,O
,inotropic,NN,O
,drugs,NNS,O
,shows,VBZ,O
,an,DT,O
,excess,JJ,O
,mortality,NN,O
,and,CC,O
,there,EX,O
,is,VBZ,O
,a,DT,O
,possibility,NN,O
,that,IN,O
,digoxin,NN,O
,may,MD,O
,increase,VB,O
,mortality,NN,O
,after,IN,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,(,(,O
,MI,NNP,B-DISEASE
,),),O
,.,.,O
,Angiotensin,NNP,O
,-,:,O
,converting,VBG,O
,enzyme,NN,O
,(,(,O
,ACE,NNP,O
,),),O
,inhibitors,NNS,O
,should,MD,O
,be,VB,O
,used,VBN,O
,first,RB,O
,as,IN,O
,they,PRP,O
,are,VBP,O
,safer,RB,O
,",",",",O
,do,VBP,O
,not,RB,O
,require,VB,O
,blood,NN,O
,level,NN,O
,monitoring,NN,O
,",",",",O
,modify,JJ,O
,progression,NN,O
,of,IN,O
,disease,NN,O
,",",",",O
,relieve,NN,O
,symptoms,NNS,O
,",",",",O
,improve,VB,O
,exercise,NN,O
,tolerance,NN,O
,and,CC,O
,reduce,VB,O
,mortality,NN,O
,.,.,O
,Caution,NN,O
,should,MD,O
,be,VB,O
,exercised,VBN,O
,in,IN,O
,using,VBG,O
,digoxin,NN,O
,until,IN,O
,large,JJ,O
,mortality,NN,O
,trials,NNS,O
,are,VBP,O
,completed,VBN,O
,showing,VBG,O
,either,CC,O
,benefit,NN,O
,or,CC,O
,harm,NN,O
,.,.,O
,Until,IN,O
,then,RB,O
,digoxin,NN,O
,should,MD,O
,be,VB,O
,considered,VBN,O
,a,DT,O
,third,JJ,O
,-,:,O
,line,NN,O
,therapy,NN,O
,.,.,O
,Isradipine,NNP,O
,treatment,NN,O
,for,IN,O
,hypertension,NN,B-DISEASE
,in,IN,O
,general,JJ,O
,practice,NN,O
,in,IN,O
,Hong,NNP,O
,Kong,NNP,O
,.,.,O
,A,DT,O
,6,CD,O
,-,:,O
,week,NN,O
,open,JJ,O
,study,NN,O
,of,IN,O
,the,DT,O
,introduction,NN,O
,of,IN,O
,isradipine,JJ,O
,treatment,NN,O
,was,VBD,O
,conducted,VBN,O
,in,IN,O
,general,JJ,O
,practice,NN,O
,in,IN,O
,Hong,NNP,O
,Kong,NNP,O
,.,.,O
,303,CD,O
,Chinese,JJ,O
,patients,NNS,O
,with,IN,O
,mild,JJ,O
,to,TO,O
,moderate,VB,O
,hypertension,NN,B-DISEASE
,entered,VBD,O
,the,DT,O
,study,NN,O
,.,.,O
,Side,JJ,O
,effects,NNS,O
,were,VBD,O
,reported,VBN,O
,in,IN,O
,21,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,and,CC,O
,caused,VBD,O
,withdrawal,NN,O
,from,IN,O
,the,DT,O
,study,NN,O
,in,IN,O
,3,CD,O
,patients,NNS,O
,.,.,O
,The,DT,O
,main,JJ,O
,side,NN,O
,-,:,O
,effects,NNS,O
,were,VBD,O
,headache,NN,B-DISEASE
,",",",",O
,dizziness,NN,B-DISEASE
,",",",",O
,palpitation,NN,B-DISEASE
,and,CC,O
,flushing,NN,B-DISEASE
,and,CC,O
,these,DT,O
,were,VBD,O
,not,RB,O
,more,RBR,O
,frequent,JJ,O
,than,IN,O
,reported,VBN,O
,in,IN,O
,other,JJ,O
,studies,NNS,O
,with,IN,O
,isradipine,NN,O
,or,CC,O
,with,IN,O
,placebo,NN,O
,.,.,O
,Supine,NNP,O
,blood,NN,O
,pressure,NN,O
,was,VBD,O
,reduced,VBN,O
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,from,IN,O
,170,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,20,CD,O
,/,$,O
,102,CD,O
,+,NNP,O
,/,NNP,O
,-,:,O
,6,CD,O
,mmHg,NN,O
,to,TO,O
,153,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,19,CD,O
,/,$,O
,92,CD,O
,+,NNP,O
,/,NNP,O
,-,:,O
,8,CD,O
,",",",",O
,147,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,18,CD,O
,/,$,O
,88,CD,O
,+,NNP,O
,/,NNP,O
,-,:,O
,7,CD,O
,and,CC,O
,144,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,14,CD,O
,/,$,O
,87,CD,O
,+,NNP,O
,/,NNP,O
,-,:,O
,6,CD,O
,mmHg,NN,O
,at,IN,O
,2,CD,O
,",",",",O
,4,CD,O
,and,CC,O
,6,CD,O
,weeks,NNS,O
,respectively,RB,O
,in,IN,O
,evaluable,JJ,O
,patients,NNS,O
,.,.,O
,Similar,JJ,O
,reductions,NNS,O
,occurred,VBD,O
,in,IN,O
,standing,VBG,O
,blood,NN,O
,pressure,NN,O
,and,CC,O
,there,EX,O
,was,VBD,O
,no,DT,O
,evidence,NN,O
,of,IN,O
,postural,JJ,B-DISEASE
,hypotension,NN,I-DISEASE
,.,.,O
,Normalization,NN,O
,and,CC,O
,responder,NN,O
,rates,NNS,O
,at,IN,O
,6,CD,O
,weeks,NNS,O
,were,VBD,O
,86,CD,O
,%,NN,O
,and,CC,O
,69,CD,O
,%,NN,O
,respectively,RB,O
,.,.,O
,Dosage,NN,O
,was,VBD,O
,increased,VBN,O
,from,IN,O
,2,CD,O
,.,.,O
,5,CD,O
,mg,NN,O
,b,NN,O
,.,.,O
,d,NN,O
,.,.,O
,to,TO,O
,5,CD,O
,mg,NN,O
,b,NN,O
,.,.,O
,d,NN,O
,.,.,O
,at,IN,O
,4,CD,O
,weeks,NNS,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,diastolic,JJ,O
,blood,NN,O
,pressure,NN,O
,greater,JJR,O
,than,IN,O
,90,CD,O
,mmHg,NNS,O
,and,CC,O
,their,PRP$,O
,further,JJ,O
,response,NN,O
,was,VBD,O
,greater,JJR,O
,than,IN,O
,those,DT,O
,remaining,VBG,O
,on,IN,O
,2,CD,O
,.,.,O
,5,CD,O
,mg,NN,O
,b,NN,O
,.,.,O
,d,NN,O
,.,.,O
,Pharmacological,JJ,O
,characteristics,NNS,O
,and,CC,O
,side,JJ,O
,effects,NNS,O
,of,IN,O
,a,DT,O
,new,JJ,O
,galenic,JJ,O
,formulation,NN,O
,of,IN,O
,propofol,NN,O
,without,IN,O
,soyabean,JJ,O
,oil,NN,O
,.,.,O
,We,PRP,O
,compared,VBN,O
,the,DT,O
,pharmacokinetics,NNS,O
,",",",",O
,pharmacodynamics,NNS,O
,and,CC,O
,safety,NN,O
,profile,NN,O
,of,IN,O
,a,DT,O
,new,JJ,O
,galenic,JJ,O
,formulation,NN,O
,of,IN,O
,propofol,NN,O
,(,(,O
,AM149,NNP,O
,1,CD,O
,%,NN,O
,),),O
,",",",",O
,which,WDT,O
,does,VBZ,O
,not,RB,O
,contain,VB,O
,soyabean,JJ,O
,oil,NN,O
,",",",",O
,with,IN,O
,a,DT,O
,standard,JJ,O
,formulation,NN,O
,of,IN,O
,propofol,NN,O
,(,(,O
,Disoprivan,NNP,O
,1,CD,O
,%,NN,O
,),),O
,.,.,O
,In,IN,O
,a,DT,O
,randomised,JJ,O
,",",",",O
,double,JJ,O
,-,:,O
,blind,NN,O
,",",",",O
,cross,SYM,O
,-,:,O
,over,IN,O
,study,NN,O
,",",",",O
,30,CD,O
,healthy,JJ,O
,volunteers,NNS,O
,received,VBD,O
,a,DT,O
,single,JJ,O
,intravenous,JJ,O
,bolus,JJ,O
,injection,NN,O
,of,IN,O
,2,CD,O
,.,.,O
,5,CD,O
,mg,NN,O
,.,.,O
,kg,VB,O
,-,:,O
,1,CD,O
,propofol,NN,O
,.,.,O
,Plasma,NNP,O
,propofol,NN,O
,levels,NNS,O
,were,VBD,O
,measured,VBN,O
,for,IN,O
,48,CD,O
,h,NN,O
,following,VBG,O
,drug,NN,O
,administration,NN,O
,and,CC,O
,evaluated,VBD,O
,according,VBG,O
,to,TO,O
,a,DT,O
,three,CD,O
,-,:,O
,compartment,NN,O
,model,NN,O
,.,.,O
,The,DT,O
,pharmacodynamic,JJ,O
,parameters,NNS,O
,assessed,VBD,O
,included,JJ,O
,induction,NN,O
,and,CC,O
,emergence,NN,O
,times,NNS,O
,",",",",O
,respiratory,NN,O
,and,CC,O
,cardiovascular,JJ,O
,effects,NNS,O
,",",",",O
,and,CC,O
,pain,NN,B-DISEASE
,on,IN,O
,injection,NN,O
,.,.,O
,Patients,NNS,O
,were,VBD,O
,monitored,VBN,O
,for,IN,O
,side,NN,O
,effects,NNS,O
,over,IN,O
,48,CD,O
,h,NN,O
,.,.,O
,Owing,VBG,O
,to,TO,O
,a,DT,O
,high,JJ,O
,incidence,NN,O
,of,IN,O
,thrombophlebitis,NN,B-DISEASE
,",",",",O
,the,DT,O
,study,NN,O
,was,VBD,O
,terminated,VBN,O
,prematurely,RB,O
,and,CC,O
,only,RB,O
,the,DT,O
,data,NN,O
,of,IN,O
,the,DT,O
,two,CD,O
,parallel,JJ,O
,treatment,NN,O
,groups,NNS,O
,(,(,O
,15,CD,O
,patients,NNS,O
,in,IN,O
,each,DT,O
,group,NN,O
,),),O
,were,VBD,O
,analysed,VBN,O
,.,.,O
,Plasma,NNP,O
,concentrations,NNS,O
,did,VBD,O
,not,RB,O
,differ,VB,O
,significantly,RB,O
,between,IN,O
,the,DT,O
,two,CD,O
,formulations,NNS,O
,.,.,O
,Anaesthesia,NNP,O
,induction,NN,O
,and,CC,O
,emergence,NN,O
,times,NNS,O
,",",",",O
,respiratory,NN,O
,and,CC,O
,cardiovascular,JJ,O
,variables,NNS,O
,showed,VBD,O
,no,DT,O
,significant,JJ,O
,differences,NNS,O
,between,IN,O
,the,DT,O
,two,CD,O
,treatment,NN,O
,groups,NNS,O
,.,.,O
,Pain,VB,B-DISEASE
,on,IN,O
,injection,NN,O
,(,(,O
,80,CD,O
,vs,NN,O
,.,.,O
,20,CD,O
,%,NN,O
,",",",",O
,p,NN,O
,<,VBD,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,and,CC,O
,thrombophlebitis,NN,B-DISEASE
,(,(,O
,93,CD,O
,.,.,O
,3,CD,O
,vs,NN,O
,.,.,O
,6,CD,O
,.,.,O
,6,CD,O
,%,NN,O
,",",",",O
,p,NN,O
,<,VBD,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,occurred,VBD,O
,more,RBR,O
,frequently,RB,O
,with,IN,O
,AM149,NNP,O
,than,IN,O
,with,IN,O
,Disoprivan,NNP,O
,.,.,O
,Although,IN,O
,both,DT,O
,formulations,NNS,O
,had,VBD,O
,similar,JJ,O
,pharmacokinetic,JJ,O
,and,CC,O
,pharmacodynamic,JJ,O
,profiles,NNS,O
,the,DT,O
,new,JJ,O
,formulation,NN,O
,is,VBZ,O
,not,RB,O
,suitable,JJ,O
,for,IN,O
,clinical,JJ,O
,use,NN,O
,due,JJ,O
,to,TO,O
,the,DT,O
,high,JJ,O
,incidence,NN,O
,of,IN,O
,thrombophlebitis,NN,B-DISEASE
,produced,VBN,O
,.,.,O
,Pure,NNP,B-DISEASE
,red,JJ,I-DISEASE
,cell,NN,I-DISEASE
,aplasia,NN,I-DISEASE
,",",",",O
,toxic,JJ,B-DISEASE
,dermatitis,NN,I-DISEASE
,and,CC,O
,lymphadenopathy,NN,B-DISEASE
,in,IN,O
,a,DT,O
,patient,NN,O
,taking,VBG,O
,diphenylhydantoin,NN,O
,.,.,O
,A,DT,O
,patient,NN,O
,taking,VBG,O
,diphenylhydantoin,NN,O
,for,IN,O
,3,CD,O
,weeks,NNS,O
,developed,VBD,O
,a,DT,O
,generalized,JJ,O
,skin,NN,B-DISEASE
,rash,NN,I-DISEASE
,",",",",O
,lymphadenopathy,JJ,B-DISEASE
,and,CC,O
,pure,JJ,B-DISEASE
,red,JJ,I-DISEASE
,cell,NN,I-DISEASE
,aplasia,NN,I-DISEASE
,.,.,O
,After,IN,O
,withdrawal,NN,O
,of,IN,O
,the,DT,O
,pharmacon,NN,O
,all,DT,O
,symptoms,NNS,O
,disappeared,VBD,O
,spontaneously,RB,O
,.,.,O
,Skin,NNP,B-DISEASE
,rash,NN,I-DISEASE
,is,VBZ,O
,a,DT,O
,well,RB,O
,-,:,O
,known,VBN,O
,complication,NN,O
,of,IN,O
,diphenylhydantoin,NN,O
,treatment,NN,O
,as,IN,O
,is,VBZ,O
,benign,JJ,O
,and,CC,O
,malignant,JJ,O
,lymphadenopathy,NN,B-DISEASE
,.,.,O
,Pure,NNP,B-DISEASE
,red,JJ,I-DISEASE
,cell,NN,I-DISEASE
,aplasia,RB,I-DISEASE
,associated,VBN,O
,with,IN,O
,diphenylhydantoin,JJ,O
,medication,NN,O
,has,VBZ,O
,been,VBN,O
,reported,VBN,O
,in,IN,O
,3,CD,O
,patients,NNS,O
,.,.,O
,The,DT,O
,exact,JJ,O
,mechanism,NN,O
,by,IN,O
,which,WDT,O
,diphenylhydantoin,NN,O
,exerts,VBZ,O
,its,PRP$,O
,toxic,JJ,O
,effects,NNS,O
,is,VBZ,O
,not,RB,O
,known,VBN,O
,.,.,O
,In,IN,O
,this,DT,O
,patient,NN,O
,the,DT,O
,time,NN,O
,relation,NN,O
,between,IN,O
,the,DT,O
,ingestion,NN,O
,of,IN,O
,diphenylhydantoin,NN,O
,and,CC,O
,the,DT,O
,occurrence,NN,O
,of,IN,O
,the,DT,O
,skin,NN,B-DISEASE
,rash,NN,I-DISEASE
,",",",",O
,lymphadenopathy,JJ,B-DISEASE
,and,CC,O
,pure,JJ,B-DISEASE
,red,JJ,I-DISEASE
,cell,NN,I-DISEASE
,aplasia,NN,I-DISEASE
,is,VBZ,O
,very,RB,O
,suggestive,JJ,O
,of,IN,O
,a,DT,O
,direct,JJ,O
,connection,NN,O
,.,.,O
,Vinorelbine,NNP,O
,-,:,O
,related,JJ,O
,cardiac,JJ,O
,events,NNS,O
,:,:,O
,a,DT,O
,meta,NN,O
,-,:,O
,analysis,NN,O
,of,IN,O
,randomized,JJ,O
,clinical,JJ,O
,trials,NNS,O
,.,.,O
,Several,JJ,O
,cases,NNS,O
,of,IN,O
,cardiac,JJ,O
,adverse,JJ,O
,reactions,NNS,O
,related,VBN,O
,to,TO,O
,vinorelbine,VB,O
,(,(,O
,VNR,NNP,O
,),),O
,have,VBP,O
,been,VBN,O
,reported,VBN,O
,in,IN,O
,the,DT,O
,literature,NN,O
,.,.,O
,In,IN,O
,order,NN,O
,to,TO,O
,quantify,VB,O
,the,DT,O
,incidence,NN,O
,of,IN,O
,these,DT,O
,cardiac,JJ,O
,events,NNS,O
,",",",",O
,we,PRP,O
,performed,VBD,O
,a,DT,O
,meta,NN,O
,-,:,O
,analysis,NN,O
,of,IN,O
,clinical,JJ,O
,trials,NNS,O
,comparing,VBG,O
,VNR,NNP,O
,with,IN,O
,other,JJ,O
,chemotherapeutic,JJ,O
,agents,NNS,O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,various,JJ,O
,malignancies,NNS,B-DISEASE
,.,.,O
,Randomized,NNP,O
,clinical,JJ,O
,trials,NNS,O
,comparing,VBG,O
,VNR,NNP,O
,with,IN,O
,other,JJ,O
,drugs,NNS,O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,cancer,NN,B-DISEASE
,were,VBD,O
,searched,VBN,O
,in,IN,O
,Medline,NNP,O
,",",",",O
,Embase,NNP,O
,",",",",O
,Evidence,NNP,O
,-,:,O
,based,VBN,O
,Medicine,NNP,O
,Reviews,NNP,O
,databases,NNS,O
,and,CC,O
,the,DT,O
,Cochrane,NNP,O
,library,NN,O
,from,IN,O
,1987,CD,O
,to,TO,O
,2002,CD,O
,.,.,O
,Outcomes,NNS,O
,of,IN,O
,interest,NN,O
,were,VBD,O
,severe,JJ,O
,cardiac,JJ,O
,events,NNS,O
,",",",",O
,toxic,JJ,O
,deaths,NNS,O
,and,CC,O
,cardiac,JJ,O
,event,NN,O
,-,:,O
,related,JJ,O
,deaths,NNS,O
,reported,VBN,O
,in,IN,O
,each,DT,O
,publication,NN,O
,.,.,O
,We,PRP,O
,found,VBD,O
,19,CD,O
,trials,NNS,O
,",",",",O
,involving,VBG,O
,2441,CD,O
,patients,NNS,O
,treated,VBN,O
,by,IN,O
,VNR,NNP,O
,and,CC,O
,2050,CD,O
,control,NN,O
,patients,NNS,O
,.,.,O
,The,DT,O
,incidence,NN,O
,of,IN,O
,cardiac,JJ,O
,events,NNS,O
,with,IN,O
,VNR,NNP,O
,was,VBD,O
,1,CD,O
,.,.,O
,19,CD,O
,%,NN,O
,[,JJ,O
,95,CD,O
,%,NN,O
,confidence,NN,O
,interval,NN,O
,(,(,O
,CI,NNP,O
,),),O
,(,(,O
,0,CD,O
,.,.,O
,75,CD,O
,;,:,O
,1,CD,O
,.,.,O
,67,CD,O
,),),O
,],NN,O
,.,.,O
,There,EX,O
,was,VBD,O
,no,DT,O
,difference,NN,O
,in,IN,O
,the,DT,O
,risk,NN,O
,of,IN,O
,cardiac,JJ,O
,events,NNS,O
,between,IN,O
,VNR,NNP,O
,and,CC,O
,other,JJ,O
,drugs,NNS,O
,[,VBP,O
,odds,NNS,O
,ratio,NN,O
,:,:,O
,0,CD,O
,.,.,O
,92,CD,O
,",",",",O
,95,CD,O
,%,NN,O
,CI,NNP,O
,(,(,O
,0,CD,O
,.,.,O
,54,CD,O
,;,:,O
,1,CD,O
,.,.,O
,55,CD,O
,),),O
,],NN,O
,.,.,O
,The,DT,O
,risk,NN,O
,of,IN,O
,VNR,NNP,O
,cardiac,JJ,O
,events,NNS,O
,was,VBD,O
,similar,JJ,O
,to,TO,O
,vindesine,VB,O
,(,(,O
,VDS,NNP,O
,),),O
,and,CC,O
,other,JJ,O
,cardiotoxic,NN,B-DISEASE
,drugs,NNS,O
,[,VBP,O
,fluorouracil,NN,O
,",",",",O
,anthracyclines,NNS,O
,",",",",O
,gemcitabine,NN,O
,(,(,O
,GEM,NNP,O
,),),O
,em,VBZ,O
,leader,NN,O
,],NNP,O
,.,.,O
,Even,RB,O
,if,IN,O
,it,PRP,O
,did,VBD,O
,not,RB,O
,reach,VB,O
,statistical,JJ,O
,significance,NN,O
,because,IN,O
,of,IN,O
,a,DT,O
,few,JJ,O
,number,NN,O
,of,IN,O
,cases,NNS,O
,",",",",O
,the,DT,O
,risk,NN,O
,was,VBD,O
,lower,JJR,O
,in,IN,O
,trials,NNS,O
,excluding,VBG,O
,patients,NNS,O
,with,IN,O
,cardiac,JJ,O
,history,NN,O
,",",",",O
,and,CC,O
,seemed,VBD,O
,to,TO,O
,be,VB,O
,higher,JJR,O
,in,IN,O
,trials,NNS,O
,including,VBG,O
,patients,NNS,O
,with,IN,O
,pre,JJ,O
,-,:,O
,existing,VBG,O
,cardiac,JJ,B-DISEASE
,diseases,NNS,I-DISEASE
,.,.,O
,Vinorelbine,NNP,O
,-,:,O
,related,JJ,O
,cardiac,JJ,O
,events,NNS,O
,concern,NN,O
,about,IN,O
,1,CD,O
,%,NN,O
,of,IN,O
,treated,JJ,O
,patients,NNS,O
,in,IN,O
,clinical,JJ,O
,trials,NNS,O
,.,.,O
,However,RB,O
,",",",",O
,the,DT,O
,risk,NN,O
,associated,VBN,O
,with,IN,O
,VNR,NNP,O
,seems,VBZ,O
,to,TO,O
,be,VB,O
,similar,JJ,O
,to,TO,O
,that,DT,O
,of,IN,O
,other,JJ,O
,chemotherapeutic,JJ,O
,agents,NNS,O
,in,IN,O
,the,DT,O
,same,JJ,O
,indications,NNS,O
,.,.,O
,MRI,NNP,O
,findings,NNS,O
,of,IN,O
,hypoxic,JJ,O
,cortical,JJ,O
,laminar,NN,O
,necrosis,NN,B-DISEASE
,in,IN,O
,a,DT,O
,child,NN,O
,with,IN,O
,hemolytic,JJ,B-DISEASE
,anemia,NN,I-DISEASE
,crisis,NN,O
,.,.,O
,We,PRP,O
,present,JJ,O
,magnetic,JJ,O
,resonance,NN,O
,imaging,VBG,O
,findings,NNS,O
,of,IN,O
,a,DT,O
,5,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,girl,NN,O
,who,WP,O
,had,VBD,O
,a,DT,O
,rapidly,RB,O
,installing,JJ,O
,hemolytic,JJ,B-DISEASE
,anemia,NN,I-DISEASE
,crisis,NN,O
,induced,VBN,O
,by,IN,O
,trimethoprim,JJ,O
,-,:,O
,sulfomethoxazole,NN,O
,",",",",O
,resulting,VBG,O
,in,IN,O
,cerebral,JJ,B-DISEASE
,anoxia,NN,I-DISEASE
,leading,VBG,O
,to,TO,O
,permanent,JJ,O
,damage,NN,O
,.,.,O
,Magnetic,JJ,O
,Resonance,NNP,O
,imaging,NN,O
,revealed,VBD,O
,cortical,JJ,O
,laminar,NN,O
,necrosis,NN,B-DISEASE
,in,IN,O
,arterial,JJ,O
,border,NN,O
,zones,NNS,O
,in,IN,O
,both,DT,O
,cerebral,JJ,O
,hemispheres,NNS,O
,",",",",O
,ischemic,JJ,O
,changes,NNS,O
,in,IN,O
,subcortical,JJ,O
,white,JJ,O
,matter,NN,O
,of,IN,O
,left,JJ,O
,cerebral,NN,O
,hemisphere,NN,O
,",",",",O
,and,CC,O
,in,IN,O
,the,DT,O
,left,JJ,O
,putamen,NNS,O
,.,.,O
,Although,IN,O
,cortical,JJ,O
,laminar,JJ,O
,necrosis,NN,B-DISEASE
,is,VBZ,O
,a,DT,O
,classic,JJ,O
,entity,NN,O
,in,IN,O
,adulthood,NN,O
,related,VBN,O
,to,TO,O
,conditions,NNS,O
,of,IN,O
,energy,NN,O
,depletions,NNS,O
,",",",",O
,there,EX,O
,are,VBP,O
,few,JJ,O
,reports,NNS,O
,available,JJ,O
,in,IN,O
,children,NNS,O
,.,.,O
,A,DT,O
,wide,JJ,O
,review,NN,O
,of,IN,O
,the,DT,O
,literature,NN,O
,is,VBZ,O
,also,RB,O
,presented,VBN,O
,.,.,O
,The,DT,O
,natural,JJ,O
,history,NN,O
,of,IN,O
,Vigabatrin,NNP,O
,associated,VBD,O
,visual,JJ,B-DISEASE
,field,NN,I-DISEASE
,defects,NNS,I-DISEASE
,in,IN,O
,patients,NNS,O
,electing,VBG,O
,to,TO,O
,continue,VB,O
,their,PRP$,O
,medication,NN,O
,.,.,O
,PURPOSE,NN,O
,:,:,O
,To,TO,O
,determine,VB,O
,the,DT,O
,natural,JJ,O
,history,NN,O
,of,IN,O
,visual,JJ,B-DISEASE
,field,NN,I-DISEASE
,defects,NNS,I-DISEASE
,in,IN,O
,a,DT,O
,group,NN,O
,of,IN,O
,patients,NNS,O
,known,VBN,O
,to,TO,O
,have,VB,O
,Vigabatrin,NNP,O
,-,:,O
,associated,VBN,O
,changes,NNS,O
,who,WP,O
,elected,VBD,O
,to,TO,O
,continue,VB,O
,the,DT,O
,medication,NN,O
,because,IN,O
,of,IN,O
,good,JJ,O
,seizure,NN,B-DISEASE
,control,NN,O
,.,.,O
,METHODS,NNS,O
,:,:,O
,All,DT,O
,patients,NNS,O
,taking,VBG,O
,Vigabatrin,NNP,O
,alone,RB,O
,or,CC,O
,in,IN,O
,combination,NN,O
,with,IN,O
,other,JJ,O
,antiepileptic,JJ,O
,drugs,NNS,O
,for,IN,O
,at,IN,O
,least,JJS,O
,5,CD,O
,years,NNS,O
,(,(,O
,range,NN,O
,5,CD,O
,-,:,O
,12,CD,O
,years,NNS,O
,),),O
,were,VBD,O
,entered,VBN,O
,into,IN,O
,a,DT,O
,visual,JJ,O
,surveillance,NN,O
,programme,NN,O
,.,.,O
,Patients,NNS,O
,were,VBD,O
,followed,VBN,O
,up,RP,O
,at,IN,O
,6,CD,O
,-,:,O
,monthly,JJ,O
,intervals,NNS,O
,for,IN,O
,not,RB,O
,less,JJR,O
,than,IN,O
,18,CD,O
,months,NNS,O
,(,(,O
,range,NN,O
,18,CD,O
,-,:,O
,43,CD,O
,months,NNS,O
,),),O
,.,.,O
,In,IN,O
,all,DT,O
,",",",",O
,16,CD,O
,patients,NNS,O
,with,IN,O
,unequivocal,JJ,O
,defects,NNS,O
,continued,VBD,O
,the,DT,O
,medication,NN,O
,.,.,O
,Following,VBG,O
,already,RB,O
,published,VBN,O
,methodology,NN,O
,(,(,O
,Eye,JJ,O
,2002,CD,O
,;,:,O
,16,CD,O
,;,:,O
,567,CD,O
,-,:,O
,571,CD,O
,),),O
,monocular,NN,O
,mean,JJ,O
,radial,JJ,O
,degrees,NNS,O
,(,(,O
,MRDs,NNP,O
,),),O
,to,TO,O
,the,DT,O
,I,PRP,O
,/,VBP,O
,4e,CD,O
,isopter,NN,O
,on,IN,O
,Goldmann,NNP,O
,perimetry,NN,O
,was,VBD,O
,calculated,VBN,O
,for,IN,O
,the,DT,O
,right,JJ,O
,eye,NN,O
,at,IN,O
,the,DT,O
,time,NN,O
,of,IN,O
,discovery,NN,O
,of,IN,O
,a,DT,O
,visual,JJ,B-DISEASE
,field,NN,I-DISEASE
,defect,NN,I-DISEASE
,and,CC,O
,again,RB,O
,after,IN,O
,not,RB,O
,less,JJR,O
,than,IN,O
,18,CD,O
,months,NNS,O
,follow,VBP,O
,-,:,O
,up,RB,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Mean,JJ,O
,right,NN,O
,eye,NN,O
,MRD,NNP,O
,at,IN,O
,presentation,NN,O
,was,VBD,O
,36,CD,O
,.,.,O
,98,CD,O
,degrees,NNS,O
,(,(,O
,range,NN,O
,22,CD,O
,.,.,O
,25,CD,O
,-,:,O
,51,CD,O
,.,.,O
,0,CD,O
,),),O
,",",",",O
,compared,VBN,O
,to,TO,O
,38,CD,O
,.,.,O
,40,CD,O
,degrees,NNS,O
,(,(,O
,range,NN,O
,22,CD,O
,.,.,O
,5,CD,O
,-,:,O
,49,CD,O
,.,.,O
,75,CD,O
,),),O
,after,IN,O
,follow,NN,O
,-,:,O
,up,RB,O
,;,:,O
,P,NNP,O
,=,VBD,O
,0,CD,O
,.,.,O
,338,CD,O
,unpaired,JJ,O
,t,NN,O
,-,:,O
,test,NN,O
,.,.,O
,Only,RB,O
,one,CD,O
,patient,NN,O
,demonstrated,VBD,O
,a,DT,O
,deterioration,NN,B-DISEASE
,in,IN,I-DISEASE
,visual,JJ,I-DISEASE
,field,NN,I-DISEASE
,during,IN,O
,the,DT,O
,study,NN,O
,period,NN,O
,and,CC,O
,discontinued,VBN,O
,treatment,NN,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Established,VBN,O
,visual,JJ,B-DISEASE
,field,NN,I-DISEASE
,defects,NNS,I-DISEASE
,presumed,VBN,O
,to,TO,O
,be,VB,O
,due,JJ,O
,to,TO,O
,Vigabatrin,NNP,O
,therapy,NN,O
,did,VBD,O
,not,RB,O
,usually,RB,O
,progress,VB,O
,in,IN,O
,spite,NN,O
,of,IN,O
,continuing,VBG,O
,use,NN,O
,of,IN,O
,the,DT,O
,medication,NN,O
,.,.,O
,These,DT,O
,data,NNS,O
,give,VBP,O
,support,NN,O
,to,TO,O
,the,DT,O
,hypothesis,NN,O
,that,IN,O
,the,DT,O
,pathogenesis,NN,O
,of,IN,O
,Vigabatrin,NNP,O
,-,:,O
,associated,VBN,O
,visual,JJ,B-DISEASE
,field,NN,I-DISEASE
,defects,NNS,I-DISEASE
,may,MD,O
,be,VB,O
,an,DT,O
,idiosyncratic,JJ,O
,adverse,JJ,O
,drug,NN,O
,reaction,NN,O
,rather,RB,O
,than,IN,O
,dose,VB,O
,-,:,O
,dependent,JJ,O
,toxicity,NN,B-DISEASE
,.,.,O
,Induction,NN,O
,of,IN,O
,rosaceiform,NN,O
,dermatitis,NN,B-DISEASE
,during,IN,O
,treatment,NN,O
,of,IN,O
,facial,JJ,B-DISEASE
,inflammatory,NN,I-DISEASE
,dermatoses,NNS,I-DISEASE
,with,IN,O
,tacrolimus,JJ,O
,ointment,NN,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Tacrolimus,NNP,O
,ointment,NN,O
,is,VBZ,O
,increasingly,RB,O
,used,VBN,O
,for,IN,O
,anti,JJ,O
,-,:,O
,inflammatory,JJ,O
,treatment,NN,O
,of,IN,O
,sensitive,JJ,O
,areas,NNS,O
,such,JJ,O
,as,IN,O
,the,DT,O
,face,NN,O
,",",",",O
,and,CC,O
,recent,JJ,O
,observations,NNS,O
,indicate,VBP,O
,that,IN,O
,the,DT,O
,treatment,NN,O
,is,VBZ,O
,effective,JJ,O
,in,IN,O
,steroid,JJ,O
,-,:,O
,aggravated,VBN,O
,rosacea,NN,B-DISEASE
,and,CC,O
,perioral,JJ,B-DISEASE
,dermatitis,NN,I-DISEASE
,.,.,O
,We,PRP,O
,report,VBP,O
,on,IN,O
,rosaceiform,NN,O
,dermatitis,NN,B-DISEASE
,as,IN,O
,a,DT,O
,complication,NN,O
,of,IN,O
,treatment,NN,O
,with,IN,O
,tacrolimus,JJ,O
,ointment,NN,O
,.,.,O
,OBSERVATIONS,CC,O
,:,:,O
,Six,CD,O
,adult,NN,O
,patients,NNS,O
,with,IN,O
,inflammatory,JJ,B-DISEASE
,facial,JJ,I-DISEASE
,dermatoses,NNS,I-DISEASE
,were,VBD,O
,treated,VBN,O
,with,IN,O
,tacrolimus,JJ,O
,ointment,NN,O
,because,IN,O
,of,IN,O
,the,DT,O
,ineffectiveness,NN,O
,of,IN,O
,standard,JJ,O
,treatments,NNS,O
,.,.,O
,Within,IN,O
,2,CD,O
,to,TO,O
,3,CD,O
,weeks,NNS,O
,of,IN,O
,initially,RB,O
,effective,JJ,O
,and,CC,O
,well,RB,O
,-,:,O
,tolerated,VBN,O
,treatment,NN,O
,",",",",O
,3,CD,O
,patients,NNS,O
,with,IN,O
,a,DT,O
,history,NN,O
,of,IN,O
,rosacea,NN,B-DISEASE
,and,CC,O
,1,CD,O
,with,IN,O
,a,DT,O
,history,NN,O
,of,IN,O
,acne,NN,B-DISEASE
,experienced,VBN,O
,sudden,JJ,O
,worsening,NN,O
,with,IN,O
,pustular,JJ,O
,rosaceiform,NN,O
,lesions,NNS,O
,.,.,O
,Biopsy,NNP,O
,revealed,VBD,O
,an,DT,O
,abundance,NN,O
,of,IN,O
,Demodex,NNP,O
,mites,NNS,O
,in,IN,O
,2,CD,O
,of,IN,O
,these,DT,O
,patients,NNS,O
,.,.,O
,In,IN,O
,1,CD,O
,patient,NN,O
,with,IN,O
,eyelid,JJ,O
,eczema,NN,B-DISEASE
,",",",",O
,rosaceiform,VB,O
,periocular,JJ,B-DISEASE
,dermatitis,NN,I-DISEASE
,gradually,RB,O
,appeared,VBD,O
,after,IN,O
,3,CD,O
,weeks,NNS,O
,of,IN,O
,treatment,NN,O
,.,.,O
,In,IN,O
,1,CD,O
,patient,NN,O
,with,IN,O
,atopic,JJ,B-DISEASE
,dermatitis,NN,I-DISEASE
,",",",",O
,telangiectatic,JJ,O
,and,CC,O
,papular,JJ,B-DISEASE
,rosacea,NN,I-DISEASE
,insidiously,RB,O
,appeared,VBD,O
,after,IN,O
,5,CD,O
,months,NNS,O
,of,IN,O
,treatment,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Our,PRP$,O
,observations,NNS,O
,suggest,VBP,O
,that,IN,O
,the,DT,O
,spectrum,NN,O
,of,IN,O
,rosaceiform,NN,O
,dermatitis,NN,B-DISEASE
,as,IN,O
,a,DT,O
,complication,NN,O
,of,IN,O
,treatment,NN,O
,with,IN,O
,tacrolimus,JJ,O
,ointment,NN,O
,is,VBZ,O
,heterogeneous,JJ,O
,.,.,O
,A,DT,O
,variety,NN,O
,of,IN,O
,factors,NNS,O
,",",",",O
,such,JJ,O
,as,IN,O
,vasoactive,JJ,O
,properties,NNS,O
,of,IN,O
,tacrolimus,NN,O
,",",",",O
,proliferation,NN,O
,of,IN,O
,Demodex,NNP,O
,due,JJ,O
,to,TO,O
,local,JJ,O
,immunosuppression,NN,O
,",",",",O
,and,CC,O
,the,DT,O
,occlusive,JJ,O
,properties,NNS,O
,of,IN,O
,the,DT,O
,ointment,NN,O
,",",",",O
,may,MD,O
,be,VB,O
,involved,VBN,O
,in,IN,O
,the,DT,O
,observed,JJ,O
,phenomena,NN,O
,.,.,O
,Future,JJ,O
,studies,NNS,O
,are,VBP,O
,needed,VBN,O
,to,TO,O
,identify,VB,O
,individual,JJ,O
,risk,NN,O
,factors,NNS,O
,.,.,O
,Intravascular,JJ,O
,hemolysis,NN,B-DISEASE
,and,CC,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,following,VBG,O
,intermittent,JJ,O
,rifampin,NN,O
,therapy,NN,O
,.,.,O
,Renal,JJ,B-DISEASE
,failure,NN,I-DISEASE
,is,VBZ,O
,a,DT,O
,rare,JJ,O
,complication,NN,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,rifampin,NN,O
,.,.,O
,Intravascular,JJ,O
,hemolysis,NN,B-DISEASE
,leading,VBG,O
,to,TO,O
,acute,VB,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,following,VBG,O
,rifampin,NN,O
,therapy,NN,O
,is,VBZ,O
,extremely,RB,O
,rare,JJ,O
,.,.,O
,Two,CD,O
,patients,NNS,O
,with,IN,O
,leprosy,NNS,B-DISEASE
,who,WP,O
,developed,VBD,O
,hemolysis,NN,B-DISEASE
,and,CC,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,following,VBG,O
,rifampin,NN,O
,are,VBP,O
,reported,VBN,O
,.,.,O
,Structural,JJ,O
,abnormalities,NNS,O
,in,IN,O
,the,DT,O
,brains,NNS,O
,of,IN,O
,human,JJ,O
,subjects,NNS,O
,who,WP,O
,use,VBP,O
,methamphetamine,NN,O
,.,.,O
,We,PRP,O
,visualize,VBP,O
,",",",",O
,for,IN,O
,the,DT,O
,first,JJ,O
,time,NN,O
,",",",",O
,the,DT,O
,profile,NN,O
,of,IN,O
,structural,JJ,B-DISEASE
,deficits,NNS,I-DISEASE
,in,IN,I-DISEASE
,the,DT,I-DISEASE
,human,JJ,I-DISEASE
,brain,NN,I-DISEASE
,associated,VBN,O
,with,IN,O
,chronic,JJ,O
,methamphetamine,NN,O
,(,(,O
,MA,NNP,O
,),),O
,abuse,NN,O
,.,.,O
,Studies,NNS,O
,of,IN,O
,human,JJ,O
,subjects,NNS,O
,who,WP,O
,have,VBP,O
,used,VBN,O
,MA,NNP,O
,chronically,RB,O
,have,VBP,O
,revealed,VBN,O
,deficits,NNS,O
,in,IN,O
,dopaminergic,NN,O
,and,CC,O
,serotonergic,JJ,O
,systems,NNS,O
,and,CC,O
,cerebral,JJ,O
,metabolic,JJ,B-DISEASE
,abnormalities,NNS,I-DISEASE
,.,.,O
,Using,VBG,O
,magnetic,JJ,O
,resonance,NN,O
,imaging,NN,O
,(,(,O
,MRI,NNP,O
,),),O
,and,CC,O
,new,JJ,O
,computational,JJ,O
,brain,NN,O
,-,:,O
,mapping,NN,O
,techniques,NNS,O
,",",",",O
,we,PRP,O
,determined,VBD,O
,the,DT,O
,pattern,NN,O
,of,IN,O
,structural,JJ,O
,brain,NN,O
,alterations,NNS,O
,associated,VBN,O
,with,IN,O
,chronic,JJ,O
,MA,NNP,O
,abuse,NN,O
,in,IN,O
,human,JJ,O
,subjects,NNS,O
,and,CC,O
,related,VBN,O
,these,DT,O
,deficits,NNS,O
,to,TO,O
,cognitive,VB,B-DISEASE
,impairment,NN,I-DISEASE
,.,.,O
,We,PRP,O
,used,VBD,O
,high,JJ,O
,-,:,O
,resolution,NN,O
,MRI,NNP,O
,and,CC,O
,surface,NN,O
,-,:,O
,based,VBN,O
,computational,JJ,O
,image,NN,O
,analyses,NNS,O
,to,TO,O
,map,VB,O
,regional,JJ,O
,abnormalities,NNS,B-DISEASE
,in,IN,I-DISEASE
,the,DT,I-DISEASE
,cortex,NN,I-DISEASE
,",",",",I-DISEASE
,hippocampus,NN,I-DISEASE
,",",",",I-DISEASE
,white,JJ,I-DISEASE
,matter,NN,I-DISEASE
,",",",",I-DISEASE
,and,CC,I-DISEASE
,ventricles,NNS,I-DISEASE
,in,IN,O
,22,CD,O
,human,JJ,O
,subjects,NNS,O
,who,WP,O
,used,VBD,O
,MA,NNP,O
,and,CC,O
,21,CD,O
,age,NN,O
,-,:,O
,matched,VBN,O
,",",",",O
,healthy,JJ,O
,controls,NNS,O
,.,.,O
,Cortical,JJ,O
,maps,NNS,O
,revealed,VBD,O
,severe,JJ,O
,gray,JJ,O
,-,:,O
,matter,NN,O
,deficits,NNS,O
,in,IN,O
,the,DT,O
,cingulate,NN,O
,",",",",O
,limbic,NN,O
,",",",",O
,and,CC,O
,paralimbic,JJ,O
,cortices,NNS,O
,of,IN,O
,MA,NNP,O
,abusers,NNS,O
,(,(,O
,averaging,VBG,O
,11,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,below,IN,O
,control,NN,O
,;,:,O
,p,CC,O
,<,$,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,On,IN,O
,average,NN,O
,",",",",O
,MA,NNP,O
,abusers,NNS,O
,had,VBD,O
,7,CD,O
,.,.,O
,8,CD,O
,%,NN,O
,smaller,JJR,O
,hippocampal,NN,O
,volumes,NNS,O
,than,IN,O
,control,NN,O
,subjects,NNS,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,01,CD,O
,;,:,O
,left,VBN,O
,",",",",O
,p,VB,O
,=,JJ,O
,0,CD,O
,.,.,O
,01,CD,O
,;,:,O
,right,RB,O
,",",",",O
,p,VB,O
,<,JJ,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,and,CC,O
,significant,JJ,O
,white,JJ,O
,-,:,O
,matter,NN,O
,hypertrophy,NN,B-DISEASE
,(,(,O
,7,CD,O
,.,.,O
,0,CD,O
,%,NN,O
,;,:,O
,p,CC,O
,<,$,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,Hippocampal,JJ,O
,deficits,NNS,O
,were,VBD,O
,mapped,VBN,O
,and,CC,O
,correlated,VBN,O
,with,IN,O
,memory,NN,O
,performance,NN,O
,on,IN,O
,a,DT,O
,word,NN,O
,-,:,O
,recall,NN,O
,test,NN,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,MRI,NNP,O
,-,:,O
,based,VBN,O
,maps,NNS,O
,suggest,VBP,O
,that,IN,O
,chronic,JJ,O
,methamphetamine,NN,O
,abuse,NN,O
,causes,VBZ,O
,a,DT,O
,selective,JJ,O
,pattern,NN,O
,of,IN,O
,cerebral,JJ,O
,deterioration,NN,O
,that,WDT,O
,contributes,VBZ,O
,to,TO,O
,impaired,JJ,B-DISEASE
,memory,NN,I-DISEASE
,performance,NN,I-DISEASE
,.,.,O
,MA,NNP,O
,may,MD,O
,selectively,RB,O
,damage,VB,O
,the,DT,O
,medial,JJ,O
,temporal,JJ,O
,lobe,NN,O
,and,CC,O
,",",",",O
,consistent,JJ,O
,with,IN,O
,metabolic,JJ,O
,studies,NNS,O
,",",",",O
,the,DT,O
,cingulate,NN,O
,-,:,O
,limbic,JJ,O
,cortex,NN,O
,",",",",O
,inducing,VBG,O
,neuroadaptation,NN,O
,",",",",O
,neuropil,JJ,O
,reduction,NN,O
,",",",",O
,or,CC,O
,cell,NN,O
,death,NN,O
,.,.,O
,Prominent,NNP,O
,white,JJ,O
,-,:,O
,matter,NN,O
,hypertrophy,NN,B-DISEASE
,may,MD,O
,result,VB,O
,from,IN,O
,altered,VBN,O
,myelination,NN,O
,and,CC,O
,adaptive,JJ,O
,glial,NN,O
,changes,NNS,O
,",",",",O
,including,VBG,O
,gliosis,NN,B-DISEASE
,secondary,JJ,O
,to,TO,O
,neuronal,JJ,B-DISEASE
,damage,NN,I-DISEASE
,.,.,O
,These,DT,O
,brain,NN,O
,substrates,NNS,O
,may,MD,O
,help,VB,O
,account,VB,O
,for,IN,O
,the,DT,O
,symptoms,NNS,O
,of,IN,O
,MA,NNP,O
,abuse,NN,O
,",",",",O
,providing,VBG,O
,therapeutic,JJ,O
,targets,NNS,O
,for,IN,O
,drug,NN,O
,-,:,O
,induced,JJ,O
,brain,NN,B-DISEASE
,injury,NN,I-DISEASE
,.,.,O
,Disruption,NN,O
,of,IN,O
,hepatic,JJ,O
,lipid,JJ,O
,homeostasis,NN,O
,in,IN,O
,mice,NN,O
,after,IN,O
,amiodarone,NN,O
,treatment,NN,O
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,peroxisome,JJ,O
,proliferator,NN,O
,-,:,O
,activated,VBN,O
,receptor,NN,O
,-,:,O
,alpha,NN,O
,target,NN,O
,gene,NN,O
,activation,NN,O
,.,.,O
,Amiodarone,NNP,O
,",",",",O
,an,DT,O
,efficacious,JJ,O
,and,CC,O
,widely,RB,O
,used,VBN,O
,antiarrhythmic,JJ,O
,agent,NN,O
,",",",",O
,has,VBZ,O
,been,VBN,O
,reported,VBN,O
,to,TO,O
,cause,VB,O
,hepatotoxicity,NN,B-DISEASE
,in,IN,O
,some,DT,O
,patients,NNS,O
,.,.,O
,To,TO,O
,gain,VB,O
,insight,NN,O
,into,IN,O
,the,DT,O
,mechanism,NN,O
,of,IN,O
,this,DT,O
,unwanted,JJ,O
,effect,NN,O
,",",",",O
,mice,NN,O
,were,VBD,O
,administered,VBN,O
,various,JJ,O
,doses,NNS,O
,of,IN,O
,amiodarone,NN,O
,and,CC,O
,examined,VBD,O
,for,IN,O
,changes,NNS,O
,in,IN,O
,hepatic,JJ,O
,histology,NN,O
,and,CC,O
,gene,NN,O
,regulation,NN,O
,.,.,O
,Amiodarone,NNP,O
,induced,VBD,O
,hepatomegaly,NN,B-DISEASE
,",",",",O
,hepatocyte,NN,O
,microvesicular,JJ,O
,lipid,JJ,O
,accumulation,NN,O
,",",",",O
,and,CC,O
,a,DT,O
,significant,JJ,O
,decrease,NN,O
,in,IN,O
,serum,NN,O
,triglycerides,NNS,O
,and,CC,O
,glucose,NN,O
,.,.,O
,Northern,NNP,O
,blot,NN,O
,analysis,NN,O
,of,IN,O
,hepatic,JJ,O
,RNA,NNP,O
,revealed,VBD,O
,a,DT,O
,dose,JJ,O
,-,:,O
,dependent,JJ,O
,increase,NN,O
,in,IN,O
,the,DT,O
,expression,NN,O
,of,IN,O
,a,DT,O
,number,NN,O
,of,IN,O
,genes,NNS,O
,critical,JJ,O
,for,IN,O
,fatty,JJ,O
,acid,JJ,O
,oxidation,NN,O
,",",",",O
,lipoprotein,NN,O
,assembly,NN,O
,",",",",O
,and,CC,O
,lipid,JJ,O
,transport,NN,O
,.,.,O
,Many,JJ,O
,of,IN,O
,these,DT,O
,genes,NNS,O
,are,VBP,O
,regulated,VBN,O
,by,IN,O
,the,DT,O
,peroxisome,NN,O
,proliferator,NN,O
,-,:,O
,activated,VBN,O
,receptor,NN,O
,-,:,O
,alpha,NN,O
,(,(,O
,PPARalpha,NNP,O
,),),O
,",",",",O
,a,DT,O
,ligand,NN,O
,-,:,O
,activated,VBN,O
,nuclear,JJ,O
,hormone,NN,O
,receptor,NN,O
,transcription,NN,O
,factor,NN,O
,.,.,O
,The,DT,O
,absence,NN,O
,of,IN,O
,induction,NN,O
,of,IN,O
,these,DT,O
,genes,NNS,O
,as,RB,O
,well,RB,O
,as,IN,O
,hepatomegaly,NN,B-DISEASE
,in,IN,O
,PPARalpha,NNP,O
,knockout,NN,O
,[,NNP,O
,PPARalpha,NNP,O
,-,:,O
,/,SYM,O
,-,:,O
,],JJ,O
,mice,NN,O
,indicated,VBD,O
,that,IN,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,amiodarone,NN,O
,were,VBD,O
,dependent,JJ,O
,upon,IN,O
,the,DT,O
,presence,NN,O
,of,IN,O
,a,DT,O
,functional,JJ,O
,PPARalpha,NNP,O
,gene,NN,O
,.,.,O
,Compared,VBN,O
,to,TO,O
,wild,VB,O
,-,:,O
,type,NN,O
,mice,NN,O
,",",",",O
,treatment,NN,O
,of,IN,O
,PPARalpha,NNP,O
,-,:,O
,/,SYM,O
,-,:,O
,mice,NN,O
,with,IN,O
,amiodarone,NN,O
,resulted,VBD,O
,in,IN,O
,an,DT,O
,increased,JJ,O
,rate,NN,O
,and,CC,O
,extent,NN,O
,of,IN,O
,total,JJ,O
,body,NN,O
,weight,JJ,B-DISEASE
,loss,NN,I-DISEASE
,.,.,O
,The,DT,O
,inability,NN,O
,of,IN,O
,amiodarone,NN,O
,to,TO,O
,directly,RB,O
,activate,VB,O
,either,DT,O
,human,JJ,O
,or,CC,O
,mouse,NN,O
,PPARalpha,NNP,O
,transiently,RB,O
,expressed,VBD,O
,in,IN,O
,human,JJ,O
,HepG2,NNP,O
,hepatoma,NN,B-DISEASE
,cells,NNS,O
,indicates,VBZ,O
,that,IN,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,amiodarone,NN,O
,on,IN,O
,the,DT,O
,function,NN,O
,of,IN,O
,this,DT,O
,receptor,NN,O
,were,VBD,O
,indirect,JJ,O
,.,.,O
,Based,VBN,O
,upon,IN,O
,these,DT,O
,results,NNS,O
,",",",",O
,we,PRP,O
,conclude,VBP,O
,that,IN,O
,amiodarone,NN,O
,disrupts,NNS,O
,hepatic,JJ,O
,lipid,JJ,O
,homeostasis,NN,O
,and,CC,O
,that,IN,O
,the,DT,O
,increased,JJ,O
,expression,NN,O
,of,IN,O
,PPARalpha,NNP,O
,target,NN,O
,genes,NNS,O
,is,VBZ,O
,secondary,JJ,O
,to,TO,O
,this,DT,O
,toxic,JJ,O
,effect,NN,O
,.,.,O
,These,DT,O
,results,NNS,O
,provide,VBP,O
,important,JJ,O
,new,JJ,O
,mechanistic,JJ,O
,information,NN,O
,regarding,VBG,O
,the,DT,O
,hepatotoxic,JJ,B-DISEASE
,effects,NNS,O
,of,IN,O
,amiodarone,NN,O
,and,CC,O
,indicate,VBP,O
,that,IN,O
,PPARalpha,NNP,O
,protects,VBZ,O
,against,IN,O
,amiodarone,NN,O
,-,:,O
,induced,JJ,O
,hepatotoxicity,NN,B-DISEASE
,.,.,O
,Safety,NN,O
,and,CC,O
,compliance,NN,O
,with,IN,O
,once,RB,O
,-,:,O
,daily,JJ,O
,niacin,NN,O
,extended,VBD,O
,-,:,O
,release,NN,O
,/,JJ,O
,lovastatin,NN,O
,as,IN,O
,initial,JJ,O
,therapy,NN,O
,in,IN,O
,the,DT,O
,Impact,NNP,O
,of,IN,O
,Medical,NNP,O
,Subspecialty,NNP,O
,on,IN,O
,Patient,NNP,O
,Compliance,NNP,O
,to,TO,O
,Treatment,NNP,O
,(,(,O
,IMPACT,NNP,O
,),),O
,study,NN,O
,.,.,O
,Niacin,NNP,O
,extended,VBD,O
,-,:,O
,release,NN,O
,/,NNP,O
,lovastatin,NN,O
,is,VBZ,O
,a,DT,O
,new,JJ,O
,combination,NN,O
,product,NN,O
,approved,VBD,O
,for,IN,O
,treatment,NN,O
,of,IN,O
,primary,JJ,O
,hypercholesterolemia,NN,B-DISEASE
,and,CC,O
,mixed,JJ,O
,dyslipidemia,NN,B-DISEASE
,.,.,O
,This,DT,O
,open,JJ,O
,-,:,O
,labeled,VBN,O
,",",",",O
,multicenter,NN,O
,study,NN,O
,evaluated,VBD,O
,the,DT,O
,safety,NN,O
,of,IN,O
,bedtime,JJ,O
,niacin,NN,O
,extended,VBD,O
,-,:,O
,release,NN,O
,/,NNP,O
,lovastatin,NN,O
,when,WRB,O
,dosed,VBN,O
,as,IN,O
,initial,JJ,O
,therapy,NN,O
,and,CC,O
,patient,JJ,O
,compliance,NN,O
,to,TO,O
,treatment,NN,O
,in,IN,O
,various,JJ,O
,clinical,JJ,O
,practice,NN,O
,settings,NNS,O
,.,.,O
,A,DT,O
,total,NN,O
,of,IN,O
,4,CD,O
,",",",",O
,499,CD,O
,patients,NNS,O
,with,IN,O
,dyslipidemia,JJ,B-DISEASE
,requiring,VBG,O
,drug,NN,O
,intervention,NN,O
,was,VBD,O
,enrolled,VBN,O
,at,IN,O
,1,CD,O
,",",",",O
,081,CD,O
,sites,NNS,O
,.,.,O
,Patients,NNS,O
,were,VBD,O
,treated,VBN,O
,with,IN,O
,1,CD,O
,tablet,NN,O
,(,(,O
,500,CD,O
,mg,NN,O
,of,IN,O
,niacin,NN,O
,extended,VBN,O
,-,:,O
,release,NN,O
,/,VBZ,O
,20,CD,O
,mg,NN,O
,of,IN,O
,lovastatin,NN,O
,),),O
,once,RB,O
,nightly,RB,O
,for,IN,O
,4,CD,O
,weeks,NNS,O
,and,CC,O
,then,RB,O
,2,CD,O
,tablets,NNS,O
,for,IN,O
,8,CD,O
,weeks,NNS,O
,.,.,O
,Patients,NNS,O
,also,RB,O
,received,VBD,O
,dietary,JJ,O
,counseling,NN,O
,",",",",O
,educational,JJ,O
,materials,NNS,O
,",",",",O
,and,CC,O
,reminders,NNS,O
,to,TO,O
,call,VB,O
,a,DT,O
,toll,NN,O
,-,:,O
,free,JJ,O
,number,NN,O
,that,WDT,O
,provided,VBD,O
,further,JJ,O
,education,NN,O
,about,IN,O
,dyslipidemia,NN,B-DISEASE
,and,CC,O
,niacin,NN,O
,extended,VBN,O
,-,:,O
,release,NN,O
,/,NNP,O
,lovastatin,NN,O
,.,.,O
,Primary,JJ,O
,end,NN,O
,points,NNS,O
,were,VBD,O
,study,JJ,O
,compliance,NN,O
,",",",",O
,increases,NNS,O
,in,IN,O
,liver,NN,O
,transaminases,NNS,O
,to,TO,O
,>,VB,O
,3,CD,O
,times,NNS,O
,the,DT,O
,upper,JJ,O
,limit,NN,O
,of,IN,O
,normal,JJ,O
,",",",",O
,and,CC,O
,clinical,JJ,O
,myopathy,NN,B-DISEASE
,.,.,O
,Final,NNP,O
,study,NN,O
,status,NN,O
,was,VBD,O
,available,JJ,O
,for,IN,O
,4,CD,O
,",",",",O
,217,CD,O
,patients,NNS,O
,(,(,O
,94,CD,O
,%,NN,O
,),),O
,.,.,O
,Compliance,NN,O
,to,TO,O
,niacin,VB,O
,extended,VBN,O
,-,:,O
,release,NN,O
,/,NNP,O
,lovastatin,NN,O
,was,VBD,O
,77,CD,O
,%,NN,O
,",",",",O
,with,IN,O
,3,CD,O
,",",",",O
,245,CD,O
,patients,NNS,O
,completing,VBG,O
,the,DT,O
,study,NN,O
,.,.,O
,Patients,NNS,O
,in,IN,O
,the,DT,O
,southeast,NN,O
,and,CC,O
,those,DT,O
,enrolled,VBN,O
,by,IN,O
,endocrinologists,NNS,O
,had,VBD,O
,the,DT,O
,lowest,JJS,O
,compliance,NN,O
,and,CC,O
,highest,JJS,O
,adverse,JJ,O
,event,NN,O
,rates,NNS,O
,.,.,O
,Flushing,NNP,B-DISEASE
,was,VBD,O
,the,DT,O
,most,RBS,O
,common,JJ,O
,adverse,JJ,O
,event,NN,O
,",",",",O
,reported,VBN,O
,by,IN,O
,18,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,and,CC,O
,leading,VBG,O
,to,TO,O
,discontinuation,NN,O
,by,IN,O
,6,CD,O
,%,NN,O
,.,.,O
,Incidence,NN,O
,of,IN,O
,increased,JJ,O
,aspartate,NN,O
,aminotransferase,NN,O
,and,CC,O
,/,NN,O
,or,CC,O
,alanine,JJ,O
,aminotransferase,NN,O
,>,VBD,O
,3,CD,O
,times,NNS,O
,the,DT,O
,upper,JJ,O
,limit,NN,O
,of,IN,O
,normal,JJ,O
,was,VBD,O
,<,JJ,O
,0,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,.,.,O
,An,DT,O
,increase,NN,O
,of,IN,O
,creatine,JJ,O
,phosphokinase,NN,O
,to,TO,O
,>,VB,O
,5,CD,O
,times,NNS,O
,the,DT,O
,upper,JJ,O
,limit,NN,O
,of,IN,O
,normal,JJ,O
,occurred,VBD,O
,in,IN,O
,0,CD,O
,.,.,O
,24,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,",",",",O
,and,CC,O
,no,DT,O
,cases,NNS,O
,of,IN,O
,drug,NN,O
,-,:,O
,induced,VBN,O
,myopathy,NNS,B-DISEASE
,were,VBD,O
,observed,VBN,O
,.,.,O
,Niacin,NNP,O
,extended,VBD,O
,-,:,O
,release,NN,O
,/,NNP,O
,lovastatin,VBZ,O
,1,CD,O
,",",",",O
,000,CD,O
,/,NN,O
,40,CD,O
,mg,NN,O
,",",",",O
,dosed,VBD,O
,as,IN,O
,initial,JJ,O
,therapy,NN,O
,",",",",O
,was,VBD,O
,associated,VBN,O
,with,IN,O
,good,JJ,O
,compliance,NN,O
,and,CC,O
,safety,NN,O
,and,CC,O
,had,VBD,O
,very,RB,O
,low,JJ,O
,incidences,NNS,O
,of,IN,O
,increased,VBN,O
,liver,NN,O
,and,CC,O
,muscle,NN,O
,enzymes,NNS,O
,.,.,O
,Protective,JJ,O
,effect,NN,O
,of,IN,O
,Terminalia,NNP,O
,chebula,NN,O
,against,IN,O
,experimental,JJ,O
,myocardial,JJ,B-DISEASE
,injury,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,isoproterenol,NN,O
,.,.,O
,Cardioprotective,JJ,O
,effect,NN,O
,of,IN,O
,ethanolic,JJ,O
,extract,NN,O
,of,IN,O
,Terminalia,NNP,O
,chebula,NN,O
,fruits,NNS,O
,(,(,O
,500,CD,O
,mg,NN,O
,/,NNP,O
,kg,VBZ,O
,body,NN,O
,wt,NN,O
,),),O
,was,VBD,O
,examined,VBN,O
,in,IN,O
,isoproterenol,NN,O
,(,(,O
,200,CD,O
,mg,NN,O
,/,NNP,O
,kg,VBZ,O
,body,NN,O
,wt,NN,O
,),),O
,induced,VBD,O
,myocardial,JJ,B-DISEASE
,damage,NN,I-DISEASE
,in,IN,O
,rats,NNS,O
,.,.,O
,In,IN,O
,isoproterenol,NN,O
,administered,VBN,O
,rats,NNS,O
,",",",",O
,the,DT,O
,level,NN,O
,of,IN,O
,lipid,JJ,O
,peroxides,NNS,O
,increased,VBD,O
,significantly,RB,O
,in,IN,O
,the,DT,O
,serum,NN,O
,and,CC,O
,heart,NN,O
,.,.,O
,A,DT,O
,significant,JJ,O
,decrease,NN,O
,was,VBD,O
,observed,VBN,O
,in,IN,O
,the,DT,O
,activity,NN,O
,of,IN,O
,the,DT,O
,myocardial,JJ,O
,marker,NN,O
,enzymes,VBZ,O
,with,IN,O
,a,DT,O
,concomitant,JJ,O
,increase,NN,O
,in,IN,O
,their,PRP$,O
,activity,NN,O
,in,IN,O
,serum,NN,O
,.,.,O
,Histopathological,JJ,O
,examination,NN,O
,was,VBD,O
,carried,VBN,O
,out,IN,O
,to,TO,O
,confirm,VB,O
,the,DT,O
,myocardial,JJ,O
,necrosis,NN,B-DISEASE
,.,.,O
,T,NNP,O
,.,.,O
,chebula,NN,O
,extract,JJ,O
,pretreatment,NN,O
,was,VBD,O
,found,VBN,O
,to,TO,O
,ameliorate,VB,O
,the,DT,O
,effect,NN,O
,of,IN,O
,isoproterenol,NN,O
,on,IN,O
,lipid,JJ,O
,peroxide,NN,O
,formation,NN,O
,and,CC,O
,retained,VBD,O
,the,DT,O
,activities,NNS,O
,of,IN,O
,the,DT,O
,diagnostic,JJ,O
,marker,NN,O
,enzymes,NNS,O
,.,.,O
,A,DT,O
,case,NN,O
,of,IN,O
,postoperative,JJ,O
,anxiety,NN,B-DISEASE
,due,JJ,O
,to,TO,O
,low,JJ,O
,dose,JJ,O
,droperidol,NN,O
,used,VBN,O
,with,IN,O
,patient,JJ,O
,-,:,O
,controlled,VBN,O
,analgesia,NN,O
,.,.,O
,A,DT,O
,multiparous,JJ,O
,woman,NN,O
,in,IN,O
,good,JJ,O
,psychological,JJ,O
,health,NN,O
,underwent,JJ,O
,urgent,JJ,O
,caesarean,JJ,O
,section,NN,O
,in,IN,O
,labour,NN,O
,.,.,O
,Postoperatively,RB,O
,",",",",O
,she,PRP,O
,was,VBD,O
,given,VBN,O
,a,DT,O
,patient,NN,O
,-,:,O
,controlled,VBN,O
,analgesia,JJ,O
,device,NN,O
,delivering,VBG,O
,boluses,NNS,O
,of,IN,O
,diamorphine,NN,O
,0,CD,O
,.,.,O
,5,CD,O
,mg,NN,O
,and,CC,O
,droperidol,NN,O
,0,CD,O
,.,.,O
,025,CD,O
,mg,NN,O
,.,.,O
,Whilst,NNP,O
,using,VBG,O
,the,DT,O
,device,NN,O
,she,PRP,O
,gradually,RB,O
,became,VBD,O
,anxious,JJ,O
,",",",",O
,the,DT,O
,feeling,NN,O
,worsening,NN,O
,after,IN,O
,each,DT,O
,bolus,NN,O
,.,.,O
,The,DT,O
,diagnosis,NN,O
,of,IN,O
,droperidol,JJ,O
,-,:,O
,induced,JJ,O
,psychological,JJ,B-DISEASE
,disturbance,NN,I-DISEASE
,was,VBD,O
,not,RB,O
,made,VBN,O
,straight,RB,O
,away,RB,O
,although,IN,O
,on,IN,O
,subsequent,JJ,O
,close,RB,O
,questioning,VBG,O
,the,DT,O
,patient,NN,O
,gave,VBD,O
,a,DT,O
,very,RB,O
,clear,JJ,O
,history,NN,O
,.,.,O
,After,IN,O
,she,PRP,O
,had,VBD,O
,received,VBN,O
,a,DT,O
,total,NN,O
,of,IN,O
,only,RB,O
,0,CD,O
,.,.,O
,9,CD,O
,mg,NN,O
,droperidol,NN,O
,",",",",O
,a,DT,O
,syringe,NN,O
,containing,VBG,O
,diamorphine,NN,O
,only,RB,O
,was,VBD,O
,substituted,VBN,O
,and,CC,O
,her,PRP$,O
,unease,NN,O
,resolved,VBD,O
,completely,RB,O
,.,.,O
,We,PRP,O
,feel,VBP,O
,that,IN,O
,",",",",O
,although,IN,O
,the,DT,O
,dramatic,JJ,O
,extrapyramidal,JJ,O
,side,NN,O
,effects,NNS,O
,of,IN,O
,dopaminergic,JJ,O
,antiemetics,NNS,O
,are,VBP,O
,well,RB,O
,known,VBN,O
,",",",",O
,more,RBR,O
,subtle,JJ,O
,manifestations,NNS,O
,may,MD,O
,easily,RB,O
,be,VB,O
,overlooked,VBN,O
,.,.,O
,Accurate,JJ,O
,patient,JJ,O
,history,NN,O
,contributes,NNS,O
,to,TO,O
,differentiating,VBG,O
,diabetes,NNS,B-DISEASE
,insipidus,NN,I-DISEASE
,:,:,O
,a,DT,O
,case,NN,O
,study,NN,O
,.,.,O
,This,DT,O
,case,NN,O
,study,VB,O
,highlights,NNS,O
,the,DT,O
,important,JJ,O
,contribution,NN,O
,of,IN,O
,nursing,NN,O
,in,IN,O
,obtaining,VBG,O
,an,DT,O
,accurate,JJ,O
,health,NN,O
,history,NN,O
,.,.,O
,The,DT,O
,case,NN,O
,discussed,VBD,O
,herein,NNS,O
,initially,RB,O
,appeared,VBD,O
,to,TO,O
,be,VB,O
,neurogenic,JJ,B-DISEASE
,diabetes,NNS,I-DISEASE
,insipidus,VBP,I-DISEASE
,(,(,O
,DI,NNP,B-DISEASE
,),),O
,secondary,VBP,O
,to,TO,O
,a,DT,O
,traumatic,JJ,B-DISEASE
,brain,NN,I-DISEASE
,injury,NN,I-DISEASE
,.,.,O
,The,DT,O
,nursing,JJ,O
,staff,NN,O
,",",",",O
,by,IN,O
,reviewing,VBG,O
,the,DT,O
,patient,NN,O
,',POS,O
,s,JJ,O
,health,NN,O
,history,NN,O
,with,IN,O
,his,PRP$,O
,family,NN,O
,",",",",O
,discovered,VBD,O
,a,DT,O
,history,NN,O
,of,IN,O
,polydipsia,NN,B-DISEASE
,and,CC,O
,long,JJ,O
,-,:,O
,standing,VBG,O
,lithium,NN,O
,use,NN,O
,.,.,O
,Lithium,NN,O
,is,VBZ,O
,implicated,VBN,O
,in,IN,O
,drug,NN,O
,-,:,O
,induced,VBN,O
,nephrogenic,JJ,B-DISEASE
,DI,NNP,I-DISEASE
,",",",",O
,and,CC,O
,because,IN,O
,the,DT,O
,patient,NN,O
,had,VBD,O
,not,RB,O
,received,VBN,O
,lithium,NN,O
,since,IN,O
,being,VBG,O
,admitted,VBN,O
,to,TO,O
,the,DT,O
,hospital,NN,O
,",",",",O
,his,PRP$,O
,treatment,NN,O
,changed,VBD,O
,to,TO,O
,focus,VB,O
,on,IN,O
,nephrogenic,JJ,B-DISEASE
,DI,NNP,I-DISEASE
,.,.,O
,By,IN,O
,combining,VBG,O
,information,NN,O
,from,IN,O
,the,DT,O
,patient,JJ,O
,history,NN,O
,",",",",O
,the,DT,O
,physical,JJ,O
,examination,NN,O
,",",",",O
,and,CC,O
,radiologic,NN,O
,and,CC,O
,laboratory,NN,O
,studies,NNS,O
,",",",",O
,the,DT,O
,critical,JJ,O
,care,NN,O
,team,NN,O
,demonstrated,VBD,O
,that,IN,O
,the,DT,O
,patient,NN,O
,had,VBD,O
,been,VBN,O
,self,VBN,O
,-,:,O
,treating,VBG,O
,his,PRP$,O
,lithium,NN,O
,-,:,O
,induced,JJ,O
,nephrogenic,JJ,B-DISEASE
,DI,NNP,I-DISEASE
,and,CC,O
,developed,VBD,O
,neurogenic,JJ,B-DISEASE
,DI,NNP,I-DISEASE
,secondary,NN,O
,to,TO,O
,brain,NN,B-DISEASE
,trauma,NN,I-DISEASE
,.,.,O
,Thus,RB,O
,successful,JJ,O
,treatment,NN,O
,required,VBN,O
,that,IN,O
,nephrogenic,JJ,O
,and,CC,O
,neurogenic,JJ,B-DISEASE
,DI,NNP,I-DISEASE
,be,VB,O
,treated,VBN,O
,concomitantly,RB,O
,.,.,O
,Factors,NNS,O
,contributing,VBG,O
,to,TO,O
,ribavirin,VB,O
,-,:,O
,induced,JJ,O
,anemia,NN,B-DISEASE
,.,.,O
,BACKGROUND,NNP,O
,AND,CC,O
,AIM,NNP,O
,:,:,O
,Interferon,NNP,O
,and,CC,O
,ribavirin,VB,O
,combination,NN,O
,therapy,NN,O
,for,IN,O
,chronic,JJ,B-DISEASE
,hepatitis,NN,I-DISEASE
,C,NNP,I-DISEASE
,produces,VBZ,O
,hemolytic,JJ,B-DISEASE
,anemia,NN,I-DISEASE
,.,.,O
,This,DT,O
,study,NN,O
,was,VBD,O
,conducted,VBN,O
,to,TO,O
,identify,VB,O
,the,DT,O
,factors,NNS,O
,contributing,VBG,O
,to,TO,O
,ribavirin,VB,O
,-,:,O
,induced,JJ,O
,anemia,NN,B-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,Eighty,NNP,O
,-,:,O
,eight,CD,O
,patients,NNS,O
,with,IN,O
,chronic,JJ,B-DISEASE
,hepatitis,NN,I-DISEASE
,C,NNP,I-DISEASE
,who,WP,O
,received,VBD,O
,interferon,SYM,O
,-,:,O
,alpha,NN,O
,-,:,O
,2b,CD,O
,at,IN,O
,a,DT,O
,dose,NN,O
,of,IN,O
,6,CD,O
,MU,NNP,O
,administered,VBD,O
,intramuscularly,RB,O
,for,IN,O
,24,CD,O
,weeks,NNS,O
,in,IN,O
,combination,NN,O
,with,IN,O
,ribavirin,NN,O
,administered,VBN,O
,orally,RB,O
,at,IN,O
,a,DT,O
,dose,NN,O
,of,IN,O
,600,CD,O
,mg,NNS,O
,or,CC,O
,800,CD,O
,mg,NNS,O
,participated,VBN,O
,in,IN,O
,the,DT,O
,study,NN,O
,.,.,O
,A,DT,O
,hemoglobin,JJ,O
,concentration,NN,O
,of,IN,O
,<,$,O
,10,CD,O
,g,NN,O
,/,NNP,O
,dL,NN,O
,was,VBD,O
,defined,VBN,O
,as,IN,O
,ribavirin,JJ,O
,-,:,O
,induced,JJ,O
,anemia,NN,B-DISEASE
,.,.,O
,RESULTS,NN,O
,:,:,O
,Ribavirin,NNP,O
,-,:,O
,induced,VBD,O
,anemia,NN,B-DISEASE
,occurred,VBD,O
,in,IN,O
,18,CD,O
,(,(,O
,20,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,),),O
,patients,NNS,O
,during,IN,O
,treatment,NN,O
,.,.,O
,A,DT,O
,2,CD,O
,g,NN,O
,/,NNP,O
,dL,NN,O
,decrease,NN,O
,in,IN,O
,hemoglobin,JJ,O
,concentrations,NNS,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,anemia,NN,B-DISEASE
,was,VBD,O
,observed,VBN,O
,at,IN,O
,week,NN,O
,2,CD,O
,after,IN,O
,the,DT,O
,start,NN,O
,of,IN,O
,treatment,NN,O
,.,.,O
,The,DT,O
,hemoglobin,JJ,O
,concentration,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,>,NNP,O
,or,CC,O
,=,$,O
,2,CD,O
,g,NN,O
,/,NNP,O
,dL,NN,O
,decrease,NN,O
,at,IN,O
,week,NN,O
,2,CD,O
,was,VBD,O
,observed,VBN,O
,to,TO,O
,be,VB,O
,significantly,RB,O
,lower,JJR,O
,even,RB,O
,after,IN,O
,week,NN,O
,2,CD,O
,than,IN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,<,JJ,O
,2,CD,O
,g,NN,O
,/,NNP,O
,dL,NN,O
,decrease,NN,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,A,DT,O
,significant,JJ,O
,relationship,NN,O
,was,VBD,O
,observed,VBN,O
,between,IN,O
,the,DT,O
,rate,NN,O
,of,IN,O
,reduction,NN,O
,of,IN,O
,hemoglobin,JJ,O
,concentrations,NNS,O
,at,IN,O
,week,NN,O
,2,CD,O
,and,CC,O
,the,DT,O
,severity,NN,O
,of,IN,O
,anemia,NN,B-DISEASE
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,Such,JJ,O
,factors,NNS,O
,as,IN,O
,sex,NN,O
,(,(,O
,female,JJ,O
,),),O
,",",",",O
,age,NN,O
,(,(,O
,>,CD,O
,or,CC,O
,=,$,O
,60,CD,O
,years,NNS,O
,old,JJ,O
,),),O
,",",",",O
,and,CC,O
,the,DT,O
,ribavirin,NN,O
,dose,NN,O
,by,IN,O
,body,NN,O
,weight,NN,O
,(,(,O
,12,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,or,CC,O
,more,JJR,O
,),),O
,were,VBD,O
,significant,JJ,O
,by,IN,O
,univariate,JJ,O
,analysis,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Careful,JJ,O
,administration,NN,O
,is,VBZ,O
,necessary,JJ,O
,in,IN,O
,patients,NNS,O
,>,VBP,O
,or,CC,O
,=,VBP,O
,60,CD,O
,years,NNS,O
,old,JJ,O
,",",",",O
,in,IN,O
,female,JJ,O
,patients,NNS,O
,",",",",O
,and,CC,O
,in,IN,O
,patients,NNS,O
,receiving,VBG,O
,a,DT,O
,ribavirin,NN,O
,dose,NN,O
,of,IN,O
,12,CD,O
,mg,NNS,O
,/,JJ,O
,kg,NN,O
,or,CC,O
,more,JJR,O
,.,.,O
,Patients,NNS,O
,who,WP,O
,experience,VBP,O
,a,DT,O
,fall,NN,O
,in,IN,O
,hemoglobin,JJ,O
,concentrations,NNS,O
,of,IN,O
,2,CD,O
,g,NNS,O
,/,JJ,O
,dL,NN,O
,or,CC,O
,more,JJR,O
,at,IN,O
,week,NN,O
,2,CD,O
,after,IN,O
,the,DT,O
,start,NN,O
,of,IN,O
,treatment,NN,O
,should,MD,O
,be,VB,O
,monitored,VBN,O
,with,IN,O
,particular,JJ,O
,care,NN,O
,.,.,O
,Zidovudine,NNP,O
,-,:,O
,induced,VBD,O
,hepatitis,NN,B-DISEASE
,.,.,O
,A,DT,O
,case,NN,O
,of,IN,O
,acute,NN,O
,hepatitis,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,zidovudine,NN,O
,in,IN,O
,a,DT,O
,38,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,patient,NN,O
,with,IN,O
,AIDS,NNP,B-DISEASE
,is,VBZ,O
,presented,VBN,O
,.,.,O
,The,DT,O
,mechanism,NN,O
,whereby,VBD,O
,the,DT,O
,hepatitis,NN,B-DISEASE
,was,VBD,O
,induced,VBN,O
,is,VBZ,O
,not,RB,O
,known,VBN,O
,.,.,O
,However,RB,O
,",",",",O
,the,DT,O
,patient,NN,O
,tolerated,VBD,O
,well,RB,O
,an,DT,O
,alternative,JJ,O
,reverse,NN,O
,transcriptase,NN,O
,inhibitor,NN,O
,",",",",O
,2,CD,O
,',POS,O
,3,CD,O
,',POS,O
,dideoxyinosine,NN,O
,.,.,O
,Physicians,NNPS,O
,caring,VBG,O
,for,IN,O
,patients,NNS,O
,with,IN,O
,AIDS,NNP,B-DISEASE
,should,MD,O
,be,VB,O
,aware,JJ,O
,of,IN,O
,this,DT,O
,hitherto,NN,O
,rarely,RB,O
,reported,VBD,O
,complication,NN,O
,.,.,O
,Oxidative,JJ,O
,damage,NN,O
,precedes,NNS,O
,nitrative,JJ,O
,damage,NN,O
,in,IN,O
,adriamycin,JJ,O
,-,:,O
,induced,JJ,O
,cardiac,JJ,O
,mitochondrial,JJ,B-DISEASE
,injury,NN,I-DISEASE
,.,.,O
,The,DT,O
,purpose,NN,O
,of,IN,O
,the,DT,O
,present,JJ,O
,study,NN,O
,was,VBD,O
,to,TO,O
,determine,VB,O
,if,IN,O
,elevated,VBN,O
,reactive,JJ,O
,oxygen,NN,O
,(,(,O
,ROS,NNP,O
,),),O
,/,VBP,O
,nitrogen,JJ,O
,species,NNS,O
,(,(,O
,RNS,NNP,O
,),),O
,reported,VBD,O
,to,TO,O
,be,VB,O
,present,JJ,O
,in,IN,O
,adriamycin,NN,O
,(,(,O
,ADR,NNP,O
,),),O
,-,:,O
,induced,VBN,O
,cardiotoxicity,NN,B-DISEASE
,actually,RB,O
,resulted,VBD,O
,in,IN,O
,cardiomyocyte,JJ,O
,oxidative,JJ,O
,/,NN,O
,nitrative,JJ,O
,damage,NN,O
,",",",",O
,and,CC,O
,to,TO,O
,quantitatively,RB,O
,determine,VB,O
,the,DT,O
,time,NN,O
,course,NN,O
,and,CC,O
,subcellular,JJ,O
,localization,NN,O
,of,IN,O
,these,DT,O
,postulated,VBN,O
,damage,NN,O
,products,NNS,O
,using,VBG,O
,an,DT,O
,in,IN,O
,vivo,NN,O
,approach,NN,O
,.,.,O
,B6C3,NNP,O
,mice,NN,O
,were,VBD,O
,treated,VBN,O
,with,IN,O
,a,DT,O
,single,JJ,O
,dose,NN,O
,of,IN,O
,20,CD,O
,mg,NNS,O
,/,JJ,O
,kg,JJ,O
,ADR,NNP,O
,.,.,O
,Ultrastructural,JJ,O
,damage,NN,O
,and,CC,O
,levels,NNS,O
,of,IN,O
,4,CD,O
,-,:,O
,hydroxy,NN,O
,-,:,O
,2,CD,O
,-,:,O
,nonenal,JJ,O
,(,(,O
,4HNE,CD,O
,),),O
,-,:,O
,protein,NN,O
,adducts,NNS,O
,and,CC,O
,3,CD,O
,-,:,O
,nitrotyrosine,NN,O
,(,(,O
,3NT,CD,O
,),),O
,were,VBD,O
,analyzed,VBN,O
,.,.,O
,Quantitative,JJ,O
,ultrastructural,JJ,O
,damage,NN,O
,using,VBG,O
,computerized,JJ,O
,image,NN,O
,techniques,NNS,O
,showed,VBD,O
,cardiomyocyte,JJ,O
,injury,NN,O
,as,RB,O
,early,RB,O
,as,IN,O
,3,CD,O
,hours,NNS,O
,",",",",O
,with,IN,O
,mitochondria,NNS,O
,being,VBG,O
,the,DT,O
,most,RBS,O
,extensively,RB,O
,and,CC,O
,progressively,RB,O
,injured,JJ,O
,subcellular,JJ,O
,organelle,NN,O
,.,.,O
,Analysis,NN,O
,of,IN,O
,4HNE,CD,O
,protein,NNS,O
,adducts,NNS,O
,by,IN,O
,immunogold,JJ,O
,electron,NN,O
,microscopy,NN,O
,showed,VBD,O
,appearance,NN,O
,of,IN,O
,4HNE,CD,O
,protein,NN,O
,adducts,NNS,O
,in,IN,O
,mitochondria,NN,O
,as,RB,O
,early,RB,O
,as,IN,O
,3,CD,O
,hours,NNS,O
,",",",",O
,with,IN,O
,a,DT,O
,peak,NN,O
,at,IN,O
,6,CD,O
,hours,NNS,O
,and,CC,O
,subsequent,JJ,O
,decline,NN,O
,at,IN,O
,24,CD,O
,hours,NNS,O
,.,.,O
,3NT,CD,O
,levels,NNS,O
,were,VBD,O
,significantly,RB,O
,increased,VBN,O
,in,IN,O
,all,DT,O
,subcellular,JJ,O
,compartments,NNS,O
,at,IN,O
,6,CD,O
,hours,NNS,O
,and,CC,O
,subsequently,RB,O
,declined,VBD,O
,at,IN,O
,24,CD,O
,hours,NNS,O
,.,.,O
,Our,PRP$,O
,data,NNS,O
,showed,VBD,O
,ADR,NNP,O
,induced,VBD,O
,4HNE,CD,O
,-,:,O
,protein,NN,O
,adducts,VBZ,O
,in,IN,O
,mitochondria,NN,O
,at,IN,O
,the,DT,O
,same,JJ,O
,time,NN,O
,point,NN,O
,as,IN,O
,when,WRB,O
,mitochondrial,JJ,B-DISEASE
,injury,NN,I-DISEASE
,initially,RB,O
,appeared,VBD,O
,.,.,O
,These,DT,O
,results,NNS,O
,document,NN,O
,for,IN,O
,the,DT,O
,first,JJ,O
,time,NN,O
,in,IN,O
,vivo,NN,O
,that,IN,O
,mitochondrial,JJ,B-DISEASE
,oxidative,JJ,I-DISEASE
,damage,NN,I-DISEASE
,precedes,NNS,O
,nitrative,JJ,O
,damage,NN,O
,.,.,O
,The,DT,O
,progressive,JJ,O
,nature,NN,O
,of,IN,O
,mitochondrial,JJ,B-DISEASE
,injury,NN,I-DISEASE
,suggests,VBZ,O
,that,IN,O
,mitochondria,NN,O
,",",",",O
,not,RB,O
,other,JJ,O
,subcellular,JJ,O
,organelles,NNS,O
,",",",",O
,are,VBP,O
,the,DT,O
,major,JJ,O
,site,NN,O
,of,IN,O
,intracellular,JJ,O
,injury,NN,O
,.,.,O
,Sotalol,NNP,O
,-,:,O
,induced,VBD,O
,coronary,JJ,B-DISEASE
,spasm,NN,I-DISEASE
,in,IN,O
,a,DT,O
,patient,NN,O
,with,IN,O
,dilated,JJ,B-DISEASE
,cardiomyopathy,NN,I-DISEASE
,associated,VBN,O
,with,IN,O
,sustained,JJ,O
,ventricular,JJ,B-DISEASE
,tachycardia,NN,I-DISEASE
,.,.,O
,A,DT,O
,54,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,man,NN,O
,with,IN,O
,severe,JJ,O
,left,VBN,O
,ventricular,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,due,JJ,O
,to,TO,O
,dilated,VB,B-DISEASE
,cardiomyopathy,NN,I-DISEASE
,was,VBD,O
,referred,VBN,O
,to,TO,O
,our,PRP$,O
,hospital,NN,O
,for,IN,O
,symptomatic,JJ,O
,incessant,NN,O
,sustained,VBD,O
,ventricular,JJ,B-DISEASE
,tachycardia,NN,I-DISEASE
,(,(,O
,VT,NNP,B-DISEASE
,),),O
,.,.,O
,After,IN,O
,the,DT,O
,administration,NN,O
,of,IN,O
,nifekalant,JJ,O
,hydrochloride,NN,O
,",",",",O
,sustained,VBD,O
,VT,NNP,B-DISEASE
,was,VBD,O
,terminated,VBN,O
,.,.,O
,An,DT,O
,alternate,JJ,O
,class,NN,O
,III,NNP,O
,agent,NN,O
,",",",",O
,sotalol,NN,O
,",",",",O
,was,VBD,O
,also,RB,O
,effective,JJ,O
,for,IN,O
,the,DT,O
,prevention,NN,O
,of,IN,O
,VT,NNP,B-DISEASE
,.,.,O
,However,RB,O
,",",",",O
,one,CD,O
,month,NN,O
,after,IN,O
,switching,VBG,O
,over,RP,O
,nifekalant,JJ,O
,to,TO,O
,sotalol,VB,O
,",",",",O
,a,DT,O
,short,JJ,O
,duration,NN,O
,of,IN,O
,ST,NNP,O
,elevation,NN,O
,was,VBD,O
,documented,VBN,O
,in,IN,O
,ECG,NNP,O
,monitoring,NN,O
,at,IN,O
,almost,RB,O
,the,DT,O
,same,JJ,O
,time,NN,O
,for,IN,O
,three,CD,O
,consecutive,JJ,O
,days,NNS,O
,.,.,O
,ST,NNP,O
,elevation,NN,O
,with,IN,O
,chest,JJ,O
,discomfort,NN,O
,disappeared,VBD,O
,since,IN,O
,he,PRP,O
,began,VBD,O
,taking,VBG,O
,long,JJ,O
,-,:,O
,acting,VBG,O
,diltiazem,NN,O
,.,.,O
,Coronary,NNP,B-DISEASE
,vasospasm,NN,I-DISEASE
,may,MD,O
,be,VB,O
,induced,VBN,O
,by,IN,O
,the,DT,O
,non,JJ,O
,-,:,O
,selective,JJ,O
,beta,NN,O
,-,:,O
,blocking,VBG,O
,properties,NNS,O
,of,IN,O
,sotalol,NN,O
,.,.,O
,Effects,NNS,O
,of,IN,O
,the,DT,O
,antidepressant,JJ,O
,trazodone,NN,O
,",",",",O
,a,DT,O
,5,CD,O
,-,:,O
,HT,$,O
,2A,CD,O
,/,$,O
,2C,CD,O
,receptor,NN,O
,antagonist,NN,O
,",",",",O
,on,IN,O
,dopamine,JJ,O
,-,:,O
,dependent,JJ,O
,behaviors,NNS,O
,in,IN,O
,rats,NNS,O
,.,.,O
,RATIONALE,NN,O
,:,:,O
,5,CD,O
,-,:,O
,Hydroxytryptamine,NN,O
,",",",",O
,via,IN,O
,stimulation,NN,O
,of,IN,O
,5,CD,O
,-,:,O
,HT,$,O
,2C,CD,O
,receptors,NNS,O
,",",",",O
,exerts,VBZ,O
,a,DT,O
,tonic,JJ,O
,inhibitory,NN,O
,influence,NN,O
,on,IN,O
,dopaminergic,NN,O
,neurotransmission,NN,O
,",",",",O
,whereas,JJ,O
,activation,NN,O
,of,IN,O
,5,CD,O
,-,:,O
,HT,$,O
,2A,CD,O
,receptors,NNS,O
,enhances,NNS,O
,stimulated,VBD,O
,DAergic,NNP,O
,neurotransmission,NN,O
,.,.,O
,The,DT,O
,antidepressant,JJ,O
,trazodone,NN,O
,is,VBZ,O
,a,DT,O
,5,CD,O
,-,:,O
,HT,$,O
,2A,CD,O
,/,$,O
,2C,CD,O
,receptor,NN,O
,antagonist,NN,O
,.,.,O
,OBJECTIVES,NN,O
,:,:,O
,To,TO,O
,evaluate,VB,O
,the,DT,O
,effect,NN,O
,of,IN,O
,trazodone,NN,O
,treatment,NN,O
,on,IN,O
,behaviors,NNS,O
,dependent,VBP,O
,on,IN,O
,the,DT,O
,functional,JJ,O
,status,NN,O
,of,IN,O
,the,DT,O
,nigrostriatal,JJ,O
,DAergic,NNP,O
,system,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,The,DT,O
,effect,NN,O
,of,IN,O
,pretreatment,NN,O
,with,IN,O
,trazodone,NN,O
,on,IN,O
,dexamphetamine,NN,O
,-,:,O
,and,CC,O
,apomorphine,VB,O
,-,:,O
,induced,JJ,O
,oral,JJ,B-DISEASE
,stereotypies,NNS,I-DISEASE
,",",",",O
,on,IN,O
,catalepsy,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,haloperidol,NN,O
,and,CC,O
,apomorphine,NN,O
,(,(,O
,0,CD,O
,.,.,O
,05,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,",",",",O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,",",",",O
,on,IN,O
,ergometrine,JJ,O
,-,:,O
,induced,JJ,O
,wet,NN,O
,dog,NN,O
,shake,NN,O
,(,(,O
,WDS,NNP,O
,),),O
,behavior,NN,O
,and,CC,O
,fluoxetine,JJ,O
,-,:,O
,induced,VBN,O
,penile,IN,O
,erections,NNS,O
,was,VBD,O
,studied,VBN,O
,in,IN,O
,rats,NNS,O
,.,.,O
,We,PRP,O
,also,RB,O
,investigated,VBD,O
,whether,IN,O
,trazodone,NN,O
,induces,NNS,O
,catalepsy,VBP,B-DISEASE
,in,IN,O
,rats,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Trazodone,NN,O
,at,IN,O
,2,CD,O
,.,.,O
,5,CD,O
,-,:,O
,20,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,did,VBD,O
,not,RB,O
,induce,VB,O
,catalepsy,NN,B-DISEASE
,",",",",O
,and,CC,O
,did,VBD,O
,not,RB,O
,antagonize,VB,O
,apomorphine,NN,O
,(,(,O
,1,CD,O
,.,.,O
,5,CD,O
,and,CC,O
,3,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,stereotypy,NN,O
,and,CC,O
,apomorphine,NN,O
,(,(,O
,0,CD,O
,.,.,O
,05,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,),),O
,-,:,O
,induced,VBN,O
,catalepsy,NN,B-DISEASE
,.,.,O
,However,RB,O
,",",",",O
,pretreatment,NN,O
,with,IN,O
,5,CD,O
,",",",",O
,10,CD,O
,and,CC,O
,20,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,trazodone,NN,O
,enhanced,VBD,O
,dexamphetamine,JJ,O
,stereotypy,NN,O
,",",",",O
,and,CC,O
,antagonized,VBD,O
,haloperidol,NN,O
,catalepsy,NN,B-DISEASE
,",",",",O
,ergometrine,JJ,O
,-,:,O
,induced,JJ,O
,WDS,NNP,O
,behavior,NN,O
,and,CC,O
,fluoxetine,JJ,O
,-,:,O
,induced,VBN,O
,penile,JJ,O
,erections,NNS,O
,.,.,O
,Trazodone,NN,O
,at,IN,O
,30,CD,O
,",",",",O
,40,CD,O
,and,CC,O
,50,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,induced,VBN,O
,catalepsy,NN,B-DISEASE
,and,CC,O
,antagonized,JJ,O
,apomorphine,NN,O
,and,CC,O
,dexamphetamine,NN,O
,stereotypies,NNS,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Our,PRP$,O
,results,NNS,O
,indicate,VBP,O
,that,IN,O
,trazodone,NN,O
,at,IN,O
,2,CD,O
,.,.,O
,5,CD,O
,-,:,O
,20,CD,O
,mg,NN,O
,/,FW,O
,kg,NN,O
,does,VBZ,O
,not,RB,O
,block,VB,O
,pre,NN,O
,-,:,O
,and,CC,O
,postsynaptic,JJ,O
,striatal,NN,O
,D2,NNP,O
,DA,NNP,O
,receptors,NNS,O
,",",",",O
,while,IN,O
,at,IN,O
,30,CD,O
,",",",",O
,40,CD,O
,and,CC,O
,50,CD,O
,mg,NN,O
,/,NN,O
,kg,VBD,O
,it,PRP,O
,blocks,VBZ,O
,postsynaptic,JJ,O
,striatal,JJ,O
,D2,NNP,O
,DA,NNP,O
,receptors,NNS,O
,.,.,O
,Furthermore,RB,O
,",",",",O
,at,IN,O
,5,CD,O
,",",",",O
,10,CD,O
,and,CC,O
,20,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,trazodone,NN,O
,blocks,NNS,O
,5,CD,O
,-,:,O
,HT,$,O
,2A,CD,O
,and,CC,O
,5,CD,O
,-,:,O
,HT,$,O
,2C,CD,O
,receptors,NNS,O
,.,.,O
,We,PRP,O
,suggest,VBP,O
,that,IN,O
,trazodone,NN,O
,(,(,O
,5,CD,O
,",",",",O
,10,CD,O
,and,CC,O
,20,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,",",",",O
,by,IN,O
,blocking,VBG,O
,the,DT,O
,5,CD,O
,-,:,O
,HT,$,O
,2C,CD,O
,receptors,NNS,O
,",",",",O
,releases,VBZ,O
,the,DT,O
,nigrostriatal,JJ,O
,DAergic,NNP,O
,neurons,NNS,O
,from,IN,O
,tonic,JJ,O
,inhibition,NN,O
,caused,VBN,O
,by,IN,O
,5,CD,O
,-,:,O
,HT,NN,O
,",",",",O
,and,CC,O
,thereby,RB,O
,potentiates,NNS,O
,dexamphetamine,VBP,O
,stereotypy,NN,O
,and,CC,O
,antagonizes,VBZ,O
,haloperidol,JJ,O
,catalepsy,NN,B-DISEASE
,.,.,O
,Swallowing,VBG,B-DISEASE
,abnormalities,NNS,I-DISEASE
,and,CC,O
,dyskinesia,NN,B-DISEASE
,in,IN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,Gastrointestinal,JJ,B-DISEASE
,abnormalities,NNS,I-DISEASE
,in,IN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,NN,I-DISEASE
,disease,NN,I-DISEASE
,(,(,O
,PD,NNP,B-DISEASE
,),),O
,have,VBP,O
,been,VBN,O
,known,VBN,O
,for,IN,O
,almost,RB,O
,two,CD,O
,centuries,NNS,O
,",",",",O
,but,CC,O
,many,JJ,O
,aspects,NNS,O
,concerning,VBG,O
,their,PRP$,O
,pathophysiology,NN,O
,have,VBP,O
,not,RB,O
,been,VBN,O
,completely,RB,O
,clarified,VBN,O
,.,.,O
,The,DT,O
,aim,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,was,VBD,O
,to,TO,O
,characterize,VB,O
,the,DT,O
,oropharyngeal,NN,O
,dynamics,NNS,O
,in,IN,O
,PD,NNP,B-DISEASE
,patients,NNS,O
,with,IN,O
,and,CC,O
,without,IN,O
,levodopa,JJ,O
,-,:,O
,induced,JJ,O
,dyskinesia,NN,B-DISEASE
,.,.,O
,Fifteen,NNP,O
,dyskinetic,JJ,B-DISEASE
,",",",",O
,12,CD,O
,nondyskinetic,JJ,O
,patients,NNS,O
,",",",",O
,and,CC,O
,a,DT,O
,control,NN,O
,group,NN,O
,were,VBD,O
,included,VBN,O
,.,.,O
,Patients,NNS,O
,were,VBD,O
,asked,VBN,O
,about,IN,O
,dysphagia,NN,B-DISEASE
,and,CC,O
,evaluated,VBN,O
,with,IN,O
,the,DT,O
,Unified,NNP,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,Disease,NNP,I-DISEASE
,Rating,NNP,O
,Scale,NNP,O
,Parts,NNP,O
,II,NNP,O
,and,CC,O
,III,NNP,O
,and,CC,O
,the,DT,O
,Hoehn,NNP,O
,and,CC,O
,Yahr,NNP,O
,scale,NN,O
,.,.,O
,Deglutition,NNP,O
,was,VBD,O
,assessed,VBN,O
,using,VBG,O
,modified,JJ,O
,barium,NN,O
,swallow,NN,O
,with,IN,O
,videofluoroscopy,NN,O
,.,.,O
,Nondyskinetic,JJ,O
,patients,NNS,O
,",",",",O
,but,CC,O
,not,RB,O
,the,DT,O
,dyskinetic,JJ,B-DISEASE
,ones,NNS,O
,",",",",O
,showed,VBD,O
,less,JJR,O
,oropharyngeal,JJ,O
,swallowing,NN,O
,efficiency,NN,O
,(,(,O
,OPSE,NNP,O
,),),O
,for,IN,O
,liquid,NN,O
,food,NN,O
,than,IN,O
,controls,NNS,O
,(,(,O
,Dunnett,NNP,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,02,CD,O
,),),O
,.,.,O
,Dyskinetic,JJ,B-DISEASE
,patients,NNS,O
,tended,VBD,O
,to,TO,O
,have,VB,O
,a,DT,O
,greater,JJR,O
,OPSE,NNP,O
,than,IN,O
,nondyskinetic,JJ,O
,(,(,O
,Dunnett,NNP,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,06,CD,O
,),),O
,.,.,O
,Patients,NNS,O
,who,WP,O
,were,VBD,O
,using,VBG,O
,a,DT,O
,higher,JJR,O
,dose,NN,O
,of,IN,O
,levodopa,NN,O
,had,VBD,O
,a,DT,O
,greater,JJR,O
,OPSE,NNP,O
,and,CC,O
,a,DT,O
,trend,NN,O
,toward,IN,O
,a,DT,O
,smaller,JJR,O
,oral,JJ,O
,transit,NN,O
,time,NN,O
,(,(,O
,Pearson,NNP,O
,',POS,O
,s,NN,O
,correlation,NN,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,01,CD,O
,and,CC,O
,0,CD,O
,.,.,O
,08,CD,O
,",",",",O
,respectively,RB,O
,),),O
,.,.,O
,Neither,CC,O
,the,DT,O
,report,NN,O
,of,IN,O
,dysphagia,NNS,B-DISEASE
,nor,CC,O
,any,DT,O
,of,IN,O
,the,DT,O
,PD,NNP,B-DISEASE
,severity,NN,O
,parameters,NNS,O
,correlated,VBD,O
,to,TO,O
,the,DT,O
,videofluoroscopic,NN,O
,variables,NNS,O
,.,.,O
,In,IN,O
,the,DT,O
,current,JJ,O
,study,NN,O
,",",",",O
,dyskinetic,JJ,B-DISEASE
,patients,NNS,O
,performed,VBD,O
,better,RBR,O
,in,IN,O
,swallowing,VBG,O
,function,NN,O
,",",",",O
,which,WDT,O
,could,MD,O
,be,VB,O
,explained,VBN,O
,on,IN,O
,the,DT,O
,basis,NN,O
,of,IN,O
,a,DT,O
,greater,JJR,O
,levodopa,NN,O
,dose,NN,O
,.,.,O
,Our,PRP$,O
,results,NNS,O
,suggest,VBP,O
,a,DT,O
,role,NN,O
,for,IN,O
,levodopa,NN,O
,in,IN,O
,the,DT,O
,oral,JJ,O
,phase,NN,O
,of,IN,O
,deglutition,NN,O
,and,CC,O
,confirm,NN,O
,that,IN,O
,dysphagia,NN,B-DISEASE
,is,VBZ,O
,not,RB,O
,a,DT,O
,good,JJ,O
,predictor,NN,O
,of,IN,O
,deglutition,NN,O
,alterations,NNS,O
,in,IN,O
,PD,NNP,B-DISEASE
,.,.,O
,Inhibition,NN,O
,of,IN,O
,nuclear,JJ,O
,factor,NN,O
,-,:,O
,kappaB,NN,O
,activation,NN,O
,attenuates,VBZ,O
,tubulointerstitial,JJ,B-DISEASE
,nephritis,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,gentamicin,NN,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Animals,NNS,O
,treated,VBD,O
,with,IN,O
,gentamicin,NN,O
,can,MD,O
,show,VB,O
,residual,JJ,O
,areas,NNS,O
,of,IN,O
,interstitial,JJ,O
,fibrosis,NN,B-DISEASE
,in,IN,O
,the,DT,O
,renal,JJ,O
,cortex,NN,O
,.,.,O
,This,DT,O
,study,NN,O
,investigated,VBD,O
,the,DT,O
,expression,NN,O
,of,IN,O
,nuclear,JJ,O
,factor,NN,O
,-,:,O
,kappaB,NN,O
,(,(,O
,NF,NNP,O
,-,:,O
,kappaB,NN,O
,),),O
,",",",",O
,mitogen,SYM,O
,-,:,O
,activated,VBN,O
,protein,NN,O
,(,(,O
,MAP,NNP,O
,),),O
,kinases,NNS,O
,and,CC,O
,macrophages,NNS,O
,in,IN,O
,the,DT,O
,renal,JJ,O
,cortex,NN,O
,and,CC,O
,structural,JJ,O
,and,CC,O
,functional,JJ,O
,renal,JJ,O
,changes,NNS,O
,of,IN,O
,rats,NNS,O
,treated,VBN,O
,with,IN,O
,gentamicin,NN,O
,or,CC,O
,gentamicin,NN,O
,+,JJ,O
,pyrrolidine,NN,O
,dithiocarbamate,NN,O
,(,(,O
,PDTC,NNP,O
,),),O
,",",",",O
,an,DT,O
,NF,NNP,O
,-,:,O
,kappaB,NN,O
,inhibitor,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,38,CD,O
,female,JJ,O
,Wistar,NNP,O
,rats,NNS,O
,were,VBD,O
,injected,VBN,O
,with,IN,O
,gentamicin,NN,O
,",",",",O
,40,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,twice,RB,O
,a,DT,O
,day,NN,O
,for,IN,O
,9,CD,O
,days,NNS,O
,",",",",O
,38,CD,O
,with,IN,O
,gentamicin,NN,O
,+,NNP,O
,PDTC,NNP,O
,",",",",O
,and,CC,O
,28,CD,O
,with,IN,O
,0,CD,O
,.,.,O
,15,CD,O
,M,NNP,O
,NaCl,NNP,O
,solution,NN,O
,.,.,O
,The,DT,O
,animals,NNS,O
,were,VBD,O
,killed,VBN,O
,5,CD,O
,and,CC,O
,30,CD,O
,days,NNS,O
,after,IN,O
,these,DT,O
,injections,NNS,O
,and,CC,O
,the,DT,O
,kidneys,NNS,O
,were,VBD,O
,removed,VBN,O
,for,IN,O
,histological,JJ,O
,and,CC,O
,immunohistochemical,JJ,O
,studies,NNS,O
,.,.,O
,The,DT,O
,results,NNS,O
,of,IN,O
,the,DT,O
,immunohistochemical,JJ,O
,studies,NNS,O
,were,VBD,O
,scored,VBN,O
,according,VBG,O
,to,TO,O
,the,DT,O
,extent,NN,O
,of,IN,O
,staining,VBG,O
,.,.,O
,The,DT,O
,fractional,JJ,O
,interstitial,JJ,O
,area,NN,O
,was,VBD,O
,determined,VBN,O
,by,IN,O
,morphometry,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Gentamicin,NNP,O
,-,:,O
,treated,VBD,O
,rats,NNS,O
,presented,VBD,O
,a,DT,O
,transitory,JJ,O
,increase,NN,O
,in,IN,O
,plasma,JJ,O
,creatinine,NN,O
,levels,NNS,O
,.,.,O
,Increased,VBN,O
,ED,NNP,O
,-,:,O
,1,CD,O
,",",",",O
,MAP,NNP,O
,kinases,VBZ,O
,and,CC,O
,NF,NNP,O
,-,:,O
,kappaB,NN,O
,staining,NN,O
,were,VBD,O
,also,RB,O
,observed,VBN,O
,in,IN,O
,the,DT,O
,renal,JJ,O
,cortex,NN,O
,from,IN,O
,all,DT,O
,gentamicin,SYM,O
,-,:,O
,treated,VBN,O
,rats,NNS,O
,compared,VBN,O
,to,TO,O
,control,VB,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,The,DT,O
,animals,NNS,O
,killed,VBN,O
,on,IN,O
,day,NN,O
,30,CD,O
,also,RB,O
,presented,VBN,O
,fibrosis,NN,B-DISEASE
,in,IN,O
,the,DT,O
,renal,JJ,O
,cortex,NN,O
,despite,IN,O
,the,DT,O
,recovery,NN,O
,of,IN,O
,renal,JJ,O
,function,NN,O
,.,.,O
,Treatment,NN,O
,with,IN,O
,PDTC,NNP,O
,reduced,VBD,O
,the,DT,O
,functional,JJ,O
,and,CC,O
,structural,JJ,O
,changes,NNS,O
,induced,VBN,O
,by,IN,O
,gentamicin,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,These,DT,O
,data,NNS,O
,show,VBP,O
,that,IN,O
,inhibition,NN,O
,of,IN,O
,NF,NNP,O
,-,:,O
,kappaB,NN,O
,activation,NN,O
,attenuates,VBZ,O
,tubulointerstitial,JJ,B-DISEASE
,nephritis,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,gentamicin,NN,O
,.,.,O
,Glucose,NNP,O
,metabolism,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,schizophrenia,NN,B-DISEASE
,treated,VBN,O
,with,IN,O
,atypical,JJ,O
,antipsychotic,JJ,O
,agents,NNS,O
,:,:,O
,a,DT,O
,frequently,RB,O
,sampled,VBN,O
,intravenous,JJ,O
,glucose,JJ,O
,tolerance,NN,O
,test,NN,O
,and,CC,O
,minimal,JJ,O
,model,NN,O
,analysis,NN,O
,.,.,O
,BACKGROUND,NNP,O
,:,:,O
,While,IN,O
,the,DT,O
,incidence,NN,O
,of,IN,O
,new,JJ,O
,-,:,O
,onset,NN,O
,diabetes,VBZ,B-DISEASE
,mellitus,NNS,I-DISEASE
,may,MD,O
,be,VB,O
,increasing,VBG,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,schizophrenia,NN,B-DISEASE
,treated,VBN,O
,with,IN,O
,certain,JJ,O
,atypical,JJ,O
,antipsychotic,JJ,O
,agents,NNS,O
,",",",",O
,it,PRP,O
,remains,VBZ,O
,unclear,JJ,O
,whether,IN,O
,atypical,JJ,O
,agents,NNS,O
,are,VBP,O
,directly,RB,O
,affecting,VBG,O
,glucose,JJ,O
,metabolism,NN,O
,or,CC,O
,simply,RB,O
,increasing,VBG,O
,known,VBN,O
,risk,NN,O
,factors,NNS,O
,for,IN,O
,diabetes,NNS,B-DISEASE
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,To,TO,O
,study,VB,O
,the,DT,O
,2,CD,O
,drugs,NNS,O
,most,RBS,O
,clearly,RB,O
,implicated,VBN,O
,(,(,O
,clozapine,NN,O
,and,CC,O
,olanzapine,NN,O
,),),O
,and,CC,O
,risperidone,NN,O
,using,VBG,O
,a,DT,O
,frequently,RB,O
,sampled,VBN,O
,intravenous,JJ,O
,glucose,JJ,O
,tolerance,NN,O
,test,NN,O
,.,.,O
,DESIGN,NN,O
,:,:,O
,A,DT,O
,cross,NN,O
,-,:,O
,sectional,JJ,O
,design,NN,O
,in,IN,O
,stable,JJ,O
,",",",",O
,treated,JJ,O
,patients,NNS,O
,with,IN,O
,schizophrenia,NN,B-DISEASE
,evaluated,VBN,O
,using,VBG,O
,a,DT,O
,frequently,RB,O
,sampled,VBN,O
,intravenous,JJ,O
,glucose,JJ,O
,tolerance,NN,O
,test,NN,O
,and,CC,O
,the,DT,O
,Bergman,NNP,O
,minimal,JJ,O
,model,NN,O
,analysis,NN,O
,.,.,O
,SETTING,NN,O
,:,:,O
,Subjects,NNS,O
,were,VBD,O
,recruited,VBN,O
,from,IN,O
,an,DT,O
,urban,JJ,O
,community,NN,O
,mental,JJ,O
,health,NN,O
,clinic,NN,O
,and,CC,O
,were,VBD,O
,studied,VBN,O
,at,IN,O
,a,DT,O
,general,JJ,O
,clinical,JJ,O
,research,NN,O
,center,NN,O
,.,.,O
,Patients,NNS,O
,Fifty,JJ,O
,subjects,NNS,O
,signed,VBD,O
,informed,JJ,O
,consent,NN,O
,and,CC,O
,41,CD,O
,underwent,NN,O
,the,DT,O
,frequently,RB,O
,sampled,VBN,O
,intravenous,JJ,O
,glucose,JJ,O
,tolerance,NN,O
,test,NN,O
,.,.,O
,Thirty,NNP,O
,-,:,O
,six,CD,O
,nonobese,JJ,O
,subjects,NNS,O
,with,IN,O
,schizophrenia,NN,B-DISEASE
,or,CC,O
,schizoaffective,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,",",",",O
,matched,VBN,O
,by,IN,O
,body,NN,O
,mass,NN,O
,index,NN,O
,and,CC,O
,treated,VBN,O
,with,IN,O
,either,DT,O
,clozapine,NN,O
,",",",",O
,olanzapine,NN,O
,",",",",O
,or,CC,O
,risperidone,NN,O
,",",",",O
,were,VBD,O
,included,VBN,O
,in,IN,O
,the,DT,O
,analysis,NN,O
,.,.,O
,MAIN,NNP,O
,OUTCOME,NNP,O
,MEASURES,NNP,O
,:,:,O
,Fasting,VBG,O
,plasma,NN,O
,glucose,NN,O
,and,CC,O
,fasting,VBG,O
,serum,JJ,O
,insulin,NN,O
,levels,NNS,O
,",",",",O
,insulin,NN,B-DISEASE
,sensitivity,NN,I-DISEASE
,index,NN,O
,",",",",O
,homeostasis,NN,O
,model,NN,O
,assessment,NN,O
,of,IN,O
,insulin,NN,B-DISEASE
,resistance,NN,I-DISEASE
,",",",",O
,and,CC,O
,glucose,JJ,O
,effectiveness,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,The,DT,O
,mean,JJ,O
,+,NNP,O
,/,NNP,O
,-,:,O
,SD,NNP,O
,duration,NN,O
,of,IN,O
,treatment,NN,O
,with,IN,O
,the,DT,O
,identified,JJ,O
,atypical,JJ,O
,antipsychotic,JJ,O
,agent,NN,O
,was,VBD,O
,68,CD,O
,.,.,O
,3,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,28,CD,O
,.,.,O
,9,CD,O
,months,NNS,O
,(,(,O
,clozapine,NN,O
,),),O
,",",",",O
,29,CD,O
,.,.,O
,5,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,17,CD,O
,.,.,O
,5,CD,O
,months,NNS,O
,(,(,O
,olanzapine,NN,O
,),),O
,",",",",O
,and,CC,O
,40,CD,O
,.,.,O
,9,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,33,CD,O
,.,.,O
,7,CD,O
,(,(,O
,risperidone,NN,O
,),),O
,.,.,O
,Fasting,VBG,O
,serum,JJ,O
,insulin,NN,O
,concentrations,NNS,O
,differed,VBD,O
,among,IN,O
,groups,NNS,O
,(,(,O
,F,NNP,O
,(,(,O
,33,CD,O
,),),O
,=,NN,O
,3,CD,O
,.,.,O
,35,CD,O
,;,:,O
,P,NNP,O
,=,NNP,O
,.,.,O
,047,CD,O
,),),O
,(,(,O
,clozapine,JJ,O
,>,NNP,O
,olanzapine,NN,O
,>,NNP,O
,risperidone,NN,O
,),),O
,with,IN,O
,significant,JJ,O
,differences,NNS,O
,between,IN,O
,clozapine,NN,O
,and,CC,O
,risperidone,NN,O
,(,(,O
,t,NN,O
,(,(,O
,33,CD,O
,),),O
,=,NN,O
,2,CD,O
,.,.,O
,32,CD,O
,;,:,O
,P,NNP,O
,=,NNP,O
,.,.,O
,03,CD,O
,),),O
,and,CC,O
,olanzapine,JJ,O
,and,CC,O
,risperidone,NN,O
,(,(,O
,t,NN,O
,(,(,O
,33,CD,O
,),),O
,=,NN,O
,2,CD,O
,.,.,O
,15,CD,O
,;,:,O
,P,NNP,O
,=,NNP,O
,.,.,O
,04,CD,O
,),),O
,.,.,O
,There,EX,O
,was,VBD,O
,a,DT,O
,significant,JJ,O
,difference,NN,O
,in,IN,O
,insulin,NN,B-DISEASE
,sensitivity,NN,I-DISEASE
,index,NN,O
,among,IN,O
,groups,NNS,O
,(,(,O
,F,NNP,O
,(,(,O
,33,CD,O
,),),O
,=,NN,O
,10,CD,O
,.,.,O
,66,CD,O
,;,:,O
,P,NNP,O
,<,NNP,O
,.,.,O
,001,CD,O
,),),O
,(,(,O
,clozapine,JJ,O
,<,NNP,O
,olanzapine,NN,O
,<,NNP,O
,risperidone,NN,O
,),),O
,",",",",O
,with,IN,O
,subjects,NNS,O
,who,WP,O
,received,VBD,O
,clozapine,NN,O
,and,CC,O
,olanzapine,NN,O
,exhibiting,VBG,O
,significant,JJ,O
,insulin,NN,B-DISEASE
,resistance,NN,I-DISEASE
,compared,VBN,O
,with,IN,O
,subjects,NNS,O
,who,WP,O
,were,VBD,O
,treated,VBN,O
,with,IN,O
,risperidone,NN,O
,(,(,O
,clozapine,JJ,O
,vs,NN,O
,risperidone,NN,O
,",",",",O
,t,NN,O
,(,(,O
,33,CD,O
,),),O
,=,SYM,O
,-,:,O
,4,CD,O
,.,.,O
,29,CD,O
,;,:,O
,P,NNP,O
,<,NNP,O
,.,.,O
,001,CD,O
,;,:,O
,olanzapine,JJ,O
,vs,NN,O
,risperidone,NN,O
,",",",",O
,t,NN,O
,(,(,O
,33,CD,O
,),),O
,=,SYM,O
,-,:,O
,3,CD,O
,.,.,O
,62,CD,O
,;,:,O
,P,NNP,O
,=,NNP,O
,.,.,O
,001,CD,O
,[,JJ,O
,P,NNP,O
,<,NNP,O
,.,.,O
,001,CD,O
,],NN,O
,),),O
,.,.,O
,The,DT,O
,homeostasis,NN,O
,model,NN,O
,assessment,NN,O
,of,IN,O
,insulin,NN,B-DISEASE
,resistance,NN,I-DISEASE
,also,RB,O
,differed,VBD,O
,significantly,RB,O
,among,IN,O
,groups,NNS,O
,(,(,O
,F,NNP,O
,(,(,O
,33,CD,O
,),),O
,=,NN,O
,4,CD,O
,.,.,O
,92,CD,O
,;,:,O
,P,NNP,O
,=,NNP,O
,.,.,O
,01,CD,O
,),),O
,(,(,O
,clozapine,JJ,O
,>,NNP,O
,olanzapine,NN,O
,>,NNP,O
,risperidone,NN,O
,),),O
,(,(,O
,clozapine,JJ,O
,vs,NN,O
,risperidone,NN,O
,",",",",O
,t,NN,O
,(,(,O
,33,CD,O
,),),O
,=,NN,O
,2,CD,O
,.,.,O
,94,CD,O
,;,:,O
,P,NNP,O
,=,NNP,O
,.,.,O
,006,CD,O
,;,:,O
,olanzapine,JJ,O
,vs,NN,O
,risperidone,NN,O
,",",",",O
,t,NN,O
,(,(,O
,33,CD,O
,),),O
,=,NN,O
,2,CD,O
,.,.,O
,42,CD,O
,;,:,O
,P,NNP,O
,=,NNP,O
,.,.,O
,02,CD,O
,),),O
,.,.,O
,There,EX,O
,was,VBD,O
,a,DT,O
,significant,JJ,O
,difference,NN,O
,among,IN,O
,groups,NNS,O
,in,IN,O
,glucose,JJ,O
,effectiveness,NN,O
,(,(,O
,F,NNP,O
,(,(,O
,30,CD,O
,),),O
,=,NN,O
,4,CD,O
,.,.,O
,18,CD,O
,;,:,O
,P,NNP,O
,=,NNP,O
,.,.,O
,02,CD,O
,),),O
,(,(,O
,clozapine,JJ,O
,<,NNP,O
,olanzapine,NN,O
,<,NNP,O
,risperidone,NN,O
,),),O
,with,IN,O
,significant,JJ,O
,differences,NNS,O
,between,IN,O
,clozapine,NN,O
,and,CC,O
,risperidone,NN,O
,(,(,O
,t,NN,O
,(,(,O
,30,CD,O
,),),O
,=,SYM,O
,-,:,O
,2,CD,O
,.,.,O
,59,CD,O
,;,:,O
,P,NNP,O
,=,NNP,O
,.,.,O
,02,CD,O
,),),O
,and,CC,O
,olanzapine,JJ,O
,and,CC,O
,risperidone,NN,O
,(,(,O
,t,NN,O
,(,(,O
,30,CD,O
,),),O
,=,SYM,O
,-,:,O
,2,CD,O
,.,.,O
,34,CD,O
,",",",",O
,P,NNP,O
,=,NNP,O
,.,.,O
,03,CD,O
,),),O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Both,DT,O
,nonobese,JJ,O
,clozapine,NN,O
,-,:,O
,and,CC,O
,olanzapine,VB,O
,-,:,O
,treated,VBN,O
,groups,NNS,O
,displayed,VBD,O
,significant,JJ,O
,insulin,NN,B-DISEASE
,resistance,NN,I-DISEASE
,and,CC,O
,impairment,NN,O
,of,IN,O
,glucose,JJ,O
,effectiveness,NN,O
,compared,VBN,O
,with,IN,O
,risperidone,NN,O
,-,:,O
,treated,JJ,O
,subjects,NNS,O
,.,.,O
,Patients,NNS,O
,taking,VBG,O
,clozapine,NN,O
,and,CC,O
,olanzapine,NN,O
,must,MD,O
,be,VB,O
,examined,VBN,O
,for,IN,O
,insulin,NN,B-DISEASE
,resistance,NN,I-DISEASE
,and,CC,O
,its,PRP$,O
,consequences,NNS,O
,.,.,O
,Thoracic,NNP,B-DISEASE
,hematomyelia,VBD,I-DISEASE
,secondary,JJ,O
,to,TO,O
,coumadin,VB,O
,anticoagulant,JJ,O
,therapy,NN,O
,:,:,O
,a,DT,O
,case,NN,O
,report,NN,O
,.,.,O
,A,DT,O
,case,NN,O
,of,IN,O
,thoracic,NN,B-DISEASE
,hematomyelia,NNS,I-DISEASE
,secondary,JJ,O
,to,TO,O
,anticoagulant,JJ,O
,therapy,NN,O
,is,VBZ,O
,presented,VBN,O
,.,.,O
,Clinical,JJ,O
,features,NNS,O
,",",",",O
,similar,JJ,O
,to,TO,O
,2,CD,O
,other,JJ,O
,previously,RB,O
,reported,VBN,O
,cases,NNS,O
,",",",",O
,are,VBP,O
,discussed,VBN,O
,.,.,O
,A,DT,O
,high,JJ,O
,index,NN,O
,of,IN,O
,suspicion,NN,O
,may,MD,O
,lead,VB,O
,to,TO,O
,a,DT,O
,quick,JJ,O
,diagnostic,JJ,O
,procedure,NN,O
,and,CC,O
,successful,JJ,O
,decompressive,JJ,O
,surgery,NN,O
,.,.,O
,Mania,NNP,B-DISEASE
,associated,VBD,O
,with,IN,O
,fluoxetine,JJ,O
,treatment,NN,O
,in,IN,O
,adolescents,NNS,O
,.,.,O
,Fluoxetine,NNP,O
,",",",",O
,a,DT,O
,selective,JJ,O
,serotonin,NN,O
,reuptake,NN,O
,inhibitor,NN,O
,",",",",O
,is,VBZ,O
,gaining,VBG,O
,increased,VBN,O
,acceptance,NN,O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,adolescent,JJ,O
,depression,NN,B-DISEASE
,.,.,O
,Generally,NNP,O
,safe,JJ,O
,and,CC,O
,well,RB,O
,tolerated,VBN,O
,by,IN,O
,adults,NNS,O
,",",",",O
,fluoxetine,NN,O
,has,VBZ,O
,been,VBN,O
,reported,VBN,O
,to,TO,O
,induce,VB,O
,mania,NN,B-DISEASE
,.,.,O
,The,DT,O
,cases,NNS,O
,of,IN,O
,five,CD,O
,depressed,JJ,B-DISEASE
,adolescents,NNS,O
,",",",",O
,14,CD,O
,-,:,O
,16,CD,O
,years,NNS,O
,of,IN,O
,age,NN,O
,",",",",O
,who,WP,O
,developed,VBD,O
,mania,NN,B-DISEASE
,during,IN,O
,pharmacotherapy,NN,O
,with,IN,O
,fluoxetine,NN,O
,",",",",O
,are,VBP,O
,reported,VBN,O
,here,RB,O
,.,.,O
,Apparent,JJ,O
,risk,NN,O
,factors,NNS,O
,for,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,mania,NN,B-DISEASE
,or,CC,O
,hypomania,NN,B-DISEASE
,during,IN,O
,fluoxetine,JJ,O
,pharmacotherapy,NN,O
,in,IN,O
,this,DT,O
,population,NN,O
,were,VBD,O
,the,DT,O
,combination,NN,O
,of,IN,O
,attention,NN,B-DISEASE
,-,:,I-DISEASE
,deficit,NN,I-DISEASE
,hyperactivity,NN,I-DISEASE
,disorder,NN,I-DISEASE
,and,CC,O
,affective,JJ,O
,instability,NN,O
,;,:,O
,major,JJ,O
,depression,NN,B-DISEASE
,with,IN,O
,psychotic,JJ,B-DISEASE
,features,NNS,O
,;,:,O
,a,DT,O
,family,NN,O
,history,NN,O
,of,IN,O
,affective,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,",",",",O
,especially,RB,O
,bipolar,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,;,:,O
,and,CC,O
,a,DT,O
,diagnosis,NN,O
,of,IN,O
,bipolar,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,.,.,O
,Further,NNP,O
,study,NN,O
,is,VBZ,O
,needed,VBN,O
,to,TO,O
,determine,VB,O
,the,DT,O
,optimal,JJ,O
,dosage,NN,O
,and,CC,O
,to,TO,O
,identify,VB,O
,risk,NN,O
,factors,NNS,O
,that,IN,O
,increase,NN,O
,individual,JJ,O
,vulnerability,NN,O
,to,TO,O
,fluoxetine,VB,O
,induced,JJ,O
,mania,NN,B-DISEASE
,in,IN,O
,adolescents,NNS,O
,.,.,O
,Acute,NNP,B-DISEASE
,renal,JJ,I-DISEASE
,insufficiency,NN,I-DISEASE
,after,IN,O
,high,JJ,O
,-,:,O
,dose,NN,O
,melphalan,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,primary,JJ,B-DISEASE
,systemic,JJ,I-DISEASE
,amyloidosis,NN,I-DISEASE
,during,IN,O
,stem,NN,O
,cell,NN,O
,transplantation,NN,O
,.,.,O
,BACKGROUND,NNP,O
,:,:,O
,Patients,NNS,O
,with,IN,O
,primary,JJ,B-DISEASE
,systemic,JJ,I-DISEASE
,amyloidosis,NN,I-DISEASE
,(,(,O
,AL,NNP,B-DISEASE
,),),O
,have,VBP,O
,a,DT,O
,poor,JJ,O
,prognosis,NN,O
,.,.,O
,Median,JJ,O
,survival,JJ,O
,time,NN,O
,from,IN,O
,standard,JJ,O
,treatments,NNS,O
,is,VBZ,O
,only,RB,O
,17,CD,O
,months,NNS,O
,.,.,O
,High,NNP,O
,-,:,O
,dose,VBP,O
,intravenous,JJ,O
,melphalan,NN,O
,followed,VBN,O
,by,IN,O
,peripheral,JJ,O
,blood,NN,O
,stem,NN,O
,cell,NN,O
,transplant,NN,O
,(,(,O
,PBSCT,NNP,O
,),),O
,appears,VBZ,O
,to,TO,O
,be,VB,O
,the,DT,O
,most,RBS,O
,promising,JJ,O
,therapy,NN,O
,",",",",O
,but,CC,O
,treatment,NN,O
,mortality,NN,O
,can,MD,O
,be,VB,O
,high,JJ,O
,.,.,O
,The,DT,O
,authors,NNS,O
,have,VBP,O
,noted,VBN,O
,the,DT,O
,development,NN,O
,of,IN,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,insufficiency,NN,I-DISEASE
,immediately,RB,O
,after,IN,O
,melphalan,NN,O
,conditioning,NN,O
,.,.,O
,This,DT,O
,study,NN,O
,was,VBD,O
,undertaken,VBN,O
,to,TO,O
,further,RBR,O
,examine,VB,O
,its,PRP$,O
,risk,NN,O
,factors,NNS,O
,and,CC,O
,impact,NN,O
,on,IN,O
,posttransplant,JJ,O
,mortality,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,Consecutive,JJ,O
,AL,NNP,B-DISEASE
,patients,NNS,O
,who,WP,O
,underwent,VBP,O
,PBSCT,NNP,O
,were,VBD,O
,studied,VBN,O
,retrospectively,RB,O
,.,.,O
,Acute,NNP,B-DISEASE
,renal,JJ,I-DISEASE
,insufficiency,NN,I-DISEASE
,(,(,O
,ARI,NNP,B-DISEASE
,),),O
,after,IN,O
,high,JJ,O
,-,:,O
,dose,NN,O
,melphalan,NN,O
,was,VBD,O
,defined,VBN,O
,by,IN,O
,a,DT,O
,minimum,JJ,O
,increase,NN,O
,of,IN,O
,0,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,/,NN,O
,dL,NN,O
,(,(,O
,44,CD,O
,micromol,NN,O
,/,NNP,O
,L,NNP,O
,),),O
,in,IN,O
,the,DT,O
,serum,NN,O
,creatinine,NN,O
,level,NN,O
,that,WDT,O
,is,VBZ,O
,greater,JJR,O
,than,IN,O
,50,CD,O
,%,NN,O
,of,IN,O
,baseline,NN,O
,immediately,RB,O
,after,IN,O
,conditioning,VBG,O
,.,.,O
,Urine,VB,O
,sediment,JJ,O
,score,NN,O
,was,VBD,O
,the,DT,O
,sum,NN,O
,of,IN,O
,the,DT,O
,individual,JJ,O
,types,NNS,O
,of,IN,O
,sediment,NN,O
,identified,VBN,O
,on,IN,O
,urine,JJ,O
,microscopy,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Of,IN,O
,the,DT,O
,80,CD,O
,patients,NNS,O
,studied,VBN,O
,",",",",O
,ARI,NNP,B-DISEASE
,developed,VBD,O
,in,IN,O
,18,CD,O
,.,.,O
,8,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,after,IN,O
,high,JJ,O
,-,:,O
,dose,NN,O
,melphalan,NN,O
,.,.,O
,Univariate,NNP,O
,analysis,NN,O
,identified,VBN,O
,age,NN,O
,",",",",O
,hypoalbuminemia,NN,B-DISEASE
,",",",",O
,heavy,JJ,O
,proteinuria,NN,B-DISEASE
,",",",",O
,diuretic,JJ,O
,use,NN,O
,",",",",O
,and,CC,O
,urine,JJ,O
,sediment,NN,O
,score,NN,O
,(,(,O
,>,JJ,O
,3,CD,O
,),),O
,as,IN,O
,risk,NN,O
,factors,NNS,O
,.,.,O
,Age,NNP,O
,and,CC,O
,urine,JJ,O
,sediment,NN,O
,score,NN,O
,remained,VBD,O
,independently,RB,O
,significant,JJ,O
,risk,NN,O
,factors,NNS,O
,in,IN,O
,the,DT,O
,multivariate,NN,O
,analysis,NN,O
,.,.,O
,Patients,NNS,O
,who,WP,O
,had,VBD,O
,ARI,NNP,B-DISEASE
,after,IN,O
,high,JJ,O
,-,:,O
,dose,NN,O
,melphalan,NN,O
,underwent,JJ,O
,dialysis,NN,O
,more,RBR,O
,often,RB,O
,(,(,O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,007,CD,O
,),),O
,",",",",O
,and,CC,O
,had,VBD,O
,a,DT,O
,worse,JJR,O
,1,CD,O
,-,:,O
,year,NN,O
,survival,NN,O
,(,(,O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,03,CD,O
,),),O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,The,DT,O
,timing,NN,O
,of,IN,O
,renal,JJ,B-DISEASE
,injury,NN,I-DISEASE
,strongly,RB,O
,suggests,VBZ,O
,melphalan,NN,O
,as,IN,O
,the,DT,O
,causative,JJ,O
,agent,NN,O
,.,.,O
,Ongoing,VBG,O
,tubular,JJ,B-DISEASE
,injury,NN,I-DISEASE
,may,MD,O
,be,VB,O
,a,DT,O
,prerequisite,NN,O
,for,IN,O
,renal,JJ,B-DISEASE
,injury,NN,I-DISEASE
,by,IN,O
,melphalan,NN,O
,as,IN,O
,evidenced,VBN,O
,by,IN,O
,the,DT,O
,active,JJ,O
,urinary,JJ,O
,sediment,NN,O
,.,.,O
,Development,NNP,O
,of,IN,O
,ARI,NNP,B-DISEASE
,adversely,RB,O
,affected,VBD,O
,the,DT,O
,outcome,NN,O
,after,IN,O
,PBSCT,NNP,O
,.,.,O
,Effective,NNP,O
,preventive,JJ,O
,measures,NNS,O
,may,MD,O
,help,VB,O
,decrease,VB,O
,the,DT,O
,treatment,NN,O
,mortality,NN,O
,of,IN,O
,PBSCT,NNP,O
,in,IN,O
,AL,NNP,B-DISEASE
,patients,NNS,O
,.,.,O
,Focal,JJ,O
,cerebral,JJ,B-DISEASE
,ischemia,NN,I-DISEASE
,in,IN,O
,rats,NNS,O
,:,:,O
,effect,NN,O
,of,IN,O
,phenylephrine,NN,O
,-,:,O
,induced,JJ,O
,hypertension,NN,B-DISEASE
,during,IN,O
,reperfusion,NN,O
,.,.,O
,After,IN,O
,180,CD,O
,min,NN,O
,of,IN,O
,temporary,JJ,O
,middle,JJ,B-DISEASE
,cerebral,JJ,I-DISEASE
,artery,NN,I-DISEASE
,occlusion,NN,I-DISEASE
,in,IN,O
,spontaneously,RB,O
,hypertensive,JJ,B-DISEASE
,rats,NNS,O
,",",",",O
,the,DT,O
,effect,NN,O
,of,IN,O
,phenylephrine,NN,O
,-,:,O
,induced,JJ,O
,hypertension,NN,B-DISEASE
,on,IN,O
,ischemic,JJ,B-DISEASE
,brain,NN,I-DISEASE
,injury,NN,I-DISEASE
,and,CC,O
,blood,NN,O
,-,:,O
,brain,NN,O
,barrier,NN,O
,permeability,NN,O
,was,VBD,O
,determined,VBN,O
,.,.,O
,Blood,NNP,O
,pressure,NN,O
,was,VBD,O
,manipulated,VBN,O
,by,IN,O
,one,CD,O
,of,IN,O
,the,DT,O
,following,JJ,O
,schedules,NNS,O
,during,IN,O
,120,CD,O
,min,NNS,O
,of,IN,O
,reperfusion,NN,O
,:,:,O
,Control,NN,O
,",",",",O
,normotensive,JJ,O
,reperfusion,NN,O
,;,:,O
,90,CD,O
,/,NN,O
,hypertension,NN,B-DISEASE
,(,(,O
,90,CD,O
,/,NNP,O
,HTN,NNP,B-DISEASE
,),),O
,",",",",O
,blood,NN,O
,pressure,NN,O
,was,VBD,O
,increased,VBN,O
,by,IN,O
,35,CD,O
,mm,NNS,O
,Hg,NNP,O
,during,IN,O
,the,DT,O
,initial,JJ,O
,90,CD,O
,min,NN,O
,of,IN,O
,reperfusion,NN,O
,only,RB,O
,;,:,O
,15,CD,O
,/,NN,O
,hypertension,NN,B-DISEASE
,(,(,O
,15,CD,O
,/,NNP,O
,HTN,NNP,B-DISEASE
,),),O
,",",",",O
,normotensive,JJ,O
,reperfusion,NN,O
,for,IN,O
,30,CD,O
,min,NN,O
,followed,VBN,O
,by,IN,O
,15,CD,O
,min,NN,O
,of,IN,O
,hypertension,NN,B-DISEASE
,and,CC,O
,75,CD,O
,min,NN,O
,of,IN,O
,normotension,NN,O
,.,.,O
,Part,VB,O
,A,NNP,O
,",",",",O
,for,IN,O
,eight,CD,O
,rats,NNS,O
,in,IN,O
,each,DT,O
,group,NN,O
,brain,NN,B-DISEASE
,injury,NN,I-DISEASE
,was,VBD,O
,evaluated,VBN,O
,by,IN,O
,staining,VBG,O
,tissue,NN,O
,using,VBG,O
,2,CD,O
,",",",",O
,3,CD,O
,",",",",O
,5,CD,O
,-,:,O
,triphenyltetrazolium,NN,O
,chloride,NN,O
,and,CC,O
,edema,NN,B-DISEASE
,was,VBD,O
,evaluated,VBN,O
,by,IN,O
,microgravimetry,NN,O
,.,.,O
,Part,NNP,O
,B,NNP,O
,",",",",O
,for,IN,O
,eight,CD,O
,different,JJ,O
,rats,NNS,O
,in,IN,O
,each,DT,O
,group,NN,O
,blood,VBD,O
,-,:,O
,brain,NN,O
,barrier,NN,O
,permeability,NN,O
,was,VBD,O
,evaluated,VBN,O
,by,IN,O
,measuring,VBG,O
,the,DT,O
,amount,NN,O
,and,CC,O
,extent,NN,O
,of,IN,O
,extravasation,NN,O
,of,IN,O
,Evans,NNP,O
,Blue,NNP,O
,dye,NN,O
,.,.,O
,Brain,NNP,B-DISEASE
,injury,NN,I-DISEASE
,(,(,O
,percentage,NN,O
,of,IN,O
,the,DT,O
,ischemic,JJ,B-DISEASE
,hemisphere,NN,I-DISEASE
,),),O
,was,VBD,O
,less,RBR,O
,in,IN,O
,the,DT,O
,15,CD,O
,/,NNP,O
,HTN,NNP,B-DISEASE
,group,NN,O
,(,(,O
,16,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,6,CD,O
,",",",",O
,mean,JJ,O
,+,NNP,O
,/,NNP,O
,-,:,O
,SD,NN,O
,),),O
,versus,IN,O
,the,DT,O
,90,CD,O
,/,NNP,O
,HTN,NNP,B-DISEASE
,group,NN,O
,(,(,O
,30,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,6,CD,O
,),),O
,",",",",O
,which,WDT,O
,was,VBD,O
,in,IN,O
,turn,NN,O
,less,RBR,O
,than,IN,O
,the,DT,O
,control,NN,O
,group,NN,O
,(,(,O
,42,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,5,CD,O
,),),O
,.,.,O
,Specific,JJ,O
,gravity,NN,O
,was,VBD,O
,greater,JJR,O
,in,IN,O
,the,DT,O
,15,CD,O
,/,NNP,O
,HTN,NNP,B-DISEASE
,group,NN,O
,(,(,O
,1,CD,O
,.,.,O
,043,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,002,CD,O
,),),O
,versus,IN,O
,the,DT,O
,90,CD,O
,/,NN,O
,HTN,NNP,B-DISEASE
,(,(,O
,1,CD,O
,.,.,O
,036,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,003,CD,O
,),),O
,and,CC,O
,control,NN,O
,(,(,O
,1,CD,O
,.,.,O
,037,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,003,CD,O
,),),O
,groups,NNS,O
,.,.,O
,Evans,NNS,O
,Blue,NNP,O
,(,(,O
,mug,FW,O
,g,SYM,O
,-,:,O
,1,CD,O
,of,IN,O
,brain,NN,O
,tissue,NN,O
,),),O
,was,VBD,O
,greater,JJR,O
,in,IN,O
,the,DT,O
,90,CD,O
,/,NNP,O
,HTN,NNP,B-DISEASE
,group,NN,O
,(,(,O
,24,CD,O
,.,.,O
,4,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,6,CD,O
,.,.,O
,0,CD,O
,),),O
,versus,IN,O
,the,DT,O
,control,NN,O
,group,NN,O
,(,(,O
,12,CD,O
,.,.,O
,3,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,4,CD,O
,.,.,O
,1,CD,O
,),),O
,",",",",O
,which,WDT,O
,was,VBD,O
,in,IN,O
,turn,NN,O
,greater,JJR,O
,than,IN,O
,the,DT,O
,15,CD,O
,/,NNP,O
,HTN,NNP,B-DISEASE
,group,NN,O
,(,(,O
,7,CD,O
,.,.,O
,3,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,3,CD,O
,.,.,O
,2,CD,O
,),),O
,.,.,O
,This,DT,O
,study,NN,O
,supports,VBZ,O
,a,DT,O
,hypothesis,NN,O
,that,WDT,O
,during,IN,O
,reperfusion,NN,O
,",",",",O
,a,DT,O
,short,JJ,O
,interval,NN,O
,of,IN,O
,hypertension,NN,B-DISEASE
,decreases,NNS,O
,brain,NN,B-DISEASE
,injury,NN,I-DISEASE
,and,CC,O
,edema,NN,B-DISEASE
,;,:,O
,and,CC,O
,that,DT,O
,sustained,VBD,O
,hypertension,NN,B-DISEASE
,increases,VBZ,O
,the,DT,O
,risk,NN,O
,of,IN,O
,vasogenic,JJ,B-DISEASE
,edema,NN,I-DISEASE
,.,.,O
,People,NNS,O
,aged,VBD,O
,over,IN,O
,75,CD,O
,in,IN,O
,atrial,JJ,B-DISEASE
,fibrillation,NN,I-DISEASE
,on,IN,O
,warfarin,NN,O
,:,:,O
,the,DT,O
,rate,NN,O
,of,IN,O
,major,JJ,O
,hemorrhage,NN,B-DISEASE
,and,CC,O
,stroke,NN,B-DISEASE
,in,IN,O
,more,JJR,O
,than,IN,O
,500,CD,O
,patient,JJ,O
,-,:,O
,years,NNS,O
,of,IN,O
,follow,NN,O
,-,:,O
,up,RB,O
,.,.,O
,OBJECTIVES,NN,O
,:,:,O
,To,TO,O
,determine,VB,O
,the,DT,O
,incidence,NN,O
,of,IN,O
,major,JJ,O
,hemorrhage,NN,B-DISEASE
,and,CC,O
,stroke,NN,B-DISEASE
,in,IN,O
,people,NNS,O
,aged,VBN,O
,76,CD,O
,and,CC,O
,older,JJR,O
,with,IN,O
,atrial,JJ,B-DISEASE
,fibrillation,NN,I-DISEASE
,on,IN,O
,adjusted,VBN,O
,-,:,O
,dose,JJ,O
,warfarin,NN,O
,who,WP,O
,had,VBD,O
,been,VBN,O
,recently,RB,O
,been,VBN,O
,admitted,VBN,O
,to,TO,O
,hospital,VB,O
,.,.,O
,DESIGN,NN,O
,:,:,O
,A,DT,O
,retrospective,JJ,O
,observational,JJ,O
,cohort,NN,O
,study,NN,O
,.,.,O
,SETTING,NN,O
,:,:,O
,A,DT,O
,major,JJ,O
,healthcare,NN,O
,network,NN,O
,involving,VBG,O
,four,CD,O
,tertiary,JJ,O
,hospitals,NNS,O
,.,.,O
,PARTICIPANTS,NNS,O
,:,:,O
,Two,CD,O
,hundred,VBD,O
,thirty,SYM,O
,-,:,O
,five,CD,O
,patients,NNS,O
,aged,VBN,O
,76,CD,O
,and,CC,O
,older,JJR,O
,admitted,VBN,O
,to,TO,O
,a,DT,O
,major,JJ,O
,healthcare,NN,O
,network,NN,O
,between,IN,O
,July,NNP,O
,1,CD,O
,",",",",O
,2001,CD,O
,",",",",O
,and,CC,O
,June,NNP,O
,30,CD,O
,",",",",O
,2002,CD,O
,",",",",O
,with,IN,O
,atrial,JJ,B-DISEASE
,fibrillation,NN,I-DISEASE
,on,IN,O
,warfarin,NNS,O
,were,VBD,O
,enrolled,VBN,O
,.,.,O
,MEASUREMENTS,NNS,O
,:,:,O
,Information,NN,O
,regarding,VBG,O
,major,JJ,O
,bleeding,VBG,B-DISEASE
,episodes,NNS,O
,",",",",O
,strokes,NNS,B-DISEASE
,",",",",O
,and,CC,O
,warfarin,NN,O
,use,NN,O
,was,VBD,O
,obtained,VBN,O
,from,IN,O
,patients,NNS,O
,",",",",O
,relatives,NNS,O
,",",",",O
,primary,JJ,O
,physicians,NNS,O
,",",",",O
,and,CC,O
,medical,JJ,O
,records,NNS,O
,.,.,O
,RESULTS,NNS,O
,:,:,O
,Two,CD,O
,hundred,VBD,O
,twenty,SYM,O
,-,:,O
,eight,CD,O
,patients,NNS,O
,(,(,O
,42,CD,O
,%,NN,O
,men,NNS,O
,),),O
,with,IN,O
,a,DT,O
,mean,JJ,O
,age,NN,O
,of,IN,O
,81,CD,O
,.,.,O
,1,CD,O
,(,(,O
,range,NN,O
,76,CD,O
,-,:,O
,94,CD,O
,),),O
,were,VBD,O
,included,VBN,O
,in,IN,O
,the,DT,O
,analysis,NN,O
,.,.,O
,Total,JJ,O
,follow,JJ,O
,-,:,O
,up,RB,O
,on,IN,O
,warfarin,NN,O
,was,VBD,O
,530,CD,O
,years,NNS,O
,(,(,O
,mean,JJ,O
,28,CD,O
,months,NNS,O
,),),O
,.,.,O
,There,EX,O
,were,VBD,O
,53,CD,O
,major,JJ,O
,hemorrhages,NNS,B-DISEASE
,",",",",O
,for,IN,O
,an,DT,O
,annual,JJ,O
,rate,NN,O
,of,IN,O
,10,CD,O
,.,.,O
,0,CD,O
,%,NN,O
,",",",",O
,including,VBG,O
,24,CD,O
,(,(,O
,45,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,),),O
,life,NN,O
,-,:,O
,threatening,NN,O
,and,CC,O
,five,CD,O
,(,(,O
,9,CD,O
,.,.,O
,4,CD,O
,%,NN,O
,),),O
,fatal,NN,O
,bleeds,NNS,O
,.,.,O
,The,DT,O
,annual,JJ,O
,stroke,NN,B-DISEASE
,rate,NN,O
,after,IN,O
,initiation,NN,O
,of,IN,O
,warfarin,NN,O
,was,VBD,O
,2,CD,O
,.,.,O
,6,CD,O
,%,NN,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,The,DT,O
,rate,NN,O
,of,IN,O
,major,JJ,O
,hemorrhage,NN,B-DISEASE
,was,VBD,O
,high,JJ,O
,in,IN,O
,this,DT,O
,old,JJ,O
,",",",",O
,frail,JJ,O
,group,NN,O
,",",",",O
,but,CC,O
,excluding,VBG,O
,fatalities,NNS,O
,",",",",O
,resulted,VBD,O
,in,IN,O
,no,DT,O
,long,JJ,O
,-,:,O
,term,NN,O
,sequelae,NN,O
,",",",",O
,and,CC,O
,the,DT,O
,stroke,NN,B-DISEASE
,rate,NN,O
,on,IN,O
,warfarin,NN,O
,was,VBD,O
,low,JJ,O
,",",",",O
,demonstrating,VBG,O
,how,WRB,O
,effective,JJ,O
,warfarin,NN,O
,treatment,NN,O
,is,VBZ,O
,.,.,O
,Safety,NN,O
,of,IN,O
,celecoxib,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,adverse,JJ,O
,skin,NN,B-DISEASE
,reactions,NNS,I-DISEASE
,to,TO,O
,acetaminophen,VB,O
,(,(,O
,paracetamol,NN,O
,),),O
,and,CC,O
,nimesulide,RB,O
,associated,VBD,O
,or,CC,O
,not,RB,O
,with,IN,O
,common,JJ,O
,non,SYM,O
,-,:,O
,steroidal,NN,O
,anti,SYM,O
,-,:,O
,inflammatory,NN,O
,drugs,NNS,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Acetaminophen,NNP,O
,(,(,O
,paracetamol,SYM,O
,-,:,O
,-,:,O
,P,NN,O
,),),O
,and,CC,O
,Nimesulide,NNP,O
,(,(,O
,N,NNP,O
,),),O
,are,VBP,O
,widely,RB,O
,used,VBN,O
,analgesic,JJ,O
,-,:,O
,antipyretic,JJ,O
,/,NN,O
,anti,SYM,O
,-,:,O
,inflammatory,NN,O
,drugs,NNS,O
,.,.,O
,The,DT,O
,rate,NN,O
,of,IN,O
,adverse,JJ,O
,hypersensitivity,NN,B-DISEASE
,reactions,NNS,O
,to,TO,O
,these,DT,O
,agents,NNS,O
,is,VBZ,O
,generally,RB,O
,low,JJ,O
,.,.,O
,On,IN,O
,the,DT,O
,contrary,JJ,O
,non,NN,O
,-,:,O
,steroidal,NN,O
,anti,SYM,O
,-,:,O
,inflammatory,NN,O
,drugs,NNS,O
,(,(,O
,NSAIDs,NNP,O
,),),O
,are,VBP,O
,commonly,RB,O
,involved,VBN,O
,in,IN,O
,such,JJ,O
,reactions,NNS,O
,.,.,O
,Celecoxib,NNP,O
,(,(,O
,CE,NNP,O
,),),O
,is,VBZ,O
,a,DT,O
,novel,JJ,O
,drug,NN,O
,",",",",O
,with,IN,O
,high,JJ,O
,selectivity,NN,O
,and,CC,O
,affinity,NN,O
,for,IN,O
,COX,NNP,O
,-,:,O
,2,CD,O
,enzyme,NN,O
,.,.,O
,OBJECTIVE,CC,O
,:,:,O
,We,PRP,O
,evaluated,VBD,O
,the,DT,O
,tolerability,NN,O
,of,IN,O
,CE,NNP,O
,in,IN,O
,a,DT,O
,group,NN,O
,of,IN,O
,patients,NNS,O
,with,IN,O
,documented,JJ,O
,history,NN,O
,of,IN,O
,adverse,JJ,O
,cutaneous,JJ,B-DISEASE
,reactions,NNS,I-DISEASE
,to,TO,O
,P,NNP,O
,and,CC,O
,N,NNP,O
,associated,VBD,O
,or,CC,O
,not,RB,O
,to,TO,O
,classic,JJ,O
,NSAIDs,NNP,O
,.,.,O
,METHODS,NN,O
,:,:,O
,We,PRP,O
,studied,VBD,O
,9,CD,O
,patients,NNS,O
,with,IN,O
,hypersensitivity,NN,B-DISEASE
,to,TO,O
,P,NNP,O
,and,CC,O
,N,NNP,O
,with,IN,O
,or,CC,O
,without,IN,O
,associated,VBN,O
,reactions,NNS,O
,to,TO,O
,classic,JJ,O
,NSAIDs,NNP,O
,.,.,O
,The,DT,O
,diagnosis,NN,O
,of,IN,O
,P,NNP,O
,and,CC,O
,N,NNP,O
,-,:,O
,induced,JJ,O
,skin,JJ,B-DISEASE
,reactions,NNS,I-DISEASE
,was,VBD,O
,based,VBN,O
,in,IN,O
,vivo,JJ,O
,challenge,NN,O
,.,.,O
,The,DT,O
,placebo,NN,O
,was,VBD,O
,blindly,RB,O
,administered,VBN,O
,at,IN,O
,the,DT,O
,beginning,NN,O
,of,IN,O
,each,DT,O
,challenge,NN,O
,.,.,O
,After,IN,O
,three,CD,O
,days,NNS,O
,",",",",O
,a,DT,O
,cumulative,JJ,O
,dosage,NN,O
,of,IN,O
,200,CD,O
,mg,NN,O
,of,IN,O
,CE,NNP,O
,in,IN,O
,refracted,JJ,O
,doses,NNS,O
,were,VBD,O
,given,VBN,O
,.,.,O
,After,IN,O
,2,CD,O
,-,:,O
,3,CD,O
,days,NNS,O
,",",",",O
,a,DT,O
,single,JJ,O
,dose,NN,O
,of,IN,O
,200,CD,O
,mg,NN,O
,was,VBD,O
,administered,VBN,O
,.,.,O
,All,DT,O
,patients,NNS,O
,were,VBD,O
,observed,VBN,O
,for,IN,O
,6,CD,O
,hours,NNS,O
,after,IN,O
,each,DT,O
,challenge,NN,O
,",",",",O
,and,CC,O
,controlled,VBD,O
,again,RB,O
,after,IN,O
,24,CD,O
,hours,NNS,O
,to,TO,O
,exclude,VB,O
,delayed,JJ,O
,reactions,NNS,O
,.,.,O
,The,DT,O
,challenge,NN,O
,was,VBD,O
,considered,VBN,O
,positive,JJ,O
,if,IN,O
,one,CD,O
,or,CC,O
,more,JJR,O
,of,IN,O
,the,DT,O
,following,JJ,O
,appeared,NN,O
,:,:,O
,erythema,NN,B-DISEASE
,",",",",O
,rush,NN,O
,or,CC,O
,urticaria,JJ,B-DISEASE
,-,:,O
,angioedema,NN,B-DISEASE
,.,.,O
,RESULTS,NN,O
,:,:,O
,No,DT,O
,reaction,NN,O
,was,VBD,O
,observed,VBN,O
,with,IN,O
,placebo,NN,O
,and,CC,O
,eight,CD,O
,patients,NNS,O
,(,(,O
,88,CD,O
,.,.,O
,8,CD,O
,%,NN,O
,),),O
,tolerated,VBD,O
,CE,NNP,O
,.,.,O
,Only,RB,O
,one,CD,O
,patient,NN,O
,developed,VBD,O
,a,DT,O
,moderate,JJ,O
,angioedema,NN,B-DISEASE
,of,IN,O
,the,DT,O
,lips,NNS,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Only,RB,O
,one,CD,O
,hypersensitivity,NN,B-DISEASE
,reaction,NN,O
,to,TO,O
,CE,NNP,O
,was,VBD,O
,documented,VBN,O
,among,IN,O
,9,CD,O
,P,NNP,O
,and,CC,O
,N,NNP,O
,-,:,O
,highly,RB,O
,NSAIDs,NNP,O
,intolerant,NN,O
,patients,NNS,O
,.,.,O
,Thus,RB,O
,",",",",O
,we,PRP,O
,conclude,VBP,O
,that,DT,O
,CE,NNP,O
,is,VBZ,O
,a,DT,O
,reasonably,RB,O
,safe,JJ,O
,alternative,NN,O
,to,TO,O
,be,VB,O
,used,VBN,O
,in,IN,O
,subjects,NNS,O
,who,WP,O
,do,VBP,O
,not,RB,O
,tolerate,VB,O
,P,NNP,O
,and,CC,O
,N,NNP,O
,.,.,O
,Case,NNP,O
,-,:,O
,control,NN,O
,study,NN,O
,of,IN,O
,regular,JJ,O
,analgesic,JJ,O
,and,CC,O
,nonsteroidal,JJ,O
,anti,NN,O
,-,:,O
,inflammatory,NN,O
,use,NN,O
,and,CC,O
,end,VB,B-DISEASE
,-,:,I-DISEASE
,stage,NN,I-DISEASE
,renal,JJ,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Studies,NNS,O
,on,IN,O
,the,DT,O
,association,NN,O
,between,IN,O
,the,DT,O
,long,JJ,O
,-,:,O
,term,NN,O
,use,NN,O
,of,IN,O
,aspirin,NN,O
,and,CC,O
,other,JJ,O
,analgesic,JJ,O
,and,CC,O
,nonsteroidal,JJ,O
,anti,NN,O
,-,:,O
,inflammatory,NN,O
,drugs,NNS,O
,(,(,O
,NSAIDs,NNP,O
,),),O
,and,CC,O
,end,VB,B-DISEASE
,-,:,I-DISEASE
,stage,NN,I-DISEASE
,renal,JJ,I-DISEASE
,disease,NN,I-DISEASE
,(,(,O
,ESRD,NNP,B-DISEASE
,),),O
,have,VBP,O
,given,VBN,O
,conflicting,VBG,O
,results,NNS,O
,.,.,O
,In,IN,O
,order,NN,O
,to,TO,O
,examine,VB,O
,this,DT,O
,association,NN,O
,",",",",O
,a,DT,O
,case,NN,O
,-,:,O
,control,NN,O
,study,NN,O
,with,IN,O
,incident,JJ,O
,cases,NNS,O
,of,IN,O
,ESRD,NNP,B-DISEASE
,was,VBD,O
,carried,VBN,O
,out,RP,O
,.,.,O
,METHODS,NN,O
,:,:,O
,The,DT,O
,cases,NNS,O
,were,VBD,O
,all,DT,O
,patients,NNS,O
,entering,VBG,O
,the,DT,O
,local,JJ,O
,dialysis,NN,O
,program,NN,O
,because,IN,O
,of,IN,O
,ESRD,NNP,B-DISEASE
,in,IN,O
,the,DT,O
,study,NN,O
,area,NN,O
,between,IN,O
,June,NNP,O
,1,CD,O
,",",",",O
,1995,CD,O
,and,CC,O
,November,NNP,O
,30,CD,O
,",",",",O
,1997,CD,O
,.,.,O
,They,PRP,O
,were,VBD,O
,classified,VBN,O
,according,VBG,O
,to,TO,O
,the,DT,O
,underlying,JJ,O
,disease,NN,O
,",",",",O
,which,WDT,O
,had,VBD,O
,presumably,RB,O
,led,VBN,O
,them,PRP,O
,to,TO,O
,ESRD,NNP,B-DISEASE
,.,.,O
,Controls,NNP,O
,were,VBD,O
,patients,NNS,O
,admitted,VBN,O
,to,TO,O
,the,DT,O
,same,JJ,O
,hospitals,NNS,O
,from,IN,O
,where,WRB,O
,the,DT,O
,cases,NNS,O
,arose,VBP,O
,",",",",O
,also,RB,O
,matched,VBN,O
,by,IN,O
,age,NN,O
,and,CC,O
,sex,NN,O
,.,.,O
,Odds,CC,O
,ratios,NNS,O
,were,VBD,O
,calculated,VBN,O
,using,VBG,O
,a,DT,O
,conditional,JJ,O
,logistic,JJ,O
,model,NN,O
,",",",",O
,including,VBG,O
,potential,JJ,O
,confounding,NN,O
,factors,NNS,O
,",",",",O
,both,DT,O
,for,IN,O
,the,DT,O
,whole,JJ,O
,study,NN,O
,population,NN,O
,and,CC,O
,for,IN,O
,the,DT,O
,various,JJ,O
,underlying,JJ,O
,diseases,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Five,CD,O
,hundred,NNS,O
,and,CC,O
,eighty,SYM,O
,-,:,O
,three,CD,O
,cases,NNS,O
,and,CC,O
,1190,CD,O
,controls,NNS,O
,were,VBD,O
,included,VBN,O
,in,IN,O
,the,DT,O
,analysis,NN,O
,.,.,O
,Long,NNP,O
,-,:,O
,term,NN,O
,use,NN,O
,of,IN,O
,any,DT,O
,analgesic,NN,O
,was,VBD,O
,associated,VBN,O
,with,IN,O
,an,DT,O
,overall,JJ,O
,odds,NNS,O
,ratio,NN,O
,of,IN,O
,1,CD,O
,.,.,O
,22,CD,O
,(,(,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,",",",",O
,0,CD,O
,.,.,O
,89,CD,O
,-,:,O
,1,CD,O
,.,.,O
,66,CD,O
,),),O
,.,.,O
,For,IN,O
,specific,JJ,O
,groups,NNS,O
,of,IN,O
,drugs,NNS,O
,",",",",O
,the,DT,O
,risks,NNS,O
,were,VBD,O
,1,CD,O
,.,.,O
,56,CD,O
,(,(,O
,1,CD,O
,.,.,O
,05,CD,O
,-,:,O
,2,CD,O
,.,.,O
,30,CD,O
,),),O
,for,IN,O
,aspirin,NN,O
,",",",",O
,1,CD,O
,.,.,O
,03,CD,O
,(,(,O
,0,CD,O
,.,.,O
,60,CD,O
,-,:,O
,1,CD,O
,.,.,O
,76,CD,O
,),),O
,for,IN,O
,pyrazolones,NNS,O
,",",",",O
,0,CD,O
,.,.,O
,80,CD,O
,(,(,O
,0,CD,O
,.,.,O
,39,CD,O
,-,:,O
,1,CD,O
,.,.,O
,63,CD,O
,),),O
,for,IN,O
,paracetamol,NN,O
,",",",",O
,and,CC,O
,0,CD,O
,.,.,O
,94,CD,O
,(,(,O
,0,CD,O
,.,.,O
,57,CD,O
,-,:,O
,1,CD,O
,.,.,O
,56,CD,O
,),),O
,for,IN,O
,nonaspirin,JJ,O
,NSAIDs,NNP,O
,.,.,O
,The,DT,O
,risk,NN,O
,of,IN,O
,ESRD,NNP,B-DISEASE
,associated,VBN,O
,with,IN,O
,aspirin,NN,O
,was,VBD,O
,related,VBN,O
,to,TO,O
,the,DT,O
,cumulated,VBN,O
,dose,NN,O
,and,CC,O
,duration,NN,O
,of,IN,O
,use,NN,O
,",",",",O
,and,CC,O
,it,PRP,O
,was,VBD,O
,particularly,RB,O
,high,JJ,O
,among,IN,O
,the,DT,O
,subset,NN,O
,of,IN,O
,patients,NNS,O
,with,IN,O
,vascular,JJ,O
,nephropathy,NNS,B-DISEASE
,as,IN,O
,underlying,JJ,O
,disease,NN,O
,[,VBD,O
,2,CD,O
,.,.,O
,35,CD,O
,(,(,O
,1,CD,O
,.,.,O
,17,CD,O
,-,:,O
,4,CD,O
,.,.,O
,72,CD,O
,),),O
,],NN,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Our,PRP$,O
,data,NNS,O
,indicate,VBP,O
,that,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,use,NN,O
,of,IN,O
,nonaspirin,JJ,O
,analgesic,JJ,O
,drugs,NNS,O
,and,CC,O
,NSAIDs,NNP,O
,is,VBZ,O
,not,RB,O
,associated,VBN,O
,with,IN,O
,an,DT,O
,increased,VBN,O
,risk,NN,O
,of,IN,O
,ESRD,NNP,B-DISEASE
,.,.,O
,However,RB,O
,",",",",O
,the,DT,O
,chronic,JJ,O
,use,NN,O
,of,IN,O
,aspirin,NN,O
,may,MD,O
,increase,VB,O
,the,DT,O
,risk,NN,O
,of,IN,O
,ESRD,NNP,B-DISEASE
,.,.,O
,Two,CD,O
,cases,NNS,O
,of,IN,O
,amisulpride,JJ,O
,overdose,NN,B-DISEASE
,:,:,O
,a,DT,O
,cause,NN,O
,for,IN,O
,prolonged,JJ,B-DISEASE
,QT,NNP,I-DISEASE
,syndrome,NN,I-DISEASE
,.,.,O
,Two,CD,O
,cases,NNS,O
,of,IN,O
,deliberate,NN,O
,self,PRP,O
,-,:,O
,poisoning,VBG,B-DISEASE
,with,IN,O
,5,CD,O
,g,NNS,O
,and,CC,O
,3,CD,O
,.,.,O
,6,CD,O
,g,NN,O
,of,IN,O
,amisulpride,NN,O
,",",",",O
,respectively,RB,O
,",",",",O
,are,VBP,O
,reported,VBN,O
,.,.,O
,In,IN,O
,both,DT,O
,cases,NNS,O
,",",",",O
,QT,NNP,B-DISEASE
,prolongation,NN,I-DISEASE
,and,CC,O
,hypocalcaemia,NN,B-DISEASE
,were,VBD,O
,noted,VBN,O
,.,.,O
,The,DT,O
,QT,NNP,B-DISEASE
,prolongation,NN,I-DISEASE
,appeared,VBD,O
,to,TO,O
,respond,VB,O
,to,TO,O
,administration,NN,O
,of,IN,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,calcium,NN,O
,gluconate,NN,O
,.,.,O
,Growth,NNP,O
,-,:,O
,associated,VBN,O
,protein,RB,O
,43,CD,O
,expression,NN,O
,in,IN,O
,hippocampal,JJ,O
,molecular,JJ,O
,layer,NN,O
,of,IN,O
,chronic,JJ,O
,epileptic,JJ,B-DISEASE
,rats,NNS,O
,treated,VBN,O
,with,IN,O
,cycloheximide,NN,O
,.,.,O
,PURPOSE,NN,O
,:,:,O
,GAP43,NNP,O
,has,VBZ,O
,been,VBN,O
,thought,VBN,O
,to,TO,O
,be,VB,O
,linked,VBN,O
,with,IN,O
,mossy,JJ,O
,fiber,NN,O
,sprouting,NN,O
,(,(,O
,MFS,NNP,O
,),),O
,in,IN,O
,various,JJ,O
,experimental,JJ,O
,models,NNS,O
,of,IN,O
,epilepsy,NN,B-DISEASE
,.,.,O
,To,TO,O
,investigate,VB,O
,how,WRB,O
,GAP43,NNP,O
,expression,NN,O
,(,(,O
,GAP43,NNP,O
,-,:,O
,ir,NN,O
,),),O
,correlates,VBZ,O
,with,IN,O
,MFS,NNP,O
,",",",",O
,we,PRP,O
,assessed,VBD,O
,the,DT,O
,intensity,NN,O
,(,(,O
,densitometry,NN,O
,),),O
,and,CC,O
,extension,NN,O
,(,(,O
,width,JJ,O
,),),O
,of,IN,O
,GAP43,NNP,O
,-,:,O
,ir,NN,O
,in,IN,O
,the,DT,O
,inner,JJ,O
,molecular,JJ,O
,layer,NN,O
,of,IN,O
,the,DT,O
,dentate,NN,O
,gyrus,NN,O
,(,(,O
,IML,NNP,O
,),),O
,of,IN,O
,rats,NNS,O
,subject,VBP,O
,to,TO,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,pilocarpine,NN,O
,(,(,O
,Pilo,NNP,O
,),),O
,",",",",O
,previously,RB,O
,injected,VBN,O
,or,CC,O
,not,RB,O
,with,IN,O
,cycloheximide,NN,O
,(,(,O
,CHX,NNP,O
,),),O
,",",",",O
,which,WDT,O
,has,VBZ,O
,been,VBN,O
,shown,VBN,O
,to,TO,O
,inhibit,VB,O
,MFS,NNP,O
,.,.,O
,METHODS,NN,O
,:,:,O
,CHX,NNP,O
,was,VBD,O
,injected,VBN,O
,before,IN,O
,the,DT,O
,Pilo,NNP,O
,injection,NN,O
,in,IN,O
,adult,NN,O
,Wistar,NNP,O
,rats,NNS,O
,.,.,O
,The,DT,O
,Pilo,NNP,O
,group,NN,O
,was,VBD,O
,injected,VBN,O
,with,IN,O
,the,DT,O
,same,JJ,O
,drugs,NNS,O
,",",",",O
,except,IN,O
,for,IN,O
,CHX,NNP,O
,.,.,O
,Animals,NNS,O
,were,VBD,O
,killed,VBN,O
,between,IN,O
,30,CD,O
,and,CC,O
,60,CD,O
,days,NNS,O
,later,RB,O
,",",",",O
,and,CC,O
,brain,NN,O
,sections,NNS,O
,were,VBD,O
,processed,VBN,O
,for,IN,O
,GAP43,NNP,O
,immunohistochemistry,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Densitometry,NN,O
,showed,VBD,O
,no,DT,O
,significant,JJ,O
,difference,NN,O
,regarding,VBG,O
,GAP43,NNP,O
,-,:,O
,ir,NN,O
,in,IN,O
,the,DT,O
,IML,NNP,O
,between,IN,O
,Pilo,NNP,O
,",",",",O
,CHX,NNP,O
,+,NNP,O
,Pilo,NNP,O
,",",",",O
,and,CC,O
,control,NN,O
,groups,NNS,O
,.,.,O
,However,RB,O
,",",",",O
,the,DT,O
,results,NNS,O
,of,IN,O
,the,DT,O
,width,NN,O
,of,IN,O
,the,DT,O
,GAP43,NNP,O
,-,:,O
,ir,NN,O
,band,NN,O
,in,IN,O
,the,DT,O
,IML,NNP,O
,showed,VBD,O
,that,IN,O
,CHX,NNP,O
,+,NNP,O
,Pilo,NNP,O
,and,CC,O
,control,NN,O
,animals,NNS,O
,had,VBD,O
,a,DT,O
,significantly,RB,O
,larger,JJR,O
,band,NN,O
,(,(,O
,p,JJ,O
,=,NN,O
,0,CD,O
,.,.,O
,03,CD,O
,),),O
,as,IN,O
,compared,VBN,O
,with,IN,O
,that,DT,O
,in,IN,O
,the,DT,O
,Pilo,NNP,O
,group,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Our,PRP$,O
,current,JJ,O
,finding,NN,O
,that,WDT,O
,animals,NNS,O
,in,IN,O
,the,DT,O
,CHX,NNP,O
,+,NNP,O
,Pilo,NNP,O
,group,NN,O
,have,VBP,O
,a,DT,O
,GAP43,NNP,O
,-,:,O
,ir,NN,O
,band,NN,O
,in,IN,O
,the,DT,O
,IML,NNP,O
,",",",",O
,similar,JJ,O
,to,TO,O
,that,DT,O
,of,IN,O
,controls,NNS,O
,",",",",O
,reinforces,NNS,O
,prior,RB,O
,data,NNS,O
,on,IN,O
,the,DT,O
,blockade,NN,O
,of,IN,O
,MFS,NNP,O
,in,IN,O
,these,DT,O
,animals,NNS,O
,.,.,O
,The,DT,O
,change,NN,O
,in,IN,O
,GAP43,NNP,O
,-,:,O
,ir,NN,O
,present,NN,O
,in,IN,O
,Pilo,NNP,O
,-,:,O
,treated,VBD,O
,animals,NNS,O
,was,VBD,O
,a,DT,O
,thinning,NN,O
,of,IN,O
,the,DT,O
,band,NN,O
,to,TO,O
,a,DT,O
,very,RB,O
,narrow,JJ,O
,layer,NN,O
,just,RB,O
,above,IN,O
,the,DT,O
,granule,NN,O
,cell,NN,O
,layer,NN,O
,that,WDT,O
,is,VBZ,O
,likely,JJ,O
,to,TO,O
,be,VB,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,loss,NN,O
,of,IN,O
,hilar,JJ,O
,cell,NN,O
,projections,NNS,O
,that,WDT,O
,express,VBP,O
,GAP,NNP,O
,-,:,O
,43,CD,O
,.,.,O
,Nicotine,NN,O
,antagonizes,VBZ,O
,caffeine,JJ,O
,-,:,O
,but,CC,O
,not,RB,O
,pentylenetetrazole,JJ,O
,-,:,O
,induced,JJ,O
,anxiogenic,JJ,O
,effect,NN,O
,in,IN,O
,mice,NN,O
,.,.,O
,RATIONALE,NN,O
,:,:,O
,Nicotine,NN,O
,and,CC,O
,caffeine,NN,O
,are,VBP,O
,widely,RB,O
,consumed,VBN,O
,licit,JJ,O
,psychoactive,JJ,O
,drugs,NNS,O
,worldwide,RB,O
,.,.,O
,Epidemiological,JJ,O
,studies,NNS,O
,showed,VBD,O
,that,IN,O
,they,PRP,O
,were,VBD,O
,generally,RB,O
,used,VBN,O
,concurrently,RB,O
,.,.,O
,Although,IN,O
,some,DT,O
,studies,NNS,O
,in,IN,O
,experimental,JJ,O
,animals,NNS,O
,indicate,VBP,O
,clear,JJ,O
,pharmacological,JJ,O
,interactions,NNS,O
,between,IN,O
,them,PRP,O
,",",",",O
,no,DT,O
,studies,NNS,O
,have,VBP,O
,shown,VBN,O
,a,DT,O
,specific,JJ,O
,interaction,NN,O
,on,IN,O
,anxiety,NN,B-DISEASE
,responses,NNS,O
,.,.,O
,OBJECTIVES,NN,O
,:,:,O
,The,DT,O
,present,JJ,O
,study,NN,O
,investigates,VBZ,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,nicotine,NN,O
,on,IN,O
,anxiety,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,caffeine,NN,O
,and,CC,O
,another,DT,O
,anxiogenic,JJ,O
,drug,NN,O
,",",",",O
,pentylenetetrazole,NN,O
,",",",",O
,in,IN,O
,mice,NN,O
,.,.,O
,The,DT,O
,elevated,JJ,O
,plus,CC,O
,-,:,O
,maze,NN,O
,(,(,O
,EPM,NNP,O
,),),O
,test,NN,O
,was,VBD,O
,used,VBN,O
,to,TO,O
,evaluate,VB,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,drugs,NNS,O
,on,IN,O
,anxiety,NN,B-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,Adult,NNP,O
,male,NN,O
,Swiss,NNP,O
,Webster,NNP,O
,mice,NNP,O
,(,(,O
,25,CD,O
,-,:,O
,32,CD,O
,g,NN,O
,),),O
,were,VBD,O
,given,VBN,O
,nicotine,JJ,O
,(,(,O
,0,CD,O
,.,.,O
,05,CD,O
,-,:,O
,0,CD,O
,.,.,O
,25,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,s,NN,O
,.,.,O
,c,NN,O
,.,.,O
,),),O
,or,CC,O
,saline,$,O
,10,CD,O
,min,NN,O
,before,IN,O
,caffeine,NN,O
,(,(,O
,70,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,or,CC,O
,pentylenetetrazole,NN,O
,(,(,O
,15,CD,O
,and,CC,O
,30,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,injections,NNS,O
,.,.,O
,After,IN,O
,15,CD,O
,min,NN,O
,",",",",O
,mice,NN,O
,were,VBD,O
,evaluated,VBN,O
,for,IN,O
,their,PRP$,O
,open,JJ,O
,-,:,O
,and,CC,O
,closed,VBD,O
,-,:,O
,arm,NN,O
,time,NN,O
,and,CC,O
,entries,NNS,O
,on,IN,O
,the,DT,O
,EPM,NNP,O
,for,IN,O
,a,DT,O
,10,CD,O
,-,:,O
,min,NN,O
,session,NN,O
,.,.,O
,Locomotor,NNP,O
,activity,NN,O
,was,VBD,O
,recorded,VBN,O
,for,IN,O
,individual,JJ,O
,groups,NNS,O
,by,IN,O
,using,VBG,O
,the,DT,O
,same,JJ,O
,treatment,NN,O
,protocol,NN,O
,with,IN,O
,the,DT,O
,EPM,NNP,O
,test,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Nicotine,NNP,O
,(,(,O
,0,CD,O
,.,.,O
,05,CD,O
,-,:,O
,0,CD,O
,.,.,O
,25,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,),),O
,itself,PRP,O
,did,VBD,O
,not,RB,O
,produce,VB,O
,any,DT,O
,significant,JJ,O
,effect,NN,O
,in,IN,O
,the,DT,O
,EPM,NNP,O
,test,NN,O
,",",",",O
,whereas,JJ,O
,caffeine,NN,O
,(,(,O
,70,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,and,CC,O
,pentylenetetrazole,JJ,O
,(,(,O
,30,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,produced,VBD,O
,an,DT,O
,anxiogenic,JJ,O
,effect,NN,O
,",",",",O
,apparent,NN,O
,with,IN,O
,decreases,NNS,O
,in,IN,O
,open,JJ,O
,-,:,O
,arm,NN,O
,time,NN,O
,and,CC,O
,entry,NN,O
,.,.,O
,Nicotine,NNP,O
,(,(,O
,0,CD,O
,.,.,O
,25,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,),),O
,pretreatment,NN,O
,blocked,VBD,O
,the,DT,O
,caffeine,NN,O
,-,:,O
,but,CC,O
,not,RB,O
,pentylenetetrazole,JJ,O
,-,:,O
,induced,JJ,O
,anxiety,NN,B-DISEASE
,.,.,O
,Administration,NNP,O
,of,IN,O
,each,DT,O
,drug,NN,O
,and,CC,O
,their,PRP$,O
,combinations,NNS,O
,did,VBD,O
,not,RB,O
,produce,VB,O
,any,DT,O
,effect,NN,O
,on,IN,O
,locomotor,NN,O
,activity,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Our,PRP$,O
,results,NNS,O
,suggest,VBP,O
,that,IN,O
,the,DT,O
,antagonistic,JJ,O
,effect,NN,O
,of,IN,O
,nicotine,NN,O
,on,IN,O
,caffeine,NN,O
,-,:,O
,induced,JJ,O
,anxiety,NN,B-DISEASE
,is,VBZ,O
,specific,JJ,O
,to,TO,O
,caffeine,VB,O
,",",",",O
,instead,RB,O
,of,IN,O
,a,DT,O
,non,JJ,O
,-,:,O
,specific,JJ,O
,anxiolytic,JJ,O
,effect,NN,O
,.,.,O
,Thus,RB,O
,",",",",O
,it,PRP,O
,may,MD,O
,extend,VB,O
,the,DT,O
,current,JJ,O
,findings,NNS,O
,on,IN,O
,the,DT,O
,interaction,NN,O
,between,IN,O
,nicotine,NN,O
,and,CC,O
,caffeine,NN,O
,.,.,O
,Long,JJ,O
,term,NN,O
,hormone,NN,O
,therapy,NN,O
,for,IN,O
,perimenopausal,NN,O
,and,CC,O
,postmenopausal,JJ,O
,women,NNS,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Hormone,NN,O
,therapy,NN,O
,(,(,O
,HT,NNP,O
,),),O
,is,VBZ,O
,widely,RB,O
,used,VBN,O
,for,IN,O
,controlling,VBG,O
,menopausal,NN,B-DISEASE
,symptoms,NNS,I-DISEASE
,.,.,O
,It,PRP,O
,has,VBZ,O
,also,RB,O
,been,VBN,O
,used,VBN,O
,for,IN,O
,the,DT,O
,management,NN,O
,and,CC,O
,prevention,NN,O
,of,IN,O
,cardiovascular,JJ,B-DISEASE
,disease,NN,I-DISEASE
,",",",",O
,osteoporosis,NN,B-DISEASE
,and,CC,O
,dementia,NN,B-DISEASE
,in,IN,O
,older,JJR,O
,women,NNS,O
,but,CC,O
,the,DT,O
,evidence,NN,O
,supporting,VBG,O
,its,PRP$,O
,use,NN,O
,for,IN,O
,these,DT,O
,indications,NNS,O
,is,VBZ,O
,largely,RB,O
,observational,JJ,O
,.,.,O
,OBJECTIVES,NN,O
,:,:,O
,To,TO,O
,assess,VB,O
,the,DT,O
,effect,NN,O
,of,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,HT,NNP,O
,on,IN,O
,mortality,NN,O
,",",",",O
,heart,NN,B-DISEASE
,disease,NN,I-DISEASE
,",",",",O
,venous,JJ,B-DISEASE
,thromboembolism,NN,I-DISEASE
,",",",",O
,stroke,NN,B-DISEASE
,",",",",O
,transient,JJ,B-DISEASE
,ischaemic,JJ,I-DISEASE
,attacks,NNS,I-DISEASE
,",",",",O
,breast,NN,B-DISEASE
,cancer,NN,I-DISEASE
,",",",",O
,colorectal,JJ,B-DISEASE
,cancer,NN,I-DISEASE
,",",",",O
,ovarian,JJ,B-DISEASE
,cancer,NN,I-DISEASE
,",",",",O
,endometrial,JJ,B-DISEASE
,cancer,NN,I-DISEASE
,",",",",O
,gallbladder,NN,B-DISEASE
,disease,NN,I-DISEASE
,",",",",O
,cognitive,JJ,O
,function,NN,O
,",",",",O
,dementia,NN,B-DISEASE
,",",",",O
,fractures,NNS,B-DISEASE
,and,CC,O
,quality,NN,O
,of,IN,O
,life,NN,O
,.,.,O
,SEARCH,NNP,O
,STRATEGY,NNP,O
,:,:,O
,We,PRP,O
,searched,VBD,O
,the,DT,O
,following,NN,O
,databases,VBZ,O
,up,RP,O
,to,TO,O
,November,NNP,O
,2004,CD,O
,:,:,O
,the,DT,O
,Cochrane,NNP,O
,Menstrual,NNP,O
,Disorders,NNP,O
,and,CC,O
,Subfertility,NNP,O
,Group,NNP,O
,Trials,NNP,O
,Register,NNP,O
,",",",",O
,Cochrane,NNP,O
,Central,NNP,O
,Register,NNP,O
,of,IN,O
,Controlled,NNP,O
,Trials,NNP,O
,(,(,O
,CENTRAL,NNP,O
,),),O
,",",",",O
,MEDLINE,NNP,O
,",",",",O
,EMBASE,NNP,O
,",",",",O
,Biological,NNP,O
,Abstracts,NNP,O
,.,.,O
,Relevant,NNP,O
,non,SYM,O
,-,:,O
,indexed,JJ,O
,journals,NNS,O
,and,CC,O
,conference,NN,O
,abstracts,NNS,O
,were,VBD,O
,also,RB,O
,searched,VBN,O
,.,.,O
,SELECTION,NNP,O
,CRITERIA,NNP,O
,:,:,O
,Randomised,VBN,O
,double,JJ,O
,-,:,O
,blind,NN,O
,trials,NNS,O
,of,IN,O
,HT,NNP,O
,(,(,O
,oestrogens,VBZ,O
,with,IN,O
,or,CC,O
,without,IN,O
,progestogens,NNS,O
,),),O
,versus,NN,O
,placebo,NN,O
,",",",",O
,taken,VBN,O
,for,IN,O
,at,IN,O
,least,JJS,O
,one,CD,O
,year,NN,O
,by,IN,O
,perimenopausal,NN,O
,or,CC,O
,postmenopausal,JJ,O
,women,NNS,O
,.,.,O
,DATA,NNP,O
,COLLECTION,NNP,O
,AND,NNP,O
,ANALYSIS,NNP,O
,:,:,O
,Fifteen,JJ,O
,RCTs,NNP,O
,were,VBD,O
,included,VBN,O
,.,.,O
,Trials,NNS,O
,were,VBD,O
,assessed,VBN,O
,for,IN,O
,quality,NN,O
,and,CC,O
,two,CD,O
,review,NN,O
,authors,NNS,O
,extracted,VBD,O
,data,NNS,O
,independently,RB,O
,.,.,O
,They,PRP,O
,calculated,VBD,O
,risk,NN,O
,ratios,NNS,O
,for,IN,O
,dichotomous,JJ,O
,outcomes,NNS,O
,and,CC,O
,weighted,JJ,O
,mean,NN,O
,differences,NNS,O
,for,IN,O
,continuous,JJ,O
,outcomes,NNS,O
,.,.,O
,Clinical,JJ,O
,heterogeneity,NN,O
,precluded,VBD,O
,meta,SYM,O
,-,:,O
,analysis,NN,O
,for,IN,O
,most,JJS,O
,outcomes,NNS,O
,.,.,O
,MAIN,JJ,O
,RESULTS,NN,O
,:,:,O
,All,PDT,O
,the,DT,O
,statistically,RB,O
,significant,JJ,O
,results,NNS,O
,were,VBD,O
,derived,VBN,O
,from,IN,O
,the,DT,O
,two,CD,O
,biggest,JJS,O
,trials,NNS,O
,.,.,O
,In,IN,O
,relatively,RB,O
,healthy,JJ,O
,women,NNS,O
,",",",",O
,combined,VBN,O
,continuous,JJ,O
,HT,NNP,O
,significantly,RB,O
,increased,VBD,O
,the,DT,O
,risk,NN,O
,of,IN,O
,venous,JJ,B-DISEASE
,thromboembolism,NN,I-DISEASE
,or,CC,O
,coronary,JJ,O
,event,NN,O
,(,(,O
,after,IN,O
,one,CD,O
,year,NN,O
,','',O
,s,NNS,O
,use,VBP,O
,),),O
,",",",",O
,stroke,VBD,B-DISEASE
,(,(,O
,after,IN,O
,3,CD,O
,years,NNS,O
,),),O
,",",",",O
,breast,JJ,B-DISEASE
,cancer,NN,I-DISEASE
,(,(,O
,after,IN,O
,5,CD,O
,years,NNS,O
,),),O
,and,CC,O
,gallbladder,JJ,B-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,Long,NNP,O
,-,:,O
,term,NN,O
,oestrogen,NN,O
,-,:,O
,only,RB,O
,HT,NNP,O
,also,RB,O
,significantly,RB,O
,increased,VBD,O
,the,DT,O
,risk,NN,O
,of,IN,O
,stroke,NN,B-DISEASE
,and,CC,O
,gallbladder,NN,B-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,Overall,UH,O
,",",",",O
,the,DT,O
,only,JJ,O
,statistically,RB,O
,significant,JJ,O
,benefits,NNS,O
,of,IN,O
,HT,NNP,O
,were,VBD,O
,a,DT,O
,decreased,JJ,O
,incidence,NN,O
,of,IN,O
,fractures,NNS,B-DISEASE
,and,CC,O
,colon,NN,B-DISEASE
,cancer,NN,I-DISEASE
,with,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,use,NN,O
,.,.,O
,Among,IN,O
,relatively,RB,O
,healthy,JJ,O
,women,NNS,O
,over,IN,O
,65,CD,O
,years,NNS,O
,taking,VBG,O
,continuous,JJ,O
,combined,VBN,O
,HT,NNP,O
,",",",",O
,there,EX,O
,was,VBD,O
,a,DT,O
,statistically,RB,O
,significant,JJ,O
,increase,NN,O
,in,IN,O
,the,DT,O
,incidence,NN,O
,of,IN,O
,dementia,NN,B-DISEASE
,.,.,O
,Among,IN,O
,women,NNS,O
,with,IN,O
,cardiovascular,JJ,B-DISEASE
,disease,NN,I-DISEASE
,",",",",O
,long,JJ,O
,-,:,O
,term,NN,O
,use,NN,O
,of,IN,O
,combined,JJ,O
,continuous,JJ,O
,HT,NNP,O
,significantly,RB,O
,increased,VBD,O
,the,DT,O
,risk,NN,O
,of,IN,O
,venous,JJ,B-DISEASE
,thromboembolism,NN,I-DISEASE
,.,.,O
,No,DT,O
,trials,NNS,O
,focussed,VBD,O
,specifically,RB,O
,on,IN,O
,younger,JJR,O
,women,NNS,O
,.,.,O
,However,RB,O
,",",",",O
,one,CD,O
,trial,NN,O
,analysed,VBD,O
,subgroups,NNS,O
,of,IN,O
,2839,CD,O
,relatively,RB,O
,healthy,JJ,O
,50,CD,O
,to,TO,O
,59,CD,O
,year,NN,O
,-,:,O
,old,JJ,O
,women,NNS,O
,taking,VBG,O
,combined,JJ,O
,continuous,JJ,O
,HT,NNP,O
,and,CC,O
,1637,CD,O
,taking,VBG,O
,oestrogen,NN,O
,-,:,O
,only,RB,O
,HT,NNP,O
,",",",",O
,versus,NN,O
,similar,JJ,O
,-,:,O
,sized,VBN,O
,placebo,NN,O
,groups,NNS,O
,.,.,O
,The,DT,O
,only,JJ,O
,significantly,RB,O
,increased,VBN,O
,risk,NN,O
,reported,VBD,O
,was,VBD,O
,for,IN,O
,venous,JJ,B-DISEASE
,thromboembolism,NN,I-DISEASE
,in,IN,O
,women,NNS,O
,taking,VBG,O
,combined,JJ,O
,continuous,JJ,O
,HT,NNP,O
,;,:,O
,their,PRP$,O
,absolute,NN,O
,risk,NN,O
,remained,VBD,O
,very,RB,O
,low,JJ,O
,.,.,O
,AUTHORS,NNP,O
,',POS,O
,CONCLUSIONS,NN,O
,:,:,O
,HT,NNP,O
,is,VBZ,O
,not,RB,O
,indicated,VBN,O
,for,IN,O
,the,DT,O
,routine,JJ,O
,management,NN,O
,of,IN,O
,chronic,JJ,B-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,We,PRP,O
,need,VBP,O
,more,JJR,O
,evidence,NN,O
,on,IN,O
,the,DT,O
,safety,NN,O
,of,IN,O
,HT,NNP,O
,for,IN,O
,menopausal,JJ,O
,symptom,NN,O
,control,NN,O
,",",",",O
,though,IN,O
,short,JJ,O
,-,:,O
,term,NN,O
,use,NN,O
,appears,VBZ,O
,to,TO,O
,be,VB,O
,relatively,RB,O
,safe,JJ,O
,for,IN,O
,healthy,JJ,O
,younger,JJR,O
,women,NNS,O
,.,.,O
,Drug,NNP,B-DISEASE
,-,:,I-DISEASE
,induced,VBD,I-DISEASE
,liver,JJ,I-DISEASE
,injury,NN,I-DISEASE
,:,:,O
,an,DT,O
,analysis,NN,O
,of,IN,O
,461,CD,O
,incidences,NNS,O
,submitted,VBN,O
,to,TO,O
,the,DT,O
,Spanish,JJ,O
,registry,NN,O
,over,IN,O
,a,DT,O
,10,CD,O
,-,:,O
,year,NN,O
,period,NN,O
,.,.,O
,BACKGROUND,NNP,O
,&,CC,O
,AIMS,NNP,O
,:,:,O
,Progress,NN,O
,in,IN,O
,the,DT,O
,understanding,NN,O
,of,IN,O
,susceptibility,NN,O
,factors,NNS,O
,to,TO,O
,drug,NN,B-DISEASE
,-,:,I-DISEASE
,induced,VBN,I-DISEASE
,liver,JJ,I-DISEASE
,injury,NN,I-DISEASE
,(,(,O
,DILI,NNP,B-DISEASE
,),),O
,and,CC,O
,outcome,JJ,O
,predictability,NN,O
,are,VBP,O
,hampered,VBN,O
,by,IN,O
,the,DT,O
,lack,NN,O
,of,IN,O
,systematic,JJ,O
,programs,NNS,O
,to,TO,O
,detect,VB,O
,bona,JJ,O
,fide,NN,O
,cases,NNS,O
,.,.,O
,METHODS,NN,O
,:,:,O
,A,DT,O
,cooperative,JJ,O
,network,NN,O
,was,VBD,O
,created,VBN,O
,in,IN,O
,1994,CD,O
,in,IN,O
,Spain,NNP,O
,to,TO,O
,identify,VB,O
,all,DT,O
,suspicions,NNS,O
,of,IN,O
,DILI,NNP,B-DISEASE
,following,VBG,O
,a,DT,O
,prospective,JJ,O
,structured,JJ,O
,report,NN,O
,form,NN,O
,.,.,O
,The,DT,O
,liver,JJ,B-DISEASE
,damage,NN,I-DISEASE
,was,VBD,O
,characterized,VBN,O
,according,VBG,O
,to,TO,O
,hepatocellular,NN,O
,",",",",O
,cholestatic,JJ,B-DISEASE
,",",",",O
,and,CC,O
,mixed,JJ,O
,laboratory,NN,O
,criteria,NNS,O
,and,CC,O
,to,TO,O
,histologic,VB,O
,criteria,NNS,O
,when,WRB,O
,available,JJ,O
,.,.,O
,Further,JJ,O
,evaluation,NN,O
,of,IN,O
,causality,NN,O
,assessment,NN,O
,was,VBD,O
,centrally,RB,O
,performed,VBN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Since,IN,O
,April,NNP,O
,1994,CD,O
,to,TO,O
,August,NNP,O
,2004,CD,O
,",",",",O
,461,CD,O
,out,IN,O
,of,IN,O
,570,CD,O
,submitted,JJ,O
,cases,NNS,O
,",",",",O
,involving,VBG,O
,505,CD,O
,drugs,NNS,O
,",",",",O
,were,VBD,O
,deemed,VBN,O
,to,TO,O
,be,VB,O
,related,VBN,O
,to,TO,O
,DILI,NNP,B-DISEASE
,.,.,O
,The,DT,O
,antiinfective,JJ,O
,group,NN,O
,of,IN,O
,drugs,NNS,O
,was,VBD,O
,the,DT,O
,more,RBR,O
,frequently,RB,O
,incriminated,VBN,O
,",",",",O
,amoxicillin,SYM,O
,-,:,O
,clavulanate,NN,O
,accounting,NN,O
,for,IN,O
,the,DT,O
,12,CD,O
,.,.,O
,8,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,whole,JJ,O
,series,NN,O
,.,.,O
,The,DT,O
,hepatocellular,JJ,O
,pattern,NN,O
,of,IN,O
,damage,NN,O
,was,VBD,O
,the,DT,O
,most,RBS,O
,common,JJ,O
,(,(,O
,58,CD,O
,%,NN,O
,),),O
,",",",",O
,was,VBD,O
,inversely,RB,O
,correlated,VBN,O
,with,IN,O
,age,NN,O
,(,(,O
,P,NNP,O
,<,NNP,O
,.,.,O
,0001,CD,O
,),),O
,",",",",O
,and,CC,O
,had,VBD,O
,the,DT,O
,worst,JJS,O
,outcome,NN,O
,(,(,O
,Cox,NNP,O
,regression,NN,O
,",",",",O
,P,NNP,O
,<,NNP,O
,.,.,O
,034,CD,O
,),),O
,.,.,O
,Indeed,RB,O
,",",",",O
,the,DT,O
,incidence,NN,O
,of,IN,O
,liver,JJ,O
,transplantation,NN,O
,and,CC,O
,death,NN,O
,in,IN,O
,this,DT,O
,group,NN,O
,was,VBD,O
,11,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,if,IN,O
,patients,NNS,O
,had,VBD,O
,jaundice,NN,B-DISEASE
,at,IN,O
,presentation,NN,O
,",",",",O
,whereas,IN,O
,the,DT,O
,corresponding,JJ,O
,figure,NN,O
,was,VBD,O
,3,CD,O
,.,.,O
,8,CD,O
,%,NN,O
,in,IN,O
,nonjaundiced,JJ,O
,patients,NNS,O
,(,(,O
,P,NNP,O
,<,NNP,O
,.,.,O
,04,CD,O
,),),O
,.,.,O
,Factors,NNS,O
,associated,VBD,O
,with,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,fulminant,JJ,B-DISEASE
,hepatic,JJ,I-DISEASE
,failure,NN,I-DISEASE
,were,VBD,O
,female,JJ,O
,sex,NN,O
,(,(,O
,OR,NNP,O
,=,VBZ,O
,25,CD,O
,;,:,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,:,:,O
,4,CD,O
,.,.,O
,1,CD,O
,-,:,O
,151,CD,O
,;,:,O
,P,NNP,O
,<,NNP,O
,.,.,O
,0001,CD,O
,),),O
,",",",",O
,hepatocellular,JJ,O
,damage,NN,O
,(,(,O
,OR,NNP,O
,=,VBZ,O
,7,CD,O
,.,.,O
,9,CD,O
,;,:,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,:,:,O
,1,CD,O
,.,.,O
,6,CD,O
,-,:,O
,37,CD,O
,;,:,O
,P,NNP,O
,<,NNP,O
,.,.,O
,009,CD,O
,),),O
,",",",",O
,and,CC,O
,higher,JJR,O
,baseline,NN,O
,plasma,NN,O
,bilirubin,NN,O
,value,NN,O
,(,(,O
,OR,NNP,O
,=,VBZ,O
,1,CD,O
,.,.,O
,15,CD,O
,;,:,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,:,:,O
,1,CD,O
,.,.,O
,09,CD,O
,-,:,O
,1,CD,O
,.,.,O
,22,CD,O
,;,:,O
,P,NNP,O
,<,NNP,O
,.,.,O
,0001,CD,O
,),),O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Patients,NNS,O
,with,IN,O
,drug,NN,O
,-,:,O
,induced,JJ,O
,hepatocellular,JJ,O
,jaundice,NN,B-DISEASE
,have,VBP,O
,11,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,chance,NN,O
,of,IN,O
,progressing,VBG,O
,to,TO,O
,death,NN,O
,or,CC,O
,transplantation,NN,O
,.,.,O
,Amoxicillin,NNP,O
,-,:,O
,clavulanate,NN,O
,stands,VBZ,O
,out,RP,O
,as,IN,O
,the,DT,O
,most,RBS,O
,common,JJ,O
,drug,NN,O
,related,VBN,O
,to,TO,O
,DILI,NNP,B-DISEASE
,.,.,O
,Morphological,NNP,O
,evaluation,NN,O
,of,IN,O
,the,DT,O
,effect,NN,O
,of,IN,O
,d,NN,O
,-,:,O
,ribose,NN,O
,on,IN,O
,adriamycin,JJ,O
,-,:,O
,evoked,JJ,O
,cardiotoxicity,NN,B-DISEASE
,in,IN,O
,rats,NNS,O
,.,.,O
,The,DT,O
,influence,NN,O
,of,IN,O
,d,NN,O
,-,:,O
,ribose,NN,O
,on,IN,O
,adriamycin,JJ,O
,-,:,O
,induced,VBN,O
,myocardiopathy,NN,B-DISEASE
,in,IN,O
,rats,NNS,O
,was,VBD,O
,studied,VBN,O
,.,.,O
,Adriamycin,NNP,O
,in,IN,O
,the,DT,O
,cumulative,JJ,O
,dose,NN,O
,of,IN,O
,25,CD,O
,mg,NNS,O
,/,JJ,O
,kg,NN,O
,evoked,VBD,O
,fully,RB,O
,developed,VBN,O
,cardiac,JJ,B-DISEASE
,toxicity,NN,I-DISEASE
,.,.,O
,D,NNP,O
,-,:,O
,ribose,NN,O
,in,IN,O
,the,DT,O
,multiple,JJ,O
,doses,NNS,O
,of,IN,O
,200,CD,O
,mg,NNS,O
,/,JJ,O
,kg,NNS,O
,did,VBD,O
,not,RB,O
,influence,VB,O
,ADR,NNP,O
,cardiotoxicity,NN,B-DISEASE
,.,.,O
,In,IN,O
,vivo,JJ,O
,evidences,NNS,O
,suggesting,VBG,O
,the,DT,O
,role,NN,O
,of,IN,O
,oxidative,JJ,O
,stress,NN,O
,in,IN,O
,pathogenesis,NN,O
,of,IN,O
,vancomycin,JJ,O
,-,:,O
,induced,JJ,O
,nephrotoxicity,NN,B-DISEASE
,:,:,O
,protection,NN,O
,by,IN,O
,erdosteine,NN,O
,.,.,O
,The,DT,O
,aims,NNS,O
,of,IN,O
,this,DT,O
,study,NN,O
,were,VBD,O
,to,TO,O
,examine,VB,O
,vancomycin,NN,O
,(,(,O
,VCM,NNP,O
,),),O
,-,:,O
,induced,VBN,O
,oxidative,JJ,O
,stress,NN,O
,that,WDT,O
,promotes,VBZ,O
,production,NN,O
,of,IN,O
,reactive,JJ,O
,oxygen,NN,O
,species,NNS,O
,(,(,O
,ROS,NNP,O
,),),O
,and,CC,O
,to,TO,O
,investigate,VB,O
,the,DT,O
,role,NN,O
,of,IN,O
,erdosteine,NN,O
,",",",",O
,an,DT,O
,expectorant,JJ,O
,agent,NN,O
,",",",",O
,which,WDT,O
,has,VBZ,O
,also,RB,O
,antioxidant,JJ,O
,properties,NNS,O
,",",",",O
,on,IN,O
,kidney,NN,O
,tissue,NN,O
,against,IN,O
,the,DT,O
,possible,JJ,O
,VCM,NNP,O
,-,:,O
,induced,VBD,O
,renal,JJ,B-DISEASE
,impairment,NN,I-DISEASE
,in,IN,O
,rats,NNS,O
,.,.,O
,Rats,NNPS,O
,were,VBD,O
,divided,VBN,O
,into,IN,O
,three,CD,O
,groups,NNS,O
,:,:,O
,sham,NN,O
,",",",",O
,VCM,NNP,O
,and,CC,O
,VCM,NNP,O
,plus,CC,O
,erdosteine,NN,O
,.,.,O
,VCM,NNP,O
,was,VBD,O
,administrated,VBN,O
,intraperitoneally,RB,O
,(,(,O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,with,IN,O
,200mgkg,CD,O
,(,(,O
,-,:,O
,1,CD,O
,),),O
,twice,RB,O
,daily,RB,O
,for,IN,O
,7,CD,O
,days,NNS,O
,.,.,O
,Erdosteine,NNP,O
,was,VBD,O
,administered,VBN,O
,orally,RB,O
,.,.,O
,VCM,NNP,O
,administration,NN,O
,to,TO,O
,control,VB,O
,rats,NNS,O
,significantly,RB,O
,increased,VBD,O
,renal,JJ,O
,malondialdehyde,NN,O
,(,(,O
,MDA,NNP,O
,),),O
,and,CC,O
,urinary,JJ,O
,N,NNP,O
,-,:,O
,acetyl,NN,O
,-,:,O
,beta,NN,O
,-,:,O
,d,NN,O
,-,:,O
,glucosaminidase,NN,O
,(,(,O
,NAG,NNP,O
,",",",",O
,a,DT,O
,marker,NN,O
,of,IN,O
,renal,JJ,B-DISEASE
,tubular,JJ,I-DISEASE
,injury,NN,I-DISEASE
,),),O
,excretion,NN,O
,but,CC,O
,decreased,VBD,O
,superoxide,JJ,O
,dismutase,NN,O
,(,(,O
,SOD,NNP,O
,),),O
,and,CC,O
,catalase,NN,O
,(,(,O
,CAT,NNP,O
,),),O
,activities,NNS,O
,.,.,O
,Erdosteine,NNP,O
,administration,NN,O
,with,IN,O
,VCM,NNP,O
,injections,NNS,O
,caused,VBD,O
,significantly,RB,O
,decreased,VBN,O
,renal,JJ,O
,MDA,NNP,O
,and,CC,O
,urinary,JJ,O
,NAG,NNP,O
,excretion,NN,O
,",",",",O
,and,CC,O
,increased,VBD,O
,SOD,NNP,O
,activity,NN,O
,",",",",O
,but,CC,O
,not,RB,O
,CAT,NNP,O
,activity,NN,O
,in,IN,O
,renal,JJ,O
,tissue,NN,O
,when,WRB,O
,compared,VBN,O
,with,IN,O
,VCM,NNP,O
,alone,RB,O
,.,.,O
,Erdosteine,NNP,O
,showed,VBD,O
,histopathological,JJ,O
,protection,NN,O
,against,IN,O
,VCM,NNP,O
,-,:,O
,induced,JJ,O
,nephrotoxicity,NN,B-DISEASE
,.,.,O
,There,EX,O
,were,VBD,O
,a,DT,O
,significant,JJ,O
,dilatation,NN,O
,of,IN,O
,tubular,JJ,O
,lumens,NNS,O
,",",",",O
,extensive,JJ,O
,epithelial,NN,O
,cell,NN,O
,vacuolization,NN,O
,",",",",O
,atrophy,NN,B-DISEASE
,",",",",O
,desquamation,NN,B-DISEASE
,",",",",O
,and,CC,O
,necrosis,NN,B-DISEASE
,in,IN,O
,VCM,NNP,O
,-,:,O
,treated,VBD,O
,rats,NNS,O
,more,RBR,O
,than,IN,O
,those,DT,O
,of,IN,O
,the,DT,O
,control,NN,O
,and,CC,O
,the,DT,O
,erdosteine,NN,O
,groups,NNS,O
,.,.,O
,Erdosteine,NNP,O
,caused,VBD,O
,a,DT,O
,marked,JJ,O
,reduction,NN,O
,in,IN,O
,the,DT,O
,extent,NN,O
,of,IN,O
,tubular,JJ,O
,damage,NN,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,concluded,VBN,O
,that,IN,O
,oxidative,JJ,O
,tubular,JJ,O
,damage,NN,O
,plays,VBZ,O
,an,DT,O
,important,JJ,O
,role,NN,O
,in,IN,O
,the,DT,O
,VCM,NNP,O
,-,:,O
,induced,JJ,O
,nephrotoxicity,NN,B-DISEASE
,and,CC,O
,the,DT,O
,modulation,NN,O
,of,IN,O
,oxidative,JJ,O
,stress,NN,O
,with,IN,O
,erdosteine,NN,O
,reduces,VBZ,O
,the,DT,O
,VCM,NNP,O
,-,:,O
,induced,VBD,O
,kidney,NN,B-DISEASE
,damage,NN,I-DISEASE
,both,DT,O
,at,IN,O
,the,DT,O
,biochemical,JJ,O
,and,CC,O
,histological,JJ,O
,levels,NNS,O
,.,.,O
,Gemfibrozil,NNP,O
,-,:,O
,lovastatin,NN,O
,therapy,NN,O
,for,IN,O
,primary,JJ,O
,hyperlipoproteinemias,NN,B-DISEASE
,.,.,O
,The,DT,O
,specific,JJ,O
,aim,NN,O
,of,IN,O
,this,DT,O
,retrospective,NN,O
,",",",",O
,observational,JJ,O
,study,NN,O
,was,VBD,O
,to,TO,O
,assess,VB,O
,safety,NN,O
,and,CC,O
,efficacy,NN,O
,of,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,(,(,O
,21,CD,O
,months,NNS,O
,/,JJ,O
,patient,NN,O
,),),O
,",",",",O
,open,JJ,O
,-,:,O
,label,NN,O
,",",",",O
,gemfibrozil,SYM,O
,-,:,O
,lovastatin,NN,O
,treatment,NN,O
,in,IN,O
,80,CD,O
,patients,NNS,O
,with,IN,O
,primary,JJ,O
,mixed,JJ,O
,hyperlipidemia,NN,B-DISEASE
,(,(,O
,68,CD,O
,%,NN,O
,of,IN,O
,whom,WP,O
,had,VBD,O
,atherosclerotic,JJ,B-DISEASE
,vascular,JJ,I-DISEASE
,disease,NN,I-DISEASE
,),),O
,.,.,O
,Because,IN,O
,ideal,JJ,O
,lipid,JJ,O
,targets,NNS,O
,were,VBD,O
,not,RB,O
,reached,VBN,O
,(,(,O
,low,JJ,O
,-,:,O
,density,NN,O
,lipoprotein,NN,O
,(,(,O
,LDL,NNP,O
,),),O
,cholesterol,NN,O
,less,JJR,O
,than,IN,O
,130,CD,O
,mg,JJ,O
,/,NNP,O
,dl,NN,O
,",",",",O
,high,JJ,O
,-,:,O
,density,NN,O
,lipoprotein,NN,O
,(,(,O
,HDL,NNP,O
,),),O
,cholesterol,NN,O
,greater,JJR,O
,than,IN,O
,35,CD,O
,mg,JJ,O
,/,NNP,O
,dl,NN,O
,",",",",O
,or,CC,O
,total,JJ,O
,cholesterol,NN,O
,/,NNP,O
,HDL,NNP,O
,cholesterol,NN,O
,less,JJR,O
,than,IN,O
,4,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,/,NNP,O
,dl,NN,O
,),),O
,with,IN,O
,diet,JJ,O
,plus,CC,O
,a,DT,O
,single,JJ,O
,drug,NN,O
,",",",",O
,gemfibrozil,NN,O
,(,(,O
,1,CD,O
,.,.,O
,2,CD,O
,g,JJ,O
,/,NNP,O
,day,NN,O
,),),O
,-,:,O
,lovastatin,NN,O
,(,(,O
,primarily,RB,O
,20,CD,O
,or,CC,O
,40,CD,O
,mg,NN,O
,),),O
,treatment,NN,O
,was,VBD,O
,given,VBN,O
,.,.,O
,Follow,NNP,O
,-,:,O
,up,RB,O
,visits,NNS,O
,were,VBD,O
,scheduled,VBN,O
,with,IN,O
,2,CD,O
,-,:,O
,drug,NN,O
,therapy,NN,O
,every,DT,O
,6,CD,O
,to,TO,O
,8,CD,O
,weeks,NNS,O
,",",",",O
,an,DT,O
,average,NN,O
,of,IN,O
,10,CD,O
,.,.,O
,3,CD,O
,visits,NNS,O
,per,IN,O
,patient,NN,O
,",",",",O
,with,IN,O
,741,CD,O
,batteries,NNS,O
,of,IN,O
,6,CD,O
,liver,JJ,O
,function,NN,O
,tests,NNS,O
,and,CC,O
,714,CD,O
,creatine,NN,O
,phosphokinase,NN,O
,levels,NNS,O
,measured,VBN,O
,.,.,O
,Only,RB,O
,1,CD,O
,of,IN,O
,the,DT,O
,4,CD,O
,",",",",O
,446,CD,O
,liver,NN,O
,function,NN,O
,tests,NNS,O
,(,(,O
,0,CD,O
,.,.,O
,02,CD,O
,%,NN,O
,),),O
,",",",",O
,a,DT,O
,gamma,NN,O
,glutamyl,NN,O
,transferase,NN,O
,",",",",O
,was,VBD,O
,greater,JJR,O
,than,IN,O
,or,CC,O
,equal,JJ,O
,to,TO,O
,3,CD,O
,times,NNS,O
,the,DT,O
,upper,JJ,O
,normal,JJ,O
,limit,NN,O
,.,.,O
,Of,IN,O
,the,DT,O
,714,CD,O
,creatine,NN,O
,phosphokinase,NN,O
,levels,NNS,O
,",",",",O
,9,CD,O
,%,NN,O
,were,VBD,O
,high,JJ,O
,;,:,O
,only,RB,O
,1,CD,O
,(,(,O
,0,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,),),O
,was,VBD,O
,greater,JJR,O
,than,IN,O
,or,CC,O
,equal,JJ,O
,to,TO,O
,3,CD,O
,times,NNS,O
,the,DT,O
,upper,JJ,O
,normal,JJ,O
,limit,NN,O
,.,.,O
,With,IN,O
,2,CD,O
,-,:,O
,drug,NN,O
,therapy,NN,O
,",",",",O
,mean,JJ,O
,total,NN,O
,cholesterol,NN,O
,decreased,VBD,O
,22,CD,O
,%,NN,O
,from,IN,O
,255,CD,O
,to,TO,O
,200,CD,O
,mg,NNS,O
,/,JJ,O
,dl,NN,O
,",",",",O
,triglyceride,NN,O
,levels,NNS,O
,decreased,VBD,O
,35,CD,O
,%,NN,O
,from,IN,O
,236,CD,O
,to,TO,O
,154,CD,O
,mg,NNS,O
,/,JJ,O
,dl,NN,O
,",",",",O
,LDL,NNP,O
,cholesterol,NN,O
,decreased,VBD,O
,26,CD,O
,%,NN,O
,from,IN,O
,176,CD,O
,to,TO,O
,131,CD,O
,mg,NNS,O
,/,JJ,O
,dl,NN,O
,",",",",O
,and,CC,O
,the,DT,O
,total,JJ,O
,cholesterol,NN,O
,/,NNP,O
,HDL,NNP,O
,cholesterol,NN,O
,ratio,NN,O
,decreased,VBD,O
,24,CD,O
,%,NN,O
,from,IN,O
,7,CD,O
,.,.,O
,1,CD,O
,to,TO,O
,5,CD,O
,.,.,O
,4,CD,O
,",",",",O
,all,DT,O
,p,NN,O
,less,JJR,O
,than,IN,O
,or,CC,O
,equal,JJ,O
,to,TO,O
,0,CD,O
,.,.,O
,0001,CD,O
,.,.,O
,Myositis,NNP,B-DISEASE
,",",",",O
,attributable,JJ,O
,to,TO,O
,the,DT,O
,drug,NN,O
,combination,NN,O
,and,CC,O
,symptomatic,JJ,O
,enough,RB,O
,to,TO,O
,discontinue,VB,O
,it,PRP,O
,",",",",O
,occurred,VBD,O
,in,IN,O
,3,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,",",",",O
,and,CC,O
,in,IN,O
,1,CD,O
,%,NN,O
,with,IN,O
,concurrent,JJ,O
,high,JJ,O
,creatine,NN,O
,phosphokinase,NN,O
,(,(,O
,769,CD,O
,U,NNP,O
,/,NNP,O
,liter,NN,O
,),),O
,;,:,O
,no,DT,O
,patients,NNS,O
,had,VBD,O
,rhabdomyolysis,NN,B-DISEASE
,or,CC,O
,myoglobinuria,NN,B-DISEASE
,.,.,O
,(,(,O
,ABSTRACT,NNP,O
,TRUNCATED,NNP,O
,AT,NNP,O
,250,CD,O
,WORDS,NNP,O
,),),O
,Does,VBZ,O
,domperidone,JJ,O
,potentiate,VB,O
,mirtazapine,JJ,O
,-,:,O
,associated,VBN,O
,restless,JJ,B-DISEASE
,legs,NNS,I-DISEASE
,syndrome,VBN,I-DISEASE
,?,.,O
,There,EX,O
,is,VBZ,O
,now,RB,O
,evidence,NN,O
,to,TO,O
,suggest,VB,O
,a,DT,O
,central,JJ,O
,role,NN,O
,for,IN,O
,the,DT,O
,dopaminergic,NN,O
,system,NN,O
,in,IN,O
,restless,JJ,B-DISEASE
,legs,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,(,(,O
,RLS,NNP,B-DISEASE
,),),O
,.,.,O
,For,IN,O
,example,NN,O
,",",",",O
,the,DT,O
,symptoms,NNS,O
,of,IN,O
,RLS,NNP,B-DISEASE
,can,MD,O
,be,VB,O
,dramatically,RB,O
,improved,VBN,O
,by,IN,O
,levodopa,NN,O
,and,CC,O
,dopamine,NN,O
,agonists,NNS,O
,",",",",O
,whereas,JJ,O
,central,JJ,O
,dopamine,NN,O
,D2,NNP,O
,receptor,NN,O
,antagonists,NNS,O
,can,MD,O
,induce,VB,O
,or,CC,O
,aggravate,VB,O
,RLS,NNP,B-DISEASE
,symptoms,NNS,O
,.,.,O
,To,TO,O
,our,PRP$,O
,knowledge,NN,O
,",",",",O
,there,EX,O
,is,VBZ,O
,no,DT,O
,previous,JJ,O
,report,NN,O
,regarding,VBG,O
,whether,IN,O
,domperidone,NN,O
,",",",",O
,a,DT,O
,peripheral,JJ,O
,dopamine,NN,O
,D2,NNP,O
,receptor,NN,O
,antagonist,NN,O
,",",",",O
,can,MD,O
,also,RB,O
,induce,VB,O
,or,CC,O
,aggravate,VB,O
,symptoms,NNS,O
,of,IN,O
,RLS,NNP,B-DISEASE
,.,.,O
,Mirtazapine,NNP,O
,",",",",O
,the,DT,O
,first,JJ,O
,noradrenergic,NN,O
,and,CC,O
,specific,JJ,O
,serotonergic,NN,O
,antidepressant,NN,O
,(,(,O
,NaSSA,NNP,O
,),),O
,",",",",O
,has,VBZ,O
,been,VBN,O
,associated,VBN,O
,with,IN,O
,RLS,NNP,B-DISEASE
,in,IN,O
,several,JJ,O
,recent,JJ,O
,publications,NNS,O
,.,.,O
,The,DT,O
,authors,NNS,O
,report,VBP,O
,here,RB,O
,a,DT,O
,depressed,JJ,O
,patient,NN,O
,comorbid,NN,O
,with,IN,O
,postprandial,JJ,B-DISEASE
,dyspepsia,NN,I-DISEASE
,who,WP,O
,developed,VBD,O
,RLS,NNP,B-DISEASE
,after,IN,O
,mirtazapine,NN,O
,had,VBD,O
,been,VBN,O
,added,VBN,O
,to,TO,O
,his,PRP$,O
,domperidone,NN,O
,therapy,NN,O
,.,.,O
,Our,PRP$,O
,patient,NN,O
,started,VBD,O
,to,TO,O
,have,VB,O
,symptoms,NNS,O
,of,IN,O
,RLS,NNP,B-DISEASE
,only,RB,O
,after,IN,O
,he,PRP,O
,had,VBD,O
,been,VBN,O
,treated,VBN,O
,with,IN,O
,mirtazapine,NN,O
,",",",",O
,and,CC,O
,his,PRP$,O
,RLS,NNP,B-DISEASE
,symptoms,NNS,O
,resolved,VBD,O
,completely,RB,O
,upon,JJ,O
,discontinuation,NN,O
,of,IN,O
,his,PRP$,O
,mirtazapine,NN,O
,.,.,O
,Such,PDT,O
,a,DT,O
,temporal,JJ,O
,relationship,NN,O
,between,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,mirtazapine,NN,O
,and,CC,O
,the,DT,O
,symptoms,NNS,O
,of,IN,O
,RLS,NNP,B-DISEASE
,in,IN,O
,our,PRP$,O
,patient,NN,O
,did,VBD,O
,not,RB,O
,support,VB,O
,a,DT,O
,potentiating,JJ,O
,effect,NN,O
,of,IN,O
,domperione,NN,O
,on,IN,O
,mirtazapine,NN,O
,-,:,O
,associated,VBN,O
,RLS,NNP,B-DISEASE
,.,.,O
,However,RB,O
,",",",",O
,physicians,NNS,O
,should,MD,O
,be,VB,O
,aware,JJ,O
,of,IN,O
,the,DT,O
,possibility,NN,O
,that,IN,O
,mirtazapine,NN,O
,can,MD,O
,be,VB,O
,associated,VBN,O
,with,IN,O
,RLS,NNP,B-DISEASE
,in,IN,O
,some,DT,O
,individuals,NNS,O
,",",",",O
,especially,RB,O
,those,DT,O
,receiving,VBG,O
,concomitant,JJ,O
,dopamine,NN,O
,D2,NNP,O
,receptor,NN,O
,antagonists,NNS,O
,.,.,O
,Antiandrogenic,JJ,O
,therapy,NN,O
,can,MD,O
,cause,VB,O
,coronary,JJ,B-DISEASE
,arterial,JJ,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,AIM,NN,O
,:,:,O
,To,TO,O
,study,VB,O
,the,DT,O
,change,NN,O
,of,IN,O
,lipid,JJ,O
,metabolism,NN,O
,by,IN,O
,antiandrogen,NN,O
,therapy,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,prostate,JJ,B-DISEASE
,cancer,NN,I-DISEASE
,.,.,O
,MATERIALS,NNP,O
,AND,CC,O
,METHODS,NNP,O
,:,:,O
,We,PRP,O
,studied,VBD,O
,with,IN,O
,a,DT,O
,2,CD,O
,.,.,O
,5,CD,O
,years,NNS,O
,follow,VBP,O
,-,:,O
,up,IN,O
,the,DT,O
,changes,NNS,O
,in,IN,O
,plasma,NN,O
,cholesterols,NNS,O
,(,(,O
,C,NNP,O
,),),O
,",",",",O
,triglycerides,NNS,O
,(,(,O
,TG,NNP,O
,),),O
,",",",",O
,lipoproteins,VBZ,O
,(,(,O
,LP,NNP,O
,),),O
,",",",",O
,and,CC,O
,apolipoproteins,NNS,O
,(,(,O
,Apo,NNP,O
,),),O
,B,NNP,O
,-,:,O
,100,CD,O
,",",",",O
,A,NNP,O
,-,:,O
,I,PRP,O
,",",",",O
,and,CC,O
,A,NNP,O
,-,:,O
,II,NNP,O
,pro,FW,O
,fi,NN,O
,les,NNS,O
,in,IN,O
,24,CD,O
,patients,NNS,O
,of,IN,O
,mean,JJ,O
,age,NN,O
,60,CD,O
,years,NNS,O
,with,IN,O
,low,JJ,O
,risk,NN,O
,prostate,NN,B-DISEASE
,cancer,NN,I-DISEASE
,(,(,O
,stage,NN,O
,:,:,O
,T1cN0M0,NNP,O
,",",",",O
,Gleason,NNP,O
,score,NN,O
,:,:,O
,2,CD,O
,-,:,O
,5,CD,O
,),),O
,during,IN,O
,treatment,NN,O
,with,IN,O
,cyproterone,NN,O
,acetate,NN,O
,(,(,O
,CPA,NNP,O
,),),O
,without,IN,O
,surgical,JJ,O
,management,NN,O
,or,CC,O
,radiation,NN,O
,therapy,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Significant,JJ,O
,decreases,NNS,O
,of,IN,O
,HDL,NNP,O
,-,:,O
,C,NNP,O
,",",",",O
,Apo,NNP,O
,A,NNP,O
,-,:,O
,I,PRP,O
,and,CC,O
,Apo,VB,O
,A,NNP,O
,-,:,O
,II,NNP,O
,and,CC,O
,an,DT,O
,increase,NN,O
,of,IN,O
,triglyceride,JJ,O
,levels,NNS,O
,in,IN,O
,VLDL,NNP,O
,were,VBD,O
,induced,VBN,O
,by,IN,O
,CPA,NNP,O
,.,.,O
,After,IN,O
,a,DT,O
,period,NN,O
,of,IN,O
,2,CD,O
,.,.,O
,5,CD,O
,years,NNS,O
,on,IN,O
,CPA,NNP,O
,treatment,NN,O
,",",",",O
,four,CD,O
,patients,NNS,O
,out,IN,O
,of,IN,O
,twenty,JJ,O
,-,:,O
,four,CD,O
,were,VBD,O
,found,VBN,O
,to,TO,O
,be,VB,O
,affected,VBN,O
,by,IN,O
,coronary,JJ,B-DISEASE
,heart,NN,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Ischaemic,NNP,O
,coronary,JJ,B-DISEASE
,arteriosclerosis,NN,I-DISEASE
,with,IN,O
,an,DT,O
,incidence,NN,O
,rate,NN,O
,of,IN,O
,16,CD,O
,.,.,O
,6,CD,O
,%,NN,O
,as,IN,O
,caused,VBN,O
,by,IN,O
,prolonged,JJ,O
,CPA,NNP,O
,therapy,NN,O
,is,VBZ,O
,mediated,VBN,O
,through,IN,O
,changes,NNS,O
,in,IN,O
,HDL,NNP,O
,cholesterol,NN,O
,",",",",O
,Apo,NNP,O
,A,NNP,O
,-,:,O
,I,PRP,O
,and,CC,O
,Apo,VB,O
,A,NNP,O
,-,:,O
,II,NNP,O
,pro,FW,O
,fi,NN,O
,les,NNS,O
,",",",",O
,other,JJ,O
,than,IN,O
,the,DT,O
,well,JJ,O
,-,:,O
,known,VBN,O
,hyperglyceridemic,JJ,B-DISEASE
,effect,NN,I-DISEASE
,caused,VBN,O
,by,IN,O
,estrogen,NN,O
,.,.,O
,5,CD,O
,-,:,O
,Fluorouracil,NNP,O
,cardiotoxicity,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,alpha,JJ,O
,-,:,O
,fluoro,NN,O
,-,:,O
,beta,NN,O
,-,:,O
,alanine,NN,O
,.,.,O
,Cardiotoxicity,NNP,B-DISEASE
,is,VBZ,O
,a,DT,O
,rare,JJ,O
,complication,NN,O
,occurring,VBG,O
,during,IN,O
,5,CD,O
,-,:,O
,fluorouracil,NN,O
,(,(,O
,5,CD,O
,-,:,O
,FU,NN,O
,),),O
,treatment,NN,O
,for,IN,O
,malignancies,NNS,B-DISEASE
,.,.,O
,We,PRP,O
,herein,VBP,O
,report,VB,O
,the,DT,O
,case,NN,O
,of,IN,O
,a,DT,O
,70,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,man,NN,O
,with,IN,O
,5,CD,O
,-,:,O
,FU,NNP,O
,-,:,O
,induced,JJ,O
,cardiotoxicity,NN,B-DISEASE
,",",",",O
,in,IN,O
,whom,WP,O
,a,DT,O
,high,JJ,O
,serum,NN,O
,level,NN,O
,of,IN,O
,alpha,JJ,O
,-,:,O
,fluoro,NN,O
,-,:,O
,beta,NN,O
,-,:,O
,alanine,NN,O
,(,(,O
,FBAL,NNP,O
,),),O
,was,VBD,O
,observed,VBN,O
,.,.,O
,The,DT,O
,patient,NN,O
,",",",",O
,who,WP,O
,had,VBD,O
,unresectable,JJ,O
,colon,NN,B-DISEASE
,cancer,NN,I-DISEASE
,metastases,VBZ,O
,to,TO,O
,the,DT,O
,liver,NN,O
,and,CC,O
,lung,NN,O
,",",",",O
,was,VBD,O
,referred,VBN,O
,to,TO,O
,us,PRP,O
,for,IN,O
,chemotherapy,NN,O
,from,IN,O
,an,DT,O
,affiliated,JJ,O
,hospital,NN,O
,;,:,O
,he,PRP,O
,had,VBD,O
,no,DT,O
,cardiac,JJ,O
,history,NN,O
,.,.,O
,After,IN,O
,admission,NN,O
,",",",",O
,the,DT,O
,patient,NN,O
,received,VBD,O
,a,DT,O
,continuous,JJ,O
,intravenous,JJ,O
,infusion,NN,O
,of,IN,O
,5,CD,O
,-,:,O
,FU,NN,O
,(,(,O
,1000,CD,O
,mg,NN,O
,/,NNP,O
,day,NN,O
,),),O
,",",",",O
,during,IN,O
,which,WDT,O
,precordial,JJ,B-DISEASE
,pain,NN,I-DISEASE
,with,IN,O
,right,JJ,B-DISEASE
,bundle,NN,I-DISEASE
,branch,NN,I-DISEASE
,block,NN,I-DISEASE
,occurred,VBD,O
,concomitantly,RB,O
,with,IN,O
,a,DT,O
,high,JJ,O
,serum,NN,O
,FBAL,NNP,O
,concentration,NN,O
,of,IN,O
,1955,CD,O
,ng,JJ,O
,/,NNP,O
,ml,NN,O
,.,.,O
,Both,CC,O
,the,DT,O
,precordial,JJ,B-DISEASE
,pain,NN,I-DISEASE
,and,CC,O
,the,DT,O
,electrocardiographic,JJ,O
,changes,NNS,O
,disappeared,VBD,O
,spontaneously,RB,O
,after,IN,O
,the,DT,O
,discontinuation,NN,O
,of,IN,O
,5,CD,O
,-,:,O
,FU,NN,O
,.,.,O
,As,IN,O
,the,DT,O
,precordial,JJ,B-DISEASE
,pain,NN,I-DISEASE
,in,IN,O
,this,DT,O
,patient,NN,O
,was,VBD,O
,considered,VBN,O
,to,TO,O
,have,VB,O
,been,VBN,O
,due,JJ,O
,to,TO,O
,5,CD,O
,-,:,O
,FU,NNP,O
,-,:,O
,induced,JJ,O
,cardiotoxicity,NN,B-DISEASE
,",",",",O
,the,DT,O
,administration,NN,O
,of,IN,O
,5,CD,O
,-,:,O
,FU,NN,O
,was,VBD,O
,abandoned,VBN,O
,.,.,O
,Instead,RB,O
,",",",",O
,oral,JJ,O
,administration,NN,O
,of,IN,O
,S,NNP,O
,-,:,O
,1,CD,O
,(,(,O
,a,DT,O
,derivative,NN,O
,of,IN,O
,5,CD,O
,-,:,O
,FU,NN,O
,),),O
,",",",",O
,at,IN,O
,200,CD,O
,mg,NNS,O
,/,JJ,O
,day,NN,O
,twice,RB,O
,a,DT,O
,week,NN,O
,",",",",O
,was,VBD,O
,instituted,VBN,O
,",",",",O
,because,IN,O
,S,NNP,O
,-,:,O
,1,CD,O
,has,VBZ,O
,a,DT,O
,strong,JJ,O
,inhibitory,NN,O
,effect,NN,O
,on,IN,O
,dihydropyrimidine,NN,O
,dehydrogenase,NN,O
,",",",",O
,which,WDT,O
,catalyzes,VBZ,O
,the,DT,O
,degradative,NN,O
,of,IN,O
,5,CD,O
,-,:,O
,FU,NN,O
,into,IN,O
,FBAL,NNP,O
,.,.,O
,The,DT,O
,serum,NN,O
,FBAL,NNP,O
,concentration,NN,O
,subsequently,RB,O
,decreased,VBD,O
,to,TO,O
,352,CD,O
,ng,NNS,O
,/,JJ,O
,ml,NN,O
,",",",",O
,the,DT,O
,same,JJ,O
,as,IN,O
,the,DT,O
,value,NN,O
,measured,VBN,O
,on,IN,O
,the,DT,O
,first,JJ,O
,day,NN,O
,of,IN,O
,S,NNP,O
,-,:,O
,1,CD,O
,administration,NN,O
,.,.,O
,Thereafter,NNP,O
,",",",",O
,no,DT,O
,cardiac,NN,B-DISEASE
,symptoms,NNS,I-DISEASE
,were,VBD,O
,observed,VBN,O
,.,.,O
,The,DT,O
,patient,NN,O
,achieved,VBD,O
,a,DT,O
,partial,JJ,O
,response,NN,O
,6,CD,O
,months,NNS,O
,after,IN,O
,the,DT,O
,initiation,NN,O
,of,IN,O
,the,DT,O
,S,NNP,O
,-,:,O
,1,CD,O
,treatment,NN,O
,.,.,O
,The,DT,O
,experience,NN,O
,of,IN,O
,this,DT,O
,case,NN,O
,",",",",O
,together,RB,O
,with,IN,O
,a,DT,O
,review,NN,O
,of,IN,O
,the,DT,O
,literature,NN,O
,",",",",O
,suggests,VBZ,O
,that,IN,O
,FBAL,NNP,O
,is,VBZ,O
,related,VBN,O
,to,TO,O
,5,CD,O
,-,:,O
,FU,NNP,O
,-,:,O
,induced,JJ,O
,cardiotoxicity,NN,B-DISEASE
,.,.,O
,S,NNP,O
,-,:,O
,1,CD,O
,may,MD,O
,be,VB,O
,administered,VBN,O
,safely,RB,O
,to,TO,O
,patients,NNS,O
,with,IN,O
,5,CD,O
,-,:,O
,FU,NNP,O
,-,:,O
,induced,JJ,O
,cardiotoxicity,NN,B-DISEASE
,.,.,O
,Hepatocellular,JJ,B-DISEASE
,carcinoma,NN,I-DISEASE
,in,IN,O
,Fanconi,NNP,B-DISEASE
,',POS,I-DISEASE
,s,NN,I-DISEASE
,anemia,NN,I-DISEASE
,treated,VBN,O
,with,IN,O
,androgen,NN,O
,and,CC,O
,corticosteroid,NN,O
,.,.,O
,The,DT,O
,case,NN,O
,of,IN,O
,an,DT,O
,11,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,boy,NN,O
,is,VBZ,O
,reported,VBN,O
,who,WP,O
,was,VBD,O
,known,VBN,O
,to,TO,O
,have,VB,O
,Fanconi,NNP,B-DISEASE
,',POS,I-DISEASE
,s,NN,I-DISEASE
,anemia,NN,I-DISEASE
,for,IN,O
,3,CD,O
,years,NNS,O
,and,CC,O
,was,VBD,O
,treated,VBN,O
,with,IN,O
,androgens,NNS,O
,",",",",O
,corticosteroids,NNS,O
,and,CC,O
,transfusions,NNS,O
,.,.,O
,Two,CD,O
,weeks,NNS,O
,before,IN,O
,his,PRP$,O
,death,NN,O
,he,PRP,O
,was,VBD,O
,readmitted,VBN,O
,because,IN,O
,of,IN,O
,aplastic,JJ,O
,crisis,NN,O
,with,IN,O
,septicemia,NN,B-DISEASE
,and,CC,O
,marked,JJ,O
,abnormalities,NNS,O
,in,IN,O
,liver,NN,O
,function,NN,O
,and,CC,O
,died,VBD,O
,of,IN,O
,hemorrhagic,NN,B-DISEASE
,bronchopneumonia,NN,I-DISEASE
,.,.,O
,At,IN,O
,autopsy,JJ,O
,peliosis,NN,B-DISEASE
,and,CC,O
,multiple,JJ,O
,hepatic,JJ,B-DISEASE
,tumors,NNS,I-DISEASE
,were,VBD,O
,found,VBN,O
,which,WDT,O
,histologically,RB,O
,proved,VBD,O
,to,TO,O
,be,VB,O
,well,RB,O
,-,:,O
,differentiated,VBN,O
,hepatocellular,JJ,B-DISEASE
,carcinoma,NN,I-DISEASE
,.,.,O
,This,DT,O
,case,NN,O
,contributes,VBZ,O
,to,TO,O
,the,DT,O
,previous,JJ,O
,observations,NNS,O
,that,WDT,O
,non,VBP,O
,-,:,O
,metastasizing,NN,O
,hepatic,JJ,B-DISEASE
,neoplasms,NNS,I-DISEASE
,and,CC,O
,peliosis,NN,B-DISEASE
,can,MD,O
,develop,VB,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,androgen,JJ,O
,-,:,O
,and,CC,O
,corticosteroid,VB,O
,-,:,O
,treated,VBN,O
,Fanconi,NNP,B-DISEASE
,',POS,I-DISEASE
,s,NN,I-DISEASE
,anemia,NN,I-DISEASE
,.,.,O
,The,DT,O
,influence,NN,O
,of,IN,O
,the,DT,O
,time,NN,O
,interval,NN,O
,between,IN,O
,monoHER,NN,O
,and,CC,O
,doxorubicin,JJ,O
,administration,NN,O
,on,IN,O
,the,DT,O
,protection,NN,O
,against,IN,O
,doxorubicin,JJ,O
,-,:,O
,induced,JJ,O
,cardiotoxicity,NN,B-DISEASE
,in,IN,O
,mice,NN,O
,.,.,O
,PURPOSE,NN,O
,:,:,O
,Despite,IN,O
,its,PRP$,O
,well,NN,O
,-,:,O
,known,VBN,O
,cardiotoxicity,NN,B-DISEASE
,",",",",O
,the,DT,O
,anthracyclin,NN,O
,doxorubicin,NN,O
,(,(,O
,DOX,NNP,O
,),),O
,continues,VBZ,O
,to,TO,O
,be,VB,O
,an,DT,O
,effective,JJ,O
,and,CC,O
,widely,RB,O
,used,VBN,O
,chemotherapeutic,JJ,O
,agent,NN,O
,.,.,O
,DOX,NNP,O
,-,:,O
,induced,VBD,O
,cardiac,JJ,B-DISEASE
,damage,NN,I-DISEASE
,presumably,RB,O
,results,NNS,O
,from,IN,O
,the,DT,O
,formation,NN,O
,of,IN,O
,free,JJ,O
,radicals,NNS,O
,by,IN,O
,DOX,NNP,O
,.,.,O
,Reactive,NNP,O
,oxygen,NN,O
,species,NNS,O
,particularly,RB,O
,affect,VBP,O
,the,DT,O
,cardiac,NN,O
,myocytes,VBZ,O
,because,IN,O
,these,DT,O
,cells,NNS,O
,seem,VBP,O
,to,TO,O
,have,VB,O
,a,DT,O
,relatively,RB,O
,poor,JJ,O
,antioxidant,NN,O
,defense,NN,O
,system,NN,O
,.,.,O
,The,DT,O
,semisynthetic,JJ,O
,flavonoid,NN,O
,monohydroxyethylrutoside,NN,O
,(,(,O
,monoHER,NN,O
,),),O
,showed,VBD,O
,cardioprotection,NN,O
,against,IN,O
,DOX,NNP,O
,-,:,O
,induced,JJ,O
,cardiotoxicity,NN,B-DISEASE
,through,IN,O
,its,PRP$,O
,radical,JJ,O
,scavenging,NN,O
,and,CC,O
,iron,NN,O
,chelating,NN,O
,properties,NNS,O
,.,.,O
,Because,IN,O
,of,IN,O
,the,DT,O
,relatively,RB,O
,short,JJ,O
,final,JJ,O
,half,NN,O
,-,:,O
,life,NN,O
,of,IN,O
,monoHER,NN,O
,(,(,O
,about,IN,O
,30,CD,O
,min,NN,O
,),),O
,",",",",O
,it,PRP,O
,is,VBZ,O
,expected,VBN,O
,that,IN,O
,the,DT,O
,time,NN,O
,interval,NN,O
,between,IN,O
,monoHER,NN,O
,and,CC,O
,DOX,NNP,O
,might,MD,O
,be,VB,O
,of,IN,O
,influence,NN,O
,on,IN,O
,the,DT,O
,cardioprotective,JJ,O
,effect,NN,O
,of,IN,O
,monoHER,NN,O
,.,.,O
,Therefore,RB,O
,",",",",O
,the,DT,O
,aim,NN,O
,of,IN,O
,the,DT,O
,present,JJ,O
,study,NN,O
,was,VBD,O
,to,TO,O
,investigate,VB,O
,this,DT,O
,possible,JJ,O
,effect,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,Six,NNP,O
,groups,NNS,O
,of,IN,O
,6,CD,O
,BALB,NNP,O
,/,NNP,O
,c,JJ,O
,mice,NNS,O
,were,VBD,O
,treated,VBN,O
,with,IN,O
,saline,NN,O
,",",",",O
,DOX,NNP,O
,alone,RB,O
,or,CC,O
,DOX,NNP,O
,(,(,O
,4,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,),),O
,preceded,VBN,O
,by,IN,O
,monoHER,NN,O
,(,(,O
,500,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,with,IN,O
,an,DT,O
,interval,NN,O
,of,IN,O
,10,CD,O
,",",",",O
,30,CD,O
,",",",",O
,60,CD,O
,or,CC,O
,120,CD,O
,min,NN,O
,.,.,O
,After,IN,O
,a,DT,O
,6,CD,O
,-,:,O
,week,NN,O
,treatment,NN,O
,period,NN,O
,and,CC,O
,additional,JJ,O
,observation,NN,O
,for,IN,O
,2,CD,O
,weeks,NNS,O
,",",",",O
,the,DT,O
,mice,NN,O
,were,VBD,O
,sacrificed,VBN,O
,.,.,O
,Their,PRP$,O
,cardiac,JJ,O
,tissues,NNS,O
,were,VBD,O
,processed,VBN,O
,for,IN,O
,light,JJ,O
,microscopy,NN,O
,",",",",O
,after,IN,O
,which,WDT,O
,cardiomyocyte,JJ,B-DISEASE
,damage,NN,I-DISEASE
,was,VBD,O
,evaluated,VBN,O
,according,VBG,O
,to,TO,O
,Billingham,NNP,O
,(,(,O
,in,IN,O
,Cancer,NNP,B-DISEASE
,Treat,NNP,O
,Rep,NNP,O
,62,CD,O
,(,(,O
,6,CD,O
,),),O
,:,:,O
,865,CD,O
,-,:,O
,872,CD,O
,",",",",O
,1978,CD,O
,),),O
,.,.,O
,Microscopic,NNP,O
,evaluation,NN,O
,revealed,VBD,O
,that,IN,O
,treatment,NN,O
,with,IN,O
,DOX,NNP,O
,alone,RB,O
,induced,VBD,O
,significant,JJ,O
,cardiac,JJ,B-DISEASE
,damage,NN,I-DISEASE
,in,IN,O
,comparison,NN,O
,to,TO,O
,the,DT,O
,saline,NN,O
,control,NN,O
,group,NN,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,.,.,O
,RESULTS,NN,O
,:,:,O
,The,DT,O
,number,NN,O
,of,IN,O
,damaged,VBN,O
,cardiomyocytes,NNS,O
,was,VBD,O
,9,CD,O
,.,.,O
,6,CD,O
,-,:,O
,fold,NN,O
,(,(,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,4,CD,O
,.,.,O
,4,CD,O
,-,:,O
,21,CD,O
,.,.,O
,0,CD,O
,),),O
,higher,JJR,O
,in,IN,O
,mice,NNS,O
,treated,VBN,O
,with,IN,O
,DOX,NNP,O
,alone,RB,O
,than,IN,O
,that,DT,O
,in,IN,O
,animals,NNS,O
,of,IN,O
,the,DT,O
,control,NN,O
,group,NN,O
,.,.,O
,The,DT,O
,ratio,NN,O
,of,IN,O
,aberrant,JJ,O
,cardiomyocytes,NNS,O
,in,IN,O
,mice,NN,O
,treated,VBN,O
,with,IN,O
,DOX,NNP,O
,preceded,VBN,O
,by,IN,O
,monoHER,NN,O
,and,CC,O
,those,DT,O
,in,IN,O
,mice,NNS,O
,treated,VBN,O
,with,IN,O
,saline,NN,O
,ranged,VBN,O
,from,IN,O
,1,CD,O
,.,.,O
,6,CD,O
,to,TO,O
,2,CD,O
,.,.,O
,8,CD,O
,(,(,O
,mean,JJ,O
,2,CD,O
,.,.,O
,2,CD,O
,",",",",O
,95,CD,O
,%,NN,O
,CI,NNP,O
,1,CD,O
,.,.,O
,2,CD,O
,-,:,O
,4,CD,O
,.,.,O
,1,CD,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,019,CD,O
,),),O
,.,.,O
,The,DT,O
,mean,JJ,O
,protective,JJ,O
,effect,NN,O
,by,IN,O
,adding,VBG,O
,monoHER,NN,O
,before,IN,O
,DOX,NNP,O
,led,VBD,O
,to,TO,O
,a,DT,O
,significant,JJ,O
,4,CD,O
,.,.,O
,4,CD,O
,-,:,O
,fold,NN,O
,reduction,NN,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,001,CD,O
,",",",",O
,95,CD,O
,%,NN,O
,CI,NNP,O
,2,CD,O
,.,.,O
,3,CD,O
,-,:,O
,8,CD,O
,.,.,O
,2,CD,O
,),),O
,of,IN,O
,abnormal,JJ,O
,cardiomyocytes,NNS,O
,.,.,O
,This,DT,O
,protective,JJ,O
,effect,NN,O
,did,VBD,O
,not,RB,O
,depend,VB,O
,on,IN,O
,the,DT,O
,time,NN,O
,interval,NN,O
,between,IN,O
,monoHER,NN,O
,and,CC,O
,DOX,NNP,O
,administration,NN,O
,(,(,O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,345,CD,O
,),),O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,The,DT,O
,results,NNS,O
,indicate,VBP,O
,that,IN,O
,in,IN,O
,an,DT,O
,outpatient,JJ,O
,clinical,JJ,O
,setting,VBG,O
,monoHER,NN,O
,may,MD,O
,be,VB,O
,administered,VBN,O
,shortly,RB,O
,before,IN,O
,DOX,NNP,O
,.,.,O
,Clinical,JJ,O
,evaluation,NN,O
,of,IN,O
,adverse,JJ,O
,effects,NNS,O
,during,IN,O
,bepridil,JJ,O
,administration,NN,O
,for,IN,O
,atrial,JJ,B-DISEASE
,fibrillation,NN,I-DISEASE
,and,CC,I-DISEASE
,flutter,NN,I-DISEASE
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Bepridil,NNP,O
,hydrochloride,NN,O
,(,(,O
,Bpd,NNP,O
,),),O
,has,VBZ,O
,attracted,VBN,O
,attention,NN,O
,as,IN,O
,an,DT,O
,effective,JJ,O
,drug,NN,O
,for,IN,O
,atrial,JJ,B-DISEASE
,fibrillation,NN,I-DISEASE
,(,(,O
,AF,NNP,B-DISEASE
,),),O
,and,CC,O
,atrial,JJ,B-DISEASE
,flutter,NN,I-DISEASE
,(,(,O
,AFL,NNP,B-DISEASE
,),),O
,.,.,O
,However,RB,O
,",",",",O
,serious,JJ,O
,adverse,JJ,O
,effects,NNS,O
,",",",",O
,including,VBG,O
,torsade,NN,B-DISEASE
,de,FW,I-DISEASE
,pointes,FW,I-DISEASE
,(,(,O
,Tdp,NNP,B-DISEASE
,),),O
,",",",",O
,have,VBP,O
,been,VBN,O
,reported,VBN,O
,.,.,O
,METHODS,NNP,O
,AND,CC,O
,RESULTS,NNP,O
,:,:,O
,Adverse,JJ,O
,effects,NNS,O
,of,IN,O
,Bpd,NNP,O
,requiring,VBG,O
,discontinuation,NN,O
,of,IN,O
,treatment,NN,O
,were,VBD,O
,evaluated,VBN,O
,.,.,O
,Bpd,NNP,O
,was,VBD,O
,administered,VBN,O
,to,TO,O
,459,CD,O
,patients,NNS,O
,(,(,O
,361,CD,O
,males,NNS,O
,",",",",O
,63,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,12,CD,O
,years,NNS,O
,old,JJ,O
,),),O
,comprising,VBG,O
,378,CD,O
,AF,NNP,B-DISEASE
,and,CC,O
,81,CD,O
,AFL,NNP,B-DISEASE
,cases,NNS,O
,.,.,O
,Mean,NNP,O
,left,VBD,O
,ventricular,JJ,O
,ejection,NN,O
,fraction,NN,O
,and,CC,O
,atrial,JJ,O
,dimension,NN,O
,(,(,O
,LAD,NNP,O
,),),O
,were,VBD,O
,66,CD,O
,+,NNP,O
,/,NNP,O
,-,:,O
,11,CD,O
,%,NN,O
,and,CC,O
,40,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,6,CD,O
,mm,NN,O
,",",",",O
,respectively,RB,O
,.,.,O
,Adverse,JJ,O
,effects,NNS,O
,were,VBD,O
,observed,VBN,O
,in,IN,O
,19,CD,O
,patients,NNS,O
,(,(,O
,4,CD,O
,%,NN,O
,),),O
,during,IN,O
,an,DT,O
,average,JJ,O
,follow,NN,O
,-,:,O
,up,IN,O
,of,IN,O
,20,CD,O
,months,NNS,O
,.,.,O
,There,EX,O
,was,VBD,O
,marked,VBN,O
,QT,NNP,B-DISEASE
,prolongation,NN,I-DISEASE
,greater,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,55,CD,O
,s,NN,O
,in,IN,O
,13,CD,O
,patients,NNS,O
,",",",",O
,bradycardia,RB,B-DISEASE
,less,JJR,O
,than,IN,O
,40,CD,O
,beats,NNS,O
,/,VBP,O
,min,NN,O
,in,IN,O
,6,CD,O
,patients,NNS,O
,",",",",O
,dizziness,NN,B-DISEASE
,and,CC,O
,general,JJ,O
,fatigue,NN,B-DISEASE
,in,IN,O
,1,CD,O
,patient,JJ,O
,each,DT,O
,.,.,O
,In,IN,O
,4,CD,O
,of,IN,O
,13,CD,O
,patients,NNS,O
,with,IN,O
,QT,NNP,B-DISEASE
,prolongation,NN,I-DISEASE
,",",",",O
,Tdp,NNP,B-DISEASE
,occurred,VBD,O
,.,.,O
,The,DT,O
,major,JJ,O
,triggering,VBG,O
,factors,NNS,O
,of,IN,O
,Tdp,NNP,B-DISEASE
,were,VBD,O
,hypokalemia,JJ,B-DISEASE
,and,CC,O
,sudden,JJ,O
,decrease,NN,O
,in,IN,O
,heart,NN,O
,rate,NN,O
,.,.,O
,There,EX,O
,were,VBD,O
,no,DT,O
,differences,NNS,O
,in,IN,O
,the,DT,O
,clinical,JJ,O
,backgrounds,NNS,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,with,IN,O
,and,CC,O
,without,IN,O
,Tdp,NNP,B-DISEASE
,other,JJ,O
,than,IN,O
,LAD,NNP,O
,and,CC,O
,age,NN,O
,",",",",O
,which,WDT,O
,were,VBD,O
,larger,JJR,O
,and,CC,O
,older,JJR,O
,in,IN,O
,the,DT,O
,patients,NNS,O
,with,IN,O
,Tdp,NNP,B-DISEASE
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Careful,JJ,O
,observation,NN,O
,of,IN,O
,serum,JJ,O
,potassium,NN,O
,concentration,NN,O
,and,CC,O
,the,DT,O
,ECG,NNP,O
,should,MD,O
,always,RB,O
,be,VB,O
,done,VBN,O
,during,IN,O
,Bpd,NNP,O
,administration,NN,O
,",",",",O
,particularly,RB,O
,in,IN,O
,elderly,JJ,O
,patients,NNS,O
,.,.,O
,Enhanced,NNP,O
,isoproterenol,JJ,O
,-,:,O
,induced,JJ,O
,cardiac,JJ,B-DISEASE
,hypertrophy,NN,I-DISEASE
,in,IN,O
,transgenic,JJ,O
,rats,NNS,O
,with,IN,O
,low,JJ,O
,brain,NN,O
,angiotensinogen,NN,O
,.,.,O
,We,PRP,O
,have,VBP,O
,previously,RB,O
,shown,VBN,O
,that,IN,O
,a,DT,O
,permanent,JJ,O
,deficiency,NN,O
,in,IN,O
,the,DT,O
,brain,NN,O
,renin,NN,O
,-,:,O
,angiotensin,NN,O
,system,NN,O
,(,(,O
,RAS,NNP,O
,),),O
,may,MD,O
,increase,VB,O
,the,DT,O
,sensitivity,NN,O
,of,IN,O
,the,DT,O
,baroreflex,JJ,O
,control,NN,O
,of,IN,O
,heart,NN,O
,rate,NN,O
,.,.,O
,In,IN,O
,this,DT,O
,study,NN,O
,we,PRP,O
,aimed,VBD,O
,at,IN,O
,studying,VBG,O
,the,DT,O
,involvement,NN,O
,of,IN,O
,the,DT,O
,brain,NN,O
,RAS,NNP,O
,in,IN,O
,the,DT,O
,cardiac,JJ,O
,reactivity,NN,O
,to,TO,O
,the,DT,O
,beta,NN,O
,-,:,O
,adrenoceptor,NN,O
,(,(,O
,beta,SYM,O
,-,:,O
,AR,NN,O
,),),O
,agonist,NN,O
,isoproterenol,NN,O
,(,(,O
,Iso,NNP,O
,),),O
,.,.,O
,Transgenic,JJ,O
,rats,NNS,O
,with,IN,O
,low,JJ,O
,brain,NN,O
,angiotensinogen,NN,O
,(,(,O
,TGR,NNP,O
,),),O
,were,VBD,O
,used,VBN,O
,.,.,O
,In,IN,O
,isolated,JJ,O
,hearts,NNS,O
,",",",",O
,Iso,NNP,O
,induced,VBD,O
,a,DT,O
,significantly,RB,O
,greater,JJR,O
,increase,NN,O
,in,IN,O
,left,JJ,O
,ventricular,NN,O
,(,(,O
,LV,NNP,O
,),),O
,pressure,NN,O
,and,CC,O
,maximal,JJ,O
,contraction,NN,O
,(,(,O
,+,JJ,O
,dP,NN,O
,/,NNP,O
,dt,NN,O
,(,(,O
,max,NN,O
,),),O
,),),O
,in,IN,O
,the,DT,O
,TGR,NNP,O
,than,IN,O
,in,IN,O
,the,DT,O
,Sprague,NNP,O
,-,:,O
,Dawley,NNP,O
,(,(,O
,SD,NNP,O
,),),O
,rats,NNS,O
,.,.,O
,LV,NNP,B-DISEASE
,hypertrophy,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,Iso,NNP,O
,treatment,NN,O
,was,VBD,O
,significantly,RB,O
,higher,JJR,O
,in,IN,O
,TGR,NNP,O
,than,IN,O
,in,IN,O
,SD,NNP,O
,rats,NNS,O
,(,(,O
,in,IN,O
,g,NN,O
,LV,NNP,O
,wt,VBD,O
,/,$,O
,100,CD,O
,g,NN,O
,body,NN,O
,wt,NN,O
,",",",",O
,0,CD,O
,.,.,O
,28,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,004,CD,O
,vs,NN,O
,.,.,O
,0,CD,O
,.,.,O
,24,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,004,CD,O
,",",",",O
,respectively,RB,O
,),),O
,.,.,O
,The,DT,O
,greater,JJR,O
,LV,NNP,B-DISEASE
,hypertrophy,NN,I-DISEASE
,in,IN,O
,TGR,NNP,O
,rats,NNS,O
,was,VBD,O
,associated,VBN,O
,with,IN,O
,more,RBR,O
,pronounced,JJ,O
,downregulation,NN,O
,of,IN,O
,beta,NN,O
,-,:,O
,AR,NNP,O
,and,CC,O
,upregulation,NN,O
,of,IN,O
,LV,NNP,O
,beta,SYM,O
,-,:,O
,AR,NNP,O
,kinase,VBD,O
,-,:,O
,1,CD,O
,mRNA,NN,O
,levels,NNS,O
,compared,VBN,O
,with,IN,O
,those,DT,O
,in,IN,O
,SD,NNP,O
,rats,NNS,O
,.,.,O
,The,DT,O
,decrease,NN,O
,in,IN,O
,the,DT,O
,heart,NN,O
,rate,NN,O
,(,(,O
,HR,NNP,O
,),),O
,induced,VBN,O
,by,IN,O
,the,DT,O
,beta,NN,O
,-,:,O
,AR,NNP,O
,antagonist,NN,O
,metoprolol,NN,O
,in,IN,O
,conscious,JJ,O
,rats,NNS,O
,was,VBD,O
,significantly,RB,O
,attenuated,VBN,O
,in,IN,O
,TGR,NNP,O
,compared,VBN,O
,with,IN,O
,SD,NNP,O
,rats,NNS,O
,(,(,O
,-,:,O
,9,CD,O
,.,.,O
,9,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,vs,NN,O
,.,.,O
,-,:,O
,18,CD,O
,.,.,O
,1,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,),),O
,",",",",O
,whereas,IN,O
,the,DT,O
,effect,NN,O
,of,IN,O
,parasympathetic,JJ,O
,blockade,NN,O
,by,IN,O
,atropine,NN,O
,on,IN,O
,HR,NNP,O
,was,VBD,O
,similar,JJ,O
,in,IN,O
,both,DT,O
,strains,NNS,O
,.,.,O
,These,DT,O
,results,NNS,O
,indicate,VBP,O
,that,IN,O
,TGR,NNP,O
,are,VBP,O
,more,RBR,O
,sensitive,JJ,O
,to,TO,O
,beta,VB,O
,-,:,O
,AR,NNP,O
,agonist,VBP,O
,-,:,O
,induced,JJ,O
,cardiac,JJ,B-DISEASE
,inotropic,NN,I-DISEASE
,response,NN,O
,and,CC,O
,hypertrophy,NN,B-DISEASE
,",",",",O
,possibly,RB,O
,due,JJ,O
,to,TO,O
,chronically,RB,O
,low,JJ,O
,sympathetic,JJ,O
,outflow,NN,O
,directed,VBD,O
,to,TO,O
,the,DT,O
,heart,NN,O
,.,.,O
,Drug,NNP,O
,-,:,O
,induced,VBD,O
,long,JJ,B-DISEASE
,QT,NNP,I-DISEASE
,syndrome,NN,I-DISEASE
,in,IN,O
,injection,JJ,O
,drug,NN,O
,users,NNS,O
,receiving,VBG,O
,methadone,NN,O
,:,:,O
,high,JJ,O
,frequency,NN,O
,in,IN,O
,hospitalized,JJ,O
,patients,NNS,O
,and,CC,O
,risk,NN,O
,factors,NNS,O
,.,.,O
,BACKGROUND,NNP,O
,:,:,O
,Drug,NNP,O
,-,:,O
,induced,VBD,O
,long,JJ,B-DISEASE
,QT,NNP,I-DISEASE
,syndrome,NN,I-DISEASE
,is,VBZ,O
,a,DT,O
,serious,JJ,O
,adverse,JJ,O
,drug,NN,O
,reaction,NN,O
,.,.,O
,Methadone,NNP,O
,prolongs,VBZ,O
,the,DT,O
,QT,NNP,O
,interval,NN,O
,in,IN,O
,vitro,NN,O
,in,IN,O
,a,DT,O
,dose,JJ,O
,-,:,O
,dependent,JJ,O
,manner,NN,O
,.,.,O
,In,IN,O
,the,DT,O
,inpatient,NN,O
,setting,NN,O
,",",",",O
,the,DT,O
,frequency,NN,O
,of,IN,O
,QT,NNP,B-DISEASE
,interval,JJ,I-DISEASE
,prolongation,NN,I-DISEASE
,with,IN,O
,methadone,NN,O
,treatment,NN,O
,",",",",O
,its,PRP$,O
,dose,JJ,O
,dependence,NN,O
,",",",",O
,and,CC,O
,the,DT,O
,importance,NN,O
,of,IN,O
,cofactors,NNS,O
,such,JJ,O
,as,IN,O
,drug,NN,O
,-,:,O
,drug,NN,O
,interactions,NNS,O
,remain,VBP,O
,unknown,JJ,O
,.,.,O
,METHODS,NN,O
,:,:,O
,We,PRP,O
,performed,VBD,O
,a,DT,O
,systematic,JJ,O
,",",",",O
,retrospective,JJ,O
,study,NN,O
,comparing,VBG,O
,active,JJ,O
,or,CC,O
,former,JJ,O
,intravenous,JJ,O
,drug,NN,O
,users,NNS,O
,receiving,VBG,O
,methadone,NN,O
,and,CC,O
,those,DT,O
,not,RB,O
,receiving,VBG,O
,methadone,NN,O
,among,IN,O
,all,DT,O
,patients,NNS,O
,hospitalized,VBN,O
,over,IN,O
,a,DT,O
,5,CD,O
,-,:,O
,year,NN,O
,period,NN,O
,in,IN,O
,a,DT,O
,tertiary,JJ,O
,care,NN,O
,hospital,NN,O
,.,.,O
,A,DT,O
,total,NN,O
,of,IN,O
,167,CD,O
,patients,NNS,O
,receiving,VBG,O
,methadone,NN,O
,fulfilled,VBD,O
,the,DT,O
,inclusion,NN,O
,criteria,NNS,O
,and,CC,O
,were,VBD,O
,compared,VBN,O
,with,IN,O
,a,DT,O
,control,NN,O
,group,NN,O
,of,IN,O
,80,CD,O
,injection,JJ,O
,drug,NN,O
,users,NNS,O
,not,RB,O
,receiving,VBG,O
,methadone,NN,O
,.,.,O
,In,IN,O
,addition,NN,O
,to,TO,O
,methadone,VB,O
,dose,NN,O
,",",",",O
,15,CD,O
,demographic,JJ,O
,",",",",O
,biological,JJ,O
,",",",",O
,and,CC,O
,pharmacological,JJ,O
,variables,NNS,O
,were,VBD,O
,considered,VBN,O
,as,IN,O
,potential,JJ,O
,risk,NN,O
,factors,NNS,O
,for,IN,O
,QT,NNP,B-DISEASE
,prolongation,NN,I-DISEASE
,.,.,O
,RESULTS,NN,O
,:,:,O
,Among,IN,O
,167,CD,O
,methadone,NN,O
,maintenance,NN,O
,patients,NNS,O
,",",",",O
,the,DT,O
,prevalence,NN,O
,of,IN,O
,QTc,NNP,O
,prolongation,NN,O
,to,TO,O
,0,CD,O
,.,.,O
,50,CD,O
,second,JJ,O
,(,(,O
,(,(,O
,1,CD,O
,/,RB,O
,2,CD,O
,),),O
,),),O
,or,CC,O
,longer,JJR,O
,was,VBD,O
,16,CD,O
,.,.,O
,2,CD,O
,%,NN,O
,compared,VBN,O
,with,IN,O
,0,CD,O
,%,NN,O
,in,IN,O
,80,CD,O
,control,NN,O
,subjects,NNS,O
,.,.,O
,Six,CD,O
,patients,NNS,O
,(,(,O
,3,CD,O
,.,.,O
,6,CD,O
,%,NN,O
,),),O
,in,IN,O
,the,DT,O
,methadone,NN,O
,group,NN,O
,presented,VBD,O
,torsades,NNS,B-DISEASE
,de,IN,I-DISEASE
,pointes,NNS,I-DISEASE
,.,.,O
,QTc,NNP,O
,length,NN,O
,was,VBD,O
,weakly,RB,O
,but,CC,O
,significantly,RB,O
,associated,VBN,O
,with,IN,O
,methadone,JJ,O
,daily,JJ,O
,dose,NN,O
,(,(,O
,Spearman,NNP,O
,rank,VBZ,O
,correlation,NN,O
,coefficient,NN,O
,",",",",O
,0,CD,O
,.,.,O
,20,CD,O
,;,:,O
,P,NNP,O
,<,NNP,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,Multivariate,NNP,O
,regression,NN,O
,analysis,NN,O
,allowed,VBN,O
,attribution,NN,O
,of,IN,O
,31,CD,O
,.,.,O
,8,CD,O
,%,NN,O
,of,IN,O
,QTc,NNP,O
,variability,NN,O
,to,TO,O
,methadone,VB,O
,dose,NN,O
,",",",",O
,cytochrome,JJ,O
,P,NNP,O
,-,:,O
,450,CD,O
,3A4,CD,O
,drug,NN,O
,-,:,O
,drug,NN,O
,interactions,NNS,O
,",",",",O
,hypokalemia,NN,B-DISEASE
,",",",",O
,and,CC,O
,altered,VBD,O
,liver,NN,O
,function,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,QT,NNP,B-DISEASE
,interval,JJ,I-DISEASE
,prolongation,NN,I-DISEASE
,in,IN,O
,methadone,JJ,O
,maintenance,NN,O
,patients,NNS,O
,hospitalized,VBN,O
,in,IN,O
,a,DT,O
,tertiary,JJ,O
,care,NN,O
,center,NN,O
,is,VBZ,O
,a,DT,O
,frequent,JJ,O
,finding,NN,O
,.,.,O
,Methadone,NNP,O
,dose,NN,O
,",",",",O
,presence,NN,O
,of,IN,O
,cytochrome,NN,O
,P,NNP,O
,-,:,O
,450,CD,O
,3A4,CD,O
,inhibitors,NNS,O
,",",",",O
,potassium,NN,O
,level,NN,O
,",",",",O
,and,CC,O
,liver,JJS,O
,function,NN,O
,contribute,NN,O
,to,TO,O
,QT,NNP,B-DISEASE
,prolongation,NN,I-DISEASE
,.,.,O
,Long,NNP,B-DISEASE
,QT,NNP,I-DISEASE
,syndrome,NN,I-DISEASE
,can,MD,O
,occur,VB,O
,with,IN,O
,low,JJ,O
,doses,NNS,O
,of,IN,O
,methadone,NN,O
,.,.,O
,Mechanisms,NNP,O
,of,IN,O
,hypertension,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,nitric,JJ,O
,oxide,NN,O
,(,(,O
,NO,NNP,O
,),),O
,deficiency,NN,O
,:,:,O
,focus,NN,O
,on,IN,O
,venous,JJ,O
,function,NN,O
,.,.,O
,Loss,NNP,O
,of,IN,O
,endothelial,JJ,O
,cell,NN,O
,-,:,O
,derived,VBN,O
,nitric,JJ,O
,oxide,NN,O
,(,(,O
,NO,NNP,O
,),),O
,in,IN,O
,hypertension,NN,B-DISEASE
,is,VBZ,O
,a,DT,O
,hallmark,NN,O
,of,IN,O
,arterial,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,.,.,O
,Experimental,JJ,O
,hypertension,NN,B-DISEASE
,created,VBN,O
,by,IN,O
,the,DT,O
,removal,NN,O
,of,IN,O
,NO,NNP,O
,",",",",O
,however,RB,O
,",",",",O
,involves,VBZ,O
,mechanisms,NNS,O
,in,IN,O
,addition,NN,O
,to,TO,O
,decreased,VBN,O
,arterial,JJ,O
,vasodilator,NN,O
,activity,NN,O
,.,.,O
,These,DT,O
,include,VBP,O
,augmented,JJ,O
,endothelin,SYM,O
,-,:,O
,1,CD,O
,(,(,O
,ET,NNP,O
,-,:,O
,1,CD,O
,),),O
,release,NN,O
,",",",",O
,increased,VBD,O
,sympathetic,JJ,O
,nervous,JJ,O
,system,NN,O
,activity,NN,O
,",",",",O
,and,CC,O
,elevated,VBD,O
,tissue,NN,O
,oxidative,JJ,O
,stress,NN,O
,.,.,O
,We,PRP,O
,hypothesized,VBD,O
,that,IN,O
,increased,VBD,O
,venous,JJ,O
,smooth,JJ,O
,muscle,NN,O
,(,(,O
,venomotor,NN,O
,),),O
,tone,NN,O
,plays,VBZ,O
,a,DT,O
,role,NN,O
,in,IN,O
,Nomega,NNP,O
,-,:,O
,nitro,JJ,O
,-,:,O
,L,NNP,O
,-,:,O
,arginine,NN,O
,(,(,O
,LNNA,NNP,O
,),),O
,hypertension,NN,B-DISEASE
,through,IN,O
,these,DT,O
,mechanisms,NNS,O
,.,.,O
,Rats,NNPS,O
,were,VBD,O
,treated,VBN,O
,with,IN,O
,the,DT,O
,NO,NNP,O
,synthase,NN,O
,inhibitor,NN,O
,LNNA,NNP,O
,(,(,O
,0,CD,O
,.,.,O
,5,CD,O
,g,JJ,O
,/,NNP,O
,L,NNP,O
,in,IN,O
,drinking,NN,O
,water,NN,O
,),),O
,for,IN,O
,2,CD,O
,weeks,NNS,O
,.,.,O
,Mean,NNP,O
,arterial,JJ,O
,pressure,NN,O
,of,IN,O
,conscious,JJ,O
,rats,NNS,O
,was,VBD,O
,119,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,2,CD,O
,mm,NN,O
,Hg,NNP,O
,in,IN,O
,control,NN,O
,and,CC,O
,194,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,5,CD,O
,mm,NN,O
,Hg,NNP,O
,in,IN,O
,LNNA,NNP,O
,rats,NNS,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,Carotid,NNP,O
,arteries,NNS,O
,and,CC,O
,vena,NNS,O
,cava,NNS,O
,were,VBD,O
,removed,VBN,O
,for,IN,O
,measurement,NN,O
,of,IN,O
,isometric,JJ,O
,contraction,NN,O
,.,.,O
,Maximal,JJ,O
,contraction,NN,O
,to,TO,O
,norepinephrine,VB,O
,was,VBD,O
,modestly,RB,O
,reduced,VBN,O
,in,IN,O
,arteries,NNS,O
,from,IN,O
,LNNA,NNP,O
,compared,VBN,O
,with,IN,O
,control,NN,O
,rats,NNS,O
,whereas,VBP,O
,the,DT,O
,maximum,JJ,O
,contraction,NN,O
,to,TO,O
,ET,NNP,O
,-,:,O
,1,CD,O
,was,VBD,O
,significantly,RB,O
,reduced,VBN,O
,(,(,O
,54,CD,O
,%,NN,O
,control,NN,O
,),),O
,.,.,O
,Maximum,JJ,O
,contraction,NN,O
,of,IN,O
,vena,NN,O
,cava,NN,O
,to,TO,O
,norepinephrine,VB,O
,(,(,O
,37,CD,O
,%,NN,O
,control,NN,O
,),),O
,also,RB,O
,was,VBD,O
,reduced,VBN,O
,but,CC,O
,no,DT,O
,change,NN,O
,in,IN,O
,response,NN,O
,to,TO,O
,ET,NNP,O
,-,:,O
,1,CD,O
,was,VBD,O
,observed,VBN,O
,.,.,O
,Mean,NNP,O
,circulatory,NN,O
,filling,NN,O
,pressure,NN,O
,",",",",O
,an,DT,O
,in,IN,O
,vivo,JJ,O
,measure,NN,O
,of,IN,O
,venomotor,NN,O
,tone,NN,O
,",",",",O
,was,VBD,O
,not,RB,O
,elevated,VBN,O
,in,IN,O
,LNNA,NNP,O
,hypertension,NN,B-DISEASE
,at,IN,O
,1,CD,O
,or,CC,O
,2,CD,O
,weeks,NNS,O
,after,IN,O
,LNNA,NNP,O
,.,.,O
,The,DT,O
,superoxide,JJ,O
,scavenger,NN,O
,tempol,NN,O
,(,(,O
,30,CD,O
,",",",",O
,100,CD,O
,",",",",O
,and,CC,O
,300,CD,O
,micromol,NN,O
,kg,NN,O
,(,(,O
,-,:,O
,1,CD,O
,),),O
,",",",",O
,IV,NNP,O
,),),O
,did,VBD,O
,not,RB,O
,change,VB,O
,arterial,JJ,O
,pressure,NN,O
,in,IN,O
,control,NN,O
,rats,NNS,O
,but,CC,O
,caused,VBD,O
,a,DT,O
,dose,JJ,O
,-,:,O
,dependent,JJ,O
,decrease,NN,O
,in,IN,O
,LNNA,NNP,O
,rats,NNS,O
,(,(,O
,-,:,O
,18,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,8,CD,O
,",",",",O
,-,:,O
,26,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,15,CD,O
,",",",",O
,and,CC,O
,-,:,O
,54,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,11,CD,O
,mm,NN,O
,Hg,NNP,O
,),),O
,.,.,O
,Similarly,RB,O
,",",",",O
,ganglionic,JJ,O
,blockade,NN,O
,with,IN,O
,hexamethonium,NN,O
,caused,VBD,O
,a,DT,O
,significantly,RB,O
,greater,JJR,O
,fall,NN,O
,in,IN,O
,LNNA,NNP,O
,hypertensive,JJ,B-DISEASE
,rats,NNS,O
,(,(,O
,76,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,9,CD,O
,mm,NN,O
,Hg,NNP,O
,),),O
,compared,VBN,O
,with,IN,O
,control,NN,O
,rats,NNS,O
,(,(,O
,35,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,10,CD,O
,mm,NN,O
,Hg,NNP,O
,),),O
,.,.,O
,Carotid,NNP,O
,arteries,NNS,O
,",",",",O
,vena,NN,O
,cava,NN,O
,",",",",O
,and,CC,O
,sympathetic,JJ,O
,ganglia,NN,O
,from,IN,O
,LNNA,NNP,O
,rats,NNS,O
,had,VBD,O
,higher,JJR,O
,basal,NN,O
,levels,NNS,O
,of,IN,O
,superoxide,NN,O
,compared,VBN,O
,with,IN,O
,those,DT,O
,from,IN,O
,control,NN,O
,rats,NNS,O
,.,.,O
,These,DT,O
,data,NNS,O
,suggest,VBP,O
,that,IN,O
,while,IN,O
,NO,DT,O
,deficiency,NN,O
,increases,VBZ,O
,oxidative,JJ,O
,stress,NN,O
,and,CC,O
,sympathetic,JJ,O
,activity,NN,O
,in,IN,O
,both,DT,O
,arterial,JJ,O
,and,CC,O
,venous,JJ,O
,vessels,NNS,O
,",",",",O
,the,DT,O
,impact,NN,O
,on,IN,O
,veins,NNS,O
,does,VBZ,O
,not,RB,O
,make,VB,O
,a,DT,O
,major,JJ,O
,contribution,NN,O
,to,TO,O
,this,DT,O
,form,NN,O
,of,IN,O
,hypertension,NN,B-DISEASE
,.,.,O
,Association,NNP,O
,of,IN,O
,DRD2,NNP,O
,polymorphisms,NNS,O
,and,CC,O
,chlorpromazine,VB,O
,-,:,O
,induced,JJ,O
,extrapyramidal,JJ,B-DISEASE
,syndrome,NN,I-DISEASE
,in,IN,O
,Chinese,NNP,O
,schizophrenic,JJ,B-DISEASE
,patients,NNS,O
,.,.,O
,AIM,NNP,O
,:,:,O
,Extrapyramidal,JJ,B-DISEASE
,syndrome,NN,I-DISEASE
,(,(,O
,EPS,NNP,B-DISEASE
,),),O
,is,VBZ,O
,most,RBS,O
,commonly,RB,O
,affected,VBN,O
,by,IN,O
,typical,JJ,O
,antipsychotic,JJ,O
,drugs,NNS,O
,that,WDT,O
,have,VBP,O
,a,DT,O
,high,JJ,O
,affinity,NN,O
,with,IN,O
,the,DT,O
,D2,NNP,O
,receptor,NN,O
,.,.,O
,Recently,RB,O
,",",",",O
,many,JJ,O
,research,NN,O
,groups,NNS,O
,have,VBP,O
,reported,VBN,O
,on,IN,O
,the,DT,O
,positive,JJ,O
,relationship,NN,O
,between,IN,O
,the,DT,O
,genetic,JJ,O
,variations,NNS,O
,in,IN,O
,the,DT,O
,DRD2,NNP,O
,gene,NN,O
,and,CC,O
,the,DT,O
,therapeutic,JJ,O
,response,NN,O
,in,IN,O
,schizophrenia,NN,B-DISEASE
,patients,NNS,O
,as,IN,O
,a,DT,O
,result,NN,O
,of,IN,O
,the,DT,O
,role,NN,O
,of,IN,O
,variations,NNS,O
,in,IN,O
,the,DT,O
,receptor,NN,O
,in,IN,O
,modulating,VBG,O
,receptor,NN,O
,expression,NN,O
,.,.,O
,In,IN,O
,this,DT,O
,study,NN,O
,",",",",O
,we,PRP,O
,evaluate,VBP,O
,the,DT,O
,role,NN,O
,DRD2,NNP,O
,plays,VBZ,O
,in,IN,O
,chlorpromazine,NN,O
,-,:,O
,induced,JJ,O
,EPS,NNP,B-DISEASE
,in,IN,O
,schizophrenic,JJ,B-DISEASE
,patients,NNS,O
,.,.,O
,METHODS,NNS,O
,:,:,O
,We,PRP,O
,identified,VBD,O
,seven,CD,O
,SNP,NNP,O
,(,(,O
,single,JJ,O
,nucleotide,RB,O
,polymorphism,NN,O
,),),O
,(,(,O
,-,:,O
,141Cins,CD,O
,>,JJ,O
,del,NN,O
,",",",",O
,TaqIB,NNP,O
,",",",",O
,TaqID,NNP,O
,",",",",O
,Ser311Cys,NNP,O
,",",",",O
,rs6275,NN,O
,",",",",O
,rs6277,NN,O
,and,CC,O
,TaqIA,NNP,O
,),),O
,in,IN,O
,the,DT,O
,DRD2,NNP,O
,gene,NN,O
,in,IN,O
,146,CD,O
,schizophrenic,JJ,B-DISEASE
,inpatients,NNS,O
,(,(,O
,59,CD,O
,with,IN,O
,EPS,NNP,B-DISEASE
,and,CC,O
,87,CD,O
,without,IN,O
,EPS,NNP,B-DISEASE
,according,VBG,O
,to,TO,O
,the,DT,O
,Simpson,NNP,O
,-,:,O
,Angus,NNP,O
,Scale,NNP,O
,),),O
,treated,VBD,O
,with,IN,O
,chlorpromazine,NN,O
,after,IN,O
,8,CD,O
,weeks,NNS,O
,.,.,O
,The,DT,O
,alleles,NNS,O
,of,IN,O
,all,DT,O
,loci,NNS,O
,were,VBD,O
,determined,VBN,O
,by,IN,O
,PCR,NNP,O
,(,(,O
,polymerase,NN,O
,chain,NN,O
,reaction,NN,O
,),),O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Polymorphisms,NNP,O
,TaqID,NNP,O
,",",",",O
,Ser311Cys,NNP,O
,and,CC,O
,rs6277,VB,O
,were,VBD,O
,not,RB,O
,polymorphic,JJ,O
,in,IN,O
,the,DT,O
,population,NN,O
,recruited,VBN,O
,in,IN,O
,the,DT,O
,present,JJ,O
,study,NN,O
,.,.,O
,No,DT,O
,statistical,JJ,O
,significance,NN,O
,was,VBD,O
,found,VBN,O
,in,IN,O
,the,DT,O
,allele,JJ,O
,distribution,NN,O
,of,IN,O
,-,:,O
,141Cins,CD,O
,>,JJ,O
,del,NN,O
,",",",",O
,TaqIB,NNP,O
,",",",",O
,rs6275,NN,O
,and,CC,O
,TaqIA,NNP,O
,or,CC,O
,in,IN,O
,the,DT,O
,estimated,VBN,O
,haplotypes,NNS,O
,(,(,O
,constituted,VBN,O
,by,IN,O
,TaqIB,NNP,O
,",",",",O
,rs6275,NN,O
,and,CC,O
,TaqIA,NNP,O
,),),O
,in,IN,O
,linkage,NN,O
,disequilibrium,NN,O
,between,IN,O
,the,DT,O
,two,CD,O
,groups,NNS,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Our,PRP$,O
,results,NNS,O
,did,VBD,O
,not,RB,O
,lend,VB,O
,strong,JJ,O
,support,NN,O
,to,TO,O
,the,DT,O
,view,NN,O
,that,IN,O
,the,DT,O
,genetic,JJ,O
,variation,NN,O
,of,IN,O
,the,DT,O
,DRD2,NNP,O
,gene,NN,O
,plays,VBZ,O
,a,DT,O
,major,JJ,O
,role,NN,O
,in,IN,O
,the,DT,O
,individually,RB,O
,variable,JJ,O
,adverse,JJ,O
,effect,NN,O
,induced,VBN,O
,by,IN,O
,chlorpromazine,NN,O
,",",",",O
,at,IN,O
,least,JJS,O
,in,IN,O
,Chinese,JJ,O
,patients,NNS,O
,with,IN,O
,schizophrenia,NN,B-DISEASE
,.,.,O
,Our,PRP$,O
,results,NNS,O
,confirmed,VBD,O
,a,DT,O
,previous,JJ,O
,study,NN,O
,on,IN,O
,the,DT,O
,relationship,NN,O
,between,IN,O
,DRD2,NNP,O
,and,CC,O
,EPS,NNP,B-DISEASE
,in,IN,O
,Caucasians,NNPS,O
,.,.,O
,Physical,JJ,O
,training,NN,O
,decreases,VBZ,O
,susceptibility,NN,O
,to,TO,O
,subsequent,VB,O
,pilocarpine,NN,O
,-,:,O
,induced,JJ,O
,seizures,NNS,B-DISEASE
,in,IN,O
,the,DT,O
,rat,NN,O
,.,.,O
,Regular,JJ,O
,motor,NN,O
,activity,NN,O
,has,VBZ,O
,many,JJ,O
,benefits,NNS,O
,for,IN,O
,mental,JJ,O
,and,CC,O
,physical,JJ,O
,condition,NN,O
,but,CC,O
,its,PRP$,O
,implications,NNS,O
,for,IN,O
,epilepsy,NN,B-DISEASE
,are,VBP,O
,still,RB,O
,controversial,JJ,O
,.,.,O
,In,IN,O
,order,NN,O
,to,TO,O
,elucidate,VB,O
,this,DT,O
,problem,NN,O
,",",",",O
,we,PRP,O
,have,VBP,O
,studied,VBN,O
,the,DT,O
,effect,NN,O
,of,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,physical,JJ,O
,activity,NN,O
,on,IN,O
,susceptibility,NN,O
,to,TO,O
,subsequent,JJ,O
,seizures,NNS,B-DISEASE
,.,.,O
,Male,NNP,O
,Wistar,NNP,O
,rats,NNS,O
,were,VBD,O
,subjected,VBN,O
,to,TO,O
,repeated,VB,O
,training,NN,O
,sessions,NNS,O
,in,IN,O
,a,DT,O
,treadmill,NN,O
,and,CC,O
,swimming,VBG,O
,pool,NN,O
,.,.,O
,Thereafter,NNP,O
,",",",",O
,seizures,NNS,B-DISEASE
,were,VBD,O
,induced,VBN,O
,by,IN,O
,pilocarpine,JJ,O
,injections,NNS,O
,in,IN,O
,trained,JJ,O
,and,CC,O
,non,JJ,O
,-,:,O
,trained,VBN,O
,control,NN,O
,groups,NNS,O
,.,.,O
,During,IN,O
,the,DT,O
,acute,JJ,O
,period,NN,O
,of,IN,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,",",",",O
,we,PRP,O
,measured,VBD,O
,:,:,O
,(,(,O
,1,CD,O
,),),O
,the,DT,O
,latency,NN,O
,of,IN,O
,the,DT,O
,first,JJ,O
,motor,NN,O
,sign,NN,O
,",",",",O
,(,(,O
,2,CD,O
,),),O
,the,DT,O
,intensity,NN,O
,of,IN,O
,seizures,NNS,B-DISEASE
,",",",",O
,(,(,O
,3,CD,O
,),),O
,the,DT,O
,time,NN,O
,when,WRB,O
,it,PRP,O
,occurred,VBD,O
,within,IN,O
,the,DT,O
,6,CD,O
,-,:,O
,h,NN,O
,observation,NN,O
,period,NN,O
,",",",",O
,and,CC,O
,(,(,O
,4,CD,O
,),),O
,the,DT,O
,time,NN,O
,when,WRB,O
,the,DT,O
,acute,JJ,O
,period,NN,O
,ended,VBN,O
,.,.,O
,All,PDT,O
,these,DT,O
,behavioral,JJ,O
,parameters,NNS,O
,showed,VBD,O
,statistically,RB,O
,significant,JJ,O
,changes,NNS,O
,suggesting,VBG,O
,that,IN,O
,regular,JJ,O
,physical,JJ,O
,exercises,NNS,O
,decrease,VBP,O
,susceptibility,NN,O
,to,TO,O
,subsequently,RB,O
,induced,JJ,O
,seizures,NNS,B-DISEASE
,and,CC,O
,ameliorate,VB,O
,the,DT,O
,course,NN,O
,of,IN,O
,experimentally,RB,O
,induced,JJ,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,.,.,O
,Tonic,NNP,O
,dopaminergic,JJ,O
,stimulation,NN,O
,impairs,NNS,B-DISEASE
,associative,JJ,I-DISEASE
,learning,NN,I-DISEASE
,in,IN,O
,healthy,JJ,O
,subjects,NNS,O
,.,.,O
,Endogenous,JJ,O
,dopamine,NN,O
,plays,VBZ,O
,a,DT,O
,central,JJ,O
,role,NN,O
,in,IN,O
,salience,NN,O
,coding,NN,O
,during,IN,O
,associative,JJ,O
,learning,NN,O
,.,.,O
,Administration,NN,O
,of,IN,O
,the,DT,O
,dopamine,NN,O
,precursor,NN,O
,levodopa,NN,O
,enhances,NNS,O
,learning,VBG,O
,in,IN,O
,healthy,JJ,O
,subjects,NNS,O
,and,CC,O
,stroke,NN,B-DISEASE
,patients,NNS,O
,.,.,O
,Because,IN,O
,levodopa,NN,O
,increases,NNS,O
,both,DT,O
,phasic,JJ,O
,and,CC,O
,tonic,JJ,O
,dopaminergic,NN,O
,neurotransmission,NN,O
,",",",",O
,the,DT,O
,critical,JJ,O
,mechanism,NN,O
,mediating,VBG,O
,the,DT,O
,enhancement,NN,O
,of,IN,O
,learning,NN,O
,is,VBZ,O
,unresolved,JJ,O
,.,.,O
,We,PRP,O
,here,RB,O
,probed,VBD,O
,how,WRB,O
,selective,JJ,O
,tonic,JJ,O
,dopaminergic,NN,O
,stimulation,NN,O
,affects,VBZ,O
,associative,JJ,O
,learning,NN,O
,.,.,O
,Forty,NNP,O
,healthy,JJ,O
,subjects,NNS,O
,were,VBD,O
,trained,VBN,O
,in,IN,O
,a,DT,O
,novel,JJ,O
,vocabulary,NN,O
,of,IN,O
,45,CD,O
,concrete,JJ,O
,nouns,RB,O
,over,IN,O
,the,DT,O
,course,NN,O
,of,IN,O
,5,CD,O
,consecutive,JJ,O
,training,NN,O
,days,NNS,O
,in,IN,O
,a,DT,O
,prospective,JJ,O
,",",",",O
,randomized,VBN,O
,",",",",O
,double,JJ,O
,-,:,O
,blind,NN,O
,",",",",O
,placebo,SYM,O
,-,:,O
,controlled,VBN,O
,design,NN,O
,.,.,O
,Subjects,VBZ,O
,received,VBD,O
,the,DT,O
,tonically,RB,O
,stimulating,JJ,O
,dopamine,NN,O
,-,:,O
,receptor,NN,O
,agonist,JJ,O
,pergolide,NN,O
,(,(,O
,0,CD,O
,.,.,O
,1,CD,O
,mg,NN,O
,),),O
,vs,NN,O
,placebo,$,O
,120,CD,O
,min,NN,O
,before,IN,O
,training,VBG,O
,on,IN,O
,each,DT,O
,training,NN,O
,day,NN,O
,.,.,O
,The,DT,O
,dopamine,JJ,O
,agonist,NN,O
,significantly,RB,O
,impaired,VBD,B-DISEASE
,novel,JJ,I-DISEASE
,word,NN,I-DISEASE
,learning,NN,I-DISEASE
,compared,VBN,O
,to,TO,O
,placebo,VB,O
,.,.,O
,This,DT,O
,learning,JJ,O
,decrement,NN,O
,persisted,VBD,O
,up,RB,O
,to,TO,O
,the,DT,O
,last,JJ,O
,follow,NN,O
,-,:,O
,up,RB,O
,4,CD,O
,weeks,NNS,O
,post,NN,O
,-,:,O
,training,NN,O
,.,.,O
,Subjects,NNS,O
,treated,VBD,O
,with,IN,O
,pergolide,NN,O
,also,RB,O
,showed,VBD,O
,restricted,JJ,O
,emotional,JJ,O
,responses,NNS,O
,compared,VBN,O
,to,TO,O
,the,DT,O
,PLACEBO,NNP,O
,group,NN,O
,.,.,O
,The,DT,O
,extent,NN,O
,of,IN,O
,','',O
,flattened,VBN,O
,',POS,O
,affect,NN,O
,with,IN,O
,pergolide,NN,O
,was,VBD,O
,related,VBN,O
,to,TO,O
,the,DT,O
,degree,NN,O
,of,IN,O
,learning,VBG,O
,inhibition,NN,O
,.,.,O
,These,DT,O
,findings,NNS,O
,suggest,VBP,O
,that,IN,O
,tonic,JJ,O
,occupation,NN,O
,of,IN,O
,dopamine,NN,O
,receptors,NNS,O
,impairs,VBP,O
,learning,VBG,O
,by,IN,O
,competition,NN,O
,with,IN,O
,phasic,JJ,O
,dopamine,NN,O
,signals,NNS,O
,.,.,O
,Thus,RB,O
,",",",",O
,phasic,JJ,O
,signaling,VBG,O
,seems,VBZ,O
,to,TO,O
,be,VB,O
,the,DT,O
,critical,JJ,O
,mechanism,NN,O
,by,IN,O
,which,WDT,O
,dopamine,NN,O
,enhances,NNS,O
,associative,VBP,O
,learning,VBG,O
,in,IN,O
,healthy,JJ,O
,subjects,NNS,O
,and,CC,O
,stroke,NN,B-DISEASE
,patients,NNS,O
,.,.,O
,Minocycline,NNP,O
,-,:,O
,induced,VBD,O
,vasculitis,NN,B-DISEASE
,fulfilling,VBG,O
,the,DT,O
,criteria,NNS,O
,of,IN,O
,polyarteritis,NN,B-DISEASE
,nodosa,NN,I-DISEASE
,.,.,O
,A,DT,O
,47,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,man,NN,O
,who,WP,O
,had,VBD,O
,been,VBN,O
,taking,VBG,O
,minocycline,NN,O
,for,IN,O
,palmoplantar,NN,B-DISEASE
,pustulosis,NN,I-DISEASE
,developed,VBD,O
,fever,RB,B-DISEASE
,",",",",O
,myalgias,NNS,B-DISEASE
,",",",",O
,polyneuropathy,NN,B-DISEASE
,",",",",O
,and,CC,O
,testicular,JJ,B-DISEASE
,pain,NN,I-DISEASE
,",",",",O
,with,IN,O
,elevated,VBN,O
,C,NNP,O
,-,:,O
,reactive,JJ,O
,protein,NN,O
,(,(,O
,CRP,NNP,O
,),),O
,.,.,O
,Neither,CC,O
,myeloperoxidase,JJ,O
,-,:,O
,nor,CC,O
,proteinase,VB,O
,-,:,O
,3,CD,O
,-,:,O
,antineutrophil,NN,O
,cytoplasmic,JJ,O
,antibody,NN,O
,was,VBD,O
,positive,JJ,O
,.,.,O
,These,DT,O
,manifestations,NNS,O
,met,VBD,O
,the,DT,O
,American,NNP,O
,College,NNP,O
,of,IN,O
,Rheumatology,NNP,O
,1990,CD,O
,criteria,NN,O
,for,IN,O
,the,DT,O
,classification,NN,O
,of,IN,O
,polyarteritis,NN,B-DISEASE
,nodosa,NN,I-DISEASE
,.,.,O
,Stopping,VBG,O
,minocycline,NN,O
,led,VBD,O
,to,TO,O
,amelioration,NN,O
,of,IN,O
,symptoms,NNS,O
,and,CC,O
,normalization,NN,O
,of,IN,O
,CRP,NNP,O
,level,NN,O
,.,.,O
,To,TO,O
,our,PRP$,O
,knowledge,NN,O
,",",",",O
,this,DT,O
,is,VBZ,O
,the,DT,O
,second,JJ,O
,case,NN,O
,of,IN,O
,minocycline,NN,O
,-,:,O
,induced,JJ,O
,vasculitis,NN,B-DISEASE
,satisfying,VBG,O
,the,DT,O
,criteria,NNS,O
,.,.,O
,Differential,JJ,O
,diagnosis,NN,O
,for,IN,O
,drug,NN,O
,-,:,O
,induced,JJ,O
,disease,NN,O
,is,VBZ,O
,invaluable,JJ,O
,even,RB,O
,for,IN,O
,patients,NNS,O
,with,IN,O
,classical,JJ,O
,polyarteritis,NN,B-DISEASE
,nodosa,NN,I-DISEASE
,.,.,O
,Intramuscular,JJ,O
,hepatitis,NN,B-DISEASE
,B,NNP,I-DISEASE
,immune,NN,O
,globulin,NN,O
,combined,VBN,O
,with,IN,O
,lamivudine,NN,O
,in,IN,O
,prevention,NN,O
,of,IN,O
,hepatitis,NN,B-DISEASE
,B,NNP,I-DISEASE
,recurrence,NN,O
,after,IN,O
,liver,JJ,O
,transplantation,NN,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Combined,VBN,O
,hepatitis,NN,B-DISEASE
,B,NNP,I-DISEASE
,immune,NN,O
,globulin,NN,O
,(,(,O
,HBIg,NNP,O
,),),O
,and,CC,O
,lamivudine,NN,O
,in,IN,O
,prophylaxis,NN,O
,of,IN,O
,the,DT,O
,recurrence,NN,O
,of,IN,O
,hepatitis,NN,B-DISEASE
,B,NNP,I-DISEASE
,after,IN,O
,liver,NN,O
,transplantation,NN,O
,has,VBZ,O
,significantly,RB,O
,improved,VBN,O
,the,DT,O
,survival,NN,O
,of,IN,O
,HBsAg,NNP,O
,positive,JJ,O
,patients,NNS,O
,.,.,O
,This,DT,O
,study,NN,O
,was,VBD,O
,undertaken,VBN,O
,to,TO,O
,evaluate,VB,O
,the,DT,O
,outcomes,NNS,O
,of,IN,O
,liver,NN,O
,transplantation,NN,O
,for,IN,O
,patients,NNS,O
,with,IN,O
,hepatitis,NN,B-DISEASE
,B,NNP,I-DISEASE
,virus,NN,O
,(,(,O
,HBV,NNP,O
,),),O
,.,.,O
,METHODS,NN,O
,:,:,O
,A,DT,O
,retrospective,JJ,O
,chart,NN,O
,analysis,NN,O
,and,CC,O
,a,DT,O
,review,NN,O
,of,IN,O
,the,DT,O
,organ,JJ,O
,transplant,JJ,O
,database,NN,O
,identified,VBD,O
,51,CD,O
,patients,NNS,O
,(,(,O
,43,CD,O
,men,NNS,O
,and,CC,O
,8,CD,O
,women,NNS,O
,),),O
,transplanted,VBD,O
,for,IN,O
,benign,JJ,O
,HBV,NNP,O
,-,:,O
,related,VBN,O
,cirrhotic,JJ,B-DISEASE
,diseases,NNS,I-DISEASE
,between,IN,O
,June,NNP,O
,2002,CD,O
,and,CC,O
,December,NNP,O
,2004,CD,O
,who,WP,O
,had,VBD,O
,survived,VBN,O
,more,RBR,O
,than,IN,O
,3,CD,O
,months,NNS,O
,.,.,O
,HBIg,NNP,O
,was,VBD,O
,administered,VBN,O
,intravenously,RB,O
,during,IN,O
,the,DT,O
,first,JJ,O
,week,NN,O
,and,CC,O
,intramuscularly,RB,O
,thereafter,RB,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,At,IN,O
,a,DT,O
,median,JJ,O
,follow,NN,O
,-,:,O
,up,IN,O
,of,IN,O
,14,CD,O
,.,.,O
,1,CD,O
,months,NNS,O
,",",",",O
,the,DT,O
,overall,JJ,O
,recurrence,NN,O
,rate,NN,O
,in,IN,O
,the,DT,O
,51,CD,O
,patients,NNS,O
,was,VBD,O
,3,CD,O
,.,.,O
,9,CD,O
,%,NN,O
,(,(,O
,2,CD,O
,/,RB,O
,51,CD,O
,),),O
,.,.,O
,The,DT,O
,overall,JJ,O
,patient,NN,O
,survival,NN,O
,was,VBD,O
,88,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,",",",",O
,and,CC,O
,82,CD,O
,.,.,O
,4,CD,O
,%,NN,O
,after,IN,O
,1,CD,O
,and,CC,O
,2,CD,O
,years,NNS,O
,",",",",O
,respectively,RB,O
,.,.,O
,A,DT,O
,daily,JJ,O
,oral,JJ,O
,dose,NN,O
,of,IN,O
,100,CD,O
,mg,NNS,O
,lamivudine,NN,O
,for,IN,O
,2,CD,O
,weeks,NNS,O
,before,IN,O
,transplantation,NN,O
,for,IN,O
,10,CD,O
,patients,NNS,O
,enabled,VBD,O
,57,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,(,(,O
,4,CD,O
,/,RB,O
,7,CD,O
,),),O
,and,CC,O
,62,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,(,(,O
,5,CD,O
,/,RB,O
,8,CD,O
,),),O
,of,IN,O
,HBV,NNP,O
,-,:,O
,DNA,NN,O
,and,CC,O
,HBeAg,NNP,O
,positive,JJ,O
,patients,NNS,O
,respectively,RB,O
,to,TO,O
,convert,VB,O
,to,TO,O
,be,VB,O
,negative,JJ,O
,.,.,O
,Intramuscular,JJ,O
,HBIg,NNP,O
,was,VBD,O
,well,RB,O
,tolerated,VBN,O
,in,IN,O
,all,DT,O
,patients,NNS,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Lamivudine,NN,O
,combined,VBN,O
,with,IN,O
,intramuscular,JJ,O
,HBIg,NNP,O
,can,MD,O
,effectively,RB,O
,prevent,VB,O
,allograft,NN,O
,from,IN,O
,the,DT,O
,recurrence,NN,O
,of,IN,O
,HBV,NNP,O
,after,IN,O
,liver,JJ,O
,transplantation,NN,O
,.,.,O
,Anticonvulsant,JJ,O
,effect,NN,O
,of,IN,O
,eslicarbazepine,NN,O
,acetate,NN,O
,(,(,O
,BIA,NNP,O
,2,CD,O
,-,:,O
,093,CD,O
,),),O
,on,IN,O
,seizures,NNS,B-DISEASE
,induced,VBN,O
,by,IN,O
,microperfusion,NN,O
,of,IN,O
,picrotoxin,NN,O
,in,IN,O
,the,DT,O
,hippocampus,NN,O
,of,IN,O
,freely,RB,O
,moving,VBG,O
,rats,NNS,O
,.,.,O
,Eslicarbazepine,NNP,O
,acetate,NN,O
,(,(,O
,BIA,NNP,O
,2,CD,O
,-,:,O
,093,CD,O
,",",",",O
,S,NNP,O
,-,:,O
,(,(,O
,-,:,O
,),),O
,-,:,O
,10,CD,O
,-,:,O
,acetoxy,JJ,O
,-,:,O
,10,CD,O
,",",",",O
,11,CD,O
,-,:,O
,dihydro,NN,O
,-,:,O
,5H,CD,O
,-,:,O
,dibenzo,NN,O
,/,NN,O
,b,NN,O
,",",",",O
,f,JJ,O
,/,NNP,O
,azepine,NN,O
,-,:,O
,5,CD,O
,-,:,O
,carboxamide,NN,O
,),),O
,is,VBZ,O
,a,DT,O
,novel,JJ,O
,antiepileptic,JJ,O
,drug,NN,O
,",",",",O
,now,RB,O
,in,IN,O
,Phase,NNP,O
,III,NNP,O
,clinical,JJ,O
,trials,NNS,O
,",",",",O
,designed,VBN,O
,with,IN,O
,the,DT,O
,aim,NN,O
,of,IN,O
,improving,VBG,O
,efficacy,NN,O
,and,CC,O
,safety,NN,O
,in,IN,O
,comparison,NN,O
,with,IN,O
,the,DT,O
,structurally,RB,O
,related,JJ,O
,drugs,NNS,O
,carbamazepine,NN,O
,(,(,O
,CBZ,NNP,O
,),),O
,and,CC,O
,oxcarbazepine,NN,O
,(,(,O
,OXC,NNP,O
,),),O
,.,.,O
,We,PRP,O
,have,VBP,O
,studied,VBN,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,oral,JJ,O
,treatment,NN,O
,with,IN,O
,eslicarbazepine,JJ,O
,acetate,NN,O
,on,IN,O
,a,DT,O
,whole,JJ,O
,-,:,O
,animal,JJ,O
,model,NN,O
,in,IN,O
,which,WDT,O
,partial,JJ,O
,seizures,NNS,B-DISEASE
,can,MD,O
,be,VB,O
,elicited,VBN,O
,repeatedly,RB,O
,on,IN,O
,different,JJ,O
,days,NNS,O
,without,IN,O
,changes,NNS,O
,in,IN,O
,threshold,NN,O
,or,CC,O
,seizure,NN,B-DISEASE
,patterns,NNS,O
,.,.,O
,In,IN,O
,the,DT,O
,animals,NNS,O
,treated,VBD,O
,with,IN,O
,threshold,JJ,O
,doses,NNS,O
,of,IN,O
,picrotoxin,NN,O
,",",",",O
,the,DT,O
,average,JJ,O
,number,NN,O
,of,IN,O
,seizures,NNS,B-DISEASE
,was,VBD,O
,2,CD,O
,.,.,O
,3,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,2,CD,O
,",",",",O
,and,CC,O
,average,JJ,O
,seizure,NN,B-DISEASE
,duration,NN,O
,was,VBD,O
,39,CD,O
,.,.,O
,5,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,8,CD,O
,.,.,O
,4s,CD,O
,.,.,O
,Pre,NNP,O
,-,:,O
,treatment,NN,O
,with,IN,O
,a,DT,O
,dose,NN,O
,of,IN,O
,30,CD,O
,mg,NNS,O
,/,JJ,O
,kg,VBD,O
,2h,CD,O
,before,IN,O
,picrotoxin,NN,O
,microperfusion,NN,O
,prevented,VBD,O
,seizures,NNS,B-DISEASE
,in,IN,O
,the,DT,O
,75,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,rats,NNS,O
,.,.,O
,Lower,JJR,O
,doses,NNS,O
,(,(,O
,3,CD,O
,and,CC,O
,10mg,CD,O
,/,NNP,O
,kg,NN,O
,),),O
,did,VBD,O
,not,RB,O
,suppress,JJ,O
,seizures,NNS,B-DISEASE
,",",",",O
,however,RB,O
,",",",",O
,after,IN,O
,administration,NN,O
,of,IN,O
,10mg,CD,O
,/,JJ,O
,kg,NN,O
,",",",",O
,significant,JJ,O
,reductions,NNS,O
,in,IN,O
,seizures,NNS,B-DISEASE
,duration,NN,O
,(,(,O
,24,CD,O
,.,.,O
,3,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,6,CD,O
,.,.,O
,8s,CD,O
,),),O
,and,CC,O
,seizure,JJ,B-DISEASE
,number,NN,O
,(,(,O
,1,CD,O
,.,.,O
,6,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,34,CD,O
,),),O
,were,VBD,O
,found,VBN,O
,.,.,O
,No,DT,O
,adverse,JJ,O
,effects,NNS,O
,of,IN,O
,eslicarbazepine,JJ,O
,acetate,NN,O
,were,VBD,O
,observed,VBN,O
,in,IN,O
,the,DT,O
,behavioral,JJ,O
,/,NNP,O
,EEG,NNP,O
,patterns,NNS,O
,studied,VBD,O
,",",",",O
,including,VBG,O
,sleep,JJ,O
,/,NNP,O
,wakefulness,NN,O
,cycle,NN,O
,",",",",O
,at,IN,O
,the,DT,O
,doses,NNS,O
,studied,VBN,O
,.,.,O
,Acute,NNP,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,associated,VBN,O
,with,IN,O
,prolonged,JJ,O
,intake,NN,O
,of,IN,O
,slimming,VBG,O
,pills,NNS,O
,containing,VBG,O
,anthraquinones,NNS,O
,.,.,O
,Chinese,JJ,O
,herbal,JJ,O
,medicine,NN,O
,preparations,NNS,O
,are,VBP,O
,widely,RB,O
,available,JJ,O
,and,CC,O
,often,RB,O
,regarded,VBN,O
,by,IN,O
,the,DT,O
,public,NN,O
,as,IN,O
,natural,JJ,O
,and,CC,O
,safe,JJ,O
,remedies,NNS,O
,for,IN,O
,a,DT,O
,variety,NN,O
,of,IN,O
,medical,JJ,O
,conditions,NNS,O
,.,.,O
,Nephropathy,NNP,B-DISEASE
,caused,VBN,O
,by,IN,O
,Chinese,JJ,O
,herbs,NN,O
,has,VBZ,O
,previously,RB,O
,been,VBN,O
,reported,VBN,O
,",",",",O
,usually,RB,O
,involving,VBG,O
,the,DT,O
,use,NN,O
,of,IN,O
,aristolochic,JJ,O
,acids,NNS,O
,.,.,O
,We,PRP,O
,report,VBP,O
,a,DT,O
,23,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,who,WP,O
,developed,VBD,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,following,VBG,O
,prolonged,JJ,O
,use,NN,O
,of,IN,O
,a,DT,O
,proprietary,JJ,O
,Chinese,JJ,O
,herbal,JJ,O
,slimming,NN,O
,pill,NN,O
,that,WDT,O
,contained,VBD,O
,anthraquinone,NN,O
,derivatives,NNS,O
,",",",",O
,extracted,VBN,O
,from,IN,O
,Rhizoma,NNP,O
,Rhei,NNP,O
,(,(,O
,rhubarb,NN,O
,),),O
,.,.,O
,The,DT,O
,renal,JJ,B-DISEASE
,injury,NN,I-DISEASE
,was,VBD,O
,probably,RB,O
,aggravated,VBN,O
,by,IN,O
,the,DT,O
,concomitant,JJ,O
,intake,NN,O
,of,IN,O
,a,DT,O
,non,JJ,O
,-,:,O
,steroidal,NN,O
,anti,SYM,O
,-,:,O
,inflammatory,JJ,O
,drug,NN,O
,",",",",O
,diclofenac,NN,O
,.,.,O
,Renal,NNP,O
,pathology,NN,O
,was,VBD,O
,that,IN,O
,of,IN,O
,hypocellular,JJ,O
,interstitial,JJ,O
,fibrosis,NN,B-DISEASE
,.,.,O
,Spontaneous,JJ,O
,renal,JJ,O
,recovery,NN,O
,occurred,VBD,O
,upon,IN,O
,cessation,NN,O
,of,IN,O
,the,DT,O
,slimming,NN,O
,pills,NNS,O
,",",",",O
,but,CC,O
,mild,JJ,O
,interstitial,JJ,O
,fibrosis,NN,B-DISEASE
,and,CC,O
,tubular,JJ,O
,atrophy,NN,B-DISEASE
,was,VBD,O
,still,RB,O
,evident,JJ,O
,histologically,RB,O
,4,CD,O
,months,NNS,O
,later,RB,O
,.,.,O
,Although,IN,O
,a,DT,O
,causal,NN,O
,relationship,NN,O
,between,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,an,DT,O
,anthraquinone,NN,O
,-,:,O
,containing,VBG,O
,herbal,JJ,O
,agent,NN,O
,and,CC,O
,renal,JJ,B-DISEASE
,injury,NN,I-DISEASE
,remains,VBZ,O
,to,TO,O
,be,VB,O
,proven,VBN,O
,",",",",O
,phytotherapy,SYM,O
,-,:,O
,associated,VBN,O
,interstitial,JJ,O
,nephropathy,NN,B-DISEASE
,should,MD,O
,be,VB,O
,considered,VBN,O
,in,IN,O
,patients,NNS,O
,who,WP,O
,present,VBP,O
,with,IN,O
,unexplained,JJ,O
,renal,JJ,B-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,Chloroacetaldehyde,NNP,O
,as,IN,O
,a,DT,O
,sulfhydryl,JJ,O
,reagent,NN,O
,:,:,O
,the,DT,O
,role,NN,O
,of,IN,O
,critical,JJ,O
,thiol,NN,O
,groups,NNS,O
,in,IN,O
,ifosfamide,JJ,O
,nephropathy,NN,B-DISEASE
,.,.,O
,Chloroacetaldehyde,NNP,O
,(,(,O
,CAA,NNP,O
,),),O
,is,VBZ,O
,a,DT,O
,metabolite,NN,O
,of,IN,O
,the,DT,O
,alkylating,VBG,O
,agent,NN,O
,ifosfamide,NN,O
,(,(,O
,IFO,NNP,O
,),),O
,and,CC,O
,putatively,RB,O
,responsible,JJ,O
,for,IN,O
,renal,JJ,B-DISEASE
,damage,NN,I-DISEASE
,following,VBG,O
,anti,JJ,O
,-,:,O
,tumor,NN,B-DISEASE
,therapy,NN,O
,with,IN,O
,IFO,NNP,O
,.,.,O
,Depletion,NN,O
,of,IN,O
,sulfhydryl,NN,O
,(,(,O
,SH,NNP,O
,),),O
,groups,NNS,O
,has,VBZ,O
,been,VBN,O
,reported,VBN,O
,from,IN,O
,cell,NN,O
,culture,NN,O
,",",",",O
,animal,NN,O
,and,CC,O
,clinical,JJ,O
,studies,NNS,O
,.,.,O
,In,IN,O
,this,DT,O
,work,NN,O
,the,DT,O
,effect,NN,O
,of,IN,O
,CAA,NNP,O
,on,IN,O
,human,JJ,O
,proximal,JJ,O
,tubule,NN,O
,cells,NNS,O
,in,IN,O
,primary,JJ,O
,culture,NN,O
,(,(,O
,hRPTEC,NN,O
,),),O
,was,VBD,O
,investigated,VBN,O
,.,.,O
,Toxicity,NN,B-DISEASE
,of,IN,O
,CAA,NNP,O
,was,VBD,O
,determined,VBN,O
,by,IN,O
,protein,NN,O
,content,NN,O
,",",",",O
,cell,NN,O
,number,NN,O
,",",",",O
,LDH,NNP,O
,release,NN,O
,",",",",O
,trypan,JJ,O
,blue,JJ,O
,exclusion,NN,O
,assay,NN,O
,and,CC,O
,caspase,NN,O
,-,:,O
,3,CD,O
,activity,NN,O
,.,.,O
,Free,JJ,O
,thiols,NNS,O
,were,VBD,O
,measured,VBN,O
,by,IN,O
,the,DT,O
,method,NN,O
,of,IN,O
,Ellman,NNP,O
,.,.,O
,CAA,NNP,O
,reduced,VBD,O
,hRPTEC,NN,O
,cell,NN,O
,number,NN,O
,and,CC,O
,protein,NN,O
,",",",",O
,induced,VBD,O
,a,DT,O
,loss,NN,O
,in,IN,O
,free,JJ,O
,intracellular,NN,O
,thiols,NNS,O
,and,CC,O
,an,DT,O
,increase,NN,O
,in,IN,O
,necrosis,JJ,B-DISEASE
,markers,NNS,O
,.,.,O
,CAA,NNP,O
,but,CC,O
,not,RB,O
,acrolein,RB,O
,inhibited,VBD,O
,the,DT,O
,cysteine,NN,O
,proteases,VBZ,O
,caspase,SYM,O
,-,:,O
,3,CD,O
,",",",",O
,caspase,NN,O
,-,:,O
,8,CD,O
,and,CC,O
,cathepsin,NN,O
,B,NNP,O
,.,.,O
,Caspase,NNP,O
,activation,NN,O
,by,IN,O
,cisplatin,NN,O
,was,VBD,O
,inhibited,VBN,O
,by,IN,O
,CAA,NNP,O
,.,.,O
,In,IN,O
,cells,NNS,O
,stained,VBN,O
,with,IN,O
,fluorescent,JJ,O
,dyes,NNS,O
,targeting,VBG,O
,lysosomes,NNS,O
,",",",",O
,CAA,NNP,O
,induced,VBD,O
,an,DT,O
,increase,NN,O
,in,IN,O
,lysosomal,JJ,O
,size,NN,O
,and,CC,O
,lysosomal,JJ,O
,leakage,NN,O
,.,.,O
,The,DT,O
,effects,NNS,O
,of,IN,O
,CAA,NNP,O
,on,IN,O
,cysteine,JJ,O
,protease,NN,O
,activities,NNS,O
,and,CC,O
,thiols,NNS,O
,could,MD,O
,be,VB,O
,reproduced,VBN,O
,in,IN,O
,cell,NN,O
,lysate,NN,O
,.,.,O
,Acidification,NNP,O
,",",",",O
,which,WDT,O
,slowed,VBD,O
,the,DT,O
,reaction,NN,O
,of,IN,O
,CAA,NNP,O
,with,IN,O
,thiol,JJ,O
,donors,NNS,O
,",",",",O
,could,MD,O
,also,RB,O
,attenuate,VB,O
,effects,NNS,O
,of,IN,O
,CAA,NNP,O
,on,IN,O
,necrosis,NN,B-DISEASE
,markers,NNS,O
,",",",",O
,thiol,JJ,O
,depletion,NN,O
,and,CC,O
,cysteine,NN,O
,protease,NN,O
,inhibition,NN,O
,in,IN,O
,living,NN,O
,cells,NNS,O
,.,.,O
,Thus,RB,O
,",",",",O
,CAA,NNP,O
,directly,RB,O
,reacts,VBZ,O
,with,IN,O
,cellular,JJ,O
,protein,NN,O
,and,CC,O
,non,JJ,O
,-,:,O
,protein,NN,O
,thiols,NNS,O
,",",",",O
,mediating,VBG,O
,its,PRP$,O
,toxicity,NN,B-DISEASE
,on,IN,O
,hRPTEC,NN,O
,.,.,O
,This,DT,O
,effect,NN,O
,can,MD,O
,be,VB,O
,reduced,VBN,O
,by,IN,O
,acidification,NN,O
,.,.,O
,Therefore,RB,O
,",",",",O
,urinary,JJ,O
,acidification,NN,O
,could,MD,O
,be,VB,O
,an,DT,O
,option,NN,O
,to,TO,O
,prevent,VB,O
,IFO,NNP,O
,nephropathy,JJ,B-DISEASE
,in,IN,O
,patients,NNS,O
,.,.,O
,Stereological,JJ,O
,methods,NNS,O
,reveal,VBP,O
,the,DT,O
,robust,JJ,O
,size,NN,O
,and,CC,O
,stability,NN,O
,of,IN,O
,ectopic,NN,O
,hilar,JJ,O
,granule,NN,O
,cells,NNS,O
,after,IN,O
,pilocarpine,JJ,O
,-,:,O
,induced,JJ,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,in,IN,O
,the,DT,O
,adult,NN,O
,rat,NN,O
,.,.,O
,Following,VBG,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,in,IN,O
,the,DT,O
,rat,NN,O
,",",",",O
,dentate,NN,O
,granule,NN,O
,cell,NN,O
,neurogenesis,NN,O
,increases,VBZ,O
,greatly,RB,O
,",",",",O
,and,CC,O
,many,JJ,O
,of,IN,O
,the,DT,O
,new,JJ,O
,neurons,NNS,O
,appear,VBP,O
,to,TO,O
,develop,VB,O
,ectopically,RB,O
,",",",",O
,in,IN,O
,the,DT,O
,hilar,JJ,O
,region,NN,O
,of,IN,O
,the,DT,O
,hippocampal,JJ,O
,formation,NN,O
,.,.,O
,It,PRP,O
,has,VBZ,O
,been,VBN,O
,suggested,VBN,O
,that,IN,O
,the,DT,O
,ectopic,NN,O
,hilar,JJ,O
,granule,NN,O
,cells,NNS,O
,could,MD,O
,contribute,VB,O
,to,TO,O
,the,DT,O
,spontaneous,JJ,O
,seizures,NNS,B-DISEASE
,that,WDT,O
,ultimately,RB,O
,develop,VBP,O
,after,IN,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,.,.,O
,However,RB,O
,",",",",O
,the,DT,O
,population,NN,O
,has,VBZ,O
,never,RB,O
,been,VBN,O
,quantified,VBN,O
,",",",",O
,so,IN,O
,it,PRP,O
,is,VBZ,O
,unclear,JJ,O
,whether,IN,O
,it,PRP,O
,is,VBZ,O
,substantial,JJ,O
,enough,RB,O
,to,TO,O
,have,VB,O
,a,DT,O
,strong,JJ,O
,influence,NN,O
,on,IN,O
,epileptogenesis,NN,O
,.,.,O
,To,TO,O
,quantify,VB,O
,this,DT,O
,population,NN,O
,",",",",O
,the,DT,O
,total,JJ,O
,number,NN,O
,of,IN,O
,ectopic,JJ,O
,hilar,JJ,O
,granule,NN,O
,cells,NNS,O
,was,VBD,O
,estimated,VBN,O
,using,VBG,O
,unbiased,JJ,O
,stereology,NN,O
,at,IN,O
,different,JJ,O
,times,NNS,O
,after,IN,O
,pilocarpine,JJ,O
,-,:,O
,induced,JJ,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,.,.,O
,The,DT,O
,number,NN,O
,of,IN,O
,hilar,JJ,O
,neurons,NNS,O
,immunoreactive,VBP,O
,for,IN,O
,Prox,NNP,O
,-,:,O
,1,CD,O
,",",",",O
,a,DT,O
,granule,NN,O
,-,:,O
,cell,NN,O
,-,:,O
,specific,JJ,O
,marker,NN,O
,",",",",O
,was,VBD,O
,estimated,VBN,O
,using,VBG,O
,the,DT,O
,optical,JJ,O
,fractionator,NN,O
,method,NN,O
,.,.,O
,The,DT,O
,results,NNS,O
,indicate,VBP,O
,that,IN,O
,the,DT,O
,size,NN,O
,of,IN,O
,the,DT,O
,hilar,JJ,O
,ectopic,NN,O
,granule,NN,O
,cell,NN,O
,population,NN,O
,after,IN,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,is,VBZ,O
,substantial,JJ,O
,",",",",O
,and,CC,O
,stable,JJ,O
,over,IN,O
,time,NN,O
,.,.,O
,Interestingly,RB,O
,",",",",O
,the,DT,O
,size,NN,O
,of,IN,O
,the,DT,O
,population,NN,O
,appears,VBZ,O
,to,TO,O
,be,VB,O
,correlated,VBN,O
,with,IN,O
,the,DT,O
,frequency,NN,O
,of,IN,O
,behavioral,JJ,O
,seizures,NNS,B-DISEASE
,",",",",O
,because,IN,O
,animals,NNS,O
,with,IN,O
,more,JJR,O
,ectopic,NN,O
,granule,NN,O
,cells,NNS,O
,in,IN,O
,the,DT,O
,hilus,NN,O
,have,VBP,O
,more,RBR,O
,frequent,JJ,O
,behavioral,JJ,O
,seizures,NNS,B-DISEASE
,.,.,O
,The,DT,O
,hilar,JJ,O
,ectopic,NN,O
,granule,NN,O
,cell,NN,O
,population,NN,O
,does,VBZ,O
,not,RB,O
,appear,VB,O
,to,TO,O
,vary,VB,O
,systematically,RB,O
,across,IN,O
,the,DT,O
,septotemporal,JJ,O
,axis,NN,O
,",",",",O
,although,IN,O
,it,PRP,O
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,an,DT,O
,increase,NN,O
,in,IN,O
,volume,NN,O
,of,IN,O
,the,DT,O
,hilus,NN,O
,.,.,O
,The,DT,O
,results,NNS,O
,provide,VBP,O
,new,JJ,O
,insight,NN,O
,into,IN,O
,the,DT,O
,potential,JJ,O
,role,NN,O
,of,IN,O
,ectopic,JJ,O
,hilar,JJ,O
,granule,NN,O
,cells,NNS,O
,in,IN,O
,the,DT,O
,pilocarpine,JJ,O
,model,NN,O
,of,IN,O
,temporal,JJ,B-DISEASE
,lobe,NN,I-DISEASE
,epilepsy,NN,I-DISEASE
,.,.,O
,A,DT,O
,prospective,JJ,O
,",",",",O
,open,JJ,O
,-,:,O
,label,JJ,O
,trial,NN,O
,of,IN,O
,galantamine,NN,O
,in,IN,O
,autistic,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,Post,NNP,O
,-,:,O
,mortem,NN,O
,studies,NNS,O
,have,VBP,O
,reported,VBN,O
,abnormalities,NNS,O
,of,IN,O
,the,DT,O
,cholinergic,NN,O
,system,NN,O
,in,IN,O
,autism,NN,B-DISEASE
,.,.,O
,The,DT,O
,purpose,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,was,VBD,O
,to,TO,O
,assess,VB,O
,the,DT,O
,use,NN,O
,of,IN,O
,galantamine,NN,O
,",",",",O
,an,DT,O
,acetylcholinesterase,NN,O
,inhibitor,NN,O
,and,CC,O
,nicotinic,JJ,O
,receptor,NN,O
,modulator,NN,O
,",",",",O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,interfering,VBG,O
,behaviors,NNS,O
,in,IN,O
,children,NNS,O
,with,IN,O
,autism,NN,B-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,Thirteen,JJ,O
,medication,NN,O
,-,:,O
,free,JJ,O
,children,NNS,O
,with,IN,O
,autism,NN,B-DISEASE
,(,(,O
,mean,JJ,O
,age,NN,O
,",",",",O
,8,CD,O
,.,.,O
,8,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,3,CD,O
,.,.,O
,5,CD,O
,years,NNS,O
,),),O
,participated,VBD,O
,in,IN,O
,a,DT,O
,12,CD,O
,-,:,O
,week,NN,O
,",",",",O
,open,JJ,O
,-,:,O
,label,JJ,O
,trial,NN,O
,of,IN,O
,galantamine,NN,O
,.,.,O
,Patients,NNS,O
,were,VBD,O
,rated,VBN,O
,monthly,JJ,O
,by,IN,O
,parents,NNS,O
,on,IN,O
,the,DT,O
,Aberrant,NNP,O
,Behavior,NNP,O
,Checklist,NNP,O
,(,(,O
,ABC,NNP,O
,),),O
,and,CC,O
,the,DT,O
,Conners,NNP,O
,',POS,O
,Parent,NN,O
,Rating,VBG,O
,Scale,NNP,O
,-,:,O
,Revised,VBN,O
,",",",",O
,and,CC,O
,by,IN,O
,a,DT,O
,physician,NN,O
,using,VBG,O
,the,DT,O
,Children,NNP,O
,',POS,O
,s,NN,O
,Psychiatric,NNP,O
,Rating,NNP,O
,Scale,NNP,O
,and,CC,O
,the,DT,O
,Clinical,NNP,O
,Global,NNP,O
,Impressions,NNP,O
,scale,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Patients,NNS,O
,showed,VBD,O
,a,DT,O
,significant,JJ,O
,reduction,NN,O
,in,IN,O
,parent,NN,O
,-,:,O
,rated,VBN,O
,irritability,NN,B-DISEASE
,and,CC,O
,social,JJ,O
,withdrawal,NN,O
,on,IN,O
,the,DT,O
,ABC,NNP,O
,as,RB,O
,well,RB,O
,as,IN,O
,significant,JJ,O
,improvements,NNS,O
,in,IN,O
,emotional,JJ,O
,lability,NN,O
,and,CC,O
,inattention,NN,O
,on,IN,O
,the,DT,O
,Conners,NNP,O
,',POS,O
,Parent,NN,O
,Rating,VBG,O
,Scale,NNP,O
,-,:,O
,-,:,O
,Revised,VBN,O
,.,.,O
,Similarly,RB,O
,",",",",O
,clinician,JJ,O
,ratings,NNS,O
,showed,VBD,O
,reductions,NNS,O
,in,IN,O
,the,DT,O
,anger,NN,O
,subscale,NN,O
,of,IN,O
,the,DT,O
,Children,NNP,O
,',POS,O
,s,NN,O
,Psychiatric,NNP,O
,Rating,NNP,O
,Scale,NNP,O
,.,.,O
,Eight,NNP,O
,of,IN,O
,13,CD,O
,participants,NNS,O
,were,VBD,O
,rated,VBN,O
,as,IN,O
,responders,NNS,O
,on,IN,O
,the,DT,O
,basis,NN,O
,of,IN,O
,their,PRP$,O
,improvement,NN,O
,scores,NNS,O
,on,IN,O
,the,DT,O
,Clinical,NNP,O
,Global,NNP,O
,Impressions,NNP,O
,scale,NN,O
,.,.,O
,Overall,JJ,O
,",",",",O
,galantamine,NN,O
,was,VBD,O
,well,RB,O
,-,:,O
,tolerated,VBN,O
,",",",",O
,with,IN,O
,no,DT,O
,significant,JJ,O
,adverse,JJ,O
,effects,NNS,O
,apart,RB,O
,from,IN,O
,headaches,NNS,B-DISEASE
,in,IN,O
,one,CD,O
,patient,NN,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,In,IN,O
,this,DT,O
,open,JJ,O
,trial,NN,O
,",",",",O
,galantamine,NN,O
,was,VBD,O
,well,RB,O
,-,:,O
,tolerated,VBN,O
,and,CC,O
,appeared,VBN,O
,to,TO,O
,be,VB,O
,beneficial,JJ,O
,for,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,interfering,VBG,O
,behaviors,NNS,O
,in,IN,O
,children,NNS,O
,with,IN,O
,autism,NN,B-DISEASE
,",",",",O
,particularly,RB,O
,aggression,NN,B-DISEASE
,",",",",O
,behavioral,JJ,B-DISEASE
,dyscontrol,NN,I-DISEASE
,",",",",O
,and,CC,O
,inattention,NN,B-DISEASE
,.,.,O
,Further,NNP,O
,controlled,VBD,O
,trials,NNS,O
,are,VBP,O
,warranted,VBN,O
,.,.,O
,Randomized,NNP,O
,comparison,NN,O
,of,IN,O
,olanzapine,JJ,O
,versus,NN,O
,risperidone,NN,O
,for,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,first,JJ,O
,-,:,O
,episode,NN,O
,schizophrenia,NN,B-DISEASE
,:,:,O
,4,CD,O
,-,:,O
,month,NN,O
,outcomes,RB,O
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,The,DT,O
,authors,NNS,O
,compared,VBN,O
,4,CD,O
,-,:,O
,month,NN,O
,treatment,NN,O
,outcomes,NNS,O
,for,IN,O
,olanzapine,JJ,O
,versus,NN,O
,risperidone,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,first,JJ,O
,-,:,O
,episode,NN,O
,schizophrenia,NN,B-DISEASE
,spectrum,NN,O
,disorders,NNS,O
,.,.,O
,METHOD,NN,O
,:,:,O
,One,CD,O
,hundred,VBD,O
,twelve,NN,O
,subjects,NNS,O
,(,(,O
,70,CD,O
,%,NN,O
,male,NN,O
,;,:,O
,mean,JJ,O
,age,NN,O
,=,VBD,O
,23,CD,O
,.,.,O
,3,CD,O
,years,NNS,O
,[,JJ,O
,SD,NNP,O
,=,NNP,O
,5,CD,O
,.,.,O
,1,CD,O
,],NN,O
,),),O
,with,IN,O
,first,JJ,O
,-,:,O
,episode,NN,O
,schizophrenia,NN,B-DISEASE
,(,(,O
,75,CD,O
,%,NN,O
,),),O
,",",",",O
,schizophreniform,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,(,(,O
,17,CD,O
,%,NN,O
,),),O
,",",",",O
,or,CC,O
,schizoaffective,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,(,(,O
,8,CD,O
,%,NN,O
,),),O
,were,VBD,O
,randomly,RB,O
,assigned,VBN,O
,to,TO,O
,treatment,NN,O
,with,IN,O
,olanzapine,NN,O
,(,(,O
,2,CD,O
,.,.,O
,5,CD,O
,-,:,O
,20,CD,O
,mg,JJ,O
,/,NNP,O
,day,NN,O
,),),O
,or,CC,O
,risperidone,NN,O
,(,(,O
,1,CD,O
,-,:,O
,6,CD,O
,mg,JJ,O
,/,NNP,O
,day,NN,O
,),),O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Response,JJ,O
,rates,NNS,O
,did,VBD,O
,not,RB,O
,significantly,RB,O
,differ,VBP,O
,between,IN,O
,olanzapine,NN,O
,(,(,O
,43,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,",",",",O
,95,CD,O
,%,NN,O
,CI,NNP,O
,=,NNP,O
,28,CD,O
,.,.,O
,8,CD,O
,%,NN,O
,-,:,O
,58,CD,O
,.,.,O
,6,CD,O
,%,NN,O
,),),O
,and,CC,O
,risperidone,NN,O
,(,(,O
,54,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,",",",",O
,95,CD,O
,%,NN,O
,CI,NNP,O
,=,NNP,O
,39,CD,O
,.,.,O
,9,CD,O
,%,NN,O
,-,:,O
,68,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,),),O
,.,.,O
,Among,IN,O
,those,DT,O
,responding,VBG,O
,to,TO,O
,treatment,NN,O
,",",",",O
,more,JJR,O
,subjects,NNS,O
,in,IN,O
,the,DT,O
,olanzapine,NN,O
,group,NN,O
,(,(,O
,40,CD,O
,.,.,O
,9,CD,O
,%,NN,O
,",",",",O
,95,CD,O
,%,NN,O
,CI,NNP,O
,=,NNP,O
,16,CD,O
,.,.,O
,8,CD,O
,%,NN,O
,-,:,O
,65,CD,O
,.,.,O
,0,CD,O
,%,NN,O
,),),O
,than,IN,O
,in,IN,O
,the,DT,O
,risperidone,NN,O
,group,NN,O
,(,(,O
,18,CD,O
,.,.,O
,9,CD,O
,%,NN,O
,",",",",O
,95,CD,O
,%,NN,O
,CI,NNP,O
,=,NNP,O
,0,CD,O
,%,NN,O
,-,:,O
,39,CD,O
,.,.,O
,2,CD,O
,%,NN,O
,),),O
,had,VBD,O
,subsequent,JJ,O
,ratings,NNS,O
,not,RB,O
,meeting,VBG,O
,response,NN,O
,criteria,NNS,O
,.,.,O
,Negative,JJ,O
,symptom,NN,O
,outcomes,NNS,O
,and,CC,O
,measures,NNS,O
,of,IN,O
,parkinsonism,NN,B-DISEASE
,and,CC,O
,akathisia,NN,B-DISEASE
,did,VBD,O
,not,RB,O
,differ,VB,O
,between,IN,O
,medications,NNS,O
,.,.,O
,Extrapyramidal,NNP,B-DISEASE
,symptom,JJ,I-DISEASE
,severity,NN,O
,scores,NNS,O
,were,VBD,O
,1,CD,O
,.,.,O
,4,CD,O
,(,(,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,=,NNP,O
,1,CD,O
,.,.,O
,2,CD,O
,-,:,O
,1,CD,O
,.,.,O
,6,CD,O
,),),O
,with,IN,O
,risperidone,NN,O
,and,CC,O
,1,CD,O
,.,.,O
,2,CD,O
,(,(,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,=,NNP,O
,1,CD,O
,.,.,O
,0,CD,O
,-,:,O
,1,CD,O
,.,.,O
,4,CD,O
,),),O
,with,IN,O
,olanzapine,NN,O
,.,.,O
,Significantly,RB,O
,more,JJR,O
,weight,JJ,B-DISEASE
,gain,NN,I-DISEASE
,occurred,VBD,O
,with,IN,O
,olanzapine,NN,O
,than,IN,O
,with,IN,O
,risperidone,NN,O
,:,:,O
,the,DT,O
,increase,NN,O
,in,IN,O
,weight,NN,O
,at,IN,O
,4,CD,O
,months,NNS,O
,relative,JJ,O
,to,TO,O
,baseline,VB,O
,weight,NN,O
,was,VBD,O
,17,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,(,(,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,=,NNP,O
,14,CD,O
,.,.,O
,2,CD,O
,%,NN,O
,-,:,O
,20,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,),),O
,with,IN,O
,olanzapine,NN,O
,and,CC,O
,11,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,(,(,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,=,NNP,O
,8,CD,O
,.,.,O
,4,CD,O
,%,NN,O
,-,:,O
,14,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,),),O
,with,IN,O
,risperidone,NN,O
,.,.,O
,Body,NNP,O
,mass,JJ,O
,index,NN,O
,at,IN,O
,baseline,NN,O
,and,CC,O
,at,IN,O
,4,CD,O
,months,NNS,O
,was,VBD,O
,24,CD,O
,.,.,O
,3,CD,O
,(,(,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,=,NNP,O
,22,CD,O
,.,.,O
,8,CD,O
,-,:,O
,25,CD,O
,.,.,O
,7,CD,O
,),),O
,versus,NN,O
,28,CD,O
,.,.,O
,2,CD,O
,(,(,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,=,NNP,O
,26,CD,O
,.,.,O
,7,CD,O
,-,:,O
,29,CD,O
,.,.,O
,7,CD,O
,),),O
,with,IN,O
,olanzapine,NN,O
,and,CC,O
,23,CD,O
,.,.,O
,9,CD,O
,(,(,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,=,NNP,O
,22,CD,O
,.,.,O
,5,CD,O
,-,:,O
,25,CD,O
,.,.,O
,3,CD,O
,),),O
,versus,NN,O
,26,CD,O
,.,.,O
,7,CD,O
,(,(,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,=,NNP,O
,25,CD,O
,.,.,O
,2,CD,O
,-,:,O
,28,CD,O
,.,.,O
,2,CD,O
,),),O
,with,IN,O
,risperidone,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Clinical,JJ,O
,outcomes,NNS,O
,with,IN,O
,risperidone,NN,O
,were,VBD,O
,equal,JJ,O
,to,TO,O
,those,DT,O
,with,IN,O
,olanzapine,JJ,O
,",",",",O
,and,CC,O
,response,NN,O
,may,MD,O
,be,VB,O
,more,RBR,O
,stable,JJ,O
,.,.,O
,Olanzapine,NN,O
,may,MD,O
,have,VB,O
,an,DT,O
,advantage,NN,O
,for,IN,O
,motor,NN,O
,side,NN,O
,effects,NNS,O
,.,.,O
,Both,DT,O
,medications,NNS,O
,caused,VBD,O
,substantial,JJ,O
,rapid,JJ,O
,weight,NN,B-DISEASE
,gain,NN,I-DISEASE
,",",",",O
,but,CC,O
,weight,VBD,B-DISEASE
,gain,NN,I-DISEASE
,was,VBD,O
,greater,JJR,O
,with,IN,O
,olanzapine,NN,O
,.,.,O
,Early,JJ,O
,paracentral,JJ,O
,visual,JJ,B-DISEASE
,field,NN,I-DISEASE
,loss,NN,I-DISEASE
,in,IN,O
,patients,NNS,O
,taking,VBG,O
,hydroxychloroquine,NN,O
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,To,TO,O
,review,VB,O
,the,DT,O
,natural,JJ,O
,history,NN,O
,and,CC,O
,ocular,JJ,O
,and,CC,O
,systemic,JJ,O
,adverse,JJ,O
,effects,NNS,O
,of,IN,O
,patients,NNS,O
,taking,VBG,O
,hydroxychloroquine,JJ,O
,sulfate,NN,O
,who,WP,O
,attended,VBD,O
,an,DT,O
,ophthalmic,JJ,O
,screening,NN,O
,program,NN,O
,.,.,O
,DESIGN,NN,O
,:,:,O
,Retrospective,JJ,O
,study,NN,O
,.,.,O
,RESULTS,NNS,O
,:,:,O
,Records,NNS,O
,of,IN,O
,262,CD,O
,patients,NNS,O
,who,WP,O
,were,VBD,O
,taking,VBG,O
,hydroxychloroquine,NN,O
,and,CC,O
,screened,VBN,O
,in,IN,O
,the,DT,O
,Department,NNP,O
,of,IN,O
,Ophthalmology,NNP,O
,were,VBD,O
,reviewed,VBN,O
,.,.,O
,Of,IN,O
,the,DT,O
,262,CD,O
,patients,NNS,O
,",",",",O
,14,CD,O
,(,(,O
,18,CD,O
,%,NN,O
,),),O
,of,IN,O
,76,CD,O
,who,WP,O
,had,VBD,O
,stopped,VBN,O
,treatment,NN,O
,at,IN,O
,the,DT,O
,time,NN,O
,of,IN,O
,the,DT,O
,study,NN,O
,experienced,VBD,O
,documented,JJ,O
,adverse,JJ,O
,effects,NNS,O
,.,.,O
,Systemic,JJ,O
,adverse,JJ,O
,effects,NNS,O
,occurred,VBD,O
,in,IN,O
,8,CD,O
,patients,NNS,O
,(,(,O
,10,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,),),O
,and,CC,O
,ocular,JJ,O
,adverse,JJ,O
,effects,NNS,O
,",",",",O
,in,IN,O
,5,CD,O
,(,(,O
,6,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,),),O
,.,.,O
,Thirty,NNP,O
,-,:,O
,five,CD,O
,patients,NNS,O
,(,(,O
,13,CD,O
,.,.,O
,4,CD,O
,%,NN,O
,),),O
,had,VBD,O
,visual,JJ,B-DISEASE
,field,NN,I-DISEASE
,abnormalities,NNS,I-DISEASE
,",",",",O
,which,WDT,O
,were,VBD,O
,attributed,VBN,O
,to,TO,O
,hydroxychloroquine,VB,O
,treatment,NN,O
,in,IN,O
,4,CD,O
,patients,NNS,O
,(,(,O
,1,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,),),O
,.,.,O
,Three,CD,O
,of,IN,O
,the,DT,O
,4,CD,O
,patients,NNS,O
,were,VBD,O
,taking,VBG,O
,less,JJR,O
,than,IN,O
,6,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,/,NNP,O
,kg,FW,O
,per,IN,O
,day,NN,O
,and,CC,O
,all,DT,O
,patients,NNS,O
,had,VBD,O
,normal,JJ,O
,renal,JJ,O
,and,CC,O
,liver,JJ,O
,function,NN,O
,test,NN,O
,results,NNS,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,The,DT,O
,current,JJ,O
,study,NN,O
,used,VBD,O
,a,DT,O
,protocol,NN,O
,of,IN,O
,visual,JJ,O
,acuity,NN,O
,and,CC,O
,color,NN,O
,vision,NN,O
,assessment,NN,O
,",",",",O
,funduscopy,NN,O
,",",",",O
,and,CC,O
,Humphrey,NNP,O
,10,CD,O
,-,:,O
,2,CD,O
,visual,JJ,O
,field,NN,O
,testing,NN,O
,and,CC,O
,shows,VBZ,O
,that,IN,O
,visual,JJ,B-DISEASE
,field,NN,I-DISEASE
,defects,NNS,I-DISEASE
,appeared,VBD,O
,before,IN,O
,any,DT,O
,corresponding,JJ,O
,changes,NNS,O
,in,IN,O
,any,DT,O
,other,JJ,O
,tested,JJ,O
,clinical,JJ,O
,parameters,NNS,O
,;,:,O
,the,DT,O
,defects,NNS,O
,were,VBD,O
,reproducible,JJ,O
,and,CC,O
,the,DT,O
,test,NN,O
,parameters,NNS,O
,were,VBD,O
,reliable,JJ,O
,.,.,O
,Patients,NNS,O
,taking,VBG,O
,hydroxychloroquine,NN,O
,can,MD,O
,demonstrate,VB,O
,a,DT,O
,toxic,JJ,O
,reaction,NN,O
,in,IN,O
,the,DT,O
,retina,NN,O
,despite,IN,O
,the,DT,O
,absence,NN,O
,of,IN,O
,known,VBN,O
,risk,NN,O
,factors,NNS,O
,.,.,O
,Screening,NNP,O
,",",",",O
,including,VBG,O
,Humphrey,NNP,O
,10,CD,O
,-,:,O
,2,CD,O
,visual,JJ,O
,field,NN,O
,assessment,NN,O
,",",",",O
,is,VBZ,O
,recommended,VBN,O
,2,CD,O
,years,NNS,O
,after,IN,O
,the,DT,O
,initial,JJ,O
,baseline,NN,O
,and,CC,O
,yearly,RB,O
,thereafter,RB,O
,.,.,O
,Peri,NNP,O
,-,:,O
,operative,JJ,O
,atrioventricular,JJ,B-DISEASE
,block,NN,I-DISEASE
,as,IN,O
,a,DT,O
,result,NN,O
,of,IN,O
,chemotherapy,NN,O
,with,IN,O
,epirubicin,NN,O
,and,CC,O
,paclitaxel,NN,O
,.,.,O
,A,DT,O
,47,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,presented,VBD,O
,for,IN,O
,mastectomy,NN,O
,and,CC,O
,immediate,JJ,O
,latissimus,NN,O
,dorsi,NN,O
,flap,NN,O
,reconstruction,NN,O
,having,VBG,O
,been,VBN,O
,diagnosed,VBN,O
,with,IN,O
,carcinoma,NN,B-DISEASE
,of,IN,I-DISEASE
,the,DT,I-DISEASE
,breast,NN,I-DISEASE
,6,CD,O
,months,NNS,O
,previously,RB,O
,.,.,O
,In,IN,O
,the,DT,O
,preceding,JJ,O
,months,NNS,O
,she,PRP,O
,had,VBD,O
,received,VBN,O
,neo,JJ,O
,-,:,O
,adjuvant,JJ,O
,chemotherapy,NN,O
,with,IN,O
,epirubicin,NN,O
,",",",",O
,paclitaxel,NN,O
,(,(,O
,Taxol,NNP,O
,),),O
,and,CC,O
,cyclophosphamide,NN,O
,.,.,O
,This,DT,O
,had,VBD,O
,been,VBN,O
,apparently,RB,O
,uncomplicated,JJ,O
,and,CC,O
,she,PRP,O
,had,VBD,O
,maintained,VBN,O
,a,DT,O
,remarkably,RB,O
,high,JJ,O
,level,NN,O
,of,IN,O
,physical,JJ,O
,activity,NN,O
,.,.,O
,She,PRP,O
,was,VBD,O
,found,VBN,O
,to,TO,O
,be,VB,O
,bradycardic,VBN,B-DISEASE
,at,IN,O
,pre,JJ,O
,-,:,O
,operative,JJ,O
,assessment,NN,O
,but,CC,O
,had,VBD,O
,no,DT,O
,cardiac,NN,O
,symptoms,NNS,O
,.,.,O
,Second,JJ,O
,degree,NN,O
,Mobitz,NNP,O
,type,NN,O
,II,NNP,O
,atrioventricular,NN,B-DISEASE
,block,NN,I-DISEASE
,was,VBD,O
,diagnosed,VBN,O
,on,IN,O
,electrocardiogram,NN,O
,",",",",O
,and,CC,O
,temporary,JJ,O
,transvenous,JJ,O
,ventricular,NN,O
,pacing,NN,O
,instituted,VBN,O
,in,IN,O
,the,DT,O
,peri,NN,O
,-,:,O
,operative,JJ,O
,period,NN,O
,.,.,O
,We,PRP,O
,discuss,VBP,O
,how,WRB,O
,evidence,NN,O
,-,:,O
,based,VBN,O
,guidelines,NNS,O
,would,MD,O
,not,RB,O
,have,VB,O
,been,VBN,O
,helpful,JJ,O
,in,IN,O
,this,DT,O
,case,NN,O
,",",",",O
,and,CC,O
,how,WRB,O
,chemotherapy,NN,O
,can,MD,O
,exhibit,VB,O
,substantial,JJ,O
,cardiotoxicity,NN,B-DISEASE
,that,WDT,O
,may,MD,O
,develop,VB,O
,over,IN,O
,many,JJ,O
,years,NNS,O
,.,.,O
,We,PRP,O
,suggest,VBP,O
,that,IN,O
,patients,NNS,O
,who,WP,O
,have,VBP,O
,received,VBN,O
,chemotherapy,NN,O
,at,IN,O
,any,DT,O
,time,NN,O
,should,MD,O
,have,VB,O
,a,DT,O
,pre,JJ,O
,-,:,O
,operative,JJ,O
,electrocardiogram,NN,O
,even,RB,O
,if,IN,O
,they,PRP,O
,are,VBP,O
,asymptomatic,JJ,O
,.,.,O
,Risks,NNS,O
,and,CC,O
,benefits,NNS,O
,of,IN,O
,COX,NNP,O
,-,:,O
,2,CD,O
,inhibitors,NNS,O
,vs,VBP,O
,non,JJ,O
,-,:,O
,selective,JJ,O
,NSAIDs,NN,O
,:,:,O
,does,VBZ,O
,their,PRP$,O
,cardiovascular,JJ,O
,risk,NN,O
,exceed,VBP,O
,their,PRP$,O
,gastrointestinal,JJ,O
,benefit,NN,O
,?,.,O
,A,DT,O
,retrospective,JJ,O
,cohort,NN,O
,study,NN,O
,.,.,O
,OBJECTIVES,CC,O
,:,:,O
,The,DT,O
,risk,NN,O
,of,IN,O
,acute,JJ,B-DISEASE
,myocardial,JJ,I-DISEASE
,infarction,NN,I-DISEASE
,(,(,O
,AMI,NNP,B-DISEASE
,),),O
,with,IN,O
,COX,NNP,O
,-,:,O
,2,CD,O
,inhibitors,NNS,O
,may,MD,O
,offset,VB,O
,their,PRP$,O
,gastrointestinal,JJ,O
,(,(,O
,GI,NNP,O
,),),O
,benefit,NN,O
,compared,VBN,O
,with,IN,O
,non,JJ,O
,-,:,O
,selective,NN,O
,(,(,O
,NS,NNP,O
,),),O
,non,SYM,O
,-,:,O
,steroidal,NN,O
,anti,SYM,O
,-,:,O
,inflammatory,NN,O
,drugs,NNS,O
,(,(,O
,NSAIDs,NNP,O
,),),O
,.,.,O
,We,PRP,O
,aimed,VBD,O
,to,TO,O
,compare,VB,O
,the,DT,O
,risks,NNS,O
,of,IN,O
,hospitalization,NN,O
,for,IN,O
,AMI,NNP,B-DISEASE
,and,CC,O
,GI,NNP,B-DISEASE
,bleeding,NN,I-DISEASE
,among,IN,O
,elderly,JJ,O
,patients,NNS,O
,using,VBG,O
,COX,NNP,O
,-,:,O
,2,CD,O
,inhibitors,NNS,O
,",",",",O
,NS,NNP,O
,-,:,O
,NSAIDs,NN,O
,and,CC,O
,acetaminophen,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,We,PRP,O
,conducted,VBD,O
,a,DT,O
,retrospective,JJ,O
,cohort,NN,O
,study,NN,O
,using,VBG,O
,administrative,JJ,O
,data,NNS,O
,of,IN,O
,patients,NNS,O
,>,VBP,O
,or,CC,O
,=,VBP,O
,65,CD,O
,years,NNS,O
,of,IN,O
,age,NN,O
,who,WP,O
,filled,VBD,O
,a,DT,O
,prescription,NN,O
,for,IN,O
,NSAID,NNP,O
,or,CC,O
,acetaminophen,NN,O
,during,IN,O
,1999,CD,O
,-,:,O
,2002,CD,O
,.,.,O
,Outcomes,NNPS,O
,were,VBD,O
,compared,VBN,O
,using,VBG,O
,Cox,NNP,O
,regression,NN,O
,models,NNS,O
,with,IN,O
,time,NN,O
,-,:,O
,dependent,JJ,O
,exposures,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Person,NNP,O
,-,:,O
,years,NNS,O
,of,IN,O
,exposure,NN,O
,among,IN,O
,non,JJ,O
,-,:,O
,users,NNS,O
,of,IN,O
,aspirin,NNS,O
,were,VBD,O
,:,:,O
,75,CD,O
,",",",",O
,761,CD,O
,to,TO,O
,acetaminophen,VB,O
,",",",",O
,42,CD,O
,",",",",O
,671,CD,O
,to,TO,O
,rofecoxib,VB,O
,65,CD,O
,",",",",O
,860,CD,O
,to,TO,O
,celecoxib,VB,O
,",",",",O
,and,CC,O
,37,CD,O
,",",",",O
,495,CD,O
,to,TO,O
,NS,NNP,O
,-,:,O
,NSAIDs,NNP,O
,.,.,O
,Among,IN,O
,users,NNS,O
,of,IN,O
,aspirin,NN,O
,",",",",O
,they,PRP,O
,were,VBD,O
,:,:,O
,14,CD,O
,",",",",O
,671,CD,O
,to,TO,O
,rofecoxib,VB,O
,",",",",O
,22,CD,O
,",",",",O
,875,CD,O
,to,TO,O
,celecoxib,VB,O
,",",",",O
,9,CD,O
,",",",",O
,832,CD,O
,to,TO,O
,NS,NNP,O
,-,:,O
,NSAIDs,NNP,O
,and,CC,O
,38,CD,O
,",",",",O
,048,CD,O
,to,TO,O
,acetaminophen,VB,O
,.,.,O
,Among,IN,O
,non,JJ,O
,-,:,O
,users,NNS,O
,of,IN,O
,aspirin,NN,O
,",",",",O
,the,DT,O
,adjusted,VBN,O
,hazard,NN,O
,ratios,NNS,O
,(,(,O
,95,CD,O
,%,NN,O
,confidence,NN,O
,interval,NN,O
,),),O
,of,IN,O
,hospitalization,NN,O
,for,IN,O
,AMI,NNP,B-DISEASE
,/,NNP,O
,GI,NNP,O
,vs,VBD,O
,the,DT,O
,acetaminophen,NN,O
,(,(,O
,with,IN,O
,no,DT,O
,aspirin,NN,O
,),),O
,group,NN,O
,were,VBD,O
,:,:,O
,rofecoxib,NN,O
,1,CD,O
,.,.,O
,27,CD,O
,(,(,O
,1,CD,O
,.,.,O
,13,CD,O
,",",",",O
,1,CD,O
,.,.,O
,42,CD,O
,),),O
,",",",",O
,celecoxib,JJ,O
,0,CD,O
,.,.,O
,93,CD,O
,(,(,O
,0,CD,O
,.,.,O
,83,CD,O
,",",",",O
,1,CD,O
,.,.,O
,03,CD,O
,),),O
,",",",",O
,naproxen,RB,O
,1,CD,O
,.,.,O
,59,CD,O
,(,(,O
,1,CD,O
,.,.,O
,31,CD,O
,",",",",O
,1,CD,O
,.,.,O
,93,CD,O
,),),O
,",",",",O
,diclofenac,JJ,O
,1,CD,O
,.,.,O
,17,CD,O
,(,(,O
,0,CD,O
,.,.,O
,99,CD,O
,",",",",O
,1,CD,O
,.,.,O
,38,CD,O
,),),O
,and,CC,O
,ibuprofen,$,O
,1,CD,O
,.,.,O
,05,CD,O
,(,(,O
,0,CD,O
,.,.,O
,74,CD,O
,",",",",O
,1,CD,O
,.,.,O
,51,CD,O
,),),O
,.,.,O
,Among,IN,O
,users,NNS,O
,of,IN,O
,aspirin,NN,O
,",",",",O
,they,PRP,O
,were,VBD,O
,:,:,O
,rofecoxib,NN,O
,1,CD,O
,.,.,O
,73,CD,O
,(,(,O
,1,CD,O
,.,.,O
,52,CD,O
,",",",",O
,1,CD,O
,.,.,O
,98,CD,O
,),),O
,",",",",O
,celecoxib,JJ,O
,1,CD,O
,.,.,O
,34,CD,O
,(,(,O
,1,CD,O
,.,.,O
,19,CD,O
,",",",",O
,1,CD,O
,.,.,O
,52,CD,O
,),),O
,",",",",O
,ibuprofen,JJ,O
,1,CD,O
,.,.,O
,51,CD,O
,(,(,O
,0,CD,O
,.,.,O
,95,CD,O
,",",",",O
,2,CD,O
,.,.,O
,41,CD,O
,),),O
,",",",",O
,diclofenac,JJ,O
,1,CD,O
,.,.,O
,69,CD,O
,(,(,O
,1,CD,O
,.,.,O
,35,CD,O
,",",",",O
,2,CD,O
,.,.,O
,10,CD,O
,),),O
,",",",",O
,naproxen,RB,O
,1,CD,O
,.,.,O
,35,CD,O
,(,(,O
,0,CD,O
,.,.,O
,97,CD,O
,",",",",O
,1,CD,O
,.,.,O
,88,CD,O
,),),O
,and,CC,O
,acetaminophen,$,O
,1,CD,O
,.,.,O
,29,CD,O
,(,(,O
,1,CD,O
,.,.,O
,17,CD,O
,",",",",O
,1,CD,O
,.,.,O
,42,CD,O
,),),O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Among,IN,O
,non,JJ,O
,-,:,O
,users,NNS,O
,of,IN,O
,aspirin,NN,O
,",",",",O
,naproxen,RB,O
,seemed,VBD,O
,to,TO,O
,carry,VB,O
,the,DT,O
,highest,JJS,O
,risk,NN,O
,for,IN,O
,AMI,NNP,B-DISEASE
,/,NNP,O
,GI,NNP,B-DISEASE
,bleeding,NN,I-DISEASE
,.,.,O
,The,DT,O
,AMI,NNP,B-DISEASE
,/,NNP,O
,GI,NNP,O
,toxicity,NN,B-DISEASE
,of,IN,O
,celecoxib,NN,O
,was,VBD,O
,similar,JJ,O
,to,TO,O
,that,DT,O
,of,IN,O
,acetaminophen,NN,O
,and,CC,O
,seemed,VBD,O
,to,TO,O
,be,VB,O
,better,JJR,O
,than,IN,O
,those,DT,O
,of,IN,O
,rofecoxib,NN,O
,and,CC,O
,NS,NNP,O
,-,:,O
,NSAIDs,NNP,O
,.,.,O
,Among,IN,O
,users,NNS,O
,of,IN,O
,aspirin,NN,O
,",",",",O
,both,DT,O
,celecoxib,NNS,O
,and,CC,O
,naproxen,NN,O
,seemed,VBD,O
,to,TO,O
,be,VB,O
,the,DT,O
,least,JJS,O
,toxic,JJ,O
,.,.,O
,Quinine,NNP,O
,-,:,O
,induced,VBD,O
,arrhythmia,NN,B-DISEASE
,in,IN,O
,a,DT,O
,patient,NN,O
,with,IN,O
,severe,JJ,B-DISEASE
,malaria,NNS,I-DISEASE
,.,.,O
,It,PRP,O
,was,VBD,O
,reported,VBN,O
,that,IN,O
,there,EX,O
,was,VBD,O
,a,DT,O
,case,NN,O
,of,IN,O
,severe,JJ,B-DISEASE
,malaria,NNS,I-DISEASE
,patient,JJ,O
,with,IN,O
,jaundice,NN,B-DISEASE
,who,WP,O
,presented,VBD,O
,with,IN,O
,arrhythmia,NN,B-DISEASE
,(,(,O
,premature,JJ,B-DISEASE
,ventricular,JJ,I-DISEASE
,contraction,NN,I-DISEASE
,),),O
,while,IN,O
,getting,VBG,O
,quinine,JJ,O
,infusion,NN,O
,was,VBD,O
,reported,VBN,O
,.,.,O
,A,DT,O
,man,NN,O
,",",",",O
,25,CD,O
,years,NNS,O
,old,JJ,O
,",",",",O
,was,VBD,O
,admitted,VBN,O
,to,TO,O
,hospital,VB,O
,with,IN,O
,high,JJ,O
,fever,NN,B-DISEASE
,",",",",O
,chill,NN,B-DISEASE
,",",",",O
,vomiting,VBG,B-DISEASE
,",",",",O
,jaundice,NN,B-DISEASE
,.,.,O
,The,DT,O
,patient,NN,O
,was,VBD,O
,fully,RB,O
,conscious,JJ,O
,",",",",O
,blood,NN,O
,pressure,NN,O
,120,CD,O
,/,NN,O
,80,CD,O
,mmHg,NN,O
,",",",",O
,pulse,JJ,O
,rate,NN,O
,100,CD,O
,x,NN,O
,/,NNP,O
,minute,NN,O
,",",",",O
,regular,JJ,O
,.,.,O
,On,IN,O
,admission,NN,O
,",",",",O
,laboratory,NN,O
,examination,NN,O
,showed,VBD,O
,Plasmodium,NNP,O
,falciparum,NN,O
,(,(,O
,+,JJ,O
,+,NNP,O
,+,NNP,O
,+,NNP,O
,),),O
,",",",",O
,total,JJ,O
,bilirubin,NN,O
,8,CD,O
,.,.,O
,25,CD,O
,mg,JJ,O
,/,NNP,O
,dL,NN,O
,",",",",O
,conjugated,VBD,O
,bilirubin,JJ,O
,4,CD,O
,.,.,O
,36,CD,O
,mg,JJ,O
,/,NNP,O
,dL,NN,O
,",",",",O
,unconjugated,JJ,O
,bilirubin,NN,O
,3,CD,O
,.,.,O
,89,CD,O
,mg,JJ,O
,/,NNP,O
,dL,NN,O
,",",",",O
,potassium,NN,O
,3,CD,O
,.,.,O
,52,CD,O
,meq,JJ,O
,/,NNP,O
,L,NNP,O
,Patient,NNP,O
,was,VBD,O
,diagnosed,VBN,O
,as,IN,O
,severe,JJ,B-DISEASE
,malaria,NN,I-DISEASE
,with,IN,O
,jaundice,NN,B-DISEASE
,and,CC,O
,got,VBD,O
,quinine,JJ,O
,infusion,NN,O
,in,IN,O
,dextrose,JJ,O
,5,CD,O
,%,NN,O
,500,CD,O
,mg,NN,O
,/,VBD,O
,8,CD,O
,hour,NN,O
,.,.,O
,On,IN,O
,the,DT,O
,second,JJ,O
,day,NN,O
,the,DT,O
,patient,NN,O
,had,VBD,O
,vomitus,NN,B-DISEASE
,",",",",O
,diarrhea,NN,B-DISEASE
,",",",",O
,tinnitus,NN,B-DISEASE
,",",",",O
,loss,NN,B-DISEASE
,of,IN,I-DISEASE
,hearing,VBG,I-DISEASE
,.,.,O
,After,IN,O
,30,CD,O
,hours,NNS,O
,of,IN,O
,quinine,JJ,O
,infusion,NN,O
,the,DT,O
,patient,NN,O
,felt,VBD,O
,palpitation,NN,B-DISEASE
,and,CC,O
,electrocardiography,NN,O
,(,(,O
,ECG,NNP,O
,),),O
,recording,NN,O
,showed,VBD,O
,premature,JJ,B-DISEASE
,ventricular,JJ,I-DISEASE
,contraction,NN,I-DISEASE
,(,(,O
,PVC,NNP,B-DISEASE
,),),O
,>,VBD,O
,5,CD,O
,x,NNP,O
,/,NNP,O
,minute,NN,O
,",",",",O
,trigemini,NN,O
,",",",",O
,constant,JJ,O
,type,NN,O
,-,:,O
,-,:,O
,sinoatrial,JJ,B-DISEASE
,block,NN,I-DISEASE
,",",",",O
,positive,JJ,O
,U,NNP,O
,wave,NN,O
,.,.,O
,He,PRP,O
,was,VBD,O
,treated,VBN,O
,with,IN,O
,lidocaine,JJ,O
,50,CD,O
,mg,NN,O
,intravenously,RB,O
,followed,VBN,O
,by,IN,O
,infusion,NN,O
,1500,CD,O
,mg,NN,O
,in,IN,O
,dextrose,JJ,O
,5,CD,O
,%,NN,O
,/,CC,O
,24,CD,O
,hour,NN,O
,and,CC,O
,potassium,NN,O
,aspartate,NN,O
,tablet,NN,O
,.,.,O
,Quinine,NNP,O
,infusion,NN,O
,was,VBD,O
,discontinued,VBN,O
,and,CC,O
,changed,VBN,O
,with,IN,O
,sulfate,JJ,O
,quinine,JJ,O
,tablets,NNS,O
,.,.,O
,Three,CD,O
,hours,NNS,O
,later,RB,O
,the,DT,O
,patient,NN,O
,felt,VBD,O
,better,RBR,O
,",",",",O
,the,DT,O
,frequency,NN,O
,of,IN,O
,PVC,NNP,B-DISEASE
,reduced,VBD,O
,to,TO,O
,4,CD,O
,-,:,O
,5,CD,O
,x,NNS,O
,/,JJ,O
,minute,NN,O
,and,CC,O
,on,IN,O
,the,DT,O
,third,JJ,O
,day,NN,O
,ECG,NNP,O
,was,VBD,O
,normal,JJ,O
,",",",",O
,potassium,JJ,O
,level,NN,O
,was,VBD,O
,3,CD,O
,.,.,O
,34,CD,O
,meq,JJ,O
,/,NNP,O
,L,NNP,O
,.,.,O
,He,PRP,O
,was,VBD,O
,discharged,VBN,O
,on,IN,O
,7th,CD,O
,day,NN,O
,in,IN,O
,good,JJ,O
,condition,NN,O
,.,.,O
,Quinine,NNP,O
,",",",",O
,like,IN,O
,quinidine,NN,O
,",",",",O
,is,VBZ,O
,a,DT,O
,chincona,JJ,O
,alkaloid,NN,O
,that,WDT,O
,has,VBZ,O
,anti,VBN,O
,-,:,O
,arrhythmic,JJ,B-DISEASE
,property,NN,O
,",",",",O
,although,IN,O
,it,PRP,O
,also,RB,O
,pro,VBZ,O
,-,:,O
,arrhythmic,NN,B-DISEASE
,that,WDT,O
,can,MD,O
,cause,VB,O
,various,JJ,O
,arrhythmias,NNS,B-DISEASE
,",",",",O
,including,VBG,O
,severe,JJ,O
,arrhythmia,NN,B-DISEASE
,such,JJ,O
,as,IN,O
,multiple,JJ,O
,PVC,NNP,B-DISEASE
,.,.,O
,Administration,NNP,O
,of,IN,O
,parenteral,JJ,O
,quinine,NN,O
,must,MD,O
,be,VB,O
,done,VBN,O
,carefully,RB,O
,and,CC,O
,with,IN,O
,good,JJ,O
,observation,NN,O
,because,IN,O
,of,IN,O
,its,PRP$,O
,pro,JJ,O
,-,:,O
,arrhythmic,JJ,B-DISEASE
,effect,NN,O
,",",",",O
,especially,RB,O
,in,IN,O
,older,JJR,O
,patients,NNS,O
,who,WP,O
,have,VBP,O
,heart,NN,B-DISEASE
,diseases,NNS,I-DISEASE
,or,CC,O
,patients,NNS,O
,with,IN,O
,electrolyte,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,(,(,O
,hypokalemia,NN,B-DISEASE
,),),O
,which,WDT,O
,frequently,RB,O
,occurs,VBZ,O
,due,JJ,O
,to,TO,O
,vomiting,VBG,B-DISEASE
,and,CC,O
,or,CC,O
,diarrhea,VB,B-DISEASE
,in,IN,O
,malaria,NN,B-DISEASE
,cases,NNS,O
,.,.,O
,Penicillamine,NNP,O
,-,:,O
,related,JJ,O
,lichenoid,JJ,B-DISEASE
,dermatitis,NN,I-DISEASE
,and,CC,O
,utility,NN,O
,of,IN,O
,zinc,NN,O
,acetate,NN,O
,in,IN,O
,a,DT,O
,Wilson,NNP,B-DISEASE
,disease,NN,I-DISEASE
,patient,NN,O
,with,IN,O
,hepatic,JJ,O
,presentation,NN,O
,",",",",O
,anxiety,NN,B-DISEASE
,and,CC,O
,SPECT,NNP,O
,abnormalities,NNS,O
,.,.,O
,Wilson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,is,VBZ,O
,an,DT,O
,autosomal,JJ,O
,recessive,JJ,O
,disorder,NN,O
,of,IN,O
,hepatic,JJ,O
,copper,NN,O
,metabolism,NN,O
,with,IN,O
,consequent,JJ,O
,copper,NN,O
,accumulation,NN,O
,and,CC,O
,toxicity,NN,B-DISEASE
,in,IN,O
,many,JJ,O
,tissues,NNS,O
,and,CC,O
,consequent,JJ,O
,hepatic,NN,B-DISEASE
,",",",",I-DISEASE
,neurologic,JJ,I-DISEASE
,and,CC,I-DISEASE
,psychiatric,JJ,I-DISEASE
,disorders,NNS,I-DISEASE
,.,.,O
,We,PRP,O
,report,VBP,O
,a,DT,O
,case,NN,O
,of,IN,O
,Wilson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,with,IN,O
,chronic,JJ,B-DISEASE
,liver,NN,I-DISEASE
,disease,NN,I-DISEASE
,;,:,O
,moreover,RB,O
,",",",",O
,in,IN,O
,our,PRP$,O
,patient,NN,O
,",",",",O
,presenting,VBG,O
,also,RB,O
,with,IN,O
,high,JJ,O
,levels,NNS,O
,of,IN,O
,state,NN,O
,anxiety,NN,B-DISEASE
,without,IN,O
,depression,NN,B-DISEASE
,",",",",O
,99mTc,CD,O
,-,:,O
,ECD,NNP,O
,-,:,O
,SPECT,NN,O
,showed,VBD,O
,cortical,JJ,O
,hypoperfusion,NN,O
,in,IN,O
,frontal,JJ,O
,lobes,NN,O
,",",",",O
,more,JJR,O
,marked,VBN,O
,on,IN,O
,the,DT,O
,left,JJ,O
,frontal,JJ,O
,lobe,NN,O
,.,.,O
,During,IN,O
,the,DT,O
,follow,JJ,O
,-,:,O
,up,IN,O
,of,IN,O
,our,PRP$,O
,patient,NN,O
,",",",",O
,penicillamine,NN,O
,was,VBD,O
,interrupted,VBN,O
,after,IN,O
,the,DT,O
,appearance,NN,O
,of,IN,O
,a,DT,O
,lichenoid,JJ,B-DISEASE
,dermatitis,NN,I-DISEASE
,",",",",O
,and,CC,O
,zinc,NN,O
,acetate,NN,O
,permitted,VBD,O
,to,TO,O
,continue,VB,O
,the,DT,O
,successful,JJ,O
,treatment,NN,O
,of,IN,O
,the,DT,O
,patient,NN,O
,without,IN,O
,side,JJ,O
,-,:,O
,effects,NNS,O
,.,.,O
,In,IN,O
,our,PRP$,O
,case,NN,O
,the,DT,O
,therapy,NN,O
,with,IN,O
,zinc,NN,O
,acetate,NN,O
,represented,VBD,O
,an,DT,O
,effective,JJ,O
,treatment,NN,O
,for,IN,O
,a,DT,O
,Wilson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,patient,NN,O
,in,IN,O
,which,WDT,O
,penicillamine,VBP,O
,-,:,O
,related,JJ,O
,side,NN,O
,effects,NNS,O
,appeared,VBD,O
,.,.,O
,The,DT,O
,safety,NN,O
,of,IN,O
,the,DT,O
,zinc,NN,O
,acetate,NN,O
,allowed,VBD,O
,us,PRP,O
,to,TO,O
,avoid,VB,O
,other,JJ,O
,potentially,RB,O
,toxic,JJ,O
,chelating,VBG,O
,drugs,NNS,O
,;,:,O
,this,DT,O
,observation,NN,O
,is,VBZ,O
,in,IN,O
,line,NN,O
,with,IN,O
,the,DT,O
,growing,VBG,O
,evidence,NN,O
,on,IN,O
,the,DT,O
,efficacy,NN,O
,of,IN,O
,the,DT,O
,drug,NN,O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,Wilson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,Since,IN,O
,most,JJS,O
,of,IN,O
,Wilson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,penicillamine,NN,O
,-,:,O
,treated,JJ,O
,patients,NNS,O
,do,VBP,O
,not,RB,O
,seem,VB,O
,to,TO,O
,develop,VB,O
,this,DT,O
,skin,NN,B-DISEASE
,lesion,NN,I-DISEASE
,",",",",O
,it,PRP,O
,could,MD,O
,be,VB,O
,conceivable,JJ,O
,that,IN,O
,a,DT,O
,specific,JJ,O
,genetic,JJ,O
,factor,NN,O
,is,VBZ,O
,involved,VBN,O
,in,IN,O
,drug,NN,O
,response,NN,O
,.,.,O
,Further,JJ,O
,studies,NNS,O
,are,VBP,O
,needed,VBN,O
,for,IN,O
,a,DT,O
,better,JJR,O
,clarification,NN,O
,of,IN,O
,Wilson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,therapy,NN,O
,",",",",O
,and,CC,O
,in,IN,O
,particular,JJ,O
,to,TO,O
,differentiate,VB,O
,specific,JJ,O
,therapies,NNS,O
,for,IN,O
,different,JJ,O
,Wilson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,phenotypes,NNS,O
,.,.,O
,A,NNP,O
,dramatic,JJ,O
,drop,NN,B-DISEASE
,in,IN,I-DISEASE
,blood,NN,I-DISEASE
,pressure,NN,I-DISEASE
,following,VBG,O
,prehospital,JJ,O
,GTN,NNP,O
,administration,NN,O
,.,.,O
,A,DT,O
,male,NN,O
,in,IN,O
,his,PRP$,O
,sixties,NNS,O
,with,IN,O
,no,DT,O
,history,NN,O
,of,IN,O
,cardiac,JJ,O
,chest,NN,B-DISEASE
,pain,NN,I-DISEASE
,awoke,VBD,O
,with,IN,O
,chest,NN,B-DISEASE
,pain,NN,I-DISEASE
,following,VBG,O
,an,DT,O
,afternoon,NN,O
,sleep,NN,O
,.,.,O
,The,DT,O
,patient,NN,O
,did,VBD,O
,not,RB,O
,self,VB,O
,medicate,NN,O
,.,.,O
,The,DT,O
,patient,NN,O
,',POS,O
,s,JJ,O
,observations,NNS,O
,were,VBD,O
,within,IN,O
,normal,JJ,O
,limits,NNS,O
,",",",",O
,he,PRP,O
,was,VBD,O
,administered,VBN,O
,oxygen,NN,O
,via,IN,O
,a,DT,O
,face,NN,O
,mask,NN,O
,and,CC,O
,glyceryl,NN,O
,trinitrate,NN,O
,(,(,O
,GTN,NNP,O
,),),O
,.,.,O
,Several,JJ,O
,minutes,NNS,O
,after,IN,O
,the,DT,O
,GTN,NNP,O
,the,DT,O
,patient,NN,O
,experienced,VBD,O
,a,DT,O
,sudden,JJ,O
,drop,NN,B-DISEASE
,in,IN,I-DISEASE
,blood,NN,I-DISEASE
,pressure,NN,I-DISEASE
,and,CC,O
,heart,NN,O
,rate,NN,O
,",",",",O
,this,DT,O
,was,VBD,O
,rectified,VBN,O
,by,IN,O
,atropine,JJ,O
,sulphate,NN,O
,and,CC,O
,a,DT,O
,fluid,NN,O
,challenge,NN,O
,.,.,O
,There,EX,O
,was,VBD,O
,no,DT,O
,further,JJ,O
,deterioration,NN,O
,in,IN,O
,the,DT,O
,patient,NN,O
,',POS,O
,s,JJ,O
,condition,NN,O
,during,IN,O
,transport,NN,O
,to,TO,O
,hospital,NN,O
,.,.,O
,There,EX,O
,are,VBP,O
,very,RB,O
,few,JJ,O
,documented,JJ,O
,case,NN,O
,like,IN,O
,this,DT,O
,in,IN,O
,the,DT,O
,prehospital,JJ,O
,scientific,JJ,O
,literature,NN,O
,.,.,O
,The,DT,O
,cause,NN,O
,appears,VBZ,O
,to,TO,O
,be,VB,O
,the,DT,O
,Bezold,NNP,O
,-,:,O
,Jarish,JJ,O
,reflex,NN,O
,",",",",O
,stimulation,NN,O
,of,IN,O
,the,DT,O
,ventricular,NN,O
,walls,NNS,O
,which,WDT,O
,in,IN,O
,turn,NN,O
,decreases,NNS,O
,sympathetic,JJ,O
,outflow,IN,O
,from,IN,O
,the,DT,O
,vasomotor,NN,O
,centre,NN,O
,.,.,O
,Prehospital,NNP,O
,care,NN,O
,providers,NNS,O
,who,WP,O
,are,VBP,O
,managing,VBG,O
,any,DT,O
,patient,NN,O
,with,IN,O
,a,DT,O
,syncopal,JJ,B-DISEASE
,episode,NN,I-DISEASE
,that,WDT,O
,fails,VBZ,O
,to,TO,O
,recover,VB,O
,within,IN,O
,a,DT,O
,reasonable,JJ,O
,time,NN,O
,frame,NN,O
,should,MD,O
,consider,VB,O
,the,DT,O
,Bezold,NNP,O
,-,:,O
,Jarisch,NNP,O
,reflex,NN,O
,as,IN,O
,the,DT,O
,cause,NN,O
,and,CC,O
,manage,VB,O
,the,DT,O
,patient,NN,O
,accordingly,RB,O
,.,.,O
,Chronic,JJ,O
,lesion,NN,O
,of,IN,O
,rostral,JJ,O
,ventrolateral,JJ,O
,medulla,NN,O
,in,IN,O
,spontaneously,RB,O
,hypertensive,JJ,B-DISEASE
,rats,NNS,O
,.,.,O
,We,PRP,O
,studied,VBD,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,chronic,JJ,O
,selective,JJ,O
,neuronal,JJ,O
,lesion,NN,O
,of,IN,O
,rostral,JJ,O
,ventrolateral,JJ,O
,medulla,NN,O
,on,IN,O
,mean,JJ,O
,arterial,JJ,O
,pressure,NN,O
,",",",",O
,heart,NN,O
,rate,NN,O
,",",",",O
,and,CC,O
,neurogenic,JJ,O
,tone,NN,O
,in,IN,O
,conscious,JJ,O
,",",",",O
,unrestrained,JJ,O
,spontaneously,RB,O
,hypertensive,JJ,B-DISEASE
,rats,NNS,O
,.,.,O
,The,DT,O
,lesions,NNS,O
,were,VBD,O
,placed,VBN,O
,via,IN,O
,bilateral,JJ,O
,microinjections,NNS,O
,of,IN,O
,30,CD,O
,nmol,JJ,O
,/,$,O
,200,CD,O
,nl,JJ,O
,N,NNP,O
,-,:,O
,methyl,NN,O
,-,:,O
,D,NNP,O
,-,:,O
,aspartic,JJ,O
,acid,NN,O
,.,.,O
,The,DT,O
,restimulation,NN,O
,of,IN,O
,this,DT,O
,area,NN,O
,with,IN,O
,N,NNP,O
,-,:,O
,methyl,NN,O
,-,:,O
,D,NNP,O
,-,:,O
,aspartic,JJ,O
,acid,NN,O
,15,CD,O
,days,NNS,O
,postlesion,NN,O
,failed,VBD,O
,to,TO,O
,produce,VB,O
,a,DT,O
,pressor,NN,O
,response,NN,O
,.,.,O
,One,CD,O
,day,NN,O
,postlesion,NN,O
,",",",",O
,the,DT,O
,resting,VBG,O
,mean,JJ,O
,arterial,JJ,O
,pressure,NN,O
,was,VBD,O
,significantly,RB,O
,decreased,VBN,O
,in,IN,O
,lesioned,JJ,O
,rats,NNS,O
,when,WRB,O
,compared,VBN,O
,with,IN,O
,sham,NN,O
,rats,NNS,O
,(,(,O
,100,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,7,CD,O
,versus,NN,O
,173,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,4,CD,O
,mm,NN,O
,Hg,NNP,O
,",",",",O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,Fifteen,NNP,O
,days,NNS,O
,later,RB,O
,",",",",O
,the,DT,O
,lesioned,VBN,O
,group,NN,O
,still,RB,O
,showed,VBD,O
,values,NNS,O
,significantly,RB,O
,lower,JJR,O
,than,IN,O
,the,DT,O
,sham,NN,O
,group,NN,O
,(,(,O
,150,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,6,CD,O
,versus,NN,O
,167,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,5,CD,O
,mm,NN,O
,Hg,NNP,O
,",",",",O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,No,DT,O
,significant,JJ,O
,heart,NN,O
,rate,NN,O
,differences,NNS,O
,were,VBD,O
,observed,VBN,O
,between,IN,O
,the,DT,O
,sham,NN,O
,and,CC,O
,lesioned,VBD,O
,groups,NNS,O
,.,.,O
,The,DT,O
,ganglionic,JJ,O
,blocker,NN,O
,trimethaphan,NN,O
,(,(,O
,5,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,),),O
,caused,VBD,O
,similar,JJ,O
,reductions,NNS,O
,in,IN,O
,mean,JJ,O
,arterial,JJ,O
,pressure,NN,O
,in,IN,O
,both,DT,O
,lesioned,JJ,O
,and,CC,O
,sham,JJ,O
,groups,NNS,O
,.,.,O
,The,DT,O
,trimethaphan,JJ,O
,-,:,O
,induced,JJ,O
,hypotension,NN,B-DISEASE
,was,VBD,O
,accompanied,VBN,O
,by,IN,O
,a,DT,O
,significant,JJ,O
,bradycardia,NN,B-DISEASE
,in,IN,O
,lesioned,JJ,O
,rats,NNS,O
,(,(,O
,-,:,O
,32,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,13,CD,O
,beats,NNS,O
,per,IN,O
,minute,NN,O
,),),O
,but,CC,O
,a,DT,O
,tachycardia,NN,B-DISEASE
,in,IN,O
,sham,NN,O
,rats,NNS,O
,(,(,O
,+,$,O
,33,CD,O
,+,NNP,O
,/,NNP,O
,-,:,O
,12,CD,O
,beats,NNS,O
,per,IN,O
,minute,NN,O
,),),O
,1,CD,O
,day,NN,O
,postlesion,NN,O
,.,.,O
,Therefore,RB,O
,",",",",O
,rostral,JJ,O
,ventrolateral,JJ,O
,medulla,NN,O
,neurons,NNS,O
,appear,VBP,O
,to,TO,O
,play,VB,O
,a,DT,O
,significant,JJ,O
,role,NN,O
,in,IN,O
,maintaining,VBG,O
,hypertension,NN,B-DISEASE
,in,IN,O
,conscious,JJ,O
,spontaneously,RB,O
,hypertensive,JJ,B-DISEASE
,rats,NNS,O
,.,.,O
,Spinal,NNP,O
,or,CC,O
,suprabulbar,NN,O
,structures,NNS,O
,could,MD,O
,be,VB,O
,responsible,JJ,O
,for,IN,O
,the,DT,O
,gradual,JJ,O
,recovery,NN,O
,of,IN,O
,the,DT,O
,hypertension,NN,B-DISEASE
,in,IN,O
,the,DT,O
,lesioned,JJ,O
,rats,NNS,O
,.,.,O
,Acute,NNP,B-DISEASE
,encephalopathy,JJ,I-DISEASE
,and,CC,O
,cerebral,JJ,B-DISEASE
,vasospasm,NN,I-DISEASE
,after,IN,O
,multiagent,JJ,O
,chemotherapy,NN,O
,including,VBG,O
,PEG,NNP,O
,-,:,O
,asparaginase,NN,O
,and,CC,O
,intrathecal,JJ,O
,cytarabine,NN,O
,for,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,acute,JJ,B-DISEASE
,lymphoblastic,JJ,I-DISEASE
,leukemia,NN,I-DISEASE
,.,.,O
,A,DT,O
,7,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,girl,NN,O
,with,IN,O
,an,DT,O
,unusual,JJ,O
,reaction,NN,O
,to,TO,O
,induction,NN,O
,chemotherapy,NN,O
,for,IN,O
,precursor,NN,O
,B,NNP,O
,-,:,O
,cell,NN,O
,acute,JJ,B-DISEASE
,lymphoblastic,JJ,I-DISEASE
,leukemia,NN,I-DISEASE
,(,(,O
,ALL,DT,B-DISEASE
,),),O
,is,VBZ,O
,described,VBN,O
,.,.,O
,The,DT,O
,patient,NN,O
,developed,VBD,O
,acute,JJ,B-DISEASE
,encephalopathy,NN,I-DISEASE
,evidenced,VBN,O
,by,IN,O
,behavioral,JJ,O
,changes,NNS,O
,",",",",O
,aphasia,NN,B-DISEASE
,",",",",O
,incontinence,NN,B-DISEASE
,",",",",O
,visual,JJ,B-DISEASE
,hallucinations,NNS,I-DISEASE
,",",",",O
,and,CC,O
,right,JJ,O
,-,:,O
,sided,VBD,O
,weakness,NN,B-DISEASE
,with,IN,O
,diffuse,JJ,O
,cerebral,JJ,B-DISEASE
,vasospasm,NN,I-DISEASE
,on,IN,O
,magnetic,JJ,O
,resonance,NN,O
,angiography,NN,O
,after,IN,O
,the,DT,O
,administration,NN,O
,of,IN,O
,intrathecal,JJ,O
,cytarabine,NN,O
,.,.,O
,Vincristine,NNP,O
,",",",",O
,dexamethasone,NN,O
,",",",",O
,and,CC,O
,polyethylene,NN,O
,glycol,NN,O
,-,:,O
,asparaginase,NN,O
,were,VBD,O
,also,RB,O
,administered,VBN,O
,before,IN,O
,the,DT,O
,episode,NN,O
,as,IN,O
,part,NN,O
,of,IN,O
,induction,NN,O
,therapy,NN,O
,.,.,O
,Neurologic,NNP,O
,status,NN,O
,returned,VBD,O
,to,TO,O
,baseline,VB,O
,within,IN,O
,10,CD,O
,days,NNS,O
,of,IN,O
,the,DT,O
,acute,JJ,O
,event,NN,O
,",",",",O
,and,CC,O
,magnetic,JJ,O
,resonance,NN,O
,angiography,NN,O
,findings,NNS,O
,returned,VBD,O
,to,TO,O
,normal,JJ,O
,4,CD,O
,months,NNS,O
,later,RB,O
,.,.,O
,Comparison,NNP,O
,of,IN,O
,valsartan,JJ,O
,/,NNP,O
,hydrochlorothiazide,NN,O
,combination,NN,O
,therapy,NN,O
,at,IN,O
,doses,VBZ,O
,up,RB,O
,to,TO,O
,320,CD,O
,/,NNS,O
,25,CD,O
,mg,NNS,O
,versus,JJ,O
,monotherapy,NN,O
,:,:,O
,a,DT,O
,double,JJ,O
,-,:,O
,blind,NN,O
,",",",",O
,placebo,SYM,O
,-,:,O
,controlled,VBN,O
,study,NN,O
,followed,VBN,O
,by,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,combination,NN,O
,therapy,NN,O
,in,IN,O
,hypertensive,JJ,B-DISEASE
,adults,NNS,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,One,CD,O
,third,NN,O
,of,IN,O
,patients,NNS,O
,treated,VBN,O
,for,IN,O
,hypertension,NN,B-DISEASE
,attain,NN,O
,adequate,JJ,O
,blood,NN,O
,pressure,NN,O
,(,(,O
,BP,NNP,O
,),),O
,control,NN,O
,",",",",O
,and,CC,O
,multidrug,NN,O
,regimens,NNS,O
,are,VBP,O
,often,RB,O
,required,VBN,O
,.,.,O
,Given,VB,O
,the,DT,O
,lifelong,JJ,O
,nature,NN,O
,of,IN,O
,hypertension,NN,B-DISEASE
,",",",",O
,there,EX,O
,is,VBZ,O
,a,DT,O
,need,NN,O
,to,TO,O
,evaluate,VB,O
,the,DT,O
,long,JJ,O
,-,:,O
,term,NN,O
,efficacy,NN,O
,and,CC,O
,tolerability,NN,O
,of,IN,O
,higher,JJR,O
,doses,NNS,O
,of,IN,O
,combination,NN,O
,anti,SYM,O
,-,:,O
,hypertensive,JJ,B-DISEASE
,therapies,NNS,O
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,This,DT,O
,study,NN,O
,investigated,VBD,O
,the,DT,O
,efficacy,NN,O
,and,CC,O
,tolerability,NN,O
,of,IN,O
,valsartan,NN,O
,(,(,O
,VAL,NNP,O
,),),O
,or,CC,O
,hydrochlorothiazide,NN,O
,(,(,O
,HCTZ,NNP,O
,),),O
,-,:,O
,monotherapy,NN,O
,and,CC,O
,higher,JJR,O
,-,:,O
,dose,JJ,O
,combinations,NNS,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,essential,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,The,DT,O
,first,JJ,O
,part,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,was,VBD,O
,an,DT,O
,8,CD,O
,-,:,O
,week,NN,O
,",",",",O
,multicenter,NN,O
,",",",",O
,randomized,VBN,O
,",",",",O
,double,JJ,O
,-,:,O
,blind,NN,O
,",",",",O
,placebo,NN,O
,controlled,VBD,O
,",",",",O
,parallel,JJ,O
,-,:,O
,group,NN,O
,trial,NN,O
,.,.,O
,Patients,NNS,O
,with,IN,O
,essential,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,(,(,O
,mean,JJ,O
,sitting,VBG,O
,diastolic,JJ,O
,BP,NNP,O
,[,NNP,O
,MSDBP,NNP,O
,],NNP,O
,",",",",O
,>,NNP,O
,or,CC,O
,=,$,O
,95,CD,O
,mm,NN,O
,Hg,NNP,O
,and,CC,O
,<,$,O
,110,CD,O
,mm,NN,O
,Hg,NNP,O
,),),O
,were,VBD,O
,randomized,VBN,O
,to,TO,O
,1,CD,O
,of,IN,O
,8,CD,O
,treatment,NN,O
,groups,NNS,O
,:,:,O
,VAL,NNP,O
,160,CD,O
,or,CC,O
,320,CD,O
,mg,NN,O
,;,:,O
,HCTZ,NNP,O
,12,CD,O
,.,.,O
,5,CD,O
,or,CC,O
,25,CD,O
,mg,NN,O
,;,:,O
,VAL,NNP,O
,/,NNP,O
,HCTZ,NNP,O
,160,CD,O
,/,NN,O
,12,CD,O
,.,.,O
,5,CD,O
,",",",",O
,320,CD,O
,/,NN,O
,12,CD,O
,.,.,O
,5,CD,O
,",",",",O
,or,CC,O
,320,CD,O
,/,JJ,O
,25,CD,O
,mg,NN,O
,;,:,O
,or,CC,O
,placebo,VB,O
,.,.,O
,Mean,NNP,O
,changes,NNS,O
,in,IN,O
,MSDBP,NNP,O
,and,CC,O
,mean,VB,O
,sitting,VBG,O
,systolic,JJ,O
,BP,NNP,O
,(,(,O
,MSSBP,NNP,O
,),),O
,were,VBD,O
,analyzed,VBN,O
,at,IN,O
,the,DT,O
,8,CD,O
,-,:,O
,week,NN,O
,core,NN,O
,study,NN,O
,end,NN,O
,point,NN,O
,.,.,O
,VAL,NNP,O
,/,NNP,O
,HCTZ,NNP,O
,320,CD,O
,/,NN,O
,12,CD,O
,.,.,O
,5,CD,O
,and,CC,O
,320,CD,O
,/,NNS,O
,25,CD,O
,mg,NNS,O
,were,VBD,O
,further,RB,O
,investigated,VBN,O
,in,IN,O
,a,DT,O
,54,CD,O
,-,:,O
,week,NN,O
,",",",",O
,open,JJ,O
,-,:,O
,label,NN,O
,extension,NN,O
,.,.,O
,Response,NNP,O
,was,VBD,O
,defined,VBN,O
,as,IN,O
,MSDBP,NNP,O
,<,VBD,O
,90,CD,O
,mm,NN,O
,Hg,NNP,O
,or,CC,O
,a,DT,O
,>,NN,O
,or,CC,O
,=,$,O
,10,CD,O
,mm,NN,O
,Hg,NNP,O
,decrease,NN,O
,compared,VBN,O
,to,TO,O
,baseline,VB,O
,.,.,O
,Control,NNP,O
,was,VBD,O
,defined,VBN,O
,as,IN,O
,MSDBP,NNP,O
,<,VBD,O
,90,CD,O
,mm,NN,O
,Hg,NNP,O
,compared,VBN,O
,with,IN,O
,baseline,NN,O
,.,.,O
,Tolerability,NN,O
,was,VBD,O
,assessed,VBN,O
,by,IN,O
,monitoring,VBG,O
,adverse,JJ,O
,events,NNS,O
,at,IN,O
,randomization,NN,O
,and,CC,O
,all,DT,O
,subsequent,JJ,O
,study,NN,O
,visits,NNS,O
,and,CC,O
,regular,JJ,O
,evaluation,NN,O
,of,IN,O
,hematology,NN,O
,and,CC,O
,blood,NN,O
,chemistry,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,A,DT,O
,total,NN,O
,of,IN,O
,1346,CD,O
,patients,NNS,O
,were,VBD,O
,randomized,VBN,O
,into,IN,O
,the,DT,O
,8,CD,O
,-,:,O
,week,NN,O
,core,NN,O
,study,NN,O
,(,(,O
,734,CD,O
,men,NNS,O
,",",",",O
,612,CD,O
,women,NNS,O
,;,:,O
,924,CD,O
,white,JJ,O
,",",",",O
,291,CD,O
,black,JJ,O
,",",",",O
,23,CD,O
,Asian,JJ,O
,",",",",O
,108,CD,O
,other,JJ,O
,;,:,O
,mean,JJ,O
,age,NN,O
,",",",",O
,52,CD,O
,.,.,O
,7,CD,O
,years,NNS,O
,;,:,O
,mean,VB,O
,weight,NN,O
,",",",",O
,92,CD,O
,.,.,O
,6,CD,O
,kg,NN,O
,),),O
,.,.,O
,All,DT,O
,active,JJ,O
,treatments,NNS,O
,were,VBD,O
,associated,VBN,O
,with,IN,O
,significantly,RB,O
,reduced,VBN,O
,MSSBP,NNP,O
,and,CC,O
,MSDBP,NNP,O
,during,IN,O
,the,DT,O
,core,NN,O
,8,CD,O
,-,:,O
,week,NN,O
,study,NN,O
,",",",",O
,with,IN,O
,each,DT,O
,monotherapy,NN,O
,significantly,RB,O
,contributing,VBG,O
,to,TO,O
,the,DT,O
,overall,JJ,O
,effect,NN,O
,of,IN,O
,combination,NN,O
,therapy,NN,O
,(,(,O
,VAL,NNP,O
,and,CC,O
,HCTZ,NNP,O
,",",",",O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,.,.,O
,Each,DT,O
,combination,NN,O
,was,VBD,O
,associated,VBN,O
,with,IN,O
,significantly,RB,O
,greater,JJR,O
,reductions,NNS,O
,in,IN,O
,MSSBP,NNP,O
,and,CC,O
,MSDBP,NNP,O
,compared,VBN,O
,with,IN,O
,the,DT,O
,monotherapies,NNS,O
,and,CC,O
,placebo,NN,O
,(,(,O
,all,DT,O
,",",",",O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,.,.,O
,The,DT,O
,mean,JJ,O
,reduction,NN,O
,in,IN,O
,MSSBP,NNP,O
,/,NNP,O
,MSDBP,NNP,O
,with,IN,O
,VAL,NNP,O
,/,NNP,O
,HCTZ,NNP,O
,320,CD,O
,/,VBD,O
,25,CD,O
,mg,NN,O
,was,VBD,O
,24,CD,O
,.,.,O
,7,CD,O
,/,JJ,O
,16,CD,O
,.,.,O
,6,CD,O
,mm,NN,O
,Hg,NNP,O
,",",",",O
,compared,VBN,O
,with,IN,O
,5,CD,O
,.,.,O
,9,CD,O
,/,JJ,O
,7,CD,O
,.,.,O
,0,CD,O
,mm,JJ,O
,Hg,NNP,O
,with,IN,O
,placebo,NN,O
,.,.,O
,The,DT,O
,reduction,NN,O
,in,IN,O
,MSSBP,NNP,O
,was,VBD,O
,significantly,RB,O
,greater,JJR,O
,with,IN,O
,VAL,NNP,O
,/,NNP,O
,HCTZ,NNP,O
,320,CD,O
,/,VBD,O
,25,CD,O
,mg,NNS,O
,compared,VBN,O
,with,IN,O
,VAL,NNP,O
,/,NNP,O
,HCTZ,NNP,O
,160,CD,O
,/,NN,O
,12,CD,O
,.,.,O
,5,CD,O
,mg,NN,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,002,CD,O
,),),O
,.,.,O
,Rates,NNS,O
,of,IN,O
,response,NN,O
,and,CC,O
,BP,NNP,O
,control,NN,O
,were,VBD,O
,significantly,RB,O
,higher,JJR,O
,in,IN,O
,the,DT,O
,groups,NNS,O
,that,WDT,O
,received,VBD,O
,combination,NN,O
,treatment,NN,O
,compared,VBN,O
,with,IN,O
,those,DT,O
,that,WDT,O
,received,VBD,O
,monotherapy,NN,O
,.,.,O
,The,DT,O
,incidence,NN,O
,of,IN,O
,hypokalemia,NN,B-DISEASE
,was,VBD,O
,lower,JJR,O
,with,IN,O
,VAL,NNP,O
,/,NNP,O
,HCTZ,NNP,O
,combinations,NNS,O
,(,(,O
,1,CD,O
,.,.,O
,8,CD,O
,%,NN,O
,-,:,O
,6,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,),),O
,than,IN,O
,with,IN,O
,HCTZ,NNP,O
,monotherapies,NNS,O
,(,(,O
,7,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,-,:,O
,13,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,),),O
,.,.,O
,The,DT,O
,majority,NN,O
,of,IN,O
,adverse,JJ,O
,events,NNS,O
,in,IN,O
,the,DT,O
,core,NN,O
,study,NN,O
,were,VBD,O
,of,IN,O
,mild,NN,O
,to,TO,O
,moderate,VB,O
,severity,NN,O
,.,.,O
,The,DT,O
,efficacy,NN,O
,and,CC,O
,tolerability,NN,O
,of,IN,O
,VAL,NNP,O
,/,NNP,O
,HCTZ,NNP,O
,combinations,NNS,O
,were,VBD,O
,maintained,VBN,O
,during,IN,O
,the,DT,O
,extension,NN,O
,(,(,O
,797,CD,O
,patients,NNS,O
,),),O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,In,IN,O
,this,DT,O
,study,NN,O
,population,NN,O
,",",",",O
,combination,NN,O
,therapies,NNS,O
,with,IN,O
,VAL,NNP,O
,/,NNP,O
,HCTZ,NNP,O
,were,VBD,O
,associated,VBN,O
,with,IN,O
,significantly,RB,O
,greater,JJR,O
,BP,NNP,O
,reductions,NNS,O
,compared,VBN,O
,with,IN,O
,either,DT,O
,monotherapy,NN,O
,",",",",O
,were,VBD,O
,well,RB,O
,tolerated,VBN,O
,",",",",O
,and,CC,O
,were,VBD,O
,associated,VBN,O
,with,IN,O
,less,JJR,O
,hypokalemia,NN,B-DISEASE
,than,IN,O
,HCTZ,NNP,O
,alone,RB,O
,.,.,O
,Succimer,NNP,O
,chelation,NN,O
,improves,VBZ,O
,learning,VBG,O
,",",",",O
,attention,NN,O
,",",",",O
,and,CC,O
,arousal,JJ,O
,regulation,NN,O
,in,IN,O
,lead,JJ,O
,-,:,O
,exposed,JJ,O
,rats,NNS,O
,but,CC,O
,produces,VBZ,O
,lasting,JJ,O
,cognitive,JJ,B-DISEASE
,impairment,NN,I-DISEASE
,in,IN,O
,the,DT,O
,absence,NN,O
,of,IN,O
,lead,JJ,O
,exposure,NN,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,There,EX,O
,is,VBZ,O
,growing,VBG,O
,pressure,NN,O
,for,IN,O
,clinicians,NNS,O
,to,TO,O
,prescribe,VB,O
,chelation,NN,O
,therapy,NN,O
,at,IN,O
,only,RB,O
,slightly,RB,O
,elevated,VBN,O
,blood,NN,O
,lead,NN,O
,levels,NNS,O
,.,.,O
,However,RB,O
,",",",",O
,very,RB,O
,few,JJ,O
,studies,NNS,O
,have,VBP,O
,evaluated,VBN,O
,whether,IN,O
,chelation,NN,O
,improves,VBZ,O
,cognitive,JJ,O
,outcomes,NNS,O
,in,IN,O
,Pb,NNP,O
,-,:,O
,exposed,VBD,O
,children,NNS,O
,",",",",O
,or,CC,O
,whether,IN,O
,these,DT,O
,agents,NNS,O
,have,VBP,O
,adverse,JJ,O
,effects,NNS,O
,that,WDT,O
,may,MD,O
,affect,VB,O
,brain,NN,O
,development,NN,O
,in,IN,O
,the,DT,O
,absence,NN,O
,of,IN,O
,Pb,NNP,O
,exposure,NN,O
,.,.,O
,OBJECTIVES,CC,O
,:,:,O
,The,DT,O
,present,JJ,O
,study,NN,O
,was,VBD,O
,designed,VBN,O
,to,TO,O
,answer,VB,O
,these,DT,O
,questions,NNS,O
,",",",",O
,using,VBG,O
,a,DT,O
,rodent,JJ,O
,model,NN,O
,of,IN,O
,early,JJ,O
,childhood,NN,O
,Pb,NNP,O
,exposure,NN,O
,and,CC,O
,treatment,NN,O
,with,IN,O
,succimer,NN,O
,",",",",O
,a,DT,O
,widely,RB,O
,used,VBN,O
,chelating,NN,O
,agent,NN,O
,for,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,Pb,NNP,B-DISEASE
,poisoning,VBG,I-DISEASE
,.,.,O
,RESULTS,NN,O
,:,:,O
,Pb,JJ,O
,exposure,NN,O
,produced,VBD,O
,lasting,JJ,O
,impairments,NNS,B-DISEASE
,in,IN,I-DISEASE
,learning,NN,I-DISEASE
,",",",",I-DISEASE
,attention,NN,I-DISEASE
,",",",",I-DISEASE
,inhibitory,JJ,I-DISEASE
,control,NN,I-DISEASE
,",",",",I-DISEASE
,and,CC,I-DISEASE
,arousal,JJ,I-DISEASE
,regulation,NN,I-DISEASE
,",",",",O
,paralleling,VBG,O
,the,DT,O
,areas,NNS,O
,of,IN,O
,dysfunction,NN,O
,seen,VBN,O
,in,IN,O
,Pb,NNP,O
,-,:,O
,exposed,VBD,O
,children,NNS,O
,.,.,O
,Succimer,NNP,O
,treatment,NN,O
,of,IN,O
,the,DT,O
,Pb,NNP,O
,-,:,O
,exposed,VBD,O
,rats,NNS,O
,significantly,RB,O
,improved,VBN,O
,learning,NN,O
,",",",",O
,attention,NN,O
,",",",",O
,and,CC,O
,arousal,JJ,O
,regulation,NN,O
,",",",",O
,although,IN,O
,the,DT,O
,efficacy,NN,O
,of,IN,O
,the,DT,O
,treatment,NN,O
,varied,VBD,O
,as,IN,O
,a,DT,O
,function,NN,O
,of,IN,O
,the,DT,O
,Pb,NNP,O
,exposure,NN,O
,level,NN,O
,and,CC,O
,the,DT,O
,specific,JJ,O
,functional,JJ,O
,deficit,NN,O
,.,.,O
,In,IN,O
,contrast,NN,O
,",",",",O
,succimer,JJ,O
,treatment,NN,O
,of,IN,O
,rats,NNS,O
,not,RB,O
,previously,RB,O
,exposed,VBN,O
,to,TO,O
,Pb,NNP,O
,produced,VBD,O
,lasting,JJ,O
,and,CC,O
,pervasive,JJ,O
,cognitive,NN,B-DISEASE
,and,CC,I-DISEASE
,affective,JJ,I-DISEASE
,dysfunction,NN,I-DISEASE
,comparable,NN,O
,in,IN,O
,magnitude,NN,O
,to,TO,O
,that,DT,O
,produced,VBN,O
,by,IN,O
,the,DT,O
,higher,JJR,O
,Pb,NNP,O
,exposure,NN,O
,regimen,NNS,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,These,DT,O
,are,VBP,O
,the,DT,O
,first,JJ,O
,data,NNS,O
,",",",",O
,to,TO,O
,our,PRP$,O
,knowledge,NN,O
,",",",",O
,to,TO,O
,show,VB,O
,that,DT,O
,treatment,NN,O
,with,IN,O
,any,DT,O
,chelating,VBG,O
,agent,NN,O
,can,MD,O
,alleviate,VB,O
,cognitive,JJ,B-DISEASE
,deficits,NNS,I-DISEASE
,due,JJ,O
,to,TO,O
,Pb,NNP,O
,exposure,NN,O
,.,.,O
,These,DT,O
,findings,NNS,O
,suggest,VBP,O
,that,IN,O
,it,PRP,O
,may,MD,O
,be,VB,O
,possible,JJ,O
,to,TO,O
,identify,VB,O
,a,DT,O
,succimer,NN,O
,treatment,NN,O
,protocol,NN,O
,that,WDT,O
,improves,VBZ,O
,cognitive,JJ,O
,outcomes,NNS,O
,in,IN,O
,Pb,NNP,O
,-,:,O
,exposed,VBD,O
,children,NNS,O
,.,.,O
,However,RB,O
,",",",",O
,they,PRP,O
,also,RB,O
,suggest,VBP,O
,that,IN,O
,succimer,JJ,O
,treatment,NN,O
,should,MD,O
,be,VB,O
,strongly,RB,O
,discouraged,VBN,O
,for,IN,O
,children,NNS,O
,who,WP,O
,do,VBP,O
,not,RB,O
,have,VB,O
,elevated,VBN,O
,tissue,NN,O
,levels,NNS,O
,of,IN,O
,Pb,NNP,O
,or,CC,O
,other,JJ,O
,heavy,JJ,O
,metals,NNS,O
,.,.,O
,Caffeine,NNP,O
,challenge,NN,O
,test,NN,O
,in,IN,O
,panic,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,and,CC,O
,depression,NN,B-DISEASE
,with,IN,O
,panic,JJ,B-DISEASE
,attacks,NNS,I-DISEASE
,.,.,O
,Our,PRP$,O
,aim,NN,O
,was,VBD,O
,to,TO,O
,observe,VB,O
,if,IN,O
,patients,NNS,O
,with,IN,O
,panic,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,(,(,O
,PD,NNP,B-DISEASE
,),),O
,and,CC,O
,patients,NNS,O
,with,IN,O
,major,JJ,B-DISEASE
,depression,NN,I-DISEASE
,with,IN,O
,panic,JJ,B-DISEASE
,attacks,NNS,I-DISEASE
,(,(,O
,MDP,NNP,B-DISEASE
,),),O
,(,(,O
,Diagnostic,JJ,O
,and,CC,O
,Statistical,JJ,O
,Manual,NNP,O
,of,IN,O
,Mental,NNP,B-DISEASE
,Disorders,NNP,I-DISEASE
,",",",",O
,Fourth,NNP,O
,Edition,NNP,O
,criteria,NNS,O
,),),O
,respond,NN,O
,in,IN,O
,a,DT,O
,similar,JJ,O
,way,NN,O
,to,TO,O
,the,DT,O
,induction,NN,O
,of,IN,O
,panic,NN,B-DISEASE
,attacks,NNS,I-DISEASE
,by,IN,O
,an,DT,O
,oral,JJ,O
,caffeine,NN,O
,challenge,NN,O
,test,NN,O
,.,.,O
,We,PRP,O
,randomly,RB,O
,selected,VBD,O
,29,CD,O
,patients,NNS,O
,with,IN,O
,PD,NNP,B-DISEASE
,",",",",O
,27,CD,O
,with,IN,O
,MDP,NNP,B-DISEASE
,",",",",O
,25,CD,O
,with,IN,O
,major,JJ,B-DISEASE
,depression,NN,I-DISEASE
,without,IN,O
,panic,JJ,B-DISEASE
,attacks,NNS,I-DISEASE
,(,(,O
,MD,NNP,B-DISEASE
,),),O
,",",",",O
,and,CC,O
,28,CD,O
,healthy,JJ,O
,volunteers,NNS,O
,.,.,O
,The,DT,O
,patients,NNS,O
,had,VBD,O
,no,DT,O
,psychotropic,JJ,O
,drug,NN,O
,for,IN,O
,at,IN,O
,least,JJS,O
,a,DT,O
,4,CD,O
,-,:,O
,week,NN,O
,period,NN,O
,.,.,O
,In,IN,O
,a,DT,O
,randomized,JJ,O
,double,JJ,O
,-,:,O
,blind,NN,O
,experiment,NN,O
,performed,VBN,O
,in,IN,O
,2,CD,O
,occasions,NNS,O
,7,CD,O
,days,NNS,O
,apart,RB,O
,",",",",O
,480,CD,O
,mg,NN,O
,caffeine,NN,O
,and,CC,O
,a,DT,O
,caffeine,NN,O
,-,:,O
,free,JJ,O
,(,(,O
,placebo,NN,O
,),),O
,solution,NN,O
,were,VBD,O
,administered,VBN,O
,in,IN,O
,a,DT,O
,coffee,NN,O
,form,NN,O
,and,CC,O
,anxiety,NN,B-DISEASE
,scales,NNS,O
,were,VBD,O
,applied,VBN,O
,before,IN,O
,and,CC,O
,after,IN,O
,each,DT,O
,test,NN,O
,.,.,O
,A,DT,O
,total,NN,O
,of,IN,O
,58,CD,O
,.,.,O
,6,CD,O
,%,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,17,CD,O
,),),O
,of,IN,O
,patients,NNS,O
,with,IN,O
,PD,NNP,B-DISEASE
,",",",",O
,44,CD,O
,.,.,O
,4,CD,O
,%,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,12,CD,O
,),),O
,of,IN,O
,patients,NNS,O
,with,IN,O
,MDP,NNP,B-DISEASE
,",",",",O
,12,CD,O
,.,.,O
,0,CD,O
,%,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,3,CD,O
,),),O
,of,IN,O
,patients,NNS,O
,with,IN,O
,MD,NNP,B-DISEASE
,",",",",O
,and,CC,O
,7,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,2,CD,O
,),),O
,of,IN,O
,control,NN,O
,subjects,NNS,O
,had,VBD,O
,a,DT,O
,panic,JJ,B-DISEASE
,attack,NN,I-DISEASE
,after,IN,O
,the,DT,O
,480,CD,O
,-,:,O
,mg,NN,O
,caffeine,NN,O
,challenge,NN,O
,test,NN,O
,(,(,O
,chi,NN,O
,(,(,O
,2,CD,O
,),),O
,(,(,O
,3,CD,O
,),),O
,=,NN,O
,16,CD,O
,.,.,O
,22,CD,O
,",",",",O
,P,NNP,O
,=,NNP,O
,.,.,O
,001,CD,O
,),),O
,.,.,O
,The,DT,O
,patients,NNS,O
,with,IN,O
,PD,NNP,B-DISEASE
,and,CC,O
,MDP,NNP,B-DISEASE
,were,VBD,O
,more,RBR,O
,sensitive,JJ,O
,to,TO,O
,caffeine,VB,O
,than,IN,O
,were,VBD,O
,patients,NNS,O
,with,IN,O
,MD,NNP,B-DISEASE
,and,CC,O
,healthy,JJ,O
,volunteers,NNS,O
,.,.,O
,No,DT,O
,panic,JJ,B-DISEASE
,attack,NN,I-DISEASE
,was,VBD,O
,observed,VBN,O
,after,IN,O
,the,DT,O
,caffeine,NN,O
,-,:,O
,free,JJ,O
,solution,NN,O
,intake,NN,O
,.,.,O
,The,DT,O
,patients,NNS,O
,with,IN,O
,MD,NNP,B-DISEASE
,had,VBD,O
,a,DT,O
,lower,JJR,O
,heart,NN,O
,rate,NN,O
,response,NN,O
,to,TO,O
,the,DT,O
,test,NN,O
,than,IN,O
,all,PDT,O
,the,DT,O
,other,JJ,O
,groups,NNS,O
,(,(,O
,2,CD,O
,-,:,O
,way,NN,O
,analysis,NN,O
,of,IN,O
,variance,NN,O
,",",",",O
,group,NN,O
,by,IN,O
,time,NN,O
,interaction,NN,O
,with,IN,O
,Greenhouse,NNP,O
,-,:,O
,Geisser,NNP,O
,correction,NN,O
,:,:,O
,F,NNP,O
,(,(,O
,3,CD,O
,",",",",O
,762,CD,O
,),),O
,=,NN,O
,2,CD,O
,.,.,O
,85,CD,O
,",",",",O
,P,NNP,O
,=,NNP,O
,.,.,O
,026,CD,O
,),),O
,.,.,O
,Our,PRP$,O
,data,NNS,O
,suggest,VBP,O
,that,IN,O
,there,EX,O
,is,VBZ,O
,an,DT,O
,association,NN,O
,between,IN,O
,panic,NN,B-DISEASE
,attacks,NNS,I-DISEASE
,",",",",O
,no,DT,O
,matter,NN,O
,if,IN,O
,associated,VBN,O
,with,IN,O
,PD,NNP,B-DISEASE
,or,CC,O
,MDP,NNP,B-DISEASE
,",",",",O
,and,CC,O
,hyperreactivity,NN,O
,to,TO,O
,an,DT,O
,oral,JJ,O
,caffeine,NN,O
,challenge,NN,O
,test,NN,O
,.,.,O
,Mitral,NNP,O
,annuloplasty,NN,O
,as,IN,O
,a,DT,O
,ventricular,JJ,O
,restoration,NN,O
,method,NN,O
,for,IN,O
,the,DT,O
,failing,NN,B-DISEASE
,left,VBD,I-DISEASE
,ventricle,NN,I-DISEASE
,:,:,O
,a,DT,O
,pilot,NN,O
,study,NN,O
,.,.,O
,BACKGROUND,NNP,O
,AND,NNP,O
,AIM,NNP,O
,OF,IN,O
,THE,NNP,O
,STUDY,NNP,O
,:,:,O
,Undersized,VBN,O
,mitral,JJ,O
,annuloplasty,NN,O
,(,(,O
,MAP,NNP,O
,),),O
,is,VBZ,O
,effective,JJ,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,dilated,VBN,B-DISEASE
,cardiomyopathy,NN,I-DISEASE
,and,CC,O
,functional,JJ,O
,mitral,JJ,B-DISEASE
,regurgitation,NN,I-DISEASE
,(,(,O
,MR,NNP,B-DISEASE
,),),O
,since,IN,O
,",",",",O
,as,RB,O
,well,RB,O
,as,IN,O
,addressing,VBG,O
,the,DT,O
,MR,NNP,B-DISEASE
,",",",",O
,the,DT,O
,MAP,NNP,O
,may,MD,O
,also,RB,O
,reshape,VB,O
,the,DT,O
,dilated,JJ,O
,left,VBD,O
,ventricular,JJ,O
,(,(,O
,LV,NNP,O
,),),O
,base,NN,O
,.,.,O
,However,RB,O
,",",",",O
,the,DT,O
,direct,JJ,O
,benefits,NNS,O
,of,IN,O
,this,DT,O
,possible,JJ,O
,reshaping,NN,O
,on,IN,O
,LV,NNP,O
,function,NN,O
,in,IN,O
,the,DT,O
,absence,NN,O
,of,IN,O
,underlying,VBG,O
,MR,NNP,B-DISEASE
,remain,VBP,O
,incompletely,RB,O
,understood,JJ,O
,.,.,O
,The,DT,O
,study,NN,O
,aim,NN,O
,was,VBD,O
,to,TO,O
,identify,VB,O
,these,DT,O
,benefits,NNS,O
,in,IN,O
,a,DT,O
,canine,JJ,O
,model,NN,O
,of,IN,O
,acute,JJ,O
,heart,NN,B-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,Six,NNP,O
,dogs,NNS,O
,underwent,JJ,O
,MAP,NNP,O
,with,IN,O
,a,DT,O
,prosthetic,JJ,O
,band,NN,O
,on,IN,O
,the,DT,O
,posterior,JJ,O
,mitral,JJ,O
,annulus,NN,O
,",",",",O
,using,VBG,O
,four,CD,O
,mattress,NN,O
,sutures,NNS,O
,.,.,O
,The,DT,O
,sutures,NNS,O
,were,VBD,O
,passed,VBN,O
,individually,RB,O
,through,IN,O
,four,CD,O
,tourniquets,NNS,O
,and,CC,O
,exteriorized,VBN,O
,untied,JJ,O
,via,IN,O
,the,DT,O
,left,JJ,O
,atriotomy,NN,O
,.,.,O
,Sonomicrometry,NN,O
,crystals,NNS,O
,were,VBD,O
,implanted,VBN,O
,around,IN,O
,the,DT,O
,mitral,JJ,O
,annulus,NN,O
,and,CC,O
,left,VBD,O
,ventricle,NN,O
,to,TO,O
,measure,VB,O
,geometry,NN,O
,and,CC,O
,regional,JJ,O
,function,NN,O
,.,.,O
,Acute,NNP,O
,heart,NN,B-DISEASE
,failure,NN,I-DISEASE
,was,VBD,O
,induced,VBN,O
,by,IN,O
,propranolol,NN,O
,and,CC,O
,volume,NN,O
,loading,NN,O
,after,IN,O
,weaning,VBG,O
,from,IN,O
,cardiopulmonary,JJ,O
,bypass,NN,O
,;,:,O
,an,DT,O
,absence,NN,O
,of,IN,O
,MR,NNP,B-DISEASE
,was,VBD,O
,confirmed,VBN,O
,by,IN,O
,echocardiography,NN,O
,.,.,O
,MAP,NNP,O
,was,VBD,O
,accomplished,VBN,O
,by,IN,O
,cinching,VBG,O
,the,DT,O
,tourniquets,NNS,O
,.,.,O
,Data,NNS,O
,were,VBD,O
,acquired,VBN,O
,at,IN,O
,baseline,NN,O
,",",",",O
,after,IN,O
,induction,NN,O
,of,IN,O
,acute,JJ,O
,heart,NN,B-DISEASE
,failure,NN,I-DISEASE
,",",",",O
,and,CC,O
,after,IN,O
,MAP,NNP,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,MAP,NNP,O
,decreased,VBD,O
,mitral,JJ,O
,annular,JJ,O
,dimensions,NNS,O
,in,IN,O
,both,DT,O
,commissure,NN,O
,-,:,O
,commissure,NN,O
,and,CC,O
,septal,JJ,O
,-,:,O
,lateral,JJ,O
,directions,NNS,O
,.,.,O
,Concomitantly,RB,O
,",",",",O
,the,DT,O
,diastolic,JJ,O
,diameter,NN,O
,of,IN,O
,the,DT,O
,LV,NNP,O
,base,NN,O
,and,CC,O
,LV,NNP,O
,sphericity,NN,O
,decreased,VBD,O
,(,(,O
,i,NN,O
,.,.,O
,e,NN,O
,.,.,O
,",",",",O
,improved,VBN,O
,),),O
,from,IN,O
,37,CD,O
,.,.,O
,4,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,9,CD,O
,.,.,O
,3,CD,O
,to,TO,O
,35,CD,O
,.,.,O
,9,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,10,CD,O
,mm,NN,O
,(,(,O
,p,JJ,O
,=,NN,O
,0,CD,O
,.,.,O
,063,CD,O
,),),O
,",",",",O
,and,CC,O
,from,IN,O
,67,CD,O
,.,.,O
,9,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,18,CD,O
,.,.,O
,6,CD,O
,%,NN,O
,to,TO,O
,65,CD,O
,.,.,O
,3,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,18,CD,O
,.,.,O
,9,CD,O
,%,NN,O
,(,(,O
,p,JJ,O
,=,NN,O
,0,CD,O
,.,.,O
,016,CD,O
,),),O
,",",",",O
,respectively,RB,O
,.,.,O
,Decreases,NNS,O
,were,VBD,O
,evident,JJ,O
,in,IN,O
,both,DT,O
,LV,NNP,O
,end,NN,O
,-,:,O
,diastolic,JJ,O
,pressure,NN,O
,(,(,O
,from,IN,O
,17,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,7,CD,O
,to,TO,O
,15,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,6,CD,O
,mmHg,NN,O
,",",",",O
,p,NN,O
,=,VBD,O
,0,CD,O
,.,.,O
,0480,CD,O
,and,CC,O
,Tau,NNP,O
,(,(,O
,from,IN,O
,48,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,8,CD,O
,to,TO,O
,45,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,8,CD,O
,ms,NN,O
,",",",",O
,p,NN,O
,<,VBD,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,",",",",O
,while,IN,O
,fractional,JJ,O
,shortening,NN,O
,at,IN,O
,the,DT,O
,LV,NNP,O
,base,NN,O
,increased,VBD,O
,from,IN,O
,7,CD,O
,.,.,O
,7,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,4,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,to,TO,O
,9,CD,O
,.,.,O
,4,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,4,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,(,(,O
,p,JJ,O
,=,NN,O
,0,CD,O
,.,.,O
,045,CD,O
,),),O
,.,.,O
,After,IN,O
,MAP,NNP,O
,",",",",O
,increases,NNS,O
,were,VBD,O
,identified,VBN,O
,in,IN,O
,both,DT,O
,cardiac,JJ,O
,output,NN,O
,(,(,O
,from,IN,O
,1,CD,O
,.,.,O
,54,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,57,CD,O
,to,TO,O
,1,CD,O
,.,.,O
,65,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,57,CD,O
,1,CD,O
,/,NNP,O
,min,NN,O
,),),O
,and,CC,O
,Emax,NNP,O
,(,(,O
,from,IN,O
,1,CD,O
,.,.,O
,86,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,9,CD,O
,to,TO,O
,2,CD,O
,.,.,O
,41,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,31,CD,O
,mmHg,JJ,O
,/,NNP,O
,ml,NN,O
,),),O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,The,DT,O
,data,NNS,O
,acquired,VBD,O
,suggest,JJS,O
,that,IN,O
,isolated,JJ,O
,MAP,NNP,O
,may,MD,O
,have,VB,O
,certain,JJ,O
,benefits,NNS,O
,on,IN,O
,LV,NNP,O
,dimension,NN,O
,/,NNP,O
,function,NN,O
,in,IN,O
,acute,JJ,O
,heart,NN,B-DISEASE
,failure,NN,I-DISEASE
,",",",",O
,even,RB,O
,in,IN,O
,the,DT,O
,absence,NN,O
,of,IN,O
,MR,NNP,B-DISEASE
,.,.,O
,However,RB,O
,",",",",O
,further,JJ,O
,investigations,NNS,O
,are,VBP,O
,warranted,VBN,O
,in,IN,O
,a,DT,O
,model,NN,O
,of,IN,O
,chronic,JJ,O
,heart,NN,B-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,Piperacillin,NNP,O
,/,NNP,O
,tazobactam,SYM,O
,-,:,O
,induced,JJ,O
,seizure,NN,B-DISEASE
,rapidly,RB,O
,reversed,VBN,O
,by,IN,O
,high,JJ,O
,flux,NN,O
,hemodialysis,NN,O
,in,IN,O
,a,DT,O
,patient,NN,O
,on,IN,O
,peritoneal,JJ,O
,dialysis,NN,O
,.,.,O
,Despite,IN,O
,popular,JJ,O
,use,NN,O
,of,IN,O
,piperacillin,NN,O
,",",",",O
,the,DT,O
,dire,JJ,O
,neurotoxicity,NN,B-DISEASE
,associated,VBN,O
,with,IN,O
,piperacillin,NN,O
,still,RB,O
,goes,VBZ,O
,unrecognized,JJ,O
,",",",",O
,leading,VBG,O
,to,TO,O
,a,DT,O
,delay,NN,O
,in,IN,O
,appropriate,JJ,O
,management,NN,O
,.,.,O
,We,PRP,O
,report,VBP,O
,a,DT,O
,57,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,with,IN,O
,end,NN,B-DISEASE
,-,:,I-DISEASE
,stage,NN,I-DISEASE
,renal,JJ,I-DISEASE
,disease,NN,I-DISEASE
,receiving,VBG,O
,continuous,JJ,O
,ambulatory,JJ,O
,peritoneal,JJ,O
,dialysis,NN,O
,(,(,O
,CAPD,NNP,O
,),),O
,",",",",O
,who,WP,O
,developed,VBD,O
,slurred,VBN,O
,speech,NN,O
,",",",",O
,tremor,NN,B-DISEASE
,",",",",O
,bizarre,JJ,O
,behavior,NN,O
,",",",",O
,progressive,JJ,O
,mental,JJ,O
,confusion,NN,B-DISEASE
,",",",",O
,and,CC,O
,2,CD,O
,episodes,NNS,O
,of,IN,O
,generalized,JJ,O
,tonic,JJ,B-DISEASE
,-,:,I-DISEASE
,clonic,JJ,I-DISEASE
,seizure,NN,I-DISEASE
,(,(,O
,GTCS,NNP,B-DISEASE
,),),O
,after,IN,O
,5,CD,O
,doses,NNS,O
,of,IN,O
,piperacillin,NN,O
,/,NNP,O
,tazobactam,NN,O
,(,(,O
,2,CD,O
,g,NN,O
,/,VBD,O
,250,CD,O
,mg,NN,O
,),),O
,were,VBD,O
,given,VBN,O
,for,IN,O
,bronchiectasis,NN,B-DISEASE
,with,IN,O
,secondary,JJ,B-DISEASE
,infection,NN,I-DISEASE
,.,.,O
,The,DT,O
,laboratory,NN,O
,data,NNS,O
,revealed,VBD,O
,normal,JJ,O
,plasma,NN,O
,electrolyte,NN,O
,and,CC,O
,ammonia,NN,O
,levels,NNS,O
,but,CC,O
,leukocytosis,NN,B-DISEASE
,.,.,O
,Neurologic,NNP,O
,examinations,NNS,O
,showed,VBD,O
,dysarthria,NNS,B-DISEASE
,and,CC,O
,bilateral,JJ,O
,Babinski,NNP,O
,sign,NN,O
,.,.,O
,Computed,NNP,O
,tomography,NN,O
,of,IN,O
,brain,NN,O
,and,CC,O
,electroencephalogram,NN,O
,were,VBD,O
,unremarkable,JJ,O
,.,.,O
,Despite,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,antiepileptic,JJ,O
,agents,NNS,O
,",",",",O
,another,DT,O
,GTCS,NNP,B-DISEASE
,episode,NN,O
,recurred,VBD,O
,after,IN,O
,the,DT,O
,sixth,JJ,O
,dose,NN,O
,of,IN,O
,piperacillin,NN,O
,/,NNP,O
,tazobactam,NN,O
,.,.,O
,Brain,NNP,O
,magnetic,JJ,O
,resonance,NN,O
,imaging,NN,O
,did,VBD,O
,not,RB,O
,demonstrate,VB,O
,acute,JJ,O
,infarction,NN,B-DISEASE
,and,CC,O
,organic,JJ,B-DISEASE
,brain,NN,I-DISEASE
,lesions,NNS,I-DISEASE
,.,.,O
,Initiation,NN,O
,of,IN,O
,high,JJ,O
,-,:,O
,flux,JJ,O
,hemodialysis,NN,O
,rapidly,RB,O
,reversed,VBD,O
,the,DT,O
,neurologic,NN,O
,symptoms,NNS,O
,within,IN,O
,4,CD,O
,hours,NNS,O
,.,.,O
,Piperacillin,NNP,O
,-,:,O
,induced,VBD,O
,encephalopathy,JJ,B-DISEASE
,should,MD,O
,be,VB,O
,considered,VBN,O
,in,IN,O
,any,DT,O
,uremic,JJ,B-DISEASE
,patients,NNS,O
,with,IN,O
,unexplained,JJ,O
,neurological,JJ,O
,manifestations,NNS,O
,.,.,O
,CAPD,NNP,O
,is,VBZ,O
,inefficient,JJ,O
,in,IN,O
,removing,VBG,O
,piperacillin,NN,O
,",",",",O
,whereas,IN,O
,hemodialysis,NN,O
,can,MD,O
,rapidly,RB,O
,terminate,VB,O
,the,DT,O
,piperacillin,NN,O
,-,:,O
,induced,VBN,O
,encephalopathy,JJ,B-DISEASE
,.,.,O
,Frequency,NN,O
,of,IN,O
,transient,JJ,O
,ipsilateral,JJ,O
,vocal,JJ,B-DISEASE
,cord,NN,I-DISEASE
,paralysis,NN,I-DISEASE
,in,IN,O
,patients,NNS,O
,undergoing,VBG,O
,carotid,JJ,O
,endarterectomy,NN,O
,under,IN,O
,local,JJ,O
,anesthesia,NN,O
,.,.,O
,BACKGROUND,NNP,O
,:,:,O
,Especially,RB,O
,because,IN,O
,of,IN,O
,improvements,NNS,O
,in,IN,O
,clinical,JJ,O
,neurologic,JJ,O
,monitoring,NN,O
,",",",",O
,carotid,JJ,O
,endarterectomy,NN,O
,done,VBN,O
,under,IN,O
,local,JJ,O
,anesthesia,NN,O
,has,VBZ,O
,become,VBN,O
,the,DT,O
,technique,NN,O
,of,IN,O
,choice,NN,O
,in,IN,O
,several,JJ,O
,centers,NNS,O
,.,.,O
,Temporary,JJ,O
,ipsilateral,JJ,O
,vocal,JJ,B-DISEASE
,nerve,NN,I-DISEASE
,palsies,NNS,I-DISEASE
,due,JJ,O
,to,TO,O
,local,JJ,O
,anesthetics,NNS,O
,have,VBP,O
,been,VBN,O
,described,VBN,O
,",",",",O
,however,RB,O
,.,.,O
,Such,JJ,O
,complications,NNS,O
,are,VBP,O
,most,RBS,O
,important,JJ,O
,in,IN,O
,situations,NNS,O
,where,WRB,O
,there,EX,O
,is,VBZ,O
,a,DT,O
,pre,JJ,O
,-,:,O
,existing,VBG,O
,contralateral,JJ,O
,paralysis,NN,B-DISEASE
,.,.,O
,We,PRP,O
,therefore,RB,O
,examined,VBD,O
,the,DT,O
,effect,NN,O
,of,IN,O
,local,JJ,O
,anesthesia,NN,O
,on,IN,O
,vocal,JJ,O
,cord,NN,O
,function,NN,O
,to,TO,O
,better,JJR,O
,understand,VB,O
,its,PRP$,O
,possible,JJ,O
,consequences,NNS,O
,.,.,O
,METHODS,NN,O
,:,:,O
,This,DT,O
,prospective,JJ,O
,study,NN,O
,included,VBD,O
,28,CD,O
,patients,NNS,O
,undergoing,JJ,O
,carotid,JJ,O
,endarterectomy,NN,O
,under,IN,O
,local,JJ,O
,anesthesia,NN,O
,.,.,O
,Vocal,NNP,O
,cord,NN,O
,function,NN,O
,was,VBD,O
,evaluated,VBN,O
,before,RB,O
,",",",",O
,during,IN,O
,",",",",O
,and,CC,O
,after,IN,O
,surgery,NN,O
,(,(,O
,postoperative,JJ,O
,day,NN,O
,1,CD,O
,),),O
,using,VBG,O
,flexible,JJ,O
,laryngoscopy,NN,O
,.,.,O
,Anesthesia,NNP,O
,was,VBD,O
,performed,VBN,O
,by,IN,O
,injecting,VBG,O
,20,CD,O
,to,TO,O
,40,CD,O
,mL,NN,O
,of,IN,O
,a,DT,O
,mixture,NN,O
,of,IN,O
,long,JJ,O
,-,:,O
,acting,NN,O
,(,(,O
,ropivacaine,NN,O
,),),O
,and,CC,O
,short,JJ,O
,-,:,O
,acting,NN,O
,(,(,O
,prilocaine,NN,O
,),),O
,anesthetic,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,All,DT,O
,patients,NNS,O
,had,VBD,O
,normal,JJ,O
,vocal,JJ,O
,cord,NN,O
,function,NN,O
,preoperatively,RB,O
,.,.,O
,Twelve,CD,O
,patients,NNS,O
,(,(,O
,43,CD,O
,%,NN,O
,),),O
,were,VBD,O
,found,VBN,O
,to,TO,O
,have,VB,O
,intraoperative,JJ,O
,ipsilateral,JJ,O
,vocal,JJ,B-DISEASE
,cord,NN,I-DISEASE
,paralysis,NN,I-DISEASE
,.,.,O
,It,PRP,O
,resolved,VBD,O
,in,IN,O
,all,DT,O
,cases,NNS,O
,<,VBP,O
,or,CC,O
,=,VBP,O
,24,CD,O
,hours,NNS,O
,.,.,O
,There,EX,O
,were,VBD,O
,no,DT,O
,significant,JJ,O
,differences,NNS,O
,in,IN,O
,operating,NN,O
,time,NN,O
,or,CC,O
,volume,NN,O
,or,CC,O
,frequency,NN,O
,of,IN,O
,anesthetic,JJ,O
,administration,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,temporary,JJ,O
,vocal,JJ,B-DISEASE
,cord,NN,I-DISEASE
,paralysis,NN,I-DISEASE
,compared,VBN,O
,with,IN,O
,those,DT,O
,without,IN,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Local,JJ,O
,anesthesia,NN,O
,led,VBD,O
,to,TO,O
,temporary,JJ,O
,ipsilateral,JJ,O
,vocal,NN,B-DISEASE
,cord,NN,I-DISEASE
,paralysis,NN,I-DISEASE
,in,IN,O
,almost,RB,O
,half,NN,O
,of,IN,O
,these,DT,O
,patients,NNS,O
,.,.,O
,Because,IN,O
,pre,JJ,O
,-,:,O
,existing,VBG,O
,paralysis,NN,B-DISEASE
,is,VBZ,O
,of,IN,O
,a,DT,O
,relevant,JJ,O
,frequency,NN,O
,(,(,O
,up,IN,O
,to,TO,O
,3,CD,O
,%,NN,O
,),),O
,",",",",O
,a,DT,O
,preoperative,JJ,O
,evaluation,NN,O
,of,IN,O
,vocal,JJ,O
,cord,NN,O
,function,NN,O
,before,IN,O
,carotid,JJ,O
,endarterectomy,NN,O
,under,IN,O
,local,JJ,O
,anesthesia,NN,O
,is,VBZ,O
,recommended,VBN,O
,to,TO,O
,avoid,VB,O
,intraoperative,JJ,O
,bilateral,JJ,O
,paralysis,NN,B-DISEASE
,.,.,O
,In,IN,O
,patients,NNS,O
,with,IN,O
,preoperative,JJ,O
,contralateral,JJ,O
,vocal,JJ,B-DISEASE
,cord,NN,I-DISEASE
,paralysis,NN,I-DISEASE
,",",",",O
,surgery,NN,O
,under,IN,O
,general,JJ,O
,anesthesia,NN,O
,should,MD,O
,be,VB,O
,considered,VBN,O
,.,.,O
,Impaired,JJ,B-DISEASE
,fear,JJ,I-DISEASE
,recognition,NN,I-DISEASE
,in,IN,O
,regular,JJ,O
,recreational,JJ,O
,cocaine,NN,O
,users,NNS,O
,.,.,O
,INTRODUCTION,NN,O
,:,:,O
,The,DT,O
,ability,NN,O
,to,TO,O
,read,VB,O
,facial,JJ,O
,expressions,NNS,O
,is,VBZ,O
,essential,JJ,O
,for,IN,O
,normal,JJ,O
,human,JJ,O
,social,JJ,O
,interaction,NN,O
,.,.,O
,The,DT,O
,aim,NN,O
,of,IN,O
,the,DT,O
,present,JJ,O
,study,NN,O
,was,VBD,O
,to,TO,O
,conduct,VB,O
,the,DT,O
,first,JJ,O
,investigation,NN,O
,of,IN,O
,facial,JJ,O
,expression,NN,O
,recognition,NN,O
,performance,NN,O
,in,IN,O
,recreational,JJ,O
,cocaine,NN,O
,users,NNS,O
,.,.,O
,MATERIALS,NNP,O
,AND,CC,O
,METHODS,NNP,O
,:,:,O
,Three,CD,O
,groups,NNS,O
,",",",",O
,comprised,VBN,O
,of,IN,O
,21,CD,O
,cocaine,NN,O
,naive,JJ,O
,participants,NNS,O
,(,(,O
,CN,NNP,O
,),),O
,",",",",O
,30,CD,O
,occasional,JJ,O
,cocaine,NN,O
,(,(,O
,OC,NNP,O
,),),O
,",",",",O
,and,CC,O
,48,CD,O
,regular,JJ,O
,recreational,JJ,O
,cocaine,NN,O
,(,(,O
,RC,NNP,O
,),),O
,users,NNS,O
,",",",",O
,were,VBD,O
,compared,VBN,O
,.,.,O
,An,DT,O
,emotional,JJ,O
,facial,JJ,O
,expression,NN,O
,(,(,O
,EFE,NNP,O
,),),O
,task,NN,O
,consisting,VBG,O
,of,IN,O
,a,DT,O
,male,NN,O
,and,CC,O
,female,JJ,O
,face,NN,O
,expressing,VBG,O
,six,CD,O
,basic,JJ,O
,emotions,NNS,O
,(,(,O
,happiness,NN,O
,",",",",O
,surprise,NN,O
,",",",",O
,sadness,NN,O
,",",",",O
,anger,NN,O
,",",",",O
,fear,NN,O
,",",",",O
,and,CC,O
,disgust,NN,O
,),),O
,was,VBD,O
,administered,VBN,O
,.,.,O
,Mean,JJ,O
,percent,NN,O
,accuracy,NN,O
,and,CC,O
,latencies,NNS,O
,for,IN,O
,correct,JJ,O
,responses,NNS,O
,across,IN,O
,eight,CD,O
,presentations,NNS,O
,of,IN,O
,each,DT,O
,basic,JJ,O
,emotion,NN,O
,were,VBD,O
,derived,VBN,O
,.,.,O
,Participants,NNS,O
,were,VBD,O
,also,RB,O
,assessed,VBN,O
,with,IN,O
,the,DT,O
,"""",JJ,O
,Eyes,NNP,O
,task,NN,O
,"""",NN,O
,to,TO,O
,investigate,VB,O
,their,PRP$,O
,ability,NN,O
,to,TO,O
,recognize,VB,O
,more,RBR,O
,complex,JJ,O
,emotional,JJ,O
,states,NNS,O
,and,CC,O
,the,DT,O
,Symptom,NNP,O
,CheckList,NNP,O
,-,:,O
,90,CD,O
,-,:,O
,Revised,VBN,O
,to,TO,O
,measure,VB,O
,psychopathology,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,There,EX,O
,were,VBD,O
,no,DT,O
,group,NN,O
,differences,VBZ,O
,in,IN,O
,psychopathology,NN,O
,or,CC,O
,"""",VB,O
,eyes,NNS,O
,task,JJ,O
,"""",JJ,O
,performance,NN,O
,",",",",O
,but,CC,O
,the,DT,O
,RC,NNP,O
,group,NN,O
,",",",",O
,who,WP,O
,otherwise,RB,O
,had,VBD,O
,similar,JJ,O
,illicit,NN,O
,substance,NN,O
,use,NN,O
,histories,NNS,O
,to,TO,O
,the,DT,O
,OC,NNP,O
,group,NN,O
,",",",",O
,exhibited,VBN,O
,impaired,JJ,B-DISEASE
,fear,NN,I-DISEASE
,recognition,NN,I-DISEASE
,accuracy,NN,O
,compared,VBN,O
,to,TO,O
,the,DT,O
,OC,NNP,O
,and,CC,O
,CN,NNP,O
,groups,NNS,O
,.,.,O
,The,DT,O
,RC,NNP,O
,group,NN,O
,also,RB,O
,correctly,RB,O
,identified,VBN,O
,anger,NN,O
,",",",",O
,fear,NN,O
,",",",",O
,happiness,NN,O
,",",",",O
,and,CC,O
,surprise,NN,O
,",",",",O
,more,RBR,O
,slowly,RB,O
,than,IN,O
,CN,NNP,O
,",",",",O
,but,CC,O
,not,RB,O
,OC,NNP,O
,participants,NNS,O
,.,.,O
,The,DT,O
,OC,NNP,O
,group,NN,O
,was,VBD,O
,slower,JJR,O
,than,IN,O
,CN,NNP,O
,when,WRB,O
,correctly,RB,O
,identifying,VBG,O
,disgust,NN,O
,.,.,O
,The,DT,O
,selective,JJ,O
,deficit,NN,B-DISEASE
,in,IN,I-DISEASE
,fear,NN,I-DISEASE
,recognition,NN,I-DISEASE
,accuracy,NN,O
,manifested,VBN,O
,by,IN,O
,the,DT,O
,RC,NNP,O
,group,NN,O
,cannot,NN,O
,be,VB,O
,explained,VBN,O
,by,IN,O
,the,DT,O
,subacute,JJ,O
,effects,NNS,O
,of,IN,O
,cocaine,NN,O
,",",",",O
,or,CC,O
,ecstasy,RB,O
,",",",",O
,because,IN,O
,recent,JJ,O
,and,CC,O
,less,RBR,O
,recent,JJ,O
,users,NNS,O
,of,IN,O
,these,DT,O
,drugs,NNS,O
,within,IN,O
,this,DT,O
,group,NN,O
,were,VBD,O
,similarly,RB,O
,impaired,VBN,O
,.,.,O
,Possible,JJ,O
,parallels,NNS,O
,between,IN,O
,RC,NNP,O
,users,NNS,O
,and,CC,O
,psychopaths,NNS,B-DISEASE
,with,IN,O
,respect,NN,O
,to,TO,O
,impaired,JJ,B-DISEASE
,fear,NN,I-DISEASE
,recognition,NN,I-DISEASE
,",",",",O
,amygdala,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,",",",",O
,and,CC,O
,etiology,NN,O
,are,VBP,O
,discussed,VBN,O
,.,.,O
,Damage,NN,B-DISEASE
,of,IN,I-DISEASE
,substantia,NN,I-DISEASE
,nigra,JJ,I-DISEASE
,pars,NNS,I-DISEASE
,reticulata,VBP,I-DISEASE
,during,IN,O
,pilocarpine,JJ,O
,-,:,O
,induced,JJ,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,in,IN,O
,the,DT,O
,rat,NN,O
,:,:,O
,immunohistochemical,JJ,O
,study,NN,O
,of,IN,O
,neurons,NNS,O
,",",",",O
,astrocytes,NNS,O
,and,CC,O
,serum,VB,O
,-,:,O
,protein,NN,O
,extravasation,NN,O
,.,.,O
,The,DT,O
,substantia,NN,O
,nigra,NN,O
,has,VBZ,O
,a,DT,O
,gating,VBG,O
,function,NN,O
,controlling,VBG,O
,the,DT,O
,spread,NN,O
,of,IN,O
,epileptic,JJ,B-DISEASE
,seizure,NN,I-DISEASE
,activity,NN,O
,.,.,O
,Additionally,RB,O
,",",",",O
,in,IN,O
,models,NNS,O
,of,IN,O
,prolonged,JJ,B-DISEASE
,status,NN,I-DISEASE
,epilepticus,VBZ,I-DISEASE
,the,DT,O
,pars,NNS,O
,reticulata,NN,O
,of,IN,O
,substantia,NN,O
,nigra,NN,O
,(,(,O
,SNR,NNP,O
,),),O
,suffers,NNS,O
,from,IN,O
,a,DT,O
,massive,JJ,O
,lesion,NN,O
,which,WDT,O
,may,MD,O
,arise,VB,O
,from,IN,O
,a,DT,O
,massive,JJ,O
,metabolic,NN,B-DISEASE
,derangement,NN,I-DISEASE
,and,CC,O
,hyperexcitation,NN,O
,developing,VBG,O
,in,IN,O
,the,DT,O
,activated,JJ,O
,SNR,NNP,O
,.,.,O
,In,IN,O
,this,DT,O
,study,NN,O
,",",",",O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,was,VBD,O
,induced,VBN,O
,by,IN,O
,systemic,JJ,O
,injection,NN,O
,of,IN,O
,pilocarpine,NN,O
,in,IN,O
,rats,NNS,O
,.,.,O
,The,DT,O
,neuropathology,NN,O
,of,IN,O
,SNR,NNP,O
,was,VBD,O
,investigated,VBN,O
,using,VBG,O
,immunohistochemical,JJ,O
,techniques,NNS,O
,with,IN,O
,the,DT,O
,major,JJ,O
,emphasis,NN,O
,on,IN,O
,the,DT,O
,time,NN,O
,-,:,O
,course,NN,O
,of,IN,O
,changes,NNS,O
,in,IN,O
,neurons,NNS,O
,and,CC,O
,astrocytes,NNS,O
,.,.,O
,Animals,NNS,O
,surviving,VBG,O
,20,CD,O
,",",",",O
,30,CD,O
,",",",",O
,40,CD,O
,",",",",O
,60,CD,O
,min,NN,O
,",",",",O
,2,CD,O
,",",",",O
,3,CD,O
,",",",",O
,6,CD,O
,hours,NNS,O
,",",",",O
,1,CD,O
,",",",",O
,2,CD,O
,",",",",O
,and,CC,O
,3,CD,O
,days,NNS,O
,after,IN,O
,induction,NN,O
,of,IN,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,were,VBD,O
,perfusion,JJ,O
,-,:,O
,fixed,VBN,O
,",",",",O
,and,CC,O
,brains,NNS,O
,processed,VBN,O
,for,IN,O
,immunohistochemical,JJ,O
,staining,NN,O
,of,IN,O
,SNR,NNP,O
,.,.,O
,Nissl,NNP,O
,-,:,O
,staining,NN,O
,and,CC,O
,antibodies,NNS,O
,against,IN,O
,the,DT,O
,neuron,NN,O
,-,:,O
,specific,JJ,O
,calcium,NN,O
,-,:,O
,binding,NN,O
,protein,NN,O
,",",",",O
,parvalbumin,NN,O
,",",",",O
,served,VBD,O
,to,TO,O
,detect,VB,O
,neuronal,JJ,B-DISEASE
,damage,NN,I-DISEASE
,in,IN,O
,SNR,NNP,O
,.,.,O
,Antibodies,NNS,O
,against,IN,O
,the,DT,O
,astroglia,JJ,O
,-,:,O
,specific,JJ,O
,cytoskeletal,JJ,O
,protein,NN,O
,",",",",O
,glial,JJ,O
,fibrillary,JJ,O
,acidic,NN,O
,protein,NN,O
,(,(,O
,GFAP,NNP,O
,),),O
,",",",",O
,and,CC,O
,against,IN,O
,the,DT,O
,glial,JJ,O
,calcium,NN,O
,-,:,O
,binding,NN,O
,protein,NN,O
,",",",",O
,S,NNP,O
,-,:,O
,100,CD,O
,protein,NN,O
,",",",",O
,were,VBD,O
,used,VBN,O
,to,TO,O
,assess,VB,O
,the,DT,O
,status,NN,O
,of,IN,O
,astrocytes,NNS,O
,.,.,O
,Immunohistochemical,JJ,O
,staining,NN,O
,for,IN,O
,serum,NN,O
,-,:,O
,albumin,NN,O
,and,CC,O
,immunoglobulins,NNS,O
,in,IN,O
,brain,NN,O
,tissue,NN,O
,was,VBD,O
,taken,VBN,O
,as,IN,O
,indicator,NN,O
,of,IN,O
,blood,NN,O
,-,:,O
,brain,NN,O
,barrier,NN,O
,disturbances,NNS,O
,and,CC,O
,vasogenic,JJ,B-DISEASE
,edema,NN,I-DISEASE
,formation,NN,O
,.,.,O
,Immunohistochemical,JJ,O
,staining,VBG,O
,indicated,JJ,O
,loss,NN,O
,of,IN,O
,GFAP,NNP,O
,-,:,O
,staining,VBG,O
,already,RB,O
,at,IN,O
,30,CD,O
,min,NN,O
,after,IN,O
,induction,NN,O
,of,IN,O
,seizures,NNS,B-DISEASE
,in,IN,O
,an,DT,O
,oval,JJ,O
,focus,NN,O
,situated,VBN,O
,in,IN,O
,the,DT,O
,center,NN,O
,of,IN,O
,SNR,NNP,O
,while,IN,O
,sparing,VBG,O
,medial,JJ,O
,and,CC,O
,lateral,JJ,O
,aspects,NNS,O
,.,.,O
,At,IN,O
,1,CD,O
,h,NN,O
,there,RB,O
,was,VBD,O
,additional,JJ,O
,vacuolation,NN,O
,in,IN,O
,S,NNP,O
,-,:,O
,100,CD,O
,protein,NN,O
,staining,VBG,O
,.,.,O
,By,IN,O
,2,CD,O
,hours,NNS,O
,",",",",O
,parvalbumin,SYM,O
,-,:,O
,staining,VBG,O
,changed,VBN,O
,in,IN,O
,the,DT,O
,central,JJ,O
,SNR,NNP,O
,indicating,VBG,O
,neuronal,JJ,B-DISEASE
,damage,NN,I-DISEASE
,",",",",O
,and,CC,O
,Nissl,NNP,O
,-,:,O
,staining,VBG,O
,visualized,VBD,O
,some,DT,O
,neuronal,JJ,O
,distortion,NN,O
,.,.,O
,Staining,VBG,O
,for,IN,O
,serum,NN,O
,-,:,O
,proteins,NNS,O
,occurred,VBD,O
,in,IN,O
,a,DT,O
,patchy,NN,O
,manner,NN,O
,throughout,IN,O
,the,DT,O
,forebrain,NN,O
,during,IN,O
,the,DT,O
,first,JJ,O
,hours,NNS,O
,.,.,O
,By,IN,O
,6,CD,O
,h,NN,O
,",",",",O
,vasogenic,JJ,B-DISEASE
,edema,NN,I-DISEASE
,covered,VBD,O
,the,DT,O
,lesioned,JJ,B-DISEASE
,SNR,NNP,I-DISEASE
,.,.,O
,By,IN,O
,24,CD,O
,h,NN,O
,",",",",O
,glial,JJ,O
,and,CC,O
,neuronal,JJ,O
,markers,NNS,O
,indicated,VBD,O
,a,DT,O
,massive,JJ,O
,lesion,NN,O
,in,IN,O
,the,DT,O
,center,NN,O
,of,IN,O
,SNR,NNP,O
,.,.,O
,By,IN,O
,48,CD,O
,-,:,O
,72,CD,O
,h,NN,O
,",",",",O
,astrocytes,VBZ,O
,surrounding,VBG,O
,the,DT,O
,lesion,NN,O
,increased,VBD,O
,in,IN,O
,size,NN,O
,",",",",O
,and,CC,O
,polymorphic,JJ,O
,phagocytotic,JJ,O
,cells,NNS,O
,invaded,VBD,O
,the,DT,O
,damaged,VBN,O
,area,NN,O
,.,.,O
,In,IN,O
,a,DT,O
,further,JJ,O
,group,NN,O
,of,IN,O
,animals,NNS,O
,surviving,VBG,O
,1,CD,O
,to,TO,O
,5,CD,O
,days,NNS,O
,",",",",O
,conventional,JJ,O
,paraffin,NN,O
,-,:,O
,sections,NNS,O
,confirmed,VBD,O
,the,DT,O
,neuronal,JJ,O
,and,CC,O
,glial,JJ,O
,damage,NN,B-DISEASE
,of,IN,I-DISEASE
,SNR,NNP,I-DISEASE
,.,.,O
,Additional,NNP,O
,pathology,NN,O
,of,IN,O
,similar,JJ,O
,quality,NN,O
,was,VBD,O
,found,VBN,O
,in,IN,O
,the,DT,O
,globus,NN,O
,pallidus,NN,O
,.,.,O
,Since,IN,O
,astrocytes,NNS,O
,were,VBD,O
,always,RB,O
,damaged,VBN,O
,in,IN,O
,parallel,NN,O
,with,IN,O
,neurons,NNS,O
,in,IN,O
,SNR,NNP,O
,it,PRP,O
,is,VBZ,O
,proposed,VBN,O
,that,IN,O
,the,DT,O
,anatomical,JJ,O
,and,CC,O
,functional,JJ,O
,interrelationship,NN,O
,between,IN,O
,neurons,NNS,O
,and,CC,O
,astrocytes,NNS,O
,is,VBZ,O
,particularly,RB,O
,tight,JJ,O
,in,IN,O
,SNR,NNP,O
,.,.,O
,Both,NNP,O
,cell,VBP,O
,elements,NNS,O
,may,MD,O
,suffer,VB,O
,in,IN,O
,common,JJ,O
,from,IN,O
,metabolic,JJ,O
,disturbance,NN,O
,and,CC,O
,neurotransmitter,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,as,IN,O
,occur,NN,O
,during,IN,O
,massive,JJ,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,.,.,O
,Neuroprotective,JJ,O
,effects,NNS,O
,of,IN,O
,melatonin,NN,O
,upon,IN,O
,the,DT,O
,offspring,VBG,O
,cerebellar,JJ,O
,cortex,NN,O
,in,IN,O
,the,DT,O
,rat,NN,O
,model,NN,O
,of,IN,O
,BCNU,NNP,O
,-,:,O
,induced,JJ,O
,cortical,JJ,B-DISEASE
,dysplasia,NN,I-DISEASE
,.,.,O
,Cortical,JJ,B-DISEASE
,dysplasia,NN,I-DISEASE
,is,VBZ,O
,a,DT,O
,malformation,NN,O
,characterized,VBN,O
,by,IN,O
,defects,NNS,O
,in,IN,O
,proliferation,NN,O
,",",",",O
,migration,NN,O
,and,CC,O
,maturation,NN,O
,.,.,O
,This,DT,O
,study,NN,O
,was,VBD,O
,designed,VBN,O
,to,TO,O
,evaluate,VB,O
,the,DT,O
,alterations,NNS,O
,in,IN,O
,offspring,VBG,O
,rat,NN,O
,cerebellum,NN,O
,induced,VBN,O
,by,IN,O
,maternal,JJ,O
,exposure,NN,O
,to,TO,O
,carmustine,VB,O
,-,:,O
,[,NN,O
,1,CD,O
,",",",",O
,3,CD,O
,-,:,O
,bis,NN,O
,(,(,O
,2,CD,O
,-,:,O
,chloroethyl,NN,O
,),),O
,-,:,O
,1,CD,O
,-,:,O
,nitrosoure,NN,O
,],NN,O
,(,(,O
,BCNU,NNP,O
,),),O
,and,CC,O
,to,TO,O
,investigate,VB,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,exogenous,JJ,O
,melatonin,NN,O
,upon,IN,O
,cerebellar,JJ,O
,BCNU,NNP,O
,-,:,O
,induced,JJ,O
,cortical,JJ,B-DISEASE
,dysplasia,NN,I-DISEASE
,",",",",O
,using,VBG,O
,histological,JJ,O
,and,CC,O
,biochemical,JJ,O
,analyses,NNS,O
,.,.,O
,Pregnant,JJ,O
,Wistar,NNP,O
,rats,NNS,O
,were,VBD,O
,assigned,VBN,O
,to,TO,O
,five,CD,O
,groups,NNS,O
,:,:,O
,intact,JJ,O
,-,:,O
,control,NN,O
,",",",",O
,saline,JJ,O
,-,:,O
,control,NN,O
,",",",",O
,melatonin,SYM,O
,-,:,O
,treated,VBN,O
,",",",",O
,BCNU,NNP,O
,-,:,O
,exposed,VBN,O
,and,CC,O
,BCNU,NNP,O
,-,:,O
,exposed,VBD,O
,plus,CC,O
,melatonin,NN,O
,.,.,O
,Rats,NNPS,O
,were,VBD,O
,exposed,VBN,O
,to,TO,O
,BCNU,NNP,O
,on,IN,O
,embryonic,JJ,O
,day,NN,O
,15,CD,O
,and,CC,O
,melatonin,NN,O
,was,VBD,O
,given,VBN,O
,until,IN,O
,delivery,NN,O
,.,.,O
,Immuno,NNP,O
,/,NNP,O
,histochemistry,NN,O
,and,CC,O
,electron,NN,O
,microscopy,NN,O
,were,VBD,O
,carried,VBN,O
,out,RP,O
,on,IN,O
,the,DT,O
,offspring,NN,O
,cerebellum,NN,O
,",",",",O
,and,CC,O
,levels,NNS,O
,of,IN,O
,malondialdehyde,NN,O
,and,CC,O
,superoxide,JJ,O
,dismutase,NN,O
,were,VBD,O
,determined,VBN,O
,.,.,O
,Histopathologically,NNP,O
,",",",",O
,typical,JJ,O
,findings,NNS,O
,were,VBD,O
,observed,VBN,O
,in,IN,O
,the,DT,O
,cerebella,NN,O
,from,IN,O
,the,DT,O
,control,NN,O
,groups,NNS,O
,",",",",O
,but,CC,O
,the,DT,O
,findings,NNS,O
,consistent,NN,O
,with,IN,O
,early,JJ,O
,embryonic,JJ,O
,development,NN,O
,were,VBD,O
,noted,VBN,O
,in,IN,O
,BCNU,NNP,O
,-,:,O
,exposed,VBD,O
,cortical,JJ,B-DISEASE
,dysplasia,NN,I-DISEASE
,group,NN,O
,.,.,O
,There,EX,O
,was,VBD,O
,a,DT,O
,marked,JJ,O
,increase,NN,O
,in,IN,O
,the,DT,O
,number,NN,O
,of,IN,O
,TUNEL,NNP,O
,positive,JJ,O
,cells,NNS,O
,and,CC,O
,nestin,JJ,O
,positive,JJ,O
,cells,NNS,O
,in,IN,O
,BCNU,NNP,O
,-,:,O
,exposed,VBN,O
,group,NN,O
,",",",",O
,but,CC,O
,a,DT,O
,decreased,JJ,O
,immunoreactivity,NN,O
,to,TO,O
,glial,JJ,O
,fibrillary,JJ,O
,acidic,NN,O
,protein,NN,O
,",",",",O
,synaptophysin,NN,O
,and,CC,O
,transforming,VBG,O
,growth,NN,O
,factor,NN,O
,beta1,NN,O
,was,VBD,O
,observed,VBN,O
,",",",",O
,indicating,VBG,O
,a,DT,O
,delayed,JJ,O
,maturation,NN,O
,",",",",O
,and,CC,O
,melatonin,VBZ,O
,significantly,RB,O
,reversed,VBN,O
,these,DT,O
,changes,NNS,O
,.,.,O
,Malondialdehyde,NNP,O
,level,NN,O
,in,IN,O
,BCNU,NNP,O
,-,:,O
,exposed,VBD,O
,group,NN,O
,was,VBD,O
,higher,JJR,O
,than,IN,O
,those,DT,O
,in,IN,O
,control,NN,O
,groups,NNS,O
,and,CC,O
,melatonin,NNS,O
,decreased,VBN,O
,malondialdehyde,NN,O
,levels,NNS,O
,in,IN,O
,BCNU,NNP,O
,group,NN,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,",",",",O
,while,IN,O
,there,EX,O
,were,VBD,O
,no,DT,O
,significant,JJ,O
,differences,NNS,O
,in,IN,O
,the,DT,O
,superoxide,JJ,O
,dismutase,NN,O
,levels,NNS,O
,between,IN,O
,these,DT,O
,groups,NNS,O
,.,.,O
,These,DT,O
,data,NNS,O
,suggest,VBP,O
,that,IN,O
,exposure,NN,O
,of,IN,O
,animals,NNS,O
,to,TO,O
,BCNU,NNP,O
,during,IN,O
,pregnancy,NN,O
,leads,VBZ,O
,to,TO,O
,delayed,VB,O
,maturation,NN,O
,of,IN,O
,offspring,VBG,O
,cerebellum,NN,O
,and,CC,O
,melatonin,NN,O
,protects,VBZ,O
,the,DT,O
,cerebellum,NN,O
,against,IN,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,BCNU,NNP,O
,.,.,O
,Reduced,NNP,O
,cardiotoxicity,NN,B-DISEASE
,of,IN,O
,doxorubicin,NN,O
,given,VBN,O
,in,IN,O
,the,DT,O
,form,NN,O
,of,IN,O
,N,NNP,O
,-,:,O
,(,(,O
,2,CD,O
,-,:,O
,hydroxypropyl,NN,O
,),),O
,methacrylamide,NN,O
,conjugates,NNS,O
,:,:,O
,and,CC,O
,experimental,JJ,O
,study,NN,O
,in,IN,O
,the,DT,O
,rat,NN,O
,.,.,O
,A,DT,O
,rat,NN,O
,model,NN,O
,was,VBD,O
,used,VBN,O
,to,TO,O
,evaluate,VB,O
,the,DT,O
,general,JJ,O
,acute,NN,O
,toxicity,NN,B-DISEASE
,and,CC,O
,the,DT,O
,late,JJ,O
,cardiotoxicity,NN,B-DISEASE
,of,IN,O
,4,CD,O
,mg,NNS,O
,/,JJ,O
,kg,NNS,O
,doxorubicin,NN,O
,(,(,O
,DOX,NNP,O
,),),O
,given,VBN,O
,either,CC,O
,as,IN,O
,free,JJ,O
,drug,NN,O
,or,CC,O
,in,IN,O
,the,DT,O
,form,NN,O
,of,IN,O
,three,CD,O
,N,NNP,O
,-,:,O
,(,(,O
,2,CD,O
,-,:,O
,hydroxypropyl,NN,O
,),),O
,methacrylamide,NN,O
,(,(,O
,HPMA,NNP,O
,),),O
,copolymer,NN,O
,conjugates,NNS,O
,.,.,O
,In,IN,O
,these,DT,O
,HPMA,NNP,O
,copolymers,NNS,O
,",",",",O
,DOX,NNP,O
,was,VBD,O
,covalently,RB,O
,bound,VBN,O
,via,IN,O
,peptide,NN,O
,linkages,NNS,O
,that,WDT,O
,were,VBD,O
,either,DT,O
,non,JJ,O
,-,:,O
,biodegradable,NN,O
,(,(,O
,Gly,NNP,O
,-,:,O
,Gly,NNP,O
,),),O
,or,CC,O
,degradable,JJ,O
,by,IN,O
,lysosomal,JJ,O
,proteinases,NNS,O
,(,(,O
,Gly,NNP,O
,-,:,O
,Phe,NNP,O
,-,:,O
,Leu,NNP,O
,-,:,O
,Gly,NNP,O
,),),O
,.,.,O
,In,IN,O
,addition,NN,O
,",",",",O
,one,CD,O
,biodegradable,JJ,O
,conjugate,NN,O
,containing,VBG,O
,galactosamine,NN,O
,was,VBD,O
,used,VBN,O
,;,:,O
,this,DT,O
,residue,NN,O
,was,VBD,O
,targeted,VBN,O
,to,TO,O
,the,DT,O
,liver,NN,O
,.,.,O
,Over,IN,O
,the,DT,O
,first,JJ,O
,3,CD,O
,weeks,NNS,O
,after,IN,O
,the,DT,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,administration,NN,O
,of,IN,O
,free,JJ,O
,and,CC,O
,polymer,JJ,O
,-,:,O
,bound,NN,O
,DOX,NNP,O
,",",",",O
,all,DT,O
,animals,NNS,O
,showed,VBD,O
,a,DT,O
,transient,JJ,O
,reduction,NN,O
,in,IN,O
,body,NN,O
,weight,NN,O
,.,.,O
,However,RB,O
,",",",",O
,the,DT,O
,maximal,JJ,O
,reduction,NN,O
,in,IN,O
,body,NN,O
,weight,NN,O
,seen,VBN,O
,in,IN,O
,animals,NNS,O
,that,WDT,O
,received,VBD,O
,polymer,JJR,O
,-,:,O
,bound,NN,O
,DOX,NNP,O
,(,(,O
,4,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,was,VBD,O
,significantly,RB,O
,lower,JJR,O
,than,IN,O
,that,DT,O
,observed,VBD,O
,in,IN,O
,those,DT,O
,that,WDT,O
,received,VBD,O
,free,JJ,O
,DOX,NNP,O
,(,(,O
,4,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,or,CC,O
,a,DT,O
,mixture,NN,O
,of,IN,O
,the,DT,O
,unmodified,JJ,O
,parent,NN,O
,HPMA,NNP,O
,copolymer,NN,O
,and,CC,O
,free,JJ,O
,DOX,NNP,O
,(,(,O
,4,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,;,:,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,Throughout,IN,O
,the,DT,O
,study,NN,O
,(,(,O
,20,CD,O
,weeks,NNS,O
,),),O
,",",",",O
,deaths,NNS,O
,related,VBN,O
,to,TO,O
,cardiotoxicity,NN,B-DISEASE
,were,VBD,O
,observed,VBN,O
,only,RB,O
,in,IN,O
,animals,NNS,O
,that,WDT,O
,received,VBD,O
,either,DT,O
,free,JJ,O
,DOX,NNP,O
,or,CC,O
,the,DT,O
,mixture,NN,O
,of,IN,O
,HPMA,NNP,O
,copolymer,NN,O
,and,CC,O
,free,JJ,O
,DOX,NNP,O
,;,:,O
,in,IN,O
,these,DT,O
,cases,NNS,O
,",",",",O
,histological,JJ,O
,investigations,NNS,O
,revealed,VBD,O
,marked,JJ,O
,changes,NNS,O
,in,IN,O
,the,DT,O
,heart,NN,O
,that,WDT,O
,were,VBD,O
,consistent,JJ,O
,with,IN,O
,DOX,NNP,O
,-,:,O
,induced,JJ,O
,cardiotoxicity,NN,B-DISEASE
,.,.,O
,Sequential,JJ,O
,measurements,NNS,O
,of,IN,O
,cardiac,JJ,O
,output,NN,O
,in,IN,O
,surviving,VBG,O
,animals,NNS,O
,that,WDT,O
,received,VBD,O
,either,DT,O
,free,JJ,O
,DOX,NNP,O
,or,CC,O
,the,DT,O
,mixture,NN,O
,of,IN,O
,HPMA,NNP,O
,copolymer,NN,O
,and,CC,O
,free,JJ,O
,DOX,NNP,O
,showed,VBD,O
,a,DT,O
,reduction,NN,O
,of,IN,O
,approximately,RB,O
,30,CD,O
,%,NN,O
,in,IN,O
,function,NN,O
,beginning,NN,O
,at,IN,O
,the,DT,O
,4th,CD,O
,week,NN,O
,after,IN,O
,drug,NN,O
,administration,NN,O
,.,.,O
,The,DT,O
,heart,NN,O
,rate,NN,O
,in,IN,O
,these,DT,O
,animals,NNS,O
,was,VBD,O
,approximately,RB,O
,12,CD,O
,%,NN,O
,lower,JJR,O
,than,IN,O
,that,DT,O
,measured,VBN,O
,in,IN,O
,age,NN,O
,-,:,O
,matched,VBN,O
,control,NN,O
,rats,NNS,O
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,Animals,NNS,O
,that,WDT,O
,were,VBD,O
,given,VBN,O
,the,DT,O
,HPMA,NNP,O
,copolymer,NN,O
,conjugates,NNS,O
,containing,VBG,O
,DOX,NNP,O
,exhibited,VBD,O
,no,DT,O
,significant,JJ,O
,change,NN,O
,in,IN,O
,cardiac,NN,O
,output,NN,O
,throughout,IN,O
,the,DT,O
,study,NN,O
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,In,IN,O
,addition,NN,O
,",",",",O
,no,DT,O
,significant,JJ,O
,histological,JJ,O
,change,NN,O
,was,VBD,O
,observed,VBN,O
,in,IN,O
,the,DT,O
,heart,NN,O
,of,IN,O
,animals,NNS,O
,that,WDT,O
,received,VBD,O
,DOX,NNP,O
,in,IN,O
,the,DT,O
,form,NN,O
,of,IN,O
,HPMA,NNP,O
,copolymer,NN,O
,conjugates,NNS,O
,and,CC,O
,were,VBD,O
,killed,VBN,O
,at,IN,O
,the,DT,O
,end,NN,O
,of,IN,O
,the,DT,O
,study,NN,O
,.,.,O
,However,RB,O
,",",",",O
,these,DT,O
,animals,NNS,O
,had,VBD,O
,shown,VBN,O
,a,DT,O
,significant,JJ,O
,increase,NN,O
,in,IN,O
,heart,NN,O
,rate,NN,O
,beginning,NN,O
,at,IN,O
,8,CD,O
,weeks,NNS,O
,after,IN,O
,drug,NN,O
,administration,NN,O
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,(,(,O
,ABSTRACT,NNP,O
,TRUNCATED,NNP,O
,AT,NNP,O
,400,CD,O
,WORDS,NNP,O
,),),O
,Corneal,NNP,B-DISEASE
,ulcers,NNS,I-DISEASE
,associated,VBD,O
,with,IN,O
,aerosolized,JJ,O
,crack,NN,O
,cocaine,NN,O
,use,NN,O
,.,.,O
,PURPOSE,NN,O
,:,:,O
,We,PRP,O
,report,VBP,O
,4,CD,O
,cases,NNS,O
,of,IN,O
,corneal,NN,B-DISEASE
,ulcers,NNS,I-DISEASE
,associated,VBN,O
,with,IN,O
,drug,NN,B-DISEASE
,abuse,NN,I-DISEASE
,.,.,O
,The,DT,O
,pathogenesis,NN,O
,of,IN,O
,these,DT,O
,ulcers,NNS,B-DISEASE
,and,CC,O
,management,NN,O
,of,IN,O
,these,DT,O
,patients,NNS,O
,are,VBP,O
,also,RB,O
,reviewed,VBN,O
,.,.,O
,METHODS,NNP,O
,:,:,O
,Review,NN,O
,of,IN,O
,all,DT,O
,cases,NNS,O
,of,IN,O
,corneal,NN,B-DISEASE
,ulcers,NNS,I-DISEASE
,associated,VBN,O
,with,IN,O
,drug,NN,B-DISEASE
,abuse,NN,I-DISEASE
,seen,VBN,O
,at,IN,O
,our,PRP$,O
,institution,NN,O
,from,IN,O
,July,NNP,O
,2006,CD,O
,to,TO,O
,December,NNP,O
,2006,CD,O
,.,.,O
,RESULTS,VB,O
,:,:,O
,Four,CD,O
,patients,NNS,O
,with,IN,O
,corneal,JJ,B-DISEASE
,ulcers,NNS,I-DISEASE
,associated,VBN,O
,with,IN,O
,crack,NN,O
,cocaine,NN,O
,use,NN,O
,were,VBD,O
,reviewed,VBN,O
,.,.,O
,All,DT,O
,corneal,JJ,B-DISEASE
,ulcers,NNS,I-DISEASE
,were,VBD,O
,cultured,VBN,O
,",",",",O
,and,CC,O
,the,DT,O
,patients,NNS,O
,were,VBD,O
,admitted,VBN,O
,to,TO,O
,the,DT,O
,hospital,NN,O
,for,IN,O
,intensive,JJ,O
,topical,JJ,O
,antibiotic,JJ,O
,treatment,NN,O
,.,.,O
,Each,DT,O
,patient,NN,O
,received,VBD,O
,comprehensive,JJ,O
,health,NN,O
,care,NN,O
,",",",",O
,including,VBG,O
,medical,JJ,O
,and,CC,O
,substance,NN,B-DISEASE
,abuse,NN,I-DISEASE
,consultations,NNS,O
,.,.,O
,Streptococcal,JJ,O
,organisms,NNS,O
,were,VBD,O
,found,VBN,O
,in,IN,O
,3,CD,O
,cases,NNS,O
,and,CC,O
,Capnocytophaga,NNP,O
,and,CC,O
,Brevibacterium,NNP,O
,casei,NN,O
,in,IN,O
,1,CD,O
,patient,NN,O
,.,.,O
,The,DT,O
,infections,NNS,B-DISEASE
,responded,VBD,O
,to,TO,O
,antibiotic,JJ,O
,treatment,NN,O
,.,.,O
,Two,CD,O
,patients,NNS,O
,needed,VBD,O
,a,DT,O
,lateral,JJ,O
,tarsorrhaphy,NN,O
,for,IN,O
,persistent,JJ,O
,epithelial,JJ,B-DISEASE
,defects,NNS,I-DISEASE
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Aerosolized,NNP,O
,crack,NN,O
,cocaine,NN,O
,use,NN,O
,can,MD,O
,be,VB,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,corneal,NN,B-DISEASE
,ulcers,NNS,I-DISEASE
,.,.,O
,Drug,NNP,B-DISEASE
,abuse,NN,I-DISEASE
,provides,VBZ,O
,additional,JJ,O
,challenges,NNS,O
,for,IN,O
,management,NN,O
,.,.,O
,Not,RB,O
,only,RB,O
,treatment,NN,O
,of,IN,O
,their,PRP$,O
,infections,NNS,B-DISEASE
,but,CC,O
,also,RB,O
,the,DT,O
,overall,JJ,O
,poor,JJ,O
,health,NN,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,and,CC,O
,increased,JJ,O
,risk,NN,O
,of,IN,O
,noncompliance,NN,O
,need,NN,O
,to,TO,O
,be,VB,O
,addressed,VBN,O
,.,.,O
,Comprehensive,NNP,O
,care,NN,O
,may,MD,O
,provide,VB,O
,the,DT,O
,patient,NN,O
,the,DT,O
,opportunity,NN,O
,to,TO,O
,discontinue,VB,O
,their,PRP$,O
,substance,NN,B-DISEASE
,abuse,NN,I-DISEASE
,",",",",O
,improve,VB,O
,their,PRP$,O
,overall,JJ,O
,health,NN,O
,",",",",O
,and,CC,O
,prevent,JJ,O
,future,NN,O
,corneal,NN,O
,complications,NNS,O
,.,.,O
,Topical,JJ,O
,0,CD,O
,.,.,O
,025,CD,O
,%,NN,O
,capsaicin,NN,O
,in,IN,O
,chronic,JJ,O
,post,NN,B-DISEASE
,-,:,I-DISEASE
,herpetic,JJ,I-DISEASE
,neuralgia,NN,I-DISEASE
,:,:,O
,efficacy,NN,O
,",",",",O
,predictors,NNS,O
,of,IN,O
,response,NN,O
,and,CC,O
,long,JJ,O
,-,:,O
,term,NN,O
,course,NN,O
,.,.,O
,In,IN,O
,order,NN,O
,to,TO,O
,evaluate,VB,O
,the,DT,O
,efficacy,NN,O
,",",",",O
,time,NN,O
,-,:,O
,course,NN,O
,of,IN,O
,action,NN,O
,and,CC,O
,predictors,NNS,O
,of,IN,O
,response,NN,O
,to,TO,O
,topical,JJ,O
,capsaicin,NN,O
,",",",",O
,39,CD,O
,patients,NNS,O
,with,IN,O
,chronic,JJ,O
,post,NN,B-DISEASE
,-,:,I-DISEASE
,herpetic,JJ,I-DISEASE
,neuralgia,NN,I-DISEASE
,(,(,O
,PHN,NNP,B-DISEASE
,),),O
,",",",",O
,median,JJ,O
,duration,NN,O
,24,CD,O
,months,NNS,O
,",",",",O
,were,VBD,O
,treated,VBN,O
,with,IN,O
,0,CD,O
,.,.,O
,025,CD,O
,%,NN,O
,capsaicin,NN,O
,cream,NN,O
,for,IN,O
,8,CD,O
,weeks,NNS,O
,.,.,O
,During,IN,O
,therapy,NN,O
,the,DT,O
,patients,NNS,O
,rated,VBD,O
,their,PRP$,O
,pain,NN,B-DISEASE
,on,IN,O
,a,DT,O
,visual,JJ,O
,analogue,NN,O
,scale,NN,O
,(,(,O
,VAS,NNP,O
,),),O
,and,CC,O
,a,DT,O
,verbal,JJ,O
,outcome,NN,O
,scale,NN,O
,.,.,O
,A,DT,O
,follow,JJ,O
,-,:,O
,up,IN,O
,investigation,NN,O
,was,VBD,O
,performed,VBN,O
,10,CD,O
,-,:,O
,12,CD,O
,months,NNS,O
,after,IN,O
,study,NN,O
,onset,NN,O
,on,IN,O
,the,DT,O
,patients,NNS,O
,who,WP,O
,had,VBD,O
,improved,VBN,O
,.,.,O
,Nineteen,JJ,O
,patients,NNS,O
,(,(,O
,48,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,),),O
,substantially,RB,O
,improved,VBN,O
,after,IN,O
,the,DT,O
,8,CD,O
,-,:,O
,week,NN,O
,trial,NN,O
,;,:,O
,5,CD,O
,(,(,O
,12,CD,O
,.,.,O
,8,CD,O
,%,NN,O
,),),O
,discontinued,VBN,O
,therapy,NN,O
,due,JJ,O
,to,TO,O
,side,VB,O
,-,:,O
,effects,NNS,O
,such,JJ,O
,as,IN,O
,intolerable,JJ,O
,capsaicin,NN,O
,-,:,O
,induced,JJ,O
,burning,NN,O
,sensations,NNS,O
,(,(,O
,4,CD,O
,),),O
,or,CC,O
,mastitis,NN,B-DISEASE
,(,(,O
,1,CD,O
,),),O
,;,:,O
,15,CD,O
,(,(,O
,38,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,),),O
,reported,VBD,O
,no,DT,O
,benefit,NN,O
,.,.,O
,The,DT,O
,decrease,NN,O
,in,IN,O
,VAS,NNP,O
,ratings,NNS,O
,was,VBD,O
,significant,JJ,O
,after,IN,O
,2,CD,O
,weeks,NNS,O
,of,IN,O
,continuous,JJ,O
,application,NN,O
,.,.,O
,Of,IN,O
,the,DT,O
,responders,NNS,O
,72,CD,O
,.,.,O
,2,CD,O
,%,NN,O
,were,VBD,O
,still,RB,O
,improved,VBN,O
,at,IN,O
,the,DT,O
,follow,NN,O
,-,:,O
,up,RB,O
,;,:,O
,only,RB,O
,one,CD,O
,-,:,O
,third,NN,O
,of,IN,O
,them,PRP,O
,had,VBD,O
,continued,VBN,O
,application,NN,O
,irregularly,RB,O
,.,.,O
,Treatment,JJ,O
,effect,NN,O
,was,VBD,O
,not,RB,O
,dependent,JJ,O
,on,IN,O
,patient,NN,O
,','',O
,s,JJ,O
,age,NN,O
,",",",",O
,duration,NN,O
,or,CC,O
,localization,NN,O
,of,IN,O
,PHN,NNP,B-DISEASE
,(,(,O
,trigeminal,JJ,O
,involvement,NN,O
,was,VBD,O
,excluded,VBN,O
,),),O
,",",",",O
,sensory,JJ,B-DISEASE
,disturbance,NN,I-DISEASE
,or,CC,O
,pain,NN,B-DISEASE
,character,NN,O
,.,.,O
,Treatment,JJ,O
,response,NN,O
,was,VBD,O
,not,RB,O
,correlated,VBN,O
,with,IN,O
,the,DT,O
,incidence,NN,O
,",",",",O
,time,NN,O
,-,:,O
,course,NN,O
,or,CC,O
,severity,NN,O
,of,IN,O
,capsaicin,NN,O
,-,:,O
,induced,JJ,O
,burning,NN,O
,.,.,O
,If,IN,O
,confirmed,VBN,O
,in,IN,O
,controlled,JJ,O
,trials,NNS,O
,",",",",O
,the,DT,O
,long,JJ,O
,-,:,O
,term,NN,O
,results,NNS,O
,of,IN,O
,this,DT,O
,open,JJ,O
,",",",",O
,non,JJ,O
,-,:,O
,randomized,VBN,O
,study,NN,O
,might,MD,O
,indicate,VB,O
,that,IN,O
,the,DT,O
,analgesic,JJ,O
,effect,NN,O
,of,IN,O
,capsaicin,NN,O
,in,IN,O
,PHN,NNP,B-DISEASE
,is,VBZ,O
,mediated,VBN,O
,by,IN,O
,both,DT,O
,interference,NN,O
,with,IN,O
,neuropeptide,JJ,O
,metabolism,NN,O
,and,CC,O
,morphological,JJ,O
,changes,NNS,O
,(,(,O
,perhaps,RB,O
,degeneration,NN,O
,),),O
,of,IN,O
,nociceptive,JJ,O
,afferents,NNS,O
,.,.,O
,Myo,NNP,O
,-,:,O
,inositol,NN,O
,-,:,O
,1,CD,O
,-,:,O
,phosphate,NN,O
,(,(,O
,MIP,NNP,O
,),),O
,synthase,NN,O
,inhibition,NN,O
,:,:,O
,in,IN,O
,-,:,O
,vivo,NN,O
,study,NN,O
,in,IN,O
,rats,NNS,O
,.,.,O
,Lithium,NN,O
,and,CC,O
,valproate,NN,O
,are,VBP,O
,the,DT,O
,prototypic,NN,O
,mood,NN,O
,stabilizers,NNS,O
,and,CC,O
,have,VBP,O
,diverse,VBN,O
,structures,NNS,O
,and,CC,O
,targets,NNS,O
,.,.,O
,Both,DT,O
,drugs,NNS,O
,influence,NN,O
,inositol,NN,O
,metabolism,NN,O
,.,.,O
,Lithium,NNP,O
,inhibits,VBZ,O
,IMPase,NNP,O
,and,CC,O
,valproate,VB,O
,inhibits,NNS,O
,MIP,NNP,O
,synthase,NN,O
,.,.,O
,This,DT,O
,study,NN,O
,shows,VBZ,O
,that,IN,O
,MIP,NNP,O
,synthase,VBD,O
,inhibition,NN,O
,does,VBZ,O
,not,RB,O
,replicate,VB,O
,or,CC,O
,augment,VB,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,lithium,NN,O
,in,IN,O
,the,DT,O
,inositol,NN,O
,sensitive,JJ,O
,pilocarpine,NN,O
,-,:,O
,induced,JJ,O
,seizures,NNS,B-DISEASE
,model,NN,O
,.,.,O
,This,DT,O
,lack,NN,O
,of,IN,O
,effects,NNS,O
,may,MD,O
,stem,VB,O
,from,IN,O
,the,DT,O
,low,JJ,O
,contribution,NN,O
,of,IN,O
,de,FW,O
,-,:,O
,novo,JJ,O
,synthesis,NN,O
,to,TO,O
,cellular,VB,O
,inositol,JJ,O
,supply,NN,O
,or,CC,O
,to,TO,O
,the,DT,O
,inhibition,NN,O
,of,IN,O
,the,DT,O
,de,FW,O
,-,:,O
,novo,JJ,O
,synthesis,NN,O
,by,IN,O
,lithium,NN,O
,itself,PRP,O
,.,.,O
,Non,NNP,O
,-,:,O
,steroidal,NN,O
,anti,SYM,O
,-,:,O
,inflammatory,NN,O
,drugs,NNS,O
,-,:,O
,associated,VBN,O
,acute,JJ,O
,interstitial,JJ,B-DISEASE
,nephritis,NN,I-DISEASE
,with,IN,O
,granular,JJ,O
,tubular,JJ,O
,basement,NN,O
,membrane,NN,O
,deposits,NNS,O
,.,.,O
,Acute,NNP,B-DISEASE
,tubulo,SYM,I-DISEASE
,-,:,I-DISEASE
,interstitial,JJ,I-DISEASE
,nephritis,NN,I-DISEASE
,(,(,O
,ATIN,NNP,B-DISEASE
,),),O
,is,VBZ,O
,an,DT,O
,important,JJ,O
,cause,NN,O
,of,IN,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,resulting,VBG,O
,from,IN,O
,a,DT,O
,variety,NN,O
,of,IN,O
,insults,NNS,O
,",",",",O
,including,VBG,O
,immune,NN,O
,complex,JJ,O
,-,:,O
,mediated,VBN,O
,tubulo,JJ,B-DISEASE
,-,:,I-DISEASE
,interstitial,JJ,I-DISEASE
,injury,NN,I-DISEASE
,",",",",O
,but,CC,O
,drugs,NNS,O
,such,JJ,O
,as,IN,O
,non,JJ,O
,-,:,O
,steroidal,NN,O
,anti,SYM,O
,-,:,O
,inflammatory,NN,O
,drugs,NNS,O
,(,(,O
,NSAIDs,NNP,O
,),),O
,are,VBP,O
,a,DT,O
,far,RB,O
,more,RBR,O
,frequent,JJ,O
,cause,NN,O
,.,.,O
,Overall,JJ,O
,",",",",O
,as,IN,O
,an,DT,O
,entity,NN,O
,",",",",O
,ATIN,NNP,B-DISEASE
,remains,VBZ,O
,under,IN,O
,-,:,O
,diagnosed,JJ,O
,",",",",O
,as,IN,O
,symptoms,NNS,O
,resolve,VBP,O
,spontaneously,RB,O
,if,IN,O
,the,DT,O
,medication,NN,O
,is,VBZ,O
,stopped,VBN,O
,.,.,O
,We,PRP,O
,report,VBP,O
,on,IN,O
,a,DT,O
,14,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,boy,NN,O
,who,WP,O
,developed,VBD,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,2,CD,O
,weeks,NNS,O
,after,IN,O
,aortic,JJ,O
,valve,NN,O
,surgery,NN,O
,.,.,O
,He,PRP,O
,was,VBD,O
,put,VBN,O
,on,IN,O
,aspirin,NN,O
,following,VBG,O
,surgery,NN,O
,and,CC,O
,took,VBD,O
,ibuprofen,NN,O
,for,IN,O
,fever,NN,B-DISEASE
,for,IN,O
,nearly,RB,O
,a,DT,O
,week,NN,O
,prior,RB,O
,to,TO,O
,presentation,NN,O
,.,.,O
,He,PRP,O
,then,RB,O
,presented,VBD,O
,to,TO,O
,the,DT,O
,emergency,NN,O
,department,NN,O
,feeling,VBG,O
,quite,RB,O
,ill,JJ,O
,and,CC,O
,was,VBD,O
,found,VBN,O
,to,TO,O
,have,VB,O
,a,DT,O
,blood,NN,O
,urea,JJ,O
,nitrogen,NN,O
,(,(,O
,BUN,NNP,O
,),),O
,concentration,NN,O
,of,IN,O
,of,IN,O
,147,CD,O
,mg,NNS,O
,/,JJ,O
,dl,NN,O
,",",",",O
,creatinine,NN,O
,of,IN,O
,15,CD,O
,.,.,O
,3,CD,O
,mg,JJ,O
,/,NNP,O
,dl,NN,O
,and,CC,O
,serum,JJ,O
,potassium,NN,O
,of,IN,O
,8,CD,O
,.,.,O
,7,CD,O
,mEq,JJ,O
,/,NNP,O
,l,NN,O
,.,.,O
,Dialysis,NN,O
,was,VBD,O
,immediately,RB,O
,initiated,VBN,O
,.,.,O
,A,DT,O
,kidney,NN,O
,biopsy,NN,O
,showed,VBD,O
,inflammatory,JJ,O
,infiltrate,JJ,O
,consistent,NN,O
,with,IN,O
,ATIN,NNP,B-DISEASE
,.,.,O
,However,RB,O
,",",",",O
,in,IN,O
,the,DT,O
,tubular,JJ,O
,basement,NN,O
,membrane,NN,O
,(,(,O
,TBM,NNP,O
,),),O
,",",",",O
,very,RB,O
,intense,JJ,O
,granular,JJ,O
,deposits,NNS,O
,of,IN,O
,polyclonal,JJ,O
,IgG,NNP,O
,and,CC,O
,C3,NNP,O
,were,VBD,O
,noted,VBN,O
,.,.,O
,He,PRP,O
,needed,VBD,O
,dialysis,NN,O
,for,IN,O
,2,CD,O
,weeks,NNS,O
,and,CC,O
,was,VBD,O
,treated,VBN,O
,successfully,RB,O
,with,IN,O
,steroids,NNS,O
,for,IN,O
,6,CD,O
,months,NNS,O
,.,.,O
,His,PRP$,O
,renal,JJ,O
,recovery,NN,O
,and,CC,O
,disappearance,NN,O
,of,IN,O
,proteinuria,NNS,B-DISEASE
,took,VBD,O
,a,DT,O
,year,NN,O
,.,.,O
,In,IN,O
,conclusion,NN,O
,",",",",O
,this,DT,O
,is,VBZ,O
,a,DT,O
,first,JJ,O
,report,NN,O
,of,IN,O
,NSAIDs,NNP,O
,-,:,O
,associated,VBN,O
,ATIN,NNP,B-DISEASE
,",",",",O
,showing,VBG,O
,deposits,NNS,O
,of,IN,O
,granular,JJ,O
,immune,NN,O
,complex,JJ,O
,present,NN,O
,only,RB,O
,in,IN,O
,the,DT,O
,TBM,NNP,O
,and,CC,O
,not,RB,O
,in,IN,O
,the,DT,O
,glomeruli,NN,O
,.,.,O
,Rifampicin,NNP,O
,-,:,O
,associated,VBN,O
,segmental,JJ,O
,necrotizing,VBG,O
,glomerulonephritis,NN,B-DISEASE
,in,IN,O
,staphylococcal,JJ,B-DISEASE
,endocarditis,NN,I-DISEASE
,.,.,O
,Segmental,JJ,O
,necrotising,VBG,O
,glomerulonephritis,NN,B-DISEASE
,has,VBZ,O
,been,VBN,O
,reported,VBN,O
,as,IN,O
,complication,NN,O
,of,IN,O
,rifampicin,NN,O
,therapy,NN,O
,in,IN,O
,patients,NNS,O
,receiving,VBG,O
,treatment,NN,O
,for,IN,O
,tuberculosis,NN,B-DISEASE
,.,.,O
,Changing,VBG,O
,epidemiology,NN,O
,of,IN,O
,infections,NNS,B-DISEASE
,such,JJ,O
,as,IN,O
,infective,JJ,B-DISEASE
,endocarditis,NN,I-DISEASE
,(,(,O
,IE,NNP,B-DISEASE
,),),O
,has,VBZ,O
,led,VBN,O
,to,TO,O
,an,DT,O
,increase,NN,O
,in,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,rifampicin,NN,O
,for,IN,O
,Staphylococcal,JJ,B-DISEASE
,infections,NNS,I-DISEASE
,.,.,O
,We,PRP,O
,describe,VBP,O
,a,DT,O
,case,NN,O
,of,IN,O
,a,DT,O
,patient,NN,O
,with,IN,O
,Staphylococcal,NNP,B-DISEASE
,IE,NNP,I-DISEASE
,who,WP,O
,developed,VBD,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,secondary,JJ,O
,to,TO,O
,a,DT,O
,segmental,JJ,O
,necrotising,NN,O
,glomerulonephritis,NN,B-DISEASE
,while,IN,O
,being,VBG,O
,treated,VBN,O
,with,IN,O
,rifampicin,NN,O
,",",",",O
,and,CC,O
,review,VB,O
,the,DT,O
,literature,NN,O
,regarding,VBG,O
,this,DT,O
,complication,NN,O
,of,IN,O
,rifampicin,JJ,O
,therapy,NN,O
,.,.,O
,Rate,NNP,O
,of,IN,O
,YMDD,NNP,O
,motif,NN,O
,mutants,NNS,O
,in,IN,O
,lamivudine,JJ,O
,-,:,O
,untreated,JJ,O
,Iranian,JJ,O
,patients,NNS,O
,with,IN,O
,chronic,JJ,B-DISEASE
,hepatitis,NN,I-DISEASE
,B,NNP,I-DISEASE
,virus,NN,I-DISEASE
,infection,NN,I-DISEASE
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Lamivudine,NN,O
,is,VBZ,O
,used,VBN,O
,for,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,chronic,JJ,B-DISEASE
,hepatitis,NN,I-DISEASE
,B,NNP,I-DISEASE
,patients,NNS,O
,.,.,O
,Recent,JJ,O
,studies,NNS,O
,show,VBP,O
,that,IN,O
,the,DT,O
,YMDD,NNP,O
,motif,NN,O
,mutants,NNS,O
,(,(,O
,resistant,JJ,O
,hepatitis,NN,B-DISEASE
,B,NNP,I-DISEASE
,virus,NN,O
,),),O
,occur,NN,O
,as,IN,O
,natural,JJ,O
,genome,NN,O
,variability,NN,O
,in,IN,O
,lamivudine,JJ,O
,-,:,O
,untreated,JJ,O
,chronic,JJ,B-DISEASE
,hepatitis,NN,I-DISEASE
,B,NNP,I-DISEASE
,patients,NNS,O
,.,.,O
,In,IN,O
,this,DT,O
,study,NN,O
,we,PRP,O
,aimed,VBD,O
,to,TO,O
,determine,VB,O
,the,DT,O
,rate,NN,O
,of,IN,O
,YMDD,NNP,O
,motif,NN,O
,mutants,NNS,O
,in,IN,O
,lamivudine,JJ,O
,-,:,O
,untreated,JJ,O
,chronic,JJ,B-DISEASE
,hepatitis,NN,I-DISEASE
,B,NNP,I-DISEASE
,patients,NNS,O
,in,IN,O
,Iran,NNP,O
,.,.,O
,PATIENTS,NNP,O
,AND,CC,O
,METHODS,NNP,O
,:,:,O
,A,DT,O
,total,NN,O
,of,IN,O
,77,CD,O
,chronic,JJ,B-DISEASE
,hepatitis,NN,I-DISEASE
,B,NNP,I-DISEASE
,patients,NNS,O
,who,WP,O
,had,VBD,O
,not,RB,O
,been,VBN,O
,treated,VBN,O
,with,IN,O
,lamivudine,NN,O
,were,VBD,O
,included,VBN,O
,in,IN,O
,the,DT,O
,study,NN,O
,.,.,O
,Serum,NNP,O
,samples,NNS,O
,from,IN,O
,patients,NNS,O
,were,VBD,O
,tested,VBN,O
,by,IN,O
,polymerase,NN,O
,chain,NN,O
,reaction,NN,O
,-,:,O
,restriction,NN,O
,fragment,NN,O
,length,NN,O
,polymorphism,NN,O
,(,(,O
,PCR,NNP,O
,-,:,O
,RFLP,NN,O
,),),O
,for,IN,O
,detection,NN,O
,of,IN,O
,YMDD,NNP,O
,motif,NN,O
,mutants,NNS,O
,.,.,O
,All,DT,O
,patients,NNS,O
,were,VBD,O
,also,RB,O
,tested,VBN,O
,for,IN,O
,liver,NN,O
,enzymes,NNS,O
,",",",",O
,anti,SYM,O
,-,:,O
,HCV,NNP,O
,",",",",O
,HBeAg,NNP,O
,",",",",O
,and,CC,O
,anti,SYM,O
,-,:,O
,HBe,NNP,O
,.,.,O
,RESULTS,NNP,O
,:,:,O
,Of,IN,O
,the,DT,O
,77,CD,O
,patients,NNS,O
,enrolled,VBN,O
,in,IN,O
,the,DT,O
,study,NN,O
,",",",",O
,73,CD,O
,%,NN,O
,were,VBD,O
,male,JJ,O
,and,CC,O
,27,CD,O
,%,NN,O
,were,VBD,O
,female,JJ,O
,.,.,O
,Mean,NNP,O
,ALT,NNP,O
,and,CC,O
,AST,NNP,O
,levels,NNS,O
,were,VBD,O
,124,CD,O
,.,.,O
,4,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,73,CD,O
,.,.,O
,4,CD,O
,and,CC,O
,103,CD,O
,.,.,O
,1,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,81,CD,O
,IU,NNP,O
,/,NNP,O
,l,NN,O
,",",",",O
,respectively,RB,O
,.,.,O
,HBeAg,NNP,O
,was,VBD,O
,positive,JJ,O
,in,IN,O
,40,CD,O
,%,NN,O
,and,CC,O
,anti,JJ,O
,-,:,O
,HBe,NN,O
,in,IN,O
,60,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,.,.,O
,Anti,NNP,O
,-,:,O
,HCV,NNP,O
,was,VBD,O
,negative,JJ,O
,in,IN,O
,all,DT,O
,of,IN,O
,them,PRP,O
,.,.,O
,YMDD,VB,O
,motif,JJ,O
,mutants,NNS,O
,were,VBD,O
,not,RB,O
,detected,VBN,O
,in,IN,O
,any,DT,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,despite,IN,O
,the,DT,O
,liver,NN,O
,enzyme,NN,O
,levels,NNS,O
,and,CC,O
,the,DT,O
,presence,NN,O
,of,IN,O
,HBeAg,NNP,O
,or,CC,O
,anti,SYM,O
,-,:,O
,HBe,NNP,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Although,IN,O
,the,DT,O
,natural,JJ,O
,occurrence,NN,O
,of,IN,O
,YMDD,NNP,O
,motif,NN,O
,mutants,NNS,O
,in,IN,O
,lamivudine,JJ,O
,-,:,O
,untreated,JJ,O
,patients,NNS,O
,with,IN,O
,chronic,JJ,B-DISEASE
,hepatitis,NN,I-DISEASE
,B,NNP,I-DISEASE
,has,VBZ,O
,been,VBN,O
,reported,VBN,O
,",",",",O
,these,DT,O
,mutants,NNS,O
,were,VBD,O
,not,RB,O
,detected,VBN,O
,in,IN,O
,Iranian,JJ,O
,lamivudine,NN,O
,-,:,O
,untreated,JJ,O
,chronic,JJ,B-DISEASE
,hepatitis,NN,I-DISEASE
,B,NNP,I-DISEASE
,patients,NNS,O
,.,.,O
,Branch,NNP,O
,retinal,JJ,B-DISEASE
,vein,NN,I-DISEASE
,occlusion,NN,I-DISEASE
,and,CC,O
,fluoxetine,NN,O
,.,.,O
,A,DT,O
,case,NN,O
,of,IN,O
,branch,NN,O
,retinal,JJ,B-DISEASE
,vein,NN,I-DISEASE
,occlusion,NN,I-DISEASE
,associated,VBN,O
,with,IN,O
,fluoxetine,JJ,O
,-,:,O
,induced,JJ,O
,secondary,JJ,O
,hypertension,NN,B-DISEASE
,is,VBZ,O
,described,VBN,O
,.,.,O
,Although,IN,O
,an,DT,O
,infrequent,JJ,O
,complication,NN,O
,of,IN,O
,selective,JJ,O
,serotonin,NNS,O
,reuptake,VBP,O
,inhibitor,NN,O
,therapy,NN,O
,",",",",O
,it,PRP,O
,is,VBZ,O
,important,JJ,O
,that,IN,O
,ophthalmologists,NNS,O
,are,VBP,O
,aware,JJ,O
,that,IN,O
,these,DT,O
,agents,NNS,O
,can,MD,O
,cause,VB,O
,hypertension,NN,B-DISEASE
,because,IN,O
,this,DT,O
,class,NN,O
,of,IN,O
,drugs,NNS,O
,is,VBZ,O
,widely,RB,O
,prescribed,VBN,O
,.,.,O
,The,DT,O
,differential,JJ,O
,effects,NNS,O
,of,IN,O
,bupivacaine,NN,O
,and,CC,O
,lidocaine,NN,O
,on,IN,O
,prostaglandin,NN,O
,E2,NNP,O
,release,NN,O
,",",",",O
,cyclooxygenase,NN,O
,gene,NN,O
,expression,NN,O
,and,CC,O
,pain,NN,B-DISEASE
,in,IN,O
,a,DT,O
,clinical,JJ,O
,pain,NN,B-DISEASE
,model,NN,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,In,IN,O
,addition,NN,O
,to,TO,O
,blocking,VBG,O
,nociceptive,JJ,O
,input,NN,O
,from,IN,O
,surgical,JJ,O
,sites,NNS,O
,",",",",O
,long,JJ,O
,-,:,O
,acting,VBG,O
,local,JJ,O
,anesthetics,NNS,O
,might,MD,O
,directly,RB,O
,modulate,VB,O
,inflammation,NN,B-DISEASE
,.,.,O
,In,IN,O
,the,DT,O
,present,JJ,O
,study,NN,O
,",",",",O
,we,PRP,O
,describe,VBP,O
,the,DT,O
,proinflammatory,JJ,O
,effects,NNS,O
,of,IN,O
,bupivacaine,NN,O
,on,IN,O
,local,JJ,O
,prostaglandin,NN,O
,E2,NNP,O
,(,(,O
,PGE2,NNP,O
,),),O
,production,NN,O
,and,CC,O
,cyclooxygenase,NN,O
,(,(,O
,COX,NNP,O
,),),O
,gene,NN,O
,expression,NN,O
,that,WDT,O
,increases,VBZ,O
,postoperative,JJ,B-DISEASE
,pain,NN,I-DISEASE
,in,IN,O
,human,JJ,O
,subjects,NNS,O
,.,.,O
,METHODS,NN,O
,:,:,O
,Subjects,NNS,O
,(,(,O
,n,JJ,O
,=,NNP,O
,114,CD,O
,),),O
,undergoing,VBG,O
,extraction,NN,O
,of,IN,O
,impacted,JJ,O
,third,JJ,O
,molars,NNS,O
,received,VBD,O
,either,RB,O
,2,CD,O
,%,NN,O
,lidocaine,NN,O
,or,CC,O
,0,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,bupivacaine,NN,O
,before,IN,O
,surgery,NN,O
,and,CC,O
,either,DT,O
,rofecoxib,NN,O
,50,CD,O
,mg,NN,O
,or,CC,O
,placebo,VB,O
,orally,RB,O
,90,CD,O
,min,NN,O
,before,IN,O
,surgery,NN,O
,and,CC,O
,for,IN,O
,the,DT,O
,following,JJ,O
,48,CD,O
,h,NN,O
,.,.,O
,Oral,JJ,O
,mucosal,NN,O
,biopsies,NNS,O
,were,VBD,O
,taken,VBN,O
,before,RB,O
,surgery,NN,O
,and,CC,O
,48,CD,O
,h,NN,O
,after,IN,O
,surgery,NN,O
,.,.,O
,After,IN,O
,extraction,NN,O
,",",",",O
,a,DT,O
,microdialysis,NN,O
,probe,NN,O
,was,VBD,O
,placed,VBN,O
,at,IN,O
,the,DT,O
,surgical,JJ,O
,site,NN,O
,for,IN,O
,PGE2,NNP,O
,and,CC,O
,thromboxane,NN,O
,B2,NNP,O
,(,(,O
,TXB2,NNP,O
,),),O
,measurements,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,The,DT,O
,bupivacaine,NN,O
,/,NNP,O
,rofecoxib,NN,O
,group,NN,O
,reported,VBD,O
,significantly,RB,O
,less,JJR,O
,pain,NN,B-DISEASE
,",",",",O
,as,IN,O
,assessed,VBN,O
,by,IN,O
,a,DT,O
,visual,JJ,O
,analog,NN,O
,scale,NN,O
,",",",",O
,compared,VBN,O
,with,IN,O
,the,DT,O
,other,JJ,O
,three,CD,O
,treatment,NN,O
,groups,NNS,O
,over,IN,O
,the,DT,O
,first,JJ,O
,4,CD,O
,h,NN,O
,.,.,O
,However,RB,O
,",",",",O
,the,DT,O
,bupivacaine,NN,O
,/,NNP,O
,placebo,NN,O
,group,NN,O
,reported,VBD,O
,significantly,RB,O
,more,RBR,O
,pain,NN,B-DISEASE
,at,IN,O
,24,CD,O
,h,NN,O
,and,CC,O
,PGE2,NNP,O
,levels,NNS,O
,during,IN,O
,the,DT,O
,first,JJ,O
,4,CD,O
,h,NN,O
,were,VBD,O
,significantly,RB,O
,higher,JJR,O
,than,IN,O
,the,DT,O
,other,JJ,O
,three,CD,O
,treatment,NN,O
,groups,NNS,O
,.,.,O
,Moreover,RB,O
,",",",",O
,bupivacaine,VB,O
,significantly,RB,O
,increased,VBN,O
,COX,NNP,O
,-,:,O
,2,CD,O
,gene,NN,O
,expression,NN,O
,at,IN,O
,48,CD,O
,h,NN,O
,as,IN,O
,compared,VBN,O
,with,IN,O
,the,DT,O
,lidocaine,NN,O
,/,NNP,O
,placebo,NN,O
,group,NN,O
,.,.,O
,Thromboxane,NN,O
,levels,NNS,O
,were,VBD,O
,not,RB,O
,significantly,RB,O
,affected,VBN,O
,by,IN,O
,any,DT,O
,of,IN,O
,the,DT,O
,treatments,NNS,O
,",",",",O
,indicating,VBG,O
,that,IN,O
,the,DT,O
,effects,NNS,O
,seen,VBN,O
,were,VBD,O
,attributable,JJ,O
,to,TO,O
,inhibition,NN,O
,of,IN,O
,COX,NNP,O
,-,:,O
,2,CD,O
,",",",",O
,but,CC,O
,not,RB,O
,COX,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,These,DT,O
,results,NNS,O
,suggest,VBP,O
,that,IN,O
,bupivacaine,NN,O
,stimulates,NNS,O
,COX,NNP,O
,-,:,O
,2,CD,O
,gene,NN,O
,expression,NN,O
,after,IN,O
,tissue,NN,B-DISEASE
,injury,NN,I-DISEASE
,",",",",O
,which,WDT,O
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,higher,JJR,O
,PGE2,NNP,O
,production,NN,O
,and,CC,O
,pain,NN,B-DISEASE
,after,IN,O
,the,DT,O
,local,JJ,O
,anesthetic,JJ,O
,effect,NN,O
,dissipates,NNS,O
,.,.,O
,p75NTR,JJ,O
,expression,NN,O
,in,IN,O
,rat,NN,O
,urinary,JJ,O
,bladder,NN,O
,sensory,JJ,O
,neurons,NNS,O
,and,CC,O
,spinal,JJ,O
,cord,NN,O
,with,IN,O
,cyclophosphamide,JJ,O
,-,:,O
,induced,JJ,O
,cystitis,NN,B-DISEASE
,.,.,O
,A,DT,O
,role,NN,O
,for,IN,O
,nerve,NN,O
,growth,NN,O
,factor,NN,O
,(,(,O
,NGF,NNP,O
,),),O
,in,IN,O
,contributing,VBG,O
,to,TO,O
,increased,VBN,O
,voiding,NN,O
,frequency,NN,O
,and,CC,O
,altered,JJ,O
,sensation,NN,O
,from,IN,O
,the,DT,O
,urinary,JJ,O
,bladder,NN,O
,has,VBZ,O
,been,VBN,O
,suggested,VBN,O
,.,.,O
,Previous,JJ,O
,studies,NNS,O
,have,VBP,O
,examined,VBN,O
,the,DT,O
,expression,NN,O
,and,CC,O
,regulation,NN,O
,of,IN,O
,tyrosine,JJ,O
,kinase,NN,O
,receptors,NNS,O
,(,(,O
,Trks,NNPS,O
,),),O
,in,IN,O
,micturition,NN,O
,reflexes,NNS,O
,with,IN,O
,urinary,JJ,B-DISEASE
,bladder,NN,I-DISEASE
,inflammation,NN,I-DISEASE
,.,.,O
,The,DT,O
,present,JJ,O
,studies,NNS,O
,examine,VBP,O
,the,DT,O
,expression,NN,O
,and,CC,O
,regulation,NN,O
,of,IN,O
,another,DT,O
,receptor,NN,O
,known,VBN,O
,to,TO,O
,bind,VB,O
,NGF,NNP,O
,",",",",O
,p75,NN,O
,(,(,O
,NTR,NNP,O
,),),O
,",",",",O
,after,IN,O
,various,JJ,O
,durations,NNS,O
,of,IN,O
,bladder,NN,B-DISEASE
,inflammation,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,cyclophosphamide,NN,O
,(,(,O
,CYP,NNP,O
,),),O
,.,.,O
,CYP,NNP,O
,-,:,O
,induced,JJ,O
,cystitis,NN,B-DISEASE
,increased,VBD,O
,(,(,O
,P,NNP,O
,<,NNP,O
,or,CC,O
,=,$,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,p75,NN,O
,(,(,O
,NTR,NNP,O
,),),O
,expression,NN,O
,in,IN,O
,the,DT,O
,superficial,JJ,O
,lateral,JJ,O
,and,CC,O
,medial,JJ,O
,dorsal,NN,O
,horn,VBN,O
,in,IN,O
,L1,NNP,O
,-,:,O
,L2,NNP,O
,and,CC,O
,L6,NNP,O
,-,:,O
,S1,NNP,O
,spinal,JJ,O
,segments,NNS,O
,.,.,O
,The,DT,O
,number,NN,O
,of,IN,O
,p75,NN,O
,(,(,O
,NTR,NNP,O
,),),O
,-,:,O
,immunoreactive,NN,O
,(,(,O
,-,:,O
,IR,NN,O
,),),O
,cells,NNS,O
,in,IN,O
,the,DT,O
,lumbosacral,JJ,O
,dorsal,NN,O
,root,NN,O
,ganglia,NN,O
,(,(,O
,DRG,NNP,O
,),),O
,also,RB,O
,increased,VBN,O
,(,(,O
,P,NNP,O
,<,NNP,O
,or,CC,O
,=,$,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,with,IN,O
,CYP,NNP,O
,-,:,O
,induced,JJ,O
,cystitis,NN,B-DISEASE
,(,(,O
,acute,JJ,O
,",",",",O
,intermediate,JJ,O
,",",",",O
,and,CC,O
,chronic,NN,O
,),),O
,.,.,O
,Quantitative,NNP,O
,",",",",O
,real,JJ,O
,-,:,O
,time,NN,O
,polymerase,NN,O
,chain,NN,O
,reaction,NN,O
,also,RB,O
,demonstrated,VBD,O
,significant,JJ,O
,increases,NNS,O
,(,(,O
,P,NNP,O
,<,NNP,O
,or,CC,O
,=,$,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,in,IN,O
,p75,NN,O
,(,(,O
,NTR,NNP,O
,),),O
,mRNA,NN,O
,in,IN,O
,DRG,NNP,O
,with,IN,O
,intermediate,JJ,O
,and,CC,O
,chronic,JJ,O
,CYP,NNP,O
,-,:,O
,induced,VBD,O
,cystitis,NN,B-DISEASE
,.,.,O
,Retrograde,NNP,O
,dye,SYM,O
,-,:,O
,tracing,VBG,O
,techniques,NNS,O
,with,IN,O
,Fastblue,NNP,O
,were,VBD,O
,used,VBN,O
,to,TO,O
,identify,VB,O
,presumptive,JJ,O
,bladder,NN,O
,afferent,NN,O
,cells,NNS,O
,in,IN,O
,the,DT,O
,lumbosacral,JJ,O
,DRG,NNP,O
,.,.,O
,In,IN,O
,bladder,NN,O
,afferent,NN,O
,cells,NNS,O
,in,IN,O
,DRG,NNP,O
,",",",",O
,p75,NN,O
,(,(,O
,NTR,NNP,O
,),),O
,-,:,O
,IR,NN,O
,was,VBD,O
,also,RB,O
,increased,VBN,O
,(,(,O
,P,NNP,O
,<,NNP,O
,or,CC,O
,=,$,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,with,IN,O
,cystitis,NN,B-DISEASE
,.,.,O
,In,IN,O
,addition,NN,O
,to,TO,O
,increases,NNS,O
,in,IN,O
,p75,NN,O
,(,(,O
,NTR,NNP,O
,),),O
,-,:,O
,IR,NN,O
,in,IN,O
,DRG,NNP,O
,cell,NN,O
,bodies,NNS,O
,",",",",O
,increases,NNS,O
,(,(,O
,P,NNP,O
,<,NNP,O
,or,CC,O
,=,$,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,in,IN,O
,pericellular,NN,O
,(,(,O
,encircling,VBG,O
,DRG,NNP,O
,cells,NNS,O
,),),O
,p75,NN,O
,(,(,O
,NTR,NNP,O
,),),O
,-,:,O
,IR,NN,O
,in,IN,O
,DRG,NNP,O
,also,RB,O
,increased,VBD,O
,.,.,O
,Confocal,JJ,O
,analyses,NNS,O
,demonstrated,VBD,O
,that,IN,O
,pericellular,JJ,O
,p75,NN,O
,(,(,O
,NTR,NNP,O
,),),O
,-,:,O
,IR,NN,O
,was,VBD,O
,not,RB,O
,colocalized,VBN,O
,with,IN,O
,the,DT,O
,glial,JJ,O
,marker,NN,O
,",",",",O
,glial,JJ,O
,fibrillary,JJ,O
,acidic,NN,O
,protein,NN,O
,(,(,O
,GFAP,NNP,O
,),),O
,.,.,O
,These,DT,O
,studies,NNS,O
,demonstrate,VBP,O
,that,IN,O
,p75,NN,O
,(,(,O
,NTR,NNP,O
,),),O
,expression,NN,O
,in,IN,O
,micturition,NN,O
,reflexes,NNS,O
,is,VBZ,O
,present,JJ,O
,constitutively,RB,O
,and,CC,O
,modified,VBN,O
,by,IN,O
,bladder,NN,B-DISEASE
,inflammation,NN,I-DISEASE
,.,.,O
,The,DT,O
,functional,JJ,O
,significance,NN,O
,of,IN,O
,p75,NN,O
,(,(,O
,NTR,NNP,O
,),),O
,expression,NN,O
,in,IN,O
,micturition,NN,O
,reflexes,NN,O
,remains,VBZ,O
,to,TO,O
,be,VB,O
,determined,VBN,O
,.,.,O
,Azathioprine,NNP,O
,-,:,O
,induced,VBD,O
,suicidal,JJ,O
,erythrocyte,JJ,O
,death,NN,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Azathioprine,NNP,O
,is,VBZ,O
,widely,RB,O
,used,VBN,O
,as,IN,O
,an,DT,O
,immunosuppressive,JJ,O
,drug,NN,O
,.,.,O
,The,DT,O
,side,NN,O
,effects,NNS,O
,of,IN,O
,azathioprine,JJ,O
,include,VBP,O
,anemia,NN,B-DISEASE
,",",",",O
,which,WDT,O
,has,VBZ,O
,been,VBN,O
,attributed,VBN,O
,to,TO,O
,bone,VB,O
,marrow,JJ,O
,suppression,NN,O
,.,.,O
,Alternatively,RB,O
,",",",",O
,anemia,NN,B-DISEASE
,could,MD,O
,result,VB,O
,from,IN,O
,accelerated,VBN,O
,suicidal,JJ,O
,erythrocyte,JJ,O
,death,NN,O
,or,CC,O
,eryptosis,NN,O
,",",",",O
,which,WDT,O
,is,VBZ,O
,characterized,VBN,O
,by,IN,O
,exposure,NN,O
,of,IN,O
,phosphatidylserine,NN,O
,(,(,O
,PS,NNP,O
,),),O
,at,IN,O
,the,DT,O
,erythrocyte,JJ,O
,surface,NN,O
,and,CC,O
,by,IN,O
,cell,NN,O
,shrinkage,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,The,DT,O
,present,JJ,O
,experiments,NNS,O
,explored,VBD,O
,whether,IN,O
,azathioprine,JJ,O
,influences,NNS,O
,eryptosis,NN,O
,.,.,O
,According,VBG,O
,to,TO,O
,annexin,NN,O
,V,NNP,O
,binding,NN,O
,",",",",O
,erythrocytes,VBZ,O
,from,IN,O
,patients,NNS,O
,indeed,RB,O
,showed,VBD,O
,a,DT,O
,significant,JJ,O
,increase,NN,O
,of,IN,O
,PS,NNP,O
,exposure,NN,O
,within,IN,O
,1,CD,O
,week,NN,O
,of,IN,O
,treatment,NN,O
,with,IN,O
,azathioprine,NN,O
,.,.,O
,In,IN,O
,a,DT,O
,second,JJ,O
,series,NN,O
,",",",",O
,cytosolic,JJ,O
,Ca2,NNP,O
,+,NN,O
,activity,NN,O
,(,(,O
,Fluo3,NNP,O
,fluorescence,NN,O
,),),O
,",",",",O
,cell,NN,O
,volume,NN,O
,(,(,O
,forward,RB,O
,scatter,NN,O
,),),O
,",",",",O
,and,CC,O
,PS,NNP,O
,-,:,O
,exposure,NN,O
,(,(,O
,annexin,JJ,O
,V,NNP,O
,binding,NN,O
,),),O
,were,VBD,O
,determined,VBN,O
,by,IN,O
,FACS,NNP,O
,analysis,NN,O
,in,IN,O
,erythrocytes,NNS,O
,from,IN,O
,healthy,JJ,O
,volunteers,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Exposure,NN,O
,to,TO,O
,azathioprine,VB,O
,(,(,O
,>,CD,O
,or,CC,O
,=,VB,O
,2,CD,O
,microg,NN,O
,/,NNP,O
,mL,NN,O
,),),O
,for,IN,O
,48,CD,O
,hours,NNS,O
,increased,VBD,O
,cytosolic,JJ,O
,Ca2,NNP,O
,+,NNP,O
,activity,NN,O
,and,CC,O
,annexin,NN,O
,V,NNP,O
,binding,NN,O
,and,CC,O
,decreased,JJ,O
,forward,RB,O
,scatter,NN,O
,.,.,O
,The,DT,O
,effect,NN,O
,of,IN,O
,azathioprine,NN,O
,on,IN,O
,both,DT,O
,annexin,JJ,O
,V,NNP,O
,binding,NN,O
,and,CC,O
,forward,RB,O
,scatter,NN,O
,was,VBD,O
,significantly,RB,O
,blunted,VBN,O
,in,IN,O
,the,DT,O
,nominal,JJ,O
,absence,NN,O
,of,IN,O
,extracellular,JJ,O
,Ca2,NNP,O
,+,NNP,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Azathioprine,JJ,O
,triggers,NNS,O
,suicidal,VBP,O
,erythrocyte,JJ,O
,death,NN,O
,",",",",O
,an,DT,O
,effect,NN,O
,presumably,RB,O
,contributing,VBG,O
,to,TO,O
,azathioprine,VB,O
,-,:,O
,induced,JJ,O
,anemia,NN,B-DISEASE
,.,.,O
,Levetiracetam,NNP,O
,as,IN,O
,an,DT,O
,adjunct,NN,O
,to,TO,O
,phenobarbital,VB,O
,treatment,NN,O
,in,IN,O
,cats,NNS,O
,with,IN,O
,suspected,JJ,O
,idiopathic,JJ,B-DISEASE
,epilepsy,NN,I-DISEASE
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,To,TO,O
,assess,VB,O
,pharmacokinetics,NNS,O
,",",",",O
,efficacy,NN,O
,",",",",O
,and,CC,O
,tolerability,NN,O
,of,IN,O
,oral,JJ,O
,levetiracetam,NN,O
,administered,VBD,O
,as,IN,O
,an,DT,O
,adjunct,NN,O
,to,TO,O
,phenobarbital,VB,O
,treatment,NN,O
,in,IN,O
,cats,NNS,O
,with,IN,O
,poorly,RB,O
,controlled,VBN,O
,suspected,JJ,O
,idiopathic,JJ,B-DISEASE
,epilepsy,NN,I-DISEASE
,.,.,O
,DESIGN,NNP,O
,-,:,O
,Open,JJ,O
,-,:,O
,label,NN,O
,",",",",O
,noncomparative,JJ,O
,clinical,JJ,O
,trial,NN,O
,.,.,O
,ANIMALS,NNS,O
,:,:,O
,12,CD,O
,cats,NNS,O
,suspected,VBN,O
,to,TO,O
,have,VB,O
,idiopathic,JJ,B-DISEASE
,epilepsy,NN,I-DISEASE
,that,WDT,O
,was,VBD,O
,poorly,RB,O
,controlled,VBN,O
,with,IN,O
,phenobarbital,NN,O
,or,CC,O
,that,DT,O
,had,VBD,O
,unacceptable,JJ,O
,adverse,JJ,O
,effects,NNS,O
,when,WRB,O
,treated,VBN,O
,with,IN,O
,phenobarbital,JJ,O
,.,.,O
,PROCEDURES,NNS,O
,:,:,O
,Cats,NNS,O
,were,VBD,O
,treated,VBN,O
,with,IN,O
,levetiracetam,NN,O
,(,(,O
,20,CD,O
,mg,NN,O
,/,NNP,O
,kg,NNP,O
,[,VBD,O
,9,CD,O
,.,.,O
,1,CD,O
,mg,JJ,O
,/,NNP,O
,lb,NN,O
,],NNP,O
,",",",",O
,PO,NNP,O
,",",",",O
,q,RB,O
,8,CD,O
,h,NN,O
,),),O
,.,.,O
,After,IN,O
,a,DT,O
,minimum,NN,O
,of,IN,O
,1,CD,O
,week,NN,O
,of,IN,O
,treatment,NN,O
,",",",",O
,serum,NN,O
,levetiracetam,JJ,O
,concentrations,NNS,O
,were,VBD,O
,measured,VBN,O
,before,IN,O
,and,CC,O
,2,CD,O
,",",",",O
,4,CD,O
,",",",",O
,and,CC,O
,6,CD,O
,hours,NNS,O
,after,IN,O
,drug,NN,O
,administration,NN,O
,",",",",O
,and,CC,O
,maximum,NN,O
,and,CC,O
,minimum,JJ,O
,serum,NN,O
,concentrations,NNS,O
,and,CC,O
,elimination,NN,O
,half,NN,O
,-,:,O
,life,NN,O
,were,VBD,O
,calculated,VBN,O
,.,.,O
,Seizure,NN,B-DISEASE
,frequencies,NNS,O
,before,IN,O
,and,CC,O
,after,IN,O
,initiation,NN,O
,of,IN,O
,levetiracetam,JJ,O
,treatment,NN,O
,were,VBD,O
,compared,VBN,O
,",",",",O
,and,CC,O
,adverse,JJ,O
,effects,NNS,O
,were,VBD,O
,recorded,VBN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Median,JJ,O
,maximum,NN,O
,serum,NN,O
,levetiracetam,JJ,O
,concentration,NN,O
,was,VBD,O
,25,CD,O
,.,.,O
,5,CD,O
,microg,JJ,O
,/,NNP,O
,mL,NN,O
,",",",",O
,median,JJ,O
,minimum,NN,O
,serum,NN,O
,levetiracetam,JJ,O
,concentration,NN,O
,was,VBD,O
,8,CD,O
,.,.,O
,3,CD,O
,microg,JJ,O
,/,NNP,O
,mL,NN,O
,",",",",O
,and,CC,O
,median,JJ,O
,elimination,NN,O
,half,NN,O
,-,:,O
,life,NN,O
,was,VBD,O
,2,CD,O
,.,.,O
,9,CD,O
,hours,NNS,O
,.,.,O
,Median,JJ,O
,seizure,NN,B-DISEASE
,frequency,NN,O
,prior,RB,O
,to,TO,O
,treatment,NN,O
,with,IN,O
,levetiracetam,NN,O
,(,(,O
,2,CD,O
,.,.,O
,1,CD,O
,seizures,NNS,B-DISEASE
,/,NNP,O
,mo,NN,O
,),),O
,was,VBD,O
,significantly,RB,O
,higher,JJR,O
,than,IN,O
,median,JJ,O
,seizure,NN,B-DISEASE
,frequency,NN,O
,after,IN,O
,initiation,NN,O
,of,IN,O
,levetiracetam,JJ,O
,treatment,NN,O
,(,(,O
,0,CD,O
,.,.,O
,42,CD,O
,seizures,NNS,B-DISEASE
,/,NNP,O
,mo,NN,O
,),),O
,",",",",O
,and,CC,O
,7,CD,O
,of,IN,O
,10,CD,O
,cats,NNS,O
,were,VBD,O
,classified,VBN,O
,as,IN,O
,having,VBG,O
,responded,VBN,O
,to,TO,O
,levetiracetam,VB,O
,treatment,NN,O
,(,(,O
,ie,NN,O
,",",",",O
,reduction,NN,O
,in,IN,O
,seizure,NN,B-DISEASE
,frequency,NN,O
,of,IN,O
,>,NN,O
,or,CC,O
,=,VB,O
,50,CD,O
,%,NN,O
,),),O
,.,.,O
,Two,CD,O
,cats,NNS,O
,had,VBD,O
,transient,JJ,O
,lethargy,NN,B-DISEASE
,and,CC,O
,inappetence,NN,B-DISEASE
,.,.,O
,CONCLUSIONS,NNP,O
,AND,NNP,O
,CLINICAL,NNP,O
,RELEVANCE,NNP,O
,:,:,O
,Results,NNS,O
,suggested,VBD,O
,that,IN,O
,levetiracetam,NN,O
,is,VBZ,O
,well,RB,O
,tolerated,VBN,O
,in,IN,O
,cats,NNS,O
,and,CC,O
,may,MD,O
,be,VB,O
,useful,JJ,O
,as,IN,O
,an,DT,O
,adjunct,NN,O
,to,TO,O
,phenobarbital,VB,O
,treatment,NN,O
,in,IN,O
,cats,NNS,O
,with,IN,O
,idiopathic,JJ,B-DISEASE
,epilepsy,NN,I-DISEASE
,.,.,O
,Serotonin,NNP,O
,reuptake,NN,O
,inhibitors,NNS,O
,",",",",O
,paranoia,NN,B-DISEASE
,",",",",O
,and,CC,O
,the,DT,O
,ventral,JJ,O
,basal,NN,O
,ganglia,NN,O
,.,.,O
,Antidepressants,NNS,O
,have,VBP,O
,previously,RB,O
,been,VBN,O
,associated,VBN,O
,with,IN,O
,paranoid,JJ,B-DISEASE
,reactions,NNS,O
,in,IN,O
,psychiatric,JJ,O
,patients,NNS,O
,.,.,O
,Five,CD,O
,cases,NNS,O
,of,IN,O
,paranoid,JJ,B-DISEASE
,exacerbation,NN,O
,with,IN,O
,the,DT,O
,serotonin,NN,O
,reuptake,NN,O
,inhibitors,NNS,O
,fluoxetine,VBP,O
,and,CC,O
,amitriptyline,NN,O
,are,VBP,O
,reported,VBN,O
,here,RB,O
,.,.,O
,Elements,NNS,O
,common,JJ,O
,to,TO,O
,these,DT,O
,cases,NNS,O
,included,VBD,O
,a,DT,O
,history,NN,O
,of,IN,O
,paranoid,JJ,B-DISEASE
,symptomatology,NN,O
,and,CC,O
,the,DT,O
,concomitant,JJ,O
,occurrence,NN,O
,of,IN,O
,depressive,JJ,B-DISEASE
,and,CC,I-DISEASE
,psychotic,JJ,I-DISEASE
,symptoms,NNS,I-DISEASE
,.,.,O
,Complicated,NNP,O
,depressive,JJ,B-DISEASE
,disorders,NNS,I-DISEASE
,(,(,O
,including,VBG,O
,atypicality,NN,O
,of,IN,O
,course,NN,O
,and,CC,O
,symptomatology,NN,O
,",",",",O
,chronicity,NN,O
,",",",",O
,psychosis,NN,B-DISEASE
,",",",",O
,bipolarity,NN,O
,",",",",O
,and,CC,O
,secondary,JJ,O
,onset,NN,O
,in,IN,O
,the,DT,O
,course,NN,O
,of,IN,O
,a,DT,O
,primary,JJ,O
,psychosis,NN,B-DISEASE
,),),O
,may,MD,O
,present,VB,O
,particular,JJ,O
,vulnerability,NN,O
,to,TO,O
,paranoid,VB,B-DISEASE
,exacerbations,NNS,O
,associated,VBN,O
,with,IN,O
,serotonin,JJ,O
,reuptake,NN,O
,inhibitors,NNS,O
,.,.,O
,Although,IN,O
,the,DT,O
,pharmacology,NN,O
,and,CC,O
,neurobiology,NN,O
,of,IN,O
,paranoia,NN,B-DISEASE
,remain,VBP,O
,cryptic,JJ,O
,",",",",O
,several,JJ,O
,mechanisms,NNS,O
,",",",",O
,including,VBG,O
,5HT3,CD,O
,receptor,NN,O
,-,:,O
,mediated,VBN,O
,dopamine,NN,O
,release,NN,O
,",",",",O
,beta,SYM,O
,-,:,O
,noradrenergic,JJ,O
,receptor,NN,O
,downregulation,NN,O
,",",",",O
,or,CC,O
,GABAB,NNP,O
,receptor,NN,O
,upregulation,NN,O
,acting,VBG,O
,in,IN,O
,the,DT,O
,vicinity,NN,O
,of,IN,O
,the,DT,O
,ventral,JJ,O
,basal,NN,O
,ganglia,NN,O
,(,(,O
,possibly,RB,O
,in,IN,O
,lateral,JJ,O
,orbitofrontal,NN,O
,or,CC,O
,anterior,JJ,O
,cingulate,NN,O
,circuits,NNS,O
,),),O
,",",",",O
,might,MD,O
,apply,VB,O
,to,TO,O
,this,DT,O
,phenomenon,NN,O
,.,.,O
,These,DT,O
,cases,NNS,O
,call,VBP,O
,attention,NN,O
,to,TO,O
,possible,JJ,O
,paranoid,JJ,B-DISEASE
,exacerbations,NNS,O
,with,IN,O
,serotonin,JJ,O
,reuptake,NN,O
,blockers,NNS,O
,in,IN,O
,select,JJ,O
,patients,NNS,O
,and,CC,O
,raise,VB,O
,neurobiological,JJ,O
,considerations,NNS,O
,regarding,VBG,O
,paranoia,NN,B-DISEASE
,.,.,O
,Clinical,JJ,O
,comparison,NN,O
,of,IN,O
,cardiorespiratory,JJ,O
,effects,NNS,O
,during,IN,O
,unilateral,JJ,O
,and,CC,O
,conventional,JJ,O
,spinal,JJ,O
,anaesthesia,NN,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Spinal,JJ,O
,anaesthesia,NN,O
,is,VBZ,O
,widely,RB,O
,employed,VBN,O
,in,IN,O
,clinical,JJ,O
,practice,NN,O
,but,CC,O
,has,VBZ,O
,the,DT,O
,main,JJ,O
,drawback,NN,O
,of,IN,O
,post,NN,O
,-,:,O
,spinal,JJ,O
,block,NN,O
,hypotension,NN,B-DISEASE
,.,.,O
,Efforts,NNS,O
,must,MD,O
,therefore,VB,O
,continue,NN,O
,to,TO,O
,be,VB,O
,made,VBN,O
,to,TO,O
,obviate,VB,O
,this,DT,O
,setback,NN,O
,OBJECTIVE,NN,O
,:,:,O
,To,TO,O
,evaluate,VB,O
,the,DT,O
,cardiovascular,NN,O
,and,CC,O
,respiratory,NN,O
,changes,NNS,O
,during,IN,O
,unilateral,JJ,O
,and,CC,O
,conventional,JJ,O
,spinal,JJ,O
,anaesthesia,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,With,IN,O
,ethical,JJ,O
,approval,NN,O
,",",",",O
,we,PRP,O
,studied,VBD,O
,74,CD,O
,American,JJ,O
,Society,NNP,O
,of,IN,O
,Anesthesiologists,NNP,O
,(,(,O
,ASA,NNP,O
,),),O
,",",",",O
,physical,JJ,O
,status,NN,O
,class,NN,O
,1,CD,O
,and,CC,O
,2,CD,O
,patients,NNS,O
,scheduled,VBN,O
,for,IN,O
,elective,JJ,O
,unilateral,JJ,O
,lower,JJR,O
,limb,NN,O
,surgery,NN,O
,.,.,O
,Patients,NNS,O
,were,VBD,O
,randomly,RB,O
,allocated,VBN,O
,into,IN,O
,one,CD,O
,of,IN,O
,two,CD,O
,groups,NNS,O
,:,:,O
,lateral,JJ,O
,and,CC,O
,conventional,JJ,O
,spinal,JJ,O
,anaesthesia,NN,O
,groups,NNS,O
,.,.,O
,In,IN,O
,the,DT,O
,lateral,JJ,O
,position,NN,O
,with,IN,O
,operative,JJ,O
,side,NN,O
,down,RB,O
,",",",",O
,patients,NNS,O
,recived,VBD,O
,10,CD,O
,mg,NN,O
,(,(,O
,2mls,CD,O
,),),O
,of,IN,O
,0,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,hyperbaric,JJ,O
,bupivacaine,NN,O
,through,IN,O
,a,DT,O
,25,CD,O
,-,:,O
,gauge,NN,O
,spinal,JJ,O
,needle,NN,O
,.,.,O
,Patients,NNS,O
,in,IN,O
,the,DT,O
,unilateral,JJ,O
,group,NN,O
,were,VBD,O
,maintained,VBN,O
,in,IN,O
,the,DT,O
,lateral,JJ,O
,position,NN,O
,for,IN,O
,15,CD,O
,minutes,NNS,O
,following,VBG,O
,spinal,JJ,O
,injection,NN,O
,while,IN,O
,those,DT,O
,in,IN,O
,the,DT,O
,conventional,JJ,O
,group,NN,O
,were,VBD,O
,turned,VBN,O
,supine,JJ,O
,immediately,RB,O
,after,IN,O
,injection,NN,O
,.,.,O
,Blood,NNP,O
,pressure,NN,O
,",",",",O
,heart,NN,O
,rate,NN,O
,",",",",O
,respiratory,NN,O
,rate,NN,O
,and,CC,O
,oxygen,NN,O
,saturation,NN,O
,were,VBD,O
,monitored,VBN,O
,over,IN,O
,1,CD,O
,hour,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Three,CD,O
,patients,NNS,O
,(,(,O
,8,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,),),O
,in,IN,O
,the,DT,O
,unilateral,JJ,O
,group,NN,O
,and,CC,O
,5,CD,O
,(,(,O
,13,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,),),O
,in,IN,O
,the,DT,O
,conventional,JJ,O
,group,NN,O
,developed,VBD,O
,hypotension,NN,B-DISEASE
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,71,CD,O
,.,.,O
,Four,CD,O
,(,(,O
,10,CD,O
,.,.,O
,8,CD,O
,%,NN,O
,),),O
,patients,NNS,O
,in,IN,O
,the,DT,O
,conventional,JJ,O
,group,NN,O
,and,CC,O
,1,CD,O
,(,(,O
,2,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,),),O
,in,IN,O
,the,DT,O
,unilateral,JJ,O
,group,NN,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,17,CD,O
,required,JJ,O
,epinephrine,NN,O
,infusion,NN,O
,to,TO,O
,treat,VB,O
,hypotension,NN,B-DISEASE
,.,.,O
,Patients,NNS,O
,in,IN,O
,the,DT,O
,conventional,JJ,O
,group,NN,O
,had,VBD,O
,statistically,RB,O
,significant,JJ,O
,greater,JJR,O
,fall,NN,O
,in,IN,O
,the,DT,O
,systolic,JJ,O
,blood,NN,O
,pressures,NNS,O
,at,IN,O
,15,CD,O
,",",",",O
,30,CD,O
,and,CC,O
,45,CD,O
,minutes,NNS,O
,when,WRB,O
,compared,VBN,O
,to,TO,O
,the,DT,O
,baseline,NN,O
,(,(,O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,003,CD,O
,",",",",O
,0,CD,O
,.,.,O
,001,CD,O
,and,CC,O
,0,CD,O
,.,.,O
,004,CD,O
,),),O
,.,.,O
,The,DT,O
,mean,JJ,O
,respiratory,NN,O
,rate,NN,O
,and,CC,O
,oxygen,NN,O
,saturations,NNS,O
,in,IN,O
,the,DT,O
,two,CD,O
,groups,NNS,O
,were,VBD,O
,similar,JJ,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Compared,VBN,O
,to,TO,O
,conventional,JJ,O
,spinal,JJ,O
,anaesthesia,NN,O
,",",",",O
,unilateral,JJ,O
,spinal,JJ,O
,anaesthesia,NN,O
,was,VBD,O
,associated,VBN,O
,with,IN,O
,fewer,JJR,O
,cardiovascular,JJ,O
,perturbations,NNS,O
,.,.,O
,Also,RB,O
,",",",",O
,the,DT,O
,type,NN,O
,of,IN,O
,spinal,JJ,O
,block,NN,O
,instituted,VBD,O
,affected,VBD,O
,neither,CC,O
,the,DT,O
,respiratory,NN,O
,rate,NN,O
,nor,CC,O
,the,DT,O
,arterial,JJ,O
,oxygen,NN,O
,saturation,NN,O
,.,.,O
,Spectrum,NNP,O
,of,IN,O
,adverse,JJ,O
,events,NNS,O
,after,IN,O
,generic,JJ,O
,HAART,NNP,O
,in,IN,O
,southern,JJ,O
,Indian,JJ,O
,HIV,NNP,B-DISEASE
,-,:,I-DISEASE
,infected,JJ,I-DISEASE
,patients,NNS,O
,.,.,O
,To,TO,O
,determine,VB,O
,the,DT,O
,incidence,NN,O
,of,IN,O
,clinically,RB,O
,significant,JJ,O
,adverse,JJ,O
,events,NNS,O
,after,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,",",",",O
,fixed,VBN,O
,-,:,O
,dose,NN,O
,",",",",O
,generic,JJ,O
,highly,RB,O
,active,JJ,O
,antiretroviral,JJ,O
,therapy,NN,O
,(,(,O
,HAART,NNP,O
,),),O
,use,NN,O
,among,IN,O
,HIV,NNP,B-DISEASE
,-,:,I-DISEASE
,infected,JJ,I-DISEASE
,individuals,NNS,O
,in,IN,O
,South,NNP,O
,India,NNP,O
,",",",",O
,we,PRP,O
,examined,VBD,O
,the,DT,O
,experiences,NNS,O
,of,IN,O
,3154,CD,O
,HIV,NNP,B-DISEASE
,-,:,I-DISEASE
,infected,JJ,I-DISEASE
,individuals,NNS,O
,who,WP,O
,received,VBD,O
,a,DT,O
,minimum,NN,O
,of,IN,O
,3,CD,O
,months,NNS,O
,of,IN,O
,generic,JJ,O
,HAART,NNP,O
,between,IN,O
,February,NNP,O
,1996,CD,O
,and,CC,O
,December,NNP,O
,2006,CD,O
,at,IN,O
,a,DT,O
,tertiary,JJ,O
,HIV,NNP,O
,care,NN,O
,referral,JJ,O
,center,NN,O
,in,IN,O
,South,NNP,O
,India,NNP,O
,.,.,O
,The,DT,O
,most,RBS,O
,common,JJ,O
,regimens,NNS,O
,were,VBD,O
,3TC,CD,O
,+,JJ,O
,d4T,NN,O
,+,NNP,O
,nevirapine,NN,O
,(,(,O
,NVP,NNP,O
,),),O
,(,(,O
,54,CD,O
,.,.,O
,8,CD,O
,%,NN,O
,),),O
,",",",",O
,zidovudine,NN,O
,(,(,O
,AZT,NNP,O
,),),O
,+,VBD,O
,3TC,CD,O
,+,NN,O
,NVP,NNP,O
,(,(,O
,14,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,),),O
,",",",",O
,3TC,CD,O
,+,NN,O
,d4T,NN,O
,+,NNP,O
,efavirenz,NN,O
,(,(,O
,EFV,NNP,O
,),),O
,(,(,O
,20,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,),),O
,",",",",O
,and,CC,O
,AZT,NNP,O
,+,NNP,O
,3TC,CD,O
,+,NNP,O
,EFV,NNP,O
,(,(,O
,5,CD,O
,.,.,O
,4,CD,O
,%,NN,O
,),),O
,.,.,O
,The,DT,O
,most,RBS,O
,common,JJ,O
,adverse,JJ,O
,events,NNS,O
,and,CC,O
,median,JJ,O
,CD4,NNP,O
,at,IN,O
,time,NN,O
,of,IN,O
,event,NN,O
,were,VBD,O
,rash,NN,B-DISEASE
,(,(,O
,15,CD,O
,.,.,O
,2,CD,O
,%,NN,O
,;,:,O
,CD4,NNP,O
,",",",",O
,285,CD,O
,cells,NNS,O
,/,JJ,O
,microL,NN,O
,),),O
,and,CC,O
,peripheral,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,(,(,O
,9,CD,O
,.,.,O
,0,CD,O
,%,NN,O
,and,CC,O
,348,CD,O
,cells,NNS,O
,/,JJ,O
,microL,NN,O
,),),O
,.,.,O
,Clinically,NNP,O
,significant,JJ,O
,anemia,NN,B-DISEASE
,(,(,O
,hemoglobin,JJ,O
,<,$,O
,7,CD,O
,g,NN,O
,/,NNP,O
,dL,NN,O
,),),O
,was,VBD,O
,observed,VBN,O
,in,IN,O
,5,CD,O
,.,.,O
,4,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,(,(,O
,CD4,NNP,O
,",",",",O
,165,CD,O
,cells,NNS,O
,/,JJ,O
,microL,NN,O
,),),O
,and,CC,O
,hepatitis,NN,B-DISEASE
,(,(,O
,clinical,JJ,O
,jaundice,NN,B-DISEASE
,with,IN,O
,alanine,JJ,O
,aminotransferase,NN,O
,>,VBD,O
,5,CD,O
,times,NNS,O
,upper,JJ,O
,limits,NNS,O
,of,IN,O
,normal,JJ,O
,),),O
,in,IN,O
,3,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,(,(,O
,CD4,NNP,O
,",",",",O
,260,CD,O
,cells,NNS,O
,/,JJ,O
,microL,NN,O
,),),O
,.,.,O
,Women,NNS,O
,were,VBD,O
,significantly,RB,O
,more,RBR,O
,likely,JJ,O
,to,TO,O
,experience,VB,O
,lactic,JJ,B-DISEASE
,acidosis,NN,I-DISEASE
,",",",",O
,while,IN,O
,men,NNS,O
,were,VBD,O
,significantly,RB,O
,more,RBR,O
,likely,JJ,O
,to,TO,O
,experience,VB,O
,immune,JJ,B-DISEASE
,reconstitution,NN,I-DISEASE
,syndrome,NN,I-DISEASE
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,Among,IN,O
,the,DT,O
,patients,NNS,O
,with,IN,O
,1,CD,O
,year,NN,O
,of,IN,O
,follow,NN,O
,-,:,O
,up,RB,O
,",",",",O
,NVP,NNP,O
,therapy,NN,O
,was,VBD,O
,significantly,RB,O
,associated,VBN,O
,with,IN,O
,developing,VBG,O
,rash,NN,B-DISEASE
,and,CC,O
,d4T,NN,O
,therapy,NN,O
,with,IN,O
,developing,VBG,O
,peripheral,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,Anemia,NNP,B-DISEASE
,and,CC,O
,hepatitis,NN,B-DISEASE
,often,RB,O
,occur,VBP,O
,within,IN,O
,12,CD,O
,weeks,NNS,O
,of,IN,O
,initiating,VBG,O
,generic,JJ,O
,HAART,NNP,O
,.,.,O
,Frequent,NNP,O
,and,CC,O
,early,JJ,O
,monitoring,NN,O
,for,IN,O
,these,DT,O
,toxicities,NNS,B-DISEASE
,is,VBZ,O
,warranted,VBN,O
,in,IN,O
,developing,VBG,O
,countries,NNS,O
,where,WRB,O
,generic,JJ,O
,HAART,NNP,O
,is,VBZ,O
,increasingly,RB,O
,available,JJ,O
,.,.,O
,Thalidomide,NNP,O
,and,CC,O
,sensory,JJ,B-DISEASE
,neurotoxicity,NN,I-DISEASE
,:,:,O
,a,DT,O
,neurophysiological,JJ,O
,study,NN,O
,.,.,O
,BACKGROUND,NNP,O
,:,:,O
,Recent,JJ,O
,studies,NNS,O
,confirmed,VBD,O
,a,DT,O
,high,JJ,O
,incidence,NN,O
,of,IN,O
,sensory,JJ,B-DISEASE
,axonal,JJ,I-DISEASE
,neuropathy,NN,I-DISEASE
,in,IN,O
,patients,NNS,O
,treated,VBN,O
,with,IN,O
,different,JJ,O
,doses,NNS,O
,of,IN,O
,thalidomide,NN,O
,.,.,O
,The,DT,O
,study,NN,O
,',POS,O
,s,NN,O
,aims,NNS,O
,were,VBD,O
,to,TO,O
,measure,VB,O
,variations,NNS,O
,in,IN,O
,sural,JJ,O
,nerve,NN,O
,sensory,JJ,O
,action,NN,O
,potential,NN,O
,(,(,O
,SAP,NNP,O
,),),O
,amplitude,VBP,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,refractory,JJ,O
,cutaneous,JJ,B-DISEASE
,lupus,NN,I-DISEASE
,erythematosus,NN,I-DISEASE
,(,(,O
,CLE,NNP,B-DISEASE
,),),O
,treated,VBD,O
,with,IN,O
,thalidomide,NN,O
,and,CC,O
,use,VB,O
,these,DT,O
,findings,NNS,O
,to,TO,O
,identify,VB,O
,the,DT,O
,neurotoxic,JJ,B-DISEASE
,potential,NN,O
,of,IN,O
,thalidomide,NN,O
,and,CC,O
,the,DT,O
,recovery,NN,O
,capacity,NN,O
,of,IN,O
,sensory,JJ,O
,fibres,NNS,O
,after,IN,O
,discontinuation,NN,O
,of,IN,O
,treatment,NN,O
,.,.,O
,PATIENTS,NNP,O
,AND,CC,O
,METHODS,NNP,O
,:,:,O
,Clinical,JJ,O
,and,CC,O
,electrophysiological,JJ,O
,data,NNS,O
,in,IN,O
,12,CD,O
,female,JJ,O
,patients,NNS,O
,with,IN,O
,CLE,NNP,B-DISEASE
,during,IN,O
,treatment,NN,O
,with,IN,O
,thalidomide,NN,O
,and,CC,O
,up,RB,O
,to,TO,O
,47,CD,O
,months,NNS,O
,after,IN,O
,discontinuation,NN,O
,of,IN,O
,treatment,NN,O
,were,VBD,O
,analysed,VBN,O
,.,.,O
,Sural,NNP,O
,nerve,NN,O
,SAP,NNP,O
,amplitude,NN,O
,reduction,NN,O
,>,NN,O
,or,CC,O
,=,VB,O
,40,CD,O
,%,NN,O
,was,VBD,O
,the,DT,O
,criteria,NNS,O
,for,IN,O
,discontinuing,VBG,O
,therapy,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,During,IN,O
,treatment,NN,O
,",",",",O
,11,CD,O
,patients,NNS,O
,showed,VBD,O
,a,DT,O
,reduction,NN,O
,in,IN,O
,sural,JJ,O
,nerve,NN,O
,SAP,NNP,O
,amplitude,NN,O
,compared,VBN,O
,to,TO,O
,baseline,VB,O
,values,NNS,O
,(,(,O
,9,CD,O
,with,IN,O
,a,DT,O
,reduction,NN,O
,>,NN,O
,or,CC,O
,=,VB,O
,50,CD,O
,%,NN,O
,and,CC,O
,2,CD,O
,<,JJ,O
,50,CD,O
,%,NN,O
,),),O
,.,.,O
,One,CD,O
,patient,NN,O
,showed,VBD,O
,no,DT,O
,changes,NNS,O
,in,IN,O
,SAP,NNP,O
,amplitude,NN,O
,.,.,O
,Five,CD,O
,patients,NNS,O
,complained,VBN,O
,of,IN,O
,paresthesias,NN,B-DISEASE
,and,CC,O
,leg,NN,O
,cramps,NNS,B-DISEASE
,.,.,O
,After,IN,O
,thalidomide,JJ,O
,treatment,NN,O
,",",",",O
,sural,JJ,O
,SAP,NNP,O
,amplitude,NN,O
,recovered,VBD,O
,in,IN,O
,3,CD,O
,patients,NNS,O
,.,.,O
,At,IN,O
,detection,NN,O
,of,IN,O
,reduction,NN,O
,in,IN,O
,sural,JJ,O
,nerve,NN,O
,SAP,NNP,O
,amplitude,NN,O
,",",",",O
,the,DT,O
,median,JJ,O
,thalidomide,NN,O
,cumulative,JJ,O
,dose,NN,O
,was,VBD,O
,21,CD,O
,.,.,O
,4,CD,O
,g,NN,O
,.,.,O
,The,DT,O
,threshold,JJ,O
,neurotoxic,JJ,B-DISEASE
,dosage,NN,O
,is,VBZ,O
,lower,JJR,O
,than,IN,O
,previously,RB,O
,reported,VBN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Sural,JJ,O
,nerve,NN,O
,SAP,NNP,O
,amplitude,NN,O
,reduction,NN,O
,is,VBZ,O
,a,DT,O
,reliable,JJ,O
,and,CC,O
,sensitive,JJ,O
,marker,NN,O
,of,IN,O
,degeneration,NN,O
,and,CC,O
,recovery,NN,O
,of,IN,O
,sensory,JJ,O
,fibres,NNS,O
,.,.,O
,This,DT,O
,electrophysiological,JJ,O
,parameter,NN,O
,provides,VBZ,O
,information,NN,O
,about,IN,O
,subclinical,JJ,O
,neurotoxic,JJ,B-DISEASE
,potential,NN,O
,of,IN,O
,thalidomide,NN,O
,but,CC,O
,is,VBZ,O
,not,RB,O
,helpful,JJ,O
,in,IN,O
,predicting,VBG,O
,the,DT,O
,appearance,NN,O
,of,IN,O
,sensory,NN,O
,symptoms,NNS,O
,.,.,O
,Five,CD,O
,cases,NNS,O
,of,IN,O
,encephalitis,NN,B-DISEASE
,during,IN,O
,treatment,NN,O
,of,IN,O
,loiasis,NN,B-DISEASE
,with,IN,O
,diethylcarbamazine,NN,O
,.,.,O
,Five,CD,O
,cases,NNS,O
,of,IN,O
,encephalitis,NN,B-DISEASE
,following,VBG,O
,treatment,NN,O
,with,IN,O
,diethylcarbamazine,NN,O
,(,(,O
,DEC,NNP,O
,),),O
,were,VBD,O
,observed,VBN,O
,in,IN,O
,Congolese,JJ,O
,patients,NNS,O
,with,IN,O
,Loa,NNP,O
,loa,JJ,O
,filariasis,NN,B-DISEASE
,.,.,O
,Two,CD,O
,cases,NNS,O
,had,VBD,O
,a,DT,O
,fatal,JJ,O
,outcome,NN,O
,and,CC,O
,one,CD,O
,resulted,VBN,O
,in,IN,O
,severe,JJ,O
,sequelae,NN,O
,.,.,O
,The,DT,O
,notable,JJ,O
,fact,NN,O
,was,VBD,O
,that,IN,O
,this,DT,O
,complication,NN,O
,occurred,VBD,O
,in,IN,O
,three,CD,O
,patients,NNS,O
,hospitalized,VBN,O
,before,IN,O
,treatment,NN,O
,began,VBD,O
,",",",",O
,with,IN,O
,whom,WP,O
,particularly,RB,O
,strict,JJ,O
,therapeutic,JJ,O
,precautions,NNS,O
,were,VBD,O
,taken,VBN,O
,",",",",O
,i,JJ,O
,.,.,O
,e,NN,O
,.,.,O
,",",",",O
,initial,JJ,O
,dose,NN,O
,less,JJR,O
,than,IN,O
,10,CD,O
,mg,NN,O
,of,IN,O
,DEC,NNP,O
,",",",",O
,very,RB,O
,gradual,JJ,O
,dose,NN,O
,increases,NNS,O
,",",",",O
,and,CC,O
,associated,VBD,O
,anti,SYM,O
,-,:,O
,allergic,JJ,O
,treatment,NN,O
,.,.,O
,This,DT,O
,type,NN,O
,of,IN,O
,drug,NN,O
,-,:,O
,induced,JJ,O
,complication,NN,O
,may,MD,O
,not,RB,O
,be,VB,O
,that,IN,O
,uncommon,JJ,O
,in,IN,O
,highly,RB,O
,endemic,JJ,O
,regions,NNS,O
,.,.,O
,It,PRP,O
,occurs,VBZ,O
,primarily,RB,O
,",",",",O
,but,CC,O
,not,RB,O
,exclusively,RB,O
,",",",",O
,in,IN,O
,subjects,NNS,O
,presenting,VBG,O
,with,IN,O
,a,DT,O
,high,JJ,O
,microfilarial,JJ,O
,load,NN,O
,.,.,O
,The,DT,O
,relationship,NN,O
,between,IN,O
,the,DT,O
,occurrence,NN,O
,of,IN,O
,encephalitis,NN,B-DISEASE
,and,CC,O
,the,DT,O
,decrease,NN,O
,in,IN,O
,microfilaremia,NN,B-DISEASE
,is,VBZ,O
,evident,JJ,O
,.,.,O
,The,DT,O
,pathophysiological,JJ,O
,mechanisms,NNS,O
,are,VBP,O
,discussed,VBN,O
,in,IN,O
,the,DT,O
,light,NN,O
,of,IN,O
,these,DT,O
,observations,NNS,O
,and,CC,O
,the,DT,O
,few,JJ,O
,other,JJ,O
,comments,NNS,O
,on,IN,O
,this,DT,O
,subject,NN,O
,published,VBN,O
,in,IN,O
,the,DT,O
,literature,NN,O
,.,.,O
,Amiodarone,NNP,O
,-,:,O
,related,JJ,O
,pulmonary,JJ,B-DISEASE
,mass,NN,I-DISEASE
,and,CC,O
,unique,JJ,O
,membranous,JJ,B-DISEASE
,glomerulonephritis,NN,I-DISEASE
,in,IN,O
,a,DT,O
,patient,NN,O
,with,IN,O
,valvular,JJ,B-DISEASE
,heart,NN,I-DISEASE
,disease,NN,I-DISEASE
,:,:,O
,Diagnostic,JJ,O
,pitfall,NN,O
,and,CC,O
,new,JJ,O
,findings,NNS,O
,.,.,O
,Amiodarone,NNP,O
,is,VBZ,O
,an,DT,O
,anti,JJ,O
,-,:,O
,arrhythmic,JJ,B-DISEASE
,drug,NN,O
,for,IN,O
,life,NN,O
,-,:,O
,threatening,JJ,O
,tachycardia,NN,B-DISEASE
,",",",",O
,but,CC,O
,various,JJ,O
,adverse,JJ,O
,effects,NNS,O
,have,VBP,O
,been,VBN,O
,reported,VBN,O
,.,.,O
,Reported,VBN,O
,herein,NN,O
,is,VBZ,O
,an,DT,O
,autopsy,JJ,O
,case,NN,O
,of,IN,O
,valvular,JJ,B-DISEASE
,heart,NN,I-DISEASE
,disease,NN,I-DISEASE
,",",",",O
,in,IN,O
,a,DT,O
,patient,NN,O
,who,WP,O
,developed,VBD,O
,a,DT,O
,lung,NN,B-DISEASE
,mass,NN,I-DISEASE
,(,(,O
,1,CD,O
,.,.,O
,5,CD,O
,cm,NN,O
,in,IN,O
,diameter,NN,O
,),),O
,and,CC,O
,proteinuria,NN,B-DISEASE
,(,(,O
,2,CD,O
,.,.,O
,76,CD,O
,g,JJ,O
,/,NNP,O
,day,NN,O
,),),O
,after,IN,O
,treatment,NN,O
,with,IN,O
,amiodarone,NN,O
,for,IN,O
,a,DT,O
,long,JJ,O
,time,NN,O
,.,.,O
,The,DT,O
,lung,NN,B-DISEASE
,mass,NN,I-DISEASE
,was,VBD,O
,highly,RB,O
,suspected,VBN,O
,to,TO,O
,be,VB,O
,lung,JJ,B-DISEASE
,cancer,NN,I-DISEASE
,on,IN,O
,CT,NNP,O
,and,CC,O
,positron,VB,O
,emission,NN,O
,tomography,NN,O
,",",",",O
,but,CC,O
,histologically,RB,O
,the,DT,O
,lesion,NN,O
,was,VBD,O
,composed,VBN,O
,of,IN,O
,lymphoplasmacytic,JJ,O
,infiltrates,NNS,O
,in,IN,O
,alveolar,JJ,O
,walls,NNS,O
,and,CC,O
,intra,JJ,O
,-,:,O
,alveolar,JJ,O
,accumulation,NN,O
,of,IN,O
,foamy,JJ,O
,macrophages,NNS,O
,containing,VBG,O
,characteristic,JJ,O
,myelinoid,NN,O
,bodies,NNS,O
,",",",",O
,indicating,VBG,O
,that,IN,O
,it,PRP,O
,was,VBD,O
,an,DT,O
,amiodarone,NN,O
,-,:,O
,related,JJ,O
,lesion,NN,O
,.,.,O
,In,IN,O
,addition,NN,O
,",",",",O
,the,DT,O
,lung,NN,O
,tissue,NN,O
,had,VBD,O
,unevenly,RB,O
,distributed,VBN,O
,hemosiderin,NN,B-DISEASE
,deposition,NN,O
,",",",",O
,and,CC,O
,abnormally,RB,O
,tortuous,JJ,O
,capillaries,NNS,O
,were,VBD,O
,seen,VBN,O
,in,IN,O
,the,DT,O
,mass,NN,O
,and,CC,O
,in,IN,O
,heavily,RB,O
,hemosiderotic,JJ,B-DISEASE
,lung,NN,O
,portions,NNS,O
,outside,IN,O
,the,DT,O
,mass,NN,O
,.,.,O
,In,IN,O
,the,DT,O
,kidneys,NNS,O
,",",",",O
,glomeruli,NNS,O
,had,VBD,O
,membrane,NN,O
,spikes,NNS,O
,",",",",O
,prominent,JJ,O
,swelling,NN,O
,of,IN,O
,podocytes,NNS,O
,and,CC,O
,subepithelial,JJ,O
,deposits,NNS,O
,",",",",O
,which,WDT,O
,were,VBD,O
,sometimes,RB,O
,large,JJ,O
,and,CC,O
,hump,JJ,O
,-,:,O
,like,IN,O
,.,.,O
,Autoimmune,NNP,B-DISEASE
,diseases,VBZ,I-DISEASE
,",",",",O
,viral,JJ,B-DISEASE
,hepatitis,NN,I-DISEASE
,",",",",O
,malignant,JJ,O
,neoplasms,NNS,B-DISEASE
,or,CC,O
,other,JJ,O
,diseases,NNS,O
,with,IN,O
,a,DT,O
,known,VBN,O
,relationship,NN,O
,to,TO,O
,membranous,JJ,B-DISEASE
,glomerulonephritis,NN,I-DISEASE
,were,VBD,O
,not,RB,O
,found,VBN,O
,.,.,O
,The,DT,O
,present,JJ,O
,case,NN,O
,highlights,VBZ,O
,the,DT,O
,possibility,NN,O
,that,IN,O
,differential,JJ,O
,diagnosis,NN,O
,between,IN,O
,an,DT,O
,amiodarone,NN,O
,-,:,O
,related,JJ,O
,pulmonary,JJ,B-DISEASE
,lesion,NN,I-DISEASE
,and,CC,O
,a,DT,O
,neoplasm,NN,B-DISEASE
,can,MD,O
,be,VB,O
,very,RB,O
,difficult,JJ,O
,radiologically,RB,O
,",",",",O
,and,CC,O
,suggests,VBZ,O
,that,IN,O
,membranous,JJ,B-DISEASE
,glomerulonephritis,NN,I-DISEASE
,might,MD,O
,be,VB,O
,another,DT,O
,possible,JJ,O
,complication,NN,O
,of,IN,O
,amiodarone,NN,O
,treatment,NN,O
,.,.,O
,Risk,NN,O
,of,IN,O
,coronary,JJ,B-DISEASE
,artery,NN,I-DISEASE
,disease,NN,I-DISEASE
,associated,VBN,O
,with,IN,O
,initial,JJ,O
,sulphonylurea,JJ,O
,treatment,NN,O
,of,IN,O
,patients,NNS,O
,with,IN,O
,type,JJ,B-DISEASE
,2,CD,I-DISEASE
,diabetes,NNS,I-DISEASE
,:,:,O
,a,DT,O
,matched,JJ,O
,case,NN,O
,-,:,O
,control,NN,O
,study,NN,O
,.,.,O
,AIMS,CC,O
,:,:,O
,This,DT,O
,study,NN,O
,sought,VBD,O
,to,TO,O
,assess,VB,O
,the,DT,O
,risk,NN,O
,of,IN,O
,developing,VBG,O
,coronary,JJ,B-DISEASE
,artery,NN,I-DISEASE
,disease,NN,I-DISEASE
,(,(,O
,CAD,NNP,B-DISEASE
,),),O
,associated,VBN,O
,with,IN,O
,initial,JJ,O
,treatment,NN,O
,of,IN,O
,type,NN,B-DISEASE
,2,CD,I-DISEASE
,diabetes,NNS,I-DISEASE
,with,IN,O
,different,JJ,O
,sulphonylureas,NNS,O
,.,.,O
,METHODS,NN,O
,:,:,O
,In,IN,O
,type,NN,B-DISEASE
,2,CD,I-DISEASE
,diabetic,JJ,I-DISEASE
,patients,NNS,O
,",",",",O
,cases,NNS,O
,who,WP,O
,developed,VBD,O
,CAD,NNP,B-DISEASE
,were,VBD,O
,compared,VBN,O
,retrospectively,RB,O
,with,IN,O
,controls,NNS,O
,that,WDT,O
,did,VBD,O
,not,RB,O
,.,.,O
,The,DT,O
,20,CD,O
,-,:,O
,year,NN,O
,risk,NN,O
,of,IN,O
,CAD,NNP,B-DISEASE
,at,IN,O
,diagnosis,NN,O
,of,IN,O
,diabetes,NNS,B-DISEASE
,",",",",O
,using,VBG,O
,the,DT,O
,UKPDS,NNP,O
,risk,NN,O
,engine,NN,O
,",",",",O
,was,VBD,O
,used,VBN,O
,to,TO,O
,match,VB,O
,cases,NNS,O
,with,IN,O
,controls,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,The,DT,O
,76,CD,O
,cases,NNS,O
,of,IN,O
,CAD,NNP,B-DISEASE
,were,VBD,O
,compared,VBN,O
,with,IN,O
,152,CD,O
,controls,NNS,O
,.,.,O
,The,DT,O
,hazard,NN,O
,of,IN,O
,developing,VBG,O
,CAD,NNP,B-DISEASE
,(,(,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,),),O
,associated,VBN,O
,with,IN,O
,initial,JJ,O
,treatment,NN,O
,increased,VBN,O
,by,IN,O
,2,CD,O
,.,.,O
,4,CD,O
,-,:,O
,fold,NN,O
,(,(,O
,1,CD,O
,.,.,O
,3,CD,O
,-,:,O
,4,CD,O
,.,.,O
,3,CD,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,004,CD,O
,),),O
,with,IN,O
,glibenclamide,NN,O
,;,:,O
,2,CD,O
,-,:,O
,fold,NN,O
,(,(,O
,0,CD,O
,.,.,O
,9,CD,O
,-,:,O
,4,CD,O
,.,.,O
,6,CD,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,099,CD,O
,),),O
,with,IN,O
,glipizide,NN,O
,;,:,O
,2,CD,O
,.,.,O
,9,CD,O
,-,:,O
,fold,NN,O
,(,(,O
,1,CD,O
,.,.,O
,6,CD,O
,-,:,O
,5,CD,O
,.,.,O
,1,CD,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,000,CD,O
,),),O
,with,IN,O
,either,DT,O
,",",",",O
,and,CC,O
,was,VBD,O
,unchanged,JJ,O
,with,IN,O
,metformin,NN,O
,.,.,O
,The,DT,O
,hazard,NN,O
,decreased,VBD,O
,0,CD,O
,.,.,O
,3,CD,O
,-,:,O
,fold,NN,O
,(,(,O
,0,CD,O
,.,.,O
,7,CD,O
,-,:,O
,1,CD,O
,.,.,O
,7,CD,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,385,CD,O
,),),O
,with,IN,O
,glimepiride,NN,O
,",",",",O
,0,CD,O
,.,.,O
,4,CD,O
,-,:,O
,fold,NN,O
,(,(,O
,0,CD,O
,.,.,O
,7,CD,O
,-,:,O
,1,CD,O
,.,.,O
,3,CD,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,192,CD,O
,),),O
,with,IN,O
,gliclazide,NN,O
,",",",",O
,and,CC,O
,0,CD,O
,.,.,O
,4,CD,O
,-,:,O
,fold,NN,O
,(,(,O
,0,CD,O
,.,.,O
,7,CD,O
,-,:,O
,1,CD,O
,.,.,O
,1,CD,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,09,CD,O
,),),O
,with,IN,O
,either,DT,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Initiating,NNP,O
,treatment,NN,O
,of,IN,O
,type,NN,B-DISEASE
,2,CD,I-DISEASE
,diabetes,NNS,I-DISEASE
,with,IN,O
,glibenclamide,NN,O
,or,CC,O
,glipizide,NN,O
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,increased,JJ,O
,risk,NN,O
,of,IN,O
,CAD,NNP,B-DISEASE
,in,IN,O
,comparison,NN,O
,to,TO,O
,gliclazide,VB,O
,or,CC,O
,glimepiride,VB,O
,.,.,O
,If,IN,O
,confirmed,VBN,O
,",",",",O
,this,DT,O
,may,MD,O
,be,VB,O
,important,JJ,O
,because,IN,O
,most,JJS,O
,Indian,JJ,O
,patients,NNS,O
,receive,VBP,O
,the,DT,O
,cheaper,JJR,O
,older,JJR,O
,sulphonylureas,NNS,O
,",",",",O
,and,CC,O
,present,JJ,O
,guidelines,NNS,O
,do,VBP,O
,not,RB,O
,distinguish,VB,O
,between,IN,O
,individual,JJ,O
,agents,NNS,O
,.,.,O
,Reduced,VBN,O
,progression,NN,O
,of,IN,O
,adriamycin,NN,O
,nephropathy,NN,B-DISEASE
,in,IN,O
,spontaneously,RB,O
,hypertensive,JJ,B-DISEASE
,rats,NNS,O
,treated,VBN,O
,by,IN,O
,losartan,NN,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,The,DT,O
,aim,NN,O
,of,IN,O
,the,DT,O
,study,NN,O
,was,VBD,O
,to,TO,O
,investigate,VB,O
,the,DT,O
,antihypertensive,JJ,O
,effects,NNS,O
,of,IN,O
,angiotensin,NN,O
,II,NNP,O
,type,NN,O
,-,:,O
,1,CD,O
,receptor,NN,O
,blocker,NN,O
,",",",",O
,losartan,NN,O
,",",",",O
,and,CC,O
,its,PRP$,O
,potential,JJ,O
,in,IN,O
,slowing,VBG,O
,down,RP,O
,renal,JJ,B-DISEASE
,disease,NN,I-DISEASE
,progression,NN,O
,in,IN,O
,spontaneously,RB,O
,hypertensive,JJ,B-DISEASE
,rats,NNS,O
,(,(,O
,SHR,NNP,O
,),),O
,with,IN,O
,adriamycin,NN,O
,(,(,O
,ADR,NNP,O
,),),O
,nephropathy,NN,B-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,Six,NNP,O
,-,:,O
,month,NN,O
,-,:,O
,old,JJ,O
,female,JJ,O
,SHR,NNP,O
,were,VBD,O
,randomly,RB,O
,selected,VBN,O
,in,IN,O
,six,CD,O
,groups,NNS,O
,.,.,O
,Two,CD,O
,control,NN,O
,groups,NNS,O
,(,(,O
,SH,NNP,O
,(,(,O
,6,CD,O
,),),O
,",",",",O
,SH,NNP,O
,(,(,O
,12,CD,O
,),),O
,),),O
,received,VBD,O
,vehicle,NN,O
,.,.,O
,Groups,NNP,O
,ADR,NNP,O
,(,(,O
,6,CD,O
,),),O
,",",",",O
,ADR,NNP,O
,+,NNP,O
,LOS,NNP,O
,(,(,O
,6,CD,O
,),),O
,and,CC,O
,ADR,NNP,O
,(,(,O
,12,CD,O
,),),O
,",",",",O
,and,CC,O
,ADR,NNP,O
,+,NNP,O
,LOS,NNP,O
,(,(,O
,12,CD,O
,),),O
,received,VBN,O
,ADR,NNP,O
,(,(,O
,2,CD,O
,mg,NN,O
,/,NNP,O
,kg,NNP,O
,/,NNP,O
,b,NN,O
,.,.,O
,w,NN,O
,.,.,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,),),O
,twice,RB,O
,in,IN,O
,a,DT,O
,3,CD,O
,-,:,O
,week,NN,O
,interval,NN,O
,.,.,O
,Group,NNP,O
,ADR,NNP,O
,+,NNP,O
,LOS,NNP,O
,(,(,O
,6,CD,O
,),),O
,received,VBN,O
,losartan,JJ,O
,(,(,O
,10,CD,O
,mg,NN,O
,/,NNP,O
,kg,NNP,O
,/,NNP,O
,b,NN,O
,.,.,O
,w,NN,O
,.,.,O
,/,JJ,O
,day,NN,O
,by,IN,O
,gavages,NNS,O
,),),O
,for,IN,O
,6,CD,O
,weeks,NNS,O
,and,CC,O
,group,NN,O
,ADR,NNP,O
,+,NNP,O
,LOS,NNP,O
,(,(,O
,12,CD,O
,),),O
,for,IN,O
,12,CD,O
,weeks,NNS,O
,after,IN,O
,second,JJ,O
,injection,NN,O
,of,IN,O
,ADR,NNP,O
,.,.,O
,Animals,NNS,O
,were,VBD,O
,killed,VBN,O
,after,IN,O
,6,CD,O
,or,CC,O
,12,CD,O
,weeks,NNS,O
,",",",",O
,respectively,RB,O
,.,.,O
,Haemodynamic,JJ,O
,measurements,NNS,O
,were,VBD,O
,performed,VBN,O
,on,IN,O
,anaesthetized,JJ,O
,animals,NNS,O
,",",",",O
,blood,NN,O
,and,CC,O
,urine,JJ,O
,samples,NNS,O
,were,VBD,O
,taken,VBN,O
,for,IN,O
,biochemical,JJ,O
,analysis,NN,O
,and,CC,O
,the,DT,O
,left,JJ,O
,kidney,NN,O
,was,VBD,O
,processed,VBN,O
,for,IN,O
,morphological,JJ,O
,studies,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Short,JJ,O
,-,:,O
,term,NN,O
,losartan,JJ,O
,treatment,NN,O
,",",",",O
,besides,IN,O
,antihypertensive,JJ,O
,effect,NN,O
,",",",",O
,improved,VBD,O
,glomerular,JJ,O
,filtration,NN,O
,rate,NN,O
,and,CC,O
,ameliorated,VBN,O
,glomerulosclerosis,NN,B-DISEASE
,resulting,VBG,O
,in,IN,O
,decreased,JJ,O
,proteinuria,NN,B-DISEASE
,.,.,O
,Prolonged,VBD,O
,treatment,NN,O
,with,IN,O
,losartan,NN,O
,showed,VBD,O
,further,JJ,O
,reduction,NN,O
,of,IN,O
,glomerulosclerosis,NN,B-DISEASE
,associated,VBN,O
,with,IN,O
,reduced,JJ,O
,progression,NN,O
,of,IN,O
,tubular,JJ,O
,atrophy,NN,B-DISEASE
,and,CC,O
,interstitial,JJ,B-DISEASE
,fibrosis,NN,I-DISEASE
,",",",",O
,thus,RB,O
,preventing,VBG,O
,heavy,JJ,O
,proteinuria,NNS,B-DISEASE
,and,CC,O
,chronic,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,Losartan,NNP,O
,reduced,VBD,O
,uraemia,JJ,B-DISEASE
,and,CC,O
,increased,VBD,O
,urea,JJ,O
,clearance,NN,O
,in,IN,O
,advanced,JJ,O
,ADR,NNP,O
,nephropathy,NN,B-DISEASE
,in,IN,O
,SHR,NNP,O
,.,.,O
,Histological,NNP,O
,examination,NN,O
,showed,VBD,O
,that,IN,O
,losartan,NN,O
,could,MD,O
,prevent,VB,O
,tubular,JJ,O
,atrophy,NN,B-DISEASE
,",",",",O
,interstitial,JJ,O
,infiltration,NN,O
,and,CC,O
,fibrosis,NN,B-DISEASE
,in,IN,O
,ADR,NNP,O
,nephropathy,NN,B-DISEASE
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Losartan,JJ,O
,reduces,VBZ,O
,the,DT,O
,rate,NN,O
,of,IN,O
,progression,NN,O
,of,IN,O
,ADR,NNP,O
,-,:,O
,induced,JJ,O
,focal,JJ,B-DISEASE
,segmental,JJ,I-DISEASE
,glomerulosclerosis,NN,I-DISEASE
,to,TO,O
,end,VB,B-DISEASE
,-,:,I-DISEASE
,stage,NN,I-DISEASE
,renal,JJ,I-DISEASE
,disease,NN,I-DISEASE
,in,IN,O
,SHR,NNP,O
,.,.,O
,The,DT,O
,risks,NNS,O
,of,IN,O
,aprotinin,NN,O
,and,CC,O
,tranexamic,JJ,O
,acid,NN,O
,in,IN,O
,cardiac,JJ,O
,surgery,NN,O
,:,:,O
,a,DT,O
,one,CD,O
,-,:,O
,year,NN,O
,follow,SYM,O
,-,:,O
,up,IN,O
,of,IN,O
,1188,CD,O
,consecutive,JJ,O
,patients,NNS,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Our,PRP$,O
,aim,NN,O
,was,VBD,O
,to,TO,O
,investigate,VB,O
,postoperative,JJ,O
,complications,NNS,O
,and,CC,O
,mortality,NN,O
,after,IN,O
,administration,NN,O
,of,IN,O
,aprotinin,NNS,O
,compared,VBN,O
,to,TO,O
,tranexamic,VB,O
,acid,NN,O
,in,IN,O
,an,DT,O
,unselected,JJ,O
,",",",",O
,consecutive,JJ,O
,cohort,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,Perioperative,JJ,O
,data,NNS,O
,from,IN,O
,consecutive,JJ,O
,cardiac,JJ,O
,surgery,NN,O
,patients,NNS,O
,were,VBD,O
,prospectively,RB,O
,collected,VBN,O
,between,IN,O
,September,NNP,O
,2005,CD,O
,and,CC,O
,June,NNP,O
,2006,CD,O
,in,IN,O
,a,DT,O
,university,NN,O
,-,:,O
,affiliated,VBN,O
,clinic,NN,O
,(,(,O
,n,JJ,O
,=,NN,O
,1188,CD,O
,),),O
,.,.,O
,During,IN,O
,the,DT,O
,first,JJ,O
,5,CD,O
,mo,NN,O
,",",",",O
,596,CD,O
,patients,NNS,O
,received,VBN,O
,aprotinin,RB,O
,(,(,O
,Group,NNP,O
,A,NNP,O
,),),O
,;,:,O
,in,IN,O
,the,DT,O
,next,JJ,O
,5,CD,O
,mo,NN,O
,",",",",O
,592,CD,O
,patients,NNS,O
,were,VBD,O
,treated,VBN,O
,with,IN,O
,tranexamic,JJ,O
,acid,NN,O
,(,(,O
,Group,NNP,O
,T,NNP,O
,),),O
,.,.,O
,Except,IN,O
,for,IN,O
,antifibrinolytic,JJ,O
,therapy,NN,O
,",",",",O
,the,DT,O
,anesthetic,JJ,O
,and,CC,O
,surgical,JJ,O
,protocols,NNS,O
,remained,VBD,O
,unchanged,JJ,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,The,DT,O
,pre,NN,O
,-,:,O
,and,CC,O
,intraoperative,JJ,O
,variables,NNS,O
,were,VBD,O
,comparable,JJ,O
,between,IN,O
,the,DT,O
,treatment,NN,O
,groups,NNS,O
,.,.,O
,Postoperatively,RB,O
,",",",",O
,a,DT,O
,significantly,RB,O
,higher,JJR,O
,incidence,NN,O
,of,IN,O
,seizures,NNS,B-DISEASE
,was,VBD,O
,found,VBN,O
,in,IN,O
,Group,NNP,O
,T,NNP,O
,(,(,O
,4,CD,O
,.,.,O
,6,CD,O
,%,NN,O
,vs,NN,O
,1,CD,O
,.,.,O
,2,CD,O
,%,NN,O
,",",",",O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,.,.,O
,This,DT,O
,difference,NN,O
,was,VBD,O
,also,RB,O
,significant,JJ,O
,in,IN,O
,the,DT,O
,primary,JJ,O
,valve,NN,O
,surgery,NN,O
,and,CC,O
,the,DT,O
,high,JJ,O
,risk,NN,O
,surgery,NN,O
,subgroups,NNS,O
,(,(,O
,7,CD,O
,.,.,O
,9,CD,O
,%,NN,O
,vs,NN,O
,1,CD,O
,.,.,O
,2,CD,O
,%,NN,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,003,CD,O
,;,:,O
,7,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,vs,NN,O
,2,CD,O
,.,.,O
,4,CD,O
,%,NN,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,035,CD,O
,",",",",O
,respectively,RB,O
,),),O
,.,.,O
,Persistent,JJ,O
,atrial,JJ,O
,fibrillation,NN,O
,(,(,O
,7,CD,O
,.,.,O
,9,CD,O
,%,NN,O
,vs,NN,O
,2,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,020,CD,O
,),),O
,and,CC,O
,renal,JJ,B-DISEASE
,failure,NN,I-DISEASE
,(,(,O
,9,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,vs,NN,O
,1,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,002,CD,O
,),),O
,were,VBD,O
,also,RB,O
,more,RBR,O
,common,JJ,O
,in,IN,O
,Group,NNP,O
,T,NNP,O
,",",",",O
,in,IN,O
,the,DT,O
,primary,JJ,O
,valve,NN,O
,surgery,NN,O
,subgroup,NN,O
,.,.,O
,On,IN,O
,the,DT,O
,contrary,JJ,O
,",",",",O
,among,IN,O
,primary,JJ,O
,coronary,JJ,O
,artery,NN,O
,bypass,NN,O
,surgery,NN,O
,patients,NNS,O
,",",",",O
,there,EX,O
,were,VBD,O
,more,JJR,O
,acute,JJ,O
,myocardial,JJ,B-DISEASE
,infarctions,NNS,I-DISEASE
,and,CC,O
,renal,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,in,IN,O
,Group,NNP,O
,A,NNP,O
,(,(,O
,5,CD,O
,.,.,O
,8,CD,O
,%,NN,O
,vs,NN,O
,2,CD,O
,.,.,O
,0,CD,O
,%,NN,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,027,CD,O
,;,:,O
,22,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,vs,NN,O
,15,CD,O
,.,.,O
,2,CD,O
,%,NN,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,036,CD,O
,",",",",O
,respectively,RB,O
,),),O
,.,.,O
,The,DT,O
,1,CD,O
,-,:,O
,yr,NN,O
,mortality,NN,O
,was,VBD,O
,significantly,RB,O
,higher,JJR,O
,after,IN,O
,aprotinin,JJ,O
,treatment,NN,O
,in,IN,O
,the,DT,O
,high,JJ,O
,risk,NN,O
,surgery,NN,O
,group,NN,O
,(,(,O
,17,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,vs,NN,O
,9,CD,O
,.,.,O
,8,CD,O
,%,NN,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,034,CD,O
,),),O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Both,DT,O
,antifibrinolytic,JJ,O
,drugs,NNS,O
,bear,VBP,O
,the,DT,O
,risk,NN,O
,of,IN,O
,adverse,JJ,O
,outcome,NN,O
,depending,VBG,O
,on,IN,O
,the,DT,O
,type,NN,O
,of,IN,O
,cardiac,JJ,O
,surgery,NN,O
,.,.,O
,Administration,NNP,O
,of,IN,O
,aprotinin,NN,O
,should,MD,O
,be,VB,O
,avoided,VBN,O
,in,IN,O
,coronary,JJ,O
,artery,NN,O
,bypass,NN,O
,graft,NN,O
,and,CC,O
,high,JJ,O
,risk,NN,O
,patients,NNS,O
,",",",",O
,whereas,JJ,O
,administration,NN,O
,of,IN,O
,tranexamic,JJ,O
,acid,NN,O
,is,VBZ,O
,not,RB,O
,recommended,VBN,O
,in,IN,O
,valve,NN,O
,surgery,NN,O
,.,.,O
,Delirium,NN,B-DISEASE
,in,IN,O
,an,DT,O
,elderly,JJ,O
,woman,NN,O
,possibly,RB,O
,associated,VBN,O
,with,IN,O
,administration,NN,O
,of,IN,O
,misoprostol,NN,O
,.,.,O
,Misoprostol,NNP,O
,has,VBZ,O
,been,VBN,O
,associated,VBN,O
,with,IN,O
,adverse,JJ,O
,reactions,NNS,O
,",",",",O
,including,VBG,O
,gastrointestinal,JJ,O
,symptoms,NNS,O
,",",",",O
,gynecologic,JJ,O
,problems,NNS,O
,",",",",O
,and,CC,O
,headache,NN,B-DISEASE
,.,.,O
,Changes,NNS,O
,in,IN,O
,mental,JJ,O
,status,NN,O
,",",",",O
,however,RB,O
,",",",",O
,have,VBP,O
,not,RB,O
,been,VBN,O
,reported,VBN,O
,.,.,O
,We,PRP,O
,present,VBD,O
,a,DT,O
,case,NN,O
,in,IN,O
,which,WDT,O
,an,DT,O
,89,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,in,IN,O
,a,DT,O
,long,JJ,O
,-,:,O
,term,NN,O
,care,NN,O
,facility,NN,O
,became,VBD,O
,confused,VBN,O
,after,IN,O
,the,DT,O
,initiation,NN,O
,of,IN,O
,misoprostol,JJ,O
,therapy,NN,O
,.,.,O
,The,DT,O
,patient,NN,O
,',POS,O
,s,JJ,O
,change,NN,O
,in,IN,O
,mental,JJ,O
,status,NN,O
,was,VBD,O
,first,RB,O
,reported,VBN,O
,nine,CD,O
,days,NNS,O
,after,IN,O
,the,DT,O
,initiation,NN,O
,of,IN,O
,therapy,NN,O
,.,.,O
,Her,PRP$,O
,delirium,NN,B-DISEASE
,significantly,RB,O
,improved,VBN,O
,after,IN,O
,misoprostol,NN,O
,was,VBD,O
,discontinued,VBN,O
,and,CC,O
,her,PRP$,O
,mental,JJ,O
,status,NN,O
,returned,VBD,O
,to,TO,O
,normal,JJ,O
,within,IN,O
,a,DT,O
,week,NN,O
,.,.,O
,Because,IN,O
,no,DT,O
,other,JJ,O
,factors,NNS,O
,related,VBN,O
,to,TO,O
,this,DT,O
,patient,NN,O
,changed,VBD,O
,significantly,RB,O
,",",",",O
,the,DT,O
,delirium,NN,B-DISEASE
,experienced,VBN,O
,by,IN,O
,this,DT,O
,patient,NN,O
,possibly,RB,O
,resulted,VBD,O
,from,IN,O
,misoprostol,JJ,O
,therapy,NN,O
,.,.,O
,The,DT,O
,biological,JJ,O
,properties,NNS,O
,of,IN,O
,the,DT,O
,optical,JJ,O
,isomers,NNS,O
,of,IN,O
,propranolol,NN,O
,and,CC,O
,their,PRP$,O
,effects,NNS,O
,on,IN,O
,cardiac,JJ,B-DISEASE
,arrhythmias,NN,I-DISEASE
,.,.,O
,1,CD,O
,.,.,O
,The,DT,O
,optical,JJ,O
,isomers,NNS,O
,of,IN,O
,propranolol,NNS,O
,have,VBP,O
,been,VBN,O
,compared,VBN,O
,for,IN,O
,their,PRP$,O
,beta,NN,O
,-,:,O
,blocking,NN,O
,and,CC,O
,antiarrhythmic,JJ,O
,activities,NNS,O
,.,.,O
,2,CD,O
,.,.,O
,In,IN,O
,blocking,VBG,O
,the,DT,O
,positive,JJ,O
,inotropic,NN,O
,and,CC,O
,chronotropic,NN,O
,responses,NNS,O
,to,TO,O
,isoprenaline,VB,O
,",",",",O
,(,(,O
,+,NN,O
,),),O
,-,:,O
,propranolol,NN,O
,had,VBD,O
,less,JJR,O
,than,IN,O
,one,CD,O
,hundredth,VBZ,O
,the,DT,O
,potency,NN,O
,of,IN,O
,(,(,O
,-,:,O
,),),O
,-,:,O
,propranolol,NN,O
,.,.,O
,At,IN,O
,dose,JJ,O
,levels,NNS,O
,of,IN,O
,(,(,O
,+,NNP,O
,),),O
,-,:,O
,propranolol,NN,O
,which,WDT,O
,attenuated,VBD,O
,the,DT,O
,responses,NNS,O
,to,TO,O
,isoprenaline,VB,O
,",",",",O
,there,EX,O
,was,VBD,O
,a,DT,O
,significant,JJ,O
,prolongation,NN,O
,of,IN,O
,the,DT,O
,PR,NNP,O
,interval,NN,O
,of,IN,O
,the,DT,O
,electrocardiogram,NN,O
,.,.,O
,3,CD,O
,.,.,O
,The,DT,O
,metabolic,JJ,O
,responses,NNS,O
,to,TO,O
,isoprenaline,VB,O
,in,IN,O
,dogs,NNS,O
,(,(,O
,an,DT,O
,increase,NN,O
,in,IN,O
,circulating,VBG,O
,glucose,NN,O
,",",",",O
,lactate,NN,O
,and,CC,O
,free,JJ,O
,fatty,JJ,O
,acids,NNS,O
,),),O
,were,VBD,O
,all,DT,O
,blocked,VBN,O
,by,IN,O
,(,(,O
,-,:,O
,),),O
,-,:,O
,propranolol,NN,O
,.,.,O
,(,(,O
,+,NN,O
,),),O
,-,:,O
,Propranolol,NN,O
,had,VBD,O
,no,DT,O
,effect,NN,O
,on,IN,O
,fatty,JJ,O
,acid,JJ,O
,mobilization,NN,O
,but,CC,O
,significantly,RB,O
,reduced,VBD,O
,the,DT,O
,increments,NNS,O
,in,IN,O
,both,DT,O
,lactate,NN,O
,and,CC,O
,glucose,NN,O
,.,.,O
,4,CD,O
,.,.,O
,Both,DT,O
,isomers,NNS,O
,of,IN,O
,propranolol,NN,O
,possessed,VBD,O
,similar,JJ,O
,depressant,NN,O
,potency,NN,O
,on,IN,O
,isolated,JJ,O
,atrial,JJ,O
,muscle,NN,O
,taken,VBN,O
,from,IN,O
,guinea,NN,O
,-,:,O
,pigs,NNS,O
,.,.,O
,5,CD,O
,.,.,O
,The,DT,O
,isomers,NNS,O
,of,IN,O
,propranolol,NN,O
,exhibited,VBD,O
,similar,JJ,O
,local,JJ,O
,anaesthetic,JJ,O
,potencies,NNS,O
,on,IN,O
,an,DT,O
,isolated,JJ,O
,frog,NN,O
,nerve,NN,O
,preparation,NN,O
,at,IN,O
,a,DT,O
,level,NN,O
,approximately,RB,O
,three,CD,O
,times,NNS,O
,that,IN,O
,of,IN,O
,procaine,NN,O
,.,.,O
,The,DT,O
,racemic,JJ,O
,compound,NN,O
,was,VBD,O
,significantly,RB,O
,less,RBR,O
,potent,JJ,O
,than,IN,O
,either,DT,O
,isomer,NN,O
,.,.,O
,6,CD,O
,.,.,O
,Both,DT,O
,isomers,NNS,O
,of,IN,O
,propranolol,NN,O
,were,VBD,O
,capable,JJ,O
,of,IN,O
,preventing,VBG,O
,adrenaline,JJ,O
,-,:,O
,induced,JJ,O
,cardiac,JJ,B-DISEASE
,arrhythmias,NN,I-DISEASE
,in,IN,O
,cats,NNS,O
,anaesthetized,VBN,O
,with,IN,O
,halothane,NN,O
,",",",",O
,but,CC,O
,the,DT,O
,mean,JJ,O
,dose,NN,O
,of,IN,O
,(,(,O
,-,:,O
,),),O
,-,:,O
,propranolol,NN,O
,was,VBD,O
,0,CD,O
,.,.,O
,09,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,02,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,whereas,NNS,O
,that,IN,O
,of,IN,O
,(,(,O
,+,NNP,O
,),),O
,-,:,O
,propranolol,NN,O
,was,VBD,O
,4,CD,O
,.,.,O
,2,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,2,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,.,.,O
,At,IN,O
,the,DT,O
,effective,JJ,O
,dose,JJ,O
,level,NN,O
,of,IN,O
,(,(,O
,+,NNP,O
,),),O
,-,:,O
,propranolol,NN,O
,there,EX,O
,was,VBD,O
,a,DT,O
,significant,JJ,O
,prolongation,NN,O
,of,IN,O
,the,DT,O
,PR,NNP,O
,interval,NN,O
,of,IN,O
,the,DT,O
,electrocardiogram,NN,O
,.,.,O
,Blockade,NNP,O
,of,IN,O
,arrhythmias,NN,B-DISEASE
,with,IN,O
,both,DT,O
,isomers,NNS,O
,was,VBD,O
,surmountable,JJ,O
,by,IN,O
,increasing,VBG,O
,the,DT,O
,dose,NN,O
,of,IN,O
,adrenaline,NN,O
,.,.,O
,7,CD,O
,.,.,O
,Both,DT,O
,isomers,NNS,O
,of,IN,O
,propranolol,NN,O
,were,VBD,O
,also,RB,O
,capable,JJ,O
,of,IN,O
,reversing,VBG,O
,ventricular,JJ,B-DISEASE
,tachycardia,NN,I-DISEASE
,caused,VBN,O
,by,IN,O
,ouabain,NN,O
,in,IN,O
,anaesthetized,JJ,O
,cats,NNS,O
,and,CC,O
,dogs,NNS,O
,.,.,O
,The,DT,O
,dose,NN,O
,of,IN,O
,(,(,O
,-,:,O
,),),O
,-,:,O
,propranolol,NN,O
,was,VBD,O
,significantly,RB,O
,smaller,JJR,O
,than,IN,O
,that,DT,O
,of,IN,O
,(,(,O
,+,NNP,O
,),),O
,-,:,O
,propranolol,NN,O
,in,IN,O
,both,DT,O
,species,NNS,O
,but,CC,O
,much,RB,O
,higher,JJR,O
,than,IN,O
,that,DT,O
,required,VBN,O
,to,TO,O
,produce,VB,O
,evidence,NN,O
,of,IN,O
,beta,NN,O
,-,:,O
,blockade,NN,O
,.,.,O
,8,CD,O
,.,.,O
,The,DT,O
,implications,NNS,O
,of,IN,O
,these,DT,O
,results,NNS,O
,are,VBP,O
,discussed,VBN,O
,.,.,O
,Topotecan,NNP,O
,in,IN,O
,combination,NN,O
,with,IN,O
,radiotherapy,NN,O
,in,IN,O
,unresectable,JJ,O
,glioblastoma,NN,B-DISEASE
,:,:,O
,a,DT,O
,phase,NN,O
,2,CD,O
,study,NN,O
,.,.,O
,Improving,VBG,O
,glioblastoma,JJ,B-DISEASE
,multiforme,NN,I-DISEASE
,(,(,O
,GBM,NNP,B-DISEASE
,),),O
,treatment,NN,O
,with,IN,O
,radio,NN,O
,-,:,O
,chemotherapy,NN,O
,remains,VBZ,O
,a,DT,O
,challenge,NN,O
,.,.,O
,Topotecan,NNP,O
,is,VBZ,O
,an,DT,O
,attractive,JJ,O
,option,NN,O
,as,IN,O
,it,PRP,O
,exhibits,VBZ,O
,growth,NN,O
,inhibition,NN,O
,of,IN,O
,human,JJ,O
,glioma,NN,B-DISEASE
,as,RB,O
,well,RB,O
,as,IN,O
,brain,NN,O
,penetration,NN,O
,.,.,O
,The,DT,O
,present,JJ,O
,study,NN,O
,assessed,VBD,O
,the,DT,O
,combination,NN,O
,of,IN,O
,radiotherapy,NN,O
,(,(,O
,60,CD,O
,Gy,NNP,O
,/,VBD,O
,30,CD,O
,fractions,NNS,O
,/,VBP,O
,40,CD,O
,days,NNS,O
,),),O
,and,CC,O
,topotecan,JJ,O
,(,(,O
,0,CD,O
,.,.,O
,9,CD,O
,mg,JJ,O
,/,NNP,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,/,FW,O
,day,NN,O
,on,IN,O
,days,NNS,O
,1,CD,O
,-,:,O
,5,CD,O
,on,IN,O
,weeks,NNS,O
,1,CD,O
,",",",",O
,3,CD,O
,and,CC,O
,5,CD,O
,),),O
,in,IN,O
,50,CD,O
,adults,NNS,O
,with,IN,O
,histologically,RB,O
,proven,VBN,O
,and,CC,O
,untreated,JJ,O
,GBM,NNP,B-DISEASE
,.,.,O
,The,DT,O
,incidence,NN,O
,of,IN,O
,non,JJ,O
,-,:,O
,hematological,JJ,O
,toxicities,NNS,B-DISEASE
,was,VBD,O
,low,JJ,O
,and,CC,O
,grade,VBD,O
,3,CD,O
,-,:,O
,4,CD,O
,hematological,JJ,O
,toxicities,NNS,B-DISEASE
,were,VBD,O
,reported,VBN,O
,in,IN,O
,20,CD,O
,patients,NNS,O
,(,(,O
,mainly,RB,O
,lymphopenia,NN,B-DISEASE
,and,CC,O
,neutropenia,NN,B-DISEASE
,),),O
,.,.,O
,Partial,JJ,O
,response,NN,O
,and,CC,O
,stabilization,NN,O
,rates,NNS,O
,were,VBD,O
,2,CD,O
,%,NN,O
,and,CC,O
,32,CD,O
,%,NN,O
,",",",",O
,respectively,RB,O
,",",",",O
,with,IN,O
,an,DT,O
,overall,JJ,O
,time,NN,O
,to,TO,O
,progression,NN,O
,of,IN,O
,12,CD,O
,weeks,NNS,O
,.,.,O
,One,CD,O
,-,:,O
,year,NN,O
,overall,JJ,O
,survival,NN,O
,(,(,O
,OS,NNP,O
,),),O
,rate,NN,O
,was,VBD,O
,42,CD,O
,%,NN,O
,",",",",O
,with,IN,O
,a,DT,O
,median,JJ,O
,OS,NNP,O
,of,IN,O
,40,CD,O
,weeks,NNS,O
,.,.,O
,Topotecan,NNP,O
,in,IN,O
,combination,NN,O
,with,IN,O
,radiotherapy,NN,O
,was,VBD,O
,well,RB,O
,tolerated,VBN,O
,.,.,O
,However,RB,O
,",",",",O
,while,IN,O
,response,NN,O
,and,CC,O
,stabilization,NN,O
,concerned,VBD,O
,one,CD,O
,-,:,O
,third,NN,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,",",",",O
,the,DT,O
,study,NN,O
,did,VBD,O
,not,RB,O
,show,VB,O
,increased,JJ,O
,benefits,NNS,O
,in,IN,O
,terms,NNS,O
,of,IN,O
,survival,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,unresectable,JJ,O
,GBM,NNP,B-DISEASE
,.,.,O
,Long,NNP,O
,-,:,O
,term,NN,O
,lithium,NN,O
,therapy,NN,O
,leading,VBG,O
,to,TO,O
,hyperparathyroidism,NN,B-DISEASE
,:,:,O
,a,DT,O
,case,NN,O
,report,NN,O
,.,.,O
,PURPOSE,NN,O
,:,:,O
,This,DT,O
,paper,NN,O
,reviews,VBZ,O
,the,DT,O
,effect,NN,O
,of,IN,O
,chronic,JJ,O
,lithium,NN,O
,therapy,NN,O
,on,IN,O
,serum,JJ,O
,calcium,NN,O
,level,NN,O
,and,CC,O
,parathyroid,JJ,O
,glands,NNS,O
,",",",",O
,its,PRP$,O
,pathogenesis,NN,O
,",",",",O
,and,CC,O
,treatment,NN,O
,options,NNS,O
,.,.,O
,We,PRP,O
,examined,VBD,O
,the,DT,O
,case,NN,O
,of,IN,O
,a,DT,O
,lithium,NN,O
,-,:,O
,treated,VBN,O
,patient,NN,O
,who,WP,O
,had,VBD,O
,recurrent,NN,O
,hypercalcemia,NN,B-DISEASE
,to,TO,O
,better,JJR,O
,understand,VB,O
,the,DT,O
,disease,NN,O
,process,NN,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Primary,JJ,B-DISEASE
,hyperparathyroidism,NN,I-DISEASE
,is,VBZ,O
,a,DT,O
,rare,JJ,O
,but,CC,O
,potentially,RB,O
,life,NN,O
,-,:,O
,threatening,JJ,O
,side,NN,O
,effect,NN,O
,of,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,lithium,NN,O
,therapy,NN,O
,.,.,O
,Careful,JJ,O
,patient,JJ,O
,selection,NN,O
,and,CC,O
,long,JJ,O
,-,:,O
,term,NN,O
,follow,SYM,O
,-,:,O
,up,RB,O
,can,MD,O
,reduce,VB,O
,morbidity,NN,O
,.,.,O
,PRACTICAL,JJ,O
,IMPLICATIONS,NN,O
,:,:,O
,As,RB,O
,much,RB,O
,as,IN,O
,15,CD,O
,%,NN,O
,of,IN,O
,lithium,NN,O
,-,:,O
,treated,JJ,O
,patients,NNS,O
,become,VBP,O
,hypercalcemic,JJ,B-DISEASE
,.,.,O
,By,IN,O
,routinely,RB,O
,monitoring,VBG,O
,serum,JJ,O
,calcium,NN,O
,levels,NNS,O
,",",",",O
,healthcare,NN,O
,providers,NNS,O
,can,MD,O
,improve,VB,O
,the,DT,O
,quality,NN,O
,of,IN,O
,life,NN,O
,of,IN,O
,this,DT,O
,patient,NN,O
,group,NN,O
,.,.,O
,Comparison,NNP,O
,of,IN,O
,laryngeal,JJ,O
,mask,NN,O
,with,IN,O
,endotracheal,JJ,O
,tube,NN,O
,for,IN,O
,anesthesia,NN,O
,in,IN,O
,endoscopic,JJ,O
,sinus,NN,O
,surgery,NN,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,The,DT,O
,purpose,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,was,VBD,O
,to,TO,O
,compare,VB,O
,surgical,JJ,O
,conditions,NNS,O
,",",",",O
,including,VBG,O
,the,DT,O
,amount,NN,O
,of,IN,O
,intraoperative,JJ,O
,bleeding,NN,B-DISEASE
,as,RB,O
,well,RB,O
,as,IN,O
,intraoperative,JJ,O
,blood,NN,O
,pressure,NN,O
,",",",",O
,during,IN,O
,functional,JJ,O
,endoscopic,NN,O
,sinus,NN,O
,surgery,NN,O
,(,(,O
,FESS,NNP,O
,),),O
,using,VBG,O
,flexible,JJ,O
,reinforced,JJ,O
,laryngeal,NN,O
,mask,NN,O
,airway,NN,O
,(,(,O
,FRLMA,NNP,O
,),),O
,versus,NN,O
,endotracheal,JJ,O
,tube,NN,O
,(,(,O
,ETT,NNP,O
,),),O
,in,IN,O
,maintaining,VBG,O
,controlled,VBN,O
,hypotension,NN,B-DISEASE
,anesthesia,NN,O
,induced,VBN,O
,by,IN,O
,propofol,JJ,O
,-,:,O
,remifentanil,NN,O
,total,JJ,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,anesthesia,NN,O
,(,(,O
,TIVA,NNP,O
,),),O
,.,.,O
,METHODS,NN,O
,:,:,O
,Sixty,NNP,O
,normotensive,JJ,O
,American,JJ,O
,Society,NNP,O
,of,IN,O
,Anesthesiologists,NNPS,O
,I,PRP,O
,-,:,O
,II,NNP,O
,adult,NN,O
,patients,NNS,O
,undergoing,VBG,O
,FESS,NNP,O
,under,IN,O
,controlled,VBN,O
,hypotension,NN,B-DISEASE
,anesthesia,NN,O
,caused,VBN,O
,by,IN,O
,propofol,JJ,O
,-,:,O
,remifentanil,NN,O
,-,:,O
,TIVA,NN,O
,were,VBD,O
,randomly,RB,O
,assigned,VBN,O
,into,IN,O
,two,CD,O
,groups,NNS,O
,:,:,O
,group,NN,O
,I,PRP,O
,",",",",O
,FRLMA,NNP,O
,;,:,O
,group,NN,O
,II,NNP,O
,",",",",O
,ETT,NNP,O
,.,.,O
,Hemorrhage,NN,B-DISEASE
,was,VBD,O
,measured,VBN,O
,and,CC,O
,the,DT,O
,visibility,NN,O
,of,IN,O
,the,DT,O
,operative,JJ,O
,field,NN,O
,was,VBD,O
,evaluated,VBN,O
,according,VBG,O
,to,TO,O
,a,DT,O
,six,CD,O
,-,:,O
,point,NN,O
,scale,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Controlled,JJ,O
,hypotension,NN,B-DISEASE
,was,VBD,O
,achieved,VBN,O
,within,IN,O
,a,DT,O
,shorter,JJR,O
,period,NN,O
,using,VBG,O
,laryngeal,JJ,O
,mask,NN,O
,using,VBG,O
,lower,JJR,O
,rates,NNS,O
,of,IN,O
,remifentanil,JJ,O
,infusion,NN,O
,and,CC,O
,lower,JJR,O
,total,NN,O
,dose,NN,O
,of,IN,O
,remifentanil,NN,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,In,IN,O
,summary,NN,O
,",",",",O
,our,PRP$,O
,results,NNS,O
,indicate,VBP,O
,that,IN,O
,airway,NN,O
,management,NN,O
,using,VBG,O
,FRLMA,NNP,O
,during,IN,O
,controlled,VBN,O
,hypotension,NN,B-DISEASE
,anesthesia,NN,O
,provided,VBD,O
,better,RBR,O
,surgical,JJ,O
,conditions,NNS,O
,in,IN,O
,terms,NNS,O
,of,IN,O
,quality,NN,O
,of,IN,O
,operative,JJ,O
,field,NN,O
,and,CC,O
,blood,NN,O
,loss,NN,O
,and,CC,O
,allowed,VBN,O
,for,IN,O
,convenient,NN,O
,induced,VBN,O
,hypotension,NN,B-DISEASE
,with,IN,O
,low,JJ,O
,doses,NNS,O
,of,IN,O
,remifentanil,NN,O
,during,IN,O
,TIVA,NNP,O
,in,IN,O
,patients,NNS,O
,undergoing,JJ,O
,FESS,NNP,O
,.,.,O
,Nonalcoholic,NNP,B-DISEASE
,fatty,RB,I-DISEASE
,liver,RB,I-DISEASE
,disease,NN,I-DISEASE
,during,IN,O
,valproate,JJ,O
,therapy,NN,O
,.,.,O
,Valproic,NNP,O
,acid,NN,O
,(,(,O
,VPA,NNP,O
,),),O
,is,VBZ,O
,effective,JJ,O
,for,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,many,JJ,O
,types,NNS,O
,of,IN,O
,epilepsy,NN,B-DISEASE
,",",",",O
,but,CC,O
,its,PRP$,O
,use,NN,O
,can,MD,O
,be,VB,O
,associated,VBN,O
,with,IN,O
,an,DT,O
,increase,NN,O
,in,IN,O
,body,NN,O
,weight,NN,O
,.,.,O
,We,PRP,O
,report,VBP,O
,a,DT,O
,case,NN,O
,of,IN,O
,nonalcoholic,JJ,B-DISEASE
,fatty,JJ,I-DISEASE
,liver,NN,I-DISEASE
,disease,NN,I-DISEASE
,(,(,O
,NAFLD,NNP,B-DISEASE
,),),O
,arising,VBG,O
,in,IN,O
,a,DT,O
,child,NN,O
,who,WP,O
,developed,VBD,O
,obesity,NN,B-DISEASE
,during,IN,O
,VPA,NNP,O
,treatment,NN,O
,.,.,O
,Laboratory,NNP,O
,data,NNS,O
,revealed,VBD,O
,hyperinsulinemia,NN,B-DISEASE
,with,IN,O
,insulin,NN,B-DISEASE
,resistance,NN,I-DISEASE
,.,.,O
,After,IN,O
,the,DT,O
,withdrawal,NN,O
,of,IN,O
,VPA,NNP,O
,therapy,NN,O
,",",",",O
,our,PRP$,O
,patient,NN,O
,showed,VBD,O
,a,DT,O
,significant,JJ,O
,weight,JJ,B-DISEASE
,loss,NN,I-DISEASE
,",",",",O
,a,DT,O
,decrease,NN,O
,of,IN,O
,body,NN,O
,mass,NN,O
,index,NN,O
,",",",",O
,and,CC,O
,normalization,NN,O
,of,IN,O
,metabolic,JJ,O
,and,CC,O
,endocrine,JJ,O
,parameters,NNS,O
,;,:,O
,moreover,RB,O
,",",",",O
,ultrasound,JJ,O
,measurements,NNS,O
,showed,VBD,O
,a,DT,O
,complete,JJ,O
,normalization,NN,O
,.,.,O
,The,DT,O
,present,JJ,O
,case,NN,O
,suggests,VBZ,O
,that,IN,O
,obesity,NN,B-DISEASE
,",",",",O
,hyperinsulinemia,NN,B-DISEASE
,",",",",O
,insulin,NN,B-DISEASE
,resistance,NN,I-DISEASE
,",",",",O
,and,CC,O
,long,RB,O
,-,:,O
,term,NN,O
,treatment,NN,O
,with,IN,O
,VPA,NNP,O
,may,MD,O
,be,VB,O
,all,DT,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,NAFLD,NNP,B-DISEASE
,;,:,O
,this,DT,O
,side,NN,O
,effect,NN,O
,is,VBZ,O
,reversible,JJ,O
,after,IN,O
,VPA,NNP,O
,withdrawal,NN,O
,.,.,O
,Carbimazole,NNP,O
,induced,VBD,O
,ANCA,NNP,B-DISEASE
,positive,JJ,I-DISEASE
,vasculitis,NN,I-DISEASE
,.,.,O
,Anti,NNP,O
,-,:,O
,thyroid,NN,O
,drugs,NNS,O
,",",",",O
,like,IN,O
,carbimazole,NN,O
,and,CC,O
,propylthiouracil,NN,O
,(,(,O
,PTU,NNP,O
,),),O
,are,VBP,O
,commonly,RB,O
,prescribed,VBN,O
,for,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,hyperthyroidism,NN,B-DISEASE
,.,.,O
,One,CD,O
,should,MD,O
,be,VB,O
,aware,JJ,O
,of,IN,O
,the,DT,O
,side,NN,O
,effects,NNS,O
,of,IN,O
,antithyroid,JJ,O
,medications,NNS,O
,.,.,O
,Antineutrophil,NNP,B-DISEASE
,cytoplasmic,JJ,I-DISEASE
,antibody,NN,I-DISEASE
,(,(,I-DISEASE
,ANCA,NNP,I-DISEASE
,),),I-DISEASE
,-,:,I-DISEASE
,-,:,I-DISEASE
,associated,VBN,I-DISEASE
,vasculitis,NN,I-DISEASE
,is,VBZ,O
,a,DT,O
,potentially,RB,O
,life,NN,O
,-,:,O
,threatening,JJ,O
,adverse,JJ,O
,effect,NN,O
,of,IN,O
,antithyroidmedications,NNS,O
,.,.,O
,We,PRP,O
,report,VBP,O
,a,DT,O
,patient,NN,O
,with,IN,O
,Graves,NNP,B-DISEASE
,',POS,I-DISEASE
,disease,NN,I-DISEASE
,who,WP,O
,developed,VBD,O
,ANCA,NNP,O
,positive,JJ,O
,carbimazole,NN,O
,induced,VBD,O
,vasculitis,NN,B-DISEASE
,.,.,O
,The,DT,O
,episode,NN,O
,was,VBD,O
,characterized,VBN,O
,by,IN,O
,a,DT,O
,vasculitic,JJ,B-DISEASE
,skin,NN,B-DISEASE
,rash,NN,I-DISEASE
,associated,VBN,O
,with,IN,O
,large,JJ,O
,joint,JJ,O
,arthritis,NN,B-DISEASE
,",",",",O
,pyrexia,NN,B-DISEASE
,and,CC,O
,parotiditis,NN,B-DISEASE
,but,CC,O
,no,DT,O
,renal,JJ,O
,or,CC,O
,pulmonary,JJ,O
,involvement,NN,O
,.,.,O
,He,PRP,O
,was,VBD,O
,referred,VBN,O
,to,TO,O
,us,PRP,O
,for,IN,O
,neurological,JJ,O
,evaluation,NN,O
,because,IN,O
,he,PRP,O
,had,VBD,O
,difficulty,NN,O
,in,IN,O
,getting,VBG,O
,up,RP,O
,from,IN,O
,squatting,VBG,O
,position,NN,O
,and,CC,O
,was,VBD,O
,suspected,VBN,O
,to,TO,O
,have,VB,O
,myositis,NN,B-DISEASE
,.,.,O
,Carbimazole,NNP,O
,and,CC,O
,methimazole,NNS,O
,have,VBP,O
,a,DT,O
,lower,JJR,O
,incidence,NN,O
,of,IN,O
,reported,VBN,O
,ANCA,NNP,O
,positive,JJ,O
,side,NN,O
,effects,NNS,O
,than,IN,O
,PUT,NNP,O
,.,.,O
,To,TO,O
,the,DT,O
,best,JJS,O
,of,IN,O
,our,PRP$,O
,knowledge,NN,O
,this,DT,O
,is,VBZ,O
,the,DT,O
,first,JJ,O
,ANCA,NNP,O
,positive,JJ,O
,carbimazole,NN,O
,induced,VBD,O
,vasculitis,NN,B-DISEASE
,case,NN,O
,reported,VBD,O
,from,IN,O
,India,NNP,O
,.,.,O
,Aspirin,NNP,O
,for,IN,O
,the,DT,O
,primary,JJ,O
,prevention,NN,O
,of,IN,O
,cardiovascular,JJ,O
,events,NNS,O
,:,:,O
,an,DT,O
,update,NN,O
,of,IN,O
,the,DT,O
,evidence,NN,O
,for,IN,O
,the,DT,O
,U,NNP,O
,.,.,O
,S,NNP,O
,.,.,O
,Preventive,NNP,O
,Services,NNPS,O
,Task,NNP,O
,Force,NNP,O
,.,.,O
,BACKGROUND,NNP,O
,:,:,O
,Coronary,JJ,B-DISEASE
,heart,NN,I-DISEASE
,disease,NN,I-DISEASE
,and,CC,O
,cerebrovascular,JJ,B-DISEASE
,disease,NN,I-DISEASE
,are,VBP,O
,leading,VBG,O
,causes,NNS,O
,of,IN,O
,death,NN,O
,in,IN,O
,the,DT,O
,United,NNP,O
,States,NNPS,O
,.,.,O
,In,IN,O
,2002,CD,O
,",",",",O
,the,DT,O
,U,NNP,O
,.,.,O
,S,NNP,O
,.,.,O
,Preventive,NNP,O
,Services,NNPS,O
,Task,NNP,O
,Force,NNP,O
,(,(,O
,USPSTF,NNP,O
,),),O
,strongly,RB,O
,recommended,VBD,O
,that,IN,O
,clinicians,NNS,O
,discuss,VBP,O
,aspirin,NN,O
,with,IN,O
,adults,NNS,O
,who,WP,O
,are,VBP,O
,at,IN,O
,increased,VBN,O
,risk,NN,O
,for,IN,O
,coronary,JJ,B-DISEASE
,heart,NN,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,PURPOSE,NN,O
,:,:,O
,To,TO,O
,determine,VB,O
,the,DT,O
,benefits,NNS,O
,and,CC,O
,harms,NNS,O
,of,IN,O
,taking,VBG,O
,aspirin,NN,O
,for,IN,O
,the,DT,O
,primary,JJ,O
,prevention,NN,O
,of,IN,O
,myocardial,JJ,B-DISEASE
,infarctions,NNS,I-DISEASE
,",",",",O
,strokes,NNS,B-DISEASE
,",",",",O
,and,CC,O
,death,NN,O
,.,.,O
,DATA,NNP,O
,SOURCES,NN,O
,:,:,O
,MEDLINE,NNP,O
,and,CC,O
,Cochrane,NNP,O
,Library,NNP,O
,(,(,O
,search,NN,O
,dates,NNS,O
,",",",",O
,1,CD,O
,January,NNP,O
,2001,CD,O
,to,TO,O
,28,CD,O
,August,NNP,O
,2008,CD,O
,),),O
,",",",",O
,recent,JJ,O
,systematic,JJ,O
,reviews,NNS,O
,",",",",O
,reference,NN,O
,lists,NNS,O
,of,IN,O
,retrieved,JJ,O
,articles,NNS,O
,",",",",O
,and,CC,O
,suggestions,NNS,O
,from,IN,O
,experts,NNS,O
,.,.,O
,STUDY,NNP,O
,SELECTION,NNP,O
,:,:,O
,English,JJ,O
,-,:,O
,language,NN,O
,randomized,VBN,O
,",",",",O
,controlled,VBN,O
,trials,NNS,O
,(,(,O
,RCTs,NNP,O
,),),O
,;,:,O
,case,NN,O
,-,:,O
,control,NN,O
,studies,NNS,O
,;,:,O
,meta,SYM,O
,-,:,O
,analyses,NNS,O
,;,:,O
,and,CC,O
,systematic,JJ,O
,reviews,NNS,O
,of,IN,O
,aspirin,JJ,O
,versus,NN,O
,control,NN,O
,for,IN,O
,the,DT,O
,primary,JJ,O
,prevention,NN,O
,of,IN,O
,cardiovascular,JJ,B-DISEASE
,disease,NN,I-DISEASE
,(,(,O
,CVD,NNP,B-DISEASE
,),),O
,were,VBD,O
,selected,VBN,O
,to,TO,O
,answer,VB,O
,the,DT,O
,following,JJ,O
,questions,NNS,O
,:,:,O
,Does,NNP,O
,aspirin,VB,O
,decrease,VB,O
,coronary,JJ,O
,heart,NN,O
,events,NNS,O
,",",",",O
,strokes,NNS,B-DISEASE
,",",",",O
,death,NN,O
,from,IN,O
,coronary,JJ,O
,heart,NN,O
,events,NNS,O
,or,CC,O
,stroke,NN,B-DISEASE
,",",",",O
,or,CC,O
,all,DT,O
,-,:,O
,cause,NN,O
,mortality,NN,O
,in,IN,O
,adults,NNS,O
,without,IN,O
,known,VBN,O
,CVD,NNP,B-DISEASE
,?,.,O
,Does,NNP,O
,aspirin,VB,O
,increase,VB,O
,gastrointestinal,JJ,B-DISEASE
,bleeding,NN,I-DISEASE
,or,CC,O
,hemorrhagic,NN,B-DISEASE
,strokes,NNS,I-DISEASE
,?,.,O
,DATA,NNP,O
,EXTRACTION,NN,O
,:,:,O
,All,DT,O
,studies,NNS,O
,were,VBD,O
,reviewed,VBN,O
,",",",",O
,abstracted,VBN,O
,",",",",O
,and,CC,O
,rated,VBN,O
,for,IN,O
,quality,NN,O
,by,IN,O
,using,VBG,O
,predefined,VBN,O
,USPSTF,NNP,O
,criteria,NNS,O
,.,.,O
,DATA,NNP,O
,SYNTHESIS,NNP,O
,:,:,O
,New,NNP,O
,evidence,NN,O
,from,IN,O
,1,CD,O
,good,JJ,O
,-,:,O
,quality,NN,O
,RCT,NNP,O
,",",",",O
,1,CD,O
,good,JJ,O
,-,:,O
,quality,NN,O
,meta,SYM,O
,-,:,O
,analysis,NN,O
,",",",",O
,and,CC,O
,2,CD,O
,fair,JJ,O
,-,:,O
,quality,NN,O
,subanalyses,NNS,O
,of,IN,O
,RCTs,NNP,O
,demonstrates,VBZ,O
,that,IN,O
,aspirin,NN,O
,use,NN,O
,reduces,VBZ,O
,the,DT,O
,number,NN,O
,of,IN,O
,CVD,NNP,B-DISEASE
,events,NNS,O
,in,IN,O
,patients,NNS,O
,without,IN,O
,known,VBN,O
,CVD,NNP,B-DISEASE
,.,.,O
,Men,NN,O
,in,IN,O
,these,DT,O
,studies,NNS,O
,experienced,VBD,O
,fewer,JJR,O
,myocardial,JJ,B-DISEASE
,infarctions,NNS,I-DISEASE
,and,CC,O
,women,NNS,O
,experienced,VBD,O
,fewer,JJR,O
,ischemic,JJ,O
,strokes,NNS,B-DISEASE
,.,.,O
,Aspirin,NNP,O
,does,VBZ,O
,not,RB,O
,seem,VB,O
,to,TO,O
,affect,VB,O
,CVD,NNP,B-DISEASE
,mortality,NN,O
,or,CC,O
,all,DT,O
,-,:,O
,cause,NN,O
,mortality,NN,O
,in,IN,O
,either,CC,O
,men,NNS,O
,or,CC,O
,women,NNS,O
,.,.,O
,The,DT,O
,use,NN,O
,of,IN,O
,aspirin,NN,O
,for,IN,O
,primary,JJ,O
,prevention,NN,O
,increases,VBZ,O
,the,DT,O
,risk,NN,O
,for,IN,O
,major,JJ,O
,bleeding,VBG,B-DISEASE
,events,NNS,O
,",",",",O
,primarily,RB,O
,gastrointestinal,JJ,B-DISEASE
,bleeding,NN,I-DISEASE
,events,NNS,O
,",",",",O
,in,IN,O
,both,DT,O
,men,NNS,O
,and,CC,O
,women,NNS,O
,.,.,O
,Men,NNS,O
,have,VBP,O
,an,DT,O
,increased,VBN,O
,risk,NN,O
,for,IN,O
,hemorrhagic,JJ,B-DISEASE
,strokes,NNS,I-DISEASE
,with,IN,O
,aspirin,NN,O
,use,NN,O
,.,.,O
,A,DT,O
,new,JJ,O
,RCT,NNP,O
,and,CC,O
,meta,SYM,O
,-,:,O
,analysis,NN,O
,suggest,VBP,O
,that,IN,O
,the,DT,O
,risk,NN,O
,for,IN,O
,hemorrhagic,JJ,B-DISEASE
,strokes,NNS,I-DISEASE
,in,IN,O
,women,NNS,O
,is,VBZ,O
,not,RB,O
,statistically,RB,O
,significantly,RB,O
,increased,VBN,O
,.,.,O
,LIMITATIONS,NNS,O
,:,:,O
,New,NNP,O
,evidence,NN,O
,on,IN,O
,aspirin,NN,O
,for,IN,O
,the,DT,O
,primary,JJ,O
,prevention,NN,O
,of,IN,O
,CVD,NNP,B-DISEASE
,is,VBZ,O
,limited,VBN,O
,.,.,O
,The,DT,O
,dose,NN,O
,of,IN,O
,aspirin,NN,O
,used,VBN,O
,in,IN,O
,the,DT,O
,RCTs,NNP,O
,varied,VBD,O
,",",",",O
,which,WDT,O
,prevented,VBD,O
,the,DT,O
,estimation,NN,O
,of,IN,O
,the,DT,O
,most,RBS,O
,appropriate,JJ,O
,dose,NN,O
,for,IN,O
,primary,JJ,O
,prevention,NN,O
,.,.,O
,Several,JJ,O
,of,IN,O
,the,DT,O
,RCTs,NNP,O
,were,VBD,O
,conducted,VBN,O
,within,IN,O
,populations,NNS,O
,of,IN,O
,health,NN,O
,professionals,NNS,O
,",",",",O
,which,WDT,O
,potentially,RB,O
,limits,VBZ,O
,generalizability,NN,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Aspirin,NNP,O
,reduces,VBZ,O
,the,DT,O
,risk,NN,O
,for,IN,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,in,IN,O
,men,NNS,O
,and,CC,O
,strokes,NNS,B-DISEASE
,in,IN,O
,women,NNS,O
,.,.,O
,Aspirin,NNP,O
,use,NN,O
,increases,VBZ,O
,the,DT,O
,risk,NN,O
,for,IN,O
,serious,JJ,O
,bleeding,VBG,B-DISEASE
,events,NNS,O
,.,.,O
,Reducing,VBG,O
,harm,NN,O
,associated,VBN,O
,with,IN,O
,anticoagulation,NN,O
,:,:,O
,practical,JJ,O
,considerations,NNS,O
,of,IN,O
,argatroban,JJ,O
,therapy,NN,O
,in,IN,O
,heparin,JJ,O
,-,:,O
,induced,JJ,O
,thrombocytopenia,NN,B-DISEASE
,.,.,O
,Argatroban,NNP,O
,is,VBZ,O
,a,DT,O
,hepatically,RB,O
,metabolized,VBN,O
,",",",",O
,direct,JJ,O
,thrombin,NN,O
,inhibitor,NN,O
,used,VBN,O
,for,IN,O
,prophylaxis,NN,O
,or,CC,O
,treatment,NN,O
,of,IN,O
,thrombosis,NN,B-DISEASE
,in,IN,O
,heparin,JJ,O
,-,:,O
,induced,VBN,O
,thrombocytopenia,NN,B-DISEASE
,(,(,O
,HIT,NNP,B-DISEASE
,),),O
,and,CC,O
,for,IN,O
,patients,NNS,O
,with,IN,O
,or,CC,O
,at,IN,O
,risk,NN,O
,of,IN,O
,HIT,NNP,B-DISEASE
,undergoing,VBG,O
,percutaneous,JJ,O
,coronary,JJ,O
,intervention,NN,O
,(,(,O
,PCI,NNP,O
,),),O
,.,.,O
,The,DT,O
,objective,NN,O
,of,IN,O
,this,DT,O
,review,NN,O
,is,VBZ,O
,to,TO,O
,summarize,VB,O
,practical,JJ,O
,considerations,NNS,O
,of,IN,O
,argatroban,JJ,O
,therapy,NN,O
,in,IN,O
,HIT,NNP,B-DISEASE
,.,.,O
,The,DT,O
,US,NNP,O
,FDA,NNP,O
,-,:,O
,recommended,VBD,O
,argatroban,JJ,O
,dose,NN,O
,in,IN,O
,HIT,NNP,B-DISEASE
,is,VBZ,O
,2,CD,O
,microg,NN,O
,/,NNP,O
,kg,NNP,O
,/,NNP,O
,min,NN,O
,(,(,O
,reduced,VBN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,hepatic,JJ,B-DISEASE
,impairment,NN,I-DISEASE
,and,CC,O
,in,IN,O
,paediatric,JJ,O
,patients,NNS,O
,),),O
,",",",",O
,adjusted,VBN,O
,to,TO,O
,achieve,VB,O
,activated,VBN,O
,partial,JJ,O
,thromboplastin,NN,O
,times,NNS,O
,(,(,O
,aPTTs,NN,O
,),),O
,1,CD,O
,.,.,O
,5,CD,O
,-,:,O
,3,CD,O
,times,NNS,O
,baseline,JJ,O
,(,(,O
,not,RB,O
,>,VB,O
,100,CD,O
,seconds,NNS,O
,),),O
,.,.,O
,Contemporary,JJ,O
,experiences,NNS,O
,indicate,VBP,O
,that,IN,O
,reduced,JJ,O
,doses,NNS,O
,are,VBP,O
,also,RB,O
,needed,VBN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,conditions,NNS,O
,associated,VBN,O
,with,IN,O
,hepatic,JJ,O
,hypoperfusion,NN,O
,",",",",O
,e,NN,O
,.,.,O
,g,NN,O
,.,.,O
,heart,NN,B-DISEASE
,failure,NN,I-DISEASE
,",",",",O
,yet,CC,O
,are,VBP,O
,unnecessary,JJ,O
,for,IN,O
,renal,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,",",",",O
,adult,NN,O
,age,NN,O
,",",",",O
,sex,NN,O
,",",",",O
,race,NN,O
,/,NNP,O
,ethnicity,NN,O
,or,CC,O
,obesity,NN,B-DISEASE
,.,.,O
,Argatroban,$,O
,0,CD,O
,.,.,O
,5,CD,O
,-,:,O
,1,CD,O
,.,.,O
,2,CD,O
,microg,JJ,O
,/,NNP,O
,kg,NN,O
,/,NNP,O
,min,NNP,O
,typically,RB,O
,supports,VBZ,O
,therapeutic,JJ,O
,aPTTs,NN,O
,.,.,O
,The,DT,O
,FDA,NNP,O
,-,:,O
,recommended,VBD,O
,dose,JJ,O
,during,IN,O
,PCI,NNP,O
,is,VBZ,O
,25,CD,O
,microg,NN,O
,/,NNP,O
,kg,NNP,O
,/,NNP,O
,min,NNP,O
,(,(,O
,350,CD,O
,microg,NN,O
,/,NNP,O
,kg,VBZ,O
,initial,JJ,O
,bolus,NN,O
,),),O
,",",",",O
,adjusted,VBN,O
,to,TO,O
,achieve,VB,O
,activated,VBN,O
,clotting,VBG,O
,times,NNS,O
,(,(,O
,ACTs,NNP,O
,),),O
,of,IN,O
,300,CD,O
,-,:,O
,450,CD,O
,sec,NN,O
,.,.,O
,For,IN,O
,PCI,NNP,O
,",",",",O
,argatroban,NN,O
,has,VBZ,O
,not,RB,O
,been,VBN,O
,investigated,VBN,O
,in,IN,O
,hepatically,RB,O
,impaired,JJ,O
,patients,NNS,O
,;,:,O
,dose,JJ,O
,adjustment,NN,O
,is,VBZ,O
,unnecessary,JJ,O
,for,IN,O
,adult,NN,O
,age,NN,O
,",",",",O
,sex,NN,O
,",",",",O
,race,NN,O
,/,NNP,O
,ethnicity,NN,O
,or,CC,O
,obesity,NN,B-DISEASE
,",",",",O
,and,CC,O
,lesser,JJR,O
,doses,NNS,O
,may,MD,O
,be,VB,O
,adequate,JJ,O
,with,IN,O
,concurrent,JJ,O
,glycoprotein,NN,O
,IIb,NNP,O
,/,NNP,O
,IIIa,NNP,O
,inhibition,NN,O
,.,.,O
,Argatroban,NNP,O
,prolongs,VBZ,O
,the,DT,O
,International,NNP,O
,Normalized,NNP,O
,Ratio,NNP,O
,",",",",O
,and,CC,O
,published,VBD,O
,approaches,NNS,O
,for,IN,O
,monitoring,VBG,O
,the,DT,O
,argatroban,JJ,O
,-,:,O
,to,TO,O
,-,:,O
,warfarin,NN,O
,transition,NN,O
,should,MD,O
,be,VB,O
,followed,VBN,O
,.,.,O
,Major,JJ,O
,bleeding,VBG,B-DISEASE
,with,IN,O
,argatroban,NN,O
,is,VBZ,O
,0,CD,O
,-,:,O
,10,CD,O
,%,NN,O
,in,IN,O
,the,DT,O
,non,JJ,O
,-,:,O
,interventional,JJ,O
,setting,NN,O
,and,CC,O
,0,CD,O
,-,:,O
,5,CD,O
,.,.,O
,8,CD,O
,%,NN,O
,periprocedurally,RB,O
,.,.,O
,Argatroban,NNP,O
,has,VBZ,O
,no,DT,O
,specific,JJ,O
,antidote,NN,O
,",",",",O
,and,CC,O
,if,IN,O
,excessive,JJ,O
,anticoagulation,NN,O
,occurs,VBZ,O
,",",",",O
,argatroban,JJ,O
,infusion,NN,O
,should,MD,O
,be,VB,O
,stopped,VBN,O
,or,CC,O
,reduced,VBN,O
,.,.,O
,Improved,VBN,O
,familiarity,NN,O
,of,IN,O
,healthcare,NN,O
,professionals,NNS,O
,with,IN,O
,argatroban,JJ,O
,therapy,NN,O
,in,IN,O
,HIT,NNP,B-DISEASE
,",",",",O
,including,VBG,O
,in,IN,O
,special,JJ,O
,populations,NNS,O
,and,CC,O
,during,IN,O
,PCI,NNP,O
,",",",",O
,may,MD,O
,facilitate,VB,O
,reduction,NN,O
,of,IN,O
,harm,NN,O
,associated,VBN,O
,with,IN,O
,HIT,NNP,B-DISEASE
,(,(,O
,e,NN,O
,.,.,O
,g,NN,O
,.,.,O
,fewer,JJR,O
,thromboses,NNS,O
,),),O
,or,CC,O
,its,PRP$,O
,treatment,NN,O
,(,(,O
,e,NN,O
,.,.,O
,g,NN,O
,.,.,O
,fewer,JJR,O
,argatroban,JJ,O
,medication,NN,O
,errors,NNS,O
,),),O
,.,.,O
,Rhabdomyolysis,NN,B-DISEASE
,and,CC,O
,brain,NN,O
,ischemic,JJ,B-DISEASE
,stroke,NN,I-DISEASE
,in,IN,O
,a,DT,O
,heroin,NN,O
,-,:,O
,dependent,JJ,O
,male,NN,O
,under,IN,O
,methadone,NN,O
,maintenance,NN,O
,therapy,NN,O
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,There,EX,O
,are,VBP,O
,several,JJ,O
,complications,NNS,O
,associated,VBN,O
,with,IN,O
,heroin,NN,B-DISEASE
,abuse,NN,I-DISEASE
,",",",",O
,some,DT,O
,of,IN,O
,which,WDT,O
,are,VBP,O
,life,NN,O
,-,:,O
,threatening,NN,O
,.,.,O
,Methadone,NN,O
,may,MD,O
,aggravate,VB,O
,this,DT,O
,problem,NN,O
,.,.,O
,METHOD,NN,O
,:,:,O
,A,DT,O
,clinical,JJ,O
,case,NN,O
,description,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,A,DT,O
,33,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,man,NN,O
,presented,VBN,O
,with,IN,O
,rhabdomyolysis,NN,B-DISEASE
,and,CC,O
,cerebral,JJ,O
,ischemic,JJ,B-DISEASE
,stroke,NN,I-DISEASE
,after,IN,O
,intravenous,JJ,O
,heroin,NN,O
,.,.,O
,He,PRP,O
,had,VBD,O
,used,VBN,O
,heroin,NN,O
,since,IN,O
,age,NN,O
,20,CD,O
,",",",",O
,and,CC,O
,had,VBD,O
,used,VBN,O
,150,CD,O
,mg,JJ,O
,methadone,NN,O
,daily,NN,O
,for,IN,O
,6,CD,O
,months,NNS,O
,.,.,O
,He,PRP,O
,was,VBD,O
,found,VBN,O
,unconsciousness,RB,B-DISEASE
,at,IN,O
,home,NN,O
,and,CC,O
,was,VBD,O
,sent,VBN,O
,to,TO,O
,our,PRP$,O
,hospital,NN,O
,.,.,O
,In,IN,O
,the,DT,O
,ER,NNP,O
,",",",",O
,his,PRP$,O
,opiate,JJ,O
,level,NN,O
,was,VBD,O
,4497,CD,O
,ng,JJ,O
,/,NNP,O
,ml,NN,O
,.,.,O
,In,IN,O
,the,DT,O
,ICU,NNP,O
,",",",",O
,we,PRP,O
,found,VBD,O
,rhabdomyolysis,NN,B-DISEASE
,",",",",O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,and,CC,O
,acute,JJ,O
,respiratory,NN,B-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,After,IN,O
,transfer,NN,O
,to,TO,O
,an,DT,O
,internal,JJ,O
,ward,NN,O
,",",",",O
,we,PRP,O
,noted,VBD,O
,aphasia,NN,B-DISEASE
,and,CC,O
,weakness,NN,B-DISEASE
,of,IN,O
,his,PRP$,O
,left,JJ,O
,limbs,NNS,O
,.,.,O
,After,IN,O
,MRI,NNP,O
,",",",",O
,we,PRP,O
,found,VBD,O
,cerebral,JJ,B-DISEASE
,ischemic,JJ,I-DISEASE
,infarction,NN,I-DISEASE
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Those,DT,O
,using,VBG,O
,methadone,NN,O
,and,CC,O
,heroin,VB,O
,simultaneously,RB,O
,may,MD,O
,increase,VB,O
,risk,NN,O
,of,IN,O
,rhabdomyolysis,NN,B-DISEASE
,and,CC,O
,ischemic,JJ,B-DISEASE
,stroke,NN,I-DISEASE
,.,.,O
,Patients,NNS,O
,under,IN,O
,methadone,NN,O
,maintenance,NN,O
,therapy,NN,O
,should,MD,O
,be,VB,O
,warned,VBN,O
,regarding,VBG,O
,these,DT,O
,serious,JJ,O
,adverse,JJ,O
,events,NNS,O
,.,.,O
,Hypotheses,NNS,O
,of,IN,O
,heroin,NN,O
,-,:,O
,related,JJ,O
,rhabdomyolysis,NN,B-DISEASE
,and,CC,O
,stroke,NN,B-DISEASE
,in,IN,O
,heroin,NN,O
,abusers,NNS,O
,are,VBP,O
,discussed,VBN,O
,.,.,O
,Increased,VBN,O
,vulnerability,NN,O
,to,TO,O
,6,CD,O
,-,:,O
,hydroxydopamine,NN,O
,lesion,NN,O
,and,CC,O
,reduced,VBD,O
,development,NN,O
,of,IN,O
,dyskinesias,NN,B-DISEASE
,in,IN,O
,mice,NN,O
,lacking,VBG,O
,CB1,NNP,O
,cannabinoid,NN,O
,receptors,NNS,O
,.,.,O
,Motor,NNP,O
,impairment,NN,O
,",",",",O
,dopamine,NN,O
,(,(,O
,DA,NNP,O
,),),O
,neuronal,JJ,O
,activity,NN,O
,and,CC,O
,proenkephalin,NN,O
,(,(,O
,PENK,NNP,O
,),),O
,gene,NN,O
,expression,NN,O
,in,IN,O
,the,DT,O
,caudate,NN,O
,-,:,O
,putamen,NNS,O
,(,(,O
,CPu,NNP,O
,),),O
,were,VBD,O
,measured,VBN,O
,in,IN,O
,6,CD,O
,-,:,O
,OHDA,NNP,O
,-,:,O
,lesioned,VBD,O
,and,CC,O
,treated,VBD,O
,(,(,O
,L,NNP,O
,-,:,O
,DOPA,NNP,O
,+,NNP,O
,benserazide,NN,O
,),),O
,CB1,NNP,O
,KO,NNP,O
,and,CC,O
,WT,NNP,O
,mice,NNP,O
,.,.,O
,A,DT,O
,lesion,NN,O
,induced,VBN,O
,by,IN,O
,6,CD,O
,-,:,O
,OHDA,NN,O
,produced,VBD,O
,more,JJR,O
,severe,JJ,O
,motor,NN,O
,deterioration,NN,O
,in,IN,O
,CB1,NNP,O
,KO,NNP,O
,mice,NN,O
,accompanied,VBN,O
,by,IN,O
,more,JJR,O
,loss,NN,O
,of,IN,O
,DA,NNP,O
,neurons,NNS,O
,and,CC,O
,increased,VBD,O
,PENK,NNP,O
,gene,NN,O
,expression,NN,O
,in,IN,O
,the,DT,O
,CPu,NNP,O
,.,.,O
,Oxidative,NNP,O
,/,NNP,O
,nitrosative,JJ,O
,and,CC,O
,neuroinflammatory,JJ,O
,parameters,NNS,O
,were,VBD,O
,estimated,VBN,O
,in,IN,O
,the,DT,O
,CPu,NNP,O
,and,CC,O
,cingulate,VB,O
,cortex,NN,O
,(,(,O
,Cg,NNP,O
,),),O
,.,.,O
,CB1,NNP,O
,KO,NNP,O
,mice,RB,O
,exhibited,VBD,O
,higher,JJR,O
,MDA,NNP,O
,levels,NNS,O
,and,CC,O
,iNOS,NN,O
,protein,NN,O
,expression,NN,O
,in,IN,O
,the,DT,O
,CPu,NNP,O
,and,CC,O
,Cg,NNP,O
,compared,VBN,O
,to,TO,O
,WT,NNP,O
,mice,NN,O
,.,.,O
,Treatment,NN,O
,with,IN,O
,L,NNP,O
,-,:,O
,DOPA,NNP,O
,+,NNP,O
,benserazide,NN,O
,(,(,O
,12,CD,O
,weeks,NNS,O
,),),O
,resulted,VBD,O
,in,IN,O
,less,RBR,O
,severe,JJ,O
,dyskinesias,NN,B-DISEASE
,in,IN,O
,CB1,NNP,O
,KO,NNP,O
,than,IN,O
,in,IN,O
,WT,NNP,O
,mice,NN,O
,.,.,O
,The,DT,O
,results,NNS,O
,revealed,VBD,O
,that,IN,O
,the,DT,O
,lack,NN,O
,of,IN,O
,cannabinoid,NN,O
,CB1,NNP,O
,receptors,NNS,O
,increased,VBD,O
,the,DT,O
,severity,NN,O
,of,IN,O
,motor,NN,O
,impairment,NN,O
,and,CC,O
,DA,NNP,O
,lesion,NN,O
,",",",",O
,and,CC,O
,reduced,VBD,O
,L,NNP,O
,-,:,O
,DOPA,NNP,O
,-,:,O
,induced,JJ,O
,dyskinesias,NN,B-DISEASE
,.,.,O
,These,DT,O
,results,NNS,O
,suggest,VBP,O
,that,IN,O
,activation,NN,O
,of,IN,O
,CB1,NNP,O
,receptors,NNS,O
,offers,VBZ,O
,neuroprotection,NN,O
,against,IN,O
,dopaminergic,JJ,O
,lesion,NN,O
,and,CC,O
,the,DT,O
,development,NN,O
,of,IN,O
,L,NNP,O
,-,:,O
,DOPA,NNP,O
,-,:,O
,induced,JJ,O
,dyskinesias,NN,B-DISEASE
,.,.,O
,Hepatocellular,NNP,O
,oxidant,JJ,O
,stress,NN,O
,following,VBG,O
,intestinal,JJ,O
,ischemia,NN,B-DISEASE
,-,:,O
,reperfusion,NN,B-DISEASE
,injury,NN,I-DISEASE
,.,.,O
,Reperfusion,NN,O
,of,IN,O
,ischemic,JJ,B-DISEASE
,intestine,NN,O
,results,NNS,O
,in,IN,O
,acute,JJ,O
,liver,NN,B-DISEASE
,dysfunction,NN,I-DISEASE
,characterized,VBN,O
,by,IN,O
,hepatocellular,JJ,O
,enzyme,NN,O
,release,NN,O
,into,IN,O
,plasma,NN,O
,",",",",O
,reduction,NN,O
,in,IN,O
,bile,JJ,O
,flow,NN,O
,rate,NN,O
,",",",",O
,and,CC,O
,neutrophil,JJ,O
,sequestration,NN,O
,within,IN,O
,the,DT,O
,liver,NN,O
,.,.,O
,The,DT,O
,pathophysiology,NN,O
,underlying,VBG,O
,this,DT,O
,acute,JJ,O
,hepatic,JJ,B-DISEASE
,injury,NN,I-DISEASE
,is,VBZ,O
,unknown,JJ,O
,.,.,O
,This,DT,O
,study,NN,O
,was,VBD,O
,undertaken,VBN,O
,to,TO,O
,determine,VB,O
,whether,IN,O
,oxidants,NNS,O
,are,VBP,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,hepatic,JJ,B-DISEASE
,injury,NN,I-DISEASE
,and,CC,O
,to,TO,O
,determine,VB,O
,the,DT,O
,relative,JJ,O
,value,NN,O
,of,IN,O
,several,JJ,O
,indirect,JJ,O
,methods,NNS,O
,of,IN,O
,assessing,VBG,O
,oxidant,JJ,O
,exposure,NN,O
,in,IN,O
,vivo,NN,O
,.,.,O
,Rats,NNPS,O
,were,VBD,O
,subjected,VBN,O
,to,TO,O
,a,DT,O
,standardized,JJ,O
,intestinal,JJ,O
,ischemia,NN,B-DISEASE
,-,:,O
,reperfusion,NN,B-DISEASE
,injury,NN,I-DISEASE
,.,.,O
,Hepatic,JJ,O
,tissue,NN,O
,was,VBD,O
,assayed,VBN,O
,for,IN,O
,lipid,JJ,O
,peroxidation,NN,O
,products,NNS,O
,and,CC,O
,oxidized,VBN,O
,and,CC,O
,reduced,VBN,O
,glutathione,NN,O
,.,.,O
,There,EX,O
,was,VBD,O
,no,DT,O
,change,NN,O
,in,IN,O
,hepatic,JJ,O
,tissue,NN,O
,total,JJ,O
,glutathione,NN,O
,following,VBG,O
,intestinal,JJ,O
,ischemia,NN,B-DISEASE
,-,:,O
,reperfusion,NN,B-DISEASE
,injury,NN,I-DISEASE
,.,.,O
,Oxidized,VBN,O
,glutathione,NN,O
,(,(,O
,GSSG,NNP,O
,),),O
,increased,VBD,O
,significantly,RB,O
,following,VBG,O
,30,CD,O
,and,CC,O
,60,CD,O
,min,NN,O
,of,IN,O
,reperfusion,NN,O
,.,.,O
,There,EX,O
,was,VBD,O
,no,DT,O
,increase,NN,O
,in,IN,O
,any,DT,O
,of,IN,O
,the,DT,O
,products,NNS,O
,of,IN,O
,lipid,JJ,O
,peroxidation,NN,O
,associated,VBN,O
,with,IN,O
,this,DT,O
,injury,NN,O
,.,.,O
,An,DT,O
,increase,NN,O
,in,IN,O
,GSSG,NNP,O
,within,IN,O
,hepatic,JJ,O
,tissue,NN,O
,during,IN,O
,intestinal,JJ,O
,reperfusion,NN,O
,suggests,VBZ,O
,exposure,NN,O
,of,IN,O
,hepatocytes,NNS,O
,to,TO,O
,an,DT,O
,oxidant,JJ,O
,stress,NN,O
,.,.,O
,The,DT,O
,lack,NN,O
,of,IN,O
,a,DT,O
,significant,JJ,O
,increase,NN,O
,in,IN,O
,products,NNS,O
,of,IN,O
,lipid,JJ,O
,peroxidation,NN,O
,suggests,VBZ,O
,that,IN,O
,the,DT,O
,oxidant,JJ,O
,stress,NN,O
,is,VBZ,O
,of,IN,O
,insufficient,JJ,O
,magnitude,NN,O
,to,TO,O
,result,VB,O
,in,IN,O
,irreversible,JJ,O
,injury,NN,O
,to,TO,O
,hepatocyte,VB,O
,cell,NN,O
,membranes,NNS,O
,.,.,O
,These,DT,O
,data,NNS,O
,also,RB,O
,suggest,VBP,O
,that,IN,O
,the,DT,O
,measurement,NN,O
,of,IN,O
,tissue,NN,O
,GSSG,NNP,O
,may,MD,O
,be,VB,O
,a,DT,O
,more,RBR,O
,sensitive,JJ,O
,indicator,NN,O
,of,IN,O
,oxidant,JJ,O
,stress,NN,O
,than,IN,O
,measurement,NN,O
,of,IN,O
,products,NNS,O
,of,IN,O
,lipid,JJ,O
,peroxidation,NN,O
,.,.,O
,Animal,NNP,O
,model,NN,O
,of,IN,O
,mania,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,ouabain,NN,O
,:,:,O
,Evidence,NN,O
,of,IN,O
,oxidative,JJ,O
,stress,NN,O
,in,IN,O
,submitochondrial,JJ,O
,particles,NNS,O
,of,IN,O
,the,DT,O
,rat,NN,O
,brain,NN,O
,.,.,O
,The,DT,O
,intracerebroventricular,JJ,O
,(,(,O
,ICV,NNP,O
,),),O
,administration,NN,O
,of,IN,O
,ouabain,NN,O
,(,(,O
,a,DT,O
,Na,NNP,O
,(,(,O
,+,NNP,O
,),),O
,/,VBP,O
,K,NNP,O
,(,(,O
,+,NNP,O
,),),O
,-,:,O
,ATPase,NNP,O
,inhibitor,NN,O
,),),O
,in,IN,O
,rats,NN,O
,has,VBZ,O
,been,VBN,O
,suggested,VBN,O
,to,TO,O
,mimic,VB,O
,some,DT,O
,symptoms,NNS,O
,of,IN,O
,human,JJ,O
,bipolar,JJ,B-DISEASE
,mania,NN,I-DISEASE
,.,.,O
,Clinical,JJ,O
,studies,NNS,O
,have,VBP,O
,shown,VBN,O
,that,IN,O
,bipolar,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,may,MD,O
,be,VB,O
,related,VBN,O
,to,TO,O
,mitochondrial,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,.,.,O
,Herein,NNP,O
,",",",",O
,we,PRP,O
,investigated,VBD,O
,the,DT,O
,behavioral,JJ,O
,and,CC,O
,biochemical,JJ,O
,effects,NNS,O
,induced,VBN,O
,by,IN,O
,the,DT,O
,ICV,NNP,O
,administration,NN,O
,of,IN,O
,ouabain,NN,O
,in,IN,O
,rats,NNS,O
,.,.,O
,To,TO,O
,achieve,VB,O
,this,DT,O
,aim,NN,O
,",",",",O
,the,DT,O
,effects,NNS,O
,of,IN,O
,ouabain,JJ,O
,injection,NN,O
,immediately,RB,O
,after,IN,O
,and,CC,O
,7,CD,O
,days,NNS,O
,following,VBG,O
,a,DT,O
,single,JJ,O
,ICV,NNP,O
,administration,NN,O
,(,(,O
,at,IN,O
,concentrations,NNS,O
,of,IN,O
,10,CD,O
,(,(,O
,-,:,O
,2,CD,O
,),),O
,and,CC,O
,10,CD,O
,(,(,O
,-,:,O
,3,CD,O
,),),O
,M,NNP,O
,),),O
,on,IN,O
,locomotion,NN,O
,was,VBD,O
,measured,VBN,O
,using,VBG,O
,the,DT,O
,open,JJ,O
,-,:,O
,field,NN,O
,test,NN,O
,.,.,O
,Additionally,RB,O
,",",",",O
,thiobarbituric,JJ,O
,acid,NN,O
,reactive,JJ,O
,substances,NNS,O
,(,(,O
,TBARSs,NNP,O
,),),O
,and,CC,O
,superoxide,JJ,O
,production,NN,O
,were,VBD,O
,measured,VBN,O
,in,IN,O
,submitochondrial,JJ,O
,particles,NNS,O
,of,IN,O
,the,DT,O
,prefrontal,JJ,O
,cortex,NN,O
,",",",",O
,hippocampus,NN,O
,",",",",O
,striatum,NN,O
,and,CC,O
,amygdala,NN,O
,.,.,O
,Our,PRP$,O
,findings,NNS,O
,demonstrated,VBD,O
,that,IN,O
,ouabain,NN,O
,at,IN,O
,10,CD,O
,(,(,O
,-,:,O
,2,CD,O
,),),O
,and,CC,O
,10,CD,O
,(,(,O
,-,:,O
,3,CD,O
,),),O
,M,NNP,O
,induced,JJ,O
,hyperlocomotion,NN,B-DISEASE
,in,IN,O
,rats,NNS,O
,",",",",O
,and,CC,O
,this,DT,O
,response,NN,O
,remained,VBD,O
,up,RB,O
,to,TO,O
,7,CD,O
,days,NNS,O
,following,VBG,O
,a,DT,O
,single,JJ,O
,ICV,NNP,O
,injection,NN,O
,.,.,O
,In,IN,O
,addition,NN,O
,",",",",O
,we,PRP,O
,observed,VBD,O
,that,IN,O
,the,DT,O
,persistent,JJ,O
,increase,NN,O
,in,IN,O
,the,DT,O
,rat,NN,O
,spontaneous,JJ,O
,locomotion,NN,O
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,increased,JJ,O
,TBARS,NNP,O
,levels,NNS,O
,and,CC,O
,superoxide,JJ,O
,generation,NN,O
,in,IN,O
,submitochondrial,JJ,O
,particles,NNS,O
,in,IN,O
,the,DT,O
,prefrontal,JJ,O
,cortex,NN,O
,",",",",O
,striatum,NN,O
,and,CC,O
,amygdala,NN,O
,.,.,O
,In,IN,O
,conclusion,NN,O
,",",",",O
,ouabain,VBP,O
,-,:,O
,induced,VBN,O
,mania,SYM,B-DISEASE
,-,:,O
,like,IN,O
,behavior,NN,O
,may,MD,O
,provide,VB,O
,a,DT,O
,useful,JJ,O
,animal,JJ,O
,model,NN,O
,to,TO,O
,test,VB,O
,the,DT,O
,hypothesis,NN,O
,of,IN,O
,the,DT,O
,involvement,NN,O
,of,IN,O
,oxidative,JJ,O
,stress,NN,O
,in,IN,O
,bipolar,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,.,.,O
,Intraoperative,JJ,O
,dialysis,NN,O
,during,IN,O
,liver,JJ,O
,transplantation,NN,O
,with,IN,O
,citrate,JJ,O
,dialysate,NN,O
,.,.,O
,Liver,NNP,O
,transplantation,NN,O
,for,IN,O
,acutely,RB,O
,ill,JJ,O
,patients,NNS,O
,with,IN,O
,fulminant,JJ,B-DISEASE
,liver,NN,I-DISEASE
,failure,NN,I-DISEASE
,carries,VBZ,O
,high,JJ,O
,intraoperative,NN,O
,and,CC,O
,immediate,JJ,O
,postoperative,JJ,O
,risks,NNS,O
,.,.,O
,These,DT,O
,are,VBP,O
,increased,VBN,O
,with,IN,O
,the,DT,O
,presence,NN,O
,of,IN,O
,concomitant,JJ,O
,acute,JJ,B-DISEASE
,kidney,NN,I-DISEASE
,injury,NN,I-DISEASE
,(,(,O
,AKI,NNP,B-DISEASE
,),),O
,and,CC,O
,intraoperative,JJ,O
,dialysis,NN,O
,is,VBZ,O
,sometimes,RB,O
,required,VBN,O
,to,TO,O
,allow,VB,O
,the,DT,O
,transplant,NN,O
,to,TO,O
,proceed,VB,O
,.,.,O
,The,DT,O
,derangements,NNS,O
,in,IN,O
,the,DT,O
,procoagulant,NN,O
,and,CC,O
,anticoagulant,JJ,O
,pathways,NNS,O
,during,IN,O
,fulminant,JJ,B-DISEASE
,liver,JJ,I-DISEASE
,failure,NN,I-DISEASE
,can,MD,O
,lead,VB,O
,to,TO,O
,difficulties,NNS,O
,with,IN,O
,anticoagulation,NN,O
,during,IN,O
,dialysis,NN,O
,",",",",O
,especially,RB,O
,when,WRB,O
,continued,VBN,O
,in,IN,O
,the,DT,O
,operating,NN,O
,room,NN,O
,.,.,O
,Systemic,JJ,O
,anticoagulation,NN,O
,is,VBZ,O
,unsafe,JJ,O
,and,CC,O
,regional,JJ,O
,citrate,NN,O
,anticoagulation,NN,O
,in,IN,O
,the,DT,O
,absence,NN,O
,of,IN,O
,a,DT,O
,functional,JJ,O
,liver,NN,O
,carries,VBZ,O
,the,DT,O
,risk,NN,O
,of,IN,O
,citrate,JJ,O
,toxicity,NN,B-DISEASE
,.,.,O
,Citrate,NNP,O
,dialysate,NN,O
,",",",",O
,a,DT,O
,new,JJ,O
,dialysate,NN,O
,with,IN,O
,citric,JJ,O
,acid,NN,O
,can,MD,O
,be,VB,O
,used,VBN,O
,for,IN,O
,anticoagulation,NN,O
,in,IN,O
,patients,NNS,O
,who,WP,O
,cannot,VBP,O
,tolerate,VB,O
,heparin,NN,O
,or,CC,O
,regional,JJ,O
,citrate,NN,O
,.,.,O
,We,PRP,O
,report,VBP,O
,a,DT,O
,case,NN,O
,of,IN,O
,a,DT,O
,40,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,female,NN,O
,with,IN,O
,acetaminophen,JJ,O
,-,:,O
,induced,JJ,O
,fulminant,JJ,B-DISEASE
,liver,NN,I-DISEASE
,failure,NN,I-DISEASE
,with,IN,O
,associated,JJ,O
,AKI,NNP,B-DISEASE
,who,WP,O
,underwent,VBD,O
,intraoperative,JJ,O
,dialytic,JJ,O
,support,NN,O
,during,IN,O
,liver,JJ,O
,transplantation,NN,O
,anticoagulated,VBN,O
,with,IN,O
,citrate,JJ,O
,dialysate,NN,O
,during,IN,O
,the,DT,O
,entire,JJ,O
,procedure,NN,O
,.,.,O
,The,DT,O
,patient,NN,O
,tolerated,VBD,O
,the,DT,O
,procedure,NN,O
,well,RB,O
,without,IN,O
,any,DT,O
,signs,NNS,O
,of,IN,O
,citrate,NN,O
,toxicity,NN,B-DISEASE
,and,CC,O
,maintained,VBD,O
,adequate,JJ,O
,anticoagulation,NN,O
,for,IN,O
,patency,NN,O
,of,IN,O
,the,DT,O
,dialysis,NN,O
,circuit,NN,O
,.,.,O
,Citrate,NNP,O
,dialysate,NN,O
,is,VBZ,O
,a,DT,O
,safe,JJ,O
,alternative,NN,O
,for,IN,O
,intradialytic,JJ,O
,support,NN,O
,of,IN,O
,liver,NN,O
,transplantation,NN,O
,in,IN,O
,fulminant,JJ,B-DISEASE
,liver,NN,I-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,Delirium,NN,B-DISEASE
,in,IN,O
,a,DT,O
,patient,NN,O
,with,IN,O
,toxic,JJ,O
,flecainide,NN,O
,plasma,NN,O
,concentrations,NNS,O
,:,:,O
,the,DT,O
,role,NN,O
,of,IN,O
,a,DT,O
,pharmacokinetic,JJ,O
,drug,NN,O
,interaction,NN,O
,with,IN,O
,paroxetine,NN,O
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,To,TO,O
,describe,VB,O
,a,DT,O
,case,NN,O
,of,IN,O
,flecainide,JJ,O
,-,:,O
,induced,JJ,O
,delirium,NN,B-DISEASE
,associated,VBN,O
,with,IN,O
,a,DT,O
,pharmacokinetic,JJ,O
,drug,NN,O
,interaction,NN,O
,with,IN,O
,paroxetine,NN,O
,.,.,O
,CASE,NNP,O
,SUMMARY,NNP,O
,:,:,O
,A,DT,O
,69,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,white,JJ,O
,female,NN,O
,presented,VBN,O
,to,TO,O
,the,DT,O
,emergency,NN,O
,department,NN,O
,with,IN,O
,a,DT,O
,history,NN,O
,of,IN,O
,confusion,NN,B-DISEASE
,and,CC,O
,paranoia,NN,B-DISEASE
,over,IN,O
,the,DT,O
,past,JJ,O
,several,JJ,O
,days,NNS,O
,.,.,O
,On,IN,O
,admission,NN,O
,the,DT,O
,patient,NN,O
,was,VBD,O
,taking,VBG,O
,carvedilol,JJ,O
,12,CD,O
,mg,JJ,O
,twice,RB,O
,daily,RB,O
,",",",",O
,warfarin,VBD,O
,2,CD,O
,mg,NNS,O
,/,JJ,O
,day,NN,O
,",",",",O
,folic,JJ,O
,acid,VBP,O
,1,CD,O
,mg,JJ,O
,/,NNP,O
,day,NN,O
,",",",",O
,levothyroxine,VBP,O
,100,CD,O
,microg,JJ,O
,/,NNP,O
,day,NN,O
,",",",",O
,pantoprazole,JJ,O
,40,CD,O
,mg,JJ,O
,/,NNP,O
,day,NN,O
,",",",",O
,paroxetine,VBP,O
,40,CD,O
,mg,JJ,O
,/,NNP,O
,day,NN,O
,",",",",O
,and,CC,O
,flecainide,RB,O
,100,CD,O
,mg,JJ,O
,twice,RB,O
,daily,RB,O
,.,.,O
,Flecainide,NNP,O
,had,VBD,O
,been,VBN,O
,started,VBN,O
,2,CD,O
,weeks,NNS,O
,prior,RB,O
,for,IN,O
,atrial,JJ,B-DISEASE
,fibrillation,NN,I-DISEASE
,.,.,O
,Laboratory,JJ,O
,test,NN,O
,findings,NNS,O
,on,IN,O
,admission,NN,O
,were,VBD,O
,notable,JJ,O
,only,RB,O
,for,IN,O
,a,DT,O
,flecainide,JJ,O
,plasma,NN,O
,concentration,NN,O
,of,IN,O
,1360,CD,O
,microg,NN,O
,/,NNP,O
,L,NNP,O
,(,(,O
,reference,NN,O
,range,NN,O
,200,CD,O
,-,:,O
,1000,CD,O
,),),O
,.,.,O
,A,DT,O
,metabolic,JJ,O
,drug,NN,O
,interaction,NN,O
,between,IN,O
,flecainide,NN,O
,and,CC,O
,paroxetine,NN,O
,",",",",O
,which,WDT,O
,the,DT,O
,patient,NN,O
,had,VBD,O
,been,VBN,O
,taking,VBG,O
,for,IN,O
,more,JJR,O
,than,IN,O
,5,CD,O
,years,NNS,O
,",",",",O
,was,VBD,O
,considered,VBN,O
,.,.,O
,Paroxetine,NNP,O
,was,VBD,O
,discontinued,VBN,O
,and,CC,O
,the,DT,O
,dose,NN,O
,of,IN,O
,flecainide,NN,O
,was,VBD,O
,reduced,VBN,O
,to,TO,O
,50,CD,O
,mg,NNS,O
,twice,RB,O
,daily,RB,O
,.,.,O
,Her,PRP$,O
,delirium,NN,B-DISEASE
,resolved,VBD,O
,3,CD,O
,days,NNS,O
,later,RB,O
,.,.,O
,DISCUSSION,NN,O
,:,:,O
,Flecainide,NNP,O
,and,CC,O
,pharmacologically,RB,O
,similar,JJ,O
,agents,NNS,O
,that,WDT,O
,interact,VBP,O
,with,IN,O
,sodium,NN,O
,channels,NNS,O
,may,MD,O
,cause,VB,O
,delirium,NN,B-DISEASE
,in,IN,O
,susceptible,JJ,O
,patients,NNS,O
,.,.,O
,A,DT,O
,MEDLINE,NNP,O
,search,NN,O
,(,(,O
,1966,CD,O
,-,:,O
,January,NNP,O
,2009,CD,O
,),),O
,revealed,VBD,O
,one,CD,O
,in,IN,O
,vivo,NN,O
,pharmacokinetic,JJ,O
,study,NN,O
,on,IN,O
,the,DT,O
,interaction,NN,O
,between,IN,O
,flecainide,NN,O
,",",",",O
,a,DT,O
,CYP2D6,NNP,O
,substrate,NN,O
,",",",",O
,and,CC,O
,paroxetine,NN,O
,",",",",O
,a,DT,O
,CYP2D6,NNP,O
,inhibitor,NN,O
,",",",",O
,as,RB,O
,well,RB,O
,as,IN,O
,3,CD,O
,case,NN,O
,reports,NNS,O
,of,IN,O
,flecainide,JJ,O
,-,:,O
,induced,JJ,O
,delirium,NN,B-DISEASE
,.,.,O
,According,VBG,O
,to,TO,O
,the,DT,O
,Naranjo,NNP,O
,probability,NN,O
,scale,NN,O
,",",",",O
,flecainide,NN,O
,was,VBD,O
,the,DT,O
,probable,JJ,O
,cause,NN,O
,of,IN,O
,the,DT,O
,patient,NN,O
,',POS,O
,s,JJ,O
,delirium,NN,B-DISEASE
,;,:,O
,the,DT,O
,Horn,NNP,O
,Drug,NNP,O
,Interaction,NNP,O
,Probability,NNP,O
,Scale,NNP,O
,indicates,VBZ,O
,a,DT,O
,possible,JJ,O
,pharmacokinetic,JJ,O
,drug,NN,O
,interaction,NN,O
,between,IN,O
,flecainide,NN,O
,and,CC,O
,paroxetine,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Supratherapeutic,JJ,O
,flecainide,NN,O
,plasma,IN,O
,concentrations,NNS,O
,may,MD,O
,cause,VB,O
,delirium,NN,B-DISEASE
,.,.,O
,Because,IN,O
,toxicity,NN,B-DISEASE
,may,MD,O
,occur,VB,O
,when,WRB,O
,flecainide,NN,O
,is,VBZ,O
,prescribed,VBN,O
,with,IN,O
,paroxetine,NN,O
,and,CC,O
,other,JJ,O
,potent,NN,O
,CYP2D6,NNP,O
,inhibitors,NNS,O
,",",",",O
,flecainide,RB,O
,plasma,JJ,O
,concentrations,NNS,O
,should,MD,O
,be,VB,O
,monitored,VBN,O
,closely,RB,O
,with,IN,O
,commencement,NN,O
,of,IN,O
,CYP2D6,NNP,O
,inhibitors,NNS,O
,.,.,O
,Efficacy,NN,O
,of,IN,O
,everolimus,NN,O
,(,(,O
,RAD001,NNP,O
,),),O
,in,IN,O
,patients,NNS,O
,with,IN,O
,advanced,JJ,O
,NSCLC,NNP,B-DISEASE
,previously,RB,O
,treated,VBD,O
,with,IN,O
,chemotherapy,NN,O
,alone,RB,O
,or,CC,O
,with,IN,O
,chemotherapy,NN,O
,and,CC,O
,EGFR,NNP,O
,inhibitors,NNS,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Treatment,NN,O
,options,NNS,O
,are,VBP,O
,scarce,JJ,O
,in,IN,O
,pretreated,JJ,O
,advanced,JJ,O
,non,SYM,B-DISEASE
,-,:,I-DISEASE
,small,JJ,I-DISEASE
,-,:,I-DISEASE
,cell,NN,I-DISEASE
,lung,NN,I-DISEASE
,cancer,NN,I-DISEASE
,(,(,O
,NSCLC,NNP,B-DISEASE
,),),O
,patients,NNS,O
,.,.,O
,RAD001,NNP,O
,",",",",O
,an,DT,O
,oral,JJ,O
,inhibitor,NN,O
,of,IN,O
,the,DT,O
,mammalian,JJ,O
,target,NN,O
,of,IN,O
,rapamycin,NN,O
,(,(,O
,mTOR,NN,O
,),),O
,",",",",O
,has,VBZ,O
,shown,VBN,O
,phase,NN,O
,I,PRP,O
,efficacy,VBP,O
,in,IN,O
,NSCLC,NNP,B-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,Stage,NN,O
,IIIb,NNP,O
,or,CC,O
,IV,NNP,O
,NSCLC,NNP,B-DISEASE
,patients,NNS,O
,",",",",O
,with,IN,O
,two,CD,O
,or,CC,O
,fewer,JJR,O
,prior,JJ,O
,chemotherapy,NN,O
,regimens,NNS,O
,",",",",O
,one,CD,O
,platinum,NN,O
,based,VBN,O
,(,(,O
,stratum,JJ,O
,1,CD,O
,),),O
,or,CC,O
,both,DT,O
,chemotherapy,NN,O
,and,CC,O
,epidermal,JJ,O
,growth,NN,O
,factor,NN,O
,receptor,NN,O
,tyrosine,NN,O
,kinase,NN,O
,inhibitors,NNS,O
,(,(,O
,stratum,VB,O
,2,CD,O
,),),O
,",",",",O
,received,VBD,O
,RAD001,NNP,O
,10,CD,O
,mg,NN,O
,/,NNP,O
,day,NN,O
,until,IN,O
,progression,NN,O
,or,CC,O
,unacceptable,JJ,O
,toxicity,NN,B-DISEASE
,.,.,O
,Primary,JJ,O
,objective,NN,O
,was,VBD,O
,overall,JJ,O
,response,NN,O
,rate,NN,O
,(,(,O
,ORR,NNP,O
,),),O
,.,.,O
,Analyses,NNS,O
,of,IN,O
,markers,NNS,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,mTOR,NN,O
,pathway,NN,O
,were,VBD,O
,carried,VBN,O
,out,RP,O
,on,IN,O
,archival,JJ,O
,tumor,NN,B-DISEASE
,from,IN,O
,a,DT,O
,subgroup,NN,O
,using,VBG,O
,immunohistochemistry,NN,O
,(,(,O
,IHC,NNP,O
,),),O
,and,CC,O
,direct,JJ,O
,mutation,NN,O
,sequencing,VBG,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Eighty,NNP,O
,-,:,O
,five,CD,O
,patients,NNS,O
,were,VBD,O
,enrolled,VBN,O
,",",",",O
,42,CD,O
,in,IN,O
,stratum,NN,O
,1,CD,O
,and,CC,O
,43,CD,O
,in,IN,O
,stratum,NN,O
,.,.,O
,ORR,NNP,O
,was,VBD,O
,4,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,(,(,O
,7,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,stratum,NN,O
,1,CD,O
,;,:,O
,2,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,stratum,NN,O
,2,CD,O
,),),O
,.,.,O
,Overall,JJ,O
,disease,NN,O
,control,NN,O
,rate,NN,O
,was,VBD,O
,47,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,.,.,O
,Median,JJ,O
,progression,NN,O
,-,:,O
,free,JJ,O
,survivals,NNS,O
,(,(,O
,PFSs,NNP,O
,),),O
,were,VBD,O
,2,CD,O
,.,.,O
,6,CD,O
,(,(,O
,stratum,VB,O
,1,CD,O
,),),O
,and,CC,O
,2,CD,O
,.,.,O
,7,CD,O
,months,NNS,O
,(,(,O
,stratum,VB,O
,2,CD,O
,),),O
,.,.,O
,Common,JJ,O
,>,NN,O
,or,CC,O
,=,NN,O
,grade,VBP,O
,3,CD,O
,events,NNS,O
,were,VBD,O
,fatigue,JJ,B-DISEASE
,",",",",O
,dyspnea,NN,B-DISEASE
,",",",",O
,stomatitis,NN,B-DISEASE
,",",",",O
,anemia,NN,B-DISEASE
,",",",",O
,and,CC,O
,thrombocytopenia,NN,B-DISEASE
,.,.,O
,Pneumonitis,NNP,B-DISEASE
,",",",",O
,probably,RB,O
,or,CC,O
,possibly,RB,O
,related,VBN,O
,",",",",O
,mainly,RB,O
,grade,VBD,O
,1,CD,O
,/,NN,O
,2,CD,O
,",",",",O
,occurred,VBD,O
,in,IN,O
,25,CD,O
,%,NN,O
,.,.,O
,Cox,NNP,O
,regression,NN,O
,analysis,NN,O
,of,IN,O
,IHC,NNP,O
,scores,NNS,O
,found,VBD,O
,that,IN,O
,only,RB,O
,phospho,VB,O
,AKT,NNP,O
,(,(,O
,pAKT,NN,O
,),),O
,was,VBD,O
,a,DT,O
,significant,JJ,O
,independent,JJ,O
,predictor,NN,O
,of,IN,O
,worse,JJR,O
,PFS,NNP,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,RAD001,NNP,O
,10,CD,O
,mg,NN,O
,/,NNP,O
,day,NN,O
,was,VBD,O
,well,RB,O
,tolerated,VBN,O
,",",",",O
,showing,VBG,O
,modest,JJ,O
,clinical,JJ,O
,activity,NN,O
,in,IN,O
,pretreated,JJ,O
,NSCLC,NNP,B-DISEASE
,.,.,O
,Evaluation,NN,O
,of,IN,O
,RAD001,NNP,O
,plus,CC,O
,standard,JJ,O
,therapy,NN,O
,for,IN,O
,metastatic,JJ,O
,NSCLC,NNP,B-DISEASE
,continues,VBZ,O
,.,.,O
,Posttransplant,JJ,O
,anemia,NN,B-DISEASE
,:,:,O
,the,DT,O
,role,NN,O
,of,IN,O
,sirolimus,NN,O
,.,.,O
,Posttransplant,NNP,O
,anemia,NN,B-DISEASE
,is,VBZ,O
,a,DT,O
,common,JJ,O
,problem,NN,O
,that,WDT,O
,may,MD,O
,hinder,VB,O
,patients,NNS,O
,',POS,O
,quality,NN,O
,of,IN,O
,life,NN,O
,.,.,O
,It,PRP,O
,occurs,VBZ,O
,in,IN,O
,12,CD,O
,to,TO,O
,76,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,",",",",O
,and,CC,O
,is,VBZ,O
,most,RBS,O
,common,JJ,O
,in,IN,O
,the,DT,O
,immediate,JJ,O
,posttransplant,JJ,O
,period,NN,O
,.,.,O
,A,DT,O
,variety,NN,O
,of,IN,O
,factors,NNS,O
,have,VBP,O
,been,VBN,O
,identified,VBN,O
,that,IN,O
,increase,VB,O
,the,DT,O
,risk,NN,O
,of,IN,O
,posttransplant,JJ,O
,anemia,NN,B-DISEASE
,",",",",O
,of,IN,O
,which,WDT,O
,the,DT,O
,level,NN,O
,of,IN,O
,renal,JJ,O
,function,NN,O
,is,VBZ,O
,most,RBS,O
,important,JJ,O
,.,.,O
,Sirolimus,NNP,O
,",",",",O
,a,DT,O
,mammalian,JJ,O
,target,NN,O
,of,IN,O
,rapamycin,JJ,O
,inhibitor,NN,O
,",",",",O
,has,VBZ,O
,been,VBN,O
,implicated,VBN,O
,as,IN,O
,playing,VBG,O
,a,DT,O
,special,JJ,O
,role,NN,O
,in,IN,O
,posttransplant,JJ,O
,anemia,NN,B-DISEASE
,.,.,O
,This,DT,O
,review,NN,O
,considers,VBZ,O
,anemia,RB,B-DISEASE
,associated,VBN,O
,with,IN,O
,sirolimus,NN,O
,",",",",O
,including,VBG,O
,its,PRP$,O
,presentation,NN,O
,",",",",O
,mechanisms,NNS,O
,",",",",O
,and,CC,O
,management,NN,O
,.,.,O
,Coronary,NNP,O
,computerized,VBD,O
,tomography,NN,O
,angiography,NN,O
,for,IN,O
,rapid,JJ,O
,discharge,NN,O
,of,IN,O
,low,JJ,O
,-,:,O
,risk,NN,O
,patients,NNS,O
,with,IN,O
,cocaine,JJ,O
,-,:,O
,associated,VBN,O
,chest,JJS,B-DISEASE
,pain,NN,I-DISEASE
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Most,JJS,O
,patients,NNS,O
,presenting,VBG,O
,to,TO,O
,emergency,NN,O
,departments,NNS,O
,(,(,O
,EDs,NNP,O
,),),O
,with,IN,O
,cocaine,NN,O
,-,:,O
,associated,VBN,O
,chest,JJS,B-DISEASE
,pain,NN,I-DISEASE
,are,VBP,O
,admitted,VBN,O
,for,IN,O
,at,IN,O
,least,JJS,O
,12,CD,O
,hours,NNS,O
,and,CC,O
,receive,VB,O
,a,DT,O
,"""",NN,O
,rule,NN,O
,out,IN,O
,acute,JJ,B-DISEASE
,coronary,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,"""",NNP,O
,protocol,NN,O
,",",",",O
,often,RB,O
,with,IN,O
,noninvasive,JJ,O
,testing,VBG,O
,prior,JJ,O
,to,TO,O
,discharge,VB,O
,.,.,O
,In,IN,O
,patients,NNS,O
,without,IN,O
,cocaine,NN,O
,use,NN,O
,",",",",O
,coronary,JJ,O
,computerized,VBD,O
,tomography,NN,O
,angiography,NN,O
,(,(,O
,CTA,NNP,O
,),),O
,has,VBZ,O
,been,VBN,O
,shown,VBN,O
,to,TO,O
,be,VB,O
,useful,JJ,O
,for,IN,O
,identifying,VBG,O
,a,DT,O
,group,NN,O
,of,IN,O
,patients,NNS,O
,at,IN,O
,low,JJ,O
,risk,NN,O
,for,IN,O
,cardiac,JJ,O
,events,NNS,O
,who,WP,O
,can,MD,O
,be,VB,O
,safely,RB,O
,discharged,VBN,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,unclear,JJ,O
,whether,IN,O
,a,DT,O
,coronary,JJ,O
,CTA,NNP,O
,strategy,NN,O
,would,MD,O
,be,VB,O
,efficacious,JJ,O
,in,IN,O
,cocaine,NN,O
,-,:,O
,associated,VBN,O
,chest,JJS,B-DISEASE
,pain,NN,I-DISEASE
,",",",",O
,as,IN,O
,coronary,JJ,B-DISEASE
,vasospasm,NN,I-DISEASE
,may,MD,O
,account,VB,O
,for,IN,O
,some,DT,O
,of,IN,O
,the,DT,O
,ischemia,NN,B-DISEASE
,.,.,O
,We,PRP,O
,studied,VBD,O
,whether,IN,O
,a,DT,O
,negative,JJ,O
,coronary,JJ,O
,CTA,NNP,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,cocaine,JJ,O
,-,:,O
,associated,VBN,O
,chest,JJS,B-DISEASE
,pain,NN,I-DISEASE
,could,MD,O
,identify,VB,O
,a,DT,O
,subset,NN,O
,safe,JJ,O
,for,IN,O
,discharge,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,We,PRP,O
,prospectively,RB,O
,evaluated,VBD,O
,the,DT,O
,safety,NN,O
,of,IN,O
,coronary,JJ,O
,CTA,NNP,O
,for,IN,O
,low,JJ,O
,-,:,O
,risk,NN,O
,patients,NNS,O
,who,WP,O
,presented,VBD,O
,to,TO,O
,the,DT,O
,ED,NNP,O
,with,IN,O
,cocaineassociated,JJ,O
,chest,NN,B-DISEASE
,pain,NN,I-DISEASE
,(,(,O
,self,PRP,O
,-,:,O
,reported,VBD,O
,or,CC,O
,positive,JJ,O
,urine,JJ,O
,test,NN,O
,),),O
,.,.,O
,Consecutive,JJ,O
,patients,NNS,O
,received,VBD,O
,either,RB,O
,immediate,JJ,O
,coronary,JJ,O
,CTA,NNP,O
,in,IN,O
,the,DT,O
,ED,NNP,O
,(,(,O
,without,IN,O
,serial,JJ,O
,markers,NNS,O
,),),O
,or,CC,O
,underwent,JJ,O
,coronary,JJ,O
,CTA,NNP,O
,after,IN,O
,a,DT,O
,brief,JJ,O
,observation,NN,O
,period,NN,O
,with,IN,O
,serial,JJ,O
,cardiac,JJ,O
,marker,NN,O
,measurements,NNS,O
,.,.,O
,Patients,NNS,O
,with,IN,O
,negative,JJ,O
,coronary,JJ,O
,CTA,NNP,O
,(,(,O
,maximal,JJ,O
,stenosis,NN,B-DISEASE
,less,JJR,O
,than,IN,O
,50,CD,O
,%,NN,O
,),),O
,were,VBD,O
,discharged,VBN,O
,.,.,O
,The,DT,O
,main,JJ,O
,outcome,NN,O
,was,VBD,O
,30,CD,O
,-,:,O
,day,NN,O
,cardiovascular,JJ,O
,death,NN,O
,or,CC,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,.,.,O
,RESULTS,NN,O
,:,:,O
,A,DT,O
,total,NN,O
,of,IN,O
,59,CD,O
,patients,NNS,O
,with,IN,O
,cocaine,JJ,O
,-,:,O
,associated,VBN,O
,chest,JJS,B-DISEASE
,pain,NN,I-DISEASE
,were,VBD,O
,evaluated,VBN,O
,.,.,O
,Patients,NNS,O
,had,VBD,O
,a,DT,O
,mean,JJ,O
,age,NN,O
,of,IN,O
,45,CD,O
,.,.,O
,6,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,6,CD,O
,.,.,O
,6,CD,O
,yrs,NN,O
,and,CC,O
,were,VBD,O
,86,CD,O
,%,NN,O
,black,JJ,O
,",",",",O
,66,CD,O
,%,NN,O
,male,NN,O
,.,.,O
,Seventy,NNP,O
,-,:,O
,nine,CD,O
,percent,NN,O
,had,VBD,O
,a,DT,O
,normal,JJ,O
,or,CC,O
,nonspecific,JJ,O
,ECG,NNP,O
,and,CC,O
,85,CD,O
,%,NN,O
,had,VBD,O
,a,DT,O
,TIMI,NNP,O
,score,NN,O
,<,VBD,O
,2,CD,O
,.,.,O
,Twenty,CD,O
,patients,NNS,O
,received,VBD,O
,coronary,JJ,O
,CTA,NNP,O
,immediately,RB,O
,in,IN,O
,the,DT,O
,ED,NNP,O
,",",",",O
,18,CD,O
,of,IN,O
,whom,WP,O
,were,VBD,O
,discharged,VBN,O
,following,VBG,O
,CTA,NNP,O
,(,(,O
,90,CD,O
,%,NN,O
,),),O
,.,.,O
,Thirty,NNP,O
,-,:,O
,nine,CD,O
,received,VBD,O
,coronary,JJ,O
,CTA,NNP,O
,after,IN,O
,a,DT,O
,brief,JJ,O
,observation,NN,O
,period,NN,O
,",",",",O
,with,IN,O
,37,CD,O
,discharged,VBD,O
,home,NN,O
,following,VBG,O
,CTA,NNP,O
,(,(,O
,95,CD,O
,%,NN,O
,),),O
,.,.,O
,Six,CD,O
,patients,NNS,O
,had,VBD,O
,coronary,JJ,B-DISEASE
,stenosis,NN,I-DISEASE
,>,NN,O
,or,CC,O
,=,VB,O
,50,CD,O
,%,NN,O
,.,.,O
,During,IN,O
,the,DT,O
,30,CD,O
,-,:,O
,day,NN,O
,follow,VB,O
,-,:,O
,up,RB,O
,period,NN,O
,",",",",O
,no,DT,O
,patients,NNS,O
,died,VBD,O
,of,IN,O
,a,DT,O
,cardiovascular,JJ,O
,event,NN,O
,(,(,O
,0,CD,O
,%,NN,O
,;,:,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,",",",",O
,0,CD,O
,-,:,O
,6,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,),),O
,and,CC,O
,no,DT,O
,patient,NN,O
,sustained,VBD,O
,a,DT,O
,nonfatal,JJ,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,(,(,O
,0,CD,O
,%,NN,O
,;,:,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,",",",",O
,0,CD,O
,-,:,O
,6,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,),),O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Although,IN,O
,cocaine,NN,O
,-,:,O
,associated,VBN,O
,myocardial,JJ,B-DISEASE
,ischemia,NN,I-DISEASE
,can,MD,O
,result,VB,O
,from,IN,O
,coronary,JJ,O
,vasoconstriction,NN,O
,",",",",O
,patients,NNS,O
,with,IN,O
,cocaine,NN,O
,associated,VBN,O
,chest,JJS,B-DISEASE
,pain,NN,I-DISEASE
,",",",",O
,a,DT,O
,non,JJ,O
,-,:,O
,ischemic,JJ,B-DISEASE
,ECG,NNP,O
,",",",",O
,and,CC,O
,a,DT,O
,TIMI,NNP,O
,risk,NN,O
,score,NN,O
,<,VBD,O
,2,CD,O
,may,MD,O
,be,VB,O
,safely,RB,O
,discharged,VBN,O
,from,IN,O
,the,DT,O
,ED,NNP,O
,after,IN,O
,a,DT,O
,negative,JJ,O
,coronary,JJ,O
,CTA,NNP,O
,with,IN,O
,a,DT,O
,low,JJ,O
,risk,NN,O
,of,IN,O
,30,CD,O
,-,:,O
,day,NN,O
,adverse,JJ,O
,events,NNS,O
,.,.,O
,Bilateral,NNP,O
,haemorrhagic,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,of,IN,I-DISEASE
,the,DT,I-DISEASE
,globus,NN,I-DISEASE
,pallidus,NN,I-DISEASE
,after,IN,O
,cocaine,NN,O
,and,CC,O
,alcohol,NN,O
,intoxication,NN,O
,.,.,O
,Cocaine,NNP,O
,is,VBZ,O
,a,DT,O
,risk,NN,O
,factor,NN,O
,for,IN,O
,both,DT,O
,ischemic,JJ,B-DISEASE
,and,CC,I-DISEASE
,haemorrhagic,JJ,I-DISEASE
,stroke,NN,I-DISEASE
,.,.,O
,We,PRP,O
,present,VBD,O
,the,DT,O
,case,NN,O
,of,IN,O
,a,DT,O
,31,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,man,NN,O
,with,IN,O
,bilateral,JJ,O
,ischemia,NN,B-DISEASE
,of,IN,I-DISEASE
,the,DT,I-DISEASE
,globus,NN,I-DISEASE
,pallidus,NN,I-DISEASE
,after,IN,O
,excessive,JJ,O
,alcohol,NN,O
,and,CC,O
,intranasal,NN,O
,cocaine,NN,O
,use,NN,O
,.,.,O
,Drug,NNP,O
,-,:,O
,related,VBN,O
,globus,NN,B-DISEASE
,pallidus,NN,I-DISEASE
,infarctions,NNS,I-DISEASE
,are,VBP,O
,most,RBS,O
,often,RB,O
,associated,VBN,O
,with,IN,O
,heroin,NN,O
,.,.,O
,Bilateral,NNP,O
,basal,NN,B-DISEASE
,ganglia,NN,I-DISEASE
,infarcts,NNS,I-DISEASE
,after,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,cocaine,NN,O
,",",",",O
,without,IN,O
,concurrent,NN,O
,heroin,NN,O
,use,NN,O
,",",",",O
,have,VBP,O
,never,RB,O
,been,VBN,O
,reported,VBN,O
,.,.,O
,In,IN,O
,our,PRP$,O
,patient,NN,O
,",",",",O
,transient,JJ,O
,cardiac,JJ,B-DISEASE
,arrhythmia,NN,I-DISEASE
,or,CC,O
,respiratory,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,related,VBN,O
,to,TO,O
,cocaine,VB,O
,and,CC,O
,/,VB,O
,or,CC,O
,ethanol,VB,O
,use,NN,O
,were,VBD,O
,the,DT,O
,most,RBS,O
,likely,JJ,O
,causes,NNS,O
,of,IN,O
,cerebral,JJ,B-DISEASE
,hypoperfusion,NN,I-DISEASE
,.,.,O
,Late,JJ,O
,fulminant,JJ,O
,posterior,NN,B-DISEASE
,reversible,JJ,I-DISEASE
,encephalopathy,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,after,IN,O
,liver,NN,O
,transplant,NN,O
,.,.,O
,OBJECTIVES,CC,O
,:,:,O
,Posterior,NNP,B-DISEASE
,leukoencephalopathy,NNS,I-DISEASE
,due,JJ,O
,to,TO,O
,calcineurin,VB,O
,-,:,O
,inhibitor,NN,O
,-,:,O
,related,JJ,O
,neurotoxicity,NN,B-DISEASE
,is,VBZ,O
,a,DT,O
,rare,JJ,O
,but,CC,O
,severe,JJ,O
,complication,NN,O
,that,WDT,O
,results,NNS,O
,from,IN,O
,treatment,NN,O
,with,IN,O
,immunosuppressive,JJ,O
,agents,NNS,O
,(,(,O
,primarily,RB,O
,those,DT,O
,administered,VBN,O
,after,IN,O
,a,DT,O
,liver,NN,O
,or,CC,O
,kidney,NN,O
,transplant,NN,O
,),),O
,.,.,O
,The,DT,O
,pathophysiologic,JJ,O
,mechanisms,NN,O
,of,IN,O
,that,DT,O
,disorder,NN,O
,remain,VBP,O
,unknown,JJ,O
,.,.,O
,CASE,NN,O
,:,:,O
,We,PRP,O
,report,VBP,O
,the,DT,O
,case,NN,O
,of,IN,O
,a,DT,O
,46,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,who,WP,O
,received,VBD,O
,a,DT,O
,liver,NN,O
,transplant,NN,O
,in,IN,O
,our,PRP$,O
,center,NN,O
,as,IN,O
,treatment,NN,O
,for,IN,O
,alcoholic,JJ,B-DISEASE
,cirrhosis,NN,I-DISEASE
,and,CC,O
,in,IN,O
,whom,WP,O
,either,CC,O
,a,DT,O
,fulminant,JJ,O
,course,NN,O
,of,IN,O
,posterior,JJ,B-DISEASE
,leukoencephalopathy,NN,I-DISEASE
,or,CC,O
,posterior,JJ,B-DISEASE
,reversible,JJ,I-DISEASE
,encephalopathy,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,developed,VBD,O
,110,CD,O
,days,NNS,O
,after,IN,O
,transplant,NN,O
,.,.,O
,After,IN,O
,an,DT,O
,initially,RB,O
,uneventful,JJ,O
,course,NN,O
,after,IN,O
,the,DT,O
,transplant,NN,O
,",",",",O
,the,DT,O
,patient,NN,O
,rapidly,RB,O
,fell,VBD,O
,into,IN,O
,deep,JJ,O
,coma,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Cerebral,JJ,O
,MRI,NNP,O
,scan,NN,O
,showed,VBD,O
,typical,JJ,O
,signs,NNS,O
,of,IN,O
,enhancement,NN,O
,in,IN,O
,the,DT,O
,pontine,NN,O
,and,CC,O
,posterior,JJ,O
,regions,NNS,O
,.,.,O
,Switching,VBG,O
,the,DT,O
,immunosuppressive,JJ,O
,regimen,NNS,O
,from,IN,O
,tacrolimus,NN,O
,to,TO,O
,cyclosporine,VB,O
,did,VBD,O
,not,RB,O
,improve,VB,O
,the,DT,O
,clinical,JJ,O
,situation,NN,O
,.,.,O
,The,DT,O
,termination,NN,O
,of,IN,O
,treatment,NN,O
,with,IN,O
,any,DT,O
,calcineurin,NN,O
,inhibitor,NN,O
,resulted,VBD,O
,in,IN,O
,a,DT,O
,complete,JJ,O
,resolution,NN,O
,of,IN,O
,that,DT,O
,complication,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Posterior,NNP,B-DISEASE
,reversible,JJ,I-DISEASE
,encephalopathy,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,after,IN,O
,liver,NN,O
,transplant,NN,O
,is,VBZ,O
,rare,JJ,O
,.,.,O
,We,PRP,O
,recommend,VBP,O
,a,DT,O
,complete,JJ,O
,cessation,NN,O
,of,IN,O
,any,DT,O
,calcineurin,JJ,O
,inhibitor,NN,O
,rather,RB,O
,than,IN,O
,a,DT,O
,dose,JJ,O
,reduction,NN,O
,.,.,O
,Prolonged,NNP,O
,hypothermia,NN,B-DISEASE
,as,IN,O
,a,DT,O
,bridge,NN,O
,to,TO,O
,recovery,NN,O
,for,IN,O
,cerebral,JJ,B-DISEASE
,edema,NN,I-DISEASE
,and,CC,O
,intracranial,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,associated,VBN,O
,with,IN,O
,fulminant,JJ,B-DISEASE
,hepatic,JJ,I-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,To,TO,O
,review,VB,O
,evidence,NN,O
,-,:,O
,based,VBN,O
,treatment,NN,O
,options,NNS,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,cerebral,JJ,B-DISEASE
,edema,NN,I-DISEASE
,complicating,VBG,O
,fulminant,JJ,B-DISEASE
,hepatic,JJ,I-DISEASE
,failure,NN,I-DISEASE
,(,(,O
,FHF,NNP,B-DISEASE
,),),O
,and,CC,O
,discuss,VB,O
,the,DT,O
,potential,JJ,O
,applications,NNS,O
,of,IN,O
,hypothermia,NN,B-DISEASE
,.,.,O
,METHOD,NN,O
,:,:,O
,Case,NNP,O
,-,:,O
,based,VBN,O
,observations,NNS,O
,from,IN,O
,a,DT,O
,medical,JJ,O
,intensive,JJ,O
,care,NN,O
,unit,NN,O
,(,(,O
,MICU,NNP,O
,),),O
,in,IN,O
,a,DT,O
,tertiary,JJ,O
,care,NN,O
,facility,NN,O
,in,IN,O
,a,DT,O
,27,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,female,NN,O
,with,IN,O
,FHF,NNP,B-DISEASE
,from,IN,O
,acetaminophen,NN,O
,and,CC,O
,resultant,JJ,O
,cerebral,JJ,B-DISEASE
,edema,NN,I-DISEASE
,.,.,O
,RESULTS,NN,O
,:,:,O
,Our,PRP$,O
,patient,NN,O
,was,VBD,O
,admitted,VBN,O
,to,TO,O
,the,DT,O
,MICU,NNP,O
,after,IN,O
,being,VBG,O
,found,VBD,O
,unresponsive,JJ,O
,with,IN,O
,presumed,JJ,O
,toxicity,NN,B-DISEASE
,from,IN,O
,acetaminophen,NN,O
,which,WDT,O
,was,VBD,O
,ingested,VBN,O
,over,IN,O
,a,DT,O
,2,CD,O
,-,:,O
,day,NN,O
,period,NN,O
,.,.,O
,The,DT,O
,patient,NN,O
,had,VBD,O
,depressed,VBN,O
,of,IN,O
,mental,JJ,O
,status,NN,O
,lasting,VBG,O
,at,IN,O
,least,JJS,O
,24,CD,O
,h,JJ,O
,prior,RB,O
,to,TO,O
,admission,NN,O
,.,.,O
,Initial,JJ,O
,evaluation,NN,O
,confirmed,VBD,O
,FHF,NNP,B-DISEASE
,from,IN,O
,acetaminophen,NN,O
,and,CC,O
,cerebral,JJ,B-DISEASE
,edema,NN,I-DISEASE
,.,.,O
,The,DT,O
,patient,NN,O
,was,VBD,O
,treated,VBN,O
,with,IN,O
,hyperosmolar,JJ,O
,therapy,NN,O
,",",",",O
,hyperventilation,NN,B-DISEASE
,",",",",O
,sedation,NN,O
,",",",",O
,and,CC,O
,chemical,JJ,O
,paralysis,NN,B-DISEASE
,.,.,O
,Her,PRP$,O
,intracranial,JJ,O
,pressure,NN,O
,remained,VBD,O
,elevated,JJ,O
,despite,IN,O
,maximal,JJ,O
,medical,JJ,O
,therapy,NN,O
,.,.,O
,We,PRP,O
,then,RB,O
,initiated,VBD,O
,therapeutic,JJ,O
,hypothermia,NN,B-DISEASE
,which,WDT,O
,was,VBD,O
,continued,VBN,O
,for,IN,O
,5,CD,O
,days,NNS,O
,.,.,O
,At,IN,O
,re,JJ,O
,-,:,O
,warming,NN,O
,",",",",O
,patient,NN,O
,had,VBD,O
,resolution,NN,O
,of,IN,O
,her,PRP$,O
,cerebral,JJ,B-DISEASE
,edema,NN,I-DISEASE
,and,CC,O
,intracranial,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,.,.,O
,At,IN,O
,discharge,NN,O
,",",",",O
,she,PRP,O
,had,VBD,O
,complete,JJ,O
,recovery,NN,O
,of,IN,O
,neurological,JJ,O
,and,CC,O
,hepatic,JJ,O
,functions,NNS,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,In,IN,O
,patients,NNS,O
,with,IN,O
,FHF,NNP,B-DISEASE
,and,CC,O
,cerebral,JJ,B-DISEASE
,edema,NN,I-DISEASE
,from,IN,O
,acetaminophen,NN,O
,overdose,NN,B-DISEASE
,",",",",O
,prolonged,VBD,O
,therapeutic,JJ,O
,hypothermia,NN,B-DISEASE
,could,MD,O
,potentially,RB,O
,be,VB,O
,used,VBN,O
,as,IN,O
,a,DT,O
,life,NN,O
,saving,VBG,O
,therapy,NN,O
,and,CC,O
,a,DT,O
,bridge,NN,O
,to,TO,O
,hepatic,JJ,O
,and,CC,O
,neurological,JJ,O
,recovery,NN,O
,.,.,O
,A,DT,O
,clinical,JJ,O
,trial,NN,O
,of,IN,O
,hypothermia,NN,B-DISEASE
,in,IN,O
,patients,NNS,O
,with,IN,O
,this,DT,O
,condition,NN,O
,is,VBZ,O
,warranted,VBN,O
,.,.,O
,Binasal,NNP,B-DISEASE
,visual,JJ,I-DISEASE
,field,NN,I-DISEASE
,defects,NNS,I-DISEASE
,are,VBP,O
,not,RB,O
,specific,JJ,O
,to,TO,O
,vigabatrin,VB,O
,.,.,O
,This,DT,O
,study,NN,O
,investigated,VBD,O
,the,DT,O
,visual,JJ,B-DISEASE
,defects,NNS,I-DISEASE
,associated,VBN,O
,with,IN,O
,the,DT,O
,antiepileptic,JJ,O
,drug,NN,O
,vigabatrin,NN,O
,(,(,O
,VGB,NNP,O
,),),O
,.,.,O
,Two,CD,O
,hundred,VBD,O
,four,CD,O
,people,NNS,O
,with,IN,O
,epilepsy,NN,B-DISEASE
,were,VBD,O
,grouped,VBN,O
,on,IN,O
,the,DT,O
,basis,NN,O
,of,IN,O
,antiepileptic,JJ,O
,drug,NN,O
,therapy,NN,O
,(,(,O
,current,JJ,O
,",",",",O
,previous,JJ,O
,",",",",O
,or,CC,O
,no,DT,O
,exposure,NN,O
,to,TO,O
,VGB,NNP,O
,),),O
,.,.,O
,Groups,NNP,O
,were,VBD,O
,matched,VBN,O
,with,IN,O
,respect,NN,O
,to,TO,O
,age,NN,O
,",",",",O
,gender,NN,O
,",",",",O
,and,CC,O
,seizure,NN,B-DISEASE
,frequency,NN,O
,.,.,O
,All,DT,O
,patients,NNS,O
,underwent,JJ,O
,objective,JJ,O
,assessment,NN,O
,of,IN,O
,electrophysiological,JJ,O
,function,NN,O
,(,(,O
,wide,JJ,O
,-,:,O
,field,NN,O
,multifocal,JJ,O
,electroretinography,NN,O
,),),O
,and,CC,O
,conventional,JJ,O
,visual,JJ,O
,field,NN,O
,testing,VBG,O
,(,(,O
,static,JJ,O
,perimetry,NN,O
,),),O
,.,.,O
,Bilateral,JJ,O
,visual,JJ,O
,field,NN,O
,constriction,NN,O
,was,VBD,O
,observed,VBN,O
,in,IN,O
,59,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,currently,RB,O
,taking,VBG,O
,VGB,NNP,O
,",",",",O
,43,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,who,WP,O
,previously,RB,O
,took,VBD,O
,VGB,NNP,O
,",",",",O
,and,CC,O
,24,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,with,IN,O
,no,DT,O
,exposure,NN,O
,to,TO,O
,VGB,NNP,O
,.,.,O
,Assessment,NNP,O
,of,IN,O
,retinal,JJ,O
,function,NN,O
,revealed,VBD,O
,abnormal,JJ,O
,responses,NNS,O
,in,IN,O
,48,CD,O
,%,NN,O
,of,IN,O
,current,JJ,O
,VGB,NNP,O
,users,NNS,O
,and,CC,O
,22,CD,O
,%,NN,O
,of,IN,O
,prior,JJ,O
,VGB,NNP,O
,users,NNS,O
,",",",",O
,but,CC,O
,in,IN,O
,none,NN,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,without,IN,O
,previous,JJ,O
,exposure,NN,O
,to,TO,O
,VGB,NNP,O
,.,.,O
,Bilateral,NNP,B-DISEASE
,visual,JJ,I-DISEASE
,field,NN,I-DISEASE
,abnormalities,NNS,I-DISEASE
,are,VBP,O
,common,JJ,O
,in,IN,O
,the,DT,O
,treated,JJ,O
,epilepsy,NN,B-DISEASE
,population,NN,O
,",",",",O
,irrespective,JJ,O
,of,IN,O
,drug,NN,O
,history,NN,O
,.,.,O
,Assessment,NN,O
,by,IN,O
,conventional,JJ,O
,static,JJ,O
,perimetry,NN,O
,may,MD,O
,neither,RB,O
,be,VB,O
,sufficiently,RB,O
,sensitive,JJ,O
,nor,CC,O
,specific,JJ,O
,to,TO,O
,reliably,VB,O
,identify,VB,O
,retinal,JJ,B-DISEASE
,toxicity,NN,I-DISEASE
,associated,VBN,O
,with,IN,O
,VGB,NNP,O
,.,.,O
,Smoking,NN,O
,of,IN,O
,crack,NN,O
,cocaine,NN,O
,as,IN,O
,a,DT,O
,risk,NN,O
,factor,NN,O
,for,IN,O
,HIV,NNP,B-DISEASE
,infection,NN,I-DISEASE
,among,IN,O
,people,NNS,O
,who,WP,O
,use,VBP,O
,injection,NN,O
,drugs,NNS,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Little,JJ,O
,is,VBZ,O
,known,VBN,O
,about,IN,O
,the,DT,O
,possible,JJ,O
,role,NN,O
,that,IN,O
,smoking,VBG,O
,crack,NN,O
,cocaine,NN,O
,has,VBZ,O
,on,IN,O
,the,DT,O
,incidence,NN,O
,of,IN,O
,HIV,NNP,B-DISEASE
,infection,NN,I-DISEASE
,.,.,O
,Given,VBN,O
,the,DT,O
,increasing,VBG,O
,use,NN,O
,of,IN,O
,crack,NN,O
,cocaine,NN,O
,",",",",O
,we,PRP,O
,sought,VBD,O
,to,TO,O
,examine,VB,O
,whether,IN,O
,use,NN,O
,of,IN,O
,this,DT,O
,illicit,JJ,O
,drug,NN,O
,has,VBZ,O
,become,VBN,O
,a,DT,O
,risk,NN,O
,factor,NN,O
,for,IN,O
,HIV,NNP,B-DISEASE
,infection,NN,I-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,We,PRP,O
,included,VBD,O
,data,NNS,O
,from,IN,O
,people,NNS,O
,participating,VBG,O
,in,IN,O
,the,DT,O
,Vancouver,NNP,O
,Injection,NNP,O
,Drug,NNP,O
,Users,NNP,O
,Study,NNP,O
,who,WP,O
,reported,VBD,O
,injecting,VBG,O
,illicit,NN,O
,drugs,NNS,O
,at,IN,O
,least,JJS,O
,once,RB,O
,in,IN,O
,the,DT,O
,month,NN,O
,before,IN,O
,enrolment,NN,O
,",",",",O
,lived,VBN,O
,in,IN,O
,the,DT,O
,greater,JJR,O
,Vancouver,NNP,O
,area,NN,O
,",",",",O
,were,VBD,O
,HIV,NNP,O
,-,:,O
,negative,JJ,O
,at,IN,O
,enrolment,NN,O
,and,CC,O
,completed,VBN,O
,at,IN,O
,least,JJS,O
,1,CD,O
,follow,JJ,O
,-,:,O
,up,RB,O
,study,NN,O
,visit,NN,O
,.,.,O
,To,TO,O
,determine,VB,O
,whether,IN,O
,the,DT,O
,risk,NN,O
,of,IN,O
,HIV,NNP,B-DISEASE
,seroconversion,NN,I-DISEASE
,among,IN,O
,daily,JJ,O
,smokers,NNS,O
,of,IN,O
,crack,NN,O
,cocaine,NN,O
,changed,VBN,O
,over,IN,O
,time,NN,O
,",",",",O
,we,PRP,O
,used,VBD,O
,Cox,NNP,O
,proportional,JJ,O
,hazards,NNS,O
,regression,NN,O
,and,CC,O
,divided,VBD,O
,the,DT,O
,study,NN,O
,into,IN,O
,3,CD,O
,periods,NNS,O
,:,:,O
,May,NNP,O
,1,CD,O
,",",",",O
,1996,CD,O
,-,:,O
,Nov,NNP,O
,.,.,O
,30,CD,O
,",",",",O
,1999,CD,O
,(,(,O
,period,NN,O
,1,CD,O
,),),O
,",",",",O
,Dec,NNP,O
,.,.,O
,1,CD,O
,",",",",O
,1999,CD,O
,-,:,O
,Nov,NNP,O
,.,.,O
,30,CD,O
,",",",",O
,2002,CD,O
,(,(,O
,period,NN,O
,2,CD,O
,),),O
,",",",",O
,and,CC,O
,Dec,NNP,O
,.,.,O
,1,CD,O
,",",",",O
,2002,CD,O
,-,:,O
,Dec,NNP,O
,.,.,O
,30,CD,O
,",",",",O
,2005,CD,O
,(,(,O
,period,NN,O
,3,CD,O
,),),O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Overall,JJ,O
,",",",",O
,1048,CD,O
,eligible,JJ,O
,injection,NN,O
,drug,NN,O
,users,NNS,O
,were,VBD,O
,included,VBN,O
,in,IN,O
,our,PRP$,O
,study,NN,O
,.,.,O
,Of,IN,O
,these,DT,O
,",",",",O
,137,CD,O
,acquired,VBD,O
,HIV,NNP,B-DISEASE
,infection,NN,I-DISEASE
,during,IN,O
,follow,JJ,O
,-,:,O
,up,RB,O
,.,.,O
,The,DT,O
,mean,JJ,O
,proportion,NN,O
,of,IN,O
,participants,NNS,O
,who,WP,O
,reported,VBD,O
,daily,JJ,O
,smoking,NN,O
,of,IN,O
,crack,NN,O
,cocaine,NN,O
,increased,VBD,O
,from,IN,O
,11,CD,O
,.,.,O
,6,CD,O
,%,NN,O
,in,IN,O
,period,NN,O
,1,CD,O
,to,TO,O
,39,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,in,IN,O
,period,NN,O
,3,CD,O
,.,.,O
,After,IN,O
,adjusting,VBG,O
,for,IN,O
,potential,JJ,O
,confounders,NNS,O
,",",",",O
,we,PRP,O
,found,VBD,O
,that,IN,O
,the,DT,O
,risk,NN,O
,of,IN,O
,HIV,NNP,B-DISEASE
,seroconversion,NN,I-DISEASE
,among,IN,O
,participants,NNS,O
,who,WP,O
,were,VBD,O
,daily,JJ,O
,smokers,NNS,O
,of,IN,O
,crack,NN,O
,cocaine,NN,O
,increased,VBN,O
,over,IN,O
,time,NN,O
,(,(,O
,period,NN,O
,1,CD,O
,:,:,O
,hazard,NN,O
,ratio,NN,O
,[,NNP,O
,HR,NNP,O
,],VBD,O
,1,CD,O
,.,.,O
,03,CD,O
,",",",",O
,95,CD,O
,%,NN,O
,confidence,NN,O
,interval,NN,O
,[,NNP,O
,CI,NNP,O
,],VBD,O
,0,CD,O
,.,.,O
,57,CD,O
,-,:,O
,1,CD,O
,.,.,O
,85,CD,O
,;,:,O
,period,NN,O
,2,CD,O
,:,:,O
,HR,$,O
,1,CD,O
,.,.,O
,68,CD,O
,",",",",O
,95,CD,O
,%,NN,O
,CI,NNP,O
,1,CD,O
,.,.,O
,01,CD,O
,-,:,O
,2,CD,O
,.,.,O
,80,CD,O
,;,:,O
,and,CC,O
,period,NN,O
,3,CD,O
,:,:,O
,HR,$,O
,2,CD,O
,.,.,O
,74,CD,O
,",",",",O
,95,CD,O
,%,NN,O
,CI,NNP,O
,1,CD,O
,.,.,O
,06,CD,O
,-,:,O
,7,CD,O
,.,.,O
,11,CD,O
,),),O
,.,.,O
,INTERPRETATION,NN,O
,:,:,O
,Smoking,NN,O
,of,IN,O
,crack,NN,O
,cocaine,NN,O
,was,VBD,O
,found,VBN,O
,to,TO,O
,be,VB,O
,an,DT,O
,independent,JJ,O
,risk,NN,O
,factor,NN,O
,for,IN,O
,HIV,NNP,B-DISEASE
,seroconversion,NN,I-DISEASE
,among,IN,O
,people,NNS,O
,who,WP,O
,were,VBD,O
,injection,JJ,O
,drug,NN,O
,users,NNS,O
,.,.,O
,This,DT,O
,finding,NN,O
,points,NNS,O
,to,TO,O
,the,DT,O
,urgent,JJ,O
,need,NN,O
,for,IN,O
,evidence,NN,O
,-,:,O
,based,VBN,O
,public,JJ,O
,health,NN,O
,initiatives,NNS,O
,targeted,VBN,O
,at,IN,O
,people,NNS,O
,who,WP,O
,smoke,VBP,O
,crack,NN,O
,cocaine,NN,O
,.,.,O
,Fluoxetine,NNP,O
,improves,VBZ,O
,the,DT,O
,memory,NN,B-DISEASE
,deficits,NNS,I-DISEASE
,caused,VBN,O
,by,IN,O
,the,DT,O
,chemotherapy,NN,O
,agent,NN,O
,5,CD,O
,-,:,O
,fluorouracil,NN,O
,.,.,O
,Cancer,NNP,B-DISEASE
,patients,NNS,O
,who,WP,O
,have,VBP,O
,been,VBN,O
,treated,VBN,O
,with,IN,O
,systemic,JJ,O
,adjuvant,NN,O
,chemotherapy,NN,O
,have,VBP,O
,described,VBN,O
,experiencing,VBG,O
,deteriorations,NNS,O
,in,IN,O
,cognition,NN,O
,.,.,O
,A,NNP,O
,widely,RB,O
,used,VBD,O
,chemotherapeutic,JJ,O
,agent,NN,O
,",",",",O
,5,CD,O
,-,:,O
,fluorouracil,NN,O
,(,(,O
,5,CD,O
,-,:,O
,FU,NN,O
,),),O
,",",",",O
,readily,RB,O
,crosses,VBZ,O
,the,DT,O
,blood,NN,O
,-,:,O
,brain,NN,O
,barrier,NN,O
,and,CC,O
,so,RB,O
,could,MD,O
,have,VB,O
,a,DT,O
,direct,JJ,O
,effect,NN,O
,on,IN,O
,brain,NN,O
,function,NN,O
,.,.,O
,In,IN,O
,particular,JJ,O
,this,DT,O
,anti,JJ,O
,mitotic,JJ,O
,drug,NN,O
,could,MD,O
,reduce,VB,O
,cell,NN,O
,proliferation,NN,O
,in,IN,O
,the,DT,O
,neurogenic,JJ,O
,regions,NNS,O
,of,IN,O
,the,DT,O
,adult,NN,O
,brain,NN,O
,.,.,O
,In,IN,O
,contrast,NN,O
,reports,NNS,O
,indicate,VBP,O
,that,IN,O
,hippocampal,JJ,O
,dependent,JJ,O
,neurogenesis,NN,O
,and,CC,O
,cognition,NN,O
,are,VBP,O
,enhanced,VBN,O
,by,IN,O
,the,DT,O
,SSRI,NNP,O
,antidepressant,JJ,O
,Fluoxetine,NNP,O
,.,.,O
,In,IN,O
,this,DT,O
,investigation,NN,O
,the,DT,O
,behavioural,JJ,O
,effects,NNS,O
,of,IN,O
,chronic,JJ,O
,(,(,O
,two,CD,O
,week,NN,O
,),),O
,treatment,NN,O
,with,IN,O
,5,CD,O
,-,:,O
,FU,NN,O
,and,CC,O
,(,(,O
,three,CD,O
,weeks,NNS,O
,),),O
,with,IN,O
,Fluoxetine,NNP,O
,either,CC,O
,separately,RB,O
,or,CC,O
,in,IN,O
,combination,NN,O
,with,IN,O
,5,CD,O
,-,:,O
,FU,NN,O
,were,VBD,O
,tested,VBN,O
,on,IN,O
,adult,NN,O
,Lister,NNP,O
,hooded,VBD,O
,rats,NNS,O
,.,.,O
,Behavioural,JJ,O
,effects,NNS,O
,were,VBD,O
,tested,VBN,O
,using,VBG,O
,a,DT,O
,context,NN,O
,dependent,NN,O
,conditioned,VBD,O
,emotional,JJ,O
,response,NN,O
,test,NN,O
,(,(,O
,CER,NNP,O
,),),O
,which,WDT,O
,showed,VBD,O
,that,IN,O
,animals,NNS,O
,treated,VBD,O
,with,IN,O
,5,CD,O
,-,:,O
,FU,NN,O
,had,VBD,O
,a,DT,O
,significant,JJ,O
,reduction,NN,O
,in,IN,O
,freezing,VBG,O
,time,NN,O
,compared,VBN,O
,to,TO,O
,controls,NNS,O
,.,.,O
,A,DT,O
,separate,JJ,O
,group,NN,O
,of,IN,O
,animals,NNS,O
,was,VBD,O
,tested,VBN,O
,using,VBG,O
,a,DT,O
,hippocampal,JJ,O
,dependent,JJ,O
,spatial,JJ,O
,working,VBG,O
,memory,NN,O
,test,NN,O
,",",",",O
,the,DT,O
,object,JJ,O
,location,NN,O
,recognition,NN,O
,test,NN,O
,(,(,O
,OLR,NNP,O
,),),O
,.,.,O
,Animals,NNS,O
,treated,VBD,O
,only,RB,O
,with,IN,O
,5,CD,O
,-,:,O
,FU,NN,O
,showed,VBD,O
,significant,JJ,O
,deficits,NNS,O
,in,IN,O
,their,PRP$,O
,ability,NN,O
,to,TO,O
,carry,VB,O
,out,RP,O
,the,DT,O
,OLR,NNP,O
,task,NN,O
,but,CC,O
,co,JJ,O
,administration,NN,O
,of,IN,O
,Fluoxetine,NNP,O
,improved,VBD,O
,their,PRP$,O
,performance,NN,O
,.,.,O
,5,CD,O
,-,:,O
,FU,NN,O
,chemotherapy,NN,O
,caused,VBD,O
,a,DT,O
,significant,JJ,O
,reduction,NN,O
,in,IN,O
,the,DT,O
,number,NN,O
,of,IN,O
,proliferating,VBG,O
,cells,NNS,O
,in,IN,O
,the,DT,O
,sub,NN,O
,granular,JJ,O
,zone,NN,O
,of,IN,O
,the,DT,O
,dentate,NN,O
,gyrus,NN,O
,compared,VBN,O
,to,TO,O
,controls,NNS,O
,.,.,O
,This,DT,O
,reduction,NN,O
,was,VBD,O
,eliminated,VBN,O
,when,WRB,O
,Fluoxetine,NNP,O
,was,VBD,O
,co,VBN,O
,administered,VBN,O
,with,IN,O
,5,CD,O
,-,:,O
,FU,NN,O
,.,.,O
,Fluoxetine,NNP,O
,on,IN,O
,its,PRP$,O
,own,JJ,O
,had,VBD,O
,no,DT,O
,effect,NN,O
,on,IN,O
,proliferating,VBG,O
,cell,NN,O
,number,NN,O
,or,CC,O
,behaviour,NN,O
,.,.,O
,These,DT,O
,findings,NNS,O
,suggest,VBP,O
,that,IN,O
,5,CD,O
,-,:,O
,FU,NN,O
,can,MD,O
,negatively,RB,O
,affect,VB,O
,both,DT,O
,cell,NN,O
,proliferation,NN,O
,and,CC,O
,hippocampal,JJ,O
,dependent,JJ,O
,working,VBG,O
,memory,NN,O
,and,CC,O
,that,IN,O
,these,DT,O
,deficits,NNS,O
,can,MD,O
,be,VB,O
,reversed,VBN,O
,by,IN,O
,the,DT,O
,simultaneous,JJ,O
,administration,NN,O
,of,IN,O
,the,DT,O
,antidepressant,JJ,O
,Fluoxetine,NNP,O
,.,.,O
,Liver,NNP,O
,-,:,O
,specific,JJ,O
,ablation,NN,O
,of,IN,O
,integrin,JJ,O
,-,:,O
,linked,VBN,O
,kinase,NN,O
,in,IN,O
,mice,JJ,O
,results,NNS,O
,in,IN,O
,enhanced,JJ,O
,and,CC,O
,prolonged,JJ,O
,cell,NN,O
,proliferation,NN,O
,and,CC,O
,hepatomegaly,NN,B-DISEASE
,after,IN,O
,phenobarbital,JJ,O
,administration,NN,O
,.,.,O
,We,PRP,O
,have,VBP,O
,recently,RB,O
,demonstrated,VBN,O
,that,IN,O
,disruption,NN,O
,of,IN,O
,extracellular,JJ,O
,matrix,NN,O
,(,(,O
,ECM,NNP,O
,),),O
,/,VBP,O
,integrin,JJ,O
,signaling,VBG,O
,via,IN,O
,elimination,NN,O
,of,IN,O
,integrin,JJ,O
,-,:,O
,linked,VBN,O
,kinase,NN,O
,(,(,O
,ILK,NNP,O
,),),O
,in,IN,O
,hepatocytes,NNS,O
,interferes,NNS,O
,with,IN,O
,signals,NNS,O
,leading,VBG,O
,to,TO,O
,termination,NN,O
,of,IN,O
,liver,JJ,O
,regeneration,NN,O
,.,.,O
,This,DT,O
,study,NN,O
,investigates,VBZ,O
,the,DT,O
,role,NN,O
,of,IN,O
,ILK,NNP,O
,in,IN,O
,liver,JJ,O
,enlargement,NN,O
,induced,VBN,O
,by,IN,O
,phenobarbital,NN,O
,(,(,O
,PB,NNP,O
,),),O
,.,.,O
,Wild,NNP,O
,-,:,O
,type,NN,O
,(,(,O
,WT,NNP,O
,),),O
,and,CC,O
,ILK,NNP,O
,:,:,O
,liver,NN,O
,-,:,O
,/,SYM,O
,-,:,O
,mice,NN,O
,were,VBD,O
,given,VBN,O
,PB,NNP,O
,(,(,O
,0,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,in,IN,O
,drinking,NN,O
,water,NN,O
,),),O
,for,IN,O
,10,CD,O
,days,NNS,O
,.,.,O
,Livers,NNS,O
,were,VBD,O
,harvested,VBN,O
,on,IN,O
,2,CD,O
,",",",",O
,5,CD,O
,",",",",O
,and,CC,O
,10,CD,O
,days,NNS,O
,during,IN,O
,PB,NNP,O
,administration,NN,O
,.,.,O
,In,IN,O
,the,DT,O
,hepatocyte,NN,O
,-,:,O
,specific,JJ,O
,ILK,NNP,O
,/,NNP,O
,liver,SYM,O
,-,:,O
,/,SYM,O
,-,:,O
,mice,NN,O
,",",",",O
,the,DT,O
,liver,NN,O
,:,:,O
,body,NN,O
,weight,VBD,O
,ratio,NN,O
,was,VBD,O
,more,RBR,O
,than,IN,O
,double,RB,O
,as,IN,O
,compared,VBN,O
,to,TO,O
,0,CD,O
,h,NNS,O
,at,IN,O
,day,NN,O
,2,CD,O
,(,(,O
,2,CD,O
,.,.,O
,5,CD,O
,times,NNS,O
,),),O
,",",",",O
,while,IN,O
,at,IN,O
,days,NNS,O
,5,CD,O
,and,CC,O
,10,CD,O
,",",",",O
,it,PRP,O
,was,VBD,O
,enlarged,VBN,O
,three,CD,O
,times,NNS,O
,.,.,O
,In,IN,O
,the,DT,O
,WT,NNP,O
,mice,NN,O
,",",",",O
,the,DT,O
,increase,NN,O
,was,VBD,O
,as,IN,O
,expected,VBN,O
,from,IN,O
,previous,JJ,O
,literature,NN,O
,(,(,O
,1,CD,O
,.,.,O
,8,CD,O
,times,NNS,O
,),),O
,and,CC,O
,seems,VBZ,O
,to,TO,O
,have,VB,O
,leveled,VBN,O
,off,RP,O
,after,IN,O
,day,NN,O
,2,CD,O
,.,.,O
,There,EX,O
,were,VBD,O
,slightly,RB,O
,increased,VBN,O
,proliferating,NN,O
,cell,NN,O
,nuclear,JJ,O
,antigen,NN,O
,-,:,O
,positive,JJ,O
,cells,NNS,O
,in,IN,O
,the,DT,O
,ILK,NNP,O
,/,NNP,O
,liver,SYM,O
,-,:,O
,/,SYM,O
,-,:,O
,animals,NNS,O
,at,IN,O
,day,NN,O
,2,CD,O
,as,IN,O
,compared,VBN,O
,to,TO,O
,WT,NNP,O
,after,IN,O
,PB,NNP,O
,administration,NN,O
,.,.,O
,In,IN,O
,the,DT,O
,WT,NNP,O
,animals,NNS,O
,",",",",O
,the,DT,O
,proliferative,JJ,O
,response,NN,O
,had,VBD,O
,come,VBN,O
,back,RB,O
,to,TO,O
,normal,JJ,O
,by,IN,O
,days,NNS,O
,5,CD,O
,and,CC,O
,10,CD,O
,.,.,O
,Hepatocytes,NNS,O
,of,IN,O
,the,DT,O
,ILK,NNP,O
,/,NNP,O
,liver,SYM,O
,-,:,O
,/,SYM,O
,-,:,O
,mice,NN,O
,continued,VBD,O
,to,TO,O
,proliferate,VB,O
,up,RP,O
,until,IN,O
,day,NN,O
,10,CD,O
,.,.,O
,ILK,NNP,O
,/,NNP,O
,liver,SYM,O
,-,:,O
,/,SYM,O
,-,:,O
,mice,NN,O
,also,RB,O
,showed,VBD,O
,increased,JJ,O
,expression,NN,O
,of,IN,O
,key,JJ,O
,genes,NNS,O
,involved,VBN,O
,in,IN,O
,hepatocyte,JJ,O
,proliferation,NN,O
,at,IN,O
,different,JJ,O
,time,NN,O
,points,NNS,O
,during,IN,O
,PB,NNP,O
,administration,NN,O
,.,.,O
,In,IN,O
,summary,JJ,O
,",",",",O
,ECM,NNP,O
,proteins,VBZ,O
,communicate,NN,O
,with,IN,O
,the,DT,O
,signaling,VBG,O
,machinery,NN,O
,of,IN,O
,dividing,VBG,O
,cells,NNS,O
,via,IN,O
,ILK,NNP,O
,to,TO,O
,regulate,VB,O
,hepatocyte,JJ,O
,proliferation,NN,O
,and,CC,O
,termination,NN,O
,of,IN,O
,the,DT,O
,proliferative,JJ,O
,response,NN,O
,.,.,O
,Lack,NNP,O
,of,IN,O
,ILK,NNP,O
,in,IN,O
,the,DT,O
,hepatocytes,NNS,O
,imparts,NNS,O
,prolonged,VBD,O
,proliferative,JJ,O
,response,NN,O
,not,RB,O
,only,RB,O
,to,TO,O
,stimuli,VB,O
,related,VBN,O
,to,TO,O
,liver,VB,O
,regeneration,NN,O
,but,CC,O
,also,RB,O
,to,TO,O
,xenobiotic,JJ,O
,chemical,NN,O
,mitogens,NNS,O
,",",",",O
,such,JJ,O
,as,IN,O
,PB,NNP,O
,.,.,O
,Decreased,VBN,O
,Expression,NN,O
,of,IN,O
,Na,NNP,O
,/,NNP,O
,K,NNP,O
,-,:,O
,ATPase,NNP,O
,",",",",O
,NHE3,NNP,O
,",",",",O
,NBC1,NNP,O
,",",",",O
,AQP1,NNP,O
,and,CC,O
,OAT,NNP,O
,in,IN,O
,Gentamicin,NNP,O
,-,:,O
,induced,VBD,O
,Nephropathy,NNP,B-DISEASE
,.,.,O
,The,DT,O
,present,JJ,O
,study,NN,O
,was,VBD,O
,aimed,VBN,O
,to,TO,O
,determine,VB,O
,whether,IN,O
,there,EX,O
,is,VBZ,O
,an,DT,O
,altered,JJ,O
,regulation,NN,O
,of,IN,O
,tubular,JJ,O
,transporters,NNS,O
,in,IN,O
,gentamicin,JJ,O
,-,:,O
,induced,VBN,O
,nephropathy,JJ,B-DISEASE
,.,.,O
,Sprague,NNP,O
,-,:,O
,Dawley,NNP,O
,male,NN,O
,rats,NNS,O
,(,(,O
,200,CD,O
,~,RB,O
,250,CD,O
,g,NN,O
,),),O
,were,VBD,O
,subcutaneously,RB,O
,injected,VBN,O
,with,IN,O
,gentamicin,NN,O
,(,(,O
,100,CD,O
,mg,NN,O
,/,NNP,O
,kg,FW,O
,per,IN,O
,day,NN,O
,),),O
,for,IN,O
,7,CD,O
,days,NNS,O
,",",",",O
,and,CC,O
,the,DT,O
,expression,NN,O
,of,IN,O
,tubular,JJ,O
,transporters,NNS,O
,was,VBD,O
,determined,VBN,O
,by,IN,O
,immunoblotting,VBG,O
,and,CC,O
,immunohistochemistry,NN,O
,.,.,O
,The,DT,O
,mRNA,NN,O
,and,CC,O
,protein,JJ,O
,expression,NN,O
,of,IN,O
,OAT,NNP,O
,was,VBD,O
,also,RB,O
,determined,VBN,O
,.,.,O
,Gentamicin,NNP,O
,-,:,O
,treated,VBD,O
,rats,NNS,O
,exhibited,VBN,O
,significantly,RB,O
,decreased,VBN,O
,creatinine,JJ,O
,clearance,NN,O
,along,IN,O
,with,IN,O
,increased,JJ,O
,plasma,NNS,O
,creatinine,NN,O
,levels,NNS,O
,.,.,O
,Accordingly,RB,O
,",",",",O
,the,DT,O
,fractional,JJ,O
,excretion,NN,O
,of,IN,O
,sodium,NN,O
,increased,VBN,O
,.,.,O
,Urine,JJ,O
,volume,NN,O
,was,VBD,O
,increased,VBN,O
,",",",",O
,while,IN,O
,urine,JJ,O
,osmolality,NN,O
,and,CC,O
,free,JJ,O
,water,NN,O
,reabsorption,NN,O
,were,VBD,O
,decreased,VBN,O
,.,.,O
,Immunoblotting,NNP,O
,and,CC,O
,immunohistochemistry,NN,O
,revealed,VBD,O
,decreased,JJ,O
,expression,NN,O
,of,IN,O
,Na,NNP,O
,(,(,O
,+,NNP,O
,),),O
,/,VBP,O
,K,NNP,O
,(,(,O
,+,NNP,O
,),),O
,-,:,O
,ATPase,NN,O
,",",",",O
,NHE3,NNP,O
,",",",",O
,NBC1,NNP,O
,",",",",O
,and,CC,O
,AQP1,NNP,O
,in,IN,O
,the,DT,O
,kidney,NN,O
,of,IN,O
,gentamicin,NN,O
,-,:,O
,treated,JJ,O
,rats,NNS,O
,.,.,O
,The,DT,O
,expression,NN,O
,of,IN,O
,OAT1,NNP,O
,and,CC,O
,OAT3,NNP,O
,was,VBD,O
,also,RB,O
,decreased,VBN,O
,.,.,O
,Gentamicin,NNP,O
,-,:,O
,induced,VBD,O
,nephropathy,JJ,B-DISEASE
,may,MD,O
,at,IN,O
,least,JJS,O
,in,IN,O
,part,NN,O
,be,VB,O
,causally,RB,O
,related,VBN,O
,with,IN,O
,a,DT,O
,decreased,JJ,O
,expression,NN,O
,of,IN,O
,Na,NNP,O
,(,(,O
,+,NNP,O
,),),O
,/,VBP,O
,K,NNP,O
,(,(,O
,+,NNP,O
,),),O
,-,:,O
,ATPase,NN,O
,",",",",O
,NHE3,NNP,O
,",",",",O
,NBC1,NNP,O
,",",",",O
,AQP1,NNP,O
,and,CC,O
,OAT,NNP,O
,.,.,O
,Acute,NNP,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,after,IN,O
,high,JJ,O
,-,:,O
,dose,JJ,O
,methotrexate,NN,O
,therapy,NN,O
,in,IN,O
,a,DT,O
,patient,NN,O
,with,IN,O
,ileostomy,NN,O
,.,.,O
,High,NNP,O
,-,:,O
,dose,NN,O
,methotrexate,NN,O
,(,(,O
,HD,NNP,O
,-,:,O
,MTX,NN,O
,),),O
,is,VBZ,O
,an,DT,O
,important,JJ,O
,treatment,NN,O
,for,IN,O
,Burkitt,NNP,B-DISEASE
,lymphoma,NN,I-DISEASE
,",",",",O
,but,CC,O
,can,MD,O
,cause,VB,O
,hepatic,JJ,B-DISEASE
,and,CC,I-DISEASE
,renal,JJ,I-DISEASE
,toxicity,NN,I-DISEASE
,when,WRB,O
,its,PRP$,O
,clearance,NN,O
,is,VBZ,O
,delayed,VBN,O
,.,.,O
,We,PRP,O
,report,VBP,O
,a,DT,O
,case,NN,O
,of,IN,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,after,IN,O
,HD,NNP,O
,-,:,O
,MTX,NNP,O
,therapy,NN,O
,in,IN,O
,a,DT,O
,patient,NN,O
,with,IN,O
,ileostomy,NN,O
,",",",",O
,The,DT,O
,patient,NN,O
,was,VBD,O
,a,DT,O
,3,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,boy,NN,O
,who,WP,O
,had,VBD,O
,received,VBN,O
,a,DT,O
,living,VBG,O
,-,:,O
,related,VBN,O
,liver,JJ,O
,transplantation,NN,O
,for,IN,O
,congenital,JJ,O
,biliary,JJ,B-DISEASE
,atresia,NN,I-DISEASE
,.,.,O
,At,IN,O
,day,NN,O
,833,CD,O
,after,IN,O
,the,DT,O
,transplantation,NN,O
,",",",",O
,he,PRP,O
,was,VBD,O
,diagnosed,VBN,O
,with,IN,O
,PTLD,NNP,B-DISEASE
,(,(,O
,post,SYM,B-DISEASE
,-,:,I-DISEASE
,transplantation,NN,I-DISEASE
,lymphoproliferative,JJ,I-DISEASE
,disorder,NN,I-DISEASE
,",",",",O
,Burkitt,NNP,B-DISEASE
,-,:,I-DISEASE
,type,NN,I-DISEASE
,malignant,JJ,I-DISEASE
,lymphoma,NN,I-DISEASE
,),),O
,.,.,O
,During,IN,O
,induction,NN,O
,therapy,NN,O
,",",",",O
,he,PRP,O
,suffered,VBD,O
,ileal,JJ,O
,perforation,NN,O
,and,CC,O
,ileostomy,NN,O
,was,VBD,O
,performed,VBN,O
,.,.,O
,Subsequent,JJ,O
,HD,NNP,O
,-,:,O
,MTX,NNP,O
,therapy,NN,O
,caused,VBD,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,that,WDT,O
,required,VBD,O
,continuous,JJ,O
,hemodialysis,NN,O
,.,.,O
,We,PRP,O
,supposed,VBD,O
,that,IN,O
,intravascular,JJ,O
,hypovolemia,NN,B-DISEASE
,due,JJ,O
,to,TO,O
,substantial,JJ,O
,drainage,NN,O
,from,IN,O
,the,DT,O
,ileostoma,NN,O
,caused,VBD,O
,acute,JJ,B-DISEASE
,prerenal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,After,IN,O
,recovery,NN,O
,of,IN,O
,his,PRP$,O
,renal,JJ,O
,function,NN,O
,",",",",O
,we,PRP,O
,could,MD,O
,safely,RB,O
,treat,VB,O
,the,DT,O
,patient,NN,O
,with,IN,O
,HD,NNP,O
,-,:,O
,MTX,NNP,O
,therapy,NN,O
,by,IN,O
,controlling,VBG,O
,drainage,NN,O
,from,IN,O
,ileostoma,NN,O
,with,IN,O
,total,JJ,O
,parenteral,JJ,O
,nutrition,NN,O
,.,.,O
,Longitudinal,NNP,O
,association,NN,O
,of,IN,O
,alcohol,NN,O
,use,NN,O
,with,IN,O
,HIV,NNP,B-DISEASE
,disease,NN,I-DISEASE
,progression,NN,O
,and,CC,O
,psychological,JJ,O
,health,NN,O
,of,IN,O
,women,NNS,O
,with,IN,O
,HIV,NNP,O
,.,.,O
,We,PRP,O
,evaluated,VBD,O
,the,DT,O
,association,NN,O
,of,IN,O
,alcohol,NN,O
,consumption,NN,O
,and,CC,O
,depression,NN,B-DISEASE
,",",",",O
,and,CC,O
,their,PRP$,O
,effects,NNS,O
,on,IN,O
,HIV,NNP,B-DISEASE
,disease,NN,I-DISEASE
,progression,NN,O
,among,IN,O
,women,NNS,O
,with,IN,O
,HIV,NNP,O
,.,.,O
,The,DT,O
,study,NN,O
,included,VBD,O
,871,CD,O
,women,NNS,O
,with,IN,O
,HIV,NNP,O
,who,WP,O
,were,VBD,O
,recruited,VBN,O
,from,IN,O
,1993,CD,O
,-,:,O
,1995,CD,O
,in,IN,O
,four,CD,O
,US,NNP,O
,cities,NNS,O
,.,.,O
,The,DT,O
,participants,NNS,O
,had,VBD,O
,physical,JJ,O
,examination,NN,O
,",",",",O
,medical,JJ,O
,record,NN,O
,extraction,NN,O
,",",",",O
,and,CC,O
,venipuncture,NN,O
,",",",",O
,CD4,NNP,O
,+,NNP,O
,T,NNP,O
,-,:,O
,cell,NN,O
,counts,VBZ,O
,determination,NN,O
,",",",",O
,measurement,NN,O
,of,IN,O
,depression,NN,B-DISEASE
,symptoms,NNS,O
,(,(,O
,using,VBG,O
,the,DT,O
,self,NN,O
,-,:,O
,report,NN,O
,Center,NNP,O
,for,IN,O
,Epidemiological,NNP,O
,Studies,NNP,O
,-,:,O
,Depression,NNP,B-DISEASE
,Scale,NNP,O
,),),O
,",",",",O
,and,CC,O
,alcohol,NN,O
,use,NN,O
,assessment,NN,O
,at,IN,O
,enrollment,NN,O
,",",",",O
,and,CC,O
,semiannually,RB,O
,until,IN,O
,March,NNP,O
,2000,CD,O
,.,.,O
,Multilevel,NNP,O
,random,JJ,O
,coefficient,JJ,O
,ordinal,JJ,O
,models,NNS,O
,as,RB,O
,well,RB,O
,as,IN,O
,multilevel,NN,O
,models,NNS,O
,with,IN,O
,joint,JJ,O
,responses,NNS,O
,were,VBD,O
,used,VBN,O
,in,IN,O
,the,DT,O
,analysis,NN,O
,.,.,O
,There,EX,O
,was,VBD,O
,no,DT,O
,significant,JJ,O
,association,NN,O
,between,IN,O
,level,NN,O
,of,IN,O
,alcohol,NN,O
,use,NN,O
,and,CC,O
,CD4,NNP,O
,+,NNP,O
,T,NNP,O
,-,:,O
,cell,NN,O
,counts,NNS,O
,.,.,O
,When,WRB,O
,participants,NNS,O
,were,VBD,O
,stratified,VBN,O
,by,IN,O
,antiretroviral,JJ,O
,therapy,NN,O
,(,(,O
,ART,NNP,O
,),),O
,use,NN,O
,",",",",O
,the,DT,O
,association,NN,O
,between,IN,O
,alcohol,NN,O
,and,CC,O
,CD4,NNP,O
,+,NNP,O
,T,NNP,O
,-,:,O
,cell,NN,O
,did,VBD,O
,not,RB,O
,reach,VB,O
,statistical,JJ,O
,significance,NN,O
,.,.,O
,The,DT,O
,association,NN,O
,between,IN,O
,alcohol,NN,O
,consumption,NN,O
,and,CC,O
,depression,NN,B-DISEASE
,was,VBD,O
,significant,JJ,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,.,.,O
,Depression,NNP,B-DISEASE
,had,VBD,O
,a,DT,O
,significant,JJ,O
,negative,JJ,O
,effect,NN,O
,on,IN,O
,CD4,NNP,O
,+,NNP,O
,T,NNP,O
,-,:,O
,cell,NN,O
,counts,VBZ,O
,over,IN,O
,time,NN,O
,regardless,NN,O
,of,IN,O
,ART,NNP,O
,use,NN,O
,.,.,O
,Our,PRP$,O
,findings,NNS,O
,suggest,VBP,O
,that,IN,O
,alcohol,NN,O
,consumption,NN,O
,has,VBZ,O
,a,DT,O
,direct,JJ,O
,association,NN,O
,with,IN,O
,depression,NN,B-DISEASE
,.,.,O
,Moreover,RB,O
,",",",",O
,depression,NN,B-DISEASE
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,HIV,NNP,B-DISEASE
,disease,NN,I-DISEASE
,progression,NN,O
,.,.,O
,Our,PRP$,O
,findings,NNS,O
,have,VBP,O
,implications,NNS,O
,for,IN,O
,the,DT,O
,provision,NN,O
,of,IN,O
,alcohol,NN,O
,use,NN,O
,interventions,NNS,O
,and,CC,O
,psychological,JJ,O
,resources,NNS,O
,to,TO,O
,improve,VB,O
,the,DT,O
,health,NN,O
,of,IN,O
,women,NNS,O
,with,IN,O
,HIV,NNP,O
,.,.,O
,Chemokine,NNP,O
,CCL2,NNP,O
,and,CC,O
,its,PRP$,O
,receptor,NN,O
,CCR2,NNP,O
,are,VBP,O
,increased,VBN,O
,in,IN,O
,the,DT,O
,hippocampus,NN,O
,following,VBG,O
,pilocarpine,JJ,O
,-,:,O
,induced,JJ,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Neuroinflammation,NN,B-DISEASE
,occurs,VBZ,O
,after,IN,O
,seizures,NNS,B-DISEASE
,and,CC,O
,is,VBZ,O
,implicated,VBN,O
,in,IN,O
,epileptogenesis,NN,O
,.,.,O
,CCR2,NNP,O
,is,VBZ,O
,a,DT,O
,chemokine,JJ,O
,receptor,NN,O
,for,IN,O
,CCL2,NNP,O
,and,CC,O
,their,PRP$,O
,interaction,NN,O
,mediates,VBZ,O
,monocyte,JJ,O
,infiltration,NN,O
,in,IN,O
,the,DT,O
,neuroinflammatory,NN,B-DISEASE
,cascade,NN,O
,triggered,VBN,O
,in,IN,O
,different,JJ,O
,brain,NN,O
,pathologies,NNS,O
,.,.,O
,In,IN,O
,this,DT,O
,work,NN,O
,CCR2,NNP,O
,and,CC,O
,CCL2,NNP,O
,expression,NN,O
,were,VBD,O
,examined,VBN,O
,following,VBG,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,(,(,O
,SE,NNP,B-DISEASE
,),),O
,induced,VBN,O
,by,IN,O
,pilocarpine,JJ,O
,injection,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,SE,NNP,B-DISEASE
,was,VBD,O
,induced,VBN,O
,by,IN,O
,pilocarpine,JJ,O
,injection,NN,O
,.,.,O
,Control,NNP,O
,rats,NNS,O
,were,VBD,O
,injected,VBN,O
,with,IN,O
,saline,JJ,O
,instead,RB,O
,of,IN,O
,pilocarpine,NN,O
,.,.,O
,Five,CD,O
,days,NNS,O
,after,IN,O
,SE,NNP,B-DISEASE
,",",",",O
,CCR2,NNP,O
,staining,VBG,O
,in,IN,O
,neurons,NNS,O
,and,CC,O
,glial,JJ,O
,cells,NNS,O
,was,VBD,O
,examined,VBN,O
,using,VBG,O
,imunohistochemical,JJ,O
,analyses,NNS,O
,.,.,O
,The,DT,O
,number,NN,O
,of,IN,O
,CCR2,NNP,O
,positive,JJ,O
,cells,NNS,O
,was,VBD,O
,determined,VBN,O
,using,VBG,O
,stereology,NN,O
,probes,NNS,O
,in,IN,O
,the,DT,O
,hippocampus,NN,O
,.,.,O
,CCL2,NNP,O
,expression,NN,O
,in,IN,O
,the,DT,O
,hippocampus,NN,O
,was,VBD,O
,examined,VBN,O
,by,IN,O
,molecular,JJ,O
,assay,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Increased,JJ,O
,CCR2,NNP,O
,was,VBD,O
,observed,VBN,O
,in,IN,O
,the,DT,O
,hippocampus,NN,O
,after,IN,O
,SE,NNP,B-DISEASE
,.,.,O
,Seizures,NNP,B-DISEASE
,also,RB,O
,resulted,VBD,O
,in,IN,O
,alterations,NNS,O
,to,TO,O
,the,DT,O
,cell,NN,O
,types,VBZ,O
,expressing,VBG,O
,CCR2,NNP,O
,.,.,O
,Increased,VBD,O
,numbers,NNS,O
,of,IN,O
,neurons,NNS,O
,that,WDT,O
,expressed,VBD,O
,CCR2,NNP,O
,was,VBD,O
,observed,VBN,O
,following,VBG,O
,SE,NNP,B-DISEASE
,.,.,O
,Microglial,NNP,O
,cells,NNS,O
,were,VBD,O
,more,RBR,O
,closely,RB,O
,apposed,VBN,O
,to,TO,O
,the,DT,O
,CCR2,NNP,O
,-,:,O
,labeled,VBD,O
,cells,NNS,O
,in,IN,O
,SE,NNP,B-DISEASE
,rats,NNS,O
,.,.,O
,In,IN,O
,addition,NN,O
,",",",",O
,rats,VBZ,O
,that,IN,O
,experienced,JJ,O
,SE,NNP,B-DISEASE
,exhibited,VBD,O
,CCR2,NNP,O
,-,:,O
,labeling,NN,O
,in,IN,O
,populations,NNS,O
,of,IN,O
,hypertrophied,JJ,B-DISEASE
,astrocytes,NNS,O
,",",",",O
,especially,RB,O
,in,IN,O
,CA1,NNP,O
,and,CC,O
,dentate,VB,O
,gyrus,NN,O
,.,.,O
,These,DT,O
,CCR2,NNP,O
,+,NN,O
,astroctytes,NNS,O
,were,VBD,O
,not,RB,O
,observed,VBN,O
,in,IN,O
,control,NN,O
,rats,NNS,O
,.,.,O
,Examination,NN,O
,of,IN,O
,CCL2,NNP,O
,expression,NN,O
,showed,VBD,O
,that,IN,O
,it,PRP,O
,was,VBD,O
,elevated,VBN,O
,in,IN,O
,the,DT,O
,hippocampus,NN,O
,following,VBG,O
,SE,NNP,B-DISEASE
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,The,DT,O
,data,NN,O
,show,NN,O
,that,IN,O
,CCR2,NNP,O
,and,CC,O
,CCL2,NNP,O
,are,VBP,O
,up,RP,O
,-,:,O
,regulated,VBN,O
,in,IN,O
,the,DT,O
,hippocampus,NN,O
,after,IN,O
,pilocarpine,JJ,O
,-,:,O
,induced,JJ,O
,SE,NNP,B-DISEASE
,.,.,O
,Seizures,NNP,B-DISEASE
,also,RB,O
,result,VBP,O
,in,IN,O
,changes,NNS,O
,to,TO,O
,CCR2,NNP,O
,receptor,NN,O
,expression,NN,O
,in,IN,O
,neurons,NNS,O
,and,CC,O
,astrocytes,NNS,O
,.,.,O
,These,DT,O
,changes,NNS,O
,might,MD,O
,be,VB,O
,involved,VBN,O
,in,IN,O
,detrimental,JJ,O
,neuroplasticity,NN,O
,and,CC,O
,neuroinflammatory,JJ,B-DISEASE
,changes,NNS,O
,that,WDT,O
,occur,VBP,O
,following,VBG,O
,seizures,NNS,B-DISEASE
,.,.,O
,Metallothionein,NNP,O
,induction,NN,O
,reduces,NNS,O
,caspase,VBP,O
,-,:,O
,3,CD,O
,activity,NN,O
,and,CC,O
,TNFalpha,NNP,O
,levels,NNS,O
,with,IN,O
,preservation,NN,O
,of,IN,O
,cognitive,JJ,O
,function,NN,O
,and,CC,O
,intact,JJ,O
,hippocampal,JJ,O
,neurons,NNS,O
,in,IN,O
,carmustine,NN,O
,-,:,O
,treated,JJ,O
,rats,NNS,O
,.,.,O
,Hippocampal,NNP,O
,integrity,NN,O
,is,VBZ,O
,essential,JJ,O
,for,IN,O
,cognitive,JJ,O
,functions,NNS,O
,.,.,O
,On,IN,O
,the,DT,O
,other,JJ,O
,hand,NN,O
,",",",",O
,induction,NN,O
,of,IN,O
,metallothionein,NN,O
,(,(,O
,MT,NNP,O
,),),O
,by,IN,O
,ZnSO,NNP,O
,(,(,O
,4,CD,O
,),),O
,and,CC,O
,its,PRP$,O
,role,NN,O
,in,IN,O
,neuroprotection,NN,O
,has,VBZ,O
,been,VBN,O
,documented,VBN,O
,.,.,O
,The,DT,O
,present,JJ,O
,study,NN,O
,aimed,VBN,O
,to,TO,O
,explore,VB,O
,the,DT,O
,effect,NN,O
,of,IN,O
,MT,NNP,O
,induction,NN,O
,on,IN,O
,carmustine,NN,O
,(,(,O
,BCNU,NNP,O
,),),O
,-,:,O
,induced,VBN,O
,hippocampal,JJ,O
,cognitive,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,in,IN,O
,rats,NNS,O
,.,.,O
,A,DT,O
,total,NN,O
,of,IN,O
,60,CD,O
,male,JJ,O
,Wistar,NNP,O
,albino,NN,O
,rats,NNS,O
,were,VBD,O
,randomly,RB,O
,divided,VBN,O
,into,IN,O
,four,CD,O
,groups,NNS,O
,(,(,O
,15,CD,O
,/,NNP,O
,group,NN,O
,),),O
,:,:,O
,The,DT,O
,control,NN,O
,group,NN,O
,injected,VBD,O
,with,IN,O
,single,JJ,O
,doses,NNS,O
,of,IN,O
,normal,JJ,O
,saline,NN,O
,(,(,O
,i,JJ,O
,.,.,O
,c,NN,O
,.,.,O
,v,NN,O
,),),O
,followed,VBD,O
,24,CD,O
,h,NN,O
,later,RB,O
,by,IN,O
,BCNU,NNP,O
,solvent,NN,O
,(,(,O
,i,JJ,O
,.,.,O
,v,NN,O
,),),O
,.,.,O
,The,DT,O
,second,JJ,O
,group,NN,O
,administered,VBD,O
,ZnSO,NNP,O
,(,(,O
,4,CD,O
,),),O
,(,(,O
,0,CD,O
,.,.,O
,1,CD,O
,micromol,JJ,O
,/,$,O
,10,CD,O
,microl,NN,O
,normal,JJ,O
,saline,NN,O
,",",",",O
,i,NN,O
,.,.,O
,c,NN,O
,.,.,O
,v,NN,O
,",",",",O
,once,RB,O
,),),O
,then,RB,O
,BCNU,NNP,O
,solvent,NN,O
,(,(,O
,i,JJ,O
,.,.,O
,v,NN,O
,),),O
,after,IN,O
,24,CD,O
,h,NN,O
,.,.,O
,Third,NNP,O
,group,NN,O
,received,VBD,O
,BCNU,NNP,O
,(,(,O
,20,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,i,NN,O
,.,.,O
,v,NN,O
,",",",",O
,once,RB,O
,),),O
,24,CD,O
,h,NN,O
,after,IN,O
,injection,NN,O
,with,IN,O
,normal,JJ,O
,saline,NN,O
,(,(,O
,i,JJ,O
,.,.,O
,c,NN,O
,.,.,O
,v,NN,O
,),),O
,.,.,O
,Fourth,NNP,O
,group,NN,O
,received,VBD,O
,a,DT,O
,single,JJ,O
,dose,NN,O
,of,IN,O
,ZnSO,NNP,O
,(,(,O
,4,CD,O
,),),O
,(,(,O
,0,CD,O
,.,.,O
,1,CD,O
,micromol,JJ,O
,/,$,O
,10,CD,O
,microl,NN,O
,normal,JJ,O
,saline,NN,O
,",",",",O
,i,NN,O
,.,.,O
,c,NN,O
,.,.,O
,v,NN,O
,),),O
,then,RB,O
,BCNU,NNP,O
,(,(,O
,20,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,i,NN,O
,.,.,O
,v,NN,O
,",",",",O
,once,RB,O
,),),O
,after,IN,O
,24,CD,O
,h,NN,O
,.,.,O
,The,DT,O
,obtained,VBN,O
,data,NNS,O
,revealed,VBD,O
,that,IN,O
,BCNU,NNP,O
,administration,NN,O
,resulted,VBD,O
,in,IN,O
,deterioration,NN,B-DISEASE
,of,IN,I-DISEASE
,learning,NN,I-DISEASE
,and,CC,I-DISEASE
,short,JJ,I-DISEASE
,-,:,I-DISEASE
,term,NN,I-DISEASE
,memory,NN,I-DISEASE
,(,(,O
,STM,NNP,O
,),),O
,",",",",O
,as,IN,O
,measured,VBN,O
,by,IN,O
,using,VBG,O
,radial,JJ,O
,arm,NN,O
,water,NN,O
,maze,NN,O
,",",",",O
,accompanied,VBN,O
,with,IN,O
,decreased,JJ,O
,hippocampal,JJ,O
,glutathione,NN,O
,reductase,NN,O
,(,(,O
,GR,NNP,O
,),),O
,activity,NN,O
,and,CC,O
,reduced,VBD,O
,glutathione,NN,O
,(,(,O
,GSH,NNP,O
,),),O
,content,NN,O
,.,.,O
,Also,RB,O
,",",",",O
,BCNU,NNP,O
,administration,NN,O
,increased,VBD,O
,serum,JJ,O
,tumor,NN,B-DISEASE
,necrosis,NN,B-DISEASE
,factor,NN,O
,-,:,O
,alpha,NN,O
,(,(,O
,TNFalpha,NNP,O
,),),O
,",",",",O
,hippocampal,JJ,O
,MT,NNP,O
,and,CC,O
,malondialdehyde,NNP,O
,(,(,O
,MDA,NNP,O
,),),O
,contents,NNS,O
,as,RB,O
,well,RB,O
,as,IN,O
,caspase,NN,O
,-,:,O
,3,CD,O
,activity,NN,O
,in,IN,O
,addition,NN,O
,to,TO,O
,histological,JJ,O
,alterations,NNS,O
,.,.,O
,ZnSO,NNP,O
,(,(,O
,4,CD,O
,),),O
,pretreatment,NN,O
,counteracted,VBN,O
,BCNU,NNP,O
,-,:,O
,induced,JJ,O
,inhibition,NN,O
,of,IN,O
,GR,NNP,O
,and,CC,O
,depletion,NN,O
,of,IN,O
,GSH,NNP,O
,and,CC,O
,resulted,VBD,O
,in,IN,O
,significant,JJ,O
,reduction,NN,O
,in,IN,O
,the,DT,O
,levels,NNS,O
,of,IN,O
,MDA,NNP,O
,and,CC,O
,TNFalpha,NNP,O
,as,RB,O
,well,RB,O
,as,IN,O
,the,DT,O
,activity,NN,O
,of,IN,O
,caspase,NN,O
,-,:,O
,3,CD,O
,.,.,O
,The,DT,O
,histological,JJ,O
,features,NNS,O
,were,VBD,O
,improved,VBN,O
,in,IN,O
,hippocampus,NN,O
,of,IN,O
,rats,NNS,O
,treated,VBN,O
,with,IN,O
,ZnSO,NNP,O
,(,(,O
,4,CD,O
,),),O
,+,NN,O
,BCNU,NNP,O
,compared,VBN,O
,to,TO,O
,only,RB,O
,BCNU,NNP,O
,-,:,O
,treated,JJ,O
,animals,NNS,O
,.,.,O
,In,IN,O
,conclusion,NN,O
,",",",",O
,MT,NNP,O
,induction,NN,O
,halts,NNS,O
,BCNU,NNP,O
,-,:,O
,induced,VBD,O
,hippocampal,JJ,O
,toxicity,NN,B-DISEASE
,as,IN,O
,it,PRP,O
,prevented,VBD,O
,GR,NNP,O
,inhibition,NN,O
,and,CC,O
,GSH,NNP,O
,depletion,NN,O
,and,CC,O
,counteracted,VBD,O
,the,DT,O
,increased,JJ,O
,levels,NNS,O
,of,IN,O
,TNFalpha,NNP,O
,",",",",O
,MDA,NNP,O
,and,CC,O
,caspase,VB,O
,-,:,O
,3,CD,O
,activity,NN,O
,with,IN,O
,subsequent,JJ,O
,preservation,NN,O
,of,IN,O
,cognition,NN,O
,.,.,O
,Fatal,JJ,O
,carbamazepine,NN,O
,induced,VBN,O
,fulminant,JJ,B-DISEASE
,eosinophilic,NN,I-DISEASE
,(,(,O
,hypersensitivity,NN,B-DISEASE
,),),O
,myocarditis,NN,B-DISEASE
,:,:,O
,emphasis,NN,O
,on,IN,O
,anatomical,JJ,O
,and,CC,O
,histological,JJ,O
,characteristics,NNS,O
,",",",",O
,mechanisms,NNS,O
,and,CC,O
,genetics,NNS,O
,of,IN,O
,drug,NN,B-DISEASE
,hypersensitivity,NN,I-DISEASE
,and,CC,O
,differential,JJ,O
,diagnosis,NN,O
,.,.,O
,The,DT,O
,most,RBS,O
,severe,JJ,O
,adverse,JJ,O
,reactions,NNS,O
,to,TO,O
,carbamazepine,VB,O
,have,VB,O
,been,VBN,O
,observed,VBN,O
,in,IN,O
,the,DT,O
,haemopoietic,JJ,O
,system,NN,O
,",",",",O
,the,DT,O
,liver,NN,O
,and,CC,O
,the,DT,O
,cardiovascular,JJ,O
,system,NN,O
,.,.,O
,A,DT,O
,frequently,RB,O
,fatal,JJ,O
,",",",",O
,although,IN,O
,exceptionally,RB,O
,rare,JJ,O
,side,NN,O
,effect,NN,O
,of,IN,O
,carbamazepine,NN,O
,is,VBZ,O
,necrotizing,VBG,O
,eosinophilic,JJ,O
,(,(,O
,hypersensitivity,NN,B-DISEASE
,),),O
,myocarditis,NN,B-DISEASE
,.,.,O
,We,PRP,O
,report,VBP,O
,a,DT,O
,case,NN,O
,of,IN,O
,hypersensitivity,NN,B-DISEASE
,myocarditis,NN,B-DISEASE
,secondary,JJ,O
,to,TO,O
,administration,NN,O
,of,IN,O
,carbamazepine,NN,O
,.,.,O
,Acute,NNP,O
,hypersensitivity,NN,B-DISEASE
,myocarditis,NN,B-DISEASE
,was,VBD,O
,not,RB,O
,suspected,VBN,O
,clinically,RB,O
,",",",",O
,and,CC,O
,the,DT,O
,diagnosis,NN,O
,was,VBD,O
,made,VBN,O
,post,NN,O
,-,:,O
,mortem,NN,O
,.,.,O
,Histology,NNP,O
,revealed,VBD,O
,diffuse,JJ,O
,infiltration,NN,O
,of,IN,O
,the,DT,O
,myocardium,NN,O
,by,IN,O
,eosinophils,NNS,O
,and,CC,O
,lymphocytes,VBZ,O
,with,IN,O
,myocyte,JJ,O
,damage,NN,O
,.,.,O
,Clinically,NNP,O
,",",",",O
,death,NN,O
,was,VBD,O
,due,JJ,O
,to,TO,O
,cardiogenic,JJ,B-DISEASE
,shock,NN,I-DISEASE
,.,.,O
,To,TO,O
,best,JJS,O
,of,IN,O
,our,PRP$,O
,knowledge,NN,O
,this,DT,O
,is,VBZ,O
,the,DT,O
,second,JJ,O
,case,NN,O
,of,IN,O
,fatal,JJ,O
,carbamazepine,NN,O
,induced,VBN,O
,myocarditis,NN,B-DISEASE
,reported,VBN,O
,in,IN,O
,English,JJ,O
,literature,NN,O
,.,.,O
,Neuropsychiatric,JJ,O
,behaviors,NNS,O
,in,IN,O
,the,DT,O
,MPTP,NNP,O
,marmoset,VBD,O
,model,NN,O
,of,IN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,OBJECTIVES,CC,O
,:,:,O
,Neuropsychiatric,NN,O
,symptoms,NNS,O
,are,VBP,O
,increasingly,RB,O
,recognised,VBN,O
,as,IN,O
,a,DT,O
,significant,JJ,O
,problem,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,NN,I-DISEASE
,disease,NN,I-DISEASE
,(,(,O
,PD,NNP,B-DISEASE
,),),O
,.,.,O
,These,DT,O
,symptoms,NNS,O
,may,MD,O
,be,VB,O
,due,JJ,O
,to,TO,O
,',POS,O
,sensitisation,NN,O
,','',O
,following,VBG,O
,repeated,VBN,O
,levodopa,JJ,O
,treatment,NN,O
,or,CC,O
,a,DT,O
,direct,JJ,O
,effect,NN,O
,of,IN,O
,dopamine,NN,O
,on,IN,O
,the,DT,O
,disease,NN,O
,state,NN,O
,.,.,O
,The,DT,O
,levodopa,JJ,O
,-,:,O
,treated,VBN,O
,MPTP,NNP,O
,-,:,O
,lesioned,VBD,O
,marmoset,NN,O
,was,VBD,O
,used,VBN,O
,as,IN,O
,a,DT,O
,model,NN,O
,of,IN,O
,neuropsychiatric,JJ,B-DISEASE
,symptoms,NNS,I-DISEASE
,in,IN,O
,PD,NNP,B-DISEASE
,patients,NNS,O
,.,.,O
,Here,RB,O
,we,PRP,O
,compare,VBP,O
,the,DT,O
,time,NN,O
,course,NN,O
,of,IN,O
,levodopa,JJ,O
,-,:,O
,induced,JJ,O
,motor,NN,O
,fluctuations,NNS,O
,and,CC,O
,neuropsychiatric,JJ,B-DISEASE
,-,:,I-DISEASE
,like,IN,I-DISEASE
,behaviors,NNS,I-DISEASE
,to,TO,O
,determine,VB,O
,the,DT,O
,relationship,NN,O
,between,IN,O
,duration,NN,O
,of,IN,O
,treatment,NN,O
,and,CC,O
,onset,NN,O
,of,IN,O
,symptoms,NNS,O
,.,.,O
,METHODS,NN,O
,:,:,O
,Marmosets,NNS,O
,were,VBD,O
,administered,VBN,O
,1,CD,O
,-,:,O
,methyl,NN,O
,-,:,O
,4,CD,O
,-,:,O
,phenyl,NN,O
,-,:,O
,1,CD,O
,",",",",O
,2,CD,O
,",",",",O
,3,CD,O
,",",",",O
,6,CD,O
,-,:,O
,tetrahydropyridine,NN,O
,(,(,O
,2,CD,O
,.,.,O
,0,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,s,NN,O
,.,.,O
,c,NN,O
,.,.,O
,),),O
,for,IN,O
,five,CD,O
,days,NNS,O
,",",",",O
,resulting,VBG,O
,in,IN,O
,stable,JJ,O
,parkinsonism,NN,B-DISEASE
,.,.,O
,Levodopa,NNP,O
,(,(,O
,15,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,and,CC,O
,benserazide,NN,O
,",",",",O
,3,CD,O
,.,.,O
,75,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,),),O
,p,NN,O
,.,.,O
,o,NN,O
,.,.,O
,b,NN,O
,.,.,O
,i,NN,O
,.,.,O
,d,NN,O
,",",",",O
,was,VBD,O
,administered,VBN,O
,for,IN,O
,30,CD,O
,days,NNS,O
,.,.,O
,Animals,NNS,O
,were,VBD,O
,evaluated,VBN,O
,for,IN,O
,parkinsonian,JJ,B-DISEASE
,disability,NN,I-DISEASE
,",",",",O
,dyskinesia,NN,B-DISEASE
,and,CC,O
,on,IN,O
,-,:,O
,time,NN,O
,(,(,O
,motor,JJ,O
,fluctuations,NNS,O
,),),O
,and,CC,O
,neuropsychiatric,JJ,B-DISEASE
,-,:,I-DISEASE
,like,IN,I-DISEASE
,behaviors,NNS,I-DISEASE
,on,IN,O
,Day,NNP,O
,0,CD,O
,(,(,O
,prior,JJ,O
,to,TO,O
,levodopa,VB,O
,),),O
,and,CC,O
,on,IN,O
,Days,NNP,O
,1,CD,O
,",",",",O
,7,CD,O
,",",",",O
,13,CD,O
,",",",",O
,27,CD,O
,and,CC,O
,30,CD,O
,of,IN,O
,treatment,NN,O
,using,VBG,O
,post,NN,O
,hoc,NN,O
,DVD,NNP,O
,analysis,NN,O
,by,IN,O
,a,DT,O
,trained,JJ,O
,rater,NN,O
,",",",",O
,blind,NN,O
,to,TO,O
,the,DT,O
,treatment,NN,O
,day,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,The,DT,O
,neuropsychiatric,JJ,B-DISEASE
,-,:,I-DISEASE
,like,IN,I-DISEASE
,behavior,NN,I-DISEASE
,rating,NN,O
,scale,NN,O
,demonstrated,VBD,O
,high,JJ,O
,interrater,NN,O
,reliability,NN,O
,between,IN,O
,three,CD,O
,trained,VBD,O
,raters,NNS,O
,of,IN,O
,differing,VBG,O
,professional,JJ,O
,backgrounds,NNS,O
,.,.,O
,As,IN,O
,anticipated,JJ,O
,",",",",O
,animals,NNS,O
,exhibited,VBD,O
,a,DT,O
,progressive,JJ,O
,increase,NN,O
,in,IN,O
,levodopa,JJ,O
,-,:,O
,induced,JJ,O
,motor,NN,O
,fluctuations,NNS,O
,",",",",O
,dyskinesia,NN,B-DISEASE
,and,CC,O
,wearing,VBG,O
,-,:,O
,off,NN,O
,",",",",O
,that,WDT,O
,correlated,VBD,O
,with,IN,O
,the,DT,O
,duration,NN,O
,of,IN,O
,levodopa,JJ,O
,therapy,NN,O
,.,.,O
,In,IN,O
,contrast,NN,O
,",",",",O
,levodopa,SYM,O
,-,:,O
,induced,VBN,O
,neuropsychiatric,JJ,B-DISEASE
,-,:,I-DISEASE
,like,IN,I-DISEASE
,behaviors,NNS,I-DISEASE
,were,VBD,O
,present,JJ,O
,on,IN,O
,Day,NNP,O
,1,CD,O
,of,IN,O
,levodopa,NN,O
,treatment,NN,O
,and,CC,O
,their,PRP$,O
,severity,NN,O
,did,VBD,O
,not,RB,O
,correlate,VB,O
,with,IN,O
,duration,NN,O
,of,IN,O
,treatment,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,The,DT,O
,data,NN,O
,suggest,NN,O
,that,IN,O
,neuropsychiatric,JJ,B-DISEASE
,disorders,NNS,I-DISEASE
,in,IN,O
,PD,NNP,B-DISEASE
,are,VBP,O
,more,RBR,O
,likely,JJ,O
,an,DT,O
,interaction,NN,O
,between,IN,O
,levodopa,NN,O
,and,CC,O
,the,DT,O
,disease,NN,O
,state,NN,O
,than,IN,O
,a,DT,O
,consequence,NN,O
,of,IN,O
,sensitisation,NN,O
,to,TO,O
,repeated,VBN,O
,dopaminergic,JJ,O
,therapy,NN,O
,.,.,O
,Contrast,NNP,O
,medium,NN,O
,nephrotoxicity,NN,B-DISEASE
,after,IN,O
,renal,JJ,O
,artery,NN,O
,and,CC,O
,coronary,JJ,O
,angioplasty,NN,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Renal,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,iodinated,JJ,O
,contrast,NN,O
,medium,NN,O
,(,(,O
,CM,NNP,O
,),),O
,administration,NN,O
,can,MD,O
,minimize,VB,O
,the,DT,O
,benefit,NN,O
,of,IN,O
,the,DT,O
,interventional,JJ,O
,procedure,NN,O
,in,IN,O
,patients,NNS,O
,undergoing,JJ,O
,renal,JJ,O
,angioplasty,NN,O
,(,(,O
,PTRA,NNP,O
,),),O
,.,.,O
,PURPOSE,NN,O
,:,:,O
,To,TO,O
,compare,VB,O
,the,DT,O
,susceptibility,NN,O
,to,TO,O
,nephrotoxic,JJ,B-DISEASE
,effect,NN,O
,of,IN,O
,CM,NNP,O
,in,IN,O
,patients,NNS,O
,undergoing,VBG,O
,PTRA,NNP,O
,with,IN,O
,that,DT,O
,of,IN,O
,patients,NNS,O
,submitted,VBN,O
,to,TO,O
,percutaneous,JJ,O
,coronary,JJ,O
,intervention,NN,O
,(,(,O
,PCI,NNP,O
,),),O
,.,.,O
,MATERIAL,NNP,O
,AND,CC,O
,METHODS,NNP,O
,:,:,O
,A,DT,O
,total,NN,O
,of,IN,O
,33,CD,O
,patients,NNS,O
,successfully,RB,O
,treated,VBN,O
,with,IN,O
,PTRA,NNP,O
,(,(,O
,PTRA,NNP,O
,group,NN,O
,",",",",O
,mean,JJ,O
,age,NN,O
,70,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,12,CD,O
,years,NNS,O
,",",",",O
,23,CD,O
,female,NN,O
,",",",",O
,basal,JJ,O
,creatinine,NN,O
,1,CD,O
,.,.,O
,46,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,79,CD,O
,",",",",O
,range,NN,O
,0,CD,O
,.,.,O
,7,CD,O
,-,:,O
,4,CD,O
,.,.,O
,9,CD,O
,mg,JJ,O
,/,NNP,O
,dl,NN,O
,),),O
,were,VBD,O
,compared,VBN,O
,with,IN,O
,33,CD,O
,patients,NNS,O
,undergoing,JJ,O
,successful,JJ,O
,PCI,NNP,O
,(,(,O
,PCI,NNP,O
,group,NN,O
,),),O
,",",",",O
,matched,VBN,O
,for,IN,O
,basal,NN,O
,creatinine,NN,O
,(,(,O
,1,CD,O
,.,.,O
,44,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,6,CD,O
,",",",",O
,range,NN,O
,0,CD,O
,.,.,O
,7,CD,O
,-,:,O
,3,CD,O
,.,.,O
,4,CD,O
,mg,JJ,O
,/,NNP,O
,dl,NN,O
,),),O
,",",",",O
,gender,NN,O
,",",",",O
,and,CC,O
,age,NN,O
,.,.,O
,In,IN,O
,both,DT,O
,groups,NNS,O
,postprocedural,VBP,O
,(,(,O
,48,CD,O
,h,NN,O
,),),O
,serum,NN,O
,creatinine,NN,O
,was,VBD,O
,measured,VBN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Postprocedural,JJ,O
,creatinine,NN,O
,level,NN,O
,decreased,VBD,O
,nonsignificantly,RB,O
,in,IN,O
,the,DT,O
,PTRA,NNP,O
,group,NN,O
,(,(,O
,1,CD,O
,.,.,O
,46,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,8,CD,O
,vs,NN,O
,.,.,O
,1,CD,O
,.,.,O
,34,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,/,NNP,O
,dl,NN,O
,",",",",O
,P,NNP,O
,=,NNP,O
,NS,NNP,O
,),),O
,and,CC,O
,increased,VBN,O
,significantly,RB,O
,in,IN,O
,the,DT,O
,PCI,NNP,O
,group,NN,O
,(,(,O
,1,CD,O
,.,.,O
,44,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,6,CD,O
,vs,NN,O
,.,.,O
,1,CD,O
,.,.,O
,57,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,7,CD,O
,mg,JJ,O
,/,NNP,O
,dl,NN,O
,",",",",O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,02,CD,O
,),),O
,.,.,O
,Changes,NNS,O
,in,IN,O
,serum,NN,O
,creatinine,NN,O
,after,IN,O
,intervention,NN,O
,(,(,O
,after,IN,O
,-,:,O
,before,IN,O
,),),O
,were,VBD,O
,significantly,RB,O
,different,JJ,O
,between,IN,O
,the,DT,O
,PTRA,NNP,O
,and,CC,O
,PCI,NNP,O
,groups,NNS,O
,(,(,O
,-,:,O
,0,CD,O
,.,.,O
,12,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,5,CD,O
,vs,NN,O
,.,.,O
,0,CD,O
,.,.,O
,13,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,3,CD,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,014,CD,O
,),),O
,.,.,O
,This,DT,O
,difference,NN,O
,was,VBD,O
,not,RB,O
,related,VBN,O
,to,TO,O
,either,CC,O
,a,DT,O
,different,JJ,O
,clinical,JJ,O
,risk,NN,O
,profile,NN,O
,or,CC,O
,to,TO,O
,the,DT,O
,volume,NN,O
,of,IN,O
,CM,NNP,O
,administered,VBD,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,In,IN,O
,this,DT,O
,preliminary,JJ,O
,study,NN,O
,patients,NNS,O
,submitted,VBD,O
,to,TO,O
,PTRA,NNP,O
,showed,VBD,O
,a,DT,O
,lower,JJR,O
,susceptibility,NN,O
,to,TO,O
,renal,JJ,B-DISEASE
,damage,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,CM,NNP,O
,administration,NN,O
,than,IN,O
,PCI,NNP,O
,patients,NNS,O
,.,.,O
,The,DT,O
,effectiveness,NN,O
,of,IN,O
,PTRA,NNP,O
,on,IN,O
,renal,JJ,O
,function,NN,O
,seems,VBZ,O
,to,TO,O
,be,VB,O
,barely,RB,O
,influenced,VBN,O
,by,IN,O
,CM,NNP,O
,toxicity,NN,B-DISEASE
,.,.,O
,Diphenhydramine,NNP,O
,prevents,VBZ,O
,the,DT,O
,haemodynamic,JJ,O
,changes,NNS,O
,of,IN,O
,cimetidine,NN,O
,in,IN,O
,ICU,NNP,O
,patients,NNS,O
,.,.,O
,Cimetidine,NNP,O
,",",",",O
,a,DT,O
,histamine,NN,O
,2,CD,O
,(,(,O
,H2,NNP,O
,),),O
,antagonist,NN,O
,",",",",O
,produces,VBZ,O
,a,DT,O
,decrease,NN,O
,in,IN,O
,arterial,JJ,O
,pressure,NN,O
,due,JJ,O
,to,TO,O
,vasodilatation,NN,O
,",",",",O
,especially,RB,O
,in,IN,O
,critically,RB,O
,ill,JJ,O
,patients,NNS,O
,.,.,O
,This,DT,O
,may,MD,O
,be,VB,O
,because,IN,O
,cimetidine,JJ,O
,acts,NNS,O
,as,IN,O
,a,DT,O
,histamine,JJ,O
,agonist,NN,O
,.,.,O
,We,PRP,O
,",",",",O
,therefore,RB,O
,",",",",O
,investigated,VBD,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,the,DT,O
,histamine,NN,O
,1,CD,O
,(,(,O
,H1,NNP,O
,),),O
,receptor,NN,O
,antagonist,NN,O
,",",",",O
,diphenhydramine,NN,O
,",",",",O
,on,IN,O
,the,DT,O
,haemodynamic,JJ,O
,changes,NNS,O
,observed,VBN,O
,after,IN,O
,cimetidine,NN,O
,in,IN,O
,ICU,NNP,O
,patients,NNS,O
,.,.,O
,Each,DT,O
,patient,NN,O
,was,VBD,O
,studied,VBN,O
,on,IN,O
,two,CD,O
,separate,JJ,O
,days,NNS,O
,.,.,O
,In,IN,O
,a,DT,O
,random,JJ,O
,fashion,NN,O
,",",",",O
,they,PRP,O
,received,VBD,O
,cimetidine,JJ,O
,200,CD,O
,mg,NN,O
,iv,NN,O
,on,IN,O
,one,CD,O
,day,NN,O
,",",",",O
,and,CC,O
,on,IN,O
,the,DT,O
,other,JJ,O
,",",",",O
,a,DT,O
,pretreatment,NN,O
,of,IN,O
,diphenhydramine,NN,O
,40,CD,O
,mg,NN,O
,iv,NN,O
,with,IN,O
,cimetidine,JJ,O
,200,CD,O
,mg,NN,O
,iv,NN,O
,.,.,O
,In,IN,O
,the,DT,O
,non,JJ,O
,-,:,O
,pretreatment,NN,O
,group,NN,O
,",",",",O
,mean,VBP,O
,arterial,JJ,O
,pressure,NN,O
,(,(,O
,MAP,NNP,O
,),),O
,decreased,VBD,O
,from,IN,O
,107,CD,O
,.,.,O
,4,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,8,CD,O
,.,.,O
,4,CD,O
,mmHg,NN,O
,to,TO,O
,86,CD,O
,.,.,O
,7,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,11,CD,O
,.,.,O
,4,CD,O
,mmHg,NN,O
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,two,CD,O
,minutes,NNS,O
,after,IN,O
,cimetidine,NN,O
,.,.,O
,Also,RB,O
,",",",",O
,systemic,JJ,O
,vascular,NN,O
,resistance,NN,O
,(,(,O
,SVR,NNP,O
,),),O
,decreased,VBD,O
,during,IN,O
,the,DT,O
,eight,CD,O
,-,:,O
,minute,NN,O
,observation,NN,O
,period,NN,O
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,In,IN,O
,contrast,NN,O
,",",",",O
,in,IN,O
,the,DT,O
,pretreatment,NN,O
,group,NN,O
,",",",",O
,little,JJ,O
,haemodynamic,JJ,O
,change,NN,O
,was,VBD,O
,seen,VBN,O
,.,.,O
,We,PRP,O
,conclude,VBP,O
,that,IN,O
,an,DT,O
,H1,NNP,O
,antagonist,NN,O
,may,MD,O
,be,VB,O
,useful,JJ,O
,in,IN,O
,preventing,VBG,O
,hypotension,NN,B-DISEASE
,caused,VBN,O
,by,IN,O
,iv,JJ,O
,cimetidine,NN,O
,",",",",O
,since,IN,O
,the,DT,O
,vasodilating,NN,O
,activity,NN,O
,of,IN,O
,cimetidine,NN,O
,is,VBZ,O
,mediated,VBN,O
,",",",",O
,in,IN,O
,part,NN,O
,",",",",O
,through,IN,O
,the,DT,O
,H1,NNP,O
,receptor,NN,O
,.,.,O
,Medical,NNP,O
,and,CC,O
,psychiatric,JJ,O
,outcomes,NNS,O
,for,IN,O
,patients,NNS,O
,transplanted,VBN,O
,for,IN,O
,acetaminophen,JJ,O
,-,:,O
,induced,JJ,O
,acute,NN,B-DISEASE
,liver,NN,I-DISEASE
,failure,NN,I-DISEASE
,:,:,O
,a,DT,O
,case,NN,O
,-,:,O
,control,NN,O
,study,NN,O
,.,.,O
,BACKGROUND,NNP,O
,:,:,O
,Acetaminophen,NNP,O
,-,:,O
,induced,JJ,O
,hepatotoxicity,NN,B-DISEASE
,is,VBZ,O
,the,DT,O
,most,RBS,O
,common,JJ,O
,cause,NN,O
,of,IN,O
,acute,JJ,B-DISEASE
,liver,NN,I-DISEASE
,failure,NN,I-DISEASE
,(,(,O
,ALF,NNP,B-DISEASE
,),),O
,in,IN,O
,the,DT,O
,UK,NNP,O
,.,.,O
,Patients,NNS,O
,often,RB,O
,consume,VBP,O
,the,DT,O
,drug,NN,O
,with,IN,O
,suicidal,JJ,O
,intent,NN,O
,or,CC,O
,with,IN,O
,a,DT,O
,background,NN,O
,of,IN,O
,substance,NN,O
,dependence,NN,O
,.,.,O
,AIMS,NNP,O
,AND,CC,O
,METHODS,NNP,O
,:,:,O
,We,PRP,O
,compared,VBN,O
,the,DT,O
,severity,NN,O
,of,IN,O
,pretransplant,JJ,O
,illness,NN,O
,",",",",O
,psychiatric,JJ,O
,co,SYM,O
,-,:,O
,morbidity,NN,O
,",",",",O
,medical,JJ,O
,and,CC,O
,psychosocial,JJ,O
,outcomes,NNS,O
,of,IN,O
,all,DT,O
,patients,NNS,O
,who,WP,O
,had,VBD,O
,undergone,JJ,O
,liver,JJ,O
,transplantation,NN,O
,(,(,O
,LT,NNP,O
,),),O
,emergently,RB,O
,between,IN,O
,1999,CD,O
,-,:,O
,2004,CD,O
,for,IN,O
,acetaminophen,JJ,O
,-,:,O
,induced,JJ,O
,ALF,NNP,B-DISEASE
,(,(,O
,n,JJ,O
,=,NNP,O
,36,CD,O
,),),O
,with,IN,O
,age,NN,O
,-,:,O
,and,CC,O
,sex,NN,O
,-,:,O
,matched,JJ,O
,patients,NNS,O
,undergoing,JJ,O
,emergent,JJ,O
,LT,NNP,O
,for,IN,O
,non,JJ,O
,-,:,O
,acetaminophen,NN,O
,-,:,O
,induced,JJ,O
,ALF,NNP,B-DISEASE
,(,(,O
,n,JJ,O
,=,NNP,O
,35,CD,O
,),),O
,and,CC,O
,elective,JJ,O
,LT,NNP,O
,for,IN,O
,chronic,JJ,B-DISEASE
,liver,NN,I-DISEASE
,disease,NN,I-DISEASE
,(,(,O
,CLD,NNP,B-DISEASE
,",",",",O
,n,JJ,O
,=,NNP,O
,34,CD,O
,),),O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Acetaminophen,NNP,O
,-,:,O
,induced,VBD,O
,ALF,NNP,B-DISEASE
,patients,NNS,O
,undergoing,VBG,O
,LT,NNP,O
,had,VBD,O
,a,DT,O
,greater,JJR,O
,severity,NN,O
,of,IN,O
,pre,JJ,O
,-,:,O
,LT,NNP,O
,illness,NN,O
,reflected,VBN,O
,by,IN,O
,higher,JJR,O
,Acute,NNP,O
,Physiology,NNP,O
,and,CC,O
,Chronic,NNP,O
,Health,NNP,O
,Evaluation,NNP,O
,II,NNP,O
,scores,NNS,O
,and,CC,O
,requirement,NN,O
,for,IN,O
,organ,JJ,O
,support,NN,O
,compared,VBN,O
,with,IN,O
,the,DT,O
,other,JJ,O
,two,CD,O
,groups,NNS,O
,.,.,O
,Twenty,NNP,O
,(,(,O
,56,CD,O
,%,NN,O
,),),O
,acetaminophen,VBZ,O
,-,:,O
,induced,JJ,O
,ALF,NNP,B-DISEASE
,patients,NNS,O
,had,VBD,O
,a,DT,O
,formal,JJ,O
,psychiatric,JJ,O
,diagnosis,NN,O
,before,IN,O
,LT,NNP,O
,(,(,O
,non,SYM,O
,-,:,O
,acetaminophen,NN,O
,-,:,O
,induced,JJ,O
,ALF,NNP,B-DISEASE
,=,NNP,O
,0,CD,O
,/,NNP,O
,35,CD,O
,",",",",O
,CLD,NNP,B-DISEASE
,=,VBZ,O
,2,CD,O
,/,JJ,O
,34,CD,O
,;,:,O
,P,NNP,O
,<,VBD,O
,0,CD,O
,.,.,O
,01,CD,O
,for,IN,O
,all,DT,O
,),),O
,and,CC,O
,nine,CD,O
,(,(,O
,25,CD,O
,%,NN,O
,),),O
,had,VBD,O
,a,DT,O
,previous,JJ,O
,suicide,NN,O
,attempt,NN,O
,.,.,O
,During,IN,O
,follow,JJ,O
,-,:,O
,up,RB,O
,(,(,O
,median,JJ,O
,5,CD,O
,years,NNS,O
,),),O
,",",",",O
,there,EX,O
,were,VBD,O
,no,DT,O
,significant,JJ,O
,differences,NNS,O
,in,IN,O
,rejection,NN,O
,(,(,O
,acute,JJ,O
,and,CC,O
,chronic,JJ,O
,),),O
,",",",",O
,graft,JJ,O
,failure,NN,O
,or,CC,O
,survival,NN,O
,between,IN,O
,the,DT,O
,groups,NNS,O
,(,(,O
,acetaminophen,SYM,O
,-,:,O
,induced,JJ,O
,ALF,NNP,B-DISEASE
,1,CD,O
,year,NN,O
,87,CD,O
,%,NN,O
,",",",",O
,5,CD,O
,years,NNS,O
,75,CD,O
,%,NN,O
,;,:,O
,non,CC,O
,-,:,O
,acetaminophen,NN,O
,-,:,O
,induced,JJ,O
,ALF,NNP,B-DISEASE
,88,CD,O
,%,NN,O
,",",",",O
,78,CD,O
,%,NN,O
,;,:,O
,CLD,NNP,B-DISEASE
,93,CD,O
,%,NN,O
,",",",",O
,82,CD,O
,%,NN,O
,:,:,O
,P,NNP,O
,>,VBZ,O
,0,CD,O
,.,.,O
,6,CD,O
,log,JJ,O
,rank,NN,O
,),),O
,.,.,O
,Two,CD,O
,acetaminophen,JJ,O
,-,:,O
,induced,JJ,O
,ALF,NNP,B-DISEASE
,patients,NNS,O
,reattempted,VBD,O
,suicide,JJ,O
,post,NN,O
,-,:,O
,LT,NNP,O
,(,(,O
,one,CD,O
,died,VBD,O
,8,CD,O
,years,NNS,O
,post,RB,O
,-,:,O
,LT,NN,O
,),),O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Despite,IN,O
,a,DT,O
,high,JJ,O
,prevalence,NN,O
,of,IN,O
,psychiatric,JJ,O
,disturbance,NN,O
,",",",",O
,outcomes,NNS,O
,for,IN,O
,patients,NNS,O
,transplanted,VBN,O
,emergently,RB,O
,for,IN,O
,acetaminophen,JJ,O
,-,:,O
,induced,JJ,O
,ALF,NNP,B-DISEASE
,were,VBD,O
,comparable,JJ,O
,to,TO,O
,those,DT,O
,transplanted,VBN,O
,for,IN,O
,non,JJ,O
,-,:,O
,acetaminophen,NN,O
,-,:,O
,induced,JJ,O
,ALF,NNP,B-DISEASE
,and,CC,O
,electively,RB,O
,for,IN,O
,CLD,NNP,B-DISEASE
,.,.,O
,Multidisciplinary,NNP,O
,approaches,NNS,O
,with,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,psychiatric,JJ,O
,follow,NN,O
,-,:,O
,up,RB,O
,may,MD,O
,contribute,VB,O
,to,TO,O
,low,JJ,O
,post,NN,O
,-,:,O
,transplant,NN,O
,suicide,NN,O
,rates,NNS,O
,seen,VBN,O
,and,CC,O
,low,JJ,O
,rates,NNS,O
,of,IN,O
,graft,NN,O
,loss,NN,O
,because,IN,O
,of,IN,O
,non,JJ,O
,-,:,O
,compliance,NN,O
,.,.,O
,Antithrombotic,JJ,O
,drug,NN,O
,use,NN,O
,",",",",O
,cerebral,JJ,B-DISEASE
,microbleeds,NNS,I-DISEASE
,",",",",O
,and,CC,O
,intracerebral,JJ,B-DISEASE
,hemorrhage,NN,I-DISEASE
,:,:,O
,a,DT,O
,systematic,JJ,O
,review,NN,O
,of,IN,O
,published,VBN,O
,and,CC,O
,unpublished,JJ,O
,studies,NNS,O
,.,.,O
,BACKGROUND,NNP,O
,AND,CC,O
,PURPOSE,NNP,O
,:,:,O
,Cerebral,JJ,B-DISEASE
,microbleeds,NNS,I-DISEASE
,(,(,O
,MB,NNP,B-DISEASE
,),),O
,are,VBP,O
,potential,JJ,O
,risk,NN,O
,factors,NNS,O
,for,IN,O
,intracerebral,JJ,B-DISEASE
,hemorrhage,NN,I-DISEASE
,(,(,O
,ICH,NNP,B-DISEASE
,),),O
,",",",",O
,but,CC,O
,it,PRP,O
,is,VBZ,O
,unclear,JJ,O
,if,IN,O
,they,PRP,O
,are,VBP,O
,a,DT,O
,contraindication,NN,O
,to,TO,O
,using,VBG,O
,antithrombotic,JJ,O
,drugs,NNS,O
,.,.,O
,Insights,NNS,O
,could,MD,O
,be,VB,O
,gained,VBN,O
,by,IN,O
,pooling,VBG,O
,data,NNS,O
,on,IN,O
,MB,NNP,B-DISEASE
,frequency,NN,O
,stratified,VBN,O
,by,IN,O
,antithrombotic,JJ,O
,use,NN,O
,in,IN,O
,cohorts,NNS,O
,with,IN,O
,ICH,NNP,B-DISEASE
,and,CC,O
,ischemic,JJ,B-DISEASE
,stroke,NN,I-DISEASE
,(,(,O
,IS,NNP,B-DISEASE
,),),O
,/,FW,O
,transient,JJ,B-DISEASE
,ischemic,JJ,I-DISEASE
,attack,NN,I-DISEASE
,(,(,O
,TIA,NNP,B-DISEASE
,),),O
,.,.,O
,METHODS,NN,O
,:,:,O
,We,PRP,O
,performed,VBD,O
,a,DT,O
,systematic,JJ,O
,review,NN,O
,of,IN,O
,published,VBN,O
,and,CC,O
,unpublished,JJ,O
,data,NNS,O
,from,IN,O
,cohorts,NNS,O
,with,IN,O
,stroke,NN,B-DISEASE
,or,CC,O
,TIA,NNP,B-DISEASE
,to,TO,O
,compare,VB,O
,the,DT,O
,presence,NN,O
,of,IN,O
,MB,NNP,B-DISEASE
,in,IN,O
,:,:,O
,(,(,O
,1,CD,O
,),),O
,antithrombotic,JJ,O
,users,NNS,O
,vs,VBP,O
,nonantithrombotic,JJ,O
,users,NNS,O
,with,IN,O
,ICH,NNP,B-DISEASE
,;,:,O
,(,(,O
,2,CD,O
,),),O
,antithrombotic,JJ,O
,users,NNS,O
,vs,VBP,O
,nonusers,NNS,O
,with,IN,O
,IS,NNP,B-DISEASE
,/,NNP,O
,TIA,NNP,B-DISEASE
,;,:,O
,and,CC,O
,(,(,O
,3,CD,O
,),),O
,ICH,NNP,B-DISEASE
,vs,VBP,O
,ischemic,JJ,B-DISEASE
,events,NNS,O
,stratified,VBN,O
,by,IN,O
,antithrombotic,JJ,O
,use,NN,O
,.,.,O
,We,PRP,O
,also,RB,O
,analyzed,VBD,O
,published,VBN,O
,and,CC,O
,unpublished,JJ,O
,follow,NN,O
,-,:,O
,up,RB,O
,data,NNS,O
,to,TO,O
,determine,VB,O
,the,DT,O
,risk,NN,O
,of,IN,O
,ICH,NNP,B-DISEASE
,in,IN,O
,antithrombotic,JJ,O
,users,NNS,O
,with,IN,O
,MB,NNP,B-DISEASE
,.,.,O
,RESULTS,NN,O
,:,:,O
,In,IN,O
,a,DT,O
,pooled,JJ,O
,analysis,NN,O
,of,IN,O
,1460,CD,O
,ICH,NNP,B-DISEASE
,and,CC,O
,3817,CD,O
,IS,NNP,B-DISEASE
,/,NNP,O
,TIA,NNP,B-DISEASE
,",",",",O
,MB,NNP,B-DISEASE
,were,VBD,O
,more,RBR,O
,frequent,JJ,O
,in,IN,O
,ICH,NNP,B-DISEASE
,vs,NN,O
,IS,NNP,B-DISEASE
,/,NNP,O
,TIA,NNP,B-DISEASE
,in,IN,O
,all,DT,O
,treatment,NN,O
,groups,NNS,O
,",",",",O
,but,CC,O
,the,DT,O
,excess,JJ,O
,increased,VBD,O
,from,IN,O
,2,CD,O
,.,.,O
,8,CD,O
,(,(,O
,odds,NNS,O
,ratio,VBP,O
,;,:,O
,range,NN,O
,",",",",O
,2,CD,O
,.,.,O
,3,CD,O
,-,:,O
,3,CD,O
,.,.,O
,5,CD,O
,),),O
,in,IN,O
,nonantithrombotic,JJ,O
,users,NNS,O
,to,TO,O
,5,CD,O
,.,.,O
,7,CD,O
,(,(,O
,range,NN,O
,",",",",O
,3,CD,O
,.,.,O
,4,CD,O
,-,:,O
,9,CD,O
,.,.,O
,7,CD,O
,),),O
,in,IN,O
,antiplatelet,NN,O
,users,NNS,O
,and,CC,O
,8,CD,O
,.,.,O
,0,CD,O
,(,(,O
,range,NN,O
,",",",",O
,3,CD,O
,.,.,O
,5,CD,O
,-,:,O
,17,CD,O
,.,.,O
,8,CD,O
,),),O
,in,IN,O
,warfarin,NN,O
,users,NNS,O
,(,(,O
,P,NNP,O
,difference,NN,O
,=,VBD,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,There,EX,O
,was,VBD,O
,also,RB,O
,an,DT,O
,excess,NN,O
,of,IN,O
,MB,NNP,B-DISEASE
,in,IN,O
,warfarin,NN,O
,users,NNS,O
,vs,VBP,O
,nonusers,NNS,O
,with,IN,O
,ICH,NNP,B-DISEASE
,(,(,O
,OR,NNP,O
,",",",",O
,2,CD,O
,.,.,O
,7,CD,O
,;,:,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,",",",",O
,1,CD,O
,.,.,O
,6,CD,O
,-,:,O
,4,CD,O
,.,.,O
,4,CD,O
,;,:,O
,P,NNP,O
,<,VBD,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,but,CC,O
,none,NN,O
,in,IN,O
,warfarin,NN,O
,users,NNS,O
,with,IN,O
,IS,NNP,B-DISEASE
,/,NNP,O
,TIA,NNP,B-DISEASE
,(,(,O
,OR,NNP,O
,",",",",O
,1,CD,O
,.,.,O
,3,CD,O
,;,:,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,",",",",O
,0,CD,O
,.,.,O
,9,CD,O
,-,:,O
,1,CD,O
,.,.,O
,7,CD,O
,;,:,O
,P,NNP,O
,=,VBD,O
,0,CD,O
,.,.,O
,33,CD,O
,;,:,O
,P,NNP,O
,difference,NN,O
,=,VBD,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,There,EX,O
,was,VBD,O
,a,DT,O
,smaller,JJR,O
,excess,NN,O
,of,IN,O
,MB,NNP,B-DISEASE
,in,IN,O
,antiplatelet,NN,O
,users,NNS,O
,vs,VBP,O
,nonusers,NNS,O
,with,IN,O
,ICH,NNP,B-DISEASE
,(,(,O
,OR,NNP,O
,",",",",O
,1,CD,O
,.,.,O
,7,CD,O
,;,:,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,",",",",O
,1,CD,O
,.,.,O
,3,CD,O
,-,:,O
,2,CD,O
,.,.,O
,3,CD,O
,;,:,O
,P,NNP,O
,<,VBD,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,",",",",O
,but,CC,O
,findings,NNS,O
,were,VBD,O
,similar,JJ,O
,for,IN,O
,antiplatelet,NN,O
,users,NNS,O
,with,IN,O
,IS,NNP,B-DISEASE
,/,NNP,O
,TIA,NNP,B-DISEASE
,(,(,O
,OR,NNP,O
,",",",",O
,1,CD,O
,.,.,O
,4,CD,O
,;,:,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,",",",",O
,1,CD,O
,.,.,O
,2,CD,O
,-,:,O
,1,CD,O
,.,.,O
,7,CD,O
,;,:,O
,P,NNP,O
,<,VBD,O
,0,CD,O
,.,.,O
,001,CD,O
,;,:,O
,P,NNP,O
,difference,NN,O
,=,VBD,O
,0,CD,O
,.,.,O
,25,CD,O
,),),O
,.,.,O
,In,IN,O
,pooled,JJ,O
,follow,NN,O
,-,:,O
,up,RB,O
,data,NNS,O
,for,IN,O
,768,CD,O
,antithrombotic,JJ,O
,users,NNS,O
,",",",",O
,presence,NN,O
,of,IN,O
,MB,NNP,B-DISEASE
,at,IN,O
,baseline,NN,O
,was,VBD,O
,associated,VBN,O
,with,IN,O
,a,DT,O
,substantially,RB,O
,increased,VBN,O
,risk,NN,O
,of,IN,O
,subsequent,JJ,O
,ICH,NNP,B-DISEASE
,(,(,O
,OR,NNP,O
,",",",",O
,12,CD,O
,.,.,O
,1,CD,O
,;,:,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,",",",",O
,3,CD,O
,.,.,O
,4,CD,O
,-,:,O
,42,CD,O
,.,.,O
,5,CD,O
,;,:,O
,P,NNP,O
,<,VBD,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,The,DT,O
,excess,NN,O
,of,IN,O
,MB,NNP,B-DISEASE
,in,IN,O
,warfarin,NN,O
,users,NNS,O
,with,IN,O
,ICH,NNP,B-DISEASE
,compared,VBN,O
,to,TO,O
,other,JJ,O
,groups,NNS,O
,suggests,VBZ,O
,that,IN,O
,MB,NNP,B-DISEASE
,increase,VB,O
,the,DT,O
,risk,NN,O
,of,IN,O
,warfarin,JJ,O
,-,:,O
,associated,VBN,O
,ICH,NNP,B-DISEASE
,.,.,O
,Limited,NNP,O
,prospective,JJ,O
,data,NNS,O
,corroborate,NN,O
,these,DT,O
,findings,NNS,O
,",",",",O
,but,CC,O
,larger,JJR,O
,prospective,JJ,O
,studies,NNS,O
,are,VBP,O
,urgently,RB,O
,required,VBN,O
,.,.,O
,Studies,NNS,O
,of,IN,O
,synergy,NN,O
,between,IN,O
,morphine,NN,O
,and,CC,O
,a,DT,O
,novel,JJ,O
,sodium,NN,O
,channel,NN,O
,blocker,NN,O
,",",",",O
,CNSB002,NNP,O
,",",",",O
,in,IN,O
,rat,NN,O
,models,NNS,O
,of,IN,O
,inflammatory,NN,O
,and,CC,O
,neuropathic,JJ,B-DISEASE
,pain,NN,I-DISEASE
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,This,DT,O
,study,NN,O
,determined,VBD,O
,the,DT,O
,antihyperalgesic,JJ,O
,effect,NN,O
,of,IN,O
,CNSB002,NNP,O
,",",",",O
,a,DT,O
,sodium,NN,O
,channel,NN,O
,blocker,NN,O
,with,IN,O
,antioxidant,JJ,O
,properties,NNS,O
,given,VBN,O
,alone,RB,O
,and,CC,O
,in,IN,O
,combinations,NNS,O
,with,IN,O
,morphine,NN,O
,in,IN,O
,rat,NN,O
,models,NNS,O
,of,IN,O
,inflammatory,NN,O
,and,CC,O
,neuropathic,JJ,B-DISEASE
,pain,NN,I-DISEASE
,.,.,O
,DESIGN,NN,O
,:,:,O
,Dose,JJ,O
,response,NN,O
,curves,NNS,O
,for,IN,O
,nonsedating,VBG,O
,doses,NNS,O
,of,IN,O
,morphine,NN,O
,and,CC,O
,CNSB002,NNP,O
,given,VBN,O
,intraperitoneally,RB,O
,alone,RB,O
,and,CC,O
,together,RB,O
,in,IN,O
,combinations,NNS,O
,were,VBD,O
,constructed,VBN,O
,for,IN,O
,antihyperalgesic,JJ,O
,effect,NN,O
,using,VBG,O
,paw,NN,O
,withdrawal,NN,O
,from,IN,O
,noxious,JJ,O
,heat,NN,O
,in,IN,O
,two,CD,O
,rat,NN,O
,pain,NN,B-DISEASE
,models,NNS,O
,:,:,O
,carrageenan,NN,O
,-,:,O
,induced,JJ,O
,paw,NN,O
,inflammation,NN,B-DISEASE
,and,CC,O
,streptozotocin,NN,O
,(,(,O
,STZ,NNP,O
,),),O
,-,:,O
,induced,VBN,O
,diabetic,JJ,B-DISEASE
,neuropathy,NNS,I-DISEASE
,.,.,O
,RESULTS,NN,O
,:,:,O
,The,DT,O
,maximum,JJ,O
,nonsedating,JJ,O
,doses,NNS,O
,were,VBD,O
,:,:,O
,morphine,NN,O
,",",",",O
,3,CD,O
,.,.,O
,2,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,;,:,O
,CNSB002,NNP,O
,10,CD,O
,.,.,O
,0,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,;,:,O
,5,CD,O
,.,.,O
,0,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,CNSB002,NNP,O
,with,IN,O
,morphine,JJ,O
,3,CD,O
,.,.,O
,2,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,in,IN,O
,combination,NN,O
,.,.,O
,The,DT,O
,doses,NNS,O
,calculated,VBD,O
,to,TO,O
,cause,VB,O
,50,CD,O
,%,NN,O
,reversal,NN,O
,of,IN,O
,hyperalgesia,NN,B-DISEASE
,(,(,O
,ED50,NNP,O
,),),O
,were,VBD,O
,7,CD,O
,.,.,O
,54,CD,O
,(,(,O
,1,CD,O
,.,.,O
,81,CD,O
,),),O
,and,CC,O
,4,CD,O
,.,.,O
,83,CD,O
,(,(,O
,1,CD,O
,.,.,O
,54,CD,O
,),),O
,in,IN,O
,the,DT,O
,carrageenan,NN,O
,model,NN,O
,and,CC,O
,44,CD,O
,.,.,O
,18,CD,O
,(,(,O
,1,CD,O
,.,.,O
,37,CD,O
,),),O
,and,CC,O
,9,CD,O
,.,.,O
,14,CD,O
,(,(,O
,1,CD,O
,.,.,O
,24,CD,O
,),),O
,in,IN,O
,the,DT,O
,STZ,NNP,O
,-,:,O
,induced,VBD,O
,neuropathy,JJ,B-DISEASE
,model,NN,O
,for,IN,O
,CNSB002,NNP,O
,and,CC,O
,morphine,NN,O
,",",",",O
,respectively,RB,O
,(,(,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,;,:,O
,mean,CC,O
,",",",",O
,SEM,NNP,O
,),),O
,.,.,O
,These,DT,O
,values,NNS,O
,were,VBD,O
,greater,JJR,O
,than,IN,O
,the,DT,O
,maximum,JJ,O
,nonsedating,JJ,O
,doses,NNS,O
,.,.,O
,The,DT,O
,ED50,NNP,O
,values,NNS,O
,for,IN,O
,morphine,NN,O
,when,WRB,O
,given,VBN,O
,in,IN,O
,combination,NN,O
,with,IN,O
,CNSB002,NNP,O
,(,(,O
,5,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,were,VBD,O
,less,JJR,O
,than,IN,O
,the,DT,O
,maximum,JJ,O
,nonsedating,NN,O
,dose,NN,O
,:,:,O
,0,CD,O
,.,.,O
,56,CD,O
,(,(,O
,1,CD,O
,.,.,O
,55,CD,O
,),),O
,in,IN,O
,the,DT,O
,carrageenan,NN,O
,model,NN,O
,and,CC,O
,1,CD,O
,.,.,O
,37,CD,O
,(,(,O
,1,CD,O
,.,.,O
,23,CD,O
,),),O
,in,IN,O
,the,DT,O
,neuropathy,JJ,B-DISEASE
,model,NN,O
,(,(,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,;,:,O
,mean,CC,O
,",",",",O
,SEM,NNP,O
,),),O
,.,.,O
,The,DT,O
,antinociception,NN,O
,after,IN,O
,morphine,NN,O
,(,(,O
,3,CD,O
,.,.,O
,2,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,),),O
,was,VBD,O
,increased,VBN,O
,by,IN,O
,co,NN,O
,-,:,O
,administration,NN,O
,with,IN,O
,CNSB002,NNP,O
,from,IN,O
,28,CD,O
,.,.,O
,0,CD,O
,and,CC,O
,31,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,to,TO,O
,114,CD,O
,.,.,O
,6,CD,O
,and,CC,O
,56,CD,O
,.,.,O
,9,CD,O
,%,NN,O
,reversal,NN,O
,of,IN,O
,hyperalgesia,NN,B-DISEASE
,in,IN,O
,the,DT,O
,inflammatory,NN,O
,and,CC,O
,neuropathic,JJ,B-DISEASE
,models,NNS,O
,",",",",O
,respectively,RB,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,01,CD,O
,;,:,O
,one,CD,O
,-,:,O
,way,NN,O
,analysis,NN,O
,of,IN,O
,variance,NN,O
,-,:,O
,significantly,RB,O
,greater,JJR,O
,than,IN,O
,either,DT,O
,drug,NN,O
,given,VBN,O
,alone,RB,O
,),),O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,The,DT,O
,maximum,JJ,O
,antihyperalgesic,JJ,O
,effect,NN,O
,achievable,JJ,O
,with,IN,O
,nonsedating,JJ,O
,doses,NNS,O
,of,IN,O
,morphine,NN,O
,may,MD,O
,be,VB,O
,increased,VBN,O
,significantly,RB,O
,when,WRB,O
,the,DT,O
,drug,NN,O
,is,VBZ,O
,used,VBN,O
,in,IN,O
,combination,NN,O
,with,IN,O
,CNSB002,NNP,O
,.,.,O
,Heparin,NNP,O
,-,:,O
,induced,VBD,O
,thrombocytopenia,NN,B-DISEASE
,:,:,O
,a,DT,O
,practical,JJ,O
,review,NN,O
,.,.,O
,Heparin,NNP,O
,-,:,O
,induced,VBN,O
,thrombocytopenia,NN,B-DISEASE
,(,(,O
,HIT,NNP,B-DISEASE
,),),O
,remains,VBZ,O
,under,IN,O
,-,:,O
,recognized,VBN,O
,despite,IN,O
,its,PRP$,O
,potentially,RB,O
,devastating,JJ,O
,outcomes,NNS,O
,.,.,O
,It,PRP,O
,begins,VBZ,O
,when,WRB,O
,heparin,JJ,O
,exposure,NN,O
,stimulates,VBZ,O
,the,DT,O
,formation,NN,O
,of,IN,O
,heparin,JJ,O
,-,:,O
,platelet,NN,O
,factor,NN,O
,4,CD,O
,antibodies,NNS,O
,",",",",O
,which,WDT,O
,in,IN,O
,turn,NN,O
,triggers,VBZ,O
,the,DT,O
,release,NN,O
,of,IN,O
,procoagulant,JJ,O
,platelet,NN,O
,particles,NNS,O
,.,.,O
,Thrombosis,NN,B-DISEASE
,and,CC,O
,thrombocytopenia,NN,B-DISEASE
,that,IN,O
,follow,JJ,O
,comprise,VB,O
,the,DT,O
,2,CD,O
,hallmark,NN,O
,traits,NNS,O
,of,IN,O
,HIT,NNP,B-DISEASE
,",",",",O
,with,IN,O
,the,DT,O
,former,JJ,O
,largely,RB,O
,responsible,JJ,O
,for,IN,O
,significant,JJ,O
,vascular,JJ,O
,complications,NNS,O
,.,.,O
,The,DT,O
,prevalence,NN,O
,of,IN,O
,HIT,NNP,B-DISEASE
,varies,NNS,O
,among,IN,O
,several,JJ,O
,subgroups,NNS,O
,",",",",O
,with,IN,O
,greater,JJR,O
,incidence,NN,O
,in,IN,O
,surgical,JJ,O
,as,IN,O
,compared,VBN,O
,with,IN,O
,medical,JJ,O
,populations,NNS,O
,.,.,O
,HIT,NNP,B-DISEASE
,must,MD,O
,be,VB,O
,acknowledged,VBN,O
,for,IN,O
,its,PRP$,O
,intense,JJ,O
,predilection,NN,O
,for,IN,O
,thrombosis,NN,B-DISEASE
,and,CC,O
,suspected,VBD,O
,whenever,WRB,O
,thrombosis,NN,B-DISEASE
,occurs,VBZ,O
,after,IN,O
,heparin,NN,O
,exposure,NN,O
,.,.,O
,Early,JJ,O
,recognition,NN,O
,that,WDT,O
,incorporates,VBZ,O
,the,DT,O
,clinical,JJ,O
,and,CC,O
,serologic,JJ,O
,clues,NNS,O
,is,VBZ,O
,paramount,JJ,O
,to,TO,O
,timely,JJ,O
,institution,NN,O
,of,IN,O
,treatment,NN,O
,",",",",O
,as,IN,O
,its,PRP$,O
,delay,NN,O
,may,MD,O
,result,VB,O
,in,IN,O
,catastrophic,JJ,O
,outcomes,NNS,O
,.,.,O
,The,DT,O
,treatment,NN,O
,of,IN,O
,HIT,NNP,B-DISEASE
,mandates,VBZ,O
,an,DT,O
,immediate,JJ,O
,cessation,NN,O
,of,IN,O
,all,DT,O
,heparin,NN,O
,exposure,NN,O
,and,CC,O
,the,DT,O
,institution,NN,O
,of,IN,O
,an,DT,O
,antithrombotic,JJ,O
,therapy,NN,O
,",",",",O
,most,RBS,O
,commonly,RB,O
,using,VBG,O
,a,DT,O
,direct,JJ,O
,thrombin,NN,O
,inhibitor,NN,O
,.,.,O
,Current,NNP,O
,"""",NNP,O
,diagnostic,JJ,O
,"""",NN,O
,tests,NNS,O
,",",",",O
,which,WDT,O
,primarily,RB,O
,include,VBP,O
,functional,JJ,O
,and,CC,O
,antigenic,JJ,O
,assays,NNS,O
,",",",",O
,have,VBP,O
,more,JJR,O
,of,IN,O
,a,DT,O
,confirmatory,NN,O
,than,IN,O
,diagnostic,JJ,O
,role,NN,O
,in,IN,O
,the,DT,O
,management,NN,O
,of,IN,O
,HIT,NNP,B-DISEASE
,.,.,O
,Special,JJ,O
,attention,NN,O
,must,MD,O
,be,VB,O
,paid,VBN,O
,to,TO,O
,cardiac,JJ,O
,patients,NNS,O
,who,WP,O
,are,VBP,O
,often,RB,O
,exposed,VBN,O
,to,TO,O
,heparin,VB,O
,multiple,JJ,O
,times,NNS,O
,during,IN,O
,their,PRP$,O
,course,NN,O
,of,IN,O
,treatment,NN,O
,.,.,O
,Direct,NNP,O
,thrombin,NN,O
,inhibitors,NNS,O
,are,VBP,O
,appropriate,JJ,O
,",",",",O
,evidence,NN,O
,-,:,O
,based,VBN,O
,alternatives,NNS,O
,to,TO,O
,heparin,VB,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,a,DT,O
,history,NN,O
,of,IN,O
,HIT,NNP,B-DISEASE
,",",",",O
,who,WP,O
,need,VBP,O
,to,TO,O
,undergo,VB,O
,percutaneous,JJ,O
,coronary,JJ,O
,intervention,NN,O
,.,.,O
,As,IN,O
,heparin,NN,O
,remains,VBZ,O
,one,CD,O
,of,IN,O
,the,DT,O
,most,RBS,O
,frequently,RB,O
,used,VBN,O
,medications,NNS,O
,today,NN,O
,with,IN,O
,potential,JJ,O
,for,IN,O
,HIT,NNP,B-DISEASE
,with,IN,O
,every,DT,O
,heparin,NN,O
,exposure,NN,O
,",",",",O
,a,DT,O
,close,JJ,O
,vigilance,NN,O
,of,IN,O
,platelet,NN,O
,counts,NNS,O
,must,MD,O
,be,VB,O
,practiced,VBN,O
,whenever,WRB,O
,heparin,NN,O
,is,VBZ,O
,initiated,VBN,O
,.,.,O
,Abductor,NNP,O
,paralysis,NN,B-DISEASE
,after,IN,O
,botox,JJ,O
,injection,NN,O
,for,IN,O
,adductor,NN,B-DISEASE
,spasmodic,JJ,I-DISEASE
,dysphonia,NN,I-DISEASE
,.,.,O
,OBJECTIVES,NNP,O
,/,JJ,O
,HYPOTHESIS,NNP,O
,:,:,O
,Botulinum,NNP,O
,toxin,NN,O
,(,(,O
,Botox,NNP,O
,),),O
,injections,NNS,O
,into,IN,O
,the,DT,O
,thyroarytenoid,NN,O
,muscles,NNS,O
,are,VBP,O
,the,DT,O
,current,JJ,O
,standard,NN,O
,of,IN,O
,care,NN,O
,for,IN,O
,adductor,NN,B-DISEASE
,spasmodic,JJ,I-DISEASE
,dysphonia,NN,I-DISEASE
,(,(,O
,ADSD,NNP,B-DISEASE
,),),O
,.,.,O
,Reported,VBN,O
,adverse,JJ,O
,effects,NNS,O
,include,VBP,O
,a,DT,O
,period,NN,O
,of,IN,O
,breathiness,NN,O
,",",",",O
,throat,NN,B-DISEASE
,pain,NN,I-DISEASE
,",",",",O
,and,CC,O
,difficulty,NN,O
,with,IN,O
,swallowing,VBG,O
,liquids,NNS,O
,.,.,O
,Here,RB,O
,we,PRP,O
,report,VBP,O
,multiple,JJ,O
,cases,NNS,O
,of,IN,O
,bilateral,JJ,O
,abductor,NN,O
,paralysis,NN,B-DISEASE
,following,VBG,O
,Botox,NNP,O
,injections,NNS,O
,for,IN,O
,ADSD,NNP,B-DISEASE
,",",",",O
,a,DT,O
,complication,NN,O
,previously,RB,O
,unreported,VBN,O
,.,.,O
,STUDY,NNP,O
,DESIGN,NNP,O
,:,:,O
,Retrospective,JJ,O
,case,NN,O
,series,NN,O
,.,.,O
,METHODS,NNP,O
,:,:,O
,Patients,NNS,O
,that,WDT,O
,received,VBD,O
,Botox,NNP,O
,injections,NNS,O
,for,IN,O
,spasmodic,JJ,B-DISEASE
,dysphonia,NN,I-DISEASE
,between,IN,O
,January,NNP,O
,2000,CD,O
,and,CC,O
,October,NNP,O
,2009,CD,O
,were,VBD,O
,evaluated,VBN,O
,.,.,O
,Patients,NNS,O
,with,IN,O
,ADSD,NNP,B-DISEASE
,were,VBD,O
,identified,VBN,O
,.,.,O
,The,DT,O
,number,NN,O
,of,IN,O
,treatments,NNS,O
,received,VBN,O
,and,CC,O
,adverse,JJ,O
,effects,NNS,O
,were,VBD,O
,noted,VBN,O
,.,.,O
,For,IN,O
,patients,NNS,O
,with,IN,O
,bilateral,JJ,O
,abductor,NN,O
,paralysis,NN,B-DISEASE
,",",",",O
,age,NN,O
,",",",",O
,sex,NN,O
,",",",",O
,paralytic,JJ,O
,Botox,NNP,O
,dose,NN,O
,",",",",O
,prior,JJ,O
,Botox,NNP,O
,dose,NN,O
,",",",",O
,and,CC,O
,course,NN,O
,following,VBG,O
,paralysis,NN,B-DISEASE
,were,VBD,O
,noted,VBN,O
,.,.,O
,RESULTS,NNS,O
,:,:,O
,From,IN,O
,a,DT,O
,database,NN,O
,of,IN,O
,452,CD,O
,patients,NNS,O
,receiving,VBG,O
,Botox,NNP,O
,",",",",O
,352,CD,O
,patients,NNS,O
,had,VBD,O
,been,VBN,O
,diagnosed,VBN,O
,with,IN,O
,ADSD,NNP,B-DISEASE
,.,.,O
,Of,IN,O
,these,DT,O
,352,CD,O
,patients,NNS,O
,",",",",O
,eight,CD,O
,patients,NNS,O
,suffered,VBD,O
,bilateral,JJ,O
,abductor,NN,O
,paralysis,NN,B-DISEASE
,",",",",O
,and,CC,O
,two,CD,O
,suffered,VBD,O
,this,DT,O
,complication,NN,O
,twice,RB,O
,.,.,O
,All,DT,O
,affected,JJ,O
,patients,NNS,O
,were,VBD,O
,females,NNS,O
,over,IN,O
,the,DT,O
,age,NN,O
,of,IN,O
,50,CD,O
,years,NNS,O
,.,.,O
,Most,JJS,O
,patients,NNS,O
,had,VBD,O
,received,VBN,O
,treatments,NNS,O
,prior,RB,O
,to,TO,O
,abductor,VB,O
,paralysis,NN,B-DISEASE
,and,CC,O
,continued,VBD,O
,receiving,VBG,O
,after,IN,O
,paralysis,NN,B-DISEASE
,.,.,O
,Seven,CD,O
,patients,NNS,O
,recovered,VBN,O
,after,IN,O
,a,DT,O
,brief,JJ,O
,period,NN,O
,of,IN,O
,activity,NN,O
,restrictions,NNS,O
,",",",",O
,and,CC,O
,one,CD,O
,underwent,NN,O
,a,DT,O
,tracheotomy,NN,O
,.,.,O
,The,DT,O
,incidence,NN,O
,of,IN,O
,abductor,NN,O
,paralysis,NN,B-DISEASE
,after,IN,O
,Botox,NNP,O
,injection,NN,O
,for,IN,O
,ADSD,NNP,B-DISEASE
,was,VBD,O
,0,CD,O
,.,.,O
,34,CD,O
,%,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Bilateral,NNP,O
,abductor,NN,O
,paralysis,NN,B-DISEASE
,is,VBZ,O
,a,DT,O
,rare,JJ,O
,complication,NN,O
,of,IN,O
,Botox,NNP,O
,injections,NNS,O
,for,IN,O
,ADSD,NNP,B-DISEASE
,",",",",O
,causing,VBG,O
,difficulty,NN,O
,with,IN,O
,breathing,VBG,O
,upon,IN,O
,exertion,NN,O
,.,.,O
,The,DT,O
,likely,JJ,O
,mechanism,NN,O
,of,IN,O
,paralysis,NN,B-DISEASE
,is,VBZ,O
,diffusion,NN,O
,of,IN,O
,Botox,NNP,O
,around,IN,O
,the,DT,O
,muscular,JJ,O
,process,NN,O
,of,IN,O
,the,DT,O
,arytenoid,NN,O
,to,TO,O
,the,DT,O
,posterior,JJ,O
,cricoarytenoid,NN,O
,muscles,NNS,O
,.,.,O
,The,DT,O
,paralysis,NN,B-DISEASE
,is,VBZ,O
,temporary,JJ,O
,",",",",O
,and,CC,O
,watchful,JJ,O
,waiting,VBG,O
,with,IN,O
,restriction,NN,O
,of,IN,O
,activity,NN,O
,is,VBZ,O
,the,DT,O
,recommended,JJ,O
,management,NN,O
,.,.,O
,Mitochondrial,JJ,B-DISEASE
,impairment,NN,I-DISEASE
,contributes,NNS,O
,to,TO,O
,cocaine,VB,O
,-,:,O
,induced,JJ,O
,cardiac,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,:,:,O
,Prevention,NN,O
,by,IN,O
,the,DT,O
,targeted,JJ,O
,antioxidant,JJ,O
,MitoQ,NNP,O
,.,.,O
,The,DT,O
,goal,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,was,VBD,O
,to,TO,O
,assess,VB,O
,mitochondrial,JJ,O
,function,NN,O
,and,CC,O
,ROS,NNP,O
,production,NN,O
,in,IN,O
,an,DT,O
,experimental,JJ,O
,model,NN,O
,of,IN,O
,cocaine,NN,O
,-,:,O
,induced,JJ,O
,cardiac,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,.,.,O
,We,PRP,O
,hypothesized,VBD,O
,that,IN,O
,cocaine,NN,B-DISEASE
,abuse,NN,I-DISEASE
,may,MD,O
,lead,VB,O
,to,TO,O
,altered,JJ,O
,mitochondrial,JJ,O
,function,NN,O
,that,IN,O
,in,IN,O
,turn,NN,O
,may,MD,O
,cause,VB,O
,left,VBD,B-DISEASE
,ventricular,JJ,I-DISEASE
,dysfunction,NN,I-DISEASE
,.,.,O
,Seven,NNP,O
,days,NNS,O
,of,IN,O
,cocaine,JJ,O
,administration,NN,O
,to,TO,O
,rats,VB,O
,led,VBN,O
,to,TO,O
,an,DT,O
,increased,VBN,O
,oxygen,NN,O
,consumption,NN,O
,detected,VBN,O
,in,IN,O
,cardiac,JJ,O
,fibers,NNS,O
,",",",",O
,specifically,RB,O
,through,IN,O
,complex,JJ,O
,I,PRP,O
,and,CC,O
,complex,JJ,O
,III,NNP,O
,.,.,O
,ROS,NNP,O
,levels,NNS,O
,were,VBD,O
,increased,VBN,O
,",",",",O
,specifically,RB,O
,in,IN,O
,interfibrillar,JJ,O
,mitochondria,NN,O
,.,.,O
,In,IN,O
,parallel,NN,O
,there,EX,O
,was,VBD,O
,a,DT,O
,decrease,NN,O
,in,IN,O
,ATP,NNP,O
,synthesis,NN,O
,",",",",O
,whereas,IN,O
,no,DT,O
,difference,NN,O
,was,VBD,O
,observed,VBN,O
,in,IN,O
,subsarcolemmal,JJ,O
,mitochondria,NN,O
,.,.,O
,This,DT,O
,uncoupling,JJ,O
,effect,NN,O
,on,IN,O
,oxidative,JJ,O
,phosphorylation,NN,O
,was,VBD,O
,not,RB,O
,detectable,JJ,O
,after,IN,O
,short,JJ,O
,-,:,O
,term,NN,O
,exposure,NN,O
,to,TO,O
,cocaine,VB,O
,",",",",O
,suggesting,VBG,O
,that,IN,O
,these,DT,O
,mitochondrial,JJ,B-DISEASE
,abnormalities,NNS,I-DISEASE
,were,VBD,O
,a,DT,O
,late,JJ,O
,rather,RB,O
,than,IN,O
,a,DT,O
,primary,JJ,O
,event,NN,O
,in,IN,O
,the,DT,O
,pathological,JJ,O
,response,NN,O
,to,TO,O
,cocaine,VB,O
,.,.,O
,MitoQ,NNP,O
,",",",",O
,a,DT,O
,mitochondrial,JJ,O
,-,:,O
,targeted,VBN,O
,antioxidant,NN,O
,",",",",O
,was,VBD,O
,shown,VBN,O
,to,TO,O
,completely,RB,O
,prevent,VB,O
,these,DT,O
,mitochondrial,JJ,B-DISEASE
,abnormalities,NNS,I-DISEASE
,as,RB,O
,well,RB,O
,as,IN,O
,cardiac,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,characterized,VBN,O
,here,RB,O
,by,IN,O
,a,DT,O
,diastolic,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,studied,VBN,O
,with,IN,O
,a,DT,O
,conductance,NN,O
,catheter,NN,O
,to,TO,O
,obtain,VB,O
,pressure,NN,O
,-,:,O
,volume,NN,O
,data,NNS,O
,.,.,O
,Taken,NNP,O
,together,RB,O
,",",",",O
,these,DT,O
,results,NNS,O
,extend,VBP,O
,previous,JJ,O
,studies,NNS,O
,and,CC,O
,demonstrate,VB,O
,that,DT,O
,cocaine,NN,O
,-,:,O
,induced,JJ,O
,cardiac,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,may,MD,O
,be,VB,O
,due,JJ,O
,to,TO,O
,a,DT,O
,mitochondrial,JJ,B-DISEASE
,defect,NN,I-DISEASE
,.,.,O
,Trimethoprim,NNP,O
,-,:,O
,induced,VBD,O
,immune,JJ,O
,hemolytic,JJ,B-DISEASE
,anemia,NN,I-DISEASE
,in,IN,O
,a,DT,O
,pediatric,JJ,O
,oncology,NN,O
,patient,NN,O
,presenting,VBG,O
,as,IN,O
,an,DT,O
,acute,JJ,O
,hemolytic,JJ,O
,transfusion,NN,O
,reaction,NN,O
,.,.,O
,A,DT,O
,10,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,male,NN,O
,with,IN,O
,acute,JJ,B-DISEASE
,leukemia,NN,I-DISEASE
,presented,VBN,O
,with,IN,O
,post,NN,O
,-,:,O
,chemotherapy,NN,O
,anemia,NN,B-DISEASE
,.,.,O
,During,IN,O
,red,JJ,O
,cell,NN,O
,transfusion,NN,O
,",",",",O
,he,PRP,O
,developed,VBD,O
,hemoglobinuria,NN,B-DISEASE
,.,.,O
,Transfusion,NNP,O
,reaction,NN,O
,workup,NN,O
,was,VBD,O
,negative,JJ,O
,.,.,O
,Drug,NNP,O
,-,:,O
,induced,VBN,O
,immune,JJ,O
,hemolytic,JJ,B-DISEASE
,anemia,NN,I-DISEASE
,was,VBD,O
,suspected,VBN,O
,because,IN,O
,of,IN,O
,positive,JJ,O
,direct,JJ,O
,antiglobulin,NN,O
,test,NN,O
,",",",",O
,negative,JJ,O
,eluate,NN,O
,",",",",O
,and,CC,O
,microspherocytes,NNS,O
,on,IN,O
,smear,JJ,O
,pre,NN,O
,-,:,O
,and,CC,O
,post,VB,O
,-,:,O
,transfusion,NN,O
,.,.,O
,Drug,NNP,O
,studies,NNS,O
,using,VBG,O
,the,DT,O
,indirect,JJ,O
,antiglobulin,NN,O
,test,NN,O
,were,VBD,O
,strongly,RB,O
,positive,JJ,O
,with,IN,O
,trimethoprim,JJ,O
,and,CC,O
,trimethoprim,JJ,O
,-,:,O
,sulfamethoxazole,NN,O
,but,CC,O
,negative,JJ,O
,with,IN,O
,sulfamethoxazole,NN,O
,.,.,O
,The,DT,O
,patient,NN,O
,recovered,VBD,O
,after,IN,O
,discontinuing,VBG,O
,the,DT,O
,drug,NN,O
,",",",",O
,with,IN,O
,no,DT,O
,recurrence,NN,O
,in,IN,O
,2,CD,O
,years,NNS,O
,.,.,O
,Other,JJ,O
,causes,NNS,O
,of,IN,O
,anemia,NN,B-DISEASE
,should,MD,O
,be,VB,O
,considered,VBN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,worse,JJR,O
,-,:,O
,than,IN,O
,-,:,O
,expected,VBN,O
,anemia,NN,B-DISEASE
,after,IN,O
,chemotherapy,NN,O
,.,.,O
,Furthermore,NNP,O
,",",",",O
,hemolysis,NN,B-DISEASE
,during,IN,O
,transfusion,NN,O
,is,VBZ,O
,not,RB,O
,always,RB,O
,a,DT,O
,transfusion,NN,O
,reaction,NN,O
,.,.,O
,Verapamil,NNP,O
,stimulation,NN,O
,test,NN,O
,in,IN,O
,hyperprolactinemia,NN,B-DISEASE
,:,:,O
,loss,NN,O
,of,IN,O
,prolactin,JJ,O
,response,NN,O
,in,IN,O
,anatomic,JJ,O
,or,CC,O
,functional,JJ,O
,stalk,NN,O
,effect,NN,O
,.,.,O
,AIM,NN,O
,:,:,O
,Verapamil,NNP,O
,stimulation,NN,O
,test,NN,O
,was,VBD,O
,previously,RB,O
,investigated,VBN,O
,as,IN,O
,a,DT,O
,tool,NN,O
,for,IN,O
,differential,JJ,O
,diagnosis,NN,O
,of,IN,O
,hyperprolactinemia,NN,B-DISEASE
,",",",",O
,but,CC,O
,with,IN,O
,conflicting,JJ,O
,results,NNS,O
,.,.,O
,Macroprolactinemia,NNP,B-DISEASE
,was,VBD,O
,never,RB,O
,considered,VBN,O
,in,IN,O
,those,DT,O
,previous,JJ,O
,studies,NNS,O
,.,.,O
,Here,RB,O
,",",",",O
,we,PRP,O
,aimed,VBD,O
,to,TO,O
,re,VB,O
,-,:,O
,investigate,VB,O
,the,DT,O
,diagnostic,JJ,O
,value,NN,O
,of,IN,O
,verapamil,NN,O
,in,IN,O
,a,DT,O
,population,NN,O
,who,WP,O
,were,VBD,O
,all,DT,O
,screened,VBN,O
,for,IN,O
,macroprolactinemia,NN,B-DISEASE
,.,.,O
,Prolactin,NNP,O
,responses,VBZ,O
,to,TO,O
,verapamil,VB,O
,in,IN,O
,65,CD,O
,female,JJ,O
,patients,NNS,O
,(,(,O
,age,NN,O
,:,:,O
,29,CD,O
,.,.,O
,9,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,8,CD,O
,.,.,O
,1,CD,O
,years,NNS,O
,),),O
,with,IN,O
,hyperprolactinemia,NN,B-DISEASE
,were,VBD,O
,tested,VBN,O
,in,IN,O
,a,DT,O
,descriptive,JJ,O
,",",",",O
,matched,VBD,O
,case,NN,O
,-,:,O
,control,NN,O
,study,NN,O
,.,.,O
,METHODS,NNP,O
,:,:,O
,Verapamil,NNP,O
,80,CD,O
,mg,NN,O
,",",",",O
,p,NN,O
,.,.,O
,o,NN,O
,.,.,O
,was,VBD,O
,administered,VBN,O
,",",",",O
,and,CC,O
,then,RB,O
,PRL,NNP,O
,levels,NNS,O
,were,VBD,O
,measured,VBN,O
,at,IN,O
,8th,CD,O
,and,CC,O
,16th,CD,O
,hours,NNS,O
,",",",",O
,by,IN,O
,immunometric,JJ,O
,chemiluminescence,NN,O
,.,.,O
,Verapamil,NNP,O
,responsiveness,NN,O
,was,VBD,O
,determined,VBN,O
,by,IN,O
,peak,JJ,O
,percent,NN,O
,change,NN,O
,in,IN,O
,basal,NN,O
,prolactin,NN,O
,levels,NNS,O
,(,(,O
,PRL,NNP,O
,),),O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Verapamil,NNP,O
,significantly,RB,O
,increased,VBD,O
,PRL,NNP,O
,levels,NNS,O
,in,IN,O
,healthy,JJ,O
,controls,NNS,O
,(,(,O
,N,NNP,O
,.,.,O
,8,CD,O
,",",",",O
,PRL,NNP,O
,:,:,O
,183,CD,O
,%,NN,O
,),),O
,",",",",O
,macroprolactinoma,FW,B-DISEASE
,(,(,O
,N,NNP,O
,.,.,O
,8,CD,O
,",",",",O
,PRL,NNP,O
,:,:,O
,7,CD,O
,%,NN,O
,),),O
,",",",",O
,microprolactinoma,FW,B-DISEASE
,(,(,O
,N,NNP,O
,.,.,O
,19,CD,O
,",",",",O
,PRL,NNP,O
,:,:,O
,21,CD,O
,%,NN,O
,),),O
,",",",",O
,macroprolactinemia,FW,B-DISEASE
,(,(,O
,N,NNP,O
,.,.,O
,23,CD,O
,",",",",O
,PRL,NNP,O
,:,:,O
,126,CD,O
,%,NN,O
,),),O
,",",",",O
,but,CC,O
,not,RB,O
,in,IN,O
,pseudoprolactinoma,NN,B-DISEASE
,(,(,O
,N,NNP,O
,.,.,O
,8,CD,O
,",",",",O
,PRL,NNP,O
,:,:,O
,0,CD,O
,.,.,O
,8,CD,O
,%,NN,O
,),),O
,",",",",O
,and,CC,O
,risperidone,SYM,O
,-,:,O
,induced,VBN,O
,hyperprolactinemia,NN,B-DISEASE
,(,(,O
,N,NNP,O
,.,.,O
,7,CD,O
,",",",",O
,PRL,NNP,O
,:,:,O
,3,CD,O
,%,NN,O
,),),O
,.,.,O
,ROC,NNP,O
,curve,NN,O
,analysis,NN,O
,revealed,VBD,O
,that,IN,O
,unresponsiveness,NN,O
,to,TO,O
,verapamil,VB,O
,defined,VBN,O
,as,IN,O
,PRL,NNP,O
,<,VBD,O
,7,CD,O
,%,NN,O
,",",",",O
,discriminated,JJ,O
,anatomical,JJ,O
,or,CC,O
,functional,JJ,O
,stalk,NN,O
,effect,NN,O
,(,(,O
,sensitivity,NN,O
,:,:,O
,74,CD,O
,%,NN,O
,",",",",O
,specificity,NN,O
,:,:,O
,73,CD,O
,%,NN,O
,",",",",O
,AUC,NNP,O
,:,:,O
,0,CD,O
,.,.,O
,855,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,04,CD,O
,",",",",O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,001,CD,O
,",",",",O
,CI,NNP,O
,:,:,O
,0,CD,O
,.,.,O
,768,CD,O
,-,:,O
,0,CD,O
,.,.,O
,942,CD,O
,),),O
,associated,VBN,O
,with,IN,O
,pseudoprolactinoma,NN,B-DISEASE
,or,CC,O
,risperidone,NN,O
,-,:,O
,induced,JJ,O
,hyperprolactinemia,NN,B-DISEASE
,",",",",O
,respectively,RB,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Verapamil,NNP,O
,responsiveness,NN,O
,is,VBZ,O
,not,RB,O
,a,DT,O
,reliable,JJ,O
,finding,NN,O
,for,IN,O
,the,DT,O
,differential,JJ,O
,diagnosis,NN,O
,of,IN,O
,hyperprolactinemia,NN,B-DISEASE
,.,.,O
,However,RB,O
,",",",",O
,verapamil,JJ,O
,unresponsiveness,JJ,O
,discriminates,NNS,O
,stalk,VBP,O
,effect,NN,O
,(,(,O
,i,NN,O
,.,.,O
,e,NN,O
,.,.,O
,",",",",O
,anatomically,RB,O
,or,CC,O
,functionally,RB,O
,inhibited,JJ,O
,dopaminergic,JJ,O
,tonus,NN,O
,),),O
,from,IN,O
,other,JJ,O
,causes,NNS,O
,of,IN,O
,hyperprolactinemia,NN,B-DISEASE
,with,IN,O
,varying,VBG,O
,degrees,NNS,O
,of,IN,O
,responsiveness,NN,O
,.,.,O
,Blockade,NNP,O
,of,IN,O
,endothelial,JJ,O
,-,:,O
,mesenchymal,JJ,O
,transition,NN,O
,by,IN,O
,a,DT,O
,Smad3,NNP,O
,inhibitor,NN,O
,delays,VBZ,O
,the,DT,O
,early,JJ,O
,development,NN,O
,of,IN,O
,streptozotocin,JJ,O
,-,:,O
,induced,VBN,O
,diabetic,JJ,B-DISEASE
,nephropathy,NN,I-DISEASE
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,A,DT,O
,multicenter,NN,O
,",",",",O
,controlled,VBN,O
,trial,NN,O
,showed,VBD,O
,that,IN,O
,early,JJ,O
,blockade,NN,O
,of,IN,O
,the,DT,O
,renin,NN,O
,-,:,O
,angiotensin,NN,O
,system,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,type,JJ,B-DISEASE
,1,CD,I-DISEASE
,diabetes,NNS,I-DISEASE
,and,CC,O
,normoalbuminuria,NNS,O
,did,VBD,O
,not,RB,O
,retard,VB,O
,the,DT,O
,progression,NN,O
,of,IN,O
,nephropathy,JJ,B-DISEASE
,",",",",O
,suggesting,VBG,O
,that,IN,O
,other,JJ,O
,mechanism,NN,O
,(,(,O
,s,NN,O
,),),O
,are,VBP,O
,involved,VBN,O
,in,IN,O
,the,DT,O
,pathogenesis,NN,O
,of,IN,O
,early,JJ,O
,diabetic,JJ,B-DISEASE
,nephropathy,NN,I-DISEASE
,(,(,O
,diabetic,JJ,B-DISEASE
,nephropathy,NN,I-DISEASE
,),),O
,.,.,O
,We,PRP,O
,have,VBP,O
,previously,RB,O
,demonstrated,VBN,O
,that,IN,O
,endothelial,JJ,O
,-,:,O
,mesenchymal,JJ,O
,-,:,O
,transition,NN,O
,(,(,O
,EndoMT,NNP,O
,),),O
,contributes,VBZ,O
,to,TO,O
,the,DT,O
,early,JJ,O
,development,NN,O
,of,IN,O
,renal,JJ,O
,interstitial,JJ,O
,fibrosis,NN,B-DISEASE
,independently,RB,O
,of,IN,O
,microalbuminuria,NNS,O
,in,IN,O
,mice,NN,O
,with,IN,O
,streptozotocin,NN,O
,(,(,O
,STZ,NNP,O
,),),O
,-,:,O
,induced,VBN,O
,diabetes,NNS,B-DISEASE
,.,.,O
,In,IN,O
,the,DT,O
,present,JJ,O
,study,NN,O
,",",",",O
,we,PRP,O
,hypothesized,VBD,O
,that,IN,O
,blocking,VBG,O
,EndoMT,NNP,O
,reduces,VBZ,O
,the,DT,O
,early,JJ,O
,development,NN,O
,of,IN,O
,diabetic,JJ,B-DISEASE
,nephropathy,NN,I-DISEASE
,.,.,O
,RESEARCH,NNP,O
,DESIGN,NNP,O
,AND,NNP,O
,METHODS,NNP,O
,:,:,O
,EndoMT,NN,O
,was,VBD,O
,induced,VBN,O
,in,IN,O
,a,DT,O
,mouse,NN,O
,pancreatic,JJ,O
,microvascular,JJ,O
,endothelial,NN,O
,cell,NN,O
,line,NN,O
,(,(,O
,MMEC,NNP,O
,),),O
,in,IN,O
,the,DT,O
,presence,NN,O
,of,IN,O
,advanced,JJ,O
,glycation,NN,O
,end,NN,O
,products,NNS,O
,(,(,O
,AGEs,NNP,O
,),),O
,and,CC,O
,in,IN,O
,the,DT,O
,endothelial,JJ,O
,lineage,NN,O
,-,:,O
,traceble,JJ,O
,mouse,NN,O
,line,NN,O
,Tie2,NNP,O
,-,:,O
,Cre,NN,O
,;,:,O
,Loxp,NNP,O
,-,:,O
,EGFP,NN,O
,by,IN,O
,administration,NN,O
,of,IN,O
,AGEs,NNP,O
,",",",",O
,with,IN,O
,nonglycated,JJ,O
,mouse,NN,O
,albumin,NN,O
,serving,VBG,O
,as,IN,O
,a,DT,O
,control,NN,O
,.,.,O
,Phosphorylated,VBD,O
,Smad3,NNP,O
,was,VBD,O
,detected,VBN,O
,by,IN,O
,immunoprecipitation,NN,O
,/,NNP,O
,Western,NNP,O
,blotting,NN,O
,and,CC,O
,confocal,JJ,O
,microscopy,NN,O
,.,.,O
,Blocking,VBG,O
,studies,NNS,O
,using,VBG,O
,receptor,NN,O
,for,IN,O
,AGE,NNP,O
,siRNA,NN,O
,and,CC,O
,a,DT,O
,specific,JJ,O
,inhibitor,NN,O
,of,IN,O
,Smad3,NNP,O
,(,(,O
,SIS3,NNP,O
,),),O
,were,VBD,O
,performed,VBN,O
,in,IN,O
,MMECs,NNP,O
,and,CC,O
,in,IN,O
,STZ,NNP,O
,-,:,O
,induced,VBD,O
,diabetic,JJ,B-DISEASE
,nephropathy,NN,I-DISEASE
,in,IN,O
,Tie2,NNP,O
,-,:,O
,Cre,NN,O
,;,:,O
,Loxp,NNP,O
,-,:,O
,EGFP,NNP,O
,mice,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Confocal,JJ,O
,microscopy,NN,O
,and,CC,O
,real,JJ,O
,-,:,O
,time,NN,O
,PCR,NNP,O
,demonstrated,VBD,O
,that,IN,O
,AGEs,NNP,O
,induced,VBD,O
,EndoMT,NNP,O
,in,IN,O
,MMECs,NNP,O
,and,CC,O
,in,IN,O
,Tie2,NNP,O
,-,:,O
,Cre,NN,O
,;,:,O
,Loxp,NNP,O
,-,:,O
,EGFP,NNP,O
,mice,NN,O
,.,.,O
,Immunoprecipitation,NNP,O
,/,NNP,O
,Western,NNP,O
,blotting,NN,O
,showed,VBD,O
,that,IN,O
,Smad3,NNP,O
,was,VBD,O
,activated,VBN,O
,by,IN,O
,AGEs,NNP,O
,but,CC,O
,was,VBD,O
,inhibited,VBN,O
,by,IN,O
,SIS3,NNP,O
,in,IN,O
,MMECs,NNP,O
,and,CC,O
,in,IN,O
,STZ,NNP,O
,-,:,O
,induced,VBD,O
,diabetic,JJ,B-DISEASE
,nephropathy,NN,I-DISEASE
,.,.,O
,Confocal,JJ,O
,microscopy,NN,O
,and,CC,O
,real,JJ,O
,-,:,O
,time,NN,O
,PCR,NNP,O
,further,RB,O
,demonstrated,VBD,O
,that,IN,O
,SIS3,NNP,O
,abrogated,VBD,O
,EndoMT,NNP,O
,",",",",O
,reduced,VBD,O
,renal,JJ,O
,fibrosis,NN,B-DISEASE
,",",",",O
,and,CC,O
,retarded,VBD,O
,progression,NN,O
,of,IN,O
,nephropathy,JJ,B-DISEASE
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,EndoMT,NNP,O
,is,VBZ,O
,a,DT,O
,novel,JJ,O
,pathway,NN,O
,leading,VBG,O
,to,TO,O
,early,JJ,O
,development,NN,O
,of,IN,O
,diabetic,JJ,B-DISEASE
,nephropathy,NN,I-DISEASE
,.,.,O
,Blockade,NNP,O
,of,IN,O
,EndoMT,NNP,O
,by,IN,O
,SIS3,NNP,O
,may,MD,O
,provide,VB,O
,a,DT,O
,new,JJ,O
,strategy,NN,O
,to,TO,O
,retard,VB,O
,the,DT,O
,progression,NN,O
,of,IN,O
,diabetic,JJ,B-DISEASE
,nephropathy,NNS,I-DISEASE
,and,CC,O
,other,JJ,O
,diabetes,NNS,B-DISEASE
,complications,NNS,I-DISEASE
,.,.,O
,Cytostatic,NNP,O
,and,CC,O
,anti,SYM,O
,-,:,O
,angiogenic,JJ,O
,effects,NNS,O
,of,IN,O
,temsirolimus,NN,O
,in,IN,O
,refractory,JJ,O
,mantle,NN,B-DISEASE
,cell,NN,I-DISEASE
,lymphoma,NN,I-DISEASE
,.,.,O
,Mantle,NNP,B-DISEASE
,cell,NN,I-DISEASE
,lymphoma,NN,I-DISEASE
,(,(,O
,MCL,NNP,B-DISEASE
,),),O
,is,VBZ,O
,a,DT,O
,rare,JJ,O
,and,CC,O
,aggressive,JJ,O
,type,NN,O
,of,IN,O
,B,NNP,B-DISEASE
,-,:,I-DISEASE
,cell,NN,I-DISEASE
,non,SYM,I-DISEASE
,-,:,I-DISEASE
,Hodgkin,NNP,I-DISEASE
,',POS,I-DISEASE
,s,NN,I-DISEASE
,lymphoma,NN,I-DISEASE
,.,.,O
,Patients,VBZ,O
,become,JJ,O
,progressively,RB,O
,refractory,JJ,O
,to,TO,O
,conventional,JJ,O
,chemotherapy,NN,O
,",",",",O
,and,CC,O
,their,PRP$,O
,prognosis,NN,O
,is,VBZ,O
,poor,JJ,O
,.,.,O
,However,RB,O
,",",",",O
,a,DT,O
,38,CD,O
,%,NN,O
,remission,NN,O
,rate,NN,O
,has,VBZ,O
,been,VBN,O
,recently,RB,O
,reported,VBN,O
,in,IN,O
,refractory,NN,O
,MCL,NNP,B-DISEASE
,treated,VBD,O
,with,IN,O
,temsirolimus,NN,O
,",",",",O
,a,DT,O
,mTOR,NN,O
,inhibitor,NN,O
,.,.,O
,Here,RB,O
,we,PRP,O
,had,VBD,O
,the,DT,O
,opportunity,NN,O
,to,TO,O
,study,VB,O
,a,DT,O
,case,NN,O
,of,IN,O
,refractory,NN,O
,MCL,NNP,B-DISEASE
,who,WP,O
,had,VBD,O
,tumor,VBN,B-DISEASE
,regression,NN,O
,two,CD,O
,months,NNS,O
,after,IN,O
,temsirolimus,JJ,O
,treatment,NN,O
,",",",",O
,and,CC,O
,a,DT,O
,progression,NN,O
,-,:,O
,free,JJ,O
,survival,NN,O
,of,IN,O
,10,CD,O
,months,NNS,O
,.,.,O
,In,IN,O
,this,DT,O
,case,NN,O
,",",",",O
,lymph,NN,O
,node,NN,O
,biopsies,NNS,O
,were,VBD,O
,performed,VBN,O
,before,IN,O
,and,CC,O
,six,CD,O
,months,NNS,O
,after,IN,O
,temsirolimus,JJ,O
,therapy,NN,O
,.,.,O
,Comparison,NNP,O
,of,IN,O
,the,DT,O
,two,CD,O
,biopsies,NNS,O
,showed,VBD,O
,that,IN,O
,temsirolimus,NN,O
,inhibited,VBD,O
,tumor,NN,B-DISEASE
,cell,NN,O
,proliferation,NN,O
,through,IN,O
,cell,NN,O
,cycle,NN,O
,arrest,NN,O
,",",",",O
,but,CC,O
,did,VBD,O
,not,RB,O
,induce,VB,O
,any,DT,O
,change,NN,O
,in,IN,O
,the,DT,O
,number,NN,O
,of,IN,O
,apoptotic,JJ,O
,tumor,NN,B-DISEASE
,cells,NNS,O
,.,.,O
,Apart,RB,O
,from,IN,O
,this,DT,O
,cytostatic,JJ,O
,effect,NN,O
,",",",",O
,temsirolimus,NN,O
,had,VBD,O
,an,DT,O
,antiangiogenic,JJ,O
,effect,NN,O
,with,IN,O
,decrease,NN,O
,of,IN,O
,tumor,NN,B-DISEASE
,microvessel,NN,O
,density,NN,O
,and,CC,O
,of,IN,O
,VEGF,NNP,O
,expression,NN,O
,.,.,O
,Moreover,RB,O
,",",",",O
,numerous,JJ,O
,patchy,NN,O
,",",",",O
,well,RB,O
,-,:,O
,limited,VBN,O
,fibrotic,JJ,O
,areas,NNS,O
,",",",",O
,compatible,JJ,O
,with,IN,O
,post,NN,O
,-,:,O
,necrotic,JJ,B-DISEASE
,tissue,NN,O
,repair,NN,O
,",",",",O
,were,VBD,O
,found,VBN,O
,after,IN,O
,6,CD,O
,-,:,O
,month,NN,O
,temsirolimus,JJ,O
,therapy,NN,O
,.,.,O
,Thus,RB,O
,",",",",O
,temsirolimus,NN,O
,reduced,VBD,O
,tumor,NN,B-DISEASE
,burden,NN,O
,through,IN,O
,associated,VBN,O
,cytostatic,JJ,O
,and,CC,O
,anti,JJ,O
,-,:,O
,angiogenic,JJ,O
,effects,NNS,O
,.,.,O
,This,DT,O
,dual,JJ,O
,effect,NN,O
,of,IN,O
,temsirolimus,NN,O
,on,IN,O
,tumor,NN,B-DISEASE
,tissue,NN,O
,could,MD,O
,contribute,VB,O
,to,TO,O
,its,PRP$,O
,recently,RB,O
,reported,VBN,O
,efficiency,NN,O
,in,IN,O
,refractory,NN,O
,MCL,NNP,B-DISEASE
,resistant,NN,O
,to,TO,O
,conventional,JJ,O
,chemotherapy,NN,O
,.,.,O
,Acute,NNP,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,due,JJ,O
,to,TO,O
,rifampicin,VB,O
,.,.,O
,A,DT,O
,23,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,male,JJ,O
,patient,NN,O
,with,IN,O
,bacteriologically,RB,O
,proven,JJ,O
,pulmonary,JJ,B-DISEASE
,tuberculosis,NN,I-DISEASE
,was,VBD,O
,treated,VBN,O
,with,IN,O
,the,DT,O
,various,JJ,O
,regimens,NNS,O
,of,IN,O
,antituberculosis,NN,O
,drugs,NNS,O
,for,IN,O
,nearly,RB,O
,15,CD,O
,months,NNS,O
,.,.,O
,Rifampicin,NNP,O
,was,VBD,O
,administered,VBN,O
,thrice,RB,O
,as,IN,O
,one,CD,O
,of,IN,O
,the,DT,O
,3,CD,O
,-,:,O
,4,CD,O
,drug,NN,O
,regimen,NNS,O
,and,CC,O
,each,DT,O
,time,NN,O
,he,PRP,O
,developed,VBD,O
,untoward,JJ,O
,side,NN,O
,effects,NNS,O
,like,IN,O
,nausea,NN,B-DISEASE
,",",",",O
,vomiting,VBG,B-DISEASE
,and,CC,O
,fever,NN,B-DISEASE
,with,IN,O
,chills,NNS,O
,and,CC,O
,rigors,NNS,O
,.,.,O
,The,DT,O
,last,JJ,O
,such,JJ,O
,episode,NN,O
,was,VBD,O
,of,IN,O
,acute,JJ,O
,renal,JJ,O
,failure,NN,O
,at,IN,O
,which,WDT,O
,stage,VBP,O
,the,DT,O
,patient,NN,O
,was,VBD,O
,seen,VBN,O
,by,IN,O
,the,DT,O
,authors,NNS,O
,of,IN,O
,this,DT,O
,report,NN,O
,.,.,O
,The,DT,O
,patient,NN,O
,",",",",O
,however,RB,O
,",",",",O
,made,VBD,O
,a,DT,O
,full,JJ,O
,recovery,NN,O
,.,.,O
,Syncope,NN,B-DISEASE
,caused,VBN,O
,by,IN,O
,hyperkalemia,NN,B-DISEASE
,during,IN,O
,use,NN,O
,of,IN,O
,a,DT,O
,combined,JJ,O
,therapy,NN,O
,with,IN,O
,the,DT,O
,angiotensin,NN,O
,-,:,O
,converting,VBG,O
,enzyme,JJ,O
,inhibitor,NN,O
,and,CC,O
,spironolactone,NN,O
,.,.,O
,A,DT,O
,76,CD,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,with,IN,O
,a,DT,O
,history,NN,O
,of,IN,O
,coronary,JJ,O
,artery,NN,O
,bypass,NN,O
,grafting,NN,O
,and,CC,O
,prior,JJ,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,was,VBD,O
,transferred,VBN,O
,to,TO,O
,the,DT,O
,emergency,NN,O
,room,NN,O
,with,IN,O
,loss,NN,B-DISEASE
,of,IN,I-DISEASE
,consciousness,NN,I-DISEASE
,due,JJ,O
,to,TO,O
,marked,JJ,O
,bradycardia,NN,B-DISEASE
,caused,VBN,O
,by,IN,O
,hyperkalemia,NN,B-DISEASE
,.,.,O
,The,DT,O
,concentration,NN,O
,of,IN,O
,serum,JJ,O
,potassium,NN,O
,was,VBD,O
,high,JJ,O
,",",",",O
,and,CC,O
,normal,JJ,O
,sinus,NN,O
,rhythm,NN,O
,was,VBD,O
,restored,VBN,O
,after,IN,O
,correction,NN,O
,of,IN,O
,the,DT,O
,serum,NN,O
,potassium,NN,O
,level,NN,O
,.,.,O
,The,DT,O
,cause,NN,O
,of,IN,O
,hyperkalemia,NN,B-DISEASE
,was,VBD,O
,considered,VBN,O
,to,TO,O
,be,VB,O
,several,JJ,O
,doses,NNS,O
,of,IN,O
,spiranolactone,NN,O
,",",",",O
,an,DT,O
,aldosterone,NN,O
,antagonist,NN,O
,",",",",O
,in,IN,O
,addition,NN,O
,to,TO,O
,the,DT,O
,long,JJ,O
,-,:,O
,term,NN,O
,intake,NN,O
,of,IN,O
,ramipril,NN,O
,",",",",O
,an,DT,O
,ACE,NNP,O
,inhibitor,NN,O
,.,.,O
,This,DT,O
,case,NN,O
,is,VBZ,O
,a,DT,O
,good,JJ,O
,example,NN,O
,of,IN,O
,electrolyte,JJ,O
,imbalance,NN,O
,causing,VBG,O
,acute,JJ,O
,life,NN,O
,-,:,O
,threatening,JJ,O
,cardiac,JJ,O
,events,NNS,O
,.,.,O
,Clinicians,NNPS,O
,should,MD,O
,be,VB,O
,alert,JJ,O
,to,TO,O
,the,DT,O
,possibility,NN,O
,of,IN,O
,hyperkalemia,NN,B-DISEASE
,",",",",O
,especially,RB,O
,in,IN,O
,elderly,JJ,O
,patients,NNS,O
,using,VBG,O
,ACE,NNP,O
,/,NNP,O
,ARB,NNP,O
,in,IN,O
,combination,NN,O
,with,IN,O
,potassium,NN,O
,sparing,VBG,O
,agents,NNS,O
,and,CC,O
,who,WP,O
,have,VBP,O
,mild,VBN,O
,renal,JJ,B-DISEASE
,disturbance,NN,I-DISEASE
,.,.,O
,Diffuse,NNP,O
,skeletal,JJ,O
,pain,NN,B-DISEASE
,after,IN,O
,administration,NN,O
,of,IN,O
,alendronate,NN,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Osteoporosis,NN,B-DISEASE
,is,VBZ,O
,caused,VBN,O
,by,IN,O
,bone,NN,O
,resorption,NN,O
,in,IN,O
,excess,NN,O
,of,IN,O
,bone,NN,O
,formation,NN,O
,",",",",O
,and,CC,O
,bisphosphonates,NNS,O
,",",",",O
,are,VBP,O
,used,VBN,O
,to,TO,O
,inhibit,VB,O
,bone,JJ,O
,resorption,NN,O
,.,.,O
,Alendronate,NNP,O
,",",",",O
,a,DT,O
,biphosphonate,NN,O
,",",",",O
,is,VBZ,O
,effective,JJ,O
,for,IN,O
,both,DT,O
,the,DT,O
,treatment,NN,O
,and,CC,O
,prevention,NN,O
,of,IN,O
,osteoporosis,NN,B-DISEASE
,in,IN,O
,postmenopausal,JJ,O
,women,NNS,O
,.,.,O
,Side,JJ,O
,effects,NNS,O
,are,VBP,O
,relatively,RB,O
,few,JJ,O
,and,CC,O
,prominently,RB,O
,gastrointestinal,JJ,O
,.,.,O
,Musculoskeletal,JJ,B-DISEASE
,pain,NN,I-DISEASE
,may,MD,O
,be,VB,O
,an,DT,O
,important,JJ,O
,side,NN,O
,effect,NN,O
,in,IN,O
,these,DT,O
,patients,NNS,O
,.,.,O
,We,PRP,O
,presented,VBD,O
,a,DT,O
,patient,NN,O
,admitted,VBN,O
,to,TO,O
,our,PRP$,O
,out,RP,O
,-,:,O
,patient,NN,O
,clinic,NN,O
,with,IN,O
,diffuse,NN,O
,skeletal,NN,O
,pain,NN,B-DISEASE
,after,IN,O
,three,CD,O
,consecutive,JJ,O
,administration,NN,O
,of,IN,O
,alendronate,NN,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,We,PRP,O
,conclude,VBP,O
,that,IN,O
,patients,NNS,O
,with,IN,O
,osteoporosis,NN,B-DISEASE
,can,MD,O
,report,VB,O
,pain,NN,B-DISEASE
,",",",",O
,and,CC,O
,bisphosphonate,SYM,O
,-,:,O
,related,JJ,O
,pain,NN,B-DISEASE
,should,MD,O
,also,RB,O
,be,VB,O
,considered,VBN,O
,before,IN,O
,ascribing,VBG,O
,this,DT,O
,complaint,NN,O
,to,TO,O
,osteoporosis,NN,B-DISEASE
,.,.,O
,Cerebrospinal,NNP,O
,fluid,JJ,O
,penetration,NN,O
,of,IN,O
,high,JJ,O
,-,:,O
,dose,NN,O
,daptomycin,NN,O
,in,IN,O
,suspected,JJ,O
,Staphylococcus,NNP,O
,aureus,NN,O
,meningitis,NN,B-DISEASE
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,To,TO,O
,report,VB,O
,a,DT,O
,case,NN,O
,of,IN,O
,methicillin,NN,O
,-,:,O
,sensitive,JJ,O
,Staphylococcus,NNP,O
,aureus,NN,O
,(,(,O
,MSSA,NNP,O
,),),O
,bacteremia,NN,B-DISEASE
,with,IN,O
,suspected,JJ,O
,MSSA,NNP,O
,meningitis,NN,B-DISEASE
,treated,VBN,O
,with,IN,O
,high,JJ,O
,-,:,O
,dose,NN,O
,daptomycin,NNS,O
,assessed,VBD,O
,with,IN,O
,concurrent,JJ,O
,serum,NN,O
,and,CC,O
,cerebrospinal,JJ,O
,fluid,NN,O
,(,(,O
,CSF,NNP,O
,),),O
,concentrations,NNS,O
,.,.,O
,CASE,NNP,O
,SUMMARY,NNP,O
,:,:,O
,A,DT,O
,54,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,male,NN,O
,presented,VBN,O
,to,TO,O
,the,DT,O
,emergency,NN,O
,department,NN,O
,with,IN,O
,generalized,JJ,O
,weakness,NN,B-DISEASE
,and,CC,O
,presumed,VBN,O
,health,NN,O
,-,:,O
,care,NN,O
,-,:,O
,associated,VBN,O
,pneumonia,JJ,B-DISEASE
,shown,VBN,O
,on,IN,O
,chest,NN,O
,radiograph,NN,O
,.,.,O
,Treatment,NNP,O
,was,VBD,O
,empirically,RB,O
,initiated,VBN,O
,with,IN,O
,vancomycin,NN,O
,",",",",O
,levofloxacin,NN,O
,",",",",O
,and,CC,O
,piperacillin,NN,O
,/,NNP,O
,tazobactam,NN,O
,.,.,O
,Blood,NNP,O
,cultures,NNS,O
,revealed,VBD,O
,S,NNP,O
,.,.,O
,aureus,NN,O
,susceptible,JJ,O
,to,TO,O
,oxacillin,VB,O
,.,.,O
,Empiric,NNP,O
,antibiotic,JJ,O
,treatment,NN,O
,was,VBD,O
,narrowed,VBN,O
,to,TO,O
,nafcillin,VB,O
,on,IN,O
,day,NN,O
,4,CD,O
,.,.,O
,On,IN,O
,day,NN,O
,8,CD,O
,",",",",O
,the,DT,O
,patient,NN,O
,developed,VBD,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,(,(,O
,serum,JJ,O
,creatinine,NN,O
,1,CD,O
,.,.,O
,9,CD,O
,mg,JJ,O
,/,NNP,O
,dL,NN,O
,",",",",O
,increased,VBD,O
,from,IN,O
,1,CD,O
,.,.,O
,2,CD,O
,mg,JJ,O
,/,NNP,O
,dL,VBZ,O
,the,DT,O
,previous,JJ,O
,day,NN,O
,and,CC,O
,0,CD,O
,.,.,O
,8,CD,O
,mg,JJ,O
,/,NNP,O
,dL,NN,O
,on,IN,O
,admission,NN,O
,),),O
,.,.,O
,The,DT,O
,patient,NN,O
,',POS,O
,s,NN,O
,Glasgow,NNP,O
,Coma,NNP,O
,Score,NNP,O
,was,VBD,O
,3,CD,O
,",",",",O
,with,IN,O
,normal,JJ,O
,findings,NNS,O
,shown,VBN,O
,on,IN,O
,computed,JJ,O
,tomography,NN,O
,scan,NN,O
,of,IN,O
,the,DT,O
,head,NN,O
,72,CD,O
,hours,NNS,O
,following,VBG,O
,an,DT,O
,episode,NN,O
,of,IN,O
,cardiac,JJ,B-DISEASE
,arrest,NN,I-DISEASE
,on,IN,O
,day,NN,O
,10,CD,O
,.,.,O
,The,DT,O
,patient,NN,O
,experienced,VBD,O
,relapsing,VBG,O
,MSSA,NNP,O
,bacteremia,NN,B-DISEASE
,on,IN,O
,day,NN,O
,9,CD,O
,",",",",O
,increasing,VBG,O
,the,DT,O
,suspicion,NN,O
,for,IN,O
,a,DT,O
,central,JJ,O
,nervous,JJ,O
,system,NN,O
,(,(,O
,CNS,NNP,O
,),),O
,infection,NN,B-DISEASE
,.,.,O
,Nafcillin,NNP,O
,was,VBD,O
,discontinued,VBN,O
,and,CC,O
,daptomycin,$,O
,9,CD,O
,mg,NN,O
,/,NNP,O
,kg,VBD,O
,daily,RB,O
,was,VBD,O
,initiated,VBN,O
,for,IN,O
,suspected,JJ,O
,meningitis,NN,B-DISEASE
,and,CC,O
,was,VBD,O
,continued,VBN,O
,until,IN,O
,the,DT,O
,patient,NN,O
,',POS,O
,s,JJ,O
,death,NN,O
,on,IN,O
,day,NN,O
,16,CD,O
,.,.,O
,Daptomycin,NNP,O
,serum,NN,O
,and,CC,O
,CSF,NNP,O
,trough,IN,O
,concentrations,NNS,O
,were,VBD,O
,11,CD,O
,.,.,O
,21,CD,O
,ug,JJ,O
,/,NNP,O
,mL,NN,O
,and,CC,O
,0,CD,O
,.,.,O
,52,CD,O
,ug,JJ,O
,/,NNP,O
,mL,NN,O
,",",",",O
,respectively,RB,O
,",",",",O
,prior,RB,O
,to,TO,O
,the,DT,O
,third,JJ,O
,dose,NN,O
,.,.,O
,Lumbar,NNP,O
,puncture,NN,O
,results,NNS,O
,were,VBD,O
,inconclusive,JJ,O
,and,CC,O
,no,DT,O
,further,JJ,O
,blood,NN,O
,cultures,NNS,O
,were,VBD,O
,positive,JJ,O
,for,IN,O
,MSSA,NNP,O
,.,.,O
,Creatine,NNP,O
,kinase,NN,O
,levels,NNS,O
,were,VBD,O
,normal,JJ,O
,prior,JJ,O
,to,TO,O
,daptomycin,VB,O
,therapy,NN,O
,and,CC,O
,were,VBD,O
,not,RB,O
,reassessed,VBN,O
,.,.,O
,DISCUSSION,NN,O
,:,:,O
,Daptomycin,NNP,O
,was,VBD,O
,initiated,VBN,O
,in,IN,O
,our,PRP$,O
,patient,NN,O
,secondary,NN,O
,to,TO,O
,possible,JJ,O
,nafcillin,JJ,O
,-,:,O
,induced,JJ,O
,acute,JJ,O
,interstitial,JJ,B-DISEASE
,nephritis,NN,I-DISEASE
,and,CC,O
,relapsing,VBG,O
,bacteremia,NN,B-DISEASE
,.,.,O
,At,IN,O
,a,DT,O
,dose,NN,O
,of,IN,O
,9,CD,O
,mg,NNS,O
,/,JJ,O
,kg,NN,O
,",",",",O
,resultant,JJ,O
,penetration,NN,O
,of,IN,O
,5,CD,O
,%,NN,O
,was,VBD,O
,higher,JJR,O
,than,IN,O
,in,IN,O
,previous,JJ,O
,reports,NNS,O
,",",",",O
,more,RBR,O
,consistent,JJ,O
,with,IN,O
,inflamed,JJ,O
,meninges,NNS,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,High,JJ,O
,-,:,O
,dose,JJ,O
,daptomycin,NN,O
,may,MD,O
,be,VB,O
,an,DT,O
,alternative,JJ,O
,option,NN,O
,for,IN,O
,MSSA,NNP,O
,bacteremia,NN,B-DISEASE
,with,IN,O
,or,CC,O
,without,IN,O
,a,DT,O
,CNS,NNP,O
,source,NN,O
,in,IN,O
,patients,NNS,O
,who,WP,O
,have,VBP,O
,failed,VBN,O
,or,CC,O
,cannot,VB,O
,tolerate,JJ,O
,standard,NN,O
,therapy,NN,O
,.,.,O
,Further,NNP,O
,clinical,JJ,O
,evaluation,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,confirmed,JJ,O
,meningitis,NN,B-DISEASE
,is,VBZ,O
,warranted,VBN,O
,.,.,O
,The,DT,O
,role,NN,O
,of,IN,O
,nitric,JJ,O
,oxide,NN,O
,in,IN,O
,convulsions,NNS,B-DISEASE
,induced,VBN,O
,by,IN,O
,lindane,NN,O
,in,IN,O
,rats,NNS,O
,.,.,O
,Lindane,NNP,O
,is,VBZ,O
,an,DT,O
,organochloride,JJ,O
,pesticide,NN,O
,and,CC,O
,scabicide,NN,O
,.,.,O
,It,PRP,O
,evokes,VBZ,O
,convulsions,NNS,B-DISEASE
,mainly,RB,O
,trough,IN,O
,the,DT,O
,blockage,NN,O
,of,IN,O
,GABA,NNP,O
,(,(,O
,A,NNP,O
,),),O
,receptors,NNS,O
,.,.,O
,Nitric,NNP,O
,oxide,IN,O
,(,(,O
,NO,NNP,O
,),),O
,",",",",O
,gaseous,JJ,O
,neurotransmitter,NN,O
,",",",",O
,has,VBZ,O
,contradictor,NN,O
,role,NN,O
,in,IN,O
,epileptogenesis,NN,O
,due,JJ,O
,to,TO,O
,opposite,JJ,O
,effects,NNS,O
,of,IN,O
,L,NNP,O
,-,:,O
,arginine,NN,O
,",",",",O
,precursor,NN,O
,of,IN,O
,NO,NNP,O
,syntheses,NNS,O
,(,(,O
,NOS,NNP,O
,),),O
,",",",",O
,and,CC,O
,L,NNP,O
,-,:,O
,NAME,NN,O
,(,(,O
,NOS,NNP,O
,inhibitor,NN,O
,),),O
,observed,VBD,O
,in,IN,O
,different,JJ,O
,epilepsy,NN,B-DISEASE
,models,NNS,O
,.,.,O
,The,DT,O
,aim,NN,O
,of,IN,O
,the,DT,O
,current,JJ,O
,study,NN,O
,was,VBD,O
,to,TO,O
,determine,VB,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,NO,NNP,O
,on,IN,O
,the,DT,O
,behavioral,JJ,O
,and,CC,O
,EEG,NNP,O
,characteristics,NNS,O
,of,IN,O
,lindane,NN,O
,-,:,O
,induced,JJ,O
,epilepsy,NN,B-DISEASE
,in,IN,O
,male,JJ,O
,Wistar,NNP,O
,albino,NN,O
,rats,NNS,O
,.,.,O
,The,DT,O
,administration,NN,O
,of,IN,O
,L,NNP,O
,-,:,O
,arginine,NN,O
,(,(,O
,600,CD,O
,",",",",O
,800,CD,O
,and,CC,O
,1000,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,in,IN,O
,dose,JJ,O
,-,:,O
,dependent,JJ,O
,manner,NN,O
,significantly,RB,O
,increased,VBD,O
,convulsion,NN,B-DISEASE
,incidence,NN,O
,and,CC,O
,severity,NN,O
,and,CC,O
,shortened,VBD,O
,latency,NN,O
,time,NN,O
,to,TO,O
,first,JJ,O
,convulsion,NN,B-DISEASE
,elicited,VBN,O
,by,IN,O
,lower,JJR,O
,lindane,NN,O
,dose,NN,O
,(,(,O
,4,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,.,.,O
,On,IN,O
,the,DT,O
,contrary,JJ,O
,",",",",O
,pretreatment,JJ,O
,with,IN,O
,L,NNP,O
,-,:,O
,NAME,NN,O
,(,(,O
,500,CD,O
,",",",",O
,700,CD,O
,and,CC,O
,900,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,decreased,VBD,O
,convulsion,NN,B-DISEASE
,incidence,NN,O
,and,CC,O
,severity,NN,O
,and,CC,O
,prolonged,JJ,O
,latency,NN,O
,time,NN,O
,to,TO,O
,convulsion,NN,B-DISEASE
,following,VBG,O
,injection,NN,O
,with,IN,O
,a,DT,O
,convulsive,JJ,B-DISEASE
,dose,NN,O
,of,IN,O
,lindane,NN,O
,(,(,O
,8,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,.,.,O
,EEG,NNP,O
,analyses,VBZ,O
,showed,VBD,O
,increase,NN,O
,of,IN,O
,number,NN,O
,and,CC,O
,duration,NN,O
,of,IN,O
,ictal,JJ,O
,periods,NNS,O
,in,IN,O
,EEG,NNP,O
,of,IN,O
,rats,NNS,O
,receiving,VBG,O
,l,NN,O
,-,:,O
,arginine,NN,O
,prior,RB,O
,to,TO,O
,lindane,VB,O
,and,CC,O
,decrease,VB,O
,of,IN,O
,this,DT,O
,number,NN,O
,in,IN,O
,rats,NNS,O
,pretreated,VBN,O
,with,IN,O
,L,NNP,O
,-,:,O
,NAME,NN,O
,.,.,O
,These,DT,O
,results,NNS,O
,support,VBD,O
,the,DT,O
,conclusion,NN,O
,that,IN,O
,NO,NNP,O
,plays,VBZ,O
,a,DT,O
,role,NN,O
,of,IN,O
,endogenous,JJ,O
,convulsant,NN,O
,in,IN,O
,rat,JJ,O
,model,NN,O
,of,IN,O
,lindane,NN,O
,seizures,NNS,B-DISEASE
,.,.,O
,Severe,NNP,O
,polyneuropathy,NN,B-DISEASE
,and,CC,O
,motor,NN,O
,loss,NN,O
,after,IN,O
,intrathecal,JJ,O
,thiotepa,NN,O
,combination,NN,O
,chemotherapy,NN,O
,:,:,O
,description,NN,O
,of,IN,O
,two,CD,O
,cases,NNS,O
,.,.,O
,Two,CD,O
,cases,NNS,O
,of,IN,O
,severe,JJ,O
,delayed,VBN,O
,neurologic,JJ,B-DISEASE
,toxicity,NN,I-DISEASE
,related,VBN,O
,to,TO,O
,the,DT,O
,administration,NN,O
,of,IN,O
,intrathecal,JJ,O
,(,(,O
,IT,NNP,O
,),),O
,combination,NN,O
,chemotherapy,NN,O
,including,VBG,O
,thiotepa,NN,O
,(,(,O
,TSPA,NNP,O
,),),O
,are,VBP,O
,presented,VBN,O
,.,.,O
,Both,DT,O
,cases,NNS,O
,developed,VBD,O
,axonal,JJ,B-DISEASE
,neuropathy,JJ,I-DISEASE
,with,IN,O
,motor,NN,O
,predominance,NN,O
,in,IN,O
,the,DT,O
,lower,JJR,O
,extremities,NNS,O
,1,CD,O
,and,CC,O
,6,CD,O
,months,NNS,O
,after,IN,O
,IT,NNP,O
,chemotherapy,NN,O
,was,VBD,O
,administered,VBN,O
,.,.,O
,Neurologic,NNP,B-DISEASE
,toxicities,NNS,I-DISEASE
,have,VBP,O
,been,VBN,O
,described,VBN,O
,with,IN,O
,IT,NNP,O
,-,:,O
,methotrexate,NN,O
,",",",",O
,IT,NNP,O
,-,:,O
,cytosine,NN,O
,arabinoside,NN,O
,and,CC,O
,IT,NNP,O
,-,:,O
,TSPA,NNP,O
,.,.,O
,To,TO,O
,our,PRP$,O
,knowledge,NN,O
,",",",",O
,however,RB,O
,",",",",O
,axonal,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,following,VBG,O
,administration,NN,O
,of,IN,O
,these,DT,O
,three,CD,O
,agents,NNS,O
,has,VBZ,O
,not,RB,O
,been,VBN,O
,previously,RB,O
,described,VBN,O
,.,.,O
,In,IN,O
,spite,NN,O
,of,IN,O
,the,DT,O
,fact,NN,O
,that,IN,O
,TSPA,NNP,O
,is,VBZ,O
,a,DT,O
,useful,JJ,O
,IT,NNP,O
,agent,NN,O
,",",",",O
,its,PRP$,O
,combination,NN,O
,with,IN,O
,MTX,NNP,O
,",",",",O
,ara,SYM,O
,-,:,O
,C,NN,O
,and,CC,O
,radiotherapy,NN,O
,could,MD,O
,cause,VB,O
,severe,JJ,O
,neurotoxicity,NN,B-DISEASE
,.,.,O
,This,DT,O
,unexpected,JJ,O
,complication,NN,O
,indicates,VBZ,O
,the,DT,O
,need,NN,O
,for,IN,O
,further,JJ,O
,toxicology,NN,O
,research,NN,O
,on,IN,O
,IT,NNP,O
,-,:,O
,TSPA,NNP,O
,.,.,O
,Effects,NNS,O
,of,IN,O
,cromakalim,NN,O
,and,CC,O
,pinacidil,NN,O
,on,IN,O
,large,JJ,O
,epicardial,JJ,O
,and,CC,O
,small,JJ,O
,coronary,JJ,O
,arteries,NNS,O
,in,IN,O
,conscious,JJ,O
,dogs,NNS,O
,.,.,O
,The,DT,O
,effects,NNS,O
,of,IN,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,bolus,CC,O
,administration,NN,O
,of,IN,O
,cromakalim,NN,O
,(,(,O
,1,CD,O
,-,:,O
,10,CD,O
,micrograms,NNS,O
,/,NNP,O
,kg,NN,O
,),),O
,and,CC,O
,pinacidil,NN,O
,(,(,O
,3,CD,O
,-,:,O
,100,CD,O
,micrograms,NNS,O
,/,NNP,O
,kg,NN,O
,),),O
,on,IN,O
,large,JJ,O
,(,(,O
,circumflex,JJ,O
,artery,NN,O
,),),O
,and,CC,O
,small,JJ,O
,coronary,JJ,O
,arteries,NNS,O
,and,CC,O
,on,IN,O
,systemic,JJ,O
,hemodynamics,NNS,O
,were,VBD,O
,investigated,VBN,O
,in,IN,O
,chronically,RB,O
,instrumented,VBN,O
,conscious,JJ,O
,dogs,NNS,O
,and,CC,O
,compared,VBN,O
,to,TO,O
,those,DT,O
,of,IN,O
,nitroglycerin,NNS,O
,(,(,O
,0,CD,O
,.,.,O
,03,CD,O
,-,:,O
,10,CD,O
,micrograms,NNS,O
,/,NNP,O
,kg,NN,O
,),),O
,.,.,O
,Nitroglycerin,NNP,O
,",",",",O
,up,RB,O
,to,TO,O
,0,CD,O
,.,.,O
,3,CD,O
,micrograms,NNS,O
,/,JJ,O
,kg,NN,O
,",",",",O
,selectively,RB,O
,increased,VBD,O
,circumflex,JJ,O
,artery,NN,O
,diameter,NN,O
,(,(,O
,CxAD,NNP,O
,),),O
,without,IN,O
,simultaneously,RB,O
,affecting,VBG,O
,any,DT,O
,other,JJ,O
,cardiac,NN,O
,or,CC,O
,systemic,JJ,O
,hemodynamic,JJ,O
,parameter,NN,O
,.,.,O
,In,IN,O
,contrast,NN,O
,",",",",O
,cromakalim,NN,O
,and,CC,O
,pinacidil,NN,O
,at,IN,O
,all,DT,O
,doses,NNS,O
,and,CC,O
,nitroglycerin,NN,O
,at,IN,O
,doses,VBZ,O
,higher,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,3,CD,O
,micrograms,NNS,O
,/,VBP,O
,kg,VB,O
,simultaneously,RB,O
,and,CC,O
,dose,VB,O
,-,:,O
,dependently,RB,O
,increased,VBD,O
,CxAD,NNP,O
,",",",",O
,coronary,JJ,O
,blood,NN,O
,flow,NN,O
,and,CC,O
,heart,NN,O
,rate,NN,O
,and,CC,O
,decreased,VBD,O
,coronary,JJ,O
,vascular,JJ,O
,resistance,NN,O
,and,CC,O
,aortic,JJ,O
,pressure,NN,O
,.,.,O
,Cromakalim,NNP,O
,was,VBD,O
,approximately,RB,O
,8,CD,O
,-,:,O
,to,TO,O
,9,CD,O
,.,.,O
,5,CD,O
,-,:,O
,fold,NN,O
,more,RBR,O
,potent,JJ,O
,than,IN,O
,pinacidil,NN,O
,in,IN,O
,increasing,VBG,O
,CxAD,NNP,O
,.,.,O
,Vasodilation,NN,O
,of,IN,O
,large,JJ,O
,and,CC,O
,small,JJ,O
,coronary,JJ,O
,vessels,NNS,O
,and,CC,O
,hypotension,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,cromakalim,NN,O
,and,CC,O
,pinacidil,NN,O
,were,VBD,O
,not,RB,O
,affected,VBN,O
,by,IN,O
,prior,JJ,O
,combined,VBN,O
,beta,NN,O
,adrenergic,NN,O
,and,CC,O
,muscarinic,JJ,O
,receptors,NNS,O
,blockade,VBP,O
,but,CC,O
,drug,NN,O
,-,:,O
,induced,JJ,O
,tachycardia,NN,B-DISEASE
,was,VBD,O
,abolished,VBN,O
,.,.,O
,When,WRB,O
,circumflex,JJ,O
,artery,NN,O
,blood,NN,O
,flow,NN,O
,was,VBD,O
,maintained,VBN,O
,constant,JJ,O
,",",",",O
,the,DT,O
,increases,NNS,O
,in,IN,O
,CxAD,NNP,O
,induced,VBN,O
,by,IN,O
,cromakalim,NN,O
,(,(,O
,10,CD,O
,micrograms,NNS,O
,/,NNP,O
,kg,NN,O
,),),O
,",",",",O
,pinacidil,NN,O
,(,(,O
,30,CD,O
,micrograms,NNS,O
,/,NNP,O
,kg,NN,O
,),),O
,and,CC,O
,nitroglycerin,$,O
,(,(,O
,10,CD,O
,micrograms,NNS,O
,/,NNP,O
,kg,NN,O
,),),O
,were,VBD,O
,reduced,VBN,O
,by,IN,O
,68,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,7,CD,O
,",",",",O
,54,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,9,CD,O
,and,CC,O
,1,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,1,CD,O
,%,NN,O
,",",",",O
,respectively,RB,O
,.,.,O
,Thus,RB,O
,",",",",O
,whereas,JJ,O
,nitroglycerin,NN,O
,preferentially,RB,O
,and,CC,O
,flow,VB,O
,-,:,O
,independently,RB,O
,dilates,VBZ,O
,large,JJ,O
,coronary,JJ,O
,arteries,NNS,O
,",",",",O
,cromakalim,NN,O
,and,CC,O
,pinacidil,NN,O
,dilate,VBP,O
,both,DT,O
,large,JJ,O
,and,CC,O
,small,JJ,O
,coronary,JJ,O
,arteries,NNS,O
,and,CC,O
,this,DT,O
,effect,NN,O
,is,VBZ,O
,not,RB,O
,dependent,JJ,O
,upon,IN,O
,the,DT,O
,simultaneous,JJ,O
,beta,NN,O
,adrenoceptors,NNS,O
,-,:,O
,mediated,VBN,O
,rise,NN,O
,in,IN,O
,myocardial,JJ,O
,metabolic,JJ,O
,demand,NN,O
,.,.,O
,Finally,RB,O
,",",",",O
,two,CD,O
,mechanisms,NNS,O
,at,IN,O
,least,JJS,O
,",",",",O
,direct,JJ,O
,vasodilation,NN,O
,and,CC,O
,flow,NN,O
,dependency,NN,O
,",",",",O
,are,VBP,O
,involved,VBN,O
,in,IN,O
,the,DT,O
,cromakalim,NN,O
,-,:,O
,and,CC,O
,pinacidil,VB,O
,-,:,O
,induced,JJ,O
,increase,NN,O
,in,IN,O
,CxAD,NNP,O
,.,.,O
,Mefenamic,NNP,O
,acid,SYM,O
,-,:,O
,induced,VBN,O
,neutropenia,NN,B-DISEASE
,and,CC,O
,renal,JJ,B-DISEASE
,failure,NN,I-DISEASE
,in,IN,O
,elderly,JJ,O
,females,NNS,O
,with,IN,O
,hypothyroidism,NN,B-DISEASE
,.,.,O
,We,PRP,O
,report,VBP,O
,mefenamic,JJ,O
,acid,SYM,O
,-,:,O
,induced,VBN,O
,non,IN,O
,-,:,O
,oliguric,JJ,O
,renal,JJ,B-DISEASE
,failure,NN,I-DISEASE
,and,CC,O
,severe,JJ,O
,neutropenia,NN,B-DISEASE
,occurring,VBG,O
,simultaneously,RB,O
,in,IN,O
,two,CD,O
,elderly,JJ,O
,females,NNS,O
,.,.,O
,The,DT,O
,neutropenia,NN,B-DISEASE
,was,VBD,O
,due,JJ,O
,to,TO,O
,maturation,VB,O
,arrest,NN,O
,of,IN,O
,the,DT,O
,myeloid,JJ,O
,series,NN,O
,in,IN,O
,one,CD,O
,patient,NN,O
,.,.,O
,Both,DT,O
,patients,NNS,O
,were,VBD,O
,also,RB,O
,hypothyroid,JJ,B-DISEASE
,",",",",O
,but,CC,O
,it,PRP,O
,is,VBZ,O
,not,RB,O
,clear,JJ,O
,whether,IN,O
,this,DT,O
,was,VBD,O
,a,DT,O
,predisposing,JJ,O
,factor,NN,O
,to,TO,O
,the,DT,O
,development,NN,O
,of,IN,O
,these,DT,O
,adverse,JJ,O
,reactions,NNS,O
,.,.,O
,However,RB,O
,",",",",O
,it,PRP,O
,would,MD,O
,seem,VB,O
,prudent,JJ,O
,not,RB,O
,to,TO,O
,use,VB,O
,mefenamic,JJ,O
,acid,NN,O
,in,IN,O
,hypothyroid,JJ,B-DISEASE
,patients,NNS,O
,until,IN,O
,the,DT,O
,hypothyroidism,NN,B-DISEASE
,has,VBZ,O
,been,VBN,O
,corrected,VBN,O
,.,.,O
,Etiology,NNP,O
,of,IN,O
,hypercalcemia,NN,B-DISEASE
,in,IN,O
,hemodialysis,NN,O
,patients,NNS,O
,on,IN,O
,calcium,NN,O
,carbonate,NN,O
,therapy,NN,O
,.,.,O
,Fourteen,NNP,O
,of,IN,O
,39,CD,O
,dialysis,NN,O
,patients,NNS,O
,(,(,O
,36,CD,O
,%,NN,O
,),),O
,became,VBD,O
,hypercalcemic,JJ,B-DISEASE
,after,IN,O
,switching,VBG,O
,to,TO,O
,calcium,VB,O
,carbonate,NN,O
,as,IN,O
,their,PRP$,O
,principal,JJ,O
,phosphate,NN,O
,binder,NN,O
,.,.,O
,In,IN,O
,order,NN,O
,to,TO,O
,identify,VB,O
,risk,NN,O
,factors,NNS,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,hypercalcemia,NN,B-DISEASE
,",",",",O
,indirect,JJ,O
,parameters,NNS,O
,of,IN,O
,intestinal,JJ,O
,calcium,NN,O
,reabsorption,NN,O
,and,CC,O
,bone,NN,O
,turnover,NN,O
,rate,NN,O
,in,IN,O
,these,DT,O
,14,CD,O
,patients,NNS,O
,were,VBD,O
,compared,VBN,O
,with,IN,O
,results,NNS,O
,in,IN,O
,14,CD,O
,eucalcemic,JJ,O
,patients,NNS,O
,matched,VBN,O
,for,IN,O
,age,NN,O
,",",",",O
,sex,NN,O
,",",",",O
,length,NN,O
,of,IN,O
,time,NN,O
,on,IN,O
,dialysis,NN,O
,",",",",O
,and,CC,O
,etiology,NN,O
,of,IN,O
,renal,JJ,B-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,In,IN,O
,addition,NN,O
,to,TO,O
,experiencing,VBG,O
,hypercalcemic,JJ,B-DISEASE
,episodes,NNS,O
,with,IN,O
,peak,JJ,O
,calcium,NN,O
,values,NNS,O
,of,IN,O
,2,CD,O
,.,.,O
,7,CD,O
,to,TO,O
,3,CD,O
,.,.,O
,8,CD,O
,mmol,JJ,O
,/,NN,O
,L,NNP,O
,(,(,O
,10,CD,O
,.,.,O
,7,CD,O
,to,TO,O
,15,CD,O
,.,.,O
,0,CD,O
,mg,JJ,O
,/,NNP,O
,dL,NN,O
,),),O
,",",",",O
,patients,NNS,O
,in,IN,O
,the,DT,O
,hypercalcemic,JJ,B-DISEASE
,group,NN,O
,exhibited,VBD,O
,a,DT,O
,significant,JJ,O
,increase,NN,O
,in,IN,O
,the,DT,O
,mean,JJ,O
,calcium,NN,O
,concentration,NN,O
,obtained,VBD,O
,during,IN,O
,6,CD,O
,months,NNS,O
,before,IN,O
,the,DT,O
,switch,NN,O
,",",",",O
,compared,VBN,O
,with,IN,O
,the,DT,O
,mean,JJ,O
,value,NN,O
,obtained,VBN,O
,during,IN,O
,the,DT,O
,7,CD,O
,months,NNS,O
,of,IN,O
,observation,NN,O
,after,IN,O
,the,DT,O
,switch,NN,O
,(,(,O
,2,CD,O
,.,.,O
,4,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,03,CD,O
,to,TO,O
,2,CD,O
,.,.,O
,5,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,03,CD,O
,mmol,JJ,O
,/,NNP,O
,L,NNP,O
,[,VBD,O
,9,CD,O
,.,.,O
,7,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,2,CD,O
,to,TO,O
,10,CD,O
,.,.,O
,2,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,1,CD,O
,mg,JJ,O
,/,NNP,O
,dL,NN,O
,],NNP,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,006,CD,O
,),),O
,.,.,O
,In,IN,O
,contrast,NN,O
,",",",",O
,eucalcemic,JJ,O
,patients,NNS,O
,exhibited,VBD,O
,no,DT,O
,change,NN,O
,in,IN,O
,mean,JJ,O
,calcium,NN,O
,values,NNS,O
,over,IN,O
,the,DT,O
,same,JJ,O
,time,NN,O
,period,NN,O
,(,(,O
,2,CD,O
,.,.,O
,3,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,05,CD,O
,to,TO,O
,2,CD,O
,.,.,O
,3,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,05,CD,O
,mmol,JJ,O
,/,NNP,O
,L,NNP,O
,[,VBD,O
,9,CD,O
,.,.,O
,2,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,2,CD,O
,to,TO,O
,9,CD,O
,.,.,O
,2,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,2,CD,O
,mg,JJ,O
,/,NNP,O
,dL,NN,O
,],NN,O
,),),O
,.,.,O
,CaCO3,NNP,O
,dosage,NN,O
,",",",",O
,calculated,VBD,O
,dietary,JJ,O
,calcium,NN,O
,intake,NN,O
,",",",",O
,and,CC,O
,circulating,VBG,O
,levels,NNS,O
,of,IN,O
,vitamin,NN,O
,D,NNP,O
,metabolites,NNS,O
,were,VBD,O
,similar,JJ,O
,in,IN,O
,both,DT,O
,groups,NNS,O
,.,.,O
,Physical,NNP,O
,activity,NN,O
,index,NN,O
,and,CC,O
,predialysis,NN,O
,serum,NN,O
,bicarbonate,NN,O
,levels,NNS,O
,also,RB,O
,were,VBD,O
,similar,JJ,O
,in,IN,O
,both,DT,O
,groups,NNS,O
,.,.,O
,However,RB,O
,",",",",O
,there,EX,O
,was,VBD,O
,a,DT,O
,significant,JJ,O
,difference,NN,O
,in,IN,O
,parameters,NNS,O
,reflecting,VBG,O
,bone,NN,O
,turnover,NN,O
,rates,NNS,O
,between,IN,O
,groups,NNS,O
,.,.,O
,(,(,O
,ABSTRACT,NNP,O
,TRUNCATED,NNP,O
,AT,NNP,O
,250,CD,O
,WORDS,NNP,O
,),),O
,Late,NNP,O
,-,:,O
,onset,NN,O
,scleroderma,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,crisis,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,tacrolimus,NN,O
,and,CC,O
,prednisolone,NN,O
,:,:,O
,a,DT,O
,case,NN,O
,report,NN,O
,.,.,O
,Scleroderma,NNP,B-DISEASE
,renal,JJ,I-DISEASE
,crisis,NN,I-DISEASE
,(,(,O
,SRC,NNP,B-DISEASE
,),),O
,is,VBZ,O
,a,DT,O
,rare,JJ,O
,complication,NN,O
,of,IN,O
,systemic,JJ,B-DISEASE
,sclerosis,NN,I-DISEASE
,(,(,O
,SSc,NNP,B-DISEASE
,),),O
,but,CC,O
,can,MD,O
,be,VB,O
,severe,JJ,O
,enough,RB,O
,to,TO,O
,require,VB,O
,temporary,JJ,O
,or,CC,O
,permanent,JJ,O
,renal,JJ,O
,replacement,NN,O
,therapy,NN,O
,.,.,O
,Moderate,NNP,O
,to,TO,O
,high,VB,O
,dose,JJ,O
,corticosteroid,NN,O
,use,NN,O
,is,VBZ,O
,recognized,VBN,O
,as,IN,O
,a,DT,O
,major,JJ,O
,risk,NN,O
,factor,NN,O
,for,IN,O
,SRC,NNP,B-DISEASE
,.,.,O
,Furthermore,RB,O
,",",",",O
,there,EX,O
,have,VBP,O
,been,VBN,O
,reports,NNS,O
,of,IN,O
,thrombotic,JJ,B-DISEASE
,microangiopathy,NN,I-DISEASE
,precipitated,VBN,O
,by,IN,O
,cyclosporine,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,SSc,NNP,B-DISEASE
,.,.,O
,In,IN,O
,this,DT,O
,article,NN,O
,",",",",O
,we,PRP,O
,report,VBP,O
,a,DT,O
,patient,NN,O
,with,IN,O
,SRC,NNP,B-DISEASE
,induced,VBN,O
,by,IN,O
,tacrolimus,NN,O
,and,CC,O
,corticosteroids,NNS,O
,.,.,O
,The,DT,O
,aim,NN,O
,of,IN,O
,this,DT,O
,work,NN,O
,is,VBZ,O
,to,TO,O
,call,VB,O
,attention,NN,O
,to,TO,O
,the,DT,O
,risk,NN,O
,of,IN,O
,tacrolimus,NN,O
,use,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,SSc,NNP,B-DISEASE
,.,.,O
,Methyldopa,NNP,O
,-,:,O
,induced,VBD,O
,hemolytic,JJ,B-DISEASE
,anemia,NN,I-DISEASE
,in,IN,O
,a,DT,O
,15,CD,O
,year,NN,O
,old,JJ,O
,presenting,NN,O
,as,IN,O
,near,IN,O
,-,:,O
,syncope,NN,B-DISEASE
,.,.,O
,Methyldopa,NNP,O
,is,VBZ,O
,an,DT,O
,antihypertensive,JJ,O
,medication,NN,O
,which,WDT,O
,is,VBZ,O
,available,JJ,O
,generically,RB,O
,and,CC,O
,under,IN,O
,the,DT,O
,trade,NN,O
,name,NN,O
,Aldomet,NNP,O
,that,WDT,O
,is,VBZ,O
,widely,RB,O
,prescribed,VBN,O
,in,IN,O
,the,DT,O
,adult,NN,O
,population,NN,O
,and,CC,O
,infrequently,RB,O
,used,VBN,O
,in,IN,O
,children,NNS,O
,.,.,O
,Methyldopa,NNP,O
,causes,VBZ,O
,an,DT,O
,autoimmune,JJ,B-DISEASE
,hemolytic,JJ,I-DISEASE
,anemia,NN,I-DISEASE
,in,IN,O
,a,DT,O
,small,JJ,O
,percentage,NN,O
,of,IN,O
,patients,NNS,O
,who,WP,O
,take,VBP,O
,the,DT,O
,drug,NN,O
,.,.,O
,We,PRP,O
,report,VBP,O
,a,DT,O
,case,NN,O
,of,IN,O
,methyldopa,NN,O
,-,:,O
,induced,JJ,O
,hemolytic,JJ,B-DISEASE
,anemia,NN,I-DISEASE
,in,IN,O
,a,DT,O
,15,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,boy,NN,O
,who,WP,O
,presented,VBD,O
,to,TO,O
,the,DT,O
,emergency,NN,B-DISEASE
,department,NN,I-DISEASE
,with,IN,O
,near,IN,O
,-,:,O
,syncope,NN,B-DISEASE
,.,.,O
,The,DT,O
,boy,NN,O
,had,VBD,O
,been,VBN,O
,treated,VBN,O
,with,IN,O
,intravenous,JJ,O
,methyldopa,NNS,O
,during,IN,O
,a,DT,O
,trauma,JJ,B-DISEASE
,admission,NN,O
,seven,CD,O
,weeks,NNS,O
,prior,RB,O
,to,TO,O
,presentation,NN,O
,.,.,O
,Evaluation,NNP,O
,revealed,VBD,O
,a,DT,O
,hemoglobin,NN,O
,of,IN,O
,three,CD,O
,grams,NNS,O
,",",",",O
,3,CD,O
,+,NN,O
,Coombs,NNP,O
,',POS,O
,test,NN,O
,with,IN,O
,polyspecific,NN,O
,anti,SYM,O
,-,:,O
,human,JJ,O
,globulin,NN,O
,and,CC,O
,monospecific,NN,O
,IgG,NNP,O
,reagents,NNS,O
,",",",",O
,and,CC,O
,a,DT,O
,warm,JJ,O
,reacting,NN,O
,autoantibody,NN,O
,.,.,O
,Transfusion,NN,O
,and,CC,O
,corticosteroid,JJ,O
,therapy,NN,O
,resulted,VBD,O
,in,IN,O
,a,DT,O
,complete,JJ,O
,recovery,NN,O
,of,IN,O
,the,DT,O
,patient,NN,O
,.,.,O
,Emergency,NNP,O
,physicians,VBZ,O
,treating,VBG,O
,children,NNS,O
,must,MD,O
,be,VB,O
,aware,JJ,O
,of,IN,O
,this,DT,O
,syndrome,NN,O
,in,IN,O
,order,NN,O
,to,TO,O
,diagnose,VB,O
,and,CC,O
,treat,VB,O
,it,PRP,O
,correctly,RB,O
,.,.,O
,A,DT,O
,brief,JJ,O
,review,NN,O
,of,IN,O
,autoimmune,NN,O
,and,CC,O
,drug,NN,O
,-,:,O
,induced,VBN,O
,hemolytic,JJ,B-DISEASE
,anemias,NN,I-DISEASE
,is,VBZ,O
,provided,VBN,O
,.,.,O
,The,DT,O
,risk,NN,O
,and,CC,O
,associated,JJ,O
,factors,NNS,O
,of,IN,O
,methamphetamine,JJ,O
,psychosis,NN,B-DISEASE
,in,IN,O
,methamphetamine,JJ,O
,-,:,O
,dependent,JJ,O
,patients,NNS,O
,in,IN,O
,Malaysia,NNP,O
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,The,DT,O
,objective,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,was,VBD,O
,to,TO,O
,determine,VB,O
,the,DT,O
,risk,NN,O
,of,IN,O
,lifetime,NN,O
,and,CC,O
,current,JJ,O
,methamphetamine,NN,O
,-,:,O
,induced,JJ,O
,psychosis,NN,B-DISEASE
,in,IN,O
,patients,NNS,O
,with,IN,O
,methamphetamine,JJ,O
,dependence,NN,O
,.,.,O
,The,DT,O
,association,NN,O
,between,IN,O
,psychiatric,JJ,O
,co,NN,O
,-,:,O
,morbidity,NN,O
,and,CC,O
,methamphetamine,VB,O
,-,:,O
,induced,JJ,O
,psychosis,NN,B-DISEASE
,was,VBD,O
,also,RB,O
,studied,VBN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,This,DT,O
,was,VBD,O
,a,DT,O
,cross,NN,O
,-,:,O
,sectional,JJ,O
,study,NN,O
,conducted,VBD,O
,concurrently,RB,O
,at,IN,O
,a,DT,O
,teaching,JJ,O
,hospital,NN,O
,and,CC,O
,a,DT,O
,drug,NN,O
,rehabilitation,NN,O
,center,NN,O
,in,IN,O
,Malaysia,NNP,O
,.,.,O
,Patients,NNS,O
,with,IN,O
,the,DT,O
,diagnosis,NN,O
,of,IN,O
,methamphetamine,NN,O
,based,VBN,O
,on,IN,O
,DSM,NNP,O
,-,:,O
,IV,NN,O
,were,VBD,O
,interviewed,VBN,O
,using,VBG,O
,the,DT,O
,Mini,NNP,O
,International,NNP,O
,Neuropsychiatric,NNP,O
,Interview,NNP,O
,(,(,O
,M,NNP,O
,.,.,O
,I,PRP,O
,.,.,O
,N,NNP,O
,.,.,O
,I,PRP,O
,.,.,O
,),),O
,for,IN,O
,methamphetamine,NN,O
,-,:,O
,induced,JJ,O
,psychosis,NN,B-DISEASE
,and,CC,O
,other,JJ,O
,Axis,NNP,O
,I,PRP,O
,psychiatric,VBP,B-DISEASE
,disorders,NNS,I-DISEASE
,.,.,O
,The,DT,O
,information,NN,O
,on,IN,O
,sociodemographic,JJ,O
,background,NN,O
,and,CC,O
,drug,NN,O
,use,NN,O
,history,NN,O
,was,VBD,O
,obtained,VBN,O
,from,IN,O
,interview,NN,O
,or,CC,O
,medical,JJ,O
,records,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Of,IN,O
,292,CD,O
,subjects,NNS,O
,",",",",O
,47,CD,O
,.,.,O
,9,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,subjects,NNS,O
,had,VBD,O
,a,DT,O
,past,JJ,O
,history,NN,O
,of,IN,O
,psychotic,JJ,B-DISEASE
,symptoms,NNS,I-DISEASE
,and,CC,O
,13,CD,O
,.,.,O
,0,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,were,VBD,O
,having,VBG,O
,current,JJ,O
,psychotic,JJ,B-DISEASE
,symptoms,NNS,I-DISEASE
,.,.,O
,Co,NNP,O
,-,:,O
,morbid,NN,O
,major,JJ,O
,depressive,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,(,(,O
,OR,NNP,O
,=,VBZ,O
,7,CD,O
,.,.,O
,18,CD,O
,",",",",O
,95,CD,O
,CI,NNP,O
,=,VBD,O
,2,CD,O
,.,.,O
,612,CD,O
,-,:,O
,19,CD,O
,.,.,O
,708,CD,O
,),),O
,",",",",O
,bipolar,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,(,(,O
,OR,NNP,O
,=,VBZ,O
,13,CD,O
,.,.,O
,807,CD,O
,",",",",O
,95,CD,O
,CI,NNP,O
,=,VBD,O
,5,CD,O
,.,.,O
,194,CD,O
,-,:,O
,36,CD,O
,.,.,O
,706,CD,O
,),),O
,",",",",O
,antisocial,JJ,B-DISEASE
,personality,NN,I-DISEASE
,disorder,NN,I-DISEASE
,(,(,O
,OR,NNP,O
,=,VBZ,O
,12,CD,O
,.,.,O
,619,CD,O
,",",",",O
,95,CD,O
,CI,NNP,O
,=,VBD,O
,6,CD,O
,.,.,O
,702,CD,O
,-,:,O
,23,CD,O
,.,.,O
,759,CD,O
,),),O
,and,CC,O
,heavy,JJ,O
,methamphetamine,NN,O
,uses,NNS,O
,were,VBD,O
,significantly,RB,O
,associated,VBN,O
,with,IN,O
,lifetime,JJ,O
,methamphetamine,NN,O
,-,:,O
,induced,JJ,O
,psychosis,NN,B-DISEASE
,after,IN,O
,adjusted,VBN,O
,for,IN,O
,other,JJ,O
,factors,NNS,O
,.,.,O
,Major,JJ,B-DISEASE
,depressive,JJ,I-DISEASE
,disorder,NN,I-DISEASE
,(,(,O
,OR,NNP,O
,=,VBZ,O
,2,CD,O
,.,.,O
,870,CD,O
,",",",",O
,CI,NNP,O
,=,VBZ,O
,1,CD,O
,.,.,O
,154,CD,O
,-,:,O
,7,CD,O
,.,.,O
,142,CD,O
,),),O
,and,CC,O
,antisocial,JJ,B-DISEASE
,personality,NN,I-DISEASE
,disorder,NN,I-DISEASE
,(,(,O
,OR,NNP,O
,=,VBZ,O
,3,CD,O
,.,.,O
,299,CD,O
,",",",",O
,95,CD,O
,CI,NNP,O
,=,VBD,O
,1,CD,O
,.,.,O
,375,CD,O
,-,:,O
,7,CD,O
,.,.,O
,914,CD,O
,),),O
,were,VBD,O
,the,DT,O
,only,JJ,O
,factors,NNS,O
,associated,VBN,O
,with,IN,O
,current,JJ,O
,psychosis,NN,B-DISEASE
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,There,EX,O
,was,VBD,O
,a,DT,O
,high,JJ,O
,risk,NN,O
,of,IN,O
,psychosis,NN,B-DISEASE
,in,IN,O
,patients,NNS,O
,with,IN,O
,methamphetamine,JJ,O
,dependence,NN,O
,.,.,O
,It,PRP,O
,was,VBD,O
,associated,VBN,O
,with,IN,O
,co,JJ,O
,-,:,O
,morbid,NN,O
,affective,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,",",",",O
,antisocial,JJ,B-DISEASE
,personality,NN,I-DISEASE
,",",",",O
,and,CC,O
,heavy,JJ,O
,methamphetamine,NN,O
,use,NN,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,recommended,VBN,O
,that,IN,O
,all,DT,O
,cases,NNS,O
,of,IN,O
,methamphetamine,JJ,O
,dependence,NN,O
,should,MD,O
,be,VB,O
,screened,VBN,O
,for,IN,O
,psychotic,JJ,B-DISEASE
,symptoms,NNS,I-DISEASE
,.,.,O
,Cerebellar,JJ,O
,sensory,JJ,O
,processing,NN,O
,alterations,NNS,O
,impact,VBP,O
,motor,NN,O
,cortical,JJ,O
,plasticity,NN,O
,in,IN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,:,:,O
,clues,NNS,O
,from,IN,O
,dyskinetic,JJ,B-DISEASE
,patients,NNS,O
,.,.,O
,The,DT,O
,plasticity,NN,O
,of,IN,O
,primary,JJ,O
,motor,NN,O
,cortex,NN,O
,(,(,O
,M1,NNP,O
,),),O
,in,IN,O
,patients,NNS,O
,with,IN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,NN,I-DISEASE
,disease,NN,I-DISEASE
,(,(,O
,PD,NNP,B-DISEASE
,),),O
,and,CC,O
,levodopa,$,O
,-,:,O
,induced,VBN,O
,dyskinesias,NN,B-DISEASE
,(,(,O
,LIDs,NNP,B-DISEASE
,),),O
,is,VBZ,O
,severely,RB,O
,impaired,JJ,O
,.,.,O
,We,PRP,O
,recently,RB,O
,reported,VBD,O
,in,IN,O
,young,JJ,O
,healthy,JJ,O
,subjects,NNS,O
,that,WDT,O
,inhibitory,VBP,O
,cerebellar,JJ,O
,stimulation,NN,O
,enhanced,VBD,O
,the,DT,O
,sensorimotor,NN,O
,plasticity,NN,O
,of,IN,O
,M1,NNP,O
,that,WDT,O
,was,VBD,O
,induced,VBN,O
,by,IN,O
,paired,JJ,O
,associative,JJ,O
,stimulation,NN,O
,(,(,O
,PAS,NNP,O
,),),O
,.,.,O
,This,DT,O
,study,NN,O
,demonstrates,VBZ,O
,that,IN,O
,the,DT,O
,deficient,NN,O
,sensorimotor,NN,O
,M1,NNP,O
,plasticity,NN,O
,in,IN,O
,16,CD,O
,patients,NNS,O
,with,IN,O
,LIDs,NNP,B-DISEASE
,could,MD,O
,be,VB,O
,reinstated,VBN,O
,by,IN,O
,a,DT,O
,single,JJ,O
,session,NN,O
,of,IN,O
,real,JJ,O
,inhibitory,JJ,O
,cerebellar,JJ,O
,stimulation,NN,O
,but,CC,O
,not,RB,O
,sham,JJ,O
,stimulation,NN,O
,.,.,O
,This,DT,O
,was,VBD,O
,evident,JJ,O
,only,RB,O
,when,WRB,O
,a,DT,O
,sensory,JJ,O
,component,NN,O
,was,VBD,O
,involved,VBN,O
,in,IN,O
,the,DT,O
,induction,NN,O
,of,IN,O
,plasticity,NN,O
,",",",",O
,indicating,VBG,O
,that,IN,O
,cerebellar,JJ,O
,sensory,NN,O
,processing,NN,O
,function,NN,O
,is,VBZ,O
,involved,VBN,O
,in,IN,O
,the,DT,O
,resurgence,NN,O
,of,IN,O
,M1,NNP,O
,plasticity,NN,O
,.,.,O
,The,DT,O
,benefit,NN,O
,of,IN,O
,inhibitory,NN,O
,cerebellar,JJ,O
,stimulation,NN,O
,on,IN,O
,LIDs,NNP,B-DISEASE
,is,VBZ,O
,known,VBN,O
,.,.,O
,To,TO,O
,explore,VB,O
,whether,IN,O
,this,DT,O
,benefit,NN,O
,is,VBZ,O
,linked,VBN,O
,to,TO,O
,the,DT,O
,restoration,NN,O
,of,IN,O
,sensorimotor,NN,O
,plasticity,NN,O
,of,IN,O
,M1,NNP,O
,",",",",O
,we,PRP,O
,conducted,VBD,O
,an,DT,O
,additional,JJ,O
,study,NN,O
,looking,VBG,O
,at,IN,O
,changes,NNS,O
,in,IN,O
,LIDs,NNP,B-DISEASE
,and,CC,O
,PAS,NNP,O
,-,:,O
,induced,JJ,O
,plasticity,NN,O
,after,IN,O
,10,CD,O
,sessions,NNS,O
,of,IN,O
,either,DT,O
,bilateral,JJ,O
,",",",",O
,real,JJ,O
,inhibitory,NN,O
,cerebellar,JJ,O
,stimulation,NN,O
,or,CC,O
,sham,JJ,O
,stimulation,NN,O
,.,.,O
,Only,RB,O
,real,JJ,O
,and,CC,O
,not,RB,O
,sham,JJ,O
,stimulation,NN,O
,had,VBD,O
,an,DT,O
,antidyskinetic,JJ,O
,effect,NN,O
,and,CC,O
,it,PRP,O
,was,VBD,O
,paralleled,VBN,O
,by,IN,O
,a,DT,O
,resurgence,NN,O
,in,IN,O
,the,DT,O
,sensorimotor,NN,O
,plasticity,NN,O
,of,IN,O
,M1,NNP,O
,.,.,O
,These,DT,O
,results,NNS,O
,suggest,VBP,O
,that,IN,O
,alterations,NNS,O
,in,IN,O
,cerebellar,JJ,O
,sensory,NN,O
,processing,NN,O
,function,NN,O
,",",",",O
,occurring,VBG,O
,secondary,JJ,O
,to,TO,O
,abnormal,VB,O
,basal,NN,O
,ganglia,JJ,O
,signals,NNS,O
,reaching,VBG,O
,it,PRP,O
,",",",",O
,may,MD,O
,be,VB,O
,an,DT,O
,important,JJ,O
,element,NN,O
,contributing,VBG,O
,to,TO,O
,the,DT,O
,maladaptive,JJ,O
,sensorimotor,NN,O
,plasticity,NN,O
,of,IN,O
,M1,NNP,O
,and,CC,O
,the,DT,O
,emergence,NN,O
,of,IN,O
,abnormal,JJ,B-DISEASE
,involuntary,JJ,I-DISEASE
,movements,NNS,I-DISEASE
,.,.,O
,The,DT,O
,long,JJ,O
,-,:,O
,term,NN,O
,safety,NN,O
,of,IN,O
,danazol,NN,O
,in,IN,O
,women,NNS,O
,with,IN,O
,hereditary,JJ,B-DISEASE
,angioedema,NN,I-DISEASE
,.,.,O
,Although,IN,O
,the,DT,O
,short,JJ,O
,-,:,O
,term,NN,O
,safety,NN,O
,(,(,O
,less,JJR,O
,than,IN,O
,or,CC,O
,equal,JJ,O
,to,TO,O
,6,CD,O
,months,NNS,O
,),),O
,of,IN,O
,danazol,NN,O
,has,VBZ,O
,been,VBN,O
,established,VBN,O
,in,IN,O
,a,DT,O
,variety,NN,O
,of,IN,O
,settings,NNS,O
,",",",",O
,no,DT,O
,information,NN,O
,exists,VBZ,O
,as,IN,O
,to,TO,O
,its,PRP$,O
,long,JJ,O
,-,:,O
,term,NN,O
,safety,NN,O
,.,.,O
,We,PRP,O
,therefore,RB,O
,investigated,VBD,O
,the,DT,O
,long,JJ,O
,-,:,O
,term,NN,O
,safety,NN,O
,of,IN,O
,danazol,NN,O
,by,IN,O
,performing,VBG,O
,a,DT,O
,retrospective,JJ,O
,chart,NN,O
,review,NN,O
,of,IN,O
,60,CD,O
,female,JJ,O
,patients,NNS,O
,with,IN,O
,hereditary,JJ,B-DISEASE
,angioedema,NNS,I-DISEASE
,treated,VBN,O
,with,IN,O
,danazol,NN,O
,for,IN,O
,a,DT,O
,continuous,JJ,O
,period,NN,O
,of,IN,O
,6,CD,O
,months,NNS,O
,or,CC,O
,longer,JJR,O
,.,.,O
,The,DT,O
,mean,JJ,O
,age,NN,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,was,VBD,O
,35,CD,O
,.,.,O
,2,CD,O
,years,NNS,O
,and,CC,O
,the,DT,O
,mean,JJ,O
,duration,NN,O
,of,IN,O
,therapy,NN,O
,was,VBD,O
,59,CD,O
,.,.,O
,7,CD,O
,months,NNS,O
,.,.,O
,Virtually,RB,O
,all,DT,O
,patients,NNS,O
,experienced,VBD,O
,one,CD,O
,or,CC,O
,more,JJR,O
,adverse,JJ,O
,reactions,NNS,O
,.,.,O
,Menstrual,JJ,B-DISEASE
,abnormalities,NNS,I-DISEASE
,(,(,O
,79,CD,O
,%,NN,O
,),),O
,",",",",O
,weight,JJ,B-DISEASE
,gain,NN,I-DISEASE
,(,(,O
,60,CD,O
,%,NN,O
,),),O
,",",",",O
,muscle,NN,B-DISEASE
,cramps,NNS,I-DISEASE
,/,VBP,O
,myalgias,NNS,B-DISEASE
,(,(,O
,40,CD,O
,%,NN,O
,),),O
,",",",",O
,and,CC,O
,transaminase,NN,O
,elevations,NNS,O
,(,(,O
,40,CD,O
,%,NN,O
,),),O
,were,VBD,O
,the,DT,O
,most,RBS,O
,common,JJ,O
,adverse,JJ,O
,reactions,NNS,O
,.,.,O
,The,DT,O
,drug,NN,O
,was,VBD,O
,discontinued,VBN,O
,due,JJ,O
,to,TO,O
,adverse,JJ,O
,reactions,NNS,O
,in,IN,O
,8,CD,O
,patients,NNS,O
,.,.,O
,No,DT,O
,patient,NN,O
,has,VBZ,O
,died,VBN,O
,or,CC,O
,suffered,VBN,O
,any,DT,O
,apparent,JJ,O
,long,JJ,O
,-,:,O
,term,NN,O
,sequelae,NN,O
,that,WDT,O
,were,VBD,O
,directly,RB,O
,attributable,JJ,O
,to,TO,O
,the,DT,O
,drug,NN,O
,.,.,O
,We,PRP,O
,conclude,VBP,O
,that,IN,O
,",",",",O
,despite,IN,O
,a,DT,O
,relatively,RB,O
,high,JJ,O
,incidence,NN,O
,of,IN,O
,adverse,JJ,O
,reactions,NNS,O
,",",",",O
,danazol,NN,O
,has,VBZ,O
,proven,VBN,O
,to,TO,O
,be,VB,O
,remarkably,RB,O
,safe,JJ,O
,over,IN,O
,the,DT,O
,long,JJ,O
,-,:,O
,term,NN,O
,in,IN,O
,this,DT,O
,group,NN,O
,of,IN,O
,patients,NNS,O
,.,.,O
,The,DT,O
,function,NN,O
,of,IN,O
,P2X3,NNP,O
,receptor,NN,O
,and,CC,O
,NK1,NNP,O
,receptor,NN,O
,antagonists,NNS,O
,on,IN,O
,cyclophosphamide,NN,O
,-,:,O
,induced,JJ,O
,cystitis,NN,B-DISEASE
,in,IN,O
,rats,NNS,O
,.,.,O
,PURPOSE,NN,O
,:,:,O
,The,DT,O
,purpose,NN,O
,of,IN,O
,the,DT,O
,study,NN,O
,is,VBZ,O
,to,TO,O
,explore,VB,O
,the,DT,O
,function,NN,O
,of,IN,O
,P2X3,NNP,O
,and,CC,O
,NK1,NNP,O
,receptors,NNS,O
,antagonists,VBZ,O
,on,IN,O
,cyclophosphamide,NN,O
,(,(,O
,CYP,NNP,O
,),),O
,-,:,O
,induced,VBN,O
,cystitis,NN,B-DISEASE
,in,IN,O
,rats,NNS,O
,.,.,O
,METHODS,NN,O
,:,:,O
,Sixty,NNP,O
,female,NN,O
,Sprague,NNP,O
,-,:,O
,Dawley,NNP,O
,(,(,O
,SD,NNP,O
,),),O
,rats,NNS,O
,were,VBD,O
,randomly,RB,O
,divided,VBN,O
,into,IN,O
,three,CD,O
,groups,NNS,O
,.,.,O
,The,DT,O
,rats,NNS,O
,in,IN,O
,the,DT,O
,control,NN,O
,group,NN,O
,were,VBD,O
,intraperitoneally,RB,O
,(,(,O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,injected,VBD,O
,with,IN,O
,0,CD,O
,.,.,O
,9,CD,O
,%,NN,O
,saline,NN,O
,(,(,O
,4,CD,O
,ml,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,;,:,O
,the,DT,O
,rats,NNS,O
,in,IN,O
,the,DT,O
,model,NN,O
,group,NN,O
,were,VBD,O
,i,RB,O
,.,.,O
,p,NN,O
,.,.,O
,injected,VBN,O
,with,IN,O
,CYP,NNP,O
,(,(,O
,150,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,;,:,O
,and,CC,O
,the,DT,O
,rats,NNS,O
,in,IN,O
,the,DT,O
,intervention,NN,O
,group,NN,O
,were,VBD,O
,i,RB,O
,.,.,O
,p,NN,O
,.,.,O
,injected,VBN,O
,with,IN,O
,CYP,NNP,O
,with,IN,O
,subsequently,JJ,O
,perfusion,NN,O
,of,IN,O
,bladder,NN,O
,with,IN,O
,P2X3,NNP,O
,and,CC,O
,NK1,NNP,O
,receptors,NNS,O
,',POS,O
,antagonists,NNS,O
,",",",",O
,Suramin,NNP,O
,and,CC,O
,GR,NNP,O
,82334,CD,O
,.,.,O
,Spontaneous,JJ,O
,pain,NN,B-DISEASE
,behaviors,NNS,O
,following,VBG,O
,the,DT,O
,administration,NN,O
,of,IN,O
,CYP,NNP,O
,were,VBD,O
,observed,VBN,O
,.,.,O
,Urodynamic,JJ,O
,parameters,NNS,O
,",",",",O
,bladder,NN,O
,pressure,NN,O
,-,:,O
,volume,NN,O
,curve,NN,O
,",",",",O
,maximum,JJ,O
,voiding,NN,O
,pressure,NN,O
,(,(,O
,MVP,NNP,O
,),),O
,",",",",O
,and,CC,O
,maximum,JJ,O
,cystometric,JJ,O
,capacity,NN,O
,(,(,O
,MCC,NNP,O
,),),O
,",",",",O
,were,VBD,O
,recorded,VBN,O
,.,.,O
,Pathological,JJ,O
,changes,NNS,O
,in,IN,O
,bladder,NN,O
,tissue,NN,O
,were,VBD,O
,observed,VBN,O
,.,.,O
,Immunofluorescence,NN,O
,was,VBD,O
,used,VBN,O
,to,TO,O
,detect,VB,O
,the,DT,O
,expression,NN,O
,of,IN,O
,P2X3,NNP,O
,and,CC,O
,NK1,NNP,O
,receptors,NNS,O
,in,IN,O
,bladder,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Cyclophosphamide,JJ,O
,treatment,NN,O
,increased,VBD,O
,the,DT,O
,spontaneous,JJ,O
,pain,NN,B-DISEASE
,behaviors,NNS,O
,scores,NNS,O
,.,.,O
,The,DT,O
,incidence,NN,O
,of,IN,O
,bladder,NN,O
,instability,NN,O
,during,IN,O
,urine,JJ,O
,storage,NN,O
,period,NN,O
,of,IN,O
,model,NN,O
,group,NN,O
,was,VBD,O
,significantly,RB,O
,higher,JJR,O
,than,IN,O
,intervention,NN,O
,group,NN,O
,(,(,O
,X,NNP,O
,(,(,O
,2,CD,O
,),),O
,=,NN,O
,7,CD,O
,.,.,O
,619,CD,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,007,CD,O
,),),O
,and,CC,O
,control,NN,O
,group,NN,O
,(,(,O
,X,NNP,O
,(,(,O
,2,CD,O
,),),O
,=,NN,O
,13,CD,O
,.,.,O
,755,CD,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,000,CD,O
,),),O
,.,.,O
,MCC,NNP,O
,in,IN,O
,the,DT,O
,model,NN,O
,group,NN,O
,was,VBD,O
,lower,JJR,O
,than,IN,O
,the,DT,O
,control,NN,O
,and,CC,O
,intervention,NN,O
,groups,NNS,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,Histological,JJ,O
,changes,NNS,O
,evident,VBP,O
,in,IN,O
,model,NN,O
,and,CC,O
,intervention,NN,O
,groups,NNS,O
,rats,NNS,O
,',POS,O
,bladder,NN,O
,included,VBD,O
,edema,NN,B-DISEASE
,",",",",O
,vasodilation,NN,O
,",",",",O
,and,CC,O
,infiltration,NN,O
,of,IN,O
,inflammatory,JJ,O
,cells,NNS,O
,.,.,O
,In,IN,O
,model,NN,O
,group,NN,O
,",",",",O
,the,DT,O
,expression,NN,O
,of,IN,O
,P2X3,NNP,O
,receptor,NN,O
,increased,VBD,O
,in,IN,O
,urothelium,NN,O
,and,CC,O
,suburothelium,NN,O
,",",",",O
,and,CC,O
,NK1,NNP,O
,receptor,NN,O
,increased,VBD,O
,in,IN,O
,suburothelium,NN,O
,",",",",O
,while,IN,O
,the,DT,O
,expression,NN,O
,of,IN,O
,them,PRP,O
,in,IN,O
,intervention,NN,O
,group,NN,O
,was,VBD,O
,lower,JJR,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,In,IN,O
,CYP,NNP,O
,-,:,O
,induced,JJ,O
,cystitis,NN,B-DISEASE
,",",",",O
,the,DT,O
,expression,NN,O
,of,IN,O
,P2X3,NNP,O
,and,CC,O
,NK1,NNP,O
,receptors,NNS,O
,increased,VBD,O
,in,IN,O
,urothelium,NN,O
,and,CC,O
,/,NN,O
,or,CC,O
,suburothelium,NN,O
,.,.,O
,Perfusion,NN,O
,of,IN,O
,bladder,NN,O
,with,IN,O
,P2X3,NNP,O
,and,CC,O
,NK1,NNP,O
,receptors,NNS,O
,antagonists,NNS,O
,ameliorated,VBD,O
,the,DT,O
,bladder,NN,O
,function,NN,O
,.,.,O
,Patient,JJ,O
,tolerance,NN,O
,study,NN,O
,of,IN,O
,topical,JJ,O
,chlorhexidine,NN,O
,diphosphanilate,NN,O
,:,:,O
,a,DT,O
,new,JJ,O
,topical,JJ,O
,agent,NN,O
,for,IN,O
,burns,NNS,B-DISEASE
,.,.,O
,Effective,JJ,O
,topical,JJ,O
,antimicrobial,JJ,O
,agents,NNS,O
,decrease,JJ,O
,infection,NN,B-DISEASE
,and,CC,O
,mortality,NN,O
,in,IN,O
,burn,NN,B-DISEASE
,patients,NNS,O
,.,.,O
,Chlorhexidine,NNP,O
,phosphanilate,NN,O
,(,(,O
,CHP,NNP,O
,),),O
,",",",",O
,a,DT,O
,new,JJ,O
,broad,JJ,O
,-,:,O
,spectrum,NN,O
,antimicrobial,JJ,O
,agent,NN,O
,",",",",O
,has,VBZ,O
,been,VBN,O
,evaluated,VBN,O
,as,IN,O
,a,DT,O
,topical,JJ,O
,burn,NN,B-DISEASE
,wound,NN,O
,dressing,NN,O
,in,IN,O
,cream,NN,O
,form,NN,O
,",",",",O
,but,CC,O
,preliminary,JJ,O
,clinical,JJ,O
,trials,NNS,O
,reported,VBD,O
,that,IN,O
,it,PRP,O
,was,VBD,O
,painful,JJ,O
,upon,IN,O
,application,NN,O
,.,.,O
,This,DT,O
,study,NN,O
,compared,VBN,O
,various,JJ,O
,concentrations,NNS,O
,of,IN,O
,CHP,NNP,O
,to,TO,O
,determine,VB,O
,if,IN,O
,a,DT,O
,tolerable,JJ,O
,concentration,NN,O
,could,MD,O
,be,VB,O
,identified,VBN,O
,with,IN,O
,retention,NN,O
,of,IN,O
,antimicrobial,JJ,O
,efficacy,NN,O
,.,.,O
,Twenty,NNP,O
,-,:,O
,nine,CD,O
,burn,NN,B-DISEASE
,patients,NNS,O
,",",",",O
,each,DT,O
,with,IN,O
,two,CD,O
,similar,JJ,O
,burns,NNS,B-DISEASE
,which,WDT,O
,could,MD,O
,be,VB,O
,separately,RB,O
,treated,VBN,O
,",",",",O
,were,VBD,O
,given,VBN,O
,pairs,NNS,O
,of,IN,O
,treatments,NNS,O
,at,IN,O
,successive,JJ,O
,12,CD,O
,-,:,O
,h,NN,O
,intervals,NNS,O
,over,IN,O
,a,DT,O
,3,CD,O
,-,:,O
,day,NN,O
,period,NN,O
,.,.,O
,One,CD,O
,burn,NN,B-DISEASE
,site,NN,O
,was,VBD,O
,treated,VBN,O
,with,IN,O
,each,DT,O
,of,IN,O
,four,CD,O
,different,JJ,O
,CHP,NNP,O
,concentrations,NNS,O
,",",",",O
,from,IN,O
,0,CD,O
,.,.,O
,25,CD,O
,per,IN,O
,cent,NN,O
,to,TO,O
,2,CD,O
,per,IN,O
,cent,NN,O
,",",",",O
,their,PRP$,O
,vehicle,NN,O
,",",",",O
,and,CC,O
,1,CD,O
,per,IN,O
,cent,NN,O
,silver,NN,O
,sulphadiazine,NN,O
,(,(,O
,AgSD,NNP,O
,),),O
,cream,NN,O
,",",",",O
,an,DT,O
,antimicrobial,JJ,O
,agent,NN,O
,frequently,RB,O
,used,VBN,O
,for,IN,O
,topical,JJ,O
,treatment,NN,O
,of,IN,O
,burn,NN,B-DISEASE
,wounds,NNS,O
,.,.,O
,The,DT,O
,other,JJ,O
,site,NN,O
,was,VBD,O
,always,RB,O
,treated,VBN,O
,with,IN,O
,AgSD,NNP,O
,cream,NN,O
,.,.,O
,There,EX,O
,was,VBD,O
,a,DT,O
,direct,JJ,O
,relationship,NN,O
,between,IN,O
,CHP,NNP,O
,concentration,NN,O
,and,CC,O
,patients,NNS,O
,',POS,O
,ratings,NNS,O
,of,IN,O
,pain,NN,B-DISEASE
,on,IN,O
,an,DT,O
,analogue,JJ,O
,scale,NN,O
,.,.,O
,The,DT,O
,0,CD,O
,.,.,O
,25,CD,O
,per,IN,O
,cent,NN,O
,CHP,NNP,O
,cream,NN,O
,was,VBD,O
,closest,JJS,O
,to,TO,O
,AgSD,NNP,O
,in,IN,O
,pain,NN,B-DISEASE
,tolerance,NN,O
,;,:,O
,however,RB,O
,",",",",O
,none,NN,O
,of,IN,O
,the,DT,O
,treatments,NNS,O
,differed,VBD,O
,statistically,RB,O
,from,IN,O
,AgSD,NNP,O
,or,CC,O
,from,IN,O
,each,DT,O
,other,JJ,O
,.,.,O
,In,IN,O
,addition,NN,O
,",",",",O
,ease,NN,O
,of,IN,O
,application,NN,O
,of,IN,O
,CHP,NNP,O
,creams,NN,O
,was,VBD,O
,less,RBR,O
,satisfactory,JJ,O
,than,IN,O
,that,DT,O
,of,IN,O
,AgSD,NNP,O
,.,.,O
,It,PRP,O
,was,VBD,O
,concluded,VBN,O
,that,IN,O
,formulations,NNS,O
,at,IN,O
,or,CC,O
,below,IN,O
,0,CD,O
,.,.,O
,5,CD,O
,per,IN,O
,cent,NN,O
,CHP,NNP,O
,may,MD,O
,prove,VB,O
,acceptable,JJ,O
,for,IN,O
,wound,NN,O
,care,NN,O
,",",",",O
,but,CC,O
,the,DT,O
,vehicle,NN,O
,system,NN,O
,needs,VBZ,O
,pharmaceutical,JJ,O
,improvement,NN,O
,to,TO,O
,render,VB,O
,it,PRP,O
,more,RBR,O
,tolerable,JJ,O
,and,CC,O
,easier,JJR,O
,to,TO,O
,use,VB,O
,.,.,O
,Acute,NNP,O
,hepatitis,NN,B-DISEASE
,associated,VBN,O
,with,IN,O
,clopidogrel,NN,O
,:,:,O
,a,DT,O
,case,NN,O
,report,NN,O
,and,CC,O
,review,NN,O
,of,IN,O
,the,DT,O
,literature,NN,O
,.,.,O
,Drug,NNP,O
,-,:,O
,induced,JJ,O
,hepatotoxicity,NN,B-DISEASE
,is,VBZ,O
,a,DT,O
,common,JJ,O
,cause,NN,O
,of,IN,O
,acute,JJ,O
,hepatitis,NN,B-DISEASE
,",",",",O
,and,CC,O
,the,DT,O
,recognition,NN,O
,of,IN,O
,the,DT,O
,responsible,JJ,O
,drug,NN,O
,may,MD,O
,be,VB,O
,difficult,JJ,O
,.,.,O
,We,PRP,O
,describe,VBP,O
,a,DT,O
,case,NN,O
,of,IN,O
,clopidogrel,NN,O
,-,:,O
,related,VBN,O
,acute,JJ,O
,hepatitis,NN,B-DISEASE
,.,.,O
,The,DT,O
,diagnosis,NN,O
,is,VBZ,O
,strongly,RB,O
,suggested,VBN,O
,by,IN,O
,an,DT,O
,accurate,JJ,O
,medical,JJ,O
,history,NN,O
,and,CC,O
,liver,NN,O
,biopsy,NN,O
,.,.,O
,Reports,NNS,O
,about,IN,O
,cases,NNS,O
,of,IN,O
,hepatotoxicity,NN,B-DISEASE
,due,JJ,O
,to,TO,O
,clopidogrel,NNS,O
,are,VBP,O
,increasing,VBG,O
,in,IN,O
,the,DT,O
,last,JJ,O
,few,JJ,O
,years,NNS,O
,",",",",O
,after,IN,O
,the,DT,O
,increased,VBN,O
,use,NN,O
,of,IN,O
,this,DT,O
,drug,NN,O
,.,.,O
,In,IN,O
,conclusion,NN,O
,",",",",O
,we,PRP,O
,believe,VBP,O
,that,IN,O
,physicians,NNS,O
,should,MD,O
,carefully,RB,O
,consider,VB,O
,the,DT,O
,risk,NN,O
,of,IN,O
,drug,NN,O
,-,:,O
,induced,VBN,O
,hepatic,JJ,B-DISEASE
,injury,NN,I-DISEASE
,when,WRB,O
,clopidogrel,NN,O
,is,VBZ,O
,prescribed,VBN,O
,.,.,O
,Bortezomib,NNP,O
,and,CC,O
,dexamethasone,NN,O
,as,IN,O
,salvage,NN,O
,therapy,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,relapsed,JJ,O
,/,NNP,O
,refractory,NN,O
,multiple,JJ,B-DISEASE
,myeloma,NN,I-DISEASE
,:,:,O
,analysis,NN,O
,of,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,clinical,JJ,O
,outcomes,NNS,O
,.,.,O
,Bortezomib,NNP,O
,(,(,O
,bort,NN,O
,),),O
,-,:,O
,dexamethasone,NN,O
,(,(,O
,dex,NN,O
,),),O
,is,VBZ,O
,an,DT,O
,effective,JJ,O
,therapy,NN,O
,for,IN,O
,relapsed,JJ,O
,/,NNP,O
,refractory,NN,O
,(,(,O
,R,NNP,O
,/,NNP,O
,R,NNP,O
,),),O
,multiple,NN,B-DISEASE
,myeloma,NN,I-DISEASE
,(,(,O
,MM,NNP,B-DISEASE
,),),O
,.,.,O
,This,DT,O
,retrospective,JJ,O
,study,NN,O
,investigated,VBD,O
,the,DT,O
,combination,NN,O
,of,IN,O
,bort,NN,O
,(,(,O
,1,CD,O
,.,.,O
,3,CD,O
,mg,JJ,O
,/,NNP,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,on,IN,O
,days,NNS,O
,1,CD,O
,",",",",O
,4,CD,O
,",",",",O
,8,CD,O
,",",",",O
,and,CC,O
,11,CD,O
,every,DT,O
,3,CD,O
,weeks,NNS,O
,),),O
,and,CC,O
,dex,NN,O
,(,(,O
,20,CD,O
,mg,NN,O
,on,IN,O
,the,DT,O
,day,NN,O
,of,IN,O
,and,CC,O
,the,DT,O
,day,NN,O
,after,IN,O
,bort,NN,O
,),),O
,as,IN,O
,salvage,NN,O
,treatment,NN,O
,in,IN,O
,85,CD,O
,patients,NNS,O
,with,IN,O
,R,NNP,O
,/,NNP,O
,R,NNP,O
,MM,NNP,B-DISEASE
,after,IN,O
,prior,RB,O
,autologous,JJ,O
,stem,NN,O
,cell,NN,O
,transplantation,NN,O
,or,CC,O
,conventional,JJ,O
,chemotherapy,NN,O
,.,.,O
,The,DT,O
,median,JJ,O
,number,NN,O
,of,IN,O
,prior,JJ,O
,lines,NNS,O
,of,IN,O
,therapy,NN,O
,was,VBD,O
,2,CD,O
,.,.,O
,Eighty,NNP,O
,-,:,O
,seven,CD,O
,percent,NN,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,had,VBD,O
,received,VBN,O
,immunomodulatory,JJ,O
,drugs,NNS,O
,included,VBN,O
,in,IN,O
,some,DT,O
,line,NN,O
,of,IN,O
,therapy,NN,O
,before,IN,O
,bort,NN,O
,-,:,O
,dex,NN,O
,.,.,O
,The,DT,O
,median,JJ,O
,number,NN,O
,of,IN,O
,bort,NN,O
,-,:,O
,dex,NN,O
,cycles,NNS,O
,was,VBD,O
,6,CD,O
,",",",",O
,up,RB,O
,to,TO,O
,a,DT,O
,maximum,NN,O
,of,IN,O
,12,CD,O
,cycles,NNS,O
,.,.,O
,On,IN,O
,an,DT,O
,intention,NN,O
,-,:,O
,to,TO,O
,-,:,O
,treat,NN,O
,basis,NN,O
,",",",",O
,55,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,achieved,VBN,O
,at,IN,O
,least,JJS,O
,partial,JJ,O
,response,NN,O
,",",",",O
,including,VBG,O
,19,CD,O
,%,NN,O
,CR,NNP,O
,and,CC,O
,35,CD,O
,%,NN,O
,achieved,VBN,O
,at,IN,O
,least,JJS,O
,very,RB,O
,good,JJ,O
,partial,JJ,O
,response,NN,O
,.,.,O
,Median,JJ,O
,durations,NNS,O
,of,IN,O
,response,NN,O
,",",",",O
,time,NN,O
,to,TO,O
,next,JJ,O
,therapy,NN,O
,and,CC,O
,treatment,NN,O
,-,:,O
,free,JJ,O
,interval,NN,O
,were,VBD,O
,8,CD,O
,",",",",O
,11,CD,O
,.,.,O
,2,CD,O
,",",",",O
,and,CC,O
,5,CD,O
,.,.,O
,1,CD,O
,months,NNS,O
,",",",",O
,respectively,RB,O
,.,.,O
,The,DT,O
,most,RBS,O
,relevant,JJ,O
,adverse,JJ,O
,event,NN,O
,was,VBD,O
,peripheral,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,",",",",O
,which,WDT,O
,occurred,VBD,O
,in,IN,O
,78,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,(,(,O
,grade,JJ,O
,II,NNP,O
,",",",",O
,38,CD,O
,%,NN,O
,;,:,O
,grade,CC,O
,III,NNP,O
,",",",",O
,21,CD,O
,%,NN,O
,),),O
,and,CC,O
,led,VBN,O
,to,TO,O
,treatment,NN,O
,discontinuation,NN,O
,in,IN,O
,6,CD,O
,%,NN,O
,.,.,O
,With,IN,O
,a,DT,O
,median,NN,O
,follow,VBP,O
,up,IN,O
,of,IN,O
,22,CD,O
,months,NNS,O
,",",",",O
,median,JJ,O
,time,NN,O
,to,TO,O
,progression,NN,O
,",",",",O
,progression,NN,O
,-,:,O
,free,JJ,O
,survival,NN,O
,(,(,O
,PFS,NNP,O
,),),O
,and,CC,O
,overall,JJ,O
,survival,NN,O
,(,(,O
,OS,NNP,O
,),),O
,were,VBD,O
,8,CD,O
,.,.,O
,9,CD,O
,",",",",O
,8,CD,O
,.,.,O
,7,CD,O
,",",",",O
,and,CC,O
,22,CD,O
,months,NNS,O
,",",",",O
,respectively,RB,O
,.,.,O
,Prolonged,NNP,O
,PFS,NNP,O
,and,CC,O
,OS,NNP,O
,were,VBD,O
,observed,VBN,O
,in,IN,O
,patients,NNS,O
,achieving,VBG,O
,CR,NNP,O
,and,CC,O
,receiving,VBG,O
,bort,NN,O
,-,:,O
,dex,NN,O
,a,DT,O
,single,JJ,O
,line,NN,O
,of,IN,O
,prior,JJ,O
,therapy,NN,O
,.,.,O
,Bort,NNP,O
,-,:,O
,dex,NN,O
,was,VBD,O
,an,DT,O
,effective,JJ,O
,salvage,NN,O
,treatment,NN,O
,for,IN,O
,MM,NNP,B-DISEASE
,patients,NNS,O
,",",",",O
,particularly,RB,O
,for,IN,O
,those,DT,O
,in,IN,O
,first,JJ,O
,relapse,NN,O
,.,.,O
,Pubertal,JJ,O
,exposure,NN,O
,to,TO,O
,Bisphenol,VB,O
,A,NNP,O
,increases,NNS,O
,anxiety,NN,B-DISEASE
,-,:,O
,like,IN,O
,behavior,NN,O
,and,CC,O
,decreases,VBZ,O
,acetylcholinesterase,JJ,O
,activity,NN,O
,of,IN,O
,hippocampus,NN,O
,in,IN,O
,adult,NN,O
,male,NN,O
,mice,NN,O
,.,.,O
,The,DT,O
,negative,JJ,O
,effects,NNS,O
,of,IN,O
,Bisphenol,NNP,O
,A,NNP,O
,(,(,O
,BPA,NNP,O
,),),O
,on,IN,O
,neurodevelopment,NN,O
,and,CC,O
,behaviors,NNS,O
,have,VBP,O
,been,VBN,O
,well,RB,O
,established,VBN,O
,.,.,O
,Acetylcholinesterase,NNP,O
,(,(,O
,AChE,NNP,O
,),),O
,is,VBZ,O
,a,DT,O
,regulatory,JJ,O
,enzyme,NN,O
,which,WDT,O
,is,VBZ,O
,involved,VBN,O
,in,IN,O
,anxiety,NN,B-DISEASE
,-,:,O
,like,IN,O
,behavior,NN,O
,.,.,O
,This,DT,O
,study,NN,O
,investigated,VBD,O
,behavioral,JJ,O
,phenotypes,NNS,O
,and,CC,O
,AChE,NNP,O
,activity,NN,O
,in,IN,O
,male,JJ,O
,mice,NN,O
,following,VBG,O
,BPA,NNP,O
,exposure,NN,O
,during,IN,O
,puberty,NN,O
,.,.,O
,On,IN,O
,postnatal,JJ,O
,day,NN,O
,(,(,O
,PND,NNP,O
,),),O
,35,CD,O
,",",",",O
,male,JJ,O
,mice,NN,O
,were,VBD,O
,exposed,VBN,O
,to,TO,O
,50mg,CD,O
,BPA,NNP,O
,/,NNP,O
,kg,NNP,O
,diet,JJ,O
,per,IN,O
,day,NN,O
,for,IN,O
,a,DT,O
,period,NN,O
,of,IN,O
,35,CD,O
,days,NNS,O
,.,.,O
,On,IN,O
,PND71,NNP,O
,",",",",O
,a,DT,O
,behavioral,JJ,O
,assay,NN,O
,was,VBD,O
,performed,VBN,O
,using,VBG,O
,the,DT,O
,elevated,JJ,O
,plus,CC,O
,maze,JJ,O
,(,(,O
,EPM,NNP,O
,),),O
,and,CC,O
,the,DT,O
,light,JJ,O
,/,NNP,O
,dark,JJ,O
,test,NN,O
,.,.,O
,In,IN,O
,addition,NN,O
,",",",",O
,AChE,NNP,O
,activity,NN,O
,was,VBD,O
,measured,VBN,O
,in,IN,O
,the,DT,O
,prefrontal,JJ,O
,cortex,NN,O
,",",",",O
,hypothalamus,NN,O
,",",",",O
,cerebellum,NN,O
,and,CC,O
,hippocampus,NN,O
,.,.,O
,Results,NNS,O
,from,IN,O
,our,PRP$,O
,behavioral,JJ,O
,phenotyping,NN,O
,indicated,VBD,O
,that,IN,O
,anxiety,NN,B-DISEASE
,-,:,O
,like,IN,O
,behavior,NN,O
,was,VBD,O
,increased,VBN,O
,in,IN,O
,mice,NN,O
,exposed,VBN,O
,to,TO,O
,BPA,NNP,O
,.,.,O
,AChE,NNP,O
,activity,NN,O
,was,VBD,O
,significantly,RB,O
,decreased,VBN,O
,in,IN,O
,the,DT,O
,hippocampus,NN,O
,of,IN,O
,mice,NN,O
,with,IN,O
,BPA,NNP,O
,compared,VBN,O
,to,TO,O
,control,VB,O
,mice,NN,O
,",",",",O
,whereas,IN,O
,no,DT,O
,difference,NN,O
,was,VBD,O
,found,VBN,O
,in,IN,O
,the,DT,O
,prefrontal,JJ,O
,cortex,NN,O
,",",",",O
,hypothalamus,NN,O
,and,CC,O
,cerebellum,NN,O
,.,.,O
,Our,PRP$,O
,findings,NNS,O
,showed,VBD,O
,that,IN,O
,pubertal,JJ,O
,BPA,NNP,O
,exposure,NN,O
,increased,VBD,O
,anxiety,NN,B-DISEASE
,-,:,O
,like,IN,O
,behavior,NN,O
,",",",",O
,which,WDT,O
,may,MD,O
,be,VB,O
,associated,VBN,O
,with,IN,O
,decreased,JJ,O
,AChE,NNP,O
,activity,NN,O
,of,IN,O
,the,DT,O
,hippocampus,NN,O
,in,IN,O
,adult,NN,O
,male,NN,O
,mice,NN,O
,.,.,O
,Further,JJ,O
,studies,NNS,O
,are,VBP,O
,necessary,JJ,O
,to,TO,O
,investigate,VB,O
,the,DT,O
,cholinergic,JJ,O
,signaling,NN,O
,of,IN,O
,the,DT,O
,hippocampus,NN,O
,in,IN,O
,PBE,NNP,O
,induced,VBD,O
,anxiety,SYM,B-DISEASE
,-,:,O
,like,IN,O
,behaviors,NNS,O
,.,.,O
,Biochemical,JJ,O
,effects,NNS,O
,of,IN,O
,Solidago,NNP,O
,virgaurea,FW,O
,extract,NN,O
,on,IN,O
,experimental,JJ,O
,cardiotoxicity,NN,B-DISEASE
,.,.,O
,Cardiovascular,JJ,B-DISEASE
,diseases,NNS,I-DISEASE
,(,(,O
,CVDs,NNP,B-DISEASE
,),),O
,are,VBP,O
,the,DT,O
,major,JJ,O
,health,NN,O
,problem,NN,O
,of,IN,O
,advanced,JJ,O
,as,RB,O
,well,RB,O
,as,IN,O
,developing,VBG,O
,countries,NNS,O
,of,IN,O
,the,DT,O
,world,NN,O
,.,.,O
,The,DT,O
,aim,NN,O
,of,IN,O
,the,DT,O
,present,JJ,O
,study,NN,O
,was,VBD,O
,to,TO,O
,investigate,VB,O
,the,DT,O
,protective,JJ,O
,effect,NN,O
,of,IN,O
,the,DT,O
,Solidago,NNP,O
,virgaurea,NN,O
,extract,NN,O
,on,IN,O
,isoproterenol,JJ,O
,-,:,O
,induced,JJ,O
,cardiotoxicity,NN,B-DISEASE
,in,IN,O
,rats,NNS,O
,.,.,O
,The,DT,O
,subcutaneous,JJ,O
,injection,NN,O
,of,IN,O
,isoproterenol,NN,O
,(,(,O
,30,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,into,IN,O
,rats,JJ,O
,twice,RB,O
,at,IN,O
,an,DT,O
,interval,NN,O
,of,IN,O
,24,CD,O
,h,NN,O
,",",",",O
,for,IN,O
,two,CD,O
,consecutive,JJ,O
,days,NNS,O
,",",",",O
,led,VBN,O
,to,TO,O
,a,DT,O
,significant,JJ,O
,increase,NN,O
,in,IN,O
,serum,JJ,O
,lactate,NN,O
,dehydrogenase,NN,O
,",",",",O
,creatine,JJ,O
,phosphokinase,NN,O
,",",",",O
,alanine,JJ,O
,transaminase,NN,O
,",",",",O
,aspartate,JJ,O
,transaminase,NN,O
,",",",",O
,and,CC,O
,angiotensin,SYM,O
,-,:,O
,converting,VBG,O
,enzyme,JJ,O
,activities,NNS,O
,",",",",O
,total,JJ,O
,cholesterol,NN,O
,",",",",O
,triglycerides,NNS,O
,",",",",O
,free,JJ,O
,serum,NN,O
,fatty,JJ,O
,acid,NN,O
,",",",",O
,cardiac,JJ,O
,tissue,NN,O
,malondialdehyde,NN,O
,(,(,O
,MDA,NNP,O
,),),O
,",",",",O
,and,CC,O
,nitric,JJ,O
,oxide,NN,O
,levels,NNS,O
,and,CC,O
,a,DT,O
,significant,JJ,O
,decrease,NN,O
,in,IN,O
,levels,NNS,O
,of,IN,O
,glutathione,NN,O
,and,CC,O
,superoxide,JJ,O
,dismutase,NN,O
,in,IN,O
,cardiac,JJ,O
,tissue,NN,O
,as,IN,O
,compared,VBN,O
,to,TO,O
,the,DT,O
,normal,JJ,O
,control,NN,O
,group,NN,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,Pretreatment,NN,O
,with,IN,O
,S,NNP,O
,.,.,O
,virgaurea,NN,O
,extract,NN,O
,for,IN,O
,5,CD,O
,weeks,NNS,O
,at,IN,O
,a,DT,O
,dose,NN,O
,of,IN,O
,250,CD,O
,mg,NNS,O
,/,JJ,O
,kg,NN,O
,followed,VBN,O
,by,IN,O
,isoproterenol,NN,O
,injection,NN,O
,significantly,RB,O
,prevented,VBD,O
,the,DT,O
,observed,JJ,O
,alterations,NNS,O
,.,.,O
,Captopril,NNP,O
,(,(,O
,50,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,/,NNP,O
,day,NN,O
,",",",",O
,given,VBN,O
,orally,RB,O
,),),O
,",",",",O
,an,DT,O
,inhibitor,NN,O
,of,IN,O
,angiotensin,NN,O
,-,:,O
,converting,VBG,O
,enzyme,NN,O
,used,VBN,O
,as,IN,O
,a,DT,O
,standard,JJ,O
,cardioprotective,JJ,O
,drug,NN,O
,",",",",O
,was,VBD,O
,used,VBN,O
,as,IN,O
,a,DT,O
,positive,JJ,O
,control,NN,O
,in,IN,O
,this,DT,O
,study,NN,O
,.,.,O
,The,DT,O
,data,NN,O
,of,IN,O
,the,DT,O
,present,JJ,O
,study,NN,O
,suggest,VBP,O
,that,IN,O
,S,NNP,O
,.,.,O
,virgaurea,NN,O
,extract,JJ,O
,exerts,VBZ,O
,its,PRP$,O
,protective,JJ,O
,effect,NN,O
,by,IN,O
,decreasing,VBG,O
,MDA,NNP,O
,level,NN,O
,and,CC,O
,increasing,VBG,O
,the,DT,O
,antioxidant,NN,O
,status,NN,O
,in,IN,O
,isoproterenol,JJ,O
,-,:,O
,treated,JJ,O
,rats,NNS,O
,.,.,O
,The,DT,O
,study,NN,O
,emphasizes,VBZ,O
,the,DT,O
,beneficial,JJ,O
,action,NN,O
,of,IN,O
,S,NNP,O
,.,.,O
,virgaurea,NN,O
,extract,NN,O
,as,IN,O
,a,DT,O
,cardioprotective,JJ,O
,agent,NN,O
,.,.,O
,"""",CC,O
,Real,JJ,O
,-,:,O
,world,NN,O
,"""",NN,O
,data,NNS,O
,on,IN,O
,the,DT,O
,efficacy,NN,O
,and,CC,O
,safety,NN,O
,of,IN,O
,lenalidomide,NN,O
,and,CC,O
,dexamethasone,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,relapsed,JJ,O
,/,NNP,O
,refractory,NN,O
,multiple,JJ,B-DISEASE
,myeloma,NN,I-DISEASE
,who,WP,O
,were,VBD,O
,treated,VBN,O
,according,VBG,O
,to,TO,O
,the,DT,O
,standard,JJ,O
,clinical,JJ,O
,practice,NN,O
,:,:,O
,a,DT,O
,study,NN,O
,of,IN,O
,the,DT,O
,Greek,NNP,O
,Myeloma,NNP,B-DISEASE
,Study,NNP,O
,Group,NNP,O
,.,.,O
,Lenalidomide,NNP,O
,and,CC,O
,dexamethasone,NN,O
,(,(,O
,RD,NNP,O
,),),O
,is,VBZ,O
,a,DT,O
,standard,NN,O
,of,IN,O
,care,NN,O
,for,IN,O
,relapsed,JJ,O
,/,NNP,O
,refractory,NN,O
,multiple,NN,B-DISEASE
,myeloma,NN,I-DISEASE
,(,(,O
,RRMM,NNP,B-DISEASE
,),),O
,",",",",O
,but,CC,O
,there,EX,O
,is,VBZ,O
,limited,JJ,O
,published,VBN,O
,data,NNS,O
,on,IN,O
,its,PRP$,O
,efficacy,NN,O
,and,CC,O
,safety,NN,O
,in,IN,O
,the,DT,O
,"""",NNP,O
,real,JJ,O
,world,NN,O
,"""",NN,O
,(,(,O
,RW,NNP,O
,),),O
,",",",",O
,according,VBG,O
,to,TO,O
,the,DT,O
,International,NNP,O
,Society,NNP,O
,of,IN,O
,Pharmacoeconomics,NNPS,O
,and,CC,O
,Outcomes,NNP,O
,Research,NNP,O
,definition,NN,O
,.,.,O
,We,PRP,O
,studied,VBD,O
,212,CD,O
,RRMM,NNP,B-DISEASE
,patients,NNS,O
,who,WP,O
,received,VBD,O
,RD,NNP,O
,in,IN,O
,RW,NNP,O
,.,.,O
,Objective,NNP,O
,response,NN,O
,(,(,O
,>,JJ,O
,PR,NNP,O
,(,(,O
,partial,JJ,O
,response,NN,O
,),),O
,),),O
,rate,NN,O
,was,VBD,O
,77,CD,O
,.,.,O
,4,CD,O
,%,NN,O
,(,(,O
,complete,JJ,O
,response,NN,O
,(,(,O
,CR,NNP,O
,),),O
,",",",",O
,20,CD,O
,.,.,O
,2,CD,O
,%,NN,O
,),),O
,.,.,O
,Median,JJ,O
,time,NN,O
,to,TO,O
,first,RB,O
,and,CC,O
,best,JJS,O
,response,NN,O
,was,VBD,O
,2,CD,O
,and,CC,O
,5,CD,O
,months,NNS,O
,",",",",O
,respectively,RB,O
,.,.,O
,Median,JJ,O
,time,NN,O
,to,TO,O
,CR,VB,O
,when,WRB,O
,RD,NNP,O
,was,VBD,O
,given,VBN,O
,as,IN,O
,2nd,CD,O
,or,CC,O
,>,VB,O
,2,CD,O
,(,(,O
,nd,NN,O
,),),O
,-,:,O
,line,NN,O
,treatment,NN,O
,at,IN,O
,4,CD,O
,and,CC,O
,11,CD,O
,months,NNS,O
,",",",",O
,respectively,RB,O
,.,.,O
,Quality,NN,O
,of,IN,O
,response,NN,O
,was,VBD,O
,independent,JJ,O
,of,IN,O
,previous,JJ,O
,lines,NNS,O
,of,IN,O
,therapies,NNS,O
,or,CC,O
,previous,JJ,O
,exposure,NN,O
,to,TO,O
,thalidomide,VB,O
,or,CC,O
,bortezomib,VB,O
,.,.,O
,Median,JJ,O
,duration,NN,O
,of,IN,O
,response,NN,O
,was,VBD,O
,34,CD,O
,.,.,O
,4,CD,O
,months,NNS,O
,",",",",O
,and,CC,O
,it,PRP,O
,was,VBD,O
,higher,RBR,O
,in,IN,O
,patients,NNS,O
,who,WP,O
,received,VBD,O
,RD,NNP,O
,until,IN,O
,progression,NN,O
,(,(,O
,not,RB,O
,reached,VBN,O
,versus,IN,O
,19,CD,O
,months,NNS,O
,",",",",O
,p,VBP,O
,<,JJ,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,.,.,O
,Improvement,NN,O
,of,IN,O
,humoral,JJ,O
,immunity,NN,O
,occurred,VBD,O
,in,IN,O
,60,CD,O
,%,NN,O
,of,IN,O
,responders,NNS,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,and,CC,O
,in,IN,O
,the,DT,O
,majority,NN,O
,of,IN,O
,patients,NNS,O
,who,WP,O
,achieved,VBD,O
,stable,JJ,O
,disease,NN,O
,.,.,O
,Adverse,JJ,O
,events,NNS,O
,were,VBD,O
,reported,VBN,O
,in,IN,O
,68,CD,O
,.,.,O
,9,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,(,(,O
,myelosuppression,NN,B-DISEASE
,in,IN,O
,49,CD,O
,.,.,O
,4,CD,O
,%,NN,O
,),),O
,and,CC,O
,12,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,needed,VBN,O
,hospitalization,NN,O
,.,.,O
,Peripheral,NNP,B-DISEASE
,neuropathy,NN,I-DISEASE
,was,VBD,O
,observed,VBN,O
,only,RB,O
,in,IN,O
,2,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,and,CC,O
,deep,JJ,B-DISEASE
,vein,NN,I-DISEASE
,thrombosis,NN,I-DISEASE
,in,IN,O
,5,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,.,.,O
,Dose,JJ,O
,reductions,NNS,O
,were,VBD,O
,needed,VBN,O
,in,IN,O
,31,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,and,CC,O
,permanent,JJ,O
,discontinuation,NN,O
,in,IN,O
,38,CD,O
,.,.,O
,9,CD,O
,%,NN,O
,.,.,O
,Median,JJ,O
,time,NN,O
,to,TO,O
,treatment,NN,O
,discontinuation,NN,O
,was,VBD,O
,16,CD,O
,.,.,O
,8,CD,O
,months,NNS,O
,.,.,O
,Performance,NN,O
,status,NN,O
,(,(,O
,PS,NNP,O
,),),O
,and,CC,O
,initial,JJ,O
,lenalidomide,NN,O
,dose,NN,O
,predicted,VBD,O
,for,IN,O
,treatment,NN,O
,discontinuation,NN,O
,.,.,O
,Extra,NNP,O
,-,:,O
,medullary,JJ,O
,relapses,NNS,O
,occurred,VBD,O
,in,IN,O
,3,CD,O
,.,.,O
,8,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,.,.,O
,Our,PRP$,O
,study,NN,O
,confirms,VBZ,O
,that,IN,O
,RD,NNP,O
,is,VBZ,O
,effective,JJ,O
,and,CC,O
,safe,JJ,O
,in,IN,O
,RRMM,NNP,B-DISEASE
,in,IN,O
,the,DT,O
,RW,NNP,O
,;,:,O
,it,PRP,O
,produces,VBZ,O
,durable,JJ,O
,responses,NNS,O
,especially,RB,O
,in,IN,O
,patients,NNS,O
,who,WP,O
,continue,VBP,O
,on,IN,O
,treatment,NN,O
,till,NN,O
,progression,NN,O
,and,CC,O
,improves,VBZ,O
,humoral,JJ,O
,immunity,NN,O
,even,RB,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,stable,JJ,O
,disease,NN,O
,.,.,O
,The,DT,O
,cytogenetic,JJ,O
,action,NN,O
,of,IN,O
,ifosfamide,NN,O
,",",",",O
,mesna,NN,O
,",",",",O
,and,CC,O
,their,PRP$,O
,combination,NN,O
,on,IN,O
,peripheral,JJ,O
,rabbit,NN,O
,lymphocytes,NNS,O
,:,:,O
,an,DT,O
,in,IN,O
,vivo,NN,O
,/,NN,O
,in,IN,O
,vitro,NNP,O
,cytogenetic,JJ,O
,study,NN,O
,.,.,O
,Ifosfamide,NNP,O
,(,(,O
,IFO,NNP,O
,),),O
,is,VBZ,O
,an,DT,O
,alkylating,VBG,O
,nitrogen,NN,O
,mustard,NN,O
,",",",",O
,administrated,VBD,O
,as,IN,O
,an,DT,O
,antineoplasmic,JJ,O
,agent,NN,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,characterized,VBN,O
,by,IN,O
,its,PRP$,O
,intense,JJ,O
,urotoxic,JJ,O
,action,NN,O
,",",",",O
,leading,VBG,O
,to,TO,O
,hemorrhagic,VB,B-DISEASE
,cystitis,NN,I-DISEASE
,.,.,O
,This,DT,O
,side,JJ,O
,effect,NN,O
,of,IN,O
,IFO,NNP,O
,raises,VBZ,O
,the,DT,O
,requirement,NN,O
,for,IN,O
,the,DT,O
,co,NN,O
,-,:,O
,administration,NN,O
,with,IN,O
,sodium,NN,O
,2,CD,O
,-,:,O
,sulfanylethanesulfonate,NN,O
,(,(,O
,Mesna,NNP,O
,),),O
,aiming,VBG,O
,to,TO,O
,avoid,VB,O
,or,CC,O
,minimize,VB,O
,this,DT,O
,effect,NN,O
,.,.,O
,IFO,NNP,O
,and,CC,O
,Mesna,NNP,O
,were,VBD,O
,administrated,VBN,O
,separately,RB,O
,on,IN,O
,rabbit,NN,O
,','',O
,s,JJ,O
,lymphocytes,NNS,O
,in,IN,O
,vivo,NN,O
,",",",",O
,which,WDT,O
,were,VBD,O
,later,RBR,O
,developed,VBN,O
,in,IN,O
,vitro,NN,O
,.,.,O
,Cytogenetic,JJ,O
,markers,NNS,O
,for,IN,O
,sister,NN,O
,chromatid,NN,O
,exchanges,NNS,O
,(,(,O
,SCEs,NNP,O
,),),O
,",",",",O
,proliferation,NN,O
,rate,NN,O
,index,NN,O
,(,(,O
,PRI,NNP,O
,),),O
,and,CC,O
,Mitotic,NNP,O
,Index,NNP,O
,were,VBD,O
,recorded,VBN,O
,.,.,O
,Mesna,NNP,O
,',POS,O
,s,JJ,O
,action,NN,O
,",",",",O
,in,IN,O
,conjunction,NN,O
,with,IN,O
,IFO,NNP,O
,reduces,VBZ,O
,the,DT,O
,frequency,NN,O
,of,IN,O
,SCEs,NNP,O
,",",",",O
,in,IN,O
,comparison,NN,O
,with,IN,O
,the,DT,O
,SCEs,NNP,O
,recordings,NNS,O
,obtained,VBD,O
,when,WRB,O
,IFO,NNP,O
,is,VBZ,O
,administered,VBN,O
,alone,RB,O
,.,.,O
,In,IN,O
,addition,NN,O
,to,TO,O
,this,DT,O
,",",",",O
,when,WRB,O
,high,JJ,O
,concentrations,NNS,O
,of,IN,O
,Mesna,NNP,O
,were,VBD,O
,administered,VBN,O
,alone,RB,O
,significant,JJ,O
,reductions,NNS,O
,of,IN,O
,the,DT,O
,PRI,NNP,O
,were,VBD,O
,noted,VBN,O
,",",",",O
,than,IN,O
,with,IN,O
,IFO,NNP,O
,acting,VBG,O
,at,IN,O
,the,DT,O
,same,JJ,O
,concentration,NN,O
,on,IN,O
,the,DT,O
,lymphocytes,NNS,O
,.,.,O
,Mesna,NNP,O
,significantly,RB,O
,reduces,VBZ,O
,IFO,NNP,O
,',POS,O
,s,NN,O
,genotoxicity,NN,B-DISEASE
,",",",",O
,while,IN,O
,when,WRB,O
,administered,VBN,O
,in,IN,O
,high,JJ,O
,concentrations,NNS,O
,it,PRP,O
,acts,VBZ,O
,in,IN,O
,an,DT,O
,inhibitory,JJ,O
,fashion,NN,O
,on,IN,O
,the,DT,O
,cytostatic,JJ,O
,action,NN,O
,of,IN,O
,the,DT,O
,drug,NN,O
,.,.,O
,Risk,NN,O
,factors,NNS,O
,and,CC,O
,predictors,NNS,O
,of,IN,O
,levodopa,JJ,O
,-,:,O
,induced,JJ,O
,dyskinesia,NN,B-DISEASE
,among,IN,O
,multiethnic,JJ,O
,Malaysians,NNPS,O
,with,IN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,Chronic,NNP,O
,pulsatile,IN,O
,levodopa,JJ,O
,therapy,NN,O
,for,IN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,NN,I-DISEASE
,disease,NN,I-DISEASE
,(,(,O
,PD,NNP,B-DISEASE
,),),O
,leads,VBZ,O
,to,TO,O
,the,DT,O
,development,NN,O
,of,IN,O
,motor,NN,O
,fluctuations,NNS,O
,and,CC,O
,dyskinesia,NN,B-DISEASE
,.,.,O
,We,PRP,O
,studied,VBD,O
,the,DT,O
,prevalence,NN,O
,and,CC,O
,predictors,NNS,O
,of,IN,O
,levodopa,JJ,O
,-,:,O
,induced,JJ,O
,dyskinesia,NN,B-DISEASE
,among,IN,O
,multiethnic,JJ,O
,Malaysian,JJ,O
,patients,NNS,O
,with,IN,O
,PD,NNP,B-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,This,DT,O
,is,VBZ,O
,a,DT,O
,cross,NN,O
,-,:,O
,sectional,JJ,O
,study,NN,O
,involving,VBG,O
,95,CD,O
,patients,NNS,O
,with,IN,O
,PD,NNP,B-DISEASE
,on,IN,O
,uninterrupted,JJ,O
,levodopa,NN,O
,therapy,NN,O
,for,IN,O
,at,IN,O
,least,JJS,O
,6,CD,O
,months,NNS,O
,.,.,O
,The,DT,O
,instrument,NN,O
,used,VBN,O
,was,VBD,O
,the,DT,O
,UPDRS,NNP,O
,questionnaires,NNS,O
,.,.,O
,The,DT,O
,predictors,NNS,O
,of,IN,O
,dyskinesia,NN,B-DISEASE
,were,VBD,O
,determined,VBN,O
,using,VBG,O
,multivariate,JJ,O
,logistic,JJ,O
,regression,NN,O
,analysis,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,The,DT,O
,mean,JJ,O
,age,NN,O
,was,VBD,O
,65,CD,O
,.,.,O
,6,CD,O
,+,JJ,O
,8,CD,O
,.,.,O
,5,CD,O
,years,NNS,O
,.,.,O
,The,DT,O
,mean,JJ,O
,onset,NN,O
,age,NN,O
,was,VBD,O
,58,CD,O
,.,.,O
,5,CD,O
,+,JJ,O
,9,CD,O
,.,.,O
,8,CD,O
,years,NNS,O
,.,.,O
,The,DT,O
,median,JJ,O
,disease,NN,O
,duration,NN,O
,was,VBD,O
,6,CD,O
,(,(,O
,7,CD,O
,),),O
,years,NNS,O
,.,.,O
,Dyskinesia,NNP,B-DISEASE
,was,VBD,O
,present,JJ,O
,in,IN,O
,44,CD,O
,%,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,42,CD,O
,),),O
,with,IN,O
,median,JJ,O
,levodopa,NN,O
,therapy,NN,O
,of,IN,O
,3,CD,O
,years,NNS,O
,.,.,O
,There,EX,O
,were,VBD,O
,64,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,Chinese,NNP,O
,",",",",O
,31,CD,O
,%,NN,O
,Malays,NNP,O
,",",",",O
,and,CC,O
,3,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,Indians,NNPS,O
,and,CC,O
,other,JJ,O
,ethnic,JJ,O
,groups,NNS,O
,.,.,O
,Eighty,NNP,O
,-,:,O
,one,CD,O
,percent,NN,O
,of,IN,O
,patients,NNS,O
,with,IN,O
,dyskinesia,NN,B-DISEASE
,had,VBD,O
,clinical,JJ,O
,fluctuations,NNS,O
,.,.,O
,Patients,NNS,O
,with,IN,O
,dyskinesia,NN,B-DISEASE
,had,VBD,O
,lower,JJR,O
,onset,VBN,O
,age,NN,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,",",",",O
,longer,JJR,O
,duration,NN,O
,of,IN,O
,levodopa,JJ,O
,therapy,NN,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,",",",",O
,longer,JJR,O
,disease,NN,O
,duration,NN,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,",",",",O
,higher,JJR,O
,total,JJ,O
,daily,JJ,O
,levodopa,NN,O
,dose,NN,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,",",",",O
,and,CC,O
,higher,JJR,O
,total,JJ,O
,UPDRS,NNP,O
,scores,NNS,O
,(,(,O
,p,VB,O
,=,RB,O
,0,CD,O
,.,.,O
,005,CD,O
,),),O
,than,IN,O
,patients,NNS,O
,without,IN,O
,dyskinesia,NN,B-DISEASE
,.,.,O
,The,DT,O
,three,CD,O
,significant,JJ,O
,predictors,NNS,O
,of,IN,O
,dyskinesia,NN,B-DISEASE
,were,VBD,O
,duration,NN,O
,of,IN,O
,levodopa,JJ,O
,therapy,NN,O
,",",",",O
,onset,VBN,O
,age,NN,O
,",",",",O
,and,CC,O
,total,JJ,O
,daily,JJ,O
,levodopa,NN,O
,dose,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,The,DT,O
,prevalence,NN,O
,of,IN,O
,levodopa,JJ,O
,-,:,O
,induced,JJ,O
,dyskinesia,NN,B-DISEASE
,in,IN,O
,our,PRP$,O
,patients,NNS,O
,was,VBD,O
,44,CD,O
,%,NN,O
,.,.,O
,The,DT,O
,most,RBS,O
,significant,JJ,O
,predictors,NNS,O
,were,VBD,O
,duration,NN,O
,of,IN,O
,levodopa,JJ,O
,therapy,NN,O
,",",",",O
,total,JJ,O
,daily,JJ,O
,levodopa,NN,O
,dose,NN,O
,",",",",O
,and,CC,O
,onset,JJ,O
,age,NN,O
,.,.,O
,Dose,NNP,O
,-,:,O
,dependent,JJ,O
,neurotoxicity,NN,B-DISEASE
,of,IN,O
,high,JJ,O
,-,:,O
,dose,NN,O
,busulfan,NN,O
,in,IN,O
,children,NNS,O
,:,:,O
,a,DT,O
,clinical,JJ,O
,and,CC,O
,pharmacological,JJ,O
,study,NN,O
,.,.,O
,Busulfan,NNP,O
,is,VBZ,O
,known,VBN,O
,to,TO,O
,be,VB,O
,neurotoxic,VBN,B-DISEASE
,in,IN,O
,animals,NNS,O
,and,CC,O
,humans,NNS,O
,",",",",O
,but,CC,O
,its,PRP$,O
,acute,JJ,O
,neurotoxicity,NN,B-DISEASE
,remains,VBZ,O
,poorly,RB,O
,characterized,VBN,O
,in,IN,O
,children,NNS,O
,.,.,O
,We,PRP,O
,report,VBP,O
,here,RB,O
,a,DT,O
,retrospective,JJ,O
,study,NN,O
,of,IN,O
,123,CD,O
,children,NNS,O
,(,(,O
,median,JJ,O
,age,NN,O
,",",",",O
,6,CD,O
,.,.,O
,5,CD,O
,years,NNS,O
,),),O
,receiving,VBG,O
,high,JJ,O
,-,:,O
,dose,NN,O
,busulfan,NN,O
,in,IN,O
,combined,JJ,O
,chemotherapy,NN,O
,before,IN,O
,bone,NN,O
,marrow,NN,O
,transplantation,NN,O
,for,IN,O
,malignant,JJ,O
,solid,JJ,O
,tumors,NNS,B-DISEASE
,",",",",O
,brain,NN,B-DISEASE
,tumors,NNS,I-DISEASE
,excluded,VBD,O
,.,.,O
,Busulfan,NNP,O
,was,VBD,O
,given,VBN,O
,p,NN,O
,.,.,O
,o,NN,O
,.,.,O
,",",",",O
,every,DT,O
,6,CD,O
,hours,NNS,O
,for,IN,O
,16,CD,O
,doses,NNS,O
,over,IN,O
,4,CD,O
,days,NNS,O
,.,.,O
,Two,CD,O
,total,JJ,O
,doses,NNS,O
,were,VBD,O
,consecutively,RB,O
,used,VBN,O
,:,:,O
,16,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,then,RB,O
,600,CD,O
,mg,NNS,O
,/,JJ,O
,m2,NN,O
,.,.,O
,The,DT,O
,dose,JJ,O
,calculation,NN,O
,on,IN,O
,the,DT,O
,basis,NN,O
,of,IN,O
,body,NN,O
,surface,JJ,O
,area,NN,O
,results,NNS,O
,in,IN,O
,higher,JJR,O
,doses,NNS,O
,in,IN,O
,young,JJ,O
,children,NNS,O
,than,IN,O
,in,IN,O
,older,JJR,O
,patients,NNS,O
,(,(,O
,16,CD,O
,to,TO,O
,28,CD,O
,mg,NNS,O
,/,NNP,O
,kg,NN,O
,),),O
,.,.,O
,Ninety,NNP,O
,-,:,O
,six,CD,O
,patients,NNS,O
,were,VBD,O
,not,RB,O
,given,VBN,O
,anticonvulsive,JJ,O
,prophylaxis,NN,O
,;,:,O
,7,CD,O
,(,(,O
,7,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,),),O
,developed,VBD,O
,seizures,NNS,B-DISEASE
,during,IN,O
,the,DT,O
,4,CD,O
,days,NNS,O
,of,IN,O
,the,DT,O
,busulfan,NN,O
,course,NN,O
,or,CC,O
,within,IN,O
,24,CD,O
,h,NN,O
,after,IN,O
,the,DT,O
,last,JJ,O
,dosing,NN,O
,.,.,O
,When,WRB,O
,the,DT,O
,total,JJ,O
,busulfan,NN,O
,dose,NN,O
,was,VBD,O
,taken,VBN,O
,into,IN,O
,account,NN,O
,",",",",O
,there,EX,O
,was,VBD,O
,a,DT,O
,significant,JJ,O
,difference,NN,O
,in,IN,O
,terms,NNS,O
,of,IN,O
,neurotoxicity,NN,B-DISEASE
,incidence,NN,O
,among,IN,O
,patients,NNS,O
,under,IN,O
,16,CD,O
,mg,NN,O
,/,NN,O
,kg,NN,O
,(,(,O
,1,CD,O
,of,IN,O
,57,CD,O
,",",",",O
,1,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,),),O
,and,CC,O
,patients,NNS,O
,under,IN,O
,600,CD,O
,mg,NN,O
,/,NN,O
,m2,NN,O
,(,(,O
,6,CD,O
,of,IN,O
,39,CD,O
,",",",",O
,15,CD,O
,.,.,O
,4,CD,O
,%,NN,O
,),),O
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,02,CD,O
,),),O
,.,.,O
,Twenty,NNP,O
,-,:,O
,seven,CD,O
,patients,NNS,O
,were,VBD,O
,given,VBN,O
,a,DT,O
,600,CD,O
,-,:,O
,mg,NN,O
,/,JJ,O
,m2,NN,O
,busulfan,NN,O
,total,JJ,O
,dose,NN,O
,with,IN,O
,continuous,JJ,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,infusion,NN,O
,of,IN,O
,clonazepam,NN,O
,;,:,O
,none,NN,O
,had,VBD,O
,any,DT,O
,neurological,JJ,B-DISEASE
,symptoms,NNS,I-DISEASE
,.,.,O
,Busulfan,NNP,O
,levels,NNS,O
,were,VBD,O
,measured,VBN,O
,by,IN,O
,a,DT,O
,gas,NN,O
,chromatographic,JJ,O
,-,:,O
,mass,NN,O
,spectrometry,NN,O
,assay,VBP,O
,in,IN,O
,the,DT,O
,plasma,NN,O
,and,CC,O
,cerebrospinal,JJ,O
,fluid,NN,O
,of,IN,O
,9,CD,O
,children,NNS,O
,without,IN,O
,central,JJ,B-DISEASE
,nervous,JJ,I-DISEASE
,system,NN,I-DISEASE
,disease,NN,I-DISEASE
,under,IN,O
,600,CD,O
,mg,NN,O
,/,NNP,O
,m2,NN,O
,busulfan,NN,O
,with,IN,O
,clonazepam,NN,O
,:,:,O
,busulfan,NN,O
,cerebrospinal,JJ,O
,fluid,NN,O
,:,:,O
,plasma,NN,O
,ratio,NN,O
,was,VBD,O
,1,CD,O
,.,.,O
,39,CD,O
,.,.,O
,This,DT,O
,was,VBD,O
,significantly,RB,O
,different,JJ,O
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,02,CD,O
,),),O
,from,IN,O
,the,DT,O
,cerebrospinal,JJ,O
,fluid,NN,O
,:,:,O
,plasma,NN,O
,ratio,VBZ,O
,previously,RB,O
,defined,VBN,O
,in,IN,O
,children,NNS,O
,receiving,VBG,O
,a,DT,O
,16,CD,O
,-,:,O
,mg,NN,O
,/,NN,O
,kg,VBD,O
,total,JJ,O
,dose,NN,O
,of,IN,O
,busulfan,NN,O
,.,.,O
,This,DT,O
,study,NN,O
,shows,VBZ,O
,that,IN,O
,busulfan,NN,O
,neurotoxicity,NN,B-DISEASE
,is,VBZ,O
,dose,JJ,O
,-,:,O
,dependent,NN,O
,in,IN,O
,children,NNS,O
,and,CC,O
,efficiently,RB,O
,prevented,VBN,O
,by,IN,O
,clonazepam,NN,O
,.,.,O
,A,DT,O
,busulfan,NN,O
,dose,NN,O
,calculated,VBN,O
,on,IN,O
,the,DT,O
,basis,NN,O
,of,IN,O
,body,NN,O
,surface,JJ,O
,area,NN,O
,",",",",O
,resulting,VBG,O
,in,IN,O
,higher,JJR,O
,doses,NNS,O
,in,IN,O
,young,JJ,O
,children,NNS,O
,",",",",O
,was,VBD,O
,followed,VBN,O
,by,IN,O
,increased,JJ,O
,neurotoxicity,NN,B-DISEASE
,",",",",O
,close,RB,O
,to,TO,O
,neurotoxicity,NN,B-DISEASE
,incidence,NN,O
,observed,VBN,O
,in,IN,O
,adults,NNS,O
,.,.,O
,Since,IN,O
,plasma,NN,O
,pharmacokinetic,JJ,O
,studies,NNS,O
,showed,VBD,O
,a,DT,O
,faster,RBR,O
,busulfan,JJ,O
,clearance,NN,O
,in,IN,O
,children,NNS,O
,than,IN,O
,in,IN,O
,adults,NNS,O
,",",",",O
,this,DT,O
,new,JJ,O
,dose,NN,O
,may,MD,O
,approximate,VB,O
,more,RBR,O
,closely,RB,O
,the,DT,O
,adult,NN,O
,systemic,JJ,O
,exposure,NN,O
,obtained,VBN,O
,after,IN,O
,the,DT,O
,usual,JJ,O
,16,CD,O
,-,:,O
,mg,NN,O
,/,NN,O
,kg,VBD,O
,total,JJ,O
,dose,NN,O
,",",",",O
,with,IN,O
,potential,JJ,O
,inferences,NNS,O
,in,IN,O
,terms,NNS,O
,of,IN,O
,anticancer,NN,O
,or,CC,O
,myeloablative,JJ,O
,effects,NNS,O
,.,.,O
,The,DT,O
,busulfan,NN,O
,dose,NN,O
,in,IN,O
,children,NNS,O
,and,CC,O
,infants,NNS,O
,undergoing,VBG,O
,bone,NN,O
,marrow,NN,O
,transplantation,NN,O
,should,MD,O
,be,VB,O
,reconsidered,VBN,O
,on,IN,O
,the,DT,O
,basis,NN,O
,of,IN,O
,pharmacokinetic,JJ,O
,studies,NNS,O
,.,.,O
,An,DT,O
,unexpected,JJ,O
,diagnosis,NN,O
,in,IN,O
,a,DT,O
,renal,JJ,O
,-,:,O
,transplant,JJ,O
,patient,NN,O
,with,IN,O
,proteinuria,NNS,B-DISEASE
,treated,VBN,O
,with,IN,O
,everolimus,NN,O
,:,:,O
,AL,NNP,B-DISEASE
,amyloidosis,NN,B-DISEASE
,.,.,O
,Proteinuria,NNP,B-DISEASE
,is,VBZ,O
,an,DT,O
,expected,JJ,O
,complication,NN,O
,in,IN,O
,transplant,JJ,O
,patients,NNS,O
,treated,VBN,O
,with,IN,O
,mammalian,JJ,O
,target,NN,O
,of,IN,O
,rapamycin,JJ,O
,inhibitors,NNS,O
,(,(,O
,mTOR,SYM,O
,-,:,O
,i,NN,O
,),),O
,.,.,O
,However,RB,O
,",",",",O
,clinical,JJ,O
,suspicion,NN,O
,should,MD,O
,always,RB,O
,be,VB,O
,supported,VBN,O
,by,IN,O
,histological,JJ,O
,evidence,NN,O
,in,IN,O
,order,NN,O
,to,TO,O
,investigate,VB,O
,potential,JJ,O
,alternate,NN,O
,diagnoses,NNS,O
,such,JJ,O
,as,IN,O
,acute,NN,O
,or,CC,O
,chronic,JJ,O
,rejection,NN,O
,",",",",O
,interstitial,JJ,O
,fibrosis,NN,B-DISEASE
,and,CC,O
,tubular,JJ,O
,atrophy,NN,B-DISEASE
,",",",",O
,or,CC,O
,recurrent,NN,O
,or,CC,O
,de,VB,O
,novo,FW,O
,glomerulopathy,NN,B-DISEASE
,.,.,O
,In,IN,O
,this,DT,O
,case,NN,O
,we,PRP,O
,report,VBP,O
,the,DT,O
,unexpected,JJ,O
,diagnosis,NN,O
,of,IN,O
,amyloidosis,NN,B-DISEASE
,in,IN,O
,a,DT,O
,renal,JJ,O
,-,:,O
,transplant,JJ,O
,patient,NN,O
,with,IN,O
,pre,JJ,O
,-,:,O
,transplant,JJ,O
,monoclonal,JJ,O
,gammapathy,NN,O
,of,IN,O
,undetermined,JJ,O
,significance,NN,O
,who,WP,O
,developed,VBD,O
,proteinuria,NN,B-DISEASE
,after,IN,O
,conversion,NN,O
,from,IN,O
,tacrolimus,NN,O
,to,TO,O
,everolimus,VB,O
,.,.,O
,Long,NNP,O
,-,:,O
,term,NN,O
,oral,JJ,O
,galactose,JJ,O
,treatment,NN,O
,prevents,NNS,O
,cognitive,JJ,B-DISEASE
,deficits,NNS,I-DISEASE
,in,IN,O
,male,JJ,O
,Wistar,NNP,O
,rats,NNS,O
,treated,VBD,O
,intracerebroventricularly,RB,O
,with,IN,O
,streptozotocin,NN,O
,.,.,O
,Basic,NNP,O
,and,CC,O
,clinical,JJ,O
,research,NN,O
,has,VBZ,O
,demonstrated,VBN,O
,that,IN,O
,dementia,NN,B-DISEASE
,of,IN,O
,sporadic,JJ,O
,Alzheimer,NNP,B-DISEASE
,',POS,I-DISEASE
,s,NN,I-DISEASE
,disease,NN,I-DISEASE
,(,(,O
,sAD,JJ,O
,),),O
,type,NN,O
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,dysfunction,NN,O
,of,IN,O
,the,DT,O
,insulin,NN,O
,-,:,O
,receptor,NN,O
,(,(,O
,IR,NNP,O
,),),O
,system,NN,O
,followed,VBN,O
,by,IN,O
,decreased,VBN,O
,glucose,JJ,O
,transport,NN,O
,via,IN,O
,glucose,JJ,O
,transporter,NN,O
,GLUT4,NNP,O
,and,CC,O
,decreased,VBD,O
,glucose,JJ,O
,metabolism,NN,O
,in,IN,O
,brain,NN,O
,cells,NNS,O
,.,.,O
,An,DT,O
,alternative,JJ,O
,source,NN,O
,of,IN,O
,energy,NN,O
,is,VBZ,O
,d,JJ,O
,-,:,O
,galactose,NN,O
,(,(,O
,the,DT,O
,C,NNP,O
,-,:,O
,4,CD,O
,-,:,O
,epimer,NN,O
,of,IN,O
,d,JJ,O
,-,:,O
,glucose,NN,O
,),),O
,which,WDT,O
,is,VBZ,O
,transported,VBN,O
,into,IN,O
,the,DT,O
,brain,NN,O
,by,IN,O
,insulin,JJ,O
,-,:,O
,independent,JJ,O
,GLUT3,NNP,O
,transporter,NN,O
,where,WRB,O
,it,PRP,O
,might,MD,O
,be,VB,O
,metabolized,VBN,O
,to,TO,O
,glucose,VB,O
,via,IN,O
,the,DT,O
,Leloir,NNP,O
,pathway,NN,O
,.,.,O
,Exclusively,RB,O
,parenteral,JJ,O
,daily,JJ,O
,injections,NNS,O
,of,IN,O
,galactose,JJ,O
,induce,JJ,O
,memory,NN,B-DISEASE
,deterioration,NN,I-DISEASE
,in,IN,O
,rodents,NNS,O
,and,CC,O
,are,VBP,O
,used,VBN,O
,to,TO,O
,generate,VB,O
,animal,JJ,O
,aging,VBG,O
,model,NN,O
,",",",",O
,but,CC,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,oral,JJ,O
,galactose,JJ,O
,treatment,NN,O
,on,IN,O
,cognitive,JJ,O
,functions,NNS,O
,have,VBP,O
,never,RB,O
,been,VBN,O
,tested,VBN,O
,.,.,O
,We,PRP,O
,have,VBP,O
,investigated,VBN,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,continuous,JJ,O
,daily,JJ,O
,oral,JJ,O
,galactose,NN,O
,(,(,O
,200,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,/,NNP,O
,day,NN,O
,),),O
,treatment,NN,O
,on,IN,O
,cognitive,JJ,B-DISEASE
,deficits,NNS,I-DISEASE
,in,IN,O
,streptozotocin,JJ,O
,-,:,O
,induced,VBN,O
,(,(,O
,STZ,NNP,O
,-,:,O
,icv,NN,O
,),),O
,rat,VBZ,O
,model,NN,O
,of,IN,O
,sAD,NN,O
,",",",",O
,tested,VBN,O
,by,IN,O
,Morris,NNP,O
,Water,NNP,O
,Maze,NNP,O
,and,CC,O
,Passive,NNP,O
,Avoidance,NNP,O
,test,NN,O
,",",",",O
,respectively,RB,O
,.,.,O
,One,CD,O
,month,NN,O
,of,IN,O
,oral,JJ,O
,galactose,JJ,O
,treatment,NN,O
,initiated,VBN,O
,immediately,RB,O
,after,IN,O
,the,DT,O
,STZ,NNP,O
,-,:,O
,icv,NN,O
,administration,NN,O
,",",",",O
,successfully,RB,O
,prevented,VBN,O
,development,NN,O
,of,IN,O
,the,DT,O
,STZ,NNP,O
,-,:,O
,icv,NN,O
,-,:,O
,induced,JJ,O
,cognitive,JJ,B-DISEASE
,deficits,NNS,I-DISEASE
,.,.,O
,Beneficial,JJ,O
,effect,NN,O
,of,IN,O
,oral,JJ,O
,galactose,NN,O
,was,VBD,O
,independent,JJ,O
,of,IN,O
,the,DT,O
,rat,NN,O
,age,NN,O
,and,CC,O
,of,IN,O
,the,DT,O
,galactose,NN,O
,dose,JJ,O
,ranging,VBG,O
,from,IN,O
,100,CD,O
,to,TO,O
,300,CD,O
,mg,NNS,O
,/,JJ,O
,kg,JJ,O
,/,NNP,O
,day,NN,O
,.,.,O
,Additionally,RB,O
,",",",",O
,oral,JJ,O
,galactose,JJ,O
,administration,NN,O
,led,VBD,O
,to,TO,O
,the,DT,O
,appearance,NN,O
,of,IN,O
,galactose,NN,O
,in,IN,O
,the,DT,O
,blood,NN,O
,.,.,O
,The,DT,O
,increase,NN,O
,of,IN,O
,galactose,JJ,O
,concentration,NN,O
,in,IN,O
,the,DT,O
,cerebrospinal,JJ,O
,fluid,NN,O
,was,VBD,O
,several,JJ,O
,times,NNS,O
,lower,JJR,O
,after,IN,O
,oral,JJ,O
,than,IN,O
,after,IN,O
,parenteral,JJ,O
,administration,NN,O
,of,IN,O
,the,DT,O
,same,JJ,O
,galactose,NN,O
,dose,NN,O
,.,.,O
,Oral,NNP,O
,galactose,JJ,O
,exposure,NN,O
,might,MD,O
,have,VB,O
,beneficial,JJ,O
,effects,NNS,O
,on,IN,O
,learning,NN,O
,and,CC,O
,memory,NN,O
,ability,NN,O
,and,CC,O
,could,MD,O
,be,VB,O
,worth,JJ,O
,investigating,VBG,O
,for,IN,O
,improvement,NN,O
,of,IN,O
,cognitive,JJ,B-DISEASE
,deficits,NNS,I-DISEASE
,associated,VBN,O
,with,IN,O
,glucose,JJ,B-DISEASE
,hypometabolism,NN,I-DISEASE
,in,IN,O
,AD,NNP,B-DISEASE
,.,.,O
,An,DT,O
,investigation,NN,O
,of,IN,O
,the,DT,O
,pattern,NN,O
,of,IN,O
,kidney,NN,B-DISEASE
,injury,NN,I-DISEASE
,in,IN,O
,HIV,NNP,O
,-,:,O
,positive,JJ,O
,persons,NNS,O
,exposed,VBN,O
,to,TO,O
,tenofovir,VB,O
,disoproxil,JJ,O
,fumarate,NN,O
,:,:,O
,an,DT,O
,examination,NN,O
,of,IN,O
,a,DT,O
,large,JJ,O
,population,NN,O
,database,NN,O
,(,(,O
,MHRA,NNP,O
,database,NN,O
,),),O
,.,.,O
,The,DT,O
,potential,JJ,O
,for,IN,O
,tenofovir,NN,O
,to,TO,O
,cause,VB,O
,a,DT,O
,range,NN,O
,of,IN,O
,kidney,NN,O
,syndromes,NNS,O
,has,VBZ,O
,been,VBN,O
,established,VBN,O
,from,IN,O
,mechanistic,JJ,O
,and,CC,O
,randomised,JJ,O
,clinical,JJ,O
,trials,NNS,O
,.,.,O
,However,RB,O
,",",",",O
,the,DT,O
,exact,JJ,O
,pattern,NN,O
,of,IN,O
,kidney,NN,O
,involvement,NN,O
,is,VBZ,O
,still,RB,O
,uncertain,JJ,O
,.,.,O
,We,PRP,O
,undertook,VBD,O
,a,DT,O
,descriptive,JJ,O
,analysis,NN,O
,of,IN,O
,Yellow,NNP,O
,Card,NNP,O
,records,NNS,O
,of,IN,O
,407,CD,O
,HIV,NNP,O
,-,:,O
,positive,JJ,O
,persons,NNS,O
,taking,VBG,O
,tenofovir,JJ,O
,disoproxil,NN,O
,fumarate,NN,O
,(,(,O
,TDF,NNP,O
,),),O
,as,IN,O
,part,NN,O
,of,IN,O
,their,PRP$,O
,antiretroviral,JJ,O
,therapy,NN,O
,regimen,NNS,O
,and,CC,O
,submitted,VBN,O
,to,TO,O
,the,DT,O
,Medicines,NNPS,O
,and,CC,O
,Healthcare,NNP,O
,Products,NNP,O
,Regulatory,NNP,O
,Agency,NNP,O
,(,(,O
,MHRA,NNP,O
,),),O
,with,IN,O
,suspected,VBN,O
,kidney,NN,O
,adverse,JJ,O
,effects,NNS,O
,.,.,O
,Reports,NNS,O
,that,IN,O
,satisfy,NN,O
,defined,VBD,O
,criteria,NNS,O
,were,VBD,O
,classified,VBN,O
,as,IN,O
,acute,JJ,B-DISEASE
,kidney,NN,I-DISEASE
,injury,NN,I-DISEASE
,",",",",O
,kidney,NN,B-DISEASE
,tubular,JJ,I-DISEASE
,dysfunction,NN,I-DISEASE
,and,CC,O
,Fanconi,NNP,B-DISEASE
,syndrome,VBP,I-DISEASE
,.,.,O
,Of,IN,O
,the,DT,O
,407,CD,O
,Yellow,NNP,O
,Card,NNP,O
,records,NNS,O
,analysed,VBD,O
,",",",",O
,106,CD,O
,satisfied,VBD,O
,criteria,NNS,O
,for,IN,O
,TDF,NNP,O
,-,:,O
,related,JJ,O
,kidney,NN,B-DISEASE
,disease,NN,I-DISEASE
,",",",",O
,of,IN,O
,which,WDT,O
,53,CD,O
,(,(,O
,50,CD,O
,%,NN,O
,),),O
,had,VBD,O
,features,NNS,O
,of,IN,O
,kidney,NN,B-DISEASE
,tubular,JJ,I-DISEASE
,dysfunction,NN,I-DISEASE
,",",",",O
,35,CD,O
,(,(,O
,33,CD,O
,%,NN,O
,),),O
,were,VBD,O
,found,VBN,O
,to,TO,O
,have,VB,O
,features,NNS,O
,of,IN,O
,glomerular,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,and,CC,O
,18,CD,O
,(,(,O
,17,CD,O
,%,NN,O
,),),O
,had,VBD,O
,Fanconi,NNP,B-DISEASE
,syndrome,NN,I-DISEASE
,.,.,O
,The,DT,O
,median,JJ,O
,TDF,NNP,O
,exposure,NN,O
,was,VBD,O
,316,CD,O
,days,NNS,O
,(,(,O
,interquartile,JJ,O
,range,NN,O
,120,CD,O
,-,:,O
,740,CD,O
,),),O
,.,.,O
,The,DT,O
,incidence,NN,O
,of,IN,O
,hospitalisation,NN,O
,for,IN,O
,TDF,NNP,O
,kidney,NNP,O
,adverse,JJ,O
,effects,NNS,O
,was,VBD,O
,high,JJ,O
,",",",",O
,particularly,RB,O
,amongst,JJ,O
,patients,NNS,O
,with,IN,O
,features,NNS,O
,of,IN,O
,Fanconi,NNP,B-DISEASE
,syndrome,NN,I-DISEASE
,.,.,O
,The,DT,O
,pattern,NN,O
,of,IN,O
,kidney,NN,O
,syndromes,NNS,O
,in,IN,O
,this,DT,O
,population,NN,O
,series,NN,O
,mirrors,NNS,O
,that,WDT,O
,reported,VBD,O
,in,IN,O
,randomised,JJ,O
,clinical,JJ,O
,trials,NNS,O
,.,.,O
,Cessation,NN,O
,of,IN,O
,TDF,NNP,O
,was,VBD,O
,associated,VBN,O
,with,IN,O
,complete,JJ,O
,restoration,NN,O
,of,IN,O
,kidney,NN,O
,function,NN,O
,in,IN,O
,up,IN,O
,half,NN,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,in,IN,O
,this,DT,O
,report,NN,O
,.,.,O
,Incidence,NNP,O
,of,IN,O
,postoperative,JJ,B-DISEASE
,delirium,NN,I-DISEASE
,is,VBZ,O
,high,JJ,O
,even,RB,O
,in,IN,O
,a,DT,O
,population,NN,O
,without,IN,O
,known,VBN,O
,risk,NN,O
,factors,NNS,O
,.,.,O
,PURPOSE,NN,O
,:,:,O
,Postoperative,JJ,B-DISEASE
,delirium,NN,I-DISEASE
,is,VBZ,O
,a,DT,O
,recognized,VBN,O
,complication,NN,O
,in,IN,O
,populations,NNS,O
,at,IN,O
,risk,NN,O
,.,.,O
,The,DT,O
,aim,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,is,VBZ,O
,to,TO,O
,assess,VB,O
,the,DT,O
,prevalence,NN,O
,of,IN,O
,early,JJ,O
,postoperative,JJ,B-DISEASE
,delirium,NN,I-DISEASE
,in,IN,O
,a,DT,O
,population,NN,O
,without,IN,O
,known,VBN,O
,risk,NN,O
,factors,NNS,O
,admitted,VBD,O
,to,TO,O
,the,DT,O
,ICU,NNP,O
,for,IN,O
,postoperative,JJ,O
,monitoring,NN,O
,after,IN,O
,elective,JJ,O
,major,JJ,O
,surgery,NN,O
,.,.,O
,The,DT,O
,secondary,JJ,O
,outcome,NN,O
,investigated,VBN,O
,is,VBZ,O
,to,TO,O
,identify,VB,O
,eventual,JJ,O
,independent,JJ,O
,risk,NN,O
,factors,NNS,O
,among,IN,O
,demographic,JJ,O
,data,NNS,O
,and,CC,O
,anesthetic,JJ,O
,drugs,NNS,O
,used,VBN,O
,.,.,O
,METHODS,NNP,O
,:,:,O
,An,DT,O
,observational,JJ,O
,",",",",O
,prospective,JJ,O
,study,NN,O
,was,VBD,O
,conducted,VBN,O
,on,IN,O
,a,DT,O
,consecutive,JJ,O
,cohort,NN,O
,of,IN,O
,patients,NNS,O
,admitted,VBN,O
,to,TO,O
,our,PRP$,O
,ICU,NNP,O
,within,IN,O
,and,CC,O
,for,IN,O
,at,IN,O
,least,JJS,O
,24,CD,O
,h,NN,O
,after,IN,O
,major,JJ,O
,surgical,JJ,O
,procedures,NNS,O
,.,.,O
,Exclusion,NN,O
,criteria,NNS,O
,were,VBD,O
,any,DT,O
,preexisting,VBG,O
,predisposing,NN,O
,factor,NN,O
,for,IN,O
,delirium,NN,B-DISEASE
,or,CC,O
,other,JJ,O
,potentially,RB,O
,confounding,VBG,O
,neurological,JJ,B-DISEASE
,dysfunctions,NNS,I-DISEASE
,.,.,O
,Patients,NNS,O
,were,VBD,O
,assessed,VBN,O
,daily,RB,O
,using,VBG,O
,the,DT,O
,confusion,NN,B-DISEASE
,assessment,NN,O
,method,NN,O
,for,IN,O
,the,DT,O
,ICU,NNP,O
,scale,NN,O
,for,IN,O
,3,CD,O
,days,NNS,O
,after,IN,O
,the,DT,O
,surgical,JJ,O
,procedure,NN,O
,.,.,O
,Early,JJ,O
,postoperative,JJ,B-DISEASE
,delirium,NN,I-DISEASE
,incidence,NN,O
,risk,NN,O
,factors,NNS,O
,were,VBD,O
,then,RB,O
,assessed,VBN,O
,through,IN,O
,three,CD,O
,different,JJ,O
,multiple,JJ,O
,regression,NN,O
,models,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,According,VBG,O
,to,TO,O
,the,DT,O
,confusion,NN,O
,assessment,NN,O
,method,NN,O
,for,IN,O
,the,DT,O
,ICU,NNP,O
,scale,NN,O
,",",",",O
,28,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,were,VBD,O
,diagnosed,VBN,O
,with,IN,O
,early,JJ,O
,postoperative,JJ,B-DISEASE
,delirium,NN,I-DISEASE
,.,.,O
,The,DT,O
,use,NN,O
,of,IN,O
,thiopentone,NN,O
,was,VBD,O
,significantly,RB,O
,associated,VBN,O
,with,IN,O
,an,DT,O
,eight,CD,O
,-,:,O
,fold,NN,O
,-,:,O
,higher,JJR,O
,risk,NN,O
,for,IN,O
,delirium,NN,B-DISEASE
,compared,VBN,O
,to,TO,O
,propofol,VB,O
,(,(,O
,57,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,vs,NN,O
,.,.,O
,7,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,",",",",O
,RR,NNP,O
,=,VBZ,O
,8,CD,O
,.,.,O
,0,CD,O
,",",",",O
,X2,NNP,O
,=,VBZ,O
,4,CD,O
,.,.,O
,256,CD,O
,;,:,O
,df,NN,O
,=,VBZ,O
,1,CD,O
,;,:,O
,0,CD,O
,.,.,O
,05,CD,O
,<,JJ,O
,p,NN,O
,<,VBD,O
,0,CD,O
,.,.,O
,02,CD,O
,),),O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,In,IN,O
,this,DT,O
,study,NN,O
,early,RB,O
,postoperative,JJ,B-DISEASE
,delirium,NN,I-DISEASE
,was,VBD,O
,found,VBN,O
,to,TO,O
,be,VB,O
,a,DT,O
,very,RB,O
,common,JJ,O
,complication,NN,O
,after,IN,O
,major,JJ,O
,surgery,NN,O
,",",",",O
,even,RB,O
,in,IN,O
,a,DT,O
,population,NN,O
,without,IN,O
,known,VBN,O
,risk,NN,O
,factors,NNS,O
,.,.,O
,Thiopentone,NN,O
,was,VBD,O
,independently,RB,O
,associated,VBN,O
,with,IN,O
,an,DT,O
,increase,NN,O
,in,IN,O
,its,PRP$,O
,relative,JJ,O
,risk,NN,O
,.,.,O
,A,DT,O
,single,JJ,O
,neurotoxic,NN,B-DISEASE
,dose,NN,O
,of,IN,O
,methamphetamine,NN,O
,induces,NNS,O
,a,DT,O
,long,JJ,O
,-,:,O
,lasting,NN,O
,depressive,JJ,B-DISEASE
,-,:,O
,like,IN,O
,behaviour,NN,O
,in,IN,O
,mice,NN,O
,.,.,O
,Methamphetamine,NNP,O
,(,(,O
,METH,NNP,O
,),),O
,triggers,VBZ,O
,a,DT,O
,disruption,NN,O
,of,IN,O
,the,DT,O
,monoaminergic,NN,O
,system,NN,O
,and,CC,O
,METH,NNP,O
,abuse,VBP,O
,leads,VBZ,O
,to,TO,O
,negative,JJ,O
,emotional,JJ,O
,states,NNS,O
,including,VBG,O
,depressive,JJ,B-DISEASE
,symptoms,NNS,I-DISEASE
,during,IN,O
,drug,NN,O
,withdrawal,NN,O
,.,.,O
,However,RB,O
,",",",",O
,it,PRP,O
,is,VBZ,O
,currently,RB,O
,unknown,JJ,O
,if,IN,O
,the,DT,O
,acute,NN,O
,toxic,JJ,O
,dosage,NN,O
,of,IN,O
,METH,NNP,O
,also,RB,O
,causes,VBZ,O
,a,DT,O
,long,JJ,O
,-,:,O
,lasting,VBG,O
,depressive,JJ,B-DISEASE
,phenotype,NN,O
,and,CC,O
,persistent,JJ,O
,monoaminergic,NN,O
,deficits,NNS,O
,.,.,O
,Thus,RB,O
,",",",",O
,we,PRP,O
,now,RB,O
,assessed,VBD,O
,the,DT,O
,depressive,JJ,B-DISEASE
,-,:,O
,like,IN,O
,behaviour,NN,O
,in,IN,O
,mice,NN,O
,at,IN,O
,early,JJ,O
,and,CC,O
,long,JJ,O
,-,:,O
,term,NN,O
,periods,NNS,O
,following,VBG,O
,a,DT,O
,single,JJ,O
,high,JJ,O
,METH,NNP,O
,dose,NN,O
,(,(,O
,30,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,.,.,O
,METH,NNP,O
,did,VBD,O
,not,RB,O
,alter,VB,O
,the,DT,O
,motor,NN,O
,function,NN,O
,and,CC,O
,procedural,JJ,O
,memory,NN,O
,of,IN,O
,mice,NN,O
,as,IN,O
,assessed,VBN,O
,by,IN,O
,swimming,VBG,O
,speed,NN,O
,and,CC,O
,escape,NN,O
,latency,NN,O
,to,TO,O
,find,VB,O
,the,DT,O
,platform,NN,O
,in,IN,O
,a,DT,O
,cued,JJ,O
,version,NN,O
,of,IN,O
,the,DT,O
,water,NN,O
,maze,NN,O
,task,NN,O
,.,.,O
,However,RB,O
,",",",",O
,METH,NNP,O
,significantly,RB,O
,increased,VBD,O
,the,DT,O
,immobility,NN,O
,time,NN,O
,in,IN,O
,the,DT,O
,tail,NN,O
,suspension,NN,O
,test,NN,O
,at,IN,O
,3,CD,O
,and,CC,O
,49,CD,O
,days,NNS,O
,post,RB,O
,-,:,O
,administration,NN,O
,.,.,O
,This,DT,O
,depressive,JJ,B-DISEASE
,-,:,O
,like,IN,O
,profile,NN,O
,induced,VBN,O
,by,IN,O
,METH,NNP,O
,was,VBD,O
,accompanied,VBN,O
,by,IN,O
,a,DT,O
,marked,JJ,O
,depletion,NN,O
,of,IN,O
,frontostriatal,JJ,O
,dopaminergic,NN,O
,and,CC,O
,serotonergic,JJ,O
,neurotransmission,NN,O
,",",",",O
,indicated,VBN,O
,by,IN,O
,a,DT,O
,reduction,NN,O
,in,IN,O
,the,DT,O
,levels,NNS,O
,of,IN,O
,dopamine,NN,O
,",",",",O
,DOPAC,NNP,O
,and,CC,O
,HVA,NNP,O
,",",",",O
,tyrosine,JJ,O
,hydroxylase,NN,O
,and,CC,O
,serotonin,NN,O
,",",",",O
,observed,VBN,O
,at,IN,O
,both,DT,O
,3,CD,O
,and,CC,O
,49,CD,O
,days,NNS,O
,post,RB,O
,-,:,O
,administration,NN,O
,.,.,O
,In,IN,O
,parallel,NN,O
,",",",",O
,another,DT,O
,neurochemical,JJ,O
,feature,NN,O
,of,IN,O
,depression,NN,B-DISEASE
,-,:,O
,-,:,O
,astroglial,JJ,O
,dysfunction,NN,O
,-,:,O
,-,:,O
,was,VBD,O
,unaffected,VBN,O
,in,IN,O
,the,DT,O
,cortex,NN,O
,and,CC,O
,the,DT,O
,striatal,JJ,O
,levels,NNS,O
,of,IN,O
,the,DT,O
,astrocytic,JJ,O
,protein,NN,O
,marker,NN,O
,",",",",O
,glial,JJ,O
,fibrillary,JJ,O
,acidic,NN,O
,protein,NN,O
,",",",",O
,were,VBD,O
,only,RB,O
,transiently,RB,O
,increased,VBN,O
,at,IN,O
,3,CD,O
,days,NNS,O
,.,.,O
,These,DT,O
,findings,NNS,O
,demonstrate,NN,O
,for,IN,O
,the,DT,O
,first,JJ,O
,time,NN,O
,that,IN,O
,a,DT,O
,single,JJ,O
,high,JJ,O
,dose,NN,O
,of,IN,O
,METH,NNP,O
,induces,NNS,O
,long,RB,O
,-,:,O
,lasting,VBG,O
,depressive,JJ,B-DISEASE
,-,:,O
,like,IN,O
,behaviour,NN,O
,in,IN,O
,mice,NN,O
,associated,VBN,O
,with,IN,O
,a,DT,O
,persistent,JJ,O
,disruption,NN,O
,of,IN,O
,frontostriatal,JJ,O
,dopaminergic,NN,O
,and,CC,O
,serotonergic,JJ,O
,homoeostasis,NN,O
,.,.,O
,Linezolid,NNP,O
,-,:,O
,induced,VBD,O
,optic,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,.,.,O
,Many,JJ,O
,systemic,JJ,O
,antimicrobials,NNS,O
,have,VBP,O
,been,VBN,O
,implicated,VBN,O
,to,TO,O
,cause,VB,O
,ocular,JJ,O
,adverse,JJ,O
,effects,NNS,O
,.,.,O
,This,DT,O
,is,VBZ,O
,especially,RB,O
,relevant,JJ,O
,in,IN,O
,multidrug,NN,O
,therapy,NN,O
,where,WRB,O
,more,JJR,O
,than,IN,O
,one,CD,O
,drug,NN,O
,can,MD,O
,cause,VB,O
,a,DT,O
,similar,JJ,O
,ocular,JJ,O
,adverse,JJ,O
,effect,NN,O
,.,.,O
,We,PRP,O
,describe,VBP,O
,a,DT,O
,case,NN,O
,of,IN,O
,progressive,JJ,O
,loss,NN,B-DISEASE
,of,IN,I-DISEASE
,vision,NN,I-DISEASE
,associated,VBN,O
,with,IN,O
,linezolid,JJ,O
,therapy,NN,O
,.,.,O
,A,DT,O
,45,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,male,JJ,O
,patient,NN,O
,who,WP,O
,was,VBD,O
,on,IN,O
,treatment,NN,O
,with,IN,O
,multiple,JJ,O
,second,JJ,O
,-,:,O
,line,NN,O
,anti,IN,O
,-,:,O
,tuberculous,JJ,O
,drugs,NNS,O
,including,VBG,O
,linezolid,NN,O
,and,CC,O
,ethambutol,NN,O
,for,IN,O
,extensively,RB,B-DISEASE
,drug,NN,I-DISEASE
,-,:,I-DISEASE
,resistant,JJ,I-DISEASE
,tuberculosis,NN,I-DISEASE
,(,(,O
,XDR,NNP,B-DISEASE
,-,:,I-DISEASE
,TB,NN,I-DISEASE
,),),O
,presented,VBD,O
,to,TO,O
,us,PRP,O
,with,IN,O
,painless,JJ,O
,progressive,JJ,O
,loss,NN,B-DISEASE
,of,IN,I-DISEASE
,vision,NN,I-DISEASE
,in,IN,O
,both,DT,O
,eyes,NNS,O
,.,.,O
,Color,NNP,O
,vision,NN,O
,was,VBD,O
,defective,JJ,O
,and,CC,O
,fundus,JJ,O
,examination,NN,O
,revealed,VBD,O
,optic,JJ,B-DISEASE
,disc,NN,I-DISEASE
,edema,NN,I-DISEASE
,in,IN,O
,both,DT,O
,eyes,NNS,O
,.,.,O
,Ethambutol,NNP,O
,-,:,O
,induced,VBD,O
,toxic,JJ,B-DISEASE
,optic,JJ,I-DISEASE
,neuropathy,NN,I-DISEASE
,was,VBD,O
,suspected,VBN,O
,and,CC,O
,tablet,VB,O
,ethambutol,NN,O
,was,VBD,O
,withdrawn,VBN,O
,.,.,O
,Deterioration,NN,B-DISEASE
,of,IN,I-DISEASE
,vision,NN,I-DISEASE
,occurred,VBD,O
,despite,IN,O
,withdrawal,NN,O
,of,IN,O
,ethambutol,NN,O
,.,.,O
,Discontinuation,NN,O
,of,IN,O
,linezolid,JJ,O
,resulted,VBN,O
,in,IN,O
,marked,JJ,O
,improvement,NN,O
,of,IN,O
,vision,NN,O
,.,.,O
,Our,PRP$,O
,report,NN,O
,emphasizes,VBZ,O
,the,DT,O
,need,NN,O
,for,IN,O
,monitoring,NN,O
,of,IN,O
,visual,JJ,O
,function,NN,O
,in,IN,O
,patients,NNS,O
,on,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,linezolid,JJ,O
,treatment,NN,O
,.,.,O
,Resuscitation,NN,O
,with,IN,O
,lipid,JJ,O
,",",",",O
,epinephrine,JJ,O
,",",",",O
,or,CC,O
,both,DT,O
,in,IN,O
,levobupivacaine,NN,O
,-,:,O
,induced,JJ,O
,cardiac,JJ,B-DISEASE
,toxicity,NN,I-DISEASE
,in,IN,O
,newborn,JJ,O
,piglets,NNS,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,The,DT,O
,optimal,JJ,O
,dosing,NN,O
,regimens,NNS,O
,of,IN,O
,lipid,JJ,O
,emulsion,NN,O
,",",",",O
,epinephrine,NN,O
,",",",",O
,or,CC,O
,both,DT,O
,are,VBP,O
,not,RB,O
,yet,RB,O
,determined,VBN,O
,in,IN,O
,neonates,NNS,O
,in,IN,O
,cases,NNS,O
,of,IN,O
,local,JJ,O
,anaesthetic,JJ,O
,systemic,JJ,O
,toxicity,NN,B-DISEASE
,(,(,O
,LAST,NNP,O
,),),O
,.,.,O
,METHODS,NN,O
,:,:,O
,Newborn,JJ,O
,piglets,NNS,O
,received,VBD,O
,levobupivacaine,JJ,O
,until,IN,O
,cardiovascular,JJ,B-DISEASE
,collapse,NN,I-DISEASE
,occurred,VBD,O
,.,.,O
,Standard,NNP,O
,cardiopulmonary,JJ,O
,resuscitation,NN,O
,was,VBD,O
,started,VBN,O
,and,CC,O
,electrocardiogram,FW,O
,(,(,O
,ECG,NNP,O
,),),O
,was,VBD,O
,monitored,VBN,O
,for,IN,O
,ventricular,JJ,B-DISEASE
,tachycardia,NN,I-DISEASE
,",",",",O
,fibrillation,NN,B-DISEASE
,",",",",O
,or,CC,O
,QRS,NNP,O
,prolongation,NN,O
,.,.,O
,Piglets,NNS,O
,were,VBD,O
,then,RB,O
,randomly,RB,O
,allocated,VBN,O
,to,TO,O
,four,CD,O
,groups,NNS,O
,:,:,O
,control,NN,O
,(,(,O
,saline,NN,O
,),),O
,",",",",O
,Intralipid,NNP,O
,(,(,O
,),),O
,alone,RB,O
,",",",",O
,epinephrine,VB,O
,alone,RB,O
,",",",",O
,or,CC,O
,a,DT,O
,combination,NN,O
,of,IN,O
,Intralipd,NNP,O
,plus,CC,O
,epinephrine,NN,O
,.,.,O
,Resuscitation,NNP,O
,continued,VBD,O
,for,IN,O
,30,CD,O
,min,NN,O
,or,CC,O
,until,IN,O
,there,EX,O
,was,VBD,O
,a,DT,O
,return,NN,O
,of,IN,O
,spontaneous,JJ,O
,circulation,NN,O
,(,(,O
,ROSC,NNP,O
,),),O
,accompanied,VBN,O
,by,IN,O
,a,DT,O
,mean,JJ,O
,arterial,JJ,O
,pressure,NN,O
,at,IN,O
,or,CC,O
,superior,JJ,O
,to,TO,O
,the,DT,O
,baseline,NN,O
,pressure,NN,O
,and,CC,O
,normal,JJ,O
,sinus,NN,O
,rhythm,NN,O
,for,IN,O
,a,DT,O
,period,NN,O
,of,IN,O
,30,CD,O
,min,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,ROSC,NNP,O
,was,VBD,O
,achieved,VBN,O
,in,IN,O
,only,RB,O
,one,CD,O
,of,IN,O
,the,DT,O
,control,NN,O
,piglets,NNS,O
,compared,VBN,O
,with,IN,O
,most,JJS,O
,of,IN,O
,the,DT,O
,treated,JJ,O
,piglets,NNS,O
,.,.,O
,Mortality,NNP,O
,was,VBD,O
,not,RB,O
,significantly,RB,O
,different,JJ,O
,between,IN,O
,the,DT,O
,three,CD,O
,treatment,NN,O
,groups,NNS,O
,",",",",O
,but,CC,O
,was,VBD,O
,significantly,RB,O
,lower,JJR,O
,in,IN,O
,all,PDT,O
,the,DT,O
,treatment,NN,O
,groups,NNS,O
,compared,VBN,O
,with,IN,O
,control,NN,O
,.,.,O
,The,DT,O
,number,NN,O
,of,IN,O
,ECG,NNP,O
,abnormalities,NNS,O
,was,VBD,O
,zero,CD,O
,in,IN,O
,the,DT,O
,Intralipid,NNP,O
,only,RB,O
,group,NN,O
,",",",",O
,but,CC,O
,14,CD,O
,and,CC,O
,17,CD,O
,",",",",O
,respectively,RB,O
,",",",",O
,in,IN,O
,the,DT,O
,epinephrine,NN,O
,and,CC,O
,epinephrine,JJ,O
,plus,CC,O
,lipid,JJ,O
,groups,NNS,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Lipid,JJ,O
,emulsion,NN,O
,with,IN,O
,or,CC,O
,without,IN,O
,epinephrine,JJ,O
,",",",",O
,or,CC,O
,epinephrine,VB,O
,alone,RB,O
,were,VBD,O
,equally,RB,O
,effective,JJ,O
,in,IN,O
,achieving,VBG,O
,a,DT,O
,return,NN,O
,to,TO,O
,spontaneous,JJ,O
,circulation,NN,O
,in,IN,O
,this,DT,O
,model,NN,O
,of,IN,O
,LAST,NNP,O
,.,.,O
,Epinephrine,NNP,O
,alone,RB,O
,or,CC,O
,in,IN,O
,combination,NN,O
,with,IN,O
,lipid,NN,O
,was,VBD,O
,associated,VBN,O
,with,IN,O
,an,DT,O
,increased,JJ,O
,number,NN,O
,of,IN,O
,ECG,NNP,O
,abnormalities,NNS,O
,compared,VBN,O
,with,IN,O
,lipid,JJ,O
,emulsion,NN,O
,alone,RB,O
,.,.,O
,Incidence,NN,O
,of,IN,O
,heparin,JJ,O
,-,:,O
,induced,VBN,O
,thrombocytopenia,IN,B-DISEASE
,type,NN,I-DISEASE
,II,NNP,I-DISEASE
,and,CC,O
,postoperative,JJ,O
,recovery,NN,O
,of,IN,O
,platelet,NN,O
,count,NN,O
,in,IN,O
,liver,NN,O
,graft,NN,O
,recipients,NNS,O
,:,:,O
,a,DT,O
,retrospective,JJ,O
,cohort,NN,O
,analysis,NN,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Thrombocytopenia,NNP,B-DISEASE
,in,IN,O
,patients,NNS,O
,with,IN,O
,end,JJ,B-DISEASE
,-,:,I-DISEASE
,stage,NN,I-DISEASE
,liver,JJ,I-DISEASE
,disease,NN,I-DISEASE
,is,VBZ,O
,a,DT,O
,common,JJ,O
,disorder,NN,O
,caused,VBN,O
,mainly,RB,O
,by,IN,O
,portal,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,",",",",O
,low,JJ,O
,levels,NNS,O
,of,IN,O
,thrombopoetin,NN,O
,",",",",O
,and,CC,O
,endotoxemia,NN,B-DISEASE
,.,.,O
,The,DT,O
,impact,NN,O
,of,IN,O
,immune,JJ,O
,-,:,O
,mediated,VBN,O
,heparin,SYM,O
,-,:,O
,induced,VBN,O
,thrombocytopenia,IN,B-DISEASE
,type,NN,I-DISEASE
,II,NNP,I-DISEASE
,(,(,O
,HIT,NNP,B-DISEASE
,type,RB,I-DISEASE
,II,NNP,I-DISEASE
,),),O
,as,IN,O
,a,DT,O
,cause,NN,O
,of,IN,O
,thrombocytopenia,NN,B-DISEASE
,after,IN,O
,liver,JJ,O
,transplantation,NN,O
,is,VBZ,O
,not,RB,O
,yet,RB,O
,understood,JJ,O
,",",",",O
,with,IN,O
,few,JJ,O
,literature,NN,O
,citations,NNS,O
,reporting,VBG,O
,contradictory,NN,O
,results,NNS,O
,.,.,O
,The,DT,O
,aim,NN,O
,of,IN,O
,our,PRP$,O
,study,NN,O
,was,VBD,O
,to,TO,O
,demonstrate,VB,O
,the,DT,O
,perioperative,JJ,O
,course,NN,O
,of,IN,O
,thrombocytopenia,NN,B-DISEASE
,after,IN,O
,liver,JJ,O
,transplantation,NN,O
,and,CC,O
,determine,VB,O
,the,DT,O
,occurrence,NN,O
,of,IN,O
,clinical,JJ,O
,HIT,NNP,B-DISEASE
,type,NN,I-DISEASE
,II,NNP,I-DISEASE
,.,.,O
,METHOD,NN,O
,:,:,O
,We,PRP,O
,retrospectively,RB,O
,evaluated,VBD,O
,the,DT,O
,medical,JJ,O
,records,NNS,O
,of,IN,O
,205,CD,O
,consecutive,JJ,O
,adult,NN,O
,patients,NNS,O
,who,WP,O
,underwent,VBP,O
,full,JJ,O
,-,:,O
,size,NN,O
,liver,NN,O
,transplantation,NN,O
,between,IN,O
,January,NNP,O
,2006,CD,O
,and,CC,O
,December,NNP,O
,2010,CD,O
,due,NN,O
,to,TO,O
,end,VB,B-DISEASE
,-,:,I-DISEASE
,stage,NN,I-DISEASE
,or,CC,I-DISEASE
,malignant,JJ,I-DISEASE
,liver,NN,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,Preoperative,JJ,O
,platelet,NN,O
,count,NN,O
,",",",",O
,postoperative,JJ,O
,course,NN,O
,of,IN,O
,platelets,NNS,O
,",",",",O
,and,CC,O
,clinical,JJ,O
,signs,NNS,O
,of,IN,O
,HIT,NNP,B-DISEASE
,type,NN,I-DISEASE
,II,NNP,I-DISEASE
,were,VBD,O
,analyzed,VBN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,A,DT,O
,total,NN,O
,of,IN,O
,155,CD,O
,(,(,O
,75,CD,O
,.,.,O
,6,CD,O
,%,NN,O
,),),O
,of,IN,O
,205,CD,O
,patients,NNS,O
,had,VBD,O
,thrombocytopenia,VBN,B-DISEASE
,before,IN,O
,transplantation,NN,O
,",",",",O
,significantly,RB,O
,influenced,VBN,O
,by,IN,O
,Model,NNP,O
,of,IN,O
,End,NNP,B-DISEASE
,-,:,I-DISEASE
,Stage,NN,I-DISEASE
,Liver,NNP,I-DISEASE
,Disease,NNP,I-DISEASE
,score,NN,O
,and,CC,O
,liver,JJ,B-DISEASE
,cirrhosis,NN,I-DISEASE
,.,.,O
,The,DT,O
,platelet,NN,O
,count,NN,O
,exceeded,VBD,O
,100,CD,O
,",",",",O
,000,CD,O
,/,NN,O
,uL,NN,O
,in,IN,O
,most,JJS,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,(,(,O
,n,JJ,O
,=,NNP,O
,193,CD,O
,),),O
,at,IN,O
,a,DT,O
,medium,NN,O
,of,IN,O
,7,CD,O
,d,NN,O
,.,.,O
,Regarding,VBG,O
,HIT,NNP,B-DISEASE
,II,NNP,I-DISEASE
,",",",",O
,there,EX,O
,were,VBD,O
,four,CD,O
,(,(,O
,1,CD,O
,.,.,O
,95,CD,O
,%,NN,O
,),),O
,patients,NNS,O
,with,IN,O
,a,DT,O
,background,NN,O
,of,IN,O
,HIT,NNP,B-DISEASE
,type,NN,I-DISEASE
,II,NNP,I-DISEASE
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,The,DT,O
,incidence,NN,O
,of,IN,O
,HIT,NNP,B-DISEASE
,in,IN,O
,patients,NNS,O
,with,IN,O
,end,JJ,B-DISEASE
,-,:,I-DISEASE
,stage,NN,I-DISEASE
,hepatic,JJ,I-DISEASE
,failure,NN,I-DISEASE
,is,VBZ,O
,",",",",O
,with,IN,O
,about,IN,O
,1,CD,O
,.,.,O
,95,CD,O
,%,NN,O
,",",",",O
,rare,JJ,O
,.,.,O
,For,IN,O
,further,JJ,O
,reduction,NN,O
,of,IN,O
,HIT,NNP,B-DISEASE
,type,NN,I-DISEASE
,II,NNP,I-DISEASE
,",",",",O
,the,DT,O
,use,NN,O
,of,IN,O
,intravenous,JJ,O
,heparin,NN,O
,should,MD,O
,be,VB,O
,avoided,VBN,O
,and,CC,O
,the,DT,O
,prophylactic,JJ,O
,anticoagulation,NN,O
,should,MD,O
,be,VB,O
,performed,VBN,O
,with,IN,O
,low,JJ,O
,-,:,O
,molecular,JJ,O
,-,:,O
,weight,NN,O
,heparin,NN,O
,after,IN,O
,normalization,NN,O
,of,IN,O
,platelet,NN,O
,count,NN,O
,.,.,O
,Takotsubo,NNP,B-DISEASE
,syndrome,NN,I-DISEASE
,(,(,O
,or,CC,O
,apical,JJ,B-DISEASE
,ballooning,NN,I-DISEASE
,syndrome,NN,I-DISEASE
,),),O
,secondary,NN,O
,to,TO,O
,Zolmitriptan,NNP,O
,.,.,O
,Takotsubo,NNP,B-DISEASE
,syndrome,NN,I-DISEASE
,(,(,O
,TS,NNP,B-DISEASE
,),),O
,",",",",O
,also,RB,O
,known,VBN,O
,as,IN,O
,broken,JJ,B-DISEASE
,heart,NN,I-DISEASE
,syndrome,NN,I-DISEASE
,",",",",O
,is,VBZ,O
,characterized,VBN,O
,by,IN,O
,left,JJ,O
,ventricle,NN,O
,apical,JJ,O
,ballooning,NN,O
,with,IN,O
,elevated,JJ,O
,cardiac,JJ,O
,biomarkers,NNS,O
,and,CC,O
,electrocardiographic,JJ,O
,changes,NNS,O
,suggestive,VBP,O
,of,IN,O
,an,DT,O
,acute,JJ,B-DISEASE
,coronary,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,(,(,O
,ie,JJ,O
,",",",",O
,ST,NNP,O
,-,:,O
,segment,NN,O
,elevation,NN,O
,",",",",O
,T,NNP,O
,wave,VBP,O
,inversions,NNS,O
,",",",",O
,and,CC,O
,pathologic,JJ,O
,Q,NNP,O
,waves,NNS,O
,),),O
,.,.,O
,We,PRP,O
,report,VBP,O
,a,DT,O
,case,NN,O
,of,IN,O
,54,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,with,IN,O
,medical,JJ,O
,history,NN,O
,of,IN,O
,mitral,JJ,B-DISEASE
,valve,NN,I-DISEASE
,prolapse,NN,I-DISEASE
,and,CC,O
,migraines,NNS,B-DISEASE
,",",",",O
,who,WP,O
,was,VBD,O
,admitted,VBN,O
,to,TO,O
,the,DT,O
,hospital,NN,O
,for,IN,O
,substernal,JJ,O
,chest,NN,B-DISEASE
,pain,NN,I-DISEASE
,and,CC,O
,electrocardiogram,NN,O
,demonstrated,VBD,O
,1,CD,O
,/,JJ,O
,2,CD,O
,mm,NN,O
,ST,NNP,O
,-,:,O
,segment,NN,O
,elevation,NN,O
,in,IN,O
,leads,NNS,O
,II,NNP,O
,",",",",O
,III,NNP,O
,",",",",O
,aVF,NN,O
,",",",",O
,V5,NNP,O
,",",",",O
,and,CC,O
,V6,NNP,O
,and,CC,O
,positive,JJ,O
,troponin,NN,O
,I,PRP,O
,.,.,O
,Emergent,JJ,O
,coronary,JJ,O
,angiogram,NN,O
,revealed,VBD,O
,normal,JJ,O
,coronary,JJ,O
,arteries,NNS,O
,with,IN,O
,moderately,RB,O
,reduced,VBN,O
,left,VBD,O
,ventricular,JJ,O
,ejection,NN,O
,fraction,NN,O
,with,IN,O
,wall,JJ,O
,motion,NN,O
,abnormalities,NNS,O
,consistent,VBP,O
,with,IN,O
,TS,NNP,B-DISEASE
,.,.,O
,Detailed,NNP,O
,history,NN,O
,obtained,VBD,O
,retrospectively,RB,O
,revealed,VBN,O
,that,IN,O
,the,DT,O
,patient,NN,O
,took,VBD,O
,zolmitriptan,NN,O
,sparingly,RB,O
,only,RB,O
,when,WRB,O
,she,PRP,O
,had,VBD,O
,migraines,NNS,B-DISEASE
,.,.,O
,But,CC,O
,before,IN,O
,this,DT,O
,event,NN,O
,",",",",O
,she,PRP,O
,was,VBD,O
,taking,VBG,O
,zolmitriptan,NN,O
,2,CD,O
,-,:,O
,3,CD,O
,times,NNS,O
,daily,RB,O
,for,IN,O
,several,JJ,O
,days,NNS,O
,because,IN,O
,of,IN,O
,a,DT,O
,persistent,JJ,O
,migraine,NN,B-DISEASE
,headache,NN,I-DISEASE
,.,.,O
,She,PRP,O
,otherwise,RB,O
,reported,VBD,O
,that,IN,O
,she,PRP,O
,is,VBZ,O
,quite,RB,O
,active,JJ,O
,",",",",O
,rides,JJ,O
,horses,NNS,O
,",",",",O
,and,CC,O
,does,VBZ,O
,show,VB,O
,jumping,VBG,O
,without,IN,O
,any,DT,O
,limitations,NNS,O
,in,IN,O
,her,PRP$,O
,physical,JJ,O
,activity,NN,O
,.,.,O
,There,EX,O
,was,VBD,O
,no,DT,O
,evidence,NN,O
,of,IN,O
,any,DT,O
,recent,JJ,O
,stress,NN,O
,or,CC,O
,status,NN,B-DISEASE
,migrainosus,NN,I-DISEASE
,.,.,O
,Extensive,JJ,O
,literature,NN,O
,search,NN,O
,revealed,VBD,O
,multiple,JJ,O
,cases,NNS,O
,of,IN,O
,coronary,JJ,B-DISEASE
,artery,NN,I-DISEASE
,vasospasm,NN,I-DISEASE
,secondary,JJ,O
,to,TO,O
,zolmitriptan,VB,O
,",",",",O
,but,CC,O
,none,NN,O
,of,IN,O
,the,DT,O
,cases,NNS,O
,were,VBD,O
,associated,VBN,O
,with,IN,O
,TS,NNP,B-DISEASE
,.,.,O
,Depression,NNP,B-DISEASE
,",",",",O
,impulsiveness,NN,B-DISEASE
,",",",",O
,sleep,NN,O
,",",",",O
,and,CC,O
,memory,NN,O
,in,IN,O
,past,JJ,O
,and,CC,O
,present,JJ,O
,polydrug,NN,O
,users,NNS,O
,of,IN,O
,3,CD,O
,",",",",O
,4,CD,O
,-,:,O
,methylenedioxymethamphetamine,NN,O
,(,(,O
,MDMA,NNP,O
,",",",",O
,ecstasy,NN,O
,),),O
,.,.,O
,RATIONALE,NN,O
,:,:,O
,Ecstasy,NNP,O
,(,(,O
,3,CD,O
,",",",",O
,4,CD,O
,-,:,O
,methylenedioxymethamphetamine,NN,O
,",",",",O
,MDMA,NNP,O
,),),O
,is,VBZ,O
,a,DT,O
,worldwide,JJ,O
,recreational,JJ,O
,drug,NN,O
,of,IN,O
,abuse,NN,O
,.,.,O
,Unfortunately,RB,O
,",",",",O
,the,DT,O
,results,NNS,O
,from,IN,O
,human,JJ,O
,research,NN,O
,investigating,VBG,O
,its,PRP$,O
,psychological,JJ,O
,effects,NNS,O
,have,VBP,O
,been,VBN,O
,inconsistent,JJ,O
,.,.,O
,OBJECTIVES,NN,O
,:,:,O
,The,DT,O
,present,JJ,O
,study,NN,O
,aimed,VBN,O
,to,TO,O
,be,VB,O
,the,DT,O
,largest,JJS,O
,to,TO,O
,date,NN,O
,in,IN,O
,sample,JJ,O
,size,NN,O
,and,CC,O
,5HT,CD,O
,-,:,O
,related,JJ,O
,behaviors,NNS,O
,;,:,O
,the,DT,O
,first,JJ,O
,to,TO,O
,compare,VB,O
,present,JJ,O
,ecstasy,JJ,O
,users,NNS,O
,with,IN,O
,past,JJ,O
,users,NNS,O
,after,IN,O
,an,DT,O
,abstinence,NN,O
,of,IN,O
,4,CD,O
,or,CC,O
,more,JJR,O
,years,NNS,O
,",",",",O
,and,CC,O
,the,DT,O
,first,JJ,O
,to,TO,O
,include,VB,O
,robust,JJ,O
,controls,NNS,O
,for,IN,O
,other,JJ,O
,recreational,JJ,O
,substances,NNS,O
,.,.,O
,METHODS,NN,O
,:,:,O
,A,DT,O
,sample,NN,O
,of,IN,O
,997,CD,O
,participants,NNS,O
,(,(,O
,52,CD,O
,%,NN,O
,male,NN,O
,),),O
,was,VBD,O
,recruited,VBN,O
,to,TO,O
,four,CD,O
,control,NN,O
,groups,NNS,O
,(,(,O
,non,JJ,O
,-,:,O
,drug,NN,O
,(,(,O
,ND,NNP,O
,),),O
,",",",",O
,alcohol,RB,O
,/,JJ,O
,nicotine,NN,O
,(,(,O
,AN,NNP,O
,),),O
,",",",",O
,cannabis,JJ,O
,/,NNP,O
,alcohol,NN,O
,/,NNP,O
,nicotine,NN,O
,(,(,O
,CAN,NNP,O
,),),O
,",",",",O
,non,JJ,O
,-,:,O
,ecstasy,JJ,O
,polydrug,NN,O
,(,(,O
,PD,NNP,O
,),),O
,),),O
,",",",",O
,and,CC,O
,two,CD,O
,ecstasy,JJ,O
,polydrug,NN,O
,groups,NNS,O
,(,(,O
,present,JJ,O
,(,(,O
,MDMA,NNP,O
,),),O
,and,CC,O
,past,JJ,O
,users,NNS,O
,(,(,O
,EX,NNP,O
,-,:,O
,MDMA,NN,O
,),),O
,.,.,O
,Participants,NNS,O
,completed,VBD,O
,a,DT,O
,drug,NN,O
,history,NN,O
,questionnaire,NN,O
,",",",",O
,Beck,NNP,O
,Depression,NNP,B-DISEASE
,Inventory,NNP,O
,",",",",O
,Barratt,NNP,O
,Impulsiveness,NNP,B-DISEASE
,Scale,NNP,O
,",",",",O
,Pittsburgh,NNP,O
,Sleep,NNP,O
,Quality,NNP,O
,Index,NNP,O
,",",",",O
,and,CC,O
,Wechsler,NNP,O
,Memory,NNP,O
,Scale,NNP,O
,-,:,O
,Revised,VBD,O
,which,WDT,O
,",",",",O
,in,IN,O
,total,JJ,O
,",",",",O
,provided,VBD,O
,13,CD,O
,psychometric,JJ,O
,measures,NNS,O
,.,.,O
,RESULTS,NNS,O
,:,:,O
,While,IN,O
,the,DT,O
,CAN,NNP,O
,and,CC,O
,PD,NNP,O
,groups,NNS,O
,tended,VBD,O
,to,TO,O
,record,VB,O
,greater,JJR,O
,deficits,NNS,O
,than,IN,O
,the,DT,O
,non,JJ,O
,-,:,O
,drug,NN,O
,controls,NNS,O
,",",",",O
,the,DT,O
,MDMA,NNP,O
,and,CC,O
,EX,NNP,O
,-,:,O
,MDMA,NN,O
,groups,NNS,O
,recorded,VBD,O
,greater,JJR,O
,deficits,NNS,O
,than,IN,O
,all,PDT,O
,the,DT,O
,control,NN,O
,groups,NNS,O
,on,IN,O
,ten,NNS,O
,of,IN,O
,the,DT,O
,13,CD,O
,psychometric,JJ,O
,measures,NNS,O
,.,.,O
,Strikingly,RB,O
,",",",",O
,despite,IN,O
,prolonged,JJ,O
,abstinence,NN,O
,(,(,O
,mean,JJ,O
,",",",",O
,4,CD,O
,.,.,O
,98,CD,O
,;,:,O
,range,NN,O
,",",",",O
,4,CD,O
,-,:,O
,9,CD,O
,years,NNS,O
,),),O
,",",",",O
,past,JJ,O
,ecstasy,NN,O
,users,NNS,O
,showed,VBD,O
,few,JJ,O
,signs,NNS,O
,of,IN,O
,recovery,NN,O
,.,.,O
,Compared,VBN,O
,with,IN,O
,present,JJ,O
,ecstasy,JJ,O
,users,NNS,O
,",",",",O
,the,DT,O
,past,JJ,O
,users,NNS,O
,showed,VBD,O
,no,DT,O
,change,NN,O
,for,IN,O
,ten,JJ,O
,measures,NNS,O
,",",",",O
,increased,VBD,O
,impairment,NN,O
,for,IN,O
,two,CD,O
,measures,NNS,O
,",",",",O
,and,CC,O
,improvement,NN,O
,on,IN,O
,just,RB,O
,one,CD,O
,measure,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Given,VBN,O
,this,DT,O
,record,NN,O
,of,IN,O
,impaired,JJ,B-DISEASE
,memory,NN,I-DISEASE
,and,CC,O
,clinically,RB,O
,significant,JJ,O
,levels,NNS,O
,of,IN,O
,depression,NN,B-DISEASE
,",",",",O
,impulsiveness,NN,B-DISEASE
,",",",",O
,and,CC,O
,sleep,JJ,B-DISEASE
,disturbance,NN,I-DISEASE
,",",",",O
,the,DT,O
,prognosis,NN,O
,for,IN,O
,the,DT,O
,current,JJ,O
,generation,NN,O
,of,IN,O
,ecstasy,JJ,O
,users,NNS,O
,is,VBZ,O
,a,DT,O
,major,JJ,O
,cause,NN,O
,for,IN,O
,concern,NN,O
,.,.,O
,Association,NNP,O
,of,IN,O
,common,JJ,O
,genetic,JJ,O
,variants,NNS,O
,of,IN,O
,HOMER1,NNP,O
,gene,NN,O
,with,IN,O
,levodopa,JJ,O
,adverse,JJ,O
,effects,NNS,O
,in,IN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,patients,NNS,O
,.,.,O
,Levodopa,NNP,O
,is,VBZ,O
,the,DT,O
,most,RBS,O
,effective,JJ,O
,symptomatic,JJ,O
,therapy,NN,O
,for,IN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,NN,I-DISEASE
,disease,NN,I-DISEASE
,",",",",O
,but,CC,O
,its,PRP$,O
,chronic,JJ,O
,use,NN,O
,could,MD,O
,lead,VB,O
,to,TO,O
,chronic,JJ,O
,adverse,JJ,O
,outcomes,NNS,O
,",",",",O
,such,JJ,O
,as,IN,O
,motor,NN,O
,fluctuations,NNS,O
,",",",",O
,dyskinesia,NN,B-DISEASE
,and,CC,O
,visual,JJ,B-DISEASE
,hallucinations,NNS,I-DISEASE
,.,.,O
,HOMER1,NNP,O
,is,VBZ,O
,a,DT,O
,protein,NN,O
,with,IN,O
,pivotal,JJ,O
,function,NN,O
,in,IN,O
,glutamate,JJ,O
,transmission,NN,O
,",",",",O
,which,WDT,O
,has,VBZ,O
,been,VBN,O
,related,VBN,O
,to,TO,O
,the,DT,O
,pathogenesis,NN,O
,of,IN,O
,these,DT,O
,complications,NNS,O
,.,.,O
,This,DT,O
,study,NN,O
,investigates,VBZ,O
,whether,IN,O
,polymorphisms,NN,O
,in,IN,O
,the,DT,O
,HOMER1,NNP,O
,gene,NN,O
,promoter,NN,O
,region,NN,O
,are,VBP,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,occurrence,NN,O
,of,IN,O
,the,DT,O
,chronic,JJ,O
,complications,NNS,O
,of,IN,O
,levodopa,JJ,O
,therapy,NN,O
,.,.,O
,A,DT,O
,total,NN,O
,of,IN,O
,205,CD,O
,patients,NNS,O
,with,IN,O
,idiopathic,JJ,B-DISEASE
,Parkinson,NNP,I-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,were,VBD,O
,investigated,VBN,O
,.,.,O
,Patients,NNS,O
,were,VBD,O
,genotyped,VBN,O
,for,IN,O
,rs4704559,NN,O
,",",",",O
,rs10942891,NN,O
,and,CC,O
,rs4704560,NN,O
,by,IN,O
,allelic,JJ,O
,discrimination,NN,O
,with,IN,O
,Taqman,NNP,O
,assays,NNS,O
,.,.,O
,The,DT,O
,rs4704559,NN,O
,G,NNP,O
,allele,NN,O
,was,VBD,O
,associated,VBN,O
,with,IN,O
,a,DT,O
,lower,JJR,O
,prevalence,NN,O
,of,IN,O
,dyskinesia,NN,B-DISEASE
,(,(,O
,prevalence,NN,O
,ratio,NN,O
,(,(,O
,PR,NNP,O
,),),O
,=,VBD,O
,0,CD,O
,.,.,O
,615,CD,O
,",",",",O
,95,CD,O
,%,NN,O
,confidence,NN,O
,interval,NN,O
,(,(,O
,CI,NNP,O
,),),O
,0,CD,O
,.,.,O
,426,CD,O
,-,:,O
,0,CD,O
,.,.,O
,887,CD,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,009,CD,O
,),),O
,and,CC,O
,visual,JJ,B-DISEASE
,hallucinations,NNS,I-DISEASE
,(,(,O
,PR,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,515,CD,O
,",",",",O
,95,CD,O
,%,NN,O
,CI,NNP,O
,0,CD,O
,.,.,O
,295,CD,O
,-,:,O
,0,CD,O
,.,.,O
,899,CD,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,020,CD,O
,),),O
,.,.,O
,Our,PRP$,O
,data,NNS,O
,suggest,VBP,O
,that,IN,O
,HOMER1,NNP,O
,rs4704559,VBD,O
,G,NNP,O
,allele,NN,O
,has,VBZ,O
,a,DT,O
,protective,JJ,O
,role,NN,O
,for,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,levodopa,JJ,O
,adverse,JJ,O
,effects,NNS,O
,.,.,O
,Crocin,NNP,O
,improves,VBZ,O
,lipid,JJ,O
,dysregulation,NN,O
,in,IN,O
,subacute,NN,O
,diazinon,NN,O
,exposure,NN,O
,through,IN,O
,ERK1,NNP,O
,/,NNP,O
,2,CD,O
,pathway,NN,O
,in,IN,O
,rat,NN,O
,liver,NN,O
,.,.,O
,INTRODUCTION,NN,O
,:,:,O
,Diazinon,NNP,O
,Yis,NNP,O
,one,CD,O
,of,IN,O
,the,DT,O
,most,RBS,O
,broadly,RB,O
,used,VBD,O
,organophosphorus,JJ,O
,insecticides,NNS,O
,in,IN,O
,agriculture,NN,O
,.,.,O
,It,PRP,O
,has,VBZ,O
,been,VBN,O
,shown,VBN,O
,that,IN,O
,exposure,NN,O
,to,TO,O
,diazinon,VB,O
,may,MD,O
,interfere,VB,O
,with,IN,O
,lipid,JJ,O
,metabolism,NN,O
,.,.,O
,Moreover,RB,O
,",",",",O
,the,DT,O
,hypolipidemic,JJ,O
,effect,NN,O
,of,IN,O
,crocin,NN,O
,has,VBZ,O
,been,VBN,O
,established,VBN,O
,.,.,O
,Earlier,JJR,O
,studies,NNS,O
,revealed,VBD,O
,the,DT,O
,major,JJ,O
,role,NN,O
,of,IN,O
,Extracellular,NNP,O
,signal,JJ,O
,-,:,O
,regulated,VBN,O
,kinase,NN,O
,(,(,O
,ERK,NNP,O
,),),O
,pathways,VBZ,O
,in,IN,O
,low,JJ,O
,-,:,O
,density,NN,O
,lipoprotein,NN,O
,receptor,NN,O
,(,(,O
,LDLr,NNP,O
,),),O
,expression,NN,O
,.,.,O
,The,DT,O
,aim,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,was,VBD,O
,to,TO,O
,evaluate,VB,O
,changes,NNS,O
,in,IN,O
,the,DT,O
,regulation,NN,O
,of,IN,O
,lipid,JJ,O
,metabolism,NN,O
,",",",",O
,ERK,NNP,O
,and,CC,O
,LDLr,NNP,O
,expression,NN,O
,in,IN,O
,the,DT,O
,liver,NN,O
,of,IN,O
,rats,NNS,O
,exposed,VBN,O
,to,TO,O
,subacute,VB,O
,diazinon,NN,O
,.,.,O
,Furthermore,IN,O
,ameliorating,VBG,O
,effect,NN,O
,of,IN,O
,crocin,NN,O
,on,IN,O
,diazinon,NN,O
,induced,VBN,O
,disturbed,VBN,O
,cholesterol,NN,O
,homeostasis,NN,O
,was,VBD,O
,studied,VBN,O
,.,.,O
,METHODS,NNP,O
,:,:,O
,24,CD,O
,Rats,NNPS,O
,were,VBD,O
,divided,VBN,O
,into,IN,O
,4,CD,O
,groups,NNS,O
,and,CC,O
,received,VBD,O
,following,VBG,O
,treatments,NNS,O
,for,IN,O
,4,CD,O
,weeks,NNS,O
,;,:,O
,Corn,NNP,O
,oil,NN,O
,(,(,O
,control,NN,O
,),),O
,",",",",O
,diazinon,NN,O
,(,(,O
,15mg,CD,O
,/,NNP,O
,kg,FW,O
,per,IN,O
,day,NN,O
,",",",",O
,orally,RB,O
,),),O
,and,CC,O
,crocin,NN,O
,(,(,O
,12,CD,O
,.,.,O
,5,CD,O
,and,CC,O
,25mg,CD,O
,/,JJ,O
,kg,NNS,O
,per,IN,O
,day,NN,O
,",",",",O
,intraperitoneally,RB,O
,),),O
,in,IN,O
,combination,NN,O
,with,IN,O
,diazinon,NN,O
,(,(,O
,15,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,.,.,O
,The,DT,O
,levels,NNS,O
,of,IN,O
,cholesterol,NN,O
,",",",",O
,triglyceride,NN,O
,and,CC,O
,LDL,NNP,O
,in,IN,O
,blood,NN,O
,of,IN,O
,rats,NNS,O
,were,VBD,O
,analyzed,VBN,O
,.,.,O
,Moreover,RB,O
,mRNA,JJ,O
,levels,NNS,O
,of,IN,O
,LDLr,NNP,O
,and,CC,O
,ERK1,NNP,O
,/,NNP,O
,2,CD,O
,as,RB,O
,well,RB,O
,as,IN,O
,protein,NN,O
,levels,NNS,O
,of,IN,O
,total,JJ,O
,and,CC,O
,activated,VBD,O
,forms,NNS,O
,of,IN,O
,ERK1,NNP,O
,/,NNP,O
,2,CD,O
,in,IN,O
,rat,NN,O
,liver,NN,O
,were,VBD,O
,evaluated,VBN,O
,by,IN,O
,Western,JJ,O
,blotting,NN,O
,and,CC,O
,quantitative,JJ,O
,real,JJ,O
,time,NN,O
,polymerase,NN,O
,chain,NN,O
,reaction,NN,O
,analysis,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Our,PRP$,O
,data,NNS,O
,showed,VBD,O
,that,IN,O
,subacute,NN,O
,exposure,NN,O
,to,TO,O
,diazinon,VB,O
,significantly,RB,O
,increased,JJ,O
,concentrations,NNS,O
,of,IN,O
,cholesterol,NN,O
,",",",",O
,triglyceride,NN,O
,and,CC,O
,LDL,NNP,O
,.,.,O
,Moreover,RB,O
,diazinon,NN,O
,decreased,VBD,O
,ERK1,NNP,O
,/,NNP,O
,2,CD,O
,protein,NN,O
,phosphorylation,NN,O
,and,CC,O
,LDLr,NNP,O
,transcript,NN,O
,.,.,O
,Crocin,NNP,O
,reduced,VBD,O
,inhibition,NN,O
,of,IN,O
,ERK,NNP,O
,activation,NN,O
,and,CC,O
,diazinon,NN,O
,-,:,O
,induced,JJ,O
,hyperlipemia,NN,B-DISEASE
,and,CC,O
,increased,JJ,O
,levels,NNS,O
,of,IN,O
,LDLr,NNP,O
,transcript,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Crocin,NN,O
,may,MD,O
,be,VB,O
,considered,VBN,O
,as,IN,O
,a,DT,O
,novel,JJ,O
,protective,JJ,O
,agent,NN,O
,in,IN,O
,diazinon,NN,O
,-,:,O
,induced,JJ,O
,hyperlipemia,NN,B-DISEASE
,through,IN,O
,modulating,NN,O
,of,IN,O
,ERK,NNP,O
,pathway,NN,O
,and,CC,O
,increase,NN,O
,of,IN,O
,LDLr,NNP,O
,expression,NN,O
,.,.,O
,GEM,NNP,O
,-,:,O
,P,NNP,O
,chemotherapy,NN,O
,is,VBZ,O
,active,JJ,O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,relapsed,JJ,O
,Hodgkin,NNP,B-DISEASE
,lymphoma,NN,I-DISEASE
,.,.,O
,Hodgkin,NNP,B-DISEASE
,lymphoma,NN,I-DISEASE
,(,(,O
,HL,NNP,B-DISEASE
,),),O
,is,VBZ,O
,a,DT,O
,relatively,RB,O
,chemosensitive,JJ,O
,malignancy,NN,B-DISEASE
,.,.,O
,However,RB,O
,",",",",O
,for,IN,O
,those,DT,O
,who,WP,O
,relapse,VBP,O
,",",",",O
,high,JJ,O
,-,:,O
,dose,JJ,O
,chemotherapy,NN,O
,with,IN,O
,autologous,JJ,O
,stem,NN,O
,cell,NN,O
,transplant,NN,O
,is,VBZ,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,choice,NN,O
,which,WDT,O
,relies,VBZ,O
,on,IN,O
,adequate,JJ,O
,disease,NN,O
,control,NN,O
,with,IN,O
,salvage,NN,O
,chemotherapy,NN,O
,.,.,O
,Regimens,VBZ,O
,commonly,RB,O
,used,VBN,O
,often,RB,O
,require,JJ,O
,inpatient,JJ,O
,administration,NN,O
,and,CC,O
,can,MD,O
,be,VB,O
,difficult,JJ,O
,to,TO,O
,deliver,VB,O
,due,JJ,O
,to,TO,O
,toxicity,NN,B-DISEASE
,.,.,O
,Gemcitabine,NNP,O
,and,CC,O
,cisplatin,NNS,O
,have,VBP,O
,activity,NN,O
,in,IN,O
,HL,NNP,B-DISEASE
,",",",",O
,non,SYM,O
,-,:,O
,overlapping,VBG,O
,toxicity,NN,B-DISEASE
,with,IN,O
,first,JJ,O
,-,:,O
,line,NN,O
,chemotherapeutics,NNS,O
,",",",",O
,and,CC,O
,may,MD,O
,be,VB,O
,delivered,VBN,O
,in,IN,O
,an,DT,O
,outpatient,JJ,O
,setting,NN,O
,.,.,O
,In,IN,O
,this,DT,O
,retrospective,JJ,O
,single,JJ,O
,-,:,O
,centre,NN,O
,analysis,NN,O
,",",",",O
,patients,NNS,O
,with,IN,O
,relapsed,JJ,O
,or,CC,O
,refractory,JJ,O
,HL,NNP,B-DISEASE
,treated,VBD,O
,with,IN,O
,gemcitabine,NN,O
,1,CD,O
,",",",",O
,000,CD,O
,mg,NN,O
,/,NNP,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,day,NN,O
,(,(,O
,D,NNP,O
,),),O
,1,CD,O
,",",",",O
,D8,NNP,O
,and,CC,O
,D15,NNP,O
,;,:,O
,methylprednisolone,CD,O
,1,CD,O
,",",",",O
,000,CD,O
,mg,NN,O
,D1,NNP,O
,-,:,O
,5,CD,O
,;,:,O
,and,CC,O
,cisplatin,VB,O
,100,CD,O
,mg,NN,O
,/,NNP,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,D15,NNP,O
,",",",",O
,every,DT,O
,28,CD,O
,days,NNS,O
,(,(,O
,GEM,NNP,O
,-,:,O
,P,NN,O
,),),O
,were,VBD,O
,included,VBN,O
,.,.,O
,Demographic,NNP,O
,",",",",O
,survival,NN,O
,",",",",O
,response,NN,O
,and,CC,O
,toxicity,NN,B-DISEASE
,data,NNS,O
,were,VBD,O
,recorded,VBN,O
,.,.,O
,Forty,NNP,O
,-,:,O
,one,CD,O
,eligible,JJ,O
,patients,NNS,O
,were,VBD,O
,identified,VBN,O
,:,:,O
,median,JJ,O
,age,NN,O
,27,CD,O
,.,.,O
,One,CD,O
,hundred,CD,O
,and,CC,O
,twenty,CD,O
,-,:,O
,two,CD,O
,cycles,NNS,O
,of,IN,O
,GEM,NNP,O
,-,:,O
,P,NN,O
,were,VBD,O
,administered,VBN,O
,in,IN,O
,total,JJ,O
,(,(,O
,median,JJ,O
,3,CD,O
,cycles,NNS,O
,;,:,O
,range,VB,O
,1,CD,O
,-,:,O
,6,CD,O
,),),O
,.,.,O
,Twenty,CD,O
,of,IN,O
,41,CD,O
,(,(,O
,48,CD,O
,%,NN,O
,),),O
,patients,NNS,O
,received,VBD,O
,GEM,NNP,O
,-,:,O
,P,NN,O
,as,IN,O
,second,JJ,O
,-,:,O
,line,NN,O
,treatment,NN,O
,and,CC,O
,11,CD,O
,/,NNS,O
,41,CD,O
,(,(,O
,27,CD,O
,%,NN,O
,),),O
,as,IN,O
,third,JJ,O
,-,:,O
,line,NN,O
,therapy,NN,O
,.,.,O
,Overall,JJ,O
,response,NN,O
,rate,NN,O
,(,(,O
,ORR,NNP,O
,),),O
,to,TO,O
,GEM,NNP,O
,-,:,O
,P,NN,O
,in,IN,O
,the,DT,O
,entire,JJ,O
,cohort,NN,O
,was,VBD,O
,80,CD,O
,%,NN,O
,(,(,O
,complete,JJ,O
,response,NN,O
,(,(,O
,CR,NNP,O
,),),O
,37,CD,O
,%,NN,O
,",",",",O
,partial,JJ,O
,response,NN,O
,44,CD,O
,%,NN,O
,),),O
,with,IN,O
,14,CD,O
,/,NNS,O
,15,CD,O
,CR,NNP,O
,confirmed,VBD,O
,as,IN,O
,a,DT,O
,metabolic,JJ,O
,CR,NNP,O
,on,IN,O
,PET,NNP,O
,and,CC,O
,ORR,NNP,O
,of,IN,O
,85,CD,O
,%,NN,O
,in,IN,O
,the,DT,O
,20,CD,O
,second,JJ,O
,-,:,O
,line,NN,O
,patients,NNS,O
,.,.,O
,The,DT,O
,most,RBS,O
,common,JJ,O
,grade,NN,O
,3,CD,O
,/,NN,O
,4,CD,O
,toxicities,NNS,B-DISEASE
,were,VBD,O
,haematological,JJ,O
,:,:,O
,neutropenia,RB,B-DISEASE
,54,CD,O
,%,NN,O
,and,CC,O
,thrombocytopenia,VB,B-DISEASE
,51,CD,O
,%,NN,O
,.,.,O
,Median,JJ,O
,follow,NN,O
,-,:,O
,up,RB,O
,from,IN,O
,the,DT,O
,start,NN,O
,of,IN,O
,GEM,NNP,O
,-,:,O
,P,NN,O
,was,VBD,O
,4,CD,O
,.,.,O
,5,CD,O
,years,NNS,O
,.,.,O
,Following,VBG,O
,GEM,NNP,O
,-,:,O
,P,NNP,O
,",",",",O
,5,CD,O
,-,:,O
,year,NN,O
,progression,NN,O
,-,:,O
,free,JJ,O
,survival,NN,O
,was,VBD,O
,46,CD,O
,%,NN,O
,(,(,O
,95,CD,O
,%,NN,O
,confidence,NN,O
,interval,NN,O
,(,(,O
,CI,NNP,O
,),),O
,",",",",O
,30,CD,O
,-,:,O
,62,CD,O
,%,NN,O
,),),O
,and,CC,O
,5,CD,O
,-,:,O
,year,NN,O
,overall,JJ,O
,survival,NN,O
,was,VBD,O
,59,CD,O
,%,NN,O
,(,(,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,",",",",O
,43,CD,O
,-,:,O
,74,CD,O
,%,NN,O
,),),O
,.,.,O
,Fourteen,NNP,O
,of,IN,O
,41,CD,O
,patients,NNS,O
,proceeded,VBD,O
,directly,RB,O
,to,TO,O
,autologous,JJ,O
,transplant,NN,O
,.,.,O
,GEM,NNP,O
,-,:,O
,P,NN,O
,is,VBZ,O
,a,DT,O
,salvage,NN,O
,chemotherapy,NN,O
,with,IN,O
,relatively,RB,O
,high,JJ,O
,response,NN,O
,rates,NNS,O
,",",",",O
,leading,VBG,O
,to,TO,O
,successful,JJ,O
,transplantation,NN,O
,in,IN,O
,appropriate,JJ,O
,patients,NNS,O
,",",",",O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,relapsed,JJ,O
,or,CC,O
,refractory,JJ,O
,HL,NNP,B-DISEASE
,.,.,O
,Basal,NNP,O
,functioning,NN,O
,of,IN,O
,the,DT,O
,hypothalamic,JJ,O
,-,:,O
,pituitary,JJ,O
,-,:,O
,adrenal,NN,O
,(,(,O
,HPA,NNP,O
,),),O
,axis,NN,O
,and,CC,O
,psychological,JJ,O
,distress,NN,O
,in,IN,O
,recreational,JJ,O
,ecstasy,JJ,O
,polydrug,NN,O
,users,NNS,O
,.,.,O
,RATIONALE,NN,O
,:,:,O
,Ecstasy,NNP,O
,(,(,O
,MDMA,NNP,O
,),),O
,is,VBZ,O
,a,DT,O
,psychostimulant,JJ,O
,drug,NN,O
,which,WDT,O
,is,VBZ,O
,increasingly,RB,O
,associated,VBN,O
,with,IN,O
,psychobiological,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,.,.,O
,While,IN,O
,some,DT,O
,recent,JJ,O
,studies,NNS,O
,suggest,VBP,O
,acute,JJ,O
,changes,NNS,O
,in,IN,O
,neuroendocrine,JJ,O
,function,NN,O
,",",",",O
,less,CC,O
,is,VBZ,O
,known,VBN,O
,about,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,changes,NNS,O
,in,IN,O
,HPA,NNP,O
,functionality,NN,O
,in,IN,O
,recreational,JJ,O
,users,NNS,O
,.,.,O
,OBJECTIVES,NN,O
,:,:,O
,The,DT,O
,current,JJ,O
,study,NN,O
,is,VBZ,O
,the,DT,O
,first,JJ,O
,to,TO,O
,explore,VB,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,ecstasy,JJ,O
,-,:,O
,polydrug,NN,O
,use,NN,O
,on,IN,O
,psychological,JJ,O
,distress,NN,O
,and,CC,O
,basal,NN,O
,functioning,NN,O
,of,IN,O
,the,DT,O
,HPA,NNP,O
,axis,NN,O
,through,IN,O
,assessing,VBG,O
,the,DT,O
,secretion,NN,O
,of,IN,O
,cortisol,NN,O
,across,IN,O
,the,DT,O
,diurnal,JJ,O
,period,NN,O
,.,.,O
,METHOD,NN,O
,:,:,O
,Seventy,NNP,O
,-,:,O
,six,CD,O
,participants,NNS,O
,(,(,O
,21,CD,O
,nonusers,NNS,O
,",",",",O
,29,CD,O
,light,NN,O
,ecstasy,SYM,O
,-,:,O
,polydrug,NN,O
,users,NNS,O
,",",",",O
,26,CD,O
,heavy,JJ,O
,ecstasy,JJ,O
,-,:,O
,polydrug,NN,O
,users,NNS,O
,),),O
,completed,VBD,O
,a,DT,O
,substance,NN,O
,use,NN,O
,inventory,NN,O
,and,CC,O
,measures,NNS,O
,of,IN,O
,psychological,JJ,O
,distress,NN,O
,at,IN,O
,baseline,NN,O
,",",",",O
,then,RB,O
,two,CD,O
,consecutive,JJ,O
,days,NNS,O
,of,IN,O
,cortisol,NN,O
,sampling,NN,O
,(,(,O
,on,IN,O
,awakening,NN,O
,",",",",O
,30,CD,O
,min,NN,O
,post,NN,O
,awakening,NN,O
,",",",",O
,between,IN,O
,1400,CD,O
,and,CC,O
,1600,CD,O
,hours,NNS,O
,and,CC,O
,pre,VB,O
,bedtime,NN,O
,),),O
,.,.,O
,On,IN,O
,day,NN,O
,2,CD,O
,",",",",O
,participants,NNS,O
,also,RB,O
,attended,VBD,O
,the,DT,O
,laboratory,NN,O
,to,TO,O
,complete,VB,O
,a,DT,O
,20,CD,O
,-,:,O
,min,NN,O
,multitasking,NN,O
,stressor,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Both,DT,O
,user,JJ,O
,groups,NNS,O
,exhibited,VBD,O
,significantly,RB,O
,greater,JJR,O
,levels,NNS,O
,of,IN,O
,anxiety,NN,B-DISEASE
,and,CC,O
,depression,NN,B-DISEASE
,than,IN,O
,nonusers,NNS,O
,.,.,O
,On,IN,O
,day,NN,O
,1,CD,O
,",",",",O
,all,DT,O
,participants,NNS,O
,exhibited,VBD,O
,a,DT,O
,typical,JJ,O
,cortisol,NN,O
,profile,NN,O
,",",",",O
,though,RB,O
,light,JJ,O
,users,NNS,O
,had,VBD,O
,significantly,RB,O
,elevated,VBN,O
,levels,NNS,O
,pre,IN,O
,-,:,O
,bed,NN,O
,.,.,O
,On,IN,O
,day,NN,O
,2,CD,O
,",",",",O
,heavy,JJ,O
,users,NNS,O
,demonstrated,VBD,O
,elevated,JJ,O
,levels,NNS,O
,upon,IN,O
,awakening,VBG,O
,and,CC,O
,all,DT,O
,ecstasy,JJ,O
,-,:,O
,polydrug,NN,O
,users,NNS,O
,demonstrated,VBD,O
,elevated,JJ,O
,pre,NN,O
,-,:,O
,bed,NN,O
,levels,NNS,O
,compared,VBN,O
,to,TO,O
,non,VB,O
,-,:,O
,users,NNS,O
,.,.,O
,Significant,NNP,O
,between,IN,O
,group,NN,O
,differences,NNS,O
,were,VBD,O
,also,RB,O
,observed,VBN,O
,in,IN,O
,afternoon,NN,O
,cortisol,NN,O
,levels,NNS,O
,and,CC,O
,in,IN,O
,overall,JJ,O
,cortisol,NN,O
,secretion,NN,O
,across,IN,O
,the,DT,O
,day,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,The,DT,O
,increases,NNS,O
,in,IN,O
,anxiety,NN,B-DISEASE
,and,CC,O
,depression,NN,B-DISEASE
,are,VBP,O
,in,IN,O
,line,NN,O
,with,IN,O
,previous,JJ,O
,observations,NNS,O
,in,IN,O
,recreational,JJ,O
,ecstasy,JJ,O
,-,:,O
,polydrug,NN,O
,users,NNS,O
,.,.,O
,Dysregulated,VBN,O
,diurnal,JJ,O
,cortisol,NN,O
,may,MD,O
,be,VB,O
,indicative,JJ,O
,of,IN,O
,inappropriate,JJ,O
,anticipation,NN,O
,of,IN,O
,forthcoming,VBG,O
,demands,NNS,O
,and,CC,O
,hypersecretion,NN,O
,may,MD,O
,lead,VB,O
,to,TO,O
,the,DT,O
,increased,VBN,O
,psychological,JJ,O
,and,CC,O
,physical,JJ,O
,morbidity,NN,O
,associated,VBN,O
,with,IN,O
,heavy,JJ,O
,recreational,JJ,O
,use,NN,O
,of,IN,O
,ecstasy,NN,O
,.,.,O
,Ifosfamide,NNP,O
,related,VBD,O
,encephalopathy,JJ,B-DISEASE
,:,:,O
,the,DT,O
,need,NN,O
,for,IN,O
,a,DT,O
,timely,JJ,O
,EEG,NNP,O
,evaluation,NN,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Ifosfamide,NNP,O
,is,VBZ,O
,an,DT,O
,alkylating,VBG,O
,agent,NN,O
,useful,JJ,O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,a,DT,O
,wide,JJ,O
,range,NN,O
,of,IN,O
,cancers,NNS,B-DISEASE
,including,VBG,O
,sarcomas,NN,B-DISEASE
,",",",",O
,lymphoma,NN,B-DISEASE
,",",",",O
,gynecologic,NN,B-DISEASE
,and,CC,I-DISEASE
,testicular,JJ,I-DISEASE
,cancers,NNS,I-DISEASE
,.,.,O
,Encephalopathy,NNP,B-DISEASE
,has,VBZ,O
,been,VBN,O
,reported,VBN,O
,in,IN,O
,10,CD,O
,-,:,O
,40,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,receiving,VBG,O
,high,JJ,O
,-,:,O
,dose,NN,O
,IV,NNP,O
,ifosfamide,NN,O
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,To,TO,O
,highlight,VB,O
,the,DT,O
,role,NN,O
,of,IN,O
,electroencephalogram,NN,O
,(,(,O
,EEG,NNP,O
,),),O
,in,IN,O
,the,DT,O
,early,JJ,O
,detection,NN,O
,and,CC,O
,management,NN,O
,of,IN,O
,ifosfamide,NN,O
,related,VBN,O
,encephalopathy,JJ,B-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,Retrospective,JJ,O
,chart,NN,O
,review,NN,O
,including,VBG,O
,clinical,JJ,O
,data,NNS,O
,and,CC,O
,EEG,NNP,O
,recordings,NNS,O
,was,VBD,O
,done,VBN,O
,on,IN,O
,five,CD,O
,patients,NNS,O
,",",",",O
,admitted,VBN,O
,to,TO,O
,MD,NNP,O
,Anderson,NNP,O
,Cancer,NNP,B-DISEASE
,Center,NNP,O
,between,IN,O
,years,NNS,O
,2009,CD,O
,and,CC,O
,2012,CD,O
,",",",",O
,who,WP,O
,developed,VBD,O
,ifosfamide,RB,O
,related,VBN,O
,acute,NN,O
,encephalopathy,NN,B-DISEASE
,.,.,O
,RESULTS,NN,O
,:,:,O
,All,DT,O
,five,CD,O
,patients,NNS,O
,experienced,VBD,O
,symptoms,NNS,O
,of,IN,O
,encephalopathy,JJ,B-DISEASE
,soon,RB,O
,after,IN,O
,(,(,O
,within,IN,O
,12,CD,O
,h,JJ,O
,-,:,O
,2,CD,O
,days,NNS,O
,),),O
,receiving,VBG,O
,ifosfamide,RB,O
,.,.,O
,Two,CD,O
,patients,NNS,O
,developed,VBD,O
,generalized,JJ,O
,convulsions,NNS,B-DISEASE
,while,IN,O
,one,CD,O
,patient,NN,O
,developed,VBD,O
,continuous,JJ,O
,non,SYM,B-DISEASE
,-,:,I-DISEASE
,convulsive,JJ,I-DISEASE
,status,NN,I-DISEASE
,epilepticus,NN,I-DISEASE
,(,(,O
,NCSE,NNP,B-DISEASE
,),),O
,that,WDT,O
,required,VBD,O
,ICU,NNP,O
,admission,NN,O
,and,CC,O
,intubation,NN,O
,.,.,O
,Initial,JJ,O
,EEG,NNP,O
,showed,VBD,O
,epileptiform,JJ,O
,discharges,NNS,O
,in,IN,O
,three,CD,O
,patients,NNS,O
,;,:,O
,run,VBN,O
,of,IN,O
,triphasic,JJ,O
,waves,NNS,O
,in,IN,O
,one,CD,O
,patient,NN,O
,and,CC,O
,moderate,JJ,O
,degree,NN,O
,diffuse,NN,O
,generalized,VBD,O
,slowing,NN,O
,.,.,O
,Mixed,JJ,O
,pattern,NN,O
,with,IN,O
,the,DT,O
,presence,NN,O
,of,IN,O
,both,DT,O
,sharps,NNS,O
,and,CC,O
,triphasic,JJ,O
,waves,NNS,O
,were,VBD,O
,also,RB,O
,noted,VBN,O
,.,.,O
,Repeat,NNP,O
,EEGs,NNP,O
,within,IN,O
,24,CD,O
,_,JJ,O
,h,NN,O
,of,IN,O
,symptom,NN,O
,onset,NN,O
,showed,VBD,O
,marked,JJ,O
,improvement,NN,O
,that,WDT,O
,was,VBD,O
,correlated,VBN,O
,with,IN,O
,clinical,JJ,O
,improvement,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Severity,NN,O
,of,IN,O
,ifosfamide,NN,O
,related,VBN,O
,encephalopathy,JJ,B-DISEASE
,correlates,NNS,O
,with,IN,O
,EEG,NNP,O
,changes,NNS,O
,.,.,O
,We,PRP,O
,suggest,VBP,O
,a,DT,O
,timely,JJ,O
,EEG,NNP,O
,evaluation,NN,O
,for,IN,O
,patients,NNS,O
,receiving,VBG,O
,ifosfamide,NN,O
,who,WP,O
,develop,VBZ,O
,features,NNS,O
,of,IN,O
,encephalopathy,NN,B-DISEASE
,.,.,O
,Incidence,NN,O
,of,IN,O
,contrast,NN,O
,-,:,O
,induced,VBN,O
,nephropathy,JJ,B-DISEASE
,in,IN,O
,hospitalised,JJ,O
,patients,NNS,O
,with,IN,O
,cancer,NN,B-DISEASE
,.,.,O
,OBJECTIVES,CC,O
,:,:,O
,To,TO,O
,determine,VB,O
,the,DT,O
,frequency,NN,O
,of,IN,O
,and,CC,O
,possible,JJ,O
,factors,NNS,O
,related,VBN,O
,to,TO,O
,contrast,VB,O
,-,:,O
,induced,VBN,O
,nephropathy,JJ,B-DISEASE
,(,(,O
,CIN,NNP,O
,),),O
,in,IN,O
,hospitalised,JJ,O
,patients,NNS,O
,with,IN,O
,cancer,NN,B-DISEASE
,.,.,O
,METHODS,NNP,O
,:,:,O
,Ninety,NN,O
,adult,NN,O
,patients,NNS,O
,were,VBD,O
,enrolled,VBN,O
,.,.,O
,Patients,NNS,O
,with,IN,O
,risk,NN,O
,factors,NNS,O
,for,IN,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,were,VBD,O
,excluded,VBN,O
,.,.,O
,Blood,NN,O
,samples,NNS,O
,were,VBD,O
,examined,VBN,O
,the,DT,O
,day,NN,O
,before,IN,O
,contrast,NN,O
,-,:,O
,enhanced,VBN,O
,computed,JJ,O
,tomography,NN,O
,(,(,O
,CT,NNP,O
,),),O
,and,CC,O
,serially,RB,O
,for,IN,O
,3,CD,O
,days,NNS,O
,thereafter,RB,O
,.,.,O
,CIN,NNP,O
,was,VBD,O
,defined,VBN,O
,as,IN,O
,an,DT,O
,increase,NN,O
,in,IN,O
,serum,JJ,O
,creatinine,NN,O
,(,(,O
,Cr,NNP,O
,),),O
,of,IN,O
,0,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,/,NNP,O
,dl,NN,O
,or,CC,O
,more,JJR,O
,",",",",O
,or,CC,O
,elevation,NN,O
,of,IN,O
,Cr,NNP,O
,to,TO,O
,25,CD,O
,%,NN,O
,over,IN,O
,baseline,NN,O
,.,.,O
,Relationships,NNP,O
,between,IN,O
,CIN,NNP,O
,and,CC,O
,possible,JJ,O
,risk,NN,O
,factors,NNS,O
,were,VBD,O
,investigated,VBN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,CIN,NNP,O
,was,VBD,O
,detected,VBN,O
,in,IN,O
,18,CD,O
,/,JJ,O
,90,CD,O
,(,(,O
,20,CD,O
,%,NN,O
,),),O
,patients,NNS,O
,.,.,O
,CIN,NNP,O
,developed,VBD,O
,in,IN,O
,25,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,patients,NNS,O
,who,WP,O
,underwent,VBP,O
,chemotherapy,NN,O
,and,CC,O
,in,IN,O
,11,CD,O
,%,NN,O
,patients,NNS,O
,who,WP,O
,did,VBD,O
,not,RB,O
,(,(,O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,1,CD,O
,),),O
,.,.,O
,CIN,NNP,O
,more,RBR,O
,frequently,RB,O
,developed,VBN,O
,in,IN,O
,patients,NNS,O
,who,WP,O
,had,VBD,O
,undergone,NN,O
,CT,NNP,O
,within,IN,O
,45,CD,O
,days,NNS,O
,after,IN,O
,the,DT,O
,last,JJ,O
,chemotherapy,NN,O
,(,(,O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,005,CD,O
,),),O
,;,:,O
,it,PRP,O
,was,VBD,O
,also,RB,O
,an,DT,O
,independent,JJ,O
,risk,NN,O
,factor,NN,O
,(,(,O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,017,CD,O
,),),O
,.,.,O
,CIN,NNP,O
,was,VBD,O
,significantly,RB,O
,more,RBR,O
,after,IN,O
,treatment,NN,O
,with,IN,O
,bevacizumab,JJ,O
,/,NNS,O
,irinotecan,JJ,O
,(,(,O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,021,CD,O
,),),O
,and,CC,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,hypertension,NN,B-DISEASE
,(,(,O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,044,CD,O
,),),O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,The,DT,O
,incidence,NN,O
,of,IN,O
,CIN,NNP,O
,after,IN,O
,CT,NNP,O
,in,IN,O
,hospitalised,JJ,O
,oncological,JJ,O
,patients,NNS,O
,was,VBD,O
,20,CD,O
,%,NN,O
,.,.,O
,CIN,NNP,O
,developed,VBD,O
,4,CD,O
,.,.,O
,5,CD,O
,-,:,O
,times,NNS,O
,more,RBR,O
,frequently,RB,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,cancer,NN,B-DISEASE
,who,WP,O
,had,VBD,O
,undergone,JJ,O
,recent,JJ,O
,chemotherapy,NN,O
,.,.,O
,Hypertension,NN,B-DISEASE
,and,CC,O
,the,DT,O
,combination,NN,O
,of,IN,O
,bevacizumab,NN,O
,/,NNS,O
,irinotecan,JJ,O
,may,MD,O
,be,VB,O
,additional,JJ,O
,risk,NN,O
,factors,NNS,O
,for,IN,O
,CIN,NNP,O
,development,NN,O
,.,.,O
,KEY,JJ,O
,POINTS,NNS,O
,:,:,O
,.,.,O
,Contrast,NNP,O
,-,:,O
,induced,VBN,O
,nephropathy,JJ,B-DISEASE
,(,(,O
,CIN,NNP,O
,),),O
,is,VBZ,O
,a,DT,O
,concern,NN,O
,for,IN,O
,oncological,JJ,O
,patients,NNS,O
,undergoing,VBG,O
,CT,NNP,O
,.,.,O
,.,.,O
,CIN,NNP,O
,occurs,VBZ,O
,more,RBR,O
,often,RB,O
,when,WRB,O
,CT,NNP,O
,is,VBZ,O
,performed,VBN,O
,<,JJ,O
,45,CD,O
,days,NNS,O
,after,IN,O
,chemotherapy,NN,O
,.,.,O
,.,.,O
,Hypertension,NN,B-DISEASE
,and,CC,O
,treatment,NN,O
,with,IN,O
,bevacizumab,NN,O
,appear,VBP,O
,to,TO,O
,be,VB,O
,additional,JJ,O
,risk,NN,O
,factors,NNS,O
,.,.,O
,Syndrome,NNP,B-DISEASE
,of,IN,I-DISEASE
,inappropriate,JJ,I-DISEASE
,antidiuretic,JJ,I-DISEASE
,hormone,NN,I-DISEASE
,secretion,NN,O
,associated,VBN,O
,with,IN,O
,desvenlafaxine,NN,O
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,To,TO,O
,report,VB,O
,a,DT,O
,case,NN,O
,of,IN,O
,syndrome,NN,B-DISEASE
,of,IN,I-DISEASE
,inappropriate,JJ,I-DISEASE
,anti,NNS,I-DISEASE
,-,:,I-DISEASE
,diuretic,JJ,I-DISEASE
,hormone,NN,I-DISEASE
,(,(,O
,SIADH,NNP,B-DISEASE
,),),O
,secretion,NN,O
,associated,VBN,O
,with,IN,O
,desvenlafaxine,NN,O
,.,.,O
,CASE,NNP,O
,SUMMARY,NNP,O
,:,:,O
,A,DT,O
,57,CD,O
,-,:,O
,year,NN,O
,old,JJ,O
,female,NN,O
,with,IN,O
,hyponatraemia,NN,B-DISEASE
,.,.,O
,Her,PRP$,O
,medications,NNS,O
,included,VBD,O
,desvenlafaxine,NN,O
,",",",",O
,and,CC,O
,symptoms,NNS,O
,included,VBD,O
,nausea,NN,B-DISEASE
,",",",",O
,anxiety,NN,B-DISEASE
,and,CC,O
,confusion,NN,B-DISEASE
,.,.,O
,The,DT,O
,serum,JJ,O
,sodium,NN,O
,at,IN,O
,this,DT,O
,time,NN,O
,was,VBD,O
,120,CD,O
,mmol,NN,O
,/,NNP,O
,L,NNP,O
,",",",",O
,serum,NN,O
,osmolality,NN,O
,was,VBD,O
,263,CD,O
,mosmol,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,urine,JJ,O
,osmolality,NN,O
,410,CD,O
,mosmol,NN,O
,/,NNP,O
,kg,NN,O
,and,CC,O
,urine,JJ,O
,sodium,NN,O
,63,CD,O
,mmol,NN,O
,/,NNP,O
,L,NNP,O
,",",",",O
,consistent,NN,O
,with,IN,O
,a,DT,O
,diagnosis,NN,O
,of,IN,O
,SIADH,NNP,B-DISEASE
,.,.,O
,Desvenlafaxine,NNP,O
,was,VBD,O
,ceased,VBN,O
,and,CC,O
,fluid,JJ,O
,restriction,NN,O
,implemented,VBN,O
,.,.,O
,After,IN,O
,4,CD,O
,days,NNS,O
,the,DT,O
,sodium,NN,O
,increased,VBD,O
,to,TO,O
,128,CD,O
,mmol,NNS,O
,/,JJ,O
,L,NNP,O
,and,CC,O
,fluid,JJ,O
,restriction,NN,O
,was,VBD,O
,relaxed,VBN,O
,.,.,O
,During,IN,O
,her,PRP$,O
,further,JJ,O
,3,CD,O
,weeks,NNS,O
,inpatient,JJ,O
,admission,NN,O
,the,DT,O
,serum,NN,O
,sodium,NN,O
,ranged,VBD,O
,from,IN,O
,134,CD,O
,to,TO,O
,137,CD,O
,mmol,NNS,O
,/,JJ,O
,L,NNP,O
,during,IN,O
,treatment,NN,O
,with,IN,O
,mirtazapine,NN,O
,.,.,O
,DISCUSSION,NN,O
,:,:,O
,SIADH,NNP,B-DISEASE
,has,VBZ,O
,been,VBN,O
,widely,RB,O
,reported,VBN,O
,with,IN,O
,a,DT,O
,range,NN,O
,of,IN,O
,antidepressants,NNS,O
,.,.,O
,This,DT,O
,case,NN,O
,report,NN,O
,suggests,VBZ,O
,that,IN,O
,desvenlafaxine,NN,O
,might,MD,O
,cause,VB,O
,clinically,RB,O
,significant,JJ,O
,hyponatremia,NN,B-DISEASE
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Clinicians,NNS,O
,should,MD,O
,be,VB,O
,aware,JJ,O
,of,IN,O
,the,DT,O
,potential,NN,O
,for,IN,O
,antidepressants,NNS,O
,to,TO,O
,cause,VB,O
,hyponatremia,NN,B-DISEASE
,",",",",O
,and,CC,O
,take,VB,O
,appropriate,JJ,O
,corrective,JJ,O
,action,NN,O
,where,WRB,O
,necessary,JJ,O
,.,.,O
,Oxidative,JJ,O
,stress,NN,O
,on,IN,O
,cardiotoxicity,NN,B-DISEASE
,after,IN,O
,treatment,NN,O
,with,IN,O
,single,JJ,O
,and,CC,O
,multiple,JJ,O
,doses,NNS,O
,of,IN,O
,doxorubicin,NN,O
,.,.,O
,The,DT,O
,mechanism,NN,O
,of,IN,O
,doxorubicin,NN,O
,(,(,O
,DOX,NNP,O
,),),O
,-,:,O
,induced,JJ,O
,cardiotoxicity,NN,B-DISEASE
,remains,VBZ,O
,controversial,JJ,O
,.,.,O
,Wistar,NNP,O
,rats,NNS,O
,(,(,O
,n,JJ,O
,=,NNP,O
,66,CD,O
,),),O
,received,VBD,O
,DOX,NNP,O
,injections,NNS,O
,intraperitoneally,RB,O
,and,CC,O
,were,VBD,O
,randomly,RB,O
,assigned,VBN,O
,to,TO,O
,2,CD,O
,experimental,JJ,O
,protocols,NNS,O
,:,:,O
,(,(,O
,1,CD,O
,),),O
,rats,NNS,O
,were,VBD,O
,killed,VBN,O
,before,RB,O
,(,(,O
,-,:,O
,24,CD,O
,h,NN,O
,",",",",O
,n,JJ,O
,=,NNP,O
,8,CD,O
,),),O
,and,CC,O
,24,CD,O
,h,NN,O
,after,IN,O
,(,(,O
,+,JJ,O
,24,CD,O
,h,NN,O
,",",",",O
,n,JJ,O
,=,NNP,O
,8,CD,O
,),),O
,a,DT,O
,single,JJ,O
,dose,NN,O
,of,IN,O
,DOX,NNP,O
,(,(,O
,4,CD,O
,mg,NN,O
,/,NNP,O
,kg,VBZ,O
,body,NN,O
,weight,NN,O
,),),O
,to,TO,O
,determine,VB,O
,the,DT,O
,DOX,NNP,O
,acute,NN,O
,effect,NN,O
,and,CC,O
,(,(,O
,2,CD,O
,),),O
,rats,NNS,O
,(,(,O
,n,JJ,O
,=,NNP,O
,58,CD,O
,),),O
,received,VBD,O
,4,CD,O
,injections,NNS,O
,of,IN,O
,DOX,NNP,O
,(,(,O
,4,CD,O
,mg,NN,O
,/,NNP,O
,kg,VBZ,O
,body,NN,O
,weight,VBD,O
,/,NNP,O
,week,NN,O
,),),O
,and,CC,O
,were,VBD,O
,killed,VBN,O
,before,IN,O
,the,DT,O
,first,JJ,O
,injection,NN,O
,(,(,O
,M0,NNP,O
,),),O
,and,CC,O
,1,CD,O
,week,NN,O
,after,IN,O
,each,DT,O
,injection,NN,O
,(,(,O
,M1,NNP,O
,",",",",O
,M2,NNP,O
,",",",",O
,M3,NNP,O
,",",",",O
,and,CC,O
,M4,NNP,O
,),),O
,to,TO,O
,determine,VB,O
,the,DT,O
,chronological,JJ,O
,effects,NNS,O
,.,.,O
,Animals,NNS,O
,used,VBD,O
,at,IN,O
,M0,NNP,O
,(,(,O
,n,JJ,O
,=,NNP,O
,8,CD,O
,),),O
,were,VBD,O
,also,RB,O
,used,VBN,O
,at,IN,O
,moment,NN,O
,-,:,O
,24,CD,O
,h,NN,O
,of,IN,O
,acute,NN,O
,study,NN,O
,.,.,O
,Cardiac,NNP,O
,total,JJ,O
,antioxidant,JJ,O
,performance,NN,O
,(,(,O
,TAP,NNP,O
,),),O
,",",",",O
,DNA,NNP,O
,damage,NN,O
,",",",",O
,and,CC,O
,morphology,NN,O
,analyses,NNS,O
,were,VBD,O
,carried,VBN,O
,out,RP,O
,at,IN,O
,each,DT,O
,time,NN,O
,point,NN,O
,.,.,O
,Single,NNP,O
,dose,NN,O
,of,IN,O
,DOX,NNP,O
,was,VBD,O
,associated,VBN,O
,with,IN,O
,increased,JJ,O
,cardiac,JJ,B-DISEASE
,disarrangement,NN,I-DISEASE
,",",",",O
,necrosis,NN,B-DISEASE
,",",",",O
,and,CC,O
,DNA,NNP,O
,damage,NN,O
,(,(,O
,strand,JJ,O
,breaks,NNS,O
,(,(,O
,SBs,NNP,O
,),),O
,and,CC,O
,oxidized,VBN,O
,pyrimidines,NNS,O
,),),O
,and,CC,O
,decreased,VBN,O
,TAP,NNP,O
,.,.,O
,The,DT,O
,chronological,JJ,O
,study,NN,O
,showed,VBD,O
,an,DT,O
,effect,NN,O
,of,IN,O
,a,DT,O
,cumulative,JJ,O
,dose,NN,O
,on,IN,O
,body,NN,O
,weight,NN,O
,(,(,O
,R,NNP,O
,=,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,99,CD,O
,",",",",O
,p,NN,O
,=,VBD,O
,0,CD,O
,.,.,O
,011,CD,O
,),),O
,",",",",O
,necrosis,NN,B-DISEASE
,(,(,O
,R,NNP,O
,=,VBZ,O
,1,CD,O
,.,.,O
,00,CD,O
,",",",",O
,p,NN,O
,=,VBD,O
,0,CD,O
,.,.,O
,004,CD,O
,),),O
,",",",",O
,TAP,NNP,O
,(,(,O
,R,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,95,CD,O
,",",",",O
,p,NN,O
,=,VBD,O
,0,CD,O
,.,.,O
,049,CD,O
,),),O
,",",",",O
,and,CC,O
,DNA,NNP,O
,SBs,NNP,O
,(,(,O
,R,NNP,O
,=,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,95,CD,O
,",",",",O
,p,NN,O
,=,VBD,O
,0,CD,O
,.,.,O
,049,CD,O
,),),O
,.,.,O
,DNA,NNP,O
,SBs,NNP,O
,damage,NN,O
,was,VBD,O
,negatively,RB,O
,associated,VBN,O
,with,IN,O
,TAP,NNP,O
,(,(,O
,R,NNP,O
,=,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,98,CD,O
,",",",",O
,p,NN,O
,=,VBD,O
,0,CD,O
,.,.,O
,018,CD,O
,),),O
,",",",",O
,and,CC,O
,necrosis,NN,B-DISEASE
,(,(,O
,R,NNP,O
,=,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,97,CD,O
,",",",",O
,p,NN,O
,=,VBD,O
,0,CD,O
,.,.,O
,027,CD,O
,),),O
,.,.,O
,Our,PRP$,O
,results,NNS,O
,suggest,VBP,O
,that,IN,O
,oxidative,JJ,O
,damage,NN,O
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,acute,JJ,O
,cardiotoxicity,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,a,DT,O
,single,JJ,O
,dose,NN,O
,of,IN,O
,DOX,NNP,O
,only,RB,O
,.,.,O
,Increased,VBD,O
,resistance,NN,O
,to,TO,O
,the,DT,O
,oxidative,JJ,O
,stress,NN,O
,is,VBZ,O
,plausible,JJ,O
,for,IN,O
,the,DT,O
,multiple,JJ,O
,dose,NN,O
,of,IN,O
,DOX,NNP,O
,.,.,O
,Thus,NNP,O
,",",",",O
,different,JJ,O
,mechanisms,NNS,O
,may,MD,O
,be,VB,O
,involved,VBN,O
,in,IN,O
,acute,JJ,O
,toxicity,NN,B-DISEASE
,versus,NN,O
,chronic,JJ,O
,toxicity,NN,B-DISEASE
,.,.,O
,Tacrolimus,NNP,O
,-,:,O
,related,JJ,O
,seizure,NN,B-DISEASE
,after,IN,O
,pediatric,JJ,O
,liver,NN,O
,transplantation,NN,O
,-,:,O
,-,:,O
,a,DT,O
,single,JJ,O
,-,:,O
,center,NN,O
,experience,NN,O
,.,.,O
,To,TO,O
,identify,VB,O
,the,DT,O
,risk,NN,O
,factors,NNS,O
,for,IN,O
,new,JJ,O
,-,:,O
,onset,NN,O
,seizures,NNS,B-DISEASE
,after,IN,O
,pediatric,JJ,O
,LT,NNP,O
,and,CC,O
,to,TO,O
,assess,VB,O
,their,PRP$,O
,clinical,JJ,O
,implications,NNS,O
,and,CC,O
,long,JJ,O
,-,:,O
,term,NN,O
,prognosis,NN,O
,.,.,O
,The,DT,O
,clinical,JJ,O
,and,CC,O
,laboratory,JJ,O
,data,NNS,O
,of,IN,O
,27,CD,O
,consecutive,JJ,O
,children,NNS,O
,who,WP,O
,underwent,VBP,O
,LT,NNP,O
,from,IN,O
,January,NNP,O
,2007,CD,O
,to,TO,O
,December,NNP,O
,2010,CD,O
,in,IN,O
,our,PRP$,O
,center,NN,O
,were,VBD,O
,analyzed,VBN,O
,retrospectively,RB,O
,.,.,O
,Patients,NNS,O
,were,VBD,O
,divided,VBN,O
,into,IN,O
,seizures,NNS,B-DISEASE
,group,NN,O
,and,CC,O
,a,DT,O
,non,JJ,O
,-,:,O
,seizures,NNS,B-DISEASE
,group,NN,O
,.,.,O
,Pre,NNP,O
,-,:,O
,operative,NN,O
,",",",",O
,intra,JJ,O
,-,:,O
,operative,NN,O
,",",",",O
,and,CC,O
,post,SYM,O
,-,:,O
,operative,JJ,O
,data,NNS,O
,were,VBD,O
,collected,VBN,O
,.,.,O
,Seizures,NNS,B-DISEASE
,occurred,VBD,O
,in,IN,O
,four,CD,O
,children,NNS,O
,",",",",O
,an,DT,O
,incidence,NN,O
,of,IN,O
,14,CD,O
,.,.,O
,8,CD,O
,%,NN,O
,.,.,O
,All,DT,O
,exhibited,VBD,O
,generalized,VBN,O
,tonic,JJ,B-DISEASE
,-,:,I-DISEASE
,clonic,NN,I-DISEASE
,seizures,NNS,I-DISEASE
,within,IN,O
,the,DT,O
,first,JJ,O
,two,CD,O
,wk,NN,O
,after,IN,O
,LT,NNP,O
,.,.,O
,Univariate,NNP,O
,analysis,NN,O
,showed,VBD,O
,that,IN,O
,the,DT,O
,risk,NN,O
,factors,NNS,O
,associated,VBN,O
,with,IN,O
,seizures,NNS,B-DISEASE
,after,IN,O
,pediatric,JJ,O
,LT,NNP,O
,included,VBD,O
,gender,NN,O
,",",",",O
,pediatric,JJ,O
,end,NN,B-DISEASE
,-,:,I-DISEASE
,stage,NN,I-DISEASE
,liver,JJ,I-DISEASE
,disease,NN,I-DISEASE
,score,NN,O
,before,IN,O
,surgery,NN,O
,",",",",O
,Child,NNP,O
,-,:,O
,Pugh,NNP,O
,score,NN,O
,before,IN,O
,surgery,NN,O
,",",",",O
,serum,VBP,O
,total,JJ,O
,bilirubin,NN,O
,after,IN,O
,surgery,NN,O
,",",",",O
,and,CC,O
,trough,IN,O
,TAC,NNP,O
,level,NN,O
,.,.,O
,Multivariate,NNP,O
,analysis,NN,O
,showed,VBD,O
,that,IN,O
,trough,IN,O
,TAC,NNP,O
,level,NN,O
,was,VBD,O
,the,DT,O
,only,JJ,O
,independent,JJ,O
,risk,NN,O
,factor,NN,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,seizures,NNS,B-DISEASE
,.,.,O
,All,DT,O
,children,NNS,O
,who,WP,O
,experienced,VBD,O
,seizures,NNS,B-DISEASE
,survived,VBN,O
,with,IN,O
,good,JJ,O
,graft,NN,O
,function,NN,O
,and,CC,O
,remained,VBD,O
,seizure,NN,B-DISEASE
,-,:,O
,free,JJ,O
,without,IN,O
,anti,JJ,O
,-,:,O
,epileptic,JJ,B-DISEASE
,drugs,NNS,O
,over,IN,O
,a,DT,O
,mean,JJ,O
,follow,NN,O
,-,:,O
,up,RB,O
,period,NN,O
,of,IN,O
,33,CD,O
,.,.,O
,7,CD,O
,+,JJ,O
,14,CD,O
,.,.,O
,6,CD,O
,months,NNS,O
,.,.,O
,High,NNP,O
,trough,IN,O
,TAC,NNP,O
,level,NN,O
,was,VBD,O
,the,DT,O
,predominant,JJ,O
,factor,NN,O
,that,WDT,O
,contributed,VBD,O
,to,TO,O
,seizures,NNS,B-DISEASE
,in,IN,O
,the,DT,O
,early,JJ,O
,post,NN,O
,-,:,O
,operative,JJ,O
,period,NN,O
,after,IN,O
,pediatric,JJ,O
,LT,NNP,O
,.,.,O
,High,NNP,O
,PELD,NNP,O
,and,CC,O
,Child,NNP,O
,-,:,O
,Pugh,NNP,O
,scores,NNS,O
,before,IN,O
,LT,NNP,O
,and,CC,O
,high,JJ,O
,post,NN,O
,-,:,O
,operative,JJ,O
,serum,NN,O
,Tbil,NNP,O
,may,MD,O
,be,VB,O
,contributory,JJ,O
,risk,NN,O
,factors,NNS,O
,for,IN,O
,TAC,NNP,O
,-,:,O
,related,JJ,O
,seizures,NNS,B-DISEASE
,.,.,O
,The,DT,O
,flavonoid,JJ,O
,apigenin,NN,O
,delays,NNS,O
,forgetting,NN,O
,of,IN,O
,passive,JJ,O
,avoidance,NN,O
,conditioning,NN,O
,in,IN,O
,rats,NNS,O
,.,.,O
,The,DT,O
,present,JJ,O
,experiments,NNS,O
,were,VBD,O
,performed,VBN,O
,to,TO,O
,study,VB,O
,the,DT,O
,effect,NN,O
,of,IN,O
,the,DT,O
,flavonoid,JJ,O
,apigenin,NN,O
,(,(,O
,20,CD,O
,mg,NN,O
,/,NNP,O
,kg,NNP,O
,intraperitoneally,RB,O
,(,(,O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,",",",",O
,1,CD,O
,h,NN,O
,before,IN,O
,acquisition,NN,O
,),),O
,",",",",O
,on,IN,O
,24,CD,O
,h,JJ,O
,retention,NN,O
,performance,NN,O
,and,CC,O
,forgetting,NN,O
,of,IN,O
,a,DT,O
,step,NN,O
,-,:,O
,through,IN,O
,passive,JJ,O
,avoidance,NN,O
,task,NN,O
,",",",",O
,in,IN,O
,young,JJ,O
,male,NN,O
,Wistar,NNP,O
,rats,NNS,O
,.,.,O
,There,EX,O
,were,VBD,O
,no,DT,O
,differences,NNS,O
,between,IN,O
,saline,JJ,O
,-,:,O
,and,CC,O
,apigenin,VB,O
,-,:,O
,treated,VBN,O
,groups,NNS,O
,in,IN,O
,the,DT,O
,24,CD,O
,h,NN,O
,retention,NN,O
,trial,NN,O
,.,.,O
,Furthermore,RB,O
,",",",",O
,apigenin,NN,O
,did,VBD,O
,not,RB,O
,prevent,VB,O
,the,DT,O
,amnesia,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,scopolamine,NN,O
,(,(,O
,1mg,CD,O
,/,NNP,O
,kg,NN,O
,",",",",O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,",",",",O
,30,CD,O
,min,NN,O
,before,IN,O
,the,DT,O
,acquisition,NN,O
,),),O
,.,.,O
,The,DT,O
,saline,JJ,O
,-,:,O
,and,CC,O
,apigenin,VB,O
,-,:,O
,treated,VBN,O
,rats,NNS,O
,that,WDT,O
,did,VBD,O
,not,RB,O
,step,VB,O
,through,IN,O
,into,IN,O
,the,DT,O
,dark,JJ,O
,compartment,NN,O
,during,IN,O
,the,DT,O
,cut,NN,O
,-,:,O
,off,IN,O
,time,NN,O
,(,(,O
,540,CD,O
,s,NN,O
,),),O
,were,VBD,O
,retested,VBN,O
,weekly,RB,O
,for,IN,O
,up,IN,O
,to,TO,O
,eight,CD,O
,weeks,NNS,O
,.,.,O
,In,IN,O
,the,DT,O
,saline,NN,O
,treated,VBN,O
,group,NN,O
,",",",",O
,the,DT,O
,first,JJ,O
,significant,JJ,O
,decline,NN,O
,in,IN,O
,passive,JJ,O
,avoidance,NN,O
,response,NN,O
,was,VBD,O
,observed,VBN,O
,at,IN,O
,four,CD,O
,weeks,NNS,O
,",",",",O
,and,CC,O
,complete,JJ,O
,memory,NN,B-DISEASE
,loss,NN,I-DISEASE
,was,VBD,O
,found,VBN,O
,five,CD,O
,weeks,NNS,O
,after,IN,O
,the,DT,O
,acquisition,NN,O
,of,IN,O
,the,DT,O
,passive,JJ,O
,avoidance,NN,O
,task,NN,O
,.,.,O
,At,IN,O
,the,DT,O
,end,NN,O
,of,IN,O
,the,DT,O
,experimental,JJ,O
,period,NN,O
,",",",",O
,60,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,animals,NNS,O
,treated,VBD,O
,with,IN,O
,apigenin,NN,O
,still,RB,O
,did,VBD,O
,not,RB,O
,step,VB,O
,through,IN,O
,.,.,O
,These,DT,O
,data,NNS,O
,suggest,VBP,O
,that,IN,O
,1,CD,O
,),),O
,apigenin,NN,O
,delays,VBZ,O
,the,DT,O
,long,JJ,O
,-,:,O
,term,NN,O
,forgetting,VBG,O
,but,CC,O
,did,VBD,O
,not,RB,O
,modulate,VB,O
,the,DT,O
,24,CD,O
,h,JJ,O
,retention,NN,O
,of,IN,O
,fear,JJ,O
,memory,NN,O
,and,CC,O
,2,CD,O
,),),O
,the,DT,O
,obtained,VBN,O
,beneficial,JJ,O
,effect,NN,O
,of,IN,O
,apigenin,NN,O
,on,IN,O
,the,DT,O
,passive,JJ,O
,avoidance,NN,O
,conditioning,NN,O
,is,VBZ,O
,mediated,VBN,O
,by,IN,O
,mechanisms,NNS,O
,that,WDT,O
,do,VBP,O
,not,RB,O
,implicate,VB,O
,its,PRP$,O
,action,NN,O
,on,IN,O
,the,DT,O
,muscarinic,JJ,O
,cholinergic,NN,O
,system,NN,O
,.,.,O
,Histamine,NNP,O
,antagonists,NNS,O
,and,CC,O
,d,VB,O
,-,:,O
,tubocurarine,NN,O
,-,:,O
,induced,JJ,O
,hypotension,NN,B-DISEASE
,in,IN,O
,cardiac,JJ,O
,surgical,JJ,O
,patients,NNS,O
,.,.,O
,Hemodynamic,NNP,O
,effects,NNS,O
,and,CC,O
,histamine,NN,O
,release,NN,O
,by,IN,O
,bolus,JJ,O
,injection,NN,O
,of,IN,O
,0,CD,O
,.,.,O
,35,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,of,IN,O
,d,JJ,O
,-,:,O
,tubocurarine,NN,O
,were,VBD,O
,studied,VBN,O
,in,IN,O
,24,CD,O
,patients,NNS,O
,.,.,O
,H1,NNP,O
,-,:,O
,and,CC,O
,H2,NNP,O
,-,:,O
,histamine,NN,O
,antagonists,NNS,O
,or,CC,O
,placebo,NN,O
,were,VBD,O
,given,VBN,O
,before,IN,O
,dosing,VBG,O
,with,IN,O
,d,JJ,O
,-,:,O
,tubocurarine,NN,O
,in,IN,O
,a,DT,O
,randomized,JJ,O
,double,JJ,O
,-,:,O
,blind,NN,O
,fashion,NN,O
,to,TO,O
,four,CD,O
,groups,NNS,O
,:,:,O
,group,NN,O
,1,CD,O
,-,:,O
,-,:,O
,placebo,NN,O
,;,:,O
,group,NN,O
,2,CD,O
,-,:,O
,-,:,O
,cimetidine,NN,O
,",",",",O
,4,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,plus,CC,O
,placebo,NN,O
,;,:,O
,group,NN,O
,3,CD,O
,-,:,O
,-,:,O
,chlorpheniramine,NN,O
,",",",",O
,0,CD,O
,.,.,O
,1,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,",",",",O
,plus,CC,O
,placebo,NN,O
,;,:,O
,and,CC,O
,group,NN,O
,4,CD,O
,-,:,O
,-,:,O
,cimetidine,NN,O
,plus,CC,O
,chlorpheniramine,NN,O
,.,.,O
,Histamine,NNP,O
,release,NN,O
,occurred,VBD,O
,in,IN,O
,most,JJS,O
,patients,NNS,O
,",",",",O
,the,DT,O
,highest,JJS,O
,level,NN,O
,2,CD,O
,minutes,NNS,O
,after,IN,O
,d,JJ,O
,-,:,O
,tubocurarine,NN,O
,dosing,NN,O
,.,.,O
,Group,NNP,O
,1,CD,O
,had,VBD,O
,a,DT,O
,moderate,JJ,O
,negative,JJ,O
,correlation,NN,O
,between,IN,O
,plasma,JJ,O
,histamine,NN,O
,change,NN,O
,and,CC,O
,systemic,JJ,O
,vascular,NN,O
,resistance,NN,O
,(,(,O
,r,VB,O
,=,RB,O
,0,CD,O
,.,.,O
,58,CD,O
,;,:,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,not,RB,O
,present,JJ,O
,in,IN,O
,group,NN,O
,4,CD,O
,.,.,O
,Prior,JJ,O
,dosing,VBG,O
,with,IN,O
,antagonists,NNS,O
,partially,RB,O
,prevented,VBD,O
,the,DT,O
,fall,NN,O
,in,IN,O
,systemic,JJ,O
,vascular,JJ,O
,resistance,NN,O
,.,.,O
,These,DT,O
,data,NNS,O
,demonstrate,NN,O
,that,IN,O
,the,DT,O
,hemodynamic,JJ,O
,changes,NNS,O
,associated,VBN,O
,with,IN,O
,d,JJ,O
,-,:,O
,tubocurarine,NN,O
,dosing,NN,O
,are,VBP,O
,only,RB,O
,partially,RB,O
,explained,VBN,O
,by,IN,O
,histamine,NN,O
,release,NN,O
,.,.,O
,Thus,RB,O
,prior,JJ,O
,dosing,VBG,O
,with,IN,O
,H1,NNP,O
,-,:,O
,and,CC,O
,H2,NNP,O
,-,:,O
,antagonists,NNS,O
,provides,VBZ,O
,only,RB,O
,partial,JJ,O
,protection,NN,O
,.,.,O
,Cholecystokinin,NNP,O
,-,:,O
,octapeptide,NN,O
,restored,VBD,O
,morphine,JJ,O
,-,:,O
,induced,JJ,O
,hippocampal,NN,O
,long,JJ,O
,-,:,O
,term,NN,O
,potentiation,NN,O
,impairment,NN,O
,in,IN,O
,rats,NNS,O
,.,.,O
,Cholecystokinin,NNP,O
,-,:,O
,octapeptide,NN,O
,(,(,O
,CCK,NNP,O
,-,:,O
,8,CD,O
,),),O
,",",",",O
,which,WDT,O
,is,VBZ,O
,a,DT,O
,typical,JJ,O
,brain,NN,O
,-,:,O
,gut,NN,O
,peptide,NN,O
,",",",",O
,exerts,VBZ,O
,a,DT,O
,wide,JJ,O
,range,NN,O
,of,IN,O
,biological,JJ,O
,activities,NNS,O
,on,IN,O
,the,DT,O
,central,JJ,O
,nervous,JJ,O
,system,NN,O
,.,.,O
,We,PRP,O
,have,VBP,O
,previously,RB,O
,reported,VBN,O
,that,IN,O
,CCK,NNP,O
,-,:,O
,8,CD,O
,significantly,RB,O
,alleviated,VBN,O
,morphine,NN,O
,-,:,O
,induced,JJ,O
,amnesia,NN,B-DISEASE
,and,CC,O
,reversed,VBD,O
,spine,NN,O
,density,NN,O
,decreases,VBZ,O
,in,IN,O
,the,DT,O
,CA1,NNP,O
,region,NN,O
,of,IN,O
,the,DT,O
,hippocampus,NN,O
,in,IN,O
,morphine,JJ,O
,-,:,O
,treated,JJ,O
,animals,NNS,O
,.,.,O
,Here,RB,O
,",",",",O
,we,PRP,O
,investigated,VBD,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,CCK,NNP,O
,-,:,O
,8,CD,O
,on,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,potentiation,NN,O
,(,(,O
,LTP,NNP,O
,),),O
,in,IN,O
,the,DT,O
,lateral,JJ,O
,perforant,JJ,O
,path,NN,O
,(,(,O
,LPP,NNP,O
,),),O
,-,:,O
,granule,NN,O
,cell,NN,O
,synapse,NN,O
,of,IN,O
,rat,NN,O
,dentate,NN,O
,gyrus,NN,O
,(,(,O
,DG,NNP,O
,),),O
,in,IN,O
,acute,JJ,O
,saline,NN,O
,or,CC,O
,morphine,VB,O
,-,:,O
,treated,VBN,O
,rats,NNS,O
,.,.,O
,Population,NNP,O
,spikes,NNS,O
,(,(,O
,PS,NNP,O
,),),O
,",",",",O
,which,WDT,O
,were,VBD,O
,evoked,VBN,O
,by,IN,O
,stimulation,NN,O
,of,IN,O
,the,DT,O
,LPP,NNP,O
,",",",",O
,were,VBD,O
,recorded,VBN,O
,in,IN,O
,the,DT,O
,DG,NNP,O
,region,NN,O
,.,.,O
,Acute,NNP,O
,morphine,NN,O
,(,(,O
,30mg,CD,O
,/,NNP,O
,kg,NN,O
,",",",",O
,s,NN,O
,.,.,O
,c,NN,O
,.,.,O
,),),O
,treatment,NN,O
,significantly,RB,O
,attenuated,VBD,O
,hippocampal,JJ,O
,LTP,NNP,O
,and,CC,O
,CCK,NNP,O
,-,:,O
,8,CD,O
,(,(,O
,1ug,CD,O
,",",",",O
,i,NN,O
,.,.,O
,c,NN,O
,.,.,O
,v,NN,O
,.,.,O
,),),O
,restored,VBD,O
,the,DT,O
,amplitude,NN,O
,of,IN,O
,PS,NNP,O
,that,WDT,O
,was,VBD,O
,attenuated,VBN,O
,by,IN,O
,morphine,NN,O
,injection,NN,O
,.,.,O
,Furthermore,NNP,O
,",",",",O
,microinjection,NN,O
,of,IN,O
,CCK,NNP,O
,-,:,O
,8,CD,O
,(,(,O
,0,CD,O
,.,.,O
,1,CD,O
,and,CC,O
,1ug,CD,O
,",",",",O
,i,NN,O
,.,.,O
,c,NN,O
,.,.,O
,v,NN,O
,.,.,O
,),),O
,also,RB,O
,significantly,RB,O
,augmented,VBN,O
,hippocampal,JJ,O
,LTP,NNP,O
,in,IN,O
,saline,JJ,O
,-,:,O
,treated,VBN,O
,(,(,O
,1ml,CD,O
,/,NNP,O
,kg,NN,O
,",",",",O
,s,NN,O
,.,.,O
,c,NN,O
,.,.,O
,),),O
,rats,NN,O
,.,.,O
,Pre,NNP,O
,-,:,O
,treatment,NN,O
,of,IN,O
,the,DT,O
,CCK2,NNP,O
,receptor,NN,O
,antagonist,NN,O
,L,NNP,O
,-,:,O
,365,CD,O
,",",",",O
,260,CD,O
,(,(,O
,10ug,CD,O
,",",",",O
,i,NN,O
,.,.,O
,c,NN,O
,.,.,O
,v,NN,O
,),),O
,reversed,VBD,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,CCK,NNP,O
,-,:,O
,8,CD,O
,",",",",O
,but,CC,O
,the,DT,O
,CCK1,NNP,O
,receptor,NN,O
,antagonist,NN,O
,L,NNP,O
,-,:,O
,364,CD,O
,",",",",O
,718,CD,O
,(,(,O
,10ug,CD,O
,",",",",O
,i,NN,O
,.,.,O
,c,NN,O
,.,.,O
,v,NN,O
,),),O
,did,VBD,O
,not,RB,O
,.,.,O
,The,DT,O
,present,JJ,O
,results,NNS,O
,demonstrate,VBP,O
,that,IN,O
,CCK,NNP,O
,-,:,O
,8,CD,O
,attenuates,VBZ,O
,the,DT,O
,effect,NN,O
,of,IN,O
,morphine,NN,O
,on,IN,O
,hippocampal,JJ,O
,LTP,NNP,O
,through,IN,O
,CCK2,NNP,O
,receptors,NNS,O
,and,CC,O
,suggest,VBP,O
,an,DT,O
,ameliorative,JJ,O
,function,NN,O
,of,IN,O
,CCK,NNP,O
,-,:,O
,8,CD,O
,on,IN,O
,morphine,NN,O
,-,:,O
,induced,JJ,O
,memory,NN,B-DISEASE
,impairment,NN,I-DISEASE
,.,.,O
,Glial,JJ,O
,activation,NN,O
,and,CC,O
,post,NN,O
,-,:,O
,synaptic,JJ,O
,neurotoxicity,NN,B-DISEASE
,:,:,O
,the,DT,O
,key,JJ,O
,events,NNS,O
,in,IN,O
,Streptozotocin,NNP,O
,(,(,O
,ICV,NNP,O
,),),O
,induced,VBD,O
,memory,NN,B-DISEASE
,impairment,NN,I-DISEASE
,in,IN,O
,rats,NNS,O
,.,.,O
,In,IN,O
,the,DT,O
,present,JJ,O
,study,NN,O
,the,DT,O
,role,NN,O
,of,IN,O
,glial,JJ,O
,activation,NN,O
,and,CC,O
,post,NN,O
,synaptic,JJ,O
,toxicity,NN,B-DISEASE
,in,IN,O
,ICV,NNP,O
,Streptozotocin,NNP,O
,(,(,O
,STZ,NNP,O
,),),O
,induced,VBD,O
,memory,NN,B-DISEASE
,impaired,JJ,I-DISEASE
,rats,NNS,O
,was,VBD,O
,explored,VBN,O
,.,.,O
,In,IN,O
,experiment,NN,O
,set,VBN,O
,up,RP,O
,1,CD,O
,:,:,O
,Memory,NN,B-DISEASE
,deficit,NN,I-DISEASE
,was,VBD,O
,found,VBN,O
,in,IN,O
,Morris,NNP,O
,water,NN,O
,maze,NN,O
,test,NN,O
,on,IN,O
,14,CD,O
,-,:,O
,16,CD,O
,days,NNS,O
,after,IN,O
,STZ,NNP,O
,(,(,O
,ICV,NNP,O
,;,:,O
,3mg,CD,O
,/,NNP,O
,Kg,NNP,O
,),),O
,administration,NN,O
,.,.,O
,STZ,JJ,O
,causes,NNS,O
,increased,VBD,O
,expression,NN,O
,of,IN,O
,GFAP,NNP,O
,",",",",O
,CD11b,NNP,O
,and,CC,O
,TNF,NNP,O
,-,:,O
,a,DT,O
,indicating,JJ,O
,glial,JJ,O
,activation,NN,O
,and,CC,O
,neuroinflammation,NN,B-DISEASE
,.,.,O
,STZ,NNP,O
,also,RB,O
,significantly,RB,O
,increased,VBD,O
,the,DT,O
,level,NN,O
,of,IN,O
,ROS,NNP,O
,",",",",O
,nitrite,RB,O
,",",",",O
,Ca,NNP,O
,(,(,O
,2,CD,O
,+,NN,O
,),),O
,and,CC,O
,reduced,VBD,O
,the,DT,O
,mitochondrial,JJ,O
,activity,NN,O
,in,IN,O
,synaptosomal,JJ,O
,preparation,NN,O
,illustrating,VBG,O
,free,JJ,O
,radical,JJ,O
,generation,NN,O
,and,CC,O
,excitotoxicity,NN,B-DISEASE
,.,.,O
,Increased,VBN,O
,expression,NN,O
,and,CC,O
,activity,NN,O
,of,IN,O
,Caspase,NNP,O
,-,:,O
,3,CD,O
,was,VBD,O
,also,RB,O
,observed,VBN,O
,in,IN,O
,STZ,NNP,O
,treated,VBD,O
,rat,NN,O
,which,WDT,O
,specify,VBZ,O
,apoptotic,JJ,O
,cell,NN,O
,death,NN,O
,in,IN,O
,hippocampus,NN,O
,and,CC,O
,cortex,NN,O
,.,.,O
,STZ,NNP,O
,treatment,NN,O
,showed,VBD,O
,decrease,JJ,O
,expression,NN,O
,of,IN,O
,post,NN,O
,synaptic,JJ,O
,markers,NNS,O
,CaMKIIa,NNP,O
,and,CC,O
,PSD,NNP,O
,-,:,O
,95,CD,O
,",",",",O
,while,IN,O
,",",",",O
,expression,NN,O
,of,IN,O
,pre,JJ,O
,synaptic,JJ,O
,markers,NNS,O
,(,(,O
,synaptophysin,NN,O
,and,CC,O
,SNAP,NNP,O
,-,:,O
,25,CD,O
,),),O
,remains,VBZ,O
,unaltered,JJ,O
,indicating,VBG,O
,selective,JJ,O
,post,NN,O
,synaptic,JJ,O
,neurotoxicity,NN,B-DISEASE
,.,.,O
,Oral,JJ,O
,treatment,NN,O
,with,IN,O
,Memantine,NNP,O
,(,(,O
,10mg,CD,O
,/,NNP,O
,kg,NN,O
,),),O
,and,CC,O
,Ibuprofen,NNP,O
,(,(,O
,50,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,daily,RB,O
,for,IN,O
,13,CD,O
,days,NNS,O
,attenuated,VBN,O
,STZ,NNP,O
,induced,VBD,O
,glial,JJ,O
,activation,NN,O
,",",",",O
,apoptotic,JJ,O
,cell,NN,O
,death,NN,O
,and,CC,O
,post,NN,O
,synaptic,JJ,O
,neurotoxicity,NN,B-DISEASE
,in,IN,O
,rat,NN,O
,brain,NN,O
,.,.,O
,Further,NNP,O
,",",",",O
,in,IN,O
,experiment,NN,O
,set,VBN,O
,up,RP,O
,2,CD,O
,:,:,O
,where,WRB,O
,memory,NN,O
,function,NN,O
,was,VBD,O
,not,RB,O
,affected,VBN,O
,i,NN,O
,.,.,O
,e,NN,O
,.,.,O
,7,CD,O
,-,:,O
,9,CD,O
,days,NNS,O
,after,IN,O
,STZ,NNP,O
,treatment,NN,O
,.,.,O
,The,DT,O
,level,NN,O
,of,IN,O
,GFAP,NNP,O
,",",",",O
,CD11b,NNP,O
,",",",",O
,TNF,NNP,O
,-,:,O
,a,DT,O
,",",",",O
,ROS,NNP,O
,and,CC,O
,nitrite,JJ,O
,levels,NNS,O
,were,VBD,O
,increased,VBN,O
,.,.,O
,On,IN,O
,the,DT,O
,other,JJ,O
,hand,NN,O
,",",",",O
,apoptotic,JJ,O
,marker,NN,O
,",",",",O
,synaptic,JJ,O
,markers,NNS,O
,",",",",O
,mitochondrial,JJ,O
,activity,NN,O
,and,CC,O
,Ca,NNP,O
,(,(,O
,2,CD,O
,+,NN,O
,),),O
,levels,NNS,O
,remained,VBN,O
,unaffected,JJ,O
,.,.,O
,Collective,NNP,O
,data,NN,O
,indicates,VBZ,O
,that,IN,O
,neuroinflammatory,JJ,B-DISEASE
,process,NN,O
,and,CC,O
,oxidative,JJ,O
,stress,NN,O
,occurs,VBZ,O
,earlier,JJR,O
,to,TO,O
,apoptosis,VB,O
,and,CC,O
,does,VBZ,O
,not,RB,O
,affect,VB,O
,memory,NN,O
,function,NN,O
,.,.,O
,Present,NNP,O
,study,VBD,O
,clearly,RB,O
,suggests,VBZ,O
,that,IN,O
,glial,JJ,O
,activation,NN,O
,and,CC,O
,post,NN,O
,synaptic,JJ,O
,neurotoxicity,NN,B-DISEASE
,are,VBP,O
,the,DT,O
,key,JJ,O
,factors,NNS,O
,in,IN,O
,STZ,NNP,O
,induced,VBD,O
,memory,NN,B-DISEASE
,impairment,NN,I-DISEASE
,and,CC,O
,neuronal,JJ,O
,cell,NN,O
,death,NN,O
,.,.,O
,Comparison,NNP,O
,of,IN,O
,effects,NNS,O
,of,IN,O
,isotonic,JJ,O
,sodium,NN,O
,chloride,NN,O
,with,IN,O
,diltiazem,NN,O
,in,IN,O
,prevention,NN,O
,of,IN,O
,contrast,NN,O
,-,:,O
,induced,VBN,O
,nephropathy,JJ,B-DISEASE
,.,.,O
,INTRODUCTION,NNP,O
,AND,CC,O
,OBJECTIVE,NNP,O
,:,:,O
,Contrast,NNP,O
,-,:,O
,induced,VBN,O
,nephropathy,JJ,B-DISEASE
,(,(,O
,CIN,NNP,O
,),),O
,significantly,RB,O
,increases,VBZ,O
,the,DT,O
,morbidity,NN,O
,and,CC,O
,mortality,NN,O
,of,IN,O
,patients,NNS,O
,.,.,O
,The,DT,O
,aim,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,is,VBZ,O
,to,TO,O
,investigate,VB,O
,and,CC,O
,compare,VB,O
,the,DT,O
,protective,JJ,O
,effects,NNS,O
,of,IN,O
,isotonic,JJ,O
,sodium,NN,O
,chloride,NN,O
,with,IN,O
,sodium,NN,O
,bicarbonate,NN,O
,infusion,NN,O
,and,CC,O
,isotonic,JJ,O
,sodium,NN,O
,chloride,NN,O
,infusion,NN,O
,with,IN,O
,diltiazem,NN,O
,",",",",O
,a,DT,O
,calcium,NN,O
,channel,NN,O
,blocker,NN,O
,",",",",O
,in,IN,O
,preventing,VBG,O
,CIN,NNP,O
,.,.,O
,MATERIALS,NNP,O
,AND,CC,O
,METHODS,NNP,O
,:,:,O
,Our,PRP$,O
,study,NN,O
,included,VBD,O
,patients,NNS,O
,who,WP,O
,were,VBD,O
,administered,VBN,O
,30,CD,O
,-,:,O
,60,CD,O
,mL,NN,O
,of,IN,O
,iodinated,JJ,O
,contrast,NN,O
,agent,NN,O
,for,IN,O
,percutaneous,JJ,O
,coronary,JJ,O
,angiography,NN,O
,(,(,O
,PCAG,NNP,O
,),),O
,",",",",O
,all,DT,O
,with,IN,O
,creatinine,NN,O
,values,NNS,O
,between,IN,O
,1,CD,O
,.,.,O
,1,CD,O
,and,CC,O
,3,CD,O
,.,.,O
,1,CD,O
,mg,JJ,O
,/,NNP,O
,dL,NN,O
,.,.,O
,Patients,NNS,O
,were,VBD,O
,divided,VBN,O
,into,IN,O
,three,CD,O
,groups,NNS,O
,and,CC,O
,each,DT,O
,group,NN,O
,had,VBD,O
,20,CD,O
,patients,NNS,O
,.,.,O
,The,DT,O
,first,JJ,O
,group,NN,O
,of,IN,O
,patients,NNS,O
,was,VBD,O
,administered,VBN,O
,isotonic,JJ,O
,sodium,NN,O
,chloride,NN,O
,;,:,O
,the,DT,O
,second,JJ,O
,group,NN,O
,was,VBD,O
,administered,VBN,O
,a,DT,O
,solution,NN,O
,that,IN,O
,of,IN,O
,5,CD,O
,%,NN,O
,dextrose,NN,O
,and,CC,O
,sodium,NN,O
,bicarbonate,NN,O
,",",",",O
,while,IN,O
,the,DT,O
,third,JJ,O
,group,NN,O
,was,VBD,O
,administered,VBN,O
,isotonic,JJ,O
,sodium,NN,O
,chloride,NN,O
,before,IN,O
,and,CC,O
,after,IN,O
,the,DT,O
,contrast,NN,O
,injection,NN,O
,.,.,O
,The,DT,O
,third,JJ,O
,group,NN,O
,received,VBD,O
,an,DT,O
,additional,JJ,O
,injection,NN,O
,of,IN,O
,diltiazem,NN,O
,the,DT,O
,day,NN,O
,before,IN,O
,and,CC,O
,first,JJ,O
,2,CD,O
,days,NNS,O
,after,IN,O
,the,DT,O
,contrast,NN,O
,injection,NN,O
,.,.,O
,All,DT,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,',POS,O
,plasma,NNS,O
,blood,VBD,O
,urea,JJ,O
,nitrogen,NN,O
,(,(,O
,BUN,NNP,O
,),),O
,and,CC,O
,creatinine,JJ,O
,levels,NNS,O
,were,VBD,O
,measured,VBN,O
,on,IN,O
,the,DT,O
,second,JJ,O
,and,CC,O
,seventh,JJ,O
,day,NN,O
,after,IN,O
,the,DT,O
,administration,NN,O
,of,IN,O
,intravenous,JJ,O
,contrast,NN,O
,material,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,The,DT,O
,basal,NN,O
,creatinine,NN,O
,levels,NNS,O
,were,VBD,O
,similar,JJ,O
,for,IN,O
,all,DT,O
,three,CD,O
,groups,NNS,O
,(,(,O
,p,JJ,O
,>,NN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,Among,IN,O
,a,DT,O
,total,NN,O
,of,IN,O
,60,CD,O
,patients,NNS,O
,included,VBN,O
,in,IN,O
,the,DT,O
,study,NN,O
,",",",",O
,16,CD,O
,patients,NNS,O
,developed,VBD,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,(,(,O
,ARF,NNP,B-DISEASE
,),),O
,on,IN,O
,the,DT,O
,second,JJ,O
,day,NN,O
,after,IN,O
,contrast,NN,O
,material,NN,O
,was,VBD,O
,injected,VBN,O
,(,(,O
,26,CD,O
,.,.,O
,6,CD,O
,%,NN,O
,),),O
,.,.,O
,The,DT,O
,number,NN,O
,of,IN,O
,patients,NNS,O
,who,WP,O
,developed,VBD,O
,ARF,NNP,B-DISEASE
,on,IN,O
,the,DT,O
,second,JJ,O
,day,NN,O
,after,IN,O
,the,DT,O
,injection,NN,O
,in,IN,O
,the,DT,O
,first,JJ,O
,group,NN,O
,was,VBD,O
,five,CD,O
,(,(,O
,25,CD,O
,%,NN,O
,),),O
,",",",",O
,in,IN,O
,the,DT,O
,second,JJ,O
,group,NN,O
,was,VBD,O
,six,CD,O
,(,(,O
,30,CD,O
,%,NN,O
,),),O
,and,CC,O
,the,DT,O
,third,JJ,O
,group,NN,O
,was,VBD,O
,five,CD,O
,(,(,O
,25,CD,O
,%,NN,O
,),),O
,(,(,O
,p,JJ,O
,>,NN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,There,EX,O
,was,VBD,O
,no,DT,O
,significant,JJ,O
,difference,NN,O
,between,IN,O
,isotonic,JJ,O
,sodium,NN,O
,chloride,NN,O
,",",",",O
,sodium,NN,O
,bicarbonate,NN,O
,and,CC,O
,isotonic,JJ,O
,sodium,NN,O
,chloride,NN,O
,with,IN,O
,diltiazem,JJ,O
,application,NN,O
,in,IN,O
,prevention,NN,O
,of,IN,O
,CIN,NNP,O
,.,.,O
,Neurocognitive,NNP,O
,and,CC,O
,neuroradiologic,JJ,O
,central,JJ,O
,nervous,JJ,O
,system,NN,O
,late,JJ,O
,effects,NNS,O
,in,IN,O
,children,NNS,O
,treated,VBN,O
,on,IN,O
,Pediatric,NNP,O
,Oncology,NNP,O
,Group,NNP,O
,(,(,O
,POG,NNP,O
,),),O
,P9605,NNP,O
,(,(,O
,standard,JJ,O
,risk,NN,O
,),),O
,and,CC,O
,P9201,NNP,O
,(,(,O
,lesser,JJR,O
,risk,NN,O
,),),O
,acute,VBZ,B-DISEASE
,lymphoblastic,JJ,I-DISEASE
,leukemia,NN,I-DISEASE
,protocols,NNS,O
,(,(,O
,ACCL0131,NNP,O
,),),O
,:,:,O
,a,DT,O
,methotrexate,NN,O
,consequence,NN,O
,?,.,O
,A,DT,O
,report,NN,O
,from,IN,O
,the,DT,O
,Children,NNP,O
,',POS,O
,s,NN,O
,Oncology,NNP,O
,Group,NNP,O
,.,.,O
,Concerns,NNS,O
,about,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,methotrexate,NN,O
,(,(,O
,MTX,NNP,O
,),),O
,neurotoxicity,NN,B-DISEASE
,in,IN,O
,the,DT,O
,1990s,CD,O
,led,VBD,O
,to,TO,O
,modifications,NNS,O
,in,IN,O
,intrathecal,JJ,O
,(,(,O
,IT,NNP,O
,),),O
,therapy,NN,O
,",",",",O
,leucovorin,NN,O
,rescue,NN,O
,",",",",O
,and,CC,O
,frequency,NN,O
,of,IN,O
,systemic,JJ,O
,MTX,NNP,O
,administration,NN,O
,in,IN,O
,children,NNS,O
,with,IN,O
,acute,JJ,B-DISEASE
,lymphoblastic,JJ,I-DISEASE
,leukemia,NN,I-DISEASE
,.,.,O
,In,IN,O
,this,DT,O
,study,NN,O
,",",",",O
,neurocognitive,JJ,O
,outcomes,NNS,O
,and,CC,O
,neuroradiologic,JJ,O
,evidence,NN,O
,of,IN,O
,leukoencephalopathy,NN,B-DISEASE
,were,VBD,O
,compared,VBN,O
,in,IN,O
,children,NNS,O
,treated,VBN,O
,with,IN,O
,intense,JJ,O
,central,JJ,O
,nervous,JJ,O
,system,NN,O
,(,(,O
,CNS,NNP,O
,),),O
,-,:,O
,directed,VBN,O
,therapy,NN,O
,(,(,O
,P9605,NNP,O
,),),O
,versus,VBP,O
,those,DT,O
,receiving,VBG,O
,fewer,JJR,O
,CNS,NNP,O
,-,:,O
,directed,VBD,O
,treatment,NN,O
,days,NNS,O
,during,IN,O
,intensive,JJ,O
,consolidation,NN,O
,(,(,O
,P9201,NNP,O
,),),O
,.,.,O
,A,DT,O
,total,NN,O
,of,IN,O
,66,CD,O
,children,NNS,O
,from,IN,O
,16,CD,O
,Pediatric,NNP,O
,Oncology,NNP,O
,Group,NNP,O
,institutions,NNS,O
,with,IN,O
,"""",NNP,O
,standard,NN,O
,-,:,O
,risk,NN,O
,"""",IN,O
,acute,JJ,B-DISEASE
,lymphoblastic,JJ,I-DISEASE
,leukemia,NN,I-DISEASE
,",",",",O
,1,CD,O
,.,.,O
,00,CD,O
,to,TO,O
,9,CD,O
,.,.,O
,99,CD,O
,years,NNS,O
,at,IN,O
,diagnosis,NN,O
,",",",",O
,without,IN,O
,evidence,NN,O
,of,IN,O
,CNS,NNP,O
,leukemia,NN,B-DISEASE
,at,IN,O
,diagnosis,NN,O
,were,VBD,O
,enrolled,VBN,O
,on,IN,O
,ACCL0131,NNP,O
,:,:,O
,28,CD,O
,from,IN,O
,P9201,NNP,O
,and,CC,O
,38,CD,O
,from,IN,O
,P9605,NNP,O
,.,.,O
,Magnetic,JJ,O
,resonance,NN,O
,imaging,NN,O
,scans,NNS,O
,and,CC,O
,standard,JJ,O
,neuropsychological,JJ,O
,tests,NNS,O
,were,VBD,O
,performed,VBN,O
,>,JJ,O
,2,CD,O
,.,.,O
,6,CD,O
,years,NNS,O
,after,IN,O
,the,DT,O
,end,NN,O
,of,IN,O
,treatment,NN,O
,.,.,O
,Significantly,RB,O
,more,RBR,O
,P9605,JJ,O
,patients,NNS,O
,developed,VBD,O
,leukoencephalopathy,JJ,B-DISEASE
,compared,VBN,O
,with,IN,O
,P9201,NNP,O
,patients,NNS,O
,(,(,O
,68,CD,O
,%,NN,O
,",",",",O
,95,CD,O
,%,NN,O
,confidence,NN,O
,interval,JJ,O
,49,CD,O
,%,NN,O
,-,:,O
,83,CD,O
,%,NN,O
,vs,NN,O
,.,.,O
,22,CD,O
,%,NN,O
,",",",",O
,95,CD,O
,%,NN,O
,confidence,NN,O
,interval,JJ,O
,5,CD,O
,%,NN,O
,-,:,O
,44,CD,O
,%,NN,O
,;,:,O
,P,NNP,O
,=,VBD,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,identified,VBN,O
,as,RB,O
,late,JJ,O
,as,IN,O
,7,CD,O
,.,.,O
,7,CD,O
,years,NNS,O
,after,IN,O
,the,DT,O
,end,NN,O
,of,IN,O
,treatment,NN,O
,.,.,O
,Overall,NNP,O
,",",",",O
,40,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,scored,VBN,O
,<,RB,O
,85,CD,O
,on,IN,O
,either,DT,O
,Verbal,NNP,O
,or,CC,O
,Performance,NNP,O
,IQ,NNP,O
,.,.,O
,Children,NNP,O
,on,IN,O
,both,DT,O
,studies,NNS,O
,had,VBD,O
,significant,JJ,O
,attention,NN,B-DISEASE
,problems,NNS,I-DISEASE
,",",",",O
,but,CC,O
,P9605,NNP,O
,children,NNS,O
,scored,VBD,O
,below,IN,O
,average,NN,O
,on,IN,O
,more,RBR,O
,neurocognitive,JJ,O
,measures,NNS,O
,than,IN,O
,those,DT,O
,treated,VBN,O
,on,IN,O
,P9201,NNP,O
,(,(,O
,82,CD,O
,%,NN,O
,",",",",O
,14,CD,O
,/,NN,O
,17,CD,O
,measures,NNS,O
,vs,RB,O
,.,.,O
,24,CD,O
,%,NN,O
,",",",",O
,4,CD,O
,/,NN,O
,17,CD,O
,measures,NNS,O
,),),O
,.,.,O
,This,DT,O
,supports,VBZ,O
,ongoing,JJ,O
,concerns,NNS,O
,about,IN,O
,intensive,JJ,O
,MTX,NNP,O
,exposure,NN,O
,as,IN,O
,a,DT,O
,major,JJ,O
,contributor,NN,O
,to,TO,O
,CNS,NNP,O
,late,JJ,O
,effects,NNS,O
,.,.,O
,Tranexamic,NNP,O
,acid,JJ,O
,overdosage,NN,O
,-,:,O
,induced,JJ,O
,generalized,JJ,O
,seizure,NN,B-DISEASE
,in,IN,O
,renal,JJ,B-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,We,PRP,O
,report,VBP,O
,a,DT,O
,45,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,lady,NN,O
,with,IN,O
,chronic,JJ,B-DISEASE
,kidney,NN,I-DISEASE
,disease,NN,I-DISEASE
,stage,NN,O
,4,CD,O
,due,JJ,O
,to,TO,O
,chronic,JJ,O
,tubulointerstial,JJ,B-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,She,PRP,O
,was,VBD,O
,admitted,VBN,O
,to,TO,O
,our,PRP$,O
,center,NN,O
,for,IN,O
,severe,JJ,O
,anemia,NN,B-DISEASE
,due,JJ,O
,to,TO,O
,menorrhagia,VB,B-DISEASE
,and,CC,O
,deterioration,NN,B-DISEASE
,of,IN,I-DISEASE
,renal,JJ,I-DISEASE
,function,NN,I-DISEASE
,.,.,O
,She,PRP,O
,was,VBD,O
,infused,VBN,O
,three,CD,O
,units,NNS,O
,of,IN,O
,packed,JJ,O
,cells,NNS,O
,during,IN,O
,a,DT,O
,session,NN,O
,of,IN,O
,hemodialysis,NN,O
,.,.,O
,Tranexamic,NNP,O
,acid,NN,O
,(,(,O
,TNA,NNP,O
,),),O
,1,CD,O
,g,$,O
,8,CD,O
,-,:,O
,hourly,NN,O
,was,VBD,O
,administered,VBN,O
,to,TO,O
,her,PRP$,O
,to,TO,O
,control,VB,O
,bleeding,VBG,B-DISEASE
,per,IN,O
,vaginum,NN,O
,.,.,O
,Two,CD,O
,hours,NNS,O
,after,IN,O
,the,DT,O
,sixth,JJ,O
,dose,NN,O
,of,IN,O
,TNA,NNP,O
,",",",",O
,she,PRP,O
,had,VBD,O
,an,DT,O
,episode,NN,O
,of,IN,O
,generalized,JJ,O
,tonic,JJ,B-DISEASE
,clonic,JJ,I-DISEASE
,convulsions,NNS,I-DISEASE
,.,.,O
,TNA,NNP,O
,was,VBD,O
,discontinued,VBN,O
,.,.,O
,Investigations,NNS,O
,of,IN,O
,the,DT,O
,patient,NN,O
,revealed,VBD,O
,no,DT,O
,biochemical,JJ,O
,or,CC,O
,structural,JJ,O
,central,JJ,O
,nervous,JJ,B-DISEASE
,system,NN,I-DISEASE
,abnormalities,NNS,I-DISEASE
,that,WDT,O
,could,MD,O
,have,VB,O
,provoked,VBN,O
,the,DT,O
,convulsions,NNS,B-DISEASE
,.,.,O
,She,PRP,O
,did,VBD,O
,not,RB,O
,require,VB,O
,any,DT,O
,further,JJ,O
,dialytic,JJ,O
,support,NN,O
,.,.,O
,She,PRP,O
,had,VBD,O
,no,DT,O
,further,JJ,O
,episodes,NNS,O
,of,IN,O
,convulsion,NN,B-DISEASE
,till,NN,O
,dis,SYM,O
,-,:,O
,charge,NN,O
,and,CC,O
,during,IN,O
,the,DT,O
,two,CD,O
,months,NNS,O
,of,IN,O
,follow,JJ,O
,-,:,O
,up,RB,O
,.,.,O
,Thus,RB,O
,",",",",O
,the,DT,O
,precipitating,NN,O
,cause,NN,O
,of,IN,O
,convulsions,NNS,B-DISEASE
,was,VBD,O
,believed,VBN,O
,to,TO,O
,be,VB,O
,an,DT,O
,overdose,NN,B-DISEASE
,of,IN,O
,TNA,NNP,O
,.,.,O
,Pre,NNP,O
,-,:,O
,treatment,NN,O
,of,IN,O
,bupivacaine,NN,O
,-,:,O
,induced,JJ,O
,cardiovascular,JJ,B-DISEASE
,depression,NN,I-DISEASE
,using,VBG,O
,different,JJ,O
,lipid,JJ,O
,formulations,NNS,O
,of,IN,O
,propofol,NN,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,Pre,NNP,O
,-,:,O
,treatment,NN,O
,with,IN,O
,lipid,JJ,O
,emulsions,NNS,O
,has,VBZ,O
,been,VBN,O
,shown,VBN,O
,to,TO,O
,increase,VB,O
,lethal,JJ,O
,doses,NNS,O
,of,IN,O
,bupivacaine,NN,O
,",",",",O
,and,CC,O
,the,DT,O
,lipid,JJ,O
,content,NN,O
,of,IN,O
,propofol,NN,O
,may,MD,O
,alleviate,VB,O
,bupivacaine,NN,O
,-,:,O
,induced,JJ,O
,cardiotoxicity,NN,B-DISEASE
,.,.,O
,The,DT,O
,aim,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,is,VBZ,O
,to,TO,O
,investigate,VB,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,propofol,NN,O
,in,IN,O
,intralipid,JJ,O
,or,CC,O
,medialipid,JJ,O
,emulsions,NNS,O
,on,IN,O
,bupivacaine,NN,O
,-,:,O
,induced,JJ,O
,cardiotoxicity,NN,B-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,Rats,NNS,O
,were,VBD,O
,anaesthetised,VBN,O
,with,IN,O
,ketamine,NN,O
,and,CC,O
,were,VBD,O
,given,VBN,O
,0,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,/,NNP,O
,min,NN,O
,propofol,NN,O
,in,IN,O
,intralipid,JJ,O
,(,(,O
,Group,NNP,O
,P,NNP,O
,),),O
,",",",",O
,propofol,NN,O
,in,IN,O
,medialipid,JJ,O
,(,(,O
,Group,NNP,O
,L,NNP,O
,),),O
,",",",",O
,or,CC,O
,saline,NN,O
,(,(,O
,Group,NNP,O
,C,NNP,O
,),),O
,over,IN,O
,20,CD,O
,min,NNS,O
,.,.,O
,Thereafter,NNP,O
,",",",",O
,2,CD,O
,mg,NN,O
,/,NNP,O
,kg,NNP,O
,/,NNP,O
,min,NNP,O
,bupivacaine,NN,O
,0,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,was,VBD,O
,infused,VBN,O
,.,.,O
,We,PRP,O
,recorded,VBD,O
,time,NN,O
,to,TO,O
,first,VB,O
,dysrhythmia,NN,B-DISEASE
,occurrence,NN,O
,",",",",O
,respective,JJ,O
,times,NNS,O
,to,TO,O
,25,CD,O
,%,NN,O
,and,CC,O
,50,CD,O
,%,NN,O
,reduction,NN,O
,of,IN,O
,the,DT,O
,heart,NN,O
,rate,NN,O
,(,(,O
,HR,NNP,O
,),),O
,and,CC,O
,mean,JJ,O
,arterial,JJ,O
,pressure,NN,O
,",",",",O
,and,CC,O
,time,NN,O
,to,TO,O
,asystole,VB,B-DISEASE
,and,CC,O
,total,JJ,O
,amount,NN,O
,of,IN,O
,bupivacaine,NN,O
,consumption,NN,O
,.,.,O
,Blood,NNP,O
,and,CC,O
,tissue,NN,O
,samples,NNS,O
,were,VBD,O
,collected,VBN,O
,following,VBG,O
,asystole,NN,B-DISEASE
,.,.,O
,RESULTS,NN,O
,:,:,O
,The,DT,O
,time,NN,O
,to,TO,O
,first,VB,O
,dysrhythmia,NN,B-DISEASE
,occurrence,NN,O
,",",",",O
,time,NN,O
,to,TO,O
,25,CD,O
,%,NN,O
,and,CC,O
,50,CD,O
,%,NN,O
,reductions,NNS,O
,in,IN,O
,HR,NNP,O
,",",",",O
,and,CC,O
,time,NN,O
,to,TO,O
,asystole,VB,B-DISEASE
,were,VBD,O
,longer,RBR,O
,in,IN,O
,Group,NNP,O
,P,NNP,O
,than,IN,O
,the,DT,O
,other,JJ,O
,groups,NNS,O
,.,.,O
,The,DT,O
,cumulative,JJ,O
,bupivacaine,NN,O
,dose,VB,O
,given,VBN,O
,at,IN,O
,those,DT,O
,time,NN,O
,points,NNS,O
,was,VBD,O
,higher,RBR,O
,in,IN,O
,Group,NNP,O
,P,NNP,O
,.,.,O
,Plasma,NNP,O
,bupivacaine,NN,O
,levels,NNS,O
,were,VBD,O
,significantly,RB,O
,lower,JJR,O
,in,IN,O
,Group,NNP,O
,P,NNP,O
,than,IN,O
,in,IN,O
,Group,NNP,O
,C,NNP,O
,.,.,O
,Bupivacaine,NNP,O
,levels,NNS,O
,in,IN,O
,the,DT,O
,brain,NN,O
,and,CC,O
,heart,NN,O
,were,VBD,O
,significantly,RB,O
,lower,JJR,O
,in,IN,O
,Group,NNP,O
,P,NNP,O
,and,CC,O
,Group,NNP,O
,L,NNP,O
,than,IN,O
,in,IN,O
,Group,NNP,O
,C,NNP,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,We,PRP,O
,conclude,VBP,O
,that,IN,O
,pre,SYM,O
,-,:,O
,treatment,NN,O
,with,IN,O
,propofol,NN,O
,in,IN,O
,intralipid,JJ,O
,",",",",O
,compared,VBN,O
,with,IN,O
,propofol,NN,O
,in,IN,O
,medialipid,NN,O
,or,CC,O
,saline,NN,O
,",",",",O
,delayed,VBD,O
,the,DT,O
,onset,NN,O
,of,IN,O
,bupivacaine,NN,O
,-,:,O
,induced,JJ,O
,cardiotoxic,JJ,B-DISEASE
,effects,NNS,O
,as,RB,O
,well,RB,O
,as,IN,O
,reduced,VBN,O
,plasma,IN,O
,bupivacaine,NN,O
,levels,NNS,O
,.,.,O
,Further,JJ,O
,studies,NNS,O
,are,VBP,O
,needed,VBN,O
,to,TO,O
,explore,VB,O
,tissue,NN,O
,bupivacaine,NN,O
,levels,NNS,O
,of,IN,O
,propofol,NN,O
,in,IN,O
,medialipid,JJ,O
,and,CC,O
,adapt,JJ,O
,these,DT,O
,results,NNS,O
,to,TO,O
,clinical,JJ,O
,practice,NN,O
,.,.,O
,Drug,NNP,B-DISEASE
,-,:,I-DISEASE
,Induced,NNP,I-DISEASE
,Acute,NNP,I-DISEASE
,Liver,NNP,I-DISEASE
,Injury,NNP,I-DISEASE
,Within,NNP,O
,12,CD,O
,Hours,NNP,O
,After,IN,O
,Fluvastatin,NNP,O
,Therapy,NNP,O
,.,.,O
,Although,IN,O
,statins,NNS,O
,are,VBP,O
,generally,RB,O
,well,RB,O
,-,:,O
,tolerated,VBN,O
,drugs,NNS,O
,",",",",O
,recent,JJ,O
,cases,NNS,O
,of,IN,O
,drug,NN,B-DISEASE
,-,:,I-DISEASE
,induced,VBN,I-DISEASE
,liver,JJ,I-DISEASE
,injury,NN,I-DISEASE
,associated,VBN,O
,with,IN,O
,their,PRP$,O
,use,NN,O
,have,VBP,O
,been,VBN,O
,reported,VBN,O
,.,.,O
,A,DT,O
,52,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,Chinese,JJ,O
,man,NN,O
,reported,VBD,O
,with,IN,O
,liver,JJ,B-DISEASE
,damage,NN,I-DISEASE
,",",",",O
,which,WDT,O
,appeared,VBD,O
,12,CD,O
,hours,NNS,O
,after,IN,O
,beginning,VBG,O
,treatment,NN,O
,with,IN,O
,fluvastatin,NN,O
,.,.,O
,Patient,NNP,O
,presented,VBD,O
,with,IN,O
,complaints,NNS,O
,of,IN,O
,increasing,VBG,O
,nausea,NN,B-DISEASE
,",",",",O
,anorexia,NN,B-DISEASE
,",",",",O
,and,CC,O
,upper,JJ,O
,abdominal,JJ,B-DISEASE
,pain,NN,I-DISEASE
,.,.,O
,His,PRP$,O
,laboratory,NN,O
,values,NNS,O
,showed,VBD,O
,elevated,JJ,O
,creatine,NN,O
,kinase,NN,O
,and,CC,O
,transaminases,NNS,O
,.,.,O
,Testing,VBG,O
,for,IN,O
,autoantibodies,NNS,O
,was,VBD,O
,also,RB,O
,negative,JJ,O
,.,.,O
,The,DT,O
,liver,NN,O
,biochemistries,VBZ,O
,eventually,RB,O
,normalized,VBN,O
,within,IN,O
,3,CD,O
,weeks,NNS,O
,of,IN,O
,stopping,VBG,O
,the,DT,O
,fluvastatin,NN,O
,.,.,O
,Therefore,RB,O
,",",",",O
,when,WRB,O
,prescribing,VBG,O
,statins,NNS,O
,",",",",O
,the,DT,O
,possibility,NN,O
,of,IN,O
,hepatic,JJ,B-DISEASE
,damage,NN,I-DISEASE
,should,MD,O
,be,VB,O
,taken,VBN,O
,into,IN,O
,account,NN,O
,.,.,O
,Fluconazole,NNP,O
,associated,VBD,O
,agranulocytosis,NN,B-DISEASE
,and,CC,O
,thrombocytopenia,NN,B-DISEASE
,.,.,O
,CASE,NN,O
,:,:,O
,We,PRP,O
,describe,VBP,O
,a,DT,O
,second,JJ,O
,case,NN,O
,of,IN,O
,fluconazole,NN,O
,associated,VBN,O
,agranulocytosis,NN,B-DISEASE
,with,IN,O
,thrombocytopenia,NN,B-DISEASE
,and,CC,O
,recovery,NN,O
,upon,IN,O
,discontinuation,NN,O
,of,IN,O
,therapy,NN,O
,.,.,O
,The,DT,O
,patient,NN,O
,began,VBD,O
,to,TO,O
,have,VB,O
,changes,NNS,O
,in,IN,O
,white,JJ,O
,blood,NN,O
,cells,NNS,O
,and,CC,O
,platelets,NNS,O
,within,IN,O
,48,CD,O
,h,NN,O
,of,IN,O
,administration,NN,O
,of,IN,O
,fluconazole,JJ,O
,and,CC,O
,began,VBD,O
,to,TO,O
,recover,VB,O
,with,IN,O
,48,CD,O
,h,NN,O
,of,IN,O
,discontinuation,NN,O
,.,.,O
,This,DT,O
,case,NN,O
,highlights,VBZ,O
,that,IN,O
,drug,NN,O
,-,:,O
,induced,JJ,O
,blood,NN,B-DISEASE
,dyscrasias,NNS,I-DISEASE
,can,MD,O
,occur,VB,O
,unexpectedly,RB,O
,as,IN,O
,a,DT,O
,result,NN,O
,of,IN,O
,treatment,NN,O
,with,IN,O
,a,DT,O
,commonly,RB,O
,used,VBN,O
,drug,NN,O
,thought,VBN,O
,to,TO,O
,be,VB,O
,"""",JJ,O
,safe,JJ,O
,"""",NN,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,According,VBG,O
,to,TO,O
,Naranjo,NNP,O
,',POS,O
,s,NN,O
,algorithm,IN,O
,the,DT,O
,likelihood,NN,O
,that,IN,O
,our,PRP$,O
,patient,NN,O
,','',O
,s,JJ,O
,agranulocytosis,NN,B-DISEASE
,and,CC,O
,thrombocytopenia,NN,B-DISEASE
,occurred,VBD,O
,as,IN,O
,a,DT,O
,result,NN,O
,of,IN,O
,therapy,NN,O
,with,IN,O
,fluconazole,NN,O
,is,VBZ,O
,probable,JJ,O
,",",",",O
,with,IN,O
,a,DT,O
,total,NN,O
,of,IN,O
,six,CD,O
,points,NNS,O
,.,.,O
,We,PRP,O
,feel,VBP,O
,that,IN,O
,the,DT,O
,weight,NN,O
,of,IN,O
,the,DT,O
,overall,JJ,O
,evidence,NN,O
,of,IN,O
,this,DT,O
,evidence,NN,O
,is,VBZ,O
,strong,JJ,O
,.,.,O
,In,IN,O
,particular,JJ,O
,the,DT,O
,temporal,JJ,O
,relationship,NN,O
,of,IN,O
,bone,NN,B-DISEASE
,marrow,NN,I-DISEASE
,suppression,NN,I-DISEASE
,to,TO,O
,the,DT,O
,initiation,NN,O
,of,IN,O
,fluconazole,NN,O
,and,CC,O
,the,DT,O
,abatement,NN,O
,of,IN,O
,symptoms,NNS,O
,that,WDT,O
,rapidly,RB,O
,reversed,VBD,O
,immediately,RB,O
,following,VBG,O
,discontinuation,NN,O
,.,.,O
,Two,CD,O
,-,:,O
,dimensional,JJ,O
,speckle,NN,O
,tracking,VBG,O
,echocardiography,NN,O
,combined,VBN,O
,with,IN,O
,high,JJ,O
,-,:,O
,sensitive,JJ,O
,cardiac,JJ,O
,troponin,NN,O
,T,NNP,O
,in,IN,O
,early,JJ,O
,detection,NN,O
,and,CC,O
,prediction,NN,O
,of,IN,O
,cardiotoxicity,NN,B-DISEASE
,during,IN,O
,epirubicine,JJ,O
,-,:,O
,based,VBN,O
,chemotherapy,NN,O
,.,.,O
,AIMS,NNS,O
,:,:,O
,To,TO,O
,investigate,VB,O
,whether,IN,O
,alterations,NNS,O
,of,IN,O
,myocardial,JJ,B-DISEASE
,strain,NN,I-DISEASE
,and,CC,O
,high,JJ,O
,-,:,O
,sensitive,JJ,O
,cardiac,JJ,O
,troponin,NN,O
,T,NNP,O
,(,(,O
,cTnT,NN,O
,),),O
,could,MD,O
,predict,VB,O
,future,JJ,O
,cardiac,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,in,IN,O
,patients,NNS,O
,after,IN,O
,epirubicin,JJ,O
,exposure,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,Seventy,NNP,O
,-,:,O
,five,CD,O
,patients,NNS,O
,with,IN,O
,non,JJ,B-DISEASE
,-,:,I-DISEASE
,Hodgkin,NNP,I-DISEASE
,lymphoma,NN,I-DISEASE
,treated,VBD,O
,with,IN,O
,epirubicin,NNS,O
,were,VBD,O
,studied,VBN,O
,.,.,O
,Blood,NNP,O
,collection,NN,O
,and,CC,O
,echocardiography,NN,O
,were,VBD,O
,performed,VBN,O
,at,IN,O
,baseline,NN,O
,",",",",O
,1,CD,O
,day,NN,O
,after,IN,O
,the,DT,O
,third,JJ,O
,cycle,NN,O
,",",",",O
,and,CC,O
,1,CD,O
,day,NN,O
,after,IN,O
,completion,NN,O
,of,IN,O
,chemotherapy,NN,O
,.,.,O
,Patients,NNS,O
,were,VBD,O
,studied,VBN,O
,using,VBG,O
,echocardiography,NN,O
,during,IN,O
,follow,JJ,O
,-,:,O
,up,RB,O
,.,.,O
,Global,NNP,O
,longitudinal,JJ,O
,(,(,O
,GLS,NNP,O
,),),O
,",",",",O
,circumferential,JJ,O
,(,(,O
,GCS,NNP,O
,),),O
,",",",",O
,and,CC,O
,radial,JJ,O
,strain,NN,O
,(,(,O
,GRS,NNP,O
,),),O
,were,VBD,O
,calculated,VBN,O
,using,VBG,O
,speckle,JJ,O
,tracking,VBG,O
,echocardiography,NN,O
,.,.,O
,Left,NNP,O
,ventricular,JJ,O
,ejection,NN,O
,fraction,NN,O
,was,VBD,O
,analysed,VBN,O
,by,IN,O
,real,JJ,O
,-,:,O
,time,NN,O
,3D,CD,O
,echocardiography,NN,O
,.,.,O
,Cardiotoxicity,NNP,B-DISEASE
,was,VBD,O
,defined,VBN,O
,as,IN,O
,a,DT,O
,reduction,NN,O
,of,IN,O
,the,DT,O
,LVEF,NNP,O
,of,IN,O
,>,NNP,O
,5,CD,O
,%,NN,O
,to,TO,O
,<,VB,O
,55,CD,O
,%,NN,O
,with,IN,O
,symptoms,NNS,O
,of,IN,O
,heart,NN,B-DISEASE
,failure,NN,I-DISEASE
,or,CC,O
,an,DT,O
,asymptomatic,JJ,O
,reduction,NN,O
,of,IN,O
,the,DT,O
,LVEF,NNP,O
,of,IN,O
,>,NNP,O
,10,CD,O
,%,NN,O
,to,TO,O
,<,VB,O
,55,CD,O
,%,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Fourteen,JJ,O
,patients,NNS,O
,(,(,O
,18,CD,O
,.,.,O
,67,CD,O
,%,NN,O
,),),O
,developed,VBD,O
,cardiotoxicity,NN,B-DISEASE
,after,IN,O
,treatment,NN,O
,.,.,O
,GLS,NNP,O
,(,(,O
,-,:,O
,18,CD,O
,.,.,O
,48,CD,O
,+,JJ,O
,1,CD,O
,.,.,O
,72,CD,O
,%,NN,O
,vs,NN,O
,.,.,O
,-,:,O
,15,CD,O
,.,.,O
,96,CD,O
,+,JJ,O
,1,CD,O
,.,.,O
,6,CD,O
,%,NN,O
,),),O
,",",",",O
,GCS,NNP,O
,(,(,O
,-,:,O
,20,CD,O
,.,.,O
,93,CD,O
,+,JJ,O
,2,CD,O
,.,.,O
,86,CD,O
,%,NN,O
,vs,NN,O
,.,.,O
,-,:,O
,19,CD,O
,.,.,O
,20,CD,O
,+,JJ,O
,3,CD,O
,.,.,O
,21,CD,O
,%,NN,O
,),),O
,",",",",O
,and,CC,O
,GRS,NNP,O
,(,(,O
,39,CD,O
,.,.,O
,23,CD,O
,+,JJ,O
,6,CD,O
,.,.,O
,44,CD,O
,%,NN,O
,vs,NN,O
,.,.,O
,34,CD,O
,.,.,O
,98,CD,O
,+,JJ,O
,6,CD,O
,.,.,O
,2,CD,O
,%,NN,O
,),),O
,were,VBD,O
,markedly,RB,O
,reduced,VBN,O
,and,CC,O
,cTnT,NN,O
,was,VBD,O
,elevated,VBN,O
,from,IN,O
,0,CD,O
,.,.,O
,0010,CD,O
,+,JJ,O
,0,CD,O
,.,.,O
,0020,CD,O
,to,TO,O
,0,CD,O
,.,.,O
,0073,CD,O
,+,JJ,O
,0,CD,O
,.,.,O
,0038,CD,O
,ng,JJ,O
,/,NNP,O
,mL,NN,O
,(,(,O
,P,NNP,O
,all,DT,O
,<,VBP,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,at,IN,O
,the,DT,O
,completion,NN,O
,of,IN,O
,chemotherapy,NN,O
,compared,VBN,O
,with,IN,O
,baseline,NN,O
,values,NNS,O
,.,.,O
,A,DT,O
,>,JJ,O
,15,CD,O
,.,.,O
,9,CD,O
,%,NN,O
,decrease,NN,O
,in,IN,O
,GLS,NNP,O
,[,NNP,O
,sensitivity,NN,O
,",",",",O
,86,CD,O
,%,NN,O
,;,:,O
,specificity,NN,O
,",",",",O
,75,CD,O
,%,NN,O
,;,:,O
,area,NN,O
,under,IN,O
,the,DT,O
,curve,NN,O
,(,(,O
,AUC,NNP,O
,),),O
,=,VBD,O
,0,CD,O
,.,.,O
,815,CD,O
,;,:,O
,P,NNP,O
,=,VBD,O
,0,CD,O
,.,.,O
,001,CD,O
,],NN,O
,and,CC,O
,a,DT,O
,>,JJ,O
,0,CD,O
,.,.,O
,004,CD,O
,ng,JJ,O
,/,NNP,O
,mL,NN,O
,elevation,NN,O
,in,IN,O
,cTnT,NN,O
,(,(,O
,sensitivity,NN,O
,",",",",O
,79,CD,O
,%,NN,O
,;,:,O
,specificity,NN,O
,",",",",O
,64,CD,O
,%,NN,O
,;,:,O
,AUC,NNP,O
,=,VBD,O
,0,CD,O
,.,.,O
,757,CD,O
,;,:,O
,P,NNP,O
,=,VBD,O
,0,CD,O
,.,.,O
,005,CD,O
,),),O
,from,IN,O
,baseline,NN,O
,to,TO,O
,the,DT,O
,third,JJ,O
,cycle,NN,O
,of,IN,O
,chemotherapy,NN,O
,predicted,VBN,O
,later,RB,O
,cardiotoxicity,NN,B-DISEASE
,.,.,O
,The,DT,O
,decrease,NN,O
,in,IN,O
,GLS,NNP,O
,remained,VBD,O
,the,DT,O
,only,JJ,O
,independent,JJ,O
,predictor,NN,O
,of,IN,O
,cardiotoxicity,NN,B-DISEASE
,(,(,O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,000,CD,O
,),),O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,GLS,NNP,O
,combined,VBD,O
,with,IN,O
,cTnT,NN,O
,may,MD,O
,provide,VB,O
,a,DT,O
,reliable,JJ,O
,and,CC,O
,non,JJ,O
,-,:,O
,invasive,JJ,O
,method,NN,O
,to,TO,O
,predict,VB,O
,cardiac,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,in,IN,O
,patients,NNS,O
,receiving,VBG,O
,anthracycline,JJ,O
,-,:,O
,based,VBN,O
,chemotherapy,NN,O
,.,.,O
,Prevention,NN,O
,of,IN,O
,etomidate,JJ,O
,-,:,O
,induced,JJ,O
,myoclonus,NN,B-DISEASE
,:,:,O
,which,WDT,O
,is,VBZ,O
,superior,JJ,O
,:,:,O
,Fentanyl,NNP,O
,",",",",O
,midazolam,NN,O
,",",",",O
,or,CC,O
,a,DT,O
,combination,NN,O
,?,.,O
,A,DT,O
,Retrospective,JJ,O
,comparative,NN,O
,study,NN,O
,.,.,O
,BACKGROUND,NNP,O
,:,:,O
,In,IN,O
,this,DT,O
,retrospective,JJ,O
,comparative,NN,O
,study,NN,O
,",",",",O
,we,PRP,O
,aimed,VBD,O
,to,TO,O
,compare,VB,O
,the,DT,O
,effectiveness,NN,O
,of,IN,O
,fentanyl,NN,O
,",",",",O
,midazolam,NN,O
,",",",",O
,and,CC,O
,a,DT,O
,combination,NN,O
,of,IN,O
,fentanyl,NN,O
,and,CC,O
,midazolam,NN,O
,to,TO,O
,prevent,VB,O
,etomidate,JJ,O
,-,:,O
,induced,JJ,O
,myoclonus,NN,B-DISEASE
,.,.,O
,MATERIAL,NNP,O
,AND,CC,O
,METHODS,NNP,O
,:,:,O
,This,DT,O
,study,NN,O
,was,VBD,O
,performed,VBN,O
,based,VBN,O
,on,IN,O
,anesthesia,NN,O
,records,NNS,O
,.,.,O
,Depending,VBG,O
,on,IN,O
,the,DT,O
,drugs,NNS,O
,that,WDT,O
,would,MD,O
,be,VB,O
,given,VBN,O
,before,IN,O
,the,DT,O
,induction,NN,O
,of,IN,O
,anesthesia,NN,O
,with,IN,O
,etomidate,NN,O
,",",",",O
,the,DT,O
,patients,NNS,O
,were,VBD,O
,separated,VBN,O
,into,IN,O
,4,CD,O
,groups,NNS,O
,:,:,O
,no,DT,O
,pretreatment,NN,O
,(,(,O
,Group,NNP,O
,NP,NNP,O
,),),O
,",",",",O
,fentanyl,$,O
,1,CD,O
,ug,NN,O
,.,.,O
,kg,VB,O
,-,:,O
,1,CD,O
,(,(,O
,Group,NNP,O
,F,NNP,O
,),),O
,",",",",O
,midazolam,$,O
,0,CD,O
,.,.,O
,03,CD,O
,mg,NN,O
,.,.,O
,kg,VB,O
,-,:,O
,1,CD,O
,(,(,O
,Group,NNP,O
,M,NNP,O
,),),O
,",",",",O
,and,CC,O
,midazolam,$,O
,0,CD,O
,.,.,O
,015,CD,O
,mg,NN,O
,.,.,O
,kg,VB,O
,-,:,O
,1,CD,O
,+,JJ,O
,fentanyl,NN,O
,0,CD,O
,.,.,O
,5,CD,O
,ug,JJ,O
,.,.,O
,kg,VB,O
,-,:,O
,1,CD,O
,(,(,O
,Group,NNP,O
,FM,NNP,O
,),),O
,.,.,O
,Patients,NNPS,O
,who,WP,O
,received,VBD,O
,the,DT,O
,same,JJ,O
,anesthetic,JJ,O
,procedure,NN,O
,were,VBD,O
,selected,VBN,O
,:,:,O
,2,CD,O
,minutes,NNS,O
,after,IN,O
,intravenous,JJ,O
,injections,NNS,O
,of,IN,O
,the,DT,O
,pretreatment,NN,O
,drugs,NNS,O
,",",",",O
,anesthesia,NN,O
,is,VBZ,O
,induced,VBN,O
,with,IN,O
,0,CD,O
,.,.,O
,3,CD,O
,mg,NN,O
,.,.,O
,kg,VB,O
,-,:,O
,1,CD,O
,etomidate,NN,O
,injected,VBD,O
,intravenously,RB,O
,over,IN,O
,a,DT,O
,period,NN,O
,of,IN,O
,20,CD,O
,-,:,O
,30,CD,O
,seconds,NNS,O
,.,.,O
,Myoclonic,JJ,B-DISEASE
,movements,NNS,I-DISEASE
,are,VBP,O
,evaluated,VBN,O
,",",",",O
,which,WDT,O
,were,VBD,O
,observed,VBN,O
,and,CC,O
,graded,VBN,O
,according,VBG,O
,to,TO,O
,clinical,JJ,O
,severity,NN,O
,during,IN,O
,the,DT,O
,2,CD,O
,minutes,NNS,O
,after,IN,O
,etomidate,JJ,O
,injection,NN,O
,.,.,O
,The,DT,O
,severity,NN,O
,of,IN,O
,pain,NN,B-DISEASE
,due,JJ,O
,to,TO,O
,etomidate,VB,O
,injection,NN,O
,",",",",O
,mean,JJ,O
,arterial,JJ,O
,pressure,NN,O
,",",",",O
,heart,NN,O
,rate,NN,O
,",",",",O
,and,CC,O
,adverse,JJ,O
,effects,NNS,O
,were,VBD,O
,also,RB,O
,evaluated,VBN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Study,NNP,O
,results,NNS,O
,showed,VBD,O
,that,IN,O
,myoclonus,NN,B-DISEASE
,incidence,NN,O
,was,VBD,O
,85,CD,O
,%,NN,O
,",",",",O
,40,CD,O
,%,NN,O
,",",",",O
,70,CD,O
,%,NN,O
,",",",",O
,and,CC,O
,25,CD,O
,%,NN,O
,in,IN,O
,Group,NNP,O
,NP,NNP,O
,",",",",O
,Group,NNP,O
,F,NNP,O
,",",",",O
,Group,NNP,O
,M,NNP,O
,",",",",O
,and,CC,O
,Group,NNP,O
,FM,NNP,O
,",",",",O
,respectively,RB,O
,",",",",O
,and,CC,O
,were,VBD,O
,significantly,RB,O
,lower,JJR,O
,in,IN,O
,Group,NNP,O
,F,NNP,O
,and,CC,O
,Group,NNP,O
,FM,NNP,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,We,PRP,O
,conclude,VBP,O
,that,DT,O
,pretreatment,NN,O
,with,IN,O
,fentanyl,NN,O
,or,CC,O
,combination,NN,O
,of,IN,O
,fentanyl,NN,O
,and,CC,O
,midazolam,NN,O
,was,VBD,O
,effective,JJ,O
,in,IN,O
,preventing,VBG,O
,etomidate,JJ,O
,-,:,O
,induced,JJ,O
,myoclonus,NN,B-DISEASE
,.,.,O
,Convulsant,JJ,O
,effect,NN,O
,of,IN,O
,lindane,NN,O
,and,CC,O
,regional,JJ,O
,brain,NN,O
,concentration,NN,O
,of,IN,O
,GABA,NNP,O
,and,CC,O
,dopamine,NN,O
,.,.,O
,Lindane,NNP,O
,(,(,O
,gamma,SYM,O
,-,:,O
,hexachlorocyclohexane,NN,O
,),),O
,is,VBZ,O
,an,DT,O
,organochlorine,JJ,O
,insecticide,NN,O
,with,IN,O
,known,VBN,O
,neurotoxic,JJ,B-DISEASE
,effects,NNS,O
,.,.,O
,Its,PRP$,O
,mechanism,NN,O
,of,IN,O
,action,NN,O
,is,VBZ,O
,not,RB,O
,well,RB,O
,understood,IN,O
,although,IN,O
,it,PRP,O
,has,VBZ,O
,been,VBN,O
,proposed,VBN,O
,that,IN,O
,lindane,NN,O
,acts,NNS,O
,as,IN,O
,a,DT,O
,non,JJ,O
,-,:,O
,competitive,JJ,O
,antagonist,NN,O
,at,IN,O
,the,DT,O
,gamma,NN,O
,-,:,O
,aminobutyric,JJ,O
,acid,NN,O
,(,(,O
,GABA,NNP,O
,),),O
,-,:,O
,A,DT,O
,receptor,NN,O
,.,.,O
,We,PRP,O
,studied,VBD,O
,the,DT,O
,effect,NN,O
,of,IN,O
,lindane,NN,O
,(,(,O
,150,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,on,IN,O
,the,DT,O
,GABAergic,NNP,O
,and,CC,O
,dopaminergic,JJ,O
,systems,NNS,O
,by,IN,O
,measuring,VBG,O
,the,DT,O
,concentration,NN,O
,of,IN,O
,GABA,NNP,O
,",",",",O
,dopamine,NN,O
,and,CC,O
,its,PRP$,O
,metabolites,NNS,O
,in,IN,O
,7,CD,O
,brain,NN,O
,areas,NNS,O
,at,IN,O
,the,DT,O
,onset,NN,O
,of,IN,O
,seizures,NNS,B-DISEASE
,.,.,O
,All,DT,O
,animals,NNS,O
,suffered,VBD,O
,tonic,JJ,O
,convulsions,NNS,B-DISEASE
,at,IN,O
,18,CD,O
,.,.,O
,3,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,4,CD,O
,min,NN,O
,after,IN,O
,lindane,JJ,O
,administration,NN,O
,.,.,O
,The,DT,O
,concentration,NN,O
,of,IN,O
,GABA,NNP,O
,was,VBD,O
,only,RB,O
,slightly,RB,O
,but,CC,O
,significantly,RB,O
,decreased,VBN,O
,in,IN,O
,the,DT,O
,colliculi,NN,O
,without,IN,O
,modifications,NNS,O
,in,IN,O
,the,DT,O
,other,JJ,O
,areas,NNS,O
,.,.,O
,The,DT,O
,concentration,NN,O
,of,IN,O
,dopamine,NN,O
,was,VBD,O
,increased,VBN,O
,in,IN,O
,the,DT,O
,mesencephalon,NN,O
,and,CC,O
,that,IN,O
,of,IN,O
,its,PRP$,O
,metabolite,JJ,O
,DOPAC,NNP,O
,was,VBD,O
,also,RB,O
,increased,VBN,O
,in,IN,O
,the,DT,O
,mesencephalon,NN,O
,and,CC,O
,the,DT,O
,striatum,NN,O
,.,.,O
,Cholestatic,JJ,B-DISEASE
,presentation,NN,O
,of,IN,O
,yellow,JJ,O
,phosphorus,NN,O
,poisoning,NN,B-DISEASE
,.,.,O
,Yellow,JJ,O
,phosphorus,NN,O
,",",",",O
,a,DT,O
,component,NN,O
,of,IN,O
,certain,JJ,O
,pesticide,NN,O
,pastes,NNS,O
,and,CC,O
,fireworks,NNS,O
,",",",",O
,is,VBZ,O
,well,RB,O
,known,VBN,O
,to,TO,O
,cause,VB,O
,hepatotoxicity,NN,B-DISEASE
,.,.,O
,Poisoning,VBG,B-DISEASE
,with,IN,O
,yellow,JJ,O
,phosphorus,NN,O
,classically,RB,O
,manifests,VBZ,O
,with,IN,O
,acute,NN,B-DISEASE
,hepatitis,NN,I-DISEASE
,leading,VBG,O
,to,TO,O
,acute,VB,B-DISEASE
,liver,NN,I-DISEASE
,failure,NN,I-DISEASE
,which,WDT,O
,may,MD,O
,need,VB,O
,liver,JJR,O
,transplantation,NN,O
,.,.,O
,We,PRP,O
,present,VBD,O
,a,DT,O
,case,NN,O
,of,IN,O
,yellow,JJ,O
,phosphorus,NN,O
,poisoning,NN,B-DISEASE
,in,IN,O
,which,WDT,O
,a,DT,O
,patient,NN,O
,presented,VBN,O
,with,IN,O
,florid,JJ,O
,clinical,JJ,O
,features,NNS,O
,of,IN,O
,cholestasis,NN,B-DISEASE
,highlighting,VBG,O
,the,DT,O
,fact,NN,O
,that,IN,O
,cholestasis,NN,B-DISEASE
,can,MD,O
,rarely,RB,O
,be,VB,O
,a,DT,O
,presenting,JJ,O
,feature,NN,O
,of,IN,O
,yellow,JJ,O
,phosphorus,NN,O
,hepatotoxicity,NN,B-DISEASE
,.,.,O
,Vasovagal,NNP,B-DISEASE
,syncope,NN,I-DISEASE
,and,CC,O
,severe,JJ,O
,bradycardia,NN,B-DISEASE
,following,VBG,O
,intranasal,JJ,O
,dexmedetomidine,NN,O
,for,IN,O
,pediatric,JJ,O
,procedural,JJ,O
,sedation,NN,O
,.,.,O
,We,PRP,O
,report,VBP,O
,syncope,NNS,B-DISEASE
,and,CC,O
,bradycardia,NN,B-DISEASE
,in,IN,O
,an,DT,O
,11,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,girl,NN,O
,following,VBG,O
,administration,NN,O
,of,IN,O
,intranasal,JJ,O
,dexmedetomidine,NN,O
,for,IN,O
,sedation,NN,O
,for,IN,O
,a,DT,O
,voiding,NN,O
,cystourethrogram,NN,O
,.,.,O
,Following,VBG,O
,successful,JJ,O
,completion,NN,O
,of,IN,O
,VCUG,NNP,O
,and,CC,O
,a,DT,O
,60,CD,O
,-,:,O
,min,NN,O
,recovery,NN,O
,period,NN,O
,",",",",O
,the,DT,O
,patient,NN,O
,',POS,O
,s,JJ,O
,level,NN,O
,of,IN,O
,consciousness,NN,O
,and,CC,O
,vital,JJ,O
,signs,NNS,O
,returned,VBD,O
,to,TO,O
,presedation,NN,O
,levels,NNS,O
,.,.,O
,Upon,IN,O
,leaving,VBG,O
,the,DT,O
,sedation,NN,O
,area,NN,O
,",",",",O
,the,DT,O
,patient,NN,O
,collapsed,VBD,O
,",",",",O
,with,IN,O
,no,DT,O
,apparent,JJ,O
,inciting,VBG,O
,event,NN,O
,.,.,O
,The,DT,O
,patient,JJ,O
,quickly,RB,O
,regained,VBD,O
,consciousness,NN,O
,and,CC,O
,no,DT,O
,injury,NN,O
,occurred,VBD,O
,.,.,O
,The,DT,O
,primary,JJ,O
,abnormality,NN,O
,found,VBD,O
,was,VBD,O
,persistent,JJ,O
,bradycardia,NN,B-DISEASE
,",",",",O
,and,CC,O
,she,PRP,O
,was,VBD,O
,admitted,VBN,O
,to,TO,O
,the,DT,O
,hospital,NN,O
,for,IN,O
,telemetric,JJ,O
,observation,NN,O
,.,.,O
,The,DT,O
,bradycardia,NN,B-DISEASE
,lasted,VBD,O
,~,$,O
,2,CD,O
,h,NN,O
,",",",",O
,and,CC,O
,further,RB,O
,cardiac,JJ,O
,workup,NN,O
,revealed,VBD,O
,no,DT,O
,underlying,JJ,O
,abnormality,NN,O
,.,.,O
,Unanticipated,VBN,O
,and,CC,O
,previously,RB,O
,unreported,JJ,O
,outcomes,NNS,O
,may,MD,O
,be,VB,O
,witnessed,VBN,O
,as,IN,O
,we,PRP,O
,expand,VBP,O
,the,DT,O
,use,NN,O
,of,IN,O
,certain,JJ,O
,sedatives,NNS,O
,to,TO,O
,alternative,VB,O
,routes,NNS,O
,of,IN,O
,administration,NN,O
,.,.,O
,Paradoxical,NNP,O
,severe,JJ,O
,agitation,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,add,JJ,O
,-,:,O
,on,IN,O
,high,JJ,O
,-,:,O
,doses,NNS,O
,quetiapine,VBP,O
,in,IN,O
,schizo,JJ,B-DISEASE
,-,:,I-DISEASE
,affective,JJ,I-DISEASE
,disorder,NN,I-DISEASE
,.,.,O
,We,PRP,O
,report,VBP,O
,the,DT,O
,case,NN,O
,of,IN,O
,a,DT,O
,35,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,patient,NN,O
,suffering,VBG,O
,from,IN,O
,schizo,JJ,B-DISEASE
,-,:,I-DISEASE
,affective,JJ,I-DISEASE
,disorder,NN,I-DISEASE
,since,IN,O
,the,DT,O
,age,NN,O
,of,IN,O
,19,CD,O
,years,NNS,O
,",",",",O
,treated,VBN,O
,by,IN,O
,a,DT,O
,combination,NN,O
,of,IN,O
,first,JJ,O
,-,:,O
,generation,NN,O
,antipsychotics,NNS,O
,",",",",O
,zuclopenthixol,NN,O
,(,(,O
,100,CD,O
,mg,NNS,O
,/,JJ,O
,day,NN,O
,),),O
,and,CC,O
,lithium,NN,O
,(,(,O
,1200,CD,O
,mg,NN,O
,/,NNP,O
,day,NN,O
,),),O
,(,(,O
,serum,JJ,O
,lithium,NN,O
,=,VBZ,O
,0,CD,O
,.,.,O
,85,CD,O
,mEq,JJ,O
,/,NNP,O
,l,NN,O
,),),O
,.,.,O
,This,DT,O
,patient,NN,O
,had,VBD,O
,no,DT,O
,associated,VBN,O
,personality,NN,B-DISEASE
,disorder,NN,I-DISEASE
,(,(,O
,particularly,RB,O
,no,DT,O
,antisocial,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,),),O
,and,CC,O
,no,DT,O
,substance,NN,B-DISEASE
,abuse,NN,I-DISEASE
,disorder,NN,I-DISEASE
,.,.,O
,Within,IN,O
,the,DT,O
,48,CD,O
,h,NN,O
,following,VBG,O
,the,DT,O
,gradual,JJ,O
,introduction,NN,O
,of,IN,O
,quetiapine,NN,O
,(,(,O
,up,IN,O
,to,TO,O
,600,CD,O
,mg,NNS,O
,/,JJ,O
,day,NN,O
,),),O
,",",",",O
,the,DT,O
,patient,NN,O
,presented,VBD,O
,severe,JJ,O
,agitation,NN,B-DISEASE
,without,IN,O
,an,DT,O
,environmental,JJ,O
,explanation,NN,O
,",",",",O
,contrasting,VBG,O
,with,IN,O
,the,DT,O
,absence,NN,O
,of,IN,O
,a,DT,O
,history,NN,O
,of,IN,O
,aggressiveness,NN,B-DISEASE
,or,CC,O
,personality,NN,B-DISEASE
,disorder,NN,I-DISEASE
,.,.,O
,The,DT,O
,diagnoses,NNS,O
,of,IN,O
,manic,JJ,B-DISEASE
,shift,NN,O
,and,CC,O
,akathisia,NN,B-DISEASE
,were,VBD,O
,dismissed,VBN,O
,.,.,O
,The,DT,O
,withdrawal,NN,O
,and,CC,O
,the,DT,O
,gradual,JJ,O
,reintroduction,NN,O
,of,IN,O
,quetiapine,JJ,O
,2,CD,O
,weeks,NNS,O
,later,RB,O
,",",",",O
,which,WDT,O
,led,VBD,O
,to,TO,O
,another,DT,O
,severe,JJ,O
,agitation,NN,B-DISEASE
,",",",",O
,enabled,VBD,O
,us,PRP,O
,to,TO,O
,attribute,VB,O
,the,DT,O
,agitation,NN,B-DISEASE
,specifically,RB,O
,to,TO,O
,quetiapine,VB,O
,.,.,O
,Antioxidant,JJ,O
,effects,NNS,O
,of,IN,O
,bovine,NN,O
,lactoferrin,NN,O
,on,IN,O
,dexamethasone,NN,O
,-,:,O
,induced,JJ,O
,hypertension,NN,B-DISEASE
,in,IN,O
,rat,NN,O
,.,.,O
,Dexamethasone,NNP,O
,-,:,O
,(,(,O
,Dex,NNP,O
,-,:,O
,),),O
,induced,JJ,O
,hypertension,NN,B-DISEASE
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,enhanced,JJ,O
,oxidative,JJ,O
,stress,NN,O
,.,.,O
,Lactoferrin,NNP,O
,(,(,O
,LF,NNP,O
,),),O
,is,VBZ,O
,an,DT,O
,iron,NN,O
,-,:,O
,binding,NN,O
,glycoprotein,NN,O
,with,IN,O
,antihypertensive,JJ,O
,properties,NNS,O
,.,.,O
,In,IN,O
,this,DT,O
,study,NN,O
,",",",",O
,we,PRP,O
,investigated,VBD,O
,the,DT,O
,effect,NN,O
,of,IN,O
,chronic,JJ,O
,administration,NN,O
,of,IN,O
,LF,NNP,O
,on,IN,O
,oxidative,JJ,O
,stress,NN,O
,and,CC,O
,hypertension,NN,B-DISEASE
,upon,IN,O
,Dex,NNP,O
,administration,NN,O
,.,.,O
,Male,NNP,O
,Wistar,NNP,O
,rats,NNS,O
,were,VBD,O
,treated,VBN,O
,by,IN,O
,Dex,NNP,O
,(,(,O
,30,CD,O
,u,RB,O
,g,JJ,O
,/,NNP,O
,kg,NN,O
,/,NNP,O
,day,NN,O
,subcutaneously,RB,O
,),),O
,or,CC,O
,saline,NN,O
,for,IN,O
,14,CD,O
,days,NNS,O
,.,.,O
,Oral,JJ,O
,bovine,NN,O
,LF,NNP,O
,(,(,O
,30,CD,O
,",",",",O
,100,CD,O
,",",",",O
,300,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,was,VBD,O
,given,VBN,O
,from,IN,O
,day,NN,O
,8,CD,O
,to,TO,O
,14,CD,O
,in,IN,O
,a,DT,O
,reversal,NN,O
,study,NN,O
,.,.,O
,In,IN,O
,a,DT,O
,prevention,NN,O
,study,NN,O
,",",",",O
,rats,VBZ,O
,received,VBD,O
,4,CD,O
,days,NNS,O
,of,IN,O
,LF,NNP,O
,treatment,NN,O
,followed,VBN,O
,by,IN,O
,Dex,NNP,O
,and,CC,O
,continued,VBD,O
,during,IN,O
,the,DT,O
,test,NN,O
,period,NN,O
,.,.,O
,Systolic,JJ,O
,blood,NN,O
,pressure,NN,O
,(,(,O
,SBP,NNP,O
,),),O
,was,VBD,O
,measured,VBN,O
,using,VBG,O
,tail,NN,O
,-,:,O
,cuff,NN,O
,method,NN,O
,.,.,O
,Thymus,NNP,O
,weight,NN,O
,was,VBD,O
,used,VBN,O
,as,IN,O
,a,DT,O
,marker,NN,O
,of,IN,O
,glucocorticoid,JJ,O
,activity,NN,O
,.,.,O
,Plasma,NNP,O
,hydrogen,NN,O
,peroxide,NN,O
,(,(,O
,H2O2,NNP,O
,),),O
,concentration,NN,O
,and,CC,O
,ferric,JJ,O
,reducing,VBG,O
,antioxidant,JJ,O
,power,NN,O
,(,(,O
,FRAP,NNP,O
,),),O
,value,NN,O
,were,VBD,O
,determined,VBN,O
,.,.,O
,Dexamethasone,NNP,O
,significantly,RB,O
,increased,VBD,O
,SBP,NNP,O
,and,CC,O
,plasma,JJ,O
,H2O2,NNP,O
,level,NN,O
,and,CC,O
,decreased,VBN,O
,thymus,NN,O
,and,CC,O
,body,NN,O
,weights,NNS,O
,.,.,O
,LF,NNP,O
,lowered,VBD,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,and,CC,O
,dose,VB,O
,dependently,RB,O
,prevented,VBN,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,Dex,NNP,O
,-,:,O
,induced,JJ,O
,hypertension,NN,B-DISEASE
,.,.,O
,LF,NNP,O
,prevented,VBD,O
,body,NN,O
,weight,JJ,B-DISEASE
,loss,NN,I-DISEASE
,and,CC,O
,significantly,RB,O
,reduced,VBD,O
,the,DT,O
,elevated,JJ,O
,plasma,NN,O
,H2O2,NNP,O
,and,CC,O
,increased,VBD,O
,FRAP,NNP,O
,values,NNS,O
,.,.,O
,Chronic,NNP,O
,administration,NN,O
,of,IN,O
,LF,NNP,O
,strongly,RB,O
,reduced,VBD,O
,the,DT,O
,blood,NN,O
,pressure,NN,O
,and,CC,O
,production,NN,O
,of,IN,O
,ROS,NNP,O
,and,CC,O
,improved,VBN,O
,antioxidant,JJ,O
,capacity,NN,O
,in,IN,O
,Dex,NNP,O
,-,:,O
,induced,JJ,O
,hypertension,NN,B-DISEASE
,",",",",O
,suggesting,VBG,O
,the,DT,O
,role,NN,O
,of,IN,O
,inhibition,NN,O
,of,IN,O
,oxidative,JJ,O
,stress,NN,O
,as,IN,O
,another,DT,O
,mechanism,NN,O
,of,IN,O
,antihypertensive,JJ,O
,action,NN,O
,of,IN,O
,LF,NNP,O
,.,.,O
,The,DT,O
,association,NN,O
,between,IN,O
,tranexamic,JJ,O
,acid,NN,O
,and,CC,O
,convulsive,JJ,B-DISEASE
,seizures,NNS,B-DISEASE
,after,IN,O
,cardiac,JJ,O
,surgery,NN,O
,:,:,O
,a,DT,O
,multivariate,NN,O
,analysis,NN,O
,in,IN,O
,11,CD,O
,529,CD,O
,patients,NNS,O
,.,.,O
,Because,IN,O
,of,IN,O
,a,DT,O
,lack,NN,O
,of,IN,O
,contemporary,JJ,O
,data,NNS,O
,regarding,VBG,O
,seizures,NNS,B-DISEASE
,after,IN,O
,cardiac,JJ,O
,surgery,NN,O
,",",",",O
,we,PRP,O
,undertook,VBP,O
,a,DT,O
,retrospective,JJ,O
,analysis,NN,O
,of,IN,O
,prospectively,RB,O
,collected,VBN,O
,data,NNS,O
,from,IN,O
,11,CD,O
,529,CD,O
,patients,NNS,O
,in,IN,O
,whom,WP,O
,cardiopulmonary,JJ,O
,bypass,NN,O
,was,VBD,O
,used,VBN,O
,from,IN,O
,January,NNP,O
,2004,CD,O
,to,TO,O
,December,NNP,O
,2010,CD,O
,.,.,O
,A,DT,O
,convulsive,JJ,B-DISEASE
,seizure,NN,B-DISEASE
,was,VBD,O
,defined,VBN,O
,as,IN,O
,a,DT,O
,transient,JJ,O
,episode,NN,O
,of,IN,O
,disturbed,JJ,O
,brain,NN,O
,function,NN,O
,characterised,VBN,O
,by,IN,O
,abnormal,JJ,B-DISEASE
,involuntary,JJ,I-DISEASE
,motor,NN,I-DISEASE
,movements,NNS,I-DISEASE
,.,.,O
,Multivariate,NNP,O
,regression,NN,O
,analysis,NN,O
,was,VBD,O
,performed,VBN,O
,to,TO,O
,identify,VB,O
,independent,JJ,O
,predictors,NNS,O
,of,IN,O
,postoperative,JJ,O
,seizures,NNS,B-DISEASE
,.,.,O
,A,DT,O
,total,NN,O
,of,IN,O
,100,CD,O
,(,(,O
,0,CD,O
,.,.,O
,9,CD,O
,%,NN,O
,),),O
,patients,NNS,O
,developed,VBD,O
,postoperative,JJ,O
,convulsive,JJ,B-DISEASE
,seizures,NNS,B-DISEASE
,.,.,O
,Generalised,VBN,B-DISEASE
,and,CC,I-DISEASE
,focal,JJ,I-DISEASE
,seizures,NNS,I-DISEASE
,were,VBD,O
,identified,VBN,O
,in,IN,O
,68,CD,O
,and,CC,O
,32,CD,O
,patients,NNS,O
,",",",",O
,respectively,RB,O
,.,.,O
,The,DT,O
,median,JJ,O
,(,(,O
,IQR,NNP,O
,[,NNP,O
,range,NN,O
,],NNP,O
,),),O
,time,NN,O
,after,IN,O
,surgery,NN,O
,when,WRB,O
,the,DT,O
,seizure,NN,B-DISEASE
,occurred,VBD,O
,was,VBD,O
,7,CD,O
,(,(,O
,6,CD,O
,-,:,O
,12,CD,O
,[,$,O
,1,CD,O
,-,:,O
,216,CD,O
,],NN,O
,),),O
,h,NN,O
,and,CC,O
,8,CD,O
,(,(,O
,6,CD,O
,-,:,O
,11,CD,O
,[,$,O
,4,CD,O
,-,:,O
,18,CD,O
,],NN,O
,),),O
,h,NN,O
,",",",",O
,respectively,RB,O
,.,.,O
,Epileptiform,NNP,O
,findings,NNS,O
,on,IN,O
,electroencephalography,NN,O
,were,VBD,O
,seen,VBN,O
,in,IN,O
,19,CD,O
,patients,NNS,O
,.,.,O
,Independent,JJ,O
,predictors,NNS,O
,of,IN,O
,postoperative,JJ,O
,seizures,NNS,B-DISEASE
,included,VBD,O
,age,NN,O
,",",",",O
,female,JJ,O
,sex,NN,O
,",",",",O
,redo,JJ,O
,cardiac,NN,O
,surgery,NN,O
,",",",",O
,calcification,NN,O
,of,IN,O
,ascending,VBG,O
,aorta,NN,O
,",",",",O
,congestive,JJ,B-DISEASE
,heart,NN,I-DISEASE
,failure,NN,I-DISEASE
,",",",",O
,deep,JJ,O
,hypothermic,JJ,B-DISEASE
,circulatory,NN,O
,arrest,NN,O
,",",",",O
,duration,NN,O
,of,IN,O
,aortic,JJ,O
,cross,NN,O
,-,:,O
,clamp,NN,O
,and,CC,O
,tranexamic,JJ,O
,acid,NN,O
,.,.,O
,When,WRB,O
,tested,VBN,O
,in,IN,O
,a,DT,O
,multivariate,JJ,O
,regression,NN,O
,analysis,NN,O
,",",",",O
,tranexamic,JJ,O
,acid,NN,O
,was,VBD,O
,a,DT,O
,strong,JJ,O
,independent,JJ,O
,predictor,NN,O
,of,IN,O
,seizures,NNS,B-DISEASE
,(,(,O
,OR,CC,O
,14,CD,O
,.,.,O
,3,CD,O
,",",",",O
,95,CD,O
,%,NN,O
,CI,NNP,O
,5,CD,O
,.,.,O
,5,CD,O
,-,:,O
,36,CD,O
,.,.,O
,7,CD,O
,;,:,O
,p,NN,O
,<,VBZ,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,.,.,O
,Patients,NNS,O
,with,IN,O
,convulsive,JJ,B-DISEASE
,seizures,NNS,B-DISEASE
,had,VBD,O
,2,CD,O
,.,.,O
,5,CD,O
,times,NNS,O
,higher,RBR,O
,in,IN,O
,-,:,O
,hospital,NN,O
,mortality,NN,O
,rates,NNS,O
,and,CC,O
,twice,RB,O
,the,DT,O
,length,NN,O
,of,IN,O
,hospital,NN,O
,stay,NN,O
,compared,VBN,O
,with,IN,O
,patients,NNS,O
,without,IN,O
,convulsive,JJ,B-DISEASE
,seizures,NNS,B-DISEASE
,.,.,O
,Mean,NNP,O
,(,(,O
,IQR,NNP,O
,[,NNP,O
,range,NN,O
,],NNP,O
,),),O
,length,NN,O
,of,IN,O
,stay,NN,O
,in,IN,O
,the,DT,O
,intensive,JJ,O
,care,NN,O
,unit,NN,O
,was,VBD,O
,115,CD,O
,(,(,O
,49,CD,O
,-,:,O
,228,CD,O
,[,$,O
,32,CD,O
,-,:,O
,481,CD,O
,],NN,O
,),),O
,h,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,convulsive,JJ,B-DISEASE
,seizures,NNS,B-DISEASE
,compared,VBN,O
,with,IN,O
,26,CD,O
,(,(,O
,22,CD,O
,-,:,O
,69,CD,O
,[,$,O
,14,CD,O
,-,:,O
,1080,CD,O
,],NN,O
,),),O
,h,NN,O
,in,IN,O
,patients,NNS,O
,without,IN,O
,seizures,NNS,B-DISEASE
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,.,.,O
,Convulsive,JJ,B-DISEASE
,seizures,NNS,B-DISEASE
,are,VBP,O
,a,DT,O
,serious,JJ,O
,postoperative,JJ,B-DISEASE
,complication,NN,I-DISEASE
,after,IN,O
,cardiac,JJ,O
,surgery,NN,O
,.,.,O
,As,IN,O
,tranexamic,JJ,O
,acid,NN,O
,is,VBZ,O
,the,DT,O
,only,JJ,O
,modifiable,JJ,O
,factor,NN,O
,",",",",O
,its,PRP$,O
,administration,NN,O
,",",",",O
,particularly,RB,O
,in,IN,O
,doses,NNS,O
,exceeding,VBG,O
,80,CD,O
,mg,NN,O
,.,.,O
,kg,NN,O
,(,(,O
,-,:,O
,1,CD,O
,),),O
,",",",",O
,should,MD,O
,be,VB,O
,weighed,VBN,O
,against,IN,O
,the,DT,O
,risk,NN,O
,of,IN,O
,postoperative,JJ,O
,seizures,NNS,B-DISEASE
,.,.,O
,Dysfunctional,NNP,B-DISEASE
,overnight,JJ,I-DISEASE
,memory,NN,I-DISEASE
,consolidation,NN,O
,in,IN,O
,ecstasy,JJ,O
,users,NNS,O
,.,.,O
,Sleep,NNP,O
,plays,VBZ,O
,an,DT,O
,important,JJ,O
,role,NN,O
,in,IN,O
,the,DT,O
,consolidation,NN,O
,and,CC,O
,integration,NN,O
,of,IN,O
,memory,NN,O
,in,IN,O
,a,DT,O
,process,NN,O
,called,VBN,O
,overnight,JJ,O
,memory,NN,O
,consolidation,NN,O
,.,.,O
,Previous,JJ,O
,studies,NNS,O
,indicate,VBP,O
,that,IN,O
,ecstasy,NN,O
,users,NNS,O
,have,VBP,O
,marked,VBN,O
,and,CC,O
,persistent,JJ,O
,neurocognitive,JJ,O
,and,CC,O
,sleep,JJ,B-DISEASE
,-,:,I-DISEASE
,related,JJ,I-DISEASE
,impairments,NNS,I-DISEASE
,.,.,O
,We,PRP,O
,extend,VBP,O
,past,JJ,O
,research,NN,O
,by,IN,O
,examining,VBG,O
,overnight,JJ,O
,memory,NN,O
,consolidation,NN,O
,among,IN,O
,regular,JJ,O
,ecstasy,NN,O
,users,NNS,O
,(,(,O
,n,JJ,O
,=,NNP,O
,12,CD,O
,),),O
,and,CC,O
,drug,NN,O
,naive,JJ,O
,healthy,JJ,O
,controls,NNS,O
,(,(,O
,n,JJ,O
,=,NNP,O
,26,CD,O
,),),O
,.,.,O
,Memory,NNP,O
,recall,NN,O
,of,IN,O
,word,NN,O
,pairs,NN,O
,was,VBD,O
,evaluated,VBN,O
,before,IN,O
,and,CC,O
,after,IN,O
,a,DT,O
,period,NN,O
,of,IN,O
,sleep,NN,O
,",",",",O
,with,IN,O
,and,CC,O
,without,IN,O
,interference,NN,O
,prior,RB,O
,to,TO,O
,testing,VBG,O
,.,.,O
,In,IN,O
,addition,NN,O
,",",",",O
,we,PRP,O
,assessed,VBD,O
,neurocognitive,JJ,O
,performances,NNS,O
,across,IN,O
,tasks,NNS,O
,of,IN,O
,learning,NN,O
,",",",",O
,memory,NN,O
,and,CC,O
,executive,NN,O
,functioning,NN,O
,.,.,O
,Ecstasy,NNP,O
,users,NNS,O
,demonstrated,VBD,O
,impaired,JJ,B-DISEASE
,overnight,JJ,I-DISEASE
,memory,NN,I-DISEASE
,consolidation,NN,O
,",",",",O
,a,DT,O
,finding,NN,O
,that,WDT,O
,was,VBD,O
,more,RBR,O
,pronounced,JJ,O
,following,VBG,O
,associative,JJ,O
,interference,NN,O
,.,.,O
,Additionally,RB,O
,",",",",O
,ecstasy,JJ,O
,users,NNS,O
,demonstrated,VBD,O
,impairments,NNS,O
,on,IN,O
,tasks,NNS,O
,recruiting,VBG,O
,frontostriatal,JJ,O
,and,CC,O
,hippocampal,JJ,O
,neural,JJ,O
,circuitry,NN,O
,",",",",O
,in,IN,O
,the,DT,O
,domains,NNS,O
,of,IN,O
,proactive,JJ,O
,interference,NN,O
,memory,NN,O
,",",",",O
,long,JJ,O
,-,:,O
,term,NN,O
,memory,NN,O
,",",",",O
,encoding,VBG,O
,",",",",O
,working,VBG,O
,memory,NN,O
,and,CC,O
,complex,JJ,O
,planning,NN,O
,.,.,O
,We,PRP,O
,suggest,VBP,O
,that,IN,O
,ecstasy,JJ,O
,-,:,O
,associated,VBN,O
,dysfunction,NN,O
,in,IN,O
,fronto,JJ,O
,-,:,O
,temporal,JJ,O
,circuitry,NN,O
,may,MD,O
,underlie,VB,O
,overnight,JJ,O
,consolidation,NN,O
,memory,NN,B-DISEASE
,impairments,NNS,I-DISEASE
,in,IN,O
,regular,JJ,O
,ecstasy,JJ,O
,users,NNS,O
,.,.,O
,Normoammonemic,NNP,O
,encephalopathy,NN,B-DISEASE
,:,:,O
,solely,RB,O
,valproate,VB,O
,induced,JJ,O
,or,CC,O
,multiple,JJ,O
,mechanisms,NNS,O
,?,.,O
,A,DT,O
,77,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,presented,VBN,O
,with,IN,O
,subacute,JJ,O
,onset,NN,O
,progressive,JJ,O
,confusion,NN,B-DISEASE
,",",",",O
,aggression,NN,B-DISEASE
,",",",",O
,auditory,JJ,B-DISEASE
,hallucinations,NNS,I-DISEASE
,and,CC,O
,delusions,NNS,B-DISEASE
,.,.,O
,In,IN,O
,the,DT,O
,preceding,JJ,O
,months,NNS,O
,",",",",O
,the,DT,O
,patient,NN,O
,had,VBD,O
,a,DT,O
,number,NN,O
,of,IN,O
,admissions,NNS,O
,with,IN,O
,transient,JJ,O
,unilateral,JJ,O
,hemiparesis,NN,B-DISEASE
,with,IN,O
,facial,JJ,O
,droop,NN,O
,",",",",O
,and,CC,O
,had,VBD,O
,been,VBN,O
,started,VBN,O
,on,IN,O
,valproate,NN,O
,for,IN,O
,presumed,JJ,O
,hemiplegic,JJ,B-DISEASE
,migraine,NN,I-DISEASE
,.,.,O
,Valproate,NNP,O
,was,VBD,O
,withdrawn,VBN,O
,soon,RB,O
,after,IN,O
,admission,NN,O
,and,CC,O
,her,PRP$,O
,cognitive,JJ,O
,abilities,NNS,O
,have,VBP,O
,gradually,RB,O
,improved,VBN,O
,over,IN,O
,3,CD,O
,months,NNS,O
,of,IN,O
,follow,JJ,O
,-,:,O
,up,RB,O
,.,.,O
,Valproate,NNP,O
,levels,NNS,O
,taken,VBN,O
,prior,RB,O
,to,TO,O
,withdrawal,VB,O
,were,VBD,O
,subtherapeutic,JJ,O
,and,CC,O
,the,DT,O
,patient,NN,O
,was,VBD,O
,normoammonaemic,JJ,O
,.,.,O
,EEG,NNP,O
,undertaken,JJ,O
,during,IN,O
,inpatient,NN,O
,stay,NN,O
,showed,VBD,O
,changes,NNS,O
,consistent,JJ,O
,with,IN,O
,encephalopathy,JJ,B-DISEASE
,",",",",O
,and,CC,O
,low,JJ,O
,titre,NN,O
,N,NNP,O
,-,:,O
,methyl,NN,O
,-,:,O
,D,NNP,O
,-,:,O
,aspartate,NN,O
,(,(,O
,NMDA,NNP,O
,),),O
,receptor,NN,O
,antibodies,NNS,O
,were,VBD,O
,present,JJ,O
,in,IN,O
,this,DT,O
,patient,NN,O
,.,.,O
,The,DT,O
,possible,JJ,O
,aetiologies,NNS,O
,of,IN,O
,valproate,NN,O
,-,:,O
,induced,VBN,O
,encephalopathy,JJ,B-DISEASE
,and,CC,O
,NMDA,NNP,O
,receptor,NN,O
,-,:,O
,associated,VBN,O
,encephalitis,NN,B-DISEASE
,present,NN,O
,a,DT,O
,diagnostic,JJ,O
,dilemma,NN,O
,.,.,O
,We,PRP,O
,present,VBD,O
,a,DT,O
,putative,JJ,O
,combinatorial,JJ,O
,hypothesis,NN,O
,to,TO,O
,explain,VB,O
,this,DT,O
,patient,NN,O
,','',O
,s,NN,O
,symptoms,NNS,O
,.,.,O
,Cerebellar,JJ,B-DISEASE
,and,CC,I-DISEASE
,oculomotor,JJ,I-DISEASE
,dysfunction,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,rapid,JJ,O
,infusion,NN,O
,of,IN,O
,pethidine,NN,O
,.,.,O
,Pethidine,NNP,O
,is,VBZ,O
,an,DT,O
,opioid,NN,O
,that,WDT,O
,gains,NNS,O
,its,PRP$,O
,popularity,NN,O
,for,IN,O
,the,DT,O
,effective,JJ,O
,pain,NN,B-DISEASE
,control,NN,O
,through,IN,O
,acting,VBG,O
,on,IN,O
,the,DT,O
,opioid,JJ,O
,-,:,O
,receptors,NNS,O
,.,.,O
,However,RB,O
,",",",",O
,rapid,JJ,O
,pain,NN,B-DISEASE
,relief,NN,O
,sometimes,RB,O
,brings,VBZ,O
,about,IN,O
,unfavourable,JJ,O
,side,NN,O
,effects,NNS,O
,that,WDT,O
,largely,RB,O
,limit,VBP,O
,its,PRP$,O
,clinical,JJ,O
,utility,NN,O
,.,.,O
,Common,JJ,O
,side,NN,O
,effects,NNS,O
,include,VBP,O
,nausea,NN,B-DISEASE
,",",",",O
,vomiting,VBG,B-DISEASE
,and,CC,O
,hypotension,NN,B-DISEASE
,.,.,O
,In,IN,O
,patients,NNS,O
,with,IN,O
,impaired,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,and,CC,I-DISEASE
,liver,JJ,I-DISEASE
,function,NN,I-DISEASE
,",",",",O
,and,CC,O
,those,DT,O
,who,WP,O
,need,VBP,O
,long,JJ,O
,-,:,O
,term,NN,O
,pain,NN,B-DISEASE
,control,NN,O
,",",",",O
,pethidine,NN,O
,may,MD,O
,cause,VB,O
,excitatory,JJ,O
,central,JJ,O
,nervous,JJ,O
,system,NN,O
,(,(,O
,CNS,NNP,O
,),),O
,effects,NNS,O
,through,IN,O
,its,PRP$,O
,neurotoxic,JJ,B-DISEASE
,metabolite,NN,O
,",",",",O
,norpethidine,NN,O
,",",",",O
,resulting,VBG,O
,in,IN,O
,irritability,NN,B-DISEASE
,and,CC,O
,seizure,NN,B-DISEASE
,attack,NN,O
,.,.,O
,On,IN,O
,the,DT,O
,contrary,JJ,O
,",",",",O
,though,IN,O
,not,RB,O
,clinically,RB,O
,apparent,JJ,O
,",",",",O
,pethidine,VB,O
,potentially,RB,O
,causes,VBZ,O
,inhibitory,JJ,O
,impacts,NNS,O
,on,IN,O
,the,DT,O
,CNS,NNP,O
,and,CC,O
,impairs,VB,O
,normal,JJ,O
,cerebellar,NN,O
,and,CC,O
,oculomotor,NN,O
,function,NN,O
,in,IN,O
,the,DT,O
,short,JJ,O
,term,NN,O
,.,.,O
,In,IN,O
,this,DT,O
,case,NN,O
,report,NN,O
,",",",",O
,we,PRP,O
,highlight,VBD,O
,opioid,RP,O
,','',O
,s,JJ,O
,inhibitory,JJ,O
,side,NN,O
,effects,NNS,O
,on,IN,O
,the,DT,O
,cerebellar,JJ,O
,structure,NN,O
,that,WDT,O
,causes,VBZ,O
,dysmetria,NNS,B-DISEASE
,",",",",O
,dysarthria,NN,B-DISEASE
,",",",",O
,reduced,VBD,O
,smooth,JJ,O
,pursuit,NN,O
,gain,NN,O
,and,CC,O
,decreased,VBD,O
,saccadic,JJ,O
,velocity,NN,O
,.,.,O
,Baboon,NNP,B-DISEASE
,syndrome,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,ketoconazole,NN,O
,.,.,O
,A,DT,O
,27,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,male,JJ,O
,patient,NN,O
,presented,VBN,O
,with,IN,O
,a,DT,O
,maculopapular,JJ,B-DISEASE
,eruption,NN,I-DISEASE
,on,IN,O
,the,DT,O
,flexural,JJ,O
,areas,NNS,O
,and,CC,O
,buttocks,NNS,O
,after,IN,O
,using,VBG,O
,oral,JJ,O
,ketoconazole,NN,O
,.,.,O
,The,DT,O
,patient,NN,O
,was,VBD,O
,diagnosed,VBN,O
,with,IN,O
,drug,NN,O
,-,:,O
,induced,JJ,O
,baboon,NN,B-DISEASE
,syndrome,NN,I-DISEASE
,based,VBN,O
,on,IN,O
,his,PRP$,O
,history,NN,O
,",",",",O
,which,WDT,O
,included,VBD,O
,prior,JJ,O
,sensitivity,NN,O
,to,TO,O
,topical,JJ,O
,ketoconazole,NN,O
,",",",",O
,a,DT,O
,physical,JJ,O
,examination,NN,O
,",",",",O
,and,CC,O
,histopathological,JJ,O
,findings,NNS,O
,.,.,O
,Baboon,NNP,B-DISEASE
,syndrome,NN,I-DISEASE
,is,VBZ,O
,a,DT,O
,drug,NN,O
,-,:,O
,or,CC,O
,contact,VB,O
,allergen,JJ,O
,-,:,O
,related,JJ,O
,maculopapular,JJ,B-DISEASE
,eruption,NN,I-DISEASE
,that,WDT,O
,typically,RB,O
,involves,VBZ,O
,the,DT,O
,flexural,JJ,O
,and,CC,O
,gluteal,JJ,O
,areas,NNS,O
,.,.,O
,To,TO,O
,the,DT,O
,best,JJS,O
,of,IN,O
,our,PRP$,O
,knowledge,NN,O
,",",",",O
,this,DT,O
,is,VBZ,O
,the,DT,O
,first,JJ,O
,reported,VBD,O
,case,NN,O
,of,IN,O
,ketoconazole,JJ,O
,-,:,O
,induced,JJ,O
,baboon,NN,B-DISEASE
,syndrome,NN,I-DISEASE
,in,IN,O
,the,DT,O
,English,JJ,O
,literature,NN,O
,.,.,O
,A,DT,O
,Case,NN,O
,of,IN,O
,Sudden,NNP,B-DISEASE
,Cardiac,NNP,I-DISEASE
,Death,NNP,I-DISEASE
,due,JJ,O
,to,TO,O
,Pilsicainide,NNP,O
,-,:,O
,Induced,NNP,O
,Torsades,NNP,B-DISEASE
,de,IN,I-DISEASE
,Pointes,NNP,I-DISEASE
,.,.,O
,An,DT,O
,84,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,male,NN,O
,received,VBD,O
,oral,JJ,O
,pilsicainide,NN,O
,",",",",O
,a,DT,O
,pure,JJ,O
,sodium,NN,O
,channel,NN,O
,blocker,NN,O
,with,IN,O
,slow,JJ,O
,recovery,NN,O
,kinetics,NNS,O
,",",",",O
,to,TO,O
,convert,VB,O
,his,PRP$,O
,paroxysmal,JJ,O
,atrial,JJ,B-DISEASE
,fibrillation,NN,I-DISEASE
,to,TO,O
,a,DT,O
,sinus,NN,O
,rhythm,NN,O
,;,:,O
,the,DT,O
,patient,NN,O
,developed,VBD,O
,sudden,JJ,B-DISEASE
,cardiac,JJ,I-DISEASE
,death,NN,I-DISEASE
,two,CD,O
,days,NNS,O
,later,RB,O
,.,.,O
,The,DT,O
,Holter,NNP,O
,electrocardiogram,NN,O
,",",",",O
,which,WDT,O
,was,VBD,O
,worn,VBN,O
,by,IN,O
,chance,NN,O
,",",",",O
,revealed,VBD,O
,torsade,NN,B-DISEASE
,de,IN,I-DISEASE
,pointes,NNS,I-DISEASE
,with,IN,O
,gradually,RB,O
,prolonged,VBN,O
,QT,NNP,O
,intervals,NNS,O
,.,.,O
,This,DT,O
,drug,NN,O
,is,VBZ,O
,rapidly,RB,O
,absorbed,VBN,O
,from,IN,O
,the,DT,O
,gastrointestinal,JJ,O
,tract,NN,O
,",",",",O
,and,CC,O
,most,JJS,O
,of,IN,O
,it,PRP,O
,is,VBZ,O
,excreted,VBN,O
,from,IN,O
,the,DT,O
,kidney,NN,O
,.,.,O
,Although,IN,O
,the,DT,O
,patient,NN,O
,',POS,O
,s,JJ,O
,renal,JJ,O
,function,NN,O
,was,VBD,O
,not,RB,O
,highly,RB,O
,impaired,JJ,O
,and,CC,O
,the,DT,O
,dose,NN,O
,of,IN,O
,pilsicainide,NN,O
,was,VBD,O
,low,JJ,O
,",",",",O
,the,DT,O
,plasma,JJ,O
,concentration,NN,O
,of,IN,O
,pilsicainide,NN,O
,may,MD,O
,have,VB,O
,been,VBN,O
,high,JJ,O
,",",",",O
,which,WDT,O
,can,MD,O
,produce,VB,O
,torsades,NNS,B-DISEASE
,de,FW,I-DISEASE
,pointes,NNS,I-DISEASE
,in,IN,O
,the,DT,O
,octogenarian,JJ,O
,.,.,O
,Although,IN,O
,the,DT,O
,oral,JJ,O
,administration,NN,O
,of,IN,O
,class,NN,O
,IC,NNP,O
,drugs,NNS,O
,",",",",O
,including,VBG,O
,pilsicainide,NN,O
,",",",",O
,is,VBZ,O
,effective,JJ,O
,to,TO,O
,terminate,VB,O
,atrial,JJ,B-DISEASE
,fibrillation,NN,I-DISEASE
,",",",",O
,careful,JJ,O
,consideration,NN,O
,must,MD,O
,be,VB,O
,taken,VBN,O
,before,IN,O
,giving,VBG,O
,these,DT,O
,drugs,NNS,O
,to,TO,O
,octogenarians,NNS,O
,.,.,O
,All,DT,O
,-,:,O
,trans,NNS,O
,retinoic,VBP,O
,acid,JJ,O
,-,:,O
,induced,JJ,O
,inflammatory,JJ,O
,myositis,NN,B-DISEASE
,in,IN,O
,a,DT,O
,patient,NN,O
,with,IN,O
,acute,JJ,B-DISEASE
,promyelocytic,JJ,I-DISEASE
,leukemia,NN,I-DISEASE
,.,.,O
,All,DT,O
,-,:,O
,trans,NNS,O
,retinoic,VBP,O
,acid,NN,O
,(,(,O
,ATRA,NNP,O
,),),O
,",",",",O
,a,DT,O
,component,NN,O
,of,IN,O
,standard,JJ,O
,therapy,NN,O
,for,IN,O
,acute,JJ,B-DISEASE
,promyelocytic,JJ,I-DISEASE
,leukemia,NN,I-DISEASE
,(,(,O
,APL,NNP,B-DISEASE
,),),O
,",",",",O
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,potentially,RB,O
,serious,JJ,O
,but,CC,O
,treatable,JJ,O
,adverse,JJ,O
,effects,NNS,O
,involving,VBG,O
,numerous,JJ,O
,organ,JJ,O
,systems,NNS,O
,",",",",O
,including,VBG,O
,rare,JJ,O
,skeletal,JJ,O
,muscle,NN,O
,involvement,NN,O
,.,.,O
,Only,RB,O
,a,DT,O
,handful,NN,O
,of,IN,O
,cases,NNS,O
,of,IN,O
,ATRA,NNP,O
,-,:,O
,induced,VBD,O
,myositis,NN,B-DISEASE
,in,IN,O
,children,NNS,O
,have,VBP,O
,been,VBN,O
,reported,VBN,O
,",",",",O
,and,CC,O
,none,NN,O
,in,IN,O
,the,DT,O
,radiology,NN,O
,literature,NN,O
,.,.,O
,We,PRP,O
,present,VBD,O
,such,PDT,O
,a,DT,O
,case,NN,O
,in,IN,O
,a,DT,O
,15,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,boy,NN,O
,with,IN,O
,APL,NNP,B-DISEASE
,",",",",O
,where,WRB,O
,recognition,NN,O
,of,IN,O
,imaging,VBG,O
,findings,NNS,O
,played,VBD,O
,a,DT,O
,crucial,JJ,O
,role,NN,O
,in,IN,O
,making,VBG,O
,the,DT,O
,diagnosis,NN,O
,and,CC,O
,facilitated,VBD,O
,prompt,NN,O
,",",",",O
,effective,JJ,O
,treatment,NN,O
,.,.,O
,Tolerability,NN,O
,of,IN,O
,lomustine,NN,O
,in,IN,O
,combination,NN,O
,with,IN,O
,cyclophosphamide,NN,O
,in,IN,O
,dogs,NNS,O
,with,IN,O
,lymphoma,NN,B-DISEASE
,.,.,O
,This,DT,O
,retrospective,JJ,O
,study,NN,O
,describes,VBZ,O
,toxicity,NN,B-DISEASE
,associated,VBN,O
,with,IN,O
,a,DT,O
,protocol,NN,O
,of,IN,O
,lomustine,NN,O
,(,(,O
,CCNU,NNP,O
,),),O
,and,CC,O
,cyclophosphamide,NN,O
,(,(,O
,CTX,NNP,O
,),),O
,in,IN,O
,dogs,NNS,O
,with,IN,O
,lymphoma,NN,B-DISEASE
,.,.,O
,CCNU,NNP,O
,was,VBD,O
,administered,VBN,O
,per,IN,O
,os,NN,O
,(,(,O
,PO,NNP,O
,),),O
,at,IN,O
,a,DT,O
,targeted,JJ,O
,dosage,NN,O
,of,IN,O
,60,CD,O
,mg,NNS,O
,/,JJ,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,body,NN,O
,surface,JJ,O
,area,NN,O
,on,IN,O
,day,NN,O
,0,CD,O
,",",",",O
,CTX,NNP,O
,was,VBD,O
,administered,VBN,O
,PO,NNP,O
,at,IN,O
,a,DT,O
,targeted,JJ,O
,dosage,NN,O
,of,IN,O
,250,CD,O
,mg,NNS,O
,/,JJ,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,divided,VBN,O
,over,IN,O
,days,NNS,O
,0,CD,O
,through,IN,O
,4,CD,O
,",",",",O
,and,CC,O
,all,DT,O
,dogs,NNS,O
,received,VBD,O
,prophylactic,JJ,O
,antibiotics,NNS,O
,.,.,O
,Ninety,NN,O
,treatments,NNS,O
,were,VBD,O
,given,VBN,O
,to,TO,O
,the,DT,O
,57,CD,O
,dogs,NNS,O
,included,VBN,O
,in,IN,O
,the,DT,O
,study,NN,O
,.,.,O
,Neutropenia,NNP,B-DISEASE
,was,VBD,O
,the,DT,O
,principal,JJ,O
,toxic,JJ,O
,effect,NN,O
,",",",",O
,and,CC,O
,the,DT,O
,overall,JJ,O
,frequency,NN,O
,of,IN,O
,grade,NN,O
,4,CD,O
,neutropenia,NN,B-DISEASE
,after,IN,O
,the,DT,O
,first,JJ,O
,treatment,NN,O
,of,IN,O
,CCNU,NNP,O
,/,NNP,O
,CTX,NNP,O
,was,VBD,O
,30,CD,O
,%,NN,O
,(,(,O
,95,CD,O
,%,NN,O
,confidence,NN,O
,interval,NN,O
,",",",",O
,19,CD,O
,-,:,O
,43,CD,O
,%,NN,O
,),),O
,.,.,O
,The,DT,O
,mean,JJ,O
,body,NN,O
,weight,NN,O
,of,IN,O
,dogs,NNS,O
,with,IN,O
,grade,JJ,O
,4,CD,O
,neutropenia,NN,B-DISEASE
,(,(,O
,19,CD,O
,.,.,O
,7,CD,O
,kg,NN,O
,+,VBD,O
,13,CD,O
,.,.,O
,4,CD,O
,kg,NN,O
,),),O
,was,VBD,O
,significantly,RB,O
,less,JJR,O
,than,IN,O
,the,DT,O
,mean,JJ,O
,body,NN,O
,weight,NN,O
,of,IN,O
,dogs,NNS,O
,that,WDT,O
,did,VBD,O
,not,RB,O
,develop,VB,O
,grade,JJ,O
,4,CD,O
,neutropenia,NN,B-DISEASE
,(,(,O
,31,CD,O
,.,.,O
,7,CD,O
,kg,NN,O
,+,VBD,O
,12,CD,O
,.,.,O
,4,CD,O
,kg,NN,O
,;,:,O
,P,NNP,O
,=,NNP,O
,.,.,O
,005,CD,O
,),),O
,.,.,O
,One,CD,O
,dog,NN,O
,(,(,O
,3,CD,O
,%,NN,O
,),),O
,developed,VBD,O
,hematologic,JJ,O
,changes,NNS,O
,suggestive,VBP,O
,of,IN,O
,hepatotoxicity,NN,B-DISEASE
,.,.,O
,No,DT,O
,dogs,NNS,O
,had,VBD,O
,evidence,NN,O
,of,IN,O
,either,DT,O
,renal,JJ,B-DISEASE
,toxicity,NN,I-DISEASE
,or,CC,O
,hemorrhagic,JJ,B-DISEASE
,cystitis,NN,I-DISEASE
,.,.,O
,Adverse,JJ,O
,gastrointestinal,JJ,O
,effects,NNS,O
,were,VBD,O
,uncommon,JJ,O
,.,.,O
,On,IN,O
,the,DT,O
,basis,NN,O
,of,IN,O
,the,DT,O
,findings,NNS,O
,reported,VBD,O
,herein,NN,O
,",",",",O
,a,DT,O
,dose,NN,O
,of,IN,O
,60,CD,O
,mg,NNS,O
,/,JJ,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,of,IN,O
,CCNU,NNP,O
,combined,VBD,O
,with,IN,O
,250,CD,O
,mg,NNS,O
,/,JJ,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,of,IN,O
,CTX,NNP,O
,(,(,O
,divided,VBN,O
,over,IN,O
,5,CD,O
,days,NNS,O
,),),O
,q,VBP,O
,4,CD,O
,wk,NN,O
,is,VBZ,O
,tolerable,JJ,O
,in,IN,O
,tumor,NN,B-DISEASE
,-,:,O
,bearing,NN,O
,dogs,NNS,O
,.,.,O
,Nelarabine,NNP,O
,neurotoxicity,NN,B-DISEASE
,with,IN,O
,concurrent,JJ,O
,intrathecal,JJ,O
,chemotherapy,NN,O
,:,:,O
,Case,NNP,O
,report,NN,O
,and,CC,O
,review,NN,O
,of,IN,O
,literature,NN,O
,.,.,O
,Severe,NNP,O
,nelarabine,JJ,O
,neurotoxicity,NN,B-DISEASE
,in,IN,O
,a,DT,O
,patient,NN,O
,who,WP,O
,received,VBD,O
,concurrent,JJ,O
,intrathecal,JJ,O
,(,(,O
,IT,NNP,O
,),),O
,chemotherapy,NN,O
,is,VBZ,O
,reported,VBN,O
,.,.,O
,A,DT,O
,37,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,Caucasian,JJ,O
,woman,NN,O
,with,IN,O
,a,DT,O
,history,NN,O
,of,IN,O
,T,NNP,B-DISEASE
,-,:,I-DISEASE
,cell,NN,I-DISEASE
,lymphoblastic,JJ,I-DISEASE
,lymphoma,NN,I-DISEASE
,was,VBD,O
,admitted,VBN,O
,for,IN,O
,relapsed,JJ,O
,disease,NN,O
,.,.,O
,She,PRP,O
,was,VBD,O
,originally,RB,O
,treated,VBN,O
,with,IN,O
,induction,NN,O
,chemotherapy,NN,O
,followed,VBN,O
,by,IN,O
,an,DT,O
,autologous,JJ,O
,transplant,NN,O
,.,.,O
,She,PRP,O
,developed,VBD,O
,relapsed,JJ,O
,disease,NN,O
,10,CD,O
,months,NNS,O
,later,RB,O
,with,IN,O
,leukemic,JJ,B-DISEASE
,involvement,NN,O
,.,.,O
,She,PRP,O
,was,VBD,O
,re,JJ,O
,-,:,O
,induced,VBN,O
,with,IN,O
,nelarabine,JJ,O
,1500,CD,O
,mg,NN,O
,/,NNP,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,on,IN,O
,days,NNS,O
,1,CD,O
,",",",",O
,3,CD,O
,",",",",O
,and,CC,O
,5,CD,O
,with,IN,O
,1,CD,O
,dose,NN,O
,of,IN,O
,IT,NNP,O
,cytarabine,VBZ,O
,100,CD,O
,mg,NN,O
,on,IN,O
,day,NN,O
,2,CD,O
,as,IN,O
,central,JJ,O
,nervous,JJ,O
,system,NN,O
,(,(,O
,CNS,NNP,O
,),),O
,prophylaxis,NN,O
,.,.,O
,At,IN,O
,the,DT,O
,time,NN,O
,of,IN,O
,treatment,NN,O
,",",",",O
,she,PRP,O
,was,VBD,O
,on,IN,O
,continuous,JJ,O
,renal,JJ,O
,replacement,NN,O
,therapy,NN,O
,due,JJ,O
,to,TO,O
,sequelae,VB,O
,of,IN,O
,tumor,NN,B-DISEASE
,lysis,NN,I-DISEASE
,syndrome,NN,I-DISEASE
,(,(,O
,TLS,NNP,B-DISEASE
,),),O
,.,.,O
,She,PRP,O
,tolerated,VBD,O
,therapy,NN,O
,well,RB,O
,",",",",O
,entered,VBD,O
,a,DT,O
,complete,JJ,O
,remission,NN,O
,",",",",O
,and,CC,O
,recovered,VBD,O
,her,PRP$,O
,renal,JJ,O
,function,NN,O
,.,.,O
,She,PRP,O
,received,VBD,O
,a,DT,O
,second,JJ,O
,cycle,NN,O
,of,IN,O
,nelarabine,NN,O
,without,IN,O
,additional,JJ,O
,IT,NNP,O
,prophylaxis,VBZ,O
,one,CD,O
,month,NN,O
,later,RB,O
,.,.,O
,A,DT,O
,week,NN,O
,after,IN,O
,this,DT,O
,second,JJ,O
,cycle,NN,O
,",",",",O
,she,PRP,O
,noted,VBD,O
,numbness,NN,O
,in,IN,O
,her,PRP$,O
,lower,JJR,O
,extremities,NNS,O
,.,.,O
,Predominantly,RB,O
,sensory,JJ,O
,",",",",O
,though,IN,O
,also,RB,O
,motor,NN,O
,and,CC,O
,autonomic,JJ,O
,",",",",O
,peripheral,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,started,VBD,O
,in,IN,O
,her,PRP$,O
,feet,NNS,O
,",",",",O
,ascended,VBD,O
,proximally,RB,O
,to,TO,O
,the,DT,O
,mid,NN,O
,-,:,O
,thoracic,NN,O
,region,NN,O
,",",",",O
,and,CC,O
,eventually,RB,O
,included,VBD,O
,her,PRP,O
,distal,JJ,O
,upper,JJ,O
,extremities,NNS,O
,.,.,O
,A,NNP,O
,magnetic,JJ,O
,resonance,NN,O
,imaging,NN,O
,(,(,O
,MRI,NNP,O
,),),O
,of,IN,O
,her,PRP$,O
,spine,NN,O
,demonstrated,VBN,O
,changes,NNS,O
,from,IN,O
,C2,NNP,O
,to,TO,O
,C6,NNP,O
,consistent,NN,O
,with,IN,O
,subacute,NN,O
,combined,VBN,O
,degeneration,NN,O
,.,.,O
,Nelarabine,NNP,O
,was,VBD,O
,felt,VBN,O
,to,TO,O
,be,VB,O
,the,DT,O
,cause,NN,O
,of,IN,O
,her,PRP$,O
,symptoms,NNS,O
,.,.,O
,Her,PRP$,O
,neuropathy,JJ,B-DISEASE
,stabilized,VBN,O
,and,CC,O
,showed,VBD,O
,slight,JJ,O
,improvement,NN,O
,and,CC,O
,ultimately,RB,O
,received,VBD,O
,an,DT,O
,unrelated,JJ,O
,",",",",O
,reduced,VBD,O
,-,:,O
,intensity,NN,O
,allogeneic,VBP,O
,transplant,NN,O
,while,IN,O
,in,IN,O
,complete,JJ,O
,remission,NN,O
,",",",",O
,but,CC,O
,relapsed,VBD,O
,disease,RB,O
,10,CD,O
,weeks,NNS,O
,later,RB,O
,.,.,O
,She,PRP,O
,is,VBZ,O
,currently,RB,O
,being,VBG,O
,treated,VBN,O
,with,IN,O
,best,RBS,O
,supportive,JJ,O
,care,NN,O
,.,.,O
,To,TO,O
,our,PRP$,O
,knowledge,NN,O
,",",",",O
,this,DT,O
,is,VBZ,O
,the,DT,O
,first,JJ,O
,published,VBN,O
,case,NN,O
,report,NN,O
,of,IN,O
,severe,JJ,O
,neurotoxicity,NN,B-DISEASE
,caused,VBN,O
,by,IN,O
,nelarabine,NN,O
,in,IN,O
,a,DT,O
,patient,NN,O
,who,WP,O
,received,VBD,O
,concurrent,NN,O
,IT,NNP,O
,chemotherapy,NN,O
,.,.,O
,Valproate,NNP,O
,-,:,O
,induced,JJ,O
,hyperammonemic,JJ,B-DISEASE
,encephalopathy,NN,B-DISEASE
,in,IN,O
,a,DT,O
,renal,JJ,O
,transplanted,JJ,O
,patient,NN,O
,.,.,O
,Neurological,JJ,B-DISEASE
,complications,NNS,I-DISEASE
,after,IN,O
,renal,JJ,O
,transplantation,NN,O
,constitute,NN,O
,an,DT,O
,important,JJ,O
,cause,NN,O
,of,IN,O
,morbidity,NN,O
,and,CC,O
,mortality,NN,O
,.,.,O
,Their,PRP$,O
,differential,JJ,O
,diagnosis,NN,O
,is,VBZ,O
,difficult,JJ,O
,and,CC,O
,essential,JJ,O
,for,IN,O
,subsequent,JJ,O
,patient,NN,O
,',POS,O
,s,JJ,O
,management,NN,O
,.,.,O
,Valproate,NNP,O
,-,:,O
,induced,JJ,O
,hyperammonemic,JJ,B-DISEASE
,encephalopathy,NN,B-DISEASE
,is,VBZ,O
,an,DT,O
,uncommon,JJ,O
,but,CC,O
,serious,JJ,O
,effect,NN,O
,of,IN,O
,valproate,NN,O
,treatment,NN,O
,.,.,O
,Here,RB,O
,",",",",O
,we,PRP,O
,describe,VBP,O
,the,DT,O
,case,NN,O
,of,IN,O
,a,DT,O
,15,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,girl,NN,O
,who,WP,O
,was,VBD,O
,on,IN,O
,a,DT,O
,long,JJ,O
,-,:,O
,term,NN,O
,therapy,NN,O
,with,IN,O
,valproate,NN,O
,due,JJ,O
,to,TO,O
,epilepsy,VB,B-DISEASE
,and,CC,O
,revealed,VB,O
,impaired,JJ,B-DISEASE
,consciousness,NN,I-DISEASE
,with,IN,O
,hyperammonemia,JJ,B-DISEASE
,12,CD,O
,days,NNS,O
,after,IN,O
,renal,JJ,O
,transplantation,NN,O
,.,.,O
,After,IN,O
,withdraw,NN,O
,of,IN,O
,valproate,NN,O
,",",",",O
,patients,NNS,O
,',POS,O
,symptoms,NNS,O
,resolved,VBD,O
,within,IN,O
,24,CD,O
,h,NN,O
,.,.,O
,Clinicians,NNPS,O
,should,MD,O
,increase,VB,O
,their,PRP$,O
,awareness,NN,O
,for,IN,O
,potential,JJ,O
,complication,NN,O
,of,IN,O
,valproate,NN,O
,",",",",O
,especially,RB,O
,in,IN,O
,transplanted,JJ,O
,patients,NNS,O
,.,.,O
,Necrotising,VBG,B-DISEASE
,fasciitis,NN,I-DISEASE
,after,IN,O
,bortezomib,NN,O
,and,CC,O
,dexamethasone,NN,O
,-,:,O
,containing,VBG,O
,regimen,NNS,O
,in,IN,O
,an,DT,O
,elderly,JJ,O
,patient,NN,O
,of,IN,O
,Waldenstrom,NNP,B-DISEASE
,macroglobulinaemia,NN,I-DISEASE
,.,.,O
,Bortezomib,NNP,O
,and,CC,O
,high,JJ,O
,-,:,O
,dose,NN,O
,dexamethasone,NN,O
,-,:,O
,containing,NN,O
,regimens,NNS,O
,are,VBP,O
,considered,VBN,O
,to,TO,O
,be,VB,O
,generally,RB,O
,tolerable,JJ,O
,with,IN,O
,few,JJ,O
,severe,JJ,O
,bacterial,JJ,B-DISEASE
,infections,NNS,I-DISEASE
,in,IN,O
,patients,NNS,O
,with,IN,O
,B,NNP,O
,-,:,O
,cell,NN,O
,malignancies,NNS,B-DISEASE
,.,.,O
,However,RB,O
,",",",",O
,information,NN,O
,is,VBZ,O
,limited,JJ,O
,concerning,VBG,O
,the,DT,O
,safety,NN,O
,of,IN,O
,the,DT,O
,regimen,NNS,O
,in,IN,O
,elderly,JJ,O
,patients,NNS,O
,.,.,O
,We,PRP,O
,report,VBP,O
,a,DT,O
,case,NN,O
,of,IN,O
,a,DT,O
,76,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,man,NN,O
,with,IN,O
,Waldenstrom,NNP,B-DISEASE
,macroglobulinaemia,NN,I-DISEASE
,who,WP,O
,suffered,VBD,O
,necrotising,VBG,B-DISEASE
,fasciitis,NN,I-DISEASE
,without,IN,O
,neutropenia,NN,B-DISEASE
,after,IN,O
,the,DT,O
,combination,NN,O
,treatment,NN,O
,with,IN,O
,bortezomib,NN,O
,",",",",O
,high,JJ,O
,-,:,O
,dose,VB,O
,dexamethasone,NN,O
,and,CC,O
,rituximab,NN,O
,.,.,O
,Despite,IN,O
,immediate,JJ,O
,intravenous,JJ,O
,antimicrobial,JJ,O
,therapy,NN,O
,",",",",O
,he,PRP,O
,succumbed,VBD,O
,23,CD,O
,h,NN,O
,after,IN,O
,the,DT,O
,onset,NN,O
,.,.,O
,Physicians,NNPS,O
,should,MD,O
,recognise,VB,O
,the,DT,O
,possibility,NN,O
,of,IN,O
,fatal,JJ,O
,bacterial,JJ,B-DISEASE
,infections,NNS,I-DISEASE
,related,VBN,O
,to,TO,O
,bortezomib,VB,O
,plus,CC,O
,high,JJ,O
,-,:,O
,dose,NN,O
,dexamethasone,NN,O
,in,IN,O
,elderly,JJ,O
,patients,NNS,O
,",",",",O
,and,CC,O
,we,PRP,O
,believe,VBP,O
,this,DT,O
,case,NN,O
,warrants,NNS,O
,further,JJ,O
,investigation,NN,O
,.,.,O
,An,DT,O
,integrated,JJ,O
,characterization,NN,O
,of,IN,O
,serological,JJ,O
,",",",",O
,pathological,JJ,O
,",",",",O
,and,CC,O
,functional,JJ,O
,events,NNS,O
,in,IN,O
,doxorubicin,JJ,O
,-,:,O
,induced,JJ,O
,cardiotoxicity,NN,B-DISEASE
,.,.,O
,Many,JJ,O
,efficacious,JJ,O
,cancer,NN,B-DISEASE
,treatments,NNS,O
,cause,VBP,O
,significant,JJ,O
,cardiac,JJ,O
,morbidity,NN,O
,",",",",O
,yet,CC,O
,biomarkers,NNS,O
,or,CC,O
,functional,JJ,O
,indices,NNS,O
,of,IN,O
,early,JJ,O
,damage,NN,O
,",",",",O
,which,WDT,O
,would,MD,O
,allow,VB,O
,monitoring,NN,O
,and,CC,O
,intervention,NN,O
,",",",",O
,are,VBP,O
,lacking,VBG,O
,.,.,O
,In,IN,O
,this,DT,O
,study,NN,O
,",",",",O
,we,PRP,O
,have,VBP,O
,utilized,VBN,O
,a,DT,O
,rat,NN,O
,model,NN,O
,of,IN,O
,progressive,JJ,O
,doxorubicin,NN,O
,(,(,O
,DOX,NNP,O
,),),O
,-,:,O
,induced,VBN,O
,cardiomyopathy,NN,B-DISEASE
,",",",",O
,applying,VBG,O
,multiple,JJ,O
,approaches,NNS,O
,",",",",O
,including,VBG,O
,cardiac,JJ,O
,magnetic,JJ,O
,resonance,NN,O
,imaging,NN,O
,(,(,O
,MRI,NNP,O
,),),O
,",",",",O
,to,TO,O
,provide,VB,O
,the,DT,O
,most,RBS,O
,comprehensive,JJ,O
,characterization,NN,O
,to,TO,O
,date,NN,O
,of,IN,O
,the,DT,O
,timecourse,NN,O
,of,IN,O
,serological,JJ,O
,",",",",O
,pathological,JJ,O
,",",",",O
,and,CC,O
,functional,JJ,O
,events,NNS,O
,underlying,VBG,O
,this,DT,O
,toxicity,NN,B-DISEASE
,.,.,O
,Hannover,NNP,O
,Wistar,NNP,O
,rats,NNS,O
,were,VBD,O
,dosed,VBN,O
,with,IN,O
,1,CD,O
,.,.,O
,25,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,DOX,NNP,O
,weekly,NN,O
,for,IN,O
,8,CD,O
,weeks,NNS,O
,followed,VBN,O
,by,IN,O
,a,DT,O
,4,CD,O
,week,NN,O
,off,IN,O
,-,:,O
,dosing,VBG,O
,"""",JJ,O
,recovery,NN,O
,"""",JJ,O
,period,NN,O
,.,.,O
,Electron,NNP,O
,microscopy,NN,O
,of,IN,O
,the,DT,O
,myocardium,NN,O
,revealed,VBD,O
,subcellular,JJ,B-DISEASE
,degeneration,NN,I-DISEASE
,and,CC,O
,marked,VBD,O
,mitochondrial,JJ,O
,changes,NNS,O
,after,IN,O
,a,DT,O
,single,JJ,O
,dose,NN,O
,.,.,O
,Histopathological,JJ,O
,analysis,NN,O
,revealed,VBD,O
,progressive,JJ,O
,cardiomyocyte,NN,B-DISEASE
,degeneration,NN,I-DISEASE
,",",",",O
,hypertrophy,NN,B-DISEASE
,/,NNP,O
,cytomegaly,NN,O
,",",",",O
,and,CC,O
,extensive,JJ,O
,vacuolation,NN,O
,after,IN,O
,two,CD,O
,doses,NNS,O
,.,.,O
,Extensive,JJ,O
,replacement,NN,O
,fibrosis,NN,B-DISEASE
,(,(,O
,quantified,VBN,O
,by,IN,O
,Sirius,NNP,O
,red,JJ,O
,staining,NN,O
,),),O
,developed,VBD,O
,during,IN,O
,the,DT,O
,off,RP,O
,-,:,O
,dosing,NN,O
,period,NN,O
,.,.,O
,Functional,JJ,O
,indices,NNS,O
,assessed,VBN,O
,by,IN,O
,cardiac,JJ,O
,MRI,NNP,O
,(,(,O
,including,VBG,O
,left,VBN,O
,ventricular,JJ,O
,ejection,NN,O
,fraction,NN,O
,(,(,O
,LVEF,NNP,O
,),),O
,",",",",O
,cardiac,JJ,O
,output,NN,O
,",",",",O
,and,CC,O
,E,NNP,O
,/,VBP,O
,A,NNP,O
,ratio,NN,O
,),),O
,declined,VBD,O
,progressively,RB,O
,",",",",O
,reaching,VBG,O
,statistical,JJ,O
,significance,NN,O
,after,IN,O
,two,CD,O
,doses,NNS,O
,and,CC,O
,culminating,VBG,O
,in,IN,O
,"""",NNP,O
,clinical,JJ,O
,"""",NNP,O
,LV,NNP,B-DISEASE
,dysfunction,NN,I-DISEASE
,by,IN,O
,12,CD,O
,weeks,NNS,O
,.,.,O
,Significant,JJ,O
,increases,NNS,O
,in,IN,O
,peak,JJ,O
,myocardial,JJ,O
,contrast,NN,O
,enhancement,NN,O
,and,CC,O
,serological,JJ,O
,cardiac,NN,O
,troponin,NN,O
,I,PRP,O
,(,(,O
,cTnI,NN,O
,),),O
,emerged,VBD,O
,after,IN,O
,eight,CD,O
,doses,NNS,O
,",",",",O
,importantly,RB,O
,preceding,VBG,O
,the,DT,O
,LVEF,NNP,O
,decline,NN,O
,to,TO,O
,<,VB,O
,50,CD,O
,%,NN,O
,.,.,O
,Troponin,NNP,O
,I,PRP,O
,levels,NNS,O
,positively,RB,O
,correlated,VBN,O
,with,IN,O
,delayed,JJ,O
,and,CC,O
,peak,JJ,O
,gadolinium,NN,O
,contrast,NN,O
,enhancement,NN,O
,",",",",O
,histopathological,JJ,O
,grading,NN,O
,",",",",O
,and,CC,O
,diastolic,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,.,.,O
,In,IN,O
,summary,JJ,O
,",",",",O
,subcellular,JJ,O
,cardiomyocyte,NN,B-DISEASE
,degeneration,NN,I-DISEASE
,was,VBD,O
,the,DT,O
,earliest,JJS,O
,marker,NN,O
,",",",",O
,followed,VBN,O
,by,IN,O
,progressive,JJ,O
,functional,JJ,O
,decline,NN,O
,and,CC,O
,histopathological,JJ,O
,manifestations,NNS,O
,.,.,O
,Myocardial,NNP,O
,contrast,NN,O
,enhancement,NN,O
,and,CC,O
,elevations,NNS,O
,in,IN,O
,cTnI,NN,O
,occurred,VBD,O
,later,RB,O
,.,.,O
,However,RB,O
,",",",",O
,all,DT,O
,indices,NNS,O
,predated,VBN,O
,"""",JJ,O
,clinical,JJ,O
,"""",NN,O
,LV,NNP,B-DISEASE
,dysfunction,NN,I-DISEASE
,and,CC,O
,thus,RB,O
,warrant,VB,O
,further,JJ,O
,evaluation,NN,O
,as,IN,O
,predictive,JJ,O
,biomarkers,NNS,O
,.,.,O
,Intradermal,JJ,O
,glutamate,NN,O
,and,CC,O
,capsaicin,JJ,O
,injections,NNS,O
,:,:,O
,intra,JJ,O
,-,:,O
,and,CC,O
,interindividual,JJ,O
,variability,NN,O
,of,IN,O
,provoked,JJ,O
,hyperalgesia,NN,B-DISEASE
,and,CC,O
,allodynia,NN,B-DISEASE
,.,.,O
,Intradermal,JJ,O
,injections,NNS,O
,of,IN,O
,glutamate,NN,O
,and,CC,O
,capsaicin,NN,O
,are,VBP,O
,attractive,JJ,O
,to,TO,O
,use,VB,O
,in,IN,O
,human,JJ,O
,experimental,JJ,O
,pain,NN,B-DISEASE
,models,NNS,O
,because,IN,O
,hyperalgesia,NN,B-DISEASE
,and,CC,O
,allodynia,JJ,B-DISEASE
,mimic,NN,O
,isolated,JJ,O
,aspects,NNS,O
,of,IN,O
,clinical,JJ,O
,pain,NN,B-DISEASE
,disorders,NNS,I-DISEASE
,.,.,O
,The,DT,O
,aim,NN,O
,of,IN,O
,the,DT,O
,present,JJ,O
,study,NN,O
,was,VBD,O
,to,TO,O
,investigate,VB,O
,the,DT,O
,reproducibility,NN,O
,of,IN,O
,these,DT,O
,models,NNS,O
,.,.,O
,Twenty,NNP,O
,healthy,JJ,O
,male,NN,O
,volunteers,NNS,O
,(,(,O
,mean,JJ,O
,age,NN,O
,24,CD,O
,years,NNS,O
,;,:,O
,range,VB,O
,18,CD,O
,-,:,O
,38,CD,O
,years,NNS,O
,),),O
,received,VBD,O
,intradermal,JJ,O
,injections,NNS,O
,of,IN,O
,glutamate,NN,O
,and,CC,O
,capsaicin,NN,O
,in,IN,O
,the,DT,O
,volar,JJ,O
,forearm,NN,O
,.,.,O
,Magnitudes,NNP,O
,of,IN,O
,secondary,JJ,O
,pinprick,NN,O
,hyperalgesia,NN,B-DISEASE
,and,CC,O
,brush,NN,O
,-,:,O
,evoked,VBN,O
,allodynia,NN,B-DISEASE
,were,VBD,O
,investigated,VBN,O
,using,VBG,O
,von,JJ,O
,Frey,NNP,O
,filaments,NNS,O
,(,(,O
,gauges,NNS,O
,10,CD,O
,",",",",O
,15,CD,O
,",",",",O
,60,CD,O
,and,CC,O
,100,CD,O
,g,NN,O
,),),O
,and,CC,O
,brush,JJ,O
,strokes,NNS,O
,.,.,O
,Areas,NNP,O
,of,IN,O
,secondary,JJ,B-DISEASE
,hyperalgesia,NN,I-DISEASE
,and,CC,O
,allodynia,NN,B-DISEASE
,were,VBD,O
,quantified,VBN,O
,immediately,RB,O
,after,IN,O
,injection,NN,O
,and,CC,O
,after,IN,O
,15,CD,O
,",",",",O
,30,CD,O
,and,CC,O
,60,CD,O
,min,NNS,O
,.,.,O
,Two,CD,O
,identical,JJ,O
,experiments,NNS,O
,separated,VBN,O
,by,IN,O
,at,IN,O
,least,JJS,O
,7,CD,O
,days,NNS,O
,were,VBD,O
,performed,VBN,O
,.,.,O
,Reproducibility,NNP,O
,across,IN,O
,and,CC,O
,within,IN,O
,volunteers,NNS,O
,(,(,O
,inter,JJ,O
,-,:,O
,and,CC,O
,intra,JJ,O
,-,:,O
,individual,JJ,O
,variation,NN,O
,",",",",O
,respectively,RB,O
,),),O
,was,VBD,O
,assessed,VBN,O
,using,VBG,O
,intraclass,NN,O
,correlation,NN,O
,coefficient,NN,O
,(,(,O
,ICC,NNP,O
,),),O
,and,CC,O
,coefficient,NN,O
,of,IN,O
,variation,NN,O
,(,(,O
,CV,NNP,O
,),),O
,.,.,O
,Secondary,JJ,O
,pinprick,NN,O
,hyperalgesia,NN,B-DISEASE
,was,VBD,O
,observed,VBN,O
,as,IN,O
,a,DT,O
,marked,JJ,O
,increase,NN,O
,in,IN,O
,the,DT,O
,visual,JJ,O
,analogue,NN,O
,scale,NN,O
,(,(,O
,VAS,NNP,O
,),),O
,response,NN,O
,to,TO,O
,von,VB,O
,Frey,NNP,O
,gauges,NNS,O
,60,CD,O
,and,CC,O
,100,CD,O
,g,NN,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,after,IN,O
,glutamate,NN,O
,injection,NN,O
,.,.,O
,For,IN,O
,capsaicin,NN,O
,",",",",O
,secondary,JJ,O
,pinprick,NN,O
,hyperalgesia,NN,B-DISEASE
,was,VBD,O
,detected,VBN,O
,with,IN,O
,all,DT,O
,von,NNS,O
,Frey,NNP,O
,gauges,NNS,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,.,.,O
,Glutamate,NNP,O
,evoked,VBD,O
,reproducible,JJ,O
,VAS,NNP,O
,response,NN,O
,to,TO,O
,all,DT,O
,von,NNP,O
,Frey,NNP,O
,gauges,NNS,O
,(,(,O
,ICC,NNP,O
,>,VBZ,O
,0,CD,O
,.,.,O
,60,CD,O
,),),O
,and,CC,O
,brush,JJ,O
,strokes,NNS,O
,(,(,O
,ICC,NNP,O
,>,VBZ,O
,0,CD,O
,.,.,O
,83,CD,O
,),),O
,.,.,O
,Capsaicin,NNP,O
,injection,NN,O
,was,VBD,O
,reproducible,JJ,O
,for,IN,O
,secondary,JJ,B-DISEASE
,hyperalgesia,NN,I-DISEASE
,(,(,O
,ICC,NNP,O
,>,VBZ,O
,0,CD,O
,.,.,O
,70,CD,O
,),),O
,and,CC,O
,allodynia,NN,B-DISEASE
,(,(,O
,ICC,NNP,O
,>,VBZ,O
,0,CD,O
,.,.,O
,71,CD,O
,),),O
,.,.,O
,Intra,NNP,O
,-,:,O
,individual,JJ,O
,variability,NN,O
,was,VBD,O
,generally,RB,O
,lower,JJR,O
,for,IN,O
,the,DT,O
,VAS,NNP,O
,response,NN,O
,to,TO,O
,von,VB,O
,Frey,NNP,O
,and,CC,O
,brush,NN,O
,compared,VBN,O
,with,IN,O
,areas,NNS,O
,of,IN,O
,secondary,JJ,B-DISEASE
,hyperalgesia,NN,I-DISEASE
,and,CC,O
,allodynia,NN,B-DISEASE
,.,.,O
,In,IN,O
,conclusion,NN,O
,",",",",O
,glutamate,NN,O
,and,CC,O
,capsaicin,JJ,O
,yield,NN,O
,reproducible,JJ,O
,hyperalgesic,JJ,B-DISEASE
,and,CC,O
,allodynic,JJ,B-DISEASE
,responses,NNS,O
,",",",",O
,and,CC,O
,the,DT,O
,present,JJ,O
,model,NN,O
,is,VBZ,O
,well,RB,O
,suited,VBN,O
,for,IN,O
,basic,JJ,O
,research,NN,O
,",",",",O
,as,RB,O
,well,RB,O
,as,IN,O
,for,IN,O
,assessing,VBG,O
,the,DT,O
,modulation,NN,O
,of,IN,O
,central,JJ,O
,phenomena,NNS,O
,.,.,O
,Ocular,NNP,O
,-,:,O
,specific,JJ,O
,ER,NNP,O
,stress,NN,O
,reduction,NN,O
,rescues,NNS,O
,glaucoma,VBP,B-DISEASE
,in,IN,O
,murine,NN,O
,glucocorticoid,NN,O
,-,:,O
,induced,JJ,O
,glaucoma,NN,B-DISEASE
,.,.,O
,Administration,NNP,O
,of,IN,O
,glucocorticoids,NNS,O
,induces,NNS,O
,ocular,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,in,IN,O
,some,DT,O
,patients,NNS,O
,.,.,O
,If,IN,O
,untreated,JJ,O
,",",",",O
,these,DT,O
,patients,NNS,O
,can,MD,O
,develop,VB,O
,a,DT,O
,secondary,JJ,O
,glaucoma,NN,B-DISEASE
,that,WDT,O
,resembles,VBZ,O
,primary,JJ,B-DISEASE
,open,JJ,I-DISEASE
,-,:,I-DISEASE
,angle,NN,I-DISEASE
,glaucoma,NN,I-DISEASE
,(,(,O
,POAG,NNP,B-DISEASE
,),),O
,.,.,O
,The,DT,O
,underlying,VBG,O
,pathology,NN,O
,of,IN,O
,glucocorticoid,JJ,O
,-,:,O
,induced,JJ,O
,glaucoma,NN,B-DISEASE
,is,VBZ,O
,not,RB,O
,fully,RB,O
,understood,JJ,O
,",",",",O
,due,JJ,O
,in,IN,O
,part,NN,O
,to,TO,O
,lack,NN,O
,of,IN,O
,an,DT,O
,appropriate,JJ,O
,animal,NN,O
,model,NN,O
,.,.,O
,Here,RB,O
,",",",",O
,we,PRP,O
,developed,VBD,O
,a,DT,O
,murine,JJ,O
,model,NN,O
,of,IN,O
,glucocorticoid,JJ,O
,-,:,O
,induced,JJ,O
,glaucoma,NN,B-DISEASE
,that,IN,O
,exhibits,VBZ,O
,glaucoma,NN,B-DISEASE
,features,NNS,O
,that,WDT,O
,are,VBP,O
,observed,VBN,O
,in,IN,O
,patients,NNS,O
,.,.,O
,Treatment,NNP,O
,of,IN,O
,WT,NNP,O
,mice,NN,O
,with,IN,O
,topical,JJ,O
,ocular,JJ,O
,0,CD,O
,.,.,O
,1,CD,O
,%,NN,O
,dexamethasone,NN,O
,led,VBD,O
,to,TO,O
,elevation,NN,O
,of,IN,O
,intraocular,JJ,O
,pressure,NN,O
,(,(,O
,IOP,NNP,O
,),),O
,",",",",O
,functional,JJ,O
,and,CC,O
,structural,JJ,O
,loss,NN,O
,of,IN,O
,retinal,JJ,B-DISEASE
,ganglion,NN,I-DISEASE
,cells,NNS,O
,",",",",O
,and,CC,O
,axonal,JJ,B-DISEASE
,degeneration,NN,I-DISEASE
,",",",",O
,resembling,VBG,O
,glucocorticoid,JJ,O
,-,:,O
,induced,JJ,O
,glaucoma,NN,B-DISEASE
,in,IN,O
,human,JJ,O
,patients,NNS,O
,.,.,O
,Furthermore,NNP,O
,",",",",O
,dexamethasone,NN,O
,-,:,O
,induced,JJ,O
,ocular,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,was,VBD,O
,associated,VBN,O
,with,IN,O
,chronic,JJ,O
,ER,NNP,O
,stress,NN,O
,of,IN,O
,the,DT,O
,trabecular,JJ,O
,meshwork,NN,O
,(,(,O
,TM,NNP,O
,),),O
,.,.,O
,Similar,JJ,O
,to,TO,O
,patients,NNS,O
,",",",",O
,withdrawal,NN,O
,of,IN,O
,dexamethasone,NN,O
,treatment,NN,O
,reduced,VBD,O
,elevated,JJ,O
,IOP,NNP,O
,and,CC,O
,ER,NNP,O
,stress,NN,O
,in,IN,O
,this,DT,O
,animal,JJ,O
,model,NN,O
,.,.,O
,Dexamethasone,NNP,O
,induced,VBD,O
,the,DT,O
,transcriptional,JJ,O
,factor,NN,O
,CHOP,NNP,O
,",",",",O
,a,DT,O
,marker,NN,O
,for,IN,O
,chronic,JJ,O
,ER,NNP,O
,stress,NN,O
,",",",",O
,in,IN,O
,the,DT,O
,anterior,JJ,O
,segment,NN,O
,tissues,NNS,O
,",",",",O
,and,CC,O
,Chop,NNP,O
,deletion,NN,O
,reduced,VBD,O
,ER,NNP,O
,stress,NN,O
,in,IN,O
,these,DT,O
,tissues,NNS,O
,and,CC,O
,prevented,VBD,O
,dexamethasone,NN,O
,-,:,O
,induced,JJ,O
,ocular,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,.,.,O
,Furthermore,NNP,O
,",",",",O
,reduction,NN,O
,of,IN,O
,ER,NNP,O
,stress,NN,O
,in,IN,O
,the,DT,O
,TM,NNP,O
,with,IN,O
,sodium,NN,O
,4,CD,O
,-,:,O
,phenylbutyrate,NN,O
,prevented,VBD,O
,dexamethasone,NN,O
,-,:,O
,induced,JJ,O
,ocular,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,in,IN,O
,WT,NNP,O
,mice,NN,O
,.,.,O
,Our,PRP$,O
,data,NNS,O
,indicate,VBP,O
,that,IN,O
,ER,NNP,O
,stress,NN,O
,contributes,NNS,O
,to,TO,O
,glucocorticoid,VB,O
,-,:,O
,induced,JJ,O
,ocular,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,and,CC,O
,suggest,VBP,O
,that,IN,O
,reducing,VBG,O
,ER,NNP,O
,stress,NN,O
,has,VBZ,O
,potential,VBN,O
,as,IN,O
,a,DT,O
,therapeutic,JJ,O
,strategy,NN,O
,for,IN,O
,treating,VBG,O
,glucocorticoid,JJ,O
,-,:,O
,induced,JJ,O
,glaucoma,NN,B-DISEASE
,.,.,O
,Effects,NNS,O
,of,IN,O
,ginsenosides,NNS,O
,on,IN,O
,opioid,JJ,O
,-,:,O
,induced,JJ,O
,hyperalgesia,NN,B-DISEASE
,in,IN,O
,mice,NN,O
,.,.,O
,Opioid,NNP,O
,-,:,O
,induced,JJ,O
,hyperalgesia,NN,B-DISEASE
,(,(,O
,OIH,NNP,B-DISEASE
,),),O
,is,VBZ,O
,characterized,VBN,O
,by,IN,O
,nociceptive,JJ,O
,sensitization,NN,O
,caused,VBN,O
,by,IN,O
,the,DT,O
,cessation,NN,O
,of,IN,O
,chronic,JJ,O
,opioid,NN,O
,use,NN,O
,.,.,O
,OIH,CC,B-DISEASE
,can,MD,O
,limit,VB,O
,the,DT,O
,clinical,JJ,O
,use,NN,O
,of,IN,O
,opioid,JJ,O
,analgesics,NNS,O
,and,CC,O
,complicate,NN,O
,withdrawal,NN,O
,from,IN,O
,opioid,JJ,B-DISEASE
,addiction,NN,I-DISEASE
,.,.,O
,In,IN,O
,this,DT,O
,study,NN,O
,",",",",O
,we,PRP,O
,investigated,VBD,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,Re,NNP,O
,",",",",O
,Rg1,NNP,O
,",",",",O
,and,CC,O
,Rb1,NNP,O
,ginsenosides,NNS,O
,",",",",O
,the,DT,O
,bioactive,JJ,O
,components,NNS,O
,of,IN,O
,ginseng,NN,O
,",",",",O
,on,IN,O
,OIH,NNP,B-DISEASE
,.,.,O
,OIH,NNP,B-DISEASE
,was,VBD,O
,achieved,VBN,O
,in,IN,O
,mice,NN,O
,after,IN,O
,subcutaneous,JJ,O
,administration,NN,O
,of,IN,O
,morphine,NN,O
,for,IN,O
,7,CD,O
,consecutive,JJ,O
,days,NNS,O
,three,CD,O
,times,NNS,O
,per,IN,O
,day,NN,O
,.,.,O
,During,IN,O
,withdrawal,NN,O
,(,(,O
,days,NNS,O
,8,CD,O
,and,CC,O
,9,CD,O
,),),O
,",",",",O
,these,DT,O
,mice,NNS,O
,were,VBD,O
,administered,VBN,O
,Re,NNP,O
,",",",",O
,Rg1,NNP,O
,",",",",O
,or,CC,O
,Rb1,NNP,O
,intragastrically,RB,O
,two,CD,O
,times,NNS,O
,per,IN,O
,day,NN,O
,.,.,O
,On,IN,O
,the,DT,O
,test,NN,O
,day,NN,O
,(,(,O
,day,NN,O
,10,CD,O
,),),O
,",",",",O
,mice,NNS,O
,were,VBD,O
,subjected,VBN,O
,to,TO,O
,the,DT,O
,thermal,JJ,O
,sensitivity,NN,O
,test,NN,O
,and,CC,O
,the,DT,O
,acetic,JJ,O
,acid,NN,O
,-,:,O
,induced,JJ,O
,writhing,JJ,O
,test,NN,O
,.,.,O
,Re,NNP,O
,(,(,O
,300,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,inhibited,VBD,O
,OIH,NNP,B-DISEASE
,in,IN,O
,both,CC,O
,the,DT,O
,thermal,JJ,O
,sensitivity,NN,O
,test,NN,O
,and,CC,O
,the,DT,O
,acetic,JJ,O
,acid,NN,O
,-,:,O
,induced,JJ,O
,writhing,JJ,O
,test,NN,O
,.,.,O
,However,RB,O
,",",",",O
,the,DT,O
,Rg1,NNP,O
,and,CC,O
,Rb1,NNP,O
,ginsenosides,NNS,O
,failed,VBD,O
,to,TO,O
,prevent,VB,O
,OIH,NNP,B-DISEASE
,in,IN,O
,either,DT,O
,test,NN,O
,.,.,O
,Furthermore,RB,O
,",",",",O
,Rg1,NNP,O
,showed,VBD,O
,a,DT,O
,tendency,NN,O
,to,TO,O
,aggravate,VB,O
,OIH,NNP,B-DISEASE
,in,IN,O
,the,DT,O
,acetic,JJ,O
,acid,NN,O
,-,:,O
,induced,JJ,O
,writhing,JJ,O
,test,NN,O
,.,.,O
,Our,PRP$,O
,data,NNS,O
,suggested,VBD,O
,that,IN,O
,the,DT,O
,ginsenoside,NN,O
,Re,NNP,O
,",",",",O
,but,CC,O
,not,RB,O
,Rg1,NNP,O
,or,CC,O
,Rb1,NNP,O
,",",",",O
,may,MD,O
,contribute,VB,O
,toward,IN,O
,reversal,NN,O
,of,IN,O
,OIH,NNP,B-DISEASE
,.,.,O
,A,NNP,O
,comparison,NN,O
,of,IN,O
,severe,JJ,O
,hemodynamic,JJ,O
,disturbances,NNS,O
,between,IN,O
,dexmedetomidine,NN,O
,and,CC,O
,propofol,NN,O
,for,IN,O
,sedation,NN,O
,in,IN,O
,neurocritical,JJ,O
,care,NN,O
,patients,NNS,O
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,Dexmedetomidine,NN,O
,and,CC,O
,propofol,NN,O
,are,VBP,O
,commonly,RB,O
,used,VBN,O
,sedatives,NNS,O
,in,IN,O
,neurocritical,JJ,O
,care,NN,O
,as,IN,O
,they,PRP,O
,allow,VBP,O
,for,IN,O
,frequent,JJ,O
,neurologic,JJ,O
,examinations,NNS,O
,.,.,O
,However,RB,O
,",",",",O
,both,DT,O
,agents,NNS,O
,are,VBP,O
,associated,VBN,O
,with,IN,O
,significant,JJ,O
,hemodynamic,JJ,O
,side,NN,O
,effects,NNS,O
,.,.,O
,The,DT,O
,primary,JJ,O
,objective,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,is,VBZ,O
,to,TO,O
,compare,VB,O
,the,DT,O
,prevalence,NN,O
,of,IN,O
,severe,JJ,O
,hemodynamic,JJ,O
,effects,NNS,O
,in,IN,O
,neurocritical,JJ,O
,care,NN,O
,patients,NNS,O
,receiving,VBG,O
,dexmedetomidine,NN,O
,and,CC,O
,propofol,NN,O
,.,.,O
,DESIGN,NN,O
,:,:,O
,Multicenter,NN,O
,",",",",O
,retrospective,JJ,O
,",",",",O
,propensity,NN,O
,-,:,O
,matched,VBN,O
,cohort,NN,O
,study,NN,O
,.,.,O
,SETTING,NN,O
,:,:,O
,Neurocritical,NNP,O
,care,VB,O
,units,NNS,O
,at,IN,O
,two,CD,O
,academic,JJ,O
,medical,JJ,O
,centers,NNS,O
,with,IN,O
,dedicated,JJ,O
,neurocritical,JJ,O
,care,NN,O
,teams,NNS,O
,and,CC,O
,board,NN,O
,-,:,O
,certified,VBN,O
,neurointensivists,NNS,O
,.,.,O
,PATIENTS,NNS,O
,:,:,O
,Neurocritical,NNP,O
,care,NN,O
,patients,NNS,O
,admitted,VBD,O
,between,IN,O
,July,NNP,O
,2009,CD,O
,and,CC,O
,September,NNP,O
,2012,CD,O
,were,VBD,O
,evaluated,VBN,O
,and,CC,O
,then,RB,O
,matched,VBD,O
,1,CD,O
,:,:,O
,1,CD,O
,based,VBN,O
,on,IN,O
,propensity,NN,O
,scoring,NN,O
,of,IN,O
,baseline,NN,O
,characteristics,NNS,O
,.,.,O
,INTERVENTIONS,NN,O
,:,:,O
,Continuous,JJ,O
,sedation,NN,O
,with,IN,O
,dexmedetomidine,NN,O
,or,CC,O
,propofol,NN,O
,.,.,O
,MEASUREMENTS,NNP,O
,AND,CC,O
,MAIN,NNP,O
,RESULTS,NNP,O
,:,:,O
,A,DT,O
,total,NN,O
,of,IN,O
,342,CD,O
,patients,NNS,O
,(,(,O
,105,CD,O
,dexmedetomidine,NN,O
,and,CC,O
,237,CD,O
,propofol,NN,O
,),),O
,were,VBD,O
,included,VBN,O
,in,IN,O
,the,DT,O
,analysis,NN,O
,",",",",O
,with,IN,O
,190,CD,O
,matched,NNS,O
,(,(,O
,95,CD,O
,in,IN,O
,each,DT,O
,group,NN,O
,),),O
,by,IN,O
,propensity,NN,O
,score,NN,O
,.,.,O
,The,DT,O
,primary,JJ,O
,outcome,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,was,VBD,O
,a,DT,O
,composite,NN,O
,of,IN,O
,severe,JJ,O
,hypotension,NN,B-DISEASE
,(,(,O
,mean,JJ,O
,arterial,JJ,O
,pressure,NN,O
,<,VBZ,O
,60,CD,O
,mm,NN,O
,Hg,NNP,O
,),),O
,and,CC,O
,bradycardia,$,B-DISEASE
,(,(,O
,heart,NN,O
,rate,NN,O
,<,VBD,O
,50,CD,O
,beats,NNS,O
,/,VBP,O
,min,NN,O
,),),O
,during,IN,O
,sedative,JJ,O
,infusion,NN,O
,.,.,O
,No,DT,O
,difference,NN,O
,in,IN,O
,the,DT,O
,primary,JJ,O
,composite,JJ,O
,outcome,NN,O
,in,IN,O
,both,CC,O
,the,DT,O
,unmatched,JJ,O
,(,(,O
,30,CD,O
,%,NN,O
,vs,JJ,O
,30,CD,O
,%,NN,O
,",",",",O
,p,NN,O
,=,VBD,O
,0,CD,O
,.,.,O
,94,CD,O
,),),O
,or,CC,O
,matched,VBN,O
,cohorts,NNS,O
,(,(,O
,28,CD,O
,%,NN,O
,vs,JJ,O
,34,CD,O
,%,NN,O
,",",",",O
,p,NN,O
,=,VBD,O
,0,CD,O
,.,.,O
,35,CD,O
,),),O
,could,MD,O
,be,VB,O
,found,VBN,O
,.,.,O
,When,WRB,O
,analyzed,JJ,O
,separately,RB,O
,",",",",O
,no,DT,O
,differences,NNS,O
,could,MD,O
,be,VB,O
,found,VBN,O
,in,IN,O
,the,DT,O
,prevalence,NN,O
,of,IN,O
,severe,JJ,O
,hypotension,NN,B-DISEASE
,or,CC,O
,bradycardia,NN,B-DISEASE
,in,IN,O
,either,CC,O
,the,DT,O
,unmatched,JJ,O
,or,CC,O
,matched,VBN,O
,cohorts,NNS,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Severe,JJ,O
,hypotension,NN,B-DISEASE
,and,CC,O
,bradycardia,NN,B-DISEASE
,occur,NN,O
,at,IN,O
,similar,JJ,O
,prevalence,NN,O
,in,IN,O
,neurocritical,JJ,O
,care,NN,O
,patients,NNS,O
,who,WP,O
,receive,VBP,O
,dexmedetomidine,NN,O
,or,CC,O
,propofol,NN,O
,.,.,O
,Providers,NNS,O
,should,MD,O
,similarly,RB,O
,consider,VB,O
,the,DT,O
,likelihood,NN,O
,of,IN,O
,hypotension,NN,B-DISEASE
,or,CC,O
,bradycardia,NN,B-DISEASE
,before,IN,O
,starting,VBG,O
,either,DT,O
,sedative,JJ,O
,.,.,O
,Hydroxytyrosol,NNP,O
,ameliorates,VBZ,O
,oxidative,JJ,O
,stress,NN,O
,and,CC,O
,mitochondrial,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,in,IN,O
,doxorubicin,JJ,O
,-,:,O
,induced,JJ,O
,cardiotoxicity,NN,B-DISEASE
,in,IN,O
,rats,NNS,O
,with,IN,O
,breast,NN,B-DISEASE
,cancer,NN,I-DISEASE
,.,.,O
,Oxidative,JJ,O
,stress,NN,O
,is,VBZ,O
,involved,VBN,O
,in,IN,O
,several,JJ,O
,processes,NNS,O
,including,VBG,O
,cancer,NN,B-DISEASE
,",",",",O
,aging,VBG,O
,and,CC,O
,cardiovascular,JJ,B-DISEASE
,disease,NN,I-DISEASE
,",",",",O
,and,CC,O
,has,VBZ,O
,been,VBN,O
,shown,VBN,O
,to,TO,O
,potentiate,VB,O
,the,DT,O
,therapeutic,JJ,O
,effect,NN,O
,of,IN,O
,drugs,NNS,O
,such,JJ,O
,as,IN,O
,doxorubicin,NN,O
,.,.,O
,Doxorubicin,NNP,O
,causes,VBZ,O
,significant,JJ,O
,cardiotoxicity,NN,B-DISEASE
,characterized,VBN,O
,by,IN,O
,marked,JJ,O
,increases,NNS,O
,in,IN,O
,oxidative,JJ,O
,stress,NN,O
,and,CC,O
,mitochondrial,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,.,.,O
,Herein,NNP,O
,",",",",O
,we,PRP,O
,investigate,VBP,O
,whether,IN,O
,doxorubicin,NN,O
,-,:,O
,associated,VBN,O
,chronic,JJ,O
,cardiac,JJ,B-DISEASE
,toxicity,NN,I-DISEASE
,can,MD,O
,be,VB,O
,ameliorated,VBN,O
,with,IN,O
,the,DT,O
,antioxidant,JJ,O
,hydroxytyrosol,NN,O
,in,IN,O
,rats,NNS,O
,with,IN,O
,breast,NN,B-DISEASE
,cancer,NN,I-DISEASE
,.,.,O
,Thirty,NNP,O
,-,:,O
,six,CD,O
,rats,NNS,O
,bearing,VBG,O
,breast,NN,B-DISEASE
,tumors,NNS,I-DISEASE
,induced,VBD,O
,chemically,RB,O
,were,VBD,O
,divided,VBN,O
,into,IN,O
,4,CD,O
,groups,NNS,O
,:,:,O
,control,NN,O
,",",",",O
,hydroxytyrosol,NN,O
,(,(,O
,0,CD,O
,.,.,O
,5mg,CD,O
,/,JJ,O
,kg,NN,O
,",",",",O
,5days,CD,O
,/,NNP,O
,week,NN,O
,),),O
,",",",",O
,doxorubicin,NN,O
,(,(,O
,1mg,CD,O
,/,NNP,O
,kg,NN,O
,/,NNP,O
,week,NN,O
,),),O
,",",",",O
,and,CC,O
,doxorubicin,JJ,O
,plus,CC,O
,hydroxytyrosol,JJ,O
,.,.,O
,Cardiac,JJ,B-DISEASE
,disturbances,NNS,I-DISEASE
,at,IN,O
,the,DT,O
,cellular,JJ,O
,and,CC,O
,mitochondrial,JJ,O
,level,NN,O
,",",",",O
,mitochondrial,JJ,O
,electron,NN,O
,transport,NN,O
,chain,NN,O
,complexes,NNS,O
,I,PRP,O
,-,:,O
,IV,NN,O
,and,CC,O
,apoptosis,NN,O
,-,:,O
,inducing,NN,O
,factor,NN,O
,",",",",O
,and,CC,O
,oxidative,JJ,O
,stress,NN,O
,markers,NNS,O
,have,VBP,O
,been,VBN,O
,analyzed,VBN,O
,.,.,O
,Hydroxytyrosol,NNP,O
,improved,VBD,O
,the,DT,O
,cardiac,JJ,B-DISEASE
,disturbances,NNS,I-DISEASE
,enhanced,VBN,O
,by,IN,O
,doxorubicin,NN,O
,by,IN,O
,significantly,RB,O
,reducing,VBG,O
,the,DT,O
,percentage,NN,O
,of,IN,O
,altered,JJ,O
,mitochondria,NNS,O
,and,CC,O
,oxidative,JJ,O
,damage,NN,O
,.,.,O
,These,DT,O
,results,NNS,O
,suggest,VBP,O
,that,IN,O
,hydroxytyrosol,NN,O
,improve,VB,O
,the,DT,O
,mitochondrial,JJ,O
,electron,NN,O
,transport,NN,O
,chain,NN,O
,.,.,O
,This,DT,O
,study,NN,O
,demonstrates,VBZ,O
,that,IN,O
,hydroxytyrosol,NN,O
,protect,VBP,O
,rat,VB,O
,heart,NN,B-DISEASE
,damage,NN,I-DISEASE
,provoked,VBN,O
,by,IN,O
,doxorubicin,NN,O
,decreasing,VBG,O
,oxidative,JJ,O
,damage,NN,O
,and,CC,O
,mitochondrial,JJ,O
,alterations,NNS,O
,.,.,O
,Amiodarone,NNP,O
,-,:,O
,induced,VBD,O
,myxoedema,JJ,B-DISEASE
,coma,NN,I-DISEASE
,.,.,O
,A,DT,O
,62,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,man,NN,O
,was,VBD,O
,found,VBN,O
,to,TO,O
,have,VB,O
,bradycardia,NN,B-DISEASE
,",",",",O
,hypothermia,NN,B-DISEASE
,and,CC,O
,respiratory,JJ,B-DISEASE
,failure,NN,I-DISEASE
,3,CD,O
,weeks,NNS,O
,after,IN,O
,initiation,NN,O
,of,IN,O
,amiodarone,NN,O
,therapy,NN,O
,for,IN,O
,atrial,JJ,B-DISEASE
,fibrillation,NN,I-DISEASE
,.,.,O
,Thyroid,NNP,O
,-,:,O
,stimulating,VBG,O
,hormone,NN,O
,was,VBD,O
,found,VBN,O
,to,TO,O
,be,VB,O
,168,CD,O
,uIU,JJ,O
,/,NN,O
,mL,NN,O
,(,(,O
,nl,JJ,O
,.,.,O
,0,CD,O
,.,.,O
,3,CD,O
,-,:,O
,5,CD,O
,uIU,JJ,O
,/,NNP,O
,mL,NN,O
,),),O
,and,CC,O
,free,JJ,O
,thyroxine,NN,O
,(,(,O
,FT4,NNP,O
,),),O
,was,VBD,O
,<,JJ,O
,0,CD,O
,.,.,O
,2,CD,O
,ng,JJ,O
,/,NN,O
,dL,NN,O
,(,(,O
,nl,JJ,O
,.,.,O
,0,CD,O
,.,.,O
,8,CD,O
,-,:,O
,1,CD,O
,.,.,O
,8,CD,O
,ng,JJ,O
,/,NNP,O
,dL,NN,O
,),),O
,.,.,O
,He,PRP,O
,received,VBD,O
,intravenous,JJ,O
,fluids,NNS,O
,",",",",O
,vasopressor,NN,O
,therapy,NN,O
,and,CC,O
,stress,NN,O
,dose,JJ,O
,steroids,NNS,O
,;,:,O
,he,PRP,O
,was,VBD,O
,intubated,VBN,O
,and,CC,O
,admitted,VBN,O
,to,TO,O
,the,DT,O
,intensive,JJ,O
,care,NN,O
,unit,NN,O
,.,.,O
,He,PRP,O
,received,VBD,O
,500,CD,O
,ug,NN,O
,of,IN,O
,intravenous,JJ,O
,levothyroxine,NN,O
,in,IN,O
,the,DT,O
,first,JJ,O
,18,CD,O
,h,NN,O
,of,IN,O
,therapy,NN,O
,",",",",O
,and,CC,O
,150,CD,O
,ug,JJ,O
,intravenous,JJ,O
,daily,JJ,O
,thereafter,RB,O
,.,.,O
,Haemodynamic,NNP,O
,improvement,NN,O
,",",",",O
,along,IN,O
,with,IN,O
,complete,JJ,O
,recovery,NN,O
,of,IN,O
,mental,JJ,O
,status,NN,O
,",",",",O
,occurred,VBD,O
,after,IN,O
,48,CD,O
,h,NN,O
,.,.,O
,Twelve,NNP,O
,hours,NNS,O
,after,IN,O
,the,DT,O
,initiation,NN,O
,of,IN,O
,therapy,NN,O
,",",",",O
,FT4,NNP,O
,was,VBD,O
,0,CD,O
,.,.,O
,96,CD,O
,ng,JJ,O
,/,NNP,O
,dL,NN,O
,.,.,O
,The,DT,O
,patient,NN,O
,was,VBD,O
,maintained,VBN,O
,on,IN,O
,levothyroxine,NN,O
,175,CD,O
,(,(,O
,g,JJ,O
,POorally,NNP,O
,daily,RB,O
,.,.,O
,A,DT,O
,thyroid,NN,O
,ultrasound,NN,O
,showed,VBD,O
,diffuse,IN,O
,heterogeneity,NN,O
,.,.,O
,The,DT,O
,24,CD,O
,hour,NN,O
,excretion,NN,O
,of,IN,O
,iodine,NN,O
,was,VBD,O
,3657,CD,O
,(,(,O
,mcg,NN,O
,(,(,O
,25,CD,O
,-,:,O
,756,CD,O
,(,(,O
,mcg,NN,O
,),),O
,.,.,O
,The,DT,O
,only,JJ,O
,two,CD,O
,cases,NNS,O
,of,IN,O
,amiodarone,NN,O
,-,:,O
,induced,JJ,O
,myxoedema,NN,B-DISEASE
,coma,NN,I-DISEASE
,in,IN,O
,the,DT,O
,literature,JJ,O
,report,NN,O
,patient,VBD,O
,death,NN,O
,despite,IN,O
,supportive,JJ,O
,therapy,NN,O
,and,CC,O
,thyroid,VB,O
,hormone,NN,O
,replacement,NN,O
,.,.,O
,This,DT,O
,case,NN,O
,represents,VBZ,O
,the,DT,O
,most,RBS,O
,thoroughly,RB,O
,investigated,JJ,O
,case,NN,O
,of,IN,O
,amiodarone,NN,O
,-,:,O
,induced,JJ,O
,myxoedema,NN,B-DISEASE
,coma,NN,I-DISEASE
,with,IN,O
,a,DT,O
,history,NN,O
,significant,JJ,O
,for,IN,O
,subclinical,JJ,O
,thyroid,JJ,B-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,Use,NNP,O
,of,IN,O
,argatroban,NN,O
,and,CC,O
,catheter,NN,O
,-,:,O
,directed,VBN,O
,thrombolysis,NN,B-DISEASE
,with,IN,O
,alteplase,NN,O
,in,IN,O
,an,DT,O
,oncology,NN,O
,patient,NN,O
,with,IN,O
,heparin,JJ,O
,-,:,O
,induced,VBN,O
,thrombocytopenia,NN,B-DISEASE
,with,IN,O
,thrombosis,NN,B-DISEASE
,.,.,O
,PURPOSE,NN,O
,:,:,O
,The,DT,O
,case,NN,O
,of,IN,O
,an,DT,O
,oncology,NN,O
,patient,NN,O
,who,WP,O
,developed,VBD,O
,heparin,SYM,O
,-,:,O
,induced,VBN,O
,thrombocytopenia,NN,B-DISEASE
,with,IN,O
,thrombosis,NN,B-DISEASE
,(,(,O
,HITT,NNP,B-DISEASE
,),),O
,and,CC,O
,was,VBD,O
,treated,VBN,O
,with,IN,O
,argatroban,JJ,O
,plus,CC,O
,catheter,JJ,O
,-,:,O
,directed,VBN,O
,thrombolysis,NN,B-DISEASE
,(,(,O
,CDT,NNP,O
,),),O
,with,IN,O
,alteplase,NN,O
,is,VBZ,O
,presented,VBN,O
,.,.,O
,SUMMARY,NN,O
,:,:,O
,A,DT,O
,63,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,Caucasian,JJ,O
,man,NN,O
,with,IN,O
,renal,JJ,O
,amyloidosis,NN,B-DISEASE
,undergoing,VBG,O
,peripheral,JJ,O
,blood,NN,O
,stem,NN,O
,cell,NN,O
,collection,NN,O
,for,IN,O
,an,DT,O
,autologous,JJ,O
,stem,NN,O
,cell,NN,O
,transplant,NN,O
,developed,VBD,O
,extensive,JJ,O
,bilateral,JJ,O
,upper,JJ,B-DISEASE
,-,:,I-DISEASE
,extremity,NN,I-DISEASE
,deep,RB,I-DISEASE
,venous,JJ,I-DISEASE
,thrombosis,NN,I-DISEASE
,(,(,O
,DVT,NNP,B-DISEASE
,),),O
,and,CC,O
,pulmonary,JJ,B-DISEASE
,embolism,NN,I-DISEASE
,secondary,JJ,O
,to,TO,O
,heparin,VB,O
,-,:,O
,induced,VBN,O
,thrombocytopenia,NN,B-DISEASE
,.,.,O
,A,DT,O
,continuous,JJ,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,infusion,NN,O
,of,IN,O
,argatroban,NN,O
,was,VBD,O
,initiated,VBN,O
,",",",",O
,and,CC,O
,the,DT,O
,patient,NN,O
,was,VBD,O
,managed,VBN,O
,on,IN,O
,the,DT,O
,general,JJ,O
,medical,JJ,O
,floor,NN,O
,.,.,O
,After,IN,O
,one,CD,O
,week,NN,O
,of,IN,O
,therapy,NN,O
,",",",",O
,he,PRP,O
,was,VBD,O
,transferred,VBN,O
,to,TO,O
,the,DT,O
,intensive,JJ,O
,care,NN,O
,unit,NN,O
,with,IN,O
,cardiopulmonary,JJ,O
,compromise,NN,O
,related,VBN,O
,to,TO,O
,superior,JJ,B-DISEASE
,vena,NN,I-DISEASE
,cava,NN,I-DISEASE
,(,(,I-DISEASE
,SVC,NNP,I-DISEASE
,),),I-DISEASE
,syndrome,NN,I-DISEASE
,.,.,O
,A,DT,O
,percutaneous,JJ,O
,mechanical,JJ,O
,thrombectomy,NN,O
,and,CC,O
,CDT,NNP,O
,with,IN,O
,alteplase,NN,O
,were,VBD,O
,attempted,VBN,O
,",",",",O
,but,CC,O
,the,DT,O
,procedure,NN,O
,was,VBD,O
,aborted,VBN,O
,due,JJ,O
,to,TO,O
,epistaxis,VB,B-DISEASE
,.,.,O
,The,DT,O
,epistaxis,NN,B-DISEASE
,resolved,VBD,O
,the,DT,O
,next,JJ,O
,day,NN,O
,",",",",O
,and,CC,O
,the,DT,O
,patient,NN,O
,was,VBD,O
,restarted,VBN,O
,on,IN,O
,argatroban,NN,O
,.,.,O
,A,DT,O
,second,JJ,O
,percutaneous,JJ,O
,mechanical,JJ,O
,thrombectomy,NN,O
,was,VBD,O
,performed,VBN,O
,six,CD,O
,days,NNS,O
,later,RB,O
,and,CC,O
,resulted,VBD,O
,in,IN,O
,partial,JJ,O
,revascularization,NN,O
,of,IN,O
,the,DT,O
,SVC,NNP,O
,and,CC,O
,central,JJ,O
,veins,NNS,O
,.,.,O
,Postthrombectomy,NNP,O
,continuous,JJ,O
,CDT,NNP,O
,with,IN,O
,alteplase,NN,O
,was,VBD,O
,commenced,VBN,O
,while,IN,O
,argatroban,NN,O
,was,VBD,O
,withheld,VBN,O
,",",",",O
,and,CC,O
,complete,JJ,O
,patency,NN,O
,of,IN,O
,the,DT,O
,SVC,NNP,O
,and,CC,O
,central,JJ,O
,veins,NNS,O
,was,VBD,O
,achieved,VBN,O
,after,IN,O
,three,CD,O
,days,NNS,O
,of,IN,O
,therapy,NN,O
,.,.,O
,Alteplase,NNP,O
,was,VBD,O
,discontinued,VBN,O
,",",",",O
,and,CC,O
,the,DT,O
,patient,NN,O
,was,VBD,O
,reinitiated,VBN,O
,on,IN,O
,argatroban,NN,O
,;,:,O
,ultimately,RB,O
,",",",",O
,he,PRP,O
,was,VBD,O
,transitioned,VBN,O
,to,TO,O
,warfarin,VB,O
,for,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,anticoagulation,NN,O
,.,.,O
,Although,IN,O
,the,DT,O
,patient,NN,O
,recovered,VBD,O
,",",",",O
,he,PRP,O
,experienced,VBD,O
,permanent,JJ,O
,vision,NN,B-DISEASE
,and,CC,I-DISEASE
,hearing,NN,I-DISEASE
,loss,NN,I-DISEASE
,",",",",O
,as,RB,O
,well,RB,O
,as,IN,O
,end,NN,B-DISEASE
,-,:,I-DISEASE
,stage,NN,I-DISEASE
,renal,JJ,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,A,DT,O
,63,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,man,NN,O
,with,IN,O
,renal,JJ,O
,amyloidosis,NN,B-DISEASE
,and,CC,O
,SVC,NNP,B-DISEASE
,syndrome,VBP,I-DISEASE
,secondary,JJ,O
,to,TO,O
,HITT,NNP,B-DISEASE
,was,VBD,O
,successfully,RB,O
,treated,VBN,O
,with,IN,O
,argatroban,NN,O
,and,CC,O
,CDT,NNP,O
,with,IN,O
,alteplase,NN,O
,.,.,O
,Effects,NNS,O
,of,IN,O
,dehydroepiandrosterone,NN,O
,in,IN,O
,amphetamine,JJ,O
,-,:,O
,induced,VBN,O
,schizophrenia,NN,B-DISEASE
,models,NNS,O
,in,IN,O
,mice,NN,O
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,To,TO,O
,examine,VB,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,dehydroepiandrosterone,NN,O
,(,(,O
,DHEA,NNP,O
,),),O
,on,IN,O
,animal,NN,O
,models,NNS,O
,of,IN,O
,schizophrenia,NN,B-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,Seventy,NNP,O
,Swiss,NNP,O
,albino,NN,O
,female,JJ,O
,mice,NN,O
,(,(,O
,25,CD,O
,-,:,O
,35,CD,O
,g,NN,O
,),),O
,were,VBD,O
,divided,VBN,O
,into,IN,O
,4,CD,O
,groups,NNS,O
,:,:,O
,amphetamine,VB,O
,-,:,O
,free,JJ,O
,(,(,O
,control,NN,O
,),),O
,",",",",O
,amphetamine,JJ,O
,",",",",O
,50,CD,O
,",",",",O
,and,CC,O
,100,CD,O
,mg,NN,O
,/,NNP,O
,kg,NNP,O
,DHEA,NNP,O
,.,.,O
,The,DT,O
,DHEA,NNP,O
,was,VBD,O
,administered,VBN,O
,intraperitoneally,RB,O
,(,(,O
,ip,NN,O
,),),O
,for,IN,O
,5,CD,O
,days,NNS,O
,.,.,O
,Amphetamine,NNP,O
,(,(,O
,3,CD,O
,mg,NN,O
,/,NNP,O
,kg,NNP,O
,ip,NN,O
,),),O
,induced,VBD,O
,hyper,JJ,B-DISEASE
,locomotion,NN,O
,",",",",O
,apomorphine,NN,O
,(,(,O
,1,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,subcutaneously,RB,O
,[,NNP,O
,sc,NNP,O
,],NNP,O
,),),O
,induced,VBD,O
,climbing,VBG,O
,",",",",O
,and,CC,O
,haloperidol,NN,O
,(,(,O
,1,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NNP,O
,sc,NN,O
,),),O
,induced,VBD,O
,catalepsy,NN,B-DISEASE
,tests,NNS,O
,were,VBD,O
,used,VBN,O
,as,IN,O
,animal,JJ,O
,models,NNS,O
,of,IN,O
,schizophrenia,NN,B-DISEASE
,.,.,O
,The,DT,O
,study,NN,O
,was,VBD,O
,conducted,VBN,O
,at,IN,O
,the,DT,O
,Animal,NNP,O
,Experiment,NNP,O
,Laboratories,NNPS,O
,",",",",O
,Department,NNP,O
,of,IN,O
,Pharmacology,NNP,O
,",",",",O
,Medical,NNP,O
,School,NNP,O
,",",",",O
,Eskisehir,NNP,O
,Osmangazi,NNP,O
,University,NNP,O
,",",",",O
,Eskisehir,NNP,O
,",",",",O
,Turkey,NNP,O
,between,IN,O
,March,NNP,O
,and,CC,O
,May,NNP,O
,2012,CD,O
,.,.,O
,Statistical,JJ,O
,analysis,NN,O
,was,VBD,O
,carried,VBN,O
,out,RP,O
,using,VBG,O
,Kruskal,NNP,O
,-,:,O
,Wallis,JJ,O
,test,NN,O
,for,IN,O
,hyper,JJR,B-DISEASE
,locomotion,NN,O
,",",",",O
,and,CC,O
,one,CD,O
,-,:,O
,way,NN,O
,ANOVA,NNP,O
,for,IN,O
,climbing,VBG,O
,and,CC,O
,catalepsy,NN,B-DISEASE
,tests,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,In,IN,O
,the,DT,O
,amphetamine,NN,O
,-,:,O
,induced,JJ,O
,locomotion,NN,O
,test,NN,O
,",",",",O
,there,EX,O
,were,VBD,O
,significant,JJ,O
,increases,NNS,O
,in,IN,O
,all,DT,O
,movements,NNS,O
,compared,VBN,O
,with,IN,O
,the,DT,O
,amphetamine,NN,O
,-,:,O
,free,JJ,O
,group,NN,O
,.,.,O
,Both,DT,O
,DHEA,NNP,O
,50,CD,O
,mg,NN,O
,/,NN,O
,kg,NN,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,",",",",O
,and,CC,O
,100,CD,O
,mg,NN,O
,/,NN,O
,kg,NN,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,significantly,RB,O
,decreased,VBN,O
,all,DT,O
,movements,NNS,O
,compared,VBN,O
,with,IN,O
,the,DT,O
,amphetamine,NN,O
,-,:,O
,induced,JJ,O
,locomotion,NN,O
,group,NN,O
,.,.,O
,There,EX,O
,was,VBD,O
,a,DT,O
,significant,JJ,O
,difference,NN,O
,between,IN,O
,groups,NNS,O
,in,IN,O
,the,DT,O
,haloperidol,NN,O
,-,:,O
,induced,JJ,O
,catalepsy,NN,B-DISEASE
,test,NN,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,There,EX,O
,was,VBD,O
,no,DT,O
,significant,JJ,O
,difference,NN,O
,between,IN,O
,groups,NNS,O
,in,IN,O
,terms,NNS,O
,of,IN,O
,total,JJ,O
,climbing,JJ,O
,time,NN,O
,in,IN,O
,the,DT,O
,apomorphine,NN,O
,-,:,O
,induced,JJ,O
,climbing,VBG,O
,test,NN,O
,(,(,O
,p,JJ,O
,>,NN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,We,PRP,O
,observed,VBD,O
,that,IN,O
,DHEA,NNP,O
,reduced,VBD,O
,locomotor,NN,O
,activity,NN,O
,and,CC,O
,increased,VBD,O
,catalepsy,NN,B-DISEASE
,at,IN,O
,both,DT,O
,doses,NNS,O
,",",",",O
,while,IN,O
,it,PRP,O
,had,VBD,O
,no,DT,O
,effect,NN,O
,on,IN,O
,climbing,VBG,O
,behavior,NN,O
,.,.,O
,We,PRP,O
,suggest,VBP,O
,that,IN,O
,DHEA,NNP,O
,displays,VBZ,O
,typical,JJ,O
,neuroleptic,JJ,O
,-,:,O
,like,IN,O
,effects,NNS,O
,",",",",O
,and,CC,O
,may,MD,O
,be,VB,O
,used,VBN,O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,schizophrenia,NN,B-DISEASE
,.,.,O
,Availability,NNP,O
,of,IN,O
,human,JJ,O
,induced,JJ,O
,pluripotent,NN,O
,stem,NN,O
,cell,SYM,O
,-,:,O
,derived,VBN,O
,cardiomyocytes,NNS,O
,in,IN,O
,assessment,NN,O
,of,IN,O
,drug,NN,O
,potential,NN,O
,for,IN,O
,QT,NNP,B-DISEASE
,prolongation,NN,I-DISEASE
,.,.,O
,Field,NNP,O
,potential,JJ,O
,duration,NN,O
,(,(,O
,FPD,NNP,O
,),),O
,in,IN,O
,human,JJ,O
,-,:,O
,induced,JJ,O
,pluripotent,JJ,O
,stem,NN,O
,cell,NN,O
,-,:,O
,derived,VBN,O
,cardiomyocytes,NNS,O
,(,(,O
,hiPS,SYM,O
,-,:,O
,CMs,NN,O
,),),O
,",",",",O
,which,WDT,O
,can,MD,O
,express,VB,O
,QT,NNP,O
,interval,NN,O
,in,IN,O
,an,DT,O
,electrocardiogram,NN,O
,",",",",O
,is,VBZ,O
,reported,VBN,O
,to,TO,O
,be,VB,O
,a,DT,O
,useful,JJ,O
,tool,NN,O
,to,TO,O
,predict,VB,O
,K,NNP,O
,(,(,O
,+,NNP,O
,),),O
,channel,NN,O
,and,CC,O
,Ca,NNP,O
,(,(,O
,2,CD,O
,+,NN,O
,),),O
,channel,NN,O
,blocker,NN,O
,effects,NNS,O
,on,IN,O
,QT,NNP,O
,interval,NN,O
,.,.,O
,However,RB,O
,",",",",O
,there,EX,O
,is,VBZ,O
,no,DT,O
,report,NN,O
,showing,VBG,O
,that,IN,O
,this,DT,O
,technique,NN,O
,can,MD,O
,be,VB,O
,used,VBN,O
,to,TO,O
,predict,VB,O
,multichannel,NN,O
,blocker,NN,O
,potential,NN,O
,for,IN,O
,QT,NNP,B-DISEASE
,prolongation,NN,I-DISEASE
,.,.,O
,The,DT,O
,aim,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,is,VBZ,O
,to,TO,O
,show,VB,O
,that,IN,O
,FPD,NNP,O
,from,IN,O
,MEA,NNP,O
,(,(,O
,Multielectrode,NNP,O
,array,NN,O
,),),O
,of,IN,O
,hiPS,NN,O
,-,:,O
,CMs,NN,O
,can,MD,O
,detect,VB,O
,QT,NNP,B-DISEASE
,prolongation,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,multichannel,NN,O
,blockers,NNS,O
,.,.,O
,hiPS,SYM,O
,-,:,O
,CMs,NN,O
,were,VBD,O
,seeded,VBN,O
,onto,IN,O
,MEA,NNP,O
,and,CC,O
,FPD,NNP,O
,was,VBD,O
,measured,VBN,O
,for,IN,O
,2min,CD,O
,every,DT,O
,10min,CD,O
,for,IN,O
,30min,CD,O
,after,IN,O
,drug,NN,O
,exposure,NN,O
,for,IN,O
,the,DT,O
,vehicle,NN,O
,and,CC,O
,each,DT,O
,drug,NN,O
,concentration,NN,O
,.,.,O
,IKr,NNP,O
,and,CC,O
,IKs,NNP,O
,blockers,NNS,O
,concentration,VBP,O
,-,:,O
,dependently,RB,O
,prolonged,VBN,O
,corrected,VBN,O
,FPD,NNP,O
,(,(,O
,FPDc,NNP,O
,),),O
,",",",",O
,whereas,JJ,O
,Ca,NNP,O
,(,(,O
,2,CD,O
,+,NN,O
,),),O
,channel,NN,O
,blockers,NNS,O
,concentration,VBP,O
,-,:,O
,dependently,RB,O
,shortened,VBN,O
,FPDc,NNP,O
,.,.,O
,Also,RB,O
,",",",",O
,the,DT,O
,multichannel,NN,O
,blockers,NNS,O
,Amiodarone,NNP,O
,",",",",O
,Paroxetine,NNP,O
,",",",",O
,Terfenadine,NNP,O
,and,CC,O
,Citalopram,NNP,O
,prolonged,VBD,O
,FPDc,NNP,O
,in,IN,O
,a,DT,O
,concentration,NN,O
,dependent,JJ,O
,manner,NN,O
,.,.,O
,Finally,RB,O
,",",",",O
,the,DT,O
,IKr,NNP,O
,blockers,NNS,O
,",",",",O
,Terfenadine,NNP,O
,and,CC,O
,Citalopram,NNP,O
,",",",",O
,which,WDT,O
,are,VBP,O
,reported,VBN,O
,to,TO,O
,cause,VB,O
,Torsade,NNP,B-DISEASE
,de,FW,I-DISEASE
,Pointes,NNP,I-DISEASE
,(,(,O
,TdP,NNP,B-DISEASE
,),),O
,in,IN,O
,clinical,JJ,O
,practice,NN,O
,",",",",O
,produced,VBD,O
,early,JJ,O
,afterdepolarization,NN,O
,(,(,O
,EAD,NNP,O
,),),O
,.,.,O
,hiPS,SYM,O
,-,:,O
,CMs,NN,O
,using,VBG,O
,MEA,NNP,O
,system,NN,O
,and,CC,O
,FPDc,NNP,O
,can,MD,O
,predict,VB,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,drug,NN,O
,candidates,NNS,O
,on,IN,O
,QT,NNP,O
,interval,NN,O
,.,.,O
,This,DT,O
,study,NN,O
,also,RB,O
,shows,VBZ,O
,that,IN,O
,this,DT,O
,assay,NN,O
,can,MD,O
,help,VB,O
,detect,VB,O
,EAD,NNP,O
,for,IN,O
,drugs,NNS,O
,with,IN,O
,TdP,NNP,B-DISEASE
,potential,NN,O
,.,.,O
,Dermal,NNP,O
,developmental,JJ,O
,toxicity,NN,B-DISEASE
,of,IN,O
,N,NNP,O
,-,:,O
,phenylimide,NN,O
,herbicides,NNS,O
,in,IN,O
,rats,NNS,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,S,NNP,O
,-,:,O
,53482,CD,O
,and,CC,O
,S,NNP,O
,-,:,O
,23121,CD,O
,are,VBP,O
,N,NNP,O
,-,:,O
,phenylimide,NN,O
,herbicides,NNS,O
,and,CC,O
,produced,VBN,O
,embryolethality,NN,B-DISEASE
,",",",",O
,teratogenicity,NN,B-DISEASE
,(,(,O
,mainly,RB,O
,ventricular,JJ,B-DISEASE
,septal,JJ,I-DISEASE
,defects,NNS,I-DISEASE
,and,CC,O
,wavy,JJ,O
,ribs,NN,O
,),),O
,",",",",O
,and,CC,O
,growth,NN,B-DISEASE
,retardation,NN,I-DISEASE
,in,IN,O
,rats,NNS,O
,in,IN,O
,conventional,JJ,O
,oral,JJ,O
,developmental,JJ,O
,toxicity,NN,B-DISEASE
,studies,NNS,O
,.,.,O
,Our,PRP$,O
,objective,NN,O
,in,IN,O
,this,DT,O
,study,NN,O
,was,VBD,O
,to,TO,O
,investigate,VB,O
,whether,IN,O
,the,DT,O
,compounds,NNS,O
,induce,VBP,O
,developmental,JJ,O
,toxicity,NN,B-DISEASE
,via,IN,O
,the,DT,O
,dermal,JJ,O
,route,NN,O
,",",",",O
,which,WDT,O
,is,VBZ,O
,more,RBR,O
,relevant,JJ,O
,to,TO,O
,occupational,JJ,O
,exposure,NN,O
,",",",",O
,hence,RB,O
,better,RBR,O
,addressing,VBG,O
,human,JJ,O
,health,NN,O
,risks,NNS,O
,.,.,O
,METHODS,NNS,O
,:,:,O
,S,NNP,O
,-,:,O
,53482,CD,O
,was,VBD,O
,administered,VBN,O
,dermally,RB,O
,to,TO,O
,rats,VB,O
,at,IN,O
,30,CD,O
,",",",",O
,100,CD,O
,",",",",O
,and,CC,O
,300,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,during,IN,O
,organogenesis,NN,O
,",",",",O
,and,CC,O
,S,NNP,O
,-,:,O
,23121,CD,O
,was,VBD,O
,administered,VBN,O
,at,IN,O
,200,CD,O
,",",",",O
,400,CD,O
,",",",",O
,and,CC,O
,800,CD,O
,mg,NN,O
,/,NN,O
,kg,NN,O
,(,(,O
,the,DT,O
,maximum,NN,O
,applicable,JJ,O
,dose,JJ,O
,level,NN,O
,),),O
,.,.,O
,Fetuses,NNS,O
,were,VBD,O
,obtained,VBN,O
,by,IN,O
,a,DT,O
,Cesarean,JJ,O
,section,NN,O
,and,CC,O
,examined,VBD,O
,for,IN,O
,external,JJ,O
,",",",",O
,visceral,JJ,O
,",",",",O
,and,CC,O
,skeletal,JJ,O
,alterations,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Dermal,JJ,O
,exposure,NN,O
,of,IN,O
,rats,NNS,O
,to,TO,O
,S,NNP,O
,-,:,O
,53482,CD,O
,at,IN,O
,300,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,produced,VBD,O
,patterns,NNS,O
,of,IN,O
,developmental,JJ,O
,toxicity,NN,B-DISEASE
,similar,JJ,O
,to,TO,O
,those,DT,O
,resulting,VBG,O
,from,IN,O
,oral,JJ,O
,exposure,NN,O
,.,.,O
,Toxicity,NNP,B-DISEASE
,included,VBD,O
,embryolethality,NN,B-DISEASE
,",",",",O
,teratogenicity,NN,B-DISEASE
,",",",",O
,and,CC,O
,growth,NN,B-DISEASE
,retardation,NN,I-DISEASE
,.,.,O
,Dermal,NNP,O
,administration,NN,O
,of,IN,O
,S,NNP,O
,-,:,O
,23121,CD,O
,at,IN,O
,800,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,resulted,VBD,O
,in,IN,O
,an,DT,O
,increased,JJ,O
,incidence,NN,O
,of,IN,O
,embryonic,JJ,B-DISEASE
,death,NN,I-DISEASE
,and,CC,O
,ventricular,JJ,B-DISEASE
,septal,NN,I-DISEASE
,defect,NN,I-DISEASE
,",",",",O
,but,CC,O
,retarded,VBD,O
,fetal,JJ,O
,growth,NN,O
,was,VBD,O
,not,RB,O
,observed,VBN,O
,as,IN,O
,it,PRP,O
,was,VBD,O
,following,VBG,O
,oral,JJ,O
,exposure,NN,O
,to,TO,O
,S,NNP,O
,-,:,O
,23121,CD,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Based,VBN,O
,on,IN,O
,the,DT,O
,results,NNS,O
,",",",",O
,S,NNP,O
,-,:,O
,53482,CD,O
,and,CC,O
,S,NNP,O
,-,:,O
,23121,CD,O
,were,VBD,O
,teratogenic,JJ,B-DISEASE
,when,WRB,O
,administered,VBN,O
,dermally,RB,O
,to,TO,O
,pregnant,VB,O
,rats,NNS,O
,as,IN,O
,were,VBD,O
,the,DT,O
,compounds,NNS,O
,administered,VBN,O
,orally,RB,O
,.,.,O
,Thus,NNP,O
,",",",",O
,investigation,NN,O
,of,IN,O
,the,DT,O
,mechanism,NN,O
,and,CC,O
,its,PRP$,O
,human,JJ,O
,relevancy,NN,O
,become,VB,O
,more,RBR,O
,important,JJ,O
,.,.,O
,Rates,NNS,O
,of,IN,O
,Renal,NNP,B-DISEASE
,Toxicity,NNP,I-DISEASE
,in,IN,O
,Cancer,NNP,B-DISEASE
,Patients,NNPS,O
,Receiving,VBG,O
,Cisplatin,NNP,O
,With,IN,O
,and,CC,O
,Without,NNP,O
,Mannitol,NNP,O
,.,.,O
,BACKGROUND,NNP,O
,:,:,O
,Cisplatin,NNP,O
,is,VBZ,O
,a,DT,O
,widely,RB,O
,used,VBN,O
,antineoplastic,JJ,O
,.,.,O
,One,CD,O
,of,IN,O
,the,DT,O
,major,JJ,O
,complications,NNS,O
,of,IN,O
,cisplatin,NN,O
,use,NN,O
,is,VBZ,O
,dose,JJ,O
,-,:,O
,limiting,VBG,O
,nephrotoxicity,NN,B-DISEASE
,.,.,O
,There,EX,O
,are,VBP,O
,many,JJ,O
,strategies,NNS,O
,to,TO,O
,prevent,VB,O
,this,DT,O
,toxicity,NN,B-DISEASE
,",",",",O
,including,VBG,O
,the,DT,O
,use,NN,O
,of,IN,O
,mannitol,NN,O
,as,IN,O
,a,DT,O
,nephroprotectant,NN,O
,in,IN,O
,combination,NN,O
,with,IN,O
,hydration,NN,O
,.,.,O
,OBJECTIVE,CC,O
,:,:,O
,We,PRP,O
,aimed,VBD,O
,to,TO,O
,evaluate,VB,O
,the,DT,O
,rates,NNS,O
,of,IN,O
,cisplatin,NN,O
,-,:,O
,induced,JJ,O
,nephrotoxicity,NN,B-DISEASE
,in,IN,O
,cancer,NN,B-DISEASE
,patients,NNS,O
,receiving,VBG,O
,single,JJ,O
,-,:,O
,agent,NN,O
,cisplatin,NN,O
,with,IN,O
,and,CC,O
,without,IN,O
,mannitol,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,This,DT,O
,single,JJ,O
,-,:,O
,center,NN,O
,retrospective,JJ,O
,analysis,NN,O
,was,VBD,O
,a,DT,O
,quasi,JJ,O
,experiment,NN,O
,created,VBN,O
,by,IN,O
,the,DT,O
,national,JJ,O
,mannitol,NN,O
,shortage,NN,O
,.,.,O
,Data,NNS,O
,were,VBD,O
,collected,VBN,O
,on,IN,O
,adult,NN,O
,cancer,NN,B-DISEASE
,patients,NNS,O
,receiving,VBG,O
,single,JJ,O
,-,:,O
,agent,NN,O
,cisplatin,NN,O
,as,IN,O
,an,DT,O
,outpatient,NN,O
,from,IN,O
,January,NNP,O
,2011,CD,O
,to,TO,O
,September,NNP,O
,2012,CD,O
,.,.,O
,The,DT,O
,primary,JJ,O
,outcome,NN,O
,was,VBD,O
,acute,JJ,B-DISEASE
,kidney,NN,I-DISEASE
,injury,NN,I-DISEASE
,(,(,O
,AKI,NNP,B-DISEASE
,),),O
,.,.,O
,RESULTS,NN,O
,:,:,O
,We,PRP,O
,evaluated,VBD,O
,143,CD,O
,patients,NNS,O
,who,WP,O
,received,VBD,O
,single,JJ,O
,-,:,O
,agent,NN,O
,cisplatin,NN,O
,;,:,O
,97,CD,O
,.,.,O
,2,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,had,VBD,O
,head,NN,B-DISEASE
,and,CC,I-DISEASE
,neck,NN,I-DISEASE
,cancer,NN,I-DISEASE
,as,IN,O
,their,PRP$,O
,primary,JJ,O
,malignancy,NN,B-DISEASE
,.,.,O
,Patients,NNS,O
,who,WP,O
,did,VBD,O
,not,RB,O
,receive,VB,O
,mannitol,NNS,O
,were,VBD,O
,more,RBR,O
,likely,JJ,O
,to,TO,O
,develop,VB,O
,nephrotoxicity,NN,B-DISEASE
,:,:,O
,odds,NNS,O
,ratio,VBP,O
,[,CD,O
,OR,NNP,O
,],NNP,O
,=,POS,O
,2,CD,O
,.,.,O
,646,CD,O
,(,(,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,=,NNP,O
,1,CD,O
,.,.,O
,008,CD,O
,",",",",O
,6,CD,O
,.,.,O
,944,CD,O
,;,:,O
,P,NNP,O
,=,VBD,O
,0,CD,O
,.,.,O
,048,CD,O
,),),O
,.,.,O
,Patients,NNPS,O
,who,WP,O
,received,VBD,O
,the,DT,O
,100,CD,O
,mg,NN,O
,/,NNP,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,dosing,NN,O
,and,CC,O
,patients,NNS,O
,who,WP,O
,had,VBD,O
,a,DT,O
,history,NN,O
,of,IN,O
,hypertension,NN,B-DISEASE
,also,RB,O
,had,VBD,O
,a,DT,O
,higher,JJR,O
,likelihood,NN,O
,of,IN,O
,developing,VBG,O
,nephrotoxicity,NN,B-DISEASE
,:,:,O
,OR,CC,O
,=,VB,O
,11,CD,O
,.,.,O
,494,CD,O
,(,(,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,=,NNP,O
,4,CD,O
,.,.,O
,149,CD,O
,",",",",O
,32,CD,O
,.,.,O
,258,CD,O
,;,:,O
,P,NNP,O
,<,VBD,O
,0,CD,O
,.,.,O
,0001,CD,O
,),),O
,and,CC,O
,OR,NNP,O
,=,VBP,O
,3,CD,O
,.,.,O
,219,CD,O
,(,(,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,=,NNP,O
,1,CD,O
,.,.,O
,228,CD,O
,",",",",O
,8,CD,O
,.,.,O
,439,CD,O
,;,:,O
,P,NNP,O
,=,VBD,O
,0,CD,O
,.,.,O
,017,CD,O
,),),O
,",",",",O
,respectively,RB,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,When,WRB,O
,limited,JJ,O
,quantities,NNS,O
,of,IN,O
,mannitol,NN,O
,are,VBP,O
,available,JJ,O
,",",",",O
,it,PRP,O
,should,MD,O
,preferentially,RB,O
,be,VB,O
,given,VBN,O
,to,TO,O
,patients,NNS,O
,at,IN,O
,particularly,RB,O
,high,JJ,O
,risk,NN,O
,of,IN,O
,nephrotoxicity,NN,B-DISEASE
,.,.,O
,Our,PRP$,O
,analysis,NN,O
,suggests,VBZ,O
,that,IN,O
,those,DT,O
,patients,NNS,O
,receiving,VBG,O
,the,DT,O
,dosing,VBG,O
,schedule,NN,O
,of,IN,O
,100,CD,O
,mg,NNS,O
,/,JJ,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,cisplatin,NN,O
,every,DT,O
,3,CD,O
,weeks,NNS,O
,and,CC,O
,those,DT,O
,with,IN,O
,hypertension,NN,B-DISEASE
,are,VBP,O
,at,IN,O
,the,DT,O
,greatest,JJS,O
,risk,NN,O
,of,IN,O
,nephrotoxicity,NN,B-DISEASE
,and,CC,O
,would,MD,O
,benefit,VB,O
,from,IN,O
,the,DT,O
,addition,NN,O
,of,IN,O
,mannitol,NN,O
,.,.,O
,Metformin,NNP,O
,protects,VBZ,O
,against,IN,O
,seizures,NNS,B-DISEASE
,",",",",O
,learning,VBG,B-DISEASE
,and,CC,I-DISEASE
,memory,NN,I-DISEASE
,impairments,NNS,I-DISEASE
,and,CC,O
,oxidative,JJ,O
,damage,NN,O
,induced,VBN,O
,by,IN,O
,pentylenetetrazole,JJ,O
,-,:,O
,induced,JJ,O
,kindling,NN,O
,in,IN,O
,mice,NN,O
,.,.,O
,Cognitive,JJ,B-DISEASE
,impairment,NN,I-DISEASE
,",",",",O
,the,DT,O
,most,RBS,O
,common,JJ,O
,and,CC,O
,severe,JJ,O
,comorbidity,NN,O
,of,IN,O
,epilepsy,NN,B-DISEASE
,",",",",O
,greatly,RB,O
,diminishes,VBZ,O
,the,DT,O
,quality,NN,O
,of,IN,O
,life,NN,O
,.,.,O
,However,RB,O
,",",",",O
,current,JJ,O
,therapeutic,JJ,O
,interventions,NNS,O
,for,IN,O
,epilepsy,NN,B-DISEASE
,can,MD,O
,also,RB,O
,cause,VB,O
,untoward,JJ,O
,cognitive,JJ,O
,effects,NNS,O
,.,.,O
,Thus,RB,O
,",",",",O
,there,EX,O
,is,VBZ,O
,an,DT,O
,urgent,JJ,O
,need,NN,O
,for,IN,O
,new,JJ,O
,kinds,NNS,O
,of,IN,O
,agents,NNS,O
,targeting,VBG,O
,both,DT,O
,seizures,NNS,B-DISEASE
,and,CC,O
,cognition,NN,B-DISEASE
,deficits,NNS,I-DISEASE
,.,.,O
,Oxidative,JJ,O
,stress,NN,O
,is,VBZ,O
,considered,VBN,O
,to,TO,O
,play,VB,O
,an,DT,O
,important,JJ,O
,role,NN,O
,in,IN,O
,epileptogenesis,NN,O
,and,CC,O
,cognitive,JJ,B-DISEASE
,deficits,NNS,I-DISEASE
,",",",",O
,and,CC,O
,antioxidants,NNS,O
,have,VBP,O
,a,DT,O
,putative,JJ,O
,antiepileptic,JJ,O
,potential,NN,O
,.,.,O
,Metformin,NNP,O
,",",",",O
,the,DT,O
,most,RBS,O
,commonly,RB,O
,prescribed,VBN,O
,antidiabetic,JJ,O
,oral,JJ,O
,drug,NN,O
,",",",",O
,has,VBZ,O
,antioxidant,JJ,O
,properties,NNS,O
,.,.,O
,This,DT,O
,study,NN,O
,was,VBD,O
,designed,VBN,O
,to,TO,O
,evaluate,VB,O
,the,DT,O
,ameliorative,JJ,O
,effects,NNS,O
,of,IN,O
,metformin,NN,O
,on,IN,O
,seizures,NNS,B-DISEASE
,",",",",O
,cognitive,JJ,B-DISEASE
,impairment,NN,I-DISEASE
,and,CC,O
,brain,NN,O
,oxidative,JJ,O
,stress,NN,O
,markers,NNS,O
,observed,VBD,O
,in,IN,O
,pentylenetetrazole,JJ,O
,-,:,O
,induced,JJ,O
,kindling,NN,O
,animals,NNS,O
,.,.,O
,Male,NNP,O
,C57BL,NNP,O
,/,NNP,O
,6,CD,O
,mice,NN,O
,were,VBD,O
,administered,VBN,O
,with,IN,O
,subconvulsive,JJ,O
,dose,NN,O
,of,IN,O
,pentylenetetrazole,NN,O
,(,(,O
,37,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,every,DT,O
,other,JJ,O
,day,NN,O
,for,IN,O
,14,CD,O
,injections,NNS,O
,.,.,O
,Metformin,NNP,O
,was,VBD,O
,injected,VBN,O
,intraperitoneally,RB,O
,in,IN,O
,dose,NN,O
,of,IN,O
,200mg,CD,O
,/,JJ,O
,kg,NNS,O
,along,IN,O
,with,IN,O
,alternate,JJ,O
,-,:,O
,day,NN,O
,PTZ,NNP,O
,.,.,O
,We,PRP,O
,found,VBD,O
,that,IN,O
,metformin,NN,O
,suppressed,VBD,O
,the,DT,O
,progression,NN,O
,of,IN,O
,kindling,NN,O
,",",",",O
,ameliorated,VBD,O
,the,DT,O
,cognitive,JJ,B-DISEASE
,impairment,NN,I-DISEASE
,and,CC,O
,decreased,VBD,O
,brain,NN,O
,oxidative,JJ,O
,stress,NN,O
,.,.,O
,Thus,VB,O
,the,DT,O
,present,JJ,O
,study,NN,O
,concluded,VBD,O
,that,IN,O
,metformin,NN,O
,may,MD,O
,be,VB,O
,a,DT,O
,potential,JJ,O
,agent,NN,O
,for,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,epilepsy,NN,B-DISEASE
,as,RB,O
,well,RB,O
,as,IN,O
,a,DT,O
,protective,JJ,O
,medicine,NN,O
,against,IN,O
,cognitive,JJ,B-DISEASE
,impairment,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,seizures,NNS,B-DISEASE
,.,.,O
,P53,NNP,O
,inhibition,NN,O
,exacerbates,VBZ,O
,late,JJ,O
,-,:,O
,stage,NN,O
,anthracycline,JJ,O
,cardiotoxicity,NN,B-DISEASE
,.,.,O
,AIMS,NN,O
,:,:,O
,Doxorubicin,NNP,O
,(,(,O
,DOX,NNP,O
,),),O
,is,VBZ,O
,an,DT,O
,effective,JJ,O
,anti,NN,O
,-,:,O
,cancer,NN,B-DISEASE
,therapeutic,JJ,O
,",",",",O
,but,CC,O
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,both,DT,O
,acute,JJ,O
,and,CC,O
,late,JJ,O
,-,:,O
,stage,NN,O
,cardiotoxicity,NN,B-DISEASE
,.,.,O
,Children,NNP,O
,are,VBP,O
,particularly,RB,O
,sensitive,JJ,O
,to,TO,O
,DOX,NNP,O
,-,:,O
,induced,JJ,O
,heart,NN,B-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,Here,RB,O
,",",",",O
,the,DT,O
,impact,NN,O
,of,IN,O
,p53,NN,O
,inhibition,NN,O
,on,IN,O
,acute,JJ,O
,vs,NN,O
,.,.,O
,late,JJ,O
,-,:,O
,stage,NN,O
,DOX,NNP,O
,cardiotoxicity,NN,B-DISEASE
,was,VBD,O
,examined,VBN,O
,in,IN,O
,a,DT,O
,juvenile,NN,O
,model,NN,O
,.,.,O
,METHODS,NNP,O
,AND,CC,O
,RESULTS,NNP,O
,:,:,O
,Two,CD,O
,-,:,O
,week,NN,O
,-,:,O
,old,JJ,O
,MHC,NNP,O
,-,:,O
,CB7,NNP,O
,mice,NN,O
,(,(,O
,which,WDT,O
,express,VBP,O
,dominant,JJ,O
,-,:,O
,interfering,VBG,O
,p53,NN,O
,in,IN,O
,cardiomyocytes,NNS,O
,),),O
,and,CC,O
,their,PRP$,O
,non,JJ,O
,-,:,O
,transgenic,NN,O
,(,(,O
,NON,NNP,O
,-,:,O
,TXG,NN,O
,),),O
,littermates,VBZ,O
,received,JJ,O
,weekly,JJ,O
,DOX,NNP,O
,injections,NNS,O
,for,IN,O
,5,CD,O
,weeks,NNS,O
,(,(,O
,25,CD,O
,mg,NN,O
,/,NNP,O
,kg,NNP,O
,cumulative,VBP,O
,dose,NN,O
,),),O
,.,.,O
,One,CD,O
,week,NN,O
,after,IN,O
,the,DT,O
,last,JJ,O
,DOX,NNP,O
,treatment,NN,O
,(,(,O
,acute,JJ,O
,stage,NN,O
,),),O
,",",",",O
,MHC,NNP,O
,-,:,O
,CB7,NNP,O
,mice,NN,O
,exhibited,VBD,O
,improved,JJ,O
,cardiac,JJ,O
,function,NN,O
,and,CC,O
,lower,JJR,O
,levels,NNS,O
,of,IN,O
,cardiomyocyte,NN,O
,apoptosis,NN,O
,when,WRB,O
,compared,VBN,O
,with,IN,O
,the,DT,O
,NON,NNP,O
,-,:,O
,TXG,NNP,O
,mice,NN,O
,.,.,O
,Surprisingly,RB,O
,",",",",O
,by,IN,O
,13,CD,O
,weeks,NNS,O
,following,VBG,O
,the,DT,O
,last,JJ,O
,DOX,NNP,O
,treatment,NN,O
,(,(,O
,late,JJ,O
,stage,NN,O
,),),O
,",",",",O
,MHC,NNP,O
,-,:,O
,CB7,NNP,O
,exhibited,VBD,O
,a,DT,O
,progressive,JJ,O
,decrease,NN,O
,in,IN,O
,cardiac,JJ,O
,function,NN,O
,and,CC,O
,higher,JJR,O
,rates,NNS,O
,of,IN,O
,cardiomyocyte,NN,O
,apoptosis,NN,O
,when,WRB,O
,compared,VBN,O
,with,IN,O
,NON,NNP,O
,-,:,O
,TXG,NNP,O
,mice,NN,O
,.,.,O
,p53,NN,O
,inhibition,NN,O
,blocked,VBD,O
,transient,JJ,O
,DOX,NNP,O
,-,:,O
,induced,VBD,O
,STAT3,NNP,O
,activation,NN,O
,in,IN,O
,MHC,NNP,O
,-,:,O
,CB7,NNP,O
,mice,NN,O
,",",",",O
,which,WDT,O
,was,VBD,O
,associated,VBN,O
,with,IN,O
,enhanced,JJ,O
,induction,NN,O
,of,IN,O
,the,DT,O
,DNA,NNP,O
,repair,NN,O
,proteins,NNS,O
,Ku70,NNP,O
,and,CC,O
,Ku80,NNP,O
,.,.,O
,Mice,NNP,O
,with,IN,O
,cardiomyocyte,JJ,O
,-,:,O
,restricted,VBN,O
,deletion,NN,O
,of,IN,O
,STAT3,NNP,O
,exhibited,VBD,O
,worse,JJR,O
,cardiac,JJ,O
,function,NN,O
,",",",",O
,higher,JJR,O
,levels,NNS,O
,of,IN,O
,cardiomyocyte,NN,O
,apoptosis,NN,O
,",",",",O
,and,CC,O
,a,DT,O
,greater,JJR,O
,induction,NN,O
,of,IN,O
,Ku70,NNP,O
,and,CC,O
,Ku80,NNP,O
,in,IN,O
,response,NN,O
,to,TO,O
,DOX,NNP,O
,treatment,NN,O
,during,IN,O
,the,DT,O
,acute,JJ,O
,stage,NN,O
,when,WRB,O
,compared,VBN,O
,with,IN,O
,control,NN,O
,animals,NNS,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,These,DT,O
,data,NNS,O
,support,NN,O
,a,DT,O
,model,NN,O
,wherein,WRB,O
,a,DT,O
,p53,NN,O
,-,:,O
,dependent,JJ,O
,cardioprotective,JJ,O
,pathway,NN,O
,",",",",O
,mediated,VBD,O
,via,IN,O
,STAT3,NNP,O
,activation,NN,O
,",",",",O
,mitigates,VBZ,O
,DOX,NNP,O
,-,:,O
,induced,VBD,O
,myocardial,JJ,O
,stress,NN,O
,during,IN,O
,drug,NN,O
,delivery,NN,O
,.,.,O
,Furthermore,NN,O
,",",",",O
,these,DT,O
,data,NNS,O
,suggest,VBP,O
,an,DT,O
,explanation,NN,O
,as,IN,O
,to,TO,O
,how,WRB,O
,p53,JJ,O
,inhibition,NN,O
,can,MD,O
,result,VB,O
,in,IN,O
,cardioprotection,NN,O
,during,IN,O
,drug,NN,O
,treatment,NN,O
,and,CC,O
,",",",",O
,paradoxically,RB,O
,",",",",O
,enhanced,VBD,O
,cardiotoxicity,NN,B-DISEASE
,long,RB,O
,after,IN,O
,the,DT,O
,cessation,NN,O
,of,IN,O
,drug,NN,O
,treatment,NN,O
,.,.,O
,Metronidazole,NNP,O
,-,:,O
,induced,VBD,O
,encephalopathy,JJ,B-DISEASE
,:,:,O
,an,DT,O
,uncommon,JJ,O
,scenario,NN,O
,.,.,O
,Metronidazole,NNP,O
,can,MD,O
,produce,VB,O
,neurological,JJ,O
,complications,NNS,O
,although,IN,O
,it,PRP,O
,is,VBZ,O
,not,RB,O
,a,DT,O
,common,JJ,O
,scenario,NN,O
,.,.,O
,We,PRP,O
,present,VBD,O
,a,DT,O
,case,NN,O
,where,WRB,O
,a,DT,O
,patient,NN,O
,developed,VBD,O
,features,NNS,O
,of,IN,O
,encephalopathy,JJ,B-DISEASE
,following,VBG,O
,prolonged,JJ,O
,metronidazole,JJ,O
,intake,NN,O
,.,.,O
,Magnetic,JJ,O
,resonance,NN,O
,imaging,NN,O
,(,(,O
,MRI,NNP,O
,),),O
,brain,NN,O
,showed,VBD,O
,abnormal,JJ,O
,signal,JJ,O
,intensity,NN,O
,involving,VBG,O
,both,DT,O
,dentate,JJ,O
,nuclei,NN,O
,of,IN,O
,cerebellum,NN,O
,and,CC,O
,splenium,NN,O
,of,IN,O
,corpus,NN,O
,callosum,NN,O
,.,.,O
,The,DT,O
,diagnosis,NN,O
,of,IN,O
,metronidazole,JJ,O
,toxicity,NN,B-DISEASE
,was,VBD,O
,made,VBN,O
,by,IN,O
,the,DT,O
,MRI,NNP,O
,findings,NNS,O
,and,CC,O
,supported,VBD,O
,clinically,RB,O
,.,.,O
,Aconitine,NNP,O
,-,:,O
,induced,VBD,O
,Ca2,NNP,O
,+,NNP,O
,overload,NN,O
,causes,VBZ,O
,arrhythmia,NN,B-DISEASE
,and,CC,O
,triggers,NNS,O
,apoptosis,VBP,O
,through,IN,O
,p38,NN,O
,MAPK,NNP,O
,signaling,VBG,O
,pathway,RB,O
,in,IN,O
,rats,NNS,O
,.,.,O
,Aconitine,NNP,O
,is,VBZ,O
,a,DT,O
,major,JJ,O
,bioactive,JJ,O
,diterpenoid,NN,O
,alkaloid,NN,O
,with,IN,O
,high,JJ,O
,content,NN,O
,derived,VBN,O
,from,IN,O
,herbal,JJ,O
,aconitum,NN,O
,plants,NNS,O
,.,.,O
,Emerging,VBG,O
,evidence,NN,O
,indicates,VBZ,O
,that,IN,O
,voltage,NN,O
,-,:,O
,dependent,NN,O
,Na,NNP,O
,(,(,O
,+,NNP,O
,),),O
,channels,NNS,O
,have,VBP,O
,pivotal,JJ,O
,roles,NNS,O
,in,IN,O
,the,DT,O
,cardiotoxicity,NN,B-DISEASE
,of,IN,O
,aconitine,NN,O
,.,.,O
,However,RB,O
,",",",",O
,no,DT,O
,reports,NNS,O
,are,VBP,O
,available,JJ,O
,on,IN,O
,the,DT,O
,role,NN,O
,of,IN,O
,Ca,NNP,O
,(,(,O
,2,CD,O
,+,NN,O
,),),O
,in,IN,O
,aconitine,NN,O
,poisoning,NN,B-DISEASE
,.,.,O
,In,IN,O
,this,DT,O
,study,NN,O
,",",",",O
,we,PRP,O
,explored,VBD,O
,the,DT,O
,importance,NN,O
,of,IN,O
,pathological,JJ,O
,Ca,NNP,O
,(,(,O
,2,CD,O
,+,NN,O
,),),O
,signaling,VBG,O
,in,IN,O
,aconitine,JJ,O
,poisoning,NN,B-DISEASE
,in,IN,O
,vitro,NN,O
,and,CC,O
,in,IN,O
,vivo,NN,O
,.,.,O
,We,PRP,O
,found,VBD,O
,that,IN,O
,Ca,NNP,O
,(,(,O
,2,CD,O
,+,NN,O
,),),O
,overload,VBZ,O
,lead,JJ,O
,to,TO,O
,accelerated,JJ,O
,beating,NN,O
,rhythm,NN,O
,in,IN,O
,adult,NN,O
,rat,NN,O
,ventricular,JJ,O
,myocytes,NNS,O
,and,CC,O
,caused,VBD,O
,arrhythmia,NN,B-DISEASE
,in,IN,O
,conscious,JJ,O
,freely,RB,O
,moving,VBG,O
,rats,NNS,O
,.,.,O
,To,TO,O
,investigate,VB,O
,effects,NNS,O
,of,IN,O
,aconitine,NN,O
,on,IN,O
,myocardial,JJ,B-DISEASE
,injury,NN,I-DISEASE
,",",",",O
,we,PRP,O
,performed,VBD,O
,cytotoxicity,NN,B-DISEASE
,assay,NN,O
,in,IN,O
,neonatal,JJ,O
,rat,NN,O
,ventricular,JJ,O
,myocytes,NNS,O
,(,(,O
,NRVMs,NNP,O
,),),O
,",",",",O
,as,RB,O
,well,RB,O
,as,IN,O
,measured,VBN,O
,lactate,NN,O
,dehydrogenase,NN,O
,level,NN,O
,in,IN,O
,the,DT,O
,culture,NN,O
,medium,NN,O
,of,IN,O
,NRVMs,NNP,O
,and,CC,O
,activities,NNS,O
,of,IN,O
,serum,NN,O
,cardiac,JJ,O
,enzymes,NNS,O
,in,IN,O
,rats,NNS,O
,.,.,O
,The,DT,O
,results,NNS,O
,showed,VBD,O
,that,IN,O
,aconitine,NN,O
,resulted,VBD,O
,in,IN,O
,myocardial,JJ,B-DISEASE
,injury,NN,I-DISEASE
,and,CC,O
,reduced,JJ,O
,NRVMs,NNP,O
,viability,NN,O
,dose,SYM,O
,-,:,O
,dependently,RB,O
,.,.,O
,To,TO,O
,confirm,VB,O
,the,DT,O
,pro,JJ,O
,-,:,O
,apoptotic,JJ,O
,effects,NNS,O
,",",",",O
,we,PRP,O
,performed,VBD,O
,flow,JJ,O
,cytometric,JJ,O
,detection,NN,O
,",",",",O
,cardiac,JJ,O
,histology,NN,O
,",",",",O
,transmission,NN,O
,electron,NN,O
,microscopy,NN,O
,and,CC,O
,terminal,JJ,O
,deoxynucleotidyl,NN,O
,transferase,NN,O
,-,:,O
,mediated,VBN,O
,dUTP,JJ,O
,-,:,O
,biotin,NN,O
,nick,JJ,O
,end,NN,O
,labeling,VBG,O
,assay,NN,O
,.,.,O
,The,DT,O
,results,NNS,O
,showed,VBD,O
,that,IN,O
,aconitine,NN,O
,stimulated,VBN,O
,apoptosis,NN,O
,time,NN,O
,-,:,O
,dependently,RB,O
,.,.,O
,The,DT,O
,expression,NN,O
,analysis,NN,O
,of,IN,O
,Ca,NNP,O
,(,(,O
,2,CD,O
,+,NN,O
,),),O
,handling,VBG,O
,proteins,NNS,O
,demonstrated,VBD,O
,that,IN,O
,aconitine,NN,O
,promoted,VBN,O
,Ca,NNP,O
,(,(,O
,2,CD,O
,+,NN,O
,),),O
,overload,NN,O
,through,IN,O
,the,DT,O
,expression,NN,O
,regulation,NN,O
,of,IN,O
,Ca,NNP,O
,(,(,O
,2,CD,O
,+,NN,O
,),),O
,handling,NN,O
,proteins,NNS,O
,.,.,O
,The,DT,O
,expression,NN,O
,analysis,NN,O
,of,IN,O
,apoptosis,NN,O
,-,:,O
,related,JJ,O
,proteins,NNS,O
,revealed,VBD,O
,that,IN,O
,pro,FW,O
,-,:,O
,apoptotic,JJ,O
,protein,NN,O
,expression,NN,O
,was,VBD,O
,upregulated,VBN,O
,",",",",O
,and,CC,O
,anti,SYM,O
,-,:,O
,apoptotic,JJ,O
,protein,NN,O
,BCL,NNP,O
,-,:,O
,2,CD,O
,expression,NN,O
,was,VBD,O
,downregulated,VBN,O
,.,.,O
,Furthermore,NNP,O
,",",",",O
,increased,VBD,O
,phosphorylation,NN,O
,of,IN,O
,MAPK,NNP,O
,family,NN,O
,members,NNS,O
,",",",",O
,especially,RB,O
,the,DT,O
,P,NNP,O
,-,:,O
,P38,NNP,O
,/,NNP,O
,P38,NNP,O
,ratio,NN,O
,was,VBD,O
,found,VBN,O
,in,IN,O
,cardiac,JJ,O
,tissues,NNS,O
,.,.,O
,Hence,NNP,O
,",",",",O
,our,PRP$,O
,results,NNS,O
,suggest,VBP,O
,that,IN,O
,aconitine,VBP,O
,significantly,RB,O
,aggravates,NNS,O
,Ca,NNP,O
,(,(,O
,2,CD,O
,+,NN,O
,),),O
,overload,NN,O
,and,CC,O
,causes,VBZ,O
,arrhythmia,NN,B-DISEASE
,and,CC,O
,finally,RB,O
,promotes,VBZ,O
,apoptotic,JJ,O
,development,NN,O
,via,IN,O
,phosphorylation,NN,O
,of,IN,O
,P38,NNP,O
,mitogen,FW,O
,-,:,O
,activated,VBN,O
,protein,JJ,O
,kinase,NN,O
,.,.,O
,Chronic,NNP,O
,treatment,NN,O
,with,IN,O
,metformin,NN,O
,suppresses,NNS,O
,toll,VBP,O
,-,:,O
,like,IN,O
,receptor,NN,O
,4,CD,O
,signaling,NN,O
,and,CC,O
,attenuates,VBZ,O
,left,VBD,B-DISEASE
,ventricular,JJ,I-DISEASE
,dysfunction,NN,I-DISEASE
,following,VBG,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,.,.,O
,Acute,NNP,O
,treatment,NN,O
,with,IN,O
,metformin,NN,O
,has,VBZ,O
,a,DT,O
,protective,JJ,O
,effect,NN,O
,in,IN,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,by,IN,O
,suppression,NN,O
,of,IN,O
,inflammatory,JJ,O
,responses,NNS,O
,due,JJ,O
,to,TO,O
,activation,NN,O
,of,IN,O
,AMP,NNP,O
,-,:,O
,activated,VBD,O
,protein,JJ,O
,kinase,NN,O
,(,(,O
,AMPK,NNP,O
,),),O
,.,.,O
,In,IN,O
,the,DT,O
,present,JJ,O
,study,NN,O
,",",",",O
,the,DT,O
,effect,NN,O
,of,IN,O
,chronic,JJ,O
,pre,NN,O
,-,:,O
,treatment,NN,O
,with,IN,O
,metformin,NN,O
,on,IN,O
,cardiac,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,and,CC,O
,toll,NN,O
,-,:,O
,like,IN,O
,receptor,NN,O
,4,CD,O
,(,(,O
,TLR4,NNP,O
,),),O
,activities,NNS,O
,following,VBG,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,and,CC,O
,their,PRP$,O
,relation,NN,O
,with,IN,O
,AMPK,NNP,O
,were,VBD,O
,assessed,VBN,O
,.,.,O
,Male,NNP,O
,Wistar,NNP,O
,rats,NNS,O
,were,VBD,O
,randomly,RB,O
,assigned,VBN,O
,to,TO,O
,one,CD,O
,of,IN,O
,5,CD,O
,groups,NNS,O
,(,(,O
,n,JJ,O
,=,NNP,O
,6,CD,O
,),),O
,:,:,O
,normal,JJ,O
,control,NN,O
,and,CC,O
,groups,NNS,O
,were,VBD,O
,injected,VBN,O
,isoproterenol,NN,O
,after,IN,O
,chronic,JJ,O
,pre,NN,O
,-,:,O
,treatment,NN,O
,with,IN,O
,0,CD,O
,",",",",O
,25,CD,O
,",",",",O
,50,CD,O
,",",",",O
,or,CC,O
,100mg,CD,O
,/,JJ,O
,kg,NN,O
,of,IN,O
,metformin,JJ,O
,twice,JJ,O
,daily,RB,O
,for,IN,O
,14,CD,O
,days,NNS,O
,.,.,O
,Isoproterenol,NNP,O
,(,(,O
,100mg,CD,O
,/,NNP,O
,kg,NN,O
,),),O
,was,VBD,O
,injected,VBN,O
,subcutaneously,RB,O
,on,IN,O
,the,DT,O
,13th,CD,O
,and,CC,O
,14th,CD,O
,days,NNS,O
,to,TO,O
,induce,VB,O
,acute,JJ,B-DISEASE
,myocardial,JJ,I-DISEASE
,infarction,NN,I-DISEASE
,.,.,O
,Isoproterenol,NNP,O
,alone,RB,O
,decreased,VBD,O
,left,JJ,O
,ventricular,JJ,O
,systolic,JJ,O
,pressure,NN,O
,and,CC,O
,myocardial,JJ,O
,contractility,NN,O
,indexed,VBN,O
,as,IN,O
,LVdp,NNP,O
,/,NNP,O
,dtmax,NN,O
,and,CC,O
,LVdp,NNP,O
,/,NNP,O
,dtmin,NN,O
,.,.,O
,The,DT,O
,left,JJ,B-DISEASE
,ventricular,JJ,I-DISEASE
,dysfunction,NN,I-DISEASE
,was,VBD,O
,significantly,RB,O
,lower,JJR,O
,in,IN,O
,the,DT,O
,groups,NNS,O
,treated,VBD,O
,with,IN,O
,25,CD,O
,and,CC,O
,50mg,CD,O
,/,JJ,O
,kg,NN,O
,of,IN,O
,metformin,NN,O
,.,.,O
,Metfromin,NNP,O
,markedly,RB,O
,lowered,VBD,O
,isoproterenol,JJ,O
,-,:,O
,induced,JJ,O
,elevation,NN,O
,in,IN,O
,the,DT,O
,levels,NNS,O
,of,IN,O
,TLR4,NNP,O
,mRNA,NN,O
,",",",",O
,myeloid,JJ,O
,differentiation,NN,O
,protein,NN,O
,88,CD,O
,(,(,O
,MyD88,NNP,O
,),),O
,",",",",O
,tumor,JJ,B-DISEASE
,necrosis,NN,B-DISEASE
,factor,NN,O
,-,:,O
,alpha,NN,O
,(,(,O
,TNF,NNP,O
,-,:,O
,a,DT,O
,),),O
,",",",",O
,and,CC,O
,interleukin,JJ,O
,6,CD,O
,(,(,O
,IL,NNP,O
,-,:,O
,6,CD,O
,),),O
,in,IN,O
,the,DT,O
,heart,NN,O
,tissues,VBZ,O
,.,.,O
,Similar,JJ,O
,changes,NNS,O
,were,VBD,O
,also,RB,O
,seen,VBN,O
,in,IN,O
,the,DT,O
,serum,NN,O
,levels,NNS,O
,of,IN,O
,TNF,NNP,O
,-,:,O
,a,DT,O
,and,CC,O
,IL,NNP,O
,-,:,O
,6,CD,O
,.,.,O
,However,RB,O
,",",",",O
,the,DT,O
,lower,JJR,O
,doses,NNS,O
,of,IN,O
,25,CD,O
,and,CC,O
,50mg,CD,O
,/,NNS,O
,kg,NNS,O
,were,VBD,O
,more,RBR,O
,effective,JJ,O
,than,IN,O
,100mg,CD,O
,/,JJ,O
,kg,NN,O
,.,.,O
,Phosphorylated,VBN,O
,AMPKa,NNP,O
,(,(,O
,p,SYM,O
,-,:,O
,AMPK,NN,O
,),),O
,in,IN,O
,the,DT,O
,myocardium,NN,O
,was,VBD,O
,significantly,RB,O
,elevated,VBN,O
,by,IN,O
,25mg,CD,O
,/,JJ,O
,kg,NN,O
,of,IN,O
,metformin,NN,O
,",",",",O
,slightly,RB,O
,by,IN,O
,50mg,CD,O
,/,NNS,O
,kg,NN,O
,",",",",O
,but,CC,O
,not,RB,O
,by,IN,O
,100mg,CD,O
,/,JJ,O
,kg,NN,O
,.,.,O
,Chronic,NNP,O
,pre,IN,O
,-,:,O
,treatment,NN,O
,with,IN,O
,metformin,NN,O
,reduces,NNS,O
,post,VBP,O
,-,:,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,cardiac,JJ,O
,dysfunction,NN,O
,and,CC,O
,suppresses,VBZ,O
,inflammatory,JJ,O
,responses,NNS,O
,",",",",O
,possibly,RB,O
,through,IN,O
,inhibition,NN,O
,of,IN,O
,TLR4,NNP,O
,activities,NNS,O
,.,.,O
,This,DT,O
,mechanism,NN,O
,can,MD,O
,be,VB,O
,considered,VBN,O
,as,IN,O
,a,DT,O
,target,NN,O
,to,TO,O
,protect,VB,O
,infarcted,JJ,O
,myocardium,NN,O
,.,.,O
,Unusual,JJ,O
,complications,NNS,O
,of,IN,O
,antithyroid,JJ,O
,drug,NN,O
,therapy,NN,O
,:,:,O
,four,CD,O
,case,NN,O
,reports,NNS,O
,and,CC,O
,review,NN,O
,of,IN,O
,literature,NN,O
,.,.,O
,Two,CD,O
,cases,NNS,O
,of,IN,O
,propylthiouracil,NN,O
,-,:,O
,associated,VBN,O
,acute,JJ,O
,hepatitis,NN,B-DISEASE
,",",",",O
,one,CD,O
,case,NN,O
,of,IN,O
,fatal,JJ,O
,methimazole,JJ,O
,-,:,O
,associated,VBN,O
,hepatocellular,JJ,B-DISEASE
,necrosis,NN,I-DISEASE
,and,CC,O
,one,CD,O
,case,NN,O
,of,IN,O
,propylthiouracil,NN,O
,-,:,O
,associated,VBN,O
,lupus,JJ,B-DISEASE
,-,:,I-DISEASE
,like,IN,I-DISEASE
,syndrome,NN,I-DISEASE
,are,VBP,O
,described,VBN,O
,.,.,O
,The,DT,O
,literature,NN,O
,related,VBN,O
,to,TO,O
,antithyroid,JJ,O
,drug,NN,O
,side,NN,O
,effects,NNS,O
,and,CC,O
,the,DT,O
,mechanisms,NNS,O
,for,IN,O
,their,PRP$,O
,occurrence,NN,O
,are,VBP,O
,reviewed,VBN,O
,and,CC,O
,the,DT,O
,efficacy,NN,O
,and,CC,O
,complications,NNS,O
,of,IN,O
,thyroidectomy,NN,O
,and,CC,O
,radioiodine,NN,O
,compared,VBN,O
,to,TO,O
,those,DT,O
,of,IN,O
,antithyroid,JJ,O
,drugs,NNS,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,concluded,VBN,O
,that,IN,O
,in,IN,O
,most,JJS,O
,circumstances,NNS,O
,131I,CD,O
,is,VBZ,O
,the,DT,O
,therapy,NN,O
,of,IN,O
,choice,NN,O
,for,IN,O
,hyperthyroidism,NN,B-DISEASE
,.,.,O
,Neuroleptic,JJ,B-DISEASE
,malignant,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,combination,NN,O
,therapy,NN,O
,with,IN,O
,tetrabenazine,NN,O
,and,CC,O
,tiapride,NN,O
,in,IN,O
,a,DT,O
,Japanese,JJ,O
,patient,NN,O
,with,IN,O
,Huntington,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,at,IN,O
,the,DT,O
,terminal,JJ,O
,stage,NN,O
,of,IN,O
,recurrent,JJ,O
,breast,NN,B-DISEASE
,cancer,NN,I-DISEASE
,.,.,O
,We,PRP,O
,herein,VBP,O
,describe,VB,O
,the,DT,O
,case,NN,O
,of,IN,O
,an,DT,O
,81,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,Japanese,JJ,O
,woman,NN,O
,with,IN,O
,neuroleptic,JJ,B-DISEASE
,malignant,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,that,WDT,O
,occurred,VBD,O
,36,CD,O
,days,NNS,O
,after,IN,O
,the,DT,O
,initiation,NN,O
,of,IN,O
,combination,NN,O
,therapy,NN,O
,with,IN,O
,tiapride,NN,O
,(,(,O
,75,CD,O
,mg,NNS,O
,/,JJ,O
,day,NN,O
,),),O
,and,CC,O
,tetrabenazine,NN,O
,(,(,O
,12,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,/,NNP,O
,day,NN,O
,),),O
,for,IN,O
,Huntington,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,The,DT,O
,patient,NN,O
,had,VBD,O
,been,VBN,O
,treated,VBN,O
,with,IN,O
,tiapride,NN,O
,or,CC,O
,tetrabenazine,VB,O
,alone,RB,O
,without,IN,O
,any,DT,O
,adverse,JJ,O
,effects,NNS,O
,before,IN,O
,the,DT,O
,administration,NN,O
,of,IN,O
,the,DT,O
,combination,NN,O
,therapy,NN,O
,.,.,O
,She,PRP,O
,also,RB,O
,had,VBD,O
,advanced,VBN,O
,breast,NN,B-DISEASE
,cancer,NN,I-DISEASE
,when,WRB,O
,the,DT,O
,combination,NN,O
,therapy,NN,O
,was,VBD,O
,initiated,VBN,O
,.,.,O
,To,TO,O
,the,DT,O
,best,JJS,O
,of,IN,O
,our,PRP$,O
,knowledge,NN,O
,",",",",O
,the,DT,O
,occurrence,NN,O
,of,IN,O
,neuroleptic,JJ,B-DISEASE
,malignant,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,due,JJ,O
,to,TO,O
,combination,VB,O
,therapy,NN,O
,with,IN,O
,tetrabenazine,NN,O
,and,CC,O
,tiapride,NN,O
,has,VBZ,O
,not,RB,O
,been,VBN,O
,previously,RB,O
,reported,VBN,O
,.,.,O
,Tetrabenazine,NN,O
,should,MD,O
,be,VB,O
,administered,VBN,O
,very,RB,O
,carefully,RB,O
,in,IN,O
,combination,NN,O
,with,IN,O
,other,JJ,O
,neuroleptic,JJ,O
,drugs,NNS,O
,",",",",O
,particularly,RB,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,a,DT,O
,worsening,VBG,O
,general,JJ,O
,condition,NN,O
,.,.,O
,A,DT,O
,metoprolol,JJ,O
,-,:,O
,terbinafine,NN,O
,combination,NN,O
,induced,VBD,O
,bradycardia,NN,B-DISEASE
,.,.,O
,To,TO,O
,report,VB,O
,a,DT,O
,sinus,JJ,B-DISEASE
,bradycardia,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,metoprolol,NN,O
,and,CC,O
,terbinafine,JJ,O
,drug,NN,O
,-,:,O
,drug,NN,O
,interaction,NN,O
,and,CC,O
,its,PRP$,O
,management,NN,O
,.,.,O
,A,DT,O
,63,CD,O
,year,NN,O
,-,:,O
,old,JJ,O
,Caucasian,JJ,O
,man,NN,O
,on,IN,O
,metoprolol,$,O
,200,CD,O
,mg,JJ,O
,/,NNP,O
,day,NN,O
,for,IN,O
,stable,JJ,O
,coronary,JJ,B-DISEASE
,artery,NN,I-DISEASE
,disease,NN,I-DISEASE
,was,VBD,O
,prescribed,VBN,O
,a,DT,O
,90,CD,O
,-,:,O
,day,NN,O
,course,NN,O
,of,IN,O
,oral,JJ,O
,terbinafine,NN,O
,250,CD,O
,mg,NN,O
,/,NNP,O
,day,NN,O
,for,IN,O
,onychomycosis,NN,B-DISEASE
,.,.,O
,On,IN,O
,the,DT,O
,49th,CD,O
,day,NN,O
,of,IN,O
,terbinafine,NN,O
,therapy,NN,O
,",",",",O
,he,PRP,O
,was,VBD,O
,brought,VBN,O
,to,TO,O
,the,DT,O
,emergency,NN,O
,room,NN,O
,for,IN,O
,a,DT,O
,decrease,NN,O
,of,IN,O
,his,PRP$,O
,global,JJ,O
,health,NN,O
,status,NN,O
,",",",",O
,confusion,NN,B-DISEASE
,and,CC,O
,falls,NNS,O
,.,.,O
,The,DT,O
,electrocardiogram,NN,O
,revealed,VBD,O
,a,DT,O
,37,CD,O
,beats,NNS,O
,/,VBP,O
,min,JJ,O
,sinus,NN,B-DISEASE
,bradycardia,NN,I-DISEASE
,.,.,O
,A,DT,O
,score,NN,O
,of,IN,O
,7,CD,O
,on,IN,O
,the,DT,O
,Naranjo,NNP,O
,adverse,JJ,B-DISEASE
,drug,NN,I-DISEASE
,reaction,NN,I-DISEASE
,probability,NN,O
,scale,NN,O
,indicates,VBZ,O
,a,DT,O
,probable,JJ,O
,relationship,NN,O
,between,IN,O
,the,DT,O
,patient,NN,O
,',POS,O
,s,JJ,O
,sinus,NNS,B-DISEASE
,bradycardia,NN,I-DISEASE
,and,CC,O
,the,DT,O
,drug,NN,O
,interaction,NN,O
,between,IN,O
,metoprolol,NN,O
,and,CC,O
,terbinafine,NN,O
,.,.,O
,The,DT,O
,heart,NN,O
,rate,NN,O
,ameliorated,VBD,O
,first,RB,O
,with,IN,O
,a,DT,O
,decrease,NN,O
,in,IN,O
,the,DT,O
,dose,NN,O
,of,IN,O
,metoprolol,NN,O
,.,.,O
,It,PRP,O
,was,VBD,O
,subsequently,RB,O
,changed,VBN,O
,to,TO,O
,bisoprolol,VB,O
,and,CC,O
,the,DT,O
,heart,NN,O
,rate,NN,O
,remained,VBD,O
,normal,JJ,O
,.,.,O
,By,IN,O
,inhibiting,VBG,O
,the,DT,O
,cytochrome,NN,O
,P450,NNP,O
,2D6,CD,O
,",",",",O
,terbinafine,NN,O
,had,VBD,O
,decreased,VBN,O
,metoprolol,NN,O
,','',O
,s,JJ,O
,clearance,NN,O
,",",",",O
,leading,VBG,O
,in,IN,O
,metoprolol,NN,O
,accumulation,NN,O
,which,WDT,O
,has,VBZ,O
,resulted,VBN,O
,in,IN,O
,clinically,RB,O
,significant,JJ,O
,sinus,JJ,B-DISEASE
,bradycardia,NN,I-DISEASE
,.,.,O
,Optochiasmatic,JJ,O
,and,CC,O
,peripheral,JJ,B-DISEASE
,neuropathy,NNS,I-DISEASE
,due,JJ,O
,to,TO,O
,ethambutol,VB,O
,overtreatment,NN,O
,.,.,O
,Ethambutol,NNP,O
,is,VBZ,O
,known,VBN,O
,to,TO,O
,cause,VB,O
,optic,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,and,CC,O
,",",",",O
,more,RBR,O
,rarely,RB,O
,",",",",O
,axonal,JJ,O
,polyneuropathy,NN,B-DISEASE
,.,.,O
,We,PRP,O
,characterize,VBP,O
,the,DT,O
,clinical,JJ,O
,",",",",O
,neurophysiological,JJ,O
,",",",",O
,and,CC,O
,neuroimaging,VBG,O
,findings,NNS,O
,in,IN,O
,a,DT,O
,72,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,man,NN,O
,who,WP,O
,developed,VBD,O
,visual,JJ,B-DISEASE
,loss,NN,I-DISEASE
,and,CC,O
,paresthesias,NN,B-DISEASE
,after,IN,O
,11,CD,O
,weeks,NNS,O
,of,IN,O
,exposure,NN,O
,to,TO,O
,a,DT,O
,supratherapeutic,JJ,O
,dose,NN,O
,of,IN,O
,ethambutol,NN,O
,.,.,O
,This,DT,O
,case,NN,O
,demonstrates,VBZ,O
,the,DT,O
,selective,JJ,O
,vulnerability,NN,O
,of,IN,O
,the,DT,O
,anterior,JJ,O
,visual,JJ,O
,pathways,NNS,O
,and,CC,O
,peripheral,JJ,O
,nerves,NNS,O
,to,TO,O
,ethambutol,VB,O
,toxicity,NN,B-DISEASE
,.,.,O
,Testosterone,CD,O
,ameliorates,VBZ,O
,streptozotocin,SYM,O
,-,:,O
,induced,JJ,O
,memory,NN,B-DISEASE
,impairment,NN,I-DISEASE
,in,IN,O
,male,JJ,O
,rats,NNS,O
,.,.,O
,AIM,NN,O
,:,:,O
,To,TO,O
,study,VB,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,testosterone,NN,O
,on,IN,O
,streptozotocin,NN,O
,(,(,O
,STZ,NNP,O
,),),O
,-,:,O
,induced,JJ,O
,memory,NN,B-DISEASE
,impairment,NN,I-DISEASE
,in,IN,O
,male,JJ,O
,rats,NNS,O
,.,.,O
,METHODS,NN,O
,:,:,O
,Adult,NNP,O
,male,NN,O
,Wistar,NNP,O
,rats,NNS,O
,were,VBD,O
,intracerebroventricularly,RB,O
,(,(,O
,icv,NN,O
,),),O
,infused,VBD,O
,with,IN,O
,STZ,NNP,O
,(,(,O
,750,CD,O
,ug,NN,O
,),),O
,on,IN,O
,d,NN,O
,1,CD,O
,and,CC,O
,d,VB,O
,3,CD,O
,",",",",O
,and,CC,O
,a,DT,O
,passive,JJ,O
,avoidance,NN,O
,task,NN,O
,was,VBD,O
,assessed,VBN,O
,2,CD,O
,weeks,NNS,O
,after,IN,O
,the,DT,O
,first,JJ,O
,injection,NN,O
,of,IN,O
,STZ,NNP,O
,.,.,O
,Castration,NN,O
,surgery,NN,O
,was,VBD,O
,performed,VBN,O
,in,IN,O
,another,DT,O
,group,NN,O
,of,IN,O
,rats,NNS,O
,",",",",O
,and,CC,O
,the,DT,O
,passive,JJ,O
,avoidance,NN,O
,task,NN,O
,was,VBD,O
,assessed,VBN,O
,4,CD,O
,weeks,NNS,O
,after,IN,O
,the,DT,O
,operation,NN,O
,.,.,O
,Testosterone,NNP,O
,(,(,O
,1,CD,O
,mg,NN,O
,.,.,O
,kg,NN,O
,(,(,O
,-,:,O
,1,CD,O
,),),O
,.,.,O
,d,NN,O
,(,(,O
,-,:,O
,1,CD,O
,),),O
,",",",",O
,sc,NN,O
,),),O
,",",",",O
,the,DT,O
,androgen,NN,O
,receptor,NN,O
,antagonist,NN,O
,flutamide,NN,O
,(,(,O
,10,CD,O
,mg,NN,O
,.,.,O
,kg,NN,O
,(,(,O
,-,:,O
,1,CD,O
,),),O
,.,.,O
,d,NN,O
,(,(,O
,-,:,O
,1,CD,O
,),),O
,",",",",O
,ip,NN,O
,),),O
,",",",",O
,the,DT,O
,estrogen,NN,O
,receptor,NN,O
,antagonist,NN,O
,tamoxifen,NN,O
,(,(,O
,1,CD,O
,mg,NN,O
,.,.,O
,kg,NN,O
,(,(,O
,-,:,O
,1,CD,O
,),),O
,.,.,O
,d,NN,O
,(,(,O
,-,:,O
,1,CD,O
,),),O
,",",",",O
,ip,NN,O
,),),O
,or,CC,O
,the,DT,O
,aromatase,NN,O
,inhibitor,NN,O
,letrozole,NN,O
,(,(,O
,4,CD,O
,mg,NN,O
,.,.,O
,kg,NN,O
,(,(,O
,-,:,O
,1,CD,O
,),),O
,.,.,O
,d,NN,O
,(,(,O
,-,:,O
,1,CD,O
,),),O
,",",",",O
,ip,NN,O
,),),O
,were,VBD,O
,administered,VBN,O
,for,IN,O
,6,CD,O
,d,NN,O
,after,IN,O
,the,DT,O
,first,JJ,O
,injection,NN,O
,of,IN,O
,STZ,NNP,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,STZ,NNP,O
,administration,NN,O
,and,CC,O
,castration,NN,O
,markedly,RB,O
,decreased,VBD,O
,both,DT,O
,STL1,NNP,O
,(,(,O
,the,DT,O
,short,JJ,O
,memory,NN,O
,),),O
,and,CC,O
,STL2,NNP,O
,(,(,O
,the,DT,O
,long,JJ,O
,memory,NN,O
,),),O
,in,IN,O
,passive,JJ,O
,avoidance,NN,O
,tests,NNS,O
,.,.,O
,Testosterone,CD,O
,replacement,NN,O
,almost,RB,O
,restored,VBD,O
,the,DT,O
,STL1,NNP,O
,and,CC,O
,STL2,NNP,O
,in,IN,O
,castrated,JJ,O
,rats,NNS,O
,",",",",O
,and,CC,O
,significantly,RB,O
,prolonged,VBD,O
,the,DT,O
,STL1,NNP,O
,and,CC,O
,STL2,NNP,O
,in,IN,O
,STZ,NNP,O
,-,:,O
,treated,VBD,O
,rats,NNS,O
,.,.,O
,Administration,NNP,O
,of,IN,O
,flutamide,RB,O
,",",",",O
,letrozole,VBD,O
,or,CC,O
,tamoxifen,VB,O
,significantly,RB,O
,impaired,VBN,B-DISEASE
,the,DT,I-DISEASE
,memory,NN,I-DISEASE
,in,IN,O
,intact,JJ,O
,rats,NNS,O
,",",",",O
,and,CC,O
,significantly,RB,O
,attenuated,VBD,O
,the,DT,O
,testosterone,NN,O
,replacement,NN,O
,in,IN,O
,improving,VBG,O
,STZ,NNP,O
,-,:,O
,and,CC,O
,castration,NN,O
,-,:,O
,induced,JJ,O
,memory,NN,B-DISEASE
,impairment,NN,I-DISEASE
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Testosterone,CD,O
,administration,NN,O
,ameliorates,VBZ,O
,STZ,NNP,O
,-,:,O
,and,CC,O
,castration,NN,O
,-,:,O
,induced,JJ,O
,memory,NN,B-DISEASE
,impairment,NN,I-DISEASE
,in,IN,O
,male,JJ,O
,Wistar,NNP,O
,rats,NNS,O
,.,.,O
,Behavioral,NNP,O
,and,CC,O
,neurochemical,JJ,O
,studies,NNS,O
,in,IN,O
,mice,NNS,O
,pretreated,VBN,O
,with,IN,O
,garcinielliptone,NN,O
,FC,NNP,O
,in,IN,O
,pilocarpine,JJ,O
,-,:,O
,induced,JJ,O
,seizures,NNS,B-DISEASE
,.,.,O
,Garcinielliptone,NNP,O
,FC,NNP,O
,(,(,O
,GFC,NNP,O
,),),O
,isolated,VBD,O
,from,IN,O
,hexanic,JJ,O
,fraction,NN,O
,seed,NN,O
,extract,NN,O
,of,IN,O
,species,NNS,O
,Platonia,NNP,O
,insignis,VBP,O
,Mart,NNP,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,widely,RB,O
,used,VBN,O
,in,IN,O
,folk,JJ,O
,medicine,NN,O
,to,TO,O
,treat,VB,O
,skin,JJ,B-DISEASE
,diseases,NNS,I-DISEASE
,in,IN,O
,both,DT,O
,humans,NNS,O
,and,CC,O
,animals,NNS,O
,as,RB,O
,well,RB,O
,as,IN,O
,the,DT,O
,seed,NN,O
,decoction,NN,O
,has,VBZ,O
,been,VBN,O
,used,VBN,O
,to,TO,O
,treat,VB,O
,diarrheas,NNS,B-DISEASE
,and,CC,O
,inflammatory,JJ,B-DISEASE
,diseases,NNS,I-DISEASE
,.,.,O
,However,RB,O
,",",",",O
,there,EX,O
,is,VBZ,O
,no,DT,O
,research,NN,O
,on,IN,O
,GFC,NNP,O
,effects,NNS,O
,in,IN,O
,the,DT,O
,central,JJ,O
,nervous,JJ,O
,system,NN,O
,of,IN,O
,rodents,NNS,O
,.,.,O
,The,DT,O
,present,JJ,O
,study,NN,O
,aimed,VBN,O
,to,TO,O
,evaluate,VB,O
,the,DT,O
,GFC,NNP,O
,effects,NNS,O
,at,IN,O
,doses,NNS,O
,of,IN,O
,25,CD,O
,",",",",O
,50,CD,O
,or,CC,O
,75,CD,O
,mg,NNS,O
,/,JJ,O
,kg,NN,O
,on,IN,O
,seizure,NN,B-DISEASE
,parameters,NNS,O
,to,TO,O
,determine,VB,O
,their,PRP$,O
,anticonvulsant,JJ,O
,activity,NN,O
,and,CC,O
,its,PRP$,O
,effects,NNS,O
,on,IN,O
,amino,NN,O
,acid,NN,O
,(,(,O
,r,JJ,O
,-,:,O
,aminobutyric,JJ,O
,acid,NN,O
,(,(,O
,GABA,NNP,O
,),),O
,",",",",O
,glutamine,NN,O
,",",",",O
,aspartate,NN,O
,and,CC,O
,glutathione,NN,O
,),),O
,levels,NNS,O
,as,RB,O
,well,RB,O
,as,IN,O
,on,IN,O
,acetylcholinesterase,NN,O
,(,(,O
,AChE,NNP,O
,),),O
,activity,NN,O
,in,IN,O
,mice,NN,O
,hippocampus,NN,O
,after,IN,O
,seizures,NNS,B-DISEASE
,.,.,O
,GFC,NNP,O
,produced,VBD,O
,an,DT,O
,increased,JJ,O
,latency,NN,O
,to,TO,O
,first,JJ,O
,seizure,NN,B-DISEASE
,",",",",O
,at,IN,O
,doses,NNS,O
,25mg,CD,O
,/,JJ,O
,kg,NN,O
,(,(,O
,20,CD,O
,.,.,O
,12,CD,O
,+,JJ,O
,2,CD,O
,.,.,O
,20,CD,O
,min,NN,O
,),),O
,",",",",O
,50mg,CD,O
,/,NN,O
,kg,NN,O
,(,(,O
,20,CD,O
,.,.,O
,95,CD,O
,+,JJ,O
,2,CD,O
,.,.,O
,21,CD,O
,min,NN,O
,),),O
,or,CC,O
,75,CD,O
,mg,NNS,O
,/,JJ,O
,kg,NN,O
,(,(,O
,23,CD,O
,.,.,O
,43,CD,O
,+,JJ,O
,1,CD,O
,.,.,O
,99,CD,O
,min,NN,O
,),),O
,when,WRB,O
,compared,VBN,O
,with,IN,O
,seized,JJ,O
,mice,NN,O
,.,.,O
,In,IN,O
,addition,NN,O
,",",",",O
,GABA,NNP,O
,content,NN,O
,of,IN,O
,mice,NNS,O
,hippocampus,NNS,O
,treated,VBD,O
,with,IN,O
,GFC75,NNP,O
,plus,CC,O
,P400,NNP,O
,showed,VBD,O
,an,DT,O
,increase,NN,O
,of,IN,O
,46,CD,O
,.,.,O
,90,CD,O
,%,NN,O
,when,WRB,O
,compared,VBN,O
,with,IN,O
,seized,JJ,O
,mice,NN,O
,.,.,O
,In,IN,O
,aspartate,NN,O
,",",",",O
,glutamine,NN,O
,and,CC,O
,glutamate,NN,O
,levels,NNS,O
,detected,VBD,O
,a,DT,O
,decrease,NN,O
,of,IN,O
,5,CD,O
,.,.,O
,21,CD,O
,%,NN,O
,",",",",O
,13,CD,O
,.,.,O
,55,CD,O
,%,NN,O
,and,CC,O
,21,CD,O
,.,.,O
,80,CD,O
,%,NN,O
,",",",",O
,respectively,RB,O
,in,IN,O
,mice,NNS,O
,hippocampus,RB,O
,treated,VBN,O
,with,IN,O
,GFC75,NNP,O
,plus,CC,O
,P400,NNP,O
,when,WRB,O
,compared,VBN,O
,with,IN,O
,seized,JJ,O
,mice,NN,O
,.,.,O
,Hippocampus,NNP,O
,mice,NN,O
,treated,VBD,O
,with,IN,O
,GFC75,NNP,O
,plus,CC,O
,P400,NNP,O
,showed,VBD,O
,an,DT,O
,increase,NN,O
,in,IN,O
,AChE,NNP,O
,activity,NN,O
,(,(,O
,63,CD,O
,.,.,O
,30,CD,O
,%,NN,O
,),),O
,when,WRB,O
,compared,VBN,O
,with,IN,O
,seized,JJ,O
,mice,NN,O
,.,.,O
,The,DT,O
,results,NNS,O
,indicate,VBP,O
,that,IN,O
,GFC,NNP,O
,can,MD,O
,exert,VB,O
,anticonvulsant,JJ,O
,activity,NN,O
,and,CC,O
,reduce,VB,O
,the,DT,O
,frequency,NN,O
,of,IN,O
,installation,NN,O
,of,IN,O
,pilocarpine,NN,O
,-,:,O
,induced,JJ,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,",",",",O
,as,IN,O
,demonstrated,VBN,O
,by,IN,O
,increase,NN,O
,in,IN,O
,latency,NN,O
,to,TO,O
,first,JJ,O
,seizure,NN,B-DISEASE
,and,CC,O
,decrease,NN,O
,in,IN,O
,mortality,NN,O
,rate,NN,O
,of,IN,O
,animals,NNS,O
,.,.,O
,In,IN,O
,conclusion,NN,O
,",",",",O
,our,PRP$,O
,data,NNS,O
,suggest,VBP,O
,that,IN,O
,GFC,NNP,O
,may,MD,O
,influence,VB,O
,in,IN,O
,epileptogenesis,NN,O
,and,CC,O
,promote,NN,O
,anticonvulsant,JJ,O
,actions,NNS,O
,in,IN,O
,pilocarpine,NN,O
,model,NN,O
,by,IN,O
,modulating,VBG,O
,the,DT,O
,GABA,NNP,O
,and,CC,O
,glutamate,JJ,O
,contents,NNS,O
,and,CC,O
,of,IN,O
,AChE,NNP,O
,activity,NN,O
,in,IN,O
,seized,JJ,O
,mice,NN,O
,hippocampus,NN,O
,.,.,O
,This,DT,O
,compound,NN,O
,may,MD,O
,be,VB,O
,useful,JJ,O
,to,TO,O
,produce,VB,O
,neuronal,JJ,O
,protection,NN,O
,and,CC,O
,it,PRP,O
,can,MD,O
,be,VB,O
,considered,VBN,O
,as,IN,O
,an,DT,O
,anticonvulsant,JJ,O
,agent,NN,O
,.,.,O
,Standard,NNP,O
,operating,NN,O
,procedures,NNS,O
,for,IN,O
,antibiotic,JJ,O
,therapy,NN,O
,and,CC,O
,the,DT,O
,occurrence,NN,O
,of,IN,O
,acute,JJ,B-DISEASE
,kidney,NN,I-DISEASE
,injury,NN,I-DISEASE
,:,:,O
,a,DT,O
,prospective,JJ,O
,",",",",O
,clinical,JJ,O
,",",",",O
,non,JJ,O
,-,:,O
,interventional,NN,O
,",",",",O
,observational,JJ,O
,study,NN,O
,.,.,O
,INTRODUCTION,NN,O
,:,:,O
,Acute,NNP,B-DISEASE
,kidney,NNP,I-DISEASE
,injury,NN,I-DISEASE
,(,(,O
,AKI,NNP,B-DISEASE
,),),O
,occurs,VBZ,O
,in,IN,O
,7,CD,O
,%,NN,O
,of,IN,O
,hospitalized,VBN,O
,and,CC,O
,66,CD,O
,%,NN,O
,of,IN,O
,Intensive,NNP,O
,Care,NNP,O
,Unit,NNP,O
,(,(,O
,ICU,NNP,O
,),),O
,patients,NNS,O
,.,.,O
,It,PRP,O
,increases,VBZ,O
,mortality,NN,O
,",",",",O
,hospital,JJ,O
,length,NN,O
,of,IN,O
,stay,NN,O
,",",",",O
,and,CC,O
,costs,NNS,O
,.,.,O
,The,DT,O
,aim,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,was,VBD,O
,to,TO,O
,investigate,VB,O
,",",",",O
,whether,IN,O
,there,EX,O
,is,VBZ,O
,an,DT,O
,association,NN,O
,between,IN,O
,adherence,NN,O
,to,TO,O
,guidelines,NNS,O
,(,(,O
,standard,JJ,O
,operating,NN,O
,procedures,NNS,O
,(,(,O
,SOP,NNP,O
,),),O
,),),O
,for,IN,O
,potentially,RB,O
,nephrotoxic,JJ,B-DISEASE
,antibiotics,NNS,O
,and,CC,O
,the,DT,O
,occurrence,NN,O
,of,IN,O
,AKI,NNP,B-DISEASE
,.,.,O
,METHODS,NN,O
,:,:,O
,This,DT,O
,study,NN,O
,was,VBD,O
,carried,VBN,O
,out,RP,O
,as,IN,O
,a,DT,O
,prospective,JJ,O
,",",",",O
,clinical,JJ,O
,",",",",O
,non,JJ,O
,-,:,O
,interventional,NN,O
,",",",",O
,observational,JJ,O
,study,NN,O
,.,.,O
,Data,NNP,O
,collection,NN,O
,was,VBD,O
,performed,VBN,O
,over,IN,O
,a,DT,O
,total,NN,O
,of,IN,O
,170,CD,O
,days,NNS,O
,in,IN,O
,three,CD,O
,ICUs,NNP,O
,at,IN,O
,Charite,NNP,O
,-,:,O
,Universitaetsmedizin,NNP,O
,Berlin,NNP,O
,.,.,O
,A,NNP,O
,total,NN,O
,of,IN,O
,675,CD,O
,patients,NNS,O
,were,VBD,O
,included,VBN,O
,;,:,O
,163,CD,O
,of,IN,O
,these,DT,O
,had,VBD,O
,therapy,NN,O
,with,IN,O
,vancomycin,NN,O
,",",",",O
,gentamicin,NN,O
,",",",",O
,or,CC,O
,tobramycin,NN,O
,;,:,O
,were,VBD,O
,>,JJ,O
,18,CD,O
,years,NNS,O
,;,:,O
,and,CC,O
,treated,VBN,O
,in,IN,O
,the,DT,O
,ICU,NNP,O
,for,IN,O
,>,NNP,O
,24,CD,O
,hours,NNS,O
,.,.,O
,Patients,NNS,O
,with,IN,O
,an,DT,O
,adherence,NN,O
,to,TO,O
,SOP,NNP,O
,>,NNP,O
,70,CD,O
,%,NN,O
,were,VBD,O
,classified,VBN,O
,into,IN,O
,the,DT,O
,high,JJ,O
,adherence,NN,O
,group,NN,O
,(,(,O
,HAG,NNP,O
,),),O
,and,CC,O
,patients,NNS,O
,with,IN,O
,an,DT,O
,adherence,NN,O
,of,IN,O
,<,$,O
,70,CD,O
,%,NN,O
,into,IN,O
,the,DT,O
,low,JJ,O
,adherence,NN,O
,group,NN,O
,(,(,O
,LAG,NNP,O
,),),O
,.,.,O
,AKI,NNP,B-DISEASE
,was,VBD,O
,defined,VBN,O
,according,VBG,O
,to,TO,O
,RIFLE,NNP,O
,criteria,NNS,O
,.,.,O
,Adherence,NN,O
,to,TO,O
,SOPs,NNP,O
,was,VBD,O
,evaluated,VBN,O
,by,IN,O
,retrospective,JJ,O
,expert,NN,O
,audit,NN,O
,.,.,O
,Development,NNP,O
,of,IN,O
,AKI,NNP,B-DISEASE
,was,VBD,O
,compared,VBN,O
,between,IN,O
,groups,NNS,O
,with,IN,O
,exact,JJ,O
,Chi2,NNP,O
,-,:,O
,test,NN,O
,and,CC,O
,multivariate,NN,O
,logistic,JJ,O
,regression,NN,O
,analysis,NN,O
,(,(,O
,two,CD,O
,-,:,O
,sided,VBD,O
,P,NNP,O
,<,NNP,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,RESULTS,NN,O
,:,:,O
,LAG,NNP,O
,consisted,VBD,O
,of,IN,O
,75,CD,O
,patients,NNS,O
,(,(,O
,46,CD,O
,%,NN,O
,),),O
,versus,NN,O
,88,CD,O
,HAG,NNP,O
,patients,NNS,O
,(,(,O
,54,CD,O
,%,NN,O
,),),O
,.,.,O
,AKI,NNP,B-DISEASE
,occurred,VBD,O
,significantly,RB,O
,more,RBR,O
,often,RB,O
,in,IN,O
,LAG,NNP,O
,with,IN,O
,36,CD,O
,%,NN,O
,versus,IN,O
,21,CD,O
,%,NN,O
,in,IN,O
,HAG,NNP,O
,(,(,O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,035,CD,O
,),),O
,.,.,O
,Basic,JJ,O
,characteristics,NNS,O
,were,VBD,O
,comparable,JJ,O
,",",",",O
,except,IN,O
,an,DT,O
,increased,JJ,O
,rate,NN,O
,of,IN,O
,soft,JJ,O
,tissue,NN,O
,infections,NNS,B-DISEASE
,in,IN,O
,LAG,NNP,O
,.,.,O
,Multivariate,NNP,O
,analysis,NN,O
,revealed,VBD,O
,an,DT,O
,odds,NNS,O
,ratio,NN,O
,of,IN,O
,2,CD,O
,.,.,O
,5,CD,O
,-,:,O
,fold,NN,O
,for,IN,O
,LAG,NNP,O
,to,TO,O
,develop,VB,O
,AKI,NNP,B-DISEASE
,compared,VBN,O
,with,IN,O
,HAG,NNP,O
,(,(,O
,95,CD,O
,%,NN,O
,confidence,NN,O
,interval,JJ,O
,1,CD,O
,.,.,O
,195,CD,O
,to,TO,O
,5,CD,O
,.,.,O
,124,CD,O
,",",",",O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,039,CD,O
,),),O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Low,JJ,O
,adherence,NN,O
,to,TO,O
,SOPs,NNP,O
,for,IN,O
,potentially,RB,O
,nephrotoxic,JJ,B-DISEASE
,antibiotics,NNS,O
,was,VBD,O
,associated,VBN,O
,with,IN,O
,a,DT,O
,higher,JJR,O
,occurrence,NN,O
,of,IN,O
,AKI,NNP,B-DISEASE
,.,.,O
,TRIAL,NNP,O
,REGISTRATION,NNP,O
,:,:,O
,Current,NN,O
,Controlled,VBD,O
,Trials,NNP,O
,ISRCTN54598675,NNP,O
,.,.,O
,Registered,VBD,O
,17,CD,O
,August,NNP,O
,2007,CD,O
,.,.,O
,Rhabdomyolysis,NN,B-DISEASE
,in,IN,O
,a,DT,O
,hepatitis,NN,B-DISEASE
,C,NNP,I-DISEASE
,virus,NN,I-DISEASE
,infected,VBD,I-DISEASE
,patient,JJ,O
,treated,VBN,O
,with,IN,O
,telaprevir,NN,O
,and,CC,O
,simvastatin,NN,O
,.,.,O
,A,DT,O
,46,CD,O
,-,:,O
,year,NN,O
,old,JJ,O
,man,NN,O
,with,IN,O
,a,DT,O
,chronic,JJ,O
,hepatitis,NN,B-DISEASE
,C,NNP,I-DISEASE
,virus,NN,I-DISEASE
,infection,NN,I-DISEASE
,received,VBD,O
,triple,JJ,O
,therapy,NN,O
,with,IN,O
,ribavirin,NN,O
,",",",",O
,pegylated,VBN,O
,interferon,NN,O
,and,CC,O
,telaprevir,NN,O
,.,.,O
,The,DT,O
,patient,NN,O
,also,RB,O
,received,VBD,O
,simvastatin,NN,O
,.,.,O
,One,CD,O
,month,NN,O
,after,IN,O
,starting,VBG,O
,the,DT,O
,antiviral,JJ,O
,therapy,NN,O
,",",",",O
,the,DT,O
,patient,NN,O
,was,VBD,O
,admitted,VBN,O
,to,TO,O
,the,DT,O
,hospital,NN,O
,because,IN,O
,he,PRP,O
,developed,VBD,O
,rhabdomyolysis,NN,B-DISEASE
,.,.,O
,At,IN,O
,admission,NN,O
,simvastatin,NN,O
,and,CC,O
,all,DT,O
,antiviral,JJ,O
,drugs,NNS,O
,were,VBD,O
,discontinued,VBN,O
,because,IN,O
,toxicity,NN,B-DISEASE
,due,JJ,O
,to,TO,O
,a,DT,O
,drug,NN,O
,-,:,O
,drug,NN,O
,interaction,NN,O
,was,VBD,O
,suspected,VBN,O
,.,.,O
,The,DT,O
,creatine,JJ,O
,kinase,NN,O
,peaked,VBD,O
,at,IN,O
,62,CD,O
,",",",",O
,246,CD,O
,IU,NNP,O
,/,NNP,O
,L,NNP,O
,and,CC,O
,the,DT,O
,patient,NN,O
,was,VBD,O
,treated,VBN,O
,with,IN,O
,intravenous,JJ,O
,normal,JJ,O
,saline,NN,O
,.,.,O
,The,DT,O
,patient,NN,O
,',POS,O
,s,JJ,O
,renal,JJ,O
,function,NN,O
,remained,VBD,O
,unaffected,JJ,O
,.,.,O
,Fourteen,NNP,O
,days,NNS,O
,after,IN,O
,hospitalization,NN,O
,",",",",O
,creatine,JJ,O
,kinase,NN,O
,level,NN,O
,had,VBD,O
,returned,VBN,O
,to,TO,O
,230,CD,O
,IU,NNP,O
,/,NNP,O
,L,NNP,O
,and,CC,O
,the,DT,O
,patient,NN,O
,was,VBD,O
,discharged,VBN,O
,.,.,O
,Telaprevir,NNP,O
,was,VBD,O
,considered,VBN,O
,the,DT,O
,probable,JJ,O
,causative,JJ,O
,agent,NN,O
,of,IN,O
,an,DT,O
,interaction,NN,O
,with,IN,O
,simvastatin,NN,O
,according,VBG,O
,to,TO,O
,the,DT,O
,Drug,NNP,O
,Interaction,NNP,O
,Probability,NNP,O
,Scale,NNP,O
,.,.,O
,The,DT,O
,interaction,NN,O
,is,VBZ,O
,due,JJ,O
,to,TO,O
,inhibition,NN,O
,of,IN,O
,CYP3A4,NNP,O
,-,:,O
,mediated,VBD,O
,simvastatin,JJ,O
,clearance,NN,O
,.,.,O
,Simvastatin,NNP,O
,plasma,JJ,O
,concentration,NN,O
,increased,VBD,O
,30,CD,O
,times,NNS,O
,in,IN,O
,this,DT,O
,patient,NN,O
,and,CC,O
,statin,NN,O
,induced,JJ,O
,muscle,NN,B-DISEASE
,toxicity,NN,I-DISEASE
,is,VBZ,O
,related,VBN,O
,to,TO,O
,the,DT,O
,concentration,NN,O
,of,IN,O
,the,DT,O
,statin,NN,O
,in,IN,O
,blood,NN,O
,.,.,O
,In,IN,O
,conclusion,NN,O
,",",",",O
,with,IN,O
,this,DT,O
,case,NN,O
,we,PRP,O
,illustrate,VBP,O
,that,DT,O
,telaprevir,NN,O
,as,RB,O
,well,RB,O
,as,IN,O
,statins,NNS,O
,are,VBP,O
,susceptible,JJ,O
,to,TO,O
,clinical,JJ,O
,relevant,JJ,O
,drug,NN,O
,-,:,O
,drug,NN,O
,interactions,NNS,O
,.,.,O
,Combination,NN,O
,of,IN,O
,bortezomib,NN,O
,",",",",O
,thalidomide,NN,O
,",",",",O
,and,CC,O
,dexamethasone,NN,O
,(,(,O
,VTD,NNP,O
,),),O
,as,IN,O
,a,DT,O
,consolidation,NN,O
,therapy,NN,O
,after,IN,O
,autologous,JJ,O
,stem,NN,O
,cell,NN,O
,transplantation,NN,O
,for,IN,O
,symptomatic,JJ,O
,multiple,JJ,B-DISEASE
,myeloma,NN,I-DISEASE
,in,IN,O
,Japanese,JJ,O
,patients,NNS,O
,.,.,O
,Consolidation,NNP,O
,therapy,NN,O
,for,IN,O
,patients,NNS,O
,with,IN,O
,multiple,JJ,B-DISEASE
,myeloma,NN,I-DISEASE
,(,(,O
,MM,NNP,B-DISEASE
,),),O
,has,VBZ,O
,been,VBN,O
,widely,RB,O
,adopted,VBN,O
,to,TO,O
,improve,VB,O
,treatment,NN,O
,response,NN,O
,following,VBG,O
,autologous,JJ,O
,stem,NN,O
,cell,NN,O
,transplantation,NN,O
,.,.,O
,In,IN,O
,this,DT,O
,study,NN,O
,",",",",O
,we,PRP,O
,retrospectively,RB,O
,analyzed,VBD,O
,the,DT,O
,safety,NN,O
,and,CC,O
,efficacy,NN,O
,of,IN,O
,combination,NN,O
,regimen,NNS,O
,of,IN,O
,bortezomib,NN,O
,",",",",O
,thalidomide,NN,O
,",",",",O
,and,CC,O
,dexamethasone,NN,O
,(,(,O
,VTD,NNP,O
,),),O
,as,IN,O
,consolidation,NN,O
,therapy,NN,O
,in,IN,O
,24,CD,O
,Japanese,JJ,O
,patients,NNS,O
,with,IN,O
,newly,RB,O
,diagnosed,VBN,O
,MM,NNP,B-DISEASE
,.,.,O
,VTD,NNP,O
,consisted,VBD,O
,of,IN,O
,bortezomib,NN,O
,at,IN,O
,a,DT,O
,dose,NN,O
,of,IN,O
,1,CD,O
,.,.,O
,3,CD,O
,mg,JJ,O
,/,NNP,O
,m,NN,O
,(,(,O
,2,CD,O
,),),O
,and,CC,O
,dexamethasone,NN,O
,at,IN,O
,a,DT,O
,dose,NN,O
,of,IN,O
,40,CD,O
,mg,NNS,O
,/,JJ,O
,day,NN,O
,on,IN,O
,days,NNS,O
,1,CD,O
,",",",",O
,8,CD,O
,",",",",O
,15,CD,O
,",",",",O
,and,CC,O
,22,CD,O
,of,IN,O
,a,DT,O
,35,CD,O
,-,:,O
,day,NN,O
,cycle,NN,O
,",",",",O
,with,IN,O
,daily,JJ,O
,oral,JJ,O
,thalidomide,NN,O
,at,IN,O
,a,DT,O
,dose,NN,O
,of,IN,O
,100,CD,O
,mg,NNS,O
,/,JJ,O
,day,NN,O
,.,.,O
,Grade,VB,O
,3,CD,O
,-,:,O
,4,CD,O
,neutropenia,NN,B-DISEASE
,and,CC,O
,thrombocytopenia,NN,B-DISEASE
,were,VBD,O
,documented,VBN,O
,in,IN,O
,four,CD,O
,and,CC,O
,three,CD,O
,patients,NNS,O
,(,(,O
,17,CD,O
,and,CC,O
,13,CD,O
,%,NN,O
,),),O
,",",",",O
,respectively,RB,O
,",",",",O
,but,CC,O
,drug,NN,O
,dose,NN,O
,reduction,NN,O
,due,JJ,O
,to,TO,O
,cytopenia,VB,B-DISEASE
,was,VBD,O
,not,RB,O
,required,VBN,O
,in,IN,O
,any,DT,O
,case,NN,O
,.,.,O
,Peripheral,NNP,B-DISEASE
,neuropathy,NN,I-DISEASE
,was,VBD,O
,common,JJ,O
,(,(,O
,63,CD,O
,%,NN,O
,),),O
,",",",",O
,but,CC,O
,severe,JJ,O
,grade,NN,O
,3,CD,O
,-,:,O
,4,CD,O
,peripheral,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,was,VBD,O
,not,RB,O
,observed,VBN,O
,.,.,O
,Very,RB,O
,good,JJ,O
,partial,JJ,O
,response,NN,O
,or,CC,O
,better,JJR,O
,response,NN,O
,(,(,O
,>,NNP,O
,VGPR,NNP,O
,),),O
,rates,NNS,O
,before,IN,O
,and,CC,O
,after,IN,O
,consolidation,NN,O
,therapy,NN,O
,were,VBD,O
,54,CD,O
,and,CC,O
,79,CD,O
,%,NN,O
,",",",",O
,respectively,RB,O
,.,.,O
,Patients,NNS,O
,had,VBD,O
,a,DT,O
,significant,JJ,O
,probability,NN,O
,of,IN,O
,improving,VBG,O
,from,IN,O
,<,NNP,O
,VGPR,NNP,O
,before,IN,O
,consolidation,NN,O
,therapy,NN,O
,to,TO,O
,>,VB,O
,VGPR,NNP,O
,after,IN,O
,consolidation,NN,O
,therapy,NN,O
,(,(,O
,p,JJ,O
,=,NN,O
,0,CD,O
,.,.,O
,041,CD,O
,),),O
,.,.,O
,The,DT,O
,VTD,NNP,O
,regimen,NNS,O
,may,MD,O
,be,VB,O
,safe,JJ,O
,and,CC,O
,effective,JJ,O
,as,IN,O
,a,DT,O
,consolidation,NN,O
,therapy,NN,O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,MM,NNP,O
,in,IN,O
,Japanese,JJ,O
,population,NN,O
,.,.,O
,Conversion,NN,O
,to,TO,O
,sirolimus,VB,O
,ameliorates,NNS,O
,cyclosporine,VBP,O
,-,:,O
,induced,VBN,O
,nephropathy,JJ,B-DISEASE
,in,IN,O
,the,DT,O
,rat,NN,O
,:,:,O
,focus,NN,O
,on,IN,O
,serum,NN,O
,",",",",O
,urine,NN,O
,",",",",O
,gene,NN,O
,",",",",O
,and,CC,O
,protein,JJ,O
,renal,JJ,O
,expression,NN,O
,biomarkers,NNS,O
,.,.,O
,Protocols,NNP,O
,of,IN,O
,conversion,NN,O
,from,IN,O
,cyclosporin,NN,O
,A,NNP,O
,(,(,O
,CsA,NNP,O
,),),O
,to,TO,O
,sirolimus,VB,O
,(,(,O
,SRL,NNP,O
,),),O
,have,VBP,O
,been,VBN,O
,widely,RB,O
,used,VBN,O
,in,IN,O
,immunotherapy,NN,O
,after,IN,O
,transplantation,NN,O
,to,TO,O
,prevent,VB,O
,CsA,NNP,O
,-,:,O
,induced,VBD,O
,nephropathy,JJ,B-DISEASE
,",",",",O
,but,CC,O
,the,DT,O
,molecular,JJ,O
,mechanisms,NNS,O
,underlying,VBG,O
,these,DT,O
,protocols,NNS,O
,remain,VBP,O
,nuclear,JJ,O
,.,.,O
,This,DT,O
,study,NN,O
,aimed,VBD,O
,to,TO,O
,identify,VB,O
,the,DT,O
,molecular,JJ,O
,pathways,NNS,O
,and,CC,O
,putative,JJ,O
,biomarkers,NNS,O
,of,IN,O
,CsA,NNP,O
,-,:,O
,to,TO,O
,-,:,O
,SRL,NNP,O
,conversion,NN,O
,in,IN,O
,a,DT,O
,rat,NN,O
,model,NN,O
,.,.,O
,Four,CD,O
,animal,NN,O
,groups,NNS,O
,(,(,O
,n,JJ,O
,=,NNP,O
,6,CD,O
,),),O
,were,VBD,O
,tested,VBN,O
,during,IN,O
,9,CD,O
,weeks,NNS,O
,:,:,O
,control,NN,O
,",",",",O
,CsA,NNP,O
,",",",",O
,SRL,NNP,O
,",",",",O
,and,CC,O
,conversion,NN,O
,(,(,O
,CsA,NNP,O
,for,IN,O
,3,CD,O
,weeks,NNS,O
,followed,VBN,O
,by,IN,O
,SRL,NNP,O
,for,IN,O
,6,CD,O
,weeks,NNS,O
,),),O
,.,.,O
,Classical,JJ,O
,and,CC,O
,emergent,JJ,O
,serum,NN,O
,",",",",O
,urinary,JJ,O
,",",",",O
,and,CC,O
,kidney,NN,O
,tissue,NN,O
,(,(,O
,gene,NN,O
,and,CC,O
,protein,JJ,O
,expression,NN,O
,),),O
,markers,NNS,O
,were,VBD,O
,assessed,VBN,O
,.,.,O
,Renal,JJ,B-DISEASE
,lesions,NNS,I-DISEASE
,were,VBD,O
,analyzed,VBN,O
,in,IN,O
,hematoxylin,NN,O
,and,CC,O
,eosin,NN,O
,",",",",O
,periodic,JJ,O
,acid,SYM,O
,-,:,O
,Schiff,NN,O
,",",",",O
,and,CC,O
,Masson,NNP,O
,',POS,O
,s,NN,O
,trichrome,NN,O
,stains,NNS,O
,.,.,O
,SRL,NNP,O
,-,:,O
,treated,VBD,O
,rats,NNS,O
,presented,VBN,O
,proteinuria,NNS,B-DISEASE
,and,CC,O
,NGAL,NNP,O
,(,(,O
,serum,NN,O
,and,CC,O
,urinary,JJ,O
,),),O
,as,IN,O
,the,DT,O
,best,JJS,O
,markers,NNS,O
,of,IN,O
,renal,JJ,B-DISEASE
,impairment,NN,I-DISEASE
,.,.,O
,Short,NNP,O
,CsA,NNP,O
,treatment,NN,O
,presented,VBD,O
,slight,JJ,O
,or,CC,O
,even,RB,O
,absent,JJ,O
,kidney,NN,B-DISEASE
,lesions,NNS,I-DISEASE
,and,CC,O
,TGF,NNP,O
,-,:,O
,b,NN,O
,",",",",O
,NF,NNP,O
,-,:,O
,kb,NN,O
,",",",",O
,mTOR,NN,O
,",",",",O
,PCNA,NNP,O
,",",",",O
,TP53,NNP,O
,",",",",O
,KIM,NNP,O
,-,:,O
,1,CD,O
,",",",",O
,and,CC,O
,CTGF,NNP,O
,as,IN,O
,relevant,JJ,O
,gene,NN,O
,and,CC,O
,protein,NN,O
,changes,NNS,O
,.,.,O
,Prolonged,VBD,O
,CsA,NNP,O
,exposure,NN,O
,aggravated,VBD,O
,renal,JJ,B-DISEASE
,damage,NN,I-DISEASE
,",",",",O
,without,IN,O
,clear,JJ,O
,changes,NNS,O
,on,IN,O
,the,DT,O
,traditional,JJ,O
,markers,NNS,O
,",",",",O
,but,CC,O
,with,IN,O
,changes,NNS,O
,in,IN,O
,serums,NNS,O
,TGF,NNP,O
,-,:,O
,b,NN,O
,and,CC,O
,IL,NNP,O
,-,:,O
,7,CD,O
,",",",",O
,TBARs,NNP,O
,clearance,NN,O
,",",",",O
,and,CC,O
,kidney,NN,O
,TGF,NNP,O
,-,:,O
,b,NN,O
,and,CC,O
,mTOR,NN,O
,.,.,O
,Conversion,NN,O
,to,TO,O
,SRL,NNP,O
,prevented,VBD,O
,CsA,NNP,O
,-,:,O
,induced,VBD,O
,renal,JJ,B-DISEASE
,damage,NN,I-DISEASE
,evolution,NN,O
,(,(,O
,absent,JJ,O
,/,NNP,O
,mild,NN,O
,grade,NN,O
,lesions,NNS,O
,),),O
,",",",",O
,while,IN,O
,NGAL,NNP,O
,(,(,O
,serum,JJ,O
,versus,NN,O
,urine,NN,O
,),),O
,seems,VBZ,O
,to,TO,O
,be,VB,O
,a,DT,O
,feasible,JJ,O
,biomarker,NN,O
,of,IN,O
,CsA,NNP,O
,replacement,NN,O
,to,TO,O
,SRL,NNP,O
,.,.,O
,Kinin,NNP,O
,B2,NNP,O
,receptor,NN,O
,deletion,NN,O
,and,CC,O
,blockage,NN,O
,ameliorates,NNS,O
,cisplatin,VBP,O
,-,:,O
,induced,JJ,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,injury,NN,I-DISEASE
,.,.,O
,Cisplatin,NNP,O
,treatment,NN,O
,has,VBZ,O
,been,VBN,O
,adopted,VBN,O
,in,IN,O
,some,DT,O
,chemotherapies,NNS,O
,;,:,O
,however,RB,O
,",",",",O
,this,DT,O
,drug,NN,O
,can,MD,O
,induce,VB,O
,acute,JJ,B-DISEASE
,kidney,NN,I-DISEASE
,injury,NN,I-DISEASE
,due,JJ,O
,its,PRP$,O
,ability,NN,O
,to,TO,O
,negatively,RB,O
,affect,JJ,O
,renal,JJ,O
,function,NN,O
,",",",",O
,augment,JJ,O
,serum,NN,O
,levels,NNS,O
,of,IN,O
,creatinine,NN,O
,and,CC,O
,urea,JJ,O
,",",",",O
,increase,VB,O
,the,DT,O
,acute,JJ,B-DISEASE
,tubular,JJ,I-DISEASE
,necrosis,NN,I-DISEASE
,score,NN,O
,and,CC,O
,up,RB,O
,-,:,O
,regulate,NN,O
,cytokines,NNS,O
,(,(,O
,e,NN,O
,.,.,O
,g,NN,O
,.,.,O
,",",",",O
,IL,NNP,O
,-,:,O
,1b,CD,O
,and,CC,O
,TNF,NNP,O
,-,:,O
,a,DT,O
,),),O
,.,.,O
,The,DT,O
,kinin,NN,O
,B2,NNP,O
,receptor,NN,O
,has,VBZ,O
,been,VBN,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,inflammation,NN,B-DISEASE
,process,NN,O
,",",",",O
,as,RB,O
,well,RB,O
,as,IN,O
,the,DT,O
,regulation,NN,O
,of,IN,O
,cytokine,JJ,O
,expression,NN,O
,",",",",O
,and,CC,O
,its,PRP$,O
,deletion,NN,O
,resulted,VBD,O
,in,IN,O
,an,DT,O
,improvement,NN,O
,in,IN,O
,the,DT,O
,diabetic,JJ,B-DISEASE
,nephropathy,JJ,I-DISEASE
,status,NN,O
,.,.,O
,To,TO,O
,examine,VB,O
,the,DT,O
,role,NN,O
,of,IN,O
,the,DT,O
,kinin,NN,O
,B2,NNP,O
,receptor,NN,O
,in,IN,O
,cisplatin,NN,O
,-,:,O
,induced,JJ,O
,acute,JJ,B-DISEASE
,kidney,NN,I-DISEASE
,injury,NN,I-DISEASE
,",",",",O
,kinin,VB,O
,B2,NNP,O
,receptor,NN,O
,knockout,NN,O
,mice,NN,O
,were,VBD,O
,challenged,VBN,O
,with,IN,O
,cisplatin,NN,O
,.,.,O
,Additionally,RB,O
,",",",",O
,WT,NNP,O
,mice,NN,O
,were,VBD,O
,treated,VBN,O
,with,IN,O
,a,DT,O
,B2,NNP,O
,receptor,NN,O
,antagonist,NN,O
,after,IN,O
,cisplatin,JJ,O
,administration,NN,O
,.,.,O
,B2,NNP,O
,receptor,NN,O
,-,:,O
,deficient,NN,O
,mice,NN,O
,were,VBD,O
,less,RBR,O
,sensitive,JJ,O
,to,TO,O
,this,DT,O
,drug,NN,O
,than,IN,O
,the,DT,O
,WT,NNP,O
,mice,NN,O
,",",",",O
,as,IN,O
,shown,VBN,O
,by,IN,O
,reduced,JJ,O
,weight,JJ,B-DISEASE
,loss,NN,I-DISEASE
,",",",",O
,better,JJR,O
,preservation,NN,O
,of,IN,O
,kidney,NN,O
,function,NN,O
,",",",",O
,down,IN,O
,regulation,NN,O
,of,IN,O
,inflammatory,JJ,O
,cytokines,NNS,O
,and,CC,O
,less,JJR,O
,acute,JJ,B-DISEASE
,tubular,JJ,I-DISEASE
,necrosis,NN,I-DISEASE
,.,.,O
,Moreover,RB,O
,",",",",O
,treatment,NN,O
,with,IN,O
,the,DT,O
,kinin,NN,O
,B2,NNP,O
,receptor,NN,O
,antagonist,NN,O
,effectively,RB,O
,reduced,VBD,O
,the,DT,O
,levels,NNS,O
,of,IN,O
,serum,NN,O
,creatinine,NN,O
,and,CC,O
,blood,NN,O
,urea,NN,O
,after,IN,O
,cisplatin,JJ,O
,administration,NN,O
,.,.,O
,Thus,RB,O
,",",",",O
,our,PRP$,O
,data,NNS,O
,suggest,VBP,O
,that,IN,O
,the,DT,O
,kinin,NN,O
,B2,NNP,O
,receptor,NN,O
,is,VBZ,O
,involved,VBN,O
,in,IN,O
,cisplatin,NN,O
,-,:,O
,induced,JJ,O
,acute,JJ,B-DISEASE
,kidney,NN,I-DISEASE
,injury,NN,I-DISEASE
,by,IN,O
,mediating,VBG,O
,the,DT,O
,necrotic,JJ,B-DISEASE
,process,NN,O
,and,CC,O
,the,DT,O
,expression,NN,O
,of,IN,O
,inflammatory,JJ,O
,cytokines,NNS,O
,",",",",O
,thus,RB,O
,resulting,VBG,O
,in,IN,O
,declined,JJ,O
,renal,JJ,O
,function,NN,O
,.,.,O
,These,DT,O
,results,NNS,O
,highlight,VBD,O
,the,DT,O
,kinin,NN,O
,B2,NNP,O
,receptor,NN,O
,antagonist,NN,O
,treatment,NN,O
,in,IN,O
,amelioration,NN,O
,of,IN,O
,nephrotoxicity,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,cisplatin,NN,O
,therapy,NN,O
,.,.,O
,Safety,NNP,O
,and,CC,O
,efficacy,NN,O
,of,IN,O
,fluocinolone,NN,O
,acetonide,NN,O
,intravitreal,NN,O
,implant,NN,O
,(,(,O
,0,CD,O
,.,.,O
,59,CD,O
,mg,NN,O
,),),O
,in,IN,O
,birdshot,NN,B-DISEASE
,retinochoroidopathy,NN,I-DISEASE
,.,.,O
,PURPOSE,NN,O
,:,:,O
,To,TO,O
,report,VB,O
,the,DT,O
,treatment,NN,O
,outcomes,NNS,O
,of,IN,O
,the,DT,O
,fluocinolone,NN,O
,acetonide,RB,O
,intravitreal,JJ,O
,implant,NN,O
,(,(,O
,0,CD,O
,.,.,O
,59,CD,O
,mg,NN,O
,),),O
,in,IN,O
,patients,NNS,O
,with,IN,O
,birdshot,JJ,B-DISEASE
,retinochoroidopathy,NN,I-DISEASE
,whose,WP$,O
,disease,NN,O
,is,VBZ,O
,refractory,JJ,O
,or,CC,O
,intolerant,JJ,O
,to,TO,O
,conventional,JJ,O
,immunomodulatory,JJ,O
,therapy,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,A,DT,O
,retrospective,JJ,O
,case,NN,O
,series,NN,O
,involving,VBG,O
,11,CD,O
,birdshot,JJ,B-DISEASE
,retinochoroidopathy,JJ,I-DISEASE
,patients,NNS,O
,(,(,O
,11,CD,O
,eyes,NNS,O
,),),O
,.,.,O
,Eleven,JJ,O
,patients,NNS,O
,(,(,O
,11,CD,O
,eyes,NNS,O
,),),O
,underwent,NN,O
,surgery,NN,O
,for,IN,O
,fluocinolone,NN,O
,acetonide,NN,O
,implant,NN,O
,(,(,O
,0,CD,O
,.,.,O
,59,CD,O
,mg,NN,O
,),),O
,.,.,O
,Treatment,NNP,O
,outcomes,RB,O
,of,IN,O
,interest,NN,O
,were,VBD,O
,noted,VBN,O
,at,IN,O
,baseline,NN,O
,",",",",O
,before,IN,O
,fluocinolone,JJ,O
,acetonide,NN,O
,implant,NN,O
,",",",",O
,and,CC,O
,then,RB,O
,at,IN,O
,6,CD,O
,months,NNS,O
,",",",",O
,1,CD,O
,year,NN,O
,",",",",O
,2,CD,O
,years,NNS,O
,",",",",O
,3,CD,O
,years,NNS,O
,",",",",O
,and,CC,O
,beyond,IN,O
,3,CD,O
,years,NNS,O
,.,.,O
,Disease,NNP,O
,activity,NN,O
,markers,NNS,O
,",",",",O
,including,VBG,O
,signs,NNS,O
,of,IN,O
,ocular,JJ,O
,inflammation,NN,B-DISEASE
,",",",",O
,evidence,NN,O
,of,IN,O
,retinal,JJ,B-DISEASE
,vasculitis,NN,I-DISEASE
,",",",",O
,Swedish,JJ,O
,interactive,JJ,O
,threshold,NN,O
,algorithm,SYM,O
,-,:,O
,short,JJ,O
,wavelength,NN,O
,automated,VBD,O
,perimetry,NN,O
,Humphrey,NNP,O
,visual,JJ,O
,field,NN,O
,analysis,NN,O
,",",",",O
,electroretinographic,JJ,O
,parameters,NNS,O
,",",",",O
,and,CC,O
,optical,JJ,O
,coherence,NN,O
,tomography,NN,O
,were,VBD,O
,recorded,VBN,O
,.,.,O
,Data,NNS,O
,on,IN,O
,occurrence,NN,O
,of,IN,O
,cataract,NN,B-DISEASE
,and,CC,O
,raised,VBD,B-DISEASE
,intraocular,JJ,I-DISEASE
,pressure,NN,I-DISEASE
,were,VBD,O
,collected,VBN,O
,in,IN,O
,all,DT,O
,eyes,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,Intraocular,JJ,O
,inflammation,NN,B-DISEASE
,was,VBD,O
,present,JJ,O
,in,IN,O
,54,CD,O
,.,.,O
,5,CD,O
,",",",",O
,9,CD,O
,.,.,O
,9,CD,O
,",",",",O
,11,CD,O
,.,.,O
,1,CD,O
,",",",",O
,and,CC,O
,0,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,at,IN,O
,baseline,NN,O
,",",",",O
,6,CD,O
,months,NNS,O
,",",",",O
,1,CD,O
,year,NN,O
,",",",",O
,2,CD,O
,years,NNS,O
,",",",",O
,3,CD,O
,years,NNS,O
,",",",",O
,and,CC,O
,beyond,IN,O
,3,CD,O
,years,NNS,O
,after,IN,O
,receiving,VBG,O
,the,DT,O
,implant,NN,O
,",",",",O
,respectively,RB,O
,.,.,O
,Active,JJ,O
,vasculitis,NN,B-DISEASE
,was,VBD,O
,noted,VBN,O
,in,IN,O
,36,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,patients,NNS,O
,at,IN,O
,baseline,NN,O
,and,CC,O
,0,CD,O
,%,NN,O
,at,IN,O
,3,CD,O
,years,NNS,O
,of,IN,O
,follow,NN,O
,-,:,O
,up,RB,O
,.,.,O
,More,JJR,O
,than,IN,O
,20,CD,O
,%,NN,O
,(,(,O
,47,CD,O
,.,.,O
,61,CD,O
,-,:,O
,67,CD,O
,.,.,O
,2,CD,O
,%,NN,O
,),),O
,reduction,NN,O
,in,IN,O
,central,JJ,O
,retinal,JJ,O
,thickness,NN,O
,was,VBD,O
,noted,VBN,O
,in,IN,O
,all,DT,O
,patients,NNS,O
,with,IN,O
,cystoid,JJ,B-DISEASE
,macular,JJ,I-DISEASE
,edema,NN,I-DISEASE
,at,IN,O
,6,CD,O
,months,NNS,O
,",",",",O
,1,CD,O
,year,NN,O
,",",",",O
,2,CD,O
,years,NNS,O
,",",",",O
,and,CC,O
,3,CD,O
,years,NNS,O
,postimplant,JJ,O
,.,.,O
,At,IN,O
,baseline,NN,O
,",",",",O
,54,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,patients,NNS,O
,were,VBD,O
,on,IN,O
,immunomodulatory,JJ,O
,agents,NNS,O
,.,.,O
,This,DT,O
,percentage,NN,O
,decreased,VBD,O
,to,TO,O
,45,CD,O
,.,.,O
,45,CD,O
,",",",",O
,44,CD,O
,.,.,O
,4,CD,O
,",",",",O
,and,CC,O
,14,CD,O
,.,.,O
,28,CD,O
,%,NN,O
,at,IN,O
,1,CD,O
,year,NN,O
,",",",",O
,2,CD,O
,years,NNS,O
,",",",",O
,and,CC,O
,3,CD,O
,years,NNS,O
,postimplant,JJ,O
,",",",",O
,respectively,RB,O
,.,.,O
,Adverse,JJ,O
,events,NNS,O
,included,VBD,O
,increased,VBN,B-DISEASE
,intraocular,JJ,I-DISEASE
,pressure,NN,I-DISEASE
,(,(,O
,54,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,),),O
,and,CC,O
,cataract,JJ,B-DISEASE
,formation,NN,O
,(,(,O
,100,CD,O
,%,NN,O
,),),O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,The,DT,O
,data,NN,O
,suggest,NN,O
,that,IN,O
,fluocinolone,NN,O
,acetonide,NN,O
,implant,NN,O
,(,(,O
,0,CD,O
,.,.,O
,59,CD,O
,mg,NN,O
,),),O
,helps,VBZ,O
,to,TO,O
,control,VB,O
,inflammation,NN,B-DISEASE
,in,IN,O
,otherwise,RB,O
,treatment,NN,O
,-,:,O
,refractory,NN,O
,cases,NNS,O
,of,IN,O
,birdshot,JJ,B-DISEASE
,retinochoroidopathy,NN,I-DISEASE
,.,.,O
,It,PRP,O
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,significant,JJ,O
,side,NN,O
,effects,NNS,O
,of,IN,O
,cataract,NN,B-DISEASE
,and,CC,O
,ocular,JJ,B-DISEASE
,hypertension,NN,I-DISEASE
,requiring,VBG,O
,treatment,NN,O
,.,.,O
,Optimal,NNP,O
,precurarizing,VBG,O
,dose,NN,O
,of,IN,O
,rocuronium,NN,O
,to,TO,O
,decrease,VB,O
,fasciculation,NN,B-DISEASE
,and,CC,O
,myalgia,NN,B-DISEASE
,following,VBG,O
,succinylcholine,JJ,O
,administration,NN,O
,.,.,O
,BACKGROUND,NNP,O
,:,:,O
,Succinylcholine,NNP,O
,commonly,RB,O
,produces,VBZ,O
,frequent,JJ,O
,adverse,JJ,O
,effects,NNS,O
,",",",",O
,including,VBG,O
,muscle,NN,B-DISEASE
,fasciculation,NN,I-DISEASE
,and,CC,O
,myalgia,NN,B-DISEASE
,.,.,O
,The,DT,O
,current,JJ,O
,study,NN,O
,identified,VBD,O
,the,DT,O
,optimal,JJ,O
,dose,NN,O
,of,IN,O
,rocuronium,NN,O
,to,TO,O
,prevent,VB,O
,succinylcholine,JJ,O
,-,:,O
,induced,JJ,O
,fasciculation,NN,B-DISEASE
,and,CC,O
,myalgia,NN,B-DISEASE
,and,CC,O
,evaluated,VBD,O
,the,DT,O
,influence,NN,O
,of,IN,O
,rocuronium,NN,O
,on,IN,O
,the,DT,O
,speed,NN,O
,of,IN,O
,onset,NN,O
,produced,VBN,O
,by,IN,O
,succinylcholine,NN,O
,.,.,O
,METHODS,NN,O
,:,:,O
,This,DT,O
,randomized,VBN,O
,",",",",O
,double,JJ,O
,-,:,O
,blinded,VBD,O
,study,NN,O
,was,VBD,O
,conducted,VBN,O
,in,IN,O
,100,CD,O
,patients,NNS,O
,randomly,RB,O
,allocated,VBN,O
,into,IN,O
,five,CD,O
,groups,NNS,O
,of,IN,O
,20,CD,O
,patients,NNS,O
,each,DT,O
,.,.,O
,Patients,NNS,O
,were,VBD,O
,randomized,VBN,O
,to,TO,O
,receive,VB,O
,0,CD,O
,.,.,O
,02,CD,O
,",",",",O
,0,CD,O
,.,.,O
,03,CD,O
,",",",",O
,0,CD,O
,.,.,O
,04,CD,O
,",",",",O
,0,CD,O
,.,.,O
,05,CD,O
,and,CC,O
,0,CD,O
,.,.,O
,06,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,rocuronium,NN,O
,as,IN,O
,a,DT,O
,precurarizing,NN,O
,dose,NN,O
,.,.,O
,Neuromuscular,JJ,O
,monitoring,NN,O
,after,IN,O
,each,DT,O
,precurarizing,VBG,O
,dose,NN,O
,was,VBD,O
,recorded,VBN,O
,from,IN,O
,the,DT,O
,adductor,NN,O
,pollicis,NN,O
,muscle,NN,O
,using,VBG,O
,acceleromyography,NN,O
,with,IN,O
,train,JJ,O
,-,:,O
,of,IN,O
,-,:,O
,four,CD,O
,stimulation,NN,O
,of,IN,O
,the,DT,O
,ulnar,JJ,O
,nerve,NN,O
,.,.,O
,All,DT,O
,patients,NNS,O
,received,VBD,O
,succinylcholine,JJ,O
,1,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,/,NN,O
,kg,NN,O
,at,IN,O
,2,CD,O
,minutes,NNS,O
,after,IN,O
,the,DT,O
,precurarization,NN,O
,",",",",O
,and,CC,O
,were,VBD,O
,assessed,VBN,O
,the,DT,O
,incidence,NN,O
,and,CC,O
,severity,NN,O
,of,IN,O
,fasciculations,NNS,B-DISEASE
,",",",",O
,while,IN,O
,myalgia,NN,B-DISEASE
,was,VBD,O
,assessed,VBN,O
,at,IN,O
,24,CD,O
,hours,NNS,O
,after,IN,O
,surgery,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,The,DT,O
,incidence,NN,O
,and,CC,O
,severity,NN,O
,of,IN,O
,visible,JJ,O
,muscle,NN,B-DISEASE
,fasciculation,NN,I-DISEASE
,was,VBD,O
,significantly,RB,O
,less,JJR,O
,with,IN,O
,increasing,VBG,O
,the,DT,O
,amount,NN,O
,of,IN,O
,precurarizing,VBG,O
,dose,NN,O
,of,IN,O
,rocuronium,NN,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,.,.,O
,Those,DT,O
,of,IN,O
,myalgia,NNS,B-DISEASE
,tend,VBP,O
,to,TO,O
,decrease,VB,O
,according,VBG,O
,to,TO,O
,increasing,VBG,O
,the,DT,O
,amount,NN,O
,of,IN,O
,precurarizing,VBG,O
,dose,NN,O
,of,IN,O
,rocuronium,NN,O
,",",",",O
,but,CC,O
,there,EX,O
,was,VBD,O
,no,DT,O
,significance,NN,O
,(,(,O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,072,CD,O
,),),O
,.,.,O
,The,DT,O
,onset,JJ,O
,time,NN,O
,of,IN,O
,succinylcholine,NN,O
,was,VBD,O
,significantly,RB,O
,longer,RBR,O
,with,IN,O
,increasing,VBG,O
,the,DT,O
,amount,NN,O
,of,IN,O
,precurarizing,VBG,O
,dose,NN,O
,of,IN,O
,rocuronium,NN,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Precurarization,NN,O
,with,IN,O
,0,CD,O
,.,.,O
,04,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,rocuronium,NN,O
,was,VBD,O
,the,DT,O
,optimal,JJ,O
,dose,NN,O
,considering,VBG,O
,the,DT,O
,reduction,NN,O
,in,IN,O
,the,DT,O
,incidence,NN,O
,and,CC,O
,severity,NN,O
,of,IN,O
,fasciculation,NN,B-DISEASE
,and,CC,O
,myalgia,NN,B-DISEASE
,with,IN,O
,acceptable,JJ,O
,onset,NN,O
,time,NN,O
,",",",",O
,and,CC,O
,the,DT,O
,safe,JJ,O
,and,CC,O
,effective,JJ,O
,precurarization,NN,O
,.,.,O
,Absence,NN,O
,of,IN,O
,PKC,NNP,O
,-,:,O
,alpha,NN,O
,attenuates,VBZ,O
,lithium,JJ,O
,-,:,O
,induced,JJ,O
,nephrogenic,JJ,B-DISEASE
,diabetes,NNS,I-DISEASE
,insipidus,VBP,I-DISEASE
,.,.,O
,Lithium,NNP,O
,",",",",O
,an,DT,O
,effective,JJ,O
,antipsychotic,NN,O
,",",",",O
,induces,VBZ,O
,nephrogenic,JJ,B-DISEASE
,diabetes,NNS,I-DISEASE
,insipidus,VBP,I-DISEASE
,(,(,O
,NDI,NNP,B-DISEASE
,),),O
,in,IN,O
,40,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,.,.,O
,The,DT,O
,decreased,JJ,O
,capacity,NN,O
,to,TO,O
,concentrate,VB,O
,urine,NN,O
,is,VBZ,O
,likely,JJ,O
,due,JJ,O
,to,TO,O
,lithium,VB,O
,acutely,RB,O
,disrupting,VBG,O
,the,DT,O
,cAMP,NN,O
,pathway,NN,O
,and,CC,O
,chronically,RB,O
,reducing,VBG,O
,urea,JJ,O
,transporter,NN,O
,(,(,O
,UT,NNP,O
,-,:,O
,A1,NNP,O
,),),O
,and,CC,O
,water,NN,O
,channel,NN,O
,(,(,O
,AQP2,NNP,O
,),),O
,expression,NN,O
,in,IN,O
,the,DT,O
,inner,JJ,O
,medulla,NN,O
,.,.,O
,Targeting,VBG,O
,an,DT,O
,alternative,JJ,O
,signaling,NN,O
,pathway,NN,O
,",",",",O
,such,JJ,O
,as,IN,O
,PKC,NNP,O
,-,:,O
,mediated,VBD,O
,signaling,JJ,O
,",",",",O
,may,MD,O
,be,VB,O
,an,DT,O
,effective,JJ,O
,method,NN,O
,of,IN,O
,treating,VBG,O
,lithium,NN,O
,-,:,O
,induced,JJ,O
,polyuria,NN,B-DISEASE
,.,.,O
,PKC,NNP,O
,-,:,O
,alpha,NN,O
,,JJ,O
,mice,NN,O
,(,(,O
,PKCa,NNP,O
,KO,NNP,O
,),),O
,and,CC,O
,strain,$,O
,-,:,O
,matched,VBN,O
,wild,JJ,O
,type,NN,O
,(,(,O
,WT,NNP,O
,),),O
,controls,NNS,O
,were,VBD,O
,treated,VBN,O
,with,IN,O
,lithium,NN,O
,for,IN,O
,0,CD,O
,",",",",O
,3,CD,O
,or,CC,O
,5,CD,O
,days,NNS,O
,.,.,O
,WT,NNP,O
,mice,NN,O
,had,VBD,O
,increased,VBN,O
,urine,JJ,O
,output,NN,O
,and,CC,O
,lowered,VBD,O
,urine,JJ,O
,osmolality,NN,O
,after,IN,O
,3,CD,O
,and,CC,O
,5,CD,O
,days,NNS,O
,of,IN,O
,treatment,NN,O
,whereas,NNS,O
,PKCa,NNP,O
,KO,NNP,O
,mice,NN,O
,had,VBD,O
,no,DT,O
,change,NN,O
,in,IN,O
,urine,JJ,O
,output,NN,O
,or,CC,O
,concentration,NN,O
,.,.,O
,Western,JJ,O
,blot,NN,O
,analysis,NN,O
,revealed,VBD,O
,that,IN,O
,AQP2,NNP,O
,expression,NN,O
,in,IN,O
,medullary,JJ,O
,tissues,NNS,O
,was,VBD,O
,lowered,VBN,O
,after,IN,O
,3,CD,O
,and,CC,O
,5,CD,O
,days,NNS,O
,in,IN,O
,WT,NNP,O
,mice,NN,O
,;,:,O
,however,RB,O
,",",",",O
,AQP2,NNP,O
,was,VBD,O
,unchanged,JJ,O
,in,IN,O
,PKCa,NNP,O
,KO,NNP,O
,.,.,O
,Similar,JJ,O
,results,NNS,O
,were,VBD,O
,observed,VBN,O
,with,IN,O
,UT,NNP,O
,-,:,O
,A1,NNP,O
,expression,NN,O
,.,.,O
,Animals,NNS,O
,were,VBD,O
,also,RB,O
,treated,VBN,O
,with,IN,O
,lithium,NN,O
,for,IN,O
,6,CD,O
,weeks,NNS,O
,.,.,O
,Lithium,NNP,O
,-,:,O
,treated,VBD,O
,WT,NNP,O
,mice,NN,O
,had,VBD,O
,19,CD,O
,-,:,O
,fold,NN,O
,increased,VBD,O
,urine,JJ,O
,output,NN,O
,whereas,NNS,O
,treated,VBD,O
,PKCa,NNP,O
,KO,NNP,O
,animals,NNS,O
,had,VBD,O
,a,DT,O
,4,CD,O
,-,:,O
,fold,JJ,O
,increase,NN,O
,in,IN,O
,output,NN,O
,.,.,O
,AQP2,NNP,O
,and,CC,O
,UT,NNP,O
,-,:,O
,A1,NNP,O
,expression,NN,O
,was,VBD,O
,lowered,VBN,O
,in,IN,O
,6,CD,O
,week,NN,O
,lithium,NN,O
,-,:,O
,treated,VBN,O
,WT,NNP,O
,animals,NNS,O
,whereas,VBP,O
,in,IN,O
,treated,JJ,O
,PKCa,NNP,O
,KO,NNP,O
,mice,NN,O
,",",",",O
,AQP2,NNP,O
,was,VBD,O
,only,RB,O
,reduced,VBN,O
,by,IN,O
,2,CD,O
,-,:,O
,fold,NN,O
,and,CC,O
,UT,NNP,O
,-,:,O
,A1,NNP,O
,expression,NN,O
,was,VBD,O
,unaffected,VBN,O
,.,.,O
,Urinary,JJ,O
,sodium,NN,O
,",",",",O
,potassium,NN,O
,and,CC,O
,calcium,NN,O
,were,VBD,O
,elevated,VBN,O
,in,IN,O
,lithium,NN,O
,-,:,O
,fed,NN,O
,WT,NNP,O
,but,CC,O
,not,RB,O
,in,IN,O
,lithium,NN,O
,-,:,O
,fed,NN,O
,PKCa,NNP,O
,KO,NNP,O
,mice,NN,O
,.,.,O
,Our,PRP$,O
,data,NNS,O
,show,VBP,O
,that,IN,O
,ablation,NN,O
,of,IN,O
,PKCa,NNP,O
,preserves,NNS,O
,AQP2,NNP,O
,and,CC,O
,UT,NNP,O
,-,:,O
,A1,NNP,O
,protein,CC,O
,expression,NN,O
,and,CC,O
,localization,NN,O
,in,IN,O
,lithium,NN,O
,-,:,O
,induced,JJ,O
,NDI,NNP,B-DISEASE
,",",",",O
,and,CC,O
,prevents,VBZ,O
,the,DT,O
,development,NN,O
,of,IN,O
,the,DT,O
,severe,JJ,O
,polyuria,NN,B-DISEASE
,associated,VBN,O
,with,IN,O
,lithium,NN,O
,therapy,NN,O
,.,.,O
,Is,VBZ,O
,Dysguesia,NNP,B-DISEASE
,Going,VBG,O
,to,TO,O
,be,VB,O
,a,DT,O
,Rare,NNP,O
,or,CC,O
,a,DT,O
,Common,JJ,O
,Side,NNP,O
,-,:,O
,effect,NN,O
,of,IN,O
,Amlodipine,NNP,O
,?,.,O
,A,DT,O
,very,RB,O
,rare,JJ,O
,side,NN,O
,-,:,O
,effect,NN,O
,of,IN,O
,amlodipine,NN,O
,is,VBZ,O
,dysguesia,JJ,B-DISEASE
,.,.,O
,A,DT,O
,review,NN,O
,of,IN,O
,the,DT,O
,literature,NN,O
,produced,VBD,O
,only,RB,O
,one,CD,O
,case,NN,O
,.,.,O
,We,PRP,O
,report,VBP,O
,a,DT,O
,case,NN,O
,about,IN,O
,a,DT,O
,female,NN,O
,with,IN,O
,essential,JJ,O
,hypertension,NN,B-DISEASE
,on,IN,O
,drug,NN,O
,treatment,NN,O
,with,IN,O
,amlodipine,NN,O
,developed,VBN,O
,loss,NN,B-DISEASE
,of,IN,I-DISEASE
,taste,NN,I-DISEASE
,sensation,NN,I-DISEASE
,.,.,O
,Condition,NNP,O
,moderately,RB,O
,improved,VBD,O
,on,IN,O
,stoppage,NN,O
,of,IN,O
,the,DT,O
,drug,NN,O
,for,IN,O
,25,CD,O
,days,NNS,O
,.,.,O
,We,PRP,O
,conclude,VBP,O
,that,IN,O
,amlodipine,NN,O
,can,MD,O
,cause,VB,O
,dysguesia,NN,B-DISEASE
,.,.,O
,Here,RB,O
,",",",",O
,we,PRP,O
,describe,VBP,O
,the,DT,O
,clinical,JJ,O
,presentation,NN,O
,and,CC,O
,review,VB,O
,the,DT,O
,relevant,JJ,O
,literature,NN,O
,on,IN,O
,amlodipine,NN,O
,and,CC,O
,dysguesia,NN,B-DISEASE
,.,.,O
,Rhabdomyolysis,NNP,B-DISEASE
,in,IN,O
,association,NN,O
,with,IN,O
,simvastatin,NN,O
,and,CC,O
,dosage,NN,O
,increment,NN,O
,in,IN,O
,clarithromycin,NN,O
,.,.,O
,Clarithromycin,NNP,O
,is,VBZ,O
,the,DT,O
,most,RBS,O
,documented,JJ,O
,cytochrome,NN,O
,P450,NNP,O
,3A4,CD,O
,(,(,O
,CYP3A4,NNP,O
,),),O
,inhibitor,NN,O
,to,TO,O
,cause,VB,O
,an,DT,O
,adverse,JJ,O
,interaction,NN,O
,with,IN,O
,simvastatin,NN,O
,.,.,O
,This,DT,O
,particular,JJ,O
,case,NN,O
,is,VBZ,O
,of,IN,O
,interest,NN,O
,as,IN,O
,rhabdomyolysis,NN,B-DISEASE
,only,RB,O
,occurred,VBD,O
,after,IN,O
,an,DT,O
,increase,NN,O
,in,IN,O
,the,DT,O
,dose,NN,O
,of,IN,O
,clarithromycin,NN,O
,.,.,O
,The,DT,O
,patient,NN,O
,developed,VBD,O
,raised,VBN,O
,cardiac,JJ,O
,biomarkers,NNS,O
,without,IN,O
,any,DT,O
,obvious,JJ,O
,cardiac,JJ,O
,issues,NNS,O
,",",",",O
,a,DT,O
,phenomenon,NN,O
,that,WDT,O
,has,VBZ,O
,been,VBN,O
,linked,VBN,O
,to,TO,O
,rhabdomyolysis,VB,B-DISEASE
,previously,RB,O
,.,.,O
,To,TO,O
,date,NN,O
,",",",",O
,there,EX,O
,has,VBZ,O
,been,VBN,O
,no,RB,O
,reported,JJ,O
,effect,NN,O
,of,IN,O
,rhabdomyolysis,NN,B-DISEASE
,on,IN,O
,the,DT,O
,structure,NN,O
,and,CC,O
,function,NN,O
,of,IN,O
,cardiac,JJ,O
,muscle,NN,O
,.,.,O
,Clinicians,NNPS,O
,need,VBP,O
,to,TO,O
,be,VB,O
,aware,JJ,O
,of,IN,O
,prescribing,VBG,O
,concomitant,JJ,O
,medications,NNS,O
,that,WDT,O
,increase,VBP,O
,the,DT,O
,risk,NN,O
,of,IN,O
,myopathy,NN,B-DISEASE
,or,CC,O
,inhibit,VB,O
,the,DT,O
,CYP3A4,NNP,O
,enzyme,NN,O
,.,.,O
,Our,PRP$,O
,case,NN,O
,suggests,VBZ,O
,that,IN,O
,troponin,NN,O
,elevation,NN,O
,could,MD,O
,be,VB,O
,associated,VBN,O
,with,IN,O
,statin,NN,O
,induced,JJ,O
,rhabdomyolysis,NN,B-DISEASE
,",",",",O
,which,WDT,O
,may,MD,O
,warrant,VB,O
,further,JJ,O
,studies,NNS,O
,.,.,O
,Characterization,NN,O
,of,IN,O
,a,DT,O
,novel,JJ,O
,BCHE,NNP,O
,"""",NNP,O
,silent,JJ,O
,"""",NNP,O
,allele,NN,O
,:,:,O
,point,NN,O
,mutation,NN,O
,(,(,O
,p,NN,O
,.,.,O
,Val204Asp,NNP,O
,),),O
,causes,VBZ,O
,loss,NN,O
,of,IN,O
,activity,NN,O
,and,CC,O
,prolonged,VBD,O
,apnea,NN,B-DISEASE
,with,IN,O
,suxamethonium,NN,O
,.,.,O
,Butyrylcholinesterase,NNP,B-DISEASE
,deficiency,NN,I-DISEASE
,is,VBZ,O
,characterized,VBN,O
,by,IN,O
,prolonged,JJ,O
,apnea,NN,B-DISEASE
,after,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,muscle,NN,O
,relaxants,NNS,O
,(,(,O
,suxamethonium,NN,O
,or,CC,O
,mivacurium,NN,O
,),),O
,in,IN,O
,patients,NNS,O
,who,WP,O
,have,VBP,O
,mutations,NNS,O
,in,IN,O
,the,DT,O
,BCHE,NNP,O
,gene,NN,O
,.,.,O
,Here,RB,O
,",",",",O
,we,PRP,O
,report,VBP,O
,a,DT,O
,case,NN,O
,of,IN,O
,prolonged,JJ,O
,neuromuscular,JJ,O
,block,NN,O
,after,IN,O
,administration,NN,O
,of,IN,O
,suxamethonium,NN,O
,leading,VBG,O
,to,TO,O
,the,DT,O
,discovery,NN,O
,of,IN,O
,a,DT,O
,novel,JJ,O
,BCHE,NNP,O
,variant,NN,O
,(,(,O
,c,NN,O
,.,.,O
,695T,CD,O
,>,NN,O
,A,NNP,O
,",",",",O
,p,NN,O
,.,.,O
,Val204Asp,NNP,O
,),),O
,.,.,O
,Inhibition,NNP,O
,studies,NNS,O
,",",",",O
,kinetic,JJ,O
,analysis,NN,O
,and,CC,O
,molecular,JJ,O
,dynamics,NNS,O
,were,VBD,O
,undertaken,VBN,O
,to,TO,O
,understand,VB,O
,how,WRB,O
,this,DT,O
,mutation,NN,O
,disrupts,VBZ,O
,the,DT,O
,catalytic,JJ,O
,triad,NN,O
,and,CC,O
,determines,VBZ,O
,a,DT,O
,"""",JJ,O
,silent,JJ,O
,"""",NN,O
,phenotype,NN,O
,.,.,O
,Low,JJ,O
,activity,NN,O
,of,IN,O
,patient,NN,O
,plasma,NN,O
,butyrylcholinesterase,NN,O
,with,IN,O
,butyrylthiocholine,NN,O
,(,(,O
,BTC,NNP,O
,),),O
,and,CC,O
,benzoylcholine,NN,O
,",",",",O
,and,CC,O
,values,NNS,O
,of,IN,O
,dibucaine,NN,O
,and,CC,O
,fluoride,JJ,O
,numbers,NNS,O
,fit,VBP,O
,with,IN,O
,heterozygous,JJ,O
,atypical,JJ,O
,silent,NN,O
,genotype,NN,O
,.,.,O
,Electrophoretic,JJ,O
,analysis,NN,O
,of,IN,O
,plasma,JJ,O
,BChE,NNP,O
,of,IN,O
,the,DT,O
,proband,NN,O
,and,CC,O
,his,PRP$,O
,mother,NN,O
,showed,VBD,O
,that,IN,O
,patient,NN,O
,has,VBZ,O
,a,DT,O
,reduced,JJ,O
,amount,NN,O
,of,IN,O
,tetrameric,JJ,O
,enzyme,NN,O
,in,IN,O
,plasma,NN,O
,and,CC,O
,that,IN,O
,minor,JJ,O
,fast,SYM,O
,-,:,O
,moving,VBG,O
,BChE,JJ,O
,components,NNS,O
,:,:,O
,monomer,NN,O
,",",",",O
,dimer,NN,O
,",",",",O
,and,CC,O
,monomer,SYM,O
,-,:,O
,albumin,NN,O
,conjugate,NN,O
,are,VBP,O
,missing,VBG,O
,.,.,O
,Kinetic,JJ,O
,analysis,NN,O
,showed,VBD,O
,that,IN,O
,the,DT,O
,p,NN,O
,.,.,O
,Val204Asp,NNP,O
,/,NNP,O
,p,NN,O
,.,.,O
,Asp70Gly,NNP,O
,-,:,O
,p,NN,O
,.,.,O
,Ala539Thr,NNP,O
,BChE,NNP,O
,displays,VBZ,O
,a,DT,O
,pure,JJ,O
,Michaelian,JJ,O
,behavior,NN,O
,with,IN,O
,BTC,NNP,O
,as,IN,O
,the,DT,O
,substrate,NN,O
,.,.,O
,Both,CC,O
,catalytic,JJ,O
,parameters,NNS,O
,Km,NNP,O
,=,VBD,O
,265,CD,O
,uM,NN,O
,for,IN,O
,BTC,NNP,O
,",",",",O
,two,CD,O
,times,NNS,O
,higher,JJR,O
,than,IN,O
,that,DT,O
,of,IN,O
,the,DT,O
,atypical,JJ,O
,enzyme,NN,O
,",",",",O
,and,CC,O
,a,DT,O
,low,JJ,O
,Vmax,NNP,O
,are,VBP,O
,consistent,JJ,O
,with,IN,O
,the,DT,O
,absence,NN,O
,of,IN,O
,activity,NN,O
,against,IN,O
,suxamethonium,NN,O
,.,.,O
,Molecular,JJ,O
,dynamic,NN,O
,(,(,O
,MD,NNP,O
,),),O
,simulations,NNS,O
,showed,VBD,O
,that,IN,O
,the,DT,O
,overall,JJ,O
,effect,NN,O
,of,IN,O
,the,DT,O
,mutation,NN,O
,p,NN,O
,.,.,O
,Val204Asp,NNP,O
,is,VBZ,O
,disruption,NN,O
,of,IN,O
,hydrogen,NN,O
,bonding,NN,O
,between,IN,O
,Gln223,NNP,O
,and,CC,O
,Glu441,NNP,O
,",",",",O
,leading,VBG,O
,Ser198,NNP,O
,and,CC,O
,His438,NNP,O
,to,TO,O
,move,VB,O
,away,RB,O
,from,IN,O
,each,DT,O
,other,JJ,O
,with,IN,O
,subsequent,JJ,O
,disruption,NN,O
,of,IN,O
,the,DT,O
,catalytic,JJ,O
,triad,NN,O
,functionality,NN,O
,regardless,NN,O
,of,IN,O
,the,DT,O
,type,NN,O
,of,IN,O
,substrate,NN,O
,.,.,O
,MD,NNP,O
,also,RB,O
,showed,VBD,O
,that,IN,O
,the,DT,O
,enzyme,NN,O
,volume,NN,O
,is,VBZ,O
,increased,VBN,O
,",",",",O
,suggesting,VBG,O
,a,DT,O
,pre,NN,O
,-,:,O
,denaturation,NN,O
,state,NN,O
,.,.,O
,This,DT,O
,fits,VBZ,O
,with,IN,O
,the,DT,O
,reduced,JJ,O
,concentration,NN,O
,of,IN,O
,p,NN,O
,.,.,O
,Ala204Asp,NNP,O
,/,NNP,O
,p,NN,O
,.,.,O
,Asp70Gly,NNP,O
,-,:,O
,p,NN,O
,.,.,O
,Ala539Thr,NNP,O
,tetrameric,JJ,O
,enzyme,NN,O
,in,IN,O
,the,DT,O
,plasma,NN,O
,and,CC,O
,non,JJ,O
,-,:,O
,detectable,JJ,O
,fast,NN,O
,moving,VBG,O
,-,:,O
,bands,NNS,O
,on,IN,O
,electrophoresis,NN,O
,gels,NNS,O
,.,.,O
,Delayed,NNP,O
,anemia,NN,B-DISEASE
,after,IN,O
,treatment,NN,O
,with,IN,O
,injectable,JJ,O
,artesunate,NN,O
,in,IN,O
,the,DT,O
,Democratic,JJ,O
,Republic,NNP,O
,of,IN,O
,the,DT,O
,Congo,NNP,O
,:,:,O
,a,DT,O
,manageable,JJ,O
,issue,NN,O
,.,.,O
,Cases,NNS,O
,of,IN,O
,delayed,JJ,O
,hemolytic,JJ,B-DISEASE
,anemia,NN,I-DISEASE
,have,VBP,O
,been,VBN,O
,described,VBN,O
,after,IN,O
,treatment,NN,O
,with,IN,O
,injectable,JJ,O
,artesunate,NN,O
,",",",",O
,the,DT,O
,current,JJ,O
,World,NNP,O
,Health,NNP,O
,Organization,NNP,O
,(,(,O
,WHO,NNP,O
,),),O
,-,:,O
,recommended,VBN,O
,first,JJ,O
,-,:,O
,line,NN,O
,drug,NN,O
,for,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,severe,JJ,O
,malaria,NN,B-DISEASE
,.,.,O
,A,DT,O
,total,NN,O
,of,IN,O
,350,CD,O
,patients,NNS,O
,(,(,O
,215,CD,O
,[,RB,O
,61,CD,O
,.,.,O
,4,CD,O
,%,NN,O
,],NNP,O
,<,VBZ,O
,5,CD,O
,years,NNS,O
,of,IN,O
,age,NN,O
,and,CC,O
,135,CD,O
,[,JJ,O
,38,CD,O
,.,.,O
,6,CD,O
,%,NN,O
,],NNP,O
,>,VBZ,O
,5,CD,O
,years,NNS,O
,of,IN,O
,age,NN,O
,),),O
,were,VBD,O
,followed,VBN,O
,-,:,O
,up,RB,O
,after,IN,O
,treatment,NN,O
,with,IN,O
,injectable,JJ,O
,artesunate,NN,O
,for,IN,O
,severe,JJ,O
,malaria,NNS,B-DISEASE
,in,IN,O
,hospitals,NNS,O
,and,CC,O
,health,NN,O
,centers,NNS,O
,of,IN,O
,the,DT,O
,Democratic,JJ,O
,Republic,NNP,O
,of,IN,O
,the,DT,O
,Congo,NNP,O
,.,.,O
,Complete,NNP,O
,series,NN,O
,of,IN,O
,hemoglobin,NN,O
,(,(,O
,Hb,NNP,O
,),),O
,measurements,NNS,O
,were,VBD,O
,available,JJ,O
,for,IN,O
,201,CD,O
,patients,NNS,O
,.,.,O
,A,DT,O
,decrease,NN,O
,in,IN,O
,Hb,NNP,O
,levels,NNS,O
,between,IN,O
,2,CD,O
,and,CC,O
,5,CD,O
,g,NN,O
,/,NNP,O
,dL,NN,O
,was,VBD,O
,detected,VBN,O
,in,IN,O
,23,CD,O
,(,(,O
,11,CD,O
,.,.,O
,4,CD,O
,%,NN,O
,),),O
,patients,NNS,O
,during,IN,O
,the,DT,O
,follow,JJ,O
,-,:,O
,up,RB,O
,period,NN,O
,.,.,O
,For,IN,O
,five,CD,O
,patients,NNS,O
,",",",",O
,Hb,NNP,O
,levels,NNS,O
,decreased,VBN,O
,below,IN,O
,5,CD,O
,g,NN,O
,/,NNP,O
,dL,NN,O
,during,IN,O
,at,IN,O
,least,JJS,O
,one,CD,O
,follow,NN,O
,-,:,O
,up,RB,O
,visit,NN,O
,.,.,O
,All,DT,O
,cases,NNS,O
,of,IN,O
,delayed,JJ,O
,anemia,NN,B-DISEASE
,were,VBD,O
,clinically,RB,O
,manageable,JJ,O
,and,CC,O
,resolved,VBD,O
,within,IN,O
,one,CD,O
,month,NN,O
,.,.,O
,Regulation,NN,O
,of,IN,O
,signal,JJ,O
,transducer,NN,O
,and,CC,O
,activator,NN,O
,of,IN,O
,transcription,NN,O
,3,CD,O
,and,CC,O
,apoptotic,JJ,O
,pathways,NNS,O
,by,IN,O
,betaine,NN,O
,attenuates,NNS,O
,isoproterenol,VBP,O
,-,:,O
,induced,JJ,O
,acute,JJ,O
,myocardial,JJ,B-DISEASE
,injury,NN,I-DISEASE
,in,IN,O
,rats,NNS,O
,.,.,O
,The,DT,O
,present,JJ,O
,study,NN,O
,was,VBD,O
,designed,VBN,O
,to,TO,O
,investigate,VB,O
,the,DT,O
,cardioprotective,JJ,O
,effects,NNS,O
,of,IN,O
,betaine,NN,O
,on,IN,O
,acute,JJ,O
,myocardial,JJ,B-DISEASE
,ischemia,NN,I-DISEASE
,induced,VBD,O
,experimentally,RB,O
,in,IN,O
,rats,NNS,O
,focusing,VBG,O
,on,IN,O
,regulation,NN,O
,of,IN,O
,signal,JJ,O
,transducer,NN,O
,and,CC,O
,activator,NN,O
,of,IN,O
,transcription,NN,O
,3,CD,O
,(,(,O
,STAT3,NNP,O
,),),O
,and,CC,O
,apoptotic,JJ,O
,pathways,NNS,O
,as,IN,O
,the,DT,O
,potential,JJ,O
,mechanism,NN,O
,underlying,VBG,O
,the,DT,O
,drug,NN,O
,effect,NN,O
,.,.,O
,Male,NNP,O
,Sprague,NNP,O
,Dawley,NNP,O
,rats,NNS,O
,were,VBD,O
,treated,VBN,O
,with,IN,O
,betaine,NN,O
,(,(,O
,100,CD,O
,",",",",O
,200,CD,O
,",",",",O
,and,CC,O
,400,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,orally,RB,O
,for,IN,O
,40,CD,O
,days,NNS,O
,.,.,O
,Acute,NNP,O
,myocardial,JJ,B-DISEASE
,ischemic,JJ,I-DISEASE
,injury,NN,I-DISEASE
,was,VBD,O
,induced,VBN,O
,in,IN,O
,rats,NNS,O
,by,IN,O
,subcutaneous,JJ,O
,injection,NN,O
,of,IN,O
,isoproterenol,NN,O
,(,(,O
,85,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,",",",",O
,for,IN,O
,two,CD,O
,consecutive,JJ,O
,days,NNS,O
,.,.,O
,Serum,NNP,O
,cardiac,JJ,O
,marker,NN,O
,enzyme,NN,O
,",",",",O
,histopathological,JJ,O
,variables,NNS,O
,and,CC,O
,expression,NN,O
,of,IN,O
,protein,NN,O
,levels,NNS,O
,were,VBD,O
,analyzed,VBN,O
,.,.,O
,Oral,JJ,O
,administration,NN,O
,of,IN,O
,betaine,NN,O
,(,(,O
,200,CD,O
,and,CC,O
,400,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,significantly,RB,O
,reduced,VBD,O
,the,DT,O
,level,NN,O
,of,IN,O
,cardiac,JJ,O
,marker,NN,O
,enzyme,NN,O
,in,IN,O
,the,DT,O
,serum,NN,O
,and,CC,O
,prevented,VBD,O
,left,VBD,O
,ventricular,JJ,B-DISEASE
,remodeling,NN,I-DISEASE
,.,.,O
,Western,JJ,O
,blot,NN,O
,analysis,NN,O
,showed,VBD,O
,that,IN,O
,isoproterenol,JJ,O
,-,:,O
,induced,JJ,O
,phosphorylation,NN,O
,of,IN,O
,STAT3,NNP,O
,was,VBD,O
,maintained,VBN,O
,or,CC,O
,further,RBR,O
,enhanced,VBN,O
,by,IN,O
,betaine,NN,O
,treatment,NN,O
,in,IN,O
,myocardium,NN,O
,.,.,O
,Furthermore,NNP,O
,",",",",O
,betaine,NN,O
,(,(,O
,200,CD,O
,and,CC,O
,400,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,treatment,NN,O
,increased,VBD,O
,the,DT,O
,ventricular,JJ,O
,expression,NN,O
,of,IN,O
,Bcl,NNP,O
,-,:,O
,2,CD,O
,and,CC,O
,reduced,VBD,O
,the,DT,O
,level,NN,O
,of,IN,O
,Bax,NNP,O
,",",",",O
,therefore,RB,O
,causing,VBG,O
,a,DT,O
,significant,JJ,O
,increase,NN,O
,in,IN,O
,the,DT,O
,ratio,NN,O
,of,IN,O
,Bcl,NNP,O
,-,:,O
,2,CD,O
,/,JJ,O
,Bax,NNP,O
,.,.,O
,The,DT,O
,protective,JJ,O
,role,NN,O
,of,IN,O
,betaine,NN,O
,on,IN,O
,myocardial,JJ,B-DISEASE
,damage,NN,I-DISEASE
,was,VBD,O
,further,RB,O
,confirmed,VBN,O
,by,IN,O
,histopathological,JJ,O
,examination,NN,O
,.,.,O
,In,IN,O
,summary,JJ,O
,",",",",O
,our,PRP$,O
,results,NNS,O
,showed,VBD,O
,that,IN,O
,betaine,JJ,O
,pretreatment,NN,O
,attenuated,VBD,O
,isoproterenol,JJ,O
,-,:,O
,induced,JJ,O
,acute,JJ,O
,myocardial,JJ,B-DISEASE
,ischemia,NN,I-DISEASE
,via,IN,O
,the,DT,O
,regulation,NN,O
,of,IN,O
,STAT3,NNP,O
,and,CC,O
,apoptotic,JJ,O
,pathways,NNS,O
,.,.,O
,Quetiapine,NNP,O
,-,:,O
,induced,VBD,O
,neutropenia,NN,B-DISEASE
,in,IN,O
,a,DT,O
,bipolar,JJ,B-DISEASE
,patient,NN,O
,with,IN,O
,hepatocellular,JJ,B-DISEASE
,carcinoma,NN,I-DISEASE
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,Quetiapine,NN,O
,is,VBZ,O
,a,DT,O
,dibenzothiazepine,JJ,O
,derivative,NN,O
,",",",",O
,similar,JJ,O
,to,TO,O
,clozapine,VB,O
,",",",",O
,which,WDT,O
,has,VBZ,O
,the,DT,O
,highest,JJS,O
,risk,NN,O
,of,IN,O
,causing,VBG,O
,blood,NN,B-DISEASE
,dyscrasias,NN,I-DISEASE
,",",",",O
,especially,RB,O
,neutropenia,RB,B-DISEASE
,.,.,O
,There,EX,O
,are,VBP,O
,some,DT,O
,case,NN,O
,reports,NNS,O
,about,IN,O
,this,DT,O
,side,NN,O
,effect,NN,O
,of,IN,O
,quetiapine,NN,O
,",",",",O
,but,CC,O
,possible,JJ,O
,risk,NN,O
,factors,NNS,O
,are,VBP,O
,seldom,RB,O
,discussed,VBN,O
,and,CC,O
,identified,VBN,O
,.,.,O
,A,DT,O
,case,NN,O
,of,IN,O
,a,DT,O
,patient,NN,O
,with,IN,O
,hepatocellular,JJ,B-DISEASE
,carcinoma,NN,I-DISEASE
,that,WDT,O
,developed,VBD,O
,neutropenia,RB,B-DISEASE
,after,IN,O
,treatment,NN,O
,with,IN,O
,quetiapine,NN,O
,is,VBZ,O
,described,VBN,O
,here,RB,O
,.,.,O
,CASE,NNP,O
,REPORT,NNP,O
,:,:,O
,A,DT,O
,62,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,Taiwanese,JJ,O
,widow,NN,O
,with,IN,O
,bipolar,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,was,VBD,O
,diagnosed,VBN,O
,with,IN,O
,hepatocellular,JJ,B-DISEASE
,carcinoma,NN,I-DISEASE
,at,IN,O
,age,NN,O
,60,CD,O
,.,.,O
,She,PRP,O
,developed,VBD,O
,leucopenia,NN,B-DISEASE
,after,IN,O
,being,VBG,O
,treated,VBN,O
,with,IN,O
,quetiapine,NN,O
,.,.,O
,After,IN,O
,quetiapine,NN,O
,was,VBD,O
,discontinued,VBN,O
,",",",",O
,her,PRP$,O
,white,JJ,O
,blood,NN,O
,cell,NN,O
,count,NN,O
,returned,VBD,O
,to,TO,O
,normal,JJ,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Although,IN,O
,neutropenia,NN,B-DISEASE
,is,VBZ,O
,not,RB,O
,a,DT,O
,common,JJ,O
,side,NN,O
,effect,NN,O
,of,IN,O
,quetiapine,NN,O
,",",",",O
,physicians,NNS,O
,should,MD,O
,be,VB,O
,cautious,JJ,O
,about,IN,O
,its,PRP$,O
,presentation,NN,O
,and,CC,O
,associated,VBN,O
,risk,NN,O
,factors,NNS,O
,.,.,O
,Hepatic,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,may,MD,O
,be,VB,O
,one,CD,O
,of,IN,O
,the,DT,O
,possible,JJ,O
,risk,NN,O
,factors,NNS,O
,",",",",O
,and,CC,O
,concomitant,JJ,O
,fever,NN,B-DISEASE
,may,MD,O
,be,VB,O
,a,DT,O
,diagnostic,JJ,O
,marker,NN,O
,for,IN,O
,adverse,JJ,O
,reaction,NN,O
,to,TO,O
,quetiapine,VB,O
,.,.,O
,Lateral,NNP,O
,antebrachial,JJ,O
,cutaneous,JJ,O
,neuropathy,NN,B-DISEASE
,after,IN,O
,steroid,JJ,O
,injection,NN,O
,at,IN,O
,lateral,JJ,O
,epicondyle,NN,O
,.,.,O
,BACKGROUND,NNP,O
,AND,CC,O
,OBJECTIVES,NNP,O
,:,:,O
,This,DT,O
,report,NN,O
,aimed,VBD,O
,to,TO,O
,present,VB,O
,a,DT,O
,case,NN,O
,of,IN,O
,lateral,JJ,O
,antebrachial,JJ,O
,cutaneous,JJ,O
,neuropathy,NN,B-DISEASE
,(,(,O
,LACNP,NNP,O
,),),O
,that,WDT,O
,occurred,VBD,O
,after,IN,O
,a,DT,O
,steroid,JJ,O
,injection,NN,O
,in,IN,O
,the,DT,O
,lateral,JJ,O
,epicondyle,NN,O
,to,TO,O
,treat,VB,O
,lateral,JJ,B-DISEASE
,epicondylitis,NN,I-DISEASE
,in,IN,O
,a,DT,O
,40,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,.,.,O
,MATERIAL,NNP,O
,AND,CC,O
,METHOD,NNP,O
,:,:,O
,A,DT,O
,40,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,presented,VBN,O
,with,IN,O
,decreased,JJ,O
,sensation,NN,O
,and,CC,O
,paresthesia,NN,B-DISEASE
,over,IN,O
,her,PRP$,O
,right,JJ,O
,lateral,JJ,O
,forearm,NN,O
,;,:,O
,the,DT,O
,paresthesia,NN,B-DISEASE
,had,VBD,O
,occurred,VBN,O
,after,IN,O
,a,DT,O
,steroid,JJ,O
,injection,NN,O
,in,IN,O
,the,DT,O
,right,JJ,O
,lateral,JJ,O
,epicondyle,JJ,O
,3,CD,O
,months,NNS,O
,before,IN,O
,.,.,O
,Her,PRP$,O
,sensation,NN,O
,of,IN,O
,light,JJ,O
,touch,NN,O
,and,CC,O
,pain,NN,B-DISEASE
,was,VBD,O
,diminished,VBN,O
,over,IN,O
,the,DT,O
,lateral,JJ,O
,side,NN,O
,of,IN,O
,the,DT,O
,right,JJ,O
,forearm,NN,O
,and,CC,O
,wrist,JJ,O
,area,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,The,DT,O
,sensory,JJ,O
,action,NN,O
,potential,JJ,O
,amplitude,NN,O
,of,IN,O
,the,DT,O
,right,JJ,O
,lateral,JJ,O
,antebrachial,JJ,O
,cutaneous,JJ,O
,nerve,NN,O
,(,(,O
,LACN,NNP,O
,),),O
,(,(,O
,6,CD,O
,.,.,O
,2,CD,O
,uV,NN,O
,),),O
,was,VBD,O
,lower,JJR,O
,than,IN,O
,that,DT,O
,of,IN,O
,the,DT,O
,left,NN,O
,(,(,O
,13,CD,O
,.,.,O
,1,CD,O
,uV,JJ,O
,),),O
,.,.,O
,The,DT,O
,difference,NN,O
,of,IN,O
,amplitude,NN,O
,between,IN,O
,both,DT,O
,sides,NNS,O
,was,VBD,O
,significant,JJ,O
,because,IN,O
,there,EX,O
,was,VBD,O
,more,JJR,O
,than,IN,O
,a,DT,O
,50,CD,O
,%,NN,O
,reduction,NN,O
,.,.,O
,She,PRP,O
,was,VBD,O
,diagnosed,VBN,O
,with,IN,O
,right,JJ,O
,LACNP,NNP,O
,(,(,O
,mainly,RB,O
,axonal,JJ,O
,involvement,NN,O
,),),O
,on,IN,O
,the,DT,O
,basis,NN,O
,of,IN,O
,the,DT,O
,clinical,JJ,O
,manifestation,NN,O
,and,CC,O
,the,DT,O
,electrodiagnostic,JJ,O
,findings,NNS,O
,.,.,O
,Her,PRP$,O
,symptoms,NNS,O
,improved,VBN,O
,through,IN,O
,physical,JJ,O
,therapy,NN,O
,but,CC,O
,persisted,VBD,O
,to,TO,O
,some,DT,O
,degree,NN,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,This,DT,O
,report,NN,O
,describes,VBZ,O
,the,DT,O
,case,NN,O
,of,IN,O
,a,DT,O
,woman,NN,O
,with,IN,O
,LACNP,NNP,O
,that,WDT,O
,developed,VBD,O
,after,IN,O
,a,DT,O
,steroid,JJ,O
,injection,NN,O
,for,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,lateral,JJ,B-DISEASE
,epicondylitis,NN,I-DISEASE
,.,.,O
,An,DT,O
,electrodiagnostic,JJ,O
,study,NN,O
,",",",",O
,including,VBG,O
,a,DT,O
,nerve,NN,O
,conduction,NN,O
,study,NN,O
,of,IN,O
,the,DT,O
,LACN,NNP,O
,",",",",O
,was,VBD,O
,helpful,JJ,O
,to,TO,O
,diagnose,VB,O
,right,JJ,O
,LACNP,NNP,O
,and,CC,O
,to,TO,O
,find,VB,O
,the,DT,O
,passage,NN,O
,of,IN,O
,the,DT,O
,LACN,NNP,O
,on,IN,O
,the,DT,O
,lateral,JJ,O
,epicondyle,NN,O
,.,.,O
,Curcumin,NNP,O
,prevents,NNS,O
,maleate,VBP,O
,-,:,O
,induced,JJ,O
,nephrotoxicity,NN,B-DISEASE
,:,:,O
,relation,NN,O
,to,TO,O
,hemodynamic,VB,O
,alterations,NNS,O
,",",",",O
,oxidative,JJ,O
,stress,NN,O
,",",",",O
,mitochondrial,JJ,O
,oxygen,NN,O
,consumption,NN,O
,and,CC,O
,activity,NN,O
,of,IN,O
,respiratory,NN,O
,complex,NN,O
,I,PRP,O
,.,.,O
,The,DT,O
,potential,JJ,O
,protective,JJ,O
,effect,NN,O
,of,IN,O
,the,DT,O
,dietary,JJ,O
,antioxidant,NN,O
,curcumin,NN,O
,(,(,O
,120,CD,O
,mg,NN,O
,/,NNP,O
,Kg,NNP,O
,/,NNP,O
,day,NN,O
,for,IN,O
,6,CD,O
,days,NNS,O
,),),O
,against,IN,O
,the,DT,O
,renal,JJ,B-DISEASE
,injury,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,maleate,NN,O
,was,VBD,O
,evaluated,VBN,O
,.,.,O
,Tubular,JJ,O
,proteinuria,NN,B-DISEASE
,and,CC,O
,oxidative,JJ,O
,stress,NN,O
,were,VBD,O
,induced,VBN,O
,by,IN,O
,a,DT,O
,single,JJ,O
,injection,NN,O
,of,IN,O
,maleate,NN,O
,(,(,O
,400,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,in,IN,O
,rats,NN,O
,.,.,O
,Maleate,NNP,O
,-,:,O
,induced,VBD,O
,renal,JJ,B-DISEASE
,injury,NN,I-DISEASE
,included,VBD,O
,increase,NN,O
,in,IN,O
,renal,JJ,O
,vascular,JJ,O
,resistance,NN,O
,and,CC,O
,in,IN,O
,the,DT,O
,urinary,JJ,O
,excretion,NN,O
,of,IN,O
,total,JJ,O
,protein,NN,O
,",",",",O
,glucose,NN,O
,",",",",O
,sodium,NN,O
,",",",",O
,neutrophil,JJ,O
,gelatinase,NN,O
,-,:,O
,associated,VBN,O
,lipocalin,NN,O
,(,(,O
,NGAL,NNP,O
,),),O
,and,CC,O
,N,NNP,O
,-,:,O
,acetyl,NN,O
,b,SYM,O
,-,:,O
,D,NNP,O
,-,:,O
,glucosaminidase,NN,O
,(,(,O
,NAG,NNP,O
,),),O
,",",",",O
,upregulation,NN,O
,of,IN,O
,kidney,NN,B-DISEASE
,injury,NN,I-DISEASE
,molecule,NN,O
,(,(,O
,KIM,NNP,O
,),),O
,-,:,O
,1,CD,O
,",",",",O
,decrease,NN,O
,in,IN,O
,renal,JJ,O
,blood,NN,O
,flow,NN,O
,and,CC,O
,claudin,VB,O
,-,:,O
,2,CD,O
,expression,NN,O
,besides,IN,O
,of,IN,O
,necrosis,NN,B-DISEASE
,and,CC,O
,apoptosis,NN,O
,of,IN,O
,tubular,JJ,O
,cells,NNS,O
,on,IN,O
,24,CD,O
,h,NN,O
,.,.,O
,Oxidative,JJ,O
,stress,NN,O
,was,VBD,O
,determined,VBN,O
,by,IN,O
,measuring,VBG,O
,the,DT,O
,oxidation,NN,O
,of,IN,O
,lipids,NNS,O
,and,CC,O
,proteins,NNS,O
,and,CC,O
,diminution,NN,O
,in,IN,O
,renal,JJ,O
,Nrf2,NNP,O
,levels,NNS,O
,.,.,O
,Studies,NNS,O
,were,VBD,O
,also,RB,O
,conducted,VBN,O
,in,IN,O
,renal,JJ,O
,epithelial,JJ,O
,LLC,NNP,O
,-,:,O
,PK1,NNP,O
,cells,NNS,O
,and,CC,O
,in,IN,O
,mitochondria,NNS,O
,isolated,VBN,O
,from,IN,O
,kidneys,NNS,O
,of,IN,O
,all,PDT,O
,the,DT,O
,experimental,JJ,O
,groups,NNS,O
,.,.,O
,Maleate,NNP,O
,induced,VBD,O
,cell,NN,O
,damage,NN,O
,and,CC,O
,reactive,JJ,O
,oxygen,NN,O
,species,NNS,O
,(,(,O
,ROS,NNP,O
,),),O
,production,NN,O
,in,IN,O
,LLC,NNP,O
,-,:,O
,PK1,NNP,O
,cells,NNS,O
,in,IN,O
,culture,NN,O
,.,.,O
,In,IN,O
,addition,NN,O
,",",",",O
,maleate,NN,O
,treatment,NN,O
,reduced,VBD,O
,oxygen,JJ,O
,consumption,NN,O
,in,IN,O
,ADP,NNP,O
,-,:,O
,stimulated,VBD,O
,mitochondria,NNS,O
,and,CC,O
,diminished,JJ,O
,respiratory,NN,O
,control,NN,O
,index,NN,O
,when,WRB,O
,using,VBG,O
,malate,NN,O
,/,NN,O
,glutamate,NN,O
,as,IN,O
,substrate,NN,O
,.,.,O
,The,DT,O
,activities,NNS,O
,of,IN,O
,both,DT,O
,complex,JJ,O
,I,PRP,O
,and,CC,O
,aconitase,VB,O
,were,VBD,O
,also,RB,O
,diminished,VBN,O
,.,.,O
,All,PDT,O
,the,DT,O
,above,JJ,O
,-,:,O
,described,JJ,O
,alterations,NNS,O
,were,VBD,O
,prevented,VBN,O
,by,IN,O
,curcumin,NN,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,concluded,VBN,O
,that,IN,O
,curcumin,NN,O
,is,VBZ,O
,able,JJ,O
,to,TO,O
,attenuate,VB,O
,in,IN,O
,vivo,NN,O
,maleate,NN,O
,-,:,O
,induced,VBN,O
,nephropathy,JJ,B-DISEASE
,and,CC,O
,in,IN,O
,vitro,NN,O
,cell,NN,O
,damage,NN,O
,.,.,O
,The,DT,O
,in,IN,O
,vivo,NN,O
,protection,NN,O
,was,VBD,O
,associated,VBN,O
,to,TO,O
,the,DT,O
,prevention,NN,O
,of,IN,O
,oxidative,JJ,O
,stress,NN,O
,and,CC,O
,preservation,NN,O
,of,IN,O
,mitochondrial,JJ,O
,oxygen,NN,O
,consumption,NN,O
,and,CC,O
,activity,NN,O
,of,IN,O
,respiratory,NN,O
,complex,NN,O
,I,PRP,O
,",",",",O
,and,CC,O
,the,DT,O
,in,IN,O
,vitro,NN,O
,protection,NN,O
,was,VBD,O
,associated,VBN,O
,to,TO,O
,the,DT,O
,prevention,NN,O
,of,IN,O
,ROS,NNP,O
,production,NN,O
,.,.,O
,Anticonvulsant,JJ,O
,actions,NNS,O
,of,IN,O
,MK,NNP,O
,-,:,O
,801,CD,O
,on,IN,O
,the,DT,O
,lithium,NN,O
,-,:,O
,pilocarpine,NN,O
,model,NN,O
,of,IN,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,in,IN,O
,rats,NNS,O
,.,.,O
,MK,NNP,O
,-,:,O
,801,CD,O
,",",",",O
,a,DT,O
,noncompetitive,JJ,O
,N,NNP,O
,-,:,O
,methyl,NN,O
,-,:,O
,D,NNP,O
,-,:,O
,aspartate,NN,O
,(,(,O
,NMDA,NNP,O
,),),O
,receptor,NN,O
,antagonist,NN,O
,",",",",O
,was,VBD,O
,tested,VBN,O
,for,IN,O
,anticonvulsant,JJ,O
,effects,NNS,O
,in,IN,O
,rats,NNS,O
,using,VBG,O
,two,CD,O
,seizure,NN,B-DISEASE
,models,NNS,O
,",",",",O
,coadministration,NN,O
,of,IN,O
,lithium,NN,O
,and,CC,O
,pilocarpine,NN,O
,and,CC,O
,administration,NN,O
,of,IN,O
,a,DT,O
,high,JJ,O
,dose,NN,O
,of,IN,O
,pilocarpine,NN,O
,alone,RB,O
,.,.,O
,Three,CD,O
,major,JJ,O
,results,NNS,O
,are,VBP,O
,reported,VBN,O
,.,.,O
,First,NNP,O
,",",",",O
,pretreatment,NN,O
,with,IN,O
,MK,NNP,O
,-,:,O
,801,CD,O
,produced,VBD,O
,an,DT,O
,effective,JJ,O
,and,CC,O
,dose,JJ,O
,-,:,O
,dependent,NN,O
,anticonvulsant,JJ,O
,action,NN,O
,with,IN,O
,the,DT,O
,lithium,NN,O
,-,:,O
,pilocarpine,NN,O
,model,NN,O
,but,CC,O
,not,RB,O
,with,IN,O
,rats,NNS,O
,treated,VBN,O
,with,IN,O
,pilocarpine,NN,O
,alone,RB,O
,",",",",O
,suggesting,VBG,O
,that,IN,O
,different,JJ,O
,biochemical,JJ,O
,mechanisms,NNS,O
,control,NN,O
,seizures,VBZ,B-DISEASE
,in,IN,O
,these,DT,O
,two,CD,O
,models,NNS,O
,.,.,O
,Second,NNP,O
,",",",",O
,the,DT,O
,anticonvulsant,JJ,O
,effect,NN,O
,of,IN,O
,MK,NNP,O
,-,:,O
,801,CD,O
,in,IN,O
,the,DT,O
,lithium,NN,O
,-,:,O
,pilocarpine,NN,O
,model,NN,O
,only,RB,O
,occurred,VBD,O
,after,IN,O
,initial,JJ,O
,periods,NNS,O
,of,IN,O
,seizure,NN,B-DISEASE
,activity,NN,O
,.,.,O
,This,DT,O
,observation,NN,O
,is,VBZ,O
,suggested,VBN,O
,to,TO,O
,be,VB,O
,an,DT,O
,in,IN,O
,vivo,JJ,O
,demonstration,NN,O
,of,IN,O
,the,DT,O
,conclusion,NN,O
,derived,VBN,O
,from,IN,O
,in,IN,O
,vitro,NN,O
,experiments,NNS,O
,that,WDT,O
,MK,NNP,O
,-,:,O
,801,CD,O
,binding,NN,O
,requires,VBZ,O
,agonist,JJ,O
,-,:,O
,induced,JJ,O
,opening,NN,O
,of,IN,O
,the,DT,O
,channel,NN,O
,sites,VBZ,O
,of,IN,O
,the,DT,O
,NMDA,NNP,O
,receptor,NN,O
,.,.,O
,Third,NNP,O
,",",",",O
,although,IN,O
,it,PRP,O
,is,VBZ,O
,relatively,RB,O
,easy,JJ,O
,to,TO,O
,block,VB,O
,seizures,NNS,B-DISEASE
,induced,VBN,O
,by,IN,O
,lithium,NN,O
,and,CC,O
,pilocarpine,NN,O
,by,IN,O
,administration,NN,O
,of,IN,O
,anticonvulsants,NNS,O
,prior,JJ,O
,to,TO,O
,pilocarpine,VB,O
,",",",",O
,it,PRP,O
,is,VBZ,O
,more,RBR,O
,difficult,JJ,O
,to,TO,O
,terminate,VB,O
,ongoing,JJ,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,and,CC,O
,block,VB,O
,the,DT,O
,lethality,NN,O
,of,IN,O
,the,DT,O
,seizures,NNS,B-DISEASE
,.,.,O
,Administration,NNP,O
,of,IN,O
,MK,NNP,O
,-,:,O
,801,CD,O
,30,CD,O
,or,CC,O
,60,CD,O
,min,NNS,O
,after,IN,O
,pilocarpine,NN,O
,",",",",O
,i,NN,O
,.,.,O
,e,NN,O
,.,.,O
,",",",",O
,during,IN,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,",",",",O
,gradually,RB,O
,reduced,JJ,O
,electrical,JJ,O
,and,CC,O
,behavioral,JJ,O
,seizure,NN,B-DISEASE
,activity,NN,O
,and,CC,O
,greatly,RB,O
,enhanced,VBD,O
,the,DT,O
,survival,NN,O
,rate,NN,O
,.,.,O
,These,DT,O
,results,NNS,O
,suggest,VBP,O
,that,IN,O
,activation,NN,O
,of,IN,O
,NMDA,NNP,O
,receptors,NNS,O
,plays,VBZ,O
,an,DT,O
,important,JJ,O
,role,NN,O
,in,IN,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,and,CC,O
,brain,NN,B-DISEASE
,damage,NN,I-DISEASE
,in,IN,O
,the,DT,O
,lithium,NN,O
,-,:,O
,pilocarpine,NN,O
,model,NN,O
,.,.,O
,This,DT,O
,was,VBD,O
,further,RBR,O
,supported,VBN,O
,by,IN,O
,results,NNS,O
,showing,VBG,O
,that,IN,O
,nonconvulsive,JJ,O
,doses,NNS,O
,of,IN,O
,NMDA,NNP,O
,and,CC,O
,pilocarpine,NN,O
,were,VBD,O
,synergistic,JJ,O
,",",",",O
,resulting,VBG,O
,in,IN,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,and,CC,O
,subsequent,JJ,O
,mortality,NN,O
,.,.,O
,Continuous,JJ,O
,infusion,NN,O
,tobramycin,NN,O
,combined,VBN,O
,with,IN,O
,carbenicillin,NN,O
,for,IN,O
,infections,NNS,B-DISEASE
,in,IN,O
,cancer,NN,B-DISEASE
,patients,NNS,O
,.,.,O
,The,DT,O
,cure,NN,O
,rate,NN,O
,of,IN,O
,infections,NNS,B-DISEASE
,in,IN,O
,cancer,NN,B-DISEASE
,patients,NNS,O
,is,VBZ,O
,adversely,RB,O
,affected,VBN,O
,by,IN,O
,neutropenia,NN,B-DISEASE
,(,(,O
,less,JJR,O
,than,IN,O
,1,CD,O
,",",",",O
,000,CD,O
,/,NNP,O
,mm3,NN,O
,),),O
,.,.,O
,In,IN,O
,particular,JJ,O
,",",",",O
,patients,NNS,O
,with,IN,O
,severe,JJ,O
,neutropenia,NN,B-DISEASE
,(,(,O
,less,JJR,O
,than,IN,O
,100,CD,O
,/,JJ,O
,mm3,NN,O
,),),O
,have,VBP,O
,shown,VBN,O
,a,DT,O
,poor,JJ,O
,response,NN,O
,to,TO,O
,antibiotics,NNS,O
,.,.,O
,To,TO,O
,overcome,VB,O
,the,DT,O
,adverse,JJ,O
,effects,NNS,O
,of,IN,O
,neutropenia,NN,B-DISEASE
,",",",",O
,tobramycin,NN,O
,was,VBD,O
,given,VBN,O
,by,IN,O
,continuous,JJ,O
,infusion,NN,O
,and,CC,O
,combined,VBN,O
,with,IN,O
,intermittent,JJ,O
,carbenicillin,NN,O
,.,.,O
,Tobramycin,NNP,O
,was,VBD,O
,given,VBN,O
,to,TO,O
,a,DT,O
,total,JJ,O
,daily,JJ,O
,dose,NN,O
,of,IN,O
,300,CD,O
,mg,NNS,O
,/,JJ,O
,m2,NN,O
,and,CC,O
,carbenicillin,NN,O
,was,VBD,O
,given,VBN,O
,at,IN,O
,a,DT,O
,dose,NN,O
,of,IN,O
,5,CD,O
,gm,NNS,O
,every,DT,O
,four,CD,O
,hours,NNS,O
,.,.,O
,There,EX,O
,were,VBD,O
,125,CD,O
,infectious,JJ,O
,episodes,NNS,O
,in,IN,O
,116,CD,O
,cancer,NN,B-DISEASE
,patients,NNS,O
,receiving,VBG,O
,myelosuppressive,JJ,O
,chemotherapy,NN,O
,.,.,O
,The,DT,O
,overall,JJ,O
,cure,NN,O
,rate,NN,O
,was,VBD,O
,70,CD,O
,%,NN,O
,.,.,O
,Pneumonia,NNP,B-DISEASE
,was,VBD,O
,the,DT,O
,most,RBS,O
,common,JJ,O
,infection,NN,B-DISEASE
,and,CC,O
,61,CD,O
,%,NN,O
,of,IN,O
,59,CD,O
,episodes,NNS,O
,were,VBD,O
,cured,VBN,O
,.,.,O
,Gram,NNP,O
,-,:,O
,negative,JJ,O
,bacilli,NN,O
,were,VBD,O
,the,DT,O
,most,RBS,O
,common,JJ,O
,causative,JJ,O
,organisms,NNS,O
,and,CC,O
,69,CD,O
,%,NN,O
,of,IN,O
,these,DT,O
,infections,NNS,B-DISEASE
,were,VBD,O
,cured,VBN,O
,.,.,O
,The,DT,O
,most,RBS,O
,common,JJ,O
,pathogen,NN,O
,was,VBD,O
,Klebsiella,NNP,O
,pneumoniae,NN,B-DISEASE
,and,CC,O
,this,DT,O
,",",",",O
,together,RB,O
,with,IN,O
,Escherichia,NNP,O
,coli,NNS,O
,and,CC,O
,Pseudomonas,NNP,O
,aeruginosa,NN,O
,",",",",O
,accounted,VBD,O
,for,IN,O
,74,CD,O
,%,NN,O
,of,IN,O
,all,DT,O
,gram,JJ,B-DISEASE
,-,:,I-DISEASE
,negative,JJ,I-DISEASE
,bacillary,JJ,I-DISEASE
,infections,NNS,I-DISEASE
,.,.,O
,Response,NNP,O
,was,VBD,O
,not,RB,O
,influenced,VBN,O
,by,IN,O
,the,DT,O
,initial,JJ,O
,neutrophil,NN,O
,count,NN,O
,",",",",O
,with,IN,O
,a,DT,O
,62,CD,O
,%,NN,O
,cure,NN,O
,rate,NN,O
,for,IN,O
,39,CD,O
,episodes,NNS,O
,associated,VBN,O
,with,IN,O
,severe,JJ,O
,neutropenia,NN,B-DISEASE
,.,.,O
,However,RB,O
,",",",",O
,failure,NN,O
,of,IN,O
,the,DT,O
,neutrophil,JJ,O
,count,NN,O
,to,TO,O
,increase,VB,O
,during,IN,O
,therapy,NN,O
,adversely,RB,O
,affected,JJ,O
,response,NN,O
,.,.,O
,Azotemia,NNP,B-DISEASE
,was,VBD,O
,the,DT,O
,major,JJ,O
,side,NN,O
,effect,NN,O
,recognized,VBN,O
,",",",",O
,and,CC,O
,it,PRP,O
,occurred,VBD,O
,in,IN,O
,11,CD,O
,%,NN,O
,of,IN,O
,episodes,NNS,O
,.,.,O
,Major,JJ,O
,azotemia,NN,B-DISEASE
,(,(,O
,serum,JJ,O
,creatinine,NN,O
,greater,JJR,O
,than,IN,O
,2,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,/,NNP,O
,dl,NN,O
,or,CC,O
,BUN,NNP,O
,greater,JJR,O
,than,IN,O
,50,CD,O
,mg,JJ,O
,/,NNP,O
,dl,NN,O
,),),O
,occurred,VBD,O
,in,IN,O
,only,RB,O
,2,CD,O
,%,NN,O
,.,.,O
,Azotemia,NNP,B-DISEASE
,was,VBD,O
,not,RB,O
,related,VBN,O
,to,TO,O
,duration,NN,O
,of,IN,O
,therapy,NN,O
,or,CC,O
,serum,NN,O
,tobramycin,JJ,O
,concentration,NN,O
,.,.,O
,This,DT,O
,antibiotic,JJ,O
,regimen,NN,O
,showed,VBD,O
,both,DT,O
,therapeutic,JJ,O
,efficacy,NN,O
,and,CC,O
,acceptable,JJ,O
,renal,JJ,B-DISEASE
,toxicity,NN,I-DISEASE
,for,IN,O
,these,DT,O
,patients,NNS,O
,.,.,O
,Incidence,NNP,O
,of,IN,O
,solid,JJ,O
,tumours,NN,B-DISEASE
,among,IN,O
,pesticide,NN,O
,applicators,NNS,O
,exposed,VBD,O
,to,TO,O
,the,DT,O
,organophosphate,JJ,O
,insecticide,NN,O
,diazinon,NN,O
,in,IN,O
,the,DT,O
,Agricultural,NNP,O
,Health,NNP,O
,Study,NNP,O
,:,:,O
,an,DT,O
,updated,JJ,O
,analysis,NN,O
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,Diazinon,NNP,O
,",",",",O
,a,DT,O
,common,JJ,O
,organophosphate,NN,O
,insecticide,NN,O
,with,IN,O
,genotoxic,NN,O
,properties,NNS,O
,",",",",O
,was,VBD,O
,previously,RB,O
,associated,VBN,O
,with,IN,O
,lung,NN,B-DISEASE
,cancer,NN,I-DISEASE
,in,IN,O
,the,DT,O
,Agricultural,NNP,O
,Health,NNP,O
,Study,NNP,O
,(,(,O
,AHS,NNP,O
,),),O
,cohort,NN,O
,",",",",O
,but,CC,O
,few,JJ,O
,other,JJ,O
,epidemiological,JJ,O
,studies,NNS,O
,have,VBP,O
,examined,VBN,O
,diazinon,SYM,O
,-,:,O
,associated,VBN,O
,cancer,NN,B-DISEASE
,risk,NN,O
,.,.,O
,We,PRP,O
,used,VBD,O
,updated,VBN,O
,diazinon,NN,O
,exposure,NN,O
,and,CC,O
,cancer,NN,B-DISEASE
,incidence,NN,O
,information,NN,O
,to,TO,O
,evaluate,VB,O
,solid,JJ,O
,tumour,NN,B-DISEASE
,risk,NN,O
,in,IN,O
,the,DT,O
,AHS,NNP,O
,.,.,O
,METHODS,NNP,O
,:,:,O
,Male,NNP,O
,pesticide,NN,O
,applicators,NNS,O
,in,IN,O
,Iowa,NNP,O
,and,CC,O
,North,NNP,O
,Carolina,NNP,O
,reported,VBD,O
,lifetime,JJ,O
,diazinon,NN,O
,use,NN,O
,at,IN,O
,enrolment,NN,O
,(,(,O
,1993,CD,O
,-,:,O
,1997,CD,O
,),),O
,and,CC,O
,follow,$,O
,-,:,O
,up,RB,O
,(,(,O
,1998,CD,O
,-,:,O
,2005,CD,O
,),),O
,;,:,O
,cancer,NN,B-DISEASE
,incidence,NN,O
,was,VBD,O
,assessed,VBN,O
,through,IN,O
,2010,CD,O
,(,(,O
,North,NNP,O
,Carolina,NNP,O
,),),O
,/,NN,O
,2011,CD,O
,(,(,O
,Iowa,NNP,O
,),),O
,.,.,O
,Among,IN,O
,applicators,NNS,O
,with,IN,O
,usage,JJ,O
,information,NN,O
,sufficient,NN,O
,to,TO,O
,evaluate,VB,O
,exposure,NN,O
,-,:,O
,response,NN,O
,patterns,NNS,O
,",",",",O
,we,PRP,O
,used,VBD,O
,Poisson,NNP,O
,regression,NN,O
,to,TO,O
,estimate,VB,O
,adjusted,JJ,O
,rate,NN,O
,ratios,NNS,O
,(,(,O
,RRs,NNP,O
,),),O
,and,CC,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,for,IN,O
,cancer,NN,B-DISEASE
,sites,NNS,O
,with,IN,O
,>,JJ,O
,10,CD,O
,exposed,JJ,O
,cases,NNS,O
,for,IN,O
,both,DT,O
,lifetime,NN,O
,(,(,O
,LT,NNP,O
,),),O
,exposure,NN,O
,days,NNS,O
,and,CC,O
,intensity,NN,O
,-,:,O
,weighted,VBN,O
,(,(,O
,IW,NNP,O
,),),O
,lifetime,NN,O
,exposure,NN,O
,days,NNS,O
,(,(,O
,accounting,VBG,O
,for,IN,O
,factors,NNS,O
,impacting,VBG,O
,exposure,NN,O
,),),O
,.,.,O
,RESULTS,NN,O
,:,:,O
,We,PRP,O
,observed,VBD,O
,elevated,JJ,O
,lung,NN,B-DISEASE
,cancer,NN,I-DISEASE
,risks,NNS,O
,(,(,O
,N,NNP,O
,=,NNP,O
,283,CD,O
,),),O
,among,IN,O
,applicators,NNS,O
,with,IN,O
,the,DT,O
,greatest,JJS,O
,number,NN,O
,of,IN,O
,LT,NNP,O
,(,(,O
,RR,NNP,O
,=,VBZ,O
,1,CD,O
,.,.,O
,60,CD,O
,;,:,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,1,CD,O
,.,.,O
,11,CD,O
,to,TO,O
,2,CD,O
,.,.,O
,31,CD,O
,;,:,O
,Ptrend,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,02,CD,O
,),),O
,and,CC,O
,IW,NNP,O
,days,NNS,O
,of,IN,O
,diazinon,NN,O
,use,NN,O
,(,(,O
,RR,NNP,O
,=,VBZ,O
,1,CD,O
,.,.,O
,41,CD,O
,;,:,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,0,CD,O
,.,.,O
,98,CD,O
,to,TO,O
,2,CD,O
,.,.,O
,04,CD,O
,;,:,O
,Ptrend,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,08,CD,O
,),),O
,.,.,O
,Kidney,NNP,B-DISEASE
,cancer,NN,I-DISEASE
,(,(,O
,N,NNP,O
,=,NNP,O
,94,CD,O
,),),O
,risks,NNS,O
,were,VBD,O
,non,JJ,O
,-,:,O
,significantly,RB,O
,elevated,VBN,O
,(,(,O
,RRLT,NNP,O
,days,NNS,O
,=,VBD,O
,1,CD,O
,.,.,O
,77,CD,O
,;,:,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,0,CD,O
,.,.,O
,90,CD,O
,to,TO,O
,3,CD,O
,.,.,O
,51,CD,O
,;,:,O
,Ptrend,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,09,CD,O
,;,:,O
,RRIW,NNP,O
,days,NNS,O
,1,CD,O
,.,.,O
,37,CD,O
,;,:,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,0,CD,O
,.,.,O
,64,CD,O
,to,TO,O
,2,CD,O
,.,.,O
,92,CD,O
,;,:,O
,Ptrend,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,50,CD,O
,),),O
,",",",",O
,as,IN,O
,were,VBD,O
,risks,NNS,O
,for,IN,O
,aggressive,JJ,O
,prostate,NN,B-DISEASE
,cancer,NN,I-DISEASE
,(,(,O
,N,NNP,O
,=,NNP,O
,656,CD,O
,),),O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Our,PRP$,O
,updated,JJ,O
,evaluation,NN,O
,of,IN,O
,diazinon,NN,O
,provides,VBZ,O
,additional,JJ,O
,evidence,NN,O
,of,IN,O
,an,DT,O
,association,NN,O
,with,IN,O
,lung,NN,B-DISEASE
,cancer,NN,I-DISEASE
,risk,NN,O
,.,.,O
,Newly,RB,O
,identified,VBN,O
,links,NNS,O
,to,TO,O
,kidney,VB,B-DISEASE
,cancer,NN,I-DISEASE
,and,CC,O
,associations,NNS,O
,with,IN,O
,aggressive,JJ,O
,prostate,NN,B-DISEASE
,cancer,NN,I-DISEASE
,require,VBP,O
,further,JJ,O
,evaluation,NN,O
,.,.,O
,Associations,NNS,O
,of,IN,O
,Ozone,NN,O
,and,CC,O
,PM2,NNP,O
,.,.,O
,5,CD,O
,Concentrations,NNPS,O
,With,IN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,Disease,NNP,I-DISEASE
,Among,IN,O
,Participants,NNPS,O
,in,IN,O
,the,DT,O
,Agricultural,NNP,O
,Health,NNP,O
,Study,NNP,O
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,This,DT,O
,study,NN,O
,describes,VBZ,O
,associations,NNS,O
,of,IN,O
,ozone,NN,O
,and,CC,O
,fine,JJ,O
,particulate,NN,O
,matter,NN,O
,with,IN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,observed,VBD,O
,among,IN,O
,farmers,NNS,O
,in,IN,O
,North,NNP,O
,Carolina,NNP,O
,and,CC,O
,Iowa,NNP,O
,.,.,O
,METHODS,NN,O
,:,:,O
,We,PRP,O
,used,VBD,O
,logistic,JJ,O
,regression,NN,O
,to,TO,O
,determine,VB,O
,the,DT,O
,associations,NNS,O
,of,IN,O
,these,DT,O
,pollutants,NNS,O
,with,IN,O
,self,NN,O
,-,:,O
,reported,VBN,O
,",",",",O
,doctor,NN,O
,-,:,O
,diagnosed,VBN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,Daily,NNP,O
,predicted,VBD,O
,pollutant,JJ,O
,concentrations,NNS,O
,were,VBD,O
,used,VBN,O
,to,TO,O
,derive,VB,O
,surrogates,NNS,O
,of,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,exposure,NN,O
,and,CC,O
,link,VB,O
,them,PRP,O
,to,TO,O
,study,VB,O
,participants,NNS,O
,',POS,O
,geocoded,VBN,O
,addresses,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,We,PRP,O
,observed,VBD,O
,positive,JJ,O
,associations,NNS,O
,of,IN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,with,IN,O
,ozone,NN,O
,(,(,O
,odds,NNS,O
,ratio,VBP,O
,=,JJ,O
,1,CD,O
,.,.,O
,39,CD,O
,;,:,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,:,:,O
,0,CD,O
,.,.,O
,98,CD,O
,to,TO,O
,1,CD,O
,.,.,O
,98,CD,O
,),),O
,and,CC,O
,fine,JJ,O
,particulate,NN,O
,matter,NN,O
,(,(,O
,odds,NNS,O
,ratio,VBP,O
,=,JJ,O
,1,CD,O
,.,.,O
,34,CD,O
,;,:,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,:,:,O
,0,CD,O
,.,.,O
,93,CD,O
,to,TO,O
,1,CD,O
,.,.,O
,93,CD,O
,),),O
,in,IN,O
,North,NNP,O
,Carolina,NNP,O
,but,CC,O
,not,RB,O
,in,IN,O
,Iowa,NNP,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,The,DT,O
,plausibility,NN,O
,of,IN,O
,an,DT,O
,effect,NN,O
,of,IN,O
,ambient,JJ,O
,concentrations,NNS,O
,of,IN,O
,these,DT,O
,pollutants,NNS,O
,on,IN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,NN,I-DISEASE
,disease,NN,I-DISEASE
,risk,NN,O
,is,VBZ,O
,supported,VBN,O
,by,IN,O
,experimental,JJ,O
,data,NNS,O
,demonstrating,VBG,O
,damage,NN,O
,to,TO,O
,dopaminergic,VB,O
,neurons,NNS,O
,at,IN,O
,relevant,JJ,O
,concentrations,NNS,O
,.,.,O
,Additional,JJ,O
,studies,NNS,O
,are,VBP,O
,needed,VBN,O
,to,TO,O
,address,VB,O
,uncertainties,NNS,O
,related,VBN,O
,to,TO,O
,confounding,VBG,O
,and,CC,O
,to,TO,O
,examine,VB,O
,temporal,JJ,O
,aspects,NNS,O
,of,IN,O
,the,DT,O
,associations,NNS,O
,we,PRP,O
,observed,VBD,O
,.,.,O
,Low,JJ,O
,functional,JJ,O
,programming,NN,O
,of,IN,O
,renal,JJ,O
,AT2R,NNP,O
,mediates,VBZ,O
,the,DT,O
,developmental,JJ,O
,origin,NN,O
,of,IN,O
,glomerulosclerosis,NN,B-DISEASE
,in,IN,O
,adult,NN,O
,offspring,VBG,O
,induced,VBN,O
,by,IN,O
,prenatal,JJ,O
,caffeine,NN,O
,exposure,NN,O
,.,.,O
,UNASSIGNED,NN,O
,:,:,O
,Our,PRP$,O
,previous,JJ,O
,study,NN,O
,has,VBZ,O
,indicated,VBN,O
,that,IN,O
,prenatal,JJ,O
,caffeine,NN,O
,exposure,NN,O
,(,(,O
,PCE,NNP,O
,),),O
,could,MD,O
,induce,VB,O
,intrauterine,JJ,B-DISEASE
,growth,NN,I-DISEASE
,retardation,NN,I-DISEASE
,(,(,O
,IUGR,NNP,B-DISEASE
,),),O
,of,IN,O
,offspring,VBG,O
,.,.,O
,Recent,JJ,O
,research,NN,O
,suggested,VBD,O
,that,IN,O
,IUGR,NNP,B-DISEASE
,is,VBZ,O
,a,DT,O
,risk,NN,O
,factor,NN,O
,for,IN,O
,glomerulosclerosis,NN,B-DISEASE
,.,.,O
,However,RB,O
,",",",",O
,whether,IN,O
,PCE,NNP,O
,could,MD,O
,induce,VB,O
,glomerulosclerosis,NN,B-DISEASE
,and,CC,O
,its,PRP$,O
,underlying,JJ,O
,mechanisms,NNS,O
,remain,VBP,O
,unknown,JJ,O
,.,.,O
,This,DT,O
,study,NN,O
,aimed,VBD,O
,to,TO,O
,demonstrate,VB,O
,the,DT,O
,induction,NN,O
,to,TO,O
,glomerulosclerosis,NN,B-DISEASE
,in,IN,O
,adult,NN,O
,offspring,NN,O
,by,IN,O
,PCE,NNP,O
,and,CC,O
,its,PRP$,O
,intrauterine,NN,O
,programming,NN,O
,mechanisms,NNS,O
,.,.,O
,A,DT,O
,rat,NN,O
,model,NN,O
,of,IN,O
,IUGR,NNP,B-DISEASE
,was,VBD,O
,established,VBN,O
,by,IN,O
,PCE,NNP,O
,",",",",O
,male,NN,O
,fetuses,NNS,O
,and,CC,O
,adult,NN,O
,offspring,NN,O
,at,IN,O
,the,DT,O
,age,NN,O
,of,IN,O
,postnatal,JJ,O
,week,NN,O
,24,CD,O
,were,VBD,O
,euthanized,VBN,O
,.,.,O
,The,DT,O
,results,NNS,O
,revealed,VBD,O
,that,IN,O
,the,DT,O
,adult,NN,O
,offspring,VBG,O
,kidneys,NNS,O
,in,IN,O
,the,DT,O
,PCE,NNP,O
,group,NN,O
,exhibited,VBD,O
,glomerulosclerosis,NN,B-DISEASE
,as,RB,O
,well,RB,O
,as,IN,O
,interstitial,JJ,B-DISEASE
,fibrosis,NN,I-DISEASE
,",",",",O
,accompanied,VBN,O
,by,IN,O
,elevated,JJ,O
,levels,NNS,O
,of,IN,O
,serum,NN,O
,creatinine,NN,O
,and,CC,O
,urine,JJ,O
,protein,NN,O
,.,.,O
,Renal,NNP,O
,angiotensin,NN,O
,II,NNP,O
,receptor,NN,O
,type,NN,O
,2,CD,O
,(,(,O
,AT2R,NNP,O
,),),O
,gene,NN,O
,expression,NN,O
,in,IN,O
,adult,NN,O
,offspring,NN,O
,was,VBD,O
,reduced,VBN,O
,by,IN,O
,PCE,NNP,O
,",",",",O
,whereas,IN,O
,the,DT,O
,renal,JJ,O
,angiotensin,NN,O
,II,NNP,O
,receptor,NN,O
,type,NN,O
,1a,CD,O
,(,(,O
,AT1aR,NNP,O
,),),O
,/,VBP,O
,AT2R,NNP,O
,expression,NN,O
,ratio,NN,O
,was,VBD,O
,increased,VBN,O
,.,.,O
,The,DT,O
,fetal,JJ,O
,kidneys,NNS,O
,in,IN,O
,the,DT,O
,PCE,NNP,O
,group,NN,O
,displayed,VBD,O
,an,DT,O
,enlarged,JJ,O
,Bowman,NNP,O
,',POS,O
,s,JJ,O
,space,NN,O
,and,CC,O
,a,DT,O
,shrunken,JJ,O
,glomerular,JJ,O
,tuft,NN,O
,",",",",O
,accompanied,VBN,O
,by,IN,O
,a,DT,O
,reduced,JJ,O
,cortex,NN,O
,width,NN,O
,and,CC,O
,an,DT,O
,increase,NN,O
,in,IN,O
,the,DT,O
,nephrogenic,JJ,O
,zone,NN,O
,/,NNP,O
,cortical,JJ,O
,zone,NN,O
,ratio,NN,O
,.,.,O
,Observation,NN,O
,by,IN,O
,electronic,JJ,O
,microscope,NN,O
,revealed,VBD,O
,structural,JJ,O
,damage,NN,O
,of,IN,O
,podocytes,NNS,O
,;,:,O
,the,DT,O
,reduced,JJ,O
,expression,NN,O
,level,NN,O
,of,IN,O
,podocyte,NN,O
,marker,NN,O
,genes,NNS,O
,",",",",O
,nephrin,NN,O
,and,CC,O
,podocin,NN,O
,",",",",O
,was,VBD,O
,also,RB,O
,detected,VBN,O
,by,IN,O
,q,JJ,O
,-,:,O
,PCR,NN,O
,.,.,O
,Moreover,RB,O
,",",",",O
,AT2R,NNP,O
,gene,NN,O
,and,CC,O
,protein,JJ,O
,expressions,NNS,O
,in,IN,O
,fetal,JJ,O
,kidneys,NNS,O
,were,VBD,O
,inhibited,VBN,O
,by,IN,O
,PCE,NNP,O
,",",",",O
,associated,VBN,O
,with,IN,O
,the,DT,O
,repression,NN,O
,of,IN,O
,the,DT,O
,gene,NN,O
,expression,NN,O
,of,IN,O
,glial,JJ,O
,-,:,O
,cell,NN,O
,-,:,O
,line,NN,O
,-,:,O
,derived,VBD,O
,neurotrophic,JJ,O
,factor,NN,O
,(,(,O
,GDNF,NNP,O
,),),O
,/,VBP,O
,tyrosine,JJ,O
,kinase,NN,O
,receptor,NN,O
,(,(,O
,c,SYM,O
,-,:,O
,Ret,NNP,O
,),),O
,signaling,VBG,O
,pathway,NN,O
,.,.,O
,These,DT,O
,results,NNS,O
,demonstrated,VBD,O
,that,IN,O
,PCE,NNP,O
,could,MD,O
,induce,VB,O
,dysplasia,NN,B-DISEASE
,of,IN,I-DISEASE
,fetal,JJ,I-DISEASE
,kidneys,NNS,I-DISEASE
,as,RB,O
,well,RB,O
,as,IN,O
,glomerulosclerosis,NN,B-DISEASE
,of,IN,O
,adult,NN,O
,offspring,NN,O
,",",",",O
,and,CC,O
,the,DT,O
,low,JJ,O
,functional,JJ,O
,programming,NN,O
,of,IN,O
,renal,JJ,O
,AT2R,NNP,O
,might,MD,O
,mediate,VB,O
,the,DT,O
,developmental,JJ,O
,origin,NN,O
,of,IN,O
,adult,NN,O
,glomerulosclerosis,NN,B-DISEASE
,.,.,O
,1,CD,O
,",",",",O
,3,CD,O
,-,:,O
,Butadiene,NNP,O
,",",",",O
,CML,NNP,B-DISEASE
,and,CC,O
,the,DT,O
,t,NN,O
,(,(,O
,9,CD,O
,:,:,O
,22,CD,O
,),),O
,translocation,NN,O
,:,:,O
,A,DT,O
,reality,NN,O
,check,NN,O
,.,.,O
,UNASSIGNED,NN,O
,:,:,O
,Epidemiological,JJ,O
,studies,NNS,O
,of,IN,O
,1,CD,O
,",",",",O
,3,CD,O
,-,:,O
,butadiene,NN,O
,have,VBP,O
,suggest,VBN,O
,that,IN,O
,exposures,VBZ,O
,to,TO,O
,humans,NNS,O
,are,VBP,O
,associated,VBN,O
,with,IN,O
,chronic,JJ,B-DISEASE
,myeloid,NN,I-DISEASE
,leukemia,NN,I-DISEASE
,(,(,O
,CML,NNP,B-DISEASE
,),),O
,.,.,O
,CML,NNP,B-DISEASE
,has,VBZ,O
,a,DT,O
,well,RB,O
,-,:,O
,documented,VBN,O
,association,NN,O
,with,IN,O
,ionizing,VBG,O
,radiation,NN,O
,",",",",O
,but,CC,O
,reports,NNS,O
,of,IN,O
,associations,NNS,O
,with,IN,O
,chemical,NN,O
,exposures,NNS,O
,have,VBP,O
,been,VBN,O
,questioned,VBN,O
,.,.,O
,Ionizing,VBG,O
,radiation,NN,O
,is,VBZ,O
,capable,JJ,O
,of,IN,O
,inducing,VBG,O
,the,DT,O
,requisite,JJ,O
,CML,NNP,B-DISEASE
,-,:,O
,associated,VBN,O
,t,NN,O
,(,(,O
,9,CD,O
,:,:,O
,22,CD,O
,),),O
,translocation,NN,O
,(,(,O
,Philadelphia,NNP,B-DISEASE
,chromosome,NN,I-DISEASE
,),),O
,in,IN,O
,appropriate,JJ,O
,cells,NNS,O
,in,IN,O
,vitro,NN,O
,but,CC,O
,",",",",O
,thus,RB,O
,far,RB,O
,",",",",O
,chemicals,NNS,O
,have,VBP,O
,not,RB,O
,shown,VBN,O
,this,DT,O
,capacity,NN,O
,.,.,O
,We,PRP,O
,have,VBP,O
,proposed,VBN,O
,that,IN,O
,1,CD,O
,",",",",O
,3,CD,O
,-,:,O
,butadiene,NN,O
,metabolites,NNS,O
,be,VB,O
,so,RB,O
,tested,VBN,O
,as,IN,O
,a,DT,O
,reality,NN,O
,check,NN,O
,on,IN,O
,the,DT,O
,epidemiological,JJ,O
,reports,NNS,O
,.,.,O
,In,IN,O
,order,NN,O
,to,TO,O
,conduct,VB,O
,reliable,JJ,O
,testing,VBG,O
,in,IN,O
,this,DT,O
,regard,NN,O
,",",",",O
,it,PRP,O
,is,VBZ,O
,essential,JJ,O
,that,IN,O
,a,DT,O
,positive,JJ,O
,control,NN,O
,for,IN,O
,induction,NN,O
,be,VB,O
,available,JJ,O
,.,.,O
,We,PRP,O
,have,VBP,O
,used,VBN,O
,ionizing,VBG,O
,radiation,NN,O
,to,TO,O
,develop,VB,O
,such,JJ,O
,a,DT,O
,control,NN,O
,.,.,O
,Results,NNS,O
,described,VBD,O
,here,RB,O
,demonstrate,JJ,O
,that,IN,O
,this,DT,O
,agent,NN,O
,does,VBZ,O
,in,IN,O
,fact,NN,O
,induce,VB,O
,pathogenic,JJ,O
,t,NN,O
,(,(,O
,9,CD,O
,:,:,O
,22,CD,O
,),),O
,translocations,NNS,O
,in,IN,O
,a,DT,O
,human,JJ,O
,myeloid,NN,O
,cell,NN,O
,line,NN,O
,in,IN,O
,vitro,NN,O
,",",",",O
,but,CC,O
,does,VBZ,O
,so,RB,O
,at,IN,O
,low,JJ,O
,frequencies,NNS,O
,.,.,O
,Conditions,NNS,O
,that,WDT,O
,will,MD,O
,be,VB,O
,required,VBN,O
,for,IN,O
,studies,NNS,O
,of,IN,O
,1,CD,O
,",",",",O
,3,CD,O
,-,:,O
,butadiene,NN,O
,are,VBP,O
,discussed,VBN,O
,.,.,O
,Cancer,NNP,B-DISEASE
,incidence,NN,O
,and,CC,O
,metolachlor,NN,O
,use,NN,O
,in,IN,O
,the,DT,O
,Agricultural,NNP,O
,Health,NNP,O
,Study,NNP,O
,:,:,O
,An,DT,O
,update,NN,O
,.,.,O
,UNASSIGNED,NN,O
,:,:,O
,Metolachlor,NNP,O
,",",",",O
,a,DT,O
,widely,RB,O
,used,VBN,O
,herbicide,NN,O
,",",",",O
,is,VBZ,O
,classified,VBN,O
,as,IN,O
,a,DT,O
,Group,NNP,O
,C,NNP,O
,carcinogen,NN,O
,by,IN,O
,the,DT,O
,U,NNP,O
,.,.,O
,S,NNP,O
,.,.,O
,Environmental,NNP,O
,Protection,NNP,O
,Agency,NNP,O
,based,VBN,O
,on,IN,O
,increased,VBN,O
,liver,NN,B-DISEASE
,neoplasms,NNS,I-DISEASE
,in,IN,O
,female,JJ,O
,rats,NNS,O
,.,.,O
,Epidemiologic,NNP,O
,studies,NNS,O
,of,IN,O
,the,DT,O
,health,NN,O
,effects,NNS,O
,of,IN,O
,metolachlor,NN,O
,have,VBP,O
,been,VBN,O
,limited,VBN,O
,.,.,O
,The,DT,O
,Agricultural,NNP,O
,Health,NNP,O
,Study,NNP,O
,(,(,O
,AHS,NNP,O
,),),O
,is,VBZ,O
,a,DT,O
,prospective,JJ,O
,cohort,NN,O
,study,NN,O
,including,VBG,O
,licensed,JJ,O
,private,JJ,O
,and,CC,O
,commercial,JJ,O
,pesticide,NN,O
,applicators,NNS,O
,in,IN,O
,Iowa,NNP,O
,and,CC,O
,North,NNP,O
,Carolina,NNP,O
,enrolled,VBD,O
,1993,CD,O
,-,:,O
,1997,CD,O
,.,.,O
,We,PRP,O
,evaluated,VBD,O
,cancer,NN,B-DISEASE
,incidence,NN,O
,through,IN,O
,2010,CD,O
,/,NN,O
,2011,CD,O
,(,(,O
,NC,NNP,O
,/,NNP,O
,IA,NNP,O
,),),O
,for,IN,O
,49,CD,O
,",",",",O
,616,CD,O
,applicators,NNS,O
,",",",",O
,53,CD,O
,%,NN,O
,of,IN,O
,whom,WP,O
,reported,VBD,O
,ever,RB,O
,using,VBG,O
,metolachlor,NN,O
,.,.,O
,We,PRP,O
,used,VBD,O
,Poisson,NNP,O
,regression,NN,O
,to,TO,O
,evaluate,VB,O
,relations,NNS,O
,between,IN,O
,two,CD,O
,metrics,NNS,O
,of,IN,O
,metolachlor,NN,O
,use,NN,O
,(,(,O
,lifetime,JJ,O
,days,NNS,O
,",",",",O
,intensity,NN,O
,-,:,O
,weighted,JJ,O
,lifetime,JJ,O
,days,NNS,O
,),),O
,and,CC,O
,cancer,NN,B-DISEASE
,incidence,NN,O
,.,.,O
,We,PRP,O
,saw,VBD,O
,no,DT,O
,association,NN,O
,between,IN,O
,metolachlor,NN,O
,use,NN,O
,and,CC,O
,incidence,NN,O
,of,IN,O
,all,DT,O
,cancers,NNS,B-DISEASE
,combined,VBN,O
,(,(,O
,n,JJ,O
,=,NN,O
,5,CD,O
,",",",",O
,701,CD,O
,with,IN,O
,a,DT,O
,5,CD,O
,-,:,O
,year,NN,O
,lag,NN,O
,),),O
,or,CC,O
,most,JJS,O
,site,NN,O
,-,:,O
,specific,JJ,O
,cancers,NNS,B-DISEASE
,.,.,O
,For,IN,O
,liver,NN,B-DISEASE
,cancer,NN,I-DISEASE
,",",",",O
,in,IN,O
,analyses,NNS,O
,restricted,VBN,O
,to,TO,O
,exposed,JJ,O
,workers,NNS,O
,",",",",O
,elevations,NNS,O
,observed,VBD,O
,at,IN,O
,higher,JJR,O
,categories,NNS,O
,of,IN,O
,use,NN,O
,were,VBD,O
,not,RB,O
,statistically,RB,O
,significant,JJ,O
,.,.,O
,However,RB,O
,",",",",O
,trends,NNS,O
,for,IN,O
,both,DT,O
,lifetime,NN,O
,and,CC,O
,intensity,NN,O
,-,:,O
,weighted,JJ,O
,lifetime,JJ,O
,days,NNS,O
,of,IN,O
,metolachor,NN,O
,use,NN,O
,were,VBD,O
,positive,JJ,O
,and,CC,O
,statistically,RB,O
,significant,JJ,O
,with,IN,O
,an,DT,O
,unexposed,JJ,O
,reference,NN,O
,group,NN,O
,.,.,O
,A,DT,O
,similar,JJ,O
,pattern,NN,O
,was,VBD,O
,observed,VBN,O
,for,IN,O
,follicular,JJ,B-DISEASE
,cell,NN,I-DISEASE
,lymphoma,NN,I-DISEASE
,",",",",O
,but,CC,O
,no,DT,O
,other,JJ,O
,lymphoma,NN,B-DISEASE
,subtypes,NNS,O
,.,.,O
,An,DT,O
,earlier,JJR,O
,suggestion,NN,O
,of,IN,O
,increased,JJ,O
,lung,NN,B-DISEASE
,cancer,NN,I-DISEASE
,risk,NN,O
,at,IN,O
,high,JJ,O
,levels,NNS,O
,of,IN,O
,metolachlor,NN,O
,use,NN,O
,in,IN,O
,this,DT,O
,cohort,NN,O
,was,VBD,O
,not,RB,O
,confirmed,VBN,O
,in,IN,O
,this,DT,O
,update,NN,O
,.,.,O
,This,DT,O
,suggestion,NN,O
,of,IN,O
,an,DT,O
,association,NN,O
,between,IN,O
,metolachlor,NN,O
,and,CC,O
,liver,JJ,B-DISEASE
,cancer,NN,I-DISEASE
,among,IN,O
,pesticide,NN,O
,applicators,NNS,O
,is,VBZ,O
,a,DT,O
,novel,JJ,O
,finding,NN,O
,and,CC,O
,echoes,JJ,O
,observation,NN,O
,of,IN,O
,increased,VBN,O
,liver,NN,B-DISEASE
,neoplasms,NN,I-DISEASE
,in,IN,O
,some,DT,O
,animal,JJ,O
,studies,NNS,O
,.,.,O
,However,RB,O
,",",",",O
,our,PRP$,O
,findings,NNS,O
,for,IN,O
,both,DT,O
,liver,JJ,B-DISEASE
,cancer,NN,I-DISEASE
,and,CC,O
,follicular,JJ,O
,cell,NN,O
,lymphoma,NN,B-DISEASE
,warrant,NN,O
,follow,SYM,O
,-,:,O
,up,RB,O
,to,TO,O
,better,JJR,O
,differentiate,JJ,O
,effects,NNS,O
,of,IN,O
,metolachlor,NN,O
,use,NN,O
,from,IN,O
,other,JJ,O
,factors,NNS,O
,.,.,O
,Mechanisms,NNP,O
,Underlying,NNP,O
,Latent,NNP,O
,Disease,NNP,O
,Risk,NNP,O
,Associated,NNP,O
,with,IN,O
,Early,NNP,O
,-,:,O
,Life,NNP,O
,Arsenic,NNP,O
,Exposure,NN,O
,:,:,O
,Current,JJ,O
,Research,NNP,O
,Trends,NNP,O
,and,CC,O
,Scientific,NNP,O
,Gaps,NNP,O
,.,.,O
,BACKGROUND,NNP,O
,:,:,O
,Millions,NNS,O
,of,IN,O
,individuals,NNS,O
,worldwide,JJ,O
,",",",",O
,particularly,RB,O
,those,DT,O
,living,VBG,O
,in,IN,O
,rural,JJ,O
,and,CC,O
,developing,VBG,O
,areas,NNS,O
,",",",",O
,are,VBP,O
,exposed,VBN,O
,to,TO,O
,harmful,JJ,O
,levels,NNS,O
,of,IN,O
,inorganic,JJ,O
,arsenic,NN,O
,(,(,O
,iAs,NN,O
,),),O
,in,IN,O
,their,PRP$,O
,drinking,NN,O
,water,NN,O
,.,.,O
,Inorganic,NNP,O
,As,IN,O
,exposure,NN,O
,during,IN,O
,key,JJ,O
,developmental,JJ,O
,periods,NNS,O
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,a,DT,O
,variety,NN,O
,of,IN,O
,adverse,JJ,O
,health,NN,O
,effects,NNS,O
,including,VBG,O
,those,DT,O
,that,WDT,O
,are,VBP,O
,evident,JJ,O
,in,IN,O
,adulthood,NN,O
,.,.,O
,There,EX,O
,is,VBZ,O
,considerable,JJ,O
,interest,NN,O
,in,IN,O
,identifying,VBG,O
,the,DT,O
,molecular,JJ,O
,mechanisms,NNS,O
,that,WDT,O
,relate,VBP,O
,early,JJ,O
,-,:,O
,life,NN,O
,iAs,NN,O
,exposure,NN,O
,to,TO,O
,the,DT,O
,development,NN,O
,of,IN,O
,these,DT,O
,latent,JJ,O
,diseases,NNS,O
,",",",",O
,particularly,RB,O
,in,IN,O
,relationship,NN,O
,to,TO,O
,cancer,NN,B-DISEASE
,.,.,O
,OBJECTIVES,CC,O
,:,:,O
,This,DT,O
,work,NN,O
,summarizes,VBZ,O
,research,NN,O
,on,IN,O
,the,DT,O
,molecular,JJ,O
,mechanisms,NNS,O
,that,WDT,O
,underlie,VBP,O
,the,DT,O
,increased,VBN,O
,risk,NN,O
,of,IN,O
,cancer,NN,B-DISEASE
,development,NN,O
,in,IN,O
,adulthood,NN,O
,that,WDT,O
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,early,JJ,O
,-,:,O
,life,NN,O
,iAs,JJ,O
,exposure,NN,O
,.,.,O
,DISCUSSION,NN,O
,:,:,O
,Epigenetic,JJ,O
,reprogramming,NN,O
,that,WDT,O
,imparts,VBZ,O
,functional,JJ,O
,changes,NNS,O
,in,IN,O
,gene,NN,O
,expression,NN,O
,",",",",O
,the,DT,O
,development,NN,O
,of,IN,O
,cancer,NN,B-DISEASE
,stem,NN,O
,cells,NNS,O
,",",",",O
,and,CC,O
,immunomodulation,NN,O
,are,VBP,O
,plausible,JJ,O
,underlying,JJ,O
,mechanisms,NNS,O
,by,IN,O
,which,WDT,O
,early,JJ,O
,-,:,O
,life,NN,O
,iAs,NN,O
,exposure,NN,O
,elicits,VBZ,O
,latent,JJ,O
,carcinogenic,JJ,O
,effects,NNS,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Evidence,NN,O
,is,VBZ,O
,mounting,VBG,O
,that,IN,O
,relates,VBZ,O
,early,JJ,O
,-,:,O
,life,NN,O
,iAs,NN,O
,exposure,NN,O
,and,CC,O
,cancer,NN,B-DISEASE
,development,NN,O
,later,RB,O
,in,IN,O
,life,NN,O
,.,.,O
,Future,JJ,O
,research,NN,O
,should,MD,O
,include,VB,O
,animal,JJ,O
,studies,NNS,O
,that,WDT,O
,address,VBP,O
,mechanistic,JJ,O
,hypotheses,NNS,O
,and,CC,O
,studies,NNS,O
,of,IN,O
,human,JJ,O
,populations,NNS,O
,that,WDT,O
,integrate,VBP,O
,early,JJ,O
,-,:,O
,life,NN,O
,exposure,NN,O
,",",",",O
,molecular,JJ,O
,alterations,NNS,O
,",",",",O
,and,CC,O
,latent,JJ,O
,disease,NN,O
,outcomes,NNS,O
,.,.,O
,Nifedipine,NNP,O
,induced,JJ,O
,bradycardia,NN,B-DISEASE
,in,IN,O
,a,DT,O
,patient,NN,O
,with,IN,O
,autonomic,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,.,.,O
,An,DT,O
,80,CD,O
,year,NN,O
,old,JJ,O
,diabetic,JJ,B-DISEASE
,male,NN,O
,with,IN,O
,evidence,NN,O
,of,IN,O
,peripheral,JJ,B-DISEASE
,and,CC,I-DISEASE
,autonomic,JJ,I-DISEASE
,neuropathy,NN,I-DISEASE
,was,VBD,O
,admitted,VBN,O
,with,IN,O
,chest,NN,B-DISEASE
,pain,NN,I-DISEASE
,.,.,O
,He,PRP,O
,was,VBD,O
,found,VBN,O
,to,TO,O
,have,VB,O
,atrial,JJ,B-DISEASE
,flutter,NN,I-DISEASE
,at,IN,O
,a,DT,O
,ventricular,JJ,O
,rate,NN,O
,of,IN,O
,70,CD,O
,/,NNS,O
,min,CD,O
,which,WDT,O
,slowed,VBD,O
,down,RB,O
,to,TO,O
,30,CD,O
,-,:,O
,40,CD,O
,/,NNS,O
,min,NN,O
,when,WRB,O
,nifedipine,NN,O
,(,(,O
,60,CD,O
,mg,NN,O
,),),O
,in,IN,O
,3,CD,O
,divided,JJ,O
,doses,NNS,O
,",",",",O
,during,IN,O
,which,WDT,O
,he,PRP,O
,was,VBD,O
,paced,VBN,O
,at,IN,O
,a,DT,O
,rate,NN,O
,of,IN,O
,70,CD,O
,/,JJ,O
,min,NN,O
,.,.,O
,This,DT,O
,is,VBZ,O
,inconsistent,JJ,O
,with,IN,O
,the,DT,O
,well,NN,O
,-,:,O
,established,VBN,O
,finding,VBG,O
,that,IN,O
,nifedipine,JJ,O
,induces,NNS,O
,tachycardia,VBP,B-DISEASE
,in,IN,O
,normally,RB,O
,innervated,VBN,O
,hearts,NNS,O
,.,.,O
,However,RB,O
,",",",",O
,in,IN,O
,hearts,NNS,O
,deprived,VBN,O
,of,IN,O
,compensatory,JJ,O
,sympathetic,JJ,O
,drive,NN,O
,",",",",O
,it,PRP,O
,may,MD,O
,lead,VB,O
,to,TO,O
,bradycardia,VB,B-DISEASE
,.,.,O
,The,DT,O
,effect,NN,O
,of,IN,O
,haloperidol,NN,O
,in,IN,O
,cocaine,NN,O
,and,CC,O
,amphetamine,JJ,O
,intoxication,NN,O
,.,.,O
,The,DT,O
,effectiveness,NN,O
,of,IN,O
,haloperidol,JJ,O
,pretreatment,NN,O
,in,IN,O
,preventing,VBG,O
,the,DT,O
,toxic,JJ,O
,effects,NNS,O
,of,IN,O
,high,JJ,O
,doses,NNS,O
,of,IN,O
,amphetamine,NN,O
,and,CC,O
,cocaine,NN,O
,was,VBD,O
,studied,VBN,O
,in,IN,O
,rats,NNS,O
,.,.,O
,In,IN,O
,this,DT,O
,model,NN,O
,",",",",O
,toxic,JJ,O
,effects,NNS,O
,were,VBD,O
,induced,VBN,O
,by,IN,O
,intraperitoneal,NN,O
,(,(,O
,i,JJ,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,injection,NN,O
,of,IN,O
,amphetamine,JJ,O
,75,CD,O
,mg,NN,O
,/,NN,O
,kg,NN,O
,(,(,O
,100,CD,O
,%,NN,O
,death,NN,O
,rate,NN,O
,),),O
,or,CC,O
,cocaine,$,O
,70,CD,O
,mg,NN,O
,/,NN,O
,kg,NN,O
,(,(,O
,82,CD,O
,%,NN,O
,death,NN,O
,rate,NN,O
,),),O
,.,.,O
,Haloperidol,NNP,O
,failed,VBD,O
,to,TO,O
,prevent,VB,O
,amphetamine,JJ,O
,-,:,O
,induced,JJ,O
,seizures,NNS,B-DISEASE
,",",",",O
,but,CC,O
,did,VBD,O
,lower,JJR,O
,the,DT,O
,mortality,NN,O
,rate,NN,O
,at,IN,O
,most,JJS,O
,doses,NNS,O
,tested,VBN,O
,.,.,O
,Haloperidol,NNP,O
,decreased,VBD,O
,the,DT,O
,incidence,NN,O
,of,IN,O
,cocaine,NN,O
,-,:,O
,induced,JJ,O
,seizures,NNS,B-DISEASE
,at,IN,O
,the,DT,O
,two,CD,O
,highest,JJS,O
,doses,NNS,O
,",",",",O
,but,CC,O
,the,DT,O
,lowering,NN,O
,of,IN,O
,the,DT,O
,mortality,NN,O
,rate,NN,O
,did,VBD,O
,not,RB,O
,reach,VB,O
,statistical,JJ,O
,significance,NN,O
,at,IN,O
,any,DT,O
,dose,NN,O
,.,.,O
,These,DT,O
,data,NNS,O
,suggest,VBP,O
,a,DT,O
,protective,JJ,O
,role,NN,O
,for,IN,O
,the,DT,O
,central,JJ,O
,dopamine,NN,O
,blocker,NN,O
,haloperidol,NN,O
,against,IN,O
,death,NN,O
,from,IN,O
,high,JJ,O
,-,:,O
,dose,JJ,O
,amphetamine,JJ,O
,exposure,NN,O
,without,IN,O
,reducing,VBG,O
,the,DT,O
,incidence,NN,O
,of,IN,O
,seizures,NNS,B-DISEASE
,.,.,O
,In,IN,O
,contrast,NN,O
,",",",",O
,haloperidol,NN,O
,demonstrated,VBD,O
,an,DT,O
,ability,NN,O
,to,TO,O
,reduce,VB,O
,cocaine,NN,O
,-,:,O
,induced,JJ,O
,seizures,NNS,B-DISEASE
,without,IN,O
,significantly,RB,O
,reducing,VBG,O
,mortality,NN,O
,.,.,O
,Autoradiographic,JJ,O
,evidence,NN,O
,of,IN,O
,estrogen,NN,O
,binding,VBG,O
,sites,NNS,O
,in,IN,O
,nuclei,NN,O
,of,IN,O
,diethylstilbesterol,NN,O
,induced,VBN,O
,hamster,RBR,O
,renal,JJ,B-DISEASE
,carcinomas,NN,I-DISEASE
,.,.,O
,Estrogen,NNP,O
,binding,VBG,O
,sites,NNS,O
,were,VBD,O
,demonstrated,VBN,O
,by,IN,O
,autoradiography,NN,O
,in,IN,O
,one,CD,O
,transplantable,NN,O
,and,CC,O
,five,CD,O
,primary,JJ,O
,diethylstilbesterol,NN,O
,induced,VBD,O
,renal,JJ,B-DISEASE
,carcinomas,NN,I-DISEASE
,in,IN,O
,three,CD,O
,hamsters,NNS,O
,.,.,O
,Radiolabelling,NNP,O
,",",",",O
,following,VBG,O
,the,DT,O
,in,IN,O
,vivo,JJ,O
,injection,NN,O
,of,IN,O
,3H,CD,O
,-,:,O
,17,CD,O
,beta,NN,O
,estradiol,NN,O
,",",",",O
,was,VBD,O
,increased,VBN,O
,only,RB,O
,over,IN,O
,the,DT,O
,nuclei,NN,O
,of,IN,O
,tumor,NN,B-DISEASE
,cells,NNS,O
,;,:,O
,stereologic,JJ,O
,analysis,NN,O
,revealed,VBD,O
,a,DT,O
,4,CD,O
,.,.,O
,5,CD,O
,-,:,O
,to,TO,O
,6,CD,O
,.,.,O
,7,CD,O
,-,:,O
,times,NNS,O
,higher,JJR,O
,concentration,NN,O
,of,IN,O
,reduced,VBN,O
,silver,NN,O
,grains,NNS,O
,over,IN,O
,nuclei,JJR,O
,than,IN,O
,cytoplasm,NN,O
,of,IN,O
,these,DT,O
,cells,NNS,O
,.,.,O
,Despite,IN,O
,rapid,JJ,O
,tubular,JJ,O
,excretion,NN,O
,of,IN,O
,estradiol,NN,O
,which,WDT,O
,peaked,VBD,O
,in,IN,O
,less,JJR,O
,than,IN,O
,1,CD,O
,h,NN,O
,",",",",O
,the,DT,O
,normal,JJ,O
,cells,NNS,O
,did,VBD,O
,not,RB,O
,appear,VB,O
,to,TO,O
,bind,VB,O
,the,DT,O
,ligand,NN,O
,.,.,O
,This,DT,O
,is,VBZ,O
,the,DT,O
,first,JJ,O
,published,VBN,O
,report,NN,O
,documenting,VBG,O
,the,DT,O
,preferential,NN,O
,in,IN,O
,vivo,JJ,O
,binding,NN,O
,of,IN,O
,estrogen,NN,O
,to,TO,O
,nuclei,VB,O
,of,IN,O
,cells,NNS,O
,in,IN,O
,estrogen,NN,O
,induced,JJ,O
,hamster,NN,O
,renal,JJ,B-DISEASE
,carcinomas,NN,I-DISEASE
,.,.,O
,Bradycardia,NNP,B-DISEASE
,due,JJ,O
,to,TO,O
,biperiden,VB,O
,.,.,O
,In,IN,O
,a,DT,O
,38,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,male,JJ,O
,patient,NN,O
,suffering,VBG,O
,from,IN,O
,a,DT,O
,severe,JJ,O
,postzosteric,JJ,B-DISEASE
,trigeminal,JJ,B-DISEASE
,neuralgia,NN,I-DISEASE
,",",",",O
,intravenous,JJ,O
,application,NN,O
,of,IN,O
,10,CD,O
,mg,NNS,O
,biperiden,JJ,O
,lactate,NN,O
,led,VBD,O
,to,TO,O
,a,DT,O
,long,JJ,O
,-,:,O
,lasting,VBG,O
,paradoxical,JJ,O
,reaction,NN,O
,characterized,VBN,O
,by,IN,O
,considerable,JJ,O
,bradycardia,NN,B-DISEASE
,",",",",O
,dysarthria,NN,B-DISEASE
,",",",",O
,and,CC,O
,dysphagia,NN,B-DISEASE
,.,.,O
,The,DT,O
,heart,NN,O
,rate,NN,O
,was,VBD,O
,back,RB,O
,to,TO,O
,normal,JJ,O
,within,IN,O
,12,CD,O
,hours,NNS,O
,upon,IN,O
,administration,NN,O
,of,IN,O
,orciprenaline,JJ,O
,under,IN,O
,cardiac,JJ,O
,monitoring,NN,O
,in,IN,O
,an,DT,O
,intensive,JJ,O
,care,NN,O
,unit,NN,O
,.,.,O
,Bradycardia,NNP,B-DISEASE
,induced,VBN,O
,by,IN,O
,biperiden,NN,O
,is,VBZ,O
,attributed,VBN,O
,to,TO,O
,the,DT,O
,speed,NN,O
,of,IN,O
,injection,NN,O
,and,CC,O
,to,TO,O
,a,DT,O
,dose,JJ,O
,-,:,O
,related,JJ,O
,dual,JJ,O
,effect,NN,O
,of,IN,O
,atropine,JJ,O
,-,:,O
,like,IN,O
,drugs,NNS,O
,on,IN,O
,muscarine,NN,O
,receptors,NNS,O
,.,.,O
,Deliberate,NNP,O
,hypotension,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,labetalol,NN,O
,with,IN,O
,halothane,NN,O
,",",",",O
,enflurane,NN,O
,or,CC,O
,isoflurane,NN,O
,for,IN,O
,middle,JJ,O
,-,:,O
,ear,NN,O
,surgery,NN,O
,.,.,O
,The,DT,O
,feasibility,NN,O
,of,IN,O
,using,VBG,O
,labetalol,NN,O
,",",",",O
,an,DT,O
,alpha,JJ,O
,-,:,O
,and,CC,O
,beta,VB,O
,-,:,O
,adrenergic,NN,O
,blocking,VBG,O
,agent,NN,O
,",",",",O
,as,IN,O
,a,DT,O
,hypotensive,JJ,B-DISEASE
,agent,NN,O
,in,IN,O
,combination,NN,O
,with,IN,O
,inhalation,NN,O
,anaesthetics,NNS,O
,(,(,O
,halothane,NN,O
,",",",",O
,enflurane,NN,O
,or,CC,O
,isoflurane,NN,O
,),),O
,was,VBD,O
,studied,VBN,O
,in,IN,O
,23,CD,O
,adult,NN,O
,patients,NNS,O
,undergoing,VBG,O
,middle,JJ,O
,-,:,O
,ear,NN,O
,surgery,NN,O
,.,.,O
,The,DT,O
,mean,JJ,O
,arterial,JJ,O
,pressure,NN,O
,was,VBD,O
,decreased,VBN,O
,from,IN,O
,86,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,5,CD,O
,(,(,O
,s,NN,O
,.,.,O
,e,NN,O
,.,.,O
,mean,NN,O
,),),O
,mmHg,NN,O
,to,TO,O
,52,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,1,CD,O
,mmHg,NN,O
,(,(,O
,11,CD,O
,.,.,O
,5,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,7,CD,O
,to,TO,O
,6,CD,O
,.,.,O
,9,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,1,CD,O
,kPa,NN,O
,),),O
,for,IN,O
,98,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,10,CD,O
,min,NN,O
,in,IN,O
,the,DT,O
,halothane,NN,O
,(,(,O
,H,NNP,O
,),),O
,group,NN,O
,",",",",O
,from,IN,O
,79,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,5,CD,O
,to,TO,O
,53,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,1,CD,O
,mmHg,NN,O
,(,(,O
,10,CD,O
,.,.,O
,5,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,7,CD,O
,to,TO,O
,7,CD,O
,.,.,O
,1,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,1,CD,O
,kPa,NN,O
,),),O
,for,IN,O
,129,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,11,CD,O
,min,NN,O
,in,IN,O
,the,DT,O
,enflurane,NN,O
,(,(,O
,E,NNP,O
,),),O
,group,NN,O
,",",",",O
,and,CC,O
,from,IN,O
,80,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,4,CD,O
,to,TO,O
,49,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,1,CD,O
,mmHg,NN,O
,(,(,O
,10,CD,O
,.,.,O
,7,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,5,CD,O
,to,TO,O
,6,CD,O
,.,.,O
,5,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,1,CD,O
,kPa,NN,O
,),),O
,for,IN,O
,135,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,15,CD,O
,min,NN,O
,in,IN,O
,the,DT,O
,isoflurane,NN,O
,(,(,O
,I,PRP,O
,),),O
,group,NN,O
,.,.,O
,The,DT,O
,mean,JJ,O
,H,NNP,O
,concentration,NN,O
,during,IN,O
,hypotension,NN,B-DISEASE
,in,IN,O
,the,DT,O
,inspiratory,NN,O
,gas,NN,O
,was,VBD,O
,0,CD,O
,.,.,O
,7,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,1,CD,O
,vol,NN,O
,%,NN,O
,",",",",O
,the,DT,O
,mean,JJ,O
,E,NNP,O
,concentration,NN,O
,1,CD,O
,.,.,O
,6,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,2,CD,O
,vol,NN,O
,%,NN,O
,",",",",O
,and,CC,O
,the,DT,O
,mean,NN,O
,I,PRP,O
,concentration,VBP,O
,1,CD,O
,.,.,O
,0,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,1,CD,O
,vol,NN,O
,%,NN,O
,.,.,O
,In,IN,O
,addition,NN,O
,",",",",O
,the,DT,O
,patients,NNS,O
,received,VBD,O
,fentanyl,JJ,O
,and,CC,O
,d,JJ,O
,-,:,O
,tubocurarine,NN,O
,.,.,O
,The,DT,O
,initial,JJ,O
,dose,NN,O
,of,IN,O
,labetalol,NN,O
,for,IN,O
,lowering,VBG,O
,blood,NN,O
,pressure,NN,O
,was,VBD,O
,similar,JJ,O
,",",",",O
,0,CD,O
,.,.,O
,52,CD,O
,-,:,O
,0,CD,O
,.,.,O
,59,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,",",",",O
,in,IN,O
,all,PDT,O
,the,DT,O
,groups,NNS,O
,.,.,O
,During,IN,O
,hypotension,NN,B-DISEASE
,",",",",O
,the,DT,O
,heart,NN,O
,rate,NN,O
,was,VBD,O
,stable,JJ,O
,without,IN,O
,tachy,JJ,B-DISEASE
,-,:,I-DISEASE
,or,CC,I-DISEASE
,bradycardia,VB,I-DISEASE
,.,.,O
,The,DT,O
,operating,NN,O
,conditions,NNS,O
,regarding,VBG,O
,bleeding,NN,B-DISEASE
,were,VBD,O
,estimated,VBN,O
,in,IN,O
,a,DT,O
,double,JJ,O
,-,:,O
,blind,NN,O
,manner,NN,O
,",",",",O
,and,CC,O
,did,VBD,O
,not,RB,O
,differ,VB,O
,significantly,RB,O
,between,IN,O
,the,DT,O
,groups,NNS,O
,.,.,O
,During,IN,O
,hypotension,NN,B-DISEASE
,",",",",O
,the,DT,O
,serum,NN,O
,creatinine,NN,O
,concentration,NN,O
,rose,VBD,O
,significantly,RB,O
,in,IN,O
,all,DT,O
,groups,NNS,O
,from,IN,O
,the,DT,O
,values,NNS,O
,before,IN,O
,hypotension,NN,B-DISEASE
,and,CC,O
,returned,VBD,O
,postoperatively,RB,O
,to,TO,O
,the,DT,O
,initial,JJ,O
,level,NN,O
,in,IN,O
,the,DT,O
,other,JJ,O
,groups,NNS,O
,",",",",O
,except,IN,O
,the,DT,O
,isoflurane,NN,O
,group,NN,O
,.,.,O
,After,IN,O
,hypotension,NN,B-DISEASE
,there,EX,O
,was,VBD,O
,no,DT,O
,rebound,NN,O
,phenomenon,NN,O
,in,IN,O
,either,DT,O
,blood,NN,O
,pressure,NN,O
,or,CC,O
,heart,NN,O
,rate,NN,O
,.,.,O
,These,DT,O
,results,NNS,O
,indicate,VBP,O
,that,IN,O
,labetalol,NN,O
,induces,NNS,O
,easily,RB,O
,adjustable,JJ,O
,hypotension,NN,B-DISEASE
,without,IN,O
,compensatory,JJ,O
,tachycardia,NN,B-DISEASE
,and,CC,O
,rebound,NN,O
,hypertension,NN,B-DISEASE
,.,.,O
,Convulsion,NN,B-DISEASE
,following,VBG,O
,intravenous,JJ,O
,fluorescein,JJ,O
,angiography,NN,O
,.,.,O
,Tonic,NNP,B-DISEASE
,-,:,I-DISEASE
,clonic,NN,I-DISEASE
,seizures,NNS,I-DISEASE
,followed,VBD,O
,intravenous,JJ,O
,fluorescein,NNS,O
,injection,NN,O
,for,IN,O
,fundus,NN,O
,angiography,NN,O
,in,IN,O
,a,DT,O
,47,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,male,NN,O
,.,.,O
,Despite,IN,O
,precautions,NNS,O
,this,DT,O
,adverse,JJ,O
,reaction,NN,O
,recurred,VBD,O
,on,IN,O
,re,NN,O
,-,:,O
,exposure,NN,O
,to,TO,O
,intravenous,JJ,O
,fluorescein,NN,O
,.,.,O
,Pharmacology,NNP,O
,of,IN,O
,ACC,NNP,O
,-,:,O
,9653,CD,O
,(,(,O
,phenytoin,VB,O
,prodrug,NN,O
,),),O
,.,.,O
,ACC,NNP,O
,-,:,O
,9653,CD,O
,",",",",O
,the,DT,O
,disodium,NN,O
,phosphate,NN,O
,ester,NN,O
,of,IN,O
,3,CD,O
,-,:,O
,hydroxymethyl,NN,O
,-,:,O
,5,CD,O
,",",",",O
,5,CD,O
,-,:,O
,diphenylhydantoin,NN,O
,",",",",O
,is,VBZ,O
,a,DT,O
,prodrug,NN,O
,of,IN,O
,phenytoin,NN,O
,with,IN,O
,advantageous,JJ,O
,physicochemical,JJ,O
,properties,NNS,O
,.,.,O
,ACC,NNP,O
,-,:,O
,9653,CD,O
,is,VBZ,O
,rapidly,RB,O
,converted,VBN,O
,enzymatically,RB,O
,to,TO,O
,phenytoin,VB,O
,in,IN,O
,vivo,NN,O
,.,.,O
,ACC,NNP,O
,-,:,O
,9653,CD,O
,and,CC,O
,phenytoin,VB,O
,sodium,NN,O
,have,VBP,O
,equivalent,JJ,O
,anticonvulsant,JJ,O
,activity,NN,O
,against,IN,O
,seizures,NNS,B-DISEASE
,induced,VBN,O
,by,IN,O
,maximal,JJ,O
,electroshock,NN,O
,(,(,O
,MES,NNP,O
,),),O
,in,IN,O
,mice,NN,O
,following,VBG,O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,",",",",O
,oral,JJ,O
,",",",",O
,or,CC,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,administration,NN,O
,.,.,O
,The,DT,O
,ED50,NNP,O
,doses,NNS,O
,were,VBD,O
,16,CD,O
,mg,NNS,O
,/,JJ,O
,kg,NN,O
,for,IN,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,ACC,NNP,O
,-,:,O
,9653,CD,O
,and,CC,O
,8,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,for,IN,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,phenytoin,JJ,O
,sodium,NN,O
,.,.,O
,ACC,NNP,O
,-,:,O
,9653,CD,O
,and,CC,O
,phenytoin,VB,O
,sodium,NN,O
,have,VBP,O
,similar,JJ,O
,antiarrhythmic,JJ,O
,activity,NN,O
,against,IN,O
,ouabain,SYM,O
,-,:,O
,induced,JJ,O
,ventricular,JJ,B-DISEASE
,tachycardia,NN,I-DISEASE
,in,IN,O
,anesthetized,JJ,O
,dogs,NNS,O
,.,.,O
,The,DT,O
,total,JJ,O
,doses,NNS,O
,of,IN,O
,ACC,NNP,O
,-,:,O
,9653,CD,O
,or,CC,O
,phenytoin,VB,O
,sodium,JJ,O
,necessary,JJ,O
,to,TO,O
,convert,VB,O
,the,DT,O
,arrhythmia,NN,B-DISEASE
,to,TO,O
,a,DT,O
,normal,JJ,O
,sinus,NN,O
,rhythm,NN,O
,were,VBD,O
,24,CD,O
,+,NNP,O
,/,NNP,O
,-,:,O
,6,CD,O
,and,CC,O
,14,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,3,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,respectively,RB,O
,.,.,O
,Only,RB,O
,phenytoin,JJ,O
,sodium,NN,O
,displayed,VBN,O
,in,IN,O
,vitro,JJ,O
,antiarrhythmic,JJ,O
,activity,NN,O
,against,IN,O
,strophanthidin,JJ,O
,-,:,O
,induced,JJ,O
,arrhythmias,NN,B-DISEASE
,in,IN,O
,guinea,NN,O
,pig,NN,O
,right,RB,O
,atria,NN,O
,.,.,O
,In,IN,O
,anesthetized,JJ,O
,dogs,NNS,O
,",",",",O
,a,DT,O
,high,JJ,O
,dose,NN,O
,of,IN,O
,ACC,NNP,O
,-,:,O
,9653,CD,O
,(,(,O
,31,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,was,VBD,O
,infused,VBN,O
,over,IN,O
,15,CD,O
,",",",",O
,20,CD,O
,",",",",O
,and,CC,O
,30,CD,O
,min,NN,O
,and,CC,O
,the,DT,O
,responses,NNS,O
,were,VBD,O
,compared,VBN,O
,to,TO,O
,an,DT,O
,equimolar,JJ,O
,dose,NN,O
,of,IN,O
,phenytoin,NN,O
,sodium,NN,O
,(,(,O
,21,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,.,.,O
,The,DT,O
,ACC,NNP,O
,-,:,O
,9653,CD,O
,and,CC,O
,phenytoin,VB,O
,sodium,NN,O
,treatments,NNS,O
,produced,VBD,O
,similar,JJ,O
,marked,JJ,O
,reductions,NNS,O
,in,IN,O
,diastolic,JJ,O
,blood,NN,O
,pressure,NN,O
,and,CC,O
,contractile,NN,O
,force,NN,O
,(,(,O
,LVdP,NNP,O
,/,NNP,O
,dt,NN,O
,),),O
,.,.,O
,The,DT,O
,maximum,JJ,O
,effects,NNS,O
,of,IN,O
,each,DT,O
,treatment,NN,O
,occurred,VBD,O
,at,IN,O
,the,DT,O
,time,NN,O
,of,IN,O
,maximum,JJ,O
,phenytoin,JJ,O
,sodium,NN,O
,levels,NNS,O
,.,.,O
,Acute,NNP,O
,toxicity,NN,B-DISEASE
,studies,NNS,O
,of,IN,O
,ACC,NNP,O
,-,:,O
,9653,CD,O
,and,CC,O
,phenytoin,VB,O
,sodium,NN,O
,were,VBD,O
,carried,VBN,O
,out,RP,O
,in,IN,O
,mice,NN,O
,",",",",O
,rats,NNS,O
,",",",",O
,rabbits,NNS,O
,",",",",O
,and,CC,O
,dogs,NNS,O
,by,IN,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,",",",",O
,i,NN,O
,.,.,O
,m,NN,O
,.,.,O
,",",",",O
,and,CC,O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,routes,NNS,O
,of,IN,O
,administration,NN,O
,.,.,O
,The,DT,O
,systemic,JJ,O
,toxic,NN,O
,signs,NNS,O
,of,IN,O
,both,DT,O
,agents,NNS,O
,were,VBD,O
,similar,JJ,O
,and,CC,O
,occurred,VBD,O
,at,IN,O
,approximately,RB,O
,equivalent,JJ,O
,doses,NNS,O
,.,.,O
,Importantly,RB,O
,",",",",O
,the,DT,O
,local,JJ,O
,irritation,NN,O
,of,IN,O
,ACC,NNP,O
,-,:,O
,9653,CD,O
,was,VBD,O
,markedly,RB,O
,less,JJR,O
,than,IN,O
,phenytoin,VB,O
,sodium,NN,O
,following,VBG,O
,i,NN,O
,.,.,O
,m,NN,O
,.,.,O
,administration,NN,O
,.,.,O
,(,(,O
,ABSTRACT,NNP,O
,TRUNCATED,NNP,O
,AT,NNP,O
,250,CD,O
,WORDS,NNP,O
,),),O
,Tachyphylaxis,NNP,O
,to,TO,O
,systemic,VB,O
,but,CC,O
,not,RB,O
,to,TO,O
,airway,VB,O
,responses,NNS,O
,during,IN,O
,prolonged,JJ,O
,therapy,NN,O
,with,IN,O
,high,JJ,O
,dose,NN,O
,inhaled,VBD,O
,salbutamol,NN,O
,in,IN,O
,asthmatics,NNS,B-DISEASE
,.,.,O
,High,JJ,O
,doses,NNS,O
,of,IN,O
,inhaled,JJ,O
,salbutamol,NN,O
,produce,VBP,O
,substantial,JJ,O
,improvements,NNS,O
,in,IN,O
,airway,JJ,O
,response,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,asthma,NN,B-DISEASE
,",",",",O
,and,CC,O
,are,VBP,O
,associated,VBN,O
,with,IN,O
,dose,JJ,O
,-,:,O
,dependent,JJ,O
,systemic,JJ,O
,beta,NN,O
,-,:,O
,adrenoceptor,NN,O
,responses,NNS,O
,.,.,O
,The,DT,O
,purpose,NN,O
,of,IN,O
,the,DT,O
,present,JJ,O
,study,NN,O
,was,VBD,O
,to,TO,O
,investigate,VB,O
,whether,IN,O
,tachyphylaxis,JJ,O
,occurs,NNS,O
,during,IN,O
,prolonged,JJ,O
,treatment,NN,O
,with,IN,O
,high,JJ,O
,dose,NN,O
,inhaled,VBD,O
,salbutamol,NN,O
,.,.,O
,Twelve,NNP,O
,asthmatic,JJ,B-DISEASE
,patients,NNS,O
,(,(,O
,FEV1,NNP,O
,",",",",O
,81,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,4,CD,O
,%,NN,O
,predicted,VBN,O
,),),O
,",",",",O
,requiring,VBG,O
,only,RB,O
,occasional,JJ,O
,inhaled,VBN,O
,beta,NN,O
,-,:,O
,agonists,NNS,O
,as,IN,O
,their,PRP$,O
,sole,JJ,O
,therapy,NN,O
,",",",",O
,were,VBD,O
,given,VBN,O
,a,DT,O
,14,CD,O
,-,:,O
,day,NN,O
,treatment,NN,O
,with,IN,O
,high,JJ,O
,dose,NN,O
,inhaled,VBN,O
,salbutamol,NN,O
,(,(,O
,HDS,NNP,O
,),),O
,",",",",O
,4,CD,O
,",",",",O
,000,CD,O
,micrograms,NNS,O
,daily,RB,O
,",",",",O
,low,JJ,O
,dose,NN,O
,inhaled,VBN,O
,salbutamol,NN,O
,(,(,O
,LDS,NNP,O
,),),O
,",",",",O
,800,CD,O
,micrograms,NNS,O
,daily,RB,O
,",",",",O
,or,CC,O
,placebo,NN,O
,(,(,O
,PI,NNP,O
,),),O
,by,IN,O
,metered,VBN,O
,-,:,O
,dose,JJ,O
,inhaler,NN,O
,in,IN,O
,a,DT,O
,double,JJ,O
,-,:,O
,blind,NN,O
,",",",",O
,randomized,VBN,O
,crossover,NN,O
,design,NN,O
,.,.,O
,During,IN,O
,the,DT,O
,14,CD,O
,-,:,O
,day,NN,O
,run,VB,O
,-,:,O
,in,IN,O
,and,CC,O
,during,IN,O
,washout,NN,O
,periods,NNS,O
,",",",",O
,inhaled,VBD,O
,beta,SYM,O
,-,:,O
,agonists,NNS,O
,were,VBD,O
,withheld,VBN,O
,and,CC,O
,ipratropium,JJ,O
,bromide,NN,O
,was,VBD,O
,substituted,VBN,O
,for,IN,O
,rescue,NN,O
,purposes,NNS,O
,.,.,O
,At,IN,O
,the,DT,O
,end,NN,O
,of,IN,O
,each,DT,O
,14,CD,O
,-,:,O
,day,NN,O
,treatment,NN,O
,",",",",O
,a,DT,O
,dose,JJ,O
,-,:,O
,response,NN,O
,curve,NN,O
,(,(,O
,DRC,NNP,O
,),),O
,was,VBD,O
,performed,VBN,O
,",",",",O
,and,CC,O
,airway,RB,O
,(,(,O
,FEV1,NNP,O
,",",",",O
,FEF25,NNP,O
,-,:,O
,75,CD,O
,),),O
,chronotropic,NN,O
,(,(,O
,HR,NNP,O
,),),O
,",",",",O
,tremor,NN,B-DISEASE
,",",",",O
,and,CC,O
,metabolic,NN,O
,(,(,O
,K,NNP,O
,",",",",O
,Glu,NNP,O
,),),O
,responses,NNS,O
,were,VBD,O
,measured,VBN,O
,at,IN,O
,each,DT,O
,step,NN,O
,(,(,O
,from,IN,O
,100,CD,O
,to,TO,O
,4,CD,O
,",",",",O
,000,CD,O
,micrograms,NNS,O
,),),O
,.,.,O
,Treatment,NNP,O
,had,VBD,O
,no,DT,O
,significant,JJ,O
,effect,NN,O
,on,IN,O
,baseline,NN,O
,values,NNS,O
,.,.,O
,There,EX,O
,were,VBD,O
,dose,JJ,O
,-,:,O
,dependent,NN,O
,increases,NNS,O
,in,IN,O
,FEV1,NNP,O
,and,CC,O
,FEF25,NNP,O
,-,:,O
,75,CD,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,",",",",O
,and,CC,O
,pretreatment,NN,O
,with,IN,O
,HDS,NNP,O
,did,VBD,O
,not,RB,O
,displace,VB,O
,the,DT,O
,DRC,NNP,O
,to,TO,O
,the,DT,O
,right,NN,O
,.,.,O
,DRC,NNP,O
,for,IN,O
,HR,NNP,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,",",",",O
,K,NNP,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,",",",",O
,and,CC,O
,Glu,NNP,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,005,CD,O
,),),O
,were,VBD,O
,attenuated,VBN,O
,after,IN,O
,treatment,NN,O
,with,IN,O
,HDS,NNP,O
,compared,VBN,O
,with,IN,O
,PI,NNP,O
,.,.,O
,There,EX,O
,were,VBD,O
,also,RB,O
,differences,NNS,O
,between,IN,O
,HDS,NNP,O
,and,CC,O
,LDS,NNP,O
,for,IN,O
,HR,NNP,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,and,CC,O
,Glu,NNP,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,responses,NNS,O
,.,.,O
,Frequency,NN,O
,and,CC,O
,severity,NN,O
,of,IN,O
,subjective,JJ,O
,adverse,JJ,O
,effects,NNS,O
,were,VBD,O
,also,RB,O
,reduced,VBN,O
,after,IN,O
,HDS,NNP,O
,:,:,O
,tremor,NN,B-DISEASE
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,",",",",O
,palpitations,NNS,B-DISEASE
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,.,.,O
,(,(,O
,ABSTRACT,NNP,O
,TRUNCATED,NNP,O
,AT,NNP,O
,250,CD,O
,WORDS,NNP,O
,),),O
,Phenytoin,NNP,O
,induced,VBD,O
,fatal,JJ,O
,hepatic,JJ,B-DISEASE
,injury,NN,I-DISEASE
,.,.,O
,A,DT,O
,61,CD,O
,year,NN,O
,old,JJ,O
,female,NN,O
,developed,VBD,O
,fatal,JJ,O
,hepatic,JJ,B-DISEASE
,failure,NN,I-DISEASE
,after,IN,O
,phenytoin,JJ,O
,administration,NN,O
,.,.,O
,A,DT,O
,typical,JJ,O
,multisystem,NN,O
,clinical,JJ,O
,pattern,NN,O
,precedes,VBZ,O
,the,DT,O
,manifestations,NNS,O
,of,IN,O
,hepatic,JJ,B-DISEASE
,injury,NN,I-DISEASE
,.,.,O
,The,DT,O
,hematologic,NN,O
,",",",",O
,biochemical,JJ,O
,and,CC,O
,pathologic,JJ,O
,features,NNS,O
,indicate,VBP,O
,a,DT,O
,mixed,JJ,O
,hepatocellular,JJ,B-DISEASE
,damage,NN,I-DISEASE
,due,JJ,O
,to,TO,O
,drug,NN,B-DISEASE
,hypersensitivity,NN,I-DISEASE
,.,.,O
,In,IN,O
,a,DT,O
,patient,NN,O
,receiving,VBG,O
,phenytoin,NN,O
,who,WP,O
,presents,VBZ,O
,a,DT,O
,viral,JJ,O
,-,:,O
,like,IN,O
,illness,NN,O
,",",",",O
,early,JJ,O
,recognition,NN,O
,and,CC,O
,discontinuation,NN,O
,of,IN,O
,the,DT,O
,drug,NN,O
,are,VBP,O
,mandatory,JJ,O
,.,.,O
,Treatment,NN,O
,of,IN,O
,lethal,JJ,O
,pertussis,NN,O
,vaccine,NN,O
,reaction,NN,O
,with,IN,O
,histamine,JJ,O
,H1,NNP,O
,antagonists,NNS,O
,.,.,O
,We,PRP,O
,studied,VBD,O
,mortality,NN,O
,after,IN,O
,pertussis,NN,B-DISEASE
,immunization,NN,O
,in,IN,O
,the,DT,O
,mouse,NN,O
,.,.,O
,Without,IN,O
,treatment,NN,O
,",",",",O
,73,CD,O
,of,IN,O
,92,CD,O
,animals,NNS,O
,(,(,O
,80,CD,O
,%,NN,O
,),),O
,died,VBD,O
,after,IN,O
,injection,NN,O
,of,IN,O
,bovine,NN,O
,serum,NN,O
,albumin,NN,O
,(,(,O
,BSA,NNP,O
,),),O
,on,IN,O
,day,NN,O
,+,VBD,O
,7,CD,O
,of,IN,O
,pertussis,NN,B-DISEASE
,immunization,NN,O
,.,.,O
,After,IN,O
,pretreatment,NN,O
,with,IN,O
,3,CD,O
,mg,NNS,O
,of,IN,O
,cyproheptadine,NN,O
,",",",",O
,2,CD,O
,mg,NN,O
,mianserin,NN,O
,",",",",O
,or,CC,O
,2,CD,O
,mg,JJ,O
,chlorpheniramine,NN,O
,",",",",O
,only,RB,O
,5,CD,O
,of,IN,O
,105,CD,O
,animals,NNS,O
,(,(,O
,5,CD,O
,%,NN,O
,),),O
,died,VBD,O
,after,IN,O
,receiving,VBG,O
,BSA,NNP,O
,on,IN,O
,day,NN,O
,+,$,O
,7,CD,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,.,.,O
,Blockade,NNP,O
,of,IN,O
,histamine,NN,O
,H1,NNP,O
,receptors,NNS,O
,may,MD,O
,reduce,VB,O
,mortality,NN,O
,in,IN,O
,pertussis,NN,B-DISEASE
,immunization,NN,O
,-,:,O
,induced,VBN,O
,encephalopathy,NN,B-DISEASE
,in,IN,O
,mice,NN,O
,.,.,O
,Support,NNP,O
,for,IN,O
,adrenaline,JJ,O
,-,:,O
,hypertension,NN,B-DISEASE
,hypothesis,NN,O
,:,:,O
,18,CD,O
,hour,NN,O
,pressor,NN,O
,effect,NN,O
,after,IN,O
,6,CD,O
,hours,NNS,O
,adrenaline,JJ,O
,infusion,NN,O
,.,.,O
,In,IN,O
,a,DT,O
,double,JJ,O
,blind,NN,O
,",",",",O
,crossover,NN,O
,study,NN,O
,6,CD,O
,h,JJ,O
,infusions,NNS,O
,of,IN,O
,adrenaline,NN,O
,(,(,O
,15,CD,O
,ng,RB,O
,/,JJ,O
,kg,NN,O
,/,NNP,O
,min,NN,O
,;,:,O
,1,CD,O
,ng,NN,O
,=,VBD,O
,5,CD,O
,.,.,O
,458,CD,O
,pmol,NN,O
,),),O
,",",",",O
,noradrenaline,JJ,O
,(,(,O
,30,CD,O
,ng,RB,O
,/,JJ,O
,kg,NN,O
,/,NNP,O
,min,NN,O
,;,:,O
,1,CD,O
,ng,NN,O
,=,VBD,O
,5,CD,O
,.,.,O
,911,CD,O
,pmol,NN,O
,),),O
,",",",",O
,and,CC,O
,a,DT,O
,5,CD,O
,%,NN,O
,dextrose,JJ,O
,solution,NN,O
,(,(,O
,5,CD,O
,.,.,O
,4,CD,O
,ml,JJ,O
,/,NNP,O
,h,NN,O
,),),O
,",",",",O
,were,VBD,O
,given,VBN,O
,to,TO,O
,ten,VB,O
,healthy,JJ,O
,volunteers,NNS,O
,in,IN,O
,random,JJ,O
,order,NN,O
,2,CD,O
,weeks,NNS,O
,apart,RB,O
,.,.,O
,By,IN,O
,means,NNS,O
,of,IN,O
,intra,JJ,O
,-,:,O
,arterial,JJ,O
,ambulatory,NN,O
,monitoring,VBG,O
,the,DT,O
,haemodynamic,JJ,O
,effects,NNS,O
,were,VBD,O
,followed,VBN,O
,for,IN,O
,18,CD,O
,h,NN,O
,after,IN,O
,the,DT,O
,infusions,NNS,O
,were,VBD,O
,stopped,VBN,O
,.,.,O
,Adrenaline,NNP,O
,",",",",O
,but,CC,O
,not,RB,O
,noradrenaline,JJ,O
,",",",",O
,caused,VBD,O
,a,DT,O
,delayed,NN,O
,and,CC,O
,protracted,JJ,O
,pressor,NN,O
,effect,NN,O
,.,.,O
,Over,IN,O
,the,DT,O
,total,JJ,O
,postinfusion,NN,O
,period,NN,O
,systolic,JJ,O
,and,CC,O
,diastolic,JJ,O
,arterial,JJ,O
,pressure,NN,O
,were,VBD,O
,6,CD,O
,(,(,O
,SEM,NNP,O
,2,CD,O
,),),O
,%,NN,O
,and,CC,O
,7,CD,O
,(,(,O
,2,CD,O
,),),O
,%,NN,O
,",",",",O
,respectively,RB,O
,",",",",O
,higher,JJR,O
,than,IN,O
,after,IN,O
,dextrose,JJ,O
,infusion,NN,O
,(,(,O
,ANOVA,NNP,O
,",",",",O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,.,.,O
,Thus,RB,O
,",",",",O
,"""",NNP,O
,stress,NN,O
,"""",NN,O
,levels,NNS,O
,of,IN,O
,adrenaline,NN,O
,(,(,O
,230,CD,O
,pg,NN,O
,/,NNP,O
,ml,NN,O
,),),O
,for,IN,O
,6,CD,O
,h,NN,O
,cause,NN,O
,a,DT,O
,delayed,NN,O
,and,CC,O
,protracted,JJ,O
,pressor,NN,O
,effect,NN,O
,.,.,O
,These,DT,O
,findings,NNS,O
,are,VBP,O
,strong,JJ,O
,support,NN,O
,for,IN,O
,the,DT,O
,adrenaline,JJ,O
,-,:,O
,hypertension,NN,B-DISEASE
,hypothesis,NN,O
,in,IN,O
,man,NN,O
,.,.,O
,Effect,NN,O
,of,IN,O
,alkylxanthines,NNS,O
,on,IN,O
,gentamicin,NN,O
,-,:,O
,induced,JJ,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,in,IN,O
,the,DT,O
,rat,NN,O
,.,.,O
,Adenosine,NNP,O
,antagonists,NNS,O
,have,VBP,O
,been,VBN,O
,previously,RB,O
,shown,VBN,O
,to,TO,O
,be,VB,O
,of,IN,O
,benefit,NN,O
,in,IN,O
,some,DT,O
,ischaemic,JJ,B-DISEASE
,and,CC,O
,nephrotoxic,JJ,B-DISEASE
,models,NNS,O
,of,IN,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,(,(,O
,ARF,NNP,B-DISEASE
,),),O
,.,.,O
,In,IN,O
,the,DT,O
,present,JJ,O
,study,NN,O
,",",",",O
,the,DT,O
,effects,NNS,O
,of,IN,O
,three,CD,O
,alkylxanthines,NNS,O
,with,IN,O
,different,JJ,O
,potencies,NNS,O
,as,IN,O
,adenosine,JJ,O
,antagonists,NNS,O
,8,CD,O
,-,:,O
,phenyltheophylline,NN,O
,",",",",O
,theophylline,NN,O
,and,CC,O
,enprofylline,NN,O
,",",",",O
,were,VBD,O
,examined,VBN,O
,in,IN,O
,rats,NNS,O
,developing,VBG,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,after,IN,O
,4,CD,O
,daily,JJ,O
,injections,NNS,O
,of,IN,O
,gentamicin,NN,O
,(,(,O
,200,CD,O
,mg,NN,O
,kg,SYM,O
,-,:,O
,1,CD,O
,),),O
,.,.,O
,Renal,JJ,O
,function,NN,O
,was,VBD,O
,assessed,VBN,O
,by,IN,O
,biochemical,JJ,O
,(,(,O
,plasma,JJ,O
,urea,NN,O
,and,CC,O
,creatinine,NN,O
,),),O
,",",",",O
,functional,JJ,O
,(,(,O
,urine,JJ,O
,analysis,NN,O
,and,CC,O
,[,$,O
,3H,CD,O
,],NNP,O
,inulin,NN,O
,and,CC,O
,[,$,O
,14C,CD,O
,],NNP,O
,p,NN,O
,-,:,O
,aminohippuric,JJ,O
,acid,NN,O
,clearances,NNS,O
,),),O
,and,CC,O
,morphological,JJ,O
,(,(,O
,degree,NN,O
,of,IN,O
,necrosis,NN,B-DISEASE
,),),O
,indices,NNS,O
,.,.,O
,The,DT,O
,various,JJ,O
,drug,NN,O
,treatments,NNS,O
,produced,VBD,O
,improvements,NNS,O
,in,IN,O
,some,DT,O
,",",",",O
,but,CC,O
,not,RB,O
,all,DT,O
,",",",",O
,measurements,NNS,O
,of,IN,O
,renal,JJ,O
,function,NN,O
,.,.,O
,However,RB,O
,",",",",O
,any,DT,O
,improvement,NN,O
,produced,VBN,O
,by,IN,O
,drug,NN,O
,treatment,NN,O
,was,VBD,O
,largely,RB,O
,a,DT,O
,result,NN,O
,of,IN,O
,a,DT,O
,beneficial,JJ,O
,effect,NN,O
,exerted,VBN,O
,by,IN,O
,its,PRP$,O
,vehicle,NN,O
,(,(,O
,polyethylene,JJ,O
,glycol,NN,O
,and,CC,O
,NaOH,NNP,O
,),),O
,.,.,O
,The,DT,O
,lack,NN,O
,of,IN,O
,any,DT,O
,consistent,JJ,O
,protective,JJ,O
,effect,NN,O
,noted,VBD,O
,with,IN,O
,the,DT,O
,alkylxanthines,NNS,O
,tested,VBN,O
,in,IN,O
,the,DT,O
,present,JJ,O
,study,NN,O
,indicates,VBZ,O
,that,IN,O
,adenosine,NN,O
,plays,VBZ,O
,little,RB,O
,",",",",O
,if,IN,O
,any,DT,O
,",",",",O
,pathophysiological,JJ,O
,role,NN,O
,in,IN,O
,gentamicin,JJ,O
,-,:,O
,induced,JJ,O
,ARF,NNP,B-DISEASE
,.,.,O
,Adverse,NNP,O
,ocular,JJ,O
,reactions,NNS,O
,possibly,RB,O
,associated,VBN,O
,with,IN,O
,isotretinoin,NN,O
,.,.,O
,A,DT,O
,total,NN,O
,of,IN,O
,261,CD,O
,adverse,JJ,O
,ocular,JJ,O
,reactions,NNS,O
,occurred,VBD,O
,in,IN,O
,237,CD,O
,patients,NNS,O
,who,WP,O
,received,VBD,O
,isotretinoin,NN,O
,",",",",O
,a,DT,O
,commonly,RB,O
,used,VBN,O
,drug,NN,O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,severe,JJ,O
,cystic,JJ,O
,acne,NN,B-DISEASE
,.,.,O
,Blepharoconjunctivitis,NNP,B-DISEASE
,",",",",O
,subjective,JJ,O
,complaints,NNS,O
,of,IN,O
,dry,JJ,B-DISEASE
,eyes,NNS,I-DISEASE
,",",",",O
,blurred,VBD,B-DISEASE
,vision,NN,I-DISEASE
,",",",",O
,contact,NN,O
,lens,NNS,O
,intolerance,NN,O
,",",",",O
,and,CC,O
,photodermatitis,NN,B-DISEASE
,are,VBP,O
,reversible,JJ,O
,side,NN,O
,effects,NNS,O
,.,.,O
,More,RBR,O
,serious,JJ,O
,ocular,JJ,O
,adverse,JJ,O
,reactions,NNS,O
,include,VBP,O
,papilledema,NN,B-DISEASE
,",",",",O
,pseudotumor,NN,B-DISEASE
,cerebri,NN,I-DISEASE
,",",",",O
,and,CC,O
,white,JJ,O
,or,CC,O
,gray,JJ,O
,subepithelial,JJ,O
,corneal,NN,B-DISEASE
,opacities,NNS,I-DISEASE
,;,:,O
,all,DT,O
,of,IN,O
,these,DT,O
,are,VBP,O
,reversible,JJ,O
,if,IN,O
,the,DT,O
,drug,NN,O
,is,VBZ,O
,discontinued,VBN,O
,.,.,O
,Reported,VBN,O
,cases,NNS,O
,of,IN,O
,decreased,JJ,O
,dark,JJ,O
,adaptation,NN,O
,are,VBP,O
,under,IN,O
,investigation,NN,O
,.,.,O
,Isotretinoin,NNP,O
,is,VBZ,O
,contraindicated,VBN,O
,in,IN,O
,pregnancy,NN,O
,because,IN,O
,of,IN,O
,the,DT,O
,many,JJ,O
,reported,VBD,O
,congenital,JJ,B-DISEASE
,abnormalities,NNS,I-DISEASE
,after,IN,O
,maternal,JJ,O
,use,NN,O
,(,(,O
,including,VBG,O
,microphthalmos,NN,B-DISEASE
,",",",",O
,orbital,JJ,O
,hypertelorism,NN,B-DISEASE
,",",",",O
,and,CC,O
,optic,JJ,B-DISEASE
,nerve,NN,I-DISEASE
,hypoplasia,NN,I-DISEASE
,),),O
,.,.,O
,Procaterol,NNP,O
,and,CC,O
,terbutaline,NN,O
,in,IN,O
,bronchial,JJ,B-DISEASE
,asthma,NN,I-DISEASE
,.,.,O
,A,DT,O
,double,JJ,O
,-,:,O
,blind,NN,O
,",",",",O
,placebo,SYM,O
,-,:,O
,controlled,VBN,O
,",",",",O
,cross,SYM,O
,-,:,O
,over,IN,O
,study,NN,O
,.,.,O
,Procaterol,NNP,O
,",",",",O
,a,DT,O
,new,JJ,O
,beta,NN,O
,-,:,O
,2,CD,O
,adrenoceptor,NN,O
,stimulant,NN,O
,",",",",O
,was,VBD,O
,studied,VBN,O
,in,IN,O
,a,DT,O
,double,JJ,O
,-,:,O
,blind,NN,O
,",",",",O
,placebo,SYM,O
,-,:,O
,controlled,VBN,O
,",",",",O
,cross,SYM,O
,-,:,O
,over,IN,O
,trial,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,bronchial,JJ,B-DISEASE
,asthma,NN,I-DISEASE
,.,.,O
,Oral,NNP,O
,procaterol,NN,O
,50,CD,O
,micrograms,NN,O
,b,NN,O
,.,.,O
,d,NN,O
,.,.,O
,",",",",O
,procaterol,VBD,O
,100,CD,O
,micrograms,NNS,O
,b,NN,O
,.,.,O
,d,NN,O
,.,.,O
,",",",",O
,and,CC,O
,terbutaline,VB,O
,5,CD,O
,mg,NN,O
,t,NN,O
,.,.,O
,i,NN,O
,.,.,O
,d,NN,O
,.,.,O
,",",",",O
,were,VBD,O
,compared,VBN,O
,when,WRB,O
,given,VBN,O
,randomly,RB,O
,in,IN,O
,1,CD,O
,-,:,O
,week,NN,O
,treatment,NN,O
,periods,NNS,O
,.,.,O
,The,DT,O
,best,JJS,O
,clinical,JJ,O
,effect,NN,O
,was,VBD,O
,found,VBN,O
,with,IN,O
,terbutaline,NN,O
,.,.,O
,Both,DT,O
,anti,JJ,O
,-,:,O
,asthmatic,JJ,B-DISEASE
,and,CC,O
,tremorgenic,JJ,B-DISEASE
,effects,NNS,O
,of,IN,O
,procaterol,NN,O
,were,VBD,O
,dose,JJ,O
,-,:,O
,related,VBN,O
,.,.,O
,Procaterol,NNP,O
,appeared,VBD,O
,effective,JJ,O
,in,IN,O
,the,DT,O
,doses,NNS,O
,tested,VBN,O
,",",",",O
,and,CC,O
,a,DT,O
,twice,JJ,O
,daily,JJ,O
,regimen,NNS,O
,would,MD,O
,appear,VB,O
,to,TO,O
,be,VB,O
,suitable,JJ,O
,with,IN,O
,this,DT,O
,drug,NN,O
,.,.,O
,Subacute,NNP,O
,effects,NNS,O
,of,IN,O
,propranolol,NN,O
,and,CC,O
,B,NNP,O
,24,CD,O
,/,NNP,O
,76,CD,O
,on,IN,O
,isoproterenol,NN,O
,-,:,O
,induced,JJ,O
,rat,JJ,O
,heart,NN,B-DISEASE
,hypertrophy,NN,I-DISEASE
,in,IN,O
,correlation,NN,O
,with,IN,O
,blood,NN,O
,pressure,NN,O
,.,.,O
,We,PRP,O
,compared,VBN,O
,the,DT,O
,potential,JJ,O
,beta,NN,O
,-,:,O
,receptor,NN,O
,blocker,NN,O
,",",",",O
,B,NNP,O
,24,CD,O
,/,NN,O
,76,CD,O
,i,NN,O
,.,.,O
,e,NN,O
,.,.,O
,1,CD,O
,-,:,O
,(,(,O
,2,CD,O
,",",",",O
,4,CD,O
,-,:,O
,dichlorophenoxy,NN,O
,),),O
,-,:,O
,3,CD,O
,[,$,O
,2,CD,O
,-,:,O
,3,CD,O
,",",",",O
,4,CD,O
,-,:,O
,dimethoxyphenyl,NN,O
,),),O
,ethanolamino,NN,O
,],SYM,O
,-,:,O
,prop,NN,O
,an,DT,O
,-,:,O
,2,CD,O
,-,:,O
,ol,NN,O
,",",",",O
,which,WDT,O
,is,VBZ,O
,characterized,VBN,O
,by,IN,O
,beta,NN,O
,1,CD,O
,-,:,O
,adrenoceptor,NN,O
,blocking,NN,O
,and,CC,O
,beta,NN,O
,2,CD,O
,-,:,O
,adrenoceptor,NN,O
,stimulating,VBG,O
,properties,NNS,O
,with,IN,O
,propranolol,NN,O
,.,.,O
,The,DT,O
,studies,NNS,O
,were,VBD,O
,performed,VBN,O
,using,VBG,O
,an,DT,O
,experimental,JJ,O
,model,NN,O
,of,IN,O
,isoproterenol,JJ,O
,-,:,O
,induced,JJ,O
,heart,NN,B-DISEASE
,hypertrophy,NN,I-DISEASE
,in,IN,O
,rats,NNS,O
,.,.,O
,A,DT,O
,correlation,NN,O
,of,IN,O
,the,DT,O
,blood,NN,O
,pressure,NN,O
,was,VBD,O
,neither,DT,O
,found,VBN,O
,in,IN,O
,the,DT,O
,development,NN,O
,nor,CC,O
,in,IN,O
,the,DT,O
,attempt,NN,O
,to,TO,O
,suppress,VB,O
,the,DT,O
,development,NN,O
,of,IN,O
,heart,NN,B-DISEASE
,hypertrophy,NN,I-DISEASE
,with,IN,O
,the,DT,O
,two,CD,O
,beta,SYM,O
,-,:,O
,receptor,NN,O
,blockers,NNS,O
,.,.,O
,Both,DT,O
,beta,SYM,O
,-,:,O
,blockers,NNS,O
,influenced,VBD,O
,the,DT,O
,development,NN,O
,of,IN,O
,hypertrophy,NN,B-DISEASE
,to,TO,O
,a,DT,O
,different,JJ,O
,",",",",O
,but,CC,O
,not,RB,O
,reproducible,JJ,O
,extent,NN,O
,.,.,O
,It,PRP,O
,was,VBD,O
,possible,JJ,O
,to,TO,O
,suppress,VB,O
,the,DT,O
,increased,JJ,O
,ornithine,JJ,O
,decarboxylase,NN,O
,activity,NN,O
,with,IN,O
,both,DT,O
,beta,SYM,O
,-,:,O
,blockers,NNS,O
,in,IN,O
,hypertrophied,JJ,B-DISEASE
,hearts,NNS,I-DISEASE
,",",",",O
,but,CC,O
,there,EX,O
,was,VBD,O
,no,DT,O
,effect,NN,O
,on,IN,O
,the,DT,O
,heart,NN,O
,mass,NN,O
,.,.,O
,Neither,CC,O
,propranolol,JJ,O
,nor,CC,O
,B,NNP,O
,24,CD,O
,/,NN,O
,76,CD,O
,could,MD,O
,stop,VB,O
,the,DT,O
,changes,NNS,O
,in,IN,O
,the,DT,O
,characteristic,JJ,O
,myosin,NN,O
,isoenzyme,NN,O
,pattern,NN,O
,of,IN,O
,the,DT,O
,hypertrophied,JJ,B-DISEASE
,rat,NN,O
,heart,NN,O
,.,.,O
,Thus,RB,O
,",",",",O
,the,DT,O
,investigations,NNS,O
,did,VBD,O
,not,RB,O
,provide,VB,O
,any,DT,O
,evidence,NN,O
,that,IN,O
,the,DT,O
,beta,NN,O
,-,:,O
,receptor,NN,O
,blockers,NNS,O
,propranolol,VBP,O
,and,CC,O
,B,NNP,O
,24,CD,O
,/,NN,O
,76,CD,O
,have,VBP,O
,the,DT,O
,potency,NN,O
,to,TO,O
,prevent,VB,O
,isoproterenol,NN,O
,from,IN,O
,producing,VBG,O
,heart,NN,B-DISEASE
,hypertrophy,NN,I-DISEASE
,.,.,O
,Increased,VBN,O
,anxiogenic,JJ,O
,effects,NNS,O
,of,IN,O
,caffeine,NN,O
,in,IN,O
,panic,JJ,B-DISEASE
,disorders,NNS,I-DISEASE
,.,.,O
,The,DT,O
,effects,NNS,O
,of,IN,O
,oral,JJ,O
,administration,NN,O
,of,IN,O
,caffeine,NN,O
,(,(,O
,10,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,on,IN,O
,behavioral,JJ,O
,ratings,NNS,O
,",",",",O
,somatic,JJ,O
,symptoms,NNS,O
,",",",",O
,blood,NN,O
,pressure,NN,O
,and,CC,O
,plasma,NN,O
,levels,NNS,O
,of,IN,O
,3,CD,O
,-,:,O
,methoxy,NN,O
,-,:,O
,4,CD,O
,-,:,O
,hydroxyphenethyleneglycol,NN,O
,(,(,O
,MHPG,NNP,O
,),),O
,and,CC,O
,cortisol,$,O
,were,VBD,O
,determined,VBN,O
,in,IN,O
,17,CD,O
,healthy,JJ,O
,subjects,NNS,O
,and,CC,O
,21,CD,O
,patients,NNS,O
,meeting,VBG,O
,DSM,NNP,O
,-,:,O
,III,NNP,O
,criteria,NNS,O
,for,IN,O
,agoraphobia,NN,B-DISEASE
,with,IN,O
,panic,JJ,B-DISEASE
,attacks,NNS,I-DISEASE
,or,CC,O
,panic,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,.,.,O
,Caffeine,NNP,O
,produced,VBD,O
,significantly,RB,O
,greater,JJR,O
,increases,NNS,O
,in,IN,O
,subject,JJ,O
,-,:,O
,rated,VBN,O
,anxiety,NN,B-DISEASE
,",",",",O
,nervousness,NN,O
,",",",",O
,fear,NN,O
,",",",",O
,nausea,NN,B-DISEASE
,",",",",O
,palpitations,NNS,B-DISEASE
,",",",",O
,restlessness,NN,B-DISEASE
,",",",",O
,and,CC,O
,tremors,NNS,B-DISEASE
,in,IN,O
,the,DT,O
,patients,NNS,O
,compared,VBN,O
,with,IN,O
,healthy,JJ,O
,subjects,NNS,O
,.,.,O
,In,IN,O
,the,DT,O
,patients,NNS,O
,",",",",O
,but,CC,O
,not,RB,O
,the,DT,O
,healthy,JJ,O
,subjects,NNS,O
,",",",",O
,these,DT,O
,symptoms,NNS,O
,were,VBD,O
,significantly,RB,O
,correlated,VBN,O
,with,IN,O
,plasma,JJ,O
,caffeine,NN,O
,levels,NNS,O
,.,.,O
,Seventy,NNP,O
,-,:,O
,one,CD,O
,percent,NN,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,reported,VBD,O
,that,IN,O
,the,DT,O
,behavioral,JJ,O
,effects,NNS,O
,of,IN,O
,caffeine,NN,O
,were,VBD,O
,similar,JJ,O
,to,TO,O
,those,DT,O
,experienced,VBN,O
,during,IN,O
,panic,JJ,B-DISEASE
,attacks,NNS,I-DISEASE
,.,.,O
,Caffeine,NNP,O
,did,VBD,O
,not,RB,O
,alter,VB,O
,plasma,NN,O
,MHPG,NNP,O
,levels,NNS,O
,in,IN,O
,either,CC,O
,the,DT,O
,healthy,JJ,O
,subjects,NNS,O
,or,CC,O
,patients,NNS,O
,.,.,O
,Caffeine,NNP,O
,increased,VBD,O
,plasma,JJ,O
,cortisol,NN,O
,levels,NNS,O
,equally,RB,O
,in,IN,O
,the,DT,O
,patient,NN,O
,and,CC,O
,healthy,JJ,O
,groups,NNS,O
,.,.,O
,Because,IN,O
,caffeine,NN,O
,is,VBZ,O
,an,DT,O
,adenosine,JJ,O
,receptor,NN,O
,antagonist,NN,O
,",",",",O
,these,DT,O
,results,NNS,O
,suggest,VBP,O
,that,IN,O
,some,DT,O
,panic,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,patients,NNS,O
,may,MD,O
,have,VB,O
,abnormalities,NNS,B-DISEASE
,in,IN,I-DISEASE
,neuronal,JJ,I-DISEASE
,systems,NNS,I-DISEASE
,involving,VBG,O
,adenosine,NN,O
,.,.,O
,Patients,NNS,O
,with,IN,O
,anxiety,NN,B-DISEASE
,disorders,NNS,I-DISEASE
,may,MD,O
,benefit,VB,O
,by,IN,O
,avoiding,VBG,O
,caffeine,JJ,O
,-,:,O
,containing,VBG,O
,foods,NNS,O
,and,CC,O
,beverages,NNS,O
,.,.,O
,Comparison,NNP,O
,of,IN,O
,the,DT,O
,effect,NN,O
,of,IN,O
,oxitropium,NN,O
,bromide,NN,O
,and,CC,O
,of,IN,O
,slow,JJ,O
,-,:,O
,release,NN,O
,theophylline,NN,O
,on,IN,O
,nocturnal,JJ,O
,asthma,NN,B-DISEASE
,.,.,O
,The,DT,O
,effects,NNS,O
,of,IN,O
,a,DT,O
,new,JJ,O
,inhaled,JJ,O
,antimuscarinic,JJ,O
,drug,NN,O
,",",",",O
,oxitropium,NN,O
,bromide,NN,O
,",",",",O
,and,CC,O
,of,IN,O
,a,DT,O
,slow,JJ,O
,-,:,O
,release,NN,O
,theophylline,JJ,O
,preparation,NN,O
,upon,IN,O
,nocturnal,JJ,O
,asthma,NN,B-DISEASE
,were,VBD,O
,compared,VBN,O
,in,IN,O
,a,DT,O
,placebo,NN,O
,-,:,O
,controlled,VBN,O
,double,JJ,O
,-,:,O
,blind,NN,O
,study,NN,O
,.,.,O
,Two,CD,O
,samples,NNS,O
,were,VBD,O
,studied,VBN,O
,:,:,O
,12,CD,O
,patients,NNS,O
,received,VBD,O
,oxitropium,NN,O
,at,IN,O
,600,CD,O
,micrograms,NNS,O
,(,(,O
,6,CD,O
,subjects,NNS,O
,),),O
,or,CC,O
,at,IN,O
,400,CD,O
,micrograms,NNS,O
,t,VBP,O
,.,.,O
,i,NN,O
,.,.,O
,d,NN,O
,.,.,O
,(,(,O
,6,CD,O
,subjects,NNS,O
,),),O
,whereas,VBP,O
,11,CD,O
,received,JJ,O
,theophylline,NN,O
,at,IN,O
,300,CD,O
,mg,NN,O
,b,NN,O
,.,.,O
,i,NN,O
,.,.,O
,d,NN,O
,.,.,O
,Morning,VBG,O
,dipping,NN,O
,",",",",O
,assessed,VBN,O
,by,IN,O
,the,DT,O
,fall,NN,O
,in,IN,O
,peak,NN,O
,flow,NN,O
,overnight,VBD,O
,",",",",O
,was,VBD,O
,significantly,RB,O
,reduced,VBN,O
,in,IN,O
,the,DT,O
,periods,NNS,O
,when,WRB,O
,either,DT,O
,active,JJ,O
,drug,NN,O
,was,VBD,O
,taken,VBN,O
,",",",",O
,whereas,VBZ,O
,no,DT,O
,difference,NN,O
,was,VBD,O
,noticed,VBN,O
,during,IN,O
,the,DT,O
,placebo,JJ,O
,administration,NN,O
,.,.,O
,No,DT,O
,significant,JJ,O
,difference,NN,O
,was,VBD,O
,noticed,VBN,O
,between,IN,O
,results,NNS,O
,obtained,VBN,O
,with,IN,O
,either,DT,O
,active,JJ,O
,drug,NN,O
,",",",",O
,as,RB,O
,well,RB,O
,as,IN,O
,with,IN,O
,either,DT,O
,dosage,NN,O
,of,IN,O
,oxitropium,NN,O
,.,.,O
,No,DT,O
,subject,NN,O
,reported,VBD,O
,side,JJ,O
,effects,NNS,O
,of,IN,O
,oxitropium,NN,O
,",",",",O
,as,IN,O
,compared,VBN,O
,to,TO,O
,three,CD,O
,subjects,NNS,O
,reporting,VBG,O
,nausea,NN,B-DISEASE
,",",",",O
,vomiting,VBG,B-DISEASE
,and,CC,O
,tremors,NNS,B-DISEASE
,after,IN,O
,theophylline,NN,O
,.,.,O
,Oxitropium,NN,O
,proves,VBZ,O
,to,TO,O
,be,VB,O
,a,DT,O
,valuable,JJ,O
,alternative,NN,O
,to,TO,O
,theophylline,VB,O
,in,IN,O
,nocturnal,JJ,O
,asthma,NN,B-DISEASE
,",",",",O
,since,IN,O
,it,PRP,O
,is,VBZ,O
,equally,RB,O
,potent,JJ,O
,",",",",O
,safer,JJR,O
,and,CC,O
,does,VBZ,O
,not,RB,O
,require,VB,O
,the,DT,O
,titration,NN,O
,of,IN,O
,dosage,NN,O
,.,.,O
,Penicillin,NNP,O
,anaphylaxis,NN,B-DISEASE
,.,.,O
,A,DT,O
,case,NN,O
,of,IN,O
,oral,JJ,O
,penicillin,NN,O
,anaphylaxis,NN,B-DISEASE
,is,VBZ,O
,described,VBN,O
,",",",",O
,and,CC,O
,the,DT,O
,terminology,NN,O
,",",",",O
,occurrence,NN,O
,",",",",O
,clinical,JJ,O
,manifestations,NNS,O
,",",",",O
,pathogenesis,NN,O
,",",",",O
,prevention,NN,O
,",",",",O
,and,CC,O
,treatment,NN,O
,of,IN,O
,anaphylaxis,NN,B-DISEASE
,are,VBP,O
,reviewed,VBN,O
,.,.,O
,Emergency,NNP,O
,physicians,NNS,O
,should,MD,O
,be,VB,O
,aware,JJ,O
,of,IN,O
,oral,JJ,O
,penicillin,NN,O
,anaphylaxis,NN,B-DISEASE
,in,IN,O
,order,NN,O
,to,TO,O
,prevent,VB,O
,its,PRP$,O
,occurrence,NN,O
,by,IN,O
,prescribing,VBG,O
,the,DT,O
,antibiotic,JJ,O
,judiciously,NN,O
,and,CC,O
,knowledgeably,RB,O
,and,CC,O
,to,TO,O
,offer,VB,O
,optimal,JJ,O
,medical,JJ,O
,therapy,NN,O
,once,RB,O
,this,DT,O
,life,NN,O
,-,:,O
,threatening,VBG,O
,reaction,NN,O
,has,VBZ,O
,begun,VBN,O
,.,.,O
,Reversible,JJ,O
,valproic,NN,O
,acid,SYM,O
,-,:,O
,induced,JJ,O
,dementia,NN,B-DISEASE
,:,:,O
,a,DT,O
,case,NN,O
,report,NN,O
,.,.,O
,Reversible,JJ,O
,valproic,NN,O
,acid,SYM,O
,-,:,O
,induced,JJ,O
,dementia,NN,B-DISEASE
,was,VBD,O
,documented,VBN,O
,in,IN,O
,a,DT,O
,21,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,man,NN,O
,with,IN,O
,epilepsy,NN,B-DISEASE
,who,WP,O
,had,VBD,O
,a,DT,O
,3,CD,O
,-,:,O
,year,NN,O
,history,NN,O
,of,IN,O
,insidious,JJ,O
,progressive,JJ,O
,decline,NN,O
,in,IN,O
,global,JJ,O
,cognitive,JJ,O
,abilities,NNS,O
,documented,VBN,O
,by,IN,O
,serial,JJ,O
,neuropsychological,JJ,O
,studies,NNS,O
,.,.,O
,Repeat,NNP,O
,neuropsychological,JJ,O
,testing,VBG,O
,7,CD,O
,weeks,NNS,O
,after,IN,O
,discontinuation,NN,O
,of,IN,O
,the,DT,O
,drug,NN,O
,revealed,VBD,O
,dramatic,JJ,O
,improvement,NN,O
,in,IN,O
,IQ,NNP,O
,",",",",O
,memory,NN,O
,",",",",O
,naming,NN,O
,",",",",O
,and,CC,O
,other,JJ,O
,tasks,NNS,O
,commensurate,VBP,O
,with,IN,O
,clinical,JJ,O
,recovery,NN,O
,in,IN,O
,his,PRP$,O
,intellectual,JJ,O
,capacity,NN,O
,.,.,O
,Possible,JJ,O
,pathophysiological,JJ,O
,mechanisms,NNS,O
,which,WDT,O
,may,MD,O
,have,VB,O
,been,VBN,O
,operative,JJ,O
,in,IN,O
,this,DT,O
,case,NN,O
,include,VBP,O
,:,:,O
,a,DT,O
,direct,JJ,O
,central,JJ,O
,nervous,JJ,O
,system,NN,O
,(,(,O
,CNS,NNP,O
,),),O
,toxic,VBP,O
,effect,NN,O
,of,IN,O
,valproic,NN,O
,acid,NN,O
,;,:,O
,a,DT,O
,paradoxical,JJ,O
,epileptogenic,JJ,O
,effect,NN,O
,secondary,JJ,O
,to,TO,O
,the,DT,O
,drug,NN,O
,;,:,O
,and,CC,O
,an,DT,O
,indirect,JJ,O
,CNS,NNP,O
,toxic,NN,O
,effect,NN,O
,mediated,VBD,O
,through,IN,O
,valproic,NN,O
,acid,SYM,O
,-,:,O
,induced,JJ,O
,hyperammonemia,NN,B-DISEASE
,.,.,O
,Reversal,NNP,O
,of,IN,O
,scopolamine,JJ,O
,-,:,O
,induced,JJ,O
,amnesia,NN,B-DISEASE
,of,IN,O
,passive,JJ,O
,avoidance,NN,O
,by,IN,O
,pre,JJ,O
,-,:,O
,and,CC,O
,post,VB,O
,-,:,O
,training,NN,O
,naloxone,NN,O
,.,.,O
,In,IN,O
,a,DT,O
,series,NN,O
,of,IN,O
,five,CD,O
,experiments,NNS,O
,",",",",O
,the,DT,O
,modulating,VBG,O
,role,NN,O
,of,IN,O
,naloxone,NN,O
,on,IN,O
,a,DT,O
,scopolamine,JJ,O
,-,:,O
,induced,JJ,O
,retention,NN,B-DISEASE
,deficit,NN,I-DISEASE
,in,IN,O
,a,DT,O
,passive,JJ,O
,avoidance,NN,O
,paradigm,NN,O
,was,VBD,O
,investigated,VBN,O
,in,IN,O
,mice,NN,O
,.,.,O
,Scopolamine,NNP,O
,",",",",O
,but,CC,O
,not,RB,O
,methyl,JJ,O
,scopolamine,NN,O
,(,(,O
,1,CD,O
,and,CC,O
,3,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,",",",",O
,induced,VBD,O
,an,DT,O
,amnesia,NN,B-DISEASE
,as,IN,O
,measured,VBN,O
,by,IN,O
,latency,NN,O
,and,CC,O
,duration,NN,O
,parameters,NNS,O
,.,.,O
,Naloxone,NNP,O
,(,(,O
,0,CD,O
,.,.,O
,3,CD,O
,",",",",O
,1,CD,O
,",",",",O
,3,CD,O
,",",",",O
,and,CC,O
,10,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,injected,VBD,O
,prior,JJ,O
,to,TO,O
,training,VBG,O
,attenuated,VBN,O
,the,DT,O
,retention,NN,B-DISEASE
,deficit,NN,I-DISEASE
,with,IN,O
,a,DT,O
,peak,NN,O
,of,IN,O
,activity,NN,O
,at,IN,O
,3,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,.,.,O
,The,DT,O
,effect,NN,O
,of,IN,O
,naloxone,NN,O
,could,MD,O
,be,VB,O
,antagonized,VBN,O
,with,IN,O
,morphine,NN,O
,(,(,O
,1,CD,O
,",",",",O
,3,CD,O
,",",",",O
,and,CC,O
,10,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,",",",",O
,demonstrating,VBG,O
,the,DT,O
,opioid,JJ,O
,specificity,NN,O
,of,IN,O
,the,DT,O
,naloxone,JJ,O
,effect,NN,O
,.,.,O
,Post,NNP,O
,-,:,O
,training,NN,O
,administration,NN,O
,of,IN,O
,naloxone,NN,O
,(,(,O
,3,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,as,IN,O
,a,DT,O
,single,JJ,O
,or,CC,O
,as,IN,O
,a,DT,O
,split,NN,O
,dose,NN,O
,also,RB,O
,attenuated,VBD,O
,the,DT,O
,scopolamine,NN,O
,-,:,O
,induced,JJ,O
,amnesia,NN,B-DISEASE
,.,.,O
,Control,NNP,O
,experiments,VBZ,O
,indicated,VBD,O
,that,IN,O
,neither,DT,O
,an,DT,O
,increase,NN,O
,in,IN,O
,pain,JJ,B-DISEASE
,sensitivity,NN,O
,(,(,O
,pre,JJ,O
,-,:,O
,training,VBG,O
,naloxone,NN,O
,),),O
,nor,CC,O
,an,DT,O
,induced,JJ,O
,aversive,JJ,O
,state,NN,O
,(,(,O
,post,NN,O
,-,:,O
,training,NN,O
,naloxone,NN,O
,),),O
,appear,VBP,O
,to,TO,O
,be,VB,O
,responsible,JJ,O
,for,IN,O
,the,DT,O
,influence,NN,O
,of,IN,O
,naloxone,NN,O
,on,IN,O
,the,DT,O
,scopolamine,NN,O
,-,:,O
,induced,JJ,O
,retention,NN,B-DISEASE
,deficit,NN,I-DISEASE
,.,.,O
,These,DT,O
,results,NNS,O
,extend,VBP,O
,previous,JJ,O
,findings,NNS,O
,implicating,VBG,O
,a,DT,O
,cholinergic,JJ,O
,-,:,O
,opioid,JJ,O
,interaction,NN,O
,in,IN,O
,memory,NN,O
,processes,NNS,O
,.,.,O
,A,DT,O
,possible,JJ,O
,mechanism,NN,O
,for,IN,O
,this,DT,O
,interaction,NN,O
,involving,VBG,O
,the,DT,O
,septo,NN,O
,-,:,O
,hippocampal,JJ,O
,cholinergic,JJ,O
,pathway,NN,O
,is,VBZ,O
,discussed,VBN,O
,.,.,O
,Electron,NNP,O
,microscopic,JJ,O
,investigations,NNS,O
,of,IN,O
,the,DT,O
,cyclophosphamide,NN,O
,-,:,O
,induced,JJ,O
,lesions,NNS,B-DISEASE
,of,IN,I-DISEASE
,the,DT,I-DISEASE
,urinary,JJ,I-DISEASE
,bladder,NN,I-DISEASE
,of,IN,O
,the,DT,O
,rat,NN,O
,and,CC,O
,their,PRP$,O
,prevention,NN,O
,by,IN,O
,mesna,NN,O
,.,.,O
,Fully,NNP,O
,developed,VBD,O
,cyclophosphamide,VB,O
,-,:,O
,induced,JJ,O
,cystitis,NN,B-DISEASE
,is,VBZ,O
,characterized,VBN,O
,by,IN,O
,nearly,RB,O
,complete,JJ,O
,detachment,NN,O
,of,IN,O
,the,DT,O
,urothelium,NN,O
,",",",",O
,severe,JJ,O
,submucosal,NN,O
,edema,NN,B-DISEASE
,owing,VBG,O
,to,TO,O
,damage,VB,O
,to,TO,O
,the,DT,O
,microvascular,JJ,O
,bed,NN,O
,and,CC,O
,focal,JJ,O
,muscle,NN,O
,necroses,NNS,B-DISEASE
,.,.,O
,The,DT,O
,initial,JJ,O
,response,NN,O
,to,TO,O
,the,DT,O
,primary,JJ,O
,attack,NN,O
,by,IN,O
,the,DT,O
,cyclophosphamide,NN,O
,metabolites,VBZ,O
,seems,VBZ,O
,to,TO,O
,be,VB,O
,fragmentation,NN,O
,of,IN,O
,the,DT,O
,luminal,JJ,O
,membrane,NN,O
,.,.,O
,This,DT,O
,damages,NNS,O
,the,DT,O
,cellular,JJ,O
,barrier,NN,O
,against,IN,O
,the,DT,O
,hypertonic,JJ,O
,urine,NN,O
,.,.,O
,Subsequent,JJ,O
,breaks,NN,O
,in,IN,O
,the,DT,O
,lateral,JJ,O
,cell,NN,O
,membranes,NNS,O
,of,IN,O
,the,DT,O
,superficial,JJ,O
,cells,NNS,O
,and,CC,O
,in,IN,O
,all,PDT,O
,the,DT,O
,plasma,JJ,O
,membranes,NNS,O
,of,IN,O
,the,DT,O
,intermediate,JJ,O
,and,CC,O
,basal,JJ,O
,cells,NNS,O
,",",",",O
,intercellular,JJ,O
,and,CC,O
,intracellular,JJ,O
,edema,NN,B-DISEASE
,and,CC,O
,disintegration,NN,O
,of,IN,O
,the,DT,O
,desmosomes,NNS,O
,and,CC,O
,hemidesmosomes,NNS,O
,lead,VBP,O
,to,TO,O
,progressive,JJ,O
,degeneration,NN,O
,and,CC,O
,detachment,NN,O
,of,IN,O
,the,DT,O
,epithelial,JJ,O
,cells,NNS,O
,with,IN,O
,exposure,NN,O
,and,CC,O
,splitting,NN,O
,of,IN,O
,the,DT,O
,basal,NN,O
,membrane,NN,O
,.,.,O
,The,DT,O
,morphological,JJ,O
,changes,NNS,O
,of,IN,O
,the,DT,O
,endothelial,JJ,O
,cells,NNS,O
,",",",",O
,which,WDT,O
,become,VBP,O
,more,RBR,O
,pronounced,JJ,O
,in,IN,O
,the,DT,O
,later,JJ,O
,stages,NNS,O
,of,IN,O
,the,DT,O
,experiment,NN,O
,",",",",O
,the,DT,O
,involvement,NN,O
,of,IN,O
,blood,NN,O
,vessels,NNS,O
,regardless,RB,O
,of,IN,O
,their,PRP$,O
,diameter,NN,O
,and,CC,O
,the,DT,O
,location,NN,O
,-,:,O
,dependent,JJ,O
,extent,NN,O
,of,IN,O
,the,DT,O
,damage,NN,O
,indicate,VBP,O
,a,DT,O
,direct,JJ,O
,type,NN,O
,of,IN,O
,damage,NN,O
,which,WDT,O
,is,VBZ,O
,preceded,VBN,O
,by,IN,O
,a,DT,O
,mediator,NN,O
,-,:,O
,induced,JJ,O
,increase,NN,O
,in,IN,O
,permeability,NN,O
,",",",",O
,the,DT,O
,morphological,JJ,O
,correlate,NN,O
,of,IN,O
,which,WDT,O
,is,VBZ,O
,the,DT,O
,formation,NN,O
,of,IN,O
,gaps,NNS,O
,in,IN,O
,the,DT,O
,interendothelial,JJ,O
,cell,NN,O
,connections,NNS,O
,on,IN,O
,the,DT,O
,venules,NNS,O
,.,.,O
,These,DT,O
,changes,NNS,O
,can,MD,O
,be,VB,O
,effectively,RB,O
,prevented,VBN,O
,by,IN,O
,mesna,NN,O
,.,.,O
,The,DT,O
,only,JJ,O
,sign,NN,O
,of,IN,O
,a,DT,O
,possible,JJ,O
,involvement,NN,O
,is,VBZ,O
,the,DT,O
,increase,NN,O
,in,IN,O
,the,DT,O
,number,NN,O
,of,IN,O
,specific,JJ,O
,granules,NNS,O
,with,IN,O
,a,DT,O
,presumed,JJ,O
,lysosomal,JJ,O
,function,NN,O
,in,IN,O
,the,DT,O
,superficial,JJ,O
,cells,NNS,O
,.,.,O
,Increase,NNP,O
,in,IN,O
,intragastric,JJ,O
,pressure,NN,O
,during,IN,O
,suxamethonium,NN,O
,-,:,O
,induced,JJ,O
,muscle,NN,B-DISEASE
,fasciculations,NNS,I-DISEASE
,in,IN,O
,children,NNS,O
,:,:,O
,inhibition,NN,O
,by,IN,O
,alfentanil,NN,O
,.,.,O
,Changes,NNS,O
,in,IN,O
,intragastric,JJ,O
,pressure,NN,O
,after,IN,O
,the,DT,O
,administration,NN,O
,of,IN,O
,suxamethonium,NN,O
,1,CD,O
,.,.,O
,5,CD,O
,mg,NN,O
,kg,SYM,O
,-,:,O
,1,CD,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,were,VBD,O
,studied,VBN,O
,in,IN,O
,32,CD,O
,children,NNS,O
,(,(,O
,mean,JJ,O
,age,NN,O
,6,CD,O
,.,.,O
,9,CD,O
,yr,NN,O
,),),O
,pretreated,VBD,O
,with,IN,O
,either,DT,O
,physiological,JJ,O
,saline,NN,O
,or,CC,O
,alfentanil,VB,O
,50,CD,O
,micrograms,NNS,O
,kg,VBD,O
,-,:,O
,1,CD,O
,.,.,O
,Anaesthesia,NNP,O
,was,VBD,O
,induced,VBN,O
,with,IN,O
,thiopentone,NN,O
,5,CD,O
,mg,NN,O
,kg,SYM,O
,-,:,O
,1,CD,O
,.,.,O
,The,DT,O
,incidence,NN,O
,and,CC,O
,intensity,NN,O
,of,IN,O
,muscle,NN,B-DISEASE
,fasciculations,NNS,I-DISEASE
,caused,VBN,O
,by,IN,O
,suxamethonium,NN,O
,were,VBD,O
,significantly,RB,O
,greater,JJR,O
,in,IN,O
,the,DT,O
,control,NN,O
,than,IN,O
,in,IN,O
,the,DT,O
,alfentanil,NN,O
,group,NN,O
,.,.,O
,The,DT,O
,intragastric,JJ,O
,pressure,NN,O
,during,IN,O
,muscle,NN,B-DISEASE
,fasciculations,NNS,I-DISEASE
,was,VBD,O
,significantly,RB,O
,higher,JJR,O
,in,IN,O
,the,DT,O
,control,NN,O
,group,NN,O
,(,(,O
,16,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,7,CD,O
,(,(,O
,SEM,NNP,O
,),),O
,cm,VBP,O
,H2O,NNP,O
,),),O
,than,IN,O
,in,IN,O
,the,DT,O
,alfentanil,NN,O
,group,NN,O
,(,(,O
,7,CD,O
,.,.,O
,7,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,5,CD,O
,(,(,O
,SEM,NNP,O
,),),O
,cm,VBP,O
,H2O,NNP,O
,),),O
,.,.,O
,The,DT,O
,increase,NN,O
,in,IN,O
,intragastric,JJ,O
,pressure,NN,O
,was,VBD,O
,directly,RB,O
,related,VBN,O
,to,TO,O
,the,DT,O
,intensity,NN,O
,of,IN,O
,muscle,NN,B-DISEASE
,fasciculations,NNS,I-DISEASE
,(,(,O
,regression,NN,O
,line,NN,O
,:,:,O
,y,NN,O
,=,VBZ,O
,0,CD,O
,.,.,O
,5,CD,O
,+,JJ,O
,4,CD,O
,.,.,O
,78x,CD,O
,with,IN,O
,r,NN,O
,of,IN,O
,0,CD,O
,.,.,O
,78,CD,O
,),),O
,.,.,O
,It,PRP,O
,is,VBZ,O
,concluded,VBN,O
,that,IN,O
,intragastric,JJ,O
,pressure,NN,O
,increases,VBZ,O
,significantly,RB,O
,during,IN,O
,muscle,NN,B-DISEASE
,fasciculations,NNS,I-DISEASE
,caused,VBN,O
,by,IN,O
,suxamethonium,NN,O
,in,IN,O
,healthy,JJ,O
,children,NNS,O
,.,.,O
,Alfentanil,$,O
,50,CD,O
,micrograms,NNS,O
,kg,VBD,O
,-,:,O
,1,CD,O
,effectively,RB,O
,inhibits,VBZ,O
,the,DT,O
,incidence,NN,O
,and,CC,O
,intensity,NN,O
,of,IN,O
,suxamethonium,NN,O
,-,:,O
,induced,JJ,O
,muscle,NN,B-DISEASE
,fasciculations,NNS,I-DISEASE
,;,:,O
,moreover,RB,O
,",",",",O
,intragastric,JJ,O
,pressure,NN,O
,remains,VBZ,O
,at,IN,O
,its,PRP$,O
,control,NN,O
,value,NN,O
,.,.,O
,Acute,NNP,O
,insulin,NN,O
,treatment,NN,O
,normalizes,VBZ,O
,the,DT,O
,resistance,NN,O
,to,TO,O
,the,DT,O
,cardiotoxic,JJ,B-DISEASE
,effect,NN,O
,of,IN,O
,isoproterenol,NN,O
,in,IN,O
,streptozotocin,JJ,O
,diabetic,JJ,B-DISEASE
,rats,NNS,O
,.,.,O
,A,DT,O
,morphometric,JJ,O
,study,NN,O
,of,IN,O
,isoproterenol,NN,O
,induced,VBN,O
,myocardial,JJ,O
,fibrosis,NN,B-DISEASE
,.,.,O
,The,DT,O
,acute,JJ,O
,effect,NN,O
,of,IN,O
,insulin,NN,O
,treatment,NN,O
,on,IN,O
,the,DT,O
,earlier,JJR,O
,reported,VBD,O
,protective,JJ,O
,effect,NN,O
,of,IN,O
,streptozotocin,NN,O
,diabetes,NNS,B-DISEASE
,against,IN,O
,the,DT,O
,cardiotoxic,JJ,B-DISEASE
,effect,NN,O
,of,IN,O
,high,JJ,O
,doses,NNS,O
,of,IN,O
,isoproterenol,NN,O
,(,(,O
,ISO,NNP,O
,),),O
,was,VBD,O
,investigated,VBN,O
,in,IN,O
,rats,NNS,O
,.,.,O
,Thirty,NNP,O
,to,TO,O
,135,CD,O
,min,NN,O
,after,IN,O
,the,DT,O
,injection,NN,O
,of,IN,O
,crystalline,NN,O
,insulin,NN,O
,",",",",O
,ISO,NNP,O
,was,VBD,O
,given,VBN,O
,subcutaneously,RB,O
,and,CC,O
,when,WRB,O
,ISO,NNP,O
,induced,VBD,O
,fibrosis,NN,B-DISEASE
,in,IN,O
,the,DT,O
,myocardium,NN,O
,was,VBD,O
,morphometrically,RB,O
,analyzed,JJ,O
,7,CD,O
,days,NNS,O
,later,RB,O
,",",",",O
,a,DT,O
,highly,RB,O
,significant,JJ,O
,correlation,NN,O
,(,(,O
,r,JJ,O
,=,NN,O
,0,CD,O
,.,.,O
,83,CD,O
,",",",",O
,2,CD,O
,p,NN,O
,=,VBD,O
,0,CD,O
,.,.,O
,006,CD,O
,),),O
,to,TO,O
,the,DT,O
,slope,NN,O
,of,IN,O
,the,DT,O
,fall,NN,O
,in,IN,O
,blood,NN,O
,glucose,NN,O
,after,IN,O
,insulin,JJ,O
,treatment,NN,O
,appeared,VBD,O
,.,.,O
,The,DT,O
,myocardial,JJ,O
,content,NN,O
,of,IN,O
,catecholamines,NNS,O
,was,VBD,O
,estimated,VBN,O
,in,IN,O
,these,DT,O
,8,CD,O
,day,NN,O
,diabetic,JJ,B-DISEASE
,rats,NNS,O
,.,.,O
,The,DT,O
,norepinephrine,JJ,O
,content,NN,O
,was,VBD,O
,significantly,RB,O
,increased,VBN,O
,while,IN,O
,epinephrine,NN,O
,remained,VBD,O
,unchanged,JJ,O
,.,.,O
,An,DT,O
,enhanced,JJ,O
,sympathetic,JJ,O
,nervous,JJ,O
,system,NN,O
,activity,NN,O
,with,IN,O
,a,DT,O
,consequent,JJ,O
,down,RP,O
,regulation,NN,O
,of,IN,O
,the,DT,O
,myocardial,JJ,O
,beta,NN,O
,-,:,O
,adrenergic,JJ,O
,receptors,NNS,O
,could,MD,O
,",",",",O
,therefore,RB,O
,",",",",O
,explain,VB,O
,this,DT,O
,catecholamine,NN,O
,resistance,NN,O
,.,.,O
,The,DT,O
,rapid,JJ,O
,reversion,NN,O
,after,IN,O
,insulin,NN,O
,treatment,NN,O
,excludes,VBZ,O
,the,DT,O
,possibility,NN,O
,that,WDT,O
,streptozotocin,NN,O
,in,IN,O
,itself,PRP,O
,causes,VBZ,O
,the,DT,O
,ISO,NNP,O
,resistance,NN,O
,and,CC,O
,points,NNS,O
,towards,IN,O
,a,DT,O
,direct,JJ,O
,insulin,NN,O
,effect,NN,O
,on,IN,O
,myocardial,JJ,O
,catecholamine,NN,O
,sensitivity,NN,O
,in,IN,O
,diabetic,JJ,B-DISEASE
,rats,NNS,O
,.,.,O
,The,DT,O
,phenomenon,NN,O
,described,VBD,O
,might,MD,O
,elucidate,VB,O
,pathogenetic,JJ,O
,mechanisms,NNS,O
,behind,IN,O
,toxic,JJ,O
,myocardial,JJ,O
,cell,NN,O
,degeneration,NN,O
,and,CC,O
,may,MD,O
,possibly,RB,O
,have,VB,O
,relevance,NN,O
,for,IN,O
,acute,JJ,O
,cardiovascular,JJ,O
,complications,NNS,O
,in,IN,O
,diabetic,JJ,B-DISEASE
,patients,NNS,O
,.,.,O
,Differential,JJ,O
,effects,NNS,O
,of,IN,O
,non,JJ,O
,-,:,O
,steroidal,NN,O
,anti,SYM,O
,-,:,O
,inflammatory,NN,O
,drugs,NNS,O
,on,IN,O
,seizures,NNS,B-DISEASE
,produced,VBN,O
,by,IN,O
,pilocarpine,NN,O
,in,IN,O
,rats,NNS,O
,.,.,O
,The,DT,O
,muscarinic,JJ,O
,cholinergic,NN,O
,agonist,NN,O
,pilocarpine,NN,O
,induces,NNS,O
,in,IN,O
,rats,NNS,O
,seizures,NNS,B-DISEASE
,and,CC,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,followed,VBN,O
,by,IN,O
,widespread,JJ,O
,damage,NN,O
,to,TO,O
,the,DT,O
,forebrain,NN,O
,.,.,O
,The,DT,O
,present,JJ,O
,study,NN,O
,was,VBD,O
,designed,VBN,O
,to,TO,O
,investigate,VB,O
,the,DT,O
,effect,NN,O
,of,IN,O
,5,CD,O
,non,JJ,O
,-,:,O
,steroidal,NN,O
,anti,SYM,O
,-,:,O
,inflammatory,NN,O
,drugs,NNS,O
,",",",",O
,sodium,NN,O
,salicylate,NN,O
,",",",",O
,phenylbutazone,NN,O
,",",",",O
,indomethacin,NN,O
,",",",",O
,ibuprofen,NN,O
,and,CC,O
,mefenamic,JJ,O
,acid,NN,O
,",",",",O
,on,IN,O
,seizures,NNS,B-DISEASE
,produced,VBN,O
,by,IN,O
,pilocarpine,NN,O
,.,.,O
,Pretreatment,NN,O
,of,IN,O
,rats,NNS,O
,with,IN,O
,sodium,NN,O
,salicylate,NN,O
,",",",",O
,ED50,NNP,O
,103,CD,O
,mg,NN,O
,/,NN,O
,kg,NN,O
,(,(,O
,60,CD,O
,-,:,O
,174,CD,O
,),),O
,",",",",O
,and,CC,O
,phenylbutazone,NN,O
,",",",",O
,59,CD,O
,mg,NN,O
,/,NN,O
,kg,NN,O
,(,(,O
,50,CD,O
,-,:,O
,70,CD,O
,),),O
,converted,VBD,O
,the,DT,O
,non,JJ,O
,-,:,O
,convulsant,NN,O
,dose,NN,O
,of,IN,O
,pilocarpine,NN,O
,",",",",O
,200,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,to,TO,O
,a,DT,O
,convulsant,JJ,O
,one,NN,O
,.,.,O
,Indomethacin,NNP,O
,",",",",O
,1,CD,O
,-,:,O
,10,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,and,CC,O
,ibuprofen,NN,O
,",",",",O
,10,CD,O
,-,:,O
,100,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,failed,VBD,O
,to,TO,O
,modulate,VB,O
,seizures,NNS,B-DISEASE
,produced,VBN,O
,by,IN,O
,pilocarpine,NN,O
,.,.,O
,Mefenamic,NNP,O
,acid,NN,O
,",",",",O
,26,CD,O
,(,(,O
,22,CD,O
,-,:,O
,30,CD,O
,),),O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,prevented,VBN,O
,seizures,NNS,B-DISEASE
,and,CC,O
,protected,VBD,O
,rats,NNS,O
,from,IN,O
,seizure,NN,B-DISEASE
,-,:,O
,related,JJ,O
,brain,NN,B-DISEASE
,damage,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,pilocarpine,NN,O
,",",",",O
,380,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,.,.,O
,These,DT,O
,results,NNS,O
,indicate,VBP,O
,that,IN,O
,non,SYM,O
,-,:,O
,steroidal,NN,O
,anti,SYM,O
,-,:,O
,inflammatory,NN,O
,drugs,NNS,O
,differentially,RB,O
,modulate,VBP,O
,the,DT,O
,threshold,NN,O
,for,IN,O
,pilocarpine,JJ,O
,-,:,O
,induced,JJ,O
,seizures,NNS,B-DISEASE
,.,.,O
,Acute,NNP,B-DISEASE
,neurologic,JJ,I-DISEASE
,dysfunction,NN,I-DISEASE
,after,IN,O
,high,JJ,O
,-,:,O
,dose,JJ,O
,etoposide,JJ,O
,therapy,NN,O
,for,IN,O
,malignant,JJ,B-DISEASE
,glioma,NN,I-DISEASE
,.,.,O
,Etoposide,NNP,O
,(,(,O
,VP,NNP,O
,-,:,O
,16,CD,O
,-,:,O
,213,CD,O
,),),O
,has,VBZ,O
,been,VBN,O
,used,VBN,O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,many,JJ,O
,solid,JJ,O
,tumors,NNS,B-DISEASE
,and,CC,O
,hematologic,JJ,B-DISEASE
,malignancies,NNS,I-DISEASE
,.,.,O
,When,WRB,O
,used,VBN,O
,in,IN,O
,high,JJ,O
,doses,NNS,O
,and,CC,O
,in,IN,O
,conjunction,NN,O
,with,IN,O
,autologous,JJ,O
,bone,NN,O
,marrow,NN,O
,transplantation,NN,O
,",",",",O
,this,DT,O
,agent,NN,O
,has,VBZ,O
,activity,NN,O
,against,IN,O
,several,JJ,O
,treatment,NN,O
,-,:,O
,resistant,NN,O
,cancers,NNS,B-DISEASE
,including,VBG,O
,malignant,JJ,B-DISEASE
,glioma,NN,I-DISEASE
,.,.,O
,In,IN,O
,six,CD,O
,of,IN,O
,eight,CD,O
,patients,NNS,O
,(,(,O
,75,CD,O
,%,NN,O
,),),O
,who,WP,O
,we,PRP,O
,treated,VBD,O
,for,IN,O
,recurrent,NN,O
,or,CC,O
,resistant,JJ,O
,glioma,NN,B-DISEASE
,",",",",O
,sudden,JJ,O
,severe,JJ,O
,neurologic,JJ,B-DISEASE
,deterioration,NN,I-DISEASE
,occurred,VBD,O
,.,.,O
,This,DT,O
,developed,VBD,O
,a,DT,O
,median,NN,O
,of,IN,O
,9,CD,O
,days,NNS,O
,after,IN,O
,initiation,NN,O
,of,IN,O
,high,JJ,O
,-,:,O
,dose,JJ,O
,etoposide,JJ,O
,therapy,NN,O
,.,.,O
,Significant,NNP,O
,clinical,JJ,O
,manifestations,NNS,O
,have,VBP,O
,included,VBN,O
,confusion,NN,B-DISEASE
,",",",",O
,papilledema,NN,B-DISEASE
,",",",",O
,somnolence,NN,B-DISEASE
,",",",",O
,exacerbation,NN,O
,of,IN,O
,motor,NN,B-DISEASE
,deficits,NNS,I-DISEASE
,",",",",O
,and,CC,O
,sharp,JJ,O
,increase,NN,O
,in,IN,O
,seizure,NN,B-DISEASE
,activity,NN,O
,.,.,O
,These,DT,O
,abnormalities,NNS,O
,resolved,VBD,O
,rapidly,RB,O
,after,IN,O
,initiation,NN,O
,of,IN,O
,high,JJ,O
,-,:,O
,dose,RB,O
,intravenous,JJ,O
,dexamethasone,NN,O
,therapy,NN,O
,.,.,O
,In,IN,O
,all,DT,O
,patients,NNS,O
,",",",",O
,computerized,VBN,O
,tomographic,NN,O
,(,(,O
,CT,NNP,O
,),),O
,brain,NN,O
,scans,NNS,O
,demonstrated,VBD,O
,stability,NN,O
,in,IN,O
,tumor,NN,B-DISEASE
,size,NN,O
,and,CC,O
,peritumor,NN,O
,edema,NN,B-DISEASE
,when,WRB,O
,compared,VBN,O
,with,IN,O
,pretransplant,JJ,O
,scans,NNS,O
,.,.,O
,This,DT,O
,complication,NN,O
,appears,VBZ,O
,to,TO,O
,represent,VB,O
,a,DT,O
,significant,JJ,O
,new,JJ,O
,toxicity,NN,B-DISEASE
,of,IN,O
,high,JJ,O
,-,:,O
,dose,JJ,O
,etoposide,JJ,O
,therapy,NN,O
,for,IN,O
,malignant,JJ,B-DISEASE
,glioma,NN,I-DISEASE
,.,.,O
,Progressive,NNP,O
,bile,IN,B-DISEASE
,duct,NN,I-DISEASE
,injury,NN,I-DISEASE
,after,IN,O
,thiabendazole,JJ,O
,administration,NN,O
,.,.,O
,A,DT,O
,27,CD,O
,-,:,O
,yr,NN,O
,-,:,O
,old,JJ,O
,man,NN,O
,developed,VBD,O
,jaundice,NN,B-DISEASE
,2,CD,O
,wk,NN,O
,after,IN,O
,exposure,NN,O
,to,TO,O
,thiabendazole,VB,O
,.,.,O
,Cholestasis,NNP,B-DISEASE
,persisted,VBD,O
,for,IN,O
,3,CD,O
,yr,NN,O
,",",",",O
,at,IN,O
,which,WDT,O
,time,NN,O
,a,DT,O
,liver,NN,O
,transplant,NN,O
,was,VBD,O
,performed,VBN,O
,.,.,O
,Two,CD,O
,liver,JJ,O
,biopsy,NN,O
,specimens,NNS,O
,and,CC,O
,the,DT,O
,hepatectomy,JJ,O
,specimen,NNS,O
,were,VBD,O
,remarkable,JJ,O
,for,IN,O
,almost,RB,O
,complete,JJ,O
,disappearance,NN,O
,of,IN,O
,interlobular,JJ,O
,bile,NN,O
,ducts,NNS,O
,.,.,O
,Prominent,JJ,O
,fibrosis,NN,B-DISEASE
,and,CC,O
,hepatocellular,JJ,O
,regeneration,NN,O
,were,VBD,O
,also,RB,O
,present,JJ,O
,;,:,O
,however,RB,O
,",",",",O
,the,DT,O
,lobular,JJ,O
,architecture,NN,O
,was,VBD,O
,preserved,VBN,O
,.,.,O
,This,DT,O
,case,NN,O
,represents,VBZ,O
,an,DT,O
,example,NN,O
,of,IN,O
,"""",NNP,O
,idiosyncratic,JJ,O
,"""",NNP,O
,drug,NN,B-DISEASE
,-,:,I-DISEASE
,induced,VBN,I-DISEASE
,liver,JJ,I-DISEASE
,damage,NN,I-DISEASE
,in,IN,O
,which,WDT,O
,the,DT,O
,primary,JJ,O
,target,NN,O
,of,IN,O
,injury,NN,O
,is,VBZ,O
,the,DT,O
,bile,JJ,O
,duct,NN,O
,.,.,O
,An,DT,O
,autoimmune,JJ,O
,pathogenesis,NN,O
,of,IN,O
,the,DT,O
,bile,JJ,B-DISEASE
,duct,NN,I-DISEASE
,destruction,NN,I-DISEASE
,is,VBZ,O
,suggested,VBN,O
,.,.,O
,Differential,JJ,O
,effects,NNS,O
,of,IN,O
,1,CD,O
,",",",",O
,4,CD,O
,-,:,O
,dihydropyridine,NN,O
,calcium,NN,O
,channel,NN,O
,blockers,NNS,O
,:,:,O
,therapeutic,JJ,O
,implications,NNS,O
,.,.,O
,Increasing,VBG,O
,recognition,NN,O
,of,IN,O
,the,DT,O
,importance,NN,O
,of,IN,O
,calcium,NN,O
,in,IN,O
,the,DT,O
,pathogenesis,NN,O
,of,IN,O
,cardiovascular,JJ,B-DISEASE
,disease,NN,I-DISEASE
,has,VBZ,O
,stimulated,VBN,O
,research,NN,O
,into,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,calcium,NN,O
,channel,NNS,O
,blocking,VBG,O
,agents,NNS,O
,for,IN,O
,treatment,NN,O
,of,IN,O
,a,DT,O
,variety,NN,O
,of,IN,O
,cardiovascular,JJ,B-DISEASE
,diseases,NNS,I-DISEASE
,.,.,O
,The,DT,O
,favorable,JJ,O
,efficacy,NN,O
,and,CC,O
,tolerability,NN,O
,profiles,NNS,O
,of,IN,O
,these,DT,O
,agents,NNS,O
,make,VBP,O
,them,PRP,O
,attractive,JJ,O
,therapeutic,JJ,O
,modalities,NNS,O
,.,.,O
,Clinical,JJ,O
,applications,NNS,O
,of,IN,O
,calcium,NN,O
,channel,NN,O
,blockers,NNS,O
,parallel,VBP,O
,their,PRP$,O
,tissue,NN,O
,selectivity,NN,O
,.,.,O
,In,IN,O
,contrast,NN,O
,to,TO,O
,verapamil,VB,O
,and,CC,O
,diltiazem,VB,O
,",",",",O
,which,WDT,O
,are,VBP,O
,roughly,RB,O
,equipotent,JJ,O
,in,IN,O
,their,PRP$,O
,actions,NNS,O
,on,IN,O
,the,DT,O
,heart,NN,O
,and,CC,O
,vascular,JJ,O
,smooth,JJ,O
,muscle,NN,O
,",",",",O
,the,DT,O
,dihydropyridine,NN,O
,calcium,NN,O
,channel,NN,O
,blockers,NNS,O
,are,VBP,O
,a,DT,O
,group,NN,O
,of,IN,O
,potent,JJ,O
,peripheral,JJ,O
,vasodilator,NN,O
,agents,NNS,O
,that,WDT,O
,exert,VBP,O
,minimal,JJ,O
,electrophysiologic,JJ,O
,effects,NNS,O
,on,IN,O
,cardiac,JJ,O
,nodal,NN,O
,or,CC,O
,conduction,NN,O
,tissue,NN,O
,.,.,O
,As,IN,O
,the,DT,O
,first,JJ,O
,dihydropyridine,NN,O
,available,JJ,O
,for,IN,O
,use,NN,O
,in,IN,O
,the,DT,O
,United,NNP,O
,States,NNPS,O
,",",",",O
,nifedipine,NN,O
,controls,NNS,O
,angina,RB,B-DISEASE
,and,CC,O
,hypertension,NN,B-DISEASE
,with,IN,O
,minimal,JJ,O
,depression,NN,O
,of,IN,O
,cardiac,JJ,O
,function,NN,O
,.,.,O
,Additional,JJ,O
,members,NNS,O
,of,IN,O
,this,DT,O
,group,NN,O
,of,IN,O
,calcium,NN,O
,channel,NN,O
,blockers,NNS,O
,have,VBP,O
,been,VBN,O
,studied,VBN,O
,for,IN,O
,a,DT,O
,variety,NN,O
,of,IN,O
,indications,NNS,O
,for,IN,O
,which,WDT,O
,they,PRP,O
,may,MD,O
,offer,VB,O
,advantages,NNS,O
,over,IN,O
,current,JJ,O
,therapy,NN,O
,.,.,O
,Once,RB,O
,or,CC,O
,twice,RB,O
,daily,JJ,O
,dosage,NN,O
,possible,JJ,O
,with,IN,O
,nitrendipine,JJ,O
,and,CC,O
,nisoldipine,JJ,O
,offers,NNS,O
,a,DT,O
,convenient,JJ,O
,administration,NN,O
,schedule,NN,O
,",",",",O
,which,WDT,O
,encourages,VBZ,O
,patient,NN,O
,compliance,NN,O
,in,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,therapy,NN,O
,of,IN,O
,hypertension,NN,B-DISEASE
,.,.,O
,The,DT,O
,coronary,JJ,O
,vasodilating,NN,O
,properties,NNS,O
,of,IN,O
,nisoldipine,NN,O
,have,VBP,O
,led,VBN,O
,to,TO,O
,the,DT,O
,investigation,NN,O
,of,IN,O
,this,DT,O
,agent,NN,O
,for,IN,O
,use,NN,O
,in,IN,O
,angina,NN,B-DISEASE
,.,.,O
,Selectivity,NN,O
,for,IN,O
,the,DT,O
,cerebrovascular,JJ,O
,bed,NN,O
,makes,VBZ,O
,nimodipine,JJ,O
,potentially,RB,O
,useful,JJ,O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,subarachnoid,JJ,B-DISEASE
,hemorrhage,NN,I-DISEASE
,",",",",O
,migraine,NN,B-DISEASE
,headache,NN,I-DISEASE
,",",",",O
,dementia,NN,B-DISEASE
,",",",",O
,and,CC,O
,stroke,NN,B-DISEASE
,.,.,O
,In,IN,O
,general,JJ,O
,",",",",O
,the,DT,O
,dihydropyridine,NN,O
,calcium,NN,O
,channel,NN,O
,blockers,NNS,O
,are,VBP,O
,usually,RB,O
,well,RB,O
,tolerated,VBN,O
,",",",",O
,with,IN,O
,headache,NN,B-DISEASE
,",",",",O
,facial,JJ,O
,flushing,NN,B-DISEASE
,",",",",O
,palpitations,NNS,B-DISEASE
,",",",",O
,edema,NN,B-DISEASE
,",",",",O
,nausea,NN,B-DISEASE
,",",",",O
,anorexia,NN,B-DISEASE
,",",",",O
,and,CC,O
,dizziness,NN,B-DISEASE
,being,VBG,O
,the,DT,O
,more,RBR,O
,common,JJ,O
,adverse,JJ,O
,effects,NNS,O
,.,.,O
,The,DT,O
,enhancement,NN,O
,of,IN,O
,aminonucleoside,JJ,O
,nephrosis,NN,B-DISEASE
,by,IN,O
,the,DT,O
,co,NN,O
,-,:,O
,administration,NN,O
,of,IN,O
,protamine,NN,O
,.,.,O
,An,DT,O
,experimental,JJ,O
,model,NN,O
,of,IN,O
,focal,JJ,B-DISEASE
,segmental,JJ,I-DISEASE
,glomerular,JJ,I-DISEASE
,sclerosis,NN,I-DISEASE
,(,(,O
,FSGS,NNP,B-DISEASE
,),),O
,was,VBD,O
,developed,VBN,O
,in,IN,O
,rats,NNS,O
,by,IN,O
,the,DT,O
,combined,JJ,O
,administration,NN,O
,of,IN,O
,puromycin,JJ,O
,-,:,O
,aminonucleoside,NN,O
,(,(,O
,AMNS,NNP,O
,),),O
,and,CC,O
,protamine,JJ,O
,sulfate,NN,O
,(,(,O
,PS,NNP,O
,),),O
,.,.,O
,Male,NNP,O
,Sprague,NNP,O
,-,:,O
,Dawley,NNP,O
,rats,NNS,O
,",",",",O
,uninephrectomized,JJ,O
,three,CD,O
,weeks,NNS,O
,before,IN,O
,",",",",O
,received,VBD,O
,daily,JJ,O
,injections,NNS,O
,of,IN,O
,subcutaneous,JJ,O
,AMNS,NNP,O
,(,(,O
,1,CD,O
,mg,NN,O
,/,VBD,O
,100,CD,O
,g,NN,O
,body,NN,O
,wt,NN,O
,),),O
,and,CC,O
,intravenous,JJ,O
,PS,NNP,O
,(,(,O
,2,CD,O
,separated,VBN,O
,doses,NNS,O
,of,IN,O
,2,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,/,$,O
,100,CD,O
,g,NN,O
,body,NN,O
,wt,NN,O
,),),O
,for,IN,O
,four,CD,O
,days,NNS,O
,.,.,O
,The,DT,O
,series,NN,O
,of,IN,O
,injections,NNS,O
,were,VBD,O
,repeated,VBN,O
,another,DT,O
,three,CD,O
,times,NNS,O
,at,IN,O
,10,CD,O
,day,NN,O
,intervals,NNS,O
,.,.,O
,The,DT,O
,animals,NNS,O
,were,VBD,O
,sacrificed,VBN,O
,on,IN,O
,days,NNS,O
,24,CD,O
,",",",",O
,52,CD,O
,",",",",O
,and,CC,O
,80,CD,O
,.,.,O
,They,PRP,O
,developed,VBD,O
,nephrotic,JJ,B-DISEASE
,syndrome,NN,I-DISEASE
,and,CC,O
,finally,RB,O
,renal,JJ,B-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,The,DT,O
,time,NN,O
,-,:,O
,course,NN,O
,curve,NN,O
,of,IN,O
,creatinine,JJ,O
,clearance,NN,O
,dropped,VBD,O
,and,CC,O
,showed,VBD,O
,significant,JJ,O
,difference,NN,O
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,from,IN,O
,that,DT,O
,of,IN,O
,each,DT,O
,control,NN,O
,group,NN,O
,",",",",O
,such,JJ,O
,as,IN,O
,",",",",O
,AMNS,NNP,O
,alone,RB,O
,",",",",O
,PS,NNP,O
,alone,RB,O
,or,CC,O
,saline,JJ,O
,injected,VBN,O
,.,.,O
,Their,PRP$,O
,glomeruli,NN,O
,showed,VBD,O
,changes,NNS,O
,of,IN,O
,progressive,JJ,O
,FSGS,NNP,B-DISEASE
,.,.,O
,The,DT,O
,ultrastructural,JJ,O
,studies,NNS,O
,in,IN,O
,the,DT,O
,initial,JJ,O
,stage,NN,O
,revealed,VBD,O
,significant,JJ,O
,lack,NN,O
,of,IN,O
,particles,NNS,O
,of,IN,O
,perfused,JJ,O
,ruthenium,NN,O
,red,VBD,O
,on,IN,O
,the,DT,O
,lamina,NN,O
,rara,NN,O
,externa,NN,O
,and,CC,O
,marked,VBD,O
,changes,NNS,O
,in,IN,O
,epithelial,JJ,O
,cell,NN,O
,cytoplasm,NN,O
,.,.,O
,Therefore,RB,O
,",",",",O
,it,PRP,O
,is,VBZ,O
,suggested,VBN,O
,that,IN,O
,the,DT,O
,administration,NN,O
,of,IN,O
,PS,NNP,O
,enhances,VBZ,O
,the,DT,O
,toxicity,NN,B-DISEASE
,of,IN,O
,AMNS,NNP,O
,on,IN,O
,the,DT,O
,glomerulus,NN,O
,and,CC,O
,readily,RB,O
,produces,VBZ,O
,progressive,JJ,O
,FSGS,NNP,B-DISEASE
,in,IN,O
,rats,NNS,O
,resulting,VBG,O
,in,IN,O
,the,DT,O
,end,NN,B-DISEASE
,-,:,I-DISEASE
,stage,NN,I-DISEASE
,renal,JJ,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,Theophylline,NNP,O
,neurotoxicity,NN,B-DISEASE
,in,IN,O
,pregnant,JJ,O
,rats,NNS,O
,.,.,O
,The,DT,O
,purpose,NN,O
,of,IN,O
,this,DT,O
,investigation,NN,O
,was,VBD,O
,to,TO,O
,determine,VB,O
,whether,IN,O
,the,DT,O
,neurotoxicity,NN,B-DISEASE
,of,IN,O
,theophylline,NN,O
,is,VBZ,O
,altered,VBN,O
,in,IN,O
,advanced,JJ,O
,pregnancy,NN,O
,.,.,O
,Sprague,NNP,O
,-,:,O
,Dawley,NNP,O
,rats,NNS,O
,that,WDT,O
,were,VBD,O
,20,CD,O
,days,NNS,O
,pregnant,JJ,O
,and,CC,O
,nonpregnant,JJ,O
,rats,NNS,O
,of,IN,O
,the,DT,O
,same,JJ,O
,age,NN,O
,and,CC,O
,strain,NN,O
,received,VBD,O
,infusions,NNS,O
,of,IN,O
,aminophylline,NN,O
,until,IN,O
,onset,NN,O
,of,IN,O
,maximal,NN,O
,seizures,NNS,B-DISEASE
,which,WDT,O
,occurred,VBD,O
,after,IN,O
,28,CD,O
,and,CC,O
,30,CD,O
,minutes,NNS,O
,respectively,RB,O
,.,.,O
,Theophylline,JJ,O
,concentrations,NNS,O
,at,IN,O
,this,DT,O
,endpoint,NN,O
,in,IN,O
,serum,NN,O
,(,(,O
,total,JJ,O
,),),O
,and,CC,O
,CSF,NNP,O
,were,VBD,O
,similar,JJ,O
,but,CC,O
,serum,NN,O
,(,(,O
,free,JJ,O
,),),O
,and,CC,O
,brain,NN,O
,concentrations,NNS,O
,were,VBD,O
,slightly,RB,O
,different,JJ,O
,in,IN,O
,pregnant,JJ,O
,rats,NNS,O
,.,.,O
,Theophylline,NNP,O
,serum,NN,O
,protein,NN,O
,binding,VBG,O
,determined,VBN,O
,by,IN,O
,equilibrium,JJ,O
,dialysis,NN,O
,was,VBD,O
,lower,JJR,O
,in,IN,O
,pregnant,JJ,O
,rats,NNS,O
,.,.,O
,Fetal,NNP,O
,serum,JJ,O
,concentrations,NNS,O
,at,IN,O
,onset,NN,O
,of,IN,O
,seizures,NNS,B-DISEASE
,in,IN,O
,the,DT,O
,mother,NN,O
,were,VBD,O
,similar,JJ,O
,to,TO,O
,maternal,JJ,O
,brain,NN,O
,and,CC,O
,CSF,NNP,O
,concentrations,NNS,O
,and,CC,O
,correlated,VBN,O
,significantly,RB,O
,with,IN,O
,the,DT,O
,former,JJ,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,concluded,VBN,O
,that,IN,O
,advanced,JJ,O
,pregnancy,NN,O
,has,VBZ,O
,a,DT,O
,negligible,JJ,O
,effect,NN,O
,on,IN,O
,the,DT,O
,neurotoxic,JJ,B-DISEASE
,response,NN,O
,to,TO,O
,theophylline,VB,O
,in,IN,O
,rats,NNS,O
,.,.,O
,Hyperkalemia,NNP,B-DISEASE
,induced,VBN,O
,by,IN,O
,indomethacin,NN,O
,and,CC,O
,naproxen,NN,O
,and,CC,O
,reversed,VBN,O
,by,IN,O
,fludrocortisone,NN,O
,.,.,O
,We,PRP,O
,have,VBP,O
,described,VBN,O
,a,DT,O
,patient,NN,O
,with,IN,O
,severe,JJ,O
,rheumatoid,NN,B-DISEASE
,arthritis,NN,I-DISEASE
,and,CC,O
,a,DT,O
,history,NN,O
,of,IN,O
,mefenamic,JJ,O
,acid,NN,O
,nephropathy,NN,B-DISEASE
,in,IN,O
,whom,WP,O
,hyperkalemia,NN,B-DISEASE
,and,CC,O
,inappropriate,JJ,O
,hypoaldosteronism,NN,B-DISEASE
,were,VBD,O
,caused,VBN,O
,by,IN,O
,both,DT,O
,indomethacin,NNS,O
,and,CC,O
,naproxen,NN,O
,",",",",O
,without,IN,O
,major,JJ,O
,decline,NN,O
,in,IN,O
,renal,JJ,O
,function,NN,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,likely,JJ,O
,that,IN,O
,preexisting,VBG,O
,renal,JJ,B-DISEASE
,disease,NN,I-DISEASE
,predisposed,VBD,O
,this,DT,O
,patient,NN,O
,to,TO,O
,type,VB,B-DISEASE
,IV,NNP,I-DISEASE
,renal,JJ,I-DISEASE
,tubular,JJ,I-DISEASE
,acidosis,NN,I-DISEASE
,with,IN,O
,prostaglandin,JJ,O
,synthetase,NN,O
,inhibitors,NNS,O
,.,.,O
,Because,IN,O
,he,PRP,O
,was,VBD,O
,unable,JJ,O
,to,TO,O
,discontinue,VB,O
,nonsteroidal,JJ,O
,anti,SYM,O
,-,:,O
,inflammatory,JJ,O
,drug,NN,O
,therapy,NN,O
,",",",",O
,fludrocortisone,NN,O
,was,VBD,O
,added,VBN,O
,",",",",O
,correcting,VBG,O
,the,DT,O
,hyperkalemia,NN,B-DISEASE
,and,CC,O
,allowing,VBG,O
,indomethacin,JJ,O
,therapy,NN,O
,to,TO,O
,be,VB,O
,continued,VBN,O
,safely,RB,O
,.,.,O
,Hypotension,NNP,B-DISEASE
,as,IN,O
,a,DT,O
,manifestation,NN,O
,of,IN,O
,cardiotoxicity,NN,B-DISEASE
,in,IN,O
,three,CD,O
,patients,NNS,O
,receiving,VBG,O
,cisplatin,NN,O
,and,CC,O
,5,CD,O
,-,:,O
,fluorouracil,NN,O
,.,.,O
,Cardiac,NNP,O
,symptoms,NNS,O
,",",",",O
,including,VBG,O
,hypotension,NN,B-DISEASE
,",",",",O
,developed,VBN,O
,in,IN,O
,three,CD,O
,patients,NNS,O
,with,IN,O
,advanced,JJ,O
,colorectal,JJ,B-DISEASE
,carcinoma,NN,I-DISEASE
,while,IN,O
,being,VBG,O
,treated,VBN,O
,with,IN,O
,cisplatin,NN,O
,(,(,O
,CDDP,NNP,O
,),),O
,and,CC,O
,5,CD,O
,-,:,O
,fluorouracil,NN,O
,(,(,O
,5,CD,O
,-,:,O
,FU,NN,O
,),),O
,.,.,O
,In,IN,O
,two,CD,O
,patients,NNS,O
,",",",",O
,hypotension,NN,B-DISEASE
,was,VBD,O
,associated,VBN,O
,with,IN,O
,severe,JJ,O
,left,VBN,B-DISEASE
,ventricular,JJ,I-DISEASE
,dysfunction,NN,I-DISEASE
,.,.,O
,All,DT,O
,three,CD,O
,patients,NNS,O
,required,VBN,O
,therapy,JJ,O
,discontinuation,NN,O
,.,.,O
,Cardiac,NNP,O
,enzymes,RB,O
,remained,VBD,O
,normal,JJ,O
,despite,IN,O
,transient,JJ,O
,electrocardiographic,JJ,O
,(,(,O
,EKG,NNP,O
,),),O
,changes,NNS,O
,.,.,O
,The,DT,O
,presentation,NN,O
,and,CC,O
,cardiac,JJ,O
,evaluation,NN,O
,(,(,O
,hemodynamic,JJ,O
,",",",",O
,echocardiographic,JJ,O
,",",",",O
,and,CC,O
,scintigraphic,JJ,O
,),),O
,of,IN,O
,these,DT,O
,patients,NNS,O
,suggest,VBP,O
,new,JJ,O
,manifestations,NNS,O
,of,IN,O
,5,CD,O
,-,:,O
,FU,NNP,O
,cardiotoxicity,NN,B-DISEASE
,that,WDT,O
,may,MD,O
,be,VB,O
,influenced,VBN,O
,by,IN,O
,CDDP,NNP,O
,.,.,O
,The,DT,O
,possible,JJ,O
,pathophysiologic,NN,O
,mechanisms,NNS,O
,are,VBP,O
,discussed,VBN,O
,.,.,O
,Fatal,NNP,O
,aplastic,JJ,B-DISEASE
,anemia,NN,I-DISEASE
,in,IN,O
,a,DT,O
,patient,NN,O
,treated,VBN,O
,with,IN,O
,carbamazepine,NN,O
,.,.,O
,A,DT,O
,case,NN,O
,of,IN,O
,fatal,JJ,O
,aplastic,JJ,B-DISEASE
,anemia,NN,I-DISEASE
,due,JJ,O
,to,TO,O
,carbamazepine,VB,O
,treatment,NN,O
,in,IN,O
,an,DT,O
,epileptic,JJ,B-DISEASE
,woman,NN,O
,is,VBZ,O
,reported,VBN,O
,.,.,O
,Despite,IN,O
,concerns,NNS,O
,of,IN,O
,fatal,JJ,O
,bone,NN,B-DISEASE
,marrow,NN,I-DISEASE
,toxicity,NN,I-DISEASE
,due,JJ,O
,to,TO,O
,carbamazepine,VB,O
,",",",",O
,this,DT,O
,is,VBZ,O
,only,RB,O
,the,DT,O
,fourth,JJ,O
,documented,JJ,O
,and,CC,O
,published,VBN,O
,report,NN,O
,.,.,O
,Carbamazepine,NNP,O
,is,VBZ,O
,a,DT,O
,safe,JJ,O
,drug,NN,O
,",",",",O
,but,CC,O
,physicians,NNS,O
,and,CC,O
,patients,NNS,O
,should,MD,O
,be,VB,O
,aware,JJ,O
,of,IN,O
,the,DT,O
,exceedingly,RB,O
,rare,JJ,O
,but,CC,O
,potentially,RB,O
,fatal,JJ,O
,side,NN,O
,effects,NNS,O
,",",",",O
,better,RB,O
,prevented,VBN,O
,by,IN,O
,clinical,JJ,O
,than,IN,O
,by,IN,O
,laboratory,JJ,O
,monitoring,NN,O
,.,.,O
,Participation,NN,O
,of,IN,O
,a,DT,O
,bulbospinal,JJ,O
,serotonergic,NN,O
,pathway,NN,O
,in,IN,O
,the,DT,O
,rat,NN,O
,brain,NN,O
,in,IN,O
,clonidine,JJ,O
,-,:,O
,induced,JJ,O
,hypotension,NN,B-DISEASE
,and,CC,O
,bradycardia,NN,B-DISEASE
,.,.,O
,The,DT,O
,effects,NNS,O
,of,IN,O
,microinjection,NN,O
,of,IN,O
,clonidine,NN,O
,(,(,O
,1,CD,O
,-,:,O
,10,CD,O
,micrograms,NNS,O
,in,IN,O
,1,CD,O
,microliter,NN,O
,),),O
,into,IN,O
,a,DT,O
,region,NN,O
,adjacent,NN,O
,to,TO,O
,the,DT,O
,ventrolateral,JJ,O
,surface,NN,O
,of,IN,O
,the,DT,O
,medulla,NN,O
,oblongata,NN,O
,on,IN,O
,cardiovascular,JJ,O
,function,NN,O
,were,VBD,O
,assessed,VBN,O
,in,IN,O
,urethane,JJ,O
,-,:,O
,anesthetized,JJ,O
,rats,NNS,O
,.,.,O
,Intramedullary,JJ,O
,administration,NN,O
,of,IN,O
,clonidine,NN,O
,",",",",O
,but,CC,O
,not,RB,O
,saline,JJ,O
,vehicle,NN,O
,",",",",O
,caused,VBD,O
,a,DT,O
,dose,JJ,O
,-,:,O
,dependent,JJ,O
,decrease,NN,O
,in,IN,O
,both,DT,O
,the,DT,O
,mean,JJ,O
,arterial,JJ,O
,pressure,NN,O
,and,CC,O
,the,DT,O
,heart,NN,O
,rate,NN,O
,.,.,O
,The,DT,O
,clonidine,NN,O
,-,:,O
,induced,JJ,O
,hypotension,NN,B-DISEASE
,was,VBD,O
,antagonized,VBN,O
,by,IN,O
,prior,JJ,O
,spinal,JJ,O
,transection,NN,O
,",",",",O
,but,CC,O
,not,RB,O
,bilateral,JJ,O
,vagotomy,NN,O
,.,.,O
,On,IN,O
,the,DT,O
,other,JJ,O
,hand,NN,O
,",",",",O
,the,DT,O
,clonidine,NN,O
,-,:,O
,induced,JJ,O
,bradycardia,NN,B-DISEASE
,was,VBD,O
,antagonized,VBN,O
,by,IN,O
,prior,JJ,O
,bilateral,JJ,O
,vagotomy,NN,O
,",",",",O
,but,CC,O
,not,RB,O
,spinal,JJ,O
,transection,NN,O
,.,.,O
,Furthermore,NNP,O
,",",",",O
,selective,JJ,O
,destruction,NN,O
,of,IN,O
,the,DT,O
,spinal,JJ,O
,5,CD,O
,-,:,O
,HT,NNP,O
,nerves,NNS,O
,",",",",O
,produced,VBN,O
,by,IN,O
,bilateral,JJ,O
,spinal,JJ,O
,injection,NN,O
,of,IN,O
,5,CD,O
,",",",",O
,7,CD,O
,-,:,O
,dihydroxytryptamine,NN,O
,",",",",O
,reduced,VBD,O
,the,DT,O
,magnitude,NN,O
,of,IN,O
,the,DT,O
,vasodepressor,NN,O
,or,CC,O
,the,DT,O
,bradycardiac,JJ,B-DISEASE
,responses,NNS,O
,to,TO,O
,clonidine,VB,O
,microinjected,VBN,O
,into,IN,O
,the,DT,O
,area,NN,O
,near,IN,O
,the,DT,O
,ventrolateral,JJ,O
,surface,NN,O
,of,IN,O
,the,DT,O
,medulla,NN,O
,oblongata,NN,O
,in,IN,O
,rats,NNS,O
,.,.,O
,The,DT,O
,data,NN,O
,indicate,NN,O
,that,IN,O
,a,DT,O
,bulbospinal,JJ,O
,serotonergic,NN,O
,pathway,NN,O
,is,VBZ,O
,involved,VBN,O
,in,IN,O
,development,NN,O
,of,IN,O
,clonidine,NN,O
,-,:,O
,induced,JJ,O
,hypotension,NN,B-DISEASE
,and,CC,O
,bradycardia,NN,B-DISEASE
,.,.,O
,The,DT,O
,induced,JJ,O
,hypotension,NN,B-DISEASE
,is,VBZ,O
,brought,VBN,O
,about,RB,O
,by,IN,O
,a,DT,O
,decrease,NN,O
,in,IN,O
,sympathetic,JJ,O
,efferent,NN,O
,activity,NN,O
,",",",",O
,whereas,IN,O
,the,DT,O
,induced,JJ,O
,bradycardia,NN,B-DISEASE
,was,VBD,O
,due,JJ,O
,to,TO,O
,an,DT,O
,increase,NN,O
,in,IN,O
,vagal,JJ,O
,efferent,NN,O
,activity,NN,O
,.,.,O
,Hypertension,NN,B-DISEASE
,in,IN,O
,neuroblastoma,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,imipramine,NN,O
,.,.,O
,Hypertension,NNP,B-DISEASE
,is,VBZ,O
,a,DT,O
,well,RB,O
,-,:,O
,known,VBN,O
,finding,NN,O
,in,IN,O
,some,DT,O
,patients,NNS,O
,with,IN,O
,neuroblastoma,NN,B-DISEASE
,.,.,O
,However,RB,O
,",",",",O
,it,PRP,O
,has,VBZ,O
,not,RB,O
,previously,RB,O
,been,VBN,O
,described,VBN,O
,in,IN,O
,association,NN,O
,with,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,Imipramine,NNP,O
,.,.,O
,We,PRP,O
,report,VBP,O
,the,DT,O
,occurrence,NN,O
,of,IN,O
,severe,JJ,O
,hypertension,NN,B-DISEASE
,(,(,O
,blood,NN,O
,pressure,NN,O
,190,CD,O
,/,$,O
,160,CD,O
,),),O
,in,IN,O
,a,DT,O
,4,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,girl,NN,O
,with,IN,O
,neuroblastoma,NN,B-DISEASE
,who,WP,O
,was,VBD,O
,given,VBN,O
,Imipramine,NNP,O
,to,TO,O
,control,VB,O
,a,DT,O
,behavior,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,.,.,O
,It,PRP,O
,was,VBD,O
,determined,VBN,O
,later,RB,O
,that,IN,O
,this,DT,O
,patient,NN,O
,','',O
,s,JJ,O
,tumor,NN,B-DISEASE
,was,VBD,O
,recurring,VBG,O
,at,IN,O
,the,DT,O
,time,NN,O
,of,IN,O
,her,PRP$,O
,hypertensive,JJ,B-DISEASE
,episode,NN,O
,.,.,O
,Since,IN,O
,she,PRP,O
,had,VBD,O
,no,DT,O
,blood,NN,O
,pressure,NN,O
,elevation,NN,O
,at,IN,O
,initial,JJ,O
,diagnosis,NN,O
,and,CC,O
,none,NN,O
,following,VBG,O
,discontinuation,NN,O
,of,IN,O
,the,DT,O
,Imipramine,NNP,O
,(,(,O
,when,WRB,O
,she,PRP,O
,was,VBD,O
,in,IN,O
,florid,JJ,O
,relapse,NN,O
,),),O
,",",",",O
,we,PRP,O
,believe,VBP,O
,that,IN,O
,this,DT,O
,drug,NN,O
,rather,RB,O
,than,IN,O
,her,PRP$,O
,underlying,JJ,O
,disease,NN,O
,alone,RB,O
,caused,VBD,O
,her,PRP$,O
,hypertension,NN,B-DISEASE
,.,.,O
,The,DT,O
,mechanism,NN,O
,for,IN,O
,this,DT,O
,reaction,NN,O
,is,VBZ,O
,believed,VBN,O
,to,TO,O
,be,VB,O
,increased,VBN,O
,levels,NNS,O
,of,IN,O
,vasoactive,JJ,O
,catecholamines,NNS,O
,due,JJ,O
,to,TO,O
,interference,VB,O
,of,IN,O
,their,PRP$,O
,physiologic,JJ,O
,inactivation,NN,O
,by,IN,O
,Imipramine,NNP,O
,.,.,O
,From,IN,O
,this,DT,O
,experience,NN,O
,",",",",O
,we,PRP,O
,urge,VBP,O
,extreme,JJ,O
,caution,NN,O
,in,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,tricyclic,JJ,O
,antidepressants,NNS,O
,in,IN,O
,children,NNS,O
,with,IN,O
,active,JJ,O
,neuroblastoma,NN,B-DISEASE
,.,.,O
,Rechallenge,NNP,O
,of,IN,O
,patients,NNS,O
,who,WP,O
,developed,VBD,O
,oral,JJ,B-DISEASE
,candidiasis,NN,I-DISEASE
,or,CC,O
,hoarseness,NN,B-DISEASE
,with,IN,O
,beclomethasone,NN,O
,dipropionate,NN,O
,.,.,O
,Of,IN,O
,158,CD,O
,asthmatic,JJ,B-DISEASE
,patients,NNS,O
,who,WP,O
,were,VBD,O
,placed,VBN,O
,on,IN,O
,inhaled,JJ,O
,beclomethasone,NN,O
,",",",",O
,15,CD,O
,(,(,O
,9,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,),),O
,developed,VBD,O
,either,CC,O
,hoarseness,NN,B-DISEASE
,(,(,O
,8,CD,O
,),),O
,",",",",O
,oral,JJ,O
,thrush,NN,B-DISEASE
,(,(,O
,6,CD,O
,),),O
,",",",",O
,or,CC,O
,both,DT,O
,(,(,O
,1,CD,O
,),),O
,.,.,O
,When,WRB,O
,their,PRP$,O
,adverse,JJ,O
,reactions,NNS,O
,subsided,VBD,O
,",",",",O
,seven,CD,O
,of,IN,O
,these,DT,O
,15,CD,O
,patients,NNS,O
,were,VBD,O
,rechallenged,VBN,O
,with,IN,O
,inhaled,JJ,O
,beclomethasone,NN,O
,.,.,O
,These,DT,O
,included,VBD,O
,five,CD,O
,cases,NNS,O
,who,WP,O
,developed,VBD,O
,hoarseness,NN,B-DISEASE
,and,CC,O
,three,CD,O
,who,WP,O
,developed,VBD,O
,Candidiasis,NNP,B-DISEASE
,.,.,O
,One,CD,O
,patient,NN,O
,had,VBD,O
,both,DT,O
,.,.,O
,Oral,NNP,O
,thrush,NN,B-DISEASE
,did,VBD,O
,not,RB,O
,recur,VB,O
,",",",",O
,but,CC,O
,60,CD,O
,%,NN,O
,(,(,O
,3,CD,O
,/,RB,O
,5,CD,O
,),),O
,of,IN,O
,patients,NNS,O
,with,IN,O
,hoarseness,NN,B-DISEASE
,had,VBD,O
,recurrence,NN,O
,.,.,O
,We,PRP,O
,conclude,VBP,O
,that,IN,O
,patients,NNS,O
,may,MD,O
,be,VB,O
,restarted,VBN,O
,on,IN,O
,inhaled,JJ,O
,beclomethasone,NN,O
,when,WRB,O
,clinically,RB,O
,indicated,VBD,O
,;,:,O
,however,RB,O
,",",",",O
,because,IN,O
,of,IN,O
,the,DT,O
,high,JJ,O
,recurrence,NN,O
,rate,NN,O
,",",",",O
,patients,NNS,O
,who,WP,O
,develop,VBP,O
,hoarseness,NN,B-DISEASE
,should,MD,O
,not,RB,O
,be,VB,O
,re,JJ,O
,-,:,O
,challenged,NN,O
,.,.,O
,Concomitant,NNP,O
,use,NN,O
,of,IN,O
,oral,JJ,O
,prednisone,NN,O
,and,CC,O
,topical,JJ,O
,beclomethasone,NN,O
,may,MD,O
,increase,VB,O
,the,DT,O
,risk,NN,O
,of,IN,O
,developing,VBG,O
,hoarseness,NN,B-DISEASE
,or,CC,O
,candidiasis,NN,B-DISEASE
,.,.,O
,Cyclophosphamide,NNP,O
,cardiotoxicity,NN,B-DISEASE
,:,:,O
,an,DT,O
,analysis,NN,O
,of,IN,O
,dosing,VBG,O
,as,IN,O
,a,DT,O
,risk,NN,O
,factor,NN,O
,.,.,O
,Patients,NNS,O
,who,WP,O
,undergo,VBP,O
,bone,NN,O
,marrow,NN,O
,transplantation,NN,O
,are,VBP,O
,generally,RB,O
,immunosuppressed,VBN,O
,with,IN,O
,a,DT,O
,dose,NN,O
,of,IN,O
,cyclophosphamide,NN,O
,(,(,O
,CYA,NNP,O
,),),O
,which,WDT,O
,is,VBZ,O
,usually,RB,O
,calculated,VBN,O
,based,VBN,O
,on,IN,O
,the,DT,O
,patient,NN,O
,',POS,O
,s,JJ,O
,weight,NN,O
,.,.,O
,At,IN,O
,these,DT,O
,high,JJ,O
,doses,NNS,O
,of,IN,O
,CYA,NNP,O
,",",",",O
,serious,JJ,O
,cardiotoxicity,NN,B-DISEASE
,may,MD,O
,occur,VB,O
,",",",",O
,but,CC,O
,definitive,JJ,O
,risk,NN,O
,factors,NNS,O
,for,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,such,JJ,O
,cardiotoxicity,NN,B-DISEASE
,have,VBP,O
,not,RB,O
,been,VBN,O
,described,VBN,O
,.,.,O
,Since,IN,O
,chemotherapeutic,JJ,O
,agent,NN,O
,toxicity,NN,B-DISEASE
,generally,RB,O
,correlates,VBZ,O
,with,IN,O
,dose,JJ,O
,per,IN,O
,body,NN,O
,surface,NN,O
,area,NN,O
,",",",",O
,we,PRP,O
,retrospectively,RB,O
,calculated,VBD,O
,the,DT,O
,dose,NN,O
,of,IN,O
,CYA,NNP,O
,in,IN,O
,patients,NNS,O
,transplanted,VBN,O
,at,IN,O
,our,PRP$,O
,institution,NN,O
,to,TO,O
,determine,VB,O
,whether,IN,O
,the,DT,O
,incidence,NN,O
,of,IN,O
,CYA,NNP,O
,cardiotoxicity,NN,B-DISEASE
,correlated,VBN,O
,with,IN,O
,the,DT,O
,dose,JJ,O
,per,IN,O
,body,NN,O
,surface,NN,O
,area,NN,O
,.,.,O
,Eighty,NNP,O
,patients,NNS,O
,who,WP,O
,were,VBD,O
,to,TO,O
,receive,VB,O
,CYA,NNP,O
,50,CD,O
,mg,NN,O
,/,NNP,O
,kg,NNP,O
,/,NNP,O
,d,NN,O
,for,IN,O
,four,CD,O
,days,NNS,O
,as,IN,O
,preparation,NN,O
,for,IN,O
,marrow,NN,O
,grafting,VBG,O
,underwent,VBD,O
,a,DT,O
,total,NN,O
,of,IN,O
,84,CD,O
,transplants,NNS,O
,for,IN,O
,aplastic,JJ,B-DISEASE
,anemia,NN,I-DISEASE
,",",",",O
,Wiskott,NNP,B-DISEASE
,-,:,I-DISEASE
,Aldrich,NNP,I-DISEASE
,syndrome,NN,I-DISEASE
,",",",",O
,or,CC,O
,severe,RB,B-DISEASE
,combined,VBN,I-DISEASE
,immunodeficiency,NN,I-DISEASE
,syndrome,NN,I-DISEASE
,.,.,O
,Fourteen,NNP,O
,of,IN,O
,84,CD,O
,(,(,O
,17,CD,O
,%,NN,O
,),),O
,patients,NNS,O
,had,VBD,O
,symptoms,NNS,O
,and,CC,O
,signs,NNS,O
,consistent,JJ,O
,with,IN,O
,CYA,NNP,O
,cardiotoxicity,NN,B-DISEASE
,within,IN,O
,ten,JJ,O
,days,NNS,O
,of,IN,O
,receiving,VBG,O
,1,CD,O
,to,TO,O
,4,CD,O
,doses,NNS,O
,of,IN,O
,CYA,NNP,O
,.,.,O
,Six,NNP,O
,of,IN,O
,the,DT,O
,14,CD,O
,patients,NNS,O
,died,VBD,O
,with,IN,O
,congestive,JJ,B-DISEASE
,heart,NN,I-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,The,DT,O
,dose,NN,O
,of,IN,O
,CYA,NNP,O
,per,IN,O
,body,NN,O
,surface,NN,O
,area,NN,O
,was,VBD,O
,calculated,VBN,O
,for,IN,O
,all,DT,O
,patients,NNS,O
,and,CC,O
,the,DT,O
,patients,NNS,O
,were,VBD,O
,divided,VBN,O
,into,IN,O
,two,CD,O
,groups,NNS,O
,based,VBN,O
,on,IN,O
,daily,JJ,O
,CYA,NNP,O
,dose,NN,O
,:,:,O
,Group,NNP,O
,1,CD,O
,",",",",O
,CYA,NNP,O
,less,JJR,O
,than,IN,O
,or,CC,O
,equal,JJ,O
,to,TO,O
,1,CD,O
,.,.,O
,55,CD,O
,g,JJ,O
,/,NNP,O
,m2,NN,O
,/,NNP,O
,d,NN,O
,;,:,O
,Group,NNP,O
,2,CD,O
,",",",",O
,CYA,NNP,O
,greater,JJR,O
,than,IN,O
,1,CD,O
,.,.,O
,55,CD,O
,g,JJ,O
,/,NNP,O
,m2,NN,O
,/,NNP,O
,d,NN,O
,.,.,O
,Cardiotoxicity,NN,B-DISEASE
,that,WDT,O
,was,VBD,O
,thought,VBN,O
,to,TO,O
,be,VB,O
,related,VBN,O
,to,TO,O
,CYA,NNP,O
,occurred,VBD,O
,in,IN,O
,1,CD,O
,/,JJ,O
,32,CD,O
,(,(,O
,3,CD,O
,%,NN,O
,),),O
,of,IN,O
,patients,NNS,O
,in,IN,O
,Group,NNP,O
,1,CD,O
,and,CC,O
,in,IN,O
,13,CD,O
,/,JJ,O
,52,CD,O
,(,(,O
,25,CD,O
,%,NN,O
,),),O
,patients,NNS,O
,in,IN,O
,Group,NNP,O
,2,CD,O
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,025,CD,O
,),),O
,.,.,O
,Congestive,JJ,B-DISEASE
,heart,NN,I-DISEASE
,failure,NN,I-DISEASE
,caused,VBD,O
,or,CC,O
,contributed,VBD,O
,to,TO,O
,death,NN,O
,in,IN,O
,0,CD,O
,/,JJ,O
,32,CD,O
,patients,NNS,O
,in,IN,O
,Group,NNP,O
,1,CD,O
,v,NN,O
,6,CD,O
,/,NN,O
,52,CD,O
,(,(,O
,12,CD,O
,%,NN,O
,),),O
,of,IN,O
,patients,NNS,O
,in,IN,O
,Group,NNP,O
,2,CD,O
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,25,CD,O
,),),O
,.,.,O
,There,EX,O
,was,VBD,O
,no,DT,O
,difference,NN,O
,in,IN,O
,the,DT,O
,rate,NN,O
,of,IN,O
,engraftment,NN,O
,of,IN,O
,evaluable,JJ,O
,patients,NNS,O
,in,IN,O
,the,DT,O
,two,CD,O
,groups,NNS,O
,(,(,O
,P,NNP,O
,greater,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,5,CD,O
,),),O
,.,.,O
,We,PRP,O
,conclude,VBP,O
,that,IN,O
,the,DT,O
,CYA,NNP,O
,cardiotoxicity,NN,B-DISEASE
,correlates,VBZ,O
,with,IN,O
,CYA,NNP,O
,dosage,NN,O
,as,IN,O
,calculated,VBN,O
,by,IN,O
,body,NN,O
,surface,JJ,O
,area,NN,O
,",",",",O
,and,CC,O
,that,IN,O
,patients,NNS,O
,with,IN,O
,aplastic,JJ,B-DISEASE
,anemia,NN,I-DISEASE
,and,CC,O
,immunodeficiencies,NNS,B-DISEASE
,can,MD,O
,be,VB,O
,effectively,RB,O
,prepared,VBN,O
,for,IN,O
,bone,NN,O
,marrow,NN,O
,grafting,VBG,O
,at,IN,O
,a,DT,O
,CYA,NNP,O
,dose,NN,O
,of,IN,O
,1,CD,O
,.,.,O
,55,CD,O
,g,JJ,O
,/,NNP,O
,m2,NN,O
,/,NNP,O
,d,NN,O
,for,IN,O
,four,CD,O
,days,NNS,O
,with,IN,O
,a,DT,O
,lower,JJR,O
,incidence,NN,O
,of,IN,O
,cardiotoxicity,NN,B-DISEASE
,than,IN,O
,patients,NNS,O
,whose,WP$,O
,CYA,NNP,O
,dosage,NN,O
,is,VBZ,O
,calculated,VBN,O
,based,VBN,O
,on,IN,O
,weight,NN,O
,.,.,O
,This,DT,O
,study,NN,O
,reaffirms,VBZ,O
,the,DT,O
,principle,NN,O
,that,WDT,O
,drug,NN,O
,toxicity,NN,B-DISEASE
,correlates,VBZ,O
,with,IN,O
,dose,JJ,O
,per,IN,O
,body,NN,O
,surface,NN,O
,area,NN,O
,.,.,O
,Studies,NNS,O
,of,IN,O
,risk,NN,O
,factors,NNS,O
,for,IN,O
,aminoglycoside,JJ,O
,nephrotoxicity,NN,B-DISEASE
,.,.,O
,The,DT,O
,epidemiology,NN,O
,of,IN,O
,aminoglycoside,JJ,O
,-,:,O
,induced,JJ,O
,nephrotoxicity,NN,B-DISEASE
,is,VBZ,O
,not,RB,O
,fully,RB,O
,understood,JJ,O
,.,.,O
,Experimental,JJ,O
,studies,NNS,O
,in,IN,O
,healthy,JJ,O
,human,JJ,O
,volunteers,NNS,O
,indicate,VBP,O
,aminoglycosides,NNS,O
,cause,VBP,O
,proximal,JJ,O
,tubular,JJ,O
,damage,NN,O
,in,IN,O
,most,JJS,O
,patients,NNS,O
,",",",",O
,but,CC,O
,rarely,RB,O
,",",",",O
,if,IN,O
,ever,RB,O
,",",",",O
,cause,VB,O
,glomerular,NN,B-DISEASE
,or,CC,I-DISEASE
,tubular,JJ,I-DISEASE
,dysfunction,NN,I-DISEASE
,.,.,O
,Clinical,JJ,O
,trials,NNS,O
,of,IN,O
,aminoglycosides,NNS,O
,in,IN,O
,seriously,RB,O
,ill,JJ,O
,patients,NNS,O
,indicate,VBP,O
,that,IN,O
,the,DT,O
,relative,JJ,O
,risk,NN,O
,for,IN,O
,developing,VBG,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,during,IN,O
,therapy,NN,O
,ranges,VBZ,O
,from,IN,O
,8,CD,O
,to,TO,O
,10,CD,O
,and,CC,O
,that,IN,O
,the,DT,O
,attributable,JJ,O
,risk,NN,O
,is,VBZ,O
,70,CD,O
,%,NN,O
,to,TO,O
,80,CD,O
,%,NN,O
,.,.,O
,Further,JJ,O
,analysis,NN,O
,of,IN,O
,these,DT,O
,data,NNS,O
,suggests,VBZ,O
,that,IN,O
,the,DT,O
,duration,NN,O
,of,IN,O
,therapy,NN,O
,",",",",O
,plasma,JJ,O
,aminoglycoside,NN,O
,levels,NNS,O
,",",",",O
,liver,RB,B-DISEASE
,disease,NN,I-DISEASE
,",",",",O
,advanced,JJ,O
,age,NN,O
,",",",",O
,high,JJ,O
,initial,JJ,O
,estimated,VBN,O
,creatinine,JJ,O
,clearance,NN,O
,and,CC,O
,",",",",O
,possibly,RB,O
,",",",",O
,female,JJ,O
,gender,NN,O
,all,DT,O
,increase,VBP,O
,the,DT,O
,risk,NN,O
,for,IN,O
,nephrotoxicity,NN,B-DISEASE
,.,.,O
,Other,JJ,O
,causes,NNS,O
,of,IN,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,",",",",O
,such,JJ,O
,as,IN,O
,shock,NN,B-DISEASE
,",",",",O
,appear,VBP,O
,to,TO,O
,have,VB,O
,an,DT,O
,additive,JJ,O
,effect,NN,O
,.,.,O
,Predictive,JJ,O
,models,NNS,O
,have,VBP,O
,been,VBN,O
,developed,VBN,O
,from,IN,O
,these,DT,O
,analyses,NNS,O
,that,WDT,O
,should,MD,O
,be,VB,O
,useful,JJ,O
,for,IN,O
,identifying,VBG,O
,patients,NNS,O
,at,IN,O
,high,JJ,O
,risk,NN,O
,.,.,O
,These,DT,O
,models,NNS,O
,may,MD,O
,also,RB,O
,be,VB,O
,useful,JJ,O
,in,IN,O
,developing,VBG,O
,insights,NNS,O
,into,IN,O
,the,DT,O
,pathophysiology,NN,O
,of,IN,O
,aminoglycoside,JJ,O
,-,:,O
,induced,JJ,O
,nephrotoxicity,NN,B-DISEASE
,.,.,O
,Central,JJ,O
,action,NN,O
,of,IN,O
,narcotic,JJ,O
,analgesics,NNS,O
,.,.,O
,Part,NNP,O
,IV,NNP,O
,.,.,O
,Noradrenergic,NNP,O
,influences,VBZ,O
,on,IN,O
,the,DT,O
,activity,NN,O
,of,IN,O
,analgesics,NNS,O
,in,IN,O
,rats,NNS,O
,.,.,O
,The,DT,O
,effect,NN,O
,of,IN,O
,clonidine,NN,O
,",",",",O
,naphazoline,NN,O
,and,CC,O
,xylometazoline,NN,O
,on,IN,O
,analgesia,NN,O
,induced,VBN,O
,by,IN,O
,morphine,NN,O
,",",",",O
,codeine,NN,O
,",",",",O
,fentanyl,NN,O
,and,CC,O
,pentazocine,NN,O
,",",",",O
,and,CC,O
,on,IN,O
,cataleptic,JJ,B-DISEASE
,effect,NN,O
,of,IN,O
,morphine,NN,O
,",",",",O
,codine,NN,O
,and,CC,O
,fentanyl,NN,O
,was,VBD,O
,studied,VBN,O
,in,IN,O
,rats,NNS,O
,.,.,O
,The,DT,O
,biochemical,JJ,O
,assays,NNS,O
,on,IN,O
,the,DT,O
,influence,NN,O
,of,IN,O
,four,CD,O
,analgesics,NNS,O
,on,IN,O
,the,DT,O
,brain,NN,O
,concentration,NN,O
,and,CC,O
,turnover,NN,O
,of,IN,O
,noradrenaline,NN,O
,(,(,O
,,JJ,O
,),),O
,were,VBD,O
,also,RB,O
,performed,VBN,O
,.,.,O
,It,PRP,O
,was,VBD,O
,found,VBN,O
,that,IN,O
,three,CD,O
,drugs,NNS,O
,stimulating,VBG,O
,central,JJ,O
,,JJ,O
,receptors,NNS,O
,failed,VBD,O
,to,TO,O
,affect,VB,O
,the,DT,O
,analgesic,JJ,O
,ED50,NNP,O
,of,IN,O
,all,DT,O
,antinociceptive,JJ,O
,agents,NNS,O
,and,CC,O
,they,PRP,O
,enhanced,VBD,O
,catalepsy,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,morphine,NN,O
,and,CC,O
,fentanyl,NN,O
,.,.,O
,Codeine,NNP,O
,catalepsy,NN,B-DISEASE
,was,VBD,O
,increased,VBN,O
,by,IN,O
,clonidine,NN,O
,and,CC,O
,decreased,VBN,O
,by,IN,O
,naphazoline,NN,O
,and,CC,O
,xylometazoline,NN,O
,.,.,O
,The,DT,O
,brain,NN,O
,concentration,NN,O
,of,IN,O
,,NN,O
,was,VBD,O
,not,RB,O
,changed,VBN,O
,by,IN,O
,morphine,NN,O
,and,CC,O
,fentanyl,NN,O
,",",",",O
,but,CC,O
,one,CD,O
,of,IN,O
,the,DT,O
,doses,NNS,O
,of,IN,O
,codeine,NN,O
,(,(,O
,45,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,slightly,RB,O
,enhanced,VBD,O
,it,PRP,O
,.,.,O
,Pentazocine,NNP,O
,dose,JJ,O
,-,:,O
,dependently,RB,O
,decreased,VBD,O
,the,DT,O
,brain,NN,O
,level,NN,O
,of,IN,O
,,NN,O
,.,.,O
,The,DT,O
,rate,NN,O
,of,IN,O
,,JJ,O
,turnover,NN,O
,was,VBD,O
,not,RB,O
,altered,VBN,O
,by,IN,O
,analgesics,NNS,O
,except,IN,O
,for,IN,O
,the,DT,O
,higher,JJR,O
,dose,NN,O
,of,IN,O
,fentanyl,NN,O
,(,(,O
,0,CD,O
,.,.,O
,2,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,),),O
,following,VBG,O
,which,WDT,O
,the,DT,O
,disappearance,NN,O
,of,IN,O
,,NN,O
,from,IN,O
,the,DT,O
,brain,NN,O
,was,VBD,O
,diminished,VBN,O
,.,.,O
,The,DT,O
,results,NNS,O
,are,VBP,O
,discussed,VBN,O
,in,IN,O
,the,DT,O
,light,NN,O
,of,IN,O
,various,JJ,O
,and,CC,O
,non,JJ,O
,-,:,O
,uniform,JJ,O
,data,NNS,O
,from,IN,O
,the,DT,O
,literature,NN,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,suggested,VBN,O
,that,IN,O
,in,IN,O
,rats,NNS,O
,the,DT,O
,brain,NN,O
,,NN,O
,plays,VBZ,O
,a,DT,O
,less,RBR,O
,important,JJ,O
,function,NN,O
,than,IN,O
,the,DT,O
,other,JJ,O
,monoamines,NNS,O
,in,IN,O
,the,DT,O
,behavioural,JJ,O
,activity,NN,O
,of,IN,O
,potent,NN,O
,analgesics,NNS,O
,.,.,O
,Flurothyl,NNP,O
,seizure,NN,B-DISEASE
,thresholds,NNS,O
,in,IN,O
,mice,NN,O
,treated,VBN,O
,neonatally,RB,O
,with,IN,O
,a,DT,O
,single,JJ,O
,injection,NN,O
,of,IN,O
,monosodium,NN,O
,glutamate,NN,O
,(,(,O
,MSG,NNP,O
,),),O
,:,:,O
,evaluation,NN,O
,of,IN,O
,experimental,JJ,O
,parameters,NNS,O
,in,IN,O
,flurothyl,JJ,O
,seizure,NN,B-DISEASE
,testing,VBG,O
,.,.,O
,Monosodium,NN,O
,glutamate,NN,O
,(,(,O
,MSG,NNP,O
,),),O
,administration,NN,O
,to,TO,O
,neonatal,JJ,O
,rodents,NNS,O
,produces,VBZ,O
,convulsions,NNS,B-DISEASE
,and,CC,O
,results,NNS,O
,in,IN,O
,numerous,JJ,O
,biochemical,JJ,O
,and,CC,O
,behavioral,JJ,O
,deficits,NNS,O
,.,.,O
,These,DT,O
,studies,NNS,O
,were,VBD,O
,undertaken,VBN,O
,to,TO,O
,determine,VB,O
,if,IN,O
,neonatal,JJ,O
,administration,NN,O
,of,IN,O
,MSG,NNP,O
,produced,VBD,O
,permanent,JJ,O
,alterations,NNS,O
,in,IN,O
,seizure,NN,B-DISEASE
,susceptibility,NN,O
,",",",",O
,since,IN,O
,previous,JJ,O
,investigations,NNS,O
,were,VBD,O
,inconclusive,JJ,O
,.,.,O
,A,DT,O
,flurothyl,NN,O
,ether,NN,O
,seizure,NN,B-DISEASE
,screening,VBG,O
,technique,NN,O
,was,VBD,O
,used,VBN,O
,to,TO,O
,evaluate,VB,O
,seizure,NN,B-DISEASE
,susceptibility,NN,O
,in,IN,O
,adult,NN,O
,mice,NN,O
,that,WDT,O
,received,VBD,O
,neonatal,JJ,O
,injections,NNS,O
,of,IN,O
,MSG,NNP,O
,(,(,O
,4,CD,O
,mg,NN,O
,/,NNP,O
,g,NN,O
,and,CC,O
,1,CD,O
,mg,NN,O
,/,NNP,O
,g,NN,O
,),),O
,.,.,O
,MSG,NNP,O
,treatment,NN,O
,resulted,VBD,O
,in,IN,O
,significant,JJ,O
,reductions,NNS,O
,in,IN,O
,whole,JJ,O
,brain,NN,O
,weight,NN,O
,but,CC,O
,did,VBD,O
,not,RB,O
,alter,VB,O
,seizure,NN,B-DISEASE
,threshold,NN,O
,.,.,O
,A,DT,O
,naloxone,NN,O
,(,(,O
,5,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,challenge,NN,O
,was,VBD,O
,also,RB,O
,ineffective,JJ,O
,in,IN,O
,altering,VBG,O
,the,DT,O
,seizure,NN,B-DISEASE
,thresholds,NNS,O
,of,IN,O
,either,DT,O
,control,NN,O
,of,IN,O
,MSG,NNP,O
,-,:,O
,treated,JJ,O
,mice,NN,O
,.,.,O
,Flurothyl,NNP,O
,ether,RB,O
,produced,VBD,O
,hypothermia,NN,B-DISEASE
,which,WDT,O
,was,VBD,O
,correlated,VBN,O
,with,IN,O
,the,DT,O
,duration,NN,O
,of,IN,O
,flurothyl,JJ,O
,exposure,NN,O
,;,:,O
,however,RB,O
,",",",",O
,the,DT,O
,relationship,NN,O
,of,IN,O
,hypothermia,NN,B-DISEASE
,to,TO,O
,seizure,VB,B-DISEASE
,induction,NN,O
,was,VBD,O
,unclear,JJ,O
,.,.,O
,Flurothyl,NNP,O
,seizure,NN,B-DISEASE
,testing,VBG,O
,proved,VBD,O
,to,TO,O
,be,VB,O
,a,DT,O
,rapid,JJ,O
,and,CC,O
,reliable,JJ,O
,technique,NN,O
,with,IN,O
,which,WDT,O
,to,TO,O
,evaluate,VB,O
,seizure,NN,B-DISEASE
,susceptibility,NN,O
,.,.,O
,Susceptibility,NN,O
,to,TO,O
,seizures,NNS,B-DISEASE
,produced,VBN,O
,by,IN,O
,pilocarpine,NN,O
,in,IN,O
,rats,NNS,O
,after,IN,O
,microinjection,NN,O
,of,IN,O
,isoniazid,NN,O
,or,CC,O
,gamma,NN,O
,-,:,O
,vinyl,NN,O
,-,:,O
,GABA,NNP,O
,into,IN,O
,the,DT,O
,substantia,NN,O
,nigra,NN,O
,.,.,O
,Pilocarpine,NNP,O
,",",",",O
,given,VBN,O
,intraperitoneally,RB,O
,to,TO,O
,rats,VB,O
,",",",",O
,reproduces,VBZ,O
,the,DT,O
,neuropathological,JJ,O
,sequelae,NN,O
,of,IN,O
,temporal,JJ,B-DISEASE
,lobe,NN,I-DISEASE
,epilepsy,NN,I-DISEASE
,and,CC,O
,provides,VBZ,O
,a,DT,O
,relevant,JJ,O
,animal,NN,O
,model,NN,O
,for,IN,O
,studying,VBG,O
,mechanisms,NNS,O
,of,IN,O
,buildup,NN,O
,of,IN,O
,convulsive,JJ,B-DISEASE
,activity,NN,O
,and,CC,O
,pathways,NNS,O
,operative,VBP,O
,in,IN,O
,the,DT,O
,generalization,NN,O
,and,CC,O
,propagation,NN,O
,of,IN,O
,seizures,NNS,B-DISEASE
,within,IN,O
,the,DT,O
,forebrain,NN,O
,.,.,O
,In,IN,O
,the,DT,O
,present,JJ,O
,study,NN,O
,",",",",O
,the,DT,O
,effects,NNS,O
,of,IN,O
,manipulating,VBG,O
,the,DT,O
,activity,NN,O
,of,IN,O
,the,DT,O
,gamma,NN,O
,-,:,O
,aminobutyric,JJ,O
,acid,NN,O
,(,(,O
,GABA,NNP,O
,),),O
,-,:,O
,mediated,VBN,O
,synaptic,JJ,O
,inhibition,NN,O
,within,IN,O
,the,DT,O
,substantia,NN,O
,nigra,NN,O
,on,IN,O
,seizures,NNS,B-DISEASE
,produced,VBN,O
,by,IN,O
,pilocarpine,NN,O
,in,IN,O
,rats,NNS,O
,",",",",O
,were,VBD,O
,investigated,VBN,O
,.,.,O
,In,IN,O
,animals,NNS,O
,pretreated,VBN,O
,with,IN,O
,microinjections,NNS,O
,of,IN,O
,isoniazid,NN,O
,",",",",O
,150,CD,O
,micrograms,NNS,O
,",",",",O
,an,DT,O
,inhibitor,NN,O
,of,IN,O
,activity,NN,O
,of,IN,O
,the,DT,O
,GABA,NNP,O
,-,:,O
,synthesizing,VBG,O
,enzyme,NN,O
,",",",",O
,L,NNP,O
,-,:,O
,glutamic,JJ,O
,acid,NN,O
,decarboxylase,NN,O
,",",",",O
,into,IN,O
,the,DT,O
,substantia,NN,O
,nigra,JJ,O
,pars,NNS,O
,reticulata,VBP,O
,(,(,O
,SNR,NNP,O
,),),O
,",",",",O
,bilaterally,RB,O
,",",",",O
,non,SYM,O
,-,:,O
,convulsant,JJ,O
,doses,NNS,O
,of,IN,O
,pilocarpine,NN,O
,",",",",O
,100,CD,O
,and,CC,O
,200,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,resulted,VBD,O
,in,IN,O
,severe,JJ,O
,motor,NN,O
,limbic,JJ,O
,seizures,NNS,B-DISEASE
,and,CC,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,.,.,O
,Electroencephalographic,NNP,O
,and,CC,O
,behavioral,JJ,O
,monitoring,NN,O
,revealed,VBD,O
,a,DT,O
,profound,JJ,O
,reduction,NN,O
,of,IN,O
,the,DT,O
,threshold,NN,O
,for,IN,O
,pilocarpine,JJ,O
,-,:,O
,induced,JJ,O
,convulsions,NNS,B-DISEASE
,.,.,O
,Morphological,JJ,O
,analysis,NN,O
,of,IN,O
,frontal,JJ,O
,forebrain,NN,O
,sections,NNS,O
,with,IN,O
,light,JJ,O
,microscopy,NNS,O
,revealed,VBD,O
,seizure,NN,B-DISEASE
,-,:,O
,related,JJ,O
,damage,NN,O
,to,TO,O
,the,DT,O
,hippocampal,JJ,O
,formation,NN,O
,",",",",O
,thalamus,NN,O
,",",",",O
,amygdala,NN,O
,",",",",O
,olfactory,JJ,O
,cortex,NN,O
,",",",",O
,substantia,NN,O
,nigra,NN,O
,and,CC,O
,neocortex,NN,O
,",",",",O
,which,WDT,O
,is,VBZ,O
,typically,RB,O
,observed,VBN,O
,with,IN,O
,pilocarpine,NN,O
,in,IN,O
,doses,NNS,O
,exceeding,VBG,O
,350,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,.,.,O
,Bilateral,NNP,O
,intrastriatal,JJ,O
,injections,NNS,O
,of,IN,O
,isoniazid,NN,O
,did,VBD,O
,not,RB,O
,augment,JJ,O
,seizures,NNS,B-DISEASE
,produced,VBN,O
,by,IN,O
,pilocarpine,NN,O
,",",",",O
,200,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,.,.,O
,Application,NNP,O
,of,IN,O
,an,DT,O
,irreversible,JJ,O
,inhibitor,NN,O
,of,IN,O
,GABA,NNP,O
,transaminase,NN,O
,",",",",O
,gamma,SYM,O
,-,:,O
,vinyl,NN,O
,-,:,O
,GABA,NNP,O
,(,(,O
,D,NNP,O
,",",",",O
,L,NNP,O
,-,:,O
,4,CD,O
,-,:,O
,amino,NN,O
,-,:,O
,hex,NN,O
,-,:,O
,5,CD,O
,-,:,O
,enoic,NN,O
,acid,NN,O
,),),O
,",",",",O
,5,CD,O
,micrograms,NN,O
,",",",",O
,into,IN,O
,the,DT,O
,SNR,NNP,O
,",",",",O
,bilaterally,RB,O
,",",",",O
,suppressed,VBD,O
,the,DT,O
,appearance,NN,O
,of,IN,O
,electrographic,JJ,O
,and,CC,O
,behavioral,JJ,O
,seizures,NNS,B-DISEASE
,produced,VBN,O
,by,IN,O
,pilocarpine,NN,O
,",",",",O
,380,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,.,.,O
,This,DT,O
,treatment,NN,O
,was,VBD,O
,also,RB,O
,sufficient,JJ,O
,to,TO,O
,protect,VB,O
,animals,NNS,O
,from,IN,O
,the,DT,O
,occurrence,NN,O
,of,IN,O
,brain,NN,B-DISEASE
,damage,NN,I-DISEASE
,.,.,O
,Microinjections,NNS,O
,of,IN,O
,gamma,NN,O
,-,:,O
,vinyl,NN,O
,-,:,O
,GABA,NNP,O
,",",",",O
,5,CD,O
,micrograms,NN,O
,",",",",O
,into,IN,O
,the,DT,O
,dorsal,NN,O
,striatum,NN,O
,",",",",O
,bilaterally,RB,O
,",",",",O
,failed,VBD,O
,to,TO,O
,prevent,VB,O
,the,DT,O
,development,NN,O
,of,IN,O
,convulsions,NNS,B-DISEASE
,produced,VBN,O
,by,IN,O
,pilocarpine,NN,O
,",",",",O
,380,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,.,.,O
,The,DT,O
,results,NNS,O
,demonstrate,VBP,O
,that,IN,O
,the,DT,O
,threshold,NN,O
,for,IN,O
,pilocarpine,JJ,O
,-,:,O
,induced,JJ,O
,seizures,NNS,B-DISEASE
,in,IN,O
,rats,NNS,O
,is,VBZ,O
,subjected,VBN,O
,to,TO,O
,the,DT,O
,regulation,NN,O
,of,IN,O
,the,DT,O
,GABA,NNP,O
,-,:,O
,mediated,VBD,O
,synaptic,JJ,O
,inhibition,NN,O
,within,IN,O
,the,DT,O
,substantia,NN,O
,nigra,NN,O
,.,.,O
,Human,NNP,O
,and,CC,O
,canine,VB,O
,ventricular,JJ,O
,vasoactive,JJ,O
,intestinal,JJ,O
,polypeptide,NN,O
,:,:,O
,decrease,NN,O
,with,IN,O
,heart,NN,B-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,Vasoactive,JJ,O
,intestinal,JJ,O
,polypeptide,NN,O
,(,(,O
,VIP,NNP,O
,),),O
,is,VBZ,O
,a,DT,O
,systemic,JJ,O
,and,CC,O
,coronary,JJ,O
,vasodilator,NN,O
,that,WDT,O
,may,MD,O
,have,VB,O
,positive,JJ,O
,inotropic,NN,O
,properties,NNS,O
,.,.,O
,Myocardial,JJ,O
,levels,NNS,O
,of,IN,O
,VIP,NNP,O
,were,VBD,O
,assayed,VBN,O
,before,IN,O
,and,CC,O
,after,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,heart,NN,B-DISEASE
,failure,NN,I-DISEASE
,in,IN,O
,two,CD,O
,canine,NN,O
,models,NNS,O
,.,.,O
,In,IN,O
,the,DT,O
,first,JJ,O
,",",",",O
,cobalt,JJ,O
,cardiomyopathy,NN,B-DISEASE
,was,VBD,O
,induced,VBN,O
,in,IN,O
,eight,CD,O
,dogs,NNS,O
,;,:,O
,VIP,NNP,O
,(,(,O
,by,IN,O
,radioimmunoassay,NN,O
,),),O
,decreased,VBD,O
,from,IN,O
,35,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,11,CD,O
,pg,NN,O
,/,NNP,O
,mg,NN,O
,protein,NN,O
,(,(,O
,mean,JJ,O
,+,NNP,O
,/,NNP,O
,-,:,O
,SD,NN,O
,),),O
,to,TO,O
,5,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,4,CD,O
,pg,NN,O
,/,NNP,O
,mg,NN,O
,protein,NN,O
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,In,IN,O
,six,CD,O
,dogs,NNS,O
,with,IN,O
,doxorubicin,JJ,O
,-,:,O
,induced,JJ,O
,heart,NN,B-DISEASE
,failure,NN,I-DISEASE
,",",",",O
,VIP,NNP,O
,decreased,VBD,O
,from,IN,O
,31,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,7,CD,O
,to,TO,O
,11,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,4,CD,O
,pg,NN,O
,/,NNP,O
,mg,NN,O
,protein,NN,O
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,In,IN,O
,addition,NN,O
,",",",",O
,VIP,NNP,O
,content,NN,O
,of,IN,O
,left,JJ,O
,ventricular,JJ,O
,muscle,NN,O
,of,IN,O
,resected,JJ,O
,failing,VBG,O
,hearts,NNS,O
,in,IN,O
,10,CD,O
,patients,NNS,O
,receiving,VBG,O
,a,DT,O
,heart,NN,O
,transplant,NN,O
,was,VBD,O
,compared,VBN,O
,with,IN,O
,the,DT,O
,papillary,JJ,O
,muscles,NNS,O
,in,IN,O
,14,CD,O
,patients,NNS,O
,(,(,O
,five,CD,O
,with,IN,O
,rheumatic,JJ,B-DISEASE
,disease,NN,I-DISEASE
,",",",",O
,nine,CD,O
,with,IN,O
,myxomatous,JJ,B-DISEASE
,degeneration,NN,I-DISEASE
,),),O
,receiving,VBG,O
,mitral,JJ,O
,valve,NN,O
,prostheses,NNS,O
,.,.,O
,The,DT,O
,lowest,JJS,O
,myocardial,JJ,O
,VIP,NNP,O
,concentration,NN,O
,was,VBD,O
,found,VBN,O
,in,IN,O
,the,DT,O
,hearts,NNS,O
,of,IN,O
,patients,NNS,O
,with,IN,O
,coronary,JJ,B-DISEASE
,disease,NN,I-DISEASE
,(,(,O
,one,CD,O
,patient,NN,O
,receiving,VBG,O
,a,DT,O
,transplant,NN,O
,and,CC,O
,three,CD,O
,receiving,VBG,O
,mitral,JJ,O
,prostheses,NNS,O
,),),O
,(,(,O
,6,CD,O
,.,.,O
,3,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,9,CD,O
,pg,JJ,O
,/,NNP,O
,mg,NNP,O
,protein,NN,O
,),),O
,.,.,O
,The,DT,O
,other,JJ,O
,patients,NNS,O
,undergoing,JJ,O
,transplantation,NN,O
,had,VBD,O
,an,DT,O
,average,JJ,O
,ejection,NN,O
,fraction,NN,O
,of,IN,O
,17,CD,O
,%,NN,O
,+,NNP,O
,/,NNP,O
,-,:,O
,6,CD,O
,%,NN,O
,and,CC,O
,a,DT,O
,VIP,NNP,O
,level,NN,O
,of,IN,O
,8,CD,O
,.,.,O
,8,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,3,CD,O
,.,.,O
,9,CD,O
,pg,JJ,O
,/,NNP,O
,mg,NN,O
,protein,NN,O
,.,.,O
,The,DT,O
,hearts,NNS,O
,without,IN,O
,coronary,JJ,B-DISEASE
,artery,NN,I-DISEASE
,disease,NN,I-DISEASE
,(,(,O
,average,JJ,O
,ejection,NN,O
,fraction,NN,O
,of,IN,O
,this,DT,O
,group,NN,O
,62,CD,O
,%,NN,O
,+,NNP,O
,/,NNP,O
,-,:,O
,10,CD,O
,%,NN,O
,),),O
,had,VBD,O
,a,DT,O
,VIP,NNP,O
,concentration,NN,O
,of,IN,O
,14,CD,O
,.,.,O
,1,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,7,CD,O
,.,.,O
,9,CD,O
,pg,JJ,O
,/,NNP,O
,mg,NN,O
,protein,NN,O
,",",",",O
,and,CC,O
,this,DT,O
,was,VBD,O
,greater,JJR,O
,than,IN,O
,in,IN,O
,hearts,NNS,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,with,IN,O
,coronary,JJ,B-DISEASE
,disease,NN,I-DISEASE
,and,CC,O
,the,DT,O
,hearts,NNS,O
,of,IN,O
,patients,NNS,O
,receiving,VBG,O
,a,DT,O
,transplant,NN,O
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,Myocardial,JJ,O
,catecholamines,NNS,O
,were,VBD,O
,also,RB,O
,determined,VBN,O
,in,IN,O
,14,CD,O
,subjects,NNS,O
,;,:,O
,a,DT,O
,weak,JJ,O
,correlation,NN,O
,(,(,O
,r,JJ,O
,=,NN,O
,0,CD,O
,.,.,O
,57,CD,O
,",",",",O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,between,IN,O
,the,DT,O
,tissue,NN,O
,concentrations,NNS,O
,of,IN,O
,VIP,NNP,O
,and,CC,O
,norepinephrine,NN,O
,was,VBD,O
,noted,VBN,O
,.,.,O
,(,(,O
,ABSTRACT,NNP,O
,TRUNCATED,NNP,O
,AT,NNP,O
,250,CD,O
,WORDS,NNP,O
,),),O
,Non,NNP,O
,-,:,O
,invasive,JJ,O
,detection,NN,O
,of,IN,O
,coronary,JJ,B-DISEASE
,artery,NN,I-DISEASE
,disease,NN,I-DISEASE
,by,IN,O
,body,NN,O
,surface,NN,O
,electrocardiographic,JJ,O
,mapping,NN,O
,after,IN,O
,dipyridamole,JJ,O
,infusion,NN,O
,.,.,O
,Electrocardiographic,JJ,O
,changes,NNS,O
,after,IN,O
,dipyridamole,JJ,O
,infusion,NN,O
,(,(,O
,0,CD,O
,.,.,O
,568,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,/,VBD,O
,4,CD,O
,min,NN,O
,),),O
,were,VBD,O
,studied,VBN,O
,in,IN,O
,41,CD,O
,patients,NNS,O
,with,IN,O
,coronary,JJ,B-DISEASE
,artery,NN,I-DISEASE
,disease,NN,I-DISEASE
,and,CC,O
,compared,VBN,O
,with,IN,O
,those,DT,O
,after,IN,O
,submaximal,JJ,O
,treadmill,NN,O
,exercise,NN,O
,by,IN,O
,use,NN,O
,of,IN,O
,the,DT,O
,body,NN,O
,surface,NN,O
,mapping,NN,O
,technique,NN,O
,.,.,O
,Patients,NNS,O
,were,VBD,O
,divided,VBN,O
,into,IN,O
,three,CD,O
,groups,NNS,O
,;,:,O
,19,CD,O
,patients,NNS,O
,without,IN,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,(,(,O
,non,JJ,O
,-,:,O
,MI,NNP,B-DISEASE
,group,NN,O
,),),O
,",",",",O
,14,CD,O
,with,IN,O
,anterior,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,(,(,O
,ANT,NNP,B-DISEASE
,-,:,I-DISEASE
,MI,NN,I-DISEASE
,),),O
,and,CC,O
,eight,CD,O
,with,IN,O
,inferior,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,(,(,O
,INF,NNP,B-DISEASE
,-,:,I-DISEASE
,MI,NN,I-DISEASE
,),),O
,.,.,O
,Eighty,NNP,O
,-,:,O
,seven,CD,O
,unipolar,JJ,O
,electrocardiograms,NNS,O
,(,(,O
,ECGs,NNP,O
,),),O
,distributed,VBD,O
,over,IN,O
,the,DT,O
,entire,JJ,O
,thoracic,NN,O
,surface,NN,O
,were,VBD,O
,simultaneously,RB,O
,recorded,VBN,O
,.,.,O
,After,IN,O
,dipyridamole,NN,O
,",",",",O
,ischemic,JJ,B-DISEASE
,ST,NNP,O
,-,:,O
,segment,NN,O
,depression,NN,B-DISEASE
,(,(,O
,0,CD,O
,.,.,O
,05,CD,O
,mV,NN,O
,or,CC,O
,more,JJR,O
,),),O
,was,VBD,O
,observed,VBN,O
,in,IN,O
,84,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,non,JJ,O
,-,:,O
,MI,NNP,B-DISEASE
,group,NN,O
,",",",",O
,29,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,ANT,NNP,B-DISEASE
,-,:,I-DISEASE
,MI,NNP,I-DISEASE
,group,NN,O
,",",",",O
,63,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,INF,NNP,B-DISEASE
,-,:,I-DISEASE
,MI,NNP,I-DISEASE
,group,NN,O
,and,CC,O
,61,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,total,JJ,O
,population,NN,O
,.,.,O
,Exercise,NNP,O
,-,:,O
,induced,VBD,O
,ST,NNP,O
,depression,NN,B-DISEASE
,was,VBD,O
,observed,VBN,O
,in,IN,O
,84,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,non,JJ,O
,-,:,O
,MI,NNP,B-DISEASE
,group,NN,O
,",",",",O
,43,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,ANT,NNP,B-DISEASE
,-,:,I-DISEASE
,MI,NNP,I-DISEASE
,group,NN,O
,",",",",O
,38,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,INF,NNP,B-DISEASE
,-,:,I-DISEASE
,MI,NNP,I-DISEASE
,group,NN,O
,and,CC,O
,61,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,total,NN,O
,.,.,O
,For,IN,O
,individual,JJ,O
,patients,NNS,O
,",",",",O
,there,EX,O
,were,VBD,O
,no,DT,O
,obvious,JJ,O
,differences,NNS,O
,between,IN,O
,the,DT,O
,body,NN,O
,surface,JJ,O
,distribution,NN,O
,of,IN,O
,ST,NNP,O
,depression,NN,B-DISEASE
,in,IN,O
,both,DT,O
,tests,NNS,O
,.,.,O
,The,DT,O
,increase,NN,O
,in,IN,O
,pressure,NN,O
,rate,NN,O
,product,NN,O
,after,IN,O
,dipyridamole,NN,O
,was,VBD,O
,significantly,RB,O
,less,JJR,O
,than,IN,O
,that,DT,O
,during,IN,O
,the,DT,O
,treadmill,NN,O
,exercise,NN,O
,.,.,O
,The,DT,O
,data,NN,O
,suggest,NN,O
,that,IN,O
,the,DT,O
,dipyridamole,JJ,O
,-,:,O
,induced,JJ,O
,myocardial,JJ,B-DISEASE
,ischemia,NN,I-DISEASE
,is,VBZ,O
,caused,VBN,O
,by,IN,O
,the,DT,O
,inhomogenous,JJ,O
,distribution,NN,O
,of,IN,O
,myocardial,JJ,O
,blood,NN,O
,flow,NN,O
,.,.,O
,We,PRP,O
,conclude,VBP,O
,that,IN,O
,the,DT,O
,dipyridamole,JJ,O
,ECG,NNP,O
,test,NN,O
,is,VBZ,O
,as,RB,O
,useful,JJ,O
,as,IN,O
,the,DT,O
,exercise,NN,O
,ECG,NNP,O
,test,NN,O
,for,IN,O
,the,DT,O
,assessment,NN,O
,of,IN,O
,coronary,JJ,B-DISEASE
,artery,NN,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,Bradycardia,NNP,B-DISEASE
,after,IN,O
,high,JJ,O
,-,:,O
,dose,RB,O
,intravenous,JJ,O
,methylprednisolone,NN,O
,therapy,NN,O
,.,.,O
,In,IN,O
,5,CD,O
,consecutive,JJ,O
,patients,NNS,O
,with,IN,O
,rheumatoid,JJ,B-DISEASE
,arthritis,NN,I-DISEASE
,who,WP,O
,received,VBD,O
,intravenous,JJ,O
,high,JJ,O
,-,:,O
,dose,NN,O
,methylprednisolone,NN,O
,(,(,O
,MP,NNP,O
,),),O
,therapy,NN,O
,(,(,O
,1,CD,O
,g,NNS,O
,daily,RB,O
,for,IN,O
,2,CD,O
,or,CC,O
,3,CD,O
,consecutive,JJ,O
,days,NNS,O
,),),O
,",",",",O
,a,DT,O
,decline,NN,O
,in,IN,O
,pulse,JJ,O
,rate,NN,O
,was,VBD,O
,observed,VBN,O
,",",",",O
,most,JJS,O
,pronounced,VBN,O
,on,IN,O
,day,NN,O
,4,CD,O
,.,.,O
,In,IN,O
,one,CD,O
,of,IN,O
,the,DT,O
,5,CD,O
,patients,NNS,O
,the,DT,O
,bradycardia,NN,B-DISEASE
,was,VBD,O
,associated,VBN,O
,with,IN,O
,complaints,NNS,O
,of,IN,O
,substernal,JJ,O
,pressure,NN,O
,.,.,O
,Reversal,NNP,O
,to,TO,O
,normal,JJ,O
,heart,NN,O
,rate,NN,O
,was,VBD,O
,found,VBN,O
,on,IN,O
,day,NN,O
,7,CD,O
,.,.,O
,Electrocardiographic,JJ,O
,registrations,NNS,O
,showed,VBD,O
,sinus,JJ,B-DISEASE
,bradycardia,NN,I-DISEASE
,in,IN,O
,all,DT,O
,cases,NNS,O
,.,.,O
,No,DT,O
,significant,JJ,O
,changes,NNS,O
,in,IN,O
,plasma,JJ,O
,concentrations,NNS,O
,of,IN,O
,electrolytes,NNS,O
,were,VBD,O
,found,VBN,O
,.,.,O
,Careful,JJ,O
,observation,NN,O
,of,IN,O
,patients,NNS,O
,receiving,VBG,O
,high,JJ,O
,-,:,O
,dose,NN,O
,MP,NNP,O
,is,VBZ,O
,recommended,VBN,O
,.,.,O
,High,NNP,O
,-,:,O
,dose,JJ,O
,MP,NNP,O
,may,MD,O
,be,VB,O
,contraindicated,VBN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,known,JJ,O
,heart,NN,B-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,Two,CD,O
,cases,NNS,O
,of,IN,O
,downbeat,NN,B-DISEASE
,nystagmus,NNS,I-DISEASE
,and,CC,O
,oscillopsia,NN,B-DISEASE
,associated,VBN,O
,with,IN,O
,carbamazepine,NN,O
,.,.,O
,Downbeat,NNP,B-DISEASE
,nystagmus,NN,I-DISEASE
,is,VBZ,O
,often,RB,O
,associated,VBN,O
,with,IN,O
,structural,JJ,O
,lesions,NNS,O
,at,IN,O
,the,DT,O
,craniocervical,JJ,O
,junction,NN,O
,",",",",O
,but,CC,O
,has,VBZ,O
,occasionally,RB,O
,been,VBN,O
,reported,VBN,O
,as,IN,O
,a,DT,O
,manifestation,NN,O
,of,IN,O
,metabolic,JJ,O
,imbalance,NN,O
,or,CC,O
,drug,NN,O
,intoxication,NN,O
,.,.,O
,We,PRP,O
,recorded,VBD,O
,the,DT,O
,eye,NN,O
,movements,NNS,O
,of,IN,O
,two,CD,O
,patients,NNS,O
,with,IN,O
,reversible,JJ,O
,downbeat,NN,B-DISEASE
,nystagmus,RB,I-DISEASE
,related,VBN,O
,to,TO,O
,carbamazepine,VB,O
,therapy,NN,O
,.,.,O
,The,DT,O
,nystagmus,NN,B-DISEASE
,of,IN,O
,both,DT,O
,patients,NNS,O
,resolved,VBN,O
,after,IN,O
,reduction,NN,O
,of,IN,O
,the,DT,O
,serum,JJ,O
,carbamazepine,NN,O
,levels,NNS,O
,.,.,O
,Neuroradiologic,NNP,O
,investigations,NNS,O
,including,VBG,O
,magnetic,JJ,O
,resonance,NN,O
,imaging,NN,O
,scans,NNS,O
,in,IN,O
,both,DT,O
,patients,NNS,O
,showed,VBD,O
,no,DT,O
,evidence,NN,O
,of,IN,O
,intracranial,JJ,O
,abnormality,NN,O
,.,.,O
,In,IN,O
,patients,NNS,O
,with,IN,O
,downbeat,JJ,B-DISEASE
,nystagmus,NNS,I-DISEASE
,who,WP,O
,are,VBP,O
,taking,VBG,O
,anticonvulsant,JJ,O
,medications,NNS,O
,",",",",O
,consideration,NN,O
,should,MD,O
,be,VB,O
,given,VBN,O
,to,TO,O
,reduction,NN,O
,in,IN,O
,dose,NN,O
,before,IN,O
,further,JJ,O
,investigation,NN,O
,is,VBZ,O
,undertaken,JJ,O
,.,.,O
,Improvement,NN,O
,by,IN,O
,denopamine,NN,O
,(,(,O
,TA,NNP,O
,-,:,O
,064,CD,O
,),),O
,of,IN,O
,pentobarbital,JJ,O
,-,:,O
,induced,JJ,O
,cardiac,JJ,B-DISEASE
,failure,NN,I-DISEASE
,in,IN,O
,the,DT,O
,dog,NN,O
,heart,NN,O
,-,:,O
,lung,NN,O
,preparation,NN,O
,.,.,O
,The,DT,O
,efficacy,NN,O
,of,IN,O
,denopamine,NN,O
,",",",",O
,an,DT,O
,orally,RB,O
,active,JJ,O
,beta,NN,O
,1,CD,O
,-,:,O
,adrenoceptor,NN,O
,agonist,NN,O
,",",",",O
,in,IN,O
,improving,VBG,O
,cardiac,JJ,B-DISEASE
,failure,NN,I-DISEASE
,was,VBD,O
,assessed,VBN,O
,in,IN,O
,dog,JJ,O
,heart,NN,O
,-,:,O
,lung,NN,O
,preparations,NNS,O
,.,.,O
,Cardiac,JJ,O
,functions,NNS,O
,depressed,VBN,O
,by,IN,O
,pentobarbital,NN,O
,(,(,O
,118,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,28,CD,O
,mg,NN,O
,;,:,O
,mean,CC,O
,value,NN,O
,+,NNP,O
,/,NNP,O
,-,:,O
,SD,NN,O
,),),O
,such,PDT,O
,that,IN,O
,cardiac,JJ,O
,output,NN,O
,and,CC,O
,maximum,JJ,O
,rate,NN,O
,of,IN,O
,rise,NN,O
,of,IN,O
,left,JJ,O
,ventricular,JJ,O
,pressure,NN,O
,(,(,O
,LV,NNP,O
,dP,VBZ,O
,/,NNP,O
,dt,NNP,O
,max,NN,O
,),),O
,had,VBD,O
,been,VBN,O
,reduced,VBN,O
,by,IN,O
,about,IN,O
,35,CD,O
,%,NN,O
,and,CC,O
,26,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,respective,JJ,O
,controls,NNS,O
,were,VBD,O
,improved,VBN,O
,by,IN,O
,denopamine,NN,O
,(,(,O
,10,CD,O
,-,:,O
,300,CD,O
,micrograms,NNS,O
,),),O
,in,IN,O
,a,DT,O
,dose,JJ,O
,-,:,O
,dependent,JJ,O
,manner,NN,O
,.,.,O
,With,IN,O
,100,CD,O
,micrograms,NNS,O
,denopamine,NN,O
,",",",",O
,almost,RB,O
,complete,JJ,O
,restoration,NN,O
,of,IN,O
,cardiac,JJ,O
,performance,NN,O
,was,VBD,O
,attained,VBN,O
,",",",",O
,associated,VBN,O
,with,IN,O
,a,DT,O
,slight,JJ,O
,increase,NN,O
,in,IN,O
,heart,NN,O
,rate,NN,O
,.,.,O
,No,CC,O
,arrhythmias,JJ,B-DISEASE
,were,VBD,O
,induced,VBN,O
,by,IN,O
,these,DT,O
,doses,NNS,O
,of,IN,O
,denopamine,NN,O
,.,.,O
,The,DT,O
,results,NNS,O
,warrant,VBP,O
,clinical,JJ,O
,trials,NNS,O
,of,IN,O
,denopamine,NN,O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,cardiac,JJ,B-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,Clonazepam,NNP,O
,monotherapy,NN,O
,for,IN,O
,epilepsy,NN,B-DISEASE
,in,IN,O
,childhood,NN,O
,.,.,O
,Sixty,CD,O
,patients,NNS,O
,(,(,O
,age,NN,O
,-,:,O
,range,NN,O
,one,CD,O
,month,NN,O
,to,TO,O
,14,CD,O
,years,NNS,O
,),),O
,with,IN,O
,other,JJ,O
,types,NNS,O
,of,IN,O
,epilepsy,NN,B-DISEASE
,than,IN,O
,infantile,JJ,B-DISEASE
,spasms,NNS,I-DISEASE
,were,VBD,O
,treated,VBN,O
,with,IN,O
,clonazepam,NN,O
,.,.,O
,Disappearance,NN,O
,of,IN,O
,seizures,NNS,B-DISEASE
,and,CC,O
,normalization,NN,O
,of,IN,O
,abnormal,JJ,O
,EEG,NNP,O
,with,IN,O
,disappearance,NN,O
,of,IN,O
,seizures,NNS,B-DISEASE
,were,VBD,O
,recognized,VBN,O
,in,IN,O
,77,CD,O
,%,NN,O
,and,CC,O
,50,CD,O
,%,NN,O
,",",",",O
,respectively,RB,O
,.,.,O
,Seizures,NNS,B-DISEASE
,disappeared,VBD,O
,in,IN,O
,71,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,with,IN,O
,generalized,JJ,O
,seizures,NNS,B-DISEASE
,and,CC,O
,89,CD,O
,%,NN,O
,of,IN,O
,partial,JJ,O
,seizures,NNS,B-DISEASE
,.,.,O
,Improvement,NN,O
,of,IN,O
,abnormal,JJ,O
,EEG,NNP,O
,was,VBD,O
,noticed,VBN,O
,in,IN,O
,76,CD,O
,%,NN,O
,of,IN,O
,diffuse,NN,O
,paroxysms,NNS,O
,and,CC,O
,in,IN,O
,67,CD,O
,%,NN,O
,of,IN,O
,focal,JJ,O
,paroxysms,NNS,O
,.,.,O
,In,IN,O
,excellent,JJ,O
,cases,NNS,O
,",",",",O
,mean,JJ,O
,effective,JJ,O
,dosages,NNS,O
,were,VBD,O
,0,CD,O
,.,.,O
,086,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,021,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,/,NNP,O
,day,NN,O
,in,IN,O
,infants,NNS,O
,and,CC,O
,0,CD,O
,.,.,O
,057,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,022,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,/,NNP,O
,day,NN,O
,in,IN,O
,schoolchildren,NN,O
,",",",",O
,this,DT,O
,difference,NN,O
,was,VBD,O
,statistically,RB,O
,significant,JJ,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,005,CD,O
,),),O
,.,.,O
,The,DT,O
,incidence,NN,O
,of,IN,O
,side,JJ,O
,effects,NNS,O
,such,JJ,O
,as,IN,O
,drowsiness,NN,B-DISEASE
,and,CC,O
,ataxia,NN,B-DISEASE
,was,VBD,O
,only,RB,O
,5,CD,O
,%,NN,O
,.,.,O
,Postmarketing,VBG,O
,study,NN,O
,of,IN,O
,timolol,JJ,O
,-,:,O
,hydrochlorothiazide,NN,O
,antihypertensive,JJ,O
,therapy,NN,O
,.,.,O
,A,DT,O
,postmarketing,NN,O
,surveillance,NN,O
,study,NN,O
,was,VBD,O
,conducted,VBN,O
,to,TO,O
,determine,VB,O
,the,DT,O
,safety,NN,O
,and,CC,O
,efficacy,NN,O
,of,IN,O
,a,DT,O
,fixed,JJ,O
,-,:,O
,ratio,NN,O
,combination,NN,O
,containing,VBG,O
,10,CD,O
,mg,NN,O
,of,IN,O
,timolol,JJ,O
,maleate,NN,O
,and,CC,O
,25,CD,O
,mg,NN,O
,of,IN,O
,hydrochlorothiazide,NN,O
,",",",",O
,administered,VBN,O
,twice,RB,O
,daily,RB,O
,for,IN,O
,one,CD,O
,month,NN,O
,to,TO,O
,hypertensive,JJ,B-DISEASE
,patients,NNS,O
,.,.,O
,Data,NNP,O
,on,IN,O
,9,CD,O
,",",",",O
,037,CD,O
,patients,NNS,O
,were,VBD,O
,collected,VBN,O
,by,IN,O
,1,CD,O
,",",",",O
,455,CD,O
,participating,VBG,O
,physicians,NNS,O
,.,.,O
,Mean,NNP,O
,systolic,JJ,O
,blood,NN,O
,pressure,NN,O
,decreased,VBD,O
,25,CD,O
,mmHg,NN,O
,and,CC,O
,mean,JJ,O
,diastolic,JJ,O
,blood,NN,O
,pressure,NN,O
,declined,VBD,O
,15,CD,O
,mmHg,NN,O
,after,IN,O
,one,CD,O
,month,NN,O
,of,IN,O
,timolol,JJ,O
,-,:,O
,hydrochlorothiazide,NN,O
,therapy,NN,O
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,01,CD,O
,",",",",O
,both,DT,O
,comparisons,NNS,O
,),),O
,.,.,O
,Age,NNP,O
,",",",",O
,race,NN,O
,",",",",O
,and,CC,O
,sex,NN,O
,appeared,VBD,O
,to,TO,O
,have,VB,O
,no,DT,O
,influence,NN,O
,on,IN,O
,the,DT,O
,decrease,NN,O
,in,IN,O
,blood,NN,O
,pressure,NN,O
,.,.,O
,The,DT,O
,antihypertensive,JJ,O
,effect,NN,O
,of,IN,O
,the,DT,O
,drug,NN,O
,was,VBD,O
,greater,JJR,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,more,RBR,O
,severe,JJ,O
,hypertension,NN,B-DISEASE
,.,.,O
,Overall,NNP,O
,",",",",O
,1,CD,O
,",",",",O
,453,CD,O
,patients,NNS,O
,experienced,VBD,O
,a,DT,O
,total,NN,O
,of,IN,O
,2,CD,O
,",",",",O
,658,CD,O
,adverse,JJ,O
,events,NNS,O
,",",",",O
,the,DT,O
,most,RBS,O
,common,JJ,O
,being,VBG,O
,fatigue,JJ,B-DISEASE
,",",",",O
,dizziness,NN,B-DISEASE
,",",",",O
,and,CC,O
,weakness,NN,B-DISEASE
,.,.,O
,Treatment,NN,O
,in,IN,O
,590,CD,O
,patients,NNS,O
,was,VBD,O
,discontinued,VBN,O
,because,IN,O
,of,IN,O
,adverse,JJ,O
,events,NNS,O
,.,.,O
,Salicylate,NNP,O
,nephropathy,NN,B-DISEASE
,in,IN,O
,the,DT,O
,Gunn,NNP,O
,rat,NN,O
,:,:,O
,potential,JJ,O
,role,NN,O
,of,IN,O
,prostaglandins,NNS,O
,.,.,O
,We,PRP,O
,examined,VBD,O
,the,DT,O
,potential,JJ,O
,role,NN,O
,of,IN,O
,prostaglandins,NNS,O
,in,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,analgesic,JJ,O
,nephropathy,NN,B-DISEASE
,in,IN,O
,the,DT,O
,Gunn,NNP,O
,strain,NN,O
,of,IN,O
,rat,NN,O
,.,.,O
,The,DT,O
,homozygous,JJ,O
,Gunn,NNP,O
,rats,NNS,O
,have,VBP,O
,unconjugated,VBN,O
,hyperbilirubinemia,NN,B-DISEASE
,due,JJ,O
,to,TO,O
,the,DT,O
,absence,NN,O
,of,IN,O
,glucuronyl,JJ,O
,transferase,NN,O
,",",",",O
,leading,VBG,O
,to,TO,O
,marked,VB,O
,bilirubin,JJ,O
,deposition,NN,O
,in,IN,O
,renal,JJ,O
,medulla,NN,O
,and,CC,O
,papilla,NN,O
,.,.,O
,These,DT,O
,rats,NNS,O
,are,VBP,O
,also,RB,O
,highly,RB,O
,susceptible,JJ,O
,to,TO,O
,develop,VB,O
,papillary,JJ,B-DISEASE
,necrosis,NN,I-DISEASE
,with,IN,O
,analgesic,JJ,O
,administration,NN,O
,.,.,O
,We,PRP,O
,used,VBD,O
,homozygous,JJ,O
,(,(,O
,jj,NN,O
,),),O
,and,CC,O
,phenotypically,RB,O
,normal,JJ,O
,heterozygous,JJ,O
,(,(,O
,jJ,NN,O
,),),O
,animals,NNS,O
,.,.,O
,Four,CD,O
,groups,NNS,O
,of,IN,O
,rats,NNS,O
,(,(,O
,n,JJ,O
,=,NNP,O
,7,CD,O
,),),O
,were,VBD,O
,studied,VBN,O
,:,:,O
,jj,NN,O
,and,CC,O
,jJ,NN,O
,rats,NNS,O
,treated,VBD,O
,either,RB,O
,with,IN,O
,aspirin,JJ,O
,300,CD,O
,mg,NN,O
,/,NN,O
,kg,NN,O
,every,DT,O
,other,JJ,O
,day,NN,O
,or,CC,O
,sham,VB,O
,-,:,O
,treated,VBN,O
,.,.,O
,After,IN,O
,one,CD,O
,week,NN,O
,",",",",O
,slices,NNS,O
,of,IN,O
,cortex,NN,O
,",",",",O
,outer,NN,O
,and,CC,O
,inner,JJ,O
,medulla,NN,O
,from,IN,O
,one,CD,O
,kidney,NN,O
,were,VBD,O
,incubated,VBN,O
,in,IN,O
,buffer,NN,O
,and,CC,O
,prostaglandin,JJ,O
,synthesis,NN,O
,was,VBD,O
,determined,VBN,O
,by,IN,O
,radioimmunoassay,NN,O
,.,.,O
,The,DT,O
,other,JJ,O
,kidney,NN,O
,was,VBD,O
,examined,VBN,O
,histologically,RB,O
,.,.,O
,A,DT,O
,marked,JJ,O
,corticomedullary,JJ,O
,gradient,NN,O
,of,IN,O
,prostaglandin,JJ,O
,synthesis,NN,O
,was,VBD,O
,observed,VBN,O
,in,IN,O
,all,DT,O
,groups,NNS,O
,.,.,O
,PGE2,NNP,O
,synthesis,NN,O
,was,VBD,O
,significantly,RB,O
,higher,JJR,O
,in,IN,O
,outer,JJR,O
,medulla,NN,O
,",",",",O
,but,CC,O
,not,RB,O
,cortex,VB,O
,or,CC,O
,inner,VB,O
,medulla,NN,O
,",",",",O
,of,IN,O
,jj,NN,O
,(,(,O
,38,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,6,CD,O
,ng,JJ,O
,/,NNP,O
,mg,NNP,O
,prot,NN,O
,),),O
,than,IN,O
,jJ,NN,O
,rats,NNS,O
,(,(,O
,15,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,3,CD,O
,),),O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,Aspirin,NNP,O
,treatment,NN,O
,reduced,VBD,O
,PGE2,NNP,O
,synthesis,NN,O
,in,IN,O
,all,DT,O
,regions,NNS,O
,",",",",O
,but,CC,O
,outer,RB,O
,medullary,JJ,O
,PGE2,NNP,O
,remained,VBD,O
,higher,RBR,O
,in,IN,O
,jj,NN,O
,(,(,O
,18,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,3,CD,O
,),),O
,than,IN,O
,jJ,NN,O
,rats,NNS,O
,(,(,O
,9,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,2,CD,O
,),),O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,PGF2,NNP,O
,alpha,NN,O
,was,VBD,O
,also,RB,O
,significantly,RB,O
,higher,RBR,O
,in,IN,O
,the,DT,O
,outer,NN,O
,medulla,NN,O
,of,IN,O
,jj,NN,O
,rats,NNS,O
,with,IN,O
,and,CC,O
,without,IN,O
,aspirin,JJ,O
,administration,NN,O
,(,(,O
,p,IN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,The,DT,O
,changes,NNS,O
,in,IN,O
,renal,JJ,O
,prostaglandin,NN,O
,synthesis,NN,O
,were,VBD,O
,accompanied,VBN,O
,by,IN,O
,evidence,NN,O
,of,IN,O
,renal,JJ,B-DISEASE
,damage,NN,I-DISEASE
,in,IN,O
,aspirin,JJ,O
,-,:,O
,treated,JJ,O
,jj,NN,O
,but,CC,O
,not,RB,O
,jJ,JJ,O
,rats,NNS,O
,as,IN,O
,evidenced,VBN,O
,by,IN,O
,:,:,O
,increased,VBN,O
,incidence,NN,O
,and,CC,O
,severity,NN,O
,of,IN,O
,hematuria,NN,B-DISEASE
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,;,:,O
,increased,VBN,O
,serum,NN,O
,creatinine,NN,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,;,:,O
,and,CC,O
,increase,VB,O
,in,IN,O
,outer,JJ,O
,medullary,JJ,O
,histopathologic,NN,O
,lesions,NNS,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,005,CD,O
,compared,VBN,O
,to,TO,O
,either,DT,O
,sham,JJ,O
,-,:,O
,treated,VBN,O
,jj,NN,O
,or,CC,O
,aspirin,VB,O
,-,:,O
,treated,VBN,O
,jJ,NN,O
,),),O
,.,.,O
,These,DT,O
,results,NNS,O
,suggest,VBP,O
,that,IN,O
,enhanced,VBD,O
,prostaglandin,JJ,O
,synthesis,NN,O
,contributes,NNS,O
,to,TO,O
,maintenance,NN,O
,of,IN,O
,renal,JJ,O
,function,NN,O
,and,CC,O
,morphological,JJ,O
,integrity,NN,O
,",",",",O
,and,CC,O
,that,DT,O
,inhibition,NN,O
,of,IN,O
,prostaglandin,JJ,O
,synthesis,NN,O
,may,MD,O
,lead,VB,O
,to,TO,O
,pathological,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,medullary,JJ,I-DISEASE
,lesions,NNS,I-DISEASE
,and,CC,O
,deterioration,NN,B-DISEASE
,of,IN,I-DISEASE
,renal,JJ,I-DISEASE
,function,NN,I-DISEASE
,.,.,O
,Prophylactic,JJ,O
,lidocaine,NN,O
,in,IN,O
,the,DT,O
,early,JJ,O
,phase,NN,O
,of,IN,O
,suspected,JJ,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,.,.,O
,Four,CD,O
,hundred,VBD,O
,two,CD,O
,patients,NNS,O
,with,IN,O
,suspected,JJ,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,seen,VBN,O
,within,IN,O
,6,CD,O
,hours,NNS,O
,of,IN,O
,the,DT,O
,onset,NN,O
,of,IN,O
,symptoms,NNS,O
,entered,VBD,O
,a,DT,O
,double,JJ,O
,-,:,O
,blind,NN,O
,randomized,JJ,O
,trial,NN,O
,of,IN,O
,lidocaine,NN,O
,vs,NN,O
,placebo,NN,O
,.,.,O
,During,IN,O
,the,DT,O
,1,CD,O
,hour,NN,O
,after,IN,O
,administration,NN,O
,of,IN,O
,the,DT,O
,drug,NN,O
,the,DT,O
,incidence,NN,O
,of,IN,O
,ventricular,JJ,B-DISEASE
,fibrillation,NN,I-DISEASE
,or,CC,O
,sustained,VBN,O
,ventricular,JJ,B-DISEASE
,tachycardia,NN,I-DISEASE
,among,IN,O
,the,DT,O
,204,CD,O
,patients,NNS,O
,with,IN,O
,acute,JJ,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,was,VBD,O
,low,JJ,O
,",",",",O
,1,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,.,.,O
,Lidocaine,NNP,O
,",",",",O
,given,VBN,O
,in,IN,O
,a,DT,O
,300,CD,O
,mg,NN,O
,dose,VBD,O
,intramuscularly,RB,O
,followed,VBN,O
,by,IN,O
,100,CD,O
,mg,NN,O
,intravenously,RB,O
,",",",",O
,did,VBD,O
,not,RB,O
,prevent,VB,O
,sustained,JJ,O
,ventricular,JJ,B-DISEASE
,tachycardia,NN,I-DISEASE
,",",",",O
,although,IN,O
,there,EX,O
,was,VBD,O
,a,DT,O
,significant,JJ,O
,reduction,NN,O
,in,IN,O
,the,DT,O
,number,NN,O
,of,IN,O
,patients,NNS,O
,with,IN,O
,warning,VBG,O
,arrhythmias,NNS,B-DISEASE
,between,IN,O
,15,CD,O
,and,CC,O
,45,CD,O
,minutes,NNS,O
,after,IN,O
,the,DT,O
,administration,NN,O
,of,IN,O
,lidocaine,NN,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,The,DT,O
,average,JJ,O
,plasma,JJ,O
,lidocaine,JJ,O
,level,NN,O
,10,CD,O
,minutes,NNS,O
,after,IN,O
,administration,NN,O
,for,IN,O
,patients,NNS,O
,without,IN,O
,a,DT,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,was,VBD,O
,significantly,RB,O
,higher,JJR,O
,than,IN,O
,that,DT,O
,for,IN,O
,patients,NNS,O
,with,IN,O
,an,DT,O
,acute,JJ,O
,infarction,NN,B-DISEASE
,.,.,O
,The,DT,O
,mean,JJ,O
,plasma,NN,O
,lidocaine,JJ,O
,level,NN,O
,of,IN,O
,patients,NNS,O
,on,IN,O
,beta,JJ,O
,-,:,O
,blocking,VBG,O
,agents,NNS,O
,was,VBD,O
,no,DT,O
,different,JJ,O
,from,IN,O
,that,DT,O
,in,IN,O
,patients,NNS,O
,not,RB,O
,on,IN,O
,beta,NN,O
,blocking,VBG,O
,agents,NNS,O
,.,.,O
,During,IN,O
,the,DT,O
,1,CD,O
,-,:,O
,hour,NN,O
,study,NN,O
,period,NN,O
,",",",",O
,the,DT,O
,incidence,NN,O
,of,IN,O
,central,JJ,O
,nervous,JJ,O
,system,NN,O
,side,NN,O
,effects,NNS,O
,was,VBD,O
,significantly,RB,O
,greater,JJR,O
,in,IN,O
,the,DT,O
,lidocaine,NN,O
,group,NN,O
,",",",",O
,hypotension,NN,B-DISEASE
,occurred,VBD,O
,in,IN,O
,11,CD,O
,patients,NNS,O
,",",",",O
,nine,CD,O
,of,IN,O
,whom,WP,O
,had,VBD,O
,received,VBN,O
,lidocaine,NN,O
,",",",",O
,and,CC,O
,four,CD,O
,patients,NNS,O
,died,VBD,O
,from,IN,O
,asystole,NN,B-DISEASE
,",",",",O
,three,CD,O
,of,IN,O
,whom,WP,O
,had,VBD,O
,had,VBN,O
,lidocaine,NN,O
,.,.,O
,We,PRP,O
,cannot,VBP,O
,advocate,VB,O
,the,DT,O
,administration,NN,O
,of,IN,O
,lidocaine,JJ,O
,prophylactically,RB,O
,in,IN,O
,the,DT,O
,early,JJ,O
,hours,NNS,O
,of,IN,O
,suspected,JJ,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,.,.,O
,Evidence,NN,O
,for,IN,O
,a,DT,O
,cholinergic,JJ,O
,role,NN,O
,in,IN,O
,haloperidol,JJ,O
,-,:,O
,induced,JJ,O
,catalepsy,NN,B-DISEASE
,.,.,O
,Experiments,NNS,O
,in,IN,O
,mice,NNS,O
,tested,VBN,O
,previous,JJ,O
,evidence,NN,O
,that,IN,O
,activation,NN,O
,of,IN,O
,cholinergic,JJ,O
,systems,NNS,O
,promotes,VBZ,O
,catalepsy,JJ,B-DISEASE
,and,CC,O
,that,DT,O
,cholinergic,JJ,O
,mechanisms,NNS,O
,need,VBP,O
,to,TO,O
,be,VB,O
,intact,JJ,O
,for,IN,O
,full,JJ,O
,expression,NN,O
,of,IN,O
,neuroleptic,JJ,O
,-,:,O
,induced,JJ,O
,catalepsy,NN,B-DISEASE
,.,.,O
,Large,JJ,O
,doses,NNS,O
,of,IN,O
,the,DT,O
,cholinomimetic,JJ,O
,",",",",O
,pilocarpine,NN,O
,",",",",O
,could,MD,O
,induce,VB,O
,catalepsy,NN,B-DISEASE
,when,WRB,O
,peripheral,JJ,O
,cholinergic,NN,O
,receptors,NNS,O
,were,VBD,O
,blocked,VBN,O
,.,.,O
,Low,JJ,O
,doses,NNS,O
,of,IN,O
,pilocarpine,NN,O
,caused,VBN,O
,a,DT,O
,pronounced,JJ,O
,enhancement,NN,O
,of,IN,O
,the,DT,O
,catalepsy,NN,B-DISEASE
,that,WDT,O
,was,VBD,O
,induced,VBN,O
,by,IN,O
,the,DT,O
,dopaminergic,NN,O
,blocker,NN,O
,",",",",O
,haloperidol,NN,O
,.,.,O
,A,DT,O
,muscarinic,JJ,O
,receptor,NN,O
,blocker,NN,O
,",",",",O
,atropine,NN,O
,",",",",O
,disrupted,VBN,O
,haloperidol,SYM,O
,-,:,O
,induced,JJ,O
,catalepsy,NN,B-DISEASE
,.,.,O
,Intracranial,JJ,O
,injection,NN,O
,of,IN,O
,an,DT,O
,acetylcholine,JJ,O
,-,:,O
,synthesis,NN,O
,inhibitor,NN,O
,",",",",O
,hemicholinium,NN,O
,",",",",O
,prevented,VBD,O
,the,DT,O
,catalepsy,NN,B-DISEASE
,that,WDT,O
,is,VBZ,O
,usually,RB,O
,induced,VBN,O
,by,IN,O
,haloperidol,NN,O
,.,.,O
,These,DT,O
,findings,NNS,O
,suggest,VBP,O
,the,DT,O
,hypothesis,NN,O
,that,IN,O
,the,DT,O
,catalepsy,NN,B-DISEASE
,that,WDT,O
,is,VBZ,O
,produced,VBN,O
,by,IN,O
,neuroleptics,NNS,O
,such,JJ,O
,as,IN,O
,haloperidol,NN,O
,is,VBZ,O
,actually,RB,O
,mediated,VBN,O
,by,IN,O
,intrinsic,JJ,O
,central,JJ,O
,cholinergic,JJ,O
,systems,NNS,O
,.,.,O
,Alternatively,RB,O
,",",",",O
,activation,NN,O
,of,IN,O
,central,JJ,O
,cholinergic,JJ,O
,systems,NNS,O
,could,MD,O
,promote,VB,O
,catalepsy,NN,B-DISEASE
,by,IN,O
,suppression,NN,O
,of,IN,O
,dopaminergic,JJ,O
,systems,NNS,O
,.,.,O
,Cardiovascular,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,and,CC,O
,hypersensitivity,NN,B-DISEASE
,to,TO,O
,sodium,VB,O
,pentobarbital,NN,O
,induced,VBN,O
,by,IN,O
,chronic,JJ,O
,barium,NN,O
,chloride,NN,O
,ingestion,NN,O
,.,.,O
,Barium,NNP,O
,-,:,O
,supplemented,VBD,O
,Long,NNP,O
,-,:,O
,Evans,NNS,O
,hooded,VBD,O
,rats,NNS,O
,were,VBD,O
,characterized,VBN,O
,by,IN,O
,a,DT,O
,persistent,JJ,O
,hypertension,NN,B-DISEASE
,that,WDT,O
,was,VBD,O
,evident,JJ,O
,after,IN,O
,1,CD,O
,month,NN,O
,of,IN,O
,barium,NN,O
,(,(,O
,100,CD,O
,micrograms,NNS,O
,/,JJ,O
,ml,JJ,O
,mineral,NN,O
,fortified,VBD,O
,water,NN,O
,),),O
,treatment,NN,O
,.,.,O
,Analysis,NN,O
,of,IN,O
,in,IN,O
,vivo,JJ,O
,myocardial,JJ,O
,excitability,NN,O
,",",",",O
,contractility,NN,O
,",",",",O
,and,CC,O
,metabolic,JJ,O
,characteristics,NNS,O
,at,IN,O
,16,CD,O
,months,NNS,O
,revealed,VBD,O
,other,JJ,O
,significant,JJ,O
,barium,NN,O
,-,:,O
,induced,JJ,O
,disturbances,NNS,B-DISEASE
,within,IN,I-DISEASE
,the,DT,I-DISEASE
,cardiovascular,JJ,I-DISEASE
,system,NN,I-DISEASE
,.,.,O
,The,DT,O
,most,RBS,O
,distinctive,JJ,O
,aspect,NN,O
,of,IN,O
,the,DT,O
,barium,NN,O
,effect,NN,O
,was,VBD,O
,a,DT,O
,demonstrated,JJ,O
,hypersensitivity,NN,B-DISEASE
,of,IN,O
,the,DT,O
,cardiovascular,JJ,O
,system,NN,O
,to,TO,O
,sodium,VB,O
,pentobarbital,JJ,O
,.,.,O
,Under,IN,O
,barbiturate,NN,O
,anesthesia,NN,O
,",",",",O
,virtually,RB,O
,all,DT,O
,of,IN,O
,the,DT,O
,myocardial,JJ,O
,contractile,NN,O
,indices,NNS,O
,were,VBD,O
,depressed,VBN,O
,significantly,RB,O
,in,IN,O
,barium,NN,O
,-,:,O
,exposed,VBN,O
,rats,NNS,O
,relative,VBP,O
,to,TO,O
,the,DT,O
,corresponding,VBG,O
,control,NN,O
,-,:,O
,fed,NN,O
,rats,NNS,O
,.,.,O
,The,DT,O
,lack,NN,O
,of,IN,O
,a,DT,O
,similar,JJ,O
,response,NN,O
,to,TO,O
,ketamine,VB,O
,and,CC,O
,xylazine,VB,O
,anesthesia,NN,O
,revealed,VBD,O
,that,IN,O
,the,DT,O
,cardiovascular,JJ,O
,actions,NNS,O
,of,IN,O
,sodium,NN,O
,pentobarbital,NN,O
,in,IN,O
,barium,NN,O
,-,:,O
,treated,VBN,O
,rats,NNS,O
,were,VBD,O
,linked,VBN,O
,specifically,RB,O
,to,TO,O
,this,DT,O
,anesthetic,JJ,O
,",",",",O
,and,CC,O
,were,VBD,O
,not,RB,O
,representative,JJ,O
,of,IN,O
,a,DT,O
,generalized,JJ,O
,anesthetic,JJ,O
,response,NN,O
,.,.,O
,Other,JJ,O
,myocardial,JJ,O
,pathophysiologic,NN,O
,and,CC,O
,metabolic,JJ,O
,changes,NNS,O
,induced,VBN,O
,by,IN,O
,barium,NN,O
,were,VBD,O
,manifest,JJS,O
,",",",",O
,irrespective,NN,O
,of,IN,O
,the,DT,O
,anesthetic,JJ,O
,employed,NN,O
,.,.,O
,The,DT,O
,contractile,JJ,O
,element,NN,O
,shortening,VBG,O
,velocity,NN,O
,of,IN,O
,the,DT,O
,cardiac,JJ,O
,muscle,NN,O
,fibers,NNS,O
,was,VBD,O
,significantly,RB,O
,slower,JJR,O
,in,IN,O
,both,DT,O
,groups,NNS,O
,of,IN,O
,barium,NN,O
,-,:,O
,treated,JJ,O
,rats,NNS,O
,relative,VBP,O
,to,TO,O
,the,DT,O
,control,NN,O
,groups,NNS,O
,",",",",O
,irrespective,NN,O
,of,IN,O
,the,DT,O
,anesthetic,JJ,O
,regimen,NNS,O
,.,.,O
,Similarly,RB,O
,",",",",O
,significant,JJ,O
,disturbances,NNS,O
,in,IN,O
,myocardial,JJ,O
,energy,NN,O
,metabolism,NN,O
,were,VBD,O
,detected,VBN,O
,in,IN,O
,the,DT,O
,barium,NN,O
,-,:,O
,exposed,VBN,O
,rats,NNS,O
,which,WDT,O
,were,VBD,O
,consistent,JJ,O
,with,IN,O
,the,DT,O
,reduced,VBN,O
,contractile,NN,O
,element,NN,O
,shortening,VBG,O
,velocity,NN,O
,.,.,O
,In,IN,O
,addition,NN,O
,",",",",O
,the,DT,O
,excitability,NN,O
,of,IN,O
,the,DT,O
,cardiac,JJ,O
,conduction,NN,O
,system,NN,O
,was,VBD,O
,depressed,VBN,O
,preferentially,RB,O
,in,IN,O
,the,DT,O
,atrioventricular,JJ,O
,nodal,JJ,O
,region,NN,O
,of,IN,O
,hearts,NNS,O
,from,IN,O
,barium,NN,O
,-,:,O
,exposed,VBN,O
,rats,NNS,O
,.,.,O
,Overall,NNP,O
,",",",",O
,the,DT,O
,altered,JJ,O
,cardiac,JJ,O
,contractility,NN,O
,and,CC,O
,excitability,NN,O
,characteristics,NNS,O
,",",",",O
,the,DT,O
,myocardial,JJ,O
,metabolic,NN,B-DISEASE
,disturbances,NNS,I-DISEASE
,",",",",O
,and,CC,O
,the,DT,O
,hypersensitivity,NN,B-DISEASE
,of,IN,O
,the,DT,O
,cardiovascular,JJ,O
,system,NN,O
,to,TO,O
,sodium,VB,O
,pentobarbital,JJ,O
,suggest,VB,O
,the,DT,O
,existence,NN,O
,of,IN,O
,a,DT,O
,heretofore,NN,O
,undescribed,JJ,O
,cardiomyopathic,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,chronic,JJ,O
,barium,NN,O
,exposure,NN,O
,.,.,O
,These,DT,O
,experimental,JJ,O
,findings,NNS,O
,represent,VBP,O
,the,DT,O
,first,JJ,O
,indication,NN,O
,that,IN,O
,life,NN,O
,-,:,O
,long,JJ,O
,barium,NN,O
,ingestion,NN,O
,may,MD,O
,have,VB,O
,significant,JJ,O
,adverse,JJ,O
,effects,NNS,O
,on,IN,O
,the,DT,O
,mammalian,JJ,O
,cardiovascular,NN,O
,system,NN,O
,.,.,O
,Propranolol,NNP,O
,antagonism,NN,O
,of,IN,O
,phenylpropanolamine,JJ,O
,-,:,O
,induced,JJ,O
,hypertension,NN,B-DISEASE
,.,.,O
,Phenylpropanolamine,NNP,O
,(,(,O
,PPA,NNP,O
,),),O
,overdose,VBP,B-DISEASE
,can,MD,O
,cause,VB,O
,severe,JJ,O
,hypertension,NN,B-DISEASE
,",",",",O
,intracerebral,JJ,B-DISEASE
,hemorrhage,NN,I-DISEASE
,",",",",O
,and,CC,O
,death,NN,O
,.,.,O
,We,PRP,O
,studied,VBD,O
,the,DT,O
,efficacy,NN,O
,and,CC,O
,safety,NN,O
,of,IN,O
,propranolol,NN,O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,PPA,NNP,O
,-,:,O
,induced,JJ,O
,hypertension,NN,B-DISEASE
,.,.,O
,Subjects,VBZ,O
,received,VBN,O
,propranolol,IN,O
,either,CC,O
,by,IN,O
,mouth,NN,O
,for,IN,O
,48,CD,O
,hours,NNS,O
,before,IN,O
,PPA,NNP,O
,or,CC,O
,as,IN,O
,a,DT,O
,rapid,JJ,O
,intravenous,JJ,O
,infusion,NN,O
,after,IN,O
,PPA,NNP,O
,.,.,O
,PPA,NNP,O
,",",",",O
,75,CD,O
,mg,NN,O
,alone,RB,O
,",",",",O
,increased,VBD,O
,blood,NN,O
,pressure,NN,O
,(,(,O
,31,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,14,CD,O
,mm,NN,O
,Hg,NNP,O
,systolic,NN,O
,",",",",O
,20,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,5,CD,O
,mm,NN,O
,Hg,NNP,O
,diastolic,NN,O
,),),O
,",",",",O
,and,CC,O
,propranolol,JJ,O
,pretreatment,NN,O
,antagonized,VBD,O
,this,DT,O
,increase,NN,O
,(,(,O
,12,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,10,CD,O
,mm,NN,O
,Hg,NNP,O
,systolic,NN,O
,",",",",O
,10,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,7,CD,O
,mm,NN,O
,Hg,NNP,O
,diastolic,NN,O
,),),O
,.,.,O
,Intravenous,JJ,O
,propranolol,NN,O
,after,IN,O
,PPA,NNP,O
,also,RB,O
,decreased,VBD,O
,blood,NN,O
,pressure,NN,O
,.,.,O
,Left,NNP,O
,ventricular,JJ,O
,function,NN,O
,(,(,O
,assessed,VBN,O
,by,IN,O
,echocardiography,NN,O
,),),O
,showed,VBD,O
,that,IN,O
,PPA,NNP,O
,increased,VBD,O
,the,DT,O
,stroke,NN,B-DISEASE
,volume,NN,O
,30,CD,O
,%,NN,O
,(,(,O
,from,IN,O
,62,CD,O
,.,.,O
,5,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,20,CD,O
,.,.,O
,9,CD,O
,to,TO,O
,80,CD,O
,.,.,O
,8,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,22,CD,O
,.,.,O
,4,CD,O
,ml,NN,O
,),),O
,",",",",O
,the,DT,O
,ejection,NN,O
,fraction,NN,O
,9,CD,O
,%,NN,O
,(,(,O
,from,IN,O
,64,CD,O
,%,NN,O
,+,NNP,O
,/,NNP,O
,-,:,O
,10,CD,O
,%,NN,O
,to,TO,O
,70,CD,O
,%,NN,O
,+,NNP,O
,/,NNP,O
,-,:,O
,7,CD,O
,%,NN,O
,),),O
,",",",",O
,and,CC,O
,cardiac,JJ,O
,output,NN,O
,14,CD,O
,%,NN,O
,(,(,O
,from,IN,O
,3,CD,O
,.,.,O
,6,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,6,CD,O
,to,TO,O
,4,CD,O
,.,.,O
,1,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,0,CD,O
,L,NNP,O
,/,NNP,O
,min,NN,O
,),),O
,.,.,O
,Intravenous,JJ,O
,propranolol,NN,O
,reversed,VBN,O
,these,DT,O
,effects,NNS,O
,.,.,O
,Systemic,NNP,O
,vascular,JJ,O
,resistance,NN,O
,was,VBD,O
,increased,VBN,O
,by,IN,O
,PPA,NNP,O
,28,CD,O
,%,NN,O
,(,(,O
,from,IN,O
,1710,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,200,CD,O
,to,TO,O
,2190,CD,O
,+,NNP,O
,/,NNP,O
,-,:,O
,700,CD,O
,dyne,NN,O
,X,NNP,O
,sec,NN,O
,/,NNP,O
,cm5,NN,O
,),),O
,and,CC,O
,was,VBD,O
,further,RBR,O
,increased,VBN,O
,by,IN,O
,propranolol,JJ,O
,22,CD,O
,%,NN,O
,(,(,O
,to,TO,O
,2660,CD,O
,+,NNP,O
,/,NNP,O
,-,:,O
,1200,CD,O
,dyne,NN,O
,X,NNP,O
,sec,NN,O
,/,NNP,O
,cm5,NN,O
,),),O
,.,.,O
,We,PRP,O
,conclude,VBP,O
,that,IN,O
,PPA,NNP,O
,increases,VBZ,O
,blood,NN,O
,pressure,NN,O
,by,IN,O
,increasing,VBG,O
,systemic,JJ,O
,vascular,JJ,O
,resistance,NN,O
,and,CC,O
,cardiac,JJ,O
,output,NN,O
,",",",",O
,and,CC,O
,that,IN,O
,propranolol,NN,O
,antagonizes,VBZ,O
,this,DT,O
,increase,NN,O
,by,IN,O
,reversing,VBG,O
,the,DT,O
,effect,NN,O
,of,IN,O
,PPA,NNP,O
,on,IN,O
,cardiac,JJ,O
,output,NN,O
,.,.,O
,That,DT,O
,propranolol,NN,O
,antagonizes,VBZ,O
,the,DT,O
,pressor,NN,O
,effect,NN,O
,of,IN,O
,PPA,NNP,O
,is,VBZ,O
,in,IN,O
,contrast,NN,O
,to,TO,O
,the,DT,O
,interaction,NN,O
,in,IN,O
,which,WDT,O
,propranolol,NN,O
,enhances,VBZ,O
,the,DT,O
,pressor,NN,O
,effect,NN,O
,of,IN,O
,norepinephrine,NN,O
,.,.,O
,This,DT,O
,is,VBZ,O
,probably,RB,O
,because,IN,O
,PPA,NNP,O
,has,VBZ,O
,less,JJR,O
,beta,JJ,O
,2,CD,O
,activity,NN,O
,than,IN,O
,does,VBZ,O
,norepinephrine,JJ,O
,.,.,O
,Mesangial,JJ,O
,function,NN,O
,and,CC,O
,glomerular,JJ,B-DISEASE
,sclerosis,NN,I-DISEASE
,in,IN,O
,rats,NNS,O
,with,IN,O
,aminonucleoside,JJ,O
,nephrosis,NN,B-DISEASE
,.,.,O
,The,DT,O
,possible,JJ,O
,relationship,NN,O
,between,IN,O
,mesangial,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,and,CC,O
,development,NN,O
,of,IN,O
,glomerular,JJ,B-DISEASE
,sclerosis,NN,I-DISEASE
,was,VBD,O
,studied,VBN,O
,in,IN,O
,the,DT,O
,puromycin,NN,O
,aminonucleoside,NN,O
,(,(,O
,PAN,NNP,O
,),),O
,model,NN,O
,.,.,O
,Five,CD,O
,male,JJ,O
,Wistar,NNP,O
,rats,NNS,O
,received,VBD,O
,repeated,VBN,O
,subcutaneous,JJ,O
,PAN,NNP,O
,injections,NNS,O
,;,:,O
,five,CD,O
,controls,NNS,O
,received,VBD,O
,saline,JJ,O
,only,RB,O
,.,.,O
,After,IN,O
,4,CD,O
,weeks,NNS,O
,the,DT,O
,PAN,NNP,O
,rats,NNS,O
,were,VBD,O
,severely,RB,O
,proteinuric,JJ,B-DISEASE
,(,(,O
,190,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,80,CD,O
,mg,NN,O
,/,VBD,O
,24,CD,O
,hr,NN,O
,),),O
,",",",",O
,and,CC,O
,all,DT,O
,rats,NNS,O
,were,VBD,O
,given,VBN,O
,colloidal,JJ,O
,carbon,NN,O
,(,(,O
,CC,NNP,O
,),),O
,intravenously,RB,O
,.,.,O
,At,IN,O
,5,CD,O
,months,NNS,O
,glomerular,JJ,B-DISEASE
,sclerosis,NN,I-DISEASE
,was,VBD,O
,found,VBN,O
,in,IN,O
,7,CD,O
,.,.,O
,6,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,3,CD,O
,.,.,O
,4,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,glomeruli,NN,O
,of,IN,O
,PAN,NNP,O
,rats,NNS,O
,;,:,O
,glomeruli,NNS,O
,of,IN,O
,the,DT,O
,controls,NNS,O
,were,VBD,O
,normal,JJ,O
,.,.,O
,Glomeruli,NNP,O
,of,IN,O
,PAN,NNP,O
,rats,NNS,O
,contained,VBD,O
,significantly,RB,O
,more,RBR,O
,CC,NNP,O
,than,IN,O
,glomeruli,NN,O
,of,IN,O
,controls,NNS,O
,.,.,O
,Glomeruli,NNP,O
,with,IN,O
,sclerosis,NN,B-DISEASE
,contained,VBN,O
,significantly,RB,O
,more,RBR,O
,CC,NNP,O
,than,IN,O
,non,SYM,O
,-,:,O
,sclerotic,JJ,O
,glomeruli,NN,O
,in,IN,O
,the,DT,O
,same,JJ,O
,kidneys,NN,O
,.,.,O
,CC,NNP,O
,was,VBD,O
,preferentially,RB,O
,localized,VBN,O
,within,IN,O
,the,DT,O
,sclerotic,JJ,O
,areas,NNS,O
,of,IN,O
,the,DT,O
,affected,JJ,O
,glomeruli,NN,O
,.,.,O
,Since,IN,O
,mesangial,JJ,O
,CC,NNP,O
,clearance,NN,O
,from,IN,O
,the,DT,O
,mesangium,NN,O
,did,VBD,O
,not,RB,O
,change,VB,O
,during,IN,O
,chronic,JJ,O
,PAN,NNP,O
,treatment,NN,O
,",",",",O
,we,PRP,O
,conclude,VBP,O
,that,IN,O
,this,DT,O
,preferential,JJ,O
,CC,NNP,O
,localization,NN,O
,within,IN,O
,the,DT,O
,lesions,NNS,O
,is,VBZ,O
,caused,VBN,O
,by,IN,O
,an,DT,O
,increased,VBN,O
,CC,NNP,O
,uptake,VBP,O
,shortly,RB,O
,after,IN,O
,injection,NN,O
,in,IN,O
,apparent,JJ,O
,vulnerable,JJ,O
,areas,NNS,O
,where,WRB,O
,sclerosis,NN,B-DISEASE
,will,MD,O
,develop,VB,O
,subsequently,RB,O
,.,.,O
,Cluster,NNP,O
,analysis,NN,O
,showed,VBD,O
,a,DT,O
,random,JJ,O
,distribution,NN,O
,of,IN,O
,lesions,NNS,O
,in,IN,O
,the,DT,O
,PAN,NNP,O
,glomeruli,NN,O
,in,IN,O
,concordance,NN,O
,with,IN,O
,the,DT,O
,random,JJ,O
,localization,NN,O
,of,IN,O
,mesangial,JJ,O
,areas,NNS,O
,with,IN,O
,dysfunction,NN,O
,in,IN,O
,this,DT,O
,model,NN,O
,.,.,O
,Similar,JJ,O
,to,TO,O
,the,DT,O
,remnant,JJ,O
,kidney,NN,O
,model,NN,O
,in,IN,O
,PAN,NNP,O
,nephrosis,VBP,B-DISEASE
,the,DT,O
,development,NN,O
,of,IN,O
,glomerular,JJ,B-DISEASE
,sclerosis,NN,I-DISEASE
,may,MD,O
,be,VB,O
,related,VBN,O
,to,TO,O
,"""",VB,O
,mesangial,JJ,O
,overloading,NN,O
,.,.,O
,"""",CC,O
,Relationship,NNP,O
,between,IN,O
,nicotine,JJ,O
,-,:,O
,induced,JJ,O
,seizures,NNS,B-DISEASE
,and,CC,O
,hippocampal,JJ,O
,nicotinic,JJ,O
,receptors,NNS,O
,.,.,O
,A,DT,O
,controversy,NN,O
,has,VBZ,O
,existed,VBN,O
,for,IN,O
,several,JJ,O
,years,NNS,O
,concerning,VBG,O
,the,DT,O
,physiological,JJ,O
,relevance,NN,O
,of,IN,O
,the,DT,O
,nicotinic,JJ,O
,receptor,NN,O
,measured,VBN,O
,by,IN,O
,alpha,JJ,O
,-,:,O
,bungarotoxin,NN,O
,binding,NN,O
,.,.,O
,Using,VBG,O
,mice,JJ,O
,derived,VBN,O
,from,IN,O
,a,DT,O
,classical,JJ,O
,F2,NNP,O
,and,CC,O
,backcross,VB,O
,genetic,JJ,O
,design,NN,O
,",",",",O
,a,DT,O
,relationship,NN,O
,between,IN,O
,nicotine,JJ,O
,-,:,O
,induced,JJ,O
,seizures,NNS,B-DISEASE
,and,CC,O
,alpha,SYM,O
,-,:,O
,bungarotoxin,NN,O
,nicotinic,JJ,O
,receptor,NN,O
,concentration,NN,O
,was,VBD,O
,found,VBN,O
,.,.,O
,Mice,NNP,O
,sensitive,JJ,O
,to,TO,O
,the,DT,O
,convulsant,JJ,O
,effects,NNS,O
,of,IN,O
,nicotine,NN,O
,had,VBD,O
,greater,JJR,O
,alpha,JJ,O
,-,:,O
,bungarotoxin,NN,O
,binding,NN,O
,in,IN,O
,the,DT,O
,hippocampus,NN,O
,than,IN,O
,seizure,NN,B-DISEASE
,insensitive,JJ,O
,mice,NN,O
,.,.,O
,The,DT,O
,binding,VBG,O
,sites,NNS,O
,from,IN,O
,seizure,NN,B-DISEASE
,sensitive,JJ,O
,and,CC,O
,resistant,JJ,O
,mice,NN,O
,were,VBD,O
,equally,RB,O
,affected,VBN,O
,by,IN,O
,treatment,NN,O
,with,IN,O
,dithiothreitol,NN,O
,",",",",O
,trypsin,NN,O
,or,CC,O
,heat,NN,O
,.,.,O
,Thus,VB,O
,it,PRP,O
,appears,VBZ,O
,that,IN,O
,the,DT,O
,difference,NN,O
,between,IN,O
,seizure,NN,B-DISEASE
,sensitive,JJ,O
,and,CC,O
,insensitive,JJ,O
,animals,NNS,O
,may,MD,O
,be,VB,O
,due,JJ,O
,to,TO,O
,a,DT,O
,difference,NN,O
,in,IN,O
,hippocampal,JJ,O
,nicotinic,JJ,O
,receptor,NN,O
,concentration,NN,O
,as,IN,O
,measured,VBN,O
,with,IN,O
,alpha,JJ,O
,-,:,O
,bungarotoxin,NN,O
,binding,NN,O
,.,.,O
,The,DT,O
,role,NN,O
,of,IN,O
,p,JJ,O
,-,:,O
,aminophenol,NN,O
,in,IN,O
,acetaminophen,JJ,O
,-,:,O
,induced,JJ,O
,nephrotoxicity,NN,B-DISEASE
,:,:,O
,effect,NN,O
,of,IN,O
,bis,NN,O
,(,(,O
,p,JJ,O
,-,:,O
,nitrophenyl,NN,O
,),),O
,phosphate,NN,O
,on,IN,O
,acetaminophen,NN,O
,and,CC,O
,p,NN,O
,-,:,O
,aminophenol,NN,O
,nephrotoxicity,NN,B-DISEASE
,and,CC,O
,metabolism,NN,O
,in,IN,O
,Fischer,NNP,O
,344,CD,O
,rats,NNS,O
,.,.,O
,Acetaminophen,NNP,O
,(,(,O
,APAP,NNP,O
,),),O
,produces,VBZ,O
,proximal,JJ,O
,tubular,JJ,B-DISEASE
,necrosis,NN,I-DISEASE
,in,IN,O
,Fischer,NNP,O
,344,CD,O
,(,(,O
,F344,NNP,O
,),),O
,rats,NNS,O
,.,.,O
,Recently,RB,O
,",",",",O
,p,SYM,O
,-,:,O
,aminophenol,NN,O
,(,(,O
,PAP,NNP,O
,),),O
,",",",",O
,a,DT,O
,known,JJ,O
,potent,NN,O
,nephrotoxicant,NN,O
,",",",",O
,was,VBD,O
,identified,VBN,O
,as,IN,O
,a,DT,O
,metabolite,NN,O
,of,IN,O
,APAP,NNP,O
,in,IN,O
,F344,NNP,O
,rats,NNS,O
,.,.,O
,The,DT,O
,purpose,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,was,VBD,O
,to,TO,O
,determine,VB,O
,if,IN,O
,PAP,NNP,O
,formation,NN,O
,is,VBZ,O
,a,DT,O
,requisite,JJ,O
,step,NN,O
,in,IN,O
,APAP,NNP,O
,-,:,O
,induced,JJ,O
,nephrotoxicity,NN,B-DISEASE
,.,.,O
,Therefore,RB,O
,",",",",O
,the,DT,O
,effect,NN,O
,of,IN,O
,bis,NN,O
,(,(,O
,p,JJ,O
,-,:,O
,nitrophenyl,NN,O
,),),O
,phosphate,NN,O
,(,(,O
,BNPP,NNP,O
,),),O
,",",",",O
,an,DT,O
,acylamidase,NN,O
,inhibitor,NN,O
,",",",",O
,on,IN,O
,APAP,NNP,O
,and,CC,O
,PAP,NNP,O
,nephrotoxicity,NN,B-DISEASE
,and,CC,O
,metabolism,NN,O
,was,VBD,O
,determined,VBN,O
,.,.,O
,BNPP,NNP,O
,(,(,O
,1,CD,O
,to,TO,O
,8,CD,O
,mM,NN,O
,),),O
,reduced,VBD,O
,APAP,NNP,O
,deacetylation,NN,O
,and,CC,O
,covalent,NN,O
,binding,NN,O
,in,IN,O
,F344,NNP,O
,renal,JJ,O
,cortical,JJ,O
,homogenates,NNS,O
,in,IN,O
,a,DT,O
,concentration,NN,O
,-,:,O
,dependent,JJ,O
,manner,NN,O
,.,.,O
,Pretreatment,NN,O
,of,IN,O
,animals,NNS,O
,with,IN,O
,BNPP,NNP,O
,prior,RB,O
,to,TO,O
,APAP,NNP,O
,or,CC,O
,PAP,NNP,O
,administration,NN,O
,resulted,VBD,O
,in,IN,O
,marked,JJ,O
,reduction,NN,O
,of,IN,O
,APAP,NNP,O
,(,(,O
,900,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,nephrotoxicity,NN,B-DISEASE
,but,CC,O
,not,RB,O
,PAP,NNP,O
,nephrotoxicity,NN,B-DISEASE
,.,.,O
,This,DT,O
,result,NN,O
,was,VBD,O
,not,RB,O
,due,JJ,O
,to,TO,O
,altered,JJ,O
,disposition,NN,O
,of,IN,O
,either,DT,O
,APAP,NNP,O
,or,CC,O
,acetylated,VBN,O
,metabolites,NNS,O
,in,IN,O
,plasma,NN,O
,or,CC,O
,renal,JJ,O
,cortical,JJ,O
,and,CC,O
,hepatic,JJ,O
,tissue,NN,O
,.,.,O
,Rather,NNP,O
,",",",",O
,BNPP,NNP,O
,pretreatment,NN,O
,reduced,VBD,O
,the,DT,O
,fraction,NN,O
,of,IN,O
,APAP,NNP,O
,excreted,VBD,O
,as,IN,O
,PAP,NNP,O
,by,IN,O
,64,CD,O
,and,CC,O
,75,CD,O
,%,NN,O
,after,IN,O
,APAP,NNP,O
,doses,NNS,O
,of,IN,O
,750,CD,O
,and,CC,O
,900,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,.,.,O
,BNPP,NNP,O
,did,VBD,O
,not,RB,O
,alter,VB,O
,the,DT,O
,excretion,NN,O
,of,IN,O
,APAP,NNP,O
,or,CC,O
,any,DT,O
,of,IN,O
,its,PRP$,O
,non,JJ,O
,-,:,O
,deacetylated,VBN,O
,metabolites,NNS,O
,nor,CC,O
,did,VBD,O
,BNPP,NNP,O
,alter,NN,O
,excretion,NN,O
,of,IN,O
,PAP,NNP,O
,or,CC,O
,its,PRP$,O
,metabolites,NNS,O
,after,IN,O
,PAP,NNP,O
,doses,NNS,O
,of,IN,O
,150,CD,O
,and,CC,O
,300,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,.,.,O
,Therefore,RB,O
,",",",",O
,the,DT,O
,BNPP,NNP,O
,-,:,O
,induced,JJ,O
,reduction,NN,O
,in,IN,O
,APAP,NNP,O
,-,:,O
,induced,JJ,O
,nephrotoxicity,NN,B-DISEASE
,appears,VBZ,O
,to,TO,O
,be,VB,O
,due,JJ,O
,to,TO,O
,inhibition,NN,O
,of,IN,O
,APAP,NNP,O
,deacetylation,NN,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,concluded,VBN,O
,that,IN,O
,PAP,NNP,O
,formation,NN,O
,",",",",O
,in,IN,O
,vivo,NN,O
,",",",",O
,accounts,NNS,O
,",",",",O
,at,IN,O
,least,JJS,O
,in,IN,O
,part,NN,O
,",",",",O
,for,IN,O
,APAP,NNP,O
,-,:,O
,induced,VBD,O
,renal,JJ,B-DISEASE
,tubular,JJ,I-DISEASE
,necrosis,NN,I-DISEASE
,.,.,O
,Morphine,NNP,O
,-,:,O
,induced,JJ,O
,seizures,NNS,B-DISEASE
,in,IN,O
,newborn,JJ,O
,infants,NNS,O
,.,.,O
,Two,CD,O
,neonates,NNS,O
,suffered,VBD,O
,from,IN,O
,generalized,JJ,O
,seizures,NNS,B-DISEASE
,during,IN,O
,the,DT,O
,course,NN,O
,of,IN,O
,intravenous,JJ,O
,morphine,NN,O
,sulfate,NN,O
,for,IN,O
,post,NN,O
,-,:,O
,operative,JJ,O
,analgesia,NN,O
,.,.,O
,They,PRP,O
,received,VBD,O
,morphine,NN,O
,in,IN,O
,doses,NNS,O
,of,IN,O
,32,CD,O
,micrograms,NNS,O
,/,VBP,O
,kg,JJ,O
,/,NNP,O
,hr,NN,O
,and,CC,O
,40,CD,O
,micrograms,NNS,O
,/,VBP,O
,kg,JJ,O
,/,NNP,O
,hr,NN,O
,larger,JJR,O
,than,IN,O
,a,DT,O
,group,NN,O
,of,IN,O
,10,CD,O
,neonates,NNS,O
,who,WP,O
,received,VBD,O
,6,CD,O
,-,:,O
,24,CD,O
,micrograms,NNS,O
,/,VBP,O
,kg,JJ,O
,/,NNP,O
,hr,NN,O
,and,CC,O
,had,VBD,O
,no,DT,O
,seizures,NNS,B-DISEASE
,.,.,O
,Plasma,NNP,O
,concentrations,NNS,O
,of,IN,O
,morphine,NN,O
,in,IN,O
,these,DT,O
,neonates,NNS,O
,was,VBD,O
,excessive,JJ,O
,(,(,O
,60,CD,O
,and,CC,O
,90,CD,O
,mg,NN,O
,/,NNP,O
,ml,NN,O
,),),O
,.,.,O
,Other,JJ,O
,known,JJ,O
,reasons,NNS,O
,for,IN,O
,seizures,NNS,B-DISEASE
,were,VBD,O
,ruled,VBN,O
,out,RP,O
,and,CC,O
,the,DT,O
,convulsions,NNS,B-DISEASE
,stopped,VBD,O
,a,DT,O
,few,JJ,O
,hours,NNS,O
,after,IN,O
,cessation,NN,O
,of,IN,O
,morphine,NN,O
,and,CC,O
,did,VBD,O
,not,RB,O
,reoccur,VB,O
,in,IN,O
,the,DT,O
,subsequent,JJ,O
,8,CD,O
,months,NNS,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,suggested,VBN,O
,that,IN,O
,post,NN,O
,-,:,O
,operative,JJ,O
,intravenous,JJ,O
,morphine,NN,O
,should,MD,O
,not,RB,O
,exceed,VB,O
,20,CD,O
,micrograms,NNS,O
,/,VBP,O
,kg,JJ,O
,/,NNP,O
,ml,NN,O
,in,IN,O
,neonates,NNS,O
,.,.,O
,Indomethacin,NNP,O
,induced,JJ,O
,hypotension,NN,B-DISEASE
,in,IN,O
,sodium,NN,O
,and,CC,O
,volume,NN,O
,depleted,VBD,O
,rats,NNS,O
,.,.,O
,After,IN,O
,a,DT,O
,single,JJ,O
,oral,JJ,O
,dose,NN,O
,of,IN,O
,4,CD,O
,mg,NNS,O
,/,JJ,O
,kg,NNS,O
,indomethacin,NN,O
,(,(,O
,IDM,NNP,O
,),),O
,to,TO,O
,sodium,VB,O
,and,CC,O
,volume,NN,O
,depleted,VBD,O
,rats,NNS,O
,plasma,VBP,O
,renin,NN,O
,activity,NN,O
,(,(,O
,PRA,NNP,O
,),),O
,and,CC,O
,systolic,JJ,O
,blood,NN,O
,pressure,NN,O
,fell,VBD,O
,significantly,RB,O
,within,IN,O
,four,CD,O
,hours,NNS,O
,.,.,O
,In,IN,O
,sodium,NN,O
,repleted,VBN,O
,animals,NNS,O
,indomethacin,VBP,O
,did,VBD,O
,not,RB,O
,change,VB,O
,systolic,JJ,O
,blood,NN,O
,pressure,NN,O
,(,(,O
,BP,NNP,O
,),),O
,although,IN,O
,plasma,JJ,O
,renin,NN,O
,activity,NN,O
,was,VBD,O
,decreased,VBN,O
,.,.,O
,Thus,RB,O
,",",",",O
,indomethacin,NN,O
,by,IN,O
,inhibition,NN,O
,of,IN,O
,prostaglandin,JJ,O
,synthesis,NN,O
,may,MD,O
,diminish,VB,O
,the,DT,O
,blood,NN,O
,pressure,NN,O
,maintaining,VBG,O
,effect,NN,O
,of,IN,O
,the,DT,O
,stimulated,VBN,O
,renin,NN,O
,-,:,O
,angiotensin,NN,O
,system,NN,O
,in,IN,O
,sodium,NN,O
,and,CC,O
,volume,NN,O
,depletion,NN,O
,.,.,O
,On,IN,O
,the,DT,O
,antiarrhythmic,JJ,O
,activity,NN,O
,of,IN,O
,one,CD,O
,N,NNP,O
,-,:,O
,substituted,VBD,O
,piperazine,JJ,O
,derivative,NN,O
,of,IN,O
,trans,NNS,O
,-,:,O
,2,CD,O
,-,:,O
,amino,NN,O
,-,:,O
,3,CD,O
,-,:,O
,hydroxy,NN,O
,-,:,O
,1,CD,O
,",",",",O
,2,CD,O
,",",",",O
,3,CD,O
,",",",",O
,4,CD,O
,-,:,O
,tetrahydroanaphthalene,NN,O
,.,.,O
,The,DT,O
,antiarrhythmic,JJ,O
,activity,NN,O
,of,IN,O
,the,DT,O
,compound,NN,O
,N,NNP,O
,-,:,O
,(,(,O
,trans,VBZ,O
,-,:,O
,3,CD,O
,-,:,O
,hydroxy,NN,O
,-,:,O
,1,CD,O
,",",",",O
,2,CD,O
,",",",",O
,3,CD,O
,",",",",O
,4,CD,O
,-,:,O
,tetrahydro,NN,O
,-,:,O
,2,CD,O
,-,:,O
,naphthyl,NN,O
,),),O
,-,:,O
,N,NNP,O
,-,:,O
,(,(,O
,3,CD,O
,-,:,O
,oxo,NN,O
,-,:,O
,3,CD,O
,-,:,O
,phenyl,NN,O
,-,:,O
,2,CD,O
,-,:,O
,methylpropyl,NN,O
,),),O
,-,:,O
,piperazine,NN,O
,hydrochloride,NN,O
,",",",",O
,referred,VBD,O
,to,TO,O
,as,IN,O
,P11,NNP,O
,",",",",O
,is,VBZ,O
,studied,VBN,O
,on,IN,O
,anaesthesized,JJ,O
,cats,NNS,O
,and,CC,O
,Wistar,NNP,O
,albino,NN,O
,rats,NNS,O
,",",",",O
,as,RB,O
,well,RB,O
,as,IN,O
,on,IN,O
,non,IN,O
,-,:,O
,anaesthesized,JJ,O
,rabbits,NNS,O
,.,.,O
,Four,CD,O
,types,NNS,O
,of,IN,O
,experimental,JJ,O
,arrhythmia,NN,B-DISEASE
,are,VBP,O
,used,VBN,O
,-,:,O
,-,:,O
,with,IN,O
,BaCl2,NNP,O
,",",",",O
,with,IN,O
,chloroform,NN,O
,-,:,O
,adrenaline,NN,O
,",",",",O
,with,IN,O
,strophantine,JJ,O
,G,NNP,O
,and,CC,O
,with,IN,O
,aconitine,NN,O
,.,.,O
,The,DT,O
,compound,NN,O
,P11,NNP,O
,is,VBZ,O
,introduced,VBN,O
,in,IN,O
,doses,NNS,O
,of,IN,O
,0,CD,O
,.,.,O
,25,CD,O
,and,CC,O
,0,CD,O
,.,.,O
,50,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,intravenously,RB,O
,and,CC,O
,10,CD,O
,mg,NN,O
,/,NNP,O
,kg,NNP,O
,orally,RB,O
,.,.,O
,The,DT,O
,compound,NN,O
,manifests,VBZ,O
,antiarrhythmic,JJ,O
,activity,NN,O
,in,IN,O
,all,DT,O
,models,NNS,O
,of,IN,O
,experimental,JJ,O
,arrhythmia,NN,B-DISEASE
,used,VBN,O
,",",",",O
,causing,VBG,O
,greatest,JJS,O
,inhibition,NN,O
,on,IN,O
,the,DT,O
,arrhythmia,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,chloroform,NN,O
,-,:,O
,adrenaline,NN,O
,(,(,O
,in,IN,O
,90,CD,O
,per,IN,O
,cent,NN,O
,),),O
,and,CC,O
,with,IN,O
,BaCl2,NNP,O
,(,(,O
,in,IN,O
,84,CD,O
,per,IN,O
,cent,NN,O
,),),O
,.,.,O
,The,DT,O
,results,NNS,O
,obtained,VBN,O
,are,VBP,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,beta,NN,O
,-,:,O
,adrenoblocking,NN,O
,and,CC,O
,with,IN,O
,the,DT,O
,membrane,NN,O
,-,:,O
,stabilizing,VBG,O
,action,NN,O
,of,IN,O
,the,DT,O
,compound,NN,O
,.,.,O
,Recurrent,NNP,O
,subarachnoid,JJ,B-DISEASE
,hemorrhage,NN,I-DISEASE
,associated,VBN,O
,with,IN,O
,aminocaproic,JJ,O
,acid,NN,O
,therapy,NN,O
,and,CC,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,artery,NN,I-DISEASE
,thrombosis,NN,I-DISEASE
,.,.,O
,Case,NNP,O
,report,NN,O
,.,.,O
,Epsilon,NNP,O
,aminocaproic,JJ,O
,acid,NN,O
,(,(,O
,EACA,NNP,O
,),),O
,has,VBZ,O
,been,VBN,O
,used,VBN,O
,to,TO,O
,prevent,VB,O
,rebleeding,VBG,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,subarachnoid,JJ,B-DISEASE
,hemorrhage,NN,I-DISEASE
,(,(,O
,SAH,NNP,B-DISEASE
,),),O
,.,.,O
,Although,IN,O
,this,DT,O
,agent,NN,O
,does,VBZ,O
,decrease,VB,O
,the,DT,O
,frequency,NN,O
,of,IN,O
,rebleeding,NN,O
,",",",",O
,several,JJ,O
,reports,NNS,O
,have,VBP,O
,described,VBN,O
,thrombotic,JJ,B-DISEASE
,complications,NNS,O
,of,IN,O
,EACA,NNP,O
,therapy,NN,O
,.,.,O
,These,DT,O
,complications,NNS,O
,have,VBP,O
,included,VBN,O
,clinical,JJ,O
,deterioration,NN,O
,and,CC,O
,intracranial,JJ,B-DISEASE
,vascular,JJ,I-DISEASE
,thrombosis,NN,I-DISEASE
,in,IN,O
,patients,NNS,O
,with,IN,O
,SAH,NNP,B-DISEASE
,",",",",O
,arteriolar,JJ,O
,and,CC,O
,capillary,JJ,O
,fibrin,NN,O
,thrombi,NN,B-DISEASE
,in,IN,O
,patients,NNS,O
,with,IN,O
,fibrinolytic,JJ,O
,syndromes,NNS,O
,treated,VBN,O
,with,IN,O
,EACA,NNP,O
,",",",",O
,or,CC,O
,other,JJ,O
,thromboembolic,JJ,B-DISEASE
,phenomena,NNS,I-DISEASE
,.,.,O
,Since,IN,O
,intravascular,JJ,O
,fibrin,NN,O
,thrombi,NN,B-DISEASE
,are,VBP,O
,often,RB,O
,observed,VBN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,fibrinolytic,JJ,O
,disorders,NNS,O
,",",",",O
,EACA,NNP,O
,should,MD,O
,not,RB,O
,be,VB,O
,implicated,VBN,O
,in,IN,O
,the,DT,O
,pathogenesis,NN,O
,of,IN,O
,fibrin,JJ,O
,thrombi,NN,B-DISEASE
,in,IN,O
,patients,NNS,O
,with,IN,O
,disseminated,JJ,B-DISEASE
,intravascular,JJ,I-DISEASE
,coagulation,NN,I-DISEASE
,or,CC,O
,other,JJ,O
,"""",JJ,O
,consumption,NN,B-DISEASE
,coagulopathies,NNS,I-DISEASE
,.,.,O
,"""",VB,O
,This,DT,O
,report,NN,O
,describes,VBZ,O
,subtotal,JJ,O
,infarction,NN,B-DISEASE
,of,IN,O
,the,DT,O
,kidney,NN,O
,due,JJ,O
,to,TO,O
,thrombosis,NN,B-DISEASE
,of,IN,I-DISEASE
,a,DT,I-DISEASE
,normal,JJ,I-DISEASE
,renal,JJ,I-DISEASE
,artery,NN,I-DISEASE
,.,.,O
,This,DT,O
,occlusion,NN,O
,occurred,VBD,O
,after,IN,O
,EACA,NNP,O
,therapy,NN,O
,in,IN,O
,a,DT,O
,patient,NN,O
,with,IN,O
,SAH,NNP,B-DISEASE
,and,CC,O
,histopathological,JJ,O
,documentation,NN,O
,of,IN,O
,recurrent,NN,O
,SAH,NNP,B-DISEASE
,.,.,O
,The,DT,O
,corresponding,JJ,O
,clinical,JJ,O
,event,NN,O
,was,VBD,O
,characterized,VBN,O
,by,IN,O
,marked,JJ,O
,hypertension,NN,B-DISEASE
,and,CC,O
,abrupt,JJ,O
,neurological,JJ,O
,deterioration,NN,O
,.,.,O
,Effect,NNP,O
,of,IN,O
,vincristine,NN,O
,sulfate,NN,O
,on,IN,O
,Pseudomonas,NNP,B-DISEASE
,infections,NNS,I-DISEASE
,in,IN,O
,monkeys,NNS,O
,.,.,O
,In,IN,O
,rhesus,NN,O
,monkeys,NNS,O
,",",",",O
,intravenous,JJ,O
,challenge,NN,O
,with,IN,O
,0,CD,O
,.,.,O
,6,CD,O
,x,JJ,O
,10,CD,O
,(,(,O
,10,CD,O
,),),O
,to,TO,O
,2,CD,O
,.,.,O
,2,CD,O
,x,JJ,O
,10,CD,O
,(,(,O
,10,CD,O
,),),O
,Pseudomonas,NNP,O
,aeruginosa,NN,O
,organisms,NNS,O
,caused,VBD,O
,acute,JJ,O
,illness,NN,O
,of,IN,O
,4,CD,O
,to,TO,O
,5,CD,O
,days,NNS,O
,',POS,O
,duration,NN,O
,with,IN,O
,spontaneous,JJ,O
,recovery,NN,O
,in,IN,O
,13,CD,O
,of,IN,O
,15,CD,O
,monkeys,NNS,O
,;,:,O
,blood,NN,O
,cultures,NNS,O
,became,VBD,O
,negative,JJ,O
,3,CD,O
,to,TO,O
,17,CD,O
,days,NNS,O
,after,IN,O
,challenge,NN,O
,.,.,O
,Leukocytosis,NN,B-DISEASE
,was,VBD,O
,observed,VBN,O
,in,IN,O
,all,DT,O
,monkeys,NNS,O
,.,.,O
,Intravenous,JJ,O
,or,CC,O
,intratracheal,JJ,O
,inoculation,NN,O
,of,IN,O
,2,CD,O
,.,.,O
,0,CD,O
,to,TO,O
,2,CD,O
,.,.,O
,5,CD,O
,mg,NN,O
,of,IN,O
,vincristine,NN,O
,sulfate,NN,O
,was,VBD,O
,followed,VBN,O
,by,IN,O
,leukopenia,NN,B-DISEASE
,in,IN,O
,4,CD,O
,to,TO,O
,5,CD,O
,days,NNS,O
,.,.,O
,Intravenous,JJ,O
,inoculation,NN,O
,of,IN,O
,4,CD,O
,.,.,O
,2,CD,O
,x,JJ,O
,10,CD,O
,(,(,O
,10,CD,O
,),),O
,to,TO,O
,7,CD,O
,.,.,O
,8,CD,O
,x,JJ,O
,10,CD,O
,(,(,O
,10,CD,O
,),),O
,pyocin,NN,O
,type,$,O
,6,CD,O
,Pseudomonas,NNP,O
,organisms,NNS,O
,in,IN,O
,monkeys,NNS,O
,given,VBN,O
,vincristine,JJ,O
,sulfate,NN,O
,4,CD,O
,days,NNS,O
,previously,RB,O
,resulted,VBD,O
,in,IN,O
,fatal,JJ,O
,infection,NN,B-DISEASE
,in,IN,O
,11,CD,O
,of,IN,O
,14,CD,O
,monkeys,NNS,O
,",",",",O
,whereas,IN,O
,none,NN,O
,of,IN,O
,four,CD,O
,receiving,VBG,O
,Pseudomonas,NNP,O
,alone,RB,O
,died,VBD,O
,.,.,O
,These,DT,O
,studies,NNS,O
,suggest,VBP,O
,that,IN,O
,an,DT,O
,antimetabolite,JJ,O
,-,:,O
,induced,VBN,O
,leukopenia,NN,B-DISEASE
,predisposes,NNS,O
,to,TO,O
,severe,VB,O
,Pseudomonas,NNP,O
,sepsis,NN,B-DISEASE
,and,CC,O
,that,IN,O
,such,JJ,O
,monkeys,NNS,O
,may,MD,O
,serve,VB,O
,as,IN,O
,a,DT,O
,biological,JJ,O
,model,NN,O
,for,IN,O
,study,NN,O
,of,IN,O
,comparative,JJ,O
,efficacy,NN,O
,of,IN,O
,antimicrobial,JJ,O
,agents,NNS,O
,.,.,O
,Modification,NN,O
,by,IN,O
,propranolol,NN,O
,of,IN,O
,cardiovascular,JJ,O
,effects,NNS,O
,of,IN,O
,induced,JJ,O
,hypoglycaemia,NN,B-DISEASE
,.,.,O
,The,DT,O
,cardiovascular,JJ,O
,effects,NNS,O
,of,IN,O
,hypoglycaemia,NN,B-DISEASE
,",",",",O
,with,IN,O
,and,CC,O
,without,IN,O
,beta,SYM,O
,-,:,O
,blockade,NN,O
,",",",",O
,were,VBD,O
,compared,VBN,O
,in,IN,O
,fourteen,JJ,O
,healthy,JJ,O
,men,NNS,O
,.,.,O
,Eight,NNP,O
,received,VBD,O
,insulin,NN,O
,alone,RB,O
,",",",",O
,and,CC,O
,eight,CD,O
,",",",",O
,including,VBG,O
,two,CD,O
,of,IN,O
,the,DT,O
,original,JJ,O
,insulin,NN,O
,-,:,O
,only,RB,O
,group,NN,O
,",",",",O
,were,VBD,O
,given,VBN,O
,propranolol,NNS,O
,and,CC,O
,insulin,NN,O
,.,.,O
,In,IN,O
,the,DT,O
,insulin,NN,O
,-,:,O
,group,NN,O
,the,DT,O
,period,NN,O
,of,IN,O
,hypoglycaemia,NN,B-DISEASE
,was,VBD,O
,associated,VBN,O
,with,IN,O
,an,DT,O
,increase,NN,O
,in,IN,O
,heart,NN,O
,-,:,O
,rate,NN,O
,and,CC,O
,a,DT,O
,fall,NN,O
,in,IN,O
,diastolic,JJ,O
,blood,NN,O
,-,:,O
,pressure,NN,O
,.,.,O
,In,IN,O
,the,DT,O
,propranolol,NN,O
,-,:,O
,insulin,NN,O
,group,NN,O
,there,EX,O
,was,VBD,O
,a,DT,O
,significant,JJ,O
,fall,NN,O
,in,IN,O
,heart,NN,O
,-,:,O
,rate,NN,O
,in,IN,O
,most,JJS,O
,subjects,NNS,O
,and,CC,O
,an,DT,O
,increase,NN,O
,in,IN,O
,diastolic,JJ,O
,pressure,NN,O
,.,.,O
,Typical,JJ,O
,S,NNP,O
,-,:,O
,T,NNP,O
,/,NNP,O
,T,NNP,O
,changes,NNS,O
,occurred,VBD,O
,in,IN,O
,the,DT,O
,insulin,NN,O
,-,:,O
,group,NN,O
,but,CC,O
,in,IN,O
,none,NN,O
,of,IN,O
,the,DT,O
,propranolol,NN,O
,-,:,O
,insulin,NN,O
,group,NN,O
,.,.,O
,Hypertension,NNP,B-DISEASE
,in,IN,O
,diabetics,NNS,B-DISEASE
,prone,VBP,O
,to,TO,O
,hypoglycaemia,VB,B-DISEASE
,attacks,NNS,O
,should,MD,O
,not,RB,O
,be,VB,O
,treated,VBN,O
,with,IN,O
,beta,NN,O
,-,:,O
,blockers,NNS,O
,because,IN,O
,these,DT,O
,drugs,NNS,O
,may,MD,O
,cause,VB,O
,a,DT,O
,sharp,JJ,O
,rise,NN,O
,in,IN,O
,blood,NN,O
,-,:,O
,pressure,NN,O
,in,IN,O
,such,JJ,O
,patients,NNS,O
,.,.,O
,Long,NNP,O
,-,:,O
,term,NN,O
,propranolol,NN,O
,therapy,NN,O
,in,IN,O
,pregnancy,NN,O
,:,:,O
,maternal,JJ,O
,and,CC,O
,fetal,JJ,O
,outcome,NN,O
,.,.,O
,Propranolol,NNP,O
,",",",",O
,a,DT,O
,beta,NN,O
,-,:,O
,adrenergic,NN,O
,blocking,VBG,O
,agent,NN,O
,",",",",O
,has,VBZ,O
,found,VBN,O
,an,DT,O
,important,JJ,O
,position,NN,O
,in,IN,O
,the,DT,O
,practice,NN,O
,of,IN,O
,medicine,NN,O
,.,.,O
,Its,PRP$,O
,use,NN,O
,in,IN,O
,pregnancy,NN,O
,",",",",O
,however,RB,O
,",",",",O
,is,VBZ,O
,an,DT,O
,open,JJ,O
,question,NN,O
,as,IN,O
,a,DT,O
,number,NN,O
,of,IN,O
,detrimental,JJ,O
,side,NN,O
,effects,NNS,O
,have,VBP,O
,been,VBN,O
,reported,VBN,O
,in,IN,O
,the,DT,O
,fetus,NN,O
,and,CC,O
,neonate,NN,O
,.,.,O
,Ten,CD,O
,patients,NNS,O
,and,CC,O
,12,CD,O
,pregnancies,NNS,O
,are,VBP,O
,reported,VBN,O
,where,WRB,O
,chronic,JJ,O
,propranolol,NN,O
,has,VBZ,O
,been,VBN,O
,administered,VBN,O
,.,.,O
,Five,CD,O
,patients,NNS,O
,with,IN,O
,serial,JJ,O
,pregnancies,NNS,O
,with,IN,O
,and,CC,O
,without,IN,O
,propranolol,JJ,O
,therapy,NN,O
,are,VBP,O
,also,RB,O
,examined,VBN,O
,.,.,O
,Maternal,NNP,O
,",",",",O
,fetal,NN,O
,",",",",O
,and,CC,O
,neonatal,JJ,O
,complications,NNS,O
,are,VBP,O
,examined,VBN,O
,.,.,O
,An,DT,O
,attempt,NN,O
,is,VBZ,O
,made,VBN,O
,to,TO,O
,differentiate,VB,O
,drug,NN,O
,-,:,O
,related,JJ,O
,complications,NNS,O
,from,IN,O
,maternal,JJ,O
,disease,NN,O
,-,:,O
,-,:,O
,related,JJ,O
,complications,NNS,O
,.,.,O
,We,PRP,O
,conclude,VBP,O
,that,DT,O
,previously,RB,O
,reported,VBN,O
,hypoglycemia,NN,B-DISEASE
,",",",",O
,hyperbilirubinemia,NN,B-DISEASE
,",",",",O
,polycythemia,NN,B-DISEASE
,",",",",O
,neonatal,JJ,B-DISEASE
,apnea,NN,I-DISEASE
,",",",",O
,and,CC,O
,bradycardia,NNS,B-DISEASE
,are,VBP,O
,not,RB,O
,invariable,JJ,O
,and,CC,O
,cannot,JJ,O
,be,VB,O
,statistically,RB,O
,correlated,VBN,O
,with,IN,O
,chronic,JJ,O
,propranolol,NN,O
,therapy,NN,O
,.,.,O
,Growth,NNP,B-DISEASE
,retardation,NN,I-DISEASE
,",",",",O
,however,RB,O
,",",",",O
,appears,VBZ,O
,to,TO,O
,be,VB,O
,significant,JJ,O
,in,IN,O
,both,DT,O
,of,IN,O
,our,PRP$,O
,series,NN,O
,.,.,O
,Central,NNP,O
,excitatory,JJ,O
,actions,NNS,O
,of,IN,O
,flurazepam,NN,O
,.,.,O
,Toxic,NNP,O
,actions,NNS,O
,of,IN,O
,flurazepam,NN,O
,(,(,O
,FZP,NNP,O
,),),O
,were,VBD,O
,studied,VBN,O
,in,IN,O
,cats,NNS,O
,",",",",O
,mice,NN,O
,and,CC,O
,rats,NNS,O
,.,.,O
,High,JJ,O
,doses,NNS,O
,caused,VBD,O
,an,DT,O
,apparent,JJ,O
,central,JJ,O
,excitation,NN,O
,",",",",O
,most,JJS,O
,clearly,RB,O
,seen,VBN,O
,as,IN,O
,clonic,JJ,O
,convulsions,NNS,B-DISEASE
,",",",",O
,superimposed,VBN,O
,on,IN,O
,general,JJ,O
,depression,NN,B-DISEASE
,.,.,O
,Following,VBG,O
,a,DT,O
,lethal,JJ,O
,dose,NN,O
,",",",",O
,death,NN,O
,was,VBD,O
,always,RB,O
,associated,VBN,O
,with,IN,O
,convulsions,NNS,B-DISEASE
,.,.,O
,Comparing,VBG,O
,the,DT,O
,relative,JJ,O
,sensitivity,NN,O
,to,TO,O
,central,JJ,O
,depression,NN,B-DISEASE
,and,CC,O
,excitation,NN,O
,revealed,VBD,O
,that,IN,O
,rats,NNS,O
,were,VBD,O
,least,RBS,O
,likely,JJ,O
,to,TO,O
,have,VB,O
,convulsions,NNS,B-DISEASE
,at,IN,O
,doses,NNS,O
,that,WDT,O
,did,VBD,O
,not,RB,O
,first,JJ,O
,cause,NN,O
,loss,NN,B-DISEASE
,of,IN,I-DISEASE
,consciousness,NN,I-DISEASE
,",",",",O
,while,IN,O
,cats,NNS,O
,most,RBS,O
,clearly,RB,O
,showed,VBD,O
,marked,JJ,O
,central,JJ,O
,excitatory,JJ,O
,actions,NNS,O
,.,.,O
,Signs,NNP,O
,of,IN,O
,FZP,NNP,O
,toxocity,NN,B-DISEASE
,in,IN,O
,cats,NNS,O
,included,VBD,O
,excessive,JJ,O
,salivation,NN,B-DISEASE
,",",",",O
,extreme,JJ,O
,apprehensive,JJ,O
,behavior,NN,O
,",",",",O
,retching,VBG,O
,",",",",O
,muscle,NN,B-DISEASE
,tremors,NNS,I-DISEASE
,and,CC,O
,convulsions,NNS,B-DISEASE
,.,.,O
,An,DT,O
,interaction,NN,O
,between,IN,O
,FZP,NNP,O
,and,CC,O
,pentylenetetrazol,NN,O
,(,(,O
,PTZ,NNP,O
,),),O
,was,VBD,O
,shown,VBN,O
,by,IN,O
,pretreating,VBG,O
,mice,NN,O
,with,IN,O
,FZP,NNP,O
,before,IN,O
,PTZ,NNP,O
,challenge,NN,O
,.,.,O
,As,IN,O
,a,DT,O
,function,NN,O
,of,IN,O
,dose,NN,O
,",",",",O
,FZP,NNP,O
,first,RB,O
,protected,VBD,O
,against,IN,O
,convulsions,NNS,B-DISEASE
,and,CC,O
,death,NN,O
,.,.,O
,At,IN,O
,higher,JJR,O
,doses,NNS,O
,",",",",O
,however,RB,O
,",",",",O
,convulsions,NNS,B-DISEASE
,again,RB,O
,emerged,VBD,O
,.,.,O
,These,DT,O
,doses,NNS,O
,of,IN,O
,FZP,NNP,O
,were,VBD,O
,lower,JJR,O
,than,IN,O
,those,DT,O
,that,WDT,O
,would,MD,O
,alone,RB,O
,cause,VB,O
,convulsions,NNS,B-DISEASE
,.,.,O
,These,DT,O
,results,NNS,O
,may,MD,O
,be,VB,O
,relevant,JJ,O
,to,TO,O
,the,DT,O
,use,NN,O
,of,IN,O
,FZP,NNP,O
,in,IN,O
,clinical,JJ,O
,situations,NNS,O
,in,IN,O
,which,WDT,O
,there,EX,O
,is,VBZ,O
,increased,JJ,O
,neural,JJ,O
,excitability,NN,O
,",",",",O
,such,JJ,O
,as,IN,O
,epilepsy,NN,B-DISEASE
,or,CC,O
,sedative,JJ,O
,-,:,O
,hypnotic,JJ,O
,drug,NN,O
,withdrawal,NN,O
,.,.,O
,Use,NNP,O
,of,IN,O
,propranolol,NN,O
,in,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,idiopathic,JJ,B-DISEASE
,orthostatic,JJ,I-DISEASE
,hypotension,NN,I-DISEASE
,.,.,O
,Five,CD,O
,patients,NNS,O
,with,IN,O
,idiopathic,JJ,B-DISEASE
,orthostatic,JJ,I-DISEASE
,hypotension,NN,I-DISEASE
,who,WP,O
,had,VBD,O
,physiologic,NN,O
,and,CC,O
,biochemical,JJ,O
,evidence,NN,O
,of,IN,O
,severe,JJ,O
,autonomic,JJ,O
,dysfunction,NN,O
,were,VBD,O
,included,VBN,O
,in,IN,O
,the,DT,O
,study,NN,O
,.,.,O
,They,PRP,O
,all,DT,O
,exhibited,VBD,O
,markedly,RB,O
,reduced,VBN,O
,plasma,NN,O
,catecholamines,NNS,O
,and,CC,O
,plasma,JJ,O
,renin,NN,O
,activity,NN,O
,in,IN,O
,both,DT,O
,recumbent,NN,O
,and,CC,O
,upright,JJ,O
,positions,NNS,O
,and,CC,O
,had,VBD,O
,marked,VBN,O
,hypersensitivity,NN,B-DISEASE
,to,TO,O
,the,DT,O
,pressor,NN,O
,effects,NNS,O
,of,IN,O
,infused,JJ,O
,norepinephrine,NN,O
,.,.,O
,Treatment,NN,O
,with,IN,O
,propanolol,NN,O
,administered,VBN,O
,intravenously,RB,O
,(,(,O
,1,CD,O
,-,:,O
,5,CD,O
,mg,NN,O
,),),O
,produced,VBD,O
,increases,NNS,O
,in,IN,O
,supine,NN,O
,and,CC,O
,upright,JJ,O
,blood,NN,O
,pressure,NN,O
,in,IN,O
,4,CD,O
,of,IN,O
,the,DT,O
,5,CD,O
,individuals,NNS,O
,with,IN,O
,rises,NNS,O
,ranging,VBG,O
,from,IN,O
,11,CD,O
,/,$,O
,6,CD,O
,to,TO,O
,22,CD,O
,/,NNS,O
,11,CD,O
,mmHg,NN,O
,.,.,O
,Chronic,NNP,O
,oral,JJ,O
,administration,NN,O
,of,IN,O
,propranolol,NN,O
,(,(,O
,40,CD,O
,-,:,O
,160,CD,O
,mg,JJ,O
,/,NNP,O
,day,NN,O
,),),O
,also,RB,O
,elevated,VBD,O
,the,DT,O
,blood,NN,O
,pressures,NNS,O
,of,IN,O
,these,DT,O
,individuals,NNS,O
,with,IN,O
,increases,NNS,O
,in,IN,O
,the,DT,O
,order,NN,O
,of,IN,O
,20,CD,O
,-,:,O
,35,CD,O
,/,$,O
,15,CD,O
,-,:,O
,25,CD,O
,mmg,NN,O
,being,VBG,O
,observed,VBN,O
,.,.,O
,In,IN,O
,1,CD,O
,patient,NN,O
,",",",",O
,marked,VBD,O
,hypertension,NN,B-DISEASE
,was,VBD,O
,induced,VBN,O
,by,IN,O
,propranolol,NN,O
,and,CC,O
,the,DT,O
,drug,NN,O
,had,VBD,O
,to,TO,O
,be,VB,O
,withdrawn,VBN,O
,.,.,O
,It,PRP,O
,otherwise,RB,O
,was,VBD,O
,well,RB,O
,tolerated,VBN,O
,and,CC,O
,no,DT,O
,important,JJ,O
,side,NN,O
,effects,NNS,O
,were,VBD,O
,observed,VBN,O
,.,.,O
,Treatment,NN,O
,has,VBZ,O
,been,VBN,O
,continued,VBN,O
,in,IN,O
,3,CD,O
,individuals,NNS,O
,for,IN,O
,6,CD,O
,-,:,O
,13,CD,O
,months,NNS,O
,with,IN,O
,persistence,NN,O
,of,IN,O
,the,DT,O
,pressor,NN,O
,effect,NN,O
,",",",",O
,although,IN,O
,there,EX,O
,appears,VBZ,O
,to,TO,O
,have,VB,O
,been,VBN,O
,some,DT,O
,decrease,NN,O
,in,IN,O
,the,DT,O
,degree,NN,O
,of,IN,O
,response,NN,O
,with,IN,O
,time,NN,O
,.,.,O
,Hemodynamic,JJ,O
,measurements,NNS,O
,in,IN,O
,1,CD,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,demonstrated,VBD,O
,an,DT,O
,increase,NN,O
,in,IN,O
,total,JJ,O
,peripheral,JJ,O
,resistance,NN,O
,and,CC,O
,essentially,RB,O
,no,DT,O
,change,NN,O
,in,IN,O
,cardiac,JJ,O
,output,NN,O
,following,VBG,O
,propranolol,JJ,O
,therapy,NN,O
,.,.,O
,The,DT,O
,studies,NNS,O
,suggest,VBP,O
,that,IN,O
,propranolol,NN,O
,is,VBZ,O
,a,DT,O
,useful,JJ,O
,drug,NN,O
,in,IN,O
,selected,VBN,O
,patients,NNS,O
,with,IN,O
,severe,JJ,O
,idiopathic,JJ,B-DISEASE
,orthostatic,JJ,I-DISEASE
,hypotension,NN,I-DISEASE
,.,.,O
,Total,JJ,O
,intravenous,JJ,O
,anesthesia,NN,O
,with,IN,O
,etomidate,NN,O
,.,.,O
,III,NNP,O
,.,.,O
,Some,DT,O
,observations,NNS,O
,in,IN,O
,adults,NNS,O
,.,.,O
,An,DT,O
,investigation,NN,O
,was,VBD,O
,undertaken,VBN,O
,to,TO,O
,determine,VB,O
,the,DT,O
,dosage,NN,O
,of,IN,O
,etomidate,NN,O
,required,VBN,O
,to,TO,O
,maintain,VB,O
,sleep,NN,O
,in,IN,O
,adults,NNS,O
,undergoing,VBG,O
,surgery,NN,O
,under,IN,O
,regional,JJ,O
,local,JJ,O
,anesthesia,NN,O
,.,.,O
,Premedication,NN,O
,of,IN,O
,diazepam,NN,O
,10,CD,O
,mg,NN,O
,and,CC,O
,atropine,JJ,O
,0,CD,O
,.,.,O
,5,CD,O
,mg,NN,O
,was,VBD,O
,given,VBN,O
,",",",",O
,and,CC,O
,sleep,NN,O
,was,VBD,O
,induced,VBN,O
,and,CC,O
,maintained,VBN,O
,by,IN,O
,intermittent,NN,O
,intravenous,JJ,O
,injections,NNS,O
,of,IN,O
,etomidate,NN,O
,0,CD,O
,.,.,O
,1,CD,O
,/,JJ,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,given,VBN,O
,whenever,WRB,O
,the,DT,O
,patient,NN,O
,would,MD,O
,open,VB,O
,his,PRP$,O
,eyes,NNS,O
,on,IN,O
,request,NN,O
,.,.,O
,A,DT,O
,mean,JJ,O
,overall,JJ,O
,dose,NN,O
,of,IN,O
,etomidate,JJ,O
,17,CD,O
,.,.,O
,4,CD,O
,microgram,JJ,O
,/,NNP,O
,kg,NN,O
,/,NNP,O
,min,NN,O
,.,.,O
,was,VBD,O
,required,VBN,O
,to,TO,O
,maintain,VB,O
,sleep,JJ,O
,",",",",O
,but,CC,O
,great,JJ,O
,individual,JJ,O
,variation,NN,O
,occurred,VBD,O
,",",",",O
,with,IN,O
,older,JJR,O
,patients,NNS,O
,requiring,VBG,O
,less,JJR,O
,drug,NN,O
,.,.,O
,The,DT,O
,investigation,NN,O
,was,VBD,O
,discontinued,VBN,O
,after,IN,O
,18,CD,O
,patients,NNS,O
,because,IN,O
,of,IN,O
,the,DT,O
,frequency,NN,O
,and,CC,O
,intensity,NN,O
,of,IN,O
,side,NN,O
,-,:,O
,effects,NNS,O
,",",",",O
,particularly,RB,O
,pain,NN,B-DISEASE
,and,CC,O
,myoclonia,NN,B-DISEASE
,",",",",O
,which,WDT,O
,caused,VBD,O
,the,DT,O
,technique,NN,O
,to,TO,O
,be,VB,O
,abandoned,VBN,O
,in,IN,O
,two,CD,O
,cases,NNS,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,considered,VBN,O
,unlikely,JJ,O
,that,IN,O
,etomidate,NN,O
,will,MD,O
,prove,VB,O
,to,TO,O
,be,VB,O
,the,DT,O
,hypnotic,NN,O
,of,IN,O
,choice,NN,O
,for,IN,O
,a,DT,O
,totally,RB,O
,intravenous,JJ,O
,anesthetic,JJ,O
,technique,NN,O
,in,IN,O
,adults,NNS,O
,because,IN,O
,of,IN,O
,the,DT,O
,high,JJ,O
,incidence,NN,O
,of,IN,O
,myoclonia,NN,B-DISEASE
,after,IN,O
,prolonged,JJ,O
,administration,NN,O
,.,.,O
,In,IN,O
,several,JJ,O
,patients,NNS,O
,uncontrollable,JJ,O
,muscle,NN,O
,movements,NNS,O
,persisted,VBD,O
,for,IN,O
,many,JJ,O
,minutes,NNS,O
,after,IN,O
,complete,JJ,O
,recovery,NN,O
,of,IN,O
,consciousness,NN,O
,.,.,O
,Evidence,NN,O
,for,IN,O
,cardiac,JJ,O
,beta,NN,O
,2,CD,O
,-,:,O
,adrenoceptors,NNS,O
,in,IN,O
,man,NN,O
,.,.,O
,We,PRP,O
,compared,VBN,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,single,JJ,O
,doses,NNS,O
,of,IN,O
,50,CD,O
,mg,NNS,O
,atenolol,RB,O
,(,(,O
,cardioselective,JJ,O
,),),O
,",",",",O
,40,CD,O
,mg,NN,O
,propranolol,NN,O
,(,(,O
,nonselective,JJ,O
,),),O
,",",",",O
,and,CC,O
,placebo,NN,O
,on,IN,O
,both,DT,O
,exercise,NN,O
,-,:,O
,and,CC,O
,isoproterenol,VB,O
,-,:,O
,induced,JJ,O
,tachycardia,NN,B-DISEASE
,in,IN,O
,two,CD,O
,experiments,NNS,O
,involving,VBG,O
,nine,CD,O
,normal,JJ,O
,subjects,NNS,O
,.,.,O
,Maximal,NNP,O
,exercise,JJ,O
,heart,NN,O
,rate,NN,O
,was,VBD,O
,reduced,VBN,O
,from,IN,O
,187,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,4,CD,O
,(,(,O
,SEM,NNP,O
,),),O
,after,IN,O
,placebo,NN,O
,to,TO,O
,146,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,7,CD,O
,bpm,NN,O
,after,IN,O
,atenolol,NN,O
,and,CC,O
,138,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,6,CD,O
,bpm,NN,O
,after,IN,O
,propranolol,NN,O
,",",",",O
,but,CC,O
,there,EX,O
,were,VBD,O
,no,DT,O
,differences,NNS,O
,between,IN,O
,the,DT,O
,drugs,NNS,O
,.,.,O
,The,DT,O
,effects,NNS,O
,on,IN,O
,isoproterenol,JJ,O
,tachycardia,NN,B-DISEASE
,were,VBD,O
,determined,VBN,O
,before,IN,O
,and,CC,O
,after,IN,O
,atropine,NN,O
,(,(,O
,0,CD,O
,.,.,O
,04,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NNP,O
,IV,NNP,O
,),),O
,.,.,O
,Isoproterenol,NNP,O
,sensitivity,NN,O
,was,VBD,O
,determined,VBN,O
,as,IN,O
,the,DT,O
,intravenous,JJ,O
,dose,NN,O
,that,WDT,O
,increased,VBD,O
,heart,NN,O
,rate,NN,O
,by,IN,O
,25,CD,O
,bpm,NN,O
,(,(,O
,CD25,NNP,O
,),),O
,and,CC,O
,this,DT,O
,was,VBD,O
,increased,VBN,O
,from,IN,O
,1,CD,O
,.,.,O
,8,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,3,CD,O
,micrograms,NNS,O
,after,IN,O
,placebo,NN,O
,to,TO,O
,38,CD,O
,.,.,O
,9,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,8,CD,O
,.,.,O
,3,CD,O
,micrograms,NNS,O
,after,IN,O
,propranolol,NN,O
,and,CC,O
,8,CD,O
,.,.,O
,3,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,7,CD,O
,micrograms,NNS,O
,after,IN,O
,atenolol,NN,O
,.,.,O
,The,DT,O
,difference,NN,O
,in,IN,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,the,DT,O
,two,CD,O
,was,VBD,O
,significant,JJ,O
,.,.,O
,After,IN,O
,atropine,IN,O
,the,DT,O
,CD25,NNP,O
,was,VBD,O
,unchanged,JJ,O
,after,IN,O
,placebo,NN,O
,(,(,O
,2,CD,O
,.,.,O
,3,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,3,CD,O
,micrograms,NNS,O
,),),O
,and,CC,O
,atenolol,NN,O
,(,(,O
,7,CD,O
,.,.,O
,7,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,3,CD,O
,micrograms,NNS,O
,),),O
,;,:,O
,it,PRP,O
,was,VBD,O
,reduced,VBN,O
,after,IN,O
,propranolol,NN,O
,(,(,O
,24,CD,O
,.,.,O
,8,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,5,CD,O
,.,.,O
,0,CD,O
,micrograms,NNS,O
,),),O
,",",",",O
,but,CC,O
,remained,VBD,O
,different,JJ,O
,from,IN,O
,atenolol,NN,O
,.,.,O
,This,DT,O
,change,NN,O
,with,IN,O
,propranolol,JJ,O
,sensitivity,NN,O
,was,VBD,O
,calculated,VBN,O
,as,IN,O
,the,DT,O
,apparent,JJ,O
,Ka,NNP,O
,",",",",O
,this,DT,O
,was,VBD,O
,unchanged,JJ,O
,by,IN,O
,atropine,NN,O
,(,(,O
,11,CD,O
,.,.,O
,7,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,2,CD,O
,.,.,O
,1,CD,O
,and,CC,O
,10,CD,O
,.,.,O
,1,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,2,CD,O
,.,.,O
,5,CD,O
,ml,JJ,O
,/,NNP,O
,ng,NN,O
,),),O
,.,.,O
,These,DT,O
,data,NNS,O
,are,VBP,O
,consistent,JJ,O
,with,IN,O
,the,DT,O
,hypothesis,NN,O
,that,WDT,O
,exercise,VBP,O
,-,:,O
,induced,JJ,O
,tachycardia,NN,B-DISEASE
,results,NNS,O
,largely,RB,O
,from,IN,O
,beta,NN,O
,1,CD,O
,-,:,O
,receptor,NN,O
,activation,NN,O
,that,WDT,O
,is,VBZ,O
,blocked,VBN,O
,by,IN,O
,both,DT,O
,cardioselective,JJ,O
,and,CC,O
,nonselective,JJ,O
,drugs,NNS,O
,",",",",O
,whereas,NNS,O
,isoproterenol,VBP,O
,activates,VBZ,O
,both,DT,O
,beta,$,O
,1,CD,O
,-,:,O
,and,CC,O
,beta,VB,O
,2,CD,O
,-,:,O
,receptors,NNS,O
,so,IN,O
,that,DT,O
,after,IN,O
,cardioselective,JJ,O
,blockade,NN,O
,there,EX,O
,remains,VBZ,O
,a,DT,O
,beta,NN,O
,2,CD,O
,-,:,O
,component,NN,O
,that,WDT,O
,can,MD,O
,be,VB,O
,blocked,VBN,O
,with,IN,O
,a,DT,O
,nonselective,JJ,O
,drug,NN,O
,.,.,O
,While,IN,O
,there,RB,O
,appear,VB,O
,to,TO,O
,be,VB,O
,beta,RB,O
,2,CD,O
,-,:,O
,receptors,NNS,O
,in,IN,O
,the,DT,O
,human,JJ,O
,heart,NN,O
,",",",",O
,their,PRP$,O
,physiologic,NN,O
,or,CC,O
,pathologic,JJ,O
,roles,NNS,O
,remain,VBP,O
,to,TO,O
,be,VB,O
,defined,VBN,O
,.,.,O
,Hormones,NNS,O
,and,CC,O
,risk,NN,O
,of,IN,O
,breast,NN,B-DISEASE
,cancer,NN,I-DISEASE
,.,.,O
,This,DT,O
,paper,NN,O
,reports,VBZ,O
,the,DT,O
,results,NNS,O
,of,IN,O
,a,DT,O
,study,NN,O
,of,IN,O
,50,CD,O
,menopausal,JJ,O
,women,NNS,O
,receiving,VBG,O
,hormonal,JJ,O
,replacement,NN,O
,therapy,NN,O
,.,.,O
,The,DT,O
,majority,NN,O
,(,(,O
,29,CD,O
,),),O
,had,VBD,O
,surgical,JJ,O
,menopause,NN,O
,;,:,O
,their,PRP$,O
,mean,JJ,O
,age,NN,O
,was,VBD,O
,45,CD,O
,.,.,O
,7,CD,O
,years,NNS,O
,.,.,O
,It,PRP,O
,was,VBD,O
,hypothesized,VBN,O
,that,IN,O
,progestins,NNS,O
,could,MD,O
,equilibrate,VB,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,the,DT,O
,estrogenic,JJ,O
,stimulation,NN,O
,on,IN,O
,the,DT,O
,mammary,JJ,O
,and,CC,O
,endometrial,JJ,O
,target,NN,O
,tissues,NNS,O
,of,IN,O
,women,NNS,O
,on,IN,O
,hormonal,JJ,O
,replacement,NN,O
,therapy,NN,O
,.,.,O
,The,DT,O
,treatment,NN,O
,schedule,NN,O
,consisted,VBD,O
,of,IN,O
,conjugated,VBN,O
,estrogens,NNS,O
,(,(,O
,Premarin,NNP,O
,),),O
,1,CD,O
,.,.,O
,25,CD,O
,mg,JJ,O
,/,NNP,O
,day,NN,O
,for,IN,O
,21,CD,O
,days,NNS,O
,and,CC,O
,Medroxyprogesterone,NNP,O
,acetate,VBP,O
,10,CD,O
,mg,JJ,O
,/,NNP,O
,day,NN,O
,for,IN,O
,10,CD,O
,days,NNS,O
,in,IN,O
,each,DT,O
,month,NN,O
,.,.,O
,The,DT,O
,mean,JJ,O
,treatment,NN,O
,period,NN,O
,was,VBD,O
,18,CD,O
,months,NNS,O
,.,.,O
,During,IN,O
,the,DT,O
,follow,JJ,O
,-,:,O
,up,RB,O
,period,NN,O
,",",",",O
,attention,NN,O
,was,VBD,O
,paid,VBN,O
,to,TO,O
,breast,VB,O
,modifications,NNS,O
,as,IN,O
,evidenced,VBN,O
,by,IN,O
,symptomatology,NN,O
,",",",",O
,physical,JJ,O
,examination,NN,O
,",",",",O
,and,CC,O
,plate,NN,O
,thermography,NN,O
,.,.,O
,Mastodynia,NNP,B-DISEASE
,was,VBD,O
,reported,VBN,O
,by,IN,O
,21,CD,O
,patients,NNS,O
,",",",",O
,and,CC,O
,physical,JJ,O
,examination,NN,O
,revealed,VBD,O
,a,DT,O
,light,JJ,O
,increase,NN,O
,in,IN,O
,breast,JJ,O
,firmness,NN,O
,in,IN,O
,12,CD,O
,women,NNS,O
,and,CC,O
,a,DT,O
,moderate,JJ,O
,increase,NN,O
,in,IN,O
,breast,JJ,O
,nodularity,NN,O
,in,IN,O
,2,CD,O
,women,NNS,O
,.,.,O
,Themography,NNP,O
,confirmed,VBD,O
,the,DT,O
,existence,NN,O
,of,IN,O
,an,DT,O
,excessive,JJ,O
,breast,NN,O
,stimulation,NN,O
,in,IN,O
,1,CD,O
,women,NNS,O
,who,WP,O
,complained,VBD,O
,of,IN,O
,moderate,JJ,O
,mastodynia,NN,B-DISEASE
,and,CC,O
,in,IN,O
,5,CD,O
,of,IN,O
,the,DT,O
,7,CD,O
,women,NNS,O
,who,WP,O
,complained,VBD,O
,of,IN,O
,severe,JJ,O
,mastodynia,NN,B-DISEASE
,.,.,O
,Normalization,NN,O
,was,VBD,O
,obtained,VBN,O
,by,IN,O
,halving,VBG,O
,the,DT,O
,estrogen,NN,O
,dose,NN,O
,.,.,O
,These,DT,O
,results,NNS,O
,suggest,VBP,O
,that,IN,O
,hormonal,JJ,O
,replacement,NN,O
,therapy,NN,O
,can,MD,O
,be,VB,O
,safely,RB,O
,prescribed,VBN,O
,if,IN,O
,the,DT,O
,following,JJ,O
,criteria,NNS,O
,are,VBP,O
,satisfied,VBN,O
,:,:,O
,1,CD,O
,),),O
,preliminary,JJ,O
,evaluation,NN,O
,of,IN,O
,patients,NNS,O
,from,IN,O
,a,DT,O
,clinical,JJ,O
,",",",",O
,metabolic,JJ,O
,",",",",O
,cytologic,JJ,O
,",",",",O
,and,CC,O
,mammographic,JJ,O
,perspective,NN,O
,;,:,O
,2,CD,O
,),),O
,cyclic,NN,O
,treatment,NN,O
,schedule,NN,O
,",",",",O
,with,IN,O
,a,DT,O
,progestative,JJ,O
,phase,NN,O
,of,IN,O
,10,CD,O
,days,NNS,O
,;,:,O
,and,CC,O
,3,CD,O
,),),O
,periodic,NN,O
,complete,JJ,O
,follow,NN,O
,-,:,O
,up,RB,O
,",",",",O
,with,IN,O
,accurate,JJ,O
,thermographic,JJ,O
,evaluation,NN,O
,of,IN,O
,the,DT,O
,breast,NN,O
,target,NN,O
,tissues,NNS,O
,.,.,O
,Early,JJ,O
,infections,NNS,B-DISEASE
,in,IN,O
,kidney,NN,O
,",",",",O
,heart,NN,O
,",",",",O
,and,CC,O
,liver,RB,O
,transplant,JJ,O
,recipients,NNS,O
,on,IN,O
,cyclosporine,NN,O
,.,.,O
,Eighty,NNP,O
,-,:,O
,one,CD,O
,renal,NN,O
,",",",",O
,seventeen,JJ,O
,heart,NN,O
,",",",",O
,and,CC,O
,twenty,SYM,O
,-,:,O
,four,CD,O
,liver,NN,O
,transplant,NN,O
,patients,NNS,O
,were,VBD,O
,followed,VBN,O
,for,IN,O
,infection,NN,B-DISEASE
,.,.,O
,Seventeen,JJ,O
,renal,JJ,O
,patients,NNS,O
,received,VBN,O
,azathioprine,JJ,O
,(,(,O
,Aza,NNP,O
,),),O
,and,CC,O
,prednisone,NN,O
,as,IN,O
,part,NN,O
,of,IN,O
,a,DT,O
,randomized,JJ,O
,trial,NN,O
,of,IN,O
,immunosuppression,NN,O
,with,IN,O
,21,CD,O
,cyclosporine,NN,O
,-,:,O
,and,CC,O
,-,:,O
,prednisone,NN,O
,-,:,O
,treated,VBN,O
,renal,JJ,O
,transplant,NN,O
,patients,NNS,O
,.,.,O
,All,DT,O
,others,NNS,O
,received,VBD,O
,cyclosporine,NN,O
,and,CC,O
,prednisone,NN,O
,.,.,O
,The,DT,O
,randomized,JJ,O
,Aza,NNP,O
,patients,NNS,O
,had,VBD,O
,more,RBR,O
,overall,JJ,O
,infections,NNS,B-DISEASE
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,and,CC,O
,more,RBR,O
,nonviral,JJ,O
,infections,NNS,B-DISEASE
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,02,CD,O
,),),O
,than,IN,O
,the,DT,O
,randomized,JJ,O
,cyclosporine,NN,O
,patients,NNS,O
,.,.,O
,Heart,NNP,O
,and,CC,O
,liver,NN,O
,patients,NNS,O
,had,VBD,O
,more,RBR,O
,infections,NNS,B-DISEASE
,than,IN,O
,cyclosporine,JJ,O
,renal,JJ,O
,patients,NNS,O
,but,CC,O
,fewer,JJR,O
,infections,NNS,B-DISEASE
,than,IN,O
,the,DT,O
,Aza,NNP,O
,renal,JJ,O
,patients,NNS,O
,.,.,O
,There,EX,O
,were,VBD,O
,no,DT,O
,infectious,JJ,O
,deaths,NNS,O
,in,IN,O
,renal,JJ,O
,transplant,NN,O
,patients,NNS,O
,on,IN,O
,cyclosporine,NN,O
,or,CC,O
,Aza,NNP,O
,",",",",O
,but,CC,O
,infection,NN,B-DISEASE
,played,VBD,O
,a,DT,O
,major,JJ,O
,role,NN,O
,in,IN,O
,3,CD,O
,out,IN,O
,of,IN,O
,6,CD,O
,cardiac,JJ,O
,transplant,NN,O
,deaths,NNS,O
,and,CC,O
,in,IN,O
,8,CD,O
,out,IN,O
,of,IN,O
,9,CD,O
,liver,NN,O
,transplant,JJ,O
,deaths,NNS,O
,.,.,O
,Renal,JJ,O
,patients,NNS,O
,on,IN,O
,cyclosporine,NN,O
,had,VBD,O
,the,DT,O
,fewest,JJS,O
,bacteremias,NN,B-DISEASE
,.,.,O
,Analysis,NN,O
,of,IN,O
,site,NN,O
,of,IN,O
,infection,NN,B-DISEASE
,showed,VBD,O
,a,DT,O
,preponderance,NN,O
,of,IN,O
,abdominal,JJ,B-DISEASE
,infections,NNS,I-DISEASE
,in,IN,O
,liver,NN,O
,patients,NNS,O
,",",",",O
,intrathoracic,JJ,O
,infections,NNS,B-DISEASE
,in,IN,O
,heart,NN,O
,patients,NNS,O
,",",",",O
,and,CC,O
,urinary,JJ,B-DISEASE
,tract,NN,I-DISEASE
,infections,NNS,I-DISEASE
,in,IN,O
,renal,JJ,O
,patients,NNS,O
,.,.,O
,Pulmonary,JJ,O
,infections,NNS,B-DISEASE
,were,VBD,O
,less,JJR,O
,common,JJ,O
,in,IN,O
,cyclosporine,JJ,O
,-,:,O
,treated,JJ,O
,renal,JJ,O
,patients,NNS,O
,than,IN,O
,in,IN,O
,Aza,NNP,O
,-,:,O
,treated,VBD,O
,patients,NNS,O
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,Aza,NNP,O
,patients,NNS,O
,had,VBD,O
,significantly,RB,O
,more,RBR,O
,staphylococcal,JJ,B-DISEASE
,infections,NNS,I-DISEASE
,than,IN,O
,all,DT,O
,other,JJ,O
,transplant,NN,O
,groups,NNS,O
,(,(,O
,P,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,005,CD,O
,),),O
,",",",",O
,and,CC,O
,systemic,JJ,O
,fungal,JJ,B-DISEASE
,infections,NNS,I-DISEASE
,occurred,VBD,O
,only,RB,O
,in,IN,O
,the,DT,O
,liver,NN,O
,transplant,NN,O
,group,NN,O
,.,.,O
,Cytomegalovirus,NNP,O
,(,(,O
,CMV,NNP,O
,),),O
,shedding,VBG,O
,or,CC,O
,serological,JJ,O
,rises,NNS,O
,in,IN,O
,antibody,NN,O
,titer,NN,O
,",",",",O
,or,CC,O
,both,DT,O
,occurred,VBN,O
,in,IN,O
,78,CD,O
,%,NN,O
,of,IN,O
,cyclosporine,NN,O
,patients,NNS,O
,and,CC,O
,76,CD,O
,%,NN,O
,of,IN,O
,Aza,NNP,O
,patients,NNS,O
,.,.,O
,Of,IN,O
,the,DT,O
,cyclosporine,NN,O
,patients,NNS,O
,",",",",O
,15,CD,O
,%,NN,O
,had,VBD,O
,symptoms,NNS,O
,related,VBN,O
,to,TO,O
,CMV,NNP,B-DISEASE
,infection,NN,I-DISEASE
,.,.,O
,Serological,JJ,O
,evidence,NN,O
,for,IN,O
,Epstein,NNP,B-DISEASE
,Barr,NNP,I-DISEASE
,Virus,NNP,I-DISEASE
,infection,NN,I-DISEASE
,was,VBD,O
,found,VBN,O
,in,IN,O
,20,CD,O
,%,NN,O
,of,IN,O
,65,CD,O
,cyclosporine,NN,O
,patients,NNS,O
,studied,VBN,O
,.,.,O
,Three,CD,O
,had,VBD,O
,associated,VBN,O
,symptoms,NNS,O
,",",",",O
,and,CC,O
,one,CD,O
,developed,VBD,O
,a,DT,O
,lymphoma,NN,B-DISEASE
,.,.,O
,Structure,NNP,O
,-,:,O
,activity,NN,O
,and,CC,O
,dose,VB,O
,-,:,O
,effect,NN,O
,relationships,NNS,O
,of,IN,O
,the,DT,O
,antagonism,NN,O
,of,IN,O
,picrotoxin,NN,O
,-,:,O
,induced,JJ,O
,seizures,NNS,B-DISEASE
,by,IN,O
,cholecystokinin,NN,O
,",",",",O
,fragments,NNS,O
,and,CC,O
,analogues,NNS,O
,of,IN,O
,cholecystokinin,NN,O
,in,IN,O
,mice,NN,O
,.,.,O
,Intraperitoneal,NNP,O
,administration,NN,O
,of,IN,O
,cholecystokinin,JJ,O
,octapeptide,JJ,O
,sulphate,NN,O
,ester,NN,O
,(,(,O
,CCK,NNP,O
,-,:,O
,8,CD,O
,-,:,O
,SE,NN,O
,),),O
,and,CC,O
,nonsulphated,VBN,O
,cholecystokinin,NN,O
,octapeptide,NN,O
,(,(,O
,CCK,NNP,O
,-,:,O
,8,CD,O
,-,:,O
,NS,NN,O
,),),O
,enhanced,VBD,O
,the,DT,O
,latency,NN,O
,of,IN,O
,seizures,NNS,B-DISEASE
,induced,VBN,O
,by,IN,O
,picrotoxin,NN,O
,in,IN,O
,mice,NN,O
,.,.,O
,Experiments,NNS,O
,with,IN,O
,N,NNP,O
,-,:,O
,and,CC,O
,C,NNP,O
,-,:,O
,terminal,JJ,O
,fragments,NNS,O
,revealed,VBD,O
,that,IN,O
,the,DT,O
,C,NNP,O
,-,:,O
,terminal,JJ,O
,tetrapeptide,NN,O
,(,(,O
,CCK,NNP,O
,-,:,O
,5,CD,O
,-,:,O
,8,CD,O
,),),O
,was,VBD,O
,the,DT,O
,active,JJ,O
,centre,NN,O
,of,IN,O
,the,DT,O
,CCK,NNP,O
,octapeptide,NN,O
,molecule,NN,O
,.,.,O
,The,DT,O
,analogues,NNS,O
,CCK,NNP,O
,-,:,O
,8,CD,O
,-,:,O
,SE,NN,O
,and,CC,O
,CCK,NNP,O
,-,:,O
,8,CD,O
,-,:,O
,NS,NN,O
,(,(,O
,dose,JJ,O
,range,NN,O
,0,CD,O
,.,.,O
,2,CD,O
,-,:,O
,6,CD,O
,.,.,O
,4,CD,O
,mumol,JJ,O
,/,NNP,O
,kg,NN,O
,),),O
,and,CC,O
,caerulein,$,O
,dose,JJ,O
,range,NN,O
,0,CD,O
,.,.,O
,1,CD,O
,-,:,O
,0,CD,O
,.,.,O
,8,CD,O
,mumol,JJ,O
,/,NNP,O
,kg,NN,O
,),),O
,showed,VBD,O
,bell,SYM,O
,-,:,O
,shaped,VBN,O
,dose,VB,O
,-,:,O
,effect,NN,O
,curves,NNS,O
,",",",",O
,with,IN,O
,the,DT,O
,greatest,JJS,O
,maximum,JJ,O
,inhibition,NN,O
,for,IN,O
,CCK,NNP,O
,-,:,O
,8,CD,O
,-,:,O
,NS,NN,O
,.,.,O
,The,DT,O
,peptide,NN,O
,CCK,NNP,O
,-,:,O
,5,CD,O
,-,:,O
,8,CD,O
,had,VBD,O
,weak,JJ,O
,anticonvulsant,JJ,O
,activity,NN,O
,in,IN,O
,comparison,NN,O
,to,TO,O
,the,DT,O
,octapeptides,NNS,O
,",",",",O
,3,CD,O
,.,.,O
,2,CD,O
,mumol,JJ,O
,/,NNP,O
,kg,NN,O
,and,CC,O
,larger,JJR,O
,doses,NNS,O
,of,IN,O
,the,DT,O
,reference,NN,O
,drug,NN,O
,",",",",O
,diazepam,NN,O
,",",",",O
,totally,RB,O
,prevented,JJ,O
,picrotoxin,NN,O
,-,:,O
,induced,JJ,O
,seizures,NNS,B-DISEASE
,and,CC,O
,mortality,NN,O
,.,.,O
,The,DT,O
,maximum,JJ,O
,effect,NN,O
,of,IN,O
,the,DT,O
,peptides,NNS,O
,tested,VBD,O
,was,VBD,O
,less,JJR,O
,than,IN,O
,that,DT,O
,of,IN,O
,diazepam,NN,O
,.,.,O
,Experiments,NNS,O
,with,IN,O
,analogues,NNS,O
,and,CC,O
,derivatives,NNS,O
,of,IN,O
,CCK,NNP,O
,-,:,O
,5,CD,O
,-,:,O
,8,CD,O
,demonstrated,VBD,O
,that,IN,O
,the,DT,O
,effectiveness,NN,O
,of,IN,O
,the,DT,O
,beta,NN,O
,-,:,O
,alanyl,JJ,O
,derivatives,NNS,O
,of,IN,O
,CCK,NNP,O
,-,:,O
,5,CD,O
,-,:,O
,8,CD,O
,were,VBD,O
,enhanced,VBN,O
,and,CC,O
,that,IN,O
,they,PRP,O
,were,VBD,O
,equipotent,JJ,O
,with,IN,O
,CCK,NNP,O
,-,:,O
,8,CD,O
,-,:,O
,SE,NNP,O
,.,.,O
,Of,IN,O
,the,DT,O
,CCK,NNP,O
,-,:,O
,2,CD,O
,-,:,O
,8,CD,O
,analogues,NNS,O
,",",",",O
,Ser,NNP,O
,(,(,O
,SO3H,NNP,O
,),),O
,7,CD,O
,-,:,O
,Ac,NNP,O
,-,:,O
,CCK,NNP,O
,-,:,O
,2,CD,O
,-,:,O
,8,CD,O
,-,:,O
,SE,NN,O
,and,CC,O
,Thr,NNP,O
,(,(,O
,SO3H,NNP,O
,),),O
,7,CD,O
,-,:,O
,Ac,NNP,O
,-,:,O
,CCK,NNP,O
,-,:,O
,2,CD,O
,-,:,O
,8,CD,O
,-,:,O
,SE,NN,O
,and,CC,O
,Hyp,NNP,O
,(,(,O
,SO3H,NNP,O
,),),O
,-,:,O
,Ac,$,O
,-,:,O
,CCK,NNP,O
,-,:,O
,2,CD,O
,-,:,O
,8,CD,O
,-,:,O
,SE,NN,O
,were,VBD,O
,slightly,RB,O
,more,RBR,O
,active,JJ,O
,than,IN,O
,CCK,NNP,O
,-,:,O
,8,CD,O
,-,:,O
,SE,NN,O
,.,.,O
,Vasopressin,NNP,O
,as,IN,O
,a,DT,O
,possible,JJ,O
,contributor,NN,O
,to,TO,O
,hypertension,NN,B-DISEASE
,.,.,O
,The,DT,O
,role,NN,O
,of,IN,O
,vasopressin,NN,O
,as,IN,O
,a,DT,O
,pressor,NN,O
,agent,NN,O
,to,TO,O
,the,DT,O
,hypertensive,JJ,B-DISEASE
,process,NN,O
,was,VBD,O
,examined,VBN,O
,.,.,O
,Vasopressin,NNP,O
,plays,VBZ,O
,a,DT,O
,major,JJ,O
,role,NN,O
,in,IN,O
,the,DT,O
,pathogenesis,NN,O
,of,IN,O
,DOCA,NNP,O
,-,:,O
,salt,NN,O
,hypertension,NN,B-DISEASE
,",",",",O
,since,IN,O
,the,DT,O
,elevation,NN,O
,of,IN,O
,blood,NN,O
,pressure,NN,O
,was,VBD,O
,not,RB,O
,substantial,JJ,O
,in,IN,O
,the,DT,O
,rats,NNS,O
,with,IN,O
,lithium,NN,O
,-,:,O
,treated,VBN,O
,diabetes,NNS,B-DISEASE
,insipidus,VBP,I-DISEASE
,after,IN,O
,DOCA,NNP,O
,-,:,O
,salt,NN,O
,treatment,NN,O
,.,.,O
,Administration,NNP,O
,of,IN,O
,DDAVP,NNP,O
,which,WDT,O
,has,VBZ,O
,antidiuretic,JJ,O
,action,NN,O
,but,CC,O
,minimal,JJ,O
,vasopressor,NN,O
,effect,NN,O
,failed,VBD,O
,to,TO,O
,increase,VB,O
,blood,NN,O
,pressure,NN,O
,to,TO,O
,the,DT,O
,levels,NNS,O
,observed,VBN,O
,after,IN,O
,administration,NN,O
,of,IN,O
,AVP,NNP,O
,.,.,O
,Furthermore,NNP,O
,",",",",O
,the,DT,O
,pressor,NN,O
,action,NN,O
,of,IN,O
,vasopressin,NN,O
,appears,VBZ,O
,to,TO,O
,be,VB,O
,important,JJ,O
,in,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,this,DT,O
,model,NN,O
,of,IN,O
,hypertension,NN,B-DISEASE
,",",",",O
,since,IN,O
,the,DT,O
,enhanced,JJ,O
,pressor,NN,O
,responsiveness,NN,O
,to,TO,O
,the,DT,O
,hormone,NN,O
,was,VBD,O
,observed,VBN,O
,in,IN,O
,the,DT,O
,initial,JJ,O
,stage,NN,O
,of,IN,O
,hypertension,NN,B-DISEASE
,.,.,O
,Increased,VBN,O
,secretion,NN,O
,of,IN,O
,vasopressin,NN,O
,from,IN,O
,neurohypophysis,NN,O
,also,RB,O
,promotes,VBZ,O
,the,DT,O
,function,NN,O
,of,IN,O
,the,DT,O
,hormone,NN,O
,as,IN,O
,a,DT,O
,pathogenetic,JJ,O
,factor,NN,O
,in,IN,O
,hypertension,NN,B-DISEASE
,.,.,O
,An,DT,O
,unproportional,JJ,O
,release,NN,O
,of,IN,O
,vasopressin,NN,O
,compared,VBN,O
,to,TO,O
,plasma,VB,O
,osmolality,NN,O
,may,MD,O
,be,VB,O
,induced,VBN,O
,by,IN,O
,the,DT,O
,absence,NN,O
,of,IN,O
,an,DT,O
,adjusting,VBG,O
,control,NN,O
,of,IN,O
,angiotensin,NN,O
,II,NNP,O
,forming,NN,O
,and,CC,O
,receptor,NN,O
,binding,NN,O
,capacity,NN,O
,for,IN,O
,sodium,NN,O
,balance,NN,O
,in,IN,O
,the,DT,O
,brain,NN,O
,.,.,O
,However,RB,O
,",",",",O
,the,DT,O
,role,NN,O
,of,IN,O
,vasopressin,NN,O
,remains,VBZ,O
,to,TO,O
,be,VB,O
,determined,VBN,O
,in,IN,O
,human,JJ,O
,essential,JJ,O
,hypertension,NN,B-DISEASE
,.,.,O
,Toxic,NNP,B-DISEASE
,hepatitis,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,disulfiram,NN,O
,in,IN,O
,a,DT,O
,non,JJ,O
,-,:,O
,alcoholic,NN,O
,.,.,O
,A,DT,O
,reversible,JJ,O
,toxic,NN,B-DISEASE
,liver,NN,I-DISEASE
,damage,NN,I-DISEASE
,was,VBD,O
,observed,VBN,O
,in,IN,O
,a,DT,O
,non,JJ,O
,-,:,O
,alcoholic,JJ,O
,woman,NN,O
,treated,VBD,O
,with,IN,O
,disulfiram,NN,O
,.,.,O
,The,DT,O
,causative,JJ,O
,relationship,NN,O
,was,VBD,O
,proven,VBN,O
,by,IN,O
,challenge,NN,O
,.,.,O
,Atrial,JJ,B-DISEASE
,thrombosis,NN,I-DISEASE
,involving,VBG,O
,the,DT,O
,heart,NN,O
,of,IN,O
,F,NNP,O
,-,:,O
,344,CD,O
,rats,NNS,O
,ingesting,VBG,O
,quinacrine,JJ,O
,hydrochloride,NN,O
,.,.,O
,Quinacrine,NNP,O
,hydrochloride,NN,O
,is,VBZ,O
,toxic,JJ,O
,for,IN,O
,the,DT,O
,heart,NN,O
,of,IN,O
,F,NNP,O
,-,:,O
,344,CD,O
,rats,NNS,O
,.,.,O
,Rats,NNS,O
,treated,VBD,O
,with,IN,O
,500,CD,O
,ppm,NNS,O
,quinacrine,JJ,O
,hydrochloride,NN,O
,in,IN,O
,the,DT,O
,diet,JJ,O
,all,DT,O
,developed,VBD,O
,a,DT,O
,high,JJ,O
,incidence,NN,O
,of,IN,O
,left,JJ,O
,atrial,JJ,B-DISEASE
,thrombosis,NN,I-DISEASE
,.,.,O
,The,DT,O
,lesion,NN,O
,was,VBD,O
,associated,VBN,O
,with,IN,O
,cardiac,JJ,B-DISEASE
,hypertrophy,NN,I-DISEASE
,and,CC,O
,dilatation,NN,O
,and,CC,O
,focal,JJ,O
,myocardial,JJ,B-DISEASE
,degeneration,NN,I-DISEASE
,.,.,O
,Rats,NNP,O
,died,VBD,O
,from,IN,O
,cardiac,JJ,B-DISEASE
,hypertrophy,NN,I-DISEASE
,with,IN,O
,severe,JJ,O
,acute,NN,O
,and,CC,O
,chronic,JJ,O
,congestion,NN,O
,of,IN,O
,the,DT,O
,lungs,NNS,O
,",",",",O
,liver,NN,O
,",",",",O
,and,CC,O
,other,JJ,O
,organs,NNS,O
,.,.,O
,Seventy,NNP,O
,percent,NN,O
,of,IN,O
,rats,NNS,O
,given,VBN,O
,250,CD,O
,ppm,JJ,O
,quinacrine,NN,O
,hydrochloride,NN,O
,and,CC,O
,1,CD,O
,",",",",O
,000,CD,O
,ppm,NN,O
,sodium,NN,O
,nitrite,RB,O
,simultaneously,RB,O
,in,IN,O
,the,DT,O
,diet,NN,O
,had,VBD,O
,thrombosis,NN,B-DISEASE
,of,IN,O
,the,DT,O
,atria,NN,O
,of,IN,O
,the,DT,O
,heart,NN,O
,",",",",O
,while,IN,O
,untreated,JJ,O
,control,NN,O
,rats,VBZ,O
,in,IN,O
,this,DT,O
,laboratory,NN,O
,did,VBD,O
,not,RB,O
,have,VB,O
,atrial,JJ,B-DISEASE
,thrombosis,NN,I-DISEASE
,.,.,O
,Sodium,NNP,O
,nitrite,RB,O
,in,IN,O
,combination,NN,O
,with,IN,O
,quinacrine,JJ,O
,hydrochloride,NN,O
,appeared,VBD,O
,to,TO,O
,have,VB,O
,no,DT,O
,additional,JJ,O
,effect,NN,O
,.,.,O
,Alternating,VBG,B-DISEASE
,sinus,JJ,I-DISEASE
,rhythm,NN,I-DISEASE
,and,CC,O
,intermittent,JJ,O
,sinoatrial,JJ,B-DISEASE
,block,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,propranolol,NN,O
,.,.,O
,Alternating,VBG,B-DISEASE
,sinus,JJ,I-DISEASE
,rhythm,NN,I-DISEASE
,and,CC,O
,intermittent,JJ,O
,sinoatrial,NN,B-DISEASE
,(,(,I-DISEASE
,S,NNP,I-DISEASE
,-,:,I-DISEASE
,A,DT,I-DISEASE
,),),I-DISEASE
,block,NN,I-DISEASE
,was,VBD,O
,observed,VBN,O
,in,IN,O
,a,DT,O
,57,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,",",",",O
,under,IN,O
,treatment,NN,O
,for,IN,O
,angina,NN,B-DISEASE
,with,IN,O
,80,CD,O
,mg,NNS,O
,propranolol,JJ,O
,daily,RB,O
,.,.,O
,The,DT,O
,electrocardiogram,NN,O
,showed,VBD,O
,alternation,NN,O
,of,IN,O
,long,JJ,O
,and,CC,O
,short,JJ,O
,P,NNP,O
,-,:,O
,P,NN,O
,intervals,NNS,O
,and,CC,O
,occasional,JJ,O
,pauses,NNS,O
,.,.,O
,These,DT,O
,pauses,NNS,O
,were,VBD,O
,always,RB,O
,preceded,VBN,O
,by,IN,O
,the,DT,O
,short,JJ,O
,P,NNP,O
,-,:,O
,P,NN,O
,intervals,NNS,O
,and,CC,O
,were,VBD,O
,usually,RB,O
,followed,VBN,O
,by,IN,O
,one,CD,O
,or,CC,O
,two,CD,O
,P,NNP,O
,-,:,O
,P,NNP,O
,intervals,NNS,O
,of,IN,O
,0,CD,O
,.,.,O
,92,CD,O
,-,:,O
,0,CD,O
,.,.,O
,95,CD,O
,s,JJ,O
,representing,VBG,O
,the,DT,O
,basic,JJ,O
,sinus,NN,O
,cycle,NN,O
,.,.,O
,Following,VBG,O
,these,DT,O
,basic,JJ,O
,sinus,NN,O
,cycles,NNS,O
,",",",",O
,alternating,VBG,B-DISEASE
,rhythm,NN,I-DISEASE
,started,VBD,O
,with,IN,O
,the,DT,O
,longer,JJR,O
,P,NNP,O
,-,:,O
,P,NNP,O
,interval,NN,O
,.,.,O
,The,DT,O
,long,JJ,O
,P,NNP,O
,-,:,O
,P,NN,O
,intervals,NNS,O
,ranged,VBD,O
,between,IN,O
,1,CD,O
,.,.,O
,04,CD,O
,-,:,O
,1,CD,O
,.,.,O
,12,CD,O
,s,NN,O
,and,CC,O
,the,DT,O
,short,JJ,O
,P,NNP,O
,-,:,O
,P,NN,O
,intervals,NNS,O
,between,IN,O
,0,CD,O
,.,.,O
,80,CD,O
,-,:,O
,0,CD,O
,.,.,O
,84,CD,O
,s,NN,O
,",",",",O
,respectively,RB,O
,.,.,O
,The,DT,O
,duration,NN,O
,of,IN,O
,the,DT,O
,pauses,NNS,O
,were,VBD,O
,equal,JJ,O
,or,CC,O
,almost,RB,O
,equal,JJ,O
,to,TO,O
,one,CD,O
,short,JJ,O
,plus,CC,O
,one,CD,O
,long,JJ,O
,P,NNP,O
,-,:,O
,P,NNP,O
,interval,NN,O
,or,CC,O
,to,TO,O
,twice,VB,O
,the,DT,O
,basic,JJ,O
,sinus,NN,O
,cycle,NN,O
,.,.,O
,In,IN,O
,one,CD,O
,recording,VBG,O
,a,DT,O
,short,JJ,O
,period,NN,O
,of,IN,O
,regular,JJ,O
,sinus,NN,O
,rhythm,NN,O
,with,IN,O
,intermittent,JJ,O
,2,CD,O
,/,JJ,O
,1,CD,O
,S,NNP,B-DISEASE
,-,:,I-DISEASE
,A,DT,I-DISEASE
,block,NN,I-DISEASE
,was,VBD,O
,observed,VBN,O
,.,.,O
,This,DT,O
,short,JJ,O
,period,NN,O
,of,IN,O
,sinus,NN,O
,rhythm,NN,O
,was,VBD,O
,interrupted,VBN,O
,by,IN,O
,sudden,JJ,O
,prolongation,NN,O
,of,IN,O
,the,DT,O
,P,NNP,O
,-,:,O
,P,NNP,O
,interval,NN,O
,starting,VBG,O
,the,DT,O
,alternative,JJ,O
,rhythm,NN,O
,.,.,O
,There,EX,O
,were,VBD,O
,small,JJ,O
,changes,NNS,O
,in,IN,O
,the,DT,O
,shape,NN,O
,of,IN,O
,the,DT,O
,P,NNP,O
,waves,NNS,O
,and,CC,O
,P,NNP,O
,-,:,O
,R,NN,O
,intervals,NNS,O
,.,.,O
,S,NNP,O
,-,:,O
,A,DT,O
,conduction,NN,O
,through,IN,O
,two,CD,O
,pathways,NNS,O
,",",",",O
,the,DT,O
,first,JJ,O
,with,IN,O
,2,CD,O
,/,NNS,O
,1,CD,O
,block,IN,O
,the,DT,O
,second,JJ,O
,having,VBG,O
,0,CD,O
,.,.,O
,12,CD,O
,-,:,O
,0,CD,O
,.,.,O
,14,CD,O
,s,JJ,O
,longer,JJR,O
,conduction,NN,O
,time,NN,O
,and,CC,O
,with,IN,O
,occasional,JJ,O
,2,CD,O
,/,JJ,O
,1,CD,O
,block,NN,O
,was,VBD,O
,proposed,VBN,O
,for,IN,O
,the,DT,O
,explanation,NN,O
,of,IN,O
,the,DT,O
,alternating,VBG,O
,P,NNP,O
,-,:,O
,P,NNP,O
,interval,NN,O
,and,CC,O
,other,JJ,O
,electrocardiographic,JJ,O
,features,NNS,O
,seen,VBN,O
,.,.,O
,Atropine,$,O
,1,CD,O
,mg,NN,O
,given,VBN,O
,intravenously,RB,O
,resulted,VBN,O
,in,IN,O
,shortening,NN,O
,of,IN,O
,all,DT,O
,P,NNP,O
,-,:,O
,P,NN,O
,intervals,NNS,O
,without,IN,O
,changing,VBG,O
,the,DT,O
,rhythm,NN,O
,.,.,O
,The,DT,O
,abnormal,JJ,O
,rhythm,NN,O
,disappeared,VBD,O
,with,IN,O
,the,DT,O
,withdrawal,NN,O
,of,IN,O
,propranolol,NN,O
,and,CC,O
,when,WRB,O
,the,DT,O
,drug,NN,O
,was,VBD,O
,restarted,VBN,O
,a,DT,O
,2,CD,O
,/,NN,O
,1,CD,O
,S,NNP,B-DISEASE
,-,:,I-DISEASE
,A,DT,I-DISEASE
,block,NN,I-DISEASE
,was,VBD,O
,seen,VBN,O
,.,.,O
,This,DT,O
,was,VBD,O
,accepted,VBN,O
,as,IN,O
,evidence,NN,O
,for,IN,O
,propranolol,NN,O
,being,VBG,O
,the,DT,O
,cause,NN,O
,of,IN,O
,this,DT,O
,conduction,NN,B-DISEASE
,disorder,NN,I-DISEASE
,.,.,O
,Antitumor,NNP,O
,effect,NN,O
,",",",",O
,cardiotoxicity,NN,B-DISEASE
,",",",",O
,and,CC,O
,nephrotoxicity,NN,B-DISEASE
,of,IN,O
,doxorubicin,NN,O
,in,IN,O
,the,DT,O
,IgM,NNP,O
,solid,JJ,O
,immunocytoma,NN,B-DISEASE
,-,:,O
,bearing,NN,O
,LOU,NNP,O
,/,NNP,O
,M,NNP,O
,/,NNP,O
,WSL,NNP,O
,rat,NN,O
,.,.,O
,Antitumor,NNP,O
,activity,NN,O
,",",",",O
,cardiotoxicity,NN,B-DISEASE
,",",",",O
,and,CC,O
,nephrotoxicity,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,doxorubicin,NN,O
,were,VBD,O
,studied,VBN,O
,in,IN,O
,LOU,NNP,O
,/,NNP,O
,M,NNP,O
,/,NNP,O
,WSL,NNP,O
,inbred,VBD,O
,rats,NNS,O
,each,DT,O
,bearing,VBG,O
,a,DT,O
,transplantable,JJ,O
,solid,JJ,O
,IgM,NNP,O
,immunocytoma,NN,B-DISEASE
,.,.,O
,Animals,NNS,O
,with,IN,O
,a,DT,O
,tumor,NN,B-DISEASE
,(,(,O
,diameter,NN,O
,",",",",O
,15,CD,O
,.,.,O
,8,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,3,CD,O
,.,.,O
,3,CD,O
,mm,NN,O
,),),O
,were,VBD,O
,treated,VBN,O
,with,IN,O
,iv,JJ,O
,injections,NNS,O
,of,IN,O
,doxorubicin,NN,O
,on,IN,O
,5,CD,O
,consecutive,JJ,O
,days,NNS,O
,",",",",O
,followed,VBN,O
,by,IN,O
,1,CD,O
,weekly,JJ,O
,injection,NN,O
,for,IN,O
,7,CD,O
,weeks,NNS,O
,(,(,O
,dose,JJ,O
,range,NN,O
,",",",",O
,0,CD,O
,.,.,O
,015,CD,O
,-,:,O
,4,CD,O
,.,.,O
,0,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,body,NN,O
,wt,NN,O
,),),O
,.,.,O
,Tumor,NNP,B-DISEASE
,regression,NN,O
,was,VBD,O
,observed,VBN,O
,with,IN,O
,0,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,doxorubicin,NN,O
,/,NNP,O
,kg,NN,O
,.,.,O
,Complete,JJ,O
,disappearance,NN,O
,of,IN,O
,the,DT,O
,tumor,NN,B-DISEASE
,was,VBD,O
,induced,VBN,O
,with,IN,O
,1,CD,O
,.,.,O
,0,CD,O
,mg,JJ,O
,doxorubicin,NN,O
,/,NNP,O
,kg,NN,O
,.,.,O
,Histologic,NNP,O
,evidence,NN,O
,of,IN,O
,cardiotoxicity,NN,B-DISEASE
,scored,VBN,O
,as,IN,O
,grade,NN,O
,III,NNP,O
,was,VBD,O
,only,RB,O
,observed,VBN,O
,at,IN,O
,a,DT,O
,dose,NN,O
,of,IN,O
,1,CD,O
,.,.,O
,0,CD,O
,mg,JJ,O
,doxorubicin,NN,O
,/,NNP,O
,kg,NN,O
,.,.,O
,Light,NNP,O
,microscopic,VBD,O
,evidence,NN,O
,of,IN,O
,renal,JJ,B-DISEASE
,damage,NN,I-DISEASE
,was,VBD,O
,seen,VBN,O
,above,IN,O
,a,DT,O
,dose,NN,O
,of,IN,O
,0,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,doxorubicin,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,which,WDT,O
,resulted,VBD,O
,in,IN,O
,albuminuria,NN,B-DISEASE
,and,CC,O
,very,RB,O
,low,JJ,O
,serum,NN,O
,albumin,NN,O
,levels,NNS,O
,.,.,O
,In,IN,O
,the,DT,O
,group,NN,O
,that,WDT,O
,received,VBD,O
,1,CD,O
,.,.,O
,0,CD,O
,mg,JJ,O
,doxorubicin,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,the,DT,O
,serum,NN,O
,albumin,JJ,O
,level,NN,O
,decreased,VBD,O
,from,IN,O
,33,CD,O
,.,.,O
,6,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,4,CD,O
,.,.,O
,1,CD,O
,to,TO,O
,1,CD,O
,.,.,O
,5,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,5,CD,O
,g,JJ,O
,/,NN,O
,liter,NN,O
,.,.,O
,Ascites,NNS,B-DISEASE
,and,CC,O
,hydrothorax,NN,B-DISEASE
,were,VBD,O
,observed,VBN,O
,simultaneously,RB,O
,.,.,O
,The,DT,O
,same,JJ,O
,experiments,NNS,O
,were,VBD,O
,performed,VBN,O
,with,IN,O
,non,JJ,O
,-,:,O
,tumor,NN,B-DISEASE
,-,:,O
,bearing,NN,O
,rats,NNS,O
,",",",",O
,in,IN,O
,which,WDT,O
,no,DT,O
,major,JJ,O
,differences,NNS,O
,were,VBD,O
,observed,VBN,O
,.,.,O
,In,IN,O
,conclusion,NN,O
,",",",",O
,antitumor,NN,O
,activity,NN,O
,",",",",O
,cardiotoxicity,NN,B-DISEASE
,",",",",O
,and,CC,O
,nephrotoxicity,NN,B-DISEASE
,were,VBD,O
,studied,VBN,O
,simultaneously,RB,O
,in,IN,O
,the,DT,O
,same,JJ,O
,LOU,NNP,O
,/,NNP,O
,M,NNP,O
,/,NNP,O
,WSL,NNP,O
,rat,NN,O
,.,.,O
,Albuminuria,NNP,B-DISEASE
,due,JJ,O
,to,TO,O
,renal,JJ,B-DISEASE
,damage,NN,I-DISEASE
,led,VBD,O
,to,TO,O
,extremely,RB,O
,low,JJ,O
,serum,NN,O
,albumin,NN,O
,levels,NNS,O
,",",",",O
,so,RB,O
,ascites,VBZ,B-DISEASE
,and,CC,O
,hydrothorax,NN,B-DISEASE
,were,VBD,O
,not,RB,O
,necessarily,RB,O
,a,DT,O
,consequence,NN,O
,of,IN,O
,the,DT,O
,observed,JJ,O
,cardiomyopathy,NN,B-DISEASE
,.,.,O
,Intraoperative,JJ,O
,bradycardia,NN,B-DISEASE
,and,CC,O
,hypotension,NN,B-DISEASE
,associated,VBN,O
,with,IN,O
,timolol,NN,O
,and,CC,O
,pilocarpine,NN,O
,eye,NN,O
,drops,NNS,O
,.,.,O
,A,DT,O
,69,CD,O
,-,:,O
,yr,NN,O
,-,:,O
,old,JJ,O
,man,NN,O
,",",",",O
,who,WP,O
,was,VBD,O
,concurrently,RB,O
,being,VBG,O
,treated,VBN,O
,with,IN,O
,pilocarpine,JJ,O
,nitrate,NN,O
,and,CC,O
,timolol,NN,O
,maleate,NN,O
,eye,NN,O
,drops,NNS,O
,",",",",O
,developed,VBD,O
,a,DT,O
,bradycardia,NN,B-DISEASE
,and,CC,O
,became,VBD,O
,hypotensive,JJ,B-DISEASE
,during,IN,O
,halothane,NN,O
,anaesthesia,NN,O
,.,.,O
,Both,DT,O
,timolol,NN,O
,and,CC,O
,pilocarpine,NN,O
,were,VBD,O
,subsequently,RB,O
,identified,VBN,O
,in,IN,O
,a,DT,O
,24,CD,O
,-,:,O
,h,NN,O
,collection,NN,O
,of,IN,O
,urine,NN,O
,.,.,O
,Timolol,NNP,O
,(,(,O
,but,CC,O
,not,RB,O
,pilocarpine,VB,O
,),),O
,was,VBD,O
,detected,VBN,O
,in,IN,O
,a,DT,O
,sample,NN,O
,of,IN,O
,plasma,NN,O
,removed,VBN,O
,during,IN,O
,surgery,NN,O
,;,:,O
,the,DT,O
,plasma,JJ,O
,concentration,NN,O
,of,IN,O
,timolol,NN,O
,(,(,O
,2,CD,O
,.,.,O
,6,CD,O
,ng,JJ,O
,ml,SYM,O
,-,:,O
,1,CD,O
,),),O
,was,VBD,O
,consistent,JJ,O
,with,IN,O
,partial,JJ,O
,beta,NN,O
,-,:,O
,adrenoceptor,NN,O
,blockade,NN,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,postulated,VBN,O
,that,IN,O
,this,DT,O
,action,NN,O
,may,MD,O
,have,VB,O
,been,VBN,O
,enhanced,VBN,O
,during,IN,O
,halothane,NN,O
,anaesthesia,NN,O
,with,IN,O
,resultant,JJ,O
,bradycardia,NN,B-DISEASE
,and,CC,O
,hypotension,NN,B-DISEASE
,.,.,O
,Pilocarpine,NN,O
,may,MD,O
,have,VB,O
,had,VBD,O
,a,DT,O
,contributory,JJ,O
,effect,NN,O
,.,.,O
,Succinylcholine,NNP,O
,apnoea,NN,B-DISEASE
,:,:,O
,attempted,VBN,O
,reversal,NN,O
,with,IN,O
,anticholinesterases,NNS,O
,.,.,O
,Anticholinesterases,NNS,O
,were,VBD,O
,administered,VBN,O
,in,IN,O
,an,DT,O
,attempt,NN,O
,to,TO,O
,antagonize,VB,O
,prolonged,JJ,O
,neuromuscular,JJ,B-DISEASE
,blockade,NN,I-DISEASE
,following,VBG,O
,the,DT,O
,administration,NN,O
,of,IN,O
,succinylcholine,NN,O
,in,IN,O
,a,DT,O
,patient,NN,O
,later,RB,O
,found,VBD,O
,to,TO,O
,be,VB,O
,homozygous,JJ,O
,for,IN,O
,atypical,JJ,O
,plasma,NN,O
,cholinesterase,NN,O
,.,.,O
,Edrophonium,NN,O
,10,CD,O
,mg,NN,O
,",",",",O
,given,VBN,O
,74,CD,O
,min,NNS,O
,after,IN,O
,succinylcholine,NN,O
,",",",",O
,when,WRB,O
,train,SYM,O
,-,:,O
,of,IN,O
,-,:,O
,four,CD,O
,stimulation,NN,O
,was,VBD,O
,characteristic,JJ,O
,of,IN,O
,phase,NN,O
,II,NNP,O
,block,NN,O
,",",",",O
,produced,VBN,O
,partial,JJ,O
,antagonism,NN,O
,which,WDT,O
,was,VBD,O
,not,RB,O
,sustained,VBN,O
,.,.,O
,Repeated,VBN,O
,doses,NNS,O
,of,IN,O
,edrophonium,NN,O
,to,TO,O
,70,CD,O
,mg,NNS,O
,and,CC,O
,neostigmine,NN,O
,to,TO,O
,2,CD,O
,.,.,O
,5,CD,O
,mg,NN,O
,did,VBD,O
,not,RB,O
,antagonize,VB,O
,or,CC,O
,augment,VB,O
,the,DT,O
,block,NN,O
,.,.,O
,Spontaneous,JJ,O
,respiration,NN,O
,recommenced,VBD,O
,200,CD,O
,min,NN,O
,after,IN,O
,succinylcholine,JJ,O
,administration,NN,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,concluded,VBN,O
,that,IN,O
,anticholinesterases,NNS,O
,are,VBP,O
,only,RB,O
,partially,RB,O
,effective,JJ,O
,in,IN,O
,restoring,VBG,O
,neuromuscular,JJ,O
,function,NN,O
,in,IN,O
,succinylcholine,NN,O
,apnoea,NN,B-DISEASE
,despite,IN,O
,muscle,NN,O
,twitch,NN,O
,activity,NN,O
,typical,JJ,O
,of,IN,O
,phase,NN,O
,II,NNP,O
,block,NN,O
,.,.,O
,Effect,NN,O
,of,IN,O
,doxorubicin,NN,O
,on,IN,O
,[,NNP,O
,omega,IN,O
,-,:,O
,I,PRP,O
,-,:,O
,131,CD,O
,],JJ,O
,heptadecanoic,NN,O
,acid,VBP,O
,myocardial,JJ,O
,scintigraphy,NN,O
,and,CC,O
,echocardiography,NN,O
,in,IN,O
,dogs,NNS,O
,.,.,O
,The,DT,O
,effects,NNS,O
,of,IN,O
,serial,JJ,O
,treatment,NN,O
,with,IN,O
,doxorubicin,NN,O
,on,IN,O
,dynamic,JJ,O
,myocardial,JJ,O
,scintigraphy,NN,O
,with,IN,O
,[,NNP,O
,omega,SYM,O
,-,:,O
,I,PRP,O
,-,:,O
,131,CD,O
,],JJ,O
,heptadecanoic,NN,O
,acid,NN,O
,(,(,O
,I,PRP,O
,-,:,O
,131,CD,O
,HA,NNP,O
,),),O
,",",",",O
,and,CC,O
,on,IN,O
,global,JJ,O
,left,VBN,O
,-,:,O
,ventricular,JJ,O
,function,NN,O
,determined,VBD,O
,echocardiographically,RB,O
,",",",",O
,were,VBD,O
,studied,VBN,O
,in,IN,O
,a,DT,O
,group,NN,O
,of,IN,O
,nine,CD,O
,mongrel,JJ,O
,dogs,NNS,O
,.,.,O
,Total,JJ,O
,extractable,JJ,O
,myocardial,JJ,O
,lipid,NN,O
,was,VBD,O
,compared,VBN,O
,postmortem,NN,O
,between,IN,O
,a,DT,O
,group,NN,O
,of,IN,O
,control,NN,O
,dogs,NNS,O
,and,CC,O
,doxorubicin,VB,O
,-,:,O
,treated,JJ,O
,dogs,NNS,O
,.,.,O
,A,DT,O
,significant,JJ,O
,and,CC,O
,then,RB,O
,progressive,JJ,O
,fall,NN,O
,in,IN,O
,global,JJ,O
,LV,NNP,O
,function,NN,O
,was,VBD,O
,observed,VBN,O
,at,IN,O
,a,DT,O
,cumulative,JJ,O
,doxorubicin,NN,O
,dose,NN,O
,of,IN,O
,4,CD,O
,mg,NNS,O
,/,JJ,O
,kg,NN,O
,.,.,O
,A,DT,O
,significant,JJ,O
,increase,NN,O
,in,IN,O
,the,DT,O
,myocardial,JJ,O
,t1,NN,O
,/,VBD,O
,2,CD,O
,of,IN,O
,the,DT,O
,I,PRP,O
,-,:,O
,131,CD,O
,HA,NNP,O
,was,VBD,O
,observed,VBN,O
,only,RB,O
,at,IN,O
,a,DT,O
,higher,JJR,O
,cumulative,JJ,O
,dose,NN,O
,",",",",O
,10,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,.,.,O
,No,DT,O
,significant,JJ,O
,alteration,NN,O
,in,IN,O
,total,JJ,O
,extractable,JJ,O
,myocardial,JJ,O
,lipids,NNS,O
,was,VBD,O
,observed,VBN,O
,between,IN,O
,control,NN,O
,dogs,NNS,O
,and,CC,O
,those,DT,O
,treated,VBN,O
,with,IN,O
,doxorubicin,NN,O
,.,.,O
,Our,PRP$,O
,findings,NNS,O
,suggest,VBP,O
,that,IN,O
,the,DT,O
,changes,NNS,O
,leading,VBG,O
,to,TO,O
,an,DT,O
,alteration,NN,O
,of,IN,O
,myocardial,JJ,O
,dynamic,JJ,O
,imaging,VBG,O
,with,IN,O
,I,PRP,O
,-,:,O
,131,CD,O
,HA,NNP,O
,are,VBP,O
,not,RB,O
,the,DT,O
,initiating,VBG,O
,factor,NN,O
,in,IN,O
,doxorubicin,JJ,O
,cardiotoxicity,NN,B-DISEASE
,.,.,O
,Hemodynamics,NNS,O
,and,CC,O
,myocardial,JJ,O
,metabolism,NN,O
,under,IN,O
,deliberate,JJ,O
,hypotension,NN,B-DISEASE
,.,.,O
,An,DT,O
,experimental,JJ,O
,study,NN,O
,in,IN,O
,dogs,NNS,O
,.,.,O
,Coronary,JJ,O
,blood,NN,O
,flow,NN,O
,",",",",O
,cardiac,JJ,O
,work,NN,O
,and,CC,O
,metabolism,NN,O
,were,VBD,O
,studied,VBN,O
,in,IN,O
,dogs,NNS,O
,under,IN,O
,sodium,NN,O
,nitroprusside,NN,O
,(,(,O
,SNP,NNP,O
,),),O
,and,CC,O
,trimetaphan,$,O
,(,(,O
,TMP,NNP,O
,),),O
,deliberate,NN,O
,hypotension,NN,B-DISEASE
,(,(,O
,20,CD,O
,%,NN,O
,and,CC,O
,40,CD,O
,%,NN,O
,mean,JJ,O
,pressure,NN,O
,decrease,NN,O
,from,IN,O
,baseline,NN,O
,),),O
,.,.,O
,Regarding,VBG,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,drug,NN,O
,-,:,O
,induced,JJ,O
,hypotension,NN,B-DISEASE
,on,IN,O
,coronary,JJ,O
,blood,NN,O
,flow,NN,O
,",",",",O
,aortic,JJ,O
,and,CC,O
,coronary,JJ,O
,sinus,NN,O
,metabolic,NN,O
,data,NNS,O
,(,(,O
,pH,NN,O
,",",",",O
,pO2,NN,O
,",",",",O
,pCO2,NN,O
,),),O
,we,PRP,O
,could,MD,O
,confirm,VB,O
,that,IN,O
,nitroprusside,JJ,O
,hypotension,NN,B-DISEASE
,could,MD,O
,be,VB,O
,safely,RB,O
,used,VBN,O
,to,TO,O
,30,CD,O
,%,NN,O
,mean,JJ,O
,blood,NN,O
,pressure,NN,O
,decrease,NN,O
,from,IN,O
,control,NN,O
,",",",",O
,trimetaphan,JJ,O
,hypotension,NN,B-DISEASE
,to,TO,O
,20,CD,O
,%,NN,O
,mean,JJ,O
,blood,NN,O
,pressure,NN,O
,decrease,NN,O
,.,.,O
,Cardiac,NNP,O
,work,NN,O
,was,VBD,O
,significantly,RB,O
,reduced,VBN,O
,during,IN,O
,SNP,NNP,O
,hypotension,NN,B-DISEASE
,.,.,O
,Myocardial,NNP,O
,O2,NNP,O
,consumption,NN,O
,and,CC,O
,O2,NNP,O
,availability,NN,O
,were,VBD,O
,directly,RB,O
,dependent,VBN,O
,on,IN,O
,the,DT,O
,coronary,JJ,O
,perfusion,NN,O
,.,.,O
,Careful,JJ,O
,invasive,JJ,O
,monitoring,NN,O
,of,IN,O
,the,DT,O
,blood,NN,O
,pressure,NN,O
,",",",",O
,blood,NN,O
,gases,NNS,O
,and,CC,O
,of,IN,O
,the,DT,O
,ECG,NNP,O
,ST,NNP,O
,-,:,O
,T,NNP,O
,segment,NN,O
,is,VBZ,O
,mandatory,JJ,O
,.,.,O
,Evidence,NN,O
,for,IN,O
,a,DT,O
,selective,JJ,O
,brain,NN,O
,noradrenergic,JJ,O
,involvement,NN,O
,in,IN,O
,the,DT,O
,locomotor,NN,O
,stimulant,JJ,O
,effects,NNS,O
,of,IN,O
,amphetamine,NN,O
,in,IN,O
,the,DT,O
,rat,NN,O
,.,.,O
,Male,JJ,O
,rats,NNS,O
,received,VBD,O
,the,DT,O
,noradrenaline,JJ,O
,neurotoxin,NN,O
,DSP4,NNP,O
,(,(,O
,50,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,7,CD,O
,days,NNS,O
,prior,RB,O
,to,TO,O
,injection,NN,O
,of,IN,O
,D,NNP,O
,-,:,O
,amphetamine,NN,O
,(,(,O
,10,CD,O
,or,CC,O
,40,CD,O
,mumol,NNS,O
,/,JJ,O
,kg,NN,O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,.,.,O
,The,DT,O
,hyperactivity,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,D,NNP,O
,-,:,O
,amphetamine,NN,O
,(,(,O
,10,CD,O
,mumol,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,was,VBD,O
,significantly,RB,O
,reduced,VBN,O
,by,IN,O
,DSP4,NNP,O
,pretreatment,NN,O
,.,.,O
,However,RB,O
,",",",",O
,the,DT,O
,increased,VBN,O
,rearings,NNS,O
,and,CC,O
,the,DT,O
,amphetamine,JJ,O
,-,:,O
,induced,JJ,O
,stereotypies,NNS,B-DISEASE
,were,VBD,O
,not,RB,O
,blocked,VBN,O
,by,IN,O
,pretreatment,NN,O
,with,IN,O
,DSP4,NNP,O
,.,.,O
,The,DT,O
,reduction,NN,O
,of,IN,O
,amphetamine,JJ,O
,hyperactivity,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,DSP4,NNP,O
,was,VBD,O
,blocked,VBN,O
,by,IN,O
,pretreatment,NN,O
,with,IN,O
,the,DT,O
,noradrenaline,JJ,O
,-,:,O
,uptake,NN,O
,blocking,NN,O
,agent,NN,O
,",",",",O
,desipramine,NN,O
,",",",",O
,which,WDT,O
,prevents,VBZ,O
,the,DT,O
,neurotoxic,JJ,B-DISEASE
,action,NN,O
,of,IN,O
,DSP4,NNP,O
,.,.,O
,The,DT,O
,present,JJ,O
,results,NNS,O
,suggest,VBP,O
,a,DT,O
,selective,JJ,O
,involvement,NN,O
,of,IN,O
,central,JJ,O
,noradrenergic,JJ,O
,neurones,NNS,O
,in,IN,O
,the,DT,O
,locomotor,NN,O
,stimulant,JJ,O
,effect,NN,O
,of,IN,O
,amphetamine,NN,O
,in,IN,O
,the,DT,O
,rat,NN,O
,.,.,O
,Accelerated,NNP,B-DISEASE
,junctional,JJ,I-DISEASE
,rhythms,NN,I-DISEASE
,during,IN,O
,oral,JJ,O
,verapamil,NN,O
,therapy,NN,O
,.,.,O
,This,DT,O
,study,NN,O
,examined,VBD,O
,the,DT,O
,frequency,NN,O
,of,IN,O
,atrioventricular,JJ,O
,(,(,O
,AV,NNP,O
,),),O
,dissociation,NN,O
,and,CC,O
,accelerated,VBD,B-DISEASE
,junctional,JJ,I-DISEASE
,rhythms,NN,I-DISEASE
,in,IN,O
,59,CD,O
,patients,NNS,O
,receiving,VBG,O
,oral,JJ,O
,verapamil,NN,O
,.,.,O
,Accelerated,NNP,B-DISEASE
,junctional,JJ,I-DISEASE
,rhythms,NN,I-DISEASE
,and,CC,O
,AV,NNP,O
,dissociation,NN,O
,were,VBD,O
,frequent,JJ,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,supraventricular,JJ,B-DISEASE
,tachyarrhythmias,NNS,I-DISEASE
,",",",",O
,particularly,RB,O
,AV,NNP,O
,nodal,JJ,O
,reentry,NN,O
,.,.,O
,Verapamil,NNP,O
,administration,NN,O
,to,TO,O
,these,DT,O
,patients,NNS,O
,led,VBD,O
,to,TO,O
,an,DT,O
,asymptomatic,JJ,O
,increase,NN,O
,in,IN,O
,activity,NN,O
,of,IN,O
,these,DT,O
,junctional,JJ,O
,pacemakers,NNS,O
,.,.,O
,In,IN,O
,patients,NNS,O
,with,IN,O
,various,JJ,O
,chest,NN,B-DISEASE
,pain,NN,I-DISEASE
,syndromes,NNS,O
,",",",",O
,verapamil,FW,O
,neither,CC,O
,increased,VBD,O
,the,DT,O
,frequency,NN,O
,of,IN,O
,junctional,JJ,O
,rhythms,NNS,O
,nor,CC,O
,suppressed,VBD,O
,their,PRP$,O
,role,NN,O
,as,IN,O
,escape,NN,O
,rhythms,NN,O
,under,IN,O
,physiologically,RB,O
,appropriate,JJ,O
,circumstances,NNS,O
,.,.,O
,Interstrain,NNP,O
,variation,NN,O
,in,IN,O
,acute,JJ,O
,toxic,NN,O
,response,NN,O
,to,TO,O
,caffeine,VB,O
,among,IN,O
,inbred,JJ,O
,mice,NNS,O
,.,.,O
,Acute,NNP,O
,toxic,JJ,O
,dosage,NN,O
,-,:,O
,dependent,JJ,O
,behavioral,JJ,O
,effects,NNS,O
,of,IN,O
,caffeine,NN,O
,were,VBD,O
,compared,VBN,O
,in,IN,O
,adult,NN,O
,males,NNS,O
,from,IN,O
,seven,CD,O
,inbred,JJ,O
,mouse,NN,O
,strains,NNS,O
,(,(,O
,A,DT,O
,/,NN,O
,J,NNP,O
,",",",",O
,BALB,NNP,O
,/,NNP,O
,cJ,NN,O
,",",",",O
,CBA,NNP,O
,/,NNP,O
,J,NNP,O
,",",",",O
,C3H,NNP,O
,/,NNP,O
,HeJ,NNP,O
,",",",",O
,C57BL,NNP,O
,/,NNP,O
,6J,CD,O
,",",",",O
,DBA,NNP,O
,/,NNP,O
,2J,CD,O
,",",",",O
,SWR,NNP,O
,/,NNP,O
,J,NNP,O
,),),O
,.,.,O
,C57BL,NNP,O
,/,VBD,O
,6J,CD,O
,",",",",O
,chosen,VBN,O
,as,IN,O
,a,DT,O
,"""",JJ,O
,prototypic,NN,O
,"""",NNP,O
,mouse,NN,O
,strain,NN,O
,",",",",O
,was,VBD,O
,used,VBN,O
,to,TO,O
,determine,VB,O
,behavioral,JJ,O
,responses,NNS,O
,to,TO,O
,a,DT,O
,broad,JJ,O
,range,NN,O
,(,(,O
,5,CD,O
,-,:,O
,500,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,of,IN,O
,caffeine,NN,O
,doses,NNS,O
,.,.,O
,Five,CD,O
,phenotypic,NN,O
,characteristics,NNS,O
,-,:,O
,-,:,O
,locomotor,NN,O
,activity,NN,O
,",",",",O
,righting,VBG,O
,ability,NN,O
,",",",",O
,clonic,JJ,B-DISEASE
,seizure,NN,I-DISEASE
,induction,NN,O
,",",",",O
,stress,NN,O
,-,:,O
,induced,JJ,O
,lethality,NN,O
,",",",",O
,death,NN,O
,without,IN,O
,external,JJ,O
,stress,NN,O
,-,:,O
,-,:,O
,were,VBD,O
,scored,VBN,O
,at,IN,O
,various,JJ,O
,caffeine,NN,O
,doses,NNS,O
,in,IN,O
,drug,NN,O
,-,:,O
,naive,JJ,O
,animals,NNS,O
,under,IN,O
,empirically,RB,O
,optimized,VBN,O
,",",",",O
,rigidly,RB,O
,constant,JJ,O
,experimental,JJ,O
,conditions,NNS,O
,.,.,O
,Mice,NNP,O
,(,(,O
,n,JJ,O
,=,VBP,O
,12,CD,O
,for,IN,O
,each,DT,O
,point,NN,O
,),),O
,received,VBD,O
,single,JJ,O
,IP,NNP,O
,injections,NNS,O
,of,IN,O
,a,DT,O
,fixed,JJ,O
,volume,NN,O
,/,NNP,O
,g,NN,O
,body,NN,O
,weight,NN,O
,of,IN,O
,physiological,JJ,O
,saline,NN,O
,carrier,NN,O
,with,IN,O
,or,CC,O
,without,IN,O
,caffeine,NN,O
,in,IN,O
,doses,NNS,O
,ranging,VBG,O
,from,IN,O
,125,CD,O
,-,:,O
,500,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,.,.,O
,Loss,NNP,O
,of,IN,O
,righting,VBG,O
,ability,NN,O
,was,VBD,O
,scored,VBN,O
,at,IN,O
,1,CD,O
,",",",",O
,3,CD,O
,",",",",O
,5,CD,O
,min,NN,O
,post,NN,O
,dosing,NN,O
,and,CC,O
,at,IN,O
,5,CD,O
,min,NN,O
,intervals,NNS,O
,thereafter,RB,O
,for,IN,O
,20,CD,O
,min,NN,O
,.,.,O
,In,IN,O
,the,DT,O
,same,JJ,O
,animals,VBZ,O
,the,DT,O
,occurrence,NN,O
,of,IN,O
,clonic,JJ,B-DISEASE
,seizures,NNS,I-DISEASE
,was,VBD,O
,scored,VBN,O
,as,IN,O
,to,TO,O
,time,NN,O
,of,IN,O
,onset,NN,O
,and,CC,O
,severity,NN,O
,for,IN,O
,20,CD,O
,min,NNS,O
,after,IN,O
,drug,NN,O
,administration,NN,O
,.,.,O
,When,WRB,O
,these,DT,O
,proceeded,VBD,O
,to,TO,O
,tonic,JJ,B-DISEASE
,seizures,NNS,I-DISEASE
,",",",",O
,death,NN,O
,occurred,VBD,O
,in,IN,O
,less,JJR,O
,than,IN,O
,20,CD,O
,min,NN,O
,.,.,O
,Animals,NNS,O
,surviving,VBG,O
,for,IN,O
,20,CD,O
,min,NNS,O
,were,VBD,O
,immediately,RB,O
,stressed,VBN,O
,by,IN,O
,a,DT,O
,swim,JJ,O
,test,NN,O
,in,IN,O
,25,CD,O
,degrees,NNS,O
,C,NNP,O
,water,NN,O
,",",",",O
,and,CC,O
,death,NN,O
,-,:,O
,producing,VBG,O
,tonic,JJ,B-DISEASE
,seizures,NNS,I-DISEASE
,were,VBD,O
,scored,VBN,O
,for,IN,O
,2,CD,O
,min,NN,O
,.,.,O
,In,IN,O
,other,JJ,O
,animals,NNS,O
,locomotor,VBP,O
,activity,NN,O
,was,VBD,O
,measured,VBN,O
,15,CD,O
,or,CC,O
,60,CD,O
,min,NNS,O
,after,IN,O
,caffeine,JJ,O
,administration,NN,O
,.,.,O
,By,IN,O
,any,DT,O
,single,JJ,O
,behavioral,JJ,O
,criterion,NN,O
,or,CC,O
,a,DT,O
,combination,NN,O
,of,IN,O
,these,DT,O
,criteria,NNS,O
,",",",",O
,marked,VBD,O
,differences,NNS,O
,in,IN,O
,response,NN,O
,to,TO,O
,toxic,VB,O
,caffeine,NN,O
,doses,NNS,O
,were,VBD,O
,observed,VBN,O
,between,IN,O
,strains,NNS,O
,.,.,O
,These,DT,O
,results,NNS,O
,indicate,VBP,O
,that,IN,O
,behavioral,JJ,O
,toxicity,NN,B-DISEASE
,testing,NN,O
,of,IN,O
,alkylxanthines,NNS,O
,in,IN,O
,a,DT,O
,single,JJ,O
,mouse,NN,O
,strain,NN,O
,may,MD,O
,be,VB,O
,misleading,VBG,O
,and,CC,O
,suggest,VBP,O
,that,IN,O
,toxic,JJ,O
,responses,NNS,O
,of,IN,O
,the,DT,O
,central,JJ,O
,nervous,JJ,O
,system,NN,O
,to,TO,O
,this,DT,O
,class,NN,O
,of,IN,O
,compounds,NNS,O
,are,VBP,O
,genetically,RB,O
,influenced,VBN,O
,in,IN,O
,mammals,NNS,O
,.,.,O
,Treatment,NN,O
,of,IN,O
,ovarian,JJ,B-DISEASE
,cancer,NN,I-DISEASE
,with,IN,O
,a,DT,O
,combination,NN,O
,of,IN,O
,cis,JJ,O
,-,:,O
,platinum,NN,O
,",",",",O
,adriamycin,NN,O
,",",",",O
,cyclophosphamide,NN,O
,and,CC,O
,hexamethylmelamine,NN,O
,.,.,O
,During,IN,O
,the,DT,O
,last,JJ,O
,2,CD,O
,1,CD,O
,/,JJ,O
,2,CD,O
,years,NNS,O
,",",",",O
,38,CD,O
,patients,NNS,O
,with,IN,O
,ovarian,JJ,B-DISEASE
,cancer,NN,I-DISEASE
,were,VBD,O
,treated,VBN,O
,with,IN,O
,a,DT,O
,combination,NN,O
,of,IN,O
,cisplatinum,NN,O
,(,(,O
,CPDD,NNP,O
,),),O
,",",",",O
,50,CD,O
,mg,NN,O
,/,NNP,O
,m2,NN,O
,",",",",O
,adriamycin,NN,O
,",",",",O
,30,CD,O
,mg,NN,O
,/,NNP,O
,m2,NN,O
,",",",",O
,cyclophosphamide,NN,O
,",",",",O
,300,CD,O
,mg,NN,O
,/,NNP,O
,m2,NN,O
,",",",",O
,on,IN,O
,day,NN,O
,1,CD,O
,;,:,O
,and,CC,O
,hexamethylmelamine,VB,O
,(,(,O
,HMM,NNP,O
,),),O
,",",",",O
,6,CD,O
,mg,NN,O
,/,NNP,O
,kg,VBD,O
,daily,RB,O
,",",",",O
,for,IN,O
,14,CD,O
,days,NNS,O
,.,.,O
,Each,DT,O
,course,NN,O
,was,VBD,O
,repeated,VBN,O
,monthly,RB,O
,.,.,O
,2,CD,O
,patients,NNS,O
,had,VBD,O
,stage,NN,O
,II,NNP,O
,",",",",O
,14,CD,O
,stage,NN,O
,III,NNP,O
,and,CC,O
,22,CD,O
,stage,NN,O
,IV,NNP,O
,disease,NN,O
,.,.,O
,14,CD,O
,of,IN,O
,the,DT,O
,38,CD,O
,patients,NNS,O
,were,VBD,O
,previously,RB,O
,treated,VBN,O
,with,IN,O
,chemotherapy,NN,O
,",",",",O
,1,CD,O
,with,IN,O
,radiation,NN,O
,",",",",O
,6,CD,O
,with,IN,O
,both,DT,O
,chemotherapy,NN,O
,and,CC,O
,radiation,NN,O
,",",",",O
,and,CC,O
,17,CD,O
,did,VBD,O
,not,RB,O
,have,VB,O
,any,DT,O
,treatment,NN,O
,before,IN,O
,CPDD,NNP,O
,combination,NN,O
,.,.,O
,31,CD,O
,of,IN,O
,the,DT,O
,38,CD,O
,cases,NNS,O
,(,(,O
,81,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,),),O
,demonstrated,VBD,O
,objective,JJ,O
,responses,NNS,O
,lasting,VBG,O
,for,IN,O
,2,CD,O
,months,NNS,O
,or,CC,O
,more,JJR,O
,.,.,O
,These,DT,O
,responses,NNS,O
,were,VBD,O
,partial,JJ,O
,in,IN,O
,19,CD,O
,and,CC,O
,complete,JJ,O
,in,IN,O
,12,CD,O
,cases,NNS,O
,.,.,O
,Hematologic,NNP,B-DISEASE
,toxicity,NN,I-DISEASE
,was,VBD,O
,moderate,JJ,O
,and,CC,O
,with,IN,O
,reversible,JJ,O
,anemia,NN,B-DISEASE
,developing,VBG,O
,in,IN,O
,71,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,.,.,O
,Gastrointestinal,JJ,O
,side,NN,O
,effects,NNS,O
,from,IN,O
,CPDD,NNP,O
,were,VBD,O
,universal,JJ,O
,.,.,O
,HMM,NNP,O
,gastrointestinal,JJ,B-DISEASE
,toxicity,NN,I-DISEASE
,necessitated,JJ,O
,discontinuation,NN,O
,of,IN,O
,the,DT,O
,drug,NN,O
,in,IN,O
,5,CD,O
,patients,NNS,O
,.,.,O
,Severe,NNP,O
,nephrotoxicity,NN,B-DISEASE
,was,VBD,O
,observed,VBN,O
,in,IN,O
,2,CD,O
,patients,NNS,O
,but,CC,O
,was,VBD,O
,reversible,JJ,O
,.,.,O
,There,EX,O
,were,VBD,O
,no,DT,O
,drug,NN,O
,-,:,O
,related,JJ,O
,deaths,NNS,O
,.,.,O
,Nontraumatic,JJ,O
,dissecting,VBG,B-DISEASE
,aneurysm,NN,I-DISEASE
,of,IN,O
,the,DT,O
,basilar,JJ,O
,artery,NN,O
,.,.,O
,A,DT,O
,case,NN,O
,of,IN,O
,nontraumatic,JJ,O
,dissecting,VBG,B-DISEASE
,aneurysm,NN,I-DISEASE
,of,IN,O
,the,DT,O
,basilar,JJ,O
,artery,NN,O
,in,IN,O
,association,NN,O
,with,IN,O
,hypertension,NN,B-DISEASE
,",",",",O
,smoke,NN,O
,",",",",O
,and,CC,O
,oral,JJ,O
,contraceptives,NNS,O
,is,VBZ,O
,reported,VBN,O
,in,IN,O
,a,DT,O
,young,JJ,O
,female,NN,O
,patient,NN,O
,with,IN,O
,a,DT,O
,locked,JJ,B-DISEASE
,-,:,I-DISEASE
,in,IN,I-DISEASE
,syndrome,NN,I-DISEASE
,.,.,O
,A,DT,O
,method,NN,O
,for,IN,O
,the,DT,O
,measurement,NN,O
,of,IN,O
,tremor,NN,B-DISEASE
,",",",",O
,and,CC,O
,a,DT,O
,comparison,NN,O
,of,IN,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,tocolytic,JJ,O
,beta,NN,O
,-,:,O
,mimetics,NNS,O
,.,.,O
,A,DT,O
,method,NN,O
,permitting,VBG,O
,measurement,NN,O
,of,IN,O
,finger,NN,O
,tremor,NN,B-DISEASE
,as,IN,O
,a,DT,O
,displacement,NN,O
,-,:,O
,time,NN,O
,curve,NN,O
,is,VBZ,O
,described,VBN,O
,",",",",O
,using,VBG,O
,a,DT,O
,test,NN,O
,system,NN,O
,with,IN,O
,simple,JJ,O
,amplitude,JJ,O
,calibration,NN,O
,.,.,O
,The,DT,O
,coordinates,NNS,O
,of,IN,O
,the,DT,O
,inversion,NN,O
,points,NNS,O
,of,IN,O
,the,DT,O
,displacement,NN,O
,-,:,O
,time,NN,O
,curves,NNS,O
,were,VBD,O
,transferred,VBN,O
,through,IN,O
,graphical,JJ,O
,input,NN,O
,equipment,NN,O
,to,TO,O
,punched,VB,O
,tape,NN,O
,.,.,O
,By,IN,O
,means,NNS,O
,of,IN,O
,a,DT,O
,computer,NN,O
,program,NN,O
,",",",",O
,periods,NNS,O
,and,CC,O
,amplitudes,NNS,O
,of,IN,O
,tremor,NN,B-DISEASE
,oscillations,NNS,O
,were,VBD,O
,calculated,VBN,O
,and,CC,O
,classified,VBN,O
,.,.,O
,The,DT,O
,event,NN,O
,frequency,NN,O
,for,IN,O
,each,DT,O
,class,NN,O
,of,IN,O
,periods,NNS,O
,and,CC,O
,amplitudes,NNS,O
,was,VBD,O
,determined,VBN,O
,.,.,O
,The,DT,O
,actions,NNS,O
,of,IN,O
,fenoterol,NN,O
,-,:,O
,hydrobromide,NN,O
,",",",",O
,ritodrin,VB,O
,-,:,O
,HCl,NNP,O
,and,CC,O
,placebo,VB,O
,given,VBN,O
,to,TO,O
,10,CD,O
,healthy,JJ,O
,subjects,NNS,O
,by,IN,O
,intravenous,JJ,O
,infusion,NN,O
,in,IN,O
,a,DT,O
,double,JJ,O
,-,:,O
,blind,NN,O
,crossover,NN,O
,study,NN,O
,were,VBD,O
,tested,VBN,O
,by,IN,O
,this,DT,O
,method,NN,O
,.,.,O
,At,IN,O
,therapeutic,JJ,O
,doses,NNS,O
,both,DT,O
,substances,NNS,O
,raised,VBD,O
,the,DT,O
,mean,JJ,O
,tremor,NN,B-DISEASE
,amplitude,NN,O
,to,TO,O
,about,IN,O
,three,CD,O
,times,NNS,O
,the,DT,O
,control,NN,O
,level,NN,O
,.,.,O
,At,IN,O
,the,DT,O
,same,JJ,O
,time,NN,O
,",",",",O
,the,DT,O
,mean,JJ,O
,period,NN,O
,within,IN,O
,each,DT,O
,class,NN,O
,of,IN,O
,amplitudes,NNS,O
,shortened,VBN,O
,by,IN,O
,10,CD,O
,-,:,O
,-,:,O
,20,CD,O
,ms,NN,O
,",",",",O
,whereas,IN,O
,the,DT,O
,mean,NN,O
,periods,NNS,O
,calculated,VBN,O
,from,IN,O
,all,DT,O
,oscillations,NNS,O
,together,RB,O
,did,VBD,O
,not,RB,O
,change,VB,O
,significantly,RB,O
,.,.,O
,After,IN,O
,the,DT,O
,end,NN,O
,of,IN,O
,fenoterol,NN,O
,-,:,O
,hydrobromide,NN,O
,infusion,NN,O
,",",",",O
,tremor,NN,B-DISEASE
,amplitudes,NNS,O
,decreased,VBD,O
,significantly,RB,O
,faster,RBR,O
,than,IN,O
,those,DT,O
,following,JJ,O
,ritodrin,JJ,O
,-,:,O
,HCl,NNP,O
,infusion,NN,O
,.,.,O
,Propylthiouracil,NNP,O
,-,:,O
,induced,VBD,O
,hepatic,JJ,B-DISEASE
,damage,NN,I-DISEASE
,.,.,O
,Two,CD,O
,cases,NNS,O
,of,IN,O
,propylthiouracil,NN,O
,-,:,O
,induced,VBN,O
,liver,RB,B-DISEASE
,damage,NN,I-DISEASE
,have,VBP,O
,been,VBN,O
,observed,VBN,O
,.,.,O
,The,DT,O
,first,JJ,O
,case,NN,O
,is,VBZ,O
,of,IN,O
,an,DT,O
,acute,JJ,O
,type,NN,O
,of,IN,O
,damage,NN,O
,",",",",O
,proven,VBN,O
,by,IN,O
,rechallenge,NN,O
,;,:,O
,the,DT,O
,second,JJ,O
,presents,VBZ,O
,a,DT,O
,clinical,JJ,O
,and,CC,O
,histologic,JJ,O
,picture,NN,O
,resembling,VBG,O
,chronic,JJ,B-DISEASE
,active,JJ,I-DISEASE
,hepatitis,NN,I-DISEASE
,",",",",O
,with,IN,O
,spontaneous,JJ,O
,remission,NN,O
,.,.,O
,Studies,NNS,O
,on,IN,O
,the,DT,O
,bradycardia,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,bepridil,NN,O
,.,.,O
,Bepridil,NNP,O
,",",",",O
,a,DT,O
,novel,JJ,O
,active,JJ,O
,compound,NN,O
,for,IN,O
,prophylactic,JJ,O
,treatment,NN,O
,of,IN,O
,anginal,JJ,B-DISEASE
,attacks,NNS,I-DISEASE
,",",",",O
,induced,VBD,O
,persistent,JJ,O
,bradycardia,NN,B-DISEASE
,and,CC,O
,a,DT,O
,non,JJ,O
,-,:,O
,specific,JJ,O
,anti,SYM,O
,-,:,O
,tachycardial,JJ,B-DISEASE
,effect,NN,O
,",",",",O
,the,DT,O
,mechanisms,NN,O
,of,IN,O
,which,WDT,O
,were,VBD,O
,investigated,VBN,O
,in,IN,O
,vitro,NN,O
,and,CC,O
,in,IN,O
,vivo,NN,O
,.,.,O
,In,IN,O
,vitro,JJ,O
,perfusion,NN,O
,of,IN,O
,bepridil,NN,O
,in,IN,O
,the,DT,O
,life,NN,O
,-,:,O
,support,NN,O
,medium,NN,O
,for,IN,O
,isolated,JJ,O
,sino,NN,O
,-,:,O
,atrial,JJ,O
,tissue,NN,O
,from,IN,O
,rabbit,NN,O
,heart,NN,O
,",",",",O
,caused,VBD,O
,a,DT,O
,reduction,NN,O
,in,IN,O
,action,NN,O
,potential,NN,O
,(,(,O
,AP,NNP,O
,),),O
,spike,NN,O
,frequency,NN,O
,(,(,O
,recorded,VBN,O
,by,IN,O
,KCl,NNP,O
,microelectrodes,NNS,O
,),),O
,starting,VBG,O
,at,IN,O
,doses,NNS,O
,of,IN,O
,5,CD,O
,X,NNS,O
,10,CD,O
,(,(,O
,-,:,O
,6,CD,O
,),),O
,M,NNP,O
,.,.,O
,This,DT,O
,effect,NN,O
,was,VBD,O
,dose,JJ,O
,-,:,O
,dependent,NN,O
,up,RB,O
,to,TO,O
,concentrations,NNS,O
,of,IN,O
,5,CD,O
,X,NNS,O
,10,CD,O
,(,(,O
,-,:,O
,5,CD,O
,),),O
,M,NNP,O
,",",",",O
,whereupon,NN,O
,blockade,NN,O
,of,IN,O
,sinus,NN,O
,activity,NN,O
,set,VBN,O
,in,IN,O
,.,.,O
,Bepridil,NNP,O
,at,IN,O
,a,DT,O
,dose,NN,O
,of,IN,O
,5,CD,O
,X,NNS,O
,10,CD,O
,(,(,O
,-,:,O
,6,CD,O
,),),O
,M,NNP,O
,",",",",O
,induced,VBD,O
,a,DT,O
,concomitant,JJ,O
,reduction,NN,O
,in,IN,O
,AP,NNP,O
,amplitude,NN,O
,(,(,O
,falling,VBG,O
,from,IN,O
,71,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,8,CD,O
,mV,NN,O
,to,TO,O
,47,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,6,CD,O
,mV,NN,O
,),),O
,",",",",O
,maximum,JJ,O
,systolic,JJ,O
,depolarization,NN,O
,velocity,NN,O
,(,(,O
,phase,VB,O
,0,CD,O
,),),O
,which,WDT,O
,fell,VBD,O
,from,IN,O
,1,CD,O
,.,.,O
,85,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,35,CD,O
,V,NNP,O
,/,NNP,O
,s,VBD,O
,to,TO,O
,0,CD,O
,.,.,O
,84,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,28,CD,O
,V,NNP,O
,/,NNP,O
,s,NN,O
,",",",",O
,together,RB,O
,with,IN,O
,maximum,JJ,O
,diastolic,JJ,O
,depolarization,NN,O
,velocity,NN,O
,(,(,O
,phase,VB,O
,4,CD,O
,),),O
,which,WDT,O
,fell,VBD,O
,from,IN,O
,38,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,3,CD,O
,mV,NN,O
,/,NN,O
,s,NN,O
,to,TO,O
,24,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,5,CD,O
,mV,NN,O
,/,NNP,O
,s,NN,O
,.,.,O
,In,IN,O
,vivo,JJ,O
,injection,NN,O
,of,IN,O
,bepridil,NN,O
,at,IN,O
,a,DT,O
,dose,NN,O
,of,IN,O
,5,CD,O
,mg,NNS,O
,/,JJ,O
,kg,NN,O
,(,(,O
,i,JJ,O
,.,.,O
,v,NN,O
,.,.,O
,),),O
,into,IN,O
,6,CD,O
,anaesthetized,JJ,O
,dogs,NNS,O
,which,WDT,O
,had,VBD,O
,undergone,JJ,O
,ablation,NN,O
,of,IN,O
,all,PDT,O
,the,DT,O
,extrinsic,JJ,O
,cardiac,JJ,O
,afferent,NN,O
,nerve,NN,O
,supply,NN,O
,",",",",O
,together,RB,O
,with,IN,O
,a,DT,O
,bilateral,JJ,O
,medullo,NN,O
,-,:,O
,adrenalectomy,NN,O
,",",",",O
,caused,VBD,O
,a,DT,O
,marked,JJ,O
,reduction,NN,O
,in,IN,O
,heart,NN,O
,rate,NN,O
,which,WDT,O
,fell,VBD,O
,from,IN,O
,98,CD,O
,.,.,O
,7,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,4,CD,O
,.,.,O
,2,CD,O
,beats,NNS,O
,/,VBP,O
,min,NN,O
,to,TO,O
,76,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,5,CD,O
,.,.,O
,3,CD,O
,beats,NNS,O
,/,VBP,O
,min,NN,O
,sustained,VBN,O
,for,IN,O
,more,JJR,O
,than,IN,O
,45,CD,O
,min,NN,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,concluded,VBN,O
,that,IN,O
,bepridil,NN,O
,reduces,NNS,O
,heart,NN,O
,rate,NN,O
,by,IN,O
,acting,VBG,O
,directly,RB,O
,on,IN,O
,the,DT,O
,sinus,NN,O
,node,NN,O
,.,.,O
,This,DT,O
,effect,NN,O
,",",",",O
,which,WDT,O
,results,NNS,O
,in,IN,O
,a,DT,O
,flattening,NN,O
,of,IN,O
,the,DT,O
,phase,NN,O
,0,CD,O
,and,CC,O
,phase,VB,O
,4,CD,O
,slope,NN,O
,",",",",O
,together,RB,O
,with,IN,O
,a,DT,O
,longer,RBR,O
,AP,NNP,O
,duration,NN,O
,",",",",O
,may,MD,O
,be,VB,O
,due,JJ,O
,to,TO,O
,an,DT,O
,increase,NN,O
,in,IN,O
,the,DT,O
,time,NN,O
,constants,NNS,O
,of,IN,O
,slow,JJ,O
,inward,NN,O
,ionic,JJ,O
,currents,NNS,O
,(,(,O
,already,RB,O
,demonstrated,VBN,O
,elsewhere,RB,O
,),),O
,",",",",O
,but,CC,O
,also,RB,O
,to,TO,O
,an,DT,O
,increased,VBN,O
,time,NN,O
,constant,NN,O
,for,IN,O
,deactivation,NN,O
,of,IN,O
,the,DT,O
,outward,JJ,O
,potassium,NN,O
,current,JJ,O
,(,(,O
,Ip,NNP,O
,),),O
,.,.,O
,Hepatitis,NNP,B-DISEASE
,and,CC,O
,renal,JJ,B-DISEASE
,tubular,NN,I-DISEASE
,acidosis,NN,I-DISEASE
,after,IN,O
,anesthesia,NN,O
,with,IN,O
,methoxyflurane,NN,O
,.,.,O
,A,DT,O
,69,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,man,NN,O
,operated,VBD,O
,for,IN,O
,acute,JJ,B-DISEASE
,cholecystitis,NN,I-DISEASE
,under,IN,O
,methoxyflurane,NN,O
,anesthesia,NN,O
,developed,VBD,O
,postoperatively,RB,O
,a,DT,O
,hepatic,JJ,B-DISEASE
,insufficiency,NN,I-DISEASE
,syndrome,NN,I-DISEASE
,and,CC,O
,renal,JJ,B-DISEASE
,tubular,JJ,I-DISEASE
,acidosis,NN,I-DISEASE
,.,.,O
,Massive,JJ,O
,bleeding,NN,B-DISEASE
,appeared,VBD,O
,during,IN,O
,surgery,NN,O
,which,WDT,O
,lasted,VBD,O
,for,IN,O
,six,CD,O
,hours,NNS,O
,.,.,O
,Postoperative,JJ,O
,evolution,NN,O
,under,IN,O
,supportive,JJ,O
,therapy,NN,O
,was,VBD,O
,favourable,JJ,O
,.,.,O
,Complete,JJ,O
,recovery,NN,O
,was,VBD,O
,confirmed,VBN,O
,by,IN,O
,repeated,VBN,O
,controls,NNS,O
,performed,VBN,O
,over,IN,O
,a,DT,O
,period,NN,O
,of,IN,O
,one,CD,O
,year,NN,O
,after,IN,O
,surgery,NN,O
,.,.,O
,Pituitary,JJ,O
,response,NN,O
,to,TO,O
,luteinizing,VBG,O
,hormone,NN,O
,-,:,O
,releasing,VBG,O
,hormone,NN,O
,during,IN,O
,haloperidol,JJ,O
,-,:,O
,induced,JJ,O
,hyperprolactinemia,NN,B-DISEASE
,.,.,O
,The,DT,O
,effects,NNS,O
,of,IN,O
,a,DT,O
,6,CD,O
,-,:,O
,hour,NN,O
,infusion,NN,O
,with,IN,O
,haloperidol,NN,O
,on,IN,O
,serum,NN,O
,prolactin,NN,O
,and,CC,O
,luteinizing,VBG,O
,hormone,NN,O
,(,(,O
,LH,NNP,O
,),),O
,levels,NNS,O
,was,VBD,O
,studied,VBN,O
,in,IN,O
,a,DT,O
,group,NN,O
,of,IN,O
,male,JJ,O
,subjects,NNS,O
,.,.,O
,Five,CD,O
,hours,NNS,O
,after,IN,O
,starting,VBG,O
,the,DT,O
,infusions,NNS,O
,",",",",O
,a,DT,O
,study,NN,O
,of,IN,O
,the,DT,O
,pituitary,JJ,O
,responses,NNS,O
,to,TO,O
,LH,NNP,O
,-,:,O
,releasing,VBG,O
,hormone,NN,O
,(,(,O
,LH,NNP,O
,-,:,O
,RH,NN,O
,),),O
,was,VBD,O
,carried,VBN,O
,out,RP,O
,.,.,O
,Control,NN,O
,patients,NNS,O
,received,VBD,O
,infusions,NNS,O
,of,IN,O
,0,CD,O
,.,.,O
,9,CD,O
,%,NN,O
,NaCl,NNP,O
,solution,NN,O
,.,.,O
,During,IN,O
,the,DT,O
,course,NN,O
,of,IN,O
,haloperidol,JJ,O
,infusions,NNS,O
,",",",",O
,significant,JJ,O
,hyperprolactinemia,NN,B-DISEASE
,was,VBD,O
,found,VBN,O
,",",",",O
,together,RB,O
,with,IN,O
,an,DT,O
,abolished,JJ,O
,pituitary,JJ,O
,response,NN,O
,to,TO,O
,LH,NNP,O
,-,:,O
,RH,NN,O
,",",",",O
,as,IN,O
,compared,VBN,O
,with,IN,O
,responses,NNS,O
,of,IN,O
,control,NN,O
,subjects,NNS,O
,.,.,O
,Antirifampicin,NNP,O
,antibodies,NNS,O
,in,IN,O
,acute,NN,O
,rifampicin,NN,O
,-,:,O
,associated,VBN,O
,renal,JJ,B-DISEASE
,failure,NN,I-DISEASE
,.,.,O
,5,CD,O
,patients,NNS,O
,with,IN,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,(,(,O
,3,CD,O
,with,IN,O
,thrombopenia,NN,B-DISEASE
,and,CC,O
,hemolysis,NN,B-DISEASE
,),),O
,induced,VBN,O
,by,IN,O
,the,DT,O
,reintroduction,NN,O
,of,IN,O
,rifampicin,NN,O
,are,VBP,O
,described,VBN,O
,.,.,O
,No,DT,O
,correlation,NN,O
,was,VBD,O
,found,VBN,O
,between,IN,O
,the,DT,O
,severity,NN,O
,of,IN,O
,clinical,JJ,O
,manifestations,NNS,O
,and,CC,O
,the,DT,O
,total,NN,O
,dose,NN,O
,taken,VBN,O
,by,IN,O
,the,DT,O
,patients,NNS,O
,.,.,O
,In,IN,O
,all,DT,O
,but,CC,O
,1,CD,O
,patient,NN,O
,",",",",O
,antirifampicin,JJ,O
,antibodies,NNS,O
,were,VBD,O
,detected,VBN,O
,.,.,O
,Antibodies,NNS,O
,suggested,VBD,O
,to,TO,O
,be,VB,O
,of,IN,O
,the,DT,O
,IgM,NNP,O
,class,NN,O
,were,VBD,O
,detected,VBN,O
,in,IN,O
,all,DT,O
,3,CD,O
,patients,NNS,O
,with,IN,O
,hematological,JJ,B-DISEASE
,disorders,NNS,I-DISEASE
,.,.,O
,The,DT,O
,pattern,NN,O
,of,IN,O
,non,JJ,O
,-,:,O
,specific,JJ,O
,acute,JJ,B-DISEASE
,tubular,JJ,I-DISEASE
,necrosis,NN,I-DISEASE
,found,VBN,O
,in,IN,O
,the,DT,O
,2,CD,O
,biopsied,VBD,O
,patients,NNS,O
,",",",",O
,indistinguishable,JJ,O
,from,IN,O
,that,DT,O
,of,IN,O
,ischemic,JJ,O
,origin,NN,O
,",",",",O
,raised,VBD,O
,the,DT,O
,possibility,NN,O
,of,IN,O
,a,DT,O
,vascular,JJ,O
,-,:,O
,mediated,VBN,O
,damage,NN,O
,.,.,O
,In,IN,O
,3,CD,O
,patients,NNS,O
,",",",",O
,the,DT,O
,possibility,NN,O
,of,IN,O
,a,DT,O
,triggering,VBG,O
,immunoallergic,JJ,O
,mechanism,NN,O
,is,VBZ,O
,discussed,VBN,O
,.,.,O
,Cardiovascular,JJ,O
,effects,NNS,O
,of,IN,O
,hypotension,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,adenosine,JJ,O
,triphosphate,NN,O
,and,CC,O
,sodium,NN,O
,nitroprusside,RB,O
,on,IN,O
,dogs,NNS,O
,with,IN,O
,denervated,JJ,O
,hearts,NNS,O
,.,.,O
,Adenosine,NNP,O
,triphosphate,NN,O
,(,(,O
,ATP,NNP,O
,),),O
,and,CC,O
,sodium,JJ,O
,nitroprusside,NN,O
,(,(,O
,SNP,NNP,O
,),),O
,are,VBP,O
,administered,VBN,O
,to,TO,O
,patients,NNS,O
,to,TO,O
,induce,VB,O
,and,CC,O
,control,VB,O
,hypotension,NN,B-DISEASE
,during,IN,O
,anesthesia,NN,O
,.,.,O
,SNP,NNP,O
,is,VBZ,O
,authorized,VBN,O
,for,IN,O
,clinical,JJ,O
,use,NN,O
,in,IN,O
,USA,NNP,O
,and,CC,O
,UK,NNP,O
,",",",",O
,and,CC,O
,ATP,NNP,O
,is,VBZ,O
,clinically,RB,O
,used,VBN,O
,in,IN,O
,other,JJ,O
,countries,NNS,O
,such,JJ,O
,as,IN,O
,Japan,NNP,O
,.,.,O
,We,PRP,O
,investigated,VBD,O
,how,WRB,O
,these,DT,O
,two,CD,O
,drugs,NNS,O
,act,NN,O
,on,IN,O
,the,DT,O
,cardiovascular,JJ,O
,systems,NNS,O
,of,IN,O
,20,CD,O
,dogs,NNS,O
,whose,WP$,O
,hearts,NNS,O
,had,VBD,O
,been,VBN,O
,denervated,VBN,O
,by,IN,O
,a,DT,O
,procedure,NN,O
,we,PRP,O
,had,VBD,O
,devised,VBN,O
,.,.,O
,ATP,NNP,O
,(,(,O
,10,CD,O
,dogs,NNS,O
,),),O
,or,CC,O
,SNP,NNP,O
,(,(,O
,10,CD,O
,dogs,NNS,O
,),),O
,was,VBD,O
,administered,VBN,O
,to,TO,O
,reduce,VB,O
,mean,JJ,O
,arterial,JJ,O
,pressure,NN,O
,by,IN,O
,30,CD,O
,%,NN,O
,to,TO,O
,70,CD,O
,%,NN,O
,of,IN,O
,control,NN,O
,.,.,O
,Before,IN,O
,",",",",O
,during,IN,O
,and,CC,O
,after,IN,O
,induced,JJ,O
,hypotension,NN,B-DISEASE
,",",",",O
,we,PRP,O
,measured,VBD,O
,major,JJ,O
,cardiovascular,JJ,O
,parameters,NNS,O
,.,.,O
,Hypotension,NNP,B-DISEASE
,induced,VBN,O
,by,IN,O
,ATP,NNP,O
,was,VBD,O
,accompanied,VBN,O
,by,IN,O
,significant,JJ,O
,decreases,NNS,O
,in,IN,O
,mean,JJ,O
,pulmonary,JJ,O
,arterial,JJ,O
,pressure,NN,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,",",",",O
,central,JJ,O
,venous,JJ,O
,pressure,NN,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,",",",",O
,left,VBD,O
,ventricular,JJ,O
,end,NN,O
,-,:,O
,diastolic,JJ,O
,pressure,NN,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,",",",",O
,total,JJ,O
,peripheral,JJ,O
,resistance,NN,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,",",",",O
,rate,NN,O
,pressure,NN,O
,product,NN,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,",",",",O
,total,JJ,O
,body,NN,O
,oxygen,NN,O
,consumption,NN,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,",",",",O
,and,CC,O
,heart,NN,O
,rate,NN,O
,(,(,O
,p,IN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,;,:,O
,all,PDT,O
,these,DT,O
,variables,NNS,O
,returned,VBD,O
,normal,JJ,O
,within,IN,O
,30,CD,O
,min,NNS,O
,after,IN,O
,ATP,NNP,O
,was,VBD,O
,stopped,VBN,O
,.,.,O
,Cardiac,NNP,O
,output,NN,O
,did,VBD,O
,not,RB,O
,change,VB,O
,.,.,O
,During,IN,O
,hypotension,NN,B-DISEASE
,produced,VBN,O
,by,IN,O
,SNP,NNP,O
,similar,JJ,O
,decreases,NNS,O
,were,VBD,O
,observed,VBN,O
,in,IN,O
,mean,JJ,O
,pulmonary,JJ,O
,arterial,JJ,O
,pressure,NN,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,",",",",O
,central,JJ,O
,venous,JJ,O
,pressure,NN,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,",",",",O
,left,VBD,O
,ventricular,JJ,O
,end,NN,O
,-,:,O
,diastolic,JJ,O
,pressure,NN,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,",",",",O
,total,JJ,O
,peripheral,JJ,O
,resistance,NN,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,",",",",O
,rate,NN,O
,pressure,NN,O
,product,NN,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,",",",",O
,and,CC,O
,oxygen,NN,O
,content,NN,O
,difference,NN,O
,between,IN,O
,arterial,JJ,O
,and,CC,O
,mixed,JJ,O
,venous,JJ,O
,blood,NN,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,",",",",O
,while,IN,O
,heart,NN,O
,rate,NN,O
,(,(,O
,p,IN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,001,CD,O
,),),O
,and,CC,O
,cardiac,JJ,O
,output,NN,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,were,VBD,O
,increased,VBN,O
,.,.,O
,Recoveries,NNS,O
,of,IN,O
,heart,NN,O
,rate,NN,O
,and,CC,O
,left,VBD,O
,ventricular,JJ,O
,end,NN,O
,-,:,O
,diastolic,JJ,O
,pressure,NN,O
,were,VBD,O
,not,RB,O
,shown,VBN,O
,within,IN,O
,60,CD,O
,min,NNS,O
,after,IN,O
,SNP,NNP,O
,had,VBD,O
,been,VBN,O
,stopped,VBN,O
,.,.,O
,Both,DT,O
,ATP,NNP,O
,and,CC,O
,SNP,NNP,O
,should,MD,O
,act,VB,O
,on,IN,O
,the,DT,O
,pacemaker,NN,O
,tissue,NN,O
,of,IN,O
,the,DT,O
,heart,NN,O
,.,.,O
,Comparative,JJ,O
,study,NN,O
,:,:,O
,Endografine,NNP,O
,(,(,O
,diatrizoate,NN,O
,),),O
,",",",",O
,Vasurix,NNP,O
,polyvidone,NN,O
,(,(,O
,acetrizoate,NN,O
,),),O
,",",",",O
,Dimer,NNP,O
,-,:,O
,X,NN,O
,(,(,O
,iocarmate,JJ,O
,),),O
,and,CC,O
,Hexabrix,NNP,O
,(,(,O
,ioxaglate,NN,O
,),),O
,in,IN,O
,hysterosalpingography,NN,O
,.,.,O
,Side,NNP,O
,effects,NNS,O
,of,IN,O
,hysterosalpingography,NN,O
,with,IN,O
,Dimer,NNP,O
,-,:,O
,X,NN,O
,",",",",O
,Hexabrix,NNP,O
,",",",",O
,Vasurix,NNP,O
,polyvidone,NN,O
,and,CC,O
,Endografine,NNP,O
,in,IN,O
,142,CD,O
,consecutive,JJ,O
,patients,NNS,O
,",",",",O
,receiving,VBG,O
,one,CD,O
,of,IN,O
,the,DT,O
,four,CD,O
,tested,VBD,O
,media,NNS,O
,were,VBD,O
,evaluated,VBN,O
,from,IN,O
,replies,NNS,O
,to,TO,O
,postal,JJ,O
,questionnaires,NNS,O
,.,.,O
,The,DT,O
,Dimer,NNP,O
,-,:,O
,X,NN,O
,group,NN,O
,had,VBD,O
,a,DT,O
,higher,JJR,O
,incidence,NN,O
,of,IN,O
,nausea,NN,B-DISEASE
,and,CC,O
,dizziness,NN,B-DISEASE
,.,.,O
,The,DT,O
,Endografine,NNP,O
,group,NN,O
,had,VBD,O
,a,DT,O
,higher,JJR,O
,incidence,NN,O
,of,IN,O
,abdominal,JJ,B-DISEASE
,pain,NN,I-DISEASE
,.,.,O
,These,DT,O
,differences,NNS,O
,occur,VBP,O
,especially,RB,O
,in,IN,O
,the,DT,O
,age,NN,O
,groups,NNS,O
,under,IN,O
,30,CD,O
,years,NNS,O
,.,.,O
,Hexabrix,NNP,O
,and,CC,O
,Vasurix,NNP,O
,polyvidone,NN,O
,are,VBP,O
,considered,VBN,O
,the,DT,O
,best,JJS,O
,contrast,NN,O
,media,NNS,O
,for,IN,O
,hysterosalpingography,NN,O
,and,CC,O
,perhaps,RB,O
,because,IN,O
,of,IN,O
,its,PRP$,O
,low,JJ,O
,toxicity,NN,B-DISEASE
,Hexabrix,NNP,O
,should,MD,O
,be,VB,O
,preferred,VBN,O
,.,.,O
,Post,NNP,O
,-,:,O
,suxamethonium,NN,O
,pains,NNS,B-DISEASE
,in,IN,O
,Nigerian,JJ,O
,surgical,JJ,O
,patients,NNS,O
,.,.,O
,Contrary,NNP,O
,to,TO,O
,an,DT,O
,earlier,JJR,O
,report,NN,O
,by,IN,O
,Coxon,NNP,O
,",",",",O
,scoline,NN,O
,pain,NN,B-DISEASE
,occurs,VBZ,O
,in,IN,O
,African,NNP,O
,negroes,NNS,O
,.,.,O
,Its,PRP$,O
,incidence,NN,O
,was,VBD,O
,determined,VBN,O
,in,IN,O
,a,DT,O
,prospective,JJ,O
,study,NN,O
,involving,VBG,O
,a,DT,O
,total,NN,O
,of,IN,O
,100,CD,O
,Nigerian,JJ,O
,patients,NNS,O
,(,(,O
,50,CD,O
,out,IN,O
,-,:,O
,patients,NNS,O
,and,CC,O
,50,CD,O
,in,IN,O
,-,:,O
,patients,NNS,O
,),),O
,.,.,O
,About,IN,O
,62,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,out,RP,O
,-,:,O
,patients,NNS,O
,developed,VBD,O
,scoline,JJ,O
,pain,NN,B-DISEASE
,as,IN,O
,compared,VBN,O
,with,IN,O
,about,RB,O
,26,CD,O
,%,NN,O
,among,IN,O
,the,DT,O
,in,IN,O
,-,:,O
,patients,NNS,O
,.,.,O
,The,DT,O
,abolition,NN,O
,of,IN,O
,muscle,NN,O
,fasciculations,NNS,B-DISEASE
,(,(,O
,by,IN,O
,0,CD,O
,.,.,O
,075mg,CD,O
,/,JJ,O
,kg,NN,O
,dose,NN,O
,of,IN,O
,Fazadinium,NNP,O
,),),O
,did,VBD,O
,not,RB,O
,influence,VB,O
,the,DT,O
,occurrence,NN,O
,of,IN,O
,scoline,NN,O
,pain,NN,B-DISEASE
,.,.,O
,Neither,CC,O
,the,DT,O
,type,NN,O
,of,IN,O
,induction,NN,O
,agent,NN,O
,(,(,O
,Althesin,NNP,O
,or,CC,O
,Thiopentone,NNP,O
,),),O
,nor,CC,O
,the,DT,O
,salt,JJ,O
,preparation,NN,O
,of,IN,O
,suxamethonium,NN,O
,used,VBN,O
,(,(,O
,chloride,JJ,O
,or,CC,O
,bromide,NN,O
,),),O
,",",",",O
,affected,VBD,O
,the,DT,O
,incidence,NN,O
,of,IN,O
,scoline,NN,O
,pain,NN,B-DISEASE
,.,.,O
,Invasive,JJ,O
,carcinoma,NN,B-DISEASE
,of,IN,I-DISEASE
,the,DT,I-DISEASE
,renal,JJ,I-DISEASE
,pelvis,NN,I-DISEASE
,following,VBG,O
,cyclophosphamide,JJ,O
,therapy,NN,O
,for,IN,O
,nonmalignant,JJ,O
,disease,NN,O
,.,.,O
,A,DT,O
,47,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,with,IN,O
,right,JJ,O
,hydroureteronephrosis,NN,B-DISEASE
,due,JJ,O
,to,TO,O
,ureterovesical,JJ,O
,junction,NN,O
,obstruction,NN,O
,had,VBD,O
,gross,JJ,O
,hematuria,NN,B-DISEASE
,after,IN,O
,being,VBG,O
,treated,VBN,O
,for,IN,O
,five,CD,O
,years,NNS,O
,wtih,JJ,O
,cyclophosphamide,NN,O
,for,IN,O
,cerebral,JJ,B-DISEASE
,vasculitis,NN,I-DISEASE
,.,.,O
,A,DT,O
,right,JJ,O
,nephroureterectomy,NN,O
,was,VBD,O
,required,VBN,O
,for,IN,O
,control,NN,O
,of,IN,O
,bleeding,VBG,B-DISEASE
,.,.,O
,The,DT,O
,pathology,NN,O
,specimen,NNS,O
,contained,VBD,O
,clinically,RB,O
,occult,JJ,O
,invasive,JJ,O
,carcinoma,NN,B-DISEASE
,of,IN,I-DISEASE
,the,DT,I-DISEASE
,renal,JJ,I-DISEASE
,pelvis,NN,I-DISEASE
,.,.,O
,Although,IN,O
,the,DT,O
,ability,NN,O
,of,IN,O
,cyclophosphamide,NN,O
,to,TO,O
,cause,VB,O
,hemorrhagic,JJ,B-DISEASE
,cystitis,NN,I-DISEASE
,and,CC,O
,urine,JJ,O
,cytologic,NN,O
,abnormalities,NNS,O
,indistinguishable,VBP,O
,from,IN,O
,high,JJ,O
,grade,NN,O
,carcinoma,NN,B-DISEASE
,is,VBZ,O
,well,RB,O
,known,VBN,O
,",",",",O
,it,PRP,O
,is,VBZ,O
,less,RBR,O
,widely,RB,O
,appreciated,VBN,O
,that,IN,O
,it,PRP,O
,is,VBZ,O
,also,RB,O
,associated,VBN,O
,with,IN,O
,carcinoma,NN,B-DISEASE
,of,IN,I-DISEASE
,the,DT,I-DISEASE
,urinary,JJ,I-DISEASE
,tract,NN,I-DISEASE
,.,.,O
,Twenty,NNP,O
,carcinomas,NN,B-DISEASE
,of,IN,I-DISEASE
,the,DT,I-DISEASE
,urinary,JJ,I-DISEASE
,bladder,NN,I-DISEASE
,and,CC,O
,one,CD,O
,carcinoma,NN,B-DISEASE
,of,IN,I-DISEASE
,the,DT,I-DISEASE
,prostate,NN,I-DISEASE
,have,VBP,O
,been,VBN,O
,reported,VBN,O
,in,IN,O
,association,NN,O
,with,IN,O
,its,PRP$,O
,use,NN,O
,.,.,O
,The,DT,O
,present,JJ,O
,case,NN,O
,is,VBZ,O
,the,DT,O
,first,JJ,O
,carcinoma,NN,B-DISEASE
,of,IN,I-DISEASE
,the,DT,I-DISEASE
,renal,JJ,I-DISEASE
,pelvis,NN,I-DISEASE
,reported,VBN,O
,in,IN,O
,association,NN,O
,with,IN,O
,cyclophosphamide,JJ,O
,treatment,NN,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,the,DT,O
,third,JJ,O
,urinary,JJ,B-DISEASE
,tract,NN,I-DISEASE
,cancer,NN,I-DISEASE
,reported,VBN,O
,in,IN,O
,association,NN,O
,with,IN,O
,cyclophosphamide,JJ,O
,treatment,NN,O
,for,IN,O
,nonmalignant,JJ,O
,disease,NN,O
,.,.,O
,The,DT,O
,association,NN,O
,of,IN,O
,the,DT,O
,tumor,NN,B-DISEASE
,with,IN,O
,preexisting,VBG,O
,hydroureteronephrosis,NN,B-DISEASE
,suggests,VBZ,O
,that,IN,O
,stasis,NN,O
,prolonged,VBD,O
,and,CC,O
,intensified,JJ,O
,exposure,NN,O
,of,IN,O
,upper,JJ,O
,urinary,JJ,O
,tract,NN,O
,epithelium,NN,O
,to,TO,O
,cyclophosphamide,VB,O
,.,.,O
,Patients,NNS,O
,who,WP,O
,are,VBP,O
,candidates,NNS,O
,for,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,cyclophosphamide,JJ,O
,treatment,NN,O
,should,MD,O
,be,VB,O
,routinely,RB,O
,evaluated,VBN,O
,for,IN,O
,obstructive,JJ,B-DISEASE
,uropathy,JJ,I-DISEASE
,.,.,O
,Medial,JJ,O
,changes,NNS,O
,in,IN,O
,arterial,JJ,O
,spasm,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,L,NNP,O
,-,:,O
,norepinephrine,NN,O
,.,.,O
,In,IN,O
,normal,JJ,O
,rats,NNS,O
,",",",",O
,the,DT,O
,media,NNS,O
,of,IN,O
,small,JJ,O
,arteries,NNS,O
,(,(,O
,0,CD,O
,.,.,O
,4,CD,O
,-,:,O
,-,:,O
,0,CD,O
,.,.,O
,2,CD,O
,mm,NN,O
,in,IN,O
,diameter,NN,O
,),),O
,previously,RB,O
,was,VBD,O
,shown,VBN,O
,to,TO,O
,contain,VB,O
,intracellular,JJ,O
,vacuoles,NNS,O
,",",",",O
,identified,VBN,O
,ultrastructurally,RB,O
,as,IN,O
,herniations,NNS,O
,of,IN,O
,one,CD,O
,smooth,JJ,O
,muscle,NN,O
,cell,NN,O
,into,IN,O
,another,DT,O
,.,.,O
,The,DT,O
,hypothesis,NN,O
,that,WDT,O
,intense,JJ,O
,vasoconstriction,NN,O
,would,MD,O
,increase,VB,O
,the,DT,O
,number,NN,O
,of,IN,O
,such,JJ,O
,vacuoles,NNS,O
,has,VBZ,O
,been,VBN,O
,tested,VBN,O
,.,.,O
,In,IN,O
,the,DT,O
,media,NNS,O
,of,IN,O
,the,DT,O
,saphenous,JJ,O
,artery,NN,O
,and,CC,O
,its,PRP$,O
,distal,JJ,O
,branch,NN,O
,",",",",O
,vasoconstriction,NN,O
,induced,VBN,O
,by,IN,O
,L,NNP,O
,-,:,O
,norepinephrine,NN,O
,produced,VBD,O
,many,JJ,O
,cell,NN,O
,-,:,O
,to,TO,O
,-,:,O
,cell,NN,O
,hernias,NN,B-DISEASE
,within,IN,O
,15,CD,O
,minutes,NNS,O
,.,.,O
,At,IN,O
,1,CD,O
,day,NN,O
,their,PRP$,O
,number,NN,O
,was,VBD,O
,reduced,VBN,O
,to,TO,O
,about,IN,O
,1,CD,O
,/,JJ,O
,10,CD,O
,of,IN,O
,the,DT,O
,original,JJ,O
,number,NN,O
,.,.,O
,By,IN,O
,7,CD,O
,days,NNS,O
,the,DT,O
,vessel,NN,O
,was,VBD,O
,almost,RB,O
,restored,VBN,O
,to,TO,O
,normal,JJ,O
,.,.,O
,Triple,JJ,O
,stimulation,NN,O
,over,IN,O
,1,CD,O
,day,NN,O
,induced,VBD,O
,more,JJR,O
,severe,JJ,O
,changes,NNS,O
,in,IN,O
,the,DT,O
,media,NNS,O
,.,.,O
,These,DT,O
,findings,NNS,O
,suggest,VBP,O
,that,IN,O
,smooth,JJ,O
,muscle,NN,O
,cells,NNS,O
,are,VBP,O
,susceptible,JJ,O
,to,TO,O
,damage,VB,O
,in,IN,O
,the,DT,O
,course,NN,O
,of,IN,O
,their,PRP$,O
,specific,JJ,O
,function,NN,O
,.,.,O
,The,DT,O
,experimental,JJ,O
,data,NNS,O
,are,VBP,O
,discussed,VBN,O
,in,IN,O
,relation,NN,O
,to,TO,O
,medial,JJ,O
,changes,NNS,O
,observed,VBN,O
,in,IN,O
,other,JJ,O
,instances,NNS,O
,of,IN,O
,arterial,JJ,O
,spasm,NN,B-DISEASE
,.,.,O
,Endothelial,JJ,O
,changes,NNS,O
,that,WDT,O
,developed,VBD,O
,in,IN,O
,the,DT,O
,same,JJ,O
,experimental,JJ,O
,model,NN,O
,were,VBD,O
,described,VBN,O
,in,IN,O
,a,DT,O
,previous,JJ,O
,paper,NN,O
,.,.,O
,Bilateral,NNP,O
,retinal,JJ,B-DISEASE
,artery,NN,I-DISEASE
,and,CC,I-DISEASE
,choriocapillaris,JJ,I-DISEASE
,occlusion,NN,I-DISEASE
,following,VBG,O
,the,DT,O
,injection,NN,O
,of,IN,O
,long,JJ,O
,-,:,O
,acting,VBG,O
,corticosteroid,NN,O
,suspensions,NNS,O
,in,IN,O
,combination,NN,O
,with,IN,O
,other,JJ,O
,drugs,NNS,O
,:,:,O
,I,PRP,O
,.,.,O
,Clinical,JJ,O
,studies,NNS,O
,.,.,O
,Two,CD,O
,well,RB,O
,-,:,O
,documented,VBN,O
,cases,NNS,O
,of,IN,O
,bilateral,JJ,O
,retinal,JJ,B-DISEASE
,artery,NN,I-DISEASE
,and,CC,I-DISEASE
,choriocapillaris,JJ,I-DISEASE
,occlusions,NNS,I-DISEASE
,with,IN,O
,blindness,NN,B-DISEASE
,following,VBG,O
,head,NN,O
,and,CC,O
,neck,NN,O
,soft,JJ,O
,-,:,O
,tissue,NN,O
,injection,NN,O
,with,IN,O
,methylprednisolone,NN,O
,acetate,NN,O
,in,IN,O
,combination,NN,O
,with,IN,O
,lidocaine,NN,O
,",",",",O
,epinephrine,NN,O
,",",",",O
,or,CC,O
,penicillin,NN,O
,are,VBP,O
,reported,VBN,O
,.,.,O
,One,CD,O
,case,NN,O
,had,VBD,O
,only,RB,O
,a,DT,O
,unilateral,JJ,O
,injection,NN,O
,.,.,O
,The,DT,O
,acute,JJ,O
,observations,NNS,O
,included,VBD,O
,hazy,JJ,O
,sensorium,NN,O
,",",",",O
,superior,JJ,O
,gaze,NN,O
,palsy,NN,B-DISEASE
,",",",",O
,pupillary,JJ,B-DISEASE
,abnormalities,NNS,I-DISEASE
,",",",",O
,and,CC,O
,conjunctival,JJ,O
,hemorrhages,NNS,B-DISEASE
,with,IN,O
,edema,NN,B-DISEASE
,.,.,O
,Follow,NNP,O
,-,:,O
,up,RP,O
,changes,NNS,O
,showed,VBD,O
,marked,JJ,O
,visual,JJ,B-DISEASE
,loss,NN,I-DISEASE
,",",",",O
,constricted,VBN,O
,visual,JJ,O
,fields,NNS,O
,",",",",O
,optic,JJ,O
,nerve,NN,O
,pallor,NN,O
,",",",",O
,vascular,JJ,O
,attenuation,NN,O
,",",",",O
,and,CC,O
,chorioretinal,JJ,B-DISEASE
,atrophy,NN,I-DISEASE
,.,.,O
,The,DT,O
,literature,NN,O
,is,VBZ,O
,reviewed,VBN,O
,",",",",O
,and,CC,O
,possible,JJ,O
,causes,NNS,O
,are,VBP,O
,discussed,VBN,O
,.,.,O
,Abnormalities,NNS,O
,of,IN,O
,the,DT,O
,pupil,NN,O
,and,CC,O
,visual,JJ,O
,-,:,O
,evoked,JJ,O
,potential,NN,O
,in,IN,O
,quinine,NN,O
,amblyopia,NN,B-DISEASE
,.,.,O
,Total,JJ,O
,blindness,NN,B-DISEASE
,with,IN,O
,a,DT,O
,transient,NN,O
,tonic,JJ,B-DISEASE
,pupillary,JJ,I-DISEASE
,response,NN,O
,",",",",O
,denervation,NN,O
,supersensitivity,NN,O
,",",",",O
,and,CC,O
,abnormal,JJ,O
,visual,JJ,O
,-,:,O
,evoked,JJ,O
,potentials,NNS,O
,developed,VBN,O
,in,IN,O
,a,DT,O
,54,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,man,NN,O
,after,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,quinine,NN,O
,sulfate,NN,O
,for,IN,O
,leg,NN,B-DISEASE
,cramps,NNS,I-DISEASE
,.,.,O
,He,PRP,O
,later,RB,O
,recovered,VBD,O
,normal,JJ,O
,visual,JJ,O
,acuity,NN,O
,.,.,O
,A,DT,O
,transient,JJ,O
,tonic,JJ,B-DISEASE
,pupillary,JJ,I-DISEASE
,response,NN,O
,",",",",O
,denervation,NN,O
,supersensitivity,NN,O
,",",",",O
,and,CC,O
,abnormal,JJ,O
,visual,JJ,O
,-,:,O
,evoked,JJ,O
,potentials,NNS,O
,in,IN,O
,quinine,JJ,O
,toxicity,NN,B-DISEASE
,",",",",O
,to,TO,O
,our,PRP$,O
,knowledge,NN,O
,",",",",O
,have,VBP,O
,not,RB,O
,been,VBN,O
,previously,RB,O
,reported,VBN,O
,.,.,O
,Suxamethonium,NNP,O
,-,:,O
,induced,VBD,O
,jaw,JJ,B-DISEASE
,stiffness,NN,I-DISEASE
,and,CC,O
,myalgia,NN,B-DISEASE
,associated,VBN,O
,with,IN,O
,atypical,JJ,O
,cholinesterase,NN,O
,:,:,O
,case,NN,O
,report,NN,O
,.,.,O
,An,DT,O
,11,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,boy,NN,O
,was,VBD,O
,given,VBN,O
,halothane,NN,O
,",",",",O
,nitrous,JJ,O
,oxide,NN,O
,and,CC,O
,oxygen,NN,O
,",",",",O
,pancuronium,NN,O
,0,CD,O
,.,.,O
,4,CD,O
,mg,NN,O
,and,CC,O
,suxamethonium,NN,O
,100,CD,O
,mg,NN,O
,for,IN,O
,induction,NN,O
,of,IN,O
,anaesthesia,NN,O
,.,.,O
,In,IN,O
,response,NN,O
,to,TO,O
,this,DT,O
,a,DT,O
,marked,JJ,O
,jaw,NN,B-DISEASE
,stiffness,NN,I-DISEASE
,occurred,VBD,O
,which,WDT,O
,lasted,VBD,O
,for,IN,O
,two,CD,O
,minutes,NNS,O
,and,CC,O
,the,DT,O
,anaesthesia,NN,O
,were,VBD,O
,terminated,VBN,O
,.,.,O
,Four,CD,O
,hours,NNS,O
,of,IN,O
,apnoea,JJ,B-DISEASE
,ensued,VBN,O
,and,CC,O
,he,PRP,O
,suffered,VBD,O
,generalized,VBN,O
,severe,JJ,O
,myalgia,NN,B-DISEASE
,lasting,VBG,O
,for,IN,O
,one,CD,O
,week,NN,O
,.,.,O
,He,PRP,O
,was,VBD,O
,found,VBN,O
,to,TO,O
,have,VB,O
,atypical,JJ,O
,plasma,NNS,O
,cholinesterase,NN,O
,with,IN,O
,a,DT,O
,dibucaine,JJ,O
,number,NN,O
,of,IN,O
,12,CD,O
,",",",",O
,indicating,VBG,O
,homozygocity,NN,O
,.,.,O
,This,DT,O
,was,VBD,O
,verified,VBN,O
,by,IN,O
,study,NN,O
,of,IN,O
,the,DT,O
,family,NN,O
,.,.,O
,The,DT,O
,case,NN,O
,shows,VBZ,O
,that,IN,O
,prolonged,VBD,B-DISEASE
,jaw,NN,I-DISEASE
,rigidity,NN,I-DISEASE
,and,CC,O
,myalgia,NN,B-DISEASE
,may,MD,O
,occur,VB,O
,after,IN,O
,suxamethonium,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,atypical,JJ,O
,cholinesterase,NN,O
,despite,IN,O
,pretreatment,NN,O
,with,IN,O
,pancuronium,NN,O
,.,.,O
,Indomethacin,NNP,O
,-,:,O
,induced,VBD,O
,hyperkalemia,NN,B-DISEASE
,in,IN,O
,three,CD,O
,patients,NNS,O
,with,IN,O
,gouty,JJ,B-DISEASE
,arthritis,NN,I-DISEASE
,.,.,O
,We,PRP,O
,describe,VBP,O
,three,CD,O
,patients,NNS,O
,in,IN,O
,whom,WP,O
,severe,JJ,O
,",",",",O
,life,NN,O
,-,:,O
,threatening,NN,O
,hyperkalemia,NN,B-DISEASE
,and,CC,O
,renal,JJ,B-DISEASE
,insufficiency,NN,I-DISEASE
,developed,VBD,O
,after,IN,O
,treatment,NN,O
,of,IN,O
,acute,JJ,O
,gouty,NN,B-DISEASE
,arthritis,NN,I-DISEASE
,with,IN,O
,indomethacin,NN,O
,.,.,O
,This,DT,O
,complication,NN,O
,may,MD,O
,result,VB,O
,from,IN,O
,an,DT,O
,inhibition,NN,O
,of,IN,O
,prostaglandin,JJ,O
,synthesis,NN,O
,and,CC,O
,consequent,JJ,O
,hyporeninemic,JJ,B-DISEASE
,hypoaidosteronism,NN,I-DISEASE
,.,.,O
,Careful,JJ,O
,attention,NN,O
,to,TO,O
,renal,JJ,O
,function,NN,O
,and,CC,O
,potassium,NN,O
,balance,NN,O
,in,IN,O
,patients,NNS,O
,receiving,VBG,O
,indomethacin,NN,O
,or,CC,O
,other,JJ,O
,nonsteroidal,JJ,O
,anti,SYM,O
,-,:,O
,inflammatory,NN,O
,agents,NNS,O
,",",",",O
,particularly,RB,O
,in,IN,O
,those,DT,O
,patients,NNS,O
,with,IN,O
,diabetes,NNS,B-DISEASE
,mellitus,VBP,I-DISEASE
,or,CC,O
,preexisting,VBG,O
,renal,JJ,B-DISEASE
,disease,NN,I-DISEASE
,",",",",O
,will,MD,O
,help,VB,O
,prevent,VB,O
,this,DT,O
,potentially,RB,O
,serious,JJ,O
,complication,NN,O
,.,.,O
,Etomidate,NN,O
,:,:,O
,a,DT,O
,foreshortened,JJ,O
,clinical,JJ,O
,trial,NN,O
,.,.,O
,A,DT,O
,clinical,JJ,O
,evaluation,NN,O
,of,IN,O
,etomidate,NN,O
,for,IN,O
,outpatient,JJ,O
,cystoscopy,NN,O
,was,VBD,O
,embarked,VBN,O
,upon,IN,O
,.,.,O
,Unpremedicated,VBN,O
,patients,NNS,O
,were,VBD,O
,given,VBN,O
,fentanyl,JJ,O
,1,CD,O
,microgram,NN,O
,/,NN,O
,kg,NN,O
,followed,VBN,O
,by,IN,O
,etomidate,NN,O
,0,CD,O
,.,.,O
,3,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,.,.,O
,Anaesthesia,NNP,O
,was,VBD,O
,maintained,VBN,O
,with,IN,O
,intermittent,JJ,O
,etomidate,NN,O
,in,IN,O
,2,CD,O
,-,:,O
,4,CD,O
,mg,NN,O
,doses,NNS,O
,.,.,O
,Patients,NNS,O
,were,VBD,O
,interviewed,VBN,O
,personally,RB,O
,later,RB,O
,the,DT,O
,same,JJ,O
,day,NN,O
,",",",",O
,and,CC,O
,by,IN,O
,questionnaire,NN,O
,three,CD,O
,to,TO,O
,four,CD,O
,weeks,NNS,O
,later,RB,O
,.,.,O
,The,DT,O
,trial,NN,O
,was,VBD,O
,discontinued,VBN,O
,after,IN,O
,20,CD,O
,cases,NNS,O
,because,IN,O
,of,IN,O
,an,DT,O
,unacceptable,JJ,O
,incidence,NN,O
,of,IN,O
,side,NN,O
,effects,NNS,O
,.,.,O
,Venous,JJ,O
,pain,NN,B-DISEASE
,occurred,VBD,O
,in,IN,O
,68,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,and,CC,O
,50,CD,O
,%,NN,O
,had,VBD,O
,redness,NN,O
,",",",",O
,pain,NN,B-DISEASE
,or,CC,O
,swelling,VBG,B-DISEASE
,related,VBN,O
,to,TO,O
,the,DT,O
,injection,NN,O
,site,NN,O
,",",",",O
,in,IN,O
,some,DT,O
,cases,NNS,O
,lasting,VBG,O
,up,RP,O
,to,TO,O
,three,CD,O
,weeks,NNS,O
,after,IN,O
,anaesthesia,NN,O
,.,.,O
,Skeletal,JJ,O
,movements,NNS,O
,occurred,VBD,O
,in,IN,O
,50,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,;,:,O
,30,CD,O
,%,NN,O
,experienced,JJ,O
,respiratory,NN,B-DISEASE
,upset,NN,I-DISEASE
,",",",",O
,one,CD,O
,sufficiently,RB,O
,severe,JJ,O
,to,TO,O
,necessitate,VB,O
,abandoning,VBG,O
,the,DT,O
,technique,NN,O
,.,.,O
,Nausea,NN,B-DISEASE
,and,CC,O
,vomiting,NN,B-DISEASE
,occurred,VBD,O
,in,IN,O
,40,CD,O
,%,NN,O
,and,CC,O
,25,CD,O
,%,NN,O
,had,VBD,O
,disturbing,JJ,O
,emergence,NN,O
,psychoses,NNS,B-DISEASE
,.,.,O
,Levodopa,NNP,O
,-,:,O
,induced,JJ,O
,dyskinesias,NNS,B-DISEASE
,are,VBP,O
,improved,VBN,O
,by,IN,O
,fluoxetine,NN,O
,.,.,O
,We,PRP,O
,evaluated,VBD,O
,the,DT,O
,severity,NN,O
,of,IN,O
,motor,NN,B-DISEASE
,disability,NN,I-DISEASE
,and,CC,O
,dyskinesias,NN,B-DISEASE
,in,IN,O
,seven,CD,O
,levodopa,SYM,O
,-,:,O
,responsive,JJ,O
,patients,NNS,O
,with,IN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,NN,I-DISEASE
,disease,NN,I-DISEASE
,after,IN,O
,an,DT,O
,acute,JJ,O
,challenge,NN,O
,with,IN,O
,the,DT,O
,mixed,JJ,O
,dopamine,NN,O
,agonist,NN,O
,",",",",O
,apomorphine,NN,O
,",",",",O
,before,IN,O
,and,CC,O
,after,IN,O
,the,DT,O
,administration,NN,O
,of,IN,O
,fluoxetine,NN,O
,(,(,O
,20,CD,O
,mg,NN,O
,twice,RB,O
,per,IN,O
,day,NN,O
,),),O
,for,IN,O
,11,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,1,CD,O
,days,NNS,O
,.,.,O
,After,IN,O
,fluoxetine,JJ,O
,treatment,NN,O
,",",",",O
,there,EX,O
,was,VBD,O
,a,DT,O
,significant,JJ,O
,47,CD,O
,%,NN,O
,improvement,NN,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,of,IN,O
,apomorphine,NN,O
,-,:,O
,induced,JJ,O
,dyskinesias,NN,B-DISEASE
,without,IN,O
,modification,NN,O
,of,IN,O
,parkinsonian,JJ,B-DISEASE
,motor,NN,B-DISEASE
,disability,NN,I-DISEASE
,.,.,O
,The,DT,O
,dyskinesias,NN,B-DISEASE
,were,VBD,O
,reduced,VBN,O
,predominantly,RB,O
,in,IN,O
,the,DT,O
,lower,JJR,O
,limbs,NN,O
,during,IN,O
,the,DT,O
,onset,NN,O
,and,CC,O
,disappearance,NN,O
,of,IN,O
,dystonic,JJ,B-DISEASE
,dyskinesias,NN,I-DISEASE
,(,(,O
,onset,VBN,O
,-,:,O
,and,CC,O
,end,VB,O
,-,:,O
,of,IN,O
,-,:,O
,dose,JJ,O
,dyskinesias,NN,B-DISEASE
,),),O
,and,CC,O
,in,IN,O
,the,DT,O
,upper,JJ,O
,limbs,NN,O
,during,IN,O
,choreic,NN,B-DISEASE
,mid,SYM,I-DISEASE
,-,:,I-DISEASE
,dose,NN,I-DISEASE
,dyskinesias,NN,I-DISEASE
,.,.,O
,The,DT,O
,results,NNS,O
,suggest,VBP,O
,that,IN,O
,increased,VBD,O
,brain,NN,O
,serotoninergic,JJ,O
,transmission,NN,O
,with,IN,O
,fluoxetine,NN,O
,may,MD,O
,reduce,VB,O
,levodopa,SYM,O
,-,:,O
,or,CC,O
,dopamine,VB,O
,agonist,JJ,O
,-,:,O
,induced,JJ,O
,dyskinesias,NN,B-DISEASE
,without,IN,O
,aggravating,VBG,O
,parkinsonian,JJ,B-DISEASE
,motor,NN,B-DISEASE
,disability,NN,I-DISEASE
,.,.,O
,A,DT,O
,large,JJ,O
,population,NN,O
,-,:,O
,based,VBN,O
,follow,SYM,O
,-,:,O
,up,IN,O
,study,NN,O
,of,IN,O
,trimethoprim,JJ,O
,-,:,O
,sulfamethoxazole,NN,O
,",",",",O
,trimethoprim,NN,O
,",",",",O
,and,CC,O
,cephalexin,NN,O
,for,IN,O
,uncommon,JJ,O
,serious,JJ,O
,drug,NN,B-DISEASE
,toxicity,NN,I-DISEASE
,.,.,O
,We,PRP,O
,conducted,VBD,O
,a,DT,O
,population,NN,O
,-,:,O
,based,VBN,O
,45,CD,O
,-,:,O
,day,NN,O
,follow,VB,O
,-,:,O
,up,IN,O
,study,NN,O
,of,IN,O
,232,CD,O
,",",",",O
,390,CD,O
,people,NNS,O
,who,WP,O
,were,VBD,O
,prescribed,VBN,O
,trimethoprim,JJ,O
,-,:,O
,sulfamethoxazole,NN,O
,(,(,O
,TMP,NNP,O
,-,:,O
,SMZ,NN,O
,),),O
,",",",",O
,266,CD,O
,",",",",O
,951,CD,O
,prescribed,JJ,O
,trimethoprim,JJ,O
,alone,RB,O
,",",",",O
,and,CC,O
,196,CD,O
,",",",",O
,397,CD,O
,prescribed,JJ,O
,cephalexin,NN,O
,",",",",O
,to,TO,O
,estimate,VB,O
,the,DT,O
,risk,NN,O
,of,IN,O
,serious,JJ,O
,liver,NN,B-DISEASE
,",",",",I-DISEASE
,blood,NN,I-DISEASE
,",",",",I-DISEASE
,skin,NN,I-DISEASE
,",",",",I-DISEASE
,and,CC,I-DISEASE
,renal,JJ,I-DISEASE
,disorders,NNS,I-DISEASE
,resulting,VBG,O
,in,IN,O
,referral,JJ,O
,or,CC,O
,hospitalization,NN,O
,associated,VBN,O
,with,IN,O
,these,DT,O
,drugs,NNS,O
,.,.,O
,The,DT,O
,results,NNS,O
,were,VBD,O
,based,VBN,O
,on,IN,O
,information,NN,O
,recorded,VBN,O
,on,IN,O
,office,NN,O
,computers,NNS,O
,by,IN,O
,selected,VBN,O
,general,JJ,O
,practitioners,NNS,O
,in,IN,O
,the,DT,O
,United,NNP,O
,Kingdom,NNP,O
,",",",",O
,together,RB,O
,with,IN,O
,a,DT,O
,review,NN,O
,of,IN,O
,clinical,JJ,O
,records,NNS,O
,.,.,O
,The,DT,O
,risk,NN,O
,of,IN,O
,clinically,RB,O
,important,JJ,O
,idiopathic,JJ,O
,liver,NN,B-DISEASE
,disease,NN,I-DISEASE
,was,VBD,O
,similar,JJ,O
,for,IN,O
,persons,NNS,O
,prescribed,VBN,O
,TMP,NNP,O
,-,:,O
,SMZ,NNP,O
,(,(,O
,5,CD,O
,.,.,O
,2,CD,O
,/,JJ,O
,100,CD,O
,",",",",O
,000,CD,O
,),),O
,and,CC,O
,those,DT,O
,prescribed,JJ,O
,trimethoprim,JJ,O
,alone,RB,O
,(,(,O
,3,CD,O
,.,.,O
,8,CD,O
,/,JJ,O
,100,CD,O
,",",",",O
,000,CD,O
,),),O
,.,.,O
,The,DT,O
,risk,NN,O
,for,IN,O
,those,DT,O
,prescribed,JJ,O
,cephalexin,NN,O
,was,VBD,O
,somewhat,RB,O
,lower,JJR,O
,(,(,O
,2,CD,O
,.,.,O
,0,CD,O
,/,JJ,O
,100,CD,O
,",",",",O
,000,CD,O
,),),O
,.,.,O
,Only,RB,O
,five,CD,O
,patients,NNS,O
,experienced,VBD,O
,blood,NN,O
,disorders,NNS,O
,",",",",O
,one,CD,O
,of,IN,O
,whom,WP,O
,was,VBD,O
,exposed,VBN,O
,to,TO,O
,TMP,NNP,O
,-,:,O
,SMZ,NNP,O
,;,:,O
,of,IN,O
,seven,CD,O
,with,IN,O
,erythema,JJ,B-DISEASE
,multiforme,NN,I-DISEASE
,and,CC,O
,Stevens,NNP,B-DISEASE
,-,:,I-DISEASE
,Johnson,NNP,I-DISEASE
,syndrome,NN,I-DISEASE
,",",",",O
,four,CD,O
,were,VBD,O
,exposed,VBN,O
,to,TO,O
,TMP,NNP,O
,-,:,O
,SMZ,NN,O
,.,.,O
,The,DT,O
,one,CD,O
,case,NN,O
,of,IN,O
,toxic,NN,B-DISEASE
,epidermal,JJ,I-DISEASE
,necrolysis,NN,I-DISEASE
,occurred,VBD,O
,in,IN,O
,a,DT,O
,patient,NN,O
,who,WP,O
,took,VBD,O
,cephalexin,NN,O
,.,.,O
,Finally,RB,O
,",",",",O
,only,RB,O
,five,CD,O
,cases,NNS,O
,of,IN,O
,acute,JJ,O
,parenchymal,JJ,O
,renal,JJ,B-DISEASE
,disease,NN,I-DISEASE
,occurred,VBD,O
,",",",",O
,none,NN,O
,likely,JJ,O
,to,TO,O
,be,VB,O
,caused,VBN,O
,by,IN,O
,a,DT,O
,study,NN,O
,drug,NN,O
,.,.,O
,We,PRP,O
,conclude,VBP,O
,that,IN,O
,the,DT,O
,risk,NN,O
,of,IN,O
,the,DT,O
,serious,JJ,O
,diseases,NNS,O
,studied,VBN,O
,is,VBZ,O
,small,JJ,O
,for,IN,O
,the,DT,O
,three,CD,O
,agents,NNS,O
,",",",",O
,and,CC,O
,compares,VBZ,O
,reasonably,RB,O
,with,IN,O
,the,DT,O
,risk,NN,O
,for,IN,O
,many,JJ,O
,other,JJ,O
,antibiotics,NNS,O
,.,.,O
,Clinical,JJ,O
,safety,NN,O
,of,IN,O
,lidocaine,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,cocaine,JJ,O
,-,:,O
,associated,VBN,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,.,.,O
,STUDY,NNP,O
,OBJECTIVE,NNP,O
,:,:,O
,To,TO,O
,evaluate,VB,O
,the,DT,O
,safety,NN,O
,of,IN,O
,lidocaine,NN,O
,in,IN,O
,the,DT,O
,setting,NN,O
,of,IN,O
,cocaine,NN,O
,-,:,O
,induced,JJ,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,(,(,O
,MI,NNP,B-DISEASE
,),),O
,.,.,O
,DESIGN,NN,O
,:,:,O
,A,DT,O
,retrospective,NN,O
,",",",",O
,multicenter,NN,O
,study,NN,O
,.,.,O
,SETTING,NN,O
,:,:,O
,Twenty,NNP,O
,-,:,O
,nine,CD,O
,university,NN,O
,",",",",O
,university,NN,O
,-,:,O
,affiliated,JJ,O
,",",",",O
,or,CC,O
,community,NN,O
,hospitals,NNS,O
,during,IN,O
,a,DT,O
,6,CD,O
,-,:,O
,year,NN,O
,period,NN,O
,(,(,O
,total,JJ,O
,of,IN,O
,117,CD,O
,cumulative,JJ,O
,hospital,NN,O
,-,:,O
,years,NNS,O
,),),O
,.,.,O
,PARTICIPANTS,NNS,O
,:,:,O
,Patients,NNS,O
,with,IN,O
,cocaine,JJ,O
,-,:,O
,associated,VBN,O
,MI,NNP,B-DISEASE
,who,WP,O
,received,VBD,O
,lidocaine,NN,O
,in,IN,O
,the,DT,O
,emergency,NN,O
,department,NN,O
,.,.,O
,RESULTS,NNP,O
,:,:,O
,Of,IN,O
,29,CD,O
,patients,NNS,O
,who,WP,O
,received,VBD,O
,lidocaine,NN,O
,in,IN,O
,the,DT,O
,setting,NN,O
,of,IN,O
,cocaine,NN,O
,-,:,O
,associated,VBN,O
,MI,NNP,B-DISEASE
,",",",",O
,no,DT,O
,patient,NN,O
,died,VBD,O
,;,:,O
,exhibited,VBN,O
,bradydysrhythmias,NN,B-DISEASE
,",",",",O
,ventricular,JJ,B-DISEASE
,tachycardia,NN,I-DISEASE
,",",",",O
,or,CC,O
,ventricular,JJ,B-DISEASE
,fibrillation,NN,I-DISEASE
,;,:,O
,or,CC,O
,experienced,VBD,O
,seizures,NNS,B-DISEASE
,after,IN,O
,administration,NN,O
,of,IN,O
,lidocaine,NN,O
,(,(,O
,95,CD,O
,%,NN,O
,confidence,NN,O
,interval,NN,O
,",",",",O
,0,CD,O
,%,NN,O
,to,TO,O
,11,CD,O
,%,NN,O
,),),O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Despite,IN,O
,theoretical,JJ,O
,concerns,NNS,O
,that,IN,O
,lidocaine,NN,O
,may,MD,O
,enhance,VB,O
,cocaine,NN,O
,toxicity,NN,B-DISEASE
,",",",",O
,the,DT,O
,use,NN,O
,of,IN,O
,lidocaine,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,cocaine,JJ,O
,-,:,O
,associated,VBN,O
,MI,NNP,B-DISEASE
,was,VBD,O
,not,RB,O
,associated,VBN,O
,with,IN,O
,significant,JJ,O
,cardiovascular,NN,B-DISEASE
,or,CC,I-DISEASE
,central,JJ,I-DISEASE
,nervous,JJ,I-DISEASE
,system,NN,I-DISEASE
,toxicity,NN,I-DISEASE
,.,.,O
,Experimental,JJ,O
,progressive,JJ,O
,muscular,NN,B-DISEASE
,dystrophy,NN,I-DISEASE
,and,CC,O
,its,PRP$,O
,treatment,NN,O
,with,IN,O
,high,JJ,O
,doses,NNS,O
,anabolizing,VBG,O
,agents,NNS,O
,.,.,O
,We,PRP,O
,are,VBP,O
,still,RB,O
,a,DT,O
,long,JJ,O
,way,NN,O
,from,IN,O
,discovering,VBG,O
,an,DT,O
,unequivocal,JJ,O
,pathogenetic,JJ,O
,interpretation,NN,O
,of,IN,O
,progressive,JJ,O
,muscular,JJ,B-DISEASE
,dystrophy,NN,I-DISEASE
,in,IN,O
,man,NN,O
,.,.,O
,Noteworthy,JJ,O
,efforts,NNS,O
,have,VBP,O
,been,VBN,O
,made,VBN,O
,in,IN,O
,the,DT,O
,experimental,JJ,O
,field,NN,O
,;,:,O
,a,DT,O
,recessive,JJ,O
,autosomic,JJ,O
,form,NN,O
,found,VBN,O
,in,IN,O
,the,DT,O
,mouse,NN,O
,seems,VBZ,O
,to,TO,O
,bear,VB,O
,the,DT,O
,closest,JJS,O
,resemblance,NN,O
,to,TO,O
,the,DT,O
,human,JJ,O
,form,NN,O
,from,IN,O
,the,DT,O
,genetic,JJ,O
,point,NN,O
,of,IN,O
,view,NN,O
,.,.,O
,Myopathy,NNP,B-DISEASE
,due,JJ,O
,to,TO,O
,lack,VB,O
,of,IN,O
,vitamin,NN,O
,E,NNP,O
,and,CC,O
,myopathy,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,certain,JJ,O
,viruses,NNS,O
,have,VBP,O
,much,JJ,O
,in,IN,O
,common,JJ,O
,anatomically,RB,O
,and,CC,O
,pathologically,RB,O
,with,IN,O
,the,DT,O
,human,JJ,O
,form,NN,O
,.,.,O
,The,DT,O
,authors,NNS,O
,induced,VBD,O
,myodystrophy,NN,B-DISEASE
,in,IN,O
,the,DT,O
,rat,NN,O
,by,IN,O
,giving,VBG,O
,it,PRP,O
,a,DT,O
,diet,JJ,O
,lacking,NN,O
,in,IN,O
,vitamin,NN,O
,E,NNP,O
,.,.,O
,The,DT,O
,pharmacological,JJ,O
,characteristics,NNS,O
,of,IN,O
,vitamin,NN,O
,E,NNP,O
,and,CC,O
,the,DT,O
,degenerative,JJ,O
,changes,NNS,O
,brought,VBN,O
,about,RB,O
,by,IN,O
,its,PRP$,O
,deficiency,NN,O
,",",",",O
,especially,RB,O
,in,IN,O
,the,DT,O
,muscles,NNS,O
,",",",",O
,are,VBP,O
,illustrated,VBN,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,thus,RB,O
,confirmed,VBN,O
,that,IN,O
,the,DT,O
,histological,JJ,O
,characteristics,NNS,O
,of,IN,O
,myopathic,JJ,B-DISEASE
,rat,NN,O
,muscle,NN,O
,induced,VBN,O
,experimentally,RB,O
,are,VBP,O
,extraordinarily,RB,O
,similar,JJ,O
,to,TO,O
,those,DT,O
,of,IN,O
,human,JJ,O
,myopathy,NN,B-DISEASE
,as,IN,O
,confirmed,VBN,O
,during,IN,O
,biopsies,NNS,O
,performed,VBN,O
,at,IN,O
,the,DT,O
,Orthopaedic,NNP,O
,Traumatological,NNP,O
,Centre,NNP,O
,",",",",O
,Florence,NNP,O
,.,.,O
,The,DT,O
,encouraging,JJ,O
,results,NNS,O
,obtained,VBN,O
,in,IN,O
,various,JJ,O
,authoratative,JJ,O
,departments,NNS,O
,in,IN,O
,myopathic,JJ,B-DISEASE
,patients,NNS,O
,by,IN,O
,using,VBG,O
,anabolizing,VBG,O
,steroids,NNS,O
,have,VBP,O
,encouraged,VBN,O
,the,DT,O
,authors,NNS,O
,to,TO,O
,investigate,VB,O
,the,DT,O
,beneficial,JJ,O
,effects,NNS,O
,of,IN,O
,one,CD,O
,anabolizing,VBG,O
,agent,NN,O
,(,(,O
,Dianabol,NNP,O
,",",",",O
,CIBA,NNP,O
,),),O
,at,IN,O
,high,JJ,O
,doses,NNS,O
,in,IN,O
,rats,NNS,O
,rendered,VBN,O
,myopathic,JJ,B-DISEASE
,by,IN,O
,a,DT,O
,diet,JJ,O
,deficient,NN,O
,in,IN,O
,vitamin,NN,O
,E,NNP,O
,.,.,O
,In,IN,O
,this,DT,O
,way,NN,O
,they,PRP,O
,obtained,VBD,O
,appreciable,JJ,O
,changes,NNS,O
,in,IN,O
,body,NN,O
,weight,NN,O
,(,(,O
,increased,VBN,O
,from,IN,O
,50,CD,O
,to,TO,O
,70,CD,O
,g,NNS,O
,after,IN,O
,forty,JJ,O
,days,NNS,O
,at,IN,O
,a,DT,O
,dose,NN,O
,of,IN,O
,5,CD,O
,mg,NNS,O
,per,IN,O
,day,NN,O
,of,IN,O
,anabolizing,VBG,O
,agent,NN,O
,),),O
,",",",",O
,but,CC,O
,most,JJS,O
,of,IN,O
,all,DT,O
,they,PRP,O
,found,VBD,O
,histological,JJ,O
,changes,NNS,O
,due,JJ,O
,to,TO,O
,"""",VB,O
,regenerative,JJ,O
,"""",NN,O
,changes,NNS,O
,in,IN,O
,the,DT,O
,muscle,NN,O
,tissue,NN,O
,",",",",O
,which,WDT,O
,however,RB,O
,maintained,VBD,O
,its,PRP$,O
,myopathic,JJ,B-DISEASE
,characteristics,NNS,O
,in,IN,O
,the,DT,O
,control,NN,O
,animals,NNS,O
,that,WDT,O
,were,VBD,O
,not,RB,O
,treated,VBN,O
,with,IN,O
,the,DT,O
,anabolizing,VBG,O
,agent,NN,O
,.,.,O
,The,DT,O
,authors,NNS,O
,conclude,VBP,O
,by,IN,O
,affirming,VBG,O
,the,DT,O
,undoubted,JJ,O
,efficacy,NN,O
,of,IN,O
,the,DT,O
,anabolizing,VBG,O
,steroids,NNS,O
,in,IN,O
,experimental,JJ,O
,myopathic,JJ,B-DISEASE
,disease,NN,I-DISEASE
,",",",",O
,but,CC,O
,they,PRP,O
,have,VBP,O
,reservations,NNS,O
,as,IN,O
,to,TO,O
,the,DT,O
,transfer,NN,O
,of,IN,O
,the,DT,O
,results,NNS,O
,into,IN,O
,the,DT,O
,human,JJ,O
,field,NN,O
,",",",",O
,where,WRB,O
,high,JJ,O
,dosage,NN,O
,cannot,NN,O
,be,VB,O
,carried,VBN,O
,out,RP,O
,continuously,RB,O
,because,IN,O
,of,IN,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,the,DT,O
,drug,NN,O
,on,IN,O
,virility,NN,O
,;,:,O
,because,IN,O
,the,DT,O
,tissue,NN,O
,injury,NN,O
,too,RB,O
,often,RB,O
,occurs,VBZ,O
,at,IN,O
,an,DT,O
,irreversible,JJ,O
,stage,NN,O
,vis,FW,O
,-,:,O
,a,DT,O
,-,:,O
,vis,NN,O
,the,DT,O
,"""",NNP,O
,regeneration,NN,O
,"""",NN,O
,of,IN,O
,the,DT,O
,muscle,NN,O
,tissue,NN,O
,;,:,O
,and,CC,O
,finally,RB,O
,because,IN,O
,the,DT,O
,dystrophic,JJ,O
,injurious,JJ,O
,agent,NN,O
,is,VBZ,O
,certainly,RB,O
,not,RB,O
,the,DT,O
,lack,NN,O
,of,IN,O
,vitamin,NN,O
,E,NNP,O
,but,CC,O
,something,NN,O
,as,IN,O
,yet,RB,O
,unknown,JJ,O
,.,.,O
,Paclitaxel,VB,O
,3,CD,O
,-,:,O
,hour,NN,O
,infusion,NN,O
,given,VBN,O
,alone,RB,O
,and,CC,O
,combined,VBN,O
,with,IN,O
,carboplatin,NN,O
,:,:,O
,preliminary,JJ,O
,results,NNS,O
,of,IN,O
,dose,JJ,O
,-,:,O
,escalation,NN,O
,trials,NNS,O
,.,.,O
,Paclitaxel,NNP,O
,(,(,O
,Taxol,NNP,O
,;,:,O
,Bristol,NNP,O
,-,:,O
,Myers,NNS,O
,Squibb,NNP,O
,Company,NNP,O
,",",",",O
,Princeton,NNP,O
,",",",",O
,NJ,NNP,O
,),),O
,by,IN,O
,3,CD,O
,-,:,O
,hour,NN,O
,infusion,NN,O
,was,VBD,O
,combined,VBN,O
,with,IN,O
,carboplatin,NN,O
,in,IN,O
,a,DT,O
,phase,NN,O
,I,PRP,O
,/,VBP,O
,II,NNP,O
,study,NN,O
,directed,VBD,O
,to,TO,O
,patients,NNS,O
,with,IN,O
,non,JJ,B-DISEASE
,-,:,I-DISEASE
,small,JJ,I-DISEASE
,cell,NN,I-DISEASE
,lung,NN,I-DISEASE
,cancer,NN,I-DISEASE
,.,.,O
,Carboplatin,NNP,O
,was,VBD,O
,given,VBN,O
,at,IN,O
,a,DT,O
,fixed,JJ,O
,target,NN,O
,area,NN,O
,under,IN,O
,the,DT,O
,concentration,NN,O
,-,:,O
,time,NN,O
,curve,NN,O
,of,IN,O
,6,CD,O
,.,.,O
,0,CD,O
,by,IN,O
,the,DT,O
,Calvert,NNP,O
,formula,NN,O
,",",",",O
,whereas,WP,O
,paclitaxel,NN,O
,was,VBD,O
,escalated,VBN,O
,in,IN,O
,patient,JJ,O
,cohorts,NNS,O
,from,IN,O
,150,CD,O
,mg,NNS,O
,/,JJ,O
,m2,NN,O
,(,(,O
,dose,JJ,O
,level,NN,O
,I,PRP,O
,),),O
,to,TO,O
,175,CD,O
,",",",",O
,200,CD,O
,",",",",O
,225,CD,O
,",",",",O
,and,CC,O
,250,CD,O
,mg,NN,O
,/,NNP,O
,m2,NN,O
,.,.,O
,The,DT,O
,225,CD,O
,mg,NN,O
,/,NNP,O
,m2,VBD,O
,level,NN,O
,was,VBD,O
,expanded,VBN,O
,for,IN,O
,the,DT,O
,phase,NN,O
,II,NNP,O
,study,NN,O
,since,IN,O
,the,DT,O
,highest,JJS,O
,level,NN,O
,achieved,VBN,O
,(,(,O
,250,CD,O
,mg,NN,O
,/,NNP,O
,m2,NN,O
,),),O
,required,VBN,O
,modification,NN,O
,because,IN,O
,of,IN,O
,nonhematologic,JJ,O
,toxicities,NNS,B-DISEASE
,(,(,O
,arthralgia,NN,B-DISEASE
,and,CC,O
,sensory,JJ,B-DISEASE
,neuropathy,NN,I-DISEASE
,),),O
,.,.,O
,Therapeutic,JJ,O
,effects,NNS,O
,were,VBD,O
,noted,VBN,O
,at,IN,O
,all,DT,O
,dose,NN,O
,levels,NNS,O
,",",",",O
,with,IN,O
,objective,JJ,O
,responses,NNS,O
,in,IN,O
,17,CD,O
,(,(,O
,two,CD,O
,complete,NN,O
,and,CC,O
,15,CD,O
,partial,JJ,O
,regressions,NNS,O
,),),O
,of,IN,O
,41,CD,O
,previously,RB,O
,untreated,JJ,O
,patients,NNS,O
,.,.,O
,Toxicities,NNS,B-DISEASE
,were,VBD,O
,compared,VBN,O
,with,IN,O
,a,DT,O
,cohort,NN,O
,of,IN,O
,patients,NNS,O
,in,IN,O
,a,DT,O
,phase,NN,O
,I,PRP,O
,trial,NN,O
,of,IN,O
,paclitaxel,NN,O
,alone,RB,O
,at,IN,O
,identical,JJ,O
,dose,NN,O
,levels,NNS,O
,.,.,O
,Carboplatin,NNPS,O
,did,VBD,O
,not,RB,O
,appear,VB,O
,to,TO,O
,add,VB,O
,to,TO,O
,the,DT,O
,hematologic,JJ,B-DISEASE
,toxicities,NNS,I-DISEASE
,observed,VBN,O
,",",",",O
,and,CC,O
,the,DT,O
,paclitaxel,NN,O
,/,NNP,O
,carboplatin,NN,O
,combination,NN,O
,could,MD,O
,be,VB,O
,dosed,VBN,O
,every,DT,O
,3,CD,O
,weeks,NNS,O
,.,.,O
,The,DT,O
,dose,JJ,O
,-,:,O
,dependent,JJ,O
,effect,NN,O
,of,IN,O
,misoprostol,NN,O
,on,IN,O
,indomethacin,JJ,O
,-,:,O
,induced,JJ,O
,renal,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,in,IN,O
,well,RB,O
,compensated,VBN,O
,cirrhosis,NN,B-DISEASE
,.,.,O
,Misoprostol,NNP,O
,(,(,O
,200,CD,O
,micrograms,NNS,O
,),),O
,has,VBZ,O
,been,VBN,O
,shown,VBN,O
,to,TO,O
,acutely,RB,O
,counteract,VB,O
,the,DT,O
,indomethacin,NN,O
,-,:,O
,induced,JJ,O
,renal,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,in,IN,O
,well,RB,O
,compensated,VBN,O
,cirrhotic,JJ,B-DISEASE
,patients,NNS,O
,.,.,O
,The,DT,O
,aim,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,was,VBD,O
,to,TO,O
,determine,VB,O
,if,IN,O
,the,DT,O
,prophylactic,JJ,O
,value,NN,O
,of,IN,O
,misoprostol,NN,O
,was,VBD,O
,dose,JJ,O
,-,:,O
,dependent,NN,O
,.,.,O
,Parameters,NNS,O
,of,IN,O
,renal,JJ,O
,hemodynamics,NNS,O
,and,CC,O
,tubular,JJ,O
,sodium,NN,O
,and,CC,O
,water,NN,O
,handling,NN,O
,were,VBD,O
,assessed,VBN,O
,by,IN,O
,clearance,NN,O
,techniques,NNS,O
,in,IN,O
,26,CD,O
,well,RB,O
,compensated,VBN,O
,cirrhotic,JJ,B-DISEASE
,patients,NNS,O
,before,IN,O
,and,CC,O
,after,IN,O
,an,DT,O
,oral,JJ,O
,combination,NN,O
,of,IN,O
,50,CD,O
,mg,NN,O
,of,IN,O
,indomethacin,NN,O
,and,CC,O
,various,JJ,O
,doses,NNS,O
,of,IN,O
,misoprostol,NN,O
,.,.,O
,The,DT,O
,200,CD,O
,-,:,O
,micrograms,NNS,O
,dose,VBP,O
,was,VBD,O
,able,JJ,O
,to,TO,O
,totally,RB,O
,abolish,VB,O
,the,DT,O
,deleterious,JJ,O
,renal,JJ,O
,effects,NNS,O
,of,IN,O
,indomethacin,NN,O
,",",",",O
,whereas,IN,O
,the,DT,O
,800,CD,O
,-,:,O
,micrograms,NNS,O
,dose,VBP,O
,resulted,VBN,O
,in,IN,O
,significant,JJ,O
,worsening,NN,O
,of,IN,O
,renal,JJ,O
,hemodynamics,NNS,O
,and,CC,O
,sodium,NN,O
,retention,NN,O
,.,.,O
,These,DT,O
,changes,NNS,O
,were,VBD,O
,maximal,JJ,O
,in,IN,O
,the,DT,O
,hour,NN,O
,immediately,RB,O
,after,IN,O
,medications,NNS,O
,and,CC,O
,slowly,RB,O
,returned,VBN,O
,toward,IN,O
,base,NN,O
,-,:,O
,line,NN,O
,levels,NNS,O
,thereafter,RB,O
,.,.,O
,These,DT,O
,results,NNS,O
,suggest,VBP,O
,that,IN,O
,the,DT,O
,renal,JJ,O
,protective,JJ,O
,effects,NNS,O
,of,IN,O
,misoprostol,NN,O
,is,VBZ,O
,dose,JJ,O
,-,:,O
,dependent,NN,O
,.,.,O
,However,RB,O
,",",",",O
,until,IN,O
,this,DT,O
,apparent,JJ,O
,ability,NN,O
,of,IN,O
,200,CD,O
,micrograms,NNS,O
,of,IN,O
,misoprostol,NN,O
,to,TO,O
,prevent,VB,O
,the,DT,O
,adverse,JJ,O
,effects,NNS,O
,of,IN,O
,indomethacin,NN,O
,on,IN,O
,renal,JJ,O
,function,NN,O
,is,VBZ,O
,confirmed,VBN,O
,with,IN,O
,chronic,JJ,O
,frequent,NN,O
,dosing,NN,O
,",",",",O
,it,PRP,O
,would,MD,O
,be,VB,O
,prudent,JJ,O
,to,TO,O
,avoid,VB,O
,nonsteroidal,JJ,O
,anti,SYM,O
,-,:,O
,inflammatory,JJ,O
,therapy,NN,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,cirrhosis,NN,B-DISEASE
,.,.,O
,Increased,VBN,O
,frequency,NN,O
,and,CC,O
,severity,NN,O
,of,IN,O
,angio,JJ,B-DISEASE
,-,:,I-DISEASE
,oedema,NN,I-DISEASE
,related,VBN,O
,to,TO,O
,long,JJ,O
,-,:,O
,term,NN,O
,therapy,NN,O
,with,IN,O
,angiotensin,JJ,O
,-,:,O
,converting,VBG,O
,enzyme,JJ,O
,inhibitor,NN,O
,in,IN,O
,two,CD,O
,patients,NNS,O
,.,.,O
,Adverse,JJ,O
,reactions,NNS,O
,to,TO,O
,drugs,NNS,O
,are,VBP,O
,well,RB,O
,recognized,VBN,O
,as,IN,O
,a,DT,O
,cause,NN,O
,of,IN,O
,acute,NN,O
,or,CC,O
,chronic,JJ,O
,urticaria,NNS,B-DISEASE
,",",",",O
,and,CC,O
,angio,SYM,B-DISEASE
,-,:,I-DISEASE
,oedema,NN,I-DISEASE
,.,.,O
,Angiotensin,NNP,O
,-,:,O
,converting,VBG,O
,enzyme,NN,O
,(,(,O
,ACE,NNP,O
,),),O
,inhibitors,NNS,O
,",",",",O
,used,VBD,O
,to,TO,O
,treat,VB,O
,hypertension,NN,B-DISEASE
,and,CC,O
,congestive,JJ,B-DISEASE
,heart,NN,I-DISEASE
,failure,NN,I-DISEASE
,",",",",O
,were,VBD,O
,introduced,VBN,O
,in,IN,O
,Europe,NNP,O
,in,IN,O
,the,DT,O
,middle,NN,O
,of,IN,O
,the,DT,O
,eighties,NNS,O
,",",",",O
,and,CC,O
,the,DT,O
,use,NN,O
,of,IN,O
,these,DT,O
,drugs,NNS,O
,has,VBZ,O
,increased,VBN,O
,progressively,RB,O
,.,.,O
,Soon,NN,O
,after,IN,O
,the,DT,O
,introduction,NN,O
,of,IN,O
,ACE,NNP,O
,inhibitors,NNS,O
,",",",",O
,acute,JJ,O
,bouts,NNS,O
,of,IN,O
,angio,JJ,B-DISEASE
,-,:,I-DISEASE
,oedema,NN,I-DISEASE
,were,VBD,O
,reported,VBN,O
,in,IN,O
,association,NN,O
,with,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,these,DT,O
,drugs,NNS,O
,.,.,O
,We,PRP,O
,wish,VBP,O
,to,TO,O
,draw,VB,O
,attention,NN,O
,to,TO,O
,the,DT,O
,possibility,NN,O
,of,IN,O
,adverse,JJ,O
,reactions,NNS,O
,to,TO,O
,ACE,NNP,O
,inhibitors,NNS,O
,after,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,use,NN,O
,and,CC,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,pre,JJ,O
,-,:,O
,existing,VBG,O
,angio,SYM,B-DISEASE
,-,:,I-DISEASE
,oedema,NN,I-DISEASE
,.,.,O
,Myoclonus,NNP,B-DISEASE
,associated,VBD,O
,with,IN,O
,lorazepam,JJ,O
,therapy,NN,O
,in,IN,O
,very,RB,O
,-,:,O
,low,JJ,O
,-,:,O
,birth,NN,O
,-,:,O
,weight,NN,O
,infants,NNS,O
,.,.,O
,Lorazepam,NNP,O
,is,VBZ,O
,being,VBG,O
,used,VBN,O
,with,IN,O
,increasing,VBG,O
,frequency,NN,O
,as,IN,O
,a,DT,O
,sedative,NN,O
,in,IN,O
,the,DT,O
,newborn,NN,O
,and,CC,O
,the,DT,O
,young,JJ,O
,infant,NN,O
,.,.,O
,Concern,NNP,O
,has,VBZ,O
,been,VBN,O
,raised,VBN,O
,with,IN,O
,regard,NN,O
,to,TO,O
,the,DT,O
,safety,NN,O
,of,IN,O
,lorazepam,NN,O
,in,IN,O
,this,DT,O
,age,NN,O
,group,NN,O
,",",",",O
,especially,RB,O
,in,IN,O
,very,RB,O
,-,:,O
,low,JJ,O
,-,:,O
,birth,NN,O
,-,:,O
,weight,NN,O
,(,(,O
,VLBW,NNP,O
,;,:,O
,<,VBZ,O
,1,CD,O
,",",",",O
,500,CD,O
,g,NN,O
,),),O
,infants,NNS,O
,.,.,O
,Three,CD,O
,young,JJ,O
,infants,NNS,O
,",",",",O
,all,DT,O
,of,IN,O
,birth,NN,O
,weight,NN,O
,<,$,O
,1,CD,O
,",",",",O
,500,CD,O
,g,NN,O
,",",",",O
,experienced,VBD,O
,myoclonus,NN,B-DISEASE
,following,VBG,O
,the,DT,O
,intravenous,JJ,O
,administration,NN,O
,of,IN,O
,lorazepam,NN,O
,.,.,O
,The,DT,O
,potential,JJ,O
,neurotoxic,JJ,B-DISEASE
,effects,NNS,O
,of,IN,O
,the,DT,O
,drug,NN,O
,(,(,O
,and,CC,O
,its,PRP$,O
,vehicle,NN,O
,),),O
,in,IN,O
,this,DT,O
,population,NN,O
,are,VBP,O
,discussed,VBN,O
,.,.,O
,Injectable,JJ,O
,lorazepam,NN,O
,should,MD,O
,be,VB,O
,used,VBN,O
,with,IN,O
,caution,NN,O
,in,IN,O
,VLBW,NNP,O
,infants,NNS,O
,.,.,O
,Transvenous,JJ,O
,right,JJ,O
,ventricular,NN,O
,pacing,VBG,O
,during,IN,O
,cardiopulmonary,JJ,O
,resuscitation,NN,O
,of,IN,O
,pediatric,JJ,O
,patients,NNS,O
,with,IN,O
,acute,JJ,O
,cardiomyopathy,NN,B-DISEASE
,.,.,O
,We,PRP,O
,describe,VBP,O
,the,DT,O
,cardiopulmonary,JJ,O
,resuscitation,NN,O
,efforts,NNS,O
,on,IN,O
,five,CD,O
,patients,NNS,O
,who,WP,O
,presented,VBD,O
,in,IN,O
,acute,JJ,O
,circulatory,JJ,B-DISEASE
,failure,NN,I-DISEASE
,from,IN,O
,myocardial,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,.,.,O
,Three,CD,O
,patients,NNS,O
,had,VBD,O
,acute,JJ,O
,viral,JJ,O
,myocarditis,NN,B-DISEASE
,",",",",O
,one,CD,O
,had,VBD,O
,a,DT,O
,carbamazepine,JJ,O
,-,:,O
,induced,JJ,O
,acute,JJ,O
,eosinophilic,JJ,B-DISEASE
,myocarditis,NN,I-DISEASE
,",",",",O
,and,CC,O
,one,CD,O
,had,VBD,O
,cardiac,VBN,O
,hemosiderosis,NN,O
,resulting,VBG,O
,in,IN,O
,acute,NN,O
,cardiogenic,NN,B-DISEASE
,shock,NN,I-DISEASE
,.,.,O
,All,DT,O
,patients,NNS,O
,were,VBD,O
,continuously,RB,O
,monitored,VBN,O
,with,IN,O
,central,JJ,O
,venous,JJ,O
,and,CC,O
,arterial,JJ,O
,catheters,NNS,O
,in,IN,O
,addition,NN,O
,to,TO,O
,routine,VB,O
,noninvasive,JJ,O
,monitoring,NN,O
,.,.,O
,An,DT,O
,introducer,JJ,O
,sheath,NN,O
,",",",",O
,a,DT,O
,pacemaker,NN,O
,",",",",O
,and,CC,O
,sterile,JJ,O
,pacing,NN,O
,wires,NNS,O
,were,VBD,O
,made,VBN,O
,readily,RB,O
,available,JJ,O
,for,IN,O
,the,DT,O
,patients,NNS,O
,",",",",O
,should,MD,O
,the,DT,O
,need,NN,O
,arise,NN,O
,to,TO,O
,terminate,VB,O
,resistant,JJ,O
,cardiac,JJ,O
,dysrhythmias,NN,B-DISEASE
,.,.,O
,All,DT,O
,patients,NNS,O
,developed,VBD,O
,cardiocirculatory,JJ,O
,arrest,RB,O
,associated,VBN,O
,with,IN,O
,extreme,JJ,O
,hypotension,NN,B-DISEASE
,and,CC,O
,dysrhythmias,NN,B-DISEASE
,within,IN,O
,the,DT,O
,first,JJ,O
,48,CD,O
,hours,NNS,O
,of,IN,O
,their,PRP$,O
,admission,NN,O
,to,TO,O
,the,DT,O
,pediatric,JJ,O
,intensive,JJ,O
,care,NN,O
,unit,NN,O
,(,(,O
,PICU,NNP,O
,),),O
,.,.,O
,Right,JJ,O
,ventricular,JJ,O
,pacemaker,NN,O
,wires,NNS,O
,were,VBD,O
,inserted,VBN,O
,in,IN,O
,all,DT,O
,of,IN,O
,them,PRP,O
,during,IN,O
,cardiopulmonary,JJ,O
,resuscitation,NN,O
,(,(,O
,CPR,NNP,O
,),),O
,.,.,O
,In,IN,O
,four,CD,O
,patients,NNS,O
,",",",",O
,cardiac,JJ,O
,pacing,NN,O
,was,VBD,O
,used,VBN,O
,",",",",O
,resulting,VBG,O
,in,IN,O
,a,DT,O
,temporary,JJ,O
,captured,JJ,O
,rhythm,NN,O
,and,CC,O
,restoration,NN,O
,of,IN,O
,their,PRP$,O
,cardiac,JJ,O
,output,NN,O
,.,.,O
,These,DT,O
,patients,NNS,O
,had,VBD,O
,a,DT,O
,second,JJ,O
,event,NN,O
,of,IN,O
,cardiac,JJ,B-DISEASE
,arrest,NN,I-DISEASE
,",",",",O
,resulting,VBG,O
,in,IN,O
,death,NN,O
,",",",",O
,within,IN,O
,10,CD,O
,to,TO,O
,60,CD,O
,minutes,NNS,O
,.,.,O
,In,IN,O
,one,CD,O
,patient,NN,O
,",",",",O
,cardiac,JJ,O
,pacing,NN,O
,was,VBD,O
,not,RB,O
,used,VBN,O
,",",",",O
,because,IN,O
,he,PRP,O
,converted,VBD,O
,to,TO,O
,normal,JJ,O
,sinus,NNS,O
,rhythm,VBN,O
,by,IN,O
,electrical,JJ,O
,defibrillation,NN,O
,within,IN,O
,three,CD,O
,minutes,NNS,O
,of,IN,O
,initiating,VBG,O
,CPR,NNP,O
,.,.,O
,We,PRP,O
,conclude,VBP,O
,that,IN,O
,cardiac,JJ,O
,pacing,NN,O
,during,IN,O
,resuscitative,JJ,O
,efforts,NNS,O
,in,IN,O
,pediatric,JJ,O
,patients,NNS,O
,suffering,VBG,O
,from,IN,O
,acute,JJ,O
,myocardial,JJ,B-DISEASE
,dysfunction,NN,I-DISEASE
,may,MD,O
,not,RB,O
,have,VB,O
,long,JJ,O
,-,:,O
,term,NN,O
,value,NN,O
,in,IN,O
,and,CC,O
,of,IN,O
,itself,PRP,O
,;,:,O
,however,RB,O
,",",",",O
,if,IN,O
,temporary,JJ,O
,hemodynamic,JJ,O
,stability,NN,O
,is,VBZ,O
,achieved,VBN,O
,by,IN,O
,this,DT,O
,procedure,NN,O
,",",",",O
,it,PRP,O
,may,MD,O
,provide,VB,O
,additional,JJ,O
,time,NN,O
,needed,VBN,O
,to,TO,O
,institute,VB,O
,other,JJ,O
,therapeutic,JJ,O
,modalities,NNS,O
,.,.,O
,Efficacy,NN,O
,and,CC,O
,safety,NN,O
,of,IN,O
,granisetron,NN,O
,",",",",O
,a,DT,O
,selective,JJ,O
,5,CD,O
,-,:,O
,hydroxytryptamine,NN,O
,-,:,O
,3,CD,O
,receptor,NN,O
,antagonist,NN,O
,",",",",O
,in,IN,O
,the,DT,O
,prevention,NN,O
,of,IN,O
,nausea,NN,B-DISEASE
,and,CC,O
,vomiting,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,high,JJ,O
,-,:,O
,dose,NN,O
,cisplatin,NN,O
,.,.,O
,PURPOSE,NN,O
,:,:,O
,To,TO,O
,assess,VB,O
,the,DT,O
,antiemetic,JJ,O
,effects,NNS,O
,and,CC,O
,safety,NN,O
,profile,NN,O
,of,IN,O
,four,CD,O
,different,JJ,O
,doses,NNS,O
,of,IN,O
,granisetron,NN,O
,(,(,O
,Kytril,NNP,O
,;,:,O
,SmithKline,NNP,O
,Beecham,NNP,O
,Pharmaceuticals,NNP,O
,",",",",O
,Philadelphia,NNP,O
,",",",",O
,PA,NNP,O
,),),O
,when,WRB,O
,administered,VBN,O
,as,IN,O
,a,DT,O
,single,JJ,O
,intravenous,JJ,O
,(,(,O
,IV,NNP,O
,),),O
,dose,NN,O
,for,IN,O
,prophylaxis,NN,O
,of,IN,O
,cisplatin,NN,O
,-,:,O
,induced,JJ,O
,nausea,NN,B-DISEASE
,and,CC,O
,vomiting,NN,B-DISEASE
,.,.,O
,PATIENTS,NNP,O
,AND,CC,O
,METHODS,NNP,O
,:,:,O
,One,CD,O
,hundred,VBD,O
,eighty,SYM,O
,-,:,O
,four,CD,O
,chemotherapy,NN,O
,-,:,O
,naive,JJ,O
,patients,NNS,O
,receiving,VBG,O
,high,JJ,O
,-,:,O
,dose,NN,O
,cisplatin,NN,O
,(,(,O
,81,CD,O
,to,TO,O
,120,CD,O
,mg,NNS,O
,/,NNP,O
,m2,NN,O
,),),O
,were,VBD,O
,randomized,VBN,O
,to,TO,O
,receive,VB,O
,one,CD,O
,of,IN,O
,four,CD,O
,granisetron,NN,O
,doses,NNS,O
,(,(,O
,5,CD,O
,",",",",O
,10,CD,O
,",",",",O
,20,CD,O
,",",",",O
,or,CC,O
,40,CD,O
,micrograms,NNS,O
,/,NNP,O
,kg,NN,O
,),),O
,administered,VBD,O
,before,IN,O
,chemotherapy,NN,O
,.,.,O
,Patients,NNS,O
,were,VBD,O
,observed,VBN,O
,on,IN,O
,an,DT,O
,inpatient,JJ,O
,basis,NN,O
,for,IN,O
,18,CD,O
,to,TO,O
,24,CD,O
,hours,NNS,O
,",",",",O
,and,CC,O
,vital,JJ,O
,signs,NNS,O
,",",",",O
,nausea,NN,B-DISEASE
,",",",",O
,vomiting,VBG,B-DISEASE
,",",",",O
,retching,VBG,O
,",",",",O
,and,CC,O
,appetite,RB,O
,were,VBD,O
,assessed,VBN,O
,.,.,O
,Safety,NN,O
,analyses,NNS,O
,included,VBD,O
,incidence,NN,O
,of,IN,O
,adverse,JJ,O
,experiences,NNS,O
,and,CC,O
,laboratory,NN,O
,parameter,NN,O
,changes,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,After,IN,O
,granisetron,NN,O
,doses,NNS,O
,of,IN,O
,5,CD,O
,",",",",O
,10,CD,O
,",",",",O
,20,CD,O
,",",",",O
,and,CC,O
,40,CD,O
,micrograms,NNS,O
,/,JJ,O
,kg,NN,O
,",",",",O
,a,DT,O
,major,JJ,O
,response,NN,O
,(,(,O
,<,CD,O
,or,CC,O
,=,VB,O
,two,CD,O
,vomiting,VBG,B-DISEASE
,or,CC,O
,retching,VBG,O
,episodes,NNS,O
,",",",",O
,and,CC,O
,no,DT,O
,antiemetic,JJ,O
,rescue,NN,O
,),),O
,was,VBD,O
,recorded,VBN,O
,in,IN,O
,23,CD,O
,%,NN,O
,",",",",O
,57,CD,O
,%,NN,O
,",",",",O
,58,CD,O
,%,NN,O
,",",",",O
,and,CC,O
,60,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,",",",",O
,respectively,RB,O
,",",",",O
,and,CC,O
,a,DT,O
,complete,JJ,O
,response,NN,O
,(,(,O
,no,DT,O
,vomiting,NN,B-DISEASE
,or,CC,O
,retching,NN,O
,",",",",O
,and,CC,O
,no,DT,O
,antiemetic,JJ,O
,rescue,NN,O
,),),O
,in,IN,O
,18,CD,O
,%,NN,O
,",",",",O
,41,CD,O
,%,NN,O
,",",",",O
,40,CD,O
,%,NN,O
,",",",",O
,and,CC,O
,47,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,",",",",O
,respectively,RB,O
,.,.,O
,There,EX,O
,was,VBD,O
,a,DT,O
,statistically,RB,O
,longer,JJR,O
,time,NN,O
,to,TO,O
,first,JJ,O
,episode,NN,O
,of,IN,O
,nausea,NN,B-DISEASE
,(,(,O
,P,NNP,O
,=,NNP,O
,.,.,O
,0015,CD,O
,),),O
,and,CC,O
,vomiting,VBG,B-DISEASE
,(,(,O
,P,NNP,O
,=,NNP,O
,.,.,O
,0001,CD,O
,),),O
,",",",",O
,and,CC,O
,fewer,JJR,O
,patients,NNS,O
,were,VBD,O
,administered,VBN,O
,additional,JJ,O
,antiemetic,JJ,O
,medication,NN,O
,in,IN,O
,the,DT,O
,10,CD,O
,-,:,O
,micrograms,NNS,O
,/,VBP,O
,kg,JJ,O
,dosing,VBG,O
,groups,NNS,O
,than,IN,O
,in,IN,O
,the,DT,O
,5,CD,O
,-,:,O
,micrograms,NNS,O
,/,VBP,O
,kg,JJ,O
,dosing,VBG,O
,group,NN,O
,.,.,O
,As,IN,O
,granisetron,NN,O
,dose,NN,O
,increased,VBD,O
,",",",",O
,appetite,JJ,O
,return,NN,O
,increased,VBN,O
,(,(,O
,P,NNP,O
,=,NNP,O
,.,.,O
,040,CD,O
,),),O
,.,.,O
,Headache,NNP,B-DISEASE
,was,VBD,O
,the,DT,O
,most,RBS,O
,frequently,RB,O
,reported,VBD,O
,adverse,JJ,O
,event,NN,O
,(,(,O
,20,CD,O
,%,NN,O
,),),O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,A,DT,O
,single,JJ,O
,10,CD,O
,-,:,O
,",",",",O
,20,CD,O
,-,:,O
,",",",",O
,or,CC,O
,40,CD,O
,-,:,O
,micrograms,NNS,O
,/,VBP,O
,kg,NNS,O
,dose,NN,O
,of,IN,O
,granisetron,NN,O
,was,VBD,O
,effective,JJ,O
,in,IN,O
,controlling,VBG,O
,vomiting,VBG,B-DISEASE
,in,IN,O
,57,CD,O
,%,NN,O
,to,TO,O
,60,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,who,WP,O
,received,VBD,O
,cisplatin,NN,O
,at,IN,O
,doses,NNS,O
,greater,JJR,O
,than,IN,O
,81,CD,O
,mg,JJ,O
,/,NNP,O
,m2,NN,O
,and,CC,O
,totally,RB,O
,prevented,JJ,O
,vomiting,NN,B-DISEASE
,in,IN,O
,40,CD,O
,%,NN,O
,to,TO,O
,47,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,.,.,O
,There,EX,O
,were,VBD,O
,no,DT,O
,statistically,RB,O
,significant,JJ,O
,differences,NNS,O
,in,IN,O
,efficacy,NN,O
,between,IN,O
,the,DT,O
,10,CD,O
,-,:,O
,micrograms,NNS,O
,/,VBP,O
,kg,NN,O
,dose,NN,O
,and,CC,O
,the,DT,O
,20,CD,O
,-,:,O
,and,CC,O
,40,CD,O
,-,:,O
,micrograms,NNS,O
,/,VBP,O
,kg,JJ,O
,doses,NNS,O
,.,.,O
,Granisetron,NNP,O
,was,VBD,O
,well,RB,O
,tolerated,VBN,O
,at,IN,O
,all,DT,O
,doses,NNS,O
,.,.,O
,Adverse,JJ,O
,interaction,NN,O
,between,IN,O
,clonidine,NN,O
,and,CC,O
,verapamil,NN,O
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,To,TO,O
,report,VB,O
,two,CD,O
,cases,NNS,O
,of,IN,O
,a,DT,O
,possible,JJ,O
,adverse,JJ,O
,interaction,NN,O
,between,IN,O
,clonidine,NN,O
,and,CC,O
,verapamil,NN,O
,resulting,VBG,O
,in,IN,O
,atrioventricular,NN,B-DISEASE
,(,(,I-DISEASE
,AV,NNP,I-DISEASE
,),),I-DISEASE
,block,NN,I-DISEASE
,in,IN,O
,both,DT,O
,patients,NNS,O
,and,CC,O
,severe,JJ,O
,hypotension,NN,B-DISEASE
,in,IN,O
,one,CD,O
,patient,NN,O
,.,.,O
,CASE,JJ,O
,SUMMARIES,NNP,O
,:,:,O
,A,DT,O
,54,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,with,IN,O
,hyperaldosteronism,NN,B-DISEASE
,was,VBD,O
,treated,VBN,O
,with,IN,O
,verapamil,JJ,O
,480,CD,O
,mg,NN,O
,/,NNP,O
,d,NN,O
,and,CC,O
,spironolactone,NN,O
,100,CD,O
,mg,NN,O
,/,NNP,O
,d,NN,O
,.,.,O
,After,IN,O
,the,DT,O
,addition,NN,O
,of,IN,O
,a,DT,O
,minimal,JJ,O
,dose,NN,O
,of,IN,O
,clonidine,NN,O
,(,(,O
,0,CD,O
,.,.,O
,15,CD,O
,mg,JJ,O
,bid,NN,O
,),),O
,",",",",O
,she,PRP,O
,developed,VBD,O
,complete,JJ,O
,AV,NNP,B-DISEASE
,block,NN,I-DISEASE
,and,CC,O
,severe,JJ,O
,hypotension,NN,B-DISEASE
,",",",",O
,which,WDT,O
,resolved,VBD,O
,upon,IN,O
,cessation,NN,O
,of,IN,O
,all,DT,O
,medications,NNS,O
,.,.,O
,A,DT,O
,65,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,was,VBD,O
,treated,VBN,O
,with,IN,O
,extended,VBN,O
,-,:,O
,release,NN,O
,verapamil,VBZ,O
,240,CD,O
,mg,NN,O
,/,NNP,O
,d,NN,O
,.,.,O
,After,IN,O
,the,DT,O
,addition,NN,O
,of,IN,O
,clonidine,NN,O
,0,CD,O
,.,.,O
,15,CD,O
,mg,NN,O
,bid,NN,O
,she,PRP,O
,developed,VBD,O
,complete,JJ,O
,AV,NNP,B-DISEASE
,block,NN,I-DISEASE
,",",",",O
,which,WDT,O
,resolved,VBD,O
,after,IN,O
,all,DT,O
,therapy,NN,O
,was,VBD,O
,stopped,VBN,O
,.,.,O
,DISCUSSION,NNP,O
,:,:,O
,An,DT,O
,adverse,JJ,O
,interaction,NN,O
,between,IN,O
,clonidine,NN,O
,and,CC,O
,verapamil,NN,O
,has,VBZ,O
,not,RB,O
,been,VBN,O
,reported,VBN,O
,previously,RB,O
,.,.,O
,We,PRP,O
,describe,VBP,O
,two,CD,O
,such,JJ,O
,cases,NNS,O
,and,CC,O
,discuss,VB,O
,the,DT,O
,various,JJ,O
,mechanisms,NNS,O
,that,WDT,O
,might,MD,O
,cause,VB,O
,such,JJ,O
,an,DT,O
,interaction,NN,O
,.,.,O
,Clinicians,NNPS,O
,should,MD,O
,be,VB,O
,acquainted,VBN,O
,with,IN,O
,this,DT,O
,possibly,RB,O
,fatal,JJ,O
,interaction,NN,O
,between,IN,O
,two,CD,O
,commonly,RB,O
,used,VBD,O
,antihypertensive,JJ,O
,drugs,NNS,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,Caution,NN,O
,is,VBZ,O
,recommended,VBN,O
,in,IN,O
,combining,VBG,O
,clonidine,NN,O
,and,CC,O
,verapamil,NN,O
,therapy,NN,O
,",",",",O
,even,RB,O
,in,IN,O
,patients,NNS,O
,who,WP,O
,do,VBP,O
,not,RB,O
,have,VB,O
,sinus,NN,O
,or,CC,O
,AV,NNP,O
,node,JJ,O
,dysfunction,NN,O
,.,.,O
,The,DT,O
,two,CD,O
,drugs,NNS,O
,may,MD,O
,act,VB,O
,synergistically,RB,O
,on,IN,O
,both,CC,O
,the,DT,O
,AV,NNP,O
,node,NN,O
,and,CC,O
,the,DT,O
,peripheral,JJ,O
,circulation,NN,O
,.,.,O
,Pharmacological,JJ,O
,studies,NNS,O
,on,IN,O
,a,DT,O
,new,JJ,O
,dihydrothienopyridine,NN,O
,calcium,NN,O
,antagonist,NN,O
,",",",",O
,S,NNP,O
,-,:,O
,312,CD,O
,-,:,O
,d,NN,O
,.,.,O
,5th,CD,O
,communication,NN,O
,:,:,O
,anticonvulsant,JJ,O
,effects,NNS,O
,in,IN,O
,mice,NN,O
,.,.,O
,S,NNP,O
,-,:,O
,312,CD,O
,",",",",O
,S,NNP,O
,-,:,O
,312,CD,O
,-,:,O
,d,NN,O
,",",",",O
,but,CC,O
,not,RB,O
,S,NNP,O
,-,:,O
,312,CD,O
,-,:,O
,l,NN,O
,",",",",O
,L,NNP,O
,-,:,O
,type,NN,O
,calcium,NN,O
,channel,NN,O
,antagonists,NNS,O
,",",",",O
,showed,VBD,O
,anticonvulsant,JJ,O
,effects,NNS,O
,on,IN,O
,the,DT,O
,audiogenic,JJ,B-DISEASE
,tonic,JJ,I-DISEASE
,convulsions,NNS,I-DISEASE
,in,IN,O
,DBA,NNP,O
,/,NNP,O
,2,CD,O
,mice,NN,O
,;,:,O
,and,CC,O
,their,PRP$,O
,ED50,NN,O
,values,NNS,O
,were,VBD,O
,18,CD,O
,.,.,O
,4,CD,O
,(,(,O
,12,CD,O
,.,.,O
,8,CD,O
,-,:,O
,27,CD,O
,.,.,O
,1,CD,O
,),),O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,p,NN,O
,.,.,O
,o,NN,O
,.,.,O
,and,CC,O
,15,CD,O
,.,.,O
,0,CD,O
,(,(,O
,10,CD,O
,.,.,O
,2,CD,O
,-,:,O
,23,CD,O
,.,.,O
,7,CD,O
,),),O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,p,NN,O
,.,.,O
,o,NN,O
,.,.,O
,",",",",O
,respectively,RB,O
,",",",",O
,while,IN,O
,that,DT,O
,of,IN,O
,flunarizine,NN,O
,was,VBD,O
,34,CD,O
,.,.,O
,0,CD,O
,(,(,O
,26,CD,O
,.,.,O
,0,CD,O
,-,:,O
,44,CD,O
,.,.,O
,8,CD,O
,),),O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,p,NN,O
,.,.,O
,o,NN,O
,.,.,O
,Although,IN,O
,moderate,JJ,O
,anticonvulsant,JJ,O
,effects,NNS,O
,of,IN,O
,S,NNP,O
,-,:,O
,312,CD,O
,-,:,O
,d,NN,O
,in,IN,O
,higher,JJR,O
,doses,NNS,O
,were,VBD,O
,observed,VBN,O
,against,IN,O
,the,DT,O
,clonic,JJ,O
,convulsions,NNS,B-DISEASE
,induced,VBN,O
,by,IN,O
,pentylenetetrazole,NN,O
,(,(,O
,85,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,s,NN,O
,.,.,O
,c,NN,O
,.,.,O
,),),O
,or,CC,O
,bemegride,NN,O
,(,(,O
,40,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,s,NN,O
,.,.,O
,c,NN,O
,.,.,O
,),),O
,",",",",O
,no,DT,O
,effects,NNS,O
,were,VBD,O
,observed,VBN,O
,in,IN,O
,convulsions,NNS,B-DISEASE
,induced,VBN,O
,by,IN,O
,N,NNP,O
,-,:,O
,methyl,NN,O
,-,:,O
,D,NNP,O
,-,:,O
,aspartate,NN,O
,",",",",O
,picrotoxin,NN,O
,",",",",O
,or,CC,O
,electroshock,NN,O
,in,IN,O
,Slc,NNP,O
,:,:,O
,ddY,NN,O
,mice,NN,O
,.,.,O
,S,NNP,O
,-,:,O
,312,CD,O
,-,:,O
,d,NN,O
,may,MD,O
,be,VB,O
,useful,JJ,O
,in,IN,O
,the,DT,O
,therapy,NN,O
,of,IN,O
,certain,JJ,O
,types,NNS,O
,of,IN,O
,human,JJ,O
,epilepsy,NN,B-DISEASE
,.,.,O
,Transmural,JJ,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,with,IN,O
,sumatriptan,NN,O
,.,.,O
,For,IN,O
,sumatriptan,NN,O
,",",",",O
,tightness,NN,O
,in,IN,O
,the,DT,O
,chest,NN,O
,caused,VBN,O
,by,IN,O
,an,DT,O
,unknown,JJ,O
,mechanism,NN,O
,has,VBZ,O
,been,VBN,O
,reported,VBN,O
,in,IN,O
,3,CD,O
,-,:,O
,5,CD,O
,%,NN,O
,of,IN,O
,users,NNS,O
,.,.,O
,We,PRP,O
,describe,VBP,O
,a,DT,O
,47,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,with,IN,O
,an,DT,O
,acute,JJ,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,after,IN,O
,administration,NN,O
,of,IN,O
,sumatriptan,JJ,O
,6,CD,O
,mg,NN,O
,subcutaneously,RB,O
,for,IN,O
,cluster,NN,B-DISEASE
,headache,NN,I-DISEASE
,.,.,O
,The,DT,O
,patient,NN,O
,had,VBD,O
,no,DT,O
,history,NN,O
,of,IN,O
,underlying,VBG,O
,ischaemic,JJ,B-DISEASE
,heart,NN,I-DISEASE
,disease,NN,I-DISEASE
,or,CC,O
,Prinzmetal,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,angina,NN,I-DISEASE
,.,.,O
,She,PRP,O
,recovered,VBD,O
,without,IN,O
,complications,NNS,O
,.,.,O
,Flumazenil,NNP,O
,induces,VBZ,O
,seizures,NNS,B-DISEASE
,and,CC,O
,death,NN,O
,in,IN,O
,mixed,JJ,O
,cocaine,NN,O
,-,:,O
,diazepam,NN,O
,intoxications,NNS,O
,.,.,O
,STUDY,NNP,O
,HYPOTHESIS,NNP,O
,:,:,O
,Administration,NN,O
,of,IN,O
,the,DT,O
,benzodiazepine,JJ,O
,antagonist,NN,O
,flumazenil,NN,O
,may,MD,O
,unmask,VB,O
,seizures,NNS,B-DISEASE
,in,IN,O
,mixed,JJ,O
,cocaine,NN,O
,-,:,O
,benzodiazepine,NN,O
,intoxication,NN,O
,.,.,O
,DESIGN,NN,O
,:,:,O
,Male,NNP,O
,Sprague,NNP,O
,-,:,O
,Dawley,NNP,O
,rats,NNS,O
,received,VBD,O
,100,CD,O
,mg,NNS,O
,/,JJ,O
,kg,FW,O
,cocaine,NN,O
,IP,NNP,O
,alone,RB,O
,",",",",O
,5,CD,O
,mg,NN,O
,/,NNP,O
,kg,NNP,O
,diazepam,NN,O
,alone,RB,O
,",",",",O
,or,CC,O
,a,DT,O
,combination,NN,O
,of,IN,O
,diazepam,NN,O
,and,CC,O
,cocaine,NN,O
,.,.,O
,Three,CD,O
,minutes,NNS,O
,later,RB,O
,",",",",O
,groups,NNS,O
,were,VBD,O
,challenged,VBN,O
,with,IN,O
,vehicle,NN,O
,or,CC,O
,flumazenil,VB,O
,5,CD,O
,or,CC,O
,10,CD,O
,mg,NNS,O
,/,JJ,O
,kg,JJ,O
,IP,NNP,O
,.,.,O
,Animal,NNP,O
,behavior,NN,O
,",",",",O
,seizures,NNS,B-DISEASE
,(,(,O
,time,NN,O
,to,TO,O
,and,CC,O
,incidence,NN,O
,),),O
,",",",",O
,death,NN,O
,(,(,O
,time,NN,O
,to,TO,O
,and,CC,O
,incidence,NN,O
,),),O
,",",",",O
,and,CC,O
,cortical,JJ,O
,EEG,NNP,O
,tracings,NNS,O
,were,VBD,O
,recorded,VBN,O
,.,.,O
,INTERVENTIONS,NN,O
,:,:,O
,Administration,NN,O
,of,IN,O
,flumazenil,NN,O
,to,TO,O
,animals,NNS,O
,after,IN,O
,they,PRP,O
,had,VBD,O
,received,VBN,O
,a,DT,O
,combination,NN,O
,dose,NN,O
,of,IN,O
,cocaine,NN,O
,and,CC,O
,diazepam,NN,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,In,IN,O
,group,NN,O
,1,CD,O
,",",",",O
,animals,NNS,O
,received,VBD,O
,cocaine,NN,O
,followed,VBN,O
,by,IN,O
,vehicle,NN,O
,.,.,O
,This,DT,O
,resulted,VBD,O
,in,IN,O
,100,CD,O
,%,NN,O
,developing,VBG,O
,seizures,NNS,B-DISEASE
,and,CC,O
,death,NN,O
,.,.,O
,Group,NNP,O
,2,CD,O
,received,VBD,O
,diazepam,NN,O
,alone,RB,O
,followed,VBN,O
,by,IN,O
,vehicle,NN,O
,.,.,O
,Animals,NNS,O
,became,VBD,O
,somnolent,JJ,O
,and,CC,O
,none,NN,O
,died,VBD,O
,.,.,O
,Group,NNP,O
,3,CD,O
,received,VBD,O
,diazepam,NN,O
,followed,VBN,O
,by,IN,O
,5,CD,O
,mg,NNS,O
,/,JJ,O
,kg,JJ,O
,flumazenil,NN,O
,.,.,O
,Animals,NNS,O
,became,VBD,O
,somnolent,JJ,O
,after,IN,O
,diazepam,NN,O
,and,CC,O
,then,RB,O
,active,JJ,O
,after,IN,O
,flumazenil,JJ,O
,administration,NN,O
,.,.,O
,In,IN,O
,group,NN,O
,4,CD,O
,",",",",O
,a,DT,O
,combination,NN,O
,of,IN,O
,cocaine,NN,O
,and,CC,O
,diazepam,NN,O
,was,VBD,O
,administered,VBN,O
,simultaneously,RB,O
,.,.,O
,This,DT,O
,resulted,VBD,O
,in,IN,O
,no,DT,O
,overt,NN,O
,or,CC,O
,EEG,NNP,O
,-,:,O
,detectable,JJ,O
,seizures,NNS,B-DISEASE
,and,CC,O
,a,DT,O
,50,CD,O
,%,NN,O
,incidence,NN,O
,of,IN,O
,death,NN,O
,.,.,O
,Group,NNP,O
,5,CD,O
,received,VBD,O
,a,DT,O
,similar,JJ,O
,combination,NN,O
,of,IN,O
,cocaine,NN,O
,and,CC,O
,diazepam,NN,O
,",",",",O
,followed,VBD,O
,later,RB,O
,by,IN,O
,5,CD,O
,mg,NNS,O
,/,JJ,O
,kg,JJ,O
,flumazenil,NN,O
,.,.,O
,This,DT,O
,resulted,VBD,O
,in,IN,O
,an,DT,O
,increased,JJ,O
,incidence,NN,O
,of,IN,O
,seizures,NNS,B-DISEASE
,",",",",O
,90,CD,O
,%,NN,O
,(,(,O
,P,NNP,O
,<,NNP,O
,.,.,O
,01,CD,O
,),),O
,",",",",O
,and,CC,O
,death,NN,O
,",",",",O
,100,CD,O
,%,NN,O
,(,(,O
,P,NNP,O
,<,NNP,O
,or,CC,O
,=,NNP,O
,.,.,O
,01,CD,O
,),),O
,",",",",O
,compared,VBN,O
,with,IN,O
,group,NN,O
,4,CD,O
,.,.,O
,Group,NNP,O
,6,CD,O
,received,VBD,O
,cocaine,NN,O
,and,CC,O
,diazepam,NN,O
,followed,VBN,O
,by,IN,O
,10,CD,O
,mg,NNS,O
,/,JJ,O
,kg,JJ,O
,flumazenil,NN,O
,.,.,O
,This,DT,O
,also,RB,O
,resulted,VBN,O
,in,IN,O
,an,DT,O
,increased,JJ,O
,incidence,NN,O
,of,IN,O
,seizures,NNS,B-DISEASE
,",",",",O
,90,CD,O
,%,NN,O
,(,(,O
,P,NNP,O
,<,NNP,O
,or,CC,O
,=,NNP,O
,.,.,O
,01,CD,O
,),),O
,",",",",O
,and,CC,O
,death,NN,O
,",",",",O
,90,CD,O
,%,NN,O
,(,(,O
,P,NNP,O
,<,NNP,O
,or,CC,O
,=,NNP,O
,.,.,O
,05,CD,O
,),),O
,",",",",O
,compared,VBN,O
,with,IN,O
,group,NN,O
,4,CD,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Flumazenil,NN,O
,can,MD,O
,unmask,VB,O
,seizures,NNS,B-DISEASE
,and,CC,O
,increase,VB,O
,the,DT,O
,incidence,NN,O
,of,IN,O
,death,NN,O
,in,IN,O
,a,DT,O
,model,NN,O
,of,IN,O
,combined,JJ,O
,cocaine,NN,O
,-,:,O
,diazepam,NN,O
,intoxications,NNS,O
,.,.,O
,Mechanisms,NNP,O
,for,IN,O
,protective,JJ,O
,effects,NNS,O
,of,IN,O
,free,JJ,O
,radical,JJ,O
,scavengers,NNS,O
,on,IN,O
,gentamicin,NN,O
,-,:,O
,mediated,VBN,O
,nephropathy,JJ,B-DISEASE
,in,IN,O
,rats,NNS,O
,.,.,O
,Studies,NNS,O
,were,VBD,O
,performed,VBN,O
,to,TO,O
,examine,VB,O
,the,DT,O
,mechanisms,NN,O
,for,IN,O
,the,DT,O
,protective,JJ,O
,effects,NNS,O
,of,IN,O
,free,JJ,O
,radical,JJ,O
,scavengers,NNS,O
,on,IN,O
,gentamicin,NN,O
,(,(,O
,GM,NNP,O
,),),O
,-,:,O
,mediated,VBN,O
,nephropathy,JJ,B-DISEASE
,.,.,O
,Administration,NN,O
,of,IN,O
,GM,NNP,O
,at,IN,O
,40,CD,O
,mg,NN,O
,/,NNP,O
,kg,VBZ,O
,sc,NN,O
,for,IN,O
,13,CD,O
,days,NNS,O
,to,TO,O
,rats,VB,O
,induced,VB,O
,a,DT,O
,significant,JJ,O
,reduction,NN,O
,in,IN,O
,renal,JJ,O
,blood,NN,O
,flow,NN,O
,(,(,O
,RBF,NNP,O
,),),O
,and,CC,O
,inulin,JJ,O
,clearance,NN,O
,(,(,O
,CIn,NNP,O
,),),O
,as,RB,O
,well,RB,O
,as,IN,O
,marked,VBN,O
,tubular,JJ,B-DISEASE
,damage,NN,I-DISEASE
,.,.,O
,A,DT,O
,significant,JJ,O
,reduction,NN,O
,in,IN,O
,urinary,JJ,O
,guanosine,NN,O
,3,CD,O
,','',O
,",",",",O
,5,CD,O
,',POS,O
,-,:,O
,cyclic,NN,O
,monophosphate,NN,O
,(,(,O
,cGMP,NN,O
,),),O
,excretion,NN,O
,and,CC,O
,a,DT,O
,significant,JJ,O
,increase,NN,O
,in,IN,O
,renal,JJ,O
,cortical,JJ,O
,renin,NN,O
,and,CC,O
,endothelin,VB,O
,-,:,O
,1,CD,O
,contents,NNS,O
,were,VBD,O
,also,RB,O
,observed,VBN,O
,in,IN,O
,GM,NNP,O
,-,:,O
,mediated,VBD,O
,nephropathy,JJ,B-DISEASE
,.,.,O
,Superoxide,JJ,O
,dismutase,NN,O
,(,(,O
,SOD,NNP,O
,),),O
,or,CC,O
,dimethylthiourea,NN,O
,(,(,O
,DMTU,NNP,O
,),),O
,significantly,RB,O
,lessened,VBD,O
,the,DT,O
,GM,NNP,O
,-,:,O
,induced,JJ,O
,decrement,NN,O
,in,IN,O
,CIn,NNP,O
,.,.,O
,The,DT,O
,SOD,NNP,O
,-,:,O
,induced,JJ,O
,increase,NN,O
,in,IN,O
,glomerular,JJ,O
,filtration,NN,O
,rate,NN,O
,was,VBD,O
,associated,VBN,O
,with,IN,O
,a,DT,O
,marked,JJ,O
,improvement,NN,O
,in,IN,O
,RBF,NNP,O
,",",",",O
,an,DT,O
,increase,NN,O
,in,IN,O
,urinary,JJ,O
,cGMP,NN,O
,excretion,NN,O
,",",",",O
,and,CC,O
,a,DT,O
,decrease,NN,O
,in,IN,O
,renal,JJ,O
,renin,NN,O
,and,CC,O
,endothelin,VB,O
,-,:,O
,1,CD,O
,content,NN,O
,.,.,O
,SOD,NNP,O
,did,VBD,O
,not,RB,O
,attenuate,VB,O
,the,DT,O
,tubular,JJ,B-DISEASE
,damage,NN,I-DISEASE
,.,.,O
,In,IN,O
,contrast,NN,O
,",",",",O
,DMTU,NNP,O
,significantly,RB,O
,reduced,VBD,O
,the,DT,O
,tubular,JJ,B-DISEASE
,damage,NN,I-DISEASE
,and,CC,O
,lipid,JJ,O
,peroxidation,NN,O
,",",",",O
,but,CC,O
,it,PRP,O
,did,VBD,O
,not,RB,O
,affect,VB,O
,renal,JJ,O
,hemodynamics,NNS,O
,and,CC,O
,vasoactive,JJ,O
,substances,NNS,O
,.,.,O
,Neither,CC,O
,SOD,NNP,O
,nor,CC,O
,DMTU,NNP,O
,affected,VBD,O
,the,DT,O
,renal,JJ,O
,cortical,JJ,O
,GM,NNP,O
,content,NN,O
,in,IN,O
,GM,NNP,O
,-,:,O
,treated,VBD,O
,rats,NNS,O
,.,.,O
,These,DT,O
,results,NNS,O
,suggest,VBP,O
,that,IN,O
,1,CD,O
,),),O
,both,DT,O
,SOD,NNP,O
,and,CC,O
,DMTU,NNP,O
,have,VBP,O
,protective,JJ,O
,effects,NNS,O
,on,IN,O
,GM,NNP,O
,-,:,O
,mediated,VBD,O
,nephropathy,JJ,B-DISEASE
,",",",",O
,2,CD,O
,),),O
,the,DT,O
,mechanisms,NN,O
,for,IN,O
,the,DT,O
,protective,JJ,O
,effects,NNS,O
,differ,VBP,O
,for,IN,O
,SOD,NNP,O
,and,CC,O
,DMTU,NNP,O
,",",",",O
,and,CC,O
,3,CD,O
,),),O
,superoxide,NN,O
,anions,NNS,O
,play,VBP,O
,a,DT,O
,critical,JJ,O
,role,NN,O
,in,IN,O
,GM,NNP,O
,-,:,O
,induced,VBD,O
,renal,JJ,O
,vasoconstriction,NN,O
,.,.,O
,Cephalothin,NNP,O
,-,:,O
,induced,VBD,O
,immune,JJ,O
,hemolytic,JJ,B-DISEASE
,anemia,NN,I-DISEASE
,.,.,O
,A,DT,O
,patient,NN,O
,with,IN,O
,renal,JJ,B-DISEASE
,disease,NN,I-DISEASE
,developed,VBD,O
,Coombs,NNP,O
,-,:,O
,positive,JJ,O
,hemolytic,JJ,B-DISEASE
,anemia,NN,I-DISEASE
,while,IN,O
,receiving,VBG,O
,cephalothin,JJ,O
,therapy,NN,O
,.,.,O
,An,DT,O
,anti,JJ,O
,-,:,O
,cephalothin,NN,O
,IgG,NNP,O
,antibody,NN,O
,was,VBD,O
,detected,VBN,O
,in,IN,O
,the,DT,O
,patient,NN,O
,',POS,O
,s,NN,O
,serum,NN,O
,and,CC,O
,in,IN,O
,the,DT,O
,eluates,NNS,O
,from,IN,O
,her,PRP$,O
,erythrocytes,NNS,O
,.,.,O
,In,IN,O
,addition,NN,O
,",",",",O
,nonimmunologic,JJ,O
,binding,NN,O
,of,IN,O
,normal,JJ,O
,and,CC,O
,patient,JJ,O
,','',O
,s,JJ,O
,serum,NN,O
,proteins,NNS,O
,to,TO,O
,her,PRP$,O
,own,JJ,O
,and,CC,O
,cephalothin,JJ,O
,-,:,O
,coated,VBN,O
,normal,JJ,O
,red,JJ,O
,cells,NNS,O
,was,VBD,O
,demonstrated,VBN,O
,.,.,O
,Skin,NNP,O
,tests,NNS,O
,and,CC,O
,in,IN,O
,vitro,JJ,O
,lymphocyte,JJ,O
,stimulation,NN,O
,revealed,VBD,O
,that,IN,O
,the,DT,O
,patient,NN,O
,was,VBD,O
,sensitized,VBN,O
,to,TO,O
,cephalothin,VB,O
,and,CC,O
,also,RB,O
,to,TO,O
,ampicillin,VB,O
,.,.,O
,Careful,JJ,O
,investigation,NN,O
,of,IN,O
,drug,NN,O
,-,:,O
,induced,VBN,O
,hemolytic,JJ,B-DISEASE
,anemias,NN,I-DISEASE
,reveals,VBZ,O
,the,DT,O
,complexity,NN,O
,of,IN,O
,the,DT,O
,immune,JJ,O
,mechanisms,NNS,O
,involved,VBN,O
,.,.,O
,Assessment,NNP,O
,of,IN,O
,cardiomyocyte,NN,O
,DNA,NNP,O
,synthesis,NN,O
,during,IN,O
,hypertrophy,NN,B-DISEASE
,in,IN,O
,adult,NN,O
,mice,NN,O
,.,.,O
,The,DT,O
,ability,NN,O
,of,IN,O
,cardiomyocytes,NNS,O
,to,TO,O
,synthesize,VB,O
,DNA,NNP,O
,in,IN,O
,response,NN,O
,to,TO,O
,experimentally,RB,O
,induced,JJ,O
,cardiac,JJ,B-DISEASE
,hypertrophy,NN,I-DISEASE
,was,VBD,O
,assessed,VBN,O
,in,IN,O
,adult,NN,O
,mice,NN,O
,.,.,O
,Isoproterenol,NNP,O
,delivered,VBN,O
,by,IN,O
,osmotic,JJ,O
,minipump,NN,O
,implantation,NN,O
,in,IN,O
,adult,NN,O
,C3Heb,NNP,O
,/,NNP,O
,FeJ,NNP,O
,mice,NN,O
,resulted,VBD,O
,in,IN,O
,a,DT,O
,46,CD,O
,%,NN,O
,increase,NN,O
,in,IN,O
,heart,NN,O
,weight,NN,O
,and,CC,O
,a,DT,O
,19,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,increase,NN,O
,in,IN,O
,cardiomyocyte,JJ,O
,area,NN,O
,.,.,O
,No,DT,O
,DNA,NN,O
,synthesis,NN,O
,",",",",O
,as,IN,O
,assessed,VBN,O
,by,IN,O
,autoradiographic,JJ,O
,analysis,NN,O
,of,IN,O
,isolated,JJ,O
,cardiomyocytes,NNS,O
,",",",",O
,was,VBD,O
,observed,VBN,O
,in,IN,O
,control,NN,O
,or,CC,O
,hypertrophic,JJ,B-DISEASE
,hearts,NNS,I-DISEASE
,.,.,O
,A,DT,O
,survey,NN,O
,of,IN,O
,15,CD,O
,independent,JJ,O
,inbred,JJ,O
,strains,NNS,O
,of,IN,O
,mice,NN,O
,revealed,VBD,O
,that,IN,O
,ventricular,JJ,O
,cardiomyocyte,NN,O
,nuclear,JJ,O
,number,NN,O
,ranged,VBN,O
,from,IN,O
,3,CD,O
,to,TO,O
,13,CD,O
,%,NN,O
,mononucleate,NN,O
,",",",",O
,suggesting,VBG,O
,that,IN,O
,cardiomyocyte,JJ,O
,terminal,JJ,O
,differentiation,NN,O
,is,VBZ,O
,influenced,VBN,O
,directly,RB,O
,or,CC,O
,indirectly,RB,O
,by,IN,O
,genetic,JJ,O
,background,NN,O
,.,.,O
,To,TO,O
,determine,VB,O
,whether,IN,O
,the,DT,O
,capacity,NN,O
,for,IN,O
,reactive,JJ,O
,DNA,NNP,O
,synthesis,NN,O
,was,VBD,O
,also,RB,O
,subject,JJ,O
,to,TO,O
,genetic,JJ,O
,regulation,NN,O
,",",",",O
,cardiac,JJ,B-DISEASE
,hypertrophy,NN,I-DISEASE
,was,VBD,O
,induced,VBN,O
,in,IN,O
,the,DT,O
,strains,NNS,O
,of,IN,O
,mice,NN,O
,comprising,VBG,O
,the,DT,O
,extremes,NNS,O
,of,IN,O
,the,DT,O
,nuclear,JJ,O
,number,NN,O
,survey,NN,O
,.,.,O
,These,DT,O
,data,NNS,O
,indicate,VBP,O
,that,IN,O
,adult,NN,O
,mouse,VBP,O
,atrial,JJ,O
,and,CC,O
,ventricular,JJ,O
,cardiomyocytes,NNS,O
,do,VBP,O
,not,RB,O
,synthesize,VB,O
,DNA,NNP,O
,in,IN,O
,response,NN,O
,to,TO,O
,isoproterenol,VB,O
,-,:,O
,induced,JJ,O
,cardiac,JJ,B-DISEASE
,hypertrophy,NN,I-DISEASE
,.,.,O
,Central,NNP,O
,cardiovascular,JJ,O
,effects,NNS,O
,of,IN,O
,AVP,NNP,O
,and,CC,O
,ANP,NNP,O
,in,IN,O
,normotensive,JJ,O
,and,CC,O
,spontaneously,RB,O
,hypertensive,JJ,B-DISEASE
,rats,NNS,O
,.,.,O
,The,DT,O
,purpose,NN,O
,of,IN,O
,the,DT,O
,present,JJ,O
,study,NN,O
,was,VBD,O
,to,TO,O
,compare,VB,O
,influence,NN,O
,of,IN,O
,central,JJ,O
,arginine,NN,O
,vasopressin,NN,O
,(,(,O
,AVP,NNP,O
,),),O
,and,CC,O
,of,IN,O
,atrial,JJ,O
,natriuretic,JJ,O
,peptide,NN,O
,(,(,O
,ANP,NNP,O
,),),O
,on,IN,O
,control,NN,O
,of,IN,O
,arterial,JJ,O
,blood,NN,O
,pressure,NN,O
,(,(,O
,MAP,NNP,O
,),),O
,and,CC,O
,heart,NN,O
,rate,NN,O
,(,(,O
,HR,NNP,O
,),),O
,in,IN,O
,normotensive,JJ,O
,(,(,O
,WKY,NNP,O
,),),O
,and,CC,O
,spontaneously,RB,O
,hypertensive,JJ,B-DISEASE
,(,(,O
,SHR,NNP,O
,),),O
,rats,NNS,O
,.,.,O
,Three,NNP,O
,series,NN,O
,of,IN,O
,experiments,NNS,O
,were,VBD,O
,performed,VBN,O
,on,IN,O
,30,CD,O
,WKY,NNP,O
,and,CC,O
,30,CD,O
,SHR,NNP,O
,",",",",O
,chronically,RB,O
,instrumented,VBN,O
,with,IN,O
,guide,JJ,O
,tubes,NNS,O
,in,IN,O
,the,DT,O
,lateral,JJ,O
,ventricle,NN,O
,(,(,O
,LV,NNP,O
,),),O
,and,CC,O
,arterial,JJ,O
,and,CC,O
,venous,JJ,O
,catheters,NNS,O
,.,.,O
,MAP,NNP,O
,and,CC,O
,HR,NNP,O
,were,VBD,O
,monitored,VBN,O
,before,IN,O
,and,CC,O
,after,IN,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,injections,NNS,O
,of,IN,O
,either,DT,O
,vehicle,NN,O
,or,CC,O
,1,CD,O
,",",",",O
,10,CD,O
,and,CC,O
,50,CD,O
,ng,NN,O
,of,IN,O
,AVP,NNP,O
,and,CC,O
,25,CD,O
,",",",",O
,125,CD,O
,and,CC,O
,500,CD,O
,ng,NN,O
,of,IN,O
,ANP,NNP,O
,.,.,O
,Sensitivity,NNP,O
,of,IN,O
,cardiac,JJ,O
,component,NN,O
,of,IN,O
,baroreflex,NN,O
,(,(,O
,CCB,NNP,O
,),),O
,",",",",O
,expressed,VBN,O
,as,IN,O
,a,DT,O
,slope,NN,O
,of,IN,O
,the,DT,O
,regression,NN,O
,line,NN,O
,was,VBD,O
,determined,VBN,O
,from,IN,O
,relationships,NNS,O
,between,IN,O
,systolic,JJ,O
,arterial,JJ,O
,pressure,NN,O
,(,(,O
,SAP,NNP,O
,),),O
,and,CC,O
,HR,NNP,O
,period,NN,O
,(,(,O
,HRp,NNP,O
,),),O
,during,IN,O
,phenylephrine,NN,O
,(,(,O
,Phe,NNP,O
,),),O
,-,:,O
,induced,VBN,O
,hypertension,NN,B-DISEASE
,and,CC,O
,sodium,NN,O
,nitroprusside,NN,O
,(,(,O
,SN,NNP,O
,),),O
,-,:,O
,induced,VBN,O
,hypotension,NN,B-DISEASE
,.,.,O
,CCB,NNP,O
,was,VBD,O
,measured,VBN,O
,before,IN,O
,and,CC,O
,after,IN,O
,administration,NN,O
,of,IN,O
,either,DT,O
,vehicle,NN,O
,",",",",O
,AVP,NNP,O
,",",",",O
,ANP,NNP,O
,",",",",O
,or,CC,O
,both,DT,O
,peptides,IN,O
,together,RB,O
,.,.,O
,Increases,NNS,O
,of,IN,O
,MAP,NNP,O
,occurred,VBD,O
,after,IN,O
,LV,NNP,O
,administration,NN,O
,of,IN,O
,1,CD,O
,",",",",O
,10,CD,O
,and,CC,O
,50,CD,O
,ng,NN,O
,of,IN,O
,AVP,NNP,O
,in,IN,O
,WKY,NNP,O
,and,CC,O
,of,IN,O
,10,CD,O
,and,CC,O
,50,CD,O
,ng,NN,O
,in,IN,O
,SHR,NNP,O
,.,.,O
,ANP,NNP,O
,did,VBD,O
,not,RB,O
,cause,VB,O
,significant,JJ,O
,changes,NNS,O
,in,IN,O
,MAP,NNP,O
,in,IN,O
,both,DT,O
,strains,NNS,O
,as,IN,O
,compared,VBN,O
,to,TO,O
,vehicle,NN,O
,",",",",O
,but,CC,O
,it,PRP,O
,abolished,VBD,O
,AVP,NNP,O
,-,:,O
,induced,VBD,O
,MAP,NNP,O
,increase,NN,O
,in,IN,O
,WKY,NNP,O
,and,CC,O
,SHR,NNP,O
,.,.,O
,CCB,NNP,O
,was,VBD,O
,reduced,VBN,O
,in,IN,O
,WKY,NNP,O
,and,CC,O
,SHR,NNP,O
,after,IN,O
,LV,NNP,O
,administration,NN,O
,of,IN,O
,AVP,NNP,O
,during,IN,O
,SN,NNP,O
,-,:,O
,induced,JJ,O
,hypotension,NN,B-DISEASE
,.,.,O
,In,IN,O
,SHR,NNP,O
,but,CC,O
,not,RB,O
,in,IN,O
,WKY,NNP,O
,administration,NN,O
,of,IN,O
,ANP,NNP,O
,",",",",O
,AVP,NNP,O
,and,CC,O
,ANP,NNP,O
,+,NNP,O
,AVP,NNP,O
,decreased,VBD,O
,CCB,NNP,O
,during,IN,O
,Phe,NNP,O
,-,:,O
,induced,VBD,O
,MAP,NNP,O
,elevation,NN,O
,.,.,O
,The,DT,O
,results,NNS,O
,indicate,VBP,O
,that,IN,O
,centrally,RB,O
,applied,VBN,O
,AVP,NNP,O
,and,CC,O
,ANP,NNP,O
,exert,VBP,O
,differential,JJ,O
,effects,NNS,O
,on,IN,O
,blood,NN,O
,pressure,NN,O
,and,CC,O
,baroreflex,JJ,O
,control,NN,O
,of,IN,O
,heart,NN,O
,rate,NN,O
,in,IN,O
,WKY,NNP,O
,and,CC,O
,SHR,NNP,O
,and,CC,O
,suggest,JJS,O
,interaction,NN,O
,of,IN,O
,these,DT,O
,two,CD,O
,peptides,NNS,O
,in,IN,O
,blood,NN,O
,pressure,NN,O
,regulation,NN,O
,at,IN,O
,the,DT,O
,level,NN,O
,of,IN,O
,central,JJ,O
,nervous,JJ,O
,system,NN,O
,.,.,O
,Cutaneous,JJ,O
,exposure,NN,O
,to,TO,O
,warfarin,VB,O
,-,:,O
,like,IN,O
,anticoagulant,NN,O
,causing,VBG,O
,an,DT,O
,intracerebral,JJ,B-DISEASE
,hemorrhage,NN,I-DISEASE
,:,:,O
,a,DT,O
,case,NN,O
,report,NN,O
,.,.,O
,A,DT,O
,case,NN,O
,of,IN,O
,intercerebral,JJ,O
,hematoma,NNS,B-DISEASE
,due,JJ,O
,to,TO,O
,warfarin,VB,O
,-,:,O
,induced,VBN,O
,coagulopathy,NN,B-DISEASE
,is,VBZ,O
,presented,VBN,O
,.,.,O
,The,DT,O
,39,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,had,VBD,O
,spread,VBN,O
,a,DT,O
,warfarin,JJ,O
,-,:,O
,type,NN,O
,rat,NN,O
,poison,NN,O
,around,IN,O
,her,PRP$,O
,house,NN,O
,weekly,JJ,O
,using,VBG,O
,her,PRP$,O
,bare,NN,O
,hands,NNS,O
,",",",",O
,with,IN,O
,no,DT,O
,washing,VBG,O
,post,NN,O
,application,NN,O
,.,.,O
,Percutaneous,JJ,O
,absorption,NN,O
,of,IN,O
,warfarin,NN,O
,causing,VBG,O
,coagulopathy,NN,B-DISEASE
,",",",",O
,reported,VBD,O
,three,CD,O
,times,NNS,O
,in,IN,O
,the,DT,O
,past,NN,O
,",",",",O
,is,VBZ,O
,a,DT,O
,significant,JJ,O
,risk,NN,O
,if,IN,O
,protective,JJ,O
,measures,NNS,O
,",",",",O
,such,JJ,O
,as,IN,O
,gloves,NNS,O
,",",",",O
,are,VBP,O
,not,RB,O
,used,VBN,O
,.,.,O
,An,DT,O
,adverse,JJ,O
,drug,NN,O
,interaction,NN,O
,with,IN,O
,piroxicam,NN,O
,",",",",O
,which,WDT,O
,she,PRP,O
,took,VBD,O
,occasionally,RB,O
,",",",",O
,may,MD,O
,have,VB,O
,exacerbated,VBN,O
,the,DT,O
,coagulopathy,NN,B-DISEASE
,.,.,O
,Pediatric,NNP,O
,heart,NN,O
,transplantation,NN,O
,without,IN,O
,chronic,JJ,O
,maintenance,NN,O
,steroids,NNS,O
,.,.,O
,From,IN,O
,1986,CD,O
,to,TO,O
,February,NNP,O
,1993,CD,O
,",",",",O
,40,CD,O
,children,NNS,O
,aged,VBD,O
,2,CD,O
,months,NNS,O
,to,TO,O
,18,CD,O
,years,NNS,O
,(,(,O
,average,JJ,O
,age,NN,O
,10,CD,O
,.,.,O
,4,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,5,CD,O
,.,.,O
,8,CD,O
,years,NNS,O
,),),O
,underwent,JJ,O
,heart,NN,O
,transplantation,NN,O
,.,.,O
,Indications,NNS,O
,for,IN,O
,transplantation,NN,O
,were,VBD,O
,idiopathic,JJ,B-DISEASE
,cardiomyopathy,NN,I-DISEASE
,(,(,O
,52,CD,O
,%,NN,O
,),),O
,",",",",O
,congenital,JJ,B-DISEASE
,heart,NN,I-DISEASE
,disease,NN,I-DISEASE
,(,(,O
,35,CD,O
,%,NN,O
,),),O
,with,IN,O
,and,CC,O
,without,IN,O
,prior,JJ,O
,repair,NN,O
,(,(,O
,71,CD,O
,%,NN,O
,and,CC,O
,29,CD,O
,%,NN,O
,",",",",O
,respectively,RB,O
,),),O
,",",",",O
,hypertrophic,JJ,B-DISEASE
,cardiomyopathy,NN,I-DISEASE
,(,(,O
,5,CD,O
,%,NN,O
,),),O
,",",",",O
,valvular,JJ,B-DISEASE
,heart,NN,I-DISEASE
,disease,NN,I-DISEASE
,(,(,O
,3,CD,O
,%,NN,O
,),),O
,",",",",O
,and,CC,O
,doxorubicin,VB,O
,cardiomyopathy,NN,B-DISEASE
,(,(,O
,5,CD,O
,%,NN,O
,),),O
,.,.,O
,Patients,NNS,O
,were,VBD,O
,managed,VBN,O
,with,IN,O
,cyclosporine,NN,O
,and,CC,O
,azathioprine,NN,O
,.,.,O
,No,DT,O
,prophylaxis,NN,O
,with,IN,O
,antilymphocyte,JJ,O
,globulin,NN,O
,was,VBD,O
,used,VBN,O
,.,.,O
,Steroids,NNS,O
,were,VBD,O
,given,VBN,O
,to,TO,O
,39,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,for,IN,O
,refractory,JJ,O
,rejection,NN,O
,",",",",O
,but,CC,O
,weaning,VBG,O
,was,VBD,O
,always,RB,O
,attempted,VBN,O
,and,CC,O
,generally,RB,O
,successful,JJ,O
,(,(,O
,64,CD,O
,%,NN,O
,),),O
,.,.,O
,Five,CD,O
,patients,NNS,O
,(,(,O
,14,CD,O
,%,NN,O
,),),O
,received,VBD,O
,maintenance,NN,O
,steroids,NNS,O
,.,.,O
,Four,CD,O
,patients,NNS,O
,died,VBN,O
,in,IN,O
,the,DT,O
,perioperative,JJ,O
,period,NN,O
,and,CC,O
,one,CD,O
,died,VBD,O
,4,CD,O
,months,NNS,O
,later,RB,O
,.,.,O
,There,EX,O
,have,VBP,O
,been,VBN,O
,no,DT,O
,deaths,NNS,O
,related,VBN,O
,to,TO,O
,rejection,NN,O
,or,CC,O
,infection,NN,B-DISEASE
,.,.,O
,Average,JJ,O
,follow,JJ,O
,-,:,O
,up,NN,O
,was,VBD,O
,36,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,19,CD,O
,months,NNS,O
,(,(,O
,range,VB,O
,1,CD,O
,to,TO,O
,65,CD,O
,months,NNS,O
,),),O
,.,.,O
,Cumulative,JJ,O
,survival,NN,O
,is,VBZ,O
,88,CD,O
,%,NN,O
,at,IN,O
,5,CD,O
,years,NNS,O
,.,.,O
,In,IN,O
,patients,NNS,O
,less,JJR,O
,than,IN,O
,7,CD,O
,years,NNS,O
,of,IN,O
,age,NN,O
,",",",",O
,rejection,NN,O
,was,VBD,O
,monitored,VBN,O
,noninvasively,RB,O
,.,.,O
,In,IN,O
,the,DT,O
,first,JJ,O
,postoperative,JJ,O
,month,NN,O
,",",",",O
,89,CD,O
,%,NN,O
,of,IN,O
,patients,NNS,O
,were,VBD,O
,treated,VBN,O
,for,IN,O
,rejection,NN,O
,.,.,O
,Freedom,NN,O
,from,IN,O
,serious,JJ,O
,infections,NNS,B-DISEASE
,was,VBD,O
,83,CD,O
,%,NN,O
,at,IN,O
,1,CD,O
,month,NN,O
,and,CC,O
,65,CD,O
,%,NN,O
,at,IN,O
,1,CD,O
,year,NN,O
,.,.,O
,Cytomegalovirus,NNP,B-DISEASE
,infections,NNS,I-DISEASE
,were,VBD,O
,treated,VBN,O
,successfully,RB,O
,with,IN,O
,ganciclovir,NN,O
,in,IN,O
,11,CD,O
,patients,NNS,O
,.,.,O
,No,DT,O
,impairment,NN,O
,of,IN,O
,growth,NN,O
,was,VBD,O
,observed,VBN,O
,in,IN,O
,children,NNS,O
,who,WP,O
,underwent,VBP,O
,transplantation,NN,O
,compared,VBN,O
,with,IN,O
,a,DT,O
,control,NN,O
,population,NN,O
,.,.,O
,Twenty,NNP,O
,-,:,O
,one,CD,O
,patients,NNS,O
,(,(,O
,60,CD,O
,%,NN,O
,),),O
,have,VBP,O
,undergone,JJ,O
,annual,JJ,O
,catheterizations,NNS,O
,and,CC,O
,no,DT,O
,sign,NN,O
,of,IN,O
,graft,NN,O
,atherosclerosis,NN,B-DISEASE
,has,VBZ,O
,been,VBN,O
,observed,VBN,O
,.,.,O
,Seizures,NNS,B-DISEASE
,occurred,VBD,O
,in,IN,O
,five,CD,O
,patients,NNS,O
,(,(,O
,14,CD,O
,%,NN,O
,),),O
,and,CC,O
,hypertension,NN,B-DISEASE
,was,VBD,O
,treated,VBN,O
,in,IN,O
,10,CD,O
,patients,NNS,O
,(,(,O
,28,CD,O
,%,NN,O
,),),O
,.,.,O
,No,DT,O
,patient,NN,O
,was,VBD,O
,disabled,VBN,O
,and,CC,O
,no,DT,O
,lymphoproliferative,JJ,B-DISEASE
,disorder,NN,I-DISEASE
,was,VBD,O
,observed,VBN,O
,.,.,O
,(,(,O
,ABSTRACT,NNP,O
,TRUNCATED,NNP,O
,AT,NNP,O
,250,CD,O
,WORDS,NNP,O
,),),O
,Delirium,NNP,B-DISEASE
,during,IN,O
,fluoxetine,JJ,O
,treatment,NN,O
,.,.,O
,A,DT,O
,case,NN,O
,report,NN,O
,.,.,O
,The,DT,O
,correlation,NN,O
,between,IN,O
,high,JJ,O
,serum,NN,O
,tricyclic,JJ,O
,antidepressant,JJ,O
,concentrations,NNS,O
,and,CC,O
,central,JJ,O
,nervous,JJ,O
,system,NN,O
,side,NN,O
,effects,NNS,O
,has,VBZ,O
,been,VBN,O
,well,RB,O
,established,VBN,O
,.,.,O
,Only,RB,O
,a,DT,O
,few,JJ,O
,reports,NNS,O
,exist,VBP,O
,",",",",O
,however,RB,O
,",",",",O
,on,IN,O
,the,DT,O
,relationship,NN,O
,between,IN,O
,the,DT,O
,serum,JJ,O
,concentrations,NNS,O
,of,IN,O
,selective,JJ,O
,serotonin,NNS,O
,reuptake,VBP,O
,inhibitors,NNS,O
,(,(,O
,SSRIs,NNP,O
,),),O
,and,CC,O
,their,PRP$,O
,toxic,JJ,O
,effects,NNS,O
,.,.,O
,In,IN,O
,some,DT,O
,cases,NNS,O
,",",",",O
,a,DT,O
,high,JJ,O
,serum,NN,O
,concentration,NN,O
,of,IN,O
,citalopram,NN,O
,(,(,O
,>,JJ,O
,600,CD,O
,nmol,JJ,O
,/,NNP,O
,L,NNP,O
,),),O
,in,IN,O
,elderly,JJ,O
,patients,NNS,O
,has,VBZ,O
,been,VBN,O
,associated,VBN,O
,with,IN,O
,increased,JJ,O
,somnolence,NN,B-DISEASE
,and,CC,O
,movement,NN,B-DISEASE
,difficulties,NNS,I-DISEASE
,.,.,O
,Widespread,JJ,O
,cognitive,JJ,B-DISEASE
,disorders,NNS,I-DISEASE
,",",",",O
,such,JJ,O
,as,IN,O
,delirium,NN,B-DISEASE
,",",",",O
,have,VBP,O
,not,RB,O
,been,VBN,O
,previously,RB,O
,linked,VBN,O
,with,IN,O
,high,JJ,O
,blood,NN,O
,levels,NNS,O
,of,IN,O
,SSRIs,NNP,O
,.,.,O
,In,IN,O
,this,DT,O
,report,NN,O
,",",",",O
,we,PRP,O
,describe,VBP,O
,a,DT,O
,patient,NN,O
,with,IN,O
,acute,JJ,O
,hyperkinetic,JJ,B-DISEASE
,delirium,NN,B-DISEASE
,connected,VBN,O
,with,IN,O
,a,DT,O
,high,JJ,O
,serum,NN,O
,total,JJ,O
,fluoxetine,NN,O
,(,(,O
,fluoxetine,JJ,O
,plus,CC,O
,desmethylfluoxetine,NN,O
,),),O
,concentration,NN,O
,.,.,O
,Pulmonary,JJ,B-DISEASE
,edema,NN,I-DISEASE
,and,CC,O
,shock,NN,B-DISEASE
,after,IN,O
,high,JJ,O
,-,:,O
,dose,JJ,O
,aracytine,JJ,O
,-,:,O
,C,NN,O
,for,IN,O
,lymphoma,NN,B-DISEASE
,;,:,O
,possible,JJ,O
,role,NN,O
,of,IN,O
,TNF,NNP,O
,-,:,O
,alpha,NN,O
,and,CC,O
,PAF,NNP,O
,.,.,O
,Four,CD,O
,out,IN,O
,of,IN,O
,23,CD,O
,consecutive,JJ,O
,patients,NNS,O
,treated,VBN,O
,with,IN,O
,high,JJ,O
,-,:,O
,dose,NN,O
,Ara,NNP,O
,-,:,O
,C,NNP,O
,for,IN,O
,lymphomas,NN,B-DISEASE
,in,IN,O
,our,PRP$,O
,institution,NN,O
,developed,VBD,O
,a,DT,O
,strikingly,RB,O
,similar,JJ,O
,syndrome,NN,O
,during,IN,O
,the,DT,O
,perfusion,NN,O
,.,.,O
,It,PRP,O
,was,VBD,O
,characterized,VBN,O
,by,IN,O
,the,DT,O
,onset,NN,O
,of,IN,O
,fever,NN,B-DISEASE
,",",",",O
,diarrhea,NN,B-DISEASE
,",",",",O
,shock,NN,B-DISEASE
,",",",",O
,pulmonary,JJ,B-DISEASE
,edema,NN,I-DISEASE
,",",",",O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,",",",",O
,metabolic,JJ,B-DISEASE
,acidosis,NN,I-DISEASE
,",",",",O
,weight,VBD,B-DISEASE
,gain,NN,I-DISEASE
,and,CC,O
,leukocytosis,NN,B-DISEASE
,.,.,O
,Thorough,NNP,O
,bacteriological,JJ,O
,screening,NN,O
,failed,VBD,O
,to,TO,O
,provide,VB,O
,evidence,NN,O
,of,IN,O
,infection,NN,B-DISEASE
,.,.,O
,Sequential,JJ,O
,biological,JJ,O
,assays,NNS,O
,of,IN,O
,IL,NNP,O
,-,:,O
,1,CD,O
,",",",",O
,IL,NNP,O
,-,:,O
,2,CD,O
,",",",",O
,TNF,NNP,O
,and,CC,O
,PAF,NNP,O
,were,VBD,O
,performed,VBN,O
,during,IN,O
,Ara,NNP,O
,-,:,O
,C,NNP,O
,infusion,NN,O
,to,TO,O
,ten,VB,O
,patients,NNS,O
,",",",",O
,including,VBG,O
,the,DT,O
,four,CD,O
,who,WP,O
,developed,VBD,O
,the,DT,O
,syndrome,NN,O
,.,.,O
,TNF,NNP,O
,and,CC,O
,PAF,NNP,O
,activity,NN,O
,was,VBD,O
,found,VBN,O
,in,IN,O
,the,DT,O
,serum,NN,O
,of,IN,O
,respectively,RB,O
,two,CD,O
,and,CC,O
,four,CD,O
,of,IN,O
,the,DT,O
,cases,NNS,O
,",",",",O
,but,CC,O
,not,RB,O
,in,IN,O
,the,DT,O
,six,CD,O
,controls,NNS,O
,.,.,O
,As,IN,O
,TNF,NNP,O
,and,CC,O
,PAF,NNP,O
,are,VBP,O
,thought,VBN,O
,to,TO,O
,be,VB,O
,involved,VBN,O
,in,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,septic,JJ,O
,shock,NN,B-DISEASE
,and,CC,O
,adult,NN,B-DISEASE
,respiratory,NN,I-DISEASE
,distress,NN,I-DISEASE
,syndrome,NN,I-DISEASE
,",",",",O
,we,PRP,O
,hypothesize,VBP,O
,that,DT,O
,high,JJ,O
,-,:,O
,dose,NN,O
,Ara,NNP,O
,-,:,O
,C,NN,O
,may,MD,O
,be,VB,O
,associated,VBN,O
,with,IN,O
,cytokine,NN,O
,release,NN,O
,.,.,O
,Protective,JJ,O
,effect,NN,O
,of,IN,O
,clentiazem,NN,O
,against,IN,O
,epinephrine,JJ,O
,-,:,O
,induced,JJ,O
,cardiac,JJ,B-DISEASE
,injury,NN,I-DISEASE
,in,IN,O
,rats,NNS,O
,.,.,O
,We,PRP,O
,investigated,VBD,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,clentiazem,NN,O
,",",",",O
,a,DT,O
,1,CD,O
,",",",",O
,5,CD,O
,-,:,O
,benzothiazepine,NN,O
,calcium,NN,O
,antagonist,NN,O
,",",",",O
,on,IN,O
,epinephrine,JJ,O
,-,:,O
,induced,VBN,O
,cardiomyopathy,NN,B-DISEASE
,in,IN,O
,rats,NNS,O
,.,.,O
,With,IN,O
,2,CD,O
,-,:,O
,week,NN,O
,chronic,JJ,O
,epinephrine,NN,O
,infusion,NN,O
,",",",",O
,16,CD,O
,of,IN,O
,30,CD,O
,rats,NNS,O
,died,VBD,O
,within,IN,O
,4,CD,O
,days,NNS,O
,",",",",O
,and,CC,O
,severe,JJ,O
,ischemic,JJ,B-DISEASE
,lesions,NNS,I-DISEASE
,and,CC,O
,fibrosis,NN,B-DISEASE
,of,IN,O
,the,DT,O
,left,JJ,O
,ventricles,NNS,O
,were,VBD,O
,observed,VBN,O
,.,.,O
,In,IN,O
,epinephrine,JJ,O
,-,:,O
,treated,JJ,O
,rats,NNS,O
,",",",",O
,left,VBD,O
,atrial,JJ,O
,and,CC,O
,left,VBD,O
,ventricular,JJ,O
,papillary,JJ,O
,muscle,NN,O
,contractile,NN,O
,responses,NNS,O
,to,TO,O
,isoproterenol,VB,O
,were,VBD,O
,reduced,VBN,O
,",",",",O
,but,CC,O
,responses,VBZ,O
,to,TO,O
,calcium,VB,O
,were,VBD,O
,normal,JJ,O
,or,CC,O
,enhanced,VBN,O
,compared,VBN,O
,to,TO,O
,controls,NNS,O
,.,.,O
,Left,NNP,O
,ventricular,JJ,O
,alpha,NN,O
,and,CC,O
,beta,NN,O
,adrenoceptor,NN,O
,densities,NNS,O
,were,VBD,O
,also,RB,O
,reduced,VBN,O
,compared,VBN,O
,to,TO,O
,controls,NNS,O
,.,.,O
,Treatment,NN,O
,with,IN,O
,clentiazem,NN,O
,prevented,VBN,O
,epinephrine,JJ,O
,-,:,O
,induced,VBN,O
,death,NN,O
,(,(,O
,P,NNP,O
,<,NNP,O
,.,.,O
,05,CD,O
,),),O
,",",",",O
,and,CC,O
,attenuated,VBD,O
,the,DT,O
,ventricular,JJ,O
,ischemic,JJ,B-DISEASE
,lesions,NNS,I-DISEASE
,and,CC,O
,fibrosis,NN,B-DISEASE
,",",",",O
,in,IN,O
,a,DT,O
,dose,JJ,O
,-,:,O
,dependent,JJ,O
,manner,NN,O
,.,.,O
,Left,NNP,O
,atrial,JJ,O
,and,CC,O
,left,VBD,O
,ventricular,JJ,O
,papillary,JJ,O
,muscle,NN,O
,contractile,NN,O
,responses,NNS,O
,to,TO,O
,isoproterenol,VB,O
,were,VBD,O
,reduced,VBN,O
,compared,VBN,O
,to,TO,O
,controls,NNS,O
,in,IN,O
,groups,NNS,O
,treated,VBN,O
,with,IN,O
,clentiazem,NN,O
,alone,RB,O
,",",",",O
,but,CC,O
,combined,VBD,O
,with,IN,O
,epinephrine,NN,O
,",",",",O
,clentiazem,NN,O
,restored,VBD,O
,left,JJ,O
,atrial,JJ,O
,responses,NNS,O
,and,CC,O
,enhanced,VBD,O
,left,VBN,O
,ventricular,JJ,O
,papillary,JJ,O
,responses,NNS,O
,to,TO,O
,isoproterenol,VB,O
,.,.,O
,On,IN,O
,the,DT,O
,other,JJ,O
,hand,NN,O
,clentiazem,NNS,O
,did,VBD,O
,not,RB,O
,prevent,VB,O
,epinephrine,JJ,O
,-,:,O
,induced,VBD,O
,down,IN,O
,-,:,O
,regulation,NN,O
,of,IN,O
,alpha,NN,O
,and,CC,O
,beta,NN,O
,adrenoceptors,NNS,O
,.,.,O
,Interestingly,RB,O
,",",",",O
,clentiazem,NN,O
,",",",",O
,infused,VBD,O
,alone,RB,O
,",",",",O
,resulted,VBD,O
,in,IN,O
,decreased,JJ,O
,adrenergic,JJ,O
,receptor,NN,O
,densities,NNS,O
,in,IN,O
,the,DT,O
,left,JJ,O
,ventricle,NN,O
,.,.,O
,Clentiazem,NNP,O
,also,RB,O
,did,VBD,O
,not,RB,O
,prevent,VB,O
,the,DT,O
,enhanced,JJ,O
,responses,NNS,O
,to,TO,O
,calcium,VB,O
,seen,VBN,O
,in,IN,O
,the,DT,O
,epinephrine,NN,O
,-,:,O
,treated,JJ,O
,animals,NNS,O
,",",",",O
,although,IN,O
,the,DT,O
,high,JJ,O
,dose,NN,O
,of,IN,O
,clentiazem,NN,O
,partially,RB,O
,attenuated,VBD,O
,the,DT,O
,maximal,JJ,O
,response,NN,O
,to,TO,O
,calcium,VB,O
,compared,VBN,O
,to,TO,O
,epinephrine,VB,O
,-,:,O
,treated,VBN,O
,animals,NNS,O
,.,.,O
,In,IN,O
,conclusion,NN,O
,",",",",O
,clentiazem,NN,O
,attenuated,VBD,O
,epinephrine,JJ,O
,-,:,O
,induced,JJ,O
,cardiac,JJ,B-DISEASE
,injury,NN,I-DISEASE
,",",",",O
,possibly,RB,O
,through,IN,O
,its,PRP$,O
,effect,NN,O
,on,IN,O
,the,DT,O
,adrenergic,JJ,O
,pathway,NN,O
,.,.,O
,Kaliuretic,JJ,O
,effect,NN,O
,of,IN,O
,L,NNP,O
,-,:,O
,dopa,NN,O
,treatment,NN,O
,in,IN,O
,parkinsonian,JJ,B-DISEASE
,patients,NNS,O
,.,.,O
,Hypokalemia,NNP,B-DISEASE
,",",",",O
,sometimes,RB,O
,severe,JJ,O
,",",",",O
,was,VBD,O
,observed,VBN,O
,in,IN,O
,some,DT,O
,L,NNP,O
,-,:,O
,dopa,NN,O
,-,:,O
,treated,JJ,O
,parkinsonian,JJ,B-DISEASE
,patients,NNS,O
,.,.,O
,The,DT,O
,influence,NN,O
,of,IN,O
,L,NNP,O
,-,:,O
,dopa,NN,O
,on,IN,O
,the,DT,O
,renal,JJ,O
,excretion,NN,O
,of,IN,O
,potassium,NN,O
,was,VBD,O
,studied,VBN,O
,in,IN,O
,3,CD,O
,patients,NNS,O
,with,IN,O
,hypokalemia,NN,B-DISEASE
,and,CC,O
,in,IN,O
,5,CD,O
,normokalemic,JJ,O
,patients,NNS,O
,by,IN,O
,determination,NN,O
,of,IN,O
,renal,JJ,O
,plasma,NN,O
,flow,NN,O
,",",",",O
,glomerular,JJ,O
,filtration,NN,O
,rate,NN,O
,",",",",O
,plasma,JJ,O
,concentration,NN,O
,of,IN,O
,potassium,NN,O
,and,CC,O
,sodium,NN,O
,as,RB,O
,well,RB,O
,as,IN,O
,urinary,JJ,O
,excretion,NN,O
,of,IN,O
,potassium,NN,O
,",",",",O
,sodium,NN,O
,and,CC,O
,aldosterone,NN,O
,.,.,O
,L,NNP,O
,-,:,O
,Dopa,NNP,O
,intake,NN,O
,was,VBD,O
,found,VBN,O
,to,TO,O
,cause,VB,O
,an,DT,O
,increased,JJ,O
,excretion,NN,O
,of,IN,O
,potassium,NN,O
,",",",",O
,and,CC,O
,sometimes,RB,O
,also,RB,O
,of,IN,O
,sodium,NN,O
,",",",",O
,in,IN,O
,the,DT,O
,hypokalemic,NN,O
,but,CC,O
,not,RB,O
,in,IN,O
,the,DT,O
,normokalemic,JJ,O
,patients,NNS,O
,.,.,O
,This,DT,O
,effect,NN,O
,on,IN,O
,the,DT,O
,renal,JJ,O
,function,NN,O
,could,MD,O
,be,VB,O
,prohibited,VBN,O
,by,IN,O
,the,DT,O
,administration,NN,O
,of,IN,O
,a,DT,O
,peripheral,JJ,O
,dopa,NN,O
,decarbodylase,NN,O
,inhibitor,NN,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,not,RB,O
,known,VBN,O
,why,WRB,O
,this,DT,O
,effect,NN,O
,occurred,VBD,O
,in,IN,O
,some,DT,O
,individuals,NNS,O
,but,CC,O
,not,RB,O
,in,IN,O
,others,NNS,O
,",",",",O
,but,CC,O
,our,PRP$,O
,results,NNS,O
,indicate,VBP,O
,a,DT,O
,correlation,NN,O
,between,IN,O
,aldosterone,NN,O
,production,NN,O
,and,CC,O
,this,DT,O
,renal,JJ,O
,effect,NN,O
,of,IN,O
,L,NNP,O
,-,:,O
,dopa,NN,O
,.,.,O
,Cocaine,NNP,O
,induced,VBD,O
,myocardial,JJ,B-DISEASE
,ischemia,NN,I-DISEASE
,.,.,O
,We,PRP,O
,report,VBP,O
,a,DT,O
,case,NN,O
,of,IN,O
,myocardial,JJ,B-DISEASE
,ischemia,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,cocaine,NN,O
,.,.,O
,The,DT,O
,ischemia,NN,B-DISEASE
,probably,RB,O
,induced,VBN,O
,by,IN,O
,coronary,JJ,B-DISEASE
,artery,NN,I-DISEASE
,spasm,NN,I-DISEASE
,was,VBD,O
,reversed,VBN,O
,by,IN,O
,nitroglycerin,NN,O
,and,CC,O
,calcium,NN,O
,blocking,NN,O
,agents,NNS,O
,.,.,O
,Doxorubicin,NNP,O
,-,:,O
,induced,JJ,O
,cardiotoxicity,NN,B-DISEASE
,monitored,VBN,O
,by,IN,O
,ECG,NNP,O
,in,IN,O
,freely,RB,O
,moving,VBG,O
,mice,NN,O
,.,.,O
,A,DT,O
,new,JJ,O
,model,NN,O
,to,TO,O
,test,VB,O
,potential,JJ,O
,protectors,NNS,O
,.,.,O
,In,IN,O
,laboratory,NN,O
,animals,NNS,O
,",",",",O
,histology,NN,O
,is,VBZ,O
,most,RBS,O
,commonly,RB,O
,used,VBN,O
,to,TO,O
,study,VB,O
,doxorubicin,JJ,O
,-,:,O
,induced,JJ,O
,cardiotoxicity,NN,B-DISEASE
,.,.,O
,However,RB,O
,",",",",O
,for,IN,O
,monitoring,VBG,O
,during,IN,O
,treatment,NN,O
,",",",",O
,large,JJ,O
,numbers,NNS,O
,of,IN,O
,animals,NNS,O
,are,VBP,O
,needed,VBN,O
,.,.,O
,Recently,RB,O
,we,PRP,O
,developed,VBD,O
,a,DT,O
,new,JJ,O
,method,NN,O
,to,TO,O
,measure,VB,O
,ECG,NNP,O
,values,NNS,O
,in,IN,O
,freely,RB,O
,moving,VBG,O
,mice,NN,O
,by,IN,O
,telemetry,NN,O
,.,.,O
,With,IN,O
,this,DT,O
,model,NN,O
,we,PRP,O
,investigated,VBD,O
,the,DT,O
,effect,NN,O
,of,IN,O
,chronic,JJ,O
,doxorubicin,NN,O
,administration,NN,O
,on,IN,O
,the,DT,O
,ECG,NNP,O
,of,IN,O
,freely,RB,O
,moving,VBG,O
,BALB,NNP,O
,/,NNP,O
,c,NN,O
,mice,NN,O
,and,CC,O
,the,DT,O
,efficacy,NN,O
,of,IN,O
,ICRF,NNP,O
,-,:,O
,187,CD,O
,as,IN,O
,a,DT,O
,protective,JJ,O
,agent,NN,O
,.,.,O
,The,DT,O
,ST,NNP,O
,interval,NN,O
,significantly,RB,O
,widened,VBD,O
,from,IN,O
,15,CD,O
,.,.,O
,0,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,5,CD,O
,to,TO,O
,56,CD,O
,.,.,O
,8,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,11,CD,O
,.,.,O
,8,CD,O
,ms,NN,O
,in,IN,O
,week,NN,O
,10,CD,O
,(,(,O
,7,CD,O
,weekly,JJ,O
,doses,NNS,O
,of,IN,O
,4,CD,O
,mg,NNS,O
,/,JJ,O
,kg,NN,O
,doxorubicin,NN,O
,given,VBN,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,plus,CC,O
,3,CD,O
,weeks,NNS,O
,of,IN,O
,observation,NN,O
,),),O
,.,.,O
,The,DT,O
,ECG,NNP,O
,of,IN,O
,the,DT,O
,control,NN,O
,animals,NNS,O
,did,VBD,O
,not,RB,O
,change,NN,O
,during,IN,O
,the,DT,O
,entire,JJ,O
,study,NN,O
,.,.,O
,After,IN,O
,sacrifice,NN,O
,the,DT,O
,hearts,NNS,O
,of,IN,O
,doxorubicin,JJ,O
,-,:,O
,treated,VBN,O
,animals,NNS,O
,were,VBD,O
,enlarged,VBN,O
,and,CC,O
,the,DT,O
,atria,NNS,O
,were,VBD,O
,hypertrophic,JJ,B-DISEASE
,.,.,O
,As,IN,O
,this,DT,O
,schedule,NN,O
,exerted,VBD,O
,more,JJR,O
,toxicity,NN,B-DISEASE
,than,IN,O
,needed,VBN,O
,to,TO,O
,investigate,VB,O
,protective,JJ,O
,agents,NNS,O
,",",",",O
,the,DT,O
,protection,NN,O
,of,IN,O
,ICRF,NNP,O
,-,:,O
,187,CD,O
,was,VBD,O
,determined,VBN,O
,using,VBG,O
,a,DT,O
,dose,JJ,O
,schedule,NN,O
,with,IN,O
,lower,JJR,O
,general,JJ,O
,toxicity,NN,B-DISEASE
,(,(,O
,6,CD,O
,weekly,JJ,O
,doses,NNS,O
,of,IN,O
,4,CD,O
,mg,NNS,O
,/,JJ,O
,kg,NN,O
,doxorubicin,NN,O
,given,VBN,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,plus,CC,O
,2,CD,O
,weeks,NNS,O
,of,IN,O
,observation,NN,O
,),),O
,.,.,O
,On,IN,O
,this,DT,O
,schedule,NN,O
,",",",",O
,the,DT,O
,animals,NNS,O
,',POS,O
,hearts,NNS,O
,appeared,VBD,O
,normal,JJ,O
,after,IN,O
,sacrifice,NN,O
,and,CC,O
,ICRF,NNP,O
,-,:,O
,187,CD,O
,(,(,O
,50,CD,O
,mg,NN,O
,/,NNP,O
,kg,VBD,O
,given,VBN,O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,1,CD,O
,h,NN,O
,before,IN,O
,doxorubicin,NN,O
,),),O
,provided,VBD,O
,almost,RB,O
,full,JJ,O
,protection,NN,O
,.,.,O
,These,DT,O
,data,NNS,O
,were,VBD,O
,confirmed,VBN,O
,by,IN,O
,histology,NN,O
,.,.,O
,The,DT,O
,results,NNS,O
,indicate,VBP,O
,that,IN,O
,this,DT,O
,new,JJ,O
,model,NN,O
,is,VBZ,O
,very,RB,O
,sensitive,JJ,O
,and,CC,O
,enables,VBZ,O
,monitoring,NN,O
,of,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,cardiotoxicity,NN,B-DISEASE
,with,IN,O
,time,NN,O
,.,.,O
,These,DT,O
,findings,NNS,O
,result,VBP,O
,in,IN,O
,a,DT,O
,model,NN,O
,that,WDT,O
,allows,VBZ,O
,the,DT,O
,testing,NN,O
,of,IN,O
,protectors,NNS,O
,against,IN,O
,doxorubicin,JJ,O
,-,:,O
,induced,JJ,O
,cardiotoxicity,NN,B-DISEASE
,as,IN,O
,demonstrated,VBN,O
,by,IN,O
,the,DT,O
,protection,NN,O
,provided,VBN,O
,by,IN,O
,ICRF,NNP,O
,-,:,O
,187,CD,O
,.,.,O
,Epinephrine,NNP,O
,dysrhythmogenicity,NN,O
,is,VBZ,O
,not,RB,O
,enhanced,VBN,O
,by,IN,O
,subtoxic,JJ,O
,bupivacaine,NN,O
,in,IN,O
,dogs,NNS,O
,.,.,O
,Since,IN,O
,bupivacaine,NN,O
,and,CC,O
,epinephrine,NN,O
,may,MD,O
,both,VB,O
,precipitate,NN,O
,dysrhythmias,NN,B-DISEASE
,",",",",O
,circulating,VBG,O
,bupivacaine,NN,O
,during,IN,O
,regional,JJ,O
,anesthesia,NN,O
,could,MD,O
,potentiate,VB,O
,dysrhythmogenic,JJ,O
,effects,NNS,O
,of,IN,O
,epinephrine,NN,O
,.,.,O
,We,PRP,O
,therefore,VBP,O
,examined,VBD,O
,whether,IN,O
,bupivacaine,NN,O
,alters,NNS,O
,the,DT,O
,dysrhythmogenicity,NN,O
,of,IN,O
,subsequent,JJ,O
,administration,NN,O
,of,IN,O
,epinephrine,NN,O
,in,IN,O
,conscious,JJ,O
,",",",",O
,healthy,JJ,O
,dogs,NNS,O
,and,CC,O
,in,IN,O
,anesthetized,JJ,O
,dogs,NNS,O
,with,IN,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,.,.,O
,Forty,NNP,O
,-,:,O
,one,CD,O
,conscious,JJ,O
,dogs,NNS,O
,received,VBD,O
,10,CD,O
,micrograms,NNS,O
,.,.,O
,kg,VB,O
,-,:,O
,1,CD,O
,.,.,O
,min,VB,O
,-,:,O
,1,CD,O
,epinephrine,NN,O
,.,.,O
,Seventeen,JJ,O
,animals,NNS,O
,responded,VBD,O
,with,IN,O
,ventricular,JJ,B-DISEASE
,tachycardia,NN,I-DISEASE
,(,(,O
,VT,NNP,B-DISEASE
,),),O
,within,IN,O
,3,CD,O
,min,NN,O
,.,.,O
,After,IN,O
,3,CD,O
,h,NN,O
,",",",",O
,these,DT,O
,responders,NNS,O
,randomly,VBP,O
,received,VBN,O
,1,CD,O
,or,CC,O
,2,CD,O
,mg,NNS,O
,/,JJ,O
,kg,JJ,O
,bupivacaine,NN,O
,or,CC,O
,saline,NN,O
,over,IN,O
,5,CD,O
,min,NNS,O
,",",",",O
,followed,VBN,O
,by,IN,O
,10,CD,O
,micrograms,NNS,O
,.,.,O
,kg,VB,O
,-,:,O
,1,CD,O
,.,.,O
,min,VB,O
,-,:,O
,1,CD,O
,epinephrine,NN,O
,.,.,O
,In,IN,O
,the,DT,O
,bupivacaine,NN,O
,groups,NNS,O
,",",",",O
,epinephrine,VBP,O
,caused,VBN,O
,fewer,JJR,O
,prodysrhythmic,JJ,O
,effects,NNS,O
,than,IN,O
,without,IN,O
,bupivacaine,NN,O
,.,.,O
,VT,NNP,B-DISEASE
,appeared,VBD,O
,in,IN,O
,fewer,JJR,O
,dogs,NNS,O
,and,CC,O
,at,IN,O
,a,DT,O
,later,JJ,O
,time,NN,O
,",",",",O
,and,CC,O
,there,EX,O
,were,VBD,O
,more,JJR,O
,sinoatrial,JJ,O
,beats,NNS,O
,and,CC,O
,less,JJR,O
,ectopies,NNS,O
,.,.,O
,Epinephrine,NNP,O
,shortened,VBD,O
,QT,NNP,O
,less,RBR,O
,after,IN,O
,bupivacaine,NN,O
,than,IN,O
,in,IN,O
,control,NN,O
,animals,NNS,O
,.,.,O
,One,CD,O
,day,NN,O
,after,IN,O
,experimental,JJ,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,",",",",O
,six,CD,O
,additional,JJ,O
,halothane,NN,O
,-,:,O
,anesthetized,JJ,O
,dogs,NNS,O
,received,VBD,O
,4,CD,O
,micrograms,NNS,O
,.,.,O
,kg,VB,O
,-,:,O
,1,CD,O
,.,.,O
,min,VB,O
,-,:,O
,1,CD,O
,epinephrine,NN,O
,until,IN,O
,VT,NNP,B-DISEASE
,appeared,VBD,O
,.,.,O
,After,IN,O
,45,CD,O
,min,NN,O
,",",",",O
,1,CD,O
,mg,NN,O
,/,NNP,O
,kg,FW,O
,bupivacaine,NN,O
,was,VBD,O
,injected,VBN,O
,over,IN,O
,5,CD,O
,min,NNS,O
,",",",",O
,again,RB,O
,followed,VBN,O
,by,IN,O
,4,CD,O
,micrograms,NNS,O
,.,.,O
,kg,VB,O
,-,:,O
,1,CD,O
,.,.,O
,min,VB,O
,-,:,O
,1,CD,O
,epinephrine,NN,O
,.,.,O
,In,IN,O
,these,DT,O
,dogs,NNS,O
,",",",",O
,the,DT,O
,prodysrhythmic,JJ,O
,response,NN,O
,to,TO,O
,epinephrine,NN,O
,was,VBD,O
,also,RB,O
,mitigated,VBN,O
,by,IN,O
,preceding,VBG,O
,bupivacaine,NN,O
,.,.,O
,Bupivacaine,NNP,O
,antagonizes,VBZ,O
,epinephrine,JJ,O
,dysrhythmogenicity,NN,O
,in,IN,O
,conscious,JJ,O
,dogs,NNS,O
,susceptible,JJ,O
,to,TO,O
,VT,NNP,B-DISEASE
,and,CC,O
,in,IN,O
,anesthetized,JJ,O
,dogs,NNS,O
,with,IN,O
,spontaneous,JJ,O
,postinfarct,NN,O
,dysrhythmias,NN,B-DISEASE
,.,.,O
,There,EX,O
,is,VBZ,O
,no,DT,O
,evidence,NN,O
,that,IN,O
,systemic,JJ,O
,subtoxic,NN,O
,bupivacaine,NN,O
,administration,NN,O
,enhances,VBZ,O
,the,DT,O
,dysrhythmogenicity,NN,O
,of,IN,O
,subsequent,JJ,O
,epinephrine,NN,O
,.,.,O
,Milk,NNP,B-DISEASE
,-,:,I-DISEASE
,alkali,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,1,CD,O
,",",",",O
,25,CD,O
,(,(,O
,OH,NNP,O
,),),O
,2D,CD,O
,in,IN,O
,a,DT,O
,patient,NN,O
,with,IN,O
,hypoparathyroidism,NN,B-DISEASE
,.,.,O
,Milk,NNP,B-DISEASE
,-,:,I-DISEASE
,alkali,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,was,VBD,O
,first,RB,O
,described,VBN,O
,70,CD,O
,years,NNS,O
,ago,RB,O
,in,IN,O
,the,DT,O
,context,NN,O
,of,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,peptic,JJ,B-DISEASE
,ulcer,JJ,I-DISEASE
,disease,NN,I-DISEASE
,with,IN,O
,large,JJ,O
,amounts,NNS,O
,of,IN,O
,calcium,NN,O
,and,CC,O
,alkali,NN,O
,.,.,O
,Although,IN,O
,with,IN,O
,current,JJ,O
,ulcer,JJ,B-DISEASE
,therapy,NN,O
,(,(,O
,H,NNP,O
,-,:,O
,2,CD,O
,blockers,NNS,O
,",",",",O
,omeprazole,NN,O
,",",",",O
,and,CC,O
,sucralfate,NN,O
,),),O
,",",",",O
,the,DT,O
,frequency,NN,O
,of,IN,O
,milk,NN,B-DISEASE
,-,:,I-DISEASE
,alkali,NN,I-DISEASE
,syndrome,NN,I-DISEASE
,has,VBZ,O
,decreased,VBN,O
,significantly,RB,O
,",",",",O
,the,DT,O
,classic,JJ,O
,triad,NN,O
,of,IN,O
,hypercalcemia,NN,B-DISEASE
,",",",",O
,alkalosis,NN,B-DISEASE
,",",",",O
,and,CC,O
,renal,JJ,B-DISEASE
,impairment,NN,I-DISEASE
,remains,VBZ,O
,the,DT,O
,hallmark,NN,O
,of,IN,O
,the,DT,O
,syndrome,NN,O
,.,.,O
,Milk,NNP,B-DISEASE
,-,:,I-DISEASE
,alkali,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,can,MD,O
,present,VB,O
,serious,JJ,O
,and,CC,O
,occasionally,RB,O
,life,NN,O
,-,:,O
,threatening,VBG,O
,illness,NN,O
,unless,IN,O
,diagnosed,VBN,O
,and,CC,O
,treated,VBN,O
,appropriately,RB,O
,.,.,O
,This,DT,O
,article,NN,O
,presents,VBZ,O
,a,DT,O
,patient,NN,O
,with,IN,O
,hypoparathyroidism,NN,B-DISEASE
,who,WP,O
,was,VBD,O
,treated,VBN,O
,with,IN,O
,calcium,NN,O
,carbonate,NN,O
,and,CC,O
,calcitriol,NN,O
,resulting,VBG,O
,in,IN,O
,two,CD,O
,admissions,NNS,O
,to,TO,O
,the,DT,O
,hospital,NN,O
,for,IN,O
,milk,NN,B-DISEASE
,-,:,I-DISEASE
,alkali,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,.,.,O
,The,DT,O
,patient,NN,O
,was,VBD,O
,successfully,RB,O
,treated,VBN,O
,with,IN,O
,intravenous,JJ,O
,pamidronate,NN,O
,on,IN,O
,his,PRP$,O
,first,JJ,O
,admission,NN,O
,and,CC,O
,with,IN,O
,hydrocortisone,NN,O
,on,IN,O
,the,DT,O
,second,JJ,O
,.,.,O
,This,DT,O
,illustrates,VBZ,O
,intravenous,JJ,O
,pamidronate,NN,O
,as,IN,O
,a,DT,O
,valuable,JJ,O
,therapeutic,JJ,O
,tool,NN,O
,when,WRB,O
,milk,NN,B-DISEASE
,-,:,I-DISEASE
,alkali,JJ,I-DISEASE
,syndrome,JJ,I-DISEASE
,presents,NNS,O
,as,IN,O
,hypercalcemic,JJ,B-DISEASE
,emergency,NN,I-DISEASE
,.,.,O
,Famotidine,NNP,O
,-,:,O
,associated,JJ,O
,delirium,NN,B-DISEASE
,.,.,O
,A,DT,O
,series,NN,O
,of,IN,O
,six,CD,O
,cases,NNS,O
,.,.,O
,Famotidine,NNP,O
,is,VBZ,O
,a,DT,O
,histamine,NN,O
,H2,NNP,O
,-,:,O
,receptor,NN,O
,antagonist,NN,O
,used,VBN,O
,in,IN,O
,inpatient,JJ,O
,settings,NNS,O
,for,IN,O
,prevention,NN,O
,of,IN,O
,stress,NN,O
,ulcers,NNS,B-DISEASE
,and,CC,O
,is,VBZ,O
,showing,VBG,O
,increasing,VBG,O
,popularity,NN,O
,because,IN,O
,of,IN,O
,its,PRP$,O
,low,JJ,O
,cost,NN,O
,.,.,O
,Although,IN,O
,all,DT,O
,of,IN,O
,the,DT,O
,currently,RB,O
,available,JJ,O
,H2,NNP,O
,-,:,O
,receptor,NN,O
,antagonists,NNS,O
,have,VBP,O
,shown,VBN,O
,the,DT,O
,propensity,NN,O
,to,TO,O
,cause,VB,O
,delirium,NN,B-DISEASE
,",",",",O
,only,RB,O
,two,CD,O
,previously,RB,O
,reported,VBN,O
,cases,NNS,O
,have,VBP,O
,been,VBN,O
,associated,VBN,O
,with,IN,O
,famotidine,NN,O
,.,.,O
,The,DT,O
,authors,NNS,O
,report,VBP,O
,on,IN,O
,six,CD,O
,cases,NNS,O
,of,IN,O
,famotidine,JJ,O
,-,:,O
,associated,JJ,O
,delirium,NN,B-DISEASE
,in,IN,O
,hospitalized,JJ,O
,patients,NNS,O
,who,WP,O
,cleared,VBD,O
,completely,RB,O
,upon,IN,O
,removal,NN,O
,of,IN,O
,famotidine,NN,O
,.,.,O
,The,DT,O
,pharmacokinetics,NNS,O
,of,IN,O
,famotidine,NN,O
,are,VBP,O
,reviewed,VBN,O
,",",",",O
,with,IN,O
,no,DT,O
,change,NN,O
,in,IN,O
,its,PRP$,O
,metabolism,NN,O
,in,IN,O
,the,DT,O
,elderly,JJ,O
,population,NN,O
,seen,VBN,O
,.,.,O
,The,DT,O
,implications,NNS,O
,of,IN,O
,using,VBG,O
,famotidine,NN,O
,in,IN,O
,elderly,JJ,O
,persons,NNS,O
,are,VBP,O
,discussed,VBN,O
,.,.,O
,Encephalopathy,NNP,B-DISEASE
,during,IN,O
,amitriptyline,JJ,O
,therapy,NN,O
,:,:,O
,are,VBP,O
,neuroleptic,JJ,B-DISEASE
,malignant,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,and,CC,O
,serotonin,JJ,B-DISEASE
,syndrome,NN,I-DISEASE
,spectrum,NN,O
,disorders,NNS,O
,?,.,O
,This,DT,O
,report,NN,O
,describes,VBZ,O
,a,DT,O
,case,NN,O
,of,IN,O
,encephalopathy,NN,B-DISEASE
,developed,VBN,O
,in,IN,O
,the,DT,O
,course,NN,O
,of,IN,O
,amitriptyline,JJ,O
,therapy,NN,O
,",",",",O
,during,IN,O
,a,DT,O
,remission,NN,O
,of,IN,O
,unipolar,JJ,B-DISEASE
,depression,NN,I-DISEASE
,.,.,O
,This,DT,O
,patient,NN,O
,could,MD,O
,have,VB,O
,been,VBN,O
,diagnosed,VBN,O
,as,IN,O
,having,VBG,O
,either,CC,O
,neuroleptic,JJ,B-DISEASE
,malignant,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,(,(,O
,NMS,NNP,B-DISEASE
,),),O
,or,CC,O
,serotonin,JJ,B-DISEASE
,syndrome,NN,I-DISEASE
,(,(,O
,SS,NNP,B-DISEASE
,),),O
,.,.,O
,The,DT,O
,major,JJ,O
,determinant,NN,O
,of,IN,O
,the,DT,O
,symptoms,NNS,O
,may,MD,O
,have,VB,O
,been,VBN,O
,dopamine,JJ,O
,/,NNP,O
,serotonin,NN,O
,imbalance,NN,O
,in,IN,O
,the,DT,O
,central,JJ,O
,nervous,JJ,O
,system,NN,O
,.,.,O
,The,DT,O
,NMS,NNP,B-DISEASE
,-,:,O
,like,IN,O
,encephalopathy,NN,B-DISEASE
,that,WDT,O
,develops,VBZ,O
,in,IN,O
,association,NN,O
,with,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,antidepressants,NNS,O
,indicates,VBZ,O
,that,IN,O
,NMS,NNP,B-DISEASE
,and,CC,O
,SS,NNP,B-DISEASE
,are,VBP,O
,spectrum,JJ,O
,disorders,NNS,O
,induced,VBN,O
,by,IN,O
,drugs,NNS,O
,with,IN,O
,both,DT,O
,antidopaminergic,NNS,O
,and,CC,O
,serotonergic,JJ,O
,effects,NNS,O
,.,.,O
,Genetic,JJ,O
,separation,NN,O
,of,IN,O
,tumor,NN,B-DISEASE
,growth,NN,O
,and,CC,O
,hemorrhagic,JJ,B-DISEASE
,phenotypes,NNS,O
,in,IN,O
,an,DT,O
,estrogen,NN,O
,-,:,O
,induced,JJ,O
,tumor,NN,B-DISEASE
,.,.,O
,Chronic,NNP,O
,administration,NN,O
,of,IN,O
,estrogen,NN,O
,to,TO,O
,the,DT,O
,Fischer,NNP,O
,344,CD,O
,(,(,O
,F344,NNP,O
,),),O
,rat,NN,O
,induces,VBZ,O
,growth,NN,O
,of,IN,O
,large,JJ,O
,",",",",O
,hemorrhagic,JJ,B-DISEASE
,pituitary,JJ,B-DISEASE
,tumors,NNS,I-DISEASE
,.,.,O
,Ten,CD,O
,weeks,NNS,O
,of,IN,O
,diethylstilbestrol,NN,O
,(,(,O
,DES,NNP,O
,),),O
,treatment,NN,O
,caused,VBN,O
,female,JJ,O
,F344,NNP,O
,rat,NN,O
,pituitaries,NNS,O
,to,TO,O
,grow,VB,O
,to,TO,O
,an,DT,O
,average,NN,O
,of,IN,O
,109,CD,O
,.,.,O
,2,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,6,CD,O
,.,.,O
,3,CD,O
,mg,NN,O
,(,(,O
,mean,JJ,O
,+,NNP,O
,/,NNP,O
,-,:,O
,SE,NN,O
,),),O
,versus,NN,O
,11,CD,O
,.,.,O
,3,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,4,CD,O
,mg,NN,O
,for,IN,O
,untreated,JJ,O
,rats,NNS,O
,",",",",O
,and,CC,O
,to,TO,O
,become,VB,O
,highly,RB,O
,hemorrhagic,JJ,B-DISEASE
,.,.,O
,The,DT,O
,same,JJ,O
,DES,NNP,O
,treatment,NN,O
,produced,VBD,O
,no,DT,O
,significant,JJ,O
,growth,NN,O
,(,(,O
,8,CD,O
,.,.,O
,9,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,5,CD,O
,mg,NN,O
,for,IN,O
,treated,JJ,O
,females,NNS,O
,versus,IN,O
,8,CD,O
,.,.,O
,7,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,1,CD,O
,for,IN,O
,untreated,JJ,O
,females,NNS,O
,),),O
,or,CC,O
,morphological,JJ,O
,changes,NNS,O
,in,IN,O
,Brown,NNP,O
,Norway,NNP,O
,(,(,O
,BN,NNP,O
,),),O
,rat,NN,O
,pituitaries,NNS,O
,.,.,O
,An,DT,O
,F1,NNP,O
,hybrid,NN,O
,of,IN,O
,F344,NNP,O
,and,CC,O
,BN,NNP,O
,exhibited,VBD,O
,significant,JJ,O
,pituitary,JJ,O
,growth,NN,O
,after,IN,O
,10,CD,O
,weeks,NNS,O
,of,IN,O
,DES,NNP,O
,treatment,NN,O
,with,IN,O
,an,DT,O
,average,JJ,O
,mass,NN,O
,of,IN,O
,26,CD,O
,.,.,O
,3,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,7,CD,O
,mg,NNS,O
,compared,VBN,O
,with,IN,O
,8,CD,O
,.,.,O
,6,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,9,CD,O
,mg,NN,O
,for,IN,O
,untreated,JJ,O
,rats,NNS,O
,.,.,O
,Surprisingly,RB,O
,",",",",O
,the,DT,O
,F1,NNP,O
,hybrid,JJ,O
,tumors,NNS,B-DISEASE
,were,VBD,O
,not,RB,O
,hemorrhagic,JJ,B-DISEASE
,and,CC,O
,had,VBD,O
,hemoglobin,VBN,O
,content,NN,O
,and,CC,O
,outward,JJ,O
,appearance,NN,O
,identical,JJ,O
,to,TO,O
,that,DT,O
,of,IN,O
,BN,NNP,O
,.,.,O
,Expression,NN,O
,of,IN,O
,both,DT,O
,growth,NN,O
,and,CC,O
,morphological,JJ,O
,changes,NNS,O
,is,VBZ,O
,due,JJ,O
,to,TO,O
,multiple,JJ,O
,genes,NNS,O
,.,.,O
,However,RB,O
,",",",",O
,while,IN,O
,DES,NNP,O
,-,:,O
,induced,VBD,O
,pituitary,JJ,O
,growth,NN,O
,exhibited,VBD,O
,quantitative,JJ,O
,",",",",O
,additive,JJ,O
,inheritance,NN,O
,",",",",O
,the,DT,O
,hemorrhagic,NN,B-DISEASE
,phenotype,NN,O
,exhibited,VBD,O
,recessive,JJ,O
,",",",",O
,epistatic,JJ,O
,inheritance,NN,O
,.,.,O
,Only,RB,O
,5,CD,O
,of,IN,O
,the,DT,O
,160,CD,O
,F2,NNP,O
,pituitaries,NNS,O
,exhibited,VBD,O
,the,DT,O
,hemorrhagic,JJ,B-DISEASE
,phenotype,NN,O
,;,:,O
,36,CD,O
,of,IN,O
,the,DT,O
,160,CD,O
,F2,NNP,O
,pituitaries,NNS,O
,were,VBD,O
,in,IN,O
,the,DT,O
,F344,NNP,O
,range,NN,O
,of,IN,O
,mass,NN,O
,",",",",O
,but,CC,O
,31,CD,O
,of,IN,O
,these,DT,O
,were,VBD,O
,not,RB,O
,hemorrhagic,JJ,B-DISEASE
,",",",",O
,indicating,VBG,O
,that,IN,O
,the,DT,O
,hemorrhagic,JJ,B-DISEASE
,phenotype,NN,O
,is,VBZ,O
,not,RB,O
,merely,RB,O
,a,DT,O
,consequence,NN,O
,of,IN,O
,extensive,JJ,O
,growth,NN,O
,.,.,O
,The,DT,O
,hemorrhagic,JJ,B-DISEASE
,F2,NNP,O
,pituitaries,NNS,O
,were,VBD,O
,all,DT,O
,among,IN,O
,the,DT,O
,most,RBS,O
,massive,JJ,O
,",",",",O
,indicating,VBG,O
,that,IN,O
,some,DT,O
,of,IN,O
,the,DT,O
,genes,NNS,O
,regulate,VB,O
,both,DT,O
,phenotypes,NNS,O
,.,.,O
,Increased,VBN,O
,expression,NN,O
,of,IN,O
,neuronal,JJ,O
,nitric,JJ,O
,oxide,NN,O
,synthase,NN,O
,in,IN,O
,bladder,NN,O
,afferent,NN,O
,pathways,NNS,O
,following,VBG,O
,chronic,JJ,O
,bladder,NN,B-DISEASE
,irritation,NN,I-DISEASE
,.,.,O
,Immunocytochemical,JJ,O
,techniques,NNS,O
,were,VBD,O
,used,VBN,O
,to,TO,O
,examine,VB,O
,alterations,NNS,O
,in,IN,O
,the,DT,O
,expression,NN,O
,of,IN,O
,neuronal,JJ,O
,nitric,JJ,O
,oxide,NN,O
,synthase,NN,O
,(,(,O
,NOS,NNP,O
,),),O
,in,IN,O
,bladder,NN,O
,pathways,NNS,O
,following,VBG,O
,acute,NN,O
,and,CC,O
,chronic,JJ,O
,irritation,NN,B-DISEASE
,of,IN,I-DISEASE
,the,DT,I-DISEASE
,urinary,JJ,I-DISEASE
,tract,NN,I-DISEASE
,of,IN,O
,the,DT,O
,rat,NN,O
,.,.,O
,Chemical,NNP,O
,cystitis,NN,B-DISEASE
,was,VBD,O
,induced,VBN,O
,by,IN,O
,cyclophosphamide,NN,O
,(,(,O
,CYP,NNP,O
,),),O
,which,WDT,O
,is,VBZ,O
,metabolized,VBN,O
,to,TO,O
,acrolein,VB,O
,",",",",O
,an,DT,O
,irritant,NN,O
,eliminated,VBN,O
,in,IN,O
,the,DT,O
,urine,NN,O
,.,.,O
,Injection,NN,O
,of,IN,O
,CYP,NNP,O
,(,(,O
,n,JJ,O
,=,NN,O
,10,CD,O
,",",",",O
,75,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,),),O
,2,CD,O
,hours,NNS,O
,prior,RB,O
,to,TO,O
,perfusion,NN,O
,(,(,O
,acute,JJ,O
,treatment,NN,O
,),),O
,of,IN,O
,the,DT,O
,animals,NNS,O
,increased,VBD,O
,Fos,NNP,O
,-,:,O
,immunoreactivity,NN,O
,(,(,O
,IR,NNP,O
,),),O
,in,IN,O
,neurons,NNS,O
,in,IN,O
,the,DT,O
,dorsal,NN,O
,commissure,NN,O
,",",",",O
,dorsal,NN,O
,horn,NN,O
,",",",",O
,and,CC,O
,autonomic,JJ,O
,regions,NNS,O
,of,IN,O
,spinal,JJ,O
,segments,NNS,O
,(,(,O
,L1,NNP,O
,-,:,O
,L2,NNP,O
,and,CC,O
,L6,NNP,O
,-,:,O
,S1,NNP,O
,),),O
,which,WDT,O
,receive,VBP,O
,afferent,NN,O
,inputs,NNS,O
,from,IN,O
,the,DT,O
,bladder,NN,O
,",",",",O
,urethra,NN,O
,",",",",O
,and,CC,O
,ureter,RB,O
,.,.,O
,Fos,NNP,O
,-,:,O
,IR,NN,O
,in,IN,O
,the,DT,O
,spinal,JJ,O
,cord,NN,O
,was,VBD,O
,not,RB,O
,changed,VBN,O
,in,IN,O
,rats,NNS,O
,receiving,VBG,O
,chronic,JJ,O
,CYP,NNP,O
,treatment,NN,O
,(,(,O
,n,JJ,O
,=,NN,O
,15,CD,O
,",",",",O
,75,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,i,NN,O
,.,.,O
,p,NN,O
,.,.,O
,",",",",O
,every,DT,O
,3rd,CD,O
,day,NN,O
,for,IN,O
,2,CD,O
,weeks,NNS,O
,),),O
,.,.,O
,In,IN,O
,control,NN,O
,animals,NNS,O
,and,CC,O
,in,IN,O
,animals,NNS,O
,treated,VBD,O
,acutely,RB,O
,with,IN,O
,CYP,NNP,O
,",",",",O
,only,RB,O
,small,JJ,O
,numbers,NNS,O
,of,IN,O
,NOS,NNP,O
,-,:,O
,IR,NNP,O
,cells,NNS,O
,(,(,O
,0,CD,O
,.,.,O
,5,CD,O
,-,:,O
,0,CD,O
,.,.,O
,7,CD,O
,cell,NN,O
,profiles,NNS,O
,/,VBP,O
,sections,NNS,O
,),),O
,were,VBD,O
,detected,VBN,O
,in,IN,O
,the,DT,O
,L6,NNP,O
,-,:,O
,S1,NNP,O
,dorsal,NN,O
,root,NN,O
,ganglia,NN,O
,(,(,O
,DRG,NNP,O
,),),O
,.,.,O
,Chronic,NNP,O
,CYP,NNP,O
,administration,NN,O
,significantly,RB,O
,(,(,O
,P,NNP,O
,<,NNP,O
,or,CC,O
,=,NNP,O
,.,.,O
,002,CD,O
,),),O
,increased,VBD,O
,bladder,NN,O
,weight,NN,O
,by,IN,O
,60,CD,O
,%,NN,O
,and,CC,O
,increased,VBD,O
,(,(,O
,7,CD,O
,-,:,O
,to,TO,O
,11,CD,O
,-,:,O
,fold,NN,O
,),),O
,the,DT,O
,numbers,NNS,O
,of,IN,O
,NOS,NNP,O
,-,:,O
,immunoreactive,NN,O
,(,(,O
,IR,NNP,O
,),),O
,afferent,NN,O
,neurons,NNS,O
,in,IN,O
,the,DT,O
,L6,NNP,O
,-,:,O
,S1,NNP,O
,DRG,NNP,O
,.,.,O
,A,NNP,O
,small,JJ,O
,increase,NN,O
,(,(,O
,1,CD,O
,.,.,O
,5,CD,O
,-,:,O
,fold,NN,O
,),),O
,also,RB,O
,occurred,VBD,O
,in,IN,O
,the,DT,O
,L1,NNP,O
,DRG,NNP,O
,",",",",O
,but,CC,O
,no,DT,O
,change,NN,O
,was,VBD,O
,detected,VBN,O
,in,IN,O
,the,DT,O
,L2,NNP,O
,and,CC,O
,L5,NNP,O
,DRG,NNP,O
,.,.,O
,Bladder,NNP,O
,afferent,JJ,O
,cells,NNS,O
,in,IN,O
,the,DT,O
,L6,NNP,O
,-,:,O
,S1,NNP,O
,DRG,NNP,O
,labeled,VBN,O
,by,IN,O
,Fluorogold,NNP,O
,(,(,O
,40,CD,O
,microliters,NNS,O
,),),O
,injected,VBD,O
,into,IN,O
,the,DT,O
,bladder,NN,O
,wall,NN,O
,did,VBD,O
,not,RB,O
,exhibit,VB,O
,NOS,NNP,O
,-,:,O
,IR,NNP,O
,in,IN,O
,control,NN,O
,animals,NNS,O
,;,:,O
,however,RB,O
,",",",",O
,following,VBG,O
,chronic,JJ,O
,CYP,NNP,O
,administration,NN,O
,",",",",O
,a,DT,O
,significant,JJ,O
,percentage,NN,O
,of,IN,O
,bladder,NN,O
,afferent,NN,O
,neurons,NNS,O
,were,VBD,O
,NOS,NNP,O
,-,:,O
,IR,NN,O
,:,:,O
,L6,NNP,O
,(,(,O
,19,CD,O
,.,.,O
,8,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,4,CD,O
,.,.,O
,6,CD,O
,%,NN,O
,),),O
,and,CC,O
,S1,NNP,O
,(,(,O
,25,CD,O
,.,.,O
,3,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,2,CD,O
,.,.,O
,9,CD,O
,%,NN,O
,),),O
,.,.,O
,These,DT,O
,results,NNS,O
,indicate,VBP,O
,that,IN,O
,neuronal,JJ,O
,gene,NN,O
,expression,NN,O
,in,IN,O
,visceral,JJ,O
,sensory,JJ,O
,pathways,NNS,O
,can,MD,O
,be,VB,O
,upregulated,VBN,O
,by,IN,O
,chemical,JJ,O
,irritation,NN,O
,of,IN,O
,afferent,JJ,O
,receptors,NNS,O
,in,IN,O
,the,DT,O
,urinary,JJ,O
,tract,NN,O
,and,CC,O
,/,NN,O
,or,CC,O
,that,DT,O
,pathological,JJ,O
,changes,NNS,O
,in,IN,O
,the,DT,O
,urinary,JJ,O
,tract,NN,O
,can,MD,O
,initiate,VB,O
,chemical,JJ,O
,signals,NNS,O
,that,WDT,O
,alter,VBP,O
,the,DT,O
,chemical,NN,O
,properties,NNS,O
,of,IN,O
,visceral,JJ,O
,afferent,JJ,O
,neurons,NNS,O
,.,.,O
,Effects,NNS,O
,of,IN,O
,a,DT,O
,new,JJ,O
,calcium,NN,O
,antagonist,NN,O
,",",",",O
,CD,NNP,O
,-,:,O
,832,CD,O
,",",",",O
,on,IN,O
,isoproterenol,JJ,O
,-,:,O
,induced,JJ,O
,myocardial,JJ,B-DISEASE
,ischemia,NN,I-DISEASE
,in,IN,O
,dogs,NNS,O
,with,IN,O
,partial,JJ,O
,coronary,JJ,B-DISEASE
,stenosis,NN,I-DISEASE
,.,.,O
,Effects,NNS,O
,of,IN,O
,CD,NNP,O
,-,:,O
,832,CD,O
,on,IN,O
,isoproterenol,NN,O
,(,(,O
,ISO,NNP,O
,),),O
,-,:,O
,induced,VBN,O
,myocardial,JJ,B-DISEASE
,ischemia,NN,I-DISEASE
,were,VBD,O
,studied,VBN,O
,in,IN,O
,dogs,NNS,O
,with,IN,O
,partial,JJ,O
,coronary,JJ,B-DISEASE
,stenosis,NN,I-DISEASE
,of,IN,O
,the,DT,O
,left,NN,O
,circumflex,JJ,O
,coronary,JJ,O
,artery,NN,O
,and,CC,O
,findings,NNS,O
,were,VBD,O
,compared,VBN,O
,with,IN,O
,those,DT,O
,for,IN,O
,nifedipine,JJ,O
,or,CC,O
,diltiazem,NN,O
,.,.,O
,In,IN,O
,the,DT,O
,presence,NN,O
,of,IN,O
,coronary,JJ,B-DISEASE
,artery,NN,I-DISEASE
,stenosis,NN,I-DISEASE
,",",",",O
,3,CD,O
,-,:,O
,min,NN,O
,periods,NNS,O
,of,IN,O
,intracoronary,JJ,O
,ISO,NNP,O
,infusion,NN,O
,(,(,O
,10,CD,O
,ng,RB,O
,/,JJ,O
,kg,NN,O
,/,NNP,O
,min,NN,O
,),),O
,increased,VBD,O
,heart,NN,O
,rate,NN,O
,and,CC,O
,maximal,JJ,O
,rate,NN,O
,of,IN,O
,left,JJ,O
,ventricular,JJ,O
,pressure,NN,O
,rise,NN,O
,",",",",O
,which,WDT,O
,resulted,VBD,O
,in,IN,O
,a,DT,O
,decrease,NN,O
,in,IN,O
,percentage,NN,O
,segmental,JJ,O
,shortening,NN,O
,and,CC,O
,ST,NNP,O
,-,:,O
,segment,NN,O
,elevation,NN,O
,of,IN,O
,the,DT,O
,epicardial,JJ,O
,electrocardiogram,NN,O
,.,.,O
,After,IN,O
,the,DT,O
,control,NN,O
,ISO,NNP,O
,infusion,NN,O
,with,IN,O
,stenosis,NN,B-DISEASE
,was,VBD,O
,performed,VBN,O
,",",",",O
,equihypotensive,JJ,O
,doses,NNS,O
,of,IN,O
,CD,NNP,O
,-,:,O
,832,CD,O
,(,(,O
,3,CD,O
,and,CC,O
,10,CD,O
,micrograms,NNS,O
,/,VBP,O
,kg,JJ,O
,/,NNP,O
,min,NN,O
,",",",",O
,n,JJ,O
,=,NNP,O
,7,CD,O
,),),O
,",",",",O
,nifedipine,JJ,O
,(,(,O
,1,CD,O
,and,CC,O
,3,CD,O
,micrograms,NNS,O
,/,VBP,O
,kg,JJ,O
,/,NNP,O
,min,NN,O
,",",",",O
,n,JJ,O
,=,NNP,O
,9,CD,O
,),),O
,or,CC,O
,diltiazem,NN,O
,(,(,O
,10,CD,O
,and,CC,O
,30,CD,O
,micrograms,NNS,O
,/,VBP,O
,kg,JJ,O
,/,NNP,O
,min,NN,O
,",",",",O
,n,JJ,O
,=,NNP,O
,7,CD,O
,),),O
,were,VBD,O
,infused,VBN,O
,5,CD,O
,min,NN,O
,before,IN,O
,and,CC,O
,during,IN,O
,the,DT,O
,second,JJ,O
,and,CC,O
,third,JJ,O
,ISO,NNP,O
,infusion,NN,O
,.,.,O
,Both,DT,O
,CD,NNP,O
,-,:,O
,832,CD,O
,and,CC,O
,diltiazem,NN,O
,",",",",O
,but,CC,O
,not,RB,O
,nifedipine,JJ,O
,",",",",O
,significantly,RB,O
,reduced,VBD,O
,the,DT,O
,increase,NN,O
,in,IN,O
,heart,NN,O
,rate,NN,O
,induced,VBN,O
,by,IN,O
,ISO,NNP,O
,infusion,NN,O
,.,.,O
,In,IN,O
,contrast,NN,O
,to,TO,O
,nifedipine,VB,O
,",",",",O
,CD,NNP,O
,-,:,O
,832,CD,O
,(,(,O
,10,CD,O
,micrograms,NNS,O
,/,VBP,O
,kg,JJ,O
,/,NNP,O
,min,NN,O
,),),O
,prevented,VBD,O
,the,DT,O
,decrease,NN,O
,in,IN,O
,percentage,NN,O
,segmental,JJ,O
,shortening,NN,O
,from,IN,O
,32,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,12,CD,O
,%,NN,O
,to,TO,O
,115,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,26,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,control,NN,O
,value,NN,O
,(,(,O
,P,NNP,O
,<,NNP,O
,.,.,O
,01,CD,O
,),),O
,and,CC,O
,ST,NNP,O
,-,:,O
,segment,NN,O
,elevation,NN,O
,from,IN,O
,5,CD,O
,.,.,O
,6,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,0,CD,O
,mV,NN,O
,to,TO,O
,1,CD,O
,.,.,O
,6,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,1,CD,O
,.,.,O
,3,CD,O
,mV,NN,O
,(,(,O
,P,NNP,O
,<,NNP,O
,.,.,O
,01,CD,O
,),),O
,at,IN,O
,3,CD,O
,min,NN,O
,after,IN,O
,ISO,NNP,O
,infusion,NN,O
,with,IN,O
,stenosis,NN,B-DISEASE
,.,.,O
,Diltiazem,NNP,O
,(,(,O
,30,CD,O
,micrograms,NNS,O
,/,VBP,O
,kg,JJ,O
,/,NNP,O
,min,NN,O
,),),O
,also,RB,O
,prevented,VBD,O
,the,DT,O
,decrease,NN,O
,in,IN,O
,percentage,NN,O
,segmental,JJ,O
,shortening,NN,O
,from,IN,O
,34,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,14,CD,O
,%,NN,O
,to,TO,O
,63,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,18,CD,O
,%,NN,O
,of,IN,O
,the,DT,O
,control,NN,O
,value,NN,O
,(,(,O
,P,NNP,O
,<,NNP,O
,.,.,O
,05,CD,O
,),),O
,and,CC,O
,ST,NNP,O
,-,:,O
,segment,NN,O
,elevation,NN,O
,from,IN,O
,4,CD,O
,.,.,O
,7,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,7,CD,O
,mV,NN,O
,to,TO,O
,2,CD,O
,.,.,O
,1,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,7,CD,O
,mV,NN,O
,(,(,O
,P,NNP,O
,<,NNP,O
,.,.,O
,01,CD,O
,),),O
,at,IN,O
,3,CD,O
,min,NN,O
,after,IN,O
,ISO,NNP,O
,infusion,NN,O
,with,IN,O
,stenosis,NN,B-DISEASE
,.,.,O
,These,DT,O
,data,NNS,O
,show,VBP,O
,that,IN,O
,CD,NNP,O
,-,:,O
,832,CD,O
,improves,NNS,O
,myocardial,JJ,B-DISEASE
,ischemia,NN,I-DISEASE
,during,IN,O
,ISO,NNP,O
,infusion,NN,O
,with,IN,O
,stenosis,NN,B-DISEASE
,and,CC,O
,suggest,VBP,O
,that,IN,O
,the,DT,O
,negative,JJ,O
,chronotropic,NN,O
,property,NN,O
,of,IN,O
,CD,NNP,O
,-,:,O
,832,CD,O
,plays,VBZ,O
,a,DT,O
,major,JJ,O
,role,NN,O
,in,IN,O
,the,DT,O
,beneficial,JJ,O
,effects,NNS,O
,of,IN,O
,CD,NNP,O
,-,:,O
,832,CD,O
,.,.,O
,The,DT,O
,effect,NN,O
,of,IN,O
,recombinant,JJ,O
,human,JJ,O
,insulin,NN,O
,-,:,O
,like,IN,O
,growth,NN,O
,factor,NN,O
,-,:,O
,I,PRP,O
,on,IN,O
,chronic,JJ,O
,puromycin,NN,O
,aminonucleoside,NN,O
,nephropathy,NN,B-DISEASE
,in,IN,O
,rats,NNS,O
,.,.,O
,We,PRP,O
,recently,RB,O
,demonstrated,VBD,O
,that,IN,O
,recombinant,JJ,O
,hGH,NN,O
,exacerbates,VBZ,O
,renal,JJ,O
,functional,JJ,O
,and,CC,O
,structural,JJ,O
,injury,NN,O
,in,IN,O
,chronic,JJ,O
,puromycin,NN,O
,aminonucleoside,NN,O
,(,(,O
,PAN,NNP,O
,),),O
,nephropathy,NN,B-DISEASE
,",",",",O
,an,DT,O
,experimental,JJ,O
,model,NN,O
,of,IN,O
,glomerular,JJ,B-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,Therefore,RB,O
,",",",",O
,we,PRP,O
,examined,VBD,O
,whether,IN,O
,recombinant,JJ,O
,human,JJ,O
,(,(,O
,rh,NN,O
,),),O
,IGF,NNP,O
,-,:,O
,I,PRP,O
,is,VBZ,O
,a,DT,O
,safer,NN,O
,alternative,NN,O
,for,IN,O
,the,DT,O
,treatment,NN,O
,of,IN,O
,growth,NN,B-DISEASE
,failure,NN,I-DISEASE
,in,IN,O
,rats,NNS,O
,with,IN,O
,chronic,JJ,O
,PAN,NNP,O
,nephropathy,NN,B-DISEASE
,.,.,O
,The,DT,O
,glomerulopathy,NN,B-DISEASE
,was,VBD,O
,induced,VBN,O
,by,IN,O
,seven,CD,O
,serial,JJ,O
,injections,NNS,O
,of,IN,O
,PAN,NNP,O
,over,IN,O
,12,CD,O
,wk,NNS,O
,.,.,O
,Experimental,JJ,O
,animals,NNS,O
,(,(,O
,n,JJ,O
,=,NNP,O
,6,CD,O
,),),O
,received,VBD,O
,rhIGF,JJ,O
,-,:,O
,I,PRP,O
,",",",",O
,400,CD,O
,micrograms,NNS,O
,/,NNP,O
,d,NN,O
,",",",",O
,whereas,WP,O
,control,NN,O
,rats,NNS,O
,(,(,O
,n,JJ,O
,=,NNP,O
,6,CD,O
,),),O
,received,VBD,O
,the,DT,O
,vehicle,NN,O
,.,.,O
,rhIGF,VB,O
,-,:,O
,I,PRP,O
,improved,VBD,O
,weight,JJ,O
,gain,NN,O
,by,IN,O
,14,CD,O
,%,NN,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,",",",",O
,without,IN,O
,altering,VBG,O
,hematocrit,NN,O
,or,CC,O
,blood,NN,O
,pressure,NN,O
,in,IN,O
,rats,NNS,O
,with,IN,O
,renal,JJ,B-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,Urinary,JJ,O
,protein,NN,O
,excretion,NN,O
,was,VBD,O
,unaltered,VBN,O
,by,IN,O
,rhIGF,JJ,O
,-,:,O
,I,PRP,O
,treatment,NN,O
,in,IN,O
,rats,NNS,O
,with,IN,O
,chronic,JJ,O
,PAN,NNP,O
,nephropathy,NN,B-DISEASE
,.,.,O
,After,IN,O
,12,CD,O
,wk,NN,O
,",",",",O
,the,DT,O
,inulin,JJ,O
,clearance,NN,O
,was,VBD,O
,higher,RBR,O
,in,IN,O
,rhIGF,JJ,O
,-,:,O
,I,PRP,O
,-,:,O
,treated,VBD,O
,rats,NNS,O
,",",",",O
,0,CD,O
,.,.,O
,48,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,08,CD,O
,versus,NN,O
,0,CD,O
,.,.,O
,24,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,06,CD,O
,mL,JJ,O
,/,NNP,O
,min,NN,O
,/,VBD,O
,100,CD,O
,g,NN,O
,of,IN,O
,body,NN,O
,weight,NN,O
,in,IN,O
,untreated,JJ,O
,PAN,NNP,O
,nephropathy,NN,B-DISEASE
,animals,NNS,O
,",",",",O
,p,VBP,O
,<,JJ,O
,0,CD,O
,.,.,O
,05,CD,O
,.,.,O
,The,DT,O
,improvement,NN,O
,in,IN,O
,GFR,NNP,O
,was,VBD,O
,not,RB,O
,associated,VBN,O
,with,IN,O
,enhanced,JJ,O
,glomerular,JJ,B-DISEASE
,hypertrophy,NN,I-DISEASE
,or,CC,O
,increased,JJ,O
,segmental,JJ,O
,glomerulosclerosis,NN,B-DISEASE
,",",",",O
,tubulointerstitial,JJ,B-DISEASE
,injury,NN,I-DISEASE
,",",",",O
,or,CC,O
,renal,JJ,O
,cortical,JJ,O
,malondialdehyde,NN,O
,content,NN,O
,.,.,O
,In,IN,O
,rats,NNS,O
,with,IN,O
,PAN,NNP,O
,nephropathy,CC,B-DISEASE
,",",",",O
,administration,NN,O
,of,IN,O
,rhIGF,JJ,O
,-,:,O
,I,PRP,O
,increased,VBD,O
,IGF,NNP,O
,-,:,O
,I,PRP,O
,and,CC,O
,GH,NNP,O
,receptor,NN,O
,gene,NN,O
,expression,NN,O
,",",",",O
,without,IN,O
,altering,VBG,O
,the,DT,O
,steady,JJ,O
,state,NN,O
,level,NN,O
,of,IN,O
,IGF,NNP,O
,-,:,O
,I,PRP,O
,receptor,VBP,O
,mRNA,JJ,O
,.,.,O
,In,IN,O
,normal,JJ,O
,rats,NNS,O
,with,IN,O
,intact,JJ,O
,kidneys,NNS,O
,",",",",O
,rhIGF,VBP,O
,-,:,O
,I,PRP,O
,administration,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,4,CD,O
,),),O
,did,VBD,O
,not,RB,O
,alter,VB,O
,weight,NN,O
,gain,NN,O
,",",",",O
,blood,NN,O
,pressure,NN,O
,",",",",O
,proteinuria,NN,B-DISEASE
,",",",",O
,GFR,NNP,O
,",",",",O
,glomerular,JJ,O
,planar,NN,O
,area,NN,O
,",",",",O
,renal,JJ,O
,cortical,JJ,O
,malondialdehyde,NN,O
,content,NN,O
,",",",",O
,or,CC,O
,glomerular,NN,O
,or,CC,O
,tubulointerstitial,JJ,B-DISEASE
,damage,NN,I-DISEASE
,",",",",O
,compared,VBN,O
,with,IN,O
,untreated,JJ,O
,animals,NNS,O
,(,(,O
,n,JJ,O
,=,NNP,O
,4,CD,O
,),),O
,.,.,O
,rhIGF,VB,O
,-,:,O
,I,PRP,O
,treatment,NN,O
,reduced,VBD,O
,the,DT,O
,steady,JJ,O
,state,NN,O
,renal,JJ,O
,IGF,NNP,O
,-,:,O
,I,PRP,O
,mRNA,VBP,O
,level,JJ,O
,but,CC,O
,did,VBD,O
,not,RB,O
,modify,VB,O
,gene,NN,O
,expression,NN,O
,of,IN,O
,the,DT,O
,IGF,NNP,O
,-,:,O
,I,PRP,O
,or,CC,O
,GH,NNP,O
,receptors,NNS,O
,.,.,O
,We,PRP,O
,conclude,VBP,O
,that,IN,O
,:,:,O
,1,CD,O
,),),O
,administration,NN,O
,of,IN,O
,rhIGF,JJ,O
,-,:,O
,I,PRP,O
,improves,VBZ,O
,growth,NN,O
,and,CC,O
,GFR,NNP,O
,in,IN,O
,rats,NNS,O
,with,IN,O
,chronic,JJ,O
,PAN,NNP,O
,nephropathy,NN,B-DISEASE
,and,CC,O
,2,CD,O
,),),O
,unlike,IN,O
,rhGH,NN,O
,",",",",O
,long,JJ,O
,-,:,O
,term,NN,O
,use,NN,O
,of,IN,O
,rhIGF,NN,O
,-,:,O
,I,PRP,O
,does,VBZ,O
,not,RB,O
,worsen,VB,O
,renal,JJ,O
,functional,JJ,O
,and,CC,O
,structural,JJ,O
,injury,NN,O
,in,IN,O
,this,DT,O
,disease,NN,O
,model,NN,O
,.,.,O
,Nefiracetam,NNP,O
,(,(,O
,DM,NNP,O
,-,:,O
,9384,CD,O
,),),O
,reverses,VBZ,O
,apomorphine,JJ,O
,-,:,O
,induced,JJ,O
,amnesia,NN,B-DISEASE
,of,IN,O
,a,DT,O
,passive,JJ,O
,avoidance,NN,O
,response,NN,O
,:,:,O
,delayed,JJ,O
,emergence,NN,O
,of,IN,O
,the,DT,O
,memory,NN,O
,retention,NN,O
,effects,NNS,O
,.,.,O
,Nefiracetam,NNP,O
,is,VBZ,O
,a,DT,O
,novel,JJ,O
,pyrrolidone,NN,O
,derivative,NN,O
,which,WDT,O
,attenuates,VBZ,O
,scopolamine,JJ,O
,-,:,O
,induced,JJ,O
,learning,NN,B-DISEASE
,and,CC,I-DISEASE
,post,NN,I-DISEASE
,-,:,I-DISEASE
,training,NN,I-DISEASE
,consolidation,NN,I-DISEASE
,deficits,NNS,I-DISEASE
,.,.,O
,Given,VBN,O
,that,IN,O
,apomorphine,JJ,O
,inhibits,NNS,O
,passive,JJ,O
,avoidance,NN,O
,retention,NN,O
,when,WRB,O
,given,VBN,O
,during,IN,O
,training,NN,O
,or,CC,O
,in,IN,O
,a,DT,O
,defined,JJ,O
,10,CD,O
,-,:,O
,12h,CD,O
,post,NN,O
,-,:,O
,training,NN,O
,period,NN,O
,",",",",O
,we,PRP,O
,evaluated,VBD,O
,the,DT,O
,ability,NN,O
,of,IN,O
,nefiracetam,NN,O
,to,TO,O
,attenuate,VB,O
,amnesia,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,dopaminergic,JJ,O
,agonism,NN,O
,.,.,O
,A,DT,O
,step,NN,O
,-,:,O
,down,RB,O
,passive,JJ,O
,avoidance,NN,O
,paradigm,NN,O
,was,VBD,O
,employed,VBN,O
,and,CC,O
,nefiracetam,JJ,O
,(,(,O
,3,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,and,CC,O
,apomorphine,NN,O
,(,(,O
,0,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,),),O
,were,VBD,O
,given,VBN,O
,alone,RB,O
,or,CC,O
,in,IN,O
,combination,NN,O
,during,IN,O
,training,NN,O
,and,CC,O
,at,IN,O
,the,DT,O
,10,CD,O
,-,:,O
,12h,CD,O
,post,NN,O
,-,:,O
,training,NN,O
,period,NN,O
,of,IN,O
,consolidation,NN,O
,.,.,O
,Co,NNP,O
,-,:,O
,administration,NN,O
,of,IN,O
,nefiracetam,JJ,O
,and,CC,O
,apomorphine,JJ,O
,during,IN,O
,training,NN,O
,or,CC,O
,10h,CD,O
,thereafter,RB,O
,produced,VBN,O
,no,DT,O
,significant,JJ,O
,anti,SYM,O
,-,:,O
,amnesic,JJ,O
,effect,NN,O
,.,.,O
,However,RB,O
,",",",",O
,administration,NN,O
,of,IN,O
,nefiracetam,JJ,O
,during,IN,O
,training,VBG,O
,completely,RB,O
,reversed,VBN,O
,the,DT,O
,amnesia,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,apomorphine,NN,O
,at,IN,O
,the,DT,O
,10h,CD,O
,post,NN,O
,-,:,O
,training,NN,O
,time,NN,O
,and,CC,O
,the,DT,O
,converse,NN,O
,was,VBD,O
,also,RB,O
,true,JJ,O
,.,.,O
,These,DT,O
,effects,NNS,O
,were,VBD,O
,not,RB,O
,mediated,VBN,O
,by,IN,O
,a,DT,O
,dopaminergic,JJ,O
,mechanism,NN,O
,as,IN,O
,nefiracetam,NN,O
,",",",",O
,at,IN,O
,millimolar,JJ,O
,concentrations,NNS,O
,",",",",O
,failed,VBD,O
,to,TO,O
,displace,VB,O
,either,RB,O
,[,JJ,O
,3H,CD,O
,],JJ,O
,SCH,NNP,O
,23390,CD,O
,or,CC,O
,[,VB,O
,3H,CD,O
,],NNP,O
,spiperone,NN,O
,binding,VBG,O
,from,IN,O
,D1,NNP,O
,or,CC,O
,D2,NNP,O
,dopamine,VBP,O
,receptor,NN,O
,subtypes,NNS,O
,",",",",O
,respectively,RB,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,suggested,VBN,O
,that,IN,O
,nefiracetam,JJ,O
,augments,NNS,O
,molecular,JJ,O
,processes,NNS,O
,in,IN,O
,the,DT,O
,early,JJ,O
,stages,NNS,O
,of,IN,O
,events,NNS,O
,which,WDT,O
,ultimately,RB,O
,lead,VBP,O
,to,TO,O
,consolidation,NN,O
,of,IN,O
,memory,NN,O
,.,.,O
,Phenytoin,NNP,O
,encephalopathy,JJ,B-DISEASE
,as,IN,O
,probable,JJ,O
,idiosyncratic,JJ,O
,reaction,NN,O
,:,:,O
,case,NN,O
,report,NN,O
,.,.,O
,A,DT,O
,case,NN,O
,of,IN,O
,phenytoin,NN,O
,(,(,O
,DPH,NNP,O
,),),O
,encephalopathy,NN,B-DISEASE
,with,IN,O
,increasing,VBG,O
,seizures,NNS,B-DISEASE
,and,CC,O
,EEG,NNP,O
,and,CC,O
,mental,JJ,O
,changes,NNS,O
,is,VBZ,O
,described,VBN,O
,.,.,O
,Despite,IN,O
,adequate,JJ,O
,oral,JJ,O
,dosage,NN,O
,of,IN,O
,DPH,NNP,O
,(,(,O
,5,CD,O
,mg,NN,O
,/,NNP,O
,kg,NNP,O
,/,NNP,O
,daily,RB,O
,),),O
,the,DT,O
,plasma,JJ,O
,level,NN,O
,was,VBD,O
,very,RB,O
,low,JJ,O
,(,(,O
,2,CD,O
,.,.,O
,8,CD,O
,microgramg,JJ,O
,/,NNP,O
,ml,NN,O
,),),O
,.,.,O
,The,DT,O
,encephalopathy,NN,B-DISEASE
,was,VBD,O
,probably,RB,O
,an,DT,O
,idiosyncratic,JJ,O
,and,CC,O
,not,RB,O
,toxic,JJ,O
,or,CC,O
,allergic,JJ,O
,reaction,NN,O
,.,.,O
,In,IN,O
,fact,NN,O
,the,DT,O
,concentration,NN,O
,of,IN,O
,free,JJ,O
,DPH,NNP,O
,was,VBD,O
,normal,JJ,O
,",",",",O
,the,DT,O
,patient,NN,O
,presented,VBD,O
,a,DT,O
,retarded,JJ,O
,morbilliform,NN,O
,rash,NN,B-DISEASE
,during,IN,O
,DPH,NNP,O
,treatment,NN,O
,",",",",O
,the,DT,O
,protidogram,NN,O
,was,VBD,O
,normal,JJ,O
,",",",",O
,and,CC,O
,an,DT,O
,intradermic,JJ,O
,DPH,NNP,O
,injection,NN,O
,had,VBD,O
,no,DT,O
,local,JJ,O
,effect,NN,O
,.,.,O
,The,DT,O
,authors,NNS,O
,conclude,VBP,O
,that,IN,O
,in,IN,O
,a,DT,O
,patient,NN,O
,starting,VBG,O
,DPH,NNP,O
,treatment,NN,O
,an,DT,O
,unexpected,JJ,O
,increase,NN,O
,in,IN,O
,seizures,NNS,B-DISEASE
,",",",",O
,with,IN,O
,EEG,NNP,O
,and,CC,O
,mental,JJ,O
,changes,NNS,O
,occurring,VBG,O
,simultaneously,RB,O
,",",",",O
,should,MD,O
,alert,VB,O
,the,DT,O
,physician,NN,O
,to,TO,O
,the,DT,O
,possible,JJ,O
,need,NN,O
,for,IN,O
,eliminating,VBG,O
,DPH,NNP,O
,from,IN,O
,the,DT,O
,therapeutic,JJ,O
,regimen,NNS,O
,",",",",O
,even,RB,O
,if,IN,O
,plasma,JJ,O
,concentrations,NNS,O
,are,VBP,O
,low,JJ,O
,.,.,O
,Prevention,NN,O
,and,CC,O
,treatment,NN,O
,of,IN,O
,endometrial,JJ,B-DISEASE
,disease,NN,I-DISEASE
,in,IN,O
,climacteric,JJ,O
,women,NNS,O
,receiving,VBG,O
,oestrogen,NN,O
,therapy,NN,O
,.,.,O
,The,DT,O
,treatment,NN,O
,regimens,NNS,O
,are,VBP,O
,described,VBN,O
,in,IN,O
,74,CD,O
,patients,NNS,O
,with,IN,O
,endometrial,JJ,B-DISEASE
,disease,NN,I-DISEASE
,among,IN,O
,850,CD,O
,climacteric,JJ,O
,women,NNS,O
,receiving,VBG,O
,oestrogen,NN,O
,therapy,NN,O
,.,.,O
,Cystic,JJ,O
,hyperplasia,NN,B-DISEASE
,was,VBD,O
,associated,VBN,O
,with,IN,O
,unopposed,JJ,O
,oestrogen,NN,O
,therapy,NN,O
,without,IN,O
,progestagen,NN,O
,.,.,O
,Two,CD,O
,courses,NNS,O
,of,IN,O
,21,CD,O
,days,NNS,O
,of,IN,O
,5,CD,O
,mg,NNS,O
,norethisterone,JJ,O
,daily,RB,O
,caused,VBN,O
,reversion,NN,O
,to,TO,O
,normal,JJ,O
,in,IN,O
,all,DT,O
,57,CD,O
,cases,NNS,O
,of,IN,O
,cystic,JJ,O
,hyperplasia,NN,B-DISEASE
,and,CC,O
,6,CD,O
,of,IN,O
,the,DT,O
,8,CD,O
,cases,NNS,O
,of,IN,O
,atypical,JJ,O
,hyperplasia,NN,B-DISEASE
,.,.,O
,4,CD,O
,cases,NNS,O
,of,IN,O
,endometrial,JJ,B-DISEASE
,carcinoma,NN,I-DISEASE
,referred,VBD,O
,from,IN,O
,elsewhere,RB,O
,demonstrated,VBN,O
,the,DT,O
,problems,NNS,O
,of,IN,O
,inappropriate,NN,O
,and,CC,O
,unsupervised,JJ,O
,unopposed,JJ,O
,oestrogen,NN,O
,therapy,NN,O
,and,CC,O
,the,DT,O
,difficulty,NN,O
,in,IN,O
,distinguishing,VBG,O
,severe,JJ,O
,hyperplasia,NN,B-DISEASE
,from,IN,O
,malignancy,NN,B-DISEASE
,.,.,O
,Cyclical,NNP,O
,low,JJ,O
,-,:,O
,dose,NN,O
,oestrogen,NN,O
,therapy,NN,O
,with,IN,O
,7,CD,O
,-,:,O
,-,:,O
,13,CD,O
,days,NNS,O
,of,IN,O
,progestagen,NN,O
,does,VBZ,O
,not,RB,O
,seem,VB,O
,to,TO,O
,increase,VB,O
,the,DT,O
,risk,NN,O
,of,IN,O
,endometrial,JJ,B-DISEASE
,hyperplasia,NN,I-DISEASE
,or,CC,O
,carcinoma,NN,B-DISEASE
,.,.,O
,Effects,NNS,O
,of,IN,O
,exercise,NN,O
,on,IN,O
,the,DT,O
,severity,NN,O
,of,IN,O
,isoproterenol,JJ,O
,-,:,O
,induced,JJ,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,.,.,O
,The,DT,O
,effect,NN,O
,of,IN,O
,exercise,NN,O
,on,IN,O
,the,DT,O
,severity,NN,O
,of,IN,O
,isoproterenol,JJ,O
,-,:,O
,induced,JJ,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,was,VBD,O
,studied,VBN,O
,in,IN,O
,male,JJ,O
,rats,NNS,O
,.,.,O
,Ninety,NNP,O
,-,:,O
,three,CD,O
,rats,NNS,O
,were,VBD,O
,randomly,RB,O
,divided,VBN,O
,into,IN,O
,three,CD,O
,groups,NNS,O
,.,.,O
,The,DT,O
,exercise,NN,O
,-,:,O
,isoproterenol,NN,O
,(,(,O
,E,NNP,O
,-,:,O
,1,CD,O
,),),O
,and,CC,O
,exercise,NN,O
,control,NN,O
,(,(,O
,EC,NNP,O
,),),O
,groups,NNS,O
,exercised,VBD,O
,daily,RB,O
,for,IN,O
,thirty,JJ,O
,days,NNS,O
,on,IN,O
,a,DT,O
,treadmill,NN,O
,at,IN,O
,1,CD,O
,mph,NN,O
,",",",",O
,2,CD,O
,%,NN,O
,grade,NN,O
,while,IN,O
,animals,NNS,O
,of,IN,O
,the,DT,O
,sedentary,JJ,O
,-,:,O
,isoproterenol,NN,O
,(,(,O
,S,NNP,O
,-,:,O
,I,PRP,O
,),),O
,group,NN,O
,remained,VBD,O
,sedentary,JJ,O
,.,.,O
,Eight,JJ,O
,animals,NNS,O
,were,VBD,O
,assigned,VBN,O
,to,TO,O
,the,DT,O
,sedentary,JJ,O
,control,NN,O
,(,(,O
,SC,NNP,O
,),),O
,group,NN,O
,which,WDT,O
,remained,VBD,O
,sedentary,JJ,O
,throughout,IN,O
,the,DT,O
,experimental,JJ,O
,period,NN,O
,.,.,O
,Forty,NNP,O
,-,:,O
,eight,CD,O
,hours,NNS,O
,after,IN,O
,the,DT,O
,final,JJ,O
,exercise,NN,O
,period,NN,O
,",",",",O
,S,NNP,O
,-,:,O
,I,PRP,O
,and,CC,O
,E,NNP,O
,-,:,O
,I,PRP,O
,animals,VBP,O
,received,VBD,O
,a,DT,O
,single,JJ,O
,subcutaneous,JJ,O
,injection,NN,O
,of,IN,O
,isoproterenol,NN,O
,(,(,O
,250,CD,O
,mg,NN,O
,/,NNP,O
,kg,VBZ,O
,body,NN,O
,weight,NN,O
,),),O
,.,.,O
,Animals,NNS,O
,of,IN,O
,the,DT,O
,S,NNP,O
,-,:,O
,I,PRP,O
,group,NN,O
,exhibited,VBD,O
,significantly,RB,O
,(,(,O
,Pp,NNP,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,greater,JJR,O
,mortality,NN,O
,from,IN,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,isoproterenol,NN,O
,than,IN,O
,animals,NNS,O
,of,IN,O
,the,DT,O
,E,NNP,O
,-,:,O
,I,PRP,O
,group,NN,O
,.,.,O
,Serum,NNP,O
,CPK,NNP,O
,activity,NN,O
,for,IN,O
,E,NNP,O
,-,:,O
,I,PRP,O
,animals,NNS,O
,was,VBD,O
,significantly,RB,O
,(,(,O
,p,NN,O
,less,JJR,O
,than,IN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,greater,JJR,O
,than,IN,O
,for,IN,O
,animals,NNS,O
,in,IN,O
,the,DT,O
,S,NNP,O
,-,:,O
,I,PRP,O
,and,CC,O
,EC,NNP,O
,groups,NNS,O
,twenty,VBP,O
,hours,NNS,O
,following,VBG,O
,isoproterenol,JJ,O
,injection,NN,O
,.,.,O
,No,DT,O
,statistically,RB,O
,significant,JJ,O
,differences,NNS,O
,were,VBD,O
,observed,VBN,O
,between,IN,O
,the,DT,O
,two,CD,O
,isoproterenol,NN,O
,treated,VBD,O
,groups,NNS,O
,for,IN,O
,severity,NN,O
,of,IN,O
,the,DT,O
,induced,JJ,O
,lesions,NNS,O
,",",",",O
,changes,NNS,O
,in,IN,O
,heart,NN,O
,weight,NN,O
,",",",",O
,or,CC,O
,heart,NN,O
,weight,NN,O
,to,TO,O
,body,NN,O
,weight,JJ,O
,ratios,NNS,O
,.,.,O
,The,DT,O
,results,NNS,O
,indicated,VBD,O
,that,IN,O
,exercise,NN,O
,reduced,VBD,O
,the,DT,O
,mortality,NN,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,effects,NNS,O
,of,IN,O
,large,JJ,O
,dosages,NNS,O
,of,IN,O
,isoproterenol,NN,O
,but,CC,O
,had,VBD,O
,little,VBN,O
,on,IN,O
,the,DT,O
,severity,NN,O
,of,IN,O
,the,DT,O
,infarction,NN,B-DISEASE
,.,.,O
,Human,NNP,O
,corticotropin,VBD,O
,-,:,O
,releasing,VBG,O
,hormone,NN,O
,and,CC,O
,thyrotropin,NN,O
,-,:,O
,releasing,VBG,O
,hormone,NN,O
,modulate,NN,O
,the,DT,O
,hypercapnic,JJ,B-DISEASE
,ventilatory,NN,O
,response,NN,O
,in,IN,O
,humans,NNS,O
,.,.,O
,Human,NNP,O
,corticotropin,VBD,O
,-,:,O
,releasing,VBG,O
,hormone,NN,O
,(,(,O
,hCRH,NN,O
,),),O
,and,CC,O
,thyrotropin,$,O
,-,:,O
,releasing,VBG,O
,hormone,NN,O
,(,(,O
,TRH,NNP,O
,),),O
,are,VBP,O
,known,VBN,O
,to,TO,O
,stimulate,VB,O
,ventilation,NN,O
,after,IN,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,administration,NN,O
,in,IN,O
,humans,NNS,O
,.,.,O
,In,IN,O
,a,DT,O
,placebo,NN,O
,-,:,O
,controlled,VBN,O
,",",",",O
,single,JJ,O
,-,:,O
,blind,NN,O
,study,NN,O
,we,PRP,O
,aimed,VBD,O
,to,TO,O
,clarify,VB,O
,if,IN,O
,both,DT,O
,peptides,NNS,O
,act,NN,O
,by,IN,O
,altering,VBG,O
,central,JJ,O
,chemosensitivity,NN,O
,.,.,O
,Two,CD,O
,subsequent,JJ,O
,CO2,NNP,O
,-,:,O
,rebreathing,NN,O
,tests,NNS,O
,were,VBD,O
,performed,VBN,O
,in,IN,O
,healthy,JJ,O
,young,JJ,O
,volunteers,NNS,O
,.,.,O
,During,IN,O
,the,DT,O
,first,JJ,O
,test,NN,O
,0,CD,O
,.,.,O
,9,CD,O
,%,NN,O
,NaCl,NNP,O
,was,VBD,O
,given,VBN,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,;,:,O
,during,IN,O
,the,DT,O
,second,JJ,O
,test,NN,O
,200,CD,O
,micrograms,NN,O
,of,IN,O
,hCRH,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,12,CD,O
,),),O
,or,CC,O
,400,CD,O
,micrograms,NNS,O
,of,IN,O
,TRH,NNP,O
,(,(,O
,n,JJ,O
,=,NNP,O
,6,CD,O
,),),O
,was,VBD,O
,administered,VBN,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,Nine,JJ,O
,subjects,NNS,O
,received,VBD,O
,0,CD,O
,.,.,O
,9,CD,O
,%,NN,O
,NaCl,NNP,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,during,IN,O
,both,DT,O
,rebreathing,VBG,O
,manoeuvres,NNS,O
,.,.,O
,The,DT,O
,CO2,NNP,O
,-,:,O
,response,NN,O
,curves,NNS,O
,for,IN,O
,the,DT,O
,two,CD,O
,tests,NNS,O
,were,VBD,O
,compared,VBN,O
,within,IN,O
,the,DT,O
,same,JJ,O
,subject,NN,O
,.,.,O
,In,IN,O
,the,DT,O
,hCRH,NN,O
,group,NN,O
,a,DT,O
,marked,VBN,O
,parallel,JJ,O
,shift,NN,O
,of,IN,O
,the,DT,O
,CO2,NNP,O
,-,:,O
,response,NN,O
,curve,NN,O
,to,TO,O
,the,DT,O
,left,NN,O
,was,VBD,O
,observed,VBN,O
,after,IN,O
,hCRH,NN,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,.,.,O
,The,DT,O
,same,JJ,O
,effect,NN,O
,occurred,VBD,O
,following,VBG,O
,TRH,NNP,O
,but,CC,O
,was,VBD,O
,less,JJR,O
,striking,JJ,O
,(,(,O
,P,NNP,O
,=,VBZ,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,hCRH,NN,O
,and,CC,O
,TRH,NNP,O
,caused,VBD,O
,a,DT,O
,reduction,NN,O
,in,IN,O
,the,DT,O
,CO2,NNP,O
,threshold,NN,O
,.,.,O
,The,DT,O
,CO2,NNP,O
,-,:,O
,response,NN,O
,curves,NNS,O
,in,IN,O
,the,DT,O
,control,NN,O
,group,NN,O
,were,VBD,O
,nearly,RB,O
,identical,JJ,O
,.,.,O
,The,DT,O
,results,NNS,O
,indicate,VBP,O
,an,DT,O
,additive,JJ,O
,effect,NN,O
,of,IN,O
,both,DT,O
,releasing,VBG,O
,hormones,NNS,O
,on,IN,O
,the,DT,O
,hypercapnic,JJ,B-DISEASE
,ventilatory,NN,O
,response,NN,O
,in,IN,O
,humans,NNS,O
,",",",",O
,presumably,RB,O
,independent,JJ,O
,of,IN,O
,central,JJ,O
,chemosensitivity,NN,O
,.,.,O
,Lamivudine,NNP,O
,is,VBZ,O
,effective,JJ,O
,in,IN,O
,suppressing,VBG,O
,hepatitis,NN,B-DISEASE
,B,NNP,I-DISEASE
,virus,NN,O
,DNA,NN,O
,in,IN,O
,Chinese,JJ,O
,hepatitis,NN,O
,B,NNP,O
,surface,NN,O
,antigen,NN,O
,carriers,NNS,O
,:,:,O
,a,DT,O
,placebo,NN,O
,-,:,O
,controlled,VBN,O
,trial,NN,O
,.,.,O
,Lamivudine,NNP,O
,is,VBZ,O
,a,DT,O
,novel,JJ,O
,2,CD,O
,','',O
,",",",",O
,3,CD,O
,',POS,O
,-,:,O
,dideoxy,NN,O
,cytosine,NN,O
,analogue,NN,O
,that,WDT,O
,has,VBZ,O
,potent,JJ,O
,inhibitory,JJ,O
,effects,NNS,O
,on,IN,O
,hepatitis,NN,B-DISEASE
,B,NNP,I-DISEASE
,virus,NN,O
,replication,NN,O
,in,IN,O
,vitro,NN,O
,and,CC,O
,in,IN,O
,vivo,NN,O
,.,.,O
,We,PRP,O
,performed,VBD,O
,a,DT,O
,single,JJ,O
,-,:,O
,blind,NN,O
,",",",",O
,placebo,SYM,O
,-,:,O
,controlled,VBN,O
,study,NN,O
,to,TO,O
,assess,VB,O
,its,PRP$,O
,effectiveness,NN,O
,and,CC,O
,safety,NN,O
,in,IN,O
,Chinese,JJ,O
,hepatitis,NN,O
,B,NNP,O
,surface,NN,O
,antigen,NN,O
,(,(,O
,HBsAg,NNP,O
,),),O
,carriers,NNS,O
,.,.,O
,Forty,NNP,O
,-,:,O
,two,CD,O
,Chinese,JJ,O
,HBsAg,NNP,O
,carriers,NNS,O
,were,VBD,O
,randomized,VBN,O
,to,TO,O
,receive,VB,O
,placebo,NN,O
,(,(,O
,6,CD,O
,patients,NNS,O
,),),O
,or,CC,O
,lamivudine,JJ,O
,orally,RB,O
,in,IN,O
,dosages,NNS,O
,of,IN,O
,25,CD,O
,mg,NNS,O
,",",",",O
,100,CD,O
,mg,NN,O
,",",",",O
,or,CC,O
,300,CD,O
,mg,JJ,O
,daily,JJ,O
,(,(,O
,12,CD,O
,patients,NNS,O
,for,IN,O
,each,DT,O
,dosage,NN,O
,),),O
,.,.,O
,The,DT,O
,drug,NN,O
,was,VBD,O
,given,VBN,O
,for,IN,O
,4,CD,O
,weeks,NNS,O
,.,.,O
,The,DT,O
,patients,NNS,O
,were,VBD,O
,closely,RB,O
,monitored,VBN,O
,clinically,RB,O
,",",",",O
,biochemically,RB,O
,",",",",O
,and,CC,O
,serologically,RB,O
,up,RB,O
,to,TO,O
,4,CD,O
,weeks,NNS,O
,after,IN,O
,drug,NN,O
,treatment,NN,O
,.,.,O
,All,DT,O
,36,CD,O
,patients,NNS,O
,receiving,VBG,O
,lamivudine,NN,O
,had,VBD,O
,a,DT,O
,decrease,NN,O
,in,IN,O
,hepatitis,NN,B-DISEASE
,B,NNP,I-DISEASE
,virus,NN,O
,(,(,O
,HBV,NNP,O
,),),O
,DNA,NNP,O
,values,NNS,O
,of,IN,O
,>,JJ,O
,90,CD,O
,%,NN,O
,(,(,O
,P,NNP,O
,<,NNP,O
,.,.,O
,001,CD,O
,compared,VBN,O
,with,IN,O
,placebo,NN,O
,),),O
,.,.,O
,Although,IN,O
,25,CD,O
,mg,NNS,O
,of,IN,O
,lamivudine,NN,O
,was,VBD,O
,slightly,RB,O
,less,RBR,O
,effective,JJ,O
,than,IN,O
,100,CD,O
,mg,NN,O
,(,(,O
,P,NNP,O
,=,NNP,O
,.,.,O
,011,CD,O
,),),O
,and,CC,O
,300,CD,O
,mg,NN,O
,(,(,O
,P,NNP,O
,=,NNP,O
,.,.,O
,005,CD,O
,),),O
,",",",",O
,it,PRP,O
,still,RB,O
,induced,VBD,O
,94,CD,O
,%,NN,O
,suppression,NN,O
,of,IN,O
,HBV,NNP,O
,DNA,NNP,O
,after,IN,O
,the,DT,O
,fourth,JJ,O
,week,NN,O
,of,IN,O
,therapy,NN,O
,.,.,O
,HBV,NNP,O
,DNA,NNP,O
,values,NNS,O
,returned,VBD,O
,to,TO,O
,pretreatment,NN,O
,levels,NNS,O
,within,IN,O
,4,CD,O
,weeks,NNS,O
,of,IN,O
,cessation,NN,O
,of,IN,O
,therapy,NN,O
,.,.,O
,There,EX,O
,was,VBD,O
,no,DT,O
,change,NN,O
,in,IN,O
,the,DT,O
,hepatitis,NN,B-DISEASE
,B,NNP,I-DISEASE
,e,NN,O
,antigen,NN,O
,status,NN,O
,or,CC,O
,in,IN,O
,aminotransferase,JJ,O
,levels,NNS,O
,.,.,O
,No,DT,O
,serious,JJ,O
,adverse,JJ,O
,events,NNS,O
,were,VBD,O
,observed,VBN,O
,.,.,O
,In,IN,O
,conclusion,NN,O
,",",",",O
,a,DT,O
,4,CD,O
,-,:,O
,week,NN,O
,course,NN,O
,of,IN,O
,lamivudine,NN,O
,was,VBD,O
,safe,JJ,O
,and,CC,O
,effective,JJ,O
,in,IN,O
,suppression,NN,O
,of,IN,O
,HBV,NNP,O
,DNA,NNP,O
,in,IN,O
,Chinese,NNP,O
,HBsAg,NNP,O
,carriers,NNS,O
,.,.,O
,The,DT,O
,suppression,NN,O
,was,VBD,O
,>,JJ,O
,90,CD,O
,%,NN,O
,but,CC,O
,reversible,JJ,O
,.,.,O
,Studies,NNS,O
,with,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,lamivudine,JJ,O
,administration,NN,O
,should,MD,O
,be,VB,O
,performed,VBN,O
,to,TO,O
,determine,VB,O
,if,IN,O
,prolonged,JJ,O
,suppression,NN,O
,of,IN,O
,HBV,NNP,O
,DNA,NNP,O
,can,MD,O
,be,VB,O
,achieved,VBN,O
,.,.,O
,Population,NNP,O
,-,:,O
,based,VBN,O
,study,NN,O
,of,IN,O
,risk,NN,O
,of,IN,O
,venous,JJ,B-DISEASE
,thromboembolism,NN,I-DISEASE
,associated,VBN,O
,with,IN,O
,various,JJ,O
,oral,JJ,O
,contraceptives,NNS,O
,.,.,O
,BACKGROUND,NNP,O
,:,:,O
,Four,CD,O
,studies,NNS,O
,published,VBN,O
,since,IN,O
,December,NNP,O
,",",",",O
,1995,CD,O
,",",",",O
,reported,VBD,O
,that,IN,O
,the,DT,O
,incidence,NN,O
,of,IN,O
,venous,JJ,B-DISEASE
,thromboembolism,NN,I-DISEASE
,(,(,O
,VTE,NNP,B-DISEASE
,),),O
,was,VBD,O
,higher,RBR,O
,in,IN,O
,women,NNS,O
,who,WP,O
,used,VBD,O
,oral,JJ,O
,contraceptives,NNS,O
,(,(,O
,OCs,NNP,O
,),),O
,containing,VBG,O
,the,DT,O
,third,JJ,O
,-,:,O
,generation,NN,O
,progestagens,VBZ,O
,gestodene,NN,O
,or,CC,O
,desogestrel,NN,O
,than,IN,O
,in,IN,O
,users,NNS,O
,of,IN,O
,OCs,NNP,O
,containing,VBG,O
,second,JJ,O
,-,:,O
,generation,NN,O
,progestagens,NNS,O
,.,.,O
,However,RB,O
,",",",",O
,confounding,VBG,O
,and,CC,O
,bias,NN,O
,in,IN,O
,the,DT,O
,design,NN,O
,of,IN,O
,these,DT,O
,studies,NNS,O
,may,MD,O
,have,VB,O
,affected,VBN,O
,the,DT,O
,findings,NNS,O
,.,.,O
,The,DT,O
,aim,NN,O
,of,IN,O
,our,PRP$,O
,study,NN,O
,was,VBD,O
,to,TO,O
,re,VB,O
,-,:,O
,examine,VB,O
,the,DT,O
,association,NN,O
,between,IN,O
,risk,NN,O
,of,IN,O
,VTE,NNP,B-DISEASE
,and,CC,O
,OC,NNP,O
,use,NN,O
,with,IN,O
,a,DT,O
,different,JJ,O
,study,NN,O
,design,NN,O
,and,CC,O
,analysis,NN,O
,to,TO,O
,avoid,VB,O
,some,DT,O
,of,IN,O
,the,DT,O
,bias,NN,O
,and,CC,O
,confounding,NN,O
,of,IN,O
,the,DT,O
,earlier,JJR,O
,studies,NNS,O
,.,.,O
,METHODS,NNS,O
,:,:,O
,We,PRP,O
,used,VBD,O
,computer,NN,O
,records,NNS,O
,of,IN,O
,patients,NNS,O
,from,IN,O
,143,CD,O
,general,JJ,O
,practices,NNS,O
,in,IN,O
,the,DT,O
,UK,NNP,O
,.,.,O
,The,DT,O
,study,NN,O
,was,VBD,O
,based,VBN,O
,on,IN,O
,the,DT,O
,medical,JJ,O
,records,NNS,O
,of,IN,O
,about,RB,O
,540,CD,O
,",",",",O
,000,CD,O
,women,NNS,O
,born,VBN,O
,between,IN,O
,1941,CD,O
,and,CC,O
,1981,CD,O
,.,.,O
,All,DT,O
,women,NNS,O
,who,WP,O
,had,VBD,O
,a,DT,O
,recorded,JJ,O
,diagnosis,NN,O
,of,IN,O
,deep,JJ,B-DISEASE
,-,:,I-DISEASE
,vein,NN,I-DISEASE
,thrombosis,NN,I-DISEASE
,",",",",O
,venous,JJ,B-DISEASE
,thrombosis,NN,I-DISEASE
,not,RB,O
,otherwise,RB,O
,specified,VBN,O
,",",",",O
,or,CC,O
,pulmonary,JJ,O
,embolus,NN,O
,during,IN,O
,the,DT,O
,study,NN,O
,period,NN,O
,",",",",O
,and,CC,O
,who,WP,O
,had,VBD,O
,been,VBN,O
,treated,VBN,O
,with,IN,O
,an,DT,O
,anticoagulant,NN,O
,were,VBD,O
,identified,VBN,O
,as,IN,O
,potential,JJ,O
,cases,NNS,O
,of,IN,O
,VTE,NNP,B-DISEASE
,.,.,O
,We,PRP,O
,did,VBD,O
,a,DT,O
,cohort,NN,O
,analysis,NN,O
,to,TO,O
,estimate,VB,O
,and,CC,O
,compare,VB,O
,incidence,NN,O
,of,IN,O
,VTE,NNP,B-DISEASE
,in,IN,O
,users,NNS,O
,of,IN,O
,the,DT,O
,main,JJ,O
,OC,NNP,O
,preparations,NNS,O
,",",",",O
,and,CC,O
,a,DT,O
,nested,JJ,O
,case,NN,O
,-,:,O
,control,NN,O
,study,NN,O
,to,TO,O
,calculate,VB,O
,the,DT,O
,odds,JJ,O
,ratios,NNS,O
,of,IN,O
,VTE,NNP,B-DISEASE
,associated,VBD,O
,with,IN,O
,use,NN,O
,of,IN,O
,different,JJ,O
,types,NNS,O
,of,IN,O
,OC,NNP,O
,",",",",O
,after,IN,O
,adjustment,NN,O
,for,IN,O
,potential,JJ,O
,confounding,NN,O
,factors,NNS,O
,.,.,O
,In,IN,O
,the,DT,O
,case,NN,O
,-,:,O
,control,NN,O
,study,NN,O
,",",",",O
,we,PRP,O
,matched,VBD,O
,cases,NNS,O
,to,TO,O
,controls,NNS,O
,by,IN,O
,exact,JJ,O
,year,NN,O
,of,IN,O
,birth,NN,O
,",",",",O
,practice,NN,O
,",",",",O
,and,CC,O
,current,JJ,O
,use,NN,O
,of,IN,O
,OCs,NNP,O
,.,.,O
,We,PRP,O
,used,VBD,O
,a,DT,O
,multiple,JJ,O
,logistic,JJ,O
,regression,NN,O
,model,NN,O
,that,WDT,O
,included,VBD,O
,body,NN,O
,-,:,O
,mass,NN,O
,index,NN,O
,",",",",O
,number,NN,O
,of,IN,O
,cycles,NNS,O
,",",",",O
,change,NN,O
,in,IN,O
,type,NN,O
,of,IN,O
,OC,NNP,O
,prescribed,VBD,O
,within,IN,O
,3,CD,O
,months,NNS,O
,of,IN,O
,the,DT,O
,event,NN,O
,",",",",O
,previous,JJ,O
,pregnancy,NN,O
,",",",",O
,and,CC,O
,concurrent,JJ,O
,disease,NN,O
,.,.,O
,FINDINGS,NN,O
,:,:,O
,85,CD,O
,women,NNS,O
,met,VBD,O
,the,DT,O
,inclusion,NN,O
,criteria,NNS,O
,for,IN,O
,VTE,NNP,B-DISEASE
,",",",",O
,two,CD,O
,of,IN,O
,whom,WP,O
,were,VBD,O
,users,NNS,O
,of,IN,O
,progestagen,NN,O
,-,:,O
,only,RB,O
,OCs,NNP,O
,.,.,O
,Of,IN,O
,the,DT,O
,83,CD,O
,cases,NNS,O
,of,IN,O
,VTE,NNP,B-DISEASE
,associated,VBD,O
,with,IN,O
,use,NN,O
,of,IN,O
,combined,JJ,O
,OCs,NNP,O
,",",",",O
,43,CD,O
,were,VBD,O
,recorded,VBN,O
,as,IN,O
,deep,JJ,B-DISEASE
,-,:,I-DISEASE
,vein,NN,I-DISEASE
,thrombosis,NN,I-DISEASE
,",",",",O
,35,CD,O
,as,IN,O
,pulmonary,JJ,O
,thrombosis,NN,B-DISEASE
,",",",",O
,and,CC,O
,five,CD,O
,as,IN,O
,venous,JJ,B-DISEASE
,thrombosis,NN,I-DISEASE
,not,RB,O
,otherwise,RB,O
,specified,VBN,O
,.,.,O
,The,DT,O
,crude,JJ,O
,rate,NN,O
,of,IN,O
,VTE,NNP,B-DISEASE
,per,IN,O
,10,CD,O
,",",",",O
,000,CD,O
,woman,NN,O
,-,:,O
,years,NNS,O
,was,VBD,O
,4,CD,O
,.,.,O
,10,CD,O
,in,IN,O
,current,JJ,O
,users,NNS,O
,of,IN,O
,any,DT,O
,OC,NNP,O
,",",",",O
,3,CD,O
,.,.,O
,10,CD,O
,in,IN,O
,users,NNS,O
,of,IN,O
,second,JJ,O
,-,:,O
,generation,NN,O
,OCs,NNP,O
,",",",",O
,and,CC,O
,4,CD,O
,.,.,O
,96,CD,O
,in,IN,O
,users,NNS,O
,of,IN,O
,third,JJ,O
,-,:,O
,generation,NN,O
,preparations,NNS,O
,.,.,O
,After,IN,O
,adjustment,NN,O
,for,IN,O
,age,NN,O
,",",",",O
,the,DT,O
,rate,NN,O
,ratio,NN,O
,of,IN,O
,VTE,NNP,B-DISEASE
,in,IN,O
,users,NNS,O
,of,IN,O
,third,JJ,O
,-,:,O
,generation,NN,O
,relative,JJ,O
,to,TO,O
,second,JJ,O
,-,:,O
,generation,NN,O
,OCs,NNP,O
,was,VBD,O
,1,CD,O
,.,.,O
,68,CD,O
,(,(,O
,95,CD,O
,%,NN,O
,CI,NNP,O
,1,CD,O
,.,.,O
,04,CD,O
,-,:,O
,2,CD,O
,.,.,O
,75,CD,O
,),),O
,.,.,O
,Logistic,JJ,O
,regression,NN,O
,showed,VBD,O
,no,DT,O
,significant,JJ,O
,difference,NN,O
,in,IN,O
,the,DT,O
,risk,NN,O
,of,IN,O
,VTE,NNP,B-DISEASE
,between,IN,O
,users,NNS,O
,of,IN,O
,third,JJ,O
,-,:,O
,generation,NN,O
,and,CC,O
,second,JJ,O
,-,:,O
,generation,NN,O
,OCs,NNP,O
,.,.,O
,Among,IN,O
,users,NNS,O
,of,IN,O
,third,JJ,O
,-,:,O
,generation,NN,O
,progestagens,NNS,O
,",",",",O
,the,DT,O
,risk,NN,O
,of,IN,O
,VTE,NNP,B-DISEASE
,was,VBD,O
,higher,RBR,O
,in,IN,O
,users,NNS,O
,of,IN,O
,desogestrel,NN,O
,with,IN,O
,20,CD,O
,g,NNS,O
,ethinyloestradiol,RB,O
,than,IN,O
,in,IN,O
,users,NNS,O
,of,IN,O
,gestodene,NN,O
,or,CC,O
,desogestrel,NN,O
,with,IN,O
,30,CD,O
,g,NNS,O
,ethinyloestradiol,RB,O
,.,.,O
,With,IN,O
,all,DT,O
,second,JJ,O
,-,:,O
,generation,NN,O
,OCs,NNP,O
,as,IN,O
,the,DT,O
,reference,NN,O
,",",",",O
,the,DT,O
,odds,NNS,O
,ratios,NNS,O
,for,IN,O
,VTE,NNP,B-DISEASE
,were,VBD,O
,3,CD,O
,.,.,O
,49,CD,O
,(,(,O
,1,CD,O
,.,.,O
,21,CD,O
,-,:,O
,10,CD,O
,.,.,O
,12,CD,O
,),),O
,for,IN,O
,desogestrel,NN,O
,plus,CC,O
,20,CD,O
,g,NN,O
,ethinyloestradiol,NN,O
,and,CC,O
,1,CD,O
,.,.,O
,18,CD,O
,(,(,O
,0,CD,O
,.,.,O
,66,CD,O
,-,:,O
,2,CD,O
,.,.,O
,17,CD,O
,),),O
,for,IN,O
,the,DT,O
,other,JJ,O
,third,JJ,O
,-,:,O
,generation,NN,O
,progestagens,NNS,O
,.,.,O
,INTERPRETATION,NN,O
,:,:,O
,The,DT,O
,previously,RB,O
,reported,VBN,O
,increase,NN,O
,in,IN,O
,odds,NNS,O
,ratio,NNS,O
,associated,VBN,O
,with,IN,O
,third,JJ,O
,-,:,O
,generation,NN,O
,OCs,NNP,O
,when,WRB,O
,compared,VBN,O
,with,IN,O
,second,JJ,O
,-,:,O
,generation,NN,O
,products,NNS,O
,is,VBZ,O
,likely,JJ,O
,to,TO,O
,have,VB,O
,been,VBN,O
,the,DT,O
,result,NN,O
,of,IN,O
,residual,JJ,O
,confounding,NN,O
,by,IN,O
,age,NN,O
,.,.,O
,The,DT,O
,increased,JJ,O
,odds,NNS,O
,ratio,NN,O
,associated,VBN,O
,with,IN,O
,products,NNS,O
,containing,VBG,O
,20,CD,O
,micrograms,NNS,O
,ethinyloestradiol,RB,O
,and,CC,O
,desogestrel,VB,O
,compared,VBN,O
,with,IN,O
,the,DT,O
,30,CD,O
,micrograms,NNS,O
,product,NN,O
,is,VBZ,O
,biologically,RB,O
,implausible,JJ,O
,",",",",O
,and,CC,O
,is,VBZ,O
,likely,JJ,O
,to,TO,O
,be,VB,O
,the,DT,O
,result,NN,O
,of,IN,O
,preferential,JJ,O
,prescribing,NN,O
,and,CC,O
,",",",",O
,thus,RB,O
,",",",",O
,confounding,VBG,O
,.,.,O
,MK,NNP,O
,-,:,O
,801,CD,O
,augments,NNS,O
,pilocarpine,JJ,O
,-,:,O
,induced,JJ,O
,electrographic,JJ,O
,seizure,NN,B-DISEASE
,but,CC,O
,protects,NNS,O
,against,IN,O
,brain,NN,B-DISEASE
,damage,NN,I-DISEASE
,in,IN,O
,rats,NNS,O
,.,.,O
,1,CD,O
,.,.,O
,The,DT,O
,authors,NNS,O
,examined,VBD,O
,the,DT,O
,anticonvulsant,JJ,O
,effects,NNS,O
,of,IN,O
,MK,NNP,O
,-,:,O
,801,CD,O
,on,IN,O
,the,DT,O
,pilocarpine,NN,O
,-,:,O
,induced,JJ,O
,seizure,NN,B-DISEASE
,model,NN,O
,.,.,O
,Intraperitoneal,NNP,O
,injection,NN,O
,of,IN,O
,pilocarpine,NN,O
,(,(,O
,400,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,induced,VBD,O
,tonic,JJ,B-DISEASE
,and,CC,I-DISEASE
,clonic,JJ,I-DISEASE
,seizure,NN,I-DISEASE
,.,.,O
,Scopolamine,NNP,O
,(,(,O
,10,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,and,CC,O
,pentobarbital,JJ,O
,(,(,O
,5,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,),),O
,prevented,VBD,O
,development,NN,O
,of,IN,O
,pilocarpine,NN,O
,-,:,O
,induced,JJ,O
,behavioral,JJ,O
,seizure,NN,B-DISEASE
,but,CC,O
,MK,NNP,O
,-,:,O
,801,CD,O
,(,(,O
,0,CD,O
,.,.,O
,5,CD,O
,mg,JJ,O
,/,NNP,O
,kg,NN,O
,),),O
,did,VBD,O
,not,RB,O
,.,.,O
,2,CD,O
,.,.,O
,An,DT,O
,electrical,JJ,O
,seizure,NN,B-DISEASE
,measured,VBN,O
,with,IN,O
,hippocampal,JJ,O
,EEG,NNP,O
,appeared,VBD,O
,in,IN,O
,the,DT,O
,pilocarpine,NN,O
,-,:,O
,treated,VBN,O
,group,NN,O
,.,.,O
,Scopolamine,NNP,O
,and,CC,O
,pentobarbital,JJ,O
,blocked,VBD,O
,the,DT,O
,pilocarpine,NN,O
,-,:,O
,induced,JJ,O
,electrographic,JJ,O
,seizure,NN,B-DISEASE
,",",",",O
,MK,NNP,O
,-,:,O
,801,CD,O
,treatment,NN,O
,augmented,VBD,O
,the,DT,O
,electrographic,JJ,O
,seizure,NN,B-DISEASE
,induced,VBN,O
,by,IN,O
,pilocarpine,NN,O
,.,.,O
,3,CD,O
,.,.,O
,Brain,NNP,B-DISEASE
,damage,NN,I-DISEASE
,was,VBD,O
,assessed,VBN,O
,by,IN,O
,examining,VBG,O
,the,DT,O
,hippocampus,NN,O
,microscopically,RB,O
,.,.,O
,Pilocarpine,NNP,O
,produced,VBD,O
,neuronal,JJ,B-DISEASE
,death,NN,I-DISEASE
,in,IN,O
,the,DT,O
,hippocampus,NN,O
,",",",",O
,which,WDT,O
,showed,VBD,O
,pyknotic,JJ,O
,changes,NNS,O
,.,.,O
,Pentobarbital,NNP,O
,",",",",O
,scopolamine,NN,O
,and,CC,O
,MK,NNP,O
,-,:,O
,801,CD,O
,protected,VBD,O
,the,DT,O
,brain,NN,B-DISEASE
,damage,NN,I-DISEASE
,by,IN,O
,pilocarpine,NN,O
,",",",",O
,though,IN,O
,in,IN,O
,the,DT,O
,MK,NNP,O
,-,:,O
,801,CD,O
,-,:,O
,treated,VBN,O
,group,NN,O
,",",",",O
,the,DT,O
,pyramidal,JJ,O
,cells,NNS,O
,of,IN,O
,hippocampus,NN,O
,appeared,VBD,O
,darker,JJR,O
,than,IN,O
,normal,JJ,O
,.,.,O
,In,IN,O
,all,DT,O
,treatments,NNS,O
,",",",",O
,granule,NN,O
,cells,NNS,O
,of,IN,O
,the,DT,O
,dentate,NN,O
,gyrus,NN,O
,were,VBD,O
,not,RB,O
,affected,VBN,O
,.,.,O
,4,CD,O
,.,.,O
,These,DT,O
,results,NNS,O
,indicate,VBP,O
,that,IN,O
,status,NN,B-DISEASE
,epilepticus,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,pilocarpine,NN,O
,is,VBZ,O
,initiated,VBN,O
,by,IN,O
,cholinergic,JJ,O
,overstimulation,NN,O
,and,CC,O
,propagated,VBN,O
,by,IN,O
,glutamatergic,JJ,O
,transmission,NN,O
,",",",",O
,the,DT,O
,elevation,NN,O
,of,IN,O
,which,WDT,O
,may,MD,O
,cause,VB,O
,brain,NN,B-DISEASE
,damage,NN,I-DISEASE
,through,IN,O
,an,DT,O
,excitatory,JJ,O
,NMDA,NNP,O
,receptor,NN,O
,-,:,O
,mediated,VBN,O
,mechanism,NN,O
,.,.,O
,Paclitaxel,NNP,O
,",",",",O
,5,CD,O
,-,:,O
,fluorouracil,NN,O
,",",",",O
,and,CC,O
,folinic,JJ,O
,acid,NN,O
,in,IN,O
,metastatic,JJ,O
,breast,NN,B-DISEASE
,cancer,NN,I-DISEASE
,:,:,O
,BRE,NNP,O
,-,:,O
,26,CD,O
,",",",",O
,a,DT,O
,phase,NN,O
,II,NNP,O
,trial,NN,O
,.,.,O
,5,CD,O
,-,:,O
,Fluorouracil,NN,O
,plus,CC,O
,folinic,JJ,O
,acid,NN,O
,and,CC,O
,paclitaxel,NN,O
,(,(,O
,Taxol,NNP,O
,;,:,O
,Bristol,NNP,O
,-,:,O
,Myers,NNS,O
,Squibb,NNP,O
,Company,NNP,O
,",",",",O
,Princeton,NNP,O
,",",",",O
,NJ,NNP,O
,),),O
,are,VBP,O
,effective,JJ,O
,salvage,NN,O
,therapies,NNS,O
,for,IN,O
,metastatic,JJ,O
,breast,NN,B-DISEASE
,cancer,NN,I-DISEASE
,patients,NNS,O
,.,.,O
,Paclitaxel,NNP,O
,and,CC,O
,5,CD,O
,-,:,O
,fluorouracil,NN,O
,have,VBP,O
,additive,JJ,O
,cytotoxicity,NN,B-DISEASE
,in,IN,O
,MCF,NNP,O
,-,:,O
,7,CD,O
,cell,NN,O
,lines,NNS,O
,.,.,O
,We,PRP,O
,performed,VBD,O
,a,DT,O
,phase,NN,O
,II,NNP,O
,trial,NN,O
,of,IN,O
,paclitaxel,NN,O
,175,CD,O
,mg,NN,O
,/,NNP,O
,m2,NN,O
,over,IN,O
,3,CD,O
,hours,NNS,O
,on,IN,O
,day,NN,O
,I,PRP,O
,followed,VBD,O
,by,IN,O
,folinic,JJ,O
,acid,NN,O
,300,CD,O
,mg,NN,O
,over,IN,O
,1,CD,O
,hour,NN,O
,before,IN,O
,5,CD,O
,-,:,O
,fluorouracil,NN,O
,350,CD,O
,mg,NN,O
,/,NNP,O
,m2,NN,O
,on,IN,O
,days,NNS,O
,1,CD,O
,to,TO,O
,3,CD,O
,every,DT,O
,28,CD,O
,days,NNS,O
,(,(,O
,TFL,NNP,O
,),),O
,in,IN,O
,women,NNS,O
,with,IN,O
,metastatic,JJ,O
,breast,NN,B-DISEASE
,cancer,NN,I-DISEASE
,.,.,O
,Analysis,NN,O
,is,VBZ,O
,reported,VBN,O
,on,IN,O
,37,CD,O
,patients,NNS,O
,with,IN,O
,a,DT,O
,minimum,NN,O
,of,IN,O
,6,CD,O
,months,NNS,O
,follow,VBP,O
,-,:,O
,up,NN,O
,who,WP,O
,received,VBD,O
,a,DT,O
,total,NN,O
,of,IN,O
,192,CD,O
,cycles,NNS,O
,of,IN,O
,TFL,NNP,O
,:,:,O
,nine,CD,O
,cycles,NNS,O
,(,(,O
,5,CD,O
,%,NN,O
,),),O
,were,VBD,O
,associated,VBN,O
,with,IN,O
,grade,NN,O
,3,CD,O
,/,NN,O
,4,CD,O
,neutropenia,NN,B-DISEASE
,requiring,VBG,O
,hospitalization,NN,O
,;,:,O
,seven,CD,O
,(,(,O
,4,CD,O
,%,NN,O
,),),O
,cycles,NNS,O
,in,IN,O
,two,CD,O
,patients,NNS,O
,required,VBN,O
,granulocyte,JJ,O
,colony,NN,O
,-,:,O
,stimulating,NN,O
,factor,NN,O
,due,JJ,O
,to,TO,O
,neutropenia,VB,B-DISEASE
,;,:,O
,no,DT,O
,patient,NN,O
,required,VBN,O
,platelet,NN,O
,transfusions,NNS,O
,.,.,O
,Grade,VB,O
,3,CD,O
,/,JJ,O
,4,CD,O
,nonhematologic,JJ,O
,toxicities,NNS,B-DISEASE
,were,VBD,O
,uncommon,JJ,O
,.,.,O
,Among,IN,O
,the,DT,O
,34,CD,O
,patients,NNS,O
,evaluable,JJ,O
,for,IN,O
,response,NN,O
,",",",",O
,there,EX,O
,were,VBD,O
,three,CD,O
,complete,JJ,O
,responses,NNS,O
,(,(,O
,9,CD,O
,%,NN,O
,),),O
,and,CC,O
,18,CD,O
,partial,JJ,O
,responses,NNS,O
,(,(,O
,53,CD,O
,%,NN,O
,),),O
,for,IN,O
,an,DT,O
,overall,JJ,O
,response,NN,O
,rate,NN,O
,of,IN,O
,62,CD,O
,%,NN,O
,.,.,O
,Of,IN,O
,the,DT,O
,19,CD,O
,evaluable,JJ,O
,patients,NNS,O
,with,IN,O
,prior,JJ,O
,doxorubicin,NN,O
,exposure,NN,O
,",",",",O
,11,CD,O
,(,(,O
,58,CD,O
,%,NN,O
,),),O
,responded,VBD,O
,compared,VBN,O
,with,IN,O
,nine,CD,O
,of,IN,O
,15,CD,O
,(,(,O
,60,CD,O
,%,NN,O
,),),O
,without,IN,O
,prior,JJ,O
,doxorubicin,NN,O
,.,.,O
,Plasma,NNP,O
,paclitaxel,JJ,O
,concentrations,NNS,O
,were,VBD,O
,measured,VBN,O
,at,IN,O
,the,DT,O
,completion,NN,O
,of,IN,O
,paclitaxel,JJ,O
,infusion,NN,O
,and,CC,O
,at,IN,O
,24,CD,O
,hours,NNS,O
,in,IN,O
,19,CD,O
,patients,NNS,O
,.,.,O
,TFL,NNP,O
,is,VBZ,O
,an,DT,O
,active,JJ,O
,",",",",O
,well,RB,O
,-,:,O
,tolerated,VBN,O
,regimen,NNS,O
,in,IN,O
,metastatic,JJ,O
,breast,NN,B-DISEASE
,cancer,NN,I-DISEASE
,.,.,O
,Efficacy,NNP,O
,and,CC,O
,proarrhythmia,NN,B-DISEASE
,with,IN,O
,the,DT,O
,use,NN,O
,of,IN,O
,d,NN,O
,",",",",O
,l,SYM,O
,-,:,O
,sotalol,NN,O
,for,IN,O
,sustained,JJ,O
,ventricular,JJ,B-DISEASE
,tachyarrhythmias,NN,I-DISEASE
,.,.,O
,This,DT,O
,study,NN,O
,prospectively,RB,O
,evaluated,VBD,O
,the,DT,O
,clinical,JJ,O
,efficacy,NN,O
,",",",",O
,the,DT,O
,incidence,NN,O
,of,IN,O
,torsades,NNS,B-DISEASE
,de,FW,I-DISEASE
,pointes,NNS,I-DISEASE
,",",",",O
,and,CC,O
,the,DT,O
,presumable,JJ,O
,risk,NN,O
,factors,NNS,O
,for,IN,O
,torsades,NNS,B-DISEASE
,de,FW,I-DISEASE
,pointes,NNS,I-DISEASE
,in,IN,O
,patients,NNS,O
,treated,VBN,O
,with,IN,O
,d,NN,O
,",",",",O
,l,SYM,O
,-,:,O
,sotalol,NN,O
,for,IN,O
,sustained,JJ,O
,ventricular,JJ,B-DISEASE
,tachyarrhythmias,NN,I-DISEASE
,.,.,O
,Eighty,NNP,O
,-,:,O
,one,CD,O
,consecutive,JJ,O
,patients,NNS,O
,(,(,O
,54,CD,O
,with,IN,O
,coronary,JJ,B-DISEASE
,artery,NN,I-DISEASE
,disease,NN,I-DISEASE
,",",",",O
,and,CC,O
,20,CD,O
,with,IN,O
,dilated,VBN,B-DISEASE
,cardiomyopathy,NN,I-DISEASE
,),),O
,with,IN,O
,inducible,JJ,O
,sustained,VBN,O
,ventricular,JJ,B-DISEASE
,tachycardia,NN,I-DISEASE
,or,CC,O
,ventricular,JJ,B-DISEASE
,fibrillation,NN,I-DISEASE
,received,VBD,O
,oral,JJ,O
,d,NN,O
,",",",",O
,l,SYM,O
,-,:,O
,sotalol,NN,O
,to,TO,O
,prevent,VB,O
,induction,NN,O
,of,IN,O
,the,DT,O
,ventricular,JJ,B-DISEASE
,tachyarrhythmia,NN,I-DISEASE
,.,.,O
,During,IN,O
,oral,JJ,O
,loading,VBG,O
,with,IN,O
,d,NN,O
,",",",",O
,l,SYM,O
,-,:,O
,sotalol,NN,O
,",",",",O
,continuous,JJ,O
,electrocardiographic,FW,O
,(,(,O
,ECG,NNP,O
,),),O
,monitoring,NN,O
,was,VBD,O
,performed,VBN,O
,.,.,O
,Those,DT,O
,patients,NNS,O
,in,IN,O
,whom,WP,O
,d,NN,O
,",",",",O
,l,SYM,O
,-,:,O
,sotalol,NN,O
,prevented,JJ,O
,induction,NN,O
,of,IN,O
,ventricular,JJ,B-DISEASE
,tachycardia,NN,I-DISEASE
,or,CC,O
,ventricular,JJ,B-DISEASE
,fibrillation,NN,I-DISEASE
,were,VBD,O
,discharged,VBN,O
,with,IN,O
,the,DT,O
,drug,NN,O
,and,CC,O
,followed,VBD,O
,up,RP,O
,on,IN,O
,an,DT,O
,outpatient,JJ,O
,basis,NN,O
,for,IN,O
,21,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,18,CD,O
,months,NNS,O
,.,.,O
,Induction,NN,O
,of,IN,O
,the,DT,O
,ventricular,JJ,B-DISEASE
,tachyarrhythmia,NN,I-DISEASE
,was,VBD,O
,prevented,VBN,O
,by,IN,O
,oral,JJ,O
,d,NN,O
,",",",",O
,l,SYM,O
,-,:,O
,sotalol,NN,O
,in,IN,O
,35,CD,O
,(,(,O
,43,CD,O
,%,NN,O
,),),O
,patients,NNS,O
,;,:,O
,the,DT,O
,ventricular,JJ,B-DISEASE
,tachyarrhythmia,NN,I-DISEASE
,remained,VBD,O
,inducible,JJ,O
,in,IN,O
,40,CD,O
,(,(,O
,49,CD,O
,%,NN,O
,),),O
,patients,NNS,O
,;,:,O
,and,CC,O
,two,CD,O
,(,(,O
,2,CD,O
,.,.,O
,5,CD,O
,%,NN,O
,),),O
,patients,NNS,O
,did,VBD,O
,not,RB,O
,tolerate,VB,O
,even,RB,O
,40,CD,O
,mg,NN,O
,of,IN,O
,d,NN,O
,",",",",O
,l,SYM,O
,-,:,O
,sotalol,NN,O
,once,RB,O
,daily,RB,O
,.,.,O
,Four,CD,O
,(,(,O
,5,CD,O
,%,NN,O
,),),O
,patients,NNS,O
,had,VBD,O
,from,IN,O
,torsades,NNS,B-DISEASE
,de,IN,I-DISEASE
,pointes,NNS,I-DISEASE
,during,IN,O
,the,DT,O
,initial,JJ,O
,oral,JJ,O
,treatment,NN,O
,with,IN,O
,d,NN,O
,",",",",O
,l,SYM,O
,-,:,O
,sotalol,NN,O
,.,.,O
,Neither,CC,O
,ECG,NNP,O
,[,NNP,O
,sinus,VBD,O
,-,:,O
,cycle,NN,O
,length,NN,O
,(,(,O
,SCL,NNP,O
,),),O
,",",",",O
,QT,NNP,O
,or,CC,O
,QTc,NNP,O
,interval,NN,O
,",",",",O
,or,CC,O
,U,NNP,O
,wave,VBP,O
,],NNP,O
,nor,CC,O
,clinical,JJ,O
,parameters,NNS,O
,identified,VBD,O
,patients,NNS,O
,at,IN,O
,risk,NN,O
,for,IN,O
,torsades,NNS,B-DISEASE
,de,FW,I-DISEASE
,pointes,NNS,I-DISEASE
,.,.,O
,However,RB,O
,",",",",O
,the,DT,O
,oral,JJ,O
,dose,NN,O
,of,IN,O
,d,NN,O
,",",",",O
,l,SYM,O
,-,:,O
,sotalol,NN,O
,was,VBD,O
,significantly,RB,O
,lower,JJR,O
,in,IN,O
,patients,NNS,O
,with,IN,O
,torsades,NNS,B-DISEASE
,de,FW,I-DISEASE
,pointes,NNS,I-DISEASE
,(,(,O
,200,CD,O
,+,NN,O
,/,NNP,O
,-,:,O
,46,CD,O
,vs,NN,O
,.,.,O
,328,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,53,CD,O
,mg,JJ,O
,/,NNP,O
,day,NN,O
,;,:,O
,p,CC,O
,=,$,O
,0,CD,O
,.,.,O
,0017,CD,O
,),),O
,.,.,O
,Risk,NN,O
,factors,NNS,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,torsades,NNS,B-DISEASE
,de,IN,I-DISEASE
,pointes,NNS,I-DISEASE
,were,VBD,O
,the,DT,O
,appearance,NN,O
,of,IN,O
,an,DT,O
,U,NNP,O
,wave,NN,O
,(,(,O
,p,JJ,O
,=,NN,O
,0,CD,O
,.,.,O
,049,CD,O
,),),O
,",",",",O
,female,JJ,O
,gender,NN,O
,(,(,O
,p,JJ,O
,=,NN,O
,0,CD,O
,.,.,O
,015,CD,O
,),),O
,",",",",O
,and,CC,O
,significant,JJ,O
,dose,JJ,O
,-,:,O
,corrected,VBN,O
,changes,NNS,O
,of,IN,O
,SCL,NNP,O
,",",",",O
,QT,NNP,O
,interval,NN,O
,",",",",O
,and,CC,O
,QTc,NNP,O
,interval,NN,O
,(,(,O
,p,JJ,O
,<,NN,O
,0,CD,O
,.,.,O
,05,CD,O
,),),O
,.,.,O
,During,IN,O
,follow,JJ,O
,-,:,O
,up,RB,O
,",",",",O
,seven,CD,O
,(,(,O
,20,CD,O
,%,NN,O
,),),O
,patients,NNS,O
,had,VBD,O
,a,DT,O
,nonfatal,JJ,O
,ventricular,JJ,B-DISEASE
,tachycardia,NN,I-DISEASE
,recurrence,NN,O
,",",",",O
,and,CC,O
,two,CD,O
,(,(,O
,6,CD,O
,%,NN,O
,),),O
,patients,NNS,O
,died,VBD,O
,suddenly,RB,O
,.,.,O
,One,CD,O
,female,JJ,O
,patient,NN,O
,with,IN,O
,stable,JJ,O
,cardiac,JJ,B-DISEASE
,disease,NN,I-DISEASE
,had,VBD,O
,recurrent,JJ,O
,torsades,NNS,B-DISEASE
,de,IN,I-DISEASE
,pointes,NNS,I-DISEASE
,after,IN,O
,2,CD,O
,years,NNS,O
,of,IN,O
,successful,JJ,O
,treatment,NN,O
,with,IN,O
,d,NN,O
,",",",",O
,l,SYM,O
,-,:,O
,sotalol,NN,O
,.,.,O
,Torsades,NNP,B-DISEASE
,de,IN,I-DISEASE
,pointes,NNS,I-DISEASE
,occurred,VBD,O
,early,JJ,O
,during,IN,O
,treatment,NN,O
,even,RB,O
,with,IN,O
,low,JJ,O
,doses,NNS,O
,of,IN,O
,oral,JJ,O
,d,NN,O
,",",",",O
,l,SYM,O
,-,:,O
,sotalol,NN,O
,.,.,O
,Pronounced,NNP,O
,changes,NNS,O
,in,IN,O
,the,DT,O
,surface,NN,O
,ECG,NNP,O
,(,(,O
,cycle,NN,O
,length,NN,O
,",",",",O
,QT,NNP,O
,",",",",O
,and,CC,O
,QTc,NNP,O
,),),O
,in,IN,O
,relation,NN,O
,to,TO,O
,the,DT,O
,dose,NN,O
,of,IN,O
,oral,JJ,O
,d,NN,O
,",",",",O
,l,SYM,O
,-,:,O
,sotalol,NN,O
,might,MD,O
,identify,VB,O
,a,DT,O
,subgroup,NN,O
,of,IN,O
,patients,NNS,O
,with,IN,O
,an,DT,O
,increased,VBN,O
,risk,NN,O
,for,IN,O
,torsades,NNS,B-DISEASE
,de,FW,I-DISEASE
,pointes,NNS,I-DISEASE
,.,.,O
,Other,JJ,O
,ECG,NNP,O
,parameters,NNS,O
,before,IN,O
,the,DT,O
,application,NN,O
,of,IN,O
,d,NN,O
,",",",",O
,l,SYM,O
,-,:,O
,sotalol,NN,O
,did,VBD,O
,not,RB,O
,identify,VB,O
,patients,NNS,O
,at,IN,O
,increased,VBN,O
,risk,NN,O
,for,IN,O
,torsades,NNS,B-DISEASE
,de,FW,I-DISEASE
,pointes,NNS,I-DISEASE
,.,.,O
,Recurrence,NNP,O
,rates,NNS,O
,of,IN,O
,ventricular,JJ,B-DISEASE
,tachyarrhythmias,NNS,I-DISEASE
,are,VBP,O
,high,JJ,O
,despite,IN,O
,complete,JJ,O
,suppression,NN,O
,of,IN,O
,the,DT,O
,arrhythmia,NN,B-DISEASE
,during,IN,O
,programmed,JJ,O
,stimulation,NN,O
,.,.,O
,Therefore,RB,O
,programmed,JJ,O
,electrical,JJ,O
,stimulation,NN,O
,in,IN,O
,the,DT,O
,case,NN,O
,of,IN,O
,d,NN,O
,",",",",O
,l,SYM,O
,-,:,O
,sotalol,NN,O
,seems,VBZ,O
,to,TO,O
,be,VB,O
,of,IN,O
,limited,JJ,O
,prognostic,JJ,O
,value,NN,O
,.,.,O
,Chronic,NNP,O
,hyperprolactinemia,NN,B-DISEASE
,and,CC,O
,changes,NNS,O
,in,IN,O
,dopamine,NN,O
,neurons,NNS,O
,.,.,O
,The,DT,O
,tuberoinfundibular,JJ,O
,dopaminergic,NN,O
,(,(,O
,TIDA,NNP,O
,),),O
,system,NN,O
,is,VBZ,O
,known,VBN,O
,to,TO,O
,inhibit,VB,O
,prolactin,NN,O
,(,(,O
,PRL,NNP,O
,),),O
,secretion,NN,O
,.,.,O
,In,IN,O
,young,JJ,O
,animals,NNS,O
,this,DT,O
,system,NN,O
,responds,VBZ,O
,to,TO,O
,acute,VB,O
,elevations,NNS,O
,in,IN,O
,serum,NN,O
,PRL,NNP,O
,by,IN,O
,increasing,VBG,O
,its,PRP$,O
,activity,NN,O
,.,.,O
,However,RB,O
,",",",",O
,this,DT,O
,responsiveness,NN,O
,is,VBZ,O
,lost,VBN,O
,in,IN,O
,aging,VBG,O
,rats,NNS,O
,with,IN,O
,chronically,RB,O
,high,JJ,O
,serum,NN,O
,PRL,NNP,O
,levels,NNS,O
,.,.,O
,The,DT,O
,purpose,NN,O
,of,IN,O
,this,DT,O
,study,NN,O
,was,VBD,O
,to,TO,O
,induce,VB,O
,hyperprolactinemia,NN,B-DISEASE
,in,IN,O
,rats,NNS,O
,for,IN,O
,extended,JJ,O
,periods,NNS,O
,of,IN,O
,time,NN,O
,and,CC,O
,examine,VB,O
,its,PRP$,O
,effects,NNS,O
,on,IN,O
,dopaminergic,JJ,O
,systems,NNS,O
,in,IN,O
,the,DT,O
,brain,NN,O
,.,.,O
,Hyperprolactinemia,NNP,B-DISEASE
,was,VBD,O
,induced,VBN,O
,by,IN,O
,treatment,NN,O
,with,IN,O
,haloperidol,NN,O
,",",",",O
,a,DT,O
,dopamine,NN,O
,receptor,NN,O
,antagonist,NN,O
,",",",",O
,and,CC,O
,Palkovits,NNP,O
,',POS,O
,microdissection,NN,O
,technique,NN,O
,in,IN,O
,combination,NN,O
,with,IN,O
,high,JJ,O
,-,:,O
,performance,NN,O
,liquid,NN,O
,chromatography,NN,O
,was,VBD,O
,used,VBN,O
,to,TO,O
,measure,VB,O
,neurotransmitter,JJ,O
,concentrations,NNS,O
,in,IN,O
,several,JJ,O
,areas,NNS,O
,of,IN,O
,the,DT,O
,brain,NN,O
,.,.,O
,After,IN,O
,6,CD,O
,months,NNS,O
,of,IN,O
,hyperprolactinemia,NN,B-DISEASE
,",",",",O
,dopamine,NN,O
,(,(,O
,DA,NNP,O
,),),O
,concentrations,NNS,O
,in,IN,O
,the,DT,O
,median,JJ,O
,eminence,NN,O
,(,(,O
,ME,NNP,O
,),),O
,increased,VBN,O
,by,IN,O
,84,CD,O
,%,NN,O
,over,IN,O
,the,DT,O
,control,NN,O
,group,NN,O
,.,.,O
,Nine,NNP,O
,months,NNS,O
,of,IN,O
,hyperprolactinemia,NN,B-DISEASE
,produced,VBD,O
,a,DT,O
,50,CD,O
,%,NN,O
,increase,NN,O
,in,IN,O
,DA,NNP,O
,concentrations,NNS,O
,in,IN,O
,the,DT,O
,ME,NNP,O
,over,IN,O
,the,DT,O
,control,NN,O
,group,NN,O
,.,.,O
,However,RB,O
,",",",",O
,DA,NNP,O
,response,NN,O
,was,VBD,O
,lost,VBN,O
,if,IN,O
,a,DT,O
,9,CD,O
,-,:,O
,month,NN,O
,long,RB,O
,haloperidol,JJ,O
,-,:,O
,induced,JJ,O
,hyperprolactinemia,NN,B-DISEASE
,was,VBD,O
,followed,VBN,O
,by,IN,O
,a,DT,O
,1,CD,O
,1,CD,O
,/,NNS,O
,2,CD,O
,month,NN,O
,-,:,O
,long,RB,O
,extremely,RB,O
,high,JJ,O
,increase,NN,O
,in,IN,O
,serum,JJ,O
,PRL,NNP,O
,levels,NNS,O
,produced,VBN,O
,by,IN,O
,implantation,NN,O
,of,IN,O
,MMQ,NNP,O
,cells,NNS,O
,under,IN,O
,the,DT,O
,kidney,NN,O
,capsule,NN,O
,.,.,O
,There,EX,O
,was,VBD,O
,no,DT,O
,change,NN,O
,in,IN,O
,the,DT,O
,levels,NNS,O
,of,IN,O
,DA,NNP,O
,",",",",O
,norepinephrine,NN,O
,(,(,O
,NE,NNP,O
,),),O
,",",",",O
,serotonin,NN,O
,(,(,O
,5,CD,O
,-,:,O
,HT,NN,O
,),),O
,",",",",O
,or,CC,O
,their,PRP$,O
,metabolites,NNS,O
,in,IN,O
,the,DT,O
,arcuate,NN,O
,nucleus,NN,O
,(,(,O
,AN,NNP,O
,),),O
,",",",",O
,medial,JJ,O
,preoptic,JJ,O
,area,NN,O
,(,(,O
,MPA,NNP,O
,),),O
,",",",",O
,caudate,JJ,O
,putamen,NNS,O
,(,(,O
,CP,NNP,O
,),),O
,",",",",O
,substantia,JJ,O
,nigra,NN,O
,(,(,O
,SN,NNP,O
,),),O
,",",",",O
,and,CC,O
,zona,NN,O
,incerta,NN,O
,(,(,O
,ZI,NNP,O
,),),O
,",",",",O
,except,IN,O
,for,IN,O
,a,DT,O
,decrease,NN,O
,in,IN,O
,5,CD,O
,-,:,O
,hydroxyindoleacetic,JJ,O
,acid,NN,O
,(,(,O
,5,CD,O
,-,:,O
,HIAA,NN,O
,),),O
,in,IN,O
,the,DT,O
,AN,NNP,O
,after,IN,O
,6,CD,O
,-,:,O
,months,NNS,O
,of,IN,O
,hyperprolactinemia,NN,B-DISEASE
,and,CC,O
,an,DT,O
,increase,NN,O
,in,IN,O
,DA,NNP,O
,concentrations,NNS,O
,in,IN,O
,the,DT,O
,AN,NNP,O
,after,IN,O
,9,CD,O
,-,:,O
,months,NNS,O
,of,IN,O
,hyperprolactinemia,NN,B-DISEASE
,.,.,O
,These,DT,O
,results,NNS,O
,demonstrate,VBP,O
,that,IN,O
,hyperprolactinemia,NN,B-DISEASE
,specifically,RB,O
,affects,VBZ,O
,TIDA,NNP,O
,neurons,NNS,O
,and,CC,O
,these,DT,O
,effects,NNS,O
,vary,VBP,O
,",",",",O
,depending,VBG,O
,on,IN,O
,the,DT,O
,duration,NN,O
,and,CC,O
,intensity,NN,O
,of,IN,O
,hyperprolactinemia,NN,B-DISEASE
,.,.,O
,The,DT,O
,age,NN,O
,-,:,O
,related,JJ,O
,decrease,NN,O
,in,IN,O
,hypothalamic,JJ,O
,dopamine,NN,O
,function,NN,O
,may,MD,O
,be,VB,O
,associated,VBN,O
,with,IN,O
,increases,NNS,O
,in,IN,O
,PRL,NNP,O
,secretion,NN,O
,.,.,O
,Treatment,NNP,O
,-,:,O
,related,VBN,O
,disseminated,JJ,O
,necrotizing,VBG,O
,leukoencephalopathy,JJ,B-DISEASE
,with,IN,O
,characteristic,JJ,O
,contrast,NN,O
,enhancement,NN,O
,of,IN,O
,the,DT,O
,white,JJ,O
,matter,NN,O
,.,.,O
,This,DT,O
,report,NN,O
,describes,VBZ,O
,unique,JJ,O
,contrast,NN,O
,enhancement,NN,O
,of,IN,O
,the,DT,O
,white,JJ,O
,matter,NN,O
,on,IN,O
,T1,NNP,O
,-,:,O
,weighted,VBD,O
,magnetic,JJ,O
,resonance,NN,O
,images,NNS,O
,of,IN,O
,two,CD,O
,patients,NNS,O
,with,IN,O
,disseminated,JJ,O
,necrotizing,VBG,O
,leukoencephalopathy,NN,B-DISEASE
,",",",",O
,which,WDT,O
,developed,VBD,O
,from,IN,O
,acute,JJ,B-DISEASE
,lymphoblastic,JJ,I-DISEASE
,leukemia,NN,I-DISEASE
,treated,VBN,O
,with,IN,O
,high,JJ,O
,-,:,O
,dose,JJ,O
,methotrexate,NN,O
,.,.,O
,In,IN,O
,both,DT,O
,patients,NNS,O
,",",",",O
,the,DT,O
,enhancement,NN,O
,was,VBD,O
,more,RBR,O
,pronounced,JJ,O
,near,IN,O
,the,DT,O
,base,NN,O
,of,IN,O
,the,DT,O
,brain,NN,O
,than,IN,O
,at,IN,O
,the,DT,O
,vertex,NN,O
,.,.,O
,Necropsy,NNP,O
,of,IN,O
,the,DT,O
,first,JJ,O
,case,NN,O
,revealed,VBD,O
,loss,NN,B-DISEASE
,of,IN,I-DISEASE
,myelination,NN,I-DISEASE
,and,CC,O
,necrosis,NN,B-DISEASE
,of,IN,O
,the,DT,O
,white,JJ,O
,matter,NN,O
,.,.,O
,Possible,JJ,O
,mechanisms,JJ,O
,causing,NN,O
,such,PDT,O
,a,DT,O
,leukoencephalopathy,NN,B-DISEASE
,are,VBP,O
,discussed,VBN,O
,.,.,O
,Thrombotic,JJ,B-DISEASE
,complications,NNS,O
,in,IN,O
,acute,JJ,B-DISEASE
,promyelocytic,JJ,I-DISEASE
,leukemia,NN,I-DISEASE
,during,IN,O
,all,DT,O
,-,:,O
,trans,NNS,O
,-,:,O
,retinoic,NN,O
,acid,JJ,O
,therapy,NN,O
,.,.,O
,A,DT,O
,case,NN,O
,of,IN,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,",",",",O
,due,JJ,O
,to,TO,O
,occlusion,NN,B-DISEASE
,of,IN,I-DISEASE
,renal,JJ,I-DISEASE
,vessels,NNS,I-DISEASE
,in,IN,O
,a,DT,O
,patient,NN,O
,with,IN,O
,acute,JJ,B-DISEASE
,promyelocytic,JJ,I-DISEASE
,leukemia,NN,I-DISEASE
,(,(,O
,APL,NNP,B-DISEASE
,),),O
,treated,VBD,O
,with,IN,O
,all,DT,O
,-,:,O
,trans,NNS,O
,-,:,O
,retinoic,NN,O
,acid,NN,O
,(,(,O
,ATRA,NNP,O
,),),O
,and,CC,O
,tranexamic,JJ,O
,acid,NN,O
,has,VBZ,O
,been,VBN,O
,described,VBN,O
,recently,RB,O
,.,.,O
,We,PRP,O
,report,VBP,O
,a,DT,O
,case,NN,O
,of,IN,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,in,IN,O
,an,DT,O
,APL,NNP,B-DISEASE
,patient,NN,O
,treated,VBD,O
,with,IN,O
,ATRA,NNP,O
,alone,RB,O
,.,.,O
,This,DT,O
,case,NN,O
,further,RBR,O
,supports,VBZ,O
,the,DT,O
,concern,NN,O
,about,IN,O
,thromboembolic,JJ,B-DISEASE
,complications,NNS,O
,associated,VBN,O
,with,IN,O
,ATRA,NNP,O
,therapy,NN,O
,in,IN,O
,APL,NNP,B-DISEASE
,patients,NNS,O
,.,.,O
,The,DT,O
,patients,NNS,O
,",",",",O
,a,DT,O
,43,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,man,NN,O
,",",",",O
,presented,VBN,O
,all,PDT,O
,the,DT,O
,signs,NNS,O
,and,CC,O
,symptoms,NNS,O
,of,IN,O
,APL,NNP,B-DISEASE
,and,CC,O
,was,VBD,O
,included,VBN,O
,in,IN,O
,a,DT,O
,treatment,NN,O
,protocol,NN,O
,with,IN,O
,ATRA,NNP,O
,.,.,O
,After,IN,O
,10,CD,O
,days,NNS,O
,of,IN,O
,treatment,NN,O
,",",",",O
,he,PRP,O
,developed,VBD,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,that,WDT,O
,was,VBD,O
,completely,RB,O
,reversible,JJ,O
,after,IN,O
,complete,JJ,O
,remission,NN,O
,of,IN,O
,APL,NNP,B-DISEASE
,was,VBD,O
,achieved,VBN,O
,and,CC,O
,therapy,JJ,O
,discontinued,VBN,O
,.,.,O
,We,PRP,O
,conclude,VBP,O
,that,DT,O
,ATRA,NNP,O
,is,VBZ,O
,a,DT,O
,valid,JJ,O
,therapeutic,JJ,O
,choice,NN,O
,for,IN,O
,patients,NNS,O
,with,IN,O
,APL,NNP,B-DISEASE
,",",",",O
,although,IN,O
,the,DT,O
,procoagulant,JJ,O
,tendency,NN,O
,is,VBZ,O
,not,RB,O
,completely,RB,O
,corrected,VBN,O
,.,.,O
,Thrombotic,JJ,B-DISEASE
,events,NNS,O
,",",",",O
,however,RB,O
,",",",",O
,could,MD,O
,be,VB,O
,avoided,VBN,O
,by,IN,O
,using,VBG,O
,low,JJ,O
,-,:,O
,dose,NN,O
,heparin,NN,O
,.,.,O
,Pupillary,JJ,O
,changes,NNS,O
,associated,VBN,O
,with,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,stimulant,JJ,O
,-,:,O
,induced,VBN,O
,mania,NN,B-DISEASE
,:,:,O
,a,DT,O
,case,NN,O
,report,NN,O
,.,.,O
,A,DT,O
,30,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,cocaine,NN,O
,-,:,O
,dependent,JJ,O
,man,NN,O
,who,WP,O
,was,VBD,O
,a,DT,O
,subject,NN,O
,in,IN,O
,a,DT,O
,study,NN,O
,evaluating,VBG,O
,the,DT,O
,anticraving,VBG,O
,efficacy,NN,O
,of,IN,O
,the,DT,O
,stimulant,JJ,O
,medication,NN,O
,diethylpropion,NN,O
,(,(,O
,DEP,NNP,O
,),),O
,became,VBD,O
,manic,JJ,B-DISEASE
,during,IN,O
,his,PRP$,O
,second,JJ,O
,week,NN,O
,on,IN,O
,the,DT,O
,study,NN,O
,drug,NN,O
,.,.,O
,Pupillometric,NNP,O
,changes,NNS,O
,while,IN,O
,on,IN,O
,DEP,NNP,O
,",",",",O
,especially,RB,O
,changes,NNS,O
,in,IN,O
,the,DT,O
,total,JJ,O
,power,NN,O
,of,IN,O
,pupillary,JJ,B-DISEASE
,oscillation,NN,I-DISEASE
,",",",",O
,were,VBD,O
,dramatically,RB,O
,different,JJ,O
,than,IN,O
,those,DT,O
,observed,VBN,O
,in,IN,O
,the,DT,O
,eight,CD,O
,other,JJ,O
,study,NN,O
,subjects,NNS,O
,who,WP,O
,did,VBD,O
,not,RB,O
,become,VB,O
,manic,JJ,B-DISEASE
,.,.,O
,The,DT,O
,large,JJ,O
,changes,NNS,O
,in,IN,O
,total,JJ,O
,power,NN,O
,of,IN,O
,pupillary,JJ,B-DISEASE
,oscillation,NN,I-DISEASE
,occurred,VBD,O
,a,DT,O
,few,JJ,O
,days,NNS,O
,before,IN,O
,the,DT,O
,patient,NN,O
,became,VBD,O
,fully,RB,O
,manic,JJ,B-DISEASE
,.,.,O
,Such,JJ,O
,medication,NN,O
,-,:,O
,associated,VBN,O
,changes,NNS,O
,in,IN,O
,the,DT,O
,total,JJ,O
,power,NN,O
,of,IN,O
,pupillary,JJ,B-DISEASE
,oscillation,NN,I-DISEASE
,might,MD,O
,be,VB,O
,of,IN,O
,utility,NN,O
,in,IN,O
,identifying,VBG,O
,persons,NNS,O
,at,IN,O
,risk,NN,O
,for,IN,O
,manic,JJ,B-DISEASE
,-,:,O
,like,IN,O
,adverse,JJ,O
,effects,NNS,O
,during,IN,O
,the,DT,O
,medical,JJ,O
,use,NN,O
,of,IN,O
,psychomotor,NN,O
,stimulants,NNS,O
,or,CC,O
,sympathomimetic,JJ,O
,agents,NNS,O
,.,.,O
,Fetal,JJ,O
,risks,NNS,O
,due,JJ,O
,to,TO,O
,warfarin,VB,O
,therapy,NN,O
,during,IN,O
,pregnancy,NN,O
,.,.,O
,Two,CD,O
,mothers,NNS,O
,with,IN,O
,heart,NN,O
,valve,NN,O
,prosthesis,NN,O
,were,VBD,O
,treated,VBN,O
,with,IN,O
,warfarin,NN,O
,during,IN,O
,pregnancy,NN,O
,.,.,O
,In,IN,O
,the,DT,O
,first,JJ,O
,case,NN,O
,a,DT,O
,caesarean,JJ,O
,section,NN,O
,was,VBD,O
,done,VBN,O
,one,CD,O
,week,NN,O
,after,IN,O
,replacement,NN,O
,of,IN,O
,warfarin,NN,O
,with,IN,O
,heparin,NN,O
,.,.,O
,The,DT,O
,baby,NN,O
,died,VBD,O
,of,IN,O
,cerebral,JJ,B-DISEASE
,and,CC,I-DISEASE
,pulmonary,JJ,I-DISEASE
,hemorrhage,NN,I-DISEASE
,.,.,O
,The,DT,O
,second,JJ,O
,mother,NN,O
,had,VBD,O
,a,DT,O
,male,JJ,O
,infant,NN,O
,by,IN,O
,caesarean,JJ,O
,section,NN,O
,.,.,O
,The,DT,O
,baby,NN,O
,showed,VBD,O
,warfarin,JJ,O
,-,:,O
,induced,VBN,O
,embryopathy,JJ,B-DISEASE
,with,IN,O
,nasal,JJ,B-DISEASE
,hypoplasia,NN,I-DISEASE
,and,CC,O
,stippled,JJ,B-DISEASE
,epiphyses,NNS,I-DISEASE
,(,(,O
,chondrodysplasia,VB,B-DISEASE
,punctata,NN,I-DISEASE
,),),O
,.,.,O
,Nasal,NNP,B-DISEASE
,hypoplasia,NN,I-DISEASE
,with,IN,O
,or,CC,O
,without,IN,O
,stippled,VBN,B-DISEASE
,epiphyses,NNS,I-DISEASE
,has,VBZ,O
,now,RB,O
,been,VBN,O
,reported,VBN,O
,in,IN,O
,11,CD,O
,infants,NNS,O
,born,VBN,O
,to,TO,O
,mothers,NNS,O
,treated,VBN,O
,with,IN,O
,warfarin,NN,O
,during,IN,O
,the,DT,O
,first,JJ,O
,trimester,NN,O
,",",",",O
,and,CC,O
,a,DT,O
,causal,NN,O
,association,NN,O
,is,VBZ,O
,probable,JJ,O
,.,.,O
,In,IN,O
,view,NN,O
,of,IN,O
,the,DT,O
,risks,NNS,O
,to,TO,O
,both,DT,O
,mother,NN,O
,and,CC,O
,fetus,NN,O
,in,IN,O
,women,NNS,O
,with,IN,O
,prosthetic,JJ,O
,cardiac,JJ,O
,valves,NNS,O
,it,PRP,O
,is,VBZ,O
,recommended,VBN,O
,that,IN,O
,therapeutic,JJ,O
,abortion,NN,O
,be,VB,O
,advised,VBN,O
,as,IN,O
,the,DT,O
,first,JJ,O
,alternative,NN,O
,.,.,O
,The,DT,O
,negative,JJ,O
,mucosal,NN,O
,potential,NN,O
,:,:,O
,separating,JJ,O
,central,JJ,O
,and,CC,O
,peripheral,JJ,O
,effects,NNS,O
,of,IN,O
,NSAIDs,NNP,O
,in,IN,O
,man,NN,O
,.,.,O
,OBJECTIVE,CC,O
,:,:,O
,We,PRP,O
,wanted,VBD,O
,to,TO,O
,test,VB,O
,whether,IN,O
,assessment,NN,O
,of,IN,O
,both,DT,O
,a,DT,O
,central,JJ,O
,pain,NN,B-DISEASE
,-,:,O
,related,JJ,O
,signal,NN,O
,(,(,O
,chemo,JJ,O
,-,:,O
,somatosensory,NN,O
,evoked,JJ,O
,potential,NN,O
,",",",",O
,CSSEP,NNP,O
,),),O
,and,CC,O
,a,DT,O
,concomitantly,RB,O
,recorded,VBN,O
,peripheral,JJ,O
,signal,NN,O
,(,(,O
,negative,JJ,O
,mucosal,NN,O
,potential,NN,O
,",",",",O
,NMP,NNP,O
,),),O
,allows,VBZ,O
,for,IN,O
,separation,NN,O
,of,IN,O
,central,JJ,O
,and,CC,O
,peripheral,JJ,O
,effects,NNS,O
,of,IN,O
,NSAIDs,NNP,O
,.,.,O
,For,IN,O
,this,DT,O
,purpose,NN,O
,",",",",O
,experimental,JJ,O
,conditions,NNS,O
,were,VBD,O
,created,VBN,O
,in,IN,O
,which,WDT,O
,NSAIDs,NNP,O
,had,VBD,O
,previously,RB,O
,been,VBN,O
,observed,VBN,O
,to,TO,O
,produce,VB,O
,effects,NNS,O
,on,IN,O
,phasic,JJ,O
,and,CC,O
,tonic,JJ,O
,pain,NN,B-DISEASE
,by,IN,O
,either,DT,O
,central,JJ,O
,or,CC,O
,peripheral,JJ,O
,mechanisms,NNS,O
,.,.,O
,METHODS,NN,O
,:,:,O
,According,VBG,O
,to,TO,O
,a,DT,O
,double,JJ,O
,-,:,O
,blind,NN,O
,",",",",O
,randomised,VBN,O
,",",",",O
,controlled,VBN,O
,",",",",O
,threefold,JJ,O
,cross,NN,O
,-,:,O
,over,IN,O
,design,NN,O
,",",",",O
,18,CD,O
,healthy,JJ,O
,subjects,NNS,O
,(,(,O
,11,CD,O
,males,NNS,O
,",",",",O
,7,CD,O
,females,NNS,O
,;,:,O
,mean,JJ,O
,age,NN,O
,26,CD,O
,years,NNS,O
,),),O
,received,VBD,O
,either,DT,O
,placebo,NN,O
,",",",",O
,400,CD,O
,mg,NN,O
,ibuprofen,NN,O
,",",",",O
,or,CC,O
,800,CD,O
,mg,JJ,O
,ibuprofen,NN,O
,.,.,O
,Phasic,NNP,O
,pain,NN,B-DISEASE
,was,VBD,O
,applied,VBN,O
,by,IN,O
,means,NNS,O
,of,IN,O
,short,JJ,O
,pulses,NNS,O
,of,IN,O
,CO2,NNP,O
,to,TO,O
,the,DT,O
,nasal,NN,O
,mucosa,NN,O
,(,(,O
,stimulus,JJ,O
,duration,NN,O
,500,CD,O
,ms,NN,O
,",",",",O
,interval,NN,O
,approximately,RB,O
,60,CD,O
,s,NN,O
,),),O
,",",",",O
,and,CC,O
,tonic,JJ,O
,pain,NN,B-DISEASE
,was,VBD,O
,induced,VBN,O
,in,IN,O
,the,DT,O
,nasal,JJ,O
,cavity,NN,O
,by,IN,O
,means,NNS,O
,of,IN,O
,dry,JJ,O
,air,NN,O
,of,IN,O
,controlled,JJ,O
,temperature,NN,O
,",",",",O
,humidity,NN,O
,and,CC,O
,flow,NN,O
,rate,NN,O
,(,(,O
,22,CD,O
,degrees,NNS,O
,C,NNP,O
,",",",",O
,0,CD,O
,%,NN,O
,relative,JJ,O
,humidity,NN,O
,",",",",O
,145,CD,O
,ml,NN,O
,.,.,O
,s,VB,O
,-,:,O
,1,CD,O
,),),O
,.,.,O
,Both,DT,O
,CSSEPs,NNP,O
,as,IN,O
,central,JJ,O
,and,CC,O
,NMPs,NNP,O
,as,IN,O
,peripheral,JJ,O
,correlates,NNS,O
,of,IN,O
,pain,NN,B-DISEASE
,were,VBD,O
,obtained,VBN,O
,in,IN,O
,response,NN,O
,to,TO,O
,the,DT,O
,CO2,NNP,O
,stimuli,NN,O
,.,.,O
,Additionally,RB,O
,",",",",O
,the,DT,O
,subjects,NNS,O
,rated,VBD,O
,the,DT,O
,intensity,NN,O
,of,IN,O
,both,DT,O
,phasic,JJ,O
,and,CC,O
,tonic,JJ,O
,pain,NN,B-DISEASE
,by,IN,O
,means,NNS,O
,of,IN,O
,visual,JJ,O
,analogue,NN,O
,scales,NNS,O
,.,.,O
,RESULTS,NN,O
,:,:,O
,As,IN,O
,described,VBN,O
,earlier,RBR,O
,",",",",O
,administration,NN,O
,of,IN,O
,ibuprofen,NN,O
,was,VBD,O
,followed,VBN,O
,by,IN,O
,a,DT,O
,decrease,NN,O
,in,IN,O
,tonic,JJ,O
,pain,NN,B-DISEASE
,but,CC,O
,-,:,O
,relative,NN,O
,to,TO,O
,placebo,VB,O
,-,:,O
,an,DT,O
,increase,NN,O
,in,IN,O
,correlates,NNS,O
,of,IN,O
,phasic,JJ,O
,pain,NN,B-DISEASE
,",",",",O
,indicating,VBG,O
,a,DT,O
,specific,JJ,O
,effect,NN,O
,of,IN,O
,ibuprofen,NN,O
,on,IN,O
,the,DT,O
,interaction,NN,O
,between,IN,O
,the,DT,O
,pain,NN,B-DISEASE
,stimuli,NN,O
,under,IN,O
,these,DT,O
,special,JJ,O
,experimental,JJ,O
,conditions,NNS,O
,.,.,O
,Based,VBN,O
,on,IN,O
,the,DT,O
,similar,JJ,O
,behaviour,NN,O
,of,IN,O
,CSSEP,NNP,O
,and,CC,O
,NMP,NNP,O
,",",",",O
,it,PRP,O
,was,VBD,O
,concluded,VBN,O
,that,IN,O
,the,DT,O
,pharmacological,JJ,O
,process,NN,O
,underlying,VBG,O
,this,DT,O
,phenomenon,NN,O
,was,VBD,O
,localised,VBN,O
,in,IN,O
,the,DT,O
,periphery,NN,O
,.,.,O
,By,IN,O
,means,NNS,O
,of,IN,O
,the,DT,O
,simultaneous,JJ,O
,recording,NN,O
,of,IN,O
,interrelated,JJ,O
,peripheral,JJ,O
,and,CC,O
,central,JJ,O
,electrophysiologic,JJ,O
,correlates,NNS,O
,of,IN,O
,nociception,NN,O
,",",",",O
,it,PRP,O
,was,VBD,O
,possible,JJ,O
,to,TO,O
,separate,JJ,O
,central,JJ,O
,and,CC,O
,peripheral,JJ,O
,effects,NNS,O
,of,IN,O
,an,DT,O
,NSAID,NNP,O
,.,.,O
,The,DT,O
,major,JJ,O
,advantage,NN,O
,of,IN,O
,this,DT,O
,pain,NN,B-DISEASE
,model,NN,O
,is,VBZ,O
,the,DT,O
,possibility,NN,O
,of,IN,O
,obtaining,VBG,O
,peripheral,JJ,O
,pain,NN,B-DISEASE
,-,:,O
,related,JJ,O
,activity,NN,O
,directly,RB,O
,using,VBG,O
,a,DT,O
,non,JJ,O
,-,:,O
,invasive,JJ,O
,technique,NN,O
,in,IN,O
,humans,NNS,O
,.,.,O
,Effect,NN,O
,of,IN,O
,D,NNP,O
,-,:,O
,Glucarates,VBZ,O
,on,IN,O
,basic,JJ,O
,antibiotic,JJ,O
,-,:,O
,induced,JJ,O
,renal,JJ,B-DISEASE
,damage,NN,I-DISEASE
,in,IN,O
,rats,NNS,O
,.,.,O
,Dehydrated,VBN,B-DISEASE
,rats,NNS,O
,regularly,RB,O
,develop,VBP,O
,acute,JJ,B-DISEASE
,renal,JJ,I-DISEASE
,failure,NN,I-DISEASE
,following,VBG,O
,single,JJ,O
,injection,NN,O
,of,IN,O
,aminoglycoside,JJ,O
,antibiotics,NNS,O
,combined,VBN,O
,with,IN,O
,dextran,NN,O
,or,CC,O
,of,IN,O
,antibiotics,NNS,O
,only,RB,O
,.,.,O
,Oral,JJ,O
,administration,NN,O
,of,IN,O
,2,CD,O
,",",",",O
,5,CD,O
,-,:,O
,di,NN,O
,-,:,O
,O,NNP,O
,-,:,O
,acetyl,NN,O
,-,:,O
,D,NNP,O
,-,:,O
,glucaro,NN,O
,-,:,O
,1,CD,O
,",",",",O
,4,CD,O
,-,:,O
,6,CD,O
,",",",",O
,3,CD,O
,-,:,O
,dilactone,NN,O
,protected,VBD,O
,rats,NNS,O
,against,IN,O
,renal,JJ,B-DISEASE
,failure,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,kanamycin,SYM,O
,-,:,O
,dextran,NN,O
,.,.,O
,The,DT,O
,protective,JJ,O
,effect,NN,O
,was,VBD,O
,prevalent,JJ,O
,among,IN,O
,D,NNP,O
,-,:,O
,glucarates,NNS,O
,",",",",O
,and,CC,O
,also,RB,O
,to,TO,O
,other,JJ,O
,saccharic,JJ,O
,acid,NN,O
,",",",",O
,hexauronic,JJ,O
,acids,NNS,O
,and,CC,O
,hexaaldonic,JJ,O
,acids,NNS,O
,",",",",O
,although,IN,O
,to,TO,O
,a,DT,O
,lesser,JJR,O
,degree,NN,O
,",",",",O
,but,CC,O
,not,RB,O
,to,TO,O
,a,DT,O
,hexaaldose,NN,O
,",",",",O
,sugar,NN,O
,alcohols,NNS,O
,",",",",O
,substances,NNS,O
,inthe,VBP,O
,TCA,NNP,O
,cycle,NN,O
,and,CC,O
,other,JJ,O
,acidic,JJ,O
,compounds,NNS,O
,.,.,O
,D,NNP,O
,-,:,O
,Glucarates,NNS,O
,were,VBD,O
,effective,JJ,O
,against,IN,O
,renal,JJ,B-DISEASE
,damage,NN,I-DISEASE
,induced,VBN,O
,by,IN,O
,peptide,JJ,O
,antibiotics,NNS,O
,as,RB,O
,well,RB,O
,as,IN,O
,various,JJ,O
,aminoglycoside,IN,O
,antibitocis,NN,O
,.,.,O
,Dose,NNP,O
,-,:,O
,responses,NNS,O
,were,VBD,O
,observed,VBN,O
,in,IN,O
,the,DT,O
,protective,JJ,O
,effect,NN,O
,of,IN,O
,D,NNP,O
,-,:,O
,Glucarates,VBZ,O
,.,.,O
,With,IN,O
,a,DT,O
,D,NNP,O
,-,:,O
,glucarate,NN,O
,of,IN,O
,a,DT,O
,fixed,JJ,O
,size,NN,O
,of,IN,O
,dose,NN,O
,",",",",O
,approximately,RB,O
,the,DT,O
,same,JJ,O
,degree,NN,O
,of,IN,O
,protection,NN,O
,was,VBD,O
,obtained,VBN,O
,against,IN,O
,renal,JJ,B-DISEASE
,damages,NNS,I-DISEASE
,induced,VBN,O
,by,IN,O
,different,JJ,O
,basic,JJ,O
,antibiotics,NNS,O
,despite,IN,O
,large,JJ,O
,disparities,NNS,O
,in,IN,O
,administration,NN,O
,doses,NNS,O
,of,IN,O
,different,JJ,O
,antibiotics,NNS,O
,.,.,O
,D,NNP,O
,-,:,O
,Glucarates,NNS,O
,had,VBD,O
,the,DT,O
,ability,NN,O
,to,TO,O
,prevent,VB,O
,renal,JJ,B-DISEASE
,damage,NN,I-DISEASE
,but,CC,O
,not,RB,O
,to,TO,O
,cure,VB,O
,it,PRP,O
,.,.,O
,Rats,NNP,O
,excreted,VBD,O
,acidic,JJ,O
,urine,NN,O
,when,WRB,O
,they,PRP,O
,were,VBD,O
,spared,VBN,O
,from,IN,O
,renal,JJ,B-DISEASE
,lesions,NNS,I-DISEASE
,by,IN,O
,monosaccharides,NNS,O
,.,.,O
,The,DT,O
,reduction,NN,O
,effect,NN,O
,of,IN,O
,D,NNP,O
,-,:,O
,glucarates,NNS,O
,against,IN,O
,nephrotoxicity,NN,B-DISEASE
,of,IN,O
,basic,JJ,O
,antibiotics,NNS,O
,was,VBD,O
,discussed,VBN,O
,.,.,O
,Acute,NNP,O
,severe,JJ,O
,depression,NN,B-DISEASE
,following,VBG,O
,peri,JJ,O
,-,:,O
,operative,JJ,O
,ondansetron,NN,O
,.,.,O
,A,DT,O
,41,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,woman,NN,O
,with,IN,O
,a,DT,O
,strong,JJ,O
,history,NN,O
,of,IN,O
,postoperative,JJ,B-DISEASE
,nausea,NN,I-DISEASE
,and,CC,I-DISEASE
,vomiting,NN,I-DISEASE
,presented,VBN,O
,for,IN,O
,abdominal,JJ,O
,hysterectomy,NN,O
,3,CD,O
,months,NNS,O
,after,IN,O
,a,DT,O
,previous,JJ,O
,anaesthetic,JJ,O
,where,WRB,O
,ondansetron,NN,O
,prophylaxis,NN,O
,had,VBD,O
,been,VBN,O
,used,VBN,O
,.,.,O
,She,PRP,O
,had,VBD,O
,developed,VBN,O
,a,DT,O
,severe,JJ,O
,acute,NN,O
,major,JJ,B-DISEASE
,depression,NN,I-DISEASE
,disorder,NN,I-DISEASE
,almost,RB,O
,immediately,RB,O
,thereafter,JJ,O
,",",",",O
,possibly,RB,O
,related,VBN,O
,to,TO,O
,the,DT,O
,use,NN,O
,of,IN,O
,a,DT,O
,serotonin,JJ,O
,antagonist,NN,O
,.,.,O
,Nine,CD,O
,years,NNS,O
,before,IN,O
,she,PRP,O
,had,VBD,O
,experienced,VBN,O
,a,DT,O
,self,NN,O
,-,:,O
,limited,JJ,O
,puerperal,JJ,O
,depressive,JJ,B-DISEASE
,episode,NN,I-DISEASE
,.,.,O
,Anaesthesia,NNP,O
,with,IN,O
,a,DT,O
,propofol,JJ,O
,infusion,NN,O
,and,CC,O
,avoidance,NN,O
,of,IN,O
,serotonin,NN,O
,antagonists,NNS,O
,provided,VBD,O
,a,DT,O
,nausea,JJ,B-DISEASE
,-,:,O
,free,JJ,O
,postoperative,JJ,O
,course,NN,O
,without,IN,O
,exacerbation,NN,O
,of,IN,O
,the,DT,O
,depression,NN,B-DISEASE
,disorder,NN,I-DISEASE
,.,.,O
,Hypertensive,JJ,B-DISEASE
,response,NN,O
,during,IN,O
,dobutamine,JJ,O
,stress,NN,O
,echocardiography,NN,O
,.,.,O
,Among,IN,O
,3,CD,O
,",",",",O
,129,CD,O
,dobutamine,NN,O
,stress,NN,O
,echocardiographic,JJ,O
,studies,NNS,O
,",",",",O
,a,DT,O
,hypertensive,JJ,B-DISEASE
,response,NN,O
,",",",",O
,defined,VBD,O
,as,IN,O
,systolic,JJ,O
,blood,NN,O
,pressure,NN,O
,(,(,O
,BP,NNP,O
,),),O
,>,VBD,O
,or,CC,O
,=,$,O
,220,CD,O
,mm,NN,O
,Hg,NNP,O
,and,CC,O
,/,NNP,O
,or,CC,O
,diastolic,JJ,O
,BP,NNP,O
,>,NN,O
,or,CC,O
,=,$,O
,110,CD,O
,mm,NN,O
,Hg,NNP,O
,",",",",O
,occurred,VBD,O
,in,IN,O
,30,CD,O
,patients,NNS,O
,(,(,O
,1,CD,O
,%,NN,O
,),),O
,.,.,O
,Patients,NNS,O
,with,IN,O
,this,DT,O
,response,NN,O
,more,RBR,O
,often,RB,O
,had,VBD,O
,a,DT,O
,history,NN,O
,of,IN,O
,hypertension,NN,B-DISEASE
,and,CC,O
,had,VBD,O
,higher,JJR,O
,resting,VBG,O
,systolic,JJ,O
,and,CC,O
,diastolic,JJ,O
,BP,NNP,O
,before,IN,O
,dobutamine,JJ,O
,infusion,NN,O
,.,.,O
,Continuously,RB,O
,nebulized,JJ,O
,albuterol,NN,O
,in,IN,O
,severe,JJ,O
,exacerbations,NNS,O
,of,IN,O
,asthma,NN,B-DISEASE
,in,IN,O
,adults,NNS,O
,:,:,O
,a,DT,O
,case,NN,O
,-,:,O
,controlled,VBN,O
,study,NN,O
,.,.,O
,A,DT,O
,retrospective,JJ,O
,",",",",O
,case,NN,O
,-,:,O
,controlled,VBN,O
,analysis,NN,O
,comparing,VBG,O
,patients,NNS,O
,admitted,VBN,O
,to,TO,O
,a,DT,O
,medical,JJ,O
,intensive,JJ,O
,care,NN,O
,unit,NN,O
,with,IN,O
,severe,JJ,O
,exacerbations,NNS,O
,of,IN,O
,asthma,NN,B-DISEASE
,who,WP,O
,received,VBD,O
,continuously,RB,O
,nebulized,VBN,O
,albuterol,NN,O
,(,(,O
,CNA,NNP,O
,),),O
,versus,FW,O
,intermittent,JJ,O
,albuterol,NN,O
,(,(,O
,INA,NNP,O
,),),O
,treatments,NNS,O
,is,VBZ,O
,reported,VBN,O
,.,.,O
,Forty,NNP,O
,matched,VBD,O
,pairs,NNS,O
,of,IN,O
,patients,NNS,O
,with,IN,O
,asthma,NNS,B-DISEASE
,are,VBP,O
,compared,VBN,O
,.,.,O
,CNA,NNP,O
,was,VBD,O
,administered,VBN,O
,for,IN,O
,a,DT,O
,mean,NN,O
,of,IN,O
,11,CD,O
,+,NNS,O
,/,SYM,O
,-,:,O
,10,CD,O
,hr,NN,O
,.,.,O
,The,DT,O
,incidence,NN,O
,of,IN,O
,cardiac,JJ,B-DISEASE
,dysrhythmias,NN,I-DISEASE
,was,VBD,O
,similar,JJ,O
,between,IN,O
,groups,NNS,O
,.,.,O
,Symptomatic,JJ,O
,hypokalemia,NN,B-DISEASE
,did,VBD,O
,not,RB,O
,occur,VB,O
,.,.,O
,CNA,NNP,O
,patients,NNS,O
,had,VBD,O
,higher,JJR,O
,heart,NN,O
,rates,NNS,O
,during,IN,O
,treatment,NN,O
,",",",",O
,which,WDT,O
,may,MD,O
,reflect,VB,O
,severity,NN,O
,of,IN,O
,illness,NN,O
,.,.,O
,The,DT,O
,incidence,NN,O
,of,IN,O
,intubation,NN,O
,was,VBD,O
,similar,JJ,O
,.,.,O
,We,PRP,O
,conclude,VBP,O
,that,IN,O
,CNA,NNP,O
,and,CC,O
,INA,NNP,O
,demonstrated,VBD,O
,similar,JJ,O
,profiles,NNS,O
,with,IN,O
,regard,NN,O
,to,TO,O
,safety,NN,O
,",",",",O
,morbidity,NN,O
,",",",",O
,and,CC,O
,mortality,NN,O
,.,.,O
,Paraplegia,NNP,B-DISEASE
,following,VBG,O
,intrathecal,JJ,O
,methotrexate,NN,O
,:,:,O
,report,NN,O
,of,IN,O
,a,DT,O
,case,NN,O
,and,CC,O
,review,NN,O
,of,IN,O
,the,DT,O
,literature,NN,O
,.,.,O
,A,DT,O
,patient,NN,O
,who,WP,O
,developed,VBD,O
,paraplegia,NN,B-DISEASE
,following,VBG,O
,the,DT,O
,intrathecal,JJ,O
,instillation,NN,O
,of,IN,O
,methotrexate,NN,O
,is,VBZ,O
,discribed,VBN,O
,.,.,O
,The,DT,O
,ten,NN,O
,previously,RB,O
,reported,VBD,O
,cases,NNS,O
,of,IN,O
,this,DT,O
,unusual,JJ,O
,complication,NN,O
,are,VBP,O
,reviewed,VBN,O
,.,.,O
,The,DT,O
,following,JJ,O
,factors,NNS,O
,appear,VBP,O
,to,TO,O
,predispose,VB,O
,to,TO,O
,the,DT,O
,development,NN,O
,of,IN,O
,this,DT,O
,complication,NN,O
,:,:,O
,abnormal,JJ,O
,cerebrospinal,JJ,O
,dynamics,NNS,O
,related,VBN,O
,to,TO,O
,the,DT,O
,presence,NN,O
,of,IN,O
,central,JJ,B-DISEASE
,nervous,JJ,I-DISEASE
,system,NN,I-DISEASE
,leukemia,NN,I-DISEASE
,",",",",O
,and,CC,O
,epidural,JJ,O
,cerebrospinal,JJ,O
,leakage,NN,O
,;,:,O
,elevated,VBN,O
,cerebrospinal,JJ,O
,fluid,NN,O
,methothexate,NN,O
,concentration,NN,O
,related,VBN,O
,to,TO,O
,abnormal,JJ,O
,cerebrospinal,JJ,O
,fluid,NN,O
,dynamics,NNS,O
,and,CC,O
,to,TO,O
,inappropriately,RB,O
,high,JJ,O
,methotrexate,NN,O
,doses,NNS,O
,based,VBN,O
,on,IN,O
,body,NN,O
,surface,JJ,O
,area,NN,O
,calculations,NNS,O
,in,IN,O
,older,JJR,O
,children,NNS,O
,and,CC,O
,adults,NNS,O
,;,:,O
,the,DT,O
,presence,NN,O
,of,IN,O
,neurotoxic,JJ,B-DISEASE
,preservatives,NNS,O
,in,IN,O
,commercially,RB,O
,available,JJ,O
,methotrexate,NN,O
,preparations,NNS,O
,and,CC,O
,diluents,NNS,O
,;,:,O
,and,CC,O
,the,DT,O
,use,NN,O
,of,IN,O
,methotrexate,NN,O
,diluents,NNS,O
,of,IN,O
,unphysiologic,JJ,O
,pH,NN,O
,",",",",O
,ionic,JJ,O
,content,NN,O
,and,CC,O
,osmolarity,NN,O
,.,.,O
,The,DT,O
,role,NN,O
,of,IN,O
,methotrexate,NN,O
,contaminants,NNS,O
,",",",",O
,local,JJ,O
,folate,NN,B-DISEASE
,deficiency,NN,I-DISEASE
,",",",",O
,and,CC,O
,cranial,JJ,O
,irradiation,NN,O
,in,IN,O
,the,DT,O
,pathogenesis,NN,O
,of,IN,O
,intrathecal,JJ,O
,methotrexate,NN,O
,toxicity,NN,B-DISEASE
,is,VBZ,O
,unclear,JJ,O
,.,.,O
,The,DT,O
,incidence,NN,O
,of,IN,O
,neurotoxicity,NN,B-DISEASE
,may,MD,O
,be,VB,O
,reduced,VBN,O
,by,IN,O
,employing,VBG,O
,lower,JJR,O
,doses,NNS,O
,of,IN,O
,methotrexate,NN,O
,in,IN,O
,the,DT,O
,presence,NN,O
,of,IN,O
,central,JJ,B-DISEASE
,nervous,JJ,I-DISEASE
,system,NN,I-DISEASE
,leukemia,NN,I-DISEASE
,",",",",O
,in,IN,O
,older,JJR,O
,children,NNS,O
,and,CC,O
,adults,NNS,O
,",",",",O
,and,CC,O
,in,IN,O
,the,DT,O
,presence,NN,O
,of,IN,O
,epidural,JJ,O
,leakage,NN,O
,.,.,O
,Only,RB,O
,preservative,JJ,O
,-,:,O
,free,JJ,O
,methotrexate,NN,O
,in,IN,O
,Elliott,NNP,O
,',POS,O
,s,NN,O
,B,NNP,O
,Solution,NNP,O
,at,IN,O
,a,DT,O
,concentration,NN,O
,of,IN,O
,not,RB,O
,more,JJR,O
,than,IN,O
,1,CD,O
,mg,JJ,O
,/,NNP,O
,ml,NN,O
,should,MD,O
,be,VB,O
,used,VBN,O
,for,IN,O
,intrathecal,JJ,O
,administration,NN,O
,.,.,O
,Periodic,JJ,O
,monitoring,NN,O
,of,IN,O
,cerebruspinal,JJ,O
,fluid,NN,O
,methotrexate,NN,O
,levels,NNS,O
,may,MD,O
,be,VB,O
,predictive,JJ,O
,of,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,serious,JJ,O
,neurotoxicity,NN,B-DISEASE
,.,.,O
,Hyperosmolar,NNP,B-DISEASE
,nonketotic,JJ,I-DISEASE
,coma,NN,I-DISEASE
,precipitated,VBN,O
,by,IN,O
,lithium,NN,O
,-,:,O
,induced,JJ,O
,nephrogenic,JJ,B-DISEASE
,diabetes,NNS,I-DISEASE
,insipidus,VBP,I-DISEASE
,.,.,O
,A,DT,O
,45,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,man,NN,O
,",",",",O
,with,IN,O
,a,DT,O
,10,CD,O
,-,:,O
,year,NN,O
,history,NN,O
,of,IN,O
,manic,JJ,B-DISEASE
,depression,NN,I-DISEASE
,treated,VBN,O
,with,IN,O
,lithium,NN,O
,",",",",O
,was,VBD,O
,admitted,VBN,O
,with,IN,O
,hyperosmolar,JJ,B-DISEASE
,",",",",I-DISEASE
,nonketotic,JJ,I-DISEASE
,coma,NN,I-DISEASE
,.,.,O
,He,PRP,O
,gave,VBD,O
,a,DT,O
,five,CD,O
,-,:,O
,year,NN,O
,history,NN,O
,of,IN,O
,polyuria,NN,B-DISEASE
,and,CC,O
,polydipsia,NN,B-DISEASE
,",",",",O
,during,IN,O
,which,WDT,O
,time,NN,O
,urinalysis,NN,O
,had,VBD,O
,been,VBN,O
,negative,JJ,O
,for,IN,O
,glucose,NN,O
,.,.,O
,After,IN,O
,recovery,NN,O
,from,IN,O
,hyperglycaemia,NN,B-DISEASE
,",",",",O
,he,PRP,O
,remained,VBD,O
,polyuric,JJ,B-DISEASE
,despite,IN,O
,normal,JJ,O
,blood,NN,O
,glucose,JJ,O
,concentrations,NNS,O
,;,:,O
,water,NN,O
,deprivation,NN,O
,testing,VBG,O
,indicated,VBD,O
,nephrogenic,JJ,B-DISEASE
,diabetes,NNS,I-DISEASE
,insipidus,NN,I-DISEASE
,",",",",O
,likely,JJ,O
,to,TO,O
,be,VB,O
,lithium,JJ,O
,-,:,O
,induced,JJ,O
,.,.,O
,We,PRP,O
,hypothesize,VBP,O
,that,IN,O
,when,WRB,O
,this,DT,O
,man,NN,O
,developed,VBD,O
,type,JJ,B-DISEASE
,2,CD,I-DISEASE
,diabetes,NNS,I-DISEASE
,",",",",O
,chronic,JJ,O
,polyuria,NNS,B-DISEASE
,due,JJ,O
,to,TO,O
,nephrogenic,JJ,B-DISEASE
,diabetes,NNS,I-DISEASE
,insipidus,NN,I-DISEASE
,was,VBD,O
,sufficient,JJ,O
,to,TO,O
,precipitate,VB,O
,hyperosmolar,JJ,O
,dehydration,NN,B-DISEASE
,.,.,O
,Effects,NNS,O
,of,IN,O
,the,DT,O
,intracoronary,JJ,O
,infusion,NN,O
,of,IN,O
,cocaine,NN,O
,on,IN,O
,left,JJ,O
,ventricular,JJ,O
,systolic,NN,O
,and,CC,O
,diastolic,JJ,O
,function,NN,O
,in,IN,O
,humans,NNS,O
,.,.,O
,BACKGROUND,NN,O
,:,:,O
,In,IN,O
,dogs,NNS,O
,",",",",O
,a,DT,O
,large,JJ,O
,amount,NN,O
,of,IN,O
,intravenous,JJ,O
,cocaine,NN,O
,causes,VBZ,O
,a,DT,O
,profound,JJ,O
,deterioration,NN,B-DISEASE
,of,IN,I-DISEASE
,left,JJ,I-DISEASE
,ventricular,NN,I-DISEASE
,(,(,I-DISEASE
,LV,NNP,I-DISEASE
,),),I-DISEASE
,systolic,JJ,I-DISEASE
,function,NN,I-DISEASE
,and,CC,O
,an,DT,O
,increase,NN,O
,in,IN,O
,LV,NNP,O
,end,VBP,O
,-,:,O
,diastolic,JJ,O
,pressure,NN,O
,.,.,O
,This,DT,O
,study,NN,O
,was,VBD,O
,done,VBN,O
,to,TO,O
,assess,VB,O
,the,DT,O
,influence,NN,O
,of,IN,O
,a,DT,O
,high,JJ,O
,intracoronary,JJ,O
,cocaine,NN,O
,concentration,NN,O
,on,IN,O
,LV,NNP,O
,systolic,NN,O
,and,CC,O
,diastolic,JJ,O
,function,NN,O
,in,IN,O
,humans,NNS,O
,.,.,O
,METHODS,NNP,O
,AND,CC,O
,RESULTS,NNP,O
,:,:,O
,In,IN,O
,20,CD,O
,patients,NNS,O
,(,(,O
,14,CD,O
,men,NNS,O
,and,CC,O
,6,CD,O
,women,NNS,O
,aged,VBD,O
,39,CD,O
,to,TO,O
,72,CD,O
,years,NNS,O
,),),O
,referred,VBD,O
,for,IN,O
,cardiac,JJ,O
,catheterization,NN,O
,for,IN,O
,the,DT,O
,evaluation,NN,O
,of,IN,O
,chest,NN,B-DISEASE
,pain,NN,I-DISEASE
,",",",",O
,we,PRP,O
,measured,VBD,O
,heart,NN,O
,rate,NN,O
,",",",",O
,systemic,JJ,O
,arterial,JJ,O
,pressure,NN,O
,",",",",O
,LV,NNP,O
,pressure,NN,O
,and,CC,O
,its,PRP$,O
,first,JJ,O
,derivative,JJ,O
,(,(,O
,dP,JJ,O
,/,NNP,O
,dt,NN,O
,),),O
,",",",",O
,and,CC,O
,LV,NNP,O
,volumes,NNS,O
,and,CC,O
,ejection,NN,O
,fraction,NN,O
,before,IN,O
,and,CC,O
,during,IN,O
,the,DT,O
,final,JJ,O
,2,CD,O
,to,TO,O
,3,CD,O
,minutes,NNS,O
,of,IN,O
,a,DT,O
,15,CD,O
,-,:,O
,minute,NN,O
,intracoronary,JJ,O
,infusion,NN,O
,of,IN,O
,saline,NN,O
,(,(,O
,n,JJ,O
,=,NN,O
,10,CD,O
,",",",",O
,control,NN,O
,subjects,NNS,O
,),),O
,or,CC,O
,cocaine,VB,O
,hydrochloride,JJ,O
,1,CD,O
,mg,NN,O
,/,NN,O
,min,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,10,CD,O
,),),O
,.,.,O
,No,DT,O
,variable,JJ,O
,changed,VBN,O
,with,IN,O
,saline,NN,O
,.,.,O
,With,IN,O
,cocaine,NN,O
,",",",",O
,the,DT,O
,drug,NN,O
,concentration,NN,O
,in,IN,O
,blood,NN,O
,obtained,VBN,O
,from,IN,O
,the,DT,O
,coronary,JJ,O
,sinus,NN,O
,was,VBD,O
,3,CD,O
,.,.,O
,0,CD,O
,+,JJ,O
,/,NNP,O
,-,:,O
,0,CD,O
,.,.,O
,4,CD,O
,(,(,O
,mean,JJ,O
,+,NNP,O
,/,NNP,O
,-,:,O
,SD,NN,O
,),),O
,mg,NN,O
,/,NNP,O
,L,NNP,O
,",",",",O
,similar,JJ,O
,in,IN,O
,magnitude,NN,O
,to,TO,O
,the,DT,O
,blood,NN,O
,cocaine,NN,O
,concentration,NN,O
,reported,VBD,O
,in,IN,O
,abusers,NNS,O
,dying,VBG,O
,of,IN,O
,cocaine,NN,O
,intoxication,NN,O
,.,.,O
,Cocaine,NNP,O
,induced,VBD,O
,no,DT,O
,significant,JJ,O
,change,NN,O
,in,IN,O
,heart,NN,O
,rate,NN,O
,",",",",O
,LV,NNP,O
,dP,VBZ,O
,/,JJ,O
,dt,NN,O
,(,(,O
,positive,JJ,O
,or,CC,O
,negative,JJ,O
,),),O
,",",",",O
,or,CC,O
,LV,NNP,O
,end,VBP,O
,-,:,O
,diastolic,JJ,O
,volume,NN,O
,",",",",O
,but,CC,O
,it,PRP,O
,caused,VBD,O
,an,DT,O
,increase,NN,O
,in,IN,O
,systolic,JJ,O
,and,CC,O
,mean,JJ,O
,arterial,JJ,O
,pressures,NNS,O
,",",",",O
,LV,NNP,O
,end,VBP,O
,-,:,O
,diastolic,JJ,O
,pressure,NN,O
,",",",",O
,and,CC,O
,LV,NNP,O
,end,VBP,O
,-,:,O
,systolic,JJ,O
,volume,NN,O
,",",",",O
,as,RB,O
,well,RB,O
,as,IN,O
,a,DT,O
,decrease,NN,O
,in,IN,O
,LV,NNP,O
,ejection,NN,O
,fraction,NN,O
,.,.,O
,CONCLUSIONS,NN,O
,:,:,O
,In,IN,O
,humans,NNS,O
,",",",",O
,the,DT,O
,intracoronary,JJ,O
,infusion,NN,O
,of,IN,O
,cocaine,NN,O
,sufficient,NN,O
,in,IN,O
,amount,NN,O
,to,TO,O
,achieve,VB,O
,a,DT,O
,high,JJ,O
,drug,NN,O
,concentration,NN,O
,in,IN,O
,coronary,JJ,O
,sinus,NN,O
,blood,NN,O
,causes,VBZ,O
,a,DT,O
,deterioration,NN,B-DISEASE
,of,IN,I-DISEASE
,LV,NNP,I-DISEASE
,systolic,NN,I-DISEASE
,and,CC,I-DISEASE
,diastolic,JJ,I-DISEASE
,performance,NN,I-DISEASE
,.,.,O
,Ascending,VBG,O
,dose,JJ,O
,tolerance,NN,O
,study,NN,O
,of,IN,O
,intramuscular,JJ,O
,carbetocin,NN,O
,administered,VBN,O
,after,IN,O
,normal,JJ,O
,vaginal,JJ,O
,birth,NN,O
,.,.,O
,OBJECTIVE,NN,O
,:,:,O
,To,TO,O
,determine,VB,O
,the,DT,O
,maximum,JJ,O
,tolerated,JJ,O
,dose,NN,O
,(,(,O
,MTD,NNP,O
,),),O
,of,IN,O
,carbetocin,NN,O
,(,(,O
,a,DT,O
,long,JJ,O
,-,:,O
,acting,VBG,O
,synthetic,JJ,O
,analogue,NN,O
,of,IN,O
,oxytocin,NN,O
,),),O
,",",",",O
,when,WRB,O
,administered,VBN,O
,immediately,RB,O
,after,IN,O
,vaginal,JJ,O
,delivery,NN,O
,at,IN,O
,term,NN,O
,.,.,O
,MATERIALS,NNP,O
,AND,CC,O
,METHODS,NNP,O
,:,:,O
,Carbetocin,NNP,O
,was,VBD,O
,given,VBN,O
,as,IN,O
,an,DT,O
,intramuscular,JJ,O
,injection,NN,O
,immediately,RB,O
,after,IN,O
,the,DT,O
,birth,NN,O
,of,IN,O
,the,DT,O
,infant,NN,O
,in,IN,O
,45,CD,O
,healthy,JJ,O
,women,NNS,O
,with,IN,O
,normal,JJ,O
,singleton,NN,O
,pregnancies,NNS,O
,who,WP,O
,delivered,VBD,O
,vaginally,RB,O
,at,IN,O
,term,NN,O
,.,.,O
,Dosage,NNP,O
,groups,NNS,O
,of,IN,O
,15,CD,O
,",",",",O
,30,CD,O
,",",",",O
,50,CD,O
,",",",",O
,75,CD,O
,",",",",O
,100,CD,O
,",",",",O
,125,CD,O
,",",",",O
,150,CD,O
,",",",",O
,175,CD,O
,or,CC,O
,200,CD,O
,microg,NNS,O
,carbetocin,NNS,O
,were,VBD,O
,assigned,VBN,O
,to,TO,O
,blocks,NNS,O
,of,IN,O
,three,CD,O
,women,NNS,O
,according,VBG,O
,to,TO,O
,the,DT,O
,continual,JJ,O
,reassessment,NN,O
,method,NN,O
,(,(,O
,CRM,NNP,O
,),),O
,.,.,O
,RESULTS,NN,O
,:,:,O
,All,DT,O
,dosage,NN,O
,groups,NNS,O
,consisted,VBD,O
,of,IN,O
,three,CD,O
,women,NNS,O
,",",",",O
,except,IN,O
,those,DT,O
,with,IN,O
,100,CD,O
,microg,NNS,O
,(,(,O
,n,JJ,O
,=,NNP,O
,6,CD,O
,),),O
,and,CC,O
,200,CD,O
,microg,NN,O
,(,(,O
,n,JJ,O
,=,NNP,O
,18,CD,O
,),),O
,.,.,O
,Recorded,VBN,O
,were,VBD,O
,dose,JJ,O
,-,:,O
,limiting,VBG,O
,adverse,JJ,O
,events,NNS,O
,:,:,O
,hyper,NN,B-DISEASE
,-,:,I-DISEASE
,or,CC,I-DISEASE
,hypotension,NN,I-DISEASE
,(,(,O
,three,CD,O
,),),O
,",",",",O
,severe,JJ,O
,abdominal,JJ,B-DISEASE
,pain,NN,I-DISEASE
,(,(,O
,0,CD,O
,),),O
,",",",",O
,vomiting,VBG,B-DISEASE
,(,(,O
,0,CD,O
,),),O
,and,CC,O
,retained,VBN,B-DISEASE
,placenta,NNS,I-DISEASE
,(,(,O
,four,CD,O
,),),O
,.,.,O
,Serious,JJ,O
,adverse,JJ,O
,events,NNS,O
,occurred,VBD,O
,in,IN,O
,seven,CD,O
,women,NNS,O
,:,:,O
,six,CD,O
,cases,NNS,O
,with,IN,O
,blood,NN,B-DISEASE
,loss,NN,I-DISEASE
,>,NN,O
,or,CC,O
,=,JJ,O
,1000,CD,O
,ml,NN,O
,",",",",O
,four,CD,O
,cases,NNS,O
,of,IN,O
,manual,JJ,O
,placenta,NN,O
,removal,NN,O
,",",",",O
,five,CD,O
,cases,NNS,O
,of,IN,O
,additional,JJ,O
,oxytocics,NNS,O
,administration,NN,O
,and,CC,O
,five,CD,O
,cases,NNS,O
,of,IN,O
,blood,NN,O
,transfusion,NN,O
,.,.,O
,Maximum,JJ,O
,blood,NN,B-DISEASE
,loss,NN,I-DISEASE
,was,VBD,O
,greatest,VBN,O
,at,IN,O
,the,DT,O
,upper,JJ,O
,and,CC,O
,lower,JJR,O
,dose,NN,O
,levels,NNS,O
,",",",",O
,and,CC,O
,lowest,JJS,O
,in,IN,O
,the,DT,O
,70,CD,O
,-,:,O
,125,CD,O
,microg,NN,O
,dose,NN,O
,range,NN,O
,.,.,O
,Four,CD,O
,out,IN,O
,of,IN,O
,six,CD,O
,cases,NNS,O
,with,IN,O
,blood,NN,B-DISEASE
,loss,NN,I-DISEASE
,>,NN,O
,or,CC,O
,=,JJ,O
,1000,CD,O
,ml,NN,O
,occurred,VBD,O
,in,IN,O
,the,DT,O
,200,CD,O
,microg,NN,O
,group,NN,O
,.,.,O
,The,DT,O
,majority,NN,O
,of,IN,O
,additional,JJ,O
,administration,NN,O
,of,IN,O
,oxytocics,NNS,O
,(,(,O
,4,CD,O
,/,RB,O
,5,CD,O
,),),O
,and,CC,O
,blood,NN,O
,transfusion,NN,O
,(,(,O
,3,CD,O
,/,RB,O
,5,CD,O
,),),O
,occurred,VBD,O
,in,IN,O
,the,DT,O
,dose,JJ,O
,groups,NNS,O
,of,IN,O
,200,CD,O
,microg,NNS,O
,.,.,O
,All,DT,O
,retained,VBD,O
,placentae,NNS,O
,were,VBD,O
,found,VBN,O
,in,IN,O
,the,DT,O
,group,NN,O
,of,IN,O
,200,CD,O
,microg,NN,O
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,The,DT,O
,MTD,NNP,O
,was,VBD,O
,calculated,VBN,O
,to,TO,O
,be,VB,O
,at,IN,O
,200,CD,O
,microg,NN,O
,carbetocin,NN,O
,.,.,O
,Heparin,NNP,O
,-,:,O
,induced,VBD,O
,thrombocytopenia,NN,B-DISEASE
,",",",",O
,paradoxical,JJ,O
,thromboembolism,NN,B-DISEASE
,",",",",O
,and,CC,O
,other,JJ,O
,side,NN,O
,effects,NNS,O
,of,IN,O
,heparin,NN,O
,therapy,NN,O
,.,.,O
,Although,IN,O
,several,JJ,O
,new,JJ,O
,anticoagulant,JJ,O
,drugs,NNS,O
,are,VBP,O
,in,IN,O
,development,NN,O
,",",",",O
,heparin,NN,O
,remains,VBZ,O
,the,DT,O
,drug,NN,O
,of,IN,O
,choice,NN,O
,for,IN,O
,most,JJS,O
,anticoagulation,NN,O
,needs,NNS,O
,.,.,O
,The,DT,O
,clinical,JJ,O
,effects,NNS,O
,of,IN,O
,heparin,NN,O
,are,VBP,O
,meritorious,JJ,O
,",",",",O
,but,CC,O
,side,JJ,O
,effects,NNS,O
,do,VBP,O
,exist,VB,O
,.,.,O
,Important,NNP,O
,untoward,JJ,O
,effects,NNS,O
,of,IN,O
,heparin,JJ,O
,therapy,NN,O
,including,VBG,O
,heparin,JJ,O
,-,:,O
,induced,JJ,O
,thrombocytopenia,NN,B-DISEASE
,",",",",O
,heparin,SYM,O
,-,:,O
,associated,VBN,O
,osteoporosis,NN,B-DISEASE
,",",",",O
,eosinophilia,NN,B-DISEASE
,",",",",O
,skin,JJ,B-DISEASE
,reactions,NNS,I-DISEASE
,",",",",O
,allergic,JJ,B-DISEASE
,reactions,NNS,I-DISEASE
,other,JJ,O
,than,IN,O
,thrombocytopenia,NN,B-DISEASE
,and,CC,O
,alopecia,NN,B-DISEASE
,will,MD,O
,be,VB,O
,discussed,VBN,O
,in,IN,O
,this,DT,O
,article,NN,O
,.,.,O
,Nonopaque,NNP,O
,crystal,JJ,O
,deposition,NN,O
,causing,VBG,O
,ureteric,JJ,B-DISEASE
,obstruction,NN,I-DISEASE
,in,IN,O
,patients,NNS,O
,with,IN,O
,HIV,NNP,O
,undergoing,VBG,O
,indinavir,JJ,O
,therapy,NN,O
,.,.,O
,OBJECTIVE,CC,O
,:,:,O
,We,PRP,O
,describe,VBP,O
,the,DT,O
,unique,JJ,O
,CT,NNP,O
,features,NNS,O
,of,IN,O
,ureteric,JJ,B-DISEASE
,calculi,NN,I-DISEASE
,in,IN,O
,six,CD,O
,HIV,NNP,B-DISEASE
,-,:,I-DISEASE
,infected,JJ,I-DISEASE
,patients,NNS,O
,receiving,VBG,O
,indinavir,NN,O
,",",",",O
,the,DT,O
,most,RBS,O
,commonly,RB,O
,used,VBD,O
,HIV,NNP,O
,protease,NN,O
,inhibitor,NN,O
,",",",",O
,which,WDT,O
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,an,DT,O
,increased,JJ,O
,incidence,NN,O
,of,IN,O
,urolithiasis,NN,B-DISEASE
,.,.,O
,CONCLUSION,NN,O
,:,:,O
,Ureteric,JJ,B-DISEASE
,obstruction,NN,I-DISEASE
,caused,VBN,O
,by,IN,O
,precipitated,JJ,O
,indinavir,JJ,O
,crystals,NNS,O
,may,MD,O
,be,VB,O
,difficult,JJ,O
,to,TO,O
,diagnose,VB,O
,with,IN,O
,unenhanced,JJ,O
,CT,NNP,O
,.,.,O
,The,DT,O
,calculi,NN,O
,are,VBP,O
,not,RB,O
,opaque,JJ,O
,",",",",O
,and,CC,O
,secondary,JJ,O
,signs,NNS,O
,of,IN,O
,obstruction,NN,O
,may,MD,O
,be,VB,O
,absent,JJ,O
,or,CC,O
,minimal,JJ,O
,and,CC,O
,should,MD,O
,be,VB,O
,sought,VBN,O
,carefully,RB,O
,.,.,O
,Images,NNS,O
,may,MD,O
,need,VB,O
,to,TO,O
,be,VB,O
,obtained,VBN,O
,using,VBG,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,contrast,NN,O
,material,NN,O
,to,TO,O
,enable,JJ,O
,diagnosis,NN,O
,of,IN,O
,ureteric,JJ,B-DISEASE
,stones,NNS,I-DISEASE
,or,CC,I-DISEASE
,obstruction,NN,I-DISEASE
,in,IN,O
,patients,NNS,O
,with,IN,O
,HIV,NNP,B-DISEASE
,infection,NN,I-DISEASE
,who,WP,O
,receive,VBP,O
,indinavir,JJ,O
,therapy,NN,O
,.,.,O
,Ischemic,NNP,B-DISEASE
,colitis,NN,I-DISEASE
,and,CC,O
,sumatriptan,NN,O
,use,NN,O
,.,.,O
,Sumatriptan,NNP,O
,succinate,NN,O
,",",",",O
,a,DT,O
,serotonin,NN,O
,-,:,O
,1,CD,O
,(,(,O
,5,CD,O
,-,:,O
,hydroxytryptamine,NN,O
,-,:,O
,1,CD,O
,),),O
,receptor,NN,O
,agonist,NN,O
,",",",",O
,is,VBZ,O
,an,DT,O
,antimigraine,JJ,O
,drug,NN,O
,that,WDT,O
,is,VBZ,O
,reported,VBN,O
,to,TO,O
,act,VB,O
,by,IN,O
,selectively,RB,O
,constricting,VBG,O
,intracranial,JJ,O
,arteries,NNS,O
,.,.,O
,Recently,RB,O
,",",",",O
,vasopressor,NN,O
,responses,NNS,O
,that,WDT,O
,are,VBP,O
,distinct,JJ,O
,from,IN,O
,the,DT,O
,cranial,JJ,O
,circulation,NN,O
,have,VBP,O
,been,VBN,O
,demonstrated,VBN,O
,to,TO,O
,occur,VB,O
,in,IN,O
,the,DT,O
,systemic,JJ,O
,",",",",O
,pulmonary,JJ,O
,",",",",O
,and,CC,O
,coronary,JJ,O
,circulations,NNS,O
,.,.,O
,Cases,NNS,O
,have,VBP,O
,been,VBN,O
,published,VBN,O
,of,IN,O
,coronary,JJ,B-DISEASE
,vasospasm,NN,I-DISEASE
,",",",",O
,myocardial,JJ,B-DISEASE
,ischemia,NN,I-DISEASE
,",",",",O
,and,CC,O
,myocardial,JJ,B-DISEASE
,infarction,NN,I-DISEASE
,occurring,VBG,O
,after,IN,O
,sumatriptan,JJ,O
,use,NN,O
,.,.,O
,We,PRP,O
,report,VBP,O
,on,IN,O
,the,DT,O
,development,NN,O
,of,IN,O
,8,CD,O
,serious,JJ,O
,cases,NNS,O
,of,IN,O
,ischemic,JJ,B-DISEASE
,colitis,NN,I-DISEASE
,in,IN,O
,patients,NNS,O
,with,IN,O
,migraine,NN,B-DISEASE
,treated,VBN,O
,with,IN,O
,sumatriptan,NN,O
,.,.,O
,Pallidotomy,NN,O
,with,IN,O
,the,DT,O
,gamma,JJ,O
,knife,NN,O
,:,:,O
,a,DT,O
,positive,JJ,O
,experience,NN,O
,.,.,O
,51,CD,O
,patients,NNS,O
,with,IN,O
,medically,RB,O
,refractory,JJ,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,underwent,JJ,O
,stereotactic,JJ,O
,posteromedial,JJ,O
,pallidotomy,NN,O
,between,IN,O
,August,NNP,O
,1993,CD,O
,and,CC,O
,February,NNP,O
,1997,CD,O
,for,IN,O
,treatment,NN,O
,of,IN,O
,bradykinesia,NN,B-DISEASE
,",",",",O
,rigidity,NN,B-DISEASE
,",",",",O
,and,CC,O
,L,NNP,O
,-,:,O
,DOPA,NNP,O
,-,:,O
,induced,JJ,O
,dyskinesias,NN,B-DISEASE
,.,.,O
,In,IN,O
,29,CD,O
,patients,NNS,O
,",",",",O
,the,DT,O
,pallidotomies,NNS,O
,were,VBD,O
,performed,VBN,O
,with,IN,O
,the,DT,O
,Leksell,NNP,O
,Gamma,NNP,O
,Knife,NNP,O
,and,CC,O
,in,IN,O
,22,CD,O
,they,PRP,O
,were,VBD,O
,performed,VBN,O
,with,IN,O
,the,DT,O
,standard,JJ,O
,radiofrequency,NN,O
,(,(,O
,RF,NNP,O
,),),O
,method,NN,O
,.,.,O
,Clinical,JJ,O
,assessment,NN,O
,as,RB,O
,well,RB,O
,as,IN,O
,blinded,VBN,O
,ratings,NNS,O
,of,IN,O
,Unified,NNP,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,Disease,NNP,I-DISEASE
,Rating,NNP,O
,Scale,NNP,O
,(,(,O
,UPDRS,NNP,O
,),),O
,scores,NNS,O
,were,VBD,O
,carried,VBN,O
,out,RP,O
,pre,JJ,O
,-,:,O
,and,CC,O
,postoperatively,RB,O
,.,.,O
,Mean,NNP,O
,follow,VBP,O
,-,:,O
,up,IN,O
,time,NN,O
,is,VBZ,O
,20,CD,O
,.,.,O
,6,CD,O
,months,NNS,O
,(,(,O
,range,NN,O
,6,CD,O
,-,:,O
,48,CD,O
,),),O
,and,CC,O
,all,DT,O
,except,IN,O
,4,CD,O
,patients,NNS,O
,have,VBP,O
,been,VBN,O
,followed,VBN,O
,more,RBR,O
,than,IN,O
,one,CD,O
,year,NN,O
,.,.,O
,85,CD,O
,percent,NN,O
,of,IN,O
,patients,NNS,O
,with,IN,O
,dyskinesias,NNS,B-DISEASE
,were,VBD,O
,relieved,VBN,O
,of,IN,O
,symptoms,NNS,O
,",",",",O
,regardless,RB,O
,of,IN,O
,whether,IN,O
,the,DT,O
,pallidotomies,NNS,O
,were,VBD,O
,performed,VBN,O
,with,IN,O
,the,DT,O
,Gamma,NNP,O
,Knife,NNP,O
,or,CC,O
,radiofrequency,NN,O
,methods,NNS,O
,.,.,O
,About,IN,O
,2,CD,O
,/,JJ,O
,3,CD,O
,of,IN,O
,the,DT,O
,patients,NNS,O
,in,IN,O
,both,DT,O
,Gamma,NNP,O
,Knife,NNP,O
,and,CC,O
,radiofrequency,NN,O
,groups,NNS,O
,showed,VBD,O
,improvements,NNS,O
,in,IN,O
,bradykinesia,NN,B-DISEASE
,and,CC,O
,rigidity,NN,B-DISEASE
,",",",",O
,although,IN,O
,when,WRB,O
,considered,VBN,O
,as,IN,O
,a,DT,O
,group,NN,O
,neither,CC,O
,the,DT,O
,Gamma,NNP,O
,Knife,NNP,O
,nor,CC,O
,the,DT,O
,radiofrequency,NN,O
,group,NN,O
,showed,VBD,O
,statistically,RB,O
,significant,JJ,O
,improvements,NNS,O
,in,IN,O
,UPDRS,NNP,O
,scores,NNS,O
,.,.,O
,One,CD,O
,patient,NN,O
,in,IN,O
,the,DT,O
,Gamma,NNP,O
,Knife,NNP,O
,group,NN,O
,(,(,O
,3,CD,O
,.,.,O
,4,CD,O
,%,NN,O
,),),O
,developed,VBD,O
,a,DT,O
,homonymous,JJ,B-DISEASE
,hemianopsia,NN,I-DISEASE
,9,CD,O
,months,NNS,O
,following,VBG,O
,treatment,NN,O
,and,CC,O
,5,CD,O
,patients,NNS,O
,(,(,O
,27,CD,O
,.,.,O
,7,CD,O
,%,NN,O
,),),O
,in,IN,O
,the,DT,O
,radiofrequency,NN,O
,group,NN,O
,became,VBD,O
,transiently,RB,O
,confused,VBN,O
,postoperatively,RB,O
,.,.,O
,No,UH,O
,other,JJ,O
,complications,NNS,O
,were,VBD,O
,seen,VBN,O
,.,.,O
,Gamma,NNP,O
,Knife,NNP,O
,pallidotomy,NN,O
,is,VBZ,O
,as,RB,O
,effective,JJ,O
,as,IN,O
,radiofrequency,NN,O
,pallidotomy,NN,O
,in,IN,O
,controlling,VBG,O
,certain,JJ,O
,of,IN,O
,the,DT,O
,symptoms,NNS,O
,of,IN,O
,Parkinson,NNP,B-DISEASE
,',POS,I-DISEASE
,s,JJ,I-DISEASE
,disease,NN,I-DISEASE
,.,.,O
,It,PRP,O
,may,MD,O
,be,VB,O
,the,DT,O
,only,JJ,O
,practical,JJ,O
,technique,NN,O
,available,JJ,O
,in,IN,O
,certain,JJ,O
,patients,NNS,O
,",",",",O
,such,JJ,O
,as,IN,O
,those,DT,O
,who,WP,O
,take,VBP,O
,anticoagulants,NNS,O
,",",",",O
,have,VBP,O
,bleeding,VBG,B-DISEASE
,diatheses,NNS,O
,or,CC,O
,serious,JJ,O
,systemic,JJ,O
,medical,JJ,O
,illnesses,NNS,O
,.,.,O
,It,PRP,O
,is,VBZ,O
,a,DT,O
,viable,JJ,O
,option,NN,O
,for,IN,O
,other,JJ,O
,patients,NNS,O
,as,IN,O
,well,RB,O
,.,.,O
,Centrally,NNP,O
,mediated,VBD,O
,cardiovascular,JJ,O
,effects,NNS,O
,of,IN,O
,intracisternal,JJ,O
,application,NN,O
,of,IN,O
,carbachol,NN,O
,in,IN,O
,anesthetized,JJ,O
,rats,NNS,O
,.,.,O
,The,DT,O
,pressor,NN,O
,response,NN,O
,to,TO,O
,the,DT,O
,intracisternal,JJ,O
,(,(,O
,i,JJ,O
,.,.,O
,c,NN,O
,.,.,O
,),),O
,injection,NN,O
,of,IN,O
,carbachol,NN,O
,(,(,O
,1,CD,O
,mug,NN,O
,),),O
,in,IN,O
,anesthetized,JJ,O
,rats,NNS,O
,was,VBD,O
,analyzed,VBN,O
,.,.,O
,This,DT,O
,response,NN,O
,was,VBD,O
,significantly,RB,O
,reduced,VBN,O
,by,IN,O
,the,DT,O
,intravenous,JJ,O
,(,(,O
,i,JJ,O
,.,.,O
,v,NN,O
,.,.,O
,),),O
,injection,NN,O
,of,IN,O
,guanethidine,NN,O
,(,(,O
,5,CD,O
,mg,NN,O
,),),O
,",",",",O
,hexamethonium,NN,O
,(,(,O
,10,CD,O
,mg,NN,O
,),),O
,or,CC,O
,phentolamine,NN,O
,(,(,O
,5,CD,O
,mg,NN,O
,),),O
,",",",",O
,and,CC,O
,conversely,RB,O
,",",",",O
,potentiated,VBN,O
,by,IN,O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,desmethylimipramine,NN,O
,(,(,O
,0,CD,O
,.,.,O
,3,CD,O
,mg,NN,O
,),),O
,",",",",O
,while,IN,O
,propranolol,NN,O
,(,(,O
,0,CD,O
,.,.,O
,5,CD,O
,mg,NN,O
,),),O
,i,NN,O
,.,.,O
,v,NN,O
,.,.,O
,selectively,RB,O
,inhibited,VBD,O
,the,DT,O
,enlargement,NN,B-DISEASE
,of,IN,I-DISEASE
,pulse,JJ,I-DISEASE
,pressure,NN,I-DISEASE
,and,CC,O
,the,DT,O
,tachycardia,NN,B-DISEASE
,following,VBG,O
,i,NN,O
,.,.,O
,c,NN,O
,.,.,O
,carbachol,NN,O
,(,(,O
,1,CD,O
,mug,NN,O
,),),O
,.,.,O
,On,IN,O
,the,DT,O
,other,JJ,O
,hand,NN,O
,",",",",O
,the,DT,O
,pressor,NN,O
,response,NN,O
,to,TO,O
,i,VB,O
,.,.,O
,c,NN,O
,.,.,O
,carbachol,NN,O
,(,(,O
,1,CD,O
,mug,NN,O
,),),O
,was,VBD,O
,almost,RB,O
,completely,RB,O
,blocked,VBN,O
,by,IN,O
,i,NN,O
,.,.,O
,c,NN,O
,.,.,O
,atropine,NN,O
,(,(,O
,3,CD,O
,mug,NN,O
,),),O
,or,CC,O
,hexamethonium,NN,O
,(,(,O
,500,CD,O
,mug,NN,O
,),),O
,",",",",O
,and,CC,O
,significantly,RB,O
,reduced,VBN,O
,by,IN,O
,i,NN,O
,.,.,O
,c,NN,O
,.,.,O
,chlorpromazine,NN,O
,(,(,O
,50,CD,O
,mug,NN,O
,),),O
,but,CC,O
,significantly,RB,O
,potentiated,VBN,O
,by,IN,O
,i,NN,O
,.,.,O
,c,NN,O
,.,.,O
,desmethylimipramine,NN,O
,(,(,O
,30,CD,O
,mug,NN,O
,),),O
,.,.,O
,The,DT,O
,pressor,NN,O
,response,NN,O
,to,TO,O
,i,VB,O
,.,.,O
,c,NN,O
,.,.,O
,carbachol,NN,O
,(,(,O
,1,CD,O
,mug,NN,O
,),),O
,remained,VBD,O
,unchanged,JJ,O
,after,IN,O
,sectioning,VBG,O
,of,IN,O
,the,DT,O
,bilateral,JJ,O
,cervical,JJ,O
,vagal,JJ,O
,nerves,NNS,O
,but,CC,O
,disappeared,VBD,O
,after,IN,O
,sectioning,VBG,O
,of,IN,O
,the,DT,O
,spinal,JJ,O
,cord,NN,O
,(,(,O
,C7,NNP,O
,-,:,O
,C8,NN,O
,),),O
,.,.,O
,From,IN,O
,the,DT,O
,above,JJ,O
,result,NN,O
,it,PRP,O
,is,VBZ,O
,suggested,VBN,O
,that,IN,O
,the,DT,O
,pressor,NN,O
,response,NN,O
,to,TO,O
,i,VB,O
,.,.,O
,c,NN,O
,.,.,O
,carbachol,JJ,O
,ortral,JJ,O
,and,CC,O
,peripheral,JJ,O
,adrenergic,NN,O
,mechanisms,NNS,O
,",",",",O
,and,CC,O
,that,IN,O
,the,DT,O
,sympathetic,JJ,O
,trunk,NN,O
,is,VBZ,O
,the,DT,O
,main,JJ,O
,pathway,NN,O
,.,.,O
,Neuroleptic,JJ,B-DISEASE
,malignant,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,and,CC,O
,methylphenidate,NN,O
,.,.,O
,A,DT,O
,1,CD,O
,-,:,O
,year,NN,O
,-,:,O
,old,JJ,O
,female,NN,O
,presented,VBN,O
,with,IN,O
,neuroleptic,JJ,B-DISEASE
,malignant,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,probably,RB,O
,caused,VBN,O
,by,IN,O
,methylphenidate,NN,O
,.,.,O
,She,PRP,O
,had,VBD,O
,defects,NNS,O
,in,IN,O
,the,DT,O
,supratentorial,JJ,O
,brain,NN,O
,including,VBG,O
,the,DT,O
,basal,NN,O
,ganglia,NN,O
,and,CC,O
,the,DT,O
,striatum,NN,O
,(,(,O
,multicystic,JJ,B-DISEASE
,encephalomalacia,NN,I-DISEASE
,),),O
,due,JJ,O
,to,TO,O
,severe,JJ,O
,perinatal,JJ,O
,hypoxic,NN,B-DISEASE
,-,:,I-DISEASE
,ischemic,JJ,I-DISEASE
,encephalopathy,NN,I-DISEASE
,",",",",O
,which,WDT,O
,was,VBD,O
,considered,VBN,O
,to,TO,O
,be,VB,O
,a,DT,O
,possible,JJ,O
,predisposing,NN,O
,factor,NN,O
,causing,VBG,O
,neuroleptic,JJ,B-DISEASE
,malignant,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,.,.,O
,A,DT,O
,dopaminergic,JJ,O
,blockade,NN,O
,mechanism,NN,O
,generally,RB,O
,is,VBZ,O
,accepted,VBN,O
,as,IN,O
,the,DT,O
,pathogenesis,NN,O
,of,IN,O
,this,DT,O
,syndrome,NN,O
,.,.,O
,However,RB,O
,",",",",O
,methylphenidate,NN,O
,is,VBZ,O
,a,DT,O
,dopamine,JJ,O
,agonist,NN,O
,via,IN,O
,the,DT,O
,inhibition,NN,O
,of,IN,O
,uptake,NN,O
,of,IN,O
,dopamine,NN,O
,",",",",O
,and,CC,O
,therefore,RB,O
,dopaminergic,JJ,O
,systems,NNS,O
,in,IN,O
,the,DT,O
,brainstem,NN,O
,(,(,O
,mainly,RB,O
,the,DT,O
,midbrain,NN,O
,),),O
,and,CC,O
,the,DT,O
,spinal,JJ,O
,cord,NN,O
,were,VBD,O
,unlikely,JJ,O
,to,TO,O
,participate,VB,O
,in,IN,O
,the,DT,O
,onset,NN,O
,of,IN,O
,this,DT,O
,syndrome,NN,O
,.,.,O
,A,DT,O
,relative,JJ,O
,gamma,NN,O
,-,:,O
,aminobutyric,JJ,O
,acid,SYM,O
,-,:,O
,ergic,JJ,O
,deficiency,NN,O
,might,MD,O
,occur,VB,O
,because,IN,O
,diazepam,NN,O
,",",",",O
,a,DT,O
,gamma,NN,O
,-,:,O
,aminobutyric,JJ,O
,acid,SYM,O
,-,:,O
,mimetic,JJ,O
,agent,NN,O
,",",",",O
,was,VBD,O
,strikingly,RB,O
,effective,JJ,O
,.,.,O
,This,DT,O
,is,VBZ,O
,the,DT,O
,first,JJ,O
,reported,VBD,O
,patient,JJ,O
,with,IN,O
,neuroleptic,JJ,B-DISEASE
,malignant,JJ,I-DISEASE
,syndrome,NN,I-DISEASE
,probably,RB,O
,caused,VBN,O
,by,IN,O
,methylphenidate,NN,O
,.,.,O
,Differential,JJ,O
,effects,NNS,O
,of,IN,O
,17alpha,CD,O
,-,:,O
,ethinylestradiol,NN,O
,on,IN,O
,the,DT,O
,neutral,JJ,O
,and,CC,O
,acidic,JJ,O
,pathways,NNS,O
,of,IN,O
,bile,NN,O
,salt,NN,O
,synthesis,NN,O
,in,IN,O
,the,DT,O
,rat,NN,O
,.,.,O
,Effects,NNS,O
,of,IN,O
,17alpha,CD,O
,-,:,O
,ethinylestradiol,NN,O
,(,(,O
,EE,NNP,O
,),),O
,on,IN,O
,the,DT,O
,neutral,JJ,O
,and,CC,O
,acidic,JJ,O
,biosynthetic,JJ,O
,pathways,NNS,O
,of,IN,O
,bile,NN,O
,salt,NN,O
,(,(,O
,BS,NNP,O
,),),O
,synthesis,NN,O
,were,VBD,O
,evaluated,VBN,O
,in,IN,O
,rats,NNS,O
,with,IN,O
,an,DT,O
,intact,JJ,O
,enterohepatic,JJ,O
,circulation,NN,O
,and,CC,O
,in,IN,O
,rats,NNS,O
,with,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,bile,JJ,O
,diversion,NN,O
,to,TO,O
,induce,VB,O
,BS,NNP,O
,synthesis,NN,O
,.,.,O
,For,IN,O
,this,DT,O
,purpose,NN,O
,",",",",O
,bile,JJ,O
,salt,NN,O
,pool,NN,O
,composition,NN,O
,",",",",O
,synthesis,NN,O
,of,IN,O
,individual,JJ,O
,BS,NNP,O
,in,IN,O
,vivo,NN,O
,",",",",O
,hepatic,JJ,O
,activities,NNS,O
,",",",",O
,and,CC,O
,expression,NN,O
,levels,NNS,O
,of,IN,O
,cholesterol,NN,O
,7alpha,CD,O
,-,:,O
,hydroxylase,NN,O
,(,(,O
,CYP7A,NNP,O
,),),O
,",",",",O
,and,CC,O
,sterol,VB,O
,27,CD,O
,-,:,O
,hydroxylase,NN,O
,(,(,O
,CYP27,NNP,O
,),),O
,",",",",O
,as,RB,O
,well,RB,O
,as,IN,O
,of,IN,O
,other,JJ,O
,enzymes,NNS,O
,involved,VBN,O
,in,IN,O
,BS,NNP,O
,synthesis,NN,O
,",",",",O
,were,VBD,O
,analyzed,VBN,O
,in,IN,O
,rats,NNS,O
,treated,VBN,O
,with,IN,O
,EE,NNP,O
,(,(,O
,5,CD,O
,mg,NN,O
,/,NNP,O
,kg,NN,O
,",",",",O
,3,CD,O
,days,NNS,O
,),),O
,or,CC,O
,its,PRP$,O
,vehicle,NN,O
,.,.,O
,BS,NNP,O
,pool,NN,O
,size,NN,O
,was,VBD,O
,decreased,VBN,O
,by,IN,O
,27,CD,O
,%,NN,O
,but,CC,O
,total,JJ,O
,BS,NNP,O
,synthesis,NN,O
,was,VBD,O
,not,RB,O
,affected,VBN,O
,by,IN,O
,EE,NNP,O
,in,IN,O
,intact,JJ,O
,rats,NNS,O
,.,.,O
,Synthesis,NN,O
,of,IN,O
,cholate,NN,O
,was,VBD,O
,reduced,VBN,O
,by,IN,O
,68,CD,O
,%,NN,O
,in,IN,O
,EE,NNP,O
,-,:,O
,treated,VBD,O
,rats,NNS,O
,",",",",O
,while,IN,O
,that,DT,O
,of,IN,O
,chenodeoxycholate,NN,O
,was,VBD,O
,increased,VBN,O
,by,IN,O
,60,CD,O
,%,NN,O
,.,.,O
,The,DT,O
,recently,RB,O
,identified,VBN,O
,Delta22,NNP,O
,-,:,O
,isomer,NN,O
,of,IN,O
,beta,NN,O
,-,:,O
,muricholate,NN,O
,contributed,VBD,O
,for,IN,O
,5,CD,O
,.,.,O
,4,CD,O
,%,NN,O
,and,CC,O
,18,CD,O
,.,.,O
,3,CD,O
,%,NN,O
,(,(,O
,P,NNP,O
,<,VBZ,O
,0,CD,O
,.,.,O
,01,CD,O
,),),O
,to,TO,O
,the,DT,O
,pool,NN,O
,in,IN,O
,control,NN,O
,and,CC,O
,EE,NNP,O
,-,:,O
,treated,VBD,O
,rats,NNS,O
,",",",",O
,respectively,RB,O
,",",",",O
,but,CC,O
,could,MD,O
,not,RB,O
,be,VB,O
,detected,VBN,O
,in,IN,O
,bile,NN,O
,after,IN,O
,exhaustion,NN,O
,of,IN,O
,the,DT,O
,pool,NN,O
,.,.,O
,A,DT,O
,clear,JJ,O
,reduction,NN,O
,of,IN,O
,BS,NNP,O
,synthesis,NN,O
,was,VBD,O
,found,VBN,O
,in,IN,O
,bile,JJ,O
,-,:,O
,diverted,VBN,O
,rats,NNS,O
,treated,VBD,O
,with,IN,O
,EE,NNP,O
,",",",",O
,yet,RB,O
,biliary,JJ,O
,BS,NNP,O
,composition,NN,O
,was,VBD,O
,only,RB,O
,minimally,RB,O
,affected,VBN,O
,.,.,O
,Activity,NN,O
,of,IN,O
,CYP7A,NNP,O
,was,VBD,O
,decreased,VBN,O
,by,IN,O
,EE,NNP,O
,in,IN,O
,both,DT,O
,intact,JJ,O
,and,CC,O
,bile,JJ,O
,-,:,O
,diverted,JJ,O
,rats,NNS,O
,",",",",O
,whereas,IN,O
,the,DT,O
,activity,NN,O
,of,IN,O
,the,DT,O
,CYP27,NNP,O
,was,VBD,O
,not,RB,O
,affected,VBN,O
,.,.,O
,Hepatic,JJ,O
,mRNA,NN,O
,levels,NNS,O
,of,IN,O
,CYP7A,NNP,O
,were,VBD,O
,significantly,RB,O
,reduced,VBN,O
,by,IN,O
,EE,NNP,O
,in,IN,O
,bile,JJ,O
,-,:,O
,diverted,VBN,O
,rats,NNS,O
,only,RB,O
,;,:,O
,CYP27,NNP,O
,mRNA,NN,O
,levels,NNS,O
,were,VBD,O
,not,RB,O
,affected,VBN,O
,by,IN,O
,EE,NNP,O
,.,.,O
,In,IN,O
,addition,NN,O
,",",",",O
,mRNA,NN,O
,levels,NNS,O
,of,IN,O
,sterol,NN,O
,12alpha,CD,O
,-,:,O
,hydroxylase,NN,O
,and,CC,O
,lithocholate,NN,O
,6beta,CD,O
,-,:,O
,hydroxylase,NN,O
,were,VBD,O
,increased,VBN,O
,by,IN,O
,bile,JJ,O
,diversion,NN,O
,and,CC,O
,suppressed,VBN,O
,by,IN,O
,EE,NNP,O
,.,.,O
,This,DT,O
,study,NN,O
,shows,VBZ,O
,that,IN,O
,17alpha,CD,O
,-,:,O
,ethinylestradiol,NN,O
,(,(,O
,EE,NNP,O
,),),O
,-,:,O
,induced,VBN,O
,intrahepatic,JJ,B-DISEASE
,cholestasis,NN,I-DISEASE
,in,IN,O
,rats,NNS,O
,is,VBZ,O
,associated,VBN,O
,with,IN,O
,selective,JJ,O
,inhibition,NN,O
,of,IN,O
,the,DT,O
,neutral,JJ,O
,pathway,NN,O
,of,IN,O
,bile,NN,O
,salt,NN,O
,(,(,O
,BS,NNP,O
,),),O
,synthesis,NN,O
,.,.,O
,Simultaneous,JJ,O
,impairment,NN,O
,of,IN,O
,other,JJ,O
,enzymes,NNS,O
,in,IN,O
,the,DT,O
,BS,NNP,O
,biosynthetic,JJ,O
,pathways,NNS,O
,may,MD,O
,contribute,VB,O
,to,TO,O
,overall,JJ,O
,effects,NNS,O
,of,IN,O
,EE,NNP,O
,on,IN,O
,BS,NNP,O
,synthesis,NN,O
,.,.,O
,Glibenclamide,NNP,O
,-,:,O
,sensitive,JJ,O
,hypotension,NN,B-DISEASE
,produced,VBN,O
,by,IN,O
,helodermin,NN,O
,assessed,VBN,O
,in,IN,O
,the,DT,O
,rat,NN,O
,.,.,O
,The,DT,O
,effects,NNS,O
,of,IN,O
,helodermin,NN,O
,",",",",O
,a,DT,O
,basic,JJ,O
,35,CD,O
,-,:,O
,amino,NN,O
,acid,JJ,O
,peptide,RB,O
,isolated,VBN,O
,from,IN,O
,the,DT,O
,venom,NN,O
,of,IN,O
,a,DT,O
,lizard,JJ,O
,salivary,JJ,O
,gland,NN,O
,",",",",O
,on,IN,O
,arterial,JJ,O
,blood,NN,O
,pressure,NN,O
,and,CC,O
,heart,NN,O
,rate,NN,O
,were,VBD,O
,examined,VBN,O
,in,IN,O
,the,DT,O
,rat,NN,O
,",",",",O
,focusing,VBG,O
,on,IN,O
,the,DT,O
,possibility,NN,O
,that,IN,O
,activation,NN,O
,of,IN,O
,ATP,NNP,O
,sensitive,JJ,O
,K,NNP,O
,+,NNP,O
,(,(,O
,K,NNP,O
,(,(,O
,ATP,NNP,O
,),),O
,),),O
,channels,NNS,O
,is,VBZ,O
,involved,VBN,O
,in,IN,O
,the,DT,O
,responses,NNS,O
,.,.,O
,The,DT,O
,results,NNS,O
,were,VBD,O
,also,RB,O
,compared,VBN,O
,with,IN,O
,those,DT,O
,of,IN,O
,vasoactive,JJ,O
,intestinal,JJ,O
,polypeptide,NN,O
,(,(,O
,VIP,NNP,O
,),),O
,.,.,O
,Helodermin,NNP,O
,produced,VBD,O
,hypotension,NN,B-DISEASE
,in,IN,O
,a,DT,O
,dose,JJ,O
,-,:,O
,dependent,JJ,O
,manner,NN,O
,with,IN,O
,approximately,RB,O
,similar,JJ,O
,potency,NN,O
,and,CC,O
,duration,NN,O
,to,TO,O
,VIP,NNP,O
,.,.,O
,Hypotension,NNP,B-DISEASE
,induced,VBN,O
,by,IN,O
,both,DT,O
,peptides,NNS,O
,was,VBD,O
,significantly,RB,O
,attenuated,VBN,O
,by,IN,O
,glibenclamide,NN,O
,",",",",O
,which,WDT,O
,abolished,VBD,O
,a,DT,O
,levcromakalim,JJ,O
,-,:,O
,produced,VBN,O
,decrease,NN,O
,in,IN,O
,arterial,JJ,O
,blood,NN,O
,pressure,NN,O
,.,.,O
,Oxyhemoglobin,NNP,O
,did,VBD,O
,not,RB,O
,affect,VB,O
,helodermin,SYM,O
,-,:,O
,induced,JJ,O
,hypotension,NN,B-DISEASE
,",",",",O
,whereas,IN,O
,it,PRP,O
,shortened,VBD,O
,the,DT,O
,duration,NN,O
,of,IN,O
,acetylcholine,NN,O
,(,(,O
,ACh,NNP,O
,),),O
,-,:,O
,produced,VBN,O
,hypotension,NN,B-DISEASE
,.,.,O
,These,DT,O
,findings,NNS,O
,suggest,VBP,O
,that,IN,O
,helodermin,SYM,O
,-,:,O
,produced,VBN,O
,hypotension,NN,B-DISEASE
,is,VBZ,O
,partly,RB,O
,attributable,JJ,O
,to,TO,O
,the,DT,O
,activation,NN,O
,of,IN,O
,glibenclamide,JJ,O
,-,:,O
,sensitive,JJ,O
,K,NNP,O
,+,NNP,O
,channels,NNS,O
,(,(,O
,K,NNP,O
,(,(,O
,ATP,NNP,O
,),),O
,channels,NNS,O
,),),O
,",",",",O
,which,WDT,O
,presumably,RB,O
,exist,VBP,O
,on,IN,O
,arterial,JJ,O
,smooth,JJ,O
,muscle,NN,O
,cells,NNS,O
,.,.,O
,EDRF,NNP,O
,(,(,O
,endothelium,SYM,O
,-,:,O
,derived,VBN,O
,relaxing,JJ,O
,factor,NN,O
,),),O
,/,VBZ,O
,nitric,JJ,O
,oxide,NN,O
,does,VBZ,O
,not,RB,O
,seem,VB,O
,to,TO,O
,play,VB,O
,an,DT,O
,important,JJ,O
,role,NN,O
,in,IN,O
,the,DT,O
,peptide,NN,O
,-,:,O
,produced,VBN,O
,hypotension,NN,B-DISEASE
,.,.,O
,Long,NNP,O
,-,:,O
,term,NN,O
,efficacy,NN,O
,and,CC,O
,adverse,JJ,O
,event,NN,O
,of,IN,O
,nifedipine,NN,O
,sustained,VBN,O
,-,:,O
,release,NN,O
,tablets,NNS,O
,for,IN,O
,cyclosporin,NN,O
,A,NNP,O
,-,:,O
,induced,JJ,O
,hypertension,NN,B-DISEASE
,in,IN,O
,patients,NNS,O
,with,IN,O
,psoriasis,NN,B-DISEASE
,.,.,O
,Thirteen,NNP,O
,psoriatic,JJ,B-DISEASE
,patients,NNS,O
,with,IN,O
,hypertension,NN,B-DISEASE
,during,IN,O
,the,DT,O
,course,NN,O
,of,IN,O
,cyclosporin,NN,O
,A,NNP,O
,therapy,NN,O
,were,VBD,O
,treated,VBN,O
,for,IN,O
,25,CD,O
,months,NNS,O
,with,IN,O
,a,DT,O
,calcium,NN,O
,channel,NN,O
,blocker,NN,O
,",",",",O
,sustained,VBN,O
,-,:,O
,release,NN,O
,nifedipine,NN,O
,",",",",O
,to,TO,O
,study,VB,O
,the,DT,O
,clinical,JJ,O
,antihypertensive,JJ,O
,effects,NNS,O
,and,CC,O
,adverse,JJ,O
,events,NNS,O
,during,IN,O
,treatment,NN,O
,with,IN,O
,both,DT,O
,drugs,NNS,O
,.,.,O
,Seven,NNP,O
,of,IN,O
,the,DT,O
,13,CD,O
,patients,NNS,O
,had,VBD,O
,exhibited,VBN,O
,a,DT,O
,subclinical,JJ,O
,hypertensive,JJ,B-DISEASE
,state,NN,O
,before,IN,O
,cyclosporin,NN,O
,A,DT,O
,therapy,NN,O
,.,.,O
,Both,DT,O
,systolic,JJ,O
,and,CC,O
,diastolic,JJ,O
,blood,NN,O
,pressures,NNS,O
,of,IN,O
,these,DT,O
,13,CD,O
,patients,NNS,O
,were,VBD,O
,decreased,VBN,O
,significantly,RB,O
,after,IN,O
,4,CD,O
,weeks,NNS,O
,of,IN,O
,nifedipine,JJ,O
,therapy,NN,O
,",",",",O
,and,CC,O
,blood,NN,O
,pressure,NN,O
,was,VBD,O
,maintained,VBN,O
,within,IN,O
,the,DT,O
,normal,JJ,O
,range,NN,O
,thereafter,RB,O
,for,IN,O
,25,CD,O
,months,NNS,O
,.,.,O
,The,DT,O
,adverse,JJ,O
,events,NNS,O
,during,IN,O
,combined,JJ,O
,therapy,NN,O
,with,IN,O
,cyclosporin,NN,O
,A,NNP,O
,and,CC,O
,nifedipine,NN,O
,included,VBD,O
,an,DT,O
,increase,NN,O
,in,IN,O
,blood,NN,O
,urea,JJ,O
,nitrogen,NN,O
,levels,NNS,O
,in,IN,O
,9,CD,O
,of,IN,O
,the,DT,O
,13,CD,O
,patients,NNS,O
,and,CC,O
,development,NN,O
,of,IN,O
,gingival,NN,B-DISEASE
,hyperplasia,NN,I-DISEASE
,in,IN,O
,2,CD,O
,of,IN,O
,the,DT,O
,13,CD,O
,patients,NNS,O
,.,.,O
,Our,PRP$,O
,findings,NNS,O
,indicate,VBP,O
,that,IN,O
,sustained,VBD,O
,-,:,O
,release,NN,O
,nifedipine,NN,O
,is,VBZ,O
,useful,JJ,O
,for,IN,O
,hypertensive,JJ,B-DISEASE
,psoriatic,JJ,B-DISEASE
,patients,NNS,O
,under,IN,O
,long,JJ,O
,-,:,O
,term,NN,O
,treatment,NN,O
,with,IN,O
,cyclosporin,NN,O
,A,NNP,O
,",",",",O
,but,CC,O
,that,IN,O
,these,DT,O
,patients,NNS,O
,should,MD,O
,be,VB,O
,monitored,VBN,O
,for,IN,O
,gingival,JJ,B-DISEASE
,hyperplasia,NN,I-DISEASE
,.,.,O
